doc_id sent_index relation_id relation trigger trigger_offset arg_num arg_base_np arg_protein arg_domain arg_site arg_sugar PSource SiteSource NProtein NID SiteName sent_text 9348299 3 5 part_of IL-4R 545:549 arg1 the published IL-4R sequence IL-4R the published IL-4R sequence PUBTATOR Site IL-4R 16190 sequence Sequence analysis of the IL-4R cDNA of BALB/c mice revealed 18 base substitutions leading to three extracellular and five cytoplasmic amino acid changes when compared with the published IL-4R sequence of C57BL/6 mice. 10889209 5 29 gly glycosylation 787:799 arg1 Asn Asn(119) Asn(119) GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site. 10889209 5 29 gly glycosylation 787:799 arg2 Asn Asn(119) Asn(119) GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site. 10889209 5 29 gly glycosylation 787:799 arg1 119 Asn(119) Asn(119) GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site. 10889209 5 29 gly glycosylation 787:799 arg2 Asn Asn(119) Asn(119) GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site. 10889209 5 29 gly glycosylation 787:799 arg1 119 Asn(119) Asn(119) GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site. 10889209 5 29 gly glycosylation 787:799 arg1 119 Asn(119) Asn(119) GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site. 22892896 4 3 gly glycosylation 787:799 arg2 glycosylation site occupancy glycosylation site occupancy site In this report, we present a quantitative glycoproteomics method that allows global scale identification and comparative quantification of glycosylation site occupancy using mass spectrometry. 24527708 2 50 gly N-glycosylated 465:478 arg1 N-glycosylated sites N-glycosylated sites sites Here we present a mass spectrometry (MS)-based workflow for the profiling of N-glycosylated sites in S. cerevisiae proteins. 24174280 0 72 gly glycosylation 26:38 arg2 N-linked glycosylation sites N-linked glycosylation sites sites Loss and gain of N-linked glycosylation sites in globular head and stem of HA found in A/H3N2 flu fatal and severe cases during 2013 Tunisia flu seasonal survey. 29426894 3 54 gly glycoproteins 505:517 arg1 recombinant FcγRIII glycoproteins recombinant FcγRIII glycoproteins PUBTATOR FcγRIII glycoproteins 2214 Although several reports describe N-glycosylation profiles of recombinant FcγRIII glycoproteins, much remains unknown regarding their native glycoforms. 29426894 3 60 gly N-glycosylation 457:471 arg1 recombinant FcγRIII glycoproteins recombinant FcγRIII glycoproteins PUBTATOR FcγRIII glycoproteins 2214 Although several reports describe N-glycosylation profiles of recombinant FcγRIII glycoproteins, much remains unknown regarding their native glycoforms. 9427707 7 66 gly glycosylation 1581:1593 arg2 an introduced potential N-linked glycosylation site an introduced potential N-linked glycosylation site site All mutant FVIII proteins were susceptible to thrombin cleavage, and the A2-domain fragment from the I566T mutant had a reduced mobility because of use of an introduced potential N-linked glycosylation site that was confirmed by N-glycanase digestion. 25202310 2 6 gly glycoproteins 375:387 arg1 glycoproteins glycoproteins Fterm glycoproteins Herein, we document and mechanistically explain the formation of subcellular-specific N-glycosylation determinants on glycoproteins trafficking through the shared biosynthetic machinery of human cells. 15737642 8 23 part_of glycosyltransferase 1768:1786 arg1 a stem region glycosyltransferase a stem region Fterm Site glycosyltransferase region The N-terminal region, which belongs to a stem region of glycosyltransferase, might also be important to the active protein structure. 10099230 0 49 gly glycoproteins 94:106 arg1 recombinant glycoproteins recombinant glycoproteins Fterm glycoproteins Ammonium ion and glucosamine dependent increases of oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells. 10099230 0 107 gly ion 9:11 arg1 recombinant glycoproteins glycoproteins ion Fterm glycoproteins Ammonium ion and glucosamine dependent increases of oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells. 10099230 0 119 gly increases 39:47 arg1 recombinant glycoproteins glycoproteins increases Fterm glycoproteins Ammonium ion and glucosamine dependent increases of oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells. 29755357 0 38 gly N-Glycosylation 0:14 arg1 Lipocalin 2 Lipocalin 2 PUBTATOR Lipocalin 2 3934 N-Glycosylation of Lipocalin 2 Is Not Required for Secretion or Exosome Targeting. 19167329 4 41 gly glycosylation 621:633 arg1 the nascent polypeptide the nascent polypeptide polypeptide The STT3A OST isoform is primarily responsible for cotranslational glycosylation of the nascent polypeptide as it enters the lumen of the endoplasmic reticulum. 7635146 5 109 part_of enzyme 1038:1043 arg1 all tryptic peptides enzyme all tryptic peptides Fterm Site enzyme peptides The amino acid sequences of all tryptic peptides of the pig liver enzyme were found, with little deviation, within the coding sequence. 17313760 11 53 part_of CCR4/CCR5 1413:1421 arg1 the 21 sequences CCR5 the 21 sequences PUBTATOR Site CCR5 1234 sequences Prediction of the potential use of co-receptors on the basis of the critical amino acids within V3 loop disclosed potential use of CCR4/CCR5 in 16 of the 21 sequences (76.19%), potential use of CCR4/CCR5 in 1 sequence (4.76%), and 4 samples (19.05%) failed to be predicted. 7904239 4 8 part_of motifs 637:642 arg1 this propeptide motifs this propeptide propeptide To identify sorting motifs in this propeptide, we have now constructed a chimera comprising the somatostatin signal peptide and proregion fused to chloramphenicol acetyl transferase (CAT) and a control protein consisting of the signal peptide fused to CAT, both of which were expressed in rat anterior-pituitary GH3 cells. 7904239 4 61 part_of somatostatin 713:724 arg1 the somatostatin signal peptide somatostatin the somatostatin signal peptide OGER Site somatostatin P60042 peptide To identify sorting motifs in this propeptide, we have now constructed a chimera comprising the somatostatin signal peptide and proregion fused to chloramphenicol acetyl transferase (CAT) and a control protein consisting of the signal peptide fused to CAT, both of which were expressed in rat anterior-pituitary GH3 cells. 15527836 2 105 gly glycosylation 316:328 arg2 two conserved N-linked glycosylation sites two conserved N-linked glycosylation sites sites The CAT1 protein contains two conserved N-linked glycosylation sites in the third extracellular loops of the mouse, rat, and hamster receptors (mCAT1, rCAT1, and hCAT1, respectively). 24497285 3 4 gly glycoprotein 699:710 arg1 phenylboronic acid based glycoprotein enrichment resin phenylboronic acid based glycoprotein enrichment resin Fterm glycoprotein METHODS: Saliva was collected from healthy individuals and glycoproteins were enriched using phenylboronic acid based glycoprotein enrichment resin. 24497285 3 119 gly glycoproteins 640:652 arg1 glycoproteins glycoproteins Fterm glycoproteins METHODS: Saliva was collected from healthy individuals and glycoproteins were enriched using phenylboronic acid based glycoprotein enrichment resin. 22815146 9 2 gly glycosylation 1913:1925 arg2 the hemagglutinin N-linked glycosylation site the hemagglutinin N-linked glycosylation site site Since N-linked glycosylation at these sites has been implicated in genetic and antigenic evolution of human influenza A viruses, we conclude that the relocation of the hemagglutinin N-linked glycosylation site from N142 to N144 renders swine influenza virus δ-cluster viruses resistant to antibody-mediated neutralization. 22815146 9 1 gly glycosylation 1737:1749 arg2 these sites sites sites Since N-linked glycosylation at these sites has been implicated in genetic and antigenic evolution of human influenza A viruses, we conclude that the relocation of the hemagglutinin N-linked glycosylation site from N142 to N144 renders swine influenza virus δ-cluster viruses resistant to antibody-mediated neutralization. 22009746 3 0 part_of proteins 723:730 arg1 the sequence proteins the sequence Fterm Site proteins sequence Here we systematically modify the sequence of these proteins toward the homomeric human α7 nAChR. 31831916 3 0 gly glycosylation 563:575 arg2 the N-glycoproteins and glycosylation sites the N-glycoproteins and glycosylation sites sites In this paper, we reviewed the human glycoproteomic profiles that have been reported in more than 80 individual studies, and mainly focused on the N-glycoproteins and glycosylation sites identified through their deglycosylated forms of glycosite-containing peptides. 31831916 3 5 gly N-glycoproteins 543:557 arg1 N-glycoproteins N-glycoproteins Fterm N-glycoproteins In this paper, we reviewed the human glycoproteomic profiles that have been reported in more than 80 individual studies, and mainly focused on the N-glycoproteins and glycosylation sites identified through their deglycosylated forms of glycosite-containing peptides. 31831916 3 33 gly deglycosylated 608:621 arg1 glycosite-containing peptides glycosite-containing peptides peptides In this paper, we reviewed the human glycoproteomic profiles that have been reported in more than 80 individual studies, and mainly focused on the N-glycoproteins and glycosylation sites identified through their deglycosylated forms of glycosite-containing peptides. 28289219 1 24 gly N-glycosylation 94:108 arg2 a conserved N-glycosylation site a conserved N-glycosylation site site IgG antibodies contain a conserved N-glycosylation site on the Fc domain to which a complex, biantennary glycan is attached. 28289219 1 64 gly attached 174:181 arg2 the Fc domain AND a complex, biantennary glycan the Fc domain a complex, biantennary glycan domain IgG antibodies contain a conserved N-glycosylation site on the Fc domain to which a complex, biantennary glycan is attached. 16343462 1 11 part_of contain 183:189 arg1 glycoproteins AND more than one glycosylation site glycoproteins more than one glycosylation site Fterm Site glycoproteins site Naturally occurring glycopeptides and glycoproteins usually contain more than one glycosylation site, and the structure of the carbohydrate attached is often different from site to site. 7635146 1 60 gly enzyme 89:94 arg1 the N-linked oligosaccharide processing pathway enzyme the N-linked oligosaccharide processing pathway Fterm enzyme Glucosidase I, the first enzyme in the N-linked oligosaccharide processing pathway, cleaves the distal alpha 1,2-linked glucose residue from the Glc3-Man9-GlcNAc2 oligosaccharide precursor highly specifically. 2603816 5 12 part_of kallikrein 533:542 arg1 the sequence kallikrein the sequence PUBTATOR Site kallikrein 9622 sequence It has been shown from the sequence of kallikrein that Arg(-1)-Ile(1) and Arg(87)-Gln(88) bonds are hydrolyzed with trypsin on rapid activation of prokallikrein and the formation of disulfide-linked two chain kallikrein. 27503338 0 38 part_of head 127:130 arg1 the N-linked glycosylation site head the N-linked glycosylation site site Re-emergence of H3N2 strains carrying potential neutralizing mutations at the N-linked glycosylation site at the hemagglutinin head, post the 2009 H1N1 pandemic. 1331083 1 70 part_of sites 201:205 arg1 human cathepsin D cathepsin D sites PUBTATOR Site cathepsin D 1509 sites We have examined the phosphorylation of Asn-linked oligosaccharides introduced at seven novel sites on human cathepsin D to determine whether the location of an oligosaccharide on a lysosomal enzyme affects its ability to serve as a substrate for UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (phosphotransferase), the enzyme that catalyzes the initial step in the biosynthesis of mannose 6-phosphate residues. 12877809 11 35 gly glycosylation 1788:1800 arg1 the tree shrew CETP the tree shrew CETP PUBTATOR CETP P11597 CONCLUSION: The possible glycosylation in the tree shrew CETP may be involved in the molecular mechanism of its insusceptibility to atherosclerosis. 16442106 3 23 gly N-glycosylation 531:545 arg2 a single N-glycosylation site a single N-glycosylation site site Further analyses revealed that M contained a single N-glycosylation site at asparagine 4. 19692476 5 74 gly glycosylation 1020:1032 arg2 a highly conserved glycosylation site a highly conserved glycosylation site site T342A, which resulted in the loss of a highly conserved glycosylation site in C3, played the primary role. 16261636 4 10 gly glycosylation 631:643 arg2 the various glycosylation sites the various glycosylation sites sites Glycosylation shows a markedly different pattern for the various glycosylation sites. 10604468 5 22 gly glycosylation 707:719 arg2 the conserved glycosylation site the conserved glycosylation site site At one interface, a single Ly49A subunit contacts one side of the MHC-I peptide-binding platform, presenting an open cavity towards the conserved glycosylation site on the H-2D(d) alpha2 domain. 9063619 0 50 gly heterogeneity 15:27 arg1 proteins proteins Fterm structure of proteins Glycosylation: heterogeneity and the 3D structure of proteins. 22689482 3 66 gly fucosylated 765:775 arg1 a biantennary N-linked glycan a biantennary N-linked glycan Five of the glycoforms carry a biantennary N-linked glycan fucosylated in the innermost N-acetylglucosamine of the core and showing from zero to four additional fucoses in the antennal region. 1740433 6 83 part_of A-SAA 941:945 arg1 the corresponding region SAA the corresponding region PUBTATOR Site SAA 6288 region The 112-residue mature molecule is 8 residues longer than human A-SAA; the size difference is due to the presence of an octapeptide between positions 70 and 77 that is not found in the corresponding region of human A-SAA. 26634432 3 19 part_of N-terminal 308:317 arg1 an N-terminal fragment N-terminal an N-terminal fragment Cterm Site N-terminal fragment After glycosylation, an N-terminal fragment of DMP1 protein was identified as a new proteoglycan (DMP1-PG) in bone matrix. 26634432 3 56 part_of protein 336:342 arg1 an N-terminal fragment DMP1 protein an N-terminal fragment PUBTATOR Site DMP1 protein 13406 fragment After glycosylation, an N-terminal fragment of DMP1 protein was identified as a new proteoglycan (DMP1-PG) in bone matrix. 25220145 0 18 gly glycoprotein 51:62 arg1 large scale core-fucosylated glycoprotein identification large scale core-fucosylated glycoprotein identification Fterm glycoprotein A precise approach in large scale core-fucosylated glycoprotein identification with low- and high-normalized collision energy. 7829269 1 23 gly glycosylation 206:218 arg2 A potential asparagine (Asn)-linked glycosylation site A potential asparagine (Asn)-linked glycosylation site site A potential asparagine (Asn)-linked glycosylation site was identified in the VK FRI sequence of an anti-B lymphoma monoclonal antibody (MAb), LL2.SDS-PAGE analysis and endo-F treatment of both murine and chimeric LL2 antibodies indicated that this site was glycosylated; however, no differences in the binding affinity to Raji cells were observed between the native murine LL2 and the endo-F-deglycosylated murine LL2 antibodies. 7829269 1 64 gly glycosylated 427:438 arg1 this site this site site A potential asparagine (Asn)-linked glycosylation site was identified in the VK FRI sequence of an anti-B lymphoma monoclonal antibody (MAb), LL2.SDS-PAGE analysis and endo-F treatment of both murine and chimeric LL2 antibodies indicated that this site was glycosylated; however, no differences in the binding affinity to Raji cells were observed between the native murine LL2 and the endo-F-deglycosylated murine LL2 antibodies. 20507882 5 4 gly glycosylation 994:1006 arg2 glycosylation site occupancy glycosylation site occupancy site The HexNAc-O-Ser/Thr, but not Hex-O-Thr glycopeptides, displayed heterogeneity regarding glycan core structures and level of glycosylation site occupancy. 20507882 5 60 gly glycopeptides 909:921 arg2 Hex-O-Thr glycopeptides Hex-O-Thr glycopeptides Thr glycopeptides The HexNAc-O-Ser/Thr, but not Hex-O-Thr glycopeptides, displayed heterogeneity regarding glycan core structures and level of glycosylation site occupancy. 9557657 3 53 gly N-glycosylation 678:692 arg2 four putative N-glycosylation sites four putative N-glycosylation sites sites The havcr-1 glycoprotein contains four putative N-glycosylation sites, two in the Cys-rich region and two in the TSP-rich region. 9557657 3 66 gly glycoprotein 642:653 arg1 The havcr-1 glycoprotein The havcr-1 glycoprotein PUBTATOR havcr-1 glycoprotein 26762 The havcr-1 glycoprotein contains four putative N-glycosylation sites, two in the Cys-rich region and two in the TSP-rich region. 27884519 10 2 gly glycosylated 1185:1196 arg1 N-terminal modified proteins N-terminal modified proteins Fterm proteins N-terminal modified proteins were well glycosylated and produced. 15009203 3 83 gly glycosylation 614:626 arg2 the glycosylation sites the glycosylation sites sites The purpose of this work was to characterize the recombinant human GM-CSF from an engineered Chinese hamster ovary cell line grown in suspension and as adherent culture for the identification of the glycosylation sites and the definition of the glycosidic moiety, including the degree of site occupancy. 23296536 3 53 gly glycosylation 641:653 arg2 glycosylation sites glycosylation sites sites In particular, the Expasy server has provided such tools to aid in the prediction of glycosylation sites of N- and O-glycans, while glycosciences.de has provided tools for the analysis of the amino acid distribution around glycosylation sites in 3D space, based on data from the Protein Data Bank (PDB). 23296536 3 12 gly glycosylation 503:515 arg2 glycosylation sites sites O-glycans sites In particular, the Expasy server has provided such tools to aid in the prediction of glycosylation sites of N- and O-glycans, while glycosciences.de has provided tools for the analysis of the amino acid distribution around glycosylation sites in 3D space, based on data from the Protein Data Bank (PDB). 23296536 3 12 gly glycosylation 503:515 arg2 glycosylation sites sites N- sites In particular, the Expasy server has provided such tools to aid in the prediction of glycosylation sites of N- and O-glycans, while glycosciences.de has provided tools for the analysis of the amino acid distribution around glycosylation sites in 3D space, based on data from the Protein Data Bank (PDB). 29944110 9 61 part_of HA1 1432:1434 arg1 residue 158 HA1 residue 158 PUBTATOR SpecificSite HA1 23526 residue 158 Through a mass spectrometric (MS) analysis of HA, the glycosylated sites of HA1 were established and we determined that residue 158 of HA1 was glycosylated and so modified a neutralization-sensitive epitope. 29944110 9 66 part_of HA1 1373:1375 arg1 the glycosylated sites HA1 the glycosylated sites PUBTATOR Site HA1 23526 sites Through a mass spectrometric (MS) analysis of HA, the glycosylated sites of HA1 were established and we determined that residue 158 of HA1 was glycosylated and so modified a neutralization-sensitive epitope. 3023956 2 5 part_of carrying 374:381 arg1 an extracellular domain AND an N glycosylation site an extracellular domain an N glycosylation site site Ten exons, 1,414 base pairs spanning 26 kilobases, contained a tyrosine kinase domain, a transmembrane domain, and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus. 8991508 0 15 part_of contains 44:51 arg1 Mouse submandibular gland salivary apomucin AND repeated N-glycosylation sites Mouse submandibular gland salivary apomucin repeated N-glycosylation sites Fterm Site apomucin 65202 sites Mouse submandibular gland salivary apomucin contains repeated N-glycosylation sites. 10413465 0 91 gly glycosylation 34:46 arg2 the glycosylation site threonine 194 site threonine 194 site threonine 194 Contribution of cysteine 158, the glycosylation site threonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide beta (1-40). 29162128 1 52 gly glycosylation 118:130 arg2 A stem glycosylation site hemagglutinin site Fterm hemagglutinin site A stem glycosylation site of hemagglutinin (HA) is important to the stability of the HA trimmer. 20795641 2 62 gly glycopeptides 263:275 arg2 glycopeptides glycopeptides glycopeptides Selective capture of glycopeptides by hydrazide resin followed by mass spectrometric identification of the peptides released by PNGaseF treatment has been most widely used. 8573180 3 50 part_of containing 454:463 arg1 epitope-tagged GLUT4 AND either wild-type (GLUT4-HA) or mutant (GLN57-HA) cDNA sequences epitope-tagged GLUT4 either wild-type (GLUT4-HA) or mutant (GLN57-HA) cDNA sequences PUBTATOR Site GLUT4 25139 sequences We transiently transfected cells with expression vectors for epitope-tagged GLUT4 containing either wild-type (GLUT4-HA) or mutant (GLN57-HA) cDNA sequences. 12742580 11 68 part_of GPI 1604:1606 arg1 a canonical GPI signal sequence GPI a canonical GPI signal sequence OGER Site GPI P06744 sequence SRA possesses a canonical GPI signal sequence, but we were unable to obtain unequivocal evidence for the presence of a GPI anchor. 12742580 11 18 part_of possesses 1582:1590 arg1 SRA AND a canonical GPI signal sequence SRA a canonical GPI signal sequence PUBTATOR Site SRA 10011 sequence SRA possesses a canonical GPI signal sequence, but we were unable to obtain unequivocal evidence for the presence of a GPI anchor. 10207016 7 110 gly O-glycosylation 1505:1519 arg2 The respective O-glycosylation site The respective O-glycosylation site site The respective O-glycosylation site was assigned to Thr-37 by digestion with carboxypeptidases in combination with MALDI-TOF-MS and by quadrupole time-of-flight electrospray mass spectrometry. 31004621 5 28 gly N-glycosylation 1032:1046 arg2 N-glycosylation sites N-glycosylation sites sites By using a BAC-based reverse genetics system, recombinant viruses expressing F proteins with loss of N-glycosylation sites were made. 1376147 6 46 part_of contains 859:866 arg1 Chymase 2 cDNA AND a novel, second potential N-glycosylation site Chymase 2 cDNA a novel, second potential N-glycosylation site OGER Site Chymase 2 cDNA P21844 site Chymase 2 cDNA contains a highly conserved intron/exon junction, a high positive charge (+17) and a novel, second potential N-glycosylation site. 9733824 9 58 part_of region 1634:1639 arg1 An additional potential glycosylation site region An additional potential glycosylation site site An additional potential glycosylation site was predicted to be present in the V2 region in all but one clone, and amino acid signatures related to protection were identified in viral DNA and RNA clones within both the V1 and V2 regions. 11559807 6 3 gly glycosylation 1381:1393 arg2 a glycosylation sequon a glycosylation sequon sequon To determine if other N-linked glycosylation differences between hAPN, feline APN (fAPN), and pAPN account for receptor specificity of pig and cat coronaviruses, a mutant hAPN protein that, like fAPN and pAPN, lacked a glycosylation sequon at 818 to 820 was studied. 19116267 3 29 part_of HA 349:350 arg1 the HA receptor-binding domain HA the HA receptor-binding domain Cterm Site HA domain Here, we demonstrate that changes in the HA receptor-binding domain alter the ability of the H5N1 virus to spread systemically in mice. 19116267 3 78 part_of receptor-binding 352:367 arg1 the HA receptor-binding domain receptor the HA receptor-binding domain Fterm Site receptor domain Here, we demonstrate that changes in the HA receptor-binding domain alter the ability of the H5N1 virus to spread systemically in mice. 24798328 6 79 part_of contain 865:871 arg1 the short linker regions AND an evolutionarily conserved O-glycosylation site the short linker regions an evolutionarily conserved O-glycosylation site site We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position -1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure. 8307000 9 28 gly N-glycosylation 1843:1857 arg2 Asn67 Asn67 Asn67 Newly introduced N-glycosylation sites at Asn67 (YN-tPA) or Asn58 (GS-tPA) as well as those at Asn184 and Asn448 were solely substituted by complex-type glycans. 8307000 9 28 gly N-glycosylation 1843:1857 arg2 Asn58 Asn58 Asn58 Newly introduced N-glycosylation sites at Asn67 (YN-tPA) or Asn58 (GS-tPA) as well as those at Asn184 and Asn448 were solely substituted by complex-type glycans. 8307000 9 28 gly N-glycosylation 1843:1857 arg2 Newly introduced N-glycosylation sites Newly introduced N-glycosylation sites sites Newly introduced N-glycosylation sites at Asn67 (YN-tPA) or Asn58 (GS-tPA) as well as those at Asn184 and Asn448 were solely substituted by complex-type glycans. 29932112 9 12 gly N-glycosylation 1264:1278 arg1 Panx2 Panx2 PUBTATOR Panx2 56666 Our study indicates that N-glycosylation may be important for folding and trafficking of Panx2. 10362834 5 25 gly glycoprotein 1095:1106 arg1 a peripheral nerve-specific glycoprotein a peripheral nerve-specific glycoprotein Fterm glycoprotein This is the first report indicating that P0, which has been considered as a peripheral nerve-specific glycoprotein, occurs also in the spinal cord of mammals. 22586465 5 97 gly N-glycosylation 787:801 arg2 a new N-glycosylation sequence motif a new N-glycosylation sequence motif motif On the other hand, variations causing a substitution that creates a new N-glycosylation sequence motif can result in the gain of glycosylation. 11804340 5 53 gly N-glycosylation 786:800 arg2 The single N-glycosylation site The single N-glycosylation site site The single N-glycosylation site is conserved in the three members of the family in both mice and humans. 2464879 1 13 gly glycoprotein 216:227 arg1 the haemagglutinin-neuraminidase (HN) glycoprotein the haemagglutinin-neuraminidase (HN) glycoprotein Fterm glycoprotein Nine neutralizing monoclonal antibodies (MAbs), each of which react with the haemagglutinin-neuraminidase (HN) glycoprotein of the Beaudette C strain of Newcastle disease virus (NDV), have been used in competitive binding assays to delineate three non-overlapping antigenic sites A, B and C. Epitopes within these sites have been identified on the basis of cross-reactivity of MAb-resistant mutants against the panel of MAbs, determined by plaque assays and Western blotting. 12954207 3 41 part_of gp120 529:533 arg1 functionally conserved gp120 regions gp120 functionally conserved gp120 regions PUBTATOR Site gp120 3700 regions Most broadly neutralizing antibodies are directed against functionally conserved gp120 regions involved in binding to either the primary virus receptor, CD4, or the viral coreceptor molecules that normally function as chemokine receptors. 27339457 10 42 part_of LOX 1648:1650 arg1 the LOX propeptide LOX the LOX propeptide PUBTATOR Site LOX 4015 propeptide We show that fibulin-4 binds stronger than fibulin-3 and -5 to LTBP1s, 3, and 4s, and to the lysyl oxidases LOX and LOXL1; the binding of fibulin-4 to the LOX propeptide was strongly reduced by the mutation E57K. 32168410 14 27 gly deglycosylation 1657:1671 arg1 the native protein the native protein Fterm protein Complete deglycosylation of the native protein was achieved by a deglycosylation workflow. 26339047 4 13 gly utilized 876:883 arg2 The introduced T116N and G130N sites The introduced T116N and G130N sites sites The introduced T116N and G130N sites were utilized as glycosylation anchors resulting in the formation of hyperglycosylated VLPs. 26482295 0 8 gly N-glycosylation 80:94 arg2 unique N-glycosylation site preferences unique N-glycosylation site preferences site Substitute sweeteners: diverse bacterial oligosaccharyltransferases with unique N-glycosylation site preferences. 17956937 6 70 gly predominant 1207:1217 arg2 the seminal plasma PSA AND high-mannose and hybrid types the seminal plasma PSA high-mannose and hybrid types PUBTATOR PSA 354 In the seminal plasma PSA, high-mannose and hybrid types of oligosaccharides were predominant, and the sialic acids attached to the latter as well as to biantennary oligosaccahrides were exclusively alpha2,6-linked because they were removed by Arthrobacter ureafaciens neuraminidase but resistant to S. pneumoniae neuraminidase. 18790849 5 49 part_of KCNQ1 884:888 arg1 the turret and pore-loop domains KCNQ1 the turret and pore-loop domains PUBTATOR Site KCNQ1 3784 domains We probed the molecular determinants governing macroscopic current amplitudes, with focus on the turret and pore-loop domains of KCNQ1 and KCNQ3. 18790849 5 103 part_of KCNQ3 894:898 arg1 the turret and pore-loop domains KCNQ3 the turret and pore-loop domains PUBTATOR Site KCNQ3 3786 domains We probed the molecular determinants governing macroscopic current amplitudes, with focus on the turret and pore-loop domains of KCNQ1 and KCNQ3. 23319596 8 42 part_of LOX 1277:1279 arg1 the LOX catalytic domain LOX the LOX catalytic domain PUBTATOR Site LOX 4015 domain The N-glycosylation site at Asn-644 in the LOX catalytic domain is not conserved in human LOX (hLOX), although the LOX catalytic domain of hLOX shares ∼50% identity and ∼70% homology with hLOXL2. 23319596 8 58 part_of LOX 1349:1351 arg1 the LOX catalytic domain LOX the LOX catalytic domain PUBTATOR Site LOX 4015 domain The N-glycosylation site at Asn-644 in the LOX catalytic domain is not conserved in human LOX (hLOX), although the LOX catalytic domain of hLOX shares ∼50% identity and ∼70% homology with hLOXL2. 23319596 8 73 part_of hLOX 1373:1376 arg1 the LOX catalytic domain hLOX the LOX catalytic domain PUBTATOR Site hLOX 4015 domain The N-glycosylation site at Asn-644 in the LOX catalytic domain is not conserved in human LOX (hLOX), although the LOX catalytic domain of hLOX shares ∼50% identity and ∼70% homology with hLOXL2. 9027352 21 92 gly glycosylation 2148:2160 arg2 a glycosylation site a glycosylation site site The I15T substitution may introduce a glycosylation site. 7781780 1 4 part_of erythropoietin 285:298 arg1 glycosylation site I erythropoietin glycosylation site I PUBTATOR Site erythropoietin 2056 site A sialidase resistant mono-charged N-glycan was isolated from glycosylation site I (Asn-24) of recombinant human erythropoietin expressed from baby hamster kidney (BHK-21) cells and constituted approximately 2-4% of the oligosaccharide material at this glycosylation site. 7781780 1 4 part_of erythropoietin 285:298 arg1 Asn-24 erythropoietin Asn-24 PUBTATOR SpecificSite erythropoietin 2056 Asn-24 A sialidase resistant mono-charged N-glycan was isolated from glycosylation site I (Asn-24) of recombinant human erythropoietin expressed from baby hamster kidney (BHK-21) cells and constituted approximately 2-4% of the oligosaccharide material at this glycosylation site. 20602265 9 56 gly glycosylation 1577:1589 arg2 a glycosylation site a glycosylation site site Four of the five antibody neutralization epitopes identified in A/RP/8/34(H1N1) were exposed, but the other was hidden by a glycosylation site. 25628020 0 55 gly N-glycosylation 25:39 arg2 novel N-glycosylation sites novel N-glycosylation sites sites The acquisition of novel N-glycosylation sites in conserved proteins during human evolution. 32110292 1 31 gly glycoproteins 174:186 arg1 glycoproteins glycoproteins Fterm glycoproteins Immunoglobulin G (IgG), which contains four subclasses (IgG1-4), is one of the most important classes of glycoproteins in the immune system. 20573835 6 6 gly glycosylation 906:918 arg2 a single N-linked glycosylation site site, N330 site, N330 Mutagenesis indicated that a single N-linked glycosylation site, N330, was critical for the specific interactions between MBL and SARS-S. 22180206 8 3 gly glycopeptides 1573:1585 arg2 mucin-type glycopeptides mucin-type glycopeptides glycopeptides This study demonstrates the capabilities of ETD MS/MS for site-specific characterisation of mucin-type glycopeptides containing high-density O-linked glycan clusters, using accessible and relative low-resolution/low-mass accuracy IT MS instrumentation. 22180206 8 32 gly containing 1587:1596 arg1 mucin-type glycopeptides AND high-density O-linked glycan clusters mucin-type glycopeptides high-density O-linked glycan clusters glycopeptides This study demonstrates the capabilities of ETD MS/MS for site-specific characterisation of mucin-type glycopeptides containing high-density O-linked glycan clusters, using accessible and relative low-resolution/low-mass accuracy IT MS instrumentation. 20198683 6 27 gly glycosylation 969:981 arg2 glycosylation site insertion mutagenesis glycosylation site insertion mutagenesis site Here, we successfully applied three molecular approaches (isotype switching, targeted mutagenesis of complementarity determining region residues, and glycosylation site insertion mutagenesis) to address the solubility problem. 26598643 5 3 gly O-glycans 1059:1067 arg1 human blood plasma proteins proteins O-glycans Fterm proteins To this end pooled human blood plasma of healthy donors was proteolytically digested using a broad-specific enzyme (Proteinase K), followed by a precipitation step, as well as a glycopeptide enrichment and fractionation step via hydrophilic interaction liquid chromatography, the latter being optimized for intact O-glycopeptides carrying short mucin-type core-1 and -2 O-glycans, which represent the vast majority of O-glycans on human blood plasma proteins. 26598643 5 19 gly O-glycopeptides 955:969 arg2 intact O-glycopeptides intact O-glycopeptides O-glycopeptides To this end pooled human blood plasma of healthy donors was proteolytically digested using a broad-specific enzyme (Proteinase K), followed by a precipitation step, as well as a glycopeptide enrichment and fractionation step via hydrophilic interaction liquid chromatography, the latter being optimized for intact O-glycopeptides carrying short mucin-type core-1 and -2 O-glycans, which represent the vast majority of O-glycans on human blood plasma proteins. 26598643 5 115 gly glycopeptide 819:830 arg2 a glycopeptide enrichment a glycopeptide enrichment glycopeptide To this end pooled human blood plasma of healthy donors was proteolytically digested using a broad-specific enzyme (Proteinase K), followed by a precipitation step, as well as a glycopeptide enrichment and fractionation step via hydrophilic interaction liquid chromatography, the latter being optimized for intact O-glycopeptides carrying short mucin-type core-1 and -2 O-glycans, which represent the vast majority of O-glycans on human blood plasma proteins. 26598643 5 20 gly carrying 971:978 arg1 intact O-glycopeptides AND -2 O-glycans intact O-glycopeptides -2 O-glycans O-glycopeptides To this end pooled human blood plasma of healthy donors was proteolytically digested using a broad-specific enzyme (Proteinase K), followed by a precipitation step, as well as a glycopeptide enrichment and fractionation step via hydrophilic interaction liquid chromatography, the latter being optimized for intact O-glycopeptides carrying short mucin-type core-1 and -2 O-glycans, which represent the vast majority of O-glycans on human blood plasma proteins. 19838169 0 27 gly glycopeptides 14:26 arg2 glycopeptides glycopeptides glycopeptides Enrichment of glycopeptides for glycan structure and attachment site identification. 26944735 2 102 part_of BMP-1 406:410 arg1 the refolded catalytic domain BMP-1 the refolded catalytic domain PUBTATOR Site BMP-1 649 domain Previous structural studies on the refolded catalytic domain of BMP-1 produced in E. coli have suggested the existence of a rare vicinal disulfide linkage near the active site. 21106559 5 84 gly glycoproteins 1125:1137 arg1 the N-glycans glycoproteins the N-glycans Fterm glycoproteins Although similar occurrence of such terminal disialyl cap on the N-glycans of several mammalian glycoproteins has been implicated, most of these correspond to only minor constituents of the full glycomic heterogeneity and remain poorly characterized. 26656560 7 5 gly N-glycosylation 946:960 arg2 N-glycosylation site N-glycosylation site site RESULTS: Analysis of TF isoforms by LC-MS confirmed the presence of increased disialo-TF and revealed a discrepancy in the mass difference between disialo-TF and tetrasialo-TF which suggested the presence of a genetic TF isoform with one abolished N-glycosylation site. 23991039 10 49 gly CD4bs 1628:1632 arg1 glycans CD4 glycans PUBTATOR CD4 920 High-resolution analyses of trimeric Env that show the orientation of glycans and polymorphic elements of the CD4bs that affect binding to antibodies like 1F7 are desirable to understand how to promote immunogenicity of more conserved elements of the CD4bs. 11238869 7 23 gly removal 1035:1041 arg3 the N-linked carbohydrate AND asparagine 197 asparagine 197 the N-linked carbohydrate asparagine 197 In the absence of the V1/V2 loops, neither removal of the N-linked carbohydrate at asparagine 197 nor lowering of the temperature increased the CD4-independent phenotypes. 9578495 2 1 gly glycosylation 338:350 arg2 the alpha52 glycosylation site the alpha52 glycosylation site site We have generated choriogonadotropin mutants in which the alpha52 glycosylation site is removed and the alpha and beta subunits are covalently linked by intersubunit disulfide bonds. 25498018 4 72 gly glycosylation 1004:1016 arg2 the glycosylation sites the glycosylation sites sites The off-line coupling of nano-LC with a MALDI-QIT-TOF mass spectrometer was demonstrated to be capable of sensitive and direct elucidation of the glycosylation difference between HMW and LMW CLEC-2, simultaneously providing information about their oligosaccharide structures and the glycosylation sites. 8636138 3 24 part_of factor 436:441 arg1 the human von Willebrand factor sequence von Willebrand factor the human von Willebrand factor sequence PUBTATOR Site von Willebrand factor 7450 sequence A secreted chimeric reporter protein, containing the human von Willebrand factor sequence, an antibody recognition epitope, and a heart muscle kinase site, was engineered and expressed in COS7 and MCF-7 cells. 8636138 3 16 part_of containing 400:409 arg1 A secreted chimeric reporter protein AND a heart muscle kinase site A secreted chimeric reporter protein a heart muscle kinase site Fterm Site protein site A secreted chimeric reporter protein, containing the human von Willebrand factor sequence, an antibody recognition epitope, and a heart muscle kinase site, was engineered and expressed in COS7 and MCF-7 cells. 8636138 3 16 part_of containing 400:409 arg1 A secreted chimeric reporter protein AND an antibody recognition epitope A secreted chimeric reporter protein an antibody recognition epitope Fterm Site protein epitope A secreted chimeric reporter protein, containing the human von Willebrand factor sequence, an antibody recognition epitope, and a heart muscle kinase site, was engineered and expressed in COS7 and MCF-7 cells. 8636138 3 16 part_of containing 400:409 arg1 A secreted chimeric reporter protein AND the human von Willebrand factor sequence A secreted chimeric reporter protein the human von Willebrand factor sequence Fterm Site protein sequence A secreted chimeric reporter protein, containing the human von Willebrand factor sequence, an antibody recognition epitope, and a heart muscle kinase site, was engineered and expressed in COS7 and MCF-7 cells. 23422691 2 2 gly N-glycosylation 305:319 arg2 one N-glycosylation site one N-glycosylation site site VEGF is a homodimeric glycoprotein that contains one N-glycosylation site. 23422691 2 15 gly glycoprotein 274:285 arg1 VEGF VEGF PUBTATOR VEGF 7422 VEGF is a homodimeric glycoprotein that contains one N-glycosylation site. 23422691 2 15 gly glycoprotein 274:285 arg1 a homodimeric glycoprotein a homodimeric glycoprotein Fterm glycoprotein VEGF is a homodimeric glycoprotein that contains one N-glycosylation site. 30708139 8 55 gly glycosylation 1184:1196 arg2 one additional glycosylation site one additional glycosylation site site Finally, two analogs with one additional glycosylation site were suggested as the qualified analogs for hyper-glycosylation of the LH, which can be considered for further experimental investigations. 9774483 1 20 gly acid 186:189 arg1 NCAM NCAM acid PUBTATOR NCAM 4684 PST and STX are polysialyltransferases that form polysialic acid in the neural cell adhesion molecule (NCAM), and these two polysialyltransferases often exist together in the same tissues. 9774483 1 20 gly acid 186:189 arg1 neural cell adhesion molecule neural cell adhesion molecule acid PUBTATOR neural cell adhesion molecule 4684 PST and STX are polysialyltransferases that form polysialic acid in the neural cell adhesion molecule (NCAM), and these two polysialyltransferases often exist together in the same tissues. 20622017 7 37 gly released 972:979 arg1 liver membrane glycoproteins AND N-Glycans liver membrane glycoproteins N-Glycans Fterm glycoproteins N-Glycans released from liver membrane glycoproteins included many glycans also identified in the kidney. 20622017 7 95 gly glycoproteins 1001:1013 arg1 liver membrane glycoproteins liver membrane glycoproteins Fterm glycoproteins N-Glycans released from liver membrane glycoproteins included many glycans also identified in the kidney. 21264968 2 33 gly O-glycosylation 689:703 arg2 O-glycosylation site(s) O-glycosylation site(s) site Here we report an efficient approach by combining MS and NMR spectroscopy that allows for the identification of O-glycosylation site(s) and the effect of O-glycosylation on the peptide backbone structures during enzymatic mucin domain assembly by using an isoform UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-T2 (ppGalNAcT2) in vitro. 21264968 2 124 gly O-glycosylation 731:745 arg1 the peptide backbone structures the peptide backbone structures peptide Here we report an efficient approach by combining MS and NMR spectroscopy that allows for the identification of O-glycosylation site(s) and the effect of O-glycosylation on the peptide backbone structures during enzymatic mucin domain assembly by using an isoform UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-T2 (ppGalNAcT2) in vitro. 12620415 4 42 gly glycosylation 558:570 arg2 The glycosylation site The glycosylation site site The glycosylation site and the anomeric configuration of the obtained nucleosides were assigned on the basis of spectroscopic studies and confirmed by molecular models. 11015576 6 18 part_of receptor 890:897 arg1 the extracellular Ig domain III receptor the extracellular Ig domain III Fterm Site receptor domain This point mutation, an N328I exchange in the extracellular Ig domain III of the receptor, seems to be unique as it affects a putative N-glycosylation site that is conserved between different FGFRs and species. 15194804 1 63 part_of protein 175:181 arg1 five potential N-glycosylation sites protein five potential N-glycosylation sites Fterm Site protein sites Nipah virus (NiV), a new member of the Paramyxoviridae, codes for a fusion (F) protein with five potential N-glycosylation sites. 11171034 10 10 gly found 1775:1779 arg1 the native protein AND carbohydrates the native protein carbohydrates Fterm protein Moreover, the presence of carbohydrates, not found on the native protein, suggests that addition of unnatural glycan structures by P. pastoris is a potential drawback that should be considered when using this expression system. 27314333 7 22 gly N-glycosylation 1287:1301 arg2 Rspo2 N-glycosylation site Rspo2 N-glycosylation site site Similar effect can be observed in the N137 Rspo1 or Rspo3 mutant engineered with Rspo2 N-glycosylation site. 19945164 4 55 part_of contain 707:713 arg1 all other epitopes AND charged residues all other epitopes charged residues residues With the exception of epitope #5, all other epitopes contain charged residues. 27234584 5 46 gly glycosylation 940:952 arg2 a conserved N-linked glycosylation site a conserved N-linked glycosylation site site It is interesting that the catalytic sites of MMPs do not contain O-linked glycans, but instead possess a conserved N-linked glycosylation site. 27234584 5 15 gly contain 873:879 arg1 the catalytic sites AND O-linked glycans the catalytic sites O-linked glycans sites It is interesting that the catalytic sites of MMPs do not contain O-linked glycans, but instead possess a conserved N-linked glycosylation site. 29842980 9 24 part_of glycoprotein 1448:1459 arg1 additional N-linked glycosylation site glycoprotein additional N-linked glycosylation site Fterm Site glycoprotein site Presence of additional N-linked glycosylation site at amino acid 283 of VP7 glycoprotein suggests that the major neutralizing epitope on the VP7 (G3) of RotaTeq vaccine differs from the currently circulating G3 strains. 29842980 9 37 part_of epitope 1498:1504 arg1 the VP7 VP7 epitope Cterm Site VP7 epitope Presence of additional N-linked glycosylation site at amino acid 283 of VP7 glycoprotein suggests that the major neutralizing epitope on the VP7 (G3) of RotaTeq vaccine differs from the currently circulating G3 strains. 2737288 0 9 gly glycosylation 41:53 arg2 the glycosylation site pancreatic elastase 1 site PUBTATOR pancreatic elastase 1 1990 site Localization and characterization of the glycosylation site of human pancreatic elastase 1. 27612916 7 87 gly glycan 1311:1316 arg1 the UGT2B7 enzyme UGT2B7 enzyme glycan PUBTATOR UGT2B7 enzyme 7364 The presence of an additional N-linked glycan on the UGT2B7 enzyme, likely affecting proper protein folding, resulted in a significant decrease of 49% and 40% in the formation of zidovudine and mycophenolic acid glucuronides, respectively. 25504159 1 3 gly glycosylation 143:155 arg1 the influenza virus hemagglutinin (HA) protein the influenza virus hemagglutinin (HA) protein Fterm protein N-linked glycosylation of the influenza virus hemagglutinin (HA) protein plays crucial roles in HA structure and function, evasion of neutralizing antibodies, and susceptibility to innate soluble antiviral factors. 8395123 1 44 gly glycosylation 305:317 arg2 Asn-X-Thr/Ser site motif, Asn site motif, Asn The amino acid sequence for the envelope protein(s) predicted from the nucleotide sequence of the E and E2/NS1 regions of the hepatitis C virus (HCV) genome is enriched with an N-linked glycosylation site motif, Asn-X-Thr/Ser, suggesting oligosaccharide moieties are present on the virion surface. 8395123 1 44 gly glycosylation 305:317 arg2 an N-linked glycosylation site motif site motif, Asn site motif, Asn The amino acid sequence for the envelope protein(s) predicted from the nucleotide sequence of the E and E2/NS1 regions of the hepatitis C virus (HCV) genome is enriched with an N-linked glycosylation site motif, Asn-X-Thr/Ser, suggesting oligosaccharide moieties are present on the virion surface. 8395123 1 44 gly glycosylation 305:317 arg2 an N-linked glycosylation site motif site motif, Asn site motif, Asn The amino acid sequence for the envelope protein(s) predicted from the nucleotide sequence of the E and E2/NS1 regions of the hepatitis C virus (HCV) genome is enriched with an N-linked glycosylation site motif, Asn-X-Thr/Ser, suggesting oligosaccharide moieties are present on the virion surface. 11439087 13 30 gly N-glycosylation 1726:1740 arg2 N-glycosylation sites N-glycosylation sites sites Thus the artificial engineering of N-glycosylation sites could be an effective method to generate homogeneous material for structural studies. 26018173 9 2 gly glycosylation 1669:1681 arg2 a newly observed O-linked glycosylation site a newly observed O-linked glycosylation site site Additionally, we report a newly observed O-linked glycosylation site, T606, and we show that the full O-linked glycosylation profile of membrane-associated Env is similar to that of soluble gp140. 26018173 9 9 gly glycosylation 1730:1742 arg1 membrane-associated Env membrane-associated Env PUBTATOR Env 100616444 Additionally, we report a newly observed O-linked glycosylation site, T606, and we show that the full O-linked glycosylation profile of membrane-associated Env is similar to that of soluble gp140. 27314333 0 47 gly N-Glycosylation 0:14 arg1 Human R-Spondin 1 Human R-Spondin 1 PUBTATOR Human R-Spondin 1 284654 N-Glycosylation of Human R-Spondin 1 Is Required for Efficient Secretion and Stability but Not for Its Heparin Binding Ability. 25451932 4 37 gly sites 467:471 arg1 N-glycans sites N-glycans sites It remains unknown, however, how N-glycans at different sites may regulate corin biosynthesis and processing. 8212855 11 90 gly glycoprotein 1692:1703 arg1 p32 p32 PUBTATOR p32 3622 This allows us to conclude that p32 is a glycoprotein and like gX of PRV accumulates in the medium of infected cells. 8212855 11 90 gly glycoprotein 1692:1703 arg1 a glycoprotein a glycoprotein Fterm glycoprotein This allows us to conclude that p32 is a glycoprotein and like gX of PRV accumulates in the medium of infected cells. 12731887 0 37 part_of p67 35:37 arg1 A glycosylation site p67 A glycosylation site PUBTATOR Site p67 64370 site A glycosylation site, 60SGTS63, of p67 is required for its ability to regulate the phosphorylation and activity of eukaryotic initiation factor 2alpha. 15353267 3 94 gly used 418:421 arg2 The T17 cDNA fragment The T17 cDNA fragment fragment The T17 cDNA fragment was used as a probe to screen the human testis cDNA-lambda gt10 library. 11259791 6 21 part_of AChE 941:944 arg1 the AChE sequences AChE the AChE sequences PUBTATOR Site AChE 43 sequences The similarity of the AChE sequences of humans and Torpedo species were compared thereby with the epitopes indicated. 17951640 0 26 gly proteins 49:56 arg1 N-linked glycan characterization proteins N-linked glycan characterization Fterm proteins N-linked glycan characterization of heterologous proteins. 17579075 5 17 part_of porin 693:697 arg1 the porin binding sites porin the porin binding sites PUBTATOR Site porin 7416 sites We have now used these species-specific differences in C4BP binding to gonococci to map the porin binding sites on CCP1 of C4BP. 17579075 5 66 part_of sites 707:711 arg1 CCP1 CCP1 sites PUBTATOR Site CCP1 23287 sites We have now used these species-specific differences in C4BP binding to gonococci to map the porin binding sites on CCP1 of C4BP. 21224233 9 42 gly N-glycosylation 1370:1384 arg2 an N-glycosylation site an N-glycosylation site site The introduction of an N-glycosylation site into EL4 confirms that at least a part of it is exposed to the extracellular fluid. 9884403 1 57 part_of glycoprotein 138:149 arg1 The N-glycosylation sites Tamm-Horsfall glycoprotein The N-glycosylation sites OGER Site Tamm-Horsfall glycoprotein P07911 sites The N-glycosylation sites of human Tamm-Horsfall glycoprotein from one healthy male donor have been characterized, based on an approach using endoproteinase Glu-C (V-8 protease, Staphylococcus aureus ) digestion and a combination of chromatographic techniques, automated Edman sequencing, and fast atom bombardment mass spectrometry. 27007620 3 8 gly glycoproteins 574:586 arg1 glycoproteins glycoproteins Fterm glycoproteins To date, a majority of efforts in disease glycoproteomics have tended to center on either determining the concentration of a given glycoprotein, or on profiling the total population of glycans released from a mixture of glycoproteins. 27007620 3 86 gly glycoprotein 485:496 arg1 a given glycoprotein a given glycoprotein Fterm glycoprotein To date, a majority of efforts in disease glycoproteomics have tended to center on either determining the concentration of a given glycoprotein, or on profiling the total population of glycans released from a mixture of glycoproteins. 11087995 4 75 gly glycosylated 766:777 arg2 both sites both sites sites Biochemical studies in transfected cell lines suggested that the amino-terminus of sst3 is glycosylated at both sites. 25113421 8 95 gly glycosylation 990:1002 arg2 the glycosylation site information the glycosylation site information site The latter approach has the advantage of retaining the glycosylation site information. 27259237 0 14 gly N-glycosylation 71:85 arg1 diverse brain proteins diverse brain proteins Fterm proteins In-depth mapping of the mouse brain N-glycoproteome reveals widespread N-glycosylation of diverse brain proteins. 10207016 5 5 gly sialylated 1226:1235 arg1 partially sialylated diantennary complex-type oligosaccharides partially sialylated diantennary complex-type oligosaccharides Pre-S2 N-glycans were characterized by anion exchange chromatography, methylation analysis, and on target sequential exoglycosidase digestions in combination with MALDI-TOF-MS, demonstrating the presence of partially sialylated diantennary complex-type oligosaccharides. 30158294 16 37 gly N-glycosylation 2481:2495 arg1 SERINC5 SERINC5 PUBTATOR SERINC5 256987 Nonetheless, N-glycosylation per se is neither required for the ability of SERINC5 to inhibit HIV-1 infectivity nor for its sensitivity to antagonism by Nef. 26813162 6 57 gly glycoproteins 1269:1281 arg1 the E1 and E2 glycoproteins the E1 and E2 glycoproteins Fterm glycoproteins Overall, these results indicate that glycosylation of the E1 and E2 glycoproteins of RRV provides important determinants of viral virulence and immunopathology in the mammalian host and replication in the mosquito vector. 26813162 6 71 gly glycosylation 1238:1250 arg1 the E1 and E2 glycoproteins the E1 and E2 glycoproteins Fterm glycoproteins Overall, these results indicate that glycosylation of the E1 and E2 glycoproteins of RRV provides important determinants of viral virulence and immunopathology in the mammalian host and replication in the mosquito vector. 14691230 10 93 part_of DPPIV 1553:1557 arg1 the highly glycosylated beta-propeller domain DPPIV the highly glycosylated beta-propeller domain PUBTATOR Site DPPIV 1803 domain ADA binds to the highly glycosylated beta-propeller domain of DPPIV, but the impact of glycosylation on binding had not previously been determined. 10397879 1 82 gly glycosylation 298:310 arg1 proteins proteins Fterm proteins The negative effects of ammonia on animal cells, especially in vitro cultures, are well known, but the mechanism of how ammonia inhibits cell growth and influences the glycosylation of proteins is not completely understood. 10942407 3 39 gly N-glycosylation 929:943 arg1 the Jk protein the Jk protein Fterm protein Transcription-translation assays revealed that the Jk(S291P) mutant was translated into a glycosylated component as efficiently as the wild-type Jk polypeptide (wt Jk)] in the presence of microsomes, thus indicating that the S291P mutation has no effect on the N-glycosylation pattern of the Jk protein. 7613162 2 37 gly glycosylation 273:285 arg2 Three potential N-linked glycosylation sites Three potential N-linked glycosylation sites sites Three potential N-linked glycosylation sites are present within the C epsilon 3 domain. 26029999 4 55 gly occupied 746:753 arg2 all eight potential N-glycosylation sites all eight potential N-glycosylation sites sites Here we analyzed the exact site(s) of N-glycosylation in CD133 by mass spectrometry and found that all eight potential N-glycosylation sites of CD133 could be indeed occupied by N-glycans. 26029999 4 46 gly N-glycosylation 699:713 arg2 all eight potential N-glycosylation sites CD133 sites PUBTATOR CD133 8842 sites Here we analyzed the exact site(s) of N-glycosylation in CD133 by mass spectrometry and found that all eight potential N-glycosylation sites of CD133 could be indeed occupied by N-glycans. 29426894 5 10 gly N-glycosylation 813:827 arg2 each N-glycosylation site each N-glycosylation site site Our data indicate a distinct and common tendency of the glycoforms exhibited at each N-glycosylation site between the native and the previously reported recombinant FcγRIII glycoproteins. 29426894 5 48 gly glycoproteins 901:913 arg1 the previously reported recombinant FcγRIII glycoproteins the previously reported recombinant FcγRIII glycoproteins PUBTATOR FcγRIII glycoproteins 2214 Our data indicate a distinct and common tendency of the glycoforms exhibited at each N-glycosylation site between the native and the previously reported recombinant FcγRIII glycoproteins. 15823038 1 54 part_of contains 263:270 arg1 a large receptor AND extensive glycosylation sites a large receptor extensive glycosylation sites Fterm Site receptor sites The low-density lipoprotein receptor-related protein (LRP) is a large receptor that contains extensive glycosylation sites and disulfide bonds. 15823038 1 54 part_of contains 263:270 arg1 The low-density lipoprotein receptor-related protein AND extensive glycosylation sites The low-density lipoprotein receptor-related protein extensive glycosylation sites Fterm Site protein sites The low-density lipoprotein receptor-related protein (LRP) is a large receptor that contains extensive glycosylation sites and disulfide bonds. 7688323 4 42 gly O-glycosylation 747:761 arg2 Ser847 Ser847 Ser847 Ser847 was identified as the O-glycosylation site. 7688323 4 42 gly O-glycosylation 747:761 arg2 the O-glycosylation site the O-glycosylation site site Ser847 was identified as the O-glycosylation site. 23263199 0 45 gly N-glycosylations 0:15 arg1 human α1,3-fucosyltransferase IX human α1,3-fucosyltransferase IX PUBTATOR fucosyltransferase IX 10690 N-glycosylations of human α1,3-fucosyltransferase IX are required for full enzyme activity. 32211339 5 12 gly N-glycosylation 788:802 arg2 the N-glycosylation sites the N-glycosylation sites sites We mutated the N-glycosylation sites either in MLD or in GCD or in both domains. 19921957 7 66 part_of glycoproteins 1463:1475 arg1 four glycopeptides glycoproteins four glycopeptides Fterm Site glycoproteins glycopeptides The standard deviation (SD) ranged from 0.06 to 0.21, for four glycopeptides from two model glycoproteins. 21439032 2 0 part_of contain 300:306 arg1 The two membrane glycoproteins AND a potential N-linked glycosylation site The two membrane glycoproteins a potential N-linked glycosylation site Fterm Site glycoproteins site The two membrane glycoproteins of JEV, prM and E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively. 22246941 2 16 gly N-glycosylation 429:443 arg2 two cysteine residues two cysteine residues cysteine residues Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)). 22246941 2 16 gly N-glycosylation 429:443 arg2 Asn(124) Asn(124) Asn(124) Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)). 22246941 2 16 gly N-glycosylation 429:443 arg2 a conserved putative N-glycosylation site a conserved putative N-glycosylation site site Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)). 20848033 5 49 gly N-glycosylation 973:987 arg2 the N-glycosylation site the N-glycosylation site site It was found that the endoglycosidase-catalyzed transglycosylation allowed efficient attachment of an intact N-glycan in a single step at the N-glycosylation site, while the recombinant human T-synthase could independently extend the O-linked GalNAc to form the core 1 O-glycan. 12706347 7 8 gly deglycosylation 1133:1147 arg1 this site this site site Enzymatic deglycosylation of this site is shown to be responsible for the inactivation of the wild-type enzyme by treatment with peptide N-glycosidase-F. 18410132 1 40 gly glycoproteins 148:160 arg1 glycoproteins glycoproteins Fterm glycoproteins Glycopeptides prepared from 1 nmol of a mixture of glycoproteins, transferrin, and ribonuclease B by lysylendopeptidase digestion were isolated by lectin and cellulose column chromatographies, and then they were analyzed by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry and MALDI-quadrupole ion trap (QIT)-TOF mass spectrometry which enables the performance of MS ( n ) analysis. 2844793 1 14 gly E1-glycoprotein 124:138 arg1 The E1-glycoprotein The E1-glycoprotein Fterm E1-glycoprotein The E1-glycoprotein (Mr = 26,014; 228 amino acids) of mouse hepatitis virus A59 is a class III membrane glycoprotein which has been used in this study as a model system in the study of membrane integration and protein transport. 2844793 1 14 gly E1-glycoprotein 124:138 arg1 a class III membrane glycoprotein a class III membrane glycoprotein Fterm glycoprotein The E1-glycoprotein (Mr = 26,014; 228 amino acids) of mouse hepatitis virus A59 is a class III membrane glycoprotein which has been used in this study as a model system in the study of membrane integration and protein transport. 2844793 1 86 gly glycoprotein 224:235 arg1 The E1-glycoprotein The E1-glycoprotein Fterm E1-glycoprotein The E1-glycoprotein (Mr = 26,014; 228 amino acids) of mouse hepatitis virus A59 is a class III membrane glycoprotein which has been used in this study as a model system in the study of membrane integration and protein transport. 2844793 1 86 gly glycoprotein 224:235 arg1 a class III membrane glycoprotein a class III membrane glycoprotein Fterm glycoprotein The E1-glycoprotein (Mr = 26,014; 228 amino acids) of mouse hepatitis virus A59 is a class III membrane glycoprotein which has been used in this study as a model system in the study of membrane integration and protein transport. 24806200 8 26 gly glycoprotein 1754:1765 arg1 human glycoprotein hormone human glycoprotein hormone Fterm glycoprotein The final assembly of the individual glycopeptide fragments involved a stepwise native chemical ligation strategy to provide the longest and most complex human glycoprotein hormone (β-hCG) as well as its closely related homologue (β-hLH) as discrete glycoforms. 24806200 8 100 gly glycopeptide 1631:1642 arg2 glycopeptide glycopeptide glycopeptide fragments The final assembly of the individual glycopeptide fragments involved a stepwise native chemical ligation strategy to provide the longest and most complex human glycoprotein hormone (β-hCG) as well as its closely related homologue (β-hLH) as discrete glycoforms. 2910856 6 3 gly glycosylation 958:970 arg2 a possible N-linked glycosylation site a possible N-linked glycosylation site site Biochemical data show that, despite the presence of a possible N-linked glycosylation site, the protein is not glycosylated. 2910856 6 55 gly glycosylated 997:1008 arg1 the protein the protein Fterm protein Biochemical data show that, despite the presence of a possible N-linked glycosylation site, the protein is not glycosylated. 21232091 7 1 part_of env 1642:1644 arg1 the env region env the env region PUBTATOR Site env 100616444 region Analyses of the env region showed positive selection (dN-dS >0), intra-host length variation and extensive amino acid diversity between clones, greater in 2009. 18340083 4 33 gly glycosylated 576:587 arg1 Human GPIHBP1 Human GPIHBP1 PUBTATOR Human GPIHBP1 338328 Human GPIHBP1 is also glycosylated. 6838832 2 25 gly Asn288-linked 296:308 arg1 a complex-type Asn288-linked oligosaccharide Asn288 a complex-type Asn288-linked oligosaccharide Asn288 A peptide isolated from plasminogen variant 1, which contains a complex-type Asn288-linked oligosaccharide, was found to possess the amino acid sequence-Ser280-Ala-Gln-Thr-Pro-His-Thr-His-Asn(CHO)-Arg-Thr290-Pro-Glu-, in agreement with the previously published sequence [Sottrup-Jensen, L., Claeys, H., Zajdel, M., Petersen, T. E., & Magnusson, S. (1978) in Progress in Chemical Fibrinolysis and Thrombolysis (Davidson, J. F., Rowan, R. M., Samama, M. M., & Desnoyers, P. C., Eds.) 32125861 1 3 gly N-glycosylation 175:189 arg1 human milk proteins human milk proteins Fterm proteins Protein N-glycosylation on human milk proteins assists in protecting an infant's health and functions among others as competitive inhibitors of pathogen binding and immunomodulators. 2721453 9 70 part_of site 1608:1611 arg1 the beta-subunit subunit site OGER Site subunit P01222 site Although great microheterogeneity is present even at the single glycosylation site on the beta-subunit of secreted TSH, a pattern of sialylation and sulfation could be discerned. 31831916 4 43 gly glycoproteins 753:765 arg1 7,000 human glycoproteins 7,000 human glycoproteins Fterm glycoproteins According to our analyses, more than 30,000 glycosite-containing peptides and 7,000 human glycoproteins have been identified from five different body fluids, twelve human tissues (or related cell lines), and four special cell types. 7510285 1 29 gly glycoprotein 192:203 arg1 the L6 antigen the L6 antigen PUBTATOR L6 antigen 4071 The murine monoclonal antibody (mAb) L6 recognizes an integral membrane glycoprotein that is highly expressed on lung, breast, colon, and ovarian carcinomas and is referred to as the L6 antigen. 7510285 1 29 gly glycoprotein 192:203 arg1 an integral membrane glycoprotein an integral membrane glycoprotein Fterm glycoprotein The murine monoclonal antibody (mAb) L6 recognizes an integral membrane glycoprotein that is highly expressed on lung, breast, colon, and ovarian carcinomas and is referred to as the L6 antigen. 18562306 3 16 gly glycopeptide 863:874 arg2 the glycopeptide transferase ppGalNAcT-10 the glycopeptide transferase ppGalNAcT-10 glycopeptide Using a set of synthetic peptides and glycopeptides based upon the sequence of the mucin, MUC5AC, we have examined the activity and glycosylation site preference of lectin domain deletion and exchange constructs of the peptide/glycopeptide transferase ppGalNAcT-2 (hT2) and the glycopeptide transferase ppGalNAcT-10 (hT10). 18562306 3 17 gly glycopeptides 623:635 arg2 glycopeptides glycopeptides peptides and glycopeptides Using a set of synthetic peptides and glycopeptides based upon the sequence of the mucin, MUC5AC, we have examined the activity and glycosylation site preference of lectin domain deletion and exchange constructs of the peptide/glycopeptide transferase ppGalNAcT-2 (hT2) and the glycopeptide transferase ppGalNAcT-10 (hT10). 18562306 3 32 gly peptide/glycopeptide 804:823 arg2 the peptide/glycopeptide transferase ppGalNAcT-2 the peptide/glycopeptide transferase ppGalNAcT-2 peptide/glycopeptide Using a set of synthetic peptides and glycopeptides based upon the sequence of the mucin, MUC5AC, we have examined the activity and glycosylation site preference of lectin domain deletion and exchange constructs of the peptide/glycopeptide transferase ppGalNAcT-2 (hT2) and the glycopeptide transferase ppGalNAcT-10 (hT10). 18562306 3 46 gly glycosylation 717:729 arg2 glycosylation site preference glycosylation site preference site Using a set of synthetic peptides and glycopeptides based upon the sequence of the mucin, MUC5AC, we have examined the activity and glycosylation site preference of lectin domain deletion and exchange constructs of the peptide/glycopeptide transferase ppGalNAcT-2 (hT2) and the glycopeptide transferase ppGalNAcT-10 (hT10). 17050611 1 6 gly Pradimicin 178:187 arg1 a low-molecular-weight (molecular weight, 838) carbohydrate binding agent Pradimicin A (PRM-A a low-molecular-weight (molecular weight, 838) carbohydrate binding agent Cterm Pradimicin A (PRM-A Pradimicin A (PRM-A), an antifungal nonpeptidic benzonaphtacenequinone antibiotic, is a low-molecular-weight (molecular weight, 838) carbohydrate binding agent (CBA) endowed with a selective inhibitory activity against human immunodeficiency virus (HIV). 1359371 2 33 part_of protein 302:308 arg1 the partial protein sequence protein the partial protein sequence Fterm Site protein sequence In this report we have examined the carbohydrates present on the protein and determined the partial protein sequence of enzymatically and CNBr-produced peptides. 12794129 1 38 part_of J 77:77 arg1 a small polypeptide J chain a small polypeptide PUBTATOR Site J chain 3512 polypeptide J chain is a small polypeptide covalently attached to polymeric IgA and IgM. 11458001 1 21 part_of protein 326:332 arg1 the major HS-binding domain protein, i the major HS-binding domain OGER Site protein, i P07355 domain To further define the major HS-binding domain of the HSV-1 attachment protein, i.e. glycoprotein C (gC), virus mutants carrying alterations of either two neighbouring basic amino acid residues or a single hydrophobic amino acid residue within the N-terminal domain of the protein (residues 26-227) were constructed. 11458001 1 80 part_of protein 528:534 arg1 the N-terminal domain protein the N-terminal domain Fterm Site protein domain To further define the major HS-binding domain of the HSV-1 attachment protein, i.e. glycoprotein C (gC), virus mutants carrying alterations of either two neighbouring basic amino acid residues or a single hydrophobic amino acid residue within the N-terminal domain of the protein (residues 26-227) were constructed. 8960909 0 40 gly N-glycosylated 3:16 arg1 An N-glycosylated tyrosinase epitope An N-glycosylated tyrosinase epitope epitope An N-glycosylated tyrosinase epitope associates with newly synthesized MHC class I molecules in melanoma cells. 32280962 2 13 part_of has 361:363 arg1 PSG1 AND seven potential N-linked glycosylation sites PSG1 seven potential N-linked glycosylation sites PUBTATOR Site PSG1 5669 sites PSG1 has seven potential N-linked glycosylation sites across its four domains. 12847262 5 62 part_of receptor 655:662 arg1 the killer cell Ig-like receptor 2 domain long tail 1 receptor 2 the killer cell Ig-like receptor 2 domain long tail 1 Fterm Site receptor 2 tail The increased binding was general, because it was observed in both the killer cell Ig-like receptor 2 domain long tail 1 and leukocyte Ig-like receptor-1. 8486380 0 7 gly glycosylation 26:38 arg2 a polymorphic glycosylation site a polymorphic glycosylation site site The loss of a polymorphic glycosylation site caused by Thr-927-->Ile is linked to a second polymorphic Val-816-->Ile substitution in lysosomal alpha-glucosidase of American blacks. 23234360 1 8 gly O-glycosylation 128:142 arg1 extracellular proteins proteins residues Fterm proteins residues The GalNAc O-glycosylation on Ser/Thr residues of extracellular proteins has not been well characterized from a proteomics perspective. 23234360 1 29 gly O-glycosylation 128:142 arg1 Ser/Thr residues residues Ser/Thr residues Site residues The GalNAc O-glycosylation on Ser/Thr residues of extracellular proteins has not been well characterized from a proteomics perspective. 23234360 1 29 gly O-glycosylation 128:142 arg1 extracellular proteins proteins residues O-glycosylation Fterm proteins residues The GalNAc O-glycosylation on Ser/Thr residues of extracellular proteins has not been well characterized from a proteomics perspective. 23234360 1 29 gly O-glycosylation 128:142 arg1 Ser/Thr residues proteins residues Ser/Thr residues Fterm Site proteins residues The GalNAc O-glycosylation on Ser/Thr residues of extracellular proteins has not been well characterized from a proteomics perspective. 23234360 1 29 gly O-glycosylation 128:142 arg1 extracellular proteins proteins O-glycosylation Fterm proteins The GalNAc O-glycosylation on Ser/Thr residues of extracellular proteins has not been well characterized from a proteomics perspective. 10731668 3 60 gly Asn 525:527 arg1 The oligosaccharide structure Asn(32 ) The oligosaccharide structure Asn(32 ) The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide. 10731668 3 66 gly fucosylated 591:601 arg1 a core fucosylated biantennary complex-type oligosaccharide a core fucosylated biantennary complex-type oligosaccharide The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide. 8573180 0 45 gly N-glycosylation 47:61 arg2 the N-glycosylation site the N-glycosylation site site Characterization of a mutant GLUT4 lacking the N-glycosylation site: studies in transfected rat adipose cells. 27048837 9 22 gly glycosylation 1088:1100 arg1 the protein the protein OGER protein can P35658 Post translational glycosylation of the protein can also be identified. 23632316 0 53 part_of sites 62:66 arg1 recombinant glycoproteins glycoproteins sites Fterm Site glycoproteins sites Mass spectrometry investigation of glycosylation on the NXS/T sites in recombinant glycoproteins. 30208353 8 87 gly glycosylation 1334:1346 arg1 protein stability protein stability Fterm protein We also obtained evidences showing that the glycosylation of ER-α at S573 by GALNT6 is essential for protein stability and nuclear localization of ER-α in breast cancer cells. 30208353 8 87 gly glycosylation 1334:1346 arg1 ER-α ER-α PUBTATOR ER-α 2099 We also obtained evidences showing that the glycosylation of ER-α at S573 by GALNT6 is essential for protein stability and nuclear localization of ER-α in breast cancer cells. 20507882 3 24 gly glycopeptides 595:607 arg2 glycopeptides glycopeptides glycopeptides Nano-liquid chromatography tandem mass spectrometry was used to identify both glycopeptides and peptides corresponding to the mucin-like and C-terminal domain of alpha-dystroglycan. 14757769 2 58 part_of sequences 306:314 arg1 secreted proteins proteins sequences Fterm Site proteins sequences Some consensus sequences in secreted proteins are not glycosylated, indicating that consensus sequences are necessary but not sufficient for glycosylation. 23758413 3 47 gly glycoprotein 460:471 arg1 a glycoprotein a glycoprotein Fterm glycoprotein It is also possible to show that a glycan seen at one site in a glycoprotein may not be present at another glycosylation site in the same glycoprotein. 23758413 3 69 gly site 517:520 arg1 a glycan site a glycan site It is also possible to show that a glycan seen at one site in a glycoprotein may not be present at another glycosylation site in the same glycoprotein. 23758413 3 87 gly glycoprotein 534:545 arg1 the same glycoprotein the same glycoprotein Fterm glycoprotein It is also possible to show that a glycan seen at one site in a glycoprotein may not be present at another glycosylation site in the same glycoprotein. 23758413 3 94 gly glycosylation 503:515 arg2 another glycosylation site another glycosylation site site It is also possible to show that a glycan seen at one site in a glycoprotein may not be present at another glycosylation site in the same glycoprotein. 23758413 3 54 gly present 484:490 arg1 another glycosylation site AND a glycan site a glycan site It is also possible to show that a glycan seen at one site in a glycoprotein may not be present at another glycosylation site in the same glycoprotein. 10725548 4 39 gly having 820:825 arg1 JHM strain AND only O-linked glycans JHM strain only O-linked glycans Fterm strain We also demonstrated that this substitution added N-linked glycans to MHV-2 M protein resulting in increment of molecular mass of MHV-2 M protein compared with JHM strain having only O-linked glycans. 2846759 4 57 part_of gH 999:1000 arg1 the gH amino acid sequences gH the gH amino acid sequences Cterm Site gH 1682472 sequences The similarity observed between the gH amino acid sequences of the two representative gammaherpesviruses is greater than that between the two human alphaherpesviruses varicella-zoster virus and herpes simplex virus. 27966990 0 44 gly N-Glycosylation 14:28 arg1 Endothelial Cell Receptor Tyrosine Kinase VEGFR-2 Endothelial Cell Receptor Tyrosine Kinase VEGFR-2 OGER VEGFR-2 P35968 Site-Specific N-Glycosylation of Endothelial Cell Receptor Tyrosine Kinase VEGFR-2. 20800224 5 5 gly N-glycosylation 706:720 arg2 the N-glycosylation site the N-glycosylation site site The NGAL sequence was confirmed by nanoLC/MS/MS following in gel and in solution trypsin digestion, and the N-glycosylation site was localized by MS/MS. 16118277 9 61 part_of residue 1506:1512 arg1 the HA glycoproteins glycoproteins residue Fterm SpecificSite glycoproteins N223 residue in Our results suggest that inclusion of the N223 residue in the HA glycoproteins of diagnostic reference viruses may facilitate the evaluation of vaccine efficacy in humans. 8620873 2 34 gly positions 555:563 arg1 6-8 6-8 positions 6 1 and 5 were also prepared as their GlcNAc-glycosylated forms at the natural N-glycosylation site NXT (positions 6-8; peptides 4 and 6). 8620873 2 34 gly positions 555:563 arg1 peptides 4 and 6 peptides 4 and 6 peptides 1 and 5 were also prepared as their GlcNAc-glycosylated forms at the natural N-glycosylation site NXT (positions 6-8; peptides 4 and 6). 8620873 2 62 gly site 545:548 arg1 their GlcNAc-glycosylated forms site their GlcNAc-glycosylated forms site 1 and 5 were also prepared as their GlcNAc-glycosylated forms at the natural N-glycosylation site NXT (positions 6-8; peptides 4 and 6). 8620873 2 87 gly N-glycosylation 529:543 arg2 the natural N-glycosylation site NXT the natural N-glycosylation site NXT site 1 and 5 were also prepared as their GlcNAc-glycosylated forms at the natural N-glycosylation site NXT (positions 6-8; peptides 4 and 6). 8620873 2 87 gly N-glycosylation 529:543 arg2 positions 6-8 positions 6-8 positions 6 1 and 5 were also prepared as their GlcNAc-glycosylated forms at the natural N-glycosylation site NXT (positions 6-8; peptides 4 and 6). 8620873 2 88 gly GlcNAc-glycosylated 488:506 arg1 their GlcNAc-glycosylated forms their GlcNAc-glycosylated forms 1 and 5 were also prepared as their GlcNAc-glycosylated forms at the natural N-glycosylation site NXT (positions 6-8; peptides 4 and 6). 24497285 7 97 gly glycosylation 1274:1286 arg2 67 independent glycosylation sites 67 independent glycosylation sites sites RESULTS: Glycoprotein enrichment identified 67 independent glycosylation sites from 24 unique proteins, a 3.9-fold increase in the number of glycosylation sites identified. 24497285 7 109 gly glycosylation 1356:1368 arg2 glycosylation sites glycosylation sites sites RESULTS: Glycoprotein enrichment identified 67 independent glycosylation sites from 24 unique proteins, a 3.9-fold increase in the number of glycosylation sites identified. 27058983 1 62 gly glycoprotein 349:360 arg1 this historic and important membrane glycoprotein this historic and important membrane glycoprotein Fterm glycoprotein The crystal structure of the dimeric membrane domain of human Band 3(1), the red cell chloride/bicarbonate anion exchanger 1 (AE1, SLC4A1), provides a structural context for over four decades of studies into this historic and important membrane glycoprotein. 9311570 1 19 part_of neuraminidase 166:178 arg1 The complete nucleotide sequences neuraminidase The complete nucleotide sequences Fterm Site neuraminidase sequences The complete nucleotide sequences of neuraminidase (NA) of two swine influenza viruses (H1N1) are presented. 11804340 6 47 part_of Itm2C 907:911 arg1 The amino acid sequence Itm2C The amino acid sequence PUBTATOR Site Itm2C 64294 sequence The amino acid sequence of Itm2C is 41 and 49% identical to those of mouse Itm2A and Itm2B, respectively. 14985108 3 35 gly glycosylated 423:434 arg1 glycosylated ONC ONC (gONC Cterm ONC (gONC We employed the Pichia pastoris expression system to produce recombinant glycosylated ONC (gONC) protein. 14715137 6 45 gly N-glycosylation 985:999 arg1 synaptotagmin 1 synaptotagmin 1 site PUBTATOR synaptotagmin 1 6857 site Our data suggest that the intravesicular N-glycosylation site of synaptotagmin 1 collaborates with its cytoplasmic C(2) domains in directing synaptotagmin 1 to synaptic vesicles via a novel N-glycosylation-dependent mechanism. 32168410 10 1 gly Deglycosylation 1132:1146 arg1 the native protein the native protein Fterm protein Deglycosylation of the native protein was achieved by repeated digestion at elevated PNGase F concentration. 23908491 5 22 part_of glycoproteins 588:600 arg1 Sequences glycoproteins Sequences Fterm glycoproteins METHODS: Sequences of HCV envelope glycoproteins from Pakistani patients infected with subtype 3a were cloned and compared with other subtype 3a sequences. 23883821 2 18 gly glycosylation 529:541 arg2 a glycosylation site a glycosylation site site In an attempt to enhance the ADCC function of SMIP-016, the chimeric version of TRU-016, SMIP-016(GV) was engineered with a modification in a glycosylation site in the Fc domain. 8163463 4 0 gly glycosylated 737:748 arg1 kainate receptor subunits kainate receptor subunits OGER subunits 2898 In this study we have shown that both AMPA receptor subunits (GluR1-4) and kainate receptor subunits (GluR6/7) are glycosylated in adult rat brain; however, the kainate receptor subunits are glycosylated to a greater extent. 8163463 4 0 gly glycosylated 737:748 arg1 GluR1-4 GluR1-4 PUBTATOR GluR1 50592 In this study we have shown that both AMPA receptor subunits (GluR1-4) and kainate receptor subunits (GluR6/7) are glycosylated in adult rat brain; however, the kainate receptor subunits are glycosylated to a greater extent. 8163463 4 0 gly glycosylated 737:748 arg1 GluR6/7 GluR6/7 PUBTATOR GluR6 54257 In this study we have shown that both AMPA receptor subunits (GluR1-4) and kainate receptor subunits (GluR6/7) are glycosylated in adult rat brain; however, the kainate receptor subunits are glycosylated to a greater extent. 8163463 4 0 gly glycosylated 737:748 arg1 both AMPA receptor subunits both AMPA receptor subunits OGER AMPA receptor subunits P19493 In this study we have shown that both AMPA receptor subunits (GluR1-4) and kainate receptor subunits (GluR6/7) are glycosylated in adult rat brain; however, the kainate receptor subunits are glycosylated to a greater extent. 8163463 4 76 gly glycosylated 813:824 arg1 the kainate receptor subunits the kainate receptor subunits OGER subunits 2898 In this study we have shown that both AMPA receptor subunits (GluR1-4) and kainate receptor subunits (GluR6/7) are glycosylated in adult rat brain; however, the kainate receptor subunits are glycosylated to a greater extent. 10471296 3 3 part_of factor 438:443 arg1 the factor V C2 domain factor V C2 the factor V C2 domain OGER Site factor V C2 P12259 domain However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells. 10471296 3 44 part_of V 445:445 arg1 the factor V C2 domain factor V C2 the factor V C2 domain OGER Site factor V C2 P12259 domain However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells. 10471296 3 91 part_of C2 447:448 arg1 the factor V C2 domain factor V C2 the factor V C2 domain OGER Site factor V C2 P12259 domain However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells. 10471296 3 85 part_of contains 464:471 arg1 the factor V C2 domain AND a single potential glycosylation site the factor V C2 domain a single potential glycosylation site site However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells. 18642129 6 7 gly non-fucosylated 976:990 arg1 diantennary, disialylated non-fucosylated (A2S2) glycans diantennary, disialylated non-fucosylated (A2S2) glycans A MALDI-MS analysis of the native protein indicated that FVII is a 50.1 kDa glycoprotein modified on two sites by diantennary, disialylated non-fucosylated (A2S2) glycans. 18642129 6 30 gly glycoprotein 912:923 arg1 a 50.1 kDa glycoprotein a 50.1 kDa glycoprotein Fterm glycoprotein A MALDI-MS analysis of the native protein indicated that FVII is a 50.1 kDa glycoprotein modified on two sites by diantennary, disialylated non-fucosylated (A2S2) glycans. 18642129 6 30 gly glycoprotein 912:923 arg1 FVII FVII OGER FVII P08709 A MALDI-MS analysis of the native protein indicated that FVII is a 50.1 kDa glycoprotein modified on two sites by diantennary, disialylated non-fucosylated (A2S2) glycans. 18642129 6 62 gly disialylated 963:974 arg1 diantennary, disialylated non-fucosylated (A2S2) glycans diantennary, disialylated non-fucosylated (A2S2) glycans A MALDI-MS analysis of the native protein indicated that FVII is a 50.1 kDa glycoprotein modified on two sites by diantennary, disialylated non-fucosylated (A2S2) glycans. 10698685 5 9 gly glycosylation 767:779 arg2 one consensus glycosylation site one consensus glycosylation site site HFARP has a highly hydrophobic region at the N-terminus that is typical of a secretory signal sequence and one consensus glycosylation site. 12356334 8 8 gly glycosylation 1498:1510 arg2 another N-linked glycosylation site site, Asn311-Ser-Ser313 site, Asn311-Ser-Ser313 In addition, we also confirmed that both SP-B variants contain another N-linked glycosylation site, Asn311-Ser-Ser313. 27489265 1 32 gly glycoprotein 144:155 arg1 Env Env PUBTATOR Env 155971 The envelope glycoprotein (Env) is the major target for HIV-1 broadly neutralizing antibodies (bNAbs). 27489265 1 32 gly glycoprotein 144:155 arg1 The envelope glycoprotein The envelope glycoprotein PUBTATOR envelope glycoprotein 155971 The envelope glycoprotein (Env) is the major target for HIV-1 broadly neutralizing antibodies (bNAbs). 23004563 1 58 gly glycopeptide 256:267 arg2 glycopeptide quantification glycopeptide quantification glycopeptide Site-specific characterization of glycoform heterogeneity currently requires glycan structure assignment and glycopeptide quantification in two independent experiments. 29109276 6 84 gly glycosylation 1043:1055 arg2 the glycosylation site the glycosylation site site Importantly, antibodies elicited in ferrets infected with the current circulating H3N2 viral strain (that possesses the glycosylation site) and humans vaccinated with baculovirus-expressed H3 antigens (that possess the glycosylation site motif) were able to efficiently recognize a glycosylated clade 3C.2a H3N2 virus. 29109276 6 8 gly glycosylation 1142:1154 arg2 the glycosylation site motif site motif site motif Importantly, antibodies elicited in ferrets infected with the current circulating H3N2 viral strain (that possesses the glycosylation site) and humans vaccinated with baculovirus-expressed H3 antigens (that possess the glycosylation site motif) were able to efficiently recognize a glycosylated clade 3C.2a H3N2 virus. 26022737 5 19 part_of N 735:735 arg1 PSA amino acid sequence N PSA amino acid sequence PUBTATOR Site N 354 sequence Among single nucleotide polymorphisms (SNPs) of KLKs families, the rs61752561 in KLK3 genes is an unusual missense mutation resulting in the conversion of D102 to N in PSA amino acid sequence. 26022737 5 75 part_of PSA 740:742 arg1 PSA amino acid sequence PSA PSA amino acid sequence PUBTATOR Site PSA P07288 sequence Among single nucleotide polymorphisms (SNPs) of KLKs families, the rs61752561 in KLK3 genes is an unusual missense mutation resulting in the conversion of D102 to N in PSA amino acid sequence. 11063734 5 13 gly glycosylation 683:695 arg2 -linked glycosylation site SP-B site PUBTATOR SP-B 6439 site Of the two SP-B polymorphisms genotyped, the Ile131Thr variation affects a putative N-terminal N:-linked glycosylation site of proSP-B and the length variation of intron 4 has previously been suggested to associate with RDS. 16927286 8 29 gly O-glycosylation 1261:1275 arg2 predicted O-glycosylation site changes predicted O-glycosylation site changes site RSV B sequences displayed more variability in stop codon usage and predicted protein length, and had a higher degree of predicted O-glycosylation site changes than RSV A. 9884403 4 29 gly contains 876:883 arg1 Glycosylation site Asn489 AND tri-charged oligosaccharides Glycosylation site Asn489 tri-charged oligosaccharides Asn489 Glycosylation site Asn489 contains mainly di- and tri-charged oligosaccharides which comprise, among others, the GalNAc4 S (beta1-4)GlcNAc terminal sequence. 9884403 4 29 gly contains 876:883 arg1 Glycosylation site Asn489 AND di- Glycosylation site Asn489 di- Asn489 Glycosylation site Asn489 contains mainly di- and tri-charged oligosaccharides which comprise, among others, the GalNAc4 S (beta1-4)GlcNAc terminal sequence. 9155874 6 6 gly glycosylated 1144:1155 arg2 residue 246 residue 246 residue 246 Evidence is presented that residue 246 is not in fact glycosylated in Phil82/BS HA, nor presumably in the parent Phil82 virus. 1385399 2 22 gly N-glycosylation 386:400 arg2 Asn65 Asn65 Asn65 Two domains comprise the CD2 extracellular segment, with all adhesion functions localized to the amino-terminal domain that contains a single N-glycosylation site at Asn65. 1385399 2 22 gly N-glycosylation 386:400 arg2 a single N-glycosylation site a single N-glycosylation site site Two domains comprise the CD2 extracellular segment, with all adhesion functions localized to the amino-terminal domain that contains a single N-glycosylation site at Asn65. 11333905 0 25 part_of CD4-induced 86:96 arg1 a CD4-induced epitope CD4 a CD4-induced epitope PUBTATOR Site CD4 920 epitope Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. 10413093 0 46 part_of gp120 46:50 arg1 the V3 region gp120 the V3 region PUBTATOR Site gp120 155971 region The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant. 18952059 6 29 gly glycosylation 755:767 arg1 IZUMO IZUMO PUBTATOR IZUMO 73456 These data suggest that glycosylation is not essential for the function of IZUMO, but has a role in protecting it from fragmentation in cauda epididymis. 23720719 0 36 gly glycoprotein 226:237 arg1 envelope glycoprotein envelope glycoprotein Fterm glycoprotein Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoprotein. 20943674 9 97 gly glycosylation 1438:1450 arg2 Asn624 Asn624 Asn624 The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF. 20943674 9 97 gly glycosylation 1438:1450 arg2 The third putative glycosylation site The third putative glycosylation site site The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF. 20943674 9 68 gly unglycosylated 1472:1485 arg1 The third putative glycosylation site site site The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF. 20943674 9 68 gly unglycosylated 1472:1485 arg1 rhLF rhLF site OGER rhLF P02788 site The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF. 20943674 9 68 gly unglycosylated 1472:1485 arg1 hLF hLF site PUBTATOR hLF 3131 site The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF. 20943674 9 68 gly unglycosylated 1472:1485 arg1 rhLF rhLF site OGER rhLF P02788 site The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF. 20943674 9 68 gly unglycosylated 1472:1485 arg1 hLF hLF site PUBTATOR hLF 3131 site The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF. 15183061 4 12 gly N-glycosylated 563:576 arg1 non-N-glycosylated or N-glycosylated CXCR4 non-N-glycosylated or N-glycosylated CXCR4 PUBTATOR N-glycosylated CXCR4 7852 Similar results were observed in binding studies using non-N-glycosylated or N-glycosylated CXCR4 expressed on cells. 15183061 4 69 gly non-N-glycosylated 541:558 arg1 non-N-glycosylated or N-glycosylated CXCR4 non-N-glycosylated or N-glycosylated CXCR4 PUBTATOR N-glycosylated CXCR4 7852 Similar results were observed in binding studies using non-N-glycosylated or N-glycosylated CXCR4 expressed on cells. 20208072 5 30 part_of GRP78 1026:1030 arg1 the putative O-linked glycosylation site Thr(648) GRP78 the putative O-linked glycosylation site Thr(648) PUBTATOR SpecificSite GRP78 3309 site Thr(648) Moreover, deletion of the C-terminal ER retention motif in GRP78 alters its cell surface presentation in a dose-dependent manner; however, mutation of the putative O-linked glycosylation site Thr(648) of human GRP78 is without effect. 20208072 5 31 part_of motif 866:870 arg1 GRP78 GRP78 motif PUBTATOR Site GRP78 3309 motif Moreover, deletion of the C-terminal ER retention motif in GRP78 alters its cell surface presentation in a dose-dependent manner; however, mutation of the putative O-linked glycosylation site Thr(648) of human GRP78 is without effect. 12356334 10 81 gly glycosylation 1810:1822 arg1 residue Asn129 residue Asn129 residue Asn129 Further, we speculate that, given the fact that this SNP is found frequently in the general population, N-linked glycosylation at residue Asn129 interferes with SP-B processing, secretion and folding under certain disease conditions. 28770921 9 57 gly N-glycosylation 1427:1441 arg2 a potential N-glycosylation site a potential N-glycosylation site site Furthermore, we identified a potential N-glycosylation site of GiENO which suggests a possible explanation for the parasite cell surface localization or host mucin oligosaccharide adhesion mechanism. 7613486 2 37 gly glycosylation 344:356 arg2 each individual glycosylation site each individual glycosylation site site However, the relative role of each individual glycosylation site has not been elucidated. 31325506 6 11 gly fucosylated 1385:1395 arg1 two sulfated glycans two sulfated glycans Of these, ten glycans (77.2%), including two sulfated glycans (8.0%), were core fucosylated, which confer unique biological functions to glycoproteins. 31325506 6 11 gly fucosylated 1385:1395 arg1 ten glycans ten glycans Of these, ten glycans (77.2%), including two sulfated glycans (8.0%), were core fucosylated, which confer unique biological functions to glycoproteins. 31325506 6 11 gly fucosylated 1385:1395 arg1 77.2% 77.2% Of these, ten glycans (77.2%), including two sulfated glycans (8.0%), were core fucosylated, which confer unique biological functions to glycoproteins. 31325506 6 29 gly glycoproteins 1442:1454 arg1 glycoproteins glycoproteins Fterm glycoproteins Of these, ten glycans (77.2%), including two sulfated glycans (8.0%), were core fucosylated, which confer unique biological functions to glycoproteins. 10828967 4 7 gly N-glycosylation 668:682 arg2 all four potential N-glycosylation sites all four potential N-glycosylation sites sites The results revealed that all four potential N-glycosylation sites in the PTH/PTHrP receptor are glycosylated. 10828967 4 33 gly glycosylated 720:731 arg1 all four potential N-glycosylation sites all four potential N-glycosylation sites sites The results revealed that all four potential N-glycosylation sites in the PTH/PTHrP receptor are glycosylated. 12901863 3 10 gly glycosylated 455:466 arg1 The human ABCC6 The human ABCC6 PUBTATOR ABCC6 368 The human ABCC6 in MDCKII cells was found to be glycosylated, in contrast to the underglycosylated form of the protein, as expressed in Sf9 cells. 12901863 3 52 gly underglycosylated 488:504 arg1 the protein form of the protein Fterm form of the protein The human ABCC6 in MDCKII cells was found to be glycosylated, in contrast to the underglycosylated form of the protein, as expressed in Sf9 cells. 9581553 8 17 gly N-glycosylation 1376:1390 arg2 each additional N-glycosylation site each additional N-glycosylation site site In both the proteins, the inclusion of each additional N-glycosylation site partly contributed to restoration of cell surface [3H]folic acid binding and receptor-mediated folate transport. 26957414 11 9 gly glycopeptides 1317:1329 arg2 glycopeptides glycopeptides glycopeptides Y1 ions of glycopeptides in tryptic digests of samples were detected. 12087059 3 5 gly nonglycosylated 663:677 arg1 N30D-Edg-1 N30D-Edg-1 PUBTATOR Edg-1 1901 We found for the first time that Edg-1 is glycosylated in its amino-terminal extracellular portion, and further identified the specific glycosylation site as asparagine 30 by creating a nonglycosylated mutant of Edg-1 (N30D-Edg-1) and transfecting it into cell lines. 12087059 3 13 gly glycosylated 519:530 arg1 Edg-1 Edg-1 PUBTATOR Edg-1 1901 We found for the first time that Edg-1 is glycosylated in its amino-terminal extracellular portion, and further identified the specific glycosylation site as asparagine 30 by creating a nonglycosylated mutant of Edg-1 (N30D-Edg-1) and transfecting it into cell lines. 12087059 3 17 gly glycosylation 613:625 arg2 the specific glycosylation site the specific glycosylation site site We found for the first time that Edg-1 is glycosylated in its amino-terminal extracellular portion, and further identified the specific glycosylation site as asparagine 30 by creating a nonglycosylated mutant of Edg-1 (N30D-Edg-1) and transfecting it into cell lines. 16253890 0 43 gly gp120 25:29 arg1 the glycans gp120 the glycans PUBTATOR gp120 3700 Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV. 12901863 4 5 gly glycosylation 585:597 arg2 the major glycosylation site the major glycosylation site site In order to localize the major glycosylation site(s) in ABCC6, we applied limited proteolysis on the fully glycosylated and underglycosylated forms, followed by immunodetection with region-specific antibodies for ABCC6. 9616152 6 49 gly observed 921:928 arg1 the plasma protein AND only complex structures the plasma protein only complex structures Fterm protein Oligomannose structures were found on the Asn 155 site of the transgenic protein, whereas only complex structures were observed on the plasma protein. 9616152 6 57 gly found 831:835 arg1 the transgenic protein AND Oligomannose structures protein Asn 155 site Oligomannose structures Fterm protein Asn 155 site Oligomannose structures were found on the Asn 155 site of the transgenic protein, whereas only complex structures were observed on the plasma protein. 18077336 5 17 part_of MRAP 573:576 arg1 C-terminal MRAP peptides MRAP C-terminal MRAP peptides PUBTATOR Site MRAP Q8TCY5 peptides Using antibodies raised against N- and C-terminal MRAP peptides, we demonstrated that both ends of endogenous MRAP face the outside in adrenal cells. 10497235 5 17 part_of triadin 688:694 arg1 the unique C terminus triadin the unique C terminus OGER Site triadin Q13061 terminus From deduced primary structures, antibodies against domains common to all triadins and an antibody against the unique C terminus of triadin 1 were raised. 9472921 12 31 gly glycosylation 1448:1460 arg2 a single putative N-linked glycosylation site a single putative N-linked glycosylation site site Mouse PLP-A contained a single putative N-linked glycosylation site and consisted of a single 29-kDa protein species, whereas rat PLP-A contained two putative N-linked glycosylation sites and consisted of two protein species, of 29 and 33 kDa. 9472921 12 55 gly glycosylation 1567:1579 arg2 two putative N-linked glycosylation sites two putative N-linked glycosylation sites sites Mouse PLP-A contained a single putative N-linked glycosylation site and consisted of a single 29-kDa protein species, whereas rat PLP-A contained two putative N-linked glycosylation sites and consisted of two protein species, of 29 and 33 kDa. 9342662 3 89 gly glycosylation 640:652 arg1 the protein the protein Fterm protein The combination of the high resolution and low solvent consumption of CE and the ultrasensitive detection and precise identification properties of mass spectrometry led to a complete glycosylation analysis of the protein. 8244420 5 57 gly glycosylation 574:586 arg2 an asparagine-linked glycosylation site an asparagine-linked glycosylation site site The deduced amino acid sequence of VL contains an asparagine-linked glycosylation site in framework 3 (N74 I75 S76). 8244420 5 66 gly contains 544:551 arg1 I75 I75 N74-I75 The deduced amino acid sequence of VL contains an asparagine-linked glycosylation site in framework 3 (N74 I75 S76). 10099230 4 63 gly glycoprotein 1088:1099 arg1 glycoprotein forms glycoprotein forms Fterm glycoprotein In the absence of glutamine, cells secreted glycoprotein forms with preponderantly biantennary, proximal fucosylated carbohydrate chains (85%) with a higher NeuAc content (58%). 10099230 4 128 gly fucosylated 1149:1159 arg1 preponderantly biantennary, proximal fucosylated carbohydrate chains preponderantly biantennary, proximal fucosylated carbohydrate chains In the absence of glutamine, cells secreted glycoprotein forms with preponderantly biantennary, proximal fucosylated carbohydrate chains (85%) with a higher NeuAc content (58%). 2143269 6 51 part_of Fc 560:561 arg1 the native human Fc fragment Fc the native human Fc fragment Cterm Site Fc fragment The recombinant protein, which presumably lacks oligosaccharides, was used along with the native human Fc fragment obtained by proteolytic digestion of a myeloma IgG1 protein. 23023102 8 29 gly site 1198:1201 arg1 The dominant determinant site The dominant determinant site The dominant determinant of resistance was the absence of a potential N-linked glycosylation site (PNGS) at the V5 N-terminus (P < 0.001), with the V2 loop length possibly influencing the degree of resistance afforded by the absence of the V5 N-terminal PNGS (P = 0.001). 23023102 8 64 gly glycosylation 1184:1196 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site The dominant determinant of resistance was the absence of a potential N-linked glycosylation site (PNGS) at the V5 N-terminus (P < 0.001), with the V2 loop length possibly influencing the degree of resistance afforded by the absence of the V5 N-terminal PNGS (P = 0.001). 12626422 4 64 gly glycosylated 757:768 arg1 alpha1-antitrypsin alpha1-antitrypsin PUBTATOR alpha1-antitrypsin 5265 Human plasma alpha1-antitrypsin is normally fully glycosylated at three asparagine residues (46, 83, and 247), but un-, mono-, di-, and fully glycosylated forms of alpha1-antitrypsin were detected by 2D PAGE in the plasma from patients with CDG-I. 12626422 4 44 gly residues 698:705 arg1 247 asparagine residues (46, 83, and 247) asparagine residues (46, 83, and 247) Human plasma alpha1-antitrypsin is normally fully glycosylated at three asparagine residues (46, 83, and 247), but un-, mono-, di-, and fully glycosylated forms of alpha1-antitrypsin were detected by 2D PAGE in the plasma from patients with CDG-I. 12626422 4 70 gly glycosylated 665:676 arg2 three asparagine residues alpha1-antitrypsin asparagine residues (46, 83, and 247) PUBTATOR alpha1-antitrypsin 5265 asparagine residues (46, 83, and 247) Human plasma alpha1-antitrypsin is normally fully glycosylated at three asparagine residues (46, 83, and 247), but un-, mono-, di-, and fully glycosylated forms of alpha1-antitrypsin were detected by 2D PAGE in the plasma from patients with CDG-I. 19248770 4 23 part_of mIL-31 567:572 arg1 the signal sequence mIL-31 the signal sequence PUBTATOR Site mIL-31 76399 sequence Introduction of the signal sequence from mIL-31 to human p53 protein failed to secrete the products, but further addition of the N-glycosylation site resulted in constitutive secretion of biologically active p53 protein into the medium in the N-glycosylated form. 8837707 3 18 gly N-glycosylated 436:449 arg1 an N-glycosylated asparagine an N-glycosylated asparagine asparagine One, 1788A-->G, results in the loss of an N-glycosylated asparagine in the protein, and the second, 2723A-->G, removes the polyadenylation signal site of the mRNA. 15649361 6 5 gly N-glycosylation 669:683 arg2 an N-glycosylation site an N-glycosylation site site Insertion of an N-glycosylation site present in several related TGFbeta proteins increases the stability of mature Nodal. 2113054 1 81 part_of receptor 287:294 arg1 four Ig-like domains receptor four Ig-like domains Fterm Site receptor domains The CD4 cell surface antigen is of interest as a marker of T lymphocytes that recognize foreign antigens in the context of MHC Class II antigen, as a receptor for the human immunodeficiency virus (HIV) and as a member of the immunoglobulin superfamily (IgSF) with four Ig-like domains present in the extracellular domain. 9616152 6 20 part_of protein 875:881 arg1 the Asn 155 site protein the Asn 155 site Fterm SpecificSite protein Asn 155 site Oligomannose structures were found on the Asn 155 site of the transgenic protein, whereas only complex structures were observed on the plasma protein. 28419665 5 10 gly N-glycosylation 791:805 arg2 an N-glycosylation site an N-glycosylation site site The wild-type dimer (E1E2) and a variant without an N-glycosylation site in the E2 polypeptide (E1E2∆N6) were expressed, and appropriate N-glycosylation pattern and functionality of the E1E2 dimers were demonstrated. 28419665 5 31 gly N-glycosylation 876:890 arg1 the E1E2 dimers the E1E2 dimers Fterm dimers The wild-type dimer (E1E2) and a variant without an N-glycosylation site in the E2 polypeptide (E1E2∆N6) were expressed, and appropriate N-glycosylation pattern and functionality of the E1E2 dimers were demonstrated. 2162043 9 63 part_of receptor-binding 1773:1788 arg1 the receptor-binding site receptor-binding the receptor-binding site Fterm Site receptor-binding site We conclude that the beta inhibitors in bovine and mouse sera are mannose-binding lectins that inhibit hemagglutination and neutralize virus infectivity by binding to carbohydrate at the tip of the HA spike, blocking access of cell-surface receptors to the receptor-binding site on HA. 22266649 1 17 gly glycosylation 86:98 arg1 proteins proteins Fterm proteins The role of glycosylation of proteins on its binding affinity is not well understood. 27377235 5 12 gly Glycosylation 887:899 arg1 Kv1.2 Kv1.2 Cterm Kv1.2 Glycosylation of Kv1.2 is important with respect to facilitating trafficking to the cell membrane and enhancing the stability of channels that have reached the cell membrane. 26256267 7 27 gly glycoproteins 1095:1107 arg1 the glycoproteins the glycoproteins Fterm glycoproteins To analyze the glycoproteins, glycosite-containing peptides were isolated from the same iTRAQ-labeled peptides from the cell lines using solid phase extraction followed by LC-MS/MS analysis. 8964581 1 45 gly N-glycosylation 199:213 arg2 one putative N-glycosylation site one putative N-glycosylation site site Corticotropin-releasing hormone-binding protein (CRFBP) is a 37-kD protein of 322 amino acids, containing one putative N-glycosylation site and 11 cysteines, 10 of which remain in the mature molecule (298 amino acids) and result essential for the action. 10536368 4 77 gly glycosylation 560:572 arg2 the three glycosylation sites the three glycosylation sites sites Deletion of any of the three glycosylation sites in the TNFR portion of the molecule, alone or in combination, resulted in a moderate or near total blockade of TNFR-IgG1 intracellular transport and secretion. 12940452 2 50 gly N-glycosylation 325:339 arg2 two N-glycosylation sites two N-glycosylation sites sites The alpha-subunit has two N-glycosylation sites at Asn52 and Asn78. 27007620 7 95 gly glycosylation 1298:1310 arg2 glycosylation site specificity glycosylation site specificity site In this concise review, the rationale for glycoprotein and glycosylation site specificity is developed in the context of human disease glycoproteomics with an emphasis on N-glycosylation. 27007620 7 99 gly glycoprotein 1281:1292 arg1 glycoprotein glycoprotein Fterm glycoprotein In this concise review, the rationale for glycoprotein and glycosylation site specificity is developed in the context of human disease glycoproteomics with an emphasis on N-glycosylation. 8157687 4 85 gly glycoprotein 1018:1029 arg1 the C3-derived glycoprotein iC3b the C3-derived glycoprotein iC3b Fterm glycoprotein Second, the binding to the C3-derived glycoprotein iC3b appears to be exclusively mediated through the Man8 or Man9 oligosaccharide on the alpha chain; there is no evidence for other N-linked oligosaccharides on C3 that are uniquely bound by conglutinin. 22119577 5 21 part_of protein 1185:1191 arg1 separate functional domains protein separate functional domains Fterm Site protein domains Similar to the human counterpart, the sea bass TPN gene comprises 8 exons, some of which correspond to separate functional domains of the protein. 2745457 0 79 gly glycosylated 36:47 arg1 a glycosylated form form of beta nerve growth factor PUBTATOR form of beta nerve growth factor 18049 Isolation and characterization of a glycosylated form of beta nerve growth factor in mouse submandibular glands. 15039521 0 51 gly glycosylation 20:32 arg2 a glycosylation site a glycosylation site site Identification of a glycosylation site in the woodchuck hepatitis virus preS2 protein and its role in protein trafficking. 24799124 1 18 gly ceruloplasmin 212:224 arg1 core-fucosylation ceruloplasmin core-fucosylation PUBTATOR ceruloplasmin 1356 A mass spectrometry-based methodology has been developed to study changes in core-fucosylation of serum ceruloplasmin that are site-specific between cirrhosis and hepatocellular carcinoma (HCC). 24799124 1 48 gly core-fucosylation 185:201 arg1 serum ceruloplasmin serum ceruloplasmin PUBTATOR ceruloplasmin 1356 A mass spectrometry-based methodology has been developed to study changes in core-fucosylation of serum ceruloplasmin that are site-specific between cirrhosis and hepatocellular carcinoma (HCC). 20335223 5 9 part_of VWF 837:839 arg1 the VWF propeptide D2 domain VWF the VWF propeptide D2 domain PUBTATOR Site VWF 7450 domain We identified an N528S homozygous mutation in the VWF propeptide D2 domain, predicting the introduction of an additional N-glycosylation site at amino acid 526 in close vicinity to a "CGLC" disulphide isomerase consensus sequence. 20335223 5 35 part_of isomerase 988:996 arg1 a "CGLC" disulphide isomerase consensus sequence isomerase a "CGLC" disulphide isomerase consensus sequence Fterm Site isomerase sequence We identified an N528S homozygous mutation in the VWF propeptide D2 domain, predicting the introduction of an additional N-glycosylation site at amino acid 526 in close vicinity to a "CGLC" disulphide isomerase consensus sequence. 20573953 4 10 part_of FN1 864:866 arg1 the FN1 residues FN1 the FN1 residues PUBTATOR Site FN1 2335 residues Unexpectedly, the structure reveals that the sites of Ig5 polysialylation are on the opposite face from the FN1 residues previously found to be critical for N-glycan polysialylation, suggesting that the Ig5-FN1 domain relationship may be flexible and/or that there is flexibility in the placement of Ig5 glycosylation sites for polysialylation. 9848675 1 30 gly glycopeptides 289:301 arg2 complex glycopeptides complex glycopeptides glycopeptides and nonglycopeptide An evaluation of capillary zone electrophoresis-mass spectrometry (CZE-MS) as an analytical methodology for the separation and characterization of complex glycopeptides and nonglycopeptide structures has been performed. 9848675 1 53 gly nonglycopeptide 307:321 arg2 nonglycopeptide nonglycopeptide glycopeptides and nonglycopeptide An evaluation of capillary zone electrophoresis-mass spectrometry (CZE-MS) as an analytical methodology for the separation and characterization of complex glycopeptides and nonglycopeptide structures has been performed. 16289048 7 89 part_of contains 1141:1148 arg1 cat myocilin AND a functional signal peptide sequence cat myocilin a functional signal peptide sequence PUBTATOR Site myocilin 4653 sequence Expression in a transformed human trabecular cell line or in Crandall feline kidney cells showed cat myocilin was secreted from these cells, similar to human myocilin, suggesting cat myocilin contains a functional signal peptide sequence. 7532677 9 115 gly glycosylation 1716:1728 arg2 the single site the single site site Asparagine 86, the single site of N-linked glycosylation on class I molecules, is in close proximity to the Bw4/Bw6 region. 7532677 9 115 gly glycosylation 1716:1728 arg2 Asparagine 86 Asparagine 86 Asparagine 86 Asparagine 86, the single site of N-linked glycosylation on class I molecules, is in close proximity to the Bw4/Bw6 region. 23775758 4 29 gly O-glycosylation 822:836 arg2 a potential O-glycosylation site a potential O-glycosylation site site An amino acid substitution was found in a potential O-glycosylation site leading to a loss of reactivity with a strain-specific MAb. 24798328 0 81 gly O-glycosylated 53:66 arg1 Low density lipoprotein receptor class A repeats regions Low density lipoprotein receptor class A repeats regions Low density lipoprotein receptor class A repeats are O-glycosylated in linker regions. 1885605 7 15 gly glycosylation 965:977 arg2 a single potential N-linked glycosylation site a single potential N-linked glycosylation site site The encoded protein included a 33-residue N-terminal signal sequence for secretion and a single potential N-linked glycosylation site. 28928219 8 85 part_of protein 1714:1720 arg1 a disordered region protein a disordered region Fterm Site protein region These results offer an unprecedented view of how a glycan modification influences a disordered region of a full-length protein. 12739007 7 46 part_of receptors 1026:1034 arg1 the N-terminal six-cysteine domain receptors the N-terminal six-cysteine domain Fterm AminoAcid receptors cysteine domain Human MGC9753 and mouse Mgc9753 proteins were 320-amino-acid seven-transmembrane receptors with the N-terminal six-cysteine domain and an N-glycosylation site (85.0% total-amino-acid identity). 12739007 7 46 part_of receptors 1026:1034 arg1 an N-glycosylation site receptors an N-glycosylation site Fterm Site receptors site Human MGC9753 and mouse Mgc9753 proteins were 320-amino-acid seven-transmembrane receptors with the N-terminal six-cysteine domain and an N-glycosylation site (85.0% total-amino-acid identity). 11122377 9 21 gly N-glycosylation 1265:1279 arg2 A single N-glycosylation site A single N-glycosylation site site A single N-glycosylation site is predicted, and shown to be utilized. 11122377 9 63 gly utilized 1316:1323 arg2 A single N-glycosylation site A single N-glycosylation site site A single N-glycosylation site is predicted, and shown to be utilized. 1402395 6 14 part_of containing 753:762 arg1 a 70 kDa glycoprotein AND four domains a 70 kDa glycoprotein four domains Fterm Site glycoprotein domains Prosaposin is a 70 kDa glycoprotein containing four domains, one for each saposin, placed in tandem. 1402395 6 14 part_of containing 753:762 arg1 Prosaposin AND four domains Prosaposin four domains PUBTATOR Site Prosaposin 5660 domains Prosaposin is a 70 kDa glycoprotein containing four domains, one for each saposin, placed in tandem. 19515763 2 15 gly glycosylation 483:495 arg2 N-linked glycosylation site N-linked glycosylation site site We studied the reversion of the Env CTL escape mutant virus to the wild type and the relationship between the reversion of CTL mutations with N-linked glycosylation site (NLGS)-driven NAb escape in pigtailed macaques. 19515763 2 21 gly -driven 508:514 arg1 N-linked glycosylation site N-linked glycosylation site site We studied the reversion of the Env CTL escape mutant virus to the wild type and the relationship between the reversion of CTL mutations with N-linked glycosylation site (NLGS)-driven NAb escape in pigtailed macaques. 2310304 6 5 gly glycosylation 1043:1055 arg2 a potential glycosylation site a potential glycosylation site site The haemagglutinin genes of the viruses were sequenced and changes were detected indicating amino acid substitutions at position 196-198 in the attenuated egg-grown virus D whereby a potential glycosylation site present in the other viruses was lost. 16360109 3 100 gly N-glycosylation 475:489 arg2 an N-glycosylation site an N-glycosylation site site Oligosaccharide structures in a humanized anti-Abeta IgG1 monoclonal antibody (Mab) with an N-glycosylation site in the complementary determining region (CDR2) of the heavy chain variable region were elucidated by LC/MS analysis following sequential exoglycosidase treatments of the endoproteinase Lys-C digest. 25389233 9 74 gly IgG 1438:1440 arg1 the glycan IgG the glycan Cterm IgG We studied associations of the glycan of complexed IgG and disease activity according to the physician's global assessment of disease activity and the systemic lupus erythematosus disease activity index 2000 documented at the moment of blood taking. 21303814 5 38 part_of proteins 1332:1339 arg1 the C-terminal tail proteins the C-terminal tail Fterm Site proteins tail In oocyte and HEK cell expression systems, affinity tag-driven C-terminal N-glycosylation may facilitate the determination of orientation of the C-terminal tail of membrane proteins relative to the membrane. 27023253 12 67 gly glycosylation 1951:1963 arg2 glycosylation motifs glycosylation motifs motifs Peptide deamidation is minimized in the protocol, limiting non-specific deamidation detected at glycosylation motifs. 27480168 2 9 gly glycosylated 387:398 arg2 48 hENT1 Asn(48) OGER hENT1 Q99808 Asn(48) Previous work, and in silico prediction, suggest that hENT1 is glycosylated at Asn(48) in the first extracellular loop of the protein and that glycosylation plays a role in correct localization and function of hENT1. 27480168 2 9 gly glycosylated 387:398 arg2 Asn hENT1 Asn(48) OGER hENT1 Q99808 Asn(48) Previous work, and in silico prediction, suggest that hENT1 is glycosylated at Asn(48) in the first extracellular loop of the protein and that glycosylation plays a role in correct localization and function of hENT1. 27480168 2 9 gly glycosylated 387:398 arg2 Asn Asn(48) Asn(48) Previous work, and in silico prediction, suggest that hENT1 is glycosylated at Asn(48) in the first extracellular loop of the protein and that glycosylation plays a role in correct localization and function of hENT1. 27612916 8 112 part_of motifs 1688:1693 arg1 the other UGT2B enzymes UGT2B enzymes motifs Cterm Site UGT2B enzymes P78381 motifs A systematic survey of the Short Genetic Variations database uncovered 32 rare, naturally occurring missense variations predicted to create or disrupt N-glycosylation sequence motifs in the other UGT2B enzymes. 17956937 5 6 gly glycopeptides 1110:1122 arg2 the glycopeptides the glycopeptides glycopeptides They were mostly sialylated, and a considerable sialic acid fraction was alpha2,3-linked as determined by Streptococcus pneumoniae neuraminidase digestion of the glycopeptides. 9792708 0 61 gly O-glycosylation 28:42 arg1 the mouse hepatitis virus membrane protein the mouse hepatitis virus membrane protein Fterm protein Structural requirements for O-glycosylation of the mouse hepatitis virus membrane protein. 15353267 3 43 part_of T17 396:398 arg1 The T17 cDNA fragment T17 cDNA The T17 cDNA fragment Cterm Site T17 cDNA fragment The T17 cDNA fragment was used as a probe to screen the human testis cDNA-lambda gt10 library. 15353267 3 107 part_of cDNA 400:403 arg1 The T17 cDNA fragment T17 cDNA The T17 cDNA fragment Cterm Site T17 cDNA fragment The T17 cDNA fragment was used as a probe to screen the human testis cDNA-lambda gt10 library. 31501225 7 68 gly glycopeptides 1163:1175 arg2 the two glycopeptides IgA2 glycopeptides OGER IgA2 P01877 glycopeptides In contrast, the two glycopeptides of IgA2 fell back down in HBV-related HCC patients. 32110292 6 18 gly N-glycopeptides 1246:1260 arg2 N-glycopeptides N-glycopeptides N-glycopeptides We report here a chemical labeling strategy to improve the electron transfer dissociation efficiency in mass spectrometry analysis, which enables a 100% peptide sequence coverage of N-glycopeptides in all subclasses of IgG. 22354962 6 51 gly HGF-β 1020:1024 arg1 the mannose receptor HGF the mannose receptor OGER HGF P14210 Mass spectrometric detection of the ligand receptor complex revealed that the binding site of HGF-β was the mannose receptor (MR). 16335806 2 9 part_of protein 350:356 arg1 one potential N-glycosylation site protein one potential N-glycosylation site Fterm Site protein site The results revealed that panda PRL cDNA encodes a precursor protein of 229 amino acids including a putative signal peptide of 30 amino acids and a mature protein of 199 residues with one potential N-glycosylation site. 16335806 2 57 part_of peptide 311:317 arg1 one potential N-glycosylation site peptide one potential N-glycosylation site site The results revealed that panda PRL cDNA encodes a precursor protein of 229 amino acids including a putative signal peptide of 30 amino acids and a mature protein of 199 residues with one potential N-glycosylation site. 20188224 1 56 gly domain 168:173 arg1 7 1/2 repeats domain 7 1/2 repeats domain PGRN is a modular protein with 7 1/2 repeats of the granulin domain separated by short spacer sequences. 20188224 1 72 gly protein 125:131 arg1 7 1/2 repeats protein 7 1/2 repeats Fterm protein PGRN is a modular protein with 7 1/2 repeats of the granulin domain separated by short spacer sequences. 2965020 5 13 part_of HP1 851:853 arg1 the cDNA sequence HP1 the cDNA sequence PUBTATOR Site HP1 23468 sequence Comparison of the cDNA sequence of HP1 with that of human interleukin 6 disclosed a homology of 65% at the DNA level and of 42% at the protein level with a maximum of 57% for the segment spanning residues 42-102 of mature HP1. 2965020 5 44 part_of HP1 1038:1040 arg1 residues 42-102 HP1 residues 42-102 PUBTATOR SpecificSite HP1 23468 residues 42-102 Comparison of the cDNA sequence of HP1 with that of human interleukin 6 disclosed a homology of 65% at the DNA level and of 42% at the protein level with a maximum of 57% for the segment spanning residues 42-102 of mature HP1. 9832151 7 37 gly unglycosylated 1178:1191 arg1 rVMAT1 form of rVMAT1 PUBTATOR form of rVMAT1 25693 It is interesting that in contrast to plasma-membrane neurotransmitter transporters, the unglycosylated form of rVMAT1 distributed in the cell as the wild-type protein. 10580643 8 89 gly glycopeptide 1803:1814 arg2 the glycopeptide the glycopeptide glycopeptide Repetition of the syntheses, with altered conditions and reagents, revealed reproducibly high levels of aspartic acid-bond isomerization of the glycopeptide as well as lack of isomerization for the non-glycosylated parent analog. 8132647 7 79 gly glycosylation 921:933 arg2 one potential N-linked glycosylation site one potential N-linked glycosylation site site The GP-3 amino acid sequence contains one potential N-linked glycosylation site at Asn-336. 20573953 4 2 gly glycosylation 1060:1072 arg2 Ig5 glycosylation sites Ig5 glycosylation sites sites Unexpectedly, the structure reveals that the sites of Ig5 polysialylation are on the opposite face from the FN1 residues previously found to be critical for N-glycan polysialylation, suggesting that the Ig5-FN1 domain relationship may be flexible and/or that there is flexibility in the placement of Ig5 glycosylation sites for polysialylation. 22123080 3 2 gly N-glycosylation 364:378 arg1 CD82 CD82 PUBTATOR CD82 3732 However, the N-glycosylation pattern of CD82 has not been described yet. 30115684 0 67 gly glycoprotein 37:48 arg1 HIV-1 envelope glycoprotein gp120 HIV-1 envelope glycoprotein gp120 Fterm glycoprotein Metabolic labeling of HIV-1 envelope glycoprotein gp120 to elucidate the role of gp120 glycosylation on antigen uptake. 1703533 8 15 part_of IgE-binding 1351:1361 arg1 At least one minor IgE-binding epitope IgE At least one minor IgE-binding epitope OGER Site IgE P01854 epitope At least one minor IgE-binding epitope still bound IgE after denaturation of the allergen. 15737642 4 69 gly N-glycosylation 948:962 arg1 Asn219 protein Asn127 and Asn219 Fterm protein Asn127 and Asn219 The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion. 15737642 4 69 gly N-glycosylation 948:962 arg2 Asn219 protein Asn127 and Asn219 Fterm protein Asn127 and Asn219 The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion. 15737642 4 69 gly N-glycosylation 948:962 arg1 Asn127 protein Asn127 and Asn219 Fterm protein Asn127 and Asn219 The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion. 15737642 4 69 gly N-glycosylation 948:962 arg2 Asn127 protein Asn127 and Asn219 Fterm protein Asn127 and Asn219 The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion. 15737642 4 69 gly N-glycosylation 948:962 arg2 Asn219 Asn127 and Asn219 Asn127 and Asn219 The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion. 15737642 4 69 gly N-glycosylation 948:962 arg1 Asn127 Asn127 and Asn219 Asn127 and Asn219 The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion. 15737642 4 69 gly N-glycosylation 948:962 arg2 Asn127 Asn127 and Asn219 Asn127 and Asn219 The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion. 15737642 4 69 gly N-glycosylation 948:962 arg1 Asn127 Asn127 and Asn219 Asn127 and Asn219 The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion. 15737642 4 69 gly N-glycosylation 948:962 arg2 Asn127 Asn127 and Asn219 Asn127 and Asn219 The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion. 15737642 4 69 gly N-glycosylation 948:962 arg2 Asn127 Asn127 and Asn219 Asn127 and Asn219 The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion. 15737642 4 71 gly N-glycosylation 871:885 arg2 The N-glycosylation at Asn219 Asn219 Asn219 The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion. 27834568 5 0 gly glycan 771:776 arg1 H-CDR2 CDR2 glycan PUBTATOR CDR2 1039 We show that an N-linked complex-type Fab glycan in H-CDR2 of 37E1B5 is directly involved in the inhibition of latent TGF-β activation. 8870657 4 16 gly N-glycosylation 594:608 arg1 Asn479 Asn138, Asn479 and Asn624 Asn138, Asn479 and Asn624 The mutations involved replacement of asparagine residues with glutamine at one or more sequons for N-glycosylation (Asn138, Asn479 and Asn624). 17222411 6 16 gly sialylated 872:881 arg1 the sialylated Corel at Thr52 the sialylated Corel at Thr52 Thr52 These results indicated that the sialylated Corel at Thr52 is critical for podoplanin-induced platelet aggregation. 1379602 3 106 part_of desmoglein 495:504 arg1 an extracellular epitope desmoglein an extracellular epitope Fterm Site desmoglein epitope We describe here the characterization of a new monoclonal antibody, AE23, against an extracellular epitope of desmoglein. 20338479 6 75 gly N-glycosylation 842:856 arg2 an N-glycosylation site mutant an N-glycosylation site mutant site However, for cells with an N-glycosylation site mutant of integrin beta1 located on the I-like domain (Mu3), these effects were dramatically inhibited. 8878691 1 15 gly glycosylation 220:232 arg2 an N-linked glycosylation site an N-linked glycosylation site site The agouti locus encodes a novel paracrine signaling molecule containing a signal sequence, an N-linked glycosylation site, a central lysine-rich basic domain, and a C-terminal tail containing 10 cysteine (Cys) residues capable of forming five disulfide bonds. 31625659 4 0 gly glycosylation 736:748 arg2 the glycosylation site the glycosylation site site A combination of biophysical experiments further suggested that Dectin-1 recognizes aromatic amino acids adjacent to the N-terminal asparagine at the glycosylation site as well as the core fucose. 31625659 4 41 gly fucose 775:780 arg1 the N-terminal asparagine the N-terminal asparagine the N-terminal asparagine AminoAcid asparagine A combination of biophysical experiments further suggested that Dectin-1 recognizes aromatic amino acids adjacent to the N-terminal asparagine at the glycosylation site as well as the core fucose. 11312284 2 17 part_of AChR 346:349 arg1 the two AChR ligand binding sites AChR the two AChR ligand binding sites OGER Site AChR sites In this paper, we have characterized subunit processing and folding events leading to formation of the two AChR ligand binding sites. 3065335 3 36 gly glycosylation 566:578 arg2 The sequence The sequence sequence, Asn-X-Thr The sequence, Asn-X-Thr(Ser), which is a common glycosylation site was found at positions 78-80, 84-86, and 141-143. 3065335 3 36 gly glycosylation 566:578 arg2 a common glycosylation site a common glycosylation site site The sequence, Asn-X-Thr(Ser), which is a common glycosylation site was found at positions 78-80, 84-86, and 141-143. 26729457 1 31 gly glycoproteins 265:277 arg1 glycoproteins glycoproteins Fterm glycoproteins In-depth site-specific investigations of protein glycosylation are the basis for understanding the biological function of glycoproteins. 22677411 10 16 gly glycosylation 1449:1461 arg2 a given glycosylation site a given glycosylation site site This way the sugar chains can be unequivocally assigned to a given glycosylation site (site-specific glycosylation pattern). 9261431 0 64 gly protein 63:69 arg1 The critical N-linked glycan protein The critical N-linked glycan Fterm protein The critical N-linked glycan of murine leukemia virus envelope protein promotes both folding of the C-terminal domains of the precursor polyprotein and stability of the postcleavage envelope complex. 27938679 1 23 gly glycoproteins 283:295 arg1 the mature surface (SU) and transmembrane (TM) glycoproteins the mature surface (SU) and transmembrane (TM) glycoproteins Fterm glycoproteins The bovine leukaemia virus (BLV) envelope protein (Env) is synthesized as a polyprotein precursor (gp72) proteolytically cleaved into the mature surface (SU) and transmembrane (TM) glycoproteins. 27938679 1 23 gly glycoproteins 283:295 arg1 TM TM Cterm TM The bovine leukaemia virus (BLV) envelope protein (Env) is synthesized as a polyprotein precursor (gp72) proteolytically cleaved into the mature surface (SU) and transmembrane (TM) glycoproteins. 10753464 6 77 gly glycosylation 1192:1204 arg2 The glycosylation site The glycosylation site site The glycosylation site and anomeric configuration were established by (1)H NMR spectroscopy. 17927214 2 17 gly CI-MPR 529:534 arg1 two high-affinity Man-6-P binding sites CI-MPR two high-affinity Man-6-P binding sites PUBTATOR CI-MPR 3482 Previous studies have mapped two high-affinity Man-6-P binding sites of the CI-MPR to domains 1-3 and 9 and one low-affinity site to domain 5 within its 15-domain extracytoplasmic region. 27471271 10 48 gly glycosylation 1508:1520 arg2 potential glycosylation sites potential glycosylation sites sites Our findings demonstrate that even addition of a single N-linked GlcNAc at potential glycosylation sites inhibits dimer formation. 29353432 9 38 gly glycosylation 1303:1315 arg2 each glycosylation site each glycosylation site site Aptamers that can be rationally tailored for a certain molecule domain can become the golden receptor to specifically detect aberrant glycosylation at each protein or even at each glycosylation site, providing new diagnostic tools for early detection of cancer. 29353432 9 58 gly glycosylation 1257:1269 arg1 each protein each protein Fterm protein Aptamers that can be rationally tailored for a certain molecule domain can become the golden receptor to specifically detect aberrant glycosylation at each protein or even at each glycosylation site, providing new diagnostic tools for early detection of cancer. 28336547 4 28 gly glycosylation 705:717 arg1 sequon N50 N50 N50 Here, we show that for the murine protein the inhibition of glycosylation at sequon N50 by substituting N50 with glutamine, lysine, or cysteine or by replacing S52 with alanine equally altered PEPT1 transport kinetics in oocytes. 29190644 0 35 gly glycoprotein 29:40 arg1 human glycoprotein butyrylcholinesterase human glycoprotein butyrylcholinesterase Fterm glycoprotein Structural analysis of human glycoprotein butyrylcholinesterase using atomistic molecular dynamics: The importance of glycosylation site ASN241. 29190644 0 24 gly glycosylation 118:130 arg2 ASN241 site ASN241 site ASN241 Structural analysis of human glycoprotein butyrylcholinesterase using atomistic molecular dynamics: The importance of glycosylation site ASN241. 9191841 8 18 part_of protein 1523:1529 arg1 E protein soluble fragment protein E protein soluble fragment Fterm Site protein fragment Residues which altered on passaging have been localized on the three-dimensional structure of the tick-borne encephalitis virus E protein soluble fragment (F. A. Rey, et al., 1995, Nature 375, 291-298). 8652881 3 79 gly glycoprotein 436:447 arg1 The glycoprotein The glycoprotein Fterm glycoprotein The glycoprotein, secreted as a single polypeptide chain, can be cleaved after Arg740 to generate a heavy-light chain complex of 90-80 kDa as revealed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. 12364335 1 55 part_of serine 223:228 arg1 proteins proteins serine Fterm AminoAcid proteins serine and threonine residues Mucin type O-glycosylation begins with the transfer of GalNAc to serine and threonine residues on proteins by a family of UDP-GalNAc:polypeptide N-acetylgalactosaminlytransferases. 12364335 1 66 part_of threonine 234:242 arg1 proteins proteins threonine Fterm AminoAcid proteins serine and threonine residues Mucin type O-glycosylation begins with the transfer of GalNAc to serine and threonine residues on proteins by a family of UDP-GalNAc:polypeptide N-acetylgalactosaminlytransferases. 3137277 3 36 gly N-glycosylation 505:519 arg2 The N-glycosylation site The N-glycosylation site site The N-glycosylation site was confirmed as Asn-80 by the detection of glucosamines in the peptide containing Asn-80. 3137277 3 36 gly N-glycosylation 505:519 arg2 Asn-80 Asn-80 Asn-80 The N-glycosylation site was confirmed as Asn-80 by the detection of glucosamines in the peptide containing Asn-80. 17496250 0 45 gly glycosylation 32:44 arg1 human insulin-like growth factor-binding protein-5 human insulin-like growth factor-binding protein-5 Fterm protein-5 The in vivo phosphorylation and glycosylation of human insulin-like growth factor-binding protein-5. 27796794 2 82 gly glycosylation 420:432 arg2 conserved Fc glycosylation sites conserved Fc glycosylation sites sites RECENT FINDINGS: Both immunoglobulin (Ig) isotype and conserved Fc glycosylation sites often dictate the downstream activity of an Ab where complexity and degree of glycosylation contribute to its ability to bind Fc receptors (FcRs) and activate complement. 2456913 0 41 part_of thyrotropin 104:114 arg1 the two sites thyrotropin sites OGER Site thyrotropin sites Rates of processing of the high mannose oligosaccharide units at the three glycosylation sites of mouse thyrotropin and the two sites of free alpha-subunits. 2456913 0 62 part_of alpha-subunits 142:155 arg1 the two sites alpha-subunits sites Fterm Site alpha-subunits sites Rates of processing of the high mannose oligosaccharide units at the three glycosylation sites of mouse thyrotropin and the two sites of free alpha-subunits. 22586465 9 55 gly glycosylation 1443:1455 arg2 glycosylation sites glycosylation sites sites Based on analysis of proteins that have a solved 3D structure at the site of variation, we find that 48% of the variations that lead to changes in glycosylation sites occur at the loop and bend regions of the proteins. 23776238 2 34 gly glycoproteins 348:360 arg1 glycoproteins glycoproteins Fterm glycoproteins In this study, we identified a panel of glycoproteins by click reaction with alkynyl sugar analogs in plasma cells coupled with mass spectrometry analysis. 28860626 3 60 gly neuraminidase 938:950 arg1 the glycan structures neuraminidase the glycan structures Fterm neuraminidase Proteomic data analyses of the full-length protein sequences determined 9 N-glycosylation sites of hemagglutinin, and defined 6 N-glycosylation sites and the glycan structures of low abundance neuraminidase, which were occupied by high-mannose, hybrid and complex-type N-glycans. 28860626 3 18 gly N-glycosylation 873:887 arg2 6 N-glycosylation sites neuraminidase sites Fterm neuraminidase sites Proteomic data analyses of the full-length protein sequences determined 9 N-glycosylation sites of hemagglutinin, and defined 6 N-glycosylation sites and the glycan structures of low abundance neuraminidase, which were occupied by high-mannose, hybrid and complex-type N-glycans. 28860626 3 31 gly N-glycosylation 819:833 arg2 9 N-glycosylation sites hemagglutinin sites Fterm hemagglutinin sites Proteomic data analyses of the full-length protein sequences determined 9 N-glycosylation sites of hemagglutinin, and defined 6 N-glycosylation sites and the glycan structures of low abundance neuraminidase, which were occupied by high-mannose, hybrid and complex-type N-glycans. 27259237 3 67 gly N-glycoproteins 317:331 arg1 N-glycoproteins N-glycoproteins Fterm N-glycoproteins However, the analysis of N-glycoproteins has been limited by the available analytical technology. 23234360 0 74 gly glycoproteins 102:114 arg1 human cerebrospinal fluid glycoproteins glycoproteins glycan structures Fterm glycoproteins LC-MS/MS characterization of O-glycosylation sites and glycan structures of human cerebrospinal fluid glycoproteins. 23234360 0 41 gly O-glycosylation 29:43 arg1 human cerebrospinal fluid glycoproteins glycoproteins sites Fterm glycoproteins sites LC-MS/MS characterization of O-glycosylation sites and glycan structures of human cerebrospinal fluid glycoproteins. 19838169 1 23 gly glycoproteins 119:131 arg1 glycoproteins glycoproteins Fterm glycoproteins We present a method to enrich for glycoproteins from proteomic samples. 21824222 7 1 gly O-glycosylation 982:996 arg2 the bioactive O-glycosylation site the bioactive O-glycosylation site site A precise analysis of their epitopes revealed that P2-0 recognized the conformation near the bioactive O-glycosylation site at the Thr(52) residue. 8207403 2 59 gly glycoprotein 581:592 arg1 the viral envelope glycoprotein the viral envelope glycoprotein Fterm glycoprotein The purpose of this investigation was to determine the significance of each of these sites in relation to the structure and function of the viral envelope glycoprotein. 8643111 2 16 gly glycosylation 360:372 arg2 a variable region-appended glycosylation site a variable region-appended glycosylation site site The antibody carries a variable region-appended glycosylation site in the light chain and is rapidly internalized upon binding to Raji target cells. 8384766 2 88 gly glycoprotein 329:340 arg1 the envelope glycoprotein the envelope glycoprotein Fterm glycoprotein The gene encoding the envelope glycoprotein of this virus was cloned and sequenced. 23853575 0 94 gly Protein 49:55 arg1 Glycan masking Protein Glycan masking Fterm Protein Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development. 8307000 2 37 gly glycosylation 545:557 arg2 individual glycosylation sites individual glycosylation sites sites Glycopeptides comprising individual glycosylation sites were isolated and oligosaccharides attached were liberated by treatment with endo-beta-N-acetylglucosaminidase H or peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase F. Oligosaccharide alditols obtained after reduction were either directly characterized by high-pH anion-exchange chromatography (high-mannose and hybrid-type glycans) or preparatively subfractionated after enzymic desialylation and separation from sulphated asialooligosaccharides (complex-type sugar chains). 3065335 1 35 part_of prokallikrein 100:112 arg1 The complete amino acid sequence prokallikrein The complete amino acid sequence Fterm Site prokallikrein 9622 sequence The complete amino acid sequence of human urinary prokallikrein has been determined by amino acid analysis and sequence determination of peptide fragments obtained from chemical and enzymological cleavages of kallikrein and by comparison of the N-terminal sequence of prokallikrein with that of kallikrein, the active form. 3065335 1 47 part_of prokallikrein 318:330 arg1 the N-terminal sequence prokallikrein the N-terminal sequence Fterm Site prokallikrein 9622 sequence The complete amino acid sequence of human urinary prokallikrein has been determined by amino acid analysis and sequence determination of peptide fragments obtained from chemical and enzymological cleavages of kallikrein and by comparison of the N-terminal sequence of prokallikrein with that of kallikrein, the active form. 1533657 5 57 gly glycosylation 745:757 arg2 a single putative N-linked glycosylation site a single putative N-linked glycosylation site site The secreted part is organized in four short consensus repeats (SCR) and has a single putative N-linked glycosylation site. 3219367 9 23 gly Asn24 1741:1745 arg1 saccharides Asn24 saccharides Asn24 It was also noted that saccharides at Asn24 are much less sialylated than those at Asn38, although these two glycosylation sites are close to each other. 3219367 9 36 gly glycosylation 1812:1824 arg2 these two glycosylation sites these two glycosylation sites sites It was also noted that saccharides at Asn24 are much less sialylated than those at Asn38, although these two glycosylation sites are close to each other. 3219367 9 94 gly sialylated 1761:1770 arg1 saccharides saccharides It was also noted that saccharides at Asn24 are much less sialylated than those at Asn38, although these two glycosylation sites are close to each other. 7904345 3 12 gly glycopeptides 533:545 arg2 rat sCD4 glycopeptides rat sCD4 glycopeptides glycopeptides Comparisons of rat sCD4 glycopeptides with mutant molecules with only single glycosylation sites and with a truncated form containing only the two NH2-terminal domains, indicate that independent processing occurs at each glycosylation site and that domain interactions can also affect oligosaccharide processing. 7904345 3 21 gly glycosylation 730:742 arg2 each glycosylation site each glycosylation site site Comparisons of rat sCD4 glycopeptides with mutant molecules with only single glycosylation sites and with a truncated form containing only the two NH2-terminal domains, indicate that independent processing occurs at each glycosylation site and that domain interactions can also affect oligosaccharide processing. 7904345 3 27 gly glycosylation 586:598 arg2 only single glycosylation sites only single glycosylation sites sites Comparisons of rat sCD4 glycopeptides with mutant molecules with only single glycosylation sites and with a truncated form containing only the two NH2-terminal domains, indicate that independent processing occurs at each glycosylation site and that domain interactions can also affect oligosaccharide processing. 12139935 1 88 part_of protein 238:244 arg1 four complement control protein (CCP) domains protein four complement control protein (CCP) domains Fterm Site protein domains beta(2)-Glycoprotein I (beta(2)GPI) is a highly glycosylated phospholipid-binding plasma protein comprised of four complement control protein (CCP) domains and a distinct fifth domain. 26415233 1 13 gly N-glycosylated 159:172 arg1 nascent immature N-glycosylated 110kDa TrkA nascent immature N-glycosylated 110kDa TrkA PUBTATOR TrkA 4914 In human SH-SY5Y neuroblastoma (NB) cells, nascent immature N-glycosylated 110kDa TrkA moves rapidly from the endoplasmic reticulum (ER) to the Golgi Network (GN), where it matures into the 140kDa receptor prior to being transported to the cell surface, creating GN and cell surface pools of inactive receptor maintained below the spontaneous activation threshold by a full compliment of inhibitory domains and endogenous PTPases. 15252014 0 55 part_of SPP 179:181 arg1 the SPP active site SPP the SPP active site PUBTATOR Site SPP 81502 site A signal peptide peptidase (SPP) reporter activity assay based on the cleavage of type II membrane protein substrates provides further evidence for an inverted orientation of the SPP active site relative to presenilin. 16689758 5 79 gly N-glycosylation 965:979 arg1 the variable region region region To evaluate the physiological effect of such a FVIII inhibition, we investigated the ability of the mutant antibody devoid of N-glycosylation in the variable region to prevent thrombosis in mice with a strong prothombotic phenotype resulting from a type II deficiency mutation in the heparin binding site of antithrombin. 7683678 7 29 gly N-glycosylation 1014:1028 arg2 one N-glycosylation site one N-glycosylation site site It was susceptible to treatment with N-glycanase, and one N-glycosylation site was identified. 18410132 2 30 gly glycopeptides 555:567 arg2 glycopeptides glycopeptides glycopeptides The lectin affinity preparation of glycopeptides with Sambucus nigra agglutinin and concanavalin A provides the glycan structure outlines for the sialyl linkage and the core structure of N-glycans. 20512925 7 36 part_of sites 970:974 arg1 RAGE RAGE sites PUBTATOR Site RAGE Q15109 sites Glycosylation of RAGE and maximum binding sites for S100A12 on RAGE are also cell type dependent. 10080942 3 16 gly glycosylation 516:528 arg2 each glycosylation site each glycosylation site site Liberation of each glycosylation site at N86 and N266 and the cleavage site interfered dramatically with expression of the intracellular and secreted DNase II activities, irrespective of cell line transfected. 10080942 3 16 gly glycosylation 516:528 arg2 N86 N86 and N266 N86 and N266 Liberation of each glycosylation site at N86 and N266 and the cleavage site interfered dramatically with expression of the intracellular and secreted DNase II activities, irrespective of cell line transfected. 30392906 8 9 gly glycosylation 960:972 arg1 Asn50 Asn50 Asn50 Our results demonstrate that glycosylation of Asn50 is essential for its function as a receptor of ConA. 2846584 2 100 part_of contains 279:286 arg1 a protein AND two amino terminal hydrophobic domains a protein two amino terminal hydrophobic domains Fterm Site protein domains It is the product of rotavirus gene 9 which potentially encodes a protein of 326 amino acids that contains two amino terminal hydrophobic domains, h1 and h2, each preceded by an initiation codon. 20573953 2 35 gly polysialylation 453:467 arg1 two N-glycans two N-glycans Our previous work indicates that the polysialylation of two N-glycans located on the fifth immunoglobulin domain (Ig5) of NCAM requires the presence of specific sequences in the adjacent fibronectin type III repeat (FN1). 22719948 8 70 gly glycosylation 1296:1308 arg2 another glycosylation site another glycosylation site site The steric clashes of the huge glycans shown at another glycosylation site, 169N, located on an adjacent HA monomer, would be more effective in preventing the binding of SA-α-2,3-Gal analogs. 23714211 15 26 gly glycosylation 2577:2589 arg1 ICAM-2 ICAM-2 PUBTATOR ICAM-2 3384 CONCLUSIONS: Reduced glycosylation of ICAM-2 significantly attenuated, but did not abolish, its ability to suppress metastatic properties of NB cells. 20826563 13 17 gly glycosylated 1647:1658 arg1 glycosylated GH glycosylated GH Cterm GH Sialic acids seem to play a pivotal role for the properties of glycosylated GH. 8939156 7 34 part_of region 907:912 arg1 a poly A tail region a poly A tail tail The sequence shows a 432 bp reading frame with a 34 bp 5' untranslated region and a 116 bp 3' untranslated region with a poly A tail. 8939156 7 34 part_of region 907:912 arg1 a 34 bp 5' untranslated region region a 34 bp 5' untranslated region region The sequence shows a 432 bp reading frame with a 34 bp 5' untranslated region and a 116 bp 3' untranslated region with a poly A tail. 14658030 2 42 gly presence 609:616 arg1 specific sites AND glycans specific sites glycans sites For glycosylation, it has been increasingly recognized to be of pivotal importance to identify whether potential glycosylation sites are actually modified by glycans, because functions of proteins may be modulated or depend on the presence of glycans at specific sites. 14658030 2 63 gly modified 524:531 arg3 potential glycosylation sites AND glycans potential glycosylation sites glycans sites For glycosylation, it has been increasingly recognized to be of pivotal importance to identify whether potential glycosylation sites are actually modified by glycans, because functions of proteins may be modulated or depend on the presence of glycans at specific sites. 14658030 2 75 gly glycosylation 491:503 arg2 potential glycosylation sites potential glycosylation sites sites For glycosylation, it has been increasingly recognized to be of pivotal importance to identify whether potential glycosylation sites are actually modified by glycans, because functions of proteins may be modulated or depend on the presence of glycans at specific sites. 7875221 3 6 part_of site 720:723 arg1 the beta-chain beta-chain site Fterm Site beta-chain site The Xenopus LG sequence has a 57% nucleotide and 52% amino acid sequence identity to human C3 and contains one potential N-glycosylation site in the beta-chain. 7875221 3 63 part_of contains 681:688 arg1 The Xenopus LG sequence AND one potential N-glycosylation site The Xenopus LG sequence one potential N-glycosylation site site The Xenopus LG sequence has a 57% nucleotide and 52% amino acid sequence identity to human C3 and contains one potential N-glycosylation site in the beta-chain. 24838853 2 2 part_of hemagglutinin 323:335 arg1 a leucine hemagglutinin a leucine Fterm AminoAcid hemagglutinin leucine Sequence analysis of the genes for the two surface glycoproteins revealed that residue 226 of the hemagglutinin (HA) of eight isolates was a leucine. 24838853 2 2 part_of hemagglutinin 323:335 arg1 residue 226 hemagglutinin residue 226 Fterm SpecificSite hemagglutinin residue 226 Sequence analysis of the genes for the two surface glycoproteins revealed that residue 226 of the hemagglutinin (HA) of eight isolates was a leucine. 12490395 6 7 gly glycosylation 1070:1082 arg1 xcCAT1 xcCAT1 Cterm xcCAT1 114246 We found that xcCAT1 expressed in Chinese hamster ovary (CHO) cells undergoes less glycosylation than rCAT1 and that the expression of xcCAT1 rendered the CHO cells more susceptible to infection with Moloney MLV. 15009203 13 20 gly O-glycosylated 2134:2147 arg2 Ser5 Ser5 Ser5 In the triply modified GM-CSF molecules, Ser5 was additionally O-glycosylated. 18420026 5 14 gly O-glycosylation 1240:1254 arg2 no O-glycosylation site no O-glycosylation site site There was no O-glycosylation site in either human NECL1 or mouse Necl1. 22677411 6 70 gly glycopeptide 918:929 arg2 glycopeptide glycopeptide glycopeptide We have developed a new algorithm and software (GlycoPattern), which evaluates single stage mass spectra, both in terms of glycopeptide identification (for minor glycoforms) and semi-quantitation. 18790849 14 5 part_of channels 2160:2167 arg1 the pore region KCNQ3 channels the pore region PUBTATOR Site KCNQ3 channels 3786 region To investigate a structural hypothesis for the effects of these mutations, we performed homology modeling of the pore region of wild-type and mutant KCNQ3 channels, using KvAP as a template. 10998266 5 37 gly glycopeptides 1168:1180 arg2 the isolated glycopeptides the isolated glycopeptides glycopeptides The detailed site-specific carbohydrate heterogeneity caused by the differences in the molecular weight, branch, linkage, and sequence was elucidated by GCC-LC/MS of the N-linked oligosaccharides released from the isolated glycopeptides. 10998266 5 82 gly released 1141:1148 arg1 the isolated glycopeptides AND the N-linked oligosaccharides the isolated glycopeptides the N-linked oligosaccharides glycopeptides The detailed site-specific carbohydrate heterogeneity caused by the differences in the molecular weight, branch, linkage, and sequence was elucidated by GCC-LC/MS of the N-linked oligosaccharides released from the isolated glycopeptides. 9774483 7 50 gly N-glycosylation 1493:1507 arg2 the sixth N-glycosylation site the sixth N-glycosylation site site We then, using various N-glycosylation site mutants of NCAM, discovered that PST strongly prefer the sixth N-glycosylation site, which is the closest to the transmembrane domain, over the fifth site. 9774483 7 80 gly N-glycosylation 1409:1423 arg2 various N-glycosylation site mutants various N-glycosylation site mutants site We then, using various N-glycosylation site mutants of NCAM, discovered that PST strongly prefer the sixth N-glycosylation site, which is the closest to the transmembrane domain, over the fifth site. 30295034 6 57 gly nonsialylated 1026:1038 arg1 nonsialylated oligosaccharides nonsialylated oligosaccharides The pattern of nonsialylated oligosaccharides was used for interpretation of the fully sialylated species using bioinformatics tools. 10837482 1 18 gly glycosylated 234:245 arg1 The alpha and beta subunits The alpha and beta subunits Fterm subunits The alpha and beta subunits of meprins, mammalian zinc metalloendopeptidases, are extensively glycosylated; approximately 25% of the total molecular mass of the subunits is carbohydrate. 21172408 0 74 gly factor 98:103 arg1 carbohydrates tissue factor carbohydrates OGER tissue factor P13726 Differences in the fractional abundances of carbohydrates of natural and recombinant human tissue factor. 8627808 2 57 gly N-glycosylation 567:581 arg2 one potential N-glycosylation site one potential N-glycosylation site site The mRNA of the SFA-1 gene is approximately 1.6 kb in size and encodes a protein of 253 amino acids, containing four putative transmembrane domains, a number of cysteine residues, and one potential N-glycosylation site in a major hydrophilic region between the third and fourth transmembrane domains. 8627808 2 57 gly N-glycosylation 567:581 arg2 cysteine residues cysteine residues cysteine residues The mRNA of the SFA-1 gene is approximately 1.6 kb in size and encodes a protein of 253 amino acids, containing four putative transmembrane domains, a number of cysteine residues, and one potential N-glycosylation site in a major hydrophilic region between the third and fourth transmembrane domains. 28900186 1 9 gly glycoprotein 205:216 arg1 a glycoprotein a glycoprotein Fterm glycoprotein To determine all potential N-glycosylation sites of a glycoprotein, one central aspect of every bottom-up N-glycoproteomic strategy is to generate suitable N-glycopeptides that can be detected and analyzed by mass spectrometry. 28900186 1 67 gly N-glycopeptides 307:321 arg2 suitable N-glycopeptides suitable N-glycopeptides N-glycopeptides To determine all potential N-glycosylation sites of a glycoprotein, one central aspect of every bottom-up N-glycoproteomic strategy is to generate suitable N-glycopeptides that can be detected and analyzed by mass spectrometry. 28900186 1 3 gly N-glycosylation 178:192 arg2 all potential N-glycosylation sites glycoprotein sites Fterm glycoprotein sites To determine all potential N-glycosylation sites of a glycoprotein, one central aspect of every bottom-up N-glycoproteomic strategy is to generate suitable N-glycopeptides that can be detected and analyzed by mass spectrometry. 26018173 8 126 gly interactions 1583:1594 arg1 native Env trimers Env trimers interactions PUBTATOR Env trimers 100616444 These site-level studies are important for understanding antibody-glycan interactions on native Env trimers. 16274239 1 56 gly glycosylation 131:143 arg1 N N(579) N(579) We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR). 16274239 1 56 gly glycosylation 131:143 arg2 N N(579) N(579) We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR). 16274239 1 56 gly glycosylation 131:143 arg1 579 N(579) N(579) We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR). 16274239 1 56 gly glycosylation 131:143 arg2 N N(579) N(579) We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR). 16274239 1 56 gly glycosylation 131:143 arg1 579 N(579) N(579) We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR). 16274239 1 56 gly glycosylation 131:143 arg1 579 N(579) N(579) We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR). 2411731 5 16 part_of possesses 1070:1078 arg1 V AND Asn-Lys-Thr alpha 2(V) Asn-Lys-Thr PUBTATOR Site alpha 2(V) 1290 Asn-Lys-Thr Compared to the interstitial procollagens, however, more divergence has occurred in alpha 2(V) surrounding the conserved N-asparaginyl-linked carbohydrate attachment site at residues 171-173, and alpha 2(V) possesses an additional potential glycosylation site (Asn-Lys-Thr) located in a hypervariable region near the NH2 terminus. 2411731 5 16 part_of possesses 1070:1078 arg1 V AND an additional potential glycosylation site alpha 2(V) site PUBTATOR Site alpha 2(V) 1290 site Compared to the interstitial procollagens, however, more divergence has occurred in alpha 2(V) surrounding the conserved N-asparaginyl-linked carbohydrate attachment site at residues 171-173, and alpha 2(V) possesses an additional potential glycosylation site (Asn-Lys-Thr) located in a hypervariable region near the NH2 terminus. 21899340 1 14 gly glycosylation 335:347 arg2 the glycosylation sites the glycosylation sites sites The glycan profiling can provide the overview of glycosylation in despite of the absence of the glycosylation sites, which in turn simplifies the complexity of disease diagnosis. 9259114 9 13 part_of LRG 936:938 arg1 a leucine-rich glycoprotein (LRG) sequence LRG a leucine-rich glycoprotein (LRG) sequence PUBTATOR Site LRG P02750 sequence Mouse GPIb beta also contained a leucine-rich glycoprotein (LRG) sequence of 24 amino acids same as human GPIb beta. 9259114 9 36 part_of contained 897:905 arg1 Mouse GPIb beta AND a leucine-rich glycoprotein (LRG) sequence Mouse GPIb beta a leucine-rich glycoprotein (LRG) sequence PUBTATOR Site Mouse GPIb beta 14724 sequence Mouse GPIb beta also contained a leucine-rich glycoprotein (LRG) sequence of 24 amino acids same as human GPIb beta. 10397879 0 16 gly structures 101:110 arg1 glycoproteins glycoproteins structures Fterm glycoproteins Incorporation of ammonium into intracellular UDP-activated N-acetylhexosamines and into carbohydrate structures in glycoproteins. 10397879 0 91 gly glycoproteins 115:127 arg1 glycoproteins glycoproteins Fterm glycoproteins Incorporation of ammonium into intracellular UDP-activated N-acetylhexosamines and into carbohydrate structures in glycoproteins. 17707131 5 68 gly glycosylation 927:939 arg2 potential glycosylation site potential glycosylation site site The topology of motifs I and III was confirmed by experiments with recombinant AGPAT1 containing potential glycosylation site near the motifs. 25755023 1 3 gly glycoproteins 82:94 arg1 Mucin glycoproteins Mucin glycoproteins Fterm glycoproteins Mucin glycoproteins are important diagnostic and therapeutic targets for cancer treatment. 9557657 11 28 gly N-glycosylation 2333:2347 arg2 its first N-glycosylation site havcr-1 site PUBTATOR havcr-1 Q96D42 site These results indicate that the Cys-rich region of havcr-1 and its first N-glycosylation site are required for binding of protective MAb 190/4 and HAV receptor function. 15809770 6 1 part_of receptors 553:561 arg1 Frizzled (Fz) domain receptors Frizzled (Fz) domain Fterm Site receptors domain Vertebrate Fzd8 orthologs were seven-transmembrane receptors with Frizzled (Fz) domain within the N-terminal extracellular region, leucine zipper motif around the fifth transmembrane domain, and Dishevelled (Dvl)-binding motif within the C-terminal cytoplasmic region. 15809770 6 39 part_of Dishevelled 697:707 arg1 Dishevelled (Dvl)-binding motif Dishevelled (Dvl Dishevelled (Dvl)-binding motif OGER Site Dishevelled (Dvl P54792 motif Vertebrate Fzd8 orthologs were seven-transmembrane receptors with Frizzled (Fz) domain within the N-terminal extracellular region, leucine zipper motif around the fifth transmembrane domain, and Dishevelled (Dvl)-binding motif within the C-terminal cytoplasmic region. 9259114 1 10 gly glycoprotein 84:95 arg1 Platelet glycoprotein Platelet glycoprotein Fterm glycoprotein Platelet glycoprotein (GP) Ib/IX/V complex is a major receptor for von Willebrand factor (vWF), which mediates platelet adhesion and aggregation under high shear stress conditions. 10397879 2 44 gly glycosylation 489:501 arg1 a recombinant human IL-2 mutant variant model glycoprotein a recombinant human IL-2 mutant variant model glycoprotein Fterm glycoprotein We investigated the ammonium action on the synthesis of the intracellular UDP-N-acetylhexos- amines (UDPGNAc), which are precursors of glycosylation as well as on N-linked oligosaccharides of a recombinant human IL-2 mutant variant model glycoprotein expressed in BHK-21 cells under defined and controlled culture conditions in a continuously perfused bioreactor. 10397879 2 72 gly glycoprotein 592:603 arg1 a recombinant human IL-2 mutant variant model glycoprotein a recombinant human IL-2 mutant variant model glycoprotein Fterm glycoprotein We investigated the ammonium action on the synthesis of the intracellular UDP-N-acetylhexos- amines (UDPGNAc), which are precursors of glycosylation as well as on N-linked oligosaccharides of a recombinant human IL-2 mutant variant model glycoprotein expressed in BHK-21 cells under defined and controlled culture conditions in a continuously perfused bioreactor. 10397879 2 90 gly precursors 475:484 arg1 N-linked oligosaccharides precursors N-linked oligosaccharides Fterm precursors We investigated the ammonium action on the synthesis of the intracellular UDP-N-acetylhexos- amines (UDPGNAc), which are precursors of glycosylation as well as on N-linked oligosaccharides of a recombinant human IL-2 mutant variant model glycoprotein expressed in BHK-21 cells under defined and controlled culture conditions in a continuously perfused bioreactor. 10995221 3 8 part_of contain 453:459 arg1 The mammalian UGT2B proteins AND at least one consensus asparagine-linked glycosylation site NX(S/T) The mammalian UGT2B proteins at least one consensus asparagine-linked glycosylation site NX(S/T) Fterm Site proteins site The mammalian UGT2B proteins contain at least one consensus asparagine-linked glycosylation site NX(S/T). 27612916 8 16 gly N-glycosylation 1663:1677 arg2 N-glycosylation sequence motifs N-glycosylation sequence motifs motifs A systematic survey of the Short Genetic Variations database uncovered 32 rare, naturally occurring missense variations predicted to create or disrupt N-glycosylation sequence motifs in the other UGT2B enzymes. 12706077 4 19 part_of HA1 948:950 arg1 the influenza virus HA1 domain HA1 the influenza virus HA1 domain OGER Site HA1 domain We conclude that the glycosylation pattern of the influenza virus HA1 domain has little impact on the murine antibody response raised to a DNA vaccine encoding the H5 HA, thereby minimizing the concern that the pattern of glycosylation sites encoded by the vaccine match those of closely related H5 viruses. 14715137 5 5 gly N-glycosylation 763:777 arg2 the intraluminal N-glycosylation site the intraluminal N-glycosylation site site In addition to the intraluminal N-glycosylation site, the cytoplasmic C(2) domains of synaptotagmin 1 were required for correct targeting but could be functionally replaced by the C(2) domains of synaptotagmin 7. 2113054 5 83 gly glycosylation 1109:1121 arg2 a N-linked glycosylation site a N-linked glycosylation site site Domain 1 alone was not expressed and introduction of a N-linked glycosylation site did not facilitate expression. 15253437 2 31 gly N-glycosylation 409:423 arg2 N-glycosylation sites N-glycosylation sites sites In a novel approach to identify N-glycosylation sites in complex biological samples, we performed an enrichment of glycosylated peptides through hydrophilic interaction liquid chromatography (HILIC) followed by partial deglycosylation using a combination of endo-beta-N-acetylglucosaminidases (EC 3.2.1.96). 15253437 2 57 gly glycosylated 492:503 arg1 glycosylated peptides glycosylated peptides peptides In a novel approach to identify N-glycosylation sites in complex biological samples, we performed an enrichment of glycosylated peptides through hydrophilic interaction liquid chromatography (HILIC) followed by partial deglycosylation using a combination of endo-beta-N-acetylglucosaminidases (EC 3.2.1.96). 9725224 3 74 gly asparagine-linked 408:424 arg1 asparagine-linked carbohydrates asparagine asparagine-linked carbohydrates asparagine Here, we examined the role of asparagine-linked carbohydrates of the murine class I MHC in the binding to Ly-49A and Ly-49C. 10397879 9 69 gly glycoprotein 1771:1782 arg1 IL-Mu6 glycoprotein IL-Mu6 glycoprotein Fterm glycoprotein IL-Mu6 glycoprotein was purified and N-glycans released were analyzed by matrix-assisted laser desorption ionization time of flight mass spectroscopy. 21672516 7 30 gly N-glycosylation 914:928 arg1 the protein the protein Fterm protein When Podnl was transfected into osteoblastic cells, the protein with N-glycosylation was detected mainly in the cultured medium, indicating that Podnl is a secreted N-glycosylated protein. 21672516 7 38 gly N-glycosylated 1010:1023 arg1 a secreted N-glycosylated protein a secreted N-glycosylated protein Fterm protein When Podnl was transfected into osteoblastic cells, the protein with N-glycosylation was detected mainly in the cultured medium, indicating that Podnl is a secreted N-glycosylated protein. 21672516 7 38 gly N-glycosylated 1010:1023 arg1 Podnl Podnl Cterm Podnl When Podnl was transfected into osteoblastic cells, the protein with N-glycosylation was detected mainly in the cultured medium, indicating that Podnl is a secreted N-glycosylated protein. 27725718 8 22 part_of transferrin 1011:1021 arg1 In NAFLD haptoglobin and transferrin glycosylation sites transferrin In NAFLD haptoglobin and transferrin glycosylation sites PUBTATOR Site transferrin 7018 sites In NAFLD haptoglobin and transferrin glycosylation sites were hyper-glycosylated, a property qualifying for its use as a potential biomarker. 8176214 10 6 gly used 1198:1201 arg2 a potential N-glycosylation site a potential N-glycosylation site site It turned out that a potential N-glycosylation site close to the proteolytic cleavage site of the IL-6R is used. 8176214 10 28 gly N-glycosylation 1122:1136 arg2 a potential N-glycosylation site a potential N-glycosylation site site It turned out that a potential N-glycosylation site close to the proteolytic cleavage site of the IL-6R is used. 12022871 8 4 gly glycosylated 1241:1252 arg1 Human TGH Human TGH PUBTATOR Human TGH 1066 Human TGH was glycosylated in the insect cells. 26957414 0 93 part_of proteins 103:110 arg1 the glycosylation sites proteins the glycosylation sites Fterm Site proteins sites Parallel data acquisition of in-source fragmented glycopeptides to sequence the glycosylation sites of proteins. 7620335 10 18 gly disialylated 1650:1661 arg1 disialylated Gal beta 3GalNAc disialylated Gal beta 3GalNAc In addition, the structures of O-linked oligosaccharides at Thr17 and Thr29 residues were suggested to be disialylated Gal beta 3GalNAc sequences by their component analyses. 7620335 10 92 gly residues 1620:1627 arg1 disialylated Gal beta 3GalNAc sequences Thr17 and Thr29 residues disialylated Gal beta 3GalNAc sequences Thr17 and Thr29 residues In addition, the structures of O-linked oligosaccharides at Thr17 and Thr29 residues were suggested to be disialylated Gal beta 3GalNAc sequences by their component analyses. 27798666 5 62 gly O-glycosylation 910:924 arg2 the O-glycosylation site the O-glycosylation site site Here, we characterized a novel splice variant which has never been investigated, NRP1-Δ7, differing from the NRP1-FS by a deletion of 7 amino acids occurring two residues downstream of the O-glycosylation site. 30295034 1 89 part_of protein 205:211 arg1 five N-type glycosylation sites protein five N-type glycosylation sites Fterm Site protein sites Alpha-1-acid glycoprotein (AGP) is a highly glycosylated protein from human plasma with five N-type glycosylation sites carrying dominantly higher antennary structures and thus represents a challenging target for characterization of glycan heterogeneity. 23714211 0 118 gly N-glycosylation 0:14 arg1 ICAM-2 ICAM-2 PUBTATOR ICAM-2 3384 N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells. 8435067 4 51 gly glycosylated 629:640 arg1 all seven sites all seven sites sites We have eliminated these sites individually by site-directed mutagenesis and thereby demonstrated that all seven sites are glycosylated. 10682309 12 44 gly non-glycosylated 1874:1889 arg1 non-glycosylated SAP-B non-glycosylated SAP-B OGER SAP O60880 Feeding studies with non-glycosylated SAP-precursor, generating non-glycosylated SAP-B, showed that the loss of the carbohydrate chain reduced the intracellular activity of the protein significantly. 10682309 12 49 gly non-glycosylated 1831:1846 arg1 non-glycosylated SAP-precursor non-glycosylated SAP-precursor OGER SAP O60880 Feeding studies with non-glycosylated SAP-precursor, generating non-glycosylated SAP-B, showed that the loss of the carbohydrate chain reduced the intracellular activity of the protein significantly. 8180202 4 11 gly glycosylated 643:654 arg1 Asn9 Asn9, Asn308, and Asn347 Asn9, Asn308, and Asn347 This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154. 8180202 4 11 gly glycosylated 643:654 arg1 Asn308 Asn9, Asn308, and Asn347 Asn9, Asn308, and Asn347 This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154. 8180202 4 11 gly glycosylated 643:654 arg1 Asn308 Asn9, Asn308, and Asn347 Asn9, Asn308, and Asn347 This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154. 8180202 4 17 gly linked 842:847 arg1 Asn74 AND more branched (most likely, triantennary) oligosaccharides Asn74 and Asn154 more branched (most likely, triantennary) oligosaccharides Asn74 and Asn154 This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154. 8180202 4 55 gly attached 682:689 arg1 Asn308 AND oligosaccharides Asn9, Asn238, Asn308, and Asn347 oligosaccharides Asn9, Asn238, Asn308, and Asn347 This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154. 8180202 4 55 gly attached 682:689 arg1 Asn238 AND oligosaccharides Asn9, Asn238, Asn308, and Asn347 oligosaccharides Asn9, Asn238, Asn308, and Asn347 This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154. 8180202 4 55 gly attached 682:689 arg1 Asn238 AND oligosaccharides Asn9, Asn238, Asn308, and Asn347 oligosaccharides Asn9, Asn238, Asn308, and Asn347 This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154. 28630087 11 16 gly sialoglycoforms 1940:1954 arg1 the HNE sialoglycoforms the HNE sialoglycoforms PUBTATOR HNE 1991 Functionally, the paucimannosidic HNE glycoforms displayed preferential binding to human mannose binding lectin compared with the HNE sialoglycoforms, suggesting a glycoform-dependent involvement of HNE in complement activation. 28630087 11 30 gly glycoforms 1844:1853 arg1 the paucimannosidic HNE glycoforms the paucimannosidic HNE glycoforms PUBTATOR HNE 1991 Functionally, the paucimannosidic HNE glycoforms displayed preferential binding to human mannose binding lectin compared with the HNE sialoglycoforms, suggesting a glycoform-dependent involvement of HNE in complement activation. 9169007 1 3 gly glycoforms 166:175 arg1 recombinant antithrombin recombinant antithrombin PUBTATOR antithrombin 462 Two major glycoforms of recombinant antithrombin which differ 10-fold in their affinity for the effector glycosaminoglycan, heparin, were previously shown to be expressed in BHK or CHO mammalian cell lines (I. Björk, et al., 1992, Biochem. 7849312 8 15 gly site 1082:1085 arg1 Asn Asn Asn This amino acid substitution occurs at a consensus N-glycosylation site (Asn. 7849312 8 65 gly N-glycosylation 1066:1080 arg2 a consensus N-glycosylation site a consensus N-glycosylation site site This amino acid substitution occurs at a consensus N-glycosylation site (Asn. 2202300 2 35 gly glycosylation 329:341 arg2 glycosylation site binding protein glycosylation site binding protein site We sought to determine if glycosylation site binding protein, a lumenal protein of the endoplasmic reticulum, also has the same primary structure. 8207403 1 34 gly glycoprotein 225:236 arg1 gp41 gp41 Cterm gp41 The transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus type 1 possesses four consensus sites (Asn-X-Ser/Thr) for the incorporation of N-linked sugars situated on the extracellular domain of the molecule. 8207403 1 34 gly glycoprotein 225:236 arg1 The transmembrane envelope glycoprotein The transmembrane envelope glycoprotein Fterm glycoprotein The transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus type 1 possesses four consensus sites (Asn-X-Ser/Thr) for the incorporation of N-linked sugars situated on the extracellular domain of the molecule. 8207403 1 63 gly sites 309:313 arg1 Asn-X-Ser/Thr Asn-X-Ser/Thr Asn The transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus type 1 possesses four consensus sites (Asn-X-Ser/Thr) for the incorporation of N-linked sugars situated on the extracellular domain of the molecule. 24501222 7 25 part_of site 1125:1128 arg1 HRG HRG site PUBTATOR Site HRG P04196 site The structure confirms that the N2 domain, which along with the N1 domain, forms an important molecular interaction site on HRG, possesses a cystatin-like fold composed of a 5-stranded antiparallel β-sheet wrapped around a 5-turn α-helix. 25614955 7 25 gly glycoprotein 1238:1249 arg1 the glycoprotein G the glycoprotein G OGER glycoprotein G P07996 In addition, sequence analysis of the glycoprotein G identified an amino acid substitution (I338→T338) unique to the IMDRV-13 within antigenic sites III (330-338), this mutation also leads to an additional potential N-glycosylation site (N336), which may represent a useful model to study relationship of N-glycosylation in G protein and specific properties such as pathogenicity or host adaption of RABV. 25614955 7 43 gly N-glycosylation 1416:1430 arg2 N336 N336 N336 In addition, sequence analysis of the glycoprotein G identified an amino acid substitution (I338→T338) unique to the IMDRV-13 within antigenic sites III (330-338), this mutation also leads to an additional potential N-glycosylation site (N336), which may represent a useful model to study relationship of N-glycosylation in G protein and specific properties such as pathogenicity or host adaption of RABV. 25614955 7 43 gly N-glycosylation 1416:1430 arg2 an additional potential N-glycosylation site an additional potential N-glycosylation site site In addition, sequence analysis of the glycoprotein G identified an amino acid substitution (I338→T338) unique to the IMDRV-13 within antigenic sites III (330-338), this mutation also leads to an additional potential N-glycosylation site (N336), which may represent a useful model to study relationship of N-glycosylation in G protein and specific properties such as pathogenicity or host adaption of RABV. 25614955 7 66 gly N-glycosylation 1505:1519 arg1 G protein G protein OGER G protein In addition, sequence analysis of the glycoprotein G identified an amino acid substitution (I338→T338) unique to the IMDRV-13 within antigenic sites III (330-338), this mutation also leads to an additional potential N-glycosylation site (N336), which may represent a useful model to study relationship of N-glycosylation in G protein and specific properties such as pathogenicity or host adaption of RABV. 10677208 8 17 part_of fibrillin-1 1461:1471 arg1 an eight-cysteine domain fibrillin-1 an eight-cysteine domain OGER AminoAcid fibrillin-1 P35555 cysteine domain On the basis of these results and on the structure of an eight-cysteine domain from fibrillin-1, we present a model of glycosylated CR3 and discuss the role of glycosylation in eight-cysteine domain protein-protein interactions. 2303059 0 20 gly glycoproteins 106:118 arg1 type-I variant surface glycoproteins type-I variant surface glycoproteins Fterm glycoproteins Characterisation of the asparagine-linked oligosaccharides from Trypanosoma brucei type-I variant surface glycoproteins. 2303059 0 29 gly asparagine-linked 24:40 arg1 the asparagine-linked oligosaccharides asparagine the asparagine-linked oligosaccharides asparagine Characterisation of the asparagine-linked oligosaccharides from Trypanosoma brucei type-I variant surface glycoproteins. 11087686 6 37 part_of factor 908:913 arg1 the alpha factor signal peptide factor the alpha factor signal peptide Fterm Site factor peptide Both the alpha factor signal peptide and the pro-enzyme region were efficiently processed during secretion. 2456913 1 48 part_of TSH 279:281 arg1 individual glycosylation sites TSH individual glycosylation sites OGER Site TSH sites We have determined the structures of high mannose (Man) oligosaccharide units at individual glycosylation sites of mouse TSH. 10970800 4 77 part_of sites 434:438 arg1 the rat EP3beta-subtype PGE(2) receptor receptor sites Fterm Site receptor sites The current study analysed the role of the two N-glycosylation sites in the rat EP3beta-subtype PGE(2) receptor for protein folding and sorting. 7528012 10 66 part_of protein 1744:1750 arg1 specific regions protein specific regions Fterm Site protein regions Comparison of the sequences of rat and human CD59, together with consideration of the published three-dimensional structure of human CD59 and functional data, implicates specific regions of the protein in interactions with C-8 and/or C-9. 25170432 0 26 gly N-glycosylation 0:14 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site N-glycosylation site occupancy in human prostaglandin H synthases expressed in Pichia pastoris. 30213862 8 7 gly N-glycosylation 1269:1283 arg2 the four other N-glycosylation sites the four other N-glycosylation sites sites This remarkable sensitivity could only be eliminated by preventing glycosylation at N162 with an Asn to Gln mutation; mutations at the four other N-glycosylation sites preserved tighter binding in the Man5 glycoform. 30213862 8 29 gly glycoform 1329:1337 arg1 the Man5 glycoform the Man5 glycoform This remarkable sensitivity could only be eliminated by preventing glycosylation at N162 with an Asn to Gln mutation; mutations at the four other N-glycosylation sites preserved tighter binding in the Man5 glycoform. 30213862 8 37 gly glycosylation 1190:1202 arg1 N162 Asn Asn This remarkable sensitivity could only be eliminated by preventing glycosylation at N162 with an Asn to Gln mutation; mutations at the four other N-glycosylation sites preserved tighter binding in the Man5 glycoform. 7654202 2 68 part_of TF 520:521 arg1 the extracellular domain TF the extracellular domain Cterm Site TF 2152 domain The abilities of TF to associate with Factor VIIa and Factor X in a ternary complex and to enable proteolytic activation of Factor X by Factor VIIa reside in the extracellular domain of TF. 8960909 2 35 gly attachment 278:287 arg1 potential immunogenic epitopes AND carbohydrate potential immunogenic epitopes carbohydrate epitopes Many endogenous antigens are glycoproteins, and it is not clear what effect the attachment of carbohydrate to potential immunogenic epitopes has on their processing and presentation (i.e., is the carbohydrate moiety removed prior to presentation, or is it presented along with the peptide to T cells?) 8960909 2 37 gly glycoproteins 227:239 arg1 glycoproteins glycoproteins Fterm glycoproteins Many endogenous antigens are glycoproteins, and it is not clear what effect the attachment of carbohydrate to potential immunogenic epitopes has on their processing and presentation (i.e., is the carbohydrate moiety removed prior to presentation, or is it presented along with the peptide to T cells?) 27679458 5 7 gly N-glycosylated 745:758 arg1 N-glycosylated peptides N-glycosylated peptides peptides This method integrated the advantages of Click Maltose and zwitterionic HILIC (ZIC-HILIC) and showed a relatively higher specificity for N-glycosylated peptides. 8180202 3 2 gly glycosylation 449:461 arg2 the six possible glycosylation sites the six possible glycosylation sites sites To study the extent of addition and processing of individual carbohydrate chains, we expressed CBG mutants, each containing only one of the six possible glycosylation sites, in Chinese hamster ovary cells and examined their electrophoretic, immunochemical, and lectin-binding properties. 30011186 5 109 gly glycoproteins 708:720 arg1 glycoproteins glycoproteins Fterm glycoproteins Despite the importance of glycoproteins, global analysis of protein glycosylation (either glycoproteins or glycans) in complex biological samples has been a daunting task, and here we mainly focus on glycoprotein analysis using mass spectrometry (MS)-based bottom-up proteomics. 30011186 5 130 gly glycoproteins 644:656 arg1 glycoproteins glycoproteins Fterm glycoproteins Despite the importance of glycoproteins, global analysis of protein glycosylation (either glycoproteins or glycans) in complex biological samples has been a daunting task, and here we mainly focus on glycoprotein analysis using mass spectrometry (MS)-based bottom-up proteomics. 30011186 5 174 gly glycoprotein 818:829 arg1 glycoprotein analysis glycoprotein analysis Fterm glycoprotein Despite the importance of glycoproteins, global analysis of protein glycosylation (either glycoproteins or glycans) in complex biological samples has been a daunting task, and here we mainly focus on glycoprotein analysis using mass spectrometry (MS)-based bottom-up proteomics. 15474009 3 7 part_of site 588:591 arg1 several glycoproteins glycoproteins site Fterm Site glycoproteins site The latter has been reported to be a minor N-glycosylation site in several glycoproteins. 30841845 0 52 gly glycosylation 32:44 arg2 glycosylation sites glycosylation sites sites Positive-unlabelled learning of glycosylation sites in the human proteome. 30158294 6 45 gly N-glycosylation 861:875 arg2 a conserved N-glycosylation site site, N294 site, N294 Sequence alignment of SERINC family proteins led us to identify a conserved N-glycosylation site, N294, in SERINC5. 24872415 6 45 gly N-glycosylation 878:892 arg2 Asn(8) Asn(8) Asn(8) We found that a single N-glycosylation site (Asn(8)) was important for MICA018 surface expression. 24872415 6 45 gly N-glycosylation 878:892 arg2 a single N-glycosylation site a single N-glycosylation site site We found that a single N-glycosylation site (Asn(8)) was important for MICA018 surface expression. 20589574 7 10 part_of kinase 1219:1224 arg1 two Casein kinase II phosphorylation sites Casein kinase II two Casein kinase II phosphorylation sites OGER Site Casein kinase II sites Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear. 20589574 7 12 part_of site 1268:1271 arg1 the EIF1 protein EIF1 protein site PUBTATOR Site EIF1 protein P41567 site Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear. 20589574 7 40 part_of site 1202:1205 arg1 the EIF1 protein EIF1 protein site PUBTATOR Site EIF1 protein P41567 site Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear. 20589574 7 64 part_of II 1226:1227 arg1 two Casein kinase II phosphorylation sites Casein kinase II two Casein kinase II phosphorylation sites OGER Site Casein kinase II sites Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear. 20589574 7 67 part_of Casein 1212:1217 arg1 two Casein kinase II phosphorylation sites Casein kinase II two Casein kinase II phosphorylation sites OGER Site Casein kinase II sites Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear. 20589574 7 80 part_of sites 1245:1249 arg1 the EIF1 protein EIF1 protein sites PUBTATOR Site EIF1 protein P41567 sites Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear. 15009203 15 137 gly glycoprotein 2505:2516 arg1 the intact glycoprotein the intact glycoprotein Fterm glycoprotein ESI-MS and MALDI-MS analysis of endoproteolytically cleaved peptides as well as MALDI-TOF MS of the intact glycoprotein demonstrated the N- and C-termini integrity of the GM-CSF preparations. 8349598 7 73 gly acceptors 1590:1598 arg1 Trf Trf acceptors PUBTATOR Trf 7018 In contrast Bowes, EL-4, and B16L6 cell extracts transferred GalNAc to oligosaccharides acceptors on Trf but not on hCG. 8349598 7 73 gly acceptors 1590:1598 arg1 hCG hCG acceptors OGER hCG In contrast Bowes, EL-4, and B16L6 cell extracts transferred GalNAc to oligosaccharides acceptors on Trf but not on hCG. 22815146 9 48 part_of hemagglutinin 1890:1902 arg1 the hemagglutinin N-linked glycosylation site hemagglutinin the hemagglutinin N-linked glycosylation site Fterm Site hemagglutinin site Since N-linked glycosylation at these sites has been implicated in genetic and antigenic evolution of human influenza A viruses, we conclude that the relocation of the hemagglutinin N-linked glycosylation site from N142 to N144 renders swine influenza virus δ-cluster viruses resistant to antibody-mediated neutralization. 22815146 9 112 part_of N-linked 1904:1911 arg1 the hemagglutinin N-linked glycosylation site N-linked the hemagglutinin N-linked glycosylation site Cterm Site N-linked site Since N-linked glycosylation at these sites has been implicated in genetic and antigenic evolution of human influenza A viruses, we conclude that the relocation of the hemagglutinin N-linked glycosylation site from N142 to N144 renders swine influenza virus δ-cluster viruses resistant to antibody-mediated neutralization. 16735497 7 72 gly glycosylation 1088:1100 arg2 a new glycosylation site a new glycosylation site site RESULTS: The deletion of two nucleotides in codon 384 (1211_1212delTC) causes a frameshift altering the last 11 residues, introduces a new glycosylation site, and elongates the molecule by seven new amino acids. 16195790 6 44 gly glycosylation 959:971 arg2 the glycosylation site the glycosylation site site Group II viruses, which predominated in Finland during the 2003-2004 season, were characterized by loss of the glycosylation site at position 126 in HA1. 16195790 6 44 gly glycosylation 959:971 arg2 position 126 position 126 position 126 Group II viruses, which predominated in Finland during the 2003-2004 season, were characterized by loss of the glycosylation site at position 126 in HA1. 15100290 5 46 gly present 628:634 arg2 CDR1 AND another carbohydrate CDR1 another carbohydrate PUBTATOR CDR1 1038 Also, when another carbohydrate was present in CDR1, CDR2, or CDR3 of the L chain, the V(H) CDR2 glycan remained high mannose. 15100290 5 46 gly present 628:634 arg1 CDR2 AND another carbohydrate CDR2 another carbohydrate OGER CDR2 P97817 Also, when another carbohydrate was present in CDR1, CDR2, or CDR3 of the L chain, the V(H) CDR2 glycan remained high mannose. 15100290 5 46 gly present 628:634 arg1 CDR3 AND another carbohydrate CDR3 another carbohydrate PUBTATOR CDR3 8163 Also, when another carbohydrate was present in CDR1, CDR2, or CDR3 of the L chain, the V(H) CDR2 glycan remained high mannose. 11152692 11 24 gly O-glycosylation 1339:1353 arg2 a potential O-glycosylation site a potential O-glycosylation site site The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54). 11152692 11 33 gly N-glycosylation 1243:1257 arg2 an N-glycosylation site an N-glycosylation site site The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54). 11152692 11 38 gly site 1259:1262 arg1 a heterogeneous oligosaccharide structure site a heterogeneous oligosaccharide structure site The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54). 11152692 11 61 gly site 1355:1358 arg1 a heterogeneous oligosaccharide structure site a heterogeneous oligosaccharide structure site The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54). 11152692 11 24 gly O-glycosylation 1339:1353 arg2 Asn Asn(281) Asn(281) The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54). 11152692 11 24 gly O-glycosylation 1339:1353 arg2 Ser Ser(54) Ser(54) The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54). 11152692 11 33 gly N-glycosylation 1243:1257 arg2 Asn Asn(281) Asn(281) The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54). 11152692 11 33 gly N-glycosylation 1243:1257 arg2 Ser Ser(54) Ser(54) The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54). 10374967 0 42 part_of herpesvirus-6 44:56 arg1 C-terminal external domains herpesvirus-6 glycoprotein H C-terminal external domains Cterm Site herpesvirus-6 glycoprotein H domains N- and C-terminal external domains of human herpesvirus-6 glycoprotein H affect a fusion-associated conformation mediated by glycoprotein L binding the N terminus. 20507882 7 7 gly glycopeptides 1308:1320 arg2 Twenty-five glycopeptides Twenty-five glycopeptides glycopeptides Twenty-five glycopeptides were characterized from human alpha-dystroglycan, which provide insight to the complex in vivo O-glycosylation of alpha-dystroglycan. 20507882 7 10 gly O-glycosylation 1417:1431 arg1 alpha-dystroglycan alpha-dystroglycan Twenty-five glycopeptides were characterized from human alpha-dystroglycan, which provide insight to the complex in vivo O-glycosylation of alpha-dystroglycan. 11428934 4 54 gly glycosylated 696:707 arg1 N-beta-Glc N-beta-Glc The solution conformational behavior of two MOG derived peptides-hMOG(30-50) (1) and the glycosylated analogue [Asn(31)(N-beta-Glc)]hMOG(30-50) (2)-were investigated through NMR analysis in a water/HFA solution. 11428934 4 54 gly glycosylated 696:707 arg1 the glycosylated analogue [Asn the glycosylated analogue [Asn The solution conformational behavior of two MOG derived peptides-hMOG(30-50) (1) and the glycosylated analogue [Asn(31)(N-beta-Glc)]hMOG(30-50) (2)-were investigated through NMR analysis in a water/HFA solution. 11428934 4 54 gly glycosylated 696:707 arg1 31 31 The solution conformational behavior of two MOG derived peptides-hMOG(30-50) (1) and the glycosylated analogue [Asn(31)(N-beta-Glc)]hMOG(30-50) (2)-were investigated through NMR analysis in a water/HFA solution. 16040252 3 32 gly glycosylation 466:478 arg2 a single C-terminal glycosylation site a single C-terminal glycosylation site site We found evolutionary conservation of a leader sequence, a single C-terminal glycosylation site, collagen-binding residues, and four specific conserved PEDF peptides. 18085777 1 2 gly glycoproteins 174:186 arg1 complex glycoproteins complex glycoproteins Fterm glycoproteins The chemical synthesis of complex glycoproteins is an ongoing challenge in protein chemistry. 25170432 1 33 gly N-glycosylated 134:147 arg1 N-glycosylated membrane proteins N-glycosylated membrane proteins Fterm proteins Prostaglandin H synthases (PGHSs) are N-glycosylated membrane proteins that catalyse the committed step in prostaglandin synthesis. 17522223 2 1 gly sites 361:365 arg1 gp120 gp120 sites PUBTATOR gp120 3700 Here, we delineate the N-linked glycosylation (N-glycan) sites in gp120 that contribute to optimal DC-SIGN binding. 11248207 2 43 part_of contains 345:352 arg1 the carboxy terminus AND an N-glycosylation site the carboxy terminus an N-glycosylation site site The model is based on hydropathy analysis and the extracellular location of the carboxy terminus, which contains an N-glycosylation site. 12662294 10 39 gly glycopeptide 1166:1177 arg2 the glycopeptide the glycopeptide glycopeptide Mass analysis of the glycopeptide verified the oligosaccharide. 23891555 6 36 part_of IgA1 906:909 arg1 IgA1 hinge-region O-glycopeptides IgA1 IgA1 hinge-region O-glycopeptides OGER Site IgA1 P01876 O-glycopeptides Following a novel strategy, IgA1 hinge-region O-glycopeptides were fractionated by reversed-phase liquid chromatography using a microgradient device and identified by MALDI-TOF/TOF tandem MS (MS/MS). 7685965 7 47 gly deglycosylation 1118:1132 arg1 HA1 HA1 OGER HA1 More extensive deglycosylation of HA1 had a differential effect on the clones, allowing one to proliferate but not the other. 12139214 3 46 part_of TIMP-2 828:833 arg1 the N-terminal domain TIMP-2 the N-terminal domain PUBTATOR Site TIMP-2 7077 domain The open reading frame corresponds to a putative hookworm tissue inhibitor of metalloproteases (TIMP) with 33% identity and 50% similarity to the N-terminal domain of human TIMP-2. 10837482 2 59 gly glycosylation 525:537 arg2 the 10 potential Asn glycosylation sites the 10 potential Asn glycosylation sites sites The aim of this study was to investigate the roles of the N-linked oligosaccharides on the secreted form of mouse meprin A. Recombinant meprin alpha and mutants in which one of the 10 potential Asn glycosylation sites was mutated to Gln were all secreted and sorted exclusively into the apical medium of polarized Madin-Darby canine kidney cells, indicating that no specific N-linked oligosaccharide acts as a determinant for apical targeting of meprin alpha. 12010970 7 4 gly attached 858:865 arg2 residue 148 AND the pilin glycan residue 148 the pilin glycan residue 148 These results showed the pilin glycan to be attached to residue 148, the carboxy-terminal amino acid. 28708860 3 12 gly N-glycosylation 462:476 arg1 NA NA PUBTATOR NA 4758 The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA). 28708860 3 12 gly N-glycosylation 462:476 arg1 neuraminidase neuraminidase PUBTATOR neuraminidase 4758 The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA). 28708860 3 12 gly N-glycosylation 462:476 arg1 hemagglutinin hemagglutinin Fterm hemagglutinin The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA). 9882683 3 66 gly glycoprotein 274:285 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Pilin is a glycoprotein, and pilin antigenic variation has been shown to be responsible for intrastrain variability with respect to the degree of adhesion in both MC and GC. 8631363 3 11 gly contained 418:426 arg1 the tumor necrosis factor-alpha AND galactose the tumor necrosis factor-alpha galactose PUBTATOR tumor necrosis factor-alpha 7124 Sugar composition analyses revealed that the tumor necrosis factor-alpha contained galactose, N-acetylgalactosamine and N-acetylneuraminic acid as sugar components. 8631363 3 11 gly contained 418:426 arg1 the tumor necrosis factor-alpha AND N-acetylneuraminic acid the tumor necrosis factor-alpha N-acetylneuraminic acid PUBTATOR tumor necrosis factor-alpha 7124 Sugar composition analyses revealed that the tumor necrosis factor-alpha contained galactose, N-acetylgalactosamine and N-acetylneuraminic acid as sugar components. 8631363 3 11 gly contained 418:426 arg1 the tumor necrosis factor-alpha AND N-acetylgalactosamine the tumor necrosis factor-alpha N-acetylgalactosamine PUBTATOR tumor necrosis factor-alpha 7124 Sugar composition analyses revealed that the tumor necrosis factor-alpha contained galactose, N-acetylgalactosamine and N-acetylneuraminic acid as sugar components. 8631363 3 11 gly contained 418:426 arg1 the tumor necrosis factor-alpha AND sugar components the tumor necrosis factor-alpha sugar components PUBTATOR tumor necrosis factor-alpha 7124 Sugar composition analyses revealed that the tumor necrosis factor-alpha contained galactose, N-acetylgalactosamine and N-acetylneuraminic acid as sugar components. 31393126 3 12 gly heterogeneity 582:594 arg1 RJ glycoproteins RJ glycoproteins Fterm glycoproteins Here, a combined glycomics and glycoproteomics strategy was developed for the site-specific analysis of N-linked glycosylation heterogeneity of RJ glycoproteins. 31393126 3 54 gly glycoproteins 602:614 arg1 RJ glycoproteins RJ glycoproteins Fterm glycoproteins Here, a combined glycomics and glycoproteomics strategy was developed for the site-specific analysis of N-linked glycosylation heterogeneity of RJ glycoproteins. 31393126 3 65 gly glycosylation 568:580 arg1 RJ glycoproteins RJ glycoproteins Fterm glycoproteins Here, a combined glycomics and glycoproteomics strategy was developed for the site-specific analysis of N-linked glycosylation heterogeneity of RJ glycoproteins. 27957769 9 91 gly glycopeptide 1941:1952 arg2 the branched core 2 glycopeptide epitopes the branched core 2 glycopeptide epitopes glycopeptide epitopes With the extended mucin core structures in hand, antibody cross-reactivity toward the branched core 2 glycopeptide epitopes is explored. 23720719 1 38 gly glycosylation 546:558 arg2 the N332 glycosylation site the N332 glycosylation site site Neutralization-resistant simian-human immunodeficiency virus AD8 (SHIVAD8) variants that emerged in an infected macaque elite neutralizer targeting the human immunodeficiency virus type 1 (HIV-1) gp120 N332 glycan acquired substitutions of critical amino acids in the V3 region rather than losing the N332 glycosylation site. 2502393 6 29 part_of precursor 1581:1589 arg1 the S-mutant precursor sequence precursor the S-mutant precursor sequence Fterm Site precursor sequence To monitor the transport steps from the endoplasmic reticulum to the Golgi compartment an RNA encoding a glycosylation site within the S-mutant precursor sequence was constructed. 2502393 6 58 part_of S-mutant 1572:1579 arg1 the S-mutant precursor sequence S-mutant the S-mutant precursor sequence Cterm Site S-mutant sequence To monitor the transport steps from the endoplasmic reticulum to the Golgi compartment an RNA encoding a glycosylation site within the S-mutant precursor sequence was constructed. 1371468 7 46 part_of LECAM-1 1209:1215 arg1 the lectin domain LECAM-1 the lectin domain PUBTATOR Site LECAM-1 281485 domain Since the lectin domain of LECAM-1 is thought to mediate lymphocyte-HEV adhesion, we sought to establish further the similarity of the bovine, mouse, and human molecules by comparing nucleotide sequences in this region of the molecule. 25544388 7 78 gly N-glycosylation 1198:1212 arg2 the new N-glycosylation site the new N-glycosylation site site Subsequently, for the purpose of glycoengineering huIFN-β, analogs with 3D structures more similar to the wild-type huIFN-β and exposed Asn residue in the new N-glycosylation site were identified. 21980282 4 84 gly glycosylation 815:827 arg2 glycosylation motifs glycosylation motifs motifs Signatures included single amino acids, glycosylation motifs, and multi-site patterns based on functional or structural groupings of amino acids. 9041240 4 19 gly mass 726:729 arg1 one N-glycosylation site one N-glycosylation site site RESULTS: The hIFC-1 cDNA contains an open reading frame for 591 amino acids (relative molecular mass = 64,826, pI = 9.4, 12 transmembrane domains, three protein kinase C phosphorylation sites, and one N-glycosylation site) with 74% DNA and 66% amino acid sequence homologies with the mouse cDNA counterpart. 9041240 4 45 gly N-glycosylation 831:845 arg2 one N-glycosylation site one N-glycosylation site site RESULTS: The hIFC-1 cDNA contains an open reading frame for 591 amino acids (relative molecular mass = 64,826, pI = 9.4, 12 transmembrane domains, three protein kinase C phosphorylation sites, and one N-glycosylation site) with 74% DNA and 66% amino acid sequence homologies with the mouse cDNA counterpart. 15147907 2 0 gly presence 333:340 arg2 the human complement serum glycoprotein C3 AND such monoglucosylated N-glycans the human complement serum glycoprotein C3 such monoglucosylated N-glycans Cterm C3 We report here the presence of such monoglucosylated N-glycans on the human complement serum glycoprotein C3. 15147907 2 53 gly glycoprotein 407:418 arg1 the human complement serum glycoprotein C3 the human complement serum glycoprotein C3 Fterm glycoprotein We report here the presence of such monoglucosylated N-glycans on the human complement serum glycoprotein C3. 12631291 9 81 gly N-glycosylation 1186:1200 arg2 four possible N-glycosylation sites four possible N-glycosylation sites sites The amino acid sequences of both isoforms of the allergen contain four possible N-glycosylation sites. 16816852 7 34 gly glycosylation 1137:1149 arg2 one more glycosylation site one more glycosylation site site The HA1 sequence data showed that the virus had replacement of 9 amino acids, and there was one more glycosylation site at 197th site. 29759137 4 40 gly glycosylation 407:419 arg1 IgG IgG Cterm IgG However, limited data is available on the glycosylation pattern of IgG in cerebrospinal fluid (CSF) compared to serum. 3200844 8 11 gly glycopeptide 1100:1111 arg2 the original glycopeptide sequence the original glycopeptide sequence glycopeptide sequence This open reading frame contained a CNBr fragment identical to the original glycopeptide sequence and a second CNBr fragment corresponding to a nonglycosylated peptide that was also isolated from the purified pore glycoprotein. 3200844 8 20 gly nonglycosylated 1168:1182 arg1 a nonglycosylated peptide a nonglycosylated peptide peptide This open reading frame contained a CNBr fragment identical to the original glycopeptide sequence and a second CNBr fragment corresponding to a nonglycosylated peptide that was also isolated from the purified pore glycoprotein. 3200844 8 33 gly glycoprotein 1238:1249 arg1 the purified pore glycoprotein the purified pore glycoprotein Fterm glycoprotein This open reading frame contained a CNBr fragment identical to the original glycopeptide sequence and a second CNBr fragment corresponding to a nonglycosylated peptide that was also isolated from the purified pore glycoprotein. 12064867 8 47 part_of gp120 1356:1360 arg1 one V1 glycosylation site gp120 one V1 glycosylation site PUBTATOR Site gp120 155971 site Finally, we determined the structural class of the glycan of one V1 glycosylation site of prototype HIV-1 LAI gp120, which remained unsolved from previous studies, and found that it belonged to the complex type of glycans. 3219367 10 43 gly glycosylation 2020:2032 arg2 a given glycosylation site a given glycosylation site site These results clearly indicate that the protein structure and, possibly, the carbohydrate chain at the neighboring site greatly influence glycosylation of a given glycosylation site. 3219367 10 71 gly glycosylation 1995:2007 arg1 a given glycosylation site a given glycosylation site site These results clearly indicate that the protein structure and, possibly, the carbohydrate chain at the neighboring site greatly influence glycosylation of a given glycosylation site. 3219367 10 90 gly site 1972:1975 arg1 the carbohydrate chain site the carbohydrate chain site These results clearly indicate that the protein structure and, possibly, the carbohydrate chain at the neighboring site greatly influence glycosylation of a given glycosylation site. 30538125 7 84 gly glycosylation 1116:1128 arg2 an extra glycosylation site an extra glycosylation site site Functional analysis showed that the rs61752561 SNP affects PSA stability and structural conformation and creates an extra glycosylation site. 3849428 1 17 part_of hemagglutinin 140:152 arg1 the 15-amino acid signal peptide hemagglutinin the 15-amino acid signal peptide Fterm Site hemagglutinin peptide A chimeric gene consisting of DNA coding for the 15-amino acid signal peptide of influenza virus hemagglutinin and the C-terminal 694 amino acids of SV40 large T antigen was inserted into a bovine papilloma virus (BPV) expression vector and introduced into NIH-3T3 cells. 15616123 1 7 gly occupied 209:216 arg2 16 asparagine residues 16 asparagine residues asparagine residues Human apolipoprotein B100 (apoB100) has 19 potential N-glycosylation sites, and 16 asparagine residues were reported to be occupied by high-mannose type, hybrid type, and monoantennary and biantennary complex type oligosaccharides. 15616123 1 10 gly N-glycosylation 139:153 arg2 19 potential N-glycosylation sites 19 potential N-glycosylation sites sites Human apolipoprotein B100 (apoB100) has 19 potential N-glycosylation sites, and 16 asparagine residues were reported to be occupied by high-mannose type, hybrid type, and monoantennary and biantennary complex type oligosaccharides. 9461526 1 51 gly glycoproteins 104:116 arg1 four small glycoproteins four small glycoproteins Fterm glycoproteins Prosaposin is the precursor of four small glycoproteins, saposins A-D, that activate lysosomal sphingolipid hydrolysis. 1587858 3 67 part_of PGG/HS 572:577 arg1 the entire translated region PGG/HS the entire translated region PUBTATOR Site PGG/HS 5742 region Sequence analysis of this clone showed that (a) it contained the entire translated region of PGG/HS and (b) it displayed an in-frame splicing of the last 111 base pairs encoded by exon 9, which resulted in the elimination of the N-glycosylation site at residue 409. 2246248 6 38 part_of protein 623:629 arg1 The predicted protein sequence protein The predicted protein sequence Fterm Site protein sequence The predicted protein sequence of 496 amino acids includes a 22-residue signal peptide and a 474-residue mature protein of Mr 51,344. 17050611 7 16 gly N-glycosylation 1118:1132 arg2 more than five N-glycosylation site deletions more than five N-glycosylation site deletions site PRM-A has a high genetic barrier, since more than five N-glycosylation site deletions in gp120 are required to afford moderate drug resistance. 3123215 5 55 gly N-glycosylation 1068:1082 arg2 a single potential N-glycosylation site a single potential N-glycosylation site site The sequence shows a single potential N-glycosylation site, which is assigned to the vesicle interior, and a carboxy-terminal tail of 89 amino acids which contains glycine-rich tetrapeptide repeats, the epitope of monoclonal antibody SY38, and a number of collagenase-sensitive sites accessible on the surface of the intact vesicles. 3123215 5 71 gly sites 1308:1312 arg1 glycine-rich tetrapeptide repeats sites glycine-rich tetrapeptide repeats sites The sequence shows a single potential N-glycosylation site, which is assigned to the vesicle interior, and a carboxy-terminal tail of 89 amino acids which contains glycine-rich tetrapeptide repeats, the epitope of monoclonal antibody SY38, and a number of collagenase-sensitive sites accessible on the surface of the intact vesicles. 3123215 5 78 gly glycine-rich 1194:1205 arg1 glycine-rich tetrapeptide repeats glycine glycine-rich tetrapeptide repeats glycine The sequence shows a single potential N-glycosylation site, which is assigned to the vesicle interior, and a carboxy-terminal tail of 89 amino acids which contains glycine-rich tetrapeptide repeats, the epitope of monoclonal antibody SY38, and a number of collagenase-sensitive sites accessible on the surface of the intact vesicles. 26773038 4 16 gly domain 631:636 arg1 the N-linked glycans domain the N-linked glycans domain We investigated how the N-linked glycans of the VWF A2 domain affect thermostability and regulate both the exposure of the ADAMTS13 binding sites and the scissile bond. 25227423 2 58 gly glycosylation 416:428 arg2 surface residues surface residues residues One common assumption is that N-glycans physically shield surface residues that are near to glycosylation sites, thereby preventing antibodies from binding to them. 25227423 2 58 gly glycosylation 416:428 arg2 glycosylation sites glycosylation sites sites One common assumption is that N-glycans physically shield surface residues that are near to glycosylation sites, thereby preventing antibodies from binding to them. 21752569 7 21 gly sequence 1006:1013 arg1 N-glycan sequence confirmation N-glycan sequence confirmation The N-glycosylation site and N-glycan sequence confirmation were also demonstrated in this study. 21752569 7 46 gly N-glycosylation 972:986 arg2 The N-glycosylation site The N-glycosylation site site The N-glycosylation site and N-glycan sequence confirmation were also demonstrated in this study. 14691230 5 56 gly residues 983:990 arg1 39-766 39-766 residues 39-766 Individual Asn-->Ala point mutants were introduced at the nine glycosylation sites in the extracellular domain of DPPIV (residues 39-766). 14691230 5 61 gly introduced 902:911 arg1 residues 39-766 residues 39-766 residues 39-766 Individual Asn-->Ala point mutants were introduced at the nine glycosylation sites in the extracellular domain of DPPIV (residues 39-766). 14691230 5 74 gly glycosylation 925:937 arg2 the nine glycosylation sites the nine glycosylation sites sites Individual Asn-->Ala point mutants were introduced at the nine glycosylation sites in the extracellular domain of DPPIV (residues 39-766). 20621099 3 5 gly N-glycosylation 542:556 arg2 N-glycosylation site N-glycosylation site site Here we performed mass spectrometric analyses of the Fc fragment of an unglycosylated mutant of mouse immunoglobulin G2b, whose conserved N-glycosylation site, i.e. Asn297, was substituted with alanine. 8294492 6 64 part_of peptides 936:943 arg1 a new glycosylation site peptides a new glycosylation site site In exon 2-V a frameshift resulted in a unique V carboxyl terminus of 53 novel peptides with a new glycosylation site. 22239659 3 33 gly N-glycoproteins 508:522 arg1 N-glycoproteins N-glycoproteins Fterm N-glycoproteins In this study, we present a workflow for the analysis of the microheterogeneity of N-glycoproteins that couples hydrophilic interaction and nanoreverse-phase C18 chromatography to tandem QTOF mass spectrometric analysis. 22239659 3 36 gly microheterogeneity 486:503 arg1 N-glycoproteins N-glycoproteins Fterm N-glycoproteins In this study, we present a workflow for the analysis of the microheterogeneity of N-glycoproteins that couples hydrophilic interaction and nanoreverse-phase C18 chromatography to tandem QTOF mass spectrometric analysis. 9242452 8 19 part_of receptor 1510:1517 arg1 T-cell receptor regions receptor T-cell receptor regions Fterm Site receptor regions Some glycopeptides were not immunogenic, suggesting that there may be holes in the T-cell repertoire due to a lack of T-cell receptor regions accommodating certain glycan structures. 9242452 8 83 part_of T-cell 1503:1508 arg1 T-cell receptor regions T-cell T-cell receptor regions Cterm Site T-cell regions Some glycopeptides were not immunogenic, suggesting that there may be holes in the T-cell repertoire due to a lack of T-cell receptor regions accommodating certain glycan structures. 17924005 4 59 part_of Pol 785:787 arg1 the Pol sequences Pol the Pol sequences OGER Site Pol sequences After analyzing the Pol sequences, results revealed a total amino acid variation of 0.75% for HLA-I and HLA-II epitopes. 17924005 4 76 part_of HLA-II 869:874 arg1 HLA-II epitopes HLA HLA-II epitopes OGER Site HLA epitopes After analyzing the Pol sequences, results revealed a total amino acid variation of 0.75% for HLA-I and HLA-II epitopes. 8163463 8 64 part_of proteins 1599:1606 arg1 extracellular domains proteins extracellular domains Fterm Site proteins domains Since N-linked glycosylation has only been found to occur on extracellular domains of plasma membrane proteins, these results suggest that the proposed transmembrane topology model for the glutamate receptor subunits is incorrect. 10858228 5 46 gly glycoprotein 838:849 arg1 an antigenically distinct, surface glycoprotein an antigenically distinct, surface glycoprotein Fterm glycoprotein We have cloned and sequenced a gene designated Cpgp40/15 that encodes gp40 as well as gp15, an antigenically distinct, surface glycoprotein also implicated in C. parvum-host cell interactions. 10858228 5 46 gly glycoprotein 838:849 arg1 gp15 gp15 Cterm gp15 We have cloned and sequenced a gene designated Cpgp40/15 that encodes gp40 as well as gp15, an antigenically distinct, surface glycoprotein also implicated in C. parvum-host cell interactions. 2721453 0 47 gly asparagine-linked 48:64 arg1 the asparagine-linked oligosaccharides asparagine the asparagine-linked oligosaccharides asparagine Characterization and charge distribution of the asparagine-linked oligosaccharides on secreted mouse thyrotropin and free alpha-subunits. 2189790 2 44 part_of contains 241:248 arg1 Mature hIL-1 alpha AND one potential N-linked glycosylation site Mature hIL-1 alpha one potential N-linked glycosylation site PUBTATOR Site Mature hIL-1 alpha 3552 site Mature hIL-1 alpha contains one potential N-linked glycosylation site that is not recognized in mammalian cells. 7999071 4 0 part_of position 681:688 arg1 the LPL mature protein protein position Fterm Site protein position 383, DNA sequence analysis of the LPL gene from the patient revealed a homozygous nucleotide change: a A-->G transition at nucleotide position 383, resulting in an amino acid substitution of Ser for Asn43, which is believed to be an N-linked glycosylation site of the LPL mature protein. 7999071 4 49 part_of protein 826:832 arg1 an N-linked glycosylation site protein an N-linked glycosylation site Fterm Site protein site DNA sequence analysis of the LPL gene from the patient revealed a homozygous nucleotide change: a A-->G transition at nucleotide position 383, resulting in an amino acid substitution of Ser for Asn43, which is believed to be an N-linked glycosylation site of the LPL mature protein. 6980014 4 44 part_of CNBr 578:581 arg1 each purified CNBr fragment CNBr each purified CNBr fragment Cterm Site CNBr fragment The oligosaccharide structure at each glycosylation site on each purified CNBr fragment was determined by compositional analysis, behavior on Con A affinity chromatography, and methylation analysis. 26946944 1 51 gly glycosylated 89:100 arg1 A glycosylated lectin A glycosylated lectin Fterm lectin A glycosylated lectin (CTL) with specificity for mannose and glucose has been detected and purified from seeds of Centrolobium tomentosum, a legume plant from Dalbergieae tribe. 1869556 9 93 gly -Asn-X-Ser/Thr-glycosylation 1426:1453 arg2 the -Asn-X-Ser/Thr-glycosylation site the -Asn-X-Ser/Thr-glycosylation site site Alteration of the uncommon Cys8 residue in the -Asn-X-Ser/Thr-glycosylation site to Ser also had no effect. 2125273 8 21 gly glycosylation 927:939 arg2 Asn58 Asn58 Asn58 The VH441 germ-line gene encodes a potential glycosylation site at Asn58 in the complementarity-determining region 2. 2125273 8 21 gly glycosylation 927:939 arg2 a potential glycosylation site a potential glycosylation site site The VH441 germ-line gene encodes a potential glycosylation site at Asn58 in the complementarity-determining region 2. 29587225 3 51 gly sialylation 439:449 arg1 EPO conformation EPO conformation PUBTATOR EPO 2056 Nonetheless, a detailed understanding of the effects of sialylation on EPO conformation and dynamics is still lacking. 23339644 10 84 gly occupied 2112:2119 arg2 This site This site site This site was partially occupied in 293T-gp120 but fully occupied in CHO-gp120. 23339644 10 159 gly occupied 2145:2152 arg2 This site This site site This site was partially occupied in 293T-gp120 but fully occupied in CHO-gp120. 9116048 0 9 part_of C5a 93:95 arg1 corrected amino acid sequence C5a corrected amino acid sequence PUBTATOR Site C5a 362119 sequence Nucleotide and corrected amino acid sequence of the functional recombinant rat anaphylatoxin C5a. 9242452 2 117 gly attached 554:561 arg1 asparagine AND different glycans asparagine different glycans asparagine To study T-cell responses to tumor-associated glycans, the mouse hemoglobin-derived decapeptide Hb(67-76), which binds well to the MHC class II molecule E(k) and is nonimmunogenic in CBA/J mice, was either O- or N-glycosylated at its primary T-cell receptor contact residue, position 72, with different glycans attached to either threonine, serine, or asparagine. 9242452 2 117 gly attached 554:561 arg1 either threonine AND different glycans threonine, serine different glycans threonine, serine To study T-cell responses to tumor-associated glycans, the mouse hemoglobin-derived decapeptide Hb(67-76), which binds well to the MHC class II molecule E(k) and is nonimmunogenic in CBA/J mice, was either O- or N-glycosylated at its primary T-cell receptor contact residue, position 72, with different glycans attached to either threonine, serine, or asparagine. 12706347 4 9 part_of asparagine 691:700 arg1 NTPDase3 NTPDase3 asparagine PUBTATOR SpecificSite NTPDase3 956 sites, asparagine 81 Only one of these putative glycosylation sites, asparagine 81 in NTPDase3, which is located near apyrase conserved region 1 (ACR1), is invariant in all the cell surface membrane eNTPDases. 20506028 0 65 gly glycosylated 25:36 arg1 the glycosylated N-terminal domain chondromodulin-I domain PUBTATOR chondromodulin-I 11061 domain A functional role of the glycosylated N-terminal domain of chondromodulin-I. 27881683 3 22 gly glycosylation 541:553 arg2 one additional glycosylation site one additional glycosylation site site In this study two rhIFN-β analogs with one additional glycosylation site, L6T and S75N, identified by a rational in silico approach, were characterized. 26980729 4 32 gly glycosylated 673:684 arg1 All mutant proteins All mutant proteins Fterm proteins All mutant proteins were dephosphorylated and incompletely glycosylated, but dephosphorylation did not explain the inactivation because the mutations inactivated a "constitutively phosphorylated" enzyme. 11248207 2 9 gly N-glycosylation 357:371 arg2 an N-glycosylation site an N-glycosylation site site The model is based on hydropathy analysis and the extracellular location of the carboxy terminus, which contains an N-glycosylation site. 16227292 0 44 gly glycoproteins 45:57 arg1 bunyamwera virus glycoproteins bunyamwera virus glycoproteins Fterm glycoproteins Role of N-linked glycans on bunyamwera virus glycoproteins in intracellular trafficking, protein folding, and virus infectivity. 24721674 1 80 gly Glycosylation 156:168 arg1 membrane proteins membrane proteins Fterm proteins Glycosylation of membrane proteins plays an important role in cellular behaviors such as cell-cell interaction, immunologic recognition and cell signaling. 10889209 3 54 gly N-glycosylation 526:540 arg2 one extracellular consensus N-glycosylation site one extracellular consensus N-glycosylation site site Both GIRK1 and GIRK4 have one extracellular consensus N-glycosylation site. 7540044 3 42 part_of sequence 720:727 arg1 this region sequence this region region The amino acid sequence of the glycoprotein in this region exhibits some degree of variability among different rabies virus and rabies virus related strains, including the replacement of the asparagine residue with aspartic acid or threonine. 7540044 3 74 part_of glycoprotein 736:747 arg1 The amino acid sequence glycoprotein The amino acid sequence Fterm Site glycoprotein sequence The amino acid sequence of the glycoprotein in this region exhibits some degree of variability among different rabies virus and rabies virus related strains, including the replacement of the asparagine residue with aspartic acid or threonine. 19284292 2 23 gly polysialylation 406:420 arg1 NCAM NCAM PUBTATOR NCAM 4684 Examples of the latter are found in the formation of the mannose-6-phosphate receptor ligand on lysosomal hydrolases, and in polysialylation of NCAM, which are regulated via conformational signal patches on the protein. 19284292 2 45 gly NCAM 425:428 arg1 polysialylation NCAM polysialylation PUBTATOR NCAM 4684 Examples of the latter are found in the formation of the mannose-6-phosphate receptor ligand on lysosomal hydrolases, and in polysialylation of NCAM, which are regulated via conformational signal patches on the protein. 17406563 4 57 gly glycoproteins 1259:1271 arg1 a thousand glycoproteins a thousand glycoproteins Fterm glycoproteins The application of this protocol to the characterization of N-linked glycoproteins from crude extracts of the nematode Caenorhabditis elegans or mouse liver provides a list of hundreds to a thousand glycoproteins and their sites of glycosylation within a week. 17406563 4 76 gly glycoproteins 1129:1141 arg1 N-linked glycoproteins N-linked glycoproteins Fterm glycoproteins The application of this protocol to the characterization of N-linked glycoproteins from crude extracts of the nematode Caenorhabditis elegans or mouse liver provides a list of hundreds to a thousand glycoproteins and their sites of glycosylation within a week. 17406563 4 82 gly glycosylation 1292:1304 arg2 their sites their sites sites The application of this protocol to the characterization of N-linked glycoproteins from crude extracts of the nematode Caenorhabditis elegans or mouse liver provides a list of hundreds to a thousand glycoproteins and their sites of glycosylation within a week. 1594597 4 34 gly N-glycosylation 798:812 arg2 asparagine-1770 asparagine-1770 asparagine-1770 In patient ARC-21, a methionine-to-threonine substitution at position 1772 in the factor VIII light chain creates a potential new N-glycosylation site at asparagine-1770. 1594597 4 34 gly N-glycosylation 798:812 arg2 a potential new N-glycosylation site a potential new N-glycosylation site site In patient ARC-21, a methionine-to-threonine substitution at position 1772 in the factor VIII light chain creates a potential new N-glycosylation site at asparagine-1770. 22573318 6 44 gly glycosylation 860:872 arg2 five glycosylation sites five glycosylation sites sites Mass spectrometric analysis identified five glycosylation sites in type I collagen (i.e. α1,2-87, α1,2-174, and α2-219. 27480293 2 44 gly N-glycopeptides 216:230 arg2 highly heterogeneous N-glycopeptides highly heterogeneous N-glycopeptides N-glycopeptides Because highly heterogeneous N-glycopeptides are present in biological sources, the enrichment procedure is a crucial step for mass spectrometry analysis. 3485444 4 17 gly glycosylation 670:682 arg2 the glycosylation site the glycosylation site site The smallest fragment observed defined the distance between the glycosylation site and the amino terminus. 8496193 0 91 gly glycosylation 42:54 arg2 a functional glycosylation site a functional glycosylation site site Mouse procathepsin L lacking a functional glycosylation site is properly folded, stable, and secreted by NIH 3T3 cells. 2868718 8 28 part_of terminus 800:807 arg1 21 residues terminus 21 residues residues One glycosylation site was found 21 residues from the amino terminus, and no stop codons were found. 11087995 6 11 gly glycosylation 980:992 arg2 both glycosylation sites both glycosylation sites sites The double mutant Asn18Thr/Asn31Thr lacking both glycosylation sites showed a significant reduction in high affinity binding and inhibition of adenylyl cyclase while peptide selectivity was not affected. 16834341 0 14 gly glycopeptide 72:83 arg2 glycopeptide analysis glycopeptide analysis glycopeptide Comparative glycomics of the glycoprotein follicle stimulating hormone: glycopeptide analysis of isolates from two mammalian species. 16834341 0 60 gly glycoprotein 29:40 arg1 the glycoprotein follicle stimulating hormone the glycoprotein follicle stimulating hormone Fterm glycoprotein Comparative glycomics of the glycoprotein follicle stimulating hormone: glycopeptide analysis of isolates from two mammalian species. 7755594 1 0 gly glycoprotein 158:169 arg1 a secretory, dimeric glycoprotein a secretory, dimeric glycoprotein Fterm glycoprotein Human interferon-gamma (IFN-gamma) is a secretory, dimeric glycoprotein that forms a compact globular structure with potential N-linked glycosylation sites at Asn-25 and Asn-97 on the surface of the dimer. 7755594 1 0 gly glycoprotein 158:169 arg1 Human interferon-gamma Human interferon-gamma PUBTATOR Human interferon-gamma 3458 Human interferon-gamma (IFN-gamma) is a secretory, dimeric glycoprotein that forms a compact globular structure with potential N-linked glycosylation sites at Asn-25 and Asn-97 on the surface of the dimer. 7755594 1 64 gly glycosylation 235:247 arg2 potential N-linked glycosylation sites potential N-linked glycosylation sites sites Human interferon-gamma (IFN-gamma) is a secretory, dimeric glycoprotein that forms a compact globular structure with potential N-linked glycosylation sites at Asn-25 and Asn-97 on the surface of the dimer. 7755594 1 64 gly glycosylation 235:247 arg2 Asn-25 Asn-25 and Asn-97 Asn-25 and Asn-97 Human interferon-gamma (IFN-gamma) is a secretory, dimeric glycoprotein that forms a compact globular structure with potential N-linked glycosylation sites at Asn-25 and Asn-97 on the surface of the dimer. 9729121 7 89 part_of contained 1239:1247 arg1 the primary sequence AND the primary sequence the primary sequence the primary sequence sequence Moreover, the primary sequence contained two hydrophobic peptides on N- and C-termini. 9729121 7 89 part_of contained 1239:1247 arg1 the primary sequence AND two hydrophobic peptides the primary sequence two hydrophobic peptides peptides Moreover, the primary sequence contained two hydrophobic peptides on N- and C-termini. 12223479 12 107 gly glycosylation 2013:2025 arg1 its auxiliary beta4 subunit its auxiliary beta4 subunit PUBTATOR beta4 subunit 10717 Taken together, these data show that the pore-forming alpha subunit of the hSlo channel promotes N-linked glycosylation of its auxiliary beta4 subunit, and this in turn influences the modulation of the channel by the beta4 subunit. 16227292 7 83 gly glycans 1148:1154 arg1 N1169 N1169 N1169 SpecificSite N1169 In contrast, mutant Gc proteins lacking glycans on either N624 or N1169, or both sites, were able to target to the Golgi. 16227292 7 83 gly glycans 1148:1154 arg1 N624 N624 N624 SpecificSite N624 In contrast, mutant Gc proteins lacking glycans on either N624 or N1169, or both sites, were able to target to the Golgi. 11208474 6 16 part_of HBV 1147:1149 arg1 Gly to Ala HBV Gly to Ala Cterm AminoAcid HBV Ala Also, HBV variant with substitution at position 145 (Gly to Ala) has been recently reported to be antigenically altered and to show impaired recognition by polyclonal hepatitis B hyperimmune globulin in vitro. 2825202 9 52 gly glycosylation 1532:1544 arg2 One potential glycosylation site One potential glycosylation site site One potential glycosylation site was previously found in mature SAP-1. 8429003 6 100 gly glycosylation 1069:1081 arg2 the conserved site site site The glycosylation at the conserved site at Asn270 of rat sCD4 was identical to that seen for the equivalent site in human sCD4, and the oligomannose and hybrid structures were restricted to the nonconserved site at Asn159 in rat sCD4. 7475306 5 72 part_of gp46 850:853 arg1 the 233-253 sequence gp46 the 233-253 sequence Cterm Site gp46 sequence We have successfully engineered and synthesized the 233-253 sequence of gp46 of HTLV-1 with and without GlcNAC at Asn244. 23821822 5 51 gly N-glycosylation 608:622 arg2 one N-glycosylation site one N-glycosylation site site The sequence analysis showed N terminal 69 bp signal sequence and one N-glycosylation site. 15811651 0 0 gly proteins 55:62 arg1 the N-linked glycans proteins the N-linked glycans Fterm proteins Role of the N-linked glycans of the prM and E envelope proteins in tick-borne encephalitis virus particle secretion. 19753315 11 10 gly glycosylation 1496:1508 arg2 the glycosylation site the glycosylation site site PNGase F treatment of CLRN1-HA resulted in an electrophoretic mobility shift consistent with sugar residue cleavage in WT and in all CLRN1 mutants except in p.N48K mutated CLRN1, in which the mutation abolishes the glycosylation site. 17636988 8 97 gly N-glycosylation 1474:1488 arg2 103 N-glycosylation sites 103 N-glycosylation sites sites The two strategies were here applied to identify 103 N-glycosylation sites in the Cohn IV fraction of human plasma. 19297464 1 57 gly glycoprotein 149:160 arg1 Each Sindbis virus (SINV) surface glycoprotein Each Sindbis virus (SINV) surface glycoprotein Fterm glycoprotein Each Sindbis virus (SINV) surface glycoprotein has two sites for N-linked glycosylation (E1 positions 139 and 245 [E1-139 and E1-245] and E2 positions 196 and 318 [E2-196 and E2-318]). 19297464 1 64 gly positions 256:264 arg1 positions 196 and 318 positions 196 and 318 positions 196 and 318 Each Sindbis virus (SINV) surface glycoprotein has two sites for N-linked glycosylation (E1 positions 139 and 245 [E1-139 and E1-245] and E2 positions 196 and 318 [E2-196 and E2-318]). 19297464 1 88 gly glycosylation 189:201 arg1 318 positions 196 and 318 positions 196 and 318 Each Sindbis virus (SINV) surface glycoprotein has two sites for N-linked glycosylation (E1 positions 139 and 245 [E1-139 and E1-245] and E2 positions 196 and 318 [E2-196 and E2-318]). 9535843 10 39 gly glycosylated 1451:1462 arg1 A site A site site A site placed in the center of the putative pore region was glycosylated, suggesting that this region may have been luminal and was reinserted into the membrane at a late stage of channel assembly. 2334684 5 35 gly glycosylation 808:820 arg2 an N-linked glycosylation site an N-linked glycosylation site site Features of the protein shared with the human homologue include all of the cysteine residues, an N-linked glycosylation site at amino acid 50, and 75% sequence identity in domain D. Much of the same region is conserved in lamprey gamma-fibrinogen. 2334684 5 35 gly glycosylation 808:820 arg2 the cysteine residues the cysteine residues cysteine residues Features of the protein shared with the human homologue include all of the cysteine residues, an N-linked glycosylation site at amino acid 50, and 75% sequence identity in domain D. Much of the same region is conserved in lamprey gamma-fibrinogen. 23908491 5 74 gly glycoproteins 588:600 arg1 HCV envelope glycoproteins HCV envelope glycoproteins Fterm glycoproteins METHODS: Sequences of HCV envelope glycoproteins from Pakistani patients infected with subtype 3a were cloned and compared with other subtype 3a sequences. 16037490 2 11 gly glycopeptides 440:452 arg2 glycopeptides glycopeptides glycopeptides In this study, recovery of glycopeptides was improved by including divalent cations or increasing the organic solvent in the binding solution, without losing specificity, whereas it was still less effective for those with a long peptide backbone exceeding 50 amino acid residues. 9882683 8 2 gly glycosylation 1038:1050 arg2 Ser63 Ser63 Ser63 In the latter species, the glycosylation of pilin at Ser63 was shown to be required for the production of a truncated monomer of S pilin. 9597548 5 34 gly presence 900:907 arg1 this human IgM AND oligosaccharides this human IgM oligosaccharides OGER IgM P01871 Of note is the presence in this human IgM of oligosaccharides containing N-glycolylneuraminic acid and N-acetylneuraminic acid in the ratio of 98:2 as determined using anion-exchange chromatography. 28860626 0 36 gly N-glycosylation 12:26 arg1 influenza proteins influenza proteins Fterm proteins Topological N-glycosylation and site-specific N-glycan sulfation of influenza proteins in the highly expressed H1N1 candidate vaccines. 28860626 0 37 gly proteins 78:85 arg1 site-specific N-glycan sulfation proteins site-specific N-glycan sulfation Fterm proteins Topological N-glycosylation and site-specific N-glycan sulfation of influenza proteins in the highly expressed H1N1 candidate vaccines. 25628020 0 19 part_of sites 41:45 arg1 conserved proteins proteins sites Fterm Site proteins sites The acquisition of novel N-glycosylation sites in conserved proteins during human evolution. 23891555 11 64 part_of A1 1725:1726 arg1 the hinge region A1 (IgA1 the hinge region OGER Site A1 (IgA1 P01876 region BIOLOGICAL SIGNIFICANCE: In this work, we studied the O-glycosylation in the hinge region of human immunoglobulin A1 (IgA1). 26991339 3 31 gly sialylated 877:886 arg1 8 different neutral and sialylated glycans 8 different neutral and sialylated glycans The heterogeneous mixture of the proteoforms derives from the combination of 8 different neutral and sialylated glycans O-linked to Threonine 50, and 33 different glycans N-linked to Asparagine residues at positions 66, 87, 108, 129, 150, 171, 192, and 213. 12438611 6 21 gly glycosylation 1097:1109 arg2 no single glycosylation site no single glycosylation site site Mutational analysis indicated that no single glycosylation site affected the ability of gp120-Fc to bind DC-SIGN. 1331508 6 10 part_of PVR 900:902 arg1 The NH2-terminal immunoglobulin-like domain PVR domain, domain PUBTATOR Site PVR 5817 domain, domain The NH2-terminal immunoglobulin-like domain, domain 1, of the second monkey PVR, which lacks a putative N-glycosylation site, mediated poliovirus infection. 7532677 7 71 part_of Bw4 1204:1206 arg1 the Bw4 epitope Bw4 the Bw4 epitope PUBTATOR Site Bw4 474272 epitope These results show that the presence of the Bw4 epitope influences recognition of HLA-B molecules by NK cells that express NKB1, and suggest that the NKB1 molecule may act as a receptor for Bw4+ HLA-B alleles. 15616123 2 30 gly glycosylation 356:368 arg1 apoB100 apoB100 PUBTATOR apoB100 338 In the present study, a site-specific glycosylation analysis of apoB100 was carried out using reversed-phase high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC/ESI MS/MS). 30063822 2 28 part_of present 344:350 arg1 proteins AND single N-glycosylation sites proteins single N-glycosylation sites Fterm Site proteins sites The procedure relies on the presence of single N-glycosylation sites that are present natively in proteins or that can be engineered into glycoproteins by mutational elimination of all but one glycosylation site. 15199058 5 65 part_of IgE 732:734 arg1 the homologous rat IgE sequence IgE the homologous rat IgE sequence PUBTATOR Site IgE P01854 sequence Replacement of the entire Cepsilon3 A-B loop (residues 341-356) with the homologous rat IgE sequence resulted in complete loss of human CD23 recognition, as did replacement of residues 346-353, indicating that class-specific effector residue(s) are contained within these eight amino acids. 25759508 7 7 gly O-glycosylation 1035:1049 arg2 potential O-glycosylation sites potential O-glycosylation sites sites The O-glycosylation site was further confirmed by the recombinant production of mutant IgG3 in which potential O-glycosylation sites had been knocked out. 25759508 7 34 gly O-glycosylation 928:942 arg2 The O-glycosylation site The O-glycosylation site site The O-glycosylation site was further confirmed by the recombinant production of mutant IgG3 in which potential O-glycosylation sites had been knocked out. 11711599 2 34 gly glycoprotein 384:395 arg1 hepatitis C virus (HCV) E1 envelope glycoprotein hepatitis C virus (HCV) E1 envelope glycoprotein Fterm glycoprotein We investigated the role played by N-glycans in the immunogenicity of hepatitis C virus (HCV) E1 envelope glycoprotein, a naturally poor immunogen. 20923142 5 14 gly sialylated 1216:1225 arg1 45 sialylated glycopeptides 45 sialylated glycopeptides glycopeptides Herein, we report a total of 45 sialylated glycopeptides and an increase of sialylation in most of the glycoproteins identified in prostate cancer serum samples. 20923142 5 65 gly glycopeptides 1227:1239 arg2 45 sialylated glycopeptides 45 sialylated glycopeptides glycopeptides Herein, we report a total of 45 sialylated glycopeptides and an increase of sialylation in most of the glycoproteins identified in prostate cancer serum samples. 20923142 5 77 gly glycoproteins 1287:1299 arg1 the glycoproteins the glycoproteins Fterm glycoproteins Herein, we report a total of 45 sialylated glycopeptides and an increase of sialylation in most of the glycoproteins identified in prostate cancer serum samples. 3219367 5 39 gly site 607:610 arg1 the saccharide structures site the saccharide structures site In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin. 3219367 5 9 gly glycosylation 593:605 arg2 each glycosylation site erythropoietin site PUBTATOR erythropoietin 2056 site In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin. 3219367 5 31 gly site 607:610 arg1 Ser126 Asn24, Asn38, Asn83, and Ser126 Asn24, Asn38, Asn83, and Ser126 In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin. 3219367 5 31 gly site 607:610 arg1 Asn38 Asn24, Asn38, Asn83, and Ser126 Asn24, Asn38, Asn83, and Ser126 In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin. 3219367 5 31 gly site 607:610 arg1 Asn24 Asn24, Asn38, Asn83, and Ser126 Asn24, Asn38, Asn83, and Ser126 In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin. 3219367 5 31 gly site 607:610 arg1 Asn38 Asn24, Asn38, Asn83, and Ser126 Asn24, Asn38, Asn83, and Ser126 In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin. 3219367 5 31 gly site 607:610 arg1 Asn24 Asn24, Asn38, Asn83, and Ser126 Asn24, Asn38, Asn83, and Ser126 In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin. 3219367 5 31 gly site 607:610 arg1 Asn24 Asn24, Asn38, Asn83, and Ser126 Asn24, Asn38, Asn83, and Ser126 In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin. 8870657 10 39 gly unglycosylated 1230:1243 arg1 unglycosylated hLF unglycosylated hLF PUBTATOR hLF 3131 The presence in supernatant of unglycosylated hLF (approx. 15890930 1 79 part_of gp120 305:309 arg1 the V2 domain 1 gp120 the V2 domain PUBTATOR Site 1 gp120 3700 domain Monoclonal antibodies (MAbs) directed against epitopes in the V2 domain of human immunodeficiency virus type 1 gp120 often possess neutralizing activity, but these generally are highly type specific, neutralize only laboratory isolates, or have low potency. 15890930 1 67 part_of epitopes 240:247 arg1 the V2 domain 1 gp120 domain PUBTATOR 1 gp120 3700 domain Monoclonal antibodies (MAbs) directed against epitopes in the V2 domain of human immunodeficiency virus type 1 gp120 often possess neutralizing activity, but these generally are highly type specific, neutralize only laboratory isolates, or have low potency. 22287049 6 62 gly glycopeptides 1404:1416 arg2 the enriched glycopeptides the enriched glycopeptides glycopeptides Conditions were also optimized for efficient elution of the enriched glycopeptides from the nanoparticles for on-line nanoflow liquid chromatography–MS/MS analysis. 27161092 5 78 gly O-glycosylation 786:800 arg1 Muc5ac Muc5ac PUBTATOR Muc5ac P98088 In this study we unraveled the O-glycosylation profile of Muc5ac from glycoengineered mice models lacking the FUT2 enzyme and therefore mimicking a non-secretor human phenotype. 27177499 17 34 gly glycoforms 2377:2386 arg1 hCG hCG OGER hCG Depending on its source of production, glycoforms of hCG display different biological activities and functions that are essential for pregnancy outcome. 22365192 10 124 gly N-glycosylation 1907:1921 arg2 a putative atypical N-glycosylation site a putative atypical N-glycosylation site site This event results in the occurrence of an additional alanine (A) residue in the protein that disrupts a putative atypical N-glycosylation site (VNGC/VNAGC) described in human lactadherin. 26977294 7 16 part_of Fc 1094:1095 arg1 the Fc region Fc the Fc region Cterm Site Fc region pdb), the Fc region of the human IGHG1 fucosylated (3SGJ) and afucosylated (3SGK) complexed with the Fc receptor subtype Fcγ RIIIA, and the Fc region of a murine immunoglobulin (1IGT). 26977294 7 24 part_of Fc 964:965 arg1 the Fc region Fc the Fc region Cterm Site Fc region pdb), the Fc region of the human IGHG1 fucosylated (3SGJ) and afucosylated (3SGK) complexed with the Fc receptor subtype Fcγ RIIIA, and the Fc region of a murine immunoglobulin (1IGT). 19609201 6 78 gly glycosylation 1113:1125 arg2 putative N-linked glycosylation site putative N-linked glycosylation site site Plasma RNA viral load, CD4(+) T-cell count, changes in the length of V1-V5 region, putative N-linked glycosylation site number and distribution were also measured. 7711058 0 53 gly glycosylation 22:34 arg1 rat 11 beta-hydroxysteroid dehydrogenase dehydrogenase sites Fterm dehydrogenase sites Mutations in putative glycosylation sites of rat 11 beta-hydroxysteroid dehydrogenase affect enzymatic activity. 23668542 9 15 gly neoglycoprotein 1290:1304 arg1 The A1AT neoglycoprotein The A1AT neoglycoprotein PUBTATOR A1AT neoglycoprotein 5265 The A1AT neoglycoprotein with an additional N-glycosylation site at position N123 exhibited a 62% increase in serum half-life. 23668542 9 19 gly N-glycosylation 1325:1339 arg2 position N123 position N123 position N123 The A1AT neoglycoprotein with an additional N-glycosylation site at position N123 exhibited a 62% increase in serum half-life. 23668542 9 19 gly N-glycosylation 1325:1339 arg2 an additional N-glycosylation site an additional N-glycosylation site site The A1AT neoglycoprotein with an additional N-glycosylation site at position N123 exhibited a 62% increase in serum half-life. 27140194 2 13 gly glycopeptides 270:282 arg1 glycosylated peptides glycosylated peptides peptides However, traditional proteomic studies at the peptide level (bottom-up) rarely characterize intact glycopeptides (glycosylated peptides without removing glycans), so no glycoprotein heterogeneity information is retained. 27140194 2 19 gly glycopeptides 270:282 arg2 intact glycopeptides intact glycopeptides glycopeptides However, traditional proteomic studies at the peptide level (bottom-up) rarely characterize intact glycopeptides (glycosylated peptides without removing glycans), so no glycoprotein heterogeneity information is retained. 27140194 2 45 gly glycoprotein 340:351 arg1 no glycoprotein heterogeneity information no glycoprotein heterogeneity information Fterm glycoprotein However, traditional proteomic studies at the peptide level (bottom-up) rarely characterize intact glycopeptides (glycosylated peptides without removing glycans), so no glycoprotein heterogeneity information is retained. 27140194 2 46 gly glycosylated 285:296 arg1 glycosylated peptides glycosylated peptides peptides However, traditional proteomic studies at the peptide level (bottom-up) rarely characterize intact glycopeptides (glycosylated peptides without removing glycans), so no glycoprotein heterogeneity information is retained. 26106863 10 77 gly glycoprotein 1539:1550 arg1 glycoprotein glycoprotein Fterm glycoprotein Each lineage is defined by multiple mutations, including non-synonymous changes in the virion protein 35 (VP35), glycoprotein (GP) and RNA-dependent RNA polymerase (L) proteins. 1740433 8 5 part_of C-SAA 1078:1082 arg1 The C-SAA octapeptide SAA The C-SAA octapeptide PUBTATOR Site SAA 6291 octapeptide The C-SAA octapeptide specifies the first two residues of a NSS tripeptide, the only potential N-linked glycosylation site in the molecule. 1512415 5 15 gly glycosylation 904:916 arg2 an intact glycosylation recognition sequence site an intact glycosylation recognition sequence site site However, a third mutation (Asn-Thr-Ser) contained an intact glycosylation recognition sequence site, and was shown to retain glycosylation. 32302771 4 22 part_of chst11 720:725 arg1 the sequence chst11 the sequence PUBTATOR Site chst11 50515 sequence Thus, in this study, the sequence of chst11 was obtained from P. clarkii for the first time and analyzed, and the expression pattern of chst11 was investigated. 20943674 1 15 gly glycosylation 170:182 arg1 a recombinant protein a recombinant protein Fterm protein The glycosylation profile of a recombinant protein is important because glycan moieties can play a significant role in the biological properties of the glycoprotein. 20943674 1 76 gly glycoprotein 318:329 arg1 the glycoprotein the glycoprotein Fterm glycoprotein The glycosylation profile of a recombinant protein is important because glycan moieties can play a significant role in the biological properties of the glycoprotein. 8659125 6 26 gly glycosylation 898:910 arg2 the N-linked glycosylation site the N-linked glycosylation site site When the N-linked glycosylation site of small HBsAg at amino acid 146 was mutated from asparagine to glutamine, the mutant HBsAg packaged only a modest amount of HDV particles. 20067810 2 4 gly occupied 441:448 arg2 only one potential asparagine-linked glycosylation site only one potential asparagine-linked glycosylation site site This protein contains only one potential asparagine-linked glycosylation site, which is partially (10-30%) occupied when the protein is synthesized in eukaryotic cells. 20067810 2 21 gly glycosylation 393:405 arg2 only one potential asparagine-linked glycosylation site only one potential asparagine-linked glycosylation site site This protein contains only one potential asparagine-linked glycosylation site, which is partially (10-30%) occupied when the protein is synthesized in eukaryotic cells. 7815476 1 10 part_of region 211:216 arg1 The human immunodeficiency virus type 1 (HIV-1) sequences region The human immunodeficiency virus type 1 (HIV-1) sequences sequences The human immunodeficiency virus type 1 (HIV-1) sequences from variable region 3 (V3) of the envelope gene were analyzed from seven infected mother-infant pairs following perinatal transmission. 27489265 15 22 gly glycosylation 2461:2473 arg2 surgical glycosylation site modification surgical glycosylation site modification site This indicates that surgical glycosylation site modification may be an effective way of sculpting epitope presentation in Env-based vaccines. 14757769 2 73 gly glycosylated 345:356 arg1 Some consensus sequences Some consensus sequences sequences Some consensus sequences in secreted proteins are not glycosylated, indicating that consensus sequences are necessary but not sufficient for glycosylation. 26729457 3 78 gly glycopeptide 554:565 arg2 glycopeptide fragmentation regimes glycopeptide fragmentation regimes glycopeptide However, the depth of information is highly dependent on the applied analytical tools, including glycopeptide fragmentation regimes and automated data analysis. 15488990 6 66 gly glycosylation 1081:1093 arg2 an N-linked glycosylation site an N-linked glycosylation site site Bovine GLUT8 retains the characteristic structural features of GLUT8 proteins previously identified from other species including membrane spanning helices, glucose transporter motifs, an N-linked glycosylation site on loop 9 and a putative dileucine internalization motif. 11380948 3 29 gly glycosylation 596:608 arg2 an N-linked glycosylation site an N-linked glycosylation site site FcgammaRIIIb-NA2-specific monoclonal antibodies (GRM1 and PEN1) did not bind to mutant neutrophils, which lack an N-linked glycosylation site. 2747653 6 7 part_of alpha-fetoproteins 1263:1280 arg1 the sequence alpha-fetoproteins the sequence Fterm Site alpha-fetoproteins sequence The 74K albumin (unlike the 68K albumin) is glycosylated; a point mutation converting Lys256 to Asn introduces an N-linked glycosylation site that is similar to one found in the sequence of mammalian alpha-fetoproteins. 6651835 3 11 part_of IgM 407:409 arg1 Asn 563 IgM Asn 563 OGER SpecificSite IgM P01872 Asn 563 Amino acid and carbohydrate analyses show that Asn 563 of murine IgM is glycosylated only about 44% of the time. 16386114 7 69 gly glycosylation 902:914 arg2 the glycosylation site the glycosylation site site The major differences in the level of the HIV-1 gene between the seronegative and seropositive states were changes at the glycosylation site (NXT) next to the inserted proline and many resistance mutations including M184V to antiretroviral drugs occurred. 2985383 5 5 gly N-glycosylation 859:873 arg2 no N-glycosylation site no N-glycosylation site site However, in contrast to these enzymes, mouse urokinase contains no N-glycosylation site. 20188224 11 54 gly Glycosylation 1514:1526 arg1 four out of five potential PGRN N-glycosylation consensus sites four out of five potential PGRN N-glycosylation consensus sites sites Glycosylation of four out of five potential PGRN N-glycosylation consensus sites was demonstrated (the final one remains undetermined), with one of the four observed to be partially occupied. 20188224 11 63 gly N-glycosylation 1563:1577 arg2 four out of five potential PGRN N-glycosylation consensus sites four out of five potential PGRN N-glycosylation consensus sites sites Glycosylation of four out of five potential PGRN N-glycosylation consensus sites was demonstrated (the final one remains undetermined), with one of the four observed to be partially occupied. 10383441 0 0 gly I 83:83 arg1 mannose phosphorylation DNase I mannose phosphorylation PUBTATOR DNase I 13419 Identification of amino acids that modulate mannose phosphorylation of mouse DNase I, a secretory glycoprotein. 10383441 0 36 gly glycoprotein 98:109 arg1 mouse DNase I mouse DNase I PUBTATOR DNase I 13419 Identification of amino acids that modulate mannose phosphorylation of mouse DNase I, a secretory glycoprotein. 10383441 0 36 gly glycoprotein 98:109 arg1 a secretory glycoprotein a secretory glycoprotein Fterm glycoprotein Identification of amino acids that modulate mannose phosphorylation of mouse DNase I, a secretory glycoprotein. 17960575 8 21 gly observed 1121:1128 arg1 glycopeptides AND Disialylated diantennary glycans glycopeptides Disialylated diantennary glycans glycopeptides Disialylated diantennary glycans were observed in glycopeptides of both N-glycosylation sites of TRFE. 17960575 8 67 gly Disialylated 1083:1094 arg1 Disialylated diantennary glycans Disialylated diantennary glycans Disialylated diantennary glycans were observed in glycopeptides of both N-glycosylation sites of TRFE. 17960575 8 30 gly N-glycosylation 1155:1169 arg1 TRFE TRFE sites PUBTATOR TRFE 7018 sites Disialylated diantennary glycans were observed in glycopeptides of both N-glycosylation sites of TRFE. 17960575 8 35 gly glycopeptides 1133:1145 arg1 TRFE TRFE glycopeptides PUBTATOR TRFE 7018 glycopeptides Disialylated diantennary glycans were observed in glycopeptides of both N-glycosylation sites of TRFE. 17960575 8 35 gly glycopeptides 1133:1145 arg1 both N-glycosylation sites TRFE sites PUBTATOR TRFE 7018 sites Disialylated diantennary glycans were observed in glycopeptides of both N-glycosylation sites of TRFE. 1725860 6 5 part_of present 1149:1155 arg1 all the other five IGFBPs AND the invariant Gly-Cys-Gly-Cys-Cys sequence all the other five IGFBPs the invariant Gly-Cys-Gly-Cys-Cys sequence PUBTATOR Site IGFBPs 3484 sequence Absence of the two and four cysteines in the N-terminal region in the human and rat IGFBP-6 resulted in the deletion of the invariant Gly-Cys-Gly-Cys-Cys sequence which is present in all the other five IGFBPs. 1725860 6 30 part_of IGFBPs 1179:1184 arg1 the invariant Gly-Cys-Gly-Cys-Cys sequence IGFBPs the invariant Gly-Cys-Gly-Cys-Cys sequence PUBTATOR Site IGFBPs 3484 sequence Absence of the two and four cysteines in the N-terminal region in the human and rat IGFBP-6 resulted in the deletion of the invariant Gly-Cys-Gly-Cys-Cys sequence which is present in all the other five IGFBPs. 8509412 8 82 gly glycosylation 1169:1181 arg2 the C-terminal glycosylation site the C-terminal glycosylation site site However, mutation of the C-terminal glycosylation site (Asn727) has the most profound negative effect on the appearance of the receptor at the cell surface. 8509412 8 82 gly glycosylation 1169:1181 arg2 Asn727 Asn727 Asn727 However, mutation of the C-terminal glycosylation site (Asn727) has the most profound negative effect on the appearance of the receptor at the cell surface. 31356638 0 39 gly N-glycosylation 118:132 arg2 a single N-glycosylation site mutation a single N-glycosylation site mutation site Endocytosis of flavivirus NS1 is required for NS1-mediated endothelial hyperpermeability and is abolished by a single N-glycosylation site mutation. 17986444 6 10 gly N-glycosylation 949:963 arg2 N-glycosylation sites 5 and 6 N-glycosylation sites 5 and 6 sites Our results revealed an identical glycosylation and almost complete polysialylation of N-glycosylation sites 5 and 6 in polySia-NCAM irrespective of the enzyme present. 17986444 6 65 gly sites 965:969 arg1 almost complete polysialylation sites almost complete polysialylation sites Our results revealed an identical glycosylation and almost complete polysialylation of N-glycosylation sites 5 and 6 in polySia-NCAM irrespective of the enzyme present. 17986444 6 5 gly glycosylation 896:908 arg1 N-glycosylation sites 5 and 6 polySia-NCAM sites PUBTATOR polySia-NCAM 17967 sites Our results revealed an identical glycosylation and almost complete polysialylation of N-glycosylation sites 5 and 6 in polySia-NCAM irrespective of the enzyme present. 17986444 6 13 gly polysialylation 930:944 arg1 N-glycosylation sites 5 and 6 polySia-NCAM sites PUBTATOR polySia-NCAM 17967 sites Our results revealed an identical glycosylation and almost complete polysialylation of N-glycosylation sites 5 and 6 in polySia-NCAM irrespective of the enzyme present. 17986444 6 91 gly polysialylation 930:944 arg1 polySia-NCAM polySia-NCAM polysialylation PUBTATOR polySia-NCAM 17967 Our results revealed an identical glycosylation and almost complete polysialylation of N-glycosylation sites 5 and 6 in polySia-NCAM irrespective of the enzyme present. 17986444 6 91 gly polysialylation 930:944 arg1 polySia-NCAM polySia-NCAM sites polysialylation PUBTATOR polySia-NCAM 17967 sites Our results revealed an identical glycosylation and almost complete polysialylation of N-glycosylation sites 5 and 6 in polySia-NCAM irrespective of the enzyme present. 19249803 4 42 gly glycosylation 641:653 arg2 the E protein glycosylation site the E protein glycosylation site site We mutated the E protein glycosylation site from NYS to IYS in a previously described full-length clone of the NY99 genotype of WNV (WT), resulting in a virus that lacked the glycan at aa154. 18952059 4 21 gly glycosylation 461:473 arg1 IZUMO IZUMO PUBTATOR IZUMO 73456 The expression of N204Q-IZUMO rescued the infertile phenotype of IZUMO disrupted mice, indicating glycosylation is not essential for fusion-facilitating activity of IZUMO. 9442070 2 52 gly glycosylation 316:328 arg1 IgG IgG Cterm IgG In contrast to IgA1, the glycosylation of IgG has been well characterized, and its interaction with various Fc receptors (Fc Rs) has been well studied. 7475306 7 22 gly non-glycosylated 1054:1069 arg1 the glycosylated and non-glycosylated epitope the glycosylated and non-glycosylated epitope epitope Chimeras of the glycosylated and non-glycosylated epitope with promiscuous T-cell epitope were synthesized and shown to elicit high titered antibodies in rabbits specific for the immunogen (SC1MVF and SC2MVF) and the B cell epitope 233-253. 7475306 7 64 gly glycosylated 1037:1048 arg1 the glycosylated and non-glycosylated epitope the glycosylated and non-glycosylated epitope epitope Chimeras of the glycosylated and non-glycosylated epitope with promiscuous T-cell epitope were synthesized and shown to elicit high titered antibodies in rabbits specific for the immunogen (SC1MVF and SC2MVF) and the B cell epitope 233-253. 31924694 5 28 gly N-glycosylation 1216:1230 arg2 over 1300 N-glycosylation sites over 1300 N-glycosylation sites sites N-glycopeptide enrichment via lectin capturing using the high mannose/paucimannose-binding lectin Concanavalin A, or the Rhizoctonia solani agglutinin which interacts with complex N-glycans, resulted in the identification of over 1300 N-glycosylation sites derived from over 600 glycoproteins. 31924694 5 33 gly N-glycopeptide 981:994 arg2 N-glycopeptide N-glycopeptide N-glycopeptide N-glycopeptide enrichment via lectin capturing using the high mannose/paucimannose-binding lectin Concanavalin A, or the Rhizoctonia solani agglutinin which interacts with complex N-glycans, resulted in the identification of over 1300 N-glycosylation sites derived from over 600 glycoproteins. 31924694 5 37 gly glycoproteins 1260:1272 arg1 over 600 glycoproteins over 600 glycoproteins Fterm glycoproteins N-glycopeptide enrichment via lectin capturing using the high mannose/paucimannose-binding lectin Concanavalin A, or the Rhizoctonia solani agglutinin which interacts with complex N-glycans, resulted in the identification of over 1300 N-glycosylation sites derived from over 600 glycoproteins. 8407981 7 4 gly glycosylated 1138:1149 arg1 the mutant protein the mutant protein Fterm protein The core glycosylation did not occur when the Asn-12 residue was mutated, whereas the mutant protein with modified Asn-180 residue was glycosylated. 31317206 1 31 part_of furin 228:232 arg1 a furin cleavage site furin a furin cleavage site PUBTATOR Site furin 5045 site The human chondromodulin-1 (Chm-1, Chm-I, CNMD, or Lect1) gene encodes a 334 amino acid type II transmembrane glycoprotein protein with characteristics of a furin cleavage site and a putative glycosylation site. 24336240 4 29 gly glycoproteins/glycopeptides 764:790 arg2 target glycoproteins/glycopeptides target glycoproteins/glycopeptides glycoproteins/glycopeptides Because the critical factor for choosing a suitable enrichment method is primarily a particular technique's selectivity and affinity towards target glycoproteins/glycopeptides, it is important to fully understand the working principles for the different approaches. 10998266 1 20 gly glycoprotein 490:501 arg1 the sialylated glycoprotein the sialylated glycoprotein Fterm glycoprotein High-performance liquid chromatography with electrospray ionization mass spectrometry (LC/MS) and liquid chromatography with tandem mass spectrometry (LC/MS/MS) were applied to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin (EPO) used as a model of the sialylated glycoprotein. 10998266 1 31 gly heterogeneity 418:430 arg1 EPO EPO heterogeneity PUBTATOR EPO 2056 High-performance liquid chromatography with electrospray ionization mass spectrometry (LC/MS) and liquid chromatography with tandem mass spectrometry (LC/MS/MS) were applied to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin (EPO) used as a model of the sialylated glycoprotein. 10998266 1 31 gly heterogeneity 418:430 arg1 erythropoietin erythropoietin heterogeneity PUBTATOR erythropoietin 2056 High-performance liquid chromatography with electrospray ionization mass spectrometry (LC/MS) and liquid chromatography with tandem mass spectrometry (LC/MS/MS) were applied to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin (EPO) used as a model of the sialylated glycoprotein. 10998266 1 64 gly sialylated 479:488 arg1 the sialylated glycoprotein the sialylated glycoprotein Fterm glycoprotein High-performance liquid chromatography with electrospray ionization mass spectrometry (LC/MS) and liquid chromatography with tandem mass spectrometry (LC/MS/MS) were applied to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin (EPO) used as a model of the sialylated glycoprotein. 24501222 8 53 gly glycosylation 1266:1278 arg2 A native N-linked glycosylation site A native N-linked glycosylation site site A native N-linked glycosylation site was identified at Asn184. 29752426 10 65 part_of FS 1685:1686 arg1 the native FS sequence FS the native FS sequence Cterm Site FS 10468 sequence This hyperglycosylated variant showed a 10-fold improved exposure and decreased clearance in mice compared with an IgG1 Fc fusion protein containing the native FS sequence. 29752426 10 87 part_of containing 1663:1672 arg1 an IgG1 Fc fusion protein AND the native FS sequence an IgG1 Fc fusion protein the native FS sequence Fterm Site protein sequence This hyperglycosylated variant showed a 10-fold improved exposure and decreased clearance in mice compared with an IgG1 Fc fusion protein containing the native FS sequence. 2295597 6 64 part_of contained 991:999 arg1 Two bovine peptide sequences AND glycosylation sites Two bovine peptide sequences glycosylation sites sites Two bovine peptide sequences contained glycosylation sites and gave positive tests for carbohydrate residues, and two others contained the consensus sequence for a glycosylation site but were negative in the carbohydrate test. 26420485 6 31 gly N-glycosylation 913:927 arg2 the N-glycosylation site the N-glycosylation site site We generated a knockin mouse expressing RDS without the N-glycosylation site (N229S). 26947874 0 52 gly N-glycosylation 11:25 arg1 the N-terminal region region region Additional N-glycosylation in the N-terminal region of recombinant human alpha-1 antitrypsin enhances the circulatory half-life in Sprague-Dawley rats. 7814877 8 52 part_of contains 1017:1024 arg1 this protein AND a potential N-glycosylation site this protein a potential N-glycosylation site Fterm Site protein site In addition to conserved C-terminal sequences and serine blocks for phosphorylation in all eukaryotic ribosomal P2 proteins, this protein also contains a potential N-glycosylation site at position 15-17. 8435067 0 11 gly glycosylation 70:82 arg2 the glycosylation sites the glycosylation sites sites Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites. 20153530 3 43 gly N-glycosylation 349:363 arg2 A new N-glycosylation site A new N-glycosylation site site A new N-glycosylation site (K311N/E313T) was introduced into the turn of a helix-turn-helix [HTH] fold that had been postulated to form a transmembrane hairpin in membrane-bound C9. 16037490 0 71 gly glycopeptide 133:144 arg2 glycopeptide enrichment glycopeptide enrichment glycopeptide Differential analysis of site-specific glycans on plasma and cellular fibronectins: application of a hydrophilic affinity method for glycopeptide enrichment. 22885023 0 36 gly glycosylation 19:31 arg1 an atypical site site site Barley γ3-hordein: glycosylation at an atypical site, disulfide bridge analysis, and reactivity with IgE from patients allergic to wheat. 23527852 8 58 gly glycosylation 1062:1074 arg2 the glycosylation site the glycosylation site site To confirm the glycan moiety and localize the glycosylation site, top-down ESI-FTICR-MS/MS and bottom-up LC-ion trap MS/MS were used. 26599345 1 3 gly glycoproteins 91:103 arg1 glycoproteins glycoproteins Fterm glycoproteins Therapeutic monoclonal antibodies (mAbs) are glycoproteins produced by living cell systems. 26041282 6 7 gly N-glycosylation 1112:1126 arg2 an N-glycosylation site an N-glycosylation site site Interestingly, the I399T mutation introduces an N-glycosylation site within HVR1 and increases the density of virions and their sensitivity to neutralization with anti-apolipoprotein E (anti-ApoE) antibodies, suggesting that this mutation likely induces conformational changes in HVR1 that in turn modulate the association with ApoE. 19050247 6 25 gly IgG1 1190:1193 arg1 oligosaccharide chains IgG1 oligosaccharide chains Cterm IgG1 Differences in the glycan composition were observed when we analyzed oligosaccharide chains from anaphylactic or non-anaphylactic IgG1, mainly the presence of more sialic acid and fucose residues in anaphylactic molecules. 19050247 6 52 gly residues 1247:1254 arg1 oligosaccharide chains residues in oligosaccharide chains residues in Differences in the glycan composition were observed when we analyzed oligosaccharide chains from anaphylactic or non-anaphylactic IgG1, mainly the presence of more sialic acid and fucose residues in anaphylactic molecules. 8806496 5 15 gly glycosylation 906:918 arg2 both glycosylation sites both glycosylation sites sites Ablation of the first or both glycosylation sites generated mutants exhibiting small plaque phenotypes, decreased virus yields, reduced cytopathic effects, impaired NS1 secretion, and depressed RNA accumulation. 28186137 7 71 gly glycoproteins 699:711 arg1 PNS myelin glycoproteins PNS myelin glycoproteins Fterm glycoproteins PNS myelin glycoproteins contain highly abundant sulfated N-glycans. 28186137 7 43 gly contain 713:719 arg1 PNS myelin glycoproteins AND highly abundant sulfated N-glycans PNS myelin glycoproteins highly abundant sulfated N-glycans Fterm glycoproteins PNS myelin glycoproteins contain highly abundant sulfated N-glycans. 25643797 5 0 gly residues 917:924 arg1 200-202 200-202 residues 200-202 Most of the isolates in lineage h9.4.2.5 lost one potential glycosylation site at residues 200-202, and had an additional one at residues 295-297 in HA1. 25643797 5 41 gly glycosylation 895:907 arg2 residues 200-202 residues 200-202 residues 200-202 Most of the isolates in lineage h9.4.2.5 lost one potential glycosylation site at residues 200-202, and had an additional one at residues 295-297 in HA1. 25643797 5 41 gly glycosylation 895:907 arg2 one potential glycosylation site one potential glycosylation site site Most of the isolates in lineage h9.4.2.5 lost one potential glycosylation site at residues 200-202, and had an additional one at residues 295-297 in HA1. 15718224 7 51 gly glycosylation 1403:1415 arg2 the deleted glycosylation sites the deleted glycosylation sites sites The mutant viruses containing the deleted glycosylation sites were markedly more infectious in CEM T-cell cultures than wild-type virus. 10861210 5 15 part_of AE1 819:821 arg1 N555 AE1 N555 PUBTATOR SpecificSite AE1 6521 N555 Moving the N-glycosylation site to the preceding extracellular loop in an AE1 glycosylation mutant (N555) resulted in processing of the oligosaccharide and production of a complex form of AE1. 18790849 6 122 gly glycosylation 934:946 arg2 the putative N289 glycosylation site the putative N289 glycosylation site site Elimination of the putative N289 glycosylation site in KCNQ1 reduced current density by approximately 56%. 8347587 12 89 part_of receptor 1441:1448 arg1 the first four N-linked glycosylation sites insulin receptor the first four N-linked glycosylation sites PUBTATOR Site insulin receptor P01308 sites Thus, glycosylation of the first four N-linked glycosylation sites of the insulin receptor is necessary for the proper processing and intracellular transport of the receptor. 23692404 2 70 gly glycosylation 518:530 arg2 novel glycosylation sites novel glycosylation sites sites OBJECTIVES: To improve the pharmacokinetics (PK) and bioavailability of FIX, a screen was performed to identify positions for the introduction of novel glycosylation sites with maximal effect on PK and maintenance of coagulation activity. 9140197 1 8 gly glycoprotein 208:219 arg1 glycoprotein 2 glycoprotein 2 PUBTATOR glycoprotein 2 2813 Two monoclonal antibody escape virus mutants (MARs), rescued from a human MAb to glycoprotein 2 (G2) and a bank vole monoclonal antibody (MAb) directed to glycoprotein 1 (G1) of Puumala virus, strain Sotkamo, were produced by using a combination of neutralization tests and antigen detection. 9140197 1 8 gly glycoprotein 208:219 arg1 G2 G2 PUBTATOR 2 (G2 2813 Two monoclonal antibody escape virus mutants (MARs), rescued from a human MAb to glycoprotein 2 (G2) and a bank vole monoclonal antibody (MAb) directed to glycoprotein 1 (G1) of Puumala virus, strain Sotkamo, were produced by using a combination of neutralization tests and antigen detection. 9140197 1 19 gly glycoprotein 282:293 arg1 glycoprotein 1 glycoprotein 1 PUBTATOR glycoprotein 1 5544 Two monoclonal antibody escape virus mutants (MARs), rescued from a human MAb to glycoprotein 2 (G2) and a bank vole monoclonal antibody (MAb) directed to glycoprotein 1 (G1) of Puumala virus, strain Sotkamo, were produced by using a combination of neutralization tests and antigen detection. 9140197 1 19 gly glycoprotein 282:293 arg1 G1 G1 Cterm G1 5544 Two monoclonal antibody escape virus mutants (MARs), rescued from a human MAb to glycoprotein 2 (G2) and a bank vole monoclonal antibody (MAb) directed to glycoprotein 1 (G1) of Puumala virus, strain Sotkamo, were produced by using a combination of neutralization tests and antigen detection. 8034709 12 38 gly N-glycosylation 1443:1457 arg2 one tentative N-glycosylation site one tentative N-glycosylation site site The sequence indicates one tentative N-glycosylation site located near the C terminus. 17634239 0 24 gly modifications 16:28 arg1 gp120 gp120 modifications PUBTATOR gp120 155971 N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. 11410585 7 32 gly N-glycosylation 1084:1098 arg2 the single N-glycosylation site the single N-glycosylation site site In this study, we report on the structural characterization of the detectable glycoforms, present on the single N-glycosylation site, using state-of-the-art NMR and mass spectrometry techniques. 1457204 6 37 gly glycosylation 799:811 arg2 This sequence This sequence sequence This sequence is a potential O-linked glycosylation site, and should protrude in a region that appears flexible in human CD4. 1457204 6 37 gly glycosylation 799:811 arg2 a potential O-linked glycosylation site a potential O-linked glycosylation site site This sequence is a potential O-linked glycosylation site, and should protrude in a region that appears flexible in human CD4. 9176120 2 55 gly N-glycosylation 395:409 arg2 Asn-16 Asn-16 Asn-16 We here describe the expression in chinese hamster ovary (CHO) cells of rat CD59 and a modified rat CD59 in which an N-glycosylation site at Asn-16 has been deleted by point mutation. 9176120 2 55 gly N-glycosylation 395:409 arg2 an N-glycosylation site an N-glycosylation site site We here describe the expression in chinese hamster ovary (CHO) cells of rat CD59 and a modified rat CD59 in which an N-glycosylation site at Asn-16 has been deleted by point mutation. 25202310 5 62 gly glycoproteins 1213:1225 arg1 endoplasmic reticulum resident glycoproteins endoplasmic reticulum resident glycoproteins Fterm glycoproteins Subcellular proteomics and gene ontology revealed substantial presence of endoplasmic reticulum resident glycoproteins in the microsomes and confirmed significant enrichment of secreted and cell-surface glycoproteins in the respective subcellular fractions. 25202310 5 87 gly glycoproteins 1311:1323 arg1 secreted and cell-surface glycoproteins secreted and cell-surface glycoproteins Fterm glycoproteins Subcellular proteomics and gene ontology revealed substantial presence of endoplasmic reticulum resident glycoproteins in the microsomes and confirmed significant enrichment of secreted and cell-surface glycoproteins in the respective subcellular fractions. 8352759 2 33 part_of FVIII 328:332 arg1 the FVIII binding domain FVIII the FVIII binding domain PUBTATOR Site FVIII 2157 domain The DNA sequence coding for part of the vWF precursor (provWF) including the FVIII binding domain has been compared in man, pig and rabbit. 7966620 8 24 part_of syn 966:968 arg1 the 10 gK syn mutant sequences syn the 10 gK syn mutant sequences OGER Site syn sequences Of the 10 gK syn mutant sequences known, 8 have mutations in the N-terminal domain of gK, suggesting that this domain, which is likely to be an ectodomain, is important for the function of the protein. 26615566 8 58 gly glycosylation 1186:1198 arg2 an additional N glycosylation site an additional N glycosylation site site It could be concluded that the substitution of Phe in the codon 101 position, which may increase the binding activity of IFNβ with its receptors and introduction of an additional N glycosylation site (Asn-X-Thr) in the position 27 of IFNβ protein may cause such an effect. 26615566 8 58 gly glycosylation 1186:1198 arg2 Asn-X-Thr Asn-X-Thr Asn-X-Thr It could be concluded that the substitution of Phe in the codon 101 position, which may increase the binding activity of IFNβ with its receptors and introduction of an additional N glycosylation site (Asn-X-Thr) in the position 27 of IFNβ protein may cause such an effect. 7937884 9 32 part_of C 1205:1205 arg1 two potential protein kinase C phosphorylation sites protein kinase C two potential protein kinase C phosphorylation sites Cterm Site protein kinase C sites Analysis of the deduced sequence identified two potential protein kinase C phosphorylation sites and a potential N-linked glycosylation site. 28916391 6 51 gly glycosylation 820:832 arg2 a single glycosylation site a single glycosylation site site ZIKV E proteins have a characteristic "herringbone" structure with a single glycosylation site. 25213400 5 17 gly glycoproteins 472:484 arg1 other myelin glycoproteins other myelin glycoproteins Fterm glycoproteins Aside from P0, no comprehensive data are available on other myelin glycoproteins. 9639536 8 84 part_of N-linked 1421:1428 arg1 the five N-linked glycopeptides N-linked the five N-linked glycopeptides Cterm Site N-linked glycopeptides The analysis of OMD gave a pattern showing signal for the sialyl Lewis(x) antigen coeluting with each of the five N-linked glycopeptides. 22538665 2 9 part_of GnTI 525:528 arg1 the catalytic domain GnTI the catalytic domain PUBTATOR Site GnTI 4245 domain For the optimal expression of human GnTI in the yeast Golgi compartment, the catalytic domain of the GnTI was fused to various N-terminal leader sequences derived from the yeast type II membrane proteins. 21153276 4 85 part_of receptor 693:700 arg1 extra glycosylation site receptor extra glycosylation site Fterm Site receptor site The receptor with extra glycosylation site displayed normal binding affinities for agonists buserelin and [D: -Ala(6)-Pro(9)-NHEt]-GnRH, and the antagonist antide, and a slightly increased affinity for GnRH. 11076040 3 32 gly glycosylation 576:588 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site The latter determines the presence or absence of a potential N-linked glycosylation site. 2841801 8 1 part_of subunit 1117:1123 arg1 the glycosylation site subunit the glycosylation site Fterm Site subunit site Nucleotide sequence analyses revealed that ts-f1 and F1-R differed from the wild-type virus by mutations at the region of the cleavage site of F and at the glycosylation site of the F2 subunit. 2303059 1 1 gly site 221:224 arg1 the Asn-linked oligosaccharides site the Asn-linked oligosaccharides site The complete primary structures of the Asn-linked oligosaccharides from the conserved glycosylation site of the type-I variant surface glycoproteins of Trypanosoma brucei MITat 1.4 and MITat 1.6 were determined using a combination of exoglycosidase digestions, permethylation analysis, acetolysis and 1H NMR. 2303059 1 23 gly glycoproteins 256:268 arg1 the type-I variant surface glycoproteins the type-I variant surface glycoproteins Fterm glycoproteins The complete primary structures of the Asn-linked oligosaccharides from the conserved glycosylation site of the type-I variant surface glycoproteins of Trypanosoma brucei MITat 1.4 and MITat 1.6 were determined using a combination of exoglycosidase digestions, permethylation analysis, acetolysis and 1H NMR. 2303059 1 53 gly Asn-linked 160:169 arg1 the Asn-linked oligosaccharides Asn the Asn-linked oligosaccharides Asn The complete primary structures of the Asn-linked oligosaccharides from the conserved glycosylation site of the type-I variant surface glycoproteins of Trypanosoma brucei MITat 1.4 and MITat 1.6 were determined using a combination of exoglycosidase digestions, permethylation analysis, acetolysis and 1H NMR. 2303059 1 5 gly glycosylation 207:219 arg1 the type-I variant surface glycoproteins glycoproteins site Fterm glycoproteins site The complete primary structures of the Asn-linked oligosaccharides from the conserved glycosylation site of the type-I variant surface glycoproteins of Trypanosoma brucei MITat 1.4 and MITat 1.6 were determined using a combination of exoglycosidase digestions, permethylation analysis, acetolysis and 1H NMR. 29992770 7 18 gly N-glycopeptides 997:1011 arg2 Thirty-eight tryptic N-glycopeptides Thirty-eight tryptic N-glycopeptides N-glycopeptides Thirty-eight tryptic N-glycopeptides are identified, having 19 unique N-glycosylation sites representing 14 glycoproteins. 29992770 7 28 gly N-glycosylation 1046:1060 arg2 19 unique N-glycosylation sites 19 unique N-glycosylation sites sites Thirty-eight tryptic N-glycopeptides are identified, having 19 unique N-glycosylation sites representing 14 glycoproteins. 29992770 7 62 gly glycoproteins 1084:1096 arg1 14 glycoproteins 14 glycoproteins Fterm glycoproteins Thirty-eight tryptic N-glycopeptides are identified, having 19 unique N-glycosylation sites representing 14 glycoproteins. 29604477 3 23 gly glycosylation 513:525 arg2 a novel glycosylation site a novel glycosylation site site An M133T mutation creating a novel glycosylation site at N131could rescue virion secretion of N146Q mutant (loss of original glycosylation site) and immune escape mutants such as G145R. 29604477 3 42 gly glycosylation 603:615 arg2 original glycosylation site original glycosylation site site An M133T mutation creating a novel glycosylation site at N131could rescue virion secretion of N146Q mutant (loss of original glycosylation site) and immune escape mutants such as G145R. 10099302 2 55 gly interferon-gamma 333:348 arg1 the incomplete intracellular sialylation interferon-gamma the incomplete intracellular sialylation PUBTATOR interferon-gamma P01579 In this study, the incomplete intracellular sialylation of interferon-gamma (IFN-gamma), produced by Chinese hamster ovary cell culture, was minimized by supplementing the culture medium with N-acetylmannosamine (ManNAc), a direct intracellular precursor for sialic acid synthesis. 10099302 2 64 gly sialylation 318:328 arg1 IFN-gamma IFN-gamma PUBTATOR IFN-gamma P01579 In this study, the incomplete intracellular sialylation of interferon-gamma (IFN-gamma), produced by Chinese hamster ovary cell culture, was minimized by supplementing the culture medium with N-acetylmannosamine (ManNAc), a direct intracellular precursor for sialic acid synthesis. 10099302 2 64 gly sialylation 318:328 arg1 interferon-gamma interferon-gamma PUBTATOR interferon-gamma P01579 In this study, the incomplete intracellular sialylation of interferon-gamma (IFN-gamma), produced by Chinese hamster ovary cell culture, was minimized by supplementing the culture medium with N-acetylmannosamine (ManNAc), a direct intracellular precursor for sialic acid synthesis. 21674342 5 33 gly glycopeptide 858:869 arg2 the desired glycopeptide the desired glycopeptide glycopeptide Subsequent protecting group removal and peptide cleavage from the resin ultimately yields the desired glycopeptide. 7525705 6 21 part_of DR 1107:1108 arg1 the DR polymorphic epitope DR the DR polymorphic epitope Cterm Site DR epitope Acid/peptide treatment also restores the DR polymorphic epitope recognized by mAb 7.3.19.1 but not the DR polymorphic epitope recognized by mAb 16.23; low pH gradually destroys the 16.23 epitope in nonmutant cells. 12941638 6 0 gly glycosylation 999:1011 arg2 Three N-linked glycosylation sites Three N-linked glycosylation sites sites Three N-linked glycosylation sites were found. 19269039 8 8 part_of C 929:929 arg1 two Protein kinase C phosphorylation sites Protein kinase C two Protein kinase C phosphorylation sites Cterm Site Protein kinase C sites Pig IL-27 p28 has one transmembrane region, one signal peptide, and one N-glycosylation site, two Protein kinase C phosphorylation sites, three Casein kinase II phosphorylation sites and one N-myristoylation site. 19269039 8 14 part_of kinase 967:972 arg1 three Casein kinase II phosphorylation sites Casein kinase II three Casein kinase II phosphorylation sites OGER Site Casein kinase II sites Pig IL-27 p28 has one transmembrane region, one signal peptide, and one N-glycosylation site, two Protein kinase C phosphorylation sites, three Casein kinase II phosphorylation sites and one N-myristoylation site. 19269039 8 47 part_of has 830:832 arg1 Pig IL-27 p28 AND one signal peptide Pig IL-27 p28 one signal peptide PUBTATOR Site IL-27 p28 493187 peptide Pig IL-27 p28 has one transmembrane region, one signal peptide, and one N-glycosylation site, two Protein kinase C phosphorylation sites, three Casein kinase II phosphorylation sites and one N-myristoylation site. 19269039 8 47 part_of has 830:832 arg1 Pig IL-27 p28 AND one transmembrane region Pig IL-27 p28 one transmembrane region PUBTATOR Site IL-27 p28 493187 region Pig IL-27 p28 has one transmembrane region, one signal peptide, and one N-glycosylation site, two Protein kinase C phosphorylation sites, three Casein kinase II phosphorylation sites and one N-myristoylation site. 19269039 8 47 part_of has 830:832 arg1 Pig IL-27 p28 AND one N-glycosylation site Pig IL-27 p28 one N-glycosylation site PUBTATOR Site IL-27 p28 493187 site Pig IL-27 p28 has one transmembrane region, one signal peptide, and one N-glycosylation site, two Protein kinase C phosphorylation sites, three Casein kinase II phosphorylation sites and one N-myristoylation site. 1597478 2 43 part_of Protein 162:168 arg1 a highly unusual multifunctional polypeptide Protein disulfide isomerase a highly unusual multifunctional polypeptide PUBTATOR Site Protein disulfide isomerase 5034 polypeptide Protein disulfide isomerase (PDI) is a highly unusual multifunctional polypeptide that is identical to the beta-subunit of prolyl 4-hydroxylase, a cellular thyroid hormone-binding protein and a subunit of the microsomal triglyceride transfer protein complex, and very similar to a polypeptide functioning in vitro as a glycosylation site binding protein of oligosaccharyl transferase. 1597478 2 79 part_of disulfide 170:178 arg1 a highly unusual multifunctional polypeptide Protein disulfide isomerase a highly unusual multifunctional polypeptide PUBTATOR Site Protein disulfide isomerase 5034 polypeptide Protein disulfide isomerase (PDI) is a highly unusual multifunctional polypeptide that is identical to the beta-subunit of prolyl 4-hydroxylase, a cellular thyroid hormone-binding protein and a subunit of the microsomal triglyceride transfer protein complex, and very similar to a polypeptide functioning in vitro as a glycosylation site binding protein of oligosaccharyl transferase. 17996106 9 48 part_of glycoprotein 1717:1728 arg1 glycoprotein sequences glycoprotein glycoprotein sequences Fterm Site glycoprotein sequences CONCLUSION: Ensembles of Support Vector Machine classifiers offer an accurate and reliable approach to automated identification of putative glycosylation sites in glycoprotein sequences. 12139214 2 43 gly glycosylation 588:600 arg2 one potential N-linked glycosylation site one potential N-linked glycosylation site site Ac-TMP (A. caninum tissue inhibitor of metalloproteinase) is encoded by a 480-bp mRNA with a predicted open reading frame of 140 amino acids (molecular weight, 16,100 Da) that contains one potential N-linked glycosylation site and an N-terminal Cys-X-Cys consensus sequence. 17623277 13 22 gly glycopeptides 1464:1476 arg2 DCE glycopeptides DCE glycopeptides glycopeptides During mass spectrometric analysis of DCE glycopeptides, their CID patterns were highly intriguing, in that some glycopeptides underwent both C-terminal rearrangement and formation of dimeric structures during CID. 17623277 13 52 gly glycopeptides 1535:1547 arg2 some glycopeptides some glycopeptides glycopeptides During mass spectrometric analysis of DCE glycopeptides, their CID patterns were highly intriguing, in that some glycopeptides underwent both C-terminal rearrangement and formation of dimeric structures during CID. 12175915 7 66 gly deglycosylated 1516:1529 arg1 deglycosylated RFC-Gln deglycosylated RFC-Gln PUBTATOR SpecificSite RFC 6573 Insertion of a consensus N-glycosylation site [NX(S/T)] into putative loops 5/6, 8/9, and 9/10 of deglycosylated RFC-Gln(58) had minimal effects on MTX transport. 12175915 7 93 gly N-glycosylation 1443:1457 arg2 a consensus N-glycosylation site [NX a consensus N-glycosylation site [NX site Insertion of a consensus N-glycosylation site [NX(S/T)] into putative loops 5/6, 8/9, and 9/10 of deglycosylated RFC-Gln(58) had minimal effects on MTX transport. 12175915 7 87 gly loops 1488:1492 arg1 58 Gln(58) Gln(58) Insertion of a consensus N-glycosylation site [NX(S/T)] into putative loops 5/6, 8/9, and 9/10 of deglycosylated RFC-Gln(58) had minimal effects on MTX transport. 12954207 9 28 gly glycoprotein 1537:1548 arg1 Envelope glycoprotein oligomers Envelope glycoprotein oligomers PUBTATOR Envelope glycoprotein 100616444 Envelope glycoprotein oligomers on the cell surface derived from the V3 glycan-deficient virus were better recognized by a CD4BS antibody and a V3 loop antibody than were the wild-type glycoproteins. 12954207 9 55 gly glycoproteins 1713:1725 arg1 the wild-type glycoproteins the wild-type glycoproteins Fterm glycoproteins Envelope glycoprotein oligomers on the cell surface derived from the V3 glycan-deficient virus were better recognized by a CD4BS antibody and a V3 loop antibody than were the wild-type glycoproteins. 9455905 1 68 gly O-glycosylation 133:147 arg2 known O-glycosylation sites known O-glycosylation sites sites From surveys of known O-glycosylation sites and in vitro glycosylation assays with synthetic peptide acceptors, it appears that the presence of charged amino acids near serine/threonine residues reduces the likelihood of O-glycosylation by UDP-GalNAc polypeptide:N-acetylgalactosaminyltransferases (ppGaNTases). 2009266 3 4 gly glycosylation 609:621 arg2 a single glycosylation site a single glycosylation site site In general, features conserved in the fibrinogens from other species also characterize the chicken sequence, including the cysteine motifs bordering an alpha-helical permissive region of fixed length and a single glycosylation site in the C-terminal region. 8666916 7 60 part_of site 1719:1722 arg1 IgA IgA site OGER Site IgA P11912 site Taken together, these results localize the mFc alpha R recognition site on IgA to the boundary region between the second and third constant domains--a site analogous to that recognized by Staphylococcus aureus protein A on IgG. 20667571 5 8 part_of site 1114:1117 arg1 the neuraminidase (NA) protein protein site Fterm Site protein site Compared to HK03 ca virus, VN04 ca virus differs by 9 amino acids including an additional glycosylation site at residue 158N of the HA protein and a shortened stalk in the neuraminidase (NA) protein. 20667571 5 43 part_of protein 1145:1151 arg1 residue 158N protein residue 158N Fterm Site protein residue Compared to HK03 ca virus, VN04 ca virus differs by 9 amino acids including an additional glycosylation site at residue 158N of the HA protein and a shortened stalk in the neuraminidase (NA) protein. 10779281 2 56 gly N-glycosylation 425:439 arg2 a single N-glycosylation site a single N-glycosylation site site The clone HD6 contained DNA encoding a 215 residue protein which contained a predicted 17 amino acid residue leader sequence, no cysteines and a single N-glycosylation site. 26858738 5 42 part_of site 1013:1016 arg1 the IgA1 alpha chain IgA1 alpha chain site PUBTATOR Site IgA1 alpha chain P01876 site Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain. 26858738 5 84 part_of IgA1 874:877 arg1 IgA1 glycopeptides IgA1 IgA1 glycopeptides PUBTATOR Site IgA1 P01876 glycopeptides Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain. 8496193 9 40 gly acceptor 1406:1413 arg1 procathepsin L procathepsin L acceptor OGER procathepsin L P06797 These studies therefore confirm that Asn-204 is the normal functional carbohydrate acceptor in procathepsin L and that carbohydrate in wild-type procathepsin L serves predominantly as a lysosomal targeting signal, with little or no role in protein folding or stability. 8496193 9 53 gly carbohydrate 1442:1453 arg1 wild-type procathepsin L procathepsin L carbohydrate OGER procathepsin L P06797 These studies therefore confirm that Asn-204 is the normal functional carbohydrate acceptor in procathepsin L and that carbohydrate in wild-type procathepsin L serves predominantly as a lysosomal targeting signal, with little or no role in protein folding or stability. 9820138 8 60 gly glycosylation 1334:1346 arg2 the second glycosylation site the second glycosylation site site One of these viruses encoded NS1 that lacked the second glycosylation site, the other encoded a Ser --> Ile change at the -3 position of the prM/E cleavage site. 30578591 3 58 gly glycopeptide 426:437 arg2 intact glycopeptide analysis intact glycopeptide analysis glycopeptide In this study, intact glycopeptide analysis is performed on an influenza NA (A/H1N1/California/2009) that is expressed in human 293T and insect Hi-5 cells. 8407981 4 34 gly glycosylated 500:511 arg1 The P-450(arom) protein The P-450(arom) protein PUBTATOR P-450(arom) protein 55010 The P-450(arom) protein expressed in the insect cells was glycosylated, and the sugar chain was sensitive to Endo H. 8557170 13 15 part_of CRF 1638:1640 arg1 central human CRF fragments CRF central human CRF fragments OGER Site CRF fragments The ligand requirements of the CRF receptor and the CRF-BP can be distinguished in that central human CRF fragments, such as CRF (6-33) and CRF (9-33), have high affinity for CRF-BP but low affinity for the CRF receptor. 9461526 5 32 gly N-glycosylation 708:722 arg2 an N-glycosylation site an N-glycosylation site site The basic three-dimensional structures of these saposins is predicted to be similar on the basis of the conservation of six cysteine residues and an N-glycosylation site. 23535299 8 25 gly N-glycosylation 799:813 arg2 Potential N-glycosylation sites Potential N-glycosylation sites sites Potential N-glycosylation sites were predicted using NetNGlyc server 1.0. 26968544 1 49 gly dystrophin-glycoprotein 198:220 arg1 dystrophin-glycoprotein dystrophin-glycoprotein OGER dystrophin P11530 Delta-sarcoglycan is a component of the sarcoglycan subcomplex within the dystrophin-glycoprotein complex located at the plasma membrane of muscle cells. 23296529 5 15 gly glycopeptides 989:1001 arg2 glycopeptides glycopeptides glycopeptides HILIC SPE can be used for glyco-profiling, i.e., for determining the glycan heterogeneity at one specific glycosylation site, for enrichment of glycopeptides from a complex mixture of peptides, as well as for pre-fractionation of complex samples at the protein or peptide level. 23296529 5 28 gly glycosylation 951:963 arg2 one specific glycosylation site one specific glycosylation site site HILIC SPE can be used for glyco-profiling, i.e., for determining the glycan heterogeneity at one specific glycosylation site, for enrichment of glycopeptides from a complex mixture of peptides, as well as for pre-fractionation of complex samples at the protein or peptide level. 1639824 3 12 part_of protein 476:482 arg1 the mature region protein the mature region Fterm Site protein region We have expressed and purified a mutant form of rat procathepsin B whose active-site cysteine residue has been changed to a serine, and which also lacks the glycosylation site in the mature region of the protein. 9254646 0 0 part_of class 186:190 arg1 major histocompatibility complex class I-restricted peptides class I-restricted major histocompatibility complex class I-restricted peptides PUBTATOR Site class I-restricted 11980 peptides Introduction of a glycosylation site into a secreted protein provides evidence for an alternative antigen processing pathway: transport of precursors of major histocompatibility complex class I-restricted peptides from the endoplasmic reticulum to the cytosol. 9254646 0 11 part_of I-restricted 192:203 arg1 major histocompatibility complex class I-restricted peptides class I-restricted major histocompatibility complex class I-restricted peptides PUBTATOR Site class I-restricted 11980 peptides Introduction of a glycosylation site into a secreted protein provides evidence for an alternative antigen processing pathway: transport of precursors of major histocompatibility complex class I-restricted peptides from the endoplasmic reticulum to the cytosol. 27007620 5 26 gly glycoprotein 985:996 arg1 any particular glycoprotein any particular glycoprotein Fterm glycoprotein As a consequence, such analyses can be of limited sensitivity, specificity, and accuracy because they do not comprehensively consider the glycosylation status of any particular glycoprotein, or of any particular glycosylation site. 27007620 5 34 gly glycosylation 1020:1032 arg2 any particular glycosylation site any particular glycosylation site site As a consequence, such analyses can be of limited sensitivity, specificity, and accuracy because they do not comprehensively consider the glycosylation status of any particular glycoprotein, or of any particular glycosylation site. 27007620 5 84 gly glycosylation 946:958 arg1 any particular glycoprotein glycoprotein site Fterm glycoprotein site As a consequence, such analyses can be of limited sensitivity, specificity, and accuracy because they do not comprehensively consider the glycosylation status of any particular glycoprotein, or of any particular glycosylation site. 19050247 9 14 gly attached 1773:1780 arg2 the Fc region AND the oligosaccharide chain the Fc region the oligosaccharide chain region Therefore, we demonstrated that the ability of murine IgG1 Abs to mediate anaphylaxis is directly dependent on the amount of sialic acid residues associated to the oligosaccharide chain attached to the Fc region of these molecules. 8088785 9 84 part_of contains 1372:1379 arg1 The extracellular domain AND a region The extracellular domain a region region The extracellular domain is composed of 420 amino acids and contains a region of 204 residues showing 15 repeats of 4 amino acids, each 1 having an acidic amino acid presumably involved in calcium coordination. 2189790 2 14 gly glycosylation 273:285 arg2 one potential N-linked glycosylation site one potential N-linked glycosylation site site Mature hIL-1 alpha contains one potential N-linked glycosylation site that is not recognized in mammalian cells. 25389233 2 132 gly fucosylated 391:401 arg1 the fucosylated tri-mannose N-type core the fucosylated tri-mannose N-type core Here we analysed the exposure of glycans containing fucosyl residues and the fucosylated tri-mannose N-type core by complexed native IgG in longitudinal serum samples of well-characterized patients with systemic lupus erythematosus. 30904681 0 13 part_of β-2-glycoprotein-1 96:113 arg1 multiple glycosylation sites -2-glycoprotein-1 multiple glycosylation sites PUBTATOR Site -2-glycoprotein-1 350 sites Simultaneous characterization of SNPs and N-glycans from multiple glycosylation sites of intact β-2-glycoprotein-1 (B2GP1) by ESI-qTOF-MS. 8107215 4 1 gly used 679:682 arg2 all three sites all three sites sites Expression of mutant proteins in mammalian cells showed that all three sites are used for the addition of N-linked oligosaccharides. 16845803 1 46 gly glycosylation 132:144 arg1 Asn302 Asn302 Asn302 OBJECTIVE: To investigate the effect of glycosylation at Asn302 of pro-urokinase (pro-UK) on the stability in culture supernatant. 17259069 1 6 gly glycosylated 199:210 arg1 a highly glycosylated protein a highly glycosylated protein Fterm protein Lipocalin-type prostaglandin D(2) synthase (L-PGDS) is a highly glycosylated protein found in several body fluids. 25485983 4 16 gly glycosylation 615:627 arg2 this defective glycosylation site antithrombin site PUBTATOR antithrombin 462 site We evaluated the effect of the aromatic sequon in this defective glycosylation site of antithrombin, despite of being located in a loop between the helix D and the strand 2A. 7780197 1 21 gly contains 140:147 arg1 TfR AND three N-linked oligosaccharides TfR three N-linked oligosaccharides PUBTATOR TfR 7037 The human transferrin receptor (TfR) contains three N-linked oligosaccharides and glycosylation is required for the proper folding and function of the molecule. 7780197 1 21 gly contains 140:147 arg1 The human transferrin receptor AND three N-linked oligosaccharides The human transferrin receptor three N-linked oligosaccharides PUBTATOR transferrin receptor 7037 The human transferrin receptor (TfR) contains three N-linked oligosaccharides and glycosylation is required for the proper folding and function of the molecule. 1597478 2 30 gly glycosylation 481:493 arg2 a glycosylation site binding protein a glycosylation site binding protein site Protein disulfide isomerase (PDI) is a highly unusual multifunctional polypeptide that is identical to the beta-subunit of prolyl 4-hydroxylase, a cellular thyroid hormone-binding protein and a subunit of the microsomal triglyceride transfer protein complex, and very similar to a polypeptide functioning in vitro as a glycosylation site binding protein of oligosaccharyl transferase. 23661698 2 41 gly glycosylation 337:349 arg1 the Asn-26 Asn-26 Asn-26 The crystal structure of the ligand-receptor complex revealed a glycosylation on the Asn-26 of ephrin-A1. 17095532 4 26 gly deglycosylated 755:768 arg1 deglycosylated Cit s 1 deglycosylated Cit s 1 PUBTATOR Cit s 1 11113 These reagents also inhibited the interaction of Cit s 1 with patients' sera, thus underlining the critical role of glycosylation in the recognition of this protein by patients' IgE and extending previous data showing that deglycosylated Cit s 1 does not possess IgE epitopes. 17095532 4 34 gly glycosylation 648:660 arg1 this protein this protein Fterm protein These reagents also inhibited the interaction of Cit s 1 with patients' sera, thus underlining the critical role of glycosylation in the recognition of this protein by patients' IgE and extending previous data showing that deglycosylated Cit s 1 does not possess IgE epitopes. 25498018 7 22 gly glycoprotein 1617:1628 arg1 target glycoprotein target glycoprotein Fterm glycoprotein Because of its simplicity and sensitivity, the method explored in this work suggests that it holds promise as a method of elucidating differences in direct N-glycosylation of target glycoprotein, even in small amount of samples. 25498018 7 54 gly N-glycosylation 1591:1605 arg1 target glycoprotein target glycoprotein Fterm glycoprotein Because of its simplicity and sensitivity, the method explored in this work suggests that it holds promise as a method of elucidating differences in direct N-glycosylation of target glycoprotein, even in small amount of samples. 9578495 1 7 gly choriogonadotropin 158:175 arg1 the N-linked oligosaccharide choriogonadotropin the N-linked oligosaccharide OGER choriogonadotropin Several studies indicate that in human choriogonadotropin the N-linked oligosaccharide at position 52 of the alpha-subunit is important for bioactivity. 9578495 1 28 gly position 209:216 arg1 the N-linked oligosaccharide position 52 the N-linked oligosaccharide position 52 Several studies indicate that in human choriogonadotropin the N-linked oligosaccharide at position 52 of the alpha-subunit is important for bioactivity. 26573365 2 22 gly glycopeptides 398:410 arg2 the glycopeptides the glycopeptides glycopeptides Succinic anhydride is used to specifically label primary amino groups of the peptide portion of the glycopeptides. 20826563 9 4 gly desialylated 1210:1221 arg1 desialylated 3N-GH desialylated 3N-GH Cterm GH The terminal half-life of 3N-GH after iv injection was 24-fold prolonged compared with wild-type GH for the pool with the most pronounced sialylation, 13-fold prolonged for the less sialylated pool, and similar to the wild-type for desialylated 3N-GH. 25094044 4 2 part_of site 660:663 arg1 UGGT1 UGGT1 site PUBTATOR Site UGGT1 171129 site In this study, we reveal the site of glycosylation (N269) and the glycan structures (Hex5-8HexNAc2) in UGGT1 obtained from rat (Rattus norvegicus), pig (Sus scrofa), cow (Bos taurus), and human (Homo sapiens). 11697887 9 10 gly N-glycosylation 1252:1266 arg2 a N-glycosylation site a N-glycosylation site site Although within this region of human CTGF is a N-glycosylation site, tunicamycin, which blocks N-linked glycosylation, has no significant effect on CTGF secretion. 16912309 14 70 gly glycoprotein 1677:1688 arg1 an improved chimeric glycoprotein an improved chimeric glycoprotein Fterm glycoprotein These studies demonstrate that serial passage can be used to rapidly evolve a VSV genome encoding an improved chimeric glycoprotein. 32331833 0 37 gly Glycosylation 0:12 arg1 DMP1 DMP1 PUBTATOR DMP1 13406 Glycosylation of DMP1 promotes bone reconstruction in long bone defects. 18371209 15 100 part_of gp120 2424:2428 arg1 the gp120 V2 region gp120 the gp120 V2 region PUBTATOR Site gp120 3700 region In addition, our results point to the importance of a glycosylation site within the gp120 V2 region for efficient DC-SIGN use of HIV-1 R5 viruses. 518919 1 9 part_of glycoprotein 250:261 arg1 glycosylation site I glycoprotein glycosylation site I Fterm Site glycoprotein site The elucidation of the structures of the carbohydrate units linked to glycosylation site I of human plasma alpha 1-acid glycoprotein is described. 20512925 7 3 gly Glycosylation 928:940 arg1 RAGE RAGE PUBTATOR RAGE Q15109 Glycosylation of RAGE and maximum binding sites for S100A12 on RAGE are also cell type dependent. 23751365 7 82 part_of peroxidase 1199:1208 arg1 five glycosites peroxidase five glycosites Fterm Site peroxidase glycosites In the evaluation of glycosylation heterogeneity coverage, five glycosites and eleven glycopeptides from horseradish peroxidase were identified after enrichment with XCharge SAX. 23751365 7 82 part_of peroxidase 1199:1208 arg1 eleven glycopeptides peroxidase eleven glycopeptides Fterm Site peroxidase glycopeptides In the evaluation of glycosylation heterogeneity coverage, five glycosites and eleven glycopeptides from horseradish peroxidase were identified after enrichment with XCharge SAX. 1390770 6 28 gly glycosylation 784:796 arg2 N-linked glycosylation sites N-linked glycosylation sites sites All other variants with mutations in N-linked glycosylation sites were secreted normally. 30011186 7 152 gly glycoproteins 1276:1288 arg1 glycoproteins glycoproteins Fterm glycoproteins In order to overcome these obstacles, considerable progress has been made in recent years, which has contributed to comprehensive analysis of glycoproteins. 31685900 9 5 gly non-glycoproteins 1347:1363 arg1 33 non-glycoproteins 33 non-glycoproteins Fterm non-glycoproteins Evaluated on N-X-S/T sequons of an independent dataset comprised of 53 glycoproteins and 33 non-glycoproteins, N-GlyDE achieves an accuracy and MCC of 0.740 and 0.499, respectively, outperforming the compared tools. 31685900 9 23 gly glycoproteins 1326:1338 arg1 53 glycoproteins 53 glycoproteins Fterm glycoproteins Evaluated on N-X-S/T sequons of an independent dataset comprised of 53 glycoproteins and 33 non-glycoproteins, N-GlyDE achieves an accuracy and MCC of 0.740 and 0.499, respectively, outperforming the compared tools. 16102305 5 29 gly glycosylation 691:703 arg2 a glycosylation site a glycosylation site site Several isolates showed a lysine-to-asparagine substitution at position 145 (K145N) in the hemagglutinin molecule, which may be noteworthy since position 145 is located within a glycosylation site and adjacent to an antibody-binding site. 26729457 5 15 gly glycopeptide 982:993 arg2 glycopeptide fragmentation glycopeptide fragmentation glycopeptide A linear dependency of m/z-ratio and optimal fragmentation energy was found, showing that with increasing m/z-ratio, more energy is required for glycopeptide fragmentation. 30063822 2 5 gly N-glycosylation 313:327 arg2 single N-glycosylation sites single N-glycosylation sites sites The procedure relies on the presence of single N-glycosylation sites that are present natively in proteins or that can be engineered into glycoproteins by mutational elimination of all but one glycosylation site. 30063822 2 22 gly glycoproteins 404:416 arg1 glycoproteins glycoproteins Fterm glycoproteins The procedure relies on the presence of single N-glycosylation sites that are present natively in proteins or that can be engineered into glycoproteins by mutational elimination of all but one glycosylation site. 30063822 2 72 gly glycosylation 459:471 arg2 one glycosylation site one glycosylation site site The procedure relies on the presence of single N-glycosylation sites that are present natively in proteins or that can be engineered into glycoproteins by mutational elimination of all but one glycosylation site. 2721453 4 20 gly glycosylation 672:684 arg2 two glycosylation sites two glycosylation sites sites Six species were obtained from TSH alpha (with two glycosylation sites), including neutral oligosaccharides as well as those with one or two negative charges. 8620873 1 118 gly region 208:213 arg1 the principal neutralizing determinant the principal neutralizing determinant Synthetic peptide antigens corresponding to the entire third variable region V3, the principal neutralizing determinant of the human immunodeficiency virus (HIV) envelope glycoprotein of HIV-1 subtype B (1), HIV-2 subtype A (5), and HIV-2 subtype B (7) were synthesized by solid-phase peptide synthesis (Table 1). 8620873 1 100 gly glycoprotein 309:320 arg1 the human immunodeficiency virus (HIV) envelope glycoprotein glycoprotein the principal neutralizing determinant Fterm glycoprotein Synthetic peptide antigens corresponding to the entire third variable region V3, the principal neutralizing determinant of the human immunodeficiency virus (HIV) envelope glycoprotein of HIV-1 subtype B (1), HIV-2 subtype A (5), and HIV-2 subtype B (7) were synthesized by solid-phase peptide synthesis (Table 1). 17956937 1 105 gly antigen 225:231 arg1 The oligosaccharide structures prostate specific antigen The oligosaccharide structures OGER prostate specific antigen P07288 The oligosaccharide structures of prostate specific antigen (PSA) are expected to be useful in discriminating prostate cancer from benign conditions both accompanied by increased serum PSA levels. 10471296 0 39 gly glycosylation 8:20 arg2 asparagine-2181 asparagine-2181 asparagine-2181 Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. 24632142 4 27 gly glycosylation 749:761 arg2 the putative glycosylation site the putative glycosylation site site However, the structure of this enzyme did not show the presence of any non-amino acid components at the putative glycosylation site. 22274805 4 26 gly N-glycosylation 596:610 arg2 N-glycosylation sites N-glycosylation sites sites We studied co-receptor utilization (the major determinant of HIV disease progression), N-glycosylation sites, and sequence variability. 29020646 0 56 gly N-glycosylation 113:127 arg2 potential N-glycosylation sites potential N-glycosylation sites sites HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites. 23830432 5 52 gly site 1579:1582 arg1 sialic acid (SA) residues site sialic acid (SA) residues site In addition, the approach was applied to characterize the sialylated status of α2-macroglobulin and transferrin, respectively, from the sera of healthy subjects and sex- and age-matched patients with thyroid cancer, and their spectra indicate that the change in the amount of the glycoforms containing different number of sialic acid (SA) residues from one glycosylation site may be used to differentiate between healthy subjects and cancer cases. 23830432 5 75 gly glycosylation 1565:1577 arg2 one glycosylation site one glycosylation site site In addition, the approach was applied to characterize the sialylated status of α2-macroglobulin and transferrin, respectively, from the sera of healthy subjects and sex- and age-matched patients with thyroid cancer, and their spectra indicate that the change in the amount of the glycoforms containing different number of sialic acid (SA) residues from one glycosylation site may be used to differentiate between healthy subjects and cancer cases. 9029108 2 44 part_of mu-chain 186:193 arg1 the C575 residue mu-chain the C575 residue Fterm Site mu-chain residue In IgM, J chain is disulfide bonded to the C575 residue of the mu-chain, located in the mu tail piece (mu tp). 8068684 9 59 gly glycosylation 1729:1741 arg2 the N75 N-linked putative glycosylation site the N75 N-linked putative glycosylation site site NHE-3, an apically-expressed epithelial isoform which does not possess the N75 N-linked putative glycosylation site and any extracellular loops enriched in serine and threonine residues, does not exhibit any detectable glycosylation. 8068684 9 105 gly serine 1788:1793 arg1 residues residues serine and threonine residues NHE-3, an apically-expressed epithelial isoform which does not possess the N75 N-linked putative glycosylation site and any extracellular loops enriched in serine and threonine residues, does not exhibit any detectable glycosylation. 21784854 6 25 gly glycosylated 1041:1052 arg1 this site this site site Here, we demonstrate that this site is glycosylated and that the effect of amino acid changes and glycosylation of the CH2/CH3 interface inhibits interaction with the pathogen IgA binding protein SSL7, while maintaining binding of pIgR, essential to the biosynthesis and transport of SIgA. 31826991 12 50 gly glycosites 1698:1707 arg2 some glycosites some glycosites glycosites Our results also demonstrate that glycan subtype can be predicted at some glycosites based on sequence comparisons and three-dimensional structural analysis.IMPORTANCE Low-pathogenicity avian influenza virus (LPAIV) subtypes can reassort with circulating human strains and pandemic viruses can emerge in human populations, as was seen in the 1957 pandemic, in which an H2 virus reassorted with the circulating H1N1 to create a novel H2N2 genotype. 11226831 0 23 gly Glycosylation 0:12 arg1 the murine estrogen receptor-alpha the murine estrogen receptor-alpha PUBTATOR estrogen receptor 13982 Glycosylation of the murine estrogen receptor-alpha. 30011186 9 10 gly glycopeptides 1909:1921 arg2 glycopeptides glycopeptides glycopeptides In this Account, we first briefly describe the glycopeptide/protein enrichment methods in the literature and then discuss the developments of boronic acid-based methods to enrich glycopeptides for large-scale analysis of protein glycosylation. 31924694 4 97 gly glycopeptide 961:972 arg2 the glycopeptide level the glycopeptide level glycopeptide A comprehensive investigation of the N-glycosylation sites from the adult stages of N. lugens was conducted, allowing a qualitative and quantitative comparison between sexes at the glycopeptide level. 31924694 4 106 gly N-glycosylation 817:831 arg2 the N-glycosylation sites the N-glycosylation sites sites A comprehensive investigation of the N-glycosylation sites from the adult stages of N. lugens was conducted, allowing a qualitative and quantitative comparison between sexes at the glycopeptide level. 6406481 10 25 part_of pepsin 974:979 arg1 Asp-32 pepsin Asp-32 Fterm SpecificSite pepsin Asp-32 The active site aspartyl residue, corresponding to Asp-32 of pepsin, is located at residue 33 in the cathepsin D light chain. 8168913 1 81 gly glycoprotein 176:187 arg1 surface glycoprotein A surface glycoprotein A Cterm surface glycoprotein A Pneumocystis carinii surface glycoprotein A (gpA) exhibits host species-specific phenotypic and genotypic variation. 6838832 0 17 gly plasminogen 96:106 arg1 the carbohydrate variants plasminogen the carbohydrate variants OGER plasminogen P00747 Amino acid sequence analysis of the asparagine-288 region of the carbohydrate variants of human plasminogen. 19249803 10 41 gly glycan 1330:1335 arg1 the WNV E protein protein can glycan OGER protein can P35658 Together these data suggest that loss of the glycan at aa154 on the WNV E protein can severely restrict viral spread in the mosquito vector. 26022737 2 6 gly glycosylation 240:252 arg2 a single glycosylation site a single glycosylation site site It is a glycoprotein possessing a single glycosylation site at N69. 26022737 2 11 gly glycoprotein 207:218 arg1 a glycoprotein a glycoprotein Fterm glycoprotein It is a glycoprotein possessing a single glycosylation site at N69. 17996106 9 50 gly glycosylation 1694:1706 arg2 putative glycosylation sites putative glycosylation sites sites CONCLUSION: Ensembles of Support Vector Machine classifiers offer an accurate and reliable approach to automated identification of putative glycosylation sites in glycoprotein sequences. 17996106 9 102 gly glycoprotein 1717:1728 arg1 glycoprotein sequences glycoprotein sequences Fterm glycoprotein CONCLUSION: Ensembles of Support Vector Machine classifiers offer an accurate and reliable approach to automated identification of putative glycosylation sites in glycoprotein sequences. 23748959 3 67 gly glycosylation 547:559 arg2 tracking gp120 N-linked glycosylation sites tracking gp120 N-linked glycosylation sites sites The web server described here, the HIV N-linked Glycosylation Site Analyzer, was developed to facilitate study of HIV diversity by tracking gp120 N-linked glycosylation sites. 2324102 4 7 part_of syndecan 768:775 arg1 the human syndecan sequence syndecan the human syndecan sequence PUBTATOR Site syndecan 6382 sequence Several interesting conserved structures were revealed by comparing the human syndecan sequence to the murine one. 9524075 12 50 gly Non-glycosylated 1303:1318 arg1 Non-glycosylated procathepsin S Non-glycosylated procathepsin S Cterm Non-glycosylated procathepsin S 1520 Non-glycosylated procathepsin S was bound to the plasma membrane at 2 degrees C, suggesting an additional sorting motif in the cathepsin S molecule besides the Man-6-phosphate residue. 22171062 4 35 gly composition 723:733 arg1 these glycoproteins glycoproteins composition Fterm glycoproteins Deciphering the glycan composition and structure on these glycoproteins may assist in the development of glycan-targeted therapeutic intervention strategies. 22171062 4 110 gly glycoproteins 758:770 arg1 these glycoproteins these glycoproteins Fterm glycoproteins Deciphering the glycan composition and structure on these glycoproteins may assist in the development of glycan-targeted therapeutic intervention strategies. 11961269 1 73 part_of possesses 235:243 arg1 The haemagglutinin AND six antigenic sites The haemagglutinin six antigenic sites Fterm Site haemagglutinin sites The haemagglutinin (HA) of influenza A/H2N2 virus possesses six antigenic sites (I-A to I-D, II-A and II-B), and sites I-A, I-B and I-C are located in the regions corresponding to sites A, B and D on the H3 HA. 2226797 0 48 gly variant 64:70 arg1 Carbohydrate structures tissue plasminogen activator variant Carbohydrate structures PUBTATOR tissue plasminogen activator variant P00750 Carbohydrate structures of a human tissue plasminogen activator variant expressed in recombinant Chinese hamster ovary cells. 21153276 1 6 gly ofN-glycosylation 140:156 arg2 Mutation ofN-glycosylation sites Mutation ofN-glycosylation sites sites Mutation ofN-glycosylation sites in the mouse gonadotropin-releasing hormone receptor was previously shown to impair its expression in COS-1 cells. 8892291 5 15 gly N-glycosylation 671:685 arg2 one N-glycosylation site one N-glycosylation site site The predicted amino acid sequence contained one N-glycosylation site, but lacked hydrophobic membrane spanning regions. 15750791 4 0 part_of Edg-1/S1P1 620:629 arg1 the N-terminal ectodomain Edg-1 the N-terminal ectodomain PUBTATOR Site Edg-1 1901 ectodomain We also demonstrated that the structure of the N-terminal ectodomain of Edg-1/S1P1 affects both its transport to the cell surface and the N-glycosylation process. 1535241 8 11 gly glycosylation 1688:1700 arg2 all four glycosylation sites all four glycosylation sites sites An allele encoding a protein that lacks all four glycosylation sites was also transformation competent. 30011186 15 52 gly glycoproteins 3047:3059 arg1 glycoproteins glycoproteins Fterm glycoproteins The last section of this Account focuses on chemical and enzymatic methods to study glycoproteins containing a particular and important glycan (the Tn antigen, i.e., O-GalNAc). 30011186 15 21 gly containing 3061:3070 arg1 glycoproteins AND a particular and important glycan glycoproteins a particular and important glycan Fterm glycoproteins The last section of this Account focuses on chemical and enzymatic methods to study glycoproteins containing a particular and important glycan (the Tn antigen, i.e., O-GalNAc). 16834341 7 2 part_of hFSH 964:967 arg1 Asn52 hFSH Asn52 OGER AminoAcid hFSH Asn52 Also, glycoforms at Asn52 of hFSH are all complex type, whereas in eFSH, both complex and hybrid structures exist at this site. 23562646 5 90 gly glycosylation 789:801 arg2 These functional glycosylation sites These functional glycosylation sites sites These functional glycosylation sites were systematically eliminated in various combinations from HN to form a panel of mutants in which the roles of individual carbohydrate chains and groups of carbohydrate chains could be analyzed. 12706347 3 52 part_of NTPDase3 560:567 arg1 The protein sequence NTPDase3 The protein sequence PUBTATOR Site NTPDase3 956 sequence The protein sequence of NTPDase3 contains seven putative N-glycosylation sites located in the ecto-domain. 12706347 3 89 part_of contains 569:576 arg1 The protein sequence AND seven putative N-glycosylation sites The protein sequence seven putative N-glycosylation sites sites The protein sequence of NTPDase3 contains seven putative N-glycosylation sites located in the ecto-domain. 23925152 6 36 gly glycosylation 937:949 arg2 N-linked glycosylation site N-linked glycosylation site site The combination of arginine insertion and loss of N-linked glycosylation site usually confers CXCR4-tropism. 3121328 7 42 gly N-glycosylation 1039:1053 arg2 The third N-glycosylation site site, Asn-448 site, Asn-448 The third N-glycosylation site, Asn-448, was found to carry a triantennary or tetraantennary N-acetyllactosamine type of carbohydrate chain. 3121328 7 19 gly carry 1083:1087 arg1 Asn-448 AND a triantennary or tetraantennary N-acetyllactosamine type site, Asn-448 a triantennary or tetraantennary N-acetyllactosamine type site, Asn-448 The third N-glycosylation site, Asn-448, was found to carry a triantennary or tetraantennary N-acetyllactosamine type of carbohydrate chain. 30042931 7 84 gly glycosylation 1311:1323 arg1 JEV E proteins JEV E proteins Fterm proteins Overall, the patterns of N-linked glycosylation on JEV E proteins may affect viral interaction with cellular lectins and contribute to viral replication and pathogenesis. 14691230 0 35 gly glycosylation 9:21 arg1 dipeptidyl peptidase IV dipeptidyl peptidase IV PUBTATOR dipeptidyl peptidase IV 1803 N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding. 14691230 0 35 gly glycosylation 9:21 arg1 CD26 CD26 PUBTATOR CD26 1803 N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding. 6406481 9 56 part_of pepsin 893:898 arg1 position 67 pepsin position 67 Fterm Site pepsin position 67 This site corresponds to position 67 of pepsin by homology. 15527836 2 107 part_of contains 284:291 arg1 The CAT1 protein AND two conserved N-linked glycosylation sites The CAT1 protein two conserved N-linked glycosylation sites PUBTATOR Site CAT1 protein 11987 sites The CAT1 protein contains two conserved N-linked glycosylation sites in the third extracellular loops of the mouse, rat, and hamster receptors (mCAT1, rCAT1, and hCAT1, respectively). 8772226 1 13 gly glycoprotein 180:191 arg1 HRG HRG PUBTATOR HRG 3273 Two forms of histidine-rich glycoprotein (HRG) were detected on SDS-PAGE by silver staining and immunoblotting after isolation of the protein from pooled plasma using immuno-affinity chromatography followed by chromatography with heparin-Sepharose. 8392347 3 23 part_of domains 563:569 arg1 carboxy-terminal cytoplasmic tail domains carboxy-terminal cytoplasmic tail tail The predicted protein exhibited structural features characteristic of members of the G-protein-coupled receptor family including seven hydrophobic segments corresponding to putative transmembrane domains, a potential N-linked glycosylation site near the amino-terminus, and multiple potential phosphorylation sites in the third cytoplasmic loop and carboxy-terminal cytoplasmic tail. 23422691 8 18 gly glycosylation 1101:1113 arg2 the VEGF glycosylation site the VEGF glycosylation site site Furthermore, substitution of asparagine at the VEGF glycosylation site with lysine or glutamic acid increased secretion of non-glycosylated VEGF, a finding not previously reported. 23422691 8 60 gly non-glycosylated 1172:1187 arg1 non-glycosylated VEGF non-glycosylated VEGF PUBTATOR VEGF 7422 Furthermore, substitution of asparagine at the VEGF glycosylation site with lysine or glutamic acid increased secretion of non-glycosylated VEGF, a finding not previously reported. 20053750 2 7 part_of have 359:362 arg1 HN AND a second receptor-binding site HN a second receptor-binding site Cterm Site HN 4758 site We recently found that in addition to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second receptor-binding site covered by an N-linked glycan at residue 173, which is near the region of the second receptor-binding site identified in Newcastle disease virus (NDV) HN (I. A. Alymova, G. Taylor, V. P. Mishin, M. Watanabe, K. G. Murti, K. Boyd, P. Chand, Y. S. Babu, and A. Portner, J. Virol. 20053750 2 7 part_of have 359:362 arg1 HN AND the region HN the region Cterm Site HN 4758 region We recently found that in addition to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second receptor-binding site covered by an N-linked glycan at residue 173, which is near the region of the second receptor-binding site identified in Newcastle disease virus (NDV) HN (I. A. Alymova, G. Taylor, V. P. Mishin, M. Watanabe, K. G. Murti, K. Boyd, P. Chand, Y. S. Babu, and A. Portner, J. Virol. 11361003 10 48 gly deglycosylated 1842:1855 arg1 deglycosylated TfR deglycosylated TfR PUBTATOR TfR 7037 To assess changes in the secondary structure of the receptor, circular dichroic spectra were recorded from TfR at pH 5.0, from heat pretreated receptor and from deglycosylated TfR. 7532677 3 37 part_of Bw6 685:687 arg1 the Bw6 epitope Bw6 the Bw6 epitope PUBTATOR Site Bw6 474275 epitope HLA-B*1513 possesses the Bw4 epitope, whereas B*1502 has the Bw6 epitope. 7532677 3 81 part_of Bw4 649:651 arg1 the Bw4 epitope Bw4 the Bw4 epitope PUBTATOR Site Bw4 474272 epitope HLA-B*1513 possesses the Bw4 epitope, whereas B*1502 has the Bw6 epitope. 17623277 13 1 part_of DCE 1460:1462 arg1 DCE glycopeptides DCE DCE glycopeptides PUBTATOR Site DCE 1718 glycopeptides During mass spectrometric analysis of DCE glycopeptides, their CID patterns were highly intriguing, in that some glycopeptides underwent both C-terminal rearrangement and formation of dimeric structures during CID. 1660522 3 67 gly glycoprotein 455:466 arg1 the gp350/220 glycoprotein the gp350/220 glycoprotein Fterm glycoprotein Human CR2 serves as a receptor for both C3dg and the gp350/220 glycoprotein of EBV, and binds the monoclonal antibody (mAb) OKB7, which blocks binding of both ligands to the receptor. 23099477 8 66 gly N-glycosylation 1242:1256 arg2 a critical N-glycosylation site a critical N-glycosylation site site In addition, the regions of the four main helices, along with a critical N-glycosylation site were well conserved. 7526855 4 40 part_of protein 590:596 arg1 conserved amino acid residue cysteine 189 protein conserved amino acid residue cysteine 189 Fterm SpecificSite protein cysteine 189 Analysis of the deduced amino acid sequence indicated a hydrophobic protein with six membrane spanning domains, one N-linked glycosylation site, two conserved NPA boxes common to MIP26 family proteins, and conserved amino acid residue cysteine 189 common to water channels. 7526855 4 40 part_of protein 590:596 arg1 one N-linked glycosylation site protein one N-linked glycosylation site Fterm Site protein site Analysis of the deduced amino acid sequence indicated a hydrophobic protein with six membrane spanning domains, one N-linked glycosylation site, two conserved NPA boxes common to MIP26 family proteins, and conserved amino acid residue cysteine 189 common to water channels. 7526855 4 40 part_of protein 590:596 arg1 six membrane spanning domains protein six membrane spanning domains Fterm Site protein domains Analysis of the deduced amino acid sequence indicated a hydrophobic protein with six membrane spanning domains, one N-linked glycosylation site, two conserved NPA boxes common to MIP26 family proteins, and conserved amino acid residue cysteine 189 common to water channels. 10989127 8 83 gly N-glycosylation 1076:1090 arg2 Potential N-glycosylation sites Potential N-glycosylation sites sites Potential N-glycosylation sites were searched in the amino acid sequences of six human hyaluronidases and several hyaluronidases from different mammalian species using the PROSITE motif database. 32110292 10 63 gly glycopeptides 1851:1863 arg2 intact glycopeptides intact glycopeptides glycopeptides Moreover, this method identifies 5 times more intact glycopeptides from human serum than the native-ETD method, implying that the approach can also accommodate large-scale site-specific profiling of glycoproteomes. 17055129 2 69 gly glycoprotein 296:307 arg1 N-glycans glycoprotein N-glycans Fterm glycoprotein However, the roles of N-glycans of hepatitis C virus (HCV) E2 envelope glycoprotein in specific cellular immune responses remain elusive. 7487957 7 39 gly enzymes 1720:1726 arg1 desialylation enzymes desialylation Fterm enzymes When saturating amounts of asialofetuin were administered together with rHuAChE, the circulatory half-life of the enzyme was dramatically increased (from 80 min to 19 h) and was found to be similar to that displayed by plasma-derived cholinesterases while desialylation of these enzymes caused a sharp decrease in the circulatory half-life to approximately 3-5 min. 7487957 7 51 gly desialylation 1697:1709 arg1 these enzymes these enzymes Fterm enzymes When saturating amounts of asialofetuin were administered together with rHuAChE, the circulatory half-life of the enzyme was dramatically increased (from 80 min to 19 h) and was found to be similar to that displayed by plasma-derived cholinesterases while desialylation of these enzymes caused a sharp decrease in the circulatory half-life to approximately 3-5 min. 7829269 3 9 gly aglycosylated 777:789 arg1 The resultant aglycosylated chimeric LL2 The resultant aglycosylated chimeric LL2 PUBTATOR LL2 633295 The resultant aglycosylated chimeric LL2 exhibited a similar Raji cell binding affinity to that of the glycosylated form. 23830432 2 66 part_of fetuin 294:299 arg1 four potential O-linked glycosylation sites fetuin sites Fterm Site fetuin sites Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 23830432 2 66 part_of fetuin 294:299 arg1 three potential N-linked glycosylation sites fetuin sites Fterm Site fetuin sites Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 23830432 2 66 part_of fetuin 294:299 arg1 three potential N-linked glycosylation sites fetuin sites Fterm Site fetuin sites Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 27957769 11 31 gly glycosylation 2185:2197 arg2 glycosylation sites glycosylation sites sites The nature of the antibody response is characteristically different for antibodies directed to glycosylation sites in either the immune-dominant PDTR or the GSTA domain. 16476981 0 7 part_of gp120 79:83 arg1 the gp120 V3 loop N-linked glycosylation site gp120 the gp120 V3 loop N-linked glycosylation site OGER Site gp120 Q14624 site CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. 25499264 3 62 gly N-glycan 465:472 arg1 the transmembrane envelope glycoprotein gp41 envelope glycoprotein gp41 N-glycan PUBTATOR envelope glycoprotein gp41 100616444 Recently, also an N-glycan on the transmembrane envelope glycoprotein gp41 was shown to be deleted during CBA resistance development. 25499264 3 112 gly glycoprotein 504:515 arg1 the transmembrane envelope glycoprotein gp41 the transmembrane envelope glycoprotein gp41 PUBTATOR envelope glycoprotein gp41 100616444 Recently, also an N-glycan on the transmembrane envelope glycoprotein gp41 was shown to be deleted during CBA resistance development. 14658030 0 82 gly N-glycosylation 18:32 arg2 N-glycosylation sites NCAM sites PUBTATOR NCAM 17967 sites Identification of N-glycosylation sites of the murine neural cell adhesion molecule NCAM by MALDI-TOF and MALDI-FTICR mass spectrometry. 11161270 0 38 gly glycosylation 107:119 arg2 the glycosylation site the glycosylation site site Varicella-zoster virus gH:gL contains a structure reactive with the anti-human gamma chain of IgG near the glycosylation site. 27343203 4 81 gly glycosylation 725:737 arg2 the N-linked glycosylation site the N-linked glycosylation site site One variant comprised the full extracellular portion of CD23, including the stalk and head domain; 1 variant was identical with the first, except for an amino acid exchange in the stalk region abolishing the N-linked glycosylation site; and 2 variants represented the head domain, 1 complete and 1 truncated. 21637915 4 51 part_of ECI 548:550 arg1 a partial ECI sequence ECI a partial ECI sequence OGER Site ECI Q9BS40 sequence We investigated whether synthetic peptides carrying a partial ECI sequence could inhibit emmprin activity. 21637915 4 20 part_of carrying 529:536 arg1 synthetic peptides AND a partial ECI sequence synthetic peptides a partial ECI sequence sequence We investigated whether synthetic peptides carrying a partial ECI sequence could inhibit emmprin activity. 1359371 5 51 gly N-glycosylation 742:756 arg2 The N-glycosylation site The N-glycosylation site site The N-glycosylation site at position 61 is the same as that in the human protein, but is different from that in the rodent (position 75). 1359371 5 51 gly N-glycosylation 742:756 arg2 position 61 position 61 position 61 The N-glycosylation site at position 61 is the same as that in the human protein, but is different from that in the rodent (position 75). 11259791 1 2 part_of acetylcholinesterase 219:238 arg1 Antigenic decapeptides acetylcholinesterase Antigenic decapeptides PUBTATOR Site acetylcholinesterase 43 decapeptides Antigenic decapeptides of human brain acetylcholinesterase (AChE) were investigated for immunoreactivity with the rabbit anti-Torpediniformes narcine timlei AChE polyclonal antibody (anti-narcine AChE polyclonal antibody). 8879142 1 41 gly glycosylation 239:251 arg2 an N glycosylation site an N glycosylation site site Based on sequence analysis, the protein encoded by the UL3 open reading frame (ORF) of herpes simplex virus type 1 (HSV-1) was predicted to contain an N glycosylation site and to be a glycoprotein. 8879142 1 51 gly glycoprotein 270:281 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Based on sequence analysis, the protein encoded by the UL3 open reading frame (ORF) of herpes simplex virus type 1 (HSV-1) was predicted to contain an N glycosylation site and to be a glycoprotein. 8380463 8 6 gly residues 1107:1114 arg1 glycans residues 41 and 102 glycans residues 41 and 102 However, mutant proteins lacking glycans at residue 102 (gN2) or residues 41 and 102 (gN1N2) showed altered reactivity with conformation-dependent gIV-specific monoclonal antibodies. 8380463 8 48 gly residue 1086:1092 arg1 glycans residue 102 glycans residue 102 However, mutant proteins lacking glycans at residue 102 (gN2) or residues 41 and 102 (gN1N2) showed altered reactivity with conformation-dependent gIV-specific monoclonal antibodies. 9008840 8 76 gly glycoforms 1325:1334 arg1 Gp21 Gp21 Cterm Gp21 These observations indicate that the terminal GlcNAc residue in the minor glycoforms of Gp21 is exclusively located in the alpha (1-->3) branch of the Gp21 glycan. 1918071 7 92 gly N-glycosylation 1470:1484 arg2 N-glycosylation site sequences site sequences site sequences We have investigated the discrepancy between this apparent lack of sequence specificity and earlier results indicating that binding of peptides to PDI was specific for N-glycosylation site sequences. 3065335 6 5 part_of kallikrein 787:796 arg1 The sequence kallikrein The sequence PUBTATOR Site kallikrein 9622 sequence The sequence of human urinary kallikrein was identical with that of human pancreatic and kidney kallikreins (Fukushima, D. et al. (1985) Biochemistry 24, 8037-8043; Baker, A.R. & Shine, J. (1985) DNA 4, 445-459), which were predicted from the nucleotide sequences of cDNAs. 15094369 5 44 gly attached 942:949 arg2 the N-glycosylation site Asn23-Glu-Ser AND N-acetylglucosamine the N-glycosylation site Asn23-Glu-Ser N-acetylglucosamine site Asn23-Glu-Ser The difference of the molecular masses of H. lutea Cu/ZnSOD, measured by MALDI-MS (15,935 Da) and calculated by its amino acid sequence (15,716 Da), is attributed to the carbohydrate chain of one mole of N-acetylglucosamine, attached to the N-glycosylation site Asn23-Glu-Ser. 15094369 5 4 gly N-glycosylation 958:972 arg2 the N-glycosylation site Asn23-Glu-Ser site Asn23-Glu-Ser site Asn23-Glu-Ser The difference of the molecular masses of H. lutea Cu/ZnSOD, measured by MALDI-MS (15,935 Da) and calculated by its amino acid sequence (15,716 Da), is attributed to the carbohydrate chain of one mole of N-acetylglucosamine, attached to the N-glycosylation site Asn23-Glu-Ser. 19706343 9 12 gly units 1519:1523 arg1 Asn-143 Asn-143 Asn-143 SpecificSite Asn-143 These data indicate that some APS patients have beta2GPI molecules with a reduced number of negatively charged sialic acid units in the glycan structure at Asn-143. 19706343 9 88 gly Asn-143 1552:1558 arg1 negatively charged sialic acid units Asn-143 negatively charged sialic acid units Asn-143 These data indicate that some APS patients have beta2GPI molecules with a reduced number of negatively charged sialic acid units in the glycan structure at Asn-143. 19706343 9 88 gly Asn-143 1552:1558 arg1 the glycan structure Asn-143 the glycan structure Asn-143 These data indicate that some APS patients have beta2GPI molecules with a reduced number of negatively charged sialic acid units in the glycan structure at Asn-143. 12527108 3 34 gly glycosylation 421:433 arg2 both glycosylation sites both glycosylation sites sites Soluble secretory forms of the enzyme (SFT3) and mutant forms with the first, second and both glycosylation sites (SFT3DN1, SFT3DN2, SFT3DN) mutated have been expressed in baby hamster kidney (BHK) and Spodoptera frugiperda (Sf9) cells. 21661761 1 13 gly glycosylation 230:242 arg2 protein glycosylation sites protein glycosylation sites sites Given the biological importance of glycosylation on proteins, the identification of protein glycosylation sites is integral to understanding broader biological structure and function. 27177499 7 7 part_of contains 1021:1028 arg1 The hCG ß-subunit AND four sites ß-subunit sites Fterm Site ß-subunit sites The hCG ß-subunit is encoded by a cluster of genes (CGB) and contains two sites of N-glycosylation and four sites of O-glycosylation. 12223479 11 102 gly glycosylation 1731:1743 arg2 the double glycosylation site mutant beta4 (beta4 N53A/N90A) the double glycosylation site mutant beta4 (beta4 N53A/N90A) site However, the double glycosylation site mutant beta4 (beta4 N53A/N90A) protects the channel less against toxin blockade, as compared with the hSlo channel coexpressed with wild type beta4 subunit. 8380463 3 73 gly glycosylation 444:456 arg2 one N-linked glycosylation site one N-linked glycosylation site site Three mutants were constructed by oligonucleotide-directed mutagenesis, in each case changing one N-linked glycosylation site from Asn-X-Thr/Ser to Ser-X-Thr/Ser. 7755594 2 19 gly N-glycosylation 441:455 arg2 the potential N-glycosylation sites the potential N-glycosylation sites sites In natural leucocyte IFN-gamma (nIFN-gamma), 52%, 39% and 9% of the monomers are core-glycosylated in two, one or none of the potential N-glycosylation sites respectively. 10764604 1 24 gly glycosylation 179:191 arg2 individual glycosylation sites individual glycosylation sites sites Complete carbohydrate composition analysis of glycoprotein hormones, their subunits, and oligosaccharides isolated from individual glycosylation sites can be accomplished using high-pH anion-exchange chromatography combined with pulsed amperometric detection. 10764604 1 75 gly glycoprotein 94:105 arg1 glycoprotein hormones glycoprotein hormones Fterm glycoprotein Complete carbohydrate composition analysis of glycoprotein hormones, their subunits, and oligosaccharides isolated from individual glycosylation sites can be accomplished using high-pH anion-exchange chromatography combined with pulsed amperometric detection. 10764604 1 94 gly carbohydrate 57:68 arg1 their subunits subunits oligosaccharides Fterm subunits Complete carbohydrate composition analysis of glycoprotein hormones, their subunits, and oligosaccharides isolated from individual glycosylation sites can be accomplished using high-pH anion-exchange chromatography combined with pulsed amperometric detection. 12911333 12 74 gly N-glycosylation 2127:2141 arg2 the N-glycosylation site the N-glycosylation site site This may imply that the native position of the N-glycosylation site may be important if the carbohydrate tree plays a role in the folding, stability, trafficking and/or function of the protein. 8663003 1 52 gly glycoprotein 205:216 arg1 Rh glycoprotein Rh glycoprotein Fterm glycoprotein We have used rabbit polyclonal antisera raised against synthetic peptides complementary to different domains of the Rh polypeptides and Rh glycoprotein to examine the topography and organization of these proteins in the human erythrocyte membrane. 7613486 9 52 part_of receptor 1696:1703 arg1 this region receptor this region Fterm Site receptor region Only partial glycosylation in this region of the receptor is required for its targeting to the cell membrane since single and double glycosylation mutants were found processed to their alpha and beta subunits on the cell surface. 15532026 9 82 gly glycosylation 1577:1589 arg2 the used glycosylation site the used glycosylation site site These data suggest that the loss of the used glycosylation site in the gamma subunit may affect the intracellular localization of GNPTAG and the overall efficiency of M6P formation. 8244416 3 90 part_of contained 674:682 arg1 The variable region AND The variable region The variable region The variable region region The variable region for the heavy chain of F11-35 contained a possible N-glycosylation site (Asn/Asp/Thr) at amino acid positions 89-91. 8244416 3 90 part_of contained 674:682 arg1 The variable region AND Asn/Asp/Thr The variable region Asn/Asp/Thr Asn/Asp/Thr The variable region for the heavy chain of F11-35 contained a possible N-glycosylation site (Asn/Asp/Thr) at amino acid positions 89-91. 8244416 3 90 part_of contained 674:682 arg1 The variable region AND a possible N-glycosylation site The variable region a possible N-glycosylation site site The variable region for the heavy chain of F11-35 contained a possible N-glycosylation site (Asn/Asp/Thr) at amino acid positions 89-91. 23958596 10 14 gly N-glycosylation 1356:1370 arg2 the 99-Asn the 99-Asn Asn These data indicate that the 99-Asn is the most critical N-glycosylation site for formation of native hLPLA2 in vivo and that the N-glycosylation of LPLA2 is crucial for biosynthesis of catalytically active hLPLA2. 23958596 10 14 gly N-glycosylation 1356:1370 arg2 the most critical N-glycosylation site the most critical N-glycosylation site site These data indicate that the 99-Asn is the most critical N-glycosylation site for formation of native hLPLA2 in vivo and that the N-glycosylation of LPLA2 is crucial for biosynthesis of catalytically active hLPLA2. 23958596 10 70 gly N-glycosylation 1429:1443 arg1 LPLA2 LPLA2 PUBTATOR LPLA2 23659 These data indicate that the 99-Asn is the most critical N-glycosylation site for formation of native hLPLA2 in vivo and that the N-glycosylation of LPLA2 is crucial for biosynthesis of catalytically active hLPLA2. 20807536 11 5 gly carbohydrates 1609:1621 arg1 ovalbumin ovalbumin carbohydrates Fterm ovalbumin Collectively, these data suggest that E. histolytica has a previously unrecognised surface lectin activity that binds to carbohydrates on ovalbumin and stimulates phagocytosis. 3087774 5 19 gly glycosylation 567:579 arg1 the sites the sites sites The different states of glycosylation of the sites cannot be explained by differences in exposure or secondary structure. 17671839 5 74 gly glycosylation 729:741 arg2 single or multiple N-linked glycosylation site (NGS) mutant GP5 single or multiple N-linked glycosylation site (NGS) mutant GP5 site The objective of this study was to construct recombinant adenoviruses expressing single or multiple N-linked glycosylation site (NGS) mutant GP5 of PRRSV, and evaluate the expression in cell culture, and potential to induce immune responses in BALB/c mice. 8029814 12 44 part_of contains 1562:1569 arg1 The mouse protein S AND two potential N-glycosylation sites The mouse protein S two potential N-glycosylation sites Cterm Site The mouse protein S sites The mouse protein S contains two potential N-glycosylation sites at positions #458 and 468 and is lacking the putative glycosylation site at #490 found in human protein S. 7730329 3 63 gly glycoprotein 247:258 arg1 a single chain glycoprotein a single chain glycoprotein Fterm glycoprotein It is a single chain glycoprotein with an apparent molecular weight of 33,000 and an isoelectric point of pH 5.2. 31685900 7 60 gly glycosites 971:980 arg2 N-linked glycosites N-linked glycosites glycosites The second stage uses a support vector machine to predict N-linked glycosites by utilizing features of gapped dipeptides, pattern-based predicted surface accessibility, and predicted secondary structure. 8601595 5 30 gly glycosylation 1065:1077 arg2 five potential N-linked glycosylation sites five potential N-linked glycosylation sites sites Using human melanoma cells stably transfected with CD44 N-linked glycosylation site-specific mutants, we show that integrity of five potential N-linked glycosylation sites within the hyaluronate recognition domain of CD44 is critical for hyaluronate binding. 25636227 3 55 gly O-glycosylation 490:504 arg1 individual proteins proteins sites Fterm proteins sites In this work, we designed a rapid and convenient workflow for characterizing the O-glycosylation sites of individual proteins and the human-plasma proteome. 20188224 10 76 gly glycosylation 1499:1511 arg2 the sites the sites sites The method developed was applied to progranulin (PGRN) to characterize the structures of the released glycans and to identify the sites of glycosylation. 23341449 0 10 part_of molecule 94:101 arg1 two domains neural cell adhesion molecule two domains PUBTATOR Site neural cell adhesion molecule 4684 domains The polysialyltransferases interact with sequences in two domains of the neural cell adhesion molecule to allow its polysialylation. 23341449 0 28 part_of sequences 41:49 arg1 two domains neural cell adhesion molecule domains PUBTATOR neural cell adhesion molecule 4684 domains The polysialyltransferases interact with sequences in two domains of the neural cell adhesion molecule to allow its polysialylation. 30299079 1 8 gly glycopeptides 193:205 arg2 glycopeptides glycopeptides glycopeptides A straightforward approach has been developed to distinguish core and antenna fucosylation in glycopeptides. 30299079 1 55 gly fucosylation 177:188 arg1 glycopeptides glycopeptides glycopeptides Site glycopeptides A straightforward approach has been developed to distinguish core and antenna fucosylation in glycopeptides. 16096263 4 42 gly N-glycosylation 950:964 arg2 single N-glycosylation sites single N-glycosylation sites sites AE1 or SAO constructs containing either the endogenous N-glycosylation site at Asn642 in extracellular loop 4 (EC4) or single N-glycosylation sites engineered into an expanded extracellular loop 1 (EC1) were used. 16096263 4 42 gly N-glycosylation 950:964 arg2 Asn642 Asn642 Asn642 AE1 or SAO constructs containing either the endogenous N-glycosylation site at Asn642 in extracellular loop 4 (EC4) or single N-glycosylation sites engineered into an expanded extracellular loop 1 (EC1) were used. 16096263 4 82 gly N-glycosylation 879:893 arg2 Asn642 Asn642 Asn642 AE1 or SAO constructs containing either the endogenous N-glycosylation site at Asn642 in extracellular loop 4 (EC4) or single N-glycosylation sites engineered into an expanded extracellular loop 1 (EC1) were used. 16096263 4 82 gly N-glycosylation 879:893 arg2 the endogenous N-glycosylation site the endogenous N-glycosylation site site AE1 or SAO constructs containing either the endogenous N-glycosylation site at Asn642 in extracellular loop 4 (EC4) or single N-glycosylation sites engineered into an expanded extracellular loop 1 (EC1) were used. 31611356 6 67 gly glycosylation 1231:1243 arg1 N295 N295 N295 Grft's ability to alter the structure of gp120, exposing the CD4 binding site, correlated with the presence of glycosylation at N295 only in clade B strains, not clade C strains. 7529232 3 11 gly glycosylation 396:408 arg1 the cell-cell recognition molecule CD2 the cell-cell recognition molecule CD2 PUBTATOR CD2 914 In this study a systematic analysis of the effect of glycosylation on the ligand-binding properties of the cell-cell recognition molecule CD2, which consists of two IgSF domains, was undertaken. 2846759 5 24 gly non-glycosylated 1345:1360 arg1 non-glycosylated precursors non-glycosylated precursors Fterm precursors The members of the gH family range in size from 706 to 743 amino acid residues for the beta- and gammaherpesviruses, to 838 to 841 for the alphaherpesviruses, giving non-glycosylated precursors with Mr values of 78,322 to 93,651. 15616123 9 1 gly occupied 1517:1524 arg2 Asn158 Asn158 Asn158 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 73 gly disialylated 1681:1692 arg1 mono- or disialylated oligosaccharides mono- or disialylated oligosaccharides It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 1496 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2955 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3438 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3074 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3868 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 4210 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 Asn 956 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2212 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2752 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2955 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3438 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3074 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3868 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 4210 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 Asn 956 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2212 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2752 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3438 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3074 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3868 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 4210 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 Asn 956 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2212 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2752 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3438 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3074 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3868 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 4210 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 Asn 956 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2212 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2752 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3074 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3868 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 4210 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 Asn 956 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2212 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2752 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 3868 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 4210 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 Asn 956 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2212 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2752 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 4210 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 Asn 956 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2212 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2752 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 Asn 956 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2212 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2752 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2212 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2752 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 15616123 9 18 gly occupied 1660:1667 arg2 2752 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides. 19500602 9 24 gly glycosylation 1687:1699 arg2 glycosylation sites glycosylation sites sites Characterization of mutants carrying all possible combinations of glycosylation sites demonstrated clear correlation between the number of glycosylation sites and the level of transporter activity, and showed that K201N could substitute for either one of the two original glycosylation sites. 19500602 9 59 gly glycosylation 1614:1626 arg2 glycosylation sites glycosylation sites sites Characterization of mutants carrying all possible combinations of glycosylation sites demonstrated clear correlation between the number of glycosylation sites and the level of transporter activity, and showed that K201N could substitute for either one of the two original glycosylation sites. 19500602 9 63 gly glycosylation 1820:1832 arg2 the two original glycosylation sites the two original glycosylation sites sites Characterization of mutants carrying all possible combinations of glycosylation sites demonstrated clear correlation between the number of glycosylation sites and the level of transporter activity, and showed that K201N could substitute for either one of the two original glycosylation sites. 11130974 8 18 gly glycosylation 1244:1256 arg2 a novel N-linked glycosylation site a novel N-linked glycosylation site site Eight ORs contain an unusual NXC sequon at the amino-terminal extracellular domain that may represent a novel N-linked glycosylation site. 24338886 3 35 gly sites 535:539 arg1 the three predicted N-linked glycosylation sites the three predicted N-linked glycosylation sites sites While the three predicted N-linked glycosylation sites (Asn24, Asn38 and Asn83) showed complete site occupancy, Pichia- and CHO-derived rhEPO showed distinct differences in the glycan structures with the former containing sialylated bi-antennary glycoforms and the latter containing a mixture of sialylated bi-, tri- and tetra-antennary structures. 24338886 3 75 gly sialylated 782:791 arg1 bi- bi- While the three predicted N-linked glycosylation sites (Asn24, Asn38 and Asn83) showed complete site occupancy, Pichia- and CHO-derived rhEPO showed distinct differences in the glycan structures with the former containing sialylated bi-antennary glycoforms and the latter containing a mixture of sialylated bi-, tri- and tetra-antennary structures. 24338886 3 77 gly glycosylation 521:533 arg2 the three predicted N-linked glycosylation sites the three predicted N-linked glycosylation sites sites While the three predicted N-linked glycosylation sites (Asn24, Asn38 and Asn83) showed complete site occupancy, Pichia- and CHO-derived rhEPO showed distinct differences in the glycan structures with the former containing sialylated bi-antennary glycoforms and the latter containing a mixture of sialylated bi-, tri- and tetra-antennary structures. 24338886 3 86 gly sialylated 708:717 arg1 sialylated bi-antennary glycoforms sialylated bi-antennary glycoforms While the three predicted N-linked glycosylation sites (Asn24, Asn38 and Asn83) showed complete site occupancy, Pichia- and CHO-derived rhEPO showed distinct differences in the glycan structures with the former containing sialylated bi-antennary glycoforms and the latter containing a mixture of sialylated bi-, tri- and tetra-antennary structures. 24338886 3 35 gly sites 535:539 arg1 Asn38 Asn24, Asn38 and Asn83 Asn24, Asn38 and Asn83 While the three predicted N-linked glycosylation sites (Asn24, Asn38 and Asn83) showed complete site occupancy, Pichia- and CHO-derived rhEPO showed distinct differences in the glycan structures with the former containing sialylated bi-antennary glycoforms and the latter containing a mixture of sialylated bi-, tri- and tetra-antennary structures. 24338886 3 77 gly glycosylation 521:533 arg2 Asn38 Asn24, Asn38 and Asn83 Asn24, Asn38 and Asn83 While the three predicted N-linked glycosylation sites (Asn24, Asn38 and Asn83) showed complete site occupancy, Pichia- and CHO-derived rhEPO showed distinct differences in the glycan structures with the former containing sialylated bi-antennary glycoforms and the latter containing a mixture of sialylated bi-, tri- and tetra-antennary structures. 12438611 12 66 gly mannosylated 2133:2144 arg1 mannosylated cell surface proteins mannosylated cell surface proteins Fterm proteins We provide evidence that this enhancement may be due to cyanovirin's ability to bridge gp120 to mannosylated cell surface proteins. 21899340 0 24 part_of glycoproteins 224:236 arg1 glycosylation site glycoproteins glycosylation site Fterm Site glycoproteins site Size-selective enrichment of N-linked glycans using highly ordered mesoporous carbon material and detection by MALDI-TOF MS. Many diseases are characterized by the changes of either glycan structure or glycosylation site of glycoproteins. 19241033 5 36 gly glycoproteins 942:954 arg1 glycoproteins glycoproteins Fterm glycoproteins Several different strategies for efficient in-solution digestion of glycoproteins are described, such as proteolytic digestion in the electrospray capillary and simultaneous analysis of the resulting (glyco)peptides. 18282281 10 9 gly O-glycosylated 1804:1817 arg1 O-glycosylated S/T sites O-glycosylated S/T sites sites Either in 1:1 or 1:5 datasets, the performance of this S+T predictor was always slightly better than those predictors where S and T sites were independently predicted, suggesting that the molecular recognition of O-glycosylated S/T sites seems to be similar and the increase of the S+T predictor's accuracy may be a result of expanded training datasets. 7540044 3 98 gly glycoprotein 736:747 arg1 the glycoprotein the glycoprotein Fterm glycoprotein The amino acid sequence of the glycoprotein in this region exhibits some degree of variability among different rabies virus and rabies virus related strains, including the replacement of the asparagine residue with aspartic acid or threonine. 15628971 5 6 gly attachment 859:868 arg2 a single N-glycan AND the C-terminal region the C-terminal region a single N-glycan region We found that (i) treatment of recombinant C4ST-1 with peptide N-glycosidase F caused a marked decrease in activity, (ii) production of the active form of C4ST-1 by COS-7 cells transfected with cDNA of C4ST-1 was inhibited by tunicamycin, (iii) deletion of the N-glycosylation site located at the C-terminal region of C4ST-1 abolished activity, (iv) attachment of a single N-glycan at the C-terminal region supported production of the active form of C4ST-1, but the resulting recombinant enzyme was much more unstable at 37 degrees C than the control recombinant protein, and (v) truncation of C-terminal region up to the N-glycosylation site at the C-terminal region resulted in total loss of activity. 15628971 5 38 gly N-glycosylation 1131:1145 arg2 the C-terminal region the C-terminal region region We found that (i) treatment of recombinant C4ST-1 with peptide N-glycosidase F caused a marked decrease in activity, (ii) production of the active form of C4ST-1 by COS-7 cells transfected with cDNA of C4ST-1 was inhibited by tunicamycin, (iii) deletion of the N-glycosylation site located at the C-terminal region of C4ST-1 abolished activity, (iv) attachment of a single N-glycan at the C-terminal region supported production of the active form of C4ST-1, but the resulting recombinant enzyme was much more unstable at 37 degrees C than the control recombinant protein, and (v) truncation of C-terminal region up to the N-glycosylation site at the C-terminal region resulted in total loss of activity. 15628971 5 38 gly N-glycosylation 1131:1145 arg2 the N-glycosylation site the N-glycosylation site site We found that (i) treatment of recombinant C4ST-1 with peptide N-glycosidase F caused a marked decrease in activity, (ii) production of the active form of C4ST-1 by COS-7 cells transfected with cDNA of C4ST-1 was inhibited by tunicamycin, (iii) deletion of the N-glycosylation site located at the C-terminal region of C4ST-1 abolished activity, (iv) attachment of a single N-glycan at the C-terminal region supported production of the active form of C4ST-1, but the resulting recombinant enzyme was much more unstable at 37 degrees C than the control recombinant protein, and (v) truncation of C-terminal region up to the N-glycosylation site at the C-terminal region resulted in total loss of activity. 15628971 5 48 gly N-glycosylation 770:784 arg2 the N-glycosylation site the N-glycosylation site site We found that (i) treatment of recombinant C4ST-1 with peptide N-glycosidase F caused a marked decrease in activity, (ii) production of the active form of C4ST-1 by COS-7 cells transfected with cDNA of C4ST-1 was inhibited by tunicamycin, (iii) deletion of the N-glycosylation site located at the C-terminal region of C4ST-1 abolished activity, (iv) attachment of a single N-glycan at the C-terminal region supported production of the active form of C4ST-1, but the resulting recombinant enzyme was much more unstable at 37 degrees C than the control recombinant protein, and (v) truncation of C-terminal region up to the N-glycosylation site at the C-terminal region resulted in total loss of activity. 7904345 2 5 gly glycosylation 255:267 arg2 the conserved glycosylation site the conserved glycosylation site site The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing. 7904345 2 4 gly presence 199:206 arg1 the conserved glycosylation site AND identical oligosaccharides site identical oligosaccharides site The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing. 7904345 2 4 gly presence 199:206 arg1 rat sCD4 AND identical oligosaccharides sCD4 site identical oligosaccharides PUBTATOR sCD4 499358 site The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing. 7904345 2 4 gly presence 199:206 arg1 rat sCD4 AND identical oligosaccharides sCD4 site identical oligosaccharides PUBTATOR sCD4 499358 site The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing. 7904345 2 4 gly presence 199:206 arg2 the conserved glycosylation site AND hybrid type glycans site hybrid type glycans site The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing. 7904345 2 4 gly presence 199:206 arg2 rat sCD4 AND hybrid type glycans sCD4 site hybrid type glycans PUBTATOR sCD4 499358 site The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing. 7904345 2 4 gly presence 199:206 arg2 rat sCD4 AND hybrid type glycans sCD4 site hybrid type glycans PUBTATOR sCD4 499358 site The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing. 7904345 2 68 gly glycosylation 395:407 arg2 the non-conserved glycosylation site sCD4 site PUBTATOR sCD4 499358 site The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing. 10648510 9 1 gly glycoproteins 1716:1728 arg1 glycoproteins glycoproteins Fterm glycoproteins We propose that this deglycosylation of glycoproteins containing high-mannose-type glycans and the subsequent degradation of the released glycans by E. faecalis may play a role in the survival and persistence of this nosocomial pathogen in vivo. 10648510 9 100 gly deglycosylation 1697:1711 arg1 glycoproteins glycoproteins Fterm glycoproteins We propose that this deglycosylation of glycoproteins containing high-mannose-type glycans and the subsequent degradation of the released glycans by E. faecalis may play a role in the survival and persistence of this nosocomial pathogen in vivo. 10648510 9 97 gly containing 1730:1739 arg1 glycoproteins AND high-mannose-type glycans glycoproteins high-mannose-type glycans Fterm glycoproteins We propose that this deglycosylation of glycoproteins containing high-mannose-type glycans and the subsequent degradation of the released glycans by E. faecalis may play a role in the survival and persistence of this nosocomial pathogen in vivo. 20188224 12 79 gly glycosylation 1726:1738 arg2 the observed glycosylation sites the observed glycosylation sites sites Two of the observed glycosylation sites occur within granulin domains, which may have important implications for understanding the structural basis of PGRN action. 8601595 2 56 gly glycosylation 234:246 arg1 CD44-hyaluronate interaction CD44-hyaluronate interaction PUBTATOR CD44 960 In the present work we examine the role of N-linked glycosylation and Ser-Gly motifs in regulating CD44-hyaluronate interaction. 7620335 0 1 gly structures 38:47 arg1 each glycosylation site each glycosylation site each glycosylation site Site site Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site. 7620335 0 67 gly site 120:123 arg1 the oligosaccharide structures site the oligosaccharide structures site Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site. 7620335 0 75 gly peptide 90:96 arg1 the oligosaccharide structures peptide the oligosaccharide structures peptide Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site. 7620335 0 89 gly glycosylation 106:118 arg2 each glycosylation site each glycosylation site site Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site. 26536155 0 54 part_of Pronase 168:174 arg1 Pronase Treated Glycopeptides Pronase Pronase Treated Glycopeptides Fterm Site Pronase Glycopeptides Site-Specific Protein N- and O-Glycosylation Analysis by a C18-Porous Graphitized Carbon-Liquid Chromatography-Electrospray Ionization Mass Spectrometry Approach Using Pronase Treated Glycopeptides. 26536155 0 89 part_of Treated 176:182 arg1 Pronase Treated Glycopeptides Treated Pronase Treated Glycopeptides Cterm Site Treated Glycopeptides Site-Specific Protein N- and O-Glycosylation Analysis by a C18-Porous Graphitized Carbon-Liquid Chromatography-Electrospray Ionization Mass Spectrometry Approach Using Pronase Treated Glycopeptides. 8419363 3 53 part_of CBG 601:603 arg1 the CBG polypeptide CBG the CBG polypeptide PUBTATOR Site CBG 866 polypeptide To assess the impact of these carbohydrate chains on CBG production and steroid binding, we mutated a human CBG cDNA so that the six consensus sites for N-glycosylation in the CBG polypeptide were eliminated individually and in various combinations. 8349598 5 85 gly acceptors 1172:1180 arg1 transferrin transferrin acceptors PUBTATOR transferrin 7018 We have examined a number of tissues and cultured cell lines for the transfer of sulfate to the trisaccharide acceptor GGnM and transfer of GalNAc to oligosaccharide acceptors on protein which do, human chorionic gonadotropin (hCG), and do not, transferrin (Trf), contain the PXR/K motif. 8349598 5 85 gly acceptors 1172:1180 arg1 protein protein acceptors Fterm protein We have examined a number of tissues and cultured cell lines for the transfer of sulfate to the trisaccharide acceptor GGnM and transfer of GalNAc to oligosaccharide acceptors on protein which do, human chorionic gonadotropin (hCG), and do not, transferrin (Trf), contain the PXR/K motif. 17050611 5 29 gly N-glycosylation 912:926 arg2 N-glycosylation site deletions N-glycosylation site deletions site Upon prolonged exposure of HIV-1-infected CEM cell cultures, PRM-A drug pressure selects for mutant HIV-1 strains containing N-glycosylation site deletions in gp120 but not gp41. 31577193 6 56 part_of sequence 738:745 arg1 N-glycosylation site sequence N-glycosylation site site METHODS: In this article, we report a random forest method, Nglyc, to predict N-glycosylation site from protein sequence, using 315 sequence features. 20943491 3 74 part_of CDS 704:706 arg1 coding region CDS coding region OGER Site CDS O35052 region The results showed that the full sequence of CuZnSOD cDNA is 658 bp (GU944822), containing 76 bp sequence of 5' UTR and 120 bp sequence of 3' UTR, and coding region (CDS, 462 bp) encodes 153 amino acids. 20943491 3 79 part_of containing 618:627 arg1 the full sequence AND 76 bp sequence sequence sequence The results showed that the full sequence of CuZnSOD cDNA is 658 bp (GU944822), containing 76 bp sequence of 5' UTR and 120 bp sequence of 3' UTR, and coding region (CDS, 462 bp) encodes 153 amino acids. 11344537 4 14 gly glycosylation 942:954 arg1 the analyzed peptide the analyzed peptide peptide In a single measurement of previously chemically untreated O-fucosylated peptides originating from the thrombospondin-1 repeats, we were able to determine the glycosylation status of the analyzed peptide, the glycosylation site, and the glycan structure. 11344537 4 21 gly O-fucosylated 842:854 arg1 previously chemically untreated O-fucosylated peptides previously chemically untreated O-fucosylated peptides peptides In a single measurement of previously chemically untreated O-fucosylated peptides originating from the thrombospondin-1 repeats, we were able to determine the glycosylation status of the analyzed peptide, the glycosylation site, and the glycan structure. 11344537 4 54 gly glycosylation 992:1004 arg2 the glycosylation site the glycosylation site site In a single measurement of previously chemically untreated O-fucosylated peptides originating from the thrombospondin-1 repeats, we were able to determine the glycosylation status of the analyzed peptide, the glycosylation site, and the glycan structure. 11344537 4 58 gly peptide 979:985 arg1 the glycan structure peptide the glycan structure peptide In a single measurement of previously chemically untreated O-fucosylated peptides originating from the thrombospondin-1 repeats, we were able to determine the glycosylation status of the analyzed peptide, the glycosylation site, and the glycan structure. 11344537 4 54 gly glycosylation 992:1004 arg1 the analyzed peptide peptide peptide In a single measurement of previously chemically untreated O-fucosylated peptides originating from the thrombospondin-1 repeats, we were able to determine the glycosylation status of the analyzed peptide, the glycosylation site, and the glycan structure. 26858738 7 26 gly disialylated 1407:1418 arg1 disialylated mucin-type core 1 O-glycans disialylated mucin-type core 1 O-glycans By co-expression of enzymes required for initiation and elongation of human O-glycosylation it was possible to generate disialylated mucin-type core 1 O-glycans on plant-produced IgA1. 26858738 7 28 gly O-glycans 1438:1446 arg1 plant-produced IgA1 IgA1 O-glycans PUBTATOR IgA1 P01876 By co-expression of enzymes required for initiation and elongation of human O-glycosylation it was possible to generate disialylated mucin-type core 1 O-glycans on plant-produced IgA1. 23046148 2 10 part_of furin 439:443 arg1 a furin cleavage site furin a furin cleavage site PUBTATOR Site furin 5045 site To investigate O-glycan-mediated masking using an assay amenable to large-scale screens, we generated a fluorescent biosensor with an O-glycosylation site situated to mask a furin cleavage site. 2324102 6 82 gly identical 1377:1385 arg1 the cytoplasmic domain the cytoplasmic domain domain Furthermore, (iv) the transmembrane domain is 96% identical, as the only change in human syndecan was an alteration of an alanine residue to glycine; and finally, (v) the cytoplasmic domain is 100% identical, including 3 identically located tyrosine residues. 19933092 5 80 gly N-glycosylation 649:663 arg2 one N-glycosylation site one N-glycosylation site site Topology prediction showed that the T2R2 protein contained one N-glycosylation site, one N-myristoylation site, and two potential protein kinase C phosphorylation sites. 9254646 0 35 gly glycosylation 18:30 arg2 a glycosylation site a glycosylation site site Introduction of a glycosylation site into a secreted protein provides evidence for an alternative antigen processing pathway: transport of precursors of major histocompatibility complex class I-restricted peptides from the endoplasmic reticulum to the cytosol. 16118277 9 79 gly glycoproteins 1524:1536 arg1 the HA glycoproteins the HA glycoproteins Fterm glycoproteins Our results suggest that inclusion of the N223 residue in the HA glycoproteins of diagnostic reference viruses may facilitate the evaluation of vaccine efficacy in humans. 2317204 8 16 part_of protein 1285:1291 arg1 the sequence protein the sequence Fterm Site protein sequence Furthermore, it allows us to report the sequence of human link protein up to residue 65. 7995985 7 46 gly N-glycosylation 1010:1024 arg2 a potential N-glycosylation site a potential N-glycosylation site site Comparison of deduced amino acid sequences demonstrated a loss of a potential N-glycosylation site in the G2 protein compared with other PUU viruses. 23090399 3 72 part_of Fab 404:406 arg1 the Fab fragment structure of the Fab the Fab fragment PUBTATOR Site structure of the Fab 2187 fragment Here, the crystal structure of the Fab fragment of an antiprion monoclonal antibody, POM1, in complex with human prion protein (huPrP(c)) has been determined to 2.4 Å resolution. 24721674 11 19 gly composition 2233:2243 arg1 sequence sequence peptides sequence Totally 811 N-glycosylation sites from 567 proteins were identified and 177 intact glycopeptides with both glycan composition and peptides sequence were characterized, which provided a solution for site-specific N-glycosylation characterization of membrane. 24721674 11 100 gly N-glycosylation 2131:2145 arg2 811 N-glycosylation sites 811 N-glycosylation sites sites Totally 811 N-glycosylation sites from 567 proteins were identified and 177 intact glycopeptides with both glycan composition and peptides sequence were characterized, which provided a solution for site-specific N-glycosylation characterization of membrane. 24721674 11 112 gly glycopeptides 2202:2214 arg2 177 intact glycopeptides glycopeptides glycan composition glycopeptides Totally 811 N-glycosylation sites from 567 proteins were identified and 177 intact glycopeptides with both glycan composition and peptides sequence were characterized, which provided a solution for site-specific N-glycosylation characterization of membrane. 10712595 7 47 gly glycosylation 1185:1197 arg2 this glycosylation site this glycosylation site site Furthermore, the invariant third-position Ser137 at this glycosylation site of mammalian and chicken antithrombins is substituted by Thr in the salmon, a replacement that has been shown to induce full glycosylation in human antithrombin. 10712595 7 59 gly glycosylation 1329:1341 arg1 human antithrombin human antithrombin PUBTATOR antithrombin 462 Furthermore, the invariant third-position Ser137 at this glycosylation site of mammalian and chicken antithrombins is substituted by Thr in the salmon, a replacement that has been shown to induce full glycosylation in human antithrombin. 18308854 0 51 gly protein 79:85 arg1 three N-linked carbohydrate chains protein three N-linked carbohydrate chains Fterm protein Topological assessment of oatp1a1: a 12-transmembrane domain integral membrane protein with three N-linked carbohydrate chains. 16372382 2 57 gly hormone 410:416 arg1 the N-linked oligosaccharides thyroid-stimulating hormone the N-linked oligosaccharides Cterm thyroid-stimulating hormone In this paper we report the first detailed structural characterization of the N-linked oligosaccharides of recombinant human thyroid-stimulating hormone (rhTSH). 27743362 6 83 gly glycopeptides 1072:1084 arg2 more hydrophobic glycopeptides more hydrophobic glycopeptides glycopeptides The LC-setup allows retention of more hydrophobic glycopeptides on C18 followed by subsequent capturing of C18-unbound (glyco)peptides by a downstream placed PGC stationary phase. 24806200 2 88 gly N-glycosylation 433:447 arg2 a common N-glycosylation site a common N-glycosylation site site Structurally, β-hCG shares a high degree of sequence similarity with β-hLH, including a common N-glycosylation site at the N-terminus but differs mainly in the presence of an extended C-terminal portion incorporating four closely spaced O-linked glycans. 12097564 7 44 gly glycosylated 1034:1045 arg1 terminally glycosylated Env terminally glycosylated Env PUBTATOR Env 100616444 We furthermore observed a preference for binding to terminally glycosylated Env over core-glycosylated Env precursor in IPs, suggesting that the epitope is at least partially conformational and dependent on glycosylation. 12097564 7 51 gly core-glycosylated 1056:1072 arg1 core-glycosylated Env precursor core-glycosylated Env precursor PUBTATOR Env precursor 100616444 We furthermore observed a preference for binding to terminally glycosylated Env over core-glycosylated Env precursor in IPs, suggesting that the epitope is at least partially conformational and dependent on glycosylation. 23692404 6 73 gly containing 1279:1288 arg1 An optimized variant AND three novel N-glycan sites An optimized variant three novel N-glycan sites Fterm variant An optimized variant containing three novel N-glycan sites (at amino acids 103, 151, and 228), and the activity enhancing 338A variant had double the specific activity of wild-type FIX, exhibited 4.5-fold reduced clearance and 2.4-fold increased subcutaneous bioavailability, and was efficacious at a fivefold lower mass dose than wild-type FIX after subcutaneous injection in a bleeding model in mice with hemophilia B. CONCLUSIONS: Glycoengineering was used to significantly improve the subcutaneous PK and efficacy of FIX and may have advantages for subcutaneous dosing. 27314333 11 55 gly N-glycosylation 1736:1750 arg1 Rspo1 Rspo1 PUBTATOR Rspo1 284654 Our findings provide evidence for the critical role of N-glycosylation in the biogenesis of Rspo1. 20795641 9 95 gly glycoproteins 1610:1622 arg1 15 glycoproteins 15 glycoproteins Fterm glycoproteins The accuracy, reproducibility, and linearity of relative quantitation were evaluated by using 15 glycoproteins spiked into mouse serum at different concentration ratios. 23632316 1 13 gly glycosylation 189:201 arg2 new N-linked glycosylation sites new N-linked glycosylation sites sites We used a targeted proteomics approach to investigate whether introduction of new N-linked glycosylation sites in a chimeric protein influence the glycosylation of the existing glycosylation sites. 23632316 1 17 gly glycosylation 245:257 arg1 the existing glycosylation sites the existing glycosylation sites sites We used a targeted proteomics approach to investigate whether introduction of new N-linked glycosylation sites in a chimeric protein influence the glycosylation of the existing glycosylation sites. 23632316 1 34 gly glycosylation 275:287 arg2 the existing glycosylation sites the existing glycosylation sites sites We used a targeted proteomics approach to investigate whether introduction of new N-linked glycosylation sites in a chimeric protein influence the glycosylation of the existing glycosylation sites. 24164424 8 83 gly glycosylation 1332:1344 arg2 the glycosylation site the glycosylation site site Furthermore, the relative position of the glycosylation site within the pore turret influences the extent of MMP-dependent proteolysis. 24520765 11 15 gly N-glycosylation 1083:1097 arg2 one N-glycosylation site one N-glycosylation site site CHN/4.05 [F] and all other genotypes of mumps virus, however, one N-glycosylation site was absent from the vaccine strains, which was at the aa position 464-466 of the HN gene. 23530821 7 61 gly glycosylation 1041:1053 arg2 the glycosylation sites the glycosylation sites sites The secretion and cytotoxicity of the E protein was also markedly impaired in case the glycosylation sites in the prM or E or both proteins were removed. 23530821 7 73 gly case 1032:1035 arg1 the glycosylation sites the glycosylation sites sites The secretion and cytotoxicity of the E protein was also markedly impaired in case the glycosylation sites in the prM or E or both proteins were removed. 10441114 9 64 part_of endostatin-related 1497:1514 arg1 immunoreactive endostatin-related C-terminal fragments endostatin immunoreactive endostatin-related C-terminal fragments PUBTATOR Site endostatin 80781 fragments Furthermore, immunoreactive endostatin-related C-terminal fragments of human collagen XV are found in the hemofiltrate. 15590981 6 68 part_of cDNA 929:932 arg1 the partial cDNA fragments cDNA the partial cDNA fragments Cterm Site cDNA fragments Ligations of the partial cDNA fragments encoded a part of the signal peptide followed by a putative 672 amino acid eLH/CG-R mature protein. 1400492 5 67 part_of mLAP 539:542 arg1 The amino acid sequence mLAP The amino acid sequence PUBTATOR Site mLAP 13708 sequence The amino acid sequence of mLAP is 92 and 81% similar to human cathepsin D and cathepsin E, respectively. 11774469 0 1 gly glycosylation 21:33 arg2 a single glycosylation site a single glycosylation site site Addition of a single glycosylation site to hAPN blocks human coronavirus-229E receptor activity. 22677411 5 82 gly glycopeptides 763:775 arg2 glycopeptides glycopeptides glycopeptides The previously developed GlycoMiner algorithm and software was used to identify glycopeptides in MS/MS spectra. 7559574 0 23 gly oligosaccharides 31:46 arg1 phosphacan phosphacan oligosaccharides PUBTATOR phosphacan 5803 Complex-type asparagine-linked oligosaccharides on phosphacan and protein-tyrosine phosphatase-zeta/beta mediate their binding to neural cell adhesion molecules and tenascin. 7559574 0 23 gly oligosaccharides 31:46 arg1 protein-tyrosine phosphatase-zeta/beta phosphatase oligosaccharides Fterm phosphatase Complex-type asparagine-linked oligosaccharides on phosphacan and protein-tyrosine phosphatase-zeta/beta mediate their binding to neural cell adhesion molecules and tenascin. 7559574 0 91 gly asparagine-linked 13:29 arg1 Complex-type asparagine-linked oligosaccharides asparagine Complex-type asparagine-linked oligosaccharides asparagine Complex-type asparagine-linked oligosaccharides on phosphacan and protein-tyrosine phosphatase-zeta/beta mediate their binding to neural cell adhesion molecules and tenascin. 11876646 8 46 gly glycosylation 1280:1292 arg2 the normal glycosylation site the normal glycosylation site site Finally, microsomes were prepared from HEK293 cells expressing the membrane domain of AE1 lacking the normal glycosylation site. 30427586 2 32 gly O-glycopeptides 412:426 arg2 O-glycopeptides O-glycopeptides O-glycopeptides Here, combining lower and stepped collisional energy fragmentation for the in-depth and site-specific analysis of N- and O-glycopeptides is proposed. 23004563 5 69 gly glycopeptide 961:972 arg2 glycopeptide detection glycopeptide detection glycopeptide Moreover, limit of detection (LOD) of glycopeptide detection was 30 attomole injection, and quantitative dynamic range spanned 4 orders magnitude. 25567004 1 87 gly hyper-glycosylated 409:426 arg1 the same Hc proteins the same Hc proteins Fterm proteins The recombinant Hc proteins of botulinum neurotoxins and tetanus toxin are exclusively produced by intracellular heterologous expression in Pichia pastoris for use in subunit vaccines; the same Hc proteins produced by secreted heterologous expression are hyper-glycosylated and immunologically inert. 1972631 9 69 gly glycosylation 1180:1192 arg2 another N-linked glycosylation site another N-linked glycosylation site site The fourth exon contains the region that was proposed as a lipid binding domain, the sixth for one putative heparin binding domain, and the eighth codes for a domain containing another N-linked glycosylation site. 17986444 5 7 gly glycopeptides 804:816 arg2 polysialylated glycopeptides polysialylated glycopeptides glycopeptides PolySia-NCAM was isolated from mouse brains and trypsinized, and polysialylated glycopeptides as well as glycans were analyzed in detail. 17986444 5 62 gly polysialylated 789:802 arg1 polysialylated glycopeptides polysialylated glycopeptides glycopeptides PolySia-NCAM was isolated from mouse brains and trypsinized, and polysialylated glycopeptides as well as glycans were analyzed in detail. 1385399 4 18 part_of CD2 878:880 arg1 native CD2 adhesion domain epitopes CD2 native CD2 adhesion domain epitopes PUBTATOR Site CD2 914 epitopes Analysis of deglycosylated soluble recombinant CD2 as well as a mutant transmembrane CD2 molecule containing a single Asn65-Gln65 substitution demonstrates that neither deglycosylated CD2 nor the mutant CD2 transmembrane receptor binds CD58 or monoclonal antibodies directed at native CD2 adhesion domain epitopes. 21970473 2 48 gly glycoproteins 357:369 arg1 glycoproteins glycoproteins Fterm glycoproteins Core fucosylation (CF), one special type of glycan structure in glycoproteins, has been linked with tumorigenesis. 7609736 8 22 gly glycosylation 912:924 arg2 the conserved glycosylation site the conserved glycosylation site site We found glycosylation in the Fab fragment of CBGA1 in addition to the conserved glycosylation site in the Fc fragment at Asn 297. 7609736 8 43 gly glycosylation 840:852 arg1 Asn 297 Asn 297 Asn 297 We found glycosylation in the Fab fragment of CBGA1 in addition to the conserved glycosylation site in the Fc fragment at Asn 297. 7609736 8 61 gly glycosylation 840:852 arg1 the Fab fragment fragment fragment We found glycosylation in the Fab fragment of CBGA1 in addition to the conserved glycosylation site in the Fc fragment at Asn 297. 31572358 5 31 part_of receptor 962:969 arg1 the B-cell receptor (BCR) variable domain receptor the B-cell receptor (BCR) variable domain Fterm Site receptor domain Given recent technological advances that have rendered autoreactive human B cells accessible for analysis, we here discuss the phenomenon of extensive N-glycosylation of the B-cell receptor (BCR) variable domain of a prototypic human autoreactive B-cell response and its potential role in the generation of autoimmunity. 28585084 1 8 gly glycoproteins 93:105 arg1 glycoproteins glycoproteins Fterm glycoproteins The structural analysis of glycoproteins is a challenging endeavor and is under steadily increasing demand, but only a very limited number of labs have the expertise required to accomplish this task. 17850901 7 51 gly N-glycosylation 786:800 arg2 one putative N-glycosylation site one putative N-glycosylation site site The predicted protein has a molecular weight of 25.1 kDa, one putative N-glycosylation site, two fibronectin type III domains, and one C terminal transmembrane domain. 21647803 2 12 gly glycoprotein 282:293 arg1 crucial to understanding glycoprotein structure crucial to understanding glycoprotein structure Fterm glycoprotein Information on glycan heterogeneity and glycosite occupancy is increasingly recognized as crucial to understanding glycoprotein structure and function. 21647803 2 68 gly glycosite 207:215 arg2 glycosite occupancy glycosite occupancy glycosite Information on glycan heterogeneity and glycosite occupancy is increasingly recognized as crucial to understanding glycoprotein structure and function. 18707900 2 14 gly N-glycosylation 445:459 arg2 a conserved N-glycosylation site a conserved N-glycosylation site site IgG1s contain a conserved N-glycosylation site in the fragment crystallizable (Fc) subunit. 22921534 1 39 part_of possesses 142:150 arg1 the second membrane protein AND a conserved motif the second membrane protein a conserved motif Fterm Site protein motif CM2 is the second membrane protein of influenza C virus and possesses a conserved motif for N-glycosylation. 16368742 5 83 part_of TRPV4 974:978 arg1 Residue N651 TRPV4 Residue N651 PUBTATOR SpecificSite TRPV4 59341 N651 Residue N651 of TRPV4 is immediately adjacent to the pore-forming loop. 9030779 5 70 gly glycosylation 669:681 arg2 the four N-terminal glycosylation sites the four N-terminal glycosylation sites sites Elimination of the four N-terminal glycosylation sites does not disturb lysosomal targeting, processing, or enzymatic activity. 14693913 3 79 part_of has 437:439 arg1 hBSSL AND one N-glycosylation site hBSSL one N-glycosylation site PUBTATOR Site hBSSL 1056 site hBSSL has one N-glycosylation site at Asn187, which was 38-40% occupied with a Man(10)GlcNAc(2) structure defined previously in Pichia as the oligosaccharide-lipid form of Man(9)GlcNAc(2) trimmed of the middle-arm terminal alpha 1,2-Man and elongated with Man alpha 1,2Man alpha 1,6-disaccharide attached to the lower-arm core alpha 1,3-Man (Trimble et al. [1991], J. Biol. 8663003 5 72 part_of has 812:814 arg1 The Rh glycoprotein AND two bromelain cleavage sites The Rh glycoprotein two bromelain cleavage sites Fterm Site glycoprotein sites The Rh glycoprotein has two bromelain cleavage sites within the first external domain. 25533529 8 51 gly positions 1828:1836 arg1 the N-glycans positions 77, 81 and 100 the N-glycans positions 77, 81 and 100 Taken together, all the glycans contribute to the pharmacokinetics of acutobin and ATB-wt in vivo, and the microenvironment around the Asn(229)-glycan appears to regulate the fibrinogen-chain specificity of acutobin while the N-glycans at positions 77, 81 and 100 are crucial for its folding. 23001782 11 20 part_of hSHBG 1946:1950 arg1 a prerequisite hSHBG a prerequisite PUBTATOR Site hSHBG 6462 prerequisite To date, this work represents the most detailed structural map of the heterogeneous hSHBG glycosylation, which is a prerequisite for investigating the functional aspects of the hSHBG glycans. 22072749 10 53 gly glycosylation 1990:2002 arg2 An artificially introduced glycosylation site An artificially introduced glycosylation site site An artificially introduced glycosylation site within the HIR was also not utilized for glycosylation. 22072749 10 89 gly utilized 2037:2044 arg2 An artificially introduced glycosylation site An artificially introduced glycosylation site site An artificially introduced glycosylation site within the HIR was also not utilized for glycosylation. 26729457 2 6 gly O-glycopeptide 311:324 arg2 O-glycopeptide O-glycopeptide O-glycopeptide Mass spectrometry-based N- and O-glycopeptide analyses enable determination of the glycosylation site, site occupancy, as well as glycan varieties present on a particular site. 26729457 2 21 gly occupancy 388:396 arg1 the glycosylation site, site occupancy the glycosylation site, site occupancy site, site Mass spectrometry-based N- and O-glycopeptide analyses enable determination of the glycosylation site, site occupancy, as well as glycan varieties present on a particular site. 26729457 2 43 gly present 427:433 arg2 a particular site AND glycan varieties a particular site glycan varieties site Mass spectrometry-based N- and O-glycopeptide analyses enable determination of the glycosylation site, site occupancy, as well as glycan varieties present on a particular site. 26729457 2 109 gly glycosylation 363:375 arg2 the glycosylation site, site occupancy the glycosylation site, site occupancy site, site Mass spectrometry-based N- and O-glycopeptide analyses enable determination of the glycosylation site, site occupancy, as well as glycan varieties present on a particular site. 28501204 2 31 gly glycosylation 290:302 arg2 glycosylation site occupancy glycosylation site occupancy site Characterizing the site-specific N-glycosylation including N-glycan macroheterogeneity (glycosylation site occupancy) and microheterogeneity (site-specific glycan structure) is important for understanding of glycoprotein biosynthesis and function. 28501204 2 35 gly site 304:307 arg1 N-glycan macroheterogeneity site N-glycan macroheterogeneity site Characterizing the site-specific N-glycosylation including N-glycan macroheterogeneity (glycosylation site occupancy) and microheterogeneity (site-specific glycan structure) is important for understanding of glycoprotein biosynthesis and function. 28501204 2 41 gly glycoprotein 410:421 arg1 glycoprotein biosynthesis glycoprotein biosynthesis Fterm glycoprotein Characterizing the site-specific N-glycosylation including N-glycan macroheterogeneity (glycosylation site occupancy) and microheterogeneity (site-specific glycan structure) is important for understanding of glycoprotein biosynthesis and function. 11230417 7 73 gly glycoprotein 1886:1897 arg1 a native glycoprotein a native glycoprotein Fterm glycoprotein The data generated using a native glycoprotein as the substrate demonstrate that mannosidase production within the viridans group streptococci is more widely distributed than had previously been considered. 8788196 5 16 gly glycosylation 816:828 arg2 one N-linked glycosylation site one N-linked glycosylation site site The predicted positions of one N-linked glycosylation site and all cysteine residues are fully conserved as well. 31831916 2 27 gly glycosylation 262:274 arg2 glycosylation sites glycosylation sites sites Over the last decade, large-scale profiling of N-linked glycoproteins and glycosylation sites from biological and clinical samples has been achieved through mass spectrometry-based glycoproteomic approaches. 31831916 2 36 gly glycoproteins 244:256 arg1 N-linked glycoproteins N-linked glycoproteins Fterm glycoproteins Over the last decade, large-scale profiling of N-linked glycoproteins and glycosylation sites from biological and clinical samples has been achieved through mass spectrometry-based glycoproteomic approaches. 15628971 7 0 gly microheterogeneity 1564:1581 arg1 N-linked oligosaccharides N-linked oligosaccharides In addition, the N-linked oligosaccharide at the C-terminal region appears to affect the glycosylation pattern of recombinant C4ST; a broad protein band of the wildtype protein resulting from microheterogeneity of N-linked oligosaccharides disappeared and four discrete protein bands with different numbers of N-linked oligosaccharides appeared when the N-linked oligosaccharide at the C-terminal region was deleted. 15628971 7 66 gly region 1432:1437 arg1 the N-linked oligosaccharide region the N-linked oligosaccharide region In addition, the N-linked oligosaccharide at the C-terminal region appears to affect the glycosylation pattern of recombinant C4ST; a broad protein band of the wildtype protein resulting from microheterogeneity of N-linked oligosaccharides disappeared and four discrete protein bands with different numbers of N-linked oligosaccharides appeared when the N-linked oligosaccharide at the C-terminal region was deleted. 15628971 7 83 gly glycosylation 1461:1473 arg1 recombinant C4ST recombinant C4ST PUBTATOR C4ST 314694 In addition, the N-linked oligosaccharide at the C-terminal region appears to affect the glycosylation pattern of recombinant C4ST; a broad protein band of the wildtype protein resulting from microheterogeneity of N-linked oligosaccharides disappeared and four discrete protein bands with different numbers of N-linked oligosaccharides appeared when the N-linked oligosaccharide at the C-terminal region was deleted. 15628971 7 104 gly region 1769:1774 arg1 the N-linked oligosaccharide region the N-linked oligosaccharide region In addition, the N-linked oligosaccharide at the C-terminal region appears to affect the glycosylation pattern of recombinant C4ST; a broad protein band of the wildtype protein resulting from microheterogeneity of N-linked oligosaccharides disappeared and four discrete protein bands with different numbers of N-linked oligosaccharides appeared when the N-linked oligosaccharide at the C-terminal region was deleted. 24527708 3 13 gly glycopeptides 543:555 arg2 proteolytic glycopeptides proteolytic glycopeptides glycopeptides In this workflow, proteolytic glycopeptides were enriched by using a hydrophilic material named Click TE-Cys to improve the glycopeptide selectivity and coverage. 24527708 3 27 gly glycopeptide 637:648 arg2 the glycopeptide selectivity the glycopeptide selectivity glycopeptide In this workflow, proteolytic glycopeptides were enriched by using a hydrophilic material named Click TE-Cys to improve the glycopeptide selectivity and coverage. 8364230 2 36 gly glycosylation 610:622 arg1 PK1de1FE1X PK1de1FE1X Cterm PK1de1FE1X 25692 Furthermore, the effect of the novel plasminogen activator (SUN9216), a plasminogen-plasminogen activator chimera, comprising the fibrin kringle 1 domain of a plasminogen, and the two kringles, and the serine protease domains of wild-type tissue plasminogen activator (t-PA), including a modification of the mannose glycosylation site on the kringle 1 of t-PA (PK1de1FE1X), was studied in this model. 8364230 2 36 gly glycosylation 610:622 arg1 t-PA t-PA PUBTATOR t-PA 25692 Furthermore, the effect of the novel plasminogen activator (SUN9216), a plasminogen-plasminogen activator chimera, comprising the fibrin kringle 1 domain of a plasminogen, and the two kringles, and the serine protease domains of wild-type tissue plasminogen activator (t-PA), including a modification of the mannose glycosylation site on the kringle 1 of t-PA (PK1de1FE1X), was studied in this model. 8364230 2 62 gly t-PA 649:652 arg1 the mannose glycosylation site t-PA the mannose glycosylation site PUBTATOR t-PA 25692 Furthermore, the effect of the novel plasminogen activator (SUN9216), a plasminogen-plasminogen activator chimera, comprising the fibrin kringle 1 domain of a plasminogen, and the two kringles, and the serine protease domains of wild-type tissue plasminogen activator (t-PA), including a modification of the mannose glycosylation site on the kringle 1 of t-PA (PK1de1FE1X), was studied in this model. 17823199 7 110 gly N-glycosylation 1195:1209 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site In CDG type-I samples, we observed a reduction in N-glycosylation site occupancy that correlated with the severity of the disease. 2187475 9 8 gly glycosylation 1268:1280 arg2 the site the site site Sequence analysis of tryptic peptides suggested that Thr29 was the site of glycosylation. 2187475 9 8 gly glycosylation 1268:1280 arg2 Thr29 Thr29 Thr29 Sequence analysis of tryptic peptides suggested that Thr29 was the site of glycosylation. 11741940 1 101 part_of contains 239:246 arg1 Secreted Frizzled-related protein-1 AND an N-terminal domain Secreted Frizzled-related protein-1 domain PUBTATOR Site Secreted Frizzled-related protein-1 6422 domain Secreted Frizzled-related protein-1 (sFRP-1), a soluble protein that binds to Wnts and modulates Wnt signaling, contains an N-terminal domain homologous to the putative Wnt-binding site of Frizzled (Fz domain) and a C-terminal heparin-binding domain with weak homology to netrin. 11741940 1 101 part_of contains 239:246 arg1 a soluble protein AND an N-terminal domain protein domain Fterm Site protein domain Secreted Frizzled-related protein-1 (sFRP-1), a soluble protein that binds to Wnts and modulates Wnt signaling, contains an N-terminal domain homologous to the putative Wnt-binding site of Frizzled (Fz domain) and a C-terminal heparin-binding domain with weak homology to netrin. 11741940 1 101 part_of contains 239:246 arg1 sFRP-1 AND an N-terminal domain sFRP-1 domain PUBTATOR Site sFRP-1 6422 domain Secreted Frizzled-related protein-1 (sFRP-1), a soluble protein that binds to Wnts and modulates Wnt signaling, contains an N-terminal domain homologous to the putative Wnt-binding site of Frizzled (Fz domain) and a C-terminal heparin-binding domain with weak homology to netrin. 15538777 8 97 gly glycosylation 1955:1967 arg2 their glycosylation sites their glycosylation sites sites The peptide or peptide + GlcNAc ions in the MS2 spectrum or the corresponding ions abundant in the MS1 spectrum were subjected to CID for determination of peptide sequences, to identify proteins and their glycosylation sites. 26701645 4 10 gly N-glycosylated 663:676 arg1 all seven sites tyrosinase sites PUBTATOR tyrosinase 7299 sites By LC-MS/MS analysis of human tyrosinase expressed in a melanoma cell, we show that all seven sites of tyrosinase are at least partially N-glycosylated. 10397812 4 19 gly glycoforms 915:924 arg1 sialylated IFN-gamma glycoforms sialylated IFN-gamma glycoforms In CHO cells, although there was a minor intracellular subpopulation of sialylated IFN-gamma glycoforms identical to the secreted product (therefore associated with late-Golgi compartments or secretory vesicles), no other intermediates were evident. 10397812 4 42 gly sialylated 894:903 arg1 sialylated IFN-gamma glycoforms sialylated IFN-gamma glycoforms In CHO cells, although there was a minor intracellular subpopulation of sialylated IFN-gamma glycoforms identical to the secreted product (therefore associated with late-Golgi compartments or secretory vesicles), no other intermediates were evident. 8399360 7 7 gly sialylated 846:855 arg1 A sialylated complex-type carbohydrate A sialylated complex-type carbohydrate A sialylated complex-type carbohydrate could also bind to the 32 kDa light-chain species. 10940860 7 39 gly occupancy 1117:1125 arg2 site occupancy site occupancy site Comparison of the cell cycle distribution across the range of cell culture factors investigated shows a consistent relationship between site occupancy and the fraction of cells in the G(0)/G(1) phase of the cell cycle. 18203712 8 21 gly N-glycosylation 1043:1057 arg2 the N-glycosylation site the N-glycosylation site site This motif begins with Glu-586 8 residues upstream of the N-glycosylation site and ends with Lys-612 near the C terminus at Leu-618. 1932748 8 21 gly glycosylation 1154:1166 arg2 this glycosylation site this glycosylation site site To determine if loss of this glycosylation site was responsible for the effects of exon 28 deletion, we removed the site from the exon 28 of intact GPIIb by oligonucleotide-mediated mutagenesis. 10640760 5 28 part_of SP-D 610:613 arg1 The complete cDNA sequence SP-D The complete cDNA sequence PUBTATOR Site SP-D 6441 sequence The complete cDNA sequence of porcine SP-D, including the 5' and 3' untranslated regions, was determined from two overlapping bacteriophage clones and by PCR cloning. 30594968 1 17 gly glycosylation 132:144 arg2 the potential glycosylation sites the potential glycosylation sites sites Variations in the potential glycosylation sites were observed in hemagglutinin (HA) sequences of H9N2 avian influenza virus isolated in China, deposited in the Influenza Virus Resource of NCBI before 2017, which showed a deleted glycosylation site at amino acid residue 218, and an introduced glycosylation site at amino acid residue 313. 30594968 1 63 gly glycosylation 333:345 arg2 a deleted glycosylation site a deleted glycosylation site site Variations in the potential glycosylation sites were observed in hemagglutinin (HA) sequences of H9N2 avian influenza virus isolated in China, deposited in the Influenza Virus Resource of NCBI before 2017, which showed a deleted glycosylation site at amino acid residue 218, and an introduced glycosylation site at amino acid residue 313. 30594968 1 63 gly glycosylation 333:345 arg2 amino acid residue 313 amino acid residue 313 residue 313 Variations in the potential glycosylation sites were observed in hemagglutinin (HA) sequences of H9N2 avian influenza virus isolated in China, deposited in the Influenza Virus Resource of NCBI before 2017, which showed a deleted glycosylation site at amino acid residue 218, and an introduced glycosylation site at amino acid residue 313. 30594968 1 63 gly glycosylation 333:345 arg2 amino acid residue 218 amino acid residue 218 residue 218 Variations in the potential glycosylation sites were observed in hemagglutinin (HA) sequences of H9N2 avian influenza virus isolated in China, deposited in the Influenza Virus Resource of NCBI before 2017, which showed a deleted glycosylation site at amino acid residue 218, and an introduced glycosylation site at amino acid residue 313. 30594968 1 67 gly glycosylation 397:409 arg2 amino acid residue 313 amino acid residue 313 residue 313 Variations in the potential glycosylation sites were observed in hemagglutinin (HA) sequences of H9N2 avian influenza virus isolated in China, deposited in the Influenza Virus Resource of NCBI before 2017, which showed a deleted glycosylation site at amino acid residue 218, and an introduced glycosylation site at amino acid residue 313. 30594968 1 67 gly glycosylation 397:409 arg2 amino acid residue 218 amino acid residue 218 residue 218 Variations in the potential glycosylation sites were observed in hemagglutinin (HA) sequences of H9N2 avian influenza virus isolated in China, deposited in the Influenza Virus Resource of NCBI before 2017, which showed a deleted glycosylation site at amino acid residue 218, and an introduced glycosylation site at amino acid residue 313. 30594968 1 67 gly glycosylation 397:409 arg2 an introduced glycosylation site an introduced glycosylation site site Variations in the potential glycosylation sites were observed in hemagglutinin (HA) sequences of H9N2 avian influenza virus isolated in China, deposited in the Influenza Virus Resource of NCBI before 2017, which showed a deleted glycosylation site at amino acid residue 218, and an introduced glycosylation site at amino acid residue 313. 9464523 3 3 part_of receptor 496:503 arg1 the published partial amino acid sequence C5a receptor the published partial amino acid sequence PUBTATOR Site C5a receptor 728 sequence We used a hybridization probe produced by PCR utilizing degenerate primers which corresponded to conserved parts of the human, canine and murine C5a receptor nucleotide sequences and to the published partial amino acid sequence of the rat C5a receptor to screen a rat macrophage cDNA library. 9464523 3 48 part_of receptor 402:409 arg1 receptor nucleotide sequences C5a receptor receptor nucleotide sequences PUBTATOR Site C5a receptor 728 sequences We used a hybridization probe produced by PCR utilizing degenerate primers which corresponded to conserved parts of the human, canine and murine C5a receptor nucleotide sequences and to the published partial amino acid sequence of the rat C5a receptor to screen a rat macrophage cDNA library. 27773655 8 36 gly N-glycosylation 1091:1105 arg2 a unique N-glycosylation site a unique N-glycosylation site site This stretch harbors a unique N-glycosylation site that is responsible for LPH retention in the ER via association with calnexin and facilitates proper folding of domains I and III before ER exit of LPH. 10675514 5 19 part_of sequence 654:661 arg1 dog AQP1 AQP1 sequence PUBTATOR Site AQP1 403732 sequence The amino acid sequence in dog AQP1 was 91-94% identical to that in the other species mentioned above. 23640819 5 70 gly glycoprotein 1146:1157 arg1 glycoprotein analysis glycoprotein analysis Fterm glycoprotein In the last decade, significant improvement of mass spectrometric techniques is being made in the aspects of both hardware spec and preanalytical purification procedures for glycoprotein analysis. 24721674 3 52 gly N-glycosylation 796:810 arg2 protein N-glycosylation sites protein N-glycosylation sites sites In this study, a systematic approach was developed which combined: an integrated hydrophilic interaction chromatography solid phase interaction (HILIC SPE) for simultaneous detergent removal and glycopeptide enrichment, and mass spectrometric identification of both protein N-glycosylation sites and site-specific glycan composition. 24721674 3 71 gly glycopeptide 717:728 arg2 glycopeptide enrichment glycopeptide enrichment glycopeptide In this study, a systematic approach was developed which combined: an integrated hydrophilic interaction chromatography solid phase interaction (HILIC SPE) for simultaneous detergent removal and glycopeptide enrichment, and mass spectrometric identification of both protein N-glycosylation sites and site-specific glycan composition. 2522450 8 66 part_of protein 961:967 arg1 the primary sequence protein the primary sequence Fterm Site protein sequence This insertion is inframe and adds 8 amino acids between amino acids 491 and 492 of the primary sequence of the normal enzyme protein. 21940909 3 44 part_of N-linked 899:906 arg1 the N-linked glycosylation site N-linked the N-linked glycosylation site Cterm Site N-linked site The current study exploited the steric hindrance of glycan units in N-linked glycoproteins, which significantly affects the efficiency of proteolytic digestion if an enzymatically active amino acid is adjacent to the N-linked glycosylation site. 8960909 0 19 part_of N-glycosylated 3:16 arg1 An N-glycosylated tyrosinase epitope N-glycosylated tyrosinase An N-glycosylated tyrosinase epitope PUBTATOR Site N-glycosylated tyrosinase 7299 epitope An N-glycosylated tyrosinase epitope associates with newly synthesized MHC class I molecules in melanoma cells. 8960909 0 30 part_of tyrosinase 18:27 arg1 An N-glycosylated tyrosinase epitope N-glycosylated tyrosinase An N-glycosylated tyrosinase epitope PUBTATOR Site N-glycosylated tyrosinase 7299 epitope An N-glycosylated tyrosinase epitope associates with newly synthesized MHC class I molecules in melanoma cells. 12097564 0 58 part_of receptor 42:49 arg1 the receptor binding site receptor the receptor binding site Fterm Site receptor site Novel monoclonal antibody directed at the receptor binding site on the avian sarcoma and leukosis virus Env complex. 30359034 2 10 gly released 271:278 arg2 glycoproteins AND glycans glycoproteins glycans Fterm glycoproteins In glycomics, glycan structures are comprehensively analyzed after glycans are released from glycoproteins. 30359034 2 41 gly glycoproteins 285:297 arg1 glycoproteins glycoproteins Fterm glycoproteins In glycomics, glycan structures are comprehensively analyzed after glycans are released from glycoproteins. 8429003 1 2 gly glycoprotein 166:177 arg1 the T-cell surface glycoprotein CD4 the T-cell surface glycoprotein CD4 Fterm glycoprotein The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human). 8429003 1 23 gly glycosylation 299:311 arg2 Asn300 Asn300 Asn300 The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human). 8429003 1 23 gly glycosylation 299:311 arg2 the second glycosylation sites the second glycosylation sites sites The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human). 8429003 1 23 gly glycosylation 299:311 arg2 Asn159 Asn159 Asn159 The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human). 8429003 1 60 gly glycosylation 198:210 arg2 a common glycosylation site a common glycosylation site site The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human). 8429003 1 60 gly glycosylation 198:210 arg2 the Asn270/271 position the Asn270/271 position position The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human). 8780172 1 102 gly glycoprotein 162:173 arg1 glycoprotein hormones glycoprotein hormones Fterm glycoprotein The carbohydrate moieties of glycoprotein hormones or growth factor molecules may have a variety of effects that impact biological potency. 2016749 3 44 gly glycosylated 638:649 arg1 Asn104 Asn104 site and Asn104 Asn70 could be identified unambiguously as a glycosylation site and Asn104 is probably also glycosylated. 2016749 3 66 gly glycosylation 591:603 arg2 a glycosylation site a glycosylation site site and Asn104 Asn70 could be identified unambiguously as a glycosylation site and Asn104 is probably also glycosylated. 2016749 3 66 gly glycosylation 591:603 arg2 Asn70 Asn70 Asn70 Asn70 could be identified unambiguously as a glycosylation site and Asn104 is probably also glycosylated. 9291187 6 7 gly N-glycosylation 790:804 arg1 the cloned human kidney enzyme enzyme site Fterm enzyme site Next, the only putative N-glycosylation site (Asn394-Leu395-Ser396) of the cloned human kidney enzyme was eliminated by site-directed mutagenesis. 26573365 3 18 gly glycopeptide 571:582 arg2 two glycopeptide profiles two glycopeptide profiles glycopeptide The heavy form (D4(13)C4) provides an 8 Da mass increment over the light natural form (H4(12)C4), allowing simultaneous analysis and direct comparison of two glycopeptide profiles in a single MS scan. 15628971 1 82 part_of position 183:190 arg1 chondroitin chondroitin position Fterm Site chondroitin position 4 C4ST-1 (chondroitin 4-sulphotransferase-1) transfers sulphate to position 4 of N-acetylgalactosamine in chondroitin. 8180202 8 9 gly glycosylation 1333:1345 arg2 Asn238 Asn238 Asn238 As we have previously found, glycosylation at Asn238 is essential for the production of CBG with steroid-binding activity, but when the mutant containing only one oligosaccharide at this position was enzymatically deglycosylated, its steroid-binding activity was unaltered. 8180202 8 9 gly glycosylation 1333:1345 arg1 CBG CBG Asn238 PUBTATOR CBG 866 Asn238 As we have previously found, glycosylation at Asn238 is essential for the production of CBG with steroid-binding activity, but when the mutant containing only one oligosaccharide at this position was enzymatically deglycosylated, its steroid-binding activity was unaltered. 8180202 8 9 gly glycosylation 1333:1345 arg1 CBG CBG Asn238 PUBTATOR CBG 866 Asn238 As we have previously found, glycosylation at Asn238 is essential for the production of CBG with steroid-binding activity, but when the mutant containing only one oligosaccharide at this position was enzymatically deglycosylated, its steroid-binding activity was unaltered. 26573365 1 7 gly glycosylation 210:222 arg2 a specific glycosylation site a specific glycosylation site site We introduce a stable isotope labeling approach for glycopeptides that allows a specific glycosylation site in a protein to be quantitatively evaluated using mass spectrometry. 26573365 1 56 gly glycopeptides 173:185 arg2 glycopeptides glycopeptides glycopeptides We introduce a stable isotope labeling approach for glycopeptides that allows a specific glycosylation site in a protein to be quantitatively evaluated using mass spectrometry. 2295597 7 39 part_of contains 1207:1214 arg1 The bovine enzyme AND 6 Trp The bovine enzyme 6 Trp Fterm AminoAcid enzyme Trp The bovine enzyme contains 6 Trp, as compared with 7 in the bovine cDNA and 8 in the human cDNA. 8772226 10 7 gly Asn 1619:1621 arg1 an extra carbohydrate group Asn 184 an extra carbohydrate group Asn 184 By removing N-linked sugars with N-glycanase, it could be demonstrated that the difference between the two forms of HRG is caused by an extra carbohydrate group at Asn 184 in form 1. 7685769 3 5 gly glycopeptides 471:483 arg2 the purified glycopeptides the purified glycopeptides glycopeptides By isolation and characterization of the purified glycopeptides obtained from cleavages by Staphylococcal aureus V-8 protease and cyanogen bromide, the O-linked glycosylation site was confirmed to be a Thr residue at position 133. 7685769 3 30 gly glycosylation 582:594 arg2 a Thr residue a Thr residue Thr residue at position 133 By isolation and characterization of the purified glycopeptides obtained from cleavages by Staphylococcal aureus V-8 protease and cyanogen bromide, the O-linked glycosylation site was confirmed to be a Thr residue at position 133. 7685769 3 30 gly glycosylation 582:594 arg2 the O-linked glycosylation site the O-linked glycosylation site site By isolation and characterization of the purified glycopeptides obtained from cleavages by Staphylococcal aureus V-8 protease and cyanogen bromide, the O-linked glycosylation site was confirmed to be a Thr residue at position 133. 2341397 0 14 gly glycoforms 57:66 arg1 nonspecific cross-reacting antigen nonspecific cross-reacting antigen PUBTATOR nonspecific cross-reacting antigen 1084 Sequence and glycosylation site identity of two distinct glycoforms of nonspecific cross-reacting antigen as demonstrated by sequence analysis and fast atom bombardment mass spectrometry. 2341397 0 60 gly glycosylation 13:25 arg2 glycosylation site identity glycosylation site identity site Sequence and glycosylation site identity of two distinct glycoforms of nonspecific cross-reacting antigen as demonstrated by sequence analysis and fast atom bombardment mass spectrometry. 24554659 3 123 gly glycosylation 691:703 arg2 the N173 glycosylation site the N173 glycosylation site site Loss of the N173 glycosylation site in the non-macrophage-tropic SIVmac239 by introducing an N173Q mutation enhanced viral replication and multinucleated giant cell formation upon infection of rhesus macrophages, while the addition of N173 to SIVmac251 had the opposite effect. 25220145 1 13 gly fucosylation 136:147 arg1 N-glycoproteins N-glycoproteins Fterm N-glycoproteins The core fucosylation (CF) of N-glycoproteins plays important roles in regulating protein functions during biological development, and it has also been shown to be up-regulated in several high metastasis cancer cell lines. 25220145 1 70 gly N-glycoproteins 157:171 arg1 N-glycoproteins N-glycoproteins The core fucosylation Fterm N-glycoproteins The core fucosylation (CF) of N-glycoproteins plays important roles in regulating protein functions during biological development, and it has also been shown to be up-regulated in several high metastasis cancer cell lines. 17766267 8 18 gly glycosylation 1538:1550 arg2 the interferon alpha2b protein O-linked glycosylation site the interferon alpha2b protein O-linked glycosylation site site The improved enzyme CgtB(OH4384)DeltaC-MalE was used to galactosylate a glyco-peptide acceptor based on the interferon alpha2b protein O-linked glycosylation site as confirmed by the CE-MS analysis of the reaction products. 1988041 13 141 gly N-glycosylation 1970:1984 arg2 the N-glycosylation site the N-glycosylation site site These chemical studies established that the active site of human milk BAL is located at serine-194, the N-glycosylation site is present at asparagine-187, the O-glycosylation region is in the 16 repeating units near the C-terminus, and the heparin binding domain is in the N-terminal region. 10952087 2 59 part_of receptor 455:462 arg1 the ET(B) receptor coding region receptor the ET(B) receptor coding region Fterm Site receptor region In the expression plasmids pPIC9KFlagET(B)Bio and pPIC9KFlag deltaGPET(B)Bio the ET(B) receptor coding region was fused in frame to the Saccharomyces cerevisiae alpha-factor prepropeptide and the FLAG-tag. 29600574 1 6 gly site 179:182 arg1 The attached carbohydrates site The attached carbohydrates site The attached carbohydrates at the highly conserved asparagine-linked glycosylation site in the CH 2 domain of the fragment crystallizable (Fc) region of monoclonal antibody therapeutics can play an essential role in their mechanism of action, including ADCC, CDC, anti-inflammatory functions, and serum half-life. 29600574 1 36 gly glycosylation 165:177 arg2 the highly conserved asparagine-linked glycosylation site the highly conserved asparagine-linked glycosylation site site The attached carbohydrates at the highly conserved asparagine-linked glycosylation site in the CH 2 domain of the fragment crystallizable (Fc) region of monoclonal antibody therapeutics can play an essential role in their mechanism of action, including ADCC, CDC, anti-inflammatory functions, and serum half-life. 15478466 0 19 part_of AL-chain 42:49 arg1 The amino acid sequence AL-chain The amino acid sequence Fterm Site AL-chain sequence The amino acid sequence of a glycosylated AL-chain from a patient with primary amyloidosis. 24721674 9 9 gly glycopeptide 1867:1878 arg2 intact glycopeptide enrichment intact glycopeptide enrichment glycopeptide It is comprised of an integrated hydrophilic interaction chromatography solid phase extraction for the simultaneous detergent removal and intact glycopeptide enrichment. 19800422 6 47 gly N-glycosylation 1294:1308 arg2 Asn772 Asn772 Asn772 It is concluded that N-glycosylation site at Asn772 of matriptase is required for the zymogen activation because it plays an important role in rendering this protease catalytically competent in the cellular environment. 19800422 6 47 gly N-glycosylation 1294:1308 arg2 N-glycosylation site N-glycosylation site site It is concluded that N-glycosylation site at Asn772 of matriptase is required for the zymogen activation because it plays an important role in rendering this protease catalytically competent in the cellular environment. 7540044 7 57 gly threonines 1610:1619 arg1 galactosyl-N-acetyl-galactosamine moieties threonines galactosyl-N-acetyl-galactosamine moieties threonines In contrast to glycosylation of the asparagine, coupling of an N-acetyl-galactosamine moiety at the serine, or galactosyl-N-acetyl-galactosamine moieties at the threonines preceding or replacing the asparagine (all O-linked sugars in the natural alpha-anomeric configuration) resulted in epitopes that lowered rather than abolished the T-cell stimulatory activity. 7540044 7 111 gly glycosylation 1464:1476 arg1 the asparagine the asparagine asparagine In contrast to glycosylation of the asparagine, coupling of an N-acetyl-galactosamine moiety at the serine, or galactosyl-N-acetyl-galactosamine moieties at the threonines preceding or replacing the asparagine (all O-linked sugars in the natural alpha-anomeric configuration) resulted in epitopes that lowered rather than abolished the T-cell stimulatory activity. 2033065 5 57 gly Glycosylation 920:932 arg2 position 248 position 248 position 248 Glycosylation at position 248 affects the intracellular processing of the internal Lys-Arg (KR) KR cleavage site, and partial glycosylation at the sequence Asn-329-X-Cys is responsible for the natural alpha-glycoform. 2033065 5 23 gly glycosylation 1046:1058 arg2 the sequence Asn-329-X-Cys Asn-329-X-Cys Asn-329-X-Cys Glycosylation at position 248 affects the intracellular processing of the internal Lys-Arg (KR) KR cleavage site, and partial glycosylation at the sequence Asn-329-X-Cys is responsible for the natural alpha-glycoform. 16823988 2 85 gly glycoprotein 377:388 arg1 the glycoprotein markers the glycoprotein markers Fterm glycoprotein This method consists of three steps: lectin affinity selection, a liquid separation and characterization of the glycoprotein markers using mass spectrometry. 20399750 1 5 part_of region 297:302 arg1 a FLAG (FL)-epitope-tagged sequence region a FLAG (FL)-epitope-tagged sequence sequence To establish a simple system for purification of recombinant infectious hepatitis C virus (HCV) particles, we designed a chimeric J6/JFH-1 virus with a FLAG (FL)-epitope-tagged sequence at the N-terminal region of the E2 hypervariable region-1 (HVR1) gene (J6/JFH-1/1FL). 20209506 3 103 part_of contains 665:672 arg1 human beta2-glycoprotein I AND multiple N-glycosylation sites human beta2-glycoprotein I multiple N-glycosylation sites PUBTATOR Site beta2-glycoprotein I 350 sites The glycopeptide analysis workflow was applied to human beta2-glycoprotein I (beta2-GPI, apolipoprotein H), which contains multiple N-glycosylation sites. 1899031 0 53 gly present 27:33 arg2 asparagine-289 AND Oligosaccharide structures asparagine-289 Oligosaccharide structures asparagine-289 Oligosaccharide structures present on asparagine-289 of recombinant human plasminogen expressed in a Chinese hamster ovary cell line. 8068684 9 33 part_of possess 1695:1701 arg1 NHE-3 AND the N75 N-linked putative glycosylation site NHE-3 the N75 N-linked putative glycosylation site PUBTATOR Site NHE-3 6550 site NHE-3, an apically-expressed epithelial isoform which does not possess the N75 N-linked putative glycosylation site and any extracellular loops enriched in serine and threonine residues, does not exhibit any detectable glycosylation. 8068684 9 33 part_of possess 1695:1701 arg1 an apically-expressed epithelial isoform AND the N75 N-linked putative glycosylation site an apically-expressed epithelial isoform the N75 N-linked putative glycosylation site Fterm Site isoform site NHE-3, an apically-expressed epithelial isoform which does not possess the N75 N-linked putative glycosylation site and any extracellular loops enriched in serine and threonine residues, does not exhibit any detectable glycosylation. 12604331 6 54 gly glycosylation 1191:1203 arg2 Asn103 Asn103 Asn103 The primary structure of BmjMIP showed a high similarity with other snake phospholipase A(2) inhibitors (PLIs) in which the carbohydrate recognition domain (CRD) and the glycosylation site (Asn103) are conserved. 12604331 6 54 gly glycosylation 1191:1203 arg2 the glycosylation site the glycosylation site site The primary structure of BmjMIP showed a high similarity with other snake phospholipase A(2) inhibitors (PLIs) in which the carbohydrate recognition domain (CRD) and the glycosylation site (Asn103) are conserved. 7628611 3 11 part_of has 432:434 arg1 the frog KBP AND three functional N-glycosylation sites the frog KBP three functional N-glycosylation sites PUBTATOR Site KBP 26128 sites We report here that the frog KBP has three functional N-glycosylation sites. 12739007 8 78 part_of MGC9753 1281:1287 arg1 the third-transmembrane domain MGC9753 the third-transmembrane domain Cterm Site MGC9753 domain Human MGC9753 protein showed 90.6% total-amino-acid identity with human CAB2 aberrant protein, which lacked the third-transmembrane domain of MGC9753 due to frame shifts within ORF. 12604783 5 46 gly N-glycosylation 823:837 arg2 an N-glycosylation site an N-glycosylation site site We tested the hypothesis that opening of the hybrid-I-like domain interface increases ligand-binding affinity by mutationally introducing an N-glycosylation site into it. 23748959 3 20 part_of gp120 532:536 arg1 tracking gp120 N-linked glycosylation sites gp120 tracking gp120 N-linked glycosylation sites PUBTATOR Site gp120 3700 sites The web server described here, the HIV N-linked Glycosylation Site Analyzer, was developed to facilitate study of HIV diversity by tracking gp120 N-linked glycosylation sites. 20621099 3 13 part_of Fc 457:458 arg1 the Fc fragment Fc the Fc fragment Cterm Site Fc fragment Here we performed mass spectrometric analyses of the Fc fragment of an unglycosylated mutant of mouse immunoglobulin G2b, whose conserved N-glycosylation site, i.e. Asn297, was substituted with alanine. 9367731 6 33 part_of HSPs 1508:1511 arg1 several eukaryotic HSP70 signature sequences HSPs several eukaryotic HSP70 signature sequences OGER Site HSPs P49903 sequences In addition to the extensive sharing of sequence homology, the identification of several eukaryotic HSP70 signature sequences and an N-linked glycosylation site characteristic of cytoplasmic HSPs strongly support the identity of the Bge cDNA as encoding an authentic HSP70. 9367731 6 83 part_of HSP70 1417:1421 arg1 several eukaryotic HSP70 signature sequences HSP70 several eukaryotic HSP70 signature sequences PUBTATOR Site HSP70 3308 sequences In addition to the extensive sharing of sequence homology, the identification of several eukaryotic HSP70 signature sequences and an N-linked glycosylation site characteristic of cytoplasmic HSPs strongly support the identity of the Bge cDNA as encoding an authentic HSP70. 11557028 12 15 gly N-glycosylation 1860:1874 arg2 an N-glycosylation site an N-glycosylation site site Finally, in in vitro translation, we show that hLAT1 is not a glycosylated protein even though an N-glycosylation site has been predicted in its extracellular loop, consistent with the property of the classical 4F2 light chain. 11557028 12 30 gly glycosylated 1824:1835 arg1 a glycosylated protein a glycosylated protein Fterm protein Finally, in in vitro translation, we show that hLAT1 is not a glycosylated protein even though an N-glycosylation site has been predicted in its extracellular loop, consistent with the property of the classical 4F2 light chain. 11557028 12 30 gly glycosylated 1824:1835 arg1 hLAT1 hLAT1 PUBTATOR hLAT1 8140 Finally, in in vitro translation, we show that hLAT1 is not a glycosylated protein even though an N-glycosylation site has been predicted in its extracellular loop, consistent with the property of the classical 4F2 light chain. 28860626 4 76 gly glycopeptides 1041:1053 arg2 ~300 glycopeptides ~300 glycopeptides glycopeptides A total of ~300 glycopeptides were analyzed and manually validated by tandem mass spectrometry. 22607976 3 18 gly N-glycosylation 387:401 arg2 the cryptic N-glycosylation site the cryptic N-glycosylation site site We report here the cryptic N-glycosylation site as a recognition signal for unfolding of a natively nonglycosylated protein, transthyretin (TTR), involved in familial amyloidosis. 22607976 3 47 gly nonglycosylated 460:474 arg1 transthyretin transthyretin PUBTATOR transthyretin 7276 We report here the cryptic N-glycosylation site as a recognition signal for unfolding of a natively nonglycosylated protein, transthyretin (TTR), involved in familial amyloidosis. 22607976 3 47 gly nonglycosylated 460:474 arg1 a natively nonglycosylated protein a natively nonglycosylated protein Fterm protein We report here the cryptic N-glycosylation site as a recognition signal for unfolding of a natively nonglycosylated protein, transthyretin (TTR), involved in familial amyloidosis. 25327667 0 54 gly glycosylation 33:45 arg1 prostate specific antigen prostate specific antigen PUBTATOR prostate specific antigen 354 Glycoproteomics: identifying the glycosylation of prostate specific antigen at normal and high isoelectric points by LC-MS/MS. 19808681 7 73 gly residues 1070:1077 arg1 the sugar chains residues in the sugar chains residues in Unlike the previously reported shift for Shaker-type Kv channels, this shift does not appear to be due to negatively charged sialic acid residues in the sugar chains. 3882692 4 32 gly glycosylation 563:575 arg2 one asparagine-linked glycosylation site one asparagine-linked glycosylation site site It contains one asparagine-linked glycosylation site and lacks cysteine. 31831916 0 45 gly glycoproteins 23:35 arg1 human N-linked glycoproteins human N-linked glycoproteins Fterm glycoproteins Mapping human N-linked glycoproteins and glycosylation sites using mass spectrometry. 31831916 0 52 gly glycosylation 41:53 arg2 glycosylation sites glycosylation sites sites Mapping human N-linked glycoproteins and glycosylation sites using mass spectrometry. 8144035 3 42 gly N-glycosylation 552:566 arg2 one putative N-glycosylation site one putative N-glycosylation site site Sequence comparison among porcine (p), human (h), and murine (m) TS indicated conservation of eight Cys residues and one putative N-glycosylation site. 1367433 6 53 gly found 1211:1215 arg2 asn 117 AND the high mannose glycan asn 117 the high mannose glycan asn 117 We found that with one exception, all mutant activators lack the high mannose glycan found at asn 117 of native t-PA. 12911333 8 53 gly glycosylation 1464:1476 arg2 native glycosylation sites native glycosylation sites sites We speculate that the S1-S2 linker is mostly a coiled-loop structure and that the strict relative position of native glycosylation sites on these linkers may be involved in the mechanism underlying the functional effects of glycosylation on some Kv1 K+ channels. 17960575 4 71 gly attached 503:510 arg2 hexapeptide AND B glycans hexapeptide B glycans hexapeptide For RNAse, B glycans of the high-mannose type (Man(4) to Man(9)) attached to either a tetra- or a hexapeptide containing the sole N-glycosylation site of the protein were detected. 17960575 4 12 gly N-glycosylation 568:582 arg1 the protein protein site Fterm protein site For RNAse, B glycans of the high-mannose type (Man(4) to Man(9)) attached to either a tetra- or a hexapeptide containing the sole N-glycosylation site of the protein were detected. 28322444 5 4 gly N229-glycosylated 854:870 arg1 the N229-glycosylated Kv3.1b protein the N229-glycosylated Kv3.1b protein Fterm protein Mass spectrometry analysis revealed a complex type Hex3 HexNAc4 Fuc1 glycan as the major glycan component of the N229-glycosylated Kv3.1b protein, as opposed to a high-mannose type Man8 GlcNAc2 glycan for N220-glycosylated Kv3.1b. Taken together, these results suggest that trafficking-dependent roles of the Kv3.1b potassium channel are dependent on N229 site-specific glycosylation and N-glycan structure, and operate through a mechanism whereby specific N-glycan structures regulate cell surface expression. 28322444 5 14 gly protein 879:885 arg1 the major glycan component protein the major glycan component Fterm protein Mass spectrometry analysis revealed a complex type Hex3 HexNAc4 Fuc1 glycan as the major glycan component of the N229-glycosylated Kv3.1b protein, as opposed to a high-mannose type Man8 GlcNAc2 glycan for N220-glycosylated Kv3.1b. Taken together, these results suggest that trafficking-dependent roles of the Kv3.1b potassium channel are dependent on N229 site-specific glycosylation and N-glycan structure, and operate through a mechanism whereby specific N-glycan structures regulate cell surface expression. 28322444 5 14 gly protein 879:885 arg1 a complex type Hex3 HexNAc4 Fuc1 glycan protein a complex type Hex3 HexNAc4 Fuc1 glycan Fterm protein Mass spectrometry analysis revealed a complex type Hex3 HexNAc4 Fuc1 glycan as the major glycan component of the N229-glycosylated Kv3.1b protein, as opposed to a high-mannose type Man8 GlcNAc2 glycan for N220-glycosylated Kv3.1b. Taken together, these results suggest that trafficking-dependent roles of the Kv3.1b potassium channel are dependent on N229 site-specific glycosylation and N-glycan structure, and operate through a mechanism whereby specific N-glycan structures regulate cell surface expression. 28322444 5 16 gly N220-glycosylated 946:962 arg1 N220-glycosylated Kv3.1b. N220-glycosylated Kv3.1b. Cterm Kv3.1b Mass spectrometry analysis revealed a complex type Hex3 HexNAc4 Fuc1 glycan as the major glycan component of the N229-glycosylated Kv3.1b protein, as opposed to a high-mannose type Man8 GlcNAc2 glycan for N220-glycosylated Kv3.1b. Taken together, these results suggest that trafficking-dependent roles of the Kv3.1b potassium channel are dependent on N229 site-specific glycosylation and N-glycan structure, and operate through a mechanism whereby specific N-glycan structures regulate cell surface expression. 25945896 0 86 gly N-glycopeptides 109:123 arg2 Intact N-glycopeptides Intact N-glycopeptides N-glycopeptides GPQuest: A Spectral Library Matching Algorithm for Site-Specific Assignment of Tandem Mass Spectra to Intact N-glycopeptides. 15100290 0 19 gly region 2:7 arg1 V region carbohydrate V region carbohydrate V region carbohydrate and antibody expression. 23296529 1 2 gly glycopeptides 183:195 arg2 particular glycopeptides particular glycopeptides glycopeptides Glycoproteins, and in particular glycopeptides, are highly hydrophilic and are often not retained by reversed phase (RP) chromatography. 1367474 4 3 gly glycosylation 608:620 arg2 this glycosylation site this glycosylation site site Removing this glycosylation site resulted in a 3-5-fold reduction in the level of tPA secretion. 9398598 3 46 part_of CD4 510:512 arg1 a murine CD4 fragment CD4 a murine CD4 fragment PUBTATOR Site CD4 12504 fragment Here, we report that a transfected Chinese hamster ovary (CHO) cell line expressing a murine CD4 fragment containing the first two N-terminal domains secretes both monomeric molecules and disulfide-linked multimers. 9398598 3 17 part_of containing 523:532 arg1 a murine CD4 fragment AND the first two N-terminal domains a murine CD4 fragment the first two N-terminal domains domains Here, we report that a transfected Chinese hamster ovary (CHO) cell line expressing a murine CD4 fragment containing the first two N-terminal domains secretes both monomeric molecules and disulfide-linked multimers. 10024532 7 31 part_of Fab 1038:1040 arg1 the Fab fragment Fab the Fab fragment PUBTATOR Site Fab 2187 fragment Furthermore, we determined N-acetylgalactosamine in the Fab fragment of this antibody, suggesting the presence of O-linked carbohydrates. 2242757 0 40 gly Glycosylation 0:12 arg1 IgG IgG Cterm IgG Glycosylation of IgG, immune complexes and IgG subclasses in the MRL-lpr/lpr mouse model of rheumatoid arthritis. 9292017 7 58 gly glycosylation 756:768 arg2 the potential glycosylation site the potential glycosylation site site The loss of the corresponding four amino acids resulted in the loss of the potential glycosylation site present in several WN strains. 28630087 7 125 gly glycosylated 1318:1329 arg1 Asn185 Asn185 Asn185 Asn185 was not glycosylated. 18420026 0 105 part_of glycoprotein 28:39 arg1 a single N-glycosylation site glycoprotein a single N-glycosylation site Fterm Site glycoprotein site Nectin-like molecule 1 is a glycoprotein with a single N-glycosylation site at N290KS which influences its adhesion activity. 1456441 5 88 gly glycosylation 832:844 arg2 the glycosylation sites the glycosylation sites sites One part of the digest of each fraction was analyzed by fast atom bombardment-mass spectrometry (FAB-MS) to identify the peptide sequences of the glycosylation sites. 10196694 0 3 gly N-glycosylation 120:134 arg2 the single N-glycosylation site the single N-glycosylation site site An Asn > Lys substitution in saposin B involving a conserved amino acidic residue and leading to the loss of the single N-glycosylation site in a patient with metachromatic leukodystrophy and normal arylsulphatase A activity. 16476981 2 50 gly glycoprotein 356:367 arg1 the gp120 envelope glycoprotein the gp120 envelope glycoprotein Fterm glycoprotein Loss of N-linked glycans and increased net charge of the third variable loop (V3) of the gp120 envelope glycoprotein have been observed to be important steps towards CXCR4 use. 21153276 1 75 part_of sites 158:162 arg1 the mouse gonadotropin-releasing hormone receptor gonadotropin-releasing hormone receptor sites PUBTATOR Site gonadotropin-releasing hormone receptor 14715 sites Mutation ofN-glycosylation sites in the mouse gonadotropin-releasing hormone receptor was previously shown to impair its expression in COS-1 cells. 31296534 3 14 gly glycosylation 468:480 arg1 roughly 1,000 acceptor sites roughly 1,000 acceptor sites sites We used a quantitative glycoproteomics procedure to compare glycosylation of roughly 1,000 acceptor sites in wild type and mutant cells. 31051246 6 19 gly glycosylation 1129:1141 arg1 glycosylated vasoinhibin isoforms glycosylated vasoinhibin isoforms Fterm isoforms Mutation to serine introduced a new N-glycosylation site and associated with increased glycosylation and release of glycosylated vasoinhibin isoforms having reduced antiangiogenic properties. 31051246 6 45 gly N-glycosylation 1078:1092 arg2 a new N-glycosylation site a new N-glycosylation site site Mutation to serine introduced a new N-glycosylation site and associated with increased glycosylation and release of glycosylated vasoinhibin isoforms having reduced antiangiogenic properties. 31051246 6 59 gly glycosylated 1158:1169 arg1 glycosylated vasoinhibin isoforms glycosylated vasoinhibin isoforms Fterm isoforms Mutation to serine introduced a new N-glycosylation site and associated with increased glycosylation and release of glycosylated vasoinhibin isoforms having reduced antiangiogenic properties. 30042931 2 56 part_of has 432:434 arg1 the related dengue virus E protein AND two glycosylation sites the related dengue virus E protein two glycosylation sites Fterm Site protein sites JEV E protein has one N-linked glycosylation site at N154 (G2 site), but the related dengue virus E protein has two glycosylation sites at N67 (G1 site) and N153 (G2 site). 30042931 2 27 part_of has 338:340 arg1 JEV E protein AND one N-linked glycosylation site JEV E protein one N-linked glycosylation site Fterm Site protein site JEV E protein has one N-linked glycosylation site at N154 (G2 site), but the related dengue virus E protein has two glycosylation sites at N67 (G1 site) and N153 (G2 site). 17623277 6 67 gly monosaccharides 635:649 arg1 mosquito DCE DCE monosaccharides PUBTATOR DCE 1718 Results showed that N-acetyl D-glucosamine and D-mannose are the major monosaccharides and L-fucose, D-xylose, and D-arabinose are the minor ones in mosquito DCE. 20936810 12 60 gly N-glycosylation 1173:1187 arg2 an N-glycosylation site an N-glycosylation site site The highly conserved nature of these three proximal sugars in N-glycans led us to speculate that introducing an N-glycosylation site into a protein that is not normally glycosylated would stabilize the protein and increase its folding rate in a manner that does not depend on the presence of specific stabilizing protein-saccharide interactions. 20936810 12 87 gly glycosylated 1230:1241 arg1 a protein a protein Fterm protein The highly conserved nature of these three proximal sugars in N-glycans led us to speculate that introducing an N-glycosylation site into a protein that is not normally glycosylated would stabilize the protein and increase its folding rate in a manner that does not depend on the presence of specific stabilizing protein-saccharide interactions. 29253009 5 31 gly glycosylation 1036:1048 arg1 the asparagine residue the asparagine residue asparagine residue The structures reveal that while glycosylation of GP392 most probably impairs binding, the glycosylation of the asparagine residue in GP92, which protrudes towards the solvent, possibly allows for immune escape and/or forms a neo-epitope that may select for a different set of CD8 T cells. 17082223 1 67 gly glycosylation 185:197 arg1 the bile salt export pump [Bsep the bile salt export pump [Bsep OGER bile salt export pump O70127 The aim of this study was to determine the role of N-linked glycosylation in protein stability, intracellular trafficking, and bile acid transport activity of the bile salt export pump [Bsep (ATP-binding cassette B11)]. 17082223 1 67 gly glycosylation 185:197 arg1 protein stability protein stability Fterm protein The aim of this study was to determine the role of N-linked glycosylation in protein stability, intracellular trafficking, and bile acid transport activity of the bile salt export pump [Bsep (ATP-binding cassette B11)]. 29309128 4 8 gly glycoprotein 704:715 arg1 optimizing glycoprotein properties optimizing glycoprotein properties Fterm glycoprotein This has been a significant limitation on rational applications of glycosylation and on optimizing glycoprotein properties. 11804340 4 74 gly N-glycosylation 715:729 arg2 A putative N-glycosylation site A putative N-glycosylation site site A putative N-glycosylation site was identified at amino acid 171, Asn. 8419363 0 43 gly Glycosylation 0:12 arg1 human corticosteroid-binding globulin human corticosteroid-binding globulin PUBTATOR corticosteroid-binding globulin 866 Glycosylation of human corticosteroid-binding globulin at aspargine 238 is necessary for steroid binding. 29190644 4 9 part_of BChE 744:747 arg1 the BChE tetramerization domain BChE the BChE tetramerization domain PUBTATOR Site BChE 590 domain From our investigation, we found that the glycan attached to ASN241 is both structurally and functionally important due to its close proximity to the BChE tetramerization domain and the active site gorge. 10878356 1 4 part_of region 247:252 arg1 Ig V domains region Ig V domains domains The distinct strand topology of TCR V alpha domains results in a flatter surface in the region encompassing the c" strand than the corresponding region in Ig V domains. 25541284 2 1 gly N-glycosylation 255:269 arg2 a single N-glycosylation site a single N-glycosylation site site MOG has a single N-glycosylation site within its extracellular domain. 11864713 6 52 gly Asn230-linked 1412:1424 arg1 the Asn230-linked glycan Asn230 the Asn230-linked glycan Asn230 These results suggest that the Asn243-linked glycan in PCI molecule possesses critical roles for its anticoagulant activity in the circulation, and the Asn230-linked glycan down-regulates the activity of PCI. 11864713 6 71 gly Asn243-linked 1291:1303 arg1 the Asn243-linked glycan Asn243 the Asn243-linked glycan Asn243 These results suggest that the Asn243-linked glycan in PCI molecule possesses critical roles for its anticoagulant activity in the circulation, and the Asn230-linked glycan down-regulates the activity of PCI. 21752569 4 2 gly glycoprotein 678:689 arg1 The deglycoproteins and unmodified glycoprotein The deglycoproteins and unmodified glycoprotein Fterm glycoprotein The deglycoproteins and unmodified glycoprotein were further digested to deglycopeptide through trypsin digestion. 21752569 4 20 gly deglycoproteins 647:661 arg1 deglycoproteins deglycoproteins Fterm deglycoproteins The deglycoproteins and unmodified glycoprotein were further digested to deglycopeptide through trypsin digestion. 21752569 4 41 gly deglycopeptide 716:729 arg2 deglycopeptide deglycopeptide deglycopeptide The deglycoproteins and unmodified glycoprotein were further digested to deglycopeptide through trypsin digestion. 8486693 5 18 gly glycosylation 1162:1174 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Dideoxy sequencing of full-length subclones of GP-3 revealed the predicted amino acid sequence for a mature protein of 452 amino acids with a potential N-linked glycosylation site and a deglycosylated molecular weight of 50,860. 27881683 8 25 gly glycosylation 1257:1269 arg2 suitable glycosylation sites suitable glycosylation sites sites These experimental studies validate the in silico strategy to predict suitable glycosylation sites that would be glycosylated, while maintaining biological function. 27881683 8 48 gly glycosylated 1291:1302 arg1 suitable glycosylation sites suitable glycosylation sites sites These experimental studies validate the in silico strategy to predict suitable glycosylation sites that would be glycosylated, while maintaining biological function. 26977294 9 47 gly fucosylation 1358:1369 arg1 Fab-TNF α interactions Fab-TNF α PUBTATOR Fab-TNF α 7124 While fucosylation does not affect Fab-TNF α interactions, we found that in the absence of fucosylation the Fc-mAb domain and Fcγ RIIIA are closer and new strong interactions are established between G129 of the receptor and S301 of the Chimera 2 Fc mAb; new polar interactions are also established between the Chimera 2 Fc residues Y299, N300, and S301 and the Fcγ RIIIA residues K128, G129, R130, and R155. 8832092 3 31 gly glycopeptides 606:618 arg2 labelled glycopeptides labelled glycopeptides glycopeptides In the case described here it allowed to follow easily the purification, by HPLC and affinity chromatography, of labelled glycopeptides obtained by controlled proteolysis of cruzipain, a cysteine proteinase isolated from the human pathogen Trypanosoma cruzi. 31944613 10 61 gly glycosylation 1818:1830 arg2 additional HA head glycosylation sites 158 or 169 additional HA head glycosylation sites 158 or 169 sites Our findings reveal that deletion of additional HA head glycosylation sites 158 or 169 enhanced the AIV virulence via activating of strong ER stress and inflammation. 30042931 5 95 gly E-glycosylation 928:942 arg1 both G1 and G2 sites sites sites The G1G2 mutant (E-D67N), with E-glycosylation on both G1 and G2 sites, showed potent in vitro viral replication and in vivo neurovirulence, but reduced neuroinvasiveness. 31251477 3 39 part_of A1AT 541:544 arg1 the N-terminal region A1AT the N-terminal region Cterm Site A1AT P01009 region Here, we investigated the features of a rare SNP (F51S) of A1AT, which introduces an additional N-glycosylation site in the N-terminal region of A1AT. 30935958 9 33 gly N-glycosylated 1111:1124 arg2 Asn197 positions Asn181 and Asn197 positions Asn181 and Asn197 In vivo PrP is N-glycosylated at positions Asn181 and Asn197. 30935958 9 33 gly N-glycosylated 1111:1124 arg1 In vivo PrP PrP positions Asn181 and Asn197 PUBTATOR PrP Q9NP58 positions Asn181 and Asn197 In vivo PrP is N-glycosylated at positions Asn181 and Asn197. 30935958 9 33 gly N-glycosylated 1111:1124 arg2 positions positions Asn181 and Asn197 positions Asn181 and Asn197 In vivo PrP is N-glycosylated at positions Asn181 and Asn197. 30935958 9 33 gly N-glycosylated 1111:1124 arg1 In vivo PrP PrP positions Asn181 and Asn197 PUBTATOR PrP Q9NP58 positions Asn181 and Asn197 In vivo PrP is N-glycosylated at positions Asn181 and Asn197. 30935958 9 33 gly N-glycosylated 1111:1124 arg2 positions positions Asn181 and Asn197 positions Asn181 and Asn197 In vivo PrP is N-glycosylated at positions Asn181 and Asn197. 30935958 9 33 gly N-glycosylated 1111:1124 arg2 positions PrP positions Asn181 and Asn197 PUBTATOR PrP Q9NP58 positions Asn181 and Asn197 In vivo PrP is N-glycosylated at positions Asn181 and Asn197. 30935958 9 40 gly positions 1129:1137 arg1 Asn197 positions Asn181 and Asn197 positions Asn181 and Asn197 In vivo PrP is N-glycosylated at positions Asn181 and Asn197. 30935958 9 40 gly positions 1129:1137 arg1 Asn181 positions Asn181 and Asn197 positions Asn181 and Asn197 In vivo PrP is N-glycosylated at positions Asn181 and Asn197. 30935958 9 40 gly positions 1129:1137 arg1 Asn181 positions Asn181 and Asn197 positions Asn181 and Asn197 In vivo PrP is N-glycosylated at positions Asn181 and Asn197. 20391591 1 38 part_of glycoproteins 119:131 arg1 Assigning glycosylation sites glycoproteins Assigning glycosylation sites Fterm Site glycoproteins sites Assigning glycosylation sites of glycoproteins and their microheterogeneity is still a very challenging analytical task despite the rapid advancements in mass spectrometry. 9757569 0 10 part_of residue 32:38 arg1 ovine angiotensinogen angiotensinogen residue PUBTATOR AminoAcid angiotensinogen 183 residue at position 14 Effects of glycosylation of the residue at position 14 in ovine angiotensinogen on the human renin reaction. 11063734 5 72 part_of proSP-B 705:711 arg1 -linked glycosylation site SP-B -linked glycosylation site PUBTATOR Site SP-B 6439 site Of the two SP-B polymorphisms genotyped, the Ile131Thr variation affects a putative N-terminal N:-linked glycosylation site of proSP-B and the length variation of intron 4 has previously been suggested to associate with RDS. 24164424 10 49 part_of site 1587:1590 arg1 CNGA1 CNGA1 site PUBTATOR Site CNGA1 1259 site Relocating the glycosylation site in CNGA1 to the position found in CNGA3 recapitulated CNGA3-like protection from MMP-dependent processing. 15247302 0 22 part_of receptor 68:75 arg1 A primate-dominant third glycosylation site beta2-adrenergic receptor A primate-dominant third glycosylation site OGER Site beta2-adrenergic receptor P07550 site A primate-dominant third glycosylation site of the beta2-adrenergic receptor routes receptors to degradation during agonist regulation. 3334850 6 16 gly N-glycosylation 813:827 arg2 one possible N-glycosylation site one possible N-glycosylation site site Amino-acid sequencing showed that there was one possible N-glycosylation site at Asn (Asn-Cys-Thr). 22015153 1 8 gly glycoproteins 167:179 arg1 oviduct-specific glycoproteins oviduct-specific glycoproteins Fterm glycoproteins Oviductins belong to a family of oviduct-specific glycoproteins believed to play an important role in fertilization and/or early embryonic development. 9140729 12 103 gly glycosylation 1999:2011 arg1 the SK2 VH region the SK2 VH region region In contrast, both versions of the heavy chains were comparable, in yielding good humanized SK2 antibodies, suggesting that the glycosylation of the SK2 VH region has no influence in recreating a functional antigen-binding site in this humanization. 24792223 2 34 gly glycosylation 372:384 arg2 the glycosylation site the glycosylation site site Anthocyanidin glycosylation is the essential step of anthocyanin biosynthesis and also the prerequisite of the further modifications of anthocyanins, which is jointly characterized by the glycosylation site, the type and number of the glycosyl as well as the glycosidic bond type. 8327483 4 17 gly glycoprotein 792:803 arg1 glycoprotein hormones glycoprotein hormones Fterm glycoprotein The identification of TSH in addition to two gonadotropins (gonadotropins I and II) in the teleost fish suggests that the divergence of three kinds of glycoprotein hormones from an ancestral molecule took place earlier than the time of divergence of teleosts from the main line of evolution leading to tetrapods. 2666404 5 59 part_of regions 738:744 arg1 Sequence and structural motifs regions Sequence and structural motifs motifs Sequence and structural motifs at the N-terminal and C-terminal regions of the proteins support the view that the genes of this superfamily arose by duplication of a common ancestral gene. 12877809 10 103 part_of Asn342 1579:1584 arg1 the tree shrew CETP protein CETP protein Asn342 PUBTATOR AminoAcid CETP protein P11597 Asn342 There is a deletion of an N-linked glycosylation site at Asn342 in the tree shrew CETP protein that may participate in the removal of peripheral cholesterol and cholesteryl ester by increasing its activity of transferring cholesteryl ester. 28931684 15 71 gly glycosylation 2686:2698 arg1 the E protein the E protein Fterm protein Our studies suggest glycosylation of the E protein as an important factor contributing to ZIKV pathogenicity. 23250914 1 13 gly N-glycosylation 95:109 arg2 the N-glycosylation site the N-glycosylation site site Mutations affecting the N-glycosylation site in Berardinelli-Seip lipodystrophy (BSCL)-associated gene BSCL2/seipin lead to a dominantly inherited spastic paraplegia termed seipinopathy. 18282281 13 107 gly O-glycosylation 2366:2380 arg2 a competitive mucin-type O-glycosylation site predictor a competitive mucin-type O-glycosylation site predictor site This suggests that it can be used as a competitive mucin-type O-glycosylation site predictor to the biological community. 25707740 4 12 gly glycoprotein 452:463 arg1 a complex glycoprotein a complex glycoprotein Fterm glycoprotein Specific to humans, hCG is a complex glycoprotein composed of two glycosylated subunits. 25707740 4 12 gly glycoprotein 452:463 arg1 hCG hCG OGER hCG Specific to humans, hCG is a complex glycoprotein composed of two glycosylated subunits. 25707740 4 89 gly glycosylated 481:492 arg1 two glycosylated subunits two glycosylated subunits Fterm subunits Specific to humans, hCG is a complex glycoprotein composed of two glycosylated subunits. 20532728 5 0 gly glycosylation 1693:1705 arg2 glycosylation site glycosylation site site Our result demonstrated that common terms in both no-tumor hepatitis/cirrhotic liver tissues and HCC include secreted extracellular region, extracellular region part, extracellular space, signal peptide, signal, disulfide bond, glycosylation site N-linked (GlcNAc...), and glycoprotein, and these terms are less relative to invasion; therefore, we deduced the weaker AFP secreted network in HCC consistent with our number computation. 20532728 5 27 gly glycoprotein 1738:1749 arg1 glycoprotein glycoprotein Fterm glycoprotein Our result demonstrated that common terms in both no-tumor hepatitis/cirrhotic liver tissues and HCC include secreted extracellular region, extracellular region part, extracellular space, signal peptide, signal, disulfide bond, glycosylation site N-linked (GlcNAc...), and glycoprotein, and these terms are less relative to invasion; therefore, we deduced the weaker AFP secreted network in HCC consistent with our number computation. 25456591 5 9 gly glycopeptides 1177:1189 arg2 multiple intact glycopeptides multiple intact glycopeptides glycopeptides Using fetuin as a model, all identified S/T elimination sites were matched to multiple intact glycopeptides with a 31% FDR. 20797752 5 9 gly glycoprotein 662:673 arg1 the envelope glycoprotein the envelope glycoprotein Fterm glycoprotein The analysis of a particular stretch of the envelope glycoprotein encompassing a potential neutralizing epitope revealed that, as in SIV, the transmitted viruses were positively charged in this region, but, in contrast to SIV, they tended to lack a glycosylation site that might protect against antibody neutralization. 20797752 5 32 gly glycosylation 858:870 arg2 a glycosylation site a glycosylation site site The analysis of a particular stretch of the envelope glycoprotein encompassing a potential neutralizing epitope revealed that, as in SIV, the transmitted viruses were positively charged in this region, but, in contrast to SIV, they tended to lack a glycosylation site that might protect against antibody neutralization. 8364023 1 12 part_of site 154:157 arg1 human lecithin lecithin:cholesterol acyltransferase site PUBTATOR Site lecithin:cholesterol acyltransferase 3931 site There are four potential N-glycosylation site (Asn-X-Ser/Thr) in human lecithin:cholesterol acyltransferase (LCAT, residues 20, 84, 272, and 384). 2451667 3 14 gly glycoprotein 648:659 arg1 vesicular stomatitis virus glycoprotein vesicular stomatitis virus glycoprotein Fterm glycoprotein When expressed in animal cells this DNA encoded the 92-amino acid hCG-alpha subunit anchored in cellular membranes by an extension composed of the 49 carboxyl-terminal amino acids of vesicular stomatitis virus glycoprotein. 26013384 0 10 part_of Ser126 59:64 arg1 Human Recombinant Erythropoietin Erythropoietin Ser126 PUBTATOR AminoAcid Erythropoietin 2056 Ser126 Structural Identification of a Non-Glycosylated Variant at Ser126 for O-Glycosylation Site from EPO BRP, Human Recombinant Erythropoietin by LC/MS Analysis. 23527139 0 87 gly glycoprotein 46:57 arg1 dengue envelope glycoprotein dengue envelope glycoprotein PUBTATOR envelope glycoprotein 100616444 Interaction and inhibition of dengue envelope glycoprotein with mammalian receptor DC-sign, an in-silico approach. 9557657 2 59 part_of havcr-1 406:412 arg1 The extracellular domain havcr-1 The extracellular domain PUBTATOR Site havcr-1 26762 domain The extracellular domain of havcr-1 has an N-terminal Cys-rich region that displays homology with sequences of members of the immunoglobulin superfamily, followed by a Thr/Ser/Pro (TSP)-rich region characteristic of mucin-like O-glycosylated proteins. 9557657 2 127 part_of has 414:416 arg1 havcr-1 AND an N-terminal Cys-rich region havcr-1 region PUBTATOR Site havcr-1 26762 region The extracellular domain of havcr-1 has an N-terminal Cys-rich region that displays homology with sequences of members of the immunoglobulin superfamily, followed by a Thr/Ser/Pro (TSP)-rich region characteristic of mucin-like O-glycosylated proteins. 2009266 3 15 part_of region 573:578 arg1 the C-terminal region region the C-terminal region region In general, features conserved in the fibrinogens from other species also characterize the chicken sequence, including the cysteine motifs bordering an alpha-helical permissive region of fixed length and a single glycosylation site in the C-terminal region. 17011210 5 61 gly N-glycosylation 1040:1054 arg2 N-glycosylation sites N-glycosylation sites sites The influences of the N- and C- terminal addition of FLAG/(His)(6) tag spaced by pentaglycine sequence and the sequentially accumulative deletions of N-glycosylation sites within hFasLECD were investigated. 31511323 10 25 gly glycosylation 1516:1528 arg2 a single intact glycosylation site a single intact glycosylation site site Interestingly, β2 with a single intact glycosylation site was as effective as the WT in promoting NaV1.5 surface localization. 21727639 4 36 part_of proteins 894:901 arg1 sequences proteins sequences Fterm Site proteins sequences RESULTS: Sequence and phylogenetic analysis revealed a large number of similar substitution mutations and close evolutionary relation among sequences of both proteins. 26059044 9 8 gly composition 1401:1411 arg1 other positions other positions other positions Site positions However, we do show that the presence of a N-glycan on Asn54 contributes to the atypical N-glycan composition of plant-produced IL-22 and influences the N-glycan composition of N-glycans on other positions. 26059044 9 20 gly IL-22 1367:1371 arg1 the atypical N-glycan composition IL-22 the atypical N-glycan composition PUBTATOR IL-22 50616 However, we do show that the presence of a N-glycan on Asn54 contributes to the atypical N-glycan composition of plant-produced IL-22 and influences the N-glycan composition of N-glycans on other positions. 26059044 9 21 gly presence 1268:1275 arg2 Asn54 AND a N-glycan Asn54 a N-glycan Asn54 However, we do show that the presence of a N-glycan on Asn54 contributes to the atypical N-glycan composition of plant-produced IL-22 and influences the N-glycan composition of N-glycans on other positions. 8407981 7 18 part_of protein 1096:1102 arg1 modified Asn-180 residue protein modified Asn-180 residue Fterm SpecificSite protein Asn-180 residue The core glycosylation did not occur when the Asn-12 residue was mutated, whereas the mutant protein with modified Asn-180 residue was glycosylated. 9535843 2 53 part_of proteins 358:365 arg1 the amino acid sequence proteins the amino acid sequence Fterm Site proteins sequence Kyte-Doolittle analysis of the amino acid sequence of Trp proteins identifies seven hydrophobic regions (H1-H7) with potential of forming transmembrane segments. 25213400 3 21 part_of Asn 286:288 arg1 MOG MOG Asn PUBTATOR SpecificSite MOG 4340 Asn(31) Other myelin glycoproteins, also with a single glycosylation site (PMP22 at Asn(36) , MOG at Asn(31) ), bind only one glycan. 25213400 3 73 part_of Asn 269:271 arg1 PMP22 PMP22 Asn PUBTATOR SpecificSite PMP22 5376 Asn(36) Other myelin glycoproteins, also with a single glycosylation site (PMP22 at Asn(36) , MOG at Asn(31) ), bind only one glycan. 25213400 3 75 part_of glycoproteins 206:218 arg1 a single glycosylation site glycoproteins a single glycosylation site Fterm Site glycoproteins site Other myelin glycoproteins, also with a single glycosylation site (PMP22 at Asn(36) , MOG at Asn(31) ), bind only one glycan. 14561640 12 4 part_of RNase 1503:1507 arg1 an RNase A family motif RNase A an RNase A family motif PUBTATOR Site RNase A 6035 motif Train A presents an RNase A family motif in its sequence. 14561640 12 48 part_of A 1509:1509 arg1 an RNase A family motif RNase A an RNase A family motif PUBTATOR Site RNase A 6035 motif Train A presents an RNase A family motif in its sequence. 14561640 12 77 part_of motif 1518:1522 arg1 its sequence motif its sequence sequence Train A presents an RNase A family motif in its sequence. 9139737 3 16 part_of COOH-terminal 845:857 arg1 the cleaved COOH-terminal fragment COOH-terminal the cleaved COOH-terminal fragment Cterm Site COOH-terminal fragment This site was identified through use of a vector encoding an SREBP-2/Ras fusion protein with a triple epitope tag that allowed immunoprecipitation of the cleaved COOH-terminal fragment. 518919 0 25 part_of glycoprotein 116:127 arg1 the first glycosylation site glycoprotein the first glycosylation site Fterm Site glycoprotein site The primary structure of the asialo-carbohydrate units of the first glycosylation site of human plasma alpha 1-acid glycoprotein. 7849028 8 83 gly glycosylation 1114:1126 arg2 the glycosylation sites the glycosylation sites sites The majority of the glycosylation sites in rat p62 are likely to occur on the six clustered Ser residues in the central Ser/Thr-rich region from Ser270 to Thr294. 27048837 4 48 gly N-glycosylation 599:613 arg2 a prospective N-glycosylation site a prospective N-glycosylation site site We report a novel variant of Apo E (c.382G>A) predicting 110Asp→Asn identified by genotyping, we were prompted to investigate this further as the amino acid substitution produced a prospective N-glycosylation site in this novel variant. 25113421 9 89 gly glycopeptides 1163:1175 arg2 intact glycopeptides intact glycopeptides glycopeptides However, the spectral data cannot be readily analyzed because of the lack of software specifically designed for the identification of intact glycopeptides. 16212939 6 78 gly N-glycosylation 1132:1146 arg1 the secretion enhancer peptide the secretion enhancer peptide peptide These results show that N-glycosylation of the secretion enhancer peptide plays an important role in increasing the secretion efficiency of the downstream target proteins. 1373379 6 51 part_of BiP 777:779 arg1 Ala-Asp-Glu-Leu BiP Ala-Asp-Glu-Leu Cterm Site BiP Ala-Asp-Glu-Leu The C-terminal four amino acids of BiP are Ala-Asp-Glu-Leu, a new variant of the XDEL sequence found at the C-termini of luminal endoplasmic reticulum proteins. 16227292 10 51 gly glycans 1538:1544 arg1 Gc Gc glycans Cterm Gc The viability of these recombinant viruses and analysis of growth kinetics indicates that the glycans on Gc are not essential for BUN replication, but they do contribute to the efficiency of virus infection. 9287313 4 24 gly glycoforms 758:767 arg1 human CD69 glycoforms human CD69 glycoforms PUBTATOR CD69 969 In the current report we show that human CD69 glycoforms are generated before the egress of CD69 proteins from the endoplasmic reticulum to the Golgi and are synthesized under conditions where Golgi processing is inhibited, effectively ruling out the possibility that CD69 heterogeneity results from the differential processing of a single glycosylation site in the Golgi complex. 9287313 4 78 gly glycosylation 1052:1064 arg2 a single glycosylation site a single glycosylation site site In the current report we show that human CD69 glycoforms are generated before the egress of CD69 proteins from the endoplasmic reticulum to the Golgi and are synthesized under conditions where Golgi processing is inhibited, effectively ruling out the possibility that CD69 heterogeneity results from the differential processing of a single glycosylation site in the Golgi complex. 4038307 5 45 gly glycoprotein 861:872 arg1 an N-glycan glycoprotein an N-glycan Fterm glycoprotein , in an N-glycan of a glycoprotein. 12742580 0 73 gly glycoprotein 46:57 arg1 variant surface glycoprotein expression variant surface glycoprotein expression Fterm glycoprotein Structural features affecting variant surface glycoprotein expression in Trypanosoma brucei. 14691230 6 37 gly glycosylation 1065:1077 arg1 DPPIV DPPIV PUBTATOR DPPIV 1803 Crystallographic and biochemical data demonstrate that N-linked glycosylation of DPPIV does not contribute significantly to its peptidase activity. 14691230 6 37 gly glycosylation 1065:1077 arg1 its peptidase activity its peptidase activity Fterm peptidase Crystallographic and biochemical data demonstrate that N-linked glycosylation of DPPIV does not contribute significantly to its peptidase activity. 29980609 8 71 gly glycosylation 1599:1611 arg2 the atypical glycosylation site the atypical glycosylation site site However, although the extent of conventional N-linked glycosylation positively correlates with AICL surface expression, the atypical glycosylation site impairs AICL surfacing. 27301377 8 101 gly consensus-glycosylation 2010:2032 arg2 the consensus-glycosylation site the consensus-glycosylation site site Decrease in DEspR-protein size after PNGase-F digest demonstrates post-translational glycosylation, concordant with the consensus-glycosylation site beyond codon#14. 8399360 8 68 gly N-glycosylation 991:1005 arg2 one potential N-glycosylation site one potential N-glycosylation site site Nucleotide sequence analysis revealed that one potential N-glycosylation site is located in the complementarity determining region 1 of the light chain, although no such site was found in the variable region of the heavy chain. 7540044 0 5 part_of epitope 150:156 arg1 the rabies virus glycoprotein glycoprotein epitope Fterm glycoprotein Comparison of the effects of amino acid substitutions and beta-N- vs. alpha-O-glycosylation on the T-cell stimulatory activity and conformation of an epitope on the rabies virus glycoprotein. 18533687 8 5 gly utilized 1341:1348 arg2 the potential N-glycosylation sites the potential N-glycosylation sites sites All of the potential N-glycosylation sites of RXFP1 were utilized in HEK-293T cells, and importantly, disruption of glycosylation at individual or combinations of double and triple sites had little effect on relaxin binding. 18533687 8 9 gly N-glycosylation 1305:1319 arg1 RXFP1 RXFP1 sites PUBTATOR RXFP1 59350 sites All of the potential N-glycosylation sites of RXFP1 were utilized in HEK-293T cells, and importantly, disruption of glycosylation at individual or combinations of double and triple sites had little effect on relaxin binding. 18642129 12 16 part_of position 1702:1709 arg1 the light chain chain position OGER SpecificSite chain P08709 position Ser(60) and Ser(52) Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively. 7642555 6 17 gly s 607:607 arg1 c-Myc c-Myc s PUBTATOR c-Myc 4609 In this paper, we identified the O-GlcNAc attachment site(s) on c-Myc. 2911604 7 30 part_of protein 1614:1620 arg1 both the catalytic and noncatalytic domains protein both the catalytic and noncatalytic domains Fterm Site protein domains The high degree of conservation in amino acid sequence throughout the catalytic, intragranular, and cytoplasmic domains of rat atrium, bovine pituitary, and frog skin PAM suggests that both the catalytic and noncatalytic domains of the protein subserve important functions. 24780636 1 19 gly Asn630 161:166 arg1 N-glycans Asn432 and Asn630 N-glycans Asn432 and Asn630 Transferrin is an iron-transport protein which possesses N-glycans at Asn432 and Asn630 in humans. 24780636 1 21 gly Asn432 150:155 arg1 N-glycans Asn432 and Asn630 N-glycans Asn432 and Asn630 Transferrin is an iron-transport protein which possesses N-glycans at Asn432 and Asn630 in humans. 24780636 1 1 gly possesses 127:135 arg1 Transferrin AND N-glycans Transferrin N-glycans PUBTATOR Transferrin 7018 Transferrin is an iron-transport protein which possesses N-glycans at Asn432 and Asn630 in humans. 24780636 1 1 gly possesses 127:135 arg1 an iron-transport protein AND N-glycans an iron-transport protein N-glycans Fterm protein Transferrin is an iron-transport protein which possesses N-glycans at Asn432 and Asn630 in humans. 30850477 7 49 gly N-glycosylation 909:923 arg2 N-glycosylation sites N-glycosylation sites sites N-glycosylation sites are clustered around CDRs and the DE loop for both H and L chains, with similar frequencies for healthy donors and patients. 28900186 1 61 part_of glycoprotein 205:216 arg1 all potential N-glycosylation sites glycoprotein all potential N-glycosylation sites Fterm Site glycoprotein sites To determine all potential N-glycosylation sites of a glycoprotein, one central aspect of every bottom-up N-glycoproteomic strategy is to generate suitable N-glycopeptides that can be detected and analyzed by mass spectrometry. 8627808 2 40 part_of containing 470:479 arg1 a protein AND one potential N-glycosylation site a protein one potential N-glycosylation site Fterm Site protein site The mRNA of the SFA-1 gene is approximately 1.6 kb in size and encodes a protein of 253 amino acids, containing four putative transmembrane domains, a number of cysteine residues, and one potential N-glycosylation site in a major hydrophilic region between the third and fourth transmembrane domains. 8627808 2 40 part_of containing 470:479 arg1 a protein AND four putative transmembrane domains a protein four putative transmembrane domains Fterm Site protein domains The mRNA of the SFA-1 gene is approximately 1.6 kb in size and encodes a protein of 253 amino acids, containing four putative transmembrane domains, a number of cysteine residues, and one potential N-glycosylation site in a major hydrophilic region between the third and fourth transmembrane domains. 8627808 2 40 part_of containing 470:479 arg1 a protein AND cysteine residues a protein cysteine residues Fterm AminoAcid protein cysteine residues The mRNA of the SFA-1 gene is approximately 1.6 kb in size and encodes a protein of 253 amino acids, containing four putative transmembrane domains, a number of cysteine residues, and one potential N-glycosylation site in a major hydrophilic region between the third and fourth transmembrane domains. 15924140 6 40 gly N-glycosylation 1059:1073 arg2 new N-glycosylation sites new N-glycosylation sites sites Thus, an unexpectedly high proportion of mutations that cause human genetic disease might lead to the creation of new N-glycosylation sites. 7613486 1 29 gly glycosylation 193:205 arg1 the insulin receptor the insulin receptor PUBTATOR insulin receptor 3643 Asparagine-linked glycosylation of the insulin receptor is required for complete biosynthesis and acquisition of function. 19479899 4 63 gly N-glycosylation 721:735 arg2 an artificial N-glycosylation site an artificial N-glycosylation site site Pex3p bearing an artificial N-glycosylation site shows an electrophoretic shift indicative of ER targeting while en route to preformed peroxisomes in normal fibroblast. 27480168 9 23 gly glycosylation 1664:1676 arg2 N48 hENT1 N48 OGER hENT1 Q99808 N48 Based on these data we propose that glycosylation at N48 is critical for the localization, function and oligomerization of hENT1. 27480168 9 23 gly glycosylation 1664:1676 arg1 N48 hENT1 N48 OGER hENT1 Q99808 N48 Based on these data we propose that glycosylation at N48 is critical for the localization, function and oligomerization of hENT1. 27480168 9 23 gly glycosylation 1664:1676 arg1 N48 N48 N48 Based on these data we propose that glycosylation at N48 is critical for the localization, function and oligomerization of hENT1. 15474009 0 23 gly N-glycosylation 0:14 arg1 the Asn-Xaa-Cys motif Cys motif Cys motif N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin. 15474009 0 23 gly N-glycosylation 0:14 arg2 491 Asn(491) Asn(491) N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin. 15474009 0 23 gly N-glycosylation 0:14 arg1 491 Asn(491) Asn(491) N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin. 15474009 0 23 gly N-glycosylation 0:14 arg2 Asn Asn(491) Asn(491) N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin. 15474009 0 23 gly N-glycosylation 0:14 arg1 491 Asn(491) Asn(491) N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin. 15474009 0 23 gly N-glycosylation 0:14 arg2 Asn Asn(491) Asn(491) N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin. 15474009 0 23 gly N-glycosylation 0:14 arg2 Asn Asn(491) Asn(491) N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin. 17823199 8 32 part_of glycoprotein 1426:1437 arg1 acceptor sequons glycoprotein acceptor sequons Fterm glycoprotein In addition, we noticed a selective underglycosylation of N-glycosylation sites, indicating preferential glycosylation of acceptor sequons of a given glycoprotein. 8070391 7 52 gly glycoprotein 980:991 arg1 this receptor this receptor Fterm receptor Complete deglycosylation with N-glycosidase caused a shift to 45 kDa, demonstrating that this receptor is an N-linked glycoprotein and agreeing with the protein size and single glycosylation site predicted from the cloned complementary DNA sequence. 8070391 7 52 gly glycoprotein 980:991 arg1 an N-linked glycoprotein an N-linked glycoprotein Fterm glycoprotein Complete deglycosylation with N-glycosidase caused a shift to 45 kDa, demonstrating that this receptor is an N-linked glycoprotein and agreeing with the protein size and single glycosylation site predicted from the cloned complementary DNA sequence. 8070391 7 55 gly glycosylation 1039:1051 arg2 single glycosylation site single glycosylation site site Complete deglycosylation with N-glycosidase caused a shift to 45 kDa, demonstrating that this receptor is an N-linked glycoprotein and agreeing with the protein size and single glycosylation site predicted from the cloned complementary DNA sequence. 22885023 6 14 gly glycosylation 739:751 arg2 the glycosylation site the glycosylation site site Disulfide bridges in native γ3-hordein were almost the same as those found in wheat γ46-gliadin, except the bridge involving the cysteine included in the glycosylation site. 2868718 8 16 gly glycosylation 744:756 arg2 One glycosylation site One glycosylation site site One glycosylation site was found 21 residues from the amino terminus, and no stop codons were found. 28060516 5 82 gly glycosylation 1030:1042 arg2 glycosylation site microheterogeneity glycosylation site microheterogeneity site We performed two semiquantitative analyses including MALDI-TOF MS permethylation analysis of released glycans and LC-MSE analysis of glycosylation site microheterogeneity. 10588947 4 78 part_of containing 616:625 arg1 A 70-amino acid peptide AND three sites A 70-amino acid peptide three sites sites A 70-amino acid peptide containing three sites for N-linked glycosylation was appended to the C-terminus of apoB-50 (amino-terminal 50% of apoB) and expressed in both hepatic and nonhepatic cell lines. 21674342 7 75 gly glycoprotein 1337:1348 arg1 the HIV-1 envelope glycoprotein gp120 the HIV-1 envelope glycoprotein gp120 Fterm glycoprotein This approach has been applied to the solid-phase synthesis of the N-linked high mannose glycosylated form of peptide T (ASTTTNYT), a fragment of the HIV-1 envelope glycoprotein gp120. 21674342 7 79 gly glycosylated 1261:1272 arg1 the N-linked high mannose glycosylated form fragment the N-linked high mannose glycosylated form fragment This approach has been applied to the solid-phase synthesis of the N-linked high mannose glycosylated form of peptide T (ASTTTNYT), a fragment of the HIV-1 envelope glycoprotein gp120. 9774483 11 35 part_of sites 2047:2051 arg1 NCAM NCAM sites PUBTATOR Site NCAM 4684 sites These results suggest that polysialylation of NCAM is influenced by the difference between PST and STX in their preference for N-glycosylation sites on NCAM. 8626443 4 9 gly N-glycosylation 749:763 arg2 the potential N-glycosylation sites the potential N-glycosylation sites sites Several ACET variants carrying mutations in one or more of the potential N-glycosylation sites were used to examine the role of glycosylation at specific sites on ACET synthesis, transport to the cell surface, cleavage processing, and enzyme activity. 23766031 1 12 gly glycosylation 220:232 arg2 a single-conserved N-linked glycosylation site a single-conserved N-linked glycosylation site site The interactions of IgG Fc region with Fc receptors are optimized by the tailoring of a single-conserved N-linked glycosylation site at Asn-297. 22674976 7 54 gly glycosylation 1477:1489 arg2 a specific glycosylation site a specific glycosylation site site We found that the loss of protective efficacy observed with FW/50 was associated with the presence of a specific glycosylation site. 20622017 6 63 gly observed 883:890 arg1 a single site AND Up to 15 different glycans a single site Up to 15 different glycans site Up to 15 different glycans were observed at a single site, with site-specific variation in glycan composition. 23422691 2 35 part_of contains 292:299 arg1 VEGF AND one N-glycosylation site VEGF one N-glycosylation site PUBTATOR Site VEGF 7422 site VEGF is a homodimeric glycoprotein that contains one N-glycosylation site. 23422691 2 35 part_of contains 292:299 arg1 a homodimeric glycoprotein AND one N-glycosylation site a homodimeric glycoprotein one N-glycosylation site Fterm Site glycoprotein site VEGF is a homodimeric glycoprotein that contains one N-glycosylation site. 25456591 3 3 gly O-glycopeptides 738:752 arg2 the corresponding intact O-glycopeptides the corresponding intact O-glycopeptides O-glycopeptides From the same sample concurrently prepared without β-elimination, the corresponding intact O-glycopeptides were mapped by accurate precursor ion mass using an in-house glycan database majorly composed of GalNAc (mucin-type) core and the retention-time shift (ΔRt). 21248038 0 57 gly glycoprotein 88:99 arg1 the HIV-1 envelope glycoprotein the HIV-1 envelope glycoprotein Fterm glycoprotein The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. 21248038 0 88 gly glycosylation 32:44 arg2 an N-linked glycosylation site an N-linked glycosylation site site The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. 32110292 8 47 gly N-glycopeptides 1557:1571 arg2 IgG3 and IgG4 intact N-glycopeptides IgG3 and IgG4 intact N-glycopeptides N-glycopeptides This comprehensive glycosylation analysis strategy for the first time allows the discrimination of IgG3 and IgG4 intact N-glycopeptides with high similarity in sequence without the antibody-based pre-separation. 12930842 6 54 gly IFN-alpha 882:890 arg1 IFN-alpha(psi2) transcripts IFN-alpha IFN-alpha(psi2) transcripts PUBTATOR IFN-alpha 111654 IFN-alpha(psi2) transcripts are the most abundant IFN-alpha transcripts detected in several mouse organs in the absence of viral infection. 18282281 0 50 gly O-glycosylation 25:39 arg2 mucin-type O-glycosylation sites mucin-type O-glycosylation sites sites Prediction of mucin-type O-glycosylation sites in mammalian proteins using the composition of k-spaced amino acid pairs. 2457333 1 3 gly heterogeneity 174:186 arg1 glycopeptides glycopeptides glycopeptides Plasma desorption mass spectrometry (PD-MS) was used to assess the molecular weight heterogeneity of glycopeptides (6-12 amino acids) from each of the three N-linked glycosylation sites of bovine fetuin (R.G. Spiro (1962) J. Biol. 2457333 1 8 gly glycopeptides 191:203 arg2 glycopeptides glycopeptides glycopeptides Plasma desorption mass spectrometry (PD-MS) was used to assess the molecular weight heterogeneity of glycopeptides (6-12 amino acids) from each of the three N-linked glycosylation sites of bovine fetuin (R.G. Spiro (1962) J. Biol. 2457333 1 85 gly glycosylation 256:268 arg1 bovine fetuin fetuin sites Fterm fetuin sites Plasma desorption mass spectrometry (PD-MS) was used to assess the molecular weight heterogeneity of glycopeptides (6-12 amino acids) from each of the three N-linked glycosylation sites of bovine fetuin (R.G. Spiro (1962) J. Biol. 2846759 1 47 part_of sequence 324:331 arg1 sequences sequence sequences sequences We present the nucleotide sequence of the glycoprotein H (gH) gene of herpesvirus saimiri (HVS), a representative of the T lymphotropic herpesviruses of New World monkeys, and compare the predicted amino acid sequence with sequences of homologous proteins from four human herpesviruses. 2846759 1 93 part_of proteins 362:369 arg1 sequences proteins sequences Fterm Site proteins sequences We present the nucleotide sequence of the glycoprotein H (gH) gene of herpesvirus saimiri (HVS), a representative of the T lymphotropic herpesviruses of New World monkeys, and compare the predicted amino acid sequence with sequences of homologous proteins from four human herpesviruses. 32168410 1 47 part_of containing 203:212 arg1 The protective/inhibitory B subunits AND two N-glycosylation sites The protective/inhibitory B subunits two N-glycosylation sites Fterm Site subunits sites BACKGROUND: The protective/inhibitory B subunits of coagulation factor XIII (FXIII-B) is a ~80 kDa glycoprotein containing two N-glycosylation sites. 32168410 1 47 part_of containing 203:212 arg1 a ~80 kDa glycoprotein AND two N-glycosylation sites a ~80 kDa glycoprotein two N-glycosylation sites Fterm Site glycoprotein sites BACKGROUND: The protective/inhibitory B subunits of coagulation factor XIII (FXIII-B) is a ~80 kDa glycoprotein containing two N-glycosylation sites. 26773038 3 24 gly Glycosylation 409:421 arg2 N1574 N1574 N1574 Glycosylation at N1574 has previously been suggested to modulate VWF A2 domain interaction with ADAMTS13 through steric hindrance by the bulky carbohydrate structure. 19874459 11 8 gly glycosylation 1624:1636 arg1 VWF functions VWF functions PUBTATOR VWF 7450 In conjunction with current models explaining VWF activity, knowledge of the complete O-glycome will facilitate research aimed at providing a better understanding of the influence of glycosylation on VWF functions. 1847449 4 13 gly glycosylation 757:769 arg2 the glycosylation site the glycosylation site site All mutants except the one that contains a single mutation at the glycosylation site were cleaved, although not completely, demonstrating that a series of basic amino acids confers susceptibility to cellular cleavage enzymes among human influenza virus HAs. 31572358 7 133 gly N-glycosylated 1265:1278 arg1 the variable domain Remarkably, ACPA domain PUBTATOR Remarkably, ACPA 5657 domain Remarkably, ACPA-IgG are heavily N-glycosylated in the variable domain due to somatic mutations that generate abundant N-glycosylation consensus sequences. 10731668 2 38 gly attached 405:412 arg2 an atypical N-glycosylation consensus sequence AND one oligosaccharide chain an atypical N-glycosylation consensus sequence one oligosaccharide chain sequence We have found that the CHO sEGFR contains one oligosaccharide chain attached to an atypical N-glycosylation consensus sequence, Asn(32 )-X( 33 )-Cys(34 ). 10731668 2 32 gly contains 370:377 arg1 the CHO sEGFR AND one oligosaccharide chain the CHO sEGFR one oligosaccharide chain PUBTATOR CHO sEGFR P00533 We have found that the CHO sEGFR contains one oligosaccharide chain attached to an atypical N-glycosylation consensus sequence, Asn(32 )-X( 33 )-Cys(34 ). 8509412 10 45 gly glycosylation 1486:1498 arg2 a new glycosylation site a new glycosylation site site Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface. 8509412 10 57 gly unglycosylated 1537:1550 arg1 the unglycosylated mutated transferrin receptor the unglycosylated mutated transferrin receptor PUBTATOR transferrin receptor 7018 Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface. 8509412 10 20 gly glycosylation 1693:1705 arg1 this receptor receptor region Fterm receptor region Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface. 8509412 10 87 gly glycosylation 1693:1705 arg1 this region region region Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface. 8509412 10 87 gly glycosylation 1693:1705 arg1 this region receptor region Fterm receptor region Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface. 2106365 5 35 gly glycosylation 507:519 arg2 the glycosylation site the glycosylation site site The 4 hydrophobic membrane spanning domains and the glycosylation site are conserved. 8806496 1 61 part_of contains 212:219 arg1 The flavivirus nonstructural glycoprotein NS1 AND two N-linked glycosylation sites The flavivirus nonstructural glycoprotein NS1 two N-linked glycosylation sites PUBTATOR Site NS1 10625 sites The flavivirus nonstructural glycoprotein NS1 is highly conserved and contains two N-linked glycosylation sites which are both utilized for addition of oligosaccharides during replication in cell culture. 29069609 9 96 part_of IgG1 1504:1507 arg1 IgG1 glycopeptides IgG1 IgG1 glycopeptides OGER Site IgG1 P01857 glycopeptides 21 glycoforms of IgG1 glycopeptides were identified including two truncated structures that are rarely reported. 8357534 4 44 gly contain 715:721 arg1 the isoforms E-3 and C-3 AND exclusively truncated, oligomannose-type chains isoforms positions exclusively truncated, oligomannose-type chains Fterm isoforms positions In contrast, the isoforms E-3 and C-3, the major forms of elastase and cathepsin G respectively, contain exclusively truncated, oligomannose-type chains at the same positions in the sequence of each protein. 8357534 4 44 gly contain 715:721 arg1 C-3 AND exclusively truncated, oligomannose-type chains E-3 and C-3 positions exclusively truncated, oligomannose-type chains PUBTATOR E-3 and C-3 P01024 positions In contrast, the isoforms E-3 and C-3, the major forms of elastase and cathepsin G respectively, contain exclusively truncated, oligomannose-type chains at the same positions in the sequence of each protein. 8357534 4 44 gly contain 715:721 arg1 E-3 AND exclusively truncated, oligomannose-type chains E-3 and C-3 positions exclusively truncated, oligomannose-type chains PUBTATOR E-3 and C-3 P01024 positions In contrast, the isoforms E-3 and C-3, the major forms of elastase and cathepsin G respectively, contain exclusively truncated, oligomannose-type chains at the same positions in the sequence of each protein. 8357534 4 44 gly contain 715:721 arg1 E-3 AND exclusively truncated, oligomannose-type chains E-3 and C-3 positions exclusively truncated, oligomannose-type chains PUBTATOR E-3 and C-3 P01024 positions In contrast, the isoforms E-3 and C-3, the major forms of elastase and cathepsin G respectively, contain exclusively truncated, oligomannose-type chains at the same positions in the sequence of each protein. 12235182 2 79 gly glycosylation 456:468 arg2 the single glycosylation site the single glycosylation site site Substituting Asn residue with Gln at the single glycosylation site within apoB-17 (N(158)) decreased its secretion efficiency to a level equivalent to that of wild-type apoB-17 treated with tunicamycin, but had little effect on its synthesis or intracellular distribution. 24527708 6 15 part_of proteins 1113:1120 arg1 nine sites proteins nine sites Fterm Site proteins sites Among the novel-type sites, nine sites from eight proteins, which were simultaneously identified via PNGase F and Endo Hf deglycosylation, are believed to possess high confidence. 10024532 4 52 gly fragment 546:553 arg1 The oligosaccharides fragment The oligosaccharides fragment The oligosaccharides of the Fab fragment were released by digestion with various endo- and exoglycosidases and analysed by anion-exchange chromatography and fluorophore-assisted carbohydrate electrophoresis. 22239659 4 3 gly N-glycopeptide 723:736 arg2 N-glycopeptide MS/MS spectra N-glycopeptide MS/MS spectra N-glycopeptide A glycan database search program, GlycoPeptideSearch, was developed to match N-glycopeptide MS/MS spectra with the glycopeptides comprised of a glycan drawn from the GlycomeDB glycan structure database and a peptide from a user-specified set of potentially glycosylated peptides. 22239659 4 46 gly glycopeptides 761:773 arg2 the glycopeptides the glycopeptides glycopeptides A glycan database search program, GlycoPeptideSearch, was developed to match N-glycopeptide MS/MS spectra with the glycopeptides comprised of a glycan drawn from the GlycomeDB glycan structure database and a peptide from a user-specified set of potentially glycosylated peptides. 22239659 4 51 gly glycosylated 903:914 arg1 potentially glycosylated peptides potentially glycosylated peptides peptides A glycan database search program, GlycoPeptideSearch, was developed to match N-glycopeptide MS/MS spectra with the glycopeptides comprised of a glycan drawn from the GlycomeDB glycan structure database and a peptide from a user-specified set of potentially glycosylated peptides. 28257906 6 58 part_of STS 1015:1017 arg1 the 5' region STS the 5' region OGER Site STS P08842 region CpG117 and CpG92 were detected within the 5' region of the human STS and ARSD genes, respectively, and miR-205 within the 3'-UTR for the human STS gene, using bioinformatic methods A proposal is described for a primordial invertebrate STS-like gene serving as an ancestor for unequal cross over events generating the gene complex on the eutherian mammalian X-chromosome. 20795641 5 34 gly glycopeptides 813:825 arg2 glycopeptides glycopeptides glycopeptides The strategy includes periodate oxidation of tryptic digests, solid-phase enrichment of glycopeptides via hydrazide-coupled magnetic beads, in conjunction with (18)O stable isotope labeling catalyzed by both trypsin and PNGaseF, and subsequent identification and quantitation by LC-MS/MS analysis. 25324212 0 42 gly glycopeptides 119:131 arg2 tumor-associated mucin glycopeptides tumor-associated mucin glycopeptides glycopeptides Delineating binding modes of Gal/GalNAc and structural elements of the molecular recognition of tumor-associated mucin glycopeptides by the human macrophage galactose-type lectin. 11258925 3 28 gly glycosylation 348:360 arg2 the glycosylation site analysis COX-2 site PUBTATOR COX-2 4513 site This paper reports on the glycosylation site analysis of recombinant COX-2 using matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) and nanoelectrospray (nanoESI) quadrupole-TOF (Q-TOF) MS. The nanoESI MS analysis of COX-2 revealed the presence of three glycoforms at average molecular masses of 71.4, 72.7, and 73.9 kDa. 10211957 5 24 part_of site 769:772 arg1 the E1 glycoprotein glycoprotein site Fterm Site glycoprotein site In this work, the unused glycosylation site on the E1 glycoprotein was identified and the influence of N-linked glycosylation on the formation of the HCV glycoprotein complex was studied by expressing a panel of E1 glycosylation mutants in HepG2 cells. 22122935 4 78 gly glycopeptides 773:785 arg2 O(126) and N(83) glycopeptides O(126) and N(83) glycopeptides N(83) glycopeptides O(126) and N(83) glycopeptides were extensively characterized. 12765790 0 49 gly polysialylated 56:69 arg1 bovine polysialylated NCAM bovine polysialylated NCAM PUBTATOR NCAM 17967 Localization of defined carbohydrate epitopes in bovine polysialylated NCAM. 25707740 7 19 part_of contains 791:798 arg1 The hCG β-subunit AND four sites β-subunit sites Fterm Site β-subunit sites The hCG β-subunit contains two sites of N-glycosylation and four sites of O-glycosylation and is encoded by a cluster of genes (CGB). 28443077 1 38 gly N-glycosylation 452:466 arg2 N-glycosylation site profile (HA) site Cterm (HA) site Increasing evidence suggests that the antigenic change occasionally occurred concomitant with the alterations of the N-glycosylation site profile and hemagglutination activity of the virion surface protein hemagglutinin (HA). 28443077 1 38 gly N-glycosylation 452:466 arg2 N-glycosylation site profile hemagglutinin site Fterm hemagglutinin site Increasing evidence suggests that the antigenic change occasionally occurred concomitant with the alterations of the N-glycosylation site profile and hemagglutination activity of the virion surface protein hemagglutinin (HA). 30011186 17 81 gly glycoprotein 3449:3460 arg1 glycoprotein functions glycoprotein functions Fterm glycoprotein These methods will have extensive applications in the fields of biology and biomedicine, which will lead to a better understanding of glycoprotein functions and the molecular mechanisms of diseases. 7609736 10 16 gly glycosylation 1041:1053 arg1 the gamma-chain the gamma-chain Fterm gamma-chain The glycosylation pattern of the gamma-chain differs from that of the lambda-chain. 22815146 7 38 gly N-glycosylation 1309:1323 arg2 predicted N-glycosylation sites predicted N-glycosylation sites sites These results were further confirmed in a reverse genetics system where syngeneic viruses varying only by predicted N-glycosylation sites at either N142 or N144 exhibited distinct antigenic characteristics like those observed in field isolates. 20512925 3 21 part_of RAGE 423:426 arg1 the V-domain RAGE the V-domain PUBTATOR Site RAGE Q15109 V-domain We earlier showed that carboxylated glycans on the V-domain of RAGE promote the binding of HMGB1 and S100A8/A9. 22642577 1 7 gly glycoprotein 87:98 arg1 The glycoprotein HA The glycoprotein HA Fterm glycoprotein The glycoprotein HA (haemagglutinin) on the surface of influenza A virus plays a central role in recognition and binding to specific host cell-surface glycan receptors and in fusion of viral membrane to the host nuclear membrane during viral replication. 26873173 6 10 part_of Hp 907:908 arg1 glycosylation site Hp glycosylation site Cterm Site Hp 3240 site In this mini review, we provided a brief overview of Hp structure and biological function, discussed its glycosylation alterations in different cancers, and described the existing technologies for analyzing glycosylation site and glycan of Hp. 2456913 10 26 part_of TSH 1407:1409 arg1 the individual glycosylation sites TSH the individual glycosylation sites OGER Site TSH sites The present study demonstrates that the early processing of oligosaccharides differs at the individual glycosylation sites of TSH and free alpha-subunits, perhaps because of local conformational differences. 2456913 10 50 part_of alpha-subunits 1420:1433 arg1 the individual glycosylation sites alpha-subunits the individual glycosylation sites Fterm Site alpha-subunits sites The present study demonstrates that the early processing of oligosaccharides differs at the individual glycosylation sites of TSH and free alpha-subunits, perhaps because of local conformational differences. 10593916 1 37 gly glycosylation 281:293 arg2 a glycosylation site a glycosylation site site The mechanisms by which antigenic peptides bearing a glycosylation site may be processed from viral glycoproteins, post-translationally modified, and presented by major histocompatibility complex class I molecules remain poorly understood. 10593916 1 65 gly glycoproteins 328:340 arg1 viral glycoproteins viral glycoproteins Fterm glycoproteins The mechanisms by which antigenic peptides bearing a glycosylation site may be processed from viral glycoproteins, post-translationally modified, and presented by major histocompatibility complex class I molecules remain poorly understood. 26018173 15 103 gly glycans 2739:2745 arg1 the natural membrane envelope glycoproteins glycoproteins glycans Fterm glycoproteins Our results provide a detailed characterization of the glycans on the natural membrane envelope glycoproteins of HIV-1, a carbohydrate profile that would be desirable to mimic with a vaccine. 26018173 15 138 gly glycoproteins 2780:2792 arg1 the natural membrane envelope glycoproteins glycoproteins a carbohydrate profile Fterm glycoproteins Our results provide a detailed characterization of the glycans on the natural membrane envelope glycoproteins of HIV-1, a carbohydrate profile that would be desirable to mimic with a vaccine. 9774483 3 87 gly attached 659:666 arg1 NCAM AND N-glycans NCAM N-glycans PUBTATOR NCAM 4684 We first examined whether PST and STX differ in the requirement of sialic acid and core structures of N-glycans attached to NCAM. 7685769 0 25 gly glycoforms 127:136 arg1 recombinant human granulocyte colony-stimulating factor recombinant human granulocyte colony-stimulating factor OGER granulocyte colony-stimulating factor P09919 Glycosidase digestion, electrophoresis and chromatographic analysis of recombinant human granulocyte colony-stimulating factor glycoforms produced in Chinese hamster ovary cells. 23829323 5 55 gly sequences 1119:1127 arg1 peptide-glycan pairs sequences peptide-glycan pairs sequences We implement a computational strategy that takes advantage of the properties of CID fragmentation spectra of N-glycopeptides, matching the MS/MS spectra to peptide-glycan pairs from protein sequences and glycan structure databases. 23829323 5 73 gly N-glycopeptides 1038:1052 arg2 N-glycopeptides N-glycopeptides N-glycopeptides We implement a computational strategy that takes advantage of the properties of CID fragmentation spectra of N-glycopeptides, matching the MS/MS spectra to peptide-glycan pairs from protein sequences and glycan structure databases. 29752426 9 41 gly glycosylation 1475:1487 arg2 a novel glycosylation site a novel glycosylation site site To further lower this risk, we introduced a novel glycosylation site into the heparin-binding loop. 1567356 0 6 part_of glycoprotein 63:74 arg1 the five glycosylation sites glycoprotein the five glycosylation sites Fterm Site glycoprotein sites Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein. 7532209 7 63 gly occupancy 1534:1542 arg2 at least one N-glycosylation site at least one N-glycosylation site site These results demonstrate that occupancy of at least one N-glycosylation site is required for the formation and maintenance of the GluR alpha 2 subunit protein in an active conformation for ligand binding. 7532209 7 90 gly N-glycosylation 1560:1574 arg2 at least one N-glycosylation site at least one N-glycosylation site site These results demonstrate that occupancy of at least one N-glycosylation site is required for the formation and maintenance of the GluR alpha 2 subunit protein in an active conformation for ligand binding. 31511323 7 76 gly nonglycosylated 1148:1162 arg1 The nonglycosylated variant The nonglycosylated variant Fterm variant The nonglycosylated variant reached the cell surface by bypassing the Golgi compartment at a rate of only approximately one-third of that of WT β2. 15538777 9 26 gly glycoproteins 2188:2200 arg1 total serum glycoproteins total serum glycoproteins Fterm glycoproteins The strategy, isolation of glycopeptides followed by MS(n) analysis, efficiently characterized the structures of beta2-glycoprotein I with four N-glycosylation sites and was applied to an analysis of total serum glycoproteins. 15538777 9 38 gly beta2-glycoprotein 2089:2106 arg1 beta2-glycoprotein I beta2-glycoprotein I OGER beta2-glycoprotein I P02749 The strategy, isolation of glycopeptides followed by MS(n) analysis, efficiently characterized the structures of beta2-glycoprotein I with four N-glycosylation sites and was applied to an analysis of total serum glycoproteins. 15538777 9 48 gly glycopeptides 2003:2015 arg2 glycopeptides glycopeptides glycopeptides The strategy, isolation of glycopeptides followed by MS(n) analysis, efficiently characterized the structures of beta2-glycoprotein I with four N-glycosylation sites and was applied to an analysis of total serum glycoproteins. 15538777 9 76 gly N-glycosylation 2120:2134 arg2 four N-glycosylation sites four N-glycosylation sites sites The strategy, isolation of glycopeptides followed by MS(n) analysis, efficiently characterized the structures of beta2-glycoprotein I with four N-glycosylation sites and was applied to an analysis of total serum glycoproteins. 7755594 6 80 part_of Asn-25 1018:1023 arg1 IFN-gamma IFN-gamma Asn-25 PUBTATOR SpecificSite IFN-gamma 3458 Asn-25 The glycan residues of IFN-gamma, especially at Asn-25, play an important role in protease resistance. 8349699 7 45 gly N-glycosylation 1047:1061 arg2 an additional site PGH synthase-2 site PUBTATOR PGH synthase-2 19225 site Using site-directed mutagenesis, we determined that there is an additional site of N-glycosylation in murine PGH synthase-2 located at Asn580. 8631761 4 67 gly glycosylation 744:756 arg2 this glycosylation site this glycosylation site site The amino acid sequence of this glycosylation site agreed with the suggested consensus sequence Cys-Xaa-Xaa-Gly-Gly-Ser/Thr-Cys described for other proteins. 20936810 0 77 gly glycosylation 40:52 arg1 Pin WW folding kinetics Pin WW folding kinetics PUBTATOR Pin 8655 Context-dependent effects of asparagine glycosylation on Pin WW folding kinetics and thermodynamics. 11015576 7 5 part_of receptor 1121:1128 arg1 the receptor domain structure of the receptor the receptor domain Fterm Site structure of the receptor domain The amino acid exchange itself most probably has no impact on the three-dimensional structure of the receptor domain, suggesting that the phenotype is the result of altered receptor glycosylation and its pathophysiological consequences. 20053750 2 70 gly residue 428:434 arg1 an N-linked glycan residue 173 an N-linked glycan residue 173 We recently found that in addition to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second receptor-binding site covered by an N-linked glycan at residue 173, which is near the region of the second receptor-binding site identified in Newcastle disease virus (NDV) HN (I. A. Alymova, G. Taylor, V. P. Mishin, M. Watanabe, K. G. Murti, K. Boyd, P. Chand, Y. S. Babu, and A. Portner, J. Virol. 23829323 2 23 gly glycopeptides 473:485 arg2 glycopeptides glycopeptides glycopeptides Direct analysis of protein N-glycosylation by tandem mass spectrometry of glycopeptides promises site-specific elucidation of N-glycan microheterogeneity, something that detached N-glycan and deglycosylated peptide analyses cannot provide. 11230989 4 67 part_of LHbeta 663:668 arg1 the mutated LHbeta peptide LHbeta the mutated LHbeta peptide PUBTATOR Site LHbeta 3972 peptide Of the two point mutations, Trp(8)Arg and Ile(15)Thr, the first one is mainly responsible for the altered immunoreactivity and the latter one introduces an extra glycosylation site into Asn(13) of the mutated LHbeta peptide. 25501675 0 84 gly glycoprotein 77:88 arg1 glycoprotein therapeutics glycoprotein therapeutics Fterm glycoprotein Direct site-specific glycoform identification and quantitative comparison of glycoprotein therapeutics: imiglucerase and velaglucerase alfa. 12237433 9 88 gly glycosylation 1236:1248 arg2 a new glycosylation site a new glycosylation site site The substitution D126N, creating a new glycosylation site, was accompanied by an increase in the sensitivity of the mutants to normal mouse serum inhibitors. 17707131 5 27 part_of containing 906:915 arg1 recombinant AGPAT1 AND potential glycosylation site recombinant AGPAT1 potential glycosylation site PUBTATOR Site AGPAT1 10554 site The topology of motifs I and III was confirmed by experiments with recombinant AGPAT1 containing potential glycosylation site near the motifs. 26873173 5 6 gly fucosylated 597:607 arg1 aberrantly fucosylated and sialylated structures aberrantly fucosylated and sialylated structures The main glycosylation alterations of Hp in cancer appear to be the presence of aberrantly fucosylated and sialylated structures as well as increased branching. 26873173 5 49 gly sialylated 613:622 arg1 aberrantly fucosylated and sialylated structures aberrantly fucosylated and sialylated structures The main glycosylation alterations of Hp in cancer appear to be the presence of aberrantly fucosylated and sialylated structures as well as increased branching. 9427707 8 3 part_of IXa 1830:1832 arg1 a factor IXa interaction site factor IXa a factor IXa interaction site Cterm Site factor IXa site To evaluate interaction of FVIII with factor IXa, we performed an inhibition assay using a synthetic peptide corresponding to FVIII residues 558 to 565, previously shown to be a factor IXa interaction site. 9427707 8 43 part_of factor 1823:1828 arg1 a factor IXa interaction site factor IXa a factor IXa interaction site Cterm Site factor IXa site To evaluate interaction of FVIII with factor IXa, we performed an inhibition assay using a synthetic peptide corresponding to FVIII residues 558 to 565, previously shown to be a factor IXa interaction site. 9427707 8 45 part_of FVIII 1771:1775 arg1 FVIII residues 558 to 565 FVIII FVIII residues 558 to 565 PUBTATOR SpecificSite FVIII 2157 residues 558 To evaluate interaction of FVIII with factor IXa, we performed an inhibition assay using a synthetic peptide corresponding to FVIII residues 558 to 565, previously shown to be a factor IXa interaction site. 10992007 8 95 gly glycosylation 1332:1344 arg2 four glycosylation sites four glycosylation sites sites However, the mutants with four glycosylation sites were fully functional in terms of TSH binding and cAMP production, although the expression levels were 30 to 40% of that in wild-type TSHR. 15538777 0 103 gly glycopeptides 84:96 arg2 glycopeptides glycopeptides glycopeptides Hydrophilic affinity isolation and MALDI multiple-stage tandem mass spectrometry of glycopeptides for glycoproteomics. 10551860 11 93 gly glycosylation 1951:1963 arg2 this glycosylation site this glycosylation site site When this glycosylation site was eliminated (HelB/N104Q mutation), the mutant lacked cyclooxygenase activity. 3121328 5 6 gly carries 805:811 arg1 Asn-117 AND the oligomannose type Asn-117 the oligomannose type Asn-117 Asn-117 carries the oligomannose type of glycan, the structure of which was completely determined. 23365085 5 27 gly glycosylation 869:881 arg2 potential glycosylation sites potential glycosylation sites sites We have compared wild-type and reverse-engineered A(H1N1)pdm IAV with differing potential glycosylation sites on HA for sensitivity to collectins and to neutralizing Abs. 8765170 10 10 gly glycosylation 1810:1822 arg2 an N-linked glycosylation site an N-linked glycosylation site site Thus, production of scFv with binding activity is not sufficient for good inhibition of gene expression although introduction of an N-linked glycosylation site is beneficial. 29562594 3 77 gly N-glycosylation 640:654 arg2 one N-glycosylation site one N-glycosylation site site Fc-fused capillary morphogenesis protein 2 (CMG2-Fc) containing one N-glycosylation site on the Fc domain, produced in Nicotiana benthamiana whole plants, served as a model protein. 16622833 2 67 part_of A1PI 270:273 arg1 The three N-glycosylation sites A1PI The three N-glycosylation sites PUBTATOR Site A1PI 5265 sites The three N-glycosylation sites of A1PI contain diantennary N-glycans but also triantennary and even traces of tetraantennary structures leading to the typical IEF pattern observed for A1PI. 17521730 6 57 gly N-glycosylation 1093:1107 arg2 one potential N-glycosylation site one potential N-glycosylation site site Cloned cDNA encoding Art v 2 contains 140 bp that codify for a polypeptide of 15.8 kDa, with a predicted pI value of 5.2, and one potential N-glycosylation site. 8068684 6 4 gly utilized 1162:1169 arg2 Asn 75 Asn 75 Asn 75 Immunoblot analysis of the expressed proteins with and without N-glycosidase F treatment showed that only the first N-glycosylation site (Asn 75) is utilized. 8068684 6 4 gly utilized 1162:1169 arg2 only the first N-glycosylation site only the first N-glycosylation site site Immunoblot analysis of the expressed proteins with and without N-glycosidase F treatment showed that only the first N-glycosylation site (Asn 75) is utilized. 8068684 6 87 gly N-glycosylation 1129:1143 arg2 Asn 75 Asn 75 Asn 75 Immunoblot analysis of the expressed proteins with and without N-glycosidase F treatment showed that only the first N-glycosylation site (Asn 75) is utilized. 8068684 6 87 gly N-glycosylation 1129:1143 arg2 only the first N-glycosylation site only the first N-glycosylation site site Immunoblot analysis of the expressed proteins with and without N-glycosidase F treatment showed that only the first N-glycosylation site (Asn 75) is utilized. 31356638 3 44 gly NS1 489:491 arg1 the molecular determinants NS1 the molecular determinants OGER NS1 Q9Y6Y0 However, the molecular determinants of NS1 required to trigger EGL disruption and the cellular pathway(s) involved remain unknown. 25759508 0 41 gly O-Glycosylation 13:27 arg1 Human Immunoglobulin G3 Human Immunoglobulin G3 PUBTATOR Human Immunoglobulin G3 3502 Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3). 25759508 0 41 gly O-Glycosylation 13:27 arg1 IgG3 IgG3 PUBTATOR IgG3 P01860 Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3). 17144668 0 29 gly glycosylation 100:112 arg1 carboxylase function carboxylase function Fterm carboxylase Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. 17144668 0 89 gly glycosylation 31:43 arg1 vitamin K-dependent carboxylase carboxylase sites Fterm carboxylase sites Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. 28921966 6 66 gly glycosylation 982:994 arg2 glycosylation site glycosylation site site Remarkably, the glycan patterns, glycosylation site, and their occupancy by N-glycans are all detected and identified in a single experimental procedure. 22200957 5 61 gly N-glycosylation 1004:1018 arg2 a N-glycosylation site a N-glycosylation site site Bioinformatics analysis predicted several phosphorylation and myristoylation sites and a N-glycosylation site and a species-specific linear B epitope in the protein. 25213400 6 80 gly linked 581:586 arg1 MOG AND the glycans MOG the glycans PUBTATOR MOG 4340 Here we review and analyze all published data on the physicochemical structure of the glycans linked to P0, PMP22, MOG, and MAG. 25213400 6 80 gly linked 581:586 arg1 P0 AND the glycans P0 the glycans Cterm P0 Here we review and analyze all published data on the physicochemical structure of the glycans linked to P0, PMP22, MOG, and MAG. 25213400 6 80 gly linked 581:586 arg1 PMP22 AND the glycans PMP22 the glycans PUBTATOR PMP22 5376 Here we review and analyze all published data on the physicochemical structure of the glycans linked to P0, PMP22, MOG, and MAG. 30935958 17 72 gly glycosylation 2227:2239 arg1 position 181 position 181 position 181 We hypothesize that glycosylation of position 181 is a key site for prion strain differentiation in vivo. 15063126 6 1 gly glycoproteins 1097:1109 arg1 gp41 envelope glycoproteins gp41 envelope glycoproteins Fterm glycoproteins A constellation of changes involving both gp120 and gp41 envelope glycoproteins was responsible for the difference in susceptibility to neutralization by most antibodies. 7476998 10 83 gly attached 1605:1612 arg3 the carbohydrate AND Asn60 Asn60 the carbohydrate Asn60 In contrast, the carbohydrate attached at Asn60 was a high mannose structure. 7476998 10 83 gly attached 1605:1612 arg2 a high mannose structure AND Asn60 Asn60 a high mannose structure Asn60 In contrast, the carbohydrate attached at Asn60 was a high mannose structure. 2041080 4 33 gly subunit 765:771 arg1 the oligosaccharide at asparagine 22 subunit the oligosaccharide at asparagine 22 Fterm subunit When the oligosaccharide at asparagine 22 of the HA1 subunit of the hemagglutinin was removed by site-directed mutagenesis of the respective glycosylation site, only three inserted arginines were required to obtain cleavage. 2041080 4 72 gly glycosylation 853:865 arg2 the respective glycosylation site the respective glycosylation site site When the oligosaccharide at asparagine 22 of the HA1 subunit of the hemagglutinin was removed by site-directed mutagenesis of the respective glycosylation site, only three inserted arginines were required to obtain cleavage. 1498098 3 3 gly glycosylation 705:717 arg2 a glycosylation site a glycosylation site site Based on a working hypothesis that tyrosinase-positive oculocutaneous albinism is a consequence of the structurally altered tyrosinase due to a point mutation in the gene of its gene coding for a glycosylation site or a membrane-binding site, which leads to the impairment in the posttranslational modification of tyrosinase and its catalytic activity, we have cloned the tyrosinase gene of one patient affected with tyrosinase-positive oculocutaneous albinism and determined its nucleotide sequence. 12970363 10 5 gly glycosylation 1397:1409 arg2 the e2 glycosylation site the e2 glycosylation site site Elimination of the e2 glycosylation site, missing in the monoglycosylated TRPC3, was sufficient to convert the tightly receptor-regulated TRPC6 into a constitutively active channel, displaying functional characteristics of TRPC3. 12970363 10 21 gly monoglycosylated 1432:1447 arg1 the monoglycosylated TRPC3 the monoglycosylated TRPC3 PUBTATOR TRPC3 7222 Elimination of the e2 glycosylation site, missing in the monoglycosylated TRPC3, was sufficient to convert the tightly receptor-regulated TRPC6 into a constitutively active channel, displaying functional characteristics of TRPC3. 15128311 9 68 gly glycoprotein 1220:1231 arg1 similarly treated deglycosylated glycoprotein similarly treated deglycosylated glycoprotein Fterm glycoprotein The peak corresponding to this peptide appeared in the mass-spectrum of similarly treated deglycosylated glycoprotein. 25213400 11 26 gly contains 1144:1151 arg1 GP4 AND one sialic acid GP4 one sialic acid PUBTATOR GP4 948 The most mannose rich are the glycans MS2 and GP4, each of them has four mannoses; OPPE1 contains five N-acetylglucosamines and one sulfated glucuronic acid; GP4 contains one sialic acid. 8912525 6 26 gly glycosylation 773:785 arg2 one potential glycosylation site one potential glycosylation site site The primary amino acid sequence of ARA indicates that it is 49.5 kDa without glycosylation, and that it has one potential glycosylation site. 26348848 5 53 gly Kv3.1a 938:943 arg1 N-glycans Kv3 N-glycans PUBTATOR Kv3 29731 Total internal reflection fluorescence microscopy images revealed that N-glycans of Kv3.1a contributed to its placement in the cell membrane while N-glycans had no effect on the distribution of Kv1.1. 27377235 1 99 part_of have 204:207 arg1 related voltage-gated potassium channels AND a highly conserved N-linked glycosylation site related voltage-gated potassium channels a highly conserved N-linked glycosylation site Fterm Site channels site Kv1.2 and related voltage-gated potassium channels have a highly conserved N-linked glycosylation site in the first extracellular loop, with complex glycosylation in COS-7 cells similar to endogenous Kv1.2 glycosylation in hippocampal neurons. 27377235 1 99 part_of have 204:207 arg1 Kv1.2 AND a highly conserved N-linked glycosylation site Kv1.2 a highly conserved N-linked glycosylation site Cterm Site Kv1.2 site Kv1.2 and related voltage-gated potassium channels have a highly conserved N-linked glycosylation site in the first extracellular loop, with complex glycosylation in COS-7 cells similar to endogenous Kv1.2 glycosylation in hippocampal neurons. 9223227 5 38 gly N-glycosylation 720:734 arg2 An N-glycosylation site An N-glycosylation site site An N-glycosylation site and five cysteine residues conserved in human, murine and rabbit IL-1ras were also found at the corresponding positions in equine IL-1ra. 9223227 5 38 gly N-glycosylation 720:734 arg2 the corresponding positions the corresponding positions positions An N-glycosylation site and five cysteine residues conserved in human, murine and rabbit IL-1ras were also found at the corresponding positions in equine IL-1ra. 23853575 4 63 gly variants 728:735 arg1 increased glycan surface coverage variants increased glycan surface coverage Fterm variants Whereas two PvDBPII glycosylation variants with increased glycan surface coverage distant from predicted interaction sites had equivalent binding activity to wild-type protein, one of them elicited slightly better DARC-binding-inhibitory activity than wild-type immunogen. 20663928 3 6 part_of Rap 589:591 arg1 the putative N-glycosylation site Rap the putative N-glycosylation site OGER Site Rap P55302 site To enhance its potency and targeted tumor therapy, we describe the generation of a novel IgG-based immunotoxin, designated 2L-Rap(Q)-hRS7, comprising Rap(Q), a mutant Rap with the putative N-glycosylation site removed, and hRS7, an internalizing, humanized antibody against Trop-2, a cell surface glycoprotein overexpressed in variety of epithelial cancers. 20663928 3 29 part_of Rap 572:574 arg1 the putative N-glycosylation site Rap the putative N-glycosylation site OGER Site Rap P55302 site To enhance its potency and targeted tumor therapy, we describe the generation of a novel IgG-based immunotoxin, designated 2L-Rap(Q)-hRS7, comprising Rap(Q), a mutant Rap with the putative N-glycosylation site removed, and hRS7, an internalizing, humanized antibody against Trop-2, a cell surface glycoprotein overexpressed in variety of epithelial cancers. 1651590 5 56 part_of site 856:859 arg1 the F2 subunit subunit site Fterm Site subunit site On the other hand, phenotypes of F1-R that remained unchanged by the revertants were bipolar budding in polarized epithelial cells, enhanced electrophoretic migration of the matrix protein, and the lack of a glycosylation site in the F2 subunit of the F protein. 2451667 1 23 gly glycosylated 193:204 arg1 a small glycosylated secretory protein a small glycosylated secretory protein Fterm protein We carried out experiments designed to generate a novel cell-surface protein from a small glycosylated secretory protein. 8706658 6 73 part_of protein 1172:1178 arg1 the two cysteine residues protein the two cysteine residues Fterm AminoAcid protein cysteine residues The potential N-glycosylation site, two protein kinase C phosphorylation sites, the two cysteine residues, and the putative inhibitor-binding domain (substitutions Thr4l-->Ser and Tyr50-->Phe) were conserved in mouse leukotriene C4 synthase. 8706658 6 73 part_of protein 1172:1178 arg1 two protein kinase C phosphorylation sites protein two protein kinase C phosphorylation sites Fterm Site protein sites The potential N-glycosylation site, two protein kinase C phosphorylation sites, the two cysteine residues, and the putative inhibitor-binding domain (substitutions Thr4l-->Ser and Tyr50-->Phe) were conserved in mouse leukotriene C4 synthase. 12911333 4 54 part_of domains 662:668 arg1 similar relative positions domains similar relative positions positions Kv1 channel S1-S2 linkers vary in length but their N-glycosylation sites are at similar relative positions from the S1 or S2 membrane domains. 16077958 11 63 part_of TCF/LEF 1266:1272 arg1 MYOD and triple TCF/LEF binding sites TCF MYOD and triple TCF/LEF binding sites PUBTATOR Site TCF 3172 sites MYOD and triple TCF/LEF binding sites were conserved between human DKK4 promoter and rodent Dkk4 promoter. 16077958 11 78 part_of MYOD 1250:1253 arg1 MYOD and triple TCF/LEF binding sites MYOD MYOD and triple TCF/LEF binding sites PUBTATOR Site MYOD 4654 sites MYOD and triple TCF/LEF binding sites were conserved between human DKK4 promoter and rodent Dkk4 promoter. 19838169 2 4 gly glycoproteins 168:180 arg1 Sialylated glycoproteins Sialylated glycoproteins Fterm glycoproteins Sialylated glycoproteins were selectively periodate-oxidized, captured on hydrazide beads, trypsinized and released by acid hydrolysis of sialic acid glycosidic bonds. 2846759 7 17 gly glycosylation 1753:1765 arg2 a conserved N-linked glycosylation site a conserved N-linked glycosylation site site Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH. 2846759 7 17 gly glycosylation 1753:1765 arg1 seven or eight residues residues residues Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH. 2846759 7 17 gly glycosylation 1753:1765 arg1 14 or 15 residues residues residues Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH. 2846759 7 17 gly glycosylation 1753:1765 arg2 14 or 15 residues residues residues Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH. 2846759 7 17 gly glycosylation 1753:1765 arg1 14 or 15 residues residues residues Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH. 2846759 7 17 gly glycosylation 1753:1765 arg2 14 or 15 residues residues residues Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH. 2846759 7 17 gly glycosylation 1753:1765 arg2 14 or 15 residues residues residues Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH. 8286753 0 64 gly glycosylation 28:40 arg2 the O-linked glycosylation site the O-linked glycosylation site site Elimination of the O-linked glycosylation site at Thr 104 results in the generation of a soluble human-transferrin receptor. 29273683 11 29 gly sites 1711:1715 arg1 N-glycans sites N-glycans sites Moreover, while glycosylation of N347 in the RCL limits these activities, N-glycans at other sites also appear to protect CBG from neutrophil elastase or chymotrypsin. 29273683 11 13 gly glycosylation 1634:1646 arg1 N347 RCL N347 OGER RCL O43598 N347 Moreover, while glycosylation of N347 in the RCL limits these activities, N-glycans at other sites also appear to protect CBG from neutrophil elastase or chymotrypsin. 17927214 7 64 part_of CI-MPR 1737:1742 arg1 domain 9 CI-MPR domain 9 PUBTATOR Site CI-MPR 3482 domain SPR analyses using these modified GAAs demonstrate that, unlike the CD-MPR or domain 9 of the CI-MPR, domain 5 exhibits a 14-18-fold higher affinity for Man-P-GlcNAc than Man-6-P, implicating this region of the receptor in targeting phosphodiester-containing lysosomal enzymes to the lysosome. 7522502 8 51 gly N-glycosylation 1199:1213 arg2 an N-glycosylation site an N-glycosylation site site A primary sequence analysis showed that each of these polypeptides contains an N-glycosylation site, phosphorylation sites for Ca2+/calmodulin-dependent protein kinase, protein kinase C and casein kinase II, and partial ATP- and GTP-binding sites. 7528012 4 41 part_of protein 521:527 arg1 the amino-terminal protein sequence protein the amino-terminal protein sequence Fterm Site protein sequence A PCR-based approach utilizing primers designed from the amino-terminal protein sequence was used to isolate a full-length cDNA clone from a rat kidney cDNA library. 3594570 0 35 gly glycoproteins 84:96 arg1 the LFA-1, Mac-1, and p150,95 glycoproteins the LFA-1, Mac-1, and p150,95 glycoproteins Fterm glycoproteins Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency. 19358553 4 46 part_of fetuin 1052:1057 arg1 three different sialoglycopeptides fetuin three different sialoglycopeptides Fterm Site fetuin sialoglycopeptides Similarly, precise quantitation was observed for various forms of N-glycans (free, permethylated, and fluorescence-labeled) using MS. In addition, three different sialoglycopeptides from fetuin were site-specifically profiled, and good correlation between peak intensities and relative abundances was found with only a minor loss of sialic acids (r = 0.9664, n = 5). 1989393 2 42 gly glycosylation 277:289 arg2 glycosylation sites glycosylation sites sites Loss of glycosylation sites at amino acids 410 and 447 did not affect the CD4 binding ability of gp 105 even when removed in pair combination. 24475074 1 51 gly glycoprotein 168:179 arg1 glycoprotein folding glycoprotein folding Fterm glycoprotein Protein N-glycosylation is found in all domains of life and has a conserved role in glycoprotein folding and stability. 24475074 1 82 gly N-glycosylation 92:106 arg1 all domains all domains domains Protein N-glycosylation is found in all domains of life and has a conserved role in glycoprotein folding and stability. 15555933 6 12 gly glycosylation 864:876 arg2 the single N-linked glycosylation site the single N-linked glycosylation site site In this form of rhAFP, the single N-linked glycosylation site was removed by mutagenesis (N233Q). 7904345 0 35 gly Glycosylation 0:12 arg1 CD4 CD4 PUBTATOR CD4 24932 Glycosylation of CD4 and Thy-1. 7904345 0 35 gly Glycosylation 0:12 arg1 Thy-1 Thy-1 PUBTATOR Thy-1 24832 Glycosylation of CD4 and Thy-1. 15028666 7 104 part_of HA1 1125:1127 arg1 the HA1 receptor binding site HA1 the HA1 receptor binding site OGER Site HA1 site Sequence analysis of the HA and NA genes identified mutations in conserved residues of the HA1 receptor binding site, in particular Leu-226 --> Ile-226/Val-226, and modification of potential glycosylation site motifs. 23050552 3 16 part_of contain 346:352 arg1 The beta and gamma subunits AND one N-glycosylation site The beta and gamma subunits one N-glycosylation site Fterm Site subunits site The beta and gamma subunits each contain one N-glycosylation site, each of which is occupied by a biantennary N-glycan. 29268168 4 23 part_of found 727:731 arg2 mFcγRIV AND the N162 glycosylation site mFcγRIV the N162 glycosylation site PUBTATOR Site FcγRIV 246256 site Here we report that the N162 glycosylation site is also found in the orthologous mouse FcγR, mFcγRIV. 9442070 4 49 part_of IgA1 639:642 arg1 the IgA1 Fc O-glycosylated hinge region IgA1 Fc the IgA1 Fc O-glycosylated hinge region OGER Site IgA1 Fc P01876 region Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied. 9442070 4 131 part_of Fc 644:645 arg1 the IgA1 Fc O-glycosylated hinge region IgA1 Fc the IgA1 Fc O-glycosylated hinge region OGER Site IgA1 Fc P01876 region Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied. 27884519 4 24 part_of hIL-11 495:500 arg1 the region hIL-11 the region PUBTATOR Site hIL-11 3589 region Modified vectors were constructed by introducing N- or O-glycosylation site on the region of hIL-11 that does not belong to the core α-helical motif based on the predicted secondary structure. 1379602 0 98 part_of desmoglein 69:78 arg1 a keratinocyte-specific extracellular epitope desmoglein a keratinocyte-specific extracellular epitope Fterm Site desmoglein epitope Characterization of a keratinocyte-specific extracellular epitope of desmoglein. 16845803 2 21 gly Nonglycosylated 232:246 arg1 Nonglycosylated pro-UK Nonglycosylated pro-UK pro METHODS: Nonglycosylated pro-UK was constructed by site-directed mutagenesis of Asn302 to Ala302. 7685965 3 40 gly glycosylation 569:581 arg2 a potential glycosylation site a potential glycosylation site site The substitution at residue 63 results in the creation of a potential glycosylation site which occurs outside the boundaries of the T-cell determinants. 1885605 6 54 part_of HBp17 843:847 arg1 proteolytic fragments HBp17 proteolytic fragments PUBTATOR Site HBp17 9982 fragments The deduced primary structure of HBp17 consisted of 234 amino acids including each of five partial peptide sequences obtained from proteolytic fragments of purified HBp17. 2324102 0 87 part_of syndecan 18:25 arg1 Sequence syndecan Sequence PUBTATOR syndecan 6382 Sequence of human syndecan indicates a novel gene family of integral membrane proteoglycans. 27938679 5 3 gly glycosylated 744:755 arg1 sites sites sites To determine which sites were actually glycosylated, we generated mutated SU forms, where each N-glycosylation site was changed to alanine (A). 27938679 5 51 gly N-glycosylation 800:814 arg2 each N-glycosylation site each N-glycosylation site site To determine which sites were actually glycosylated, we generated mutated SU forms, where each N-glycosylation site was changed to alanine (A). 8638940 1 5 gly glycoproteins 205:217 arg1 N-linked glycoproteins N-linked glycoproteins Fterm glycoproteins Glycosylasparaginase (EC 3.5.1.26) is a lysosomal amidase which hydrolyzes the bond between asparagine and the sugar moiety in N-linked glycoproteins. 29162128 7 72 gly glycosylation 1363:1375 arg2 the 11N glycosylation site the 11N glycosylation site site Therefore, our study suggests that the 11N glycosylation site plays a key role in HA cleavage, structural stability and pathogenicity in H5 subtype avian influenza virus. 27489265 3 70 gly it 578:579 arg1 a site a site site Previous studies have shown that the removal of a particular conserved glycan at N197 increases the neutralization sensitivity of the virus to antibodies targeting the CD4 binding site (CD4bs), making it a site of significant interest from the perspective of vaccine design. 27489265 3 75 gly removal 414:420 arg3 a particular conserved glycan AND N197 N197 a particular conserved glycan N197 Previous studies have shown that the removal of a particular conserved glycan at N197 increases the neutralization sensitivity of the virus to antibodies targeting the CD4 binding site (CD4bs), making it a site of significant interest from the perspective of vaccine design. 8496594 7 48 part_of contains 742:749 arg1 The protein AND a hydrophobic transmembrane region The protein a hydrophobic transmembrane region Fterm Site protein region The protein contains a hydrophobic transmembrane region between amino acids 41 and 61 but no N-terminal signal peptide, which suggests that it is a type II membrane protein. 8496594 7 48 part_of contains 742:749 arg1 The protein AND no N-terminal signal peptide The protein no N-terminal signal peptide Fterm Site protein peptide The protein contains a hydrophobic transmembrane region between amino acids 41 and 61 but no N-terminal signal peptide, which suggests that it is a type II membrane protein. 29981279 5 20 gly N-glycosylation 1250:1264 arg2 The N-glycosylation site The N-glycosylation site site The N-glycosylation site in 240th was losen because of mutation. 31296534 7 6 gly hyperglycosylated 1058:1074 arg1 GRP94 GRP94 PUBTATOR GRP94 7184 GRP94 was also hyperglycosylated in wild-type cells treated with ER stress inducers including thapsigargin, dithiothreitol, and NGI-1. 8360166 1 5 part_of terminus 251:258 arg1 a hydrophobic signal sequence terminus a hydrophobic signal sequence sequence Cytochromes P450 are inserted into and anchored to the endoplasmic reticulum (ER) membrane by a hydrophobic signal sequence at the NH2 terminus. 15128311 10 7 gly utilized 1309:1316 arg2 Asn29 Asn29 Asn29 These data show that the potential N-glycosylation site at Asn29 in CX3 is utilized for glycan attachment and that the glycoprotein is glycosylated CX3. 15128311 10 7 gly utilized 1309:1316 arg2 the potential N-glycosylation site the potential N-glycosylation site site These data show that the potential N-glycosylation site at Asn29 in CX3 is utilized for glycan attachment and that the glycoprotein is glycosylated CX3. 15128311 10 15 gly N-glycosylation 1269:1283 arg2 Asn29 Asn29 Asn29 These data show that the potential N-glycosylation site at Asn29 in CX3 is utilized for glycan attachment and that the glycoprotein is glycosylated CX3. 15128311 10 15 gly N-glycosylation 1269:1283 arg2 the potential N-glycosylation site the potential N-glycosylation site site These data show that the potential N-glycosylation site at Asn29 in CX3 is utilized for glycan attachment and that the glycoprotein is glycosylated CX3. 15128311 10 41 gly glycosylated 1369:1380 arg1 the glycoprotein the glycoprotein Fterm glycoprotein These data show that the potential N-glycosylation site at Asn29 in CX3 is utilized for glycan attachment and that the glycoprotein is glycosylated CX3. 15128311 10 44 gly glycoprotein 1353:1364 arg1 the glycoprotein the glycoprotein Fterm glycoprotein These data show that the potential N-glycosylation site at Asn29 in CX3 is utilized for glycan attachment and that the glycoprotein is glycosylated CX3. 3896487 2 22 gly glycopeptides 532:544 arg2 Isolated glycopeptides Isolated glycopeptides glycopeptides Isolated glycopeptides were assigned to the known amino acid sequence of the protein by amino acid analysis and by determination of the NH2-termini. 26853155 8 19 part_of syncytin-2 1616:1625 arg1 the coding sequence syncytin-2 the coding sequence PUBTATOR Site syncytin-2 P60508 sequence We also sequenced the coding sequence of syncytin-2 in 125 severe pre-eclamptic patients and 272 normal pregnant Chinese women. 2456913 1 55 gly glycosylation 250:262 arg2 individual glycosylation sites TSH sites OGER TSH sites We have determined the structures of high mannose (Man) oligosaccharide units at individual glycosylation sites of mouse TSH. 15009203 10 115 gly sialylated 1686:1695 arg1 the N-glycans the N-glycans More than 90% of terminal galactose residues of the N-glycans were found alpha2-3 sialylated with NeuNAc (93%) or NeuNGc (7%). 15009203 10 115 gly sialylated 1686:1695 arg1 terminal galactose residues terminal galactose residues More than 90% of terminal galactose residues of the N-glycans were found alpha2-3 sialylated with NeuNAc (93%) or NeuNGc (7%). 1367433 6 16 part_of t-PA 1238:1241 arg1 asn 117 t-PA asn 117 PUBTATOR SpecificSite t-PA 18791 asn 117 We found that with one exception, all mutant activators lack the high mannose glycan found at asn 117 of native t-PA. 27111718 9 30 gly structures 1721:1730 arg1 glycopeptides glycopeptides glycopeptides Site glycopeptides Hence, GlycoSeq is ready to be used for the characterization of glycan structures in glycopeptides from MS/MS analysis. 27111718 9 61 gly glycopeptides 1735:1747 arg2 glycopeptides glycopeptides glycopeptides Hence, GlycoSeq is ready to be used for the characterization of glycan structures in glycopeptides from MS/MS analysis. 19008394 0 33 gly glycosylated 2:13 arg1 A glycosylated peptide A glycosylated peptide peptide A glycosylated peptide in the West Nile virus envelope protein is immunogenic during equine infection. 8163463 6 50 gly glycosylation 1267:1279 arg2 the consensus glycosylation site the consensus glycosylation site site To test the proposed transmembrane topology model for these receptors, we have used site-specific mutagenesis of the GluR6 subunit to remove the consensus glycosylation site located within the proposed intracellular loop. 11063734 11 59 gly SP-B 1581:1584 arg1 a determinant SP-B a determinant PUBTATOR SP-B 6439 We propose that the SP-B Ile131Thr polymorphism is a determinant for certain SP-A alleles as factors causing genetic susceptibility to RDS (6A(2), 1A(0)) or protection against it (6A(3), 1A(2)). 24806200 0 62 gly glycoprotein 96:107 arg1 glycoprotein hormones glycoprotein hormones PUBTATOR chorionic gonadotropin (hCG) glycoprotein 93659 Chemical synthesis of the β-subunit of human luteinizing (hLH) and chorionic gonadotropin (hCG) glycoprotein hormones. 8354274 4 65 part_of contained 624:632 arg1 The composite cDNA sequence AND a 3' untranslated region region region The composite cDNA sequence contained a 5' untranslated region of 7 bases, an open reading frame of 2019 bases that encoded 673 amino acids, a 3' untranslated region of 2662 bases, and part of a poly(A) tail. 22186995 5 38 gly glycosylation 814:826 arg2 an additional (third) N-linked glycosylation site an additional (third) N-linked glycosylation site site We demonstrate that D49N exerts its deleterious effect by generating an additional (third) N-linked glycosylation site, resulting in protein misfolding and degradation in the killer cell. 19767389 0 5 gly Asparagine-linked 0:16 arg1 Asparagine-linked oligosaccharides Asparagine Asparagine-linked oligosaccharides Asparagine Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies. 19767389 0 60 gly present 35:41 arg2 a non-consensus amino acid sequence AND Asparagine-linked oligosaccharides a non-consensus amino acid sequence Asparagine-linked oligosaccharides sequence Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies. 22355413 3 38 gly glycosite 447:455 arg2 glycosite migration glycosite migration glycosite More importantly, glycosite migration was likely a more effectively alteration way for the host adaption of human influenza H1N1 viruses. 26618514 8 66 gly sialylated 1107:1116 arg1 the sialylated anti-SNEC IgG the sialylated anti-SNEC IgG Cterm anti-SNEC Ig Moreover, the sialylated anti-SNEC IgG was not simply anti-inflammatory, but switched the cytokine secretion profiles from interleukin (IL)-6/IL-8 to tumour necrosis factor (TNF)-α/IL-1β. 20795641 1 58 gly glycoproteins 142:154 arg1 glycoproteins glycoproteins Fterm glycoproteins Global analysis of glycoproteins shows great promise for the discovery of therapeutic targets and clinical biomarkers. 7730329 11 41 part_of TSV-PA 1433:1438 arg1 The sequence TSV-PA The sequence Cterm Site TSV-PA sequence The sequence of TSV-PA exhibits a high degree of sequence identity with other snake venom proteases: 66% with the protein C activator from Agkistrodon contortrix contortrix venom, 63% with batroxobin, and 60% with the factor V activator from Russell's viper venom. 26022737 4 28 part_of PSA 523:525 arg1 This extra glycosylation site PSA This extra glycosylation site PUBTATOR Site PSA P07288 site This extra glycosylation site of PSA is associated with a mutation in KLK3 genes. 9063619 4 7 gly glycoprotein 742:753 arg1 a glycoprotein a glycoprotein Fterm glycoprotein A full understanding of the implications of glycosylation for the structure and function of a protein can only be reached when a glycoprotein is viewed as a single entity. 11931388 1 37 part_of NHE-1 230:234 arg1 rat NHE-1 sequences NHE-1 rat NHE-1 sequences PUBTATOR Site NHE-1 24782 sequences A cDNA for the Mus musculus Na/H exchanger-isoform 1 (NHE-1) was identified in a BALB/c myoblast library by its hybridization to rat NHE-1 sequences. 1736898 0 49 part_of Cysteine 78:85 arg1 Secreted Protein Secreted Protein Cysteine Cterm AminoAcid Secreted Protein P09486 Cysteine Molecular analysis of Xenopus laevis SPARC (Secreted Protein, Acidic, Rich in Cysteine). 1932748 0 35 gly glycoprotein 81:92 arg1 the platelet glycoprotein IIb/IIIa complex the platelet glycoprotein IIb/IIIa complex Fterm glycoprotein Effect of deletion of glycoprotein IIb exon 28 on the expression of the platelet glycoprotein IIb/IIIa complex. 1932748 0 60 gly glycoprotein 22:33 arg1 glycoprotein IIb exon 28 glycoprotein IIb exon 28 Fterm glycoprotein Effect of deletion of glycoprotein IIb exon 28 on the expression of the platelet glycoprotein IIb/IIIa complex. 7620335 2 73 gly glycosylation 518:530 arg2 a glycosylation site a glycosylation site site We determined the structure of oligosaccharides in the XAP region of human factor X. Four glycopeptides each containing a glycosylation site were isolated by digestion of XAP with endoproteinase Asp-N followed by reversed-phase HPLC. 7620335 2 78 gly glycopeptides 486:498 arg2 X. Four glycopeptides X. Four glycopeptides glycopeptides We determined the structure of oligosaccharides in the XAP region of human factor X. Four glycopeptides each containing a glycosylation site were isolated by digestion of XAP with endoproteinase Asp-N followed by reversed-phase HPLC. 18272752 6 50 gly glycosylation 904:916 arg2 the conserved N-linked glycosylation site the conserved N-linked glycosylation site site Nucleotide sequencing of WN25A viruses recovered from the brains of B-cell-deficient mice revealed that the conserved N-linked glycosylation site in the viral envelope protein was abolished by substitution of a serine residue at position 155. 16212439 3 35 gly glycosylation 799:811 arg2 a novel glycosylation site a novel glycosylation site site Using the above strategies, we identify 29 phosphorylation sites (19 novel and 10 previously reported) and a novel glycosylation site on Ser 74. 15616123 10 84 part_of LDL-receptor 1761:1772 arg1 the LDL-receptor binding site LDL-receptor the LDL-receptor binding site OGER Site LDL-receptor P01130 site Asn3384, the nearest N-glycosylation site to the LDL-receptor binding site (amino acids 3359-3369), was occupied by a variety of oligosaccharides, including high-mannose, hybrid, and complex types. 23319596 6 34 gly Asn-644 1045:1051 arg1 N-linked glycans Asn-455 and Asn-644 N-linked glycans Asn-455 and Asn-644 After phenylhydrazine derivatization and trypsin digestion, we used mass spectrometry to identify peptides containing the derivatized lysine tyrosylquinone cross-link at Lys-653 and Tyr-689, as well as N-linked glycans at Asn-455 and Asn-644. 23319596 6 66 gly Asn-455 1033:1039 arg1 N-linked glycans Asn-455 and Asn-644 N-linked glycans Asn-455 and Asn-644 After phenylhydrazine derivatization and trypsin digestion, we used mass spectrometry to identify peptides containing the derivatized lysine tyrosylquinone cross-link at Lys-653 and Tyr-689, as well as N-linked glycans at Asn-455 and Asn-644. 8486693 5 44 part_of protein 1109:1115 arg1 a potential N-linked glycosylation site protein a potential N-linked glycosylation site Fterm Site protein site Dideoxy sequencing of full-length subclones of GP-3 revealed the predicted amino acid sequence for a mature protein of 452 amino acids with a potential N-linked glycosylation site and a deglycosylated molecular weight of 50,860. 17065148 7 48 gly glycosylation 1145:1157 arg2 the relevant N-linked glycosylation site the relevant N-linked glycosylation site site To separate assembly from trafficking, we investigated the maturation of TRPM8 protein by identifying and mutating the relevant N-linked glycosylation site and showing that glycosylation is neither essential for multimerization nor for transport to the plasma membrane per se but appears to facilitate efficient multimerization and transport. 18308854 8 67 gly glycosylation 1534:1546 arg2 more than one glycosylation site more than one glycosylation site site Constructs in which more than one glycosylation site were eliminated had reduced transport activity but not necessarily reduced transporter expression. 8644914 3 50 gly glycopeptides 630:642 arg2 glycopeptides glycopeptides glycopeptides Liquid chromatography/electrospray mass spectrometry was used for peptide mapping and selective identification of glycopeptides, and Edman degradation and tandem mass spectrometry were used to define the sequences of selected peptides. 15859596 10 18 gly glycopeptides 1609:1621 arg2 select glycopeptides select glycopeptides glycopeptides In contrast, samples labeled with the heavy isoform of the coding agent were applied to a Con A lectin column alone to select glycopeptides containing complex biantennary N-linked, hybrid, and high-mannose glycans, without regard to sialylation. 15859596 10 57 gly containing 1623:1632 arg1 select glycopeptides AND complex biantennary N-linked, hybrid, and high-mannose glycans glycopeptides complex biantennary N-linked, hybrid, and high-mannose glycans glycopeptides In contrast, samples labeled with the heavy isoform of the coding agent were applied to a Con A lectin column alone to select glycopeptides containing complex biantennary N-linked, hybrid, and high-mannose glycans, without regard to sialylation. 1935985 0 55 part_of desmoglein 46:55 arg1 the epidermal desmoglein precursor polypeptide desmoglein the epidermal desmoglein precursor polypeptide Fterm Site desmoglein polypeptide Complete amino acid sequence of the epidermal desmoglein precursor polypeptide and identification of a second type of desmoglein gene. 11595658 3 28 gly nonglycosylated 320:334 arg1 The nonglycosylated receptor The nonglycosylated receptor Fterm receptor The nonglycosylated receptor did not bind the radioligand and had a decreased cAMP stimulation potency in response to CRF. 17916798 6 64 gly glycopeptides 1112:1124 arg2 glycopeptides glycopeptides glycopeptides Subsequently, the resulting complex mixture of peptides and glycopeptides was subjected to LC-MALDI analysis and database searching. 23853575 7 38 part_of DARC 1578:1581 arg1 the predicted DARC interaction site DARC the predicted DARC interaction site OGER Site DARC Q16570 site Our findings suggest that DARC-binding-inhibitory antibody epitope(s) lie close to the predicted DARC interaction site, and that addition of N-glycan sites distant from this site may augment inhibitory antibodies. 9254044 5 34 part_of glucosidase 737:747 arg1 The glucosidase II sequence glucosidase II The glucosidase II sequence OGER Site glucosidase II sequence The glucosidase II sequence did not contain known ER retention signals nor hydrophobic regions which could represent a transmembrane domain; however, it contained a single N-glycosylation site close to the amino terminus. 9254044 5 29 part_of contain 769:775 arg1 The glucosidase II sequence AND hydrophobic regions The glucosidase II sequence hydrophobic regions regions The glucosidase II sequence did not contain known ER retention signals nor hydrophobic regions which could represent a transmembrane domain; however, it contained a single N-glycosylation site close to the amino terminus. 8631363 9 64 gly glycosylated 1387:1398 arg1 the glycosylated peptides the glycosylated peptides peptides An amino acid sequence analysis of the glycosylated peptides was performed after Staphylococcus aureus V8 protease digestion of tumor necrosis factor-alpha had been completed, and it was proved that the 0-glycosylation site of tumor necrosis factor-alpha was Ser 4. 8631363 9 62 gly 0-glycosylation 1551:1565 arg2 the 0-glycosylation site tumor necrosis factor-alpha site PUBTATOR tumor necrosis factor-alpha 7124 site An amino acid sequence analysis of the glycosylated peptides was performed after Staphylococcus aureus V8 protease digestion of tumor necrosis factor-alpha had been completed, and it was proved that the 0-glycosylation site of tumor necrosis factor-alpha was Ser 4. 8631363 9 62 gly 0-glycosylation 1551:1565 arg2 Ser 4 tumor necrosis factor-alpha Ser 4 PUBTATOR tumor necrosis factor-alpha 7124 Ser 4 An amino acid sequence analysis of the glycosylated peptides was performed after Staphylococcus aureus V8 protease digestion of tumor necrosis factor-alpha had been completed, and it was proved that the 0-glycosylation site of tumor necrosis factor-alpha was Ser 4. 31393126 9 94 gly attached 1435:1442 arg2 MRJP2 AND 18, 17, and 2 N-glycans MRJP2 18, 17, and 2 N-glycans PUBTATOR MRJP2 406091 There were 18, 17, and 2 N-glycans attached to MRJP1, MRJP2, and MRJP3, respectively. 31393126 9 94 gly attached 1435:1442 arg2 MRJP3 AND 18, 17, and 2 N-glycans MRJP3 18, 17, and 2 N-glycans PUBTATOR MRJP3 406121 There were 18, 17, and 2 N-glycans attached to MRJP1, MRJP2, and MRJP3, respectively. 31393126 9 94 gly attached 1435:1442 arg1 MRJP1 AND 18, 17, and 2 N-glycans MRJP1 18, 17, and 2 N-glycans PUBTATOR MRJP1 406090 There were 18, 17, and 2 N-glycans attached to MRJP1, MRJP2, and MRJP3, respectively. 9365923 1 34 gly glycoprotein 157:168 arg1 Human alpha-lactalbumin Human alpha-lactalbumin PUBTATOR Human alpha-lactalbumin 3906 Human alpha-lactalbumin has not been described as a glycoprotein, despite the fact that several alpha-lactalbumins of both ruminant and nonruminant species are known to be glycosylated. 9365923 1 34 gly glycoprotein 157:168 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Human alpha-lactalbumin has not been described as a glycoprotein, despite the fact that several alpha-lactalbumins of both ruminant and nonruminant species are known to be glycosylated. 21637915 2 12 part_of containing 273:282 arg1 a glycosylated transmembrane protein AND two immunoglobulin (Ig) domains a glycosylated transmembrane protein two immunoglobulin (Ig) domains Fterm Site protein domains Emmprin is a glycosylated transmembrane protein containing two immunoglobulin (Ig) domains that is expressed in carcinoma cells and stimulates MMP production by adjacent stromal cells. 21637915 2 12 part_of containing 273:282 arg1 Emmprin AND two immunoglobulin (Ig) domains Emmprin two immunoglobulin (Ig) domains PUBTATOR Site Emmprin 682 domains Emmprin is a glycosylated transmembrane protein containing two immunoglobulin (Ig) domains that is expressed in carcinoma cells and stimulates MMP production by adjacent stromal cells. 11559807 0 76 gly determinants 10:21 arg1 the coronavirus receptor aminopeptidase N aminopeptidase N determinants PUBTATOR aminopeptidase N 290 Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): influence of N-linked glycosylation. 11559807 0 76 gly determinants 10:21 arg1 CD13 CD13 determinants PUBTATOR CD13 290 Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): influence of N-linked glycosylation. 32125861 3 33 gly N-glycopeptides 794:808 arg2 intact N-glycopeptides intact N-glycopeptides N-glycopeptides Here, we describe an automated platform using hydrophilic-interaction chromatography (HILIC)-based cartridges enabling the proteome-wide monitoring of intact N-glycopeptides using just a digest of 150 μg of breast milk protein. 15252014 3 20 part_of factor 552:557 arg1 the NH2 terminus factor the NH2 terminus Fterm Site factor terminus This assay utilizes a substrate consisting of the NH2 terminus of the ATF6 transcription factor fused to a transmembrane domain susceptible to SPP cleavage in vitro. 9820138 4 52 gly glycosylation 751:763 arg2 glycosylation sites glycosylation sites sites Using an SV40-based expression system, we previously analysed dimerization and secretion of the NS1 protein of dengue virus type 2 (DEN-2) with mutations in the conserved Cys residues, or within hydrophilic or hydrophobic regions, or at glycosylation sites. 18602996 4 3 gly glycosylation 775:787 arg2 only one N-linked glycosylation site only one N-linked glycosylation site site Its cDNA predicts a protein of 300 amino acids that share 51-56% sequence identity with known mammalian 11HSD1 proteins, while in contrast to most mammals, ch11HSD1 contains only one N-linked glycosylation site. 3498943 1 59 gly glycoprotein 110:121 arg1 The murine Ly-2/3 glycoprotein The murine Ly-2/3 glycoprotein Fterm glycoprotein The murine Ly-2/3 glycoprotein is a surface marker of T cells restricted by class I major histocompatibility complex antigens. 10099545 2 7 gly glycosylation 313:325 arg2 Potential glycosylation sites Potential glycosylation sites sites Potential glycosylation sites are not always occupied with oligosaccharide, and site occupancy can change with the culture environment. 10099545 2 54 gly occupied 348:355 arg2 Potential glycosylation sites Potential glycosylation sites sites Potential glycosylation sites are not always occupied with oligosaccharide, and site occupancy can change with the culture environment. 21899340 0 39 gly glycoproteins 224:236 arg1 glycoproteins glycoproteins glycan structure Fterm glycoproteins Size-selective enrichment of N-linked glycans using highly ordered mesoporous carbon material and detection by MALDI-TOF MS. Many diseases are characterized by the changes of either glycan structure or glycosylation site of glycoproteins. 21899340 0 32 gly glycosylation 202:214 arg1 glycoproteins glycoproteins site Fterm glycoproteins site Size-selective enrichment of N-linked glycans using highly ordered mesoporous carbon material and detection by MALDI-TOF MS. Many diseases are characterized by the changes of either glycan structure or glycosylation site of glycoproteins. 9524075 9 36 gly non-glycosylated 1048:1063 arg1 the glycosylated and non-glycosylated procathepsin S the glycosylated and non-glycosylated procathepsin S Cterm the glycosylated and non-glycosylated procathepsin S 1520 A reuptake of the glycosylated and non-glycosylated procathepsin S by HEK 293-cells could be observed. 9524075 9 55 gly glycosylated 1031:1042 arg1 the glycosylated and non-glycosylated procathepsin S the glycosylated and non-glycosylated procathepsin S Cterm the glycosylated and non-glycosylated procathepsin S 1520 A reuptake of the glycosylated and non-glycosylated procathepsin S by HEK 293-cells could be observed. 7524670 6 51 gly N-glycosylation 991:1005 arg2 a single N-glycosylation site a single N-glycosylation site site Each beta-subunit contained a single N-glycosylation site, but a high degree of microheterogeneity was observed in the structure of its N-linked oligosaccharides. 15527836 9 21 part_of rCAT1 1495:1499 arg1 the glycosylation site rCAT1 the glycosylation site PUBTATOR Site rCAT1 25648 site An amino acid substitution in the glycosylation site of the wild-type rCAT1 conferred higher infection susceptibility, but that of the rCAT1 mutant 1 did not. 18524814 4 6 part_of protein 1157:1163 arg1 protein compositions protein protein compositions Fterm Site protein positions The loss of prM N glycosylation, without significantly altering the intracellular levels of viral RNA and proteins, led to an approximately 20-fold reduction in the production of extracellular virions, which had protein compositions and infectivities nearly identical to those of wild-type virions; this reduction occurred at the stage of virus release, rather than assembly. 21153780 0 0 part_of oncoprotein 83:93 arg1 epitopes oncoprotein epitopes Fterm Site oncoprotein epitopes Computer-aided analysis of structural properties and epitopes of Iranian HPV-16 E7 oncoprotein. 16360109 3 33 part_of site 491:494 arg1 CDR2 CDR2 site PUBTATOR Site CDR2 1039 site Oligosaccharide structures in a humanized anti-Abeta IgG1 monoclonal antibody (Mab) with an N-glycosylation site in the complementary determining region (CDR2) of the heavy chain variable region were elucidated by LC/MS analysis following sequential exoglycosidase treatments of the endoproteinase Lys-C digest. 27604319 5 62 gly glycosylation 949:961 arg1 gp120 gp120 site PUBTATOR gp120 Q14624 site While most prior studies have focused on glycan analysis of recombinant forms of gp120, here we report the first systematic glycosylation site analysis of gp120 derived from virions produced by infected T lymphoid cells and show that a single site is exclusively substituted with complex glycans. 10419504 0 29 gly glycoprotein 95:106 arg1 the Niemann-Pick C1 glycoprotein the Niemann-Pick C1 glycoprotein Fterm glycoprotein Mutations in the leucine zipper motif and sterol-sensing domain inactivate the Niemann-Pick C1 glycoprotein. 2310304 0 41 gly glycosylation 116:128 arg2 a potential glycosylation site a potential glycosylation site site A host-cell-selected variant of influenza B virus with a single nucleotide substitution in HA affecting a potential glycosylation site was attenuated in virulence for volunteers. 30898876 0 50 gly glycoproteins 28:40 arg1 mammalian glycoproteins mammalian glycoproteins Fterm glycoproteins Identification of mammalian glycoproteins with type-I LacdiNAc structures synthesized by the glycosyltransferase B3GALNT2. 17707131 6 38 part_of acyltransferase 1098:1112 arg1 the acyltransferase motifs acyltransferase the acyltransferase motifs Fterm Site acyltransferase motifs This topology conflicts with the expectation that catalytically important sites are near one another, raising questions of whether the acyltransferase motifs really are important for AGPAT catalysis, and how substrates access motifs II-III on the lumenal side of the endoplasmic reticulum membrane. 27798666 6 38 part_of contains 952:959 arg1 This short sequence AND two aspartic residues This short sequence two aspartic residues aspartic residues This short sequence contains two aspartic residues critical for efficient glycosylation. 22573926 4 11 part_of stanniocalcin 578:590 arg1 the opossum stanniocalcin 1 cDNA sequence stanniocalcin 1 the opossum stanniocalcin 1 cDNA sequence PUBTATOR Site stanniocalcin 1 6781 sequence In this study, we identified the opossum stanniocalcin 1 cDNA sequence. 3525855 5 7 part_of has 789:791 arg1 The minimal transforming region AND 15 residues The minimal transforming region 15 residues residues The minimal transforming region of the v-sis gene product defined by this analysis has 15 residues missing at the N terminus when compared with the PDGF-B chain. 8639654 2 39 gly N-glycosylation 380:394 arg2 the four consensus N-glycosylation sites the four consensus N-glycosylation sites sites The functional role of N-linked carbohydrates in the human vasoactive intestinal peptide (VIP) 1 receptor was investigated by site-directed mutagenesis (Asn-->Thr) of the four consensus N-glycosylation sites on Asn58, Asn69, Asn100 (N-terminal extracellular domain) and Asn293 (second extracellular loop). 12460944 1 55 gly attached 219:226 arg1 protein AND O-Glucose protein O-Glucose Fterm protein O-Glucose is an unusual form of posttranslational modification consisting of glucose directly attached to protein through O-linkage. 8144579 1 14 part_of alpha-mannosidase 144:160 arg1 The amino acid sequence alpha-mannosidase The amino acid sequence PUBTATOR Site alpha-mannosidase 852721 sequence The amino acid sequence of the specific alpha-mannosidase involved in N-oligosaccharide processing in Saccharomyces cerevisiae was found to have a high degree of similarity to the deduced amino acid sequence of a rabbit liver alpha-mannosidase partial cDNA, demonstrating that processing mannosidases have been conserved through eukaryotic evolution. 17599380 3 20 part_of HIV 326:328 arg1 Asp 386 HIV Env variant Asp 386 PUBTATOR SpecificSite HIV Env variant 100616444 Asp 386 Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-associated dementia (HAD) compared with non-HAD patients. 17599380 3 23 part_of variant 334:340 arg1 the V4 region HIV Env variant the V4 region PUBTATOR Site HIV Env variant 100616444 region Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-associated dementia (HAD) compared with non-HAD patients. 17599380 3 31 part_of gp120 362:366 arg1 the V4 region gp120 the V4 region PUBTATOR Site gp120 3700 region Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-associated dementia (HAD) compared with non-HAD patients. 17599380 3 70 part_of Env 330:332 arg1 Asp 386 HIV Env variant Asp 386 PUBTATOR SpecificSite HIV Env variant 100616444 Asp 386 Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-associated dementia (HAD) compared with non-HAD patients. 26977294 8 42 part_of Fc 1338:1339 arg1 the fucosylated/afucosylated Fc fragments Fc the fucosylated/afucosylated Fc fragments Cterm Site Fc fragments After few thousand steps of energy minimization on the resulting 3D mAb models, minimized final models were used to quantify interactions occurring between Fcγ RIIIA and the fucosylated/afucosylated Fc fragments. 23050552 8 46 gly fibrinogen 1086:1095 arg1 The previously reported N-glycan attachment sites fibrinogen The previously reported N-glycan attachment sites PUBTATOR fibrinogen 2244 The previously reported N-glycan attachment sites of human fibrinogen could be confirmed. 9450242 2 43 gly glycosylation 507:519 arg2 one predicted potential N-linked glycosylation site one predicted potential N-linked glycosylation site site When nucleotide sequence of the mutated gD of YP11mu strain (gD(YP11mu)) was compared with that of gDs of other CHV strains, gD(YP11mu) lacked 12 nucleotides encoding 4 amino acids, NKTI, including one predicted potential N-linked glycosylation site and no other change was found in other regions. 29463651 3 44 gly glycosylation 583:595 arg2 the ZIKV E glycosylation site the ZIKV E glycosylation site site Our data further show that removal of the ZIKV E glycosylation site prevents mosquito infection by flaviviruses via the oral route, whereas there is no effect on infection by intrathoracic microinjection, which bypasses the midgut. 11031254 2 32 gly serine 418:423 arg1 the putative N-linked glycosylation site asparagine 206 by a serine residue serine residue the putative N-linked glycosylation site asparagine 206 by a serine residue serine residue The mutation involves a substitution of the putative N-linked glycosylation site asparagine 206 by a serine residue (N206S) and results in reduced glycosylation of the transporter and decreased uptake activity. 11031254 2 71 gly glycosylation 379:391 arg2 the putative N-linked glycosylation site asparagine 206 by a serine residue the putative N-linked glycosylation site asparagine 206 by a serine residue serine residue The mutation involves a substitution of the putative N-linked glycosylation site asparagine 206 by a serine residue (N206S) and results in reduced glycosylation of the transporter and decreased uptake activity. 8325864 2 79 part_of beta-glucosidase 180:195 arg1 The five potential N-glycosylation sites acid beta-glucosidase sites OGER Site acid beta-glucosidase P04062 sites The five potential N-glycosylation sites (sequons) of human acid beta-glucosidase were individually mutated to determine site occupancy and the effect of site occupancy on selected catalytic and stability properties of this enzyme. 7890742 5 57 part_of CD52 591:594 arg1 the single CD52 N-glycosylation site CD52 the single CD52 N-glycosylation site PUBTATOR Site CD52 1043 site The results showed that the single CD52 N-glycosylation site is occupied by large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides. 26957414 15 21 gly glycopeptide 1917:1928 arg2 glycopeptide sequencing glycopeptide sequencing glycopeptide The formation of Y1 ions and oxonium ions in ISF facilitates glycopeptide sequencing and glycan composition identification. 12954207 8 90 part_of gp120 1402:1406 arg1 gp120 third variable region gp120 gp120 third variable region PUBTATOR Site gp120 3700 region Surprisingly, removal of a single N-linked glycosylation site at the base of the gp120 third variable region (V3 loop) increased the sensitivity of the primary viruses to neutralization by CD4BS antibodies. 1457969 2 72 gly glycosylated 414:425 arg2 Asn 23 hTSH beta Asn 23 PUBTATOR hTSH beta 7252 Asn 23 Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23). 1457969 2 72 gly glycosylated 414:425 arg1 its subunits subunits Asn 23 Fterm subunits Asn 23 Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23). 1457969 2 85 gly glycosylated 364:375 arg2 Asn 52 Asn 52 and Asn 78 Asn 52 and Asn 78 Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23). 1457969 2 85 gly glycosylated 364:375 arg1 hTSH alpha hTSH alpha Asn 52 and Asn 78 PUBTATOR hTSH alpha 1081 Asn 52 and Asn 78 Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23). 1457969 2 85 gly glycosylated 364:375 arg1 its subunits subunits Asn 52 and Asn 78 Fterm subunits Asn 52 and Asn 78 Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23). 1457969 2 85 gly glycosylated 364:375 arg1 hTSH alpha hTSH alpha Asn 52 and Asn 78 PUBTATOR hTSH alpha 1081 Asn 52 and Asn 78 Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23). 1457969 2 85 gly glycosylated 364:375 arg1 its subunits subunits Asn 52 and Asn 78 Fterm subunits Asn 52 and Asn 78 Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23). 9030779 2 63 gly sphingomyelinase 379:394 arg1 the six potential N-linked oligosaccharide chains acid sphingomyelinase the six potential N-linked oligosaccharide chains PUBTATOR acid sphingomyelinase 6609 We have determined the influence of the six potential N-linked oligosaccharide chains of human acid sphingomyelinase (ASM) on catalytic activity, targeting, and processing of the enzyme. 7768336 0 36 gly N-glycosylation 18:32 arg2 N-glycosylation sites N-glycosylation sites sites Identification of N-glycosylation sites in the gonadotropin-releasing hormone receptor: role in receptor expression but not ligand binding. 11485624 1 50 gly oligosaccharide 302:316 arg1 this region this region this region Site region The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potential neutralization target, but the oligosaccharide of one conserved N-glycosylation site in this region protects it from neutralizing antibodies. 11485624 1 60 gly N-glycosylation 335:349 arg2 one conserved N-glycosylation site one conserved N-glycosylation site site The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potential neutralization target, but the oligosaccharide of one conserved N-glycosylation site in this region protects it from neutralizing antibodies. 11485624 1 81 gly site 351:354 arg1 the oligosaccharide site the oligosaccharide site The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potential neutralization target, but the oligosaccharide of one conserved N-glycosylation site in this region protects it from neutralizing antibodies. 11485624 1 88 gly region 364:369 arg1 the oligosaccharide region the oligosaccharide region The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potential neutralization target, but the oligosaccharide of one conserved N-glycosylation site in this region protects it from neutralizing antibodies. 1607530 2 46 gly glycosylation 431:443 arg2 Asn184 site Asn184 site Asn184 K2P, a mutant of rt-PA lacking the fibronectin fingerlike, epidermal growth factor-like and first kringle domains (amino acids 6 to 173) and having the glycosylation site Asn184 mutagenized to Gln, has been produced in Chinese hamster ovary cells. 21970473 0 32 gly fucosylated 55:65 arg1 core fucosylated glycoprotein core fucosylated glycoprotein Fterm glycoprotein Fragmentation and site-specific quantification of core fucosylated glycoprotein by multiple reaction monitoring-mass spectrometry. 21970473 0 74 gly glycoprotein 67:78 arg1 core fucosylated glycoprotein core fucosylated glycoprotein Fterm glycoprotein Fragmentation and site-specific quantification of core fucosylated glycoprotein by multiple reaction monitoring-mass spectrometry. 16077958 8 19 gly glycosylation 1008:1020 arg2 Asn-linked glycosylation site Asn-linked glycosylation site site Asn-linked glycosylation site at codon 52 was conserved among mammalian Dkk2 orthologs; however, Asn-linked glycosylation site was not identified among mammalian Dkk4 orthologs. 16077958 8 40 gly glycosylation 911:923 arg2 Asn-linked glycosylation site Asn-linked glycosylation site site Asn-linked glycosylation site at codon 52 was conserved among mammalian Dkk2 orthologs; however, Asn-linked glycosylation site was not identified among mammalian Dkk4 orthologs. 8601595 5 58 part_of CD44 1130:1133 arg1 the hyaluronate recognition domain CD44 the hyaluronate recognition domain PUBTATOR Site CD44 960 domain Using human melanoma cells stably transfected with CD44 N-linked glycosylation site-specific mutants, we show that integrity of five potential N-linked glycosylation sites within the hyaluronate recognition domain of CD44 is critical for hyaluronate binding. 1726785 4 43 gly glycosylation 740:752 arg2 residues 77 and 198 residues 77 and 198 residues 77 and 198 Mutation of two glycosylation sites (residues 77 and 198) was shown to significantly decrease high affinity TSH binding but not the activity of a TSAb. 1726785 4 43 gly glycosylation 740:752 arg2 two glycosylation sites two glycosylation sites sites Mutation of two glycosylation sites (residues 77 and 198) was shown to significantly decrease high affinity TSH binding but not the activity of a TSAb. 23776650 8 2 gly glycosylation 1037:1049 arg1 the DCIR the DCIR PUBTATOR DCIR 50856 Nevertheless, altering the glycosylation status of the DCIR expressing cell or mutating the N-glycosylation site of DCIR itself did not increase glycan binding. 23776650 8 41 gly N-glycosylation 1102:1116 arg2 the N-glycosylation site DCIR site PUBTATOR DCIR 50856 site Nevertheless, altering the glycosylation status of the DCIR expressing cell or mutating the N-glycosylation site of DCIR itself did not increase glycan binding. 7711052 4 55 gly presence 769:776 arg1 ribonuclease AND an oligomannose sugar ribonuclease an oligomannose sugar Fterm ribonuclease The presence of an oligomannose sugar on ribonuclease (at Asn-34) alters its overall dynamics, increases its stability towards proteinases and decreases its functional activity towards double-stranded RNA. 10861210 7 81 gly glycoprotein 1137:1148 arg1 the glycoprotein the glycoprotein Fterm form of the glycoprotein The complex form of the N555 mutant could be biotinylated showing that this form of the glycoprotein was at the cell surface. 22389730 9 49 part_of strain 1775:1780 arg1 The basal position ZIKV strain The basal position Cterm Site ZIKV strain 10413 position CONCLUSIONS/SIGNIFICANCE: The basal position of the ZIKV strain isolated in Malaysia in 1966 suggests that the recent outbreak in Micronesia was initiated by a strain from Southeast Asia. 25705359 4 55 gly glycosylation 749:761 arg2 amino acid position 306 amino acid position 306 position 306 RESULTS: One new potential glycosylation site (PGS) at amino acid position 306 was observed in one of the studied isolates (A/Chicken/Iran/N102/2011). 25705359 4 55 gly glycosylation 749:761 arg2 One new potential glycosylation site One new potential glycosylation site site RESULTS: One new potential glycosylation site (PGS) at amino acid position 306 was observed in one of the studied isolates (A/Chicken/Iran/N102/2011). 18707900 0 10 gly N-glycosylation 51:65 arg1 recombinant IgGs recombinant IgGs Cterm IgGs Comparison of LC and LC/MS methods for quantifying N-glycosylation in recombinant IgGs. 1459141 0 19 gly glycosylation 93:105 arg2 an asparagine-linked glycosylation site an asparagine-linked glycosylation site site Non-lysosomal degradation of misfolded human lysozymes with and without an asparagine-linked glycosylation site. 17158912 4 8 gly N-glycosylation 599:613 arg2 the N-glycosylation site the N-glycosylation site site Modifications of the large extracellular loop of UPIb, such as mutation of the N-glycosylation site or the cysteines involved in the formation of three disulfide bridges, or exchanging the large luminal loop of UPIb with that of UPIa did not affect the ability of UPIb to reach the cell surface. 23853575 6 15 part_of DARC 1346:1349 arg1 critical DARC binding residues DARC critical DARC binding residues OGER Site DARC Q16570 residues PvDBP is composed of three subdomains and is thought to function as a dimer; a meta-analysis of published PvDBP mutants and the new DBPII glycosylation variants indicates that critical DARC binding residues are concentrated at the dimer interface and along a relatively flat surface spanning portions of two subdomains. 2522450 9 45 gly glycosylation 1024:1036 arg2 a possible glycosylation site a possible glycosylation site site It is located only 5 amino acids away from a possible glycosylation site. 7533854 9 87 gly glycoprotein 2197:2208 arg1 the HXB2 V1/V2 fusion glycoprotein the HXB2 V1/V2 fusion glycoprotein Fterm glycoprotein Similar heterogeneity in glycosylation was also observed when the HXB2 V1/V2 fusion glycoprotein was expressed without most of the gp70 carrier protein, and thus, this appeared to be an intrinsic property of the V1/V2 domain. 7730329 10 23 gly N-glycosylation 1385:1399 arg2 a single potential N-glycosylation site a single potential N-glycosylation site site The deduced complete amino acid sequence of TSV-PA indicates that the mature TSV-PA protein is composed of 234 amino acids and contains a single potential N-glycosylation site at Asn161. 8578865 9 32 gly glycosylation 1213:1225 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Both PUU90-13 and PUUBerkel lack a potential N-linked glycosylation site found on the G2 glycoprotein of other PUU viruses. 8578865 9 43 gly glycoprotein 1248:1259 arg1 the G2 glycoprotein the G2 glycoprotein Fterm glycoprotein Both PUU90-13 and PUUBerkel lack a potential N-linked glycosylation site found on the G2 glycoprotein of other PUU viruses. 9557657 11 1 part_of havcr-1 2311:2317 arg1 its first N-glycosylation site havcr-1 its first N-glycosylation site PUBTATOR Site havcr-1 Q96D42 site These results indicate that the Cys-rich region of havcr-1 and its first N-glycosylation site are required for binding of protective MAb 190/4 and HAV receptor function. 9557657 11 1 part_of havcr-1 2311:2317 arg1 the Cys-rich region havcr-1 the Cys-rich region PUBTATOR Site havcr-1 Q96D42 region These results indicate that the Cys-rich region of havcr-1 and its first N-glycosylation site are required for binding of protective MAb 190/4 and HAV receptor function. 31393126 10 40 part_of glycoproteins 1565:1577 arg1 each single glycosylation site glycoproteins each single glycosylation site Fterm Site glycoproteins site The diversity of N-glycans attached to each single glycosylation site of these glycoproteins confirmed that MRJP1 and MRJP2 heterogeneity was mostly associated with their glycoform populations. 8496193 8 30 gly glycosylated 1239:1250 arg1 glycosylated procathepsin L glycosylated procathepsin L OGER procathepsin L P06797 Nonglycosylated and endogenous glycosylated procathepsin L were secreted by NIH 3T3 cells with identical kinetics. 10725548 3 50 part_of strain 509:514 arg1 a highly virulent strain MHV-2 M-coding region strain a highly virulent strain MHV-2 M-coding region Fterm Site strain region We analyzed the nucleotide sequence of a highly virulent strain MHV-2 M-coding region and demonstrated that MHV-2 had a unique amino acid, Asn, at position 2 at the conserved O-glycosylation site. 10725548 3 54 part_of MHV-2 516:520 arg1 a highly virulent strain MHV-2 M-coding region MHV-2 a highly virulent strain MHV-2 M-coding region Cterm Site MHV-2 region We analyzed the nucleotide sequence of a highly virulent strain MHV-2 M-coding region and demonstrated that MHV-2 had a unique amino acid, Asn, at position 2 at the conserved O-glycosylation site. 8964581 5 59 part_of CRF 673:675 arg1 CRF receptor-bindings sites CRF CRF receptor-bindings sites OGER Site CRF sites In brain, the central distribution of CRFBP shares some regional overlap with CRF receptor-bindings sites. 1402806 5 0 gly N-glycosylation 894:908 arg2 a potential N-glycosylation site protein site Fterm protein site The M protein of HCV-OC43 shows features typical of all coronavirus M proteins studied: a hydrophilic, presumably external N terminus including about 10% of the protein, and a potential N-glycosylation site followed by three major hydrophobic transmembrane domains. 8798755 1 65 gly N-glycosylation 428:442 arg2 one potential N-glycosylation site one potential N-glycosylation site site Cloning of the cDNA encoding a novel human protein- tyrosine phosphatase (PTP) called islet cell antigen-related PTP (IAR) predicts a receptor-like molecule with an extracellular domain of 614 amino acids containing a hydrophobic signal peptide, one potential N-glycosylation site, and an RGDS peptide which is a possible adhesive recognition sequence. 31498587 6 55 part_of MUC1 926:929 arg1 MUC1 glycopeptides MUC1 MUC1 glycopeptides PUBTATOR Site MUC1 17829 glycopeptides The IgG antibodies recognized a wide range of MUC1 glycopeptides bearing diverse glycans. 8068684 1 99 part_of contains 181:188 arg1 NHE-1 AND three consensus sites NHE-1 three consensus sites PUBTATOR Site NHE-1 6548 sites The ubiquitously-expressed human Na+H+ exchanger (NHE-1) contains three consensus sites (Asn-X-Ser/Thr) for N-linked glycosylation at asparagines 75, 370, and 410. 26156869 2 53 gly immunoglobulin 460:473 arg1 N-linked glycans immunoglobulin G N-linked glycans Fterm immunoglobulin G Two endoglycosidases from the human pathogen Streptococcus pyogenes, EndoS and EndoS2, have recently been shown to hydrolyze N-linked glycans of human immunoglobulin G. However, detailed characterization and comparison of the hydrolyzing activities have not been performed. 8347587 4 29 part_of subunit 508:514 arg1 the amino terminus subunit the amino terminus OGER Site subunit 16337 terminus The codons for asparagine in the first four sites at the amino terminus of the alpha subunit were mutated to code for glutamine. 8347587 4 37 part_of terminus 486:493 arg1 the first four sites terminus the first four sites sites The codons for asparagine in the first four sites at the amino terminus of the alpha subunit were mutated to code for glutamine. 8797081 16 1 gly glycoprotein 1991:2002 arg1 calobin calobin Fterm calobin As calobin is a glycoprotein, its possible glycosylation site, Asn-X-Thr, is located at amino acid residues 81-83. 8797081 16 1 gly glycoprotein 1991:2002 arg1 a glycoprotein a glycoprotein Fterm glycoprotein As calobin is a glycoprotein, its possible glycosylation site, Asn-X-Thr, is located at amino acid residues 81-83. 8797081 16 6 gly glycosylation 2018:2030 arg2 amino acid residues 81-83 amino acid residues 81-83 residues 81-83 As calobin is a glycoprotein, its possible glycosylation site, Asn-X-Thr, is located at amino acid residues 81-83. 8797081 16 49 gly residues 2074:2081 arg1 81-83 81-83 residues 81-83 As calobin is a glycoprotein, its possible glycosylation site, Asn-X-Thr, is located at amino acid residues 81-83. 8797081 16 6 gly glycosylation 2018:2030 arg2 its possible glycosylation site site, Asn-X-Thr site, Asn-X-Thr As calobin is a glycoprotein, its possible glycosylation site, Asn-X-Thr, is located at amino acid residues 81-83. 26623630 5 42 gly glycosylation 972:984 arg2 N-link glycosylation site N-link glycosylation site site Additionally, a few mutations with amino acid substitutions such as M226I at N-link glycosylation site were identified in two of these isolates. 31671706 6 16 part_of protein 1308:1314 arg1 the five glycosylation sites protein the five glycosylation sites Fterm Site protein sites Based on the mapping results, the unique features in glycan microheterogeneity for the five glycosylation sites of VEGFR-IgG fusion protein were compared site-specifically and further discussed to understand the functional meaning of each glycosylation pattern. 10413093 1 12 gly N-glycosylation 188:202 arg2 an N-glycosylation site an N-glycosylation site site We have previously shown that an N-glycosylation site of N306 of HIV-1 gp120 is not necessary for the HIV-1 infectivity but protects HIV-1 from neutralising antibodies. 10413093 1 12 gly N-glycosylation 188:202 arg1 N306 N306 N306 We have previously shown that an N-glycosylation site of N306 of HIV-1 gp120 is not necessary for the HIV-1 infectivity but protects HIV-1 from neutralising antibodies. 30063822 1 34 gly glycoproteins 220:232 arg1 glycoproteins glycoproteins Fterm glycoproteins An enzyme- and click chemistry-mediated methodology for the site-specific nitroxide spin labeling of glycoproteins has been developed and applied. 10585855 10 44 part_of proteins 1607:1614 arg1 membrane-spanning regions proteins membrane-spanning regions Fterm Site proteins regions This approach might provide a general method for dissecting the interactions between membrane-spanning regions of polytopic membrane proteins. 18533687 9 19 gly glycosylation 1534:1546 arg2 glycosylation sites glycosylation sites sites However, combinations of glycosylation sites were required for cell surface expression and cAMP signaling. 26773038 0 22 part_of VWF 37:39 arg1 the VWF A2 domain VWF the VWF A2 domain PUBTATOR Site VWF 7450 domain N-linked glycan stabilization of the VWF A2 domain. 19619305 6 36 part_of gp120 1520:1524 arg1 the outer domain gp120 the outer domain PUBTATOR Site gp120 3700 domain These findings suggest that exposure of the b12 epitope, rather than exposure of the CD4 binding site per se, enhances HIV macrophage tropism, possibly by exposing a region on the outer domain of gp120 that is initially recognized by CD4. 19619305 6 38 part_of CD4 1409:1411 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 713807 site These findings suggest that exposure of the b12 epitope, rather than exposure of the CD4 binding site per se, enhances HIV macrophage tropism, possibly by exposing a region on the outer domain of gp120 that is initially recognized by CD4. 19619305 6 67 part_of region 1490:1495 arg1 gp120 gp120 domain PUBTATOR gp120 3700 domain These findings suggest that exposure of the b12 epitope, rather than exposure of the CD4 binding site per se, enhances HIV macrophage tropism, possibly by exposing a region on the outer domain of gp120 that is initially recognized by CD4. 26536155 3 91 gly glycopeptides 698:710 arg2 glycopeptides glycopeptides glycopeptides The use of unspecific proteases such as Pronase can largely overcome this problem by generating glycopeptides with a small peptide portion. 16834341 6 27 part_of hFSH 872:875 arg1 Asn7 hFSH Asn7 OGER AminoAcid hFSH Asn7 For instance, except for one site in the beta subunit (Asn7) of hFSH all other sites in both species have sulfated glycoforms. 9365923 3 33 gly glycosylation 457:469 arg2 the glycosylation site the glycosylation site site We have found that human alpha-lactalbumin is glycosylated and the glycosylation site has been determined by protein sequencing and mass spectrometry. 9365923 3 37 gly glycosylated 436:447 arg1 human alpha-lactalbumin human alpha-lactalbumin PUBTATOR alpha-lactalbumin 3906 We have found that human alpha-lactalbumin is glycosylated and the glycosylation site has been determined by protein sequencing and mass spectrometry. 21329800 4 3 gly N-glycosylation 641:655 arg2 N-glycosylation sites N-glycosylation sites sites In this chapter, we describe current methods enabling the determination of N-glycosylation by assessment of cellular dolichol phosphate levels, dolichol-linked oligosaccharides, and the occupancy of N-glycosylation sites. 21329800 4 16 gly occupancy 628:636 arg2 N-glycosylation sites N-glycosylation sites sites In this chapter, we describe current methods enabling the determination of N-glycosylation by assessment of cellular dolichol phosphate levels, dolichol-linked oligosaccharides, and the occupancy of N-glycosylation sites. 21329800 4 34 gly sites 657:661 arg1 dolichol-linked oligosaccharides sites dolichol-linked oligosaccharides sites In this chapter, we describe current methods enabling the determination of N-glycosylation by assessment of cellular dolichol phosphate levels, dolichol-linked oligosaccharides, and the occupancy of N-glycosylation sites. 26536155 1 2 gly O-glycopeptides 222:236 arg2 O-glycopeptides O-glycopeptides O-glycopeptides The analysis of N- and O-glycopeptides remains challenging due to the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of the glycoprotein. 26536155 1 13 gly macroheterogeneity 350:367 arg1 the glycoprotein the glycoprotein Fterm glycoprotein The analysis of N- and O-glycopeptides remains challenging due to the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of the glycoprotein. 26536155 1 30 gly glycosylation 326:338 arg2 one glycosylation site one glycosylation site site The analysis of N- and O-glycopeptides remains challenging due to the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of the glycoprotein. 26536155 1 50 gly glycoprotein 393:404 arg1 the glycoprotein the glycoprotein Fterm glycoprotein The analysis of N- and O-glycopeptides remains challenging due to the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of the glycoprotein. 26536155 1 75 gly microheterogeneity 269:286 arg1 the glycoprotein the glycoprotein Fterm glycoprotein The analysis of N- and O-glycopeptides remains challenging due to the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of the glycoprotein. 27480168 5 21 gly glycosylation 945:957 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site Substitution of N48 prevents hENT1 glycosylation, confirming a single N-linked glycosylation site. 31393126 2 90 gly glycoproteins 440:452 arg1 these glycoproteins these glycoproteins Fterm glycoproteins Although there have been analyses on the glycosylation modification of RJ proteins, none of these methods have been conducted on a site-specific analysis of glycosylation from these glycoproteins. 3200844 11 46 gly glycoprotein 1571:1582 arg1 the 62-kDa nuclear pore glycoprotein the 62-kDa nuclear pore glycoprotein Fterm glycoprotein The partial sequence of the 62-kDa nuclear pore glycoprotein shows little similarity to other characterized proteins and elucidates structural features of a member of the family of nuclear pore glycoproteins. 3200844 11 77 gly glycoproteins 1717:1729 arg1 nuclear pore glycoproteins nuclear pore glycoproteins Fterm glycoproteins The partial sequence of the 62-kDa nuclear pore glycoprotein shows little similarity to other characterized proteins and elucidates structural features of a member of the family of nuclear pore glycoproteins. 15737642 6 72 gly N-glycosylation 1343:1357 arg1 glycosyltransferase glycosyltransferase Asn79 Fterm glycosyltransferase Asn79 The truncated protein consisting of amino acids 82-397 (GFP(uv)-beta3GnT2Delta83), which lacked both one N-glycosylation site at Asn79 and the stem region of glycosyltransferase, was expressed as only a small form and showed no beta3GnT activity. 15737642 6 72 gly N-glycosylation 1343:1357 arg2 one N-glycosylation site glycosyltransferase site Fterm glycosyltransferase site The truncated protein consisting of amino acids 82-397 (GFP(uv)-beta3GnT2Delta83), which lacked both one N-glycosylation site at Asn79 and the stem region of glycosyltransferase, was expressed as only a small form and showed no beta3GnT activity. 31888963 6 69 gly glycosylation 905:917 arg2 glycosylation site glycosylation site site The composition of CD16a N-glycans varied by glycosylation site and donor. 14749183 6 8 gly glycosylation 804:816 arg2 a glycosylation site a glycosylation site site However, these substitutions restore a glycosylation site present in NDV HN, but not in hPIV3 HN. 27301377 5 152 part_of DEspR 1203:1207 arg1 distinct DEspR epitopes DEspR distinct DEspR epitopes Cterm Site DEspR 1906 epitopes To comply with the highest level multiple UNIPROT criteria for determining DEspR's existence, we performed various experiments using multiple anti-DEspR monoclonal antibodies (mAbs) targeting distinct DEspR epitopes with one spanning the contested tryptophan [TGG]-codon#14, assessing: (a) DEspR protein expression, (b) predicted full-length protein size, (c) sequence-predicted protein-specific properties beyond codon#14: receptor glycosylation and internalization, (d) protein-partner interactions, and (e) DEspR functionality via DEspR-inhibition effects. 28303575 2 37 gly glycosylation 321:333 arg2 its N-linked glycosylation site its N-linked glycosylation site site Human monocyte populations express Dectin-1 isoforms A and B, which differ by the presence of a stalk region and its N-linked glycosylation site. 8892291 7 49 part_of contains 931:938 arg1 This same C terminal peptide region AND a non-linear epitope This same C terminal peptide region a non-linear epitope epitope This same C terminal peptide region contains a non-linear epitope bound by mAb C6B6. 6234658 2 11 gly glycosylation 342:354 arg2 one glycosylation site one glycosylation site site PreproANF is composed of a hydrophobic leader segment (20 amino acids), a precursor containing one glycosylation site (106 amino acids), and ANF (24 amino acids). 27506355 0 92 gly glycopeptides 57:69 arg1 Direct glycan structure determination glycopeptides Direct glycan structure determination glycopeptides Direct glycan structure determination of intact N-linked glycopeptides by low-energy collision-induced dissociation tandem mass spectrometry and predicted spectral library searching. 21902591 1 82 part_of gp120 216:220 arg1 variable and constant regions gp120 variable and constant regions PUBTATOR Site gp120 155971 regions We have analyzed purine (R) and pyrimidine (Y) codon patterns in variable and constant regions of HIV-1 gp120 in seven patients infected with different HIV-1 subtypes and naive to antiretroviral therapy. 1918071 8 88 part_of containing 1597:1606 arg1 peptides AND photoreactive-Asn-Xaa-Ser/Thr- sequences peptides photoreactive-Asn-Xaa-Ser/Thr- sequences sequences We now demonstrate that PDI in the lumen of microsomes is more efficiently labeled by peptides containing photoreactive-Asn-Xaa-Ser/Thr- sequences than by nonacceptor site sequences because the former become glycosylated. 23029648 0 31 gly glycosylation 43:55 arg2 mass spectrometry-based glycosylation site annotation mass spectrometry-based glycosylation site annotation site N-glycoproteomics: mass spectrometry-based glycosylation site annotation. 2747653 6 13 gly glycosylated 1107:1118 arg1 The 74K albumin The 74K albumin PUBTATOR 74K albumin 24186 The 74K albumin (unlike the 68K albumin) is glycosylated; a point mutation converting Lys256 to Asn introduces an N-linked glycosylation site that is similar to one found in the sequence of mammalian alpha-fetoproteins. 2747653 6 18 gly glycosylation 1186:1198 arg2 an N-linked glycosylation site an N-linked glycosylation site site The 74K albumin (unlike the 68K albumin) is glycosylated; a point mutation converting Lys256 to Asn introduces an N-linked glycosylation site that is similar to one found in the sequence of mammalian alpha-fetoproteins. 11312284 3 26 part_of subunit 379:385 arg1 alpha subunit residues subunit alpha subunit residues Fterm Site subunit residues alpha subunit residues, 187-199, which are part of overlapping ACh and alpha-bungarotoxin (Bgt) binding sites on AChRs, were assayed using a monoclonal antibody (mAb) specific for these residues. 19500602 4 69 gly glycosylation 720:732 arg2 a potential third glycosylation site a potential third glycosylation site site Here we examine a non-synonymous single nucleotide polymorphism (SNP) in EL2 that gives rise to a potential third glycosylation site due to substitution of a lysine at position 201 with an asparagine (K201N). 1926782 9 65 gly glycosylation 1543:1555 arg2 at least one major glycosylation site at least one major glycosylation site site This implied that Ad2 fiber is a substrate for GlcNAc O-seryl transferase in insect cell cytoplasm and that at least one major glycosylation site is located in the shaft domain, between Met61 and Asn410. 9104789 4 34 part_of found 477:481 arg1 the predicted protein AND No potential glycosylation site the predicted protein No potential glycosylation site Fterm Site protein site No potential glycosylation site was found in the predicted protein. 3517854 0 27 part_of interleukin 44:54 arg1 sequence interleukin 2 sequence PUBTATOR Site interleukin 2 280822 sequence Cloning, sequence, and expression of bovine interleukin 2. 10413465 5 26 part_of apoE2 1166:1170 arg1 the O-glycosylation site apoE2 the O-glycosylation site PUBTATOR Site apoE2 348 site This analysis showed that a mutation in the O-glycosylation site of apoE2 (Thr194-Ala) did not affect the SDS-stable binding of apoE to Abeta. 19753315 7 68 gly N-glycosylation 762:776 arg1 CLRN1 CLRN1 PUBTATOR CLRN1 P58418 The N-glycosylation status of CLRN1 was studied by using the N-glycosidase F (PNGase F) enzyme and western blotting. 17496250 11 1 gly O-glycosylated 1382:1395 arg1 IGFBP-5 IGFBP-5 PUBTATOR IGFBP-5 3488 IGFBP-5 was heterogeneously O-glycosylated mainly by sialylated core 1 type glycans. 17496250 11 64 gly sialylated 1407:1416 arg1 sialylated core 1 type glycans sialylated core 1 type glycans IGFBP-5 was heterogeneously O-glycosylated mainly by sialylated core 1 type glycans. 18700760 6 31 gly ST6Gal-I 930:937 arg1 The catalytic domain The catalytic domain The catalytic domain Site domain The catalytic domain from rat ST6Gal-I was expressed in mammalian HEK293 cells. 26977294 9 84 part_of Fc-mAb 1460:1465 arg1 the Fc-mAb domain Fc the Fc-mAb domain Cterm Site Fc domain While fucosylation does not affect Fab-TNF α interactions, we found that in the absence of fucosylation the Fc-mAb domain and Fcγ RIIIA are closer and new strong interactions are established between G129 of the receptor and S301 of the Chimera 2 Fc mAb; new polar interactions are also established between the Chimera 2 Fc residues Y299, N300, and S301 and the Fcγ RIIIA residues K128, G129, R130, and R155. 26977294 9 85 part_of Fc 1672:1673 arg1 the Chimera 2 Fc residues Y299 Fc the Chimera 2 Fc residues Y299 Cterm Site Fc residues While fucosylation does not affect Fab-TNF α interactions, we found that in the absence of fucosylation the Fc-mAb domain and Fcγ RIIIA are closer and new strong interactions are established between G129 of the receptor and S301 of the Chimera 2 Fc mAb; new polar interactions are also established between the Chimera 2 Fc residues Y299, N300, and S301 and the Fcγ RIIIA residues K128, G129, R130, and R155. 26977294 9 98 part_of Fcγ 1713:1715 arg1 the Fcγ RIIIA residues Fc the Fcγ RIIIA residues Cterm Site Fc residues While fucosylation does not affect Fab-TNF α interactions, we found that in the absence of fucosylation the Fc-mAb domain and Fcγ RIIIA are closer and new strong interactions are established between G129 of the receptor and S301 of the Chimera 2 Fc mAb; new polar interactions are also established between the Chimera 2 Fc residues Y299, N300, and S301 and the Fcγ RIIIA residues K128, G129, R130, and R155. 30659065 4 60 part_of have 838:841 arg1 IgGs AND a single N-glycosylation site IgGs a single N-glycosylation site Cterm Site IgGs site Although IgGs usually have a single N-glycosylation site and are well studied, other antibody isotypes, e.g. IgA and IgM, that are the first responders in certain diseases, have two to five sites/monomer of antibody, and little is known about their N-glycosylation. 31516400 7 10 gly N-glycoproteins 1308:1322 arg1 more than 7200 N-glycoproteins more than 7200 N-glycoproteins Fterm N-glycoproteins Results: The N-GlycositeAtlas database contains more than 30,000 glycosite-containing peptides (representing > 14,000 N-glycosylation sites) from more than 7200 N-glycoproteins from different biological sources including human-derived tissues, body fluids and cell lines from over 100 studies. 31516400 7 46 gly N-glycosylation 1265:1279 arg2 more than 30,000 glycosite-containing peptides more than 30,000 glycosite-containing peptides peptides Results: The N-GlycositeAtlas database contains more than 30,000 glycosite-containing peptides (representing > 14,000 N-glycosylation sites) from more than 7200 N-glycoproteins from different biological sources including human-derived tissues, body fluids and cell lines from over 100 studies. 31516400 7 46 gly N-glycosylation 1265:1279 arg2 representing > 14,000 N-glycosylation sites representing > 14,000 N-glycosylation sites sites Results: The N-GlycositeAtlas database contains more than 30,000 glycosite-containing peptides (representing > 14,000 N-glycosylation sites) from more than 7200 N-glycoproteins from different biological sources including human-derived tissues, body fluids and cell lines from over 100 studies. 8099782 2 31 gly B 360:360 arg1 The carbohydrate chain saposin B The carbohydrate chain Cterm saposin B The carbohydrate chain of saposin B was removed and deglycosylated saposin B was characterized and compared with native saposin B. Deglycosylated saposin B stimulated the enzymatic hydrolysis of ganglioside GM1 by acid beta-galactosidase and sulfatide by arylsulfatase A to the same extent as native saposin B. 8099782 2 73 gly deglycosylated 378:391 arg1 deglycosylated saposin B deglycosylated saposin B Cterm deglycosylated saposin B The carbohydrate chain of saposin B was removed and deglycosylated saposin B was characterized and compared with native saposin B. Deglycosylated saposin B stimulated the enzymatic hydrolysis of ganglioside GM1 by acid beta-galactosidase and sulfatide by arylsulfatase A to the same extent as native saposin B. 2324102 5 39 gly N-glycosylation 1043:1057 arg2 the single putative N-glycosylation site the single putative N-glycosylation site site (i) Although the ectodomains are only 70% identical, all putative glycosaminoglycan attachment sites are identical (two of them belong to the consensus sequence SGXG and three others to (E/D)GSG(E/D), as are also (ii) the single putative N-glycosylation site and (iii) the proteinase-sensitive dibasic RK site adjacent to the extracellular face of the transmembrane domain. 12527193 7 65 part_of has 992:994 arg1 CRB3 AND a very short extracellular domain CRB3 a very short extracellular domain PUBTATOR Site CRB3 92359 domain In contrast to Drosophila Crumbs and CRB1, CRB3 has a very short extracellular domain but like these proteins it has a conserved intracellular domain that allows it to complex with Pals1 and PATJ. 11248207 4 34 part_of NaDC-1 540:545 arg1 the amino terminus NaDC-1 the amino terminus OGER Site NaDC-1 Q13183 terminus The Flag epitope tag (DYKDDDDK) was fused to the amino terminus of NaDC-1 (Flag-NaDC-1), and a monoclonal antibody against the Flag epitope was used to determine the location of the N-terminus. 26940363 9 19 gly glycoproteins 1798:1810 arg1 mammalian glycoproteins mammalian glycoproteins Fterm glycoproteins CONCLUSIONS: Updates and improvements to UniCarbKB have introduced unique features for storing and displaying glycosylation features of mammalian glycoproteins. 17496250 13 86 gly sialylated 1570:1579 arg1 sialylated core 2 type glycan sialylated core 2 type glycan A small amount of sialylated core 2 type glycan was also present. 8829802 4 35 part_of had 679:681 arg1 Rat transferrin AND the potential N-linked glycosylation site Rat transferrin the potential N-linked glycosylation site PUBTATOR Site Rat transferrin 24825 site Rat transferrin, like other transferrins, had the potential N-linked glycosylation site only in the C-terminal domain, although lactoferrins characterized so far contained the glycosylation sites in both the N- and C-terminal domains. 10211957 4 35 part_of E1 713:714 arg1 the five potential glycosylation sites E1 the five potential glycosylation sites Cterm Site E1 sites A recent study has revealed that upon partial deglycosylation with endoglycosidase H only four of the five potential glycosylation sites of HCV glycoprotein E1 are utilized. 9442070 9 36 gly N-glycans 1540:1548 arg1 the C alpha 2 domain the C alpha 2 domain the C alpha 2 domain Site domain Neutrophil Fcα R binding studies, using recombinant IgA1, indicated that neither the tailpiece region nor the N-glycans in the C alpha 2 domain contribute to IgA1-neutrophil Fcα R binding. 1448922 6 9 part_of proteins 1335:1342 arg1 the sequence proteins the sequence Fterm Site proteins sequence The signal-anchor and glycosylation features of 11.6K are preserved in Ad2 and Ad5 (group C), and in Ad3 and Ad7 (group B), but the sequence of 11.6K is more diverged among these serotypes than is the sequence of most other adenovirus proteins. 1448922 6 29 part_of 11.6K 1244:1248 arg1 the sequence 11.6K the sequence Cterm Site 11.6K sequence The signal-anchor and glycosylation features of 11.6K are preserved in Ad2 and Ad5 (group C), and in Ad3 and Ad7 (group B), but the sequence of 11.6K is more diverged among these serotypes than is the sequence of most other adenovirus proteins. 11202411 8 51 gly glycosylation 1360:1372 arg2 an extra glycosylation site an extra glycosylation site site The variant LH beta allele contains two point mutations, which introduce to LH two amino acid changes and an extra glycosylation site. 25451932 10 2 gly N-Glycosylation 1248:1262 arg2 Asn-1022 Asn-1022 Asn-1022 N-Glycosylation at Asn-1022 may be switched to different sites to promote corin zymogen activation. 26940363 2 80 gly glycoproteins 560:572 arg1 single purified glycoproteins single purified glycoproteins The database comprises two levels of annotation (i) global-specific data of oligosaccharides released and characterised from single purified glycoproteins and (ii) information pertaining to site-specific glycan heterogeneity. 29932112 4 17 gly N-glycosylation 547:561 arg2 the predicted N-glycosylation site Panx2 site PUBTATOR Panx2 56666 site Our objectives were to validate the predicted N-glycosylation site of Panx2 and to study the effects of Panx2 glycosylation on localization and its capacity to interact with Panx1. 10678398 3 16 gly glycosylation 701:713 arg2 a conserved N-linked glycosylation site a conserved N-linked glycosylation site site Predicted primary structures of both the feline Cgamma1 genes, designated as Cgamma1a and Cgamma1b, were similar to that of human Cgamma1 gene, for instance, as to the size of constant domains, the presence of six conserved cysteine residues involved in formation of the domain structure, and the location of a conserved N-linked glycosylation site. 27725718 5 4 gly glycosylation 695:707 arg2 the glycosylation site occupancy the glycosylation site occupancy site Using an optimized method protocol, we determined the glycosylation site occupancy from four proteins of hepatic and lymphatic origin from CDG and NAFLD patients. 26972907 4 71 gly glycosylation 561:573 arg2 a single glycosylation site a single glycosylation site site A site-directed mutagenesis verified a single glycosylation site in UT-A3 at Asn279. 26972907 4 71 gly glycosylation 561:573 arg2 Asn279 Asn279 Asn279 A site-directed mutagenesis verified a single glycosylation site in UT-A3 at Asn279. 23908491 6 81 gly glycoprotein 792:803 arg1 HCV glycoprotein HCV glycoprotein Fterm glycoprotein The entry functions and the sensitivity to antibody neutralization of selected HCV glycoprotein sequences were tested in the HCV pseudotyped particles (HCVpp) system. 9455905 4 71 gly O-glycosylation 1057:1071 arg1 six secreted recombinant reporter proteins six secreted recombinant reporter proteins Fterm proteins To determine whether the charge distribution effect on O-glycosylation is limited to a specific sequence context or restricted to unique isoforms of ppGaNTase, we have analyzed the in vivo O-glycosylation of six secreted recombinant reporter proteins in three different cell backgrounds. 19065542 0 39 gly glycopeptides 20:32 arg2 glycopeptides glycopeptides glycopeptides Characterization of glycopeptides by combining collision-induced dissociation and electron-transfer dissociation mass spectrometry data. 9139737 5 60 gly Alanine 1051:1057 arg1 Alanine scanning mutagenesis Alanine Alanine scanning mutagenesis Alanine Alanine scanning mutagenesis revealed that only two amino acids are necessary for recognition by the sterol-regulated protease: 1) the leucine at the cleavage site (leucine 522), and 2) the arginine at the P4 position (arginine 519). 26348848 9 37 gly glycoproteins 1746:1758 arg1 these glycoproteins these glycoproteins Our findings provide direct evidence that N-glycans of Kv3.1 splice variants contribute to the placement of these glycoproteins in the plasma membrane of neuronal-derived cells while those of Kv1.1 were absent. 31637569 1 3 gly N-glycopeptide 175:188 arg2 a small synthetic N-glycopeptide library a small synthetic N-glycopeptide library N-glycopeptide We established a small synthetic N-glycopeptide library to systematically evaluate the effect of glycosylation site location and glycan size on the efficiency of electron transfer dissociation (ETD) fragmentation and subsequent automated identification. 31637569 1 67 gly glycosylation 239:251 arg2 glycosylation site location glycosylation site location site We established a small synthetic N-glycopeptide library to systematically evaluate the effect of glycosylation site location and glycan size on the efficiency of electron transfer dissociation (ETD) fragmentation and subsequent automated identification. 27641734 4 72 gly N-glycosylation 869:883 arg2 N-glycosylation site N-glycosylation site site Both wild-type (WT) CD97-ECD and its truncated, GPS mutated, PNGase F-deglycosylated, and N-glycosylation site mutated forms were expressed and purified. 27641734 4 125 gly mutated 890:896 arg1 N-glycosylation site N-glycosylation site site Both wild-type (WT) CD97-ECD and its truncated, GPS mutated, PNGase F-deglycosylated, and N-glycosylation site mutated forms were expressed and purified. 27574189 16 21 gly containing 1662:1671 arg1 immune- or clearance receptors AND carbohydrate recognition domains immune- or clearance receptors carbohydrate recognition domains Fterm receptors Overall, our findings highlight the complexity of glycan modifications on ADAMTS13, which may have implications for its interaction with immune- or clearance receptors containing carbohydrate recognition domains. 26944735 7 3 gly O-glycosylation 1547:1561 arg2 a previously unknown O-glycosylation site a previously unknown O-glycosylation site site In addition, three consensus N-glycosylation sites at N142, N363, and N599 could be identified together with a previously unknown O-glycosylation site and an Asn-hydroxylation. 26944735 7 37 gly N-glycosylation 1446:1460 arg2 three consensus N-glycosylation sites three consensus N-glycosylation sites sites In addition, three consensus N-glycosylation sites at N142, N363, and N599 could be identified together with a previously unknown O-glycosylation site and an Asn-hydroxylation. 26944735 7 37 gly N-glycosylation 1446:1460 arg2 N142 N142, N363, and N599 N142, N363, and N599 In addition, three consensus N-glycosylation sites at N142, N363, and N599 could be identified together with a previously unknown O-glycosylation site and an Asn-hydroxylation. 26944735 7 37 gly N-glycosylation 1446:1460 arg2 N599 N142, N363, and N599 N142, N363, and N599 In addition, three consensus N-glycosylation sites at N142, N363, and N599 could be identified together with a previously unknown O-glycosylation site and an Asn-hydroxylation. 26944735 7 37 gly N-glycosylation 1446:1460 arg2 N599 N142, N363, and N599 N142, N363, and N599 In addition, three consensus N-glycosylation sites at N142, N363, and N599 could be identified together with a previously unknown O-glycosylation site and an Asn-hydroxylation. 16118277 3 64 gly glycosylation 557:569 arg2 a potential glycosylation site a potential glycosylation site site Their HA1 amino acid sequences differ at 10 positions, one of which (N154) introduces a potential glycosylation site in A/Vietnam/1203/04 (H5N1). 16331960 3 68 gly nonglycosylated 607:621 arg1 normal glycosylated and nonglycosylated recombinant human transferrin normal glycosylated and nonglycosylated recombinant human transferrin PUBTATOR transferrin 7018 Differential susceptibility to proteolysis by chymotrypsin was demonstrated for normal glycosylated and nonglycosylated recombinant human transferrin, using reverse-phase (RP) HPLC, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry, and LC-tandem mass spectrometry (MS/MS). 16331960 3 71 gly glycosylated 590:601 arg1 normal glycosylated and nonglycosylated recombinant human transferrin normal glycosylated and nonglycosylated recombinant human transferrin PUBTATOR transferrin 7018 Differential susceptibility to proteolysis by chymotrypsin was demonstrated for normal glycosylated and nonglycosylated recombinant human transferrin, using reverse-phase (RP) HPLC, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry, and LC-tandem mass spectrometry (MS/MS). 12572058 7 22 gly N-glycosylation 1331:1345 arg2 one N-glycosylation site one N-glycosylation site site Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II. 8652881 8 59 gly glycosylated 1472:1483 arg1 recombinant FVIII-delta II recombinant FVIII-delta II OGER FVIII P00451 The difference from the theoretical molecular molecular masses and the observation of broad molecular peaks suggest that recombinant FVIII-delta II has been effectively glycosylated by the host cell on both heavy and light chains. 3980466 9 123 gly underglycosylated 1695:1711 arg1 a more C-terminal underglycosylated site a more C-terminal underglycosylated site site The alpha-chains of each class II antigen also contain a more C-terminal underglycosylated site where sialylation and branching are reduced to differing degrees depending upon the site. 17312998 2 11 gly glycosylation 481:493 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Analysis of the deduced amino acid sequence indicated that SPV2 has its core arginine residue, a potential N-linked glycosylation site near its N-terminal, and one transmembrane domain in its C-terminal. 9774483 2 49 gly NCAM 541:544 arg1 polysialylation NCAM polysialylation PUBTATOR NCAM 4684 To determine the individual and combined roles of PST and STX in polysialic acid synthesis, in the present study we asked if PST and STX differ in the acceptor requirement and if PST and STX act together in polysialylation of NCAM. 9774483 2 63 gly polysialylation 522:536 arg1 NCAM NCAM PUBTATOR NCAM 4684 To determine the individual and combined roles of PST and STX in polysialic acid synthesis, in the present study we asked if PST and STX differ in the acceptor requirement and if PST and STX act together in polysialylation of NCAM. 10218949 2 19 gly glycosylated 492:503 arg1 All three asparagine residues AT1-R asparagine residues PUBTATOR AT1-R 24180 asparagine residues All three asparagine residues (Asn4, Asn176, Asn188) contained within consensus sites for N-linked glycosylation could be glycosylated in Cos-7 cells and appeared to be glycosylated on the endogenous AT1-R in bovine adrenal glomerulosa cells. 10218949 2 19 gly glycosylated 492:503 arg2 All three asparagine residues AT1-R asparagine residues PUBTATOR AT1-R 24180 asparagine residues All three asparagine residues (Asn4, Asn176, Asn188) contained within consensus sites for N-linked glycosylation could be glycosylated in Cos-7 cells and appeared to be glycosylated on the endogenous AT1-R in bovine adrenal glomerulosa cells. 10218949 2 19 gly glycosylated 492:503 arg2 All three asparagine residues asparagine residues asparagine residues All three asparagine residues (Asn4, Asn176, Asn188) contained within consensus sites for N-linked glycosylation could be glycosylated in Cos-7 cells and appeared to be glycosylated on the endogenous AT1-R in bovine adrenal glomerulosa cells. 10218949 2 54 gly glycosylated 445:456 arg2 All three asparagine residues asparagine residues asparagine residues All three asparagine residues (Asn4, Asn176, Asn188) contained within consensus sites for N-linked glycosylation could be glycosylated in Cos-7 cells and appeared to be glycosylated on the endogenous AT1-R in bovine adrenal glomerulosa cells. 1567356 11 51 part_of OMD 1664:1666 arg1 the individual glycosylation sites OMD the individual glycosylation sites OGER Site OMD Q99983 sites The results indicate that the 'site-directed' model of processing offers the most consistent explanation for the structures seen at the individual glycosylation sites of OMD. 16669630 8 1 gly glycosylation 1307:1319 arg2 the glycosylation site the glycosylation site site Deglycosylation of aspartoacylase or mutation at the glycosylation site causes decreased enzyme stability and diminished catalytic activity. 16669630 8 47 gly Deglycosylation 1254:1268 arg2 the glycosylation site aspartoacylase site OGER aspartoacylase P45381 site Deglycosylation of aspartoacylase or mutation at the glycosylation site causes decreased enzyme stability and diminished catalytic activity. 16669630 8 47 gly Deglycosylation 1254:1268 arg1 the glycosylation site aspartoacylase site OGER aspartoacylase P45381 site Deglycosylation of aspartoacylase or mutation at the glycosylation site causes decreased enzyme stability and diminished catalytic activity. 16669630 8 47 gly Deglycosylation 1254:1268 arg1 the glycosylation site site site Deglycosylation of aspartoacylase or mutation at the glycosylation site causes decreased enzyme stability and diminished catalytic activity. 14660594 4 8 gly glycosylation 832:844 arg2 glycosylation site mapping glycosylation site mapping site Here, we use protease protection, glycosylation site mapping, and cysteine derivitization to define the topology of the 277-amino acid human Insig-1. 21439032 0 54 gly glycosylation 30:42 arg2 putative N-linked glycosylation sites putative N-linked glycosylation sites sites Mutation of putative N-linked glycosylation sites in Japanese encephalitis virus premembrane and envelope proteins enhances humoral immunity in BALB/C mice after DNA vaccination. 15342690 3 5 gly glycosylation 505:517 arg2 Each putative glycosylation site Each putative glycosylation site site Each putative glycosylation site was examined by site-directed mutagenesis of the asparagine (Asn). 11054460 3 51 gly O 914:914 arg1 -glycosylated belt region -glycosylated belt region region The third single-residue mutation was made to decrease flexibility and increase O:-glycosylation in the already highly O:-glycosylated belt region that extends around the globular catalytic domain. 11054460 3 53 gly -glycosylated 955:967 arg1 -glycosylated belt region -glycosylated belt region region The third single-residue mutation was made to decrease flexibility and increase O:-glycosylation in the already highly O:-glycosylated belt region that extends around the globular catalytic domain. 6175959 10 1 part_of C3d 1196:1198 arg1 a peptide C3d a peptide PUBTATOR Site C3d 100861467 peptide Comparison of residues 1-49 of C3d with a peptide from alpha(2)-macroglobulin [Swenson, R. P. & Howard, J. B. (1980) J. Biol. 6175959 10 24 part_of C3d 1196:1198 arg1 1-49 C3d 1-49 PUBTATOR SpecificSite C3d 100861467 residues 1-49 Comparison of residues 1-49 of C3d with a peptide from alpha(2)-macroglobulin [Swenson, R. P. & Howard, J. B. (1980) J. Biol. 6175959 10 47 part_of -macroglobulin 1228:1241 arg1 a peptide alpha(2)-macroglobulin a peptide PUBTATOR Site alpha(2)-macroglobulin 2 peptide Comparison of residues 1-49 of C3d with a peptide from alpha(2)-macroglobulin [Swenson, R. P. & Howard, J. B. (1980) J. Biol. 20800224 4 2 gly N-glycosylated 546:559 arg1 mutant (C87S) recombinant NGAL mutant (C87S) recombinant NGAL PUBTATOR NGAL 3934 This study demonstrated that 7-9% of mutant (C87S) recombinant NGAL was N-glycosylated and no O-glycosylation was detected. 16253890 3 28 gly glycosylation 459:471 arg2 glycosylation site deletions glycosylation site deletions site There is evidence that mutant HIV strains containing glycosylation site deletions trigger the production of specific neutralising antibodies to previously hidden gp120 epitopes. 16823988 8 3 gly sialylated 1151:1160 arg1 sialylated glycoproteins sialylated glycoproteins Fterm glycoproteins We applied this approach to the analysis of sialylated glycoproteins in pancreatic cancer serum. 16823988 8 57 gly glycoproteins 1162:1174 arg1 sialylated glycoproteins sialylated glycoproteins Fterm glycoproteins We applied this approach to the analysis of sialylated glycoproteins in pancreatic cancer serum. 8352759 7 4 gly N-glycosylation 1074:1088 arg2 The Asn-94 N-glycosylation site The Asn-94 N-glycosylation site site The Asn-94 N-glycosylation site is present in the human and rabbit sequences but absent in the pig sequence. 8352759 7 7 gly human 1113:1117 arg1 sequences sequences sequences The Asn-94 N-glycosylation site is present in the human and rabbit sequences but absent in the pig sequence. 8352759 7 11 gly human 1113:1117 arg1 The Asn-94 N-glycosylation site The Asn-94 N-glycosylation site The Asn-94 N-glycosylation site Site site The Asn-94 N-glycosylation site is present in the human and rabbit sequences but absent in the pig sequence. 19735085 1 48 gly glycosylation 186:198 arg1 these peptides peptides peptides We tested the possibility that we may express unique peptide probes on cell surfaces, and detect site-specific glycosylation on these peptides using flow cytometry. 17963278 5 77 gly glycosylation 839:851 arg2 more than one potential glycosylation site more than one potential glycosylation site site Approximately 90% of the proteins identified contained more than one potential glycosylation site. 2347305 5 16 gly N-glycosylation 556:570 arg2 the N-glycosylation site the N-glycosylation site site The bend region between segments S1 and S2 is unusually long and does not contain the N-glycosylation site commonly found in this region. 6433976 6 65 gly differences 1265:1275 arg1 this peptide this peptide this peptide Site peptide Since carbohydrate was present in this peptide for variant I and since a marked difference in chromatographic behavior for T15 was observed in variant II, we conclude that carbohydrate differences in this peptide (i.e., Asn-184 in the numbering system of the cDNA-derived amino acid sequence) are the explanation for the size differences between variants I and II. 6433976 6 13 gly present 1103:1109 arg2 this peptide AND carbohydrate peptide carbohydrate peptide Since carbohydrate was present in this peptide for variant I and since a marked difference in chromatographic behavior for T15 was observed in variant II, we conclude that carbohydrate differences in this peptide (i.e., Asn-184 in the numbering system of the cDNA-derived amino acid sequence) are the explanation for the size differences between variants I and II. 27725718 9 50 gly occupied 1247:1254 arg2 glycosylation sites glycosylation sites sites Furthermore, we observed, that glycosylation sites of liver-originating transferrin and haptoglobin are differentially occupied under physiological conditions, a further instance not noticed in serum proteins to date. 27725718 9 28 gly glycosylation 1159:1171 arg2 glycosylation sites haptoglobin sites PUBTATOR haptoglobin 3240 sites Furthermore, we observed, that glycosylation sites of liver-originating transferrin and haptoglobin are differentially occupied under physiological conditions, a further instance not noticed in serum proteins to date. 27725718 9 28 gly glycosylation 1159:1171 arg1 liver-originating transferrin transferrin sites PUBTATOR transferrin 7018 sites Furthermore, we observed, that glycosylation sites of liver-originating transferrin and haptoglobin are differentially occupied under physiological conditions, a further instance not noticed in serum proteins to date. 10211957 0 74 gly glycoprotein 139:150 arg1 the HCV glycoprotein complex the HCV glycoprotein complex Fterm glycoprotein Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. 10211957 0 102 gly glycoprotein 63:74 arg1 hepatitis C virus (HCV) glycoprotein E1 hepatitis C virus (HCV) glycoprotein E1 Fterm glycoprotein Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. 10211957 0 56 gly glycosylation 16:28 arg2 the glycosylation sites E1 sites Cterm E1 sites Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. 11562540 6 71 gly glycosylation 1343:1355 arg2 a new glycosylation site a new glycosylation site site It was also found that most of the escape mutants selected by antibodies to sites I-A, I-B and I-C acquired a new glycosylation site at position 160, 187 or 131, respectively, which indicates that A/H2N2 viruses have the potential to gain at least one additional oligosaccharide on the tip of the HA, although this has never occurred during 11 years of its circulation in humans. 21507336 0 60 gly N-glycosylation 122:136 arg2 an N-glycosylation site an N-glycosylation site site Enhanced accumulation of secreted human growth hormone by transgenic tobacco cells correlates with the introduction of an N-glycosylation site. 9461526 7 29 part_of B 864:864 arg1 The predicted amino acid sequence saposin B The predicted amino acid sequence Cterm Site saposin B sequence The predicted amino acid sequence of saposin B matched exactly that of purified chicken saposin B protein. 23820512 2 55 gly N-glycosites 448:459 arg2 N-glycosites N-glycosites N-glycosites In this study we report a simple and rapid sample preparation platform, the GlycoFilter, which allows a comprehensive characterization of N-glycans, N-glycosites, and proteins in a single workflow. 20153530 7 65 gly glycosylated 1130:1141 arg1 this glycosylated C9 this glycosylated C9 PUBTATOR C9 117512 Again, this glycosylated C9 was as active as native C9 and could be induced to polymerize by heating or incubation with metal ions. 11371512 0 38 part_of saposin 18:24 arg1 the saposin A domain saposin A the saposin A domain Cterm Site saposin A domain A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse. 11371512 0 86 part_of A 26:26 arg1 the saposin A domain saposin A the saposin A domain Cterm Site saposin A domain A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse. 7613477 9 74 gly glycosylation 1830:1842 arg2 the glycosylation site the glycosylation site site Previous studies of LCAT indicated that removal of the glycosylation site at Asn272 converts this protein to a phospholipase (Francone OL, Evangelista L, Fielding CJ, 1993, Biochim Biophys Acta 1166:301-304). 7635146 2 117 part_of glucosidase 454:464 arg1 tryptic peptides glucosidase I tryptic peptides PUBTATOR Site glucosidase I 7841 peptides A human hippocampus cDNA library was screened against oligonucleotide probes, generated by PCR using primers derived from the amino acid sequences of tryptic peptides of pig liver glucosidase I. Two independent lambda clones were isolated which allowed the construction of a full-length glucosidase I cDNA of 2881 bp. 19284292 3 1 gly sequence 711:718 arg1 specific protein (sequence) determinants specific protein (sequence) determinants Distinct from these examples, the beta4-GalNAc modification of N-linked glycans on a selected panel of proteins, such as carbonic anhydrase or glycodelin, was demonstrated recently to require specific protein (sequence) determinants proximal to the glycosylation site that function as cis-regulatory elements. 19284292 3 22 gly glycosylation 750:762 arg2 the glycosylation site the glycosylation site site Distinct from these examples, the beta4-GalNAc modification of N-linked glycans on a selected panel of proteins, such as carbonic anhydrase or glycodelin, was demonstrated recently to require specific protein (sequence) determinants proximal to the glycosylation site that function as cis-regulatory elements. 9882683 11 55 gly nonglycosylated 1458:1472 arg1 nonglycosylated variants nonglycosylated variants Fterm variants However, nonglycosylated variants remained capable of producing large amounts of S pilin. 10992007 4 31 gly glycosylation 901:913 arg2 the first or third glycosylation site the first or third glycosylation site site Also the expression levels and function of TSHR mutants with a Ser/Thr to Ala substitution at the first or third glycosylation site were found to be intact. 24838853 2 0 gly glycoproteins 276:288 arg1 the two surface glycoproteins the two surface glycoproteins Fterm glycoproteins Sequence analysis of the genes for the two surface glycoproteins revealed that residue 226 of the hemagglutinin (HA) of eight isolates was a leucine. 3485444 5 12 gly glycosylation 787:799 arg2 the glycosylation site the glycosylation site site The procedure was first tested on a protein for which the location of the glycosylation site is known, HLA-B7 antigen. 8070391 6 59 gly deglycosylation 755:769 arg1 the cross-linked receptor the cross-linked receptor Fterm receptor Partial deglycosylation of the cross-linked receptor with neuraminidase caused a shift in apparent size to 52 kDa. 31471966 4 17 part_of regions 899:905 arg1 the signal peptide regions the signal peptide peptide Mutational analyses including insertion of a glycosylation site for the tagged PTHrP revealed that the evolutionarily conserved regions in the signal peptide and the pro-region facilitate the redirection of ppPTHrP from the secretory pathway to the nuclear targeting pathway. 31471966 4 17 part_of regions 899:905 arg1 the pro-region regions the pro-region pro Mutational analyses including insertion of a glycosylation site for the tagged PTHrP revealed that the evolutionarily conserved regions in the signal peptide and the pro-region facilitate the redirection of ppPTHrP from the secretory pathway to the nuclear targeting pathway. 11152692 11 64 part_of contains 1231:1238 arg1 The protein AND an N-glycosylation site protein site Fterm Site protein site The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54). 8987398 2 24 gly glycosylation 318:330 arg2 the only site the only site site For human MHC class I molecules, Asn is the only site of glycosylation and the attached oligosaccharides are remarkably uniform. 8987398 2 24 gly glycosylation 318:330 arg2 Asn Asn Asn For human MHC class I molecules, Asn is the only site of glycosylation and the attached oligosaccharides are remarkably uniform. 2500441 0 69 gly glycosylated 36:47 arg1 human insulin-like growth factor I human insulin-like growth factor I Fterm factor I Isolation and characterization of a glycosylated form of human insulin-like growth factor I produced in Saccharomyces cerevisiae. 16938437 7 53 gly N-glycosylation 1190:1204 arg2 any single N-glycosylation site any single N-glycosylation site site All hNCT mutants interacted with calnexin and ERGIC-53, indicating that the association was not mediated by any single N-glycosylation site. 24336240 0 54 gly glycopeptide 36:47 arg2 glycopeptide glycopeptide glycopeptide Interaction modes and approaches to glycopeptide and glycoprotein enrichment. 24336240 0 62 gly glycoprotein 53:64 arg1 glycoprotein enrichment glycoprotein enrichment Fterm glycoprotein Interaction modes and approaches to glycopeptide and glycoprotein enrichment. 15039521 3 28 gly positions 435:443 arg1 3-5 3-5 positions 3 The preS2 region of woodchuck hepatitis virus (WHV) contains a potential glycosylation site Asn-Gln-Thr at amino acid (aa) positions 3-5. 15039521 3 56 gly glycosylation 385:397 arg2 a potential glycosylation site a potential glycosylation site site Asn-Gln-Thr The preS2 region of woodchuck hepatitis virus (WHV) contains a potential glycosylation site Asn-Gln-Thr at amino acid (aa) positions 3-5. 8364023 8 41 part_of LCAT 1217:1220 arg1 Asn20-->Thr LCAT Asn20-->Thr PUBTATOR AminoAcid LCAT 3931 Asn20 The amount secreted, specific activity, and Vmax of LCAT (Asn20-->Thr) were similar to those of the wild-type LCAT. 23192877 5 21 part_of NiV-F 877:881 arg1 the NiV-F cytoplasmic tail NiV-F the NiV-F cytoplasmic tail Cterm Site NiV-F tail Truncation of the NiV-F cytoplasmic tail (T5F) alone, combined with full-length NiV-G, resulted in optimal titers of NiV-pseudotyped particles (NiVpp) (∼10(6) IU/ml), even without ultracentrifugation. 25213400 9 5 gly containing 825:834 arg1 MS2 AND one glucuronic acid MS2 one glucuronic acid PUBTATOR MS2 100271694 The most charged glycan is MS2 containing three sulfate groups and one glucuronic acid; whereas the least charged one is the BA2 residue. 18636497 3 4 gly glycosylation 688:700 arg2 two potential N-linked glycosylation sites two potential N-linked glycosylation sites sites Sialylation profiles were quantitated by reversed-phase HPLC separations of the site-specific pools of tryptic glycopeptides representing IFN-gamma's two potential N-linked glycosylation sites (i.e., Asn(25) and Asn(97)). 18636497 3 67 gly IFN-gamma 653:661 arg1 two potential N-linked glycosylation sites two potential N-linked glycosylation sites sites Sialylation profiles were quantitated by reversed-phase HPLC separations of the site-specific pools of tryptic glycopeptides representing IFN-gamma's two potential N-linked glycosylation sites (i.e., Asn(25) and Asn(97)). 18636497 3 69 gly glycopeptides 626:638 arg2 tryptic glycopeptides tryptic glycopeptides glycopeptides Sialylation profiles were quantitated by reversed-phase HPLC separations of the site-specific pools of tryptic glycopeptides representing IFN-gamma's two potential N-linked glycosylation sites (i.e., Asn(25) and Asn(97)). 30427586 3 53 gly glycoproteins 509:521 arg1 IgG IgG Cterm IgG Using a set of four representative and biopharmaceutically relevant glycoproteins (IgG, fibrinogen, lactotransferrin, and ribonuclease B), the benefits and limitations of the developed workflow are highlighted and a state-of-the-art blueprint for conducting high-quality in-depth N- and O-glycoproteomic analyses is provided. 30427586 3 53 gly glycoproteins 509:521 arg1 four representative and biopharmaceutically relevant glycoproteins four representative and biopharmaceutically relevant glycoproteins Fterm glycoproteins Using a set of four representative and biopharmaceutically relevant glycoproteins (IgG, fibrinogen, lactotransferrin, and ribonuclease B), the benefits and limitations of the developed workflow are highlighted and a state-of-the-art blueprint for conducting high-quality in-depth N- and O-glycoproteomic analyses is provided. 30427586 3 53 gly glycoproteins 509:521 arg1 lactotransferrin lactotransferrin OGER lactotransferrin P02788 Using a set of four representative and biopharmaceutically relevant glycoproteins (IgG, fibrinogen, lactotransferrin, and ribonuclease B), the benefits and limitations of the developed workflow are highlighted and a state-of-the-art blueprint for conducting high-quality in-depth N- and O-glycoproteomic analyses is provided. 12438611 7 62 gly sugars 1363:1368 arg1 gp120 gp120 sugars OGER gp120 Q14624 To further guide our efforts in mapping the DC-SIGN binding sites on gp120, we used two well-characterized HIV inhibitory agents (2G12 monoclonal antibody and cyanovirin) that bind to high-mannose sugars on gp120. 24497285 2 42 gly glycoproteins 422:434 arg1 glycoproteins glycoproteins Fterm glycoproteins Saliva can be non-invasively sampled and is rich in glycoproteins, giving it the potential to be a useful biofluid for the discovery and detection of disease biomarkers associated with changes in glycosylation. 1380164 11 61 gly glycosylation 1601:1613 arg2 a potential glycosylation site a potential glycosylation site site The mongoose like the snake AcChoR has a potential glycosylation site in the binding site domain. 7628611 0 13 gly glycosylation 56:68 arg2 Asn-265 Asn-265 Asn-265 Asn-265 of frog kainate binding protein is a functional glycosylation site: implications for the transmembrane topology of glutamate receptors. 7628611 0 13 gly glycosylation 56:68 arg2 a functional glycosylation site a functional glycosylation site site Asn-265 of frog kainate binding protein is a functional glycosylation site: implications for the transmembrane topology of glutamate receptors. 14757769 6 8 gly O-glycosylation 1011:1025 arg2 Ser126 Ser126 Ser126 One N-linked consensus sequence (Asn123-Thr125) introduced into a position close to the existing O-glycosylation site (Ser126) had an additional O-linked carbohydrate chain and not an additional N-linked carbohydrate chain suggesting that structural requirements in this region favored O-glycosylation over N-glycosylation. 14757769 6 8 gly O-glycosylation 1011:1025 arg2 the existing O-glycosylation site the existing O-glycosylation site site One N-linked consensus sequence (Asn123-Thr125) introduced into a position close to the existing O-glycosylation site (Ser126) had an additional O-linked carbohydrate chain and not an additional N-linked carbohydrate chain suggesting that structural requirements in this region favored O-glycosylation over N-glycosylation. 14757769 6 68 gly had 1041:1043 arg1 One N-linked consensus sequence AND an additional O-linked carbohydrate chain One N-linked consensus sequence an additional O-linked carbohydrate chain sequence One N-linked consensus sequence (Asn123-Thr125) introduced into a position close to the existing O-glycosylation site (Ser126) had an additional O-linked carbohydrate chain and not an additional N-linked carbohydrate chain suggesting that structural requirements in this region favored O-glycosylation over N-glycosylation. 14757769 6 68 gly had 1041:1043 arg1 One N-linked consensus sequence AND an additional N-linked carbohydrate chain One N-linked consensus sequence an additional N-linked carbohydrate chain sequence One N-linked consensus sequence (Asn123-Thr125) introduced into a position close to the existing O-glycosylation site (Ser126) had an additional O-linked carbohydrate chain and not an additional N-linked carbohydrate chain suggesting that structural requirements in this region favored O-glycosylation over N-glycosylation. 15128311 4 74 gly glycoprotein 375:386 arg1 the glycoprotein the glycoprotein Fterm glycoprotein MALDI MS of the glycoprotein contained an array of peaks in the range from approximately 8900 to approximately 9400 Da indicating its microheterogeneity. 16212939 4 58 gly N-glycosylation 700:714 arg2 potential N-glycosylation site potential N-glycosylation site site The mutation of potential N-glycosylation site, by substituting Gln for either Asn7 of N-terminal 24 amino acids of hIL-1beta (Asn7Gln) or Asn84 of IL-1ra (Asn84Gln), resulted in a dramatic reduction of rhG-CSF secretion efficiency. 8349699 10 4 gly N-glycosylation 1444:1458 arg2 the N-glycosylation sites PGH synthase-1 sites PUBTATOR PGH synthase-1 19224 sites Assuming that the N-glycosylation sites of PGH synthase-1 are on the luminal side of the endoplasmic reticulum (ER), and that the site of tryptic cleavage of ovine PGH synthase-1 (Arg277) is on the cytoplasmic side of the ER, we propose that both the NH2 and COOH termini of PGH synthase-1 are located in the lumen of the ER and that there are two transmembrane domains located between Asn144 and Arg277 and between Arg277 and Asn410, respectively. 10725548 3 52 gly O-glycosylation 627:641 arg2 the conserved O-glycosylation site the conserved O-glycosylation site site We analyzed the nucleotide sequence of a highly virulent strain MHV-2 M-coding region and demonstrated that MHV-2 had a unique amino acid, Asn, at position 2 at the conserved O-glycosylation site. 17144668 3 24 gly N-glycosylation 439:453 arg1 carboxylase carboxylase sites Fterm carboxylase sites In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. 20084966 8 14 gly glycosylation 1454:1466 arg2 one glycosylation site one glycosylation site site CONCLUSION: 5 measles virus circulated in Jilin province in 2001-2008 lose one glycosylation site which probably affected antigenencity. 7999071 0 14 gly glycosylation 98:110 arg2 the proposed N-linked glycosylation site lipoprotein lipase site PUBTATOR lipoprotein lipase 4023 site A naturally occurring mutation at the second base of codon asparagine 43 in the proposed N-linked glycosylation site of human lipoprotein lipase: in vivo evidence that asparagine 43 is essential for catalysis and secretion. 8798624 5 22 part_of ICAM-3 1381:1386 arg1 the BED face ICAM-3 the BED face PUBTATOR Site ICAM-3 3385 face These five residues are predicted by molecular modeling, based on the structure of vascular cell adhesion molecule 1 (VCAM-1), to cluster in two distinct locations on domain 1 of ICAM-3 on the BED face (Asn23 and Ser25) and on the C strand or CD loop (E37), the E strand (F54), and the FG loop (Q75). 8798624 5 74 part_of domain 1369:1374 arg1 the BED face domain the BED face face These five residues are predicted by molecular modeling, based on the structure of vascular cell adhesion molecule 1 (VCAM-1), to cluster in two distinct locations on domain 1 of ICAM-3 on the BED face (Asn23 and Ser25) and on the C strand or CD loop (E37), the E strand (F54), and the FG loop (Q75). 8798624 5 81 part_of face 1399:1402 arg1 domain 1 face domain 1 domain These five residues are predicted by molecular modeling, based on the structure of vascular cell adhesion molecule 1 (VCAM-1), to cluster in two distinct locations on domain 1 of ICAM-3 on the BED face (Asn23 and Ser25) and on the C strand or CD loop (E37), the E strand (F54), and the FG loop (Q75). 8798624 5 81 part_of face 1399:1402 arg1 ICAM-3 ICAM-3 face PUBTATOR Site ICAM-3 3385 face These five residues are predicted by molecular modeling, based on the structure of vascular cell adhesion molecule 1 (VCAM-1), to cluster in two distinct locations on domain 1 of ICAM-3 on the BED face (Asn23 and Ser25) and on the C strand or CD loop (E37), the E strand (F54), and the FG loop (Q75). 8798624 5 82 part_of ICAM-3 1381:1386 arg1 domain 1 ICAM-3 domain 1 PUBTATOR Site ICAM-3 3385 domain These five residues are predicted by molecular modeling, based on the structure of vascular cell adhesion molecule 1 (VCAM-1), to cluster in two distinct locations on domain 1 of ICAM-3 on the BED face (Asn23 and Ser25) and on the C strand or CD loop (E37), the E strand (F54), and the FG loop (Q75). 26400346 7 9 part_of C 977:977 arg1 11 protein kinase C phosphorylation sites 11 protein kinase C 11 protein kinase C phosphorylation sites Cterm Site 11 protein kinase C sites There was 1 cAMP- and cGMP-dependent protein kinase phosphorylation site, 11 protein kinase C phosphorylation sites, 4 casein kinase II phosphorylation sites, 1 amidation site, 1 N-glycosylation site, and 1 tyrosine kinase phosphorylation site in FGF5. 26400346 7 42 part_of kinase 1011:1016 arg1 4 casein kinase II phosphorylation sites casein kinase II 4 casein kinase II phosphorylation sites OGER Site casein kinase II sites There was 1 cAMP- and cGMP-dependent protein kinase phosphorylation site, 11 protein kinase C phosphorylation sites, 4 casein kinase II phosphorylation sites, 1 amidation site, 1 N-glycosylation site, and 1 tyrosine kinase phosphorylation site in FGF5. 26400346 7 45 part_of kinase 1101:1106 arg1 1 tyrosine kinase phosphorylation site kinase 1 tyrosine kinase phosphorylation site Fterm Site kinase site There was 1 cAMP- and cGMP-dependent protein kinase phosphorylation site, 11 protein kinase C phosphorylation sites, 4 casein kinase II phosphorylation sites, 1 amidation site, 1 N-glycosylation site, and 1 tyrosine kinase phosphorylation site in FGF5. 26400346 7 48 part_of kinase 930:935 arg1 1 cAMP- and cGMP-dependent protein kinase phosphorylation site kinase 1 cAMP- and cGMP-dependent protein kinase phosphorylation site Fterm Site kinase site There was 1 cAMP- and cGMP-dependent protein kinase phosphorylation site, 11 protein kinase C phosphorylation sites, 4 casein kinase II phosphorylation sites, 1 amidation site, 1 N-glycosylation site, and 1 tyrosine kinase phosphorylation site in FGF5. 29944110 8 31 part_of HA1 1157:1159 arg1 HA1 position N158 HA1 HA1 position N158 PUBTATOR SpecificSite HA1 23526 position N158 We found that clade 3C.2a viruses, possessing an additional potential glycosylation site at HA1 position N158, were poorly recognized by some of the mAbs, but other residues, notably at position 159, also affected antibody binding. 9820847 1 28 gly glycoprotein 178:189 arg1 the serotype-specific glycoprotein gene the serotype-specific glycoprotein gene Fterm glycoprotein We have investigated the serotype-specific glycoprotein gene (VP7) of a short electropherotype and subgroup I rotavirus (ID 45/2) recovered from a child suffering from acute diarrhea. 31251477 3 55 gly N-glycosylation 492:506 arg2 an additional N-glycosylation site an additional N-glycosylation site site Here, we investigated the features of a rare SNP (F51S) of A1AT, which introduces an additional N-glycosylation site in the N-terminal region of A1AT. 15113920 2 1 gly glycoproteins 287:299 arg1 The glycoproteins The glycoproteins Fterm glycoproteins The glycoproteins contain six potential sites for the attachment of N-linked oligosaccharides, five sites on Gn and one on Gc. 25504159 0 0 part_of hemagglutinin 63:75 arg1 the head hemagglutinin the head Fterm Site hemagglutinin head The N-linked glycosylation site at position 158 on the head of hemagglutinin and the virulence of H5N1 avian influenza virus in mice. 6838832 6 67 gly glycosylation 1116:1128 arg2 the Asn288-linked glycosylation site the Asn288-linked glycosylation site site Thus, the basis for the lack of the complex-type oligosaccharide in human plasminogen variant 2 does not reside in substitution of essential amino acid residues in the region of the Asn288-linked glycosylation site. 24497285 5 43 gly deglycosylated 845:858 arg1 deglycosylated peptides deglycosylated peptides peptides Desalted peptides and deglycosylated peptides were separated by reversed-phase liquid chromatography and detected with on-line electrospray ionization quadrupole-time-of-flight mass spectrometry using a 5600 TripleTof instrument. 8765005 6 43 gly O-glycosylation 928:942 arg2 an O-glycosylation site an O-glycosylation site site This tetrapeptide repeat includes an O-glycosylation site. 28931684 4 28 gly glycosylation 893:905 arg1 the E protein the E protein Fterm protein In the present study, we interrogated the role of this sequence motif and glycosylation of the E protein in pathogenicity of ZIKV. 24421913 8 3 part_of site 1330:1333 arg1 the envelope protein protein site Fterm Site protein site Moreover, we present evidence that ZIKV has possibly undergone recombination in nature and that a loss of the N154 glycosylation site in the envelope protein was a possible adaptive response to the Aedes dalzieli vector. 18203712 10 0 gly N-glycosylation 1436:1450 arg1 Asn-594 Asn-594 Asn-594 The last 16 residues of the 27-IM, including Leu-610 and Leu-611, appear to promote N-glycosylation of Asn-594 perhaps by causing this residue to become exposed to appropriate glycosyl transferases. 3485444 1 4 part_of has 95:97 arg1 The band 3 protein AND a single glycosylation site The band 3 protein a single glycosylation site Fterm Site protein site The band 3 protein has a single glycosylation site on the carboxy-terminal 55 000-dalton tryptic fragment that defines a sequence of the polypeptide on the extracytoplasmic surface of the cell. 10226365 2 46 gly glycopeptide 368:379 arg2 The glycopeptide structures The glycopeptide structures glycopeptide The glycopeptide structures were chosen to demonstrate the feasibility of this sensitive and accurate approach, where isobaric peptide structures either (i) with the same number of attachment sites in different position in the peptide backbone, and (ii) with the same number of sugar moieties distributed on different attachment sites in the peptide backbone, can be clearly distinguished. 1456441 9 38 part_of h-STF 1361:1365 arg1 the two N-glycosylation sites h-STF the two N-glycosylation sites Cterm Site h-STF 7018 sites Di- and triantennary oligosaccharides were found to occur on each of the two N-glycosylation sites of h-STF (Asn413 and Asn611) in the ratio of approximately 85:15. 8286855 1 46 gly sialoglycoprotein 144:160 arg1 The human red blood cell sialoglycoprotein The human red blood cell sialoglycoprotein Fterm sialoglycoprotein The human red blood cell sialoglycoprotein, glycophorin A (GpA), contains a 'mucin-like' extensively O-glycosylated extracellular domain which carries the MN blood group antigens. 8286855 1 46 gly sialoglycoprotein 144:160 arg1 glycophorin A glycophorin A PUBTATOR glycophorin A 2993 The human red blood cell sialoglycoprotein, glycophorin A (GpA), contains a 'mucin-like' extensively O-glycosylated extracellular domain which carries the MN blood group antigens. 2318516 7 95 part_of alpha 1351:1355 arg1 human leader, alpha 1, and alpha 2 domains alpha 1 human leader, alpha 1, and alpha 2 domains PUBTATOR Site alpha 1 146 domains The reciprocal construct, encoding human leader, alpha 1, and alpha 2 domains fused to the mouse alpha 3, transmembrane, and cytoplasmic regions, resulted in biosynthesis of a hybrid glycoprotein which was not transported to the cell surface. 19358553 0 97 gly glycopeptides 41:53 arg2 N-linked glycopeptides N-linked glycopeptides glycopeptides Site-specific glycoprofiling of N-linked glycopeptides using MALDI-TOF MS: strong correlation between signal strength and glycoform quantities. 1449065 8 18 gly utilized 881:888 arg2 A single N-linked glycosylation site A single N-linked glycosylation site site A single N-linked glycosylation site is utilized at Asn248. 1449065 8 59 gly glycosylation 859:871 arg2 A single N-linked glycosylation site A single N-linked glycosylation site site A single N-linked glycosylation site is utilized at Asn248. 15809769 2 19 part_of WNT14 155:159 arg1 paralogous regions WNT14 paralogous regions PUBTATOR Site WNT14 7483 regions WNT3A-WNT9A (WNT14) locus at chromosome 1q42.13 and WNT3-WNT9B (WNT14B) locus at chromosome 17q21.31 are paralogous regions within the human genome. 15809769 2 31 part_of WNT3A-WNT9A 142:152 arg1 paralogous regions WNT3A-WNT9A paralogous regions PUBTATOR Site WNT3A-WNT9A 89780 regions WNT3A-WNT9A (WNT14) locus at chromosome 1q42.13 and WNT3-WNT9B (WNT14B) locus at chromosome 17q21.31 are paralogous regions within the human genome. 15809769 2 59 part_of WNT14B 206:211 arg1 paralogous regions WNT14B paralogous regions PUBTATOR Site WNT14B 7484 regions WNT3A-WNT9A (WNT14) locus at chromosome 1q42.13 and WNT3-WNT9B (WNT14B) locus at chromosome 17q21.31 are paralogous regions within the human genome. 15809769 2 67 part_of WNT3-WNT9B 194:203 arg1 paralogous regions WNT9B paralogous regions PUBTATOR Site WNT9B 7484 regions WNT3A-WNT9A (WNT14) locus at chromosome 1q42.13 and WNT3-WNT9B (WNT14B) locus at chromosome 17q21.31 are paralogous regions within the human genome. 27038555 10 4 part_of NA 1468:1469 arg1 the NA sequences NA the NA sequences Cterm Site NA 4758 sequences No drug-resistant sites were noticed in the NA sequences. 10536368 5 23 gly glycosylation 783:795 arg2 the glycosylation site mutants the glycosylation site mutants site Pulse chase experiments suggested that the glycosylation site mutants accumulated in the endoplasmic reticulum (ER) and were inefficiently exported to the Golgi apparatus (GA). 15063126 7 47 gly glycosylation 1240:1252 arg2 an N-linked glycosylation site an N-linked glycosylation site site Surprisingly, the gain of an N-linked glycosylation site in the gp41 ectodomain contributed greatly to neutralization sensitivity. 3896487 0 25 gly glycoprotein 101:112 arg1 Friend murine leukemia virus glycoprotein Friend murine leukemia virus glycoprotein Fterm glycoprotein Isolation of glycopeptides containing individual glycosylation sites of Friend murine leukemia virus glycoprotein: studies of glycosylation by methylation analysis. 3896487 0 44 gly glycopeptides 13:25 arg2 glycopeptides glycopeptides glycopeptides Isolation of glycopeptides containing individual glycosylation sites of Friend murine leukemia virus glycoprotein: studies of glycosylation by methylation analysis. 3896487 0 54 gly glycosylation 49:61 arg1 Friend murine leukemia virus glycoprotein glycoprotein sites Fterm glycoprotein sites Isolation of glycopeptides containing individual glycosylation sites of Friend murine leukemia virus glycoprotein: studies of glycosylation by methylation analysis. 18700760 8 37 gly desialylated 1340:1351 arg1 the desialylated ST6Gal-I the desialylated ST6Gal-I The isotopic labeling approach involved removal of the native NeuAc residues from ST6Gal-I with neuraminidase, separation of the neuramindase with a lectin affinity column, and addition of synthesized 13C-CMP-NeuAc to the desialylated ST6Gal-I. 23751365 6 59 gly glycopeptides 895:907 arg2 glycopeptides glycopeptides glycopeptides In the selectivity assessment, glycopeptides were effectively isolated from a peptide mixture (human serum immunoglobulin G (IgG) and human serum albumin digests) and a tryptic digest of human serum using XCharge SAX. 17823199 6 52 gly N-glycosylation 1082:1096 arg2 all N-glycosylation sites transferrin sites PUBTATOR transferrin 7018 sites In healthy control samples, we determined 98-100% occupancy for all N-glycosylation sites of transferrin and alpha(1)-antitrypsin. 17823199 6 52 gly N-glycosylation 1082:1096 arg1 alpha(1)-antitrypsin alpha(1)-antitrypsin sites PUBTATOR alpha(1)-antitrypsin 5265 sites In healthy control samples, we determined 98-100% occupancy for all N-glycosylation sites of transferrin and alpha(1)-antitrypsin. 19358553 2 33 gly glycopeptides 419:431 arg2 widely different glycopeptides widely different glycopeptides glycopeptides Thus, a systematic study of widely different glycopeptides was performed to determine the relationship between the relative abundances of the individual glycoforms and the MALDI-TOF MS signal strength. 1427854 5 19 gly glycoprotein 681:692 arg1 the pregnancy-specific glycoprotein (PSG) subgroup the pregnancy-specific glycoprotein (PSG) subgroup Fterm glycoprotein We have previously suggested the number of genes in the pregnancy-specific glycoprotein (PSG) subgroup to be 11, which together with this study indicates that the CEA gene family contains 22 genes in all. 22573318 7 10 gly glycosylation 962:974 arg2 the predominant glycosylation site the predominant glycosylation site site Of these, the predominant glycosylation site was α1-87, one of the major helical cross-linking sites. 26439794 5 45 part_of glycoproteins 821:833 arg1 63 sites glycoproteins 63 sites Fterm Site glycoproteins sites The glycoproteomic approach to the human fetal lung fibroblasts membrane fraction resulted in the identification of over 272 glycoforms on 63 sites of the 44 glycoproteins. 15538777 5 22 gly glycopeptide 1208:1219 arg2 a tryptic glycopeptide mixture a tryptic glycopeptide mixture glycopeptide The MALDI ion trap mass spectrum of a tryptic glycopeptide mixture from N-linked glycoproteins was composed of the [M + H]+ ions of component glycopeptides. 15538777 5 49 gly glycoproteins 1243:1255 arg1 N-linked glycoproteins N-linked glycoproteins Fterm glycoproteins The MALDI ion trap mass spectrum of a tryptic glycopeptide mixture from N-linked glycoproteins was composed of the [M + H]+ ions of component glycopeptides. 15538777 5 112 gly glycopeptides 1304:1316 arg2 component glycopeptides component glycopeptides glycopeptides The MALDI ion trap mass spectrum of a tryptic glycopeptide mixture from N-linked glycoproteins was composed of the [M + H]+ ions of component glycopeptides. 1639824 7 50 part_of form 1051:1054 arg1 the correct amino terminus form of cathepsin B the correct amino terminus PUBTATOR Site form of cathepsin B P07858 terminus The action of a combination of cathepsin B with dipeptidylpeptidase I produced a single-chain form of cathepsin B with the correct amino terminus. 11604992 2 3 part_of protein 181:187 arg1 an N-linked glycosylation site protein an N-linked glycosylation site Fterm Site protein site WNT14B encoded 357-amino acid WNT family protein with the signal peptide and an N-linked glycosylation site. 11604992 2 3 part_of protein 181:187 arg1 the signal peptide protein the signal peptide Fterm Site protein peptide WNT14B encoded 357-amino acid WNT family protein with the signal peptide and an N-linked glycosylation site. 12421952 6 10 gly N-glycosylation 731:745 arg2 a potential N-glycosylation site a potential N-glycosylation site site CL-46 has two cysteine residues in the N-terminal segment, a potential N-glycosylation site in the collagen region, and an extended hydrophilic loop close to the binding site of the carbohydrate recognition domain. 12421952 6 18 gly domain 867:872 arg1 the carbohydrate recognition domain the carbohydrate recognition domain CL-46 has two cysteine residues in the N-terminal segment, a potential N-glycosylation site in the collagen region, and an extended hydrophilic loop close to the binding site of the carbohydrate recognition domain. 31498587 6 87 gly glycopeptides 931:943 arg2 MUC1 glycopeptides MUC1 glycopeptides glycopeptides The IgG antibodies recognized a wide range of MUC1 glycopeptides bearing diverse glycans. 21940909 1 7 part_of sites 345:349 arg1 an N-linked glycoprotein glycoprotein sites Fterm Site glycoprotein sites A simple mass spectrometric approach for the discovery and validation of biomarkers in human plasma was developed by targeting nonglycosylated tryptic peptides adjacent to glycosylation sites in an N-linked glycoprotein, one of the most important biomarkers for early detection, prognoses, and disease therapies. 11595658 1 16 gly N-glycosylation 178:192 arg2 five potential N-glycosylation sites five potential N-glycosylation sites sites The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 55 gly sites 194:198 arg1 five potential N-glycosylation sites five potential N-glycosylation sites sites The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 16 gly N-glycosylation 178:192 arg2 N98 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 16 gly N-glycosylation 178:192 arg2 N90 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 16 gly N-glycosylation 178:192 arg2 N45 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 16 gly N-glycosylation 178:192 arg2 N78 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 16 gly N-glycosylation 178:192 arg2 N90 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 16 gly N-glycosylation 178:192 arg2 N45 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 16 gly N-glycosylation 178:192 arg2 N78 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 16 gly N-glycosylation 178:192 arg2 N45 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 16 gly N-glycosylation 178:192 arg2 N78 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 16 gly N-glycosylation 178:192 arg2 N78 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 55 gly sites 194:198 arg1 N98 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 55 gly sites 194:198 arg1 N78 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 55 gly sites 194:198 arg1 N38 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 55 gly sites 194:198 arg1 N90 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 55 gly sites 194:198 arg1 N78 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 55 gly sites 194:198 arg1 N38 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 55 gly sites 194:198 arg1 N90 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 55 gly sites 194:198 arg1 N38 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 55 gly sites 194:198 arg1 N90 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 55 gly sites 194:198 arg1 N90 N38, N45, N78, N90, and N98 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 17715132 9 40 gly N-glycosylation 1149:1163 arg1 Pannexin1 Pannexin1 PUBTATOR Pannexin1 24145 We propose that N-glycosylation of Pannexin1 could be a significant mechanism for regulating the trafficking of these membrane proteins to the cell surface in different tissues. 10675514 7 39 part_of found 1008:1012 arg2 human and rodent AQP1 AND two glycosylation sites human and rodent AQP1 two glycosylation sites PUBTATOR Site AQP1 358 sites However, dog and bovine AQP1 have only one N-glycosylation site, while two glycosylation sites were found in human and rodent AQP1. 10675514 7 7 part_of have 937:940 arg1 bovine AQP1 AND only one N-glycosylation site bovine AQP1 only one N-glycosylation site PUBTATOR Site AQP1 282653 site However, dog and bovine AQP1 have only one N-glycosylation site, while two glycosylation sites were found in human and rodent AQP1. 2457922 5 34 part_of I-specific 980:989 arg1 The BGP I-specific domain BGP I The BGP I-specific domain PUBTATOR Site BGP I 634 domain The BGP I-specific domain, designated A', was 56.7% and 55.8% identical at the nucleotide level and 42.6% and 39.6% identical at the amino acid level to the immunoglobulin-like domain of NCA and the first immunoglobulin-like domain of CEA, respectively. 2457922 5 100 part_of BGP 976:978 arg1 The BGP I-specific domain BGP I The BGP I-specific domain PUBTATOR Site BGP I 634 domain The BGP I-specific domain, designated A', was 56.7% and 55.8% identical at the nucleotide level and 42.6% and 39.6% identical at the amino acid level to the immunoglobulin-like domain of NCA and the first immunoglobulin-like domain of CEA, respectively. 2457922 5 38 part_of NCA 1159:1161 arg1 the immunoglobulin-like domain NCA domain PUBTATOR Site NCA 1084 domain The BGP I-specific domain, designated A', was 56.7% and 55.8% identical at the nucleotide level and 42.6% and 39.6% identical at the amino acid level to the immunoglobulin-like domain of NCA and the first immunoglobulin-like domain of CEA, respectively. 2457922 5 113 part_of CEA 1207:1209 arg1 the immunoglobulin-like domain CEA domain PUBTATOR Site CEA 1084 domain The BGP I-specific domain, designated A', was 56.7% and 55.8% identical at the nucleotide level and 42.6% and 39.6% identical at the amino acid level to the immunoglobulin-like domain of NCA and the first immunoglobulin-like domain of CEA, respectively. 10913840 4 5 gly occupied 731:738 arg2 both sites both sites sites Results obtained with singly mutated forms of rFuc-TIV indicate that both sites are occupied in mammalian cells. 17259069 5 5 gly glycosylation 755:767 arg2 Asn51 Asn51 Asn51 Point mutations created in a glycosylation site (Asn51), a protein kinase C phosphorylation site (Ser106), and the enzymatic active site (Cys65) all inhibited L-PGDS-induced apoptosis as determined by both terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) and caspase3 activity. 17259069 5 5 gly glycosylation 755:767 arg2 a glycosylation site a glycosylation site site Point mutations created in a glycosylation site (Asn51), a protein kinase C phosphorylation site (Ser106), and the enzymatic active site (Cys65) all inhibited L-PGDS-induced apoptosis as determined by both terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) and caspase3 activity. 6651835 3 25 gly glycosylated 414:425 arg1 Asn 563 Asn 563 Asn 563 Amino acid and carbohydrate analyses show that Asn 563 of murine IgM is glycosylated only about 44% of the time. 18844296 4 41 gly glycoforms 760:769 arg1 native protein glycoforms native protein glycoforms Fterm protein Mass spectrometry constitutes a key tool for characterization of CDG-I defects by mass resolution of native protein glycoforms that differ for glycosylation-site occupancy. 11386850 2 68 part_of Slc19a2 349:355 arg1 genomic sequences Slc19a2 genomic sequences PUBTATOR Site Slc19a2 116914 sequences Here, we report the cloning and characterization of the full-length cDNA and genomic sequences of mouse Slc19a2. 12646046 3 86 part_of contains 473:480 arg1 a 131-residue mature protein AND six cysteine residues a 131-residue mature protein six cysteine residues Fterm AminoAcid protein cysteine residues All three Pla l 1 cDNAs code for a 25-residue leader peptide and a 131-residue mature protein that contains two polymorphic positions, an N-glycosylation site at position 107 and six cysteine residues involved in three disulphide bridges. 12646046 3 86 part_of contains 473:480 arg1 a 131-residue mature protein AND an N-glycosylation site a 131-residue mature protein an N-glycosylation site Fterm Site protein site All three Pla l 1 cDNAs code for a 25-residue leader peptide and a 131-residue mature protein that contains two polymorphic positions, an N-glycosylation site at position 107 and six cysteine residues involved in three disulphide bridges. 12646046 3 86 part_of contains 473:480 arg1 a 131-residue mature protein AND two polymorphic positions a 131-residue mature protein two polymorphic positions Fterm Site protein positions, All three Pla l 1 cDNAs code for a 25-residue leader peptide and a 131-residue mature protein that contains two polymorphic positions, an N-glycosylation site at position 107 and six cysteine residues involved in three disulphide bridges. 31637569 0 7 gly glycopeptide 113:124 arg2 automated glycopeptide identification automated glycopeptide identification glycopeptide Glycan size and attachment site location affect electron transfer dissociation (ETD) fragmentation and automated glycopeptide identification. 1594597 3 10 part_of factor 572:577 arg1 the factor VIII-coding DNA sequence factor VIII the factor VIII-coding DNA sequence OGER Site factor VIII P00451 sequence The molecular defects were identified by denaturing gradient gel electrophoresis screening of PCR-amplified products of the factor VIII-coding DNA sequence followed by nucleotide sequencing of the abnormal PCR products. 1594597 3 51 part_of VIII-coding 579:589 arg1 the factor VIII-coding DNA sequence factor VIII the factor VIII-coding DNA sequence OGER Site factor VIII P00451 sequence The molecular defects were identified by denaturing gradient gel electrophoresis screening of PCR-amplified products of the factor VIII-coding DNA sequence followed by nucleotide sequencing of the abnormal PCR products. 7741215 1 72 gly glycopeptide 279:290 arg2 glycopeptide glycopeptide glycopeptide fragments The microheterogeneity of the carbohydrate structures on recombinant human erythropoietin (rHuEPO) expressed in Chinese hamster ovary cells has been evaluated by electrospray ionization (ESI) mass spectrometry (MS) of glycopeptide fragments. 7741215 1 93 gly microheterogeneity 65:82 arg1 the carbohydrate structures the carbohydrate structures The microheterogeneity of the carbohydrate structures on recombinant human erythropoietin (rHuEPO) expressed in Chinese hamster ovary cells has been evaluated by electrospray ionization (ESI) mass spectrometry (MS) of glycopeptide fragments. 20391591 4 60 part_of glycoproteins 880:892 arg1 the glycosylation sites glycoproteins the glycosylation sites Fterm Site glycoproteins sites The combination of the very informative collision-induced dissociation spectra acquired in the linear ion trap with the distinct features of HCD offers very useful information aiding in the characterization of the glycosylation sites of glycoproteins. 23005037 9 41 gly N-glycosylation 1456:1470 arg1 CD147 CD147 PUBTATOR CD147 682 The present study reveals the important role of N-glycosylation of CD147 in its biological function and implied that targeting aberrant β1,6-branching of N-glycans on CD147 would be valuable for the development of novel therapeutic modalities against carcinoma. 12515161 8 10 part_of NS3 842:844 arg1 the NS3 region NS3 the NS3 region PUBTATOR Site NS3 3845 region In addition, a N-glycosylation site was found in the NS3 region of all the six isolates. 10995221 3 80 gly glycosylation 502:514 arg2 at least one consensus asparagine-linked glycosylation site NX(S/T) at least one consensus asparagine-linked glycosylation site NX(S/T) site The mammalian UGT2B proteins contain at least one consensus asparagine-linked glycosylation site NX(S/T). 19916043 5 51 part_of residue 600:606 arg1 the VP7 VP7 residue PUBTATOR SpecificSite VP7 3773131 residue 67 Similar to other human group C rotaviruses, one N-glycosylation site was predicted at amino acid residue 67 on the VP7 of strain GUP188. 16527321 4 14 gly glycosylation 982:994 arg2 one N-linked glycosylation site one N-linked glycosylation site site DeltaV2gp140 is derived from SF162gp140 following the deletion of 30 amino acids and one N-linked glycosylation site from the V2 loop. 27604319 4 0 gly glycosylation 713:725 arg1 gp120 gp120 PUBTATOR gp120 Q14624 Knowing the site-specific glycosylation of gp120 can facilitate the rational design of glycopeptide antigens for HIV vaccine development. 27604319 4 63 gly glycopeptide 774:785 arg2 glycopeptide antigens glycopeptide antigens glycopeptide Knowing the site-specific glycosylation of gp120 can facilitate the rational design of glycopeptide antigens for HIV vaccine development. 22389730 8 13 gly glycosylation 1610:1622 arg2 a potential glycosylation site a potential glycosylation site site Examination of the nucleotide and amino acid sequence alignments revealed the loss of a potential glycosylation site in some of the virus strains, which may correlate with the passage history of the virus. 22248643 13 60 gly N-glycosylation 1912:1926 arg2 N-glycosylation sites N-glycosylation sites sites Taken together, we propose that the number of N-glycosylation sites in the G protein is one of the determinants of the pathogenicity of street rabies viruses. 22248643 13 66 gly sites 1928:1932 arg1 the determinants sites the determinants sites Taken together, we propose that the number of N-glycosylation sites in the G protein is one of the determinants of the pathogenicity of street rabies viruses. 22815146 0 23 part_of N-linked 63:70 arg1 the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site N-linked the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site Cterm Site N-linked site Migration of the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site from N142 to N144 results in loss of antibody cross-reactivity. 22815146 0 57 part_of hemagglutinin 49:61 arg1 the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site hemagglutinin the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site Fterm Site hemagglutinin site Migration of the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site from N142 to N144 results in loss of antibody cross-reactivity. 8392347 2 60 part_of 464-amino-acid 339:352 arg1 a 464-amino-acid polypeptide 464-amino-acid a 464-amino-acid polypeptide Cterm Site 464-amino-acid polypeptide Sequence analysis of Clone 5 revealed a 1,395-bp open reading frame encoding a 464-amino-acid polypeptide. 16227249 7 40 gly glycosylation 869:881 arg2 the E protein glycosylation site the E protein glycosylation site site Addition of the E protein glycosylation site in a lineage II strain that lacked this site increased SVP production. 28889970 6 47 gly glycosylation 1124:1136 arg2 the glycosylation site the glycosylation site site Furthermore, the HA protein had S137A and S227R substitutions in the receptor-binding site and A160T in the glycosylation site, potentially increasing viral ability to bind human-type receptors. 23527852 9 4 gly fucosylated 1205:1215 arg1 the fucosylated isoforms the fucosylated isoforms A large variation in the presence and abundance of the fucosylated isoforms was found in a set of 96 serum samples. 10861210 2 70 gly contained 502:510 arg1 Human AE1 AND a high-mannose oligosaccharide Human AE1 a high-mannose oligosaccharide PUBTATOR Human AE1 6521 Human AE1 expressed in transfected human embryonic kidney (HEK)-293 or COS-7 cells contained a high-mannose oligosaccharide. 9494090 6 26 gly N-glycosylation 952:966 arg2 a potential N-glycosylation site a potential N-glycosylation site site Carbohydrate analyses of major allergens indicated that they are monoglycosylated but not N-glycosylated in spite of the presence of a potential N-glycosylation site. 24798328 5 49 part_of sites 718:722 arg1 recombinant LDLR LDLR sites PUBTATOR Site LDLR 3949 sites Herein, we have systematically characterized O-glycosylation sites on recombinant LDLR shed from HEK293 SimpleCells and CHO wild-type cells. 26972907 4 39 part_of site 575:578 arg1 UT-A3 UT-A3 site PUBTATOR Site UT-A3 27411 site A site-directed mutagenesis verified a single glycosylation site in UT-A3 at Asn279. 12646046 1 15 gly glycoprotein 124:135 arg1 The glycoprotein Pla l 1 The glycoprotein Pla l 1 Fterm glycoprotein The glycoprotein Pla l 1 is the major allergen from English plantain (Plantago lanceolata) pollen, which is a common cause of pollinosis in temperate areas. 15331613 1 48 gly glycosylation 496:508 arg1 NGC NGC PUBTATOR NGC 29873 NGC dramatically changed its structure from a proteoglycan to a nonproteoglycan form with cerebellar development, whereas a small portion of NGC molecules existed in a nonproteoglycan form in the other areas of the mature CNS, suggesting that the CS glycosylation of NGC is developmentally regulated in the whole CNS. 20053750 0 65 gly residue 19:25 arg1 N-linked glycan residue 523 N-linked glycan residue 523 N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site. 20053750 0 66 gly hemagglutinin-neuraminidase 67:93 arg1 N-linked glycan neuraminidase N-linked glycan PUBTATOR neuraminidase 4758 N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site. 23250752 5 9 gly N-glycosylation 885:899 arg2 the conserved putative N-glycosylation site the conserved putative N-glycosylation site site All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site. 23250752 5 58 gly glycosylation 812:824 arg2 consensus N-linked glycosylation sites consensus N-linked glycosylation sites sites All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site. 16037490 1 68 gly glycopeptides 171:183 arg2 glycopeptides glycopeptides glycopeptides Isolation of glycopeptides utilizing hydrogen bonding between glycopeptide glycans and a carbohydrate-gel matrix in the organic phase is useful for site-specific characterization of oligosaccharides of glycoproteins, when combined with mass spectrometry. 16037490 1 65 gly glycoproteins 360:372 arg1 oligosaccharides glycoproteins oligosaccharides Fterm glycoproteins Isolation of glycopeptides utilizing hydrogen bonding between glycopeptide glycans and a carbohydrate-gel matrix in the organic phase is useful for site-specific characterization of oligosaccharides of glycoproteins, when combined with mass spectrometry. 22203233 2 51 gly fucosylated 353:363 arg1 fucosylated glycoproteins fucosylated glycoproteins Fterm glycoproteins Given the biological importance of post-translational glycosylation, a specific and robust strategy for the identification of fucosylated glycoproteins is highly desirable. 22203233 2 54 gly glycoproteins 365:377 arg1 fucosylated glycoproteins fucosylated glycoproteins Fterm glycoproteins Given the biological importance of post-translational glycosylation, a specific and robust strategy for the identification of fucosylated glycoproteins is highly desirable. 27503338 1 4 gly glycosylation 322:334 arg2 asparagine (N)-linked glycosylation sites asparagine (N)-linked glycosylation sites sites Seasonally prevalent H1N1 and H3N2 influenza A viruses have evolved by antigenic drift; this evolution has resulted in the acquisition of asparagine (N)-linked glycosylation sites (NGSs) in the globular head of hemagglutinin (HA), thereby affecting the antigenic and receptor-binding properties, as well as virulence. 32197300 1 38 gly HIV-1 187:191 arg1 the C-terminal heptad repeat (CHR) region HIV-1 gp41 the C-terminal heptad repeat (CHR) region Cterm HIV-1 gp41 Peptides derived from the C-terminal heptad repeat (CHR) region of HIV-1 gp41 is potent viral membrane fusion inhibitors, such as the first clinically approved peptide drug T20 and a group of newly-designed peptides. 12364335 0 29 gly O-glycosylation 95:109 arg1 a polypeptide a polypeptide polypeptide The lectin domain of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 1 is involved in O-glycosylation of a polypeptide with multiple acceptor sites. 27035572 4 10 gly glycosylation 700:712 arg2 a potential glycosylation site aa8 a potential glycosylation site aa8 site Four non-synonymous substitutions, three localizing at antigenic sites T144A, A; R158G, B; L173S, D, and one H9Y in close proximity to a potential glycosylation site aa8 in HA1 domain along with the substitution T329N in NA are likely to influence the antigenicity/virulence of Mo/H3N2 viruses. 11386425 3 44 gly glycosylation 526:538 arg2 an Asn-67-linked glycosylation site an Asn-67-linked glycosylation site site A unique amino acid, Ile-69 for Mochizuki strain at E protein resulted in the loss of an Asn-67-linked glycosylation site. 6935656 5 24 gly glycosylated 936:947 arg1 gp70 gp70 Cterm gp70 The observed differences in gel electrophoretic mobilities and glycopeptide profiles of the respective glycosylated envelope gene cleavage products (gp70) may be accounted for by the presence of an additional oligosaccharide chain on the gp70 of the GIX- virus. 6935656 5 91 gly glycopeptide 896:907 arg2 glycopeptide profiles glycopeptide profiles glycopeptide The observed differences in gel electrophoretic mobilities and glycopeptide profiles of the respective glycosylated envelope gene cleavage products (gp70) may be accounted for by the presence of an additional oligosaccharide chain on the gp70 of the GIX- virus. 6935656 5 107 gly presence 1016:1023 arg1 the gp70 AND an additional oligosaccharide chain the gp70 an additional oligosaccharide chain Cterm gp70 The observed differences in gel electrophoretic mobilities and glycopeptide profiles of the respective glycosylated envelope gene cleavage products (gp70) may be accounted for by the presence of an additional oligosaccharide chain on the gp70 of the GIX- virus. 3828456 1 5 gly glycoprotein 225:236 arg1 The proline-rich glycoprotein The proline-rich glycoprotein Fterm glycoprotein The proline-rich glycoprotein from human parotid saliva has a common heptapeptide sequence around four of six N-glycosylation sites (Maeda, N., H. S. Kim, E. A. Azen, and O. J. Smithies, 1985, J. Biol. 3828456 1 66 gly N-glycosylation 318:332 arg2 four of six N-glycosylation sites four of six N-glycosylation sites sites The proline-rich glycoprotein from human parotid saliva has a common heptapeptide sequence around four of six N-glycosylation sites (Maeda, N., H. S. Kim, E. A. Azen, and O. J. Smithies, 1985, J. Biol. 11588155 5 12 gly apoB100 982:988 arg1 The N-glycan composition apoB100 The N-glycan composition PUBTATOR apoB100 338 The N-glycan composition of apoB100 derived from five LDL subpopulations (LDL1, d = 1.018-1.023; LDL2, d = 1.023-1.030; LDL3, d = 1.030-1.040; LDL4, d = 1.040-1.051; LDL5, d = 1.051-1.065 g/ml) did not vary in normolipidemic or hypercholesterolemic subjects. 21645732 3 57 gly N-glycosylation 655:669 arg2 N-glycosylation sites N-glycosylation sites sites An endoglycosidase of Endo H and the conventional PNGase F were employed, with a similar accessible procedure, for large-scale assignment of N-glycosylation sites and then N-glycoproteome for rat liver tissue. 29775240 0 21 part_of PNGase 12:17 arg1 PNGase F-Resistant N-Glycopeptides PNGase PNGase F-Resistant N-Glycopeptides PUBTATOR Site PNGase 59007 N-Glycopeptides Analysis of PNGase F-Resistant N-Glycopeptides Using SugarQb for Proteome Discoverer 2.1 Reveals Cryptic Substrate Specificities. 28353332 6 26 gly glycoprotein 901:912 arg1 any target glycoprotein any target glycoprotein Fterm glycoprotein For any target glycoprotein, judicious selection of the most favorable MS1/MS2 transitions can first be determined from prior analysis of a purified surrogate standard that carries similar site-specific glycosylation but may differ in its exact range of glycoforms. 9802575 2 30 gly N-glycosylation 468:482 arg2 N-glycosylation site N-glycosylation site site Sequencing analysis revealed that the open reading frame of feline CD3epsilon consists of 606 base pairs encoding a predicted molecular mass of 25 kDa transmembrane protein which lacks N-glycosylation site. 26180195 3 89 part_of site 474:477 arg1 hCLRN1 hCLRN1 site PUBTATOR Site hCLRN1 7401 site The missense mutation CLRN1(N48K), which affects a conserved N-glycosylation site in hCLRN1, is a common causative USH3 mutation among Ashkenazi Jews. 26224460 7 46 gly N-glycosylation 1254:1268 arg2 the N-glycosylation site the N-glycosylation site site Moreover, reverse genetic studies established that an E627K substitution in PB2 and the loss of the N-glycosylation site in the HA protein (aa166) are critical virulence markers in the mouse-adapted H9N2 virus. 20963501 7 26 gly site 1197:1200 arg1 N N N(205) There are a signal peptide at the N-terminus (1-22 aa), a transmembrane domain at the C-terminus (302-319 aa), and an extracellular Ig-like region in the middle (161-252 aa) with a putative N-linked glycosylation site (N(205)-N-S). 20963501 7 67 gly glycosylation 1183:1195 arg2 a putative N-linked glycosylation site a putative N-linked glycosylation site site There are a signal peptide at the N-terminus (1-22 aa), a transmembrane domain at the C-terminus (302-319 aa), and an extracellular Ig-like region in the middle (161-252 aa) with a putative N-linked glycosylation site (N(205)-N-S). 11705953 3 48 gly glycoproteins 647:659 arg1 glycoproteins glycoproteins Fterm glycoproteins The enzymes differ in only 10 amino acids, and both are glycoproteins that have cleavable signal peptides and unusual N-terminal extensions. 20498311 1 93 gly lectin 160:165 arg1 a monomeric carbohydrate-binding agent lectin a monomeric carbohydrate-binding agent Fterm lectin The lectin actinohivin (AH) is a monomeric carbohydrate-binding agent (CBA) with three carbohydrate-binding sites. 7711052 6 9 gly plasminogen 1451:1461 arg1 the N-linked sugar plasminogen the N-linked sugar OGER plasminogen P00747 Additionally, in fibrinolysis, within a ternary complex of fibrin, plasminogen and tissue plasminogen activator, the N-linked sugar of plasminogen hinders the initial interaction with tissue plasminogen activator (i.e., it alters Km). 11226831 9 28 gly glycopeptides 812:824 arg2 glycopeptides glycopeptides glycopeptides Analyses of glycopeptides identified two additional sites of modification on mER-alpha, at Ser(10) and Thr(50) near the N-terminus. 27140194 0 30 gly glycopeptide 7:18 arg2 Intact glycopeptide characterization Intact glycopeptide characterization glycopeptide Intact glycopeptide characterization using mass spectrometry. 28531887 11 35 gly N-glycosylation 1425:1439 arg2 the single N-glycosylation site MT4-MMP site PUBTATOR MT4-MMP 4326 site Moreover, we identified Asn318 as the single N-glycosylation site of MT4-MMP. 28531887 11 35 gly N-glycosylation 1425:1439 arg2 Asn318 MT4-MMP Asn318 PUBTATOR MT4-MMP 4326 Asn318 Moreover, we identified Asn318 as the single N-glycosylation site of MT4-MMP. 28708860 4 48 part_of variants 652:659 arg1 epitopes variants sites and epitopes Fterm Site variants sites and epitopes METHODS: A total of 700 HA genes (691 NA genes) of A/H3N2 viruses were chronologically analyzed for the mutational variants in amino acid features, N-glycosylation sites and epitopes since its emergence in 1968. 18524814 10 116 gly N-glycosylation 1955:1969 arg2 this highly conserved N-glycosylation motif this highly conserved N-glycosylation motif motif Overall, our findings indicate that this highly conserved N-glycosylation motif in prM is crucial for multiple stages of JEV biology: prM biogenesis, virus release, and pathogenesis. 11738084 1 6 gly glycosylated 154:165 arg1 glycosylated variants glycosylated variants Fterm variants Although human serum albumin is synthesized without carbohydrate, glycosylated variants of the protein can be found. 15538777 2 57 gly glycopeptides 508:520 arg2 glycopeptides glycopeptides glycopeptides Considering that structural issues are elucidated by studying glycopeptides and that the tandem MS of a tryptic peptide composed of several amino acid residues is enough for protein identification, construction of an MS-based method handling tryptic glycopeptides would be of considerable benefit in research. 15538777 2 66 gly glycopeptides 696:708 arg2 an MS-based method handling tryptic glycopeptides an MS-based method handling tryptic glycopeptides glycopeptides Considering that structural issues are elucidated by studying glycopeptides and that the tandem MS of a tryptic peptide composed of several amino acid residues is enough for protein identification, construction of an MS-based method handling tryptic glycopeptides would be of considerable benefit in research. 21940909 1 8 gly glycoprotein 366:377 arg1 an N-linked glycoprotein an N-linked glycoprotein Fterm glycoprotein A simple mass spectrometric approach for the discovery and validation of biomarkers in human plasma was developed by targeting nonglycosylated tryptic peptides adjacent to glycosylation sites in an N-linked glycoprotein, one of the most important biomarkers for early detection, prognoses, and disease therapies. 21940909 1 53 gly nonglycosylated 286:300 arg1 nonglycosylated tryptic peptides nonglycosylated tryptic peptides peptides A simple mass spectrometric approach for the discovery and validation of biomarkers in human plasma was developed by targeting nonglycosylated tryptic peptides adjacent to glycosylation sites in an N-linked glycoprotein, one of the most important biomarkers for early detection, prognoses, and disease therapies. 21940909 1 98 gly glycosylation 331:343 arg2 glycosylation sites glycosylation sites sites A simple mass spectrometric approach for the discovery and validation of biomarkers in human plasma was developed by targeting nonglycosylated tryptic peptides adjacent to glycosylation sites in an N-linked glycoprotein, one of the most important biomarkers for early detection, prognoses, and disease therapies. 24338886 2 0 gly glycosylation 308:320 arg1 rhEPO rhEPO OGER rhEPO P29676 Using mass spectrometry, we characterized the N-/O-linked glycosylation of recombinant human EPO (rhEPO) produced in glycoengineered Pichia pastoris and compared with the glycosylation of Chinese hamster ovary (CHO) cell-derived rhEPO. 24338886 2 0 gly glycosylation 308:320 arg1 recombinant human EPO recombinant human EPO PUBTATOR EPO 2056 Using mass spectrometry, we characterized the N-/O-linked glycosylation of recombinant human EPO (rhEPO) produced in glycoengineered Pichia pastoris and compared with the glycosylation of Chinese hamster ovary (CHO) cell-derived rhEPO. 24338886 2 28 gly glycosylation 421:433 arg1 Chinese hamster ovary (CHO) cell-derived rhEPO Chinese hamster ovary (CHO) cell-derived rhEPO OGER rhEPO P29676 Using mass spectrometry, we characterized the N-/O-linked glycosylation of recombinant human EPO (rhEPO) produced in glycoengineered Pichia pastoris and compared with the glycosylation of Chinese hamster ovary (CHO) cell-derived rhEPO. 22123080 2 62 gly glycosylation 254:266 arg1 CD82 CD82 PUBTATOR CD82 3732 The glycosylation of CD82 has been shown to be involved in a correlative cell adhesion and motility. 19706343 2 86 part_of beta2GPI 482:489 arg1 the Gly40-Arg43 motif beta2GPI the Gly40-Arg43 motif PUBTATOR Site beta2GPI 350 motif beta2GPI is N-glycosylated at several asparagine residues and the glycan moiety conjugated to residue 143 has been proposed to interact with the Gly40-Arg43 motif of beta2GPI. 21940909 8 15 part_of protein 1935:1941 arg1 nonglycosylated tryptic peptide protein nonglycosylated tryptic peptide Fterm Site protein peptide The area under the receiver operating characteristic curve generated through analyses of nonglycosylated tryptic peptide from vitronectin precursor protein was 0.978, the highest observed in a group of patients with hepatocellular carcinoma. 8188681 1 13 gly glycosylation 236:248 arg2 each glycosylation site each glycosylation site site To determine the specific role of each follicle-stimulating hormone (FSH) oligosaccharide, we mutated Asn to Gln at each glycosylation site (alpha Gln52, alpha Gln78, alpha Gln52-78, beta Gln7, beta Gln24, and beta Gln7-24) to selectively inhibit oligosaccharide attachment. 8188681 1 67 gly site 250:253 arg1 beta Gln7 beta Gln7 Gln7 To determine the specific role of each follicle-stimulating hormone (FSH) oligosaccharide, we mutated Asn to Gln at each glycosylation site (alpha Gln52, alpha Gln78, alpha Gln52-78, beta Gln7, beta Gln24, and beta Gln7-24) to selectively inhibit oligosaccharide attachment. 16227292 3 84 gly glycoproteins 408:420 arg1 the glycoproteins the glycoproteins Fterm glycoproteins Digestion of the glycoproteins with endo-beta-N-acetylglucosaminidase H (endo H) or peptide:N-glycosidase F revealed that Gn and Gc differ significantly in their glycan status and that late in infection Gc glycans remain endo H sensitive. 25755023 2 41 gly glycopeptides 260:272 arg2 MUC1 glycopeptides MUC1 glycopeptides glycopeptides Although several strategies have been developed to explore anti-tumor vaccines based on MUC1 glycopeptides, only few studies have focused on vaccines directed against the tumor-associated MUC4 glycoprotein. 25755023 2 53 gly glycoprotein 360:371 arg1 the tumor-associated MUC4 glycoprotein the tumor-associated MUC4 glycoprotein PUBTATOR MUC4 glycoprotein Q99102 Although several strategies have been developed to explore anti-tumor vaccines based on MUC1 glycopeptides, only few studies have focused on vaccines directed against the tumor-associated MUC4 glycoprotein. 10419520 6 64 gly glycosylation 965:977 arg2 glycosylation site mapping glycosylation site mapping site Here, we use protease protection and glycosylation site mapping to define the topology of S2P in ER membranes. 28921966 4 35 gly glycopeptides 712:724 arg2 intact glycopeptides intact glycopeptides glycopeptides Here we present a strategy for the permethylation of intact glycopeptides, obtained via controlled protease digest, and their characterization by using advanced mass spectrometry. 8638940 8 2 gly glycosylation 1454:1466 arg1 the beta-subunit site the beta-subunit site site Deletion of the beta-subunit oligosaccharide oat N308 by an aspartic acid substitution resulted in very little protein or enzyme activity in the transfected cells, reemphasizing that glycosylation of the beta-subunit site is important for efficient folding and/or targeting. 26944735 11 34 part_of EGF 2233:2235 arg1 the EGF domain EGF the EGF domain OGER Site EGF P01133 domain Further, we report a previously unknown O-glycosylation site and Asn-hydroxylation site, indicating a novel feature of BMP-1 in the EGF domain. 24048266 5 39 gly glycosylation 807:819 arg2 glycosylation sites glycosylation sites sites Experimental identification of glycosylation sites is expensive and laborious. 16125194 3 69 gly glycosylated 721:732 arg1 recombinant wild-type cathepsin B recombinant wild-type cathepsin B OGER cathepsin B P07858 However, when produced in P. pastoris we found that recombinant wild-type cathepsin B was preferentially secreted as a heterogeneously glycosylated molecule that migrated at 39 kDa, 41 kDa and a smear of >50 kDa on SDS-PAGE, and was susceptible to treatment with Endo H and PGNase F. 18524885 4 69 part_of receptor 892:899 arg1 the N terminus trace amine associated receptor 1 the N terminus PUBTATOR Site trace amine associated receptor 1 134864 terminus In the present study, we show that the addition of an asparagine-linked glycosylation site to the N terminus of the human trace amine associated receptor 1 (TAAR1) is sufficient to enable its plasma membrane expression, and thus its pharmacological characterization with a novel cAMP EPAC (exchange protein directly activated by cAMP) protein based bioluminescence resonance energy transfer (BRET) biosensor. 8573180 1 43 part_of contains 211:218 arg1 GLUT4 AND a single N-glycosylation site GLUT4 a single N-glycosylation site PUBTATOR Site GLUT4 25139 site GLUT4, the insulin-responsive glucose transporter expressed primarily in muscle and adipose tissue, contains a single N-glycosylation site. 7476998 8 1 gly sialylated 1371:1380 arg1 The variable region carbohydrate structures The variable region carbohydrate structures The variable region carbohydrate structures attached at Asn54 and Asn58 were also complex-type but more highly sialylated than were the Fc-associated sugars. 7476998 8 23 gly region 1273:1278 arg1 The variable region carbohydrate structures The variable region carbohydrate structures The variable region carbohydrate structures attached at Asn54 and Asn58 were also complex-type but more highly sialylated than were the Fc-associated sugars. 7476998 8 72 gly attached 1304:1311 arg2 The variable region carbohydrate structures AND Asn58 Asn54 and Asn58 The variable region carbohydrate structures Asn54 and Asn58 The variable region carbohydrate structures attached at Asn54 and Asn58 were also complex-type but more highly sialylated than were the Fc-associated sugars. 19706343 2 103 gly N-glycosylated 328:341 arg1 beta2GPI beta2GPI asparagine residues PUBTATOR beta2GPI 350 asparagine residues beta2GPI is N-glycosylated at several asparagine residues and the glycan moiety conjugated to residue 143 has been proposed to interact with the Gly40-Arg43 motif of beta2GPI. 8601595 8 40 gly glycosylation 1726:1738 arg1 CD44 CD44 PUBTATOR CD44 960 Taken together, these observations indicate that changes in glycosylation of CD44 can have profound effects on its interaction with hyaluronic acid and suggest that glycosylation may provide an important regulatory mechanism of CD44 function. 12010970 0 55 gly glycosylation 56:68 arg2 the Pseudomonas aeruginosa 1244 pilin glycosylation site the Pseudomonas aeruginosa 1244 pilin glycosylation site site Identification of the Pseudomonas aeruginosa 1244 pilin glycosylation site. 12185264 5 48 gly glycosylation 925:937 arg2 an additional potential glycosylation site an additional potential glycosylation site site Relative to the G1 glycoprotein of other HPS-associated hantaviruses, an additional potential glycosylation site was found but this is located in the predicted cytoplasmic domain and is therefore unlikely to be glycosylated. 12185264 5 90 gly glycoprotein 850:861 arg1 the G1 glycoprotein the G1 glycoprotein Fterm glycoprotein Relative to the G1 glycoprotein of other HPS-associated hantaviruses, an additional potential glycosylation site was found but this is located in the predicted cytoplasmic domain and is therefore unlikely to be glycosylated. 10764604 5 46 gly site 940:943 arg1 oligosaccharides site oligosaccharides site Mass spectrometric analysis before and after elimination of oligosaccharides from a single glycosylation site can provide an estimate of the average oligosaccharide mass, which facilitates interpretation of oligosaccharide composition data. 10764604 5 84 gly glycosylation 926:938 arg2 a single glycosylation site a single glycosylation site site Mass spectrometric analysis before and after elimination of oligosaccharides from a single glycosylation site can provide an estimate of the average oligosaccharide mass, which facilitates interpretation of oligosaccharide composition data. 23028207 3 28 gly N-glycosylation 591:605 arg2 Three N-glycosylation sites Three N-glycosylation sites sites Three N-glycosylation sites were found to be occupied by four biantennary complex type N-glycans using N-glycan analysis and the ETD/CID method. 23028207 3 40 gly occupied 630:637 arg2 Three N-glycosylation sites Three N-glycosylation sites sites Three N-glycosylation sites were found to be occupied by four biantennary complex type N-glycans using N-glycan analysis and the ETD/CID method. 20807536 10 41 gly deglycosylated 1448:1461 arg1 deglycosylated ovalbumin deglycosylated ovalbumin Fterm ovalbumin Biotinylated ovalbumin bound the surface of fixed E. histolytica trophozoites saturably; furthermore, denatured ovalbumin and native ovalbumin both specifically inhibited ovalbumin-biotin binding, but deglycosylated ovalbumin had no effect. 25910922 7 7 gly glycosylation 1287:1299 arg2 potential glycosylation site potential glycosylation site site In addition, a single amino acid substitution (N165H), which removes potential glycosylation site at the HA globular head of two classic strains (A/chicken/Egypt/527/2012 and A/chicken/Egypt/102d/2010) broadened the reactivity to antisera generated against H5N1 viruses from different clusters. 25910922 7 7 gly glycosylation 1287:1299 arg2 the HA globular head the HA globular head head In addition, a single amino acid substitution (N165H), which removes potential glycosylation site at the HA globular head of two classic strains (A/chicken/Egypt/527/2012 and A/chicken/Egypt/102d/2010) broadened the reactivity to antisera generated against H5N1 viruses from different clusters. 2040275 11 1 gly glycoforms 1633:1642 arg1 the tail peptide the tail peptide peptide Various roles for the different glycoforms of the tail peptide are discussed. 9726253 9 5 gly glycosylation 1712:1724 arg2 a putative glycosylation site a putative glycosylation site site Furthermore, introduction of a putative glycosylation site at amino acid 185 in the gpP450c17 enzyme did not alter substrate specificity. 2431063 5 17 gly glycosylation 736:748 arg2 the glycosylation site the glycosylation site site The cytoplasmic fluorescence appeared locally in a polar, juxtanuclear position, which overlapped the Golgi apparatus, probably reflecting the glycosylation site of the newly formed IFN-gamma molecules. 19706343 5 80 gly glycopeptide 891:902 arg2 comparative glycopeptide profiling comparative glycopeptide profiling glycopeptide To test this hypothesis we used mass spectrometry (MS) for comparative glycopeptide profiling of human beta2GPI obtained from blood serum from four healthy test subjects and six APS patients. 1385399 6 7 part_of domain 1238:1243 arg1 the human receptor receptor domain Fterm receptor Based on a model of human CD2 secondary structure, we propose that N-glycosylation is required for stabilizing domain 1 in the human receptor. 8360166 4 86 gly glycosylation 969:981 arg2 the NH2-terminal glycosylation site the NH2-terminal glycosylation site site Hybrid proteins with the NH2-terminal glycosylation site were glycosylated in COS1 cells, and the carbohydrate moiety was sensitive to endoglycosidase H digestion, providing further evidence that the proteins were retained in the ER. 8360166 4 88 gly glycosylated 993:1004 arg1 Hybrid proteins Hybrid proteins Fterm proteins Hybrid proteins with the NH2-terminal glycosylation site were glycosylated in COS1 cells, and the carbohydrate moiety was sensitive to endoglycosidase H digestion, providing further evidence that the proteins were retained in the ER. 8289366 6 92 gly glycosylation 892:904 arg2 position 229 position 229 position 229 The glycosylation site at position 229 of the MDTF receptor cDNA was eliminated by substituting a threonine codon for the asparagine codon. 8289366 6 92 gly glycosylation 892:904 arg2 The glycosylation site The glycosylation site site The glycosylation site at position 229 of the MDTF receptor cDNA was eliminated by substituting a threonine codon for the asparagine codon. 17899080 3 23 gly glycosylation 438:450 arg1 the NH(2) terminus the NH(2) terminus terminus Examination of the glycosylation pattern of the NH(2) terminus of FV and FVIII revealed N-glycans at positions 23 and 27 in FV and at position 41 in FVIII. 29479800 6 28 gly glycoproteins 1124:1136 arg1 other recombinant human glycoproteins other recombinant human glycoproteins Fterm glycoproteins Co-expression of LmSTT3D with immunoglobulins and other recombinant human glycoproteins resulted in a substantially increased N-glycosylation site occupancy on all N-glycosylation sites except those that were already more than 90% occupied. 29479800 6 42 gly N-glycosylation 1176:1190 arg2 a substantially increased N-glycosylation site occupancy a substantially increased N-glycosylation site occupancy site Co-expression of LmSTT3D with immunoglobulins and other recombinant human glycoproteins resulted in a substantially increased N-glycosylation site occupancy on all N-glycosylation sites except those that were already more than 90% occupied. 29479800 6 61 gly N-glycosylation 1214:1228 arg2 all N-glycosylation sites all N-glycosylation sites sites Co-expression of LmSTT3D with immunoglobulins and other recombinant human glycoproteins resulted in a substantially increased N-glycosylation site occupancy on all N-glycosylation sites except those that were already more than 90% occupied. 16331329 7 0 part_of LIM 1380:1382 arg1 the LIM domain LIM the LIM domain PUBTATOR Site LIM 414421 domain Phylogenetic tree was constructed by aligning the amino acid sequences of the LIM domain from different species. 8411368 2 9 gly glycosylation 363:375 arg2 a conserved glycosylation site a conserved glycosylation site site Nucleotide sequence analysis has indicated that the NA of WSN virus lacks a conserved glycosylation site at position 130 (corresponding to position 146 in the N2 subtype). 19961828 10 44 gly sialylated 1611:1620 arg1 sialylated N-glycans sialylated N-glycans Each phenomenon is unique for K(v)1 channel isoforms, indicating that sialylated N-glycans modulate gating of homologous K(v)1 channels through isoform-specific mechanisms. 9758750 1 67 part_of receptor 217:224 arg1 the entire extracellular domain granulocyte-colony stimulating factor receptor the entire extracellular domain PUBTATOR Site granulocyte-colony stimulating factor receptor Q99062 domain Previously, we have shown that the entire extracellular domain of the granulocyte-colony stimulating factor receptor (sG-CSFr) produced in Chinese hamster ovary (CHO) cells forms a stable complex with its ligand G-CSF, at a stoichiometry of 2:2. 11222739 3 26 gly glycosylation 425:437 arg2 the betaAsn24 glycosylation site the betaAsn24 glycosylation site site The betaThr26Ala mutation results in elimination of the betaAsn24 glycosylation site, yielding protein more suitable for crystallization without affecting the receptor binding and signal transduction activity of the glycohormone. 3898078 4 13 gly glycosylation 559:571 arg2 one potential N-linked glycosylation site one potential N-linked glycosylation site site There is one potential N-linked glycosylation site on MuTNF, in contrast to human TNF, which lacks any such site. 7683678 8 16 part_of 24p3 1236:1239 arg1 the deduced sequences 24p3 the deduced sequences Cterm Site 24p3 sequences The sequence did not match any known human protein, but showed a high degree of similarity with the deduced sequences of rat alpha 2-microglobulin-related protein and the mouse protein 24p3. 7683678 8 17 part_of protein 1206:1212 arg1 the deduced sequences alpha 2-microglobulin-related protein the deduced sequences PUBTATOR Site alpha 2-microglobulin-related protein 170496 sequences The sequence did not match any known human protein, but showed a high degree of similarity with the deduced sequences of rat alpha 2-microglobulin-related protein and the mouse protein 24p3. 1602549 8 103 gly residue 1254:1260 arg1 an important determinant residue 87 an important determinant residue 87 The results confirm the importance of carbohydrate at residue 165 for inhibitor sensitivity of H3 viruses and implicate carbohydrate at residue 87 (94a in the H3 numbering system) as an important determinant in the sensitivity of H1-subtype viruses to the bovine inhibitor. 1602549 8 103 gly residue 1254:1260 arg1 carbohydrate residue 87 carbohydrate residue 87 The results confirm the importance of carbohydrate at residue 165 for inhibitor sensitivity of H3 viruses and implicate carbohydrate at residue 87 (94a in the H3 numbering system) as an important determinant in the sensitivity of H1-subtype viruses to the bovine inhibitor. 31199881 3 115 gly glycosylation 623:635 arg2 the Fc N-linked glycosylation site the Fc N-linked glycosylation site site TfRMAbs have Fc effector function side effects, and removal of the Fc N-linked glycosylation site by substituting Asn with Gly reduces the Fc effector function. 9210490 8 37 gly N-glycosylation 1310:1324 arg2 Asn319 Asn319 Asn319 Our data suggest that the N-glycosylation at Asn319 is involved in protein trafficking and correct protein folding. 12527303 10 97 part_of IgG-Fc 1786:1791 arg1 IgG-Fc fragments IgG IgG-Fc fragments Cterm Site IgG fragments The observed conformational changes in the Cgamma2 domain affect the interface between IgG-Fc fragments and FcgammaRs. 2771955 7 16 gly glycosylation 1405:1417 arg2 1 N-linked glycosylation site 1 N-linked glycosylation site site The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site. 2771955 7 16 gly glycosylation 1405:1417 arg2 134 residues residues residues The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site. 2771955 7 16 gly glycosylation 1405:1417 arg1 20 residues residues residues The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site. 2771955 7 16 gly glycosylation 1405:1417 arg1 134 residues residues residues The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site. 2771955 7 16 gly glycosylation 1405:1417 arg1 20 residues residues residues The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site. 2771955 7 16 gly glycosylation 1405:1417 arg1 134 residues residues residues The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site. 2771955 7 16 gly glycosylation 1405:1417 arg1 134 residues residues residues The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site. 2965020 4 21 gly O-glycosylation 751:765 arg2 several potential O-glycosylation sites several potential O-glycosylation sites sites No N-glycosylation site but several potential O-glycosylation sites were identified in the predicted sequence. 2965020 4 32 gly N-glycosylation 708:722 arg2 No N-glycosylation site No N-glycosylation site site No N-glycosylation site but several potential O-glycosylation sites were identified in the predicted sequence. 22689482 4 73 gly monofucosylated 943:957 arg1 a monoantennary monofucosylated oligosaccharide a monoantennary monofucosylated oligosaccharide The sixth glycoform carries a monoantennary monofucosylated oligosaccharide. 20602265 8 17 gly glycosylation 1417:1429 arg2 an extra glycosylation site an extra glycosylation site site The 2009 S-OIV HA also has an extra glycosylation site at position 276. 10397812 1 68 gly glycoprotein 196:207 arg1 a recombinant glycoprotein a recombinant glycoprotein Fterm glycoprotein In this study we compare intracellular transport and processing of a recombinant glycoprotein in mammalian and insect cells. 7559469 2 6 part_of osteonectin 263:273 arg1 the binding region osteonectin the binding region PUBTATOR Site osteonectin 282077 region In this study we demonstrate that the binding region of recombinant truncated human bone osteonectin (tHON) for type V collagen resides between amino acids 1 and 146. 26641950 2 80 gly glycoproteins 453:465 arg1 such proteins such proteins Fterm proteins High resolution separation and mass spectrometry (MS) analysis of intact proteoforms can contribute significantly to the characterization of such proteins, many of which are glycoproteins. 26641950 2 80 gly glycoproteins 453:465 arg1 glycoproteins glycoproteins Fterm glycoproteins High resolution separation and mass spectrometry (MS) analysis of intact proteoforms can contribute significantly to the characterization of such proteins, many of which are glycoproteins. 28920453 4 19 gly O-glycans 623:631 arg1 rhEPOs rhEPOs O-glycans Cterm rhEPOs We developed selective and sensitive method to profile native O-glycans on rhEPOs. 32110292 8 100 part_of IgG3 1536:1539 arg1 IgG3 and IgG4 intact N-glycopeptides IgG3 IgG3 and IgG4 intact N-glycopeptides OGER Site IgG3 P01860 N-glycopeptides This comprehensive glycosylation analysis strategy for the first time allows the discrimination of IgG3 and IgG4 intact N-glycopeptides with high similarity in sequence without the antibody-based pre-separation. 32110292 8 102 part_of IgG4 1545:1548 arg1 IgG3 and IgG4 intact N-glycopeptides IgG4 IgG3 and IgG4 intact N-glycopeptides OGER Site IgG4 P01861 N-glycopeptides This comprehensive glycosylation analysis strategy for the first time allows the discrimination of IgG3 and IgG4 intact N-glycopeptides with high similarity in sequence without the antibody-based pre-separation. 2350186 1 26 part_of sites 197:201 arg1 the mu-chain mu-chain sites Fterm Site mu-chain sites The glycosylation and processing of the asparagine-linked oligosaccharides at individual glycosylation sites on the mu-chain of murine immunoglobulin M were investigated using variant cell lines that synthesize and secrete IgM heavy chains with known peptide deletions. 27127844 5 75 gly N-glycosylated 591:604 arg2 the predicted site site, Asn489 site, Asn489 Here we ask if human a4 (ATP6V0A4) is N-glycosylated at the predicted site, Asn489. 27127844 5 75 gly N-glycosylated 591:604 arg1 ATP6V0A4 ATP6V0A4 site, Asn489 PUBTATOR ATP6V0A4 50617 site, Asn489 Here we ask if human a4 (ATP6V0A4) is N-glycosylated at the predicted site, Asn489. 27127844 5 75 gly N-glycosylated 591:604 arg1 human a4 a4 site, Asn489 Cterm a4 site, Asn489 Here we ask if human a4 (ATP6V0A4) is N-glycosylated at the predicted site, Asn489. 27127844 5 75 gly N-glycosylated 591:604 arg1 ATP6V0A4 ATP6V0A4 site, Asn489 PUBTATOR ATP6V0A4 50617 site, Asn489 Here we ask if human a4 (ATP6V0A4) is N-glycosylated at the predicted site, Asn489. 27127844 5 75 gly N-glycosylated 591:604 arg1 human a4 a4 site, Asn489 Cterm a4 site, Asn489 Here we ask if human a4 (ATP6V0A4) is N-glycosylated at the predicted site, Asn489. 8189524 9 46 part_of PrV 1278:1280 arg1 the PrV UL1 sequence PrV the PrV UL1 sequence Cterm Site PrV sequence Since the PrV UL1 sequence did not reveal the presence of a consensus N-linked glycosylation site, concanavalin A affinity chromatography and enzymatic deglycosylation of virion glycoproteins were used to ascertain that the PrV UL1 product is O glycosylated. 8189524 9 107 part_of UL1 1282:1284 arg1 the PrV UL1 sequence UL1 the PrV UL1 sequence PUBTATOR Site UL1 2952527 sequence Since the PrV UL1 sequence did not reveal the presence of a consensus N-linked glycosylation site, concanavalin A affinity chromatography and enzymatic deglycosylation of virion glycoproteins were used to ascertain that the PrV UL1 product is O glycosylated. 25755023 2 45 part_of MUC1 255:258 arg1 MUC1 glycopeptides MUC1 MUC1 glycopeptides PUBTATOR Site MUC1 17829 glycopeptides Although several strategies have been developed to explore anti-tumor vaccines based on MUC1 glycopeptides, only few studies have focused on vaccines directed against the tumor-associated MUC4 glycoprotein. 23925152 1 34 part_of gp120 171:175 arg1 The third variable region envelope glycoprotein gp120 The third variable region PUBTATOR Site envelope glycoprotein gp120 155971 region The third variable region (V3) of HIV-1 envelope glycoprotein gp120 plays a key role in determination of viral coreceptor usage (tropism). 7922031 2 74 gly glycoprotein 288:299 arg1 glycoprotein hormones glycoprotein hormones Fterm glycoprotein It is a member of a family of glycoprotein hormones that are disulfide-rich heterodimers, with a common alpha-chain and distinctive beta-chains specific to their particular G-protein linked receptors. 11270865 4 5 gly N-glycosylation 688:702 arg2 One N-glycosylation site One N-glycosylation site site One N-glycosylation site was identified in the heavy chain with non-sialylated bianntenary fucosylated structures. 11270865 4 7 gly fucosylated 775:785 arg1 non-sialylated bianntenary fucosylated structures non-sialylated bianntenary fucosylated structures One N-glycosylation site was identified in the heavy chain with non-sialylated bianntenary fucosylated structures. 11270865 4 32 gly non-sialylated 748:761 arg1 non-sialylated bianntenary fucosylated structures non-sialylated bianntenary fucosylated structures One N-glycosylation site was identified in the heavy chain with non-sialylated bianntenary fucosylated structures. 22815146 8 118 part_of hemagglutinin 1652:1664 arg1 the hemagglutinin head domain hemagglutinin the hemagglutinin head domain Fterm Site hemagglutinin domain Molecular modeling of the hemagglutinin protein containing N142 or N144 in complex with a neutralizing antibody suggested that N144-induced potential glycosylation may sterically hinder access of antibodies to the hemagglutinin head domain, allowing viruses to escape neutralization. 22815146 8 52 part_of containing 1486:1495 arg1 the hemagglutinin protein AND N144 the hemagglutinin protein N144 Fterm SpecificSite protein N144 Molecular modeling of the hemagglutinin protein containing N142 or N144 in complex with a neutralizing antibody suggested that N144-induced potential glycosylation may sterically hinder access of antibodies to the hemagglutinin head domain, allowing viruses to escape neutralization. 22815146 8 52 part_of containing 1486:1495 arg1 the hemagglutinin protein AND N142 the hemagglutinin protein N142 Fterm SpecificSite protein N142 Molecular modeling of the hemagglutinin protein containing N142 or N144 in complex with a neutralizing antibody suggested that N144-induced potential glycosylation may sterically hinder access of antibodies to the hemagglutinin head domain, allowing viruses to escape neutralization. 3200844 11 4 part_of glycoprotein 1571:1582 arg1 The partial sequence glycoprotein The partial sequence Fterm Site glycoprotein sequence The partial sequence of the 62-kDa nuclear pore glycoprotein shows little similarity to other characterized proteins and elucidates structural features of a member of the family of nuclear pore glycoproteins. 31097672 3 81 part_of fetuin 433:438 arg1 The backbone amino acid sequences fetuin The backbone amino acid sequences Fterm Site fetuin sequences The backbone amino acid sequences of fetuin coded by the AHSG*1 and AHSG*2 genes differ in two amino acids including one known O-glycosylation site (aa position 256). 11258925 8 7 gly peptides 1293:1300 arg1 Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 Asn 396-Arg 414 Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580. 11258925 8 7 gly peptides 1293:1300 arg1 Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 Thr 576-Arg 587 Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580. 11258925 8 7 gly peptides 1293:1300 arg1 GlcNAc containing Asn 580 GlcNAc containing Asn 580 Asn 580 Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580. 11258925 8 54 gly glycosylation 1213:1225 arg2 the Asn 53 and Asn 130 sites Asn 53 and Asn 130 sites Asn 53 and Asn 130 sites Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580. 11258925 8 54 gly glycosylation 1213:1225 arg1 the Asn 53 and Asn 130 sites Asn 53 and Asn 130 sites Asn 53 and Asn 130 sites Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580. 11258925 8 54 gly glycosylation 1213:1225 arg1 the Asn 53 and Asn 130 sites Asn 53 and Asn 130 sites Asn 53 and Asn 130 sites Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580. 11258925 8 54 gly glycosylation 1213:1225 arg1 the Asn 53 and Asn 130 sites Asn 53 and Asn 130 sites Asn 53 and Asn 130 sites Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580. 11258925 8 54 gly glycosylation 1213:1225 arg1 the Asn 53 and Asn 130 sites Asn 53 and Asn 130 sites Asn 53 and Asn 130 sites Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580. 11258925 8 54 gly glycosylation 1213:1225 arg1 the Asn 53 and Asn 130 sites Asn 53 and Asn 130 sites Asn 53 and Asn 130 sites Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580. 27038031 7 3 gly had 970:972 arg1 Asn171 AND predominantly complex type glycans Asn171, Asn332, and Asn395 predominantly complex type glycans Asn171, Asn332, and Asn395 While Asn171, Asn332, and Asn395 all had predominantly complex type glycans, differences in glycan branching and sialylation were observed between the sites. 27038031 7 3 gly had 970:972 arg1 Asn332 AND predominantly complex type glycans Asn171, Asn332, and Asn395 predominantly complex type glycans Asn171, Asn332, and Asn395 While Asn171, Asn332, and Asn395 all had predominantly complex type glycans, differences in glycan branching and sialylation were observed between the sites. 27038031 7 3 gly had 970:972 arg1 Asn332 AND predominantly complex type glycans Asn171, Asn332, and Asn395 predominantly complex type glycans Asn171, Asn332, and Asn395 While Asn171, Asn332, and Asn395 all had predominantly complex type glycans, differences in glycan branching and sialylation were observed between the sites. 22355413 4 28 part_of NA 953:954 arg1 antigenic sites NA antigenic sites Cterm Site NA 4758 sites In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA. 8349699 6 16 gly glycosylation 850:862 arg1 ovine PGH synthase-1 PGH synthase-1 sites PUBTATOR PGH synthase-1 19224 sites N-Glycosylation consensus sequences corresponding to the three glycosylation sites of ovine PGH synthase-1 are conserved in the deduced amino acid sequences of PGH synthases-2. 28186137 9 10 gly glycoprotein 1006:1017 arg1 the most abundant glycoprotein the most abundant glycoprotein Fterm glycoprotein P0 protein, the most abundant glycoprotein in PNS myelin and mutations in which at the glycosylation site cause Charcot-Marie-Tooth neuropathy, has abundant GlcNAc-6-O-sulfated N-glycans. 28186137 9 10 gly glycoprotein 1006:1017 arg1 P0 protein P0 protein Fterm protein P0 protein, the most abundant glycoprotein in PNS myelin and mutations in which at the glycosylation site cause Charcot-Marie-Tooth neuropathy, has abundant GlcNAc-6-O-sulfated N-glycans. 28186137 9 27 gly glycosylation 1063:1075 arg2 the glycosylation site the glycosylation site site P0 protein, the most abundant glycoprotein in PNS myelin and mutations in which at the glycosylation site cause Charcot-Marie-Tooth neuropathy, has abundant GlcNAc-6-O-sulfated N-glycans. 28186137 9 62 gly has 1120:1122 arg1 the most abundant glycoprotein AND abundant GlcNAc-6-O-sulfated N-glycans the most abundant glycoprotein abundant GlcNAc-6-O-sulfated N-glycans Fterm glycoprotein P0 protein, the most abundant glycoprotein in PNS myelin and mutations in which at the glycosylation site cause Charcot-Marie-Tooth neuropathy, has abundant GlcNAc-6-O-sulfated N-glycans. 28186137 9 62 gly has 1120:1122 arg1 P0 protein AND abundant GlcNAc-6-O-sulfated N-glycans P0 protein abundant GlcNAc-6-O-sulfated N-glycans Fterm protein P0 protein, the most abundant glycoprotein in PNS myelin and mutations in which at the glycosylation site cause Charcot-Marie-Tooth neuropathy, has abundant GlcNAc-6-O-sulfated N-glycans. 1602549 6 59 part_of hemagglutinin 806:818 arg1 residue 165 hemagglutinin residue 165 Fterm SpecificSite hemagglutinin residue 165 For the H3-subtype virus A/Memphis/1/71 x A/Bel/42 (H3N1), sensitivity to beta inhibitors is determined by the oligosaccharide at residue 165 of the hemagglutinin, this glycosylation site being lost in a resistant mutant selected by growth in the presence of bovine serum. 23758413 3 69 part_of site 517:520 arg1 the same glycoprotein glycoprotein site Fterm Site glycoprotein site It is also possible to show that a glycan seen at one site in a glycoprotein may not be present at another glycosylation site in the same glycoprotein. 6148073 8 63 gly glycosylated 1412:1423 arg1 Both these sites Both these sites sites Both these sites were shown to be variably glycosylated. 25629924 8 59 gly glycosylation 1473:1485 arg2 each glycosylation site each glycosylation site site This represents the most comprehensive report to date detailing the complexity of glycan micro-heterogeneity with relative quantitation of glycoforms for each glycosylation site on milk sIgA. 26018173 11 35 gly glycoproteins 2124:2136 arg1 the surface envelope glycoproteins the surface envelope glycoproteins Fterm glycoproteins IMPORTANCE: A vaccine that protects against human immunodeficiency virus type 1 (HIV-1) infection should elicit antibodies that bind to the surface envelope glycoproteins on the membrane of the virus. 8706738 9 51 gly N-deglycosylated 1079:1094 arg1 rGal-T rGal-T The N-deglycosylated form of rGal-T retained full activity and showed only three isoforms by IEF analysis. 2820710 1 31 part_of precursor 211:219 arg1 the entire 575-amino acid sequence thrombomodulin precursor the entire 575-amino acid sequence PUBTATOR Site thrombomodulin precursor 7056 sequence We have deduced the entire 575-amino acid sequence of the human thrombomodulin precursor from cDNA clones. 29268168 1 4 part_of IgG 233:235 arg1 the Fc-domain IgG the Fc-domain Cterm Site IgG Fc-domain The binding strength between IgG and FcγR is influenced by the composition of the N-linked glycan at position N297 in the Fc-domain of IgG. 29268168 1 40 part_of position 199:206 arg1 IgG IgG position Cterm SpecificSite IgG position N297 The binding strength between IgG and FcγR is influenced by the composition of the N-linked glycan at position N297 in the Fc-domain of IgG. 24899172 1 99 part_of AGL 339:341 arg1 the antigenic loop (AGL) region AGL the antigenic loop (AGL) region OGER Site AGL P35573 region The envelope proteins of hepatitis B virus (HBV) bear an N-linked glycosylation site at N146 within the immunodominant a-determinant in the antigenic loop (AGL) region. 24899172 1 65 part_of bear 232:235 arg1 The envelope proteins AND an N-linked glycosylation site The envelope proteins an N-linked glycosylation site Fterm Site proteins site The envelope proteins of hepatitis B virus (HBV) bear an N-linked glycosylation site at N146 within the immunodominant a-determinant in the antigenic loop (AGL) region. 31325506 4 24 gly sialylated 1197:1206 arg1 no hybrid-type or sialylated N-glycans no hybrid-type or sialylated N-glycans Seventeen N-glycans comprising ten complex-type [Fucose0~2Hexose3~4N-acetylhexosamine1~6Sulfate0~1; 61.1% (the sum of the relative quantities of each N-glycan out of the total N-glycans)], two high-mannose-type (Hexose5~6N-acetylhexosamine2; 12.0%), and five paucimannose type (Fucose0~1Hexose3~4N-acetylhexosamine2~3; 26.9%) were identified, but no hybrid-type or sialylated N-glycans were found. 8798624 2 4 part_of LFA-1 577:581 arg1 a single LFA-1 binding site LFA-1 a single LFA-1 binding site PUBTATOR Site LFA-1 3683 site Deletion of individual immunoglobulin superfamily (IgSF) domains of ICAM-3 and ICAM-3 IgSF domain chimeras with CD21 showed there is a single LFA-1 binding site in ICAM-3 and that IgSF domain 1 is necessary and sufficient for LFA-1 binding. 8798624 2 13 part_of site 591:594 arg1 ICAM-3 ICAM-3 site PUBTATOR Site ICAM-3 3385 site Deletion of individual immunoglobulin superfamily (IgSF) domains of ICAM-3 and ICAM-3 IgSF domain chimeras with CD21 showed there is a single LFA-1 binding site in ICAM-3 and that IgSF domain 1 is necessary and sufficient for LFA-1 binding. 8798624 2 66 part_of ICAM-3 514:519 arg1 ICAM-3 IgSF domain ICAM-3 ICAM-3 IgSF domain PUBTATOR Site ICAM-3 3385 domain Deletion of individual immunoglobulin superfamily (IgSF) domains of ICAM-3 and ICAM-3 IgSF domain chimeras with CD21 showed there is a single LFA-1 binding site in ICAM-3 and that IgSF domain 1 is necessary and sufficient for LFA-1 binding. 29232830 2 37 gly N-glycoproteins 228:242 arg1 serum N-glycoproteins serum N-glycoproteins Fterm N-glycoproteins The aim of this pilot study was to evaluate changes in serum N-glycoproteins and their glycosylation status prior to clinical presentation of pancreatic cancer that may be potential biomarkers. 2825202 10 30 gly glycosylation 1616:1628 arg2 Three additional potential glycosylation sites Three additional potential glycosylation sites sites Three additional potential glycosylation sites are present in the processed carboxyl-terminal polypeptide, which we designate as P-2. 2825202 10 30 gly glycosylation 1616:1628 arg1 the processed carboxyl-terminal polypeptide the processed carboxyl-terminal polypeptide polypeptide Three additional potential glycosylation sites are present in the processed carboxyl-terminal polypeptide, which we designate as P-2. 11876646 1 1 part_of AE1 115:117 arg1 the band 3 (AE1) polypeptide 3 (AE1 the band 3 (AE1) polypeptide PUBTATOR Site 3 (AE1 6521 polypeptide The topology of the band 3 (AE1) polypeptide of the erythrocyte membrane is not fully established despite extensive study. 2886334 1 23 gly glycoprotein 337:348 arg1 the cell surface glycoprotein Thy-1 the cell surface glycoprotein Thy-1 Fterm glycoprotein To examine the extent to which protein structure and tissue-type influence glycosylation, we have determined the oligosaccharide structures at each of the three glycosylation sites (Asn-23, 74 and 98) of the cell surface glycoprotein Thy-1 isolated from rat brain and thymus. 2886334 1 53 gly sites 291:295 arg1 Asn-23 Asn-23 Asn-23, 74 and 98 To examine the extent to which protein structure and tissue-type influence glycosylation, we have determined the oligosaccharide structures at each of the three glycosylation sites (Asn-23, 74 and 98) of the cell surface glycoprotein Thy-1 isolated from rat brain and thymus. 2886334 1 35 gly glycosylation 277:289 arg1 the cell surface glycoprotein Thy-1 Thy-1 sites PUBTATOR Thy-1 24832 sites To examine the extent to which protein structure and tissue-type influence glycosylation, we have determined the oligosaccharide structures at each of the three glycosylation sites (Asn-23, 74 and 98) of the cell surface glycoprotein Thy-1 isolated from rat brain and thymus. 30115684 1 6 gly glycoprotein 154:165 arg1 the envelope glycoprotein gp120 the envelope glycoprotein gp120 Fterm glycoprotein The glycan shield on the envelope glycoprotein gp120 of human immunodeficiency virus 1 (HIV-1) has drawn immense attention as a vulnerable site for broadly neutralizing antibodies (bNAbs) and for its significant impact on host adaptive immune response to HIV-1. 30115684 1 29 gly glycan 124:129 arg1 the envelope glycoprotein gp120 gp120 glycan PUBTATOR gp120 155971 The glycan shield on the envelope glycoprotein gp120 of human immunodeficiency virus 1 (HIV-1) has drawn immense attention as a vulnerable site for broadly neutralizing antibodies (bNAbs) and for its significant impact on host adaptive immune response to HIV-1. 7755594 6 80 gly Asn-25 1018:1023 arg1 The glycan residues Asn-25 The glycan residues Asn-25 The glycan residues of IFN-gamma, especially at Asn-25, play an important role in protease resistance. 7755594 6 86 gly IFN-gamma 993:1001 arg1 The glycan residues IFN-gamma The glycan residues PUBTATOR IFN-gamma 3458 The glycan residues of IFN-gamma, especially at Asn-25, play an important role in protease resistance. 31533374 2 31 gly glycosylation 581:593 arg2 dengue virus (DENV) envelope protein glycosylation site dengue virus (DENV) envelope protein glycosylation site site The virtual approach was based on generating different docking cycles of tetra, penta, hexa, and heptapeptide libraries by maximizing the discrimination between the amino acid motif in the ZIKV and dengue virus (DENV) envelope protein glycosylation site. 10196694 6 14 part_of B 1117:1117 arg1 the only N-glycosylation site saposin B the only N-glycosylation site Cterm Site saposin B site The mutation involves a highly conserved amino acidic residue and abolishes the only N-glycosylation site of saposin B. 18585921 3 8 part_of seipin 636:641 arg1 functional domains seipin functional domains PUBTATOR Site seipin 26580 domains Here, we determined the subcellular localization, functional domains, and distribution of seipin in tissues. 8352759 1 57 part_of FVIII 169:173 arg1 the FVIII binding domain FVIII the FVIII binding domain PUBTATOR Site FVIII 2157 domain von Willebrand factor (vWF) binds to Factor VIII (FVIII) and the FVIII binding domain has been localized to the amino-terminal of the vWF subunit. 18282281 3 104 part_of mucin-type 468:477 arg1 mucin-type O-glycosylation sites mucin mucin-type O-glycosylation sites PUBTATOR Site mucin 100508689 sites A new encoding scheme was employed to improve the prediction of mucin-type O-glycosylation sites in mammalian proteins. 9116048 4 38 gly N-glycosylation 705:719 arg2 the proposed N-glycosylation site the proposed N-glycosylation site site As a consequence, the proposed N-glycosylation site was absent, suggesting O-glycosylation of the mature molecule. 7780197 6 35 part_of found 886:890 arg2 the TfR AND Asn-727 the TfR Asn-727 PUBTATOR SpecificSite TfR 7037 Asn-727 Glycosylation of Asn-727 found in the TfR purified from human placentae was analysed by high-pH anion-exchange chromatography with pulsed amperometric detection (HPAE-PAD) and mass spectrometry following tryptic digestion, peptide purification via reverse-phase high-performance liquid chromatography (RP-HPLC) and peptide sequencing. 29992770 5 12 gly N-glycopeptides 748:762 arg2 the statistically significantly different N-glycopeptides the statistically significantly different N-glycopeptides N-glycopeptides Quantitative label-free N-glycoproteomics is performed, with MS/MS analysis of the statistically significantly different N-glycopeptides. 12466483 1 15 gly glycosylation 296:308 arg2 overlapping glycosylation sequons overlapping glycosylation sequons The haemagglutinin (HA) protein of influenza A/H2N2 virus possesses five oligosaccharide attachment sites, two of which have overlapping glycosylation sequons at positions 20-23 (NNST) and 169-172 (NNTS). 12466483 1 72 gly positions 321:329 arg1 20-23 20-23 positions 20 The haemagglutinin (HA) protein of influenza A/H2N2 virus possesses five oligosaccharide attachment sites, two of which have overlapping glycosylation sequons at positions 20-23 (NNST) and 169-172 (NNTS). 12466483 1 44 gly possesses 217:225 arg1 The haemagglutinin (HA) protein AND five oligosaccharide attachment sites The haemagglutinin (HA) protein five oligosaccharide attachment sites Fterm protein The haemagglutinin (HA) protein of influenza A/H2N2 virus possesses five oligosaccharide attachment sites, two of which have overlapping glycosylation sequons at positions 20-23 (NNST) and 169-172 (NNTS). 15342690 2 16 gly glycosylated 469:480 arg1 EL EL PUBTATOR EL 9388 Reduction in molecular mass of EL after treatment with glycosidases and after treatment of EL-expressing cells with the glycosylation inhibitor tunicamycin demonstrated that EL is a glycosylated protein. 15342690 2 16 gly glycosylated 469:480 arg1 a glycosylated protein a glycosylated protein Fterm protein Reduction in molecular mass of EL after treatment with glycosidases and after treatment of EL-expressing cells with the glycosylation inhibitor tunicamycin demonstrated that EL is a glycosylated protein. 31356638 4 14 part_of NS1 646:648 arg1 a single glycosylated residue NS1 a single glycosylated residue OGER Site NS1 Q9Y6Y0 residue Here we report that mutation of a single glycosylated residue of NS1 (N207Q) abolishes the ability of NS1 to trigger EGL disruption and induce endothelial hyperpermeability. 23748959 2 30 gly glycosylation 251:263 arg2 N-linked glycosylation sites N-linked glycosylation sites sites In particular, enrichment of N-linked glycosylation sites can be found within Envelope variable loops, regions that play an essential role in HIV pathogenesis and immunogenicity. 15500445 7 60 gly glycosylation 1142:1154 arg2 an N-linked glycosylation site an N-linked glycosylation site site One monoclonal epitope was relatively surface accessible and in close proximity to an N-linked glycosylation site, while three others required additional thermal energy to expose the epitopes. 8366859 4 27 part_of containing 562:571 arg1 a proteolytic fragment AND the C-terminal tripeptide a proteolytic fragment the C-terminal tripeptide tripeptide The antigenic epitope is found in a proteolytic fragment containing the C-terminal tripeptide and the GPI anchor. 1383332 4 47 part_of epitopes 662:669 arg1 DAF DAF epitopes PUBTATOR DAF 13136 The epitopes on DAF for 16 murine mAb were mapped by immunoprecipitation studies as follows: SCR1, 6; SCR2, 3; SCR3, 3; SCR4, 3; S/T, 1. 24612669 0 62 part_of ligand 45:50 arg1 recombinant human Fas ligand extracellular domain Fas ligand recombinant human Fas ligand extracellular domain PUBTATOR Site Fas ligand 356 domain Improved production of recombinant human Fas ligand extracellular domain in Pichia pastoris: yield enhancement using disposable culture-bag and its application to site-specific chemical modifications. 19534833 0 67 gly N-glycosylation 30:44 arg1 SARS-CoV membrane protein SARS-CoV membrane protein Fterm protein Studies on membrane topology, N-glycosylation and functionality of SARS-CoV membrane protein. 20795641 3 80 gly glycoprotein 536:547 arg1 glycoprotein alternations glycoprotein alternations Fterm glycoprotein However, the majority of the reports using this approach focus on global profiling, rather than relative quantitation of glycoprotein alternations in pathological states. 10687132 0 17 part_of mucin 95:99 arg1 a mucin peptide mucin a mucin peptide PUBTATOR Site mucin 100508689 peptide Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. 7711058 2 52 gly glycoprotein 338:349 arg1 a widely distributed glycoprotein a widely distributed glycoprotein Fterm glycoprotein The 'liver' or 'Type I' isozyme is a widely distributed glycoprotein that utilizes NADP+ as a co-factor. 12940452 8 35 part_of alpha-subunit 1358:1370 arg1 the N-terminal region alpha-subunit the N-terminal region Fterm Site alpha-subunit region These data indicate that the newly introduced N-glycosylation consensus sequence is functional, and that the N-terminal region of the alpha-subunit is flexible and can be modified without affecting the intracellular function. 2846759 1 68 gly glycoprotein 157:168 arg1 the glycoprotein H (gH) gene the glycoprotein H (gH) gene PUBTATOR glycoprotein H 1682472 We present the nucleotide sequence of the glycoprotein H (gH) gene of herpesvirus saimiri (HVS), a representative of the T lymphotropic herpesviruses of New World monkeys, and compare the predicted amino acid sequence with sequences of homologous proteins from four human herpesviruses. 25567004 4 14 part_of BHc 1052:1054 arg1 the BHc sequences BHc the BHc sequences PUBTATOR Site BHc 192285 sequences Unexpectedly, deglycosylated proBHc contained an unexpected pro-peptide of an α-factor signal and fortuitous N-linked glycosylation sites in the non-cleaved pro-peptide sequences, but not in the BHc sequences. 25567004 4 20 part_of contained 893:901 arg1 deglycosylated proBHc AND an unexpected pro-peptide deglycosylated proBHc an unexpected pro-peptide PUBTATOR AminoAcid BHc 192285 pro Unexpectedly, deglycosylated proBHc contained an unexpected pro-peptide of an α-factor signal and fortuitous N-linked glycosylation sites in the non-cleaved pro-peptide sequences, but not in the BHc sequences. 23829323 9 57 gly glycosylation 2048:2060 arg2 the four N-linked glycosylation sites the four N-linked glycosylation sites sites We further demonstrate the effectiveness of this approach by analyzing plasma-derived haptoglobin, identifying 136 N-linked glycopeptide spectra at a false discovery rate of 0.4%, representing 15 distinct glycopeptides on at least three of the four N-linked glycosylation sites. 23829323 9 67 gly glycopeptide 1914:1925 arg2 136 N-linked glycopeptide spectra 136 N-linked glycopeptide spectra glycopeptide We further demonstrate the effectiveness of this approach by analyzing plasma-derived haptoglobin, identifying 136 N-linked glycopeptide spectra at a false discovery rate of 0.4%, representing 15 distinct glycopeptides on at least three of the four N-linked glycosylation sites. 23829323 9 90 gly glycopeptides 1995:2007 arg2 15 distinct glycopeptides 15 distinct glycopeptides glycopeptides We further demonstrate the effectiveness of this approach by analyzing plasma-derived haptoglobin, identifying 136 N-linked glycopeptide spectra at a false discovery rate of 0.4%, representing 15 distinct glycopeptides on at least three of the four N-linked glycosylation sites. 2016749 6 57 part_of ACT 1164:1166 arg1 This region ACT This region OGER Site ACT P01011 region This region of ACT is involved in DNA binding. 32211339 6 105 gly glycosylation 873:885 arg2 the glycosylation sites the glycosylation sites sites We showed that the glycosylation sites in both the MLD and GCD domains contribute to the steric shielding. 11161270 1 9 gly glycoproteins 156:168 arg1 Varicella-zoster virus (VZV) glycoproteins Varicella-zoster virus (VZV) glycoproteins Fterm glycoproteins Varicella-zoster virus (VZV) glycoproteins were purified from infected cells using monoclonal antibodies and gH:gL was found to react with antibodies to the gamma chain of human IgG (h-IgG), whereas gE:gI and gB did not. 19609201 9 91 gly glycosylation 1436:1448 arg2 putative N-linked glycosylation sites putative N-linked glycosylation sites sites Analysis of putative N-linked glycosylation sites revealed several common variations between the virus populations in the two host species. 12466483 6 18 gly linked 1116:1121 arg1 Asn 169 or 170 AND oligosaccharide chains Asn 20 or 21 and Asn 169 or 170 oligosaccharide chains Asn 20 or 21 and Asn 169 or 170 Even if oligosaccharide chains linked to Asn 20 or 21 and Asn 169 or 170 are eliminated, the antigenic properties, intracellular transport and biological activities are not influenced strongly. 12466483 6 18 gly linked 1116:1121 arg1 21 AND oligosaccharide chains Asn 20 or 21 and Asn 169 or 170 oligosaccharide chains Asn 20 or 21 and Asn 169 or 170 Even if oligosaccharide chains linked to Asn 20 or 21 and Asn 169 or 170 are eliminated, the antigenic properties, intracellular transport and biological activities are not influenced strongly. 12466483 6 18 gly linked 1116:1121 arg1 21 AND oligosaccharide chains Asn 20 or 21 and Asn 169 or 170 oligosaccharide chains Asn 20 or 21 and Asn 169 or 170 Even if oligosaccharide chains linked to Asn 20 or 21 and Asn 169 or 170 are eliminated, the antigenic properties, intracellular transport and biological activities are not influenced strongly. 8157687 3 73 gly glycosylation 952:964 arg2 Asn-917 site Asn-917 site Asn-917 First, the interaction of conglutinin is profoundly influenced by the state of the protein moiety of the alpha chain in the vicinity of the glycosylation site Asn-917. 24338886 5 37 part_of Pichia-produced 988:1002 arg1 the O-linked glycosylation site Pichia-produced rhEPO the O-linked glycosylation site OGER Site Pichia-produced rhEPO P29676 site A low level of O-linked mannosylation was detected on Pichia-produced rhEPO at position Ser126, which is also the O-linked glycosylation site for endogenous human EPO and CHO-derived rhEPO. 24338886 5 93 part_of position 1013:1020 arg1 Pichia-produced rhEPO Pichia-produced rhEPO position OGER AminoAcid Pichia-produced rhEPO P29676 position Ser126 A low level of O-linked mannosylation was detected on Pichia-produced rhEPO at position Ser126, which is also the O-linked glycosylation site for endogenous human EPO and CHO-derived rhEPO. 11390601 4 89 gly glycosylation 883:895 arg2 The glycosylation site mutations The glycosylation site mutations site The glycosylation site mutations near the V1/V2 loop compromised the use of CCR5 and CXCR4 equally. 15500847 4 29 gly glycosylation 769:781 arg2 an N-linked glycosylation site an N-linked glycosylation site site This enzyme contains glucosamine and an N-linked glycosylation site. 15500847 4 52 gly contains 732:739 arg1 This enzyme AND glucosamine This enzyme glucosamine Fterm enzyme This enzyme contains glucosamine and an N-linked glycosylation site. 8180202 5 19 gly attached 906:913 arg2 Asn9 AND the biantennary chains Asn9 the biantennary chains Asn9 Only one of the biantennary chains (attached to Asn9) contains significant amounts of fucose. 26784534 4 56 gly glycopeptides 522:534 arg2 the purified glycopeptides the purified glycopeptides glycopeptides Subsequently, the purified glycopeptides were analyzed by glycosidase digestion and mass spectrometry. 25533529 3 64 gly acutobin 438:445 arg1 single glycan-knockout mutants acutobin single glycan-knockout mutants Fterm acutobin The wild-type (ATB-wt) and single glycan-knockout mutants of recombinant acutobin were prepared from HEK293T, demonstrating that mutations at Asn(77), Asn(81) and Asn(100) impaired the folding while the S79A mutant and various Asn(229)-deglycosylated mutants were correctly folded. 11533192 6 23 gly glycosylation 949:961 arg2 position 130 position 130 position 130 Furthermore, another mutant WSN virus, possessing an NA with a glycosylation site at position 130 (146 in N2 numbering), leading to the loss of neurovirulence, failed to grow in cell culture in the presence of plasminogen. 11533192 6 23 gly glycosylation 949:961 arg2 a glycosylation site a glycosylation site site Furthermore, another mutant WSN virus, possessing an NA with a glycosylation site at position 130 (146 in N2 numbering), leading to the loss of neurovirulence, failed to grow in cell culture in the presence of plasminogen. 9733824 9 65 gly glycosylation 1577:1589 arg2 An additional potential glycosylation site An additional potential glycosylation site site An additional potential glycosylation site was predicted to be present in the V2 region in all but one clone, and amino acid signatures related to protection were identified in viral DNA and RNA clones within both the V1 and V2 regions. 9733824 9 65 gly glycosylation 1577:1589 arg1 the V2 region the V2 region region An additional potential glycosylation site was predicted to be present in the V2 region in all but one clone, and amino acid signatures related to protection were identified in viral DNA and RNA clones within both the V1 and V2 regions. 15956584 4 10 gly glycosylation 583:595 arg2 the potential glycosylation site the potential glycosylation site site The mutants were named with an N followed by a number related to the relative position of the potential glycosylation site in each glycoprotein (E1N1 to E1N4 for E1 mutants and E2N1 to E2N11 for E2 mutants). 15956584 4 63 gly glycoprotein 610:621 arg1 each glycoprotein each glycoprotein Fterm glycoprotein The mutants were named with an N followed by a number related to the relative position of the potential glycosylation site in each glycoprotein (E1N1 to E1N4 for E1 mutants and E2N1 to E2N11 for E2 mutants). 26773038 0 51 gly domain 44:49 arg1 N-linked glycan stabilization domain N-linked glycan stabilization domain N-linked glycan stabilization of the VWF A2 domain. 8659125 8 54 gly glycosylation 1266:1278 arg1 the envelope proteins the envelope proteins Fterm proteins Therefore HDV, similar to influenza and vesicular stomatitis viruses, depends on glycosylation of the envelope proteins as a signal for envelope protein maturation and for virion formation. 7559574 4 37 gly glycopeptide 990:1001 arg2 a 13-kDa glycopeptide a 13-kDa glycopeptide glycopeptide The larger of these (17 kDa) begins at Gln-209 near the end of the carbonic anhydrase-like domain of phosphacan/RPTP zeta/beta, whereas a 13-kDa glycopeptide begins at His-361 located in the middle of the fibronectin type III-like domain. 8307000 4 107 part_of YN-tPA 1366:1371 arg1 Asn117 tPA Asn117 OGER AminoAcid tPA P00750 Asn117 The results revealed that Asn117 of YN-tPA carried exclusively high-mannose-type glycans with five to nine mannose residues similar to wild-type tPA expressed in this cell line [Pfeiffer, G., Schmidt, M., Strube, K.-H. 17001073 9 44 part_of COX-1 1397:1401 arg1 the C terminus COX-1 the C terminus PUBTATOR Site COX-1 4512 terminus Conversely, inserting the COX-2 19-AA cassette near the C terminus of COX-1 yields a mutant ins594-612 COX-1 that is unstable (t(1/2) approximately 3 h). 8702538 0 51 gly glycosylation 18:30 arg2 A single N-linked glycosylation site A single N-linked glycosylation site site A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CD33. 8841141 10 37 part_of NPR-A 1686:1690 arg1 the binding domain NPR-A the binding domain PUBTATOR Site NPR-A 24603 domain It displays the species variability and the high surface probability expected for a portion of the binding domain of NPR-A in contact with ANP. 21535396 0 85 gly Glycosylation 0:12 arg1 tissue factor tissue factor PUBTATOR tissue factor 2152 Glycosylation of tissue factor is not essential for its transport or functions. 12356334 5 33 part_of variant 848:854 arg1 a potential N-linked glycosylation site SP-B variant a potential N-linked glycosylation site PUBTATOR Site SP-B variant 6439 site, Asn129-Gln-Thr131 The Thr131-->Ile substitution can eliminate a potential N-linked glycosylation site, Asn129-Gln-Thr131, which is present in the SP-B variant of the C allele (ACT/Thr) but not in that of the T allele (ATT/Ile). 12356334 5 88 part_of present 828:834 arg2 the SP-B variant AND a potential N-linked glycosylation site SP-B variant site, Asn129-Gln-Thr131 PUBTATOR Site SP-B variant 6439 site, Asn129-Gln-Thr131 The Thr131-->Ile substitution can eliminate a potential N-linked glycosylation site, Asn129-Gln-Thr131, which is present in the SP-B variant of the C allele (ACT/Thr) but not in that of the T allele (ATT/Ile). 16823988 11 11 gly glycosylation 1503:1515 arg1 alpha1-antitrypsin alpha1-antitrypsin OGER alpha1-antitrypsin P01009 Changes in glycosylation sites in cancer serum are also observed by glycopeptide mapping using microLC-ESI-TOF-MS where the N83 glycosylation of alpha1-antitrypsin is down regulated. 16823988 11 46 gly glycopeptide 1443:1454 arg2 glycopeptide mapping glycopeptide mapping glycopeptide Changes in glycosylation sites in cancer serum are also observed by glycopeptide mapping using microLC-ESI-TOF-MS where the N83 glycosylation of alpha1-antitrypsin is down regulated. 16823988 11 79 gly glycosylation 1386:1398 arg2 glycosylation sites glycosylation sites sites Changes in glycosylation sites in cancer serum are also observed by glycopeptide mapping using microLC-ESI-TOF-MS where the N83 glycosylation of alpha1-antitrypsin is down regulated. 10889209 0 43 gly Glycosylation 0:12 arg2 Asn119 GIRK1 Asn119 PUBTATOR GIRK1 3760 Asn119 Glycosylation of GIRK1 at Asn119 and ROMK1 at Asn117 has different consequences in potassium channel function. 9857985 4 0 gly glycosylation 631:643 arg2 other glycosylation sites other glycosylation sites sites The DVIM HE protein has a unique N-linked glycosylation site in addition to other glycosylation sites common to many MHV strains. 9857985 4 7 gly glycosylation 591:603 arg2 a unique N-linked glycosylation site a unique N-linked glycosylation site site The DVIM HE protein has a unique N-linked glycosylation site in addition to other glycosylation sites common to many MHV strains. 10441114 8 93 part_of collagen 1418:1425 arg1 the NC-1 domain collagen XVIII the NC-1 domain PUBTATOR Site collagen XVIII 80781 domain The described glycosylated endostatins may represent intermediates in the proteolytic pathway of the NC-1 domain of collagen XVIII resulting in bioactive endostatins. 8798755 3 45 part_of Recombinant 597:607 arg1 Recombinant IAR polypeptide Recombinant IAR Recombinant IAR polypeptide PUBTATOR Site Recombinant IAR 5799 polypeptide Recombinant IAR polypeptide has phosphatase activity. 8798755 3 71 part_of IAR 609:611 arg1 Recombinant IAR polypeptide Recombinant IAR Recombinant IAR polypeptide PUBTATOR Site Recombinant IAR 5799 polypeptide Recombinant IAR polypeptide has phosphatase activity. 6195967 9 43 gly carbohydrate 1252:1263 arg1 Gc1 Gc1 carbohydrate PUBTATOR Gc1 79751 The cyanogen bromide fragment containing the galactosamine-containing carbohydrate in Gc1 was partially sequenced through 20 residues from the amino terminus. 6195967 9 12 gly containing 1212:1221 arg1 The cyanogen bromide fragment AND the galactosamine-containing carbohydrate The cyanogen bromide fragment the galactosamine-containing carbohydrate fragment The cyanogen bromide fragment containing the galactosamine-containing carbohydrate in Gc1 was partially sequenced through 20 residues from the amino terminus. 17924005 0 62 part_of Pol 105:107 arg1 Pol amino acid sequences Pol Pol amino acid sequences OGER Site Pol sequences Mapping the molecular characteristics of Brazilian human T-cell lymphotropic virus type 1 Env (gp46) and Pol amino acid sequences for vaccine design. 7711052 0 66 gly glycosylation 24:36 arg1 ribonuclease ribonuclease Fterm ribonuclease The effects of variable glycosylation on the functional activities of ribonuclease, plasminogen and tissue plasminogen activator. 27927205 3 19 gly aglycosylated 551:563 arg1 aglycosylated homodimer aglycosylated homodimer Fterm homodimer Three different forms of IgG1 Fc fragments, including the wild type, aglycosylated homodimer and aglycosylated single chain, were each fused with IFN-α and designated as IFN-α/Fc-WT, IFN-α/Fc-MD, and IFN-α/Fc-SC, respectively. 18437557 2 71 gly N-glycosylation 417:431 arg2 an additional N-glycosylation site an additional N-glycosylation site site A common single nucleotide polymorphism in the human SHBG gene results in an amino acid substitution (Asp327Asn), which introduces an additional N-glycosylation site, and is associated with reduced breast cancer risk in postmenopausal women. 7968693 6 5 part_of termini 1156:1162 arg1 The glycosylation site termini The glycosylation site site The glycosylation site in preM and hydrophobic regions at the carboxyl termini of M and E were well conserved. 24806200 6 21 gly glycosylation 1224:1236 arg2 all native glycosylation sites all native glycosylation sites sites Using the powerful tools of chemical synthesis, the work presented herein focuses on the highly convergent syntheses of homogeneous β-hLH and β-hCG bearing model glycans at all native glycosylation sites. 16834341 3 33 gly glycopeptides 370:382 arg1 human pituitary follicle stimulating hormone follicle stimulating hormone glycopeptides Cterm follicle stimulating hormone glycopeptides In the present study the negatively charged glycopeptides of equine and human pituitary follicle stimulating hormone (eFSH and hFSH) have been characterized in a glycosylation site-specific manner using FT-ICR-MS and Edman sequencing. 2318516 7 42 gly glycoprotein 1485:1496 arg1 a hybrid glycoprotein a hybrid glycoprotein Fterm glycoprotein The reciprocal construct, encoding human leader, alpha 1, and alpha 2 domains fused to the mouse alpha 3, transmembrane, and cytoplasmic regions, resulted in biosynthesis of a hybrid glycoprotein which was not transported to the cell surface. 26598643 12 29 gly O-glycosylation 1838:1852 arg2 23 O-glycosylation sites 23 O-glycosylation sites sites In total 23 O-glycosylation sites could be pinpointed. 29220102 9 79 part_of oxidase 1143:1149 arg1 a putative N-glycosylation site oxidase a putative N-glycosylation site Fterm Site oxidase site Using a combined transcriptomic and proteomic approach, the high molecular mass allergen in A. annua pollen was shown to be a 62-kDa putative galactose oxidase, with a putative N-glycosylation site. 6651835 0 18 gly glycosylation 11:23 arg1 Asn 563 IgM Asn 563 OGER IgM P01872 Asn 563 Incomplete glycosylation of Asn 563 in mouse immunoglobulin M. Mouse immunoglobulin IgM was prepared from MOPC 104E ascites fluid and [3H]-mannose labeled tumor cells. 11238869 9 17 part_of gp120 1415:1419 arg1 the CCR5-binding region gp120 the CCR5-binding region PUBTATOR Site gp120 3700 region These results suggest that the CCR5-binding region of gp120 is occluded by the V1/V2 variable loops, the position of which can be modulated by temperature, CD4 binding, or an N-linked glycan in the V1/V2 stem. 11238869 9 55 part_of CCR5-binding 1392:1403 arg1 the CCR5-binding region CCR5 the CCR5-binding region PUBTATOR Site CCR5 1234 region These results suggest that the CCR5-binding region of gp120 is occluded by the V1/V2 variable loops, the position of which can be modulated by temperature, CD4 binding, or an N-linked glycan in the V1/V2 stem. 31461788 7 61 gly glycosylation 716:728 arg2 a DMP1 glycosylation site mutation mouse model a DMP1 glycosylation site mutation mouse model site By using a DMP1 glycosylation site mutation mouse model, DMP1-S89G mice, we compared the suture development in it with control mice. 23562646 6 62 gly N-glycans 1039:1047 arg1 the hPIV-3 HN protein protein N-glycans Fterm protein Removal of individual or multiple N-glycans on the hPIV-3 HN protein had no effects on transport to the cell surface, expression and NA activity. 29470411 11 57 gly Hypoglycosylation 1322:1338 arg1 the α₂δ subunit the α₂δ subunit Fterm subunit Hypoglycosylation of the α₂δ subunit also participates in the gain-of-function effect by promoting voltage-dependent opening of the CaV2.1 channel. 26947874 2 25 gly N-glycosylation 264:278 arg1 the unstructured region region region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 the protein protein region Fterm protein region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 the loop region region region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 A1AT A1AT region PUBTATOR A1AT 5265 region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 the unstructured region region region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 the protein protein region Fterm protein region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 the loop region region region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 A1AT A1AT region PUBTATOR A1AT 5265 region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 the unstructured region region region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 the loop region protein region Fterm protein region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 the unstructured region protein region Fterm protein region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 A1AT A1AT region PUBTATOR A1AT 5265 region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 the unstructured region region region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 26947874 2 50 gly N-glycosylation 264:278 arg1 the unstructured region A1AT region PUBTATOR A1AT 5265 region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 18562306 2 45 gly glycopeptide 520:531 arg2 the strict glycopeptide specificity the strict glycopeptide specificity glycopeptide Previous studies have suggested that the lectin domain modulates the glycosylation of glycopeptide substrates and may underlie the strict glycopeptide specificity of some isoforms (ppGalNAcT-7 and -10). 18562306 2 102 gly glycopeptide 468:479 arg2 glycopeptide substrates glycopeptide substrates glycopeptide Previous studies have suggested that the lectin domain modulates the glycosylation of glycopeptide substrates and may underlie the strict glycopeptide specificity of some isoforms (ppGalNAcT-7 and -10). 22287049 7 13 gly glycoproteins 1534:1546 arg1 single glycoproteins single glycoproteins Fterm glycoproteins Successful applications to single glycoproteins as well as total proteomic mixtures derived from biological fluids established the unrivaled practical versatility of this method, with enrichment efficiency comparable to other HILIC-based methods. 10856884 8 43 gly glycosylation 936:948 arg2 two putative N-linked glycosylation sites two putative N-linked glycosylation sites sites Rat PLP-J cDNA encodes for a predicted 211 amino acid protein containing a 29 amino acid signal peptide and two putative N-linked glycosylation sites, whereas the mouse PLP-J cDNA encodes for a 212 amino acid protein containing a 29 amino acid signal peptide with a single N-linked glycosylation site. 10856884 8 97 gly glycosylation 1088:1100 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site Rat PLP-J cDNA encodes for a predicted 211 amino acid protein containing a 29 amino acid signal peptide and two putative N-linked glycosylation sites, whereas the mouse PLP-J cDNA encodes for a 212 amino acid protein containing a 29 amino acid signal peptide with a single N-linked glycosylation site. 27834568 6 39 part_of Fab 880:882 arg1 the Fab N-glycosylation site Fab the Fab N-glycosylation site PUBTATOR Site Fab 2187 site Removal of the Fab N-glycosylation site by single amino acid substitution, or removal of N-linked glycans by enzymatic digestion, drastically reduced the antibody's ability to inhibit latency-associated peptide (LAP) and αvβ8 association, and TGF-β activation in an αvβ8-mediated TGF-β signaling reporter assay. 12766998 5 87 gly glycoproteins 1002:1014 arg1 glycoproteins glycoproteins Fterm glycoproteins Analysis of the cross-reactivity of antibodies raised against glycoproteins of genotype 1a strains showed that three of five monoclonal antibodies that recognise linear epitopes were able to detect E2 from strain HCV3a-Gla. 11312284 6 37 gly glycosylation 1176:1188 arg2 a glycosylation site a glycosylation site site When alpha subunits were mutated to add a glycosylation site at residue 187, the number of Bgt binding sites increased threefold, AChRs assembled more efficiently, and 2.5-fold more AChRs reached the cell surface. 15147907 4 1 gly glycosylation 643:655 arg2 this glycosylation site this glycosylation site site The presence of the glucose moiety in 5% of the human C3 glycoprotein suggests that this glycosylation site is sequestered within the protein and is consistent with previous studies identifying a cryptic conglutinin binding site on C3 that becomes exposed upon its conversion to iC3b. 15147907 4 15 gly presence 558:565 arg2 the human C3 glycoprotein AND the glucose moiety the human C3 glycoprotein the glucose moiety Fterm glycoprotein The presence of the glucose moiety in 5% of the human C3 glycoprotein suggests that this glycosylation site is sequestered within the protein and is consistent with previous studies identifying a cryptic conglutinin binding site on C3 that becomes exposed upon its conversion to iC3b. 15147907 4 21 gly glycoprotein 611:622 arg1 the human C3 glycoprotein the human C3 glycoprotein Fterm glycoprotein The presence of the glucose moiety in 5% of the human C3 glycoprotein suggests that this glycosylation site is sequestered within the protein and is consistent with previous studies identifying a cryptic conglutinin binding site on C3 that becomes exposed upon its conversion to iC3b. 18642129 5 84 gly heterogeneity 732:744 arg1 pd-FVII pd-FVII OGER FVII P08709 N- and O-glycosylation sites and site specific heterogeneity of pd-FVII were studied by various complementary qualitative and quantitative techniques. 18642129 5 14 gly O-glycosylation 692:706 arg1 pd-FVII FVII sites OGER FVII P08709 sites N- and O-glycosylation sites and site specific heterogeneity of pd-FVII were studied by various complementary qualitative and quantitative techniques. 2457333 6 30 gly glycopeptides 726:738 arg2 glycopeptides glycopeptides glycopeptides Assignment of molecular ions, within 3 to 5 amu of the theoretical mass, of glycopeptides from each glycosylation site was made from amino acid composition, peptide sequence around the glycosylation sites, and previously reported triantennary oligosaccharide structures (B. Nilsson, N.E. Nordén, and S. Svensson (1979) J. Biol. 2457333 6 30 gly glycopeptides 726:738 arg1 each glycosylation site each glycosylation site site Assignment of molecular ions, within 3 to 5 amu of the theoretical mass, of glycopeptides from each glycosylation site was made from amino acid composition, peptide sequence around the glycosylation sites, and previously reported triantennary oligosaccharide structures (B. Nilsson, N.E. Nordén, and S. Svensson (1979) J. Biol. 2457333 6 41 gly glycosylation 835:847 arg2 the glycosylation sites the glycosylation sites sites Assignment of molecular ions, within 3 to 5 amu of the theoretical mass, of glycopeptides from each glycosylation site was made from amino acid composition, peptide sequence around the glycosylation sites, and previously reported triantennary oligosaccharide structures (B. Nilsson, N.E. Nordén, and S. Svensson (1979) J. Biol. 2457333 6 62 gly glycosylation 750:762 arg2 each glycosylation site each glycosylation site site Assignment of molecular ions, within 3 to 5 amu of the theoretical mass, of glycopeptides from each glycosylation site was made from amino acid composition, peptide sequence around the glycosylation sites, and previously reported triantennary oligosaccharide structures (B. Nilsson, N.E. Nordén, and S. Svensson (1979) J. Biol. 8496193 4 2 gly glycosylation 625:637 arg1 procathepsin L trafficking procathepsin L OGER procathepsin L P06797 To study the role of glycosylation in procathepsin L trafficking, we constructed a cDNA in which the codon for Asn-204 was mutated to encode Gln. 31406333 6 19 gly glycosylation 1139:1151 arg2 the glycosylation site the glycosylation site site X-ray crystallography showed that the glycosylation site at residue 245 is within a conserved epitope that overlaps the NA active site, explaining why it impacts antibody binding. 31406333 6 19 gly glycosylation 1139:1151 arg2 residue 245 residue 245 residue X-ray crystallography showed that the glycosylation site at residue 245 is within a conserved epitope that overlaps the NA active site, explaining why it impacts antibody binding. 10397879 8 36 gly glycoprotein 1606:1617 arg1 the human IL-2 mutant glycoprotein variant IL-Mu6 the human IL-2 mutant glycoprotein variant IL-Mu6 Fterm glycoprotein In order to confirm the direct influence of ammonia on protein glycosylation, the human IL-2 mutant glycoprotein variant IL-Mu6, bearing a novel N-glycosylation site, has been produced under defined protein-free medium conditions in the presence of 15NH4Cl. 10397879 8 102 gly N-glycosylation 1651:1665 arg2 a novel N-glycosylation site a novel N-glycosylation site site In order to confirm the direct influence of ammonia on protein glycosylation, the human IL-2 mutant glycoprotein variant IL-Mu6, bearing a novel N-glycosylation site, has been produced under defined protein-free medium conditions in the presence of 15NH4Cl. 23075397 4 64 part_of contains 835:842 arg1 the N-terminal domain (1-20) AND a glycosylation site the N-terminal domain (1-20) a glycosylation site site Mass spectrometry indicates that the N-terminal domain (1-20) is post-translationally modified by phosphorylations at three sites and probably contains a glycosylation site. 19950248 5 38 part_of hemagglutinin 704:716 arg1 positions 197-199 hemagglutinin positions 197-199 Fterm Site hemagglutinin positions 197 Non-synonymous mutations resulting in the loss of the N-glycosylation site at positions 197-199 of hemagglutinin have been positively selected to a far greater degree in egg-cultured strains than in other strains. 22577028 4 30 gly deglycosylated 931:944 arg1 the deglycosylated tryptic peptides the deglycosylated tryptic peptides peptides In this study, N-linked glycosylation patterns of the recombinant HAs from both insect and plant hosts were characterized by precursor ion scan-driven data-dependent analysis followed by high-resolution MS/MS analysis of the deglycosylated tryptic peptides. 24721674 6 62 part_of proteins 1378:1385 arg1 811 N-glycosylation sites proteins 811 N-glycosylation sites Fterm Site proteins sites 200μg total protein digest was processed using this approach, leading to the identification of 811 N-glycosylation sites from 567 proteins within two experimental replicates. 21604132 6 11 gly glycopeptides 913:925 arg2 the enriched sialylated glycopeptides the enriched sialylated glycopeptides glycopeptides After enzymatic release of the glycans, the enriched sialylated glycopeptides are analyzed by mass spectrometry. 21604132 6 25 gly sialylated 902:911 arg1 the enriched sialylated glycopeptides the enriched sialylated glycopeptides glycopeptides After enzymatic release of the glycans, the enriched sialylated glycopeptides are analyzed by mass spectrometry. 19961828 3 7 part_of contains 447:454 arg1 Each isoform AND one potential N-glycosylation site Each isoform one potential N-glycosylation site Fterm Site isoform site Each isoform contains one potential N-glycosylation site located along the S1-S2 linker; immunoblot analyses verified that K(v)1.4 and K(v)1.5 were N-glycosylated. 15135404 6 38 part_of factor 891:896 arg1 the alpha-mating factor signal sequence factor the alpha-mating factor signal sequence Fterm Site factor sequence The N-terminal of r-SAP purified from the supernatant showed non-complete cleavage of the alpha-mating factor signal sequence. 17406563 0 71 gly glycopeptides 46:58 arg2 N-linked glycopeptides N-linked glycopeptides glycopeptides Mass spectrometric identification of N-linked glycopeptides using lectin-mediated affinity capture and glycosylation site-specific stable isotope tagging. 1594597 0 64 gly N-glycosylation 46:60 arg2 new N-glycosylation sites new N-glycosylation sites sites Hemophilia A due to mutations that create new N-glycosylation sites. 21526855 6 12 gly glycosylation 1171:1183 arg2 the Thr/Ser sites the Thr/Ser sites sites Ladder sequencing of the 17-18.5 kD MUC1 hexarepeat domains revealed (1) cell-specific glycosylation site patterns on comparison of probes expressed in human HEK-293 or Drosophila S2 cells, and (2) a site-specific microheterogeneity at the Thr/Ser sites with variations of the glycan compositions from zero to four monosaccharides. 21526855 6 12 gly glycosylation 1171:1183 arg2 cell-specific glycosylation site patterns cell-specific glycosylation site patterns site Ladder sequencing of the 17-18.5 kD MUC1 hexarepeat domains revealed (1) cell-specific glycosylation site patterns on comparison of probes expressed in human HEK-293 or Drosophila S2 cells, and (2) a site-specific microheterogeneity at the Thr/Ser sites with variations of the glycan compositions from zero to four monosaccharides. 11711599 1 23 gly glycoproteins 155:167 arg1 viral glycoproteins viral glycoproteins Fterm glycoproteins Deglycosylation of viral glycoproteins has been shown to influence the number of available epitopes and to modulate immune recognition of antigens. 11711599 1 70 gly Deglycosylation 130:144 arg1 viral glycoproteins viral glycoproteins Fterm glycoproteins Deglycosylation of viral glycoproteins has been shown to influence the number of available epitopes and to modulate immune recognition of antigens. 28353332 1 15 gly glycosylation 200:212 arg2 each glycosylation site each glycosylation site site A hallmark of protein N-glycosylation is extensive heterogeneity associated with each glycosylation site. 12706347 0 38 part_of invariant 18:26 arg1 Asparagine 81 invariant Asparagine 81 Fterm SpecificSite invariant Asparagine 81 Asparagine 81, an invariant glycosylation site near apyrase conserved region 1, is essential for full enzymatic activity of ecto-nucleoside triphosphate diphosphohydrolase 3. 12706347 0 38 part_of invariant 18:26 arg1 an invariant glycosylation site invariant an invariant glycosylation site Fterm Site invariant site Asparagine 81, an invariant glycosylation site near apyrase conserved region 1, is essential for full enzymatic activity of ecto-nucleoside triphosphate diphosphohydrolase 3. 22279061 10 80 gly detected 1483:1490 arg1 382 AND A bisecting GlcNAc Asn(382) and Asn(393) A bisecting GlcNAc Asn(382) and Asn(393) A bisecting GlcNAc was also detected at Asn(382) and Asn(393). 22279061 10 80 gly detected 1483:1490 arg1 Asn AND A bisecting GlcNAc Asn(382) and Asn(393) A bisecting GlcNAc Asn(382) and Asn(393) A bisecting GlcNAc was also detected at Asn(382) and Asn(393). 22279061 10 80 gly detected 1483:1490 arg1 Asn AND A bisecting GlcNAc Asn(382) and Asn(393) A bisecting GlcNAc Asn(382) and Asn(393) A bisecting GlcNAc was also detected at Asn(382) and Asn(393). 22279061 10 80 gly detected 1483:1490 arg1 Asn AND A bisecting GlcNAc Asn(382) and Asn(393) A bisecting GlcNAc Asn(382) and Asn(393) A bisecting GlcNAc was also detected at Asn(382) and Asn(393). 22279061 10 80 gly detected 1483:1490 arg1 Asn AND A bisecting GlcNAc Asn(382) and Asn(393) A bisecting GlcNAc Asn(382) and Asn(393) A bisecting GlcNAc was also detected at Asn(382) and Asn(393). 22279061 10 80 gly detected 1483:1490 arg1 Asn AND A bisecting GlcNAc Asn(382) and Asn(393) A bisecting GlcNAc Asn(382) and Asn(393) A bisecting GlcNAc was also detected at Asn(382) and Asn(393). 20470225 0 22 part_of mucin 40:44 arg1 mucin 1 peptides mucin 1 mucin 1 peptides PUBTATOR Site mucin 1 4582 peptides Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions. 16845394 3 44 gly N-glycosylation 549:563 arg2 an N-glycosylation site an N-glycosylation site site To determine whether the extended conformation has higher affinity for ligand, we introduced an N-glycosylation site to 'wedge open' the interface between the lectin and EGF-like domains of P-selectin. 22287049 5 70 gly N-glycosylation 1287:1301 arg2 N-glycosylation sites N-glycosylation sites sites We present here a variation of this method using amine-derivatized Fe(3)O(4) nanoparticles, in concert with in situ peptide N-glycosidase F digestion for direct matrix-assisted laser desorption/ionization–mass spectrometry analysis of N-glycosylation sites and the released glycans. 8706738 14 23 gly N-deglycosylated 1727:1742 arg1 N-deglycosylated rGal-T N-deglycosylated rGal-T The kinetic parameters of N-deglycosylated rGal-T were shown not to differ to any significant extent from those of the hGal-T. 1455401 0 41 gly glycosylation 17:29 arg1 pro-urokinase pro-urokinase pro The influence of glycosylation on the catalytic and fibrinolytic properties of pro-urokinase. 11822873 1 62 part_of receptor 309:316 arg1 this region receptor this region Fterm Site receptor region We have analyzed the respective roles of the stalk and/or the O-glycosylation sites in apical sorting by producing partially deleted mutants in this region of the human receptor for neurotrophins (P75(NTR)). 3200844 3 43 gly glycoprotein 402:413 arg1 np62 np62 PUBTATOR np62 65274 The major (62 kDa) nuclear pore glycoprotein (np62) was purified from rat liver nuclear envelopes by immunoaffinity chromatography and preparative gel electrophoresis. 3200844 3 43 gly glycoprotein 402:413 arg1 The major (62 kDa) nuclear pore glycoprotein The major (62 kDa) nuclear pore glycoprotein Fterm glycoprotein The major (62 kDa) nuclear pore glycoprotein (np62) was purified from rat liver nuclear envelopes by immunoaffinity chromatography and preparative gel electrophoresis. 12706379 13 99 gly glycosylation 1850:1862 arg2 a glycosylation site a glycosylation site site The two Old World monkeys share with other lower mammals the absence of a glycosylation site at 113-115. 10682309 0 45 gly non-glycosylated 2:17 arg1 SAP-B SAP-B OGER SAP O60880 A non-glycosylated and functionally deficient mutant (N215H) of the sphingolipid activator protein B (SAP-B) in a novel case of metachromatic leukodystrophy (MLD). 7613162 5 14 gly glycosylation 717:729 arg2 N394 N394 N394 We find that only N371 and N394 are glycosylated, and that the residues surrounding the glycosylation site at N394 are required for Fc epsilon RI alpha binding activity. 7613162 5 14 gly glycosylation 717:729 arg2 the glycosylation site the glycosylation site site We find that only N371 and N394 are glycosylated, and that the residues surrounding the glycosylation site at N394 are required for Fc epsilon RI alpha binding activity. 7613162 5 55 gly glycosylated 665:676 arg1 N371 N371 and N394 N371 and N394 We find that only N371 and N394 are glycosylated, and that the residues surrounding the glycosylation site at N394 are required for Fc epsilon RI alpha binding activity. 17050611 0 5 gly Pradimicin 0:9 arg1 a carbohydrate-binding nonpeptidic lead compound Pradimicin A a carbohydrate-binding nonpeptidic lead compound Cterm Pradimicin A Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus. 12867358 2 24 part_of hNaSi-1 360:366 arg1 the N-glycosylation site hNaSi-1 the N-glycosylation site PUBTATOR Site hNaSi-1 6561 site In this study, the location and functional role of the N-glycosylation site of hNaSi-1 were studied using antifusion protein antibodies. 22689482 2 5 gly glycosylation 643:655 arg2 the asparagine residue the asparagine residue asparagine residue MS analyses on the intact glycoproteins before and after N-deglycosylation with PNGase F and high-resolution MS/MS sequencing by LTQ Orbitrap XL of peptides and glycopeptides from tryptic digests allowed the structural characterization of the glycan moieties and the polypeptide backbone, as well as to establish the glycosylation site at the asparagine residue at 98th position. 22689482 2 5 gly glycosylation 643:655 arg2 the glycosylation site the glycosylation site site MS analyses on the intact glycoproteins before and after N-deglycosylation with PNGase F and high-resolution MS/MS sequencing by LTQ Orbitrap XL of peptides and glycopeptides from tryptic digests allowed the structural characterization of the glycan moieties and the polypeptide backbone, as well as to establish the glycosylation site at the asparagine residue at 98th position. 22689482 2 30 gly glycoproteins 352:364 arg1 the intact glycoproteins the intact glycoproteins Fterm glycoproteins MS analyses on the intact glycoproteins before and after N-deglycosylation with PNGase F and high-resolution MS/MS sequencing by LTQ Orbitrap XL of peptides and glycopeptides from tryptic digests allowed the structural characterization of the glycan moieties and the polypeptide backbone, as well as to establish the glycosylation site at the asparagine residue at 98th position. 22689482 2 33 gly glycopeptides 487:499 arg2 glycopeptides glycopeptides glycopeptides MS analyses on the intact glycoproteins before and after N-deglycosylation with PNGase F and high-resolution MS/MS sequencing by LTQ Orbitrap XL of peptides and glycopeptides from tryptic digests allowed the structural characterization of the glycan moieties and the polypeptide backbone, as well as to establish the glycosylation site at the asparagine residue at 98th position. 18642129 9 80 gly fucosylated 1308:1318 arg1 the triantennary glycans the triantennary glycans Moreover, the triantennary glycans were shown to be fucosylated. 30158294 14 21 gly glycosylated 2296:2307 arg1 SERINC5 SERINC5 PUBTATOR SERINC5 256987 Here we show that SERINC5 is a glycosylated protein and that N-glycosylation is important for its steady state expression. 30158294 14 21 gly glycosylated 2296:2307 arg1 a glycosylated protein a glycosylated protein Fterm protein Here we show that SERINC5 is a glycosylated protein and that N-glycosylation is important for its steady state expression. 19208354 8 35 gly N-glycosylation 1020:1034 arg2 an additional N-glycosylation site an additional N-glycosylation site site Interestingly, the mutation creates an additional N-glycosylation site that is characteristic of a temperature-sensitive protein. 19418565 0 66 part_of glycoproteins 99:111 arg1 control N-glycosylation site-occupancy glycoproteins control N-glycosylation site-occupancy Fterm Site glycoproteins site-occupancy Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells. 10584881 2 19 gly glycoforms 385:394 arg1 AFP AFP PUBTATOR AFP 174 However, there exist glycoforms of AFP which may be more specific for particular tumours. 11463517 6 63 part_of protein 1256:1262 arg1 a potential protein glycosylation site protein a potential protein glycosylation site Fterm Site protein site We report one subject with childhood absence epilepsy (CAE) that evolved to juvenile myoclonic epilepsy (JME) that has a unique de novo mutation that results in a non-conservative amino acid change at a potential protein glycosylation site. 25521995 1 32 part_of PNGase 88:93 arg1 PNGase F-catalyzed glycosylation site PNGase F PNGase F-catalyzed glycosylation site Cterm Site PNGase F site PNGase F-catalyzed glycosylation site (18)O-labeling is a widely used method for glycoprotein quantitation owing to its efficiency and simplicity. 25521995 1 44 part_of F-catalyzed 95:105 arg1 PNGase F-catalyzed glycosylation site PNGase F PNGase F-catalyzed glycosylation site Cterm Site PNGase F site PNGase F-catalyzed glycosylation site (18)O-labeling is a widely used method for glycoprotein quantitation owing to its efficiency and simplicity. 18340083 6 22 gly glycan 846:851 arg1 GPIHBP1 GPIHBP1 glycan PUBTATOR GPIHBP1 68453 The glycan was marginally sensitive to endoglycosidase F2 digestion but resistant to endoglycosidase F3 digestion, suggesting that the glycan on GPIHBP1 is of the oligomannose type. 25759508 3 37 gly O-glycosylation 402:416 arg1 the IgG3 hinge region the IgG3 hinge region region This study reports partial O-glycosylation of the IgG3 hinge region, observed with nanoLC-ESI-IT-MS(/MS) analysis after proteolytic digestion. 29522492 5 67 gly glycosylation 813:825 arg2 the glycosylation site the glycosylation site site The H5N1 viruses acquired enhanced bird-to-human transmissibility by (1) altering amino acids in hemagglutinin (HA) that enable binding affinity to human-type receptors, (2) loss of the glycosylation site and 130 loop in the HA protein and (3) mutation of E627K in the PB2 protein to enhance viral replication in mammalian hosts. 25690651 3 58 gly N-glycosylation 438:452 arg2 an N-glycosylation site an N-glycosylation site site We found that human GPR109A (hGPR109A) has an N-glycosylation site at Asn(17) in the N-terminal atypical motif, Asn(17)-Cys(18)-Cys(19). 25690651 3 58 gly N-glycosylation 438:452 arg2 Asn Asn(17)-Cys(18) Asn(17)-Cys(18) We found that human GPR109A (hGPR109A) has an N-glycosylation site at Asn(17) in the N-terminal atypical motif, Asn(17)-Cys(18)-Cys(19). 26598643 8 34 gly O-glycosylation 1465:1479 arg2 the O-glycosylation sites the O-glycosylation sites sites glycopeptides To pinpoint the O-glycosylation sites glycopeptides were fragmented using electron transfer dissociation. 26598643 8 39 gly glycopeptides 1487:1499 arg2 glycopeptides glycopeptides sites glycopeptides To pinpoint the O-glycosylation sites glycopeptides were fragmented using electron transfer dissociation. 27048837 1 24 gly glycoprotein 183:194 arg1 Apolipoprotein E Apolipoprotein E PUBTATOR Apolipoprotein E 348 BACKGROUND: Apolipoprotein E (Apo E) is a glycoprotein which acts as a ligand facilitating the uptake of lipids. 27048837 1 24 gly glycoprotein 183:194 arg1 a glycoprotein a glycoprotein Fterm glycoprotein BACKGROUND: Apolipoprotein E (Apo E) is a glycoprotein which acts as a ligand facilitating the uptake of lipids. 17877633 1 58 part_of position 277:284 arg1 the A118G variant variant position Fterm Site variant position 118 The most common single nucleotide polymorphism in the coding region of the human mu opioid receptor gene is the A118G variant, an adenine to guanine transition at nucleotide position 118 of the coding sequence of the gene. 2911604 3 55 part_of region 623:628 arg1 rPAM-2 PAM region PUBTATOR Site PAM 25508 region The two types of cDNA, rPAM-1 and rPAM-2, are identical except for the deletion of a 315-base-pair segment within the protein coding region in rPAM-2, suggesting that rPAM-1 and rPAM-2 arise by alternative splicing. 2911604 3 71 part_of protein 608:614 arg1 the protein coding region protein the protein coding region Fterm Site protein region The two types of cDNA, rPAM-1 and rPAM-2, are identical except for the deletion of a 315-base-pair segment within the protein coding region in rPAM-2, suggesting that rPAM-1 and rPAM-2 arise by alternative splicing. 2082620 2 45 gly N-glycosylation 353:367 arg1 HIV-1 gp120 HIV-1 gp120 PUBTATOR gp120 155971 To address the possible role of N-glycosylation of HIV-1 gp120 in binding CD4, we mutated different conserved N-glycosylation site Asn-residues in the vicinity of the putative CD4 binding site, as single mutations or in combinations. 2082620 2 72 gly N-glycosylation 431:445 arg2 different conserved N-glycosylation site Asn-residues site Asn-residues site Asn-residues To address the possible role of N-glycosylation of HIV-1 gp120 in binding CD4, we mutated different conserved N-glycosylation site Asn-residues in the vicinity of the putative CD4 binding site, as single mutations or in combinations. 2985383 3 53 part_of urokinase 522:530 arg1 the entire coding region urokinase region Fterm Site urokinase region The longest cDNA insert contains the entire coding region of mouse urokinase, 58 base pairs of the 5' non-coding region, and the entire 3' non-coding region, which is 942 base pairs long. 28714086 11 12 gly sugars 2082:2087 arg1 the identity position the identity position In the present study, we show that altering glycan content on kainate receptors (KARs) changes the functional properties of the receptors in a manner dependent on the identity of both the modified sugars and the subunit composition of the receptor to which they are attached. 9020858 3 6 gly O-glycosylated 510:523 arg1 only the liver isoform only the liver isoform Fterm isoform All TNAPs proved to be N-glycosylated, and only the liver isoform (LAP) is not O-glycosylated. 9020858 3 6 gly O-glycosylated 510:523 arg1 LAP LAP PUBTATOR LAP P11117 All TNAPs proved to be N-glycosylated, and only the liver isoform (LAP) is not O-glycosylated. 9020858 3 60 gly N-glycosylated 454:467 arg1 All TNAPs All TNAPs OGER APs All TNAPs proved to be N-glycosylated, and only the liver isoform (LAP) is not O-glycosylated. 24884609 10 23 gly O-glycoforms 1413:1424 arg1 isoform-specific ITIH4 O-glycoforms isoform-specific ITIH4 O-glycoforms PUBTATOR ITIH4 3700 We also identified isoform-specific ITIH4 O-glycoforms and documented that utilization of O-glycosylation sites on ITIH4 differed between the cell line and serum. 24884609 10 51 gly O-glycosylation 1461:1475 arg2 O-glycosylation sites O-glycosylation sites sites We also identified isoform-specific ITIH4 O-glycoforms and documented that utilization of O-glycosylation sites on ITIH4 differed between the cell line and serum. 26858738 6 82 gly O-glycosylation 1109:1123 arg2 nine potential O-glycosylation sites nine potential O-glycosylation sites sites Analysis of the peptide carrying nine potential O-glycosylation sites in the IgA1 alpha chain hinge region showed the presence of plant-specific modifications including hydroxyproline formation and the attachment of pentoses. 10940860 1 10 gly glycosylation 197:209 arg2 Asn-184 Asn-184 Asn-184 Human tissue-type plasminogen activator (t-PA) contains a variably occupied glycosylation site at Asn-184 in naturally produced t-PA and in t-PA produced in recombinant Chinese hamster ovary (CHO) cells. 10940860 1 10 gly glycosylation 197:209 arg2 a variably occupied glycosylation site a variably occupied glycosylation site site Human tissue-type plasminogen activator (t-PA) contains a variably occupied glycosylation site at Asn-184 in naturally produced t-PA and in t-PA produced in recombinant Chinese hamster ovary (CHO) cells. 14711516 6 3 gly Recombinant 1003:1013 arg1 GlcNAc Recombinant Thy-1 GlcNAc PUBTATOR Recombinant Thy-1 P04216 Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5). 14711516 6 3 gly Recombinant 1003:1013 arg1 2 Recombinant Thy-1 2 PUBTATOR Recombinant Thy-1 P04216 Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5). 14711516 6 3 gly Recombinant 1003:1013 arg1 Man Recombinant Thy-1 Man PUBTATOR Recombinant Thy-1 P04216 Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5). 14711516 6 3 gly Recombinant 1003:1013 arg1 5 Recombinant Thy-1 5 PUBTATOR Recombinant Thy-1 P04216 Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5). 14711516 6 41 gly oligosaccharides 1097:1112 arg1 asparagine 23 and 100 asparagine 23 and 100 asparagine 23 and 100 SpecificSite asparagine 23 and 100 Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5). 14711516 6 41 gly oligosaccharides 1097:1112 arg1 100 100 100 SpecificSite asparagine 23 and 100 Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5). 22691915 11 49 gly N-glycosylation 1396:1410 arg2 poor N-glycosylation site occupancy poor N-glycosylation site occupancy site It can be used to screen for compounds that reverse poor N-glycosylation site occupancy. 22855498 5 99 gly glycoprotein 587:598 arg1 E1E2 glycoprotein gene sequences E1E2 glycoprotein gene sequences Fterm glycoprotein E1E2 glycoprotein gene sequences in the donor inoculum and recipient mice were determined following single-genome amplification (SGA). 7510285 0 4 part_of protein 62:68 arg1 the protein epitope protein the protein epitope Fterm Site protein epitope Membrane topology of the L6 antigen and identification of the protein epitope recognized by the L6 monoclonal antibody. 9295302 9 29 part_of has 1511:1513 arg1 MRP AND an extracytosolic NH2 terminus MRP an extracytosolic NH2 terminus PUBTATOR Site MRP 4363 terminus N-Glycosylation of Asn19 and Asn23 provides the first direct experimental evidence that MRP has an extracytosolic NH2 terminus. 20011150 0 57 part_of sites 63:67 arg1 hemagglutinin protein protein sites Fterm Site protein sites Identification of mutations at the antigenic and glycosylation sites in hemagglutinin protein of H5N1 strain. 27927205 8 64 gly N-glycosylation 1507:1521 arg2 putative N-glycosylation site putative N-glycosylation site site CONCLUSIONS: The results demonstrate that the elimination of N-glycosylation by mutation of putative N-glycosylation site further prolongs the half-life of the IFN-α/Fc fusion protein and could present an alternative strategy for extending the half-life of low-molecular-weight proteins expressed by P. pastoris for in vivo studies as well as for future clinical applications. 17459925 11 93 gly present 1539:1545 arg1 the E protein AND the two glycans the E protein the two glycans Fterm protein Overall, our data defined different roles for the two glycans present at the E protein during dengue virus infection, highlighting the involvement of distinct host functions from mammalian and mosquito cells during dengue virus propagation. 11390601 2 85 part_of sites 426:430 arg1 gp120 gp120 sites PUBTATOR Site gp120 155971 sites In this study, specific glycosylation sites on gp120 of a dualtropic primary HIV-1 isolate, DH12, were eliminated by site-directed mutagenesis and the properties of the resulting mutant envelopes were evaluated using a recombinant vaccinia virus-based cell-to-cell fusion assay alone or in the context of viral infections. 8980650 4 4 gly N-glycosylation 844:858 arg1 a site site site The newly synthesized p31 species was quantitatively converted to p27 by treatment with endoglycosidase H, consistent with efficient N-glycosylation at a site in the N-terminal propeptide region (Asn63-Met64-Thr65). 8307000 3 45 gly deglycosylated 1229:1242 arg1 corresponding deglycosylated peptides corresponding deglycosylated peptides peptides Individual (sub)fractions of glucans were studied by methylation analysis, liquid secondary-ion mass spectrometry and, in part, by exoglycosidase digestion, whereas corresponding deglycosylated peptides were identified by amino acid analysis and N-terminal amino acid sequencing. 22573926 5 61 part_of stanniocalcin 621:633 arg1 The opossum stanniocalcin 1 amino acid sequence stanniocalcin 1 The opossum stanniocalcin 1 amino acid sequence PUBTATOR Site stanniocalcin 1 6781 sequence The opossum stanniocalcin 1 amino acid sequence had 83% homology with human stanniocalcin 1, and has a conserved putative N-linked glycosylation site. 22573926 5 62 part_of has 706:708 arg1 The opossum stanniocalcin 1 amino acid sequence AND a conserved putative N-linked glycosylation site The opossum stanniocalcin 1 amino acid sequence a conserved putative N-linked glycosylation site site The opossum stanniocalcin 1 amino acid sequence had 83% homology with human stanniocalcin 1, and has a conserved putative N-linked glycosylation site. 1379602 6 88 part_of desmoglein 1110:1119 arg1 several proteolytic fragments desmoglein several proteolytic fragments Fterm Site desmoglein fragments Characterization of several proteolytic fragments of this epidermal desmoglein enabled us to map the DG3.4 epitope to a 96-kDa intracellular domain and the AE23 epitope to an extracellular domain flanked by the plasma membrane and the distal N-glycosylation site(s). 26869352 9 79 gly fucosylated 1513:1523 arg1 Lewis-type and core-type fucosylated N-glycans Lewis-type and core-type fucosylated N-glycans Lewis-type and core-type fucosylated N-glycans were increased in gastroenterological cancer samples, but only core-type fucosylated N-glycan was relatively increased in prostate cancer samples. 26869352 9 101 gly fucosylated 1608:1618 arg1 only core-type fucosylated N-glycan only core-type fucosylated N-glycan Lewis-type and core-type fucosylated N-glycans were increased in gastroenterological cancer samples, but only core-type fucosylated N-glycan was relatively increased in prostate cancer samples. 6411351 4 29 gly glycosylation 633:645 arg2 a glycosylation site a glycosylation site site There is also loss of a glycosylation site that is used in all class I antigens. 6411351 4 56 gly used 660:663 arg2 a glycosylation site a glycosylation site site There is also loss of a glycosylation site that is used in all class I antigens. 9365923 2 36 gly glycosylation 316:328 arg2 the glycosylation site the glycosylation site site In all these species the glycosylation site is the 45Asn in the usual triplet 45Asn-Gly/Gln-47Ser. 27356208 6 74 part_of hFIX 997:1000 arg1 the first 45 residues hFIX the first 45 residues PUBTATOR Site hFIX 2158 residues With this aim, the first 45 residues of mature hFIX were explored to find out suitable positions for introducing either Asn or Ser/Thr residues, to create new N-glycosylation site(s). 30659065 4 50 gly N-glycosylation 852:866 arg2 a single N-glycosylation site a single N-glycosylation site site Although IgGs usually have a single N-glycosylation site and are well studied, other antibody isotypes, e.g. IgA and IgM, that are the first responders in certain diseases, have two to five sites/monomer of antibody, and little is known about their N-glycosylation. 26400346 6 53 part_of FGF 815:817 arg1 an FGF domain FGF an FGF domain PUBTATOR Site FGF 2250 domain Bioinformatic analysis revealed that FGF5 contained a signal peptide, an FGF domain, and a heparin-binding growth factor/FGF family signature. 26400346 6 46 part_of contained 784:792 arg1 FGF5 AND a signal peptide FGF5 a signal peptide PUBTATOR Site FGF5 102171226 peptide Bioinformatic analysis revealed that FGF5 contained a signal peptide, an FGF domain, and a heparin-binding growth factor/FGF family signature. 26400346 6 46 part_of contained 784:792 arg1 FGF5 AND an FGF domain FGF5 an FGF domain PUBTATOR Site FGF5 102171226 domain Bioinformatic analysis revealed that FGF5 contained a signal peptide, an FGF domain, and a heparin-binding growth factor/FGF family signature. 16512686 3 16 gly glycoprotein 963:974 arg1 a glycoprotein mixture a glycoprotein mixture Fterm glycoprotein Previously reported methods to facilitate glycopeptide identification require either several pre-enrichment steps, involve complex derivatization procedures, or are restricted to a subset of all the glycan structures that are present in a glycoprotein mixture. 16512686 3 90 gly glycopeptide 766:777 arg2 glycopeptide identification glycopeptide identification glycopeptide Previously reported methods to facilitate glycopeptide identification require either several pre-enrichment steps, involve complex derivatization procedures, or are restricted to a subset of all the glycan structures that are present in a glycoprotein mixture. 31637569 3 12 gly glycopeptide 647:658 arg2 a glycopeptide a glycopeptide glycopeptide Factors such as glycan size, glycosylation site position within a glycopeptide and individual precursor m/z all significantly impacted the number and quality of assignable glycopeptide backbone fragments. 31637569 3 79 gly glycopeptide 753:764 arg2 glycopeptide glycopeptide glycopeptide Factors such as glycan size, glycosylation site position within a glycopeptide and individual precursor m/z all significantly impacted the number and quality of assignable glycopeptide backbone fragments. 31637569 3 59 gly glycosylation 610:622 arg2 glycosylation site position site position site position Factors such as glycan size, glycosylation site position within a glycopeptide and individual precursor m/z all significantly impacted the number and quality of assignable glycopeptide backbone fragments. 22292921 3 33 gly glycosylation 720:732 arg2 the N-linked glycosylation site the N-linked glycosylation site site To determine which domain/motif of DC-SIGN facilitates its presence in microdomains, we studied mutations at key locations including truncation of the cytoplasmic tail, and ectodomain mutations that resulted in the removal of the N-linked glycosylation site, the tandem repeats and the carbohydrate recognition domain (CRD), as well as modification of the calcium sites in the CRD required for carbohydrate binding. 17215147 2 14 gly glycosylation 134:146 arg2 A glycosylation site A glycosylation site site A glycosylation site in the first extracellular loop of TRPV5 is enzymatically cleaved by a secreted glucuronidase, indirectly regulating channel function. 21829533 2 29 gly glycoprotein 537:548 arg1 glycoprotein structures glycoprotein structures Fterm glycoprotein In this study, the patterns and conservation of glycosylation sites on HA and NA of influenza A/H1N1 viruses isolated from various hosts at different time periods were systematically analyzed, by employing a new strategy combining genome-based glycosylation site prediction and 3D modeling of glycoprotein structures, for elucidation of the modes and laws of glycosylation site alteration in the evolution of influenza A/H1N1 viruses. 21829533 2 47 gly glycosylation 603:615 arg2 glycosylation site alteration glycosylation site alteration site In this study, the patterns and conservation of glycosylation sites on HA and NA of influenza A/H1N1 viruses isolated from various hosts at different time periods were systematically analyzed, by employing a new strategy combining genome-based glycosylation site prediction and 3D modeling of glycoprotein structures, for elucidation of the modes and laws of glycosylation site alteration in the evolution of influenza A/H1N1 viruses. 21829533 2 86 gly glycosylation 488:500 arg2 genome-based glycosylation site prediction genome-based glycosylation site prediction site In this study, the patterns and conservation of glycosylation sites on HA and NA of influenza A/H1N1 viruses isolated from various hosts at different time periods were systematically analyzed, by employing a new strategy combining genome-based glycosylation site prediction and 3D modeling of glycoprotein structures, for elucidation of the modes and laws of glycosylation site alteration in the evolution of influenza A/H1N1 viruses. 21829533 2 104 gly glycosylation 292:304 arg2 glycosylation sites glycosylation sites sites In this study, the patterns and conservation of glycosylation sites on HA and NA of influenza A/H1N1 viruses isolated from various hosts at different time periods were systematically analyzed, by employing a new strategy combining genome-based glycosylation site prediction and 3D modeling of glycoprotein structures, for elucidation of the modes and laws of glycosylation site alteration in the evolution of influenza A/H1N1 viruses. 1331083 0 37 gly Asn-linked 19:28 arg1 Asn-linked oligosaccharides Asn Asn-linked oligosaccharides Asn Phosphorylation of Asn-linked oligosaccharides located at novel sites on the lysosomal enzyme cathepsin D. 8307000 4 13 gly carried 1373:1379 arg1 Asn117 AND high-mannose-type glycans Asn117 high-mannose-type glycans Asn117 The results revealed that Asn117 of YN-tPA carried exclusively high-mannose-type glycans with five to nine mannose residues similar to wild-type tPA expressed in this cell line [Pfeiffer, G., Schmidt, M., Strube, K.-H. 18077336 10 15 gly glycosylated 1418:1429 arg1 the MC2 receptor the MC2 receptor OGER MC2 receptor P33032 In the absence of MRAP, MC2 receptor was trapped in the endoplasmic reticulum, but with MRAP, the MC2 receptor was glycosylated and localized on the plasma membrane, where it signaled in response to ACTH. 23527023 1 34 gly glycoforms 94:103 arg1 the cellular prion protein the cellular prion protein Fterm protein The four glycoforms of the cellular prion protein (PrP(C)) variably glycosylated at the two N-linked glycosylation sites are converted into their pathological forms (PrP(Sc)) in most cases of sporadic prion diseases. 23527023 1 85 gly glycosylation 186:198 arg2 the two N-linked glycosylation sites the two N-linked glycosylation sites sites The four glycoforms of the cellular prion protein (PrP(C)) variably glycosylated at the two N-linked glycosylation sites are converted into their pathological forms (PrP(Sc)) in most cases of sporadic prion diseases. 23527023 1 59 gly glycosylated 153:164 arg2 the two N-linked glycosylation sites protein sites Fterm protein sites The four glycoforms of the cellular prion protein (PrP(C)) variably glycosylated at the two N-linked glycosylation sites are converted into their pathological forms (PrP(Sc)) in most cases of sporadic prion diseases. 9210490 6 30 gly N-glycosylation 874:888 arg2 the first (Asn83-->Gln) or eighth (Asn686-->Gln) N-glycosylation site the first (Asn83-->Gln) or eighth (Asn686-->Gln) N-glycosylation site site Mutation of the first (Asn83-->Gln) or eighth (Asn686-->Gln) N-glycosylation site had only a small effect on its enzymatic activity, cell-surface expression and dimer formation, whereas the mutation of the sixth N-glycosylation site (Asn319-->Gln) abolished the enzymatic activity, eliminated cell-surface expression and prevented the dimerization of the DPPIV protein. 9210490 6 67 gly N-glycosylation 1025:1039 arg2 the sixth N-glycosylation site the sixth N-glycosylation site site Mutation of the first (Asn83-->Gln) or eighth (Asn686-->Gln) N-glycosylation site had only a small effect on its enzymatic activity, cell-surface expression and dimer formation, whereas the mutation of the sixth N-glycosylation site (Asn319-->Gln) abolished the enzymatic activity, eliminated cell-surface expression and prevented the dimerization of the DPPIV protein. 9210490 6 67 gly N-glycosylation 1025:1039 arg2 Asn319-->Gln Asn319-->Gln Asn319 Mutation of the first (Asn83-->Gln) or eighth (Asn686-->Gln) N-glycosylation site had only a small effect on its enzymatic activity, cell-surface expression and dimer formation, whereas the mutation of the sixth N-glycosylation site (Asn319-->Gln) abolished the enzymatic activity, eliminated cell-surface expression and prevented the dimerization of the DPPIV protein. 8442916 3 88 gly glycoprotein 531:542 arg1 the external glycoprotein the external glycoprotein Fterm glycoprotein The molecular analysis of the env region encompassed all variable domains of the external glycoprotein, gp120. 8442916 3 88 gly glycoprotein 531:542 arg1 gp120 gp120 PUBTATOR gp120 3700 The molecular analysis of the env region encompassed all variable domains of the external glycoprotein, gp120. 23365085 2 10 gly Glycans 309:315 arg1 the head the head the head Site head Glycans on the head of HA promote virus survival by shielding antigenic sites, but highly glycosylated seasonal IAV are inactivated by soluble lectins of the innate immune system. 25202310 3 19 gly glycoproteins 726:738 arg1 the high-mannose-rich microsomal glycoproteins the high-mannose-rich microsomal glycoproteins LC-MS/MS-based quantitative glycomics showed that the secreted glycoproteins of eight human breast epithelial cells displaying diverse geno- and phenotypes consistently displayed more processed, primarily complex type, N-glycans than the high-mannose-rich microsomal glycoproteins. 25202310 3 73 gly glycoproteins 522:534 arg1 the secreted glycoproteins the secreted glycoproteins Fterm glycoproteins LC-MS/MS-based quantitative glycomics showed that the secreted glycoproteins of eight human breast epithelial cells displaying diverse geno- and phenotypes consistently displayed more processed, primarily complex type, N-glycans than the high-mannose-rich microsomal glycoproteins. 3932064 9 45 part_of had 1044:1046 arg1 The 32-kd polypeptide sequence AND one possible N-linked glycosylation site The 32-kd polypeptide sequence one possible N-linked glycosylation site site The 32-kd polypeptide sequence consisted of 210 amino acids and had one possible N-linked glycosylation site. 11754244 0 34 part_of MUC5AC 39:44 arg1 MUC5AC mucin motif peptides MUC5AC MUC5AC mucin motif peptides PUBTATOR Site MUC5AC 4586 peptides Identification of substituted sites on MUC5AC mucin motif peptides after enzymatic O-glycosylation combining beta-elimination and fixed-charge derivatization. 7613477 8 16 gly sialylated 1678:1687 arg1 sialylated triantennary oligosaccharides sialylated triantennary oligosaccharides These glycopeptides were determined to bear sialylated triantennary oligosaccharides or fucosylated sialylated biantennary oligosaccharides. 7613477 8 35 gly fucosylated 1722:1732 arg1 fucosylated sialylated biantennary oligosaccharides fucosylated sialylated biantennary oligosaccharides These glycopeptides were determined to bear sialylated triantennary oligosaccharides or fucosylated sialylated biantennary oligosaccharides. 7613477 8 73 gly glycopeptides 1640:1652 arg2 These glycopeptides These glycopeptides glycopeptides These glycopeptides were determined to bear sialylated triantennary oligosaccharides or fucosylated sialylated biantennary oligosaccharides. 7613477 8 89 gly sialylated 1734:1743 arg1 fucosylated sialylated biantennary oligosaccharides fucosylated sialylated biantennary oligosaccharides These glycopeptides were determined to bear sialylated triantennary oligosaccharides or fucosylated sialylated biantennary oligosaccharides. 7613477 8 53 gly bear 1673:1676 arg1 These glycopeptides AND fucosylated sialylated biantennary oligosaccharides These glycopeptides fucosylated sialylated biantennary oligosaccharides glycopeptides These glycopeptides were determined to bear sialylated triantennary oligosaccharides or fucosylated sialylated biantennary oligosaccharides. 7613477 8 53 gly bear 1673:1676 arg1 These glycopeptides AND sialylated triantennary oligosaccharides These glycopeptides sialylated triantennary oligosaccharides glycopeptides These glycopeptides were determined to bear sialylated triantennary oligosaccharides or fucosylated sialylated biantennary oligosaccharides. 21338062 7 100 gly compositions 1581:1592 arg1 three Hpt tryptic glycopeptides three Hpt tryptic glycopeptides three Hpt tryptic glycopeptides Site glycopeptides A total of 26 glycoforms/glycan compositions on three Hpt tryptic glycopeptides were identified and quantified from 10 LC-MS runs with a consumption of 100 fmol of Hpt digest (13 ng of protein, 10 fmol per injection). 21338062 7 116 gly glycopeptides 1615:1627 arg2 three Hpt tryptic glycopeptides three Hpt tryptic glycopeptides glycopeptides A total of 26 glycoforms/glycan compositions on three Hpt tryptic glycopeptides were identified and quantified from 10 LC-MS runs with a consumption of 100 fmol of Hpt digest (13 ng of protein, 10 fmol per injection). 11356836 3 41 part_of contains 520:527 arg1 Saposin A AND an additional glycosylation site Saposin A an additional glycosylation site Cterm Site Saposin A site Saposin A contains an additional glycosylation site and a single tryptophan. 11356836 3 41 part_of contains 520:527 arg1 Saposin A AND a single tryptophan Saposin A a single tryptophan Cterm AminoAcid Saposin A tryptophan Saposin A contains an additional glycosylation site and a single tryptophan. 27573070 9 23 gly used 1824:1827 arg2 N-glycopeptides N-glycopeptides N-glycopeptides Thus, gFinder is a convenient, high-throughput analytical tool for interpreting the tandem mass spectra of N-glycopeptides, which can then be used for identification of potential missing proteins having glycans. 27573070 9 78 gly N-glycopeptides 1789:1803 arg2 N-glycopeptides N-glycopeptides N-glycopeptides Thus, gFinder is a convenient, high-throughput analytical tool for interpreting the tandem mass spectra of N-glycopeptides, which can then be used for identification of potential missing proteins having glycans. 27573070 9 85 gly having 1878:1883 arg1 potential missing proteins AND glycans potential missing proteins glycans Fterm proteins Thus, gFinder is a convenient, high-throughput analytical tool for interpreting the tandem mass spectra of N-glycopeptides, which can then be used for identification of potential missing proteins having glycans. 22407978 5 61 gly glycosylation 780:792 arg2 the N-linked glycosylation site the N-linked glycosylation site site The removal of the glycan through enzymatic deglycosylation or mutagenesis of the N-linked glycosylation site has been reported to "silence" FcγR-binding and effector functions, particularly with assays that measure monomeric binding. 22407978 5 67 gly deglycosylation 733:747 arg1 the N-linked glycosylation site the N-linked glycosylation site site The removal of the glycan through enzymatic deglycosylation or mutagenesis of the N-linked glycosylation site has been reported to "silence" FcγR-binding and effector functions, particularly with assays that measure monomeric binding. 9677334 12 42 gly O-glycosylation 1606:1620 arg2 the O-glycosylation site the O-glycosylation site site We also demonstrate that the O-glycosylation site located at position 110 of TPO is not necessary for the bioactivity of the cytokine. 2737165 2 68 part_of site 336:339 arg1 hGH-V hGH-V site PUBTATOR Site hGH-V 2689 site There is a predicted N-linked glycosylation site in hGH-V at amino acid 140 that is absent in both hGH-V2 and in the highly homologous normal pituitary GH (hGH-N). 3896487 1 21 gly glycoprotein 230:241 arg1 the glycoprotein the glycoprotein Fterm glycoprotein Glycopeptides containing individual N-glycosylation sites of the glycoprotein from Friend murine leukemia virus were isolated by digestion of the viral glycoprotein with protease of S. aureus (V8) or with trypsin followed by fractionation of the resulting (glyco)peptides by gel filtration and reversed-phase, high-performance liquid chromatography at pH 6. 3896487 1 42 gly glycoprotein 317:328 arg1 the viral glycoprotein the viral glycoprotein Fterm glycoprotein Glycopeptides containing individual N-glycosylation sites of the glycoprotein from Friend murine leukemia virus were isolated by digestion of the viral glycoprotein with protease of S. aureus (V8) or with trypsin followed by fractionation of the resulting (glyco)peptides by gel filtration and reversed-phase, high-performance liquid chromatography at pH 6. 3896487 1 6 gly N-glycosylation 201:215 arg2 individual N-glycosylation sites glycoprotein sites Fterm glycoprotein sites Glycopeptides containing individual N-glycosylation sites of the glycoprotein from Friend murine leukemia virus were isolated by digestion of the viral glycoprotein with protease of S. aureus (V8) or with trypsin followed by fractionation of the resulting (glyco)peptides by gel filtration and reversed-phase, high-performance liquid chromatography at pH 6. 11087686 5 21 gly N-glycosylation 823:837 arg2 a single N-glycosylation site a single N-glycosylation site site The secreted protein was heterogeneously glycosylated at a single N-glycosylation site and had an apparent molecular mass of 35-50 kDa. 11087686 5 26 gly glycosylated 798:809 arg1 The secreted protein protein site Fterm protein site The secreted protein was heterogeneously glycosylated at a single N-glycosylation site and had an apparent molecular mass of 35-50 kDa. 8912525 6 42 part_of ARA 686:688 arg1 The primary amino acid sequence ARA The primary amino acid sequence PUBTATOR Site ARA 368 sequence The primary amino acid sequence of ARA indicates that it is 49.5 kDa without glycosylation, and that it has one potential glycosylation site. 31501225 6 80 gly glycopeptides 974:986 arg2 the glycopeptides IgA2 glycopeptides OGER IgA2 P01877 glycopeptides TPLTAN 205ITK (H5N5S1F1) and (H5N4S2F1) corresponding to the glycopeptides of IgA2 were significantly elevated in serum from patients with HBV infection and even higher in HBV-related LC patients, as compared with healthy donor. 25673720 8 110 gly glycosylation 1249:1261 arg2 both or the first PrP(C) glycosylation site both or the first PrP(C) glycosylation site site The absence of glycosylation at both or the first PrP(C) glycosylation site in the host results in almost complete resistance to disease. 7929344 6 42 gly glycosylation 1201:1213 arg2 an asparagine-linked glycosylation site an asparagine-linked glycosylation site site We increased the secretion rate of one of the sFvs by introducing an asparagine-linked glycosylation site in FR1 of the heavy chain, and by using tunicamycin (an inhibitor of glycosylation) we found that glycosylated antibody sFvs were secreted faster than their nonglycosylated counterparts. 21431619 6 29 gly glycosylation 1055:1067 arg2 the 2nd glycosylation site the 2nd glycosylation site site In case 1, a peptide with mutation p.Asn630Thr in the 2nd glycosylation site was identified, resulting in an additional band at disialotransferrin position on IEF. 15765924 2 22 gly glycosylation 489:501 arg2 the glycosylation site the glycosylation site site DrotAA is a serine protease (approximately 55 kD molecular weight) with the same amino acid sequence and the glycosylation site as human plasma-derived APC. 3102971 6 18 gly glycosylation 1108:1120 arg2 no N-linked glycosylation site no N-linked glycosylation site site The major gamma-gene transcribed in mature, alpha beta-bearing T cells (V gamma 1.2C gamma 2)encodes no N-linked glycosylation site so these results suggest that the fetal gamma delta receptor defines a distinct T-cell lineage whose development in the thymus precedes classical alpha beta-bearing cells. 17900180 1 74 part_of proteins 637:644 arg1 the sequence proteins the sequence Fterm Site proteins sequence We have expanded our recent on-line LC-MS platform for large peptide analysis to combine collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID of an isolated charge-reduced (CRCID) species derived from ETD to determine sites of phosphorylation and glycosylation modifications, as well as the sequence of large peptide fragments (i.e., 2000-10,000 Da) from complex proteins, such as beta-casein, epidermal growth factor receptor (EGFR), and tissue plasminogen activator (t-PA) at the low femtomol level. 17900180 1 74 part_of proteins 637:644 arg1 large peptide fragments proteins large peptide fragments Fterm Site proteins fragments We have expanded our recent on-line LC-MS platform for large peptide analysis to combine collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID of an isolated charge-reduced (CRCID) species derived from ETD to determine sites of phosphorylation and glycosylation modifications, as well as the sequence of large peptide fragments (i.e., 2000-10,000 Da) from complex proteins, such as beta-casein, epidermal growth factor receptor (EGFR), and tissue plasminogen activator (t-PA) at the low femtomol level. 17900180 1 96 part_of sequence 565:572 arg1 complex proteins proteins sequence Fterm Site proteins sequence We have expanded our recent on-line LC-MS platform for large peptide analysis to combine collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID of an isolated charge-reduced (CRCID) species derived from ETD to determine sites of phosphorylation and glycosylation modifications, as well as the sequence of large peptide fragments (i.e., 2000-10,000 Da) from complex proteins, such as beta-casein, epidermal growth factor receptor (EGFR), and tissue plasminogen activator (t-PA) at the low femtomol level. 17900180 1 96 part_of sequence 565:572 arg1 tissue plasminogen activator tissue plasminogen activator sequence OGER Site tissue plasminogen activator P00750 sequence We have expanded our recent on-line LC-MS platform for large peptide analysis to combine collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID of an isolated charge-reduced (CRCID) species derived from ETD to determine sites of phosphorylation and glycosylation modifications, as well as the sequence of large peptide fragments (i.e., 2000-10,000 Da) from complex proteins, such as beta-casein, epidermal growth factor receptor (EGFR), and tissue plasminogen activator (t-PA) at the low femtomol level. 17900180 1 96 part_of sequence 565:572 arg1 beta-casein beta-casein sequence OGER Site beta-casein P05814 sequence We have expanded our recent on-line LC-MS platform for large peptide analysis to combine collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID of an isolated charge-reduced (CRCID) species derived from ETD to determine sites of phosphorylation and glycosylation modifications, as well as the sequence of large peptide fragments (i.e., 2000-10,000 Da) from complex proteins, such as beta-casein, epidermal growth factor receptor (EGFR), and tissue plasminogen activator (t-PA) at the low femtomol level. 17900180 1 96 part_of sequence 565:572 arg1 epidermal growth factor receptor epidermal growth factor receptor sequence PUBTATOR Site epidermal growth factor receptor 1956 sequence We have expanded our recent on-line LC-MS platform for large peptide analysis to combine collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID of an isolated charge-reduced (CRCID) species derived from ETD to determine sites of phosphorylation and glycosylation modifications, as well as the sequence of large peptide fragments (i.e., 2000-10,000 Da) from complex proteins, such as beta-casein, epidermal growth factor receptor (EGFR), and tissue plasminogen activator (t-PA) at the low femtomol level. 10207016 2 58 part_of protein 385:391 arg1 The pre-S2 domain M protein The pre-S2 domain OGER Site M protein P54296 domain The pre-S2 domain, present only in M and L proteins, is further N-glycosylated at Asn-4 exclusively in the M protein. 16720579 4 83 gly C6ST-1 801:806 arg1 N-glycans C6ST-1 N-glycans OGER C6ST-1 Q7LGC8 A nearly complete removal of N-glycans of the recombinant C6ST-1 by peptide N-glycosidase F increased the C6ST activity but decreased the KSST activity. 8349699 6 100 part_of synthase-1 883:892 arg1 the three glycosylation sites PGH synthase-1 the three glycosylation sites PUBTATOR Site PGH synthase-1 19224 sites N-Glycosylation consensus sequences corresponding to the three glycosylation sites of ovine PGH synthase-1 are conserved in the deduced amino acid sequences of PGH synthases-2. 21196036 1 34 gly glycoprotein 138:149 arg1 oviductin oviductin OGER oviductin Q12889 Oviduct-specific glycoprotein (oviductin) plays an important role during fertilization and early embryonic development. 21196036 1 34 gly glycoprotein 138:149 arg1 Oviduct-specific glycoprotein Oviduct-specific glycoprotein OGER Oviduct-specific glycoprotein Q12889 Oviduct-specific glycoprotein (oviductin) plays an important role during fertilization and early embryonic development. 8244416 6 24 gly unglycosylated 1359:1372 arg1 their unglycosylated peptides their unglycosylated peptides peptides The resulting chimeric heavy chain of F11-35 showed a slightly but significantly higher molecular weight than that of F11-39, but the molecular weights of their unglycosylated peptides synthesized in the presence of tunicamycin were similar, indicating the glycosylation at the possible N-glycosylation site in the variable region of the Ch F11-35 heavy chain. 8244416 6 98 gly N-glycosylation 1485:1499 arg2 the possible N-glycosylation site the possible N-glycosylation site site The resulting chimeric heavy chain of F11-35 showed a slightly but significantly higher molecular weight than that of F11-39, but the molecular weights of their unglycosylated peptides synthesized in the presence of tunicamycin were similar, indicating the glycosylation at the possible N-glycosylation site in the variable region of the Ch F11-35 heavy chain. 8244416 6 95 gly glycosylation 1455:1467 arg1 the possible N-glycosylation site site site The resulting chimeric heavy chain of F11-35 showed a slightly but significantly higher molecular weight than that of F11-39, but the molecular weights of their unglycosylated peptides synthesized in the presence of tunicamycin were similar, indicating the glycosylation at the possible N-glycosylation site in the variable region of the Ch F11-35 heavy chain. 19735085 3 46 gly glycoprotein 463:474 arg1 P-selectin glycoprotein ligand-1 P-selectin glycoprotein ligand-1 Fterm glycoprotein To this end, the N-terminal section of the human leukocyte glycoprotein PSGL-1 (P-selectin glycoprotein ligand-1) was modified to contain a poly-histidine tag followed by a proteolytic cleavage site. 19735085 3 58 gly glycoprotein 431:442 arg1 the human leukocyte glycoprotein PSGL-1 the human leukocyte glycoprotein PSGL-1 Fterm glycoprotein To this end, the N-terminal section of the human leukocyte glycoprotein PSGL-1 (P-selectin glycoprotein ligand-1) was modified to contain a poly-histidine tag followed by a proteolytic cleavage site. 26420485 11 39 gly glycosylation 1477:1489 arg1 RDS RDS PUBTATOR RDS 19133 These data suggest that glycosylation of RDS is required for RDS function or stability in cones, a difference that may be due to extracellular versus intradiscal localization of the RDS glycan in cones versus rods. 15628971 6 51 gly attached 1280:1287 arg1 C4ST-1 AND N-linked oligosaccharides C4ST-1 N-linked oligosaccharides PUBTATOR C4ST-1 314694 These observations strongly suggest that N-linked oligosaccharides attached to C4ST-1 contribute to the production and stability of the active form of C4ST-1. 18815274 9 9 gly glycosylated 1250:1261 arg1 SV2A SV2A PUBTATOR SV2A 64051 Together, the data reported here demonstrate that glycosylated SV2A and SV2B act in conjunction with gangliosides to mediate the entry of BoNT/E into neurons. 25521995 5 27 gly glycopeptides 1008:1020 arg2 glycopeptides glycopeptides glycopeptides Furthermore, PCGOL combined with our previously developed TOSIL method (tandem (18)O stable isotope labeling for N-glycoproteome quantitation) can be used for comprehensive N-glycosylation quantification, achieving simultaneous quantification of glycans, glycopeptides and glycoproteins in a single workflow, which was also used to analyze glycosylation changes in immunoglobulin G (IgG) associated with hepatocellular carcinoma in the present work. 25521995 5 36 gly glycoproteins 1026:1038 arg1 glycoproteins glycoproteins Fterm glycoproteins Furthermore, PCGOL combined with our previously developed TOSIL method (tandem (18)O stable isotope labeling for N-glycoproteome quantitation) can be used for comprehensive N-glycosylation quantification, achieving simultaneous quantification of glycans, glycopeptides and glycoproteins in a single workflow, which was also used to analyze glycosylation changes in immunoglobulin G (IgG) associated with hepatocellular carcinoma in the present work. 8639654 11 107 gly N-glycosylation 2147:2161 arg1 the human VIP 1 receptor the human VIP 1 receptor PUBTATOR VIP 1 receptor 7432 These studies highlight the functional importance of the N-glycosylation of the human VIP 1 receptor which belongs to a new subfamily of seven membrane-spanning receptors. 26701645 5 64 gly N-glycosylation 780:794 arg2 an N-glycosylation site an N-glycosylation site site Using human CD8+ T-cell clones specific for the tyrosinase epitope YMDGTMSQV (369-377), including an N-glycosylation site, we found that transfectants of single and triple N-glycosylation mutants are recognized by specific T cells. 24780636 5 23 gly disialylated 732:743 arg1 disialylated biantennary glycans disialylated biantennary glycans Mass spectrometric analyses confirmed that Tf-2 is modified with disialylated biantennary glycans at both of the two N-glycosylation sites, which are similar to the N-glycans of sTf. 24780636 5 41 gly N-glycosylation 784:798 arg2 the two N-glycosylation sites the two N-glycosylation sites sites Mass spectrometric analyses confirmed that Tf-2 is modified with disialylated biantennary glycans at both of the two N-glycosylation sites, which are similar to the N-glycans of sTf. 24780636 5 84 gly sTf 845:847 arg1 the N-glycans sTf the N-glycans Cterm sTf 7018 Mass spectrometric analyses confirmed that Tf-2 is modified with disialylated biantennary glycans at both of the two N-glycosylation sites, which are similar to the N-glycans of sTf. 1988041 11 53 part_of BAL 1512:1514 arg1 The amino acid sequence BAL The amino acid sequence PUBTATOR Site BAL P19835 sequence The amino acid sequence of human BAL is related to that of pancreatic lysophospholipase, cholesterol esterase, cholinesterase, acetylcholinesterase, and thyroglobulin. 9557657 2 136 gly O-glycosylated 605:618 arg1 mucin-like O-glycosylated proteins mucin-like O-glycosylated proteins Fterm proteins The extracellular domain of havcr-1 has an N-terminal Cys-rich region that displays homology with sequences of members of the immunoglobulin superfamily, followed by a Thr/Ser/Pro (TSP)-rich region characteristic of mucin-like O-glycosylated proteins. 25707740 18 23 gly glycoforms 2053:2062 arg1 hCG hCG OGER hCG Depending on its source of production, glycoforms of hCG display different biological activities and functions that are essential for pregnancy outcome. 29069609 2 8 gly glycopeptides 302:314 arg2 glycopeptides glycopeptides glycopeptides Identification of glycopeptides from data-dependent acquisition (DDA) relies on high quality MS/MS spectra of glycopeptide precursors and often requires manual validation to ensure confident assignments. 29069609 2 87 gly glycopeptide 394:405 arg2 glycopeptide glycopeptide glycopeptide Identification of glycopeptides from data-dependent acquisition (DDA) relies on high quality MS/MS spectra of glycopeptide precursors and often requires manual validation to ensure confident assignments. 31685900 2 19 gly glycosite 314:322 arg2 glycosite glycosite glycosite Since experimental characterization of glycosites is challenging, glycosite prediction is crucial. 31685900 2 37 gly glycosites 287:296 arg2 glycosites glycosites glycosites Since experimental characterization of glycosites is challenging, glycosite prediction is crucial. 12504572 5 18 gly glycosylation 955:967 arg2 this glycosylation site this glycosylation site site This suggests that loss of this glycosylation site may make the V3 loop more susceptible to immune surveillance. 1649612 3 58 gly N-glycosylation 308:322 arg2 one potential N-glycosylation site one potential N-glycosylation site site According to cDNA cloning studies, it has a molecular weight of 33,300 Dalton, one potential N-glycosylation site at the vesicle inside, four major hydrophobic domains as well as a C-terminus containing approximately 90 amino acids. 10413465 6 23 part_of apoE4 1298:1302 arg1 position 158 apoE4 position 158 PUBTATOR SpecificSite apoE4 348 cysteine at position 158 In contrast, introduction of cysteine at position 158 of apoE4 (Arg112, Cys158) increased the SDS-stable binding of apoE to Abeta to the levels similar to those observed in apoE2. 11595658 0 38 gly N-glycosylation 0:14 arg1 CRF receptor type 1 CRF receptor type 1 PUBTATOR CRF receptor type 1 1394 N-glycosylation of CRF receptor type 1 is important for its ligand-specific interaction. 12773316 9 48 gly glycosylation 1411:1423 arg2 the seven glycosylation sites the seven glycosylation sites sites Therefore, six of the seven glycosylation sites in the beta-subunit are essential for the plasma membrane delivery of the beta-subunit of the gastric H,K-ATPase, whereas the second glycosylation site (Asn103), which is not conserved among the beta-subunits from different species, is not critical for plasma delivery of the protein. 12773316 9 69 gly glycosylation 1564:1576 arg2 Asn103 Asn103 Asn103 Therefore, six of the seven glycosylation sites in the beta-subunit are essential for the plasma membrane delivery of the beta-subunit of the gastric H,K-ATPase, whereas the second glycosylation site (Asn103), which is not conserved among the beta-subunits from different species, is not critical for plasma delivery of the protein. 12773316 9 69 gly glycosylation 1564:1576 arg2 the second glycosylation site the second glycosylation site site Therefore, six of the seven glycosylation sites in the beta-subunit are essential for the plasma membrane delivery of the beta-subunit of the gastric H,K-ATPase, whereas the second glycosylation site (Asn103), which is not conserved among the beta-subunits from different species, is not critical for plasma delivery of the protein. 2846759 9 11 gly glycoprotein 2269:2280 arg1 this glycoprotein family this glycoprotein family Fterm glycoprotein Together with the observation that gH of these viruses are major targets for virus neutralization by antibody, this suggests that this glycoprotein family is essential among all herpesviruses and represents a major component involved in herpesvirus infectivity. 21153276 9 1 gly glycosylation 1669:1681 arg2 an extra glycosylation site an extra glycosylation site site These results demonstrate that addition of an extra glycosylation site enhances expression of the human GnRHR, a strategy that may be applicable to other cell-surface receptors. 15968392 6 5 gly glycosylation 1034:1046 arg1 Asn473 Asn473 Asn473 Substitution of Thr475 by Ala, Pro, Lys or Arg (all of which abolish the glycosylation consensus sequence) also severely reduced the level of secreted FXI:Ag suggesting that glycosylation at Asn473 is required for folding or secretion. 1402806 6 40 gly O-glycosylation 1114:1128 arg2 six potential O-glycosylation sites six potential O-glycosylation sites sites The amino acid sequence of the M protein of HCV-OC43 has 94% identity with that of the Mebus strain of BCV, and also contains six potential O-glycosylation sites in the exposed N-terminal domain. 26482295 7 60 gly glycosylate 1332:1342 arg1 the Fc domain human immunoglobulin G domain Cterm human immunoglobulin G domain One notable example is D. gigas PglB, which was the only bacterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon. 8419363 4 21 gly glycoproteins 871:883 arg1 the recombinant glycoproteins the recombinant glycoproteins Fterm glycoproteins Expression of the mutant cDNAs in Chinese hamster ovary cells showed that all consensus sites may be utilized during the CBG biosynthesis and that the immunochemical properties of the recombinant glycoproteins are similar to those of CBG isolated from human serum. 8419363 4 63 gly utilized 776:783 arg2 all consensus sites all consensus sites sites Expression of the mutant cDNAs in Chinese hamster ovary cells showed that all consensus sites may be utilized during the CBG biosynthesis and that the immunochemical properties of the recombinant glycoproteins are similar to those of CBG isolated from human serum. 8366859 3 6 part_of glycoprotein 394:405 arg1 one N-linked glycosylation site glycoprotein one N-linked glycosylation site Fterm Site glycoprotein site The antigen is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids and one N-linked glycosylation site at Asn3. 8366859 3 6 part_of glycoprotein 394:405 arg1 a mature peptide glycoprotein a mature peptide Fterm Site glycoprotein peptide The antigen is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids and one N-linked glycosylation site at Asn3. 25281832 8 13 gly glycosylation 1139:1151 arg2 the glycosylation sites the glycosylation sites sites All these seven strains maintained most of the glycosylation sites except subtype H1a, which lost one glycosylation site. 25281832 8 72 gly glycosylation 1194:1206 arg2 one glycosylation site one glycosylation site site All these seven strains maintained most of the glycosylation sites except subtype H1a, which lost one glycosylation site. 29069609 5 4 gly N-glycosylation 922:936 arg2 all three N-glycosylation sites all three N-glycosylation sites sites The advantage of MRM-HR over DDA for N-glycopeptide detection was demonstrated from targeted analysis of bovine fetuin where all three N-glycosylation sites were detected, which was not the case with DDA. 29069609 5 75 gly N-glycopeptide 824:837 arg2 N-glycopeptide detection N-glycopeptide detection N-glycopeptide The advantage of MRM-HR over DDA for N-glycopeptide detection was demonstrated from targeted analysis of bovine fetuin where all three N-glycosylation sites were detected, which was not the case with DDA. 31004621 0 58 gly N-glycosylation 32:46 arg2 N-glycosylation sites N-glycosylation sites sites Characterization of the role of N-glycosylation sites in the respiratory syncytial virus fusion protein in virus replication, syncytium formation and antigenicity. 9027352 20 29 part_of found 2092:2096 arg1 CG beta AND residues CG beta residues PUBTATOR Site CG beta 1082 residues The LH variant consists of two amino acid substitutions (W8R; I15T) that correspond to residues normally found in CG beta. 10970800 6 23 gly N-glycosylation 658:672 arg2 Both potential N-glycosylation sites Both potential N-glycosylation sites sites Both potential N-glycosylation sites were used. 10970800 6 53 gly used 685:688 arg2 Both potential N-glycosylation sites Both potential N-glycosylation sites sites Both potential N-glycosylation sites were used. 21674342 0 36 gly glycopeptide 35:46 arg2 a glycopeptide a glycopeptide glycopeptide On-resin convergent synthesis of a glycopeptide from HIV gp120 containing a high mannose type N-linked oligosaccharide. 21752569 2 9 gly attached 384:391 arg2 Human IgA1 AND The glycans Human IgA1 The glycans PUBTATOR Human IgA1 P01876 The glycans attached to Human IgA1 were removed from their attachment sites by an array of enzymes. 21752569 2 42 gly removed 412:418 arg2 their attachment sites AND The glycans their attachment sites The glycans sites The glycans attached to Human IgA1 were removed from their attachment sites by an array of enzymes. 2503511 15 97 gly carried 2374:2380 arg1 Asn-184 AND diantennary, 2,4-branched triantennary, 2,6-branched triantennary, and tetraantennary N- acetyllactosamine oligosaccharides Asn-184 diantennary, 2,4-branched triantennary, 2,6-branched triantennary, and tetraantennary N- acetyllactosamine oligosaccharides Asn-184 When glycosylated, Asn-184 carried diantennary, 2,4-branched triantennary, 2,6-branched triantennary, and tetraantennary N- acetyllactosamine oligosaccharides in the ratio 9.0:4.5:1.4:1. 12638188 6 7 gly glycoprotein 624:635 arg1 closely related glycoprotein products closely related glycoprotein products Fterm glycoprotein Models of closely related glycoprotein products used in this study are rhEPOs produced from three different sources. 2226797 1 7 gly N-glycosylation 242:256 arg2 a single N-glycosylation site a single N-glycosylation site site The carbohydrate structures of a genetically engineered human tissue plasminogen activator variant bearing a single N-glycosylation site at Asn 448 are reported. 2226797 1 24 gly variant 217:223 arg1 The carbohydrate structures tissue plasminogen activator variant The carbohydrate structures PUBTATOR tissue plasminogen activator variant P00750 The carbohydrate structures of a genetically engineered human tissue plasminogen activator variant bearing a single N-glycosylation site at Asn 448 are reported. 9689919 7 79 part_of 45,000-Mr 1131:1139 arg1 a precursor polypeptide of 45 a precursor polypeptide OGER Site of 45 Q9NQ76 polypeptide Cell-free expression of the bovine PEDF cDNA by in vitro transcription and translation yields a precursor polypeptide of 45,000-Mr that immunoprecipitates with an antibody to human PEDF. 7532677 10 123 gly glycosylation 1801:1813 arg2 The glycosylation site The glycosylation site site The glycosylation site of the Bw4-positive molecule B*5801 was mutated, and the mutant molecules tested for inhibition of NKB1+ NK cells. 18941134 2 3 gly epitopes 620:627 arg1 complex type N-glycans complex type N-glycans Using a concerted proteomics and glycomics approach with advanced mass spectrometry-based glycan sequencing capability, we show in this work that 24p3, an abundant mouse uterine luminal fluid (ULF) glycoprotein also called lipocalin 2 (Lcn2), is highly fucosylated in the context of carrying multiple Lewis X and Y epitopes on complex type N-glycans at its single glycosylation site. 18941134 2 25 gly glycoprotein 503:514 arg1 an abundant mouse uterine luminal fluid (ULF) glycoprotein an abundant mouse uterine luminal fluid (ULF) glycoprotein Fterm glycoprotein Using a concerted proteomics and glycomics approach with advanced mass spectrometry-based glycan sequencing capability, we show in this work that 24p3, an abundant mouse uterine luminal fluid (ULF) glycoprotein also called lipocalin 2 (Lcn2), is highly fucosylated in the context of carrying multiple Lewis X and Y epitopes on complex type N-glycans at its single glycosylation site. 18941134 2 71 gly fucosylated 558:568 arg1 an abundant mouse uterine luminal fluid (ULF) glycoprotein an abundant mouse uterine luminal fluid (ULF) glycoprotein Fterm glycoprotein Using a concerted proteomics and glycomics approach with advanced mass spectrometry-based glycan sequencing capability, we show in this work that 24p3, an abundant mouse uterine luminal fluid (ULF) glycoprotein also called lipocalin 2 (Lcn2), is highly fucosylated in the context of carrying multiple Lewis X and Y epitopes on complex type N-glycans at its single glycosylation site. 18941134 2 104 gly glycosylation 669:681 arg2 its single glycosylation site its single glycosylation site site Using a concerted proteomics and glycomics approach with advanced mass spectrometry-based glycan sequencing capability, we show in this work that 24p3, an abundant mouse uterine luminal fluid (ULF) glycoprotein also called lipocalin 2 (Lcn2), is highly fucosylated in the context of carrying multiple Lewis X and Y epitopes on complex type N-glycans at its single glycosylation site. 12527108 0 44 gly N-glycosylation 0:14 arg1 recombinant human fucosyltransferase III recombinant human fucosyltransferase III PUBTATOR fucosyltransferase III 2525 N-glycosylation of recombinant human fucosyltransferase III is required for its in vivo folding in mammalian and insect cells. 11822873 1 23 gly O-glycosylation 202:216 arg2 the O-glycosylation sites the O-glycosylation sites sites We have analyzed the respective roles of the stalk and/or the O-glycosylation sites in apical sorting by producing partially deleted mutants in this region of the human receptor for neurotrophins (P75(NTR)). 22642577 4 25 gly glycosylation 753:765 arg2 one such conserved glycosylation site one such conserved glycosylation site site In the present study, it was demonstrated that one such conserved glycosylation site at Asn(91) in H1N1 HA critically governs the glycan receptor-binding specificity and hence would potentially impinge on the host adaptation of the virus. 22642577 4 25 gly glycosylation 753:765 arg2 91 Asn(91) Asn(91) In the present study, it was demonstrated that one such conserved glycosylation site at Asn(91) in H1N1 HA critically governs the glycan receptor-binding specificity and hence would potentially impinge on the host adaptation of the virus. 20188224 8 28 gly deglycosylated 1157:1170 arg1 deglycosylated protein deglycosylated protein Fterm protein In-gel tryptic digestion was further applied to the gel pieces containing deglycosylated protein, for N-glycosylation site determination. 2538306 7 41 gly O-glycosylation 1739:1753 arg2 the O-glycosylation site the O-glycosylation site site This was shown by determining the ratio of the unglycosylated and glycosylated forms of the tryptic peptide from free alpha that contains the O-glycosylation site (residues 36-42). 2538306 7 41 gly O-glycosylation 1739:1753 arg2 residues 36-42 residues 36-42 residues 36-42 This was shown by determining the ratio of the unglycosylated and glycosylated forms of the tryptic peptide from free alpha that contains the O-glycosylation site (residues 36-42). 2538306 7 106 gly residues 1761:1768 arg1 36-42 36-42 residues 36-42 This was shown by determining the ratio of the unglycosylated and glycosylated forms of the tryptic peptide from free alpha that contains the O-glycosylation site (residues 36-42). 2538306 7 131 gly glycosylated 1663:1674 arg1 the tryptic peptide the tryptic peptide peptide This was shown by determining the ratio of the unglycosylated and glycosylated forms of the tryptic peptide from free alpha that contains the O-glycosylation site (residues 36-42). 2538306 7 138 gly unglycosylated 1644:1657 arg1 the tryptic peptide the tryptic peptide peptide This was shown by determining the ratio of the unglycosylated and glycosylated forms of the tryptic peptide from free alpha that contains the O-glycosylation site (residues 36-42). 14658030 8 35 gly glycosylated 1712:1723 arg1 all six consensus sequences all six consensus sequences sequences By using these procedures all six consensus sequences were shown to be glycosylated; the observation of an unmodified peptide with the consensus sequence N-1 indicates only partial glycosylation at this site. 14658030 8 54 gly glycosylation 1822:1834 arg1 this site this site site By using these procedures all six consensus sequences were shown to be glycosylated; the observation of an unmodified peptide with the consensus sequence N-1 indicates only partial glycosylation at this site. 17097711 0 23 gly glycoproteins 70:82 arg1 HIV-1 consensus subtype B envelope glycoproteins HIV-1 consensus subtype B envelope glycoproteins Fterm glycoproteins Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. 25567004 3 33 gly hyper-glycosylated 752:769 arg1 BSG BSG PUBTATOR BSG 12215 Recombinant low-glycosylated secreted BHc products (BSK) were also immunologically inert, similar to hyper-glycosylated BHc products (BSG), although deglycosylation restored their immunological activities. 25567004 3 50 gly low-glycosylated 663:678 arg1 BSK BSK PUBTATOR BSK 450219 Recombinant low-glycosylated secreted BHc products (BSK) were also immunologically inert, similar to hyper-glycosylated BHc products (BSG), although deglycosylation restored their immunological activities. 31671706 6 58 gly glycosylation 1268:1280 arg2 the five glycosylation sites protein sites Fterm protein sites Based on the mapping results, the unique features in glycan microheterogeneity for the five glycosylation sites of VEGFR-IgG fusion protein were compared site-specifically and further discussed to understand the functional meaning of each glycosylation pattern. 22642577 3 44 gly glycosylation 605:617 arg2 specific glycosylation sites specific glycosylation sites sites Although addition of glycosylation sites on HA are a part of viral evolution to evade the host immune responses, there are specific glycosylation sites that are conserved during most of the evolution of the virus. 22642577 3 50 gly glycosylation 494:506 arg2 glycosylation sites glycosylation sites sites Although addition of glycosylation sites on HA are a part of viral evolution to evade the host immune responses, there are specific glycosylation sites that are conserved during most of the evolution of the virus. 9600940 1 73 part_of mZP3 296:299 arg1 the sperm combining site mZP3 the sperm combining site PUBTATOR Site mZP3 22788 site To initiate fertilization, mouse sperm bind to Ser- (O-) linked oligosaccharides located at the sperm combining site of zona pellucida glycoprotein mZP3. 11258925 9 63 gly glycosylated 1451:1462 arg1 the Asn 396 site the Asn 396 site Asn 396 site It was not possible to conclusively determine whether the Asn 396 site was glycosylated via an MS/MS experiment, so the tryptic digest was deglycosylated to confirm the presence of the glycopeptides. 11258925 9 79 gly glycopeptides 1561:1573 arg2 the glycopeptides the glycopeptides glycopeptides It was not possible to conclusively determine whether the Asn 396 site was glycosylated via an MS/MS experiment, so the tryptic digest was deglycosylated to confirm the presence of the glycopeptides. 20348522 3 43 gly non-glycosylated 572:587 arg1 either glycosylated or non-glycosylated variants either glycosylated or non-glycosylated variants Fterm variants To determine how E protein glycosylation affects the interactions between WN virus and avian hosts, we inoculated young chicks with NY strains of WN virus containing either glycosylated or non-glycosylated variants of the E protein. 20348522 3 72 gly glycosylated 556:567 arg1 either glycosylated or non-glycosylated variants either glycosylated or non-glycosylated variants Fterm variants To determine how E protein glycosylation affects the interactions between WN virus and avian hosts, we inoculated young chicks with NY strains of WN virus containing either glycosylated or non-glycosylated variants of the E protein. 10419520 1 11 part_of proteins 261:268 arg1 the NH(2)-terminal domains proteins the NH(2)-terminal domains Fterm Site proteins domains In sterol-depleted mammalian cells, a two-step proteolytic process releases the NH(2)-terminal domains of sterol regulatory element-binding proteins (SREBPs) from membranes of the endoplasmic reticulum (ER). 12706347 0 44 gly glycosylation 28:40 arg2 Asparagine 81 Asparagine 81 Asparagine 81 Asparagine 81, an invariant glycosylation site near apyrase conserved region 1, is essential for full enzymatic activity of ecto-nucleoside triphosphate diphosphohydrolase 3. 12706347 0 44 gly glycosylation 28:40 arg2 an invariant glycosylation site an invariant glycosylation site site Asparagine 81, an invariant glycosylation site near apyrase conserved region 1, is essential for full enzymatic activity of ecto-nucleoside triphosphate diphosphohydrolase 3. 8706658 6 29 gly N-glycosylation 1146:1160 arg2 The potential N-glycosylation site The potential N-glycosylation site site The potential N-glycosylation site, two protein kinase C phosphorylation sites, the two cysteine residues, and the putative inhibitor-binding domain (substitutions Thr4l-->Ser and Tyr50-->Phe) were conserved in mouse leukotriene C4 synthase. 8706658 6 49 gly substitutions 1282:1294 arg1 Tyr50-->Phe Tyr50-->Phe Phe The potential N-glycosylation site, two protein kinase C phosphorylation sites, the two cysteine residues, and the putative inhibitor-binding domain (substitutions Thr4l-->Ser and Tyr50-->Phe) were conserved in mouse leukotriene C4 synthase. 8706658 6 49 gly substitutions 1282:1294 arg1 Thr4l-->Ser Thr4l-->Ser Ser and Tyr50 The potential N-glycosylation site, two protein kinase C phosphorylation sites, the two cysteine residues, and the putative inhibitor-binding domain (substitutions Thr4l-->Ser and Tyr50-->Phe) were conserved in mouse leukotriene C4 synthase. 21071054 1 67 part_of envelope 229:236 arg1 envelope sequences envelope envelope sequences PUBTATOR Site envelope 155971 sequences To examine mutational pathways that lead to CXCR4 use of HIV-1, we analyzed the genotypic and phenotypic characteristics of envelope sequences from a large panel of patient virus populations and individual clones containing different V3 mutations. 1457969 1 76 gly asparagine-linked 100:116 arg1 The asparagine-linked carbohydrate structures asparagine The asparagine-linked carbohydrate structures asparagine The asparagine-linked carbohydrate structures at each of the three glycosylation sites of human thyrotrophin were investigated by 400 MHz 1H-NMR spectroscopy. 1457969 1 9 gly glycosylation 163:175 arg1 human thyrotrophin thyrotrophin sites Fterm thyrotrophin sites The asparagine-linked carbohydrate structures at each of the three glycosylation sites of human thyrotrophin were investigated by 400 MHz 1H-NMR spectroscopy. 25300029 3 44 gly observed 678:685 arg1 α3 integrin AND Higher molecular weight glycan structures integrin sites Higher molecular weight glycan structures Fterm integrin sites Higher molecular weight glycan structures with a different monosaccharide composition were observed at two sites, namely, Asn-925 and Asn-928 sites in α3 integrin isolated from Pkd1(+/+) cells compared with Pkd1(-/-) cells. 25300029 3 44 gly observed 678:685 arg1 α3 integrin AND Higher molecular weight glycan structures integrin Asn-925 and Asn-928 sites Higher molecular weight glycan structures Fterm integrin Asn-925 and Asn-928 sites Higher molecular weight glycan structures with a different monosaccharide composition were observed at two sites, namely, Asn-925 and Asn-928 sites in α3 integrin isolated from Pkd1(+/+) cells compared with Pkd1(-/-) cells. 18723043 4 16 part_of contains 773:780 arg1 This enzyme AND an N-linked glycosylation site This enzyme an N-linked glycosylation site Fterm Site enzyme site This enzyme contains glucosamine and an N-linked glycosylation site. 31577193 3 45 part_of sequons 334:340 arg1 proteins proteins sequons Fterm proteins However, not all N-X-[S/T] sequons in proteins are glycosylated. 16981714 2 85 gly N-glycosylation 403:417 arg2 a single N-glycosylation site a single N-glycosylation site site The PTX3 C-terminal domain is required for C1q recognition and complement activation and contains a single N-glycosylation site on Asn 220. 27480168 3 8 gly glycosylation 609:621 arg2 potential glycosylation sites potential glycosylation sites sites Site-directed mutagenesis of wild-type (wt) hENT1 removed potential glycosylation sites. 21674342 1 49 gly glycopeptides 216:228 arg2 N-linked glycopeptides N-linked glycopeptides glycopeptides This chapter describes a rapid and efficient approach for the solid-phase synthesis of N-linked glycopeptides that utilizes on-resin glycosylamine coupling to produce N-linked glycosylation sites. 21674342 1 54 gly glycosylation 296:308 arg2 N-linked glycosylation sites N-linked glycosylation sites sites This chapter describes a rapid and efficient approach for the solid-phase synthesis of N-linked glycopeptides that utilizes on-resin glycosylamine coupling to produce N-linked glycosylation sites. 8388021 8 26 gly glycoprotein 1280:1291 arg1 the envelope glycoprotein the envelope glycoprotein PUBTATOR envelope glycoprotein 17276 The results demonstrate the importance of critical sites within the envelope glycoprotein as determinants of virus virulence. 6980014 4 0 gly site 556:559 arg1 The oligosaccharide structure site The oligosaccharide structure site The oligosaccharide structure at each glycosylation site on each purified CNBr fragment was determined by compositional analysis, behavior on Con A affinity chromatography, and methylation analysis. 6980014 4 11 gly structure 524:532 arg1 each purified CNBr fragment each purified CNBr fragment each purified CNBr fragment Site fragment The oligosaccharide structure at each glycosylation site on each purified CNBr fragment was determined by compositional analysis, behavior on Con A affinity chromatography, and methylation analysis. 6980014 4 14 gly glycosylation 542:554 arg2 each glycosylation site each glycosylation site site The oligosaccharide structure at each glycosylation site on each purified CNBr fragment was determined by compositional analysis, behavior on Con A affinity chromatography, and methylation analysis. 27127844 9 67 gly glycosylated 1245:1256 arg1 the a4 subunit the a4 subunit Fterm subunit This relative mobility was identical to that of unglycosylated mutant a4N489D , demonstrating that the a4 subunit is glycosylated. 8388021 5 48 gly glycoprotein 718:729 arg1 the envelope glycoprotein gene the envelope glycoprotein gene PUBTATOR envelope glycoprotein 17276 The nucleotide sequence of the envelope glycoprotein gene of each of the seven mutants was determined and the deduced amino acid sequence was compared with parent virus. 25504159 6 5 gly glycosylation 860:872 arg2 the glycosylation site the glycosylation site site The mutant lacking the glycosylation site at position 158 showed unaltered growth kinetics in vitro and a comparable level of sensitivity to a major antiviral protein found in respiratory secretions, surfactant protein D (SP-D). 17963278 3 84 gly glycoproteins 484:496 arg1 The recovered glycoproteins The recovered glycoproteins Fterm glycoproteins The recovered glycoproteins were subjected to treatment with peptide-N-glycosidase F (PNGase F) and in-gel digestion by trypsin. 21978153 9 5 gly glycosylation 1688:1700 arg2 glycosylation site mutation glycosylation site mutation site Thus, in the future, vaccination with glycosylated 2009 H1N1 virus may prevent the seasonal epidemic caused by strains with glycosylation site mutation near the receptor binding domain (RBD). 7711052 7 57 gly Asn-184 1590:1596 arg1 an N-linked glycan Asn-184 an N-linked glycan Asn-184 The presence of an N-linked glycan (at Asn-184) in the kringle 2 domain of tissue plasminogen activator hinders the rearrangement of this ternary complex, decreasing the turnover rate (Kcat). 7711052 7 51 gly presence 1555:1562 arg2 tissue plasminogen activator AND an N-linked glycan tissue plasminogen activator domain an N-linked glycan OGER tissue plasminogen activator P00750 domain The presence of an N-linked glycan (at Asn-184) in the kringle 2 domain of tissue plasminogen activator hinders the rearrangement of this ternary complex, decreasing the turnover rate (Kcat). 31325506 7 71 gly N-glycosylation 1461:1475 arg2 The N-glycosylation sites The N-glycosylation sites sites The N-glycosylation sites were identified from the analysis of glycopeptides from BSM. 31325506 7 38 gly glycopeptides 1520:1532 arg2 glycopeptides BSM glycopeptides Cterm BSM 281333 glycopeptides The N-glycosylation sites were identified from the analysis of glycopeptides from BSM. 6980014 6 52 gly contain 902:908 arg1 II AND one carbohydrate chain II fragments one carbohydrate chain Cterm Site II fragments On the other hand, fragments II and III each contain one carbohydrate chain exclusively by the biantennary type of complex N-glycoside. 31113887 9 1 gly glycoprotein 1606:1617 arg1 Env Env PUBTATOR Env 105221759 Differentially glycosylated CD4 receptors were biochemically purified and used in neutralization assays and microscale thermophoresis to show that the glycans on chimpanzee CD4 reduce binding affinity with the lentiviral surface glycoprotein, Env. 31113887 9 1 gly glycoprotein 1606:1617 arg1 the lentiviral surface glycoprotein the lentiviral surface glycoprotein Fterm glycoprotein Differentially glycosylated CD4 receptors were biochemically purified and used in neutralization assays and microscale thermophoresis to show that the glycans on chimpanzee CD4 reduce binding affinity with the lentiviral surface glycoprotein, Env. 31113887 9 24 gly glycosylated 1392:1403 arg1 Differentially glycosylated CD4 receptors Differentially glycosylated CD4 receptors PUBTATOR CD4 receptors 450124 Differentially glycosylated CD4 receptors were biochemically purified and used in neutralization assays and microscale thermophoresis to show that the glycans on chimpanzee CD4 reduce binding affinity with the lentiviral surface glycoprotein, Env. 31113887 9 31 gly glycans 1528:1534 arg1 chimpanzee CD4 CD4 glycans PUBTATOR CD4 450124 Differentially glycosylated CD4 receptors were biochemically purified and used in neutralization assays and microscale thermophoresis to show that the glycans on chimpanzee CD4 reduce binding affinity with the lentiviral surface glycoprotein, Env. 16289048 6 22 gly glycosylation 814:826 arg2 N-linked glycosylation site N-linked glycosylation site site Comparison of cat myocilin to human myocilin shows a 87% similarity, including conservation of the N-terminal leucine zipper, N-linked glycosylation site, C-terminal olfactomedin domain, and all five cysteine residues thought to be involved in disulfide bond formation. 8877373 2 12 part_of has 359:361 arg1 The enzyme AND one glycosylation site The enzyme one glycosylation site Fterm Site enzyme site The enzyme is composed of two non-identical alpha/beta subunits joined by strong non-covalent forces and has one glycosylation site located in the alpha subunit. 15253437 0 27 gly glycosylation 97:109 arg2 their glycosylation sites their glycosylation sites sites A new strategy for identification of N-glycosylated proteins and unambiguous assignment of their glycosylation sites using HILIC enrichment and partial deglycosylation. 15253437 0 65 gly N-glycosylated 37:50 arg1 N-glycosylated proteins N-glycosylated proteins Fterm proteins A new strategy for identification of N-glycosylated proteins and unambiguous assignment of their glycosylation sites using HILIC enrichment and partial deglycosylation. 21106559 0 43 gly disialylated 9:20 arg1 Terminal disialylated multiantennary complex-type N-glycans Terminal disialylated multiantennary complex-type N-glycans Terminal disialylated multiantennary complex-type N-glycans carried on acutobin define the glycosylation characteristics of the Deinagkistrodon acutus venom. 21345964 0 63 gly glycoprotein 38:49 arg1 varicella-zoster virus glycoprotein I varicella-zoster virus glycoprotein I Fterm glycoprotein I Mutagenesis of varicella-zoster virus glycoprotein I (gI) identifies a cysteine residue critical for gE/gI heterodimer formation, gI structure, and virulence in skin cells. 22009746 1 34 part_of receptor 234:241 arg1 the ligand-binding domain nicotinic acetylcholine receptor the ligand-binding domain PUBTATOR Site nicotinic acetylcholine receptor 1137 domain Determining the structure of the ligand-binding domain of the nicotinic acetylcholine receptor (nAChR) has been a long standing goal in the design of selective drugs useful in implicated diseases for this prevalent receptor family. 20622017 0 46 gly glycosylation 26:38 arg1 renal and hepatic γ-glutamyl transpeptidase renal and hepatic γ-glutamyl transpeptidase PUBTATOR -glutamyl transpeptidase 102724197 Analysis of site-specific glycosylation of renal and hepatic γ-glutamyl transpeptidase from normal human tissue. 8987398 1 8 part_of have 142:145 arg1 Major histocompatibility complex (MHC) class I heavy chain glycoproteins AND an invariant N-linked glycosylation site Major histocompatibility complex (MHC) class I heavy chain glycoproteins an invariant N-linked glycosylation site Fterm Site glycoproteins site Major histocompatibility complex (MHC) class I heavy chain glycoproteins have an invariant N-linked glycosylation site at Asn86, which is found between two extremely variable protein domains. 18524814 10 112 part_of motif 1971:1975 arg1 prM prM motif Cterm Site prM motif Overall, our findings indicate that this highly conserved N-glycosylation motif in prM is crucial for multiple stages of JEV biology: prM biogenesis, virus release, and pathogenesis. 24554659 0 49 part_of V2 107:108 arg1 the simian immunodeficiency virus envelope glycoprotein V2 region envelope glycoprotein V2 the simian immunodeficiency virus envelope glycoprotein V2 region PUBTATOR Site envelope glycoprotein V2 1490007 region Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission. 24554659 0 106 part_of glycoprotein 94:105 arg1 the simian immunodeficiency virus envelope glycoprotein V2 region envelope glycoprotein V2 the simian immunodeficiency virus envelope glycoprotein V2 region PUBTATOR Site envelope glycoprotein V2 1490007 region Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission. 27095603 6 43 gly glycopeptides 1108:1120 arg1 native transferrin transferrin glycopeptides PUBTATOR transferrin 7018 glycopeptides In this technical note, the aberrant glycosylation profiles of CDG cases are presented to shed light on the MS of native transferrin and glycopeptides from the viewpoint of clinical glycoproteomics. 15694591 3 13 part_of chitinase 335:343 arg1 the chitinase family 18 active site chitinase the chitinase family 18 active site Fterm Site chitinase site AvChit1 possesses the chitinase family 18 active site signature and one N-glycosylation site. 26599345 3 1 gly glycoprotein 287:298 arg1 a glycoprotein product a glycoprotein product Fterm glycoprotein Therefore, glycan variants of a glycoprotein product must be adequately analyzed and controlled to ensure product quality. 2451667 8 59 gly glycosylation 1274:1286 arg2 the second glycosylation site the second glycosylation site site Also, mutations eliminating the second glycosylation site (at amino acid 78) in both the anchored or secreted forms apparently led to partial denaturation or a conformational change interfering with transport of the protein. 1318404 1 20 gly glycoprotein 184:195 arg1 the major envelope glycoprotein the major envelope glycoprotein Fterm glycoprotein The role of the N-linked glycosylation sites in the major envelope glycoprotein, SU (gp70), of Moloney murine leukemia virus has been examined. 1318404 1 20 gly glycoprotein 184:195 arg1 SU (gp70) SU (gp70) Cterm SU The role of the N-linked glycosylation sites in the major envelope glycoprotein, SU (gp70), of Moloney murine leukemia virus has been examined. 1318404 1 64 gly glycosylation 142:154 arg2 the N-linked glycosylation sites the N-linked glycosylation sites sites The role of the N-linked glycosylation sites in the major envelope glycoprotein, SU (gp70), of Moloney murine leukemia virus has been examined. 20805301 5 12 gly glycosylation 689:701 arg1 CYP2W1 CYP2W1 Asn177 PUBTATOR CYP2W1 54905 Asn177 Bioinformatic analysis identified Asn177 as the only possible glycosylation site of CYP2W1, which was supported by the inability of an N177A mutant to be glycosylated in HEK 293 cells. 20805301 5 12 gly glycosylation 689:701 arg2 the only possible glycosylation site CYP2W1 site PUBTATOR CYP2W1 54905 site Bioinformatic analysis identified Asn177 as the only possible glycosylation site of CYP2W1, which was supported by the inability of an N177A mutant to be glycosylated in HEK 293 cells. 22213703 2 30 gly glycoprotein 323:334 arg1 glycoprotein molecules glycoprotein molecules Fterm glycoprotein mAbs are glycoprotein molecules undergoing posttranslational modifications. 10471296 3 16 gly glycosylation 492:504 arg2 a single potential glycosylation site a single potential glycosylation site site However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells. 10471296 3 16 gly glycosylation 492:504 arg2 Asn-2181 Asn-2181 Asn-2181 However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells. 10471296 3 53 gly glycosylated 538:549 arg1 the factor V C2 domain the factor V C2 domain domain However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells. 22015141 4 26 part_of site 820:823 arg1 the PCV2 Cap protein protein site Fterm Site protein site These results indicate that deletion of the N-glycosylation site in the PCV2 Cap protein enhances specific immune responses and may have a role in Cap-based DNA vaccines with enhanced immunogenicity. 25673720 14 6 gly glycosylated 2165:2176 arg1 C C Cterm C Q9NP58 We infected mice that express different forms of glycosylated PrP(C) with three different TSE agents. 25673720 14 6 gly glycosylated 2165:2176 arg1 glycosylated PrP glycosylated PrP OGER PrP Q9NP58 We infected mice that express different forms of glycosylated PrP(C) with three different TSE agents. 31831916 1 7 gly glycoprotein 95:106 arg1 N-linked glycoprotein N-linked glycoprotein Fterm glycoprotein N-linked glycoprotein is a highly interesting class of proteins for clinical and biological research. 18404209 3 48 gly glycoprotein 647:658 arg1 the hemagglutinin (HA) glycoprotein the hemagglutinin (HA) glycoprotein Fterm glycoprotein 4758 We generated and tested 31 recombinants of A/Vietnam/1203/04 (H5N1) influenza virus carrying single, double, or triple mutations located within or near the receptor binding site in the hemagglutinin (HA) glycoprotein that alter H5 HA binding affinity or specificity. 9578495 5 11 gly choriogonadotropin 693:710 arg1 the alpha52 oligosaccharide choriogonadotropin the alpha52 oligosaccharide OGER choriogonadotropin Therefore, we conclude that the alpha52 oligosaccharide of choriogonadotropin is not involved in signal transduction, but in the stability of the heterodimer. 28708860 5 16 gly N-glycosylation 798:812 arg2 HA N-glycosylation sites HA N-glycosylation sites sites RESULTS: It was found that both the number of HA N-glycosylation sites and the electric charge of HA increased gradually up to 2016. 15243097 3 19 part_of HA1 354:356 arg1 the HA1 region HA1 the HA1 region OGER Site HA1 region An amino acid substitution in the HA1 region caused them to acquire an N-linked glycosylation site. 12911333 9 3 gly N-glycosylation 1706:1720 arg2 an N-glycosylation site an N-glycosylation site site The S3-S4 linker, with 16 amino acids and no N-glycosylation site, was not glycosylated when an N-glycosylation site was added. 12911333 9 95 gly N-glycosylation 1655:1669 arg2 no N-glycosylation site no N-glycosylation site site The S3-S4 linker, with 16 amino acids and no N-glycosylation site, was not glycosylated when an N-glycosylation site was added. 27743357 4 1 gly glycopeptides 618:630 arg2 The tryptic glycopeptides The tryptic glycopeptides glycopeptides The tryptic glycopeptides are separated almost exclusively on their peptide backbone. 23829323 8 46 gly glycosylation 1769:1781 arg2 the four haptoglobin N-linked glycosylation sites the four haptoglobin N-linked glycosylation sites sites Our software, GlycoPeptideSearch (GPS), assigned glycopeptide identifications to 246 of the spectra at a false discovery rate of 5.58%, identifying 42 distinct haptoglobin peptide-glycan pairs at each of the four haptoglobin N-linked glycosylation sites. 23829323 8 56 gly glycopeptide 1584:1595 arg2 glycopeptide identifications glycopeptide identifications glycopeptide Our software, GlycoPeptideSearch (GPS), assigned glycopeptide identifications to 246 of the spectra at a false discovery rate of 5.58%, identifying 42 distinct haptoglobin peptide-glycan pairs at each of the four haptoglobin N-linked glycosylation sites. 14985108 4 7 gly glycosylated 555:566 arg2 N69 N69 N69 Approximately 10 mg of ONC protein was secreted per liter of culture media, of which about 80% was glycosylated at N69. 32197300 6 37 part_of site 1045:1048 arg1 gp41 gp41 site Cterm Site gp41 site Third, the N126K mutation did not interfere with the expression and processing of viral Env glycoproteins, but it disrupted the Asn126-based glycosylation site in gp41. 11738084 6 11 gly glycosylated 804:815 arg1 glycosylated albumin variants glycosylated albumin variants Fterm variants The structure is principally the same as that of glycans bound to two other types of glycosylated albumin variants. 22355413 2 1 gly glycosites 302:311 arg2 glycosites glycosites glycosites Our previous work had shown that not only the increase of glycosylation sites (glycosites) numbers, but also glycosite migration might be involved in the evolution of human seasonal influenza H1N1 viruses. 22355413 2 53 gly glycosylation 281:293 arg2 glycosylation sites glycosylation sites sites Our previous work had shown that not only the increase of glycosylation sites (glycosites) numbers, but also glycosite migration might be involved in the evolution of human seasonal influenza H1N1 viruses. 22355413 2 87 gly glycosite 332:340 arg2 glycosite migration glycosite migration glycosite Our previous work had shown that not only the increase of glycosylation sites (glycosites) numbers, but also glycosite migration might be involved in the evolution of human seasonal influenza H1N1 viruses. 28844738 3 9 gly glycosylation 530:542 arg2 the N-linked glycosylation site the N-linked glycosylation site site This domain also contains the N-linked glycosylation site conserved in other isotypes. 10867989 2 42 gly glycosylation 375:387 arg2 glycosylation site glycosylation site site One of glycosylation site (GS) located at the tip of HA spike near the receptor binding site is lost because of mutations in both variants: GS 158 (Asn158Asp substitution) in USSR/90-MS and GS131 (Asp131Asp substitution) in USSR/90-ML. 11230989 4 18 gly glycosylation 616:628 arg2 an extra glycosylation site an extra glycosylation site site Of the two point mutations, Trp(8)Arg and Ile(15)Thr, the first one is mainly responsible for the altered immunoreactivity and the latter one introduces an extra glycosylation site into Asn(13) of the mutated LHbeta peptide. 17823199 2 46 gly N-glycosylation 368:382 arg2 N-glycosylation sites N-glycosylation sites sites In CDG type-I, deficiency of lipid-linked oligosaccharide assembly leads to the underoccupancy of N-glycosylation sites on glycoproteins. 17823199 2 113 gly glycoproteins 393:405 arg1 glycoproteins glycoproteins Fterm glycoproteins In CDG type-I, deficiency of lipid-linked oligosaccharide assembly leads to the underoccupancy of N-glycosylation sites on glycoproteins. 30299079 8 22 gly glycosylation 1168:1180 arg2 the same glycosylation site the same glycosylation site site Monitoring the change in the proportion of core and antenna fucosylation at the same glycosylation site is also feasible. 28928219 5 1 part_of Skp1 1203:1206 arg1 the intrinsically flexible F-box-binding domain Skp1 the intrinsically flexible F-box-binding domain PUBTATOR Site Skp1 6500 domain Here, NMR and MS approaches were used to determine the glycan structure, and then a combination of NMR and molecular dynamics simulations were employed to characterize the impact of the glycan on the conformation and motions of the intrinsically flexible F-box-binding domain of Skp1. 27911897 6 47 gly glycosylation 1336:1348 arg2 a putative N-linked glycosylation site a putative N-linked glycosylation site site Furthermore, using next generation deep sequencing, we found in vivo restoration of a putative N-linked glycosylation site upon replication in macaques that is absent in numerous MR766 strains that are widely being used by the research community. 28414420 7 45 gly used 1280:1283 arg2 The identified glycopeptides The identified glycopeptides glycopeptides The identified glycopeptides can be used as potential templates for HIV vaccine design. 28414420 7 61 gly glycopeptides 1259:1271 arg2 The identified glycopeptides The identified glycopeptides glycopeptides The identified glycopeptides can be used as potential templates for HIV vaccine design. 26993603 5 33 gly Removal 712:718 arg2 N-glycans AND Asn144 Asn144 N-glycans Asn144 Removal of N-glycans at Asn144 enhanced the motility and invasiveness of hepatocellular carcinoma cells, possibly due to inhibition of cell adhesion related to the changes of cell membrane glycosylation. 12364335 7 9 gly glycosylation 1145:1157 arg2 a single glycosylation site a single glycosylation site site In our experiments, the former activity is represented by the O-glycosylation of apomucin, an acceptor that contains multiple glycosylation sites, and the latter is represented by synthetic peptides that contain a single glycosylation site. 12364335 7 10 gly glycosylation 1050:1062 arg2 multiple glycosylation sites multiple glycosylation sites sites In our experiments, the former activity is represented by the O-glycosylation of apomucin, an acceptor that contains multiple glycosylation sites, and the latter is represented by synthetic peptides that contain a single glycosylation site. 12364335 7 73 gly O-glycosylation 986:1000 arg1 apomucin apomucin Fterm apomucin In our experiments, the former activity is represented by the O-glycosylation of apomucin, an acceptor that contains multiple glycosylation sites, and the latter is represented by synthetic peptides that contain a single glycosylation site. 21774247 8 36 gly glycosylation 1188:1200 arg2 one glycosylation site protein site Fterm protein site Furthermore, one glycosylation site of HA protein and NA protein were changed respectively. 21774247 8 36 gly glycosylation 1188:1200 arg1 HA protein protein Fterm protein Furthermore, one glycosylation site of HA protein and NA protein were changed respectively. 21774247 8 36 gly glycosylation 1188:1200 arg1 HA protein protein site Fterm protein site Furthermore, one glycosylation site of HA protein and NA protein were changed respectively. 29909010 1 62 gly used 219:222 arg2 antigen-binding fragments antigen-binding fragments fragments The production of therapeutic monoclonal antibodies is costly; therefore, antigen-binding fragments (Fabs) can be used instead. 11559807 4 83 gly N-glycosylation 822:836 arg2 an N-glycosylation site an N-glycosylation site site Substitution of two amino acids that inserted an N-glycosylation site at amino acid 291 also resulted in a mutant hAPN that lacked receptor activity because it failed to bind HCoV-229E. 7780197 5 6 gly contains 794:801 arg1 the Asn-727 site AND high-mannose or Endo-H-sensitive hybrid oligosaccharides the Asn-727 site high-mannose or Endo-H-sensitive hybrid oligosaccharides Asn-727 site These studies suggested that the Asn-727 site contains high-mannose or Endo-H-sensitive hybrid oligosaccharides. 3219367 8 26 gly glycopeptides 1058:1070 arg2 glycopeptides glycopeptides glycopeptides The analysis of glycopeptides and saccharides by fast atom bombardment mass spectrometry and high-performance liquid chromatography provided the following conclusions on N-glycans: (1) saccharides at Asn24 are heterogeneous and consist of biantennary, triantennary, and tetraantennary saccharides with or without N-acetyllactosaminyl repeats; (2) saccharides at Asn38 mainly consist of well-processed saccharides such as tetraantennary saccharides with or without N-acetyllactosaminyl repeats; (3) saccharides at Asn83, on the other hand, are homogeneous in the backbone structure and are composed mainly of tetraantennary without N-acetyllactosaminyl repeats. 3219367 8 60 gly Asn24 1242:1246 arg1 (1) saccharides Asn24 (1) saccharides Asn24 The analysis of glycopeptides and saccharides by fast atom bombardment mass spectrometry and high-performance liquid chromatography provided the following conclusions on N-glycans: (1) saccharides at Asn24 are heterogeneous and consist of biantennary, triantennary, and tetraantennary saccharides with or without N-acetyllactosaminyl repeats; (2) saccharides at Asn38 mainly consist of well-processed saccharides such as tetraantennary saccharides with or without N-acetyllactosaminyl repeats; (3) saccharides at Asn83, on the other hand, are homogeneous in the backbone structure and are composed mainly of tetraantennary without N-acetyllactosaminyl repeats. 1331083 6 66 gly glycosylation 1496:1508 arg2 glycosylation sites glycosylation sites sites These results demonstrate that there is considerable flexibility in the placement of glycosylation sites on cathepsin D in terms of the ability of the oligosaccharides to serve as substrates for phosphotransferase, although oligosaccharides located closer to the phosphotransferase recognition determinant are preferentially phosphorylated. 31637569 2 33 gly sialylated 546:555 arg1 fully sialylated, biantennary N-glycans fully sialylated, biantennary N-glycans The glycopeptides within this library differed in glycosylation site position and glycan size ranging from the pentasaccharide N-glycan core to fully sialylated, biantennary N-glycans. 31637569 2 74 gly glycopeptides 400:412 arg2 The glycopeptides The glycopeptides glycopeptides The glycopeptides within this library differed in glycosylation site position and glycan size ranging from the pentasaccharide N-glycan core to fully sialylated, biantennary N-glycans. 31637569 2 69 gly glycosylation 446:458 arg2 glycosylation site position site position site position The glycopeptides within this library differed in glycosylation site position and glycan size ranging from the pentasaccharide N-glycan core to fully sialylated, biantennary N-glycans. 8429003 8 103 gly glycosylation 1587:1599 arg2 individual glycosylation sites individual glycosylation sites sites These results indicate that not only the local three-dimensional structure but also domain interactions can influence the processing at individual glycosylation sites. 17924005 3 25 part_of Env 737:739 arg1 Env epitopes II Env Env epitopes PUBTATOR Site II Env 1491939 epitopes The total variation on the amino acid composition was 9 and 17% for human leukocyte antigen (HLA) class I and class II Env epitopes, respectively. 9050863 1 15 gly glycosylation 221:233 arg1 glycoproteins glycoproteins Fterm glycoproteins The role of N-linked glycosylation and glycan trimming in the function of glycoproteins remains a central question in biology. 9050863 1 56 gly glycoproteins 274:286 arg1 glycoproteins glycoproteins Fterm glycoproteins The role of N-linked glycosylation and glycan trimming in the function of glycoproteins remains a central question in biology. 31501225 2 27 gly N-glycopeptides 183:197 arg2 N-glycopeptides N-glycopeptides N-glycopeptides Characterizing N-glycopeptides that correspond to N-glycan structure with specific site information enables better understanding of the molecular pathogenesis of liver damage and cancer. 22209231 6 33 gly glycosylation 897:909 arg2 the 295 glycosylation site the 295 glycosylation site site However, the addition of the 295 glycosylation site increased the inhibition of transfer. 17916798 2 58 gly glycoproteins 510:522 arg1 glycoproteins glycoproteins Fterm glycoproteins Human serum contains a high number of glycoproteins, comprising several orders of magnitude in concentration. 9401066 10 0 part_of fibrinogen 1513:1522 arg1 the D domain fibrinogen the D domain PUBTATOR Site fibrinogen 2244 domain Further analysis of the D domain of purified fibrinogen established that calcium binding to the high affinity site remained unaffected by the bulky carbohydrate side chain or negatively charged sialic acid residues. 31826991 6 54 gly glycosylation 943:955 arg2 each head glycosylation site each head glycosylation site site Using mass spectrometry, we determined the glycan subclasses and heterogeneities at each head glycosylation site. 22122935 0 73 gly glycopeptides 45:57 arg2 recombinant human erythropoietin glycopeptides recombinant human erythropoietin glycopeptides glycopeptides Analysis of recombinant human erythropoietin glycopeptides by capillary electrophoresis electrospray-time of flight-mass spectrometry. 7613162 1 31 part_of E 84:84 arg1 The Fc region immunoglobulin E The Fc region Cterm Site immunoglobulin E P01854 region The Fc region of immunoglobulin E (IgE) comprising the C epsilon 3 and C epsilon 4 domains (residues 329-547) is sufficient for binding to the high-affinity IgE Fc receptor (Fc epsilon RI alpha). 9427707 7 4 part_of A2-domain 1466:1474 arg1 the A2-domain fragment A2-domain the A2-domain fragment Cterm Site A2-domain fragment All mutant FVIII proteins were susceptible to thrombin cleavage, and the A2-domain fragment from the I566T mutant had a reduced mobility because of use of an introduced potential N-linked glycosylation site that was confirmed by N-glycanase digestion. 8702538 8 96 gly glycoprotein 1372:1383 arg1 myelin-associated glycoprotein myelin-associated glycoprotein OGER myelin-associated glycoprotein P20916 Site-directed mutagenesis of similar NC(T/S) motifs in the first or second Ig domains of the I-type lectins myelin-associated glycoprotein, and sialoadhesin did not disrupt their ability to mediate sialic acid binding. 8411368 6 66 gly glycosylation 1090:1102 arg2 the introduced glycosylation site the introduced glycosylation site site Nucleotide sequence analysis revealed that the NAs of the revertant viruses had lost the introduced glycosylation site. 8429003 6 59 part_of Asn159 1280:1285 arg1 rat sCD4 sCD4 Asn159 PUBTATOR AminoAcid sCD4 499358 Asn159 The glycosylation at the conserved site at Asn270 of rat sCD4 was identical to that seen for the equivalent site in human sCD4, and the oligomannose and hybrid structures were restricted to the nonconserved site at Asn159 in rat sCD4. 8429003 6 65 part_of sCD4 1122:1125 arg1 Asn270 sCD4 Asn270 PUBTATOR AminoAcid sCD4 499358 Asn270 The glycosylation at the conserved site at Asn270 of rat sCD4 was identical to that seen for the equivalent site in human sCD4, and the oligomannose and hybrid structures were restricted to the nonconserved site at Asn159 in rat sCD4. 8429003 6 78 part_of site 1173:1176 arg1 human sCD4 sCD4 site PUBTATOR Site sCD4 79966 site The glycosylation at the conserved site at Asn270 of rat sCD4 was identical to that seen for the equivalent site in human sCD4, and the oligomannose and hybrid structures were restricted to the nonconserved site at Asn159 in rat sCD4. 7529232 4 25 gly glycosylation 623:635 arg2 each glycosylation site each glycosylation site site A form of human soluble CD2 (hsCD2) with single N-acetylglucosamine residues at each glycosylation site was produced by inhibiting glucosidase I with N-butyldeoxynojirimycin during expression in Chinese hamster ovary cells and digesting the expressed hsCD2 with endoglycosidase H. 7529232 4 33 gly site 637:640 arg1 single N-acetylglucosamine residues site single N-acetylglucosamine residues site A form of human soluble CD2 (hsCD2) with single N-acetylglucosamine residues at each glycosylation site was produced by inhibiting glucosidase I with N-butyldeoxynojirimycin during expression in Chinese hamster ovary cells and digesting the expressed hsCD2 with endoglycosidase H. 7529232 4 61 gly CD2 562:564 arg1 single N-acetylglucosamine residues CD2 single N-acetylglucosamine residues PUBTATOR CD2 914 A form of human soluble CD2 (hsCD2) with single N-acetylglucosamine residues at each glycosylation site was produced by inhibiting glucosidase I with N-butyldeoxynojirimycin during expression in Chinese hamster ovary cells and digesting the expressed hsCD2 with endoglycosidase H. 18410132 0 41 gly glycopeptides 12:24 arg2 glycopeptides glycopeptides glycopeptides Analysis of glycopeptides using lectin affinity chromatography with MALDI-TOF mass spectrometry. 12087059 4 11 gly nonglycosylated 749:763 arg1 The nonglycosylated mutant receptors The nonglycosylated mutant receptors Fterm receptors The nonglycosylated mutant receptors, resembling their wild-type controls, were predominantly expressed in the plasma membrane. 12706347 3 66 gly N-glycosylation 593:607 arg2 seven putative N-glycosylation sites seven putative N-glycosylation sites sites The protein sequence of NTPDase3 contains seven putative N-glycosylation sites located in the ecto-domain. 18700760 5 58 gly glycoprotein 768:779 arg1 a glycoprotein a glycoprotein Fterm glycoprotein ST6Gal-I is itself a glycoprotein, and in this initial application, labeling of its own glycans and observation of these glycans by NMR are illustrated. 28822114 5 39 gly glycosylation 704:716 arg2 The only glycosylation site DMP1 site PUBTATOR DMP1 13406 site The only glycosylation site of DMP1 is serine89 (S89) in the N-terminal domain of the protein in mouse. 28822114 5 39 gly glycosylation 704:716 arg2 serine89 DMP1 serine89 PUBTATOR DMP1 13406 serine89 The only glycosylation site of DMP1 is serine89 (S89) in the N-terminal domain of the protein in mouse. 19167329 6 11 gly glycosylation 934:946 arg1 a carboxyl-terminal glycosylation site a carboxyl-terminal glycosylation site site Unlike STT3A, STT3B efficiently mediates posttranslational glycosylation of a carboxyl-terminal glycosylation site in an unfolded protein. 19167329 6 24 gly glycosylation 971:983 arg2 a carboxyl-terminal glycosylation site a carboxyl-terminal glycosylation site site Unlike STT3A, STT3B efficiently mediates posttranslational glycosylation of a carboxyl-terminal glycosylation site in an unfolded protein. 9472921 12 23 part_of contained 1411:1419 arg1 Mouse PLP-A AND a single putative N-linked glycosylation site Mouse PLP-A a single putative N-linked glycosylation site PUBTATOR Site Mouse PLP-A 19110 site Mouse PLP-A contained a single putative N-linked glycosylation site and consisted of a single 29-kDa protein species, whereas rat PLP-A contained two putative N-linked glycosylation sites and consisted of two protein species, of 29 and 33 kDa. 9472921 12 5 part_of contained 1535:1543 arg1 rat PLP-A AND two putative N-linked glycosylation sites rat PLP-A two putative N-linked glycosylation sites PUBTATOR Site PLP-A 24656 sites Mouse PLP-A contained a single putative N-linked glycosylation site and consisted of a single 29-kDa protein species, whereas rat PLP-A contained two putative N-linked glycosylation sites and consisted of two protein species, of 29 and 33 kDa. 8991508 9 4 part_of contain 1064:1070 arg1 The final domain AND Cys The final domain Cys Cys The final domain is composed mainly of basic and non-polar amino acids and does not contain Cys. 7688818 5 95 gly glycoproteins 853:865 arg1 the E1 and E2 glycoproteins the E1 and E2 glycoproteins Fterm glycoproteins Heating Sindbis virions at 51 degrees C for a short time induced a similar, although not identical, exposition of transitional epitopes on the E1 and E2 glycoproteins (W. J. Meyer, S. Gidwitz, V. K. Ayers, R. J. Schoepp, and R. E. Johnston, J. Virol. 21940909 7 37 gly nonglycosylated 1666:1680 arg1 the newly discovered nonglycosylated tryptic peptide targets the newly discovered nonglycosylated tryptic peptide targets peptide Finally, the method was validated using a multiple reaction monitoring analysis, demonstrating that the newly discovered nonglycosylated tryptic peptide targets were present at different levels in normal and hepatocellular carcinoma plasmas. 11038011 9 60 gly glycopeptide 1534:1545 arg2 glycopeptide glycopeptide glycopeptide Finally, the mutant vasopressin gene lacking the N-linked glycosylation site in glycopeptide had no effect on vasopressin expression. 11038011 9 99 gly glycosylation 1512:1524 arg2 the N-linked glycosylation site the N-linked glycosylation site site Finally, the mutant vasopressin gene lacking the N-linked glycosylation site in glycopeptide had no effect on vasopressin expression. 25213400 2 43 gly linked 142:147 arg1 the unique glycosylation site AND six different glycans the unique glycosylation site six different glycans site It can bind six different glycans, all linked to Asn(93) , the unique glycosylation site. 25213400 2 52 gly glycosylation 173:185 arg2 the unique glycosylation site the unique glycosylation site site It can bind six different glycans, all linked to Asn(93) , the unique glycosylation site. 25213400 2 52 gly glycosylation 173:185 arg2 Asn Asn Asn(93) It can bind six different glycans, all linked to Asn(93) , the unique glycosylation site. 25213400 2 43 gly linked 142:147 arg1 Asn AND six different glycans Asn(93) six different glycans Asn(93) It can bind six different glycans, all linked to Asn(93) , the unique glycosylation site. 11226831 1 2 gly found 139:143 arg1 nuclear and cytoplasmic proteins AND O-linked N-acetylglucosamine nuclear and cytoplasmic proteins O-linked N-acetylglucosamine Fterm proteins O-linked N-acetylglucosamine (O-GlcNAc) is a highly dynamic and abundant modification found on nuclear and cytoplasmic proteins of nearly all eukaryotes. 12773316 7 66 gly glycosylation 1144:1156 arg2 the second glycosylation site the second glycosylation site site Only the mutant lacking the second glycosylation site (Asn103Gln) was localized both intracellularly and on the plasma membrane. 7487957 4 5 gly sites 879:883 arg1 either four or five occupied N-glycosylation sites either four or five occupied N-glycosylation sites sites On the other hand, hyperglycosylated mutants containing either four or five occupied N-glycosylation sites, analagous to those present on the slowly cleared fetal bovine serum acetylcholinesterase (FBS-AChE), were also cleared more rapidly from the bloodstream than the wild-type species. 7487957 4 40 gly N-glycosylation 863:877 arg2 either four or five occupied N-glycosylation sites either four or five occupied N-glycosylation sites sites On the other hand, hyperglycosylated mutants containing either four or five occupied N-glycosylation sites, analagous to those present on the slowly cleared fetal bovine serum acetylcholinesterase (FBS-AChE), were also cleared more rapidly from the bloodstream than the wild-type species. 25541284 1 42 gly glycoprotein 132:143 arg1 a type I integral membrane protein a type I integral membrane protein Fterm protein Myelin oligodendrocyte glycoprotein (MOG) is a type I integral membrane protein that is expressed in the central nervous system. 25541284 1 42 gly glycoprotein 132:143 arg1 MOG MOG PUBTATOR MOG 4340 Myelin oligodendrocyte glycoprotein (MOG) is a type I integral membrane protein that is expressed in the central nervous system. 25541284 1 42 gly glycoprotein 132:143 arg1 Myelin oligodendrocyte glycoprotein Myelin oligodendrocyte glycoprotein PUBTATOR Myelin oligodendrocyte glycoprotein 4340 Myelin oligodendrocyte glycoprotein (MOG) is a type I integral membrane protein that is expressed in the central nervous system. 12742580 1 48 gly glycoprotein 157:168 arg1 The glycosylphosphatidylinositol (GPI)-anchored variant surface glycoprotein The glycosylphosphatidylinositol (GPI)-anchored variant surface glycoprotein Fterm glycoprotein The glycosylphosphatidylinositol (GPI)-anchored variant surface glycoprotein (VSG) of Trypanosoma brucei is the most abundant GPI-anchored protein expressed on any cell, and is an essential virulence factor. 12742580 1 48 gly glycoprotein 157:168 arg1 the most abundant GPI-anchored protein the most abundant GPI-anchored protein Fterm protein The glycosylphosphatidylinositol (GPI)-anchored variant surface glycoprotein (VSG) of Trypanosoma brucei is the most abundant GPI-anchored protein expressed on any cell, and is an essential virulence factor. 26485397 6 46 part_of cAPRIL 856:861 arg1 the cAPRIL (csAPRIL) fragment cAPRIL the cAPRIL (csAPRIL) fragment Cterm Site cAPRIL O75888 fragment The extracellular soluble domain of the cAPRIL (csAPRIL) fragment was cloned into the expression vector pET43.1a. SDS-PAGE and Western blotting analysis indicated a high-level expression of csAPRIL protein in Escherichia coli BL21 (DE3). 26485397 6 62 part_of csAPRIL 864:870 arg1 the cAPRIL (csAPRIL) fragment csAPRIL the cAPRIL (csAPRIL) fragment Cterm Site csAPRIL O75888 fragment The extracellular soluble domain of the cAPRIL (csAPRIL) fragment was cloned into the expression vector pET43.1a. SDS-PAGE and Western blotting analysis indicated a high-level expression of csAPRIL protein in Escherichia coli BL21 (DE3). 30063822 0 6 gly Tag 13:15 arg1 Glycoproteins Glycoproteins Tag Fterm Glycoproteins Paramagnetic Tag for Glycosylation Sites in Glycoproteins: Structural Constraints on Heparan Sulfate Binding to Robo1. 19116267 10 1 part_of receptor 1709:1716 arg1 receptor binding domain receptor receptor binding domain Fterm Site receptor domain These results show that VN1203 HA glycoprotein confers pathogenicity by facilitating systemic spread in mice; they also suggest that a minor change in receptor binding domain may modulate the virulence of H5N1 viruses. 11929783 4 72 gly glycosylation 932:944 arg2 a potential CH3 glycosylation site a potential CH3 glycosylation site site The cryoglobulin activity of the IgG3 6-19 mutant bearing more negatively charged residues at VH 6 and 23 was found to be reduced but still highly significant, whereas that of the mutant lacking a potential CH3 glycosylation site remained unchanged. 8946177 3 18 gly glycosylation 436:448 arg2 glycosylation site glycosylation site site In Poland we estimated the incidence of the Pd allele at 6% and that of isolated 1788 mutation (loss of glycosylation site) at 3%. 25498018 5 69 gly fucosylated 1216:1226 arg1 bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form. 25498018 5 8 gly glycosylation 1060:1072 arg2 a specific glycosylation site site, Asn 134 site, Asn 134 The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form. 25498018 5 46 gly glycosylated 1104:1115 arg1 Asn 134 site, Asn 134 site, Asn 134 The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form. 25498018 5 46 gly glycosylated 1104:1115 arg2 a specific glycosylation site site, Asn 134 site, Asn 134 The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form. 25498018 5 46 gly glycosylated 1104:1115 arg1 a specific glycosylation site site, Asn 134 site, Asn 134 The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form. 25498018 5 46 gly glycosylated 1104:1115 arg2 a specific glycosylation site site, Asn 134 site, Asn 134 The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form. 25498018 5 46 gly glycosylated 1104:1115 arg1 a specific glycosylation site site, Asn 134 site, Asn 134 The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form. 25498018 5 46 gly glycosylated 1104:1115 arg1 a specific glycosylation site site, Asn 134 site, Asn 134 The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form. 27798666 4 63 gly O-glycosylation 686:700 arg2 serine612 serine612 serine612 NRP1 is further post-translationally modified by the addition of glycosaminoglycans (GAG) side chains through an O-glycosylation site at serine612. 27798666 4 63 gly O-glycosylation 686:700 arg2 an O-glycosylation site an O-glycosylation site site NRP1 is further post-translationally modified by the addition of glycosaminoglycans (GAG) side chains through an O-glycosylation site at serine612. 31826991 9 37 gly glycosite 1263:1271 arg2 glycosite glycosite glycosite We found that glycosite "N165" (H3 numbering) is occupied by high-mannose glycans in H3 HA but by complex glycans in all LPAIV HAs. 24899172 3 1 gly glycosylated 635:646 arg1 the glycosylated and nonglycosylated isoforms the glycosylated and nonglycosylated isoforms Fterm isoforms Here we investigated the requirement for a precise positioning of N-linked glycan at amino acid 146 and the functions associated with the glycosylated and nonglycosylated isoforms. 24899172 3 124 gly nonglycosylated 652:666 arg1 the glycosylated and nonglycosylated isoforms the glycosylated and nonglycosylated isoforms Fterm isoforms Here we investigated the requirement for a precise positioning of N-linked glycan at amino acid 146 and the functions associated with the glycosylated and nonglycosylated isoforms. 2350186 4 90 gly glycosylation 789:801 arg2 more distal glycosylation sites more distal glycosylation sites sites The peptide deletion of the C mu 1 constant region domain in the heavy chains synthesized by one variant cell line did not prevent subsequent glycosylation at more distal glycosylation sites. 2350186 4 76 gly glycosylation 760:772 arg2 more distal glycosylation sites sites sites The peptide deletion of the C mu 1 constant region domain in the heavy chains synthesized by one variant cell line did not prevent subsequent glycosylation at more distal glycosylation sites. 24899172 11 37 gly N-glycosylation 2101:2115 arg2 an N-glycosylation site an N-glycosylation site site It contains an N-glycosylation site at position 146, which is functional on only half of the envelope proteins. 24899172 11 37 gly N-glycosylation 2101:2115 arg2 position 146 position 146 position 146, It contains an N-glycosylation site at position 146, which is functional on only half of the envelope proteins. 17015441 7 81 gly glycosylation 1117:1129 arg2 The glycosylation site The glycosylation site site The glycosylation site is flanked in the pore by two cysteine residues that we mutated, to prove that they are involved in a conserved double cysteine motif, which is essential for channel function. 1390770 5 39 part_of variant 549:555 arg1 Gln38,83 variant Gln38,83 Fterm SpecificSite variant Gln38,83 A variant with a double mutation (Gln38,83) and another with a triple mutation (Gln24,38,83) were secreted poorly from COS1 and CHO cells even though RNA encoding these variants was present. 30427586 6 4 gly N-glycopeptides 1201:1215 arg2 all N-glycopeptides all N-glycopeptides N-glycopeptides It is shown for the first time that this fragmentation signature can consistently be found across all N-glycopeptides, but not on O-glycopeptides. 30427586 6 36 gly O-glycopeptides 1229:1243 arg2 O-glycopeptides O-glycopeptides O-glycopeptides It is shown for the first time that this fragmentation signature can consistently be found across all N-glycopeptides, but not on O-glycopeptides. 25861032 3 3 gly N-glycosylation 507:521 arg2 a single conserved N-glycosylation site a single conserved N-glycosylation site site Key structural features previously described in LPPs, including the three conserved domains proposed as catalytic sites, a single conserved N-glycosylation site, and putative transmembrane domains were discovered in the three resulting EtLPP amino acid sequences. 11038011 10 65 gly glycopeptide 2013:2024 arg2 the carboxy-terminal glycopeptide the carboxy-terminal glycopeptide glycopeptide Our data suggest that 1) intact neurophysin is not indispensable for vasopressin expression, although an altered structure of neurophysin significantly affects the secretion of the hormone; 2) the pathogenesis of diabetes insipidus with the two naturally-occurring mutations found in the rat (Brattleboro rat) and human (familial central diabetes insipidus) seem to be different; and 3) glycosylation of the carboxy-terminal glycopeptide is not essential for the expression of vasopressin. 11038011 10 73 gly glycosylation 1975:1987 arg1 vasopressin vasopressin glycopeptide PUBTATOR vasopressin 551 glycopeptide Our data suggest that 1) intact neurophysin is not indispensable for vasopressin expression, although an altered structure of neurophysin significantly affects the secretion of the hormone; 2) the pathogenesis of diabetes insipidus with the two naturally-occurring mutations found in the rat (Brattleboro rat) and human (familial central diabetes insipidus) seem to be different; and 3) glycosylation of the carboxy-terminal glycopeptide is not essential for the expression of vasopressin. 14985108 7 38 gly glycosylation 749:761 arg2 N69 N69 N69 Importantly, glycosylation of ONC at N69 greatly increased its toxicity for K-562 cancer cells. 1421757 0 1 part_of receptor 75:82 arg1 the O-linked glycosylation site transferrin receptor the O-linked glycosylation site PUBTATOR Site transferrin receptor 7037 site Identification of the O-linked glycosylation site of the human transferrin receptor. 4038307 2 10 part_of possesses 372:380 arg1 the protein AND only one N-glycosylation site the protein only one N-glycosylation site Fterm Site protein site Although the protein possesses only one N-glycosylation site, di-, tri- and tetra-antennary glycans in a ratio of 40:15:45 were found to be present. 24468271 4 16 gly N-glycosylation 727:741 arg2 each N-glycosylation site each N-glycosylation site site Using the site-directed mutagenesis technique, we made two mutant hIL4 cDNA clones (N38A and N105L) and subsequently expressed them in P. pastoris to analyze the relevant function of each N-glycosylation site on hIL4. 25755023 0 62 gly glycoprotein 62:73 arg1 the tumor-associated MUC4 glycoprotein the tumor-associated MUC4 glycoprotein PUBTATOR MUC4 glycoprotein Q99102 Antibody induction directed against the tumor-associated MUC4 glycoprotein. 12911333 11 7 gly N-glycosylation 2042:2056 arg2 similarly positioned native N-glycosylation sites similarly positioned native N-glycosylation sites sites Thus other ion channels or membrane proteins may also have a high glycosylation potential on a linker but yet have similarly positioned native N-glycosylation sites among isoforms. 24798328 6 35 gly O-glycosylation 901:915 arg2 position -1 position -1 position We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position -1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure. 24798328 6 35 gly O-glycosylation 901:915 arg2 an evolutionarily conserved O-glycosylation site an evolutionarily conserved O-glycosylation site site We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position -1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure. 24798328 6 51 gly sialylated 1046:1055 arg1 the typical sialylated core 1 structure the typical sialylated core 1 structure We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position -1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure. 24798328 6 53 gly cysteine 950:957 arg1 most repeats cysteine residue most repeats cysteine residue We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position -1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure. 24798328 6 44 gly glycosylated 1016:1027 arg1 an evolutionarily conserved O-glycosylation site site site We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position -1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure. 19008394 2 66 part_of protein 415:421 arg1 the WNV NY99 E protein glycosylation site protein the WNV NY99 E protein glycosylation site Fterm Site protein site Using synthetic peptides, this epitope was mapped to a 19 aa sequence (WN19: E147-165) encompassing the WNV NY99 E protein glycosylation site at position 154. 15754041 9 62 part_of Wnt3-Wnt9b 1293:1302 arg1 The Wnt3-Wnt9b intergenic conserved region Wnt9b The Wnt3-Wnt9b intergenic conserved region PUBTATOR Site Wnt9b O14905 region The Wnt3-Wnt9b intergenic conserved region (IGCR), corresponding to nucleotide position 124747-125252 of AC105632.3 genome sequence, showed 85.6% nucleotide identity with human WNT3-WNT9B IGCR. 27966990 7 5 part_of sites 1339:1343 arg1 VEGFR-2 VEGFR-2 sites PUBTATOR Site VEGFR-2 P35968 sites MS/MS analyses of glycopeptides and deamidated, deglycosylated (PNGase F-treated) peptides from ectopically expressed VEGFR-2 in porcine aortic endothelial (PAE) cells identified N-glycans at the majority of the 17 potential N-glycosylation sites on VEGFR-2 in a site-specific manner. 27966990 7 71 part_of VEGFR-2 1216:1222 arg1 deamidated, deglycosylated (PNGase F-treated) peptides VEGFR-2 deamidated, deglycosylated (PNGase F-treated) peptides PUBTATOR Site VEGFR-2 P35968 peptides MS/MS analyses of glycopeptides and deamidated, deglycosylated (PNGase F-treated) peptides from ectopically expressed VEGFR-2 in porcine aortic endothelial (PAE) cells identified N-glycans at the majority of the 17 potential N-glycosylation sites on VEGFR-2 in a site-specific manner. 8357534 2 39 part_of has 374:376 arg1 cathepsin G AND Asn-64 cathepsin G Asn-64 PUBTATOR SpecificSite cathepsin G 1511 Asn-64 Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64). 8357534 2 38 part_of has 293:295 arg1 Elastase AND two N-glycosylation sites Elastase two N-glycosylation sites Fterm Site Elastase sites Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64). 8357534 2 38 part_of has 293:295 arg1 Elastase AND Asn-45 Elastase Asn-45 and Asn-144 Fterm SpecificSite Elastase Asn-45 and Asn-144 Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64). 25861032 3 62 part_of EtLPP 603:607 arg1 EtLPP amino acid sequences EtLPP EtLPP amino acid sequences Cterm Site EtLPP sequences Key structural features previously described in LPPs, including the three conserved domains proposed as catalytic sites, a single conserved N-glycosylation site, and putative transmembrane domains were discovered in the three resulting EtLPP amino acid sequences. 23830432 4 19 gly multisialylated 1177:1191 arg1 multisialylated glycopeptides multisialylated glycopeptides glycopeptides The mass spectra of the enriched glycopeptides derived from fetuin reveal that several series of the ion clusters with mass difference of 291 Da correspond to the presence of multisialylated glycopeptides. 23830432 4 49 gly glycopeptides 1035:1047 arg2 the enriched glycopeptides the enriched glycopeptides glycopeptides The mass spectra of the enriched glycopeptides derived from fetuin reveal that several series of the ion clusters with mass difference of 291 Da correspond to the presence of multisialylated glycopeptides. 23830432 4 70 gly glycopeptides 1193:1205 arg2 multisialylated glycopeptides multisialylated glycopeptides glycopeptides The mass spectra of the enriched glycopeptides derived from fetuin reveal that several series of the ion clusters with mass difference of 291 Da correspond to the presence of multisialylated glycopeptides. 22674976 6 26 gly glycosylation 1343:1355 arg2 glycosylation sites glycosylation sites sites The hemagglutinins (HAs) of AK/35, FM/47, and FW/50 differ in the presence of glycosylation sites. 2844793 9 49 part_of N-protein 1595:1603 arg1 Ile145 N-protein Ile145 Fterm AminoAcid N-protein Ile145 Various NH2-terminal portions of E1 were fused to Ile145 of the cytoplasmic N-protein of mouse hepatitis virus. 28414420 5 9 gly glycosylation 859:871 arg2 glycosylation site promiscuity glycosylation site promiscuity site It was found that antibody PGT128 exhibited specificity for high-mannose N-glycan with glycosylation site promiscuity, PGT121 showed binding specificity for glycopeptide carrying a sialylated N-glycan at N301 site, and 10-1074 was specific for glycopeptide carrying a high-mannose N-glycan at N332 site. 28414420 5 13 gly glycopeptide 929:940 arg2 glycopeptide glycopeptide glycopeptide It was found that antibody PGT128 exhibited specificity for high-mannose N-glycan with glycosylation site promiscuity, PGT121 showed binding specificity for glycopeptide carrying a sialylated N-glycan at N301 site, and 10-1074 was specific for glycopeptide carrying a high-mannose N-glycan at N332 site. 28414420 5 36 gly glycopeptide 1016:1027 arg2 glycopeptide glycopeptide glycopeptide It was found that antibody PGT128 exhibited specificity for high-mannose N-glycan with glycosylation site promiscuity, PGT121 showed binding specificity for glycopeptide carrying a sialylated N-glycan at N301 site, and 10-1074 was specific for glycopeptide carrying a high-mannose N-glycan at N332 site. 28414420 5 65 gly sialylated 953:962 arg1 a sialylated N-glycan at N301 site a sialylated N-glycan at N301 site It was found that antibody PGT128 exhibited specificity for high-mannose N-glycan with glycosylation site promiscuity, PGT121 showed binding specificity for glycopeptide carrying a sialylated N-glycan at N301 site, and 10-1074 was specific for glycopeptide carrying a high-mannose N-glycan at N332 site. 28414420 5 57 gly carrying 1029:1036 arg1 glycopeptide AND a high-mannose N-glycan glycopeptide a high-mannose N-glycan glycopeptide It was found that antibody PGT128 exhibited specificity for high-mannose N-glycan with glycosylation site promiscuity, PGT121 showed binding specificity for glycopeptide carrying a sialylated N-glycan at N301 site, and 10-1074 was specific for glycopeptide carrying a high-mannose N-glycan at N332 site. 20943674 0 46 gly N-glycosylation 52:66 arg1 wild-type and recombinant human lactoferrin wild-type and recombinant human lactoferrin OGER lactoferrin P02788 Comprehensive characterization of the site-specific N-glycosylation of wild-type and recombinant human lactoferrin expressed in the milk of transgenic cloned cattle. 27612916 1 50 gly glycoproteins 163:175 arg1 glycoproteins glycoproteins Fterm glycoproteins The UDP glucuronosyltransferase (UGT) superfamily comprises glycoproteins that reside in the endoplasmic reticulum membranes and that undergo post-translational modifications (PTMs). 7780197 6 19 gly Glycosylation 861:873 arg1 Asn-727 Asn-727 Asn-727 Glycosylation of Asn-727 found in the TfR purified from human placentae was analysed by high-pH anion-exchange chromatography with pulsed amperometric detection (HPAE-PAD) and mass spectrometry following tryptic digestion, peptide purification via reverse-phase high-performance liquid chromatography (RP-HPLC) and peptide sequencing. 2036367 16 49 gly glycosylation 2160:2172 arg2 residue 21 residue 21 residue 21 The N-terminal amino acid sequence was Ile1-Val2-Gly3-Gly4-Gln5-Glu6-Ala7-+ ++Ser8-Gly9-Asn10-Lys11-Trp12-Pro13- Trp14- Gln15-Val16-Ser17-Leu18-Arg19-Val20- --21-Asp-22Thr23-Tyr24-Typ25-, with a putative glycosylation site at residue 21. 2036367 16 49 gly glycosylation 2160:2172 arg2 a putative glycosylation site a putative glycosylation site site The N-terminal amino acid sequence was Ile1-Val2-Gly3-Gly4-Gln5-Glu6-Ala7-+ ++Ser8-Gly9-Asn10-Lys11-Trp12-Pro13- Trp14- Gln15-Val16-Ser17-Leu18-Arg19-Val20- --21-Asp-22Thr23-Tyr24-Typ25-, with a putative glycosylation site at residue 21. 8626811 6 11 gly N-glycosylation 1039:1053 arg2 a single N-glycosylation site a single N-glycosylation site site The gene encodes a polypeptide of 416 amino acids (Mr 45,947) with a leader peptide of 35 residues; the mature protein has a single N-glycosylation site. 17927214 5 65 gly N-glycosylation 1107:1121 arg2 position 711 position 711 position 711 Furthermore, the N-glycosylation site at position 711 of domain 5, which is predicted to be located near the binding pocket, has no influence on the carbohydrate binding affinity. 17927214 5 65 gly N-glycosylation 1107:1121 arg2 the N-glycosylation site the N-glycosylation site site Furthermore, the N-glycosylation site at position 711 of domain 5, which is predicted to be located near the binding pocket, has no influence on the carbohydrate binding affinity. 9658108 5 48 gly N-glycosylation 963:977 arg2 its first N-glycosylation site its first N-glycosylation site site The six Cys residues of the extracellular domain of havcr-1 and its first N-glycosylation site were conserved in huhavcr-1. 6148073 1 24 gly glycoprotein 218:229 arg1 purified mouse thymocyte Thy-1 glycoprotein purified mouse thymocyte Thy-1 glycoprotein OGER Thy-1 glycoprotein P01831 Four glycopeptides (I, IIA, IIB, III) with different oligosaccharide structures were isolated from purified mouse thymocyte Thy-1 glycoprotein. 6148073 1 27 gly glycopeptides 93:105 arg2 Four glycopeptides glycopeptides different oligosaccharide structures glycopeptides Four glycopeptides (I, IIA, IIB, III) with different oligosaccharide structures were isolated from purified mouse thymocyte Thy-1 glycoprotein. 7849028 3 58 gly Glycosylation 282:294 arg1 p62 p62 PUBTATOR p62 117268 Glycosylation of the major rat nuclear pore glycoprotein, p62, was examined in vitro using recombinant p62 as a substrate. 7849028 3 58 gly Glycosylation 282:294 arg1 the major rat nuclear pore glycoprotein the major rat nuclear pore glycoprotein Fterm glycoprotein Glycosylation of the major rat nuclear pore glycoprotein, p62, was examined in vitro using recombinant p62 as a substrate. 7849028 3 102 gly glycoprotein 326:337 arg1 p62 p62 PUBTATOR p62 117268 Glycosylation of the major rat nuclear pore glycoprotein, p62, was examined in vitro using recombinant p62 as a substrate. 7849028 3 102 gly glycoprotein 326:337 arg1 the major rat nuclear pore glycoprotein the major rat nuclear pore glycoprotein Fterm glycoprotein Glycosylation of the major rat nuclear pore glycoprotein, p62, was examined in vitro using recombinant p62 as a substrate. 24554659 0 54 gly glycoprotein 94:105 arg1 the simian immunodeficiency virus envelope glycoprotein the simian immunodeficiency virus envelope glycoprotein PUBTATOR envelope glycoprotein V2 1490007 Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission. 24554659 0 70 gly glycosylation 29:41 arg2 a conserved N-linked glycosylation site a conserved N-linked glycosylation site site Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission. 8349699 4 24 gly glycosylation 545:557 arg2 Inactive PGH synthase-1 glycosylation site mutant Inactive PGH synthase-1 glycosylation site mutant site Inactive PGH synthase-1 glycosylation site mutant proteins do not appear to achieve their native conformations. 25707740 16 71 gly glycosylated 1824:1835 arg1 Other abnormally glycosylated hCG Other abnormally glycosylated hCG OGER hCG Other abnormally glycosylated hCG are described in aneuploidies. 16720579 5 51 part_of terminus 991:998 arg1 the fourth or sixth site terminus the fourth or sixth site site Among six potential N-glycosylation sites, deletion of the fourth or sixth site from the amino terminus inhibited production of the active C6ST-1, whereas deletion of the fifth site resulted in a marked loss of the KSST activity. 17715132 5 1 gly glycosylated 694:705 arg1 Pannexin1 Pannexin1 Asn-254 PUBTATOR Pannexin1 24145 Asn-254 We show for the first time that Pannexin1 is glycosylated at Asn-254 and that this residue is important for plasma membrane targeting. 23820512 1 24 gly N-glycosites 250:261 arg2 N-glycosites N-glycosites N-glycosites Current strategies to study N-glycoproteins in complex samples are often discrete, focusing on either N-glycans or N-glycosites enriched by sugar-based techniques. 23820512 1 53 gly N-glycoproteins 163:177 arg1 N-glycoproteins N-glycoproteins Fterm N-glycoproteins Current strategies to study N-glycoproteins in complex samples are often discrete, focusing on either N-glycans or N-glycosites enriched by sugar-based techniques. 17158203 4 72 part_of receptor 746:753 arg1 deleted LDL-A domain LGR7 receptor deleted LDL-A domain PUBTATOR Site LGR7 receptor 59350 domain Point mutants for the conserved cysteines (Cys(47) and Cys(53)) and for calcium binding asparagine (Asp(58)), a mutant with deleted LDL-A domain and chimeric LGR7 receptor with LGR8 LDL-A all showed no cAMP response to human relaxins H1 or H2. 16883437 7 101 part_of glycoproteins 1094:1106 arg1 the epitopes glycoproteins the epitopes Fterm Site glycoproteins epitopes To predict the epitopes of glycoproteins, 21 different scales were used. 26858738 6 0 part_of IgA1 1138:1141 arg1 the IgA1 alpha chain hinge region IgA1 alpha chain the IgA1 alpha chain hinge region PUBTATOR Site IgA1 alpha chain P01876 region Analysis of the peptide carrying nine potential O-glycosylation sites in the IgA1 alpha chain hinge region showed the presence of plant-specific modifications including hydroxyproline formation and the attachment of pentoses. 26858738 6 48 part_of alpha 1143:1147 arg1 the IgA1 alpha chain hinge region IgA1 alpha chain the IgA1 alpha chain hinge region PUBTATOR Site IgA1 alpha chain P01876 region Analysis of the peptide carrying nine potential O-glycosylation sites in the IgA1 alpha chain hinge region showed the presence of plant-specific modifications including hydroxyproline formation and the attachment of pentoses. 26858738 6 86 part_of chain 1149:1153 arg1 the IgA1 alpha chain hinge region IgA1 alpha chain the IgA1 alpha chain hinge region PUBTATOR Site IgA1 alpha chain P01876 region Analysis of the peptide carrying nine potential O-glycosylation sites in the IgA1 alpha chain hinge region showed the presence of plant-specific modifications including hydroxyproline formation and the attachment of pentoses. 26858738 6 80 part_of carrying 1085:1092 arg1 the peptide AND nine potential O-glycosylation sites the peptide nine potential O-glycosylation sites sites Analysis of the peptide carrying nine potential O-glycosylation sites in the IgA1 alpha chain hinge region showed the presence of plant-specific modifications including hydroxyproline formation and the attachment of pentoses. 9472610 2 31 part_of gp120 308:312 arg1 the gp120 V3 region gp120 the gp120 V3 region OGER Site gp120 Q14624 region Direct sequencing of the gp120 V3 region obtained from 33 persons showed that faecal and serum sequences could be nearly homologous (0.3% different) or very dissimilar (11.3% different). 21733886 7 10 gly glycosylation 1182:1194 arg2 the conserved glycosylation site the conserved glycosylation site site MVEV mutants containing a unique ALFV sequence in the flexible hinge region (residues 273-277) or lacking the conserved glycosylation site at position 154 were significantly less neuroinvasive in mice than wild-type MVEV, as determined by delayed time to death or increased LD(50). 12087059 7 20 gly presence 1580:1587 arg1 the receptor AND N-linked glycan the receptor N-linked glycan Fterm receptor Although the precise molecular mechanism of the internalization of the N-glycosylated Edg-1 localized in the microdomain remains to be examined, the present study suggested that the presence of N-linked glycan in the receptor may play a regulatory role in the receptor dynamics in ligand-stimulated mammalian cells. 12087059 7 58 gly N-glycosylated 1469:1482 arg1 the N-glycosylated Edg-1 the N-glycosylated Edg-1 PUBTATOR Edg-1 1901 Although the precise molecular mechanism of the internalization of the N-glycosylated Edg-1 localized in the microdomain remains to be examined, the present study suggested that the presence of N-linked glycan in the receptor may play a regulatory role in the receptor dynamics in ligand-stimulated mammalian cells. 16845394 3 0 part_of EGF-like 623:630 arg1 the lectin and EGF-like domains EGF the lectin and EGF-like domains OGER Site EGF P01133 domains To determine whether the extended conformation has higher affinity for ligand, we introduced an N-glycosylation site to 'wedge open' the interface between the lectin and EGF-like domains of P-selectin. 16845394 3 10 part_of P-selectin 643:652 arg1 the lectin and EGF-like domains P-selectin the lectin and EGF-like domains PUBTATOR Site P-selectin 6403 domains To determine whether the extended conformation has higher affinity for ligand, we introduced an N-glycosylation site to 'wedge open' the interface between the lectin and EGF-like domains of P-selectin. 16845394 3 36 part_of lectin 612:617 arg1 the lectin and EGF-like domains lectin the lectin and EGF-like domains Fterm Site lectin domains To determine whether the extended conformation has higher affinity for ligand, we introduced an N-glycosylation site to 'wedge open' the interface between the lectin and EGF-like domains of P-selectin. 23365085 6 48 gly glycan 964:969 arg1 Asn Asn(136) Asn(136) Addition of a glycan (Asn(136)) to A(H1N1)pdm HA was associated with resistance to neutralizing Abs but did not increase sensitivity to collectins. 20147616 1 7 gly glycosylation 206:218 arg2 the glycosylation site the glycosylation site site Otelixizumab is a chimeric CD3 antibody that has been genetically engineered to remove the glycosylation site in the Fc domain. 18579437 10 11 part_of site 1241:1244 arg1 HN HN site Cterm Site HN 935188 site A potential new glycosylation site in HN, in addition to minor changes observed in the predicted structure for the variant strains could explain their antigenic variation. 7540044 1 2 part_of glycoprotein 253:264 arg1 The first potential N-glycosylation site glycoprotein The first potential N-glycosylation site Fterm Site glycoprotein site The first potential N-glycosylation site of the rabies virus glycoprotein, the antigen that carries epitopes for glycoprotein-specific T-cells and virus neutralizing antibodies, is glycosylated inefficiently. 7540044 1 7 part_of carries 284:290 arg1 the rabies virus glycoprotein AND epitopes the rabies virus glycoprotein epitopes Fterm Site glycoprotein epitopes The first potential N-glycosylation site of the rabies virus glycoprotein, the antigen that carries epitopes for glycoprotein-specific T-cells and virus neutralizing antibodies, is glycosylated inefficiently. 10640760 7 11 part_of contains 969:976 arg1 The collagen region AND an extra cysteine residue The collagen region an extra cysteine residue cysteine residue The collagen region contains an extra cysteine residue, which may have important structural consequences. 3200844 8 8 part_of CNBr 1135:1138 arg1 a second CNBr fragment CNBr a second CNBr fragment Cterm Site CNBr fragment This open reading frame contained a CNBr fragment identical to the original glycopeptide sequence and a second CNBr fragment corresponding to a nonglycosylated peptide that was also isolated from the purified pore glycoprotein. 3200844 8 59 part_of CNBr 1060:1063 arg1 a CNBr fragment CNBr a CNBr fragment Cterm Site CNBr fragment This open reading frame contained a CNBr fragment identical to the original glycopeptide sequence and a second CNBr fragment corresponding to a nonglycosylated peptide that was also isolated from the purified pore glycoprotein. 26224460 6 9 gly N-glycosylation 1112:1126 arg2 an N-glycosylation site an N-glycosylation site site The HA gene showed the most mutations (at least 11) with one resulting in the loss of an N-glycosylation site (at amino acid 166). 7628611 1 5 gly glycosylated 209:220 arg1 Kainate binding proteins Kainate binding proteins Fterm proteins Kainate binding proteins (KBPs) from frog and goldfish brain are glycosylated, integral membrane proteins. 7609736 11 76 gly N-glycosylation 1172:1186 arg2 a potential N-glycosylation site a potential N-glycosylation site site Sequence analysis of the VH gene shows a potential N-glycosylation site located in framework III at position Asn 75. 9367731 8 37 part_of HSP70 1803:1807 arg1 the first reported sequence HSP70 the first reported sequence PUBTATOR Site HSP70 3308 sequence This is the first reported sequence of an inducible HSP70 from cells originating from a freshwater gastropod and provides a first step in the development of a genetic transformation system for molluscs of medical importance. 23341449 9 6 part_of FN1 1591:1593 arg1 the FN1 domain FN1 the FN1 domain PUBTATOR Site FN1 2335 domain Taken together, these results indicate that the polySTs not only recognize an acidic patch in the FN1 domain of NCAM but also must contact sequences in the Ig5 domain for polysialylation of Ig5 N-glycans to occur. 23341449 9 41 part_of NCAM 1605:1608 arg1 the FN1 domain NCAM the FN1 domain PUBTATOR Site NCAM 4684 domain Taken together, these results indicate that the polySTs not only recognize an acidic patch in the FN1 domain of NCAM but also must contact sequences in the Ig5 domain for polysialylation of Ig5 N-glycans to occur. 18815274 6 4 part_of receptor 744:751 arg1 the extracellular domain low-density lipoprotein receptor the extracellular domain PUBTATOR Site low-density lipoprotein receptor 16835 domain The fourth luminal domain of SV2A or SV2B alone, expressed in chimeric receptors by replacing the extracellular domain of the low-density lipoprotein receptor, can restore the binding and entry of BoNT/E into neurons lacking SV2A/B. 18815274 6 10 part_of SV2B 631:634 arg1 The fourth luminal domain SV2B The fourth luminal domain PUBTATOR Site SV2B 64176 domain The fourth luminal domain of SV2A or SV2B alone, expressed in chimeric receptors by replacing the extracellular domain of the low-density lipoprotein receptor, can restore the binding and entry of BoNT/E into neurons lacking SV2A/B. 18815274 6 15 part_of SV2A 623:626 arg1 The fourth luminal domain SV2A The fourth luminal domain PUBTATOR Site SV2A 64051 domain The fourth luminal domain of SV2A or SV2B alone, expressed in chimeric receptors by replacing the extracellular domain of the low-density lipoprotein receptor, can restore the binding and entry of BoNT/E into neurons lacking SV2A/B. 18636497 0 45 gly sialylation 26:36 arg1 recombinant human interferon-gamma recombinant human interferon-gamma PUBTATOR interferon-gamma 3458 Site- and branch-specific sialylation of recombinant human interferon-gamma in Chinese hamster ovary cell culture. 18636497 0 92 gly interferon-gamma 59:74 arg1 branch-specific sialylation interferon-gamma branch-specific sialylation PUBTATOR interferon-gamma 3458 Site- and branch-specific sialylation of recombinant human interferon-gamma in Chinese hamster ovary cell culture. 14693913 2 99 gly glycoprotein 358:369 arg1 The 76.3-kDa glycoprotein The 76.3-kDa glycoprotein Fterm glycoprotein The 76.3-kDa glycoprotein was associated with 75-80 Man and a small amount of GlcNAc. 25324212 6 57 gly glycopeptides 1059:1071 arg2 the Tn-presenting glycopeptides the Tn-presenting glycopeptides glycopeptides NMR data were complemented with molecular dynamics simulations and Corcema-ST to establish a 3D view on the molecular recognition process between Gal, GalNAc, and the Tn-presenting glycopeptides and MGL. 21526855 0 47 gly O-glycoproteins 23:37 arg1 O-glycoproteins O-glycoproteins Fterm O-glycoproteins Top-down sequencing of O-glycoproteins by in-source decay matrix-assisted laser desorption ionization mass spectrometry for glycosylation site analysis. 21526855 0 93 gly glycosylation 124:136 arg2 glycosylation site analysis glycosylation site analysis site Top-down sequencing of O-glycoproteins by in-source decay matrix-assisted laser desorption ionization mass spectrometry for glycosylation site analysis. 9725224 6 17 gly glycosylation 940:952 arg2 the alpha2 domain glycosylation site the alpha2 domain glycosylation site site Only the mutation of the alpha2 domain glycosylation site significantly reduced the binding of Dd to Ly-49A and Ly-49C. 30850477 10 43 gly N-glycosylation 1365:1379 arg2 35 out of 38 (92%) nongermline N-glycosylation sites 35 out of 38 (92%) nongermline N-glycosylation sites sites When expressed as rmAb, 35 out of 38 (92%) nongermline N-glycosylation sites became occupied. 11916258 5 1 part_of contain 639:645 arg1 The deduced amino acid sequences AND seven putative transmembrane domains The deduced amino acid sequences seven putative transmembrane domains domains The deduced amino acid sequences (AAS) appear to contain seven putative transmembrane domains with an extracellular N-terminus in each species. 31596095 5 84 gly glycosylation 960:972 arg2 a glycosylation site a glycosylation site site We then generated 24 mutant AAV2 vectors modified to potentially create or disrupt a glycosylation site in its capsid. 3087774 0 13 gly glycopeptides 36:48 arg2 the glycopeptides the glycopeptides glycopeptides Amino acid sequence analysis of the glycopeptides from human complement component C3. 8073631 5 5 gly glycosylated 888:899 arg1 the closely glycosylated region the closely glycosylated region region Moreover, one of these structural changes occurred in the closely glycosylated region at amino acid residues 168-240, which appeared to be a biologically important functional domain. 9597548 6 29 gly glycoproteins 1217:1229 arg1 Gal alpha (1,3)Gal glycoproteins Gal alpha (1,3)Gal Fterm glycoproteins Furthermore, we observed oligosaccharide structures containing Gal alpha (1,3)Gal that have not been reported as components of human glycoproteins. 25113421 10 0 gly glycopeptides 1330:1342 arg2 intact N-linked glycopeptides intact N-linked glycopeptides glycopeptides To address this need, we developed a novel software tool, GlycoMaster DB, to assist the automated and high-throughput identification of intact N-linked glycopeptides from MS/MS spectra. 2209609 2 57 gly N-glycosylation 347:361 arg2 two N-glycosylation sites two N-glycosylation sites sites, Asn271 and Asn300 The glycoprotein has two N-glycosylation sites, Asn271 and Asn300, at both of which evidence for the presence of complex type biantennary sialo-oligosaccharides has been obtained previously by mass spectrometric analyses [Carr, S.A., Hemling, M.E., Folena-Wasserman, G., Sweet, R.W., Anumula, K., Barr, J.R., Huddleston, M.J. & Taylor, P. (1989) J. Biol. 2209609 2 58 gly glycoprotein 326:337 arg1 The glycoprotein The glycoprotein Fterm glycoprotein The glycoprotein has two N-glycosylation sites, Asn271 and Asn300, at both of which evidence for the presence of complex type biantennary sialo-oligosaccharides has been obtained previously by mass spectrometric analyses [Carr, S.A., Hemling, M.E., Folena-Wasserman, G., Sweet, R.W., Anumula, K., Barr, J.R., Huddleston, M.J. & Taylor, P. (1989) J. Biol. 21071054 3 60 gly glycosylation 683:695 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site In contrast, basic amino acid substitutions at position 25, or substitutions at positions 6-8 resulting in the loss of a potential N-linked glycosylation site, contributed to CXCR4-mediated entry but required additional substitutions acting cooperatively to confer efficient CXCR4 use. 20573835 2 26 gly glycoprotein 495:506 arg1 severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein Fterm glycoprotein The objective of this study was to assess the interactions between MBL and severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein (SARS-S). 23004563 6 65 gly glycopeptides 1104:1116 arg2 glycopeptides glycopeptides glycopeptides Therefore, both quantification of glycopeptides and assignment of their glycan structures were achieved by a simple analysis procedure. 17011210 7 116 gly N-glycosylation 1376:1390 arg2 single N-glycosylation site single N-glycosylation site site As judged from SDS-PAGE analysis of the culture supernatant, the N-terminal addition of FLAG-(Gly)(5) tag and the deletion of single N-glycosylation site via N184Q mutation increased the secretion level of the product. 2303254 4 13 gly N-glycosylation 1873:1887 arg2 a potential N-glycosylation site a potential N-glycosylation site site The results indicate that (1) 69% of the amino acids in the catalytic domain, but only 23% of the amino acids in the activation peptide, are identical in humans and the six species; (2) the catalytic domain evolves at a slower rate, but the extent and pattern of conservation of amino acids in the activation peptide suggest that the peptide functions as more than a cleavage spacer that separates the heavy and light chains in the catalytically inactive zymogen; (3) 37% of the amino acids in the activation peptide and 34% of the amino acids in the catalytic domain are factor IX-specific; i.e., they are either identical or changed in a highly conservative fashion in factor IX, but not in other related coagulation proteases; (4) these conserved factor IX-specific amino acids fall into three clusters, which are candidates for involvement in the protein interactions specific to factor IX; (5) there is a human-specific deletion after lysine 142 and a rodent-specific insertion after alanine 161; (6) in guinea pig, the insertion is associated with a seven-amino-acid repeat that corresponds to a perfect repeat of a 21-bp sequence; (7) humans have lost a potential N-glycosylation site that is conserved in the other species; (8) in each species, a few nonconservative changes occur in amino acids that are otherwise completely conserved, suggesting that compensatory mutations may have occurred; and (9) when compared to that of mouse, the amino acid identity with guinea pig factor IX is no greater than that found for the non-rodent species, a result compatible with the postulated increased rate of evolution in rodents. 2303254 4 67 gly domain 1263:1268 arg1 the catalytic domain are factor IX-specific; i.e., they are either identical or changed in a highly conservative fashion in factor IX, but not in other related coagulation proteases; (4) these conserved factor IX-specific amino acids fall into three clusters, which are candidates for involvement in the protein interactions specific to factor IX; (5) there is a human-specific deletion after lysine 142 and a rodent-specific insertion after alanine 161; (6) in guinea pig, the insertion is associated with a seven-amino-acid repeat that corresponds to a perfect repeat of a 21-bp sequence; (7) humans the catalytic domain are factor IX-specific; i.e., they are either identical or changed in a highly conservative fashion in factor IX, but not in other related coagulation proteases; (4) these conserved factor IX-specific amino acids fall into three clusters, which are candidates for involvement in the protein interactions specific to factor IX; (5) there is a human-specific deletion after lysine 142 and a rodent-specific insertion after alanine 161; (6) in guinea pig, the insertion is associated with a seven-amino-acid repeat that corresponds to a perfect repeat of a 21-bp sequence; (7) humans The results indicate that (1) 69% of the amino acids in the catalytic domain, but only 23% of the amino acids in the activation peptide, are identical in humans and the six species; (2) the catalytic domain evolves at a slower rate, but the extent and pattern of conservation of amino acids in the activation peptide suggest that the peptide functions as more than a cleavage spacer that separates the heavy and light chains in the catalytically inactive zymogen; (3) 37% of the amino acids in the activation peptide and 34% of the amino acids in the catalytic domain are factor IX-specific; i.e., they are either identical or changed in a highly conservative fashion in factor IX, but not in other related coagulation proteases; (4) these conserved factor IX-specific amino acids fall into three clusters, which are candidates for involvement in the protein interactions specific to factor IX; (5) there is a human-specific deletion after lysine 142 and a rodent-specific insertion after alanine 161; (6) in guinea pig, the insertion is associated with a seven-amino-acid repeat that corresponds to a perfect repeat of a 21-bp sequence; (7) humans have lost a potential N-glycosylation site that is conserved in the other species; (8) in each species, a few nonconservative changes occur in amino acids that are otherwise completely conserved, suggesting that compensatory mutations may have occurred; and (9) when compared to that of mouse, the amino acid identity with guinea pig factor IX is no greater than that found for the non-rodent species, a result compatible with the postulated increased rate of evolution in rodents. 2303254 4 125 gly sequence 1830:1837 arg1 a perfect repeat a perfect repeat The results indicate that (1) 69% of the amino acids in the catalytic domain, but only 23% of the amino acids in the activation peptide, are identical in humans and the six species; (2) the catalytic domain evolves at a slower rate, but the extent and pattern of conservation of amino acids in the activation peptide suggest that the peptide functions as more than a cleavage spacer that separates the heavy and light chains in the catalytically inactive zymogen; (3) 37% of the amino acids in the activation peptide and 34% of the amino acids in the catalytic domain are factor IX-specific; i.e., they are either identical or changed in a highly conservative fashion in factor IX, but not in other related coagulation proteases; (4) these conserved factor IX-specific amino acids fall into three clusters, which are candidates for involvement in the protein interactions specific to factor IX; (5) there is a human-specific deletion after lysine 142 and a rodent-specific insertion after alanine 161; (6) in guinea pig, the insertion is associated with a seven-amino-acid repeat that corresponds to a perfect repeat of a 21-bp sequence; (7) humans have lost a potential N-glycosylation site that is conserved in the other species; (8) in each species, a few nonconservative changes occur in amino acids that are otherwise completely conserved, suggesting that compensatory mutations may have occurred; and (9) when compared to that of mouse, the amino acid identity with guinea pig factor IX is no greater than that found for the non-rodent species, a result compatible with the postulated increased rate of evolution in rodents. 25501675 9 81 gly glycopeptides 1487:1499 arg2 additional glycopeptides additional glycopeptides glycopeptides In addition to those previously reported, additional glycopeptides were detected with moderate abundance. 26536155 6 5 gly glycoprotein 1442:1453 arg1 glycoprotein standards glycoprotein standards Fterm glycoprotein The approach was evaluated on glycoprotein standards and also applied to investigate the glycosylation of human IgG3 providing details on the hitherto uncharacterized glycosylation site Asn392 of the CH3 domain. 26536155 6 38 gly glycosylation 1501:1513 arg1 human IgG3 human IgG3 PUBTATOR IgG3 P01860 The approach was evaluated on glycoprotein standards and also applied to investigate the glycosylation of human IgG3 providing details on the hitherto uncharacterized glycosylation site Asn392 of the CH3 domain. 26536155 6 33 gly glycosylation 1579:1591 arg2 the hitherto uncharacterized glycosylation site Asn392 site Asn392 site Asn392 The approach was evaluated on glycoprotein standards and also applied to investigate the glycosylation of human IgG3 providing details on the hitherto uncharacterized glycosylation site Asn392 of the CH3 domain. 26536155 6 33 gly glycosylation 1579:1591 arg2 the CH3 domain domain domain The approach was evaluated on glycoprotein standards and also applied to investigate the glycosylation of human IgG3 providing details on the hitherto uncharacterized glycosylation site Asn392 of the CH3 domain. 26439794 9 57 gly glycoproteins 1366:1378 arg1 glycoproteins glycoproteins Fterm glycoproteins Our method provides new insights into transport, biosynthesis, and degradation of glycoproteins. 18369607 4 30 part_of regions 899:905 arg1 peptides regions peptides peptides The primary structure determination of a large number of peptides from the antibody variable regions was obtained through de novo interpretation of the data. 31296534 5 18 part_of STT3B-dependent 847:861 arg1 STT3B-dependent site STT3B STT3B-dependent site PUBTATOR Site STT3B Q8TCJ2 site Acceptor sites located in short loops of multi-spanning membrane proteins represent a new class of STT3B-dependent site. 1587858 6 39 gly N-glycosylation 1372:1386 arg2 the four N-glycosylation sites the four N-glycosylation sites sites The elimination of one of the four N-glycosylation sites by the alternative splicing of exon 9 and the differential regulation of this process by relevant cytokines and growth factors may represent a mechanism for the regulation of PGG/HS enzymatic activity under physiological or pathological conditions. 11344537 5 61 gly O-fucosylation 1213:1226 arg1 proteins proteins O-fucosylation Fterm proteins The abundance of glycosylated peptide fragment ions in MS(2) spectra suggests that nano-ESI Q-TOF mass spectrometry can be used as a general approach in structural studies of O-fucosylation in proteins. 1512415 0 43 part_of subunit 40:46 arg1 the human thyrotropin-beta subunit glycosylation site subunit the human thyrotropin-beta subunit glycosylation site Fterm Site subunit site Mutations of the human thyrotropin-beta subunit glycosylation site reduce thyrotropin synthesis independent of changes in glycosylation status. 1512415 0 48 part_of thyrotropin-beta 23:38 arg1 the human thyrotropin-beta subunit glycosylation site thyrotropin-beta the human thyrotropin-beta subunit glycosylation site OGER Site thyrotropin-beta site Mutations of the human thyrotropin-beta subunit glycosylation site reduce thyrotropin synthesis independent of changes in glycosylation status. 17097711 3 31 gly glycosylation 672:684 arg2 full-length (gp160), uncleaved (gp160-UNC), truncated (gp145), and N-linked glycosylation site deleted (gp160-201N/S) versions full-length (gp160), uncleaved (gp160-UNC), truncated (gp145), and N-linked glycosylation site deleted (gp160-201N/S) versions site Glycoprotein expressed from full-length (gp160), uncleaved (gp160-UNC), truncated (gp145), and N-linked glycosylation site deleted (gp160-201N/S) versions of the ConB env gene were packaged into virions and, except for the fusion defective gp160-UNC, mediated infection via the CCR5 co-receptor. 16186239 5 30 gly glycosylation 1200:1212 arg2 no newly acquired glycosylation sites no newly acquired glycosylation sites sites Analysis of the readapted variants revealed that the reacquisition of virulence was not necessarily achieved by reacquisition of the wild-type HA gene sequence, but was also associated either with the removal of a glycosylation site (the one acquired previously by the escape mutant) without the exact restoration of the initial wild-type amino acid sequence, or, for an H5 escape mutant that had no newly acquired glycosylation sites, with an additional amino acid change in a remote part of the HA molecule. 16186239 5 79 gly glycosylation 999:1011 arg2 a glycosylation site a glycosylation site site Analysis of the readapted variants revealed that the reacquisition of virulence was not necessarily achieved by reacquisition of the wild-type HA gene sequence, but was also associated either with the removal of a glycosylation site (the one acquired previously by the escape mutant) without the exact restoration of the initial wild-type amino acid sequence, or, for an H5 escape mutant that had no newly acquired glycosylation sites, with an additional amino acid change in a remote part of the HA molecule. 2825202 9 89 part_of found 1566:1570 arg1 mature SAP-1 AND One potential glycosylation site mature SAP-1 One potential glycosylation site PUBTATOR Site SAP-1 5660 site One potential glycosylation site was previously found in mature SAP-1. 1937055 5 11 part_of KEX2 806:809 arg1 the KEX2 protease cleavage site KEX2 protease the KEX2 protease cleavage site PUBTATOR Site KEX2 protease 855483 site The role of the KEX2 protease cleavage site was investigated by mutation of the yeast alpha-factor KEX2 site (cleavage after Lys-Arg). 1937055 5 33 part_of protease 811:818 arg1 the KEX2 protease cleavage site KEX2 protease the KEX2 protease cleavage site PUBTATOR Site KEX2 protease 855483 site The role of the KEX2 protease cleavage site was investigated by mutation of the yeast alpha-factor KEX2 site (cleavage after Lys-Arg). 1937055 5 38 part_of KEX2 889:892 arg1 cleavage after Lys-Arg KEX2 cleavage after Lys-Arg PUBTATOR Site KEX2 855483 Lys-Arg The role of the KEX2 protease cleavage site was investigated by mutation of the yeast alpha-factor KEX2 site (cleavage after Lys-Arg). 1937055 5 38 part_of KEX2 889:892 arg1 the yeast alpha-factor KEX2 site KEX2 the yeast alpha-factor KEX2 site PUBTATOR Site KEX2 855483 site The role of the KEX2 protease cleavage site was investigated by mutation of the yeast alpha-factor KEX2 site (cleavage after Lys-Arg). 22072749 5 56 part_of gp41 1050:1053 arg1 the cytoplasmic domain gp41 the cytoplasmic domain Cterm Site gp41 domain Sera from SIV-infected rhesus macaques consistently reacted with overlapping oligopeptides corresponding to a region located within the cytoplasmic domain of gp41 by the generally accepted model, at intensities comparable to those observed for immunodominant areas of the surface component gp120. 17636988 9 36 gly N-glycosylation 1619:1633 arg2 23 fucosylated N-glycosylation sites 23 fucosylated N-glycosylation sites sites In addition, Endo D/H digestion uniquely enabled identification of 23 fucosylated N-glycosylation sites. 17636988 9 80 gly fucosylated 1607:1617 arg1 23 fucosylated N-glycosylation sites 23 fucosylated N-glycosylation sites sites In addition, Endo D/H digestion uniquely enabled identification of 23 fucosylated N-glycosylation sites. 8289366 5 58 gly glycosylation 771:783 arg1 the third extracellular regions the third extracellular regions regions Two potential N-linked glycosylation sites are present in the third extracellular regions of both the NIH 3T3 and MDTF ecotropic receptors. 8289366 5 58 gly glycosylation 771:783 arg2 Two potential N-linked glycosylation sites Two potential N-linked glycosylation sites sites Two potential N-linked glycosylation sites are present in the third extracellular regions of both the NIH 3T3 and MDTF ecotropic receptors. 21846136 2 52 gly deglycosylated 776:789 arg1 the deglycosylated glycopeptide the deglycosylated glycopeptide glycopeptide With such a system, the deglycosylated glycopeptide from the digests of avidin with the coexistence of 50 times (mass ratio) BSA could be selectively detected, and the detection limit as low as 5 fmol was achieved. 21846136 2 73 gly glycopeptide 791:802 arg2 the deglycosylated glycopeptide the deglycosylated glycopeptide glycopeptide With such a system, the deglycosylated glycopeptide from the digests of avidin with the coexistence of 50 times (mass ratio) BSA could be selectively detected, and the detection limit as low as 5 fmol was achieved. 22649382 2 66 gly N-glycosylation 399:413 arg2 the four extracellular domain putative N-glycosylation sites the four extracellular domain putative N-glycosylation sites sites We probed the role of each of the four extracellular domain putative N-glycosylation sites for cell surface localization and function of the receptor. 19208354 8 3 part_of protein 1091:1097 arg1 an additional N-glycosylation site protein an additional N-glycosylation site Fterm Site protein site Interestingly, the mutation creates an additional N-glycosylation site that is characteristic of a temperature-sensitive protein. 31004621 2 122 part_of contain 453:459 arg1 both proteins AND potential glycosylation sites both proteins potential glycosylation sites Fterm Site proteins sites Two major RSV glycoproteins, attachment (G) and fusion (F) protein, regulate viral replication and both proteins contain potential glycosylation sites which are highly variable for the G protein and conserved for the F protein among virus isolates. 27140194 3 24 gly glycopeptide 399:410 arg2 Intact glycopeptide characterization Intact glycopeptide characterization glycopeptide Intact glycopeptide characterization, on the other hand, provides opportunities to simultaneously elucidate the glycan structure and the glycosylation site needed to reveal the actual biological function of protein glycosylation. 27140194 3 25 gly glycosylation 529:541 arg2 the glycosylation site the glycosylation site site Intact glycopeptide characterization, on the other hand, provides opportunities to simultaneously elucidate the glycan structure and the glycosylation site needed to reveal the actual biological function of protein glycosylation. 3485444 6 6 part_of protein 961:967 arg1 the carboxy terminus protein the carboxy terminus Fterm Site protein terminus It was then used to show that the glycosylation site of human band 3 is 28 000 +/- 3000 daltons from the carboxy terminus of the protein. 3485444 6 34 part_of terminus 945:952 arg1 the glycosylation site terminus the glycosylation site site It was then used to show that the glycosylation site of human band 3 is 28 000 +/- 3000 daltons from the carboxy terminus of the protein. 14749323 8 5 gly glycosylation 1484:1496 arg1 individual sites OAT sites OGER OAT P04181 sites Single replacement of asparagines at other sites had no effect on transport activity indicating that glycosylation at individual sites is not essential for OAT function. 14749323 8 5 gly glycosylation 1484:1496 arg2 individual sites OAT sites OGER OAT P04181 sites Single replacement of asparagines at other sites had no effect on transport activity indicating that glycosylation at individual sites is not essential for OAT function. 14749323 8 5 gly glycosylation 1484:1496 arg2 individual sites sites sites Single replacement of asparagines at other sites had no effect on transport activity indicating that glycosylation at individual sites is not essential for OAT function. 9201996 8 74 gly glycosylation 1328:1340 arg2 the glycosylation site the glycosylation site site The deletion of amino acids from the N-terminal side of the glycosylation site suggested that five amino acids from position -1 to +3 were especially important for glycosylation. 30427586 4 8 gly glycopeptide 897:908 arg2 glycopeptide enrichment glycopeptide enrichment glycopeptide Further, a modified and improved version of cotton hydrophilic interaction liquid chromatography-based solid phase extraction for glycopeptide enrichment is described. 17496250 14 81 gly O-glycosylation 1638:1652 arg1 insulin-like growth factor insulin-like growth factor Fterm factor Phosphorylation and O-glycosylation both affected IGFBP-5 binding to heparin but not insulin-like growth factor binding or ternary complex formation with the acid-labile subunit. 21637915 2 45 gly glycosylated 238:249 arg1 a glycosylated transmembrane protein a glycosylated transmembrane protein Fterm protein Emmprin is a glycosylated transmembrane protein containing two immunoglobulin (Ig) domains that is expressed in carcinoma cells and stimulates MMP production by adjacent stromal cells. 21637915 2 45 gly glycosylated 238:249 arg1 Emmprin Emmprin PUBTATOR Emmprin 682 Emmprin is a glycosylated transmembrane protein containing two immunoglobulin (Ig) domains that is expressed in carcinoma cells and stimulates MMP production by adjacent stromal cells. 8991508 8 10 gly O-glycosylated 964:977 arg1 The third domain The third domain domain The third domain lacks a repeat motif, but is rich in both Thr and Ser, and therefore is potentially highly O-glycosylated. 14691230 4 66 gly glycosylation 705:717 arg2 each glycosylation site each glycosylation site site However, the importance of each glycosylation site on physiologically relevant reactions such as dipeptide cleavage, dimer formation, and adenosine deaminase (ADA) binding remains obscure. 23776650 3 21 gly Immunoreceptor 447:460 arg1 glycan specificity Dendritic Cell Immunoreceptor glycan specificity OGER Dendritic Cell Immunoreceptor Q9UMR7 Little is known on the glycan specificity and ligands of the Dendritic Cell Immunoreceptor (DCIR), the only classical C-type lectin that contains an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM). 12734349 6 37 gly N-glycosylation 970:984 arg2 a single N-glycosylation site a single N-glycosylation site site Analysis of glycosylation pattern demonstrates the usage of a single N-glycosylation site, while no O-glycosylation is observed. 3137277 1 38 part_of interferon-beta 120:134 arg1 The complete amino acid sequence interferon-beta 1 The complete amino acid sequence PUBTATOR Site interferon-beta 1 3456 sequence The complete amino acid sequence of fibroblast human interferon-beta 1 (IFN-beta 1) was determined, and the higher-order structure of the protein was characterized with Raman spectroscopy. 7980452 1 24 gly glycoprotein 146:157 arg1 a secretory glycoprotein a secretory glycoprotein Fterm glycoprotein Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain. 7980452 1 24 gly glycoprotein 146:157 arg1 Human interferon-gamma Human interferon-gamma PUBTATOR Human interferon-gamma 3458 Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain. 7980452 1 53 gly glycosylation 193:205 arg2 two potential N-linked glycosylation sites two potential N-linked glycosylation sites sites Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain. 7980452 1 88 gly positions 216:224 arg1 Asn-97 positions Asn-25 and Asn-97 positions Asn-25 and Asn-97 Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain. 7980452 1 88 gly positions 216:224 arg1 Asn-25 positions Asn-25 and Asn-97 positions Asn-25 and Asn-97 Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain. 7980452 1 88 gly positions 216:224 arg1 Asn-25 positions Asn-25 and Asn-97 positions Asn-25 and Asn-97 Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain. 7620335 1 11 gly residues 274:281 arg1 two O-linked oligosaccharides Thr17 and Thr29 residues two O-linked oligosaccharides Thr17 and Thr29 residues Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa. 7620335 1 11 gly residues 274:281 arg1 two N-linked oligosaccharides Thr17 and Thr29 residues two N-linked oligosaccharides Thr17 and Thr29 residues Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa. 7620335 1 14 gly residues 212:219 arg1 two O-linked oligosaccharides Asn39 and Asn49 residues two O-linked oligosaccharides Asn39 and Asn49 residues Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa. 7620335 1 14 gly residues 212:219 arg1 two N-linked oligosaccharides Asn39 and Asn49 residues two N-linked oligosaccharides Asn39 and Asn49 residues Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa. 7620335 1 59 gly has 159:161 arg1 Human blood coagulation factor X AND two N-linked oligosaccharides Human blood coagulation factor X two N-linked oligosaccharides OGER factor X P00742 Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa. 7620335 1 59 gly has 159:161 arg1 Human blood coagulation factor X AND two O-linked oligosaccharides Human blood coagulation factor X two O-linked oligosaccharides OGER factor X P00742 Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa. 10942407 3 92 part_of Jk 813:814 arg1 the wild-type Jk polypeptide Jk the wild-type Jk polypeptide Cterm Site Jk polypeptide Transcription-translation assays revealed that the Jk(S291P) mutant was translated into a glycosylated component as efficiently as the wild-type Jk polypeptide (wt Jk)] in the presence of microsomes, thus indicating that the S291P mutation has no effect on the N-glycosylation pattern of the Jk protein. 9295302 8 82 part_of sites 1356:1360 arg1 MRP MRP sites PUBTATOR Site MRP 4363 sites Subsequent site-directed mutagenesis studies established that Asn19 and Asn23 in the NH2-terminal MSD and Asn1006 in the COOH-terminal MSD are the only sites in MRP that are modified with N-linked oligosaccharides. 31912551 12 19 gly glycosylation 1758:1770 arg2 the Asn-297 glycosylation site the Asn-297 glycosylation site site Additionally, maternal serum from allergic mothers had significantly higher levels of pro-inflammatory IgG1, shown by decreased galactosylation and sialylation at the Asn-297 glycosylation site. 20077667 6 84 gly glycosylation 1096:1108 arg2 the 3 glycosylation site the 3 glycosylation site site In F gene,the 3 glycosylation site (aa32, aa64 and aa70), aa112 and aa195 which played the important role to viral fusion had no changes. 8806496 0 11 part_of protein 78:84 arg1 the N-linked glycosylation sites NS1 protein the N-linked glycosylation sites PUBTATOR Site NS1 protein 10625 sites Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence. 22015141 4 27 gly N-glycosylation 804:818 arg2 the N-glycosylation site the N-glycosylation site site These results indicate that deletion of the N-glycosylation site in the PCV2 Cap protein enhances specific immune responses and may have a role in Cap-based DNA vaccines with enhanced immunogenicity. 20378933 6 5 gly glycosylation 736:748 arg2 glycosylation site glycosylation site site To identify which glycosylation site is responsible for increased IgA binding, we performed site-directed mutagenesis at each N-linked glycosylation site by changing asparagine to glutamine. 20378933 6 38 gly glycosylation 853:865 arg2 each N-linked glycosylation site each N-linked glycosylation site site To identify which glycosylation site is responsible for increased IgA binding, we performed site-directed mutagenesis at each N-linked glycosylation site by changing asparagine to glutamine. 2500441 4 34 gly glycosylation 675:687 arg2 The glycosylation site The glycosylation site site The glycosylation site was determined to threonine-29 (Thr29), by 1H NMR spectroscopy and protein sequence analysis of an isolated tryptic peptide(22-36). 28630087 10 54 gly glycosylation 1662:1674 arg2 The three glycosylation sites HNE sites PUBTATOR HNE 1991 sites The three glycosylation sites of HNE were located distal to the active site indicating glycan functions other than interference with HNE enzyme activity. 18956678 11 27 gly glycosylation 1620:1632 arg2 glycosylation sites glycosylation sites sites The sequences at the receptor-binding sites and glycosylation sites were conserved. 22407978 3 19 gly N-glycosylation 502:516 arg2 Asn297 Asn297 Asn297 Human IgGs have an N-glycosylation site at Asn297, located in the second heavy chain constant region (CH2). 22407978 3 19 gly N-glycosylation 502:516 arg2 an N-glycosylation site an N-glycosylation site site Human IgGs have an N-glycosylation site at Asn297, located in the second heavy chain constant region (CH2). 14749323 6 60 gly glycosylated 1022:1033 arg1 Asp-39 Asp-39 Asp-39 We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated. 14749323 6 60 gly glycosylated 1022:1033 arg1 the corresponding site the corresponding site site We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated. 14749323 6 72 gly glycosylated 960:971 arg1 the putative glycosylation site Asp-39 the putative glycosylation site Asp-39 site Asp-39 We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated. 14749323 6 43 gly glycosylation 917:929 arg2 Asp-39 site Asp-39 site Asp-39 We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated. 21569239 8 34 part_of found 1130:1134 arg2 mindin AND The integrin-binding motif mindin The integrin-binding motif PUBTATOR Site mindin 10417 motif The integrin-binding motif found in mindin is not conserved in the F-spondin FS domain. 21569239 8 51 part_of F-spondin 1170:1178 arg1 the F-spondin FS domain F-spondin the F-spondin FS domain PUBTATOR Site F-spondin 10418 domain The integrin-binding motif found in mindin is not conserved in the F-spondin FS domain. 8188681 4 6 gly glycosylation 981:993 arg1 beta Tyr9 beta Tyr9 Tyr9 At each FSH beta glycosylation site, we made a second amino acid substitution to inhibit glycosylation (beta Tyr9 and beta Tyr26) and an amino acid substitution that preserved glycosylation (beta Ser9 and beta Ser26). 8188681 4 6 gly glycosylation 981:993 arg1 beta Tyr26 beta Tyr26 Tyr26 At each FSH beta glycosylation site, we made a second amino acid substitution to inhibit glycosylation (beta Tyr9 and beta Tyr26) and an amino acid substitution that preserved glycosylation (beta Ser9 and beta Ser26). 8188681 4 40 gly glycosylation 1068:1080 arg1 beta Ser9 beta Ser9 Ser9 At each FSH beta glycosylation site, we made a second amino acid substitution to inhibit glycosylation (beta Tyr9 and beta Tyr26) and an amino acid substitution that preserved glycosylation (beta Ser9 and beta Ser26). 8188681 4 40 gly glycosylation 1068:1080 arg1 beta Ser26 beta Ser26 Ser26 At each FSH beta glycosylation site, we made a second amino acid substitution to inhibit glycosylation (beta Tyr9 and beta Tyr26) and an amino acid substitution that preserved glycosylation (beta Ser9 and beta Ser26). 8188681 4 71 gly glycosylation 909:921 arg2 each FSH beta glycosylation site each FSH beta glycosylation site site At each FSH beta glycosylation site, we made a second amino acid substitution to inhibit glycosylation (beta Tyr9 and beta Tyr26) and an amino acid substitution that preserved glycosylation (beta Ser9 and beta Ser26). 28630087 0 55 gly N-glycosylation 18:32 arg1 Spatiotemporally Regulated Human Neutrophil Elastase Spatiotemporally Regulated Human Neutrophil Elastase PUBTATOR Human Neutrophil Elastase 1991 Paucimannose-Rich N-glycosylation of Spatiotemporally Regulated Human Neutrophil Elastase Modulates Its Immune Functions. 28630087 0 122 gly Elastase 81:88 arg1 Paucimannose-Rich N-glycosylation Human Neutrophil Elastase Paucimannose-Rich N-glycosylation PUBTATOR Human Neutrophil Elastase 1991 Paucimannose-Rich N-glycosylation of Spatiotemporally Regulated Human Neutrophil Elastase Modulates Its Immune Functions. 9292017 0 9 gly glycoprotein 63:74 arg1 the envelope glycoprotein gene the envelope glycoprotein gene Fterm glycoprotein Extensive nucleotide changes and deletions within the envelope glycoprotein gene of Euro-African West Nile viruses. 23808883 7 71 gly glycosylated 1275:1286 arg1 differentially glycosylated IgGs differentially glycosylated IgGs Cterm IgGs Under physiological conditions, differentially glycosylated IgGs mediate their pro- or anti-inflammatory effector functions obviously as immune complexes (IC) in an antigen-specific manner. 1535241 2 99 part_of protein 404:410 arg1 structural motifs Wnt-1 protein structural motifs PUBTATOR Site Wnt-1 protein 22408 motifs To attempt to correlate structural motifs of Wnt-1 protein with its function, 12 mutations were introduced singly and in several combinations into the coding sequence of Wnt-1 cDNA by site-directed mutagenesis. 3594570 1 27 gly glycoproteins 261:273 arg1 Mac-1 Mac-1 PUBTATOR Mac-1 3689 Leukocyte adhesion deficiency (LAD) is a heritable disease involving deficient expression of three related leukocyte adhesion glycoproteins: LFA-1, Mac-1, and p150,95. 3594570 1 27 gly glycoproteins 261:273 arg1 p150,95 p150,95 PUBTATOR p150 10036 Leukocyte adhesion deficiency (LAD) is a heritable disease involving deficient expression of three related leukocyte adhesion glycoproteins: LFA-1, Mac-1, and p150,95. 3594570 1 27 gly glycoproteins 261:273 arg1 LFA-1 LFA-1 PUBTATOR LFA-1 3683 Leukocyte adhesion deficiency (LAD) is a heritable disease involving deficient expression of three related leukocyte adhesion glycoproteins: LFA-1, Mac-1, and p150,95. 3594570 1 27 gly glycoproteins 261:273 arg1 three related leukocyte adhesion glycoproteins three related leukocyte adhesion glycoproteins Fterm glycoproteins Leukocyte adhesion deficiency (LAD) is a heritable disease involving deficient expression of three related leukocyte adhesion glycoproteins: LFA-1, Mac-1, and p150,95. 15100290 1 30 gly found 85:89 arg1 the V region AND N-Linked carbohydrates the V region N-Linked carbohydrates region N-Linked carbohydrates are frequently found in the V region of Ig H chains and can have a positive or negative effect on Ag binding affinity. 30172908 3 39 part_of PsGILT 494:499 arg1 a 5'-untranslated region PsGILT a 5'-untranslated region PUBTATOR Site PsGILT 102460690 region The full-length cDNA of PsGILT is 1631 nucleotides (nt), including a 5'-untranslated region (UTR) of 3 nt, a 3'-UTR of 860 nt and an open reading frame (ORF) of 768 nt encoding 255 amino acids (aa). 31004621 2 103 gly glycosylation 471:483 arg2 potential glycosylation sites potential glycosylation sites sites Two major RSV glycoproteins, attachment (G) and fusion (F) protein, regulate viral replication and both proteins contain potential glycosylation sites which are highly variable for the G protein and conserved for the F protein among virus isolates. 31004621 2 113 gly glycoproteins 354:366 arg1 fusion (F) protein fusion (F) protein Fterm protein Two major RSV glycoproteins, attachment (G) and fusion (F) protein, regulate viral replication and both proteins contain potential glycosylation sites which are highly variable for the G protein and conserved for the F protein among virus isolates. 31004621 2 113 gly glycoproteins 354:366 arg1 Two major RSV glycoproteins Two major RSV glycoproteins Fterm glycoproteins Two major RSV glycoproteins, attachment (G) and fusion (F) protein, regulate viral replication and both proteins contain potential glycosylation sites which are highly variable for the G protein and conserved for the F protein among virus isolates. 22762186 4 39 part_of TRAIL 849:853 arg1 the functional extracellular domains TRAIL the functional extracellular domains OGER Site TRAIL P50591 domains In contrast to the efficient production of the functional extracellular domains of TRAIL, TNFα and LTα by intracellular expression systems using Escherichia coli or Pichia pastoris, that of Fas ligand requires the secretory expression systems using P. pastoris or Dictyostelium discoideum, and the productivity in P. pastoris was largely dependent on tag sequence, potential N-glycosylation site and expressed protein region. 12235182 0 30 gly terminus 43:50 arg1 The N-linked oligosaccharides terminus The N-linked oligosaccharides terminus The N-linked oligosaccharides at the amino terminus of human apoB are important for the assembly and secretion of VLDL. 21645732 0 54 gly N-glycosylation 26:40 arg2 N-glycosylation sites N-glycosylation sites sites Large-scale assignment of N-glycosylation sites using complementary enzymatic deglycosylation. 9104789 4 21 gly glycosylation 454:466 arg2 No potential glycosylation site No potential glycosylation site site No potential glycosylation site was found in the predicted protein. 7730609 3 19 gly N-glycosylation 457:471 arg2 an N-glycosylation site an N-glycosylation site site We have established transgenic A.CA mice expressing either the wild-type E alpha d molecule (E alpha/E beta), or an E alpha d molecule altered at an N-glycosylation site on the E alpha chain (residue 78, 78E alpha/E beta or residue 118, 118E alpha/E beta) to identify a possible role for carbohydrates in thymic selection and peripheral T cell activation. 7730609 3 65 gly altered 443:449 arg1 residue 118 residue 118 residue 118 We have established transgenic A.CA mice expressing either the wild-type E alpha d molecule (E alpha/E beta), or an E alpha d molecule altered at an N-glycosylation site on the E alpha chain (residue 78, 78E alpha/E beta or residue 118, 118E alpha/E beta) to identify a possible role for carbohydrates in thymic selection and peripheral T cell activation. 7730609 3 65 gly altered 443:449 arg1 residue 78 residue 78 residue 78 We have established transgenic A.CA mice expressing either the wild-type E alpha d molecule (E alpha/E beta), or an E alpha d molecule altered at an N-glycosylation site on the E alpha chain (residue 78, 78E alpha/E beta or residue 118, 118E alpha/E beta) to identify a possible role for carbohydrates in thymic selection and peripheral T cell activation. 28327546 3 81 gly N-glycosylation 340:354 arg1 FVIII FVIII N582 PUBTATOR FVIII 2157 N582 Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking. 28327546 3 81 gly N-glycosylation 340:354 arg1 the A2 domain domain domain Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking. 28327546 3 81 gly N-glycosylation 340:354 arg1 FVIII FVIII domain PUBTATOR FVIII 2157 domain Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking. 28327546 3 81 gly N-glycosylation 340:354 arg1 FVIII FVIII domain PUBTATOR FVIII 2157 domain Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking. 28327546 3 81 gly N-glycosylation 340:354 arg1 FVIII FVIII site PUBTATOR FVIII 2157 site Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking. 28835497 2 89 gly glycoprotein 256:267 arg1 Glycoprotein K Glycoprotein K Cterm Glycoprotein K (gK Glycoprotein K (gK) is a conserved virion glycoprotein of all alphaherpesviruses that is not found in other herpesvirus subfamilies. 28835497 2 89 gly glycoprotein 256:267 arg1 a conserved virion glycoprotein a conserved virion glycoprotein Fterm glycoprotein Glycoprotein K (gK) is a conserved virion glycoprotein of all alphaherpesviruses that is not found in other herpesvirus subfamilies. 11583587 4 1 gly N-glycosylation 629:643 arg2 a single N-glycosylation site a single N-glycosylation site site The DD16 cDNA encoded a polypeptide of 415 amino acids containing a single N-glycosylation site and an N-terminal hydrophobic stretch of 19 amino acids forming a transmembrane segment, indicating that DD16 is a glycosylated membrane-bound protein. 11583587 4 42 gly glycosylated 765:776 arg1 a glycosylated membrane-bound protein a glycosylated membrane-bound protein Fterm protein The DD16 cDNA encoded a polypeptide of 415 amino acids containing a single N-glycosylation site and an N-terminal hydrophobic stretch of 19 amino acids forming a transmembrane segment, indicating that DD16 is a glycosylated membrane-bound protein. 25451932 0 77 part_of corin 56:60 arg1 different sites corin different sites PUBTATOR Site corin 10699 sites Distinct roles of N-glycosylation at different sites of corin in cell membrane targeting and ectodomain shedding. 21673010 7 57 gly hormone 1015:1021 arg1 two N-glycan sites growth hormone two N-glycan sites PUBTATOR growth hormone 81668 For this purpose, rat growth hormone (rGH) with two N-glycan sites (rGH-2N) inserted into the rGH portion (NAS and NFT) was fused to green fluorescent protein (GFP) and expressed in MDCK cells. 2317204 6 45 part_of sites 824:828 arg1 human link proteins proteins sites Fterm Site proteins sites Both cathepsins L and B generate multiple but distinct cleavage sites on human link proteins, and the hydrolysed bonds have been identified in the region between residues 18 and 29. 3023956 2 23 gly glycosylation 388:400 arg2 an N glycosylation site an N glycosylation site site Ten exons, 1,414 base pairs spanning 26 kilobases, contained a tyrosine kinase domain, a transmembrane domain, and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus. 9294006 2 10 gly N-glycosylation 428:442 arg2 one potential N-glycosylation site one potential N-glycosylation site site Mouse CD151 mRNA comprises approximately 1.8 kb, has 253 amino acid residues with 93% identity to human CD151 and contains four putative transmembrane domains, a number of cysteine residues and one potential N-glycosylation site located at a site corresponding to that in human CD151. 9294006 2 10 gly N-glycosylation 428:442 arg1 cysteine residues cysteine residues cysteine residues Mouse CD151 mRNA comprises approximately 1.8 kb, has 253 amino acid residues with 93% identity to human CD151 and contains four putative transmembrane domains, a number of cysteine residues and one potential N-glycosylation site located at a site corresponding to that in human CD151. 3148445 6 50 gly glycosylated 980:991 arg1 the human protein protein site Fterm protein site The site at Asn-187 is glycosylated in the human protein, revealing a different glycosylation pattern between the human and rat proteins. 3148445 6 50 gly glycosylated 980:991 arg2 The site site site The site at Asn-187 is glycosylated in the human protein, revealing a different glycosylation pattern between the human and rat proteins. 3148445 6 50 gly glycosylated 980:991 arg2 The site protein site Fterm protein site The site at Asn-187 is glycosylated in the human protein, revealing a different glycosylation pattern between the human and rat proteins. 20422033 5 81 part_of envelope 778:785 arg1 356 HIV-1 subtype C gp160 envelope (env) gene sequences gp160 envelope 356 HIV-1 subtype C gp160 envelope (env) gene sequences PUBTATOR Site gp160 envelope 155971 sequences METHODOLOGY/PRINCIPAL FINDINGS: We compared 356 HIV-1 subtype C gp160 envelope (env) gene sequences from the plasma and breast milk of 13 breastfeeding women. 20422033 5 84 part_of env 788:790 arg1 356 HIV-1 subtype C gp160 envelope (env) gene sequences env 356 HIV-1 subtype C gp160 envelope (env) gene sequences PUBTATOR Site env 155971 sequences METHODOLOGY/PRINCIPAL FINDINGS: We compared 356 HIV-1 subtype C gp160 envelope (env) gene sequences from the plasma and breast milk of 13 breastfeeding women. 20422033 5 100 part_of gp160 772:776 arg1 356 HIV-1 subtype C gp160 envelope (env) gene sequences gp160 envelope 356 HIV-1 subtype C gp160 envelope (env) gene sequences PUBTATOR Site gp160 envelope 155971 sequences METHODOLOGY/PRINCIPAL FINDINGS: We compared 356 HIV-1 subtype C gp160 envelope (env) gene sequences from the plasma and breast milk of 13 breastfeeding women. 18829751 2 10 part_of sites 513:517 arg1 gp41 gp41 sites Cterm Site gp41 sites We infected rhesus monkeys with a variant of cloned SIVmac239 lacking the second and third sites or with a variant strain lacking all three of SIVmac239's glycosylation sites in gp41. 31826991 14 56 gly have 2317:2320 arg1 H3 HAs AND one or more key high-mannose glycosites H3 HAs one or more key high-mannose glycosites OGER H3 HAs Q92839 While it is known that both H1 and H3 HAs have one or more key high-mannose glycosites in the head region, little is known about similar glycosylation of LPAIV strains H2N1, H5N1, H6N1, or H11N9, which may pose future health risks. 31507595 1 6 gly glycosylation 166:178 arg2 asparagine 3 asparagine 3 asparagine 3 Human CD52 is a small glycopeptide (12 amino acid residues) with one N-linked glycosylation site at asparagine 3 (Asn3) and several potential O-glycosylation serine/threonine sites. 31507595 1 6 gly glycosylation 166:178 arg2 one N-linked glycosylation site one N-linked glycosylation site site Human CD52 is a small glycopeptide (12 amino acid residues) with one N-linked glycosylation site at asparagine 3 (Asn3) and several potential O-glycosylation serine/threonine sites. 31507595 1 6 gly glycosylation 166:178 arg2 Asn3 Asn3 Asn3 Human CD52 is a small glycopeptide (12 amino acid residues) with one N-linked glycosylation site at asparagine 3 (Asn3) and several potential O-glycosylation serine/threonine sites. 31507595 1 6 gly glycosylation 166:178 arg2 several potential O-glycosylation serine/threonine sites several potential O-glycosylation serine/threonine sites sites Human CD52 is a small glycopeptide (12 amino acid residues) with one N-linked glycosylation site at asparagine 3 (Asn3) and several potential O-glycosylation serine/threonine sites. 31507595 1 20 gly glycopeptide 110:121 arg2 12 amino acid residues 12 amino acid residues residues Human CD52 is a small glycopeptide (12 amino acid residues) with one N-linked glycosylation site at asparagine 3 (Asn3) and several potential O-glycosylation serine/threonine sites. 31507595 1 20 gly glycopeptide 110:121 arg2 a small glycopeptide a small glycopeptide glycopeptide Human CD52 is a small glycopeptide (12 amino acid residues) with one N-linked glycosylation site at asparagine 3 (Asn3) and several potential O-glycosylation serine/threonine sites. 31507595 1 48 gly O-glycosylation 230:244 arg2 several potential O-glycosylation serine/threonine sites several potential O-glycosylation serine/threonine sites sites Human CD52 is a small glycopeptide (12 amino acid residues) with one N-linked glycosylation site at asparagine 3 (Asn3) and several potential O-glycosylation serine/threonine sites. 15737642 2 27 gly N-glycosylation 541:555 arg2 potential N-glycosylation sites potential N-glycosylation sites sites To obtain insight into the structure of beta3GnT2, the effects of N-glycosylation on its biological function were evaluated using the addition of inhibitors, site-directed mutagenesis of potential N-glycosylation sites, and deletion of its N-terminal region using a fusion protein with GFP(uv) in a baculovirus expression system. 8193553 0 39 gly O-glycans 36:44 arg1 recombinant glycophorin A glycophorin A O-glycans PUBTATOR glycophorin A 2993 Biochemical characterization of the O-glycans on recombinant glycophorin A expressed in Chinese hamster ovary cells. 15538777 1 3 gly glycosylation 199:211 arg2 glycosylation sites glycosylation sites sites In glycoproteomics, key structural issues, protein identification, locations of glycosylation sites, and evaluation of the glycosylation site microheterogeneity should be easily evaluated in a large number of glycoproteins, while mass spectrometry (MS) provides substantial information about individual purified glycoproteins. 15538777 1 24 gly glycoproteins 328:340 arg1 glycoproteins glycoproteins Fterm glycoproteins In glycoproteomics, key structural issues, protein identification, locations of glycosylation sites, and evaluation of the glycosylation site microheterogeneity should be easily evaluated in a large number of glycoproteins, while mass spectrometry (MS) provides substantial information about individual purified glycoproteins. 15538777 1 35 gly glycosylation 242:254 arg2 the glycosylation site microheterogeneity the glycosylation site microheterogeneity site In glycoproteomics, key structural issues, protein identification, locations of glycosylation sites, and evaluation of the glycosylation site microheterogeneity should be easily evaluated in a large number of glycoproteins, while mass spectrometry (MS) provides substantial information about individual purified glycoproteins. 15538777 1 118 gly glycoproteins 431:443 arg1 individual purified glycoproteins individual purified glycoproteins Fterm glycoproteins In glycoproteomics, key structural issues, protein identification, locations of glycosylation sites, and evaluation of the glycosylation site microheterogeneity should be easily evaluated in a large number of glycoproteins, while mass spectrometry (MS) provides substantial information about individual purified glycoproteins. 24527708 7 48 gly N-glycosylated 1298:1311 arg1 N-glycosylated sites N-glycosylated sites sites The established workflow, together with the profile of N-glycosylated sites, will contribute to the improvement of S. cerevisiae model for revealing the pathogenesis of CDG. 30898876 5 6 gly presence 1178:1185 arg1 protein 1 low-density lipoprotein receptor-related protein 1 presence PUBTATOR low-density lipoprotein receptor-related protein 1 4035 Our results further revealed that LDN presence on low-density lipoprotein receptor-related protein 1 and nicastrin depends on B3GALNT2, indicating the occurrence of type-I LDN in vivo in mammalian cells. 30898876 5 6 gly presence 1178:1185 arg1 nicastrin nicastrin presence OGER nicastrin Q92542 Our results further revealed that LDN presence on low-density lipoprotein receptor-related protein 1 and nicastrin depends on B3GALNT2, indicating the occurrence of type-I LDN in vivo in mammalian cells. 26773038 4 59 part_of VWF 624:626 arg1 the VWF A2 domain VWF the VWF A2 domain PUBTATOR Site VWF 7450 domain We investigated how the N-linked glycans of the VWF A2 domain affect thermostability and regulate both the exposure of the ADAMTS13 binding sites and the scissile bond. 26062906 3 10 gly glycosylation 550:562 arg2 Asn4 Asn4 Asn4 Among these envelope proteins, the middle HBV surface antigen (MHBs) contains a constitutive N-linked glycosylation site at position 4 (Asn4) in the amino-terminal portion (MQWNSTTFHQ) of pre-S2 domain. 26062906 3 10 gly glycosylation 550:562 arg2 position 4 position 4 position 4 Among these envelope proteins, the middle HBV surface antigen (MHBs) contains a constitutive N-linked glycosylation site at position 4 (Asn4) in the amino-terminal portion (MQWNSTTFHQ) of pre-S2 domain. 26062906 3 10 gly glycosylation 550:562 arg2 a constitutive N-linked glycosylation site a constitutive N-linked glycosylation site site Among these envelope proteins, the middle HBV surface antigen (MHBs) contains a constitutive N-linked glycosylation site at position 4 (Asn4) in the amino-terminal portion (MQWNSTTFHQ) of pre-S2 domain. 17684490 4 53 gly glycosylation 589:601 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site Both NRG4A1 and NRG4A2 were shown to be expressed on the cell surface, as expected by the presence of a predicted transmembrane sequence, and were modified at a single N-linked glycosylation site in the extracellular domain. 17634239 3 68 gly glycosylation 507:519 arg2 position 295 position 295 position 295 This has been attributed to the absence of a glycosylation site at position 295 in most subtype C gp120s, which instead is typically occupied by a Val residue. 17634239 3 68 gly glycosylation 507:519 arg2 a glycosylation site a glycosylation site site This has been attributed to the absence of a glycosylation site at position 295 in most subtype C gp120s, which instead is typically occupied by a Val residue. 17634239 3 79 gly occupied 595:602 arg2 position 295 position 295 position 295 This has been attributed to the absence of a glycosylation site at position 295 in most subtype C gp120s, which instead is typically occupied by a Val residue. 17634239 3 79 gly occupied 595:602 arg2 a glycosylation site a glycosylation site site This has been attributed to the absence of a glycosylation site at position 295 in most subtype C gp120s, which instead is typically occupied by a Val residue. 18700760 4 38 gly glycoproteins 683:695 arg1 glycoproteins glycoproteins Fterm glycoproteins Here an approach is presented that that uses alpha-2,6-sialyltransferase (ST6Gal-I) to enzymatically add 13C-N-acetylneuraminic acid (NeuAc or sialic acid) to glycoproteins after their preparation using nonbacterial hosts. 8034709 10 83 part_of proteinases 1319:1329 arg1 the conserved active site regions proteinases the conserved active site regions Fterm Site proteinases regions The deduced amino acid sequence contains the conserved active site regions of serine proteinases. 8034709 10 68 part_of contains 1266:1273 arg1 The deduced amino acid sequence AND the conserved active site regions The deduced amino acid sequence the conserved active site regions regions The deduced amino acid sequence contains the conserved active site regions of serine proteinases. 24048266 6 59 gly glycosylation 965:977 arg2 glycosylation sites glycosylation sites sites Hence, there is a significant interest in the development of computational methods for reliable prediction of glycosylation sites from amino acid sequences. 19116267 2 19 part_of HA 205:206 arg1 The HA receptor-binding domain HA The HA receptor-binding domain Cterm Site HA domain The HA receptor-binding domain determines the species of sialyl receptors recognized by influenza viruses. 19116267 2 66 part_of receptor-binding 208:223 arg1 The HA receptor-binding domain receptor The HA receptor-binding domain Fterm Site receptor domain The HA receptor-binding domain determines the species of sialyl receptors recognized by influenza viruses. 10942407 4 20 part_of Jk 1028:1029 arg1 the Jk(S291P) polypeptide Jk the Jk(S291P) polypeptide Cterm Site Jk polypeptide Expression studies in Xenopus oocytes revealed that the Jk(S291P) polypeptide functions as a urea transporter, but the transport activity and the membrane expression level of the mutant protein was reduced to a similar extent. 9140197 0 14 gly glycoproteins 58:70 arg1 Puumala virus envelope glycoproteins G1 and G2 Puumala virus envelope glycoproteins G1 and G2 Fterm glycoproteins Single amino acid substitutions in Puumala virus envelope glycoproteins G1 and G2 eliminate important neutralization epitopes. 9140197 0 14 gly glycoproteins 58:70 arg1 G2 G2 Cterm G2 2813 Single amino acid substitutions in Puumala virus envelope glycoproteins G1 and G2 eliminate important neutralization epitopes. 9140197 0 14 gly glycoproteins 58:70 arg1 G1 G1 Cterm G1 5544 Single amino acid substitutions in Puumala virus envelope glycoproteins G1 and G2 eliminate important neutralization epitopes. 7479385 4 94 gly contains 771:778 arg1 PSA AND a carbohydrate residue PSA a carbohydrate residue PUBTATOR PSA 354 The predominant PSA molecular species detected by ISMS was at relative molecular mass (M(r)) of 28,430, indicating that PSA contains a carbohydrate residue of M(r) 2,351, for a total percentage of carbohydrate of 8.3%. 22078945 5 53 gly N-glycosylation 604:618 arg2 position 509 position 509 position 509 The position 509 (NKTN) was the potential N-glycosylation site. 22078945 5 53 gly N-glycosylation 604:618 arg2 the potential N-glycosylation site the potential N-glycosylation site site The position 509 (NKTN) was the potential N-glycosylation site. 7727375 5 11 gly O-glycosylation 843:857 arg2 Thr125 Thr125 Thr125 and Ser126 One form was glycosylated only at residue 125, and a second form was glycosylated at both Thr125 and Ser126, the normal O-glycosylation site. 7727375 5 11 gly O-glycosylation 843:857 arg2 the normal O-glycosylation site the normal O-glycosylation site site One form was glycosylated only at residue 125, and a second form was glycosylated at both Thr125 and Ser126, the normal O-glycosylation site. 7727375 5 38 gly glycosylated 736:747 arg2 residue 125 residue 125 residue 125 One form was glycosylated only at residue 125, and a second form was glycosylated at both Thr125 and Ser126, the normal O-glycosylation site. 7727375 5 43 gly glycosylated 792:803 arg2 the normal O-glycosylation site the normal O-glycosylation site site One form was glycosylated only at residue 125, and a second form was glycosylated at both Thr125 and Ser126, the normal O-glycosylation site. 7727375 5 43 gly glycosylated 792:803 arg2 Thr125 Thr125 and Ser126 Thr125 and Ser126 One form was glycosylated only at residue 125, and a second form was glycosylated at both Thr125 and Ser126, the normal O-glycosylation site. 8366859 3 8 gly glycoprotein 394:405 arg1 a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein Fterm glycoprotein The antigen is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids and one N-linked glycosylation site at Asn3. 8366859 3 25 gly glycosylation 477:489 arg2 Asn3 Asn3 Asn3 The antigen is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids and one N-linked glycosylation site at Asn3. 8366859 3 25 gly glycosylation 477:489 arg2 one N-linked glycosylation site one N-linked glycosylation site site The antigen is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids and one N-linked glycosylation site at Asn3. 3932064 9 26 gly glycosylation 1070:1082 arg2 one possible N-linked glycosylation site one possible N-linked glycosylation site site The 32-kd polypeptide sequence consisted of 210 amino acids and had one possible N-linked glycosylation site. 22815146 5 64 gly glycosylation 864:876 arg2 predicted N-linked glycosylation sites predicted N-linked glycosylation sites sites Interestingly, neutralization-sensitive viruses all had predicted N-linked glycosylation sites at N137 or N142, with threonine (T) occupying position 144 of HA. 2574658 1 3 gly glycoprotein 157:168 arg1 a multifunctional glycoprotein a multifunctional glycoprotein Fterm glycoprotein Nidogen, a multifunctional glycoprotein, is an integral part of all basement membranes. 27127844 10 25 gly unglycosylated 1313:1326 arg1 the unglycosylated subunit the unglycosylated subunit Fterm subunit Cycloheximide pulse-chase experiments showed that the unglycosylated subunit degraded at a higher rate than the N-glycosylated form. 8286855 9 49 gly glycosylation 1234:1246 arg1 GpA GpA domain PUBTATOR GpA 2993 domain These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA. 8286855 9 49 gly glycosylation 1234:1246 arg1 the extracellular domain domain domain These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA. 8286855 9 49 gly glycosylation 1234:1246 arg1 GpA GpA Ser/Thr PUBTATOR GpA 2993 Ser/Thr These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA. 8286855 9 49 gly glycosylation 1234:1246 arg1 21 of 22 Ser/Thr Ser/Thr Ser/Thr These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA. 8286855 9 49 gly glycosylation 1234:1246 arg1 the extracellular domain GpA domain PUBTATOR GpA 2993 domain These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA. 8286855 9 49 gly glycosylation 1234:1246 arg1 21 of 22 Ser/Thr GpA Ser/Thr PUBTATOR GpA 2993 Ser/Thr These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA. 21111695 3 12 part_of contained 712:720 arg1 a glycosylated protein AND a glycosylation site a glycosylated protein a glycosylation site Fterm Site protein site Results of western blot analysis showed that about 36 kDa make specific antibodies appeared specific antibodies in antiserum of immune mice, whereas the best immune effects became visible at the induction time of 48 h. Analyses of 2-dimensional electrophoresis identified the specific antigen was annexin A2, which was a glycosylated protein that contained a glycosylation site, closely related to oncogenesis, cancer development, invasion and metastasis. 21111695 3 12 part_of contained 712:720 arg1 annexin A2 AND a glycosylation site annexin A2 a glycosylation site PUBTATOR Site annexin A2 12306 site Results of western blot analysis showed that about 36 kDa make specific antibodies appeared specific antibodies in antiserum of immune mice, whereas the best immune effects became visible at the induction time of 48 h. Analyses of 2-dimensional electrophoresis identified the specific antigen was annexin A2, which was a glycosylated protein that contained a glycosylation site, closely related to oncogenesis, cancer development, invasion and metastasis. 25751231 2 27 gly glycosylation 393:405 arg2 25 potential N-linked glycosylation sites 25 potential N-linked glycosylation sites sites METHODS: In our previous work, 25 potential N-linked glycosylation sites (PNGS) of a CRF07_BC isolate of HIV-1 were individually mutated, and the resulting effects on infectivity and antibody-mediated neutralization were evaluated. 7543206 3 37 gly glycosylated 523:534 arg2 Asn371 Asn371 Asn371 Comparison of wild-type and mutant products revealed that Asn371 is rarely glycosylated in Chinese hamster ovary cells. 10989127 12 43 gly N-glycosylation 1751:1765 arg2 A second potential N-glycosylation site A second potential N-glycosylation site site A second potential N-glycosylation site was observed at a location further in the polypeptide chain. 25220145 5 91 gly CF-glycoproteins 1106:1121 arg1 209 CF-glycoproteins 209 CF-glycoproteins Fterm CF-glycoproteins To demonstrate the feasibility of LHNCE, the CF-glycopeptides of target proteins in clinical plasma samples were applied and compared as a preliminary demonstration and resulted in the assignment of 357 unique CF-glycosylation sites from 209 CF-glycoproteins. 25220145 5 102 gly CF-glycosylation 1074:1089 arg2 357 unique CF-glycosylation sites 357 unique CF-glycosylation sites sites To demonstrate the feasibility of LHNCE, the CF-glycopeptides of target proteins in clinical plasma samples were applied and compared as a preliminary demonstration and resulted in the assignment of 357 unique CF-glycosylation sites from 209 CF-glycoproteins. 25220145 5 62 gly CF-glycopeptides 909:924 arg2 the CF-glycopeptides proteins CF-glycopeptides Fterm proteins CF-glycopeptides To demonstrate the feasibility of LHNCE, the CF-glycopeptides of target proteins in clinical plasma samples were applied and compared as a preliminary demonstration and resulted in the assignment of 357 unique CF-glycosylation sites from 209 CF-glycoproteins. 2113054 9 12 gly glycopeptides 1559:1571 arg2 glycopeptides glycopeptides glycopeptides The disulfide bonds of sCD4 were determined to be within domains 1, 2, and 4 and isolation of glycopeptides showed that both N-linked sites were glycosylated. 2113054 9 80 gly glycosylated 1610:1621 arg1 both N-linked sites both N-linked sites sites The disulfide bonds of sCD4 were determined to be within domains 1, 2, and 4 and isolation of glycopeptides showed that both N-linked sites were glycosylated. 17579075 9 69 gly glycosylation 1150:1162 arg2 a glycosylation site a glycosylation site site Altering D15 (found in man) to N15 (found in rhesus) introduced a glycosylation site that blocked binding to Por1A gonococci. 7904345 2 14 part_of sCD4 303:306 arg1 domain 3 sCD4 domain 3 PUBTATOR Site sCD4 79966 domain The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing. 7904345 2 43 part_of sCD4 421:424 arg1 the non-conserved glycosylation site sCD4 the non-conserved glycosylation site PUBTATOR Site sCD4 499358 site The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing. 7904345 2 60 part_of site 269:272 arg1 human sCD4 sCD4 site PUBTATOR Site sCD4 79966 site The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing. 28714086 11 8 part_of modified 2073:2080 arg1 both the modified sugars subunit both the modified sugars Fterm Site subunit position In the present study, we show that altering glycan content on kainate receptors (KARs) changes the functional properties of the receptors in a manner dependent on the identity of both the modified sugars and the subunit composition of the receptor to which they are attached. 7615551 5 79 part_of proteins 767:774 arg1 one consensus N-glycosylation site proteins one consensus N-glycosylation site Fterm Site proteins site KS43 and KS32 encoded proteins with multiple hydrophobic domains, one consensus N-glycosylation site, and predicted molecular masses of 65 and 58 kDa, respectively. 7615551 5 79 part_of proteins 767:774 arg1 multiple hydrophobic domains proteins multiple hydrophobic domains Fterm Site proteins domains KS43 and KS32 encoded proteins with multiple hydrophobic domains, one consensus N-glycosylation site, and predicted molecular masses of 65 and 58 kDa, respectively. 1331083 2 12 gly glycosylation 545:557 arg2 The glycosylation sites The glycosylation sites sites The glycosylation sites were introduced into the cathepsin D cDNA by site-directed mutagenesis and were selected to be widely distributed over the surface of the molecule. 25499076 5 45 gly present 859:865 arg1 native, pituitary G-hPRL AND the N-glycan structures native, pituitary G-hPRL the N-glycan structures PUBTATOR hPRL 5617 The main objective of this study was to determine the N-glycan structures present in native, pituitary G-hPRL and compare them with those present in the recombinant hormone. 9249051 6 69 gly glycosylation 1382:1394 arg2 the glycosylation site the glycosylation site site It also provides results suggesting that the carbohydrate moiety reduces the local mobility around the glycosylation site, which could be responsible for the stabilising effect observed on the glycoprotein. 9249051 6 73 gly glycoprotein 1472:1483 arg1 the glycoprotein the glycoprotein Fterm glycoprotein It also provides results suggesting that the carbohydrate moiety reduces the local mobility around the glycosylation site, which could be responsible for the stabilising effect observed on the glycoprotein. 10597188 9 41 gly N-glycosylation 1564:1578 arg2 Asn-85 Asn-85 Asn-85 We also detected a splicing variant lacking exon 4, which includes the nucleotide sequence encoding the potential N-glycosylation site at Asn-85. 10597188 9 41 gly N-glycosylation 1564:1578 arg2 the potential N-glycosylation site the potential N-glycosylation site site We also detected a splicing variant lacking exon 4, which includes the nucleotide sequence encoding the potential N-glycosylation site at Asn-85. 9030779 1 22 gly asparagine-linked 209:225 arg1 asparagine-linked oligosaccharides asparagine asparagine-linked oligosaccharides asparagine Most soluble lysosomal enzymes require a mannose-6-phosphate recognition marker present on asparagine-linked oligosaccharides for proper targeting to lysosomes. 1402395 3 30 gly glycosylation 417:429 arg2 a glycosylation site a glycosylation site site All four saposins are structurally similar to one another including placement of six cysteines, a glycosylation site, and conserved prolines in identical positions. 1402395 3 30 gly glycosylation 417:429 arg1 six cysteines cysteines cysteines All four saposins are structurally similar to one another including placement of six cysteines, a glycosylation site, and conserved prolines in identical positions. 19193194 3 27 gly glycosylation 924:936 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site The deduced protein, BbPlgl, consisted of 430 amino acids, which is structurally characterized by the presence of an N-terminal signal peptide of 16 amino acids, 2 kringle domains with a Lys-binding site structure, a serine protease domain with the putative tPA (tissue plasminogen activator)-cleavage site (between Arg297 and Val298), the catalytic triad His237-Asp288-Ser379 expected for protease function, and a potential N-linked glycosylation site, all characteristic of Plgs. 12527193 0 34 gly linked 51:56 arg2 protein AND Mammalian Crumbs3 protein Mammalian Crumbs3 Fterm protein Mammalian Crumbs3 is a small transmembrane protein linked to protein associated with Lin-7 (Pals1). 25213400 3 20 gly glycoproteins 206:218 arg1 Other myelin glycoproteins Other myelin glycoproteins Fterm glycoproteins Other myelin glycoproteins, also with a single glycosylation site (PMP22 at Asn(36) , MOG at Asn(31) ), bind only one glycan. 25213400 3 78 gly glycosylation 240:252 arg2 a single glycosylation site a single glycosylation site site Other myelin glycoproteins, also with a single glycosylation site (PMP22 at Asn(36) , MOG at Asn(31) ), bind only one glycan. 11087995 3 48 gly glycosylation 606:618 arg2 the two putative N-linked glycosylation sites the two putative N-linked glycosylation sites sites The influence of the amino-terminal domain and of the two putative N-linked glycosylation sites located in this region of rat sst3 was analysed. 18829751 10 3 gly carbohydrates 1866:1878 arg1 the ectodomain the ectodomain the ectodomain Site ectodomain Based on the reactivity of antibodies to peptides in this region and the colocalization of neutralization escape mutations, we conclude that N-linked carbohydrates in the ectodomain of the transmembrane protein shield underlying epitopes that would otherwise be the direct targets of neutralizing antibodies. 18829751 10 3 gly carbohydrates 1866:1878 arg1 the transmembrane protein protein carbohydrates Fterm protein Based on the reactivity of antibodies to peptides in this region and the colocalization of neutralization escape mutations, we conclude that N-linked carbohydrates in the ectodomain of the transmembrane protein shield underlying epitopes that would otherwise be the direct targets of neutralizing antibodies. 31944613 4 14 gly glycosylation 677:689 arg2 HA head glycosylation sites 144, 158 or 169 HA head glycosylation sites 144, 158 or 169 sites In this study, several AIVs with different deletions at HA head glycosylation sites 144, 158 or 169 were tested for their biological characteristics to clarify the possible mechanism. 25202310 4 17 gly glycoproteins 877:889 arg1 secreted glycoproteins secreted glycoproteins Fterm glycoproteins Detailed subcellular glycome profiling of proteins derived from three breast cell lines (MCF7/MDA468/MCF10A) demonstrated that secreted glycoproteins displayed significantly more α-sialylation and α1,6-fucosylation, but less α-mannosylation, than both the intermediately glycan-processed cell-surface glycoproteomes and the under-processed microsomal glycoproteomes. 29842980 9 51 gly glycoprotein 1448:1459 arg1 VP7 glycoprotein VP7 glycoprotein Fterm glycoprotein Presence of additional N-linked glycosylation site at amino acid 283 of VP7 glycoprotein suggests that the major neutralizing epitope on the VP7 (G3) of RotaTeq vaccine differs from the currently circulating G3 strains. 29842980 9 39 gly glycosylation 1404:1416 arg1 VP7 glycoprotein glycoprotein site Fterm glycoprotein site Presence of additional N-linked glycosylation site at amino acid 283 of VP7 glycoprotein suggests that the major neutralizing epitope on the VP7 (G3) of RotaTeq vaccine differs from the currently circulating G3 strains. 8509412 9 15 gly glycosylation 1310:1322 arg1 Asn727 Asn727 Asn727 The mutants lacking glycosylation at Asn727 appear to be retained in the endoplasmic reticulum as an increased association with binding immunoglobulin protein (BiP) is observed. 28322444 1 13 gly glycosylated 198:209 arg1 The potassium ion channel Kv3.1b The potassium ion channel Kv3.1b Cterm Kv3.1b The potassium ion channel Kv3.1b is a member of a family of voltage-gated ion channels that are glycosylated in their mature form. 3896487 0 12 part_of glycoprotein 101:112 arg1 individual glycosylation sites glycoprotein individual glycosylation sites Fterm Site glycoprotein sites Isolation of glycopeptides containing individual glycosylation sites of Friend murine leukemia virus glycoprotein: studies of glycosylation by methylation analysis. 11002250 7 25 gly aa 1210:1211 arg1 leucine leucine leucine These changes to VP7 occurred within the glycosylation site at aa 70 (leucine to serine), at antigenic region A (aa 96, asparagine to threonine), and at aa 318 (aspartic acid to glycine). 11002250 7 42 gly glycosylation 1188:1200 arg2 the glycosylation site the glycosylation site site These changes to VP7 occurred within the glycosylation site at aa 70 (leucine to serine), at antigenic region A (aa 96, asparagine to threonine), and at aa 318 (aspartic acid to glycine). 11002250 7 61 gly aa 1300:1301 arg1 aspartic acid aspartic acid aspartic acid These changes to VP7 occurred within the glycosylation site at aa 70 (leucine to serine), at antigenic region A (aa 96, asparagine to threonine), and at aa 318 (aspartic acid to glycine). 11002250 7 65 gly A 1257:1257 arg1 asparagine asparagine asparagine These changes to VP7 occurred within the glycosylation site at aa 70 (leucine to serine), at antigenic region A (aa 96, asparagine to threonine), and at aa 318 (aspartic acid to glycine). 25707740 7 47 gly O-glycosylation 847:861 arg2 four sites sites sites The hCG β-subunit contains two sites of N-glycosylation and four sites of O-glycosylation and is encoded by a cluster of genes (CGB). 25707740 7 92 gly N-glycosylation 813:827 arg2 four sites sites sites The hCG β-subunit contains two sites of N-glycosylation and four sites of O-glycosylation and is encoded by a cluster of genes (CGB). 32331833 6 11 gly glycosylation 1026:1038 arg2 the glycosylation site mutant DMP1-PG (S89-G89, S89G-DMP1) mouse the glycosylation site mutant DMP1-PG (S89-G89, S89G-DMP1) mouse site To further detect the potential function of DMP1-PG in the defect healing, we employed a bone defect intramembranous ossification model using the glycosylation site mutant DMP1-PG (S89-G89, S89G-DMP1) mouse. 9442070 13 46 gly Fc 2176:2177 arg1 sialylation IgA1 Fc sialylation OGER IgA1 Fc P01876 The accessibility of the Cα 2 N-glycans provides an explanation for the increased sialylation and galactosylation of IgA1 Fc over that of IgG Fc N-glycans, which are confined in the space between the two Cγ 2 domains. 9442070 13 93 gly sialylation 2136:2146 arg1 IgA1 Fc IgA1 Fc OGER IgA1 Fc P01876 The accessibility of the Cα 2 N-glycans provides an explanation for the increased sialylation and galactosylation of IgA1 Fc over that of IgG Fc N-glycans, which are confined in the space between the two Cγ 2 domains. 27038031 4 8 gly glycopeptides 688:700 arg2 HILIC-enriched tryptic and GluC glycopeptides HILIC-enriched tryptic and GluC glycopeptides glycopeptides In this study, the N-glycosylation of recombinant pentameric and hexameric IgM produced by the same human cell type and culture conditions was site-specifically profiled by RP-LC-CID/ETD-MS/MS using HILIC-enriched tryptic and GluC glycopeptides. 27038031 4 20 gly N-glycosylation 476:490 arg1 recombinant pentameric and hexameric IgM recombinant pentameric and hexameric IgM OGER IgM P01871 In this study, the N-glycosylation of recombinant pentameric and hexameric IgM produced by the same human cell type and culture conditions was site-specifically profiled by RP-LC-CID/ETD-MS/MS using HILIC-enriched tryptic and GluC glycopeptides. 27664852 4 4 gly N-glycosylation 669:683 arg2 Asn47 Asn47 Asn47 The heavier chain contains one N-glycosylation site (Asn47) occupied with either pauci-mannose type [GlcNAc2(Fuc)Man3(Xyl)] or complex type [GlcNAc2(Fuc)Man3(Xyl)GlcNAc(Fuc)Gal] N-glycans. 27664852 4 4 gly N-glycosylation 669:683 arg2 one N-glycosylation site one N-glycosylation site site The heavier chain contains one N-glycosylation site (Asn47) occupied with either pauci-mannose type [GlcNAc2(Fuc)Man3(Xyl)] or complex type [GlcNAc2(Fuc)Man3(Xyl)GlcNAc(Fuc)Gal] N-glycans. 2041080 6 13 gly HA1 1200:1202 arg1 the carbohydrate HA1 the carbohydrate Cterm HA1 The observation that these mutants were not cleaved, even when the carbohydrate at asparagine 22 of HA1 was absent, underscores the fact that the basic peptide had to be generated by insertion to obtain cleavage. 2041080 6 60 gly asparagine 1183:1192 arg1 the carbohydrate asparagine 22 the carbohydrate asparagine 22 The observation that these mutants were not cleaved, even when the carbohydrate at asparagine 22 of HA1 was absent, underscores the fact that the basic peptide had to be generated by insertion to obtain cleavage. 23661698 9 52 gly glycosylation 1255:1267 arg1 ephrin-A1 ephrin-A1 PUBTATOR ephrin-A1 1942 These findings suggest that the glycosylation on ephrin-A1 plays a critical role in the binding and activation of the EphA2 receptor. 29867209 2 58 gly glycoproteins 264:276 arg1 glycoproteins glycoproteins Fterm glycoproteins Nevertheless glycoproteins with an identical polypeptide backbone mostly differ in their glycosylation patterns. 2033065 0 110 gly Glycosylation 0:12 arg1 human protein C human protein C OGER protein C P02810 Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. 25499264 2 52 gly gp120 440:444 arg1 multiple N-linked glycans envelope glycoprotein gp120 multiple N-linked glycans PUBTATOR envelope glycoprotein gp120 Q14624 The development of phenotypic resistance to CBAs by the virus is accompanied by the deletion of multiple N-linked glycans of the surface envelope glycoprotein gp120. 25499264 2 128 gly glycoprotein 427:438 arg1 the surface envelope glycoprotein gp120 the surface envelope glycoprotein gp120 PUBTATOR envelope glycoprotein gp120 Q14624 The development of phenotypic resistance to CBAs by the virus is accompanied by the deletion of multiple N-linked glycans of the surface envelope glycoprotein gp120. 8286061 10 14 gly glycosylation 1649:1661 arg2 the glycosylation site the glycosylation site site Two functional motifs in the V3 loop, i.e., the glycosylation site and the GPG-crest, form defined structures: a turn is located at the glycosylation site, and the GPG-crest forms a protruding domain with a type-II GPGQ turn. 8286061 10 46 gly glycosylation 1737:1749 arg2 the glycosylation site the glycosylation site site Two functional motifs in the V3 loop, i.e., the glycosylation site and the GPG-crest, form defined structures: a turn is located at the glycosylation site, and the GPG-crest forms a protruding domain with a type-II GPGQ turn. 2324102 3 8 gly containing 546:555 arg1 three domains AND putative glycosaminoglycan attachment sites three domains putative glycosaminoglycan attachment sites domains 108, 1547-1556), the core protein of human syndecan can be divided into three domains: a matrix-interacting ectodomain containing putative glycosaminoglycan attachment sites, a 25-residue hydrophobic membrane-spanning domain, and a 34-residue cytoplasmic domain. 2324102 3 8 gly containing 546:555 arg1 a matrix-interacting ectodomain AND putative glycosaminoglycan attachment sites a matrix-interacting ectodomain putative glycosaminoglycan attachment sites ectodomain 108, 1547-1556), the core protein of human syndecan can be divided into three domains: a matrix-interacting ectodomain containing putative glycosaminoglycan attachment sites, a 25-residue hydrophobic membrane-spanning domain, and a 34-residue cytoplasmic domain. 2324102 3 50 gly domains 505:511 arg1 a 25-residue hydrophobic membrane-spanning domain domain domain 108, 1547-1556), the core protein of human syndecan can be divided into three domains: a matrix-interacting ectodomain containing putative glycosaminoglycan attachment sites, a 25-residue hydrophobic membrane-spanning domain, and a 34-residue cytoplasmic domain. 24627221 3 27 part_of protein 699:705 arg1 the pro-domain protein the pro-domain Fterm AminoAcid protein pro In our recent study of the functional consequences of matrix metalloproteinase (MMP)-9 SNPs, we discovered that expression of a coding exon SNP in the pro-domain of the protein resulted in a profound decrease in the secreted protein. 16720579 6 24 gly N-glycosylation 1244:1258 arg2 the fourth N-glycosylation site the fourth N-glycosylation site site Wild-type recombinant C6ST-1 showed a typical Golgi localization, whereas M-4 recombinant C6ST-1, in which the fourth N-glycosylation site was deleted, colocalized with calnexin, an endoplasmic reticulum-resident protein. 24527708 4 28 gly glycopeptides 743:755 arg2 the enriched glycopeptides the enriched glycopeptides glycopeptides To enhance the reliability of the identified results, the enriched glycopeptides were subjected to parallel deglycosylation by using two endoglycosidases (i.e., PNGase F and Endo Hf), respectively, prior to LC-MS/MS analysis. 29891966 3 22 part_of IGF-1 391:395 arg1 a common IGF-1 mature sequence IGF-1 a common IGF-1 mature sequence PUBTATOR Site IGF-1 3479 sequence These proIGF-1s have a common IGF-1 mature sequence but different E-domains. 1584795 3 70 part_of neurophysin 821:831 arg1 a neurophysin domain neurophysin a neurophysin domain Fterm Site neurophysin domain The predicted preproconopressin has the overall architecture of vertebrate preprovasopressin, with a signal peptide, Lys-conopressin, that is flanked at the C terminus by an amidation signal and a pair of basic residues, followed by a neurophysin domain. 15911445 1 64 gly glycoproteins 273:285 arg1 glycoproteins glycoproteins Fterm glycoproteins BACKGROUND: Influenza A viruses are divided into subtypes based on their hemagglutinin (H1 to H15) and neuraminidase (N1 to N9) glycoproteins. 17766267 4 28 gly containing 887:896 arg1 a peptide AND alpha-linked GalNAc a peptide alpha-linked GalNAc The three variants were evaluated for their ability to use a derivitized monosaccharide, a GM2 ganglioside mimic, a GA2 ganglioside mimic as well as a peptide containing alpha-linked GalNAc. 1970443 13 71 part_of G2 2185:2186 arg1 the SR-11 G2 coding sequences SR-11 G2 the SR-11 G2 coding sequences Cterm Site SR-11 G2 sequences One potential glycosylation site was identified in the SR-11 G2 coding sequences and was conserved among Hantaan, SR-11 and Hällnäs viruses. 1970443 13 107 part_of SR-11 2179:2183 arg1 the SR-11 G2 coding sequences SR-11 G2 the SR-11 G2 coding sequences Cterm Site SR-11 G2 sequences One potential glycosylation site was identified in the SR-11 G2 coding sequences and was conserved among Hantaan, SR-11 and Hällnäs viruses. 22122935 6 39 gly glycopeptide 1200:1211 arg2 this glycopeptide this glycopeptide glycopeptide In the case of O(126), different sialoforms with different types of sialic acids (Neu5Gc and Neu5Ac) were detected and an estimation of the relative percentage of Neu5Gc versus Neu5Ac was also carried out for this glycopeptide. 17134389 4 80 gly glycoproteins 657:669 arg1 Recombinant glycoproteins Recombinant glycoproteins Fterm glycoproteins Recombinant glycoproteins could be retained within the endoplasmic reticulum (ER) to prevent such glycan modifications occurring in the late Golgi compartment. 2033065 7 4 gly glycosylation 1316:1328 arg2 glycosylation sites glycosylation sites sites However, elimination of glycosylation sites in the heavy chain resulted in a 2- to 3-fold increase in anticoagulant activity. 2187193 3 87 part_of tryptase 410:417 arg1 The C-terminal undecapeptide tryptase The C-terminal undecapeptide PUBTATOR Site tryptase 100049001 undecapeptide The C-terminal undecapeptide of the human preprosequence is identical in dog tryptase and appears to be part of a prosequence unique among serine proteases. 23763973 11 12 gly glycosylation 1089:1101 arg2 a predicted N-linked glycosylation site a predicted N-linked glycosylation site site CL2 has a predicted N-linked glycosylation site confirmed by using mass spectrometry. 1856695 9 86 part_of protein 1620:1626 arg1 the N terminus TCV M protein the N terminus OGER Site TCV M protein P54296 terminus A potential N-glycosylation site was found at the N terminus of the TCV M protein and is situated at the same location in BCV, MHV and transmissible gastroenteritis virus. 29775240 1 13 gly glycopeptides 267:279 arg2 intact glycopeptides intact glycopeptides glycopeptides SugarQb (www.imba.oeaw.ac.at/sugarqb) is a freely available collection of computational tools for the automated identification of intact glycopeptides from high-resolution HCD MS/MS datasets in the Proteome Discoverer environment. 21172408 1 3 gly glycoprotein 179:190 arg1 Tissue factor Tissue factor PUBTATOR Tissue factor 2152 BACKGROUND: Tissue factor (TF) is a single polypeptide integral membrane glycoprotein composed of 263 residues and is essential to life in its role as the initiator of blood coagulation. 21172408 1 3 gly glycoprotein 179:190 arg1 a single polypeptide integral membrane glycoprotein a single polypeptide integral membrane glycoprotein Fterm glycoprotein BACKGROUND: Tissue factor (TF) is a single polypeptide integral membrane glycoprotein composed of 263 residues and is essential to life in its role as the initiator of blood coagulation. 27604319 1 35 gly glycoprotein 148:159 arg1 SU SU Cterm SU Q14624 The surface envelope glycoprotein (SU) of Human immunodeficiency virus type 1 (HIV-1), gp120(SU) plays an essential role in virus binding to target CD4+ T-cells and is a major vaccine target. 27604319 1 35 gly glycoprotein 148:159 arg1 The surface envelope glycoprotein The surface envelope glycoprotein PUBTATOR envelope glycoprotein 155971 The surface envelope glycoprotein (SU) of Human immunodeficiency virus type 1 (HIV-1), gp120(SU) plays an essential role in virus binding to target CD4+ T-cells and is a major vaccine target. 9733824 7 109 part_of RNA 1403:1405 arg1 plasma RNA sequences RNA plasma RNA sequences Cterm Site RNA sequences Sequences derived from plasma viral RNA were found to be more closely related than corresponding viral DNA sequences, and protection correlated with a significant reduction in variation in plasma RNA sequences in animals given the identical inocula of HIV-2287. 2502393 2 93 part_of protein 509:515 arg1 a C-terminal poly(lysine) sequence protein (B-mutant precursor a C-terminal poly(lysine) sequence OGER Site protein (B-mutant precursor Q8IVL6 sequence Translation of mRNA for the mutant (Brattleboro) vasopressin precursor which lacks a translational stop codon as a consequence of a frame-shift mutation, gives rise to a mutated protein (B-mutant precursor) with a C-terminal poly(lysine) sequence encoded by the poly(A) tail. 20512925 10 57 gly N-glycans 1432:1440 arg1 RAGE RAGE N-glycans PUBTATOR RAGE Q15109 These results demonstrate that carboxylated N-glycans on RAGE enhance binding potential and promote receptor clustering and subsequent signaling events following oligomeric S100A12 binding. 9689919 4 52 part_of PEDF 562:565 arg1 a human PEDF cDNA fragment PEDF a human PEDF cDNA fragment PUBTATOR Site PEDF 5176 fragment Northern analysis of RNA from bovine retinal pigment epithelium (RPE) and neural retina using a human PEDF cDNA fragment reveals expression of the PEDF gene only for RPE. 22577028 8 44 gly glycoforms 1518:1527 arg2 each specific glycosylation site each specific glycosylation site site The relative abundance of the glycoforms at each specific glycosylation site and the relative quantitation for each glycoform among three HAs were determined. 22577028 8 53 gly glycosylation 1546:1558 arg2 each specific glycosylation site each specific glycosylation site site The relative abundance of the glycoforms at each specific glycosylation site and the relative quantitation for each glycoform among three HAs were determined. 9254044 1 6 gly glycoproteins 327:339 arg1 glycoproteins glycoproteins Fterm glycoproteins Glucosidase II is an ER resident glycoprotein involved in the processing of N-linked glycans and probably a component of the ER quality control of glycoproteins. 9254044 1 23 gly glycoprotein 213:224 arg1 Glucosidase II Glucosidase II OGER Glucosidase II Glucosidase II is an ER resident glycoprotein involved in the processing of N-linked glycans and probably a component of the ER quality control of glycoproteins. 9254044 1 23 gly glycoprotein 213:224 arg1 an ER resident glycoprotein an ER resident glycoprotein Fterm glycoprotein Glucosidase II is an ER resident glycoprotein involved in the processing of N-linked glycans and probably a component of the ER quality control of glycoproteins. 26336134 7 46 gly glycosylation 1007:1019 arg1 HRG HRG PUBTATOR HRG 3273 The glycosylation of HRG may play a key competitive role in the interaction between HRG and heparin sulfate for binding bFGF and activating the FGF receptor. 10080942 5 23 part_of precursor 990:998 arg1 the inherent signal peptide precursor the inherent signal peptide Fterm Site precursor peptide Therefore, a simultaneous attachment of a carbohydrate moiety to N86 and N266, cleavage of the propeptide from the single DNase II precursor, and the inherent signal peptide might be required for subcellular sorting and proteolytic maturation of the enzyme. 27641734 7 161 gly N-glycosylation 1168:1182 arg2 Potential N-glycosylation sites Potential N-glycosylation sites sites Potential N-glycosylation sites were identified using MS and were modulated with PNGase F digestion and glyco-site mutations. 9832151 4 16 gly glycosylation 586:598 arg2 the glycosylation sites the glycosylation sites sites Therefore, to assess the contribution of each of the glycosylation sites to the transporter activity, the three putative N-glycosylation sites were mutated individually, in combination, and in toto ("triple" mutant). 9832151 4 57 gly N-glycosylation 654:668 arg2 the three putative N-glycosylation sites the three putative N-glycosylation sites sites Therefore, to assess the contribution of each of the glycosylation sites to the transporter activity, the three putative N-glycosylation sites were mutated individually, in combination, and in toto ("triple" mutant). 20888351 7 10 gly glycosylation 1178:1190 arg2 the glycosylation site the glycosylation site site Mutation of Asn68 to Gln in the heavy chain of scFv 9B9 eliminated the glycosylation site and significantly improved the binding affinity of scFv 9B9 to human ACE as determined by cell ELISA and Western Blot. 15616123 8 49 gly glycosylation 1413:1425 arg2 a site a site site Our data showed that Asn2212, not previously identified as a site of glycosylation, could be glycosylated. 15616123 8 54 gly glycosylated 1437:1448 arg1 Asn2212 Asn2212 Asn2212 Our data showed that Asn2212, not previously identified as a site of glycosylation, could be glycosylated. 15128311 2 43 gly glycosylated 130:141 arg1 different glycosylated proteins different glycosylated proteins Fterm proteins There are different glycosylated proteins in snake venoms, but no glycosylated representatives of a large family of three-fingered toxins have previously been detected. 12488050 1 13 gly N-glycosylation 344:358 arg2 a single N-glycosylation site a single N-glycosylation site site The hexose transporter family, which mediates a facilitated uptake in mammalian cells, consists of more than 10 members containing 12 membrane-spanning segments with a single N-glycosylation site. 27023253 5 43 gly glycopeptides 847:859 arg2 glycopeptides glycopeptides glycopeptides Though some high-throughput purification schemes have been developed, they have yet to find widespread adoption and often rely on the enrichment of glycopeptides. 2477364 8 64 gly glycopeptides 1231:1243 arg1 the wild-type subunits subunits glycopeptides Fterm subunits glycopeptides Second, tryptic glycopeptides of the wild-type subunits were examined. 25220145 6 68 gly CF-glycosylation 1164:1179 arg2 the largest human plasma CF-glycosylation site database the largest human plasma CF-glycosylation site database site In this study, the largest human plasma CF-glycosylation site database was constructed, and at least three-fold more CF-sites were identified compared to previously published studies. 15737642 7 68 gly N-glycosylation 1516:1530 arg2 Asn219 Asn219 Asn219 These results suggest that the N-glycosylation site at Asn219, which is conserved throughout the beta1,3-glycosyltransferase family, is indispensable not only with regard to its biological function, but also to its secretion. 15737642 7 68 gly N-glycosylation 1516:1530 arg2 the N-glycosylation site the N-glycosylation site site These results suggest that the N-glycosylation site at Asn219, which is conserved throughout the beta1,3-glycosyltransferase family, is indispensable not only with regard to its biological function, but also to its secretion. 12867358 5 18 gly N-glycosylation 839:853 arg2 two N-glycosylation site two N-glycosylation site site Wild-type hNaSi-1 and two N-glycosylation site mutant proteins, N591Y and N591A, were functionally expressed and studied in Xenopus oocytes. 29944110 2 37 gly glycoprotein 346:357 arg1 the haemagglutinin glycoprotein the haemagglutinin glycoprotein Fterm glycoprotein The impact can be reduced by vaccination, which induces neutralizing antibodies that mainly target the haemagglutinin glycoprotein (HA). 18703501 7 48 gly glycosylation 1295:1307 arg2 Asn(309) Asn(309) Asn(309) Mass spectrometry experiments showed that CA IX contains an intramolecular disulfide bridge (Cys(119)-Cys(299)) and a unique N-linked glycosylation site (Asn(309)) that bears high mannose-type glycan structures. 18703501 7 48 gly glycosylation 1295:1307 arg2 a unique N-linked glycosylation site a unique N-linked glycosylation site site Mass spectrometry experiments showed that CA IX contains an intramolecular disulfide bridge (Cys(119)-Cys(299)) and a unique N-linked glycosylation site (Asn(309)) that bears high mannose-type glycan structures. 18703501 7 69 gly bears 1330:1334 arg1 Asn(309) AND high mannose-type glycan structures Asn(309) high mannose-type glycan structures Asn(309) Mass spectrometry experiments showed that CA IX contains an intramolecular disulfide bridge (Cys(119)-Cys(299)) and a unique N-linked glycosylation site (Asn(309)) that bears high mannose-type glycan structures. 18703501 7 69 gly bears 1330:1334 arg1 a unique N-linked glycosylation site AND high mannose-type glycan structures a unique N-linked glycosylation site high mannose-type glycan structures site Mass spectrometry experiments showed that CA IX contains an intramolecular disulfide bridge (Cys(119)-Cys(299)) and a unique N-linked glycosylation site (Asn(309)) that bears high mannose-type glycan structures. 2844797 3 23 part_of ATP-binding 635:645 arg1 the ATP-binding site ATP the ATP-binding site OGER Site ATP site Rat brain, kidney, and stomach cDNA libraries were screened with an oligonucleotide hybridization probe corresponding to a 23-amino acid sequence from part of the ATP-binding site of the sarcoplasmic reticulum Ca-ATPase. 2844797 3 48 part_of Ca-ATPase 682:690 arg1 the ATP-binding site ATPase the ATP-binding site OGER Site ATPase site Rat brain, kidney, and stomach cDNA libraries were screened with an oligonucleotide hybridization probe corresponding to a 23-amino acid sequence from part of the ATP-binding site of the sarcoplasmic reticulum Ca-ATPase. 30208353 7 52 part_of ER-α 1248:1251 arg1 an F domain ER-α an F domain PUBTATOR Site ER-α 2099 domain We confirmed GALNT6-dependent ER-α O-glycosylation and identified O-glycosylation of S573 in an F domain of ER-α by GALNT6 through LC-MS/MS analysis. 10536368 0 19 part_of activator 104:112 arg1 the signal/pro sequence tissue plasminogen activator the signal/pro sequence PUBTATOR Site tissue plasminogen activator P00750 sequence Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activator. 9620884 2 6 gly chains 334:339 arg1 this lysosomal hydrolase hydrolase chains Fterm hydrolase The type, site occupancy and function of the N-linked oligosaccharide chains on this lysosomal hydrolase were determined. 9620884 2 9 gly occupancy 279:287 arg1 the N-linked oligosaccharide chains site the N-linked oligosaccharide chains site The type, site occupancy and function of the N-linked oligosaccharide chains on this lysosomal hydrolase were determined. 29708975 8 11 gly glycosylation 1118:1130 arg2 an extra N-linked glycosylation site an extra N-linked glycosylation site site Pakistani G3 strains belonged to lineage 3 within sub-lineage 3d, containing an extra N-linked glycosylation site compared to the G3 strain of RotaTeqTM. 9989600 2 54 gly glycosylated 277:288 arg1 the first glycosylated neurotoxin the first glycosylated neurotoxin Fterm neurotoxin It is the first glycosylated neurotoxin from scorpion venom to be described. 15582650 8 67 part_of CD4 1674:1676 arg1 the CD4 binding site CD4 the CD4 binding site OGER Site CD4 P01730 site Our study suggests that modified HIV Env proteins with reduced glycosylation in domains surrounding the CD4 binding site or variable loop-deleted mutants expose important neutralizing epitopes at higher levels than wild type and may provide novel vaccine immunogens. 2456913 8 0 part_of beta-subunits 1077:1089 arg1 Asn23 TSH beta Asn23 PUBTATOR AminoAcid TSH beta 7252 Asn23 The processing at Asn23 of TSH beta-subunits was slower than that at Asn56 or Asn82 of alpha-subunits. 2456913 8 37 part_of alpha-subunits 1133:1146 arg1 Asn82 alpha-subunits Asn82 Fterm AminoAcid alpha-subunits Asn82 The processing at Asn23 of TSH beta-subunits was slower than that at Asn56 or Asn82 of alpha-subunits. 2456913 8 37 part_of alpha-subunits 1133:1146 arg1 Asn56 alpha-subunits Asn56 Fterm AminoAcid alpha-subunits Asn56 The processing at Asn23 of TSH beta-subunits was slower than that at Asn56 or Asn82 of alpha-subunits. 18279659 4 55 gly glycosylation 725:737 arg2 glycosylation site mapping experiments glycosylation site mapping experiments site We defined the potential role of this hydrophobic extension of ABCB6 by glycosylation site mapping experiments, and demonstrated that the first hydrophobic segment acts as a type I signal-anchor sequence, which mediates N-terminal translocation through the ER membrane. 9570739 10 21 gly glycosylation 1506:1518 arg2 a conserved N-linked glycosylation site a conserved N-linked glycosylation site site This alternative splicing results in the inclusion or exclusion of exon 8, which encodes for three amino acid residues (QDQ) that are implicated in the sphingolipid binding affinity of saposin B. Sequence aligment indicates that all saposins share a common motif characterized by six conserved cysteines, a conserved N-linked glycosylation site, a conserved proline residue, and 15 positions that are characterized by large hydrophobic amino acids. 9570739 10 21 gly glycosylation 1506:1518 arg2 a conserved proline residue a conserved proline residue proline residue This alternative splicing results in the inclusion or exclusion of exon 8, which encodes for three amino acid residues (QDQ) that are implicated in the sphingolipid binding affinity of saposin B. Sequence aligment indicates that all saposins share a common motif characterized by six conserved cysteines, a conserved N-linked glycosylation site, a conserved proline residue, and 15 positions that are characterized by large hydrophobic amino acids. 25629924 2 0 gly glycosylated 241:252 arg1 a highly glycosylated protein a highly glycosylated protein Fterm protein Although it is a highly glycosylated protein, its site-specific glycosylation and associated glycan micro-heterogeneity have still not been fully elucidated. 2033065 2 19 part_of HPC 463:465 arg1 amino acid positions 97, 248, and 313 HPC amino acid positions 97, 248, and 313 OGER Site HPC P11498 positions 97, 248, and 313 To examine the role of glycosylation in the function of this protein, we singly eliminated each of the four potential N-linked glycosylation sites by site-directed mutagenesis of Asn to Gln at amino acid positions 97, 248, and 313 (HPC derivatives Q097, Q248, and Q313) or at the unusual consensus sequence Asn-X-Cys at 329 (HPC derivative Q329). 2033065 2 90 part_of 329 551:553 arg1 the unusual consensus sequence Asn-X-Cys 329 (HPC the unusual consensus sequence Asn-X-Cys OGER Site 329 (HPC P11498 Asn-X-Cys To examine the role of glycosylation in the function of this protein, we singly eliminated each of the four potential N-linked glycosylation sites by site-directed mutagenesis of Asn to Gln at amino acid positions 97, 248, and 313 (HPC derivatives Q097, Q248, and Q313) or at the unusual consensus sequence Asn-X-Cys at 329 (HPC derivative Q329). 20512925 6 6 gly modified 816:823 arg1 RAGE AND complex glycans RAGE complex glycans PUBTATOR RAGE Q15109 When expressed in mammalian cells, RAGE is modified by complex glycans predominantly at the first glycosylation site (N25IT) that retains S100A12 binding. 20512925 6 61 gly glycosylation 871:883 arg2 the first glycosylation site the first glycosylation site site When expressed in mammalian cells, RAGE is modified by complex glycans predominantly at the first glycosylation site (N25IT) that retains S100A12 binding. 9461526 3 10 part_of contains 384:391 arg1 chicken prosaposin AND 518 residues chicken prosaposin 518 residues PUBTATOR Site prosaposin 395602 residues The deduced amino acid sequence predicted that, similarly to human and other mammalian species studied, chicken prosaposin contains 518 residues, including four domains that correspond to saposins A-D. 9461526 3 10 part_of contains 384:391 arg1 chicken prosaposin AND four domains chicken prosaposin four domains PUBTATOR Site prosaposin 395602 domains The deduced amino acid sequence predicted that, similarly to human and other mammalian species studied, chicken prosaposin contains 518 residues, including four domains that correspond to saposins A-D. 26634432 3 19 gly N-terminal 308:317 arg1 a new proteoglycan N-terminal a new proteoglycan Cterm N-terminal After glycosylation, an N-terminal fragment of DMP1 protein was identified as a new proteoglycan (DMP1-PG) in bone matrix. 26634432 3 56 gly protein 336:342 arg1 a new proteoglycan DMP1 protein a new proteoglycan PUBTATOR DMP1 protein 13406 After glycosylation, an N-terminal fragment of DMP1 protein was identified as a new proteoglycan (DMP1-PG) in bone matrix. 22238065 8 13 gly aglycosylated 1720:1732 arg1 aglycosylated H10-Mut aglycosylated H10-Mut OGER H10-Mut P22033 In the case of aglycosylated H10-Mut, more than 95% of the heavy chain was cleaved, confirming the pivotal role of the sugar moiety in protein stability. 11130974 8 30 part_of contain 1135:1141 arg1 the amino-terminal extracellular domain AND an unusual NXC sequon the amino-terminal extracellular domain an unusual NXC sequon sequon Eight ORs contain an unusual NXC sequon at the amino-terminal extracellular domain that may represent a novel N-linked glycosylation site. 21515415 3 34 part_of containing 365:374 arg1 six variants AND serine six variants serine Fterm AminoAcid variants serine To study the impact of these sites on PLTP secretion and activity, six variants containing serine to alanine point mutations were prepared by site-directed mutagenesis and expressed in Chinese hamster ovary Flp-In cells. 28921966 7 64 gly attached 1334:1341 arg1 the peptides AND the glycan structures the peptides the glycan structures peptides Acquisition on a high resolution tandem-MSn system with fragmentation methodologies such as high-energy collision dissociation (HCD) and collision induced dissociation (CID), provided the complete sequence of the glycan structures attached to the peptides. 22764522 2 44 gly N-glycosylation 277:291 arg2 the N-glycosylation site the N-glycosylation site site To clear the effect of N-glycosylation on JEV immunity, the N-glycosylation site of prME and NS1 gene were eliminated by site-directed mutant PCR, subtituting the N to Q. And the the mutant genes were subcloned into eukaryotic expression plasmid. 17956937 0 46 gly antigen 50:56 arg1 Oligosaccharide profiles prostate specific antigen Oligosaccharide profiles OGER prostate specific antigen P07288 Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach. 17956937 0 59 gly glycopeptide 150:161 arg2 glycopeptide glycopeptide glycopeptide Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach. 25707740 17 1 gly glycoprotein 1914:1925 arg1 the major pregnancy glycoprotein hormone the major pregnancy glycoprotein hormone Fterm glycoprotein In conclusion, hCG is the major pregnancy glycoprotein hormone, whose maternal concentration and glycan structure change all along pregnancy. 8207403 0 75 gly glycosylation 30:42 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gp160 preventing env-mediated fusion. 9063619 6 15 gly glycosylation 1002:1014 arg1 IgG IgG Cterm IgG Examples include protein-specific glycosylation within the immunoglobulins and immunoglobulin superfamily and site-specific processing in ribonuclease, Thy-1, IgG, tissue plasminogen activator, and influenza A hemagglutinin. 9063619 6 15 gly glycosylation 1002:1014 arg1 Thy-1 Thy-1 PUBTATOR Thy-1 7070 Examples include protein-specific glycosylation within the immunoglobulins and immunoglobulin superfamily and site-specific processing in ribonuclease, Thy-1, IgG, tissue plasminogen activator, and influenza A hemagglutinin. 9063619 6 15 gly glycosylation 1002:1014 arg1 influenza A hemagglutinin influenza A hemagglutinin Fterm hemagglutinin Examples include protein-specific glycosylation within the immunoglobulins and immunoglobulin superfamily and site-specific processing in ribonuclease, Thy-1, IgG, tissue plasminogen activator, and influenza A hemagglutinin. 9063619 6 15 gly glycosylation 1002:1014 arg1 ribonuclease ribonuclease Fterm ribonuclease Examples include protein-specific glycosylation within the immunoglobulins and immunoglobulin superfamily and site-specific processing in ribonuclease, Thy-1, IgG, tissue plasminogen activator, and influenza A hemagglutinin. 23002422 5 41 gly N-glycopeptides 1054:1068 arg2 lectin-captured N-glycopeptides lectin-captured N-glycopeptides N-glycopeptides We identified a large number of candidates for the target proteins specific to β4GalT-I by comparative analysis of β4GalT-I-deleted and wild-type mice using the LC/MS-based technique with the isotope-coded glycosylation site-specific tagging (IGOT) of lectin-captured N-glycopeptides. 23675430 7 82 gly unglycosylated 1274:1287 arg1 the N-glycosylation site Asn-135 the N-glycosylation site Asn-135 site Asn-135 Binding of AT to the surface of keratinocytes is dependent on a functional heparin binding site, Lys-125, and that the N-glycosylation site Asn-135 be unglycosylated. 23675430 7 75 gly N-glycosylation 1242:1256 arg2 the N-glycosylation site Asn-135 site Asn-135 site Asn-135 Binding of AT to the surface of keratinocytes is dependent on a functional heparin binding site, Lys-125, and that the N-glycosylation site Asn-135 be unglycosylated. 26348848 11 111 gly N-glycosylation 2012:2026 arg1 Kv3.1a Kv3.1a PUBTATOR Kv3 29731 Our study demonstrates that N-glycosylation of Kv3.1a, like Kv3.1b, provides a mechanism for the distribution of these proteins to the cell body and outgrowths and thereby can generate different voltage-dependent conductances in these membranes. 18562306 8 10 gly glycosylation 1792:1804 arg1 serine serine serine The latter mode may facilitate the glycosylation of serine or threonine residues, which occur in sequence contexts that would not be efficiently glycosylated by the catalytic domain alone. 18562306 8 10 gly glycosylation 1792:1804 arg1 threonine threonine threonine residues The latter mode may facilitate the glycosylation of serine or threonine residues, which occur in sequence contexts that would not be efficiently glycosylated by the catalytic domain alone. 18562306 8 39 gly serine 1809:1814 arg1 residues residues threonine residues The latter mode may facilitate the glycosylation of serine or threonine residues, which occur in sequence contexts that would not be efficiently glycosylated by the catalytic domain alone. 12773316 6 50 gly glycosylation 974:986 arg2 the seven glycosylation sites the seven glycosylation sites sites Removing each of the seven glycosylation sites, except the second one, from the extracellular loop of YFP-beta prevented plasma membrane delivery of the protein. 27314333 4 12 gly N-glycosylated 695:708 arg1 Rspo3 Rspo3 N137 PUBTATOR Rspo3 84870 N137 Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain. 27314333 4 12 gly N-glycosylated 695:708 arg1 human Rspo1 Rspo1 N137 PUBTATOR Rspo1 284654 N137 Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain. 27314333 4 12 gly N-glycosylated 695:708 arg1 Rspo3 Rspo3 site PUBTATOR Rspo3 84870 site Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain. 27314333 4 12 gly N-glycosylated 695:708 arg1 human Rspo1 Rspo1 site PUBTATOR Rspo1 284654 site Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain. 27314333 4 50 gly N-glycosylated 789:802 arg2 N160 Rspo2 N160 PUBTATOR Rspo2 340419 N160 Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain. 27314333 4 50 gly N-glycosylated 789:802 arg2 a position Rspo2 position PUBTATOR Rspo2 340419 position Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain. 2318516 4 119 gly glycoproteins 833:845 arg1 class I glycoproteins class I glycoproteins Fterm glycoproteins We have now determined that the surface expression of class I glycoproteins in T2 depends on the origin of the alpha 1 and alpha 2 domains. 10677208 8 87 gly glycosylation 1537:1549 arg1 eight-cysteine domain protein-protein interactions cysteine domain cysteine domain On the basis of these results and on the structure of an eight-cysteine domain from fibrillin-1, we present a model of glycosylated CR3 and discuss the role of glycosylation in eight-cysteine domain protein-protein interactions. 10731668 1 56 gly used 228:231 arg2 The extracellular domain The extracellular domain domain The extracellular domain of human EGF receptor (sEGFR) produced by CHO cells has been used in various biophysical studies to elucidate the molecular mechanism of EGF-induced receptor activation. 8798755 6 22 part_of region 851:856 arg1 The IAR PTP IAR PTP region PUBTATOR Site IAR PTP 5799 region The IAR PTP is homologous in its intracellular region to IA-2, a putative PTP that is an insulin-dependent diabetes mellitus (IDDM) autoantigen. 26062906 10 69 gly glycosylation 1463:1475 arg2 a N-linked glycosylation site a N-linked glycosylation site site Moreover, the MHBs protein that carries a N-linked glycosylation site at position 5 or 7 retained the properties similar to wild-type MHBs. 11087686 4 81 part_of factor 659:664 arg1 the Saccharomyces cerevisiae alpha factor pre-pro sequence factor the Saccharomyces cerevisiae alpha factor pre-pro sequence Fterm AminoAcid factor pro sequence Fusion of either the pro-enzyme form or the mature form to the Saccharomyces cerevisiae alpha factor pre-pro sequence resulted in secretion of the mature form of the protein from P. pastoris. 9882683 12 5 gly glycosylation 1591:1603 arg1 Ser63 S-pilin Ser63 Fterm S-pilin Ser63 These data demonstrated that for GC, unlike for MC, glycosylation at Ser63 is not required for S-pilin production, suggesting that the mechanisms leading to the production of S pilin in GC and MC are different. 9882683 12 5 gly glycosylation 1591:1603 arg2 Ser63 S-pilin Ser63 Fterm S-pilin Ser63 These data demonstrated that for GC, unlike for MC, glycosylation at Ser63 is not required for S-pilin production, suggesting that the mechanisms leading to the production of S pilin in GC and MC are different. 9882683 12 5 gly glycosylation 1591:1603 arg2 Ser63 Ser63 Ser63 These data demonstrated that for GC, unlike for MC, glycosylation at Ser63 is not required for S-pilin production, suggesting that the mechanisms leading to the production of S pilin in GC and MC are different. 30659065 2 7 gly N-glycosylation 331:345 arg1 the N-linked glycans domain the N-linked glycans domain The isotype/subclass of the antibody, the co-translational N-glycosylation on the CH2 domain, and the remodeling of the N-linked glycans during passage through the ER and Golgi are the known variables within the Fc domain that program antibody effector function. 30659065 2 25 gly N-glycosylation 331:345 arg1 the CH2 domain domain domain The isotype/subclass of the antibody, the co-translational N-glycosylation on the CH2 domain, and the remodeling of the N-linked glycans during passage through the ER and Golgi are the known variables within the Fc domain that program antibody effector function. 30659065 2 25 gly N-glycosylation 331:345 arg1 the CH2 domain domain the N-linked glycans domain The isotype/subclass of the antibody, the co-translational N-glycosylation on the CH2 domain, and the remodeling of the N-linked glycans during passage through the ER and Golgi are the known variables within the Fc domain that program antibody effector function. 7533854 11 73 gly utilized 2601:2608 arg2 the closely spaced glycosylation sites the closely spaced glycosylation sites sites These results suggested that the closely spaced glycosylation sites 156 and 160 are often alternatively utilized and that the pattern of glycosylation at these positions affects the formation of the conformational structures needed for both expression of native epitopes in this region and processing of gPr160 to mature env products. 7533854 11 84 gly glycosylation 2545:2557 arg2 the closely spaced glycosylation sites the closely spaced glycosylation sites sites These results suggested that the closely spaced glycosylation sites 156 and 160 are often alternatively utilized and that the pattern of glycosylation at these positions affects the formation of the conformational structures needed for both expression of native epitopes in this region and processing of gPr160 to mature env products. 7533854 11 59 gly glycosylation 2634:2646 arg2 these positions positions positions These results suggested that the closely spaced glycosylation sites 156 and 160 are often alternatively utilized and that the pattern of glycosylation at these positions affects the formation of the conformational structures needed for both expression of native epitopes in this region and processing of gPr160 to mature env products. 17960575 9 37 gly glycopeptides 1265:1277 arg2 glycopeptides glycopeptides glycopeptides These results demonstrate the feasibility of direct structure determination of glycopeptides in proteolytic mixtures without any further refurbishment. 10839980 7 32 gly site 1079:1082 arg1 the carbohydrate site the carbohydrate site Thus placing a carbohydrate at site II stimulates the branching and the elongation of the carbohydrate at the other site. 8885240 2 104 gly glycosylation 756:768 arg2 N-linked glycosylation sites N-linked glycosylation sites sites The identity of each of these products was established by mutagenesis of proteolytic processing sites and N-linked glycosylation sites, combined with the analysis of transfection products by immunoprecipitation and one- and two-dimensional SDS-PAGE (SDS/SDS-beta-ME). 8832092 4 6 part_of cruzipain 808:816 arg1 Asn33 cruzipain Asn33 Fterm AminoAcid cruzipain Asn33 It was thus determined that the N-glycosylation site in Asn33 of cruzipain is occupied by high mannose-type oligosaccharides. 8663003 4 80 part_of proteins 782:789 arg1 the first external domain proteins the first external domain Fterm Site proteins domain All Rh polypeptide species were found to be susceptible to cleavage with trypsin and subtilisin within the first external domain of these proteins. 17144668 7 7 gly glycosylation 1128:1140 arg2 all five natural glycosylation sites all five natural glycosylation sites sites Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. 17144668 7 18 gly glycosylated 1090:1101 arg1 the potential glycosylation site the potential glycosylation site site Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. 17144668 7 42 gly glycosylation 1060:1072 arg2 the potential glycosylation site the potential glycosylation site site Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. 17144668 7 42 gly glycosylation 1060:1072 arg2 N570 N570 N570 Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. 16125194 6 8 gly non-glycosylated 1250:1265 arg1 The non-glycosylated recombinant cathepsin B The non-glycosylated recombinant cathepsin B OGER cathepsin B P07858 The non-glycosylated recombinant cathepsin B migrated as a single band of 39 kDa on SDS-PAGE. 22688517 5 0 gly glycopeptides 1059:1071 arg2 glycopeptides glycopeptides glycopeptides Here, an approach using nonspecific protease (Pronase E) digestion followed by MALDI-QIT-TOF MS and multistage MS (MS(3)) analysis is explored to obtain site-specific N-glycosylation information of recombinant human LOX-1, in combination with glycan structure confirmation through characterizing released glycans using tandem MS. The results reveal that N-glycans structures as well as their corresponding attached site of LOX-1 can be identified simultaneously by direct MS analysis of glycopeptides from non-specific protease digestion. 22688517 5 67 gly LOX-1 995:999 arg1 N-glycans structures LOX-1 N-glycans structures PUBTATOR LOX-1 4973 Here, an approach using nonspecific protease (Pronase E) digestion followed by MALDI-QIT-TOF MS and multistage MS (MS(3)) analysis is explored to obtain site-specific N-glycosylation information of recombinant human LOX-1, in combination with glycan structure confirmation through characterizing released glycans using tandem MS. The results reveal that N-glycans structures as well as their corresponding attached site of LOX-1 can be identified simultaneously by direct MS analysis of glycopeptides from non-specific protease digestion. 10207016 1 10 gly glycosylated 243:254 arg1 their S domains proteins domains Fterm proteins domains The surface antigen of hepatitis B virus comprises a nested set of small (S), middle (M), and large (L) proteins, all of which are partially glycosylated in their S domains. 28630087 10 83 part_of HNE 1685:1687 arg1 The three glycosylation sites HNE The three glycosylation sites PUBTATOR Site HNE 1991 sites The three glycosylation sites of HNE were located distal to the active site indicating glycan functions other than interference with HNE enzyme activity. 2457333 5 81 gly asialoglycopeptides 517:535 arg2 these asialoglycopeptides these asialoglycopeptides asialoglycopeptides Since no detectable fragmentation was observed in the PD-MS of these asialoglycopeptides, the observation of multiple molecular ions could be attributed to either carbohydrate or peptide heterogeneity. 27111718 7 32 gly glycopeptides 1400:1412 arg2 N-linked glycopeptides cell lines N-linked glycopeptides cell lines glycopeptides We tested the tool on two sets of tandem mass spectra of N-linked glycopeptides cell lines acquired from breast cancer patients. 28970103 13 42 gly O-glycosylated 2613:2626 arg1 singly O-glycosylated peptides singly O-glycosylated peptides peptides We demonstrated that multiple enzyme digestion or multidimensional separation can make sample preparation more efficient and that EThcD was not only suitable for the identification of singly O-glycosylated peptides (50.3%) but also doubly (21.2%) and triply (28.5%) O-glycosylated peptides. 28970103 13 163 gly O-glycosylated 2688:2701 arg1 doubly (21.2%) and triply (28.5%) O-glycosylated peptides doubly (21.2%) and triply (28.5%) O-glycosylated peptides peptides We demonstrated that multiple enzyme digestion or multidimensional separation can make sample preparation more efficient and that EThcD was not only suitable for the identification of singly O-glycosylated peptides (50.3%) but also doubly (21.2%) and triply (28.5%) O-glycosylated peptides. 8750609 2 37 gly N-glycosylation 612:626 arg2 an N-glycosylation site an N-glycosylation site site The pseudodeficiency is due to a single base substitution in the 3'-untranslated region of the ASA gene (1524+95 A-->G) and it has been reported that this mutation (PD2) always occurs on a chromosome carrying a second mutation in the ASA gene (PD1), which abolishes an N-glycosylation site (N350S). 15557236 1 42 part_of protein 320:326 arg1 the envelope (E) protein sequence protein the envelope (E) protein sequence Fterm Site protein sequence Two New York (NY) strains of the West Nile (WN) virus were plaque-purified and four variants that had different amino acid sequences at the N-linked glycosylation site in the envelope (E) protein sequence were isolated. 15557236 1 13 part_of had 230:232 arg1 four variants AND different amino acid sequences four variants different amino acid sequences Fterm Site variants sequences Two New York (NY) strains of the West Nile (WN) virus were plaque-purified and four variants that had different amino acid sequences at the N-linked glycosylation site in the envelope (E) protein sequence were isolated. 6935656 1 40 gly glycoprotein 240:251 arg1 the major envelope glycoprotein glycoprotein an antigenic determinant Fterm glycoprotein The GIX antigen, which is expressed on the surface of thymocytes of certain mouse strains, is an antigenic determinant of the major envelope glycoprotein of murine leukemia virus (gp70). 31507595 9 44 gly di-sialylated 1660:1672 arg1 O-glycan core type-2 di-sialylated structures O-glycan core type-2 di-sialylated structures In addition, O-glycan core type-2 di-sialylated structures at Ser12 were more abundant in bioactive CD52 fractions. 31507595 9 98 gly Ser12 1688:1692 arg1 O-glycan core type-2 di-sialylated structures Ser12 O-glycan core type-2 di-sialylated structures Ser12 In addition, O-glycan core type-2 di-sialylated structures at Ser12 were more abundant in bioactive CD52 fractions. 1736898 3 50 gly N-glycosylation 358:372 arg2 one potential N-glycosylation site one potential N-glycosylation site site On the basis of cDNA sequence analysis, Xenopus SPARC has a core Mr of 32643, with one potential N-glycosylation site. 15128311 13 96 gly glycosylated 1724:1735 arg1 a glycosylated three-fingered snake venom toxin wherein a glycosylated three-fingered snake venom toxin wherein Fterm wherein Thus for the first time we have isolated a glycosylated three-fingered snake venom toxin wherein glycosylation appears to modulate its biological activity. 28759313 8 62 gly glycosylation 1129:1141 arg2 a glycosylation site a glycosylation site site To further investigate the role of DMP1-PG in condylar chondrogenesis, a glycosylation site mutant (S89-G89) mouse model was established with knock-in methods. 18160168 5 28 gly glycosylation 815:827 arg2 an N-linked glycosylation site an N-linked glycosylation site site Characterization of the hemagglutinin gene revealed conserved sequences at the receptor-binding site as well as variations due to amino acid substitutions at the antigenic site, potentially resulting in an N-linked glycosylation site. 29069609 10 63 gly glycopeptides 1694:1706 arg2 specific glycopeptides specific glycopeptides glycopeptides SIGNIFICANCE: We developed a data-independent mass spectrometry workflow to identify specific glycopeptides from complex biological mixtures. 6175959 12 28 part_of -macroglobulin 1475:1488 arg1 a known glycosylation site alpha(2)-macroglobulin a known glycosylation site PUBTATOR Site alpha(2)-macroglobulin 2 site 255, 8087-8091] shows a previously recognized identity of seven residues around the thiol ester site and a second region of identity around a known glycosylation site of alpha(2)-macroglobulin. 15500847 4 52 part_of contains 732:739 arg1 This enzyme AND an N-linked glycosylation site This enzyme an N-linked glycosylation site glucosamine Fterm Site enzyme site This enzyme contains glucosamine and an N-linked glycosylation site. 31302509 8 30 gly glycosylated 1190:1201 arg1 an unidentified glycosylated cofactor an unidentified glycosylated cofactor Fterm cofactor Our data also suggest that an unidentified glycosylated cofactor may influence X/P-MLV entry. 10362834 3 65 gly glycoprotein 646:657 arg1 a glycoprotein a glycoprotein Fterm glycoprotein The most prominent evidence is that a glycoprotein with an apparent molecular weight of 30 kDa (gp30) was detected in the aged rats, but not in the young adult rats. 10837482 3 72 gly deglycosylation 895:909 arg1 the wild-type protein the wild-type protein Fterm protein Several of the mutant proteins had decreased enzymatic activity using a bradykinin analog as substrate, and deglycosylation of the wild-type protein resulted in loss of 75-100% activity. 8982862 6 4 gly glycosylated 1119:1130 arg1 glycosylated sequences glycosylated sequences sequences One amino acid substitution resulted in the loss of a potential glycosylation site in accordance with the finding on glycopeptide analyses that porcine vitronectin contained two kinds of glycosylated sequences, while human vitronectin contained three. 8982862 6 35 gly glycosylation 996:1008 arg2 a potential glycosylation site a potential glycosylation site site One amino acid substitution resulted in the loss of a potential glycosylation site in accordance with the finding on glycopeptide analyses that porcine vitronectin contained two kinds of glycosylated sequences, while human vitronectin contained three. 8982862 6 40 gly glycopeptide 1049:1060 arg2 glycopeptide glycopeptide glycopeptide One amino acid substitution resulted in the loss of a potential glycosylation site in accordance with the finding on glycopeptide analyses that porcine vitronectin contained two kinds of glycosylated sequences, while human vitronectin contained three. 6138751 0 54 part_of cDNA 59:62 arg1 a human renin cDNA fragment renin cDNA a human renin cDNA fragment PUBTATOR Site renin cDNA 5972 fragment Molecular cloning and nucleotide sequence of a human renin cDNA fragment. 6138751 0 55 part_of renin 53:57 arg1 a human renin cDNA fragment renin cDNA a human renin cDNA fragment PUBTATOR Site renin cDNA 5972 fragment Molecular cloning and nucleotide sequence of a human renin cDNA fragment. 8157687 1 5 gly glycoprotein 657:668 arg1 this glycoprotein this glycoprotein Fterm glycoprotein In the present study, the interactions of conglutinin and mannan-binding protein were evaluated with the complement glycoprotein C3, including various physiologically derived fragments of this glycoprotein, and neoglycolipids prepared from oligosaccharides released from C3 and its isolated alpha and beta chains. 8157687 1 13 gly glycoprotein 580:591 arg1 the complement glycoprotein C3 the complement glycoprotein C3 Fterm glycoprotein In the present study, the interactions of conglutinin and mannan-binding protein were evaluated with the complement glycoprotein C3, including various physiologically derived fragments of this glycoprotein, and neoglycolipids prepared from oligosaccharides released from C3 and its isolated alpha and beta chains. 23527852 10 11 gly fucosylated 1284:1294 arg1 fucosylated apolipoprotein-CIII isoforms fucosylated apolipoprotein-CIII isoforms These findings of fucosylated apolipoprotein-CIII isoforms warrant further research to elucidate the implications these glycoforms may have for the plethora of studies where alterations in apoCIII have been linked to the development of many different pathologies. 26599345 2 20 gly attached 158:165 arg2 the proteins AND The glycan moieties the proteins The glycan moieties Fterm proteins The glycan moieties attached to the proteins can directly affect protein stability, bioactivity, and immunogenicity. 7772241 6 60 part_of contained 1209:1217 arg1 the hagfish neurophysin AND a potential N-linked glycosylation site the hagfish neurophysin a potential N-linked glycosylation site Fterm Site neurophysin site In contrast, the hagfish neurophysin showed at least two insertions and one deletion in the conserved central region including 14 Cys residues, but contained a potential N-linked glycosylation site and had a high proportion of Leu residues in the C-terminal region, like the neurophysin of another hagfish, Eptatretus stouti. 10942407 2 86 gly N-glycosylation 624:638 arg2 a consensus N-glycosylation site a consensus N-glycosylation site site The remaining 15 Jk(null) donors from Finland were homozygous for a new T871C transition resulting in a S291P amino acid substitution at a consensus N-glycosylation site of the Jk polypeptide. 10942407 2 86 gly N-glycosylation 624:638 arg1 the Jk polypeptide polypeptide polypeptide The remaining 15 Jk(null) donors from Finland were homozygous for a new T871C transition resulting in a S291P amino acid substitution at a consensus N-glycosylation site of the Jk polypeptide. 14699159 2 45 gly glycosylation 462:474 arg2 three evolutionarily conserved N-linked glycosylation sites three evolutionarily conserved N-linked glycosylation sites sites ATF6, a 90-kDa ER transmembrane protein, contains three evolutionarily conserved N-linked glycosylation sites within its carboxyl luminal domain. 12515161 7 14 part_of NS3 736:738 arg1 NS3 region NS3 NS3 region PUBTATOR Site NS3 3845 region Three amino acid variations were found in NS3 region of all the three Chinese isolates of HGV. 8603082 7 45 gly glycosylation 1102:1114 arg2 this glycosylation site this glycosylation site site Using N-glycanase-F treatment and an in vitro translation system, we provide evidence that this glycosylation site is not actually utilised in Chinese hamster MCT1. 28970103 6 28 gly O-glycoprotein 1236:1249 arg1 49 O-glycoprotein groups 49 O-glycoprotein groups Fterm O-glycoprotein Totally, with the strict scoring criteria, 499 non-redundant intact O-glycopeptides, 173 O-glycosylation sites and 6 types of O-glycans originating from 49 O-glycoprotein groups were identified in human serum, including 121 novel O-glycosylation sites. 28970103 6 117 gly O-glycosylation 1310:1324 arg2 121 novel O-glycosylation sites 121 novel O-glycosylation sites sites Totally, with the strict scoring criteria, 499 non-redundant intact O-glycopeptides, 173 O-glycosylation sites and 6 types of O-glycans originating from 49 O-glycoprotein groups were identified in human serum, including 121 novel O-glycosylation sites. 28970103 6 86 gly O-glycopeptides 1148:1162 arg1 O-glycans O-glycopeptides O-glycans O-glycopeptides Totally, with the strict scoring criteria, 499 non-redundant intact O-glycopeptides, 173 O-glycosylation sites and 6 types of O-glycans originating from 49 O-glycoprotein groups were identified in human serum, including 121 novel O-glycosylation sites. 28970103 6 129 gly O-glycosylation 1169:1183 arg1 O-glycans sites O-glycans sites Totally, with the strict scoring criteria, 499 non-redundant intact O-glycopeptides, 173 O-glycosylation sites and 6 types of O-glycans originating from 49 O-glycoprotein groups were identified in human serum, including 121 novel O-glycosylation sites. 17727280 1 38 part_of protein 215:221 arg1 each N-glycosylation site protein each N-glycosylation site Fterm Site protein site We describe Peptoonist, a program that can automatically identify the glycans (sugars) present at each N-glycosylation site of a protein. 9774483 6 69 gly structures 1221:1230 arg1 NCAM NCAM structures PUBTATOR NCAM 4684 These results indicate that both PST and STX have relatively broad specificity on N-glycan core structures in NCAM and no remarkable difference exists between PST and STX for the requirement of core structures and sialic acid attached to the N-glycans of NCAM. 9774483 6 78 gly NCAM 1380:1383 arg1 the N-glycans NCAM the N-glycans PUBTATOR NCAM 4684 These results indicate that both PST and STX have relatively broad specificity on N-glycan core structures in NCAM and no remarkable difference exists between PST and STX for the requirement of core structures and sialic acid attached to the N-glycans of NCAM. 16883437 6 47 part_of glycoprotein 898:909 arg1 The predicted antigenic sites glycoprotein The predicted antigenic sites Fterm Site glycoprotein sites The predicted antigenic sites and secondary structure of the envelope glycoprotein of HTLV-1, present in Iran, have been compared with the antigenic sites and secondary structure of the homologous domains in subtypes A, B, C of the virus. 11741940 8 32 gly moiety 1571:1576 arg1 Asn Asn Asn SpecificSite Asn(172) Analysis of glycosylation sites showed that sFRP-1 contains a relatively large carbohydrate moiety on Asn(172) (approximately 2.8 kDa), whereas Asn(262), the second potential N-linked glycosylation site, is not modified. 11741940 8 32 gly moiety 1571:1576 arg1 172 172 172 SpecificSite Asn(172) Analysis of glycosylation sites showed that sFRP-1 contains a relatively large carbohydrate moiety on Asn(172) (approximately 2.8 kDa), whereas Asn(262), the second potential N-linked glycosylation site, is not modified. 11741940 8 42 gly glycosylation 1491:1503 arg2 glycosylation sites glycosylation sites sites Analysis of glycosylation sites showed that sFRP-1 contains a relatively large carbohydrate moiety on Asn(172) (approximately 2.8 kDa), whereas Asn(262), the second potential N-linked glycosylation site, is not modified. 11741940 8 100 gly glycosylation 1663:1675 arg2 Asn Asn Asn(262) Analysis of glycosylation sites showed that sFRP-1 contains a relatively large carbohydrate moiety on Asn(172) (approximately 2.8 kDa), whereas Asn(262), the second potential N-linked glycosylation site, is not modified. 11741940 8 100 gly glycosylation 1663:1675 arg2 the second potential N-linked glycosylation site the second potential N-linked glycosylation site site Analysis of glycosylation sites showed that sFRP-1 contains a relatively large carbohydrate moiety on Asn(172) (approximately 2.8 kDa), whereas Asn(262), the second potential N-linked glycosylation site, is not modified. 11741940 8 87 gly contains 1530:1537 arg1 sFRP-1 AND a relatively large carbohydrate moiety sFRP-1 a relatively large carbohydrate moiety PUBTATOR sFRP-1 6422 Analysis of glycosylation sites showed that sFRP-1 contains a relatively large carbohydrate moiety on Asn(172) (approximately 2.8 kDa), whereas Asn(262), the second potential N-linked glycosylation site, is not modified. 23891555 6 3 gly O-glycopeptides 924:938 arg2 IgA1 hinge-region O-glycopeptides IgA1 hinge-region O-glycopeptides O-glycopeptides Following a novel strategy, IgA1 hinge-region O-glycopeptides were fractionated by reversed-phase liquid chromatography using a microgradient device and identified by MALDI-TOF/TOF tandem MS (MS/MS). 18533687 10 28 gly N-glycosylation 1631:1645 arg1 optimal intracellular cAMP signaling cAMP Asn-303 OGER cAMP Q96JM3 Asn-303 In particular, N-glycosylation at Asn-303 of RXFP1 was required for optimal intracellular cAMP signaling. 18533687 10 28 gly N-glycosylation 1631:1645 arg2 Asn-303 Asn-303 Asn-303 In particular, N-glycosylation at Asn-303 of RXFP1 was required for optimal intracellular cAMP signaling. 18533687 10 28 gly N-glycosylation 1631:1645 arg2 Asn-303 cAMP Asn-303 OGER cAMP Q96JM3 Asn-303 In particular, N-glycosylation at Asn-303 of RXFP1 was required for optimal intracellular cAMP signaling. 20622017 8 34 gly glycopeptides 1101:1113 arg2 hepatic GGT glycopeptides hepatic GGT glycopeptides glycopeptides However, analysis of hepatic GGT glycopeptides revealed 11 glycan compositions, with 12 unique structures, none of which were observed on kidney GGT. 27957769 10 108 gly glycosylation 2058:2070 arg2 very high glycosylation site specificity very high glycosylation site specificity site It is observed that the induced antibodies recognize MUC1 peptides with very high glycosylation site specificity. 1371468 15 59 part_of epitopes 2542:2549 arg1 leucocyte LECAM-1 LECAM-1 epitopes PUBTATOR Site LECAM-1 281485 epitopes Finally, by testing anti-human LECAM-1 antibodies in a different species we have established the co-expression of antigenic epitopes on leucocyte LECAM-1 and a molecule(s) expressed by endothelial cells. 19371135 5 53 gly glycoprotein 601:612 arg1 glycoprotein enrichment glycoprotein enrichment Fterm glycoprotein The process developed for the isolation of Hp is based on glycoprotein enrichment from crude plasma samples by means of ConA lectin affinity separation. 15252014 9 63 part_of SPP 1641:1643 arg1 the SPP and presenilin active sites SPP the SPP and presenilin active sites PUBTATOR Site SPP 81502 sites These data provide strong evidence that although the SPP and presenilin active sites have some similarities, their presumptive catalytic domains are inverted. 27234584 4 4 gly glycoproteins 622:634 arg1 glycoproteins glycoproteins Fterm glycoproteins As glycosylation modifies the structures and functions of glycoproteins and many MMPs contain N- or O-linked oligosaccharides, we examine, compare and evaluate the evidence for whether glycosylation affects MMP catalytic activity and other functions. 10682309 5 82 part_of SAP-B 849:853 arg1 the SAP-B domain SAP the SAP-B domain OGER Site SAP O60880 domain So far, four different point mutations have been identified on the SAP-B domain of the SAP-precursor gene. 25289757 6 71 part_of clathrin-coated 1160:1174 arg1 the caveolae and clathrin-coated pit microdomains clathrin the caveolae and clathrin-coated pit microdomains Fterm Site clathrin microdomains In addition, glycosylation on the N-terminus mediates the internalization of D₂and D₃receptors within the caveolae and clathrin-coated pit microdomains of the plasma membrane, respectively, by regulating receptor interactions with caveolin-1 and clathrin. 22561161 1 47 gly N-glycosylation 221:235 arg2 a common N-glycosylation site a common N-glycosylation site site Doppel (Dpl) protein is a paralog of the prion protein (PrP) that shares 25% sequence similarity with the C-terminus of PrP, a common N-glycosylation site and a C-terminal signal peptide for attachment of a glycosylphophatidyl inositol anchor. 15247302 11 21 gly glycosylation 1653:1665 arg2 this third glycosylation site this third glycosylation site site However, Gln-187 beta(2)AR failed to co-localize with lysosomes despite agonist treatments up to 18 h. Phylogenetic analysis revealed that this third glycosylation site is found in humans and other higher order primates but not in lower order primates such as the monkey. 27259237 2 17 gly glycosylation 277:289 arg1 mammalian proteins mammalian proteins Fterm proteins It is estimated that over 50% of mammalian proteins undergo glycosylation. 7518124 0 6 gly N-glycosylation 94:108 arg2 the N-glycosylation site the N-glycosylation site site Enhancement of the complement regulatory function of CD59 by site-directed mutagenesis at the N-glycosylation site. 15557236 5 28 gly non-glycosylated 874:889 arg1 the E protein the E protein Fterm protein In contrast, intracerebral infection of mice with viruses carrying either the glycosylated or non-glycosylated forms of the E protein resulted in lethal infection. 15557236 5 49 gly glycosylated 858:869 arg1 the E protein the E protein Fterm protein In contrast, intracerebral infection of mice with viruses carrying either the glycosylated or non-glycosylated forms of the E protein resulted in lethal infection. 26873173 6 10 gly Hp 907:908 arg1 glycan Hp glycan Cterm Hp 3240 In this mini review, we provided a brief overview of Hp structure and biological function, discussed its glycosylation alterations in different cancers, and described the existing technologies for analyzing glycosylation site and glycan of Hp. 26873173 6 35 gly glycosylation 874:886 arg2 glycosylation site Hp site Cterm Hp 3240 site In this mini review, we provided a brief overview of Hp structure and biological function, discussed its glycosylation alterations in different cancers, and described the existing technologies for analyzing glycosylation site and glycan of Hp. 22586465 9 87 part_of proteins 1505:1512 arg1 the loop and bend regions proteins the loop and bend regions Fterm Site proteins regions Based on analysis of proteins that have a solved 3D structure at the site of variation, we find that 48% of the variations that lead to changes in glycosylation sites occur at the loop and bend regions of the proteins. 9857985 5 42 gly glycoprotein 770:781 arg1 the S glycoprotein molecules the S glycoprotein molecules Fterm glycoprotein Unlike in some typical MHV strain, such as MHV-A59 and MHV-JHM, the vast majority of the S glycoprotein molecules in DVIM exist an uncleaved form probably due to several amino acid substitutions around the cleavage site. 27938679 3 21 gly N-glycosylation 561:575 arg2 eight asparagine (N) residues eight asparagine (N) residues residues The SU contains eight asparagine (N) residues that are putative N-glycosylation sites. 27938679 3 21 gly N-glycosylation 561:575 arg2 putative N-glycosylation sites putative N-glycosylation sites sites The SU contains eight asparagine (N) residues that are putative N-glycosylation sites. 21573946 6 62 gly core-fucosylated 981:996 arg1 The EC-SOD N-glycans The EC-SOD N-glycans The EC-SOD N-glycans were basically core-fucosylated (98.3% of the total N-glycan content), and were high mannose sugar chain, and mono-, bi-, tri-, and tetra-antennary complex sugar chains exhibiting varying degrees of sialylation. 21573946 6 62 gly core-fucosylated 981:996 arg1 the total N-glycan content the total N-glycan content The EC-SOD N-glycans were basically core-fucosylated (98.3% of the total N-glycan content), and were high mannose sugar chain, and mono-, bi-, tri-, and tetra-antennary complex sugar chains exhibiting varying degrees of sialylation. 22674977 4 59 gly glycosylation 663:675 arg2 a potential glycosylation site a potential glycosylation site site A mutation which introduces a potential glycosylation site at Asn123 in the NL219 hemagglutinin was postulated to contribute to the pathogenic properties of this virus. 22674977 4 59 gly glycosylation 663:675 arg2 Asn123 Asn123 Asn123 A mutation which introduces a potential glycosylation site at Asn123 in the NL219 hemagglutinin was postulated to contribute to the pathogenic properties of this virus. 9820842 7 16 gly glycoprotein 1331:1342 arg1 a glycoprotein a glycoprotein Fterm glycoprotein These findings establish that US5 does encode a glycoprotein and confirm the appropriateness of naming the US5 gene product gJ. 9820842 7 16 gly glycoprotein 1331:1342 arg1 US5 US5 PUBTATOR US5 2703406 These findings establish that US5 does encode a glycoprotein and confirm the appropriateness of naming the US5 gene product gJ. 31498587 5 16 gly glycopeptides 676:688 arg2 MUC1-Tf and -STn glycopeptides MUC1-Tf and -STn glycopeptides glycopeptides The conjugates of MUC1-Tf and -STn glycopeptides with Qβ were utilized to immunize immune-tolerant human MUC1 transgenic (MUC1.Tg) mice, which elicited superior levels of anti-MUC1 IgG antibodies with titers reaching over 2 million units. 11326277 9 26 part_of Tas1r3 1150:1155 arg1 the sequence Tas1r3 the sequence PUBTATOR Site Tas1r3 83771 sequence By comparing the sequence of Tas1r3 from several independently derived strains of mice, we identified a specific polymorphism that assorts between taster and non-taster strains. 22279061 6 13 gly Asn 1122:1124 arg1 the N-glycan Asn(382) the N-glycan Asn(382) These results indicate that the N-glycan of Asn(393) regulates the intracellular sorting of SREC-I and that the N-glycan of Asn(382) controls ligand-binding affinity. 22279061 6 20 gly Asn 1042:1044 arg1 the N-glycan Asn(393) the N-glycan Asn(393) These results indicate that the N-glycan of Asn(393) regulates the intracellular sorting of SREC-I and that the N-glycan of Asn(382) controls ligand-binding affinity. 9758750 4 43 gly nonglycosylated 665:679 arg1 nonglycosylated receptor nonglycosylated receptor Fterm receptor To address the importance of glycosylation toward receptor activity and stability, and possibly obtain nonglycosylated receptor for crystallization, mutations were made to replace four Asn residues which are N-glycosylated in the truncated receptor. 9758750 4 78 gly N-glycosylated 770:783 arg1 four Asn residues receptor Asn residues Fterm receptor Asn residues To address the importance of glycosylation toward receptor activity and stability, and possibly obtain nonglycosylated receptor for crystallization, mutations were made to replace four Asn residues which are N-glycosylated in the truncated receptor. 9758750 4 78 gly N-glycosylated 770:783 arg2 four Asn residues receptor Asn residues Fterm receptor Asn residues To address the importance of glycosylation toward receptor activity and stability, and possibly obtain nonglycosylated receptor for crystallization, mutations were made to replace four Asn residues which are N-glycosylated in the truncated receptor. 9758750 4 78 gly N-glycosylated 770:783 arg2 four Asn residues Asn residues Asn residues To address the importance of glycosylation toward receptor activity and stability, and possibly obtain nonglycosylated receptor for crystallization, mutations were made to replace four Asn residues which are N-glycosylated in the truncated receptor. 23562646 4 107 part_of site 693:696 arg1 HN protein protein site Fterm SpecificSite protein N485 site Electrophoretic mobility analysis of mutated HN proteins indicated that N308, N351 and N523 sites, but not the N485 site in HN protein, were targeted for the addition of glycans in BHK-21 cells. 22180207 2 15 gly glycopeptides 340:352 arg2 mucin-like glycopeptides mucin-like glycopeptides glycopeptides In particular, the determination of O-glycosylated amino acids in mucin-like glycopeptides lags far behind the techniques for phosphorylation site and N-glycosylation site identification, for which well-established enrichment techniques are available. 22180207 2 41 gly N-glycosylation 414:428 arg2 N-glycosylation site N-glycosylation site site In particular, the determination of O-glycosylated amino acids in mucin-like glycopeptides lags far behind the techniques for phosphorylation site and N-glycosylation site identification, for which well-established enrichment techniques are available. 14571263 1 25 gly N-glycosylation 344:358 arg2 the commonly associated N-glycosylation site variant the commonly associated N-glycosylation site variant site A late infantile metachromatic leukodystrophy patient was found to be heterozygous for the arylsulfatase A (ARSA) pseudodeficiency (pd) polyadenylation site variant ((*)96A>G) in the absence of the commonly associated N-glycosylation site variant (N350S). 8344280 2 0 part_of proteins 229:236 arg1 artificially introduced N-glycosylation or O-glycosylation sites proteins artificially introduced N-glycosylation or O-glycosylation sites Fterm Site proteins sites Human interleukin 2 (IL-2) and human IL-2 mutant proteins, with artificially introduced N-glycosylation or O-glycosylation sites, have been expressed in a lepidopteran cell line (Sf21, Spodoptera frugiperda) using recombinant baculovirus vectors. 19358553 1 19 gly glycopeptides 185:197 arg2 N-linked glycopeptides N-linked glycopeptides glycopeptides Site-specific glycoprofiling of N-linked glycopeptides using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is an emerging technique, but its quantitative accuracy lacks documentation. 8395123 7 62 gly asparagine-linked 1263:1279 arg1 asparagine-linked sugar chains asparagine asparagine-linked sugar chains asparagine Our results suggest that asparagine-linked sugar chains are present on the surface of native virions of HCV, very similar to those for HBV. 7529232 6 68 gly present 1161:1167 arg2 domain 1 AND the single N-acetylglucosamine residue domain 1 the single N-acetylglucosamine residue domain The protein also formed diffraction quality crystals and analysis of the 2.5-A resolution crystal structure indicated that the single N-acetylglucosamine residue present on domain 1 is unlikely to stabilize the ligand binding face of hsCD2. 2846759 3 86 part_of gH 727:728 arg1 its gH amino acid sequence gH its gH amino acid sequence PUBTATOR Site gH 1682472 sequence In agreement with the biological grouping of HVS as a lymphotropic gammaherpesvirus, its gH amino acid sequence shows greatest similarity to that of the B lymphotropic Epstein-Barr virus, although the nucleotide sequences of their respective gH genes show little similarity given different G + C compositions of 31% and 54%. 7479385 7 5 gly N-glycosylation 1249:1263 arg2 only one N-glycosylation site only one N-glycosylation site site The experimentally determined carbohydrate content of PSA confirms that only one N-glycosylation site is occupied in the protein. 7479385 7 12 gly PSA 1222:1224 arg1 The experimentally determined carbohydrate content PSA The experimentally determined carbohydrate content PUBTATOR PSA 354 The experimentally determined carbohydrate content of PSA confirms that only one N-glycosylation site is occupied in the protein. 7479385 7 60 gly occupied 1273:1280 arg2 only one N-glycosylation site only one N-glycosylation site site The experimentally determined carbohydrate content of PSA confirms that only one N-glycosylation site is occupied in the protein. 17766267 8 23 part_of alpha2b 1513:1519 arg1 the interferon alpha2b protein O-linked glycosylation site interferon alpha2b protein the interferon alpha2b protein O-linked glycosylation site PUBTATOR Site interferon alpha2b protein 3440 site The improved enzyme CgtB(OH4384)DeltaC-MalE was used to galactosylate a glyco-peptide acceptor based on the interferon alpha2b protein O-linked glycosylation site as confirmed by the CE-MS analysis of the reaction products. 17766267 8 26 part_of O-linked 1529:1536 arg1 the interferon alpha2b protein O-linked glycosylation site O-linked the interferon alpha2b protein O-linked glycosylation site Cterm Site O-linked site The improved enzyme CgtB(OH4384)DeltaC-MalE was used to galactosylate a glyco-peptide acceptor based on the interferon alpha2b protein O-linked glycosylation site as confirmed by the CE-MS analysis of the reaction products. 17766267 8 75 part_of interferon 1502:1511 arg1 the interferon alpha2b protein O-linked glycosylation site interferon alpha2b protein the interferon alpha2b protein O-linked glycosylation site PUBTATOR Site interferon alpha2b protein 3440 site The improved enzyme CgtB(OH4384)DeltaC-MalE was used to galactosylate a glyco-peptide acceptor based on the interferon alpha2b protein O-linked glycosylation site as confirmed by the CE-MS analysis of the reaction products. 17766267 8 77 part_of protein 1521:1527 arg1 the interferon alpha2b protein O-linked glycosylation site interferon alpha2b protein the interferon alpha2b protein O-linked glycosylation site PUBTATOR Site interferon alpha2b protein 3440 site The improved enzyme CgtB(OH4384)DeltaC-MalE was used to galactosylate a glyco-peptide acceptor based on the interferon alpha2b protein O-linked glycosylation site as confirmed by the CE-MS analysis of the reaction products. 6838832 5 63 part_of variant 901:907 arg1 the corresponding variant 1 peptide variant 1 the corresponding variant 1 peptide Fterm Site variant 1 peptide A similar peptide isolated from plasminogen variant 2 did not contain oligosaccharide but possessed an amino acid sequence identical with the corresponding variant 1 peptide. 6838832 5 3 part_of possessed 835:843 arg1 A similar peptide AND an amino acid sequence A similar peptide an amino acid sequence sequence A similar peptide isolated from plasminogen variant 2 did not contain oligosaccharide but possessed an amino acid sequence identical with the corresponding variant 1 peptide. 8486693 0 14 gly glycosylated 84:95 arg1 a glycosylated membrane-associated lipase a glycosylated membrane-associated lipase Fterm lipase Identification and cloning of GP-3 from rat pancreatic acinar zymogen granules as a glycosylated membrane-associated lipase. 9287313 5 65 gly Cys-containing 1336:1349 arg1 the second, "cryptic" CD69 N-glycan attachment site Cys the second, "cryptic" CD69 N-glycan attachment site Cys Importantly, these data demonstrate that contrary to current belief, not one but two sites for N-glycan addition exist within the human CD69 extracellular domain and identify the second, "cryptic" CD69 N-glycan attachment site as the atypical Cys-containing glycosylation motif, Asn-Ala-Cys. 9287313 5 0 gly glycosylation 1351:1363 arg2 Asn-Ala-Cys motif, Asn-Ala-Cys motif, Asn-Ala-Cys Importantly, these data demonstrate that contrary to current belief, not one but two sites for N-glycan addition exist within the human CD69 extracellular domain and identify the second, "cryptic" CD69 N-glycan attachment site as the atypical Cys-containing glycosylation motif, Asn-Ala-Cys. 11786923 1 53 gly glycoproteins 141:153 arg1 secreted-type glycoproteins secreted-type glycoproteins Fterm glycoproteins WNTs are a family of secreted-type glycoproteins implicated in embryogenesis and carcinogenesis. 20622017 4 62 gly released 711:718 arg2 isolated GGT AND glycans isolated GGT glycans OGER GGT Recent advances in mass spectrometry enabled us to identify the microheterogeneity and relative abundance of glycans on specific glycopeptides and revealed a broader spectrum of glycans than was observed among glycans enzymatically released from isolated GGT. 20622017 4 70 gly microheterogeneity 543:560 arg1 glycans glycans Recent advances in mass spectrometry enabled us to identify the microheterogeneity and relative abundance of glycans on specific glycopeptides and revealed a broader spectrum of glycans than was observed among glycans enzymatically released from isolated GGT. 20622017 4 85 gly glycans 588:594 arg1 specific glycopeptides specific glycopeptides specific glycopeptides Site glycopeptides Recent advances in mass spectrometry enabled us to identify the microheterogeneity and relative abundance of glycans on specific glycopeptides and revealed a broader spectrum of glycans than was observed among glycans enzymatically released from isolated GGT. 20622017 4 90 gly glycopeptides 608:620 arg2 specific glycopeptides specific glycopeptides glycopeptides Recent advances in mass spectrometry enabled us to identify the microheterogeneity and relative abundance of glycans on specific glycopeptides and revealed a broader spectrum of glycans than was observed among glycans enzymatically released from isolated GGT. 9753616 8 7 part_of STC2 866:869 arg1 opposite STC2 opposite PUBTATOR Site STC2 O76061 opposite Therefore, the function of STC2 seems to be opposite to that of STC1 on Na-phosphate cotransporter. 9520292 5 34 part_of D 857:857 arg1 the antigenic epitopes cathepsin D, the antigenic epitopes PUBTATOR Site cathepsin D, 1509 epitopes To define the antigenic epitopes of cathepsin D, tryptic fragments were prepared from UL-1-derived procathepsin D. 15113889 0 20 part_of site 64:67 arg1 the vesicular stomatitis virus glycoprotein glycoprotein site Fterm Site glycoprotein site Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein. 23527852 0 86 gly glycoforms 42:51 arg1 new apolipoprotein-CIII glycoforms new apolipoprotein-CIII glycoforms PUBTATOR apolipoprotein-CIII 345 Identification of new apolipoprotein-CIII glycoforms with ultrahigh resolution MALDI-FTICR mass spectrometry of human sera. 8244416 3 32 gly N-glycosylation 695:709 arg2 Asn/Asp/Thr Asn/Asp/Thr Asn/Asp/Thr The variable region for the heavy chain of F11-35 contained a possible N-glycosylation site (Asn/Asp/Thr) at amino acid positions 89-91. 8244416 3 32 gly N-glycosylation 695:709 arg2 a possible N-glycosylation site a possible N-glycosylation site site The variable region for the heavy chain of F11-35 contained a possible N-glycosylation site (Asn/Asp/Thr) at amino acid positions 89-91. 8244416 3 85 gly positions 744:752 arg1 89-91 89-91 positions 89 The variable region for the heavy chain of F11-35 contained a possible N-glycosylation site (Asn/Asp/Thr) at amino acid positions 89-91. 8286855 0 39 part_of motifs 88:93 arg1 human glycophorin A glycophorin A motifs PUBTATOR Site glycophorin A 2993 motifs Glycosylation sites identified by solid-phase Edman degradation: O-linked glycosylation motifs on human glycophorin A. 25213400 14 1 gly glycoproteins 1504:1516 arg1 glycoproteins glycoproteins Fterm glycoproteins Although peripheral myelin is made up largely of glycoproteins, mutations altering glycosylation have been described only in P0. 9254044 5 15 gly N-glycosylation 905:919 arg2 a single N-glycosylation site a single N-glycosylation site site The glucosidase II sequence did not contain known ER retention signals nor hydrophobic regions which could represent a transmembrane domain; however, it contained a single N-glycosylation site close to the amino terminus. 20622017 12 91 part_of glycoprotein 1657:1668 arg1 individual glycopeptides glycoprotein individual glycopeptides Fterm Site glycoprotein glycopeptides This is the first analysis at the level of individual glycopeptides of a human glycoprotein produced by two different tissues in vivo and provides novel insights into tissue-specific and site-specific glycosylation in normal human tissues. 7620335 2 21 part_of factor 471:476 arg1 the XAP region factor X the XAP region OGER Site factor X P00742 region We determined the structure of oligosaccharides in the XAP region of human factor X. Four glycopeptides each containing a glycosylation site were isolated by digestion of XAP with endoproteinase Asp-N followed by reversed-phase HPLC. 7620335 2 85 part_of X. 478:479 arg1 X. Four glycopeptides factor X X. Four glycopeptides OGER Site factor X P00742 glycopeptides We determined the structure of oligosaccharides in the XAP region of human factor X. Four glycopeptides each containing a glycosylation site were isolated by digestion of XAP with endoproteinase Asp-N followed by reversed-phase HPLC. 7737160 0 59 gly glycosylated 34:45 arg1 glycosylated porcine platelet factor 4 glycosylated porcine platelet factor 4 OGER platelet factor 4 P02776 The complete primary structure of glycosylated porcine platelet factor 4. 2317204 7 55 part_of residue 1095:1101 arg1 human link proteins proteins residue Fterm SpecificSite proteins residue 41 Protein sequencing analysis of these modified link-protein components also provided evidence for the location of a second N-linked glycosylation site at residue 41 in human link proteins, in addition to that previously described at residue 6 on a proportion of the link proteins. 29587225 1 7 gly glycoprotein 186:197 arg1 a therapeutic glycoprotein a therapeutic glycoprotein Fterm glycoprotein Recombinant human erythropoietin (EPO) is a therapeutic glycoprotein widely used for treating anemia. 29587225 1 7 gly glycoprotein 186:197 arg1 Recombinant human erythropoietin Recombinant human erythropoietin PUBTATOR erythropoietin 2056 Recombinant human erythropoietin (EPO) is a therapeutic glycoprotein widely used for treating anemia. 10226365 1 7 gly glycosylation 266:278 arg2 glycosylation site glycosylation site site Sequencing of eight O-glycosylated peptides by nanoESI-QTOF-MS/MS was carried out to provide a sensitive general characterization method for determination of glycosylation site(s) and of the type of the attached carbohydrate moiety in a single experiment. 10226365 1 36 gly O-glycosylated 128:141 arg1 eight O-glycosylated peptides eight O-glycosylated peptides peptides Sequencing of eight O-glycosylated peptides by nanoESI-QTOF-MS/MS was carried out to provide a sensitive general characterization method for determination of glycosylation site(s) and of the type of the attached carbohydrate moiety in a single experiment. 16512686 1 58 part_of sites 303:307 arg1 glycoproteins glycoproteins sites Fterm Site glycoproteins sites Proteomic techniques, such as HPLC coupled to tandem mass spectrometry (LC-MS/MS), have proved useful for the identification of specific glycosylation sites on glycoproteins (glycoproteomics). 7476998 4 0 gly glycosylation 603:615 arg2 the glycosylation site the glycosylation site site In addition to the glycosylation site in the Fc portion, each antibody has a different glycosylation site in the second complementarity determining region (CDR2) of the heavy chain (Asn54, Asn58, or Asn60). 7476998 4 69 gly chain 759:763 arg1 Asn60 Asn60 Asn60 In addition to the glycosylation site in the Fc portion, each antibody has a different glycosylation site in the second complementarity determining region (CDR2) of the heavy chain (Asn54, Asn58, or Asn60). 7476998 4 71 gly glycosylation 671:683 arg2 a different glycosylation site a different glycosylation site site In addition to the glycosylation site in the Fc portion, each antibody has a different glycosylation site in the second complementarity determining region (CDR2) of the heavy chain (Asn54, Asn58, or Asn60). 7476998 4 69 gly chain 759:763 arg1 Asn54 Asn54, Asn58 Asn54, Asn58 In addition to the glycosylation site in the Fc portion, each antibody has a different glycosylation site in the second complementarity determining region (CDR2) of the heavy chain (Asn54, Asn58, or Asn60). 10588947 3 1 gly glycosylation 537:549 arg2 glycosylation site utilization studies glycosylation site utilization studies site To examine apoB's translocation behavior under various metabolic conditions, glycosylation site utilization studies were performed. 26869352 11 29 gly fucosylated 1824:1834 arg1 fucosylated haptoglobin fucosylated haptoglobin PUBTATOR haptoglobin 3240 These data suggest that the original tissue/cell producing fucosylated haptoglobin is different in each cancer type and linkage of fucosylation might be a clue of primary lesion, thereby enabling a differential diagnosis between gastroenterological cancers and non-gastroenterological cancers. 7499420 3 56 gly glycoprotein 519:530 arg1 an integral membrane glycoprotein an integral membrane glycoprotein Fterm glycoprotein The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein. 7499420 3 50 gly N-glycosylation 417:431 arg1 PMP22 PMP22 site PUBTATOR PMP22 5376 site The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein. 7499420 3 50 gly N-glycosylation 417:431 arg2 the four lipophilic domains domains domains The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein. 7499420 3 50 gly N-glycosylation 417:431 arg1 PMP22 PMP22 domains PUBTATOR PMP22 5376 domains The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein. 7499420 3 50 gly N-glycosylation 417:431 arg1 PMP22 PMP22 domains PUBTATOR PMP22 5376 domains The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein. 1840295 0 25 gly site 39:42 arg1 Oligosaccharides site Oligosaccharides site Oligosaccharides at each glycosylation site make structure-dependent contributions to biological properties of human tissue plasminogen activator. 1840295 0 58 gly glycosylation 25:37 arg2 each glycosylation site each glycosylation site site Oligosaccharides at each glycosylation site make structure-dependent contributions to biological properties of human tissue plasminogen activator. 10989127 9 60 part_of observed 1341:1348 arg1 HYAL1 AND site 1 HYAL1 site PUBTATOR Site HYAL1 3373 site A potential N-glycosylation site (site 1) with similar tripeptide patterns was observed at the same position in human plasma (HYAL1), human lysosomes (HYAL2) and in two newly reported hyaluronidases (HYAL4 and HYALP1). 2180485 0 73 part_of region 43:48 arg1 amyloid precursor protein amyloid precursor protein region OGER Site amyloid precursor protein P05067 region Enzyme specificity of proteinase inhibitor region in amyloid precursor protein of Alzheimer's disease: different properties compared with protease nexin I. Senile plaques, often surrounded by abnormally grown neurites, are characteristic of Alzheimer's diseased brain. 14715137 0 25 gly N-glycosylation 0:14 arg1 synaptotagmin 1 synaptotagmin 1 PUBTATOR synaptotagmin 1 6857 N-glycosylation is essential for vesicular targeting of synaptotagmin 1. 11230417 2 60 part_of glycoprotein 442:453 arg1 a single glycosylation site glycoprotein a single glycosylation site Fterm Site glycoprotein site RNase B is an excellent substrate for the demonstration of mannosidase activity since it is a glycoprotein with a single glycosylation site which is occupied by high-mannose-type glycoforms containing five to nine mannose residues. 27966990 2 3 part_of VEGFR-2 290:296 arg1 The extracellular domain VEGFR-2 The extracellular domain PUBTATOR Site VEGFR-2 P35968 domain The extracellular domain of VEGFR-2 is composed of seven immunoglobulin-like domains, each with multiple potential N-glycosylation sites (sequons). 26022737 6 79 gly glycosylation 793:805 arg2 a new N-linked glycosylation site a new N-linked glycosylation site site Accordingly, a new N-linked glycosylation site is created with an N102MS motif. 12921785 4 14 part_of TFPI-2 719:724 arg1 The deduced sequence TFPI-2 The deduced sequence PUBTATOR Site TFPI-2 360007 sequence The deduced sequence of mature bovine TFPI-2 revealed a short acidic amino-terminal region, three tandem Kunitz-type domains, and a carboxy-terminal tail highly enriched in basic amino acids. 12901863 0 26 gly N-glycosylation 29:43 arg1 human ABCC6 human ABCC6 PUBTATOR ABCC6 368 Subcellular localization and N-glycosylation of human ABCC6, expressed in MDCKII cells. 12930842 10 28 gly N-glycosylation 1405:1419 arg2 two N-glycosylation sites two N-glycosylation sites sites Secondly, it contains two N-glycosylation sites, in contrast to other murine IFN-alpha subtypes that contain either one or no N-glycosylation site. 12930842 10 30 gly N-glycosylation 1505:1519 arg2 no N-glycosylation site no N-glycosylation site site Secondly, it contains two N-glycosylation sites, in contrast to other murine IFN-alpha subtypes that contain either one or no N-glycosylation site. 11259791 8 66 gly N-glycosylation 1179:1193 arg2 no N-glycosylation site no N-glycosylation site site In view of this, no N-glycosylation site was found in the antigenic decapeptides tested, they all belong to oligopeptide epitopes. 20943674 8 25 gly glycosylated 1364:1375 arg2 the same two sites rhLF sites OGER rhLF P02788 sites Monosaccharide composition analysis of rhLF revealed small amounts of N-glycolylneuraminic acid, which were not detected by MS. hLF and rhLF appear to be glycosylated at the same two sites: Asn138 and Asn479. 20943674 8 25 gly glycosylated 1364:1375 arg2 the same two sites hLF sites PUBTATOR hLF 3131 sites Monosaccharide composition analysis of rhLF revealed small amounts of N-glycolylneuraminic acid, which were not detected by MS. hLF and rhLF appear to be glycosylated at the same two sites: Asn138 and Asn479. 20943674 8 39 gly amounts 1269:1275 arg1 Asn138 Asn138 and Asn479 Asn138 and Asn479 Monosaccharide composition analysis of rhLF revealed small amounts of N-glycolylneuraminic acid, which were not detected by MS. hLF and rhLF appear to be glycosylated at the same two sites: Asn138 and Asn479. 1367474 3 4 gly glycosylation 480:492 arg1 the catalytic domain tPA domain PUBTATOR tPA P00750 domain Employing one of these strains to study the effect of glycosylation on secretion, we show that glycosylation in the catalytic domain of tPA plays an important role in folding and/or secretion of the molecule. 1367474 3 38 gly glycosylation 480:492 arg1 the catalytic domain tPA domain PUBTATOR tPA P00750 domain Employing one of these strains to study the effect of glycosylation on secretion, we show that glycosylation in the catalytic domain of tPA plays an important role in folding and/or secretion of the molecule. 1367474 3 38 gly glycosylation 480:492 arg1 the catalytic domain domain domain Employing one of these strains to study the effect of glycosylation on secretion, we show that glycosylation in the catalytic domain of tPA plays an important role in folding and/or secretion of the molecule. 1567356 3 79 part_of site 444:447 arg1 its molecular variants variants site Fterm Site variants site Standard h.p.l.c. profiles have been developed to analyse the percentage and distribution of the glycoforms present at each glycosylation site in OMD and its molecular variants. 1567356 3 79 part_of site 444:447 arg1 OMD OMD site OGER Site OMD Q99983 site Standard h.p.l.c. profiles have been developed to analyse the percentage and distribution of the glycoforms present at each glycosylation site in OMD and its molecular variants. 30208353 9 33 gly O-glycosylation 1538:1552 arg2 the O-glycosylation site the O-glycosylation site site Furthermore, we designed cell membrane-permeable peptides including the O-glycosylation site and found a significant decrease of the cell viability of breast cancer cells by treatment of these peptides in a GALNT6 expression-dependent manner. 10459158 7 39 gly glycosylation 834:846 arg2 a potential glycosylation site a potential glycosylation site site Furthermore, a potential glycosylation site at position 233 was lost. 10459158 7 39 gly glycosylation 834:846 arg2 position 233 position 233 position 233 Furthermore, a potential glycosylation site at position 233 was lost. 6175959 5 15 part_of C3d 565:567 arg1 the radiolabeled C3d fragment C3d the radiolabeled C3d fragment PUBTATOR Site C3d 100861467 fragment Partial sequence analysis of the radiolabeled C3d fragment showed that both components of the thiol ester are located close to the amino terminus (residues 23 and 26). 19249803 1 52 part_of site 202:205 arg1 their envelope (E) proteins proteins site Fterm Site proteins site Many, but not all, strains of West Nile virus (WNV) contain a single N-linked glycosylation site on their envelope (E) proteins. 26085161 9 56 gly glycosylation 1434:1446 arg1 the bovine leukemia virus (BLV) SU protein the bovine leukemia virus (BLV) SU protein Fterm protein We show that N-linked glycosylation of the bovine leukemia virus (BLV) SU protein is, as expected, essential for cell infection in vitro. 1380164 0 15 part_of receptor 85:92 arg1 the binding site acetylcholine receptor the binding site OGER Site acetylcholine receptor site How the mongoose can fight the snake: the binding site of the mongoose acetylcholine receptor. 10779281 2 11 part_of contained 338:346 arg1 a 215 residue protein AND no cysteines a 215 residue protein no cysteines Fterm AminoAcid protein cysteines The clone HD6 contained DNA encoding a 215 residue protein which contained a predicted 17 amino acid residue leader sequence, no cysteines and a single N-glycosylation site. 10779281 2 11 part_of contained 338:346 arg1 a 215 residue protein AND predicted 17 amino acid residue leader sequence a 215 residue protein predicted 17 amino acid residue leader sequence Fterm Site protein sequence The clone HD6 contained DNA encoding a 215 residue protein which contained a predicted 17 amino acid residue leader sequence, no cysteines and a single N-glycosylation site. 10779281 2 11 part_of contained 338:346 arg1 a 215 residue protein AND a single N-glycosylation site a 215 residue protein a single N-glycosylation site Fterm Site protein site The clone HD6 contained DNA encoding a 215 residue protein which contained a predicted 17 amino acid residue leader sequence, no cysteines and a single N-glycosylation site. 19747940 7 27 part_of CD9 901:903 arg1 bird CD9 sequence CD9 bird CD9 sequence PUBTATOR Site CD9 P21926 sequence Phylogenetic analysis showed that the turtle CD9 sequence clustered together with bird CD9 sequence. 19747940 7 50 part_of CD9 859:861 arg1 the turtle CD9 sequence CD9 the turtle CD9 sequence PUBTATOR Site CD9 P21926 sequence Phylogenetic analysis showed that the turtle CD9 sequence clustered together with bird CD9 sequence. 18381078 2 19 gly contain 340:346 arg1 ADAM10 AND high-mannose and complex-type glycans ADAM10 high-mannose and complex-type glycans PUBTATOR ADAM10 102 In this work, ADAM10 was found to contain high-mannose and complex-type glycans. 31888963 11 75 gly sites 1905:1909 arg1 N145 N64 and N145 N64 and N145 The additional analysis of CD32a from monocytes revealed different features than observed for CD16a including the presence of a predominantly biantennary complex-type N-glycans with two sialic acids at both sites (N64 and N145). 31888963 11 78 gly sites 1905:1909 arg1 two sialic acids sites two sialic acids sites The additional analysis of CD32a from monocytes revealed different features than observed for CD16a including the presence of a predominantly biantennary complex-type N-glycans with two sialic acids at both sites (N64 and N145). 31924694 11 36 gly N-glycosylation 2040:2054 arg2 N-glycosylation sites N-glycosylation sites sites Furthermore, original data on N-glycosylation sites of N. lugens adults are presented, providing novel insights into planthopper's biology and information for future biological pest control strategies. 32280962 6 5 part_of PSG1 1126:1129 arg1 only the N and A2 domains PSG1 only the N and A2 domains PUBTATOR Site PSG1 5669 domains In addition, we determined that out of the three N-glycosylation-carrying domains, only the N and A2 domains of recombinant PSG1 interact with Gal-1. 32280962 6 9 part_of A2 1100:1101 arg1 only the N and A2 domains A2 only the N and A2 domains PUBTATOR Site A2 170589 domains In addition, we determined that out of the three N-glycosylation-carrying domains, only the N and A2 domains of recombinant PSG1 interact with Gal-1. 12766998 0 71 gly glycoproteins 79:91 arg1 hepatitis C virus genotype 3 and 1 glycoproteins hepatitis C virus genotype 3 and 1 glycoproteins Fterm glycoproteins Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins. 9242452 7 32 gly glycopeptides 1283:1295 arg2 4 N-glycosylated glycopeptides 4 N-glycosylated glycopeptides glycopeptides Six of 12 O-glycosylated and 0 of 4 N-glycosylated glycopeptides were able to induce a T-cell proliferative response with a stimulation index above 3.0. 9242452 7 93 gly N-glycosylated 1268:1281 arg1 4 N-glycosylated glycopeptides 4 N-glycosylated glycopeptides glycopeptides Six of 12 O-glycosylated and 0 of 4 N-glycosylated glycopeptides were able to induce a T-cell proliferative response with a stimulation index above 3.0. 7559574 6 10 gly sialylated 1695:1704 arg1 sialylated complex-type oligosaccharides sialylated complex-type oligosaccharides Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex-type oligosaccharides. 7559574 6 34 gly glycopeptides 1652:1664 arg2 the isolated glycopeptides the isolated glycopeptides glycopeptides Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex-type oligosaccharides. 7559574 6 68 gly N-glycosylation 1576:1590 arg2 one potential N-glycosylation site one potential N-glycosylation site site Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex-type oligosaccharides. 7559574 6 68 gly N-glycosylation 1576:1590 arg2 Asn-381 Asn-232 and Asn-381 Asn-232 and Asn-381 Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex-type oligosaccharides. 9520292 0 24 part_of D 10:10 arg1 Cathepsin D antigenic epitopes Cathepsin D Cathepsin D antigenic epitopes PUBTATOR Site Cathepsin D 1509 epitopes Cathepsin D antigenic epitopes identified by the humoral responses of ovarian cancer patients. 9520292 0 29 part_of Cathepsin 0:8 arg1 Cathepsin D antigenic epitopes Cathepsin D Cathepsin D antigenic epitopes PUBTATOR Site Cathepsin D 1509 epitopes Cathepsin D antigenic epitopes identified by the humoral responses of ovarian cancer patients. 16899459 4 14 gly N-glycosylation 696:710 arg2 the only N-glycosylation site 34 amino acids the only N-glycosylation site 34 amino acids site The mutation truncated the distal ectodomain and positioned the only N-glycosylation site 34 amino acids from the newly formed C terminus, which impaired efficient N-glycosylation. 11754244 2 41 gly glycosylated 515:526 arg1 the formerly glycosylated sites the formerly glycosylated sites sites The beta-elimination-addition reaction (using dimethylamine and concomitantly ethanethiol) on the formerly glycosylated sites through a Michael-type condensation produced efficient deglycosylation with appropriate chemical modification. 30904681 9 12 gly B2GP1 1411:1415 arg1 glycan compositions B2GP1 glycan compositions PUBTATOR B2GP1 350 Our method allows a fast determination of genetic variants and glycan compositions of human B2GP1 to be potentially used as diagnostic marker. 2082620 10 4 part_of CD4-binding 1385:1395 arg1 the CD4-binding site CD4 the CD4-binding site PUBTATOR Site CD4 920 site These results suggest that the attached carbohydrates around the CD4-binding site of gp120, may contribute to the generation of this protein domain required for high affinity receptor interaction. 2082620 10 31 part_of gp120 1405:1409 arg1 the CD4-binding site gp120 the CD4-binding site PUBTATOR Site gp120 3700 site These results suggest that the attached carbohydrates around the CD4-binding site of gp120, may contribute to the generation of this protein domain required for high affinity receptor interaction. 23758413 5 81 gly glycoprotein 730:741 arg1 all the glycoprotein species all the glycoprotein species Fterm glycoprotein Although all the glycoprotein species bearing a particular glycan feature will be captured by an affinity column, there is no way of knowing whether the ligand being targeted appears alone or coresides with a series of other glycan features in the same oligosaccharide conjugate. 28231306 1 14 part_of domain 308:313 arg1 the C-terminal region domain the C-terminal region region BACKGROUND: ADAMTS14 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), which are proteolytic enzymes with a variety of further ancillary domain in the C-terminal region for substrate specificity and enzyme localization via extracellular matrix association. 28231306 1 32 part_of region 333:338 arg1 further ancillary domain region further ancillary domain domain BACKGROUND: ADAMTS14 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), which are proteolytic enzymes with a variety of further ancillary domain in the C-terminal region for substrate specificity and enzyme localization via extracellular matrix association. 28231306 1 51 part_of metalloproteinase 195:211 arg1 thrombospondin motifs metalloproteinase thrombospondin motifs Fterm Site metalloproteinase motifs BACKGROUND: ADAMTS14 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), which are proteolytic enzymes with a variety of further ancillary domain in the C-terminal region for substrate specificity and enzyme localization via extracellular matrix association. 28231306 1 54 part_of enzymes 264:270 arg1 further ancillary domain enzymes further ancillary domain Fterm Site enzymes domain BACKGROUND: ADAMTS14 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), which are proteolytic enzymes with a variety of further ancillary domain in the C-terminal region for substrate specificity and enzyme localization via extracellular matrix association. 28231306 1 62 part_of disintegrin 179:189 arg1 thrombospondin motifs disintegrin thrombospondin motifs Fterm Site disintegrin motifs BACKGROUND: ADAMTS14 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), which are proteolytic enzymes with a variety of further ancillary domain in the C-terminal region for substrate specificity and enzyme localization via extracellular matrix association. 7937884 9 35 gly glycosylation 1254:1266 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Analysis of the deduced sequence identified two potential protein kinase C phosphorylation sites and a potential N-linked glycosylation site. 7689340 4 42 gly unglycosylated 393:406 arg1 the unglycosylated mature protein the unglycosylated mature protein Fterm protein The calculated molecular mass for the unglycosylated mature protein was 26,147 Da. 23527023 6 40 gly diglycosylated 1447:1460 arg1 the diglycosylated PrP the diglycosylated PrP PUBTATOR PrP Q9NP58 Furthermore, PrP(V180I) with a typical glycoform profile from cultured cells generates detectable PrP(res) that also contains the diglycosylated PrP in addition to mono- and unglycosylated forms upon PK-treatment. 8176214 9 59 part_of receptor 1037:1044 arg1 the cytoplasmic domain receptor the cytoplasmic domain Fterm Site receptor domain Deletion of the cytoplasmic domain of the receptor had no influence on shedding of the protein. 8870657 1 3 gly glycoprotein 164:175 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Human lactoferrin (hLF) is a glycoprotein involved in the host defence against infection and excessive inflammation. 8870657 1 3 gly glycoprotein 164:175 arg1 Human lactoferrin Human lactoferrin OGER Human lactoferrin P02788 Human lactoferrin (hLF) is a glycoprotein involved in the host defence against infection and excessive inflammation. 8068684 3 17 gly N-glycosylation 569:583 arg2 the individual potential N-glycosylation sites the individual potential N-glycosylation sites sites In order to determine unambiguously the sites of glycosylation and their role in biosynthesis and cation transport, site-directed mutagenesis at the individual potential N-glycosylation sites (Asn to Asp) was performed and all possible double and triple mutants were constructed. 8068684 3 17 gly N-glycosylation 569:583 arg2 Asn to Asp Asn to Asp Asp In order to determine unambiguously the sites of glycosylation and their role in biosynthesis and cation transport, site-directed mutagenesis at the individual potential N-glycosylation sites (Asn to Asp) was performed and all possible double and triple mutants were constructed. 8068684 3 43 gly glycosylation 448:460 arg2 the sites the sites sites In order to determine unambiguously the sites of glycosylation and their role in biosynthesis and cation transport, site-directed mutagenesis at the individual potential N-glycosylation sites (Asn to Asp) was performed and all possible double and triple mutants were constructed. 7875221 3 96 gly N-glycosylation 704:718 arg2 one potential N-glycosylation site one potential N-glycosylation site site The Xenopus LG sequence has a 57% nucleotide and 52% amino acid sequence identity to human C3 and contains one potential N-glycosylation site in the beta-chain. 23533650 0 5 gly glycoproteins 124:136 arg1 monovalent or trivalent envelope glycoproteins monovalent or trivalent envelope glycoproteins Fterm glycoproteins Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins. 19763269 5 98 part_of gp120 933:937 arg1 the region gp120 the region PUBTATOR Site gp120 3700 region In one subject, Nab escape was driven predominantly by changes in the region of gp120 that extends from the beginning of the V3 domain to the end of the V5 domain (V3V5). 2329007 6 12 gly glycosylation 1180:1192 arg2 an N-linked glycosylation site an N-linked glycosylation site site Second, the distinguishing polymorphism between mice of phenotype 1 and phenotypes 2 or 3 was due to the presence of an N-linked glycosylation site within the Tcrg-Cl gene segment, previously described for BALB.B and C57BL/6 Tcrg-Cl genes. 27808502 7 54 gly N-glycopeptides 1509:1523 arg2 609 N-glycopeptides 609 N-glycopeptides N-glycopeptides In this study, simultaneous analysis of the combined oligomannosylated N-glycopeptidome and the native glycopeptidome leads to the identification of 609 N-glycopeptides from the secretome and lysates of Huh7 cells. 17001073 11 69 gly glycosylation 1793:1805 arg1 Asn-594 Asn-594 Asn-594 Thus, although glycosylation of Asn-594 is necessary for COX-2 degradation, at least part of the remainder of the 19-AA insert is also required. 31958346 2 37 gly N-glycosylation 556:570 arg2 six potential N-glycosylation sites six potential N-glycosylation sites sites In this study, we performed a comprehensive N-glycosylation analysis of mouse GluA1, one of the major subunits of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate type glutamate receptor, which possesses six potential N-glycosylation sites in the N-terminal domain. 31958346 2 38 gly N-glycosylation 381:395 arg1 the major subunits the major subunits OGER subunits 14799 In this study, we performed a comprehensive N-glycosylation analysis of mouse GluA1, one of the major subunits of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate type glutamate receptor, which possesses six potential N-glycosylation sites in the N-terminal domain. 31958346 2 38 gly N-glycosylation 381:395 arg1 mouse GluA1 mouse GluA1 PUBTATOR GluA1 14799 In this study, we performed a comprehensive N-glycosylation analysis of mouse GluA1, one of the major subunits of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate type glutamate receptor, which possesses six potential N-glycosylation sites in the N-terminal domain. 26231935 2 56 gly N-glycosylation 335:349 arg1 AChE AChE PUBTATOR AChE 43 Several lines of evidence demonstrated that N-glycosylation of AChE affected the enzymatic activity, as well as its biosynthesis. 19921957 3 98 part_of peptide 680:686 arg1 single glycosylation site peptide single glycosylation site site Comparing samples treated in H(2)(18)O and samples treated in H(2)(16)O, a unique mass shift of 6 Da can be shown for N-glycosylated peptide with single glycosylation site, which could be easily distinguished from those nonglycosite peptide pairs with a mass difference of 4 Da only. 7994575 0 15 part_of CD2 82:84 arg1 the extracellular region CD2 the extracellular region PUBTATOR Site CD2 914 region Crystal structure of the extracellular region of the human cell adhesion molecule CD2 at 2.5 A resolution. 16883437 0 49 gly glycoprotein 46:57 arg1 the envelope glycoprotein the envelope glycoprotein Fterm glycoprotein Comparison of antigenic sites of the envelope glycoprotein of the Iranian isolate of human T-cell leukemia virus type 1 with different subtypes of the virus. 9792708 4 56 gly O-glycosylated 573:586 arg1 O-glycosylated coronavirus M proteins O-glycosylated coronavirus M proteins Fterm proteins The hydroxylamino acid cluster, which is quite conserved among O-glycosylated coronavirus M proteins, is not in itself sufficient for O-glycosylation. 29992770 9 56 gly N-glycopeptides 1236:1250 arg1 haptoglobin haptoglobin N-glycopeptides Fterm haptoglobin 3240 N-glycopeptides N-glycopeptides of IgG1, IgG4, haptoglobin, and transferrin have statistically significant different abundances between cases and controls. 29992770 9 56 gly N-glycopeptides 1236:1250 arg1 transferrin transferrin N-glycopeptides Fterm transferrin 7018 N-glycopeptides N-glycopeptides of IgG1, IgG4, haptoglobin, and transferrin have statistically significant different abundances between cases and controls. 25737293 5 29 gly deglycosylated 1007:1020 arg1 a given glycosylation site a given glycosylation site site Combining deglycosylation with the more general peptide-N-glycosidase F enzyme with AspN protease digest allowed robust automated differentiation of nonglycosylated and deglycosylated forms of a given glycosylation site. 25737293 5 39 gly nonglycosylated 987:1001 arg1 a given glycosylation site a given glycosylation site site Combining deglycosylation with the more general peptide-N-glycosidase F enzyme with AspN protease digest allowed robust automated differentiation of nonglycosylated and deglycosylated forms of a given glycosylation site. 25737293 5 52 gly glycosylation 1039:1051 arg2 a given glycosylation site a given glycosylation site site Combining deglycosylation with the more general peptide-N-glycosidase F enzyme with AspN protease digest allowed robust automated differentiation of nonglycosylated and deglycosylated forms of a given glycosylation site. 25289757 1 25 gly glycosylated 209:220 arg2 extracellular regions receptors regions Fterm receptors regions Numerous G protein-coupled receptors (GPCRs) are glycosylated at extracellular regions. 3008092 6 60 gly glycosylation 1034:1046 arg2 one less glycosylation site one less glycosylation site site Of the few nucleotide differences between C4d and C4w7, a single base change resulting in one less glycosylation site in the C4w7 alpha chain could account for its 4-fold reduced hemolytic efficiency. 10889259 4 44 gly N-glycosylation 798:812 arg2 one putative N-glycosylation site one putative N-glycosylation site site In contrast to the corresponding enzymes from animals, all plant GnTI sequences identified are characterized by a much shorter hydrophobic membrane anchor and contain one putative N-glycosylation site that is conserved in potato and tobacco, but differs in Arabidopsis. 8760363 6 68 gly glycosylation 1154:1166 arg2 an additional glycosylation site an additional glycosylation site site Features unique to chicken fibromodulin include an additional glycosylation site as well as a decreased number of tyrosine residues that could be sulphated, and therefore potential changes in the charge of the molecule. 8760363 6 68 gly glycosylation 1154:1166 arg1 tyrosine residues tyrosine residues tyrosine residues Features unique to chicken fibromodulin include an additional glycosylation site as well as a decreased number of tyrosine residues that could be sulphated, and therefore potential changes in the charge of the molecule. 22355413 5 83 part_of neuraminidase 1174:1186 arg1 the enzymatic cleavage sites neuraminidase the enzymatic cleavage sites PUBTATOR Site neuraminidase 4758 sites The results showed that glycosite migrations in human influenza viruses have at least five possible functions: to more effectively mask the antigenic sites, to more effectively protect the enzymatic cleavage sites of neuraminidase (NA), to stabilize the polymeric structures, to regulate the receptor binding and catalytic activities and to balance the binding activity of hemagglutinin (HA) with the release activity of NA. 11361003 1 76 gly O-glycosylated 135:148 arg1 a N- and O-glycosylated transmembrane protein a N- and O-glycosylated transmembrane protein Fterm protein The transferrin receptor (TfR) is a N- and O-glycosylated transmembrane protein mediating the cellular iron uptake by binding and internalization of diferric transferrin. 11361003 1 76 gly O-glycosylated 135:148 arg1 The transferrin receptor The transferrin receptor PUBTATOR transferrin receptor 7037 The transferrin receptor (TfR) is a N- and O-glycosylated transmembrane protein mediating the cellular iron uptake by binding and internalization of diferric transferrin. 1726785 2 39 gly glycosylation 567:579 arg2 potential N-linked glycosylation sites potential N-linked glycosylation sites sites Deletion mutants of the extracellular domain of the rat TSH receptor as well as point mutations of potential N-linked glycosylation sites were created. 15113920 8 43 gly glycosylation 1303:1315 arg2 glycosylation sites N235 and N399 sites N235 and N399 sites N235 and N399 Mutation at glycosylation sites N235 and N399 together resulted in Gn misfolding. 15113920 8 43 gly glycosylation 1303:1315 arg2 N235 sites N235 and N399 sites N235 and N399 Mutation at glycosylation sites N235 and N399 together resulted in Gn misfolding. 15113920 8 43 gly glycosylation 1303:1315 arg2 N235 sites N235 and N399 sites N235 and N399 Mutation at glycosylation sites N235 and N399 together resulted in Gn misfolding. 15113920 8 66 gly sites 1317:1321 arg1 N399 sites N235 and N399 sites N235 and N399 Mutation at glycosylation sites N235 and N399 together resulted in Gn misfolding. 15113920 8 66 gly sites 1317:1321 arg1 N235 sites N235 and N399 sites N235 and N399 Mutation at glycosylation sites N235 and N399 together resulted in Gn misfolding. 15113920 8 66 gly sites 1317:1321 arg1 N235 sites N235 and N399 sites N235 and N399 Mutation at glycosylation sites N235 and N399 together resulted in Gn misfolding. 11386850 7 19 part_of Slc19a2 1018:1024 arg1 the Slc19a2 amino acid sequence Slc19a2 the Slc19a2 amino acid sequence PUBTATOR Site Slc19a2 10560 sequence Comparison of the Slc19a2 amino acid sequence with those of the other known SLC19A solute carriers highlighted interesting patterns of conservation and divergence in various domains, allowing insight into potential structure-function relationships. 8985413 6 47 gly glycoproteins 1024:1036 arg1 Soluble gp120 mutant glycoproteins Soluble gp120 mutant glycoproteins Fterm glycoproteins Soluble gp120 mutant glycoproteins showed increased affinities for soluble CD4 and monoclonal antibodies specific for a number of epitopes overlapping the CD4 binding site, confirming that length increases in V2 affect exposure of the CD4 binding site. 17313760 13 32 gly glycosylation 1628:1640 arg2 N-linked glycosylation site analysis N-linked glycosylation site analysis site N-linked glycosylation site analysis showed that most of the 21 sequences were relatively conservative. 9725224 4 3 gly glycosylation 566:578 arg2 amino acid residues 86 amino acid residues 86 residues 86 We have generated H-2Dd mutants that lack the highly conserved glycosylation sites at amino acid residues 86 in the alpha1 domain and 176 in the alpha2 domain, respectively. 9725224 4 3 gly glycosylation 566:578 arg2 the highly conserved glycosylation sites the highly conserved glycosylation sites sites We have generated H-2Dd mutants that lack the highly conserved glycosylation sites at amino acid residues 86 in the alpha1 domain and 176 in the alpha2 domain, respectively. 30967460 4 15 gly glycosylation 871:883 arg2 a predicted glycosylation site a predicted glycosylation site site The impact of these differences on in vitro inhibition of enzyme activity was not evident for polyclonal antisera until viruses emerged in 2013 without a predicted glycosylation site at amino acid 386 in NA. 29309128 3 9 gly glycoproteins 545:557 arg1 glycoproteins glycoproteins Fterm structure of glycoproteins While appreciation of glycosylation's importance is growing in the scientific community, especially in recent years, a lack of homogeneous glycoproteins with well-defined glycan structures has made it difficult to understand the correlation between the structure of glycoproteins and their properties at a quantitative level. 29309128 3 23 gly glycoproteins 418:430 arg1 well-defined glycan structures glycoproteins well-defined glycan structures Fterm glycoproteins While appreciation of glycosylation's importance is growing in the scientific community, especially in recent years, a lack of homogeneous glycoproteins with well-defined glycan structures has made it difficult to understand the correlation between the structure of glycoproteins and their properties at a quantitative level. 8702538 4 34 gly glycosylation 660:672 arg2 N-linked glycosylation sites N-linked glycosylation sites sites These observations suggest that N-linked glycosylation sites on the CD22 molecule may play a role in the regulation of CD22-mediated adhesion. 22773269 0 46 gly N-glycosylation 9:23 arg2 N-glycosylation site exploitation N-glycosylation site exploitation site Enhanced N-glycosylation site exploitation of sialoglycopeptides by peptide IPG-IEF assisted TiO2 chromatography. 22773269 0 58 gly sialoglycopeptides 46:63 arg2 sialoglycopeptides sialoglycopeptides sialoglycopeptides Enhanced N-glycosylation site exploitation of sialoglycopeptides by peptide IPG-IEF assisted TiO2 chromatography. 18533687 8 89 part_of RXFP1 1330:1334 arg1 the potential N-glycosylation sites RXFP1 the potential N-glycosylation sites PUBTATOR Site RXFP1 59350 sites All of the potential N-glycosylation sites of RXFP1 were utilized in HEK-293T cells, and importantly, disruption of glycosylation at individual or combinations of double and triple sites had little effect on relaxin binding. 22180206 5 30 gly glycopeptides 1020:1032 arg2 infused or capillary LC-separated glycopeptides infused or capillary LC-separated glycopeptides glycopeptides ETD MS/MS of infused or capillary LC-separated glycopeptides provided broad peptide sequence coverage (c/z·-type fragment ions) with intact glycans still attached to the Ser/Thr residues. 22180206 5 43 gly attached 1127:1134 arg1 the Ser/Thr residues AND intact glycans the Ser/Thr residues intact glycans residues ETD MS/MS of infused or capillary LC-separated glycopeptides provided broad peptide sequence coverage (c/z·-type fragment ions) with intact glycans still attached to the Ser/Thr residues. 23001782 4 28 gly glycans 814:820 arg1 intact hSHBG hSHBG glycans PUBTATOR hSHBG 6462 MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG. 23001782 4 91 gly hSHBG 832:836 arg1 detailed glycan structures hSHBG detailed glycan structures PUBTATOR hSHBG 6462 MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG. 23001782 4 91 gly hSHBG 832:836 arg1 glycans hSHBG glycans PUBTATOR hSHBG 6462 MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG. 23001782 4 91 gly hSHBG 832:836 arg1 monosaccharide compositions hSHBG monosaccharide compositions PUBTATOR hSHBG 6462 MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG. 23001782 4 117 gly structures 766:775 arg1 intact hSHBG hSHBG structures PUBTATOR hSHBG 6462 MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG. 23001782 4 124 gly compositions 736:747 arg1 intact hSHBG hSHBG compositions PUBTATOR hSHBG 6462 MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG. 23001782 4 61 gly glycosylation 670:682 arg1 glycans sites glycans sites MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG. 24799124 7 17 gly ceruloplasmin 1559:1571 arg1 core-fucosylation ceruloplasmin core-fucosylation PUBTATOR ceruloplasmin 1356 However, in HBV- or HCV-related liver diseases, no significant site-specific change in core-fucosylation of ceruloplasmin was observed between HCC and cirrhosis. 24799124 7 20 gly core-fucosylation 1538:1554 arg1 ceruloplasmin ceruloplasmin PUBTATOR ceruloplasmin 1356 However, in HBV- or HCV-related liver diseases, no significant site-specific change in core-fucosylation of ceruloplasmin was observed between HCC and cirrhosis. 16253890 4 65 gly glycosylation 910:922 arg1 gp120 gp120 I present a hypothesis that development of resistance against drugs that target the glycans on gp120 would result in a marked enhancement of neutralisation of HIV by the immune system--ie, drugs directed against the carbohydrate component of gp120 will select for mutant virus strains that progressively gain deletions in the glycosylation sites of gp120. 10099230 2 59 gly N-glycosylation 511:525 arg2 a novel N-glycosylation site a novel N-glycosylation site site The human interleukin-2 (IL-2) mutant glycoprotein variant IL-Mu6, which bears a novel N-glycosylation site (created by a single amino acid exchange of Gln100 to Asn), was produced under different defined protein-free culture conditions in the presence or absence of either glutamine, NH4Cl, or glucosamine. 10099230 2 76 gly glycoprotein 462:473 arg1 The human interleukin-2 (IL-2) mutant glycoprotein variant IL-Mu6 The human interleukin-2 (IL-2) mutant glycoprotein variant IL-Mu6 Fterm glycoprotein The human interleukin-2 (IL-2) mutant glycoprotein variant IL-Mu6, which bears a novel N-glycosylation site (created by a single amino acid exchange of Gln100 to Asn), was produced under different defined protein-free culture conditions in the presence or absence of either glutamine, NH4Cl, or glucosamine. 27773655 9 7 gly N-glycosylation 1284:1298 arg2 a similar N-glycosylation site a similar N-glycosylation site site Notably, a similar N-glycosylation site is also found in domain IV with comparable effects on the trafficking of LPH-derived molecules. 1546316 4 32 gly glycosylation 436:448 arg2 A conserved N-linked glycosylation site A conserved N-linked glycosylation site site A conserved N-linked glycosylation site within the V3 region, present in each mother's sequence set, was absent in all of the infants' sequence sets. 8193553 6 95 gly monosialylated 1156:1169 arg1 the monosialylated oligosaccharide the monosialylated oligosaccharide However, in contrast to human erythrocyte glycophorin A, the monosialylated oligosaccharide was the most abundant structure on the recombinant protein. 26784534 3 67 gly VWF-O-glycopeptides 363:381 arg2 Tryptic VWF-O-glycopeptides Tryptic VWF-O-glycopeptides VWF-O-glycopeptides METHODS: Tryptic VWF-O-glycopeptides were isolated by lectin affinity chromatography and/or by reverse-phase high-performance liquid chromatography. 26013384 7 35 gly O-glycopeptides 836:850 arg2 The O-glycopeptides The O-glycopeptides O-glycopeptides The O-glycopeptides were not detected in the fraction of the variant. 1904072 8 120 gly N-glycosylation 1513:1527 arg2 a potential N-glycosylation site a potential N-glycosylation site site The variable sequence differed from the V kappa IV germline gene by nine point mutations, including an Asp----Asn substitution at position +70 resulting in a potential N-glycosylation site. 1385443 6 34 gly glycosylation 1286:1298 arg2 a glycosylation site a glycosylation site site Since N-linked glycosylation is postulated to facilitate the transport of proteins to the cell surface, we engineered a glycosylation site into hGH-DAF. 10725548 1 35 gly contain 205:211 arg1 The membrane (M) proteins AND only O-linked oligosaccharides The membrane (M) proteins only O-linked oligosaccharides Fterm proteins The membrane (M) proteins of murine coronavirus (MHV) strains have been reported to contain only O-linked oligosaccharides. 32211339 11 85 gly N-glycosylation 1683:1697 arg2 N-glycosylation sites N-glycosylation sites sites However, these mutations directed to N-glycosylation sites had restored immune cell function otherwise impaired due to steric shielding over immune cell ligands by WT Ebola GP. 25533529 0 63 gly N-glycosylation 18:32 arg2 single N-glycosylation site knockout single N-glycosylation site knockout site Effects of single N-glycosylation site knockout on folding and defibrinogenating activities of acutobin recombinants from HEK293T. 10992007 10 62 part_of TSHR 1611:1614 arg1 TSHR ectodomain 1) TSHR TSHR ectodomain PUBTATOR Site 1) TSHR 7253 ectodomain These data indicate that 1) TSHR ectodomain contains six N-linked carbohydrates, and 2) glycosylation of at least four sites appears necessary for expression of the functional TSHR. 11754244 1 14 gly glycopeptides 218:230 arg2 glycopeptides glycopeptides glycopeptides A strategy for determination of O-glycosylation site(s) in glycopeptides has been developed using model compounds obtained by enzymatic glycosylation (by human GaNTase-T2 isoform) on peptides derived from the human MUC5AC mucin tandem repeat motif. 11754244 1 49 gly O-glycosylation 191:205 arg2 O-glycosylation site(s) O-glycosylation site(s) site A strategy for determination of O-glycosylation site(s) in glycopeptides has been developed using model compounds obtained by enzymatic glycosylation (by human GaNTase-T2 isoform) on peptides derived from the human MUC5AC mucin tandem repeat motif. 11754244 1 32 gly glycosylation 295:307 arg1 peptides peptides peptides A strategy for determination of O-glycosylation site(s) in glycopeptides has been developed using model compounds obtained by enzymatic glycosylation (by human GaNTase-T2 isoform) on peptides derived from the human MUC5AC mucin tandem repeat motif. 1379602 6 72 gly N-glycosylation 1284:1298 arg2 the distal N-glycosylation site the distal N-glycosylation site site Characterization of several proteolytic fragments of this epidermal desmoglein enabled us to map the DG3.4 epitope to a 96-kDa intracellular domain and the AE23 epitope to an extracellular domain flanked by the plasma membrane and the distal N-glycosylation site(s). 27641734 11 24 part_of EGF 2017:2019 arg1 GAIN and EGF domains EGF GAIN and EGF domains OGER Site EGF P01133 domains SAXS data for WT and deglycosylated CD97ECD revealed a spatula-like shape with GAIN and EGF domains constituting the body and handle, respectively. 21673010 11 100 part_of rGH-2N 1643:1648 arg1 the fusion site rGH the fusion site Cterm Site rGH 81668 site Transfer of the GAG modification domain from the PG serglycin to the fusion site of rGH-2N and GFP allowed polymerization of GAG chains onto the novel protein variant and influenced the microheterogeneity of the N-glycans toward more acidic glycans, but did not alter the relative site occupancy. 7613477 7 58 gly glycosylation 1594:1606 arg2 potential N-linked glycosylation sites potential N-linked glycosylation sites sites The three additional glycopeptides were determined to be from a copurifying protein, apolipoprotein D, which contains potential N-linked glycosylation sites at Asn45 and Asn78. 7613477 7 98 gly glycopeptides 1478:1490 arg2 The three additional glycopeptides The three additional glycopeptides glycopeptides The three additional glycopeptides were determined to be from a copurifying protein, apolipoprotein D, which contains potential N-linked glycosylation sites at Asn45 and Asn78. 2787353 1 22 gly glycoprotein 181:192 arg1 the human urinary glycoprotein uromodulin the human urinary glycoprotein uromodulin Fterm glycoprotein Utilizing a solid phase binding assay, we have demonstrated that rIL-2 binds with high affinity to the human urinary glycoprotein uromodulin. 30290305 4 33 gly N-glycosylation 785:799 arg2 specific hFSTL1 N-glycosylation sites specific hFSTL1 N-glycosylation sites sites We used modified mRNA (modRNA) technology to investigate the possible role of specific hFSTL1 N-glycosylation sites in the induction, by hFSTL1, of CM proliferation and cardiac regeneration. 28298204 3 55 gly N-glycosylation 637:651 arg2 one potential N-glycosylation site one potential N-glycosylation site site Sea bass IgT consists of 552 aa (Accession Number KM410929) and it contains a putative 19 amino acids long signal peptide and one potential N-glycosylation site. 31202607 7 18 gly N-glycosylation 1427:1441 arg2 a single N-glycosylation site a single N-glycosylation site site We also found that AAL has the most profound effect on GluN1/GluN3 receptors, and this effect is mediated partly by a single N-glycosylation site on the GluN3 subunit (specifically, N565 on GluN3A and N465 on GluN3B). 31202607 7 56 gly subunit 1461:1467 arg1 N565 N565 N565 We also found that AAL has the most profound effect on GluN1/GluN3 receptors, and this effect is mediated partly by a single N-glycosylation site on the GluN3 subunit (specifically, N565 on GluN3A and N465 on GluN3B). 16873272 4 16 part_of subunit 647:653 arg1 The extracellular domains subunit The extracellular domains Fterm Site subunit domains The extracellular domains of the C-terminal TM subunit as well as targeting of the recombinant immunoadhesins by the cognate LP to the secretory pathway were dispensable for target cell binding, suggesting that the PFV Env RBD is contained within the SU subunit. 22279061 8 22 gly glycosylation 1347:1359 arg2 all glycosylation sites all glycosylation sites sites Glycan structure analyses revealed that the core-fucosylated bi-antennary is the common major structure at all glycosylation sites. 10716496 5 14 gly glycosylation 1402:1414 arg2 a V3 region N-linked glycosylation site a V3 region N-linked glycosylation site site Increasing quasispecies diversity in HIV-1 strains, over time, abrogation of a V3 region N-linked glycosylation site in > 60% of the clones, and, importantly, an extended V2 region were unique features of HIV-1 strains from SP and LTNP. 27095603 6 47 part_of transferrin 1092:1102 arg1 glycopeptides transferrin glycopeptides PUBTATOR Site transferrin 7018 glycopeptides In this technical note, the aberrant glycosylation profiles of CDG cases are presented to shed light on the MS of native transferrin and glycopeptides from the viewpoint of clinical glycoproteomics. 11107645 2 25 gly glycosylation 333:345 arg2 potential glycosylation site potential glycosylation site site Discusses the significance of molecular mechanisms (loss of potential glycosylation site(s), optimum pH of HA-mediated fusion, beta-inhibitor sensitivity, pH-dependent association/dissociation of M1 protein with viral RNP, and host factors) involved in adaptation of influenza virus to a new host. 31501225 9 76 gly N-glycopeptides 1351:1365 arg2 The altered N-glycopeptides The altered N-glycopeptides N-glycopeptides The altered N-glycopeptides might be part of a unique glycan signature indicating an IgA-mediated mechanism and providing potential diagnostic clues in HBV-related liver diseases. 22355413 5 35 gly glycosite 981:989 arg2 glycosite migrations glycosite migrations glycosite The results showed that glycosite migrations in human influenza viruses have at least five possible functions: to more effectively mask the antigenic sites, to more effectively protect the enzymatic cleavage sites of neuraminidase (NA), to stabilize the polymeric structures, to regulate the receptor binding and catalytic activities and to balance the binding activity of hemagglutinin (HA) with the release activity of NA. 15342690 1 4 gly glycosylation 192:204 arg2 five potential N-linked glycosylation sites five potential N-linked glycosylation sites sites Human endothelial lipase (EL), a member of the triglyceride lipase gene family, has five potential N-linked glycosylation sites, two of which are conserved in both lipoprotein lipase and hepatic lipase. 10940860 1 13 part_of contains 168:175 arg1 t-PA AND a variably occupied glycosylation site t-PA a variably occupied glycosylation site OGER Site t-PA P00750 site Human tissue-type plasminogen activator (t-PA) contains a variably occupied glycosylation site at Asn-184 in naturally produced t-PA and in t-PA produced in recombinant Chinese hamster ovary (CHO) cells. 10940860 1 13 part_of contains 168:175 arg1 Human tissue-type plasminogen activator AND a variably occupied glycosylation site Human tissue-type plasminogen activator a variably occupied glycosylation site OGER Site tissue-type plasminogen activator P00750 site Human tissue-type plasminogen activator (t-PA) contains a variably occupied glycosylation site at Asn-184 in naturally produced t-PA and in t-PA produced in recombinant Chinese hamster ovary (CHO) cells. 10940860 1 61 part_of site 211:214 arg1 t-PA t-PA site OGER Site t-PA P00750 site Human tissue-type plasminogen activator (t-PA) contains a variably occupied glycosylation site at Asn-184 in naturally produced t-PA and in t-PA produced in recombinant Chinese hamster ovary (CHO) cells. 27177499 5 101 gly N-glycosylation 729:743 arg2 two N-glycosylation sites two N-glycosylation sites sites The α-subunit is identical to the pituitary gonadotropin hormones (LH, FSH, TSH), contains two N-glycosylation sites, and is encoded by a single gene (CGA). 8349699 2 104 gly glycosylated 335:346 arg1 A fourth consensus N-glycosylation sequence A fourth consensus N-glycosylation sequence sequence A fourth consensus N-glycosylation sequence at Asn104 is not glycosylated. 6267033 0 10 gly glycopeptide 81:92 arg2 pro-opiomelanocortin NH2-terminal glycopeptide pro-opiomelanocortin NH2-terminal glycopeptide glycopeptide Primary structure of the major human pituitary pro-opiomelanocortin NH2-terminal glycopeptide. 18636497 4 20 gly glycosylation 766:778 arg2 each glycosylation site each glycosylation site site Although sialylation at each glycosylation site was found to be incomplete, glycans of Asn(25) were more heavily sialylated than those of Asn(97). 18636497 4 41 gly Asn 824:826 arg1 glycans Asn(25) glycans Asn(25) Although sialylation at each glycosylation site was found to be incomplete, glycans of Asn(25) were more heavily sialylated than those of Asn(97). 18636497 4 64 gly sialylated 850:859 arg1 glycans glycans Although sialylation at each glycosylation site was found to be incomplete, glycans of Asn(25) were more heavily sialylated than those of Asn(97). 18636497 4 84 gly site 780:783 arg1 sialylation site sialylation site Although sialylation at each glycosylation site was found to be incomplete, glycans of Asn(25) were more heavily sialylated than those of Asn(97). 18636497 4 85 gly sialylation 746:756 arg1 each glycosylation site each glycosylation site site Although sialylation at each glycosylation site was found to be incomplete, glycans of Asn(25) were more heavily sialylated than those of Asn(97). 8352759 0 34 part_of VIII 32:35 arg1 the factor VIII binding domain structure of the factor VIII the factor VIII binding domain PUBTATOR Site structure of the factor VIII 2157 domain Primary structure of the factor VIII binding domain of human, porcine and rabbit von Willebrand factor. 8352759 0 37 part_of factor 25:30 arg1 the factor VIII binding domain structure of the factor VIII the factor VIII binding domain PUBTATOR Site structure of the factor VIII 2157 domain Primary structure of the factor VIII binding domain of human, porcine and rabbit von Willebrand factor. 11410585 4 34 gly present 798:804 arg1 bovine peripheral myelin P0 AND the HNK-1 epitope bovine peripheral myelin P0 the HNK-1 epitope Cterm P0 We recently described the structure of the N-glycan carrying the HNK-1 epitope, present on bovine peripheral myelin P0 (Voshol, H., van Zuylen, C. W. E. M., Orberger, G., Vliegenthart, J. F. G., and Schachner, M. (1996) J. Biol. 16118277 2 28 gly glycoproteins 371:383 arg1 antigenically different hemagglutinin (HA) glycoproteins antigenically different hemagglutinin (HA) glycoproteins Fterm glycoproteins Two human vaccine candidates recently generated by reverse genetics are based on antigenically different hemagglutinin (HA) glycoproteins derived from the A/HK/213/03 (H5N1) and A/Vietnam/1203/04 (H5N1) viruses. 19808681 6 21 gly N-glycosylation 733:747 arg1 Kv12.2 Kv12.2 PUBTATOR Kv12.2 23416 As an effect of N-glycosylation on the function of Kv12.2, we demonstrate that removal of sugar chains causes a depolarizing shift in the steady-state activation without a significant reduction in current amplitude. 7768952 9 75 gly N-glycosylation 1208:1222 arg2 Asn127 Asn127 Asn127 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg2 A potential N-glycosylation site A potential N-glycosylation site site A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg2 His53 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg2 Asp102 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg1 Ser206 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg1 His53 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg2 Ser206 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg2 Asp102 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg1 Ser206 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg1 His53 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg2 Ser206 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg1 Ser206 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg1 His53 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg2 Ser206 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg1 His53 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg2 Ser206 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 7768952 9 75 gly N-glycosylation 1208:1222 arg2 Ser206 His53, Asp102, and Ser206 His53, Asp102, and Ser206 A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified. 16476981 0 49 gly glycosylation 102:114 arg2 the gp120 V3 loop N-linked glycosylation site the gp120 V3 loop N-linked glycosylation site site CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. 14693913 5 54 gly O-glycosylation 958:972 arg2 potential O-glycosylation sites potential O-glycosylation sites sites The C-terminal 192 residues of hBSSL contain 16 Pro-rich 11-amino-acid repeats, which include 32 Ser/Thr residues as potential O-glycosylation sites. 14693913 5 54 gly O-glycosylation 958:972 arg2 32 Ser/Thr residues 32 Ser/Thr residues residues The C-terminal 192 residues of hBSSL contain 16 Pro-rich 11-amino-acid repeats, which include 32 Ser/Thr residues as potential O-glycosylation sites. 14693913 5 108 gly Pro-rich 879:886 arg1 16 Pro-rich 11-amino-acid repeats Pro 16 Pro-rich 11-amino-acid repeats Pro The C-terminal 192 residues of hBSSL contain 16 Pro-rich 11-amino-acid repeats, which include 32 Ser/Thr residues as potential O-glycosylation sites. 14693913 5 2 gly contain 868:874 arg1 hBSSL AND 16 Pro-rich 11-amino-acid repeats hBSSL residues 16 Pro-rich 11-amino-acid repeats PUBTATOR hBSSL 1056 residues The C-terminal 192 residues of hBSSL contain 16 Pro-rich 11-amino-acid repeats, which include 32 Ser/Thr residues as potential O-glycosylation sites. 29162128 3 83 gly glycosylation 581:593 arg2 the overlapping glycosylation site the overlapping glycosylation site site In this study, site-directed mutagenesis was used to generate single or double mutant rSY-Δ10(10NNAT), rSY-Δ11(10NNSA), and rSY-Δ10/11(10NNAA) of the overlapping glycosylation site (10NNST) on the HA of A/Mallard/Huadong/S/2005(SY). 26853155 0 60 gly N-glycosylation 33:47 arg2 individually silenced N-glycosylation sites individually silenced N-glycosylation sites sites Effects of individually silenced N-glycosylation sites and non-synonymous single-nucleotide polymorphisms on the fusogenic function of human syncytin-2. 9442070 12 41 gly sequence 1949:1956 arg1 the N-glycans sequence the N-glycans sequence As a consequence of both the primary sequence and S-S bond pattern, the N-glycans in IgA1 Fc are not confined within the inter-α-chain space. 9442070 12 117 gly N-glycans 1984:1992 arg1 IgA1 Fc IgA1 Fc N-glycans OGER IgA1 Fc P01876 As a consequence of both the primary sequence and S-S bond pattern, the N-glycans in IgA1 Fc are not confined within the inter-α-chain space. 8573180 1 12 gly N-glycosylation 229:243 arg2 a single N-glycosylation site a single N-glycosylation site site GLUT4, the insulin-responsive glucose transporter expressed primarily in muscle and adipose tissue, contains a single N-glycosylation site. 7717992 5 10 part_of Tf 787:788 arg1 14 translated Tf nucleotide sequences Tf 14 translated Tf nucleotide sequences PUBTATOR Site Tf 24825 sequences Phylogenetic analysis was carried out using 14 translated Tf nucleotide sequences, and the derived evolutionary tree shows that at least three gene duplication events have occurred during Tf evolution, one of which generated the N- and C-terminal domains and occurred before separation of arthropods and chordates. 12538726 2 70 part_of contains 363:370 arg1 The amino acid sequence AND two potential N-linked glycosylation consensus sites sites, N404 and N424 sites, N404 and N424 The amino acid sequence contains two potential N-linked glycosylation consensus sites, N404 and N424. 12538726 2 70 part_of contains 363:370 arg1 The amino acid sequence AND N424 sites, N404 and N424 sites, N404 and N424 The amino acid sequence contains two potential N-linked glycosylation consensus sites, N404 and N424. 12538726 2 70 part_of contains 363:370 arg1 The amino acid sequence AND N424 sites, N404 and N424 sites, N404 and N424 The amino acid sequence contains two potential N-linked glycosylation consensus sites, N404 and N424. 16720579 8 18 gly attached 1579:1586 arg1 the fourth N-glycosylation site AND N-glycan the fourth N-glycosylation site N-glycan site These observations suggest that N-glycan attached to the fourth N-glycosylation site may function in the proper processing of N-glycans required for the Golgi localization, thereby causing the production of the active C6ST-1, and that N-glycan attached to the fifth N-glycosylation site may contribute to the KSST activity of C6ST-1. 16720579 8 32 gly N-glycosylation 1804:1818 arg2 the fifth N-glycosylation site the fifth N-glycosylation site site These observations suggest that N-glycan attached to the fourth N-glycosylation site may function in the proper processing of N-glycans required for the Golgi localization, thereby causing the production of the active C6ST-1, and that N-glycan attached to the fifth N-glycosylation site may contribute to the KSST activity of C6ST-1. 16720579 8 81 gly N-glycosylation 1602:1616 arg2 the fourth N-glycosylation site the fourth N-glycosylation site site These observations suggest that N-glycan attached to the fourth N-glycosylation site may function in the proper processing of N-glycans required for the Golgi localization, thereby causing the production of the active C6ST-1, and that N-glycan attached to the fifth N-glycosylation site may contribute to the KSST activity of C6ST-1. 16720579 8 82 gly attached 1782:1789 arg1 the fifth N-glycosylation site AND N-glycan the fifth N-glycosylation site N-glycan site These observations suggest that N-glycan attached to the fourth N-glycosylation site may function in the proper processing of N-glycans required for the Golgi localization, thereby causing the production of the active C6ST-1, and that N-glycan attached to the fifth N-glycosylation site may contribute to the KSST activity of C6ST-1. 26784534 7 62 gly glycosylation 912:924 arg2 all 10 glycosylation sites all 10 glycosylation sites sites The presence of core 2 O-glycan was also confirmed; interestingly, this structure was not evenly distributed among all 10 glycosylation sites. 2113054 0 28 gly glycoprotein 90:101 arg1 CD4 T lymphocyte glycoprotein CD4 T lymphocyte glycoprotein Fterm glycoprotein High level expression in Chinese hamster ovary cells of soluble forms of CD4 T lymphocyte glycoprotein including glycosylation variants. 8189524 3 75 gly glycoprotein 501:512 arg1 another essential glycoprotein another essential glycoprotein Fterm glycoprotein Since HSV-1 gH is found associated with another essential glycoprotein, gL, we analyzed whether PrV also encodes a gL homolog. 31852790 9 25 gly glycosylation 1702:1714 arg2 residue 144 residue 144 residue 144 Mice were vaccinated with VLPs expressing HA antigens that lacked a glycosylation site at residue 144 and a deleted lysine at position 147 residue were more effective at protecting against morbidity and mortality following infection with pandemic-like and seasonal-like H1N1 influenza viruses.IMPORTANCE There is a great need to develop broadly reactive or universal vaccines against influenza viruses. 31852790 9 25 gly glycosylation 1702:1714 arg2 a glycosylation site a glycosylation site site Mice were vaccinated with VLPs expressing HA antigens that lacked a glycosylation site at residue 144 and a deleted lysine at position 147 residue were more effective at protecting against morbidity and mortality following infection with pandemic-like and seasonal-like H1N1 influenza viruses.IMPORTANCE There is a great need to develop broadly reactive or universal vaccines against influenza viruses. 10191360 4 72 part_of has 557:559 arg1 Kv2.1 AND a consensus site Kv2.1 a consensus site PUBTATOR Site Kv2.1 3745 site Kv2.1, which has a consensus site in the second extracellular interhelical domain, is not N-glycosylated. 9873838 7 71 gly N-glycosylation 1234:1248 arg2 the N-glycosylation site the N-glycosylation site site However, N-glycosylation rate of soluble TCR beta chain in the ER was significantly increased possibly due to the increased exposure of the N-glycosylation site. 9261431 1 84 part_of terminus 435:442 arg1 its envelope protein protein terminus Fterm Site protein terminus The infectivity of Friend ecotropic murine leukemia virus was previously shown to be highly sensitive to modification in its envelope protein (Env) at only one of the eight signals for N-linked glycan attachment, the fourth from the N terminus (gs4). 17606981 7 27 gly glycoprotein 1189:1200 arg1 selective glycoprotein glycosylation selective glycoprotein glycosylation Fterm glycoprotein As specific glycans on specific glycoprotein backbones control critical events in T-cell maturation and survival, understanding mechanisms of selective glycoprotein glycosylation is important for regulating T-cell development and function. 17606981 7 66 gly glycoprotein 1069:1080 arg1 specific glycoprotein backbones specific glycoprotein backbones Fterm glycoprotein As specific glycans on specific glycoprotein backbones control critical events in T-cell maturation and survival, understanding mechanisms of selective glycoprotein glycosylation is important for regulating T-cell development and function. 10580643 0 44 gly glycopeptide 87:98 arg2 an N-linked tau glycopeptide an N-linked tau glycopeptide glycopeptide High level of aspartic acid-bond isomerization during the synthesis of an N-linked tau glycopeptide. 30355697 13 95 gly glycosylation 2233:2245 arg2 hemagglutinin glycosylation site composition hemagglutinin glycosylation site composition position Differences in hemagglutinin glycosylation site composition and heterogeneity seen in antigens produced in different cell substrates suggest differences in processing and downstream immune responses. 30355697 13 95 gly glycosylation 2233:2245 arg2 hemagglutinin glycosylation site composition hemagglutinin glycosylation site composition site Differences in hemagglutinin glycosylation site composition and heterogeneity seen in antigens produced in different cell substrates suggest differences in processing and downstream immune responses. 15514484 6 72 gly glycosylation 1340:1352 arg2 the glycosylation site the glycosylation site site However, hypocalcemic activity, calcitonin-receptor binding activity and the biodistribution of the derivatives were affected by the glycosylation and were dependent on both the carbohydrate structure and the glycosylation site. 6148073 9 34 gly linked 1444:1449 arg2 Asn-75 AND The major glycans Asn-75 The major glycans Asn-75 The major glycans linked to Asn-75 were of structures I and IIB, whereas all three 'complex-type' chains were represented at Asn-99. 17222411 0 0 gly factor 96:101 arg1 glycan structure factor glycan structure Fterm factor Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. 17222411 0 29 gly glycosylation 11:23 arg1 human podoplanin human podoplanin OGER podoplanin Q86YL7 Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. 30295034 1 14 gly glycoprotein 161:172 arg1 a highly glycosylated protein a highly glycosylated protein Fterm protein Alpha-1-acid glycoprotein (AGP) is a highly glycosylated protein from human plasma with five N-type glycosylation sites carrying dominantly higher antennary structures and thus represents a challenging target for characterization of glycan heterogeneity. 30295034 1 14 gly glycoprotein 161:172 arg1 Alpha-1-acid glycoprotein Alpha-1-acid glycoprotein Fterm glycoprotein Alpha-1-acid glycoprotein (AGP) is a highly glycosylated protein from human plasma with five N-type glycosylation sites carrying dominantly higher antennary structures and thus represents a challenging target for characterization of glycan heterogeneity. 30295034 1 29 gly glycosylation 248:260 arg2 five N-type glycosylation sites five N-type glycosylation sites sites Alpha-1-acid glycoprotein (AGP) is a highly glycosylated protein from human plasma with five N-type glycosylation sites carrying dominantly higher antennary structures and thus represents a challenging target for characterization of glycan heterogeneity. 30295034 1 53 gly glycosylated 192:203 arg1 Alpha-1-acid glycoprotein Alpha-1-acid glycoprotein Fterm glycoprotein Alpha-1-acid glycoprotein (AGP) is a highly glycosylated protein from human plasma with five N-type glycosylation sites carrying dominantly higher antennary structures and thus represents a challenging target for characterization of glycan heterogeneity. 30295034 1 53 gly glycosylated 192:203 arg1 a highly glycosylated protein a highly glycosylated protein Fterm protein Alpha-1-acid glycoprotein (AGP) is a highly glycosylated protein from human plasma with five N-type glycosylation sites carrying dominantly higher antennary structures and thus represents a challenging target for characterization of glycan heterogeneity. 30295034 1 40 gly carrying 268:275 arg1 five N-type glycosylation sites AND dominantly higher antennary structures five N-type glycosylation sites dominantly higher antennary structures sites Alpha-1-acid glycoprotein (AGP) is a highly glycosylated protein from human plasma with five N-type glycosylation sites carrying dominantly higher antennary structures and thus represents a challenging target for characterization of glycan heterogeneity. 9581553 6 34 gly glycosylated 1034:1045 arg1 the candidate sites the candidate sites sites Treatment with N-glycanase and analysis by Western blotting of the wild-type and mutant proteins revealed that all of the candidate sites in both FR-alpha and FR-beta are glycosylated. 27938679 7 10 gly glycosylated 1078:1089 arg1 the asparagine residues N256 and N271 asparagine residues N256 and N271 asparagine residues N256 and N271 The increase of electrophoretic mobility of EnvA256 and EnvA271 derived SU showed that the asparagine residues N256 and N271 were also glycosylated. 27938679 7 10 gly glycosylated 1078:1089 arg1 N271 asparagine residues N256 and N271 asparagine residues N256 and N271 The increase of electrophoretic mobility of EnvA256 and EnvA271 derived SU showed that the asparagine residues N256 and N271 were also glycosylated. 27938679 7 10 gly glycosylated 1078:1089 arg1 N271 asparagine residues N256 and N271 asparagine residues N256 and N271 The increase of electrophoretic mobility of EnvA256 and EnvA271 derived SU showed that the asparagine residues N256 and N271 were also glycosylated. 11741940 11 110 part_of protein 1932:1938 arg1 Phe protein Asp(41) and Phe(50) Fterm SpecificSite protein Asp(41) and Phe(50) The predominant N terminus was Ser(31), although minor amounts of the protein with Asp(41) and Phe(50) as the N termini were observed. 11741940 11 110 part_of protein 1932:1938 arg1 Asp(41) protein Asp(41) and Phe(50) Fterm SpecificSite protein Asp(41) and Phe(50) The predominant N terminus was Ser(31), although minor amounts of the protein with Asp(41) and Phe(50) as the N termini were observed. 11741940 11 110 part_of protein 1932:1938 arg1 Asp(41) protein Asp(41) and Phe(50) Fterm SpecificSite protein Asp(41) and Phe(50) The predominant N terminus was Ser(31), although minor amounts of the protein with Asp(41) and Phe(50) as the N termini were observed. 10998266 4 42 gly glycosylation 863:875 arg2 each glycosylation site each glycosylation site site Glycosylation sites and the preliminary glycosylation pattern at each glycosylation site were determined by LC/MS of endoproteinase Glu-C-digested EPO. 10998266 4 71 gly glycosylation 833:845 arg2 each glycosylation site each glycosylation site site Glycosylation sites and the preliminary glycosylation pattern at each glycosylation site were determined by LC/MS of endoproteinase Glu-C-digested EPO. 1455401 4 14 gly nonglycosylated 658:672 arg1 The nonglycosylated pro-UKs The nonglycosylated pro-UKs pro The nonglycosylated pro-UKs were activated by plasmin more efficiently (approximately 2-fold) and were more active in clot lysis (1.5-fold) than the (+)pro-UK. 24196967 7 58 part_of ROM1 1126:1129 arg1 glycosylation site ROM1 glycosylation site PUBTATOR Site ROM1 6094 site Peripherin, but not ROM1, is glycosylated and we examined the glycosylation site and glycan composition of ROM1 by liquid chromatographic tandem mass spectrometry. 26871442 6 46 gly glycoproteins 988:1000 arg1 the E1E2 envelope glycoproteins the E1E2 envelope glycoproteins Fterm glycoproteins At the end of lectin exposure, the genome of the isolated strains was sequenced and several potential resistance mutations in the E1E2 envelope glycoproteins were identified. 16689758 5 11 part_of antithrombin 1147:1158 arg1 the heparin binding site antithrombin the heparin binding site PUBTATOR Site antithrombin 11905 site To evaluate the physiological effect of such a FVIII inhibition, we investigated the ability of the mutant antibody devoid of N-glycosylation in the variable region to prevent thrombosis in mice with a strong prothombotic phenotype resulting from a type II deficiency mutation in the heparin binding site of antithrombin. 6935656 0 57 gly glycosylation 46:58 arg1 murine leukemia virus glycoprotein murine leukemia virus glycoprotein Fterm glycoprotein Relationship of GIX antigen expression to the glycosylation of murine leukemia virus glycoprotein. 6935656 0 98 gly glycoprotein 85:96 arg1 murine leukemia virus glycoprotein murine leukemia virus glycoprotein Fterm glycoprotein Relationship of GIX antigen expression to the glycosylation of murine leukemia virus glycoprotein. 21902591 2 57 part_of gp120 459:463 arg1 variable and constant regions gp120 variable and constant regions PUBTATOR Site gp120 3700 regions We have calculated the relative frequency of each in-frame codon RNY, YNR, RNR, and YNY (N=any nucleotide) in variable and constant regions of gp120, in the sequence within indels and at indels' flanking sites. 23891555 21 94 gly O-glycopeptides 3372:3386 arg1 IgA1 IgA1 O-glycopeptides OGER IgA1 P01876 O-glycopeptides The novelty and biological significance reside in the demonstration, for the first time, of the distribution of the most abundant isoforms of HR O-glycopeptides of IgA1. 30841845 5 122 gly glycosylation 841:853 arg2 glycosylation sites glycosylation sites sites For this purpose, a number of supervised-learning approaches have been proposed to identify glycosylation sites, demonstrating a promising predictive performance. 27679458 7 2 gly N-glycoproteins 1022:1036 arg1 115 serum N-glycoproteins 115 serum N-glycoproteins Fterm N-glycoproteins Subsequent LC-MS/MS analysis allowed for the assignment of 219 N-glycosylation sites from 115 serum N-glycoproteins. 27679458 7 50 gly N-glycosylation 985:999 arg2 219 N-glycosylation sites 219 N-glycosylation sites sites Subsequent LC-MS/MS analysis allowed for the assignment of 219 N-glycosylation sites from 115 serum N-glycoproteins. 11259791 5 55 part_of AChE 825:828 arg1 11 antigenic synthetic decapeptides AChE 11 antigenic synthetic decapeptides PUBTATOR Site AChE 43 decapeptides Seven of 11 antigenic synthetic decapeptides of human brain AChE showed obvious immunoreactivity with the rabbit anti-narcine AChE polyclonal antibodies. 1402806 5 55 part_of protein 869:875 arg1 a potential N-glycosylation site protein a potential N-glycosylation site Fterm Site protein site The M protein of HCV-OC43 shows features typical of all coronavirus M proteins studied: a hydrophilic, presumably external N terminus including about 10% of the protein, and a potential N-glycosylation site followed by three major hydrophobic transmembrane domains. 14736728 0 52 gly glycosylated 16:27 arg1 the glycosylated asparagine residue 286 the glycosylated asparagine residue 286 asparagine residue 286 Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity. 26336134 6 23 gly glycosylation 975:987 arg2 the glycosylation site Asn 125 site Asn 125 site Asn 125 On the other hand, the functional expression of HRG was also dependent on the glycosylation status at its N-terminal, especially at the glycosylation site Asn 125. 9802575 3 35 part_of CD3epsilon 548:557 arg1 the predicted amino acid sequence CD3epsilon the predicted amino acid sequence PUBTATOR Site CD3epsilon 916 sequence Comparison of the predicted amino acid sequence of feline CD3epsilon with those of other mammalians' homologues revealed that a relatively low homology was present in the extracellular domain. 1334131 2 48 gly glycoprotein 312:323 arg1 the glycoprotein genes the glycoprotein genes Fterm glycoprotein Rotavirus positive samples were analyzed for their antigenic properties and amino acid sequences of the glycoprotein genes. 31507595 8 85 gly glycoforms 1353:1362 arg1 CD52-Fc CD52-Fc PUBTATOR CD52 P31358 When glycoforms of CD52-Fc were fractionated by anion exchange MonoQ-GL chromatography, bioactive fractions displayed mainly tetra-antennary, α-2,3 sialylated N-glycan structures and a lower relative abundance of bisecting GlcNAc structures compared to non-bioactive fractions. 31507595 8 115 gly sialylated 1496:1505 arg1 sialylated N-glycan structures sialylated N-glycan structures When glycoforms of CD52-Fc were fractionated by anion exchange MonoQ-GL chromatography, bioactive fractions displayed mainly tetra-antennary, α-2,3 sialylated N-glycan structures and a lower relative abundance of bisecting GlcNAc structures compared to non-bioactive fractions. 26634432 9 58 gly glycosylation 1070:1082 arg1 DMP1 DMP1 PUBTATOR DMP1 13406 These findings indicate that glycosylation of DMP1 is a key posttranslational modification process during development and that DMP1-PG functions as an indispensable proteoglycan in osteogenesis. 1376147 6 61 gly N-glycosylation 968:982 arg2 a novel, second potential N-glycosylation site a novel, second potential N-glycosylation site site Chymase 2 cDNA contains a highly conserved intron/exon junction, a high positive charge (+17) and a novel, second potential N-glycosylation site. 31202607 5 60 gly N-glycosylation 848:862 arg2 putative N-glycosylation sites putative N-glycosylation sites sites We found that removing putative N-glycosylation sites alters the functional properties of GluN1/GluN3B receptors, but has no effect on GluN1/GluN3A receptors. 29274340 8 48 gly glycosylation 1736:1748 arg2 three M6P glycosylation sites three M6P glycosylation sites sites The glycopeptides obtained from protease-digested rhGAA were analyzed using nano-LC-ESI-HCD-MS/MS, and the extracted-ion chromatograms of M6P-derived oxonium ions confirmed three M6P glycosylation sites comprising Asn 140, Asn 233 (newly found), and Asn 470 attached heterogeneously to nine M6P glycans (two types), eight M6P glycans (four types), and seven M6P glycans (two types), respectively. 29274340 8 71 gly glycopeptides 1557:1569 arg2 The glycopeptides The glycopeptides glycopeptides The glycopeptides obtained from protease-digested rhGAA were analyzed using nano-LC-ESI-HCD-MS/MS, and the extracted-ion chromatograms of M6P-derived oxonium ions confirmed three M6P glycosylation sites comprising Asn 140, Asn 233 (newly found), and Asn 470 attached heterogeneously to nine M6P glycans (two types), eight M6P glycans (four types), and seven M6P glycans (two types), respectively. 22649382 4 63 gly N-glycosylation 803:817 arg2 Asn117 Asn117 Asn117 The ability of JAK2 to promote cell surface localization and stability of TpoR required the first N-glycosylation site (Asn117). 22649382 4 63 gly N-glycosylation 803:817 arg2 the first N-glycosylation site the first N-glycosylation site site The ability of JAK2 to promote cell surface localization and stability of TpoR required the first N-glycosylation site (Asn117). 12631291 9 80 part_of isoforms 1139:1146 arg1 The amino acid sequences isoforms The amino acid sequences Fterm Site isoforms sequences The amino acid sequences of both isoforms of the allergen contain four possible N-glycosylation sites. 12631291 9 82 part_of contain 1164:1170 arg1 The amino acid sequences AND four possible N-glycosylation sites The amino acid sequences four possible N-glycosylation sites sites The amino acid sequences of both isoforms of the allergen contain four possible N-glycosylation sites. 7559469 3 8 gly osteonectin 452:462 arg1 oligosaccharide chain structures osteonectin oligosaccharide chain structures PUBTATOR osteonectin 282077 After removal of oligosaccharide chain structures from tHON, bovine bone osteonectin (BBON) and human platelet osteonectin (HPON) by N-glycanase, their ability to bind to type V collagen is increased, and HPON affinity to collagen V is the same as that of BBON. 7559469 3 45 gly osteonectin 414:424 arg1 oligosaccharide chain structures osteonectin oligosaccharide chain structures PUBTATOR osteonectin 282077 After removal of oligosaccharide chain structures from tHON, bovine bone osteonectin (BBON) and human platelet osteonectin (HPON) by N-glycanase, their ability to bind to type V collagen is increased, and HPON affinity to collagen V is the same as that of BBON. 7559469 3 76 gly tHON 396:399 arg1 oligosaccharide chain structures tHON oligosaccharide chain structures Cterm tHON 282077 After removal of oligosaccharide chain structures from tHON, bovine bone osteonectin (BBON) and human platelet osteonectin (HPON) by N-glycanase, their ability to bind to type V collagen is increased, and HPON affinity to collagen V is the same as that of BBON. 27111718 4 74 gly glycopeptides 753:765 arg2 intact glycopeptides intact glycopeptides glycopeptides Complete characterization of protein glycosylation requires the identification of intact glycopeptides in samples, including identification of the modification site as well as the structure of the attached glycans. 22009746 0 37 part_of protein 89:95 arg1 an α7 nicotinic acetylcholine recognition domain protein an α7 nicotinic acetylcholine recognition domain Fterm Site protein domain Creating an α7 nicotinic acetylcholine recognition domain from the acetylcholine-binding protein: crystallographic and ligand selectivity analyses. 26105790 9 39 gly N-glycosylation 1466:1480 arg2 a potential N-glycosylation site a potential N-glycosylation site site Substitution N386K in NA removes a potential N-glycosylation site in neuraminidases of A/Chita/1114/2014, A/Chita/1115/2014, A/Chita/853/2014, A/Barnaul/269/2014, A/Novosibirsk/114/2014, and A/Blagoveshensk/252/2014. 19284292 1 53 gly determinants 252:263 arg1 the protein protein determinants Fterm protein The term 'protein-specific glycosylation' refers to important functional implications of a subset of glycosylation types that are under direct control of recognition determinants on the protein. 8349598 2 18 part_of 6-9 536:538 arg1 present in each of these glycoproteins 6-9 residues 6-9 present in each of these glycoproteins 6-9 residues Cterm Site 6-9 residues The peptide motif ProXaaArg/Lys (PXR/K), which is recognized by a PXR/K-specific GalNAc-transferase, is present in each of these glycoproteins 6-9 residues NH2-terminal to an Asn glycosylation site. 8349598 2 18 part_of 6-9 536:538 arg1 The peptide motif ProXaaArg/Lys 6-9 The peptide motif ProXaaArg/Lys Cterm Site 6-9 ProXaaArg/Lys The peptide motif ProXaaArg/Lys (PXR/K), which is recognized by a PXR/K-specific GalNAc-transferase, is present in each of these glycoproteins 6-9 residues NH2-terminal to an Asn glycosylation site. 23758413 12 44 gly glycoprotein 1859:1870 arg1 the same glycoprotein the same glycoprotein Fterm glycoprotein The other is that multiple targetable glycan features were coresident in the same glycoprotein. 8364230 2 7 part_of activator 552:560 arg1 the serine protease domains tissue plasminogen activator the serine protease domains OGER Site tissue plasminogen activator P19637 domains Furthermore, the effect of the novel plasminogen activator (SUN9216), a plasminogen-plasminogen activator chimera, comprising the fibrin kringle 1 domain of a plasminogen, and the two kringles, and the serine protease domains of wild-type tissue plasminogen activator (t-PA), including a modification of the mannose glycosylation site on the kringle 1 of t-PA (PK1de1FE1X), was studied in this model. 8364230 2 22 part_of plasminogen 453:463 arg1 the fibrin kringle 1 domain plasminogen the fibrin kringle 1 domain OGER Site plasminogen Q01177 domain Furthermore, the effect of the novel plasminogen activator (SUN9216), a plasminogen-plasminogen activator chimera, comprising the fibrin kringle 1 domain of a plasminogen, and the two kringles, and the serine protease domains of wild-type tissue plasminogen activator (t-PA), including a modification of the mannose glycosylation site on the kringle 1 of t-PA (PK1de1FE1X), was studied in this model. 8980650 0 39 gly glycosylation 42:54 arg2 the N-linked glycosylation site the N-linked glycosylation site site Site-directed mutagenesis of the N-linked glycosylation site in platelet-derived growth factor B-chain results in diminished intracellular retention. 10698685 5 7 part_of has 652:654 arg1 HFARP AND a highly hydrophobic region HFARP a highly hydrophobic region PUBTATOR Site HFARP 51129 region HFARP has a highly hydrophobic region at the N-terminus that is typical of a secretory signal sequence and one consensus glycosylation site. 17222411 2 38 part_of podoplanin 333:342 arg1 the PLAG domain podoplanin the PLAG domain OGER Site podoplanin Q86YL7 domain Podoplanin possesses a platelet aggregation-stimulating (PLAG) domain, and Thr52 in the PLAG domain of human podoplanin is important for its activity. 17222411 2 47 part_of Thr52 299:303 arg1 human podoplanin podoplanin Thr52 OGER AminoAcid podoplanin Q86YL7 domain, and Thr52 Podoplanin possesses a platelet aggregation-stimulating (PLAG) domain, and Thr52 in the PLAG domain of human podoplanin is important for its activity. 17222411 2 48 part_of possesses 235:243 arg1 Podoplanin AND a platelet aggregation-stimulating (PLAG) domain Podoplanin a platelet aggregation-stimulating (PLAG) domain OGER AminoAcid Podoplanin Q86YL7 domain, and Thr52 Podoplanin possesses a platelet aggregation-stimulating (PLAG) domain, and Thr52 in the PLAG domain of human podoplanin is important for its activity. 31097672 3 4 gly O-glycosylation 523:537 arg2 one known O-glycosylation site one known O-glycosylation site site The backbone amino acid sequences of fetuin coded by the AHSG*1 and AHSG*2 genes differ in two amino acids including one known O-glycosylation site (aa position 256). 31097672 3 4 gly O-glycosylation 523:537 arg2 aa position 256 aa position 256 position 256 The backbone amino acid sequences of fetuin coded by the AHSG*1 and AHSG*2 genes differ in two amino acids including one known O-glycosylation site (aa position 256). 25636227 3 16 part_of proteins 526:533 arg1 the O-glycosylation sites proteins the O-glycosylation sites Fterm Site proteins sites In this work, we designed a rapid and convenient workflow for characterizing the O-glycosylation sites of individual proteins and the human-plasma proteome. 7890742 5 25 gly occupied 620:627 arg2 the single CD52 N-glycosylation site the single CD52 N-glycosylation site site The results showed that the single CD52 N-glycosylation site is occupied by large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides. 7890742 5 47 gly N-glycosylation 596:610 arg2 the single CD52 N-glycosylation site the single CD52 N-glycosylation site site The results showed that the single CD52 N-glycosylation site is occupied by large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides. 7890742 5 73 gly sialylated 638:647 arg1 large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides The results showed that the single CD52 N-glycosylation site is occupied by large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides. 7916636 6 24 gly N-glycosylation 765:779 arg2 a N-glycosylation site a N-glycosylation site site Only human kallikrein evolves with an additional Thr-108 and with a N-glycosylation site at aa-141. 12527303 6 18 part_of Cgamma3 994:1000 arg1 the C-terminal Cgamma3 domains Cgamma3 the C-terminal Cgamma3 domains PUBTATOR Site Cgamma3 3502 domains The IgG-Fc is a homodimer of N-linked glycopeptide chains comprised of two immunoglobulin domains (Cgamma2, Cgamma3) that dimerise via inter-heavy chain disulphide bridges at the N-terminal region and non-covalent interactions between the C-terminal Cgamma3 domains. 15175256 2 80 gly glycosylation 351:363 arg2 N-linked glycosylation site (sequon) variation N-linked glycosylation site (sequon) variation site Here we explore N-linked glycosylation site (sequon) variation at the population level in these viruses, using a new Web-based program developed to facilitate the sequon tracking and to define patterns (www.hiv.lanl.gov). 12237433 10 2 part_of positions 1423:1431 arg1 H2 drift variants variants positions Fterm Site variants positions Several amino acid changes in the H5 escape mutants occurred at the positions of reported changes in H2 drift variants. 12237433 10 36 part_of variants 1465:1472 arg1 the positions variants the positions Fterm Site variants positions Several amino acid changes in the H5 escape mutants occurred at the positions of reported changes in H2 drift variants. 24334224 3 61 gly glycosylation 785:797 arg2 the specific O-linked glycosylation site the specific O-linked glycosylation site site Peptide mappings using protease and chemical cleavages were performed to determine the specific O-linked glycosylation site used by Pichia-derived rhG-CSF. 23883840 6 1 gly glycosylation 1015:1027 arg2 a glycosylation site a glycosylation site site In addition, two additional rare mutations were also observed at positions S162N (addition of a glycosylation site, 6.25%) and A186T (receptor binding region, 6.25%). 23883840 6 9 gly positions 984:992 arg1 receptor binding region receptor binding region region In addition, two additional rare mutations were also observed at positions S162N (addition of a glycosylation site, 6.25%) and A186T (receptor binding region, 6.25%). 31325506 0 31 gly sialylated 93:102 arg1 sialylated glycans sialylated glycans N-glycans of bovine submaxillary mucin contain core-fucosylated and sulfated glycans but not sialylated glycans. 31325506 0 47 gly mucin 33:37 arg1 N-glycans mucin N-glycans PUBTATOR mucin 281333 N-glycans of bovine submaxillary mucin contain core-fucosylated and sulfated glycans but not sialylated glycans. 31325506 0 70 gly core-fucosylated 47:62 arg1 core-fucosylated and sulfated glycans core-fucosylated and sulfated glycans N-glycans of bovine submaxillary mucin contain core-fucosylated and sulfated glycans but not sialylated glycans. 29759137 1 21 gly N-glycosylation 120:134 arg2 a conserved N-glycosylation site a conserved N-glycosylation site site Immunoglobulin G (IgG) harbors a conserved N-glycosylation site which is important for its effector functions. 11948877 5 48 gly glycosylation 1526:1538 arg2 the single glycosylation site ovalbumin site Fterm ovalbumin site The degree of Gal-biotin tag transfer onto agalactosylated hybrid N-glycans present at the single glycosylation site of ovalbumin was dependent on the Gal-T used (either beta3Gal-T5, beta4Gal-T4, or beta4Gal-T1), which indicates that the acceptor specificity may direct the transfer of the Gal-biotin tag. 11948877 5 65 gly present 1504:1510 arg1 the single glycosylation site AND agalactosylated hybrid N-glycans ovalbumin site agalactosylated hybrid N-glycans Fterm ovalbumin site The degree of Gal-biotin tag transfer onto agalactosylated hybrid N-glycans present at the single glycosylation site of ovalbumin was dependent on the Gal-T used (either beta3Gal-T5, beta4Gal-T4, or beta4Gal-T1), which indicates that the acceptor specificity may direct the transfer of the Gal-biotin tag. 21264968 0 47 gly O-glycosylation 90:104 arg1 synthetic mucin peptides synthetic mucin peptides peptides An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides. 21264968 0 103 gly glycopeptides 61:73 arg2 mucin-type glycopeptides mucin-type glycopeptides glycopeptides An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides. 14517968 4 8 part_of site 726:729 arg1 all four human gamma-crystallins gamma-crystallins site OGER Site gamma-crystallins P22914 site An N-glycosylation site in human gammaD-crystallin and several phosphorylation sites in all four human gamma-crystallins were predicted by the PROSITE search. 14517968 4 8 part_of site 726:729 arg1 human gammaD-crystallin gammaD-crystallin site Fterm Site gammaD-crystallin site An N-glycosylation site in human gammaD-crystallin and several phosphorylation sites in all four human gamma-crystallins were predicted by the PROSITE search. 14517968 4 32 part_of sites 786:790 arg1 all four human gamma-crystallins gamma-crystallins sites OGER Site gamma-crystallins P22914 sites An N-glycosylation site in human gammaD-crystallin and several phosphorylation sites in all four human gamma-crystallins were predicted by the PROSITE search. 14517968 4 32 part_of sites 786:790 arg1 human gammaD-crystallin gammaD-crystallin sites Fterm Site gammaD-crystallin sites An N-glycosylation site in human gammaD-crystallin and several phosphorylation sites in all four human gamma-crystallins were predicted by the PROSITE search. 11897784 0 66 part_of has 89:91 arg1 The protein kinase/endoribonuclease IRE1alpha AND a luminal N-terminal ligand-independent dimerization domain The protein kinase/endoribonuclease IRE1alpha a luminal N-terminal ligand-independent dimerization domain PUBTATOR Site IRE1alpha 2081 domain The protein kinase/endoribonuclease IRE1alpha that signals the unfolded protein response has a luminal N-terminal ligand-independent dimerization domain. 30115684 5 56 gly glycopeptides 1026:1038 arg2 tryptic glycopeptides tryptic glycopeptides glycopeptides Selective labeling of gp120 by N-azidoacetylmannosamine (ManNAz) and N-azidoacetylgalactosamine (GalNAz) incorporation into the gp120 glycan shield was characterized by mass spectrometry of tryptic glycopeptides. 27725718 4 43 gly glycosylation 582:594 arg2 the reduced glycosylation site occupancy the reduced glycosylation site occupancy site A hallmark in a subset of CDG cases is the reduced glycosylation site occupancy of asparagine-linked glycans. 27725718 4 52 gly asparagine-linked 614:630 arg1 asparagine-linked glycans asparagine asparagine-linked glycans asparagine A hallmark in a subset of CDG cases is the reduced glycosylation site occupancy of asparagine-linked glycans. 27725718 4 27 gly occupancy 601:609 arg1 asparagine-linked glycans site asparagine-linked glycans site A hallmark in a subset of CDG cases is the reduced glycosylation site occupancy of asparagine-linked glycans. 11948877 3 28 gly albumin-p-aminophenyl 1094:1114 arg1 BSA-(GlcNAc)17 albumin BSA-(GlcNAc)17 OGER albumin P02768 It could be demonstrated for the first time, by use of UDP-6-biotinyl-Gal as a donor substrate, that the human recombinant galactosyltransferases beta3Gal-T5, beta4Gal-T1, and beta4Gal-T4 mediate biotinylation of the neoglycoconjugate bovine serum albumin-p-aminophenyl N-acetyl-beta-D-glucosaminide (BSA-(GlcNAc)17) and ovalbumin. 8879142 3 56 part_of UL3 520:522 arg1 synthetic UL3 peptides UL3 synthetic UL3 peptides PUBTATOR Site UL3 2703461 peptides Western blotting was done using polyclonal antibody raised against synthetic UL3 peptides. 2033065 8 1 gly glycosylation 1511:1523 arg2 the specific glycosylation site the specific glycosylation site site Utilizing synthetic substrate, both the Km and kcat were affected, depending on the specific glycosylation site eliminated. 9524075 0 57 gly non-glycosylated 11:26 arg1 non-glycosylated human procathepsin non-glycosylated human procathepsin Fterm procathepsin S 1520 Sorting of non-glycosylated human procathepsin S in mammalian cells. 30841845 12 109 gly glycosylation 2296:2308 arg2 protein glycosylation sites protein glycosylation sites sites In addition, we developed an online web server as an implementation of the optimized model (available at http://glycomine.erc.monash.edu/Lab/GlycoMine_PU/ ) to facilitate community-wide efforts for accurate prediction of protein glycosylation sites. 12626422 9 86 gly glycoproteins 1755:1767 arg1 glycoproteins glycoproteins Fterm glycoproteins The implications of this observation for the intracellular transport and sorting of glycoproteins are discussed. 7476998 5 87 part_of Fc 844:845 arg1 purified Fab and Fc fragments Fc purified Fab and Fc fragments Cterm Site Fc fragments The sugar chains were released from purified Fab and Fc fragments by hydrazinolysis and converted to radioactive oligosaccharides by reduction with sodium borotritide. 9472921 6 46 part_of DNA 683:685 arg1 A mouse genomic DNA fragment DNA A mouse genomic DNA fragment Cterm Site DNA fragment A mouse genomic DNA fragment was found to hybridize with a rat PLP-A cDNA. 23029648 5 6 gly glycosylation 622:634 arg2 glycosylation site detection glycosylation site detection site This review presents a short overview about common enrichment techniques and glycosylation site detection for N-glycopeptides, including benefits and challenges of analysis. 23029648 5 40 gly N-glycopeptides 655:669 arg2 N-glycopeptides N-glycopeptides N-glycopeptides This review presents a short overview about common enrichment techniques and glycosylation site detection for N-glycopeptides, including benefits and challenges of analysis. 17263644 7 43 gly glycosylation 986:998 arg2 a predicted glycosylation site a predicted glycosylation site site The V3 region of CXCR4-using viruses contained genetic traits characteristic of CXCR4-using subtype B and C viruses, such as increased charge, the presence of positively charged residues at positions 11 and 25, and loss of a predicted glycosylation site. 7559653 4 21 gly glycosylation 832:844 arg2 no N-linked glycosylation site no N-linked glycosylation site site Binding of pneumococci to COS cells transfected with the human PAF receptor is greatly reduced for a receptor mutant that bears no N-linked glycosylation site. 6195967 9 39 part_of terminus 1331:1338 arg1 20 residues terminus 20 residues residues The cyanogen bromide fragment containing the galactosamine-containing carbohydrate in Gc1 was partially sequenced through 20 residues from the amino terminus. 15514484 5 42 gly glycosylation 1111:1123 arg2 the glycosylation site the glycosylation site site The conformation of the peptide backbone did not change irrespective of the carbohydrate structure or the glycosylation site. 26458842 0 44 gly N-glycosylation 18:32 arg2 ancestral N-glycosylation sites ancestral N-glycosylation sites sites Loss of ancestral N-glycosylation sites in conserved proteins during human evolution. 18083044 4 18 gly glycosylation 651:663 arg2 a glycosylation site a glycosylation site site This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members. 18083044 4 18 gly glycosylation 651:663 arg1 transmembrane region region region This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members. 14691230 7 78 gly N-glycosylation 1232:1246 arg2 the N-glycosylation site mutants the N-glycosylation site mutants site The kinetic parameters of dipeptidyl peptidase cleavage of wild-type DPPIV and the N-glycosylation site mutants were determined by using Ala-Pro-AFC and Gly-Pro-pNA as substrates and varied by <50%. 23921623 1 35 part_of possess 166:172 arg1 Most street rabies virus glycoproteins AND two N-glycosylation sites Most street rabies virus glycoproteins two N-glycosylation sites Fterm Site glycoproteins sites Most street rabies virus glycoproteins (G proteins) possess two N-glycosylation sites, at Asn(37) and Asn(319), whereas an additional N-glycosylation site is present in several fixed (laboratory-adapted) rabies virus strains at Asn(247), which suggests that the N-glycosylation addition may be a marker of fixed viruses. 23921623 1 35 part_of possess 166:172 arg1 G proteins AND two N-glycosylation sites G proteins two N-glycosylation sites Fterm Site proteins sites Most street rabies virus glycoproteins (G proteins) possess two N-glycosylation sites, at Asn(37) and Asn(319), whereas an additional N-glycosylation site is present in several fixed (laboratory-adapted) rabies virus strains at Asn(247), which suggests that the N-glycosylation addition may be a marker of fixed viruses. 7937884 6 1 part_of protein 742:748 arg1 the partial protein sequence protein the partial protein sequence Fterm Site protein sequence Inosine-containing oligonucleotides based on the partial protein sequence were used to isolate a 679-bp cDNA for LTC4S from THP-1 cells. 10861210 0 67 gly glycoprotein 101:112 arg1 membrane glycoprotein membrane glycoprotein Fterm glycoprotein Processing of N-linked oligosaccharide depends on its location in the anion exchanger, AE1, membrane glycoprotein. 15351488 5 63 part_of sites 812:816 arg1 the two envelope proteins proteins sites Fterm Site proteins sites In addition, postulated N- and O-linked glycosylation sites in the two envelope proteins (Gn and Gc) were investigated individually by site-directed mutagenesis followed by gel-shift analysis. 2123094 0 58 part_of sequence 15:22 arg1 secretory immunoglobulin A secretory immunoglobulin A sequence Cterm Site secretory immunoglobulin A sequence The amino acid sequence of rabbit J chain in secretory immunoglobulin A. 8991508 5 22 gly O-glycosylation 540:554 arg2 only a few probable O-glycosylation sites only a few probable O-glycosylation sites sites The first of these contains over 30% Thr, Ser, and Pro, but only a few probable O-glycosylation sites. 14695241 2 11 part_of Asn357 312:317 arg1 factor V factor V Asn357 OGER AminoAcid factor V P12259 Asn357 This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions. 14695241 2 11 part_of Asn357 312:317 arg1 FV FV Asn357 Cterm AminoAcid FV P12259 Asn357 This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions. 14695241 2 30 part_of site 271:274 arg1 factor V factor V site OGER Site factor V P12259 site This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions. 14695241 2 30 part_of site 271:274 arg1 FV FV site Cterm Site FV P12259 site This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions. 31004621 7 10 gly N-glycosylation 1256:1270 arg2 the individual RSV F N-glycosylation sites the individual RSV F N-glycosylation sites sites Although the individual RSV F N-glycosylation sites were shown not to be essential for viral replication, they do contribute to the efficiency of in vitro and in vivo viral infection. 23562646 7 64 gly glycosylation 1158:1170 arg2 Single glycosylation site mutants Single glycosylation site mutants site Single glycosylation site mutants (G1, G2 and G4) not only impaired fusion promotion activity but also reduced HAD activity of HN protein, which was even more obvious for all three double mutants (G12, G14 and G24) and the triple mutant (G124). 16386114 3 25 part_of motif 316:320 arg1 the C3 region motif the C3 region region We found a novel GPGGMI motif in the V3 loop, a novel insertion of a proline in the C3 region, and persistent deletion of two amino acids in the vif gene. 16386114 3 30 part_of region 379:384 arg1 a novel GPGGMI motif region a novel GPGGMI motif motif We found a novel GPGGMI motif in the V3 loop, a novel insertion of a proline in the C3 region, and persistent deletion of two amino acids in the vif gene. 8349598 2 24 gly glycosylation 572:584 arg2 an Asn glycosylation site an Asn glycosylation site site The peptide motif ProXaaArg/Lys (PXR/K), which is recognized by a PXR/K-specific GalNAc-transferase, is present in each of these glycoproteins 6-9 residues NH2-terminal to an Asn glycosylation site. 8349598 2 87 gly glycoproteins 522:534 arg1 these glycoproteins these glycoproteins Fterm glycoproteins The peptide motif ProXaaArg/Lys (PXR/K), which is recognized by a PXR/K-specific GalNAc-transferase, is present in each of these glycoproteins 6-9 residues NH2-terminal to an Asn glycosylation site. 22855498 12 97 gly glycoprotein 1688:1699 arg1 glycoprotein fitness glycoprotein fitness Fterm glycoprotein Mathematical modeling of the dynamics of competing HCV variants indicated that relatively modest differences in glycoprotein fitness can result in marked shifts in virus population composition. 26956484 10 22 gly glycosylation 1429:1441 arg1 Orai1 Orai1 PUBTATOR Orai1 84876 In summary, the glycosylation state of Orai1 influences SOCE-mediated Ca(2+) signaling and, thus, may contribute to pathophysiological Ca(2+) signaling observed in immune disease and cancer. 20077667 7 86 part_of sites 1379:1383 arg1 Fusion protein protein sites Fterm Site protein sites CONCLUSION: The F genes of H1 genotype measles virus circulated in China mainland during 1999-2003 had no sig-nificant vibration, and known important functional sites in Fusion protein didn't have deviation, it could be postulated that the structure and functions of F protein of wild Measles viruses circulated in mainland China from 1999 to 2003 were conserved. 27007620 1 31 gly glycosylation 99:111 arg1 proteins proteins Fterm proteins Abnormal glycosylation of proteins is known to be either resultant or causative of a variety of diseases. 17927214 3 77 gly CI-MPR 846:851 arg1 Man-6-P binding CI-MPR Man-6-P binding PUBTATOR CI-MPR 3482 A structure-based sequence alignment predicts that domain 5 contains the four conserved residues (Gln, Arg, Glu, Tyr) identified as essential for Man-6-P binding by the CD-MPR and domains 1-3 and 9 of the CI-MPR. 8636138 2 0 gly O-glycosylation 284:298 arg2 a single well characterized O-glycosylation site a single well characterized O-glycosylation site site We have developed a novel in vivo system to analyze the role of flanking sequence on the modification of a single well characterized O-glycosylation site derived from human von Willebrand factor (PHMAQVTVGPGL). 12175915 7 80 part_of RFC-Gln 1531:1537 arg1 deglycosylated RFC-Gln RFC deglycosylated RFC-Gln PUBTATOR SpecificSite RFC 6573 Gln(58) Insertion of a consensus N-glycosylation site [NX(S/T)] into putative loops 5/6, 8/9, and 9/10 of deglycosylated RFC-Gln(58) had minimal effects on MTX transport. 17951640 2 16 part_of plasminogen 364:374 arg1 a His-tagged Kringle 3 domain plasminogen a His-tagged Kringle 3 domain OGER Site plasminogen P00747 domain A reporter protein with a single N-linked glycosylation site, a His-tagged Kringle 3 domain of human plasminogen (K3), was used to identify combinations of optimal leader/catalytic domain(s) to recreate human N-glycan processing in the Pichia system. 17951640 2 48 part_of protein 274:280 arg1 a single N-linked glycosylation site protein a single N-linked glycosylation site Fterm Site protein site A reporter protein with a single N-linked glycosylation site, a His-tagged Kringle 3 domain of human plasminogen (K3), was used to identify combinations of optimal leader/catalytic domain(s) to recreate human N-glycan processing in the Pichia system. 12490395 2 42 part_of containing 470:479 arg1 Env protein AND R peptide Env protein R peptide PUBTATOR Site Env protein 30816 peptide This cell line is unique in its response to the ecotropic MLV envelope (Env) protein in that it undergoes syncytium formation with cells expressing Env protein containing R peptide (R+ Env), which is known to suppress the fusogenic potential of the Env protein in other susceptible cells. 20506028 2 63 gly glycosylation 331:343 arg2 an N-linked glycosylation site an N-linked glycosylation site site ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein. 20506028 2 24 gly domains 255:261 arg1 a C-terminal hydrophobic domain domain domain ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein. 26029999 6 31 gly glycosylation 907:919 arg2 Asn548 site Asn548 site Asn548 However, mutation at glycosylation site Asn548 significantly decreased the ability of CD133 to promote hepatoma cell growth. 17636988 3 19 gly N-glycosylation 603:617 arg2 N-glycosylation site analysis N-glycosylation site analysis site Here, we have used two different enzymatic deglycosylation strategies for N-glycosylation site analysis. 9639536 2 35 gly alpha1-acid-glycoprotein 448:471 arg1 human plasma alpha1-acid-glycoprotein human plasma alpha1-acid-glycoprotein Fterm alpha1-acid-glycoprotein High performance liquid chromatography-electrospray mass spectrometry (HPLC-ESI/MS) was used to identify which of the five N-linked glycosylation sites of human plasma alpha1-acid-glycoprotein (orosomucoid, OMD) contain the sialyl Lewis(x) antigen. 9639536 2 91 gly glycosylation 412:424 arg2 the five N-linked glycosylation sites alpha1-acid-glycoprotein sites Fterm alpha1-acid-glycoprotein sites High performance liquid chromatography-electrospray mass spectrometry (HPLC-ESI/MS) was used to identify which of the five N-linked glycosylation sites of human plasma alpha1-acid-glycoprotein (orosomucoid, OMD) contain the sialyl Lewis(x) antigen. 31514875 3 1 gly glycoproteins 635:647 arg1 glycoproteins glycoproteins Fterm glycoproteins In this work, two Immobilized Enzyme Reactors (IMERs) based on trypsin and pepsin protease were used for the first time to fasten and improve the reliability of the specific mapping of the N-glycosylation heterogeneity of glycoproteins. 31514875 3 4 gly heterogeneity 618:630 arg1 glycoproteins glycoproteins Fterm glycoproteins In this work, two Immobilized Enzyme Reactors (IMERs) based on trypsin and pepsin protease were used for the first time to fasten and improve the reliability of the specific mapping of the N-glycosylation heterogeneity of glycoproteins. 15616123 0 37 gly glycosylation 14:26 arg1 human apolipoprotein B100 human apolipoprotein B100 PUBTATOR apolipoprotein B100 338 Site-specific glycosylation analysis of human apolipoprotein B100 using LC/ESI MS/MS. 18340083 7 55 gly N-glycosylation 906:920 arg2 the N-glycosylation site the N-glycosylation site site Mutating the N-glycosylation site in mouse GPIHBP1 results in an accumulation of GPIHBP1 in the endoplasmic reticulum and a markedly reduced amount of the protein on the cell surface. 9658108 5 67 part_of havcr-1 941:947 arg1 its first N-glycosylation site havcr-1 its first N-glycosylation site OGER Site havcr-1 Q96D42 site The six Cys residues of the extracellular domain of havcr-1 and its first N-glycosylation site were conserved in huhavcr-1. 9658108 5 67 part_of havcr-1 941:947 arg1 the extracellular domain havcr-1 the extracellular domain OGER Site havcr-1 Q96D42 domain The six Cys residues of the extracellular domain of havcr-1 and its first N-glycosylation site were conserved in huhavcr-1. 12235182 3 15 gly glycosylation 767:779 arg2 the five N-linked glycosylation sites the five N-linked glycosylation sites sites When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected. 12235182 3 62 gly apoB-37 794:800 arg1 N(1341) N(158), N(956), N(1341), N(1350), and N(1496) N(158), N(956), N(1341), N(1350), and N(1496) When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected. 12235182 3 62 gly apoB-37 794:800 arg1 N(956) N(158), N(956), N(1341), N(1350), and N(1496) N(158), N(956), N(1341), N(1350), and N(1496) When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected. 12235182 3 62 gly apoB-37 794:800 arg1 N(158) N(158), N(956), N(1341), N(1350), and N(1496) N(158), N(956), N(1341), N(1350), and N(1496) When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected. 12235182 3 62 gly apoB-37 794:800 arg1 N(1496) N(158), N(956), N(1341), N(1350), and N(1496) N(158), N(956), N(1341), N(1350), and N(1496) When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected. 12235182 3 62 gly apoB-37 794:800 arg1 N(956) N(158), N(956), N(1341), N(1350), and N(1496) N(158), N(956), N(1341), N(1350), and N(1496) When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected. 12235182 3 62 gly apoB-37 794:800 arg1 N(158) N(158), N(956), N(1341), N(1350), and N(1496) N(158), N(956), N(1341), N(1350), and N(1496) When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected. 12235182 3 62 gly apoB-37 794:800 arg1 N(1496) N(158), N(956), N(1341), N(1350), and N(1496) N(158), N(956), N(1341), N(1350), and N(1496) When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected. 12235182 3 62 gly apoB-37 794:800 arg1 N(158) N(158), N(956), N(1341), N(1350), and N(1496) N(158), N(956), N(1341), N(1350), and N(1496) When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected. 12235182 3 62 gly apoB-37 794:800 arg1 N(1496) N(158), N(956), N(1341), N(1350), and N(1496) N(158), N(956), N(1341), N(1350), and N(1496) When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected. 12235182 3 62 gly apoB-37 794:800 arg1 N(1496) N(158), N(956), N(1341), N(1350), and N(1496) N(158), N(956), N(1341), N(1350), and N(1496) When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected. 12022871 0 60 gly glycosylation 137:149 arg2 a glycosylation site a glycosylation site site Structure-function analysis of human triacylglycerol hydrolase by site-directed mutagenesis: identification of the catalytic triad and a glycosylation site. 12022871 0 70 gly analysis 19:26 arg1 a glycosylation site a glycosylation site site Structure-function analysis of human triacylglycerol hydrolase by site-directed mutagenesis: identification of the catalytic triad and a glycosylation site. 10597188 1 87 gly glycoprotein 83:94 arg1 Glycodelin Glycodelin PUBTATOR Glycodelin 5047 Glycodelin is a 28 kDa glycoprotein with structural homology to beta-lactoglobulins, particularly expressed in steroid-responsive tissues of the female reproductive tract. 10597188 1 87 gly glycoprotein 83:94 arg1 a 28 kDa glycoprotein a 28 kDa glycoprotein Fterm glycoprotein Glycodelin is a 28 kDa glycoprotein with structural homology to beta-lactoglobulins, particularly expressed in steroid-responsive tissues of the female reproductive tract. 7309750 13 12 gly glycosylation 1696:1708 arg2 Each glycosylation site Each glycosylation site site Each glycosylation site is partially phosphorylated. 22677411 9 78 gly glycopeptide 1323:1334 arg2 the glycopeptide level the glycopeptide level glycopeptide Glycosylation is studied at the glycopeptide level (i.e. following proteolytic digestion). 22561161 1 48 part_of C-terminal 248:257 arg1 a C-terminal signal peptide C a C-terminal signal peptide Cterm Site C 19122 peptide Doppel (Dpl) protein is a paralog of the prion protein (PrP) that shares 25% sequence similarity with the C-terminus of PrP, a common N-glycosylation site and a C-terminal signal peptide for attachment of a glycosylphophatidyl inositol anchor. 23050552 5 38 gly glycopeptides 562:574 arg2 proteinase K-generated fibrinogen glycopeptides proteinase K-generated fibrinogen glycopeptides glycopeptides Here, we make use of tryptic- and proteinase K-generated fibrinogen glycopeptides for the detailed analysis of the protein's O-glycosylation by combining information obtained from both one- and two-dimensional nanoLC-ESI-ion trap (IT)-MS approaches. 18585921 2 24 part_of seipin 285:290 arg1 the N-glycosylation site seipin the N-glycosylation site PUBTATOR Site seipin 26580 site Mutations in the N-glycosylation site of seipin are associated with the disease states and result in accumulation of unfolded protein in the endoplasmic reticulum (ER), leading to the unfolded protein response (UPR) and cell death, suggesting that these diseases are tightly associated with ER stress. 7980452 7 36 part_of IFN-gamma 1186:1194 arg1 IFN-gamma polypeptides IFN-gamma IFN-gamma polypeptides PUBTATOR Site IFN-gamma 3458 polypeptides The formation of biologically active dimers was more efficient for IFN-gamma polypeptides that had the intact glycosylation site at Asn-25 as compared with the other two mutant forms of IFN-gamma. 10713140 6 32 gly N-glycosylation 1098:1112 arg2 less than two N-glycosylation sites less than two N-glycosylation sites sites The mutants with less than two N-glycosylation sites do not interact with calnexin and show a complete absence of enzyme activity. 20591501 4 11 gly N-glycosylation 577:591 arg2 a potential N-glycosylation site a potential N-glycosylation site site The deduced amino acid sequence contains a predicted transmembrane domain, a putative furin protease cleavage site, a potential N-glycosylation site and conserved cysteine residues similar to that identified in other mammalian BAFF. 12466020 2 26 part_of contains 378:385 arg1 hCTR1 AND three transmembrane domains hCTR1 three transmembrane domains PUBTATOR Site hCTR1 1317 domains Both approaches indicated that hCTR1 contains three transmembrane domains and that the N-terminus of hCTR1, which contains several putative copper-binding sites, is localized extracellularly, whereas the C-terminus is exposed to the cytosol. 8379944 12 2 gly N-glycosylation 1779:1793 arg2 all four potential N-glycosylation sites all four potential N-glycosylation sites sites The results demonstrate that all four potential N-glycosylation sites in LCAT are used and the presence of carbohydrate at each site has diverse effects on the enzyme activity. 8379944 12 35 gly presence 1826:1833 arg1 each site AND carbohydrate each site carbohydrate site The results demonstrate that all four potential N-glycosylation sites in LCAT are used and the presence of carbohydrate at each site has diverse effects on the enzyme activity. 8379944 12 43 gly used 1813:1816 arg2 all four potential N-glycosylation sites all four potential N-glycosylation sites sites The results demonstrate that all four potential N-glycosylation sites in LCAT are used and the presence of carbohydrate at each site has diverse effects on the enzyme activity. 23090399 0 2 part_of protein 59:65 arg1 the folded domain protein the folded domain Fterm Site protein domain Structural studies on the folded domain of the human prion protein bound to the Fab fragment of the antibody POM1. 23090399 0 17 part_of Fab 80:82 arg1 the Fab fragment Fab the Fab fragment PUBTATOR Site Fab 2187 fragment Structural studies on the folded domain of the human prion protein bound to the Fab fragment of the antibody POM1. 29273683 3 59 gly N-glycosylation 287:301 arg2 N-glycosylation sites N-glycosylation sites sites Glycosylation of human CBG influences its steroid-binding activity, and there are N-glycosylation sites in the reactive center loops (RCLs) of human and rat CBGs. 29273683 3 75 gly Glycosylation 205:217 arg1 human CBG human CBG PUBTATOR CBG 866 Glycosylation of human CBG influences its steroid-binding activity, and there are N-glycosylation sites in the reactive center loops (RCLs) of human and rat CBGs. 20622017 8 41 part_of GGT 1097:1099 arg1 hepatic GGT glycopeptides GGT hepatic GGT glycopeptides OGER Site GGT glycopeptides However, analysis of hepatic GGT glycopeptides revealed 11 glycan compositions, with 12 unique structures, none of which were observed on kidney GGT. 25628020 4 24 part_of Asn-76 821:826 arg1 thyroglobulin thyroglobulin Asn-76 PUBTATOR SpecificSite thyroglobulin 7038 Asn-76 Three of them, Asn-196 in adipocyte plasma membrane-associated protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are human-specific. 25628020 4 33 part_of Asn-91 761:766 arg1 thyroglobulin thyroglobulin Asn-91 PUBTATOR SpecificSite thyroglobulin 7038 Asn-91 Three of them, Asn-196 in adipocyte plasma membrane-associated protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are human-specific. 25628020 4 73 part_of Asn-196 696:702 arg1 adipocyte plasma membrane-associated protein adipocyte plasma membrane-associated protein Asn-196 PUBTATOR SpecificSite adipocyte plasma membrane-associated protein 57136 Asn-196 Three of them, Asn-196 in adipocyte plasma membrane-associated protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are human-specific. 25628020 4 73 part_of Asn-196 696:702 arg1 APMAP APMAP Asn-196 PUBTATOR SpecificSite APMAP 57136 Asn-196 Three of them, Asn-196 in adipocyte plasma membrane-associated protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are human-specific. 8029814 2 52 part_of PCR 307:309 arg1 Seven overlapping PCR fragments PCR Seven overlapping PCR fragments Cterm Site PCR fragments Seven overlapping PCR fragments covering all of the mature protein, part of the propeptide, and the 3' noncoding region were generated and sequenced. 9311148 8 25 gly N-glycosylation 970:984 arg2 All N-glycosylation sites All N-glycosylation sites sites All N-glycosylation sites exhibited fucose-containing complex-type glycans. 25479596 9 1 gly glycosylation 1542:1554 arg1 the NA protein protein site Fterm protein site A potential new N-linked glycosylation site was observed in the NA protein of an H1N1pdm IAV strain isolated in Brazil. 16735497 11 51 gly glycosylation 1688:1700 arg2 a new glycosylation site a new glycosylation site site CONCLUSIONS: In this first late termination variant of complete TBG deficiency, alteration of beta-strand 5B, located in the core of the molecule, rather than elongation of the molecule or introduction of a new glycosylation site, suffices to disrupt secretion of TBG-CDNI. 18197704 2 36 gly N-glycosylation 345:359 arg1 terminal sialic acid residues terminal sialic acid residues FSH glycosylation varies due to inhibition of FSHbeta N-glycosylation, elaboration of 1-4 branches possessed by mature N-glycans, and the number and linkage of terminal sialic acid residues. 22122935 2 4 gly glycoforms 582:591 arg1 N(83) N(83) N(83), N(24)-N(38) and N(24) and N rhEPO was digested with trypsin and Glu-C and analyzed by CE-TOF-MS to detect O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms, respectively. 22122935 2 4 gly glycoforms 582:591 arg1 O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms N(24) and N(38) glycopeptide rhEPO was digested with trypsin and Glu-C and analyzed by CE-TOF-MS to detect O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms, respectively. 22122935 2 16 gly glycopeptide 569:580 arg2 O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms N(24) and N(38) glycopeptide rhEPO was digested with trypsin and Glu-C and analyzed by CE-TOF-MS to detect O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms, respectively. 22122935 2 4 gly glycoforms 582:591 arg1 N(24)-N(38) N(24)-N(38) and N(24) and N N(24)-N(38) and N(24) and N rhEPO was digested with trypsin and Glu-C and analyzed by CE-TOF-MS to detect O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms, respectively. 17001073 10 68 gly glycosylated 1644:1655 arg2 Asn-594 Asn-594 Asn-594 Mutation of Asn-594, an N-glycosylation site at the beginning of the 19-AA cassette, stabilizes both COX-2 and ins594-612 COX-1; nonetheless, COX mutants that are glycosylated at Asn-594 but lack the remainder of the 19-amino acid cassette (i.e. del597-612 COX-2 and ins594-596 COX-1) are stable. 17001073 10 83 gly N-glycosylation 1505:1519 arg2 an N-glycosylation site an N-glycosylation site site Mutation of Asn-594, an N-glycosylation site at the beginning of the 19-AA cassette, stabilizes both COX-2 and ins594-612 COX-1; nonetheless, COX mutants that are glycosylated at Asn-594 but lack the remainder of the 19-amino acid cassette (i.e. del597-612 COX-2 and ins594-596 COX-1) are stable. 17001073 10 83 gly N-glycosylation 1505:1519 arg2 Asn-594 Asn-594 Asn-594 Mutation of Asn-594, an N-glycosylation site at the beginning of the 19-AA cassette, stabilizes both COX-2 and ins594-612 COX-1; nonetheless, COX mutants that are glycosylated at Asn-594 but lack the remainder of the 19-amino acid cassette (i.e. del597-612 COX-2 and ins594-596 COX-1) are stable. 18930737 0 14 gly alpha2-glycoprotein 59:77 arg1 ZAG ZAG PUBTATOR ZAG 563 Crystal structure of the novel complex formed between zinc alpha2-glycoprotein (ZAG) and prolactin-inducible protein (PIP) from human seminal plasma. 18930737 0 14 gly alpha2-glycoprotein 59:77 arg1 zinc alpha2-glycoprotein zinc alpha2-glycoprotein PUBTATOR zinc alpha2-glycoprotein 563 Crystal structure of the novel complex formed between zinc alpha2-glycoprotein (ZAG) and prolactin-inducible protein (PIP) from human seminal plasma. 8601595 0 33 gly Glycosylation 0:12 arg1 CD44 CD44 PUBTATOR CD44 960 Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. 22239659 5 60 gly N-glycoproteins 1013:1027 arg1 two microheterogeneous N-glycoproteins two microheterogeneous N-glycoproteins Fterm N-glycoproteins Application of the workflow to human haptoglobin and hemopexin, two microheterogeneous N-glycoproteins, identified a total of 57 distinct site-specific glycoforms in the case of haptoglobin and 14 site-specific glycoforms of hemopexin. 22239659 5 60 gly N-glycoproteins 1013:1027 arg1 hemopexin hemopexin PUBTATOR hemopexin 3263 Application of the workflow to human haptoglobin and hemopexin, two microheterogeneous N-glycoproteins, identified a total of 57 distinct site-specific glycoforms in the case of haptoglobin and 14 site-specific glycoforms of hemopexin. 22239659 5 72 gly glycoforms 1137:1146 arg1 hemopexin hemopexin PUBTATOR hemopexin 3263 Application of the workflow to human haptoglobin and hemopexin, two microheterogeneous N-glycoproteins, identified a total of 57 distinct site-specific glycoforms in the case of haptoglobin and 14 site-specific glycoforms of hemopexin. 8509412 6 17 gly glycosylation 878:890 arg2 glycosylation sites glycosylation sites sites Of the seven possible combinations of glycosylation sites, single mutations eliminating glycosylation at either Asn251 or Asn317 do not affect the processing and surface localization of the receptor. 8509412 6 35 gly glycosylation 928:940 arg1 Asn317 Asn317 Asn317 Of the seven possible combinations of glycosylation sites, single mutations eliminating glycosylation at either Asn251 or Asn317 do not affect the processing and surface localization of the receptor. 8509412 6 35 gly glycosylation 928:940 arg1 Asn251 Asn251 Asn251 Of the seven possible combinations of glycosylation sites, single mutations eliminating glycosylation at either Asn251 or Asn317 do not affect the processing and surface localization of the receptor. 9295302 6 39 gly deglycosylation 887:901 arg1 intact MRP intact MRP PUBTATOR MRP 4363 Limited proteolysis of MRP-enriched membranes and deglycosylation of intact MRP and its tryptic fragments with PNGase F was carried out followed by immunoblotting with antibodies known to react with specific regions of MRP. 27259237 6 55 gly N-glycosylation 845:859 arg2 large-scale N-glycosylation site large-scale N-glycosylation site site After evaluating the performance of the above methods, we proposed a simple and efficient workflow for large-scale N-glycosylation site mapping. 31958346 0 77 gly glycosylation 15:27 arg1 α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate-type glutamate receptors α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate-type glutamate receptors Fterm receptors Monitoring the glycosylation of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate-type glutamate receptors using specific antibodies reveals a novel regulatory mechanism of N-glycosylation occupancy by molecular chaperones in mice. 10764604 7 65 gly glycosylation 1423:1435 arg2 individual glycosylation sites individual glycosylation sites sites Oligosaccharide mapping can be applied to the entire hormone, individual subunits, or individual glycosylation sites by varying PNGase digestion conditions or substrates. 10677208 0 7 gly linked 31:36 arg2 the conserved N-glycosylation site AND Hybrid and complex glycans the conserved N-glycosylation site Hybrid and complex glycans site Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells. 10677208 0 7 gly linked 31:36 arg1 the third eight-cysteine domain AND Hybrid and complex glycans the third eight-cysteine domain Hybrid and complex glycans cysteine domain Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells. 10677208 0 30 gly N-glycosylation 55:69 arg1 the third eight-cysteine domain cysteine domain cysteine domain Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells. 10677208 0 30 gly N-glycosylation 55:69 arg1 LTBP-1 LTBP-1 cysteine domain OGER LTBP-1 Q14766 cysteine domain Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells. 10677208 0 30 gly N-glycosylation 55:69 arg1 LTBP-1 LTBP-1 cysteine domain OGER LTBP-1 Q14766 cysteine domain Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells. 10677208 0 30 gly N-glycosylation 55:69 arg2 the conserved N-glycosylation site LTBP-1 site OGER LTBP-1 Q14766 site Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells. 7642555 9 10 part_of c-Myc 1120:1124 arg1 threonine 58 c-Myc threonine 58 PUBTATOR SpecificSite c-Myc 4609 threonine 58 These analyses show that threonine 58, an in vivo phosphorylation site in the transactivation domain, is the major O-GlcNAc glycosylation site of c-Myc. 26599345 6 5 gly glycosylation 761:773 arg2 glycosylation site glycosylation site site Emphasis is placed on comparison of the major types of analytics for use in determining unique glycan features such as glycosylation site, glycan structure, and content. 11676606 2 26 part_of CD40 321:324 arg1 the CD40 binding site CD40 the CD40 binding site PUBTATOR Site CD40 P25942 site Previous studies have described the CD40 binding site as a shallow groove formed between two monomers of CD154. 25673720 10 23 gly glycosylation 1557:1569 arg1 C C Cterm C Q9NP58 These results highlight glycosylation of PrP(C) as a key factor in determining the transmission efficiency of TSEs between different species. 25673720 10 23 gly glycosylation 1557:1569 arg1 PrP PrP PUBTATOR PrP 19122 These results highlight glycosylation of PrP(C) as a key factor in determining the transmission efficiency of TSEs between different species. 31924694 7 29 gly N-glycosylation 1409:1423 arg2 Male- and female-specific N-glycosylation sites Male- and female-specific N-glycosylation sites sites Male- and female-specific N-glycosylation sites were identified, and some of these sex-specific N-glycosylation sites were shown to be derived from proteins with a putative role in insect reproduction. 31924694 7 79 gly N-glycosylation 1479:1493 arg2 these sex-specific N-glycosylation sites these sex-specific N-glycosylation sites sites Male- and female-specific N-glycosylation sites were identified, and some of these sex-specific N-glycosylation sites were shown to be derived from proteins with a putative role in insect reproduction. 12911333 2 52 gly N-glycosylation 332:346 arg1 some Kv1 voltage-gated potassium (K+) channels [Watanabe, Wang, Sutachan, Zhu, Recio-Pinto and Thornhill (2003) J. Physiol some Kv1 voltage-gated potassium (K+) channels [Watanabe, Wang, Sutachan, Zhu, Recio-Pinto and Thornhill (2003) J. Physiol Fterm channels We have shown previously that N-glycosylation affected the function of some Kv1 voltage-gated potassium (K+) channels [Watanabe, Wang, Sutachan, Zhu, Recio-Pinto and Thornhill (2003) J. Physiol. 28708860 10 83 gly N-glycosylation 1517:1531 arg2 its adjacent N-glycosylation site NYT158-160 its adjacent N-glycosylation site NYT158-160 site Epitope B and its adjacent N-glycosylation site NYT158-160 mutated more frequently, which might be under greater immune pressure than the rest. 22688517 5 67 part_of LOX-1 995:999 arg1 their corresponding attached site LOX-1 their corresponding attached site PUBTATOR Site LOX-1 4973 site Here, an approach using nonspecific protease (Pronase E) digestion followed by MALDI-QIT-TOF MS and multistage MS (MS(3)) analysis is explored to obtain site-specific N-glycosylation information of recombinant human LOX-1, in combination with glycan structure confirmation through characterizing released glycans using tandem MS. The results reveal that N-glycans structures as well as their corresponding attached site of LOX-1 can be identified simultaneously by direct MS analysis of glycopeptides from non-specific protease digestion. 26018173 14 125 gly glycoprotein 2670:2681 arg1 the envelope glycoprotein the envelope glycoprotein PUBTATOR envelope glycoprotein 100616444 This pattern was very different from the carbohydrate profile seen for a more easily produced soluble version of the envelope glycoprotein. 29426894 6 17 part_of FcγRIIIb 969:976 arg1 the six N-glycosylation sites FcγRIIIb the six N-glycosylation sites PUBTATOR Site FcγRIIIb 2215 sites Among the six N-glycosylation sites of serum soluble FcγRIIIb, Asn45 was shown to be exclusively occupied by high-mannose-type oligosaccharides, whereas the remaining sites were solely modified by the complex-type oligosaccharides with sialic acid and fucose residues. 18723043 0 45 part_of enzyme 41:46 arg1 Amino acid sequence enzyme Amino acid sequence Fterm Site enzyme sequence Amino acid sequence of a kinin-releasing enzyme, KR-E-1, from the venom of Agkistrodon caliginosus (Kankoku-mamushi). 11208474 5 57 gly glycosylation 1055:1067 arg2 a putative glycosylation site a putative glycosylation site site However, the substitution of substitution glycine to alanine at position 129 introduce a putative glycosylation site (Asn-Gly-Thr), which may interfere with the antigenicity of HbsAg. 11208474 5 57 gly glycosylation 1055:1067 arg2 Asn-Gly-Thr Asn-Gly-Thr Asn-Gly-Thr However, the substitution of substitution glycine to alanine at position 129 introduce a putative glycosylation site (Asn-Gly-Thr), which may interfere with the antigenicity of HbsAg. 22815146 6 88 gly glycosylation 1106:1118 arg2 the potential N-linked glycosylation site the potential N-linked glycosylation site site Consistent with the HTSN assay, hemagglutination inhibition (HI) and serum neutralization (SN) assays demonstrated that migration of the potential N-linked glycosylation site from N137 or N142 to N144 resulted in a >8-fold decrease in titers. 21980282 0 78 gly glycoproteins 55:67 arg1 HIV-1 B clade envelope glycoproteins HIV-1 B clade envelope glycoproteins PUBTATOR envelope glycoproteins 155971 Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. 8212855 6 56 gly glycoprotein 942:953 arg1 glycoprotein G glycoprotein G OGER glycoprotein G P07996 These common structural features of the gX-like proteins were also found in glycoprotein G (gG) of human herpes simplex virus type 2 (HSV-2) and equine herpesvirus type 4 (EHV-4). 31004621 9 85 gly N-glycosylation 1641:1655 arg2 the N-glycosylation site the N-glycosylation site site Infection with recombinant virus lacking the N-glycosylation site at position N116 (RSV F N116Q) resulted in significant higher neutralizing antibody titers compared to RSV F WT infection, which is surprising since this N-glycan is present in the p27 peptide which is assumed to be absent from the mature F protein in virions. 31004621 9 41 gly present 1828:1834 arg1 the p27 peptide AND this N-glycan peptide this N-glycan peptide Infection with recombinant virus lacking the N-glycosylation site at position N116 (RSV F N116Q) resulted in significant higher neutralizing antibody titers compared to RSV F WT infection, which is surprising since this N-glycan is present in the p27 peptide which is assumed to be absent from the mature F protein in virions. 23069765 3 16 gly N-glycopeptide 582:595 arg2 the tryptic N-glycopeptide 63-69 the tryptic N-glycopeptide 63-69 N-glycopeptide Orbitrap mass analyses of the tryptic N-glycopeptide 63-69 indicated that the N-glycosylation was of the GalNAc-terminated type characteristic of cultured kidney cells. 30355697 2 122 gly glycosylation 382:394 arg1 hemagglutinin hemagglutinin Fterm hemagglutinin Antigenic differences between strains are found in the glycosylation patterns of the major influenza virus antigen, hemagglutinin (HA). 27808502 3 13 gly glycosylation 758:770 arg2 glycosylation site glycosylation site site Oligomannosylated glycopeptidome produced by NGlycoReduction can be mixed with the intact N-glycopeptidome and analyzed by HPLC-ESI-MS together to enable the identification of peptide sequence, glycosylation site and the structure of intact glycopeptides. 27808502 3 59 gly glycopeptides 805:817 arg2 intact glycopeptides intact glycopeptides glycopeptides Oligomannosylated glycopeptidome produced by NGlycoReduction can be mixed with the intact N-glycopeptidome and analyzed by HPLC-ESI-MS together to enable the identification of peptide sequence, glycosylation site and the structure of intact glycopeptides. 27808502 3 13 gly glycosylation 758:770 arg1 intact glycopeptides glycopeptides glycopeptides Oligomannosylated glycopeptidome produced by NGlycoReduction can be mixed with the intact N-glycopeptidome and analyzed by HPLC-ESI-MS together to enable the identification of peptide sequence, glycosylation site and the structure of intact glycopeptides. 10488137 5 46 part_of mEH 786:788 arg1 mEH domains mEH mEH domains PUBTATOR Site mEH 13849 domains To further characterize the membrane topology and targeting of this protein, an N-glycosylation site was engineered into mEH to serve as a topological probe for the elucidation of the cellular location of mEH domains. 22015141 0 14 part_of protein 90:96 arg1 the single putative N-glycosylation site protein the single putative N-glycosylation site Fterm Site protein site Deletion of the single putative N-glycosylation site of the porcine circovirus type 2 Cap protein enhances specific immune responses by DNA immunisation in mice. 8360166 4 40 part_of proteins 938:945 arg1 the NH2-terminal glycosylation site proteins the NH2-terminal glycosylation site Fterm Site proteins site Hybrid proteins with the NH2-terminal glycosylation site were glycosylated in COS1 cells, and the carbohydrate moiety was sensitive to endoglycosidase H digestion, providing further evidence that the proteins were retained in the ER. 12911333 5 15 gly N-glycosylation 845:859 arg2 N-glycosylation sites N-glycosylation sites sites In the present study, by a scanning mutagenesis approach, we determined the allowed N-glycosylation sites on the Kv1.2 S1-S2 linker, which has 39 amino acids, by engineering N-glycosylation sites and assaying for glycosylation, using their sensitivity to glycosidases. 12911333 5 48 gly N-glycosylation 755:769 arg2 the allowed N-glycosylation sites the allowed N-glycosylation sites sites In the present study, by a scanning mutagenesis approach, we determined the allowed N-glycosylation sites on the Kv1.2 S1-S2 linker, which has 39 amino acids, by engineering N-glycosylation sites and assaying for glycosylation, using their sensitivity to glycosidases. 25751231 1 77 gly modified 176:183 arg3 HIV-1 gp120/gp41 AND n-linked carbohydrates HIV-1 gp120/gp41 n-linked carbohydrates PUBTATOR HIV-1 gp120 3700 BACKGROUND: HIV-1 gp120/gp41 is heavily modified by n-linked carbohydrates that play important roles either in correct folding or in shielding vulnerable viral protein surfaces from antibody recognition. 23891555 12 30 gly glycosylation 1745:1757 arg1 the protein the protein Fterm protein Aberrant glycosylation of the protein plays a key role in the pathogenesis of IgA nephropathy. 8702538 5 108 gly glycosylation 841:853 arg2 potential N-linked glycosylation sites potential N-linked glycosylation sites sites In this work we have performed site-specific mutagenesis of potential N-linked glycosylation sites on CD22 in an effort to determine whether they might be involved in ligand recognition. 29232830 9 48 gly glycosylation 1379:1391 arg1 several serum proteins several serum proteins Fterm proteins In conclusion, we provide preliminary evidence of altered glycosylation of several serum proteins prior to pancreatic cancer diagnosis, warranting further investigation of these proteins as early biomarkers. 21846136 5 43 gly glycosylation 1224:1236 arg2 196 N-linked glycosylation sites 196 N-linked glycosylation sites sites A total of 120 unique glycoprotein groups and 196 N-linked glycosylation sites were identified by nanoreversed phase liquid chromatography-electrospray ionization-tandem mass spectrometry (nanoRPLC-ESI-MS/MS), with the injected digests amount as 6 μg. 21846136 5 70 gly glycoprotein 1187:1198 arg1 120 unique glycoprotein groups 120 unique glycoprotein groups Fterm glycoprotein A total of 120 unique glycoprotein groups and 196 N-linked glycosylation sites were identified by nanoreversed phase liquid chromatography-electrospray ionization-tandem mass spectrometry (nanoRPLC-ESI-MS/MS), with the injected digests amount as 6 μg. 25422509 6 59 gly sialylated 879:888 arg1 sialylated N-linked glycans sialylated N-linked glycans In this study, to our knowledge, we show for the first time that sialylated N-linked glycans induce the internalization of IgM by T cells, which in turn causes severe inhibition of T cell responses. 25737293 4 25 gly N-acetylglucosamine 666:684 arg1 asparagines asparagines asparagines AminoAcid asparagines Deglycosylation with peptide-endoglycosidase H, leaving a remnant N-acetylglucosamine on asparagines previously carrying high-mannose glycans, followed by trypsin digestion allowed robust automated measurement of occupancy at many sites. 25737293 4 10 gly carrying 712:719 arg1 asparagines AND high-mannose glycans asparagines high-mannose glycans asparagines Deglycosylation with peptide-endoglycosidase H, leaving a remnant N-acetylglucosamine on asparagines previously carrying high-mannose glycans, followed by trypsin digestion allowed robust automated measurement of occupancy at many sites. 11527935 5 61 gly glycosylation 825:837 arg2 a consensus glycosylation site a consensus glycosylation site site RESULTS: The authors found 77 sequence changes likely to be pathogenic: 21 null mutations (15 novel), 55 missense changes (26 novel), and one deletion of a consensus glycosylation site (also novel). 15606797 6 77 gly N-glycosylation 1253:1267 arg2 an N-glycosylation site an N-glycosylation site site N-deglycosylation of the collagen-resistant fragment, reduced the molecular mass to approximately 21,000 MW showing the presence of an N-glycosylation site located in the CRD. 15606797 6 92 gly N-deglycosylation 1118:1134 arg1 the collagen-resistant fragment the collagen-resistant fragment fragment N-deglycosylation of the collagen-resistant fragment, reduced the molecular mass to approximately 21,000 MW showing the presence of an N-glycosylation site located in the CRD. 15488990 5 30 part_of GLUT8 722:726 arg1 The deduced amino acid sequence GLUT8 The deduced amino acid sequence PUBTATOR Site GLUT8 282867 sequence The deduced amino acid sequence of bovine GLUT8 is 90%, 84%, 84% and 58% identical to human, mouse, rat and chicken GLUT8, and is 26%, 27% and 24% identical to bovine GLUT1, GLUT3 and GLUT4, respectively. 28366604 4 55 gly glycosylation 690:702 arg2 N277 site N277 site N277 We identified a highly conserved N-linked glycosylation site N277 in the C2 region which strongly affected the immunogenicity of the CD4i Ab domain. 22354962 6 51 part_of HGF-β 1020:1024 arg1 the binding site HGF the binding site OGER Site HGF P14210 site Mass spectrometric detection of the ligand receptor complex revealed that the binding site of HGF-β was the mannose receptor (MR). 10471642 3 74 gly glycoproteins 555:567 arg1 serum glycoproteins glycoproteins The N-glycans Fterm glycoproteins METHODS: The N-glycans of serum glycoproteins were compared in sera of patients with alcoholism, patients with CDG1, and controls by two-dimensional electrophoresis, neuraminidase, peptide:N-glycosidase F, and endoglycosidase F2 treatments. 12761189 3 40 gly glycosylated 621:632 arg1 the mutant protein the mutant protein Fterm protein When an N-glycosylation site was introduced at the carboxy-terminal end of b5LMY/AAA, a substantial amount of the glycosylated form of the mutant protein was recovered in the cytosol fraction. 12761189 3 58 gly N-glycosylation 515:529 arg2 an N-glycosylation site an N-glycosylation site site When an N-glycosylation site was introduced at the carboxy-terminal end of b5LMY/AAA, a substantial amount of the glycosylated form of the mutant protein was recovered in the cytosol fraction. 1482348 1 18 gly HGF 185:187 arg1 O-glycosylated oligosaccharide HGF O-glycosylated oligosaccharide PUBTATOR HGF 3082 The glycosylation site and the structure of O-glycosylated oligosaccharide of recombinant human HGF were investigated. 1482348 1 37 gly O-glycosylated 133:146 arg1 O-glycosylated oligosaccharide O-glycosylated oligosaccharide The glycosylation site and the structure of O-glycosylated oligosaccharide of recombinant human HGF were investigated. 1482348 1 15 gly glycosylation 93:105 arg1 O-glycosylated oligosaccharide site O-glycosylated oligosaccharide site The glycosylation site and the structure of O-glycosylated oligosaccharide of recombinant human HGF were investigated. 11278567 1 51 part_of glycoprotein 227:238 arg1 The variable V1V2 and V3 regions glycoprotein The variable V1V2 and V3 regions Fterm Site glycoprotein regions The variable V1V2 and V3 regions of the human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein (gp120) can influence viral coreceptor usage. 11292534 4 37 part_of CD28 680:683 arg1 The amino acid sequence CD28 The amino acid sequence PUBTATOR Site CD28 P10747 sequence The amino acid sequence of the canine CD28 showed 91.9, 80, and 79.6% similarities with those of the cat, cattle, and human counterparts, respectively. 1449065 6 35 part_of proteins 675:682 arg1 662-664 residues proteins 662-664 residues Fterm Site proteins residues The cDNAs code for 73kDa proteins with 662-664 residues (86% identity). 28916391 10 41 part_of dimer 1337:1341 arg1 two dimer epitopes dimer two dimer epitopes Fterm Site dimer epitopes Quaternary E:E dimer epitopes located at the interaction site of prM and E dimers can be further divided into two dimer epitopes. 28916391 10 95 part_of dimers 1298:1303 arg1 the interaction site dimers the interaction site Fterm Site dimers site Quaternary E:E dimer epitopes located at the interaction site of prM and E dimers can be further divided into two dimer epitopes. 28916391 10 145 part_of dimer 1238:1242 arg1 Quaternary E:E dimer epitopes dimer Quaternary E:E dimer epitopes Fterm Site dimer epitopes Quaternary E:E dimer epitopes located at the interaction site of prM and E dimers can be further divided into two dimer epitopes. 10406958 10 79 gly N-glycosylation 1648:1662 arg2 the single N-glycosylation site the single N-glycosylation site site The analysis of the sugar moiety of saposin D revealed that the single N-glycosylation site present in the molecule is mainly modified by high-mannose-type structures varying from two to six hexose residues. 10406958 10 111 gly modified 1703:1710 arg1 the single N-glycosylation site AND high-mannose-type structures the single N-glycosylation site high-mannose-type structures site The analysis of the sugar moiety of saposin D revealed that the single N-glycosylation site present in the molecule is mainly modified by high-mannose-type structures varying from two to six hexose residues. 10406958 10 112 gly D 1621:1621 arg1 the sugar moiety saposin D the sugar moiety Cterm saposin D The analysis of the sugar moiety of saposin D revealed that the single N-glycosylation site present in the molecule is mainly modified by high-mannose-type structures varying from two to six hexose residues. 10348716 7 28 gly glycosylation 963:975 arg2 a single asparagine-linked glycosylation site a single asparagine-linked glycosylation site site The enzyme contains a single asparagine-linked glycosylation site, NFT, bearing neutral and amino sugars that account for 8.3% of the enzyme's total molecular weight of 29,027. 23751365 0 58 gly glycopeptides 142:154 arg2 glycopeptides glycopeptides glycopeptides Application of a strong anion exchange material in electrostatic repulsion-hydrophilic interaction chromatography for selective enrichment of glycopeptides. 15128311 6 57 gly glycoprotein 658:669 arg1 the glycoprotein the glycoprotein Fterm glycoprotein The N-terminal sequence of the glycoprotein was identical to that of cytotoxin 3 (CX3) from N. kaouthia, and CD spectra of the glycoprotein and CX3 were almost the same. 15128311 6 64 gly glycoprotein 754:765 arg1 glycoprotein glycoprotein Fterm glycoprotein The N-terminal sequence of the glycoprotein was identical to that of cytotoxin 3 (CX3) from N. kaouthia, and CD spectra of the glycoprotein and CX3 were almost the same. 19619305 4 58 part_of CD4 983:985 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 713807 site Neutralization assays using pseudotyped viruses showed an association between the capacity of HIV to enter macrophages and increased sensitivity to the broadly neutralizing monoclonal antibody (mAb) b12, which recognizes a conserved epitope overlapping the CD4 binding site, but not sensitivity to soluble CD4 (sCD4) or b6, a non-neutralizing CD4 binding site mAb. 27773655 1 17 gly glycoprotein 205:216 arg1 a membrane anchored type I glycoprotein a membrane anchored type I glycoprotein Fterm glycoprotein Lactase phlorizin-hydrolase (LPH) is a membrane anchored type I glycoprotein of the intestinal epithelium that is composed of four homologous structural domains. 27773655 1 17 gly glycoprotein 205:216 arg1 Lactase phlorizin-hydrolase Lactase phlorizin-hydrolase PUBTATOR Lactase phlorizin-hydrolase 3938 Lactase phlorizin-hydrolase (LPH) is a membrane anchored type I glycoprotein of the intestinal epithelium that is composed of four homologous structural domains. 17727280 1 5 gly N-glycosylation 189:203 arg1 a protein protein site Fterm protein site We describe Peptoonist, a program that can automatically identify the glycans (sugars) present at each N-glycosylation site of a protein. 17727280 1 30 gly present 173:179 arg1 a protein AND sugars protein site sugars Fterm protein site We describe Peptoonist, a program that can automatically identify the glycans (sugars) present at each N-glycosylation site of a protein. 17727280 1 30 gly present 173:179 arg1 a protein AND the glycans protein site the glycans Fterm protein site We describe Peptoonist, a program that can automatically identify the glycans (sugars) present at each N-glycosylation site of a protein. 25504159 5 18 gly glycosylation 783:795 arg2 this glycosylation site this glycosylation site site Here, we show that elimination of this glycosylation site increases viral virulence in mice. 18956678 12 82 part_of HA1 1741:1743 arg1 the HA1 region HA1 the HA1 region OGER Site HA1 region Compared with referring viruses, A/SZ/68/2007 had 50 amino acid substitutions in the HA1 region. 27266248 3 8 gly unglycosylated 379:392 arg1 unglycosylated rhAFPO unglycosylated rhAFPO Cterm rhAFPO 174 A/rhAFP0, which produces unglycosylated rhAFPO and secretes it to the culture medium, has been constructed. 19692476 2 77 part_of CD4 449:451 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 920 site The adapted virus, termed TA1, retained the V3 truncation, was exquisitely sensitive to neutralization by the CD4 binding site monoclonal antibody b12 and by HIV-positive human sera, used CCR5 to enter cells, and was completely resistant to small molecule CCR5 antagonists. 30094950 4 2 gly glycopeptide 669:680 arg2 glycopeptide glycopeptide glycopeptide In this issue, Saraswat et al. describe mass spectrometry-based investigations of glycopeptide changes in oral cavity squamous cell carcinoma (OSCC). 2771955 1 19 gly glycoprotein 124:135 arg1 glycoprotein glycoprotein Fterm glycoprotein The glycoprotein (GP) Ib-IX complex on the surface of human platelets functions as the von Willebrand factor receptor and mediates von Willebrand factor-dependent platelet adhesion to blood vessels. 21264968 5 79 part_of MUC5AC 1749:1754 arg1 naked MUC5AC peptide MUC5AC naked MUC5AC peptide PUBTATOR Site MUC5AC 4586 peptide On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8. 12867358 6 45 gly N-glycosylation 1152:1166 arg2 the N-glycosylation site the N-glycosylation site site The apparent mass of N591Y was not affected by treatment with peptide-N-glycosylase F, in contrast to the mass of wild-type hNaSi-1, which was reduced by up to 15 kDa, indicating that Asn591 is the N-glycosylation site. 12867358 6 45 gly N-glycosylation 1152:1166 arg2 Asn591 Asn591 Asn591 The apparent mass of N591Y was not affected by treatment with peptide-N-glycosylase F, in contrast to the mass of wild-type hNaSi-1, which was reduced by up to 15 kDa, indicating that Asn591 is the N-glycosylation site. 14658030 4 58 gly N-glycosylation 1093:1107 arg2 the six potential N-glycosylation sites the six potential N-glycosylation sites sites Here we report the mass spectrometric analysis of the six potential N-glycosylation sites of the neural cell adhesion molecule NCAM from adult mouse brain. 8244416 6 40 part_of chain 1552:1556 arg1 the variable region chain the variable region OGER Site chain region The resulting chimeric heavy chain of F11-35 showed a slightly but significantly higher molecular weight than that of F11-39, but the molecular weights of their unglycosylated peptides synthesized in the presence of tunicamycin were similar, indicating the glycosylation at the possible N-glycosylation site in the variable region of the Ch F11-35 heavy chain. 17406563 2 53 gly glycoproteins 515:527 arg1 N-linked glycoproteins N-linked glycoproteins Fterm glycoproteins We describe here a protocol for isotope-coded glycosylation site-specific tagging (IGOT), a method for the large-scale identification of N-linked glycoproteins from complex biological samples. 27798666 0 48 gly Neuropilin-1 68:79 arg1 A Novel Physiological Glycosaminoglycan-Deficient Splice Variant Neuropilin-1 A Novel Physiological Glycosaminoglycan-Deficient Splice Variant PUBTATOR Neuropilin-1 8829 A Novel Physiological Glycosaminoglycan-Deficient Splice Variant of Neuropilin-1 Is Anti-Tumorigenic In Vitro and In Vivo. 24150277 2 64 gly N-glycosylation 374:388 arg2 the conserved N-glycosylation site the conserved N-glycosylation site site A potential mechanism for site-specific conjugation involves utilization of the conserved N-glycosylation site in the CH2 domain. 10725548 0 22 gly glycosylation 101:113 arg2 the conserved O-linked glycosylation site the conserved O-linked glycosylation site site Unique N-linked glycosylation of murine coronavirus MHV-2 membrane protein at the conserved O-linked glycosylation site. 10725548 0 6 gly glycosylation 16:28 arg2 the conserved O-linked glycosylation site protein site Fterm protein site Unique N-linked glycosylation of murine coronavirus MHV-2 membrane protein at the conserved O-linked glycosylation site. 10725548 0 6 gly glycosylation 16:28 arg1 the conserved O-linked glycosylation site protein site Fterm protein site Unique N-linked glycosylation of murine coronavirus MHV-2 membrane protein at the conserved O-linked glycosylation site. 10725548 0 6 gly glycosylation 16:28 arg1 the conserved O-linked glycosylation site site site Unique N-linked glycosylation of murine coronavirus MHV-2 membrane protein at the conserved O-linked glycosylation site. 27743362 9 63 gly peptide 1538:1544 arg1 the glycan and peptide sequence the glycan and peptide sequence This allows simultaneous site-specific identification of the glycan and peptide sequence of a glycoprotein. 27743362 9 59 gly glycoprotein 1560:1571 arg1 the glycan and peptide sequence glycoprotein the glycan and peptide sequence Fterm glycoprotein This allows simultaneous site-specific identification of the glycan and peptide sequence of a glycoprotein. 7505151 1 27 gly glycosylation 250:262 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site P0, the major structural protein of peripheral myelin, is a homophilic adhesion molecule with a single immunoglobulin (Ig) domain, which contains a single N-linked glycosylation site and two cysteines. 31855143 4 24 part_of site 618:621 arg1 phosphoprotein phosphoprotein site Fterm Site phosphoprotein site Sequence alignments indicated conservation of the ephrin-B2 and ephrin-B3 receptor binding sites, the glycosylation site on the G attachment protein, as well as the editing site in phosphoprotein, suggesting production of nonstructural proteins V and W, known to counteract the host innate immunity. 31855143 4 24 part_of site 618:621 arg1 the G attachment protein protein site Fterm Site protein site Sequence alignments indicated conservation of the ephrin-B2 and ephrin-B3 receptor binding sites, the glycosylation site on the G attachment protein, as well as the editing site in phosphoprotein, suggesting production of nonstructural proteins V and W, known to counteract the host innate immunity. 31855143 4 33 part_of site 675:678 arg1 phosphoprotein phosphoprotein site Fterm Site phosphoprotein site Sequence alignments indicated conservation of the ephrin-B2 and ephrin-B3 receptor binding sites, the glycosylation site on the G attachment protein, as well as the editing site in phosphoprotein, suggesting production of nonstructural proteins V and W, known to counteract the host innate immunity. 31855143 4 33 part_of site 675:678 arg1 the G attachment protein protein site Fterm Site protein site Sequence alignments indicated conservation of the ephrin-B2 and ephrin-B3 receptor binding sites, the glycosylation site on the G attachment protein, as well as the editing site in phosphoprotein, suggesting production of nonstructural proteins V and W, known to counteract the host innate immunity. 31855143 4 42 part_of sites 593:597 arg1 phosphoprotein phosphoprotein sites Fterm Site phosphoprotein sites Sequence alignments indicated conservation of the ephrin-B2 and ephrin-B3 receptor binding sites, the glycosylation site on the G attachment protein, as well as the editing site in phosphoprotein, suggesting production of nonstructural proteins V and W, known to counteract the host innate immunity. 31855143 4 42 part_of sites 593:597 arg1 the G attachment protein protein sites Fterm Site protein sites Sequence alignments indicated conservation of the ephrin-B2 and ephrin-B3 receptor binding sites, the glycosylation site on the G attachment protein, as well as the editing site in phosphoprotein, suggesting production of nonstructural proteins V and W, known to counteract the host innate immunity. 31855143 4 61 part_of ephrin-B3 566:574 arg1 the ephrin-B2 and ephrin-B3 receptor binding sites ephrin-B3 the ephrin-B2 and ephrin-B3 receptor binding sites OGER Site ephrin-B3 Q15768 sites Sequence alignments indicated conservation of the ephrin-B2 and ephrin-B3 receptor binding sites, the glycosylation site on the G attachment protein, as well as the editing site in phosphoprotein, suggesting production of nonstructural proteins V and W, known to counteract the host innate immunity. 10441114 14 48 part_of collagen 1976:1983 arg1 collagen XVIII- and XV-related fragments collagen XVIII collagen XVIII- and XV-related fragments PUBTATOR Site collagen XVIII 80781 fragments Due to the high degree of homology between collagen XV and collagen XVIII as well as their analoqous proteolytic processing, functional similarities of collagen XVIII- and XV-related fragments should be revealed in future experiments. 10441114 14 91 part_of XV-related 1996:2005 arg1 collagen XVIII- and XV-related fragments XV-related collagen XVIII- and XV-related fragments Cterm Site XV-related fragments Due to the high degree of homology between collagen XV and collagen XVIII as well as their analoqous proteolytic processing, functional similarities of collagen XVIII- and XV-related fragments should be revealed in future experiments. 10441114 14 94 part_of XVIII- 1985:1990 arg1 collagen XVIII- and XV-related fragments collagen XVIII collagen XVIII- and XV-related fragments PUBTATOR Site collagen XVIII 80781 fragments Due to the high degree of homology between collagen XV and collagen XVIII as well as their analoqous proteolytic processing, functional similarities of collagen XVIII- and XV-related fragments should be revealed in future experiments. 8289366 10 8 gly glycosylation 1520:1532 arg2 a single asparagine-linked glycosylation site a single asparagine-linked glycosylation site site Sequence analysis of these receptors together with our analysis of MDTF receptor function suggests that a single asparagine-linked glycosylation site is responsible for glycosylation inactivation of these receptors. 26977294 3 96 gly glycosylation 466:478 arg2 a single glycosylation site a single glycosylation site site The crystallizable fragment (Fc) of these IgG1 contains a single glycosylation site at Asn 297/300 that is essential for the CDC and ADCC. 26977294 3 96 gly glycosylation 466:478 arg2 Asn 297/300 Asn 297/300 Asn The crystallizable fragment (Fc) of these IgG1 contains a single glycosylation site at Asn 297/300 that is essential for the CDC and ADCC. 14699159 6 52 gly N-glycoprotein 1256:1269 arg1 N-glycoprotein N-glycoprotein Fterm N-glycoprotein This mutation sharply reduces p90ATF6 association with calreticulin, a major Ca(2+)-binding chaperone for N-glycoprotein. 21338062 0 146 gly glycosylation 49:61 arg1 affinity-purified haptoglobin affinity-purified haptoglobin PUBTATOR haptoglobin 3240 Ultrasensitive characterization of site-specific glycosylation of affinity-purified haptoglobin from lung cancer patient plasma using 10 μm i.d. porous layer open tubular liquid chromatography-linear ion trap collision-induced dissociation/electron transfer dissociation mass spectrometry. 15331613 0 67 gly site 14:17 arg1 neuroglycan C. Neuroglycan C site neuroglycan C. Neuroglycan C site Glycosylation site for chondroitin sulfate on the neural part-time proteoglycan, neuroglycan C. Neuroglycan C (NGC) is a membrane-spanning chondroitin sulfate (CS) proteoglycan that is expressed predominantly in the central nervous system (CNS). 15331613 0 67 gly site 14:17 arg1 the neural part-time proteoglycan site the neural part-time proteoglycan site Glycosylation site for chondroitin sulfate on the neural part-time proteoglycan, neuroglycan C. Neuroglycan C (NGC) is a membrane-spanning chondroitin sulfate (CS) proteoglycan that is expressed predominantly in the central nervous system (CNS). 24806200 1 30 gly glycoprotein 200:211 arg1 human glycoprotein hormones human glycoprotein hormones Fterm glycoprotein Human luteinizing hormone (hLH) and human chorionic gonadotropin (hCG) are human glycoprotein hormones each consisting of two subunits, an identical α-subunit and a unique β-subunit, that form noncovalent heterodimers. 10099468 2 39 gly N-glycosylation 482:496 arg1 secreted recombinant IFN-gamma secreted recombinant IFN-gamma Cterm IFN-gamma During establishment of the culture, the N-glycosylation of secreted recombinant IFN-gamma was monitored by capillary electrophoresis of intact IFN-gamma proteins and by HPLC analysis of released N-glycans. 19269039 6 82 part_of IL-27 669:673 arg1 The deduced amino acid sequence IL-27 p28 The deduced amino acid sequence PUBTATOR Site IL-27 p28 493187 sequence The deduced amino acid sequence of pig IL-27 p28 showed a high degree of homology to human (63%) and mouse (58%). 1281197 8 51 part_of epitopes 1255:1262 arg1 the large hydrophilic domain epitopes the large hydrophilic domain domain There were at least four T cell epitopes in the large hydrophilic domain. 17579075 3 21 part_of C4BP 482:485 arg1 complement control protein domain 1 C4BP complement control protein domain 1 PUBTATOR Site C4BP 722 domain The entire binding site for both porin molecules resides within complement control protein domain 1 (CCP1) of C4BP. 17579075 3 64 part_of protein 455:461 arg1 complement control protein domain 1 protein complement control protein domain 1 Fterm Site protein domain The entire binding site for both porin molecules resides within complement control protein domain 1 (CCP1) of C4BP. 18381078 0 41 gly N-glycosylation 19:33 arg1 the enzyme the enzyme Fterm enzyme Functional role of N-glycosylation from ADAM10 in processing, localization and activity of the enzyme. 29562594 1 78 gly residues 253:260 arg1 glycoproteins glycoproteins residues Fterm glycoproteins Kifunensine, a potent and selective inhibitor of class I α-mannosidases, prevents α-mannosidases I from trimming mannose residues on glycoproteins, thus resulting in oligomannose-type glycans. 29562594 1 86 gly glycoproteins 265:277 arg1 glycoproteins glycoproteins Fterm glycoproteins Kifunensine, a potent and selective inhibitor of class I α-mannosidases, prevents α-mannosidases I from trimming mannose residues on glycoproteins, thus resulting in oligomannose-type glycans. 21177759 9 55 gly glycosylation 1352:1364 arg2 the same putative glycosylation site the same putative glycosylation site site Two other ALS variants mutated in the same putative glycosylation site, D440N/T442A-ALS and T442A-ALS, showed similar chromatographic profiles to wild-type ALS. 24554659 2 21 part_of glycoprotein 555:566 arg1 the V2 region SIV envelope glycoprotein the V2 region PUBTATOR Site SIV envelope glycoprotein 1490007 region Here, we identify a highly conserved N-linked glycosylation site (N173 in SIV, corresponding to N160 in HIV) in the V2 region of the SIV envelope glycoprotein (Env) as a novel determinant of macrophage tropism and characterize mechanisms underlying this phenotype. 10215412 9 20 gly N-glycosylation 778:792 arg2 a potential N-glycosylation site a potential N-glycosylation site site The A/G substitution led to the replacement of Asn by Ser in the G allele and the abolition of a potential N-glycosylation site. 26348848 4 117 gly N-glycosylation 789:803 arg2 the N-glycosylation site the N-glycosylation site site Western blots revealed that wild type Kv3.1a and Kv1.1 α-subunits had complex and oligomannose N-glycans, respectively, and that abolishment of the N-glycosylation site(s) generated Kv proteins without N-glycans. 26348848 4 81 gly had 707:709 arg1 wild type Kv3.1a and Kv1.1 α-subunits AND oligomannose N-glycans wild type Kv3.1a and Kv1.1 α-subunits oligomannose N-glycans PUBTATOR Kv1.1 α-subunits 3736 Western blots revealed that wild type Kv3.1a and Kv1.1 α-subunits had complex and oligomannose N-glycans, respectively, and that abolishment of the N-glycosylation site(s) generated Kv proteins without N-glycans. 19276077 0 44 gly N-glycosylation 3:17 arg2 An N-glycosylation site An N-glycosylation site site An N-glycosylation site on the beta-propeller domain of the integrin alpha5 subunit plays key roles in both its function and site-specific modification by beta1,4-N-acetylglucosaminyltransferase III. 7559574 4 67 part_of zeta/beta 962:970 arg1 the carbonic anhydrase-like domain RPTP zeta/beta the carbonic anhydrase-like domain PUBTATOR Site RPTP zeta/beta 5803 domain The larger of these (17 kDa) begins at Gln-209 near the end of the carbonic anhydrase-like domain of phosphacan/RPTP zeta/beta, whereas a 13-kDa glycopeptide begins at His-361 located in the middle of the fibronectin type III-like domain. 10411918 2 74 gly glycosylation 434:446 arg2 glycosylation site glycosylation site site Functional analysis of agouti mutations in transgenic mice indicate that the cysteine-rich C terminus, signal peptide, and glycosylation site are required for agouti activity in vivo. 3219367 4 57 gly O-glycosylation 436:450 arg2 one O-glycosylation site one O-glycosylation site site The carbohydrate chains are distributed in three N-glycosylation sites and one O-glycosylation site. 3219367 4 88 gly N-glycosylation 406:420 arg2 three N-glycosylation sites three N-glycosylation sites sites The carbohydrate chains are distributed in three N-glycosylation sites and one O-glycosylation site. 10419520 9 33 part_of S2P 1212:1214 arg1 the long hydrophilic sequences S2P the long hydrophilic sequences PUBTATOR Site S2P 51360 sequences All three of the long hydrophilic sequences of S2P can be glycosylated, indicating that they all project into the lumen. 27515086 1 41 gly glycoprotein 310:321 arg1 glycoprotein analysis glycoprotein analysis Fterm glycoprotein In recent years, the study of glycans is progressing remarkably by the development of glycan analysis systems using mass spectrometry, glycan profiling systems using lectin microarrays, and glycoprotein analysis by the isotope-coded glycosylation site-specific tagging method. 17681482 6 71 gly N-glycosylation 866:880 arg2 a putative N-glycosylation site a putative N-glycosylation site site Mutagenesis of a putative N-glycosylation site (N591S) produced a single band that was not shifted by endoglycosidase H or PNGase F, confirming a single glycosylation site at residue 591. 17681482 6 92 gly glycosylation 993:1005 arg2 residue 591 residue 591 residue 591 Mutagenesis of a putative N-glycosylation site (N591S) produced a single band that was not shifted by endoglycosidase H or PNGase F, confirming a single glycosylation site at residue 591. 17681482 6 92 gly glycosylation 993:1005 arg2 a single glycosylation site a single glycosylation site site Mutagenesis of a putative N-glycosylation site (N591S) produced a single band that was not shifted by endoglycosidase H or PNGase F, confirming a single glycosylation site at residue 591. 9662708 7 48 gly glycosylated 1129:1140 arg1 the enzyme the enzyme Fterm enzyme Western blot studies of extracts from stably transfected CHO cells showed a band corresponding to the schistosome fucosyltransferase at 50 kDa, suggesting that the enzyme is indeed glycosylated. 23668542 7 38 gly monofucosylated 1026:1040 arg1 monofucosylated bi- monofucosylated bi- The N-glycan profile of the recombinant A1AT variants was mostly composed of monofucosylated bi-, tri-, and tetraantennary complex-type N-glycans, with a tendency toward higher antennary structures compared to the wild-type. 23668542 7 68 gly variants 994:1001 arg1 The N-glycan profile A1AT variants The N-glycan profile PUBTATOR A1AT variants 5265 The N-glycan profile of the recombinant A1AT variants was mostly composed of monofucosylated bi-, tri-, and tetraantennary complex-type N-glycans, with a tendency toward higher antennary structures compared to the wild-type. 22122935 8 68 part_of rhEPO 1534:1538 arg1 rhEPO glycopeptides rhEPO rhEPO glycopeptides OGER Site rhEPO P29676 glycopeptides This study provided a reliable glycopeptide map of rhEPO and may be regarded as an excellent starting point to analyze rhEPO glycopeptides in biological fluids and detect the use of this hormone in sports. 2503511 14 89 gly carry 2298:2302 arg1 Asn-117 AND exclusively high mannose oligosaccharides Asn-117 exclusively high mannose oligosaccharides Asn-117 By this analysis, Asn-117 was demonstrated to carry exclusively high mannose oligosaccharides. 32273875 6 58 gly removal 1175:1181 arg3 mannose-ending glycans AND N2118 N2118 mannose-ending glycans N2118 However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse antigen-presenting cells. 11333905 5 9 gly glycosylation 1267:1279 arg2 an N-linked glycosylation site an N-linked glycosylation site site The N386K mutation resulted in loss of an N-linked glycosylation site, but additional mutagenesis showed that it was the presence of a lysine rather than loss of the glycosylation site that contributed to CD4 independence. 11333905 5 51 gly glycosylation 1382:1394 arg2 the glycosylation site the glycosylation site site The N386K mutation resulted in loss of an N-linked glycosylation site, but additional mutagenesis showed that it was the presence of a lysine rather than loss of the glycosylation site that contributed to CD4 independence. 18952059 2 25 gly glycosylation 207:219 arg2 a conserved glycosylation site a conserved glycosylation site site It contains one immunoglobulin-like domain with a conserved glycosylation site within. 16372382 0 67 gly thyrotropin 51:61 arg1 N-glycans thyrotropin N-glycans Fterm thyrotropin Characterization of N-glycans of recombinant human thyrotropin using mass spectrometry. 23853575 5 20 gly N-glycosylation 998:1012 arg2 an N-glycosylation site an N-glycosylation site site Conversely, the addition of an N-glycosylation site adjacent to a predicted PvDBP interaction site both abolished its interaction with DARC and resulted in weaker inhibitory antibody responses. 8543280 1 76 gly glycoprotein 131:142 arg1 Acidic epididymal glycoprotein Acidic epididymal glycoprotein Fterm glycoprotein Acidic epididymal glycoprotein (AEG) is an androgen-dependent, epididymal secretory protein assumed to play a major role in sperm maturation. 8543280 1 76 gly glycoprotein 131:142 arg1 an androgen-dependent, epididymal secretory protein an androgen-dependent, epididymal secretory protein Fterm protein Acidic epididymal glycoprotein (AEG) is an androgen-dependent, epididymal secretory protein assumed to play a major role in sperm maturation. 10471642 9 8 part_of glycoproteins 1478:1490 arg1 specific N-glycosylation sites glycoproteins specific N-glycosylation sites Fterm Site glycoproteins sites CONCLUSION: Antibodies directed against specific N-glycosylation sites of glycoproteins could be useful for developing more specific immunochemical tests for the diagnosis of chronic alcohol abuse. 7518437 0 17 gly glycosylation 84:96 arg2 glycosylation site insertion glycosylation site insertion site Mapping of cystic fibrosis transmembrane conductance regulator membrane topology by glycosylation site insertion. 19747940 4 45 part_of CCG 569:571 arg1 A CCG motif CCG A CCG motif OGER Site CCG motif A CCG motif, a potential N-linked glycosylation site and 10 cysteine residues were well conserved. 27834568 6 4 gly N-glycosylation 884:898 arg2 the Fab N-glycosylation site the Fab N-glycosylation site site Removal of the Fab N-glycosylation site by single amino acid substitution, or removal of N-linked glycans by enzymatic digestion, drastically reduced the antibody's ability to inhibit latency-associated peptide (LAP) and αvβ8 association, and TGF-β activation in an αvβ8-mediated TGF-β signaling reporter assay. 17900180 4 21 gly glycosylated 1399:1410 arg1 the glycosylated precursors the glycosylated precursors Fterm precursors The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors. 17900180 4 34 gly glycosylation 1233:1245 arg2 N-linked glycosylation sites N-linked glycosylation sites sites The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors. 17900180 4 117 gly glycosylation 1277:1289 arg2 an O-linked glycosylation site an O-linked glycosylation site site The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors. 17900180 4 117 gly glycosylation 1277:1289 arg2 N-linked glycosylation sites sites sites The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors. 21535396 12 1 gly Non-glycosylated 1573:1588 arg1 Non-glycosylated TF Non-glycosylated TF Cterm Non-glycosylated TF 2152 Non-glycosylated TF is also capable of supporting FVIIa cleavage of PAR2 and PAR2-dependent p44/42 MAPK activation. 23908491 1 63 gly glycoprotein 163:174 arg1 The envelope glycoprotein E2 The envelope glycoprotein E2 Fterm glycoprotein BACKGROUND: The envelope glycoprotein E2 of hepatitis C virus (HCV) contains several hypervariable regions. 32258897 1 13 gly glycosylation 182:194 arg2 an additional glycosylation site an additional glycosylation site site We previously developed a biobetter version of rhIFN-β (R27T) that possesses an additional glycosylation site compared with rhIFN-β 1a. 10474032 3 98 part_of protein 450:456 arg1 the N-terminal amino acid sequence IgE-binding protein the N-terminal amino acid sequence OGER Site IgE-binding protein P17931 sequence METHODS: A degenerate primer was designed to the N-terminal amino acid sequence of a 15-kD IgE-binding protein in A. siro extract. 2780569 9 66 part_of subunit 1580:1586 arg1 the cloned region subunit the cloned region Fterm Site subunit region Sequence comparison revealed that the cloned region of the snake alpha subunit is highly homologous (75-80%) to other muscle AcChoRs and not to neuronal AcChoR, which also does not bind alpha-bungarotoxin. 22239659 6 32 gly glycopeptide 1215:1226 arg2 glycopeptide glycopeptide glycopeptide Using glycan oxonium ions and peptide-characteristic glycopeptide fragment ions and by collapsing topologically redundant glycans, the search software was able to make unique N-glycopeptide assignments for 51% of assigned spectra, with the remaining assignments primarily representing isobaric topological rearrangements. 22239659 6 42 gly N-glycopeptide 1337:1350 arg2 unique N-glycopeptide assignments unique N-glycopeptide assignments N-glycopeptide Using glycan oxonium ions and peptide-characteristic glycopeptide fragment ions and by collapsing topologically redundant glycans, the search software was able to make unique N-glycopeptide assignments for 51% of assigned spectra, with the remaining assignments primarily representing isobaric topological rearrangements. 10727230 6 41 gly glycosylated 1136:1147 arg1 two glycosylated peptides two glycosylated peptides peptides The 2-D mass spectrum of two glycosylated peptides showed these to have high-mannose structures, -GlcNAc-(hex)(n)(), demonstrating that Fcepsilon(2-3-4) has a single such structure of n = 5-9. 31511323 5 58 gly N-glycosylated 844:857 arg2 residues 42, 66, and 74 residues 42, 66, and 74 residues 42, 66, and 74 Using heterologous expression in polarized Madin-Darby canine kidney cells, we show that β2 is N-glycosylated in vivo and in vitro at residues 42, 66, and 74, becoming sialylated only at Asn-42. 31511323 5 82 gly sialylated 917:926 arg2 Asn-42 Asn-42 Asn-42 Using heterologous expression in polarized Madin-Darby canine kidney cells, we show that β2 is N-glycosylated in vivo and in vitro at residues 42, 66, and 74, becoming sialylated only at Asn-42. 16720579 5 61 gly N-glycosylation 916:930 arg2 six potential N-glycosylation sites six potential N-glycosylation sites sites Among six potential N-glycosylation sites, deletion of the fourth or sixth site from the amino terminus inhibited production of the active C6ST-1, whereas deletion of the fifth site resulted in a marked loss of the KSST activity. 8212855 3 63 part_of protein 429:435 arg1 The predicted protein sequence protein The predicted protein sequence Fterm Site protein sequence The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region. 8212855 3 96 part_of region 527:532 arg1 four potential N-glycosylation sites region four potential N-glycosylation sites sites The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region. 8212855 3 96 part_of region 527:532 arg1 a signal sequence region a signal sequence sequence The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region. 8212855 3 33 part_of has 446:448 arg1 The predicted protein sequence AND a signal sequence The predicted protein sequence a signal sequence sequence The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region. 8212855 3 33 part_of has 446:448 arg1 The predicted protein sequence AND four potential N-glycosylation sites The predicted protein sequence four potential N-glycosylation sites sites The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region. 16331960 10 58 gly glycosylation 1876:1888 arg2 the Asn413 glycosylation site the Asn413 glycosylation site site Based on its proximity to the Asn413 glycosylation site, a 15-mer peptide, m/z 1690.472 (NKSDNCEDTPEAGYF), was identified as a suitable candidate for raising anti-peptide antibodies for subsequent immunological detection. 22287049 2 28 gly glycopeptides 495:507 arg2 glycopeptides glycopeptides glycopeptides While mapping of specific glycan structures can be performed at the level of released glycans, site-specific glycosylation and identification of specific protein carriers can only be determined by analysis of glycopeptides. 12440958 1 70 gly receptor 193:200 arg1 the first two short consensus repeats complement receptor (CR) 2 the first two short consensus repeats PUBTATOR complement receptor (CR) 2 1380 Using X-ray crystallography, we have determined the structure of the first two short consensus repeats (SCRs) of human complement receptor (CR) 2 in complex with C3d. 9063619 5 54 gly glycoproteins 796:808 arg1 Individual glycoproteins Individual glycoproteins Fterm glycoproteins Individual glycoproteins, by virtue of their unique structures, can selectively control their own glycosylation by modulating interactions with the glycosylating enzymes in the cell. 7613477 1 31 gly glycosylation 289:301 arg1 human lecithin human lecithin PUBTATOR lecithin:cholesterol acyltransferase 3931 Site-specific structural characterization of the glycosylation of human lecithin:cholesterol acyltransferase (LCAT) was carried out using microbore reversed-phase high performance liquid chromatography coupled with electrospray ionization mass spectrometry (HPLC/ESIMS). 23692404 3 87 gly glycosylation 686:698 arg2 one additional N-linked glycosylation site one additional N-linked glycosylation site site METHODS: Two hundred fifty-one variants, each containing one additional N-linked glycosylation site, were screened in vitro, and the PK profiles of selected variants mapping to spatially distinct regions of FIX were evaluated in mice. 7513281 8 61 part_of isoforms 1166:1173 arg1 the deduced amino acid sequences isoforms the deduced amino acid sequences Fterm Site isoforms sequences Comparison of the deduced amino acid sequences of these Syr v I isoforms to each other revealed identities of 90-97%. 18707900 3 53 gly glycosylated 844:855 arg1 the glycosylated tryptic fragment the glycosylated tryptic fragment fragment Six methods were compared: (1) LC/ESI-MS analysis of intact IgG, (2) LC/ESI-MS analysis of the Fc fragment produced by limited proteolysis with Lys-C, (3) LC/ESI-MS analysis of the IgG heavy chain produced by reduction, (4) LC/ESI-MS analysis of Fc/2 fragment produced by limited proteolysis and reduction, (5) LC/MS analysis of the glycosylated tryptic fragment (293EEQYNSTYR301) using extracted ion chromatograms, and (6) normal phase HPLC analysis of N-glycans cleaved from the IgG using PNGase F. 23319596 8 74 gly N-glycosylation 1238:1252 arg2 Asn-644 Asn-644 Asn-644 The N-glycosylation site at Asn-644 in the LOX catalytic domain is not conserved in human LOX (hLOX), although the LOX catalytic domain of hLOX shares ∼50% identity and ∼70% homology with hLOXL2. 23319596 8 74 gly N-glycosylation 1238:1252 arg2 The N-glycosylation site The N-glycosylation site site The N-glycosylation site at Asn-644 in the LOX catalytic domain is not conserved in human LOX (hLOX), although the LOX catalytic domain of hLOX shares ∼50% identity and ∼70% homology with hLOXL2. 27966990 6 61 part_of VEGFR-2 1013:1019 arg1 all seven VEGFR-2 immunoglobulin-like domains VEGFR-2 all seven VEGFR-2 immunoglobulin-like domains PUBTATOR Site VEGFR-2 P35968 domains The data demonstrated that all seven VEGFR-2 immunoglobulin-like domains have at least one occupied N-glycosylation site. 27966990 6 34 part_of have 1049:1052 arg1 all seven VEGFR-2 immunoglobulin-like domains AND at least one occupied N-glycosylation site all seven VEGFR-2 immunoglobulin-like domains at least one occupied N-glycosylation site site The data demonstrated that all seven VEGFR-2 immunoglobulin-like domains have at least one occupied N-glycosylation site. 10995221 4 9 gly glycosylated 662:673 arg1 UGT2B15 UGT2B15 PUBTATOR UGT2B15 7366 Endoglycosidase H digestion of the human and monkey UGT2B proteins demonstrates that only UGT2B7, UGT2B15, UGT2B17, and UGT2B20 are glycosylated. 10995221 4 9 gly glycosylated 662:673 arg1 UGT2B7 UGT2B7 PUBTATOR UGT2B7 7364 Endoglycosidase H digestion of the human and monkey UGT2B proteins demonstrates that only UGT2B7, UGT2B15, UGT2B17, and UGT2B20 are glycosylated. 10995221 4 9 gly glycosylated 662:673 arg1 UGT2B17 UGT2B17 PUBTATOR UGT2B17 7367 Endoglycosidase H digestion of the human and monkey UGT2B proteins demonstrates that only UGT2B7, UGT2B15, UGT2B17, and UGT2B20 are glycosylated. 10995221 4 9 gly glycosylated 662:673 arg1 UGT2B20 UGT2B20 Cterm UGT2B20 Endoglycosidase H digestion of the human and monkey UGT2B proteins demonstrates that only UGT2B7, UGT2B15, UGT2B17, and UGT2B20 are glycosylated. 29775240 2 20 gly N-glycopeptides 506:520 arg2 PNGase F-resistant N-glycopeptides PNGase F-resistant N-glycopeptides N-glycopeptides We report the migration of SugarQb to the latest and free version of Proteome Discoverer 2.1, and apply it to the analysis of PNGase F-resistant N-glycopeptides from mouse embryonic stem cells. 17144668 4 64 gly positions 657:665 arg1 N550 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 64 gly positions 657:665 arg1 N459 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 64 gly positions 657:665 arg1 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 64 gly positions 657:665 arg1 N605 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 64 gly positions 657:665 arg1 N459 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 64 gly positions 657:665 arg1 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 64 gly positions 657:665 arg1 N605 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 64 gly positions 657:665 arg1 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 64 gly positions 657:665 arg1 N605 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 64 gly positions 657:665 arg1 N605 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg1 carboxylase carboxylase positions N459, N550, N605, and N627 Fterm carboxylase positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 N459 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 N550 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 N627 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 N459 carboxylase positions N459, N550, N605, and N627 Fterm carboxylase positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 positions N459, N550, N605, and N627 carboxylase positions N459, N550, N605, and N627 Fterm carboxylase positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 N550 carboxylase positions N459, N550, N605, and N627 Fterm carboxylase positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 N627 carboxylase positions N459, N550, N605, and N627 Fterm carboxylase positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 N550 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 N627 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 N550 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 N627 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 17144668 4 66 gly glycosylation 618:630 arg2 N627 positions N459, N550, N605, and N627 positions N459, N550, N605, and N627 Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. 15194804 3 4 gly utilized 658:665 arg2 four sites four sites sites Each of the five potential glycosylation sites was removed either individually or in combination, revealing that four sites are actually utilized (g2 and g3 in the F(2) subunit and g4 and g5 in the F(1) subunit). 15194804 3 14 gly glycosylation 548:560 arg2 the five potential glycosylation sites the five potential glycosylation sites sites Each of the five potential glycosylation sites was removed either individually or in combination, revealing that four sites are actually utilized (g2 and g3 in the F(2) subunit and g4 and g5 in the F(1) subunit). 29992770 6 67 gly glycosylation 911:923 arg2 glycosylation site glycosylation site site RESULTS: Combined with a database search using web-based software (GlycopeptideID), MS/MS provided detailed N-glycopeptide information, including glycosylation site, glycan composition, and proposed structures. 29992770 6 40 gly N-glycopeptide 873:886 arg1 detailed N-glycopeptide information N-glycopeptide detailed N-glycopeptide information N-glycopeptide RESULTS: Combined with a database search using web-based software (GlycopeptideID), MS/MS provided detailed N-glycopeptide information, including glycosylation site, glycan composition, and proposed structures. 10374967 1 18 gly glycoprotein 309:320 arg1 the glycoprotein gH/gL complex the glycoprotein gH/gL complex Fterm glycoprotein Human herpesvirus-6 (HHV-6), like other betaherpesviruses, shows cell fusion with wild-type strains, and this cellular spread is mediated by the glycoprotein gH/gL complex. 22180206 2 95 gly glycosylated 459:470 arg1 densely glycosylated mucin-type O-linked glycopeptides densely glycosylated mucin-type O-linked glycopeptides glycopeptides Here, we report the use of electron transfer dissociation (ETD) for the site-specific characterisation of densely glycosylated mucin-type O-linked glycopeptides using ESI-IT-MS/MS. 22180206 2 113 gly glycopeptides 492:504 arg2 densely glycosylated mucin-type O-linked glycopeptides densely glycosylated mucin-type O-linked glycopeptides glycopeptides Here, we report the use of electron transfer dissociation (ETD) for the site-specific characterisation of densely glycosylated mucin-type O-linked glycopeptides using ESI-IT-MS/MS. 19050247 7 74 gly residues 1344:1351 arg1 anaphylactic IgG1 IgG1 residues Cterm IgG1 Interestingly, the enzymatic removal of terminal sialic acid residues in anaphylactic IgG1 resulted in loss of the ability to trigger mast cell degranulation and in vivo anaphylactic reaction, similarly to the deglycosylated IgG1 Ab. 9931494 8 56 part_of contains 1097:1104 arg1 The translated protein AND a single, putative N-glycosylation site The translated protein a single, putative N-glycosylation site Fterm Site protein site The translated protein contains a single, putative N-glycosylation site. 26993603 4 27 gly glycoforms 629:638 arg2 Asn144 Asn144 Asn144 We found five glycoforms on Asn144, including biantennary, triantennary and fucosylated glycans. 26993603 4 42 gly fucosylated 691:701 arg1 fucosylated glycans fucosylated glycans We found five glycoforms on Asn144, including biantennary, triantennary and fucosylated glycans. 10998266 7 48 gly glycosylation 1538:1550 arg2 glycosylation sites glycosylation sites sites Our method is useful for the determination of glycosylation sites, the site-specific carbohydrate heterogeneity of glycoproteins, and the carbohydrate structure. 10998266 7 50 gly sites 1552:1556 arg1 the carbohydrate structure sites the carbohydrate structure sites Our method is useful for the determination of glycosylation sites, the site-specific carbohydrate heterogeneity of glycoproteins, and the carbohydrate structure. 10998266 7 50 gly sites 1552:1556 arg1 the site-specific carbohydrate heterogeneity sites the site-specific carbohydrate heterogeneity sites Our method is useful for the determination of glycosylation sites, the site-specific carbohydrate heterogeneity of glycoproteins, and the carbohydrate structure. 10998266 7 81 gly glycoproteins 1607:1619 arg1 glycoproteins glycoproteins the carbohydrate structure Fterm glycoproteins Our method is useful for the determination of glycosylation sites, the site-specific carbohydrate heterogeneity of glycoproteins, and the carbohydrate structure. 10998266 7 81 gly glycoproteins 1607:1619 arg1 glycoproteins glycoproteins the site-specific carbohydrate heterogeneity Fterm glycoproteins Our method is useful for the determination of glycosylation sites, the site-specific carbohydrate heterogeneity of glycoproteins, and the carbohydrate structure. 10998266 7 83 gly heterogeneity 1590:1602 arg1 glycosylation sites glycoproteins sites Fterm glycoproteins sites Our method is useful for the determination of glycosylation sites, the site-specific carbohydrate heterogeneity of glycoproteins, and the carbohydrate structure. 30841845 7 92 gly non-glycosylation 1085:1101 arg2 non-glycosylation sites non-glycosylation sites sites However, in practice, a large portion of negative samples (i.e. non-glycosylation sites) are mislabelled due to the limitation of current experimental technologies. 2302219 4 8 part_of SAP-1 686:690 arg1 the SAP-1 coding domain SAP-1 the SAP-1 coding domain PUBTATOR Site SAP-1 Q9HD43 domain Examination of the cDNA from two siblings with SAP-1 deficiency revealed a point mutation of nucleotide #650 (counting from the initiation ATG) which is in the SAP-1 coding domain. 8307000 0 44 gly N-glycosylation 108:122 arg2 an additional N-glycosylation site an additional N-glycosylation site site Glycosylation of two recombinant human uterine tissue plasminogen activator variants carrying an additional N-glycosylation site in the epidermal-growth-factor-like domain. 8307000 0 118 gly Glycosylation 0:12 arg1 two recombinant human uterine tissue plasminogen activator variants two recombinant human uterine tissue plasminogen activator variants PUBTATOR tissue plasminogen activator variants P00750 Glycosylation of two recombinant human uterine tissue plasminogen activator variants carrying an additional N-glycosylation site in the epidermal-growth-factor-like domain. 7829269 5 60 part_of LL2 1222:1224 arg1 the LL2 VK domain LL2 the LL2 VK domain PUBTATOR Site LL2 633295 domain The finding is interesting because it enables a wider choice of human framework sequences, which in most cases do not have a corresponding glycosylation site, for the humanization of the LL2 VK domain, as well as a greater latitude of host expression systems. 7829269 5 4 part_of have 1153:1156 arg1 human framework sequences AND a corresponding glycosylation site human framework sequences a corresponding glycosylation site site The finding is interesting because it enables a wider choice of human framework sequences, which in most cases do not have a corresponding glycosylation site, for the humanization of the LL2 VK domain, as well as a greater latitude of host expression systems. 9295302 2 15 gly phosphoglycoprotein 205:223 arg1 Multidrug resistance protein Multidrug resistance protein PUBTATOR Multidrug resistance protein 4363 Multidrug resistance protein, MRP, is a 190-kDa integral membrane phosphoglycoprotein that belongs to the ATP-binding cassette superfamily of transport proteins and is capable of conferring resistance to multiple chemotherapeutic agents. 9295302 2 15 gly phosphoglycoprotein 205:223 arg1 a 190-kDa integral membrane phosphoglycoprotein a 190-kDa integral membrane phosphoglycoprotein Fterm phosphoglycoprotein Multidrug resistance protein, MRP, is a 190-kDa integral membrane phosphoglycoprotein that belongs to the ATP-binding cassette superfamily of transport proteins and is capable of conferring resistance to multiple chemotherapeutic agents. 12739007 7 41 gly N-glycosylation 1083:1097 arg2 an N-glycosylation site an N-glycosylation site site Human MGC9753 and mouse Mgc9753 proteins were 320-amino-acid seven-transmembrane receptors with the N-terminal six-cysteine domain and an N-glycosylation site (85.0% total-amino-acid identity). 7831962 4 72 part_of positions 735:743 arg1 the HA1 subunit subunit positions Fterm Site subunit positions Nucleotide sequence analysis of the HA gene of these two variants demonstrated differences at several amino acid positions in the HA1 subunit including one glycosylation site. 15754041 6 98 gly glycosylation 927:939 arg2 one Asn-linked glycosylation site one Asn-linked glycosylation site site The rat Wnt9b gene, consisting of four exons, encoded a 359-aa protein with N-terminal signal peptide, 24 conserved Cys residues and one Asn-linked glycosylation site. 15754041 6 98 gly glycosylation 927:939 arg2 N-terminal signal peptide N-terminal signal peptide peptide The rat Wnt9b gene, consisting of four exons, encoded a 359-aa protein with N-terminal signal peptide, 24 conserved Cys residues and one Asn-linked glycosylation site. 26957414 12 80 gly glycopeptides 1387:1399 arg2 glycopeptides glycopeptides different sialic acid groups glycopeptides Y1 ions of glycopeptides with different sialic acid groups are observed at different retention times, representing the various numbers of sialic acid moieties associated with the same peptide backbone sequence. 21902591 8 73 gly N-glycosylation 1441:1455 arg2 a potential N-glycosylation site a potential N-glycosylation site site Analysis of the distribution of RNY strings equal to or longer than five codons in the full genome of HXB2 also shows that these sequences are mostly out of frame, unless they contain a potential N-glycosylation site or an asparagine. 10218949 4 57 gly glycosylation 695:707 arg2 each glycosylation site each glycosylation site site Mutation at each glycosylation site, either alone or in combination, had little effect on ligand binding parameters (although the N4K mutant had higher affinity) or signaling activity. 2477364 15 110 gly glycosylation 2051:2063 arg1 this site hCG site PUBTATOR hCG 93659 site Because glycosylation at this site is essential for hCG assembly and signal transduction, these data imply a critical link between the site-specific processing and hormone function. 2477364 15 110 gly glycosylation 2051:2063 arg2 this site hCG site PUBTATOR hCG 93659 site Because glycosylation at this site is essential for hCG assembly and signal transduction, these data imply a critical link between the site-specific processing and hormone function. 2477364 15 110 gly glycosylation 2051:2063 arg2 this site site site Because glycosylation at this site is essential for hCG assembly and signal transduction, these data imply a critical link between the site-specific processing and hormone function. 23001782 6 4 gly occupied 999:1006 arg2 Both sites Both sites sites Both sites are occupied by the same six sialylated and partly core fucosylated bi- and triantennary N-Glycoforms with lactosamine-type antennas of the form (±NeuAcα6)Galβ4GlcNAc. 10551780 0 54 part_of globulin 68:75 arg1 the thyroxine-binding site thyroxine-binding globulin the thyroxine-binding site OGER Site thyroxine-binding globulin P05543 site Characterization of the thyroxine-binding site of thyroxine-binding globulin by site-directed mutagenesis. 9705240 5 29 gly glycosylation 591:603 arg2 a putative glycosylation site a putative glycosylation site site The mutation appears to abolish a putative glycosylation site in a region in which other missense mutations have been identified, indicating that this region of the enzyme must be important for enzyme activity. 12460944 8 46 gly glycosylation 1260:1272 arg2 the predicted glycosylation site the predicted glycosylation site site Mutation of the serine to alanine in the predicted glycosylation site abrogates glycosylation, as does reduction and alkylation of the EGF repeat, suggesting that the enzyme recognizes not only the consensus sequence but also the 3D structure of the EGF repeat. 28928219 2 8 gly attached 533:540 arg2 hydroxylated Pro-143 AND a unique pentasaccharide hydroxylated Pro-143 a unique pentasaccharide Pro-143 In Dictyostelium (a social amoeba), Toxoplasma gondii (the agent for human toxoplasmosis), and other protists, Skp1 is regulated by a unique pentasaccharide attached to hydroxylated Pro-143 within its C-terminal F-box-binding domain. 23326351 5 11 part_of C3 886:887 arg1 C3 and V5, C3 and V4, or V4 regions C3 and V5 C3 and V5, C3 and V4, or V4 regions PUBTATOR Site C3 and V5 718 regions The sera contained different neutralizing activities dependent on C3 and V5, C3 and V4, or V4 regions located on the glycan-rich outer domain of gp120. 23326351 5 39 part_of V5 893:894 arg1 C3 and V5, C3 and V4, or V4 regions C3 and V5 C3 and V5, C3 and V4, or V4 regions PUBTATOR Site C3 and V5 718 regions The sera contained different neutralizing activities dependent on C3 and V5, C3 and V4, or V4 regions located on the glycan-rich outer domain of gp120. 26070719 3 10 gly glycopeptides 542:554 arg2 glycopeptides glycopeptides glycopeptides However, glycopeptide analysis is still challenging given that glycopeptides are usually low in abundance and relatively difficult to detect and the resulting data require expertise to analyze. 26070719 3 14 gly glycopeptide 488:499 arg2 glycopeptide analysis glycopeptide analysis glycopeptide However, glycopeptide analysis is still challenging given that glycopeptides are usually low in abundance and relatively difficult to detect and the resulting data require expertise to analyze. 1726785 5 14 gly glycosylation 884:896 arg2 A third glycosylation site mutant A third glycosylation site mutant site A third glycosylation site mutant (residue 302) was identified that enhanced TSAb activity but had no effect on high affinity TSH binding, and a deletion mutant (residues 308-410) lost TSAb activity but preserved TSH binding. 1726785 5 14 gly glycosylation 884:896 arg2 residue 302 residue 302 residue 302 A third glycosylation site mutant (residue 302) was identified that enhanced TSAb activity but had no effect on high affinity TSH binding, and a deletion mutant (residues 308-410) lost TSAb activity but preserved TSH binding. 1726785 5 48 gly residues 1038:1045 arg1 308-410 308-410 residues 308-410 A third glycosylation site mutant (residue 302) was identified that enhanced TSAb activity but had no effect on high affinity TSH binding, and a deletion mutant (residues 308-410) lost TSAb activity but preserved TSH binding. 9050863 0 21 gly glycosylation 153:165 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. 9050863 0 65 gly glycoproteins 33:45 arg1 Hepatitis B virus (HBV) envelope glycoproteins Hepatitis B virus (HBV) envelope glycoproteins Fterm glycoproteins Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. 8806496 3 35 gly one 591:593 arg1 glycosylation sites glycosylation sites sites To study the function of NS1 during yellow fever virus replication, six mutant viruses which lack either one or both glycosylation sites and another one containing silent mutations at both sites were generated by site-directed mutagenesis. 8806496 3 83 gly glycosylation 603:615 arg2 glycosylation sites glycosylation sites sites To study the function of NS1 during yellow fever virus replication, six mutant viruses which lack either one or both glycosylation sites and another one containing silent mutations at both sites were generated by site-directed mutagenesis. 32211339 12 42 part_of GCD 1972:1974 arg1 GCD domains GCD GCD domains OGER Site GCD Q92947 domains Overall, we showed that the GP-mediated steric shielding aimed to impair immune function is facilitated by the N-glycans protruding from its MLD and GCD domains, but these N-glycans are not controlling the close distance between GP and its shielded proteins. 7688956 5 31 gly serine 796:801 arg1 residues residues serine and threonine residues There is one N-linked glycosylation site, but no evidence for O-glycosylation despite the presence of several serine and threonine residues. 7688956 5 37 gly glycosylation 708:720 arg2 one N-linked glycosylation site one N-linked glycosylation site site There is one N-linked glycosylation site, but no evidence for O-glycosylation despite the presence of several serine and threonine residues. 21604132 7 57 gly sialoglycopeptides 1134:1151 arg2 sialoglycopeptides sialoglycopeptides sialoglycopeptides This strategy was applied to a crude membrane fraction of EGF-stimulated HeLa cells metabolically labeled with SILAC enabling both qualitative and quantitative analyses of sialoglycopeptides. 9774483 5 22 gly acid 996:999 arg1 NCAM.Fc NCAM acid PUBTATOR NCAM 4684 PST and STX were found to add polysialic acid on NCAM.Fc molecules sialylated by alpha-2,3- or alpha-2,6-linkage in vitro, but not on NCAM.Fc lacking either sialic acid. 19527756 7 33 part_of rhGCSF 1229:1234 arg1 the O-glycosylation site rhGCSF the O-glycosylation site OGER Site rhGCSF P09919 site Mutagenesis of the O-glycosylation site of rhGCSF (Thr(133) to Leu(133)) showed a single peak on bioanalyzer, which overlapped with the peak obtained for a non-glycosylated rhGCSF. 16899459 4 27 part_of terminus 756:763 arg1 the only N-glycosylation site 34 amino acids terminus the only N-glycosylation site 34 amino acids site The mutation truncated the distal ectodomain and positioned the only N-glycosylation site 34 amino acids from the newly formed C terminus, which impaired efficient N-glycosylation. 11251288 11 97 gly glycosylated 2326:2337 arg1 Erythropoietin Erythropoietin PUBTATOR Erythropoietin 2056 CONCLUSIONS: Erythropoietin expressed in E. coli bearing specific Asn-->Cys mutations at natural glycosylation sites can be glycosylated using beta-N-glycosyl iodoacetamides even in the presence of two disulfide bonds. 11251288 11 107 gly glycosylation 2299:2311 arg2 natural glycosylation sites natural glycosylation sites sites CONCLUSIONS: Erythropoietin expressed in E. coli bearing specific Asn-->Cys mutations at natural glycosylation sites can be glycosylated using beta-N-glycosyl iodoacetamides even in the presence of two disulfide bonds. 9140729 3 108 gly carbohydrates 433:445 arg1 Asn-30 Asn-30 Asn-30 SpecificSite Asn-30 Since this antibody possesses N-linked carbohydrates on Asn-30 of VH region, which seems to be very close to an antigen-binding site, influence of these carbohydrates on antigen-binding was investigated. 17951640 2 39 gly used 386:389 arg2 a His-tagged Kringle 3 domain a His-tagged Kringle 3 domain domain A reporter protein with a single N-linked glycosylation site, a His-tagged Kringle 3 domain of human plasminogen (K3), was used to identify combinations of optimal leader/catalytic domain(s) to recreate human N-glycan processing in the Pichia system. 17951640 2 47 gly glycosylation 305:317 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site A reporter protein with a single N-linked glycosylation site, a His-tagged Kringle 3 domain of human plasminogen (K3), was used to identify combinations of optimal leader/catalytic domain(s) to recreate human N-glycan processing in the Pichia system. 15865444 10 25 part_of has 1621:1623 arg1 rat bone OPN AND an additional site rat bone OPN an additional site PUBTATOR Site OPN 25353 site In comparison to the previously characterized cow milk isoform, rat bone OPN is sulfated and has an additional site of glycosylation, many different sites of phosphorylation, and a lower overall phosphate content. 15865444 10 25 part_of has 1621:1623 arg1 rat bone OPN AND many different sites rat bone OPN many different sites PUBTATOR Site OPN 25353 sites In comparison to the previously characterized cow milk isoform, rat bone OPN is sulfated and has an additional site of glycosylation, many different sites of phosphorylation, and a lower overall phosphate content. 18197704 6 93 gly N-glycosylation 1172:1186 arg2 two N-glycosylation sites two N-glycosylation sites sites Glycopeptide mass spectrometry assessment of glycan branching in these isoforms extensively characterized two N-glycosylation sites, one at alphaAsn52, the critical glycan for FSH function, and the other at betaAsn24. 16927286 4 77 gly glycoprotein 570:581 arg1 attachment glycoprotein glycoprotein (G OGER glycoprotein (G P07996 Therefore, we analyzed viral attachment glycoprotein (G) gene sequences from 106 RSV subgroup A isolates collected in New Zealand between 1967 and 2003, and 38 subgroup B viruses collected between 1984 and 2004. 2886334 0 13 gly Thy-1 109:113 arg1 Tissue-specific N-glycosylation, site-specific oligosaccharide patterns Thy-1 Tissue-specific N-glycosylation, site-specific oligosaccharide patterns PUBTATOR Thy-1 24832 Tissue-specific N-glycosylation, site-specific oligosaccharide patterns and lentil lectin recognition of rat Thy-1. 2180485 1 80 part_of have 382:385 arg1 APP AND serine proteinase inhibitor regions APP serine proteinase inhibitor regions OGER Site APP P05067 regions The core of the plaque is mainly composed of amyloid beta protein (beta-AP), two of whose three precursors (APP) have serine proteinase inhibitor regions (APPI). 2180485 1 80 part_of have 382:385 arg1 three precursors AND serine proteinase inhibitor regions three precursors serine proteinase inhibitor regions Fterm Site precursors regions The core of the plaque is mainly composed of amyloid beta protein (beta-AP), two of whose three precursors (APP) have serine proteinase inhibitor regions (APPI). 1457969 3 23 gly glycopeptides 505:517 arg2 two glycopeptides two glycopeptides glycopeptides The alpha-subunit was further treated with trypsin which gave two glycopeptides that were subsequently separated by reverse-phase HPLC and identified by amino acid sequence analysis. 8639654 0 114 gly N-glycosylation 15:29 arg2 N-glycosylation sites N-glycosylation sites sites Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. 1377692 3 29 part_of 15-amino 312:319 arg1 a 15-amino acid NH2-terminal signal peptide a 15 a 15-amino acid NH2-terminal signal peptide OGER Site a 15 P41732 peptide The single long open reading frame encodes a polypeptide of 331 amino acids consisting of a 15-amino acid NH2-terminal signal peptide, a propeptide of 99 amino acids, and a mature polypeptide of 217 amino acids. 26687240 2 50 gly glycosylated 188:199 arg1 IgE IgE PUBTATOR IgE P01854 IgE is the most heavily glycosylated antibody, but in comparison to other antibodies little is known about its glycan structure function relationships. 18533687 10 61 part_of RXFP1 1661:1665 arg1 Asn-303 RXFP1 Asn-303 PUBTATOR SpecificSite RXFP1 59350 Asn-303 In particular, N-glycosylation at Asn-303 of RXFP1 was required for optimal intracellular cAMP signaling. 24806200 5 97 gly glycoproteins 1025:1037 arg1 these glycoproteins these glycoproteins Fterm glycoproteins In clinical applications, these hormones are administered as mixtures of glycoforms due to limitations of biological methods in producing homogeneous samples of these glycoproteins. 26256267 9 51 gly glycoproteins 1471:1483 arg1 the altered glycoproteins the altered glycoproteins Fterm glycoproteins A majority of the altered glycoproteins were also observed with changes in their global protein expression levels. 25541284 0 28 gly glycoprotein 89:100 arg1 myelin oligodendrocyte glycoprotein myelin oligodendrocyte glycoprotein PUBTATOR myelin oligodendrocyte glycoprotein 4340 The role of N-glycan in folding, trafficking and pathogenicity of myelin oligodendrocyte glycoprotein (MOG). 25541284 0 28 gly glycoprotein 89:100 arg1 MOG MOG PUBTATOR MOG 4340 The role of N-glycan in folding, trafficking and pathogenicity of myelin oligodendrocyte glycoprotein (MOG). 23263199 2 68 gly N-glycosylation 365:379 arg2 three putative N-glycosylation sites three putative N-glycosylation sites sites It contains three putative N-glycosylation sites (Asn62, Asn101 and Asn153). 23263199 2 40 gly contains 341:348 arg1 Asn101 Asn62, Asn101 and Asn153 Asn62, Asn101 and Asn153 It contains three putative N-glycosylation sites (Asn62, Asn101 and Asn153). 23263199 2 40 gly contains 341:348 arg1 Asn62 Asn62, Asn101 and Asn153 Asn62, Asn101 and Asn153 It contains three putative N-glycosylation sites (Asn62, Asn101 and Asn153). 23263199 2 40 gly contains 341:348 arg1 Asn62 Asn62, Asn101 and Asn153 Asn62, Asn101 and Asn153 It contains three putative N-glycosylation sites (Asn62, Asn101 and Asn153). 17822916 8 6 gly N-glycosylation 1031:1045 arg2 The conserved potential N-glycosylation site The conserved potential N-glycosylation site site The conserved potential N-glycosylation site and the cysteine residues were found in both the two ligands. 27177499 7 25 gly N-glycosylation 1043:1057 arg2 four sites sites sites The hCG ß-subunit is encoded by a cluster of genes (CGB) and contains two sites of N-glycosylation and four sites of O-glycosylation. 27177499 7 89 gly O-glycosylation 1077:1091 arg2 four sites sites sites The hCG ß-subunit is encoded by a cluster of genes (CGB) and contains two sites of N-glycosylation and four sites of O-glycosylation. 8327483 2 48 part_of containing 387:396 arg1 a signal peptide AND one potential N-glycosylation site a signal peptide one potential N-glycosylation site site The precursor of rainbow trout TSH beta consists of 147 aa, which can be cleaved into a signal peptide (20 aa) and a mature protein (127 aa) containing one potential N-glycosylation site and 12 cysteine residues. 8327483 2 48 part_of containing 387:396 arg1 a signal peptide AND 12 cysteine residues a signal peptide 12 cysteine residues cysteine residues The precursor of rainbow trout TSH beta consists of 147 aa, which can be cleaved into a signal peptide (20 aa) and a mature protein (127 aa) containing one potential N-glycosylation site and 12 cysteine residues. 10878356 4 32 gly position 600:607 arg1 An additional N-linked carbohydrate position An additional N-linked carbohydrate position An additional N-linked carbohydrate at this position would create a protrusion on the V alpha domain surface, and this may interfere with TCR aggregation and/or recruitment of signaling molecules. 23824818 7 98 gly glycosylation 1673:1685 arg2 a critical N-linked glycosylation site a critical N-linked glycosylation site site Overall, a single, acid-stabilizing mutation was found to enhance the growth of an H5N1 influenza virus in the mammalian upper respiratory tract, and yet it was insufficient to enable contact transmission in ferrets in the absence of additional mutations that confer α(2,6) receptor binding specificity and remove a critical N-linked glycosylation site. 16335952 4 38 gly glycoproteins 793:805 arg1 N-linked glycoproteins N-linked glycoproteins Fterm glycoproteins N-linked glycoproteins were then captured from the depleted plasma using hydrazide resin and enzymatically digested, and the bound N-linked glycopeptides were released using peptide-N-glycosidase F (PNGase F). 16335952 4 68 gly glycopeptides 924:936 arg2 the bound N-linked glycopeptides the bound N-linked glycopeptides glycopeptides N-linked glycoproteins were then captured from the depleted plasma using hydrazide resin and enzymatically digested, and the bound N-linked glycopeptides were released using peptide-N-glycosidase F (PNGase F). 23751365 10 5 gly glycosylation 1638:1650 arg2 global glycosylation site analysis global glycosylation site analysis site Our results collectively support the utility of XCharge SAX as a suitable chromatographic material for global glycosylation site analysis. 8379944 10 64 gly glycosylation 1495:1507 arg2 all four potential glycosylation sites all four potential glycosylation sites sites In addition, a quadruple mutant was constructed such that all four potential glycosylation sites were eliminated. 27966990 5 42 part_of sites 681:685 arg1 VEGFR-2 VEGFR-2 sites PUBTATOR Site VEGFR-2 P35968 sites The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides. 27966990 5 64 part_of VEGFR-2 953:959 arg1 VEGFR-2 glycopeptides VEGFR-2 VEGFR-2 glycopeptides PUBTATOR Site VEGFR-2 P35968 glycopeptides The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides. 21674342 3 83 gly glycosylation 454:466 arg2 The glycosylation site The glycosylation site site The glycosylation site is then introduced through an orthogonally protected 2-phenylisopropyl (PhiPr) aspartic acid (Asp) residue. 30257863 7 33 part_of Kir7.1 990:995 arg1 the sole Kir7.1 glycosylation site Kir7.1 the sole Kir7.1 glycosylation site PUBTATOR Site Kir7.1 3769 site Of note, mutagenesis of the sole Kir7.1 glycosylation site reduced conductance and open probability, as indicated by single-channel recording. 25628020 6 43 part_of thyroglobulin 1002:1014 arg1 the Asn-76 thyroglobulin the Asn-76 PUBTATOR SpecificSite thyroglobulin 7038 Asn-76 Notably, the Asn-76 of thyroglobulin might be involved in the increased production of thyroid hormones in humans, especially thyroxine (T4), because the removal of the glycan moiety from this site was reported to result in a significant decrease in T4 production. 25324212 5 14 gly non-glycosylated 758:773 arg1 non-glycosylated MUC1 peptides non-glycosylated MUC1 peptides peptides Moreover, control experiments with non-glycosylated MUC1 peptides unequivocally showed that the sugar residue is essential for MGL binding, as is Ca(2+) . 7688818 10 86 gly glycoprotein 1604:1615 arg1 the glycoprotein genes the glycoprotein genes Fterm glycoprotein Sequencing the glycoprotein genes of the escape mutants identified specific E1 and E2 loci where mutation prevented MAb binding to transitional epitopes. 2202300 0 42 gly glycosylation 41:53 arg2 glycosylation site glycosylation site site Thyroid hormone binding protein contains glycosylation site binding protein activity. 17222411 4 43 part_of l-3 637:639 arg1 NeuAc alpha2-3Gal beta l-3(NeuAc alpha2-6)GalNAc alpha l-O-Thr l-3 NeuAc alpha2-3Gal beta l-3(NeuAc alpha2-6)GalNAc alpha l-O-Thr OGER AminoAcid l-3 Q96MH2 Thr Analyses of glycopeptides produced by Edman degradation and mass spectrometry revealed that the disialyl-corel (NeuAc alpha2-3Gal beta l-3(NeuAc alpha2-6)GalNAc alpha l-O-Thr) structure was primarily attached to a glycosylation site at residue Thr52. 22773269 4 49 gly sialoglycopeptides 718:735 arg2 sialoglycopeptides sialoglycopeptides sialoglycopeptides Furthermore, considering the highly negatively charged nature of sialic acids, we developed a new strategy, peptide immobilized pH gradient isoelectric focusing (IPG-IEF) assisted TiO(2) chromatography (PIAT), for the highly efficient enrichment of sialoglycopeptides. 26784534 9 13 gly glycopeptides 1293:1305 arg2 both glycopeptides both glycopeptides glycopeptides Disialosyl motifs were present on both glycopeptides flanking the A1 domain and on the glycosylation site T(2298) in the C1 domain. 26784534 9 53 gly glycosylation 1341:1353 arg2 the glycosylation site T(2298) the glycosylation site T(2298) site T(2298) Disialosyl motifs were present on both glycopeptides flanking the A1 domain and on the glycosylation site T(2298) in the C1 domain. 26784534 9 70 gly site 1355:1358 arg1 2298 site T(2298) site T(2298) Disialosyl motifs were present on both glycopeptides flanking the A1 domain and on the glycosylation site T(2298) in the C1 domain. 12901863 5 34 gly N-glycosylation 891:905 arg2 Asn15 Asn15 Asn15 Our results indicate that Asn15, which is located in the extracellular N-terminal region of human ABCC6, is the only N-glycosylation site in this protein. 12901863 5 34 gly N-glycosylation 891:905 arg2 the only N-glycosylation site the only N-glycosylation site site Our results indicate that Asn15, which is located in the extracellular N-terminal region of human ABCC6, is the only N-glycosylation site in this protein. 7875221 7 95 part_of found 1613:1617 arg2 the intact alpha-chain AND the ligand binding sites the intact alpha-chain the ligand binding sites Fterm Site alpha-chain sites This transcript encoded a putative 102-kDa protein comprising the beta-chain of C3, together with the first 59 residues and the last 103 residues of the alpha-chain; it would therefore lack many of the ligand binding sites found in the intact alpha-chain. 7875221 7 61 part_of alpha-chain 1543:1553 arg1 the last 103 residues alpha-chain residues Fterm Site alpha-chain residues This transcript encoded a putative 102-kDa protein comprising the beta-chain of C3, together with the first 59 residues and the last 103 residues of the alpha-chain; it would therefore lack many of the ligand binding sites found in the intact alpha-chain. 19921957 3 16 gly nonglycosite 767:778 arg2 those nonglycosite peptide pairs those nonglycosite peptide pairs nonglycosite Comparing samples treated in H(2)(18)O and samples treated in H(2)(16)O, a unique mass shift of 6 Da can be shown for N-glycosylated peptide with single glycosylation site, which could be easily distinguished from those nonglycosite peptide pairs with a mass difference of 4 Da only. 19921957 3 32 gly glycosylation 700:712 arg2 single glycosylation site single glycosylation site site Comparing samples treated in H(2)(18)O and samples treated in H(2)(16)O, a unique mass shift of 6 Da can be shown for N-glycosylated peptide with single glycosylation site, which could be easily distinguished from those nonglycosite peptide pairs with a mass difference of 4 Da only. 19921957 3 39 gly N-glycosylated 665:678 arg1 N-glycosylated peptide N-glycosylated peptide peptide Comparing samples treated in H(2)(18)O and samples treated in H(2)(16)O, a unique mass shift of 6 Da can be shown for N-glycosylated peptide with single glycosylation site, which could be easily distinguished from those nonglycosite peptide pairs with a mass difference of 4 Da only. 17159231 6 45 gly glycosylation 1348:1360 arg2 an N-linked glycosylation site an N-linked glycosylation site site Of 124 amino acid sites analyzed, 3 codons in V2, a 2-amino acid shift in an N-linked glycosylation site, and variation at 2 sites in the highly charged region were consistently evolving under either directional or diversifying selection at days 40 and 70 p.i. 2209609 1 16 gly glycoprotein 251:262 arg1 sCD4 sCD4 PUBTATOR sCD4 79966 Structures of the N-linked oligosaccharides of a recombinant soluble form of human CD4 glycoprotein (sCD4) have been investigated by enzymic microsequencing. 2209609 1 16 gly glycoprotein 251:262 arg1 human CD4 glycoprotein human CD4 glycoprotein PUBTATOR CD4 glycoprotein P01730 Structures of the N-linked oligosaccharides of a recombinant soluble form of human CD4 glycoprotein (sCD4) have been investigated by enzymic microsequencing. 22015141 2 61 gly glycosylation 397:409 arg2 N-linked glycosylation site mutant Cap N-linked glycosylation site mutant Cap site Eukaryotic vectors expressing wild-type PCV2 Cap (pCap) and N-linked glycosylation site mutant Cap (pCap-m) were constructed and the immunogenicity of these proteins was determined following DNA vaccination in BALB/c mice. 9694881 11 12 gly deglycosylated 1226:1239 arg1 This deglycosylated recombinant human angiotensinogen This deglycosylated recombinant human angiotensinogen PUBTATOR angiotensinogen 183 This deglycosylated recombinant human angiotensinogen could be of value for x-ray crystallography studies. 1990068 3 62 gly glycosylation 586:598 arg2 one potential N-linked glycosylation site one potential N-linked glycosylation site site Each subunit has one potential N-linked glycosylation site. 14520005 4 1 gly glycoprotein 925:936 arg1 an insect glycoprotein an insect glycoprotein Fterm glycoprotein To our knowledge, this is the first report that succeeded in identifying an insect glycoprotein bearing the beta1-3 galactosylated N-glycan. 12466483 0 42 gly glycosylation 20:32 arg2 overlapping glycosylation sequons overlapping glycosylation sequons Role of overlapping glycosylation sequons in antigenic properties, intracellular transport and biological activities of influenza A/H2N2 virus haemagglutinin. 10749666 6 78 gly SERP-1 1294:1299 arg1 Sialylation SERP-1 Sialylation PUBTATOR SERP-1 27230 Sialylation of SERP-1 by the MST3N gene product creates a uniquely charged species of secreted SERP-1 that is distinct from SERP-1 produced from other eukaryotic expression systems, though this has no apparent effect upon the kinetics of in vitro proteinase inhibition. 28835497 9 132 gly glycosylation 1692:1704 arg2 glycosylation site mutants glycosylation site mutants site Specifically, cysteine mutations caused defects in the accumulation of infectious virus in both the cellular and supernatant fractions, while glycosylation site mutants did not adversely affect virion egress from infected cells. 26035318 5 21 gly glycosylation 948:960 arg2 lower potential N-linked glycosylation site (PNGS) densities lower potential N-linked glycosylation site (PNGS) densities site RESULTS: Cluster analysis of V1V5 Env sequences (n = 215) identified that acute infection viruses had lower potential N-linked glycosylation site (PNGS) densities than viruses from chronic infection, with a higher amino acid length/PNGS ratio. 28060516 7 5 gly N193 1275:1278 arg1 the globular head the globular head the globular head Our major findings include (1) decreasing complexity of glycosylation from the stem to the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences between the three-dimensional structures of H3 and H5 HAs that may explain glycan type preferences at selected sites. 28060516 7 18 gly N10 1267:1269 arg1 the globular head the globular head the globular head Our major findings include (1) decreasing complexity of glycosylation from the stem to the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences between the three-dimensional structures of H3 and H5 HAs that may explain glycan type preferences at selected sites. 28060516 7 33 gly site 1361:1364 arg1 the globular head the globular head the globular head Our major findings include (1) decreasing complexity of glycosylation from the stem to the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences between the three-dimensional structures of H3 and H5 HAs that may explain glycan type preferences at selected sites. 28060516 7 72 gly head 1229:1232 arg1 the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences Our major findings include (1) decreasing complexity of glycosylation from the stem to the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences between the three-dimensional structures of H3 and H5 HAs that may explain glycan type preferences at selected sites. 28060516 7 86 gly N165 1304:1307 arg1 the globular head the globular head the globular head Our major findings include (1) decreasing complexity of glycosylation from the stem to the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences between the three-dimensional structures of H3 and H5 HAs that may explain glycan type preferences at selected sites. 21829533 5 11 gly glycosylation 1101:1113 arg2 the glycosylation sites the glycosylation sites sites The other was a change in the positional conversion of the glycosylation sites, which was the dominating mode with relatively low frequency in the later evolutionary stages. 26853155 2 58 gly glycoprotein 361:372 arg1 The human endogenous retrovirus envelope glycoprotein syncytin-2 The human endogenous retrovirus envelope glycoprotein syncytin-2 Fterm glycoprotein The human endogenous retrovirus envelope glycoprotein syncytin-2 is the most important player in mediating trophoblast cell-cell fusion as a fusogen. 28414420 4 4 gly glycosylation 685:697 arg2 site site site Antibody binding studies revealed that both the nature and site of glycosylation in the context of the V3 domain were critical for high-affinity binding. 20800224 7 51 gly unsialylated 990:1001 arg1 the more abundant N-glycans the more abundant N-glycans Forty-one N-glycans were detected in sample A and the more abundant N-glycans were unsialylated. 30841845 9 38 gly glycosylation 1548:1560 arg2 protein glycosylation site prediction protein glycosylation site prediction site RESULTS: In this study, we propose a positive unlabelled (PU) learning-based method, PA2DE (V2.0), based on the AlphaMax algorithm for protein glycosylation site prediction. 26977294 10 73 gly fucosylated 1820:1830 arg1 the fucosylated mAbs the fucosylated mAbs PUBTATOR mAbs 72935 These data help to explain the reduced ADCC observed in the fucosylated mAbs suggesting the specific AA residues involved in binding interactions. 10839980 0 53 gly bis-glycosylated 74:89 arg1 bis-glycosylated human lysozyme bis-glycosylated human lysozyme PUBTATOR lysozyme 4069 Glycosylation-site-selective synthesis of N-acetyl-lactosamine repeats in bis-glycosylated human lysozyme. 19358553 6 87 gly glycopeptides 1527:1539 arg2 glycopeptides glycopeptides glycopeptides In conclusion, MALDI-TOF MS signal strength of glycopeptides has been found to accurately reflect the relative quantities of glycoforms, providing that certain technical issues are considered, i.e., nonbiased sample handling, matrix choice, and instrumental settings. 23050552 3 61 gly occupied 397:404 arg2 one N-glycosylation site one N-glycosylation site site The beta and gamma subunits each contain one N-glycosylation site, each of which is occupied by a biantennary N-glycan. 23050552 3 71 gly N-glycosylation 358:372 arg2 one N-glycosylation site one N-glycosylation site site The beta and gamma subunits each contain one N-glycosylation site, each of which is occupied by a biantennary N-glycan. 11231274 6 19 gly core-fucosylated 1188:1203 arg1 sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides The glycan pools from siglec-5 and siglec-7 contained a larger proportion of sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides, whereas the carbohydrate mixture released from siglec-8 is noticeably less sialylated and is more abundant in 'high-mannose'-type glycans. 11231274 6 26 gly released 1302:1309 arg1 siglec-8 AND the carbohydrate mixture siglec-8 the carbohydrate mixture OGER siglec-8 Q9NYZ4 The glycan pools from siglec-5 and siglec-7 contained a larger proportion of sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides, whereas the carbohydrate mixture released from siglec-8 is noticeably less sialylated and is more abundant in 'high-mannose'-type glycans. 11231274 6 27 gly sialylated 1173:1182 arg1 sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides The glycan pools from siglec-5 and siglec-7 contained a larger proportion of sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides, whereas the carbohydrate mixture released from siglec-8 is noticeably less sialylated and is more abundant in 'high-mannose'-type glycans. 11231274 6 48 gly siglec-7 1131:1138 arg1 The glycan pools siglec-7 The glycan pools OGER siglec-7 Q9Y286 The glycan pools from siglec-5 and siglec-7 contained a larger proportion of sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides, whereas the carbohydrate mixture released from siglec-8 is noticeably less sialylated and is more abundant in 'high-mannose'-type glycans. 11231274 6 74 gly siglec-5 1118:1125 arg1 The glycan pools siglec-5 The glycan pools OGER siglec-5 O15389 The glycan pools from siglec-5 and siglec-7 contained a larger proportion of sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides, whereas the carbohydrate mixture released from siglec-8 is noticeably less sialylated and is more abundant in 'high-mannose'-type glycans. 11231274 6 75 gly sialylated 1344:1353 arg1 the carbohydrate mixture the carbohydrate mixture The glycan pools from siglec-5 and siglec-7 contained a larger proportion of sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides, whereas the carbohydrate mixture released from siglec-8 is noticeably less sialylated and is more abundant in 'high-mannose'-type glycans. 22180206 4 25 part_of glycoprotein 854:865 arg1 a glycopeptide glycoprotein a glycopeptide Fterm Site glycoprotein glycopeptide In addition, a glycopeptide from the anti-freeze glycoprotein of Antarctic and Arctic notothenoids, bearing four O-linked, per-acetylated T antigens was characterised. 20667571 5 14 gly glycosylation 1100:1112 arg2 residue 158N residue 158N residue Compared to HK03 ca virus, VN04 ca virus differs by 9 amino acids including an additional glycosylation site at residue 158N of the HA protein and a shortened stalk in the neuraminidase (NA) protein. 20667571 5 14 gly glycosylation 1100:1112 arg2 an additional glycosylation site an additional glycosylation site site Compared to HK03 ca virus, VN04 ca virus differs by 9 amino acids including an additional glycosylation site at residue 158N of the HA protein and a shortened stalk in the neuraminidase (NA) protein. 9916943 5 34 part_of CD44 1270:1273 arg1 CD44 variant epitopes CD44 CD44 variant epitopes PUBTATOR Site CD44 960 epitopes Our findings demonstrate that (1) specific exon assortment and/or posttranslational modifications of CD44v molecules can mask CD44 exon-specific epitopes; (2) glycosaminoglycan side chains, carried by some CD44v isoforms of high molecular weight, may play a critical role in determining the exact conformation of the molecule, which is necessary for the detection of CD44 variant epitopes by specific mAbs; and (3) in a panel of stable transfectants expressing CD44 N-glycosylation site-specific mutants, generated in the constant region of CD44 extracellular domain, asparagine-isoleucine substitution is sufficient per se to impair the immunoreactivity of several mAbs to pan-CD44. 9916943 5 52 part_of CD44 1444:1447 arg1 CD44 extracellular domain CD44 CD44 extracellular domain PUBTATOR Site CD44 960 domain Our findings demonstrate that (1) specific exon assortment and/or posttranslational modifications of CD44v molecules can mask CD44 exon-specific epitopes; (2) glycosaminoglycan side chains, carried by some CD44v isoforms of high molecular weight, may play a critical role in determining the exact conformation of the molecule, which is necessary for the detection of CD44 variant epitopes by specific mAbs; and (3) in a panel of stable transfectants expressing CD44 N-glycosylation site-specific mutants, generated in the constant region of CD44 extracellular domain, asparagine-isoleucine substitution is sufficient per se to impair the immunoreactivity of several mAbs to pan-CD44. 9916943 5 74 part_of CD44 1029:1032 arg1 CD44 exon-specific epitopes CD44 CD44 exon-specific epitopes PUBTATOR Site CD44 960 epitopes Our findings demonstrate that (1) specific exon assortment and/or posttranslational modifications of CD44v molecules can mask CD44 exon-specific epitopes; (2) glycosaminoglycan side chains, carried by some CD44v isoforms of high molecular weight, may play a critical role in determining the exact conformation of the molecule, which is necessary for the detection of CD44 variant epitopes by specific mAbs; and (3) in a panel of stable transfectants expressing CD44 N-glycosylation site-specific mutants, generated in the constant region of CD44 extracellular domain, asparagine-isoleucine substitution is sufficient per se to impair the immunoreactivity of several mAbs to pan-CD44. 18815311 10 48 gly glycosylation 1491:1503 arg2 glycosylation site positions site positions site positions Finally, by mapping structural conservation and glycosylation site positions from other members of the paramyxovirus family, we suggest the molecular surface involved in oligomerization. 7510285 9 43 part_of antigen 1411:1417 arg1 the 42-residue hydrophilic domain L6 antigen the 42-residue hydrophilic domain PUBTATOR Site L6 antigen 4071 domain Now, using chimeric cDNA constructs encoding human-murine L6 antigen hybrids in conjunction with monoclonal antibody binding experiments, we show that the 42-residue hydrophilic domain of the L6 antigen, located between the third and fourth hydrophobic domains, is outside the cell and that residues in the NH2-terminal region of this domain are critical for the binding of the murine L6 mAb to H-L6. 30850477 6 47 gly N-glycosylation 675:689 arg2 N-glycosylation sites N-glycosylation sites sites We analyzed the distribution and acquisition of N-glycosylation sites within Ab V regions of peripheral blood and bone marrow B cells of 12 healthy individuals, eight myasthenia gravis patients, and six systemic lupus erythematosus patients, obtained by next-generation sequencing. 21846136 1 7 gly glycopeptide 479:490 arg2 the simultaneous glycopeptide enrichment the simultaneous glycopeptide enrichment glycopeptide An integrated sample pretreatment system, composed of a click maltose hydrophilic interaction chromatography (HILIC) column, a strong cation exchange (SCX) precolumn, and a PNGase F immobilized enzymatic reactor (IMER), was established for the simultaneous glycopeptide enrichment, sample buffer exchange, and online deglycosylation, by which the sample pretreatment for glycoproteome could be performed online automatically, beneficial to improve the efficiency and sensitivity of the N-linked glycosylation site identification. 20660348 5 18 gly glycosylation 908:920 arg2 a novel N-linked glycosylation site a novel N-linked glycosylation site site A single-nucleotide polymorphism in the first short consensus repeat of Sle1c Crry introduced a novel N-linked glycosylation site likely responsible for this structural alteration. 24497285 11 37 gly glycoproteins 2179:2191 arg1 diverse salivary glycoproteins diverse salivary glycoproteins Fterm glycoproteins CONCLUSIONS: We developed a sample preparation and mass spectrometry detection strategy for rapid and efficient measurement of site-specific glycosylation occupancy on diverse salivary glycoproteins suitable for biomarker discovery and detection of changes in glycosylation occupancy in human disease. 11303872 1 8 part_of containing 153:162 arg1 lymphotactin AND eight sites lymphotactin eight sites PUBTATOR Site lymphotactin 6375 sites The synthesis of a 93-residue chemokine, lymphotactin, containing eight sites of O-linked glycosylation, was achieved using the technique of native chemical ligation. 10429212 1 26 gly N-glycosylation 142:156 arg2 the natural N-glycosylation site the natural N-glycosylation site site We have used the natural N-glycosylation site in the N-tail of cig30, a eukaryotic polytopic membrane protein, as a marker for N-tail translocation across the microsomal membrane. 9235960 3 9 gly glycosylated 530:541 arg1 B-fragment B-fragment Fterm B-fragment B-fragment with a nonfunctional KDEL sequence (B-Glyc-KDELGL) was glycosylated with about the same kinetics as B-Glyc-KDEL but localized at steady state to the Golgi apparatus. 15113920 2 39 part_of contain 301:307 arg1 The glycoproteins AND five sites glycoproteins sites Fterm Site glycoproteins sites The glycoproteins contain six potential sites for the attachment of N-linked oligosaccharides, five sites on Gn and one on Gc. 28620050 4 70 part_of contains 800:807 arg1 Hexa-Fc AND two N-linked sites Hexa-Fc two N-linked sites PUBTATOR Site Hexa 3073 sites Hexa-Fc contains two N-linked sites at Asn-77 (equivalent to Asn-297 in the Fc of IgG1) and Asn-236 (equivalent to Asn-563 in the tail piece of IgM). 18642129 4 66 gly glycosylation 665:677 arg2 each glycosylation site each glycosylation site site Despite glycosylation of recombinant FVIIa has been fully characterized, nothing is reported on the N- and O-glycans of plasma-derived FVII (pd-FVII) and on their structural heterogeneity at each glycosylation site. 18642129 4 93 gly FVII 604:607 arg1 N- FVII N- OGER FVII P08709 Despite glycosylation of recombinant FVIIa has been fully characterized, nothing is reported on the N- and O-glycans of plasma-derived FVII (pd-FVII) and on their structural heterogeneity at each glycosylation site. 2317204 2 62 gly B 275:275 arg1 degrading proteoglycan aggregates cathepsin B degrading proteoglycan aggregates PUBTATOR cathepsin B 1508 Cathepsin L was found to be much more extensive than cathepsin B in degrading proteoglycan aggregates. 14749323 11 82 gly glycosylation 2054:2066 arg1 OAT1 OAT1 PUBTATOR OAT1 9356 This study is the first molecular identification and characterization of glycosylation of OAT1 and may provide important insights into the structure-function relationships of the organic anion transporter family. 22355413 0 71 gly glycosylation 38:50 arg2 glycosylation site migrations glycosylation site migrations site Prediction of biological functions on glycosylation site migrations in human influenza H1N1 viruses. 7532677 0 109 part_of Bw4 4:6 arg1 The Bw4 public epitope Bw4 The Bw4 public epitope PUBTATOR Site Bw4 474272 epitope The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. 31703583 15 84 part_of Pfs230C1 2448:2455 arg1 the Pfs230C1 fragment Pfs230C1 the Pfs230C1 fragment Cterm Site Pfs230C1 fragment An intact protein at higher yield than that previously observed for the Pfs230C1 fragment was achieved. 27216994 11 50 gly receptors 1960:1968 arg1 the N-glycan composition receptors the N-glycan composition Fterm receptors We examined the N-glycan composition of NMDA receptors (NMDARs) using deglycosylating enzymes, lectin-based biochemistry, and electrophysiology. 18330979 3 57 gly glycosylation 572:584 arg1 Env Env PUBTATOR Env 100616444 Thus, characterizing glycosylation patterns of Env and native virions and correlating glycosylation profiles with infectivity and Env immunogenicity are necessary first steps in designing effective immunogens. 18330979 3 91 gly glycosylation 637:649 arg1 Env Env PUBTATOR Env 100616444 Thus, characterizing glycosylation patterns of Env and native virions and correlating glycosylation profiles with infectivity and Env immunogenicity are necessary first steps in designing effective immunogens. 16862166 7 69 gly glycosylation 1255:1267 arg2 a new potential N-linked glycosylation site a new potential N-linked glycosylation site site One light chain sequence encoded a new potential N-linked glycosylation site, and another showed evidence of antigen selection. 16862166 7 69 gly glycosylation 1255:1267 arg2 One light chain sequence One light chain sequence sequence One light chain sequence encoded a new potential N-linked glycosylation site, and another showed evidence of antigen selection. 16368742 6 13 gly glycosylation 1366:1378 arg2 a nearly identically situated and experimentally confirmed N-linked glycosylation site a nearly identically situated and experimentally confirmed N-linked glycosylation site site Although glycosylation in this vicinity has not been reported for a TRP channel, the structurally related hexahelical hyperpolarization-activated cyclic nucleotide-gated channel, HCN2, and the voltage-gated potassium channel, human ether-a-go-go-related (HERG), share a nearly identically situated and experimentally confirmed N-linked glycosylation site which promotes rather than limits channel insertion into the plasma membrane. 20881037 8 62 gly glycosylation 1343:1355 arg2 the site the site site The M133T mutation could also overcome the secretion defect caused by the G145R immune-escape mutation or mutation at N146, the site of N-linked glycosylation. 20881037 8 62 gly glycosylation 1343:1355 arg2 N146 N146 N146 The M133T mutation could also overcome the secretion defect caused by the G145R immune-escape mutation or mutation at N146, the site of N-linked glycosylation. 9435448 13 15 gly chain 2269:2273 arg1 hSHBG hSHBG chain PUBTATOR hSHBG 6462 This study demonstrated that an additional carbohydrate chain on hSHBG decreases the clearance rate of this protein. 7620335 0 22 part_of factor 70:75 arg1 human coagulation factor X activation peptide factor X human coagulation factor X activation peptide OGER Site factor X P00742 peptide Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site. 7620335 0 72 part_of X 77:77 arg1 human coagulation factor X activation peptide factor X human coagulation factor X activation peptide OGER Site factor X P00742 peptide Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site. 7620335 0 94 part_of coagulation 58:68 arg1 human coagulation factor X activation peptide coagulation factor X human coagulation factor X activation peptide OGER Site coagulation factor X P00742 peptide Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site. 31406333 3 0 gly glycosylation 688:700 arg2 an N-linked glycosylation site an N-linked glycosylation site site This antigenic drift was mainly caused by amino acid mutations at NA residues 245, 247 (S245N/S247T; introducing an N-linked glycosylation site at residue 245) and 468. 31113887 7 78 gly glycosylated 1040:1051 arg1 chimpanzee CD4 chimpanzee CD4 PUBTATOR CD4 450124 Doubly glycosylated forms of chimpanzee CD4 reduce HIV-1 and SIVcpz infection by as much as two orders of magnitude. 23909558 5 3 gly O-glycopeptide 668:681 arg2 O-glycopeptide ETD spectra O-glycopeptide ETD spectra O-glycopeptide Nonetheless, new software is necessary for interpreting O-glycopeptide ETD spectra in order to expedite the analysis workflow. 30147434 9 45 gly glycosylation 1639:1651 arg2 the glycosylation site ratios the glycosylation site ratios site In addition, we normalized the glycosylation site ratios by the corresponding parent protein ratios to reflect the real modification changes. 30898876 8 14 gly glycoproteins 1775:1787 arg1 mammalian glycoproteins mammalian glycoproteins Fterm glycoproteins Taken together, our results indicate the presence of mammalian glycoproteins carrying type-I LDN on N-glycans and suggest that type-I and type-II LDNs have different roles in vivo. 30898876 8 85 gly carrying 1789:1796 arg1 mammalian glycoproteins AND type-I LDN mammalian glycoproteins type-I LDN Fterm glycoproteins Taken together, our results indicate the presence of mammalian glycoproteins carrying type-I LDN on N-glycans and suggest that type-I and type-II LDNs have different roles in vivo. 18562306 7 55 gly glycosylation 1645:1657 arg2 distal sites distal sites sites These results highlight the existence of two modes of site selection used by these ppGalNAcTs: local sequence recognition by the catalytic domain and the concerted recognition of distal sites of prior glycosylation together with local sequence binding mediated, respectively, by the lectin and catalytic domains. 11171034 3 31 gly N-glycosylation 447:461 arg2 The single potential N-glycosylation site The single potential N-glycosylation site site The single potential N-glycosylation site was mutated and a sequence encoding a hexahistidine tag was introduced at the C-terminal of the construction to aid purification by immobilized metal-chelate chromatography. 9139737 4 62 part_of fragment 894:901 arg1 The NH2 terminus fragment The NH2 terminus Fterm Site fragment terminus The NH2 terminus of this fragment was pinpointed by radiochemical sequencing after replacement of selected codons with methionine codons and labeling the cells with [35S]methionine. 21750110 1 52 gly N-glycosylation 189:203 arg2 the N-glycosylation site BSCL2 site PUBTATOR BSCL2 14705 site Heterozygosity for mutations (N88S and P90L) in the N-glycosylation site of seipin/BSCL2 is associated with the autosomal dominant motor neuron diseases, spastic paraplegia 17 and distal hereditary motor neuropathy type V, referred to as 'seipinopathies'. 25327667 5 52 gly glycosylation 651:663 arg2 Asn69 Asn69 Asn69 PSA has a single glycosylation site at Asn69, with glycans constituting approximately 8% of the protein by weight. 25327667 5 52 gly glycosylation 651:663 arg2 a single glycosylation site a single glycosylation site site PSA has a single glycosylation site at Asn69, with glycans constituting approximately 8% of the protein by weight. 19500602 5 4 gly glycosylation 863:875 arg2 an additional glycosylation site an additional glycosylation site site In agreement with introduction of an additional glycosylation site, western blot analysis showed migration of hSERT K201N corresponding to a higher molecular weight than wild type hSERT upon expression in both HEK293 cells and primary cultures of cortical neurons. 24369354 1 12 gly glycoprotein 217:228 arg1 the envelope glycoprotein gp120 the envelope glycoprotein gp120 Fterm glycoprotein VRC01, a broadly neutralizing monoclonal antibody (bnmAb), can neutralize a diverse array of HIV-1 isolates by mimicking CD4 binding to the envelope glycoprotein gp120. 11072064 5 86 gly N-glycosylation 753:767 arg2 an N-glycosylation site an N-glycosylation site site The stalk region contains a leucine-zipper, and an N-glycosylation site was also found in the CRD. 19208354 9 79 gly N-glycosylation 1337:1351 arg2 the N-glycosylation site the N-glycosylation site site The intracellular transport and enzymatic activity, but not correct folding, of LPH-G1363S were partially restored by expression at 20 degrees C. However, a form of LPH that contains the mutations G1363S and N1361A, which eliminates the N-glycosylation site, did not restore the features of wild-type LPH. 1482348 3 8 gly O-glycosylated 431:444 arg1 O-glycosylated oligosaccharide O-glycosylated oligosaccharide Sugar analysis and amino acid sequence analysis of peptide fragments produced by limited degradation revealed that O-glycosylated oligosaccharide linked to Thr445 of the alpha chain. 1482348 3 28 gly linked 462:467 arg1 Thr445 AND O-glycosylated oligosaccharide Thr445 O-glycosylated oligosaccharide Thr445 Sugar analysis and amino acid sequence analysis of peptide fragments produced by limited degradation revealed that O-glycosylated oligosaccharide linked to Thr445 of the alpha chain. 7510285 8 59 part_of protein 1155:1161 arg1 a protein epitope protein a protein epitope Fterm Site protein epitope We have previously demonstrated that the murine L6 mAb recognizes a protein epitope expressed on human tumor-derived cell lines. 14595005 3 68 gly glycoproteins 652:664 arg1 The envelope glycoproteins The envelope glycoproteins Fterm glycoproteins The envelope glycoproteins carried by plasma virus in CD4-depleted animals were found to contain specific alterations affecting the V2 region of gp120; similar V2 changes were observed during independent monkey infections. 29479800 3 9 gly N-glycosylation 494:508 arg2 Not all potential N-glycosylation sites Not all potential N-glycosylation sites sites Not all potential N-glycosylation sites are recognized in vivo and the site occupancy can vary in different expression systems, resulting in underglycosylation of recombinant glycoproteins. 29479800 3 16 gly glycoproteins 651:663 arg1 recombinant glycoproteins recombinant glycoproteins Fterm glycoproteins Not all potential N-glycosylation sites are recognized in vivo and the site occupancy can vary in different expression systems, resulting in underglycosylation of recombinant glycoproteins. 29479800 3 60 gly underglycosylation 617:634 arg1 recombinant glycoproteins recombinant glycoproteins Fterm glycoproteins Not all potential N-glycosylation sites are recognized in vivo and the site occupancy can vary in different expression systems, resulting in underglycosylation of recombinant glycoproteins. 25451932 7 24 part_of frizzled-1 949:958 arg1 the frizzled-1 domain frizzled-1 the frizzled-1 domain OGER Site frizzled-1 Q9UP38 domain Similarly, N-glycosylation at Asn-231 protected corin from autocleavage in the frizzled-1 domain. 19369259 4 9 gly F-deglycosylated 790:805 arg1 purified and peptide N-glycosidase F-deglycosylated CD36 purified and peptide N-glycosidase F-deglycosylated CD36 OGER CD36 P16671 Using mass spectrometry on purified and peptide N-glycosidase F-deglycosylated CD36 and also by comparing the electrophoretic mobility of different glycosylation site mutants, we have determined that 9 of the 10 sites can be modified by glycosylation. 19369259 4 53 gly glycosylation 876:888 arg2 different glycosylation site mutants different glycosylation site mutants site Using mass spectrometry on purified and peptide N-glycosidase F-deglycosylated CD36 and also by comparing the electrophoretic mobility of different glycosylation site mutants, we have determined that 9 of the 10 sites can be modified by glycosylation. 17634239 4 14 part_of epitope 739:745 arg1 subtype C gp120 gp120 epitope PUBTATOR Site gp120 3700 epitope Here we show that N-linked glycans in addition to the one at position 295 are important in the formation of the 2G12 epitope in subtype C gp120. 2788224 3 5 gly glycosylation 636:648 arg2 a potential glycosylation site a potential glycosylation site site In contrast, our results suggest that vpu is not glycosylated, even though the protein contains a potential glycosylation site. 1990068 0 64 gly glycoprotein 42:53 arg1 the fusion glycoprotein the fusion glycoprotein Fterm glycoprotein Deduced amino acid sequence of the fusion glycoprotein of turkey rhinotracheitis virus has greater identity with that of human respiratory syncytial virus, a pneumovirus, than that of paramyxoviruses and morbilliviruses. 25533529 1 35 part_of contains 196:203 arg1 Acutobin AND four N-glycosylation sites Acutobin four N-glycosylation sites Fterm Site Acutobin sites Acutobin, the α-fibrinogenase from Deinagkistrodon acutus venom, contains four N-glycosylation sites with disialylated complex-typed glycans. 25533529 1 35 part_of contains 196:203 arg1 the α-fibrinogenase AND four N-glycosylation sites the α-fibrinogenase four N-glycosylation sites Fterm Site α-fibrinogenase 2244 sites Acutobin, the α-fibrinogenase from Deinagkistrodon acutus venom, contains four N-glycosylation sites with disialylated complex-typed glycans. 10419504 10 39 part_of have 1441:1444 arg1 NPC1 AND an intact sterol-sensing domain NPC1 an intact sterol-sensing domain PUBTATOR AminoAcid NPC1 O15118 domain and leucine We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity. 10419504 10 39 part_of have 1441:1444 arg1 NPC1 AND leucine zipper motif NPC1 leucine zipper motif PUBTATOR Site NPC1 O15118 motif We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity. 10419504 10 39 part_of have 1441:1444 arg1 a glycoprotein AND an intact sterol-sensing domain a glycoprotein an intact sterol-sensing domain Fterm AminoAcid glycoprotein domain and leucine We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity. 10419504 10 39 part_of have 1441:1444 arg1 a glycoprotein AND leucine zipper motif a glycoprotein leucine zipper motif Fterm Site glycoprotein motif We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity. 22577028 5 76 gly sites 983:987 arg1 Five glycosylation sites Five glycosylation sites sites Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA. 22577028 5 79 gly glycosylation 969:981 arg2 Five glycosylation sites Five glycosylation sites sites Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA. 22577028 5 76 gly sites 983:987 arg1 N481 N11, N23, N276, N287, and N481 N11, N23, N276, N287, and N481 Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA. 22577028 5 76 gly sites 983:987 arg1 N23 N11, N23, N276, N287, and N481 N11, N23, N276, N287, and N481 Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA. 22577028 5 76 gly sites 983:987 arg1 N23 N11, N23, N276, N287, and N481 N11, N23, N276, N287, and N481 Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA. 22577028 5 79 gly glycosylation 969:981 arg2 N287 N11, N23, N276, N287, and N481 N11, N23, N276, N287, and N481 Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA. 22577028 5 79 gly glycosylation 969:981 arg2 N23 N11, N23, N276, N287, and N481 N11, N23, N276, N287, and N481 Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA. 22577028 5 79 gly glycosylation 969:981 arg2 N23 N11, N23, N276, N287, and N481 N11, N23, N276, N287, and N481 Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA. 25094044 0 30 part_of glycoprotein 62:73 arg1 site glycoprotein site Fterm Site glycoprotein site Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human. 25094044 0 42 part_of site 21:24 arg1 the ER-resident glycoprotein glycoprotein site Fterm Site glycoprotein site Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human. 8603082 2 20 part_of MCT1-related 432:443 arg1 MCT1-related sequence MCT1 MCT1-related sequence PUBTATOR Site MCT1 P53985 sequence We have cloned and sequenced the lactate transporter from Ehrlich Lettré tumour cells by using the polymerase chain reaction (PCR) to amplify MCT1-related sequence from cDNA. 8509412 2 50 gly asparagine-linked 334:350 arg1 three asparagine-linked oligosaccharides asparagine three asparagine-linked oligosaccharides asparagine In its mature form, the receptor possesses three asparagine-linked oligosaccharides. 8509412 2 74 gly possesses 318:326 arg1 the receptor AND three asparagine-linked oligosaccharides the receptor three asparagine-linked oligosaccharides Fterm receptor In its mature form, the receptor possesses three asparagine-linked oligosaccharides. 26062906 7 77 gly glycosylation 1068:1080 arg2 a N-linked glycosylation site a N-linked glycosylation site site In addition, each of three mutant MHBs proteins contains a N-linked glycosylation site (N-X-S/T), relocated to position 5 (MQWQNTTFHQ), 6 (MQWQSNTSHQ) or 7 (MQWQSTNFTQ) in pre-S2 domain. 26062906 7 79 gly position 1111:1118 arg1 5 5 position 5 In addition, each of three mutant MHBs proteins contains a N-linked glycosylation site (N-X-S/T), relocated to position 5 (MQWQNTTFHQ), 6 (MQWQSNTSHQ) or 7 (MQWQSTNFTQ) in pre-S2 domain. 21380457 4 44 gly fucosylated 614:624 arg1 a fucosylated glycan a fucosylated glycan MALDI-QIT-TOF mass spectrometry revealed the intensity of m/z 1809.6, identified as a fucosylated glycan, was much higher in samples from patients with LC and HCC relative to the patients with HBV and healthy controls. 27007620 8 0 gly heterogeneity 1709:1721 arg1 glycans glycans Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site. 27007620 8 22 gly glycosylation 1575:1587 arg1 a specific protein a specific protein Fterm protein Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site. 27007620 8 40 gly glycosylation 1652:1664 arg2 a given glycosylation site a given glycosylation site site Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site. 27007620 8 66 gly glycosylation 1755:1767 arg2 a given glycosylation site a given glycosylation site site Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site. 27007620 8 87 gly occupancy 1631:1639 arg2 a given glycosylation site a given glycosylation site site Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site. 1280945 5 33 gly glycosylation 868:880 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site, and lysine These substitutions include threonine for lysine at position 71, resulting in the addition of a potential N-linked glycosylation site, and lysine for glutamic acid at position 147. 31471966 4 10 gly glycosylation 816:828 arg2 a glycosylation site a glycosylation site site Mutational analyses including insertion of a glycosylation site for the tagged PTHrP revealed that the evolutionarily conserved regions in the signal peptide and the pro-region facilitate the redirection of ppPTHrP from the secretory pathway to the nuclear targeting pathway. 18420026 6 20 gly glycoprotein 1539:1550 arg1 an N-linked glycoprotein an N-linked glycoprotein Fterm glycoprotein Based on the results of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with human wild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is an N-linked glycoprotein with a single glycosylation site at position N290KS. 18420026 6 20 gly glycoprotein 1539:1550 arg1 human NECL1 human NECL1 PUBTATOR NECL1 57863 Based on the results of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with human wild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is an N-linked glycoprotein with a single glycosylation site at position N290KS. 18420026 6 43 gly glycosylation 1443:1455 arg2 glycosylation site mutant glycosylation site mutant site Based on the results of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with human wild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is an N-linked glycoprotein with a single glycosylation site at position N290KS. 18420026 6 104 gly glycosylation 1566:1578 arg2 position position position Based on the results of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with human wild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is an N-linked glycoprotein with a single glycosylation site at position N290KS. 18420026 6 104 gly glycosylation 1566:1578 arg2 a single glycosylation site a single glycosylation site site Based on the results of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with human wild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is an N-linked glycoprotein with a single glycosylation site at position N290KS. 2457117 2 20 gly glycosylation 389:401 arg2 a new glycosylation site a new glycosylation site site An SA11 mutant with a new glycosylation site at amino acid 211 of VP7 was shown to escape neutralization by hyperimmune but not infection sera. 8380463 6 31 gly utilized 873:880 arg2 the three (residues 41, 102, and 411) potential sites the three (residues 41, 102, and 411) potential sites sites Analysis of these mutants revealed that only two (residues 41 and 102) of the three (residues 41, 102, and 411) potential sites for the addition of N-linked glycans are actually utilized. 8380463 6 31 gly utilized 873:880 arg2 residues 41, 102, and 411 residues 41, 102, and 411 residues 41, 102, and 411 Analysis of these mutants revealed that only two (residues 41 and 102) of the three (residues 41, 102, and 411) potential sites for the addition of N-linked glycans are actually utilized. 8380463 6 31 gly utilized 873:880 arg2 residues 41 and 102 residues 41 and 102 residues 41 and 102 Analysis of these mutants revealed that only two (residues 41 and 102) of the three (residues 41, 102, and 411) potential sites for the addition of N-linked glycans are actually utilized. 11371512 1 23 gly glycoproteins 252:264 arg1 Sphingolipid activator proteins Sphingolipid activator proteins Fterm proteins Sphingolipid activator proteins (saposins A, B, C and D) are small homologous glycoproteins derived from a common precursor protein (prosaposin) encoded by a single gene. 11371512 1 23 gly glycoproteins 252:264 arg1 small homologous glycoproteins small homologous glycoproteins Fterm glycoproteins Sphingolipid activator proteins (saposins A, B, C and D) are small homologous glycoproteins derived from a common precursor protein (prosaposin) encoded by a single gene. 21569239 6 32 part_of mindin 838:843 arg1 the FS domains mindin the FS domains PUBTATOR Site mindin 10417 domains Though the primary sequences of the FS domains of F-spondin and mindin are less than 36% identical, their overall structures are very similar. 21569239 6 38 part_of F-spondin 824:832 arg1 the FS domains F-spondin the FS domains PUBTATOR Site F-spondin 10418 domains Though the primary sequences of the FS domains of F-spondin and mindin are less than 36% identical, their overall structures are very similar. 29604477 2 44 gly glycosylation 392:404 arg1 N146 N146 N146 Virion secretion requires N-linked glycosylation at N146 in the S domain but can be impaired by immune escape mutations. 29604477 2 44 gly glycosylation 392:404 arg1 the S domain the S domain domain Virion secretion requires N-linked glycosylation at N146 in the S domain but can be impaired by immune escape mutations. 7944407 1 72 part_of cysteine 125:132 arg1 secreted protein protein cysteine Fterm AminoAcid protein cysteine SPARC (secreted protein, acidic and rich in cysteine) is a secreted, Ca+2-binding glycoprotein that modulates interactions between cells and their immediate extracellular matrix. 2168975 8 31 gly glycosylation 1114:1126 arg2 the new glycosylation site the new glycosylation site site The proximity of the new glycosylation site to a sequence of 19 uncharged amino acids (residues 118 to 136) that is conserved in the glycoproteins of the two VSV serotypes suggests that this region may be involved in membrane fusion. 2168975 8 43 gly glycoproteins 1222:1234 arg1 the glycoproteins the glycoproteins Fterm glycoproteins The proximity of the new glycosylation site to a sequence of 19 uncharged amino acids (residues 118 to 136) that is conserved in the glycoproteins of the two VSV serotypes suggests that this region may be involved in membrane fusion. 7730329 8 29 part_of TSV-PA 1028:1033 arg1 the internal peptide sequences TSV-PA the internal peptide sequences Cterm Site TSV-PA sequences Oligonucleotide primers designed on the basis of the N-terminal and the internal peptide sequences of TSV-PA were used for the amplification of cDNA fragments by polymerase chain reaction. 7730329 8 91 part_of cDNA 1070:1073 arg1 cDNA fragments cDNA cDNA fragments Cterm Site cDNA fragments Oligonucleotide primers designed on the basis of the N-terminal and the internal peptide sequences of TSV-PA were used for the amplification of cDNA fragments by polymerase chain reaction. 8829802 3 36 part_of transferrin 524:534 arg1 The amino-acid sequence transferrin The amino-acid sequence PUBTATOR Site transferrin 24825 sequence The amino-acid sequence of rat transferrin had 69.8% identity with that of human transferrin and 48.8% identity with that of human lactoferrin. 16360109 8 46 gly structures 1817:1826 arg1 the Fv region the Fv region the Fv region Site region In contrast to many other non-antibody glycosylated therapeutics, there is no strong correlation between oligosaccharide structures in the Fv region and their clearance rates in vivo. 9461526 4 36 part_of prosaposin 526:535 arg1 prosaposin amino acid sequences prosaposin prosaposin amino acid sequences PUBTATOR Site prosaposin 395602 sequences There was 59% identity and 76% similarity of human and chicken prosaposin amino acid sequences. 7974384 1 61 gly glycosylation 527:539 arg2 an additional glycosylation site an additional glycosylation site site rt-PA-K, a variant of recombinant tissue-type plasminogen activator (rt-PA) with substitution of amino acids 296 to 299 with alanine (KHRR296-299AAAA) has increased fibrin-specificity and reduced sensitivity to plasminogen activator inhibitor-1; rt-PA-T, with threonine 103 replaced by asparagine has an additional glycosylation site and a reduced clearance; and rt-PA-N, with asparagine 117 mutagenized to glutamine lacks the high mannose carbohydrate side chain. 19415532 6 51 gly glycosylation 779:791 arg2 a glycosylation site a glycosylation site site It results in the replacement of the normal asparagine 233 by isoleucine and, subsequently, in disruption of a glycosylation site. 10073697 6 27 part_of protein 1334:1340 arg1 the deduced sequence protein the deduced sequence Fterm Site protein sequence Genetic comparison showed sequence differences in all three genome segments of the two DOB isolates, including an additional N-glycosylation site in the deduced sequence of the G2 protein from the Estonian virus. 29562594 2 33 gly glycosylation 437:449 arg1 a recombinant protein a recombinant protein Fterm protein We report for the first time that through one-time vacuum infiltration of kifunensine in plant tissue, N-linked glycosylation of a recombinant protein transiently produced in whole-plants shifted completely from complex-type to oligomannose-type. 17055129 4 47 gly N-glycosylation 675:689 arg2 N-glycosylation sites N-glycosylation sites sites Here, we made plasmids containing genes encoding either wild type or mutant E2 proteins in which N-glycosylation sites (N560NT and N576ST) close to these important regions were mutated separately or in combination. 17055129 4 64 gly sites 691:695 arg1 N-glycosylation sites N-glycosylation sites sites Here, we made plasmids containing genes encoding either wild type or mutant E2 proteins in which N-glycosylation sites (N560NT and N576ST) close to these important regions were mutated separately or in combination. 26701645 6 75 gly N-glycosylation 1009:1023 arg2 the epitope located N-glycosylation site the epitope located N-glycosylation site site Importantly, single, triple, and the aglycosylated tyrosinase mutants lacking the epitope located N-glycosylation site (N371D) were able to trigger higher CD8+ T-cell activation. 7730329 12 38 part_of u-PA 1776:1779 arg1 the catalytic domains u-PA the catalytic domains PUBTATOR Site u-PA 5328 domains On the other hand, TSV-PA shows only 21-23% sequence similarity with the catalytic domains of u-PA and t-PA. 7730329 12 46 part_of t-PA 1785:1788 arg1 the catalytic domains t-PA the catalytic domains PUBTATOR Site t-PA 5327 domains On the other hand, TSV-PA shows only 21-23% sequence similarity with the catalytic domains of u-PA and t-PA. 25094044 1 37 gly glycoprotein 302:313 arg1 glycoprotein glucosyltransferase glycoprotein glucosyltransferase Fterm glycoprotein Here we report glycan structures and their position of attachment to a carrier protein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferase (UGGT1), as detected using tandem mass spectrometry. 7755594 3 27 gly occupied 581:588 arg2 4, 3, 2 or 1 glycosylation sites 4, 3, 2 or 1 glycosylation sites sites Chemical cross-linking of nIFN-gamma with glutaraldehyde revealed that 4, 3, 2 or 1 glycosylation sites occupied 28%, 40%, 26% and 6% of the dimers respectively. 7755594 3 42 gly glycosylation 561:573 arg2 4, 3, 2 or 1 glycosylation sites 4, 3, 2 or 1 glycosylation sites sites Chemical cross-linking of nIFN-gamma with glutaraldehyde revealed that 4, 3, 2 or 1 glycosylation sites occupied 28%, 40%, 26% and 6% of the dimers respectively. 26656560 9 38 part_of TF 1187:1188 arg1 one N-glycosylation site TF one N-glycosylation site Cterm Site TF 7018 site p.N432S is a novel mutation that abolishes one N-glycosylation site of TF, while p.P589S is the polymorphism that defines the C2 isoform of TF. 12538726 9 32 gly N-glycosylated 1350:1363 arg1 rNCC rNCC sites PUBTATOR rNCC 54300 sites Thus, we have demonstrated that rNCC is N-glycosylated in vivo at two sites, that glycosylation is essential for efficient function and surface expression of the cotransporter, and that the elimination of glycosylation allows much greater access of thiazide diuretics to their binding site. 7487957 3 7 gly N-glycosylation 668:682 arg2 only one N-glycosylation site only one N-glycosylation site site An engineered rHuAChE mutant containing only one N-glycosylation site was cleared from the circulation more rapidly than the wild-type triglycosylated enzyme. 7487957 3 107 gly triglycosylated 754:768 arg1 the wild-type triglycosylated enzyme the wild-type triglycosylated enzyme Fterm enzyme An engineered rHuAChE mutant containing only one N-glycosylation site was cleared from the circulation more rapidly than the wild-type triglycosylated enzyme. 2000403 0 6 gly glycoprotein 64:75 arg1 N-linked glycoprotein synthesis N-linked glycoprotein synthesis Fterm glycoprotein Glycosylation site-binding protein is not required for N-linked glycoprotein synthesis. 15199058 8 4 gly glycosylation 1312:1324 arg2 the Cepsilon3 glycosylation site the Cepsilon3 glycosylation site site Mutation of the Cepsilon3 glycosylation site at asparagine 371 to threonine or glutamine did not significantly affect CD23 recognition. 15199058 8 55 gly asparagine 1334:1343 arg1 threonine threonine threonine Mutation of the Cepsilon3 glycosylation site at asparagine 371 to threonine or glutamine did not significantly affect CD23 recognition. 25713063 0 59 gly glycosylated 44:55 arg1 Multidomain human peroxidasin 1 Multidomain human peroxidasin 1 Fterm peroxidasin 1 Multidomain human peroxidasin 1 is a highly glycosylated and stable homotrimeric high spin ferric peroxidase. 25713063 0 59 gly glycosylated 44:55 arg1 a highly glycosylated and stable homotrimeric high spin ferric peroxidase a highly glycosylated and stable homotrimeric high spin ferric peroxidase Fterm peroxidase Multidomain human peroxidasin 1 is a highly glycosylated and stable homotrimeric high spin ferric peroxidase. 12706077 1 4 gly glycoprotein 352:363 arg1 surface glycoprotein surface glycoprotein Fterm glycoprotein Avian H5N1 influenza viruses isolated from humans in Hong Kong in 1997 were divided into two antigenic groups based on the presence or absence of a potential glycosylation site at amino acid residues 154-156 in the HA1 region of the viral hemagglutinin (HA) surface glycoprotein. 12706077 1 47 gly glycosylation 244:256 arg2 amino acid residues 154-156 amino acid residues 154-156 residues 154-156 Avian H5N1 influenza viruses isolated from humans in Hong Kong in 1997 were divided into two antigenic groups based on the presence or absence of a potential glycosylation site at amino acid residues 154-156 in the HA1 region of the viral hemagglutinin (HA) surface glycoprotein. 12706077 1 47 gly glycosylation 244:256 arg2 a potential glycosylation site a potential glycosylation site site Avian H5N1 influenza viruses isolated from humans in Hong Kong in 1997 were divided into two antigenic groups based on the presence or absence of a potential glycosylation site at amino acid residues 154-156 in the HA1 region of the viral hemagglutinin (HA) surface glycoprotein. 28620050 3 13 gly attached 597:604 arg2 the unique N-linked glycan AND Asn-297 Asn-297 the unique N-linked glycan Asn-297 The critical influence of the unique N-linked glycan attached at Asn-297 on the structure and function of IgG1-Fc is well documented; however, whether the N-linked glycan has a similarly critical role in multimeric, avidly binding Fcs, is unknown. 8419363 7 26 gly N-glycosylation 1454:1468 arg2 only one N-glycosylation site only one N-glycosylation site site In addition, concanavalin A chromatography of mutants containing only one N-glycosylation site at either Asn74 or Asn238 indicated that processing of the oligosaccharides at these positions is site-specific. 9223509 6 54 part_of CD46 877:880 arg1 the SCR2 domain CD46 the SCR2 domain PUBTATOR Site CD46 P15529 domain Subsequent studies demonstrated that the SCR2 domain of baboon CD46 contained an Arg-to-Gln mutation at amino acid position 103 which accounted for reduced hemagglutination activity. 9223509 6 60 part_of SCR2 855:858 arg1 the SCR2 domain SCR2 the SCR2 domain OGER Site SCR2 P29558 domain Subsequent studies demonstrated that the SCR2 domain of baboon CD46 contained an Arg-to-Gln mutation at amino acid position 103 which accounted for reduced hemagglutination activity. 9223509 6 72 part_of contained 882:890 arg1 baboon CD46 AND the SCR2 domain CD46 domain PUBTATOR Site CD46 P15529 domain Subsequent studies demonstrated that the SCR2 domain of baboon CD46 contained an Arg-to-Gln mutation at amino acid position 103 which accounted for reduced hemagglutination activity. 11944983 7 42 gly glycosylation 887:899 arg2 a glycosylation site a glycosylation site site The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 42 gly glycosylation 887:899 arg2 two EF-hand Ca2+-binding domains two EF-hand Ca2+-binding domains domains The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 7559653 6 65 gly glycosylation 1186:1198 arg2 the NH2 terminus the NH2 terminus terminus A mutant receptor encoding a functional glycosylation site at the NH2 terminus is better expressed at the cell surface compared with the non-glycosylated form, indicating that trafficking to the cell surface is facilitated by glycosylation, but its location is relatively unimportant. 7559653 6 65 gly glycosylation 1186:1198 arg2 a functional glycosylation site a functional glycosylation site site A mutant receptor encoding a functional glycosylation site at the NH2 terminus is better expressed at the cell surface compared with the non-glycosylated form, indicating that trafficking to the cell surface is facilitated by glycosylation, but its location is relatively unimportant. 20498311 4 102 part_of epitope 788:794 arg1 gp120 gp120 epitope PUBTATOR Site gp120 3700 epitope AH binding to gp120 prevents binding of alpha1,2-mannose-specific monoclonal antibody 2G12, and AH covers a broader epitope on gp120 than 2G12. 15737642 6 37 part_of Asn79 1367:1371 arg1 glycosyltransferase glycosyltransferase Asn79 Fterm AminoAcid glycosyltransferase Asn79 The truncated protein consisting of amino acids 82-397 (GFP(uv)-beta3GnT2Delta83), which lacked both one N-glycosylation site at Asn79 and the stem region of glycosyltransferase, was expressed as only a small form and showed no beta3GnT activity. 15737642 6 49 part_of glycosyltransferase 1396:1414 arg1 one N-glycosylation site glycosyltransferase one N-glycosylation site Fterm Site glycosyltransferase site The truncated protein consisting of amino acids 82-397 (GFP(uv)-beta3GnT2Delta83), which lacked both one N-glycosylation site at Asn79 and the stem region of glycosyltransferase, was expressed as only a small form and showed no beta3GnT activity. 15737642 6 49 part_of glycosyltransferase 1396:1414 arg1 the stem region glycosyltransferase the stem region Fterm Site glycosyltransferase region The truncated protein consisting of amino acids 82-397 (GFP(uv)-beta3GnT2Delta83), which lacked both one N-glycosylation site at Asn79 and the stem region of glycosyltransferase, was expressed as only a small form and showed no beta3GnT activity. 7711052 4 67 part_of Asn-34 823:828 arg1 ribonuclease ribonuclease Asn-34 Fterm SpecificSite ribonuclease Asn-34 The presence of an oligomannose sugar on ribonuclease (at Asn-34) alters its overall dynamics, increases its stability towards proteinases and decreases its functional activity towards double-stranded RNA. 17996106 5 63 gly glycosylated 743:754 arg1 the amino acid residues the amino acid residues residues RESULTS: We explore machine learning methods for training classifiers to predict the amino acid residues that are likely to be glycosylated using information derived from the target amino acid residue and its sequence neighbors. 30427586 1 9 gly glycopeptides 201:213 arg2 glycopeptides glycopeptides glycopeptides The unambiguous mass spectrometric identification and characterization of glycopeptides is crucial to elucidate the micro- and macroheterogeneity of glycoproteins. 30427586 1 15 gly macroheterogeneity 254:271 arg1 glycoproteins glycoproteins Fterm glycoproteins The unambiguous mass spectrometric identification and characterization of glycopeptides is crucial to elucidate the micro- and macroheterogeneity of glycoproteins. 30427586 1 26 gly glycoproteins 276:288 arg1 glycoproteins glycoproteins Fterm glycoproteins The unambiguous mass spectrometric identification and characterization of glycopeptides is crucial to elucidate the micro- and macroheterogeneity of glycoproteins. 26348848 2 55 gly N-glycosylation 338:352 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site Recently, we showed that N-glycosylation site occupancy of Kv3.1b modulated its placement in the cell body and neurites of a neuronal-derived cell line, B35 neuroblastoma cells. 26348848 2 49 gly occupancy 359:367 arg1 Kv3.1b Kv3 site PUBTATOR Kv3 29731 site Recently, we showed that N-glycosylation site occupancy of Kv3.1b modulated its placement in the cell body and neurites of a neuronal-derived cell line, B35 neuroblastoma cells. 12706379 14 38 gly glycosylation 1912:1924 arg2 four glycosylation sites four glycosylation sites sites Sea Bass and Tilapia have four glycosylation sites, whereas the two salmon receptors have only three. 22649382 10 12 gly N-glycosylation 1582:1596 arg2 TpoR N-glycosylation sites TpoR N-glycosylation sites sites We discuss how mutations around TpoR N-glycosylation sites might contribute to inefficient receptor traffic and disease. 20053750 7 5 part_of site 1741:1744 arg1 hPIV-3 HN hPIV-3 HN site Cterm Site hPIV-3 HN 4758 site Our data are consistent with the idea that, similar to the case for hPIV-1, the N-linked glycan shields a second receptor-binding site on hPIV-3 HN. 8188681 5 33 gly glycosylation 1161:1173 arg2 the second beta subunit glycosylation site the second beta subunit glycosylation site site The amino acid sequence of the second beta subunit glycosylation site was important for signal transduction, regardless of the presence or absence of the oligosaccharide. 7524670 14 11 part_of termini 1959:1965 arg1 both Gal and GalNAc residues termini both Gal and GalNAc residues residues at Oligosaccharides from the sialylated/sulfated fraction of eLH beta contained both Gal and GalNAc residues at nonreducing termini, and those GalNAc residues were preferentially distributed to the Man alpha 1-->3 side of the trimannosyl core. 10227483 5 7 part_of IL-15 827:831 arg1 mammalian IL-15 sequences IL-15 mammalian IL-15 sequences PUBTATOR Site IL-15 P40933 sequences Chicken IL-15 contained all 4 highly conserved cysteine residues present in mammalian IL-15 sequences. 10227483 5 75 part_of contained 755:763 arg1 Chicken IL-15 AND all 4 highly conserved cysteine residues Chicken IL-15 all 4 highly conserved cysteine residues PUBTATOR AminoAcid Chicken IL-15 P40933 cysteine residues Chicken IL-15 contained all 4 highly conserved cysteine residues present in mammalian IL-15 sequences. 9515054 2 26 gly N-glycosylation 224:238 arg2 An N-glycosylation site An N-glycosylation site site An N-glycosylation site was generated in the amino-terminal hydrophilic sequence of the reductase, and the mutated protein was expressed in a cell-free system in the presence of microsomal vesicles. 21507336 4 0 gly N-glycosylated 673:686 arg1 Three N-glycosylated hGH fusion proteins Three N-glycosylated hGH fusion proteins Fterm proteins Three N-glycosylated hGH fusion proteins, designated NAS-EK-hGH, NAS-Kex2-hGH and hGH-NAS, were expressed in tobacco BY-2 cells. 21053369 6 69 gly glycopeptides 883:895 arg2 the glycopeptides the glycopeptides glycopeptides Both the glycopeptides and their corresponding deglycosylated forms in each collected HPLC fraction were studied by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (LTQ-Orbitrap) for glycosylation site profiling. 21053369 6 88 gly glycosylation 1067:1079 arg2 glycosylation site profiling glycosylation site profiling site Both the glycopeptides and their corresponding deglycosylated forms in each collected HPLC fraction were studied by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (LTQ-Orbitrap) for glycosylation site profiling. 7529232 6 74 part_of hsCD2 1233:1237 arg1 the ligand binding face hsCD2 the ligand binding face Cterm Site hsCD2 914 face The protein also formed diffraction quality crystals and analysis of the 2.5-A resolution crystal structure indicated that the single N-acetylglucosamine residue present on domain 1 is unlikely to stabilize the ligand binding face of hsCD2. 2318821 7 20 gly glycosylation 879:891 arg2 two potential N-linked glycosylation sites two potential N-linked glycosylation sites sites Using site-specific mutagenesis, Ala residues were substituted for Asn residues at two potential N-linked glycosylation sites (positions 43 and 359) and at a third unrelated Asn (position 257) in the LPL cDNA. 2318821 7 20 gly glycosylation 879:891 arg2 positions 43 and 359 positions 43 and 359 positions 43 and 359 Using site-specific mutagenesis, Ala residues were substituted for Asn residues at two potential N-linked glycosylation sites (positions 43 and 359) and at a third unrelated Asn (position 257) in the LPL cDNA. 23001782 5 6 gly N-glycosylated 880:893 arg2 367 Asn(351) and Asn(367) Asn(351) and Asn(367) It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively. 23001782 5 6 gly N-glycosylated 880:893 arg2 Asn Asn(351) and Asn(367) Asn(351) and Asn(367) It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively. 23001782 5 6 gly N-glycosylated 880:893 arg1 serum-derived hSHBG hSHBG Asn(351) and Asn(367) PUBTATOR hSHBG 6462 Asn(351) and Asn(367) It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively. 23001782 5 6 gly N-glycosylated 880:893 arg2 Asn Asn(351) and Asn(367) Asn(351) and Asn(367) It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively. 23001782 5 6 gly N-glycosylated 880:893 arg2 Asn Asn(351) and Asn(367) Asn(351) and Asn(367) It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively. 23001782 5 6 gly N-glycosylated 880:893 arg1 serum-derived hSHBG hSHBG Asn(351) and Asn(367) PUBTATOR hSHBG 6462 Asn(351) and Asn(367) It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively. 23001782 5 6 gly N-glycosylated 880:893 arg2 Asn Asn(351) and Asn(367) Asn(351) and Asn(367) It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively. 23001782 5 6 gly N-glycosylated 880:893 arg1 serum-derived hSHBG hSHBG Asn(351) and Asn(367) PUBTATOR hSHBG 6462 Asn(351) and Asn(367) It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively. 23001782 5 6 gly N-glycosylated 880:893 arg2 Asn Asn(351) and Asn(367) Asn(351) and Asn(367) It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively. 23001782 5 6 gly N-glycosylated 880:893 arg2 Asn hSHBG Asn(351) and Asn(367) PUBTATOR hSHBG 6462 Asn(351) and Asn(367) It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively. 9098904 2 38 gly N-glycosylation 411:425 arg2 a potential N-glycosylation site a potential N-glycosylation site site To facilitate structural studies of the protein, the wild-type sequence of the protease has been mutated so as to replace a potential N-glycosylation site. 18282281 3 120 gly O-glycosylation 479:493 arg2 mucin-type O-glycosylation sites mucin-type O-glycosylation sites sites A new encoding scheme was employed to improve the prediction of mucin-type O-glycosylation sites in mammalian proteins. 31671706 2 76 gly glycosylation 390:402 arg2 five N-linked glycosylation sites five N-linked glycosylation sites sites The prepared fusion protein was expected to possess a total of five N-linked glycosylation sites: two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region. 23776650 0 36 gly glycosylation 89:101 arg1 the carbohydrate recognition domain the carbohydrate recognition domain Ligand binding and signaling of dendritic cell immunoreceptor (DCIR) is modulated by the glycosylation of the carbohydrate recognition domain. 16512686 6 13 gly glycopeptides 1573:1585 arg2 glycopeptides glycopeptides glycopeptides Analyses performed on human serum showed that this SEC glycopeptide isolation procedure results in at least a 3-fold increase in the total number of glycopeptides identified by LC-MS/MS, demonstrating that this simple, nonselective, rapid method is an effective tool to facilitate the identification of peptides with N-linked glycosylation sites. 16512686 6 30 gly glycosylation 1750:1762 arg2 N-linked glycosylation sites N-linked glycosylation sites sites Analyses performed on human serum showed that this SEC glycopeptide isolation procedure results in at least a 3-fold increase in the total number of glycopeptides identified by LC-MS/MS, demonstrating that this simple, nonselective, rapid method is an effective tool to facilitate the identification of peptides with N-linked glycosylation sites. 16512686 6 34 gly glycopeptide 1479:1490 arg2 this SEC glycopeptide isolation procedure this SEC glycopeptide isolation procedure glycopeptide Analyses performed on human serum showed that this SEC glycopeptide isolation procedure results in at least a 3-fold increase in the total number of glycopeptides identified by LC-MS/MS, demonstrating that this simple, nonselective, rapid method is an effective tool to facilitate the identification of peptides with N-linked glycosylation sites. 25213400 0 37 gly proteins 18:25 arg1 Glycans proteins Glycans Fterm proteins Glycans of myelin proteins. 11390601 1 70 gly glycosylation 346:358 arg2 approximately 23 asparagine (N)-linked glycosylation sites approximately 23 asparagine (N)-linked glycosylation sites sites The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is extensively glycosylated, containing approximately 23 asparagine (N)-linked glycosylation sites on its gp120 subunit. 11390601 1 80 gly glycosylated 282:293 arg1 The envelope glycoprotein The envelope glycoprotein Fterm glycoprotein The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is extensively glycosylated, containing approximately 23 asparagine (N)-linked glycosylation sites on its gp120 subunit. 11390601 1 88 gly glycoprotein 207:218 arg1 The envelope glycoprotein The envelope glycoprotein Fterm glycoprotein The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is extensively glycosylated, containing approximately 23 asparagine (N)-linked glycosylation sites on its gp120 subunit. 29268168 3 12 gly position 623:630 arg1 the IgG-Fc glycan position 162 the IgG-Fc glycan position 162 The increase in affinity for afucosylated IgG has previously been shown to depend on direct carbohydrate-carbohydrate interactions between the IgG-Fc glycan with an N-linked glycan at position 162 unique to hFcγRIIIa and hFcγRIIIb. 29268168 3 15 gly afucosylated 468:479 arg1 afucosylated IgG afucosylated IgG Cterm IgG The increase in affinity for afucosylated IgG has previously been shown to depend on direct carbohydrate-carbohydrate interactions between the IgG-Fc glycan with an N-linked glycan at position 162 unique to hFcγRIIIa and hFcγRIIIb. 18258114 4 29 gly glycosylation 705:717 arg2 the envelope-protein glycosylation site the envelope-protein glycosylation site site All South African lineage 2 strains possessed the envelope-protein glycosylation site previously postulated to be associated with virulence. 27966990 2 37 gly N-glycosylation 377:391 arg2 sequons sites sites The extracellular domain of VEGFR-2 is composed of seven immunoglobulin-like domains, each with multiple potential N-glycosylation sites (sequons). 2154881 7 29 gly used 1165:1168 arg2 a new N-linked glycosylation site a new N-linked glycosylation site site Two Ib MAbs (DL11 and 4S) selected a Ser to Asn change at residue 140; this alteration creates a new N-linked glycosylation site, which is used. 2154881 7 37 gly glycosylation 1136:1148 arg2 a new N-linked glycosylation site a new N-linked glycosylation site site Two Ib MAbs (DL11 and 4S) selected a Ser to Asn change at residue 140; this alteration creates a new N-linked glycosylation site, which is used. 25629924 7 34 part_of IgA1 1215:1218 arg1 the IgA1 hinge region IgA1 the IgA1 hinge region PUBTATOR Site IgA1 P01876 region Additionally, 54 O-linked glycan compositions located at the IgA1 hinge region (HR) were identified by comparison against a theoretical O-glycopeptide library. 31393126 11 39 gly glycoproteins 1768:1780 arg1 the RJ glycoproteins the RJ glycoproteins Fterm glycoproteins Understanding the properties of the site-specific glycosylation heterogeneity of the RJ glycoproteins can be potentially useful for producing a glycoprotein with desirable pharmacokinetic and biological activity. 31393126 11 43 gly heterogeneity 1744:1756 arg1 the RJ glycoproteins the RJ glycoproteins Fterm glycoproteins Understanding the properties of the site-specific glycosylation heterogeneity of the RJ glycoproteins can be potentially useful for producing a glycoprotein with desirable pharmacokinetic and biological activity. 31393126 11 58 gly glycoprotein 1824:1835 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Understanding the properties of the site-specific glycosylation heterogeneity of the RJ glycoproteins can be potentially useful for producing a glycoprotein with desirable pharmacokinetic and biological activity. 31393126 11 95 gly glycosylation 1730:1742 arg1 the RJ glycoproteins the RJ glycoproteins Fterm glycoproteins Understanding the properties of the site-specific glycosylation heterogeneity of the RJ glycoproteins can be potentially useful for producing a glycoprotein with desirable pharmacokinetic and biological activity. 10413465 10 66 part_of apoE 1997:2000 arg1 carboxy-terminal residues apoE carboxy-terminal residues PUBTATOR Site apoE 348 residues These findings suggest that the amino- and carboxy-terminal residues of apoE are required for SDS-stable binding of apoE to Abeta and that the presence of at least one cysteine contributes to the efficient Abeta binding. 17963278 0 86 gly glycoprotein 33:44 arg1 putative serum glycoprotein biomarkers putative serum glycoprotein biomarkers Fterm glycoprotein Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. 25327667 5 49 part_of has 638:640 arg1 PSA AND a single glycosylation site PSA a single glycosylation site OGER Site PSA P07288 site PSA has a single glycosylation site at Asn69, with glycans constituting approximately 8% of the protein by weight. 8407981 8 39 gly glycosylation 1198:1210 arg2 Asn-12 Asn-12 Asn-12 These results demonstrated that the potential glycosylation site (Asn-12) in the N-terminal portion of P-450(arom) is the site of glycosylation. 8407981 8 39 gly glycosylation 1198:1210 arg2 the site site site These results demonstrated that the potential glycosylation site (Asn-12) in the N-terminal portion of P-450(arom) is the site of glycosylation. 8407981 8 72 gly glycosylation 1282:1294 arg2 the site site site These results demonstrated that the potential glycosylation site (Asn-12) in the N-terminal portion of P-450(arom) is the site of glycosylation. 8132647 1 68 gly glycoprotein 200:211 arg1 the rat zymogen granule membrane glycoprotein GP-3 the rat zymogen granule membrane glycoprotein GP-3 Fterm glycoprotein We have recently reported the cloning of the rat zymogen granule membrane glycoprotein GP-3 and the related pancreatic secretory lipase (Wishart, M. J., Andrews, P. C., Nichols, R., Blevins, G. T., Logsdon, C.D., and Williams, J. A. (1993) J. Biol. 8442916 9 84 gly N-glycosylation 1283:1297 arg2 an additional potential N-glycosylation site an additional potential N-glycosylation site site Interestingly, the viruses of this subtype are characterized by an additional potential N-glycosylation site C-terminal to the CD4-binding domain. 1456441 12 5 gly attached 1707:1714 arg1 glycosylation site Asn413 AND 2,4-triantennary vs 2,6-triantennary oligosaccharides glycosylation site Asn413 2,4-triantennary vs 2,6-triantennary oligosaccharides site Asn413 The ratio of 2,4-triantennary vs 2,6-triantennary oligosaccharides attached to glycosylation site Asn413 was found to be approximately 5:1, whereas the two isomeric triantennary oligosaccharides were found to be attached to glycosylation site Asn611 in the ratio approximately 1:1. 1456441 12 25 gly attached 1852:1859 arg2 glycosylation site Asn611 AND the two isomeric triantennary oligosaccharides glycosylation site Asn611 the two isomeric triantennary oligosaccharides site Asn611 The ratio of 2,4-triantennary vs 2,6-triantennary oligosaccharides attached to glycosylation site Asn413 was found to be approximately 5:1, whereas the two isomeric triantennary oligosaccharides were found to be attached to glycosylation site Asn611 in the ratio approximately 1:1. 1456441 12 46 gly glycosylation 1719:1731 arg2 Asn413 site Asn413 site Asn413 The ratio of 2,4-triantennary vs 2,6-triantennary oligosaccharides attached to glycosylation site Asn413 was found to be approximately 5:1, whereas the two isomeric triantennary oligosaccharides were found to be attached to glycosylation site Asn611 in the ratio approximately 1:1. 1456441 12 52 gly glycosylation 1864:1876 arg2 Asn611 site Asn611 site Asn611 The ratio of 2,4-triantennary vs 2,6-triantennary oligosaccharides attached to glycosylation site Asn413 was found to be approximately 5:1, whereas the two isomeric triantennary oligosaccharides were found to be attached to glycosylation site Asn611 in the ratio approximately 1:1. 25755023 8 42 gly glycopeptide 1089:1100 arg2 glycopeptide microarrays glycopeptide microarrays glycopeptide In addition, antibody binding epitope analysis on glycopeptide microarrays, were demonstrating a clear glycosylation site dependence of the induced antibodies. 25755023 8 61 gly glycosylation 1142:1154 arg2 a clear glycosylation site dependence a clear glycosylation site dependence site In addition, antibody binding epitope analysis on glycopeptide microarrays, were demonstrating a clear glycosylation site dependence of the induced antibodies. 16512686 1 14 gly glycosylation 289:301 arg2 specific glycosylation sites specific glycosylation sites sites Proteomic techniques, such as HPLC coupled to tandem mass spectrometry (LC-MS/MS), have proved useful for the identification of specific glycosylation sites on glycoproteins (glycoproteomics). 16512686 1 79 gly glycoproteins 312:324 arg1 glycoproteins glycoproteins Fterm glycoproteins Proteomic techniques, such as HPLC coupled to tandem mass spectrometry (LC-MS/MS), have proved useful for the identification of specific glycosylation sites on glycoproteins (glycoproteomics). 9375919 4 19 gly glycosylation 822:834 arg2 the glycosylation site mutation the glycosylation site mutation site The NlaIII2 site is relatively rare and was found only in association with the pseudodeficiency variant carrying the glycosylation site mutation alone. 15194804 2 18 gly glycoproteins 339:351 arg1 viral glycoproteins viral glycoproteins Fterm glycoproteins Because glycans are known to be important structural components affecting the conformation and function of viral glycoproteins, we analyzed the effect of the deletion of N-linked oligosaccharides on cell surface transport, proteolytic cleavage, and the biological activity of the NiV F protein. 9620884 1 15 gly glycoprotein 160:171 arg1 the homodimeric glycoprotein the homodimeric glycoprotein Fterm glycoprotein Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. 9620884 1 15 gly glycoprotein 160:171 arg1 Human alpha-galactosidase A Human alpha-galactosidase A PUBTATOR Human alpha-galactosidase A 2717 Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. 9620884 1 28 gly glycoproteins 249:261 arg1 glycoproteins glycoproteins Fterm glycoproteins Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. 15616124 6 12 gly N-glycosylation 908:922 arg1 FVII FVII Cterm FVII 2155 Immediately after pulse, most labeled intracellular FVII had one N-glycan, but during a 1-h chase, the vast majority was processed into FVII with two N-glycans, demonstrating posttranslational N-glycosylation of FVII. 15616124 6 79 gly FVII 851:854 arg1 two N-glycans FVII two N-glycans Cterm FVII 2155 Immediately after pulse, most labeled intracellular FVII had one N-glycan, but during a 1-h chase, the vast majority was processed into FVII with two N-glycans, demonstrating posttranslational N-glycosylation of FVII. 15616124 6 39 gly had 772:774 arg1 most labeled intracellular FVII AND one N-glycan most labeled intracellular FVII one N-glycan Cterm FVII 2155 Immediately after pulse, most labeled intracellular FVII had one N-glycan, but during a 1-h chase, the vast majority was processed into FVII with two N-glycans, demonstrating posttranslational N-glycosylation of FVII. 8638940 11 37 gly glycosylation 1851:1863 arg1 the beta-subunit subunit site OGER subunit P20933 site The N308 glycosylation site of the beta-subunit appears to be more important in maintaining normal transport and stability of human glycosylasparaginase. 21338062 7 77 part_of Hpt 1603:1605 arg1 three Hpt tryptic glycopeptides Hpt three Hpt tryptic glycopeptides PUBTATOR Site Hpt 3240 glycopeptides A total of 26 glycoforms/glycan compositions on three Hpt tryptic glycopeptides were identified and quantified from 10 LC-MS runs with a consumption of 100 fmol of Hpt digest (13 ng of protein, 10 fmol per injection). 23004563 3 72 gly glycopeptide 679:690 arg2 a glycopeptide precursor a glycopeptide precursor glycopeptide We demonstrated that monitoring the yields of oligosaccharide-derived fragment ions (oxonium ions) over a wide range of collision induced dissociation (CID) energy applied to a glycopeptide precursor exhibits a glycan structure-unique fragmentation pattern. 23004563 3 101 gly fragment 572:579 arg1 oligosaccharide-derived fragment ions oligosaccharide-derived fragment ions We demonstrated that monitoring the yields of oligosaccharide-derived fragment ions (oxonium ions) over a wide range of collision induced dissociation (CID) energy applied to a glycopeptide precursor exhibits a glycan structure-unique fragmentation pattern. 31577193 2 61 gly N-glycosylation 204:218 arg2 N-X-[S/T] sequon N-X-[S/T] sequon sequon N-glycosylation predominantly occurs in N-X-[S/T] sequon where X is any amino acid other than proline. 15754041 5 19 part_of protein 673:679 arg1 two Asn-linked glycosylation sites protein two Asn-linked glycosylation sites Fterm Site protein sites The rat Wnt3 gene, consisting of five exons, encoded a 355-aa protein with N-terminal signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites. 15754041 5 19 part_of protein 673:679 arg1 24 conserved Cys residues protein 24 conserved Cys residues Fterm AminoAcid protein Cys residues The rat Wnt3 gene, consisting of five exons, encoded a 355-aa protein with N-terminal signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites. 15754041 5 19 part_of protein 673:679 arg1 N-terminal signal peptide protein N-terminal signal peptide Fterm Site protein peptide The rat Wnt3 gene, consisting of five exons, encoded a 355-aa protein with N-terminal signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites. 8132208 5 45 gly glycosylation 621:633 arg2 no putative N-linked glycosylation site no putative N-linked glycosylation site site Besides, no putative N-linked glycosylation site was found. 25997386 7 57 gly glycosylation 1121:1133 arg2 an N-linked glycosylation site an N-linked glycosylation site site X4 prediction was significantly associated with more than 35 amino acids in the V3 domain (p < 0.0001) and loss of an N-linked glycosylation site (p < 0.0001). 12739007 0 8 part_of receptor 123:130 arg1 extracellular six-cystein domain receptor extracellular six-cystein domain Fterm Site receptor domain MGC9753 gene, located within PPP1R1B-STARD3-ERBB2-GRB7 amplicon on human chromosome 17q12, encodes the seven-transmembrane receptor with extracellular six-cystein domain. 15809770 12 82 part_of ELK1- 1527:1531 arg1 ELK1- and PAX4-binding sites ELK1 ELK1- and PAX4-binding sites PUBTATOR Site ELK1 314436 sites Match program revealed that ELK1- and PAX4-binding sites were conserved between rat Fzd8 and human FZD8 promoters. 15809770 12 86 part_of PAX4-binding 1537:1548 arg1 ELK1- and PAX4-binding sites PAX4 ELK1- and PAX4-binding sites OGER Site PAX4 O88436 sites Match program revealed that ELK1- and PAX4-binding sites were conserved between rat Fzd8 and human FZD8 promoters. 1400492 8 2 part_of mLAP 854:857 arg1 The mLAP sequence mLAP The mLAP sequence PUBTATOR Site mLAP 13708 sequence The mLAP sequence shares putative phosphorylation determinants, which in cathepsins D are linked to the formation of mannose 6-phosphate. 22649382 10 83 part_of TpoR 1577:1580 arg1 TpoR N-glycosylation sites TpoR TpoR N-glycosylation sites PUBTATOR Site TpoR 4352 sites We discuss how mutations around TpoR N-glycosylation sites might contribute to inefficient receptor traffic and disease. 12921785 3 41 gly O-glycosylation 659:673 arg2 one putative O-glycosylation site one putative O-glycosylation site site Following a 22 residue signal peptide, the mature protein contains 212 amino acids with 18 cysteines, three putative N-glycosylation sites, and one putative O-glycosylation site. 12921785 3 64 gly N-glycosylation 619:633 arg2 three putative N-glycosylation sites three putative N-glycosylation sites sites Following a 22 residue signal peptide, the mature protein contains 212 amino acids with 18 cysteines, three putative N-glycosylation sites, and one putative O-glycosylation site. 18533687 0 29 part_of receptor 72:79 arg1 the N-linked glycosylation sites receptor the N-linked glycosylation sites Fterm Site receptor sites Identification of the N-linked glycosylation sites of the human relaxin receptor and effect of glycosylation on receptor function. 23326351 4 15 part_of gp120 742:746 arg1 each variable and constant domain gp120 each variable and constant domain PUBTATOR Site gp120 155971 domain Pseudoviruses were created by exchanging each variable and constant domain of JR-CSF gp120 with that of JR-FL or with mutations in putative N-glycosylation sites. 25118381 9 57 gly glycosylation 1236:1248 arg2 a glycosylation site a glycosylation site site The D151N mutation added a glycosylation site to the activity center of NA. 27177499 4 49 gly glycosylated 611:622 arg1 two highly glycosylated subunits two highly glycosylated subunits Fterm subunits Specific to humans, hCG is a complex glycoprotein composed of two highly glycosylated subunits. 27177499 4 84 gly glycoprotein 575:586 arg1 hCG hCG OGER hCG Specific to humans, hCG is a complex glycoprotein composed of two highly glycosylated subunits. 27177499 4 84 gly glycoprotein 575:586 arg1 a complex glycoprotein a complex glycoprotein Fterm glycoprotein Specific to humans, hCG is a complex glycoprotein composed of two highly glycosylated subunits. 9689919 3 39 part_of PEDF 454:457 arg1 cDNA sequence PEDF cDNA sequence PUBTATOR Site PEDF 281386 sequence Here, we show the cDNA sequence and expression analysis of bovine PEDF. 17986444 4 82 gly NCAM 718:721 arg1 polysialylation NCAM polysialylation PUBTATOR NCAM 17967 Using mutant mice, lacking either enzyme, we now assessed in vivo the contribution of ST8SiaII and ST8SiaIV to polysialylation of NCAM. 17986444 4 83 gly polysialylation 699:713 arg1 NCAM NCAM PUBTATOR NCAM 17967 Using mutant mice, lacking either enzyme, we now assessed in vivo the contribution of ST8SiaII and ST8SiaIV to polysialylation of NCAM. 16372382 14 25 gly attached 2387:2394 arg1 Asn-alpha78 AND triantennary glycans Asn-alpha78 triantennary glycans Asn These data demonstrate site-specificity of glycosylation in the alpha subunit but not in the beta subunit of rhTSH with Asn-alpha52 bearing essentially di- and triantennary glycans with or without core fucosylation and bi- and triantennary glycans with no core fucosylation being attached to Asn-alpha78. 16372382 14 25 gly attached 2387:2394 arg2 Asn-alpha78 AND no core fucosylation Asn-alpha78 no core fucosylation Asn These data demonstrate site-specificity of glycosylation in the alpha subunit but not in the beta subunit of rhTSH with Asn-alpha52 bearing essentially di- and triantennary glycans with or without core fucosylation and bi- and triantennary glycans with no core fucosylation being attached to Asn-alpha78. 26618514 2 48 gly sialylation 231:241 arg1 IgG IgG Cterm IgG Glycan sialylation is critical for structure and for certain effector functions of IgG. 29069609 3 64 gly glycopeptide 620:631 arg2 glycopeptide analysis glycopeptide analysis glycopeptide In this study, we investigated pseudo-MRM (MRM-HR) and data-independent acquisition (DIA) as alternative acquisition strategies for glycopeptide analysis. 24533768 3 64 gly glycosylation 480:492 arg2 the native glycosylation site the native glycosylation site site We have developed a novel site-specific conjugation method by targeting the native glycosylation site on antibodies as an approach to address these limitations. 11916258 4 5 part_of PAFr 476:479 arg1 Each PAFr coding sequence Each PAFr Each PAFr coding sequence PUBTATOR Site Each PAFr 518283 sequence Each PAFr coding sequence (cds) in these three species is 1029 nucleotides long and contains no intervening sequences. 11916258 4 63 part_of contains 555:562 arg1 Each PAFr coding sequence AND no intervening sequences cds sequences OGER Site cds Q92903 sequences Each PAFr coding sequence (cds) in these three species is 1029 nucleotides long and contains no intervening sequences. 8702538 8 84 part_of motifs 1291:1296 arg1 the first or second Ig domains motifs the first or second Ig domains domains Site-directed mutagenesis of similar NC(T/S) motifs in the first or second Ig domains of the I-type lectins myelin-associated glycoprotein, and sialoadhesin did not disrupt their ability to mediate sialic acid binding. 25227423 0 5 gly glycans 9:15 arg1 influenza A H3N2 hemagglutinin hemagglutinin glycans Fterm hemagglutinin N-linked glycans on influenza A H3N2 hemagglutinin constrain binding of host antibodies, but shielding is limited. 10191360 6 5 gly chains 906:911 arg1 Kv1.1 and Kv1.2 but not Kv1.4 channels Kv1.4 channels chains PUBTATOR Kv1.4 channels 3739 The extent of processing of N-linked chains on Kv1.1 and Kv1.2 but not Kv1.4 channels expressed in transfected cells differs from that seen for native brain channels, reflecting the different efficiencies of transport of K+ channel polypeptides from the endoplasmic reticulum to the Golgi apparatus. 18585921 1 5 gly glycoprotein 132:143 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Seipin, which is encoded by the BSCL2 gene, is a glycoprotein of unknown biochemical function that is associated with dominant hereditary motor neuron diseases. 18585921 1 5 gly glycoprotein 132:143 arg1 Seipin Seipin PUBTATOR Seipin 26580 Seipin, which is encoded by the BSCL2 gene, is a glycoprotein of unknown biochemical function that is associated with dominant hereditary motor neuron diseases. 16118277 3 39 part_of HA1 465:467 arg1 Their HA1 amino acid sequences HA1 Their HA1 amino acid sequences OGER Site HA1 sequences Their HA1 amino acid sequences differ at 10 positions, one of which (N154) introduces a potential glycosylation site in A/Vietnam/1203/04 (H5N1). 14693913 6 60 gly occupied 1100:1107 arg2 these sites these sites sites Using hBSSL as a platform to study Pichia's O-glycosylation capabilities, we found that nearly all of these sites were occupied by mannose-containing O-glycans, whose structures, after beta-elimination and purification, were assigned by (1)H NMR and, in some cases, by linkage-specific exoglycosidases and methylation analysis. 8128610 3 20 part_of contain 565:571 arg1 The mature gerbil IL-2 AND 135 amino acid residues The mature gerbil IL-2 135 amino acid residues PUBTATOR Site IL-2 16183 residues The mature gerbil IL-2 is deduced to contain 135 amino acid residues and has a calculated MW of 15,496. 11251288 12 60 gly glycoproteins 2581:2593 arg1 semi-synthetic glycoproteins semi-synthetic glycoproteins Fterm glycoproteins The findings provide the basis for further elaboration of the glycan structures and development of this general methodology for the synthesis of semi-synthetic glycoproteins. 25636227 0 47 part_of sites 83:87 arg1 human chorionic gonadotropin chorionic gonadotropin sites OGER Site chorionic gonadotropin sites From individual proteins to proteomic samples: characterization of O-glycosylation sites in human chorionic gonadotropin and human-plasma proteins. 25636227 0 47 part_of sites 83:87 arg1 human-plasma proteins proteins sites Fterm Site proteins sites From individual proteins to proteomic samples: characterization of O-glycosylation sites in human chorionic gonadotropin and human-plasma proteins. 24164424 6 73 gly glycosylation 1076:1088 arg2 one extracellular core glycosylation site one extracellular core glycosylation site site CNGA subunits are known to possess one extracellular core glycosylation site, located at one of two possible positions within the turret loop near the pore-forming region. 20209506 2 99 gly glycopeptide 354:365 arg2 glycopeptide isolation glycopeptide isolation glycopeptide We present an optimized, sensitive workflow for glycopeptide isolation and characterization that exploits the complementary features of RP (Poros R2) and hydrophilic (zwitter-ionic hydrophilic interaction chromatography) chromatographic resins. 8885240 1 2 gly glycosylation 543:555 arg1 the proteolytic processing sites the proteolytic processing sites sites The present study verifies that the wide variation in the size of these products is due to incomplete cleavage of the proteolytic processing sites and the differential glycosylation of the N-linked glycosylation site at amino acid number 302 in the alpha C-subunit. 8885240 1 2 gly glycosylation 543:555 arg1 the N-linked glycosylation site the N-linked glycosylation site site The present study verifies that the wide variation in the size of these products is due to incomplete cleavage of the proteolytic processing sites and the differential glycosylation of the N-linked glycosylation site at amino acid number 302 in the alpha C-subunit. 8885240 1 10 gly glycosylation 573:585 arg2 the N-linked glycosylation site the N-linked glycosylation site site The present study verifies that the wide variation in the size of these products is due to incomplete cleavage of the proteolytic processing sites and the differential glycosylation of the N-linked glycosylation site at amino acid number 302 in the alpha C-subunit. 11410585 3 36 part_of cell 625:628 arg1 the human natural keller cell (HNK)-1 epitope natural keller cell (HNK)-1 the human natural keller cell (HNK)-1 epitope PUBTATOR Site natural keller cell (HNK)-1 27087 epitope Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans. 11410585 3 44 part_of HNK 631:633 arg1 the human natural keller cell (HNK)-1 epitope natural keller cell (HNK)-1 the human natural keller cell (HNK)-1 epitope PUBTATOR Site natural keller cell (HNK)-1 27087 epitope Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans. 11410585 3 63 part_of natural 610:616 arg1 the human natural keller cell (HNK)-1 epitope natural keller cell (HNK)-1 the human natural keller cell (HNK)-1 epitope PUBTATOR Site natural keller cell (HNK)-1 27087 epitope Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans. 11410585 3 83 part_of keller 618:623 arg1 the human natural keller cell (HNK)-1 epitope natural keller cell (HNK)-1 the human natural keller cell (HNK)-1 epitope PUBTATOR Site natural keller cell (HNK)-1 27087 epitope Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans. 27490136 9 10 gly glycoprotein 1798:1809 arg1 glycoprotein trafficking glycoprotein trafficking Fterm glycoprotein These observations unfold unique properties of the M protein in the HBV life cycle during unfolded protein response and point to alternative mechanisms employed by EDEMs to alleviate this stress in case of necessity by promoting glycoprotein trafficking rather than degradation. 1482348 5 40 gly O-glycosylated 633:646 arg1 the O-glycosylated oligosaccharide the O-glycosylated oligosaccharide From these studies, the structure of the O-glycosylated oligosaccharide on the alpha chain of HGF was concluded as [formula: see text]. 27038555 12 67 part_of epitope 1706:1712 arg1 the glycosylation sites epitope the glycosylation sites sites CONCLUSION: We highlighted the interplay between mutations in the glycosylation sites and epitope during HA evolution. 17065148 6 32 part_of TRPM8 1001:1005 arg1 the membrane-attached C-terminal region TRPM8 the membrane-attached C-terminal region PUBTATOR Site TRPM8 79054 region Furthermore, wild-type currents can be suppressed by expressing the membrane-attached C-terminal region of TRPM8. 1719383 9 92 part_of sequence 1531:1538 arg1 the amino-terminal region sequence the amino-terminal region region The missing cysteines in IGFBP-6 resulted in the absence of the invariant Gly-Cys-Gly-Cys-Cys sequence in the amino-terminal region of the molecule. 1719383 9 100 part_of cysteines 1449:1457 arg1 IGFBP-6 IGFBP-6 cysteines PUBTATOR AminoAcid IGFBP-6 P24592 cysteines The missing cysteines in IGFBP-6 resulted in the absence of the invariant Gly-Cys-Gly-Cys-Cys sequence in the amino-terminal region of the molecule. 3980466 11 71 gly glycoproteins 2008:2020 arg1 structurally related glycoproteins structurally related glycoproteins Fterm glycoproteins First, the overall distributions of oligosaccharides at corresponding sites on structurally related glycoproteins are similar. 3980466 11 91 gly sites 1978:1982 arg1 oligosaccharides sites oligosaccharides sites First, the overall distributions of oligosaccharides at corresponding sites on structurally related glycoproteins are similar. 28493121 2 41 gly glycoproteins 248:260 arg1 These glycoproteins These glycoproteins Fterm glycoproteins These glycoproteins include oligosaccharide or glycan attachments that represent one of the principal components dictating product quality. 10413465 5 42 gly O-glycosylation 1142:1156 arg2 the O-glycosylation site Thr194-Ala site Cterm Thr194-Ala 348 site This analysis showed that a mutation in the O-glycosylation site of apoE2 (Thr194-Ala) did not affect the SDS-stable binding of apoE to Abeta. 10413465 5 42 gly O-glycosylation 1142:1156 arg2 the O-glycosylation site apoE2 site PUBTATOR apoE2 348 site This analysis showed that a mutation in the O-glycosylation site of apoE2 (Thr194-Ala) did not affect the SDS-stable binding of apoE to Abeta. 1318404 0 70 gly glycosylation 36:48 arg1 the SU envelope protein protein sites Fterm protein sites Mutational analysis of the N-linked glycosylation sites of the SU envelope protein of Moloney murine leukemia virus. 16274239 3 10 gly glycosylated 509:520 arg2 N N(579) N(579) To characterize the subpopulation of receptors not glycosylated at N(579), we established a 32D cell line expressing a point mutant of the EGFR (N579Q), which cannot be glycosylated at this position. 16274239 3 10 gly glycosylated 509:520 arg1 receptors receptors N(579) Fterm receptors N(579) To characterize the subpopulation of receptors not glycosylated at N(579), we established a 32D cell line expressing a point mutant of the EGFR (N579Q), which cannot be glycosylated at this position. 16274239 3 10 gly glycosylated 509:520 arg1 receptors receptors N(579) Fterm receptors N(579) To characterize the subpopulation of receptors not glycosylated at N(579), we established a 32D cell line expressing a point mutant of the EGFR (N579Q), which cannot be glycosylated at this position. 16274239 3 24 gly glycosylated 627:638 arg2 this position EGFR (N579Q) position PUBTATOR EGFR (N579Q) 13649 position To characterize the subpopulation of receptors not glycosylated at N(579), we established a 32D cell line expressing a point mutant of the EGFR (N579Q), which cannot be glycosylated at this position. 19088065 6 94 gly N-glycosylation 668:682 arg1 this protein this protein Fterm protein Our aim was to characterize and compare the N-glycosylation status of this protein in ovarian cancer ascites fluid and cerebrospinal fluid. 1388166 7 4 gly Asn-linked 1450:1459 arg1 sulfated Asn-linked oligosaccharides Asn sulfated Asn-linked oligosaccharides Asn Chinese hamster ovary (CHO) cells do not contain detectable levels of either transferase and rTFPI expressed in CHO cells does not contain sulfated Asn-linked oligosaccharides. 17636988 2 49 gly attached 369:376 arg2 protein AND glycans protein glycans Fterm protein It is therefore common to enzymatically remove glycans attached to protein or peptide chains prior to mass spectrometric analysis, thereby reducing the complexity and facilitating glycosylation site determinations. 17636988 2 86 gly glycosylation 494:506 arg2 glycosylation site determinations glycosylation site determinations site It is therefore common to enzymatically remove glycans attached to protein or peptide chains prior to mass spectrometric analysis, thereby reducing the complexity and facilitating glycosylation site determinations. 26420485 7 64 gly unglycosylated 972:985 arg1 the unglycosylated RDS binding partner rod outer segment membrane protein 1 the unglycosylated RDS binding partner rod outer segment membrane protein 1 PUBTATOR rod outer segment membrane protein 1 19881 Normal levels of RDS and the unglycosylated RDS binding partner rod outer segment membrane protein 1 (ROM-1) were found in N229S retinas. 26420485 7 64 gly unglycosylated 972:985 arg1 ROM-1 ROM-1 PUBTATOR ROM-1 19881 Normal levels of RDS and the unglycosylated RDS binding partner rod outer segment membrane protein 1 (ROM-1) were found in N229S retinas. 17606981 6 9 gly epitope 856:862 arg1 increased sialylation epitope increased sialylation epitope This indicates that increased sialylation of the CZ-1 epitope occurs during CD4 T cell activation, and that loss of cell surface sialic acid during T-cell activation is a selective event rather than affecting all cell surface glycans. 17606981 6 87 gly sialylation 832:842 arg1 the CZ-1 epitope the CZ-1 epitope epitope This indicates that increased sialylation of the CZ-1 epitope occurs during CD4 T cell activation, and that loss of cell surface sialic acid during T-cell activation is a selective event rather than affecting all cell surface glycans. 8144579 7 38 part_of protein 1298:1304 arg1 a cytoplasmic region protein a cytoplasmic region Fterm Site protein region It contains an open reading frame which encodes a type II membrane protein of 73 kDa with a cytoplasmic region of about 35 amino acids, a Ca2+ binding consensus sequence, and a single N-glycosylation site. 8144579 7 38 part_of protein 1298:1304 arg1 a Ca2+ binding consensus sequence protein a Ca2+ binding consensus sequence Fterm Site protein sequence It contains an open reading frame which encodes a type II membrane protein of 73 kDa with a cytoplasmic region of about 35 amino acids, a Ca2+ binding consensus sequence, and a single N-glycosylation site. 8144579 7 38 part_of protein 1298:1304 arg1 a single N-glycosylation site protein a single N-glycosylation site Fterm Site protein site It contains an open reading frame which encodes a type II membrane protein of 73 kDa with a cytoplasmic region of about 35 amino acids, a Ca2+ binding consensus sequence, and a single N-glycosylation site. 8144579 7 56 part_of Ca2+ 1369:1372 arg1 a Ca2+ binding consensus sequence Ca2 a Ca2+ binding consensus sequence OGER Site Ca2 P00920 sequence It contains an open reading frame which encodes a type II membrane protein of 73 kDa with a cytoplasmic region of about 35 amino acids, a Ca2+ binding consensus sequence, and a single N-glycosylation site. 14680951 1 27 part_of protein 282:288 arg1 the Drosophila immunoglobulin-binding protein signal sequence protein the Drosophila immunoglobulin-binding protein signal sequence Fterm Site protein sequence Human pituitary glutaminyl cyclase (hQC) was expressed in Drosophila S2 cells under the control of an inducible metallothionene promoter and fused to the Drosophila immunoglobulin-binding protein signal sequence to enable secretion into the culture media. 9030779 0 65 part_of sphingomyelinase 71:86 arg1 the N-glycosylation sites acid sphingomyelinase the N-glycosylation sites PUBTATOR Site acid sphingomyelinase 6609 sites Functional characterization of the N-glycosylation sites of human acid sphingomyelinase by site-directed mutagenesis. 10464659 2 4 gly N-glycosylation 409:423 arg2 the third N-glycosylation site the third N-glycosylation site site To confirm that the PD individual in the present study is homozygous for the PD allele without any other mutations, direct solid-phase sequencing was done and the two A-to-G transitions--one at the third N-glycosylation site (N350S) and the other at the first polyadenylation signal (ATTAAC to AGTAAC)--were identified. 10580643 3 9 gly glycosylated 586:597 arg1 The carbohydrate-protected, glycosylated asparagine The carbohydrate-protected, glycosylated asparagine asparagine The carbohydrate-protected, glycosylated asparagine was incorporated as a building block during conventional Fmoc-solid phase peptide synthesis. 9020858 8 43 gly N-glycosylation 1072:1086 arg2 a possible N-glycosylation site a possible N-glycosylation site site According to the deduced amino acid sequence of TNAP cDNA, Asn-213 is a possible N-glycosylation site, and our present findings suggest that this sugar chain plays a key role in enzyme regulation. 9020858 8 43 gly N-glycosylation 1072:1086 arg2 Asn-213 Asn-213 Asn-213 According to the deduced amino acid sequence of TNAP cDNA, Asn-213 is a possible N-glycosylation site, and our present findings suggest that this sugar chain plays a key role in enzyme regulation. 18420026 0 40 gly N-glycosylation 55:69 arg2 a single N-glycosylation site a single N-glycosylation site site Nectin-like molecule 1 is a glycoprotein with a single N-glycosylation site at N290KS which influences its adhesion activity. 18420026 0 60 gly glycoprotein 28:39 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Nectin-like molecule 1 is a glycoprotein with a single N-glycosylation site at N290KS which influences its adhesion activity. 18420026 0 60 gly glycoprotein 28:39 arg1 Nectin-like molecule 1 Nectin-like molecule 1 PUBTATOR Nectin-like molecule 1 57863 Nectin-like molecule 1 is a glycoprotein with a single N-glycosylation site at N290KS which influences its adhesion activity. 8382971 0 44 gly glycosylation 8:20 arg1 a modified human tissue plasminogen activator a modified human tissue plasminogen activator PUBTATOR tissue plasminogen activator P00750 Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties. 7609736 8 17 part_of Fc 938:939 arg1 the Fc fragment Fc the Fc fragment Cterm Site Fc fragment We found glycosylation in the Fab fragment of CBGA1 in addition to the conserved glycosylation site in the Fc fragment at Asn 297. 7609736 8 31 part_of Fab 861:863 arg1 the Fab fragment Fab the Fab fragment PUBTATOR Site Fab 2187 fragment We found glycosylation in the Fab fragment of CBGA1 in addition to the conserved glycosylation site in the Fc fragment at Asn 297. 8076650 8 9 part_of protein 1439:1445 arg1 the N-terminal domain Set protein the N-terminal domain OGER Site Set protein Q01105 domain The sequences of functinin-related peptides, especially peptide 3, exhibit high similarity to the N-terminal domain of the Set protein and a putative human leukocyte antigen-associated protein. 8076650 8 57 part_of protein 1497:1503 arg1 the N-terminal domain protein the N-terminal domain Fterm Site protein domain The sequences of functinin-related peptides, especially peptide 3, exhibit high similarity to the N-terminal domain of the Set protein and a putative human leukocyte antigen-associated protein. 31852790 8 83 gly glycosylation 1437:1449 arg2 glycosylation sites glycosylation sites sites and residues in Primarily, the pattern of glycosylation sites and residues in the Sa antigenic region, around the receptor binding site (RBS), served as signatures for the elicitation of broadly reactive antibodies by these HA immunogens. 3148445 5 61 part_of t-PA 809:812 arg1 The rat t-PA sequence t-PA The rat t-PA sequence PUBTATOR Site t-PA 25692 sequence The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187. 3148445 5 38 part_of has 908:910 arg1 human t-PA AND an additional glycosylation site human t-PA an additional glycosylation site PUBTATOR Site t-PA 5327 site The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187. 3148445 5 24 part_of contains 823:830 arg1 The rat t-PA sequence AND two putative N-glycosylation sites The rat t-PA sequence two putative N-glycosylation sites sites The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187. 3148445 5 24 part_of contains 823:830 arg1 The rat t-PA sequence AND The rat t-PA sequence The rat t-PA sequence The rat t-PA sequence sequence The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187. 10687132 0 57 gly glycosylation 122:134 arg2 a glycosylation site a glycosylation site site Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. 25945896 10 1 part_of peptides 1733:1740 arg1 glycopeptides peptides glycopeptides glycopeptides Without enrichment of glycopeptides from global tryptic peptides and at a false discovery rate of 1%, 1008 glycan-containing MS/MS spectra were assigned to 769 unique intact N-linked glycopeptides, representing 344 N-linked glycosites with 57 different N-glycans. 16227292 4 78 gly glycoproteins 693:705 arg1 the glycoproteins the glycoproteins Fterm glycoproteins The roles of the N-glycans in intracellular trafficking of the glycoproteins to the Golgi, protein folding, and virus replication were investigated by mutational analysis and confocal immunofluorescence. 8027066 1 54 gly linked 200:205 arg2 the insulin receptor (IR) beta subunit AND the oligosaccharide chains the insulin receptor (IR) beta subunit the oligosaccharide chains Fterm subunit The functional role of the oligosaccharide chains linked to the insulin receptor (IR) beta subunit was investigated by site-directed mutagenesis of each of the 4 acceptor asparagines (N1 to N4 from the amino to the carboxyl terminus) and stable expression of the receptors in CHO cells. 24527708 5 19 gly N-glycosylated 947:960 arg1 135 N-glycosylated sites sites sites On the basis of the workflow, a total of 135 N-glycosylated sites including 6 known, 93 potential, and 36 novel sites were identified and mapped to 79 proteins. 3463996 5 26 gly glycosylation 1099:1111 arg2 a potential glycosylation site a potential glycosylation site site In particular, two conserved sequences in the propeptide that may be functionally significant include a potential glycosylation site and the presence of a single cysteine at position 59. 3463996 5 26 gly glycosylation 1099:1111 arg2 position 59 cysteine at position 59 cysteine at position 59 In particular, two conserved sequences in the propeptide that may be functionally significant include a potential glycosylation site and the presence of a single cysteine at position 59. 3463996 5 26 gly glycosylation 1099:1111 arg2 a single cysteine cysteine at position 59 cysteine at position 59 In particular, two conserved sequences in the propeptide that may be functionally significant include a potential glycosylation site and the presence of a single cysteine at position 59. 3463996 5 26 gly glycosylation 1099:1111 arg2 a single cysteine cysteine at position 59 cysteine at position 59 In particular, two conserved sequences in the propeptide that may be functionally significant include a potential glycosylation site and the presence of a single cysteine at position 59. 19418565 12 18 gly glycoproteins 1913:1925 arg1 recombinant glycoproteins recombinant glycoproteins Fterm glycoproteins These results highlight the importance of understanding how cell culture conditions and media components can affect the product quality of recombinant glycoproteins expressed in mammalian cell cultures. 2143269 8 10 gly glycosylation 1035:1047 arg2 the glycosylation site the glycosylation site site It has been concluded that (1) the overall structure of the recombinant protein is quite similar to that of the native protein, which possesses asparagine-linked oligosaccharides, but (2) a significant difference in structure exists in the neighborhood of the glycosylation site. 2143269 8 37 gly asparagine-linked 919:935 arg1 asparagine-linked oligosaccharides asparagine asparagine-linked oligosaccharides asparagine It has been concluded that (1) the overall structure of the recombinant protein is quite similar to that of the native protein, which possesses asparagine-linked oligosaccharides, but (2) a significant difference in structure exists in the neighborhood of the glycosylation site. 2143269 8 24 gly possesses 909:917 arg1 the native protein AND asparagine-linked oligosaccharides the native protein asparagine-linked oligosaccharides Fterm protein It has been concluded that (1) the overall structure of the recombinant protein is quite similar to that of the native protein, which possesses asparagine-linked oligosaccharides, but (2) a significant difference in structure exists in the neighborhood of the glycosylation site. 17670834 6 9 gly glycosylation 1074:1086 arg2 two new potential glycosylation site motifs site motifs site motifs This change occurred concurrently with the acquisition of two new potential glycosylation site motifs in HA. 12928435 10 35 gly glycosylation 1545:1557 arg1 HCN channels HCN channels Fterm channels These results indicate that N-linked glycosylation is required for cell surface trafficking of HCN channels. 1401897 0 87 part_of receptors 81:89 arg1 the extracellular faces receptors the extracellular faces Fterm Site receptors faces Structural diversity in the extracellular faces of peptidergic G-protein-coupled receptors. 29190644 4 28 gly attached 643:650 arg1 ASN241 AND the glycan ASN241 the glycan ASN241 From our investigation, we found that the glycan attached to ASN241 is both structurally and functionally important due to its close proximity to the BChE tetramerization domain and the active site gorge. 18416605 4 3 gly glycosylation 843:855 arg1 PrP PrP OGER PrP Q9NP58 Moreover we have shown that brain material from mice infected with TSE that have only unglycosylated PrP(Sc) is capable of transmitting infection to wild-type mice, demonstrating that glycosylation of PrP is not essential for establishing infection within a host or for transmitting TSE infectivity to a new host. 21338062 4 131 gly glycopeptides 961:973 arg2 glycopeptides glycopeptides glycopeptides To improve the sensitivity of LC-MS analysis for glycopeptides, an ultranarrow porous layer open tubular (PLOT) LC column (2.5 m × 10 μm i.d.) was coupled to a linear ion trap (LTQ) collision-induced dissociation/electron transfer dissociation mass spectrometer to provide sensitive analysis of N-linked protein glycosylation heterogeneity. 10839980 4 29 gly glycosylated 708:719 arg2 site II site site It contains more N-acetyl-lactosamine repeats when site II is glycosylated in the same molecule. 30578591 6 51 gly glycosites 978:987 arg2 different glycosites different glycosites glycosites Different types of glycans are identified from different glycosites of NA expressed in human cells, which implies the site-dependence of glycosylation on NA. 20032207 0 62 gly glycosylation 115:127 arg2 a potential glycosylation site a potential glycosylation site site Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. 20622017 1 12 gly glycoprotein 130:141 arg1 The cell surface glycoprotein γ-glutamyl transpeptidase The cell surface glycoprotein γ-glutamyl transpeptidase Fterm glycoprotein The cell surface glycoprotein γ-glutamyl transpeptidase (GGT) was isolated from healthy human kidney and liver to characterize its glycosylation in normal human tissue in vivo. 23028207 2 3 gly N-glycopeptides 458:472 arg2 chymotryptic N-glycopeptides chymotryptic N-glycopeptides N-glycopeptides Herein, the detailed N-glycosylation pattern of human serum alpha-2-macroglobulin was studied using an integrative approach, including permethylation of N-glycans, collision induced dissociation (CID) and electron transfer dissociation (ETD) of chymotryptic N-glycopeptides, and partial deglycosylation of chymotryptic N-glycopeptides with endo-β-N-acetylglucosaminidase F3 (Endo F3). 23028207 2 33 gly N-glycopeptides 519:533 arg2 chymotryptic N-glycopeptides chymotryptic N-glycopeptides N-glycopeptides Herein, the detailed N-glycosylation pattern of human serum alpha-2-macroglobulin was studied using an integrative approach, including permethylation of N-glycans, collision induced dissociation (CID) and electron transfer dissociation (ETD) of chymotryptic N-glycopeptides, and partial deglycosylation of chymotryptic N-glycopeptides with endo-β-N-acetylglucosaminidase F3 (Endo F3). 23028207 2 46 gly N-glycosylation 221:235 arg1 human serum alpha-2-macroglobulin human serum alpha-2-macroglobulin PUBTATOR alpha-2-macroglobulin 2 Herein, the detailed N-glycosylation pattern of human serum alpha-2-macroglobulin was studied using an integrative approach, including permethylation of N-glycans, collision induced dissociation (CID) and electron transfer dissociation (ETD) of chymotryptic N-glycopeptides, and partial deglycosylation of chymotryptic N-glycopeptides with endo-β-N-acetylglucosaminidase F3 (Endo F3). 23028207 2 53 gly deglycosylation 487:501 arg1 N-glycans N-glycopeptides N-glycans N-glycopeptides Herein, the detailed N-glycosylation pattern of human serum alpha-2-macroglobulin was studied using an integrative approach, including permethylation of N-glycans, collision induced dissociation (CID) and electron transfer dissociation (ETD) of chymotryptic N-glycopeptides, and partial deglycosylation of chymotryptic N-glycopeptides with endo-β-N-acetylglucosaminidase F3 (Endo F3). 23028207 2 53 gly deglycosylation 487:501 arg1 chymotryptic N-glycopeptides N-glycopeptides N-glycopeptides Herein, the detailed N-glycosylation pattern of human serum alpha-2-macroglobulin was studied using an integrative approach, including permethylation of N-glycans, collision induced dissociation (CID) and electron transfer dissociation (ETD) of chymotryptic N-glycopeptides, and partial deglycosylation of chymotryptic N-glycopeptides with endo-β-N-acetylglucosaminidase F3 (Endo F3). 23028207 2 53 gly deglycosylation 487:501 arg1 chymotryptic N-glycopeptides N-glycopeptides N-glycans N-glycopeptides Herein, the detailed N-glycosylation pattern of human serum alpha-2-macroglobulin was studied using an integrative approach, including permethylation of N-glycans, collision induced dissociation (CID) and electron transfer dissociation (ETD) of chymotryptic N-glycopeptides, and partial deglycosylation of chymotryptic N-glycopeptides with endo-β-N-acetylglucosaminidase F3 (Endo F3). 17660510 3 82 gly N-glycosylation 487:501 arg2 overall N-glycosylation sites overall N-glycosylation sites sites Regarding analysis of overall N-glycosylation sites in the past, this has been achieved by several approaches proving to be more or less complicated and specific. 3463996 4 8 part_of B 815:815 arg1 procathepsin B sequences procathepsin B procathepsin B sequences Cterm Site procathepsin B 1508 sequences A comparison of procathepsin B sequences from three species (human, mouse, and rat) reveals that the homology between the propeptides is relatively conserved with a minimum of 68% sequence identity. 3463996 4 56 part_of procathepsin 802:813 arg1 procathepsin B sequences procathepsin B procathepsin B sequences Cterm Site procathepsin B 1508 sequences A comparison of procathepsin B sequences from three species (human, mouse, and rat) reveals that the homology between the propeptides is relatively conserved with a minimum of 68% sequence identity. 8797081 13 93 part_of contains 1646:1653 arg1 Calobin AND 12 cysteine residues Calobin 12 cysteine residues Fterm AminoAcid Calobin cysteine residues Calobin contains 12 cysteine residues. 7613477 3 27 gly glycopeptides 885:897 arg2 three additional glycopeptides three additional glycopeptides glycopeptides In addition to the four expected N-linked glycopeptides of LCAT, a di-O-linked glycopeptide was detected, as well as three additional glycopeptides. 7613477 3 109 gly glycopeptide 830:841 arg2 a di-O-linked glycopeptide a di-O-linked glycopeptide glycopeptide In addition to the four expected N-linked glycopeptides of LCAT, a di-O-linked glycopeptide was detected, as well as three additional glycopeptides. 7613477 3 117 gly glycopeptides 793:805 arg1 LCAT LCAT glycopeptides PUBTATOR LCAT 3931 glycopeptides In addition to the four expected N-linked glycopeptides of LCAT, a di-O-linked glycopeptide was detected, as well as three additional glycopeptides. 9535843 7 34 gly glycosylation 1062:1074 arg2 ten separate glycosylation sites ten separate glycosylation sites sites After removal of this site and insertion of ten separate glycosylation sites, we defined two additional extracellular loops between H4 and H5, and H6 and H7. 29226084 3 84 gly N-glycosylation 444:458 arg2 N12 N12 N12 In this study, we investigated the post-translational modification of GPR61 by N-glycosylation at an identified consensus N-glycosylation site (N12) and the impact of this modification upon the subcellular expression of the protein. 29226084 3 84 gly N-glycosylation 444:458 arg2 an identified consensus N-glycosylation site an identified consensus N-glycosylation site site In this study, we investigated the post-translational modification of GPR61 by N-glycosylation at an identified consensus N-glycosylation site (N12) and the impact of this modification upon the subcellular expression of the protein. 29226084 3 55 gly N-glycosylation 401:415 arg2 N12 N12 N12 In this study, we investigated the post-translational modification of GPR61 by N-glycosylation at an identified consensus N-glycosylation site (N12) and the impact of this modification upon the subcellular expression of the protein. 29226084 3 55 gly N-glycosylation 401:415 arg2 an identified consensus N-glycosylation site site site In this study, we investigated the post-translational modification of GPR61 by N-glycosylation at an identified consensus N-glycosylation site (N12) and the impact of this modification upon the subcellular expression of the protein. 26957414 3 108 gly glycoproteins 369:381 arg1 glycoproteins glycoproteins Fterm glycoproteins Hence, qualitative and quantitative analyses of glycoproteins are necessary to understand physiological processes. 26573365 5 38 gly glycopeptides 873:885 arg2 IgG1 Fc glycopeptides IgG1 Fc glycopeptides glycopeptides We provide the first demonstration of this approach by comparing IgG1 Fc glycopeptides from polyclonal IgG samples with respect to their galactosylation and sialylation patterns using MALDI MS and LC-ESI-MS. 25759508 4 1 gly threonine 606:614 arg1 The repeat regions threonine The repeat regions threonine The repeat regions within the IgG3 hinge were found to be in part O-glycosylated at the threonine in the triple repeat motif. 25759508 4 1 gly threonine 606:614 arg1 the triple repeat motif threonine the triple repeat motif threonine The repeat regions within the IgG3 hinge were found to be in part O-glycosylated at the threonine in the triple repeat motif. 25759508 4 49 gly O-glycosylated 584:597 arg2 The repeat regions The repeat regions within the IgG3 hinge were found to be in part O-glycosylated at the threonine in the triple repeat motif. 25759508 4 49 gly O-glycosylated 584:597 arg2 the threonine threonine threonine The repeat regions within the IgG3 hinge were found to be in part O-glycosylated at the threonine in the triple repeat motif. 25759508 4 49 gly O-glycosylated 584:597 arg2 the threonine threonine threonine The repeat regions within the IgG3 hinge were found to be in part O-glycosylated at the threonine in the triple repeat motif. 7980452 0 86 gly N-glycosylation 8:22 arg1 human interferon-gamma human interferon-gamma PUBTATOR interferon-gamma 3458 Role of N-glycosylation in the synthesis, dimerization and secretion of human interferon-gamma. 7922031 5 26 part_of has 836:838 arg1 Each subunit AND a cystine-knot motif Each subunit a cystine-knot motif OGER Site Each subunit Q05195 motif Each subunit has a cystine-knot motif at its core of extended hairpin loops. 8578865 9 68 part_of found 1232:1236 arg2 the G2 glycoprotein AND a potential N-linked glycosylation site the G2 glycoprotein a potential N-linked glycosylation site Fterm Site glycoprotein site Both PUU90-13 and PUUBerkel lack a potential N-linked glycosylation site found on the G2 glycoprotein of other PUU viruses. 7730329 10 86 part_of TSV-PA 1274:1279 arg1 The deduced complete amino acid sequence TSV-PA The deduced complete amino acid sequence Cterm Site TSV-PA sequence The deduced complete amino acid sequence of TSV-PA indicates that the mature TSV-PA protein is composed of 234 amino acids and contains a single potential N-glycosylation site at Asn161. 7730329 10 104 part_of contains 1357:1364 arg1 the mature TSV-PA protein AND a single potential N-glycosylation site the mature TSV-PA protein a single potential N-glycosylation site Fterm Site protein site The deduced complete amino acid sequence of TSV-PA indicates that the mature TSV-PA protein is composed of 234 amino acids and contains a single potential N-glycosylation site at Asn161. 1590788 3 32 part_of has 331:333 arg1 Mouse saposin AND four functional domains Mouse saposin four functional domains Fterm Site saposin domains Mouse saposin also has four functional domains, which are structurally similar to each other, and each domain has cysteines, prolines, and a potential glycosylation site at an almost identical position. 1590788 3 27 part_of has 422:424 arg1 each domain AND a potential glycosylation site each domain a potential glycosylation site site Mouse saposin also has four functional domains, which are structurally similar to each other, and each domain has cysteines, prolines, and a potential glycosylation site at an almost identical position. 1590788 3 27 part_of has 422:424 arg1 each domain AND prolines cysteines, prolines cysteines, prolines Mouse saposin also has four functional domains, which are structurally similar to each other, and each domain has cysteines, prolines, and a potential glycosylation site at an almost identical position. 8076650 7 10 part_of possesses 1213:1221 arg1 peptide 3 AND two consensus sequences peptide 3 two consensus sequences sequences One of the three polypeptides, peptide 3, possesses two consensus sequences for phosphorylation and a consensus sequence for myristoylation. 8076650 7 10 part_of possesses 1213:1221 arg1 peptide 3 AND a consensus sequence peptide 3 a consensus sequence sequence One of the three polypeptides, peptide 3, possesses two consensus sequences for phosphorylation and a consensus sequence for myristoylation. 17956937 3 48 gly PSA 610:612 arg1 the glycan profiles PSA the glycan profiles PUBTATOR PSA 354 In the present study, the glycan profiles of free and complexed forms of PSA from cancer patient serum and of seminal plasma PSA were compared by analyzing the glycopeptides obtained by lysylendopeptidase digestion of the electrophoretically separated PSA with mass spectrometry. 17956937 3 73 gly PSA 558:560 arg1 free and complexed forms PSA free and complexed forms PUBTATOR PSA 354 In the present study, the glycan profiles of free and complexed forms of PSA from cancer patient serum and of seminal plasma PSA were compared by analyzing the glycopeptides obtained by lysylendopeptidase digestion of the electrophoretically separated PSA with mass spectrometry. 17956937 3 93 gly glycopeptides 645:657 arg2 the glycopeptides the glycopeptides glycopeptides In the present study, the glycan profiles of free and complexed forms of PSA from cancer patient serum and of seminal plasma PSA were compared by analyzing the glycopeptides obtained by lysylendopeptidase digestion of the electrophoretically separated PSA with mass spectrometry. 31336133 6 23 gly O-glycosylation 948:962 arg2 a single O-glycosylation site a single O-glycosylation site site The aim of the present study was to compare the influence of ANITVNITV peptide fusion on the physicochemical, biological and pharmacokinetic properties of native hIFN-α2b (IFNwt), which contains a single O-glycosylation site, and a hyperglycosylated variant (IFN4N), that bears, in addition, 4 N-linked glycans. 31336133 6 29 gly hyperglycosylated 976:992 arg1 a hyperglycosylated variant a hyperglycosylated variant Fterm variant The aim of the present study was to compare the influence of ANITVNITV peptide fusion on the physicochemical, biological and pharmacokinetic properties of native hIFN-α2b (IFNwt), which contains a single O-glycosylation site, and a hyperglycosylated variant (IFN4N), that bears, in addition, 4 N-linked glycans. 10551780 7 59 gly glycosylation 1205:1217 arg2 this glycosylation site this glycosylation site site In most other serpins, this glycosylation site is highly conserved and has been shown to be crucial for cortisol binding of corticosteroid-binding globulin, the only other member of the serpins with a transport function. 25220145 7 100 gly CF-glycoprotein 1387:1401 arg1 CF-glycoprotein function studies CF-glycoprotein function studies Fterm CF-glycoprotein The results further demonstrated that LHNCE provides an important approach for CF-glycoprotein function studies and biomarker screening in cancer research. 22238065 3 92 gly glycosylation 702:714 arg2 the glycosylation site the glycosylation site site To this aim, three procedures have been assayed: (1) Site-directed mutagenesis to abolish the glycosylation site; (2) endoplasmic reticulum retention (C-terminal SEKDEL fusion) to ensure predominantly high-mannose type glycans; and (3) expression in a N. benthamiana RNAi down-regulated line in which β1,2-xylosyltransferase and α1,3-fucosyltransferase gene expression is silenced. 16912309 3 37 gly glycoprotein 321:332 arg1 the native VSV-G glycoprotein the native VSV-G glycoprotein Fterm glycoprotein This rrVSV did not express the native VSV-G glycoprotein (gp). 17924005 6 56 gly N-glycosylation 1161:1175 arg2 a N-glycosylation site a N-glycosylation site site The potential protein domain analysis of Env sequences showed the loss of a CK-2 phosphorylation site caused by D197N mutation in one epitope, and a N-glycosylation site caused by S246Y and V247I mutations in another epitope. 9140197 5 40 gly glycosylation 996:1008 arg2 a glycosylation site a glycosylation site site The mutation was found to be in close vicinity to a glycosylation site. 30011186 10 47 gly glycoproteins 2136:2148 arg1 glycoproteins glycoproteins Fterm glycoproteins Boronic acids can form reversible covalent interactions with sugars, but the low binding affinity of normal boronic acid-based methods prevents us from capturing glycoproteins with low abundance, which often contain more valuable information. 17707131 7 31 part_of acyltransferase 1371:1385 arg1 the four acyltransferase motifs acyltransferase the four acyltransferase motifs Fterm Site acyltransferase motifs Using human AGPAT1 as a model, we have examined the catalytic roles of highly conserved residues in the four acyltransferase motifs by site-directed mutagenesis. 3882692 5 5 part_of lymphotoxin 653:663 arg1 the amino acid sequence lymphotoxin the amino acid sequence Fterm Site lymphotoxin sequence The salient features of the amino acid sequence of lymphotoxin are described. 20573953 2 49 part_of NCAM 538:541 arg1 the fifth immunoglobulin domain NCAM the fifth immunoglobulin domain PUBTATOR Site NCAM 4684 domain Our previous work indicates that the polysialylation of two N-glycans located on the fifth immunoglobulin domain (Ig5) of NCAM requires the presence of specific sequences in the adjacent fibronectin type III repeat (FN1). 16331960 9 42 gly glycoforms 1827:1836 arg1 the different transferrin glycoforms the different transferrin glycoforms PUBTATOR transferrin 7018 After fragmentation, a range of peptides representing previously cryptic epitopes were identified as potential candidates for an immunological approach to differentiate between the different transferrin glycoforms. 9455905 9 15 gly O-glycosylation 1961:1975 arg2 solitary O-glycosylation sites solitary O-glycosylation sites sites Charge distribution would appear, therefore, to play a more general role in determining the extent to which solitary O-glycosylation sites are modified. 24048266 4 9 gly glycosylation 661:673 arg2 glycosylation site glycosylation site site Therefore, investigating the exact position of glycosylation site in GPCR sequence can provide useful clues for drug design and other biotechnology applications. 8765005 0 29 gly Glutamine 0:8 arg1 Glutamine and tetrapeptide repeat variations Glutamine Glutamine and tetrapeptide repeat variations Glutamine Glutamine and tetrapeptide repeat variations affect the biological activity of different mouse interleukin-2 alleles. 17640971 3 8 gly O-glycosylation 640:654 arg1 CD52 CD52 PUBTATOR CD52 1043 Although the amount of posttranslational modification is already remarkable for such a small polypeptide, O-glycosylation of CD52 has additionally been implicated by several studies, but never rigorously characterized. 10856884 11 71 gly glycosylation 1605:1617 arg2 one putative N-linked glycosylation site one putative N-linked glycosylation site site The rat PLP-K cDNA encodes for a predicted 228 amino acid protein containing a 31 amino acid signal peptide and one putative N-linked glycosylation site; the mouse PLP-M cDNA encodes for a predicted 228 amino acid protein containing a 28 amino acid signal peptide and one putative N-linked glycosylation site. 10856884 11 148 gly glycosylation 1449:1461 arg2 one putative N-linked glycosylation site one putative N-linked glycosylation site site The rat PLP-K cDNA encodes for a predicted 228 amino acid protein containing a 31 amino acid signal peptide and one putative N-linked glycosylation site; the mouse PLP-M cDNA encodes for a predicted 228 amino acid protein containing a 28 amino acid signal peptide and one putative N-linked glycosylation site. 27725718 7 71 gly occupied 959:966 arg2 In CDG glycosylation sites In CDG glycosylation sites sites In CDG glycosylation sites of IgG2 and IgA1 were occupied to normal levels. 27725718 7 80 gly glycosylation 917:929 arg2 In CDG glycosylation sites IgA1 sites PUBTATOR IgA1 3493 sites In CDG glycosylation sites of IgG2 and IgA1 were occupied to normal levels. 27725718 7 80 gly glycosylation 917:929 arg2 In CDG glycosylation sites IgG2 sites Cterm IgG2 sites In CDG glycosylation sites of IgG2 and IgA1 were occupied to normal levels. 7525705 7 8 part_of DRA 1325:1327 arg1 the DRA coding region DRA the DRA coding region OGER Site DRA P40879 region Mutant 10.24.6, which has a mutation in the DRA coding region creating an extra glycosylation site, also has unstable DR dimers whose stability is restored by acid/peptide treatment. 31826991 13 31 gly head 2239:2242 arg1 influenza type A virus (IAV) through interaction with hemagglutinin (HA) head region high-mannose glycan(s) influenza type A virus (IAV) through interaction with hemagglutinin (HA) head region high-mannose glycan(s) Lung surfactant protein D (SP-D), a key factor in first-line innate immunity defense, removes influenza type A virus (IAV) through interaction with hemagglutinin (HA) head region high-mannose glycan(s). 31826991 13 53 gly region 2244:2249 arg1 influenza type A virus (IAV) through interaction with hemagglutinin (HA) head region high-mannose glycan(s) influenza type A virus (IAV) through interaction with hemagglutinin (HA) head region high-mannose glycan(s) Lung surfactant protein D (SP-D), a key factor in first-line innate immunity defense, removes influenza type A virus (IAV) through interaction with hemagglutinin (HA) head region high-mannose glycan(s). 31429052 6 81 part_of MS/MS 1371:1375 arg1 substantially more MS/MS fragments MS/MS substantially more MS/MS fragments Cterm Site MS/MS fragments UVPD used as a standalone technique for ADC subunit analysis afforded, within the same liquid chromatography-MS/MS run, enhanced performance in terms of primary sequence coverage compared to HCD- or ETD-based MD approaches, and generated substantially more MS/MS fragments containing either drug conjugation or glycosylation site information, leading to confident drug/glycosylation site identification. 26911932 11 35 gly glycans 1929:1935 arg1 FSHβ subunit subunit glycans Fterm subunit Our genetic approach provides direct in vivo evidence that N-linked glycans on FSHβ subunit are essential for its efficient assembly with the α-subunit to form FSH heterodimer in pituitary. 9401066 0 29 part_of Fibrinogen 0:9 arg1 gamma 380 Lys to Asn Fibrinogen Kaiserslautern gamma 380 Lys to Asn PUBTATOR AminoAcid Fibrinogen Kaiserslautern 2244 Asn Fibrinogen Kaiserslautern (gamma 380 Lys to Asn): a new glycosylated fibrinogen variant with delayed polymerization. 17916798 7 87 gly glycopeptides 1309:1321 arg2 LC-MALDI intact glycopeptides LC-MALDI intact glycopeptides glycopeptides In parallel, a second magnetic bead capturing was performed on the peptide level to separate and analyze by LC-MALDI intact glycopeptides, both peptide sequence and glycan structure. 17916798 7 87 gly glycopeptides 1309:1321 arg2 peptide sequence peptide sequence sequence In parallel, a second magnetic bead capturing was performed on the peptide level to separate and analyze by LC-MALDI intact glycopeptides, both peptide sequence and glycan structure. 18533687 11 83 gly N-glycosylation 1774:1788 arg1 the receptor the receptor Fterm receptor Hence, as is the case for other LGR family members, N-glycosylation is essential for the transport of the receptor to the cell surface. 32168410 7 33 gly deglycosylated 895:908 arg1 deglycosylated FXIII-B deglycosylated FXIII-B PUBTATOR FXIII-B 2165 The structure of deglycosylated FXIII-B was investigated by gel filtration. 8543840 10 43 gly glycosylation 1348:1360 arg2 an N-linked glycosylation site an N-linked glycosylation site site Thus, the naturally processed form of an env epitope containing an N-linked glycosylation site is derived from env protein that is not glycosylated at the relevant asparagine during biosynthesis. 8543840 10 104 gly glycosylated 1407:1418 arg2 the relevant asparagine env protein asparagine PUBTATOR env protein 100616444 asparagine Thus, the naturally processed form of an env epitope containing an N-linked glycosylation site is derived from env protein that is not glycosylated at the relevant asparagine during biosynthesis. 12742580 5 62 gly N-glycosylation 791:805 arg2 the intervening N-glycosylation site the intervening N-glycosylation site site In VSG 117, which contains two carboxy-terminal subdomains, point mutation of the intervening N-glycosylation site reduced expression about 15-fold. 27725718 7 74 part_of IgA1 949:952 arg1 In CDG glycosylation sites IgA1 In CDG glycosylation sites PUBTATOR Site IgA1 3493 sites In CDG glycosylation sites of IgG2 and IgA1 were occupied to normal levels. 27725718 7 81 part_of IgG2 940:943 arg1 In CDG glycosylation sites IgG2 In CDG glycosylation sites Cterm Site IgG2 sites In CDG glycosylation sites of IgG2 and IgA1 were occupied to normal levels. 28144240 2 88 part_of Ig-like 336:342 arg1 Ig-like domains Ig-like Ig-like domains Cterm Site Ig-like domains Unlike KIR2DL1-3, recognizing HLA-C allotypes through Ig-like domains of the D1-D2 type, KIR2DL5 shares a D0-D2 configuration with KIR2DL4, and its ligands have not been identified. 28887103 0 70 gly glycosylation 8:20 arg1 the universal sequon proteins sequon Fterm proteins sequon Unusual glycosylation of proteins: Beyond the universal sequon and other amino acids. 10441114 0 43 gly glycosylated 6:17 arg1 human plasma endostatin human plasma endostatin PUBTATOR endostatin 80781 Novel glycosylated forms of human plasma endostatin and circulating endostatin-related fragments of collagen XV. 32110292 3 42 gly N-glycosylation 618:632 arg2 only a single N-glycosylation site only a single N-glycosylation site site N-Glycosylation of IgG is crucial for its effector function and makes IgG highly heterogeneous both in structure and function, although all four subclasses of IgG contain only a single N-glycosylation site in the Fc region with a highly similar amino acid sequence. 32110292 3 87 gly N-Glycosylation 433:447 arg1 IgG IgG Cterm IgG N-Glycosylation of IgG is crucial for its effector function and makes IgG highly heterogeneous both in structure and function, although all four subclasses of IgG contain only a single N-glycosylation site in the Fc region with a highly similar amino acid sequence. 11786923 5 44 gly glycosylation 859:871 arg2 an N-linked glycosylation site an N-linked glycosylation site site Mouse Wnt14b was found to encode a 359-amino-acid WNT family protein with the N-terminal signal peptide, an N-linked glycosylation site, and 24 conserved cysteine residues. 8991508 6 24 gly contains 581:588 arg1 The second domain AND 10 repeats The second domain 10 repeats domain The second domain contains 10 repeats, each 9 or 13 amino acids in length, with Thr representing more than 50% of the amino acids, while Ser accounts for only 2%. 26598643 11 12 gly O-glycosylation 1775:1789 arg2 11 novel O-glycosylation sites 11 novel O-glycosylation sites sites Strikingly, also 11 novel O-glycosylation sites and regions were identified. 8099782 3 95 gly deglycosylated 649:662 arg1 deglycosylated saposin B deglycosylated saposin B Cterm deglycosylated saposin B In addition deglycosylated saposin B bound sulfatide and GM1 ganglioside identical to native saposin B. 17916798 0 81 gly glycopeptide 137:148 arg2 automated glycopeptide detection automated glycopeptide detection glycopeptide Analysis of glycoproteins in human serum by means of glycospecific magnetic bead separation and LC-MALDI-TOF/TOF analysis with automated glycopeptide detection. 17916798 0 104 gly glycoproteins 12:24 arg1 glycoproteins glycoproteins Fterm glycoproteins Analysis of glycoproteins in human serum by means of glycospecific magnetic bead separation and LC-MALDI-TOF/TOF analysis with automated glycopeptide detection. 8207403 1 24 part_of possesses 284:292 arg1 gp41 AND four consensus sites gp41 four consensus sites Cterm Site gp41 sites The transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus type 1 possesses four consensus sites (Asn-X-Ser/Thr) for the incorporation of N-linked sugars situated on the extracellular domain of the molecule. 8207403 1 24 part_of possesses 284:292 arg1 The transmembrane envelope glycoprotein AND four consensus sites The transmembrane envelope glycoprotein four consensus sites Fterm Site glycoprotein sites The transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus type 1 possesses four consensus sites (Asn-X-Ser/Thr) for the incorporation of N-linked sugars situated on the extracellular domain of the molecule. 26784534 8 1 gly glycopeptides 949:961 arg2 the glycopeptides the glycopeptides glycopeptides Analysis of the glycopeptides flanking the A1 domain revealed that generally more core-2-type O-glycan was present on the C-terminal Cluster 2 glycopeptide (encompassing T(1468) , T(1477) , S(1486) and T(1487) ) compared with the N-terminal Cluster 1 glycopeptide (encompassing T(1248) , T(1255) , T(1256) and S(1263) ). 26784534 8 14 gly glycopeptide 1184:1195 arg2 the N-terminal Cluster 1 glycopeptide the N-terminal Cluster 1 glycopeptide glycopeptide Analysis of the glycopeptides flanking the A1 domain revealed that generally more core-2-type O-glycan was present on the C-terminal Cluster 2 glycopeptide (encompassing T(1468) , T(1477) , S(1486) and T(1487) ) compared with the N-terminal Cluster 1 glycopeptide (encompassing T(1248) , T(1255) , T(1256) and S(1263) ). 26784534 8 23 gly glycopeptide 1076:1087 arg2 the C-terminal Cluster 2 glycopeptide the C-terminal Cluster 2 glycopeptide glycopeptide Analysis of the glycopeptides flanking the A1 domain revealed that generally more core-2-type O-glycan was present on the C-terminal Cluster 2 glycopeptide (encompassing T(1468) , T(1477) , S(1486) and T(1487) ) compared with the N-terminal Cluster 1 glycopeptide (encompassing T(1248) , T(1255) , T(1256) and S(1263) ). 26784534 8 55 gly present 1040:1046 arg2 the C-terminal Cluster 2 glycopeptide AND generally more core-2-type O-glycan glycopeptide generally more core-2-type O-glycan glycopeptide Analysis of the glycopeptides flanking the A1 domain revealed that generally more core-2-type O-glycan was present on the C-terminal Cluster 2 glycopeptide (encompassing T(1468) , T(1477) , S(1486) and T(1487) ) compared with the N-terminal Cluster 1 glycopeptide (encompassing T(1248) , T(1255) , T(1256) and S(1263) ). 1972631 8 62 gly glycosylation 911:923 arg2 the N-linked glycosylation site the N-linked glycosylation site site The second exon includes the protein domain coding for the N-linked glycosylation site that is required for the expression of enzyme activity. 7499420 3 35 part_of PMP22 441:445 arg1 the N-glycosylation site PMP22 the N-glycosylation site PUBTATOR Site PMP22 5376 site The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein. 7499420 3 35 part_of PMP22 441:445 arg1 the four lipophilic domains PMP22 the four lipophilic domains PUBTATOR Site PMP22 5376 domains The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein. 7499420 3 35 part_of PMP22 441:445 arg1 The positions PMP22 The positions PUBTATOR Site PMP22 5376 positions The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein. 20053750 5 45 gly glycosylation 938:950 arg2 this N-linked glycosylation site this N-linked glycosylation site site Removal of this N-linked glycosylation site by an Asn-to-Asp substitution at residue 523 (N523D) changed the spectrum of the mutant virus's receptor specificity, delayed its elution from both turkey and chicken red blood cells, reduced mutant sensitivity (by about half) to the selective HN inhibitor BCX 2855 in hemagglutination inhibition tests, and slowed its growth in LLC-MK(2) cells. 15264219 0 52 gly N-glycosylation 15:29 arg2 Three putative N-glycosylation sites Three putative N-glycosylation sites sites Three putative N-glycosylation sites within the murine 5-HT3A receptor sequence affect plasma membrane targeting, ligand binding, and calcium influx in heterologous mammalian cells. 22171471 5 21 gly N-glycosylation 1012:1026 arg2 Asn181 Asn181 Asn181 The HA gene of the 2009 viruses contained an N-glycosylation site at Asn181 (an analog to Asn 65 numbering from a signal peptide), which correlated with the long-stalk NA gene. 22171471 5 21 gly N-glycosylation 1012:1026 arg2 an N-glycosylation site an N-glycosylation site site The HA gene of the 2009 viruses contained an N-glycosylation site at Asn181 (an analog to Asn 65 numbering from a signal peptide), which correlated with the long-stalk NA gene. 21264968 6 74 part_of MUC4 2024:2027 arg1 Thr10 MUC4 Thr10 PUBTATOR AminoAcid MUC4 4585 Thr10 The solution structures determined by NMR spectroscopic studies elicited that the preferential introduction of α-GalNAc at Thr10 of MUC4 stabilizes specifically a β-like extended backbone structure at this area, whereas other synthetic models with a single α-GalNAc residue at Thr1, Thr6, or Thr15 did not exhibit any converged three-dimensional structure at the proximal peptide moiety. 28322444 3 20 gly unglycosylated 495:508 arg1 N220-glycosylated and unglycosylated Kv3.1b N220-glycosylated and unglycosylated Kv3.1b Cterm Kv3.1b Large quantities of asparagine 229 (N229)-glycosylated Kv3.1b reached the plasma membrane, whereas N220-glycosylated and unglycosylated Kv3.1b were mainly retained in the endoplasmic reticulum (ER). 28322444 3 33 gly N220-glycosylated 473:489 arg1 N220-glycosylated and unglycosylated Kv3.1b N220-glycosylated and unglycosylated Kv3.1b Cterm Kv3.1b Large quantities of asparagine 229 (N229)-glycosylated Kv3.1b reached the plasma membrane, whereas N220-glycosylated and unglycosylated Kv3.1b were mainly retained in the endoplasmic reticulum (ER). 28322444 3 51 gly -glycosylated 415:427 arg1 asparagine 229 (N229)-glycosylated Kv3.1b asparagine 229 (N229)-glycosylated Kv3.1b Cterm Kv3.1b Large quantities of asparagine 229 (N229)-glycosylated Kv3.1b reached the plasma membrane, whereas N220-glycosylated and unglycosylated Kv3.1b were mainly retained in the endoplasmic reticulum (ER). 25945896 6 57 gly glycopeptide 1128:1139 arg2 glycopeptide spectra glycopeptide spectra glycopeptide Spectra of intact glycopeptides were selected by using glycan oxonium ions as signature ions for glycopeptide spectra. 25945896 6 119 gly glycopeptides 1049:1061 arg2 intact glycopeptides intact glycopeptides glycopeptides Spectra of intact glycopeptides were selected by using glycan oxonium ions as signature ions for glycopeptide spectra. 2503511 12 67 gly glycopeptides 2010:2022 arg2 Tryptic glycopeptides Tryptic glycopeptides glycopeptides Tryptic glycopeptides were isolated by reversed phase high performance liquid chromatography and treated with peptide:N-glycosidase F. 15859596 14 16 gly glycopeptides 1960:1972 arg2 All glycopeptides All glycopeptides glycopeptides All glycopeptides identified contained sialic acid except one. 15859596 14 2 gly contained 1985:1993 arg1 All glycopeptides AND sialic acid All glycopeptides sialic acid glycopeptides All glycopeptides identified contained sialic acid except one. 21048158 4 28 gly glycosylation 682:694 arg2 a glycosylation site a glycosylation site site This variant (AT-N135Q-Pro394) combines 2 mutations: substitution of Asn135 by a Gln to remove a glycosylation site and increase affinity for heparins, and the insertion of a Pro between Arg393 and Ser394 to abolish its anticoagulant activity. 12235182 9 42 gly terminus 1897:1904 arg1 the N-glycans terminus the N-glycans terminus These data imply that the N-glycans at the amino terminus of apoB play an important role in the assembly and secretion of lipoproteins containing the carboxyl terminally truncated apoB. 3087774 3 5 gly beta-chain 361:370 arg1 carbohydrate attachment beta-chain carbohydrate attachment Fterm beta-chain Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment. 3087774 3 6 gly alpha-chain 391:401 arg1 carbohydrate attachment alpha-chain carbohydrate attachment PUBTATOR alpha-chain 2217 Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment. 3087774 3 18 gly contained 283:291 arg1 Two peptides AND glucosamine Two peptides glucosamine peptides Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment. 29596458 10 6 gly N-glycopeptides 1322:1336 arg2 Twenty four N-glycopeptides Twenty four N-glycopeptides N-glycopeptides Twenty four N-glycopeptides were identified with high confidence together with elucidation of the peptide sequence, N-glycosylation site, glycan composition and proposed glycan structures. 29596458 10 57 gly N-glycosylation 1426:1440 arg2 N-glycosylation site N-glycosylation site site Twenty four N-glycopeptides were identified with high confidence together with elucidation of the peptide sequence, N-glycosylation site, glycan composition and proposed glycan structures. 15500847 2 20 part_of protease 605:612 arg1 the catalytic amino acid residues protease the catalytic amino acid residues Fterm Site protease residues Elegaxobin II consisted of 233 amino acids and showed conservation of the catalytic amino acid residues (His(57), Asp(102), and Ser(195)) of chymotrypsin family serine protease in its amino acid sequence. 15500847 2 20 part_of protease 605:612 arg1 His(57) protease His(57), Asp(102), and Ser(195) Fterm SpecificSite protease His(57), Asp(102), and Ser(195) Elegaxobin II consisted of 233 amino acids and showed conservation of the catalytic amino acid residues (His(57), Asp(102), and Ser(195)) of chymotrypsin family serine protease in its amino acid sequence. 15500847 2 20 part_of protease 605:612 arg1 Ser protease His(57), Asp(102), and Ser(195) Fterm SpecificSite protease His(57), Asp(102), and Ser(195) Elegaxobin II consisted of 233 amino acids and showed conservation of the catalytic amino acid residues (His(57), Asp(102), and Ser(195)) of chymotrypsin family serine protease in its amino acid sequence. 15500847 2 20 part_of protease 605:612 arg1 Ser protease His(57), Asp(102), and Ser(195) Fterm SpecificSite protease His(57), Asp(102), and Ser(195) Elegaxobin II consisted of 233 amino acids and showed conservation of the catalytic amino acid residues (His(57), Asp(102), and Ser(195)) of chymotrypsin family serine protease in its amino acid sequence. 9291187 9 36 gly N-glycoprotein 1398:1411 arg1 human 11beta-HSD2 human 11beta-HSD2 PUBTATOR 11beta-HSD2 3291 We conclude that human 11beta-HSD2 is not a N-glycoprotein and N-glycosylation is not essential for the expression of enzyme activity. 9291187 9 36 gly N-glycoprotein 1398:1411 arg1 a N-glycoprotein a N-glycoprotein Fterm N-glycoprotein We conclude that human 11beta-HSD2 is not a N-glycoprotein and N-glycosylation is not essential for the expression of enzyme activity. 20739565 5 41 gly glycosylation 663:675 arg2 the N-linked glycosylation site the N-linked glycosylation site site We show that this acceleration is attributed to the removal of the N-linked glycosylation site within insert B. NLG-1DeltaB also increases synaptic density at neuro-neuronal synapses more than does full-length NLG-1. 20188224 1 6 part_of granulin 159:166 arg1 the granulin domain granulin the granulin domain PUBTATOR Site granulin 2896 domain PGRN is a modular protein with 7 1/2 repeats of the granulin domain separated by short spacer sequences. 10103002 5 60 gly glycoproteins 818:830 arg1 egg-envelope glycoproteins egg-envelope glycoproteins Fterm glycoproteins The deduced amino acid sequence of gp42 showed significant similarity to egg-envelope glycoproteins of the ZPC family of several other vertebrate species, including human ZP3, mouse ZP3, Xenopus laevis gp43 and medaka (Oryzias latipes) ZI3 (LS-F), which play important roles for sperm-egg interaction. 8806496 1 2 gly glycoprotein 171:182 arg1 The flavivirus nonstructural glycoprotein NS1 The flavivirus nonstructural glycoprotein NS1 Fterm glycoprotein The flavivirus nonstructural glycoprotein NS1 is highly conserved and contains two N-linked glycosylation sites which are both utilized for addition of oligosaccharides during replication in cell culture. 8806496 1 16 gly glycosylation 234:246 arg2 two N-linked glycosylation sites two N-linked glycosylation sites sites The flavivirus nonstructural glycoprotein NS1 is highly conserved and contains two N-linked glycosylation sites which are both utilized for addition of oligosaccharides during replication in cell culture. 8806496 1 41 gly utilized 269:276 arg2 two N-linked glycosylation sites two N-linked glycosylation sites sites The flavivirus nonstructural glycoprotein NS1 is highly conserved and contains two N-linked glycosylation sites which are both utilized for addition of oligosaccharides during replication in cell culture. 25504159 3 40 gly glycosylation 564:576 arg2 this glycosylation site this glycosylation site site H5N1 viruses show heterogeneity with respect to the presence of this glycosylation site. 2952720 3 94 gly N-glycosylation 591:605 arg2 one N-glycosylation site one N-glycosylation site site The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain. 31113887 4 76 gly glycosylation 698:710 arg2 a second glycosylation site a second glycosylation site site Additionally, a single nucleotide polymorphism (SNP) has arisen in chimpanzee CD4 (68T) that creates a second glycosylation site on the same virus-binding interface. 1740433 9 31 gly glycosylated 1273:1284 arg1 these sites these sites sites Studies indicate that approximately 50% of these sites are glycosylated, thereby giving rise to two size classes, 14 and 19 kDa, of C-SAA in vivo. 9261431 0 11 part_of polyprotein 136:146 arg1 the C-terminal domains polyprotein the C-terminal domains Fterm Site polyprotein domains The critical N-linked glycan of murine leukemia virus envelope protein promotes both folding of the C-terminal domains of the precursor polyprotein and stability of the postcleavage envelope complex. 12409833 9 69 gly N-glycosylation 974:988 arg2 no putative N-glycosylation site no putative N-glycosylation site site There was no putative N-glycosylation site. 8212855 3 66 gly N-glycosylation 465:479 arg2 the N-terminal region the N-terminal region region The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region. 8212855 3 66 gly N-glycosylation 465:479 arg2 four potential N-glycosylation sites four potential N-glycosylation sites sites The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region. 31577193 6 81 gly N-glycosylation 704:718 arg2 N-glycosylation site N-glycosylation site site METHODS: In this article, we report a random forest method, Nglyc, to predict N-glycosylation site from protein sequence, using 315 sequence features. 19418565 7 37 part_of t-PA 1168:1171 arg1 site-occupancy t-PA site-occupancy OGER Site t-PA P00750 site-occupancy In addition, the thyroid hormones triiodothyronine and thyroxine increased site-occupancy of t-PA compared to control conditions by about 2%. 25690651 5 21 part_of hGPR109A 663:670 arg1 Asn(17)-Cys(18)-Cys(19) sequence hGPR109A Asn(17)-Cys(18)-Cys(19) sequence PUBTATOR Site hGPR109A 338442 sequence Here we show that Asn(17)-Cys(18)-Cys(19) sequence of hGPR109A possesses 2 biologic roles. 18410132 4 13 gly glycosylation 837:849 arg2 glycosylation sites glycosylation sites sites Amino acid sequences and location of glycosylation sites were determined by MALDI-QIT-TOF MS/MS/MS. 11343303 6 61 gly glycosylation 1078:1090 arg2 an additional glycosylation site an additional glycosylation site site The same mutation was found in his heterozygous mother and resulted in a change of Ileu360Asn that might generate an additional glycosylation site. 7528012 9 4 gly N-glycosylation 1342:1356 arg2 An N-glycosylation site An N-glycosylation site site An N-glycosylation site was identified at Asn-16 and a putative glycosylphosphatidylinositol anchor addition site at Asn-79, indicating that the mature processed protein was two residues longer than human CD59. 15869468 10 45 gly N-glycosylation 1447:1461 arg2 the N-glycosylation sites the N-glycosylation sites sites These results show how positioning of the N-glycosylation sites altered many properties of the AT1 receptor, such as targeting, folding, affinity, cell surface expression and quality control. 20888351 6 31 gly glycosylation 989:1001 arg2 a putative glycosylation site a putative glycosylation site site Sequence analysis revealed a putative glycosylation site in close proximity to the complementarity determining region 2 (CDR2) of the scFv 9B9 heavy chain. 8128610 7 76 gly N-glycosylation 1016:1030 arg2 A N-glycosylation site A N-glycosylation site site A N-glycosylation site present in bovine, ovine and porcine IL-2 respectively, is absent in gerbil. 7829269 6 91 gly used 1353:1356 arg2 a novel conjugation site a novel conjugation site site Most importantly, the LL2 VK carbohydrate moiety might be used as a novel conjugation site for drugs and radionuclides without compromising the immunoreactivity of the antibody. 21970473 4 67 gly chains 579:584 arg1 the peptide the peptide the peptide Site peptide In commonly used methods, sugar chains on the peptide were released using endoglycosidase, and the glycan and peptides were analyzed separately with mass spectrometry. 9409770 8 66 gly N-glycosylation 1205:1219 arg2 only one putative N-glycosylation site only one putative N-glycosylation site site Unlike cathepsin Ds in other species, however, rainbow trout cathepsin D appears to have only one putative N-glycosylation site, rather than two. 22203233 5 26 gly glycoproteins 833:845 arg1 alkyne-modified fucosylated glycoproteins alkyne-modified fucosylated glycoproteins Fterm glycoproteins Interestingly, this system could be applied to labeling of alkyne-modified fucosylated glycoproteins. 22203233 5 29 gly fucosylated 821:831 arg1 alkyne-modified fucosylated glycoproteins alkyne-modified fucosylated glycoproteins Fterm glycoproteins Interestingly, this system could be applied to labeling of alkyne-modified fucosylated glycoproteins. 22015153 7 36 gly glycosylation 1029:1041 arg2 six O-linked glycosylation sites six O-linked glycosylation sites sites Feline oviductin contained one putative N-linked glycosylation site, six O-linked glycosylation sites, a potential heparin binding site, and two cholesterol recognition and/or interaction amino acid consensus (CRAC) domains. 22015153 7 63 gly glycosylation 996:1008 arg2 one putative N-linked glycosylation site one putative N-linked glycosylation site site Feline oviductin contained one putative N-linked glycosylation site, six O-linked glycosylation sites, a potential heparin binding site, and two cholesterol recognition and/or interaction amino acid consensus (CRAC) domains. 25737293 6 44 part_of peptides 1098:1105 arg1 the corresponding proteins proteins peptides Fterm Site proteins peptides Ratiometric analysis of deglycosylated peptides and the total intensities of all peptides from the corresponding proteins allowed relative quantification of site-specific glycosylation occupancy between yeast strains with various isoforms of oligosaccharyltransferase. 25737293 6 83 part_of proteins 1172:1179 arg1 deglycosylated peptides proteins peptides Fterm Site proteins peptides Ratiometric analysis of deglycosylated peptides and the total intensities of all peptides from the corresponding proteins allowed relative quantification of site-specific glycosylation occupancy between yeast strains with various isoforms of oligosaccharyltransferase. 7999071 0 40 part_of lipase 138:143 arg1 the proposed N-linked glycosylation site lipoprotein lipase the proposed N-linked glycosylation site PUBTATOR Site lipoprotein lipase 4023 site A naturally occurring mutation at the second base of codon asparagine 43 in the proposed N-linked glycosylation site of human lipoprotein lipase: in vivo evidence that asparagine 43 is essential for catalysis and secretion. 1559965 2 4 gly glycosylation 534:546 arg2 a glycosylation site a glycosylation site site Protein disulfide isomerase (PDI, EC 5.3.4.1) is a highly unusual multifunctional polypeptide, being identical to the beta subunit of prolyl 4-hydroxylase, a cellular thyroid hormone binding protein and a component of the microsomal triglyceride transfer protein complex, and highly similar to a polypeptide acting in vitro as a glycosylation site binding protein. 29470411 10 68 gly N-glycosylation 1221:1235 arg2 Unoccupied N-glycosylation site N283 site N283 site N283 Unoccupied N-glycosylation site N283 at α1A contributes to a gain-of-function by lessening CaV2.1 inactivation. 25451932 2 76 part_of has 238:240 arg1 Human corin AND 19 predicted N-glycosylation sites Human corin 19 predicted N-glycosylation sites PUBTATOR Site Human corin 10699 sites Human corin has 19 predicted N-glycosylation sites in its extracellular domains. 2846759 0 64 gly Conservation 0:11 arg1 nucleotide sequence nucleotide sequence sequence Conservation of glycoprotein H (gH) in herpesviruses: nucleotide sequence of the gH gene from herpesvirus saimiri. 2846759 0 120 gly glycoprotein 16:27 arg1 glycoprotein H glycoprotein H PUBTATOR glycoprotein H 1682472 Conservation of glycoprotein H (gH) in herpesviruses: nucleotide sequence of the gH gene from herpesvirus saimiri. 29020646 6 5 gly glycosylation 860:872 arg2 the glycosylation site N301 site N301 site N301 Specifically, the glycosylation site N301 in the V3 loop was seen less frequently in AE subtype and CXCR4 topic viruses. 21507336 3 1 gly N-glycosylation 559:573 arg2 an N-glycosylation site an N-glycosylation site site Inspired by early successes, we tested the possibility of introducing an N-glycosylation site to facilitate the secretion of human growth hormone (hGH) from cultured tobacco cells. 10889259 9 1 gly glycoproteins 1479:1491 arg1 heterologous glycoproteins heterologous glycoproteins Fterm glycoproteins The latter observation indicates that production of heterologous glycoproteins with little or no antigenic glycans can be achieved in whole plants, and not in just Arabidopsis, using antisense technology. 23758413 1 68 gly glycoproteins 220:232 arg1 glycoproteins glycoproteins Fterm glycoproteins Glycan-targeting affinity chromatography systems are becoming increasingly important as tools in the purification, enrichment, and identification of glycoproteins. 29109276 3 1 gly glycosylation 618:630 arg2 the new putative glycosylation site the new putative glycosylation site site The 2016-2017 seasonal influenza vaccine was updated to include a clade 3C.2a H3N2 strain; however, the egg-adapted version of this viral strain lacks the new putative glycosylation site. 10677208 3 76 gly N-glycosylation 652:666 arg2 an N-glycosylation site an N-glycosylation site site CR3 contains an N-glycosylation site, which is conserved in all forms of LTBP known to date. 32054416 7 27 gly glycosylation 1088:1100 arg1 CTLA-4 CTLA-4 PUBTATOR CTLA-4 12477 This finding may also contribute to the understanding of the glycosylation of CTLA-4 and its related biologic function. 11439087 6 4 gly N-glycosylation 927:941 arg2 four putative N-glycosylation sites four putative N-glycosylation sites sites BST-1 contains four putative N-glycosylation sites. 12829816 2 89 gly glycoprotein 431:442 arg1 a type III bitopic N(endo)C(exo) nuclear membrane and Golgi glycoprotein a type III bitopic N(endo)C(exo) nuclear membrane and Golgi glycoprotein Fterm glycoprotein ADP is a type III bitopic N(endo)C(exo) nuclear membrane and Golgi glycoprotein that is produced at high levels in late adenovirus infection (>24 h postinfection). 30042931 6 81 gly glycosylation 1262:1274 arg2 this G1 site this G1 site site Furthermore, the JEV mutants with G1 glycosylation showed enhanced DC-SIGN binding, which may then lead to reduced brain invasion and explain the reason why WT JEV is devoid of this G1 site of glycosylation. 18790849 9 71 part_of KCNQ4 1303:1307 arg1 the carboxy terminus KCNQ4 the carboxy terminus PUBTATOR Site KCNQ4 9132 terminus A triple chimera containing the TD of KCNQ1 and the carboxy terminus of KCNQ4 yielded current density 10- or sixfold larger than wild-type KCNQ3 or KCNQ1, respectively, suggesting that the effects on current amplitudes of the TD and the carboxy-terminus are additive. 24174280 1 31 part_of protein 223:229 arg1 the globular head protein the globular head Fterm Site protein head Glycosylation on the globular head of the hemagglutinin (HA) protein of influenza virus acts as an important target for recognition and destruction of virus by innate immune proteins of the collectin family. 28694069 9 98 gly aglycosylated 1574:1586 arg1 an aglycosylated variant an aglycosylated variant Fterm variant Thus, in this study, we have found an aglycosylated variant that may effectively substitute for wild-type Fc. 2558633 2 21 gly glycosylation 429:441 arg2 only one potential glycosylation site only one potential glycosylation site site The genes were each 1,062 nucleotides long with two long open reading frames for proteins of either 326 or 297 amino acids and containing only one potential glycosylation site at amino acid position 69. 20011150 0 73 gly glycosylation 49:61 arg2 the antigenic and glycosylation sites the antigenic and glycosylation sites sites Identification of mutations at the antigenic and glycosylation sites in hemagglutinin protein of H5N1 strain. 14680951 6 4 gly deglycosylation 996:1010 arg1 the expressed enzyme the expressed enzyme Fterm enzyme The two cysteines were disulfide bonded, and the lone predicted glycosylation site, asparagine 49, was shown by both enzymatic deglycosylation of the expressed enzyme and site-directed mutagenesis to be glycosylated. 14680951 6 35 gly glycosylation 933:945 arg2 the lone predicted glycosylation site site, asparagine 49 site, asparagine 49 The two cysteines were disulfide bonded, and the lone predicted glycosylation site, asparagine 49, was shown by both enzymatic deglycosylation of the expressed enzyme and site-directed mutagenesis to be glycosylated. 14680951 6 44 gly glycosylated 1072:1083 arg1 the lone predicted glycosylation site site, asparagine 49 site, asparagine 49 The two cysteines were disulfide bonded, and the lone predicted glycosylation site, asparagine 49, was shown by both enzymatic deglycosylation of the expressed enzyme and site-directed mutagenesis to be glycosylated. 8543840 5 33 part_of protein 701:707 arg1 the extracellular domain HIV-1 env protein the extracellular domain PUBTATOR Site HIV-1 env protein 155971 domain To clarify the site of processing of viral env proteins, we examined the processing of an HLA B*3501-restricted epitope in the extracellular domain of the HIV-1 env protein. 8543840 5 55 part_of HLA 626:628 arg1 an HLA B*3501-restricted epitope HLA an HLA B*3501-restricted epitope OGER Site HLA epitope To clarify the site of processing of viral env proteins, we examined the processing of an HLA B*3501-restricted epitope in the extracellular domain of the HIV-1 env protein. 12742580 6 21 gly N-glycosylation 929:943 arg2 the N-glycosylation site the N-glycosylation site site Deleting the most carboxy-terminal subdomain and intervening region, including the N-glycosylation site, reduced expression to 15-20% of wild type VSG, and deletion of both subdomains reduced expression to <1%. 18077336 2 53 part_of has 280:282 arg1 MRAP AND a single transmembrane domain MRAP a single transmembrane domain PUBTATOR Site structure of MRAP Q8TCY5 domain The mechanism of action and structure of MRAP, which has a single transmembrane domain, are unknown. 9658108 2 27 gly glycoprotein 433:444 arg1 havcr-1 havcr-1 OGER havcr-1 Q96D42 The HAVcr-1 cDNA codes for havcr-1, a 451-amino-acid class I integral-membrane mucin-like glycoprotein of unknown natural function. 9658108 2 27 gly glycoprotein 433:444 arg1 a 451-amino-acid class I integral-membrane mucin-like glycoprotein a 451-amino-acid class I integral-membrane mucin-like glycoprotein Fterm glycoprotein The HAVcr-1 cDNA codes for havcr-1, a 451-amino-acid class I integral-membrane mucin-like glycoprotein of unknown natural function. 7527739 4 70 gly N-glycosylation 646:660 arg2 a putative N-glycosylation site a putative N-glycosylation site site Both regions contain two Cys residues in close proximity, and the region at residues 554-569 contains a putative N-glycosylation site, which are factors that previously have been suggested to affect the immune recognition of the e2 protein. 18203712 1 18 gly N-glycosylated 102:115 arg1 Cyclooxygenases Cyclooxygenases PUBTATOR Cyclooxygenases (COX-1 4512 Cyclooxygenases (COX-1 and COX-2) are N-glycosylated, endoplasmic reticulum-resident, integral membrane proteins that catalyze the committed step in prostanoid synthesis. 18203712 1 18 gly N-glycosylated 102:115 arg1 N-glycosylated, endoplasmic reticulum-resident, integral membrane proteins N-glycosylated, endoplasmic reticulum-resident, integral membrane proteins Fterm proteins Cyclooxygenases (COX-1 and COX-2) are N-glycosylated, endoplasmic reticulum-resident, integral membrane proteins that catalyze the committed step in prostanoid synthesis. 26598643 1 69 gly glycoproteins 166:178 arg1 glycoproteins glycoproteins Fterm glycoproteins Site-specific glycosylation analysis is key to investigate structure-function relationships of glycoproteins, e.g. in the context of antigenicity and disease progression. 16227292 2 33 gly glycosylated 377:388 arg1 all three sites all three sites sites We determined that all three sites are glycosylated. 8496193 5 68 gly nonglycosylated 822:836 arg1 procathepsin L form of procathepsin L OGER form of procathepsin L P06797 When this mutated cDNA was transfected into NIH 3T3 cells, a completely nonglycosylated form of procathepsin L was expressed. 24073194 8 51 gly glycosylation 1373:1385 arg2 a predicted N-linked glycosylation site a predicted N-linked glycosylation site site However, most of the genotype H1 cluster1 viruses had an amino acid substitution (Ser240Asn), which removed a predicted N-linked glycosylation site. 21515415 5 12 gly N-glycosylation 711:725 arg2 each N-glycosylation site each N-glycosylation site site The size of the carbohydrate at each N-glycosylation site ranged from 3.14 to 4.2kDa. 26813162 4 11 gly glycosylation 698:710 arg2 the E1-141 glycosylation site the E1-141 glycosylation site site A viral mutant lacking the E1-141 glycosylation site was attenuated for virus-induced disease, with reduced myositis and higher levels of IFN-γ induction at peak disease contributing to improved viral clearance, suggesting that glycosylation of the E1 glycoprotein plays a major role in the pathogenesis of RRV. 26813162 4 20 gly glycoprotein 916:927 arg1 the E1 glycoprotein the E1 glycoprotein Fterm glycoprotein A viral mutant lacking the E1-141 glycosylation site was attenuated for virus-induced disease, with reduced myositis and higher levels of IFN-γ induction at peak disease contributing to improved viral clearance, suggesting that glycosylation of the E1 glycoprotein plays a major role in the pathogenesis of RRV. 26813162 4 55 gly glycosylation 892:904 arg1 the E1 glycoprotein the E1 glycoprotein Fterm glycoprotein A viral mutant lacking the E1-141 glycosylation site was attenuated for virus-induced disease, with reduced myositis and higher levels of IFN-γ induction at peak disease contributing to improved viral clearance, suggesting that glycosylation of the E1 glycoprotein plays a major role in the pathogenesis of RRV. 18085777 3 18 gly glycopeptide 501:512 arg2 glycopeptide glycopeptide peptides and glycopeptide A three-segment native chemical ligation strategy was employed using unprotected peptides and glycopeptide. 25499264 1 51 gly glycoproteins 266:278 arg1 the HIV-1 envelope glycoproteins the HIV-1 envelope glycoproteins Fterm glycoproteins BACKGROUND: Carbohydrate-binding agents (CBAs) are potent antiretroviral compounds that target the N-glycans on the HIV-1 envelope glycoproteins. 25499264 1 88 gly N-glycans 234:242 arg1 the HIV-1 envelope glycoproteins glycoproteins N-glycans Fterm glycoproteins BACKGROUND: Carbohydrate-binding agents (CBAs) are potent antiretroviral compounds that target the N-glycans on the HIV-1 envelope glycoproteins. 19116267 8 70 gly glycosylation 1234:1246 arg2 the residue-158 glycosylation site the residue-158 glycosylation site site Recombinant VN1203 virus carrying the S227N change alone or with the residue-158 glycosylation site removed showed reduced lethality and systemic spread in mice but not in domestic chickens. 12755619 2 18 gly glycoprotein 362:373 arg1 extraparotid glycoprotein extraparotid glycoprotein Fterm glycoprotein GCDFP-15/PIP is also identified as gp17 and/or seminal actin-binding protein (SABP) from seminal vesicles and as extraparotid glycoprotein (EP-GP) from salivary glands. 12755619 2 18 gly glycoprotein 362:373 arg1 GCDFP-15/PIP GCDFP-15/PIP PUBTATOR PIP 5304 GCDFP-15/PIP is also identified as gp17 and/or seminal actin-binding protein (SABP) from seminal vesicles and as extraparotid glycoprotein (EP-GP) from salivary glands. 8706738 15 11 gly N-deglycosylated 1898:1913 arg1 N-deglycosylated rGal-T N-deglycosylated rGal-T No significant changes in CD spectra were observed between hGal-T and N-deglycosylated rGal-T. 21177759 5 42 gly N-glycosylation 796:810 arg2 an N-glycosylation site an N-glycosylation site site The D440N mutation was proposed to generate an N-glycosylation site additional to the seven existing motifs in ALS. 26956484 6 10 part_of Orai1 901:905 arg1 the only glycosylation site Orai1 the only glycosylation site PUBTATOR Site Orai1 84876 site Ca(2+) imaging experiments and patch-clamp experiments revealed that mutation of the only glycosylation site of Orai1 (Orai1N223A) enhanced SOCE in Jurkat T cells. 22180206 1 4 gly heterogeneity 234:246 arg1 occupied glycosylation sites occupied glycosylation sites sites Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites. 22180206 1 4 gly heterogeneity 234:246 arg1 glycosylation site consensus sequence glycosylation site consensus sequence sequence Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites. 22180206 1 10 gly glycosylation 257:269 arg2 glycosylation site consensus sequence glycosylation site consensus sequence site Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites. 22180206 1 10 gly glycosylation 257:269 arg2 glycosylation site consensus sequence glycosylation site consensus sequence sequence Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites. 22180206 1 35 gly sites 338:342 arg1 glycan heterogeneity sites glycan heterogeneity sites Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites. 22180206 1 36 gly glycosylation 324:336 arg2 occupied glycosylation sites occupied glycosylation sites sites Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites. 22180206 1 112 gly sequence 286:293 arg1 glycan heterogeneity sequence glycan heterogeneity sequence Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites. 14715137 3 35 gly N-glycosylation 434:448 arg1 synaptotagmin 1 synaptotagmin 1 site PUBTATOR synaptotagmin 1 6857 site Conversely, mutation of the N-terminal N-glycosylation site of synaptotagmin 1 redirects synaptotagmin 1 from vesicles to the plasma membrane. 19933092 3 72 part_of contains 393:400 arg1 This sequence AND This sequence This sequence This sequence sequence This sequence contains a complete single exon (without intron) 915 bp in size, which encodes 304 amino acid residues. 8706738 12 29 gly N-deglycosylated 1509:1524 arg1 N-deglycosylated rGal-T N-deglycosylated rGal-T When analyzed by IEF, N-deglycosylated rGal-T was resolved in two bands. 1455401 6 5 gly glycosylation 1010:1022 arg2 Asn-302 Asn-302 Asn-302 These findings indicate that glycosylation at Asn-302 influences the activity of pro-UK/UK and could be the major factor responsible for the enhanced activity of E. coli-derived pro-UK. 2500441 7 28 gly glycoprotein 1173:1184 arg1 an O-linked glycoprotein structure an O-linked glycoprotein structure The carbohydrate structure, determined by 1H and 13C NMR spectroscopy, was found to be alpha-D-Manp(1----2)alpha-D-Manp(1----3)Thr corresponding to an O-linked glycoprotein structure. 6651835 2 22 gly glycosylation 322:334 arg2 the C-terminal glycosylation site the C-terminal glycosylation site site Gel filtration allows complete separation of the C-terminal glycosylation site. 9242452 2 82 part_of receptor 492:499 arg1 its primary T-cell receptor contact residue receptor residue, position 72, Fterm Site receptor residue, position 72, To study T-cell responses to tumor-associated glycans, the mouse hemoglobin-derived decapeptide Hb(67-76), which binds well to the MHC class II molecule E(k) and is nonimmunogenic in CBA/J mice, was either O- or N-glycosylated at its primary T-cell receptor contact residue, position 72, with different glycans attached to either threonine, serine, or asparagine. 25636227 1 29 gly heterogeneity 250:262 arg1 O-glycan core structures O-glycan core structures O-glycosylation-site characterization of individual glycoproteins is a major challenge because of the heterogeneity of O-glycan core structures. 25636227 1 61 gly glycoproteins 200:212 arg1 individual glycoproteins individual glycoproteins Fterm glycoproteins O-glycosylation-site characterization of individual glycoproteins is a major challenge because of the heterogeneity of O-glycan core structures. 12438611 7 5 part_of sites 1226:1230 arg1 gp120 gp120 sites OGER Site gp120 Q14624 sites To further guide our efforts in mapping the DC-SIGN binding sites on gp120, we used two well-characterized HIV inhibitory agents (2G12 monoclonal antibody and cyanovirin) that bind to high-mannose sugars on gp120. 12438611 7 8 part_of DC-SIGN 1210:1216 arg1 the DC-SIGN binding sites DC-SIGN the DC-SIGN binding sites OGER Site DC-SIGN Q9NNX6 sites To further guide our efforts in mapping the DC-SIGN binding sites on gp120, we used two well-characterized HIV inhibitory agents (2G12 monoclonal antibody and cyanovirin) that bind to high-mannose sugars on gp120. 27773655 11 20 part_of domains 1617:1623 arg1 pro-LPH LPH domains PUBTATOR LPH 3938 Elucidation of the structural-functional relevance of the domains in pro-LPH is crucial in unravelling and understanding the molecular basis of carbohydrate malabsorption disorders that are associated with lactase deficiency or lactase malfunction. 23527852 1 10 gly glycoprotein 175:186 arg1 Apolipoprotein-CIII Apolipoprotein-CIII PUBTATOR Apolipoprotein-CIII 345 Apolipoprotein-CIII (apoCIII) is an abundant blood glycoprotein associated with lipoprotein particles. 23527852 1 10 gly glycoprotein 175:186 arg1 an abundant blood glycoprotein an abundant blood glycoprotein Fterm glycoprotein Apolipoprotein-CIII (apoCIII) is an abundant blood glycoprotein associated with lipoprotein particles. 20943491 5 54 gly N-glycosylation 899:913 arg2 one N-glycosylation site one N-glycosylation site site There were one O-glycosylation site at the third amino acid and one N-glycosylation site at the eighty-fourth amino acid. 20943491 5 90 gly O-glycosylation 846:860 arg2 one O-glycosylation site one O-glycosylation site site There were one O-glycosylation site at the third amino acid and one N-glycosylation site at the eighty-fourth amino acid. 15616124 2 83 gly N-glycosylation 312:326 arg1 FVII FVII Cterm FVII 2155 In the present study, however, we demonstrate posttranslational N-glycosylation of recombinant human coagulation factor VII (FVII) in CHO-K1 and 293A cells. 15616124 2 83 gly N-glycosylation 312:326 arg1 recombinant human coagulation factor VII recombinant human coagulation factor VII PUBTATOR coagulation factor VII 2155 In the present study, however, we demonstrate posttranslational N-glycosylation of recombinant human coagulation factor VII (FVII) in CHO-K1 and 293A cells. 24806200 7 89 gly O-glycosylation 1469:1483 arg2 closely spaced O-glycosylation sites closely spaced O-glycosylation sites sites Key steps in these syntheses include a successful double Lansbury glycosylation en route to the N-terminal fragment of β-hCG and the sequential installation of four O-linked glycosyl-amino acid cassettes into closely spaced O-glycosylation sites in a single, high-yielding solid-supported synthesis to access the C-terminal portion of the molecule. 20573953 5 27 gly glycosylation 1141:1153 arg2 new Ig5 glycosylation sites new Ig5 glycosylation sites sites To test the latter possibility, new Ig5 glycosylation sites were engineered and their polysialylation tested. 29268168 2 0 gly afucosylated 383:394 arg1 the afucosylated IgG the afucosylated IgG Cterm IgG Particularly, afucosylation increases the binding affinity of human IgG1 to human FcγRIIIa up to ∼20 fold, and additional galactosylation of the afucosylated IgG increases the affinity up to ∼40 fold. 8347587 12 4 gly glycosylation 1406:1418 arg2 the first four N-linked glycosylation sites insulin receptor sites PUBTATOR insulin receptor P01308 sites Thus, glycosylation of the first four N-linked glycosylation sites of the insulin receptor is necessary for the proper processing and intracellular transport of the receptor. 8347587 12 57 gly glycosylation 1365:1377 arg1 the first four N-linked glycosylation sites insulin receptor sites PUBTATOR insulin receptor P01308 sites Thus, glycosylation of the first four N-linked glycosylation sites of the insulin receptor is necessary for the proper processing and intracellular transport of the receptor. 31944613 2 38 gly glycosylation 339:351 arg2 the glycosylation sites the glycosylation sites sites The natural mutation on the glycosylation sites of the AIV HA head occurs frequently. 31944613 2 38 gly glycosylation 339:351 arg2 the AIV HA head head head The natural mutation on the glycosylation sites of the AIV HA head occurs frequently. 1482348 2 33 gly O-glycosylated 284:297 arg1 O-glycosylated oligosaccharide O-glycosylated oligosaccharide N-acetylgalactosamine (GalNAc) in the alpha chain suggested the presence of O-glycosylated oligosaccharide. 16883437 9 77 part_of site 1341:1344 arg1 all these studied envelope glycoproteins glycoproteins site Fterm Site glycoproteins site One potential glycosylation site, on all these studied envelope glycoproteins, was predicted. 7780197 0 43 part_of receptor 53:60 arg1 The critical glycosylation site transferrin receptor The critical glycosylation site PUBTATOR Site transferrin receptor 7037 site The critical glycosylation site of human transferrin receptor contains a high-mannose oligosaccharide. 29268168 0 47 gly fucosylated 45:55 arg1 fucosylated and afucosylated IgG fucosylated and afucosylated IgG Cterm IgG Conserved FcγR- glycan discriminates between fucosylated and afucosylated IgG in humans and mice. 29268168 0 53 gly afucosylated 61:72 arg1 fucosylated and afucosylated IgG fucosylated and afucosylated IgG Cterm IgG Conserved FcγR- glycan discriminates between fucosylated and afucosylated IgG in humans and mice. 21053369 4 37 gly occupancy 605:613 arg2 each site each site site In this work, glycosylation profiles of soluble recombinant human IL-23r (rhIL-23r) were established using mass spectrometry (MS), which included defining glycosylation sites, degree of glycosylation occupancy of each site and structure of attached oligosaccharides. 21053369 4 75 gly glycosylation 419:431 arg1 rhIL-23r rhIL-23r OGER rhIL-23r Q5VWK5 In this work, glycosylation profiles of soluble recombinant human IL-23r (rhIL-23r) were established using mass spectrometry (MS), which included defining glycosylation sites, degree of glycosylation occupancy of each site and structure of attached oligosaccharides. 21053369 4 75 gly glycosylation 419:431 arg1 soluble recombinant human IL-23r soluble recombinant human IL-23r PUBTATOR IL-23r 149233 In this work, glycosylation profiles of soluble recombinant human IL-23r (rhIL-23r) were established using mass spectrometry (MS), which included defining glycosylation sites, degree of glycosylation occupancy of each site and structure of attached oligosaccharides. 21053369 4 18 gly glycosylation 560:572 arg2 glycosylation sites sites attached oligosaccharides sites In this work, glycosylation profiles of soluble recombinant human IL-23r (rhIL-23r) were established using mass spectrometry (MS), which included defining glycosylation sites, degree of glycosylation occupancy of each site and structure of attached oligosaccharides. 16335952 6 62 gly N-glycoproteins 1311:1325 arg1 303 nonredundant N-glycoproteins 303 nonredundant N-glycoproteins Fterm N-glycoproteins Using stringent criteria, a total of 2053 different N-glycopeptides were confidently identified, covering 303 nonredundant N-glycoproteins. 16335952 6 71 gly N-glycopeptides 1240:1254 arg2 2053 different N-glycopeptides 2053 different N-glycopeptides N-glycopeptides Using stringent criteria, a total of 2053 different N-glycopeptides were confidently identified, covering 303 nonredundant N-glycoproteins. 6433976 7 66 part_of positions 1486:1494 arg1 the protein protein positions Fterm Site protein positions Carbohydrate was also found at two other positions in the protein, corresponding to Asn-117 and Asn-448. 25300029 2 14 gly glycosylation 503:515 arg1 α3 integrin subunit α3 integrin subunit Fterm subunit In this study we have utilized a powerful nano-HPLC-mass spectrometric approach to characterize patterns of normal and abnormal N-linked glycosylation of α3 integrin subunit in Pkd1(-/-) cells derived from mouse kidneys. 23632316 2 51 part_of IgG 409:411 arg1 the Fc region IgG the Fc region Cterm Site IgG region To accomplish our goals, we over-expressed and purified a chimeric construct that contained the Fc region of the IgG fused to the exons 7 & 8 of mouse ZP3 (IgG-Fc-ZP3E7 protein). 9729121 3 26 part_of APN 575:577 arg1 the N-terminal sequence APN the N-terminal sequence PUBTATOR Site APN P15144 sequence However, the N-terminal sequence of 110-kDa APN, DPAFRLPTTTRPRHYQVTLT, was highly homologous with those of Manduca sexta and Heliothis virescens APNs, which were identified as a receptor for an insecticidal toxin of Bacillus thuringiensis. 8643111 6 61 part_of CDR-grafted 959:969 arg1 the CDR-grafted variable regions CDR the CDR-grafted variable regions OGER Site CDR Q06455 regions Construction of the CDR-grafted variable regions was accomplished by a rapid and simplified method that involved long DNA oligonucleotide synthesis and the polymerase chain reaction (PCR). 30850477 11 24 gly N-glycosylation 1468:1482 arg2 N-glycosylation site acquisition N-glycosylation site acquisition site These results point toward a differential selection pressure of N-glycosylation site acquisition during affinity maturation of B cells, which depends on the location within the V region and is isotype and subclass dependent. 21526855 7 0 gly O-glycosylation 1422:1436 arg2 Novel O-glycosylation sites Novel O-glycosylation sites sites Novel O-glycosylation sites in the C-terminal domains of fetuin (T334) and κ-caseinoglycopeptide (S154 and T156) were assigned, the former representing a sequence conflict with the published T154. 21526855 7 41 gly κ-caseinoglycopeptide 1491:1511 arg2 κ-caseinoglycopeptide κ-caseinoglycopeptide κ-caseinoglycopeptide Novel O-glycosylation sites in the C-terminal domains of fetuin (T334) and κ-caseinoglycopeptide (S154 and T156) were assigned, the former representing a sequence conflict with the published T154. 16212939 5 4 gly N-glycosylation 956:970 arg2 an additional N-glycosylation site an additional N-glycosylation site site In contrast, the mutant containing an additional N-glycosylation site on the N-terminal 24 amino acids of hIL-1beta (Gln15Asn) secreted twice as much rhG-CSF into culture media as wild type hIL-1beta. 10648510 2 39 part_of glycoprotein 336:347 arg1 a single N-glycosylation site glycoprotein a single N-glycosylation site Fterm Site glycoprotein site The ability of RNase B, a model glycoprotein with a single N-glycosylation site occupied by a family of high-mannose-type glycans (Man(5)- to Man(9)-GlcNAc(2)), to support growth of E. faecalis was investigated. 27216994 13 5 gly N-glycosylation 2244:2258 arg2 11 out of 12 predicted N-glycosylation sites 11 out of 12 predicted N-glycosylation sites sites Furthermore, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans. 27216994 13 29 gly occupied 2326:2333 arg2 11 out of 12 predicted N-glycosylation sites 11 out of 12 predicted N-glycosylation sites sites Furthermore, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans. 27216994 13 46 gly 7 N-glycosylation 2288:2304 arg2 7 N-glycosylation sites 7 N-glycosylation sites sites Furthermore, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans. 32321762 2 30 gly acid 426:429 arg1 a GPI side-chain side-chain acid Fterm side-chain The glycosylphosphatidylinositol (GPI) anchor of PrPC is involved in prion disease pathogenesis, and especially sialic acid in a GPI side-chain reportedly affects the PrPC conversion. 8380463 2 41 part_of contains 262:269 arg1 The protein AND three potential sites The protein three potential sites Fterm Site protein sites The protein contains three potential sites for the addition of N-linked carbohydrates. 28900186 2 45 gly N-glycopeptides 449:463 arg2 N-glycopeptides N-glycopeptides N-glycopeptides Specific proteases, such as trypsin, bear the potential of generating N-glycopeptides that either carry more than one N-glycosylation site or are too long to be readily analyzed by mass spectrometry- both due to the lack of tryptic cleavage sites near the N-glycosylation site. 28900186 2 51 gly N-glycosylation 635:649 arg2 the N-glycosylation site the N-glycosylation site site Specific proteases, such as trypsin, bear the potential of generating N-glycopeptides that either carry more than one N-glycosylation site or are too long to be readily analyzed by mass spectrometry- both due to the lack of tryptic cleavage sites near the N-glycosylation site. 28900186 2 81 gly N-glycosylation 497:511 arg2 more than one N-glycosylation site more than one N-glycosylation site site Specific proteases, such as trypsin, bear the potential of generating N-glycopeptides that either carry more than one N-glycosylation site or are too long to be readily analyzed by mass spectrometry- both due to the lack of tryptic cleavage sites near the N-glycosylation site. 22015141 0 53 gly N-glycosylation 32:46 arg1 the porcine circovirus type 2 Cap protein protein site Fterm protein site Deletion of the single putative N-glycosylation site of the porcine circovirus type 2 Cap protein enhances specific immune responses by DNA immunisation in mice. 10620492 3 12 gly glycosylation 389:401 arg2 A glycosylation site A glycosylation site site A glycosylation site was demonstrated between conserved Domains 1 and 2. 8352759 3 23 part_of subunit 605:611 arg1 the propolypeptide vWF subunit the propolypeptide PUBTATOR Site vWF subunit 7450 propolypeptide The sequenced fragment corresponds to nucleotides 2416 to 2886 of the human vWF cDNA and encodes for the last 41 amino acids of the propolypeptide, the cleavage site and the first 116 amino acids of the mature vWF subunit. 8352759 3 23 part_of subunit 605:611 arg1 the cleavage site vWF subunit the cleavage site PUBTATOR Site vWF subunit 7450 site The sequenced fragment corresponds to nucleotides 2416 to 2886 of the human vWF cDNA and encodes for the last 41 amino acids of the propolypeptide, the cleavage site and the first 116 amino acids of the mature vWF subunit. 17960575 5 36 gly N-glycosylation 656:670 arg2 all three N-glycosylation sites FETUA sites PUBTATOR FETUA 197 sites Glycopeptides derived from all three N-glycosylation sites of FETUA were observed, and the corresponding CID spectra proved the respective glycans to be oligosaccharides of the triantennary complex type. 8638940 11 83 part_of beta-subunit 1877:1888 arg1 The N308 glycosylation site subunit The N308 glycosylation site OGER Site subunit P20933 site The N308 glycosylation site of the beta-subunit appears to be more important in maintaining normal transport and stability of human glycosylasparaginase. 7540044 1 45 gly glycoprotein 253:264 arg1 the rabies virus glycoprotein the rabies virus glycoprotein Fterm glycoprotein The first potential N-glycosylation site of the rabies virus glycoprotein, the antigen that carries epitopes for glycoprotein-specific T-cells and virus neutralizing antibodies, is glycosylated inefficiently. 7540044 1 11 gly glycosylated 373:384 arg1 The first potential N-glycosylation site glycoprotein site Fterm glycoprotein site The first potential N-glycosylation site of the rabies virus glycoprotein, the antigen that carries epitopes for glycoprotein-specific T-cells and virus neutralizing antibodies, is glycosylated inefficiently. 7540044 1 71 gly N-glycosylation 212:226 arg1 the rabies virus glycoprotein glycoprotein site Fterm glycoprotein site The first potential N-glycosylation site of the rabies virus glycoprotein, the antigen that carries epitopes for glycoprotein-specific T-cells and virus neutralizing antibodies, is glycosylated inefficiently. 23341449 3 48 gly NCAM 433:436 arg1 the first fibronectin type III repeat NCAM the first fibronectin type III repeat PUBTATOR NCAM 4684 Previous work demonstrated that the first fibronectin type III repeat (FN1) of NCAM is required for polyST recognition and the polysialylation of the N-glycans on the adjacent Ig5 domain. 23341449 3 26 gly polysialylation 481:495 arg1 the adjacent Ig5 domain domain the adjacent Ig5 domain Site domain Previous work demonstrated that the first fibronectin type III repeat (FN1) of NCAM is required for polyST recognition and the polysialylation of the N-glycans on the adjacent Ig5 domain. 23341449 3 26 gly polysialylation 481:495 arg1 the N-glycans domain the N-glycans domain Previous work demonstrated that the first fibronectin type III repeat (FN1) of NCAM is required for polyST recognition and the polysialylation of the N-glycans on the adjacent Ig5 domain. 21653661 6 33 gly glycosylation 1388:1400 arg2 their glycosylation site occupancies their glycosylation site occupancies site Compared to 293T-derived recombinant Envs from viruses isolated from chronic HIV-1, transmitted/founder Envs displayed marked differences in their glycosylation site occupancies and in their amounts of complex glycans. 8496594 2 9 gly glycoprotein 196:207 arg1 a cell surface glycoprotein a cell surface glycoprotein Fterm glycoprotein It is a cell surface glycoprotein that can only be detected after stimulation of lymphocytes. 28221766 7 8 gly N-glycosylation 1349:1363 arg2 a third novel, albeit low abundant, N-glycosylation site a third novel, albeit low abundant, N-glycosylation site site Additionally, next to the two known glycosylation sites, a third novel, albeit low abundant, N-glycosylation site on C9 is identified, which surprisingly does not possess the canonical N-glycosylation sequence N-X-S/T. 28221766 7 79 gly glycosylation 1292:1304 arg2 the two known glycosylation sites the two known glycosylation sites sites Additionally, next to the two known glycosylation sites, a third novel, albeit low abundant, N-glycosylation site on C9 is identified, which surprisingly does not possess the canonical N-glycosylation sequence N-X-S/T. 11278567 0 12 gly CXCR4 104:108 arg1 a major determinant CXCR4 a major determinant PUBTATOR CXCR4 7852 N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. 11278567 0 28 gly CCR5 95:98 arg1 a major determinant CCR5 a major determinant PUBTATOR CCR5 1234 N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. 11278567 0 41 gly glycosylation 9:21 arg1 the HIV type-1 gp120 envelope glycoprotein the HIV type-1 gp120 envelope glycoprotein Fterm glycoprotein N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. 11278567 0 69 gly glycoprotein 56:67 arg1 the HIV type-1 gp120 envelope glycoprotein the HIV type-1 gp120 envelope glycoprotein Fterm glycoprotein N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. 1706753 4 8 part_of HA1 1457:1459 arg1 HA1 273 Pro----Leu HA1 HA1 273 Pro----Leu PUBTATOR AminoAcid HA1 70719 Pro In addition, novel laboratory mutants were obtained containing substitutions in the HA1 subunit that had not been reported previously for H3 subtype viruses, either natural variants or laboratory mutants, at residues: HA1 62 Ile----Arg; HA1 165 Asn----Ser (resulting in the loss of a N-glycosylation site); and HA1 273 Pro----Leu. 1706753 4 34 part_of HA1 1383:1385 arg1 HA1 165 Asn----Ser HA1 HA1 165 Asn----Ser PUBTATOR AminoAcid HA1 70719 Asn In addition, novel laboratory mutants were obtained containing substitutions in the HA1 subunit that had not been reported previously for H3 subtype viruses, either natural variants or laboratory mutants, at residues: HA1 62 Ile----Arg; HA1 165 Asn----Ser (resulting in the loss of a N-glycosylation site); and HA1 273 Pro----Leu. 1706753 4 91 part_of residues 1354:1361 arg1 natural variants variants residues Fterm SpecificSite variants residues: HA1 62 Ile In addition, novel laboratory mutants were obtained containing substitutions in the HA1 subunit that had not been reported previously for H3 subtype viruses, either natural variants or laboratory mutants, at residues: HA1 62 Ile----Arg; HA1 165 Asn----Ser (resulting in the loss of a N-glycosylation site); and HA1 273 Pro----Leu. 10905635 1 48 gly N-glycosylation 163:177 arg2 potential N-glycosylation sites potential N-glycosylation sites sites Glycosyltransferase cDNAs contain a variable number of potential N-glycosylation sites. 29115822 5 51 gly glycosylated 932:943 arg1 a glycosylated peptide peptide peptide In the presence of OGT, it catalyzes the glycosylation reaction to generate a glycosylated peptide that is a protease-protection peptide. 20543007 9 17 gly N-glycosylation 1463:1477 arg2 the N-glycosylation site the N-glycosylation site site Peptide mapping and mass spectrometric analysis revealed that the N-glycosylation site was generally occupied. 20543007 9 38 gly occupied 1498:1505 arg2 the N-glycosylation site the N-glycosylation site site Peptide mapping and mass spectrometric analysis revealed that the N-glycosylation site was generally occupied. 21338062 3 58 gly glycoprotein 864:875 arg1 glycoprotein glycoprotein Fterm glycoprotein However, due to the low ionization efficiency of glycopeptides during electrospray ionization, 200-500 fmol of sample per injection is needed for a single LC-MS run, which makes it challenging for the analysis of limited amounts of glycoprotein purified from biological matrixes. 21338062 3 123 gly glycopeptides 681:693 arg2 glycopeptides glycopeptides glycopeptides However, due to the low ionization efficiency of glycopeptides during electrospray ionization, 200-500 fmol of sample per injection is needed for a single LC-MS run, which makes it challenging for the analysis of limited amounts of glycoprotein purified from biological matrixes. 22691915 10 14 gly N-glycosylation 1307:1321 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site This marker is a highly sensitive tool to study N-glycosylation site occupancy. 17960575 4 9 part_of protein 596:602 arg1 the sole N-glycosylation site protein the sole N-glycosylation site Fterm Site protein site For RNAse, B glycans of the high-mannose type (Man(4) to Man(9)) attached to either a tetra- or a hexapeptide containing the sole N-glycosylation site of the protein were detected. 7768952 4 97 part_of cDNA 557:560 arg1 A full-length cDNA sequence cDNA A full-length cDNA sequence Cterm Site cDNA sequence A full-length cDNA sequence encoding prostasin was obtained by amplification of the 5'- and 3'-ends of the cDNA. 2318516 5 49 part_of alpha 987:991 arg1 the leader, alpha 1, and alpha 2 sequences alpha 1 the leader, alpha 1, and alpha 2 sequences PUBTATOR Site alpha 1 146 sequences Human (HLA-B7) and mouse (H-2Dp) hybrid class I genes, encoding the leader, alpha 1, and alpha 2 sequences of one species fused to the alpha 3, transmembrane, and cytoplasmic domains of the other, were transfected into T2. 15748209 6 41 gly glycosylation 779:791 arg2 dual N-linked glycosylation site dual N-linked glycosylation site site A comparison of wild-type (WT) and dual N-linked glycosylation site, N11A/N176A, mutant CXCR4 expressed in 3T3 and HEK-293 cells served to implicate variabilities in glycosylation and oligomerization in almost half of the isoforms. 27743362 1 67 part_of glycoprotein 167:178 arg1 only one glycosylation site glycoprotein only one glycosylation site Fterm Site glycoprotein site The vast heterogeneity of protein glycosylation, even of a single glycoprotein with only one glycosylation site, can give rise to a set of macromolecules with different physicochemical properties. 10731668 6 65 gly glycosylation 967:979 arg1 32 Asn(32 ) Asn(32 ) Thus, CHO sEGFR itself is heterogeneous with respect to the glycosylation at Asn(32 ), which may cause problems in biophysical studies. 10731668 6 65 gly glycosylation 967:979 arg2 Asn Asn(32 ) Asn(32 ) Thus, CHO sEGFR itself is heterogeneous with respect to the glycosylation at Asn(32 ), which may cause problems in biophysical studies. 10731668 6 65 gly glycosylation 967:979 arg1 Asn Asn(32 ) Asn(32 ) Thus, CHO sEGFR itself is heterogeneous with respect to the glycosylation at Asn(32 ), which may cause problems in biophysical studies. 10731668 6 65 gly glycosylation 967:979 arg2 Asn Asn(32 ) Asn(32 ) Thus, CHO sEGFR itself is heterogeneous with respect to the glycosylation at Asn(32 ), which may cause problems in biophysical studies. 10731668 6 65 gly glycosylation 967:979 arg1 Asn Asn(32 ) Asn(32 ) Thus, CHO sEGFR itself is heterogeneous with respect to the glycosylation at Asn(32 ), which may cause problems in biophysical studies. 10731668 6 65 gly glycosylation 967:979 arg1 Asn Asn(32 ) Asn(32 ) Thus, CHO sEGFR itself is heterogeneous with respect to the glycosylation at Asn(32 ), which may cause problems in biophysical studies. 7533854 3 91 gly glycoprotein 557:568 arg1 A fusion glycoprotein expression system A fusion glycoprotein expression system Fterm glycoprotein A fusion glycoprotein expression system that expressed the isolated V1/V2 domain of gp120 in native form was used to analyze the structural characteristics of these epitopes. 27471271 7 10 gly glycosylation 1034:1046 arg2 one prominent glycosylation site one prominent glycosylation site site These have led to distinctly different proposals for dimer interfaces, one involving interactions of ABED β-strands and the other involving GFCC'C″ β-strands, with the former burying one prominent glycosylation site. 3778488 4 3 gly glycosylation 613:625 arg1 aFGF aFGF site PUBTATOR aFGF 2246 site A potential glycosylation site Asn114-Gly115-Ser116 is present in aFGF but the mitogen does not bind to lectins suggesting that it may not be glycosylated. 23908491 1 61 part_of contains 206:213 arg1 The envelope glycoprotein E2 AND several hypervariable regions The envelope glycoprotein E2 several hypervariable regions Cterm Site E2 regions BACKGROUND: The envelope glycoprotein E2 of hepatitis C virus (HCV) contains several hypervariable regions. 15308721 1 22 gly glycoprotein 200:211 arg1 the host glycoprotein PrP the host glycoprotein PrP Fterm glycoprotein A key feature of prion encephalopathies is the accumulation of a misfolded form of the host glycoprotein PrP. 23776238 3 8 gly glycoprotein 598:609 arg1 a glycoprotein a glycoprotein Fterm glycoprotein The B-cell maturation antigen (BCMA), an essential membrane protein for maintaining the survival of plasma cells, was identified as a glycoprotein exhibiting complex-type N-glycans at a single N-glycosylation site, asparagine 42. 23776238 3 8 gly glycoprotein 598:609 arg1 B-cell maturation antigen B-cell maturation antigen PUBTATOR B-cell maturation antigen 608 The B-cell maturation antigen (BCMA), an essential membrane protein for maintaining the survival of plasma cells, was identified as a glycoprotein exhibiting complex-type N-glycans at a single N-glycosylation site, asparagine 42. 23776238 3 58 gly N-glycosylation 657:671 arg2 a single N-glycosylation site site, asparagine 42 site, asparagine 42 The B-cell maturation antigen (BCMA), an essential membrane protein for maintaining the survival of plasma cells, was identified as a glycoprotein exhibiting complex-type N-glycans at a single N-glycosylation site, asparagine 42. 6838832 5 14 gly contain 807:813 arg1 A similar peptide AND oligosaccharide A similar peptide oligosaccharide peptide A similar peptide isolated from plasminogen variant 2 did not contain oligosaccharide but possessed an amino acid sequence identical with the corresponding variant 1 peptide. 11686319 10 60 part_of antithrombin 1343:1354 arg1 residue 82 antithrombin residue 82 Fterm SpecificSite antithrombin residue 82 The addition of an extra carbohydrate side chain to residue 82 of antithrombin may block post-translational folding. 3484703 5 28 gly glycosylation 637:649 arg2 position 30 position 30 position 30 Three carbohydrate side chains were found in the heavy chain, all of them N-glycosidically linked to asparagine, which is present in the acceptor sequon Asn-Xaa-Thr (or -Ser); one additional potential glycosylation site devoid of a sugar side chain is found at position 30. 3484703 5 28 gly glycosylation 637:649 arg2 one additional potential glycosylation site one additional potential glycosylation site site Three carbohydrate side chains were found in the heavy chain, all of them N-glycosidically linked to asparagine, which is present in the acceptor sequon Asn-Xaa-Thr (or -Ser); one additional potential glycosylation site devoid of a sugar side chain is found at position 30. 17011210 2 39 part_of ligand 435:440 arg1 recombinant human Fas ligand extracellular domain Fas ligand recombinant human Fas ligand extracellular domain PUBTATOR Site Fas ligand 356 domain A new secretory expression and purification method was devised for the production of a large amount of recombinant human Fas ligand extracellular domain (hFasLECD) by Pichia pastoris. 17011210 2 97 part_of Fas 431:433 arg1 recombinant human Fas ligand extracellular domain Fas ligand recombinant human Fas ligand extracellular domain PUBTATOR Site Fas ligand 356 domain A new secretory expression and purification method was devised for the production of a large amount of recombinant human Fas ligand extracellular domain (hFasLECD) by Pichia pastoris. 23005037 3 48 gly N-glycosylated 437:450 arg1 the purified native CD147 the purified native CD147 PUBTATOR CD147 682 In the present study, mass spectrum analysis demonstrated that the purified native CD147 from human lung cancer tissue was N-glycosylated and contained a series of high-mannose and complex-type N-linked glycan structures. 26869352 1 70 gly fucosylated 263:273 arg1 fucosylated proteins fucosylated proteins Fterm proteins Fucosylation is an important type of glycosylation involved in cancer, and fucosylated proteins could be employed as cancer biomarkers. 17660510 0 30 gly N-glycosylation 9:23 arg1 sialoglycopeptides sialoglycopeptides sialoglycopeptides Enhanced N-glycosylation site analysis of sialoglycopeptides by strong cation exchange prefractionation applied to platelet plasma membranes. 17660510 0 30 gly N-glycosylation 9:23 arg2 N-glycosylation site analysis N-glycosylation site analysis site Enhanced N-glycosylation site analysis of sialoglycopeptides by strong cation exchange prefractionation applied to platelet plasma membranes. 17660510 0 39 gly sialoglycopeptides 42:59 arg2 sialoglycopeptides sialoglycopeptides sialoglycopeptides Enhanced N-glycosylation site analysis of sialoglycopeptides by strong cation exchange prefractionation applied to platelet plasma membranes. 15009203 12 101 gly O-glycosylation 1916:1930 arg1 Thr10 Thr10 Thr10 O-glycosylation at the N-terminus of the polypeptide was detected at Ser7 and Ser9 or Thr10, in the predominantly doubly O-glycosylated glycoprotein form. 15009203 12 126 gly glycoprotein 2052:2063 arg1 the predominantly doubly O-glycosylated glycoprotein form the predominantly doubly O-glycosylated glycoprotein form Fterm glycoprotein O-glycosylation at the N-terminus of the polypeptide was detected at Ser7 and Ser9 or Thr10, in the predominantly doubly O-glycosylated glycoprotein form. 15009203 12 101 gly O-glycosylation 1916:1930 arg1 Ser9 Ser7 and Ser9 Ser7 and Ser9 O-glycosylation at the N-terminus of the polypeptide was detected at Ser7 and Ser9 or Thr10, in the predominantly doubly O-glycosylated glycoprotein form. 22354569 7 49 gly glycosylation 989:1001 arg2 glycosylation site glycosylation site site In one experiment, nonspecific proteolysis is combined with a two-tiered mass spectrometry approach (MALDI-TOF and LC-MS/MS) to gain glycosylation site and glycan identity. 29273683 5 11 part_of N230 549:552 arg1 rat CBG CBG N230 PUBTATOR SpecificSite CBG 299270 N230 We now show that mutations of conserved N-glycosylation sites at N238 in human CBG and N230 in rat CBG disrupt steroid binding. 29273683 5 58 part_of N238 527:530 arg1 human CBG CBG N238 PUBTATOR SpecificSite CBG 866 N238 We now show that mutations of conserved N-glycosylation sites at N238 in human CBG and N230 in rat CBG disrupt steroid binding. 8960909 4 15 gly glycosylation 807:819 arg2 an N-linked glycosylation site an N-linked glycosylation site site One such antigenic epitope, corresponding to amino acids 369-377 of the enzyme tyrosinase, possesses an N-linked glycosylation site. 7688956 3 26 gly glycoprotein 474:485 arg1 a very small glycosylphosphatidylinositol (GPI)-anchored glycoprotein a very small glycosylphosphatidylinositol (GPI)-anchored glycoprotein Fterm glycoprotein We find that the antigen is a very small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids. 1703533 6 37 gly N-glycosylation 1024:1038 arg2 One potential N-glycosylation site One potential N-glycosylation site site One potential N-glycosylation site was identified in one of the CNBr fragments. 30172908 4 24 part_of found 824:828 arg2 the putative PsGILT protein AND signal peptide the putative PsGILT protein signal peptide PUBTATOR Site PsGILT protein 102460690 peptide The conserved features in known GILTs, such as signal peptide, CXXC motif, GILT signature sequence, N-glycosylation site and conserved cysteines, were all found in the putative PsGILT protein. 30172908 4 31 part_of GILT 744:747 arg1 signal peptide GILT signal peptide PUBTATOR Site GILT P13284 peptide The conserved features in known GILTs, such as signal peptide, CXXC motif, GILT signature sequence, N-glycosylation site and conserved cysteines, were all found in the putative PsGILT protein. 30172908 4 31 part_of GILT 744:747 arg1 GILT signature sequence GILT GILT signature sequence PUBTATOR Site GILT P13284 sequence The conserved features in known GILTs, such as signal peptide, CXXC motif, GILT signature sequence, N-glycosylation site and conserved cysteines, were all found in the putative PsGILT protein. 14759610 0 49 gly N-glycosylation 43:57 arg2 the N-glycosylation site the N-glycosylation site site Single chain antibodies that recognize the N-glycosylation site. 11093789 5 6 gly residues 960:967 arg1 20 20 20 SpecificSite Asn(20) Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 11093789 5 6 gly residues 960:967 arg1 Asn Asn Asn SpecificSite Asn(24) Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 11093789 5 6 gly residues 960:967 arg1 24 24 24 SpecificSite Asn(24) Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 11093789 5 6 gly residues 960:967 arg1 Asn Asn Asn SpecificSite Asn(191) Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 11093789 5 6 gly residues 960:967 arg1 Asn Asn Asn SpecificSite Asn(5) Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 11093789 5 6 gly residues 960:967 arg1 191 191 191 SpecificSite Asn(191) Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 11093789 5 6 gly residues 960:967 arg1 5 5 5 SpecificSite Asn(5) Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 11093789 5 6 gly residues 960:967 arg1 Asn Asn Asn SpecificSite Asn(20) Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 11093789 5 17 gly Asn 1054:1056 arg1 carbohydrate residues Asn(191) carbohydrate residues Asn(191) Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 11093789 5 55 gly glycosylated 929:940 arg1 all four potential extracellular sites all four potential extracellular sites sites Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 11093789 5 68 gly Asn 1032:1034 arg1 carbohydrate residues Asn(24) carbohydrate residues Asn(24) Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 11093789 5 93 gly Asn 996:998 arg1 carbohydrate residues Asn(5) carbohydrate residues Asn(5) Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 11093789 5 105 gly Asn 1014:1016 arg1 carbohydrate residues Asn(20) carbohydrate residues Asn(20) Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). 9393962 6 2 gly glycosylated 574:585 arg1 glycosylated residues residues specifically sialic acid residues It has also been shown by X-ray crystallography that glycosylated residues (specifically sialic acid) are influential in the contacts of the CH1 to CH2 as well as the CH2 to CH2 domains in a human IgG1 antibody. 3882692 2 36 part_of Peptide 189:195 arg1 Peptide fragments Peptide Peptide fragments OGER Site Peptide fragments Peptide fragments obtained by trypsin, lysine-C peptidase, cyanogen bromide, and acetic acid cleavage of the intact protein were purified by reverse-phase high performance liquid chromatography and analyzed by amino acid composition and by automated Edman degradation. 2768262 11 77 part_of deiminase 1477:1485 arg1 the amino acid sequence deiminase the amino acid sequence Fterm Site deiminase sequence Possible similarity of the amino acid sequence of peptidylarginine deiminase to those of other calcium binding proteins is discussed. 27939162 1 25 gly glycosylation 139:151 arg2 the potential glycosylation site NA264N the potential glycosylation site NA264N site To determine the role of the potential glycosylation site NA264N, which has been shown to be prevalent in recent Chinese H9N2 isolates, four reverse genetic viruses, rgWS1-NA264N, rgWS1-NA264H, rgBJ-NA264H and rgBJ-NA264N, were rescued. 18160168 6 53 part_of enzyme 976:981 arg1 the catalytic or framework sites enzyme the catalytic or framework sites Fterm Site enzyme sites As for the neuraminidase gene, amino acid substitutions were found in N1 and N2 but not directly at the catalytic or framework sites of this enzyme. 23296536 1 15 gly glycoproteins 199:211 arg1 glycoproteins glycoproteins Fterm glycoproteins Although the field of glycome informatics has established several methods, standards and technologies for carbohydrate analysis, the analysis of glycoproteins and other glycoconjugates is still in its infancy. 24164424 9 98 gly Glycosylation 1426:1438 arg2 the site the site site Glycosylation at the site found in CNGA3 subunits was found to be protective, while glycosylation at the bovine CNGA1 site was not. 24164424 9 72 gly glycosylation 1510:1522 arg2 the bovine CNGA1 site site site Glycosylation at the site found in CNGA3 subunits was found to be protective, while glycosylation at the bovine CNGA1 site was not. 21535396 11 68 gly non-glycosylated 1459:1474 arg1 A fully non-glycosylated TF A fully non-glycosylated TF Cterm TF 2152 A fully non-glycosylated TF is shown to bind FVIIa and interact with FX with the same efficiency as that of wild-type TF. 22072749 0 23 part_of region 64:69 arg1 the simian immunodeficiency virus gp41 transmembrane protein protein region Fterm Site protein region Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein. 22072749 0 23 part_of region 64:69 arg1 the C-terminal domain region the C-terminal domain domain Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein. 22072749 0 25 part_of protein 152:158 arg1 the C-terminal domain protein the C-terminal domain Fterm Site protein domain Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein. 10992007 9 44 gly glycosylated 1569:1580 arg1 all six glycosylation sites all six glycosylation sites sites Finally, Western blot revealed that all six glycosylation sites are actually glycosylated. 10992007 9 51 gly glycosylation 1536:1548 arg2 all six glycosylation sites all six glycosylation sites sites Finally, Western blot revealed that all six glycosylation sites are actually glycosylated. 26853155 3 14 part_of syncytin-2 567:576 arg1 10 N-glycosylation sites syncytin-2 10 N-glycosylation sites PUBTATOR Site syncytin-2 P60508 sites We constructed expression plasmids of wild-type and 21 single-amino-acid substitution mutants of syncytin-2, including 10 N-glycosylation sites individually silenced by mutagenizing N to Q, 1 naturally occurring single-nucleotide polymorphism (SNP) N118S that introduced an N-glycosylation site, and another 10 non-synonymous SNPs located within important functional domains. 28747502 3 23 gly glycosylation 451:463 arg1 mouse DPP4 mouse DPP4 PUBTATOR DPP4 P27487 Previous work revealed that glycosylation of mouse DPP4 plays a role in blocking MERS-CoV infection. 3485444 6 25 gly glycosylation 866:878 arg2 the glycosylation site the glycosylation site site It was then used to show that the glycosylation site of human band 3 is 28 000 +/- 3000 daltons from the carboxy terminus of the protein. 28257906 2 34 part_of ARS 423:425 arg1 known human STS and ARS amino acid sequences ARS known human STS and ARS amino acid sequences OGER Site ARS P55000 sequences Bioinformatic analyses of mammalian genomes were undertaken using known human STS and ARS amino acid sequences to study the evolution of these genes and proteins encoded on eutherian and marsupial genomes. 12731887 1 5 gly glycoprotein 203:214 arg1 2- (eIF2-) associated glycoprotein p67 2- (eIF2-) associated glycoprotein p67 Fterm glycoprotein Eukaryotic initiation factor 2- (eIF2-) associated glycoprotein p67 blocks eIF2alpha phosphorylation by kinases, and its N-terminal 1-97 amino acid segment can induce efficient translation. 20923142 7 76 gly glycopeptides 1676:1688 arg2 N-linked glycopeptides N-linked glycopeptides glycopeptides Thus, LTL quantitative technique is potentially an useful method for obtaining simultaneous unambiguous identification and reliable quantification of N-linked glycopeptides. 9804815 5 12 gly sites 772:776 arg1 the MUC1 tandem repeat sequence sites the MUC1 tandem repeat sequence sites GalNAc-T4 transferred GalNAc to two sites in the MUC1 tandem repeat sequence (Ser in GVTSA and Thr in PDTR) using a 24-mer glycopeptide with GalNAc residues attached at sites utilized by GalNAc-T1, -T2, and -T3 (TAPPAHGVTSAPDTRPAPGSTAPPA, GalNAc attachment sites underlined). 9804815 5 34 gly attached 893:900 arg3 GalNAc residues AND sites sites GalNAc residues sites GalNAc-T4 transferred GalNAc to two sites in the MUC1 tandem repeat sequence (Ser in GVTSA and Thr in PDTR) using a 24-mer glycopeptide with GalNAc residues attached at sites utilized by GalNAc-T1, -T2, and -T3 (TAPPAHGVTSAPDTRPAPGSTAPPA, GalNAc attachment sites underlined). 9804815 5 82 gly glycopeptide 859:870 arg1 GalNAc residues glycopeptide GalNAc residues glycopeptide GalNAc-T4 transferred GalNAc to two sites in the MUC1 tandem repeat sequence (Ser in GVTSA and Thr in PDTR) using a 24-mer glycopeptide with GalNAc residues attached at sites utilized by GalNAc-T1, -T2, and -T3 (TAPPAHGVTSAPDTRPAPGSTAPPA, GalNAc attachment sites underlined). 23751365 2 6 gly non-glycosylated 334:349 arg1 non-glycosylated peptides non-glycosylated peptides peptides However, glycopeptide signals are significantly suppressed by coeluting non-glycosylated peptides in mass spectrometry-based analysis. 23751365 2 55 gly glycopeptide 271:282 arg2 glycopeptide signals glycopeptide signals glycopeptide However, glycopeptide signals are significantly suppressed by coeluting non-glycosylated peptides in mass spectrometry-based analysis. 17222411 4 9 gly glycopeptides 514:526 arg2 glycopeptides glycopeptides glycopeptides Analyses of glycopeptides produced by Edman degradation and mass spectrometry revealed that the disialyl-corel (NeuAc alpha2-3Gal beta l-3(NeuAc alpha2-6)GalNAc alpha l-O-Thr) structure was primarily attached to a glycosylation site at residue Thr52. 17222411 4 20 gly glycosylation 716:728 arg2 residue Thr52 residue Thr52 residue Thr52 Analyses of glycopeptides produced by Edman degradation and mass spectrometry revealed that the disialyl-corel (NeuAc alpha2-3Gal beta l-3(NeuAc alpha2-6)GalNAc alpha l-O-Thr) structure was primarily attached to a glycosylation site at residue Thr52. 17222411 4 20 gly glycosylation 716:728 arg2 a glycosylation site a glycosylation site site Analyses of glycopeptides produced by Edman degradation and mass spectrometry revealed that the disialyl-corel (NeuAc alpha2-3Gal beta l-3(NeuAc alpha2-6)GalNAc alpha l-O-Thr) structure was primarily attached to a glycosylation site at residue Thr52. 18420026 4 30 gly positions 1132:1140 arg1 positions positions positions Bioinformatics analysis showed there were two putative N-glycosylation sites within human NECL1 at positions N25LS and N290KS and within mouse Necl1 at positions N23LS and N288KS, respectively. 18420026 4 58 gly N-glycosylation 1088:1102 arg2 two putative N-glycosylation sites two putative N-glycosylation sites sites Bioinformatics analysis showed there were two putative N-glycosylation sites within human NECL1 at positions N25LS and N290KS and within mouse Necl1 at positions N23LS and N288KS, respectively. 18420026 4 71 gly positions 1185:1193 arg1 positions positions positions Bioinformatics analysis showed there were two putative N-glycosylation sites within human NECL1 at positions N25LS and N290KS and within mouse Necl1 at positions N23LS and N288KS, respectively. 18524814 0 44 part_of site 32:35 arg1 the Japanese encephalitis virus prM protein protein site Fterm Site protein site A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice. 10471296 9 4 gly glycosylation 1430:1442 arg2 asparagine-2181 factor V asparagine-2181 OGER factor V P12259 asparagine-2181 These results indicate that partial glycosylation of factor V at asparagine-2181 is the structural basis of the light chain doublet and that the presence of this oligosaccharide reduces the affinity of factor Va for biological membranes. 10471296 9 4 gly glycosylation 1430:1442 arg1 asparagine-2181 factor V asparagine-2181 OGER factor V P12259 asparagine-2181 These results indicate that partial glycosylation of factor V at asparagine-2181 is the structural basis of the light chain doublet and that the presence of this oligosaccharide reduces the affinity of factor Va for biological membranes. 10471296 9 4 gly glycosylation 1430:1442 arg1 asparagine-2181 asparagine-2181 asparagine-2181 These results indicate that partial glycosylation of factor V at asparagine-2181 is the structural basis of the light chain doublet and that the presence of this oligosaccharide reduces the affinity of factor Va for biological membranes. 9223509 11 55 part_of SCR2 1689:1692 arg1 the SCR2 glycosylation site SCR2 the SCR2 glycosylation site OGER Site SCR2 P29558 site Mutations which mimicked the change found in baboon CD46 or another which deleted the SCR2 glycosylation site reduced binding substantially. 29479800 1 0 gly glycoprotein 192:203 arg1 recombinant glycoprotein production recombinant glycoprotein production Fterm glycoprotein N-glycosylation is critical for recombinant glycoprotein production as it influences the heterogeneity of products and affects their biological function. 29479800 1 32 gly N-glycosylation 148:162 arg1 recombinant glycoprotein production recombinant glycoprotein production Fterm glycoprotein N-glycosylation is critical for recombinant glycoprotein production as it influences the heterogeneity of products and affects their biological function. 1457969 0 47 gly glycosylation 53:65 arg2 individual glycosylation sites individual glycosylation sites sites The asparagine-linked oligosaccharides at individual glycosylation sites in human thyrotrophin. 7749412 4 21 gly N-glycosylation 646:660 arg2 an N-glycosylation site an N-glycosylation site site Two mutations are A to G transitions in the ARSA gene at positions 1788 and 2723, causing the loss of an N-glycosylation site and a polyadenylation signal, respectively. 25094044 3 8 gly attached 576:583 arg1 UGGT1 AND glycan UGGT1 glycan PUBTATOR UGGT1 56886 The structure of glycan attached to UGGT1, however, has not been investigated. 15809769 9 40 part_of Wnt9a 1152:1156 arg1 Wnt9a 5'-flanking promoter regions Wnt9a Wnt9a 5'-flanking promoter regions PUBTATOR Site Wnt9a 7483 regions Transcription-factor-binding sites conserved between human WNT9A and rodent Wnt9a 5'-flanking promoter regions were not identified by using the Match program. 1371468 12 96 gly glycosylation 1989:2001 arg2 one additional N-linked glycosylation site one additional N-linked glycosylation site site The nucleotide sequence of the bovine lectin domain predicts one additional N-linked glycosylation site compared to mouse and human. 30605224 2 41 gly glycoprotein 336:347 arg1 glycoprotein functions glycoprotein functions Fterm glycoprotein Global and site-specific analysis of glycoproteins in complex biological samples can advance our understanding of glycoprotein functions and cellular activities. 30605224 2 54 gly glycoproteins 259:271 arg1 glycoproteins glycoproteins Fterm glycoproteins Global and site-specific analysis of glycoproteins in complex biological samples can advance our understanding of glycoprotein functions and cellular activities. 21653661 5 13 gly glycosylation 1176:1188 arg2 glycosylation site occupancy glycosylation site occupancy site Our results show that both transmitted/founder Envs had similar degrees of glycosylation site occupancy as well as similar glycan profiles. 14691230 3 0 gly glycosylation 628:640 arg1 nine Asn residues DPPIV Asn residues PUBTATOR DPPIV 1803 Asn residues Crystallographic studies on DPPIV reveal clear N-linked glycosylation of nine Asn residues in DPPIV. 9242452 6 78 gly glycopeptides 1096:1108 arg2 All 16 glycopeptides All 16 glycopeptides glycopeptides All 16 glycopeptides bound well to E(k), although those with the more complex carbohydrates bound more weakly than those with monosaccharides. 32321762 8 19 gly PrPC 1645:1648 arg1 the GPI-glycan structure PrPC the GPI-glycan structure PUBTATOR PrPC 5621 In summary, we report the GPI-glycan structure of human PrPC, including the ω-site amino acid for GPI attachment and the sialic acid linkage type. 3828456 0 68 gly glycoprotein 168:179 arg1 a proline-rich glycoprotein a proline-rich glycoprotein Fterm glycoprotein Nuclear magnetic resonance spectroscopic and computer-stimulated structural analyses of a heptapeptide sequence found around the N-glycosylation site of a proline-rich glycoprotein from human parotid saliva. 3828456 0 42 gly N-glycosylation 129:143 arg1 a proline-rich glycoprotein glycoprotein site Fterm glycoprotein site Nuclear magnetic resonance spectroscopic and computer-stimulated structural analyses of a heptapeptide sequence found around the N-glycosylation site of a proline-rich glycoprotein from human parotid saliva. 1584795 2 79 part_of vasopressin-related 457:475 arg1 a vasopressin-related peptide vasopressin peptide, Lys Fterm AminoAcid vasopressin peptide, Lys To investigate this issue, we cloned a cDNA encoding a vasopressin-related peptide, Lys-conopressin, produced in the central nervous system of the gastropod mollusc Lymnaea stagnalis. 23824793 9 20 gly glycosylation 1759:1771 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site CD4 independence and neutralization sensitivity were both conferred by Env amino acid changes E84K and D470N that arose independently in multiple animals, with the latter introducing a potential N-linked glycosylation site within a predicted CD4-binding pocket of gp120. 22248643 6 52 part_of sites 983:987 arg1 the G protein G protein sites OGER Site G protein sites Street viruses usually possess one or two N-glycosylation sites on the G protein, 1088 has two, while an additional N-glycosylation site is observed in laboratory-adapted strains. 9639536 2 30 part_of N-linked 403:410 arg1 the five N-linked glycosylation sites N-linked the five N-linked glycosylation sites Cterm Site N-linked sites High performance liquid chromatography-electrospray mass spectrometry (HPLC-ESI/MS) was used to identify which of the five N-linked glycosylation sites of human plasma alpha1-acid-glycoprotein (orosomucoid, OMD) contain the sialyl Lewis(x) antigen. 9639536 2 33 part_of alpha1-acid-glycoprotein 448:471 arg1 the five N-linked glycosylation sites alpha1-acid-glycoprotein the five N-linked glycosylation sites Fterm Site alpha1-acid-glycoprotein sites High performance liquid chromatography-electrospray mass spectrometry (HPLC-ESI/MS) was used to identify which of the five N-linked glycosylation sites of human plasma alpha1-acid-glycoprotein (orosomucoid, OMD) contain the sialyl Lewis(x) antigen. 8349699 3 99 gly Glycosylation 349:361 arg1 PGH synthase-1 PGH synthase-1 Asn410 PUBTATOR PGH synthase-1 19224 Asn410 Glycosylation of PGH synthase-1 at Asn410 and at either Asn68 or Asn144 was required for expression of both the cyclooxygenase and the peroxidase activities of the enzyme. 8349699 3 99 gly Glycosylation 349:361 arg1 PGH synthase-1 PGH synthase-1 Asn144 PUBTATOR PGH synthase-1 19224 Asn144 Glycosylation of PGH synthase-1 at Asn410 and at either Asn68 or Asn144 was required for expression of both the cyclooxygenase and the peroxidase activities of the enzyme. 8349699 3 99 gly Glycosylation 349:361 arg2 Asn68 PGH synthase-1 Asn68 PUBTATOR PGH synthase-1 19224 Asn68 Glycosylation of PGH synthase-1 at Asn410 and at either Asn68 or Asn144 was required for expression of both the cyclooxygenase and the peroxidase activities of the enzyme. 12773316 8 60 gly first 1266:1270 arg1 glycosylation sites glycosylation sites sites A double mutant lacking the first (Asn99Gln) and the second (Asn103Gln) glycosylation sites displayed intracellular accumulation of the protein. 12773316 8 80 gly glycosylation 1310:1322 arg2 glycosylation sites glycosylation sites sites A double mutant lacking the first (Asn99Gln) and the second (Asn103Gln) glycosylation sites displayed intracellular accumulation of the protein. 17963278 5 63 part_of contained 805:813 arg1 the proteins AND more than one potential glycosylation site the proteins more than one potential glycosylation site Fterm Site proteins site Approximately 90% of the proteins identified contained more than one potential glycosylation site. 21528535 8 21 gly glycosylation 1268:1280 arg2 a glycosylation site a glycosylation site site HA1 domain of H3N2 influenza strains in 2009 has lost a glycosylation site at amino acid position 144 while the glycosylation sites of HA1 domain of H3N2 influenza stains isolated in 2008 remained. 21528535 8 21 gly glycosylation 1268:1280 arg2 amino acid position 144 amino acid position 144 position 144 HA1 domain of H3N2 influenza strains in 2009 has lost a glycosylation site at amino acid position 144 while the glycosylation sites of HA1 domain of H3N2 influenza stains isolated in 2008 remained. 21528535 8 74 gly glycosylation 1324:1336 arg2 the glycosylation sites the glycosylation sites sites HA1 domain of H3N2 influenza strains in 2009 has lost a glycosylation site at amino acid position 144 while the glycosylation sites of HA1 domain of H3N2 influenza stains isolated in 2008 remained. 21528535 8 74 gly glycosylation 1324:1336 arg2 HA1 domain domain domain HA1 domain of H3N2 influenza strains in 2009 has lost a glycosylation site at amino acid position 144 while the glycosylation sites of HA1 domain of H3N2 influenza stains isolated in 2008 remained. 9352200 7 23 part_of furin-like 875:884 arg1 a furin-like (convertase) site furin a furin-like (convertase) site OGER Site furin P09958 site In mammalian and Xenopus sequences, a furin-like (convertase) site and a C-terminal transmembrane domain were present reflecting the biosynthesis of ZPC in these species via the secretory glycoprotein pathway. 9352200 7 62 part_of sequences 862:870 arg1 a C-terminal transmembrane domain sequences a C-terminal transmembrane domain domain In mammalian and Xenopus sequences, a furin-like (convertase) site and a C-terminal transmembrane domain were present reflecting the biosynthesis of ZPC in these species via the secretory glycoprotein pathway. 9352200 7 62 part_of sequences 862:870 arg1 a furin-like (convertase) site sequences a furin-like (convertase) site site In mammalian and Xenopus sequences, a furin-like (convertase) site and a C-terminal transmembrane domain were present reflecting the biosynthesis of ZPC in these species via the secretory glycoprotein pathway. 11258925 10 6 gly non-glycosylated 1587:1602 arg1 a non-glycosylated tryptic peptide a non-glycosylated tryptic peptide peptide Finally, a non-glycosylated tryptic peptide was observed containing the Asn 592. 21196036 7 51 gly glycosylation 1183:1195 arg2 potential O-linked glycosylation sites potential O-linked glycosylation sites sites The observed higher molecular weight has been attributed to the presence of large number of potential O-linked glycosylation sites. 6148073 4 5 gly glycopeptides 674:686 arg2 glycopeptides glycopeptides glycopeptides Size determinations of intact and exoglycosidase- and endoglycosidase-digested glycopeptides were performed by gel filtration on Bio-Gel P-6, calibrated with glycopeptides of known structure. 6148073 4 64 gly glycopeptides 595:607 arg2 intact and exoglycosidase- and endoglycosidase-digested glycopeptides intact and exoglycosidase- and endoglycosidase-digested glycopeptides glycopeptides Size determinations of intact and exoglycosidase- and endoglycosidase-digested glycopeptides were performed by gel filtration on Bio-Gel P-6, calibrated with glycopeptides of known structure. 15538777 3 87 gly glycopeptides 961:973 arg2 tryptic glycopeptides tryptic glycopeptides glycopeptides To this end, a simple and efficient method, utilizing hydrophilic binding of carbohydrate matrixes such as cellulose and Sepharose to oligosaccharides, was successfully applied to the isolation of tryptic glycopeptides. 26458842 3 15 part_of sites 487:491 arg1 37 proteins proteins sites Fterm Site proteins sites In the present study, a mouse glycoproteome dataset and mammalian proteome data were assessed to identify 40 ancestral N-glycosylation sites in 37 proteins that disappeared during human evolution since the last common ancestor of the Euarchonta (primates and treeshrews). 8663003 1 8 part_of Rh 182:183 arg1 the Rh polypeptides Rh the Rh polypeptides Cterm Site Rh polypeptides We have used rabbit polyclonal antisera raised against synthetic peptides complementary to different domains of the Rh polypeptides and Rh glycoprotein to examine the topography and organization of these proteins in the human erythrocyte membrane. 7476998 0 90 gly Glycosylation 0:12 arg1 the variable region the variable region region Glycosylation of the variable region of immunoglobulin G--site specific maturation of the sugar chains. 6510420 4 32 gly glycosylation 435:447 arg2 a single glycosylation site a single glycosylation site site Each domain contains a single iron-binding site and a single glycosylation site (asparagine residues 137 and 490) located in homologous positions. 6510420 4 32 gly glycosylation 435:447 arg2 asparagine residues 137 and 490 asparagine residues 137 and 490 asparagine residues 137 and 490 Each domain contains a single iron-binding site and a single glycosylation site (asparagine residues 137 and 490) located in homologous positions. 7813575 4 19 gly glycosylation 714:726 arg1 tissue-type plasminogen activator tissue-type plasminogen activator PUBTATOR tissue-type plasminogen activator 25692 The mannose glycosylation site on the kringle 1 of tissue-type plasminogen activator is modified to yield a compound with a longer half-life in the blood than native tissue-type plasminogen activator. 7813575 4 93 gly activator 777:785 arg1 The mannose glycosylation site tissue-type plasminogen activator The mannose glycosylation site PUBTATOR tissue-type plasminogen activator 25692 The mannose glycosylation site on the kringle 1 of tissue-type plasminogen activator is modified to yield a compound with a longer half-life in the blood than native tissue-type plasminogen activator. 15754041 5 38 gly glycosylation 758:770 arg2 two Asn-linked glycosylation sites two Asn-linked glycosylation sites sites The rat Wnt3 gene, consisting of five exons, encoded a 355-aa protein with N-terminal signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites. 15754041 5 38 gly glycosylation 758:770 arg2 N-terminal signal peptide N-terminal signal peptide peptide The rat Wnt3 gene, consisting of five exons, encoded a 355-aa protein with N-terminal signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites. 31501225 8 65 gly glycopeptides 1280:1292 arg2 two glycopeptides two glycopeptides glycopeptides In addition, the variation in the abundance of two glycopeptides was not caused by its protein concentration. 28860626 6 0 gly fucosylation 1314:1325 arg1 the two influenza proteins proteins N-glycans Fterm proteins Interestingly, sulfation, fucosylation and bisecting N-acetylglucosamine of N-glycans were also reliably identified at the specific glycosylation sites of the two influenza proteins that may serve a crucial role in regulating the protein structure and increasing the protein abundance of the influenza virus reassortants. 28860626 6 0 gly fucosylation 1314:1325 arg1 the specific glycosylation sites sites N-glycans sites Interestingly, sulfation, fucosylation and bisecting N-acetylglucosamine of N-glycans were also reliably identified at the specific glycosylation sites of the two influenza proteins that may serve a crucial role in regulating the protein structure and increasing the protein abundance of the influenza virus reassortants. 28860626 6 0 gly fucosylation 1314:1325 arg1 the specific glycosylation sites proteins sites Fterm proteins sites Interestingly, sulfation, fucosylation and bisecting N-acetylglucosamine of N-glycans were also reliably identified at the specific glycosylation sites of the two influenza proteins that may serve a crucial role in regulating the protein structure and increasing the protein abundance of the influenza virus reassortants. 28860626 6 59 gly glycosylation 1420:1432 arg1 the two influenza proteins proteins sites Fterm proteins sites Interestingly, sulfation, fucosylation and bisecting N-acetylglucosamine of N-glycans were also reliably identified at the specific glycosylation sites of the two influenza proteins that may serve a crucial role in regulating the protein structure and increasing the protein abundance of the influenza virus reassortants. 12527108 7 32 gly site 1108:1111 arg1 the glycans site the glycans site A significant amount of protein was accumulated intracellularly in Sf9 cells which for SFT3 was active and for SFT3DN2 was inactive, indicating the importance of the glycans from the second glycosylation site for protein folding. 12527108 7 54 gly glycosylation 1094:1106 arg2 the second glycosylation site the second glycosylation site site A significant amount of protein was accumulated intracellularly in Sf9 cells which for SFT3 was active and for SFT3DN2 was inactive, indicating the importance of the glycans from the second glycosylation site for protein folding. 26015261 6 25 gly afucosylated 1201:1212 arg1 uniform afucosylated complex type glycans uniform afucosylated complex type glycans The N-linked glycosylation pathway in Pichia pastoris has been engineered to produce human-like N-linked glycosylation with uniform afucosylated complex type glycans. 15028666 7 32 gly glycosylation 1225:1237 arg2 potential glycosylation site motifs site motifs site motifs Sequence analysis of the HA and NA genes identified mutations in conserved residues of the HA1 receptor binding site, in particular Leu-226 --> Ile-226/Val-226, and modification of potential glycosylation site motifs. 12116009 7 33 gly glycosylation 1109:1121 arg2 an eighth potential glycosylation site an eighth potential glycosylation site site In addition, most strains (30/31) had an eighth potential glycosylation site at position 329, whereas a ninth one was found at position 93 in 16 strains. 23234360 6 4 gly glycoproteins 1237:1249 arg1 glycoproteins glycoproteins Fterm glycoproteins The characterization of glycans and glycosylation sites in glycoproteins from human clinical samples provides a basis for future studies addressing the biological and diagnostic importance of specific protein glycosylations in relation to human disease. 23234360 6 20 gly glycans 1202:1208 arg1 glycoproteins glycoproteins glycans Fterm glycoproteins The characterization of glycans and glycosylation sites in glycoproteins from human clinical samples provides a basis for future studies addressing the biological and diagnostic importance of specific protein glycosylations in relation to human disease. 23234360 6 43 gly glycosylation 1214:1226 arg2 glycosylation sites glycosylation sites sites The characterization of glycans and glycosylation sites in glycoproteins from human clinical samples provides a basis for future studies addressing the biological and diagnostic importance of specific protein glycosylations in relation to human disease. 10191360 6 30 part_of channel 1093:1099 arg1 K+ channel polypeptides channel K+ channel polypeptides Fterm Site channel polypeptides The extent of processing of N-linked chains on Kv1.1 and Kv1.2 but not Kv1.4 channels expressed in transfected cells differs from that seen for native brain channels, reflecting the different efficiencies of transport of K+ channel polypeptides from the endoplasmic reticulum to the Golgi apparatus. 11263562 3 18 gly glycopeptides 701:713 arg2 only glycopeptides only glycopeptides glycopeptides Both glycopeptides and peptides were eluted with trifluoroacetic acid as the eluent, whereas only glycopeptides were eluted selectively with ammonium acetate in the following order: N38, N24, 0126, and N83. 11263562 3 62 gly eluted 640:645 arg1 N83 N83 N83 Both glycopeptides and peptides were eluted with trifluoroacetic acid as the eluent, whereas only glycopeptides were eluted selectively with ammonium acetate in the following order: N38, N24, 0126, and N83. 11263562 3 1 gly glycopeptides 608:620 arg2 glycopeptides glycopeptides and peptides glycopeptides and peptides Both glycopeptides and peptides were eluted with trifluoroacetic acid as the eluent, whereas only glycopeptides were eluted selectively with ammonium acetate in the following order: N38, N24, 0126, and N83. 11263562 3 62 gly eluted 640:645 arg1 N24 N38, N24 N38, N24 Both glycopeptides and peptides were eluted with trifluoroacetic acid as the eluent, whereas only glycopeptides were eluted selectively with ammonium acetate in the following order: N38, N24, 0126, and N83. 18623533 3 22 gly fucosylated 742:752 arg1 3 3 Complex biantennary oligosaccharides (particularly Gal(2)GlcNAc(4)Man(3) which was core alephl-6 fucosylated at Asn(25) but not at Asng(97)) were most prevalent at both glycosylation sites. 18623533 3 22 gly fucosylated 742:752 arg1 Gal(2)GlcNAc(4)Man Gal(2)GlcNAc(4)Man Complex biantennary oligosaccharides (particularly Gal(2)GlcNAc(4)Man(3) which was core alephl-6 fucosylated at Asn(25) but not at Asng(97)) were most prevalent at both glycosylation sites. 18623533 3 71 gly glycosylation 814:826 arg2 both glycosylation sites both glycosylation sites sites Complex biantennary oligosaccharides (particularly Gal(2)GlcNAc(4)Man(3) which was core alephl-6 fucosylated at Asn(25) but not at Asng(97)) were most prevalent at both glycosylation sites. 2457922 6 57 part_of cDNA 1285:1288 arg1 the 3' region BGP I cDNA the 3' region PUBTATOR Site BGP I cDNA 634 region Beyond nucleotide position 1375 the 3' region of the BGP I cDNA was found to be specific for BGP I. Hybridization of a probe from this region to electrophoretic blots of RNAs from different human tissues showed a predominant 2.8-kilobase (kb) message accompanied by weaker bands 4.1 and 2.1 kb in size. 23046148 2 16 gly O-glycosylation 399:413 arg2 an O-glycosylation site an O-glycosylation site site To investigate O-glycan-mediated masking using an assay amenable to large-scale screens, we generated a fluorescent biosensor with an O-glycosylation site situated to mask a furin cleavage site. 21053369 2 84 gly glycosylated 326:337 arg1 a heterodimeric receptor a heterodimeric receptor Fterm receptor It signals through a heterodimeric receptor consisting of IL-23r, which is heavily glycosylated. 14693913 10 32 gly glycoproteins 2022:2034 arg1 glycoproteins glycoproteins Fterm glycoproteins This is the first report of the synthesis of beta-Man- and phosphate-containing O-linked constituents on glycoproteins synthesized by P. pastoris. 18790849 6 44 part_of site 948:951 arg1 KCNQ1 KCNQ1 site PUBTATOR Site KCNQ1 3784 site Elimination of the putative N289 glycosylation site in KCNQ1 reduced current density by approximately 56%. 8419363 5 71 gly N-glycosylation 1054:1068 arg2 N-glycosylation sites N-glycosylation sites sites Removal of sugar chains generally led to a reduction in the secretion of recombinant CBG, but complete removal of N-glycosylation sites did not prevent production or secretion of the protein. 10374967 4 15 gly N-glycosylation 620:634 arg2 an N-glycosylation site an N-glycosylation site site A conserved motif here has an N-glycosylation site and characteristics of a beta turn. 21829533 6 33 gly glycosylation 1268:1280 arg2 glycosylation site alteration glycosylation site alteration site The mechanisms and possibly biological functions of glycosylation site alteration for the evolution of influenza A/H1N1 viruses were also discussed. 10687132 1 3 part_of MUC1 142:145 arg1 MUC1 mucin peptides MUC1 mucin MUC1 mucin peptides PUBTATOR Site MUC1 mucin 4582 peptides MUC1 mucin peptides stimulated cytotoxic T lymphocytes (CTL) from humans with adenocarcinomas. 10687132 1 7 part_of mucin 147:151 arg1 MUC1 mucin peptides MUC1 mucin MUC1 mucin peptides PUBTATOR Site MUC1 mucin 4582 peptides MUC1 mucin peptides stimulated cytotoxic T lymphocytes (CTL) from humans with adenocarcinomas. 31731738 4 56 gly N-glycosylation 1074:1088 arg2 a unique N-glycosylation site a unique N-glycosylation site site In the present study, we further characterize ZIKV E proteins by investigating the roles of residues isoleucine 152 (Ile152), threonine 156 (Thr156), and histidine 158 (His158) (i.e., the E-152/156/158 residues), which surround a unique N-glycosylation site (E-154), in permissiveness of human host cells to epidemic ZIKV infection. 8286855 2 8 part_of site 556:559 arg1 GpA GpA site PUBTATOR Site GpA 2993 site We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site. 8286855 2 15 part_of sites 319:323 arg1 GpA GpA sites PUBTATOR Site GpA 2993 sites We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site. 8286855 2 19 part_of GpA 375:377 arg1 the extracellular domain GpA the extracellular domain PUBTATOR Site GpA 2993 domain We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site. 2825202 12 115 gly glycosylated 1900:1911 arg1 glycosylated pro-SAP-1 glycosylated pro-SAP-1 PUBTATOR AminoAcid SAP-1 22941 The value is close to the reported 70-kDa value for glycosylated pro-SAP-1. 7829269 2 1 gly glycosylation 619:631 arg2 the glycosylation site the glycosylation site site Elimination of the glycosylation site from the chimeric LL2 antibody was accomplished by an Asn to Gln mutation in the tri-acceptor site found in the light chain. 9677334 11 70 part_of TPO 1513:1515 arg1 the Arg10 and Arg17 residues TPO the Arg10 and Arg17 residues PUBTATOR AminoAcid TPO 7066 Arg10 and Arg17 residues Moreover we found that the Arg10 and Arg17 residues of TPO seem to be specific determinants for TPO/c-Mpl recognition. 9820847 4 17 part_of proteins 730:737 arg1 the sequences proteins the sequences Fterm Site proteins sequences Comparison of the deduced amino acid sequence of ID 45/2 VP7 protein to the sequences of other VP7 proteins showed that the majority of the amino acid differences are clustered at the N-terminus (residues 1-49), with a positional shift of the initiation codons as well as possession of one stretch of hydrophobic signal peptide instead of two. 9820847 4 66 part_of protein 692:698 arg1 the deduced amino acid sequence protein the deduced amino acid sequence Fterm Site protein sequence Comparison of the deduced amino acid sequence of ID 45/2 VP7 protein to the sequences of other VP7 proteins showed that the majority of the amino acid differences are clustered at the N-terminus (residues 1-49), with a positional shift of the initiation codons as well as possession of one stretch of hydrophobic signal peptide instead of two. 12175915 3 75 part_of has 703:705 arg1 the human RFC protein AND 12 transmembrane domains the human RFC protein 12 transmembrane domains PUBTATOR Site RFC protein 6573 domains The primary amino acid sequence from the cloned cDNAs predicts that the human RFC protein has 12 transmembrane domains (TMDs) with a large cytosolic loop between TMDs 6 and 7, and cytosolic-facing N- and C-termini. 15582650 5 39 part_of CD4 967:969 arg1 the CD4 binding site CD4 the CD4 binding site OGER Site CD4 P01730 site A unique mutant designated 3G with mutations in three glycosylation motifs within the V3/C3 domains surrounding the CD4 binding site showed higher levels of binding to most broadly neutralizing Mabs (b12 and 2F5) in both insect and mammalian expression systems. 20235580 6 16 gly glycoproteins 1232:1244 arg1 glycoproteins glycoproteins Fterm glycoproteins The sensitivity of SPEG for detection of glycoproteins in depleted, non-fractionated plasma was found to be in the 10-100 pmol/mL range corresponding to glycoprotein levels ranging from 100's of nanograms/mL to 10's of micrograms/mL. 20235580 6 52 gly glycoprotein 1344:1355 arg1 glycoprotein levels glycoprotein levels Fterm glycoprotein The sensitivity of SPEG for detection of glycoproteins in depleted, non-fractionated plasma was found to be in the 10-100 pmol/mL range corresponding to glycoprotein levels ranging from 100's of nanograms/mL to 10's of micrograms/mL. 20660348 6 87 gly repeat 1068:1073 arg1 the signal peptide the signal peptide the signal peptide Site peptide Five additional single-nucleotide polymorphisms in the signal peptide and short consensus repeat 1 of Sle1c Crry were identified. 19808681 8 20 gly unglycosylated 1169:1182 arg1 the unglycosylated Kv12.2 channels the unglycosylated Kv12.2 channels PUBTATOR Kv12.2 channels 23416 We next examined the trafficking in CHO cells to address whether the unglycosylated Kv12.2 channels are utilized in vivo. 1970443 12 39 gly glycosylation 1932:1944 arg2 Five potential asparagine-linked glycosylation sites Five potential asparagine-linked glycosylation sites sites Five potential asparagine-linked glycosylation sites were identified in the SR-11 G1 coding sequences, four of which were conserved between Hantaan and SR-11 viruses and three of which were conserved among all three viruses. 15811651 7 69 gly glycosylated 1134:1145 arg2 position 66 position 66 position 66 However, in the mutant which was glycosylated at position 66 only, E protein secretion was reduced to only 10% of the wild-type level. 1932748 1 13 gly glycoprotein 221:232 arg1 the platelet membrane glycoprotein IIb the platelet membrane glycoprotein IIb PUBTATOR platelet membrane glycoprotein IIb 3674 We have isolated from an HEL cell cDNA library an alternatively spliced transcript for the platelet membrane glycoprotein IIb (GPIIb) that resulted from the deletion of the 34 amino acids of exon 28 of the GPIIb gene. 15555933 9 47 gly glycosylation 1309:1321 arg2 the glycosylation site the glycosylation site site Near- and far-UV circular dichroism spectra of human umbilical cord blood AFP and rhAFP were essentially identical, suggesting that the structure is not affected by removal of the glycosylation site. 20348522 1 7 gly glycosylation 199:211 arg2 a glycosylation site a glycosylation site site Many West Nile (WN) virus isolates associated with significant outbreaks possess a glycosylation site on the envelope (E) protein. 23339644 3 36 gly glycoprotein 616:627 arg1 recombinant HIV-1 surface glycoprotein recombinant HIV-1 surface glycoprotein Fterm glycoprotein As part of our continuing effort in the analysis of glycosylation profiles of recombinant HIV-1 envelope-based immunogens, we evaluated and compared the host-cell specific glycosylation pattern of recombinant HIV-1 surface glycoprotein, gp120, derived from clade C transmitted/founder virus 1086.C expressed in Chinese hamster ovary (CHO) and human embryonic kidney containing T antigen (293T) cell lines. 23339644 3 36 gly glycoprotein 616:627 arg1 gp120 gp120 PUBTATOR gp120 155971 As part of our continuing effort in the analysis of glycosylation profiles of recombinant HIV-1 envelope-based immunogens, we evaluated and compared the host-cell specific glycosylation pattern of recombinant HIV-1 surface glycoprotein, gp120, derived from clade C transmitted/founder virus 1086.C expressed in Chinese hamster ovary (CHO) and human embryonic kidney containing T antigen (293T) cell lines. 23339644 3 50 gly glycosylation 565:577 arg1 recombinant HIV-1 surface glycoprotein recombinant HIV-1 surface glycoprotein Fterm glycoprotein As part of our continuing effort in the analysis of glycosylation profiles of recombinant HIV-1 envelope-based immunogens, we evaluated and compared the host-cell specific glycosylation pattern of recombinant HIV-1 surface glycoprotein, gp120, derived from clade C transmitted/founder virus 1086.C expressed in Chinese hamster ovary (CHO) and human embryonic kidney containing T antigen (293T) cell lines. 23339644 3 50 gly glycosylation 565:577 arg1 gp120 gp120 PUBTATOR gp120 155971 As part of our continuing effort in the analysis of glycosylation profiles of recombinant HIV-1 envelope-based immunogens, we evaluated and compared the host-cell specific glycosylation pattern of recombinant HIV-1 surface glycoprotein, gp120, derived from clade C transmitted/founder virus 1086.C expressed in Chinese hamster ovary (CHO) and human embryonic kidney containing T antigen (293T) cell lines. 7737160 10 72 gly carrying 1330:1337 arg1 the 19 amino-terminal residues AND the carbohydrate moiety the 19 amino-terminal residues the carbohydrate moiety residues Removal of the 19 amino-terminal residues carrying the carbohydrate moiety results in no change in the biological activity. 22213703 5 3 gly glycosylation 610:622 arg2 glycosylation sites sites the glycans sites Therefore, the profile of the glycans and glycosylation sites should be determined to produce safe, good quality, consistent mAb drugs for human use. 11390601 3 93 gly glycosylation 718:730 arg2 the glycosylation sites the glycosylation sites sites Of the glycosylation sites that were evaluated, those proximal to the V1/V2 loops (N135, N141, N156, N160) and the V3 loops (N301) of gp120 were functionally critical. 11390601 3 22 gly loops 787:791 arg1 N160 N135, N141, N156, N160 N135, N141, N156, N160 Of the glycosylation sites that were evaluated, those proximal to the V1/V2 loops (N135, N141, N156, N160) and the V3 loops (N301) of gp120 were functionally critical. 26035318 10 33 part_of gp120 1686:1690 arg1 the V1V2 and V4V5 gp120 regions V4V5 gp120 the V1V2 and V4V5 gp120 regions PUBTATOR Site V4V5 gp120 3700 regions CONCLUSION: Our observations are consistent with a structural association between the V1V2 and V4V5 gp120 regions that is lost following viral transmission. 26035318 10 82 part_of V4V5 1681:1684 arg1 the V1V2 and V4V5 gp120 regions V4V5 gp120 the V1V2 and V4V5 gp120 regions PUBTATOR Site V4V5 gp120 3700 regions CONCLUSION: Our observations are consistent with a structural association between the V1V2 and V4V5 gp120 regions that is lost following viral transmission. 23050552 7 62 gly O-glycopeptides 910:924 arg2 the generated O-glycopeptides the generated O-glycopeptides O-glycopeptides MS3 spectra of the generated O-glycopeptides showed cleavages of the peptide backbone and provided essential information on the peptide sequence. 8829802 4 24 gly glycosylation 706:718 arg2 the potential N-linked glycosylation site the potential N-linked glycosylation site site Rat transferrin, like other transferrins, had the potential N-linked glycosylation site only in the C-terminal domain, although lactoferrins characterized so far contained the glycosylation sites in both the N- and C-terminal domains. 8829802 4 46 gly glycosylation 813:825 arg2 the glycosylation sites the glycosylation sites sites Rat transferrin, like other transferrins, had the potential N-linked glycosylation site only in the C-terminal domain, although lactoferrins characterized so far contained the glycosylation sites in both the N- and C-terminal domains. 27266248 1 13 gly glycosylation 219:231 arg2 the glycosylation site the glycosylation site site A system for the production of mutant recombinant human alpha-fetoprotein (rhAFPO) lacking the glycosylation site has been engineered in the yeast Pichia pastoris. 30659065 1 17 gly glycoproteins 166:178 arg1 critical glycoproteins critical glycoproteins Fterm glycoproteins Antibodies are critical glycoproteins that bridge the innate and adaptive immune systems to provide protection against infection. 7781780 1 27 gly glycosylation 425:437 arg2 this glycosylation site this glycosylation site site A sialidase resistant mono-charged N-glycan was isolated from glycosylation site I (Asn-24) of recombinant human erythropoietin expressed from baby hamster kidney (BHK-21) cells and constituted approximately 2-4% of the oligosaccharide material at this glycosylation site. 7781780 1 7 gly glycosylation 234:246 arg1 recombinant human erythropoietin erythropoietin Asn-24 PUBTATOR erythropoietin 2056 Asn-24 A sialidase resistant mono-charged N-glycan was isolated from glycosylation site I (Asn-24) of recombinant human erythropoietin expressed from baby hamster kidney (BHK-21) cells and constituted approximately 2-4% of the oligosaccharide material at this glycosylation site. 7781780 1 7 gly glycosylation 234:246 arg1 recombinant human erythropoietin erythropoietin site PUBTATOR erythropoietin 2056 site A sialidase resistant mono-charged N-glycan was isolated from glycosylation site I (Asn-24) of recombinant human erythropoietin expressed from baby hamster kidney (BHK-21) cells and constituted approximately 2-4% of the oligosaccharide material at this glycosylation site. 2841801 4 59 gly glycoprotein 466:477 arg1 the fusion (F) glycoprotein the fusion (F) glycoprotein Fterm glycoprotein This was attributed to proteolytic activation of the fusion (F) glycoprotein of the host range mutants, in cell nonpermissive to wild-type virus. 17823199 3 87 gly N-glycosylation 586:600 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site Although the level of residual glycosylation activity is known to correlate with the clinical phenotype linked to individual CDG mutations, it is not known whether the degree of N-glycosylation site occupancy by itself correlates with the severity of the disease. 8029814 12 8 gly glycosylation 1661:1673 arg2 the putative glycosylation site the putative glycosylation site site The mouse protein S contains two potential N-glycosylation sites at positions #458 and 468 and is lacking the putative glycosylation site at #490 found in human protein S. 8029814 12 30 gly N-glycosylation 1585:1599 arg2 two potential N-glycosylation sites two potential N-glycosylation sites sites The mouse protein S contains two potential N-glycosylation sites at positions #458 and 468 and is lacking the putative glycosylation site at #490 found in human protein S. 17963278 2 41 gly glycoproteins 331:343 arg1 glycoproteins glycoproteins Fterm glycoproteins In this study, we isolated glycoproteins from the sera of three healthy individuals and three lung adenocarcinoma patients using multilectin affinity chromatography. 20084883 5 7 part_of sites 1399:1403 arg1 Fusion protein protein sites Fterm Site protein sites CONCLUSION: The F genes of measles virus of china in 2006 had no significant variation, the genetic diversity was not predominance comparing with strains of 1999-2003, and important functional sites in Fusion protein didn't change, the measles epidemic was not correlate with the F gene variation. 15737642 3 14 gly occupied 736:743 arg2 Four of five potential N-glycosylation sites Four of five potential N-glycosylation sites sites Four of five potential N-glycosylation sites were found to be occupied, and their biological function and secretion were inhibited with the treatment of N-glycosylation inhibitor, tunicamycin. 15737642 3 57 gly N-glycosylation 697:711 arg2 Four of five potential N-glycosylation sites Four of five potential N-glycosylation sites sites Four of five potential N-glycosylation sites were found to be occupied, and their biological function and secretion were inhibited with the treatment of N-glycosylation inhibitor, tunicamycin. 10992007 10 33 gly glycosylation 1671:1683 arg1 at least four sites at least four sites sites These data indicate that 1) TSHR ectodomain contains six N-linked carbohydrates, and 2) glycosylation of at least four sites appears necessary for expression of the functional TSHR. 10992007 10 16 gly contains 1627:1634 arg1 TSHR ectodomain AND six N-linked carbohydrates TSHR ectodomain six N-linked carbohydrates ectodomain These data indicate that 1) TSHR ectodomain contains six N-linked carbohydrates, and 2) glycosylation of at least four sites appears necessary for expression of the functional TSHR. 23001782 1 72 gly glycoprotein 195:206 arg1 Human sex hormone binding globulin Human sex hormone binding globulin PUBTATOR Human sex hormone binding globulin 6462 Human sex hormone binding globulin (hSHBG) is a serum glycoprotein central to the transport and targeted delivery of sex hormones to steroid-sensitive tissues. 23001782 1 72 gly glycoprotein 195:206 arg1 a serum glycoprotein a serum glycoprotein Fterm glycoprotein Human sex hormone binding globulin (hSHBG) is a serum glycoprotein central to the transport and targeted delivery of sex hormones to steroid-sensitive tissues. 10207016 2 49 gly N-glycosylated 340:353 arg1 the M protein M protein Asn-4 OGER M protein P54296 Asn-4 The pre-S2 domain, present only in M and L proteins, is further N-glycosylated at Asn-4 exclusively in the M protein. 10207016 2 49 gly N-glycosylated 340:353 arg1 the M protein M protein domain OGER M protein P54296 domain The pre-S2 domain, present only in M and L proteins, is further N-glycosylated at Asn-4 exclusively in the M protein. 10207016 2 49 gly N-glycosylated 340:353 arg2 The pre-S2 domain domain domain The pre-S2 domain, present only in M and L proteins, is further N-glycosylated at Asn-4 exclusively in the M protein. 10207016 2 49 gly N-glycosylated 340:353 arg2 The pre-S2 domain M protein domain OGER M protein P54296 domain The pre-S2 domain, present only in M and L proteins, is further N-glycosylated at Asn-4 exclusively in the M protein. 1385443 4 69 part_of containing 885:894 arg1 hGH-DAF fusion proteins AND COOH-terminal hydrophobic domain hGH-DAF fusion proteins COOH-terminal hydrophobic domain Fterm Site proteins domain Retention requires the presence of either a functional or a noncleavable GPI signal; hGH-DAF fusion proteins containing only the COOH-terminal hydrophobic domain (a component of the GPI signal) are secreted. 8349598 1 4 gly glycoprotein 286:297 arg1 the glycoprotein hormones lutropin and thyrotropin the glycoprotein hormones lutropin and thyrotropin Fterm glycoprotein Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 12 gly Asn-linked 155:164 arg1 Asn-linked oligosaccharides Asn Asn-linked oligosaccharides Asn Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 74 gly sequence 204:211 arg1 the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 61 gly present 271:277 arg1 pro-opiomelanocortin AND Asn-linked oligosaccharides thyrotropin pro Asn-linked oligosaccharides OGER thyrotropin pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg2 thyrotropin AND Asn-linked oligosaccharides thyrotropin Asn-linked oligosaccharides OGER thyrotropin Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg1 pro-opiomelanocortin AND Asn-linked oligosaccharides thyrotropin pro Asn-linked oligosaccharides OGER thyrotropin pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 61 gly present 271:277 arg1 tissue factor pathway inhibitor AND Asn-linked oligosaccharides tissue factor pathway inhibitor pro Asn-linked oligosaccharides OGER tissue factor pathway inhibitor P10646 pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 61 gly present 271:277 arg1 lutropin AND Asn-linked oligosaccharides lutropin pro Asn-linked oligosaccharides OGER lutropin pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg2 thyrotropin AND Asn-linked oligosaccharides thyrotropin pro Asn-linked oligosaccharides OGER thyrotropin pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg1 pro-opiomelanocortin AND Asn-linked oligosaccharides pro Asn-linked oligosaccharides pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg1 tissue factor pathway inhibitor AND Asn-linked oligosaccharides tissue factor pathway inhibitor pro Asn-linked oligosaccharides OGER tissue factor pathway inhibitor P10646 pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg1 lutropin AND Asn-linked oligosaccharides lutropin pro Asn-linked oligosaccharides OGER lutropin pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg1 pro-opiomelanocortin AND Asn-linked oligosaccharides tissue factor pathway inhibitor pro Asn-linked oligosaccharides OGER tissue factor pathway inhibitor P10646 pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg1 tissue factor pathway inhibitor AND Asn-linked oligosaccharides tissue factor pathway inhibitor Asn-linked oligosaccharides OGER tissue factor pathway inhibitor P10646 Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg1 pro-opiomelanocortin AND Asn-linked oligosaccharides lutropin pro Asn-linked oligosaccharides OGER lutropin pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg1 lutropin AND Asn-linked oligosaccharides lutropin Asn-linked oligosaccharides OGER lutropin Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg1 pro-opiomelanocortin AND Asn-linked oligosaccharides thyrotropin pro Asn-linked oligosaccharides OGER thyrotropin pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg1 tissue factor pathway inhibitor AND Asn-linked oligosaccharides tissue factor pathway inhibitor pro Asn-linked oligosaccharides OGER tissue factor pathway inhibitor P10646 pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 8349598 1 90 gly present 271:277 arg1 lutropin AND Asn-linked oligosaccharides lutropin pro Asn-linked oligosaccharides OGER lutropin pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 9620884 3 40 gly occupied 586:593 arg2 the four potential N-glycosylation consensus sequences the four potential N-glycosylation consensus sequences sequences Endoglycosidase treatment of the purified recombinant enzyme and mutagenesis studies indicated that three (Asn-139, Asn-192 and Asn-215) of the four potential N-glycosylation consensus sequences were occupied by complex, high-mannose and hybrid-type oligosaccharides respectively. 9620884 3 10 gly three 486:490 arg1 Asn-192 Asn-139, Asn-192 and Asn-215 Asn-139, Asn-192 and Asn-215 Endoglycosidase treatment of the purified recombinant enzyme and mutagenesis studies indicated that three (Asn-139, Asn-192 and Asn-215) of the four potential N-glycosylation consensus sequences were occupied by complex, high-mannose and hybrid-type oligosaccharides respectively. 9620884 3 10 gly three 486:490 arg1 Asn-139 Asn-139, Asn-192 and Asn-215 Asn-139, Asn-192 and Asn-215 Endoglycosidase treatment of the purified recombinant enzyme and mutagenesis studies indicated that three (Asn-139, Asn-192 and Asn-215) of the four potential N-glycosylation consensus sequences were occupied by complex, high-mannose and hybrid-type oligosaccharides respectively. 9620884 3 10 gly three 486:490 arg1 Asn-139 Asn-139, Asn-192 and Asn-215 Asn-139, Asn-192 and Asn-215 Endoglycosidase treatment of the purified recombinant enzyme and mutagenesis studies indicated that three (Asn-139, Asn-192 and Asn-215) of the four potential N-glycosylation consensus sequences were occupied by complex, high-mannose and hybrid-type oligosaccharides respectively. 22649382 5 43 gly N-glycosylation 857:871 arg2 Asn298 Asn298 Asn298 In contrast, the third N-glycosylation site (Asn298) decreased receptor maturation and stability. 22649382 5 43 gly N-glycosylation 857:871 arg2 the third N-glycosylation site the third N-glycosylation site site In contrast, the third N-glycosylation site (Asn298) decreased receptor maturation and stability. 22750213 5 14 gly glycosylation 837:849 arg2 the N-linked glycosylation site PRiMA site PUBTATOR PRiMA 170952 site By using site-directed mutagenesis, the asparagine-43 was identified to be the N-linked glycosylation site of PRiMA. 22750213 5 14 gly glycosylation 837:849 arg2 the asparagine-43 PRiMA asparagine-43 PUBTATOR PRiMA 170952 asparagine-43 By using site-directed mutagenesis, the asparagine-43 was identified to be the N-linked glycosylation site of PRiMA. 19277548 5 0 gly glycoproteins 922:934 arg1 isolated glycoproteins isolated glycoproteins Fterm glycoproteins This method is suitable for large scale analysis of glycoproteins as well as isolated glycoproteins and can be applied readily to a number of different samples. 19277548 5 43 gly glycoproteins 888:900 arg1 glycoproteins glycoproteins Fterm glycoproteins This method is suitable for large scale analysis of glycoproteins as well as isolated glycoproteins and can be applied readily to a number of different samples. 28630087 5 14 gly fucosylated 1044:1054 arg1 The equally unusual core fucosylated monoantenna complex-type N-sialoglycans The equally unusual core fucosylated monoantenna complex-type N-sialoglycans The equally unusual core fucosylated monoantenna complex-type N-sialoglycans also decorated these two fully occupied sites. 23296533 3 30 gly N-glycosylated 753:766 arg1 N-glycosylated peptides N-glycosylated peptides peptides Here, we describe a protocol for peptide-N-glycanase-mediated (18)O labeling of N-glycosylated peptides, termed "isotope-coded glycosylation site-specific tagging." 23613470 7 9 gly modified 995:1002 arg1 Wnt11 AND high-mannose(Asn90)- Wnt11 high-mannose(Asn90)- PUBTATOR Wnt11 7481 Mass-spectrometric analyses revealed that Wnt11 is modified with complex/hybrid(Asn40)-, high-mannose(Asn90)- and high-mannose/hybrid(Asn300)-type glycans and that Wnt3a is modified with two high-mannose-type glycans (Asn87 and Asn298). 23613470 7 9 gly modified 995:1002 arg3 Wnt11 AND high-mannose/hybrid(Asn300)-type glycans Wnt11 high-mannose/hybrid(Asn300)-type glycans PUBTATOR Wnt11 7481 Mass-spectrometric analyses revealed that Wnt11 is modified with complex/hybrid(Asn40)-, high-mannose(Asn90)- and high-mannose/hybrid(Asn300)-type glycans and that Wnt3a is modified with two high-mannose-type glycans (Asn87 and Asn298). 23613470 7 40 gly modified 1117:1124 arg1 Wnt3a AND two high-mannose-type glycans Wnt3a two high-mannose-type glycans PUBTATOR Wnt3a 89780 Mass-spectrometric analyses revealed that Wnt11 is modified with complex/hybrid(Asn40)-, high-mannose(Asn90)- and high-mannose/hybrid(Asn300)-type glycans and that Wnt3a is modified with two high-mannose-type glycans (Asn87 and Asn298). 23613470 7 38 gly glycans 1153:1159 arg1 Asn87 Asn87 and Asn298 Asn87 and Asn298 Mass-spectrometric analyses revealed that Wnt11 is modified with complex/hybrid(Asn40)-, high-mannose(Asn90)- and high-mannose/hybrid(Asn300)-type glycans and that Wnt3a is modified with two high-mannose-type glycans (Asn87 and Asn298). 18420581 1 16 gly glycosylation 282:294 arg2 the unique N-linked glycosylation site the unique N-linked glycosylation site site To resolve primary (glycosylation-assisted) from secondary (glycosylation-independent) quality control steps in the biosynthesis of HLA (human leukocyte antigen) class I glycoproteins, the unique N-linked glycosylation site of the HLA-Cw1 heavy chain was deleted by site-directed mutagenesis. 18420581 1 86 gly glycoproteins 247:259 arg1 HLA (human leukocyte antigen) class I glycoproteins HLA (human leukocyte antigen) class I glycoproteins Fterm glycoproteins To resolve primary (glycosylation-assisted) from secondary (glycosylation-independent) quality control steps in the biosynthesis of HLA (human leukocyte antigen) class I glycoproteins, the unique N-linked glycosylation site of the HLA-Cw1 heavy chain was deleted by site-directed mutagenesis. 6192439 2 18 part_of DNA 339:341 arg1 a cloned genomic DNA fragment DNA a cloned genomic DNA fragment Cterm Site DNA fragment Analysis of three overlapping cDNA clones revealed most of the nucleotide sequence of AFP mRNA, and the remaining nucleotides at the 5' end of the mRNA were elucidated from a cloned genomic DNA fragment. 8663003 9 62 part_of Rh 1413:1414 arg1 truncated Rh polypeptides Rh truncated Rh polypeptides Cterm Site Rh polypeptides These data indicate that the hypothesis that suggests Rh C/c antigens are expressed on truncated Rh polypeptides by a mechanism of alternate splicing is incorrect and support the hypothesis that Rh Cc and Ee antigens are expressed on a single polypeptide chain. 26773038 9 55 gly domain 1345:1350 arg1 Glycan stabilization domain Glycan stabilization domain Glycan stabilization of the VWF A2 domain acts together with the Ca(2+)binding site and vicinal cysteine disulfide bond to control unfolding and ADAMTS13 proteolysis. 10551860 10 91 gly N-glycosylation 1912:1926 arg2 an extra site an extra site site The HelB mutant retained about 20% of the cyclooxygenase activity of native oPGHS-1 and partitioned in subcellular fractions like native oPGHS-1; however, the HelB mutant exhibited an extra site of N-glycosylation at Asn(104). 17636988 0 29 gly O-glycosylation 94:108 arg2 O-glycosylation site O-glycosylation site site An enzymatic deglycosylation scheme enabling identification of core fucosylated N-glycans and O-glycosylation site mapping of human plasma proteins. 17636988 0 72 gly fucosylated 68:78 arg1 core fucosylated N-glycans core fucosylated N-glycans An enzymatic deglycosylation scheme enabling identification of core fucosylated N-glycans and O-glycosylation site mapping of human plasma proteins. 7737160 7 52 gly deglycosylated 870:883 arg1 the intact and deglycosylated protein the intact and deglycosylated protein Fterm protein Sequencing of the intact and deglycosylated protein show that the glycosylation site is at Thr8. 7737160 7 56 gly glycosylation 907:919 arg2 the glycosylation site the glycosylation site site Sequencing of the intact and deglycosylated protein show that the glycosylation site is at Thr8. 31577193 14 17 gly N-glycosylation 1670:1684 arg2 human and mouse N-glycosylation sites human and mouse N-glycosylation sites sites Applicability and success of our method was further evaluated using human and mouse N-glycosylation sites. 7711058 3 13 gly glycosylation 513:525 arg2 the two potential N-linked glycosylation sites the two potential N-linked glycosylation sites sites To study the role of glycosylation in maintaining enzymatic activity, we introduced mutations into the two potential N-linked glycosylation sites (asparagine-X-serine, residues 158-160 and 203-205) predicted from the rat cDNA sequence. 7711058 3 41 gly asparagine-X-serine 534:552 arg1 203-205 residues 158-160 and 203-205 residues 158-160 and 203-205 To study the role of glycosylation in maintaining enzymatic activity, we introduced mutations into the two potential N-linked glycosylation sites (asparagine-X-serine, residues 158-160 and 203-205) predicted from the rat cDNA sequence. 24257604 7 28 gly glycosylation 1258:1270 arg2 a glycosylation site a glycosylation site site We demonstrate that Israel810 HA can be cleaved in cells with high levels of furin expression and that a mutation that eliminates a glycosylation site in HA(1) allows the Israel810 HA to gain universal cleavage in cell culture. 11251288 10 83 gly glycoproteins 2085:2097 arg1 the purified glycoproteins the purified glycoproteins Fterm glycoproteins Dynamic light scattering analysis of the purified glycoproteins suggested that the glycoforms produced were monomeric and folded identically to the wild-type protein. 11238869 1 5 gly glycoprotein 181:192 arg1 The gp120 envelope glycoprotein The gp120 envelope glycoprotein Fterm glycoprotein The gp120 envelope glycoprotein of primary human immunodeficiency virus type 1 (HIV-1) promotes virus entry by sequentially binding CD4 and the CCR5 chemokine receptor on the target cell. 2302219 6 41 part_of site 844:847 arg1 mature SAP-1 SAP-1 site PUBTATOR Site SAP-1 Q9HD43 site This eliminated the only glycosylation site in mature SAP-1 and could explain the findings made at the protein level. 7711052 7 32 part_of activator 1645:1653 arg1 the kringle 2 domain tissue plasminogen activator the kringle 2 domain OGER Site tissue plasminogen activator P00750 domain The presence of an N-linked glycan (at Asn-184) in the kringle 2 domain of tissue plasminogen activator hinders the rearrangement of this ternary complex, decreasing the turnover rate (Kcat). 9804815 10 9 gly glycosylation 1518:1530 arg1 MUC1 MUC1 PUBTATOR MUC1 4582 The function of GalNAc-T4 complements other GalNAc-transferases in O-glycosylation of MUC1 showing that glycosylation of MUC1 is a highly ordered process and changes in the repertoire or topology of GalNAc-transferases will result in altered pattern of O-glycan attachments. 9804815 10 41 gly O-glycosylation 1481:1495 arg1 MUC1 MUC1 PUBTATOR MUC1 4582 The function of GalNAc-T4 complements other GalNAc-transferases in O-glycosylation of MUC1 showing that glycosylation of MUC1 is a highly ordered process and changes in the repertoire or topology of GalNAc-transferases will result in altered pattern of O-glycan attachments. 11231274 5 8 gly siglec-8 953:960 arg1 the glycan composition siglec-8 the glycan composition OGER siglec-8 Q9NYZ4 To determine any differences in the glycan composition of siglec-5, siglec-7 and siglec-8 that may modify their function, we released and characterized the N-linked oligosaccharide distribution in these three glycoproteins. 11231274 5 30 gly siglec-7 940:947 arg1 the glycan composition siglec-7 the glycan composition OGER siglec-7 Q9Y286 To determine any differences in the glycan composition of siglec-5, siglec-7 and siglec-8 that may modify their function, we released and characterized the N-linked oligosaccharide distribution in these three glycoproteins. 11231274 5 58 gly glycoproteins 1081:1093 arg1 these three glycoproteins these three glycoproteins Fterm glycoproteins To determine any differences in the glycan composition of siglec-5, siglec-7 and siglec-8 that may modify their function, we released and characterized the N-linked oligosaccharide distribution in these three glycoproteins. 11231274 5 65 gly siglec-5 930:937 arg1 the glycan composition siglec-5 the glycan composition OGER siglec-5 O15389 To determine any differences in the glycan composition of siglec-5, siglec-7 and siglec-8 that may modify their function, we released and characterized the N-linked oligosaccharide distribution in these three glycoproteins. 16461214 5 52 gly glycosylation 1087:1099 arg2 a novel N-linked glycosylation site a novel N-linked glycosylation site site Several core promoter mutants were defective in virion secretion, and mapping experiments revealed three missense mutations in the small envelope protein to be responsible: I110M, G119E, and R169P The effect of I110M and G119E mutations can be relieved by another point mutation that creates a novel N-linked glycosylation site. 18371209 15 126 gly glycosylation 2394:2406 arg2 a glycosylation site a glycosylation site site In addition, our results point to the importance of a glycosylation site within the gp120 V2 region for efficient DC-SIGN use of HIV-1 R5 viruses. 12954207 11 82 part_of regions 1895:1901 arg1 gp120 gp120 regions PUBTATOR Site gp120 155971 regions Thus, carbohydrates that flank receptor-binding regions on gp120 protect primary HIV-1 isolates from antibody-mediated neutralization. 12954207 11 97 part_of receptor-binding 1878:1893 arg1 receptor-binding regions receptor receptor-binding regions Fterm Site receptor regions Thus, carbohydrates that flank receptor-binding regions on gp120 protect primary HIV-1 isolates from antibody-mediated neutralization. 10318794 5 32 gly glycosylation 967:979 arg2 residues 53-55 (N53SS) or 55-57 (N55QS) residues 53-55 (N53SS) or 55-57 (N55QS) residues 53-55 To determine which of these two models is correct, we generated two G6PT mutants, T53N and S55N, that created a potential Asn-linked glycosylation site at residues 53-55 (N53SS) or 55-57 (N55QS), respectively. 10318794 5 32 gly glycosylation 967:979 arg2 a potential Asn-linked glycosylation site a potential Asn-linked glycosylation site site To determine which of these two models is correct, we generated two G6PT mutants, T53N and S55N, that created a potential Asn-linked glycosylation site at residues 53-55 (N53SS) or 55-57 (N55QS), respectively. 10318794 5 62 gly residues 989:996 arg1 53-55 53-55 residues 53-55 To determine which of these two models is correct, we generated two G6PT mutants, T53N and S55N, that created a potential Asn-linked glycosylation site at residues 53-55 (N53SS) or 55-57 (N55QS), respectively. 24923165 8 39 gly glycosylation 1274:1286 arg2 glycosylation site deletion glycosylation site deletion site Overall, the wild-type measles virus genotype circulating in Henan Province from 2008 to 2012 was H1a, with high homology between strains; there were some variations in amino acid sequences, resulting in glycosylation site deletion. 9210490 0 48 gly N-glycosylation 16:30 arg1 the membrane glycoprotein dipeptidylpeptidase IV the membrane glycoprotein dipeptidylpeptidase IV PUBTATOR dipeptidylpeptidase IV 25253 Domain-specific N-glycosylation of the membrane glycoprotein dipeptidylpeptidase IV (CD26) influences its subcellular trafficking, biological stability, enzyme activity and protein folding. 9210490 0 48 gly N-glycosylation 16:30 arg1 CD26 CD26 PUBTATOR CD26 25253 Domain-specific N-glycosylation of the membrane glycoprotein dipeptidylpeptidase IV (CD26) influences its subcellular trafficking, biological stability, enzyme activity and protein folding. 9210490 0 63 gly glycoprotein 48:59 arg1 the membrane glycoprotein dipeptidylpeptidase IV the membrane glycoprotein dipeptidylpeptidase IV Fterm glycoprotein Domain-specific N-glycosylation of the membrane glycoprotein dipeptidylpeptidase IV (CD26) influences its subcellular trafficking, biological stability, enzyme activity and protein folding. 23326351 5 52 gly gp120 965:969 arg1 the glycan-rich outer domain gp120 the glycan-rich outer domain PUBTATOR gp120 3700 The sera contained different neutralizing activities dependent on C3 and V5, C3 and V4, or V4 regions located on the glycan-rich outer domain of gp120. 9008840 2 66 gly N-glycosylation 398:412 arg2 a single N-glycosylation site a single N-glycosylation site site The peptide chain of Gp21 contains a single N-glycosylation site to which a diantennary oligosaccharide is attached. 9008840 2 94 gly attached 461:468 arg1 a single N-glycosylation site AND a diantennary oligosaccharide a single N-glycosylation site a diantennary oligosaccharide site The peptide chain of Gp21 contains a single N-glycosylation site to which a diantennary oligosaccharide is attached. 1847449 2 11 gly chain 426:430 arg1 the cleavage site the cleavage site the cleavage site Site site Two structural features are involved in the cleavage of avian influenza A virus HAs: a series of basic amino acids at the cleavage site and an oligosaccharide side chain in the near vicinity. 1847449 2 79 gly site 393:396 arg1 an oligosaccharide side chain site an oligosaccharide side chain site Two structural features are involved in the cleavage of avian influenza A virus HAs: a series of basic amino acids at the cleavage site and an oligosaccharide side chain in the near vicinity. 8892291 5 53 part_of contained 657:665 arg1 The predicted amino acid sequence AND one N-glycosylation site The predicted amino acid sequence one N-glycosylation site site The predicted amino acid sequence contained one N-glycosylation site, but lacked hydrophobic membrane spanning regions. 18642129 7 11 gly sialylated 1136:1145 arg1 triantennary sialylated glycans triantennary sialylated glycans LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans. 18642129 7 20 gly N-glycosylated 1081:1094 arg1 heavy chain chain OGER chain P08709 LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans. 20067810 2 20 part_of contains 347:354 arg1 This protein AND only one potential asparagine-linked glycosylation site This protein only one potential asparagine-linked glycosylation site Fterm Site protein site This protein contains only one potential asparagine-linked glycosylation site, which is partially (10-30%) occupied when the protein is synthesized in eukaryotic cells. 16372382 14 60 part_of rhTSH 2216:2220 arg1 Asn-alpha52 rhTSH Asn-alpha52 Cterm AminoAcid rhTSH Asn These data demonstrate site-specificity of glycosylation in the alpha subunit but not in the beta subunit of rhTSH with Asn-alpha52 bearing essentially di- and triantennary glycans with or without core fucosylation and bi- and triantennary glycans with no core fucosylation being attached to Asn-alpha78. 16372382 14 82 part_of site-specificity 2130:2145 arg1 the beta subunit subunit site-specificity Fterm Site subunit site-specificity These data demonstrate site-specificity of glycosylation in the alpha subunit but not in the beta subunit of rhTSH with Asn-alpha52 bearing essentially di- and triantennary glycans with or without core fucosylation and bi- and triantennary glycans with no core fucosylation being attached to Asn-alpha78. 29109276 1 5 gly glycoprotein 207:218 arg1 the hemagglutinin (HA) glycoprotein the hemagglutinin (HA) glycoprotein Fterm glycoprotein H3N2 viruses continuously acquire mutations in the hemagglutinin (HA) glycoprotein that abrogate binding of human antibodies. 15128311 3 5 gly glycoprotein 285:296 arg1 A new glycoprotein A new glycoprotein Fterm glycoprotein A new glycoprotein was isolated from the venom of the Thai cobra Naja kaouthia. 18642129 11 45 gly difucosylated 1589:1601 arg1 triantennary difucosylated structures triantennary difucosylated structures Glycan sequencing using different glycanases led to the identification of triantennary difucosylated structures. 8327483 2 33 gly N-glycosylation 412:426 arg2 one potential N-glycosylation site one potential N-glycosylation site site The precursor of rainbow trout TSH beta consists of 147 aa, which can be cleaved into a signal peptide (20 aa) and a mature protein (127 aa) containing one potential N-glycosylation site and 12 cysteine residues. 15247302 12 25 gly utilized 1837:1844 arg2 this third site this third site site Nor is this third site found in rodents, which are frequently utilized as animal models. 27381217 0 10 gly glycosylation 66:78 arg2 residue 133 residue 133 residue 133 The S128N mutation combined with an additional potential N-linked glycosylation site at residue 133 in hemagglutinin affects the antigenicity of the human H7N9 virus. 27381217 0 10 gly glycosylation 66:78 arg2 an additional potential N-linked glycosylation site an additional potential N-linked glycosylation site site The S128N mutation combined with an additional potential N-linked glycosylation site at residue 133 in hemagglutinin affects the antigenicity of the human H7N9 virus. 11303872 1 13 gly glycosylation 188:200 arg2 eight sites eight sites sites The synthesis of a 93-residue chemokine, lymphotactin, containing eight sites of O-linked glycosylation, was achieved using the technique of native chemical ligation. 7535613 12 79 part_of serine 1800:1805 arg1 trypsin trypsin serine Fterm AminoAcid trypsin serine The bottom of the substrate specificity pocket, residue S1, is a serine (Ser 189) as in chymotrypsin, rather than aspartate (Asp 189) as in tonin, kallikrein, and trypsin. 7535613 12 79 part_of serine 1800:1805 arg1 kallikrein kallikrein serine PUBTATOR AminoAcid kallikrein 9622 serine The bottom of the substrate specificity pocket, residue S1, is a serine (Ser 189) as in chymotrypsin, rather than aspartate (Asp 189) as in tonin, kallikrein, and trypsin. 7535613 12 79 part_of serine 1800:1805 arg1 chymotrypsin chymotrypsin serine Fterm AminoAcid chymotrypsin serine The bottom of the substrate specificity pocket, residue S1, is a serine (Ser 189) as in chymotrypsin, rather than aspartate (Asp 189) as in tonin, kallikrein, and trypsin. 10424400 3 35 gly N-glycosylation 693:707 arg2 an additional N-glycosylation site an additional N-glycosylation site site A variant SHBG with a point mutation in exon 8, causing an aminoacid substitution (Asp 327-->Asn) and thus, the introduction of an additional N-glycosylation site, has been reported. 12069081 4 6 part_of VEGF 601:604 arg1 the sequences VEGF the sequences PUBTATOR Site VEGF 7422 sequences The predicted fVEGF amino acid sequence shared 98.4, 94.2 and 94.2% homology with the sequences of canine, bovine and human VEGF, respectively. 12069081 4 26 part_of fVEGF 491:495 arg1 The predicted fVEGF amino acid sequence fVEGF The predicted fVEGF amino acid sequence Cterm Site fVEGF 7422 sequence The predicted fVEGF amino acid sequence shared 98.4, 94.2 and 94.2% homology with the sequences of canine, bovine and human VEGF, respectively. 18404400 4 53 gly glycosylation 745:757 arg2 an invariant glycosylation site an invariant glycosylation site site This conserved lysine is located between apyrase conserved region 1 (ACR1) and an invariant glycosylation site (N81), in a region previously hypothesized to be important for NTPDase3 oligomeric structure. 18404400 4 53 gly glycosylation 745:757 arg2 N81 N81 N81 This conserved lysine is located between apyrase conserved region 1 (ACR1) and an invariant glycosylation site (N81), in a region previously hypothesized to be important for NTPDase3 oligomeric structure. 2571506 5 57 gly glycosylation 804:816 arg2 Asn 58 Asn 58 Asn 58 The VH441 gene segment and all seven mAb contain a potential glycosylation site at Asn 58 in complementarity-determining region (CDR)2. 2571506 5 57 gly glycosylation 804:816 arg2 a potential glycosylation site a potential glycosylation site site The VH441 gene segment and all seven mAb contain a potential glycosylation site at Asn 58 in complementarity-determining region (CDR)2. 11738084 4 19 gly disialylated 573:584 arg1 a disialylated biantennary complex type oligosaccharide a disialylated biantennary complex type oligosaccharide The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn. 11738084 4 19 gly disialylated 573:584 arg1 The glycan The glycan The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn. 24164424 9 18 part_of CNGA1 1538:1542 arg1 the bovine CNGA1 site CNGA1 the bovine CNGA1 site PUBTATOR Site CNGA1 281700 site Glycosylation at the site found in CNGA3 subunits was found to be protective, while glycosylation at the bovine CNGA1 site was not. 24164424 9 52 part_of found 1452:1456 arg2 CNGA3 subunits AND the site CNGA3 subunits the site PUBTATOR Site CNGA3 subunits 281701 site Glycosylation at the site found in CNGA3 subunits was found to be protective, while glycosylation at the bovine CNGA1 site was not. 11122377 6 48 part_of P 832:832 arg1 the mammalian selenoprotein P sequences selenoprotein P the mammalian selenoprotein P sequences PUBTATOR Site selenoprotein P 6414 sequences Two histidine-rich regions present in the mammalian selenoprotein P sequences are conserved in the zebrafish protein, and two SECIS elements are present in the 3' untranslated region. 11122377 6 66 part_of selenoprotein 818:830 arg1 the mammalian selenoprotein P sequences selenoprotein P the mammalian selenoprotein P sequences PUBTATOR Site selenoprotein P 6414 sequences Two histidine-rich regions present in the mammalian selenoprotein P sequences are conserved in the zebrafish protein, and two SECIS elements are present in the 3' untranslated region. 18308854 7 5 gly utilized 1434:1441 arg2 the potential glycosylation site the potential glycosylation site site These studies revealed that oatp1a1 is a 12-transmembrane-domain protein in which the second and fifth extracellular loops are glycosylated at asparagines 124, 135, and 492, whereas the potential glycosylation site at asparagine 62 is not utilized, consistent with its position in a transmembrane domain. 18308854 7 5 gly utilized 1434:1441 arg2 asparagine 62 asparagine 62 asparagine 62 These studies revealed that oatp1a1 is a 12-transmembrane-domain protein in which the second and fifth extracellular loops are glycosylated at asparagines 124, 135, and 492, whereas the potential glycosylation site at asparagine 62 is not utilized, consistent with its position in a transmembrane domain. 18308854 7 58 gly glycosylation 1391:1403 arg2 the potential glycosylation site the potential glycosylation site site These studies revealed that oatp1a1 is a 12-transmembrane-domain protein in which the second and fifth extracellular loops are glycosylated at asparagines 124, 135, and 492, whereas the potential glycosylation site at asparagine 62 is not utilized, consistent with its position in a transmembrane domain. 18308854 7 58 gly glycosylation 1391:1403 arg2 asparagine 62 asparagine 62 asparagine 62 These studies revealed that oatp1a1 is a 12-transmembrane-domain protein in which the second and fifth extracellular loops are glycosylated at asparagines 124, 135, and 492, whereas the potential glycosylation site at asparagine 62 is not utilized, consistent with its position in a transmembrane domain. 18308854 7 69 gly glycosylated 1322:1333 arg2 asparagines 124, 135, and 492 protein asparagines 124, 135, and 492 Fterm protein asparagines 124, 135, and 492 These studies revealed that oatp1a1 is a 12-transmembrane-domain protein in which the second and fifth extracellular loops are glycosylated at asparagines 124, 135, and 492, whereas the potential glycosylation site at asparagine 62 is not utilized, consistent with its position in a transmembrane domain. 18790849 0 33 part_of channels 65:72 arg1 the turret and pore-loop domains channels the turret and pore-loop domains Fterm Site channels domains Determinants within the turret and pore-loop domains of KCNQ3 K+ channels governing functional activity. 2771955 6 46 part_of protein 1010:1016 arg1 a predicted protein sequence protein a predicted protein sequence Fterm Site protein sequence Translation of the cDNA sequence gives a predicted protein sequence beginning with a truncated putative signal sequence of 5 amino acid followed by a sequence of 17 amino acids matching that determined directly by Edman degradation of intact GPIX. 11741940 6 81 part_of sFRP-1 1131:1136 arg1 an NTR-type domain sFRP-1 domain PUBTATOR Site sFRP-1 6422 domain This latter set of assignments provides experimental verification of one of the disulfide patterns proposed for netrin (NTR) modules and thereby supports the prediction that the C-terminal heparin-binding domain of sFRP-1 is an NTR-type domain. 24475074 3 0 gly glycoproteins 657:669 arg1 glycoproteins glycoproteins Fterm glycoproteins Here we ask whether the natural tension between increasing diversity (glycan-protein interactions) and site multiplicity (backup and status quo) might be revealed by a phylogenic examination of glycoproteins and NXS/T(X ≠ P) N-glycosylation sites. 24475074 3 93 gly N-glycosylation 688:702 arg2 N-glycosylation sites N-glycosylation sites sites Here we ask whether the natural tension between increasing diversity (glycan-protein interactions) and site multiplicity (backup and status quo) might be revealed by a phylogenic examination of glycoproteins and NXS/T(X ≠ P) N-glycosylation sites. 24475074 3 99 gly examination 642:652 arg1 N-glycosylation sites N-glycosylation sites sites Here we ask whether the natural tension between increasing diversity (glycan-protein interactions) and site multiplicity (backup and status quo) might be revealed by a phylogenic examination of glycoproteins and NXS/T(X ≠ P) N-glycosylation sites. 15183061 5 25 gly glycoproteins 803:815 arg1 HIV-1 envelope glycoproteins HIV-1 envelope glycoproteins Fterm glycoproteins Mutation of the N-glycosylation site N11 in CXCR4 (N11Q-CXCR4) enhanced CD4-dependent binding of X4 and R5 gp120s and allowed more efficient entry of viruses pseudotyped with X4 or R5 HIV-1 envelope glycoproteins. 15183061 5 60 gly N-glycosylation 620:634 arg2 the N-glycosylation site N11 site N11 site N11 Mutation of the N-glycosylation site N11 in CXCR4 (N11Q-CXCR4) enhanced CD4-dependent binding of X4 and R5 gp120s and allowed more efficient entry of viruses pseudotyped with X4 or R5 HIV-1 envelope glycoproteins. 2040275 1 12 gly glycosylation 265:277 arg2 a single asparagine glycosylation site a single asparagine glycosylation site site 1H-NMR spectroscopy has been used to study the conformation and dynamics of the isolated tailpiece from human serum immunoglobulin M, a 22-residue peptide containing a single asparagine glycosylation site. 8884270 0 6 part_of site 51:54 arg1 fibrillin-1 fibrillin-1 site PUBTATOR Site fibrillin-1 2200 site A point mutation creating an extra N-glycosylation site in fibrillin-1 results in neonatal Marfan syndrome. 2457922 12 7 gly glycosylation 2435:2447 arg2 five glycosylation sites five glycosylation sites sites Protein structural analysis of BGP I isolated from human bile revealed a blocked N terminus, 129 amino acids of internal sequence that are in agreement with the translated cDNA sequence, and five glycosylation sites in the peptides sequenced. 2457922 12 7 gly glycosylation 2435:2447 arg1 internal sequence sequence sequence Protein structural analysis of BGP I isolated from human bile revealed a blocked N terminus, 129 amino acids of internal sequence that are in agreement with the translated cDNA sequence, and five glycosylation sites in the peptides sequenced. 25485983 4 30 part_of antithrombin 637:648 arg1 this defective glycosylation site antithrombin this defective glycosylation site PUBTATOR Site antithrombin 462 site We evaluated the effect of the aromatic sequon in this defective glycosylation site of antithrombin, despite of being located in a loop between the helix D and the strand 2A. 24475074 9 52 part_of sites 1726:1730 arg1 proteins proteins sites Fterm AminoAcid proteins Lys sites An examination of acetyl-Lys sites in proteins indicated similar evolutionary dynamics, consistent with asymmetry of the target and recognition portions of modified sites. 19276077 0 0 part_of subunit 76:82 arg1 the beta-propeller domain integrin alpha5 subunit the beta-propeller domain PUBTATOR Site integrin alpha5 subunit 3678 domain An N-glycosylation site on the beta-propeller domain of the integrin alpha5 subunit plays key roles in both its function and site-specific modification by beta1,4-N-acetylglucosaminyltransferase III. 19276077 0 1 part_of site 19:22 arg1 the integrin alpha5 subunit integrin alpha5 subunit site PUBTATOR Site integrin alpha5 subunit 3678 site An N-glycosylation site on the beta-propeller domain of the integrin alpha5 subunit plays key roles in both its function and site-specific modification by beta1,4-N-acetylglucosaminyltransferase III. 2477364 12 84 part_of sites 1782:1786 arg1 wild-type and mutant monomeric alpha subunits subunits sites Fterm Site subunits sites Both sites are processed independently because no significant differences were observed between the oligosaccharides at the same sites in wild-type and mutant monomeric alpha subunits. 15514484 4 53 gly glycosylation 894:906 arg2 glycosylation site glycosylation site site Using these N-glycosylated calcitonin derivatives, the effect of carbohydrate structure and glycosylation site on the three-dimensional structure and the biological activity of the peptide were studied. 7499346 2 23 gly glycosylation 550:562 arg2 a functional glycosylation site a functional glycosylation site site To investigate the function of asparagine-linked carbohydrates in neutrophil serine proteases, we constructed a mutant cDNA, coding for human cathepsin G deficient of a functional glycosylation site, for use in a transgenic cellular model. 7499346 2 35 gly asparagine-linked 401:417 arg1 asparagine-linked carbohydrates asparagine asparagine-linked carbohydrates asparagine To investigate the function of asparagine-linked carbohydrates in neutrophil serine proteases, we constructed a mutant cDNA, coding for human cathepsin G deficient of a functional glycosylation site, for use in a transgenic cellular model. 16476981 3 31 gly V3 579:580 arg1 N-linked glycosylation motifs N-linked glycosylation motifs motifs All reported sequences using CCR5 or CXCR4 exclusively, or using both, were gathered from the Los Alamos HIV Database and analysed with regard to the V3 N-linked glycosylation motifs (sequons) and charge. 16476981 3 40 gly glycosylation 591:603 arg2 N-linked glycosylation motifs motifs motifs All reported sequences using CCR5 or CXCR4 exclusively, or using both, were gathered from the Los Alamos HIV Database and analysed with regard to the V3 N-linked glycosylation motifs (sequons) and charge. 9658108 4 62 gly glycoprotein 807:818 arg1 a 359-amino-acid glycoprotein a 359-amino-acid glycoprotein Fterm glycoprotein Nucleotide sequence analysis revealed that the amplified liver and kidney huHAVcr-1 cDNAs were identical and that they coded for a 359-amino-acid glycoprotein, termed huhavcr-1, which was approximately 79% identical to havcr-1. 2911604 5 12 gly N-glycosylation 1118:1132 arg2 a consensus N-glycosylation site a consensus N-glycosylation site site The 105 amino acid segment that distinguishes the two forms of atrial PAM contains a consensus N-glycosylation site and a paired basic amino acid site of potential importance in endoproteolytic processing. 12706816 3 28 part_of has 514:516 arg1 the CLN3 protein AND five to seven membrane-spanning domains the CLN3 protein five to seven membrane-spanning domains PUBTATOR Site CLN3 protein Q13286 domains Protein secondary structure prediction programs suggest that the CLN3 protein has five to seven membrane-spanning domains (MSDs). 21637915 5 62 gly N-glycosylation 652:666 arg2 a putative N-glycosylation site sequence site sequence site sequence Only the second peptide (emp#2), which contains a putative N-glycosylation site sequence, inhibited emmprin-stimulated production of MMP-2 in co-cultures of fibroblasts and several different human tumor cells types, including carcinoma, sarcoma, melanoma, leukemia and glioma cells. 11361003 9 49 gly desialylated 1563:1574 arg1 all desialylated and N-deglycosylated TfR variants all desialylated and N-deglycosylated TfR variants PUBTATOR TfR variants 7037 In contrast to the parameters described above, all desialylated and N-deglycosylated TfR variants had exactly the same transferrin binding properties as the native TfR. 11361003 9 53 gly N-deglycosylated 1580:1595 arg1 all desialylated and N-deglycosylated TfR variants all desialylated and N-deglycosylated TfR variants PUBTATOR TfR variants 7037 In contrast to the parameters described above, all desialylated and N-deglycosylated TfR variants had exactly the same transferrin binding properties as the native TfR. 17606981 2 18 gly glycans 292:298 arg1 many glycoproteins glycoproteins glycans Fterm glycoproteins These changes have been considered to be general cellular events that affect many glycans on many glycoproteins. 17606981 2 48 gly glycoproteins 308:320 arg1 many glycoproteins many glycoproteins Fterm glycoproteins These changes have been considered to be general cellular events that affect many glycans on many glycoproteins. 19065542 9 43 gly glycopeptides 1297:1309 arg2 several tryptic glycopeptides several tryptic glycopeptides glycopeptides This is demonstrated here with several tryptic glycopeptides. 27259237 7 49 gly N-glycosylation 938:952 arg2 the initially identified N-glycosylation sites the initially identified N-glycosylation sites sites The optimized workflow yielded 80% of the initially identified N-glycosylation sites with considerably less effort. 27314333 3 15 part_of TSR1 500:503 arg1 a thrombospondin type 1 (TSR1) domain TSR1 a thrombospondin type 1 (TSR1) domain PUBTATOR Site TSR1 55720 domain All Rspo proteins feature two amino-terminal furin-like repeats, which are responsible for Wnt signal potentiation, and a thrombospondin type 1 (TSR1) domain that can provide affinity towards heparan sulfate proteoglycans. 27314333 3 20 part_of type 492:495 arg1 a thrombospondin type 1 (TSR1) domain thrombospondin type 1 a thrombospondin type 1 (TSR1) domain OGER Site thrombospondin type 1 P07996 domain All Rspo proteins feature two amino-terminal furin-like repeats, which are responsible for Wnt signal potentiation, and a thrombospondin type 1 (TSR1) domain that can provide affinity towards heparan sulfate proteoglycans. 27314333 3 79 part_of thrombospondin 477:490 arg1 a thrombospondin type 1 (TSR1) domain thrombospondin type 1 a thrombospondin type 1 (TSR1) domain OGER Site thrombospondin type 1 P07996 domain All Rspo proteins feature two amino-terminal furin-like repeats, which are responsible for Wnt signal potentiation, and a thrombospondin type 1 (TSR1) domain that can provide affinity towards heparan sulfate proteoglycans. 24931470 4 20 part_of gp120 652:656 arg1 the gp120 inner domain gp120 the gp120 inner domain PUBTATOR Site gp120 3700 domain CD4 activation induces the reorganization of bridging sheet elements, V1/V2 and V3, much of the gp120 inner domain, and the gp41 fusion subunit. 24884609 6 60 part_of trypsin-GluC 890:901 arg1 ITIH4 trypsin-GluC glycopeptides GluC ITIH4 trypsin-GluC glycopeptides PUBTATOR Site GluC 57733 glycopeptides Next, we performed glycosidase-assisted LC-MS/MS analysis of ITIH4 trypsin-GluC glycopeptides enriched via hydrophilic interaction liquid chromatography to characterize ITIH4 N-glycoforms. 24884609 6 67 part_of ITIH4 884:888 arg1 ITIH4 trypsin-GluC glycopeptides ITIH4 ITIH4 trypsin-GluC glycopeptides PUBTATOR Site ITIH4 3700 glycopeptides Next, we performed glycosidase-assisted LC-MS/MS analysis of ITIH4 trypsin-GluC glycopeptides enriched via hydrophilic interaction liquid chromatography to characterize ITIH4 N-glycoforms. 2603816 4 28 gly glycosylation 420:432 arg2 glycosylation site glycosylation site site The sequence of Asn-X-Thr(Ser), common to glycosylation site, was identified at positions 78-80, 84-86 and 141-143. 18623533 2 20 gly attached 462:469 arg2 each glycosylation site AND the carbohydrate structures IFN-gamma site the carbohydrate structures PUBTATOR IFN-gamma 3458 site In addition to cell growth, metabolite, and productivity data, a detailed analysis of the carbohydrate structures attached to each glycosylation site of IFN-gamma was achieved using matrix-assisted laser desorption mass spectrometry (MALDI-MS) in combination with exoglycosidase array sequencing. 18623533 2 32 gly glycosylation 479:491 arg2 each glycosylation site IFN-gamma site PUBTATOR IFN-gamma 3458 site In addition to cell growth, metabolite, and productivity data, a detailed analysis of the carbohydrate structures attached to each glycosylation site of IFN-gamma was achieved using matrix-assisted laser desorption mass spectrometry (MALDI-MS) in combination with exoglycosidase array sequencing. 8702538 6 67 gly glycosylation 1002:1014 arg2 a single potential N-linked glycosylation site a single potential N-linked glycosylation site site We show that mutation of a single potential N-linked glycosylation site in the first immunoglobulin domain of CD22 completely abrogates ligand recognition. 26018173 1 8 gly glycoprotein 184:195 arg1 The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein PUBTATOR HIV-1) envelope glycoprotein 155971 The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer, which consists of the gp120 and gp41 subunits, is the focus of multiple strategies for vaccine development. 26018173 1 8 gly glycoprotein 184:195 arg1 Env Env PUBTATOR Env 155971 The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer, which consists of the gp120 and gp41 subunits, is the focus of multiple strategies for vaccine development. 24899172 1 7 gly a-determinant 302:314 arg1 the antigenic loop (AGL) region the antigenic loop (AGL) region the antigenic loop (AGL) region Site region The envelope proteins of hepatitis B virus (HBV) bear an N-linked glycosylation site at N146 within the immunodominant a-determinant in the antigenic loop (AGL) region. 24899172 1 108 gly glycosylation 249:261 arg2 an N-linked glycosylation site an N-linked glycosylation site site The envelope proteins of hepatitis B virus (HBV) bear an N-linked glycosylation site at N146 within the immunodominant a-determinant in the antigenic loop (AGL) region. 24899172 1 108 gly glycosylation 249:261 arg2 N146 N146 N146 The envelope proteins of hepatitis B virus (HBV) bear an N-linked glycosylation site at N146 within the immunodominant a-determinant in the antigenic loop (AGL) region. 27713246 1 44 part_of has 76:78 arg1 Human IgG AND only one conserved glycosylation site Human IgG only one conserved glycosylation site Cterm Site Human Ig site Human IgG has only one conserved glycosylation site located in the Cγ2 domain of the Fc region that accounts for the presence of two sugar moieties per IgG. 2317204 7 30 gly glycosylation 1073:1085 arg2 residue 41 residue 41 residue 41 Protein sequencing analysis of these modified link-protein components also provided evidence for the location of a second N-linked glycosylation site at residue 41 in human link proteins, in addition to that previously described at residue 6 on a proportion of the link proteins. 2317204 7 30 gly glycosylation 1073:1085 arg2 a second N-linked glycosylation site a second N-linked glycosylation site site Protein sequencing analysis of these modified link-protein components also provided evidence for the location of a second N-linked glycosylation site at residue 41 in human link proteins, in addition to that previously described at residue 6 on a proportion of the link proteins. 23820512 0 36 gly glycosylation 104:116 arg2 glycosylation site assignment glycosylation site assignment site The GlycoFilter: a simple and comprehensive sample preparation platform for proteomics, N-glycomics and glycosylation site assignment. 26536155 5 15 gly glycoproteins 1218:1230 arg1 Pronase treated glycoproteins Pronase treated glycoproteins Fterm glycoproteins Here, we describe a universal workflow for site-specific N- and O-glycopeptide analysis of Pronase treated glycoproteins with integrated, sequential C18 reverse phase and porous graphitized carbon-LC-ESI-QTOF-MS/MS employing a combination of lower- and enhanced-energy collision-induced dissociation. 26536155 5 55 gly O-glycopeptide 1175:1188 arg2 O-glycopeptide analysis O-glycopeptide analysis O-glycopeptide Here, we describe a universal workflow for site-specific N- and O-glycopeptide analysis of Pronase treated glycoproteins with integrated, sequential C18 reverse phase and porous graphitized carbon-LC-ESI-QTOF-MS/MS employing a combination of lower- and enhanced-energy collision-induced dissociation. 9191841 7 36 gly glycosylation 1270:1282 arg2 Asn 153 Asn 153 Asn 153 Two independent passage series in mosquito cells each resulted in the loss of a conserved glycosylation site at Asn 153 in E. Passage in mouse brain selected for mutations at E residues 18, 54, 277, 401, and 403. 9191841 7 36 gly glycosylation 1270:1282 arg2 a conserved glycosylation site a conserved glycosylation site site Two independent passage series in mosquito cells each resulted in the loss of a conserved glycosylation site at Asn 153 in E. Passage in mouse brain selected for mutations at E residues 18, 54, 277, 401, and 403. 7922031 7 25 gly sugars 1155:1160 arg1 the beta-subunit subunit sugars OGER subunit P0DN86 The carboxy-terminal peptide of the beta-subunit, which is rich in O-linked sugars, is disordered. 2341397 4 26 gly glycosylation 813:825 arg2 glycosylation sites glycosylation sites sites The structural characterization of TEX and NCA and the assignment of glycosylation sites was performed by fast atom bombardment mass spectrometry and microsequence analysis of the resulting peptides. 22688517 7 49 gly glycopeptides 1434:1446 arg2 glycopeptides glycopeptides glycopeptides In addition, manual annotation of multistage MS data utilizing diagnostic ions, which were found to be particularly useful in defining the structure of glycopeptides and glycans was addressed for proper spectra interpretation. 3476950 4 61 gly N-glycosylation 662:676 arg2 one possible N-glycosylation site one possible N-glycosylation site site The first 95 amino acids of the mature enzyme show no sequence homology with other sequenced proteins and there is one possible N-glycosylation site (Asn-89). 3476950 4 61 gly N-glycosylation 662:676 arg2 Asn-89 Asn-89 Asn-89 The first 95 amino acids of the mature enzyme show no sequence homology with other sequenced proteins and there is one possible N-glycosylation site (Asn-89). 7309750 12 27 gly glycosylation 1658:1670 arg2 3 glycosylation sites 3 glycosylation sites sites Proteolytic fragmentation of [3H]mannose-labeled beta-glucuronidase and partial digestion of [3H]leucine-labeled beta-glucuronidase with endo-beta-N-acetylglucosaminidase H suggest that there are 3 glycosylation sites per subunit. 8760433 3 11 gly N-glycosylation 761:775 arg2 Asn-Thr-Ser site, Asn-Thr-Ser site, Asn-Thr-Ser Clones from three patients had Asn-130 (Gly in the wild-type), which generated a potential N-glycosylation site, Asn-Thr-Ser, spanning amino acids 130-132 of the S-gene product. 21526855 1 24 gly O-glycosylation 177:191 arg2 The sites The sites sites The sites of mucin-type O-glycosylation are largely unpredictable, making structural analysis by mass spectrometry (MS) indispensible. 2574658 9 83 part_of DNA 1313:1315 arg1 four discrete DNA fragments DNA four discrete DNA fragments Cterm Site DNA fragments In particular, digestions with Pvu II revealed polymorphism in four discrete DNA fragments, which could be discriminated by hybridizations with nidogen subclones. 9063619 1 38 gly glycosylated 111:122 arg1 glycosylated variants glycosylated variants Fterm variants Glycoproteins generally exist as populations of glycosylated variants (glycoforms) of a single polypeptide. 26947874 3 22 gly N-glycosylation 588:602 arg2 the three naturally occurring N-glycosylation sites the three naturally occurring N-glycosylation sites sites In this study, we investigated the role of an additional N-glycosylation site (Q4N/D6T, Q9N, D12N/S14T, A70N, G148T, R178N, or V212N) to the three naturally occurring N-glycosylation sites in human A1AT. 26947874 3 41 gly N-glycosylation 478:492 arg2 an additional N-glycosylation site an additional N-glycosylation site site In this study, we investigated the role of an additional N-glycosylation site (Q4N/D6T, Q9N, D12N/S14T, A70N, G148T, R178N, or V212N) to the three naturally occurring N-glycosylation sites in human A1AT. 10441114 13 23 gly glycosylated 1749:1760 arg1 three glycosylated polypeptides three glycosylated polypeptides polypeptides ESMS and immunoblotting analyses reveal three glycosylated polypeptides with a molecular mass ranging from 16 to 21 kDa. 23192877 3 22 gly glycoprotein 553:564 arg1 glycoprotein glycoprotein Fterm glycoprotein Here we took advantage of the natural tropism of Nipah virus (NiV), whose attachment envelope glycoprotein has picomolar affinity for ephrinB2, a molecule proposed as a molecular marker of "stemness" (present on embryonic, hematopoietic, and neural stem cells) as well as being implicated in tumorigenesis of specific cancers. 6510420 4 27 part_of contains 386:393 arg1 Each domain AND 490 asparagine residues 137 and 490 asparagine residues 137 and 490 Each domain contains a single iron-binding site and a single glycosylation site (asparagine residues 137 and 490) located in homologous positions. 6510420 4 27 part_of contains 386:393 arg1 Each domain AND a single iron-binding site site site Each domain contains a single iron-binding site and a single glycosylation site (asparagine residues 137 and 490) located in homologous positions. 23891555 13 58 gly IgA1 1882:1885 arg1 the O-glycan composition IgA1 the O-glycan composition OGER IgA1 P01876 Thus identification of the O-glycan composition of IgA1 is important for a deeper understanding of the disease mechanism, biomarker discovery and validation, and implementation and monitoring of disease-specific therapies. 22561424 11 3 gly glycosylation 1742:1754 arg2 N-linked glycosylation site N-linked glycosylation site site Our results demonstrated that OVF has its unique features as following: 1) The N-terminal amino acid sequence of OVF γ chain is different from that of other known CVFs, suggesting that the OVF γ chain might be further processed; 2) Unlike N. kaouthia CVF and A. superbus AVF-1, which have potential N-linked glycosylation sites located in both α and β chain, OVF only has N-linked glycosylation site in its α chain as revealed by Schiff's reagent staining and protein sequence analysis; 3) In addition to the 27 well conserved cysteine residues in all known CVFs, OVF have an additional cysteine residue in its γ chain. 22561424 11 96 gly glycosylation 1669:1681 arg2 potential N-linked glycosylation sites potential N-linked glycosylation sites sites Our results demonstrated that OVF has its unique features as following: 1) The N-terminal amino acid sequence of OVF γ chain is different from that of other known CVFs, suggesting that the OVF γ chain might be further processed; 2) Unlike N. kaouthia CVF and A. superbus AVF-1, which have potential N-linked glycosylation sites located in both α and β chain, OVF only has N-linked glycosylation site in its α chain as revealed by Schiff's reagent staining and protein sequence analysis; 3) In addition to the 27 well conserved cysteine residues in all known CVFs, OVF have an additional cysteine residue in its γ chain. 16823988 13 70 gly glycoprotein 1720:1731 arg1 glycoprotein abundance glycoprotein abundance This strategy offers the ability to quantitatively analyze changes in glycoprotein abundance and detect the extent of glycosylation alteration as well as the carbohydrate structure that correlate with cancer. 26161579 6 15 gly N-glycosylation 820:834 arg2 N-glycosylation sites N-glycosylation sites sites In this study, we developed a convenient and precise approach for mapping N-glycosylation sites utilizing with optimized TFA hydrolysis, ZIC-HILIC enrichment, and characteristic ions of N-acetylglucosamine (GlcNAc) from higher-energy collisional dissociation (HCD) fragmentation. 21573946 1 14 gly N-glycosylated 229:242 arg1 EC-SOD EC-SOD PUBTATOR EC-SOD 20657 Extracellular superoxide dismutase (EC-SOD), the major SOD isoenzyme in biological fluids, is known to be N-glycosylated and heterogeneous as was detected in most glycoproteins. 21573946 1 14 gly N-glycosylated 229:242 arg1 Extracellular superoxide dismutase Extracellular superoxide dismutase PUBTATOR Extracellular superoxide dismutase 20657 Extracellular superoxide dismutase (EC-SOD), the major SOD isoenzyme in biological fluids, is known to be N-glycosylated and heterogeneous as was detected in most glycoproteins. 21573946 1 14 gly N-glycosylated 229:242 arg1 the major SOD isoenzyme the major SOD isoenzyme PUBTATOR SOD isoenzyme 6649 Extracellular superoxide dismutase (EC-SOD), the major SOD isoenzyme in biological fluids, is known to be N-glycosylated and heterogeneous as was detected in most glycoproteins. 21573946 1 58 gly glycoproteins 286:298 arg1 most glycoproteins most glycoproteins Fterm glycoproteins Extracellular superoxide dismutase (EC-SOD), the major SOD isoenzyme in biological fluids, is known to be N-glycosylated and heterogeneous as was detected in most glycoproteins. 9337875 4 28 gly used 511:514 arg2 the potential sites the potential sites sites Although each of the potential sites was used, none of the eight glycosylation sites appeared to be essential for lysosomal targeting. 9337875 4 57 gly glycosylation 535:547 arg2 the eight glycosylation sites the eight glycosylation sites sites Although each of the potential sites was used, none of the eight glycosylation sites appeared to be essential for lysosomal targeting. 18464039 5 5 part_of DGAT1 523:527 arg1 buffalo DGAT1 mRNA sequence DGAT1 buffalo DGAT1 mRNA sequence PUBTATOR Site DGAT1 282609 sequence The similarity of buffalo DGAT1 mRNA sequence with that of cattle, pig, monkey, human, mice and rat were determined as 98.4, 90.7, 85.4, 85.0, 77.4 and 77.1%, respectively. 27743357 1 57 part_of G 253:253 arg1 the conserved Fc N-glycosylation site immunoglobulin G the conserved Fc N-glycosylation site Cterm Site immunoglobulin G site This chapter contains a nanoscale liquid chromatography-mass spectrometry method for the glycoform profiling of the conserved Fc N-glycosylation site of monoclonal and polyclonal immunoglobulin G (IgG). 25094044 0 5 gly structure 7:15 arg1 the ER-resident glycoprotein glycoprotein structure Fterm glycoprotein Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human. 25094044 0 23 gly glycoprotein 108:119 arg1 glycoprotein glucosyltransferases 1 glycoprotein glucosyltransferases 1 Fterm glycoprotein Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human. 25094044 0 41 gly ER-resident 50:60 arg1 uridine 5'-diphosphate-glucose ER-resident uridine 5'-diphosphate-glucose Cterm ER-resident Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human. 25094044 0 42 gly site 21:24 arg1 uridine 5'-diphosphate-glucose site uridine 5'-diphosphate-glucose site Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human. 25094044 0 10 gly glycoprotein 62:73 arg1 uridine 5'-diphosphate-glucose glycoprotein uridine 5'-diphosphate-glucose Fterm glycoprotein Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human. 25094044 0 30 gly glycoprotein 62:73 arg1 Glycan structure glycoprotein Glycan structure Fterm glycoprotein Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human. 25094044 0 36 gly glycosylation 29:41 arg1 the ER-resident glycoprotein glycoprotein site Fterm glycoprotein site Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human. 25094044 0 36 gly glycosylation 29:41 arg1 uridine 5'-diphosphate-glucose site uridine 5'-diphosphate-glucose site Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human. 25094044 0 36 gly glycosylation 29:41 arg1 uridine 5'-diphosphate-glucose glycoprotein uridine 5'-diphosphate-glucose Fterm glycoprotein Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human. 1567356 1 10 gly contains 95:102 arg1 Orosomucoid AND tetra-antennary glycan chains Orosomucoid (OMD tetra-antennary glycan chains OGER Orosomucoid (OMD Q99983 Orosomucoid (OMD) contains complex bi-, tri- and tetra-antennary glycan chains. 1567356 1 10 gly contains 95:102 arg1 Orosomucoid AND tri- Orosomucoid (OMD tri- OGER Orosomucoid (OMD Q99983 Orosomucoid (OMD) contains complex bi-, tri- and tetra-antennary glycan chains. 1567356 1 10 gly contains 95:102 arg1 Orosomucoid AND complex bi- Orosomucoid (OMD complex bi- OGER Orosomucoid (OMD Q99983 Orosomucoid (OMD) contains complex bi-, tri- and tetra-antennary glycan chains. 27796794 9 88 gly glycosylation 1516:1528 arg1 IgG IgG Cterm IgG Significantly more is known about the functional effects of glycosylation of IgG than for other Ig isotypes. 7914890 5 43 part_of containing 687:696 arg1 a mutant arylsulfatase A AND only the second N-glycosylation site a mutant arylsulfatase A only the second N-glycosylation site PUBTATOR Site arylsulfatase A 410 site An earlier study had shown that a mutant arylsulfatase A containing only the second N-glycosylation site at Asn-184 folds correctly and is phosphorylated (Gieselmann, V., Schmidt, B., and von Figura, K. (1992) J. Biol. 25945896 4 17 gly glycopeptides 761:773 arg2 intact glycopeptides intact glycopeptides glycopeptides Here, we report an algorithm, named GPQuest, for site-specific identification of intact glycopeptides using higher-energy collisional dissociation (HCD) fragmentation of complex samples. 9472610 9 9 gly glycosylation 1438:1450 arg2 a glycosylation site a glycosylation site site Four of these 7 harboured serum variants lacking a glycosylation site at this position. 7527739 4 39 part_of contain 546:552 arg1 Both regions AND two Cys residues Both regions two Cys residues Cys residues Both regions contain two Cys residues in close proximity, and the region at residues 554-569 contains a putative N-glycosylation site, which are factors that previously have been suggested to affect the immune recognition of the e2 protein. 7527739 4 66 part_of contains 626:633 arg1 the region AND a putative N-glycosylation site the region a putative N-glycosylation site site Both regions contain two Cys residues in close proximity, and the region at residues 554-569 contains a putative N-glycosylation site, which are factors that previously have been suggested to affect the immune recognition of the e2 protein. 31924694 6 10 gly N-glycopeptides 1295:1309 arg2 these N-glycopeptides these N-glycopeptides N-glycopeptides Comparison of these N-glycopeptides revealed striking differences in protein N-glycosylation between sexes. 10682309 1 12 gly glycosylated 258:269 arg1 small glycosylated non-enzymatic sphingolipid activator proteins small glycosylated non-enzymatic sphingolipid activator proteins Fterm proteins The lysosomal degradation of sphingolipids with short oligosaccharide chains depends on small glycosylated non-enzymatic sphingolipid activator proteins (SAPs, saposins). 15135404 3 29 gly histidine 538:546 arg1 a C-terminal histidine tag histidine a C-terminal histidine tag histidine Recombinant SAP (r-SAP) was produced in a bioreactor with computer controlled fed-batch mode and purified by use of a C-terminal histidine tag. 25451932 11 33 gly sites 1403:1407 arg1 N-glycans sites N-glycans sites Together, our results show that N-glycans at different sites may play distinct roles in regulating the cell membrane targeting, zymogen activation, and ectodomain shedding of corin. 26348848 8 75 gly unglycosylated 1581:1594 arg1 the oligomannose and unglycosylated Kv1.1 subunit the oligomannose and unglycosylated Kv1.1 subunit Cell dissociation assays revealed that cell-cell adhesion was increased by the presence of complex N-glycans of Kv3.1a, like Kv3.1b, whereas cell adhesion was similar in the oligomannose and unglycosylated Kv1.1 subunit containing B35 cells. 26348848 8 119 gly Kv3.1a 1502:1507 arg1 complex N-glycans Kv3 complex N-glycans PUBTATOR Kv3 29731 Cell dissociation assays revealed that cell-cell adhesion was increased by the presence of complex N-glycans of Kv3.1a, like Kv3.1b, whereas cell adhesion was similar in the oligomannose and unglycosylated Kv1.1 subunit containing B35 cells. 518919 3 16 gly glycosylation 552:564 arg2 glycosylation sites II to V glycosylation sites II to V sites The structural variability of the carbohydrate units of glycosylation site I and also of glycosylation sites II to V (Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J.F.G., Binette, J.P. and Schmid, K. (1978) Biochemistry 17, 5206--5214) accounts largely for the microheterogeneity of alpha 1-acid glycoprotein. 518919 3 20 gly glycoprotein 798:809 arg1 alpha 1-acid glycoprotein alpha 1-acid glycoprotein Fterm glycoprotein The structural variability of the carbohydrate units of glycosylation site I and also of glycosylation sites II to V (Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J.F.G., Binette, J.P. and Schmid, K. (1978) Biochemistry 17, 5206--5214) accounts largely for the microheterogeneity of alpha 1-acid glycoprotein. 518919 3 31 gly microheterogeneity 763:780 arg1 alpha 1-acid glycoprotein alpha 1-acid glycoprotein Fterm glycoprotein The structural variability of the carbohydrate units of glycosylation site I and also of glycosylation sites II to V (Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J.F.G., Binette, J.P. and Schmid, K. (1978) Biochemistry 17, 5206--5214) accounts largely for the microheterogeneity of alpha 1-acid glycoprotein. 518919 3 34 gly glycosylation 519:531 arg2 glycosylation site I glycosylation site I site The structural variability of the carbohydrate units of glycosylation site I and also of glycosylation sites II to V (Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J.F.G., Binette, J.P. and Schmid, K. (1978) Biochemistry 17, 5206--5214) accounts largely for the microheterogeneity of alpha 1-acid glycoprotein. 518919 3 40 gly site 533:536 arg1 the carbohydrate units site the carbohydrate units site The structural variability of the carbohydrate units of glycosylation site I and also of glycosylation sites II to V (Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J.F.G., Binette, J.P. and Schmid, K. (1978) Biochemistry 17, 5206--5214) accounts largely for the microheterogeneity of alpha 1-acid glycoprotein. 518919 3 48 gly sites 566:570 arg1 glycosylation sites II to V sites the carbohydrate units sites The structural variability of the carbohydrate units of glycosylation site I and also of glycosylation sites II to V (Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J.F.G., Binette, J.P. and Schmid, K. (1978) Biochemistry 17, 5206--5214) accounts largely for the microheterogeneity of alpha 1-acid glycoprotein. 19249803 1 10 gly glycosylation 188:200 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site Many, but not all, strains of West Nile virus (WNV) contain a single N-linked glycosylation site on their envelope (E) proteins. 29528338 6 3 gly glycosylation 885:897 arg2 the glycosylation site the glycosylation site site One of the polymorphisms controlled addition of an N-linked glycan, and that mutation of the glycosylation site altered binding to all ligands tested, including enhancing binding to UL18. 8631761 6 69 gly glycopeptide 1064:1075 arg2 the glycopeptide the glycopeptide glycopeptide Direct evidence for the occurrence of fucosyl-threonine was obtained by mass spectrometry after digestion of the glycopeptide with a mixture of peptidases. 18707900 3 2 part_of Fc/2 757:760 arg1 Fc/2 fragment Fc Fc/2 fragment Cterm Site Fc fragment Six methods were compared: (1) LC/ESI-MS analysis of intact IgG, (2) LC/ESI-MS analysis of the Fc fragment produced by limited proteolysis with Lys-C, (3) LC/ESI-MS analysis of the IgG heavy chain produced by reduction, (4) LC/ESI-MS analysis of Fc/2 fragment produced by limited proteolysis and reduction, (5) LC/MS analysis of the glycosylated tryptic fragment (293EEQYNSTYR301) using extracted ion chromatograms, and (6) normal phase HPLC analysis of N-glycans cleaved from the IgG using PNGase F. 18707900 3 7 part_of LC/ESI-MS 666:674 arg1 Lys-C ESI Lys-C OGER AminoAcid ESI P19957 Lys Six methods were compared: (1) LC/ESI-MS analysis of intact IgG, (2) LC/ESI-MS analysis of the Fc fragment produced by limited proteolysis with Lys-C, (3) LC/ESI-MS analysis of the IgG heavy chain produced by reduction, (4) LC/ESI-MS analysis of Fc/2 fragment produced by limited proteolysis and reduction, (5) LC/MS analysis of the glycosylated tryptic fragment (293EEQYNSTYR301) using extracted ion chromatograms, and (6) normal phase HPLC analysis of N-glycans cleaved from the IgG using PNGase F. 18707900 3 48 part_of LC/ESI-MS 735:743 arg1 Lys-C ESI Lys-C OGER AminoAcid ESI P19957 Lys Six methods were compared: (1) LC/ESI-MS analysis of intact IgG, (2) LC/ESI-MS analysis of the Fc fragment produced by limited proteolysis with Lys-C, (3) LC/ESI-MS analysis of the IgG heavy chain produced by reduction, (4) LC/ESI-MS analysis of Fc/2 fragment produced by limited proteolysis and reduction, (5) LC/MS analysis of the glycosylated tryptic fragment (293EEQYNSTYR301) using extracted ion chromatograms, and (6) normal phase HPLC analysis of N-glycans cleaved from the IgG using PNGase F. 18707900 3 69 part_of Fc 606:607 arg1 the Fc fragment Fc the Fc fragment Cterm Site Fc fragment Six methods were compared: (1) LC/ESI-MS analysis of intact IgG, (2) LC/ESI-MS analysis of the Fc fragment produced by limited proteolysis with Lys-C, (3) LC/ESI-MS analysis of the IgG heavy chain produced by reduction, (4) LC/ESI-MS analysis of Fc/2 fragment produced by limited proteolysis and reduction, (5) LC/MS analysis of the glycosylated tryptic fragment (293EEQYNSTYR301) using extracted ion chromatograms, and (6) normal phase HPLC analysis of N-glycans cleaved from the IgG using PNGase F. 15341529 5 71 gly glycosylation 726:738 arg2 the N-terminal glycosylation site mOR-EG site PUBTATOR mOR-EG 117004 site Disruption of the N-terminal glycosylation site of the mOR-EG completely impaired its membrane trafficking to the cell surface. 7998391 1 0 part_of hemagglutinin 300:312 arg1 hemagglutinin (HA) Asn127-->Asp hemagglutinin hemagglutinin (HA) Asn127-->Asp Fterm AminoAcid hemagglutinin Asn127 Passages of influenza A/USSR/90/77 virus in mouse lungs produced a virulent virus (18th passage) carrying two mutations in hemagglutinin (HA) Asn127-->Asp and Tre89-->Ala. 10913840 3 4 part_of rFuc-TIV 515:522 arg1 The two potential N-glycosylation sites rFuc-TIV The two potential N-glycosylation sites PUBTATOR Site rFuc-TIV 60670 sites The two potential N-glycosylation sites of rFuc-TIV were mutated to determine site occupancy and the effect of site occupancy on enzyme activity and targeting of this enzyme. 3137277 4 43 part_of detected 647:654 arg1 the S-carboxymethylated protein AND An S-carboxymethyl Cys-17 the S-carboxymethylated protein An S-carboxymethyl Cys-17 Fterm SpecificSite protein Cys-17 An S-carboxymethyl Cys-17 was detected in the S-carboxymethylated protein, suggesting that Cys-17 is unpaired. 20795641 7 57 gly glycosylated 1351:1362 arg1 singly and doubly glycosylated peptides singly and doubly glycosylated peptides peptides Thus, mass shifts of 6 and 8 Da are indicative of singly and doubly glycosylated peptides, respectively. 8639654 10 26 gly Asn69 2075:2079 arg1 carbohydrate Asn69 carbohydrate Asn69 Further pharmacological studies involving incubation of Cos-7 cells with castanospermine or deoxymannojirimycin immediately after transfection of mutated cDNAs encoding receptors with a single glycosylation site at Asn58 or Asn69 suggested that carbohydrate at Asn58 was involved in a calnexin-dependent folding process of the receptor whereas carbohydrate at Asn69 was not. 8639654 10 98 gly glycosylation 1908:1920 arg2 a single glycosylation site a single glycosylation site site Further pharmacological studies involving incubation of Cos-7 cells with castanospermine or deoxymannojirimycin immediately after transfection of mutated cDNAs encoding receptors with a single glycosylation site at Asn58 or Asn69 suggested that carbohydrate at Asn58 was involved in a calnexin-dependent folding process of the receptor whereas carbohydrate at Asn69 was not. 8639654 10 98 gly glycosylation 1908:1920 arg2 Asn69 Asn69 Asn69 Further pharmacological studies involving incubation of Cos-7 cells with castanospermine or deoxymannojirimycin immediately after transfection of mutated cDNAs encoding receptors with a single glycosylation site at Asn58 or Asn69 suggested that carbohydrate at Asn58 was involved in a calnexin-dependent folding process of the receptor whereas carbohydrate at Asn69 was not. 8639654 10 98 gly glycosylation 1908:1920 arg2 Asn58 Asn58 Asn58 Further pharmacological studies involving incubation of Cos-7 cells with castanospermine or deoxymannojirimycin immediately after transfection of mutated cDNAs encoding receptors with a single glycosylation site at Asn58 or Asn69 suggested that carbohydrate at Asn58 was involved in a calnexin-dependent folding process of the receptor whereas carbohydrate at Asn69 was not. 8639654 10 105 gly Asn58 1976:1980 arg1 carbohydrate Asn58 carbohydrate Asn58 Further pharmacological studies involving incubation of Cos-7 cells with castanospermine or deoxymannojirimycin immediately after transfection of mutated cDNAs encoding receptors with a single glycosylation site at Asn58 or Asn69 suggested that carbohydrate at Asn58 was involved in a calnexin-dependent folding process of the receptor whereas carbohydrate at Asn69 was not. 7628611 3 21 gly N-glycosylation 453:467 arg2 three functional N-glycosylation sites three functional N-glycosylation sites sites We report here that the frog KBP has three functional N-glycosylation sites. 29759137 3 9 gly glycosylation 307:319 arg1 serum IgG serum IgG Cterm IgG Therefore, the glycosylation pattern of serum IgG is well characterized. 14759610 5 10 part_of isomerase 850:858 arg1 N-glycosylation site protein disulfide isomerase N-glycosylation site OGER Site protein disulfide isomerase P07237 site The scFv proteins recognized NCS/T and N-glycosylation site of mutant yeast protein disulfide isomerase when they were in their native but not denatured state. 31004621 8 38 gly N-glycosylation 1434:1448 arg2 N-glycosylation sites N-glycosylation sites sites To evaluate the role of N-glycosylation sites on RSV F antigenicity, serum antibody titers were determined after infection of BALB/c mice with RSV expressing the glycomutant F proteins. 8806496 2 26 part_of contain 369:375 arg1 NS1 AND epitopes NS1 epitopes PUBTATOR Site NS1 10625 epitopes NS1 has been shown to contain epitopes for protective antibodies; however, its roles in virus replication and pathogenesis remain unknown. 18585921 2 7 gly N-glycosylation 261:275 arg2 the N-glycosylation site seipin site PUBTATOR seipin 26580 site Mutations in the N-glycosylation site of seipin are associated with the disease states and result in accumulation of unfolded protein in the endoplasmic reticulum (ER), leading to the unfolded protein response (UPR) and cell death, suggesting that these diseases are tightly associated with ER stress. 31577193 9 0 gly N-glycosylation 1116:1130 arg2 human and mouse N-glycosylation sites human and mouse N-glycosylation sites sites Further, the performance of Nglyc was evaluated using human and mouse N-glycosylation sites. 21053369 5 52 gly glycopeptides 859:871 arg2 glycopeptides glycopeptides glycopeptides Specifically, precursor ion scan of oxonium ion protonated N-acetylglucosamine (GlcNAc(+)) (m/z 204) was performed using a triple quadrupole MS instrument to locate the retention time of glycopeptides. 23758413 4 24 gly glycoproteins 698:710 arg1 the oligosaccharide portions glycoproteins the oligosaccharide portions Fterm glycoproteins A problem with single-column affinity chromatography is how to obtain information on glycan diversity within the oligosaccharide portions of captured glycoproteins. 10497235 7 60 gly glycosylated 943:954 arg1 not a distinct triadin 2 isoform not a distinct triadin 2 isoform Fterm isoform The 40-kDa mobility form was shown to correspond to the glycosylated form of triadin 1, not a distinct triadin 2 isoform as previously hypothesized. 10497235 7 60 gly glycosylated 943:954 arg1 triadin 1 triadin 1 OGER triadin Q13061 The 40-kDa mobility form was shown to correspond to the glycosylated form of triadin 1, not a distinct triadin 2 isoform as previously hypothesized. 27259237 5 39 gly N-glycosylation 674:688 arg2 8386 N-glycosylation sites 8386 N-glycosylation sites sites Altogether, 13492 N-glycopeptides containing 8386 N-glycosylation sites on 3982 proteins were identified. 27259237 5 74 gly N-glycopeptides 642:656 arg2 13492 N-glycopeptides 13492 N-glycopeptides N-glycopeptides Altogether, 13492 N-glycopeptides containing 8386 N-glycosylation sites on 3982 proteins were identified. 1414488 4 13 gly site 674:677 arg1 Asn-X-Ser/Thr Asn-X-Ser/Thr Asn The peptide (osteopontin-k) had a potential glycosylation site (Asn-X-Ser/Thr), a GRGDS receptor binding region, a high level of asparagine residues, and a high abundance of acid amino acids characteristic of osteopontin-like cell adhesion molecules. 1414488 4 42 gly glycosylation 660:672 arg2 a potential glycosylation site a potential glycosylation site site The peptide (osteopontin-k) had a potential glycosylation site (Asn-X-Ser/Thr), a GRGDS receptor binding region, a high level of asparagine residues, and a high abundance of acid amino acids characteristic of osteopontin-like cell adhesion molecules. 1414488 4 42 gly glycosylation 660:672 arg2 asparagine residues asparagine residues asparagine residues The peptide (osteopontin-k) had a potential glycosylation site (Asn-X-Ser/Thr), a GRGDS receptor binding region, a high level of asparagine residues, and a high abundance of acid amino acids characteristic of osteopontin-like cell adhesion molecules. 15063126 4 23 gly glycoproteins 820:832 arg1 the parental SHIV-HXBc2P 3.2 envelope glycoproteins the parental SHIV-HXBc2P 3.2 envelope glycoproteins Fterm glycoproteins Viruses with the envelope glycoproteins of SHIV-HXBc2P 3.2N exhibited increased sensitivity to soluble CD4 and several neutralizing antibodies compared with viruses with the parental SHIV-HXBc2P 3.2 envelope glycoproteins. 15063126 4 58 gly glycoproteins 638:650 arg1 the envelope glycoproteins the envelope glycoproteins Fterm glycoproteins Viruses with the envelope glycoproteins of SHIV-HXBc2P 3.2N exhibited increased sensitivity to soluble CD4 and several neutralizing antibodies compared with viruses with the parental SHIV-HXBc2P 3.2 envelope glycoproteins. 12877809 2 105 part_of CETP 313:316 arg1 The cDNA sequence CETP The cDNA sequence PUBTATOR Site CETP P11597 sequence METHODS: The cDNA sequence of the tree shrew CETP was obtained by utilizing the technique of switching mechanism at 5' end of RNA transcript (SMART) and rapid amplification of cDNA end (RACE) from the first strand of the cDNA. 15538777 6 85 gly peptide 1537:1543 arg1 the peptide and peptide + N-acetylglucosamine (GlcNAc) species the peptide and peptide + N-acetylglucosamine (GlcNAc) species Collision-induced dissociation (CID) of the glycopeptide [M + H]+ ion generated saccharide-spaced peaks, with an interval of, for example, 146, 162, and 203 Da, and their fragment ions corresponding to the peptide and peptide + N-acetylglucosamine (GlcNAc) species in the MS2 spectrum. 15538777 6 90 gly peptide 1525:1531 arg1 the peptide and peptide + N-acetylglucosamine (GlcNAc) species the peptide and peptide + N-acetylglucosamine (GlcNAc) species Collision-induced dissociation (CID) of the glycopeptide [M + H]+ ion generated saccharide-spaced peaks, with an interval of, for example, 146, 162, and 203 Da, and their fragment ions corresponding to the peptide and peptide + N-acetylglucosamine (GlcNAc) species in the MS2 spectrum. 15538777 6 115 gly glycopeptide 1363:1374 arg2 the glycopeptide [M the glycopeptide [M glycopeptide Collision-induced dissociation (CID) of the glycopeptide [M + H]+ ion generated saccharide-spaced peaks, with an interval of, for example, 146, 162, and 203 Da, and their fragment ions corresponding to the peptide and peptide + N-acetylglucosamine (GlcNAc) species in the MS2 spectrum. 15823038 5 13 gly glycosylation 858:870 arg1 LRP folding LRP folding PUBTATOR LRP 4035 The roles of N-linked glycosylation and the lectin chaperone, calnexin, in LRP folding were further dissected using LRP minireceptors that carry mutations at individual glycosylation sites. 15823038 5 21 gly glycosylation 1005:1017 arg2 individual glycosylation sites individual glycosylation sites sites The roles of N-linked glycosylation and the lectin chaperone, calnexin, in LRP folding were further dissected using LRP minireceptors that carry mutations at individual glycosylation sites. 10191360 3 86 gly N-glycosylated 483:496 arg1 Kv1.1 Kv1.1 PUBTATOR Kv1.1 3736 We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains. 10191360 3 86 gly N-glycosylated 483:496 arg1 Kv1.2 Kv1.2 PUBTATOR Kv1.2 3737 We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains. 10191360 3 86 gly N-glycosylated 483:496 arg1 Kv1.4 Kv1.4 PUBTATOR Kv1.4 3739 We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains. 10191360 3 97 gly glycosylation 412:424 arg2 a single consensus glycosylation site a single consensus glycosylation site site We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains. 30063822 5 1 gly N-glycosylation 953:967 arg2 a single N-glycosylation site a single N-glycosylation site site To illustrate the procedure, we have made an application to a two-domain construct of Robo1, a protein that carries a single N-glycosylation site in its N-terminal domains. 1380164 6 21 part_of subunit 892:898 arg1 cDNA fragments subunit cDNA fragments OGER Site subunit P02708 fragments cDNA fragments of the alpha subunit of mongoose AcChoR corresponding to codons 122-205 and including the presumed ligand binding site were cloned, sequenced, and expressed in Escherichia coli. 1380164 6 54 part_of cDNA 864:867 arg1 cDNA fragments cDNA cDNA fragments Cterm Site cDNA fragments cDNA fragments of the alpha subunit of mongoose AcChoR corresponding to codons 122-205 and including the presumed ligand binding site were cloned, sequenced, and expressed in Escherichia coli. 9729121 6 57 gly N-glycosylation 1093:1107 arg2 One potential N-glycosylation site One potential N-glycosylation site site One potential N-glycosylation site, HEXXHXW zinc-binding motif and characteristic proline-rich repeats were observed in the ORF. 9729121 6 66 gly proline-rich 1161:1172 arg1 characteristic proline-rich repeats proline characteristic proline-rich repeats proline One potential N-glycosylation site, HEXXHXW zinc-binding motif and characteristic proline-rich repeats were observed in the ORF. 1370483 1 40 part_of containing 162:171 arg1 Surfactant protein D AND a collagen-like domain Surfactant protein D a collagen-like domain PUBTATOR Site Surfactant protein D 25350 domain Surfactant protein D (SP-D) is a carbohydrate-binding glycoprotein containing a collagen-like domain that is synthesized by alveolar type II epithelial cells. 21645732 1 11 gly attached 300:307 arg1 its parent protein AND the innermost GlcNAc its parent protein the innermost GlcNAc Fterm protein Endoglycosidase is a class of glycosidases that specifically cleaves the glycosidic bond between two proximal residues of GlcNAc in the pentasaccharide core of N-glycan, leaving the innermost GlcNAc still attached to its parent protein, which provides a different diagnostic maker for N-glycosylation site assignment. 21645732 1 31 gly N-glycosylation 380:394 arg2 N-glycosylation site N-glycosylation site site Endoglycosidase is a class of glycosidases that specifically cleaves the glycosidic bond between two proximal residues of GlcNAc in the pentasaccharide core of N-glycan, leaving the innermost GlcNAc still attached to its parent protein, which provides a different diagnostic maker for N-glycosylation site assignment. 9352200 8 92 gly glycoproteins 1070:1082 arg1 fish envelope glycoproteins fish envelope glycoproteins Fterm glycoproteins However, fish envelope glycoproteins lack these sequences since they are synthesized via a different route (in the liver, transported to the ovary, and assembled into the egg envelope surrounding the oocyte). 9607309 4 2 part_of PAP-2b 484:489 arg1 PAP-2b sequences PAP PAP-2b sequences PUBTATOR Site PAP 8613 sequences With this report we describe a third isoform, PAP-2c, that we found by searching the database of expressed sequence tags (dbEST) with PAP-2a and PAP-2b sequences. 16227249 6 4 part_of prM 702:704 arg1 the prM glycosylation site prM the prM glycosylation site Cterm Site prM site Removing the prM glycosylation site in a lineage I or II strain decreased SVP release, as did removal of the glycosylation site in a lineage I E protein. 16227249 6 41 part_of site 812:815 arg1 a lineage I E protein protein site Fterm Site protein site Removing the prM glycosylation site in a lineage I or II strain decreased SVP release, as did removal of the glycosylation site in a lineage I E protein. 16227249 6 90 part_of site 720:723 arg1 a lineage I or II strain strain site Fterm Site strain site Removing the prM glycosylation site in a lineage I or II strain decreased SVP release, as did removal of the glycosylation site in a lineage I E protein. 1457969 8 18 gly hTSH 1609:1612 arg1 the N-glycans hTSH the N-glycans OGER hTSH Some interesting structural features, not previously reported for the N-glycans of hTSH, included 3-O-sulphated galactose (SO4-3Gal) and peripheral fucose (Fuc alpha 1-3GlcNAc) in the Man alpha 1-6 branch of some diantennary structures; the former suggests the presence of a hitherto uncharacterized galactose-3-O-sulphotransferase in thyrotroph cells of the human anterior pituitary gland. 11082042 3 89 part_of K 646:646 arg1 The deduced amino acid sequence cathepsin K The deduced amino acid sequence PUBTATOR Site cathepsin K 1513 sequence The deduced amino acid sequence of porcine thyroid cathepsin K predicted a 37 kDa preproenzyme, with the active site residues Cys-140, His-277 and Asn-297, and one potential N-glycosylation site. 23530120 5 60 part_of Env 958:960 arg1 variable region 5 Env variable region 5 PUBTATOR Site Env 100616444 region However, we found that the elimination of a conserved glycosylation site located in Loop D and two glycosylation sites located in variable region 5 of Env allows Env-binding to, and activation of, B cells expressing the germline-reverted BCRs of two potent broadly neutralizing antibodies, VRC01 and NIH45-46. 8163463 3 2 part_of have 481:484 arg1 Ionotropic receptor subunits AND four hydrophobic transmembrane domains Ionotropic receptor subunits four hydrophobic transmembrane domains OGER Site subunits 2898 domains Ionotropic receptor subunits are integral membrane proteins that have been proposed to have a large extracellular ligand-binding N-terminal domain, four hydrophobic transmembrane domains, and an extracellular C-terminal domain. 8163463 3 2 part_of have 481:484 arg1 integral membrane proteins AND four hydrophobic transmembrane domains integral membrane proteins four hydrophobic transmembrane domains Fterm Site proteins domains Ionotropic receptor subunits are integral membrane proteins that have been proposed to have a large extracellular ligand-binding N-terminal domain, four hydrophobic transmembrane domains, and an extracellular C-terminal domain. 8163463 3 2 part_of have 481:484 arg1 Ionotropic receptor subunits AND a large extracellular ligand-binding N-terminal domain subunits domain OGER Site subunits 2898 domain Ionotropic receptor subunits are integral membrane proteins that have been proposed to have a large extracellular ligand-binding N-terminal domain, four hydrophobic transmembrane domains, and an extracellular C-terminal domain. 8163463 3 2 part_of have 481:484 arg1 integral membrane proteins AND a large extracellular ligand-binding N-terminal domain proteins domain Fterm Site proteins domain Ionotropic receptor subunits are integral membrane proteins that have been proposed to have a large extracellular ligand-binding N-terminal domain, four hydrophobic transmembrane domains, and an extracellular C-terminal domain. 23776238 0 42 gly modified 29:36 arg3 B-cell maturation antigen AND a single N-glycan chain B-cell maturation antigen a single N-glycan chain PUBTATOR B-cell maturation antigen 608 B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention. 12527303 8 37 gly glycosylated 1385:1396 arg1 "wild-type" glycosylated IgG1-Fc "wild-type" glycosylated IgG1-Fc OGER IgG1 P01857 To investigate the influence of individual sugar (monosaccharide) residues of the oligosaccharide on the structure and function of IgG-Fc we have compared the structure of "wild-type" glycosylated IgG1-Fc with that of four glycoforms bearing consecutively truncated oligosaccharides. 8168913 7 86 gly glycosylation 1447:1459 arg2 a similar position a similar position position Furthermore, the spacing of two proline residues is invariant, and a potential N-linked glycosylation site is found at a similar position in all of the gpAs. 8168913 7 86 gly glycosylation 1447:1459 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Furthermore, the spacing of two proline residues is invariant, and a potential N-linked glycosylation site is found at a similar position in all of the gpAs. 19947664 11 38 gly N-glycosylation 1453:1467 arg2 This N-glycosylation site This N-glycosylation site site This N-glycosylation site was confirmed using a recently developed electron-transfer dissociation (ETD) technique. 7559574 1 43 part_of phosphatase 385:395 arg1 the entire extracellular domain phosphatase the entire extracellular domain Fterm Site phosphatase domain Phosphacan, a soluble nervous tissue-specific chondroitin sulfate proteoglycan, is an alternative splicing product representing the entire extracellular domain of a transmembrane receptor-type protein-tyrosine phosphatase (RPTP zeta/beta) that also occurs as a chondroitin sulfate proteoglycan in brain. 10211957 6 95 gly glycosylation 1019:1031 arg2 the five potential N-linked glycosylation sites the five potential N-linked glycosylation sites sites Each of the five potential N-linked glycosylation sites, located at amino acid positions 196, 209, 234, 305 and 325, respectively, on the HCV polyprotein, was mutated separately as well as in combination with the other sites. 1989393 0 43 part_of site 84:87 arg1 the external glycoprotein glycoprotein site Fterm Site glycoprotein site Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2. 19088065 0 38 gly N-glycosylation 13:27 arg1 kallikrein 6 kallikrein 6 Fterm kallikrein 6 Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. 3898078 4 25 part_of site 573:576 arg1 MuTNF MuTNF site Cterm Site MuTNF P06804 site There is one potential N-linked glycosylation site on MuTNF, in contrast to human TNF, which lacks any such site. 9365923 4 7 gly glycosylation 562:574 arg2 an unusual glycosylation site an unusual glycosylation site site We report an unusual glycosylation site at 71Asn in the triplet 71Asn-Ile-73Cys, which is conserved in all known alpha-lactalbumins except red-necked wallaby. 32168410 1 59 gly glycoprotein 190:201 arg1 The protective/inhibitory B subunits The protective/inhibitory B subunits Fterm subunits BACKGROUND: The protective/inhibitory B subunits of coagulation factor XIII (FXIII-B) is a ~80 kDa glycoprotein containing two N-glycosylation sites. 32168410 1 59 gly glycoprotein 190:201 arg1 a ~80 kDa glycoprotein a ~80 kDa glycoprotein Fterm glycoprotein BACKGROUND: The protective/inhibitory B subunits of coagulation factor XIII (FXIII-B) is a ~80 kDa glycoprotein containing two N-glycosylation sites. 32168410 1 78 gly N-glycosylation 218:232 arg2 two N-glycosylation sites two N-glycosylation sites sites BACKGROUND: The protective/inhibitory B subunits of coagulation factor XIII (FXIII-B) is a ~80 kDa glycoprotein containing two N-glycosylation sites. 21784854 5 68 gly glycosylation 920:932 arg2 a putative N-linked glycosylation site a putative N-linked glycosylation site site Curiously, mouse but not rat IgA contains a putative N-linked glycosylation site in the center of this host receptor and pathogen-binding site. 28353332 3 32 gly glycopeptide 428:439 arg2 the glycopeptide level the glycopeptide level glycopeptide The efficient identification of these glycoforms at the glycopeptide level by mass spectrometry (MS) requires a precursor sampling technique that is not dictated by signal intensity or by preset targets during MS2 data acquisition. 19035324 4 12 part_of position 625:632 arg1 HA1 HA1 position OGER Site HA1 position 11, 23, 87 and 276 sites HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2. 19035324 4 12 part_of position 625:632 arg1 HA2 HA2 position OGER Site HA2 position 11, 23, 87 and 276 sites HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2. 19035324 4 31 part_of HA2 713:715 arg1 23, 87 and 276 sites HA2 23, 87 and 276 sites OGER Site HA2 position 11, 23, 87 and 276 sites HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2. 19035324 4 31 part_of HA2 713:715 arg1 highly conservative N-glycosylation site HA2 highly conservative N-glycosylation site OGER Site HA2 site HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2. 19035324 4 31 part_of HA2 713:715 arg1 two more at position 154 and 213 sites HA2 two more at position 154 and 213 sites OGER Site HA2 position 154 and 213 sites HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2. 19035324 4 36 part_of HA1 662:664 arg1 23, 87 and 276 sites HA1 23, 87 and 276 sites OGER Site HA1 position 11, 23, 87 and 276 sites HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2. 19035324 4 36 part_of HA1 662:664 arg1 highly conservative N-glycosylation site HA1 highly conservative N-glycosylation site OGER Site HA1 site HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2. 19035324 4 36 part_of HA1 662:664 arg1 two more at position 154 and 213 sites HA1 two more at position 154 and 213 sites OGER Site HA1 position 154 and 213 sites HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2. 8702538 10 0 part_of position 1684:1691 arg1 the CD22 and CD33 glycoproteins CD33 glycoproteins position PUBTATOR Site CD33 glycoproteins 945 position These observations suggest that a single N-linked glycosylation site located at a similar position in the CD22 and CD33 glycoproteins is critical for regulating ligand recognition by both receptors. 20826563 3 65 part_of variants 261:268 arg1 a single potential N-glycosylation site variants a single potential N-glycosylation site Fterm Site variants site Human GH variants with a single potential N-glycosylation site (N-X-S/T) introduced by site-directed mutagenesis were expressed in HEK293 cells. 17144668 2 35 gly glycosylation 387:399 arg2 N-linked glycosylation sites N-linked glycosylation sites sites Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. 17144668 2 90 gly glycoprotein 360:371 arg1 carboxylase carboxylase Fterm carboxylase Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. 17144668 2 90 gly glycoprotein 360:371 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. 8870657 12 4 gly unglycosylated 1428:1441 arg1 unglycosylated hLF unglycosylated hLF PUBTATOR hLF 3131 The pronounced degradation of unglycosylated hLF in supernatant after mutation at all three glycosylation sites (Asn138/479/624 mutant) but not after mutation at both Asn138 and Asn479 suggests that an altered conformation rather than the lack of glycosylation has rendered the Asn138/479/624 mutant susceptible to intra- and/or extra-cellular degradation. 8870657 12 41 gly glycosylation 1490:1502 arg2 all three glycosylation sites all three glycosylation sites sites The pronounced degradation of unglycosylated hLF in supernatant after mutation at all three glycosylation sites (Asn138/479/624 mutant) but not after mutation at both Asn138 and Asn479 suggests that an altered conformation rather than the lack of glycosylation has rendered the Asn138/479/624 mutant susceptible to intra- and/or extra-cellular degradation. 19284292 7 3 gly glycosylation 1284:1296 arg2 a putative glycosylation site a putative glycosylation site site Such cis-controlling elements provide a higher level of protein specificity, because a putative glycosylation site cannot result from a single point mutation. 15863355 3 110 gly glycosylation 474:486 arg2 glycosylation sites glycosylation sites sites We investigated alteration of N-glycans at each of glycosylation sites of AGP in the sera of patients with acute and chronic inflammation. 8870657 7 47 gly Glycosylation 852:864 arg2 Asn479 Asn479 Asn479 Glycosylation at a single site (Asn479) or at all three sites occurs in approx, 5% and 9% of hLF respectively. 8870657 7 47 gly Glycosylation 852:864 arg2 a single site a single site site Glycosylation at a single site (Asn479) or at all three sites occurs in approx, 5% and 9% of hLF respectively. 8870657 7 47 gly Glycosylation 852:864 arg2 all three sites all three sites sites Glycosylation at a single site (Asn479) or at all three sites occurs in approx, 5% and 9% of hLF respectively. 9223227 5 30 part_of positions 851:859 arg1 equine IL-1ra IL-1ra positions PUBTATOR Site IL-1ra 100034236 positions An N-glycosylation site and five cysteine residues conserved in human, murine and rabbit IL-1ras were also found at the corresponding positions in equine IL-1ra. 6192439 5 40 gly N-glycosylation 646:660 arg2 one potential N-glycosylation site one potential N-glycosylation site site There is one potential N-glycosylation site, Asn-Phe-Thr, in the amino acid sequence. 30290305 4 54 part_of hFSTL1 778:783 arg1 specific hFSTL1 N-glycosylation sites hFSTL1 specific hFSTL1 N-glycosylation sites PUBTATOR Site hFSTL1 11167 sites We used modified mRNA (modRNA) technology to investigate the possible role of specific hFSTL1 N-glycosylation sites in the induction, by hFSTL1, of CM proliferation and cardiac regeneration. 27490136 3 13 gly glycosylation 760:772 arg2 an N-linked glycosylation site an N-linked glycosylation site site The HBV small (S), medium (M), and large (L) surface proteins bear an N-linked glycosylation site in the common S domain that is partially occupied in all proteins. 27490136 3 19 gly occupied 820:827 arg2 the common S domain the common S domain domain The HBV small (S), medium (M), and large (L) surface proteins bear an N-linked glycosylation site in the common S domain that is partially occupied in all proteins. 10998266 3 8 gly sialylated 667:676 arg1 Many different sialylated oligosaccharides Many different sialylated oligosaccharides Many different sialylated oligosaccharides of EPO were separated and characterized by LC/MS equipped with a graphitized carbon column (GCC). 10998266 3 84 gly EPO 698:700 arg1 Many different sialylated oligosaccharides EPO Many different sialylated oligosaccharides PUBTATOR EPO 2056 Many different sialylated oligosaccharides of EPO were separated and characterized by LC/MS equipped with a graphitized carbon column (GCC). 23909558 0 44 gly glycopeptides 24:36 arg2 O-linked glycopeptides O-linked glycopeptides glycopeptides Characterizing O-linked glycopeptides by electron transfer dissociation: fragmentation rules and applications in data analysis. 8325990 4 27 gly oligosaccharide 1018:1032 arg1 Asn289 Asn289 Asn289 AminoAcid Asn289 Removal of both N- and O-linked oligosaccharide from HPg resulted in a slight increase in the Kcat/Km for its activation, while a glycoform containing tetrasialyl-tetra-antennary complex oligosaccharide on Asn289 was a slightly poorer substrate for UK than plasma HPg, which contains bisialyl-biantennary complex carbohydrate on Asn289. 8325990 4 44 gly carbohydrate 1144:1155 arg1 Asn289 Asn289 Asn289 AminoAcid Asn289 Removal of both N- and O-linked oligosaccharide from HPg resulted in a slight increase in the Kcat/Km for its activation, while a glycoform containing tetrasialyl-tetra-antennary complex oligosaccharide on Asn289 was a slightly poorer substrate for UK than plasma HPg, which contains bisialyl-biantennary complex carbohydrate on Asn289. 7540044 8 70 gly non-glycosylated 1818:1833 arg1 All non-glycosylated peptides All non-glycosylated peptides peptides All non-glycosylated peptides assumed a low-to-medium helicity in trifluoroethanol. 8841141 2 25 part_of ANP- 377:380 arg1 the amino terminus ANP the amino terminus OGER Site ANP P01160 terminus Affinity purified NPR-A was UV-cross-linked to the amino terminus of 125I-[Tyr2] rat ANP-(2-27). 1634772 5 11 part_of found 680:684 arg2 the protein AND An additional glycosylation site the protein An additional glycosylation site Fterm Site protein site An additional glycosylation site, compared with those of human DRA, was found in the second external domain of the protein. 1634772 5 45 part_of protein 723:729 arg1 the second external domain protein the second external domain Fterm Site protein domain An additional glycosylation site, compared with those of human DRA, was found in the second external domain of the protein. 23028207 1 5 gly glycosylation 103:115 arg2 glycosylation sites glycosylation sites sites Assignment of glycosylation sites and site microheterogeneity is of both biological and clinical significance. 20589574 7 19 gly N-glycosylation 1186:1200 arg2 one N-glycosylation site one N-glycosylation site site Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear. 15474009 3 25 gly glycoproteins 604:616 arg1 several glycoproteins several glycoproteins Fterm glycoproteins The latter has been reported to be a minor N-glycosylation site in several glycoproteins. 15474009 3 35 gly N-glycosylation 572:586 arg2 a minor N-glycosylation site a minor N-glycosylation site site The latter has been reported to be a minor N-glycosylation site in several glycoproteins. 23909558 7 58 gly O-glycosylated 1044:1057 arg1 erythropoietin erythropoietin PUBTATOR erythropoietin 2056 By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS data, we applied the method to glycopeptides generated from various O-glycosylated proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120. 23909558 7 58 gly O-glycosylated 1044:1057 arg1 an HIV envelope protein an HIV envelope protein Fterm protein By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS data, we applied the method to glycopeptides generated from various O-glycosylated proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120. 23909558 7 58 gly O-glycosylated 1044:1057 arg1 mucin mucin PUBTATOR mucin 100508689 By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS data, we applied the method to glycopeptides generated from various O-glycosylated proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120. 23909558 7 58 gly O-glycosylated 1044:1057 arg1 various O-glycosylated proteins various O-glycosylated proteins Fterm proteins By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS data, we applied the method to glycopeptides generated from various O-glycosylated proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120. 23909558 7 58 gly O-glycosylated 1044:1057 arg1 fetuin fetuin Fterm fetuin By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS data, we applied the method to glycopeptides generated from various O-glycosylated proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120. 23909558 7 60 gly glycopeptides 1007:1019 arg2 glycopeptides glycopeptides glycopeptides By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS data, we applied the method to glycopeptides generated from various O-glycosylated proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120. 16037490 4 17 part_of isoform 1052:1058 arg1 Asn1007 isoform Asn1007 Fterm AminoAcid isoform Asn1007 and Asn2108 There was a remarkable site-specific difference in fucosylation between these isoforms; Asn1244 selectively escaped the global fucosylation of cellular FN, whereas only Asn1007 and Asn2108 of the plasma isoform underwent modification. 8349699 1 93 gly N-glycosylated 258:271 arg1 Asn410 Asn68, Asn144, and Asn410 Asn68, Asn144, and Asn410 Using site-directed mutagenesis, we have determined that Asn68, Asn144, and Asn410 of ovine prostaglandin endoperoxide (PGH) synthase-1 are N-glycosylated. 8349699 1 93 gly N-glycosylated 258:271 arg1 Asn68 Asn68, Asn144, and Asn410 Asn68, Asn144, and Asn410 Using site-directed mutagenesis, we have determined that Asn68, Asn144, and Asn410 of ovine prostaglandin endoperoxide (PGH) synthase-1 are N-glycosylated. 8349699 1 93 gly N-glycosylated 258:271 arg1 Asn68 Asn68, Asn144, and Asn410 Asn68, Asn144, and Asn410 Using site-directed mutagenesis, we have determined that Asn68, Asn144, and Asn410 of ovine prostaglandin endoperoxide (PGH) synthase-1 are N-glycosylated. 25673720 7 106 gly glycosylated 1091:1102 arg1 C C Cterm C Q9NP58 We infected mice carrying different glycosylated forms of PrP(C) with two human agents (sCJDMM2 and vCJD) and one hamster strain (263K). 25673720 7 106 gly glycosylated 1091:1102 arg1 PrP PrP PUBTATOR PrP 19122 We infected mice carrying different glycosylated forms of PrP(C) with two human agents (sCJDMM2 and vCJD) and one hamster strain (263K). 2787353 7 51 part_of site 1345:1348 arg1 rIL-2 rIL-2 site PUBTATOR Site rIL-2 116562 site Thus the carbohydrate-binding site of rIL-2 is distinct from the cell surface receptor-binding site, and might function preferentially in acidic microenvironments. 9126611 3 98 gly N-glycosylation 562:576 arg1 this site site site Removal of the N-glycosylation consensus sequence at Asn580 (N580Q and S582A mutants) resulted in the expression of protein comprising a single glycoform, consistent with the partial N-glycosylation at this site in the wild-type (WT) enzyme. 31514875 10 63 gly glycosylation 1862:1874 arg1 a protein a protein Fterm protein The potential of IMERs for the study of the glycosylation of a protein was illustrated with the comparison of two hCG-based drugs, Ovitrelle® and Pregnyl®. 22689482 6 75 gly trifucosylated 1146:1159 arg1 the trifucosylated glycoform the trifucosylated glycoform Level of fucosylation showed interindividual variability with the major relative abundance for the trifucosylated glycoform. 32321762 0 15 part_of site 79:82 arg1 human prion protein protein site Fterm Site protein site α2, 3-linkage of sialic acid to a GPI-anchor and an unpredicted GPI attachment site in human prion protein. 26896935 6 48 gly N-glycosylation 952:966 arg2 the N-glycosylation site the N-glycosylation site site Presence of the N-glycosylation site had limited impact on virus virulence and the 5'UTR does not seem to influence pathogenesis. 12356334 6 36 gly glycosylated 982:993 arg1 the C allele SP-B variant the C allele SP-B variant PUBTATOR SP-B variant 6439 To determine whether the C allele SP-B variant is indeed glycosylated at Asn(129)-Gln-Thr131, we first generated stably transfected Chinese hamster ovary cell lines that expressed each version of SP-B, and developed specific SP-B polyclonal anti-peptide antibodies. 23296536 0 49 gly glycoprotein 31:42 arg1 glycoprotein analysis glycoprotein analysis Fterm glycoprotein Introduction to informatics in glycoprotein analysis. 1318404 3 51 gly glycosylation 440:452 arg2 a single glycosylation site a single glycosylation site site Mutations resulting in the loss of a single glycosylation site produced, intracellularly, stable precursor SU-TM proteins which were 4 to 5 kDa smaller than the wild-type virus SU-TM protein. 7543206 2 50 gly glycosylation 299:311 arg2 Two surface glycosylation sites Two surface glycosylation sites sites Two surface glycosylation sites at Asn265 and Asn371 have been changed to glutamine, to obtain a more homogeneous preparation of hIgE-Fc for structural studies. 7543206 2 50 gly glycosylation 299:311 arg2 Asn265 Asn265 and Asn371 Asn265 and Asn371 Two surface glycosylation sites at Asn265 and Asn371 have been changed to glutamine, to obtain a more homogeneous preparation of hIgE-Fc for structural studies. 27641734 19 42 part_of CD97 3509:3512 arg1 the CD97 GAIN domain CD97 the CD97 GAIN domain PUBTATOR Site CD97 976 domain Finally, the GAIN and EGF domains are also important for CD97-HeLa adhesion, whereas N-glycosylation of the CD97 GAIN domain and GPS auto-proteolysis are not required for HeLa cell attachment. 27641734 19 53 part_of EGF 3423:3425 arg1 the GAIN and EGF domains EGF the GAIN and EGF domains OGER Site EGF P01133 domains Finally, the GAIN and EGF domains are also important for CD97-HeLa adhesion, whereas N-glycosylation of the CD97 GAIN domain and GPS auto-proteolysis are not required for HeLa cell attachment. 23684631 6 70 gly glycosylation 1315:1327 arg2 a glycosylation site a glycosylation site site The Tunisian G4 RVA were closely related to the G4 vaccine strain in RotaTeq, belonging to the same lineage, but the alignment of their VP7 amino acids revealed an insertion of an asparagine residue at position 76 which is close to a glycosylation site (aa 69-71). 8756556 4 62 part_of contains 709:716 arg1 PLP-D AND one putative N-glycosylation site PLP-D one putative N-glycosylation site PUBTATOR Site PLP-D 64368 site PLP-D contains one putative N-glycosylation site and six cysteine residues that are highly conserved in the placental PRL family. 8756556 4 62 part_of contains 709:716 arg1 PLP-D AND six cysteine residues PLP-D six cysteine residues PUBTATOR AminoAcid PLP-D 64368 cysteine residues PLP-D contains one putative N-glycosylation site and six cysteine residues that are highly conserved in the placental PRL family. 10992007 7 59 gly glycosylation 1280:1292 arg2 three glycosylation sites three glycosylation sites sites Neither TSH binding nor cAMP response was detected in TSHR mutants with three glycosylation sites. 25521995 3 8 gly glycoproteins 455:467 arg1 glycoproteins glycoproteins Fterm glycoproteins In this study, PNGase F-mediated incorporation of (18)O into glycans during the N-glycan release from glycoproteins by PNGase F was finally realized, named as PCGOL (PNGase F-catalyzed glycan (18)O-labeling), which offers a potential strategy for relative glycan quantitation. 18524814 1 10 part_of contains 247:254 arg1 The prM protein AND a single potential N-linked glycosylation site The prM protein a single potential N-linked glycosylation site Fterm Site protein site The prM protein of Japanese encephalitis virus (JEV) contains a single potential N-linked glycosylation site, N(15)-X(16)-T(17), which is highly conserved among JEV strains and closely related flaviviruses. 15616123 7 72 gly glycosylation 1285:1297 arg2 17 glycosylation sites 17 glycosylation sites sites The heterogeneity of carbohydrate structures at 17 glycosylation sites was determined using this methodology. 15616123 7 80 gly heterogeneity 1238:1250 arg1 carbohydrate structures carbohydrate structures The heterogeneity of carbohydrate structures at 17 glycosylation sites was determined using this methodology. 26858738 5 49 gly present 982:988 arg2 the N-glycosylation site AND terminal N-acetylglucosamine the N-glycosylation site terminal N-acetylglucosamine site Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain. 26858738 5 49 gly present 982:988 arg1 the CH2 domain AND terminal N-acetylglucosamine the CH2 domain terminal N-acetylglucosamine domain Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain. 26858738 5 50 gly glycopeptides 879:891 arg2 IgA1 glycopeptides IgA1 glycopeptides glycopeptides Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain. 26858738 5 68 gly N-glycosylation 997:1011 arg2 the N-glycosylation site the N-glycosylation site site Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain. 26858738 5 68 gly N-glycosylation 997:1011 arg1 the CH2 domain domain domain Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain. 19629045 5 23 gly glycosylation 796:808 arg2 specific glycosylation sites specific glycosylation sites sites Selective knockdown and analysis of parasite protein N-glycosylation showed that TbSTT3A selectively transfers biantennary Man(5)GlcNAc(2) to specific glycosylation sites whereas TbSTT3B selectively transfers triantennary Man(9)GlcNAc(2) to others. 28327546 3 82 part_of FVIII 388:392 arg1 N582 FVIII N582 PUBTATOR SpecificSite FVIII 2157 N582 Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking. 28327546 3 82 part_of FVIII 388:392 arg1 the A2 domain FVIII the A2 domain PUBTATOR Site FVIII 2157 domain Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking. 2341397 2 52 gly glycoforms 393:402 arg1 NCA NCA PUBTATOR NCA 1089 Two glycoforms of NCA were purified from a single liver metastasis of a colonic carcinoma and characterized with respect to their primary sequence and position of glycosylation sites. 2341397 2 70 gly glycosylation 552:564 arg2 glycosylation sites glycosylation sites sites Two glycoforms of NCA were purified from a single liver metastasis of a colonic carcinoma and characterized with respect to their primary sequence and position of glycosylation sites. 8892291 1 24 gly glycoprotein 204:215 arg1 p23 p23 PUBTATOR p23 56351 Two mAb, C6B6 and 7D10, each significantly reduced infection of mice by Cryptosporidium parvum and reacted with a 23-kDa glycoprotein (p23) of geographically disperse C. parvum isolates. 8892291 1 24 gly glycoprotein 204:215 arg1 a 23-kDa glycoprotein a 23-kDa glycoprotein Fterm glycoprotein Two mAb, C6B6 and 7D10, each significantly reduced infection of mice by Cryptosporidium parvum and reacted with a 23-kDa glycoprotein (p23) of geographically disperse C. parvum isolates. 8497072 0 19 part_of gp120 164:168 arg1 the third variable and conserved regions gp120 the third variable and conserved regions PUBTATOR Site gp120 155971 regions Association of human immunodeficiency virus type 1 envelope glycoprotein with particles depends on interactions between the third variable and conserved regions of gp120. 15754041 6 101 part_of protein 842:848 arg1 one Asn-linked glycosylation site protein one Asn-linked glycosylation site Fterm Site protein site The rat Wnt9b gene, consisting of four exons, encoded a 359-aa protein with N-terminal signal peptide, 24 conserved Cys residues and one Asn-linked glycosylation site. 15754041 6 101 part_of protein 842:848 arg1 24 conserved Cys residues protein 24 conserved Cys residues Fterm AminoAcid protein Cys residues The rat Wnt9b gene, consisting of four exons, encoded a 359-aa protein with N-terminal signal peptide, 24 conserved Cys residues and one Asn-linked glycosylation site. 15754041 6 101 part_of protein 842:848 arg1 N-terminal signal peptide protein N-terminal signal peptide Fterm Site protein peptide The rat Wnt9b gene, consisting of four exons, encoded a 359-aa protein with N-terminal signal peptide, 24 conserved Cys residues and one Asn-linked glycosylation site. 23527023 2 83 part_of Val 582:584 arg1 PrP PrP Val PUBTATOR AminoAcid PrP Q9NP58 Val However, a prominent molecular characteristic of PrP(Sc) in the recently identified variably protease-sensitive prionopathy (VPSPr) is the absence of a diglycosylated form, also notable in familial Creutzfeldt-Jakob disease (fCJD), which is linked to mutations in PrP either from Val to Ile at residue 180 (fCJD(V180I)) or from Thr to Ala at residue 183 (fCJD(T183A)). 23527023 2 106 part_of Thr 630:632 arg1 PrP PrP Thr PUBTATOR AminoAcid PrP Q9NP58 Thr However, a prominent molecular characteristic of PrP(Sc) in the recently identified variably protease-sensitive prionopathy (VPSPr) is the absence of a diglycosylated form, also notable in familial Creutzfeldt-Jakob disease (fCJD), which is linked to mutations in PrP either from Val to Ile at residue 180 (fCJD(V180I)) or from Thr to Ala at residue 183 (fCJD(T183A)). 8884270 1 50 gly glycoprotein 145:156 arg1 a large cysteine-rich glycoprotein a large cysteine-rich glycoprotein Fterm glycoprotein Fibrillin-1 is a large cysteine-rich glycoprotein of the 10-nm microfibrils in the extracellular matrix. 8884270 1 50 gly glycoprotein 145:156 arg1 Fibrillin-1 Fibrillin-1 PUBTATOR Fibrillin-1 2200 Fibrillin-1 is a large cysteine-rich glycoprotein of the 10-nm microfibrils in the extracellular matrix. 12706347 8 14 gly glycosylation 1290:1302 arg1 this conserved site this conserved site site In addition, glycosylation of this conserved site is necessary for the stabilization/stimulation of nucleotidase activity upon treatment with the lectin concanavalin A. However, lack of glycosylation at this site did not result in large changes in tertiary or quaternary structure, as measured by Cibacron blue binding, chemical cross-linking, and native gel electrophoretic analysis. 15590981 5 73 part_of cDNAs 790:794 arg1 overlapping partial fragments LH/CG-R cDNAs overlapping partial fragments PUBTATOR Site LH/CG-R cDNAs 3973 fragments Based on sequence homologies among mammalian sequences for the LH/CG-R, overlapping partial fragments of LH/CG-R cDNAs were obtained from mare luteal RNA using reverse transcription-PCR and 5'-rapid amplification of cDNA ends. 15795530 3 32 gly glycosylation 615:627 arg2 the N-linked glycosylation site the N-linked glycosylation site site Moreover, compared to NSI or R5 isolates, SI or X4 HIV-1 isolates significantly prefer higher net charges and the loss of the N-linked glycosylation site in the V3 loop, but they show no preference in either net charge or N-linked glycosylation of the V1V2 region. 15795530 3 39 gly glycosylation 711:723 arg1 the V1V2 region the V1V2 region region Moreover, compared to NSI or R5 isolates, SI or X4 HIV-1 isolates significantly prefer higher net charges and the loss of the N-linked glycosylation site in the V3 loop, but they show no preference in either net charge or N-linked glycosylation of the V1V2 region. 19921957 7 52 gly glycoproteins 1463:1475 arg1 two model glycoproteins two model glycoproteins Fterm glycoproteins The standard deviation (SD) ranged from 0.06 to 0.21, for four glycopeptides from two model glycoproteins. 19921957 7 45 gly glycopeptides 1434:1446 arg2 four glycopeptides glycoproteins glycopeptides Fterm glycoproteins glycopeptides The standard deviation (SD) ranged from 0.06 to 0.21, for four glycopeptides from two model glycoproteins. 24554659 12 69 gly determinant 2060:2070 arg1 N173 N173 N173 SpecificSite N173 IMPORTANCE: In this study, we identify a genetic determinant in the viral envelope (N173) that increases replication and spreading infection of SIV strains in macrophages by enhancing cell-to-cell virus transmission. 3896487 4 1 gly glycoprotein 790:801 arg1 the glycoprotein glycosylation the glycoprotein glycosylation Fterm glycoprotein A high selectivity of the glycoprotein glycosylation was found with regard to the distribution of oligomannosidic, mixed, and N-acetyl-lactosaminic oligosaccharides. 8349699 7 10 part_of site 1039:1042 arg1 murine PGH synthase-2 PGH synthase-2 site PUBTATOR Site PGH synthase-2 19225 site Using site-directed mutagenesis, we determined that there is an additional site of N-glycosylation in murine PGH synthase-2 located at Asn580. 24334224 4 20 gly glycosylation 898:910 arg2 Thr134 Thr134 Thr134 Our results demonstrated that Thr134, the equivalent O-linked glycosylation site found on endogenous human G-CSF, is the only site modified with a single mannose, allowing glycoengineered P. pastoris to be used as a viable production platform for therapeutic rhG-CSF. 24334224 4 20 gly glycosylation 898:910 arg2 the equivalent O-linked glycosylation site the equivalent O-linked glycosylation site site Our results demonstrated that Thr134, the equivalent O-linked glycosylation site found on endogenous human G-CSF, is the only site modified with a single mannose, allowing glycoengineered P. pastoris to be used as a viable production platform for therapeutic rhG-CSF. 20208072 6 35 part_of GRP78 1106:1110 arg1 multiple domains GRP78 multiple domains PUBTATOR Site GRP78 3309 domains We also identified the exposure of multiple domains of GRP78 on the cell surface and determined that binding of extracellular GRP78 to the cell surface is unlikely. 25707740 10 50 gly hyperglycosylated 1323:1339 arg1 hCG hCG OGER hCG The invasive extravillous trophoblast also secretes hCG, and in particular like choriocarcinoma cells, hyperglycosylated forms of hCG (hCG-H). 10604468 3 7 part_of Ly49A 424:428 arg1 the Ly49A NK receptor domain Ly49A the Ly49A NK receptor domain PUBTATOR Site Ly49A 16627 domain Here we report the crystal structure of the complex between the Ly49A NK receptor domain and unglycosylated H-2D(d). 10604468 3 59 part_of receptor 433:440 arg1 the Ly49A NK receptor domain receptor the Ly49A NK receptor domain Fterm Site receptor domain Here we report the crystal structure of the complex between the Ly49A NK receptor domain and unglycosylated H-2D(d). 19116267 7 11 gly glycosylation 1070:1082 arg2 residue 158 residue 158 residue 158 Introduction of an S227N change and removal of N-linked glycosylation at residue 158 increased the alpha2,6-binding affinity of VN1203 HA. 27038555 3 49 part_of neuraminidase 382:394 arg1 Taiwanese influenza B viral HA and neuraminidase (NA) sequences neuraminidase Taiwanese influenza B viral HA and neuraminidase (NA) sequences PUBTATOR Site neuraminidase 4758 sequences METHODS: Taiwanese influenza B viral HA and neuraminidase (NA) sequences between 2003 and 2014 were determined and analyzed. 24884609 9 6 part_of contained 1294:1302 arg1 recombinant ITIH4 AND Site N274 recombinant ITIH4 Site N274 high-mannose N-linked glycans PUBTATOR SpecificSite ITIH4 3700 N274 Site N274 contained high-mannose N-linked glycans in both serum and recombinant ITIH4. 23808883 6 55 gly sialylated 1211:1220 arg1 immunosuppressive galactosylated and sialylated IgGs immunosuppressive galactosylated and sialylated IgGs Cterm IgGs It has become increasingly evident that pro-inflammatory immune responses, such as autoimmune reactions, primarily induce antigen-specific G0 IgGs, whereas tolerance induces immunosuppressive galactosylated and sialylated IgGs. 15811651 8 44 part_of site 1314:1317 arg1 protein E protein E site Cterm Site protein E site These data suggest that the glycan associated with the N-linked glycosylation site at position 154 in protein E plays an important role in VLP secretion. 10731668 1 18 part_of receptor 180:187 arg1 The extracellular domain EGF receptor The extracellular domain OGER Site EGF receptor P01133 domain The extracellular domain of human EGF receptor (sEGFR) produced by CHO cells has been used in various biophysical studies to elucidate the molecular mechanism of EGF-induced receptor activation. 16372382 13 116 gly present 2085:2091 arg2 this site AND Bi-, tri-, and tetraantennary N-glycans site Bi-, tri-, and tetraantennary N-glycans site Bi-, tri-, and tetraantennary N-glycans were present at this site. 19767389 2 109 gly oligosaccharides 332:347 arg1 a non-consensus asparaginyl residue a non-consensus asparaginyl residue a non-consensus asparaginyl residue AminoAcid residue in We have observed oligosaccharides on a non-consensus asparaginyl residue in the C(H)1 constant domain of IgG1 and IgG2 antibodies. 7561759 8 102 gly N-glycosylation 1368:1382 arg2 one N-glycosylation site one N-glycosylation site site The sequence data further showed that the Bucyrus-derived viruses contain one N-glycosylation site, whereas the field isolates DL8 and DL11 possess two sites, both of which are used. 15253437 5 32 gly glycoproteins 1297:1309 arg1 37 glycoproteins 37 glycoproteins Fterm glycoproteins We first tested our approach on a mixture of known glycoproteins, and subsequently the method was applied to samples of human plasma obtained by lectin chromatography followed by 1D gel-electrophoresis for determination of 62 glycosylation sites in 37 glycoproteins. 15253437 5 42 gly glycoproteins 1096:1108 arg1 known glycoproteins known glycoproteins Fterm glycoproteins We first tested our approach on a mixture of known glycoproteins, and subsequently the method was applied to samples of human plasma obtained by lectin chromatography followed by 1D gel-electrophoresis for determination of 62 glycosylation sites in 37 glycoproteins. 15253437 5 58 gly glycosylation 1271:1283 arg2 62 glycosylation sites 62 glycosylation sites sites We first tested our approach on a mixture of known glycoproteins, and subsequently the method was applied to samples of human plasma obtained by lectin chromatography followed by 1D gel-electrophoresis for determination of 62 glycosylation sites in 37 glycoproteins. 32110292 5 66 gly glycosylation 1025:1037 arg1 the protein sequence the protein sequence sequence However, site-specific and comprehensive N-glycosylation analysis of IgG subclasses still cannot be achieved by MS alone due to the partial sequence coverage and loss of connections among glycosylation of the protein sequence. 21153780 7 38 gly N-glycosylation 851:865 arg2 this analysis 1 N-glycosylation site this analysis 1 N-glycosylation site site According to this analysis 1 N-glycosylation site, 2 PKC sites, 4 CK2 sites and 3 disulfide sites were predicted. 16567801 8 19 gly proteins 1697:1704 arg1 The drastically different carbohydrate processing UPIb proteins The drastically different carbohydrate processing PUBTATOR UPIb proteins 7348 The drastically different carbohydrate processing of the UPIa and UPIb proteins, two closely related members of the tetraspanin family, may reflect differences in their folding and masking due to their interactions with their associated proteins, UPII and UPIIIa, respectively. 22407978 3 22 part_of have 494:497 arg1 Human IgGs AND an N-glycosylation site Human IgGs an N-glycosylation site Cterm Site Human IgGs site Human IgGs have an N-glycosylation site at Asn297, located in the second heavy chain constant region (CH2). 3896487 3 23 gly glycosylation 706:718 arg2 each glycosylation site each glycosylation site site The carbohydrate moieties of each glycosylation site were analysed by methylation analysis. 3896487 3 59 gly site 720:723 arg1 The carbohydrate moieties site The carbohydrate moieties site The carbohydrate moieties of each glycosylation site were analysed by methylation analysis. 8496193 11 89 gly utilized 1820:1827 arg2 Asn-251 Asn-251 Asn-251 In experiments with a second mutant, the glycosylation signal at Asn-251, which normally is not utilized, was capable of serving as a carbohydrate acceptor, suggesting that there is normally a structural impediment to glycosylation at Asn-251 in procathepsin L. 8496193 11 47 gly glycosylation 1942:1954 arg1 Asn-251 Asn-251 Asn-251 In experiments with a second mutant, the glycosylation signal at Asn-251, which normally is not utilized, was capable of serving as a carbohydrate acceptor, suggesting that there is normally a structural impediment to glycosylation at Asn-251 in procathepsin L. 8496193 11 47 gly glycosylation 1942:1954 arg1 procathepsin L procathepsin L Asn-251 OGER procathepsin L P06797 Asn-251 In experiments with a second mutant, the glycosylation signal at Asn-251, which normally is not utilized, was capable of serving as a carbohydrate acceptor, suggesting that there is normally a structural impediment to glycosylation at Asn-251 in procathepsin L. 8496193 11 47 gly glycosylation 1942:1954 arg1 procathepsin L procathepsin L Asn-251 OGER procathepsin L P06797 Asn-251 In experiments with a second mutant, the glycosylation signal at Asn-251, which normally is not utilized, was capable of serving as a carbohydrate acceptor, suggesting that there is normally a structural impediment to glycosylation at Asn-251 in procathepsin L. 7525705 7 34 gly glycosylation 1361:1373 arg2 an extra glycosylation site an extra glycosylation site site Mutant 10.24.6, which has a mutation in the DRA coding region creating an extra glycosylation site, also has unstable DR dimers whose stability is restored by acid/peptide treatment. 26620227 3 44 part_of proSP-B 418:424 arg1 Asn129 SP-B Asn129 OGER AminoAcid SP-B P07988 Asn129 The SNP causes an altered N-linked glycosylation modification at Asn129 of proSP-B, e.g. the C allele with this glycosylation site but not in the T allele. 15500445 6 61 part_of protein 1021:1027 arg1 protein surface epitopes protein protein surface epitopes Fterm Site protein epitopes The antigenicity of native IDS was higher in regions without glycosylation, but reactivity was not restricted to protein surface epitopes. 23319596 2 22 part_of oxidase 428:434 arg1 the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain lysyl oxidase the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain PUBTATOR Site lysyl oxidase 4015 domain hloxl2 encodes four N-terminal scavenger receptor cysteine-rich domains and the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain. 23319596 2 27 part_of lysyl 422:426 arg1 the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain lysyl oxidase the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain PUBTATOR Site lysyl oxidase 4015 domain hloxl2 encodes four N-terminal scavenger receptor cysteine-rich domains and the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain. 23319596 2 52 part_of LOX 437:439 arg1 the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain LOX the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain PUBTATOR Site LOX 4015 domain hloxl2 encodes four N-terminal scavenger receptor cysteine-rich domains and the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain. 10849765 3 11 gly glycosylation 746:758 arg2 the glycosylation site the glycosylation site site The cells were transiently transfected with four cathepsin B-EGFP fusion constructs: full-length preprocathepsin B-EGFP, cathepsin B preregion-EGFP, cathepsin B prepro region-EGFP, and cathepsin B prepro region-EGFP with a mutation of the glycosylation site in the pro region. 28322444 0 63 gly N-glycosylation 53:67 arg1 the potassium channel Kv3.1b the potassium channel Kv3.1b Cterm Kv3.1b Identification and characterization of site-specific N-glycosylation in the potassium channel Kv3.1b. 11741940 7 25 part_of protein 1470:1476 arg1 the Fz domain protein the Fz domain Fterm Site protein domain Interestingly, two subsets of sFRPs appear to have alternate disulfide linkage patterns compared with sFRP-1, one of which involves the loss of a disulfide due to deletion of a single cysteine from the NTR module, whereas the remaining cysteine may pair with a new cysteine introduced in the Fz domain of the protein. 31625659 0 9 gly Dectin-1 62:69 arg1 The Core Fucose Dectin-1 The Core Fucose PUBTATOR Dectin-1 Q9BXN2 The Core Fucose on an IgG Antibody is an Endogenous Ligand of Dectin-1. 11948877 5 17 part_of ovalbumin 1548:1556 arg1 the single glycosylation site ovalbumin the single glycosylation site Fterm Site ovalbumin site The degree of Gal-biotin tag transfer onto agalactosylated hybrid N-glycans present at the single glycosylation site of ovalbumin was dependent on the Gal-T used (either beta3Gal-T5, beta4Gal-T4, or beta4Gal-T1), which indicates that the acceptor specificity may direct the transfer of the Gal-biotin tag. 10488137 11 44 gly glycosylation 1690:1702 arg2 glycosylation site analysis glycosylation site analysis site The introduction of one positive charge led to a significant inversion in mEH topology based on glycosylation site analysis. 9261431 7 49 gly position 1800:1807 arg1 a glycan position a glycan position Although the gs4 glycan was not essential for infectivity, processing of all mutant Envs lacking this glycan was significantly impaired, suggesting that efficient folding of gPrEnv requires a glycan at this position. 8771709 0 82 gly N-glycosylation 93:107 arg2 an N-glycosylation site an N-glycosylation site site Secretion of a variant of human single-chain urokinase-type plasminogen activator without an N-glycosylation site in the methylotrophic yeast, Pichia pastoris and characterization of the secreted product. 10374967 4 60 part_of has 613:615 arg1 A conserved motif AND an N-glycosylation site A conserved motif an N-glycosylation site site A conserved motif here has an N-glycosylation site and characteristics of a beta turn. 23661698 8 6 gly EphA2 1196:1200 arg1 the ligand's carbohydrates EphA2 the ligand's carbohydrates PUBTATOR EphA2 1969 Analysis of Eph/ephrin crystal structures reveals an interaction between the ligand's carbohydrates and two residues of EphA2: Asp-78 and Lys-136. 6300470 10 4 gly glycosylation 1317:1329 arg2 a glycosylation site a glycosylation site site The Rauscher MCF virus glycoprotein lacks a glycosylation site found at position 12 of the ecotropic sequence. 6300470 10 56 gly glycoprotein 1296:1307 arg1 The Rauscher MCF virus glycoprotein The Rauscher MCF virus glycoprotein Fterm glycoprotein The Rauscher MCF virus glycoprotein lacks a glycosylation site found at position 12 of the ecotropic sequence. 19610667 4 2 gly motifs 781:786 arg1 each glycosylation site each glycosylation site each glycosylation site Site site Here, we describe a mass spectrometry-based approach to characterize the glycosylation profiles of two rVV-expressed clade C Envs by identifying the glycan motifs on each glycosylation site and determining the degree of glycosylation site occupancy. 19610667 4 48 gly glycosylation 845:857 arg2 glycosylation site occupancy glycosylation site occupancy site Here, we describe a mass spectrometry-based approach to characterize the glycosylation profiles of two rVV-expressed clade C Envs by identifying the glycan motifs on each glycosylation site and determining the degree of glycosylation site occupancy. 19610667 4 62 gly glycosylation 796:808 arg2 each glycosylation site each glycosylation site site Here, we describe a mass spectrometry-based approach to characterize the glycosylation profiles of two rVV-expressed clade C Envs by identifying the glycan motifs on each glycosylation site and determining the degree of glycosylation site occupancy. 8841141 4 4 gly N-glycosylation 643:657 arg2 one N-glycosylation site one N-glycosylation site site This fragment yielded a major microsequence corresponding to a region from Met173 to Phe188 of the receptor extracellular domain and containing one N-glycosylation site at Asn180. 23748959 0 53 gly glycosylation 13:25 arg2 HIV N-linked glycosylation site analyzer HIV N-linked glycosylation site analyzer site HIV N-linked glycosylation site analyzer and its further usage in anchored alignment. 2457333 12 21 gly desialylated 1836:1847 arg1 desialylated glycopeptides desialylated glycopeptides glycopeptides A preparation scheme was developed to obtain molecular ions of desialylated glycopeptides by PD-MS. 2457333 12 73 gly glycopeptides 1849:1861 arg2 desialylated glycopeptides desialylated glycopeptides glycopeptides A preparation scheme was developed to obtain molecular ions of desialylated glycopeptides by PD-MS. 12460944 3 51 gly glycosylation 440:452 arg2 the glycosylation sites the glycosylation sites sites Comparison of the glycosylation sites on these proteins revealed a putative consensus sequence for O-glucose modification: C(1)XSXPC(2), where C(1) and C(2) are the first and second conserved cysteines of the EGF repeat. 12460944 3 80 gly sequence 508:515 arg1 a putative consensus sequence for O-glucose modification: C(1)XSXPC(2), where C(1) and C(2) are the first and second conserved cysteines of the EGF repeat a putative consensus sequence for O-glucose modification: C(1)XSXPC(2), where C(1) and C(2) are the first and second conserved cysteines of the EGF repeat Comparison of the glycosylation sites on these proteins revealed a putative consensus sequence for O-glucose modification: C(1)XSXPC(2), where C(1) and C(2) are the first and second conserved cysteines of the EGF repeat. 9689919 6 46 part_of peptide 855:861 arg1 the conserved residues peptide the conserved residues residues It has an N-terminal signal peptide, a consensus glycosylation site and homology with serpins including the conserved residues required for maintaining the serpin tertiary structure. 22649382 7 80 gly N-glycosylation 1143:1157 arg2 all four N-glycosylation sites all four N-glycosylation sites sites The TpoR mutant defective in all four N-glycosylation sites was severely impaired in plasma membrane localization and was degraded by the proteasome. 26993603 0 54 part_of Asn144 24:29 arg1 GP73 N-glycosylation GP73 N-glycosylation Asn144 PUBTATOR AminoAcid GP73 N-glycosylation 51280 Asn144 GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness. 12847262 6 1 gly glycosylation 859:871 arg2 the glycosylation site the glycosylation site site The increased binding was functional, was not dependent on the interaction with viral hemagglutinin-neuraminidase, was not dependent on the glycosylation site, and was not abolished after mutating the transmembrane or cytosolic portions of the class I MHC proteins. 9597548 1 13 gly N-glycosylation 279:293 arg2 five conserved N-glycosylation sites five conserved N-glycosylation sites sites The oligosaccharide side chains of a human anti-lipopolysaccharide IgM produced by a human-human-mouse heterohybridoma were analyzed at each of its five conserved N-glycosylation sites. 21053369 9 91 gly glycosylation 1398:1410 arg2 the glycosylation sites the glycosylation sites sites Most of the glycosylation sites were > 95% occupied except Asn250 and Asn6. 8364023 0 6 part_of acyltransferase 96:110 arg1 the N-glycosylation sites lecithin:cholesterol acyltransferase the N-glycosylation sites PUBTATOR Site lecithin:cholesterol acyltransferase 3931 sites Effects of site-directed mutagenesis on the N-glycosylation sites of human lecithin:cholesterol acyltransferase. 20884611 8 35 gly N-glycosylation 1233:1247 arg2 an N-glycosylation site an N-glycosylation site site Among these mutants, activation was maximized in one integrin with an N-glycosylation site located behind the α-genu. 25541284 2 31 part_of has 242:244 arg1 MOG AND a single N-glycosylation site MOG a single N-glycosylation site PUBTATOR Site MOG 4340 site MOG has a single N-glycosylation site within its extracellular domain. 8706658 2 38 part_of protein 519:525 arg1 residues 41 -62 protein residues 41 -62 Fterm SpecificSite protein residues 41 -62 Human leukotriene C4 synthase shares substantial amino acid identity in its consensus N-terminal two-thirds with 5-lipoxygenase-activating protein and has a region (residues 37-58) that exhibits 46% amino acid identity with a domain of this protein (residues 41 -62) to which an inhibitor binds. 8706658 2 38 part_of protein 519:525 arg1 a domain protein a domain Fterm Site protein domain Human leukotriene C4 synthase shares substantial amino acid identity in its consensus N-terminal two-thirds with 5-lipoxygenase-activating protein and has a region (residues 37-58) that exhibits 46% amino acid identity with a domain of this protein (residues 41 -62) to which an inhibitor binds. 8706658 2 23 part_of has 429:431 arg1 Human leukotriene C4 synthase AND a region Human leukotriene C4 synthase a region PUBTATOR Site Human leukotriene C4 synthase 4056 region Human leukotriene C4 synthase shares substantial amino acid identity in its consensus N-terminal two-thirds with 5-lipoxygenase-activating protein and has a region (residues 37-58) that exhibits 46% amino acid identity with a domain of this protein (residues 41 -62) to which an inhibitor binds. 8706658 2 23 part_of has 429:431 arg1 Human leukotriene C4 synthase AND residues 37-58 Human leukotriene C4 synthase residues 37-58 PUBTATOR SpecificSite Human leukotriene C4 synthase 4056 residues 37-58 Human leukotriene C4 synthase shares substantial amino acid identity in its consensus N-terminal two-thirds with 5-lipoxygenase-activating protein and has a region (residues 37-58) that exhibits 46% amino acid identity with a domain of this protein (residues 41 -62) to which an inhibitor binds. 31888963 5 86 part_of CD16a 809:813 arg1 the composition CD16a the composition PUBTATOR Site CD16a 2214 position Here we isolated monocytes from individual donors and characterized the composition of CD16a and CD32a N-glycans from all modified sites. 29333671 3 34 gly glycosylation 584:596 arg2 broader glycosylation site coverage broader glycosylation site coverage site This material has exhibited superior selectivity and broader glycosylation site coverage over commercial Sepharose in glycoproteomic evaluation. 10471642 4 88 gly N-glycosylation 847:861 arg2 the N-432 N-glycosylation site transferrin site PUBTATOR transferrin 7018 site A specific antibody directed against the amino acid sequence surrounding the N-432 N-glycosylation site of transferrin was prepared (SZ-350 antibody). 7688818 11 78 gly glycosylation 1918:1930 arg2 an N-linked glycosylation site an N-linked glycosylation site site One of the transitional epitopes identified (E2 residues 200 to 202) lies in the E2 190-216 region, which harbors two major neutralization sites, E2a and E2b, and an N-linked glycosylation site at E2 196. 8347587 13 61 gly glycosylation 1557:1569 arg1 the four sites sites sites This is in contrast to glycosylation at the four sites on the beta subunit which appear not to be important for processing but necessary for signal transduction. 26911932 12 19 gly N-glycans 2080:2088 arg1 FSHβ subunit subunit N-glycans Fterm subunit Our studies also reveal that N-glycans on FSHβ subunit are essential for FSH secretion and FSH in vivo bioactivity to regulate gonadal growth and physiology. 9557657 3 25 part_of TSP-rich 743:750 arg1 the TSP-rich region TSP the TSP-rich region OGER Site TSP P07996 region The havcr-1 glycoprotein contains four putative N-glycosylation sites, two in the Cys-rich region and two in the TSP-rich region. 9557657 3 36 part_of contains 655:662 arg1 The havcr-1 glycoprotein AND four putative N-glycosylation sites The havcr-1 glycoprotein four putative N-glycosylation sites PUBTATOR Site havcr-1 glycoprotein 26762 sites The havcr-1 glycoprotein contains four putative N-glycosylation sites, two in the Cys-rich region and two in the TSP-rich region. 26256267 8 29 gly glycoproteins 1373:1385 arg1 176 glycoproteins 176 glycoproteins Fterm glycoproteins Among the 1810 unique N-linked glycosite-containing peptides from 653 identified N-glycoproteins, 176 glycoproteins were observed to be different between the two cell lines. 26256267 8 92 gly N-glycoproteins 1352:1366 arg1 N-glycoproteins N-glycoproteins Fterm N-glycoproteins Among the 1810 unique N-linked glycosite-containing peptides from 653 identified N-glycoproteins, 176 glycoproteins were observed to be different between the two cell lines. 19369259 2 19 gly glycoprotein 234:245 arg1 This plasma membrane glycoprotein This plasma membrane glycoprotein Fterm glycoprotein This plasma membrane glycoprotein has a wide range of ligands including oxidized low density lipoprotein and long chain fatty acids which involves the receptor in diseases such as atherosclerosis and insulin resistance. 26439794 7 18 gly monosialo-fucosylated 1061:1081 arg1 monosialo-fucosylated biantennary oligosaccharides monosialo-fucosylated biantennary oligosaccharides The most frequently occurring forms at N-glycosylation site were high-mannose type containing nine mannose residues (M9) and monosialo-fucosylated biantennary oligosaccharides. 26439794 7 42 gly site 991:994 arg1 high-mannose type site high-mannose type site The most frequently occurring forms at N-glycosylation site were high-mannose type containing nine mannose residues (M9) and monosialo-fucosylated biantennary oligosaccharides. 26439794 7 47 gly N-glycosylation 975:989 arg2 N-glycosylation site N-glycosylation site site The most frequently occurring forms at N-glycosylation site were high-mannose type containing nine mannose residues (M9) and monosialo-fucosylated biantennary oligosaccharides. 9352200 7 5 gly glycoprotein 1025:1036 arg1 the secretory glycoprotein pathway the secretory glycoprotein pathway Fterm glycoprotein In mammalian and Xenopus sequences, a furin-like (convertase) site and a C-terminal transmembrane domain were present reflecting the biosynthesis of ZPC in these species via the secretory glycoprotein pathway. 20338479 8 18 gly beta1 1099:1103 arg1 sialylation integrin beta1 sialylation PUBTATOR integrin beta1 3688 When sialylation of integrin beta1 was targeted with a sulfonamide chalcone compound, inhibition of radiation-induced sialylation of integrin beta1 and inhibition of radiation-induced adhesion and migration occurred. 20338479 8 28 gly sialylation 1188:1198 arg1 integrin beta1 integrin beta1 PUBTATOR integrin beta1 3688 When sialylation of integrin beta1 was targeted with a sulfonamide chalcone compound, inhibition of radiation-induced sialylation of integrin beta1 and inhibition of radiation-induced adhesion and migration occurred. 20338479 8 42 gly sialylation 1075:1085 arg1 integrin beta1 integrin beta1 PUBTATOR integrin beta1 3688 When sialylation of integrin beta1 was targeted with a sulfonamide chalcone compound, inhibition of radiation-induced sialylation of integrin beta1 and inhibition of radiation-induced adhesion and migration occurred. 20338479 8 81 gly beta1 1212:1216 arg1 radiation-induced sialylation integrin beta1 radiation-induced sialylation PUBTATOR integrin beta1 3688 When sialylation of integrin beta1 was targeted with a sulfonamide chalcone compound, inhibition of radiation-induced sialylation of integrin beta1 and inhibition of radiation-induced adhesion and migration occurred. 7765932 4 46 gly glycosylation 700:712 arg2 glycosylation site occupancy glycosylation site occupancy site The observed increase in glycosylation site occupancy upon addition of cycloheximide is consistent with the current opinion that the initial glycosylation event occurs cotranslationally during a limited time period. 8514796 1 2 gly unglycosylated 303:316 arg1 The erythropoietin receptor The erythropoietin receptor PUBTATOR erythropoietin receptor 13857 The erythropoietin receptor (EPO-R) is synthesized in transfected Ba/F3 cells as a major 64-kDa endoglycosidase H (Endo H)-sensitive species, with a single N-linked oligosaccharide, and a minor 62-kDa unglycosylated form. 16755913 4 45 gly glycosylation 897:909 arg2 glycosylation sites glycosylation sites sites Several mutants with specific glycosylation modification were identified from the expressed products by Western blot, including two mutants with one glycosylation site mutated and one without any mutation at glycosylation sites. 16755913 4 46 gly glycosylation 838:850 arg2 one glycosylation site one glycosylation site site Several mutants with specific glycosylation modification were identified from the expressed products by Western blot, including two mutants with one glycosylation site mutated and one without any mutation at glycosylation sites. 8578865 6 46 gly glycoprotein 836:847 arg1 the glycoprotein precursor the glycoprotein precursor Fterm glycoprotein The M RNA is 3681 nt in length and encodes the glycoprotein precursor. 22649382 9 7 gly N-glycosylation 1453:1467 arg2 extracellular domain N-glycosylation sites extracellular domain N-glycosylation sites sites Our data indicate that extracellular domain N-glycosylation sites regulate in a combinatorial manner cell surface localization of TpoR. 20208072 5 9 gly glycosylation 989:1001 arg2 the putative O-linked glycosylation site Thr(648) GRP78 site Thr(648) PUBTATOR GRP78 3309 site Thr(648) Moreover, deletion of the C-terminal ER retention motif in GRP78 alters its cell surface presentation in a dose-dependent manner; however, mutation of the putative O-linked glycosylation site Thr(648) of human GRP78 is without effect. 20208072 5 69 gly site 1003:1006 arg1 648 site Thr(648) site Thr(648) Moreover, deletion of the C-terminal ER retention motif in GRP78 alters its cell surface presentation in a dose-dependent manner; however, mutation of the putative O-linked glycosylation site Thr(648) of human GRP78 is without effect. 11705953 5 69 gly glycosylation 913:925 arg2 at least four glycosylation sites at least four glycosylation sites sites Mass spectrometry analyses indicate that both enzymes carry high-mannose type oligosaccharides on at least four glycosylation sites. 11705953 5 74 gly oligosaccharides 879:894 arg1 at least four glycosylation sites at least four glycosylation sites at least four glycosylation sites Site sites Mass spectrometry analyses indicate that both enzymes carry high-mannose type oligosaccharides on at least four glycosylation sites. 11705953 5 35 gly carry 855:859 arg1 both enzymes AND high-mannose type oligosaccharides both enzymes high-mannose type oligosaccharides Fterm enzymes Mass spectrometry analyses indicate that both enzymes carry high-mannose type oligosaccharides on at least four glycosylation sites. 15527836 9 92 gly glycosylation 1459:1471 arg2 the glycosylation site rCAT1 site PUBTATOR rCAT1 25648 site An amino acid substitution in the glycosylation site of the wild-type rCAT1 conferred higher infection susceptibility, but that of the rCAT1 mutant 1 did not. 14561640 8 69 gly N-glycosylation 1082:1096 arg2 a potential N-glycosylation site a potential N-glycosylation site site The deduced protein is composed of 213 amino acids, including a 23-amino acid peptide signal and a potential N-glycosylation site. 9820842 1 24 gly N-glycosylation 242:256 arg2 an N-glycosylation site an N-glycosylation site site Based on sequence analysis, the protein encoded by the US5 open reading frame (ORF) of herpes simplex virus type 1 (HSV-1) was predicted to contain an N-glycosylation site and was given the designation of glycoprotein J (gJ). 9820842 1 63 gly glycoprotein 296:307 arg1 glycoprotein J glycoprotein J Fterm glycoprotein J Based on sequence analysis, the protein encoded by the US5 open reading frame (ORF) of herpes simplex virus type 1 (HSV-1) was predicted to contain an N-glycosylation site and was given the designation of glycoprotein J (gJ). 2952720 6 92 part_of region 1323:1328 arg1 the delta subunits subunits region Fterm Site subunits region The 16-amino acid region flanking Ser 126 was totally conserved (100%) in the gamma subunits, yet showed little homology (38 to 44%) with the corresponding region in the delta subunits, in spite of the otherwise high degree of conservation (61 to 68%) between the remainder of the cytoplasmic domains of the gamma and delta chains. 26348848 6 16 gly glycosylated 1127:1138 arg1 Kv3.1b Kv3.1b PUBTATOR Kv3 29731 Based on particle analysis of EGFP-Kv proteins in the adhered membrane, glycosylated forms of Kv3.1a, Kv1.1, and Kv3.1b had differences in the number, size or density of Kv protein clusters in the cell membrane of neurites and cell body of B35 cells. 7711052 2 50 gly glycosylation 483:495 arg2 N-linked glycosylation sites N-linked glycosylation sites sites This review focuses on the occupancy of N-linked glycosylation sites on three enzymes, ribonuclease, plasminogen and tissue plasminogen activator. 7711052 2 73 gly occupancy 461:469 arg2 N-linked glycosylation sites N-linked glycosylation sites sites This review focuses on the occupancy of N-linked glycosylation sites on three enzymes, ribonuclease, plasminogen and tissue plasminogen activator. 21750110 1 59 part_of seipin/BSCL2 213:224 arg1 the N-glycosylation site BSCL2 the N-glycosylation site PUBTATOR Site BSCL2 14705 site Heterozygosity for mutations (N88S and P90L) in the N-glycosylation site of seipin/BSCL2 is associated with the autosomal dominant motor neuron diseases, spastic paraplegia 17 and distal hereditary motor neuropathy type V, referred to as 'seipinopathies'. 25713063 4 56 gly N-glycosylation 456:470 arg2 The N-glycosylation site occupancy The N-glycosylation site occupancy site The N-glycosylation site occupancy and disulfide pattern, the oligomeric structure, and unfolding pathway are reported. 23613470 9 66 gly glycosylation 1399:1411 arg2 the Asn40 glycosylation site Wnt11 site PUBTATOR Wnt11 7481 site By the fusion of the Asn40 glycosylation site of Wnt11, Wnt3a was secreted apically. 3200844 4 86 gly glycopeptide 566:577 arg2 a glycopeptide a glycopeptide glycopeptide After CNBr fragmentation, a glycopeptide was isolated and microsequenced. 11439087 0 55 gly N-glycosylation 25:39 arg2 N-glycosylation sites N-glycosylation sites sites Site-directed removal of N-glycosylation sites in BST-1/CD157: effects on molecular and functional heterogeneity. 26056814 8 9 gly glycosylation 1544:1556 arg2 a glycosylation site a glycosylation site site The K123N mutation which introduces a glycosylation site proximal to the receptor binding site, did not impact the α2,3/α2,6 glycan selectivity, however, it lowered the overall glycan binding affinity of the HA; suggesting glycosylation may interfere with receptor binding. 29528338 4 10 part_of LILRB1 640:645 arg1 the binding domains LILRB1 the binding domains PUBTATOR Site LILRB1 10859 domains The altered functional recognition was recapitulated in binding assays with the binding domains of LILRB1. 19619305 5 28 gly glycosylation 1124:1136 arg2 position 386 position 386 position 386 Furthermore, loss of an N-linked glycosylation site at position 386 in the V4 region of Env enhanced macrophage tropism together with b12 sensitivity, but not neutralization by sCD4, b6, or a broadly neutralizing AIDS patient serum. 19619305 5 28 gly glycosylation 1124:1136 arg2 an N-linked glycosylation site an N-linked glycosylation site site Furthermore, loss of an N-linked glycosylation site at position 386 in the V4 region of Env enhanced macrophage tropism together with b12 sensitivity, but not neutralization by sCD4, b6, or a broadly neutralizing AIDS patient serum. 8806496 6 7 gly first 1121:1125 arg1 glycosylation sites glycosylation sites sites In addition, mutants lacking the first or both glycosylation sites exhibited significant reduction in mouse neurovirulence after intracerebral inoculation. 8806496 6 21 gly glycosylation 1135:1147 arg2 glycosylation sites glycosylation sites sites In addition, mutants lacking the first or both glycosylation sites exhibited significant reduction in mouse neurovirulence after intracerebral inoculation. 2868718 5 19 part_of S-1.1 517:521 arg1 The nucleotide sequence S-1.1 The nucleotide sequence PUBTATOR Site S-1.1 6267 sequence The nucleotide sequence of S-1.1 was determined. 8706658 10 105 part_of synthase 2342:2349 arg1 the C-terminal domain leukotriene C4 synthase the C-terminal domain PUBTATOR Site leukotriene C4 synthase 17001 domain These findings confirm that the leukotriene C4 synthases belong to a gene family that includes the 5-lypoxygenase-activating protein and suggest that the C-terminal domain of leukotriene C4 synthase may not be critical for its conjugation function. 23422691 4 0 gly glycosylated 643:654 arg1 glycosylated VEGF glycosylated VEGF PUBTATOR VEGF 7422 The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF. 24899172 2 44 gly glycosylation 357:369 arg2 This glycosylation site This glycosylation site site This glycosylation site is never fully functional, leading to a nearly 1/1 ratio of glycosylated/nonglycosylated isoforms in the viral envelope. 24899172 2 113 gly glycosylated/nonglycosylated 436:463 arg1 glycosylated/nonglycosylated isoforms glycosylated/nonglycosylated isoforms Fterm isoforms This glycosylation site is never fully functional, leading to a nearly 1/1 ratio of glycosylated/nonglycosylated isoforms in the viral envelope. 10099230 1 71 gly glycoprotein 410:421 arg1 a secretory recombinant glycoprotein glycoprotein the final carbohydrate structures Fterm glycoprotein The effect of different ammonium concentrations and glucosamine on baby hamster kidney (BHK)-21 cell cultures grown in continuously perfused double membrane bioreactors was investigated with respect to the final carbohydrate structures of a secretory recombinant glycoprotein. 27573070 3 13 gly N-glycopeptides 614:628 arg2 native N-glycopeptides native N-glycopeptides N-glycopeptides Here we report on the development of gFinder, a web-based bioinformatics tool that analyzes mixtures of native N-glycopeptides that have been profiled by tandem MS. gFinder not only enables the simultaneous integration of collision-induced dissociation (CID) and high-energy collisional dissociation (HCD) fragmentation but also merges the spectra for high-throughput analysis. 7711052 5 69 gly sugar 984:988 arg1 plasminogen plasminogen sugar OGER plasminogen P00747 The N-linked sugar on plasminogen (at Asn-288) within kringle 3 reduces the rate of the beta- to alpha-conformational change, modulates the transport of plasminogen into the extravascular compartment, decreases plasminogen binding to U937 cells and downregulates the activation of plasminogen by both urokinase and tissue plasminogen activator. 1367433 8 56 gly glycosylation 1489:1501 arg2 the actual glycosylation site the actual glycosylation site site These results demonstrate for the first time that structural alterations in the primary sequence distal to the actual glycosylation site can result in altered processing of N-linked oligosacharides. 18077336 6 7 gly glycosylated 697:708 arg2 the single endogenous N-terminal glycosylation site the single endogenous N-terminal glycosylation site site Nearly half of MRAP was glycosylated at the single endogenous N-terminal glycosylation site, and over half was glycosylated when the natural glycosylation site was replaced by one in the C-terminal domain. 18077336 6 63 gly glycosylation 746:758 arg2 the single endogenous N-terminal glycosylation site the single endogenous N-terminal glycosylation site site Nearly half of MRAP was glycosylated at the single endogenous N-terminal glycosylation site, and over half was glycosylated when the natural glycosylation site was replaced by one in the C-terminal domain. 18077336 6 72 gly glycosylation 814:826 arg2 the natural glycosylation site the natural glycosylation site site Nearly half of MRAP was glycosylated at the single endogenous N-terminal glycosylation site, and over half was glycosylated when the natural glycosylation site was replaced by one in the C-terminal domain. 1972631 9 73 part_of containing 1152:1161 arg1 a domain AND another N-linked glycosylation site a domain another N-linked glycosylation site site The fourth exon contains the region that was proposed as a lipid binding domain, the sixth for one putative heparin binding domain, and the eighth codes for a domain containing another N-linked glycosylation site. 22855498 11 29 gly glycoprotein 1426:1437 arg1 increased envelope glycoprotein increased envelope glycoprotein Fterm glycoprotein Together, these data demonstrate that increased envelope glycoprotein fitness can drive selective outgrowth of minor variants posttransmission and that loss of a PNGS is integral to this improved phenotype. 19088065 9 80 gly N-glycosylation 1099:1113 arg2 a single N-glycosylation site a single N-glycosylation site site The presence of a single N-glycosylation site on KLK6 was confirmed by site-directed mutagenesis. 2040275 10 41 gly oligosaccharide 1463:1477 arg1 a glycoprotein glycoprotein oligosaccharide Fterm glycoprotein Thus, the conformational space available to an N-linked oligosaccharide in a glycoprotein relative to the protein may depend to a large extent upon the flexibility of the asparagine side chain. 2040275 10 56 gly glycoprotein 1484:1495 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Thus, the conformational space available to an N-linked oligosaccharide in a glycoprotein relative to the protein may depend to a large extent upon the flexibility of the asparagine side chain. 11550262 2 54 part_of cDNA 303:306 arg1 testis-specific cDNA fragment cDNA testis-specific cDNA fragment Cterm Site cDNA fragment On screening the human testis-(lambda)gt10-cDNA library with testis-specific cDNA fragment, a novel cDNA encoding for a sperm antigen, designated TSA-1, was obtained. 12631291 7 22 gly nonglycosylated 908:922 arg1 the nonglycosylated recombinant protein isoforms the nonglycosylated recombinant protein isoforms Fterm protein Accordingly, the nonglycosylated recombinant protein isoforms did not bind IgE of tomato allergic patients. 15956584 1 6 gly glycoproteins 138:150 arg1 two viral envelope glycoproteins two viral envelope glycoproteins Fterm glycoproteins Hepatitis C virus (HCV) encodes two viral envelope glycoproteins. 15253437 5 10 part_of sites 1285:1289 arg1 37 glycoproteins glycoproteins sites Fterm Site glycoproteins sites We first tested our approach on a mixture of known glycoproteins, and subsequently the method was applied to samples of human plasma obtained by lectin chromatography followed by 1D gel-electrophoresis for determination of 62 glycosylation sites in 37 glycoproteins. 19035324 3 22 part_of decrease 482:489 arg1 The amino acids sequence IPSIQSR decrease G The amino acids sequence Cterm Site IPSIQSR decrease G sequence The amino acids sequence of cleavage site of HA is IPSIQSR decrease G, suggesting that LM did not have the molecular characteristics of high pathogen. 29404897 7 46 gly N-glycosylation 1273:1287 arg2 the N-glycosylation site the N-glycosylation site site The reduction of the N-glycosylation site at position 42 of NA was observed in some strains. 24899172 9 89 gly nonglycosylated 1704:1718 arg1 the nonglycosylated N146 the nonglycosylated N146 N146 Taken together, these findings suggest that the nonglycosylated N146 is essential for infectivity, while the glycosylated form, in addition to its importance for HBV virion secretion, is instrumental in shielding the a-determinant from neutralizing antibodies. 1370483 1 11 gly Surfactant 95:104 arg1 a carbohydrate-binding glycoprotein Surfactant protein D a carbohydrate-binding glycoprotein PUBTATOR Surfactant protein D 25350 Surfactant protein D (SP-D) is a carbohydrate-binding glycoprotein containing a collagen-like domain that is synthesized by alveolar type II epithelial cells. 1370483 1 46 gly protein 106:112 arg1 a carbohydrate-binding glycoprotein Surfactant protein D a carbohydrate-binding glycoprotein PUBTATOR Surfactant protein D 25350 Surfactant protein D (SP-D) is a carbohydrate-binding glycoprotein containing a collagen-like domain that is synthesized by alveolar type II epithelial cells. 1370483 1 7 gly glycoprotein 149:160 arg1 Surfactant protein D Surfactant protein D a carbohydrate-binding glycoprotein PUBTATOR Surfactant protein D 25350 Surfactant protein D (SP-D) is a carbohydrate-binding glycoprotein containing a collagen-like domain that is synthesized by alveolar type II epithelial cells. 19700364 3 16 gly glycosylation 331:343 arg2 the sites the sites sites Glycoprotein analysis requires determining both the sites of glycosylation as well as the glycan structures associated with each site. 19418565 5 23 part_of t-PA 904:907 arg1 site-occupancy t-PA site-occupancy OGER Site t-PA P00750 site-occupancy Decreasing the cultivation temperature from 37 to 33 degrees C or 31 degrees C gradually increased site-occupancy of t-PA up to 4%. 25614584 3 12 part_of sites 522:526 arg1 the mumps virus surface glycoproteins glycoproteins sites Fterm Site glycoproteins sites In the work presented here we sought to identify new neutralization sites on the mumps virus surface glycoproteins. 14759610 2 23 part_of NCS/T 251:255 arg1 synthetic Asn-Cys-Ser/Thr(NCS/T) tripeptides NCS synthetic Asn-Cys-Ser/Thr(NCS/T) tripeptides OGER Site NCS tripeptides We used synthetic Asn-Cys-Ser/Thr(NCS/T) tripeptides conjugated to bovine serum albumin to isolate single chain antibody fragments of a variable region (scFv) from the Griffin 1 phage antibody library. 10849765 11 23 part_of B 1831:1831 arg1 the pro region cathepsin B the pro region PUBTATOR AminoAcid cathepsin B 1508 pro region Our results suggest that: 1) tumor cells have an alternative mechanism for trafficking of cathepsin B which is independent of the mannose-6-phosphate receptor pathway, and 2) the pro region of cathepsin B may contain the sorting sequence necessary for its trafficking via this pathway. 10849765 11 19 part_of contain 1837:1843 arg1 the pro region AND the sorting sequence the pro region the sorting sequence sequence Our results suggest that: 1) tumor cells have an alternative mechanism for trafficking of cathepsin B which is independent of the mannose-6-phosphate receptor pathway, and 2) the pro region of cathepsin B may contain the sorting sequence necessary for its trafficking via this pathway. 20667571 6 81 gly glycosylation 1317:1329 arg1 the HA protein the HA protein Fterm protein Increased cytokine production by HK03 ca virus was only observed when HK03 ca virus acquired an additional glycosylation in the HA protein and when its NA protein was replaced by that of VN04. 28366604 8 4 gly domain 1308:1313 arg1 a determinant domain a determinant domain Thus, we identified a determinant of the CD4i domain that might affect vaccine-elicited anti-V2 Ab and ADCC responses to SIVmac239. 10593916 3 26 part_of glycoprotein 802:813 arg1 a glycosylation motif -NXS- glycoprotein a glycosylation motif -NXS- Fterm Site glycoprotein motif LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response. 9851685 6 6 part_of has 921:923 arg1 guinea pig IL-2 AND a possible N-linked glycosylation site guinea pig IL-2 a possible N-linked glycosylation site PUBTATOR Site IL-2 P60568 site In addition, guinea pig IL-2 has a possible N-linked glycosylation site as seen in bovine and porcine IL-2. 8360166 2 29 gly N-glycosylation 466:480 arg2 an N-glycosylation site an N-glycosylation site site To determine whether the NH2-terminal sequence might also have an ER retention function, the NH2-terminal 29 amino acids of cytochrome P450 2C1, with and without an additional 29 amino acids containing an N-glycosylation site, were fused either to a soluble cytoplasmic protein, Escherichia coli beta-galactosidase, or to a secreted protein, E. coli alkaline phosphatase, and the hybrid proteins were expressed in COS1 cells. 11356836 1 26 gly glycoprotein 133:144 arg1 small, heat-stable glycoprotein activators small, heat-stable glycoprotein activators Fterm glycoprotein Saposins are small, heat-stable glycoprotein activators of lysosomal glycosphingolipid hydrolases that derive from a single precursor, prosaposin, by proteolytic cleavage. 26482295 7 22 part_of sequon 1406:1411 arg1 human immunoglobulin G human immunoglobulin G sequon Cterm Site human immunoglobulin G sequon One notable example is D. gigas PglB, which was the only bacterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon. 26482295 7 22 part_of sequon 1406:1411 arg1 the Fc domain sequon the Fc domain domain One notable example is D. gigas PglB, which was the only bacterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon. 26482295 7 26 part_of G 1382:1382 arg1 the Fc domain human immunoglobulin G the Fc domain Cterm Site human immunoglobulin G domain One notable example is D. gigas PglB, which was the only bacterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon. 26482295 7 36 part_of domain 1351:1356 arg1 its native 'QYNST' sequon domain its native 'QYNST' sequon sequon One notable example is D. gigas PglB, which was the only bacterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon. 7922031 7 80 part_of beta-subunit 1115:1126 arg1 The carboxy-terminal peptide subunit The carboxy-terminal peptide OGER Site subunit P0DN86 peptide The carboxy-terminal peptide of the beta-subunit, which is rich in O-linked sugars, is disordered. 9597548 2 17 gly glycosylated 419:430 arg1 a potential sixth N-glycosylation site a potential sixth N-glycosylation site site This antibody also has a potential sixth N-glycosylation site in the variable region of its heavy chain which is not glycosylated. 9597548 2 25 gly N-glycosylation 343:357 arg2 a potential sixth N-glycosylation site a potential sixth N-glycosylation site site This antibody also has a potential sixth N-glycosylation site in the variable region of its heavy chain which is not glycosylated. 18623533 0 42 gly interferon-gamma 31:46 arg1 N-glycans interferon-gamma N-glycans PUBTATOR interferon-gamma 3458 N-glycans of recombinant human interferon-gamma change during batch culture of chinese hamster ovary cells. 2780569 8 57 part_of contains 1405:1412 arg1 the snake alpha subunit AND the two tandem cysteines the snake alpha subunit the two tandem cysteines Fterm SpecificSite subunit cysteines at positions 192 and 193 The deduced amino acid sequence showed that the snake alpha subunit contains the two tandem cysteines at positions 192 and 193, resembling all other AcChoR alpha subunits. 2318516 0 20 part_of alpha 113:117 arg1 the alpha 1 and alpha 2 protein domains alpha 1 and alpha 2 the alpha 1 and alpha 2 protein domains PUBTATOR Site alpha 1 and alpha 2 146 domains The transport of class I major histocompatibility complex antigens is determined by sequences in the alpha 1 and alpha 2 protein domains. 2318516 0 27 part_of sequences 84:92 arg1 the alpha 1 and alpha 2 protein domains sequences the alpha 1 and alpha 2 protein domains domains The transport of class I major histocompatibility complex antigens is determined by sequences in the alpha 1 and alpha 2 protein domains. 2318516 0 112 part_of alpha 101:105 arg1 the alpha 1 and alpha 2 protein domains alpha 1 and alpha 2 the alpha 1 and alpha 2 protein domains PUBTATOR Site alpha 1 and alpha 2 146 domains The transport of class I major histocompatibility complex antigens is determined by sequences in the alpha 1 and alpha 2 protein domains. 9950772 3 2 gly glycosylation 633:645 arg2 a glycosylation site a glycosylation site site The shark sequence maintains six extracellular Cys present in other NPR-B but lacks a glycosylation site and a Glu residue previously considered important for CNP binding. 1331508 8 44 part_of receptor 1136:1143 arg1 domain 1 receptor domain 1 Fterm Site receptor domain These results suggest that domain 1 of the monkey receptor also harbors the binding site for poliovirus and that sugar moieties possibly attached to this domain of human PVR are dispensable for the virus-receptor interaction. 1331508 8 54 part_of PVR 1256:1258 arg1 this domain PVR this domain PUBTATOR Site PVR 5817 domain These results suggest that domain 1 of the monkey receptor also harbors the binding site for poliovirus and that sugar moieties possibly attached to this domain of human PVR are dispensable for the virus-receptor interaction. 8639654 4 72 gly used 855:858 arg2 Asn293 Asn293 Asn293 Mutations of each consensus site revealed that Asn58, Asn69, and Asn100 were occupied by a 9-kDa N-linked carbohydrate whereas Asn293 was not used for glycosylation. 8639654 4 3 gly occupied 790:797 arg2 Asn100 Asn58, Asn69, and Asn100 Asn58, Asn69, and Asn100 Mutations of each consensus site revealed that Asn58, Asn69, and Asn100 were occupied by a 9-kDa N-linked carbohydrate whereas Asn293 was not used for glycosylation. 8639654 4 3 gly occupied 790:797 arg2 Asn69 Asn58, Asn69, and Asn100 Asn58, Asn69, and Asn100 Mutations of each consensus site revealed that Asn58, Asn69, and Asn100 were occupied by a 9-kDa N-linked carbohydrate whereas Asn293 was not used for glycosylation. 8639654 4 3 gly occupied 790:797 arg2 Asn69 Asn58, Asn69, and Asn100 Asn58, Asn69, and Asn100 Mutations of each consensus site revealed that Asn58, Asn69, and Asn100 were occupied by a 9-kDa N-linked carbohydrate whereas Asn293 was not used for glycosylation. 24150277 14 11 gly glycosylation 1796:1808 arg2 N-linked glycosylation site N-linked glycosylation site site We were able to utilize this azide to label the antibody with biotin or fluorescent label and demonstrate that the label is added in a site-specific manner to the heavy chain, N-linked glycosylation site. 29109276 0 92 gly glycosylation 43:55 arg2 a glycosylation site a glycosylation site site Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. 7559574 6 39 part_of phosphacan 1487:1496 arg1 the amino acid sequence phosphacan the amino acid sequence PUBTATOR Site phosphacan 5803 sequence Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex-type oligosaccharides. 7559574 6 87 part_of contains 1553:1560 arg1 the tryptic peptides AND one potential N-glycosylation site the tryptic peptides one potential N-glycosylation site site Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex-type oligosaccharides. 11604992 4 26 part_of WNT15 320:324 arg1 WNT15 cDNA fragment WNT15 cDNA WNT15 cDNA fragment PUBTATOR Site WNT15 cDNA 7484 fragment WNT15 cDNA fragment previously isolated by another group corresponds to a part of ORF of the WNT14B cDNA (codon 216-335). 11604992 4 35 part_of cDNA 326:329 arg1 WNT15 cDNA fragment WNT15 cDNA WNT15 cDNA fragment PUBTATOR Site WNT15 cDNA 7484 fragment WNT15 cDNA fragment previously isolated by another group corresponds to a part of ORF of the WNT14B cDNA (codon 216-335). 15119761 10 70 gly glycosylation 1481:1493 arg2 the glycosylation site the glycosylation site site The results show that the two viruses differ by 5 amino acids in the envelope (E) protein, including loss of the glycosylation site. 15341529 5 36 part_of mOR-EG 752:757 arg1 the N-terminal glycosylation site mOR-EG the N-terminal glycosylation site PUBTATOR Site mOR-EG 117004 site Disruption of the N-terminal glycosylation site of the mOR-EG completely impaired its membrane trafficking to the cell surface. 22245433 5 6 gly glycosylation 804:816 arg2 the glycosylation site the glycosylation site site Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors. 22245433 5 14 gly glycosylation 855:867 arg2 580 Asn(580) Asn(580) Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors. 22245433 5 14 gly glycosylation 855:867 arg1 Asn Asn(580) Asn(580) Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors. 22245433 5 14 gly glycosylation 855:867 arg2 Asn Asn(580) Asn(580) Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors. 22245433 5 14 gly glycosylation 855:867 arg1 COX-2 COX-2 Asn(580) PUBTATOR COX-2 5743 Asn(580) Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors. 22245433 5 14 gly glycosylation 855:867 arg1 Asn Asn(580) Asn(580) Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors. 22245433 5 14 gly glycosylation 855:867 arg2 Asn Asn(580) Asn(580) Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors. 22245433 5 14 gly glycosylation 855:867 arg1 COX-2 COX-2 Asn(580) PUBTATOR COX-2 5743 Asn(580) Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors. 22245433 5 14 gly glycosylation 855:867 arg2 Asn Asn(580) Asn(580) Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors. 22245433 5 14 gly glycosylation 855:867 arg1 COX-2 COX-2 Asn(580) PUBTATOR COX-2 5743 Asn(580) Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors. 22245433 5 14 gly glycosylation 855:867 arg1 COX-2 COX-2 Asn(580) PUBTATOR COX-2 5743 Asn(580) Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors. 7688818 13 4 gly glycoprotein 2296:2307 arg1 the glycoprotein spike the glycoprotein spike Fterm structure of the glycoprotein The absence of a carbohydrate moiety did not expose the transitional epitopes mapped to this locus, suggesting that on native virions, the inaccessibility of the E2 200-202 determinant was inherent in the structure of the glycoprotein spike. 20235580 4 76 gly glycopeptide 921:932 arg2 a glycopeptide capture specificity a glycopeptide capture specificity glycopeptide Evaluation of a range of capture and elution conditions led to an optimized protocol with a 24% intraday and 30% interday CV and a glycopeptide capture specificity of 99%. 12064867 7 27 part_of CD4-binding 1228:1238 arg1 the CD4-binding site CD4 the CD4-binding site PUBTATOR Site CD4 920 site However, the difference in gp120 orientation indicates that antibodies in HIV-infected individuals, at least partly, bind to epitopes different from the CD4-binding site. 15100290 2 13 gly carbohydrate 261:272 arg1 complementarity-determining region 2 complementarity-determining region 2 complementarity-determining region 2 Site region We have studied a murine anti-alpha(1-->6) dextran V(H) that contains a carbohydrate in complementarity-determining region 2 (CDR2). 15100290 2 13 gly carbohydrate 261:272 arg1 CDR2 2 (CDR2 carbohydrate OGER 2 (CDR2 P97817 We have studied a murine anti-alpha(1-->6) dextran V(H) that contains a carbohydrate in complementarity-determining region 2 (CDR2). 2457333 4 71 gly glycopeptides 346:358 arg2 The glycopeptides The glycopeptides glycopeptides The glycopeptides were purified by a combination of anion exchange chromatography and reverse-phase HPLC. 2771955 7 10 part_of GPIX 1251:1254 arg1 The predicted amino acid sequence GPIX The predicted amino acid sequence PUBTATOR Site GPIX 2815 sequence The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site. 22213703 7 14 gly glycosylation 902:914 arg2 the glycosylation site the glycosylation site site In this article, chromatographic methods for the analysis of the glycoforms on the glycosylation site and the glycans in mAb biopharmaceuticals have been evaluated. 22213703 7 25 gly glycans 929:935 arg1 the glycosylation site the glycosylation site the glycosylation site Site site In this article, chromatographic methods for the analysis of the glycoforms on the glycosylation site and the glycans in mAb biopharmaceuticals have been evaluated. 22213703 7 26 gly glycoforms 884:893 arg2 the glycosylation site the glycosylation site site In this article, chromatographic methods for the analysis of the glycoforms on the glycosylation site and the glycans in mAb biopharmaceuticals have been evaluated. 11063734 8 61 part_of SP-B 1217:1220 arg1 Thr/Thr SP-B Thr/Thr PUBTATOR Site SP-B 6439 Thr/Thr On the basis of chi(2) and logistic regression analyses, the SP-A allele, haplotype and genotype distributions differed significantly between the RDS infants and controls only when the SP-B genotype was Thr/Thr. 7529232 5 35 gly glycosylated 927:938 arg1 fully glycosylated hsCD2 fully glycosylated hsCD2 Cterm hsCD2 914 The ligand and antibody binding properties of this form of hsCD2 were indistinguishable from those of fully glycosylated hsCD2 as determined by surface plasmon resonance analyses. 22750213 7 6 gly glycoproteins 1167:1179 arg1 membrane glycoproteins membrane glycoproteins Fterm glycoproteins This result is contrary to the reports that glycosylation is essential for conformation and trafficking of membrane glycoproteins. 22750213 7 48 gly glycosylation 1095:1107 arg1 membrane glycoproteins membrane glycoproteins Fterm glycoproteins This result is contrary to the reports that glycosylation is essential for conformation and trafficking of membrane glycoproteins. 11559807 3 20 gly N-glycosylation 674:688 arg2 an N-glycosylation sequon an N-glycosylation sequon sequon Substitution of pAPN amino acids 283 to 290 into hAPN for the corresponding amino acids 288 to 295 introduced an N-glycosylation sequon at amino acids 291 to 293 that blocked HCoV-229E receptor activity of hAPN. 9455905 6 10 gly O-glycosylation 1320:1334 arg2 a single site a single site site Each reporter, which contains a single site of O-glycosylation, was O-glycosylated in a cell-background-specific manner; digestion with O-glycanase and alpha-N-acetylgalactosaminidase following mild acid hydrolysis suggested that simple type II core structures were acquired. 2477364 10 37 gly present 1479:1485 arg1 Asn-52 AND Oligosaccharides Asn-52 Oligosaccharides Asn-52 Oligosaccharides present at Asn-52 are almost exclusively ConA-unbound and contain three sialic acid residues. 29190644 5 34 gly glycoforms 888:897 arg1 monomeric human BChE glycoforms monomeric human BChE glycoforms PUBTATOR BChE 590 To investigate the effects of populating glycosylation site ASN241, monomeric human BChE glycoforms were simulated with and without site ASN241 glycosylated. 29190644 5 3 gly glycosylation 840:852 arg2 ASN241 site ASN241 site ASN241 To investigate the effects of populating glycosylation site ASN241, monomeric human BChE glycoforms were simulated with and without site ASN241 glycosylated. 12139935 0 79 gly -glycoprotein 46:58 arg1 human and bovine beta(2)-glycoprotein I human and bovine beta(2)-glycoprotein I PUBTATOR beta(2)-glycoprotein I 281006 Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering. 19933092 9 97 part_of T2R2 1571:1574 arg1 the transmembrane regions T2R2 the transmembrane regions Cterm Site T2R2 regions The results of nucleotide acid substitution computation and selective test showed that strong purifying selection (functional constraint) occurred between hog badger and the six species, respectively, which mainly existed in the transmembrane regions of T2R2. 12706077 2 29 gly residues 575:582 arg1 154-156 154-156 residues 154-156, 165-167, and 286-288 To assess the impact of glycosylation on the immunogenicity of an HA-expressing DNA vaccine, a series of plasmid vaccine constructs that differed in the presence of potential glycosylation sites at amino acid residues 154-156, 165-167, and 286-288 were used to immunize BALB/c mice. 12706077 2 32 gly glycosylation 541:553 arg2 potential glycosylation sites potential glycosylation sites sites To assess the impact of glycosylation on the immunogenicity of an HA-expressing DNA vaccine, a series of plasmid vaccine constructs that differed in the presence of potential glycosylation sites at amino acid residues 154-156, 165-167, and 286-288 were used to immunize BALB/c mice. 12706077 2 32 gly glycosylation 541:553 arg2 286-288 residues 154-156, 165-167, and 286-288 residues 154-156, 165-167, and 286-288 To assess the impact of glycosylation on the immunogenicity of an HA-expressing DNA vaccine, a series of plasmid vaccine constructs that differed in the presence of potential glycosylation sites at amino acid residues 154-156, 165-167, and 286-288 were used to immunize BALB/c mice. 12706077 2 32 gly glycosylation 541:553 arg2 165-167 residues 154-156, 165-167, and 286-288 residues 154-156, 165-167, and 286-288 To assess the impact of glycosylation on the immunogenicity of an HA-expressing DNA vaccine, a series of plasmid vaccine constructs that differed in the presence of potential glycosylation sites at amino acid residues 154-156, 165-167, and 286-288 were used to immunize BALB/c mice. 12706077 2 32 gly glycosylation 541:553 arg2 165-167 residues 154-156, 165-167, and 286-288 residues 154-156, 165-167, and 286-288 To assess the impact of glycosylation on the immunogenicity of an HA-expressing DNA vaccine, a series of plasmid vaccine constructs that differed in the presence of potential glycosylation sites at amino acid residues 154-156, 165-167, and 286-288 were used to immunize BALB/c mice. 1916293 3 5 gly utilized 556:563 arg2 Asn45 Asn45 Asn45 The results show that, at least in frog oocytes, the first potential N-glycosylation site (Asn45) is utilized exclusively. 1916293 3 5 gly utilized 556:563 arg2 the first potential N-glycosylation site the first potential N-glycosylation site site The results show that, at least in frog oocytes, the first potential N-glycosylation site (Asn45) is utilized exclusively. 1916293 3 64 gly N-glycosylation 524:538 arg2 Asn45 Asn45 Asn45 The results show that, at least in frog oocytes, the first potential N-glycosylation site (Asn45) is utilized exclusively. 1916293 3 64 gly N-glycosylation 524:538 arg2 the first potential N-glycosylation site the first potential N-glycosylation site site The results show that, at least in frog oocytes, the first potential N-glycosylation site (Asn45) is utilized exclusively. 19241033 0 50 gly N-glycoproteins 22:36 arg1 N-glycoproteins N-glycoproteins Fterm N-glycoproteins Structure analysis of N-glycoproteins. 9050863 2 28 gly glycoproteins 361:373 arg1 three glycoproteins three glycoproteins Fterm glycoproteins Hepatitis B virus specifies three glycoproteins (L, M, and S) that are derived from alternate translation of the same ORF. 9581553 9 57 gly N-glycosylation 1582:1596 arg2 an additional unnatural site an additional unnatural site site Further, in FR-beta the introduction of an additional unnatural site of N-glycosylation resulted in the enhancement of the expression of the cell surface receptor compared with the wild-type protein. 8985413 7 32 gly glycoprotein 1363:1374 arg1 the envelope glycoprotein the envelope glycoprotein Fterm glycoprotein In summary, these data demonstrate that differences in V2 length modulate immunoreactivity of the envelope glycoprotein and support an association between the V2 and CD4 binding site regions. 17055129 0 57 gly N-glycosylation 15:29 arg1 hepatitis C virus envelope protein E2 hepatitis C virus envelope protein E2 Cterm E2 Engineering of N-glycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization. 18340083 3 14 gly N-glycosylated 505:518 arg2 Asn-76 GPIHBP1 Asn-76 PUBTATOR GPIHBP1 68453 Asn-76 Here, we show that mouse GPIHBP1 is N-glycosylated at Asn-76 within the Ly-6 domain. 15956584 2 53 gly glycosylation 181:193 arg2 4 or 5 N-linked glycosylation sites 4 or 5 N-linked glycosylation sites sites E1 contains 4 or 5 N-linked glycosylation sites and E2 contains up to 11, with most of the sites being well conserved, suggesting that they play an essential role in some functions of these proteins. 28822114 6 54 gly glycosylation 897:909 arg1 the protein the protein Fterm protein Mutant mice with DMP1 point mutations changing S89 to glycine (S89G), which completely eradicated glycosylation of the protein, demonstrated severe BBB disruption. 15754041 1 23 part_of WNT-binding 125:135 arg1 extracellular WNT-binding domain WNT extracellular WNT-binding domain PUBTATOR Site WNT 7473 domain WNT signals, transduced through Frizzled (FZD) receptors with extracellular WNT-binding domain and cytoplasmic Dishevelled-binding domain, are implicated in carcinogenesis and embryogenesis. 18585921 4 16 part_of domains 695:701 arg1 seipin seipin domains PUBTATOR Site seipin 26580 domains Our studies show that the transmembrane domains in seipin are critical for ER retention, ubiquitination, formation of inclusions, and activation of UPR. 10218949 0 49 gly glycosylation 9:21 arg1 optimal AT1a angiotensin receptor expression optimal AT1a angiotensin receptor expression Fterm receptor N-linked glycosylation is required for optimal AT1a angiotensin receptor expression in COS-7 cells. 10218949 0 49 gly glycosylation 9:21 arg1 optimal AT1a angiotensin receptor expression AT1a angiotensin PUBTATOR AT1a angiotensin 24180 N-linked glycosylation is required for optimal AT1a angiotensin receptor expression in COS-7 cells. 10471642 0 5 gly N-glycosylation 200:214 arg1 transferrin transferrin PUBTATOR transferrin 7018 Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. BACKGROUND: Chronic alcohol abuse alters the normal N-glycosylation of transferrin, producing the carbohydrate-deficient transferrin isoforms. 10471642 0 34 gly glycoprotein 118:129 arg1 carbohydrate-deficient glycoprotein syndrome type carbohydrate-deficient glycoprotein syndrome type Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. BACKGROUND: Chronic alcohol abuse alters the normal N-glycosylation of transferrin, producing the carbohydrate-deficient transferrin isoforms. 10471642 0 59 gly glycoproteins 28:40 arg1 serum glycoproteins serum glycoproteins Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. BACKGROUND: Chronic alcohol abuse alters the normal N-glycosylation of transferrin, producing the carbohydrate-deficient transferrin isoforms. 10471642 0 86 gly Microheterogeneity 0:17 arg1 serum glycoproteins serum glycoproteins Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. BACKGROUND: Chronic alcohol abuse alters the normal N-glycosylation of transferrin, producing the carbohydrate-deficient transferrin isoforms. 15353267 8 79 gly N-glycosylation 1040:1054 arg2 one potential N-glycosylation site one potential N-glycosylation site site The deduced amino acid (aa) has one potential N-glycosylation site, and several phosphorylation and myristoylation sites. 1647209 8 39 gly glycosylated 1291:1302 arg1 CHO cell-derived IFN-omega 1 CHO cell-derived IFN-omega 1 PUBTATOR IFN-omega 1 3467 Upon treatment with peptide:N-glycosidase F, both bands were shifted to lower molecular masses (20.5 and 18.5 kDa), indicating that CHO cell-derived IFN-omega 1 is glycosylated; Asn-78 was identified as the glycosylation site. 1647209 8 109 gly glycosylation 1334:1346 arg2 the glycosylation site the glycosylation site site Upon treatment with peptide:N-glycosidase F, both bands were shifted to lower molecular masses (20.5 and 18.5 kDa), indicating that CHO cell-derived IFN-omega 1 is glycosylated; Asn-78 was identified as the glycosylation site. 1647209 8 109 gly glycosylation 1334:1346 arg2 Asn-78 Asn-78 Asn-78 Upon treatment with peptide:N-glycosidase F, both bands were shifted to lower molecular masses (20.5 and 18.5 kDa), indicating that CHO cell-derived IFN-omega 1 is glycosylated; Asn-78 was identified as the glycosylation site. 8985413 0 44 gly glycoprotein 106:117 arg1 the human immunodeficiency virus type 1 envelope glycoprotein the human immunodeficiency virus type 1 envelope glycoprotein Fterm glycoprotein Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site. 16823988 1 59 gly glycoprotein 221:232 arg1 sialylated glycoprotein markers sialylated glycoprotein markers Fterm glycoprotein A strategy is developed in this study for identifying sialylated glycoprotein markers in human cancer serum. 1990068 1 42 gly glycoprotein 252:263 arg1 the fusion (F) glycoprotein the fusion (F) glycoprotein Fterm glycoprotein The sequence of the fusion (F) glycoprotein of turkey rhinotracheitis virus (TRTV) has been deduced from cDNA clones derived from oligo(dT)-selected infected cell RNA. 21515415 2 54 gly N-glycosylation 262:276 arg2 six potential N-glycosylation sites six potential N-glycosylation sites sites It has six potential N-glycosylation sites. 12364335 7 8 part_of contains 1032:1039 arg1 apomucin AND multiple glycosylation sites apomucin multiple glycosylation sites Fterm Site apomucin sites In our experiments, the former activity is represented by the O-glycosylation of apomucin, an acceptor that contains multiple glycosylation sites, and the latter is represented by synthetic peptides that contain a single glycosylation site. 12364335 7 72 part_of contain 1128:1134 arg1 synthetic peptides AND a single glycosylation site synthetic peptides a single glycosylation site site In our experiments, the former activity is represented by the O-glycosylation of apomucin, an acceptor that contains multiple glycosylation sites, and the latter is represented by synthetic peptides that contain a single glycosylation site. 14699159 0 90 gly Underglycosylation 0:17 arg1 ATF6 ATF6 PUBTATOR ATF6 22926 Underglycosylation of ATF6 as a novel sensing mechanism for activation of the unfolded protein response. 11152692 1 21 gly leucine-rich 70:81 arg1 the leucine-rich repeat protein family leucine the leucine-rich repeat protein family leucine a novel member of the leucine-rich repeat protein family closely related to decorin and biglycan. 11485624 2 39 gly domains 473:479 arg1 N-linked glycans domains N-linked glycans domains Here, we determined whether N-linked glycans of other gp120 domains were also involved in protection of V3 neutralization epitopes. 3004936 9 38 gly glycosylated 1497:1508 arg1 a glycosylated MUP protein a glycosylated MUP protein PUBTATOR MUP protein 381531 We show here that mouse urine does indeed contain a glycosylated MUP protein with those properties, presumably the product of the gene that corresponds to pMUP15. 20053750 4 63 part_of hPIV-3 745:750 arg1 superposition hPIV-3 HN superposition Cterm Site hPIV-3 HN 4758 position Sequence analysis and superposition of the NDV and hPIV-3 HN dimer structures revealed that, similar to what was seen in hPIV-1, the N-linked glycan at residue 523 on hPIV-3 HN may cover a second receptor-binding site. 10585855 3 38 gly glycosylation 554:566 arg2 the endogenous glycosylation site the endogenous glycosylation site site We used an N-glycosylation mutagenesis approach to examine the orientation of the N-terminus and the endogenous glycosylation site of each C-terminal fragment by cell-free translation. 10585855 3 38 gly glycosylation 554:566 arg1 each C-terminal fragment fragment fragment We used an N-glycosylation mutagenesis approach to examine the orientation of the N-terminus and the endogenous glycosylation site of each C-terminal fragment by cell-free translation. 24721674 2 48 gly glycopeptides 395:407 arg2 glycopeptides glycopeptides glycopeptides However, the effective extraction of membrane proteins, the selective isolation of glycopeptides and the mass spectrometric characterization of glycosylation are challenging with current analytical techniques. 22733248 3 7 gly glycosylation 539:551 arg2 glycosylation sites glycosylation sites sites The following article will briefly describe recently utilized mass spectrometry methods to identify glycosylation sites and measure glycan composition, sequence, branching, and relative quantities. 28900186 7 0 part_of albumin 1504:1510 arg1 complex-type glycosylated human lactotransferrin and bovine serum albumin peptides serum albumin complex-type glycosylated human lactotransferrin and bovine serum albumin peptides PUBTATOR Site serum albumin 213 peptides and N-glycopeptides We demonstrate this newly discovered specificity of flavastacin by in-depth LC-MS(/MS) analysis of complex-type glycosylated human lactotransferrin and bovine serum albumin peptides and N-glycopeptides that were generated by trypsin and flavastacin digestion. 28900186 7 7 part_of lactotransferrin 1470:1485 arg1 complex-type glycosylated human lactotransferrin and bovine serum albumin peptides lactotransferrin complex-type glycosylated human lactotransferrin and bovine serum albumin peptides PUBTATOR Site lactotransferrin 4057 peptides and N-glycopeptides We demonstrate this newly discovered specificity of flavastacin by in-depth LC-MS(/MS) analysis of complex-type glycosylated human lactotransferrin and bovine serum albumin peptides and N-glycopeptides that were generated by trypsin and flavastacin digestion. 12867358 0 49 part_of hNaSi-1 43:49 arg1 the N-glycosylation site hNaSi-1 the N-glycosylation site PUBTATOR Site hNaSi-1 6561 site Mutagenesis of the N-glycosylation site of hNaSi-1 reduces transport activity. 20332087 3 30 gly MPO 470:472 arg1 the N-glycan composition MPO the N-glycan composition PUBTATOR MPO 4353 Here, the N-glycan composition of native dimeric human MPO purified from neutrophils and of monomeric MPO recombinantly expressed in Chinese hamster ovary cells has been investigated. 20332087 3 48 gly MPO 517:519 arg1 the N-glycan composition MPO the N-glycan composition PUBTATOR MPO 4353 Here, the N-glycan composition of native dimeric human MPO purified from neutrophils and of monomeric MPO recombinantly expressed in Chinese hamster ovary cells has been investigated. 6175959 9 76 part_of C3d 1075:1077 arg1 The partial sequence C3d The partial sequence PUBTATOR Site C3d 100861467 sequence The partial sequence of C3d was extended by completion of the sequence of a previously described tryptic peptide. 11146224 6 30 part_of MRP7 964:967 arg1 the MRP7 amino acid sequence MRP7 the MRP7 amino acid sequence PUBTATOR Site MRP7 89845 sequence Comparisons of the MRP7 amino acid sequence indicated that while it is most closely related to other MRP subfamily members, its degree of relatedness is the lowest of any of the known MRP-related transporters. 21528263 6 4 part_of P-glycoprotein 1076:1089 arg1 the first potential N-glycosylation site P-glycoprotein the first potential N-glycosylation site PUBTATOR Site P-glycoprotein 5243 site An A to G nucleotide substitution giving rise to an amino acid substitution (Asn-->Asp) in codon 21 at the first potential N-glycosylation site of the P-glycoprotein was seen in primary tumors from four patients and in an axillar lymph node metastases from one of these patients. 15194804 1 31 gly N-glycosylation 203:217 arg2 five potential N-glycosylation sites five potential N-glycosylation sites sites Nipah virus (NiV), a new member of the Paramyxoviridae, codes for a fusion (F) protein with five potential N-glycosylation sites. 10580643 5 93 gly glycopeptides 949:961 arg2 the two glycopeptides the two glycopeptides glycopeptides Surprisingly, the two glycopeptides switched positions on the reversed-phase high performance liquid chromatogram after removal of the sugar-protecting acetyl groups. 18330979 2 50 gly glycosylation 394:406 arg2 glycosylation sites glycosylation sites sites While Env is typically about 50% glycan by mass, glycosylation sites are known to evolve, with some glycosylation profiles presumably being more effective at facilitating neutralization escape than others. 18083528 5 7 gly glycosylation 902:914 arg2 glycosylation site glycosylation site site The correlation between glycosylation site and elution order is used to provide additional structural confirmation. 7532209 0 37 gly glycosylation 9:21 arg1 the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)-selective glutamate receptor channel alpha 2 subunit the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)-selective glutamate receptor channel alpha 2 subunit Fterm subunit N-linked glycosylation of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)-selective glutamate receptor channel alpha 2 subunit is essential for the acquisition of ligand-binding activity. 27216994 8 13 gly N-glycosylation 1551:1565 arg2 7 out of 7 N-glycosylation sites 7 out of 7 N-glycosylation sites sites Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans. 27216994 8 57 gly N-glycosylation 1505:1519 arg2 11 out of 12 predicted N-glycosylation sites 11 out of 12 predicted N-glycosylation sites sites Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans. 27216994 8 20 gly occupied 1587:1594 arg2 7 out of 7 N-glycosylation sites sites sites Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans. 11676606 6 69 gly structures 768:777 arg1 sCD154 CD154 structures PUBTATOR CD154 959 Detailed carbohydrate analysis revealed high-mannose structures on sCD154 purified from Pichia pastoris, whereas CD154 purified from Chinese hamster ovary E1A contained heterogeneous populations of complex carbohydrates. 9464523 7 40 gly N-glycosylation 1009:1023 arg2 An N-glycosylation site An N-glycosylation site site An N-glycosylation site is present within the N-terminal sequence at residue 6. 17899080 3 11 part_of position 553:560 arg1 FVIII FVIII position PUBTATOR Site FVIII 2157 position 41 Examination of the glycosylation pattern of the NH(2) terminus of FV and FVIII revealed N-glycans at positions 23 and 27 in FV and at position 41 in FVIII. 17899080 3 20 part_of FVIII 492:496 arg1 the NH(2) terminus FVIII the NH(2) terminus PUBTATOR Site FVIII 2157 terminus Examination of the glycosylation pattern of the NH(2) terminus of FV and FVIII revealed N-glycans at positions 23 and 27 in FV and at position 41 in FVIII. 18420026 6 9 part_of glycoprotein 1539:1550 arg1 a single glycosylation site glycoprotein a single glycosylation site Fterm Site glycoprotein site Based on the results of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with human wild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is an N-linked glycoprotein with a single glycosylation site at position N290KS. 1719383 6 46 part_of IGFBP-6 944:950 arg1 a tryptic fragment IGFBP-6 a tryptic fragment PUBTATOR Site IGFBP-6 P24592 fragment Using amino acid sequence information from a tryptic fragment of pig IGFBP-6 to prepare a probe, cDNA clones encoding rat and human IGFBP-6 have been isolated and characterized. 7717992 4 49 part_of containing 632:641 arg1 the mature protein AND one N-glycosylation site the mature protein one N-glycosylation site Fterm Site protein site This includes a 19-amino acid signal sequence and the mature protein containing 676 amino acids and one N-glycosylation site in the C-terminal domain at residue 490. 24468271 1 9 gly N-glycosylated 167:180 arg1 Secretory human interleukin 4 Secretory human interleukin 4 PUBTATOR interleukin 4 3565 Secretory human interleukin 4 (hIL4) is an N-glycosylated pleiotropic cytokine. 31572358 13 110 gly N-glycosylation 2304:2318 arg2 N-glycosylation sites N-glycosylation sites sites Based on these data, and taking into account recent insights into the dynamics of the ACPA-response during disease development, we here discuss the hypothesis that N-glycosylation sites in ACPA-IgG variable domains could lead to alternative, possibly antibody affinity-independent selection forces. 3980466 4 77 gly glycosylation 712:724 arg2 11 purified glycosylation sites 11 purified glycosylation sites sites [3H]Mannose-labeled oligosaccharides were released from each of 11 purified glycosylation sites by the almond peptide:N-glycosidase and analyzed by a variety of chromatographic procedures and glycosidase treatments. 3980466 4 90 gly released 678:685 arg1 11 purified glycosylation sites AND [3H]Mannose-labeled oligosaccharides 11 purified glycosylation sites [3H]Mannose-labeled oligosaccharides sites [3H]Mannose-labeled oligosaccharides were released from each of 11 purified glycosylation sites by the almond peptide:N-glycosidase and analyzed by a variety of chromatographic procedures and glycosidase treatments. 10383441 1 9 gly glycoprotein 162:173 arg1 a secretory glycoprotein a secretory glycoprotein Fterm glycoprotein We have reported that bovine DNase I, a secretory glycoprotein, acquires mannose 6-phosphate residues on 12.6% of its Asn-linked oligosaccharides when expressed in COS-1 cells and that the extent of phosphorylation increases to 79.2% when lysines are placed at positions 27 and 74 of the mature protein (Nishikawa, A., Gregory, W. , Frenz, J., Cacia, J., and Kornfeld, S. (1997) J. Biol. 10383441 1 9 gly glycoprotein 162:173 arg1 bovine DNase I bovine DNase I PUBTATOR DNase I 282217 We have reported that bovine DNase I, a secretory glycoprotein, acquires mannose 6-phosphate residues on 12.6% of its Asn-linked oligosaccharides when expressed in COS-1 cells and that the extent of phosphorylation increases to 79.2% when lysines are placed at positions 27 and 74 of the mature protein (Nishikawa, A., Gregory, W. , Frenz, J., Cacia, J., and Kornfeld, S. (1997) J. Biol. 10383441 1 11 gly Asn-linked 230:239 arg1 its Asn-linked oligosaccharides Asn its Asn-linked oligosaccharides Asn We have reported that bovine DNase I, a secretory glycoprotein, acquires mannose 6-phosphate residues on 12.6% of its Asn-linked oligosaccharides when expressed in COS-1 cells and that the extent of phosphorylation increases to 79.2% when lysines are placed at positions 27 and 74 of the mature protein (Nishikawa, A., Gregory, W. , Frenz, J., Cacia, J., and Kornfeld, S. (1997) J. Biol. 23958596 0 52 gly N-glycosylation 8:22 arg1 human lysosomal phospholipase A2 human lysosomal phospholipase A2 PUBTATOR lysosomal phospholipase A2 23659 Role of N-glycosylation of human lysosomal phospholipase A2 for the formation of catalytically active enzyme. 22511783 8 41 gly glycosylation 1311:1323 arg2 N-linked glycosylation site insertion N-linked glycosylation site insertion site We thus evaluated topology by N-linked glycosylation site insertion and protein lipidation mapping in conjunction with cellular fractionation and fluorescence imaging. 25755023 4 25 gly glycopeptide 633:644 arg2 tumor-associated glycopeptide antigens tumor-associated glycopeptide antigens glycopeptide The aberrant glycosylation of MUC4 in tumor cells results in an exposure of its peptide backbone and the formation of tumor-associated glycopeptide antigens. 25755023 4 59 gly glycosylation 511:523 arg1 MUC4 MUC4 PUBTATOR MUC4 Q99102 The aberrant glycosylation of MUC4 in tumor cells results in an exposure of its peptide backbone and the formation of tumor-associated glycopeptide antigens. 18381078 3 30 gly occupied 514:521 arg2 all sites all sites sites Individual N-glycosylation site mutants S269A, T280A, S441A, T553A were constructed, and results indicated that all sites were occupied. 18381078 3 43 gly N-glycosylation 398:412 arg2 Individual N-glycosylation site mutants Individual N-glycosylation site mutants site Individual N-glycosylation site mutants S269A, T280A, S441A, T553A were constructed, and results indicated that all sites were occupied. 2318516 12 9 part_of glycoprotein 2169:2180 arg1 the alpha 1 and/or alpha 2 domains glycoprotein the alpha 1 and/or alpha 2 domains Fterm Site glycoprotein domains These data demonstrate that the HLA/H-2 transport dichotomy in T2 is a function of the origin of the alpha 1 and/or alpha 2 domains of the class I glycoprotein, and is not a reflection of glycosylation differences between the human and mouse molecules. 2318516 12 51 part_of alpha 2123:2127 arg1 the alpha 1 and/or alpha 2 domains alpha 1 the alpha 1 and/or alpha 2 domains PUBTATOR Site alpha 1 146 domains These data demonstrate that the HLA/H-2 transport dichotomy in T2 is a function of the origin of the alpha 1 and/or alpha 2 domains of the class I glycoprotein, and is not a reflection of glycosylation differences between the human and mouse molecules. 17001080 4 28 gly glycosylation 751:763 arg2 position 67 position 67 position 67 We introduced a glycosylation site at position 67 into West Nile virus E. Reporter virus particles pseudotyped with this E protein infected cells using either CD209 or CD209L. 17001080 4 28 gly glycosylation 751:763 arg2 a glycosylation site a glycosylation site site We introduced a glycosylation site at position 67 into West Nile virus E. Reporter virus particles pseudotyped with this E protein infected cells using either CD209 or CD209L. 25793890 7 86 gly glycosylation 1386:1398 arg2 this glycosylation site this glycosylation site site Although N136 has previously been implicated in the binding of broadly neutralizing monoclonal antibodies, this glycosylation site appears to inhibit the binding of neutralizing antibodies in plasma from HIV-1 infected subjects. 9063619 7 58 gly glycoproteins 1234:1246 arg1 glycoproteins glycoproteins Fterm glycoproteins General roles for the range of sugars on glycoproteins such as the leukocyte antigens include orientating the molecules on the cell surface. 1916293 9 35 part_of IL-6 1534:1537 arg1 corresponding murine IL-6 (mIL-6) sequences IL-6 corresponding murine IL-6 (mIL-6) sequences PUBTATOR Site IL-6 16193 sequences Finally, we have produced two proteins with aa 29-33 or 97-104 substituted by corresponding murine IL-6 (mIL-6) sequences. 3498943 0 79 gly glycoprotein 67:78 arg1 the murine cytotoxic T-cell membrane glycoprotein Ly-3 the murine cytotoxic T-cell membrane glycoprotein Ly-3 PUBTATOR T-cell membrane glycoprotein Ly-3 12526 Molecular characterization of the murine cytotoxic T-cell membrane glycoprotein Ly-3 (CD8). 19277548 3 41 gly N-glycosylation 564:578 arg2 N-glycosylation site analysis N-glycosylation site analysis site For N-glycosylation site analysis the last two steps are usually similar, while methods differ in the affinity purification step. 16037490 7 70 gly sites 1711:1715 arg1 N-glycan structures sites N-glycan structures sites In addition, the method was applied to apolipoprotein B-100 (apoB100) whose N-glycan structures at 17 of 19 potential sites have been reported, and characterized the remaining sites. 17634239 1 19 gly glycoprotein 297:308 arg1 envelope glycoprotein gp120 envelope glycoprotein gp120 Fterm glycoprotein The monoclonal antibody (MAb) 2G12 recognizes a cluster of high-mannose oligosaccharides on the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 and is one of a select group of MAbs with broad neutralizing activity. 1383332 9 63 gly O-glycosylated 1596:1609 arg1 the O-glycosylated S/T region the O-glycosylated S/T region region Surprisingly, deletion of the S/T region totally abrogated DAF function, but this could be restored by a fusion construct placing the four SCR domains of DAF onto the HLA-B44 molecule, implying that the O-glycosylated S/T region serves as an important but nonspecific spacer projecting the DAF functional domains above the plasma membrane. 8325864 4 68 gly glycosylated 718:729 arg1 the four sequons By expression of the normal and mutated cDNAs in insect (Sf9) and COS-1 cells and subsequent immunoblotting with anti-human acid beta-glucosidase antibodies, the four sequons at Asn-19, Asn-59, Asn-146, and Asn-270 were shown to be glycosylated in either source. 17158912 5 43 part_of UPIb 883:886 arg1 the four transmembrane domains UPIb the four transmembrane domains PUBTATOR Site UPIb 7348 domains However, modifications of any of the four transmembrane domains of UPIb led to ER retention, suggesting that the proper formation of helical bundles consisting of the tetraspanin transmembrane domains is a prerequisite for UPIb to exit from the ER. 27773655 0 16 gly glycoprotein 127:138 arg1 a multi-domain membrane glycoprotein a multi-domain membrane glycoprotein Fterm glycoprotein Structural determinants for transport of lactase phlorizin-hydrolase in the early secretory pathway as a multi-domain membrane glycoprotein. 2503511 17 38 gly presence 2730:2737 arg2 position 184 AND carbohydrate position 184 carbohydrate position 184 The distributions of Asn-linked oligosaccharides at positions 117 and 448 were found not to be affected by the presence or absence of carbohydrate at position 184. 2503511 17 60 gly Asn-linked 2640:2649 arg1 Asn-linked oligosaccharides Asn Asn-linked oligosaccharides Asn The distributions of Asn-linked oligosaccharides at positions 117 and 448 were found not to be affected by the presence or absence of carbohydrate at position 184. 12175779 11 16 gly has 1468:1470 arg1 GLUT11-L AND glucose transport activity GLUT11-L glucose transport activity PUBTATOR GLUT11 66035 Furthermore, a liposome reconstitution functional assay showed that GLUT11-L has glucose transport activity. 23050552 9 69 part_of regions 1167:1173 arg1 human fibrinogen fibrinogen regions PUBTATOR Site fibrinogen 2244 regions Moreover, we describe seven novel O-glycosylation regions in human fibrinogen, all occupied by a monosialylated T-antigen. 27140194 5 21 gly glycopeptide 883:894 arg2 currently available intact glycopeptide characterization methods currently available intact glycopeptide characterization methods glycopeptide In this review, we recapitulated currently available intact glycopeptide characterization methods with respect to their advantages and limitations as well as their potential applications. 10094503 3 7 part_of contains 555:562 arg1 This protein AND six potential Ca(2+)-binding domains This protein six potential Ca(2+)-binding domains Fterm Site protein domains This protein contains six potential Ca(2+)-binding domains, one N-glycosylation site, and a large amount of acidic amino acid residues. 10094503 3 7 part_of contains 555:562 arg1 This protein AND acidic amino acid residues This protein acidic amino acid residues Fterm Site protein residues This protein contains six potential Ca(2+)-binding domains, one N-glycosylation site, and a large amount of acidic amino acid residues. 10094503 3 7 part_of contains 555:562 arg1 This protein AND one N-glycosylation site This protein one N-glycosylation site Fterm Site protein site This protein contains six potential Ca(2+)-binding domains, one N-glycosylation site, and a large amount of acidic amino acid residues. 19619305 0 53 part_of CD4 124:126 arg1 the broadly neutralizing CD4 binding site CD4 the broadly neutralizing CD4 binding site PUBTATOR Site CD4 713807 site Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12. 29757379 6 52 gly glycosylation 871:883 arg2 a highly conserved N-linked glycosylation site a highly conserved N-linked glycosylation site site We found a highly conserved N-linked glycosylation site to be required for QSOX1 secretion from fibroblasts and other cell types. 8987499 1 5 gly glycosylation 232:244 arg2 a glycosylation site a glycosylation site site Pro-UKS1 was designed as a thrombin-resistant derivative of pro-urokinase (pro-UK) by introducing a glycosylation site using site-directed mutagenesis. 18340083 0 43 gly Glycosylation 0:12 arg1 Asn-76 Asn-76 Asn-76 Glycosylation of Asn-76 in mouse GPIHBP1 is critical for its appearance on the cell surface and the binding of chylomicrons and lipoprotein lipase. 18282281 2 4 gly glycosylation 307:319 arg2 glycosylation sites glycosylation sites sites Computational identification of glycosylation sites in protein sequences becomes increasingly important in the post-genomic era. 11251288 7 37 gly glycosylation 1366:1378 arg2 glycosylation site asparagine residues site asparagine residues site asparagine residues RESULTS: Wild-type recombinant erythropoietin and three mutants in which glycosylation site asparagine residues had been changed to cysteines (His(10)-WThEPO, His(10)-Asn24Cys, His(10)-Asn38Cys, His(10)-Asn83CyshEPO) were overexpressed and purified in yields of 13 mg l(-1) from Escherichia coli. 11251288 7 123 gly changed 1414:1420 arg1 His His(10) His(10) RESULTS: Wild-type recombinant erythropoietin and three mutants in which glycosylation site asparagine residues had been changed to cysteines (His(10)-WThEPO, His(10)-Asn24Cys, His(10)-Asn38Cys, His(10)-Asn83CyshEPO) were overexpressed and purified in yields of 13 mg l(-1) from Escherichia coli. 11251288 7 123 gly changed 1414:1420 arg1 His His(10) His(10) RESULTS: Wild-type recombinant erythropoietin and three mutants in which glycosylation site asparagine residues had been changed to cysteines (His(10)-WThEPO, His(10)-Asn24Cys, His(10)-Asn38Cys, His(10)-Asn83CyshEPO) were overexpressed and purified in yields of 13 mg l(-1) from Escherichia coli. 11251288 7 123 gly changed 1414:1420 arg1 His His(10) His(10) RESULTS: Wild-type recombinant erythropoietin and three mutants in which glycosylation site asparagine residues had been changed to cysteines (His(10)-WThEPO, His(10)-Asn24Cys, His(10)-Asn38Cys, His(10)-Asn83CyshEPO) were overexpressed and purified in yields of 13 mg l(-1) from Escherichia coli. 20378933 7 47 gly deglycosylation 1115:1129 arg2 N58 N58 N58 Flow cytometry analysis of IgA binding to CHO cells transfected with mutated FcalphaR showed that deglycosylation of FcalphaR at individual N44, N120, N156, N165 or N177 site did not affect IgA binding but deglycosylation at N58 resulted in marked increase of IgA binding. 20378933 7 84 gly deglycosylation 1007:1021 arg1 IgA binding IgA N44, N120, N156, N165 OGER IgA P11912 N44, N120, N156, N165 Flow cytometry analysis of IgA binding to CHO cells transfected with mutated FcalphaR showed that deglycosylation of FcalphaR at individual N44, N120, N156, N165 or N177 site did not affect IgA binding but deglycosylation at N58 resulted in marked increase of IgA binding. 20378933 7 84 gly deglycosylation 1007:1021 arg1 N120, N156, N165 or N177 site IgA N177 site OGER IgA P11912 N177 site Flow cytometry analysis of IgA binding to CHO cells transfected with mutated FcalphaR showed that deglycosylation of FcalphaR at individual N44, N120, N156, N165 or N177 site did not affect IgA binding but deglycosylation at N58 resulted in marked increase of IgA binding. 21215105 11 104 gly glycosylation 1987:1999 arg2 glycosylation site glycosylation site site CONCLUSION: The HA and NA genes of the epidemic strains showed high homology, some mutations in the HA and NA proteins were found, the antigenic site and glycosylation site of some strains were changed during the epidemic process. 2464879 8 26 gly Asn-Ser-Pro 1377:1387 arg1 Asn-Ser-Ser Asn-Ser-Ser Asn-Ser-Ser This correlates well with the creation of an additional potential glycosylation site in this mutant from Asn-Ser-Pro(325) to Asn-Ser-Ser(325). 2464879 8 44 gly glycosylation 1338:1350 arg2 an additional potential glycosylation site an additional potential glycosylation site site This correlates well with the creation of an additional potential glycosylation site in this mutant from Asn-Ser-Pro(325) to Asn-Ser-Ser(325). 8749323 2 32 gly O-glycosylation 269:283 arg2 an O-glycosylation site rich domain an O-glycosylation site rich domain site We investigated the roles of the sixth epidermal growth factor (EGF)-like structure (E6) in the second domain (D2) and of an O-glycosylation site rich domain (D3) in the function of TM in more detail using deletion analysis. 8749323 2 32 gly O-glycosylation 269:283 arg2 an O-glycosylation site rich domain an O-glycosylation site rich domain domain We investigated the roles of the sixth epidermal growth factor (EGF)-like structure (E6) in the second domain (D2) and of an O-glycosylation site rich domain (D3) in the function of TM in more detail using deletion analysis. 7654202 3 17 part_of TF 576:577 arg1 the surface domain TF the surface domain Cterm Site TF 2152 domain We describe the expression of the surface domain of TF (truncated TF, tTF) in both Saccharomyces cerevisiae and Escherichia coli and the biochemical and physical characterization of the recombinant proteins. 23365085 3 59 gly glycosylation 561:573 arg2 a single glycosylation site a single glycosylation site site In 2009, human strains of pandemic H1N1 [A(H1N1)pdm] expressed a single glycosylation site (Asn(104)) on the head of HA. 23365085 3 59 gly glycosylation 561:573 arg2 Asn(104) Asn(104) Asn(104) In 2009, human strains of pandemic H1N1 [A(H1N1)pdm] expressed a single glycosylation site (Asn(104)) on the head of HA. 23776650 1 44 gly self-glycoproteins 284:301 arg1 self-glycoproteins self-glycoproteins Fterm self-glycoproteins C-type lectins are innate receptors expressed on antigen-presenting cells that are involved in the recognition of glycosylated pathogens and self-glycoproteins. 10889209 0 50 part_of Asn117 46:51 arg1 ROMK1 ROMK1 Asn117 PUBTATOR AminoAcid ROMK1 3758 Asn117 Glycosylation of GIRK1 at Asn119 and ROMK1 at Asn117 has different consequences in potassium channel function. 14561640 14 33 part_of RNase 1802:1806 arg1 RNase catalytic site RNase RNase catalytic site OGER Site RNase P07998 site However, the presence of a long-conserved N-terminal specific sequence and the absence of RNase catalytic site for Train A indicate that Train A protein is a member of a new family of RNase A. 27743362 6 34 part_of C18-unbound 1129:1139 arg1 C18-unbound (glyco)peptides C18 C18-unbound (glyco)peptides PUBTATOR Site C18 27241 peptides The LC-setup allows retention of more hydrophobic glycopeptides on C18 followed by subsequent capturing of C18-unbound (glyco)peptides by a downstream placed PGC stationary phase. 1587858 3 20 gly N-glycosylation 708:722 arg2 residue 409 residue 409 residue 409 Sequence analysis of this clone showed that (a) it contained the entire translated region of PGG/HS and (b) it displayed an in-frame splicing of the last 111 base pairs encoded by exon 9, which resulted in the elimination of the N-glycosylation site at residue 409. 1587858 3 20 gly N-glycosylation 708:722 arg2 the N-glycosylation site the N-glycosylation site site Sequence analysis of this clone showed that (a) it contained the entire translated region of PGG/HS and (b) it displayed an in-frame splicing of the last 111 base pairs encoded by exon 9, which resulted in the elimination of the N-glycosylation site at residue 409. 10727230 5 62 gly glycosylation 948:960 arg2 The single glycosylation site The single glycosylation site site The single glycosylation site in these constructs was identified, and quantities were determined of five glycoforms that agreed within +/-2% of the molecular ion values. 19629045 3 59 gly glycosylate 480:490 arg1 sites sites sites The two enzymes have overlapping but distinct peptide acceptor specificities, with TbSTT3C displaying an enhanced ability to glycosylate sites flanked by acidic residues. 8107215 3 82 gly glycosylation 507:519 arg2 the three potential glycosylation sites the three potential glycosylation sites sites Each of the three potential glycosylation sites was mutated separately as well as in combination with the other sites. 8411360 5 23 gly glycoprotein 1151:1162 arg1 the envelope (E) glycoprotein the envelope (E) glycoprotein Fterm glycoprotein A comparison of the amino acid sequences of the parent and its mouse neurovirulent mutant proteins revealed that there were only five amino acid differences in the structural protein region, and three of these were located in the envelope (E) glycoprotein. 23296536 4 11 gly glycoprotein 872:883 arg1 glycoprotein information glycoprotein information Fterm glycoprotein In addition to these tools, databases of glycoprotein information are available that may aid in glycoprotein prediction; GlycoProtDB is a database of glycoprotein information characterized by the Japanese Consortium for Glycobiology and Glycotechnology, and UniProt includes glycosylation site information along with its protein sequence data. 23296536 4 27 gly glycoprotein 763:774 arg1 glycoprotein information glycoprotein information Fterm glycoprotein In addition to these tools, databases of glycoprotein information are available that may aid in glycoprotein prediction; GlycoProtDB is a database of glycoprotein information characterized by the Japanese Consortium for Glycobiology and Glycotechnology, and UniProt includes glycosylation site information along with its protein sequence data. 23296536 4 45 gly glycosylation 997:1009 arg2 glycosylation site information glycosylation site information site In addition to these tools, databases of glycoprotein information are available that may aid in glycoprotein prediction; GlycoProtDB is a database of glycoprotein information characterized by the Japanese Consortium for Glycobiology and Glycotechnology, and UniProt includes glycosylation site information along with its protein sequence data. 23296536 4 58 gly glycoprotein 818:829 arg1 glycoprotein prediction glycoprotein prediction Fterm glycoprotein In addition to these tools, databases of glycoprotein information are available that may aid in glycoprotein prediction; GlycoProtDB is a database of glycoprotein information characterized by the Japanese Consortium for Glycobiology and Glycotechnology, and UniProt includes glycosylation site information along with its protein sequence data. 22072749 1 106 gly glycoprotein 247:258 arg1 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein topology human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein topology Fterm glycoprotein The generally accepted model for human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein topology includes a single membrane-spanning domain. 2118657 8 68 gly glycosylation 1148:1160 arg2 a new glycosylation site a new glycosylation site site These data, together with biochemical analysis of the protein and cell-free translation studies, suggest that this deletion, by altering the normal amino acid sequence from Asn-Lys-Ile-Ser to Asn-Ile-Ser, creates a new glycosylation site. 1402806 7 10 gly glycosylation 1182:1194 arg1 the M protein the M protein OGER M protein P54296 Indeed, the glycosylation of the M protein was not inhibited in the presence of tunicamycin, which is indicative of O-glycosylation, as previously reported for BCV and murine hepatitis virus. 23075397 4 18 gly glycosylation 846:858 arg2 a glycosylation site a glycosylation site site Mass spectrometry indicates that the N-terminal domain (1-20) is post-translationally modified by phosphorylations at three sites and probably contains a glycosylation site. 20209663 5 66 gly glycosylation 1528:1540 arg2 the glycosylation site the glycosylation site site The [M+Na](+) CAD mass spectra of the three isomeric tetrahydrofurans revealed four different pathways involving the loss of the glucose moiety, which allowed the assignment of the glycosylation site. 1456441 4 27 gly glycopeptide 613:624 arg2 glycopeptide glycopeptide glycopeptide The glycopeptide fractions were then individually digested with N-glycanase. 10671487 3 10 gly N-glycosylation 555:569 arg2 the only N-glycosylation site the only N-glycosylation site site Unlike GLUT1-5, GLUTX1 has a short extracellular loop between transmembrane domain (TM) 1 and TM2 and a long extracellular loop between TM9 and TM10 that contains the only N-glycosylation site. 12139935 5 19 part_of GPI 825:827 arg1 the CCP2 domain GPI the CCP2 domain PUBTATOR Site GPI 281006 domain Due to an additional glycosylation site located on the CCP2 domain of bovine beta(2)GPI a small change in the characteristic SAXS parameters was observed, which coincided with results obtained from SDS-PAGE. 12139935 5 57 part_of CCP2 796:799 arg1 the CCP2 domain CCP2 the CCP2 domain PUBTATOR Site CCP2 79841 domain Due to an additional glycosylation site located on the CCP2 domain of bovine beta(2)GPI a small change in the characteristic SAXS parameters was observed, which coincided with results obtained from SDS-PAGE. 20470225 1 24 gly glycosylation 123:135 arg1 Mucin1 Mucin1 PUBTATOR Mucin1 4582 Mucin1 (MUC1) with altered glycosylation behaves as an antigen unique to adenocarcinomas (ADCs). 20470225 1 24 gly glycosylation 123:135 arg1 MUC1 MUC1 PUBTATOR MUC1 4582 Mucin1 (MUC1) with altered glycosylation behaves as an antigen unique to adenocarcinomas (ADCs). 12901863 4 11 part_of site 599:602 arg1 ABCC6 ABCC6 site PUBTATOR Site ABCC6 368 site In order to localize the major glycosylation site(s) in ABCC6, we applied limited proteolysis on the fully glycosylated and underglycosylated forms, followed by immunodetection with region-specific antibodies for ABCC6. 8798624 4 12 part_of ICAM-3 1079:1084 arg1 domain 1 ICAM-3 domain 1 PUBTATOR Site ICAM-3 3385 domain Analysis of a panel of 45 point mutants of domain 1 of ICAM-3 identified five residues that may contact LFA-1 as part of the binding site, Asn23, Ser25, Glu37, Phe54, and Gln75. 19276077 1 45 gly N-glycans 226:234 arg1 the beta-propeller domain the beta-propeller domain the beta-propeller domain Site domain Recently we reported that N-glycans on the beta-propeller domain of the integrin alpha5 subunit (S-3,4,5) are essential for alpha5beta1 heterodimerization, expression, and cell adhesion. 19276077 1 45 gly N-glycans 226:234 arg1 the integrin alpha5 subunit integrin alpha5 subunit N-glycans PUBTATOR integrin alpha5 subunit 3678 Recently we reported that N-glycans on the beta-propeller domain of the integrin alpha5 subunit (S-3,4,5) are essential for alpha5beta1 heterodimerization, expression, and cell adhesion. 7504082 4 16 gly glycosylation 799:811 arg2 Asp59 Asp59 Asp59 The epitope for 4E7 includes the oligosaccharide conjugated to Asp59, an N-linked glycosylation site not present in mouse AChE. 7504082 4 16 gly glycosylation 799:811 arg2 an N-linked glycosylation site an N-linked glycosylation site site The epitope for 4E7 includes the oligosaccharide conjugated to Asp59, an N-linked glycosylation site not present in mouse AChE. 7642555 11 69 gly glycosylation 1333:1345 arg1 this biologically significant amino acid residue residue residue The reciprocal glycosylation and phosphorylation at this biologically significant amino acid residue may play an important role in the regulation of the functions of c-Myc. 29528338 5 8 part_of LILRB1 701:706 arg1 the first 2 LILRB1 immunoglobulin domains 2 LILRB1 the first 2 LILRB1 immunoglobulin domains PUBTATOR Site 2 LILRB1 10859 domains Each of 4 nonsynonymous substitutions in the first 2 LILRB1 immunoglobulin domains contributed to binding with UL18, classical MHCI, and HLA-G. 31302509 5 33 part_of receptor-critical 853:869 arg1 a shared, previously unrecognized receptor-critical site receptor a shared, previously unrecognized receptor-critical site Fterm Site receptor site Mutation of the cow and hamster XPR1 genes identified a shared, previously unrecognized receptor-critical site. 10604468 8 17 part_of Ly49A 1071:1075 arg1 Both Ly49A binding sites Both Ly49A Both Ly49A binding sites PUBTATOR Site Both Ly49A 16627 sites Both Ly49A binding sites on MHC-I are spatially distinct from that of the T-cell receptor. 17097085 7 34 part_of kinase 1093:1098 arg1 a N-terminal signal peptide casein kinase II a N-terminal signal peptide OGER Site casein kinase II peptide Sequence analysis showed that CP12 has a N-terminal signal peptide, a transmembrane region, a N-glycosylation site, a casein kinase II phosphorylation site and two N-myristoylation sites. 17097085 7 34 part_of kinase 1093:1098 arg1 a casein kinase II phosphorylation site casein kinase II a casein kinase II phosphorylation site OGER Site casein kinase II site Sequence analysis showed that CP12 has a N-terminal signal peptide, a transmembrane region, a N-glycosylation site, a casein kinase II phosphorylation site and two N-myristoylation sites. 17636988 6 8 gly residues 1105:1112 arg1 the conserved N-glycan core structure residues in the conserved N-glycan core structure residues in (2) Digestion with two endo-beta-N-acetylglucosaminidases (Endo D and Endo H) that cleave the glycosidic bond between the two N-acetylglucosamine (GlcNAc) residues in the conserved N-glycan core structure, leaving single GlcNAc residues with putative fucosyl side chains attached to the peptide. 12203836 6 143 gly glycosylation 789:801 arg2 one potential N-linked glycosylation site one potential N-linked glycosylation site site It has one potential N-linked glycosylation site and one tyrosine phosphorylation site, besides several O-linked glycosylation and serine and threonine phosphorylation sites. 27641734 19 148 gly N-glycosylation 3486:3500 arg1 the CD97 GAIN domain HeLa domain OGER HeLa P0DMC3 domain Finally, the GAIN and EGF domains are also important for CD97-HeLa adhesion, whereas N-glycosylation of the CD97 GAIN domain and GPS auto-proteolysis are not required for HeLa cell attachment. 15128311 12 94 gly glycoprotein 1523:1534 arg1 the glycoprotein the glycoprotein Fterm glycoprotein The cytotoxic activity of the glycoprotein towards HL60 cells was about two orders of magnitude lower than that of CX3, but could be made equal to the CX3 cytotoxicity by deglycosylation. 16343462 2 23 gly glycosylated 384:395 arg1 peptides proteins peptides Fterm proteins peptides Therefore, synthetic methods for preparing peptides and proteins that are glycosylated at multiple sites, possibly with different carbohydrate structures, are needed. 16343462 2 23 gly glycosylated 384:395 arg2 multiple sites proteins sites Fterm proteins sites Therefore, synthetic methods for preparing peptides and proteins that are glycosylated at multiple sites, possibly with different carbohydrate structures, are needed. 28443077 3 30 gly glycosylated 707:718 arg1 the glycosylated HA trimers the glycosylated HA trimers Fterm trimers To address this issue, we performed molecular dynamics simulations of the glycosylated HA trimers of the A(H3N2), which has a novel pattern of Asn-X-Ser/Thr sequons unique in the new A(H3N2) epidemic clade 3C.2a and is characterized by attenuated ability to agglutinate nonhuman erythrocytes. 22180206 4 47 gly glycoprotein 854:865 arg1 the anti-freeze glycoprotein the anti-freeze glycoprotein Fterm glycoprotein In addition, a glycopeptide from the anti-freeze glycoprotein of Antarctic and Arctic notothenoids, bearing four O-linked, per-acetylated T antigens was characterised. 22180206 4 24 gly glycopeptide 820:831 arg1 the anti-freeze glycoprotein glycoprotein glycopeptide Fterm glycoprotein glycopeptide In addition, a glycopeptide from the anti-freeze glycoprotein of Antarctic and Arctic notothenoids, bearing four O-linked, per-acetylated T antigens was characterised. 12706077 1 6 part_of HA1 301:303 arg1 the HA1 region HA1 the HA1 region OGER Site HA1 region Avian H5N1 influenza viruses isolated from humans in Hong Kong in 1997 were divided into two antigenic groups based on the presence or absence of a potential glycosylation site at amino acid residues 154-156 in the HA1 region of the viral hemagglutinin (HA) surface glycoprotein. 12706077 1 23 part_of hemagglutinin 325:337 arg1 the HA1 region hemagglutinin the HA1 region Fterm Site hemagglutinin region Avian H5N1 influenza viruses isolated from humans in Hong Kong in 1997 were divided into two antigenic groups based on the presence or absence of a potential glycosylation site at amino acid residues 154-156 in the HA1 region of the viral hemagglutinin (HA) surface glycoprotein. 20923142 0 101 gly glycopeptides 52:64 arg2 N-linked glycopeptides N-linked glycopeptides glycopeptides Investigation of sialylation aberration in N-linked glycopeptides by lectin and tandem labeling (LTL) quantitative proteomics. 20923142 0 96 gly sialylation 17:27 arg1 N-linked glycopeptides glycopeptides N-linked glycopeptides Site glycopeptides Investigation of sialylation aberration in N-linked glycopeptides by lectin and tandem labeling (LTL) quantitative proteomics. 15135404 2 45 part_of factor 385:390 arg1 the Saccharomyces cerevisiae alpha-mating factor signal sequence factor the Saccharomyces cerevisiae alpha-mating factor signal sequence Fterm Site factor sequence SAP cDNA was placed under control of regulatory sequences derived from the alcohol oxidase gene (AOX1), and its protein product was secreted using the Saccharomyces cerevisiae alpha-mating factor signal sequence. 16720579 1 30 gly glycoprotein 273:284 arg1 a glycoprotein a glycoprotein Fterm glycoprotein We have shown previously that purified chondroitin 6-sulfotransferase-1 (C6ST-1) was a glycoprotein abundant in N-linked oligosaccharides and could sulfate both chondroitin (C6ST activity) and keratan sulfate (KSST activity); however, functional roles of the N-glycans have remained unclear. 16720579 1 30 gly glycoprotein 273:284 arg1 purified chondroitin 6-sulfotransferase-1 purified chondroitin 6-sulfotransferase-1 OGER chondroitin 6-sulfotransferase Q7LGC8 We have shown previously that purified chondroitin 6-sulfotransferase-1 (C6ST-1) was a glycoprotein abundant in N-linked oligosaccharides and could sulfate both chondroitin (C6ST activity) and keratan sulfate (KSST activity); however, functional roles of the N-glycans have remained unclear. 22180206 3 64 gly glycosylation 717:729 arg2 different glycosylation site occupancies different glycosylation site occupancies site Synthetic glycopeptides from the human mucin-1 (MUC-1) tandem repeat region containing a range of O-linked, tumour-associated carbohydrate antigens, namely Tn, T and sialyl T, with different glycosylation site occupancies and an increasing number of tandem repeats were studied. 22180206 3 69 gly region 595:600 arg1 Synthetic glycopeptides Synthetic glycopeptides Synthetic glycopeptides Site glycopeptides Synthetic glycopeptides from the human mucin-1 (MUC-1) tandem repeat region containing a range of O-linked, tumour-associated carbohydrate antigens, namely Tn, T and sialyl T, with different glycosylation site occupancies and an increasing number of tandem repeats were studied. 22180206 3 53 gly glycopeptides 536:548 arg1 the human mucin-1 (MUC-1) tandem repeat region glycopeptides glycopeptides Synthetic glycopeptides from the human mucin-1 (MUC-1) tandem repeat region containing a range of O-linked, tumour-associated carbohydrate antigens, namely Tn, T and sialyl T, with different glycosylation site occupancies and an increasing number of tandem repeats were studied. 22180206 3 60 gly occupancies 736:746 arg2 different glycosylation site occupancies site tandem repeats site Synthetic glycopeptides from the human mucin-1 (MUC-1) tandem repeat region containing a range of O-linked, tumour-associated carbohydrate antigens, namely Tn, T and sialyl T, with different glycosylation site occupancies and an increasing number of tandem repeats were studied. 9725224 8 57 gly linked 1177:1182 arg2 residue 176 AND carbohydrates residue 176 carbohydrates residue 176 These results suggest that, while carbohydrates linked to residue 176 seem to function as a part of the ligand structure for the Ly-49 family of NK receptors, there are additional structural features involved in this recognition. 30755292 7 11 gly glycosylation 1358:1370 arg2 one N-linked glycosylation site one N-linked glycosylation site site The isolates in clades 3C.2A1a and 3C.2A3 lost one N-linked glycosylation site in HA relative to other clades. 25544388 2 45 gly sequences 316:324 arg1 Asn Asn Asn One aspect of glycoengineering is to introduce new N-linked glycosylation consensus sequences (Asn, X, Thr/Ser) into desirable positions in the peptide backbone by mutational insertion to generate proteins with increased sialic acid content. 25544388 2 45 gly sequences 316:324 arg1 Thr/Ser Thr/Ser Thr/Ser One aspect of glycoengineering is to introduce new N-linked glycosylation consensus sequences (Asn, X, Thr/Ser) into desirable positions in the peptide backbone by mutational insertion to generate proteins with increased sialic acid content. 15094369 1 2 gly glycosylated 179:190 arg1 a naturally glycosylated Cu/Zn-superoxide dismutase a naturally glycosylated Cu/Zn-superoxide dismutase Fterm dismutase The fungal strain Humicola lutea 103 produces a naturally glycosylated Cu/Zn-superoxide dismutase (Cu/ZnSOD) (HLSOD). 25389233 11 160 part_of lectin-reactive 1973:1987 arg1 Aleuria aurantia lectin-reactive fucosyl residues lectin Aleuria aurantia lectin-reactive fucosyl residues Fterm Site lectin residues Disease activity in systemic lupus erythematosus correlated with higher exposure of Aleuria aurantia lectin-reactive fucosyl residues by immobilized IgG complexes. 22677411 2 40 gly glycoprotein 343:354 arg1 A few pmol glycoprotein A few pmol glycoprotein Fterm glycoprotein A few pmol glycoprotein is sufficient to determine glycosylation patterns (which opens the way for biomedical applications) and requires at least two separate chromatographic runs. 22365690 1 28 part_of site 288:291 arg1 the target glycoprotein glycoprotein site Fterm Site glycoprotein site A novel strategy combining iTRAQ with (18)O stable isotope labeling (iTRAQ plus (18)O) was established to identify N-glycosylation site, quantify the glycopeptides and non-glycosylated peptides, and obtain N-glycosylation site ratio on the target glycoprotein. 11263562 0 40 gly glycopeptide 10:21 arg2 Selective glycopeptide mapping Selective glycopeptide mapping glycopeptide Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography--electrospray ionization mass spectrometry. 7628611 4 8 gly N-glycosylation 607:621 arg2 a functional N-glycosylation site a functional N-glycosylation site site Of particular interest, Asn-265, a residue located between two putative membrane spanning regions of the frog KBP, is a functional N-glycosylation site. 7628611 4 8 gly N-glycosylation 607:621 arg2 Asn-265 Asn-265 Asn-265 Of particular interest, Asn-265, a residue located between two putative membrane spanning regions of the frog KBP, is a functional N-glycosylation site. 21535396 5 9 gly glycosylation 594:606 arg2 one or more potential N-linked glycosylation sites one or more potential N-linked glycosylation sites sites Site-specific mutagenesis of one or more potential N-linked glycosylation sites in TF was used to generate TF mutants lacking glycans. 6935656 7 9 gly glycosylation 1284:1296 arg2 an extra glycosylation site an extra glycosylation site site These results suggest that the GIX- virus codes for an extra glycosylation site relative to the GIX+ virus, and this oligosaccharide chain is present both on the envelope gene precursor (Prenv) and on the major cleavage product (gp70). 6935656 7 72 gly present 1365:1371 arg1 gp70 AND this oligosaccharide chain gp70 this oligosaccharide chain Cterm gp70 These results suggest that the GIX- virus codes for an extra glycosylation site relative to the GIX+ virus, and this oligosaccharide chain is present both on the envelope gene precursor (Prenv) and on the major cleavage product (gp70). 6935656 7 108 gly present 1365:1371 arg1 the envelope gene precursor AND this oligosaccharide chain precursor this oligosaccharide chain Fterm precursor These results suggest that the GIX- virus codes for an extra glycosylation site relative to the GIX+ virus, and this oligosaccharide chain is present both on the envelope gene precursor (Prenv) and on the major cleavage product (gp70). 17178093 0 12 gly glycoproteins 55:67 arg1 glycoproteins glycoproteins Fterm glycoproteins Analysis of variable N-glycosylation site occupancy in glycoproteins by liquid chromatography electrospray ionization mass spectrometry. 17178093 0 13 gly N-glycosylation 21:35 arg2 variable N-glycosylation site occupancy variable N-glycosylation site occupancy site Analysis of variable N-glycosylation site occupancy in glycoproteins by liquid chromatography electrospray ionization mass spectrometry. 25456591 4 19 gly glycopeptide 917:928 arg2 glycopeptide glycopeptide glycopeptide Each glycopeptide assignment was verified by the detection of glycan-specific fragments using collision-induced dissociation (CID) to estimate False Discovery Rate (FDR). 12646046 3 5 gly N-glycosylation 512:526 arg2 position 107 position 107 position 107 All three Pla l 1 cDNAs code for a 25-residue leader peptide and a 131-residue mature protein that contains two polymorphic positions, an N-glycosylation site at position 107 and six cysteine residues involved in three disulphide bridges. 12646046 3 5 gly N-glycosylation 512:526 arg2 an N-glycosylation site an N-glycosylation site site All three Pla l 1 cDNAs code for a 25-residue leader peptide and a 131-residue mature protein that contains two polymorphic positions, an N-glycosylation site at position 107 and six cysteine residues involved in three disulphide bridges. 12646046 3 5 gly N-glycosylation 512:526 arg2 two polymorphic positions two polymorphic positions positions, All three Pla l 1 cDNAs code for a 25-residue leader peptide and a 131-residue mature protein that contains two polymorphic positions, an N-glycosylation site at position 107 and six cysteine residues involved in three disulphide bridges. 25094044 4 22 gly glycosylation 668:680 arg2 the site UGGT1 site PUBTATOR UGGT1 171129 site In this study, we reveal the site of glycosylation (N269) and the glycan structures (Hex5-8HexNAc2) in UGGT1 obtained from rat (Rattus norvegicus), pig (Sus scrofa), cow (Bos taurus), and human (Homo sapiens). 8543840 10 51 part_of env 1313:1315 arg1 an env epitope env an env epitope PUBTATOR Site env 100616444 epitope Thus, the naturally processed form of an env epitope containing an N-linked glycosylation site is derived from env protein that is not glycosylated at the relevant asparagine during biosynthesis. 8543840 10 49 part_of containing 1325:1334 arg1 an env epitope AND an N-linked glycosylation site an env epitope an N-linked glycosylation site site Thus, the naturally processed form of an env epitope containing an N-linked glycosylation site is derived from env protein that is not glycosylated at the relevant asparagine during biosynthesis. 29333671 1 11 gly glycopeptides 267:279 arg1 glycans glycopeptides glycans glycopeptides Glycosylation analysis of proteins from biological sources utilizing mass spectrometry based approaches is challenging due to the relatively low abundance of glycopeptides, the structural diversity of glycans, and the coexisting matrices. 31317206 1 2 gly glycosylation 263:275 arg2 a putative glycosylation site a putative glycosylation site site The human chondromodulin-1 (Chm-1, Chm-I, CNMD, or Lect1) gene encodes a 334 amino acid type II transmembrane glycoprotein protein with characteristics of a furin cleavage site and a putative glycosylation site. 31317206 1 20 gly glycoprotein 181:192 arg1 a 334 amino acid type II transmembrane glycoprotein protein a 334 amino acid type II transmembrane glycoprotein protein Fterm glycoprotein The human chondromodulin-1 (Chm-1, Chm-I, CNMD, or Lect1) gene encodes a 334 amino acid type II transmembrane glycoprotein protein with characteristics of a furin cleavage site and a putative glycosylation site. 27356208 3 20 gly hyper-glycosylation 535:553 arg1 recombinant proteins recombinant proteins Fterm proteins Glyco-engineering is an approach to facilitate the hyper-glycosylation of recombinant proteins by application of the site-directed mutagenesis methods. 9242452 9 50 gly O-glycosylated 1622:1635 arg1 The four strongest immunogenic glycopeptides The four strongest immunogenic glycopeptides glycopeptides The four strongest immunogenic glycopeptides were all O-glycosylated, and interestingly, three of them carried the tumor-associated Tn or T antigen. 9242452 9 101 gly glycopeptides 1599:1611 arg2 The four strongest immunogenic glycopeptides The four strongest immunogenic glycopeptides glycopeptides The four strongest immunogenic glycopeptides were all O-glycosylated, and interestingly, three of them carried the tumor-associated Tn or T antigen. 10675514 7 16 gly glycosylation 983:995 arg2 two glycosylation sites two glycosylation sites sites However, dog and bovine AQP1 have only one N-glycosylation site, while two glycosylation sites were found in human and rodent AQP1. 10675514 7 33 gly N-glycosylation 951:965 arg2 only one N-glycosylation site only one N-glycosylation site site However, dog and bovine AQP1 have only one N-glycosylation site, while two glycosylation sites were found in human and rodent AQP1. 10211957 4 59 gly utilized 720:727 arg2 the five potential glycosylation sites the five potential glycosylation sites sites A recent study has revealed that upon partial deglycosylation with endoglycosidase H only four of the five potential glycosylation sites of HCV glycoprotein E1 are utilized. 10211957 4 88 gly glycoprotein 700:711 arg1 HCV glycoprotein E1 HCV glycoprotein E1 Fterm glycoprotein A recent study has revealed that upon partial deglycosylation with endoglycosidase H only four of the five potential glycosylation sites of HCV glycoprotein E1 are utilized. 10211957 4 82 gly glycosylation 673:685 arg2 the five potential glycosylation sites E1 sites Cterm E1 sites A recent study has revealed that upon partial deglycosylation with endoglycosidase H only four of the five potential glycosylation sites of HCV glycoprotein E1 are utilized. 23714211 12 15 gly glycosylation 2122:2134 arg2 glycosylation site variants glycosylation site variants site RESULTS: The in vitro and in vivo phenotypes of cells expressing glycosylation site variants differed from cells expressing fully-glycosylated ICAM-2 or no ICAM-2. 23714211 12 55 gly fully-glycosylated 2181:2198 arg1 fully-glycosylated ICAM-2 or no ICAM-2 fully-glycosylated ICAM-2 or no ICAM-2 PUBTATOR ICAM-2 3384 RESULTS: The in vitro and in vivo phenotypes of cells expressing glycosylation site variants differed from cells expressing fully-glycosylated ICAM-2 or no ICAM-2. 9832151 8 53 gly glycosylation 1364:1376 arg2 all the potential glycosylation sites all the potential glycosylation sites sites Pro43 is a highly conserved residue located at the beginning of the large loop in which all the potential glycosylation sites are found. 15718224 0 35 gly glycosylation 20:32 arg2 glycosylation sites glycosylation sites sites Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis. 2318516 4 57 part_of alpha 882:886 arg1 the alpha 1 and alpha 2 domains alpha 1 and alpha 2 the alpha 1 and alpha 2 domains PUBTATOR Site alpha 1 and alpha 2 146 domains We have now determined that the surface expression of class I glycoproteins in T2 depends on the origin of the alpha 1 and alpha 2 domains. 2318516 4 120 part_of alpha 894:898 arg1 the alpha 1 and alpha 2 domains alpha 1 and alpha 2 the alpha 1 and alpha 2 domains PUBTATOR Site alpha 1 and alpha 2 146 domains We have now determined that the surface expression of class I glycoproteins in T2 depends on the origin of the alpha 1 and alpha 2 domains. 14695241 2 13 gly site 271:274 arg1 Asn-X-Ser/Thr Asn-X-Ser/Thr Asn This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions. 14695241 2 18 gly glycosylation 257:269 arg2 an additional potential N-linked glycosylation site an additional potential N-linked glycosylation site site This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions. 14695241 2 18 gly glycosylation 257:269 arg2 Asn357 Asn357 Asn357 This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions. 10488137 5 57 gly N-glycosylation 661:675 arg2 an N-glycosylation site an N-glycosylation site site To further characterize the membrane topology and targeting of this protein, an N-glycosylation site was engineered into mEH to serve as a topological probe for the elucidation of the cellular location of mEH domains. 24164424 6 21 part_of possess 1045:1051 arg1 CNGA subunits AND one extracellular core glycosylation site CNGA subunits one extracellular core glycosylation site Cterm Site CNGA subunits 281700 site CNGA subunits are known to possess one extracellular core glycosylation site, located at one of two possible positions within the turret loop near the pore-forming region. 2457922 12 27 part_of terminus 2322:2329 arg1 the peptides terminus the peptides peptides Protein structural analysis of BGP I isolated from human bile revealed a blocked N terminus, 129 amino acids of internal sequence that are in agreement with the translated cDNA sequence, and five glycosylation sites in the peptides sequenced. 8429003 3 0 gly oligosaccharides 626:641 arg1 rat sCD4 sCD4 oligosaccharides PUBTATOR sCD4 499358 The most obvious differences between the rat and human sCD4 oligosaccharides were the greater abundance of oligomannose and hybrid oligosaccharides on rat sCD4 and the presence of oligosaccharides carrying a terminal alpha-galactose residue on human sCD4. 8429003 3 24 gly residue 728:734 arg1 human sCD4 sCD4 residue PUBTATOR sCD4 79966 The most obvious differences between the rat and human sCD4 oligosaccharides were the greater abundance of oligomannose and hybrid oligosaccharides on rat sCD4 and the presence of oligosaccharides carrying a terminal alpha-galactose residue on human sCD4. 23339644 0 79 gly glycosylation 44:56 arg1 early transmitted/founder HIV-1 gp120 envelope proteins early transmitted/founder HIV-1 gp120 envelope proteins Fterm proteins Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. 18272752 6 81 part_of site 918:921 arg1 the viral envelope protein envelope protein site PUBTATOR Site envelope protein 17276 site Nucleotide sequencing of WN25A viruses recovered from the brains of B-cell-deficient mice revealed that the conserved N-linked glycosylation site in the viral envelope protein was abolished by substitution of a serine residue at position 155. 9435448 9 47 gly glycosylation 1389:1401 arg2 such an additional glycosylation site such an additional glycosylation site site The influence of such an additional glycosylation site on the biological half-life of variant hSHBG was investigated. 2000403 2 33 gly N-glycosylation 513:527 arg1 proteins proteins Fterm proteins It was hypothesized that this multifunctional protein, called glycosylation site-binding protein (GSBP), participated in the process of N-glycosylation of proteins. 12235182 9 34 part_of apoB 1909:1912 arg1 the amino terminus apoB the amino terminus PUBTATOR Site apoB 338 terminus These data imply that the N-glycans at the amino terminus of apoB play an important role in the assembly and secretion of lipoproteins containing the carboxyl terminally truncated apoB. 7772241 6 42 gly glycosylation 1240:1252 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site In contrast, the hagfish neurophysin showed at least two insertions and one deletion in the conserved central region including 14 Cys residues, but contained a potential N-linked glycosylation site and had a high proportion of Leu residues in the C-terminal region, like the neurophysin of another hagfish, Eptatretus stouti. 9343410 6 1 gly glycosylation 1174:1186 arg2 the mapped glycosylation site the mapped glycosylation site site In HeLa cells, the mutation at the mapped glycosylation site was permissive for transcriptional activation. 22773269 2 31 gly sialoglycopeptides 257:274 arg2 The efficient sialoglycopeptides enrichment methods The efficient sialoglycopeptides enrichment methods sialoglycopeptides The efficient sialoglycopeptides enrichment methods are therefore attracting considerable attention. 8496193 1 0 gly glycosylation 132:144 arg1 procathepsin L procathepsin L OGER procathepsin L P06797 The role of glycosylation in the synthesis, transport, and localization of procathepsin L has been analyzed. 16213030 2 3 gly N-glycosylation 597:611 arg2 a putative N-glycosylation site a putative N-glycosylation site site Using bioinformatics and molecular cloning techniques, we isolated a bovine gene that encodes a polypeptide of 206 amino acids with structural features shared by mouse and human dectin-2, including a high homology with mouse dectin-2 (66%), a type II configuration, a short cytoplasmic domain without tyrosine-based signal motifs, a carbohydrate recognition domain, a putative N-glycosylation site, and an EPN motif involved in the Ca(2+)-dependent binding of hexose carbohydrates. 16213030 2 3 gly N-glycosylation 597:611 arg2 tyrosine-based signal motifs tyrosine-based signal motifs motifs Using bioinformatics and molecular cloning techniques, we isolated a bovine gene that encodes a polypeptide of 206 amino acids with structural features shared by mouse and human dectin-2, including a high homology with mouse dectin-2 (66%), a type II configuration, a short cytoplasmic domain without tyrosine-based signal motifs, a carbohydrate recognition domain, a putative N-glycosylation site, and an EPN motif involved in the Ca(2+)-dependent binding of hexose carbohydrates. 16213030 2 47 gly tyrosine-based 521:534 arg1 a carbohydrate recognition domain tyrosine a carbohydrate recognition domain tyrosine Using bioinformatics and molecular cloning techniques, we isolated a bovine gene that encodes a polypeptide of 206 amino acids with structural features shared by mouse and human dectin-2, including a high homology with mouse dectin-2 (66%), a type II configuration, a short cytoplasmic domain without tyrosine-based signal motifs, a carbohydrate recognition domain, a putative N-glycosylation site, and an EPN motif involved in the Ca(2+)-dependent binding of hexose carbohydrates. 26348848 7 74 gly unglycosylated 1349:1362 arg1 the Kv proteins the Kv proteins Fterm proteins Differences were also observed between the unglycosylated forms of the Kv proteins. 8987398 1 3 gly glycosylation 169:181 arg2 Asn86 Asn86 Asn86 Major histocompatibility complex (MHC) class I heavy chain glycoproteins have an invariant N-linked glycosylation site at Asn86, which is found between two extremely variable protein domains. 8987398 1 3 gly glycosylation 169:181 arg2 an invariant N-linked glycosylation site an invariant N-linked glycosylation site site Major histocompatibility complex (MHC) class I heavy chain glycoproteins have an invariant N-linked glycosylation site at Asn86, which is found between two extremely variable protein domains. 8987398 1 37 gly glycoproteins 128:140 arg1 Major histocompatibility complex (MHC) class I heavy chain glycoproteins Major histocompatibility complex (MHC) class I heavy chain glycoproteins Fterm glycoproteins Major histocompatibility complex (MHC) class I heavy chain glycoproteins have an invariant N-linked glycosylation site at Asn86, which is found between two extremely variable protein domains. 26993603 0 38 gly N-glycosylation 5:19 arg2 Asn144 Asn144 Asn144 GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness. 12731887 6 30 part_of p67 1145:1147 arg1 the (60)SGTS(63) sequence p67 the (60)SGTS(63) sequence PUBTATOR Site p67 64370 sequence These results suggest that glycosylation within the (60)SGTS(63) sequence of p67 plays an important role in its stability and thus its regulation of protein synthesis by modulating the phosphorylation of the alpha-subunit of eIF2. 22719948 4 33 part_of receptor-binding 651:666 arg1 the receptor-binding domains receptor the receptor-binding domains Fterm Site receptor domains Protein sequence alignment in various clades indicates the high conservation in the receptor-binding domains (RBDs) is essential for binding with the SA receptor. 25945896 2 42 gly glycosylation 555:567 arg2 each specific glycosylation site each specific glycosylation site site Recent advances in mass spectrometry instrumentation and techniques have facilitated analysis of intact glycopeptides in complex biological samples by allowing the users to generate spectra of intact glycopeptides with glycans attached to each specific glycosylation site. 25945896 2 43 gly glycopeptides 406:418 arg2 intact glycopeptides intact glycopeptides glycopeptides Recent advances in mass spectrometry instrumentation and techniques have facilitated analysis of intact glycopeptides in complex biological samples by allowing the users to generate spectra of intact glycopeptides with glycans attached to each specific glycosylation site. 25945896 2 97 gly attached 529:536 arg1 each specific glycosylation site AND glycans each specific glycosylation site glycans site Recent advances in mass spectrometry instrumentation and techniques have facilitated analysis of intact glycopeptides in complex biological samples by allowing the users to generate spectra of intact glycopeptides with glycans attached to each specific glycosylation site. 25945896 2 111 gly glycopeptides 502:514 arg2 intact glycopeptides glycopeptides glycans glycopeptides Recent advances in mass spectrometry instrumentation and techniques have facilitated analysis of intact glycopeptides in complex biological samples by allowing the users to generate spectra of intact glycopeptides with glycans attached to each specific glycosylation site. 22607976 7 26 part_of proteins 1289:1296 arg1 cryptic N-glycosylation sites proteins cryptic N-glycosylation sites Fterm Site proteins sites Hence we postulate that STT3B-dependent posttranslational N-glycosylation is part of a triage-salvage system recognizing cryptic N-glycosylation sites of secretory proteins to preserve protein homeostasis. 15264219 4 54 gly glycosylation 723:735 arg1 each site each site site To address this question, we used tunicamycin treatment and site-directed mutagenesis to inhibit selectively N-linked glycosylation at each site and then examined the effects of these treatments on receptor expression and function in transiently transfected heterologous cells. 9455905 2 51 gly O-glycosylation 468:482 arg1 a sequence a sequence sequence Previously, we demonstrated that the in vivo O-glycosylation of a sequence derived from a known glycosylation site of human von Willebrand factor (PHMAQVTVGPGL) was markedly reduced when charged residues were substituted at position -1 and +3 relative to the single threonine. 9455905 2 41 gly glycosylation 519:531 arg2 a known glycosylation site von Willebrand factor site PUBTATOR von Willebrand factor 7450 site Previously, we demonstrated that the in vivo O-glycosylation of a sequence derived from a known glycosylation site of human von Willebrand factor (PHMAQVTVGPGL) was markedly reduced when charged residues were substituted at position -1 and +3 relative to the single threonine. 9455905 2 41 gly glycosylation 519:531 arg2 a known glycosylation site PHMAQVTVGPGL site Cterm PHMAQVTVGPGL 7450 site Previously, we demonstrated that the in vivo O-glycosylation of a sequence derived from a known glycosylation site of human von Willebrand factor (PHMAQVTVGPGL) was markedly reduced when charged residues were substituted at position -1 and +3 relative to the single threonine. 12928435 0 97 gly glycosylation 46:58 arg1 functional hyperpolarization-activated cyclic nucleotide-gated channels functional hyperpolarization-activated cyclic nucleotide-gated channels Fterm channels Role of subunit heteromerization and N-linked glycosylation in the formation of functional hyperpolarization-activated cyclic nucleotide-gated channels. 9080302 3 14 gly glycosylation 864:876 arg2 more than one glycosylation site more than one glycosylation site site These results may occur as a consequence of more than one glycosylation site which is differentially glycosylated, but more likely by changes in the level of bisecting N-acetylglucosamine. 22750213 4 34 gly glycoprotein 682:693 arg1 PRiMA PRiMA PUBTATOR PRiMA 170952 PRiMA is a glycoprotein containing two putative N-linked glycosylation sites. 22750213 4 34 gly glycoprotein 682:693 arg1 a glycoprotein a glycoprotein Fterm glycoprotein PRiMA is a glycoprotein containing two putative N-linked glycosylation sites. 22750213 4 46 gly glycosylation 728:740 arg2 two putative N-linked glycosylation sites two putative N-linked glycosylation sites sites PRiMA is a glycoprotein containing two putative N-linked glycosylation sites. 15320803 7 44 gly N-glycosylation 1471:1485 arg2 N-glycosylation site(s) N-glycosylation site(s) site This review introduces the anti-DIC action of PCI and about the modification of N-glycosylation site(s) of PCI to heighten the value of PCI as an anti-DIC agent. 21053369 13 6 gly observed 1784:1791 arg1 Asn157 AND hybrid type glycans Asn157 hybrid type glycans Asn157 High mannose and hybrid type glycans were only observed on Asn157. 21053369 13 6 gly observed 1784:1791 arg1 Asn157 AND High mannose Asn157 High mannose Asn157 High mannose and hybrid type glycans were only observed on Asn157. 26956484 5 37 gly glycosylation 743:755 arg1 Orai1 Orai1 PUBTATOR Orai1 84876 Using Western blot analysis and lectin-binding assays from various primary human cells and cancer cell lines, we found that glycosylation of Orai1 is cell type-specific. 8756556 4 25 gly N-glycosylation 731:745 arg2 one putative N-glycosylation site one putative N-glycosylation site site PLP-D contains one putative N-glycosylation site and six cysteine residues that are highly conserved in the placental PRL family. 7613477 6 37 gly glycosylation 1278:1290 arg2 Two unanticipated O-linked glycosylation sites Two unanticipated O-linked glycosylation sites sites Two unanticipated O-linked glycosylation sites were identified at Thr407 and Ser409 of the LCAT O-linked glycopeptide, each of which contain sialylated galactose beta 1-->3N-acetylgalactosamine structures. 7613477 6 56 gly glycopeptide 1356:1367 arg2 the LCAT O-linked glycopeptide the LCAT O-linked glycopeptide glycopeptide Two unanticipated O-linked glycosylation sites were identified at Thr407 and Ser409 of the LCAT O-linked glycopeptide, each of which contain sialylated galactose beta 1-->3N-acetylgalactosamine structures. 15616123 1 0 part_of has 122:124 arg1 Human apolipoprotein B100 AND 19 potential N-glycosylation sites Human apolipoprotein B100 19 potential N-glycosylation sites PUBTATOR Site Human apolipoprotein B100 338 sites Human apolipoprotein B100 (apoB100) has 19 potential N-glycosylation sites, and 16 asparagine residues were reported to be occupied by high-mannose type, hybrid type, and monoantennary and biantennary complex type oligosaccharides. 15616123 1 0 part_of has 122:124 arg1 apoB100 AND 19 potential N-glycosylation sites apoB100 19 potential N-glycosylation sites PUBTATOR Site apoB100 338 sites Human apolipoprotein B100 (apoB100) has 19 potential N-glycosylation sites, and 16 asparagine residues were reported to be occupied by high-mannose type, hybrid type, and monoantennary and biantennary complex type oligosaccharides. 31572782 3 34 gly glycoproteins 360:372 arg1 intact glycoproteins intact glycoproteins Fterm glycoproteins Here, we present an NMR-based strategy to delineate the N-glycan composition in intact glycoproteins and under physiological conditions. 31572782 3 44 gly composition 338:348 arg1 intact glycoproteins glycoproteins composition Fterm glycoproteins Here, we present an NMR-based strategy to delineate the N-glycan composition in intact glycoproteins and under physiological conditions. 26059044 10 9 gly glycoproteins 1597:1609 arg1 IL-22 IL-22 PUBTATOR IL-22 50616 Altogether, our data demonstrate that plants offer an excellent tool to investigate the role of N-glycosylation on folding and activity of recombinant glycoproteins, such as IL-22. 26059044 10 9 gly glycoproteins 1597:1609 arg1 recombinant glycoproteins recombinant glycoproteins Fterm glycoproteins Altogether, our data demonstrate that plants offer an excellent tool to investigate the role of N-glycosylation on folding and activity of recombinant glycoproteins, such as IL-22. 32168410 11 82 gly FXIII-B 1271:1277 arg1 The total N-glycan profile FXIII-B The total N-glycan profile PUBTATOR FXIII-B 2165 The total N-glycan profile of FXIII-B featured nine individual structures; three were fucosylated and each structure contained at least one sialic acid. 15765924 2 18 part_of protease 399:406 arg1 the same amino acid sequence protease the same amino acid sequence Fterm Site protease sequence DrotAA is a serine protease (approximately 55 kD molecular weight) with the same amino acid sequence and the glycosylation site as human plasma-derived APC. 15765924 2 18 part_of protease 399:406 arg1 the glycosylation site protease the glycosylation site Fterm Site protease site DrotAA is a serine protease (approximately 55 kD molecular weight) with the same amino acid sequence and the glycosylation site as human plasma-derived APC. 7620335 6 61 gly Asn49 1079:1083 arg1 the neutral oligosaccharides Asn39 and Asn49 residues the neutral oligosaccharides Asn39 and Asn49 residues The contents of the neutral oligosaccharides at Asn39 and Asn49 residues were 32.5% and 30.0%, respectively. 7620335 6 79 gly Asn39 1069:1073 arg1 the neutral oligosaccharides Asn39 and Asn49 residues the neutral oligosaccharides Asn39 and Asn49 residues The contents of the neutral oligosaccharides at Asn39 and Asn49 residues were 32.5% and 30.0%, respectively. 30257863 0 59 gly glycosylation 52:64 arg1 the inwardly rectifying potassium channel Kir7.1 the inwardly rectifying potassium channel Kir7.1 PUBTATOR Kir7.1 3769 G protein-coupled receptors differentially regulate glycosylation and activity of the inwardly rectifying potassium channel Kir7.1. 7904345 3 10 part_of sCD4 528:531 arg1 rat sCD4 glycopeptides sCD4 rat sCD4 glycopeptides PUBTATOR Site sCD4 499358 glycopeptides Comparisons of rat sCD4 glycopeptides with mutant molecules with only single glycosylation sites and with a truncated form containing only the two NH2-terminal domains, indicate that independent processing occurs at each glycosylation site and that domain interactions can also affect oligosaccharide processing. 27038031 9 21 part_of protein 1486:1492 arg1 the site-heterogeneity protein the site-heterogeneity Fterm Site protein site-heterogeneity This study highlights the information obtained by characterization of the site-heterogeneity of a highly glycosylated protein of high molecular mass with quaternary structure, revealing differences that would not be seen by global glycan or deglycosylated peptide profiling. 30392906 4 11 part_of MPZL1 545:549 arg1 the extracellular domain MPZL1 the extracellular domain PUBTATOR Site MPZL1 9019 domain To elucidate the functional basis, we have determined the crystal structure of the extracellular domain of MPZL1 at 2.7 Å resolution. 25759508 6 57 gly O-glycosylation 907:921 arg2 the site the site site NanoLC-ESI-IT-MS/MS with electron transfer dissociation fragmentation and CE-MS/MS with CID fragmentation were used to determine the site of IgG3 O-glycosylation. 17313760 8 37 gly N-glycosylation 865:879 arg2 N-glycosylation site analysis N-glycosylation site analysis site The amino acid similarity analysis was done with DNASIS, and N-glycosylation site analysis was done with N-GLYCOSIDE program. 31004621 7 24 part_of F 1254:1254 arg1 the individual RSV F N-glycosylation sites RSV F N-glycosylation the individual RSV F N-glycosylation sites Cterm Site RSV F N-glycosylation sites Although the individual RSV F N-glycosylation sites were shown not to be essential for viral replication, they do contribute to the efficiency of in vitro and in vivo viral infection. 31004621 7 88 part_of N-glycosylation 1256:1270 arg1 the individual RSV F N-glycosylation sites RSV F N-glycosylation the individual RSV F N-glycosylation sites Cterm Site RSV F N-glycosylation sites Although the individual RSV F N-glycosylation sites were shown not to be essential for viral replication, they do contribute to the efficiency of in vitro and in vivo viral infection. 31004621 7 93 part_of RSV 1250:1252 arg1 the individual RSV F N-glycosylation sites RSV F N-glycosylation the individual RSV F N-glycosylation sites Cterm Site RSV F N-glycosylation sites Although the individual RSV F N-glycosylation sites were shown not to be essential for viral replication, they do contribute to the efficiency of in vitro and in vivo viral infection. 28166830 1 36 gly determinants 341:352 arg1 hemagglutinin hemagglutinin determinants Fterm hemagglutinin We generated and characterized site-directed HA mutants on the genetic backbone of H5N1 clade 2.3.4 virus preferentially binding to α-2,3 receptors in order to identify the key determinants in hemagglutinin rendering the dual affinity to both α-2,3 (avian-type) and α-2,6 (human-type) linked sialic acid receptors of the current clade 2.3.4.4 H5NX subtype avian influenza reassortants. 10413093 1 52 part_of gp120 226:230 arg1 N306 gp120 N306 PUBTATOR SpecificSite gp120 155971 N306 We have previously shown that an N-glycosylation site of N306 of HIV-1 gp120 is not necessary for the HIV-1 infectivity but protects HIV-1 from neutralising antibodies. 7689338 2 30 gly glycosylation 275:287 arg2 a glycosylation site a glycosylation site site The clone contains an open reading frame that encodes a 138 amino acid polypeptide including a glycosylation site and a signal peptide containing 30 amino acids. 1359371 2 60 gly present 252:258 arg1 the protein AND the carbohydrates the protein the carbohydrates Fterm protein In this report we have examined the carbohydrates present on the protein and determined the partial protein sequence of enzymatically and CNBr-produced peptides. 16212939 0 46 gly N-Glycosylation 0:14 arg1 secretion enhancer peptide secretion enhancer peptide peptide N-Glycosylation of secretion enhancer peptide as influencing factor for the secretion of target proteins from Saccharomyces cerevisiae. 25485983 1 6 gly glycoforms 191:200 arg1 this key anticoagulant serpin this key anticoagulant serpin Fterm serpin The inefficient glycosylation of consensus sequence on N135 in antithrombin explains the two glycoforms of this key anticoagulant serpin found in plasma: α and β, with four and three N-glycans, respectively. 25485983 1 41 gly glycosylation 114:126 arg1 N135 N135 N135 The inefficient glycosylation of consensus sequence on N135 in antithrombin explains the two glycoforms of this key anticoagulant serpin found in plasma: α and β, with four and three N-glycans, respectively. 25485983 1 41 gly glycosylation 114:126 arg1 antithrombin antithrombin N135 PUBTATOR antithrombin 462 N135 The inefficient glycosylation of consensus sequence on N135 in antithrombin explains the two glycoforms of this key anticoagulant serpin found in plasma: α and β, with four and three N-glycans, respectively. 25485983 1 41 gly glycosylation 114:126 arg1 antithrombin antithrombin N135 PUBTATOR antithrombin 462 N135 The inefficient glycosylation of consensus sequence on N135 in antithrombin explains the two glycoforms of this key anticoagulant serpin found in plasma: α and β, with four and three N-glycans, respectively. 25485983 1 41 gly glycosylation 114:126 arg1 antithrombin antithrombin sequence PUBTATOR antithrombin 462 sequence The inefficient glycosylation of consensus sequence on N135 in antithrombin explains the two glycoforms of this key anticoagulant serpin found in plasma: α and β, with four and three N-glycans, respectively. 29274340 3 27 gly glycosylation 708:720 arg1 rhGAA rhGAA OGER rhGAA Q6P7A9 This study investigated M6P glycosylation on rhGAA using liquid chromatography (LC)-electrospray ionization (ESI)-high-energy collisional dissociation (HCD) tandem mass spectrometry (MS/MS). 9295302 7 47 gly utilized 1143:1150 arg2 the sequon the sequon sequon The results obtained indicated that the sequon at Asn354 in the middle MSD is not utilized and suggested approximate sites of N-glycosylation. 9295302 7 47 gly utilized 1143:1150 arg2 Asn354 Asn354 Asn354 The results obtained indicated that the sequon at Asn354 in the middle MSD is not utilized and suggested approximate sites of N-glycosylation. 9295302 7 93 gly N-glycosylation 1187:1201 arg2 approximate sites approximate sites sites The results obtained indicated that the sequon at Asn354 in the middle MSD is not utilized and suggested approximate sites of N-glycosylation. 8236140 1 6 gly glycosylation 185:197 arg2 an additional glycosylation site an additional glycosylation site site Site directed mutagenesis was used to construct a t-PA variant that contains an additional glycosylation site in the first kringle domain (T103N) combined with a tetra-alanine substitution in the protease domain (KHRR 296-299 AAAA). 9639536 1 10 gly presence 211:218 arg1 an N-linked glycoprotein AND the sialyl Lewis(x) antigen an N-linked glycoprotein the sialyl Lewis(x) antigen Fterm glycoprotein A simple, fast and sensitive method was developed to verify the presence of the sialyl Lewis(x) antigen on an N-linked glycoprotein. 9639536 1 59 gly glycoprotein 266:277 arg1 an N-linked glycoprotein an N-linked glycoprotein Fterm glycoprotein A simple, fast and sensitive method was developed to verify the presence of the sialyl Lewis(x) antigen on an N-linked glycoprotein. 20589319 2 52 gly glycosylation 548:560 arg2 a canonical glycosylation site a canonical glycosylation site site This frameshift results in 25 amino acid substitutions, late termination of translation with elongation by 15 amino acids, and the introduction of a canonical glycosylation site. 29285644 7 5 gly glycopeptides 1282:1294 arg2 Ninety-six glycopeptides Ninety-six glycopeptides glycopeptides Ninety-six glycopeptides, each corresponding to a unique glycan/glycosite pairing, were tracked across all cancer and control samples. 8639654 9 119 gly N-glycosylation 1525:1539 arg2 three out of four N-glycosylation sites three out of four N-glycosylation sites sites The construction of other mutants in which three out of four N-glycosylation sites were altered, demonstrated that N-glycosylation at either Asn58 or Asn69 is necessary and sufficient to ensure correct delivery of the receptor to the plasma membrane. 8639654 9 68 gly N-glycosylation 1579:1593 arg1 Asn69 Asn69 Asn69 The construction of other mutants in which three out of four N-glycosylation sites were altered, demonstrated that N-glycosylation at either Asn58 or Asn69 is necessary and sufficient to ensure correct delivery of the receptor to the plasma membrane. 8639654 9 68 gly N-glycosylation 1579:1593 arg2 Asn58 Asn58 Asn58 The construction of other mutants in which three out of four N-glycosylation sites were altered, demonstrated that N-glycosylation at either Asn58 or Asn69 is necessary and sufficient to ensure correct delivery of the receptor to the plasma membrane. 18638581 8 18 gly glycosylation 1683:1695 arg2 glycosylation site frequencies glycosylation site frequencies site Serial application of custom-made microcolumns of mixed, immobilized lectins proved efficient for recovery and analysis of glycopeptides from serum samples of breast cancer patients and healthy individuals to assess glycosylation site frequencies. 18638581 8 58 gly glycopeptides 1590:1602 arg2 glycopeptides glycopeptides glycopeptides Serial application of custom-made microcolumns of mixed, immobilized lectins proved efficient for recovery and analysis of glycopeptides from serum samples of breast cancer patients and healthy individuals to assess glycosylation site frequencies. 20378933 0 49 gly Deglycosylation 0:14 arg1 N58 N58 N58 Deglycosylation of FcalphaR at N58 increases its binding to IgA. 2477364 9 92 gly site 1398:1401 arg1 the oligosaccharides site the oligosaccharides site Concanavalin A (ConA) binding and sialic acid content indicated that the oligosaccharides at each glycosylation site of the uncombined alpha subunit are processed differently. 2477364 9 41 gly glycosylation 1384:1396 arg1 the uncombined alpha subunit subunit site Fterm subunit site Concanavalin A (ConA) binding and sialic acid content indicated that the oligosaccharides at each glycosylation site of the uncombined alpha subunit are processed differently. 21153780 10 44 gly glycosylated 1240:1251 arg1 MHC-II epitopes 19 and 21 MHC-II epitopes 19 and 21 epitopes MHC-II epitopes 19 and 21 was predicted to be glycosylated. 2123094 6 35 gly glycosylation 1048:1060 arg2 one unique glycosylation site one unique glycosylation site site There is one unique glycosylation site at asparagine-48. 2123094 6 35 gly glycosylation 1048:1060 arg2 asparagine-48 asparagine-48 asparagine-48 There is one unique glycosylation site at asparagine-48. 1367433 4 49 gly glycosylation 783:795 arg2 the glycosylation sites the glycosylation sites sites These variant molecules are identical in regard to the glycosylation sites originally situated in particular domains, but differ with respect to the sequential alignment of the domains. 15968392 8 68 gly glycosylation 1328:1340 arg2 Asn473 Asn473 Asn473 Thr/Ser475 is highly conserved in serine protease domains but the glycosylation site (Asn473) is not. 15968392 8 68 gly glycosylation 1328:1340 arg2 the glycosylation site the glycosylation site site Thr/Ser475 is highly conserved in serine protease domains but the glycosylation site (Asn473) is not. 16512686 5 6 gly deglycosylation 1392:1406 arg1 the peptide the peptide peptide The glycosylated peptides were then identified by LC-MS/MS after treatment with PNGase-F by the monoisotopic mass increase of 0.984 Da caused by the deglycosylation of the peptide. 16512686 5 70 gly glycosylated 1247:1258 arg1 The glycosylated peptides The glycosylated peptides peptides The glycosylated peptides were then identified by LC-MS/MS after treatment with PNGase-F by the monoisotopic mass increase of 0.984 Da caused by the deglycosylation of the peptide. 10419027 8 51 gly N-glycosylation 1414:1428 arg2 an additional N-glycosylation site an additional N-glycosylation site site The mutated SHBG is characterized by a point mutation (Asp 327 --> Asn) causing an additional N-glycosylation site, which does not affect the binding of steroids to SHBG. 15616124 4 68 gly FVII 541:544 arg1 one and two N-glycans FVII one and two N-glycans Cterm FVII 2155 Pulse-chase labeled intracellular FVII migrated as two bands corresponding to FVII with one and two N-glycans, respectively. 10989127 10 88 part_of present 1504:1510 arg1 HYAL1 AND The same site HYAL1 The same site PUBTATOR Site HYAL1 15586 site The same site was also present in mouse plasma (HYAL1) and mouse lysosomes (HYAL2), and in rat lysosomes (HYAL2). 2040275 2 50 gly attached 385:392 arg2 the oligosaccharide AND the glycosylation site the glycosylation site the oligosaccharide site The peptide is isolated as a set of glycoforms, varying only in the sequence of the oligosaccharide attached at the glycosylation site. 2040275 2 72 gly glycosylation 401:413 arg2 the glycosylation site the glycosylation site site The peptide is isolated as a set of glycoforms, varying only in the sequence of the oligosaccharide attached at the glycosylation site. 1388166 4 38 gly glycoproteins 833:845 arg1 these glycoproteins these glycoproteins Fterm glycoproteins A GalNAc-transferase that recognizes the tripeptide motif Pro-Xaa-Arg/Lys 6-9 residues N-terminal to Asn glycosylation sites accounts for the specific addition of GalNAc to the oligosaccharide acceptor on these glycoproteins, whereas a GalNAc beta 1,4GlcNAc beta 1, 2Man alpha-4-sulfotransferase accounts for the addition of sulfate. 1388166 4 66 gly glycosylation 727:739 arg2 Asn glycosylation sites Asn glycosylation sites sites A GalNAc-transferase that recognizes the tripeptide motif Pro-Xaa-Arg/Lys 6-9 residues N-terminal to Asn glycosylation sites accounts for the specific addition of GalNAc to the oligosaccharide acceptor on these glycoproteins, whereas a GalNAc beta 1,4GlcNAc beta 1, 2Man alpha-4-sulfotransferase accounts for the addition of sulfate. 1388166 4 74 gly acceptor 815:822 arg1 these glycoproteins glycoproteins acceptor Fterm glycoproteins A GalNAc-transferase that recognizes the tripeptide motif Pro-Xaa-Arg/Lys 6-9 residues N-terminal to Asn glycosylation sites accounts for the specific addition of GalNAc to the oligosaccharide acceptor on these glycoproteins, whereas a GalNAc beta 1,4GlcNAc beta 1, 2Man alpha-4-sulfotransferase accounts for the addition of sulfate. 2808434 13 84 gly has 1374:1376 arg1 The protein AND N-linked oligosaccharides The protein N-linked oligosaccharides Fterm protein The protein has N-linked oligosaccharides that are cleaved by Peptide N-glycosidase F. 11897784 3 3 part_of PERK 487:490 arg1 The N-terminal luminal domains PERK The N-terminal luminal domains PUBTATOR Site PERK 9451 domains The N-terminal luminal domains (NLDs) of IRE1 and PERK sense ER stress conditions by a common mechanism and transmit the signal to regulate the cytoplasmic domains of these receptors. 11897784 3 47 part_of receptors 610:618 arg1 the cytoplasmic domains receptors the cytoplasmic domains Fterm Site receptors domains The N-terminal luminal domains (NLDs) of IRE1 and PERK sense ER stress conditions by a common mechanism and transmit the signal to regulate the cytoplasmic domains of these receptors. 11897784 3 54 part_of IRE1 478:481 arg1 The N-terminal luminal domains IRE1 The N-terminal luminal domains PUBTATOR Site IRE1 2081 domains The N-terminal luminal domains (NLDs) of IRE1 and PERK sense ER stress conditions by a common mechanism and transmit the signal to regulate the cytoplasmic domains of these receptors. 2303059 7 28 part_of site 1019:1022 arg1 both variants variants site Fterm Site variants site The close similarity of the oligomannose series indicates identical processing at the conserved site in both variants. 25629924 1 52 gly glycoprotein 125:136 arg1 a major glycoprotein a major glycoprotein Fterm glycoprotein Secretory immunoglobulin A (sIgA) is a major glycoprotein in milk and plays a key role in mediating immune protection of the gut mucosa. 25629924 1 52 gly glycoprotein 125:136 arg1 Secretory immunoglobulin A Secretory immunoglobulin A Cterm Secretory immunoglobulin A Secretory immunoglobulin A (sIgA) is a major glycoprotein in milk and plays a key role in mediating immune protection of the gut mucosa. 26944735 0 62 part_of EGF 199:201 arg1 the EGF domain EGF the EGF domain OGER Site EGF P01133 domain Characterization of post-translational modifications in full-length human BMP-1 confirms the presence of a rare vicinal disulfide linkage in the catalytic domain and highlights novel features of the EGF domain. 19358553 5 34 gly glycopeptide 1236:1247 arg2 glycopeptide purification glycopeptide purification glycopeptide For glycopeptide purification, a range of hydrophilic and graphite materials packed in microcolumn format proved capable of performing desalting without loss of quantitative information, but highlighted the column capacity as a critical parameter. 29253009 2 53 gly N-glycosylation 580:594 arg2 a N-glycosylation site a N-glycosylation site site Lymphocytic choriomeningitis virus (LCMV) infection of H-2b mice generates CD8+ CTL responses directed towards several MHC-I-restricted epitopes including the peptides GP92 (CSANNSHHYI) and GP392 (WLVTNGSYL), both with a N-glycosylation site. 1456441 10 78 gly glycopeptides 1438:1450 arg2 The SNA-bound glycopeptides The SNA-bound glycopeptides glycopeptides The SNA-bound glycopeptides were further fractionated by LPHA affinity chromatography. 15590981 1 38 gly have 185:188 arg1 Pituitary equine luteinizing hormone AND different linked carbohydrates Pituitary equine luteinizing hormone different linked carbohydrates OGER luteinizing hormone Pituitary equine luteinizing hormone (eLH) and fetal chorionic gonadotrophin (eCG) have identical polypeptidic chains, but different linked carbohydrates. 15590981 1 38 gly have 185:188 arg1 fetal chorionic gonadotrophin AND different linked carbohydrates fetal chorionic gonadotrophin different linked carbohydrates OGER chorionic gonadotrophin Pituitary equine luteinizing hormone (eLH) and fetal chorionic gonadotrophin (eCG) have identical polypeptidic chains, but different linked carbohydrates. 14660594 5 63 part_of Insig-1 1012:1018 arg1 Insig-1 face Insig-1 Insig-1 face PUBTATOR Site Insig-1 3638 face The data indicate that short segments at the N and C termini of Insig-1 face the cytosol. 1421757 2 12 gly glycopeptide 307:318 arg2 a glycopeptide a glycopeptide glycopeptide Tryptic digestion of the receptor, followed by chromatography on BioGel P-2 and reverse-phase HPLC, yields a glycopeptide (amino acids 101-120) containing the O-linked site. 15500847 1 26 part_of thrombin 148:155 arg1 The amino acid sequence thrombin The amino acid sequence PUBTATOR Site thrombin 280685 sequence The amino acid sequence of a thrombin like enzyme , named elegaxobin II, isolated from the venom of Trimeresurus elegans (Sakishima-habu) was determined by Edman sequencing of the peptides which was derived from digests with cyanogen bromide, achromobacter protease I, trypsin, endoproteinase Asp-N, and chymotrypsin. 10424400 0 89 gly glycosylated 17:28 arg1 The additionally glycosylated variant The additionally glycosylated variant Fterm variant The additionally glycosylated variant of human sex hormone-binding globulin (SHBG) is linked to estrogen-dependence of breast cancer. 15956584 11 37 gly glycoproteins 1640:1652 arg1 some glycans glycoproteins some glycans Fterm glycoproteins Altogether, the data indicate that some glycans of HCV envelope glycoproteins play a major role in protein folding and others play a role in HCV entry. 24280012 5 32 gly glycosylation 611:623 arg2 a single potential N-linked glycosylation site a single potential N-linked glycosylation site site The complete open reading frame (ORF) of GoIL-17A contains 510 base pairs that encode 169 amino acid residues, including a 29-amino acid signal peptide and a single potential N-linked glycosylation site. 11595658 5 21 gly glycosylation 686:698 arg2 each glycosylation site each glycosylation site site Two sets of mutations were performed for each glycosylation site: N to Q and S/T to A, respectively. 9758750 10 2 gly glycosylation 1679:1691 arg1 sG-CSFr sG-CSFr Cterm sG-CSFr Q99062 These results show that while glycosylation of sG-CSFr is not necessary for ligand binding, it appears to be crucial in folding and export from the cell. 11333905 7 78 part_of CD4-induced 1661:1671 arg1 the CD4-induced epitope CD4 the CD4-induced epitope PUBTATOR Site CD4 920 epitope Exposure of the CD4-induced epitope recognized by monoclonal antibody 17b and which overlaps the coreceptor binding site was highly sensitive to an R298K mutation at the base of the V3 loop and was often but not always associated with CD4 independence. 19241033 2 11 gly deglycosylated 417:430 arg1 deglycosylated peptides deglycosylated peptides peptides The well-established method utilizes Peptide-N-glycosidase F (PNGase F) for in-gel or in-solution release of N-linked glycans from the polypeptide chains (along with the conversion of the formerly N-glycosylated Asn to Asp), thus allowing separate analysis of glycan moieties and deglycosylated peptides. 19241033 2 64 gly N-glycosylated 334:347 arg1 the formerly N-glycosylated Asn the formerly N-glycosylated Asn Asn The well-established method utilizes Peptide-N-glycosidase F (PNGase F) for in-gel or in-solution release of N-linked glycans from the polypeptide chains (along with the conversion of the formerly N-glycosylated Asn to Asp), thus allowing separate analysis of glycan moieties and deglycosylated peptides. 22642577 0 28 gly Glycosylation 0:12 arg2 Asn91 Asn91 Asn91 Glycosylation at Asn91 of H1N1 haemagglutinin affects binding to glycan receptors. 26062906 12 43 gly glycosylation 1760:1772 arg1 an appropriate position position position In conclusion, N-linked glycosylation at an appropriate position in pre-S2 domain is an essential requirement for DNA vaccine expressing MHBs. 30355697 13 7 part_of hemagglutinin 2219:2231 arg1 hemagglutinin glycosylation site composition hemagglutinin hemagglutinin glycosylation site composition Fterm Site hemagglutinin position Differences in hemagglutinin glycosylation site composition and heterogeneity seen in antigens produced in different cell substrates suggest differences in processing and downstream immune responses. 1791827 3 16 gly glycosylation 642:654 arg2 position 169 position 169 position 169 The deduced amino acid sequence reveals a sequence of 492 amino acids that contains a stretch of 7 glutamic acid from position 169 and one potential glycosylation site at position 274. 1791827 3 16 gly glycosylation 642:654 arg2 one potential glycosylation site one potential glycosylation site site The deduced amino acid sequence reveals a sequence of 492 amino acids that contains a stretch of 7 glutamic acid from position 169 and one potential glycosylation site at position 274. 1791827 3 16 gly glycosylation 642:654 arg2 position 274 position 274 position 274 The deduced amino acid sequence reveals a sequence of 492 amino acids that contains a stretch of 7 glutamic acid from position 169 and one potential glycosylation site at position 274. 1791827 3 16 gly glycosylation 642:654 arg1 7 glutamic acid glutamic acid glutamic acid The deduced amino acid sequence reveals a sequence of 492 amino acids that contains a stretch of 7 glutamic acid from position 169 and one potential glycosylation site at position 274. 19500602 3 29 part_of contains 464:471 arg1 EL2 AND two sites EL2 two sites PUBTATOR Site EL2 6708 sites The hSERT contains in the second extracellular loop (EL2) two sites for N-linked glycosylation that are critical for functional transporter expression. 19500602 3 29 part_of contains 464:471 arg1 The hSERT AND two sites The hSERT two sites PUBTATOR Site hSERT 6532 sites The hSERT contains in the second extracellular loop (EL2) two sites for N-linked glycosylation that are critical for functional transporter expression. 12538726 2 69 gly glycosylation 395:407 arg2 two potential N-linked glycosylation consensus sites sites, N404 and N424 sites, N404 and N424 The amino acid sequence contains two potential N-linked glycosylation consensus sites, N404 and N424. 12538726 2 69 gly glycosylation 395:407 arg2 N424 sites, N404 and N424 sites, N404 and N424 The amino acid sequence contains two potential N-linked glycosylation consensus sites, N404 and N424. 12538726 2 69 gly glycosylation 395:407 arg2 N424 sites, N404 and N424 sites, N404 and N424 The amino acid sequence contains two potential N-linked glycosylation consensus sites, N404 and N424. 3192519 1 27 gly glycosylation 65:77 arg1 ApoCIII secretion ApoCIII secretion PUBTATOR ApoCIII 345 O-linked glycosylation is not required for ApoCIII secretion and lipid binding. 28887103 10 15 gly glycosylation 1473:1485 arg1 the atypical sites the atypical sites sites All of these phenomena that yield glycosylation at the atypical sites are reported in a variety of biological systems, including different pathological conditions. 15119761 11 67 gly protein 1559:1565 arg1 a major determinant protein a major determinant Fterm protein Comparison of our panel of 27 WNV strains suggests that E protein glycosylation is a major determinant of the mouse neuroinvasive phenotype. 7613486 3 14 gly glycosylation 489:501 arg2 the four amino terminal glycosylation sites the four amino terminal glycosylation sites sites Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823). 7613486 3 14 gly glycosylation 489:501 arg2 N111 N111 N16,N25,N78, and N111 Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823). 7613486 3 14 gly glycosylation 489:501 arg2 N16 N16 N16,N25 Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823). 7613486 3 56 gly sites 503:507 arg1 N16 N16 N16,N25 Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823). 7613486 3 56 gly sites 503:507 arg1 the four amino terminal glycosylation sites the four amino terminal glycosylation sites sites Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823). 7613486 3 56 gly sites 503:507 arg1 N111 N111 N16,N25,N78, and N111 Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823). 7613486 3 14 gly glycosylation 489:501 arg2 N78 N25-N78 N25-N78 Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823). 7613486 3 56 gly sites 503:507 arg1 N25 N25-N78 N25-N78 Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823). 3980466 3 34 gly glycosylation 592:604 arg2 potential N-linked glycosylation sites potential N-linked glycosylation sites sites This cell line simultaneously synthesizes two classes of major histocompatibility antigens that, within each class, share a high degree of amino acid sequence homology and possess potential N-linked glycosylation sites at invariant positions. 3980466 3 34 gly glycosylation 592:604 arg2 invariant positions invariant positions positions This cell line simultaneously synthesizes two classes of major histocompatibility antigens that, within each class, share a high degree of amino acid sequence homology and possess potential N-linked glycosylation sites at invariant positions. 1634550 7 51 gly glycosylation 1260:1272 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site One component, pre-a, has a potential N-linked glycosylation site on the Asn of residues 2 through 4, Asn-Leu-Ser. 29470411 13 58 gly N-glycosylation 1559:1573 arg1 PMM2-CDG PMM2-CDG PUBTATOR PMM2 5373 Aberrant CaV2.1 N-glycosylation as a novel pathomechanism in PMM2-CDG opens new therapeutic possibilities. 26439794 5 52 gly glycoproteins 821:833 arg1 the 44 glycoproteins the 44 glycoproteins Fterm glycoproteins The glycoproteomic approach to the human fetal lung fibroblasts membrane fraction resulted in the identification of over 272 glycoforms on 63 sites of the 44 glycoproteins. 26439794 5 64 gly glycoforms 788:797 arg2 63 sites 63 sites sites The glycoproteomic approach to the human fetal lung fibroblasts membrane fraction resulted in the identification of over 272 glycoforms on 63 sites of the 44 glycoproteins. 23250752 5 61 part_of possess 785:791 arg1 the K(2P) channels AND consensus N-linked glycosylation sites the K(2P) channels consensus N-linked glycosylation sites Fterm Site channels sites All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site. 23250752 5 28 part_of site 901:904 arg1 K K(2P site OGER Site K(2P Q01546 site All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site. 23250752 5 28 part_of site 901:904 arg1 K K(2P site OGER Site K(2P Q01546 site All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site. 23250752 5 28 part_of site 901:904 arg1 2P K(2P site OGER Site K(2P Q01546 site All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site. 23250752 5 28 part_of site 901:904 arg1 K K(2P site OGER Site K(2P Q01546 site All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site. 23250752 5 28 part_of site 901:904 arg1 2P K(2P site OGER Site K(2P Q01546 site All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site. 23250752 5 28 part_of site 901:904 arg1 2P K(2P site OGER Site K(2P Q01546 site All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site. 26582203 2 68 gly N-glycosylation 324:338 arg2 its potential N-glycosylation site its potential N-glycosylation site site In order to decipher the function of its potential N-glycosylation site, we produced pro-KLK2 in Leishmania tarentolae cells and compared it with its non-glycosylated counterpart from Escherichia coli expression. 23894062 8 84 gly N-glycosylation 1170:1184 arg2 a N-glycosylation site a N-glycosylation site site We showed a SOST peptide (SOST-S146, with homology to a bacterial glycotransferase peptide) binds to a NOG peptide (NOG-N54), which contains a N-glycosylation site. 7613477 7 22 part_of contains 1566:1573 arg1 apolipoprotein D AND potential N-linked glycosylation sites apolipoprotein D potential N-linked glycosylation sites PUBTATOR Site apolipoprotein D 347 sites The three additional glycopeptides were determined to be from a copurifying protein, apolipoprotein D, which contains potential N-linked glycosylation sites at Asn45 and Asn78. 7613477 7 22 part_of contains 1566:1573 arg1 a copurifying protein AND potential N-linked glycosylation sites a copurifying protein potential N-linked glycosylation sites Fterm Site protein sites The three additional glycopeptides were determined to be from a copurifying protein, apolipoprotein D, which contains potential N-linked glycosylation sites at Asn45 and Asn78. 18652900 7 63 gly glycosylation 1149:1161 arg1 GlcNAc(2)Man(3)Xyl GlcNAc(2)Man(3)Xyl The high resolution structure established a glycosylation pattern of GlcNAc(2)Man(3)Xyl. 11428934 3 16 part_of MOG 513:515 arg1 a MOG peptide epitope MOG a MOG peptide epitope PUBTATOR Site MOG 4340 epitope It has been recently described that glycosylation of a MOG peptide epitope improved the detection of specific autoantibodies in sera of MS patients. 25737293 3 84 gly glycosylation 579:591 arg2 many glycosylation sites many glycosylation sites sites Here, we developed methods combining enzymatic deglycosylation and protease digestion with SWATH-MS to enable automated measurement of site-specific occupancy at many glycosylation sites. 2732722 2 0 part_of HA1 505:507 arg1 at least four distinct HA1 sequences HA1 at least four distinct HA1 sequences PUBTATOR Site HA1 23526 sequences Sequence analysis indicated that the haemagglutinin (HA) genes of the six virus preparations contained at least four distinct HA1 sequences which differed by up to six amino acids. 8180202 7 60 gly glycosylation 1224:1236 arg1 recombinant CBG recombinant CBG PUBTATOR CBG 866 Thus, the glycosylation of recombinant CBG appears to resemble that of natural human CBG. 26161579 5 4 gly N-glycosylation 638:652 arg2 N-glycosylation site identification N-glycosylation site identification site Additionally, a common error in N-glycosylation site identification, resulting from protein chemical deamidation, has largely been ignored. 15353267 2 6 part_of cDNA 284:287 arg1 a human cDNA fragment cDNA a human cDNA fragment Cterm Site cDNA fragment Using the differential display technology, a human cDNA fragment of 322-bp, designated as T17, was identified showing specific expression in the human testis. 1457969 4 51 gly glycopeptides 674:686 arg2 hTSH alpha glycopeptides hTSH alpha glycopeptides glycopeptides The oligosaccharides were liberated from hTSH alpha glycopeptides and from intact hTSH beta by hydrazinolysis, and were fractionated as alditols by anion-exchange and ion-suppression amine-adsorption HPLC preparatory to structural analysis. 1457969 4 89 gly liberated 648:656 arg1 hTSH alpha glycopeptides AND The oligosaccharides hTSH beta glycopeptides The oligosaccharides PUBTATOR hTSH beta 7252 glycopeptides The oligosaccharides were liberated from hTSH alpha glycopeptides and from intact hTSH beta by hydrazinolysis, and were fractionated as alditols by anion-exchange and ion-suppression amine-adsorption HPLC preparatory to structural analysis. 28353332 8 23 gly glycoprotein 1582:1593 arg1 the target glycoprotein the target glycoprotein Fterm glycoprotein Using a case example, we show that, in targeted mode, it identified more site-specific glycoforms than the more commonly used data-dependent acquisition method when the amount of the target glycoprotein was limited in a sample of high complexity. 12604331 2 21 gly glycoprotein 557:568 arg1 an oligomeric glycoprotein an oligomeric glycoprotein Fterm glycoprotein Biochemical characterization of this myotoxin inhibitor protein (BmjMIP) showed it to be an oligomeric glycoprotein with a M(r) of 23,000-25,000 for the monomeric subunit. 15616124 9 22 gly glycosylation 1397:1409 arg2 N332 N332 N332 We propose that the cotranslational conformation(s) of FVII are unfavorable for glycosylation at N332, whereas a more favorable conformation is obtained during the posttranslational folding. 1385399 2 37 part_of contains 368:375 arg1 the amino-terminal domain AND a single N-glycosylation site the amino-terminal domain a single N-glycosylation site site Two domains comprise the CD2 extracellular segment, with all adhesion functions localized to the amino-terminal domain that contains a single N-glycosylation site at Asn65. 7904239 2 12 part_of precursors 305:314 arg1 the propeptide precursors the propeptide Fterm Site precursors propeptide Work from several laboratories, including our own, has implicated the propeptide of various precursors in mediating intracellular transport and targeting to secretory granules. 20881037 9 32 gly glycosylation 1411:1423 arg2 a novel N-linked glycosylation site a novel N-linked glycosylation site site In fact, the M133T mutation creates a novel N-linked glycosylation site ((131)NST(133)). 7526855 6 4 part_of channel 948:954 arg1 a primary site channel a primary site Fterm Site channel site The results presented here confirm the presence of water channel gene in the bovine ciliary epithelium, a primary site for the aqueous humor production. 30898876 1 11 gly glycoproteins 365:377 arg1 many mammalian glycoproteins many mammalian glycoproteins Fterm glycoproteins The type-I LacdiNAc (LDN; GalNAcβ1-3GlcNAc) has rarely been observed in mammalian cells except in the O-glycan of α-dystroglycan, in contrast to type-II LDN structures (GalNAcβ1-4GlcNAc) in N- and O-glycans that are present in many mammalian glycoproteins, such as pituitary and hypothalamic hormones. 30898876 1 69 gly present 339:345 arg1 many mammalian glycoproteins AND O-glycans glycoproteins O-glycans Fterm glycoproteins The type-I LacdiNAc (LDN; GalNAcβ1-3GlcNAc) has rarely been observed in mammalian cells except in the O-glycan of α-dystroglycan, in contrast to type-II LDN structures (GalNAcβ1-4GlcNAc) in N- and O-glycans that are present in many mammalian glycoproteins, such as pituitary and hypothalamic hormones. 30898876 1 69 gly present 339:345 arg1 many mammalian glycoproteins AND N- glycoproteins N- Fterm glycoproteins The type-I LacdiNAc (LDN; GalNAcβ1-3GlcNAc) has rarely been observed in mammalian cells except in the O-glycan of α-dystroglycan, in contrast to type-II LDN structures (GalNAcβ1-4GlcNAc) in N- and O-glycans that are present in many mammalian glycoproteins, such as pituitary and hypothalamic hormones. 16755913 6 35 gly glycosylation 1015:1027 arg2 glycosylation sites glycosylation sites sites The wild type proteins and those with one of glycosylation sites mutated were digested, resulting in their molecular weights reduced, while the molecular weights of products with mutations at both glycosylation sites were not changed. 16755913 6 51 gly glycosylation 1167:1179 arg2 both glycosylation sites both glycosylation sites sites The wild type proteins and those with one of glycosylation sites mutated were digested, resulting in their molecular weights reduced, while the molecular weights of products with mutations at both glycosylation sites were not changed. 9520292 6 1 part_of protein 951:957 arg1 The epitopes protein The epitopes Fterm Site protein epitopes The epitopes of the core protein recognized by sera from more than one patient were identified using a peptide-specific enzyme-linked immunosorbent assay and microsequencing of positive immunoreactive peptides. 9884403 1 45 gly glycoprotein 138:149 arg1 human Tamm-Horsfall glycoprotein human Tamm-Horsfall glycoprotein OGER Tamm-Horsfall glycoprotein P07911 The N-glycosylation sites of human Tamm-Horsfall glycoprotein from one healthy male donor have been characterized, based on an approach using endoproteinase Glu-C (V-8 protease, Staphylococcus aureus ) digestion and a combination of chromatographic techniques, automated Edman sequencing, and fast atom bombardment mass spectrometry. 9884403 1 0 gly N-glycosylation 93:107 arg2 The N-glycosylation sites Tamm-Horsfall glycoprotein sites OGER Tamm-Horsfall glycoprotein P07911 sites The N-glycosylation sites of human Tamm-Horsfall glycoprotein from one healthy male donor have been characterized, based on an approach using endoproteinase Glu-C (V-8 protease, Staphylococcus aureus ) digestion and a combination of chromatographic techniques, automated Edman sequencing, and fast atom bombardment mass spectrometry. 9235960 3 22 part_of B-fragment 464:473 arg1 a nonfunctional KDEL sequence B-fragment a nonfunctional KDEL sequence Fterm Site B-fragment sequence B-fragment with a nonfunctional KDEL sequence (B-Glyc-KDELGL) was glycosylated with about the same kinetics as B-Glyc-KDEL but localized at steady state to the Golgi apparatus. 29755357 3 34 part_of contains 461:468 arg1 Human LCN2 AND one N-glycosylation site Human LCN2 one N-glycosylation site PUBTATOR Site LCN2 3934 site Human LCN2 contains one N-glycosylation site conserved in other species. 23981355 5 24 gly glycosylation 952:964 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Asn-109 was chosen as the PEGylated site for it is a potential N-linked glycosylation site. 23981355 5 75 gly site 916:919 arg1 a potential N-linked glycosylation site a potential N-linked glycosylation site site Asn-109 was chosen as the PEGylated site for it is a potential N-linked glycosylation site. 2347305 5 4 part_of contain 544:550 arg1 The bend region AND the N-glycosylation site The bend region the N-glycosylation site site The bend region between segments S1 and S2 is unusually long and does not contain the N-glycosylation site commonly found in this region. 8088785 7 7 gly glycosylation 1229:1241 arg2 glycosylation site glycosylation site site Sequence analysis showed that NAGR1 is a glycine-, tryptophan-, and methionine-rich protein with no cysteine residues or glycosylation site. 7475306 7 25 part_of epitope 1071:1077 arg1 promiscuous T-cell epitope epitope promiscuous T-cell epitope epitope Chimeras of the glycosylated and non-glycosylated epitope with promiscuous T-cell epitope were synthesized and shown to elicit high titered antibodies in rabbits specific for the immunogen (SC1MVF and SC2MVF) and the B cell epitope 233-253. 22691915 5 52 gly N-glycosylation 552:566 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site Therefore, we engineered a green fluorescent protein (GFP) construct to measure N-glycosylation site occupancy. 19285979 2 27 gly N-glycosylation 326:340 arg2 the N-glycosylation site g15 the N-glycosylation site g15 site However, we have isolated primary viruses all lacking the N-glycosylation site g15 due to mutations (NNNT>YRNA, HNTV, SIQK), which showed resistance to neutralizing antibodies present in autologous or heterologous HIV-1 positive sera. 23234360 2 70 gly glycopeptide 475:486 arg2 glycopeptide glycopeptide glycopeptide We previously reported a sialic acid capture-and-release protocol to enrich tryptic N- and O-glycopeptides from human cerebrospinal fluid glycoproteins using nano-LC-ESI-MS/MS with collision-induced dissociation (CID) for glycopeptide characterization. 23234360 2 73 gly O-glycopeptides 344:358 arg2 O-glycopeptides O-glycopeptides O-glycopeptides We previously reported a sialic acid capture-and-release protocol to enrich tryptic N- and O-glycopeptides from human cerebrospinal fluid glycoproteins using nano-LC-ESI-MS/MS with collision-induced dissociation (CID) for glycopeptide characterization. 23234360 2 81 gly glycoproteins 391:403 arg1 tryptic N- and O-glycopeptides from human cerebrospinal fluid glycoproteins tryptic N- and O-glycopeptides from human cerebrospinal fluid glycoproteins Fterm glycoproteins We previously reported a sialic acid capture-and-release protocol to enrich tryptic N- and O-glycopeptides from human cerebrospinal fluid glycoproteins using nano-LC-ESI-MS/MS with collision-induced dissociation (CID) for glycopeptide characterization. 12773316 3 45 gly glycosylation 614:626 arg2 the seven beta-subunit glycosylation sites the seven beta-subunit glycosylation sites sites Then plasma membrane delivery of wild-type CFP-alpha, wild-type YFP-beta, and YFP-beta mutants lacking one or two of the seven beta-subunit glycosylation sites was determined using confocal microscopy and surface biotinylation. 22607976 7 0 gly N-glycosylation 1254:1268 arg1 secretory proteins proteins sites Fterm proteins sites Hence we postulate that STT3B-dependent posttranslational N-glycosylation is part of a triage-salvage system recognizing cryptic N-glycosylation sites of secretory proteins to preserve protein homeostasis. 9140729 5 49 gly N-glycosylation 862:876 arg2 the N-glycosylation site the N-glycosylation site site Furthermore, a mutant chimeric SK2 antibody, in which the N-glycosylation site was removed from the VH region, showed a Kd of 11 nM, almost similar to that of the original chimeric SK2 antibody, determined by Scatchard analysis with 125I-IL-6. 19767389 0 19 part_of sequence 73:80 arg1 the CH1 domain sequence the CH1 domain domain Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies. 19767389 0 83 part_of CH1 89:91 arg1 the CH1 domain CH1 the CH1 domain OGER Site CH1 Q9UBS9 domain Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies. 23958596 1 11 gly N-glycosylation 206:220 arg2 four potential N-glycosylation sites four potential N-glycosylation sites sites To understand the role of N-glycosylation of lysosomal phospholipase A2 (LPLA2), four potential N-glycosylation sites in human LPLA2 (hLPLA2) were individually modified replacing asparagine (Asn) with alanine by site-direct mutagenesis. 23958596 1 50 gly N-glycosylation 136:150 arg1 LPLA2 LPLA2 PUBTATOR LPLA2 23659 To understand the role of N-glycosylation of lysosomal phospholipase A2 (LPLA2), four potential N-glycosylation sites in human LPLA2 (hLPLA2) were individually modified replacing asparagine (Asn) with alanine by site-direct mutagenesis. 23958596 1 50 gly N-glycosylation 136:150 arg1 lysosomal phospholipase A2 lysosomal phospholipase A2 PUBTATOR lysosomal phospholipase A2 23659 To understand the role of N-glycosylation of lysosomal phospholipase A2 (LPLA2), four potential N-glycosylation sites in human LPLA2 (hLPLA2) were individually modified replacing asparagine (Asn) with alanine by site-direct mutagenesis. 7522502 3 40 part_of cis-acting 505:514 arg1 a composite cis-acting motif cis a composite cis-acting motif OGER Site cis Q62225 motif The boxes I and II sequence is a composite cis-acting motif that is thought to be involved in the regulation of the downstream promoter. 7522502 3 40 part_of cis-acting 505:514 arg1 The boxes I and II sequence cis The boxes I and II sequence OGER Site cis Q62225 sequence The boxes I and II sequence is a composite cis-acting motif that is thought to be involved in the regulation of the downstream promoter. 16567801 7 92 gly contained 1535:1543 arg1 Human UPIa AND high mannose glycans Human UPIa high mannose glycans PUBTATOR UPIa 11045 Human UPIa contained exclusively high mannose glycans, and human UPIb contained only complex glycans. 16567801 7 26 gly contained 1594:1602 arg1 human UPIb AND only complex glycans human UPIb only complex glycans PUBTATOR UPIb 7348 Human UPIa contained exclusively high mannose glycans, and human UPIb contained only complex glycans. 26957414 4 79 gly glycopeptide 493:504 arg2 the low glycopeptide signal intensities the low glycopeptide signal intensities glycopeptide LC-MS/MS analysis of glycopeptides is faced with the low glycopeptide signal intensities and low peptide sequence identification. 26957414 4 87 gly glycopeptides 457:469 arg2 glycopeptides glycopeptides glycopeptides LC-MS/MS analysis of glycopeptides is faced with the low glycopeptide signal intensities and low peptide sequence identification. 28935113 2 88 gly glycoproteins 310:322 arg1 glycoproteins glycoproteins Fterm glycoproteins Because of the abundance and importance of glycosylation in nature, directed evolution of glycopeptides and glycoproteins is also highly desirable. 28935113 2 90 gly glycopeptides 292:304 arg2 glycopeptides glycopeptides glycopeptides Because of the abundance and importance of glycosylation in nature, directed evolution of glycopeptides and glycoproteins is also highly desirable. 10998266 0 70 gly heterogeneity 161:173 arg1 erythropoietin erythropoietin heterogeneity PUBTATOR erythropoietin 2056 Application of liquid chromatography/mass spectrometry and liquid chromatography with tandem mass spectrometry to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin. 2808434 8 1 gly glycosylated 634:645 arg1 a membrane-associated glycosylated enzyme enzyme two major sialic acid esterases Fterm enzyme Rat liver contained two major sialic acid esterases: a cytosolic nonglycosylated enzyme and a membrane-associated glycosylated enzyme. 2808434 8 54 gly nonglycosylated 585:599 arg1 two major sialic acid esterases enzyme two major sialic acid esterases Fterm enzyme Rat liver contained two major sialic acid esterases: a cytosolic nonglycosylated enzyme and a membrane-associated glycosylated enzyme. 10889259 4 39 part_of GnTI 683:686 arg1 all plant GnTI sequences GnTI all plant GnTI sequences PUBTATOR Site GnTI P26572 sequences In contrast to the corresponding enzymes from animals, all plant GnTI sequences identified are characterized by a much shorter hydrophobic membrane anchor and contain one putative N-glycosylation site that is conserved in potato and tobacco, but differs in Arabidopsis. 10889259 4 8 part_of contain 777:783 arg1 all plant GnTI sequences AND one putative N-glycosylation site all plant GnTI sequences one putative N-glycosylation site site In contrast to the corresponding enzymes from animals, all plant GnTI sequences identified are characterized by a much shorter hydrophobic membrane anchor and contain one putative N-glycosylation site that is conserved in potato and tobacco, but differs in Arabidopsis. 10362834 0 13 gly glycoprotein 53:64 arg1 major peripheral myelin glycoprotein major peripheral myelin glycoprotein Fterm glycoprotein Evidence for the presence of major peripheral myelin glycoprotein P0 in mammalian spinal cord and a change of its glycosylation state during aging. 20520733 4 10 gly N-glycosylation 747:761 arg2 N-glycosylation site N-glycosylation site site Here, we present the experimentally-solved topological models for FIT1 and FIT2 using N-glycosylation site mapping and indirect immunofluorescence techniques. 9442070 8 8 part_of site 1406:1409 arg1 processing at one Fc N-glycosylation site Fc site Cterm Site Fc site Further analysis of these data suggested that processing at one Fc N-glycosylation site affects the other. 9442070 8 61 part_of Fc 1387:1388 arg1 processing at one Fc N-glycosylation site Fc processing at one Fc N-glycosylation site Cterm Site Fc site Further analysis of these data suggested that processing at one Fc N-glycosylation site affects the other. 8509412 3 26 gly glycosylation 402:414 arg1 the human transferrin receptor the human transferrin receptor PUBTATOR transferrin receptor 7018 The effect of asparagine-linked glycosylation on the processing and cell surface localization of the human transferrin receptor is examined here by site-directed mutagenesis. 10889209 8 6 gly N-glycosylation 1526:1540 arg1 ROMK1 ROMK1 PUBTATOR ROMK1 3758 Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol. 10889209 8 14 gly N-glycosylation 1301:1315 arg1 GIRK1 GIRK1 Asn(119) PUBTATOR GIRK1 3760 Asn(119) Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol. 10889209 8 14 gly N-glycosylation 1301:1315 arg2 119 Asn(119) Asn(119) Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol. 10889209 8 14 gly N-glycosylation 1301:1315 arg1 119 Asn(119) Asn(119) Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol. 10889209 8 14 gly N-glycosylation 1301:1315 arg2 Asn Asn(119) Asn(119) Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol. 10889209 8 14 gly N-glycosylation 1301:1315 arg2 119 GIRK1 Asn(119) PUBTATOR GIRK1 3760 Asn(119) Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol. 10889209 8 14 gly N-glycosylation 1301:1315 arg1 119 GIRK1 Asn(119) PUBTATOR GIRK1 3760 Asn(119) Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol. 10889209 8 14 gly N-glycosylation 1301:1315 arg2 Asn GIRK1 Asn(119) PUBTATOR GIRK1 3760 Asn(119) Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol. 10889209 8 14 gly N-glycosylation 1301:1315 arg1 119 Asn(119) Asn(119) Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol. 10889209 8 14 gly N-glycosylation 1301:1315 arg2 Asn Asn(119) Asn(119) Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol. 10889209 8 14 gly N-glycosylation 1301:1315 arg2 Asn Asn(119) Asn(119) Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol. 11711599 3 30 gly glycosylation 513:525 arg2 the four N-linked glycosylation sites protein sites Fterm protein sites Eight plasmids were engineered, encoding E1 protein mutants in which the four N-linked glycosylation sites of the protein were mutated separately or in combination. 3498943 3 72 part_of Ly-3.1 559:564 arg1 Ly-3.1 peptides Ly-3 Ly-3.1 peptides PUBTATOR Site Ly-3 12526 peptides The nucleotide and predicted amino acid sequence of the murine Ly-3 cDNA, isolated by using the rat Ly-3 cDNA clone pX9.15, together with the amino acid sequence of Ly-3.1 peptides and the N terminus, are presented here. 12877809 10 54 gly glycosylation 1557:1569 arg2 an N-linked glycosylation site an N-linked glycosylation site site There is a deletion of an N-linked glycosylation site at Asn342 in the tree shrew CETP protein that may participate in the removal of peripheral cholesterol and cholesteryl ester by increasing its activity of transferring cholesteryl ester. 12877809 10 54 gly glycosylation 1557:1569 arg2 Asn342 Asn342 Asn342 There is a deletion of an N-linked glycosylation site at Asn342 in the tree shrew CETP protein that may participate in the removal of peripheral cholesterol and cholesteryl ester by increasing its activity of transferring cholesteryl ester. 2082620 0 66 gly N-glycosylation 22:36 arg2 conserved N-glycosylation sites conserved N-glycosylation sites sites Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity. 24497285 0 54 gly N-glycoproteins 27:41 arg1 salivary N-glycoproteins salivary N-glycoproteins Fterm N-glycoproteins Identification of salivary N-glycoproteins and measurement of glycosylation site occupancy by boronate glycoprotein enrichment and liquid chromatography/electrospray ionization tandem mass spectrometry. 24497285 0 58 gly glycosylation 62:74 arg2 glycosylation site occupancy glycosylation site occupancy site Identification of salivary N-glycoproteins and measurement of glycosylation site occupancy by boronate glycoprotein enrichment and liquid chromatography/electrospray ionization tandem mass spectrometry. 24497285 0 102 gly glycoprotein 103:114 arg1 boronate glycoprotein enrichment boronate glycoprotein enrichment Fterm glycoprotein Identification of salivary N-glycoproteins and measurement of glycosylation site occupancy by boronate glycoprotein enrichment and liquid chromatography/electrospray ionization tandem mass spectrometry. 8760363 5 3 gly containing 1035:1044 arg1 a central leucine-rich domain AND eleven repeats a central leucine-rich domain eleven repeats domain Structural features of the deduced sequence include an 18-amino-acid signal peptide, cysteine residues in conserved positions in the N- and C-terminal regions, and a central leucine-rich domain containing eleven repeats of the sequence LXXLXLXXNXL/I. 9620884 8 0 part_of enzyme 1521:1526 arg1 the enzyme polypeptide enzyme the enzyme polypeptide Fterm Site enzyme polypeptide Absence of the site 3 hybrid-type oligosaccharide exposed an adjacent, normally protected, hydrophobic region, resulting in aggregation of the enzyme polypeptide in the endoplasmic reticulum. 23530120 7 56 part_of Env 1426:1428 arg1 the most conserved Env regions Env the most conserved Env regions PUBTATOR Site Env 100616444 regions Importantly, they provide key information as to how such immunogens can be engineered to initiate the process of antibody-affinity maturation against one of the most conserved Env regions. 21940909 9 122 gly nonglycosylated 2095:2109 arg1 nonglycosylated tryptic peptides nonglycosylated tryptic peptides peptides This work provides a targeted means of discovering and validating nonglycosylated tryptic peptides as biomarkers in human plasma, without the need for complex enrichment processes or expensive antibody preparations. 8344280 0 63 gly glycoprotein 50:61 arg1 human interleukin 2 glycoprotein variants human interleukin 2 glycoprotein variants PUBTATOR interleukin 2 glycoprotein 3558 Biosynthesis and secretion of human interleukin 2 glycoprotein variants from baculovirus-infected Sf21 cells. 11093789 6 27 gly glycosylation 1081:1093 arg2 three glycosylation sites three glycosylation sites sites Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported. 11093789 6 111 gly deglycosylation 1328:1342 arg1 the native receptor the native receptor Fterm receptor Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported. 11093789 6 95 gly deglycosylation 1215:1229 arg2 Asn Asn(191) Asn(191) Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported. 11093789 6 95 gly deglycosylation 1215:1229 arg1 Asn Asn(191) Asn(191) Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported. 11093789 6 95 gly deglycosylation 1215:1229 arg2 191 Asn(191) Asn(191) Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported. 11093789 6 95 gly deglycosylation 1215:1229 arg1 Asn Asn(191) Asn(191) Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported. 11093789 6 95 gly deglycosylation 1215:1229 arg2 191 Asn(191) Asn(191) Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported. 11093789 6 95 gly deglycosylation 1215:1229 arg2 191 Asn(191) Asn(191) Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported. 12064867 4 10 gly deglycosylation 703:717 arg1 gp120 gp120 PUBTATOR gp120 3700 We found that soluble CD4 inhibited the deglycosylation of gp120 only when gp120 was caught by D7324 and not by NEA9205. 31186110 5 107 gly N-glycosylation 852:866 arg2 potential N-glycosylation site potential N-glycosylation site site Glycoengineering strategy was employed to construct IFN α2b with potential N-glycosylation site to evade the drawbacks of approved recombinant human IFN α2b drugs. 2826671 5 100 gly N-glycosylation 524:538 arg2 a putative N-glycosylation site a putative N-glycosylation site site Like most other MuIFN-alpha species it contained a putative N-glycosylation site at amino acid positions 78 to 80. 26869352 10 67 gly fucosylated 1724:1734 arg1 Lewis-type fucosylated N-glycan Lewis-type fucosylated N-glycan In metastatic prostate cancer, Lewis-type fucosylated N-glycan was also increased. 9254044 2 25 part_of glucosidase 493:503 arg1 proteolytic fragments glucosidase II proteolytic fragments OGER Site glucosidase II fragments For cloning of glucosidase II cDNA, degenerate oligonucleotides based on amino acid sequences derived from proteolytic fragments of purified pig liver glucosidase II were used. 10828967 0 32 gly asparagine-linked 8:24 arg1 asparagine-linked oligosaccharides asparagine asparagine-linked oligosaccharides asparagine Role of asparagine-linked oligosaccharides in the function of the rat PTH/PTHrP receptor. 7533854 4 136 part_of gp120 938:942 arg1 the V1/V2 domain HXB2 gp120 the V1/V2 domain PUBTATOR Site HXB2 gp120 3700 domain A number of MAbs (C108G, G3-4, 684-238, SC258, 11/68b, 38/66a, 38/66c, 38/62c, and CRA3) that did not bind with high affinity to peptides immunoprecipitated a fusion glycoprotein expressing the V1/V2 domain of HXB2 gp120 in the absence of other human immunodeficiency virus sequences, establishing that their epitopes were fully specified within this region. 17715132 4 34 gly glycosylation 564:576 arg2 three putative N-linked glycosylation sites three putative N-linked glycosylation sites sites Using site-directed mutagenesis we analyzed three putative N-linked glycosylation sites and examined the effects of each mutation on channel expression. 22365192 5 19 gly glycosylated 844:855 arg1 A highly glycosylated 70-kDa protein A highly glycosylated 70-kDa protein Fterm protein A highly glycosylated 70-kDa protein was characterized for equine butyrophilin, whereas proteins of 64 and 67 kDa were characterized for cow and goat butyrophilin, respectively. 17681482 4 49 part_of Hexahistidyl-tagged 570:588 arg1 NaSi-1-His Hexahistidyl-tagged NaSi-1 NaSi-1-His PUBTATOR AminoAcid Hexahistidyl-tagged NaSi-1 Q9BZW2 His Hexahistidyl-tagged NaSi-1 (NaSi-1-His) proteins expressed in Xenopus oocytes, appeared as two bands of about 60 and 75 kDa. 27743357 1 9 gly N-glycosylation 188:202 arg2 the conserved Fc N-glycosylation site IgG site Cterm IgG site This chapter contains a nanoscale liquid chromatography-mass spectrometry method for the glycoform profiling of the conserved Fc N-glycosylation site of monoclonal and polyclonal immunoglobulin G (IgG). 27743357 1 9 gly N-glycosylation 188:202 arg1 immunoglobulin G immunoglobulin G site Cterm immunoglobulin G site This chapter contains a nanoscale liquid chromatography-mass spectrometry method for the glycoform profiling of the conserved Fc N-glycosylation site of monoclonal and polyclonal immunoglobulin G (IgG). 7620335 3 64 gly released 656:663 arg1 the glycopeptides AND N-linked oligosaccharides the glycopeptides N-linked oligosaccharides glycopeptides N-linked oligosaccharides released from the glycopeptides by glycoamidase A digestion were derivatized with 2-aminopyridine. 7620335 3 98 gly glycopeptides 674:686 arg2 the glycopeptides the glycopeptides glycopeptides N-linked oligosaccharides released from the glycopeptides by glycoamidase A digestion were derivatized with 2-aminopyridine. 11258925 0 25 part_of sites 38:42 arg1 cyclooxygenase-2 cyclooxygenase-2 sites PUBTATOR Site cyclooxygenase-2 5743 sites Characterization of the glycosylation sites in cyclooxygenase-2 using mass spectrometry. 12706379 15 44 gly TSHR 2161:2164 arg1 an important determinant TSHR an important determinant PUBTATOR TSHR P16473 Changes in some critical residues raise questions about variation in function: thus S281 is conserved in all mammals and an important determinant of negative agonist function of TSHR is replaced by R in Sea Bass. 18700760 0 64 gly glycoproteins 39:51 arg1 glycoproteins glycoproteins 13C-sialic acid labeling of glycans on glycoproteins using ST6Gal-I. 26846480 12 36 gly N-glycosylation 1501:1515 arg2 an N-glycosylation site an N-glycosylation site site This codon comprised in an N-glycosylation site was found to be under positive selection. 29479800 2 57 gly N-glycosylation 400:414 arg1 proteins proteins Fterm proteins In most eukaryotes, the oligosaccharyltransferase is the central-protein complex facilitating the N-glycosylation of proteins in the lumen of the endoplasmic reticulum (ER). 21899340 3 31 gly derived 724:730 arg1 ovalbumin AND Twenty four N-linked glycans ovalbumin Twenty four N-linked glycans Fterm ovalbumin Twenty four N-linked glycans derived from ovalbumin could be efficiently detected with high signal-to-noise (S/N) ratios and sufficient peak intensities. 12034885 3 61 gly glycosylation 566:578 arg2 a potential O-linked glycosylation site a potential O-linked glycosylation site site The vCD30 protein contains 110 aa, including a 21-residue signal peptide, a potential O-linked glycosylation site, and a 58-aa sequence sharing 51-59% identity with highly conserved extracellular segments of both mouse and human CD30. 12538726 0 45 gly N-Glycosylation 0:14 arg2 two sites two sites sites N-Glycosylation at two sites critically alters thiazide binding and activity of the rat thiazide-sensitive Na(+):Cl(-) cotransporter. 24884609 5 57 gly glycopeptides 764:776 arg2 ITIH4 tryptic/GluC glycopeptides ITIH4 tryptic/GluC glycopeptides glycopeptides First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 78 gly glycosylated 720:731 arg1 the four ITIH4 N-X-S/T sequons N81, N207, N517, and N577 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 78 gly glycosylated 720:731 arg1 N517 N81, N207, N517, and N577 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 78 gly glycosylated 720:731 arg1 N577 N81, N207, N517, and N577 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 78 gly glycosylated 720:731 arg1 N207 N81, N207, N517, and N577 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 78 gly glycosylated 720:731 arg1 N517 N81, N207, N517, and N577 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 78 gly glycosylated 720:731 arg1 N577 N81, N207, N517, and N577 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 78 gly glycosylated 720:731 arg1 N207 N81, N207, N517, and N577 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 78 gly glycosylated 720:731 arg1 N577 N81, N207, N517, and N577 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 78 gly glycosylated 720:731 arg1 N207 N81, N207, N517, and N577 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 78 gly glycosylated 720:731 arg1 N207 N81, N207, N517, and N577 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 2457922 1 41 gly glycoprotein 320:331 arg1 biliary glycoprotein I biliary glycoprotein I PUBTATOR biliary glycoprotein I 634 We have isolated and sequenced four overlapping cDNA clones from a normal adult human colon library, which together gave the entire nucleotide sequence for biliary glycoprotein I (BGP I). 9689919 9 95 gly glycoprotein 1557:1568 arg1 a functional soluble secreted PEDF glycoprotein a functional soluble secreted PEDF glycoprotein PUBTATOR PEDF glycoprotein 281386 Thus, the bovine PEDF cDNA isolated here codes for a functional soluble secreted PEDF glycoprotein. 30578591 2 49 gly glycosylation 224:236 arg1 neuraminidase neuraminidase Fterm neuraminidase The glycosylation of neuraminidase (NA) could affect the infectivity and virulence of the influenza virus, but detailed site-specific glycosylation information of NA is still missing. 19369259 6 78 gly sites 1281:1285 arg1 Asn-321 sites Asn-247, Asn-321, and Asn-417 sites Asn-247, Asn-321, and Asn-417 Minimally glycosylated mutants that supported trafficking were identified and indicated the importance of carboxyl-terminal sites Asn-247, Asn-321, and Asn-417. 19369259 6 78 gly sites 1281:1285 arg1 Asn-417 sites Asn-247, Asn-321, and Asn-417 sites Asn-247, Asn-321, and Asn-417 Minimally glycosylated mutants that supported trafficking were identified and indicated the importance of carboxyl-terminal sites Asn-247, Asn-321, and Asn-417. 19369259 6 78 gly sites 1281:1285 arg1 Asn-247 sites Asn-247, Asn-321, and Asn-417 sites Asn-247, Asn-321, and Asn-417 Minimally glycosylated mutants that supported trafficking were identified and indicated the importance of carboxyl-terminal sites Asn-247, Asn-321, and Asn-417. 19369259 6 78 gly sites 1281:1285 arg1 Asn-417 sites Asn-247, Asn-321, and Asn-417 sites Asn-247, Asn-321, and Asn-417 Minimally glycosylated mutants that supported trafficking were identified and indicated the importance of carboxyl-terminal sites Asn-247, Asn-321, and Asn-417. 19369259 6 78 gly sites 1281:1285 arg1 Asn-247 sites Asn-247, Asn-321, and Asn-417 sites Asn-247, Asn-321, and Asn-417 Minimally glycosylated mutants that supported trafficking were identified and indicated the importance of carboxyl-terminal sites Asn-247, Asn-321, and Asn-417. 19369259 6 78 gly sites 1281:1285 arg1 Asn-247 sites Asn-247, Asn-321, and Asn-417 sites Asn-247, Asn-321, and Asn-417 Minimally glycosylated mutants that supported trafficking were identified and indicated the importance of carboxyl-terminal sites Asn-247, Asn-321, and Asn-417. 23808883 5 18 gly sialylated 765:774 arg1 sialylated IgGs sialylated IgGs Cterm IgGs In contrast, it has been shown that sialylated IgGs are responsible for anti-inflammatory effects of intravenous immunoglobulin (IVIG; purified IgG from pooled human plasma), which is administered at high doses (2 g/kg) for the systemic treatment of autoimmune patients. 21303814 2 14 gly N-glycosylation 392:406 arg2 an N-glycosylation site an N-glycosylation site site Here, we describe the efficient utilization of an N-glycosylation site engineered within the luminal extreme C-terminal residues of distinct integral membrane glycoproteins, a native ER resident protein and an engineered secreted protein. 21303814 2 29 gly glycoproteins 501:513 arg1 distinct integral membrane glycoproteins distinct integral membrane glycoproteins Fterm glycoproteins Here, we describe the efficient utilization of an N-glycosylation site engineered within the luminal extreme C-terminal residues of distinct integral membrane glycoproteins, a native ER resident protein and an engineered secreted protein. 21303814 2 29 gly glycoproteins 501:513 arg1 a native ER resident protein protein Fterm protein Here, we describe the efficient utilization of an N-glycosylation site engineered within the luminal extreme C-terminal residues of distinct integral membrane glycoproteins, a native ER resident protein and an engineered secreted protein. 27377235 1 13 gly glycosylation 237:249 arg2 a highly conserved N-linked glycosylation site a highly conserved N-linked glycosylation site site Kv1.2 and related voltage-gated potassium channels have a highly conserved N-linked glycosylation site in the first extracellular loop, with complex glycosylation in COS-7 cells similar to endogenous Kv1.2 glycosylation in hippocampal neurons. 9507052 2 31 part_of position 484:491 arg1 mammalian cathepsins E cathepsins E position OGER Site cathepsins E P25774 position The nematode proteins have a potential N-glycosylation site at the same position as mammalian cathepsins E and in common with these have atypically long N-terminal extensions. 9507052 2 8 part_of have 434:437 arg1 The nematode proteins AND a potential N-glycosylation site The nematode proteins a potential N-glycosylation site Fterm Site proteins site The nematode proteins have a potential N-glycosylation site at the same position as mammalian cathepsins E and in common with these have atypically long N-terminal extensions. 8783018 4 22 part_of IFN-gamma 766:774 arg1 the IFN-gamma sequence IFN-gamma the IFN-gamma sequence PUBTATOR Site IFN-gamma 3458 sequence The peptide map obtained by MALDI-MS after digestion in the gel covers 92% of the IFN-gamma sequence and revealed an N-terminal pyroglutamate residue and one oxidized methionine residue. 2477364 8 7 part_of subunits 1262:1269 arg1 tryptic glycopeptides subunits tryptic glycopeptides Fterm Site subunits glycopeptides Second, tryptic glycopeptides of the wild-type subunits were examined. 17001080 0 77 gly asparagine-linked 16:32 arg1 asparagine-linked glycans asparagine asparagine-linked glycans asparagine The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin). 17144668 2 32 part_of glycoprotein 360:371 arg1 N-linked glycosylation sites glycoprotein N-linked glycosylation sites Fterm Site glycoprotein sites Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. 14711516 4 4 gly N-glycosylation 752:766 arg1 recombinant chicken Thy-1 Thy-1 site PUBTATOR Thy-1 P04216 site The disulfide linkage pattern and glycoform distribution on each N-glycosylation site of recombinant chicken Thy-1 from both cell lines were determined by a combination of amino-terminal sequencing and mass spectrometry. 2721453 11 0 gly oligosaccharides 2265:2280 arg1 secreted TSH TSH oligosaccharides OGER TSH This suggests that the probability of sialylation or sulfation at a second site on these oligosaccharides is similar to that at the first and that anionic oligosaccharides in secreted TSH and free alpha are distributed binomially with regard to sialic acid and sulfate residues. 2721453 11 14 gly site 2185:2188 arg1 these oligosaccharides site these oligosaccharides site This suggests that the probability of sialylation or sulfation at a second site on these oligosaccharides is similar to that at the first and that anionic oligosaccharides in secreted TSH and free alpha are distributed binomially with regard to sialic acid and sulfate residues. 21153276 4 38 gly glycosylation 713:725 arg2 extra glycosylation site extra glycosylation site site The receptor with extra glycosylation site displayed normal binding affinities for agonists buserelin and [D: -Ala(6)-Pro(9)-NHEt]-GnRH, and the antagonist antide, and a slightly increased affinity for GnRH. 30718403 7 41 gly domain 1214:1219 arg1 at least one D1 domain glycan at least one D1 domain glycan CD4 polymorphisms also reduced Env-mediated cell entry of monkey SIVs, which was dependent on at least one D1 domain glycan. 19945164 5 22 gly N-glycosylation 770:784 arg2 the 3rd putative N-glycosylation site the 3rd putative N-glycosylation site site Epitope #8 contains the 3rd putative N-glycosylation site of Hev b 13 and should consist of a glycotope, whereas all other identified IgE-binding areas occur outside the two remaining putative N-glycosylation sites. 19945164 5 25 gly N-glycosylation 926:940 arg2 the two remaining putative N-glycosylation sites the two remaining putative N-glycosylation sites sites Epitope #8 contains the 3rd putative N-glycosylation site of Hev b 13 and should consist of a glycotope, whereas all other identified IgE-binding areas occur outside the two remaining putative N-glycosylation sites. 30011186 18 6 gly glycoproteins 3526:3538 arg1 glycoproteins glycoproteins Fterm glycoproteins Eventually, glycoproteins will be identified as effective biomarkers for disease detection and drug targets for disease treatment. 2033065 12 56 gly glycosylation 2171:2183 arg2 different sites HPC sites OGER HPC P11498 sites Overall, our studies demonstrate that glycosylation at different sites in HPC affects distinct properties of this complex protein. 2033065 12 56 gly glycosylation 2171:2183 arg1 different sites HPC sites OGER HPC P11498 sites Overall, our studies demonstrate that glycosylation at different sites in HPC affects distinct properties of this complex protein. 2033065 12 56 gly glycosylation 2171:2183 arg1 different sites sites sites Overall, our studies demonstrate that glycosylation at different sites in HPC affects distinct properties of this complex protein. 2033065 12 56 gly glycosylation 2171:2183 arg1 this complex protein protein sites Fterm protein sites Overall, our studies demonstrate that glycosylation at different sites in HPC affects distinct properties of this complex protein. 2033065 12 56 gly glycosylation 2171:2183 arg1 this complex protein protein sites Fterm protein sites Overall, our studies demonstrate that glycosylation at different sites in HPC affects distinct properties of this complex protein. 11310976 3 33 gly galactose 924:932 arg1 glycophorin A glycophorin A galactose PUBTATOR glycophorin A 2993 The results showed a large deficit of N-acetylgalactosamine, galactose, and sialic acid residues in glycophorin A from patients with CDA type I and type II amounting to about 45% and 55%, respectively. 11310976 3 61 gly N-acetylgalactosamine 901:921 arg1 glycophorin A glycophorin A N-acetylgalactosamine PUBTATOR glycophorin A 2993 The results showed a large deficit of N-acetylgalactosamine, galactose, and sialic acid residues in glycophorin A from patients with CDA type I and type II amounting to about 45% and 55%, respectively. 11310976 3 68 gly residues 951:958 arg1 glycophorin A glycophorin A residues PUBTATOR glycophorin A 2993 The results showed a large deficit of N-acetylgalactosamine, galactose, and sialic acid residues in glycophorin A from patients with CDA type I and type II amounting to about 45% and 55%, respectively. 9367731 5 112 part_of HSP70 1097:1101 arg1 the deduced amino acid sequence Bge HSP70 the deduced amino acid sequence PUBTATOR Site Bge HSP70 3308 sequence Comparison of a conserved region of 209 amino acid residues revealed > 80% identity between the deduced amino acid sequence of Bge HSP70 and that of yeast (81%), the human blood fluke Schistosoma mansoni (for which B. glabrata serves as intermediate host) (81%), Drosophila (81%), human (84%), and the marine gastropod Aplysia californica (88%, 90%). 18416605 3 29 gly unglycosylated 560:573 arg1 only unglycosylated PrP only unglycosylated PrP OGER PrP Q9NP58 We have uniquely demonstrated that mice expressing only unglycosylated PrP can sustain a TSE infection, despite altered cellular location of the host PrP. 31596095 3 4 gly glycosylation 603:615 arg2 glycosylation sites glycosylation sites sites Because glycosylation of capsid proteins is known to be rate limiting in the life cycle of many viruses, we reasoned that perturbation of glycosylation sites in AAV2 capsid will enhance gene delivery. 31596095 3 91 gly glycosylation 473:485 arg1 capsid proteins capsid proteins Fterm proteins Because glycosylation of capsid proteins is known to be rate limiting in the life cycle of many viruses, we reasoned that perturbation of glycosylation sites in AAV2 capsid will enhance gene delivery. 9140729 6 19 part_of SK2 1095:1097 arg1 mouse SK2 VH region SK2 mouse SK2 VH region PUBTATOR Site SK2 56848 region These data indicate the carbohydrates of mouse SK2 VH region do not significantly influence antigen-binding activity. 22607976 4 15 gly N-glycosylation 680:694 arg2 cryptic N-glycosylation site cryptic N-glycosylation site site Folding and ER-associated degradation (ERAD) perturbation analyses revealed that prolonged TTR unfolding induces externalization of cryptic N-glycosylation site and triggers STT3B-dependent posttranslational N-glycosylation. 19065542 6 6 gly glycopeptide 902:913 arg2 a glycopeptide a glycopeptide glycopeptide Accordingly, ETD allows not only the identification of the amino acid sequence of a glycopeptide, but also the unambiguous assignment of its glycosylation site. 19065542 6 24 gly glycosylation 959:971 arg2 its glycosylation site its glycosylation site site Accordingly, ETD allows not only the identification of the amino acid sequence of a glycopeptide, but also the unambiguous assignment of its glycosylation site. 31611356 3 36 gly glycosylation 663:675 arg2 nearly every glycosylation site nearly every glycosylation site site Here, we unify previous work on the importance of other glycans to Grft potency against HIV-1 and Grft's role in mediating the conformational change of gp120 by mutating nearly every glycosylation site in gp120. 27314333 7 69 part_of Rspo2 1281:1285 arg1 Rspo2 N-glycosylation site Rspo2 Rspo2 N-glycosylation site PUBTATOR Site Rspo2 340419 site Similar effect can be observed in the N137 Rspo1 or Rspo3 mutant engineered with Rspo2 N-glycosylation site. 9242452 12 10 gly glycopeptide 2082:2093 arg2 a glycopeptide a glycopeptide glycopeptide T cells primed to a glycopeptide carrying the more complex T antigen showed a complicated pattern of cross-responses to glycopeptides with simpler glycan moieties. 9242452 12 120 gly carrying 2095:2102 arg1 a glycopeptide AND the more complex T antigen a glycopeptide the more complex T antigen glycopeptide T cells primed to a glycopeptide carrying the more complex T antigen showed a complicated pattern of cross-responses to glycopeptides with simpler glycan moieties. 9242452 12 53 gly glycopeptides 2182:2194 arg2 glycopeptides glycopeptides simpler glycan moieties glycopeptides T cells primed to a glycopeptide carrying the more complex T antigen showed a complicated pattern of cross-responses to glycopeptides with simpler glycan moieties. 8288048 0 0 part_of alpha-subunit 84:96 arg1 the NH2-terminal glycosylation sites subunit the NH2-terminal glycosylation sites OGER Site subunit 3643 sites Mutational analysis of the NH2-terminal glycosylation sites of the insulin receptor alpha-subunit. 19534833 3 69 gly N-glycosylation 693:707 arg2 the N-glycosylation site the N-glycosylation site site Although the N-glycosylation site of M seems to be highly conserved between group 1 and 3 coronaviruses, studies using a recombinant SARS-CoV expressing a glycosylation-deficient M revealed that N-glycosylation of M neither influence the shape of the virions nor their infectivity in cell culture. 19241033 4 16 gly glycosylation 636:648 arg2 their original glycosylation sites their original glycosylation sites sites Intact glycopeptides (i.e., proteolytic mixtures in which the glycan chains stay attached at their original glycosylation sites) can be analyzed either by a direct infusion or with HPLC separation prior to MALDI or ESI mass spectrometric analysis to provide both information on the glycan structure and glycosylation site in the same experiment. 19241033 4 47 gly site 845:848 arg1 the glycan structure site the glycan structure site Intact glycopeptides (i.e., proteolytic mixtures in which the glycan chains stay attached at their original glycosylation sites) can be analyzed either by a direct infusion or with HPLC separation prior to MALDI or ESI mass spectrometric analysis to provide both information on the glycan structure and glycosylation site in the same experiment. 19241033 4 57 gly glycopeptides 535:547 arg2 Intact glycopeptides Intact glycopeptides glycopeptides Intact glycopeptides (i.e., proteolytic mixtures in which the glycan chains stay attached at their original glycosylation sites) can be analyzed either by a direct infusion or with HPLC separation prior to MALDI or ESI mass spectrometric analysis to provide both information on the glycan structure and glycosylation site in the same experiment. 19241033 4 61 gly glycosylation 831:843 arg2 glycosylation site glycosylation site site Intact glycopeptides (i.e., proteolytic mixtures in which the glycan chains stay attached at their original glycosylation sites) can be analyzed either by a direct infusion or with HPLC separation prior to MALDI or ESI mass spectrometric analysis to provide both information on the glycan structure and glycosylation site in the same experiment. 29273683 2 27 gly N-glycosylation 182:196 arg2 six N-glycosylation sites six N-glycosylation sites sites Human and rat CBGs have six N-glycosylation sites. 27966990 6 52 gly N-glycosylation 1076:1090 arg2 at least one occupied N-glycosylation site at least one occupied N-glycosylation site site The data demonstrated that all seven VEGFR-2 immunoglobulin-like domains have at least one occupied N-glycosylation site. 8357534 3 10 gly site 527:530 arg1 the carbohydrate structures site the carbohydrate structures site Analysis of a minor form of elastase (E-1) and cathepsin G (C-1) indicates that the carbohydrate structures at each glycosylation site are complex-type bi-antennary chains usually associated with secretory glycoproteins. 8357534 3 10 gly site 527:530 arg1 complex-type bi-antennary chains site complex-type bi-antennary chains site Analysis of a minor form of elastase (E-1) and cathepsin G (C-1) indicates that the carbohydrate structures at each glycosylation site are complex-type bi-antennary chains usually associated with secretory glycoproteins. 8357534 3 23 gly glycosylation 513:525 arg2 each glycosylation site each glycosylation site site Analysis of a minor form of elastase (E-1) and cathepsin G (C-1) indicates that the carbohydrate structures at each glycosylation site are complex-type bi-antennary chains usually associated with secretory glycoproteins. 8357534 3 50 gly glycoproteins 603:615 arg1 secretory glycoproteins secretory glycoproteins Fterm glycoproteins Analysis of a minor form of elastase (E-1) and cathepsin G (C-1) indicates that the carbohydrate structures at each glycosylation site are complex-type bi-antennary chains usually associated with secretory glycoproteins. 26231935 1 1 gly glycosylation 187:199 arg2 three conserved N-linked glycosylation sites three conserved N-linked glycosylation sites sites Acetylcholinesterase (AChE; EC 3.1.1.7) is a glycoprotein possessing three conserved N-linked glycosylation sites in mammalian species, locating at 296, 381, and 495 residues of the human sequence. 26231935 1 30 gly glycoprotein 138:149 arg1 Acetylcholinesterase Acetylcholinesterase PUBTATOR Acetylcholinesterase 43 Acetylcholinesterase (AChE; EC 3.1.1.7) is a glycoprotein possessing three conserved N-linked glycosylation sites in mammalian species, locating at 296, 381, and 495 residues of the human sequence. 26231935 1 30 gly glycoprotein 138:149 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Acetylcholinesterase (AChE; EC 3.1.1.7) is a glycoprotein possessing three conserved N-linked glycosylation sites in mammalian species, locating at 296, 381, and 495 residues of the human sequence. 14595005 4 63 gly glycosylation 965:977 arg2 a highly conserved N-linked glycosylation site a highly conserved N-linked glycosylation site site The altered V2 loops contained double amino acid deletions and the loss of a highly conserved N-linked glycosylation site. 2040275 1 44 part_of immunoglobulin 195:208 arg1 a 22-residue peptide immunoglobulin M a 22-residue peptide OGER Site immunoglobulin M P01871 peptide 1H-NMR spectroscopy has been used to study the conformation and dynamics of the isolated tailpiece from human serum immunoglobulin M, a 22-residue peptide containing a single asparagine glycosylation site. 2040275 1 77 part_of containing 234:243 arg1 human serum immunoglobulin M AND a single asparagine glycosylation site immunoglobulin M site OGER Site immunoglobulin M P01871 site 1H-NMR spectroscopy has been used to study the conformation and dynamics of the isolated tailpiece from human serum immunoglobulin M, a 22-residue peptide containing a single asparagine glycosylation site. 26231935 3 32 gly sites 477:481 arg1 glycan composition sites glycan composition sites In order to determine the role of three N-glycosylation sites in AChE activity and glycan composition, the site-directed mutagenesis of N-glycosylation sites in wild-type human AChE(T) sequence was employed to generate the single-site mutants (i.e., AChE(T) (N296Q), AChET (N381Q), and AChE(T) (N495Q)) and all site mutant (i.e., AChE(T) (3N→3Q)). 26231935 3 46 gly N-glycosylation 557:571 arg2 N-glycosylation sites N-glycosylation sites sites In order to determine the role of three N-glycosylation sites in AChE activity and glycan composition, the site-directed mutagenesis of N-glycosylation sites in wild-type human AChE(T) sequence was employed to generate the single-site mutants (i.e., AChE(T) (N296Q), AChET (N381Q), and AChE(T) (N495Q)) and all site mutant (i.e., AChE(T) (3N→3Q)). 26231935 3 63 gly N-glycosylation 461:475 arg2 three N-glycosylation sites three N-glycosylation sites sites In order to determine the role of three N-glycosylation sites in AChE activity and glycan composition, the site-directed mutagenesis of N-glycosylation sites in wild-type human AChE(T) sequence was employed to generate the single-site mutants (i.e., AChE(T) (N296Q), AChET (N381Q), and AChE(T) (N495Q)) and all site mutant (i.e., AChE(T) (3N→3Q)). 24798328 9 82 gly glycosylation 1344:1356 arg1 the linker regions the linker regions regions Probing into which isoform(s) contributed to glycosylation of the linker regions of the LDLR class A repeats by in vitro enzyme assays suggested a major role of GalNAc-T11. 25422509 7 20 gly sialylated 1110:1119 arg1 sialylated N-glycans sialylated N-glycans The absence of sialic acid residues abolishes these inhibitory activities, showing a key role of sialylated N-glycans in inducing the IgM-mediated immune suppression. 1706753 3 19 part_of HA1 1133:1135 arg1 HA1 158 Gly HA1 HA1 158 Gly PUBTATOR AminoAcid HA1 70719 Gly Single nucleotide substitutions in the HA genes of mutant viruses identified both novel and immunodominant antigenic sites on the HA1 subunit: a majority of mAbs, from different donors, were of the IgG2a isotype and were specific for HA1 158 Gly. 1706753 3 62 part_of sites 1016:1020 arg1 the HA1 subunit HA1 subunit sites PUBTATOR Site HA1 subunit 70719 sites Single nucleotide substitutions in the HA genes of mutant viruses identified both novel and immunodominant antigenic sites on the HA1 subunit: a majority of mAbs, from different donors, were of the IgG2a isotype and were specific for HA1 158 Gly. 10196694 6 12 gly N-glycosylation 1085:1099 arg2 the only N-glycosylation site saposin B site Cterm saposin B site The mutation involves a highly conserved amino acidic residue and abolishes the only N-glycosylation site of saposin B. 11410585 3 36 gly cell 625:628 arg1 3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc natural keller cell (HNK)-1 3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc PUBTATOR natural keller cell (HNK)-1 27087 Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans. 11410585 3 44 gly HNK 631:633 arg1 3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc natural keller cell (HNK)-1 3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc PUBTATOR natural keller cell (HNK)-1 27087 Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans. 11410585 3 59 gly glycoprotein 558:569 arg1 the P0 glycoprotein the P0 glycoprotein Fterm glycoprotein Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans. 11410585 3 63 gly natural 610:616 arg1 3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc natural keller cell (HNK)-1 3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc PUBTATOR natural keller cell (HNK)-1 27087 Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans. 11410585 3 83 gly keller 618:623 arg1 3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc natural keller cell (HNK)-1 3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc PUBTATOR natural keller cell (HNK)-1 27087 Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans. 11015576 0 7 gly N-glycosylation 47:61 arg2 a putative N-glycosylation site a putative N-glycosylation site site A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia. 26231935 8 19 gly glycosylation 1319:1331 arg2 the three glycosylation sites the three glycosylation sites sites Although the three glycosylation sites within AChE sequence have different extent in affecting the enzymatic activity, their glycan compositions are very similar. 7994575 4 12 gly glycosylation 615:627 arg2 each glycosylation site each glycosylation site site RESULTS: We therefore determined the crystal structure of a form of human sCD2 with single N-acetylglucosamine residues at each glycosylation site to 2.5 A resolution with an R-factor of 19.3%. 22187327 2 7 gly ICAM-5 309:314 arg1 the N-glycan structures ICAM-5 the N-glycan structures PUBTATOR ICAM-5 15898 Although we have determined the N-glycan structures of ICAM-5 in a previous report, their function is unknown. 20602265 8 47 part_of has 1404:1406 arg1 The 2009 S-OIV HA AND an extra glycosylation site The 2009 S-OIV HA an extra glycosylation site Cterm Site HA site The 2009 S-OIV HA also has an extra glycosylation site at position 276. 15113920 0 40 gly glycosylation 21:33 arg1 protein folding protein folding Fterm protein Analysis of N-linked glycosylation of hantaan virus glycoproteins and the role of oligosaccharide side chains in protein folding and intracellular trafficking. 15113920 0 40 gly glycosylation 21:33 arg1 hantaan virus glycoproteins hantaan virus glycoproteins Fterm glycoproteins Analysis of N-linked glycosylation of hantaan virus glycoproteins and the role of oligosaccharide side chains in protein folding and intracellular trafficking. 15113920 0 44 gly glycoproteins 52:64 arg1 hantaan virus glycoproteins hantaan virus glycoproteins Fterm glycoproteins Analysis of N-linked glycosylation of hantaan virus glycoproteins and the role of oligosaccharide side chains in protein folding and intracellular trafficking. 12526344 4 57 gly glycosylation 610:622 arg2 one more glycosylation site one more glycosylation site site Except one more glycosylation site located at 156 position in the chicken strain, there were 7 glycosylation sites at same positions in three virus HA protein molecules. 12526344 4 79 gly glycosylation 689:701 arg2 7 glycosylation sites 7 glycosylation sites sites Except one more glycosylation site located at 156 position in the chicken strain, there were 7 glycosylation sites at same positions in three virus HA protein molecules. 31507595 5 5 gly sialylated 829:838 arg1 N-glycosylation and multi-antennary sialylated N-glycans N-glycosylation and multi-antennary sialylated N-glycans Analysis of native CD52 purified from human spleen revealed extensive heterogeneity in N-glycosylation and multi-antennary sialylated N-glycans with abundant polyLacNAc extensions, together with mainly di-sialylated O-glycosylation type structures. 31507595 5 28 gly di-sialylated 908:920 arg1 mainly di-sialylated O-glycosylation type structures mainly di-sialylated O-glycosylation type structures Analysis of native CD52 purified from human spleen revealed extensive heterogeneity in N-glycosylation and multi-antennary sialylated N-glycans with abundant polyLacNAc extensions, together with mainly di-sialylated O-glycosylation type structures. 16107205 2 78 gly glycosylation 521:533 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site A sequence comparison reveals some conserved characteristics: all the mammalian DNase X proteins have an N-terminal signal peptide, a potential N-linked glycosylation site and a C-terminal hydrophobic domain. 15859596 6 33 gly glycoproteins 885:897 arg1 glycoproteins glycoproteins Fterm glycoproteins Using this method the concentration of sialic acid containing glycoproteins from a normal individual were compared to those in a pooled serum sample from a large number of normal individuals. 2574462 0 20 gly N-glycosylation 73:87 arg2 N-glycosylation site N-glycosylation site site Arylsulfatase A pseudodeficiency: loss of a polyadenylylation signal and N-glycosylation site. 9753616 5 63 gly N-glycosylation 507:521 arg2 a conserved N-glycosylation site a conserved N-glycosylation site site STC2 has a conserved N-glycosylation site and is rich in cysteines as is the case with other stanniocalcins. 29779877 6 36 part_of Ephrin-B1 1188:1196 arg1 the extracellular domain Ephrin-B1 the extracellular domain PUBTATOR Site Ephrin-B1 1947 domain This silencing activity is independent of Eph receptors and involves a N-glycosylation site (N-139) in the extracellular domain of Ephrin-B1. 27743362 3 35 gly O-glycopeptide 480:493 arg2 O-glycopeptide O-glycopeptide O-glycopeptide This chapter describes a universal workflow for site-specific N- and O-glycopeptide analysis. 7620335 1 44 part_of X 311:311 arg1 the factor X activation peptide factor X the factor X activation peptide OGER Site factor X P00742 peptide Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa. 7620335 1 95 part_of factor 304:309 arg1 the factor X activation peptide factor X the factor X activation peptide OGER Site factor X P00742 peptide Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa. 21733886 9 12 part_of protein 1630:1636 arg1 the hinge region protein the hinge region Fterm Site protein region These results identify the hinge region and E protein glycosylation as motifs that contribute to the attenuation of ALFV. 21733886 9 12 part_of protein 1630:1636 arg1 motifs protein motifs Fterm Site protein motifs These results identify the hinge region and E protein glycosylation as motifs that contribute to the attenuation of ALFV. 11310976 0 50 gly unglycosylated 100:113 arg1 Glycophorin A Glycophorin A PUBTATOR Glycophorin A 2993 Glycophorin A in two patients with congenital dyserythropoietic anemia type I and type II is partly unglycosylated. 7532677 2 31 part_of Bw6 473:475 arg1 the Bw4 and Bw6 serological epitopes Bw6 the Bw4 and Bw6 serological epitopes PUBTATOR Site Bw6 474275 epitopes Using class I alleles HLA-B*1502 and B*1513 which differ only at residues 77-83 which define the Bw4 and Bw6 serological epitopes, we tested the hypothesis that the presence of the Bw4 epitope on class I molecules determines recognition by NKB1+ NK cells. 7532677 2 82 part_of Bw4 465:467 arg1 the Bw4 and Bw6 serological epitopes Bw4 the Bw4 and Bw6 serological epitopes PUBTATOR Site Bw4 474272 epitopes Using class I alleles HLA-B*1502 and B*1513 which differ only at residues 77-83 which define the Bw4 and Bw6 serological epitopes, we tested the hypothesis that the presence of the Bw4 epitope on class I molecules determines recognition by NKB1+ NK cells. 7532677 2 104 part_of Bw4 549:551 arg1 the Bw4 epitope Bw4 the Bw4 epitope PUBTATOR Site Bw4 474272 epitope Using class I alleles HLA-B*1502 and B*1513 which differ only at residues 77-83 which define the Bw4 and Bw6 serological epitopes, we tested the hypothesis that the presence of the Bw4 epitope on class I molecules determines recognition by NKB1+ NK cells. 2721453 5 7 gly glycosylation 803:815 arg2 one glycosylation site one glycosylation site site For TSH beta (with one glycosylation site) at least eight oligosaccharide species were noted, representing nearly every permutation of sialylation and sulfation; approximately 30% contained three or more negative charges. 12638188 4 25 gly glycosylation 321:333 arg2 each glycosylation site each glycosylation site site Using this method, both peptides and glycosylation at each glycosylation site can be elucidated based on the mass chromatogram and mass spectrum. 12638188 4 38 gly glycosylation 299:311 arg1 each glycosylation site site site Using this method, both peptides and glycosylation at each glycosylation site can be elucidated based on the mass chromatogram and mass spectrum. 17082223 8 41 gly Bsep 1644:1647 arg1 one glycan Bsep one glycan PUBTATOR Bsep 83569 To determine whether a specific glycosylation site or the number of glycans was critical for protein stability, we studied the protein expression of combinations of N-glycan-deficient mutants and observed that Bsep with one glycan was considerably unstable compared with Bsep harboring two or more glycans. 17082223 8 44 gly glycosylation 1466:1478 arg1 glycans site glycans site To determine whether a specific glycosylation site or the number of glycans was critical for protein stability, we studied the protein expression of combinations of N-glycan-deficient mutants and observed that Bsep with one glycan was considerably unstable compared with Bsep harboring two or more glycans. 25793890 9 60 gly glycosylation 1885:1897 arg2 these glycosylation sites these glycosylation sites sites Our results suggest that vaccine immunogens based on recombinant envelope proteins from clade CRF01_AE viruses might be improved by inclusion of envelope proteins that lack these glycosylation sites. 23758413 6 101 gly glycans 1159:1165 arg1 specific proteins proteins glycans Fterm proteins The work being described here examines the utility of serial affinity columns in determining whether individual glycan structures appear alone or together with other glycans in specific proteins. 9753616 5 13 part_of has 491:493 arg1 STC2 AND a conserved N-glycosylation site STC2 a conserved N-glycosylation site PUBTATOR Site STC2 8614 site STC2 has a conserved N-glycosylation site and is rich in cysteines as is the case with other stanniocalcins. 11390601 0 49 gly glycosylation 9:21 arg2 N-linked glycosylation sites N-linked glycosylation sites sites N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. 16261636 1 7 gly glycosylation 227:239 arg1 human alpha-1-acid glycoprotein human alpha-1-acid glycoprotein Fterm glycoprotein A new anionic surfactant (RapiGest SF) was successfully used for site-specific analysis of glycosylation in human alpha-1-acid glycoprotein (AGP). 16261636 1 19 gly glycoprotein 263:274 arg1 human alpha-1-acid glycoprotein human alpha-1-acid glycoprotein Fterm glycoprotein A new anionic surfactant (RapiGest SF) was successfully used for site-specific analysis of glycosylation in human alpha-1-acid glycoprotein (AGP). 8347587 8 78 gly chains 926:931 arg1 the mutant proreceptor proreceptor chains Fterm proreceptor The carbohydrate chains on the mutant proreceptor remained endoglycosidase H sensitive. 20011150 10 13 gly glycosylation 1233:1245 arg2 an additional glycosylation site an additional glycosylation site site In some strains of HA from non-human sources because of mutation, an additional glycosylation site appeared at the antigenic site. 11676606 4 9 gly glycosylation 544:556 arg2 asparagine 240 asparagine 240 asparagine 240 Human CD154 contains a single N-linked glycosylation site at asparagine 240. 11676606 4 9 gly glycosylation 544:556 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site Human CD154 contains a single N-linked glycosylation site at asparagine 240. 17727280 3 4 gly glycosylated 430:441 arg1 glycosylated peptides glycosylated peptides peptides The program uses MS/MS to identify glycosylated peptides and single-MS to identify the N-glycans present on each of these peptides, at least to the level of monosaccharide composition. 17727280 3 24 gly present 492:498 arg1 these peptides AND the N-glycans these peptides the N-glycans peptides The program uses MS/MS to identify glycosylated peptides and single-MS to identify the N-glycans present on each of these peptides, at least to the level of monosaccharide composition. 25499076 0 42 gly glycoprotein 38:49 arg1 a simple glycoprotein model a simple glycoprotein model Fterm glycoprotein N-glycoprofiling analysis in a simple glycoprotein model: a comparison between recombinant and pituitary glycosylated human prolactin. 25499076 0 79 gly glycosylated 105:116 arg1 recombinant and pituitary glycosylated human prolactin recombinant and pituitary glycosylated human prolactin PUBTATOR prolactin 5617 N-glycoprofiling analysis in a simple glycoprotein model: a comparison between recombinant and pituitary glycosylated human prolactin. 14517968 4 50 gly N-glycosylation 710:724 arg2 An N-glycosylation site An N-glycosylation site site An N-glycosylation site in human gammaD-crystallin and several phosphorylation sites in all four human gamma-crystallins were predicted by the PROSITE search. 21569239 0 25 part_of F-spondin 68:76 arg1 the Ca²+-binding, glycosylated F-spondin domain F-spondin the Ca²+-binding, glycosylated F-spondin domain PUBTATOR Site F-spondin 10418 domain The structure of the Ca²+-binding, glycosylated F-spondin domain of F-spondin - A C2-domain variant in an extracellular matrix protein. 21569239 0 44 part_of F-spondin 48:56 arg1 the Ca²+-binding, glycosylated F-spondin domain F-spondin the Ca²+-binding, glycosylated F-spondin domain PUBTATOR Site F-spondin 10418 domain The structure of the Ca²+-binding, glycosylated F-spondin domain of F-spondin - A C2-domain variant in an extracellular matrix protein. 10913840 6 33 gly glycosylation 1030:1042 arg2 site 218-220 site site These results show that N-glycosylation is necessary for optimal enzyme activity, with glycosylation at site 218-220 playing the major role. 10362834 4 60 gly glycosylation 823:835 arg2 the glycosylation site the glycosylation site site Based on the amino acid sequence data around the glycosylation site, the gp30 was identified as P0, which is a member of immunoglobulin superfamily and a major structural component of mammalian peripheral nerve myelin. 22872643 6 10 gly glycosylation 1005:1017 arg2 a novel glycosylation site a novel glycosylation site site Our prior site-mapping studies demonstrated that O-glucose consensus sites are modified at high but variable stoichiometries in mouse Notch1 and identified a novel glycosylation site with alanine in place of proline, suggesting a revised, broader consensus sequence (CXSX(P/A)C). 31097672 1 18 gly glycoproteins 220:232 arg1 the more abundant glycoproteins the more abundant glycoproteins Fterm glycoproteins Fetuin, also known as α-2-HS-glycoprotein (gene name: AHSG), is one of the more abundant glycoproteins secreted into the bloodstream. 31097672 1 48 gly α-2-HS-glycoprotein 153:171 arg1 gene name: AHSG gene name: AHSG OGER AHSG P02765 Fetuin, also known as α-2-HS-glycoprotein (gene name: AHSG), is one of the more abundant glycoproteins secreted into the bloodstream. 31097672 1 48 gly α-2-HS-glycoprotein 153:171 arg1 α-2-HS-glycoprotein α-2-HS-glycoprotein Fterm α-2-HS-glycoprotein Fetuin, also known as α-2-HS-glycoprotein (gene name: AHSG), is one of the more abundant glycoproteins secreted into the bloodstream. 18340083 7 52 part_of site 922:925 arg1 mouse GPIHBP1 GPIHBP1 site PUBTATOR Site GPIHBP1 68453 site Mutating the N-glycosylation site in mouse GPIHBP1 results in an accumulation of GPIHBP1 in the endoplasmic reticulum and a markedly reduced amount of the protein on the cell surface. 30427586 5 14 gly N-glycopeptides 973:987 arg2 N-glycopeptides N-glycopeptides N-glycopeptides For the unambiguous identification of N-glycopeptides, the use of a conserved yet, rarely employed-fragmentation signature [Mpeptide +H+0,2 X GlcNAc]+ is proposed. 8349598 11 76 part_of PXR/K 2258:2262 arg1 the PXR/K motif PXR the PXR/K motif PUBTATOR Site PXR 8856 motif The Trf-specific GalNAc-transferase may account for the presence of beta 1,4-linked GalNAc on glycoproteins which do not contain the PXR/K motif. 8349598 11 38 part_of contain 2246:2252 arg1 glycoproteins AND the PXR/K motif glycoproteins the PXR/K motif Fterm Site glycoproteins motif The Trf-specific GalNAc-transferase may account for the presence of beta 1,4-linked GalNAc on glycoproteins which do not contain the PXR/K motif. 27127844 11 74 gly Unglycosylated 1392:1405 arg1 Unglycosylated a4 Unglycosylated a4 Cterm Unglycosylated a4 Unglycosylated a4 was degraded mostly in the proteasomal pathway, but also, in part, through the lysosomal pathway. 21048158 8 32 gly used 1476:1479 arg2 AT-N135Q-Pro394 AT-N135Q-Pro394 Pro394 These results clearly demonstrate that AT-N135Q-Pro394 can reverse the anticoagulant activity of fondaparinux and thus could be used as an antidote for this drug. 29775240 3 43 gly glycopeptides 578:590 arg2 intact glycopeptides intact glycopeptides glycopeptides The analysis of intact glycopeptides highlights unexpected technical limitations to PNGase F-dependent glycoproteomic workflows at the proteome level, and warrants a critical reinterpretation of seminal datasets in the context of N-glycosylation-site prediction. 21526855 5 2 gly desialylated 1061:1072 arg1 the natural bovine glycoproteins the natural bovine glycoproteins Fterm glycoproteins The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein. 21526855 5 2 gly desialylated 1061:1072 arg1 desialylated κ-casein desialylated κ-casein Fterm κ-casein The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein. 21526855 5 18 gly O-glycosylation 890:904 arg2 O-glycosylation sites O-glycosylation sites sites The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein. 21526855 5 32 gly MUC1 1001:1004 arg1 the tandem repeat domain MUC1 the tandem repeat domain PUBTATOR MUC1 281333 The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein. 21526855 5 33 gly glycoproteins 1030:1042 arg1 the natural bovine glycoproteins the natural bovine glycoproteins Fterm glycoproteins The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein. 21526855 5 33 gly glycoproteins 1030:1042 arg1 asialofetuin asialofetuin PUBTATOR asialofetuin 280988 The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein. 21526855 5 33 gly glycoproteins 1030:1042 arg1 desialylated κ-casein desialylated κ-casein Fterm κ-casein The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein. 21526855 5 15 gly O-glycopeptides 944:958 arg1 recombinant MUC1 MUC1 O-glycopeptides PUBTATOR MUC1 281333 O-glycopeptides The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein. 7999071 4 48 gly glycosylation 789:801 arg2 an N-linked glycosylation site protein site Fterm protein site DNA sequence analysis of the LPL gene from the patient revealed a homozygous nucleotide change: a A-->G transition at nucleotide position 383, resulting in an amino acid substitution of Ser for Asn43, which is believed to be an N-linked glycosylation site of the LPL mature protein. 27396161 8 53 gly N-glycosylation 906:920 arg2 one N-glycosylation site one N-glycosylation site site F genotype MuV added one N-glycosylation site in 464th-466th amino acids. 7613477 0 59 gly glycosylation 63:75 arg1 apolipoprotein D apolipoprotein D PUBTATOR apolipoprotein D 347 Site-specific detection and structural characterization of the glycosylation of human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion. 7613477 0 59 gly glycosylation 63:75 arg1 human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D Fterm proteins Site-specific detection and structural characterization of the glycosylation of human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion. 7613477 0 59 gly glycosylation 63:75 arg1 lecithin:cholesterol acyltransferase lecithin:cholesterol acyltransferase PUBTATOR lecithin:cholesterol acyltransferase 3931 Site-specific detection and structural characterization of the glycosylation of human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion. 11326277 6 24 part_of receptor 905:912 arg1 this region G protein-coupled receptor this region PUBTATOR Site G protein-coupled receptor 23890 region From this search, we identified a likely candidate: T1R3, a previously unknown G protein-coupled receptor (GPCR) and the only GPCR in this region. 11326277 6 33 part_of GPCR 934:937 arg1 this region GPCR this region PUBTATOR Site GPCR 23890 region From this search, we identified a likely candidate: T1R3, a previously unknown G protein-coupled receptor (GPCR) and the only GPCR in this region. 9557657 0 67 part_of virus 35:39 arg1 The Cys-rich region hepatitis A virus cellular receptor 1 The Cys-rich region OGER Site hepatitis A virus cellular receptor 1 Q96D42 region The Cys-rich region of hepatitis A virus cellular receptor 1 is required for binding of hepatitis A virus and protective monoclonal antibody 190/4. 23820512 4 13 gly de-N-glycosylated 695:711 arg1 de-N-glycosylated peptides de-N-glycosylated peptides peptides Both N-glycans and peptides (including de-N-glycosylated peptides) are separately collected by filtration. 21727639 0 19 part_of proteins 92:99 arg1 Comparative sequence proteins Comparative sequence Fterm Site proteins sequence Comparative sequence, antigenic and phylogenetic analysis of avian influenza (H9N2) surface proteins isolated in Pakistan between 1999 and 2008. 18652900 9 48 part_of cucurmosin 1309:1318 arg1 the active site cucurmosin the active site Fterm Site cucurmosin site Residues Tyr70, Tyr109, Glu158 and Arg161 define the active site of cucurmosin as an RNA N-glycosidase. 18652900 9 58 part_of RNA 1326:1328 arg1 the active site RNA the active site Cterm Site RNA site Residues Tyr70, Tyr109, Glu158 and Arg161 define the active site of cucurmosin as an RNA N-glycosidase. 14715137 3 23 part_of synaptotagmin 458:470 arg1 the N-terminal N-glycosylation site synaptotagmin 1 the N-terminal N-glycosylation site PUBTATOR Site synaptotagmin 1 6857 site Conversely, mutation of the N-terminal N-glycosylation site of synaptotagmin 1 redirects synaptotagmin 1 from vesicles to the plasma membrane. 25910922 7 63 part_of head 1325:1328 arg1 potential glycosylation site head potential glycosylation site site In addition, a single amino acid substitution (N165H), which removes potential glycosylation site at the HA globular head of two classic strains (A/chicken/Egypt/527/2012 and A/chicken/Egypt/102d/2010) broadened the reactivity to antisera generated against H5N1 viruses from different clusters. 8019599 5 40 gly glycosylated 701:712 arg1 either glycosylated or unglycosylated b3 either glycosylated or unglycosylated b3 Cterm b3 443978 Greater cleavage of b3 was obtained when human red cell glycophorin A (GPA) was co-expressed with either glycosylated or unglycosylated b3. 8019599 5 44 gly unglycosylated 717:730 arg1 either glycosylated or unglycosylated b3 either glycosylated or unglycosylated b3 Cterm b3 443978 Greater cleavage of b3 was obtained when human red cell glycophorin A (GPA) was co-expressed with either glycosylated or unglycosylated b3. 18925417 5 36 gly N-glycosylation 820:834 arg2 N-glycosylation site N-glycosylation site site No signal peptide or N-glycosylation site was found in the sequence. 29333671 0 50 gly glycopeptides 33:45 arg2 N-linked glycopeptides N-linked glycopeptides glycopeptides Selective enrichment of N-linked glycopeptides and glycans by using a dextran-modified hydrophilic material. 8364023 2 20 part_of AAC 370:372 arg1 Thr AAC Thr OGER AminoAcid AAC Q6IB77 Thr To study the role of the N-linked sugars, the codon for Asn at these positions was replaced with one for Thr (AAC to ACC). 11230417 2 59 gly glycoprotein 442:453 arg1 a glycoprotein a glycoprotein Fterm glycoprotein RNase B is an excellent substrate for the demonstration of mannosidase activity since it is a glycoprotein with a single glycosylation site which is occupied by high-mannose-type glycoforms containing five to nine mannose residues. 11230417 2 80 gly glycosylation 469:481 arg2 a single glycosylation site a single glycosylation site site RNase B is an excellent substrate for the demonstration of mannosidase activity since it is a glycoprotein with a single glycosylation site which is occupied by high-mannose-type glycoforms containing five to nine mannose residues. 11230417 2 91 gly occupied 497:504 arg2 a single glycosylation site a single glycosylation site site RNase B is an excellent substrate for the demonstration of mannosidase activity since it is a glycoprotein with a single glycosylation site which is occupied by high-mannose-type glycoforms containing five to nine mannose residues. 7685769 4 4 gly attached 838:845 arg2 two possible carbohydrate structures AND Thr-133 Thr-133 two possible carbohydrate structures Thr-133 Neuraminidase and O-glycanase digestion followed by sodium dodecyl sulfate polyacrylamide and isoelectric focusing gel electrophoreses distinguished two possible carbohydrate structures attached at Thr-133: structure A, NeuNAc-Gal-beta(1,3)-GalNAc-O-Thr; and structure B, NeuNAc-Gal-beta(1,3)-[NeuNAc]-GalNAc-O-Thr. 7685769 4 8 gly -GalNAc-O-Thr 953:965 arg1 two possible carbohydrate structures Thr two possible carbohydrate structures Thr Neuraminidase and O-glycanase digestion followed by sodium dodecyl sulfate polyacrylamide and isoelectric focusing gel electrophoreses distinguished two possible carbohydrate structures attached at Thr-133: structure A, NeuNAc-Gal-beta(1,3)-GalNAc-O-Thr; and structure B, NeuNAc-Gal-beta(1,3)-[NeuNAc]-GalNAc-O-Thr. 7685769 4 53 gly -GalNAc-O-Thr 892:904 arg1 two possible carbohydrate structures Thr two possible carbohydrate structures Thr Neuraminidase and O-glycanase digestion followed by sodium dodecyl sulfate polyacrylamide and isoelectric focusing gel electrophoreses distinguished two possible carbohydrate structures attached at Thr-133: structure A, NeuNAc-Gal-beta(1,3)-GalNAc-O-Thr; and structure B, NeuNAc-Gal-beta(1,3)-[NeuNAc]-GalNAc-O-Thr. 25220145 4 1 gly CF-glycosylation 720:735 arg2 a precise CF-glycosylation site identification strategy a precise CF-glycosylation site identification strategy site In this study, we established a precise CF-glycosylation site identification strategy with UHPLC LTQ-Orbitrap Elite under low- and high-normalized collision energy (LHNCE) conditions. 18941134 4 109 gly sialylated 1223:1232 arg1 sialylated complex type N-glycans sialylated complex type N-glycans A comparative glycomics analysis of the male genital tract fluids revealed that there is a gradient of glycomic complexity from the cauda to caput regions of the epididymis, varying from high mannose to sialylated complex type N-glycans but mostly devoid of fucosylation. 22586465 0 45 gly N-glycosylation 62:76 arg2 the N-glycosylation sequon the N-glycosylation sequon sequon Proteome-wide analysis of single-nucleotide variations in the N-glycosylation sequon of human genes. 2825202 3 2 part_of EcoRI 490:494 arg1 the longer two EcoRI fragments EcoRI the longer two EcoRI fragments Cterm Site EcoRI fragments We report here the nucleotide sequence of the longer two EcoRI fragments of S-1.2 and S-1.3 that were not the same and the derived amino acid sequences of mature SAP-1 and its prepro form. 2825202 3 101 part_of SAP-1 595:599 arg1 the derived amino acid sequences SAP-1 the derived amino acid sequences PUBTATOR Site SAP-1 5660 sequences We report here the nucleotide sequence of the longer two EcoRI fragments of S-1.2 and S-1.3 that were not the same and the derived amino acid sequences of mature SAP-1 and its prepro form. 2825202 3 101 part_of SAP-1 595:599 arg1 the nucleotide sequence SAP-1 the nucleotide sequence PUBTATOR Site SAP-1 5660 sequence We report here the nucleotide sequence of the longer two EcoRI fragments of S-1.2 and S-1.3 that were not the same and the derived amino acid sequences of mature SAP-1 and its prepro form. 20348522 0 44 gly Glycosylation 0:12 arg1 the West Nile Virus envelope protein the West Nile Virus envelope protein Fterm protein Glycosylation of the West Nile Virus envelope protein increases in vivo and in vitro viral multiplication in birds. 28231306 5 12 gly O-glycosylation 1300:1314 arg2 essential post-translation O-glycosylation site essential post-translation O-glycosylation site site Moreover, an additional integrated in silico analysis proposed that rs12774070 and rs61573157 affected essential post-translation O-glycosylation site within the 3rd thrombospondin type 1 repeat and a novel proline-rich region embedded within the C-terminal extension, respectively. 9008840 4 20 gly Gp21 701:704 arg1 the glycan Gp21 the glycan Cterm Gp21 Different glycoforms were found for the glycan of Gp21 derived from two different batches of commercial HSTF. 9140197 9 57 gly glycosylated 1427:1438 arg1 the epitopes the epitopes epitopes This indicates that the epitopes are non-linear and/or glycosylated in the native state, or alternatively, that the G1 and G2 MAbs binds to regions away from the mutations. 26993603 3 7 part_of GP73 560:563 arg1 three GP73 N-glycosylation sites GP73 three GP73 N-glycosylation sites PUBTATOR Site GP73 51280 sites We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26993603 3 7 part_of GP73 560:563 arg1 Asn144 GP73 Asn109, Asn144 and Asn398 PUBTATOR AminoAcid GP73 51280 Asn109, Asn144 and Asn398 We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26993603 3 7 part_of GP73 560:563 arg1 Asn109 GP73 Asn109, Asn144 and Asn398 PUBTATOR AminoAcid GP73 51280 Asn109, Asn144 and Asn398 We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26993603 3 7 part_of GP73 560:563 arg1 Asn109 GP73 Asn109, Asn144 and Asn398 PUBTATOR AminoAcid GP73 51280 Asn109, Asn144 and Asn398 We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 1383332 0 84 gly glycosylation 21:33 arg2 glycosylation sites glycosylation sites sites Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. 11251288 5 13 gly glycosylated 969:980 arg1 homogeneously glycosylated proteins homogeneously glycosylated proteins Fterm proteins This provides a general method for the synthesis of homogeneously glycosylated proteins that carry saccharide side chains at natural or unnatural glycosylation sites. 11251288 5 119 gly glycosylation 1049:1061 arg2 natural or unnatural glycosylation sites natural or unnatural glycosylation sites sites This provides a general method for the synthesis of homogeneously glycosylated proteins that carry saccharide side chains at natural or unnatural glycosylation sites. 11251288 5 18 gly carry 996:1000 arg1 homogeneously glycosylated proteins AND saccharide side chains homogeneously glycosylated proteins natural or unnatural glycosylation sites saccharide side chains Fterm Site proteins sites This provides a general method for the synthesis of homogeneously glycosylated proteins that carry saccharide side chains at natural or unnatural glycosylation sites. 17459925 7 35 gly one 916:918 arg1 glycosylation sites glycosylation sites sites In contrast, ablation of one or both glycosylation sites yielded viruses that replicate and propagate in mosquito cells. 17459925 7 43 gly glycosylation 928:940 arg2 glycosylation sites glycosylation sites sites In contrast, ablation of one or both glycosylation sites yielded viruses that replicate and propagate in mosquito cells. 26420485 1 2 gly glycoprotein 165:176 arg1 The photoreceptor-specific glycoprotein retinal degeneration slow The photoreceptor-specific glycoprotein retinal degeneration slow Fterm glycoprotein The photoreceptor-specific glycoprotein retinal degeneration slow (RDS, also called PRPH2) is necessary for the formation of rod and cone outer segments. 20188224 11 66 part_of PGRN 1558:1561 arg1 four out of five potential PGRN N-glycosylation consensus sites PGRN four out of five potential PGRN N-glycosylation consensus sites PUBTATOR Site PGRN 2896 sites Glycosylation of four out of five potential PGRN N-glycosylation consensus sites was demonstrated (the final one remains undetermined), with one of the four observed to be partially occupied. 20209506 4 90 part_of beta2-GPI 819:827 arg1 beta2-GPI glycopeptides GPI beta2-GPI glycopeptides PUBTATOR Site GPI 350 glycopeptides Conditions for rapid proteolytic digestion of beta2-GPI using low-specificity proteases were optimized to detect beta2-GPI glycopeptides by MS. We demonstrate the importance of ensuring sufficient column capacity of both hydrophobic and hydrophilic stationary phases for optimal glycoprofiling by MS. The enriched glycopeptides were characterized using MALDI quadrupole TOF MS/MS. 17599380 3 78 gly glycosylation 413:425 arg2 position 386 position 386 position 386, Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-associated dementia (HAD) compared with non-HAD patients. 17599380 3 78 gly glycosylation 413:425 arg2 an N-linked glycosylation site an N-linked glycosylation site site Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-associated dementia (HAD) compared with non-HAD patients. 15247302 0 42 gly glycosylation 25:37 arg2 A primate-dominant third glycosylation site beta2-adrenergic receptor site OGER beta2-adrenergic receptor P07550 site A primate-dominant third glycosylation site of the beta2-adrenergic receptor routes receptors to degradation during agonist regulation. 17823199 0 49 gly glycoproteins 40:52 arg1 serum glycoproteins serum glycoproteins Fterm glycoproteins N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. 17823199 0 109 gly N-glycosylation 0:14 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. 15863355 6 67 gly N-glycosylation 949:963 arg2 N-glycosylation sites 1, 3, 4 and 5 N-glycosylation sites 1, 3, 4 and 5 sites RESULTS: Site-specific differences in branching structures were observed among N-glycosylation sites 1, 3, 4 and 5. 25759508 9 83 gly occupancy 1302:1310 arg2 the three O-glycosylation sites the three O-glycosylation sites sites The occupancy of each of the three O-glycosylation sites was found to be ∼10% in six serum-derived IgG3 samples and ∼13% in two monoclonal IgG3 allotypes. 25759508 9 90 gly O-glycosylation 1333:1347 arg2 the three O-glycosylation sites the three O-glycosylation sites sites The occupancy of each of the three O-glycosylation sites was found to be ∼10% in six serum-derived IgG3 samples and ∼13% in two monoclonal IgG3 allotypes. 20011150 9 64 gly glycosylation 1025:1037 arg2 Seven potential glycosylation sites Seven potential glycosylation sites sites Seven potential glycosylation sites in human HA and in some strains of non-human sources have been predicted by computer program, Scan Prosite. 15342690 0 53 gly glycosylation 17:29 arg1 endothelial lipase endothelial lipase PUBTATOR endothelial lipase 9388 Role of N-linked glycosylation in the secretion and activity of endothelial lipase. 3932069 9 62 gly N-glycosylation 1440:1454 arg2 no potential N-glycosylation site no potential N-glycosylation site site In contrast to mouse TNF, it contains no potential N-glycosylation site. 29522492 5 71 part_of site 827:830 arg1 the HA protein protein site Fterm Site protein site The H5N1 viruses acquired enhanced bird-to-human transmissibility by (1) altering amino acids in hemagglutinin (HA) that enable binding affinity to human-type receptors, (2) loss of the glycosylation site and 130 loop in the HA protein and (3) mutation of E627K in the PB2 protein to enhance viral replication in mammalian hosts. 9832151 1 43 gly N-glycosylation 180:194 arg1 rVMAT1 rVMAT1 PUBTATOR rVMAT1 25693 The role of N-glycosylation in the expression, ligand recognition, activity, and intracellular localization of a rat vesicular monoamine transporter (rVMAT1) was investigated. 9832151 1 43 gly N-glycosylation 180:194 arg1 a rat vesicular monoamine transporter a rat vesicular monoamine transporter OGER monoamine transporter Q01827 The role of N-glycosylation in the expression, ligand recognition, activity, and intracellular localization of a rat vesicular monoamine transporter (rVMAT1) was investigated. 32109505 3 75 gly N-glycosylated 390:403 arg1 TRPM8 TRPM8 PUBTATOR TRPM8 79054 TRPM8 is N-glycosylated, with a single site per subunit. 25113421 6 72 gly glycopeptides 780:792 arg2 glycopeptides glycopeptides glycans glycopeptides One consists of isolating glycans from glycopeptides and generating MS/MS spectra of the glycans and peptides separately. 1584795 1 61 part_of nonapeptides 279:290 arg1 oxytocin oxytocin nonapeptides Fterm Site oxytocin nonapeptides Although the nonapeptide hormones vasopressin, oxytocin, and related peptides from vertebrates and some nonapeptides from invertebrates share similarities in amino acid sequence, their evolutionary relationships are not clear. 1584795 1 61 part_of nonapeptides 279:290 arg1 the nonapeptide hormones vasopressin vasopressin nonapeptides Fterm Site vasopressin nonapeptides Although the nonapeptide hormones vasopressin, oxytocin, and related peptides from vertebrates and some nonapeptides from invertebrates share similarities in amino acid sequence, their evolutionary relationships are not clear. 23422691 7 61 gly N-glycosylation 951:965 arg1 the pro region pro region pro region N-glycosylation in the pro region was required for the prepro sequence to promote VEGF secretion. 26573365 4 15 gly glycopeptides 785:797 arg2 purified and labeled glycopeptides purified and labeled glycopeptides glycopeptides We have optimized a protocol for an in-solution trypsin digestion, a one-pot labeling procedure, and a post-labeling solid-phase extraction to obtain purified and labeled glycopeptides. 8496594 5 30 part_of CD69.13 525:531 arg1 The nucleotide sequence CD69 The nucleotide sequence PUBTATOR Site CD69 Q07108 sequence The nucleotide sequence of clone CD69.13 is 1676 bp in length and contains a single open reading frame of 600 bp encoding a protein of 199 amino acids. 10471642 9 66 gly glycoproteins 1478:1490 arg1 glycoproteins glycoproteins Fterm glycoproteins CONCLUSION: Antibodies directed against specific N-glycosylation sites of glycoproteins could be useful for developing more specific immunochemical tests for the diagnosis of chronic alcohol abuse. 10471642 9 10 gly N-glycosylation 1453:1467 arg2 specific N-glycosylation sites glycoproteins sites Fterm glycoproteins sites CONCLUSION: Antibodies directed against specific N-glycosylation sites of glycoproteins could be useful for developing more specific immunochemical tests for the diagnosis of chronic alcohol abuse. 22750213 5 17 part_of PRiMA 859:863 arg1 the asparagine-43 PRiMA the asparagine-43 PUBTATOR SpecificSite PRiMA 170952 asparagine-43 By using site-directed mutagenesis, the asparagine-43 was identified to be the N-linked glycosylation site of PRiMA. 22750213 5 17 part_of PRiMA 859:863 arg1 the N-linked glycosylation site PRiMA the N-linked glycosylation site PUBTATOR Site PRiMA 170952 site By using site-directed mutagenesis, the asparagine-43 was identified to be the N-linked glycosylation site of PRiMA. 7613477 6 91 part_of LCAT 1342:1345 arg1 the LCAT O-linked glycopeptide LCAT the LCAT O-linked glycopeptide PUBTATOR Site LCAT 3931 glycopeptide Two unanticipated O-linked glycosylation sites were identified at Thr407 and Ser409 of the LCAT O-linked glycopeptide, each of which contain sialylated galactose beta 1-->3N-acetylgalactosamine structures. 23296533 2 16 gly glycoproteins 439:451 arg1 glycoproteins glycoproteins Fterm glycoproteins Because abnormal glycosylation is also associated with various pathologies, including cancer, and inflammatory and degenerative diseases, technology for comprehensive analysis of glycoproteins, or glycoproteomics, is important not only for biological studies but also for biomedical and clinical research, including the discovery of biomarkers for disease diagnosis, prognosis, and therapeutic response to drugs. 21698149 6 80 gly glycosylation 1089:1101 arg2 glycosylation sites glycosylation sites sites Phylogenetic relationships were determined for these quasispecies and the length and number of asparagine (N) linked glycosylation sites (NLGS) in their variable loops compared to that for HIV-1B globally. 12388686 5 38 gly DAF 1197:1199 arg1 the sialic acid residues DAF the sialic acid residues OGER DAF P08174 Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface. 12388686 5 26 gly O-glycosylated 1063:1076 arg1 the O-glycosylated domain DAF domain OGER DAF P08174 domain Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface. 12388686 5 52 gly glycosylation 989:1001 arg2 the single N-linked glycosylation site DAF site OGER DAF P08174 site Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface. 12388686 5 52 gly glycosylation 989:1001 arg1 a chimeric receptor protein protein site Fterm protein site Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface. 8382971 7 96 gly glycosylation 1174:1186 arg1 Asn-184 Asn-184 Asn-184 By site-directed mutagenesis of tPA-6, we eliminated variable glycosylation at Asn-184 and engineered a new glycosylation signal at a remnant site in the kringle. 3828456 0 21 part_of glycoprotein 168:179 arg1 the N-glycosylation site glycoprotein the N-glycosylation site Fterm Site glycoprotein site Nuclear magnetic resonance spectroscopic and computer-stimulated structural analyses of a heptapeptide sequence found around the N-glycosylation site of a proline-rich glycoprotein from human parotid saliva. 10580643 1 35 gly site 169:172 arg1 the fourth repeat unit site the fourth repeat unit site An increased degree of utilization of the potential N-glycosylation site in the fourth repeat unit of the human tau protein may be involved in the inability of tau to bind to the corresponding tubulin sequence(s) and in the subsequent development of the paired helical filaments of Alzheimer's disease. 10580643 1 62 gly protein 217:223 arg1 the fourth repeat unit protein the fourth repeat unit Fterm protein An increased degree of utilization of the potential N-glycosylation site in the fourth repeat unit of the human tau protein may be involved in the inability of tau to bind to the corresponding tubulin sequence(s) and in the subsequent development of the paired helical filaments of Alzheimer's disease. 10580643 1 85 gly N-glycosylation 153:167 arg2 the potential N-glycosylation site the potential N-glycosylation site site An increased degree of utilization of the potential N-glycosylation site in the fourth repeat unit of the human tau protein may be involved in the inability of tau to bind to the corresponding tubulin sequence(s) and in the subsequent development of the paired helical filaments of Alzheimer's disease. 8331735 7 3 gly glycosylation 1233:1245 arg2 the TBE pre-M glycosylation site the TBE pre-M glycosylation site site In contrast, ablation of the second DEN4 NS1 glycosylation site or the TBE pre-M glycosylation site or amino acid substitution at two positions in the TBEV E protein increased neurovirulence. 8331735 7 70 gly glycosylation 1197:1209 arg2 the second DEN4 NS1 glycosylation site the second DEN4 NS1 glycosylation site site In contrast, ablation of the second DEN4 NS1 glycosylation site or the TBE pre-M glycosylation site or amino acid substitution at two positions in the TBEV E protein increased neurovirulence. 15199058 2 36 gly glycosylation 429:441 arg2 the glycosylation site the glycosylation site site We have previously identified the importance of amino acid residues in the A-B loop of the Cepsilon3 domain of human IgE and implicated a region close to the glycosylation site at asparagine 371 as contributing to IgE-CD23 interaction. 15199058 2 36 gly glycosylation 429:441 arg2 asparagine 371 asparagine 371 asparagine 371 We have previously identified the importance of amino acid residues in the A-B loop of the Cepsilon3 domain of human IgE and implicated a region close to the glycosylation site at asparagine 371 as contributing to IgE-CD23 interaction. 21153276 7 46 part_of receptor 1177:1184 arg1 extra glycosylation site GnRH receptor extra glycosylation site PUBTATOR Site GnRH receptor 2798 site The GnRH receptor (GnRHR) with extra glycosylation site conferred a markedly enhanced signaling response to agonist. 9030779 0 59 gly N-glycosylation 35:49 arg1 human acid sphingomyelinase acid sphingomyelinase sites PUBTATOR acid sphingomyelinase 6609 sites Functional characterization of the N-glycosylation sites of human acid sphingomyelinase by site-directed mutagenesis. 15590981 7 46 part_of contained 1149:1157 arg1 The mature eLH/CG-R AND one unique seventh N-glycosylation site The mature eLH/CG-R one unique seventh N-glycosylation site PUBTATOR Site LH/CG-R 3973 site The mature eLH/CG-R displayed 88.2-92.8% overall sequence homology with the other mammalian LH/CG-Rs and contained one unique seventh N-glycosylation site in its extracellular domain. 21338062 10 3 gly glycosylated 2295:2306 arg1 glycosylated proteins glycosylated proteins Fterm proteins The PLOT LC-MS system is shown to have sufficient sensitivity to allow characterization of site-specific protein glycosylation from trace levels of glycosylated proteins. 2451667 2 36 part_of glycoprotein 424:435 arg1 the transmembrane and cytoplasmic domains glycoprotein the transmembrane and cytoplasmic domains Fterm Site glycoprotein domains DNA encoding the entire precursor of human chorionic gonadotropin (hCG, alpha subunit) was fused precisely to DNA encoding the transmembrane and cytoplasmic domains of the vesicular stomatitis virus glycoprotein. 17494553 8 55 part_of motif 1001:1005 arg1 the NA stalk region motif the NA stalk region region The virus had a multiple basic amino acid motif at the cleavage site of HA, deletions in the NA stalk region, a five amino acid deletion in the NS1 gene, and genetic markers for amantadine resistance in the M2 gene. 25533529 1 22 gly N-glycosylation 210:224 arg2 four N-glycosylation sites four N-glycosylation sites sites Acutobin, the α-fibrinogenase from Deinagkistrodon acutus venom, contains four N-glycosylation sites with disialylated complex-typed glycans. 25533529 1 26 gly disialylated 237:248 arg1 disialylated complex-typed glycans disialylated complex-typed glycans Acutobin, the α-fibrinogenase from Deinagkistrodon acutus venom, contains four N-glycosylation sites with disialylated complex-typed glycans. 25533529 1 55 gly sites 226:230 arg1 disialylated complex-typed glycans sites disialylated complex-typed glycans sites Acutobin, the α-fibrinogenase from Deinagkistrodon acutus venom, contains four N-glycosylation sites with disialylated complex-typed glycans. 7849028 11 80 gly O-Glycosylation 1604:1618 arg1 this linker region this linker region region O-Glycosylation and phosphorylation of this linker region could provide a dynamic means of altering the conformation of p62 during nuclear pore assembly and disassembly. 11711599 0 72 gly N-glycosylation 107:121 arg2 N-glycosylation sites N-glycosylation sites sites Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. 1457969 5 43 gly present 877:883 arg1 hTSH AND The N-glycans hTSH The N-glycans OGER hTSH The N-glycans present on hTSH were mainly diantennary complex-type structures with a common Man alpha 1-3 branch that terminated with 4-O-sulphated GalNAc. 1457969 5 43 gly present 877:883 arg2 hTSH AND diantennary complex-type structures hTSH diantennary complex-type structures OGER hTSH The N-glycans present on hTSH were mainly diantennary complex-type structures with a common Man alpha 1-3 branch that terminated with 4-O-sulphated GalNAc. 25504159 0 44 gly glycosylation 13:25 arg2 position 158 position 158 position 158 The N-linked glycosylation site at position 158 on the head of hemagglutinin and the virulence of H5N1 avian influenza virus in mice. 25504159 0 44 gly glycosylation 13:25 arg2 The N-linked glycosylation site The N-linked glycosylation site site The N-linked glycosylation site at position 158 on the head of hemagglutinin and the virulence of H5N1 avian influenza virus in mice. 9725224 0 34 gly glycosylation 18:30 arg2 conserved glycosylation site conserved glycosylation site site Role of conserved glycosylation site unique to murine class I MHC in recognition by Ly-49 NK cell receptor. 10524207 2 11 gly attached 323:330 arg2 a small glycosylphosphatidylinositol (GPI) anchored peptide AND a large carbohydrate moiety a small glycosylphosphatidylinositol (GPI) anchored peptide a large carbohydrate moiety peptide It comprises a small glycosylphosphatidylinositol (GPI) anchored peptide to which a large carbohydrate moiety is attached. 1359371 0 14 gly glycoprotein 59:70 arg1 the avian Thy-1 glycoprotein the avian Thy-1 glycoprotein PUBTATOR Thy-1 glycoprotein 7070 Molecular cloning and primary structure of the avian Thy-1 glycoprotein. 7747487 12 16 part_of positions 1552:1560 arg1 antigenic variants variants positions Fterm Site variants positions The positions of mutations in antigenic variants and their antigenicity were determined by parental background genes and VP7 glycosylation. 7747487 12 30 part_of variants 1588:1595 arg1 The positions variants The positions Fterm Site variants positions The positions of mutations in antigenic variants and their antigenicity were determined by parental background genes and VP7 glycosylation. 18083044 4 69 part_of 23-mer 608:613 arg1 a 23-mer fragment mer a 23-mer fragment OGER Site mer Q12866 fragment This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members. 18083044 4 1 part_of contains 583:590 arg1 This deduced protein AND a 23-mer fragment This deduced protein a 23-mer fragment Fterm Site protein fragment This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members. 18083044 4 1 part_of contains 583:590 arg1 This deduced protein AND a glycosylation site This deduced protein a glycosylation site Fterm Site protein site This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members. 18083044 4 1 part_of contains 583:590 arg1 This deduced protein AND transmembrane region This deduced protein transmembrane region Fterm Site protein region This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members. 18083044 4 1 part_of contains 583:590 arg1 This deduced protein AND 231 protein Cys(231) Fterm SpecificSite protein Cys(231) This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members. 2458190 1 0 gly N-glycosylation 299:313 arg2 the N-glycosylation site sequence Asn-Lys-Thr the N-glycosylation site sequence Asn-Lys-Thr site A 57 kd component of oligosaccharyl transferase, termed glycosylation site binding protein, specifically recognizes a photoaffinity probe containing the N-glycosylation site sequence Asn-Lys-Thr. 2458190 1 0 gly N-glycosylation 299:313 arg2 the N-glycosylation site sequence Asn-Lys-Thr the N-glycosylation site sequence Asn-Lys-Thr Asn-Lys-Thr A 57 kd component of oligosaccharyl transferase, termed glycosylation site binding protein, specifically recognizes a photoaffinity probe containing the N-glycosylation site sequence Asn-Lys-Thr. 2458190 1 11 gly glycosylation 202:214 arg2 glycosylation site binding protein glycosylation site binding protein site A 57 kd component of oligosaccharyl transferase, termed glycosylation site binding protein, specifically recognizes a photoaffinity probe containing the N-glycosylation site sequence Asn-Lys-Thr. 3980466 13 76 part_of glycoproteins 2358:2370 arg1 corresponding glycosylation sites glycoproteins corresponding glycosylation sites Fterm Site glycoproteins sites These data suggest that subtle changes in peptide structure are reflected in the extent of sialylation and branching of oligosaccharides found at corresponding glycosylation sites of structurally related glycoproteins. 10952087 4 91 gly N-glycosylation 706:720 arg2 the putative N-glycosylation site the putative N-glycosylation site site Additionally, in pPIC9KFlag deltaGPET(B)Bio the putative N-glycosylation site and a protease site have been deleted by site directed mutagenesis. 15351488 7 73 gly O-glycosylation 1100:1114 arg2 one possible O-glycosylation site one possible O-glycosylation site site Also, one possible O-glycosylation site was identified in Gc (T985). 16227249 10 107 gly glycosylation 1282:1294 arg1 the E protein the E protein Fterm protein Those particles lacking glycosylation on the E protein were modestly more infectious per genome copy on BHK-21 and QT6 cells, while this absence greatly enhanced the infection of C6/36 cells. 8344280 11 45 part_of peptide 1670:1676 arg1 position 4 peptide position 4 position 4, An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins. 8344280 11 52 part_of interferon-beta 1687:1701 arg1 an 11-amino-acid peptide interferon-beta an 11-amino-acid peptide PUBTATOR Site interferon-beta 3456 peptide An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins. 8344280 11 104 part_of position 1706:1713 arg1 human interferon-beta interferon-beta position PUBTATOR Site interferon-beta 3456 position 4, An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins. 8509412 10 39 part_of receptor 1572:1579 arg1 the C-terminal region transferrin receptor the C-terminal region PUBTATOR Site transferrin receptor 7018 region Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface. 21645732 5 29 gly N-glycosites 892:903 arg2 1063 unique N-glycosites 1063 unique N-glycosites N-glycosites As a result, a total of 1063 unique N-glycosites were identified by nano liquid chromatography tandem mass spectrometry, of which 53.0% were unknown in the Swiss-Prot database and 47.1% could be assigned only by either of the methods, confirmed the possibility of large-scale glycoproteomics by use of endoglycosidase. 14699159 2 11 part_of contains 413:420 arg1 a 90-kDa ER transmembrane protein AND three evolutionarily conserved N-linked glycosylation sites a 90-kDa ER transmembrane protein three evolutionarily conserved N-linked glycosylation sites Fterm Site protein sites ATF6, a 90-kDa ER transmembrane protein, contains three evolutionarily conserved N-linked glycosylation sites within its carboxyl luminal domain. 14699159 2 11 part_of contains 413:420 arg1 ATF6 AND three evolutionarily conserved N-linked glycosylation sites ATF6 three evolutionarily conserved N-linked glycosylation sites PUBTATOR Site ATF6 22926 sites ATF6, a 90-kDa ER transmembrane protein, contains three evolutionarily conserved N-linked glycosylation sites within its carboxyl luminal domain. 1380164 7 76 part_of receptors 1126:1134 arg1 The expressed protein fragments receptors The expressed protein fragments Fterm Site receptors fragments The expressed protein fragments of the mongoose, as well as of snake receptors, do not bind alpha-BTX. 9259114 8 59 part_of contained 789:797 arg1 The promoter region AND putative GATA and ets binding motif The promoter region putative GATA and ets binding motif motif The promoter region contained putative GATA and ets binding motif implicated in megakaryocytic expression. 10828967 3 17 gly glycosylation 508:520 arg2 the four potential glycosylation sites the four potential glycosylation sites sites Site-directed mutagenesis of the rat PTH/PTHrP receptor cDNA was performed at single or combination of the four potential glycosylation sites to determine the effect of the putative carbohydrate chains on the activities of the receptor. 26070719 2 12 gly glycosylation 417:429 arg1 proteins proteins Fterm proteins To unveil the structure-function relationship of glycoproteins, glycopeptide-centric analysis using mass spectrometry (MS) has become a method of choice because the glycan is preserved on the glycosylation site and site-specific glycosylation profiles of proteins can be readily determined. 26070719 2 24 gly glycosylation 380:392 arg2 the glycosylation site the glycosylation site site To unveil the structure-function relationship of glycoproteins, glycopeptide-centric analysis using mass spectrometry (MS) has become a method of choice because the glycan is preserved on the glycosylation site and site-specific glycosylation profiles of proteins can be readily determined. 26070719 2 31 gly glycoproteins 237:249 arg1 glycoproteins glycoproteins Fterm glycoproteins To unveil the structure-function relationship of glycoproteins, glycopeptide-centric analysis using mass spectrometry (MS) has become a method of choice because the glycan is preserved on the glycosylation site and site-specific glycosylation profiles of proteins can be readily determined. 9169007 9 58 gly glycosylation 1604:1616 arg2 the mutated glycosylation site the mutated glycosylation site site The extent of heparin-affinity enhancement was correlated with the distance of the mutated glycosylation site to the putative heparin-binding site in the X-ray structure of antithrombin. 7688323 1 17 gly glycoprotein 247:258 arg1 platelet glycoprotein IIb platelet glycoprotein IIb Fterm glycoprotein The human alloantigen system Baka/b is associated with a Ile843-->Ser replacement on platelet glycoprotein IIb, the alpha-subunit of the integrin receptor for fibrinogen (GPIIb/IIIa). 7685769 6 63 gly glycoprotein 1224:1235 arg1 glycoprotein structures glycoprotein structures Fterm glycoprotein The approach described in this report provides a simple and valuable procedure to characterize glycoprotein structures containing simple carbohydrate moieties. 10989127 1 12 gly N-glycosylation 136:150 arg2 conserved hyaluronidase potential N-glycosylation sites conserved hyaluronidase potential N-glycosylation sites sites Evidence for conserved hyaluronidase potential N-glycosylation sites in different mammalian species. 26729457 9 88 gly N-glycopeptides 1622:1636 arg2 Twenty-six out of 30 N-glycopeptides Twenty-six out of 30 N-glycopeptides N-glycopeptides Twenty-six out of 30 N-glycopeptides and four out of five O-glycopeptides carrying >110 different glycoforms could be identified by this optimized LC-ESI tandem MS method with minimal user input. 26729457 9 98 gly O-glycopeptides 1659:1673 arg2 four out of five O-glycopeptides four out of five O-glycopeptides O-glycopeptides Twenty-six out of 30 N-glycopeptides and four out of five O-glycopeptides carrying >110 different glycoforms could be identified by this optimized LC-ESI tandem MS method with minimal user input. 17660510 8 0 gly glycosylation 1277:1289 arg2 platelet glycosylation sites platelet glycosylation sites sites Results on platelet glycosylation sites may imply an impact on research of bleeding disorders as well as potential new functions in inflammation and immunoactivity. 11152692 2 4 gly leucine-rich 177:188 arg1 the leucine-rich repeat family leucine the leucine-rich repeat family leucine Asporin, a novel member of the leucine-rich repeat family of proteins, was partially purified from human articular cartilage and meniscus. 20235580 7 47 gly glycoproteins 1479:1491 arg1 glycoproteins glycoproteins Fterm glycoproteins Despite high capture specificity, the total number of glycoproteins detected and the sensitivity of SPEG in plasma is surprisingly limited. 22586465 10 82 gly glycosylation 1623:1635 arg2 the glycosylation motif the glycosylation motif motif Pathway and function enrichment analysis show that a significant number of proteins that gained or lost the glycosylation motif are involved in kinase activity, immune response, and blood coagulation. 15039521 3 9 part_of preS2 316:320 arg1 The preS2 region preS2 The preS2 region Cterm Site preS2 region The preS2 region of woodchuck hepatitis virus (WHV) contains a potential glycosylation site Asn-Gln-Thr at amino acid (aa) positions 3-5. 15039521 3 15 part_of contains 364:371 arg1 The preS2 region AND a potential glycosylation site The preS2 region a potential glycosylation site site Asn-Gln-Thr The preS2 region of woodchuck hepatitis virus (WHV) contains a potential glycosylation site Asn-Gln-Thr at amino acid (aa) positions 3-5. 18320936 5 3 gly glycosylation 901:913 arg2 glycosylation sites glycosylation sites sites The CVN-MR virus at mouse passage 7 was a mixture of clones, consisting of a single mutation (Asp225Gly) and double mutations (Asn63Ser+Asp225Gly or Asn94a+Asp225Gly), eliminating glycosylation sites. 28661444 10 73 gly glycosylation 1587:1599 arg2 the main glycosylation site the main glycosylation site site Lys30 of Ag85B, identified as the main glycosylation site, proved to be the most important site involved in the formation of T-cell epitopes, reasonably explaining why its glycosylation strongly influenced the T-cell activity. 2328698 9 69 gly N-glycosylation 1181:1195 arg2 one potential N-glycosylation site one potential N-glycosylation site site These data are consistent with the presence of one potential N-glycosylation site derived from the rPLP-B mRNA sequence. 14715137 5 1 part_of synaptotagmin 927:939 arg1 the C(2) domains synaptotagmin 7 the C(2) domains PUBTATOR SpecificSite synaptotagmin 7 9066 C(2) domains In addition to the intraluminal N-glycosylation site, the cytoplasmic C(2) domains of synaptotagmin 1 were required for correct targeting but could be functionally replaced by the C(2) domains of synaptotagmin 7. 14715137 5 21 part_of synaptotagmin 817:829 arg1 the cytoplasmic C(2) domains synaptotagmin 1 the cytoplasmic C(2) domains PUBTATOR SpecificSite synaptotagmin 1 6857 C(2) domains In addition to the intraluminal N-glycosylation site, the cytoplasmic C(2) domains of synaptotagmin 1 were required for correct targeting but could be functionally replaced by the C(2) domains of synaptotagmin 7. 3463996 3 64 part_of residues 691:698 arg1 mature (single chain) cathepsin B cathepsin B residues PUBTATOR AminoAcid cathepsin B 1508 residues in The nucleotide sequences predict that the primary structure of preprocathepsin B contains 339 amino acids organized as follows: a 17-residue NH2-terminal prepeptide sequence followed by a 62-residue propeptide region, 254 residues in mature (single chain) cathepsin B, and a 6-residue extension at the COOH terminus. 3463996 3 90 part_of terminus 776:783 arg1 254 residues terminus 254 residues residues in The nucleotide sequences predict that the primary structure of preprocathepsin B contains 339 amino acids organized as follows: a 17-residue NH2-terminal prepeptide sequence followed by a 62-residue propeptide region, 254 residues in mature (single chain) cathepsin B, and a 6-residue extension at the COOH terminus. 3463996 3 90 part_of terminus 776:783 arg1 a 62-residue propeptide region terminus a 62-residue propeptide region region The nucleotide sequences predict that the primary structure of preprocathepsin B contains 339 amino acids organized as follows: a 17-residue NH2-terminal prepeptide sequence followed by a 62-residue propeptide region, 254 residues in mature (single chain) cathepsin B, and a 6-residue extension at the COOH terminus. 14691230 12 91 part_of DPPIV 1823:1827 arg1 a prerequisite DPPIV a prerequisite PUBTATOR Site DPPIV 1803 prerequisite Taken together, these data indicate that in contrast to the generally accepted view, glycosylation of DPPIV is not a prerequisite for catalysis, dimerization, or ADA binding. 19921957 2 8 gly N-glycosylated 245:258 arg1 N-glycosylated peptides N-glycosylated peptides peptides Three heavy oxygen atoms are introduced into N-glycosylated peptides: two (18)O atoms are incorporated into the carboxyl terminal of all peptides during a tryptic digestion, and the third (18)O atom is incorporated into the N-glycosylation site of asparagines-linked sugar chains specifically via a N-glycosidase F (PNGase F)-mediated hydrolysis. 19921957 2 31 gly asparagines-linked 448:465 arg1 asparagines-linked sugar chains asparagines asparagines-linked sugar chains asparagines Three heavy oxygen atoms are introduced into N-glycosylated peptides: two (18)O atoms are incorporated into the carboxyl terminal of all peptides during a tryptic digestion, and the third (18)O atom is incorporated into the N-glycosylation site of asparagines-linked sugar chains specifically via a N-glycosidase F (PNGase F)-mediated hydrolysis. 19921957 2 93 gly N-glycosylation 424:438 arg1 asparagines-linked sugar chains site asparagines-linked sugar chains site Three heavy oxygen atoms are introduced into N-glycosylated peptides: two (18)O atoms are incorporated into the carboxyl terminal of all peptides during a tryptic digestion, and the third (18)O atom is incorporated into the N-glycosylation site of asparagines-linked sugar chains specifically via a N-glycosidase F (PNGase F)-mediated hydrolysis. 17890101 3 21 gly glycoforms 604:613 arg1 different complex type glycoforms different complex type glycoforms No significant difference in the serum half-life was found between the two antibody glycoforms, nor was any difference observed in the serum half-lives of different complex type glycoforms. 11019861 7 14 gly glycosylation 1271:1283 arg2 an N-linked glycosylation site an N-linked glycosylation site site Moreover 80% of all kappa1 amyloidogenic V(L)s are identifiable by the presence of at least one of three single-site substitutions or the acquisition of an N-linked glycosylation site through mutations. 11876646 8 44 part_of AE1 1257:1259 arg1 the membrane domain AE1 the membrane domain PUBTATOR Site AE1 6521 domain Finally, microsomes were prepared from HEK293 cells expressing the membrane domain of AE1 lacking the normal glycosylation site. 8756556 2 68 part_of cDNA 400:403 arg1 a complementary DNA (cDNA) fragment cDNA a complementary DNA (cDNA) fragment Cterm Site cDNA fragment During investigation of pregnancy stage-specific placental factors by the differential display method, we obtained a complementary DNA (cDNA) fragment (199 bp) encoding a peptide homologous to PRL-like protein (PLP)-C. By using the 3' and 5' rapid amplification of cDNA ends method, a full-length cDNA was cloned and tentatively named PLP-D. 10419504 7 77 gly N-glycosylation 1001:1015 arg2 all four potential N-glycosylation sites all four potential N-glycosylation sites sites However, mutation of all four potential N-glycosylation sites reduced ability to correct the NPC phenotype commensurate with reduced expression of the protein. 20807536 8 60 gly deglycosylate 1128:1140 arg1 ovalbumin ovalbumin Fterm ovalbumin We used both trifluoromethanesulfonic acid and N-glycanase to deglycosylate ovalbumin and tested the effect. 10419504 10 68 gly glycoprotein 1418:1429 arg1 NPC1 NPC1 PUBTATOR NPC1 O15118 We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity. 10419504 10 68 gly glycoprotein 1418:1429 arg1 a glycoprotein a glycoprotein Fterm glycoprotein We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity. 15532026 9 14 part_of site 1591:1594 arg1 the gamma subunit subunit site OGER Site subunit Q9UJJ9 site These data suggest that the loss of the used glycosylation site in the gamma subunit may affect the intracellular localization of GNPTAG and the overall efficiency of M6P formation. 11278567 7 23 gly glycosylation 1215:1227 arg2 this V3 N-linked glycosylation site this V3 N-linked glycosylation site site By comparing the amino acid sequences of primary HIV-1 isolates, we identified a strong association between high V3 charge and the loss of this V3 N-linked glycosylation site. 12970363 5 58 gly glycosylation 842:854 arg1 TRPC6 TRPC6 PUBTATOR TRPC6 7225 To identify potential molecular correlates accounting for the functional difference, we analyzed the glycosylation pattern of TRPC6 compared with TRPC3. 19008394 4 47 gly glycosylated 837:848 arg1 the glycosylated WN19 fusion protein the glycosylated WN19 fusion protein Fterm protein N-linked glycosylation of WN19 was achieved through expression of the peptide as a C-terminal fusion protein in mammalian cells and specific reactivity of WNV-positive horse sera to the glycosylated WN19 fusion protein was shown by Western blot. 23234360 3 12 gly O-glycopeptides 665:679 arg2 O-glycopeptides O-glycopeptides O-glycopeptides Here, we have introduced peptide N-glycosidase F (PNGase F) pretreatment of CSF samples to remove the N-glycans facilitating the selective characterization of O-glycopeptides and enabling the use of an automated CID-MS(2)/MS(3) search protocol for glycopeptide identification. 23234360 3 35 gly glycopeptide 754:765 arg2 glycopeptide identification glycopeptide identification glycopeptide Here, we have introduced peptide N-glycosidase F (PNGase F) pretreatment of CSF samples to remove the N-glycans facilitating the selective characterization of O-glycopeptides and enabling the use of an automated CID-MS(2)/MS(3) search protocol for glycopeptide identification. 18638581 0 85 gly glycoproteins 88:100 arg1 serum glycoproteins serum glycoproteins Fterm glycoproteins Assessment of lectin and HILIC based enrichment protocols for characterization of serum glycoproteins by mass spectrometry. 22122935 8 9 gly glycopeptide 1446:1457 arg2 a reliable glycopeptide map a reliable glycopeptide map glycopeptide This study provided a reliable glycopeptide map of rhEPO and may be regarded as an excellent starting point to analyze rhEPO glycopeptides in biological fluids and detect the use of this hormone in sports. 22122935 8 15 gly glycopeptides 1540:1552 arg2 rhEPO glycopeptides rhEPO glycopeptides glycopeptides This study provided a reliable glycopeptide map of rhEPO and may be regarded as an excellent starting point to analyze rhEPO glycopeptides in biological fluids and detect the use of this hormone in sports. 8093354 3 36 part_of NTT4 365:368 arg1 the amino acid sequence NTT4 the amino acid sequence PUBTATOR Site NTT4 613226 sequence Alignment of the amino acid sequence of NTT4 with other members of the neurotransmitter transporter family revealed a marked deviation from the conserved structure of all other members of the family. 18956678 2 8 part_of HA1 286:288 arg1 The HA1 region HA1 The HA1 region OGER Site HA1 region METHODS: The HA1 region was analyzed by RT-PCR and subsequently sequenced to analyze the HA1 genetic evolution. 15867500 3 9 gly glycosylation 436:448 arg2 Two glycosylation sites Two glycosylation sites sites Two glycosylation sites recovered 2G12 binding completely, but some binding was evident after the reintroduction of a single glycosylation site at Asn295. 15867500 3 10 gly glycosylation 557:569 arg2 a single glycosylation site a single glycosylation site site Two glycosylation sites recovered 2G12 binding completely, but some binding was evident after the reintroduction of a single glycosylation site at Asn295. 15867500 3 10 gly glycosylation 557:569 arg2 Asn295 Asn295 Asn295 Two glycosylation sites recovered 2G12 binding completely, but some binding was evident after the reintroduction of a single glycosylation site at Asn295. 8073631 3 1 gly glycosylation 436:448 arg2 An additional potential N-linked glycosylation site An additional potential N-linked glycosylation site site An additional potential N-linked glycosylation site was added by point mutation, which was supported by the observation that the hemagglutinin of the AK-1 strain was stained more heavily after NaDodSO4-PAGE and periodic acid-Schiff (PAS) staining than the Edmonston strain. 19241033 3 29 gly glycosylation 492:504 arg2 a glycosylation site a glycosylation site site However, no assignment of individual glycans to a glycosylation site can be realized. 16125194 5 37 gly glycosylation 1212:1224 arg2 its potential glycosylation site its potential glycosylation site site To avoid this non-specific reactivity, a non-glycosylated mutant form of cathepsin B, engineered by disrupting its potential glycosylation site, was produced. 16125194 5 13 gly non-glycosylated 1128:1143 arg1 cathepsin B form of cathepsin B OGER form of cathepsin B P07858 To avoid this non-specific reactivity, a non-glycosylated mutant form of cathepsin B, engineered by disrupting its potential glycosylation site, was produced. 23028207 5 8 gly N-glycosylation 883:897 arg2 six out of eight potential N-glycosylation sites six out of eight potential N-glycosylation sites sites In total, six out of eight potential N-glycosylation sites were identified using this approach. 19804409 5 58 gly glycosylation 651:663 arg2 an N-terminal glycosylation site an N-terminal glycosylation site site Insertion of an N-terminal glycosylation site and shortening of the N-terminus improved isoQC secretion 100-fold. 11897784 7 64 gly glycosylation 1263:1275 arg2 the highly conserved N-linked glycosylation site the highly conserved N-linked glycosylation site site Functional and spectral studies suggested that the highly conserved N-linked glycosylation site is not required for proper protein folding and self-association. 9442070 0 42 part_of Fc 62:63 arg1 Fc regions Fc Fc regions Cterm Site Fc regions The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions. 9343410 4 8 gly glycosylation 899:911 arg2 this glycosylation site this glycosylation site site When the model Sp1 peptide was overexpressed in primate cells, this 97-amino-acid domain of Sp1 was found to contain a dominant O-GlcNAc residue at high stoichiometry, which allowed the mapping and mutagenesis of this glycosylation site. 9343410 4 12 gly contain 790:796 arg1 this 97-amino-acid domain AND a dominant O-GlcNAc residue Sp1 domain a dominant O-GlcNAc residue OGER Sp1 Q8N907 domain When the model Sp1 peptide was overexpressed in primate cells, this 97-amino-acid domain of Sp1 was found to contain a dominant O-GlcNAc residue at high stoichiometry, which allowed the mapping and mutagenesis of this glycosylation site. 22072749 11 43 part_of protein 2160:2166 arg1 a single membrane-spanning domain protein a single membrane-spanning domain Fterm Site protein domain Together, these data support the conventional model of SIV envelope as a type Ia transmembrane protein with a single membrane-spanning domain and without any extracellular loops. 8207403 3 65 part_of gp160 657:661 arg1 gp160 sequence gp160 gp160 sequence PUBTATOR Site gp160 2028 sequence Each of the four sites was removed by in vitro mutagenesis of gp160 sequence in the non-infectious viral clone pEVd1443, so that amino acids 616, 621, 642 and 679 were each changed from asparagine to serine. 1512415 1 10 part_of subunits 287:294 arg1 the tripeptide glycosylation recognition sequences subunits the tripeptide glycosylation recognition sequences Fterm Site subunits sequences In recent studies, site-directed mutagenesis has been used to alter the tripeptide glycosylation recognition sequences of glycoprotein hormone subunits, thereby affecting their structure and function. 19284292 3 48 part_of cis-regulatory 786:799 arg1 the glycosylation site cis the glycosylation site OGER Site cis Q9NSE2 site Distinct from these examples, the beta4-GalNAc modification of N-linked glycans on a selected panel of proteins, such as carbonic anhydrase or glycodelin, was demonstrated recently to require specific protein (sequence) determinants proximal to the glycosylation site that function as cis-regulatory elements. 12527303 0 45 gly glycoforms 36:45 arg1 human IgG-Fc glycoforms human IgG-Fc glycoforms Cterm IgG Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. 18602996 4 28 part_of contains 748:755 arg1 ch11HSD1 AND only one N-linked glycosylation site ch11HSD1 only one N-linked glycosylation site Cterm Site 11HSD1 site Its cDNA predicts a protein of 300 amino acids that share 51-56% sequence identity with known mammalian 11HSD1 proteins, while in contrast to most mammals, ch11HSD1 contains only one N-linked glycosylation site. 27259237 5 33 part_of sites 690:694 arg1 3982 proteins proteins sites Fterm Site proteins sites Altogether, 13492 N-glycopeptides containing 8386 N-glycosylation sites on 3982 proteins were identified. 24280012 8 48 part_of observed 882:889 arg1 GoIL-17A AND The six conserved cysteine residues GoIL-17A The six conserved cysteine residues Cterm AminoAcid GoIL-17A 3605 cysteine residues The six conserved cysteine residues were also observed in GoIL-17A. 29980609 7 9 gly glycosylation 1403:1415 arg1 at least one conventional glycosylation site at least one conventional glycosylation site site One atypical and three conventional N-linked glycosylation sites in the AICL C-type lectin-like domain critically impact maturation and surfacing of AICL, which is strictly dependent on glycosylation of at least one conventional glycosylation site. 29980609 7 13 gly glycosylation 1446:1458 arg2 at least one conventional glycosylation site at least one conventional glycosylation site site One atypical and three conventional N-linked glycosylation sites in the AICL C-type lectin-like domain critically impact maturation and surfacing of AICL, which is strictly dependent on glycosylation of at least one conventional glycosylation site. 29980609 7 91 gly glycosylation 1262:1274 arg2 three conventional N-linked glycosylation sites three conventional N-linked glycosylation sites sites One atypical and three conventional N-linked glycosylation sites in the AICL C-type lectin-like domain critically impact maturation and surfacing of AICL, which is strictly dependent on glycosylation of at least one conventional glycosylation site. 10584881 0 35 gly alpha-fetoprotein 28:44 arg1 Glycan composition alpha-fetoprotein Glycan composition PUBTATOR alpha-fetoprotein 174 Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour. 32168410 13 88 gly attached 1596:1603 arg1 FXIII-B AND the glycan moieties FXIII-B the glycan moieties PUBTATOR FXIII-B 2165 CONCLUSION: Characterization of the glycan moieties attached to FXIII-B is reported for the first time. 18700760 1 11 gly O-linked 119:126 arg2 threonine AND Glycans threonine Glycans threonine Glycans that are either N-linked to asparagine or O-linked to serine or threonine are the hallmark of glycoproteins, a class of protein that dominates the mammalian proteome. 18700760 1 11 gly O-linked 119:126 arg2 serine AND Glycans serine Glycans serine Glycans that are either N-linked to asparagine or O-linked to serine or threonine are the hallmark of glycoproteins, a class of protein that dominates the mammalian proteome. 18700760 1 56 gly N-linked 93:100 arg2 asparagine AND Glycans asparagine Glycans asparagine Glycans that are either N-linked to asparagine or O-linked to serine or threonine are the hallmark of glycoproteins, a class of protein that dominates the mammalian proteome. 18700760 1 44 gly glycoproteins 171:183 arg1 Glycans glycoproteins Glycans Fterm glycoproteins Glycans that are either N-linked to asparagine or O-linked to serine or threonine are the hallmark of glycoproteins, a class of protein that dominates the mammalian proteome. 23668542 0 78 gly N-glycosylation 91:105 arg2 additional N-glycosylation sites additional N-glycosylation sites sites Development and analysis of alpha 1-antitrypsin neoglycoproteins: the impact of additional N-glycosylation sites on serum half-life. 23668542 0 92 gly neoglycoproteins 48:63 arg1 alpha 1-antitrypsin neoglycoproteins alpha 1-antitrypsin neoglycoproteins PUBTATOR alpha 1-antitrypsin neoglycoproteins 5265 Development and analysis of alpha 1-antitrypsin neoglycoproteins: the impact of additional N-glycosylation sites on serum half-life. 22691915 3 10 gly N-glycosylation 289:303 arg2 some N-glycosylation sites some N-glycosylation sites sites As a result, some N-glycosylation sites are unoccupied. 8960909 3 64 gly possess 576:582 arg1 natural antigenic epitopes AND N-linked carbohydrate natural antigenic epitopes N-linked carbohydrate epitopes A major question in this regard is whether natural antigenic epitopes that possess N-linked carbohydrate can associate with class I molecules during assembly in the endoplasmic reticulum (ER). 9169007 7 5 part_of antithrombin 1124:1135 arg1 Asn 155 antithrombin Asn 155 PUBTATOR SpecificSite antithrombin 462 Asn 155 These results demonstrate that heterogeneous glycosylation of Asn 155 of recombinant antithrombin is responsible for generating the low heparin affinity glycoform. 16755913 8 39 gly non-N-glycosylation 1429:1447 arg1 the modified PrP the modified PrP OGER PrP F7VJQ1 Moreover, the modified PrP with mono- and non-N-glycosylation were able to be expressed transitantly in Hela cells, which could be a useful means for studying prions. 23069765 5 4 gly O-glycosylation 907:921 arg1 Thr26 Thr26 Thr26 These were caused by unpredicted partial O-glycosylation of Thr26 with the mucin-like structure -GalNAc(-NeuNAc)-Gal-NeuNAc. 22750213 0 45 gly glycosylation 9:21 arg1 globular tetrameric acetylcholinesterase globular tetrameric acetylcholinesterase PUBTATOR acetylcholinesterase 11423 N-linked glycosylation of proline-rich membrane anchor (PRiMA) is not required for assembly and trafficking of globular tetrameric acetylcholinesterase. 22750213 0 45 gly glycosylation 9:21 arg1 PRiMA PRiMA PUBTATOR PRiMA 170952 N-linked glycosylation of proline-rich membrane anchor (PRiMA) is not required for assembly and trafficking of globular tetrameric acetylcholinesterase. 10211957 2 92 gly glycoproteins 362:374 arg1 These glycoproteins These glycoproteins Fterm glycoproteins These glycoproteins interact to form a noncovalent heterodimeric complex, which is retained in the endoplasmic reticulum. 2503511 3 142 gly released 516:523 arg1 the protein AND High mannose and hybrid oligosaccharides protein High mannose and hybrid oligosaccharides Fterm protein High mannose and hybrid oligosaccharides were released from the protein by endoglycosidase H digestion, whereas N-acetyllactosamine-type ("complex") oligosaccharides were released by peptide:N-glycosidase F digestion. 15128311 8 18 gly glycoprotein 960:971 arg1 reduced glycoprotein S-pyridylethylated reduced glycoprotein S-pyridylethylated Fterm glycoprotein MALDI MS of the tryptic digest of reduced glycoprotein S-pyridylethylated at cysteine residues, contained peaks corresponding to all tryptic fragments of CX3, with the exception of fragment 24-30. 26773038 2 38 part_of Ca 351:352 arg1 a Ca(2+)binding site Ca(2 a Ca(2+)binding site OGER Site Ca(2 P00918 site The conformational transition depends upon a Ca(2+)binding site and a vicinal cysteine disulfide bond. 23069765 2 14 part_of protein 467:473 arg1 a melittin signal sequence protein a melittin signal sequence Fterm Site protein sequence Its polypeptide monomer contains one canonical N-glycosylation site at Asn68, and human recombinant IL-17A was partly N-glycosylated when expressed in human kidney (HEK293) cells as a fusion protein with a melittin signal sequence and an N-terminal hexahistidine tag. 9472610 8 63 gly glycosylation 1336:1348 arg2 a glycosylation site a glycosylation site site Sequences from faecal subpopulations of all 7 persons contained a glycosylation site at amino acid position 331-333. 11231274 7 44 gly glycosylation 1511:1523 arg2 the conserved potentially N-linked glycosylation site the conserved potentially N-linked glycosylation site site In addition, we show that, in contrast with CD22 and CD33, mutating the conserved potentially N-linked glycosylation site in the first domain has no effect on binding mediated by siglec-5 or siglec-7. 8029814 10 2 gly cysteine-rich 1389:1401 arg1 four cysteine-rich repeat sequences cysteine four cysteine-rich repeat sequences cysteine Amino acid residues #80-244 are defined as four cysteine-rich repeat sequences homologous to epidermal growth factor. 26911932 1 42 gly glycoprotein 204:215 arg1 a gonadotrope-derived heterodimeric glycoprotein a gonadotrope-derived heterodimeric glycoprotein Fterm glycoprotein Follicle-stimulating hormone (FSH) is a gonadotrope-derived heterodimeric glycoprotein. 2825202 13 85 part_of protein 2010:2016 arg1 the sequence protein the sequence Fterm Site protein sequence A computer search failed to reveal homology between P-2 and the sequence of any other protein; its function is uncertain. 31577193 3 30 gly glycosylated 358:369 arg1 not all N-X-[S/T] sequons not all N-X-[S/T] sequons However, not all N-X-[S/T] sequons in proteins are glycosylated. 20378933 10 23 gly glycosylation 1491:1503 arg1 glycosylation at N58 site N58 site N58 site These data demonstrated that glycosylation at N58 site influenced FcalphaR binding to IgA. 18533687 0 92 gly glycosylation 95:107 arg1 receptor function receptor function Fterm receptor Identification of the N-linked glycosylation sites of the human relaxin receptor and effect of glycosylation on receptor function. 18533687 0 100 gly glycosylation 31:43 arg2 the N-linked glycosylation sites receptor sites Fterm receptor sites Identification of the N-linked glycosylation sites of the human relaxin receptor and effect of glycosylation on receptor function. 27314333 10 39 gly Rspo1 1590:1594 arg1 N-glycan Rspo1 N-glycan PUBTATOR Rspo1 284654 While N-glycan of Rspo1 plays a role in its intracellular stability, it had little effect on secreted Rspo1. 17994628 1 45 gly core-fucosylated 243:258 arg1 biantennary, largely core-fucosylated and partially truncated oligosaccharides biantennary, largely core-fucosylated and partially truncated oligosaccharides All four subclasses of human serum IgG contain a single N-glycosylation site in the constant region of their heavy chain, which is occupied by biantennary, largely core-fucosylated and partially truncated oligosaccharides, that may carry a bisecting N-acetylglucosamine and sialic acid residues. 17994628 1 48 gly occupied 210:217 arg2 a single N-glycosylation site a single N-glycosylation site site All four subclasses of human serum IgG contain a single N-glycosylation site in the constant region of their heavy chain, which is occupied by biantennary, largely core-fucosylated and partially truncated oligosaccharides, that may carry a bisecting N-acetylglucosamine and sialic acid residues. 17994628 1 54 gly N-glycosylation 135:149 arg2 a single N-glycosylation site a single N-glycosylation site site All four subclasses of human serum IgG contain a single N-glycosylation site in the constant region of their heavy chain, which is occupied by biantennary, largely core-fucosylated and partially truncated oligosaccharides, that may carry a bisecting N-acetylglucosamine and sialic acid residues. 11248207 1 61 part_of contains 206:213 arg1 NaDC-1 AND 11 transmembrane domains NaDC-1 11 transmembrane domains OGER Site NaDC-1 Q13183 domains The current secondary structure model of the Na(+)/dicarboxylate cotransporter, NaDC-1, contains 11 transmembrane domains. 28303575 7 27 gly non-glycosylated 874:889 arg1 non-glycosylated isoform B non-glycosylated isoform B Fterm isoform B Glycosylated Dectin-1 isoform A was predominantly localized at the cell surface, non-glycosylated isoform B was retained intracellularly. 12409833 10 68 part_of chymopasin 1027:1036 arg1 The amino acid sequence chymopasin The amino acid sequence PUBTATOR Site chymopasin 117184 sequence The amino acid sequence of rat chymopasin showed 54.5% identity to rat chymotrypsin B. Northern blot analysis showed that the transcript was strongly expressed in the pancreas. 21673010 11 81 gly microheterogeneity 1745:1762 arg1 the N-glycans the N-glycans Transfer of the GAG modification domain from the PG serglycin to the fusion site of rGH-2N and GFP allowed polymerization of GAG chains onto the novel protein variant and influenced the microheterogeneity of the N-glycans toward more acidic glycans, but did not alter the relative site occupancy. 23422691 8 30 part_of VEGF 1096:1099 arg1 the VEGF glycosylation site VEGF the VEGF glycosylation site PUBTATOR Site VEGF 7422 site Furthermore, substitution of asparagine at the VEGF glycosylation site with lysine or glutamic acid increased secretion of non-glycosylated VEGF, a finding not previously reported. 1590788 2 34 gly glycoprotein 298:309 arg1 rat sertoli cell glycoprotein rat sertoli cell glycoprotein Fterm glycoprotein The amino acid sequence predicted by the cDNA sequence revealed that mouse saposin was highly homologous to human saposin and also to rat sertoli cell glycoprotein. 2009266 0 55 part_of thrombin 58:65 arg1 an atypical thrombin cleavage site thrombin an atypical thrombin cleavage site PUBTATOR Site thrombin 395306 site The beta chain of chicken fibrinogen contains an atypical thrombin cleavage site. 32321762 6 59 gly acid 1339:1342 arg1 the side-chain side-chain acid Fterm side-chain Gly-229 in human PrPC does not correspond to Ser-231, the previously reported ω site of Syrian hamster PrPC We found that approximately 41% and 28% of GPI anchors in human PrPCs from human and mouse knock-in brains, respectively, have N-acetylneuraminic acid in the side-chain. 19921957 10 12 gly N-glycosylation 1890:1904 arg2 three N-glycosylation sites three N-glycosylation sites sites Most changes in N-glycosylation at specific sites have the same trends as those of protein expression levels; however, the occupancies of three N-glycosylation sites were significantly changed with no change in proteins levels. 19921957 10 41 gly occupancies 1869:1879 arg2 three N-glycosylation sites three N-glycosylation sites sites Most changes in N-glycosylation at specific sites have the same trends as those of protein expression levels; however, the occupancies of three N-glycosylation sites were significantly changed with no change in proteins levels. 19921957 10 106 gly N-glycosylation 1762:1776 arg1 specific sites sites sites Most changes in N-glycosylation at specific sites have the same trends as those of protein expression levels; however, the occupancies of three N-glycosylation sites were significantly changed with no change in proteins levels. 31577193 4 80 gly N-glycosylation 406:420 arg2 N-glycosylation sites N-glycosylation sites sites Therefore, accurate prediction of N-glycosylation sites is essential to understand Nglycosylation mechanism. 23874792 0 49 gly glycosylation 9:21 arg2 The N276 glycosylation site The N276 glycosylation site site The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody. 25324212 0 24 part_of mucin 113:117 arg1 tumor-associated mucin glycopeptides mucin tumor-associated mucin glycopeptides PUBTATOR Site mucin P15941 glycopeptides Delineating binding modes of Gal/GalNAc and structural elements of the molecular recognition of tumor-associated mucin glycopeptides by the human macrophage galactose-type lectin. 2771955 0 101 gly glycoproteins 70:82 arg1 leucine-rich glycoproteins leucine-rich glycoproteins Fterm glycoproteins Human platelet glycoprotein IX: an adhesive prototype of leucine-rich glycoproteins with flank-center-flank structures. 2771955 0 116 gly glycoprotein 15:26 arg1 Human platelet glycoprotein IX Human platelet glycoprotein IX PUBTATOR platelet glycoprotein IX 2815 Human platelet glycoprotein IX: an adhesive prototype of leucine-rich glycoproteins with flank-center-flank structures. 19008394 7 83 gly glycosylation 1499:1511 arg1 the infecting viral strain the infecting viral strain Fterm strain Together, these results suggest that the induction of antibodies to the WN19 epitope during WNV infection of horses is generally associated with E protein glycosylation of the infecting viral strain. 8349598 1 48 part_of glycoprotein 286:297 arg1 pro-opiomelanocortin glycoprotein pro-opiomelanocortin Fterm AminoAcid glycoprotein pro Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. 24899172 5 68 gly glycosylation 1018:1030 arg2 the glycosylation acceptor site the glycosylation acceptor site site Several positions in the AGL could substitute for position 146 as the glycosylation acceptor site. 23004563 4 21 gly glycopeptides 803:815 arg2 purified immunoglobulin glycopeptides purified immunoglobulin glycopeptides glycopeptides In the analysis of purified immunoglobulin glycopeptides, the energy-resolved oxonium ion profile was shown to clearly distinguish between isomeric glycopeptides. 23004563 4 32 gly glycopeptides 908:920 arg2 isomeric glycopeptides isomeric glycopeptides glycopeptides In the analysis of purified immunoglobulin glycopeptides, the energy-resolved oxonium ion profile was shown to clearly distinguish between isomeric glycopeptides. 23874792 0 0 part_of CD4 72:74 arg1 the CD4 binding site specific HJ16 monoclonal antibody CD4 the CD4 binding site specific HJ16 monoclonal antibody PUBTATOR Site CD4 920 site The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody. 23748959 4 27 gly glycosylation 660:672 arg2 variable loop N-linked glycosylation sites variable loop N-linked glycosylation sites sites This server provides an automated platform for mapping and comparing variable loop N-linked glycosylation sites across populations of HIV-1 sequences. 15816151 4 13 gly HA1 975:977 arg1 position 197 position 197 position 197 Vaccination in autumn 2002 prevented 42% of the URIs during the influenza B outbreak and 71% (95% CI 42-85) of infections interpreted as influenza B. Despite the low genetic variability of the Shangdong/7/97-like viruses, breakages of a potential glycosylation site in haemagglutinin (HA1, position 197) were frequent; their biological significance is discussed. 15816151 4 33 gly glycosylation 937:949 arg2 a potential glycosylation site a potential glycosylation site site Vaccination in autumn 2002 prevented 42% of the URIs during the influenza B outbreak and 71% (95% CI 42-85) of infections interpreted as influenza B. Despite the low genetic variability of the Shangdong/7/97-like viruses, breakages of a potential glycosylation site in haemagglutinin (HA1, position 197) were frequent; their biological significance is discussed. 8941718 6 78 gly N-glycosylation 1118:1132 arg1 an additional N-glycosylation at N271 N271 N271 These data confirmed that an additional N-glycosylation at N271 was responsible for the 56 kDa form of the protein produced from the L273S allele. 7755594 8 32 gly glycosylated 1286:1297 arg1 Fully glycosylated nIFN-gamma Fully glycosylated nIFN-gamma Cterm nIFN-gamma 25712 Fully glycosylated nIFN-gamma and baculovirus Wt and N97Q IFN-gamma showed full or partial resistance to these proteases. 30594968 7 33 gly glycosylation 1141:1153 arg2 the glycosylation sites the glycosylation sites sites HA protein migration demonstrated that the glycosylation sites at amino acid residues 313 and 218 were both functional. 30594968 7 33 gly glycosylation 1141:1153 arg2 amino acid residues 313 and 218 amino acid residues 313 and 218 residues 313 and 218 HA protein migration demonstrated that the glycosylation sites at amino acid residues 313 and 218 were both functional. 30594968 7 74 gly residues 1175:1182 arg1 218 residues 313 and 218 residues 313 and 218 HA protein migration demonstrated that the glycosylation sites at amino acid residues 313 and 218 were both functional. 16891628 10 51 gly glycosylation 1655:1667 arg2 the fourth gp41 glycosylation site the fourth gp41 glycosylation site site Mutation N126K (observed in six enfuvirtide-treated patients, never found at baseline) abrogates the fourth gp41 glycosylation site and correlates with a 2.1-fold CD4 increase at week 24. 30718403 5 61 gly glycosylation 828:840 arg2 a second N-linked glycosylation site a second N-linked glycosylation site site The most striking differences were observed for three substitutions (Q25R, Q40R, and P68T), with P68T generating a second N-linked glycosylation site (N66) in addition to an invariant N32 encoded by all chimpanzee CD4 alleles. 23530821 1 30 part_of contain 277:283 arg1 Premembrane (prM) and envelope (E) proteins AND single potential N-glycosylation site proteins site Fterm Site proteins site Premembrane (prM) and envelope (E) proteins, the major structural proteins of Japanese encephalitis virus (JEV) each contain single potential N-glycosylation site. 8307000 1 105 gly N-glycosylation 279:293 arg2 an additional N-glycosylation site an additional N-glycosylation site site Recombinant human uterine tissue plasminogen activator (tPA) glycosylation mutants carrying an additional N-glycosylation site in the epidermal-growth-factor-like domain due to the replacement of either Tyr67 by Asn (YN-tPA) or Gly60 by Ser (GS-tPA) were expressed in mouse epithelial cells (C127) in the presence of [6-3H]glucosamine. 1651590 2 11 gly glycoprotein 222:233 arg1 The fusion (F) glycoprotein The fusion (F) glycoprotein Fterm glycoprotein The fusion (F) glycoprotein of F1-R is susceptible to activation cleavage by ubiquitous cellular proteases and is thus responsible for pantropism in mice (Tashiro et al., 1988. 1280945 4 19 gly glycoprotein 609:620 arg1 the E2 envelope glycoprotein the E2 envelope glycoprotein Fterm glycoprotein Two amino acid substitutions in the E2 envelope glycoprotein, not seen in either other isolates sequenced, probably contributed to the antigenic difference with respect to other EEEV strains. 9194614 11 61 gly hyperglycosylated 1680:1696 arg1 This rPhl p 1 This rPhl p 1 PUBTATOR rPhl p 1 1423 This rPhl p 1 is hyperglycosylated compared to the nPhl p 1, which only has a 5% carbohydrate content. 9194614 11 7 gly has 1735:1737 arg1 the nPhl p 1 AND a 5% carbohydrate content the nPhl p 1 a 5% carbohydrate content PUBTATOR nPhl p 1 1423 This rPhl p 1 is hyperglycosylated compared to the nPhl p 1, which only has a 5% carbohydrate content. 7914890 0 34 gly Glycosylation 0:12 arg1 arylsulfatase A arylsulfatase A PUBTATOR arylsulfatase A 410 Glycosylation and phosphorylation of arylsulfatase A. 20800224 5 13 part_of NGAL 602:605 arg1 The NGAL sequence NGAL The NGAL sequence PUBTATOR Site NGAL 3934 sequence The NGAL sequence was confirmed by nanoLC/MS/MS following in gel and in solution trypsin digestion, and the N-glycosylation site was localized by MS/MS. 12235182 0 64 part_of apoB 61:64 arg1 the amino terminus apoB the amino terminus PUBTATOR Site apoB 338 terminus The N-linked oligosaccharides at the amino terminus of human apoB are important for the assembly and secretion of VLDL. 28714086 6 26 gly molecular 1002:1010 arg1 the molecular composition position the molecular composition position Our results show that the molecular composition of N-glycans can influence KAR biophysical properties, revealing a potential mechanism for fine-tuning the function of these receptors. 27503338 0 24 gly glycosylation 87:99 arg2 the hemagglutinin head the hemagglutinin head head Re-emergence of H3N2 strains carrying potential neutralizing mutations at the N-linked glycosylation site at the hemagglutinin head, post the 2009 H1N1 pandemic. 27503338 0 24 gly glycosylation 87:99 arg2 the N-linked glycosylation site the N-linked glycosylation site site Re-emergence of H3N2 strains carrying potential neutralizing mutations at the N-linked glycosylation site at the hemagglutinin head, post the 2009 H1N1 pandemic. 26784534 11 85 gly O-glycosylation 1615:1629 arg2 all 10 O-glycosylation sites all 10 O-glycosylation sites sites CONCLUSIONS: This is the first study to describe the qualitative and semi-quantitative distribution of O-glycan structures on all 10 O-glycosylation sites, which will provide a valuable starting point for further studies exploring the functional and structural implications of O-glycosylation in VWF. 23536797 7 85 gly glycosylation 1075:1087 arg2 an O-linked glycosylation site an O-linked glycosylation site site In addition, to eliminate an O-linked glycosylation site in yeast a Ser167Ala mutation was introduced, thus allowing large-scale, homogenous protein production in Pichia pastoris. 27259237 4 3 gly N-glycosylation 435:449 arg2 the N-glycosylation sites the N-glycosylation sites sites In this study, we comprehensively mapped the N-glycosylation sites in the mouse brain proteome by combining complementary methods, which included seven protease treatments, four enrichment techniques and two fractionation strategies. 1584795 6 42 gly glycosylation 1102:1114 arg2 a putative N-linked glycosylation site a putative N-linked glycosylation site site It contains a putative N-linked glycosylation site at a position in the vertebrate neurophysins where a strictly conserved tyrosine residue, which plays an essential role in binding of the nonapeptide hormones, is found. 23919378 6 9 part_of sites 1069:1073 arg1 eIF3L eIF3L sites PUBTATOR Site eIF3L 51386 sites It was also predicted several potential interaction sites in eIF3L, indicating that the protein is likely capable of interacting with other molecules as experimentally shown in other functional studies. 16213030 2 18 part_of EPN 626:628 arg1 an EPN motif EPN an EPN motif OGER Site EPN Q61391 motif Using bioinformatics and molecular cloning techniques, we isolated a bovine gene that encodes a polypeptide of 206 amino acids with structural features shared by mouse and human dectin-2, including a high homology with mouse dectin-2 (66%), a type II configuration, a short cytoplasmic domain without tyrosine-based signal motifs, a carbohydrate recognition domain, a putative N-glycosylation site, and an EPN motif involved in the Ca(2+)-dependent binding of hexose carbohydrates. 16213030 2 18 part_of EPN 626:628 arg1 tyrosine-based signal motifs EPN tyrosine-based signal motifs OGER Site EPN Q61391 motifs Using bioinformatics and molecular cloning techniques, we isolated a bovine gene that encodes a polypeptide of 206 amino acids with structural features shared by mouse and human dectin-2, including a high homology with mouse dectin-2 (66%), a type II configuration, a short cytoplasmic domain without tyrosine-based signal motifs, a carbohydrate recognition domain, a putative N-glycosylation site, and an EPN motif involved in the Ca(2+)-dependent binding of hexose carbohydrates. 21978153 8 45 gly glycosylation 1496:1508 arg2 a new glycosylation site a new glycosylation site site It is of particular interest that Haishu/SWL110/10 and Beijing/SE2649/09, isolated after November 2009, gained a new glycosylation site at the position 179 of HA protein, near the RBD. 21978153 8 45 gly glycosylation 1496:1508 arg2 the position 179 the position 179 position 179 It is of particular interest that Haishu/SWL110/10 and Beijing/SE2649/09, isolated after November 2009, gained a new glycosylation site at the position 179 of HA protein, near the RBD. 15264219 0 49 part_of 5-HT3A 55:60 arg1 the murine 5-HT3A receptor sequence 5-HT3A receptor the murine 5-HT3A receptor sequence PUBTATOR Site 5-HT3A receptor 15561 sequence Three putative N-glycosylation sites within the murine 5-HT3A receptor sequence affect plasma membrane targeting, ligand binding, and calcium influx in heterologous mammalian cells. 15264219 0 75 part_of receptor 62:69 arg1 the murine 5-HT3A receptor sequence 5-HT3A receptor the murine 5-HT3A receptor sequence PUBTATOR Site 5-HT3A receptor 15561 sequence Three putative N-glycosylation sites within the murine 5-HT3A receptor sequence affect plasma membrane targeting, ligand binding, and calcium influx in heterologous mammalian cells. 8638940 4 81 gly alpha-subunit 787:799 arg1 N308 N308 N308 Each subunit of glycosylasparaginase contains one N-linked oligosaccharide (N38, alpha-subunit; N308, beta-subunit). 8638940 4 6 gly contains 743:750 arg1 Each subunit AND one N-linked oligosaccharide Each subunit N38 one N-linked oligosaccharide OGER Each subunit P20933 N38 Each subunit of glycosylasparaginase contains one N-linked oligosaccharide (N38, alpha-subunit; N308, beta-subunit). 26018173 12 90 gly glycoproteins 2181:2193 arg1 The envelope glycoproteins The envelope glycoproteins Fterm glycoproteins The envelope glycoproteins have an extensive coat of carbohydrates (glycans), some of which are recognized by virus-neutralizing antibodies and some of which protect the virus from neutralizing antibodies. 9050863 7 3 part_of sequon 1071:1076 arg1 the pre-S2 domain sequon the pre-S2 domain domain Site-directed mutagenesis provides evidence that virion secretion requires the glycosylation sequon in the pre-S2 domain of M. 23668542 3 3 gly N-glycosylation 634:648 arg2 the three naturally occurring N-glycosylation sites the three naturally occurring N-glycosylation sites sites Utilizing PCR-based site-directed mutagenesis, new A1AT variants were created with single, double, or triple additional N-glycosylation sites to the three naturally occurring N-glycosylation sites. 23668542 3 57 gly N-glycosylation 579:593 arg2 single, double, or triple additional N-glycosylation sites single, double, or triple additional N-glycosylation sites sites Utilizing PCR-based site-directed mutagenesis, new A1AT variants were created with single, double, or triple additional N-glycosylation sites to the three naturally occurring N-glycosylation sites. 15299656 1 14 gly N-glycosylation 247:261 arg2 an N-glycosylation site an N-glycosylation site site To facilitate crystallization of the proform two mutations were introduced: Cys29Ser to avoid self-processing and Ser115Ala to eliminate an N-glycosylation site. 31685900 0 69 gly glycosylation 30:42 arg2 a two-stage N-linked glycosylation site prediction a two-stage N-linked glycosylation site prediction site N-GlyDE: a two-stage N-linked glycosylation site prediction incorporating gapped dipeptides and pattern-based encoding. 10191360 2 65 gly glycosylation 243:255 arg1 voltage-gated K+ channel alpha subunits voltage-gated K+ channel alpha subunits Fterm subunits Here we characterize the asparagine (N)-linked glycosylation of voltage-gated K+ channel alpha subunits in rat brain and transfected cells. 19167329 5 45 gly glycosylation 775:787 arg1 an acceptor site an acceptor site site The STT3B isoform is required for efficient cotranslational glycosylation of an acceptor site adjacent to the N-terminal signal sequence of a secreted protein. 30683699 1 25 gly deglycosylation 338:352 arg1 the unique Asn297 N-X-(T/S) sequon the unique Asn297 N-X-(T/S) sequon sequon In therapeutic applications in which the Fc of IgG is critically important, the receptor binding and functional properties of the Fc are lost after deglycosylation or removal of the unique Asn297 N-X-(T/S) sequon. 8706738 7 48 gly heterogeneity 974:986 arg1 rGal-T rGal-T Analysis by IEF revealed considerable heterogeneity of rGal-T. 17727280 2 40 gly glycoproteins 380:392 arg1 proteolytically digested purified glycoproteins proteolytically digested purified glycoproteins Fterm glycoproteins The input to Peptoonist is a series of mass spectra, both MS and MS/MS, obtained from a liquid chromatography (LC) run of proteolytically digested purified glycoproteins. 22815146 0 30 gly glycosylation 72:84 arg2 the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site site Migration of the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site from N142 to N144 results in loss of antibody cross-reactivity. 8601595 6 62 gly glycosylation 1220:1232 arg2 these potential N-linked glycosylation sites these potential N-linked glycosylation sites sites Mutation of any one of these potential N-linked glycosylation sites abrogates CD44-mediated melanoma cell attachment to hyaluronate-coated surfaces, suggesting that all five sites are necessary to maintain the HA-recognition domain in the appropriate conformation. 26018173 4 30 gly glycoprotein 896:907 arg1 the glycoprotein the glycoprotein Fterm glycoprotein Here we show that exogenous membrane-anchored Envs, which can be produced in large quantities in mammalian cells, also display a virion-like glycan profile, where the glycoprotein is extensively decorated with high-mannose glycans. 20470225 2 21 gly glycosylation 328:340 arg2 O-linked glycosylation sites O-linked glycosylation sites sites As a step toward DNA vaccines, the goal of this work was to determine whether MUC1 peptides substituted with an asparagine at O-linked glycosylation sites, might expose MUC1 peptide backbone to serve as immunogens to generate cytotoxic T lymphocytes (CTL) from peripheral blood mononuclear cells of patients with ADCs. 12877809 4 60 part_of CETP 881:884 arg1 the complete sequence CETP the complete sequence PUBTATOR Site CETP P11597 sequence RESULTS: The sequence of CETP cDNA from tree shrew (GenBank accession number AF334033) covers 1636 bp, including 178 bp at the 3' end of the untranslated region and a 1458 bp fragment in a coding region, which provides the complete sequence of mature tree shrew CETP, although not the initiator methionine. 12877809 4 107 part_of fragment 794:801 arg1 a coding region fragment a coding region region RESULTS: The sequence of CETP cDNA from tree shrew (GenBank accession number AF334033) covers 1636 bp, including 178 bp at the 3' end of the untranslated region and a 1458 bp fragment in a coding region, which provides the complete sequence of mature tree shrew CETP, although not the initiator methionine. 27957769 6 35 gly glycopeptide 1300:1311 arg2 the most extensive glycopeptide libraries the most extensive glycopeptide libraries glycopeptide This is one of the most extensive glycopeptide libraries ever made through total synthesis. 1448922 3 34 gly Asn-glycosylated 535:550 arg1 11.6K 11.6K Asn complex (endo H-resistant) oligosaccharides Cterm 11.6K Asn We show here that 11.6K is Asn-glycosylated with complex (endo H-resistant) oligosaccharides and that 11.6K is an integral membrane protein. 16622833 6 38 gly attached 954:961 arg1 N70 AND triantennary structures N70 triantennary structures N70 Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed. 16622833 6 14 gly present 1015:1021 arg2 the isoforms AND exclusively diantennary structures isoforms site N271 exclusively diantennary structures Fterm isoforms site N271 Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed. 16622833 6 15 gly present 1015:1021 arg2 site N271 AND exclusively diantennary structures site N271 exclusively diantennary structures site N271 Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed. 16622833 6 15 gly present 1015:1021 arg2 the isoforms AND exclusively diantennary structures isoforms site N271 exclusively diantennary structures Fterm isoforms site N271 Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed. 16622833 6 15 gly present 1015:1021 arg2 site N271 AND exclusively diantennary structures isoforms site N271 exclusively diantennary structures Fterm isoforms site N271 Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed. 16622833 6 15 gly present 1015:1021 arg2 the isoforms AND exclusively diantennary structures isoforms site N271 exclusively diantennary structures Fterm isoforms site N271 Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed. 16622833 6 15 gly present 1015:1021 arg2 the isoforms AND exclusively diantennary structures isoforms site N271 exclusively diantennary structures Fterm isoforms site N271 Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed. 18829751 7 52 part_of sequences 1278:1286 arg1 this region sequences this region region Unlike monkeys infected with the parental virus, monkeys infected with the mutant viruses made antibodies that reacted with peptides corresponding to the sequences in this region. 26858738 8 76 gly IgA1 1582:1585 arg1 defined human-type N- IgA1 defined human-type N- PUBTATOR IgA1 P01876 Our data demonstrate that ΔXT/FT N. benthamiana plants can be engineered toward the production of recombinant IgA1 with defined human-type N- and O-linked glycans. 26858738 8 76 gly IgA1 1582:1585 arg1 O-linked glycans IgA1 O-linked glycans PUBTATOR IgA1 P01876 Our data demonstrate that ΔXT/FT N. benthamiana plants can be engineered toward the production of recombinant IgA1 with defined human-type N- and O-linked glycans. 31498587 3 36 gly glycopeptides 439:451 arg2 MUC1 glycopeptides SAPDT*RPAP (T* is the glycosylation site) MUC1 glycopeptides SAPDT*RPAP (T* is the glycosylation site) glycopeptides In order to target these antigens as potential anticancer vaccines, MUC1 glycopeptides SAPDT*RPAP (T* is the glycosylation site) bearing the Tf and the STn antigen, respectively, have been synthesized. 31498587 3 78 gly glycosylation 475:487 arg2 the glycosylation site the glycosylation site site In order to target these antigens as potential anticancer vaccines, MUC1 glycopeptides SAPDT*RPAP (T* is the glycosylation site) bearing the Tf and the STn antigen, respectively, have been synthesized. 31498587 3 90 gly RPAP 459:462 arg1 the glycosylation site the glycosylation site site In order to target these antigens as potential anticancer vaccines, MUC1 glycopeptides SAPDT*RPAP (T* is the glycosylation site) bearing the Tf and the STn antigen, respectively, have been synthesized. 19418565 2 51 gly occupied 495:502 arg2 a N-glycosylation site a N-glycosylation site site Both molecules contain a N-glycosylation site that is variably occupied. 19418565 2 91 gly N-glycosylation 457:471 arg2 a N-glycosylation site a N-glycosylation site site Both molecules contain a N-glycosylation site that is variably occupied. 11676606 4 22 part_of contains 517:524 arg1 Human CD154 AND a single N-linked glycosylation site Human CD154 a single N-linked glycosylation site PUBTATOR Site Human CD154 959 site Human CD154 contains a single N-linked glycosylation site at asparagine 240. 26056814 3 1 gly A/California/07/09 679:696 arg1 The glycan-binding selectivity A/California/07/09 HAs The glycan-binding selectivity OGER A/California/07/09 HAs Q92839 The glycan-binding selectivity of three A/California/07/09 vaccine production strains, and purified recombinant A/California/07/09 HAs harboring these mutations was examined via a solid-phase ELISA assay. 19706343 8 38 gly sialylated 1329:1338 arg1 sialylated biantennary glycan structures sialylated biantennary glycan structures In APS patient samples we observed a decrease in sialylated triantennary glycans and an increase in sialylated biantennary glycan structures, as compared to controls. 19706343 8 82 gly sialylated 1278:1287 arg1 sialylated triantennary glycans sialylated triantennary glycans In APS patient samples we observed a decrease in sialylated triantennary glycans and an increase in sialylated biantennary glycan structures, as compared to controls. 20923142 3 32 gly glycosylation 944:956 arg2 true positive glycosylation sites true positive glycosylation sites sites We successfully used fetuin as a model protein to test the feasibility of this LTL strategy not only to find true positive glycosylation sites but also to obtain accurate quantitative results on the glycosylation changes. 9690810 9 20 gly glycoprotein 970:981 arg1 a leucine-rich glycoprotein sequence a leucine-rich glycoprotein sequence Fterm glycoprotein Mouse GPIX contained a leucine-rich glycoprotein sequence composed of 24 amino acids, as did human GPIX. 16622833 1 46 gly glycoprotein 140:151 arg1 a well-known glycoprotein a well-known glycoprotein Fterm glycoprotein Human alpha1-antitrypsin (A1PI) is a well-known glycoprotein in human plasma important for the protection of tissues from proteolytic enzymes. 16622833 1 46 gly glycoprotein 140:151 arg1 Human alpha1-antitrypsin Human alpha1-antitrypsin PUBTATOR Human alpha1-antitrypsin 5265 Human alpha1-antitrypsin (A1PI) is a well-known glycoprotein in human plasma important for the protection of tissues from proteolytic enzymes. 18829751 10 49 part_of protein 1919:1925 arg1 the ectodomain protein the ectodomain Fterm Site protein ectodomain Based on the reactivity of antibodies to peptides in this region and the colocalization of neutralization escape mutations, we conclude that N-linked carbohydrates in the ectodomain of the transmembrane protein shield underlying epitopes that would otherwise be the direct targets of neutralizing antibodies. 18829751 10 56 part_of peptides 1757:1764 arg1 this region peptides this region region Based on the reactivity of antibodies to peptides in this region and the colocalization of neutralization escape mutations, we conclude that N-linked carbohydrates in the ectodomain of the transmembrane protein shield underlying epitopes that would otherwise be the direct targets of neutralizing antibodies. 23263199 5 76 gly N-glycosylation 668:682 arg2 each N-glycosylation site each N-glycosylation site site To analyze the relevance of each N-glycosylation site, several genomic mutant DNAs encoding a glutamine (Gln/Q) instead of the asparagine residue were created prosperously using site-directed mutagenesis and subsequently expressed in Spodoptera frugiperda cells applying a baculovirus expression system. 27567024 4 36 gly glycosylation 451:463 arg2 the glycosylation site the glycosylation site site In this study, we found that the glycosylation site on EC-SOD is well conserved and that a glycosylation-deficient EC-SOD mutant retains its enzymatic activity, but is not secreted. 25135642 10 2 gly glycosylation 1283:1295 arg2 N-497 site N-497 site N-497 However, mutation of glycosylation site N-497 abrogates transport of ARSG to lysosomes in human fibrosarcoma cells, due to impaired mannose 6-phosphate modification. 21526855 4 79 gly O-glycosylation 771:785 arg2 O-glycosylation sites O-glycosylation sites sites It allows a ladder sequencing from both termini with assignment of O-glycosylation sites based on intense c-, y-, and z-type ions. 8892291 9 7 part_of containing 1229:1238 arg1 recombinant proteins AND these epitopes recombinant proteins these epitopes Fterm Site proteins epitopes The occurrence of neutralization-sensitive epitopes encoded by defined regions of the C. parvum genome suggests that recombinant proteins or synthetic peptides containing these epitopes may prove useful for inducing immune responses that diminish infection. 12087059 6 2 gly N-glycosylated 1359:1372 arg1 N-glycosylated Edg-1 N-glycosylated Edg-1 PUBTATOR Edg-1 1901 Unlike the wild-type receptor, which was associated with the caveolae, nonglycosylated N30D-Edg-1 was dispersed broadly in the membrane fractions separated by sucrose density gradient centrifugation, suggesting that internalization and microdomain localization of N-glycosylated Edg-1 might be related. 12087059 6 24 gly nonglycosylated 1166:1180 arg1 nonglycosylated N30D-Edg-1 nonglycosylated N30D-Edg-1 PUBTATOR Edg-1 1901 Unlike the wild-type receptor, which was associated with the caveolae, nonglycosylated N30D-Edg-1 was dispersed broadly in the membrane fractions separated by sucrose density gradient centrifugation, suggesting that internalization and microdomain localization of N-glycosylated Edg-1 might be related. 21698149 3 2 part_of env 546:548 arg1 the env V1-C4 env the env V1-C4 PUBTATOR SiteSequence env 155971 V1-C4 In this study we investigate the genetic properties of the env V1-C4 of HIV-1B soon after transmission to Trinidadian heterosexuals. 31356638 4 12 gly glycosylated 622:633 arg1 N207Q N207Q residue Cterm N207Q Q9Y6Y0 residue Here we report that mutation of a single glycosylated residue of NS1 (N207Q) abolishes the ability of NS1 to trigger EGL disruption and induce endothelial hyperpermeability. 31356638 4 12 gly glycosylated 622:633 arg1 NS1 NS1 residue OGER NS1 Q9Y6Y0 residue Here we report that mutation of a single glycosylated residue of NS1 (N207Q) abolishes the ability of NS1 to trigger EGL disruption and induce endothelial hyperpermeability. 31113887 3 8 gly glycosylation 519:531 arg2 a glycosylation site a glycosylation site site By surveying the sequence and function of CD4 in 50 chimpanzee individuals, we find that all chimpanzee CD4 alleles encode a fixed, chimpanzee-specific substitution (34T) that creates a glycosylation site on the virus binding surface of the CD4 receptor. 11463517 4 6 part_of protein 791:797 arg1 the N-terminal DNA-binding domain protein the N-terminal DNA-binding domain Fterm Site protein domain We report corrected cDNA sequences and extended open reading frames for the mouse jerky and human JRK/JH8 genes, which add 48 amino acids to the N-terminus of the Jerky protein and which extends the region of homology with the N-terminal DNA-binding domain of the centromere-binding protein, CENP-B. 25452312 3 0 gly glycoproteins 284:296 arg1 vesicle surface glycoproteins vesicle surface glycoproteins Fterm glycoproteins One potential targeting mechanism is adhesion between vesicle surface glycoproteins and target cells. 6267033 2 6 gly glycopeptide 196:207 arg2 a human glycopeptide a human glycopeptide glycopeptide The isolation and complete purification of a human glycopeptide representing the major immunoreactive form of the pituitary NH2-terminal segment of pro-opiomelanocortin is presented. 10441114 7 15 gly asialoglycoprotein 1146:1163 arg1 sialoglycoprotein (22 000 and 21 841 Da +/- 0.02%) and asialoglycoprotein structures sialoglycoprotein (22 000 and 21 841 Da +/- 0.02%) and asialoglycoprotein structures Fterm asialoglycoprotein Circulating endostatins are present as sialoglycoprotein (22 000 and 21 841 Da +/- 0.02%) and asialoglycoprotein structures (21 710 and 21 549 Da +/- 0.02%), while the two completely deglycosylated forms are obtained only after enzymatic incubation. 10441114 7 73 gly sialoglycoprotein 1091:1107 arg1 sialoglycoprotein (22 000 and 21 841 Da +/- 0.02%) and asialoglycoprotein structures sialoglycoprotein (22 000 and 21 841 Da +/- 0.02%) and asialoglycoprotein structures Fterm sialoglycoprotein Circulating endostatins are present as sialoglycoprotein (22 000 and 21 841 Da +/- 0.02%) and asialoglycoprotein structures (21 710 and 21 549 Da +/- 0.02%), while the two completely deglycosylated forms are obtained only after enzymatic incubation. 23632316 7 1 part_of NST/S 1076:1080 arg1 the original NST/S glycosylation site NST the original NST/S glycosylation site OGER Site NST P63046 site We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated. 23632316 7 12 part_of region 1113:1118 arg1 the original NST/S glycosylation site region the original NST/S glycosylation site site We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated. 23632316 7 15 part_of protein 1140:1146 arg1 the Fc region IgG-Fc-ZP3E7 protein the Fc region PUBTATOR Site IgG-Fc-ZP3E7 protein 7784 region We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated. 9757569 1 7 part_of angiotensinogen 165:179 arg1 Ser14 angiotensinogen Ser14 PUBTATOR AminoAcid angiotensinogen P01019 Ser14 A mutant angiotensinogen, S14N, in which Ser14 of ovine angiotensinogen was replaced by Asn to form a N-glycosylation site, was produced in CHO cells. 29353432 10 31 gly glycoproteins 1465:1477 arg1 aberrant glycoproteins aberrant glycoproteins Fterm glycoproteins Graphical abstract Aptamers may specifically differentiate normal from aberrant glycoproteins. 21980282 5 36 part_of CCR5 955:958 arg1 the CCR5 co-receptor-binding region CCR5 the CCR5 co-receptor-binding region PUBTATOR Site CCR5 1234 region We identified signatures near the CCR5 co-receptor-binding region, near the CD4 binding site, and in the signal peptide and cytoplasmic domain, which may influence Env expression and processing. 21980282 5 48 part_of CD4 997:999 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 920 site We identified signatures near the CCR5 co-receptor-binding region, near the CD4 binding site, and in the signal peptide and cytoplasmic domain, which may influence Env expression and processing. 28935113 9 45 gly glycoprotein 1569:1580 arg1 the HIV envelope glycoprotein gp120 the HIV envelope glycoprotein gp120 Fterm glycoprotein The target described here is the HIV broadly neutralizing monoclonal antibody 2G12; 2G12 binds to cluster of high-mannose oligosaccharides on the HIV envelope glycoprotein gp120; and glycopeptides that mimic this epitope may be useful in HIV vaccine applications. 28935113 9 48 gly glycopeptides 1593:1605 arg2 glycopeptides glycopeptides glycopeptides The target described here is the HIV broadly neutralizing monoclonal antibody 2G12; 2G12 binds to cluster of high-mannose oligosaccharides on the HIV envelope glycoprotein gp120; and glycopeptides that mimic this epitope may be useful in HIV vaccine applications. 28935113 9 64 gly oligosaccharides 1532:1547 arg1 the HIV envelope glycoprotein gp120 gp120 oligosaccharides PUBTATOR gp120 155971 The target described here is the HIV broadly neutralizing monoclonal antibody 2G12; 2G12 binds to cluster of high-mannose oligosaccharides on the HIV envelope glycoprotein gp120; and glycopeptides that mimic this epitope may be useful in HIV vaccine applications. 31888963 3 44 part_of CD16a 542:546 arg1 N162 CD16a N162 PUBTATOR SpecificSite CD16a 2214 N162 Furthermore, post-translational modification impacts antibody binding affinity, most notably the composition of the asparagine(N)-linked glycan at N162 of CD16a. 21647803 5 6 gly glycopeptides 749:761 arg2 informative glycopeptides informative glycopeptides glycopeptides Glycoproteins were digested by controlled non-specific proteolysis in order to produce informative glycopeptides. 27127844 12 35 gly unglycosylated 1559:1572 arg1 unglycosylated a4 unglycosylated a4 Cterm a4 Immunofluorescence colocalization data showed that unglycosylated a4 was mostly retained in the ER, and that plasma membrane trafficking was defective. 7768952 3 99 part_of cDNA 381:384 arg1 A cDNA fragment cDNA A cDNA fragment Cterm Site cDNA fragment A cDNA fragment was obtained by polymerase chain reaction using degenerate oligonucleotide primers derived from the NH2-terminal and internal amino acid sequences. 16212939 4 55 part_of IL-1ra 822:827 arg1 Asn84 IL-1ra Asn84 PUBTATOR AminoAcid IL-1ra 3557 Asn84 The mutation of potential N-glycosylation site, by substituting Gln for either Asn7 of N-terminal 24 amino acids of hIL-1beta (Asn7Gln) or Asn84 of IL-1ra (Asn84Gln), resulted in a dramatic reduction of rhG-CSF secretion efficiency. 16212939 4 55 part_of IL-1ra 822:827 arg1 Asn7 IL-1ra Asn7 PUBTATOR AminoAcid IL-1ra 3557 Asn7 The mutation of potential N-glycosylation site, by substituting Gln for either Asn7 of N-terminal 24 amino acids of hIL-1beta (Asn7Gln) or Asn84 of IL-1ra (Asn84Gln), resulted in a dramatic reduction of rhG-CSF secretion efficiency. 31030759 4 47 gly glycosylated 477:488 arg1 heterogeneously glycosylated proteins heterogeneously glycosylated proteins Fterm proteins Unlike structure-defined small molecule-based anti-cancer drugs, the expensive MAb is a mixture of heterogeneously glycosylated proteins. 22688517 3 77 gly N-glycosylation 362:376 arg1 LOX-1 LOX-1 PUBTATOR LOX-1 4973 However, the N-glycosylation pattern of LOX-1 has not been described yet. 11458001 0 41 gly glycoprotein 95:106 arg1 glycoprotein C. Heparan sulfate glycoprotein C. Heparan sulfate Fterm glycoprotein C Mutational analysis of the major heparan sulfate-binding domain of herpes simplex virus type 1 glycoprotein C. Heparan sulfate (HS) has been identified as a receptor molecule for numerous microbial pathogens, including herpes simplex virus type 1 (HSV-1). 9032350 6 36 gly glycosylation 1146:1158 arg2 the glycosylation site the glycosylation site site Furthermore, mutagenesis of the glycosylation site which is positionally conserved in all herpesvirus gH sequences in close proximity to the transmembrane domain generated a recombinant virus that grew in vitro with wild-type single-step kinetics. 18638581 4 31 gly glycopeptides 837:849 arg2 glycopeptides glycopeptides glycopeptides We assessed the utility of lectin-based and HILIC-based affinity enrichment techniques, alone or in combination, for preparation of glycoproteins and glycopeptides for subsequent analysis by MALDI and ESI mass spectrometry. 18638581 4 82 gly glycoproteins 819:831 arg1 glycoproteins glycoproteins Fterm glycoproteins We assessed the utility of lectin-based and HILIC-based affinity enrichment techniques, alone or in combination, for preparation of glycoproteins and glycopeptides for subsequent analysis by MALDI and ESI mass spectrometry. 25170432 9 11 gly N-glycosylation 902:916 arg2 similar N-glycosylation site occupancy similar N-glycosylation site occupancy site The isoforms exhibited similar N-glycosylation site occupancy. 20943674 4 36 gly fucosylated 837:847 arg1 highly branched, highly sialylated and highly fucosylated complex-type structures highly branched, highly sialylated and highly fucosylated complex-type structures N-glycans from hLF are comprised entirely of highly branched, highly sialylated and highly fucosylated complex-type structures, and many contain Lewis(x) epitopes. 20943674 4 51 gly sialylated 815:824 arg1 highly branched, highly sialylated and highly fucosylated complex-type structures highly branched, highly sialylated and highly fucosylated complex-type structures N-glycans from hLF are comprised entirely of highly branched, highly sialylated and highly fucosylated complex-type structures, and many contain Lewis(x) epitopes. 20943674 4 100 gly hLF 761:763 arg1 N-glycans hLF N-glycans PUBTATOR hLF 3131 N-glycans from hLF are comprised entirely of highly branched, highly sialylated and highly fucosylated complex-type structures, and many contain Lewis(x) epitopes. 16823988 9 6 gly sialylated 1222:1231 arg1 Approximately 130 sialylated glycoproteins Approximately 130 sialylated glycoproteins Fterm glycoproteins Approximately 130 sialylated glycoproteins are identified using microLC-MS/MS. 16823988 9 66 gly glycoproteins 1233:1245 arg1 Approximately 130 sialylated glycoproteins Approximately 130 sialylated glycoproteins Fterm glycoproteins Approximately 130 sialylated glycoproteins are identified using microLC-MS/MS. 25793890 8 85 gly glycosylation 1632:1644 arg2 fewer glycosylation sites fewer glycosylation sites sites Previous studies have reported that the length of the V1/V2 domain in transmitted founder viruses is shorter and possesses fewer glycosylation sites compared to viruses isolated from chronic infections. 19619305 5 47 part_of Env 1179:1181 arg1 the V4 region Env the V4 region PUBTATOR Site Env 100616444 region Furthermore, loss of an N-linked glycosylation site at position 386 in the V4 region of Env enhanced macrophage tropism together with b12 sensitivity, but not neutralization by sCD4, b6, or a broadly neutralizing AIDS patient serum. 22885023 3 7 gly N-glycosylation 394:408 arg1 an atypical Asn-Leu-Cys site site site N-glycosylation was found at an atypical Asn-Leu-Cys site. 23776650 10 61 gly glycosylation 1388:1400 arg1 DCIR DCIR region PUBTATOR DCIR 50856 region These results show that glycan binding to DCIR is influenced by the glycosylation of the CRD region in DCIR and that interaction with its ligands result in signaling via its ITIM motif. 20800224 0 43 gly glycoprotein 31:42 arg1 glycoprotein NGAL glycoprotein NGAL Fterm glycoprotein Structural characterization of glycoprotein NGAL, an early predictive biomarker for acute kidney injury. 1400492 7 1 part_of mLAP 759:762 arg1 the mLAP sequence mLAP the mLAP sequence PUBTATOR Site mLAP 13708 sequence A single glycosylation site occurs in the mLAP sequence at a position corresponding to the first glycosylation site of cathepsins D. 1400492 7 18 part_of cathepsins 836:845 arg1 the first glycosylation site cathepsins D the first glycosylation site OGER Site cathepsins D P25774 site A single glycosylation site occurs in the mLAP sequence at a position corresponding to the first glycosylation site of cathepsins D. 21248038 1 18 gly glycosylation 325:337 arg1 gp120 gp120 sites PUBTATOR gp120 3700 sites The broadly neutralizing human monoclonal antibody 2G12 binds to a carbohydrate-dependent epitope involving three major potential N-linked glycosylation sites (PNGS) of gp120 (N295, N332, and N392). 21248038 1 34 gly gp120 355:359 arg1 N295 N295, N332, and N392 N295, N332, and N392 The broadly neutralizing human monoclonal antibody 2G12 binds to a carbohydrate-dependent epitope involving three major potential N-linked glycosylation sites (PNGS) of gp120 (N295, N332, and N392). 21248038 1 34 gly gp120 355:359 arg1 N332 N295, N332, and N392 N295, N332, and N392 The broadly neutralizing human monoclonal antibody 2G12 binds to a carbohydrate-dependent epitope involving three major potential N-linked glycosylation sites (PNGS) of gp120 (N295, N332, and N392). 21248038 1 34 gly gp120 355:359 arg1 N332 N295, N332, and N392 N295, N332, and N392 The broadly neutralizing human monoclonal antibody 2G12 binds to a carbohydrate-dependent epitope involving three major potential N-linked glycosylation sites (PNGS) of gp120 (N295, N332, and N392). 8442916 1 53 part_of env 285:287 arg1 the env region env the env region PUBTATOR Site env 155971 region OBJECTIVE: To gain molecular insights into different HIV-1 strains present in two different states of India, nucleotide sequences derived from the env region of four HIV-1 strains were analysed. 16899459 8 34 part_of laminin 1633:1639 arg1 scattered deposition laminin scattered deposition OGER Site laminin position Functional consequences of the strong reduction of collagen XVII on the cell surface included scattered deposition of cell adhesion molecule laminin 5 into the extracellular environment and, as a consequence of faulty collagen XVII-laminin ligand interactions, aberrant motility of the mutant cells. 8344280 2 76 gly O-glycosylation 287:301 arg2 artificially introduced N-glycosylation or O-glycosylation sites artificially introduced N-glycosylation or O-glycosylation sites sites Human interleukin 2 (IL-2) and human IL-2 mutant proteins, with artificially introduced N-glycosylation or O-glycosylation sites, have been expressed in a lepidopteran cell line (Sf21, Spodoptera frugiperda) using recombinant baculovirus vectors. 8344280 2 79 gly N-glycosylation 268:282 arg1 Human interleukin 2 (IL-2) and human IL-2 mutant proteins Human interleukin 2 (IL-2) and human IL-2 mutant proteins Fterm proteins Human interleukin 2 (IL-2) and human IL-2 mutant proteins, with artificially introduced N-glycosylation or O-glycosylation sites, have been expressed in a lepidopteran cell line (Sf21, Spodoptera frugiperda) using recombinant baculovirus vectors. 1318404 0 0 part_of protein 75:81 arg1 the N-linked glycosylation sites protein the N-linked glycosylation sites Fterm Site protein sites Mutational analysis of the N-linked glycosylation sites of the SU envelope protein of Moloney murine leukemia virus. 10970800 4 43 gly N-glycosylation 418:432 arg2 the two N-glycosylation sites the two N-glycosylation sites sites The current study analysed the role of the two N-glycosylation sites in the rat EP3beta-subtype PGE(2) receptor for protein folding and sorting. 7527739 10 79 part_of protein 1963:1969 arg1 the two hypervariable regions protein the two hypervariable regions Fterm Site protein regions In conclusion, we have identified and characterized two major linear antigenic regions outside the two hypervariable regions of the e2 protein. 12116009 5 32 part_of enzyme 855:860 arg1 the catalytic site enzyme the catalytic site Fterm Site enzyme site The 8 functional and 10 framework residues that compose the catalytic site of the NA enzyme were completely conserved over the study period. 12766998 6 82 gly glycoproteins 1277:1289 arg1 the HCV3a-Gla glycoproteins the HCV3a-Gla glycoproteins OGER Gla glycoproteins P06280 However, neither conformational E2 antibodies nor antibodies raised against E1 were able to detect the HCV3a-Gla glycoproteins. 26656560 11 37 gly N-glycosylation 1589:1603 arg2 the N-glycosylation site the N-glycosylation site site CONCLUSIONS: An individual initially suspected of alcohol abuse based on elevated %CDT was shown to be carrier of a novel mutation in the TF gene that abolishes the N-glycosylation site at position p.N432. 22015153 5 31 part_of N-terminal 813:822 arg1 the N-terminal protein region N-terminal the N-terminal protein region Cterm Site N-terminal region Identities between species range from 74% (mouse) to 80% (human, baboon, and rhesus) within the N-terminal protein region. 22015153 5 86 part_of protein 824:830 arg1 the N-terminal protein region protein the N-terminal protein region Fterm Site protein region Identities between species range from 74% (mouse) to 80% (human, baboon, and rhesus) within the N-terminal protein region. 1736898 2 25 part_of Cysteine 202:209 arg1 Secreted Protein Secreted Protein Cysteine Cterm AminoAcid Secreted Protein P09486 Cysteine SPARC (Secreted Protein, Acidic, Rich in Cysteine) is expressed as a 1.6 kb mRNA in Xenopus laevis. 23069765 4 92 part_of N-glycosylated 837:850 arg1 unglycosylated and N-glycosylated polypeptides N-glycosylated unglycosylated and N-glycosylated polypeptides Cterm Site N-glycosylated polypeptides The mass spectrum of IL-17A monomer also included peaks shifted by +948 Da from the respective masses of unglycosylated and N-glycosylated polypeptides. 25614584 4 23 part_of residues 626:633 arg1 the F protein protein residues Fterm SpecificSite protein residues 221, 323 and 373 By using anti-mumps mAbs, three amino acid positions at residues 221, 323 and 373 in the F protein of mumps virus were shown to be located in at least two conformational neutralization epitopes. 20602265 3 61 part_of epitopes 669:676 arg1 the HA protein protein epitopes Fterm Site protein epitopes We analyzed receptor binding sites, basic patch, neutralization antibody epitopes and T cell epitopes in the HA protein of the current S-OIV according to the corresponding functional and structural modules previously characterized in other H1 HA molecules or HA molecules of other subtypes. 20602265 3 67 part_of epitopes 649:656 arg1 the HA protein protein epitopes Fterm Site protein epitopes We analyzed receptor binding sites, basic patch, neutralization antibody epitopes and T cell epitopes in the HA protein of the current S-OIV according to the corresponding functional and structural modules previously characterized in other H1 HA molecules or HA molecules of other subtypes. 22613618 3 27 gly N-glycosylation 269:283 arg2 Two successive N-glycosylation consensus sites Two successive N-glycosylation consensus sites sites Two successive N-glycosylation consensus sites, N228NS and N229ST, are present on the S1-S2 linker of rat Kv1.3. 2451667 6 74 gly asparagine-linked 1037:1053 arg1 the two asparagine-linked glycans asparagine the two asparagine-linked glycans asparagine Experiments employing in vitro mutagenesis and the glycosylation inhibitor tunicamycin established that the presence of at least one of the two asparagine-linked glycans was required for expression of the anchored molecule on the cell surface. 12755619 7 63 gly N-glycosylation 1258:1272 arg2 a single N-glycosylation site a single N-glycosylation site site Both showed a single N-glycosylation site. 26956484 6 49 gly glycosylation 879:891 arg2 the only glycosylation site Orai1N223A site PUBTATOR Orai1N223A 84876 site Ca(2+) imaging experiments and patch-clamp experiments revealed that mutation of the only glycosylation site of Orai1 (Orai1N223A) enhanced SOCE in Jurkat T cells. 26956484 6 49 gly glycosylation 879:891 arg2 the only glycosylation site Orai1 site PUBTATOR Orai1 84876 site Ca(2+) imaging experiments and patch-clamp experiments revealed that mutation of the only glycosylation site of Orai1 (Orai1N223A) enhanced SOCE in Jurkat T cells. 16227292 1 17 part_of contain 215:221 arg1 The membrane glycoproteins AND three potential sites The membrane glycoproteins three potential sites Fterm Site glycoproteins sites The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc. 16227292 1 17 part_of contain 215:221 arg1 The membrane glycoproteins AND one site The membrane glycoproteins one site Fterm Site glycoproteins site The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc. 16227292 1 17 part_of contain 215:221 arg1 The membrane glycoproteins AND N60 The membrane glycoproteins N60 Fterm SpecificSite glycoproteins N60 The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc. 16227292 1 17 part_of contain 215:221 arg1 Gc AND three potential sites Gc three potential sites Cterm Site Gc sites The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc. 16227292 1 17 part_of contain 215:221 arg1 Gc AND one site Gc one site Cterm Site Gc site The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc. 16227292 1 17 part_of contain 215:221 arg1 Gc AND N60 Gc N60 Cterm SpecificSite Gc N60 The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc. 14711516 8 33 gly glycoproteins 1572:1584 arg1 intact glycoproteins intact glycoproteins Fterm glycoproteins The ability to generate recombinant glycoproteins with restricted carbohydrate heterogeneity is the first step toward the systematic study of structure-function relationships in intact glycoproteins. 14711516 8 60 gly glycoproteins 1423:1435 arg1 recombinant glycoproteins recombinant glycoproteins The ability to generate recombinant glycoproteins with restricted carbohydrate heterogeneity is the first step toward the systematic study of structure-function relationships in intact glycoproteins. 19297464 5 32 gly glycosylation 885:897 arg2 either E2 glycosylation site either E2 glycosylation site site Elimination of either E2 glycosylation site increased virus binding to heparin and increased replication in BHK cells. 26977294 3 32 part_of IgG1 443:446 arg1 The crystallizable fragment IgG1 The crystallizable fragment OGER Site IgG1 P01857 fragment The crystallizable fragment (Fc) of these IgG1 contains a single glycosylation site at Asn 297/300 that is essential for the CDC and ADCC. 26977294 3 72 part_of contains 448:455 arg1 The crystallizable fragment AND a single glycosylation site Fc site Cterm Site Fc site The crystallizable fragment (Fc) of these IgG1 contains a single glycosylation site at Asn 297/300 that is essential for the CDC and ADCC. 1367433 1 64 gly glycoproteins 177:189 arg1 eukaryotic glycoproteins glycoproteins N-linked oligosaccharides Fterm glycoproteins The formation of N-linked oligosaccharides of eukaryotic glycoproteins starts with the attachment of a common precursor at the recognition site Asn-X-Ser/Thr. 8286855 4 7 part_of Ser23 661:665 arg1 GpA GpA Ser23 PUBTATOR AminoAcid GpA 2993 Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 Carbohydrate was absent on Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 in GpA. 8286855 4 13 part_of Ser15 654:658 arg1 GpA GpA Ser15 PUBTATOR AminoAcid GpA 2993 Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 Carbohydrate was absent on Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 in GpA. 8286855 4 18 part_of Ser14 647:651 arg1 GpA GpA Ser14 PUBTATOR AminoAcid GpA 2993 Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 Carbohydrate was absent on Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 in GpA. 8286855 4 25 part_of Ser1 641:644 arg1 GpA GpA Ser1 PUBTATOR AminoAcid GpA 2993 Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 Carbohydrate was absent on Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 in GpA. 8286855 4 63 part_of Thr58 678:682 arg1 GpA GpA Thr58 PUBTATOR AminoAcid GpA 2993 Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 Carbohydrate was absent on Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 in GpA. 8286855 4 69 part_of Thr28 668:672 arg1 GpA GpA Thr28 PUBTATOR AminoAcid GpA 2993 Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 Carbohydrate was absent on Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 in GpA. 10474032 5 23 gly 6-histidine 664:674 arg1 a 6-histidine tag histidine a 6-histidine tag histidine The protein was expressed in Escherichia coli with a 6-histidine tag at its C-terminus. 19822741 2 44 gly glycoprotein 330:341 arg1 glycoprotein glycoprotein Fterm glycoprotein Viral transmission begins with a critical interaction between hemagglutinin (HA) glycoprotein, which is on the viral coat of influenza, and sialic acid (SA) containing glycans, which are on the host cell surface. 19822741 2 29 gly containing 406:415 arg1 HA AND glycans HA glycans Cterm HA Viral transmission begins with a critical interaction between hemagglutinin (HA) glycoprotein, which is on the viral coat of influenza, and sialic acid (SA) containing glycans, which are on the host cell surface. 19822741 2 29 gly containing 406:415 arg1 hemagglutinin AND glycans hemagglutinin glycans Fterm hemagglutinin Viral transmission begins with a critical interaction between hemagglutinin (HA) glycoprotein, which is on the viral coat of influenza, and sialic acid (SA) containing glycans, which are on the host cell surface. 8798624 6 32 gly glycosylation 1564:1576 arg2 a consensus N-linked glycosylation site a consensus N-linked glycosylation site site The residues, Asn23 and Ser25, comprise a consensus N-linked glycosylation site. 1597478 9 1 part_of PDI 1541:1543 arg1 the multifunctional PDI polypeptide PDI the multifunctional PDI polypeptide PUBTATOR Site PDI 5034 polypeptide These data thus suggested that efficient expression of the multifunctional PDI polypeptide is secured by multiple CCAAT elements, some of which appear to be functionally redundant. 3898078 3 43 part_of pre-TNF 459:465 arg1 The 235 amino acid murine pre-TNF polypeptide TNF The 235 amino acid murine pre-TNF polypeptide PUBTATOR Site TNF 21926 polypeptide The 235 amino acid murine pre-TNF polypeptide is 79% homologous to the human pre-TNF protein. 12867358 7 34 gly glycosylation 1221:1233 arg2 the two glycosylation site mutants the two glycosylation site mutants site Although the cell surface abundance of the two glycosylation site mutants, N591Y and N591A, was greater than that of wild-type hNaSi-1, both mutants had greatly reduced Vmax, with no change in Km. 17015441 0 2 part_of contains 36:43 arg1 The cold and menthol receptor TRPM8 AND a functionally important double cysteine motif The cold and menthol receptor TRPM8 a functionally important double cysteine motif PUBTATOR AminoAcid TRPM8 Q7Z2W7 cysteine motif The cold and menthol receptor TRPM8 contains a functionally important double cysteine motif. 7524670 0 34 gly gonadotropin 69:80 arg1 N-linked oligosaccharides chorionic gonadotropin N-linked oligosaccharides OGER chorionic gonadotropin Structural analysis of N-linked oligosaccharides of equine chorionic gonadotropin and lutropin beta-subunits. 7524670 0 102 gly beta-subunits 95:107 arg1 N-linked oligosaccharides lutropin beta N-linked oligosaccharides OGER lutropin beta Structural analysis of N-linked oligosaccharides of equine chorionic gonadotropin and lutropin beta-subunits. 23296533 0 36 gly N-glycosylated 27:40 arg1 N-glycosylated peptides N-glycosylated peptides peptides Stable isotope labeling of N-glycosylated peptides by enzymatic deglycosylation for mass spectrometry-based glycoproteomics. 25452312 13 30 gly glycoproteins 1539:1551 arg1 37 glycoproteins 37 glycoproteins Fterm glycoproteins In total 126 N-glycopeptides from 51 N-glycosylation sites belonging to 37 glycoproteins were found in our results. 25452312 13 35 gly N-glycosylation 1501:1515 arg2 51 N-glycosylation sites 51 N-glycosylation sites sites In total 126 N-glycopeptides from 51 N-glycosylation sites belonging to 37 glycoproteins were found in our results. 25452312 13 93 gly N-glycopeptides 1477:1491 arg1 51 N-glycosylation sites 51 N-glycosylation sites sites In total 126 N-glycopeptides from 51 N-glycosylation sites belonging to 37 glycoproteins were found in our results. 25452312 13 93 gly N-glycopeptides 1477:1491 arg2 126 N-glycopeptides 126 N-glycopeptides N-glycopeptides In total 126 N-glycopeptides from 51 N-glycosylation sites belonging to 37 glycoproteins were found in our results. 8382971 1 71 gly glycosylation 161:173 arg2 a variable glycosylation site a variable glycosylation site site Native tissue plasminogen activator (ntPA) has a variable glycosylation site on its kringle-2 domain. 28922609 12 12 gly FAC 2195:2197 arg1 secreted, glycosylation site secreted, glycosylation site site Conversely, disulfide bond was unique to FAC; secreted, glycosylation site: N-linked, glycosylation, glycoprotein, polymorphism, and sequence variant were associated solely with FAP. 28922609 12 76 gly glycoprotein 2255:2266 arg1 glycoprotein glycoprotein Fterm glycoprotein Conversely, disulfide bond was unique to FAC; secreted, glycosylation site: N-linked, glycosylation, glycoprotein, polymorphism, and sequence variant were associated solely with FAP. 8918585 8 60 gly N-glycosylation 1293:1307 arg2 a N-glycosylation site a N-glycosylation site site, and Thr53 Additional peculiarities were observed in the V region, including a Thr74-->Asn substitution creating a N-glycosylation site, and Thr53-->Ile, which was only reported once among human kappa III chains, in another LCDD case, and may be of special significance at a position usually harbouring a polar amino acid. 28493121 3 6 gly glycoproteins 460:472 arg1 many recombinant glycoproteins many recombinant glycoproteins Fterm glycoproteins Especially important are the N-glycan attachments present on many recombinant glycoproteins of commercial interest. 28493121 3 53 gly present 432:438 arg2 many recombinant glycoproteins AND the N-glycan attachments many recombinant glycoproteins the N-glycan attachments Fterm glycoproteins Especially important are the N-glycan attachments present on many recombinant glycoproteins of commercial interest. 22407978 7 64 gly aglycosylated 1221:1233 arg1 aglycosylated IgGs aglycosylated IgGs Cterm IgGs We show here that under in vitro conditions, which allowed avidity binding, aglycosylated IgGs can bind to one of the FcγRs, FcγRI, and mediate effector functions. 25499076 8 0 gly fucosylated 1507:1517 arg1 fucosylated (90.5%) glycans fucosylated (90.5%) glycans Among the main differences found in the pituitary sample were an extremely low presence of sialylated (1.7%) and a high percentage of sulfated (74.0%) and of fucosylated (90.5%) glycans. 25499076 8 0 gly fucosylated 1507:1517 arg1 90.5% 90.5% Among the main differences found in the pituitary sample were an extremely low presence of sialylated (1.7%) and a high percentage of sulfated (74.0%) and of fucosylated (90.5%) glycans. 19700364 0 3 gly glycoproteins 72:84 arg1 glycoproteins glycoproteins Fterm glycoproteins Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. 19700364 0 17 gly glycosylation 17:29 arg2 glycosylation sites glycosylation sites sites Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. 19700364 0 27 gly heterogeneity 55:67 arg1 glycosylation sites glycosylation sites sites Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. 8837707 3 72 part_of asparagine 451:460 arg1 the protein protein asparagine Fterm AminoAcid protein asparagine One, 1788A-->G, results in the loss of an N-glycosylated asparagine in the protein, and the second, 2723A-->G, removes the polyadenylation signal site of the mRNA. 8407981 9 11 gly glycosylated 1408:1419 arg1 the N terminus the N terminus terminus We conclude that the N terminus of P-450(arom) is translocated across the endoplasmic reticulum membrane to be glycosylated at the luminal side. 22365690 1 19 gly N-glycosylation 272:286 arg2 N-glycosylation site N-glycosylation site site A novel strategy combining iTRAQ with (18)O stable isotope labeling (iTRAQ plus (18)O) was established to identify N-glycosylation site, quantify the glycopeptides and non-glycosylated peptides, and obtain N-glycosylation site ratio on the target glycoprotein. 22365690 1 29 gly N-glycosylation 181:195 arg2 N-glycosylation site N-glycosylation site site A novel strategy combining iTRAQ with (18)O stable isotope labeling (iTRAQ plus (18)O) was established to identify N-glycosylation site, quantify the glycopeptides and non-glycosylated peptides, and obtain N-glycosylation site ratio on the target glycoprotein. 22365690 1 47 gly glycoprotein 313:324 arg1 the target glycoprotein the target glycoprotein Fterm glycoprotein A novel strategy combining iTRAQ with (18)O stable isotope labeling (iTRAQ plus (18)O) was established to identify N-glycosylation site, quantify the glycopeptides and non-glycosylated peptides, and obtain N-glycosylation site ratio on the target glycoprotein. 22365690 1 64 gly glycopeptides 216:228 arg2 the glycopeptides the glycopeptides glycopeptides A novel strategy combining iTRAQ with (18)O stable isotope labeling (iTRAQ plus (18)O) was established to identify N-glycosylation site, quantify the glycopeptides and non-glycosylated peptides, and obtain N-glycosylation site ratio on the target glycoprotein. 22365690 1 75 gly non-glycosylated 234:249 arg1 non-glycosylated peptides non-glycosylated peptides peptides A novel strategy combining iTRAQ with (18)O stable isotope labeling (iTRAQ plus (18)O) was established to identify N-glycosylation site, quantify the glycopeptides and non-glycosylated peptides, and obtain N-glycosylation site ratio on the target glycoprotein. 31511323 0 80 gly N-Glycosylation 0:14 arg1 the voltage-gated sodium channel β2 subunit the voltage-gated sodium channel β2 subunit OGER subunit Q99250 N-Glycosylation of the voltage-gated sodium channel β2 subunit is required for efficient trafficking of NaV1.5/β2 to the plasma membrane. 9063619 3 66 gly glycoproteins 557:569 arg1 glycoproteins glycoproteins Fterm glycoproteins The factors that control the composition of the glycoform populations and the role that heterogeneity plays in the function of glycoproteins are important questions for glycobiology. 7510240 2 57 part_of protein 421:427 arg1 its encoded protein sequence protein its encoded protein sequence Fterm Site protein sequence Expression cloning of the ACT35 antigen from a pCDM8 library of the HUT-102 cell line revealed strong homology of the cDNA and its encoded protein sequence with the formerly described rat OX40 antigen. 19808681 5 53 gly N-glycosylated 610:623 arg1 Kv12.2 Kv12.2 PUBTATOR Kv12.2 23416 We show that Kv12.2 is N-glycosylated in Chinese hamster ovary (CHO) cells and in cultured neurons as well as in the mouse brain. 23891555 21 136 part_of IgA1 3391:3394 arg1 HR O-glycopeptides IgA1 HR O-glycopeptides OGER Site IgA1 P01876 O-glycopeptides The novelty and biological significance reside in the demonstration, for the first time, of the distribution of the most abundant isoforms of HR O-glycopeptides of IgA1. 15811651 6 51 gly glycosylated 969:980 arg2 154 positions 66 and 154 positions 66 and 154 Furthermore, the mutant which was glycosylated at positions 66 and 154 in protein E, the level of secreted E protein was four-fold higher than that of the wild-type. 12954207 0 39 gly deglycosylation 26:40 arg1 HIV-1 gp120 HIV-1 gp120 PUBTATOR HIV-1 gp120 155971 Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. 25707740 5 66 gly N-glycosylation 599:613 arg2 two N-glycosylation sites two N-glycosylation sites sites The α-subunit is identical to the pituitary gonadotropin hormones (LH, FSH, TSH), contains two N-glycosylation sites, and is encoded by a single gene (CGA). 12237688 1 28 gly glycosylated 152:163 arg2 site 25 Asn Asn Asn Human recombinant interferon-gamma(IFN-gamma) is not glycosylated at site 25 Asn or 97 Asn, but its bioactivity is the same as the native one. 12237688 1 28 gly glycosylated 152:163 arg1 Human recombinant interferon-gamma interferon-gamma(IFN-gamma Asn PUBTATOR interferon-gamma(IFN-gamma 3458 Asn Human recombinant interferon-gamma(IFN-gamma) is not glycosylated at site 25 Asn or 97 Asn, but its bioactivity is the same as the native one. 12237688 1 28 gly glycosylated 152:163 arg1 IFN-gamma interferon-gamma(IFN-gamma Asn PUBTATOR interferon-gamma(IFN-gamma 3458 Asn Human recombinant interferon-gamma(IFN-gamma) is not glycosylated at site 25 Asn or 97 Asn, but its bioactivity is the same as the native one. 12237688 1 28 gly glycosylated 152:163 arg1 Human recombinant interferon-gamma interferon-gamma(IFN-gamma Asn PUBTATOR interferon-gamma(IFN-gamma 3458 Asn Human recombinant interferon-gamma(IFN-gamma) is not glycosylated at site 25 Asn or 97 Asn, but its bioactivity is the same as the native one. 12237688 1 28 gly glycosylated 152:163 arg1 IFN-gamma interferon-gamma(IFN-gamma Asn PUBTATOR interferon-gamma(IFN-gamma 3458 Asn Human recombinant interferon-gamma(IFN-gamma) is not glycosylated at site 25 Asn or 97 Asn, but its bioactivity is the same as the native one. 12237688 1 28 gly glycosylated 152:163 arg1 IFN-gamma interferon-gamma(IFN-gamma PUBTATOR interferon-gamma(IFN-gamma 3458 Human recombinant interferon-gamma(IFN-gamma) is not glycosylated at site 25 Asn or 97 Asn, but its bioactivity is the same as the native one. 14520005 3 22 gly glycoprotein 727:738 arg1 this insect glycoprotein this insect glycoprotein Fterm glycoprotein The structural analysis showed that the 350-kDa RJGP bears Galbeta1-3GlcNAcbeta1-4(GlcNAcbeta1-2)Manalpha1-3 (Manalpha1-3Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc, suggesting this insect glycoprotein is one of the substrates for both beta1-3 galactosyl and beta1-4 N-acetylglucosamininyl transferases. 17522223 0 36 part_of site 46:49 arg1 human immunodeficiency virus type 1 gp120 1 gp120 site PUBTATOR Site 1 gp120 155971 site Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. 17522223 0 47 part_of DC-SIGN 30:36 arg1 the optimal DC-SIGN binding site DC-SIGN the optimal DC-SIGN binding site PUBTATOR Site DC-SIGN 30835 site Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. 10099230 3 51 gly glycoprotein 744:755 arg1 Recombinant glycoprotein products Recombinant glycoprotein products Fterm glycoprotein Recombinant glycoprotein products were purified and characterized by amino acid sequencing and carbohydrate structural analysis using matrix-assisted laser desorption ionization time of flight mass spectrometry, high-pH anion-exchange chromatography with pulsed amperometric detection, and methylation analysis. 12069081 5 32 gly glycosylation 724:736 arg2 a potential glycosylation site a potential glycosylation site site Though predicted fVEGF polypeptide was two amino acid residues shorter than human VEGF165, a potential glycosylation site and regions critical for receptor binding were conserved in all the species examined. 21647803 6 43 gly glycopeptides 832:844 arg2 the glycopeptides the glycopeptides glycopeptides High-resolution, isomer-sensitive chromatographic separation of the glycopeptides was achieved using microfluidic chip-based capillaries packed with graphitized carbon. 2429951 4 41 gly glycosylation 517:529 arg2 one potential asparagine-linked glycosylation site one potential asparagine-linked glycosylation site site There is one potential asparagine-linked glycosylation site. 28585084 2 15 gly glycoproteins 384:396 arg1 glycoproteins glycoproteins Fterm glycoproteins This tutorial is aimed at researchers from the fields of molecular biology and biochemistry that have discovered that glycoproteins are important in their biological research and are looking for the tools to elucidate their structure. 12116009 6 72 gly glycosylation 972:984 arg2 the seven conserved asparagine-linked glycosylation sites the seven conserved asparagine-linked glycosylation sites sites All isolates contained the seven conserved asparagine-linked glycosylation sites found in the NA of the progenitor A/Hong Kong/8/68 strain. 8663003 3 15 part_of has 446:448 arg1 The Rh D protein AND two specific bromelain cleavage sites The Rh D protein two specific bromelain cleavage sites PUBTATOR Site Rh D protein 6007 sites The Rh D protein has two specific bromelain cleavage sites located within the first and sixth predicted external domains, with the site of cleavage localized in the sixth domain to lie between residues 353 and 354. 23661698 6 44 gly deglycosylated 911:924 arg1 deglycosylated ephrin-A1 deglycosylated ephrin-A1 PUBTATOR ephrin-A1 1942 Data obtained by surface plasmon resonance confirms that deglycosylated ephrin-A1 does not bind EphA2 with high affinity. 32109505 5 66 gly glycosylation 681:693 arg2 the sole glycosylation site the sole glycosylation site site Here, experimental data performed with deglycosylating agents assess that the sole glycosylation site contains complex glycans with a molecular weight of 2.5 kDa. 32109505 5 35 gly contains 700:707 arg1 the sole glycosylation site AND complex glycans the sole glycosylation site complex glycans site Here, experimental data performed with deglycosylating agents assess that the sole glycosylation site contains complex glycans with a molecular weight of 2.5 kDa. 2844793 0 40 gly glycoprotein 106:117 arg1 a class III membrane glycoprotein a class III membrane glycoprotein Fterm glycoprotein Membrane integration and intracellular transport of the coronavirus glycoprotein E1, a class III membrane glycoprotein. 2844793 0 77 gly glycoprotein 68:79 arg1 the coronavirus glycoprotein E1 the coronavirus glycoprotein E1 Fterm glycoprotein Membrane integration and intracellular transport of the coronavirus glycoprotein E1, a class III membrane glycoprotein. 24104458 8 6 gly glycosylation 911:923 arg2 CEACAM5 glycosylation site CEACAM5 glycosylation site site Therefore, conformational changes in CEACAM5 glycosylation site are critical for its interaction with CD8α. 17916798 3 27 gly glycoproteins 647:659 arg1 low-abundant glycoproteins low-abundant glycoproteins Fterm glycoproteins Thereby, isolation and subsequent identification of low-abundant glycoproteins from serum is a challenging task. 7628611 4 55 part_of KBP 586:588 arg1 two putative membrane spanning regions KBP two putative membrane spanning regions PUBTATOR Site KBP 26128 regions Of particular interest, Asn-265, a residue located between two putative membrane spanning regions of the frog KBP, is a functional N-glycosylation site. 8364023 0 53 gly N-glycosylation 44:58 arg1 human lecithin:cholesterol acyltransferase lecithin:cholesterol acyltransferase sites PUBTATOR lecithin:cholesterol acyltransferase 3931 sites Effects of site-directed mutagenesis on the N-glycosylation sites of human lecithin:cholesterol acyltransferase. 9070436 1 2 part_of CD2 243:245 arg1 the glycosylated human CD2 adhesion domain CD2 the glycosylated human CD2 adhesion domain PUBTATOR Site CD2 914 domain We have used 15N NMR relaxation experiments to probe, for the glycosylated human CD2 adhesion domain, the overall molecular motion, as well as very fast nanosecond-picosecond (ns-ps) and slow millisecond-microsecond (ms-microsecond) internal motions. 31703583 14 23 gly O-glycosylation 2154:2168 arg2 an O-glycosylation site an O-glycosylation site site CONCLUSION: By elimination of an O-glycosylation site, a potential N-glycosylation site, and two proteolytic cleavage sites, an improved N-terminal Pfs230 fragment was produced, termed D1+, which is non-glycosylated, homogeneous, and biologically active. 31703583 14 40 gly N-glycosylation 2188:2202 arg2 a potential N-glycosylation site a potential N-glycosylation site site CONCLUSION: By elimination of an O-glycosylation site, a potential N-glycosylation site, and two proteolytic cleavage sites, an improved N-terminal Pfs230 fragment was produced, termed D1+, which is non-glycosylated, homogeneous, and biologically active. 11410585 1 9 gly glycoproteins 207:219 arg1 the glycoproteins the glycoproteins Fterm glycoproteins The carbohydrate structures present on the glycoproteins in the central and peripheral nerve systems are essential in many cell adhesion processes. 11410585 1 40 gly present 192:198 arg2 the glycoproteins AND The carbohydrate structures the glycoproteins The carbohydrate structures Fterm glycoproteins The carbohydrate structures present on the glycoproteins in the central and peripheral nerve systems are essential in many cell adhesion processes. 25533529 4 49 gly glycosylation 812:824 arg2 each glycosylation site each glycosylation site site Based on homology modeling of acutobin and multiple sequence alignment with various venom thrombin-like enzymes, the importance of a hydrophilic environment at each glycosylation site to the enzyme folding could be rationalized. 16343462 7 33 gly glycopeptides 1297:1309 arg2 glycopeptides glycopeptides glycopeptides Thus, we were able to obtain glycopeptides containing not only two complex-type carbohydrates, but also both complex and high-mannose-type oligosaccharides in a single molecule. 16343462 7 24 gly containing 1311:1320 arg1 glycopeptides AND both complex and high-mannose-type oligosaccharides glycopeptides both complex and high-mannose-type oligosaccharides glycopeptides Thus, we were able to obtain glycopeptides containing not only two complex-type carbohydrates, but also both complex and high-mannose-type oligosaccharides in a single molecule. 16343462 7 24 gly containing 1311:1320 arg1 glycopeptides AND two complex-type carbohydrates glycopeptides two complex-type carbohydrates glycopeptides Thus, we were able to obtain glycopeptides containing not only two complex-type carbohydrates, but also both complex and high-mannose-type oligosaccharides in a single molecule. 19088065 10 62 gly modified 1329:1336 arg3 ovarian cancer-derived KLK6 AND alpha2-6-linked sialic acid ovarian cancer-derived KLK6 alpha2-6-linked sialic acid Cterm KLK6 Using a Sambucus nigra agglutinin-monoclonal antibody sandwich enzyme-linked immunosorbent assay approach, it was shown that ovarian cancer-derived KLK6 was modified with alpha2-6-linked sialic acid. 8841141 5 26 part_of ANP 815:817 arg1 the carboxy terminus ANP the carboxy terminus OGER Site ANP P01160 terminus Bovine NPR-A receptor was then cross-linked to the carboxy terminus of the highly efficient photoaffinity derivative 125I-[Tyr18,Bpa27] rat ANP(1-27). 23028207 4 26 gly N-glycosylation 788:802 arg2 five N-glycosylation sites five N-glycosylation sites sites Endo F3 assisted mass spectrometric analysis yielded five N-glycosylation sites with and without core fucosylation. 20032207 1 11 gly glycosylation 204:216 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site It has been reported that the addition of a potential N-linked glycosylation site (PNGS) to the gp120 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein provides protection against neutralizing antibodies (NAbs) by acting as a 'glycan shield'. 20032207 1 15 gly glycoprotein 296:307 arg1 the gp120 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein the gp120 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein Fterm glycoprotein It has been reported that the addition of a potential N-linked glycosylation site (PNGS) to the gp120 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein provides protection against neutralizing antibodies (NAbs) by acting as a 'glycan shield'. 2985383 5 34 part_of contains 847:854 arg1 mouse urokinase AND no N-glycosylation site mouse urokinase no N-glycosylation site Fterm Site urokinase site However, in contrast to these enzymes, mouse urokinase contains no N-glycosylation site. 12175779 6 3 part_of GLUT11 818:823 arg1 The putative glycosylation site GLUT11 The putative glycosylation site PUBTATOR Site GLUT11 66035 site The putative glycosylation site of GLUT11 is present in loop 1. 19919546 6 18 gly glycoproteins 1264:1276 arg1 These candidate glycoproteins These candidate glycoproteins Fterm glycoproteins These candidate glycoproteins were immunoprecipitated from serum using commercially available antibodies, and their glycan alteration was examined by a lectin microarray. 14563681 3 40 gly N-glycosylation 522:536 arg2 an N-glycosylation site an N-glycosylation site site The polymorphism causes a benign T to A amino acid mutation at position 8 (T8A) that destroys an N-glycosylation site of MiRP1. 20826563 4 0 gly utilized 526:533 arg2 four positions four positions positions In a scan of 15 different positions for N-glycosylation sites, four positions (amino acids 93, 98, 99, and 101) were efficiently utilized and did not influence GH in vitro activity. 20826563 4 9 gly N-glycosylation 437:451 arg2 N-glycosylation sites N-glycosylation sites sites In a scan of 15 different positions for N-glycosylation sites, four positions (amino acids 93, 98, 99, and 101) were efficiently utilized and did not influence GH in vitro activity. 26260331 2 43 gly N-glycosylation 442:456 arg2 an additional potential N-glycosylation site an additional potential N-glycosylation site site Some mutants harboring substitutions to Asn in HBsAg MHR may have an additional potential N-glycosylation site. 8344280 9 75 gly glycopeptide 1169:1180 arg2 the tryptic glycopeptide APTPPPK the tryptic glycopeptide APTPPPK glycopeptide Fast atom bombardment mass spectrometry, compositional analysis and methylation analysis, of the tryptic glycopeptide APTPPPK, revealed the presence of either GalNAc or the disaccharide Gal(beta 1-3)GalNAc as the only carbohydrate constituents attached exclusively to Thr in this peptide, in a specific ratio for each individual IL-2 mutant protein. 8344280 9 110 gly attached 1308:1315 arg2 Thr AND the only carbohydrate constituents Thr the only carbohydrate constituents Thr Fast atom bombardment mass spectrometry, compositional analysis and methylation analysis, of the tryptic glycopeptide APTPPPK, revealed the presence of either GalNAc or the disaccharide Gal(beta 1-3)GalNAc as the only carbohydrate constituents attached exclusively to Thr in this peptide, in a specific ratio for each individual IL-2 mutant protein. 30944176 4 6 part_of site 517:520 arg1 the envelope (E) protein protein site Fterm Site protein site All contemporary ZIKV isolates encode an N-linked glycosylation site in the envelope (E) protein (N154), but this glycosylation site is absent in many historical ZIKV isolates. 15514484 7 17 gly glycosylation 1601:1613 arg2 the site the site site Although the larger oligosaccharides tended to hinder receptor binding, the biodistribution altered by N-glycosylation appeared to enhance the hypocalcemic activity in some cases, and the magnitude of the effect was dependent on the site of glycosylation. 9352200 2 56 part_of pars 233:236 arg1 the pars recta region pars the pars recta region OGER Site pars P07814 region As the unfertilizable coelomic egg transits the pars recta region of the oviduct, it is converted to a fertilizable egg by limited proteolysis of the envelope glycoprotein gp43 to gp41. 28144240 9 54 gly N-glycosylation 1636:1650 arg2 an otherwise conserved N-glycosylation site an otherwise conserved N-glycosylation site site In contrast, substitution of aspartate for asparagine 152 has only a minor effect on surface expression, despite destroying an otherwise conserved N-glycosylation site. 29980609 1 17 gly glycoproteins 123:135 arg1 AICL glycoproteins AICL glycoproteins PUBTATOR AICL glycoproteins 9976 AICL glycoproteins are cognate activation-induced ligands of the C-type lectin-like receptor NKp80, which is expressed on virtually all mature human NK cells, and NKp80-AICL interaction stimulates NK cell effector functions such as cytotoxicity and cytokine secretion. 2477364 13 18 gly sites 1910:1914 arg1 the oligosaccharides sites the oligosaccharides sites By contrast, the majority of the oligosaccharides at both glycosylation sites of the dimer alpha are bound to ConA. 2477364 13 54 gly glycosylation 1896:1908 arg2 both glycosylation sites dimer alpha sites Fterm dimer alpha sites By contrast, the majority of the oligosaccharides at both glycosylation sites of the dimer alpha are bound to ConA. 17095532 4 5 part_of IgE 795:797 arg1 IgE epitopes IgE IgE epitopes PUBTATOR Site IgE 3497 epitopes These reagents also inhibited the interaction of Cit s 1 with patients' sera, thus underlining the critical role of glycosylation in the recognition of this protein by patients' IgE and extending previous data showing that deglycosylated Cit s 1 does not possess IgE epitopes. 17095532 4 65 part_of possess 787:793 arg1 deglycosylated Cit s 1 AND IgE epitopes deglycosylated Cit s 1 IgE epitopes PUBTATOR Site Cit s 1 11113 epitopes These reagents also inhibited the interaction of Cit s 1 with patients' sera, thus underlining the critical role of glycosylation in the recognition of this protein by patients' IgE and extending previous data showing that deglycosylated Cit s 1 does not possess IgE epitopes. 11093789 0 102 gly Glycosylation 0:12 arg1 the gastrin-releasing peptide receptor the gastrin-releasing peptide receptor PUBTATOR gastrin-releasing peptide receptor 14829 Glycosylation of the gastrin-releasing peptide receptor and its effect on expression, G protein coupling, and receptor modulatory processes. 26944735 11 101 gly O-glycosylation 2141:2155 arg2 a previously unknown O-glycosylation site a previously unknown O-glycosylation site site and Asn Further, we report a previously unknown O-glycosylation site and Asn-hydroxylation site, indicating a novel feature of BMP-1 in the EGF domain. 18703501 3 16 part_of IX 548:549 arg1 the CA IX catalytic domain CA IX the CA IX catalytic domain PUBTATOR Site CA IX 768 domain The recombinant proteins consisted of either the CA IX catalytic domain only (CA form) or the extracellular domain, which included both the proteoglycan and catalytic domains (PG + CA form). 18703501 3 66 part_of CA 545:546 arg1 the CA IX catalytic domain CA IX the CA IX catalytic domain PUBTATOR Site CA IX 768 domain The recombinant proteins consisted of either the CA IX catalytic domain only (CA form) or the extracellular domain, which included both the proteoglycan and catalytic domains (PG + CA form). 2295597 1 32 part_of protease 114:121 arg1 Fifty-eight tryptic and Staphylococcus aureus V8 protease generated peptides protease Fifty-eight tryptic and Staphylococcus aureus V8 protease generated peptides Fterm Site protease peptides Fifty-eight tryptic and Staphylococcus aureus V8 protease generated peptides from bovine dopamine beta-hydroxylase were isolated by reverse-phase high pressure liquid chromatography and sequenced. 2295597 1 66 part_of beta-hydroxylase 163:178 arg1 Fifty-eight tryptic and Staphylococcus aureus V8 protease generated peptides dopamine beta-hydroxylase Fifty-eight tryptic and Staphylococcus aureus V8 protease generated peptides PUBTATOR Site dopamine beta-hydroxylase 280758 peptides Fifty-eight tryptic and Staphylococcus aureus V8 protease generated peptides from bovine dopamine beta-hydroxylase were isolated by reverse-phase high pressure liquid chromatography and sequenced. 23530120 5 61 gly glycosylation 861:873 arg2 a conserved glycosylation site a conserved glycosylation site site However, we found that the elimination of a conserved glycosylation site located in Loop D and two glycosylation sites located in variable region 5 of Env allows Env-binding to, and activation of, B cells expressing the germline-reverted BCRs of two potent broadly neutralizing antibodies, VRC01 and NIH45-46. 23530120 5 70 gly glycosylation 906:918 arg2 two glycosylation sites two glycosylation sites sites However, we found that the elimination of a conserved glycosylation site located in Loop D and two glycosylation sites located in variable region 5 of Env allows Env-binding to, and activation of, B cells expressing the germline-reverted BCRs of two potent broadly neutralizing antibodies, VRC01 and NIH45-46. 10856884 8 36 part_of peptide 1057:1063 arg1 a single N-linked glycosylation site peptide a single N-linked glycosylation site site Rat PLP-J cDNA encodes for a predicted 211 amino acid protein containing a 29 amino acid signal peptide and two putative N-linked glycosylation sites, whereas the mouse PLP-J cDNA encodes for a 212 amino acid protein containing a 29 amino acid signal peptide with a single N-linked glycosylation site. 10856884 8 82 part_of containing 1023:1032 arg1 a 212 amino acid protein AND a 29 amino acid signal peptide a 212 amino acid protein a 29 amino acid signal peptide Fterm Site protein peptide Rat PLP-J cDNA encodes for a predicted 211 amino acid protein containing a 29 amino acid signal peptide and two putative N-linked glycosylation sites, whereas the mouse PLP-J cDNA encodes for a 212 amino acid protein containing a 29 amino acid signal peptide with a single N-linked glycosylation site. 10856884 8 31 part_of containing 868:877 arg1 a predicted 211 amino acid protein AND two putative N-linked glycosylation sites a predicted 211 amino acid protein two putative N-linked glycosylation sites Fterm Site protein sites Rat PLP-J cDNA encodes for a predicted 211 amino acid protein containing a 29 amino acid signal peptide and two putative N-linked glycosylation sites, whereas the mouse PLP-J cDNA encodes for a 212 amino acid protein containing a 29 amino acid signal peptide with a single N-linked glycosylation site. 10856884 8 31 part_of containing 868:877 arg1 a predicted 211 amino acid protein AND a 29 amino acid signal peptide a predicted 211 amino acid protein a 29 amino acid signal peptide Fterm Site protein peptide Rat PLP-J cDNA encodes for a predicted 211 amino acid protein containing a 29 amino acid signal peptide and two putative N-linked glycosylation sites, whereas the mouse PLP-J cDNA encodes for a 212 amino acid protein containing a 29 amino acid signal peptide with a single N-linked glycosylation site. 8354274 7 91 part_of enzyme 1106:1111 arg1 The Arg 352 enzyme The Arg 352 Fterm SpecificSite enzyme Arg 352 The Arg 352 of the enzyme was converted to a citrulline residue and the potential Asn-linked glycosylation site (Asn542-Glu543-Ser544) had no carbohydrate moiety. 29162128 2 5 gly glycosylation 259:271 arg2 glycosylation site glycosylation site site A previous study shows that the stem 10/11 overlap glycosylation site of the H5 subtype avian influenza virus may influence the cleavage of HA, whereas the exact site and its effect on virulence remain unclear. 31507595 1 49 part_of Human 88:92 arg1 a small glycopeptide Human CD52 a small glycopeptide PUBTATOR Site Human CD52 P31358 glycopeptide Human CD52 is a small glycopeptide (12 amino acid residues) with one N-linked glycosylation site at asparagine 3 (Asn3) and several potential O-glycosylation serine/threonine sites. 16873272 0 42 part_of receptor-binding 68:83 arg1 the prototype foamy virus envelope glycoprotein receptor-binding domain receptor the prototype foamy virus envelope glycoprotein receptor-binding domain Fterm Site receptor domain Characterization of the prototype foamy virus envelope glycoprotein receptor-binding domain. 16873272 0 102 part_of glycoprotein 55:66 arg1 the prototype foamy virus envelope glycoprotein receptor-binding domain glycoprotein the prototype foamy virus envelope glycoprotein receptor-binding domain Fterm Site glycoprotein domain Characterization of the prototype foamy virus envelope glycoprotein receptor-binding domain. 19629045 7 13 gly glycoprotein 1180:1191 arg1 recombinant glycoprotein engineering recombinant glycoprotein engineering Fterm glycoprotein This embodiment of distinct specificities in single-subunit OTases may have implications for recombinant glycoprotein engineering. 22586465 8 4 part_of have 1229:1232 arg1 1091 proteins AND modified N-glycosylation sequons 1091 proteins modified N-glycosylation sequons Fterm proteins We find that 1091 proteins have modified N-glycosylation sequons due to nsSNVs in the genome. 2844793 4 63 gly glycosylation 672:684 arg1 a newly introduced N-glycosylation site a newly introduced N-glycosylation site site Domain I alone was sufficient to translocate the hydrophilic NH2 terminus of E1 across the membranes as evidenced by glycosylation of a newly introduced N-glycosylation site. 2844793 4 92 gly N-glycosylation 708:722 arg2 a newly introduced N-glycosylation site a newly introduced N-glycosylation site site Domain I alone was sufficient to translocate the hydrophilic NH2 terminus of E1 across the membranes as evidenced by glycosylation of a newly introduced N-glycosylation site. 23853575 1 16 gly glycosylated 279:290 arg1 the already heavily glycosylated HIV gp120 envelope glycoprotein the already heavily glycosylated HIV gp120 envelope glycoprotein Fterm glycoprotein Glycan masking is an emerging vaccine design strategy to focus antibody responses to specific epitopes, but it has mostly been evaluated on the already heavily glycosylated HIV gp120 envelope glycoprotein. 23853575 1 21 gly glycoprotein 311:322 arg1 the already heavily glycosylated HIV gp120 envelope glycoprotein the already heavily glycosylated HIV gp120 envelope glycoprotein Fterm glycoprotein Glycan masking is an emerging vaccine design strategy to focus antibody responses to specific epitopes, but it has mostly been evaluated on the already heavily glycosylated HIV gp120 envelope glycoprotein. 29522492 6 93 part_of HA 986:987 arg1 The receptor binding site HA The receptor binding site Cterm Site HA site The receptor binding site of HA of Egyptian H9N2 viruses has been shown to contain the Q234L substitution along with a H191 mutation, which can increase human-like receptor specificity. 12116009 6 13 part_of found 992:996 arg2 the NA AND the seven conserved asparagine-linked glycosylation sites the NA the seven conserved asparagine-linked glycosylation sites Cterm Site NA sites All isolates contained the seven conserved asparagine-linked glycosylation sites found in the NA of the progenitor A/Hong Kong/8/68 strain. 15033560 7 65 gly glycosylation 1335:1347 arg2 an N-linked glycosylation site an N-linked glycosylation site site Genetic sequence analysis combined with mutagenesis studies on clonal, chimeric viruses derived from CC1/85 and the PTCA variant showed that the most important changes were in the V1/V2 loop structure, one of them involving the loss of an N-linked glycosylation site. 28327546 0 84 gly N-glycosylation 28:42 arg2 the N-glycosylation site the N-glycosylation site site Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII. 28327546 0 84 gly N-glycosylation 28:42 arg2 the A2 domain domain domain Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII. 1533657 7 9 part_of SCR2 1083:1086 arg1 identical sequences SCR2 sequences PUBTATOR Site SCR2 5937 sequences Amino acid comparison of these factor H-related proteins showed identical leader sequences, an exchange of three amino acids in SCR1, identical sequences of SCR2, and a lower degree of homology between SCR3-4 (h24 and h29) and SCR4-5 (h37 and h42). 16002696 8 85 gly glycosylation 1101:1113 arg2 the N-linked glycosylation site the N-linked glycosylation site site Removal of the N-linked glycosylation site from the FcRn H chain resulted in a decreased association of the FcRn H chain for beta(2)m. However, the absence of CNX did not significantly affect FcRn assembly as defined by the ability of FcRn to bind IgG and exit to the cell surface. 23422691 4 3 part_of factor 525:530 arg1 the mating factor α1 (MFα1) signal sequence mating factor α1 (MFα1 the mating factor α1 (MFα1) signal sequence PUBTATOR Site mating factor α1 (MFα1 855914 sequence The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF. 23422691 4 6 part_of MFα1 602:605 arg1 the entire MFα1 prepro signal sequence MFα1 the entire MFα1 prepro signal sequence PUBTATOR Site MFα1 855914 sequence The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF. 23422691 4 43 part_of α1 532:533 arg1 the mating factor α1 (MFα1) signal sequence mating factor α1 (MFα1 the mating factor α1 (MFα1) signal sequence PUBTATOR Site mating factor α1 (MFα1 855914 sequence The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF. 23422691 4 46 part_of mating 518:523 arg1 the mating factor α1 (MFα1) signal sequence mating factor α1 (MFα1 the mating factor α1 (MFα1) signal sequence PUBTATOR Site mating factor α1 (MFα1 855914 sequence The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF. 23422691 4 51 part_of MFα1 536:539 arg1 the mating factor α1 (MFα1) signal sequence mating factor α1 (MFα1 the mating factor α1 (MFα1) signal sequence PUBTATOR Site mating factor α1 (MFα1 855914 sequence The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF. 26956484 0 86 gly glycosylation 19:31 arg1 Orai1 Orai1 PUBTATOR Orai1 84876 Cell type-specific glycosylation of Orai1 modulates store-operated Ca2+ entry. 11015576 6 55 gly N-glycosylation 944:958 arg2 a putative N-glycosylation site a putative N-glycosylation site site This point mutation, an N328I exchange in the extracellular Ig domain III of the receptor, seems to be unique as it affects a putative N-glycosylation site that is conserved between different FGFRs and species. 31501225 0 74 gly N-glycopeptide 0:13 arg2 N-glycopeptide Signatures N-glycopeptide Signatures N-glycopeptide N-glycopeptide Signatures of IgA2 in Serum from Patients with Hepatitis B Virus-related Liver Diseases. 8806496 0 66 gly glycosylation 28:40 arg1 the yellow fever virus NS1 protein NS1 protein sites PUBTATOR NS1 protein 10625 sites Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence. 16938437 0 40 gly N-glycosylation 0:14 arg1 human nicastrin human nicastrin PUBTATOR nicastrin 23385 N-glycosylation of human nicastrin is required for interaction with the lectins from the secretory pathway calnexin and ERGIC-53. 20378933 2 0 gly glycosylation 252:264 arg2 six potential N-linked glycosylation sites six potential N-linked glycosylation sites sites It is a heavily glycosylated protein with six potential N-linked glycosylation sites. 20378933 2 25 gly glycosylated 203:214 arg1 a heavily glycosylated protein a heavily glycosylated protein Fterm protein It is a heavily glycosylated protein with six potential N-linked glycosylation sites. 31514875 0 29 gly heterogeneity 89:101 arg1 a protein a protein Fterm protein Development of Immobilized Enzyme Reactors for the characterization of the glycosylation heterogeneity of a protein. 31514875 0 75 gly glycosylation 75:87 arg1 a protein a protein Fterm protein Development of Immobilized Enzyme Reactors for the characterization of the glycosylation heterogeneity of a protein. 8168913 0 37 gly glycoprotein 71:82 arg1 glycoprotein A glycoprotein A Fterm glycoprotein A Conserved sequence homology of cysteine-rich regions in genes encoding glycoprotein A in Pneumocystis carinii derived from different host species. 27957769 12 15 gly structures 2334:2343 arg1 MUC1 MUC1 structures OGER MUC1 P15941 All antibody sera show high reactivity to the tumor-associated saccharide structures on MUC1. 7609092 11 0 gly glycosylation 1926:1938 arg2 the glycosylation site the glycosylation site site A mutant chimera containing the Thr-435-->Leu substitution, which ablates the potential glycosylation site sequence, produced an E protein identical in size to that of wild-type DEN3 E, indicating that the glycosylation site is normally not used. 7609092 11 52 gly used 1961:1964 arg2 the glycosylation site the glycosylation site site A mutant chimera containing the Thr-435-->Leu substitution, which ablates the potential glycosylation site sequence, produced an E protein identical in size to that of wild-type DEN3 E, indicating that the glycosylation site is normally not used. 7609092 11 12 gly glycosylation 1808:1820 arg2 the potential glycosylation site sequence site sequence site sequence A mutant chimera containing the Thr-435-->Leu substitution, which ablates the potential glycosylation site sequence, produced an E protein identical in size to that of wild-type DEN3 E, indicating that the glycosylation site is normally not used. 17222411 1 36 gly sialoglycoprotein 140:156 arg1 Podoplanin Podoplanin OGER Podoplanin Q86YL7 Podoplanin (Aggrus) is a mucin-type sialoglycoprotein that plays a key role in tumor cell-induced platelet aggregation. 17222411 1 36 gly sialoglycoprotein 140:156 arg1 a mucin-type sialoglycoprotein a mucin-type sialoglycoprotein Fterm sialoglycoprotein Podoplanin (Aggrus) is a mucin-type sialoglycoprotein that plays a key role in tumor cell-induced platelet aggregation. 7980452 2 57 gly glycosylation 444:456 arg2 the potential N-linked glycosylation sites the potential N-linked glycosylation sites sites In order to understand the role of glycan residues in the synthesis and secretion of human IFN-gamma, both or either one of the potential N-linked glycosylation sites were mutated to Gln. 23581850 6 14 gly glycopeptide 752:763 arg2 each identified glycopeptide each identified glycopeptide glycopeptide Further, relative quantification was performed on each identified glycopeptide using stable isotope labeling by amino acids in cell culture (SILAC). 9201996 1 15 gly O-glycosylation 141:155 arg2 mucin-type O-glycosylation sites mucin-type O-glycosylation sites sites The consensus primary amino acid sequence for mucin-type O-glycosylation sites has not been identified. 30889014 0 50 gly glycosylation 52:64 arg2 potential N-linked glycosylation sites potential N-linked glycosylation sites sites Critical amino acid residues and potential N-linked glycosylation sites contribute to circulating recombinant form 01_AE pathogenesis in Northeast China. 26784534 1 25 gly O-glycosylation 77:91 arg1 von Willebrand factor von Willebrand factor PUBTATOR von Willebrand factor 7450 BACKGROUND: O-glycosylation of von Willebrand factor (VWF) affects many of its functions; however, there is currently no information on the occupancy of the 10 putative O-glycosylation sites. 26784534 1 25 gly O-glycosylation 77:91 arg1 VWF VWF PUBTATOR VWF 7450 BACKGROUND: O-glycosylation of von Willebrand factor (VWF) affects many of its functions; however, there is currently no information on the occupancy of the 10 putative O-glycosylation sites. 26784534 1 26 gly occupancy 205:213 arg2 the 10 putative O-glycosylation sites the 10 putative O-glycosylation sites sites BACKGROUND: O-glycosylation of von Willebrand factor (VWF) affects many of its functions; however, there is currently no information on the occupancy of the 10 putative O-glycosylation sites. 26784534 1 76 gly O-glycosylation 234:248 arg2 the 10 putative O-glycosylation sites the 10 putative O-glycosylation sites sites BACKGROUND: O-glycosylation of von Willebrand factor (VWF) affects many of its functions; however, there is currently no information on the occupancy of the 10 putative O-glycosylation sites. 20943674 2 96 gly N-glycosylation 369:383 arg1 rhLF rhLF OGER rhLF P02788 Here we determined the site-specific N-glycosylation profile of human lactoferrin (hLF) and recombinant human lactoferrin (rhLF) expressed in the milk of transgenic cloned cattle. 20943674 2 96 gly N-glycosylation 369:383 arg1 hLF hLF PUBTATOR hLF 3131 Here we determined the site-specific N-glycosylation profile of human lactoferrin (hLF) and recombinant human lactoferrin (rhLF) expressed in the milk of transgenic cloned cattle. 20943674 2 96 gly N-glycosylation 369:383 arg1 human lactoferrin lactoferrin OGER lactoferrin P02788 Here we determined the site-specific N-glycosylation profile of human lactoferrin (hLF) and recombinant human lactoferrin (rhLF) expressed in the milk of transgenic cloned cattle. 8991508 7 67 gly N-glycosylation 761:775 arg2 a putative N-glycosylation site a putative N-glycosylation site site Each repeat begins with a putative N-glycosylation site; hence this domain likely contains both N- and O-linked oligosaccharides. 8991508 7 68 gly contains 808:815 arg1 this domain AND O-linked oligosaccharides this domain O-linked oligosaccharides domain Each repeat begins with a putative N-glycosylation site; hence this domain likely contains both N- and O-linked oligosaccharides. 8991508 7 68 gly contains 808:815 arg1 this domain AND N- this domain N- domain Each repeat begins with a putative N-glycosylation site; hence this domain likely contains both N- and O-linked oligosaccharides. 28931684 12 61 gly glycosylation 2211:2223 arg2 an N-linked glycosylation site an N-linked glycosylation site site All isolates from the recent outbreaks contain an N-linked glycosylation site within the viral envelope (E) protein whereas many isolates of the African lineage virus lack this site. 27506355 12 66 gly N-glycosylation 1610:1624 arg1 recombinant human acetylcholinesterase recombinant human acetylcholinesterase PUBTATOR acetylcholinesterase 43 In addition, we further applied our method to reveal, for the first time, the site-specific N-glycosylation profile of recombinant human acetylcholinesterase expressed in HEK293 cells. 23661698 2 23 part_of ephrin-A1 368:376 arg1 the Asn-26 ephrin-A1 the Asn-26 PUBTATOR SpecificSite ephrin-A1 1942 Asn-26 The crystal structure of the ligand-receptor complex revealed a glycosylation on the Asn-26 of ephrin-A1. 22122935 0 52 part_of erythropoietin 30:43 arg1 recombinant human erythropoietin glycopeptides erythropoietin recombinant human erythropoietin glycopeptides PUBTATOR Site erythropoietin 2056 glycopeptides Analysis of recombinant human erythropoietin glycopeptides by capillary electrophoresis electrospray-time of flight-mass spectrometry. 16883437 6 35 gly glycoprotein 898:909 arg1 the envelope glycoprotein the envelope glycoprotein Fterm glycoprotein The predicted antigenic sites and secondary structure of the envelope glycoprotein of HTLV-1, present in Iran, have been compared with the antigenic sites and secondary structure of the homologous domains in subtypes A, B, C of the virus. 12697062 7 67 gly N-glycosylation 1004:1018 arg2 an N-glycosylation site an N-glycosylation site site We determined that the differential migration exhibited is due to an N-glycosylation site that is present in human (Asn57), monkey and mouse myocilin but absent in rabbit (Ser43), rat and bovine myocilin. 9725224 9 66 gly glycosylation 1364:1376 arg2 This glycosylation site This glycosylation site site This glycosylation site is highly conserved among murine class I MHC but is not found among those of other species, suggesting that its role is unique to the murine immune system. 8486693 2 113 gly glycoprotein 492:503 arg1 a approximately 53-kDa glycoprotein a approximately 53-kDa glycoprotein Fterm glycoprotein NH2-terminal amino acid sequence was obtained for a approximately 53-kDa glycoprotein denoted GP-3, present only in granule membrane preparations where it was resistant to washing with Na2CO3 and KBr. 30172908 4 29 gly N-glycosylation 769:783 arg2 N-glycosylation site N-glycosylation site site The conserved features in known GILTs, such as signal peptide, CXXC motif, GILT signature sequence, N-glycosylation site and conserved cysteines, were all found in the putative PsGILT protein. 30172908 4 29 gly N-glycosylation 769:783 arg2 signal peptide signal peptide peptide The conserved features in known GILTs, such as signal peptide, CXXC motif, GILT signature sequence, N-glycosylation site and conserved cysteines, were all found in the putative PsGILT protein. 10103002 3 21 gly glycoprotein 550:561 arg1 gp42 gp42 Cterm gp42 By using a DNA probe amplified with degenerative primers derived from the protein's partial amino acid sequences, a cDNA clone encoding the egg-envelope 42-kDa glycoprotein (gp42) was isolated from a hen's ovary cDNA library. 10103002 3 21 gly glycoprotein 550:561 arg1 the egg-envelope 42-kDa glycoprotein the egg-envelope 42-kDa glycoprotein Fterm glycoprotein By using a DNA probe amplified with degenerative primers derived from the protein's partial amino acid sequences, a cDNA clone encoding the egg-envelope 42-kDa glycoprotein (gp42) was isolated from a hen's ovary cDNA library. 23748959 5 61 gly glycosylation 812:824 arg2 N-linked glycosylation sites N-linked glycosylation sites sites Furthermore, this server allows for refinement of HIV-1 sequence alignment by using N-linked glycosylation sites in variable loops as alignment anchors. 15527836 3 85 gly Glycosylation 451:463 arg1 the rCAT1 and hCAT1 receptors the rCAT1 and hCAT1 receptors PUBTATOR hCAT1 receptors 6541 Glycosylation of the rCAT1 and hCAT1 receptors inhibits ecotropic MLV infection of CAT1-expressing cells, but that of the mCAT1 does not afford the cells this protection. 2209609 0 44 gly glycoprotein 117:128 arg1 a recombinant soluble CD4 glycoprotein a recombinant soluble CD4 glycoprotein PUBTATOR CD4 glycoprotein P01730 The spectrum of N-linked oligosaccharide structures detected by enzymic microsequencing on a recombinant soluble CD4 glycoprotein from Chinese hamster ovary cells. 7831962 7 36 part_of HA1 1291:1293 arg1 the HA1 region HA1 the HA1 region OGER Site HA1 region In the highly pathogenic Australian isolate; A/Ck/Victoria/75, both HA variants are cleavable in fibroblasts, without added trypsin, and the differences are localized within the HA1 region. 9581553 0 41 gly N-glycosylated 93:106 arg1 N-glycosylated sites N-glycosylated sites sites Expression levels of functional folate receptors alpha and beta are related to the number of N-glycosylated sites. 32005658 6 15 gly modified 1356:1363 arg3 HEK-sKlotho AND an unusual N-glycan structure HEK-sKlotho an unusual N-glycan structure OGER HEK P29319 MS and glycopeptide-mapping analyses revealed that HEK-sKlotho is uniquely modified with an unusual N-glycan structure consisting of N,N'-di-N-acetyllactose diamine at multiple N-linked sites, one of which at Asn-126 was adjacent to a putative GalNAc transfer motif. 10593916 4 57 gly glycoprotein 1160:1171 arg1 the viral glycoprotein the viral glycoprotein Fterm glycoprotein By analyzing the functional properties of natural and synthetic peptides and by identifying the viral sequence(s) from the pool of naturally occurring peptides, we demonstrated that multiple forms of LCMV GP92-101 were generated from the viral glycoprotein and co-presented at the surface of LCMV-infected cells. 2965389 3 9 gly glycosylation 838:850 arg2 One possible N-linked glycosylation site One possible N-linked glycosylation site site One possible N-linked glycosylation site was found in each of the extracellular domains. 9070436 0 44 part_of CD2 42:44 arg1 The counterreceptor binding site CD2 The counterreceptor binding site PUBTATOR Site CD2 914 site The counterreceptor binding site of human CD2 exhibits an extended surface patch with multiple conformations fluctuating with millisecond to microsecond motions. 25451932 9 5 gly N-glycosylation 1186:1200 arg2 the N-glycosylation site the N-glycosylation site site We also found that the location of the N-glycosylation site in the protease domain was not critical. 19945164 2 52 part_of IgE-binding 450:460 arg1 sequential IgE-binding peptides IgE sequential IgE-binding peptides OGER Site IgE P01854 peptides Up to 12 sets of sequential IgE-binding peptides were identified in SPOT experiments along the amino acid sequence of Hev b 13. 26439794 2 50 gly glycopeptides 343:355 arg2 glycopeptides glycopeptides glycopeptides However, one has trouble in mass spectrometric glycoproteomics of membrane fraction because of lower intensity of glycopeptides in the existence of surfactants. 7815476 7 35 gly glycosylation 982:994 arg2 The conserved N-linked glycosylation site The conserved N-linked glycosylation site site The conserved N-linked glycosylation site proximal to the first cysteine of the V3 loop was absent only in one infant's sequence set and in some variants of two other infants' sequences. 26536155 4 9 gly glycopeptides 762:774 arg2 the resulting glycopeptides the resulting glycopeptides glycopeptides While the resulting glycopeptides are very useful for tandem mass spectrometric investigation, the analysis with conventional 1D-LC-ESI-MS/MS approaches can lead to incomplete glycosylation coverage because of the very heterogeneous physicochemical properties of the glycopeptides depending on the peptide sequence as well as the size and charges of the glycan moiety. 26536155 4 63 gly glycopeptides 1009:1021 arg2 the glycopeptides the glycopeptides glycopeptides While the resulting glycopeptides are very useful for tandem mass spectrometric investigation, the analysis with conventional 1D-LC-ESI-MS/MS approaches can lead to incomplete glycosylation coverage because of the very heterogeneous physicochemical properties of the glycopeptides depending on the peptide sequence as well as the size and charges of the glycan moiety. 12638188 5 45 gly glycoprotein 575:586 arg1 glycoprotein products glycoprotein products Fterm glycoprotein In this study, we evaluated the mass spectrometric peptide mapping with regard to its use in comparability assessment of both protein parts and carbohydrates parts in glycoprotein products. 8543840 9 1 part_of env 1204:1206 arg1 the naturally processed, B*3501-restricted, env peptide env the naturally processed, B*3501-restricted, env peptide PUBTATOR Site env 100616444 peptide Second, the naturally processed, B*3501-restricted, env peptide is identical with a nonglycosylated, synthetic nonamer. 2737288 2 13 part_of containing 176:185 arg1 Two peptides AND the potential N-glycosylation sites Two peptides the potential N-glycosylation sites sites Two peptides, containing the potential N-glycosylation sites at Asn-86 and Asn-125, were isolated and analyzed by amino acid analysis, sequencing and carbohydrate component analysis. 1906892 7 84 gly glycosylation 950:962 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Compared with common-type TBG, the mutated polypeptide results in 1) 22 different amino acids on its carboxy-terminus, 2) a 22-amino acid truncation, and 3) the absence of a potential N-linked glycosylation site. 27111718 5 34 gly glycopeptide 1097:1108 arg2 glycopeptide glycopeptide glycopeptide In this paper, we present GlycoSeq, an open-source software tool that implements a heuristic iterated glycan sequencing algorithm coupled with prior knowledge for automated elucidation of the glycan structure within a glycopeptide from its collision-induced dissociation tandem mass spectrum. 24899172 8 29 gly N-glycosylation 1391:1405 arg2 Infectivity-compatible N-glycosylation sites Infectivity-compatible N-glycosylation sites sites Infectivity-compatible N-glycosylation sites could be inserted at 3 positions (positions 115, 129, and 136), but when all three positions were glycosylated, the hyperglycosylated mutant was substantially attenuated at viral entry, while it acquired resistance to neutralizing antibodies. 24899172 8 109 gly glycosylated 1511:1522 arg1 all three positions all three positions positions Infectivity-compatible N-glycosylation sites could be inserted at 3 positions (positions 115, 129, and 136), but when all three positions were glycosylated, the hyperglycosylated mutant was substantially attenuated at viral entry, while it acquired resistance to neutralizing antibodies. 1492495 1 4 part_of 35,000 302:307 arg1 a polypeptide 35,000 (35K a polypeptide Cterm Site 35,000 (35K polypeptide Cells infected with vaccinia virus strain Lister secrete a polypeptide of approximate molecular weight 35,000 (35K) into the medium. 10024532 8 26 part_of Fv 1180:1181 arg1 the glycosylated variable (Fv) fragment Fv the glycosylated variable (Fv) fragment Cterm Site Fv fragment A three-dimensional structure of the glycosylated variable (Fv) fragment was suggested using computer-assisted modelling. 20936810 15 51 gly glycosylation 1930:1942 arg1 highly structured positions positions positions Comparison between computational predictions and experimental observations suggests that generic glycan-based excluded volume effects are responsible for the destabilizing effect of glycosylation at highly structured positions. 2920185 9 60 gly glycosylation 1061:1073 arg2 An N-linked glycosylation site An N-linked glycosylation site site An N-linked glycosylation site in the COOH region has been conserved across all three species. 9050863 3 16 gly glycoproteins 460:472 arg1 All three glycoproteins All three glycoproteins Fterm glycoproteins All three glycoproteins contain a common N-glycosylation site in the S domain while M possesses an additional N-glycosylation site at its amino terminus. 9050863 3 31 gly N-glycosylation 560:574 arg2 an additional N-glycosylation site an additional N-glycosylation site site All three glycoproteins contain a common N-glycosylation site in the S domain while M possesses an additional N-glycosylation site at its amino terminus. 9050863 3 31 gly N-glycosylation 560:574 arg2 its amino terminus its amino terminus terminus All three glycoproteins contain a common N-glycosylation site in the S domain while M possesses an additional N-glycosylation site at its amino terminus. 9050863 3 66 gly N-glycosylation 491:505 arg2 a common N-glycosylation site a common N-glycosylation site site All three glycoproteins contain a common N-glycosylation site in the S domain while M possesses an additional N-glycosylation site at its amino terminus. 27480293 4 31 gly N-glycosylation 595:609 arg2 the identified N-glycosylation sites the identified N-glycosylation sites sites On the basis of our results, the identified N-glycosylation sites were 1891, 1241, 891, 869, and 710 and the FDR values were 3.29, 5.62, 9.54, 9.54, and 20.02%, respectively. 10828943 9 86 part_of SP-A 1544:1547 arg1 the hydrophobic neck region SP-A the hydrophobic neck region PUBTATOR Site SP-A 24773 region The molecular model indicated that the hydrophobic neck region of the SP-A did not interact with lipid monolayers but was instead involved in intratrimeric subunit interactions. 23820512 5 39 gly glycoproteins 861:873 arg1 model glycoproteins model glycoproteins Fterm glycoproteins The condition to effectively collect complex and heterogeneous N-glycans was established on model glycoproteins, bovine ribonuclease B, bovine fetuin, and human serum IgG. 23820512 5 39 gly glycoproteins 861:873 arg1 bovine ribonuclease B bovine ribonuclease B Cterm bovine ribonuclease B The condition to effectively collect complex and heterogeneous N-glycans was established on model glycoproteins, bovine ribonuclease B, bovine fetuin, and human serum IgG. 23820512 5 39 gly glycoproteins 861:873 arg1 bovine fetuin bovine fetuin Fterm fetuin The condition to effectively collect complex and heterogeneous N-glycans was established on model glycoproteins, bovine ribonuclease B, bovine fetuin, and human serum IgG. 23820512 5 39 gly glycoproteins 861:873 arg1 human serum IgG human serum IgG Cterm IgG The condition to effectively collect complex and heterogeneous N-glycans was established on model glycoproteins, bovine ribonuclease B, bovine fetuin, and human serum IgG. 8603082 8 58 gly glycosylation 1252:1264 arg1 membrane proteins membrane proteins Fterm proteins These results are discussed in relation to current understanding of the roles of glycosylation of membrane proteins. 17015441 5 9 gly glycosylation 717:729 arg2 two potential N-linked glycosylation sites two potential N-linked glycosylation sites sites We identified two potential N-linked glycosylation sites in TRPM8 (Asn-821 and Asn-934) and mutated them to show that only the site in the putative pore region at position 934 is modified and that glycosylation of this site is not absolutely necessary for cell surface expression or responsiveness to icilin, menthol, and cool temperatures. 17015441 5 43 gly glycosylation 877:889 arg1 this site this site site We identified two potential N-linked glycosylation sites in TRPM8 (Asn-821 and Asn-934) and mutated them to show that only the site in the putative pore region at position 934 is modified and that glycosylation of this site is not absolutely necessary for cell surface expression or responsiveness to icilin, menthol, and cool temperatures. 17015441 5 24 gly identified 683:692 arg1 Asn-821 Asn-821 and Asn-934 Asn-821 and Asn-934 We identified two potential N-linked glycosylation sites in TRPM8 (Asn-821 and Asn-934) and mutated them to show that only the site in the putative pore region at position 934 is modified and that glycosylation of this site is not absolutely necessary for cell surface expression or responsiveness to icilin, menthol, and cool temperatures. 26634432 4 3 part_of site 476:479 arg1 mouse DMP1 DMP1 site PUBTATOR Site DMP1 13406 site In vitro investigations showed that Ser(89) is the key glycosylation site in mouse DMP1. 18638581 5 27 part_of sites 1006:1010 arg1 45 proteins proteins sites Fterm Site proteins sites The methods were successfully applied to human serum samples and a total of 86 N-glycosylation sites in 45 proteins were identified using a mixture of three immobilized lectins for consecutive glycoprotein enrichment and glycopeptide enrichment. 29867209 7 56 part_of EPO 1026:1028 arg1 an engineered O-glycosylation site EPO an engineered O-glycosylation site PUBTATOR Site EPO 2056 site Therefore we present an alternative method for the synthesis of active glycosylated EPO with an engineered O-glycosylation site by combining eukaryotic cell-free protein synthesis and site-directed incorporation of non-canonical amino acids with subsequent chemoselective modifications. 24923165 6 15 gly glycosylation 898:910 arg2 One glycosylation site One glycosylation site site One glycosylation site changed in all the 12 sequences because of the amino acid mutation from serine to asparagine at the 240th site, as compared with Edmonston-wt. 8706658 3 25 part_of synthase 782:789 arg1 the translated human leukotriene C4 synthase cDNA sequence leukotriene C4 synthase cDNA the translated human leukotriene C4 synthase cDNA sequence PUBTATOR Site leukotriene C4 synthase cDNA 4056 sequence We have now cloned mouse leukotriene C4 synthase CDNA using the polymerase chain reaction to screen a mouse pcDNA3 expression library with oligonucleotide primers based on the translated human leukotriene C4 synthase cDNA sequence. 8706658 3 31 part_of leukotriene 767:777 arg1 the translated human leukotriene C4 synthase cDNA sequence leukotriene C4 synthase cDNA the translated human leukotriene C4 synthase cDNA sequence PUBTATOR Site leukotriene C4 synthase cDNA 4056 sequence We have now cloned mouse leukotriene C4 synthase CDNA using the polymerase chain reaction to screen a mouse pcDNA3 expression library with oligonucleotide primers based on the translated human leukotriene C4 synthase cDNA sequence. 8706658 3 96 part_of cDNA 791:794 arg1 the translated human leukotriene C4 synthase cDNA sequence leukotriene C4 synthase cDNA the translated human leukotriene C4 synthase cDNA sequence PUBTATOR Site leukotriene C4 synthase cDNA 4056 sequence We have now cloned mouse leukotriene C4 synthase CDNA using the polymerase chain reaction to screen a mouse pcDNA3 expression library with oligonucleotide primers based on the translated human leukotriene C4 synthase cDNA sequence. 8706658 3 101 part_of C4 779:780 arg1 the translated human leukotriene C4 synthase cDNA sequence leukotriene C4 synthase cDNA the translated human leukotriene C4 synthase cDNA sequence PUBTATOR Site leukotriene C4 synthase cDNA 4056 sequence We have now cloned mouse leukotriene C4 synthase CDNA using the polymerase chain reaction to screen a mouse pcDNA3 expression library with oligonucleotide primers based on the translated human leukotriene C4 synthase cDNA sequence. 16360109 1 34 part_of found 137:141 arg1 human immunoglobulin Gs (IgGs) AND Variable (Fv) domain N-glycosylation sites human immunoglobulin Gs (IgGs) Variable (Fv) domain N-glycosylation sites Cterm Site IgG sites Variable (Fv) domain N-glycosylation sites are found in approximately 20% of human immunoglobulin Gs (IgGs) in addition to the conserved N-glycosylation sites in the C(H)2 domains. 16335952 5 48 gly deglycosylated 1052:1065 arg1 the deglycosylated peptides the deglycosylated peptides peptides Following strong cation exchange (SCX) fractionation, the deglycosylated peptides were analyzed by reversed-phase capillary liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). 10494958 4 37 gly glycosylation 702:714 arg2 a glycosylation site a glycosylation site site The egg-grown influenza B/Memphis/1/93 variant differed from cell-grown counterparts at amino acid position 198 (Pro-Thr) and lost a glycosylation site. 15956584 3 20 gly glycoproteins 441:453 arg1 mutated HCV envelope glycoproteins mutated HCV envelope glycoproteins Fterm glycoproteins For this study, we used retroviral pseudotyped particles harboring mutated HCV envelope glycoproteins to study these glycans. 21673010 6 8 gly glycoprotein 910:921 arg1 a single glycoprotein species a single glycoprotein species Fterm glycoprotein We have now also determined the detailed N-glycan structures acquired by a single glycoprotein species in the same apical and basolateral secretory pathways. 2158103 4 29 gly glycosylation 585:597 arg2 a consensus N-linked glycosylation site a consensus N-linked glycosylation site site The deduced amino acid sequence displays many features of guanyl nucleotide-binding protein-coupled receptors except it does not have a consensus N-linked glycosylation site near the amino terminus. 17956937 8 8 gly site 1856:1859 arg1 a complexed form site a complexed form site The results suggest that identification of alpha2,3-linked sialic acids on PSA potentially discriminates malignant from benign conditions, if the analysis is applied to oligosaccharides specifically attached to the N-glycosylation site of PSA in either a free or a complexed form in the serum. 17956937 8 37 gly attached 1824:1831 arg1 the N-glycosylation site AND oligosaccharides PSA site oligosaccharides PUBTATOR PSA 354 site The results suggest that identification of alpha2,3-linked sialic acids on PSA potentially discriminates malignant from benign conditions, if the analysis is applied to oligosaccharides specifically attached to the N-glycosylation site of PSA in either a free or a complexed form in the serum. 17956937 8 104 gly N-glycosylation 1840:1854 arg1 PSA PSA site PUBTATOR PSA 354 site The results suggest that identification of alpha2,3-linked sialic acids on PSA potentially discriminates malignant from benign conditions, if the analysis is applied to oligosaccharides specifically attached to the N-glycosylation site of PSA in either a free or a complexed form in the serum. 8307000 12 25 gly Asn117 2470:2475 arg1 complex-type glycans Asn117 complex-type glycans Asn117 The relative amounts of complex-type glycans at Asn117 of GS-tPA correlated with the degree of carbohydrate substitution of Asn58. 8307000 12 76 gly Asn58 2546:2550 arg1 carbohydrate substitution Asn58 carbohydrate substitution Asn58 The relative amounts of complex-type glycans at Asn117 of GS-tPA correlated with the degree of carbohydrate substitution of Asn58. 7559469 5 92 gly N-glycosylation 947:961 arg2 each N-glycosylation site each N-glycosylation site site To determine the specific role of each N-glycosylation site in tHON, Asn71 and Asn99 were mutated to Gln (N71Q, N99Q) and Thr73 and Thr101 mutated to Ala (T73A, T101A) to selectively inhibit oligosaccharide attachment. 15039521 8 14 gly glycosylation 1036:1048 arg1 viral proteins viral proteins Fterm proteins These results are consistent with earlier findings that incorrect glycosylation of viral proteins may interfere with virus assembly. 27725718 9 30 part_of haptoglobin 1216:1226 arg1 glycosylation sites haptoglobin glycosylation sites PUBTATOR Site haptoglobin 3240 sites Furthermore, we observed, that glycosylation sites of liver-originating transferrin and haptoglobin are differentially occupied under physiological conditions, a further instance not noticed in serum proteins to date. 27725718 9 45 part_of transferrin 1200:1210 arg1 glycosylation sites transferrin glycosylation sites PUBTATOR Site transferrin 7018 sites Furthermore, we observed, that glycosylation sites of liver-originating transferrin and haptoglobin are differentially occupied under physiological conditions, a further instance not noticed in serum proteins to date. 18524814 3 101 gly glycosylation 925:937 arg2 this potential glycosylation site this potential glycosylation site site An analysis of these mutants in the presence or absence of endoglycosidases confirmed the addition of oligosaccharides to this potential glycosylation site. 11676606 8 46 part_of CD154 1220:1224 arg1 asparagine 240 CD154 asparagine 240 PUBTATOR SpecificSite CD154 959 asparagine 240 Together, these results indicate that the presence of varied types of N-linked glycans on asparagine 240 of CD154 does not play a significant role in the CD40-CD154 interactions. 9600940 2 65 gly present 339:345 arg1 five Ser residues AND the oligosaccharides Ser residues the oligosaccharides Ser residues Apparently, the oligosaccharides are present on one or more of five Ser residues clustered in the carboxyl-terminal region of the mZP3 polypeptide. 12877809 3 94 part_of CETP 522:525 arg1 The amino acid sequence CETP The amino acid sequence PUBTATOR Site CETP P11597 sequence The amino acid sequence of CETP was deduced from the cDNA sequence and its primary and secondary structures were predicted. 31296534 6 30 gly glycans 968:974 arg1 five silent sites five silent sites five silent sites Site sites Remarkably, the lumenal ER chaperone GRP94 was hyperglycosylated in STT3A-deficient cells, bearing glycans on five silent sites in addition to the normal glycosylation site. 31296534 6 63 gly hyperglycosylated 916:932 arg1 the lumenal ER chaperone GRP94 the lumenal ER chaperone GRP94 PUBTATOR GRP94 7184 Remarkably, the lumenal ER chaperone GRP94 was hyperglycosylated in STT3A-deficient cells, bearing glycans on five silent sites in addition to the normal glycosylation site. 31296534 6 70 gly glycosylation 1023:1035 arg2 the normal glycosylation site the normal glycosylation site site Remarkably, the lumenal ER chaperone GRP94 was hyperglycosylated in STT3A-deficient cells, bearing glycans on five silent sites in addition to the normal glycosylation site. 8379944 11 66 gly unglycosylated 1550:1563 arg1 the unglycosylated LCAT the unglycosylated LCAT PUBTATOR LCAT 3931 The amount of the unglycosylated LCAT secreted into the culture medium was less than 10% of the wild-type level and the specific activity of this enzyme was decreased to 5% of that of the wild type. 19008394 0 18 part_of peptide 15:21 arg1 the West Nile virus envelope protein protein peptide Fterm Site protein peptide A glycosylated peptide in the West Nile virus envelope protein is immunogenic during equine infection. 24612669 2 51 part_of ligand 479:484 arg1 Human Fas ligand extracellular domain Human Fas ligand Human Fas ligand extracellular domain PUBTATOR Site Human Fas ligand 356 domain Human Fas ligand extracellular domain (hFasLECD) is an agonistic death ligand protein that has potential applications for medical purposes. 24612669 2 53 part_of Human 469:473 arg1 Human Fas ligand extracellular domain Human Fas ligand Human Fas ligand extracellular domain PUBTATOR Site Human Fas ligand 356 domain Human Fas ligand extracellular domain (hFasLECD) is an agonistic death ligand protein that has potential applications for medical purposes. 24612669 2 116 part_of Fas 475:477 arg1 Human Fas ligand extracellular domain Human Fas ligand Human Fas ligand extracellular domain PUBTATOR Site Human Fas ligand 356 domain Human Fas ligand extracellular domain (hFasLECD) is an agonistic death ligand protein that has potential applications for medical purposes. 20153530 4 9 gly glycosylated 530:541 arg1 human C9 human C9 PUBTATOR C9 117512 This glycosylated form of human C9 was as active as the native protein suggesting that the glycan chain remains on the external side of the membrane and that translocation of this hairpin is not required for membrane anchoring. 26339047 11 3 gly N-glycosylation 2351:2365 arg2 additional N-glycosylation sites additional N-glycosylation sites sites We have generated virus-like particles (VLPs) composed of hepatitis B virus envelope proteins (HBsAgS) with additional N-glycosylation sites. 11439087 6 43 part_of contains 904:911 arg1 BST-1 AND four putative N-glycosylation sites BST-1 four putative N-glycosylation sites PUBTATOR Site BST-1 683 sites BST-1 contains four putative N-glycosylation sites. 7535613 4 2 part_of proteins 564:571 arg1 The structurally conserved regions proteins The structurally conserved regions Fterm Site proteins regions The structurally conserved regions of the 4 reference X-ray proteins provided the core structure of PSA, whereas the loop structures were modeled on the loops of tonin and kallikrein. 15557236 6 56 gly protein 975:981 arg1 a molecular determinant protein a molecular determinant Fterm protein These results suggested that E protein glycosylation is a molecular determinant of neuroinvasiveness in the NY strains of WN virus. 3200844 2 49 part_of protein 333:339 arg1 the primary sequence protein the primary sequence Fterm Site protein sequence We sought to determine the primary sequence of a nuclear pore protein modified by O-linked GlcNAc. 22872643 0 32 gly notch 83:87 arg1 the epidermal growth factor-like (EGF) repeats notch the epidermal growth factor-like (EGF) repeats PUBTATOR notch 18128 Site-specific O-glucosylation of the epidermal growth factor-like (EGF) repeats of notch: efficiency of glycosylation is affected by proper folding and amino acid sequence of individual EGF repeats. 18320936 7 12 gly attached 1133:1140 arg2 glycans AND other sites other sites glycans sites Propagating these viruses in cells treated with 1 mM deoxymannojirimycin (dMJ, mannosidase inhibitor) increased sensitivity to CVN, suggesting that glycans attached at other sites on HA1 that typically are not high-mannosidic became so due to dMJ treatment. 17823199 8 29 gly glycosylation 1381:1393 arg1 acceptor sequons acceptor sequons In addition, we noticed a selective underglycosylation of N-glycosylation sites, indicating preferential glycosylation of acceptor sequons of a given glycoprotein. 17823199 8 79 gly underglycosylation 1312:1329 arg1 N-glycosylation sites N-glycosylation sites sites In addition, we noticed a selective underglycosylation of N-glycosylation sites, indicating preferential glycosylation of acceptor sequons of a given glycoprotein. 17823199 8 82 gly N-glycosylation 1334:1348 arg2 N-glycosylation sites N-glycosylation sites sites In addition, we noticed a selective underglycosylation of N-glycosylation sites, indicating preferential glycosylation of acceptor sequons of a given glycoprotein. 17823199 8 108 gly glycoprotein 1426:1437 arg1 a given glycoprotein a given glycoprotein Fterm glycoprotein In addition, we noticed a selective underglycosylation of N-glycosylation sites, indicating preferential glycosylation of acceptor sequons of a given glycoprotein. 19933092 8 89 part_of T2R2 1000:1003 arg1 the T2R2 gene sequences T2R2 the T2R2 gene sequences Cterm Site T2R2 sequences Homology analysis of the T2R2 gene sequences by Clustal W indicated that the cDNA sequence homology of T2R2 gene in hog badger with dog, cat, cattle, horse, chimpanzee, and mouse is 91.4%, 90.6%, 84.4%, 85.4%, 83.8%and 72.1%, respectively, and the homology of amino acid sequence is 85.5%, 85.8%, 74.0%, 77.6%, 75.3% and 61.5%, respectively. 11371512 7 31 part_of saposin 820:826 arg1 the saposin A domain saposin A the saposin A domain Cterm Site saposin A domain We introduced an amino acid substitution (C106F) into the saposin A domain by the Cre/loxP system which eliminated one of the three conserved disulfide bonds. 11371512 7 84 part_of A 828:828 arg1 the saposin A domain saposin A the saposin A domain Cterm Site saposin A domain We introduced an amino acid substitution (C106F) into the saposin A domain by the Cre/loxP system which eliminated one of the three conserved disulfide bonds. 18562306 0 43 gly glycosylation 129:141 arg2 glycosylation site selection glycosylation site selection site The catalytic and lectin domains of UDP-GalNAc:polypeptide alpha-N-Acetylgalactosaminyltransferase function in concert to direct glycosylation site selection. 21280237 3 44 gly glycosylation 774:786 arg2 glycosylation site glycosylation site site However, the advent of glycoproteomics has produced major strides in glycoprotein identification and glycosylation site mapping. 21280237 3 58 gly glycoprotein 742:753 arg1 glycoprotein identification glycoprotein identification Fterm glycoprotein However, the advent of glycoproteomics has produced major strides in glycoprotein identification and glycosylation site mapping. 27679458 9 1 gly glycopeptides 1244:1256 arg2 glycopeptides enrichment glycopeptides enrichment glycopeptides Graphical abstract Proposed mechanism of glycopeptides enrichment using DEAE-Sepharose. 22674977 6 67 gly glycosylation 1223:1235 arg2 the glycosylation site the glycosylation site site Glycan microarray and kinetic analysis were performed to compare the receptor binding profile of the wild-type recombinant NL219 HA to a variant with a threonine-to-alanine mutation at position 125, resulting in loss of the glycosylation site at Asn123. 22674977 6 67 gly glycosylation 1223:1235 arg2 Asn123 Asn123 Asn123 Glycan microarray and kinetic analysis were performed to compare the receptor binding profile of the wild-type recombinant NL219 HA to a variant with a threonine-to-alanine mutation at position 125, resulting in loss of the glycosylation site at Asn123. 2320574 1 14 gly glycoproteins 131:143 arg1 small, heat-stable glycoproteins small, heat-stable glycoproteins Fterm glycoproteins Saposins are small, heat-stable glycoproteins required for the hydrolysis of sphingolipids by specific lysosomal hydrolases. 25651845 1 16 gly glycoprotein 161:172 arg1 a vitamin K-dependent plasma glycoprotein a vitamin K-dependent plasma glycoprotein Fterm glycoprotein Protein C (PC) is a vitamin K-dependent plasma glycoprotein, which upon activation by thrombin in complex with thrombomodulin (TM), regulates the coagulation cascade through a feedback loop inhibition mechanism. 25651845 1 16 gly glycoprotein 161:172 arg1 Protein C Protein C OGER Protein C P02810 Protein C (PC) is a vitamin K-dependent plasma glycoprotein, which upon activation by thrombin in complex with thrombomodulin (TM), regulates the coagulation cascade through a feedback loop inhibition mechanism. 19806925 8 73 gly N-glycosylation 1168:1182 arg2 N214 N214 N214 FcIRL contained a predicted N-terminal acetylation site (M1-K5) and a NADPH-binding motif (G10-G-T-G13-Y-I-G16) in the N-terminal region, a conserved NmrA (nitrogen metabolite repression regulator) domain (V6-N244), multi-phosphorylation sites and one conserved N-glycosylation site (N214). 19806925 8 73 gly N-glycosylation 1168:1182 arg2 one conserved N-glycosylation site one conserved N-glycosylation site site FcIRL contained a predicted N-terminal acetylation site (M1-K5) and a NADPH-binding motif (G10-G-T-G13-Y-I-G16) in the N-terminal region, a conserved NmrA (nitrogen metabolite repression regulator) domain (V6-N244), multi-phosphorylation sites and one conserved N-glycosylation site (N214). 18930737 1 26 gly alpha2-glycoprotein 218:236 arg1 zinc alpha2-glycoprotein zinc alpha2-glycoprotein PUBTATOR zinc alpha2-glycoprotein 563 This is the first report on the formation of a complex between zinc alpha2-glycoprotein (ZAG) and prolactin-inducible protein (PIP). 18930737 1 26 gly alpha2-glycoprotein 218:236 arg1 ZAG ZAG PUBTATOR ZAG 563 This is the first report on the formation of a complex between zinc alpha2-glycoprotein (ZAG) and prolactin-inducible protein (PIP). 2033065 4 92 gly glycosylation 772:784 arg2 position 97 position 97 position 97 We demonstrate that N-linked glycosylation at position 97 in the light chain of HPC is critical for efficient secretion and affects the degree of core glycosylation at Asn-329. 25499264 6 2 gly glycosylation 1128:1140 arg2 an intact N616 glycosylation site an intact N616 glycosylation site site In particular, lack of an intact N616 glycosylation site was shown to result in the loss of viral infectivity of several (i.e. the X4-tropic IIIB and NL4.3 strains, and the X4/R5-tropic HE strain), but not all (i.e. the R5-tropic ADA strain) studied HIV-1 strains. 27574189 13 37 gly found 1304:1308 arg1 the disintegrin domain AND one additional O-fucosylation site the disintegrin domain one additional O-fucosylation site domain Unexpectedly, one additional O-fucosylation site was found in the disintegrin domain. 10364275 7 50 gly glycosylation 1371:1383 arg2 a potential glycosylation site a potential glycosylation site site However, the removal of a potential glycosylation site in the V1 domain or the creation of such a site in the V3 domain did allow the virus to escape serum neutralization antibodies that recognized parental SHIVSF33. 18636497 5 11 gly glycosylation 1033:1045 arg2 each glycosylation site each glycosylation site site Furthermore, Man(alpha1-3) arms of the predominant complex biantennary structures were more favorably sialylated than Man(alpha1-6) branches at each glycosylation site. 18636497 5 34 gly sialylated 986:995 arg1 the predominant complex biantennary structures the predominant complex biantennary structures Furthermore, Man(alpha1-3) arms of the predominant complex biantennary structures were more favorably sialylated than Man(alpha1-6) branches at each glycosylation site. 18636497 5 34 gly sialylated 986:995 arg2 each glycosylation site site site Furthermore, Man(alpha1-3) arms of the predominant complex biantennary structures were more favorably sialylated than Man(alpha1-6) branches at each glycosylation site. 18636497 5 34 gly sialylated 986:995 arg2 each glycosylation site site the predominant complex biantennary structures site Furthermore, Man(alpha1-3) arms of the predominant complex biantennary structures were more favorably sialylated than Man(alpha1-6) branches at each glycosylation site. 8870657 11 58 gly glycosylation 1327:1339 arg1 hLF hLF PUBTATOR hLF 3131 60% of the total) after mutations of Asn138 and Asn479 suggests that glycosylation of hLF is not an absolute requirement for its secretion. 25707740 5 34 part_of contains 586:593 arg1 The α-subunit AND two N-glycosylation sites The α-subunit two N-glycosylation sites Fterm Site α-subunit sites The α-subunit is identical to the pituitary gonadotropin hormones (LH, FSH, TSH), contains two N-glycosylation sites, and is encoded by a single gene (CGA). 15527836 0 90 gly glycosylation 88:100 arg1 the rat receptor the rat receptor Fterm receptor Determinant for the inhibition of ecotropic murine leukemia virus infection by N-linked glycosylation of the rat receptor. 26968544 4 83 gly dystrophin-glycoprotein 876:898 arg1 the dystrophin-glycoprotein complex the dystrophin-glycoprotein complex OGER dystrophin P11530 This study demonstrates that DCM mutant δ-sarcoglycans can be stably expressed in adult rat cardiac myocytes and traffic similarly to wild-type δ-sarcoglycan to the plasma membrane, without perturbing assembly of the dystrophin-glycoprotein complex. 10090557 4 29 gly N-glycosylation 762:776 arg2 a new N-glycosylation site a new N-glycosylation site site Molecular genetic studies showed a point mutation in the fibrillin 1 gene that creates a new N-glycosylation site, which has been described once before. 8132647 7 40 part_of contains 889:896 arg1 The GP-3 amino acid sequence AND one potential N-linked glycosylation site The GP-3 amino acid sequence one potential N-linked glycosylation site site The GP-3 amino acid sequence contains one potential N-linked glycosylation site at Asn-336. 8132647 7 40 part_of contains 889:896 arg1 The GP-3 amino acid sequence AND The GP-3 amino acid sequence The GP-3 amino acid sequence The GP-3 amino acid sequence sequence The GP-3 amino acid sequence contains one potential N-linked glycosylation site at Asn-336. 9367731 4 113 part_of 636-amino-acid 894:907 arg1 a 636-amino-acid polypeptide 636-amino-acid a 636-amino-acid polypeptide Cterm Site 636-amino-acid polypeptide The cDNA was 2453 bp in length and contained an open reading frame of 1908 bp encoding a 636-amino-acid polypeptide with calculated molecular mass of 70,740 Da. 16274239 9 6 gly glycosylation 1753:1765 arg1 N N(579) N(579) Moreover, although WT-EGFRs confer cell survival in 32D cells in the absence of interleukin-3 and EGF, we found that receptors lacking glycosylation at N(579) do not. 19008394 2 24 gly glycosylation 423:435 arg2 the WNV NY99 E protein glycosylation site the WNV NY99 E protein glycosylation site site Using synthetic peptides, this epitope was mapped to a 19 aa sequence (WN19: E147-165) encompassing the WNV NY99 E protein glycosylation site at position 154. 26156869 1 14 gly glycoproteins 187:199 arg1 glycoproteins glycoproteins Fterm glycoproteins Enzymes that affect glycoproteins of the human immune system, and thereby modulate defense responses, are abundant among bacterial pathogens. 20209506 5 89 gly sialylated 1130:1139 arg1 sialylated bi- and tri-antennary complex type glycans sialylated bi- and tri-antennary complex type glycans A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI. 20209506 5 17 gly N-glycosylation 1213:1227 arg1 beta2-GPI GPI sites PUBTATOR GPI 350 sites A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI. 20209506 5 17 gly N-glycosylation 1213:1227 arg2 Asn-234 GPI Asn-143, Asn-174 and Asn-234 PUBTATOR GPI 350 Asn-143, Asn-174 and Asn-234 A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI. 20209506 5 17 gly N-glycosylation 1213:1227 arg2 Asn-143 GPI Asn-143, Asn-174 and Asn-234 PUBTATOR GPI 350 Asn-143, Asn-174 and Asn-234 A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI. 20209506 5 17 gly N-glycosylation 1213:1227 arg2 Asn-174 GPI Asn-143, Asn-174 and Asn-234 PUBTATOR GPI 350 Asn-143, Asn-174 and Asn-234 A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI. 20209506 5 17 gly N-glycosylation 1213:1227 arg2 Asn-143 Asn-143, Asn-174 and Asn-234 Asn-143, Asn-174 and Asn-234 A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI. 20209506 5 17 gly N-glycosylation 1213:1227 arg2 Asn-174 Asn-143, Asn-174 and Asn-234 Asn-143, Asn-174 and Asn-234 A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI. 20209506 5 17 gly N-glycosylation 1213:1227 arg2 Asn-174 Asn-143, Asn-174 and Asn-234 Asn-143, Asn-174 and Asn-234 A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI. 30904681 1 52 gly glycosylated 150:161 arg1 a 50 kDa human plasma protein a 50 kDa human plasma protein Fterm protein The highly glycosylated ß-2-glycoprotein-1 (B2GP1), also called apolipoprotein H, is a 50 kDa human plasma protein with four or five N-glycosylation sites. 30904681 1 52 gly glycosylated 150:161 arg1 B2GP1 B2GP1 PUBTATOR B2GP1 350 The highly glycosylated ß-2-glycoprotein-1 (B2GP1), also called apolipoprotein H, is a 50 kDa human plasma protein with four or five N-glycosylation sites. 30904681 1 52 gly glycosylated 150:161 arg1 The highly glycosylated ß-2-glycoprotein-1 The highly glycosylated ß-2-glycoprotein-1 Fterm ß-2-glycoprotein-1 350 The highly glycosylated ß-2-glycoprotein-1 (B2GP1), also called apolipoprotein H, is a 50 kDa human plasma protein with four or five N-glycosylation sites. 30904681 1 52 gly glycosylated 150:161 arg1 also called apolipoprotein H also called apolipoprotein H PUBTATOR apolipoprotein H 350 The highly glycosylated ß-2-glycoprotein-1 (B2GP1), also called apolipoprotein H, is a 50 kDa human plasma protein with four or five N-glycosylation sites. 30904681 1 63 gly N-glycosylation 272:286 arg2 four or five N-glycosylation sites four or five N-glycosylation sites sites The highly glycosylated ß-2-glycoprotein-1 (B2GP1), also called apolipoprotein H, is a 50 kDa human plasma protein with four or five N-glycosylation sites. 23341449 9 40 gly polysialylation 1664:1678 arg1 Ig5 N-glycans Ig5 N-glycans Taken together, these results indicate that the polySTs not only recognize an acidic patch in the FN1 domain of NCAM but also must contact sequences in the Ig5 domain for polysialylation of Ig5 N-glycans to occur. 7533854 11 124 part_of epitopes 2759:2766 arg1 this region epitopes this region region These results suggested that the closely spaced glycosylation sites 156 and 160 are often alternatively utilized and that the pattern of glycosylation at these positions affects the formation of the conformational structures needed for both expression of native epitopes in this region and processing of gPr160 to mature env products. 25113421 7 27 gly glycopeptides 920:932 arg2 intact glycopeptides intact glycopeptides glycopeptides The other approach produces spectra directly from intact glycopeptides. 11278567 5 44 gly glycosylation 779:791 arg2 an N-linked glycosylation site an N-linked glycosylation site site Loss of an N-linked glycosylation site within the V3 region had a major influence on the virus switching from the R5 to X4 phenotype in a V3 charge-dependent manner. 16720579 2 59 gly attached 537:544 arg1 C6ST-1 AND N-glycans C6ST-1 N-glycans OGER C6ST-1 Q7LGC8 In the present study, we show essential roles of N-glycans attached to C6ST-1 in the generation of the active enzyme and in its KSST activity. 7890742 11 59 part_of CD52 1580:1583 arg1 the CD52 epitope CD52 the CD52 epitope PUBTATOR Site CD52 1043 epitope The alkali-lability of the CD52 epitope recognized by the Campath-1H monoclonal antibody was studied. 30158294 8 94 part_of site 1100:1103 arg1 SERINC5 SERINC5 site PUBTATOR Site SERINC5 256987 site Our results demonstrate that N294 is the major site of N-glycosylation in SERINC5. 10588947 0 53 gly glycosylation 10:22 arg2 Efficient glycosylation site utilization Efficient glycosylation site utilization site Efficient glycosylation site utilization by intracellular apolipoprotein B. Implications for proteasomal degradation. 30755292 4 60 gly N-glycosylation 811:825 arg2 potential N-glycosylation sites potential N-glycosylation sites sites METHODS: We determined the HA sequences of A(H3N2) viruses detected in Yokohama, Japan during the 2016/17 and 2017/18 influenza seasons to identify amino acid substitutions and the loss or gain of potential N-glycosylation sites in HA, both of which potentially affect the antigenicity of HA. 26618514 5 32 gly IgG 693:695 arg1 the sialylation status IgG the sialylation status Cterm IgG Analysing the sialylation status of affinity-purified anti-histone IgG in patients with systemic lupus erythematosus (SLE), we demonstrated that the anti-histone IgG was contained preferentially in the non-sialylated fraction. 26618514 5 60 gly non-sialylated 828:841 arg1 the non-sialylated fraction the non-sialylated fraction Analysing the sialylation status of affinity-purified anti-histone IgG in patients with systemic lupus erythematosus (SLE), we demonstrated that the anti-histone IgG was contained preferentially in the non-sialylated fraction. 26618514 5 71 gly sialylation 640:650 arg1 affinity-purified anti-histone IgG affinity-purified anti-histone IgG Cterm IgG Analysing the sialylation status of affinity-purified anti-histone IgG in patients with systemic lupus erythematosus (SLE), we demonstrated that the anti-histone IgG was contained preferentially in the non-sialylated fraction. 7737160 2 5 gly glycoproteins 259:271 arg1 glycoproteins glycoproteins Fterm glycoproteins The purified protein migrated as a broad band at approximately 14,000 Da, characteristic of glycoproteins. 20543007 8 48 gly N-glycosylation 1188:1202 arg2 the consensus N-glycosylation site the consensus N-glycosylation site site On the basis of the spatial proximity and germline sequence, we reintroduced the consensus N-glycosylation site in H-CDR2 which was found in the original antibody, anticipating that the carbohydrate moiety would shield the aggregation 'hot spot' in H-CDR3 while not interfering with antigen binding. 31958346 4 46 gly N401-glycosylation 782:799 arg2 only the N401-glycosylation site only the N401-glycosylation site site In addition, only the N401-glycosylation site demonstrated incomplete N-glycosylation occupancy. 28708860 3 1 part_of epitopes 482:489 arg1 NA NA epitopes PUBTATOR NA 4758 The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA). 28708860 3 1 part_of epitopes 482:489 arg1 neuraminidase neuraminidase epitopes PUBTATOR neuraminidase 4758 The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA). 28708860 3 1 part_of epitopes 482:489 arg1 hemagglutinin hemagglutinin epitopes Fterm hemagglutinin The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA). 1918071 1 62 part_of containing 290:299 arg1 glycosylatable photoreactive peptides AND the sequence-Asn-Xaa-Ser/Thr- glycosylatable photoreactive peptides the sequence-Asn-Xaa-Ser/Thr- Asn Previously we had demonstrated by photoaffinity labeling that a 57-kDa protein of the endoplasmic reticulum can bind and become covalently linked to glycosylatable photoreactive peptides containing the sequence-Asn-Xaa-Ser/Thr-. 18712764 3 55 gly glycoprotein 866:877 arg1 the purified glycoprotein the purified glycoprotein Fterm glycoprotein Following PNGase F digestion of the purified glycoprotein, the characterization of protein microheterogeneity by N-glycan MS analysis was performed in a patient with CDG group II (processing disorders). 24884609 8 19 gly N-glycosylation 1202:1216 arg2 A fifth N-glycosylation site A fifth N-glycosylation site site A fifth N-glycosylation site was discovered at N274 with the rare nonconsensus NVV motif. 9337875 3 65 gly N-glycosylation 418:432 arg2 the eight potential N-glycosylation sites the eight potential N-glycosylation sites sites IDS mutant cDNAs, lacking one of the eight potential N-glycosylation sites, were expressed in COS cells. 17599380 9 56 part_of CD4 1494:1496 arg1 the CD4 binding site CD4 the CD4 binding site OGER Site CD4 P01730 site These findings suggest that increased exposure of the b12 epitope overlapping the CD4 binding site via elimination of a glycan at position 386 is associated with enhanced HIV macrophage tropism, and provide evidence that determinants of macrophage and microglia tropism are overlapping but distinct. 16331960 0 81 gly glycoforms 43:52 arg1 transferrin glycoforms transferrin glycoforms PUBTATOR transferrin 7018 Differential susceptibility of transferrin glycoforms to chymotrypsin: a proteomics approach to the detection of carbohydrate-deficient transferrin. 27489265 2 105 gly glycosylation 362:374 arg1 Env Env PUBTATOR Env 100616444 One of the mechanisms that HIV has evolved to escape the host's immune response is to mask conserved epitopes on Env with dense glycosylation. 19167329 1 6 gly glycosylation 124:136 arg1 polypeptides polypeptides polypeptides Asparagine-linked glycosylation of polypeptides in the lumen of the endoplasmic reticulum is catalyzed by the hetero-oligomeric oligosaccharyltransferase (OST). 23530821 3 2 gly N-glycosylation 482:496 arg2 N-glycosylation sites N-glycosylation sites sites Three mutant prM and/or E (prM-E) genes lacking N-glycosylation sites were generated by site-directed mutagenesis. 8806496 4 19 gly glycosylation 753:765 arg2 the second glycosylation site the second glycosylation site site Mutants lacking the second glycosylation site and those bearing silent mutations were similar to the parental virus in their cell culture properties. 18955570 5 49 gly glycosylation 961:973 arg1 GM-CSF-Ralpha GM-CSF-Ralpha PUBTATOR GM-CSF-Ralpha 1438 The other, a point mutation in the paternal X chromosome allele encoding a G174R substitution, altered an N-linked glycosylation site within the cytokine binding domain and glycosylation of GM-CSF-Ralpha, severely reducing GM-CSF binding, receptor signaling, and GM-CSF-dependent functions in primary myeloid cells. 18955570 5 77 gly glycosylation 903:915 arg2 an N-linked glycosylation site an N-linked glycosylation site site The other, a point mutation in the paternal X chromosome allele encoding a G174R substitution, altered an N-linked glycosylation site within the cytokine binding domain and glycosylation of GM-CSF-Ralpha, severely reducing GM-CSF binding, receptor signaling, and GM-CSF-dependent functions in primary myeloid cells. 1869556 2 91 gly glycosylation 431:443 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Human interleukin-1 beta (IL-1 beta) is expressed in activated monocytes as a 31-kDa precursor protein which is processed and secreted as a mature, unglycosylated 17-kDa carboxyl-terminal fragment, despite the fact that it contains a potential N-linked glycosylation site near the NH2 terminus (-Asn7-Cys8-Thr9-). 19919546 2 11 gly glycoproteins 280:292 arg1 glycoproteins glycoproteins One methodology for cancer biomarker discovery exploits the fact that glycoproteins produced by cancer cells have altered glycan structures, although the proteins themselves are common, ubiquitous, abundant, and familiar. 1373379 5 15 part_of contains 679:686 arg1 the BiP protein AND an N-linked glycosylation site the BiP protein an N-linked glycosylation site Fterm Site protein site Unexpectedly, we find the BiP protein contains an N-linked glycosylation site which can be utilized. 11439087 8 0 gly N-glycosylation 1182:1196 arg2 a single N-glycosylation site a single N-glycosylation site site Site-directed mutagenesis was performed to generate sBST-1 mutants (N1-N4), each preserving a single N-glycosylation site. 23527023 4 2 gly glycosylation 1106:1118 arg2 residue 181 residue 181 residue 181 Remarkably, the absence of the diglycosylated PrP(res) species in both fCJD(V180I) and VPSPr is likewise attributable to the absence of PrP(res) glycosylated at the first N-linked glycosylation site at residue 181, as in fCJD(T183A). 23527023 4 2 gly glycosylation 1106:1118 arg2 the first N-linked glycosylation site the first N-linked glycosylation site site Remarkably, the absence of the diglycosylated PrP(res) species in both fCJD(V180I) and VPSPr is likewise attributable to the absence of PrP(res) glycosylated at the first N-linked glycosylation site at residue 181, as in fCJD(T183A). 23527023 4 53 gly diglycosylated 957:970 arg1 the diglycosylated PrP the diglycosylated PrP OGER PrP Q9NP58 Remarkably, the absence of the diglycosylated PrP(res) species in both fCJD(V180I) and VPSPr is likewise attributable to the absence of PrP(res) glycosylated at the first N-linked glycosylation site at residue 181, as in fCJD(T183A). 518919 1 26 gly glycoprotein 250:261 arg1 human plasma alpha 1-acid glycoprotein human plasma alpha 1-acid glycoprotein Fterm glycoprotein The elucidation of the structures of the carbohydrate units linked to glycosylation site I of human plasma alpha 1-acid glycoprotein is described. 518919 1 22 gly glycosylation 200:212 arg1 human plasma alpha 1-acid glycoprotein glycoprotein site Fterm glycoprotein site The elucidation of the structures of the carbohydrate units linked to glycosylation site I of human plasma alpha 1-acid glycoprotein is described. 518919 1 42 gly linked 190:195 arg1 glycosylation site I AND the carbohydrate units glycoprotein site the carbohydrate units Fterm glycoprotein site The elucidation of the structures of the carbohydrate units linked to glycosylation site I of human plasma alpha 1-acid glycoprotein is described. 18533687 2 52 gly leucine-rich 332:343 arg1 leucine-rich repeats leucine leucine-rich repeats leucine These receptors are characterized by a large extracellular ectodomain containing leucine-rich repeats which contain the primary ligand binding site. 18533687 2 27 gly containing 321:330 arg1 a large extracellular ectodomain AND leucine-rich repeats a large extracellular ectodomain leucine-rich repeats ectodomain These receptors are characterized by a large extracellular ectodomain containing leucine-rich repeats which contain the primary ligand binding site. 30935958 0 91 gly N-glycosylation 10:24 arg2 N-glycosylation site variants N-glycosylation site variants site Impact of N-glycosylation site variants during human PrP aggregation and fibril nucleation. 7559574 3 42 gly glycopeptides 786:798 arg2 two glycopeptides two glycopeptides glycopeptides Tryptic digests of 125I-labeled phosphacan contain two glycopeptides that bind to Ng-CAM/L1, N-CAM, and tenascin. 10441114 5 19 gly O-glycosylated 730:743 arg2 residue 9 residue 9 residue 9 These polypetides are found to be O-glycosylated at T(125) (residue 9) with a glycan structure of the mucin type consisting of galactose N-acetylgalactosamine and N-acetylneuraminic acid residues. 10441114 5 100 gly galactose 823:831 arg1 residues residues residues These polypetides are found to be O-glycosylated at T(125) (residue 9) with a glycan structure of the mucin type consisting of galactose N-acetylgalactosamine and N-acetylneuraminic acid residues. 10441114 5 19 gly O-glycosylated 730:743 arg2 125 T(125) T(125) These polypetides are found to be O-glycosylated at T(125) (residue 9) with a glycan structure of the mucin type consisting of galactose N-acetylgalactosamine and N-acetylneuraminic acid residues. 1359371 3 12 part_of protein 368:374 arg1 The protein sequences protein The protein sequences Fterm Site protein sequences The protein sequences enabled us to clone an essentially full-length (1854 bp) cDNA using PCR and colony screening of an embryonic day (ED) 18 forebrain pUEX-1 cDNA library. 8968752 7 22 gly glycosylation 1223:1235 arg2 an additional glycosylation site an additional glycosylation site site The latter include a single base deletion and a novel amino acid change (Met378Thr), which generates an additional glycosylation site. 15113889 2 0 part_of sequence 379:386 arg1 a neutralizing epitope sequence a neutralizing epitope epitope The foreign epitope inserted was the six-amino-acid sequence ELDKWA, a sequence in a neutralizing epitope from human immunodeficiency virus type 1. 8354274 2 48 part_of residues 342:349 arg1 proteins proteins residues Fterm AminoAcid proteins arginine residues Peptidylarginine deiminase is a protein-modulating enzyme which converts the arginine residues in proteins to citrulline residues. 23883840 7 78 part_of HA1 1134:1136 arg1 the HA1 domain HA1 the HA1 domain OGER Site HA1 domain On the basis of amino acid substitutions in the HA1 domain, majority of the Turkish isolates were classified in the genetic group v and others in the genetic groups ii, iii, and vi. 12940452 1 27 gly glycoprotein 188:199 arg1 heterodimeric glycoprotein hormones heterodimeric glycoprotein hormones Fterm glycoprotein hCG, LH, FSH, and TSH are a family of heterodimeric glycoprotein hormones that contain a common alpha-subunit, but differ in their hormone-specific beta-subunits. 9311148 9 24 gly occupied 1151:1158 arg2 Asn24 Asn24 Asn24 The N-glycosylation sites at Asn38 and Asn83 are mainly occupied by tetraantennary glycans, whereas Asn24 is occupied by a mixture of bi-, tri- and tetraantennary glycans. 9311148 9 36 gly N-glycosylation 1046:1060 arg2 The N-glycosylation sites The N-glycosylation sites sites The N-glycosylation sites at Asn38 and Asn83 are mainly occupied by tetraantennary glycans, whereas Asn24 is occupied by a mixture of bi-, tri- and tetraantennary glycans. 9311148 9 56 gly occupied 1098:1105 arg2 The N-glycosylation sites The N-glycosylation sites sites The N-glycosylation sites at Asn38 and Asn83 are mainly occupied by tetraantennary glycans, whereas Asn24 is occupied by a mixture of bi-, tri- and tetraantennary glycans. 9311148 9 36 gly N-glycosylation 1046:1060 arg2 Asn38 Asn38 and Asn83 Asn38 and Asn83 The N-glycosylation sites at Asn38 and Asn83 are mainly occupied by tetraantennary glycans, whereas Asn24 is occupied by a mixture of bi-, tri- and tetraantennary glycans. 9311148 9 56 gly occupied 1098:1105 arg2 Asn38 Asn38 and Asn83 Asn38 and Asn83 The N-glycosylation sites at Asn38 and Asn83 are mainly occupied by tetraantennary glycans, whereas Asn24 is occupied by a mixture of bi-, tri- and tetraantennary glycans. 25498018 2 59 gly glycosylation 508:520 arg1 CLEC-2 CLEC-2 OGER CLEC-2 Q9P126 The two forms appear to have different ligand-binding abilities, indicating that the differential glycosylation of CLEC-2 possibly produces functionally distinct glycoforms. 8027066 6 75 gly glycosylation 1311:1323 arg2 each N-linked glycosylation site IR beta subunit site Cterm IR beta subunit 3643 site These data provide evidence for (i) glycosylation of each N-linked glycosylation site of the IR beta subunit, (ii) absence of correlation between internalization and transmembrane signaling, and (iii) a major role for oligosaccharide side chain(s) located close to the cell membrane in IR activation and transmembrane signaling. 8027066 6 93 gly glycosylation 1280:1292 arg1 each N-linked glycosylation site IR beta subunit site Cterm IR beta subunit 3643 site These data provide evidence for (i) glycosylation of each N-linked glycosylation site of the IR beta subunit, (ii) absence of correlation between internalization and transmembrane signaling, and (iii) a major role for oligosaccharide side chain(s) located close to the cell membrane in IR activation and transmembrane signaling. 24334224 4 49 part_of found 917:921 arg2 endogenous human G-CSF AND the equivalent O-linked glycosylation site endogenous human G-CSF the equivalent O-linked glycosylation site PUBTATOR Site G-CSF 1440 site Our results demonstrated that Thr134, the equivalent O-linked glycosylation site found on endogenous human G-CSF, is the only site modified with a single mannose, allowing glycoengineered P. pastoris to be used as a viable production platform for therapeutic rhG-CSF. 24334224 4 49 part_of found 917:921 arg2 endogenous human G-CSF AND Thr134 endogenous human G-CSF Thr134 PUBTATOR AminoAcid G-CSF 1440 Thr134 Our results demonstrated that Thr134, the equivalent O-linked glycosylation site found on endogenous human G-CSF, is the only site modified with a single mannose, allowing glycoengineered P. pastoris to be used as a viable production platform for therapeutic rhG-CSF. 20084966 6 19 gly glycosylation 1272:1284 arg2 the fifth glycosylation site NLS238-240 the fifth glycosylation site NLS238-240 site H protein of 5 measles virus all keep 4 glycosylation sites, the fifth glycosylation site NLS238-240 was losen because of the mutation from Set to Asn. 20084966 6 86 gly glycosylation 1241:1253 arg2 4 glycosylation sites 4 glycosylation sites sites H protein of 5 measles virus all keep 4 glycosylation sites, the fifth glycosylation site NLS238-240 was losen because of the mutation from Set to Asn. 10970800 8 31 gly glycosylated 1038:1049 arg1 the glycosylated receptor the glycosylated receptor Fterm receptor Ligand binding to intact stably transfected cells and confocal laser microscopic immunocytochemistry showed that the glycosylated receptor was correctly inserted into the plasma membrane to a much larger extent than the non-glycosylated receptor, which tended to accumulate in the perinuclear zone of the endoplasmic reticulum. 10970800 8 56 gly non-glycosylated 1141:1156 arg1 the non-glycosylated receptor the non-glycosylated receptor Fterm receptor Ligand binding to intact stably transfected cells and confocal laser microscopic immunocytochemistry showed that the glycosylated receptor was correctly inserted into the plasma membrane to a much larger extent than the non-glycosylated receptor, which tended to accumulate in the perinuclear zone of the endoplasmic reticulum. 28694069 10 18 gly aglycosylated 1652:1664 arg1 These aglycosylated variants These aglycosylated variants Fterm variants These aglycosylated variants have the potential to allow therapeutic antibodies to be produced in virtually any expression system and still maintain effector function. 30257863 7 48 gly glycosylation 997:1009 arg2 the sole Kir7.1 glycosylation site the sole Kir7.1 glycosylation site site Of note, mutagenesis of the sole Kir7.1 glycosylation site reduced conductance and open probability, as indicated by single-channel recording. 30605224 3 42 gly glycoproteins 464:476 arg1 many glycoproteins many glycoproteins Fterm glycoproteins However, it is extraordinarily challenging because of the low abundance of many glycoproteins and the heterogeneity of glycan structures. 30605224 3 55 gly heterogeneity 486:498 arg1 glycan structures glycoproteins glycan structures Fterm glycoproteins However, it is extraordinarily challenging because of the low abundance of many glycoproteins and the heterogeneity of glycan structures. 28221766 6 60 gly glycans 1222:1228 arg1 the N-terminal region the N-terminal region the N-terminal region Site region Our study provides a detailed specification, validation, and quantification of 15 co-occurring C9 proteoforms and the first direct experimental evidence of O-linked glycans in the N-terminal region. 7772241 5 54 gly glycopeptide 1012:1023 arg2 the glycopeptide (copeptin) moiety the glycopeptide (copeptin) moiety glycopeptide The C-terminal region did not have a distinctive Leu-rich core segment, which is always found in the glycopeptide (copeptin) moiety of VP precursors. 7526855 4 44 gly glycosylation 647:659 arg2 one N-linked glycosylation site one N-linked glycosylation site site Analysis of the deduced amino acid sequence indicated a hydrophobic protein with six membrane spanning domains, one N-linked glycosylation site, two conserved NPA boxes common to MIP26 family proteins, and conserved amino acid residue cysteine 189 common to water channels. 20512925 8 40 gly non-glycosylated 1204:1219 arg1 non-glycosylated sRAGE non-glycosylated sRAGE OGER RAGE 177 Carboxylated glycan-enriched population of RAGE forms higher order multimeric complexes with S100A12, and this ability to multimerize is reduced upon deglycosylation or by using non-glycosylated sRAGE expressed in E. coli. 20512925 8 50 gly RAGE 1069:1072 arg1 Carboxylated glycan-enriched population RAGE Carboxylated glycan-enriched population PUBTATOR RAGE Q15109 Carboxylated glycan-enriched population of RAGE forms higher order multimeric complexes with S100A12, and this ability to multimerize is reduced upon deglycosylation or by using non-glycosylated sRAGE expressed in E. coli. 26022737 6 35 part_of N-linked 784:791 arg1 a new N-linked glycosylation site N a new N-linked glycosylation site PUBTATOR Site N 354 site Accordingly, a new N-linked glycosylation site is created with an N102MS motif. 32125861 5 2 gly glycoproteins 1104:1116 arg1 50 glycoproteins 50 glycoproteins Fterm glycoproteins We next quantified 287 of these glycopeptides originating from 50 glycoproteins using a targeted proteomics approach. 32125861 5 17 gly glycopeptides 1070:1082 arg2 these glycopeptides these glycopeptides glycopeptides We next quantified 287 of these glycopeptides originating from 50 glycoproteins using a targeted proteomics approach. 2445888 3 108 gly glycosylation 416:428 arg2 the unique glycosylation site the unique glycosylation site site A conservative substitution of asparagine to glutamine at amino acid 86 in HLA-B7 was created to abolish the unique glycosylation site present on all HLA molecules. 28708860 4 33 gly N-glycosylation 685:699 arg2 N-glycosylation sites N-glycosylation sites sites and epitopes METHODS: A total of 700 HA genes (691 NA genes) of A/H3N2 viruses were chronologically analyzed for the mutational variants in amino acid features, N-glycosylation sites and epitopes since its emergence in 1968. 17960575 7 25 gly glycopeptides 1013:1025 arg2 glycopeptides glycopeptides glycopeptides An in-solution tryptic/chymotryptic digest of human transferrin (TRFE) was analyzed directly for glycopeptides subsequent to the addition of methanol and formic acid. 15113920 7 21 gly chain 1143:1147 arg1 residue N134 residue N134 residue N134 SpecificSite residue N134 The oligosaccharide chain on residue N134 was found to be crucial for protein folding, whereas single mutations at the other glycosylation sites were better tolerated. 15113920 7 52 gly glycosylation 1248:1260 arg2 the other glycosylation sites the other glycosylation sites sites The oligosaccharide chain on residue N134 was found to be crucial for protein folding, whereas single mutations at the other glycosylation sites were better tolerated. 8163463 8 47 gly glycosylation 1512:1524 arg2 extracellular domains extracellular domains domains Since N-linked glycosylation has only been found to occur on extracellular domains of plasma membrane proteins, these results suggest that the proposed transmembrane topology model for the glutamate receptor subunits is incorrect. 7532209 2 30 gly N-glycosylation 437:451 arg2 five putative N-glycosylation sites five putative N-glycosylation sites sites The receptor subunit protein has five putative N-glycosylation sites. 25289757 4 2 gly glycosylation 675:687 arg2 the glycosylation site mutant the glycosylation site mutant site We used the pharmacological inhibitor, tunicamycin, to inhibit glycosylation, generated chimeric D₂and D₃receptors by swapping their respective N-termini, and produced the glycosylation site mutant D₂and D₃receptors to study the roles of glycosylation on receptor functions, including cell surface expression, signaling, and internalization through specific microdomains. 32211339 8 87 gly N-glycosylation 1125:1139 arg2 N-glycosylation site removal N-glycosylation site removal site We then employed the fluorescence resonance energy transfer (FRET) method to measure the effect of N-glycosylation site removal on the distance in the cell membrane between the EBOV-GP and HLA-I (HLA.A*0201 allele). 28531887 11 45 part_of MT4-MMP 1449:1455 arg1 the single N-glycosylation site MT4-MMP the single N-glycosylation site PUBTATOR Site MT4-MMP 4326 site Moreover, we identified Asn318 as the single N-glycosylation site of MT4-MMP. 28531887 11 45 part_of MT4-MMP 1449:1455 arg1 Asn318 MT4-MMP Asn318 PUBTATOR AminoAcid MT4-MMP 4326 Asn318 Moreover, we identified Asn318 as the single N-glycosylation site of MT4-MMP. 1988041 5 21 part_of BAL 648:650 arg1 the amino-terminal sequence BAL the amino-terminal sequence PUBTATOR Site BAL P19835 sequence There is a putative signal sequence of 20 residues which is followed by the amino-terminal sequence of BAL, and the mature BAL contains 722 amino acid residues. 1988041 5 112 part_of contains 672:679 arg1 the mature BAL AND 722 amino acid residues the mature BAL 722 amino acid residues PUBTATOR Site BAL P19835 residues There is a putative signal sequence of 20 residues which is followed by the amino-terminal sequence of BAL, and the mature BAL contains 722 amino acid residues. 17144668 0 71 part_of carboxylase 74:84 arg1 the N-linked glycosylation sites carboxylase the N-linked glycosylation sites Fterm Site carboxylase sites Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. 8543840 12 79 part_of containing 1747:1756 arg1 signal sequence AND polypeptides signal sequence polypeptides polypeptides Low-frequency failure of signal sequence containing polypeptides to engage the translocation apparatus, resulting in synthesis and degradation in the cytosol, may represent an important mechanism for the generation of class I-restricted CTL responses. 10585855 1 61 gly N-glycosylated 269:282 arg1 a multispanning membrane protein protein Asn-642 Fterm protein Asn-642 The red-cell anion exchanger (band 3; AE1) is a multispanning membrane protein that traverses the bilayer up to 14 times and is N-glycosylated at Asn-642. 15067359 11 55 gly glycosylation 1607:1619 arg2 a conserved Asn glycosylation site a conserved Asn glycosylation site site TMEM16 family members were eight-transmenbrane proteins with TM16H1-TM16H3 domains and a conserved Asn glycosylation site. 25213400 1 0 gly glycoprotein 56:67 arg1 the main myelin glycoprotein the main myelin glycoprotein Fterm glycoprotein Human P0 is the main myelin glycoprotein of the peripheral nervous system. 25213400 1 0 gly glycoprotein 56:67 arg1 Human P0 Human P0 Cterm Human P0 Human P0 is the main myelin glycoprotein of the peripheral nervous system. 10837482 0 5 gly oligosaccharides 9:24 arg1 the meprin A metalloprotease metalloprotease oligosaccharides Fterm metalloprotease N-Linked oligosaccharides on the meprin A metalloprotease are important for secretion and enzymatic activity, but not for apical targeting. 17459925 1 56 part_of contains 141:148 arg1 Dengue virus envelope protein AND two N-linked glycosylation sites Dengue virus envelope protein two N-linked glycosylation sites Fterm Site protein sites Dengue virus envelope protein (E) contains two N-linked glycosylation sites, at Asn-67 and Asn-153. 9851685 6 51 gly glycosylation 945:957 arg2 a possible N-linked glycosylation site a possible N-linked glycosylation site site In addition, guinea pig IL-2 has a possible N-linked glycosylation site as seen in bovine and porcine IL-2. 1647289 2 5 part_of transferase 666:676 arg1 a glycosylation site-binding polypeptide oligosaccharyl transferase a glycosylation site-binding polypeptide OGER Site oligosaccharyl transferase polypeptide The beta-subunit of prolyl 4-hydroxylase (P4HB) is a highly unusual multifunctional polypeptide that is identical to the enzyme protein disulfide isomerase and a major cellular thyroid hormone-binding protein and is highly similar to a glycosylation site-binding polypeptide of oligosaccharyl transferase. 1647289 2 38 part_of 4-hydroxylase 400:412 arg1 a highly unusual multifunctional polypeptide prolyl 4-hydroxylase a highly unusual multifunctional polypeptide OGER Site prolyl 4-hydroxylase polypeptide The beta-subunit of prolyl 4-hydroxylase (P4HB) is a highly unusual multifunctional polypeptide that is identical to the enzyme protein disulfide isomerase and a major cellular thyroid hormone-binding protein and is highly similar to a glycosylation site-binding polypeptide of oligosaccharyl transferase. 20602265 10 32 part_of sequences 1713:1721 arg1 2009 S-OIV HA HA sequences Cterm Site HA sequences The previously identified cytotoxic T cell epitopes in various HA molecules were summarized and their corresponding sequences in 2009 S-OIV HA were defined. 19933092 5 59 part_of C 731:731 arg1 two potential protein kinase C phosphorylation sites protein kinase C two potential protein kinase C phosphorylation sites Cterm Site protein kinase C sites Topology prediction showed that the T2R2 protein contained one N-glycosylation site, one N-myristoylation site, and two potential protein kinase C phosphorylation sites. 19933092 5 34 part_of contained 635:643 arg1 the T2R2 protein AND two potential protein kinase C phosphorylation sites the T2R2 protein two potential protein kinase C phosphorylation sites Fterm Site protein sites Topology prediction showed that the T2R2 protein contained one N-glycosylation site, one N-myristoylation site, and two potential protein kinase C phosphorylation sites. 19933092 5 34 part_of contained 635:643 arg1 the T2R2 protein AND one N-myristoylation site protein site Fterm Site protein site Topology prediction showed that the T2R2 protein contained one N-glycosylation site, one N-myristoylation site, and two potential protein kinase C phosphorylation sites. 11230417 1 31 gly B 298:298 arg1 the high-mannose-type glycans RNase B the high-mannose-type glycans OGER RNase B P07998 The production of mannosidase activity by all currently recognized species of human viridans group streptococci was determined using an assay in which bacterial growth was dependent on the degradation of the high-mannose-type glycans of RNase B and subsequent utilization of released mannose. 15183061 2 40 gly glycosylation 221:233 arg1 CXCR4 CXCR4 PUBTATOR CXCR4 7852 We investigated the role of N-linked glycosylation in the N-terminus of CXCR4 in binding to HIV-1 gp120 envelope glycoproteins. 15183061 2 67 gly glycoproteins 297:309 arg1 HIV-1 gp120 envelope glycoproteins HIV-1 gp120 envelope glycoproteins Fterm glycoproteins We investigated the role of N-linked glycosylation in the N-terminus of CXCR4 in binding to HIV-1 gp120 envelope glycoproteins. 15375526 11 58 gly glycosylation 1674:1686 arg2 one Asn-linked glycosylation site one Asn-linked glycosylation site site Membrane topology and extracellular loop containing three Cys residues and one Asn-linked glycosylation site were evolutionarily conserved among mammalian CDC50 homologs and yeast Cdc50p homologs. 8325990 1 10 gly glycosylation 336:348 arg2 its sole N-linked glycosylation site its sole N-linked glycosylation site site Several strategies have been used to obtain recombinant (r) human plasminogens (HPg) containing different oligosaccharide side chains on its sole N-linked glycosylation site, present at Asn289. 8325990 1 7 gly containing 266:275 arg1 recombinant (r) human plasminogens AND different oligosaccharide side chains plasminogens site different oligosaccharide side chains Fterm plasminogens site Several strategies have been used to obtain recombinant (r) human plasminogens (HPg) containing different oligosaccharide side chains on its sole N-linked glycosylation site, present at Asn289. 21265812 5 7 gly glycoproteins 869:881 arg1 a N-glycan core substitution a N-glycan core substitution Backing this claim for a perspective in clinical practice are recent discoveries that even seemingly subtle changes in the glycan structure of glycoproteins, such as a N-glycan core substitution by a single sugar moiety, have far-reaching functional consequences. 7545918 5 22 gly glycosylation 999:1011 arg2 a glycosylation site a glycosylation site site This correlates with antigenic variations demonstrated between A/NJ/8/76, A/Sw/WI/49/76, and Québec isolate A/Sw/QC/5393/91 of swine influenza virus A. Another mutation was responsible for the loss of a glycosylation site, which may have also affected the antigenicity. 11251288 6 32 gly glycoprotein 1130:1141 arg1 the glycoprotein hormone erythropoietin the glycoprotein hormone erythropoietin Fterm glycoprotein Here, we have shown that the approach can be applied to the glycoprotein hormone erythropoietin, an important therapeutic glycoprotein with three sites of N-glycosylation that are essential for in vivo biological activity. 11251288 6 78 gly N-glycosylation 1225:1239 arg2 three sites three sites sites Here, we have shown that the approach can be applied to the glycoprotein hormone erythropoietin, an important therapeutic glycoprotein with three sites of N-glycosylation that are essential for in vivo biological activity. 11251288 6 104 gly glycoprotein 1192:1203 arg1 the glycoprotein hormone erythropoietin the glycoprotein hormone erythropoietin PUBTATOR erythropoietin 2056 Here, we have shown that the approach can be applied to the glycoprotein hormone erythropoietin, an important therapeutic glycoprotein with three sites of N-glycosylation that are essential for in vivo biological activity. 11251288 6 104 gly glycoprotein 1192:1203 arg1 an important therapeutic glycoprotein an important therapeutic glycoprotein Fterm glycoprotein Here, we have shown that the approach can be applied to the glycoprotein hormone erythropoietin, an important therapeutic glycoprotein with three sites of N-glycosylation that are essential for in vivo biological activity. 12515161 8 25 gly N-glycosylation 804:818 arg2 a N-glycosylation site a N-glycosylation site site In addition, a N-glycosylation site was found in the NS3 region of all the six isolates. 27574189 2 17 gly ADAMTS13 254:261 arg1 the glycan composition ADAMTS13 the glycan composition PUBTATOR ADAMTS13 11093 Here, we studied the glycan composition of plasma-derived ADAMTS13. 28770921 6 9 part_of GiENO 898:902 arg1 Our proposed GiENO plasminogen binding site GiENO plasminogen Our proposed GiENO plasminogen binding site OGER Site GiENO plasminogen P00747 site Our proposed GiENO plasminogen binding site (PLGBs) was identified at Lys266 based on the sequence comparison with bacterial enolase known to act as a plasminogen receptor. 28770921 6 54 part_of plasminogen 904:914 arg1 Our proposed GiENO plasminogen binding site GiENO plasminogen Our proposed GiENO plasminogen binding site OGER Site GiENO plasminogen P00747 site Our proposed GiENO plasminogen binding site (PLGBs) was identified at Lys266 based on the sequence comparison with bacterial enolase known to act as a plasminogen receptor. 17996106 8 5 gly glycosylation 1523:1535 arg2 glycosylation site prediction glycosylation site prediction site The resulting methods have been implemented in EnsembleGly, a web server for glycosylation site prediction. 24792223 3 14 gly glycosylation 756:768 arg2 the glycosylation site the glycosylation site site It generally enhances the stability, results in the hypsochromic effect and blueing, decreases the bioavailability and anticancer activity, and decreases, increases, or does not change the antioxidant activity of the anthocyanidins or anthocyanins, which is synergetically determined by the glycosylation site and the type and number of the glycosyl. 31186110 0 43 gly glycosylated 6:17 arg1 Novel glycosylated human interferon alpha 2b Novel glycosylated human interferon alpha 2b PUBTATOR interferon alpha 2b 3440 Novel glycosylated human interferon alpha 2b expressed in glycoengineered Pichia pastoris and its biological activity: N-linked glycoengineering approach. 26022737 11 58 gly glycosylation 1435:1447 arg1 N102 N102 N102 The different glycosylation of N102 relative to N69 might be influenced by the close vicinity of N102 to these functional sites and steric hindrance. 10913840 1 40 gly N-glycosylation 214:228 arg2 potential N-glycosylation sites potential N-glycosylation sites sites All mammalian alpha-1,3-fucosyltransferases (Fuc-Ts) so far characterized have potential N-glycosylation sites, but the role of these sites in enzymatic activity or localization has not been investigated. 8325864 7 70 gly glycosylation 1221:1233 arg1 this site site site Alteration of this sequon, Asn-19-Ala-20-Thr-21, by the substitutions N19Q, N19D, N19E, or T21G led to a lack of glycosylation at this site. 8985413 0 19 part_of glycoprotein 106:117 arg1 the second variable region glycoprotein the second variable region Fterm Site glycoprotein region Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site. 23668542 11 32 gly neoglycoprotein 1588:1602 arg1 the recombinant A1AT neoglycoprotein the recombinant A1AT neoglycoprotein PUBTATOR A1AT neoglycoprotein 5265 The results suggest the recombinant A1AT neoglycoprotein as a serious alternative to A1AT derived from human plasma. 8780172 10 128 gly glycosylation 1588:1600 arg2 75 asparagine 75 asparagine asparagine Tryptic mapping by reverse-phase HPLC confirmed that the potential glycosylation site at 75 asparagine was occupied by N-linked carbohydrate for the Chinese hamster ovary-derived VEGF/VPF, but not for E. coli-derived VEGF/VPF. 8780172 10 128 gly glycosylation 1588:1600 arg2 the potential glycosylation site the potential glycosylation site site Tryptic mapping by reverse-phase HPLC confirmed that the potential glycosylation site at 75 asparagine was occupied by N-linked carbohydrate for the Chinese hamster ovary-derived VEGF/VPF, but not for E. coli-derived VEGF/VPF. 8780172 10 132 gly occupied 1628:1635 arg2 75 asparagine 75 asparagine asparagine Tryptic mapping by reverse-phase HPLC confirmed that the potential glycosylation site at 75 asparagine was occupied by N-linked carbohydrate for the Chinese hamster ovary-derived VEGF/VPF, but not for E. coli-derived VEGF/VPF. 8780172 10 132 gly occupied 1628:1635 arg2 the potential glycosylation site the potential glycosylation site site Tryptic mapping by reverse-phase HPLC confirmed that the potential glycosylation site at 75 asparagine was occupied by N-linked carbohydrate for the Chinese hamster ovary-derived VEGF/VPF, but not for E. coli-derived VEGF/VPF. 32280962 7 27 gly glycoprotein 1344:1355 arg1 its glycoprotein ligands its glycoprotein ligands Fterm glycoprotein Lastly, we observed that the interaction between PSG1 and Gal-1 protects this lectin from oxidative inactivation and that PSG1 competes the ability of Gal-1 to bind to some but not all of its glycoprotein ligands. 2295597 2 37 part_of beta-hydroxylase 367:382 arg1 the deduced amino acid sequences dopamine beta-hydroxylase the deduced amino acid sequences PUBTATOR Site dopamine beta-hydroxylase 1621 sequences These peptide sequences were compared with the deduced amino acid sequences of bovine and human dopamine beta-hydroxylase obtained from the cloned cDNAs. 1970443 12 120 part_of G1 1981:1982 arg1 the SR-11 G1 coding sequences SR-11 G1 the SR-11 G1 coding sequences Cterm Site SR-11 G1 sequences Five potential asparagine-linked glycosylation sites were identified in the SR-11 G1 coding sequences, four of which were conserved between Hantaan and SR-11 viruses and three of which were conserved among all three viruses. 31336133 2 1 gly glycosylated 300:311 arg1 glycosylated peptides glycosylated peptides peptides The genetic fusion to natural or synthetic glycosylated peptides constitutes a promising strategy since it conserves the protein sequence and results in the improvement of the pharmacokinetic properties. 31336133 2 79 gly natural 279:285 arg1 glycosylated peptides glycosylated peptides peptides The genetic fusion to natural or synthetic glycosylated peptides constitutes a promising strategy since it conserves the protein sequence and results in the improvement of the pharmacokinetic properties. 15859596 8 103 gly glycoproteins 1170:1182 arg1 glycoproteins glycoproteins Fterm glycoproteins Further studies were done on the degree of sialylation within glycoproteins. 23714211 13 79 gly glycosylation 2309:2321 arg2 glycosylation site variants glycosylation site variants site Most striking was the finding that mice injected intravenously with NB cells expressing glycosylation site variants survived longer (P ≤ 0.002) than mice receiving SK-N-AS cells with undetectable ICAM-2. 22389730 9 6 gly Asia 1900:1903 arg1 a strain strain Asia Fterm strain 10413 CONCLUSIONS/SIGNIFICANCE: The basal position of the ZIKV strain isolated in Malaysia in 1966 suggests that the recent outbreak in Micronesia was initiated by a strain from Southeast Asia. 25793890 10 101 gly glycosylation 2113:2125 arg2 glycosylation sites glycosylation sites sites This strategy might improve the efficacy of the vaccines used in the partially successful RV144 HIV vaccine trial, where the two CRF01_AE immunogens (derived from the A244 and TH023 isolates) both possessed glycosylation sites at N136 and N149. 21978153 8 2 part_of protein 1541:1547 arg1 the position 179 protein the position 179 Fterm Site protein position 179 It is of particular interest that Haishu/SWL110/10 and Beijing/SE2649/09, isolated after November 2009, gained a new glycosylation site at the position 179 of HA protein, near the RBD. 11705953 6 11 gly glycosylation 1073:1085 arg2 N glycosylation site 4 site site Glycosylation sites 1 to 3 of OvGST1a (OvGST1b sites 2 to 4) are occupied by truncated N-glycans (Man(2)GlcNAc2 to Man(5)GlcNAc(2)), and N glycosylation site 4 of OvGST1a (OvGST1b site 5) carries Man(5)GlcNAc2 to Man(9)GlcNAc(2). 11705953 6 54 gly occupied 999:1006 arg2 OvGST1b sites 2 to 4 sites sites Glycosylation sites 1 to 3 of OvGST1a (OvGST1b sites 2 to 4) are occupied by truncated N-glycans (Man(2)GlcNAc2 to Man(5)GlcNAc(2)), and N glycosylation site 4 of OvGST1a (OvGST1b site 5) carries Man(5)GlcNAc2 to Man(9)GlcNAc(2). 11705953 6 38 gly carries 1122:1128 arg1 N glycosylation site 4 AND Man(5)GlcNAc2 site Man(5)GlcNAc2 site Glycosylation sites 1 to 3 of OvGST1a (OvGST1b sites 2 to 4) are occupied by truncated N-glycans (Man(2)GlcNAc2 to Man(5)GlcNAc(2)), and N glycosylation site 4 of OvGST1a (OvGST1b site 5) carries Man(5)GlcNAc2 to Man(9)GlcNAc(2). 9884403 6 39 gly glycoprotein 1322:1333 arg1 native human Tamm-Horsfall glycoprotein native human Tamm-Horsfall glycoprotein OGER Tamm-Horsfall glycoprotein P07911 Profiling of the carbohydrate moieties of Asn208 indicates a large heterogeneity, similar to that established for native human Tamm-Horsfall glycoprotein, namely, multiply charged complex-type carbohydrate structures, terminated by sulfate groups, sialic acid residues, and/or the Sda-determinant. 9884403 6 66 gly Asn208 1223:1228 arg1 the carbohydrate moieties Asn208 the carbohydrate moieties Asn208 Profiling of the carbohydrate moieties of Asn208 indicates a large heterogeneity, similar to that established for native human Tamm-Horsfall glycoprotein, namely, multiply charged complex-type carbohydrate structures, terminated by sulfate groups, sialic acid residues, and/or the Sda-determinant. 10682309 8 70 part_of SAP-B 1357:1361 arg1 the single glycosylation site SAP the single glycosylation site OGER Site SAP O60880 site A 643A > C transversion results in the exchange of asparagine 215 to histidine and eliminates the single glycosylation site of SAP-B. 1988041 15 10 part_of BAL 2432:2434 arg1 the deduced cDNA sequence BAL the deduced cDNA sequence PUBTATOR Site BAL P19835 sequence The cyanogen bromide cleavage and the partial sequencing of CNBr peptides also confirmed the location of methionines in the polypeptide chain as well as the deduced cDNA sequence of BAL. 8289366 5 43 part_of receptors 877:885 arg1 the third extracellular regions receptors the third extracellular regions Fterm Site receptors regions Two potential N-linked glycosylation sites are present in the third extracellular regions of both the NIH 3T3 and MDTF ecotropic receptors. 7688323 3 24 part_of GPIIb 635:639 arg1 this GPIIb domain GPIIb this GPIIb domain PUBTATOR Site GPIIb 3674 domain Here we show that the GPIIb fragment 704-856 contains the whole Baka epitope, and that chemical cleavage of a single O-linked oligosaccharide chain within this GPIIb domain correlates with the loss of its anti-Baka antibodies binding ability. 7688323 3 25 part_of GPIIb 497:501 arg1 the GPIIb fragment 704-856 GPIIb the GPIIb fragment 704-856 PUBTATOR Site GPIIb 3674 fragment Here we show that the GPIIb fragment 704-856 contains the whole Baka epitope, and that chemical cleavage of a single O-linked oligosaccharide chain within this GPIIb domain correlates with the loss of its anti-Baka antibodies binding ability. 7688323 3 33 part_of contains 520:527 arg1 the GPIIb fragment 704-856 AND the whole Baka epitope the GPIIb fragment 704-856 the whole Baka epitope epitope Here we show that the GPIIb fragment 704-856 contains the whole Baka epitope, and that chemical cleavage of a single O-linked oligosaccharide chain within this GPIIb domain correlates with the loss of its anti-Baka antibodies binding ability. 28844738 3 74 part_of contains 508:515 arg1 This domain AND the N-linked glycosylation site This domain the N-linked glycosylation site site This domain also contains the N-linked glycosylation site conserved in other isotypes. 19418565 0 33 gly glycoproteins 99:111 arg1 recombinant glycoproteins recombinant glycoproteins Fterm glycoproteins Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells. 11310976 4 7 gly unglycosylated 1141:1154 arg1 glycophorin A glycophorin A PUBTATOR glycophorin A 2993 The results strongly suggest that glycophorin A in these patients is partly unglycosylated with respect to O-linked glycans. 10024532 8 70 gly glycosylated 1157:1168 arg1 the glycosylated variable (Fv) fragment the glycosylated variable (Fv) fragment fragment A three-dimensional structure of the glycosylated variable (Fv) fragment was suggested using computer-assisted modelling. 2033065 2 101 gly glycosylation 358:370 arg2 the four potential N-linked glycosylation sites the four potential N-linked glycosylation sites sites To examine the role of glycosylation in the function of this protein, we singly eliminated each of the four potential N-linked glycosylation sites by site-directed mutagenesis of Asn to Gln at amino acid positions 97, 248, and 313 (HPC derivatives Q097, Q248, and Q313) or at the unusual consensus sequence Asn-X-Cys at 329 (HPC derivative Q329). 10536368 6 4 part_of activator 1014:1022 arg1 the signal/pro sequence tissue plasminogen activator the signal/pro sequence PUBTATOR Site tissue plasminogen activator P00750 sequence Replacement of the TNFR signal sequence with the signal/pro sequence of human tissue plasminogen activator (tPA) overcame the blockade to intracellular transport, and restored secretion to levels comparable to those achieved with the fully glycosylated molecule. 10536368 6 52 part_of TNFR 936:939 arg1 the TNFR signal sequence TNFR the TNFR signal sequence PUBTATOR Site TNFR 7132 sequence Replacement of the TNFR signal sequence with the signal/pro sequence of human tissue plasminogen activator (tPA) overcame the blockade to intracellular transport, and restored secretion to levels comparable to those achieved with the fully glycosylated molecule. 3192519 0 83 part_of ApoCIII 47:53 arg1 the glycosylation site ApoCIII the glycosylation site PUBTATOR Site ApoCIII 345 site Mutagenesis of the glycosylation site of human ApoCIII. 22365690 7 48 gly glycoproteins 1447:1459 arg1 the target glycoproteins the target glycoproteins Fterm glycoproteins This novel approach supports the screening of the target glycoproteins as biomarkers in clinical application. 20338479 5 19 gly beta1 711:715 arg1 sialylation integrin beta1 sialylation PUBTATOR integrin beta1 3688 RESULTS: IR increased sialylation of integrin beta1 responsible for its increased protein stability and adhesion and migration of colon cancer cells. 20338479 5 70 gly sialylation 687:697 arg1 integrin beta1 integrin beta1 PUBTATOR integrin beta1 3688 RESULTS: IR increased sialylation of integrin beta1 responsible for its increased protein stability and adhesion and migration of colon cancer cells. 27033547 4 15 gly glycosylation 547:559 arg2 154 154 Asn(154) The structure of Zika virus is similar to other known flavivirus structures, except for the ~10 amino acids that surround the Asn(154) glycosylation site in each of the 180 envelope glycoproteins that make up the icosahedral shell. 27033547 4 15 gly glycosylation 547:559 arg2 the Asn(154) glycosylation site the Asn(154) glycosylation site site The structure of Zika virus is similar to other known flavivirus structures, except for the ~10 amino acids that surround the Asn(154) glycosylation site in each of the 180 envelope glycoproteins that make up the icosahedral shell. 27033547 4 42 gly glycoproteins 594:606 arg1 the 180 envelope glycoproteins the 180 envelope glycoproteins Fterm glycoproteins The structure of Zika virus is similar to other known flavivirus structures, except for the ~10 amino acids that surround the Asn(154) glycosylation site in each of the 180 envelope glycoproteins that make up the icosahedral shell. 8783018 5 5 gly glycosylated 875:886 arg1 One glycosylated peptide One glycosylated peptide peptide One glycosylated peptide was detected after treatment of the peptide mixture with neuraminidase, and the carbohydrate structure partially elucidated by sequential glycosidase digestion monitored by MALDI-MS. 28747502 10 40 gly glycosylation 1694:1706 arg2 this glycosylation site this glycosylation site site Thus, one mouse model strategy has been to modify the mouse genome to remove this glycosylation site. 9620884 0 67 gly glycosylation 29:41 arg2 glycosylation site 3 glycosylation site 3 site Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility. 9620884 0 72 gly A 26:26 arg1 glycosylation site 3 glycosylation site 3 site Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility. 27713246 1 28 gly glycosylation 99:111 arg2 only one conserved glycosylation site only one conserved glycosylation site site Human IgG has only one conserved glycosylation site located in the Cγ2 domain of the Fc region that accounts for the presence of two sugar moieties per IgG. 17681482 11 36 gly glycosylated 1737:1748 arg2 N591 protein N591 Fterm protein N591 Our data demonstrates that NaSi-1 forms a dimeric protein which is glycosylated at N591, whose sorting to the apical membrane in renal epithelial cells is brefeldin A-sensitive and independent of lipid rafts or glycosylation. 12766998 8 30 gly glycoproteins 1496:1508 arg1 genotype 1a glycoproteins genotype 1a glycoproteins Fterm glycoproteins Absence of binding to CD81 and lack of recognition by most antibodies raised to genotype 1a glycoproteins indicate important differences between these glycoproteins representative of genotypes 3a and 1a. 12766998 8 39 gly glycoproteins 1555:1567 arg1 these glycoproteins these glycoproteins Fterm glycoproteins Absence of binding to CD81 and lack of recognition by most antibodies raised to genotype 1a glycoproteins indicate important differences between these glycoproteins representative of genotypes 3a and 1a. 19808681 4 79 gly N-glycosylation 560:574 arg1 Kv12.2 Kv12.2 PUBTATOR Kv12.2 23416 Because glycosylation plays important roles in the folding, trafficking, and function of various Kv channels, we focused on the N-glycosylation of Kv12.2. 6195967 7 26 gly glycosylation 999:1011 arg2 The glycosylation site The glycosylation site site The glycosylation site, a threonine residue, appears to be in a sequence which differs between Gc1 and Gc2. 6195967 7 26 gly glycosylation 999:1011 arg2 a threonine residue a threonine residue threonine residue The glycosylation site, a threonine residue, appears to be in a sequence which differs between Gc1 and Gc2. 7559653 3 87 part_of bears 526:530 arg1 the human platelet-activating factor (PAF) receptor AND a single N-linked glycosylation sequence the human platelet-activating factor (PAF) receptor a single N-linked glycosylation sequence PUBTATOR Site platelet-activating factor (PAF) receptor 5724 sequence Because bacterial binding is in part carbohydrate dependent, and the human platelet-activating factor (PAF) receptor bears a single N-linked glycosylation sequence in the second extracellular loop, we undertook studies to determine the role of this epitope in PAF receptor function. 1388166 8 63 gly glycosylation 1548:1560 arg2 the glycosylation site the glycosylation site site TFPI contains the sequence Pro-Phe-Lys, 9 residues N-terminal to the glycosylation site at position 228; this tripeptide may act as the recognition sequence for the GalNAc-transferase. 12177162 2 99 part_of apob-48r 304:311 arg1 the murine macrophage apob-48r cDNA gene sequence apob-48r the murine macrophage apob-48r cDNA gene sequence PUBTATOR Site apob-48r 171504 sequence Now we have identified and characterized the murine macrophage apob-48r cDNA gene sequence and its chromosomal location. 1988041 6 111 part_of contains 729:736 arg1 The cDNA sequence AND a 678-base 5'-untranslated sequence The cDNA sequence a 678-base 5'-untranslated sequence sequence The cDNA sequence also contains a 678-base 5'-untranslated sequence, a 97-base 3'-untranslated region, and a 14-base poly(A) tail. 1988041 6 111 part_of contains 729:736 arg1 The cDNA sequence AND a 14-base poly(A) tail The cDNA sequence a 14-base poly(A) tail tail The cDNA sequence also contains a 678-base 5'-untranslated sequence, a 97-base 3'-untranslated region, and a 14-base poly(A) tail. 1988041 6 111 part_of contains 729:736 arg1 The cDNA sequence AND a 97-base 3'-untranslated region The cDNA sequence a 97-base 3'-untranslated region region The cDNA sequence also contains a 678-base 5'-untranslated sequence, a 97-base 3'-untranslated region, and a 14-base poly(A) tail. 23234360 1 67 part_of proteins 181:188 arg1 Ser/Thr residues proteins Ser/Thr residues Fterm Site proteins residues The GalNAc O-glycosylation on Ser/Thr residues of extracellular proteins has not been well characterized from a proteomics perspective. 8702538 9 35 part_of CD33 1546:1549 arg1 the first Ig domain CD33 the first Ig domain PUBTATOR Site CD33 945 domain In contrast, mutation of a NCS motif in the first Ig domain of the I-type lectin CD33 unmasked its sialic acid binding activity. 8702538 9 73 part_of NCS 1492:1494 arg1 a NCS motif NCS a NCS motif OGER Site NCS motif In contrast, mutation of a NCS motif in the first Ig domain of the I-type lectin CD33 unmasked its sialic acid binding activity. 19131501 4 84 gly glycosylation 581:593 arg2 a conserved putative N-linked glycosylation site a conserved putative N-linked glycosylation site site The opossum STC2 amino acid sequence had 78.8% homology with human STC2, and has a conserved putative N-linked glycosylation site. 26944735 4 68 part_of BMP-1 872:876 arg1 the vicinal disulfide linkage C185-C186 BMP-1 the vicinal disulfide linkage C185-C186 PUBTATOR SiteSequence BMP-1 649 C185-C186 Ten disulfide linkages of BMP-1, including the vicinal disulfide linkage C185-C186 could be unambiguously identified. 19629045 6 9 gly glycosylation 916:928 arg2 T. brucei glycosylation site occupancy T. brucei glycosylation site occupancy site Analysis of T. brucei glycosylation site occupancy showed that TbSTT3A and TbSTT3B glycosylate sites in acidic to neutral and neutral to basic regions of polypeptide, respectively. 19629045 6 30 gly glycosylate 977:987 arg1 sites sites sites Analysis of T. brucei glycosylation site occupancy showed that TbSTT3A and TbSTT3B glycosylate sites in acidic to neutral and neutral to basic regions of polypeptide, respectively. 23775758 3 46 part_of strain-specific 642:656 arg1 strain-specific or variable epitopes strain strain-specific or variable epitopes Fterm Site strain epitopes The antigenic analysis of G-gene was carried out with a panel of anti-G and anti-F monoclonal antibodies that recognized strain-specific or variable epitopes which were originally derived against long strain (subtype GA1) and MON-3-88 strain (GA2). 14699159 8 16 gly N-glycosylation 1559:1573 arg2 single or multiple N-glycosylation sites single or multiple N-glycosylation sites sites Additional analysis of p90ATF6 mutants targeting single or multiple N-glycosylation sites also showed higher constitutive transactivating activity than wild type ATF6. 31184281 12 3 part_of has 2000:2002 arg1 The mouse TSHR A-subunit AND one less glycosylation site The mouse TSHR A-subunit one less glycosylation site PUBTATOR Site TSHR A-subunit 22095 site The mouse TSHR A-subunit differs from the human TSHR A-subunit in terms of its amino acid sequence and has one less glycosylation site than the human TSHR A-subunit. 17707131 2 5 part_of acyltransferase 407:421 arg1 amino acid sequences acyltransferase amino acid sequences Fterm Site acyltransferase sequences Alignment of amino acid sequences from AGPAT, sn-glycerol-3-phosphate acyltransferase, and dihydroxyacetonephosphate acyltransferase reveals four regions with strong homology (acyltransferase motifs I-IV). 17707131 2 77 part_of acyltransferase 360:374 arg1 amino acid sequences acyltransferase amino acid sequences Fterm Site acyltransferase sequences Alignment of amino acid sequences from AGPAT, sn-glycerol-3-phosphate acyltransferase, and dihydroxyacetonephosphate acyltransferase reveals four regions with strong homology (acyltransferase motifs I-IV). 15809770 8 46 gly glycosylation 911:923 arg2 One Asn-linked glycosylation site One Asn-linked glycosylation site site One Asn-linked glycosylation site within the second extracellular loop was conserved among mammalian Fzd8 orthologs, but not in Xenopus and zebrafish fzd8 orthologs. 19277548 4 7 gly glycopeptides 787:799 arg2 glycopeptides glycopeptides glycopeptides Here, we describe the oxidative derivatisation of carbohydrate moieties and covalent trapping of glycopeptides on hydrazide functionalized beads. 18258114 4 17 part_of envelope-protein 688:703 arg1 the envelope-protein glycosylation site protein the envelope-protein glycosylation site Fterm Site protein site All South African lineage 2 strains possessed the envelope-protein glycosylation site previously postulated to be associated with virulence. 11263562 2 51 gly glycopeptides 544:556 arg2 four glycopeptides four glycopeptides glycopeptides rhEPO expressed in a Chinese hamster ovary clone was exhaustively digested into four glycopeptides and nine peptides with endoproteinase Glu-C. 19371135 11 49 gly disialylated 1267:1278 arg1 disialylated biantennary complex-type glycans disialylated biantennary complex-type glycans The glycoprofile is dominated by disialylated biantennary complex-type glycans. 8573180 2 0 gly N-glycosylation 295:309 arg2 Asn57-->Gln Asn57-->Gln Asn57 We characterized a mutant GLUT4 lacking the N-glycosylation site (Asn57-->Gln) in primary cultures of rat adipose cells. 8573180 2 0 gly N-glycosylation 295:309 arg2 the N-glycosylation site the N-glycosylation site site We characterized a mutant GLUT4 lacking the N-glycosylation site (Asn57-->Gln) in primary cultures of rat adipose cells. 12022871 9 13 gly nonglycosylated 1349:1363 arg1 an active nonglycosylated enzyme an active nonglycosylated enzyme Fterm enzyme Mutagenesis of the putative N-glycosylation site (N79A) yielded an active nonglycosylated enzyme. 12022871 9 18 gly N-glycosylation 1303:1317 arg2 the putative N-glycosylation site the putative N-glycosylation site site Mutagenesis of the putative N-glycosylation site (N79A) yielded an active nonglycosylated enzyme. 22691915 0 74 gly N-glycosylation 51:65 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site A sensitive green fluorescent protein biomarker of N-glycosylation site occupancy. 8019599 1 7 gly glycosylation 160:172 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site The human erythrocyte anion transporter (band 3; AE1) has a single N-linked glycosylation site at amino residue Asn-642. 8019599 1 7 gly glycosylation 160:172 arg2 amino residue Asn-642 amino residue Asn-642 Asn-642 The human erythrocyte anion transporter (band 3; AE1) has a single N-linked glycosylation site at amino residue Asn-642. 2503511 10 78 gly glycosylation 1813:1825 arg2 individual glycosylation sites individual glycosylation sites sites The distribution of oligosaccharide structures at individual glycosylation sites (Asn residues 117, 184, and 448) was also determined. 2503511 10 78 gly glycosylation 1813:1825 arg2 448 Asn residues 117, 184, and 448 Asn residues 117, 184, and 448 The distribution of oligosaccharide structures at individual glycosylation sites (Asn residues 117, 184, and 448) was also determined. 2503511 10 78 gly glycosylation 1813:1825 arg2 184 Asn residues 117, 184, and 448 Asn residues 117, 184, and 448 The distribution of oligosaccharide structures at individual glycosylation sites (Asn residues 117, 184, and 448) was also determined. 2503511 10 78 gly glycosylation 1813:1825 arg2 184 Asn residues 117, 184, and 448 Asn residues 117, 184, and 448 The distribution of oligosaccharide structures at individual glycosylation sites (Asn residues 117, 184, and 448) was also determined. 31671706 2 23 part_of VEGFR-2 461:467 arg1 the VEGFR-2 region VEGFR-2 the VEGFR-2 region PUBTATOR Site VEGFR-2 3791 region The prepared fusion protein was expected to possess a total of five N-linked glycosylation sites: two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region. 31671706 2 68 part_of IgG 503:505 arg1 the human IgG Fc region IgG the human IgG Fc region Cterm Site IgG region The prepared fusion protein was expected to possess a total of five N-linked glycosylation sites: two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region. 31671706 2 86 part_of VEGFR-1 428:434 arg1 the VEGFR-1 region VEGFR the VEGFR-1 region PUBTATOR Site VEGFR 3791 region The prepared fusion protein was expected to possess a total of five N-linked glycosylation sites: two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region. 7798256 5 56 gly glycosylated 996:1007 arg1 the extracytosolic domain the extracytosolic domain domain Furthermore, the extracytosolic domain following the seventh transmembrane segment was properly translocated across the microsomal membrane and glycosylated whether the seventh transmembrane segment was the first, last, or the only transmembrane segment in the construct. 10828943 10 71 gly glycosylation 1656:1668 arg2 The glycosylation site SP-A site PUBTATOR SP-A 24773 site The glycosylation site of SP-A was located at the side of each subunit, suggesting that the covalently linked carbohydrate moiety probably occupies the spaces between the adjacent globular domains, a location that would not sterically interfere with ligand binding. 9249051 4 37 gly glycoprotein 766:777 arg1 the whole glycoprotein the whole glycoprotein Fterm glycoprotein To clarify the molecular basis for the stabilisation effect of saccharide moieties on human G-CSF the whole glycoprotein expressed in CHO cells has been investigated by means of two 1H-NMR-spectroscopy and two 1H-detected-heteronuclear 1H-13C experiments at natural abundance, and compared with the non-glycosylated form. 12766998 4 29 gly glycoproteins 763:775 arg1 the H77c glycoproteins the H77c glycoproteins Fterm glycoproteins Expression studies showed that, in common with the H77c glycoproteins, E1 and E2 from HCV3a-Gla localised to the endoplasmic reticulum (ER) membrane in both Huh-7 and BHK tissue culture cells and interacted to form native complexes. 20943674 6 91 gly rhLF 996:999 arg1 N-glycans rhLF N-glycans OGER rhLF P02788 However, N-glycans from rhLF are of the high mannose-, hybrid- and complex-type structures, with less N-acetylneuraminic acid and fucose. 3004936 7 24 gly glycosylation 1238:1250 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Unlike the Group 1 sequences, pMUP15 contains a potential N-linked glycosylation site. 9337875 6 40 part_of position 956:963 arg1 IDS IDS position PUBTATOR Site IDS 3423 position 84 This conserved cysteine, located at amino acid position 84 in IDS, was replaced either by an alanine (C84A) or by a threonine (C84T) using site-directed mutagenesis. 14736728 2 13 gly N-glycosylation 368:382 arg2 a potential N-glycosylation site a potential N-glycosylation site site We previously detected in two LINCL patients a homozygous missense mutation, p.Asn286Ser, that affects a potential N-glycosylation site. 20422033 7 76 gly glycosylation 1059:1071 arg2 potential N-linked glycosylation site numbers potential N-linked glycosylation site numbers site No differences in potential N-linked glycosylation site numbers or in gp160 variable loop amino acid lengths were identified. 8240107 6 19 gly glycosylation 802:814 arg2 a glycosylation site a glycosylation site site This altered a glycosylation site in the intradiscal portion of the rhodopsin molecule. 2737165 2 23 gly glycosylation 322:334 arg2 a predicted N-linked glycosylation site a predicted N-linked glycosylation site site There is a predicted N-linked glycosylation site in hGH-V at amino acid 140 that is absent in both hGH-V2 and in the highly homologous normal pituitary GH (hGH-N). 1379602 2 23 gly glycoprotein 194:205 arg1 desmoglein desmoglein Fterm desmoglein Despite the presumed importance of desmoglein, a 160-kDa glycoprotein, in desmosome formation and its possible involvement in certain blistering skin diseases, the precise location and function of this protein have not yet been firmly established. 1379602 2 23 gly glycoprotein 194:205 arg1 a 160-kDa glycoprotein a 160-kDa glycoprotein Fterm glycoprotein Despite the presumed importance of desmoglein, a 160-kDa glycoprotein, in desmosome formation and its possible involvement in certain blistering skin diseases, the precise location and function of this protein have not yet been firmly established. 2347305 4 33 part_of proteins 394:401 arg1 The primary sequences proteins The primary sequences Fterm Site proteins sequences The primary sequences of the HBK2/RCK2 K+ channel proteins exhibit major differences to other members of the RCK gene family. 26776361 2 24 gly glycosylation 553:565 arg2 each single naturally occurring glycosylation site each single naturally occurring glycosylation site site In this work we utilized the non-natural amino acid p-azidophenylalanine (pAzF) in combination with the chemoselective Staudinger-phosphite reaction to install branched PEG chains to recombinant unglycosylated erythropoietin (EPO) at each single naturally occurring glycosylation site. 26776361 2 57 gly unglycosylated 482:495 arg1 recombinant unglycosylated erythropoietin recombinant unglycosylated erythropoietin PUBTATOR erythropoietin 2056 In this work we utilized the non-natural amino acid p-azidophenylalanine (pAzF) in combination with the chemoselective Staudinger-phosphite reaction to install branched PEG chains to recombinant unglycosylated erythropoietin (EPO) at each single naturally occurring glycosylation site. 26776361 2 57 gly unglycosylated 482:495 arg1 EPO EPO PUBTATOR EPO 2056 In this work we utilized the non-natural amino acid p-azidophenylalanine (pAzF) in combination with the chemoselective Staudinger-phosphite reaction to install branched PEG chains to recombinant unglycosylated erythropoietin (EPO) at each single naturally occurring glycosylation site. 26062906 0 19 part_of Pre-S2 57:62 arg1 the Pre-S2 Domain Pre-S2 the Pre-S2 Domain Cterm Pre-S2 N-Linked Glycosylation at an Appropriate Position in the Pre-S2 Domain Is Critical for Cellular and Humoral Immunity against Middle HBV Surface Antigen. 30889014 6 12 gly glycosylation 859:871 arg2 Potential N-linked glycosylation site Potential N-linked glycosylation site site Potential N-linked glycosylation site (PNGS) number was calculated using the online N-glycosite software. 30889014 6 14 gly N-glycosite 924:934 arg2 the online N-glycosite software the online N-glycosite software N-glycosite Potential N-linked glycosylation site (PNGS) number was calculated using the online N-glycosite software. 15863355 8 23 gly sites 1318:1322 arg1 tri-antennary alpha1,3-fucosylation sites tri-antennary alpha1,3-fucosylation sites In the sera of patients with chronic inflammation, increased rates of tri-antennary alpha1,3-fucosylation at sites 3 and 4 and tetra-antennary alpha1,3-fucosylation at sites 3, 4 and 5 were detected. 15863355 8 23 gly sites 1318:1322 arg1 tetra-antennary alpha1,3-fucosylation sites tetra-antennary alpha1,3-fucosylation sites In the sera of patients with chronic inflammation, increased rates of tri-antennary alpha1,3-fucosylation at sites 3 and 4 and tetra-antennary alpha1,3-fucosylation at sites 3, 4 and 5 were detected. 15863355 8 34 gly alpha1,3-fucosylation 1293:1313 arg1 sites 3 and 4 sites 3 and 4 sites In the sera of patients with chronic inflammation, increased rates of tri-antennary alpha1,3-fucosylation at sites 3 and 4 and tetra-antennary alpha1,3-fucosylation at sites 3, 4 and 5 were detected. 15863355 8 44 gly alpha1,3-fucosylation 1352:1372 arg1 sites 3 and 4 sites 3 and 4 sites In the sera of patients with chronic inflammation, increased rates of tri-antennary alpha1,3-fucosylation at sites 3 and 4 and tetra-antennary alpha1,3-fucosylation at sites 3, 4 and 5 were detected. 23808883 1 68 gly N-glycosylation 128:142 arg2 one conserved N-glycosylation site one conserved N-glycosylation site site IgG antibodies have one conserved N-glycosylation site at Asn 297 in each of their constant heavy chain regions. 20506028 0 69 part_of chondromodulin-I 59:74 arg1 the glycosylated N-terminal domain chondromodulin-I the glycosylated N-terminal domain PUBTATOR Site chondromodulin-I 11061 domain A functional role of the glycosylated N-terminal domain of chondromodulin-I. 24872415 0 44 gly N-glycosylation 0:14 arg1 asparagine 8 asparagine 8 asparagine 8 N-glycosylation of asparagine 8 regulates surface expression of major histocompatibility complex class I chain-related protein A (MICA) alleles dependent on threonine 24. 30605224 5 66 gly glycopeptide/glycoprotein 757:781 arg1 glycopeptide/glycoprotein enrichment glycopeptide/glycoprotein enrichment glycopeptide/glycoprotein In this review, we first summarize major methods for glycopeptide/glycoprotein enrichment, followed by the chemical and enzymatic methods to generate a mass tag for glycosylation site identification. 30605224 5 90 gly glycosylation 869:881 arg2 glycosylation site identification glycosylation site identification site In this review, we first summarize major methods for glycopeptide/glycoprotein enrichment, followed by the chemical and enzymatic methods to generate a mass tag for glycosylation site identification. 16331960 10 27 part_of 15-mer 1898:1903 arg1 a 15-mer peptide mer a 15-mer peptide OGER Site mer Q12866 peptide Based on its proximity to the Asn413 glycosylation site, a 15-mer peptide, m/z 1690.472 (NKSDNCEDTPEAGYF), was identified as a suitable candidate for raising anti-peptide antibodies for subsequent immunological detection. 19800422 0 59 gly glycosylation 30:42 arg2 asparagine-linked glycosylation site asparagine-linked glycosylation site site The role of asparagine-linked glycosylation site on the catalytic domain of matriptase in its zymogen activation. 7524670 6 24 part_of contained 972:980 arg1 Each beta-subunit AND a single N-glycosylation site Each beta-subunit a single N-glycosylation site Fterm Site beta-subunit site Each beta-subunit contained a single N-glycosylation site, but a high degree of microheterogeneity was observed in the structure of its N-linked oligosaccharides. 10965162 4 17 gly N-glycosylation 627:641 arg2 the N-glycosylation site the N-glycosylation site site One of the examined MLD patients was additionally a carrier of an isolated mutation leading to the loss of the N-glycosylation site. 12421952 5 31 part_of protein 594:600 arg1 an included leader peptide protein an included leader peptide Fterm Site protein peptide The mRNA comprises 1188 nucleotides encoding a protein of 371 aa with an included leader peptide of 20 residues. 28887103 1 21 gly Glycosylation 86:98 arg1 proteins proteins Fterm proteins Glycosylation of proteins is the most common, multifaceted co- and post-translational modification responsible for many biological processes and cellular functions. 27259237 10 26 gly N-glycosylation 1458:1472 arg2 numerous N-glycosylation sites numerous N-glycosylation sites sites These data confirm that N-glycosylation is important in both physiological and pathological processes in the brain, and provide useful details about numerous N-glycosylation sites in brain proteins. 8702538 5 83 part_of sites 855:859 arg1 CD22 CD22 sites PUBTATOR Site CD22 933 sites In this work we have performed site-specific mutagenesis of potential N-linked glycosylation sites on CD22 in an effort to determine whether they might be involved in ligand recognition. 9352200 6 39 part_of Conserved 675:683 arg1 Conserved ZPC domains Conserved ZPC Conserved ZPC domains PUBTATOR Site Conserved ZPC 7784 domains Conserved ZPC domains and motifs present in the Xenopus sequence included a signal peptide sequence, an N-linked glycosylation site, and 12 aligned Cys residues. 9352200 6 96 part_of ZPC 685:687 arg1 Conserved ZPC domains Conserved ZPC Conserved ZPC domains PUBTATOR Site Conserved ZPC 7784 domains Conserved ZPC domains and motifs present in the Xenopus sequence included a signal peptide sequence, an N-linked glycosylation site, and 12 aligned Cys residues. 23820512 9 38 gly glycoprotein 1462:1473 arg1 glycoprotein quantification glycoprotein quantification Fterm glycoprotein Given the likely high prevalence and variability of partial occupancy, glycoprotein quantification based exclusively on deglycosylated peptides may lead to inaccurate quantification. 23820512 9 50 gly deglycosylated 1511:1524 arg1 deglycosylated peptides deglycosylated peptides peptides Given the likely high prevalence and variability of partial occupancy, glycoprotein quantification based exclusively on deglycosylated peptides may lead to inaccurate quantification. 19369259 3 35 gly glycosylation 522:534 arg2 10 putative glycosylation sites 10 putative glycosylation sites sites CD36 is heavily modified post-translationally by N-linked glycosylation, and 10 putative glycosylation sites situated in the large extracellular loop of the protein have been identified; however, their utilization and role in the folding and function of the protein have not been characterized. 17144668 3 82 part_of carboxylase 464:474 arg1 the N-glycosylation sites carboxylase the N-glycosylation sites Fterm Site carboxylase sites In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. 10364275 4 23 gly glycosylation 831:843 arg2 potential glycosylation sites potential glycosylation sites sites Of interest are changes that resulted in the removal, repositioning, and addition of potential glycosylation sites within the V1, V2, and V3 regions of envelope gp120. 22266649 2 14 gly glycosylation 204:216 arg2 a glycosylation site a glycosylation site site Even a monosaccharide (magenta) placed at a glycosylation site can significantly enhance binding of peptides to their receptor. 30541852 13 14 part_of SLC19A1 1989:1995 arg1 SLC19A1 and also other residues SLC19A1 SLC19A1 and also other residues PUBTATOR Site SLC19A1 20509 residues We show that GLN infection is limited to mouse cells due to both a mutation in the mouse gene preventing the glycosylation of SLC19A1 and also other residues conserved within the rat but not in the hamster and human proteins. 3980466 2 18 gly sialylation 285:295 arg1 their asparagine-linked oligosaccharides their asparagine-linked oligosaccharides The influence of peptide structure of endogenous cell-surface glycoproteins on the branching and sialylation of their asparagine-linked oligosaccharides was evaluated in a murine B cell lymphoma, AKTB-1b. 3980466 2 26 gly asparagine-linked 306:322 arg1 their asparagine-linked oligosaccharides asparagine their asparagine-linked oligosaccharides asparagine The influence of peptide structure of endogenous cell-surface glycoproteins on the branching and sialylation of their asparagine-linked oligosaccharides was evaluated in a murine B cell lymphoma, AKTB-1b. 3980466 2 89 gly glycoproteins 250:262 arg1 endogenous cell-surface glycoproteins endogenous cell-surface glycoproteins Fterm glycoproteins The influence of peptide structure of endogenous cell-surface glycoproteins on the branching and sialylation of their asparagine-linked oligosaccharides was evaluated in a murine B cell lymphoma, AKTB-1b. 7688956 6 11 part_of containing 930:939 arg1 a proteolytic fragment AND the C-terminal tripeptide a proteolytic fragment the C-terminal tripeptide tripeptide The antibodies were found to bind, albeit with a generally reduced affinity, to a proteolytic fragment containing the C-terminal tripeptide and the GPI anchor. 10998266 6 6 gly trisialylated 1390:1402 arg1 di- and trisialylated triantennary oligosaccharides di- and trisialylated triantennary oligosaccharides Structural details of the isomers were analyzed by LC/MS/MS, and it was indicated that di- and trisialylated tetraantennary oligosaccharides are attached to Asn24, 38, and 83, whereas their isomers, di- and trisialylated triantennary oligosaccharides containing N-acetyllactosamines, are combined with Asn24. 9804815 5 60 part_of 24-mer 852:857 arg1 a 24-mer glycopeptide mer a 24-mer glycopeptide OGER Site mer Q12866 glycopeptide GalNAc-T4 transferred GalNAc to two sites in the MUC1 tandem repeat sequence (Ser in GVTSA and Thr in PDTR) using a 24-mer glycopeptide with GalNAc residues attached at sites utilized by GalNAc-T1, -T2, and -T3 (TAPPAHGVTSAPDTRPAPGSTAPPA, GalNAc attachment sites underlined). 21431619 4 53 gly glycoforms 650:659 arg1 transferrin glycoforms transferrin glycoforms PUBTATOR transferrin 7018 In some cases, these protein variants co-migrate with transferrin glycoforms, which complicates interpretation. 7711052 3 35 gly glycosylation 745:757 arg2 one glycosylation site one glycosylation site site Each of these proteins occurs naturally as two populations of molecules, distinguished from each other only by the presence or absence of an oligosaccharide at one glycosylation site. 7711052 3 82 gly presence 696:703 arg2 one glycosylation site AND an oligosaccharide one glycosylation site an oligosaccharide site Each of these proteins occurs naturally as two populations of molecules, distinguished from each other only by the presence or absence of an oligosaccharide at one glycosylation site. 29273683 9 80 gly presence 1298:1305 arg2 this conserved position AND an N-glycan this conserved position an N-glycan position Thus, the presence and composition of an N-glycan in this conserved position both appear to influence the steroid binding of CBG. 20371379 6 10 gly glycosylation 692:704 arg1 the recombinant protein the recombinant protein OGER protein, it P35900 In order to overcome non-native glycosylation of the recombinant protein, it was necessary to delete a glycosylation site. 20371379 6 19 gly glycosylation 763:775 arg2 a glycosylation site a glycosylation site site In order to overcome non-native glycosylation of the recombinant protein, it was necessary to delete a glycosylation site. 24468271 6 2 gly glycosylated 855:866 arg1 The glycosylated form form of hIL4 PUBTATOR form of hIL4 3565 The glycosylated form of hIL4 unexpectedly has lower biological activity and lower stability when compared to its non-glycosylated form. 8068684 7 84 gly contains 1270:1277 arg1 NHE-1 AND O-linked oligosaccharide NHE-1 O-linked oligosaccharide PUBTATOR NHE-1 6548 In addition, treatment of NHE-1 with neuraminidase and O-glycosidase demonstrated that NHE-1 also contains O-linked oligosaccharide. 9287313 0 62 gly glycosylation 136:148 arg2 typical (Asn-X-Ser/Thr) and atypical (Asn-X-cys) glycosylation motifs typical (Asn-X-Ser/Thr) and atypical (Asn-X-cys) glycosylation motifs motifs Multiple dimeric forms of human CD69 result from differential addition of N-glycans to typical (Asn-X-Ser/Thr) and atypical (Asn-X-cys) glycosylation motifs. 17001080 3 58 gly glycosylation 638:650 arg2 residue 154 residue 154 residue 154 The West Nile virus envelope (E) protein contains a single N-linked glycosylation site at residue 154, whereas Dengue virus E contains sites at residues 153 and 67. 17001080 3 58 gly glycosylation 638:650 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site The West Nile virus envelope (E) protein contains a single N-linked glycosylation site at residue 154, whereas Dengue virus E contains sites at residues 153 and 67. 26993603 2 4 gly glycosylation 303:315 arg2 glycosylation sites glycosylation sites sites In this study, we used mass spectrometry to identify glycosylation sites and the glycan structure, high-throughput lectin microarray to provide rapid and sensitive profiling of glycoconjugates, and site-directed mutagenesis to clarify the impact of glycans on target glycoproteins in vivo. 26993603 2 24 gly glycoproteins 517:529 arg1 target glycoproteins target glycoproteins Fterm glycoproteins In this study, we used mass spectrometry to identify glycosylation sites and the glycan structure, high-throughput lectin microarray to provide rapid and sensitive profiling of glycoconjugates, and site-directed mutagenesis to clarify the impact of glycans on target glycoproteins in vivo. 25224661 6 73 part_of regions 959:965 arg1 E2 region regions E2 region region RESULTS: Genetic analysis of full length genome revealed two hypervariable regions (HVR) in E2 region - HVR496 and HVR576, with a variable 5-8 amino-acid insertion sequence and a putative N-glycosylation site. 16927286 4 3 part_of glycoprotein 570:581 arg1 viral attachment glycoprotein (G) gene sequences glycoprotein (G viral attachment glycoprotein (G) gene sequences OGER Site glycoprotein (G P07996 sequences Therefore, we analyzed viral attachment glycoprotein (G) gene sequences from 106 RSV subgroup A isolates collected in New Zealand between 1967 and 2003, and 38 subgroup B viruses collected between 1984 and 2004. 16512686 6 95 part_of peptides 1727:1734 arg1 N-linked glycosylation sites peptides N-linked glycosylation sites sites Analyses performed on human serum showed that this SEC glycopeptide isolation procedure results in at least a 3-fold increase in the total number of glycopeptides identified by LC-MS/MS, demonstrating that this simple, nonselective, rapid method is an effective tool to facilitate the identification of peptides with N-linked glycosylation sites. 11944983 7 1 part_of S100A14 758:764 arg1 The deduced amino acid sequence S100A14 The deduced amino acid sequence PUBTATOR Site S100A14 57402 sequence The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 28 part_of Ca2+-binding 839:850 arg1 several potential protein kinase phosphorylation sites EF-hand Ca2 several potential protein kinase phosphorylation sites OGER Site EF-hand Ca2 P00920 sites The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 28 part_of Ca2+-binding 839:850 arg1 a glycosylation site EF-hand Ca2 a glycosylation site OGER Site EF-hand Ca2 P00920 site The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 28 part_of Ca2+-binding 839:850 arg1 a myristoylation motif EF-hand Ca2 a myristoylation motif OGER Site EF-hand Ca2 P00920 motif The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 28 part_of Ca2+-binding 839:850 arg1 two EF-hand Ca2+-binding domains EF-hand Ca2 two EF-hand Ca2+-binding domains OGER Site EF-hand Ca2 P00920 domains The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 70 part_of protein 929:935 arg1 two EF-hand Ca2+-binding domains protein two EF-hand Ca2+-binding domains Fterm Site protein domains The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 70 part_of protein 929:935 arg1 several potential protein kinase phosphorylation sites protein several potential protein kinase phosphorylation sites Fterm Site protein sites The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 93 part_of EF-hand 831:837 arg1 several potential protein kinase phosphorylation sites EF-hand Ca2 several potential protein kinase phosphorylation sites OGER Site EF-hand Ca2 P00920 sites The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 93 part_of EF-hand 831:837 arg1 a glycosylation site EF-hand Ca2 a glycosylation site OGER Site EF-hand Ca2 P00920 site The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 93 part_of EF-hand 831:837 arg1 a myristoylation motif EF-hand Ca2 a myristoylation motif OGER Site EF-hand Ca2 P00920 motif The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 93 part_of EF-hand 831:837 arg1 two EF-hand Ca2+-binding domains EF-hand Ca2 two EF-hand Ca2+-binding domains OGER Site EF-hand Ca2 P00920 domains The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 63 part_of contains 818:825 arg1 The deduced amino acid sequence AND two EF-hand Ca2+-binding domains The deduced amino acid sequence two EF-hand Ca2+-binding domains domains The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 63 part_of contains 818:825 arg1 The deduced amino acid sequence AND a glycosylation site The deduced amino acid sequence a glycosylation site site The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 63 part_of contains 818:825 arg1 The deduced amino acid sequence AND a myristoylation motif The deduced amino acid sequence a myristoylation motif motif The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 11944983 7 63 part_of contains 818:825 arg1 The deduced amino acid sequence AND several potential protein kinase phosphorylation sites The deduced amino acid sequence several potential protein kinase phosphorylation sites sites The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites. 15100290 6 26 gly used 843:846 arg2 the glycosylation site the glycosylation site site Importantly, we found that when the anti-dextran V(H) CDR2 replaced CDR2 of an anti-dansyl V(H), the glycosylation site was used, but H chains were withheld in the endoplasmic reticulum and did not traffic to the Golgi apparatus. 15100290 6 36 gly glycosylation 820:832 arg2 the glycosylation site the glycosylation site site Importantly, we found that when the anti-dextran V(H) CDR2 replaced CDR2 of an anti-dansyl V(H), the glycosylation site was used, but H chains were withheld in the endoplasmic reticulum and did not traffic to the Golgi apparatus. 26458842 2 22 gly N-glycosylation 267:281 arg2 ancestrally conserved N-glycosylation sites ancestrally conserved N-glycosylation sites sites The loss of ancestrally conserved N-glycosylation sites may result in the evolution of protein structure and function. 24806200 7 15 part_of β-hCG 1364:1368 arg1 the N-terminal fragment hCG the N-terminal fragment PUBTATOR Site hCG 93659 fragment Key steps in these syntheses include a successful double Lansbury glycosylation en route to the N-terminal fragment of β-hCG and the sequential installation of four O-linked glycosyl-amino acid cassettes into closely spaced O-glycosylation sites in a single, high-yielding solid-supported synthesis to access the C-terminal portion of the molecule. 24806200 7 72 part_of N-terminal 1341:1350 arg1 the N-terminal fragment N-terminal the N-terminal fragment Cterm Site N-terminal fragment Key steps in these syntheses include a successful double Lansbury glycosylation en route to the N-terminal fragment of β-hCG and the sequential installation of four O-linked glycosyl-amino acid cassettes into closely spaced O-glycosylation sites in a single, high-yielding solid-supported synthesis to access the C-terminal portion of the molecule. 11038011 1 17 part_of neurophysin 218:228 arg1 three polypeptides neurophysin three polypeptides Fterm Site neurophysin polypeptides The vasopressin gene encodes three polypeptides besides the signal peptide: vasopressin, neurophysin II (neurophysin), and the carboxy-terminal glycopeptide (glycopeptide). 11038011 1 22 part_of vasopressin 133:143 arg1 three polypeptides vasopressin three polypeptides PUBTATOR Site vasopressin 551 polypeptides The vasopressin gene encodes three polypeptides besides the signal peptide: vasopressin, neurophysin II (neurophysin), and the carboxy-terminal glycopeptide (glycopeptide). 7559574 7 0 gly present 1919:1925 arg1 fibronectin type III-like domains AND asparagine-linked oligosaccharides fibronectin type III-like domains asparagine-linked oligosaccharides domains Our results therefore indicate that the interactions of phosphacan/RPTP zeta/beta with neural cell adhesion molecules and tenascin are mediated by asparagine-linked oligosaccharides present in their carbonic anhydrase- and fibronectin type III-like domains. 7559574 7 55 gly asparagine-linked 1884:1900 arg1 asparagine-linked oligosaccharides asparagine asparagine-linked oligosaccharides asparagine Our results therefore indicate that the interactions of phosphacan/RPTP zeta/beta with neural cell adhesion molecules and tenascin are mediated by asparagine-linked oligosaccharides present in their carbonic anhydrase- and fibronectin type III-like domains. 10191272 5 23 gly N-glycosylation 1052:1066 arg2 three defective N-glycosylation sites three defective N-glycosylation sites sites We showed that: (i) each of the three N-glycosylation sites are utilized in COS-7 cells; (ii) the mutant with three defective N-glycosylation sites was not (or was very inefficiently) expressed at the plasma membrane and accumulated inside the cell at the perinuclear zone; (iii) the preservation of two sites allowed normal receptor delivery to the plasma membrane, the presence of only Asn176 ensuring a behaviour similar to that of the wild-type receptor; and (iv) all expressed receptors displayed unchanged pharmacological properties (Kd for 125I-sarcosine1-AII; sarcosine1-AII-induced inositol phosphate production). 10191272 5 27 gly N-glycosylation 964:978 arg2 the three N-glycosylation sites the three N-glycosylation sites sites We showed that: (i) each of the three N-glycosylation sites are utilized in COS-7 cells; (ii) the mutant with three defective N-glycosylation sites was not (or was very inefficiently) expressed at the plasma membrane and accumulated inside the cell at the perinuclear zone; (iii) the preservation of two sites allowed normal receptor delivery to the plasma membrane, the presence of only Asn176 ensuring a behaviour similar to that of the wild-type receptor; and (iv) all expressed receptors displayed unchanged pharmacological properties (Kd for 125I-sarcosine1-AII; sarcosine1-AII-induced inositol phosphate production). 10191272 5 79 gly utilized 990:997 arg2 the three N-glycosylation sites the three N-glycosylation sites sites We showed that: (i) each of the three N-glycosylation sites are utilized in COS-7 cells; (ii) the mutant with three defective N-glycosylation sites was not (or was very inefficiently) expressed at the plasma membrane and accumulated inside the cell at the perinuclear zone; (iii) the preservation of two sites allowed normal receptor delivery to the plasma membrane, the presence of only Asn176 ensuring a behaviour similar to that of the wild-type receptor; and (iv) all expressed receptors displayed unchanged pharmacological properties (Kd for 125I-sarcosine1-AII; sarcosine1-AII-induced inositol phosphate production). 7613486 5 20 gly glycosylation 1063:1075 arg2 these glycosylation sites these glycosylation sites sites Chinese hamster ovary cells were transfected with the wild-type human insulin receptor cDNA, or cDNA that had Q substituted for N at one, two, or all four of these glycosylation sites. 18533687 1 73 gly leucine-rich 179:190 arg1 the leucine-rich repeat-containing G-protein-coupled receptor (LGR) family leucine the leucine-rich repeat-containing G-protein-coupled receptor (LGR) family leucine The relaxin receptor, RXFP1, is a member of the leucine-rich repeat-containing G-protein-coupled receptor (LGR) family. 8554050 4 48 gly glycoprotein 664:675 arg1 the "PRB2-like" Con2 glycoprotein the "PRB2-like" Con2 glycoprotein Fterm glycoprotein Because of a probable gene conversion encompassing > or = 684 bp of DNA, the "PRB2-like" Con2 glycoprotein is encoded in exon 3 of a PRB1 allele (PRB1M CON2+) with a potential glycosylation site. 8554050 4 76 gly glycosylation 746:758 arg2 a potential glycosylation site a potential glycosylation site site Because of a probable gene conversion encompassing > or = 684 bp of DNA, the "PRB2-like" Con2 glycoprotein is encoded in exon 3 of a PRB1 allele (PRB1M CON2+) with a potential glycosylation site. 8349598 4 22 gly Asn-linked 818:827 arg1 bear Asn-linked oligosaccharides Asn bear Asn-linked oligosaccharides Asn Glycoproteins which do not contain the PXR/K motif but bear Asn-linked oligosaccharides terminating with GGnM or sialic acid alpha 2,3/6GGnM have also been described, suggesting a distinct GalNAc-transferase may be responsible for their synthesis. 23891555 3 34 gly sialylated 556:565 arg1 both sugars both sugars Normal IgA1 hinge region carries 3 to 6 O-glycans consisting of N-acetylgalactosamine (GalNAc) and galactose (Gal); both sugars may be sialylated. 23891555 3 42 gly carries 446:452 arg1 Normal IgA1 hinge region AND 3 to 6 O-glycans Normal IgA1 hinge region 3 to 6 O-glycans region Normal IgA1 hinge region carries 3 to 6 O-glycans consisting of N-acetylgalactosamine (GalNAc) and galactose (Gal); both sugars may be sialylated. 9472003 5 9 gly N-glycosylation 729:743 arg2 an otherwise partially used N-glycosylation site an otherwise partially used N-glycosylation site site The occupancy of an otherwise partially used N-glycosylation site of reduced NGFRe was complete suggesting that, normally, folding and disulfide formation occurred as rapidly as N-glycosylation. 9472003 5 50 gly occupancy 688:696 arg2 an otherwise partially used N-glycosylation site an otherwise partially used N-glycosylation site site The occupancy of an otherwise partially used N-glycosylation site of reduced NGFRe was complete suggesting that, normally, folding and disulfide formation occurred as rapidly as N-glycosylation. 10604468 2 33 part_of receptor 343:350 arg1 its C-type-lectin-like NK receptor domain receptor its C-type-lectin-like NK receptor domain Fterm Site receptor domain The murine NK receptor Ly49A inhibits NK cell activity by interacting with H-2D(d) through its C-type-lectin-like NK receptor domain. 23326351 4 48 gly N-glycosylation 797:811 arg2 putative N-glycosylation sites putative N-glycosylation sites sites Pseudoviruses were created by exchanging each variable and constant domain of JR-CSF gp120 with that of JR-FL or with mutations in putative N-glycosylation sites. 16168483 6 26 part_of protein 833:839 arg1 The protein sequence protein The protein sequence Fterm Site protein sequence The protein sequence showed all the important features: leader peptide, alpha1, alpha2 and CP/TM/CYT regions, conserved cysteines and N-glycosylation site. 12626422 6 7 gly glycoforms 1235:1244 arg1 alpha1-antitrypsin alpha1-antitrypsin PUBTATOR alpha1-antitrypsin 5265 It was found that asparagine 46 was always glycosylated and that asparagine 83 was never glycosylated in the underglycosylated glycoforms of alpha1-antitrypsin. 12626422 6 26 gly glycosylated 1151:1162 arg1 asparagine 46 asparagine 46 asparagine 46 It was found that asparagine 46 was always glycosylated and that asparagine 83 was never glycosylated in the underglycosylated glycoforms of alpha1-antitrypsin. 12626422 6 54 gly underglycosylated 1217:1233 arg1 alpha1-antitrypsin alpha1-antitrypsin PUBTATOR alpha1-antitrypsin 5265 It was found that asparagine 46 was always glycosylated and that asparagine 83 was never glycosylated in the underglycosylated glycoforms of alpha1-antitrypsin. 12626422 6 2 gly glycosylated 1197:1208 arg1 asparagine 83 asparagine 83 asparagine 83 It was found that asparagine 46 was always glycosylated and that asparagine 83 was never glycosylated in the underglycosylated glycoforms of alpha1-antitrypsin. 7609736 9 1 gly glycosylation 966:978 arg1 the lambda-chain lambda-chain region Fterm lambda-chain region Fab glycosylation was detected in both the Fd region and the lambda-chain. 10099302 3 29 gly glycosylation 705:717 arg2 the Asn97 glycosylation site the Asn97 glycosylation site site By introducing 20 mM ManNAc into the culture medium, incompletely sialylated biantennary glycan structures were reduced from 35% to 20% at the Asn97 glycosylation site. 10099302 3 40 gly sialylated 622:631 arg1 incompletely sialylated biantennary glycan structures incompletely sialylated biantennary glycan structures By introducing 20 mM ManNAc into the culture medium, incompletely sialylated biantennary glycan structures were reduced from 35% to 20% at the Asn97 glycosylation site. 7524670 13 13 gly contained 1788:1796 arg1 nonreducing termini AND GalNAc residues nonreducing termini GalNAc residues termini Oligosaccharides derived from the sulfated fraction of eLH beta contained GalNAc residues at nonreducing termini. 7524670 13 13 gly contained 1788:1796 arg1 nonreducing termini AND Oligosaccharides nonreducing termini Oligosaccharides termini Oligosaccharides derived from the sulfated fraction of eLH beta contained GalNAc residues at nonreducing termini. 23365085 4 72 gly glycosylation 647:659 arg2 additional glycosylation sites additional glycosylation sites sites Since then, variants with additional glycosylation sites have been detected, and the location of these sites has been distinct to those of recent seasonal H1N1 strains. 18829751 0 79 gly Glycosylation 0:12 arg1 gp41 gp41 Cterm gp41 Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies. 14520005 1 5 gly glycoprotein 412:423 arg1 the insect glycoprotein the insect glycoprotein Fterm glycoprotein While doing a structural analysis of minor component N-glycans linked to 350-kDa royal jelly glycoprotein (RJGP), which stimulates the proliferation of human monocytes, we found that a Galbeta1-3GlcNAcbeta1-4Man unit occurs on the insect glycoprotein. 14520005 1 31 gly linked 237:242 arg2 350-kDa royal jelly glycoprotein AND minor component N-glycans 350-kDa royal jelly glycoprotein minor component N-glycans Fterm glycoprotein While doing a structural analysis of minor component N-glycans linked to 350-kDa royal jelly glycoprotein (RJGP), which stimulates the proliferation of human monocytes, we found that a Galbeta1-3GlcNAcbeta1-4Man unit occurs on the insect glycoprotein. 14520005 1 32 gly glycoprotein 267:278 arg1 350-kDa royal jelly glycoprotein 350-kDa royal jelly glycoprotein Fterm glycoprotein While doing a structural analysis of minor component N-glycans linked to 350-kDa royal jelly glycoprotein (RJGP), which stimulates the proliferation of human monocytes, we found that a Galbeta1-3GlcNAcbeta1-4Man unit occurs on the insect glycoprotein. 7613477 4 25 gly glycopeptides 1032:1044 arg2 the glycopeptides the glycopeptides glycopeptides Structural information on the oligosaccharides from all eight glycopeptides was obtained by sequential glycosidase digestion of the glycopeptides followed by HPLC/ESIMS. 7613477 4 103 gly glycopeptides 962:974 arg1 the oligosaccharides glycopeptides the oligosaccharides glycopeptides Structural information on the oligosaccharides from all eight glycopeptides was obtained by sequential glycosidase digestion of the glycopeptides followed by HPLC/ESIMS. 18562306 3 96 part_of mucin 668:672 arg1 the sequence mucin the sequence PUBTATOR Site mucin 100508689 sequence Using a set of synthetic peptides and glycopeptides based upon the sequence of the mucin, MUC5AC, we have examined the activity and glycosylation site preference of lectin domain deletion and exchange constructs of the peptide/glycopeptide transferase ppGalNAcT-2 (hT2) and the glycopeptide transferase ppGalNAcT-10 (hT10). 17606981 3 13 gly acid 351:354 arg1 CD45 CD45 acid PUBTATOR CD45 5788 For example, loss of sialic acid from core 1 O-glycans on T-cell surface glycoproteins CD45, CD43 and CD8, detected with peanut agglutinin (PNA), is a hallmark of immature thymocytes and activated peripheral T cells. 17606981 3 13 gly acid 351:354 arg1 T-cell surface glycoproteins CD45, CD43 and CD8 glycoproteins acid Fterm glycoproteins For example, loss of sialic acid from core 1 O-glycans on T-cell surface glycoproteins CD45, CD43 and CD8, detected with peanut agglutinin (PNA), is a hallmark of immature thymocytes and activated peripheral T cells. 17606981 3 13 gly acid 351:354 arg1 CD43 CD43 acid OGER CD43 P16150 For example, loss of sialic acid from core 1 O-glycans on T-cell surface glycoproteins CD45, CD43 and CD8, detected with peanut agglutinin (PNA), is a hallmark of immature thymocytes and activated peripheral T cells. 17606981 3 30 gly glycoproteins 396:408 arg1 CD45 CD45 PUBTATOR CD45 5788 For example, loss of sialic acid from core 1 O-glycans on T-cell surface glycoproteins CD45, CD43 and CD8, detected with peanut agglutinin (PNA), is a hallmark of immature thymocytes and activated peripheral T cells. 17606981 3 30 gly glycoproteins 396:408 arg1 T-cell surface glycoproteins CD45, CD43 and CD8 T-cell surface glycoproteins CD45, CD43 and CD8 Fterm glycoproteins For example, loss of sialic acid from core 1 O-glycans on T-cell surface glycoproteins CD45, CD43 and CD8, detected with peanut agglutinin (PNA), is a hallmark of immature thymocytes and activated peripheral T cells. 17606981 3 30 gly glycoproteins 396:408 arg1 CD43 CD43 OGER CD43 P16150 For example, loss of sialic acid from core 1 O-glycans on T-cell surface glycoproteins CD45, CD43 and CD8, detected with peanut agglutinin (PNA), is a hallmark of immature thymocytes and activated peripheral T cells. 26846480 13 65 gly N-glycosylation 1617:1631 arg2 predicted N-glycosylation sites predicted N-glycosylation sites sites Interspecific variation in the presence of predicted N-glycosylation sites was observed. 1379039 6 50 part_of contained 1186:1194 arg1 The sequence AND five amino acid residues The sequence five amino acid residues residues The sequence of the light chain from patient Aub was related to the V lambda 3 subgroup, and contained five amino acid residues that had not previously been described at the corresponding positions; two of them (His-36 and Ser-77) were located in beta-sheets (3-1 and 4-3 respectively). 27377235 2 93 gly glycosylation 463:475 arg1 Kv1.2 Kv1.2 Cterm Kv1.2 COS-7 cells expressing Kv1.2 show a crucial role of this N-linked glycosylation in the forward trafficking of Kv1.2 to the cell membrane. 17634239 8 56 gly glycosylation 1339:1351 arg2 position 442 position 442 position 442, Interestingly, a glycosylation site at position 442, which is common among subtype C viruses, also contributed to the 2G12 epitope. 17634239 8 56 gly glycosylation 1339:1351 arg2 a glycosylation site a glycosylation site site Interestingly, a glycosylation site at position 442, which is common among subtype C viruses, also contributed to the 2G12 epitope. 26869352 6 9 gly difucosylated 1169:1181 arg1 difucosylated N-glycans difucosylated N-glycans Moreover, difucosylated N-glycans were detected at Asn 184, Asn207 and Asn241 only in cancer samples. 26869352 6 90 gly detected 1198:1205 arg2 Asn241 AND difucosylated N-glycans Asn 184, Asn207 and Asn241 difucosylated N-glycans Asn 184, Asn207 and Asn241 Moreover, difucosylated N-glycans were detected at Asn 184, Asn207 and Asn241 only in cancer samples. 26869352 6 90 gly detected 1198:1205 arg2 Asn 184 AND difucosylated N-glycans Asn 184, Asn207 and Asn241 difucosylated N-glycans Asn 184, Asn207 and Asn241 Moreover, difucosylated N-glycans were detected at Asn 184, Asn207 and Asn241 only in cancer samples. 26869352 6 90 gly detected 1198:1205 arg2 Asn 184 AND difucosylated N-glycans Asn 184, Asn207 and Asn241 difucosylated N-glycans Asn 184, Asn207 and Asn241 Moreover, difucosylated N-glycans were detected at Asn 184, Asn207 and Asn241 only in cancer samples. 17134389 2 26 gly glycoproteins 409:421 arg1 glycoproteins glycoproteins Fterm glycoproteins However, glycoproteins require particular attention as inherent differences in the N-glycosylation pathways of plants and mammals result in the production of glycoproteins bearing core-xylose and core-alpha(1,3)-fucose glyco-epitopes. 17134389 2 55 gly glycoproteins 260:272 arg1 glycoproteins glycoproteins Fterm glycoproteins However, glycoproteins require particular attention as inherent differences in the N-glycosylation pathways of plants and mammals result in the production of glycoproteins bearing core-xylose and core-alpha(1,3)-fucose glyco-epitopes. 2457922 10 86 part_of found 1971:1975 arg2 CEA AND the domains CEA the domains PUBTATOR Site CEA 1084 domains We propose that BGP I diverged from NCA by acquiring an immunoglobulin-like domain substantially different from the domains found in NCA or CEA and also a new cytoplasmic domain. 2457922 10 86 part_of found 1971:1975 arg2 NCA AND the domains NCA the domains PUBTATOR Site NCA 1084 domains We propose that BGP I diverged from NCA by acquiring an immunoglobulin-like domain substantially different from the domains found in NCA or CEA and also a new cytoplasmic domain. 27471271 9 58 gly glycosylation 1259:1271 arg1 CEACAM1-IgV dimerization CEACAM1-IgV dimerization OGER CEACAM1 P13688 Here, we use NMR cross-correlation measurements to examine the effect of glycosylation on CEACAM1-IgV dimerization and use residual dipolar coupling (RDC) measurements to characterize the solution structure of the non-glycosylated form. 22719948 0 47 gly glycosylation 4:16 arg2 Two glycosylation sites Two glycosylation sites sites Two glycosylation sites in H5N1 influenza virus hemagglutinin that affect binding preference by computer-based analysis. 10858228 6 64 part_of terminus 1165:1172 arg1 an N-terminal signal peptide terminus an N-terminal signal peptide peptide Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor. 10858228 6 64 part_of terminus 1165:1172 arg1 a hydrophobic region terminus a hydrophobic region region Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor. 10858228 6 64 part_of terminus 1165:1172 arg1 multiple predicted O-glycosylation sites terminus multiple predicted O-glycosylation sites sites Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor. 10858228 6 64 part_of terminus 1165:1172 arg1 a single potential N-glycosylation site terminus a single potential N-glycosylation site site Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor. 10858228 6 64 part_of terminus 1165:1172 arg1 a polyserine domain terminus a polyserine domain domain Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor. 10858228 6 68 part_of Cpgp40/15 962:970 arg1 the deduced amino acid sequence 981-bp Cpgp40/15 the deduced amino acid sequence Cterm Site 981-bp Cpgp40/15 sequence Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor. 7510240 4 8 part_of protein 716:722 arg1 one protein kinase C phosphorylation site protein one protein kinase C phosphorylation site Fterm Site protein site Conservation included one N-linked glycosylation site and one protein kinase C phosphorylation site. 20188224 3 40 gly N-glycosylation 419:433 arg2 five N-glycosylation consensus sequons five N-glycosylation consensus sequons PGRN is a glycoprotein, containing five N-glycosylation consensus sequons, three of which fall within granulin domains. 20188224 3 46 gly glycoprotein 389:400 arg1 PGRN PGRN PUBTATOR PGRN 2896 PGRN is a glycoprotein, containing five N-glycosylation consensus sequons, three of which fall within granulin domains. 20188224 3 46 gly glycoprotein 389:400 arg1 a glycoprotein a glycoprotein Fterm glycoprotein PGRN is a glycoprotein, containing five N-glycosylation consensus sequons, three of which fall within granulin domains. 9032350 0 20 gly glycoprotein 78:89 arg1 glycoprotein H glycoprotein H Cterm 1 glycoprotein H Site-directed and linker insertion mutagenesis of herpes simplex virus type 1 glycoprotein H. 25324212 3 69 gly epitopes 469:476 arg1 the sugar and matching key amino acids epitopes the sugar and matching key amino acids epitopes Cognate epitopes on the sugar and matching key amino acids involved in the interaction were identified by saturation transfer difference (STD) NMR spectroscopy. 14693913 5 41 part_of hBSSL 862:866 arg1 The C-terminal 192 residues hBSSL The C-terminal 192 residues PUBTATOR Site hBSSL 1056 residues The C-terminal 192 residues of hBSSL contain 16 Pro-rich 11-amino-acid repeats, which include 32 Ser/Thr residues as potential O-glycosylation sites. 12765790 4 20 gly glycosylation 867:879 arg2 glycosylation sites 2, 4, 5 and 6 glycosylation sites 2, 4, 5 and 6 sites Using a combination of enzymatic deglycosylation, peptide fractionation, mass spectrometry and Edman degradation, HNK1-N-glycans could be assigned to glycosylation sites 2, 4, 5 and 6. 21573946 3 3 gly EC-SOD 483:488 arg1 a precise N-glycan profile EC-SOD a precise N-glycan profile PUBTATOR EC-SOD 20657 Thus, a precise N-glycan profile of the recombinant EC-SOD is not available. 19277548 0 32 gly N-glycosylation 0:14 arg2 N-glycosylation site analysis proteins site Fterm proteins site N-glycosylation site analysis of human platelet proteins by hydrazide affinity capturing and LC-MS/MS. 18279659 3 52 part_of has 416:418 arg1 ABCB6 AND an N-terminal hydrophobic region ABCB6 an N-terminal hydrophobic region a primary determinant PUBTATOR Site ABCB6 10058 region We show here that ABCB6 has an N-terminal hydrophobic region of 220 residues that functions as a primary determinant of co-translational targeting to the endoplasmic reticulum (ER), but it does not have any known features of a mitochondrial targeting sequence. 1567356 0 19 gly glycoprotein 63:74 arg1 human alpha 1-acid glycoprotein human alpha 1-acid glycoprotein Fterm glycoprotein Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein. 1567356 0 67 gly glycosylation 21:33 arg2 the five glycosylation sites glycoprotein sites Fterm glycoprotein sites Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein. 8644914 4 16 gly site 1040:1043 arg1 the carbohydrates site the carbohydrates site Matrix-assisted laser desorption/ionization mass spectrometry provided the M(r) of the intact protein and was used to characterize endo- and exoglycosidase digests of isolated glycopeptides to identify the glycosylation-site peptide and define the structures of the carbohydrates at that site. 8644914 4 83 gly glycopeptides 928:940 arg2 isolated glycopeptides isolated glycopeptides glycopeptides Matrix-assisted laser desorption/ionization mass spectrometry provided the M(r) of the intact protein and was used to characterize endo- and exoglycosidase digests of isolated glycopeptides to identify the glycosylation-site peptide and define the structures of the carbohydrates at that site. 21647803 9 41 gly glycopeptide 1593:1604 arg2 glycopeptide isomers glycopeptide isomers glycopeptide Porous graphitized carbon provided effective separation of glycopeptide isomers. 26333807 3 47 gly glycosylation 387:399 arg2 the second glycosylation site Tf site PUBTATOR Tf 7018 site We present a Tf variant affecting the second glycosylation site of Tf and the complications it causes in diagnosing alcoholism. 18723043 4 51 gly glycosylation 810:822 arg2 an N-linked glycosylation site an N-linked glycosylation site site This enzyme contains glucosamine and an N-linked glycosylation site. 18723043 4 16 gly contains 773:780 arg1 This enzyme AND glucosamine This enzyme an N-linked glycosylation site glucosamine Fterm Site enzyme site This enzyme contains glucosamine and an N-linked glycosylation site. 18330979 6 62 gly motifs 1376:1381 arg1 glycan motifs glycan motifs Our results show that the immunogens displayed different degrees of glycosylation as well as a different characteristic set of glycan motifs. 19110214 6 69 gly N-glycosylation 1391:1405 arg2 a functional N-glycosylation site a functional N-glycosylation site site Expression of the normal and mutant G3 domains in mammalian cells showed that the mutation created a functional N-glycosylation site but did not adversely affect protein trafficking and secretion. 25451932 5 51 gly N-glycosylation 597:611 arg2 the 19 predicted N-glycosylation sites the 19 predicted N-glycosylation sites sites In this study, we examined corin mutants, in which each of the 19 predicted N-glycosylation sites was mutated individually. 22122935 7 17 gly glycosylation 1230:1242 arg2 N(24) and N(38) glycosylation sites N(24) and N(38) glycosylation sites sites N(24) and N(38) glycosylation sites were also characterized by CE-TOF-MS after Glu-C digestion and these results permitted to rule out some glycan combinations for N(24)-N(38) glycopeptide glycoforms. 22122935 7 55 gly glycoforms 1403:1412 arg1 N(24)-N(38) glycopeptide glycoforms N(24)-N(38) glycopeptide glycoforms N(24)-N(38) glycopeptide N(24) and N(38) glycosylation sites were also characterized by CE-TOF-MS after Glu-C digestion and these results permitted to rule out some glycan combinations for N(24)-N(38) glycopeptide glycoforms. 22122935 7 55 gly glycoforms 1403:1412 arg1 N(24)-N(38) glycopeptide glycoforms N(24)-N(38) glycopeptide glycoforms N(24)-N(38) N(24) and N(38) glycosylation sites were also characterized by CE-TOF-MS after Glu-C digestion and these results permitted to rule out some glycan combinations for N(24)-N(38) glycopeptide glycoforms. 22122935 7 61 gly glycopeptide 1390:1401 arg2 N(24)-N(38) glycopeptide glycoforms N(24)-N(38) glycopeptide glycoforms N(24)-N(38) glycopeptide N(24) and N(38) glycosylation sites were also characterized by CE-TOF-MS after Glu-C digestion and these results permitted to rule out some glycan combinations for N(24)-N(38) glycopeptide glycoforms. 1567356 7 70 gly glycosylation 1019:1031 arg2 Only glycosylation site II Only glycosylation site II site Only glycosylation site II of the five present is 100% biantennary in the retained and weakly retained variants. 22287049 3 15 gly glycopeptides 642:654 arg2 the glycopeptides the glycopeptides glycopeptides A key enabling step in mass spectrometry (MS)-based glycoproteomics is the ability to selectively or non-selectively enrich for the glycopeptides from a total pool of a digested proteome for MS analysis since the highly heterogeneous glycopeptides are usually present at low abundance and ionize poorly compared with non-glycosylated peptides. 22287049 3 79 gly non-glycosylated 827:842 arg1 non-glycosylated peptides non-glycosylated peptides peptides A key enabling step in mass spectrometry (MS)-based glycoproteomics is the ability to selectively or non-selectively enrich for the glycopeptides from a total pool of a digested proteome for MS analysis since the highly heterogeneous glycopeptides are usually present at low abundance and ionize poorly compared with non-glycosylated peptides. 22287049 3 92 gly glycopeptides 744:756 arg2 the highly heterogeneous glycopeptides the highly heterogeneous glycopeptides glycopeptides A key enabling step in mass spectrometry (MS)-based glycoproteomics is the ability to selectively or non-selectively enrich for the glycopeptides from a total pool of a digested proteome for MS analysis since the highly heterogeneous glycopeptides are usually present at low abundance and ionize poorly compared with non-glycosylated peptides. 8321151 4 60 gly glycosylation 785:797 arg2 a new potential glycosylation site a new potential glycosylation site site The HA genes of the M and L type strains of MV were found to have a nucleotide substitution which introduces a new potential glycosylation site. 23289760 9 126 part_of gp120 2039:2043 arg1 the V1-V5 region gp120 the V1-V5 region OGER SiteSequence gp120 Q14624 V1-V5 region CONCLUSIONS: These findings suggest that the HIV-1 subtype B' viruses may mutate under the immune pressure, thus becoming resistant to the autologous nAbs, possibly by changing the number of PNGS in the V1-V5 region of the viral gp120. 18672252 1 27 gly glycoprotein 240:251 arg1 the hemagglutinin glycoprotein the hemagglutinin glycoprotein Fterm glycoprotein Adaptation of avian influenza viruses for replication and transmission in the human host is believed to require mutations in the hemagglutinin glycoprotein (HA) which enable binding to human alpha2-6 sialosides and concomitant reduction in affinity for avian alpha2-3 linked sialosides. 8407981 6 14 gly glycosylation 937:949 arg1 the two mutant proteins the two mutant proteins Fterm proteins Since the P-450(arom) molecule has two potential glycosylation sites (Asn-12 and Asn-180), we replaced each of the 2 asparagine residues with alanine by site-directed mutagenesis and examined the glycosylation of the two mutant proteins in the cell-free system. 8407981 6 19 gly glycosylation 790:802 arg2 two potential glycosylation sites two potential glycosylation sites sites Since the P-450(arom) molecule has two potential glycosylation sites (Asn-12 and Asn-180), we replaced each of the 2 asparagine residues with alanine by site-directed mutagenesis and examined the glycosylation of the two mutant proteins in the cell-free system. 8407981 6 54 gly sites 804:808 arg1 two potential glycosylation sites two potential glycosylation sites sites Since the P-450(arom) molecule has two potential glycosylation sites (Asn-12 and Asn-180), we replaced each of the 2 asparagine residues with alanine by site-directed mutagenesis and examined the glycosylation of the two mutant proteins in the cell-free system. 8407981 6 19 gly glycosylation 790:802 arg2 Asn-12 Asn-12 and Asn-180 Asn-12 and Asn-180 Since the P-450(arom) molecule has two potential glycosylation sites (Asn-12 and Asn-180), we replaced each of the 2 asparagine residues with alanine by site-directed mutagenesis and examined the glycosylation of the two mutant proteins in the cell-free system. 8407981 6 54 gly sites 804:808 arg1 Asn-12 Asn-12 and Asn-180 Asn-12 and Asn-180 Since the P-450(arom) molecule has two potential glycosylation sites (Asn-12 and Asn-180), we replaced each of the 2 asparagine residues with alanine by site-directed mutagenesis and examined the glycosylation of the two mutant proteins in the cell-free system. 30011186 14 58 gly glycoproteins 2857:2869 arg1 surface glycoproteins surface glycoproteins Fterm glycoproteins The methods enable us to specifically identify surface glycoproteins and to quantify their abundance changes and dynamics together with quantitative proteomics. 8844219 0 0 gly glycosylation 65:77 arg2 the single glycosylation site the single glycosylation site site Charcot-Marie-Tooth type 1B neuropathy: a mutation at the single glycosylation site in the major peripheral myelin glycoprotein Po. 8844219 0 1 gly glycoprotein 115:126 arg1 the major peripheral myelin glycoprotein Po the major peripheral myelin glycoprotein Po Fterm glycoprotein Charcot-Marie-Tooth type 1B neuropathy: a mutation at the single glycosylation site in the major peripheral myelin glycoprotein Po. 26059044 6 12 gly N-glycans 861:869 arg1 IL-22 IL-22 N-glycans PUBTATOR IL-22 50616 Surprisingly, upon engineering of human-like N-glycans on IL-22 by co-expressing mouse FUT8 in ΔXT/FT plants a strong reduction in Lewis A was observed. 15626342 2 17 gly N-glycosylation 361:375 arg2 a single N-glycosylation site a single N-glycosylation site site The M protein is predicted to contain a triple-spanning transmembrane (TM) region, a single N-glycosylation site near its N-terminus that is in the exterior of the virion, and a long C-terminal region in the interior. 1567356 4 80 gly variants 672:679 arg1 the glycan structures variants the glycan structures Fterm variants The ability to quantify the glycoforms present at each site allows us to extend the earlier results of others and resolve the remaining questions concerning the glycan structures of these variants. 26062906 3 80 part_of contains 517:524 arg1 MHBs AND a constitutive N-linked glycosylation site MHBs a constitutive N-linked glycosylation site Cterm Site MHBs site Among these envelope proteins, the middle HBV surface antigen (MHBs) contains a constitutive N-linked glycosylation site at position 4 (Asn4) in the amino-terminal portion (MQWNSTTFHQ) of pre-S2 domain. 25945896 10 29 gly glycopeptides 1860:1872 arg2 769 unique intact N-linked glycopeptides 769 unique intact N-linked glycopeptides glycopeptides Without enrichment of glycopeptides from global tryptic peptides and at a false discovery rate of 1%, 1008 glycan-containing MS/MS spectra were assigned to 769 unique intact N-linked glycopeptides, representing 344 N-linked glycosites with 57 different N-glycans. 25945896 10 87 gly glycopeptides 1699:1711 arg1 global tryptic peptides global tryptic peptides peptides Without enrichment of glycopeptides from global tryptic peptides and at a false discovery rate of 1%, 1008 glycan-containing MS/MS spectra were assigned to 769 unique intact N-linked glycopeptides, representing 344 N-linked glycosites with 57 different N-glycans. 25945896 10 87 gly glycopeptides 1699:1711 arg2 glycopeptides glycopeptides glycopeptides Without enrichment of glycopeptides from global tryptic peptides and at a false discovery rate of 1%, 1008 glycan-containing MS/MS spectra were assigned to 769 unique intact N-linked glycopeptides, representing 344 N-linked glycosites with 57 different N-glycans. 25945896 10 115 gly glycosites 1901:1910 arg2 344 N-linked glycosites glycosites 57 different N-glycans glycosites Without enrichment of glycopeptides from global tryptic peptides and at a false discovery rate of 1%, 1008 glycan-containing MS/MS spectra were assigned to 769 unique intact N-linked glycopeptides, representing 344 N-linked glycosites with 57 different N-glycans. 9694881 5 34 gly glycosylation 605:617 arg1 the Asn14 the Asn14 Asn14 All of the sites were N-glycosylated with preferential glycosylation of the Asn14 and the Asn271. 9694881 5 34 gly glycosylation 605:617 arg1 the Asn271 the Asn271 Asn271 All of the sites were N-glycosylated with preferential glycosylation of the Asn14 and the Asn271. 9694881 5 65 gly N-glycosylated 572:585 arg1 the sites the sites sites All of the sites were N-glycosylated with preferential glycosylation of the Asn14 and the Asn271. 7765932 1 53 gly glycosylation 159:171 arg2 N-linked glycosylation site occupancy N-linked glycosylation site occupancy site The relationship between synthesis and N-linked glycosylation site occupancy of recombinant human prolactin produced from C127 cells was studied with the aid of a battery of protein synthesis inhibitors. 7765932 1 5 gly occupancy 178:186 arg1 recombinant human prolactin prolactin site PUBTATOR prolactin 5617 site The relationship between synthesis and N-linked glycosylation site occupancy of recombinant human prolactin produced from C127 cells was studied with the aid of a battery of protein synthesis inhibitors. 2721453 3 58 gly subunit 508:514 arg1 Oligosaccharides subunit Oligosaccharides OGER subunit Oligosaccharides from each subunit displayed a distinct anion exchange HPLC profile due to a specific pattern of sialylation and sulfation. 16883437 0 99 part_of glycoprotein 46:57 arg1 antigenic sites glycoprotein antigenic sites Fterm Site glycoprotein sites Comparison of antigenic sites of the envelope glycoprotein of the Iranian isolate of human T-cell leukemia virus type 1 with different subtypes of the virus. 31004621 9 25 part_of RSV 1680:1682 arg1 position N116 RSV F N116Q position N116 Cterm SpecificSite RSV F N116Q position N116 Infection with recombinant virus lacking the N-glycosylation site at position N116 (RSV F N116Q) resulted in significant higher neutralizing antibody titers compared to RSV F WT infection, which is surprising since this N-glycan is present in the p27 peptide which is assumed to be absent from the mature F protein in virions. 31004621 9 89 part_of p27 1843:1845 arg1 the p27 peptide p27 the p27 peptide OGER Site p27 P40305 peptide Infection with recombinant virus lacking the N-glycosylation site at position N116 (RSV F N116Q) resulted in significant higher neutralizing antibody titers compared to RSV F WT infection, which is surprising since this N-glycan is present in the p27 peptide which is assumed to be absent from the mature F protein in virions. 31004621 9 106 part_of protein 1903:1909 arg1 the p27 peptide protein the p27 peptide Fterm Site protein peptide Infection with recombinant virus lacking the N-glycosylation site at position N116 (RSV F N116Q) resulted in significant higher neutralizing antibody titers compared to RSV F WT infection, which is surprising since this N-glycan is present in the p27 peptide which is assumed to be absent from the mature F protein in virions. 31004621 9 108 part_of F 1684:1684 arg1 position N116 RSV F N116Q position N116 Cterm SpecificSite RSV F N116Q position N116 Infection with recombinant virus lacking the N-glycosylation site at position N116 (RSV F N116Q) resulted in significant higher neutralizing antibody titers compared to RSV F WT infection, which is surprising since this N-glycan is present in the p27 peptide which is assumed to be absent from the mature F protein in virions. 12662294 0 11 gly nonglycosylated 63:77 arg1 one glycosylated and one nonglycosylated AL-protein one glycosylated and one nonglycosylated AL-protein Fterm AL-protein Biclonal systemic AL-amyloidosis with one glycosylated and one nonglycosylated AL-protein. 7780197 3 41 gly present 401:407 arg2 this site AND The oligosaccharide(s) this site The oligosaccharide(s) site The oligosaccharide(s) present at this site have been analysed using a combination of site-directed mutagenesis and chemical analysis. 23527139 7 28 gly glycoprotein 991:1002 arg1 dengue envelope glycoprotein dengue envelope glycoprotein PUBTATOR envelope glycoprotein 100616444 Pre-processed the PDB coordinates of dengue envelope glycoprotein and other candidate proteins were prepared and energy minimized through AMBER99 force field distributed in MOE software. 25614584 6 18 gly glycosylation 872:884 arg2 The newly acquired glycosylation site The newly acquired glycosylation site site The newly acquired glycosylation site at position 373 or loss of the existing one at position 323 was identified as the mechanism behind the escape from the specific mAbs. 25614584 6 18 gly glycosylation 872:884 arg2 position 323 position 323 position 323 The newly acquired glycosylation site at position 373 or loss of the existing one at position 323 was identified as the mechanism behind the escape from the specific mAbs. 25614584 6 18 gly glycosylation 872:884 arg2 position 373 position 373 position 373 The newly acquired glycosylation site at position 373 or loss of the existing one at position 323 was identified as the mechanism behind the escape from the specific mAbs. 21645732 8 22 gly N-glycosite 1479:1489 arg2 the two N-glycosite assignment methods the two N-glycosite assignment methods N-glycosite Briefly, Endo H provides a more confident assignment but a smaller dataset compared with PNGase F, showing the complementary nature of the two N-glycosite assignment methods. 23508902 12 56 gly glycosylation 1318:1330 arg2 glycosylation site site the antigenic determinant site Some of them were located on the receptor-binding site, glycosylation site and the region of the antigenic determinant. 23316195 7 2 gly N-glycosylation 1035:1049 arg2 a single N-glycosylation site a single N-glycosylation site site The human PTX3 protein contains a single N-glycosylation site that is fully occupied by complex type oligosaccharides, mainly fucosylated and sialylated biantennary glycans. 23316195 7 21 gly occupied 1070:1077 arg2 a single N-glycosylation site a single N-glycosylation site site The human PTX3 protein contains a single N-glycosylation site that is fully occupied by complex type oligosaccharides, mainly fucosylated and sialylated biantennary glycans. 23316195 7 47 gly sialylated 1136:1145 arg1 sialylated biantennary glycans sialylated biantennary glycans The human PTX3 protein contains a single N-glycosylation site that is fully occupied by complex type oligosaccharides, mainly fucosylated and sialylated biantennary glycans. 23316195 7 47 gly sialylated 1136:1145 arg1 complex type oligosaccharides complex type oligosaccharides The human PTX3 protein contains a single N-glycosylation site that is fully occupied by complex type oligosaccharides, mainly fucosylated and sialylated biantennary glycans. 9365923 0 24 part_of site 72:75 arg1 human alpha-lactalbumin alpha-lactalbumin site PUBTATOR Site alpha-lactalbumin 3906 site The unusual amino acid triplet Asn-Ile-Cys is a glycosylation consensus site in human alpha-lactalbumin. 26573365 1 49 part_of site 224:227 arg1 a protein protein site Fterm Site protein site We introduce a stable isotope labeling approach for glycopeptides that allows a specific glycosylation site in a protein to be quantitatively evaluated using mass spectrometry. 7741215 0 90 gly Microheterogeneity 0:17 arg1 erythropoietin carbohydrate structure erythropoietin carbohydrate structure Microheterogeneity of erythropoietin carbohydrate structure. 21172408 6 32 gly glycosylation 731:743 arg2 the three glycosylation sites the three glycosylation sites sites RESULTS AND CONCLUSIONS: Fractional abundance of each glycan composition at each of the three glycosylation sites reveals the most pronounced difference to be at asparagine (Asn) 11. 20848033 6 69 gly glycoforms 1218:1227 arg1 various homogeneous CD52 glycoforms various homogeneous CD52 glycoforms PUBTATOR CD52 1043 This chemoenzymatic approach is highly convergent and permits easy construction of various homogeneous CD52 glycoforms from a common polypeptide precursor. 12755619 11 30 part_of protein 1736:1742 arg1 the specific FN binding-domain protein the specific FN binding-domain Fterm Site protein binding-domain Moreover, we defined the specific FN binding-domain of this protein. 12755619 11 57 part_of FN 1710:1711 arg1 the specific FN binding-domain FN the specific FN binding-domain Cterm Site FN 2335 binding-domain Moreover, we defined the specific FN binding-domain of this protein. 11390601 3 42 part_of gp120 845:849 arg1 N301 gp120 N301 PUBTATOR SpecificSite gp120 3700 N301 Of the glycosylation sites that were evaluated, those proximal to the V1/V2 loops (N135, N141, N156, N160) and the V3 loops (N301) of gp120 were functionally critical. 11146224 7 75 part_of MRP7 1186:1189 arg1 the predicted MRP7 coding sequence MRP7 the predicted MRP7 coding sequence PUBTATOR Site MRP7 89845 sequence The integrity of the predicted MRP7 coding sequence was confirmed by the synthesis of an approximately 158 kDa protein in reticulocyte lysates programmed with the MRP7 cDNA. 22586465 4 30 gly N-glycosylation 637:651 arg2 the N-glycosylation sequence motif the N-glycosylation sequence motif motif Any variation (e.g. non-synonymous single nucleotide polymorphism or mutation) that abolishes the N-glycosylation sequence motif will lead to the loss of a glycosylation site. 22586465 4 63 gly glycosylation 695:707 arg2 a glycosylation site a glycosylation site site Any variation (e.g. non-synonymous single nucleotide polymorphism or mutation) that abolishes the N-glycosylation sequence motif will lead to the loss of a glycosylation site. 9242452 11 73 gly glycopeptides 1971:1983 arg2 other glycopeptides other glycopeptides glycopeptides T cells primed to a glycopeptide with a simple glycan structure such as Tn did not cross-respond significantly to other glycopeptides, indicating a high degree of carbohydrate specificity in T-cell recognition. 9242452 11 104 gly glycopeptide 1871:1882 arg2 a glycopeptide a glycopeptide glycopeptide T cells primed to a glycopeptide with a simple glycan structure such as Tn did not cross-respond significantly to other glycopeptides, indicating a high degree of carbohydrate specificity in T-cell recognition. 26869352 8 88 gly released 1379:1386 arg1 haptoglobin AND N-glycan alditols haptoglobin N-glycan alditols PUBTATOR haptoglobin 3240 We next analyzed N-glycan alditols released from haptoglobin using graphitized carbon column LC-ESI MS to identify the linkage of fucosylation. 9442070 7 21 gly N-glycosylation 1181:1195 arg2 the Cα 2 N-glycosylation site the Cα 2 N-glycosylation site site Analysis of the N-glycans attached to recombinant IgA1 indicated that the Cα 2 N-glycosylation site contained mostly biantennary glycans, while the tailpiece site, absent in IgG, contained mostly triantennary structures. 9442070 7 68 gly attached 1128:1135 arg1 recombinant IgA1 AND the N-glycans recombinant IgA1 the N-glycans OGER IgA1 P01876 Analysis of the N-glycans attached to recombinant IgA1 indicated that the Cα 2 N-glycosylation site contained mostly biantennary glycans, while the tailpiece site, absent in IgG, contained mostly triantennary structures. 9442070 7 107 gly contained 1281:1289 arg1 the tailpiece site AND triantennary structures the tailpiece site triantennary structures site Analysis of the N-glycans attached to recombinant IgA1 indicated that the Cα 2 N-glycosylation site contained mostly biantennary glycans, while the tailpiece site, absent in IgG, contained mostly triantennary structures. 9442070 7 78 gly contained 1202:1210 arg1 the Cα 2 N-glycosylation site AND biantennary glycans the Cα 2 N-glycosylation site biantennary glycans site Analysis of the N-glycans attached to recombinant IgA1 indicated that the Cα 2 N-glycosylation site contained mostly biantennary glycans, while the tailpiece site, absent in IgG, contained mostly triantennary structures. 17636988 5 83 gly glycosylated 864:875 arg1 the formerly glycosylated peptide the formerly glycosylated peptide peptide The reaction is carried out in H218O to facilitate identification of the formerly glycosylated peptide by incorporatation of 18O into the formed aspartic acid residue. 26991339 0 56 gly glycosylation 16:28 arg2 N- and O-linked glycosylation site N- and O-linked glycosylation site site N- and O-linked glycosylation site profiling of the human basic salivary proline-rich protein 3M. 25094044 2 7 gly glycosylated 440:451 arg1 newly synthesized glycosylated polypeptides newly synthesized glycosylated polypeptides polypeptides UGGT1 acts as a folding sensor of newly synthesized glycosylated polypeptides in the endoplasmic reticulum, and the transferase itself is known to be glycosylated. 25094044 2 40 gly glycosylated 538:549 arg1 the transferase itself the transferase itself Fterm transferase UGGT1 acts as a folding sensor of newly synthesized glycosylated polypeptides in the endoplasmic reticulum, and the transferase itself is known to be glycosylated. 18562306 0 76 part_of alpha-N-Acetylgalactosaminyltransferase 59:97 arg1 The catalytic and lectin domains alpha-N-Acetylgalactosaminyltransferase The catalytic and lectin domains Fterm Site alpha-N-Acetylgalactosaminyltransferase domains The catalytic and lectin domains of UDP-GalNAc:polypeptide alpha-N-Acetylgalactosaminyltransferase function in concert to direct glycosylation site selection. 10227483 2 84 gly glycosylation 394:406 arg2 a single potential N-linked glycosylation site a single potential N-linked glycosylation site site The chicken IL-15 cDNA contains an open reading frame of 143 amino acids with a single potential N-linked glycosylation site. 18282281 6 71 gly non-glycosylation 952:968 arg2 non-glycosylation sites non-glycosylation sites sites When the ratio of O-glycosylation to non-glycosylation sites in training datasets was set as 1:1, 10-fold cross-validation tests showed that the proposed method yielded a high accuracy of 83.1% and 81.4% in predicting O-glycosylated S and T sites, respectively. 1566570 6 58 gly utilized 938:945 arg2 These acceptor sites These acceptor sites sites These acceptor sites are apparently utilized for the addition of high-mannose carbohydrate chains as shown by endoglycosidase analyses of immunoprecipitated E proteins. 9254044 3 13 part_of glucosidase 589:599 arg1 a 760 bp glucosidase II specific cDNA fragment glucosidase II a 760 bp glucosidase II specific cDNA fragment OGER Site glucosidase II fragment An unamplified cDNA library from pig liver was screened with a 760 bp glucosidase II specific cDNA fragment obtained by RT-PCR. 9254044 3 77 part_of cDNA 613:616 arg1 a 760 bp glucosidase II specific cDNA fragment cDNA a 760 bp glucosidase II specific cDNA fragment Cterm Site cDNA fragment An unamplified cDNA library from pig liver was screened with a 760 bp glucosidase II specific cDNA fragment obtained by RT-PCR. 9254044 3 81 part_of II 601:602 arg1 a 760 bp glucosidase II specific cDNA fragment glucosidase II a 760 bp glucosidase II specific cDNA fragment OGER Site glucosidase II fragment An unamplified cDNA library from pig liver was screened with a 760 bp glucosidase II specific cDNA fragment obtained by RT-PCR. 22171062 9 50 gly heterogeneity 1763:1775 arg1 O-linked sites O-linked sites O-linked sites Site sites The striking characteristic of both proteins was glycan heterogeneity in both N- and O-linked sites. 22171062 9 94 gly proteins 1743:1750 arg1 glycan heterogeneity proteins glycan heterogeneity Fterm proteins The striking characteristic of both proteins was glycan heterogeneity in both N- and O-linked sites. 18295294 4 23 gly glycosylation 559:571 arg2 nsp4 glycosylation site N176 site N176 site N176 We used reverse genetics to generate infectious clone viruses (icv) with an alanine substitution at nsp4 glycosylation site N176 or N237, or an asparagine to threonine substitution (nsp4-N258T), which is proposed to confer a temperature sensitive phenotype. 27939162 0 26 gly glycosylation 22:34 arg2 a potential glycosylation site a potential glycosylation site site Impact of a potential glycosylation site at neuraminidase amino acid 264 of influenza A/H9N2 virus. 10580643 4 90 gly non-glycosylated 719:734 arg1 a single peptide a single peptide peptide While the crude non-glycosylated analog was obtained as a single peptide, two peptides with the identical, expected masses, in approximately equal amounts, were detected after the cleavage of the peracetylated glycopeptide. 10580643 4 99 gly glycopeptide 913:924 arg2 the peracetylated glycopeptide the peracetylated glycopeptide glycopeptide While the crude non-glycosylated analog was obtained as a single peptide, two peptides with the identical, expected masses, in approximately equal amounts, were detected after the cleavage of the peracetylated glycopeptide. 8557170 2 55 gly N-glycosylation 381:395 arg2 one N-glycosylation site one N-glycosylation site site The human and rat CRF-BP cDNAs encode proteins of 322 amino acids with one putative signal sequence, one N-glycosylation site, and 10 conserved cysteines. 28970103 15 154 gly O-glycopeptides 2859:2873 arg1 the serum samples IgAN O-glycopeptides PUBTATOR IgAN 60498 O-glycopeptides Furthermore, quantitative analysis of intact O-glycopeptides from the serum samples of IgA nephropathy (IgAN) patients and healthy donors was performed, and the results showed the potential of the strategy to discover O-glycosylation biomarkers. 17144668 9 80 gly glycosylation 1605:1617 arg2 the five natural glycosylation sites the five natural glycosylation sites sites In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. 31501225 7 62 part_of IgA2 1180:1183 arg1 the two glycopeptides IgA2 the two glycopeptides OGER Site IgA2 P01877 glycopeptides In contrast, the two glycopeptides of IgA2 fell back down in HBV-related HCC patients. 20826563 5 50 part_of variant 584:590 arg1 all these sites variant all these sites Fterm Site variant sites A GH variant (3N-GH) with all these sites was produced in CHOK1SV cells and contained up to three N-glycans. 27480293 6 9 gly N-glycoproteins 987:1001 arg1 1597 N-glycoproteins 1597 N-glycoproteins Fterm N-glycoproteins In this work, we identified a total of 3446 unique glycosylation sites conforming to the N-glycosylation consensus motif (N-X-T/S/C; X ≠ P) with (18)O labeling in 1597 N-glycoproteins. 27480293 6 36 gly glycosylation 870:882 arg2 3446 unique glycosylation sites 3446 unique glycosylation sites sites In this work, we identified a total of 3446 unique glycosylation sites conforming to the N-glycosylation consensus motif (N-X-T/S/C; X ≠ P) with (18)O labeling in 1597 N-glycoproteins. 27480293 6 57 gly N-glycosylation 908:922 arg2 the N-glycosylation consensus motif the N-glycosylation consensus motif motif In this work, we identified a total of 3446 unique glycosylation sites conforming to the N-glycosylation consensus motif (N-X-T/S/C; X ≠ P) with (18)O labeling in 1597 N-glycoproteins. 28531887 6 55 gly Glycosylation 791:803 arg1 the SK-Mel-28 protein the SK-Mel-28 protein Fterm protein Glycosylation of the SK-Mel-28 protein was studied via glucosidases and site directed mutagenesis of the MT4-MMP cDNA prior to transfection. 30935958 10 41 gly positions 1204:1212 arg1 their glycans positions their glycans positions Little is known about the importance of these positions and their glycans for PrP stability, aggregation and fibril formation. 8068684 1 88 gly glycosylation 241:253 arg1 asparagines 75, 370, and 410 asparagines 75, 370, and 410 asparagines 75, 370, and 410 The ubiquitously-expressed human Na+H+ exchanger (NHE-1) contains three consensus sites (Asn-X-Ser/Thr) for N-linked glycosylation at asparagines 75, 370, and 410. 18330979 0 63 gly glycosylation 109:121 arg2 glycosylation site occupancy glycosylation site occupancy site Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. 7635146 4 47 gly N-glycosylation 768:782 arg2 Asn655 Asn655 Asn655 The 92-kDa protein contains a single N-glycosylation site of the Asn-Xaa-Thr/Ser type at Asn655, as well as a strongly hydrophobic sequence close to its N-terminus (amino acids 38-58) which, most likely, functions as a transmembrane anchor. 7635146 4 47 gly N-glycosylation 768:782 arg2 a single N-glycosylation site a single N-glycosylation site site The 92-kDa protein contains a single N-glycosylation site of the Asn-Xaa-Thr/Ser type at Asn655, as well as a strongly hydrophobic sequence close to its N-terminus (amino acids 38-58) which, most likely, functions as a transmembrane anchor. 6433976 0 3 gly glycosylation 149:161 arg2 glycosylation sites glycosylation sites sites Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences. 8207403 7 46 gly glycoprotein 1379:1390 arg1 the glycoprotein the glycoprotein Fterm glycoprotein The results of this study indicate that N-linked glycosylation of Asn-642 in the glycoprotein produced by the pEVd1443 expression system is necessary for the correct intracellular processing of gp160 to yield surface-expressed, fusogenic gp41. 8207403 7 79 gly glycosylation 1347:1359 arg1 the glycoprotein glycoprotein Asn-642 Fterm glycoprotein Asn-642 The results of this study indicate that N-linked glycosylation of Asn-642 in the glycoprotein produced by the pEVd1443 expression system is necessary for the correct intracellular processing of gp160 to yield surface-expressed, fusogenic gp41. 15718224 6 89 part_of gp120 1268:1272 arg1 regions gp120 regions PUBTATOR Site gp120 3700 regions The affected glycosylation sites were predominantly clustered in regions of gp120 that are not involved in the direct interaction with either CD4, CCR5, CXCR4, or gp41. 15113920 10 28 gly glycosylation 1527:1539 arg1 HTNV glycoproteins HTNV glycoproteins Fterm glycoproteins Our data demonstrate that N-linked glycosylation of HTNV glycoproteins plays important and differential roles in protein folding and intracellular trafficking. 15113920 10 68 gly glycoproteins 1549:1561 arg1 HTNV glycoproteins HTNV glycoproteins Fterm glycoproteins Our data demonstrate that N-linked glycosylation of HTNV glycoproteins plays important and differential roles in protein folding and intracellular trafficking. 23234360 6 68 part_of sites 1228:1232 arg1 glycoproteins glycoproteins sites Fterm Site glycoproteins sites The characterization of glycans and glycosylation sites in glycoproteins from human clinical samples provides a basis for future studies addressing the biological and diagnostic importance of specific protein glycosylations in relation to human disease. 17996106 4 15 gly glycosylation 569:581 arg2 glycosylation sites glycosylation sites sites Hence, there is significant interest in the development of computational methods for reliable prediction of glycosylation sites from amino acid sequences. 23758413 11 39 gly glycoprotein 1763:1774 arg1 the same glycoprotein the same glycoprotein Fterm glycoprotein One is the independent occurrence of different affinity-targetable glycan features in the same glycoprotein. 14699159 4 74 gly glycosylation 968:980 arg1 newly synthesized p90ATF6 newly synthesized p90ATF6 Cterm p90ATF6 22926 Here we show that ER Ca(2+) depletion stress, a triggering mechanism for the UPR, induces the formation of ATF6(f), which represents de novo partial glycosylation of newly synthesized p90ATF6. 12892756 2 30 part_of preprocathepsin 231:245 arg1 Pre-Pro-CE preprocathepsin E Pre-Pro-CE Cterm AminoAcid preprocathepsin E Pro We cloned a cDNA encoding preprocathepsin E (Pre-Pro-CE) from the library. 15183061 0 26 gly glycoproteins 82:94 arg1 HIV-1 envelope glycoproteins HIV-1 envelope glycoproteins Fterm glycoproteins N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins. 11380948 0 4 gly glycosylation 58:70 arg1 the IgG receptor IIIB IIIB (CD16 PUBTATOR IIIB (CD16 2214 Evidence for a novel polymorphism affecting both N-linked glycosylation and ligand binding of the IgG receptor IIIB (CD16). 26015261 4 103 gly site 721:724 arg1 the Fc glycan composition N297 site the Fc glycan composition N297 site Modulations of the Fc glycan composition at the N297 site by selective mutations or afucosylation have been explored as strategies to develop bio-better therapeutics with enhanced ADCC activity. 20378933 2 61 part_of protein 216:222 arg1 six potential N-linked glycosylation sites protein six potential N-linked glycosylation sites Fterm Site protein sites It is a heavily glycosylated protein with six potential N-linked glycosylation sites. 12610728 5 20 gly glycosylation 826:838 arg2 the glycosylation site the glycosylation site site The point-mutated variant missing the glycosylation site for lysosomal targeting followed the secretory pathway. 15500445 5 8 part_of regions 880:886 arg1 the IDS protein IDS protein regions PUBTATOR Site IDS protein 3423 regions The linear sequence epitope reactivity of a polyclonal antibody raised against the native protein and the monoclonal antibodies were defined and mapped to distinct regions on the IDS protein. 17599380 0 86 gly glycosylation 21:33 arg2 position 386 position 386 position 386 Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. 17599380 0 86 gly glycosylation 21:33 arg2 the N-linked glycosylation site the N-linked glycosylation site site Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. 17623277 5 8 gly N-glycosylation 494:508 arg2 N-glycosylation site N-glycosylation site site A mosquito DCE was purified and its monosaccharide composition, N-glycosylation site, and oligosaccharide structures were determined. 7613477 3 65 part_of LCAT 810:813 arg1 the four expected N-linked glycopeptides LCAT the four expected N-linked glycopeptides PUBTATOR Site LCAT 3931 glycopeptides In addition to the four expected N-linked glycopeptides of LCAT, a di-O-linked glycopeptide was detected, as well as three additional glycopeptides. 20391591 4 67 gly glycoproteins 880:892 arg1 glycoproteins glycoproteins Fterm glycoproteins The combination of the very informative collision-induced dissociation spectra acquired in the linear ion trap with the distinct features of HCD offers very useful information aiding in the characterization of the glycosylation sites of glycoproteins. 20391591 4 37 gly glycosylation 857:869 arg2 the glycosylation sites glycoproteins sites Fterm glycoproteins sites The combination of the very informative collision-induced dissociation spectra acquired in the linear ion trap with the distinct features of HCD offers very useful information aiding in the characterization of the glycosylation sites of glycoproteins. 16845803 9 29 gly glycosylation 1236:1248 arg2 The glycosylation site The glycosylation site site The glycosylation site on Asn302 is beneficial to pro-UK stability in culture supernatant. 21904849 4 38 part_of protein 1281:1287 arg1 the glycosylation site protein the glycosylation site Fterm Site protein site On the basis of the molecular analysis, we also found that there was a deletion of the glycosylation site (NSS) in amino acid 156 of the hemagglutinin (HA) protein when compared with that of the other Clade 2.3.2 viruses isolated between 2007 and 2011. 27216994 8 12 part_of sites 1521:1525 arg1 GluN2B GluN2B sites PUBTATOR Site GluN2B 2904 sites Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans. 27216994 8 12 part_of sites 1521:1525 arg1 GluN1 GluN1 sites PUBTATOR Site GluN1 2902 sites Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans. 27216994 8 33 part_of sites 1567:1571 arg1 GluN2B GluN2B sites PUBTATOR Site GluN2B 2904 sites Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans. 27216994 8 33 part_of sites 1567:1571 arg1 GluN1 GluN1 sites PUBTATOR Site GluN1 2902 sites Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans. 23234360 0 23 part_of glycoproteins 102:114 arg1 O-glycosylation sites glycoproteins O-glycosylation sites Fterm Site glycoproteins sites LC-MS/MS characterization of O-glycosylation sites and glycan structures of human cerebrospinal fluid glycoproteins. 1482348 0 41 gly O-glycosylated 38:51 arg1 O-glycosylated oligosaccharide O-glycosylated oligosaccharide Hepatocyte growth factor is linked by O-glycosylated oligosaccharide on the alpha chain. 9857985 3 22 part_of S 473:473 arg1 the S protein sequence S protein the S protein sequence OGER Site S protein P04004 sequence The deduced amino acid sequence of the HE protein was most similar to that of MHV-S strain (94% identity), and the S protein sequence was most similar to that of MHV-Y strain (90% identity). 9857985 3 29 part_of protein 400:406 arg1 The deduced amino acid sequence protein The deduced amino acid sequence Fterm Site protein sequence The deduced amino acid sequence of the HE protein was most similar to that of MHV-S strain (94% identity), and the S protein sequence was most similar to that of MHV-Y strain (90% identity). 9857985 3 43 part_of protein 475:481 arg1 the S protein sequence S protein the S protein sequence OGER Site S protein P04004 sequence The deduced amino acid sequence of the HE protein was most similar to that of MHV-S strain (94% identity), and the S protein sequence was most similar to that of MHV-Y strain (90% identity). 21215105 9 60 part_of protein 1760:1766 arg1 site 40 protein site 40 Fterm Site protein position 80, 106, 241, 248, 351, 369 and 386, site In NA protein, seven amino acids were changed, including position 80, 106, 241, 248, 351, 369 and 386, site 40 of NA protein were glycosylated. 23005037 5 72 gly glycosylation 718:730 arg2 The glycosylation site mutation results The glycosylation site mutation results site The glycosylation site mutation results indicated that, among three N-glycan attachment sites, the N152Q mutants were retained in the endoplasmic reticulum and unfolded protein response signalling was activated. 21528263 1 0 gly P-glycoprotein 145:158 arg1 P-glycoprotein P-glycoprotein PUBTATOR P-glycoprotein 5243 Increased expression of P-glycoprotein, encoded by the MDR1 gene, is considered to be responsible for chemotherapy failure in a number of human cancers. 18371209 9 127 gly glycosylation 1379:1391 arg2 potential N-linked glycosylation sites potential N-linked glycosylation sites sites We found that end-stage R5 viruses lacked potential N-linked glycosylation sites (PNGS) in the gp120 V2 and V4 regions, which were present in the majority of the chronic stage R5 variants. 19735085 4 14 gly glycosylation 635:647 arg2 a single O-linked glycosylation site a single O-linked glycosylation site site Amino acids preceding the cleavage site have a single O-linked glycosylation site. 9398598 4 32 gly glycosylation 671:683 arg2 the predicted N-linked glycosylation site the predicted N-linked glycosylation site site Elimination of the predicted N-linked glycosylation site at residue 161 that is next to the fourth cysteine does not affect the formation of interchain disulfide bonds. 10024532 0 47 gly IgG 62:64 arg1 Variable domain-linked oligosaccharides IgG Variable domain-linked oligosaccharides Cterm IgG Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding. 8392347 3 79 gly glycosylation 593:605 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site The predicted protein exhibited structural features characteristic of members of the G-protein-coupled receptor family including seven hydrophobic segments corresponding to putative transmembrane domains, a potential N-linked glycosylation site near the amino-terminus, and multiple potential phosphorylation sites in the third cytoplasmic loop and carboxy-terminal cytoplasmic tail. 9242452 0 91 gly glycopeptide 123:134 arg2 glycopeptide immunogenicity glycopeptide immunogenicity glycopeptide T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. 25945896 1 72 gly occupancy 196:204 arg2 each glycosylation site each glycosylation site site Glycoprotein changes occur in not only protein abundance but also the occupancy of each glycosylation site by different glycoforms during biological or pathological processes. 25945896 1 101 gly glycosylation 214:226 arg2 each glycosylation site each glycosylation site site Glycoprotein changes occur in not only protein abundance but also the occupancy of each glycosylation site by different glycoforms during biological or pathological processes. 25113421 5 68 gly glycopeptides 726:738 arg2 glycopeptides glycopeptides glycopeptides Two experimental approaches exist to obtain MS/MS spectral data of glycopeptides. 2033065 6 96 gly glycosylation 1151:1163 arg1 the protein the protein Fterm protein Altering the glycosylation pattern of the protein had no significant effect on the level of fully gamma-carboxylated HPC secreted from the 293 cell line. 25499264 4 96 gly glycoprotein 754:765 arg1 envelope glycoprotein incorporation envelope glycoprotein incorporation PUBTATOR envelope glycoprotein 100616444 RESULTS: We generated HIV-1 mutants lacking gp41 N-glycans and determined the influence of these glycan deletions on the viral phenotype (infectivity, CD4 binding, envelope glycoprotein incorporation in the viral particle and on the transfected cell, virus capture by DC-SIGN(+) cells and transmission of DC-SIGN-captured virions to CD4(+) T-lymphocytes) and on the phenotypic susceptibility of HIV-1 to a selection of CBAs. 8352759 0 34 gly VIII 32:35 arg1 human structure of the factor VIII human PUBTATOR structure of the factor VIII 2157 Primary structure of the factor VIII binding domain of human, porcine and rabbit von Willebrand factor. 8352759 0 37 gly factor 25:30 arg1 human structure of the factor VIII human PUBTATOR structure of the factor VIII 2157 Primary structure of the factor VIII binding domain of human, porcine and rabbit von Willebrand factor. 23921623 1 17 gly N-glycosylation 178:192 arg2 two N-glycosylation sites two N-glycosylation sites sites Most street rabies virus glycoproteins (G proteins) possess two N-glycosylation sites, at Asn(37) and Asn(319), whereas an additional N-glycosylation site is present in several fixed (laboratory-adapted) rabies virus strains at Asn(247), which suggests that the N-glycosylation addition may be a marker of fixed viruses. 23921623 1 46 gly glycoproteins 139:151 arg1 Most street rabies virus glycoproteins Most street rabies virus glycoproteins Fterm glycoproteins Most street rabies virus glycoproteins (G proteins) possess two N-glycosylation sites, at Asn(37) and Asn(319), whereas an additional N-glycosylation site is present in several fixed (laboratory-adapted) rabies virus strains at Asn(247), which suggests that the N-glycosylation addition may be a marker of fixed viruses. 23921623 1 46 gly glycoproteins 139:151 arg1 G proteins G proteins Fterm proteins Most street rabies virus glycoproteins (G proteins) possess two N-glycosylation sites, at Asn(37) and Asn(319), whereas an additional N-glycosylation site is present in several fixed (laboratory-adapted) rabies virus strains at Asn(247), which suggests that the N-glycosylation addition may be a marker of fixed viruses. 23921623 1 60 gly N-glycosylation 248:262 arg2 an additional N-glycosylation site an additional N-glycosylation site site Most street rabies virus glycoproteins (G proteins) possess two N-glycosylation sites, at Asn(37) and Asn(319), whereas an additional N-glycosylation site is present in several fixed (laboratory-adapted) rabies virus strains at Asn(247), which suggests that the N-glycosylation addition may be a marker of fixed viruses. 15616124 7 18 gly N-glycosylation 957:971 arg2 N-glycosylation site knockout mutants N-glycosylation site knockout mutants site Pulse-chase analysis of N-glycosylation site knockout mutants demonstrated cotranslational glycosylation of N145 but primarily or exclusively posttranslational glycosylation of N322. 15616124 7 40 gly glycosylation 1024:1036 arg1 N145 N145 N145 Pulse-chase analysis of N-glycosylation site knockout mutants demonstrated cotranslational glycosylation of N145 but primarily or exclusively posttranslational glycosylation of N322. 15616124 7 63 gly glycosylation 1093:1105 arg1 N322 N322 N322 Pulse-chase analysis of N-glycosylation site knockout mutants demonstrated cotranslational glycosylation of N145 but primarily or exclusively posttranslational glycosylation of N322. 8486693 3 1 part_of sequence 725:732 arg1 The sequence sequence The sequence sequence The sequence of this protein showed homology to pancreatic lipase but was distinct from the NH2-terminal sequence of a 50-kDa content protein presumed to be secretory lipase. 8486693 3 7 part_of protein 754:760 arg1 the NH2-terminal sequence protein the NH2-terminal sequence Fterm Site protein sequence The sequence of this protein showed homology to pancreatic lipase but was distinct from the NH2-terminal sequence of a 50-kDa content protein presumed to be secretory lipase. 8486693 3 19 part_of protein 641:647 arg1 The sequence protein The sequence Fterm Site protein sequence The sequence of this protein showed homology to pancreatic lipase but was distinct from the NH2-terminal sequence of a 50-kDa content protein presumed to be secretory lipase. 28822114 7 80 part_of DMP1 1036:1039 arg1 the C-terminal domain DMP1 the C-terminal domain PUBTATOR Site DMP1 13406 domain Another breed of DMP1 mutant mice, which lacked the C-terminal domain of DMP1, manifested normal BBB function. 26062906 11 55 part_of carrying 1604:1611 arg1 the secretion-defective mutant protein AND Asn the secretion-defective mutant protein Asn Fterm SpecificSite protein Asn at position 6 In contrast, the secretion-defective mutant protein carrying Asn at position 6 induced only marginal humoral and cellular immune responses in mice, despite the N-linked glycosylation. 15039521 0 25 part_of site 34:37 arg1 the woodchuck hepatitis virus preS2 protein protein site Fterm Site protein site Identification of a glycosylation site in the woodchuck hepatitis virus preS2 protein and its role in protein trafficking. 9050863 3 18 part_of terminus 594:601 arg1 an additional N-glycosylation site terminus an additional N-glycosylation site site All three glycoproteins contain a common N-glycosylation site in the S domain while M possesses an additional N-glycosylation site at its amino terminus. 9050863 3 4 part_of contain 474:480 arg1 All three glycoproteins AND a common N-glycosylation site All three glycoproteins a common N-glycosylation site Fterm Site glycoproteins site All three glycoproteins contain a common N-glycosylation site in the S domain while M possesses an additional N-glycosylation site at its amino terminus. 24806200 3 59 gly glycoproteins 599:611 arg1 These glycoproteins These glycoproteins Fterm glycoproteins These glycoproteins play important roles in reproduction and are used clinically in the treatment of infertility. 8884270 0 66 gly N-glycosylation 35:49 arg2 an extra N-glycosylation site an extra N-glycosylation site site A point mutation creating an extra N-glycosylation site in fibrillin-1 results in neonatal Marfan syndrome. 19358553 3 26 gly glycoproteins 603:615 arg1 glycoproteins glycoproteins Fterm glycoproteins Glycopeptides derived from glycoproteins containing neutral glycans (ribonuclease B, IgG, and ovalbumin) were initially profiled and yielded excellent and reproducible quantitation (correlation coefficient r = 0.9958, n = 5) when evaluated against a normal phase HPLC 2-AB glycan profile. 19358553 3 64 gly ribonuclease 645:656 arg1 neutral glycans ribonuclease B neutral glycans Cterm ribonuclease B Glycopeptides derived from glycoproteins containing neutral glycans (ribonuclease B, IgG, and ovalbumin) were initially profiled and yielded excellent and reproducible quantitation (correlation coefficient r = 0.9958, n = 5) when evaluated against a normal phase HPLC 2-AB glycan profile. 19358553 3 40 gly containing 617:626 arg1 glycoproteins AND neutral glycans glycoproteins neutral glycans Fterm glycoproteins Glycopeptides derived from glycoproteins containing neutral glycans (ribonuclease B, IgG, and ovalbumin) were initially profiled and yielded excellent and reproducible quantitation (correlation coefficient r = 0.9958, n = 5) when evaluated against a normal phase HPLC 2-AB glycan profile. 15147907 4 54 part_of site 778:781 arg1 C3 C3 site Cterm Site C3 site The presence of the glucose moiety in 5% of the human C3 glycoprotein suggests that this glycosylation site is sequestered within the protein and is consistent with previous studies identifying a cryptic conglutinin binding site on C3 that becomes exposed upon its conversion to iC3b. 11152692 10 10 part_of asporin 1116:1122 arg1 The deduced amino acid sequence asporin The deduced amino acid sequence PUBTATOR Site asporin 54829 sequence The deduced amino acid sequence of asporin was confirmed by mass spectrometry of the isolated protein resulting in 84% sequence coverage. 29426894 6 33 gly occupied 1013:1020 arg2 Asn45 Asn45 Asn45 Among the six N-glycosylation sites of serum soluble FcγRIIIb, Asn45 was shown to be exclusively occupied by high-mannose-type oligosaccharides, whereas the remaining sites were solely modified by the complex-type oligosaccharides with sialic acid and fucose residues. 29426894 6 44 gly modified 1101:1108 arg1 the remaining sites AND the complex-type oligosaccharides the remaining sites the complex-type oligosaccharides sites Among the six N-glycosylation sites of serum soluble FcγRIIIb, Asn45 was shown to be exclusively occupied by high-mannose-type oligosaccharides, whereas the remaining sites were solely modified by the complex-type oligosaccharides with sialic acid and fucose residues. 29426894 6 36 gly N-glycosylation 930:944 arg1 serum soluble FcγRIIIb FcγRIIIb sites PUBTATOR FcγRIIIb 2215 sites Among the six N-glycosylation sites of serum soluble FcγRIIIb, Asn45 was shown to be exclusively occupied by high-mannose-type oligosaccharides, whereas the remaining sites were solely modified by the complex-type oligosaccharides with sialic acid and fucose residues. 11054460 0 16 part_of glucoamylase 98:109 arg1 belt region glucoamylase belt region Fterm Site glucoamylase region Replacement and deletion mutations in the catalytic domain and belt region of Aspergillus awamori glucoamylase to enhance thermostability. 11054460 0 16 part_of glucoamylase 98:109 arg1 catalytic domain glucoamylase catalytic domain Fterm Site glucoamylase domain Replacement and deletion mutations in the catalytic domain and belt region of Aspergillus awamori glucoamylase to enhance thermostability. 28620050 5 43 gly glycosylation 962:974 arg1 Asn-297 Asn-297 Asn-297 We report here that glycosylation at Asn-297 is critical for interactions with Fc receptors and complement and that glycosylation at Asn-563 is essential for controlling multimerization. 28620050 5 75 gly glycosylation 1058:1070 arg2 Asn-563 Asn-563 Asn-563 We report here that glycosylation at Asn-297 is critical for interactions with Fc receptors and complement and that glycosylation at Asn-563 is essential for controlling multimerization. 15718224 4 39 gly N-glycosylation 1071:1085 arg2 the N-glycosylation motifs the N-glycosylation motifs motifs These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs. 15718224 4 71 gly glycoprotein 996:1007 arg1 the viral envelope glycoprotein gp120 the viral envelope glycoprotein gp120 Fterm glycoprotein These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs. 15718224 4 80 gly glycosylation 954:966 arg2 up to seven or eight of 22 glycosylation sites up to seven or eight of 22 glycosylation sites sites These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs. 11015576 3 42 part_of FGFR3-tyrosine 561:574 arg1 the intracellular FGFR3-tyrosine kinase domain FGFR3 the intracellular FGFR3-tyrosine kinase domain PUBTATOR Site FGFR3 2261 domain Hypochondroplasia (HCH), the mildest form of this group of short-limbed dwarfism disorders, results in approximately 60% of cases from a mutation in the intracellular FGFR3-tyrosine kinase domain. 11931388 8 18 gly residues 1593:1600 arg1 60-80 60-80 residues 60-80 Amino acid sequence comparison of the mouse NHE-1 (derived from the fully processed message) with that of other mammalian species demonstrated two exceptionally divergent regions; the C-terminal cytoplasmic tail (residues 750-790), containing a region of 6-8 contiguous acidic amino acids variably composed of aspartate and glutamate residues, and the N-terminal extracellular domain that includes an N-linked glycosylation site (residues 60-80). 11931388 8 25 gly glycosylation 1573:1585 arg2 residues 60-80 residues 60-80 residues 60-80 Amino acid sequence comparison of the mouse NHE-1 (derived from the fully processed message) with that of other mammalian species demonstrated two exceptionally divergent regions; the C-terminal cytoplasmic tail (residues 750-790), containing a region of 6-8 contiguous acidic amino acids variably composed of aspartate and glutamate residues, and the N-terminal extracellular domain that includes an N-linked glycosylation site (residues 60-80). 11931388 8 25 gly glycosylation 1573:1585 arg2 an N-linked glycosylation site an N-linked glycosylation site site Amino acid sequence comparison of the mouse NHE-1 (derived from the fully processed message) with that of other mammalian species demonstrated two exceptionally divergent regions; the C-terminal cytoplasmic tail (residues 750-790), containing a region of 6-8 contiguous acidic amino acids variably composed of aspartate and glutamate residues, and the N-terminal extracellular domain that includes an N-linked glycosylation site (residues 60-80). 19276077 1 17 part_of subunit 288:294 arg1 the beta-propeller domain integrin alpha5 subunit the beta-propeller domain PUBTATOR Site integrin alpha5 subunit 3678 domain Recently we reported that N-glycans on the beta-propeller domain of the integrin alpha5 subunit (S-3,4,5) are essential for alpha5beta1 heterodimerization, expression, and cell adhesion. 12072497 8 11 part_of gp120 1409:1413 arg1 the V1/V2 and V3 regions gp120 the V1/V2 and V3 regions PUBTATOR Site gp120 3700 regions Sequence analysis of the V1/V2 and V3 regions of the viral envelope protein gp120 revealed that the more efficient CXCR4 usage of the later isolate might be caused by an additional potential N-glycosylation site in the V1/V2 loop. 8797081 14 57 part_of enzymes 1751:1757 arg1 the amino acid sequences enzymes the amino acid sequences Fterm Site enzymes sequences As judged on alignment of the amino acid sequences of other thrombin-like enzymes (batroxobin, ancrod, and flavoxobin), calobin constitute the formation of six disulfide bridges. 25643797 5 8 part_of residues 964:971 arg1 HA1 HA1 residues PUBTATOR SpecificSite HA1 23526 residues 295-297 Most of the isolates in lineage h9.4.2.5 lost one potential glycosylation site at residues 200-202, and had an additional one at residues 295-297 in HA1. 12421952 6 40 part_of has 666:668 arg1 CL-46 AND a potential N-glycosylation site CL-46 a potential N-glycosylation site PUBTATOR Site CL-46 415114 site CL-46 has two cysteine residues in the N-terminal segment, a potential N-glycosylation site in the collagen region, and an extended hydrophilic loop close to the binding site of the carbohydrate recognition domain. 12421952 6 40 part_of has 666:668 arg1 CL-46 AND two cysteine residues CL-46 two cysteine residues PUBTATOR AminoAcid CL-46 415114 cysteine residues CL-46 has two cysteine residues in the N-terminal segment, a potential N-glycosylation site in the collagen region, and an extended hydrophilic loop close to the binding site of the carbohydrate recognition domain. 12185264 4 62 gly glycoprotein 707:718 arg1 a glycoprotein precursor 1138 aa a glycoprotein precursor 1138 aa Fterm glycoprotein The Andes virus M RNA segment is 3671 nt in length and is predicted to encode a glycoprotein precursor 1138 aa in length; it generally resembles the other HPS-associated hantaviruses in its organization. 21380457 1 9 gly N-glycosylation 164:178 arg2 four potential N-glycosylation sites four potential N-glycosylation sites sites Human haptoglobin is a serum glycoprotein secreted by the liver with four potential N-glycosylation sites on its β chain. 21380457 1 41 gly glycoprotein 109:120 arg1 a serum glycoprotein a serum glycoprotein Fterm glycoprotein Human haptoglobin is a serum glycoprotein secreted by the liver with four potential N-glycosylation sites on its β chain. 21380457 1 41 gly glycoprotein 109:120 arg1 Human haptoglobin Human haptoglobin PUBTATOR Human haptoglobin 3240 Human haptoglobin is a serum glycoprotein secreted by the liver with four potential N-glycosylation sites on its β chain. 1457969 6 42 gly 2-3-sialylated 1124:1137 arg1 chiefly alpha 2-3-sialylated Gal chiefly alpha 2-3-sialylated Gal The Man alpha 1-6 branch displayed structural heterogeneity in the terminal sequence, with chiefly alpha 2-3-sialylated Gal and/or 4-O-sulphated GalNAc. 11310976 5 32 gly unglycosylated 1398:1411 arg1 its N-glycosylation site its N-glycosylation site site In addition, glycophorin A from erythrocytes of a patient with CDA II but not CDA I exhibited a significant deficit of mannose and N-acetylglucosamine suggesting that its N-glycosylation site was also partly unglycosylated. 11310976 5 55 gly N-glycosylation 1361:1375 arg2 its N-glycosylation site its N-glycosylation site site In addition, glycophorin A from erythrocytes of a patient with CDA II but not CDA I exhibited a significant deficit of mannose and N-acetylglucosamine suggesting that its N-glycosylation site was also partly unglycosylated. 18712764 1 8 gly glycoproteins 586:598 arg1 the native intact glycoproteins the native intact glycoproteins Fterm glycoproteins Serum transferrin (Tf) and alpha1-antitrypsin (AAT) that are markers for CDG, were purified sequentially to obtain high-quality MALDI mass spectra to differentiate single glycoforms of the native intact glycoproteins. 18712764 1 45 gly glycoforms 554:563 arg1 the native intact glycoproteins the native intact glycoproteins Fterm glycoproteins Serum transferrin (Tf) and alpha1-antitrypsin (AAT) that are markers for CDG, were purified sequentially to obtain high-quality MALDI mass spectra to differentiate single glycoforms of the native intact glycoproteins. 2768262 5 67 gly glycosylation 736:748 arg2 A potential N-linked glycosylation site A potential N-linked glycosylation site site A potential N-linked glycosylation site is present at asparagine-534. 2768262 5 67 gly glycosylation 736:748 arg1 asparagine-534 asparagine-534 asparagine-534 A potential N-linked glycosylation site is present at asparagine-534. 18941134 5 122 gly fucosylation 1444:1455 arg1 the terminal galactose the terminal galactose The seminal vesicle fluid glycome, on the other hand, carries equally abundant multimeric Lewis X structures but is distinctively lacking in additional fucosylation of the terminal galactose to give the Lewis Y epitope typifying the glycome of female ULF. 9726253 9 34 part_of site 1726:1729 arg1 the gpP450c17 enzyme gpP450c17 enzyme site Cterm Site gpP450c17 enzyme 13074 site Furthermore, introduction of a putative glycosylation site at amino acid 185 in the gpP450c17 enzyme did not alter substrate specificity. 9802575 4 24 part_of contained 715:723 arg1 the cytoplasmic domain AND several characteristic motifs the cytoplasmic domain several characteristic motifs motifs However, the cytoplasmic domain contained several characteristic motifs highly conserved across the species. 25389233 10 140 part_of lectin 1704:1709 arg1 Aleuria aurantia lectin and Lens culinaris agglutinin binding sites lectin Aleuria aurantia lectin and Lens culinaris agglutinin binding sites Fterm Site lectin sites Our results showed significantly higher levels of Aleuria aurantia lectin and Lens culinaris agglutinin binding sites exposed on IgG complexes of patients with systemic lupus erythematosus than on those of normal healthy blood donors. 25389233 10 151 part_of agglutinin 1730:1739 arg1 Aleuria aurantia lectin and Lens culinaris agglutinin binding sites agglutinin Aleuria aurantia lectin and Lens culinaris agglutinin binding sites Fterm Site agglutinin sites Our results showed significantly higher levels of Aleuria aurantia lectin and Lens culinaris agglutinin binding sites exposed on IgG complexes of patients with systemic lupus erythematosus than on those of normal healthy blood donors. 10527944 6 72 gly glycosylation 967:979 arg2 A partly occupied N-linked glycosylation site A partly occupied N-linked glycosylation site site A partly occupied N-linked glycosylation site was characterized in human SP-D. 2318821 1 11 gly glycosylation 114:126 arg2 Potential N-linked glycosylation site asparagine 43 site asparagine 43 site asparagine 43 Potential N-linked glycosylation site asparagine 43 is important for both enzyme activity and secretion. 30061671 8 28 gly N-glycosylation 976:990 arg2 a predicted N-glycosylation site a predicted N-glycosylation site site Candid#1 VHH-escape viruses had acquired a predicted N-glycosylation site in the surface glycoprotein GP1 that is present in highly pathogenic JUNV strains. 30061671 8 42 gly glycoprotein 1012:1023 arg1 the surface glycoprotein GP1 the surface glycoprotein GP1 Fterm glycoprotein Candid#1 VHH-escape viruses had acquired a predicted N-glycosylation site in the surface glycoprotein GP1 that is present in highly pathogenic JUNV strains. 10764840 1 3 gly glycosylation 277:289 arg2 1 O- glycosylation site 1 O- glycosylation site site Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells. 10764840 1 3 gly glycosylation 277:289 arg2 Ser-126 Ser-126 Ser-126 Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells. 10764840 1 10 gly N-glycosylation 217:231 arg2 three N-glycosylation sites three N-glycosylation sites sites Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells. 10764840 1 39 gly sites 233:237 arg1 three N-glycosylation sites three N-glycosylation sites sites Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells. 10764840 1 10 gly N-glycosylation 217:231 arg2 Asn-24 Asn-24, Asn-38, and Asn-83 Asn-24, Asn-38, and Asn-83 Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells. 10764840 1 10 gly N-glycosylation 217:231 arg2 Asn-83 Asn-24, Asn-38, and Asn-83 Asn-24, Asn-38, and Asn-83 Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells. 10764840 1 10 gly N-glycosylation 217:231 arg2 Asn-83 Asn-24, Asn-38, and Asn-83 Asn-24, Asn-38, and Asn-83 Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells. 10764840 1 39 gly sites 233:237 arg1 Asn-83 Asn-24, Asn-38, and Asn-83 Asn-24, Asn-38, and Asn-83 Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells. 10764840 1 39 gly sites 233:237 arg1 Asn-24 Asn-24, Asn-38, and Asn-83 Asn-24, Asn-38, and Asn-83 Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells. 10764840 1 39 gly sites 233:237 arg1 Asn-24 Asn-24, Asn-38, and Asn-83 Asn-24, Asn-38, and Asn-83 Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells. 19916043 5 54 gly N-glycosylation 551:565 arg2 one N-glycosylation site one N-glycosylation site site Similar to other human group C rotaviruses, one N-glycosylation site was predicted at amino acid residue 67 on the VP7 of strain GUP188. 19236877 1 15 gly glycosylation 142:154 arg2 a conserved glycosylation site a conserved glycosylation site site Antibodies contain a conserved glycosylation site that has emerged as a target for the modulation of antibody effector functions. 26618514 7 9 gly sialylated 1031:1040 arg1 sialylated IgG sialylated IgG Cterm IgG In contrast, sialylated IgG reduced the phagocytosis by monocytes of SNEC. 21053369 8 61 gly glycosylation 1275:1287 arg2 Eight glycosylation sites Eight glycosylation sites sites Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6). 21053369 8 38 gly identified 1300:1309 arg1 Asn250 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6). 21053369 8 38 gly identified 1300:1309 arg1 Asn209 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6). 21053369 8 38 gly identified 1300:1309 arg1 Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6). 21053369 8 38 gly identified 1300:1309 arg1 Asn157 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6). 21053369 8 38 gly identified 1300:1309 arg1 Asn209 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6). 21053369 8 38 gly identified 1300:1309 arg1 Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6). 21053369 8 38 gly identified 1300:1309 arg1 Asn157 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6). 21053369 8 38 gly identified 1300:1309 arg1 Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6). 21053369 8 38 gly identified 1300:1309 arg1 Asn157 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6). 21053369 8 38 gly identified 1300:1309 arg1 Asn157 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6 Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6). 7530394 6 27 gly glycosylated 1058:1069 arg1 a glycosylated E protein a glycosylated E protein Fterm protein PNGase F digestions of KUN isolates indicated that 19 of the 33 viruses possessed a glycosylated E protein. 8554050 7 20 gly glycoprotein 1132:1143 arg1 a glycoprotein a glycoprotein Fterm glycoprotein The Po protein and a glycoprotein (II-1) are encoded in the PRB4 gene, and both proteins are absent in the presence of a mutation in the PRB4M PO- allele that contains a single nt change (G--C) at the +1 invariant position of the intron 3 5'donor splice site. 8554050 7 20 gly glycoprotein 1132:1143 arg1 II-1 II-1 Cterm II-1 The Po protein and a glycoprotein (II-1) are encoded in the PRB4 gene, and both proteins are absent in the presence of a mutation in the PRB4M PO- allele that contains a single nt change (G--C) at the +1 invariant position of the intron 3 5'donor splice site. 15911445 10 6 gly glycosylation 1544:1556 arg2 a new glycosylation site a new glycosylation site site Furthermore, nine of twenty two A H1N2 isolates from the winter of 2002-2003 shared a T90A amino acid change which has not been observed in any A H1N1 isolate; resulting in the introduction of a new glycosylation site close to the antigenic site E. 27966990 4 63 gly N-glycosylation 554:568 arg1 VEGFR-2 VEGFR-2 PUBTATOR VEGFR-2 P35968 However, despite its importance, the functional role of N-glycosylation of VEGFR-2 remains poorly understood. 24899172 7 61 part_of AGL 1219:1221 arg1 5 AGL glycosylation sites 5 AGL 5 AGL glycosylation sites OGER Site 5 AGL P35573 sites Envelope proteins bearing 5 AGL glycosylation sites became hyperglycosylated, leading to an increased capacity for SVP secretion at the expense of HBV and HDV virion secretion. 10099468 4 46 gly sialylated 1072:1081 arg1 at least 11 differently sialylated glycoforms at least 11 differently sialylated glycoforms Analysis of IFN-gamma by capillary isoelectric focusing resolved at least 11 differently sialylated glycoforms over a pI range of 3.4 to 6.4, enabling rapid quantitation of this important source of microheterogeneity. 20622017 3 35 gly glycoproteins 464:476 arg1 renal membrane glycoproteins renal membrane glycoproteins Fterm glycoproteins The spectrum of N-glycans released from kidney GGT constituted a subset of the N-glycans identified from renal membrane glycoproteins. 20622017 3 72 gly released 370:377 arg2 kidney GGT AND N-glycans kidney GGT N-glycans OGER GGT The spectrum of N-glycans released from kidney GGT constituted a subset of the N-glycans identified from renal membrane glycoproteins. 12440958 3 55 gly glycosylation 706:718 arg2 a new glycosylation site a new glycosylation site site In addition, a polymorphism that results in decreased C3d binding and introduces a new glycosylation site predicted to disrupt the dimer interface was found in the New Zealand White autoimmune mouse strain. 15067359 11 54 part_of proteins 1551:1558 arg1 TM16H1-TM16H3 domains proteins TM16H1-TM16H3 domains Fterm Site proteins domains TMEM16 family members were eight-transmenbrane proteins with TM16H1-TM16H3 domains and a conserved Asn glycosylation site. 15067359 11 54 part_of proteins 1551:1558 arg1 a conserved Asn glycosylation site proteins a conserved Asn glycosylation site Fterm Site proteins site TMEM16 family members were eight-transmenbrane proteins with TM16H1-TM16H3 domains and a conserved Asn glycosylation site. 2477364 4 63 gly glycosylation 651:663 arg2 the two alpha N-linked glycosylation sites the two alpha N-linked glycosylation sites sites Previous studies demonstrated different roles of each of the two alpha N-linked glycosylation sites (Asn-52 and Asn-78) in secretion of the uncombined subunit and the biologic activity of hCG dimer. 2477364 4 112 gly sites 665:669 arg1 the two alpha N-linked glycosylation sites the two alpha N-linked glycosylation sites sites Previous studies demonstrated different roles of each of the two alpha N-linked glycosylation sites (Asn-52 and Asn-78) in secretion of the uncombined subunit and the biologic activity of hCG dimer. 2477364 4 63 gly glycosylation 651:663 arg2 Asn-52 Asn-52 and Asn-78 Asn-52 and Asn-78 Previous studies demonstrated different roles of each of the two alpha N-linked glycosylation sites (Asn-52 and Asn-78) in secretion of the uncombined subunit and the biologic activity of hCG dimer. 2477364 4 112 gly sites 665:669 arg1 Asn-78 Asn-52 and Asn-78 Asn-52 and Asn-78 Previous studies demonstrated different roles of each of the two alpha N-linked glycosylation sites (Asn-52 and Asn-78) in secretion of the uncombined subunit and the biologic activity of hCG dimer. 8407981 9 8 part_of P-450 1332:1336 arg1 the N terminus P-450(arom) the N terminus PUBTATOR Site P-450(arom) 55010 terminus We conclude that the N terminus of P-450(arom) is translocated across the endoplasmic reticulum membrane to be glycosylated at the luminal side. 12794129 5 58 gly glycosylation 691:703 arg2 an N-linked glycosylation site an N-linked glycosylation site site The only highly conserved segment in all known J chains is a block of residues surrounding an N-linked glycosylation site. 12064867 3 51 part_of gp120 546:550 arg1 Orientation-specific exposition gp120 Orientation-specific exposition PUBTATOR Site gp120 3700 position Orientation-specific exposition of gp120 in ELISA microplates was achieved by catching with either anti-C5 antibody D7324 or anti-V3 antibody NEA-9205. 11738084 3 48 gly released 344:351 arg1 the protein AND The oligosaccharide the protein The oligosaccharide Fterm protein The oligosaccharide was released from the protein using anhydrous hydrazine, and its structure was investigated using neuraminidase and a reagent array analysis method, which is based on the use of specific exoglycosidases. 9520292 4 31 gly deglycosylated 679:692 arg1 the cathepsin D the cathepsin D PUBTATOR cathepsin D, 1509 No significant difference was detected in the immunoreactivity of patient serum with the glycosylated and deglycosylated forms of the cathepsin D, suggesting that patient humoral responses are directed primarily against the core protein. 9520292 4 55 gly glycosylated 662:673 arg1 the cathepsin D the cathepsin D PUBTATOR cathepsin D, 1509 No significant difference was detected in the immunoreactivity of patient serum with the glycosylated and deglycosylated forms of the cathepsin D, suggesting that patient humoral responses are directed primarily against the core protein. 22239659 4 55 part_of peptide 854:860 arg1 the glycopeptides peptide the glycopeptides glycopeptides A glycan database search program, GlycoPeptideSearch, was developed to match N-glycopeptide MS/MS spectra with the glycopeptides comprised of a glycan drawn from the GlycomeDB glycan structure database and a peptide from a user-specified set of potentially glycosylated peptides. 30841845 3 106 gly glycosylation 478:490 arg2 glycosylation sites glycosylation sites sites Mutations on and in the proximity of glycosylation sites are highly associated with human diseases. 21196036 0 15 gly glycoprotein 76:87 arg1 goat oviduct-specific glycoprotein goat oviduct-specific glycoprotein OGER oviduct-specific glycoprotein Q12889 Purification, sequence characterization and effect of goat oviduct-specific glycoprotein on in vitro embryo development. 20805301 5 69 part_of CYP2W1 711:716 arg1 Asn177 CYP2W1 Asn177 PUBTATOR AminoAcid CYP2W1 54905 Asn177 Bioinformatic analysis identified Asn177 as the only possible glycosylation site of CYP2W1, which was supported by the inability of an N177A mutant to be glycosylated in HEK 293 cells. 20805301 5 69 part_of CYP2W1 711:716 arg1 the only possible glycosylation site CYP2W1 the only possible glycosylation site PUBTATOR Site CYP2W1 54905 site Bioinformatic analysis identified Asn177 as the only possible glycosylation site of CYP2W1, which was supported by the inability of an N177A mutant to be glycosylated in HEK 293 cells. 27007620 6 15 gly glycoproteins 1186:1198 arg1 individual glycoproteins individual glycoproteins Fterm glycoproteins Therefore, significant opportunities exist to improve glycoproteomic inquiry into disease by engaging in these studies at the level of individual glycoproteins and their exact loci of glycosylation. 17522223 8 12 gly glycosylation 1544:1556 arg2 only one glycosylation site mutation only one glycosylation site mutation site Significantly, 124mut and 134mut differed by only one glycosylation site mutation in each construct, and both 124mut and 134mut viruses exhibited wild-type levels of infectivity when used in a direct infection assay. 25202310 6 39 gly glycosylation 1399:1411 arg2 the glycosylation sites the glycosylation sites sites The solvent accessibility of the glycosylation sites on maturely folded proteins of the 100 most abundant putative N-glycoproteins observed uniquely in the three subcellular glycoproteomes correlated with the glycan type processing thereby mechanistically explaining the formation of subcellular-specific N-glycosylation. 25202310 6 53 gly N-glycoproteins 1481:1495 arg1 the 100 most abundant putative N-glycoproteins the 100 most abundant putative N-glycoproteins Fterm N-glycoproteins The solvent accessibility of the glycosylation sites on maturely folded proteins of the 100 most abundant putative N-glycoproteins observed uniquely in the three subcellular glycoproteomes correlated with the glycan type processing thereby mechanistically explaining the formation of subcellular-specific N-glycosylation. 18076768 0 95 gly glycoprotein 88:99 arg1 HIV-1 envelope glycoprotein HIV-1 envelope glycoprotein PUBTATOR 1 envelope glycoprotein variants 155971 Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. 26911932 5 53 gly N-glycosylation 956:970 arg2 a human FSHβ(Asn7Δ 24Δ) double N-glycosylation site mutant subunit a human FSHβ(Asn7Δ 24Δ) double N-glycosylation site mutant subunit site Here, we have generated transgenic mice with gonadotrope-specific expression of either an HFSHB(WT) transgene that encodes human FSHβ WT subunit or an HFSHB(dgc) transgene that encodes a human FSHβ(Asn7Δ 24Δ) double N-glycosylation site mutant subunit, and separately introduced these transgenes onto Fshb null background using a genetic rescue strategy. 12911333 6 92 gly glycosylated 993:1004 arg2 every position every position position, The middle section of the linker (54% of linker) was glycosylated at every position, whereas both end sections (46% of linker) near the S1 or S2 membrane domains were not. 11978064 2 29 part_of possesses 250:258 arg1 PGH AND one glycosylation site PGH one glycosylation site Cterm Site PGH P01241 site PGH differs from pituitary growth hormone by 13 amino acids and possesses one glycosylation site. 19741058 4 51 part_of enzyme 810:815 arg1 the native human enzyme sequence enzyme the native human enzyme sequence Fterm Site enzyme sequence In contrast to imiglucerase and prGCD, velaglucerase alfa contains the native human enzyme sequence. 2886334 1 14 part_of Thy-1 350:354 arg1 the three glycosylation sites Thy-1 the three glycosylation sites PUBTATOR Site Thy-1 24832 sites To examine the extent to which protein structure and tissue-type influence glycosylation, we have determined the oligosaccharide structures at each of the three glycosylation sites (Asn-23, 74 and 98) of the cell surface glycoprotein Thy-1 isolated from rat brain and thymus. 25499076 2 26 gly N-glycosylation 349:363 arg2 a single, partially occupied N-glycosylation site a single, partially occupied N-glycosylation site site It has a single, partially occupied N-glycosylation site located at Asn-31, which makes it a particularly simple and interesting model for glycosylation studies. 7535613 11 62 part_of PSA 1606:1608 arg1 The PSA glycosylation site PSA site, Asn 61 PUBTATOR SpecificSite PSA P07288 site, Asn 61 The PSA glycosylation site, Asn 61, is fully accessible to the solvent and is enclosed in a positive region of the isopotential map. 27023253 8 79 gly glycosylation 1375:1387 arg2 tandem, shotgun proteomics and glycosylation site analysis tandem, shotgun proteomics and glycosylation site analysis site Furthermore, we designed new functionality to the protocol by achieving tandem, shotgun proteomics and glycosylation site analysis on hen plasma. 31572782 4 37 gly receptor 498:505 arg1 the glycan pattern IgE high-affinity receptor (FcεRIα) the glycan pattern PUBTATOR IgE high-affinity receptor (FcεRIα) 2205 The employed methodology allowed dissecting the glycan pattern of the IgE high-affinity receptor (FcεRIα) expressed in human HEK 293 cells, identifying the presence and relative abundance of specific glycan epitopes. 11069304 6 45 gly glycosylation 1491:1503 arg1 the channel itself the channel itself Fterm channel The evidence indicates that the hSlo protein possesses intrinsic information for transport to the apical cell surface through a mechanism that may involve association with lipid rafts and that is independent of glycosylation of the channel itself or an associated protein. 9169007 11 11 gly antithrombin 2012:2023 arg1 all carbohydrate chains antithrombin all carbohydrate chains PUBTATOR antithrombin 462 These results indicate that all carbohydrate chains of recombinant antithrombin adversely affect heparin-binding affinity to an extent that correlates with their relative proximity to the putative heparin-binding site in antithrombin. 7768336 6 42 gly glycosylation 948:960 arg2 All the glycosylation site mutants All the glycosylation site mutants site All the glycosylation site mutants were capable of normal signal transduction, as indicated by their ability to stimulate inositol phosphate production. 9169007 0 100 gly antithrombin 56:67 arg1 individual carbohydrate chains antithrombin individual carbohydrate chains PUBTATOR antithrombin 462 Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity. 17459925 3 77 gly chains 385:390 arg1 flavivirus E proteins proteins chains Fterm proteins N-linked oligosaccharide side chains on flavivirus E proteins have been associated with viral morphogenesis, infectivity, and tropism. 10989127 13 93 part_of present 1846:1852 arg2 all mammalian hyaluronidase isoenzymes AND This site all mammalian hyaluronidase isoenzymes This site Fterm Site isoenzymes site This site is present in all mammalian hyaluronidase isoenzymes reported in the present study whatever the species and organ localization. 24246999 4 9 gly glycosylation 658:670 arg2 its glycosylation site its glycosylation site site An additional mutant was created for the α1 ECD restoring its glycosylation site within the Cys-loop and its α-bungarotoxin binding ability. 19706343 1 68 gly Beta2-glycoprotein 144:161 arg1 Beta2-glycoprotein I Beta2-glycoprotein I PUBTATOR Beta2-glycoprotein I 350 Beta2-glycoprotein I (beta2GPI) is a five-domain protein associated with the antiphospholipid syndrome (APS), however, its normal biological function is yet to be defined. 27641734 16 29 gly N-glycosylation 2981:2995 arg1 CD97 CD97 PUBTATOR CD97 976 A comparison of the HeLa binding affinities of PNGase F-digested, GPS-mutated and N-glycosylation-mutated CD97 samples revealed diverse findings, suggesting that the functions of CD97 ECD were complex, and various technologies for function validation should be utilized to avoid single-approach bias when investigating N-glycosylation and auto-proteolysis of CD97. 26296369 5 67 part_of CD69 1094:1097 arg1 the glycosylation site CD69 the glycosylation site PUBTATOR Site CD69 969 site In agreement, the glycomics analysis determines the glycosylation site and the N-glycan composition of CD69, and terminal removal of sialic acid from that N-linked glycans reverses the generation of forkhead box P3-positive Treg cells (23.21%; P < 0.05). 6980014 3 33 gly contained 467:475 arg1 these CNBr fragments AND one oligosaccharide chain these CNBr fragments one oligosaccharide chain fragments Composition data revealed that each of these CNBr fragments contained one oligosaccharide chain. 15500445 1 54 gly enzymes 116:122 arg1 Mammalian sulphatases enzymes Mammalian sulphatases Fterm enzymes Mammalian sulphatases (EC 3.1.6) are a family of enzymes that have a high degree of similarity in amino acid sequence, structure and catalytic mechanism. 22122935 3 26 gly glycopeptides 669:681 arg2 the glycopeptides the glycopeptides glycopeptides Neuraminidase was first used to enhance the detection of the glycopeptides and detect all possible glycoforms contained in each glycosylation site. 22122935 3 72 gly glycosylation 736:748 arg2 each glycosylation site each glycosylation site site Neuraminidase was first used to enhance the detection of the glycopeptides and detect all possible glycoforms contained in each glycosylation site. 20209506 4 19 gly glycopeptides 1020:1032 arg2 The enriched glycopeptides The enriched glycopeptides glycopeptides Conditions for rapid proteolytic digestion of beta2-GPI using low-specificity proteases were optimized to detect beta2-GPI glycopeptides by MS. We demonstrate the importance of ensuring sufficient column capacity of both hydrophobic and hydrophilic stationary phases for optimal glycoprofiling by MS. The enriched glycopeptides were characterized using MALDI quadrupole TOF MS/MS. 20209506 4 96 gly glycopeptides 829:841 arg2 beta2-GPI glycopeptides beta2-GPI glycopeptides glycopeptides Conditions for rapid proteolytic digestion of beta2-GPI using low-specificity proteases were optimized to detect beta2-GPI glycopeptides by MS. We demonstrate the importance of ensuring sufficient column capacity of both hydrophobic and hydrophilic stationary phases for optimal glycoprofiling by MS. The enriched glycopeptides were characterized using MALDI quadrupole TOF MS/MS. 22855498 9 0 gly glycosylation 1162:1174 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Notably, all posttransmission E1E2s had lost a potential N-linked glycosylation site (PNGS) in E2. 9535843 6 71 gly glycosylation 913:925 arg2 a unique glycosylation site a unique glycosylation site site We also demonstrate presence of a unique glycosylation site in position 418, which defines one extracellular loop between H2 and H3. 27301377 7 69 part_of DEspR 1813:1817 arg1 distinct DEspR epitopes DEspR distinct DEspR epitopes Cterm Site DEspR 1906 epitopes Western blot analysis using anti-DEspR mAbs targeting distinct DEspR epitopes detect the identical glycosylated 17.5 kDa pull-down protein. 12364335 9 4 gly residues 1466:1473 arg1 the beta and the gamma repeats residues in the beta and the gamma repeats residues in A further reduction of the GalNAc-inhibitable activity was observed when both Asp(444) and the corresponding aspartate residues in the beta and the gamma repeats were mutated. 22365690 5 37 gly N-glycosylation 1007:1021 arg2 N-glycosylation site ratios N-glycosylation site ratios site Furthermore, N-glycosylation site ratios on serum haptoglobin (Hp) β chain in healthy individuals as well as patients with hepatitis B virus (HBV), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) were quantified to validate the novel 'iTRAQ plus (18)O' method. 29980609 7 0 part_of AICL 1289:1292 arg1 the AICL C-type lectin-like domain AICL the AICL C-type lectin-like domain PUBTATOR Site AICL 9976 domain One atypical and three conventional N-linked glycosylation sites in the AICL C-type lectin-like domain critically impact maturation and surfacing of AICL, which is strictly dependent on glycosylation of at least one conventional glycosylation site. 8193553 4 11 gly disialylated 901:912 arg1 the disialylated structure the disialylated structure The O-glycans of human erythrocyte glycophorin A consist mainly of short oligosaccharides with one, two, or three sialic acid residues linked to a common disaccharide core, Gal beta 1-3GalNAc alpha 1-Ser/Thr, with the disialylated structure being the most abundant. 8193553 4 72 gly A 730:730 arg1 The O-glycans glycophorin A The O-glycans PUBTATOR glycophorin A 2993 The O-glycans of human erythrocyte glycophorin A consist mainly of short oligosaccharides with one, two, or three sialic acid residues linked to a common disaccharide core, Gal beta 1-3GalNAc alpha 1-Ser/Thr, with the disialylated structure being the most abundant. 26618514 1 29 gly glycosylation 204:216 arg2 a single glycosylation site a single glycosylation site site The Fc portion of immunoglobulin (Ig)G harbours a single glycosylation site. 8639654 7 113 gly N-glycosylation 1200:1214 arg2 consensus N-glycosylation sites consensus N-glycosylation sites sites In contrast, no VIP binding to Cos-7 cells could be observed with the mutant devoid of consensus N-glycosylation sites due to a strict sequestration of this mutant in the perinuclear endoplasmic reticulum. 11399819 15 32 part_of FcgammaRIIIb 2274:2285 arg1 an FcgammaRIIIb N-glycosylation site FcgammaRIIIb an FcgammaRIIIb N-glycosylation site PUBTATOR Site FcgammaRIIIb 2215 site CONCLUSIONS: NA2 expression is affected by polymorphisms in FcgammaRIIIB 227 and FcgammaRIIIB 277, both of which are involved in an FcgammaRIIIb N-glycosylation site. 7579578 5 39 gly glycosylation 525:537 arg2 a potential glycosylation site a potential glycosylation site site There is a strongly hydrophobic signal sequence consisting of the first 20 amino acids and a potential glycosylation site at amino acids 134-136. 1385399 1 0 gly glycoprotein 85:96 arg1 The T-lymphocyte glycoprotein receptor The T-lymphocyte glycoprotein receptor Fterm glycoprotein The T-lymphocyte glycoprotein receptor, CD2, mediates cell-cell adhesion by binding to the surface molecule CD58 (LFA-3) on many cell types including antigen presenting cells. 32012121 8 53 gly glycosylation 1173:1185 arg2 glycosylation site analyses glycosylation site analyses site Molecular characterization of the Saudi strains was further carried out by mutational, selection pressure and glycosylation site analyses. 17947537 2 21 part_of positions 489:497 arg1 the H protein protein positions Fterm Site protein positions 195 and 200 We have demonstrated that rodent neurovirulence is modulated by two mutations at amino acid positions 195 and 200 in the H protein, one of these positions (200) being a potential glycosylation site. 1388166 1 92 gly Asn-linked 225:234 arg1 sulfated Asn-linked oligosaccharides Asn sulfated Asn-linked oligosaccharides Asn Tissue factor pathway inhibitor (TFPI) produced by endothelial cells contains sulfated Asn-linked oligosaccharides. 1388166 1 88 gly contains 207:214 arg1 TFPI AND sulfated Asn-linked oligosaccharides TFPI sulfated Asn-linked oligosaccharides PUBTATOR TFPI 7035 Tissue factor pathway inhibitor (TFPI) produced by endothelial cells contains sulfated Asn-linked oligosaccharides. 1388166 1 88 gly contains 207:214 arg1 Tissue factor pathway inhibitor AND sulfated Asn-linked oligosaccharides Tissue factor pathway inhibitor sulfated Asn-linked oligosaccharides PUBTATOR Tissue factor pathway inhibitor 7035 Tissue factor pathway inhibitor (TFPI) produced by endothelial cells contains sulfated Asn-linked oligosaccharides. 29232830 5 29 gly N-glycosylation 733:747 arg2 426 putative sites 426 putative sites sites Across the sample groups, 703 proteins were quantified and 426 putative sites of N-glycosylation were identified with evidence of several novel sites. 8286855 0 12 gly glycosylation 74:86 arg2 O-linked glycosylation motifs O-linked glycosylation motifs motifs Glycosylation sites identified by solid-phase Edman degradation: O-linked glycosylation motifs on human glycophorin A. 22773269 6 25 gly Sialoglycopeptides 825:842 arg2 Sialoglycopeptides Sialoglycopeptides Sialoglycopeptides Sialoglycopeptides were relatively concentrated in low-pH fractions of the immobilized pH strips and were captured using TiO(2) chromatography. 27506355 9 43 gly glycopeptide 962:973 arg2 possible glycopeptide sequences possible glycopeptide sequences glycopeptide sequences Given a list of possible glycopeptide sequences as input, a sample-specific spectral library of MassAnalyzer-predicted spectra is built using SpectraST. 14660594 2 23 part_of protein 477:483 arg1 the membranous sterol-sensing domain SREBP cleavage-activating protein the membranous sterol-sensing domain PUBTATOR Site SREBP cleavage-activating protein 22937 domain When cellular levels of sterols rise, Insig-1 binds to the membranous sterol-sensing domain of SREBP cleavage-activating protein (SCAP), retaining the SCAP/SREBP complex in the ER and preventing it from moving to the Golgi for proteolytic processing. 24421913 8 43 gly glycosylation 1316:1328 arg2 the N154 glycosylation site the N154 glycosylation site site Moreover, we present evidence that ZIKV has possibly undergone recombination in nature and that a loss of the N154 glycosylation site in the envelope protein was a possible adaptive response to the Aedes dalzieli vector. 18464039 8 66 gly glycosylation 1016:1028 arg2 246th position 246th position position Four motifs were predicted in buffalo DGAT1 peptide sequence, one N-linked glycosylation site (246th position), two putative tyrosine phosphorylation site (316 and 261), one putative diacylglycerol binding site (382-392 amino acid position) and a conserved domain MBOAT (membrane bound acyl transferase from 150 to 474 amino acids) with a histidine as an active residue. 18464039 8 66 gly glycosylation 1016:1028 arg2 one N-linked glycosylation site one N-linked glycosylation site site Four motifs were predicted in buffalo DGAT1 peptide sequence, one N-linked glycosylation site (246th position), two putative tyrosine phosphorylation site (316 and 261), one putative diacylglycerol binding site (382-392 amino acid position) and a conserved domain MBOAT (membrane bound acyl transferase from 150 to 474 amino acids) with a histidine as an active residue. 27343203 4 50 part_of glycosylation 725:737 arg1 the N-linked glycosylation site variants the N-linked glycosylation site Fterm Site variants site One variant comprised the full extracellular portion of CD23, including the stalk and head domain; 1 variant was identical with the first, except for an amino acid exchange in the stalk region abolishing the N-linked glycosylation site; and 2 variants represented the head domain, 1 complete and 1 truncated. 27343203 4 73 part_of N-linked 716:723 arg1 the N-linked glycosylation site variants the N-linked glycosylation site Fterm Site variants site One variant comprised the full extracellular portion of CD23, including the stalk and head domain; 1 variant was identical with the first, except for an amino acid exchange in the stalk region abolishing the N-linked glycosylation site; and 2 variants represented the head domain, 1 complete and 1 truncated. 29198943 5 64 gly glycosylation 916:928 arg2 an extra glycosylation site an extra glycosylation site site Although Cysless hASBT had significantly reduced function correlated with lowered surface expression, it featured an extra glycosylation site that facilitated its differentiation from wt-hASBT on immunoblots. 7613477 5 92 gly sites 1112:1116 arg1 All four potential N-linked glycosylation sites All four potential N-linked glycosylation sites sites All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 All four potential N-linked glycosylation sites AND triantennary LCAT All four potential N-linked glycosylation sites triantennary PUBTATOR LCAT 3931 sites All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 All four potential N-linked glycosylation sites AND sialylated triantennary and/or biantennary complex structures LCAT All four potential N-linked glycosylation sites sialylated triantennary and/or biantennary complex structures PUBTATOR LCAT 3931 sites All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 92 gly sites 1112:1116 arg1 Asn384 Asn20, Asn84, Asn272, and Asn384 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 92 gly sites 1112:1116 arg1 Asn84 Asn20, Asn84, Asn272, and Asn384 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 92 gly sites 1112:1116 arg1 Asn84 Asn20, Asn84, Asn272, and Asn384 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 101 gly glycosylation 1098:1110 arg1 LCAT LCAT sites PUBTATOR LCAT 3931 sites All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 101 gly glycosylation 1098:1110 arg1 LCAT LCAT Asn20, Asn84, Asn272, and Asn384 PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 101 gly glycosylation 1098:1110 arg2 Asn84 Asn20, Asn84, Asn272, and Asn384 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 101 gly glycosylation 1098:1110 arg2 Asn384 Asn20, Asn84, Asn272, and Asn384 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 101 gly glycosylation 1098:1110 arg2 Asn84 LCAT Asn20, Asn84, Asn272, and Asn384 PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 101 gly glycosylation 1098:1110 arg2 Asn384 LCAT Asn20, Asn84, Asn272, and Asn384 PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 101 gly glycosylation 1098:1110 arg2 Asn384 Asn20, Asn84, Asn272, and Asn384 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 Asn84 AND triantennary Asn20, Asn84, Asn272, and Asn384 triantennary Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 LCAT AND triantennary LCAT Asn20, Asn84, Asn272, and Asn384 triantennary PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 Asn272 AND triantennary LCAT Asn20, Asn84, Asn272, and Asn384 triantennary PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 Asn84 AND sialylated triantennary and/or biantennary complex structures Asn20, Asn84, Asn272, and Asn384 sialylated triantennary and/or biantennary complex structures Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 LCAT AND sialylated triantennary and/or biantennary complex structures LCAT Asn20, Asn84, Asn272, and Asn384 sialylated triantennary and/or biantennary complex structures PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 Asn272 AND sialylated triantennary and/or biantennary complex structures LCAT Asn20, Asn84, Asn272, and Asn384 sialylated triantennary and/or biantennary complex structures PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 LCAT AND triantennary LCAT Asn20, Asn84, Asn272, and Asn384 triantennary PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 Asn272 AND triantennary LCAT Asn20, Asn84, Asn272, and Asn384 triantennary PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 LCAT AND sialylated triantennary and/or biantennary complex structures LCAT Asn20, Asn84, Asn272, and Asn384 sialylated triantennary and/or biantennary complex structures PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 Asn272 AND sialylated triantennary and/or biantennary complex structures LCAT Asn20, Asn84, Asn272, and Asn384 sialylated triantennary and/or biantennary complex structures PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 Asn272 AND triantennary LCAT Asn20, Asn84, Asn272, and Asn384 triantennary PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 46 gly contain 1180:1186 arg1 Asn272 AND sialylated triantennary and/or biantennary complex structures LCAT Asn20, Asn84, Asn272, and Asn384 sialylated triantennary and/or biantennary complex structures PUBTATOR LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 8029814 5 16 part_of protein 776:782 arg1 The mouse protein S cDNA sequence The mouse protein S cDNA The mouse protein S cDNA sequence Cterm Site The mouse protein S cDNA sequence The mouse protein S cDNA sequence of the coding region shares 82% identity to human. 8029814 5 18 part_of cDNA 786:789 arg1 The mouse protein S cDNA sequence The mouse protein S cDNA The mouse protein S cDNA sequence Cterm Site The mouse protein S cDNA sequence The mouse protein S cDNA sequence of the coding region shares 82% identity to human. 8029814 5 75 part_of mouse 770:774 arg1 The mouse protein S cDNA sequence The mouse protein S cDNA The mouse protein S cDNA sequence Cterm Site The mouse protein S cDNA sequence The mouse protein S cDNA sequence of the coding region shares 82% identity to human. 8029814 5 78 part_of S 784:784 arg1 The mouse protein S cDNA sequence The mouse protein S cDNA The mouse protein S cDNA sequence Cterm Site The mouse protein S cDNA sequence The mouse protein S cDNA sequence of the coding region shares 82% identity to human. 15247302 2 75 part_of has 312:314 arg1 the human beta(2)AR AND a potential third N-glycosylation site the human beta(2)AR a potential third N-glycosylation site PUBTATOR Site beta(2)AR 154 site However, the human beta(2)AR has a potential third N-glycosylation site at ECL2 residue 187. 29463651 0 39 gly Protein 27:33 arg1 the Determinant Protein the Determinant Fterm Protein N-glycosylation of Viral E Protein Is the Determinant for Vector Midgut Invasion by Flaviviruses. 29463651 0 85 gly N-glycosylation 0:14 arg1 Viral E Protein Viral E Protein Fterm Protein N-glycosylation of Viral E Protein Is the Determinant for Vector Midgut Invasion by Flaviviruses. 2295597 0 80 part_of beta-hydroxylase 47:62 arg1 Primary amino acid sequence dopamine beta-hydroxylase Primary amino acid sequence PUBTATOR Site dopamine beta-hydroxylase 280758 sequence Primary amino acid sequence of bovine dopamine beta-hydroxylase. 31514875 9 5 gly glycosylation 1798:1810 arg2 the 4 glycosylation site the 4 glycosylation site site For the first time, the complementarity of trypsin and pepsin was illustrated for the glycosylation mapping as trypsin led to identifications on 2 out of 4 glycosylation site while pepsin was informative on the 4 glycosylation site. 31514875 9 24 gly glycosylation 1741:1753 arg2 2 out of 4 glycosylation site 2 out of 4 glycosylation site site For the first time, the complementarity of trypsin and pepsin was illustrated for the glycosylation mapping as trypsin led to identifications on 2 out of 4 glycosylation site while pepsin was informative on the 4 glycosylation site. 19995346 4 1 gly N-glycosylation 392:406 arg2 an N-glycosylation site an N-glycosylation site site A Tat chimaera carrying an N-glycosylation site did not become glycosylated when expressed in cells, while the chimaera was glycosylated when mechanically introduced into purified microsomes. 26536155 7 8 gly O-glycopeptide 1715:1728 arg2 O-glycopeptide analysis O-glycopeptide analysis O-glycopeptide This analytical tool can be applied to a variety of glycoproteins for site-specific N- and O-glycopeptide analysis, resulting in a good glycopeptide coverage within a single sample run and, thus, requiring only small amounts of sample. 26536155 7 17 gly glycoproteins 1676:1688 arg1 glycoproteins glycoproteins Fterm glycoproteins This analytical tool can be applied to a variety of glycoproteins for site-specific N- and O-glycopeptide analysis, resulting in a good glycopeptide coverage within a single sample run and, thus, requiring only small amounts of sample. 26536155 7 39 gly glycopeptide 1760:1771 arg2 a good glycopeptide coverage a good glycopeptide coverage glycopeptide This analytical tool can be applied to a variety of glycoproteins for site-specific N- and O-glycopeptide analysis, resulting in a good glycopeptide coverage within a single sample run and, thus, requiring only small amounts of sample. 15811651 6 34 part_of positions 985:993 arg1 protein E protein E positions Cterm Site protein E positions 66 and 154 Furthermore, the mutant which was glycosylated at positions 66 and 154 in protein E, the level of secreted E protein was four-fold higher than that of the wild-type. 24048266 4 64 part_of GPCR 683:686 arg1 GPCR sequence GPCR GPCR sequence PUBTATOR Site GPCR 441931 sequence Therefore, investigating the exact position of glycosylation site in GPCR sequence can provide useful clues for drug design and other biotechnology applications. 24048266 4 83 part_of sequence 688:695 arg1 the exact position sequence the exact position position Therefore, investigating the exact position of glycosylation site in GPCR sequence can provide useful clues for drug design and other biotechnology applications. 12716971 5 71 gly glycosylation 846:858 arg2 Ala Ala Ala The polymorphism results in an amino acid substitution of Thr-47 to Ala in exon 6, a potential O- and N-linked glycosylation site. 12716971 5 71 gly glycosylation 846:858 arg2 a potential O- and N-linked glycosylation site a potential O- and N-linked glycosylation site site The polymorphism results in an amino acid substitution of Thr-47 to Ala in exon 6, a potential O- and N-linked glycosylation site. 9639536 0 11 gly antigen 37:43 arg1 alpha1-acid glycoprotein glycoprotein antigen Fterm glycoprotein Site localization of sialyl Lewis(x) antigen on alpha1-acid glycoprotein by high performance liquid chromatography-electrospray mass spectrometry. 9639536 0 25 gly glycoprotein 60:71 arg1 alpha1-acid glycoprotein alpha1-acid glycoprotein Fterm glycoprotein Site localization of sialyl Lewis(x) antigen on alpha1-acid glycoprotein by high performance liquid chromatography-electrospray mass spectrometry. 11082042 3 58 gly N-glycosylation 759:773 arg2 one potential N-glycosylation site one potential N-glycosylation site site The deduced amino acid sequence of porcine thyroid cathepsin K predicted a 37 kDa preproenzyme, with the active site residues Cys-140, His-277 and Asn-297, and one potential N-glycosylation site. 8364023 10 14 gly glycosylation 1381:1393 arg1 residues 20 and 384 residues 20 and 384 residues 20 and 384 These results suggest that glycosylation at residues 20 and 384 is not essential for intracellular processing, secretion, or activity. 8364023 10 14 gly glycosylation 1381:1393 arg1 384 residues 20 and 384 residues 20 and 384 These results suggest that glycosylation at residues 20 and 384 is not essential for intracellular processing, secretion, or activity. 8364023 10 14 gly glycosylation 1381:1393 arg2 384 residues 20 and 384 residues 20 and 384 These results suggest that glycosylation at residues 20 and 384 is not essential for intracellular processing, secretion, or activity. 8364023 10 14 gly glycosylation 1381:1393 arg1 384 residues 20 and 384 residues 20 and 384 These results suggest that glycosylation at residues 20 and 384 is not essential for intracellular processing, secretion, or activity. 8364023 10 14 gly glycosylation 1381:1393 arg2 384 residues 20 and 384 residues 20 and 384 These results suggest that glycosylation at residues 20 and 384 is not essential for intracellular processing, secretion, or activity. 8364023 10 14 gly glycosylation 1381:1393 arg2 384 residues 20 and 384 residues 20 and 384 These results suggest that glycosylation at residues 20 and 384 is not essential for intracellular processing, secretion, or activity. 19753315 14 13 gly glycoprotein 1696:1707 arg1 WT CLRN1 WT CLRN1 PUBTATOR WT CLRN1 P58418 CONCLUSIONS: WT CLRN1 is a glycoprotein localized to the plasma membrane in transfected BHK-21 cells. 19753315 14 13 gly glycoprotein 1696:1707 arg1 a glycoprotein a glycoprotein Fterm glycoprotein CONCLUSIONS: WT CLRN1 is a glycoprotein localized to the plasma membrane in transfected BHK-21 cells. 26968544 7 30 gly glycosylation 1380:1392 arg2 an ectopic N-linked glycosylation site an ectopic N-linked glycosylation site site Additionally, the R71T mutation creates an ectopic N-linked glycosylation site that results in aberrant glycosylation of the extracellular domain of δ-sarcoglycan. 26968544 7 24 gly glycosylation 1424:1436 arg1 the extracellular domain domain δ-sarcoglycan domain Additionally, the R71T mutation creates an ectopic N-linked glycosylation site that results in aberrant glycosylation of the extracellular domain of δ-sarcoglycan. 10839980 2 23 gly glycosylation 297:309 arg2 glycosylation sites glycosylation sites sites We reported previously that a combination of glycosylation sites at the 49th (site IV) and 68th (site II) amino acid residues of the protein particularly stimulates the synthesis of N-acetyl-lactosamine repeats [Melcher, Grosch, Grosse and Hasilik (1998) Glycoconjugate J. 15, 987-993]. 10839980 2 23 gly glycosylation 297:309 arg2 the 49th (site IV) and 68th (site II) amino acid residues the 49th (site IV) and 68th (site II) amino acid residues residues We reported previously that a combination of glycosylation sites at the 49th (site IV) and 68th (site II) amino acid residues of the protein particularly stimulates the synthesis of N-acetyl-lactosamine repeats [Melcher, Grosch, Grosse and Hasilik (1998) Glycoconjugate J. 15, 987-993]. 11410585 2 41 gly glycoprotein 319:330 arg1 The P0 glycoprotein The P0 glycoprotein Fterm glycoprotein The P0 glycoprotein, expressed by myelinating Schwann cells, plays an important role during the formation and maintenance of myelin, and it is the most abundant constituent of myelin. 16200726 6 0 part_of CETP 1208:1211 arg1 the amino acid sequence CETP the amino acid sequence PUBTATOR Site CETP P11597 sequence The homology of tree shrew CETP and human CETP and rabbit CETP is 88% and 82% respectively judged by comparing the amino acid sequence of tree shrew CETP and those of human beings and rabbit. 27489265 3 90 part_of CD4 545:547 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 920 site Previous studies have shown that the removal of a particular conserved glycan at N197 increases the neutralization sensitivity of the virus to antibodies targeting the CD4 binding site (CD4bs), making it a site of significant interest from the perspective of vaccine design. 25945896 11 15 gly glycopeptides 2034:2046 arg2 intact glycopeptides intact glycopeptides glycopeptides Spectral library matching using GPQuest assigns the HCD LC-MS/MS generated spectra of intact glycopeptides in an automated and high-throughput manner. 17956937 2 98 gly glycoprotein 428:439 arg1 alpha(1)-antichymotrypsin alpha(1)-antichymotrypsin PUBTATOR alpha(1)-antichymotrypsin 12 A large proportion of PSA forms a covalent complex with a glycoprotein, alpha(1)-antichymotrypsin, in human blood. 17956937 2 98 gly glycoprotein 428:439 arg1 a glycoprotein a glycoprotein Fterm glycoprotein A large proportion of PSA forms a covalent complex with a glycoprotein, alpha(1)-antichymotrypsin, in human blood. 7476998 5 49 gly released 813:820 arg2 purified Fab and Fc fragments AND The sugar chains purified Fab and Fc fragments The sugar chains fragments The sugar chains were released from purified Fab and Fc fragments by hydrazinolysis and converted to radioactive oligosaccharides by reduction with sodium borotritide. 6195967 0 38 gly heterogeneity 19:31 arg1 group-specific component group-specific component OGER group-specific component P02774 Post-translational heterogeneity of the human vitamin D-binding protein (group-specific component). 6195967 0 38 gly heterogeneity 19:31 arg1 the human vitamin D-binding protein the human vitamin D-binding protein PUBTATOR vitamin D-binding protein 2638 Post-translational heterogeneity of the human vitamin D-binding protein (group-specific component). 10374967 5 54 gly glycoprotein 743:754 arg1 glycoprotein gL glycoprotein gL Fterm glycoprotein Motif deletion abrogated MAb recognition while co-expression with glycoprotein gL restored this conformational epitope, indicating the importance of folding and not glycosylation at this site. 16168483 6 86 gly N-glycosylation 963:977 arg2 N-glycosylation site N-glycosylation site site The protein sequence showed all the important features: leader peptide, alpha1, alpha2 and CP/TM/CYT regions, conserved cysteines and N-glycosylation site. 11683378 7 42 part_of gamma2b 690:696 arg1 mu, gamma3, gamma1, gamma2b constant region gamma1, gamma2b mu, gamma3, gamma1, gamma2b constant region PUBTATOR Site gamma1, gamma2b 16016 region PCR analysis reveals that previous recombination events have led to deletion of the mu, gamma3, gamma1, gamma2b constant region genes from both the productive and the unproductive chromosome but the former has retained gamma2a, epsilon and alpha, the latter only alpha. 30605224 11 14 gly glycoproteins 1649:1661 arg1 glycoproteins glycoproteins Fterm glycoproteins Innovative and effective MS-based methods will exponentially advance glycoscience, and enable us to identify glycoproteins as effective biomarkers for disease detection and drug targets for disease treatment. 1457204 0 8 part_of protein 75:81 arg1 the second Ig-like domain CD4 protein the second Ig-like domain PUBTATOR Site CD4 protein 920 domain Unusual amino acid sequence of the second Ig-like domain of the feline CD4 protein. 22245433 3 4 gly glycosylation 424:436 arg1 580 Asn(580) Asn(580) COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580). 22245433 3 4 gly glycosylation 424:436 arg2 Asn Asn(580) Asn(580) COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580). 22245433 3 4 gly glycosylation 424:436 arg1 Asn Asn(580) Asn(580) COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580). 22245433 3 4 gly glycosylation 424:436 arg2 Asn Asn(580) Asn(580) COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580). 22245433 3 4 gly glycosylation 424:436 arg1 Asn Asn(580) Asn(580) COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580). 22245433 3 4 gly glycosylation 424:436 arg1 Asn Asn(580) Asn(580) COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580). 9223227 4 61 part_of IL-1ra 605:610 arg1 The predicted amino acid sequence IL-1ra The predicted amino acid sequence PUBTATOR Site IL-1ra 100034236 sequence The predicted amino acid sequence of equine IL-1ra shared 75.7, 75.3 and 76.3% similarity with sequences of human, murine and rabbit IL-1ras, respectively. 8419363 1 57 gly glycoprotein 162:173 arg1 Human corticosteroid binding-globulin Human corticosteroid binding-globulin PUBTATOR Human corticosteroid binding-globulin 866 Human corticosteroid binding-globulin (CBG) is a plasma glycoprotein that binds and regulates the biological activity of glucocorticoids and progesterone. 8419363 1 57 gly glycoprotein 162:173 arg1 a plasma glycoprotein a plasma glycoprotein Fterm glycoprotein Human corticosteroid binding-globulin (CBG) is a plasma glycoprotein that binds and regulates the biological activity of glucocorticoids and progesterone. 12064867 6 62 gly have 1037:1040 arg1 the CD4-binding site AND N-glycans the CD4-binding site N-glycans site These results demonstrated that both the CD4-binding site and the epitopes recognised by antibodies from HIV-infected individuals have N-glycans in the close vicinity. 12064867 6 62 gly have 1037:1040 arg1 the epitopes AND N-glycans the epitopes N-glycans epitopes These results demonstrated that both the CD4-binding site and the epitopes recognised by antibodies from HIV-infected individuals have N-glycans in the close vicinity. 1367474 3 14 part_of tPA 521:523 arg1 the catalytic domain tPA the catalytic domain PUBTATOR Site tPA P00750 domain Employing one of these strains to study the effect of glycosylation on secretion, we show that glycosylation in the catalytic domain of tPA plays an important role in folding and/or secretion of the molecule. 16372382 3 110 gly released 571:578 arg1 recombinant human thyrotropin AND the N-glycans recombinant human thyrotropin the N-glycans Fterm thyrotropin Using a strategy combining mass spectrometric analysis and sequential exoglycosidase digestion, we have defined the structures of the N-glycans released from recombinant human thyrotropin by peptide N-glycosidase F. All glycans are complex-type glycans and are mainly of the bi- and triantennary type with variable degrees of fucosylation and sialylation. 22078945 2 17 part_of protein 227:233 arg1 The sequence protein The sequence Fterm Site protein sequence METHODS: The sequence of ORF1 protein of Torque teno virus was analyzed by bioinformatics using some web tools. 11588155 6 45 gly desialylated 1252:1263 arg1 "desialylated" apoB100 glycans "desialylated" apoB100 glycans Furthermore, we found no evidence for "desialylated" apoB100 glycans in any of the samples analyzed. 23050552 1 55 gly glycoprotein 132:143 arg1 Human fibrinogen Human fibrinogen PUBTATOR Human fibrinogen 2244 Human fibrinogen is a 340 kDa, soluble plasma glycoprotein composed of paired sets of three subunits (α, β, γ). 23050552 1 55 gly glycoprotein 132:143 arg1 a 340 kDa, soluble plasma glycoprotein a 340 kDa, soluble plasma glycoprotein Fterm glycoprotein Human fibrinogen is a 340 kDa, soluble plasma glycoprotein composed of paired sets of three subunits (α, β, γ). 9557657 4 16 part_of TSP-rich 857:864 arg1 the TSP-rich region TSP the TSP-rich region OGER Site TSP P07996 region To characterize havcr-1 and define region(s) involved in HAV receptor function, we expressed the TSP-rich region in Escherichia coli fused to glutathione S-transferase and generated antibodies (Ab) in rabbits (anti-GST2 Ab). 1725860 7 39 gly glycosylation 1240:1252 arg2 multiple N-linked glycosylation sites multiple N-linked glycosylation sites sites Both rat and human IGFBP-3 possess multiple N-linked glycosylation sites at the mid-region of the molecule, which accounts for their apparent molecular size being larger than the calculated molecular weight, based on the amino acid sequence. 23829323 8 53 part_of N-linked 1760:1767 arg1 the four haptoglobin N-linked glycosylation sites haptoglobin N-linked the four haptoglobin N-linked glycosylation sites PUBTATOR Site haptoglobin N-linked 3240 sites Our software, GlycoPeptideSearch (GPS), assigned glycopeptide identifications to 246 of the spectra at a false discovery rate of 5.58%, identifying 42 distinct haptoglobin peptide-glycan pairs at each of the four haptoglobin N-linked glycosylation sites. 23829323 8 109 part_of haptoglobin 1748:1758 arg1 the four haptoglobin N-linked glycosylation sites haptoglobin N-linked the four haptoglobin N-linked glycosylation sites PUBTATOR Site haptoglobin N-linked 3240 sites Our software, GlycoPeptideSearch (GPS), assigned glycopeptide identifications to 246 of the spectra at a false discovery rate of 5.58%, identifying 42 distinct haptoglobin peptide-glycan pairs at each of the four haptoglobin N-linked glycosylation sites. 12139935 5 5 gly glycosylation 762:774 arg2 an additional glycosylation site an additional glycosylation site site Due to an additional glycosylation site located on the CCP2 domain of bovine beta(2)GPI a small change in the characteristic SAXS parameters was observed, which coincided with results obtained from SDS-PAGE. 1373379 5 6 gly glycosylation 700:712 arg2 an N-linked glycosylation site an N-linked glycosylation site site Unexpectedly, we find the BiP protein contains an N-linked glycosylation site which can be utilized. 1373379 5 32 gly utilized 732:739 arg2 an N-linked glycosylation site an N-linked glycosylation site site Unexpectedly, we find the BiP protein contains an N-linked glycosylation site which can be utilized. 9235960 1 13 gly N-glycosylation 211:225 arg2 an N-glycosylation site an N-glycosylation site site To investigate retrograde transport along the biosynthetic/secretory pathway, we have constructed a recombinant Shiga toxin B-fragment carrying an N-glycosylation site and a KDEL retrieval motif at its carboxyl terminus (B-Glyc-KDEL). 1448922 5 42 part_of have 856:859 arg1 The 11.6K protein AND a single signal-anchor sequence The 11.6K protein a single signal-anchor sequence Fterm Site protein sequence The 11.6K protein is predicted to have a single signal-anchor sequence at residues 41-62 and only one potential Asn-linked glycosylation site at residue 14; thus, 11.6K must be oriented in the membranes with its NH2-terminus in the lumen and its COOH-terminus in the cytoplasm. 11386850 6 70 gly N-glycosylation 926:940 arg2 one potential N-glycosylation site one potential N-glycosylation site site The predicted Slc19a2 protein, like SLC19A2, was predicted to have 12 transmembrane domains and shared a number of other conserved sequence motifs with the human orthologue, including one potential N-glycosylation site (N(63)) and several potential phosphorylation sites. 11386850 6 70 gly N-glycosylation 926:940 arg2 N(63) N(63) N(63) The predicted Slc19a2 protein, like SLC19A2, was predicted to have 12 transmembrane domains and shared a number of other conserved sequence motifs with the human orthologue, including one potential N-glycosylation site (N(63)) and several potential phosphorylation sites. 22171062 2 99 gly glycoproteins 381:393 arg1 the attachment (G) and the fusion (F) glycoproteins the attachment (G) and the fusion (F) glycoproteins Fterm glycoproteins HeV has two structural membrane glycoproteins that mediate the infection of host cells: the attachment (G) and the fusion (F) glycoproteins that are essential for receptor binding and virion-host cell membrane fusion, respectively. 22171062 2 123 gly glycoproteins 287:299 arg1 two structural membrane glycoproteins two structural membrane glycoproteins Fterm glycoproteins HeV has two structural membrane glycoproteins that mediate the infection of host cells: the attachment (G) and the fusion (F) glycoproteins that are essential for receptor binding and virion-host cell membrane fusion, respectively. 18320936 4 34 gly glycosylation 701:713 arg2 this glycosylation site this glycosylation site site The CVN-R virus possessed a single amino acid change at position 94a (Asn94aAsp) of HA1 that eliminated this glycosylation site. 18282281 12 35 part_of mucin-type 2171:2180 arg1 mucin-type O-glycosylation sites mucin mucin-type O-glycosylation sites PUBTATOR Site mucin 100508689 sites CONCLUSION: Because of CKSAAP encoding's ability of reflecting characteristics of the sequences surrounding mucin-type O-glycosylation sites, CKSAAP_ OGlySite has been proved more powerful than the conventional binary encoding based method. 25220145 3 50 gly CF-glycosylation 582:597 arg2 CF-glycosylation sites CF-glycosylation sites sites However, due to the complex fragmentation pattern of CF-glycopeptides, accurately identifying CF-glycosylation sites via mass spectrometry with high throughput remains a formidable challenge. 25220145 3 81 gly CF-glycopeptides 541:556 arg2 CF-glycopeptides CF-glycopeptides CF-glycopeptides However, due to the complex fragmentation pattern of CF-glycopeptides, accurately identifying CF-glycosylation sites via mass spectrometry with high throughput remains a formidable challenge. 14658030 3 59 gly glycosylated 1004:1015 arg1 consensus sequences consensus sequences sequences Several recent reports have established that mass spectrometric techniques such as matrix-assisted laser desorption/ionization or electrospray ionization mass spectrometry (MALDI-TOF or ESI-MS, respectively) with or without preceding HPLC and in combination with PNGase F treatment are suited to analyze whether consensus sequences for N-glycosylation are glycosylated or not. 7772252 4 52 gly glycosylation 564:576 arg2 an N-linked glycosylation site an N-linked glycosylation site site The mature polypeptide has a calculated molecular weight of 21.6 kD and includes an N-linked glycosylation site near the carboxyl terminus. 19706343 11 43 gly beta2GPI 1953:1960 arg1 site-specific glycan profiles beta2GPI site-specific glycan profiles PUBTATOR beta2GPI 350 Thus, our study suggests a link between site-specific glycan profiles of beta2GPI and the pathology of antiphospholipid syndrome. 31888963 8 41 gly sites 1251:1255 arg1 >75% hybrid and oligomannose forms sites >75% hybrid and oligomannose forms sites The CD16a N45-glycans contain markedly less processing than other sites with >75% hybrid and oligomannose forms. 28661444 12 49 gly glycosylated 1955:1966 arg1 B-cell epitopic lysines B-cell epitopic lysines lysines In contrast, B-cell epitopic lysines of Ag85B were found to be poorly glycosylated and, thus, the antibody interaction of Ag85B was only marginally affected after coupling with mono- or disaccharides. 17956937 8 26 part_of PSA 1864:1866 arg1 the N-glycosylation site PSA the N-glycosylation site PUBTATOR Site PSA 354 site The results suggest that identification of alpha2,3-linked sialic acids on PSA potentially discriminates malignant from benign conditions, if the analysis is applied to oligosaccharides specifically attached to the N-glycosylation site of PSA in either a free or a complexed form in the serum. 11093789 7 56 gly glycosylation 1410:1422 arg2 any single glycosylation site any single glycosylation site site Removal of any single glycosylation site did not interfere with GRP-R induced chronic desensitization or down-regulation. 9820842 1 58 part_of contain 231:237 arg1 the protein AND an N-glycosylation site the protein an N-glycosylation site Fterm Site protein site Based on sequence analysis, the protein encoded by the US5 open reading frame (ORF) of herpes simplex virus type 1 (HSV-1) was predicted to contain an N-glycosylation site and was given the designation of glycoprotein J (gJ). 1401897 8 9 part_of receptors 1073:1081 arg1 the deduced amino acid sequences receptors the deduced amino acid sequences Fterm Site receptors sequences Overall, the deduced amino acid sequences of the receptors are 65% identical given the analogous gene structures. 1390770 3 18 gly N-glycosylation 339:353 arg2 the three N-glycosylation sites the three N-glycosylation sites sites We constructed human EPO variants that eliminated the three N-glycosylation sites by replacing the asparagines with glutamines singly or in combination. 20589319 1 40 part_of position 296:303 arg1 FGG FGG position OGER Site FGG P02679 position We found a novel hypofibrinogenemia designated as Matsumoto VII (M-VII), which is caused by a heterozygous nucleotide deletion at position g.7651 in FGG and a subsequent frameshift mutation in codon 387 of the gamma-chain. 21661761 2 44 gly glycosylation 396:408 arg2 the site the site site Unfortunately, the determination of the microheterogeneity at the site of glycosylation still remains a significant challenge. 27259237 8 53 gly N-glycosylated 1085:1098 arg1 the mouse brain proteins the mouse brain proteins Fterm proteins Analysis of the identified N-glycoproteins revealed that many of the mouse brain proteins are N-glycosylated, including those proteins in critical pathways for nervous system development and neurological disease. 27259237 8 71 gly N-glycoproteins 1018:1032 arg1 the identified N-glycoproteins the identified N-glycoproteins Fterm N-glycoproteins Analysis of the identified N-glycoproteins revealed that many of the mouse brain proteins are N-glycosylated, including those proteins in critical pathways for nervous system development and neurological disease. 1597478 0 63 part_of isomerase 63:71 arg1 the multifunctional protein disulfide isomerase polypeptide protein disulfide isomerase the multifunctional protein disulfide isomerase polypeptide PUBTATOR Site protein disulfide isomerase 5034 polypeptide Promoter of the gene for the multifunctional protein disulfide isomerase polypeptide. 23296529 4 67 gly glycopeptides 656:668 arg2 glycopeptides glycopeptides glycopeptides HILIC provides a versatile tool for enrichment of glycopeptides before mass spectrometric (MS) analysis, particularly when used for solid phase extraction (SPE), or in combination with other chromatographic resins or ion-pairing reagents. 15351488 5 55 gly glycosylation 798:810 arg2 postulated N- and O-linked glycosylation sites postulated N- and O-linked glycosylation sites sites In addition, postulated N- and O-linked glycosylation sites in the two envelope proteins (Gn and Gc) were investigated individually by site-directed mutagenesis followed by gel-shift analysis. 14693913 3 51 gly N-glycosylation 445:459 arg2 Asn187 Asn187 Asn187 hBSSL has one N-glycosylation site at Asn187, which was 38-40% occupied with a Man(10)GlcNAc(2) structure defined previously in Pichia as the oligosaccharide-lipid form of Man(9)GlcNAc(2) trimmed of the middle-arm terminal alpha 1,2-Man and elongated with Man alpha 1,2Man alpha 1,6-disaccharide attached to the lower-arm core alpha 1,3-Man (Trimble et al. [1991], J. Biol. 14693913 3 51 gly N-glycosylation 445:459 arg2 one N-glycosylation site one N-glycosylation site site hBSSL has one N-glycosylation site at Asn187, which was 38-40% occupied with a Man(10)GlcNAc(2) structure defined previously in Pichia as the oligosaccharide-lipid form of Man(9)GlcNAc(2) trimmed of the middle-arm terminal alpha 1,2-Man and elongated with Man alpha 1,2Man alpha 1,6-disaccharide attached to the lower-arm core alpha 1,3-Man (Trimble et al. [1991], J. Biol. 2162043 5 16 gly glycosylation 921:933 arg2 Asn-165-Val-166-Thr-167 site Asn-165-Val-166-Thr-167 site Asn-165-Val-166-Thr-167 This change leads to loss of the potential glycosylation site Asn-165-Val-166-Thr-167 at the tip of the HA spike, which in viruses of the H3 subtype is known to bear a high-mannose (type II) carbohydrate side chain N-linked to Asn-165. 7747487 11 95 gly glycosylation 1481:1493 arg2 a new, utilized glycosylation site a new, utilized glycosylation site site A G2-specific N-MAb selected variants with a mutation at aa 190 producing a new, utilized glycosylation site which we propose to be in new antigenic site E. 1740433 8 71 gly glycosylation 1178:1190 arg2 a NSS tripeptide a NSS tripeptide tripeptide The C-SAA octapeptide specifies the first two residues of a NSS tripeptide, the only potential N-linked glycosylation site in the molecule. 1740433 8 71 gly glycosylation 1178:1190 arg2 the only potential N-linked glycosylation site the only potential N-linked glycosylation site site The C-SAA octapeptide specifies the first two residues of a NSS tripeptide, the only potential N-linked glycosylation site in the molecule. 15863355 7 20 gly sites 1202:1206 arg1 alpha1,3-fucosylation sites alpha1,3-fucosylation sites Within the sera of patients with acute inflammation, increases in bi-antennary and decreases in tri- and tetra-antennary structures were observed, as well as increases in alpha1,3-fucosylation, at most glycosylation sites. 15863355 7 95 gly glycosylation 1188:1200 arg2 most glycosylation sites most glycosylation sites sites Within the sera of patients with acute inflammation, increases in bi-antennary and decreases in tri- and tetra-antennary structures were observed, as well as increases in alpha1,3-fucosylation, at most glycosylation sites. 15863355 7 111 gly alpha1,3-fucosylation 1157:1177 arg1 most glycosylation sites most glycosylation sites sites Within the sera of patients with acute inflammation, increases in bi-antennary and decreases in tri- and tetra-antennary structures were observed, as well as increases in alpha1,3-fucosylation, at most glycosylation sites. 1455401 2 15 gly pro-UK 412:417 arg1 pro-UK pro-UK pro To determine whether this difference is related to the lack of glycosylation of the E. coli product, we compared the activity of E. coli-derived pro-UK [(-)pro-UK] with that of a glycosylated pro-UK [(+)pro-UK] and of a mutant of pro-UK missing the glycosylation site at Asn-302 [(-)(302)pro-UK]. 1455401 2 55 gly glycosylation 516:528 arg2 the glycosylation site the glycosylation site site To determine whether this difference is related to the lack of glycosylation of the E. coli product, we compared the activity of E. coli-derived pro-UK [(-)pro-UK] with that of a glycosylated pro-UK [(+)pro-UK] and of a mutant of pro-UK missing the glycosylation site at Asn-302 [(-)(302)pro-UK]. 1455401 2 20 gly glycosylated 446:457 arg1 a glycosylated pro-UK pro pro To determine whether this difference is related to the lack of glycosylation of the E. coli product, we compared the activity of E. coli-derived pro-UK [(-)pro-UK] with that of a glycosylated pro-UK [(+)pro-UK] and of a mutant of pro-UK missing the glycosylation site at Asn-302 [(-)(302)pro-UK]. 14749323 10 96 gly glycosylation 1816:1828 arg1 individual sites OAT1 sites PUBTATOR OAT1 9356 sites In summary, we provided the evidence that 1) Asp-39 is crucially involved in substrate recognition of OAT1, 2) glycosylation at individual sites is not required for OAT1 function, and 3) glycosylation plays an important role in the targeting of OAT1 onto the plasma membrane. 14749323 10 96 gly glycosylation 1816:1828 arg2 individual sites OAT1 sites PUBTATOR OAT1 9356 sites In summary, we provided the evidence that 1) Asp-39 is crucially involved in substrate recognition of OAT1, 2) glycosylation at individual sites is not required for OAT1 function, and 3) glycosylation plays an important role in the targeting of OAT1 onto the plasma membrane. 14749323 10 96 gly glycosylation 1816:1828 arg2 individual sites sites sites In summary, we provided the evidence that 1) Asp-39 is crucially involved in substrate recognition of OAT1, 2) glycosylation at individual sites is not required for OAT1 function, and 3) glycosylation plays an important role in the targeting of OAT1 onto the plasma membrane. 16368742 0 76 gly Glycosylation 0:12 arg1 the osmoresponsive transient receptor potential channel TRPV4 the osmoresponsive transient receptor potential channel TRPV4 PUBTATOR TRPV4 59341 Glycosylation of the osmoresponsive transient receptor potential channel TRPV4 on Asn-651 influences membrane trafficking. 9607309 5 52 gly glycosylation 580:592 arg2 the glycosylation site the glycosylation site site Key structural features described previously in PAP-2a and -2b, including the glycosylation site, putative transmembrane domains, and the proposed catalytic site, are conserved in the novel phosphatase. 9599010 3 13 part_of subunit 702:708 arg1 the additional glycosylation at Asn-187 subunit the additional glycosylation at Asn-187 Fterm SpecificSite subunit Asn-187 The mongoose glycosylated alpha-subunit has a higher apparent molecular mass than that of the rat glycosylated alpha-subunit, probably resulting from the additional glycosylation at Asn-187 of the mongoose subunit. 2187193 4 70 gly N-glycosylation 587:601 arg2 a consensus N-glycosylation site a consensus N-glycosylation site site The differences among the three human tryptase catalytic domains include the loss of a consensus N-glycosylation site in one cDNA, which may explain some of the heterogeneity in size and susceptibility to deglycosylation seen in tryptase preparations. 8029814 6 94 part_of cDNA 894:897 arg1 The 3' noncoding region mouse protein S cDNA The 3' noncoding region Cterm Site mouse protein S cDNA region The 3' noncoding region of mouse protein S cDNA has several small deletions and insertions compared to human protein S cDNA. 8307000 13 110 gly presence 2593:2600 arg2 the position AND a sugar chain the position a sugar chain position Therefore, it can be concluded that the presence of a sugar chain at the position and not the Gly to Ser mutation itself is responsible for the observed alteration of GS-tPA glycosylation. 28419665 5 71 part_of E2 819:820 arg1 the E2 polypeptide E2 the E2 polypeptide Cterm Site E2 polypeptide The wild-type dimer (E1E2) and a variant without an N-glycosylation site in the E2 polypeptide (E1E2∆N6) were expressed, and appropriate N-glycosylation pattern and functionality of the E1E2 dimers were demonstrated. 12773316 2 37 gly determinants 210:221 arg1 fusion proteins proteins determinants Fterm proteins To identify such determinants in the gastric H,K-ATPase, fusion proteins of yellow fluorescent protein (YFP) and the gastric H,K-ATPase beta-subunit (YFP-beta) and cyan fluorescent protein (CFP) and the gastric H,K-ATPase alpha-subunit (CFP-alpha) were expressed in HEK-293 cells. 12773316 2 37 gly determinants 210:221 arg1 the gastric H gastric H,K-ATPase beta-subunit (YFP-beta determinants PUBTATOR gastric H,K-ATPase beta-subunit (YFP-beta 496 To identify such determinants in the gastric H,K-ATPase, fusion proteins of yellow fluorescent protein (YFP) and the gastric H,K-ATPase beta-subunit (YFP-beta) and cyan fluorescent protein (CFP) and the gastric H,K-ATPase alpha-subunit (CFP-alpha) were expressed in HEK-293 cells. 12773316 2 37 gly determinants 210:221 arg1 the gastric H gastric H,K-ATPase determinants OGER gastric H,K-ATPase To identify such determinants in the gastric H,K-ATPase, fusion proteins of yellow fluorescent protein (YFP) and the gastric H,K-ATPase beta-subunit (YFP-beta) and cyan fluorescent protein (CFP) and the gastric H,K-ATPase alpha-subunit (CFP-alpha) were expressed in HEK-293 cells. 12911333 0 45 gly N-glycosylation 8:22 arg2 N-glycosylation sites N-glycosylation sites sites Allowed N-glycosylation sites on the Kv1.2 potassium channel S1-S2 linker: implications for linker secondary structure and the glycosylation effect on channel function. 12572058 7 44 part_of kinase 1230:1235 arg1 one casein kinase II phosphorylation site casein kinase II one casein kinase II phosphorylation site OGER Site casein kinase II site Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II. 12572058 7 55 part_of casein 1223:1228 arg1 one casein kinase II phosphorylation site casein kinase II one casein kinase II phosphorylation site OGER Site casein kinase II site Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II. 12572058 7 31 part_of has 1285:1287 arg1 Sj-Ts5 protein AND two phosphorylation sites Sj-Ts5 protein two phosphorylation sites Fterm Site protein sites Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II. 12572058 7 5 part_of contains 1170:1177 arg1 Sj-Ts3 protein AND one casein kinase II phosphorylation site Sj-Ts3 protein one casein kinase II phosphorylation site Fterm Site protein site Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II. 12572058 7 40 part_of contains 1007:1014 arg1 Sj-Ts1 protein AND one N-myristoylation site Sj-Ts1 protein one N-myristoylation site Fterm Site protein site Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II. 12572058 7 40 part_of contains 1007:1014 arg1 Sj-Ts1 protein AND two phosphorylation sites Sj-Ts1 protein two phosphorylation sites Fterm Site protein sites Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II. 12572058 7 31 part_of has 1285:1287 arg1 Sj-Ts5 protein AND one N-myristoylation site protein site Fterm Site protein site Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II. 30659065 10 52 gly N-glycosylation 1818:1832 arg1 N92 N92 N92 In digests of the sera from a subset of donors, we detected an unmodified peptide containing a proline residue at position 93; this substitution would strongly disfavor N-glycosylation at N92. 8554050 8 80 gly glycoprotein 1418:1429 arg1 the II-1 glycoprotein the II-1 glycoprotein Fterm glycoprotein The genetically determined absence of the II-1 glycoprotein leads to altered in vitro binding of Streptococcus sanguis 10556 to salivary proteins, which suggests a biological consequence for null mutations of the PRB4 gene. 22180206 0 104 part_of mucin-type 57:66 arg1 densely O-glycosylated mucin-type peptides mucin densely O-glycosylated mucin-type peptides PUBTATOR Site mucin 100508689 peptides Site-specific characterisation of densely O-glycosylated mucin-type peptides using electron transfer dissociation ESI-MS/MS. 29162128 1 65 part_of hemagglutinin 140:152 arg1 A stem glycosylation site hemagglutinin A stem glycosylation site Fterm Site hemagglutinin site A stem glycosylation site of hemagglutinin (HA) is important to the stability of the HA trimmer. 8407981 2 26 gly glycosylated 215:226 arg1 cytochrome P-450 cytochrome P-450(arom) PUBTATOR cytochrome P-450(arom) 55010 It was found that cytochrome P-450(arom) purified from human placenta microsomes is glycosylated, and the sugar chain was cleaved with endoglycosidase H (Endo H). 23991039 1 42 part_of CD4 207:209 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 920 site Primary isolates of HIV-1 resist neutralization by most antibodies to the CD4 binding site (CD4bs) on gp120 due to occlusion of this site on the trimeric spike. 23991039 1 56 part_of site 219:222 arg1 gp120 gp120 site PUBTATOR Site gp120 155971 site Primary isolates of HIV-1 resist neutralization by most antibodies to the CD4 binding site (CD4bs) on gp120 due to occlusion of this site on the trimeric spike. 9367731 6 13 gly glycosylation 1459:1471 arg2 an N-linked glycosylation site characteristic an N-linked glycosylation site characteristic site In addition to the extensive sharing of sequence homology, the identification of several eukaryotic HSP70 signature sequences and an N-linked glycosylation site characteristic of cytoplasmic HSPs strongly support the identity of the Bge cDNA as encoding an authentic HSP70. 30208353 3 74 gly O-glycosylation 555:569 arg1 ER-α ER-α PUBTATOR ER-α) 2099 Here we further report O-glycosylation of estrogen receptor alpha (ER-α) by GALNT6 and the significant role of its nuclear localization in breast cancer cells. 1840295 1 51 part_of activator 240:248 arg1 sites 184 and 448 tissue plasminogen activator sites 184 and 448 PUBTATOR Site tissue plasminogen activator P00750 sites The effect of altering oligosaccharide structures at sites 184 and 448 of tissue plasminogen activator (tPA) has been examined. 21280237 4 42 gly glycoprotein 903:914 arg1 glycoprotein fractions glycoprotein fractions Fterm glycoprotein The use of lectins, proteins that have strong affinity for specific carbohydrate epitopes, to enrich glycoprotein fractions coupled with modern MS, have yielded techniques to elucidate the glycoproteome in AD. 12538726 4 54 gly glycoprotein 672:683 arg1 the high-mannose glycoprotein the high-mannose glycoprotein Glycosylation site single mutants expressed in oocytes ran as thick bands at 115 kD, consistent with the high-mannose glycoprotein. 24338886 4 76 gly rhEPO 891:895 arg1 the N-linked glycans Pichia-produced rhEPO the N-linked glycans OGER Pichia-produced rhEPO P29676 Additionally, the N-linked glycans from Pichia-produced rhEPO were similar across all three sites. 3463996 5 65 part_of sequences 1014:1022 arg1 the propeptide sequences the propeptide propeptide In particular, two conserved sequences in the propeptide that may be functionally significant include a potential glycosylation site and the presence of a single cysteine at position 59. 15331613 7 12 part_of site 1515:1518 arg1 the NGC core protein protein site Fterm Site protein site As the first step in investigating the CS glycosylation mechanism using Neuro 2a cells, we determined the CS attachment site as Ser-123 on the NGC core protein by site-directed mutagenesis. 22577028 7 70 gly glycopeptide 1342:1353 arg2 each glycopeptide isoform each glycopeptide isoform glycopeptide Multiple-reaction monitoring based quantitation analysis was developed for each glycopeptide isoform and the quantitative results indicate that the Man(8) GlcNAc(2) is the dominant glycan for all sites in plant-expressed HAs. 10364275 0 74 gly glycoprotein 169:180 arg1 the extracellular envelope glycoprotein the extracellular envelope glycoprotein Fterm glycoprotein Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. 7945294 4 3 gly glycosylation 511:523 arg2 one N glycosylation site one N glycosylation site site The sequencing showed the possibility for 21 phosphorylation sites, 4 myristylation sites, and one N glycosylation site. 31507595 6 13 gly sialylated 1206:1215 arg1 tetra-antennary α-2,3/6 sialylated N-glycans tetra-antennary α-2,3/6 sialylated N-glycans Glycomic (porous graphitized carbon-ESI-MS/MS) and glycopeptide (C8-LC-ESI-MS) analysis of recombinant soluble human CD52-immunoglobulin Fc fusion proteins revealed that CD52 bioactivity was correlated with a high abundance of tetra-antennary α-2,3/6 sialylated N-glycans. 31507595 6 70 gly glycopeptide 1006:1017 arg2 glycopeptide glycopeptide glycopeptide Glycomic (porous graphitized carbon-ESI-MS/MS) and glycopeptide (C8-LC-ESI-MS) analysis of recombinant soluble human CD52-immunoglobulin Fc fusion proteins revealed that CD52 bioactivity was correlated with a high abundance of tetra-antennary α-2,3/6 sialylated N-glycans. 8514796 11 39 part_of COOH-terminal 1510:1522 arg1 These membrane-anchored COOH-terminal fragments COOH-terminal These membrane-anchored COOH-terminal fragments Cterm Site COOH-terminal fragments These membrane-anchored COOH-terminal fragments are probably degraded in lysosomes or in other acidic vesicles as cell fractionation demonstrates that they colocalize with lysosomes, and similar to the intact EPO-R, their degradation is inhibited by NH4Cl. 31516400 8 22 gly http 1629:1632 arg1 //nglycositeatlas.biomarkercenter.org //nglycositeatlas.biomarkercenter.org //nglycositeatlas.biomarkercenter.org Conclusions: The entire human N-glycoproteome database as well as 22 sub-databases associated with individual tissues or body fluids can be downloaded from the N-GlycositeAtlas website at http://nglycositeatlas.biomarkercenter.org. 8560778 4 30 gly glycosylation 584:596 arg2 a glycosylation site a glycosylation site site Analysis showed that the virulence capabilities of the NWS HA involve at least three different mechanisms: (a) loss of a glycosylation site; (b) a change at the cleavage site; and (c) a substitution in HA2, which may increase the pH of fusion. 2082620 0 20 part_of GP120 111:115 arg1 the CD4-binding site 1 GP120 the CD4-binding site PUBTATOR Site 1 GP120 3700 site Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity. 2082620 0 58 part_of CD4-binding 55:65 arg1 the CD4-binding site CD4 the CD4-binding site PUBTATOR Site CD4 920 site Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity. 17947537 5 41 gly glycosylation 1155:1167 arg1 position 200 position 200, position 200, Interestingly, viruses caused acute encephalitis only if the amino acid Ser at position 200 was coupled with Gly at position 195, whereas viruses with single or combined mutations at these positions, including glycosylation at position 200, were attenuated. 16504352 7 88 gly glycosylated 1139:1150 arg1 the fully glycosylated WT F protein the fully glycosylated WT F protein Fterm protein Gly2/4 elicited a higher antibody titer than the fully glycosylated WT F protein. 8344280 12 73 gly proteins 2032:2039 arg1 complex oligosaccharide chains proteins complex oligosaccharide chains Fterm proteins No evidence was obtained for the presence of secreted proteins with complex oligosaccharide chains, irrespective of the cell-culture conditions used or the harvesting time, for infected cells with recombinant baculovirus constructs. 12766998 2 88 part_of polyprotein 338:348 arg1 the structural region polyprotein the structural region Fterm Site polyprotein region A cDNA encoding the structural region of the hepatitis C polyprotein was constructed to match the majority sequence of viral RNA extracted from a patient infected with genotype 3a (designated strain HCV3a-Gla). 28617578 6 1 gly glycopeptides 745:757 arg2 synthetic MUC16 glycopeptides synthetic MUC16 glycopeptides glycopeptides Using synthetic MUC16 glycopeptides, we developed novel N-glycosylation site directed monoclonal antibodies that block Galectin-3-mediated MUC16 interactions with cell surface signaling molecules. 28617578 6 61 gly N-glycosylation 779:793 arg2 novel N-glycosylation site novel N-glycosylation site site Using synthetic MUC16 glycopeptides, we developed novel N-glycosylation site directed monoclonal antibodies that block Galectin-3-mediated MUC16 interactions with cell surface signaling molecules. 11122377 2 7 part_of contain 260:266 arg1 most selenoproteins AND a single selenocysteine residue most selenoproteins a single selenocysteine residue OGER Site selenoproteins Q9BQE4 residue Whereas most selenoproteins contain a single selenocysteine residue, the human, bovine and rodent selenoprotein P genes encode proteins containing 10-12 selenocysteines. 17996106 7 86 gly glycosylation 1339:1351 arg2 glycosylation sites glycosylation sites sites The results of our experiments show that the ensembles of Support Vector Machine classifiers outperform single Support Vector Machine classifiers on the problem of predicting glycosylation sites in terms of a range of standard measures for comparing the performance of classifiers. 7730609 0 54 gly N-glycosylation 15:29 arg2 N-glycosylation sites N-glycosylation sites sites Replacement of N-glycosylation sites on the MHC class II E alpha chain. 1726785 0 49 part_of receptor 36:43 arg1 The extracellular domain TSH receptor The extracellular domain PUBTATOR Site TSH receptor 7253 domain The extracellular domain of the TSH receptor has an immunogenic epitope reactive with Graves' IgG but unrelated to receptor function as well as determinants having different roles for high affinity TSH binding and the activity of thyroid-stimulating autoantibodies. 1726785 0 62 part_of has 45:47 arg1 the TSH receptor AND an immunogenic epitope TSH receptor epitope PUBTATOR Site TSH receptor 7253 epitope The extracellular domain of the TSH receptor has an immunogenic epitope reactive with Graves' IgG but unrelated to receptor function as well as determinants having different roles for high affinity TSH binding and the activity of thyroid-stimulating autoantibodies. 1446688 9 12 gly N-glycosylation 1168:1182 arg2 the N-glycosylation site the N-glycosylation site site The defective N-glycosylation was assumed to be caused by interference or tension from a disulfide bond near the N-glycosylation site. 11822873 2 55 part_of P75 485:487 arg1 the stalk domain P75(NTR) the stalk domain PUBTATOR Site P75(NTR) 4923 domain The mere presence of O-glycosylations was not sufficient for efficient delivery to the apical surface since changing the stalk domain of P75(NTR) for the heavily O-glycosylated stalk from human decay-accelerating factor led to random distribution of the chimera. 17091191 2 8 gly sequence 437:444 arg1 an expression sequence tag an expression sequence tag Using mRNA differential display, we found an expression sequence tag (EST) differentially expressed in F1 hybrids and their parents, designated as EST55, which was homologous to human and murine skeletal muscle protein (SMPX), and the full-length cDNA of porcine SMPX was cloned by the rapid amplification of cDNA end (RACE) method. 25793890 0 17 part_of gp120 111:115 arg1 the V1/V2 domain gp120 the V1/V2 domain PUBTATOR Site gp120 155971 domain Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses. 10536368 1 10 gly glycoproteins 191:203 arg1 nascent glycoproteins nascent glycoproteins Fterm glycoproteins Strategies that prevent the attachment of N-linked carbohydrates to nascent glycoproteins often impair intracellular transport and secretion. 10536368 1 14 gly attachment 143:152 arg1 nascent glycoproteins AND N-linked carbohydrates nascent glycoproteins N-linked carbohydrates Fterm glycoproteins Strategies that prevent the attachment of N-linked carbohydrates to nascent glycoproteins often impair intracellular transport and secretion. 20573835 7 22 part_of receptor-binding 1036:1051 arg1 the receptor-binding motif receptor the receptor-binding motif Fterm Site receptor motif Despite the proximity of N330 to the receptor-binding motif of SARS-S, MBL did not affect interactions with the ACE2 receptor or cathepsin L-mediated activation of SARS-S-driven membrane fusion. 20573835 7 43 part_of SARS-S 1062:1067 arg1 the receptor-binding motif SARS-S, MBL the receptor-binding motif PUBTATOR Site SARS-S, MBL 4153 motif Despite the proximity of N330 to the receptor-binding motif of SARS-S, MBL did not affect interactions with the ACE2 receptor or cathepsin L-mediated activation of SARS-S-driven membrane fusion. 15865444 10 63 gly glycosylation 1647:1659 arg2 an additional site an additional site site In comparison to the previously characterized cow milk isoform, rat bone OPN is sulfated and has an additional site of glycosylation, many different sites of phosphorylation, and a lower overall phosphate content. 15865444 10 63 gly glycosylation 1647:1659 arg2 many different sites many different sites sites In comparison to the previously characterized cow milk isoform, rat bone OPN is sulfated and has an additional site of glycosylation, many different sites of phosphorylation, and a lower overall phosphate content. 18829751 2 26 gly glycosylation 499:511 arg2 SIVmac239's glycosylation sites SIVmac239's glycosylation sites sites We infected rhesus monkeys with a variant of cloned SIVmac239 lacking the second and third sites or with a variant strain lacking all three of SIVmac239's glycosylation sites in gp41. 22292921 0 38 part_of DC-SIGN 31:37 arg1 DC-SIGN microdomains DC-SIGN DC-SIGN microdomains PUBTATOR Site DC-SIGN 170786 microdomains The formation and stability of DC-SIGN microdomains require its extracellular moiety. 15113920 4 49 gly glycoprotein 640:651 arg1 Ten glycoprotein gene mutants Ten glycoprotein gene mutants Fterm glycoprotein Ten glycoprotein gene mutants were constructed by site-directed mutagenesis, including six single N glycosylation site mutants and four double-site mutants. 15113920 4 87 gly glycosylation 736:748 arg2 six single N glycosylation site mutants six single N glycosylation site mutants site Ten glycoprotein gene mutants were constructed by site-directed mutagenesis, including six single N glycosylation site mutants and four double-site mutants. 7609029 2 22 part_of gp120 485:489 arg1 a region gp120 a region PUBTATOR Site gp120 155971 region Viral sequences were determined for the 22 patients with AIDS, and all were subtype E HIV-1 on the basis of sequence analysis of a region from the envelope protein gp120. 20622017 12 32 gly glycoprotein 1657:1668 arg1 a human glycoprotein a human glycoprotein Fterm glycoprotein This is the first analysis at the level of individual glycopeptides of a human glycoprotein produced by two different tissues in vivo and provides novel insights into tissue-specific and site-specific glycosylation in normal human tissues. 20622017 12 38 gly glycopeptides 1632:1644 arg2 individual glycopeptides glycoprotein glycopeptides Fterm glycoprotein glycopeptides This is the first analysis at the level of individual glycopeptides of a human glycoprotein produced by two different tissues in vivo and provides novel insights into tissue-specific and site-specific glycosylation in normal human tissues. 19276077 2 10 gly N-glycosylation 423:437 arg2 N-glycosylation site N-glycosylation site site Herein to further investigate which N-glycosylation site is the most important for the biological function and regulation, we characterized the S-3,4,5 mutants in detail. 16504352 0 36 gly glycoprotein 50:61 arg1 bovine respiratory syncytial virus F glycoprotein bovine respiratory syncytial virus F glycoprotein Influence of bovine respiratory syncytial virus F glycoprotein N-linked glycans on in vitro expression and on antibody responses in BALB/c mice. 10858228 4 43 gly glycoprotein 643:654 arg1 this glycoprotein this glycoprotein Fterm glycoprotein gp40-specific antibodies neutralize infection in vitro, and native gp40 binds specifically to host cells, implicating this glycoprotein in C. parvum attachment to and invasion of host cells. 12829816 6 91 gly glycosylation 986:998 arg2 the single predicted N glycosylation site the single predicted N glycosylation site site Mutation of the single predicted N glycosylation site eliminated N glycosylation. 29632412 3 38 part_of IgG 394:396 arg1 the IgG glycome composition IgG the IgG glycome composition Cterm Site IgG position By analyzing the IgG glycome composition of 95 CC strains, we made several important observations: (i) glycome variation between mouse strains was higher than between individual humans, despite all mice having the same environmental influences; (ii) five genetic loci were found to be associated with murine IgG glycosylation; (iii) variants outside traditional glycosylation site motifs affected glycome variation; (iv) bisecting N-acetylglucosamine (GlcNAc) was produced by several strains although most previous studies have reported the absence of glycans containing the bisecting GlcNAc on murine IgGs; and (v) common laboratory mouse strains are not optimal animal models for studying effects of glycosylation on IgG function. 23296529 7 25 gly glycopeptides 1392:1404 arg2 glycopeptides glycopeptides glycopeptides Finally, we demonstrate HILIC enrichment using trifluoroacetic acid as an ion-pairing reagent for the enrichment of glycopeptides prior to mass spectrometry analysis. 25435177 10 71 gly glycosylation 1580:1592 arg2 position 211 position 211 position 211, The HA protein of most of the Singaporean specimens isolated post 2000 contained a glycosylation site at position 211, which was not dominant prior to 2000. 25435177 10 71 gly glycosylation 1580:1592 arg2 a glycosylation site a glycosylation site site The HA protein of most of the Singaporean specimens isolated post 2000 contained a glycosylation site at position 211, which was not dominant prior to 2000. 8355714 7 0 part_of protein 1122:1128 arg1 an amino terminus protein an amino terminus Fterm Site protein terminus In contrast, a chimeric protein with an amino terminus from FGF5 was efficiently secreted and biologically active in cell transformation assays. 8355714 7 23 part_of FGF5 1158:1161 arg1 an amino terminus FGF5 an amino terminus PUBTATOR Site FGF5 14176 terminus In contrast, a chimeric protein with an amino terminus from FGF5 was efficiently secreted and biologically active in cell transformation assays. 8349598 4 29 part_of PXR/K 797:801 arg1 the PXR/K motif PXR the PXR/K motif PUBTATOR Site PXR 8856 motif Glycoproteins which do not contain the PXR/K motif but bear Asn-linked oligosaccharides terminating with GGnM or sialic acid alpha 2,3/6GGnM have also been described, suggesting a distinct GalNAc-transferase may be responsible for their synthesis. 8349598 4 52 part_of contain 785:791 arg1 Glycoproteins AND the PXR/K motif Glycoproteins the PXR/K motif Fterm Site Glycoproteins motif Glycoproteins which do not contain the PXR/K motif but bear Asn-linked oligosaccharides terminating with GGnM or sialic acid alpha 2,3/6GGnM have also been described, suggesting a distinct GalNAc-transferase may be responsible for their synthesis. 12527303 9 102 gly N-glycosylation 1677:1691 arg2 the N-glycosylation site the N-glycosylation site site Removal of terminal N-acetylglucosamine as well as mannose sugar residues resulted in the largest conformational changes in both the oligosaccharide and in the polypeptide loop containing the N-glycosylation site. 20399750 2 39 gly N-glycosylation 433:447 arg2 the potential N-glycosylation site the potential N-glycosylation site site We found that introduction of an adaptive mutation at the potential N-glycosylation site (E2N151K) leads to efficient production of the chimeric virus. 18533687 5 86 gly glycosylation 797:809 arg1 RXFP1 RXFP1 PUBTATOR RXFP1 59350 We herein investigate the actual N-linked glycosylation status of RXFP1 and the functional ramifications of these post-translational modifications. 9311148 10 8 gly glycosylation 1253:1265 arg2 each glycosylation site each glycosylation site site A molecular mass glycoprofile for each glycosylation site was established based on the relative peak intensities observed in the MALDI mass spectra of the desialylated glycopeptides. 9311148 10 15 gly desialylated 1369:1380 arg1 the desialylated glycopeptides the desialylated glycopeptides glycopeptides A molecular mass glycoprofile for each glycosylation site was established based on the relative peak intensities observed in the MALDI mass spectra of the desialylated glycopeptides. 9311148 10 27 gly glycopeptides 1382:1394 arg2 the desialylated glycopeptides the desialylated glycopeptides glycopeptides A molecular mass glycoprofile for each glycosylation site was established based on the relative peak intensities observed in the MALDI mass spectra of the desialylated glycopeptides. 8497072 2 76 part_of gp120 425:429 arg1 the second conserved (C2) and third variable (V3) regions gp120 the second conserved (C2) and third variable (V3) regions PUBTATOR Site gp120 155971 regions We have previously reported that the interaction of the second conserved (C2) and third variable (V3) regions of gp120 influences the ability of HIV-1 to establish a productive infection in susceptible cells. 6234658 2 8 part_of containing 327:336 arg1 a precursor AND one glycosylation site a precursor one glycosylation site Fterm Site precursor site PreproANF is composed of a hydrophobic leader segment (20 amino acids), a precursor containing one glycosylation site (106 amino acids), and ANF (24 amino acids). 23883840 8 52 part_of HA2 1376:1378 arg1 the HA1 and HA2 domains HA2 the HA1 and HA2 domains OGER Site HA2 domains In the present study, we observed an increase in the variety and ratio of mutations detected in the HA1 and HA2 domains of the HA gene; however, these alterations have not yet resulted in vaccine escape mutants in Turkey. 23883840 8 97 part_of HA1 1368:1370 arg1 the HA1 and HA2 domains HA1 the HA1 and HA2 domains OGER Site HA1 domains In the present study, we observed an increase in the variety and ratio of mutations detected in the HA1 and HA2 domains of the HA gene; however, these alterations have not yet resulted in vaccine escape mutants in Turkey. 30683699 2 62 gly sialylated 432:441 arg1 sialylated glycans sialylated glycans A population of Fcs bearing sialylated glycans has been identified as contributing to this functionality, and high levels of sialylation also lead to longer serum retention times advantageous for therapy. 27314333 4 52 part_of TSR1 847:850 arg1 TSR1 domain TSR1 TSR1 domain PUBTATOR Site TSR1 55720 domain Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain. 12794129 8 54 part_of chain 1210:1214 arg1 J chain sequences J chain J chain sequences PUBTATOR Site J chain 3512 sequences Analysis of J chain sequences in diverse species is in agreement with accepted phylogenetic relationships, with the exception of the earthworm, suggesting that the reported presence of J chain in invertebrates should be reassessed. 12794129 8 78 part_of J 1208:1208 arg1 J chain sequences J chain J chain sequences PUBTATOR Site J chain 3512 sequences Analysis of J chain sequences in diverse species is in agreement with accepted phylogenetic relationships, with the exception of the earthworm, suggesting that the reported presence of J chain in invertebrates should be reassessed. 30541852 13 111 gly glycosylation 1972:1984 arg1 SLC19A1 and also other residues SLC19A1 and also other residues residues We show that GLN infection is limited to mouse cells due to both a mutation in the mouse gene preventing the glycosylation of SLC19A1 and also other residues conserved within the rat but not in the hamster and human proteins. 22180206 8 92 part_of mucin-type 1562:1571 arg1 mucin-type glycopeptides mucin mucin-type glycopeptides PUBTATOR Site mucin 100508689 glycopeptides This study demonstrates the capabilities of ETD MS/MS for site-specific characterisation of mucin-type glycopeptides containing high-density O-linked glycan clusters, using accessible and relative low-resolution/low-mass accuracy IT MS instrumentation. 15113889 10 49 gly glycosylation 1412:1424 arg2 a glycosylation site a glycosylation site site Two additional insertions were made in a conserved sequence adjacent to a glycosylation site and near the transmembrane domain. 29268168 4 5 gly glycosylation 700:712 arg2 the N162 glycosylation site the N162 glycosylation site site Here we report that the N162 glycosylation site is also found in the orthologous mouse FcγR, mFcγRIV. 20338479 0 39 gly beta1 24:28 arg1 Sialylation integrin beta1 Sialylation PUBTATOR integrin beta1 3688 Sialylation of integrin beta1 is involved in radiation-induced adhesion and migration in human colon cancer cells. 23661698 8 6 part_of EphA2 1196:1200 arg1 two residues EphA2 two residues PUBTATOR Site EphA2 1969 residues Analysis of Eph/ephrin crystal structures reveals an interaction between the ligand's carbohydrates and two residues of EphA2: Asp-78 and Lys-136. 23661698 8 6 part_of EphA2 1196:1200 arg1 Asp-78 EphA2 Asp-78 and Lys-136 PUBTATOR SpecificSite EphA2 1969 Asp-78 and Lys-136 Analysis of Eph/ephrin crystal structures reveals an interaction between the ligand's carbohydrates and two residues of EphA2: Asp-78 and Lys-136. 10913840 2 14 gly unglycosylated 402:415 arg1 the unglycosylated form form of rFuc-TIV PUBTATOR form of rFuc-TIV 60670 When one member of this family, rFuc-TIV, is expressed in bacteria, the unglycosylated form of rFuc-TIV has no detectable enzymatic activity. 25479596 9 49 part_of observed 1565:1572 arg1 the NA protein AND A potential new N-linked glycosylation site the NA protein A potential new N-linked glycosylation site Fterm Site protein site A potential new N-linked glycosylation site was observed in the NA protein of an H1N1pdm IAV strain isolated in Brazil. 16335952 8 44 gly glycosylation 1729:1741 arg2 these glycosylation site assignments these glycosylation site assignments site A total of 639 N-glycosylation sites were identified, and the overall high accuracy of these glycosylation site assignments as assessed by accurate mass measurement using high-resolution liquid chromatography coupled to Fourier transform ion cyclotron resonance mass spectrometry (LC-FTICR) is initially demonstrated. 16335952 8 91 gly N-glycosylation 1651:1665 arg2 639 N-glycosylation sites 639 N-glycosylation sites sites A total of 639 N-glycosylation sites were identified, and the overall high accuracy of these glycosylation site assignments as assessed by accurate mass measurement using high-resolution liquid chromatography coupled to Fourier transform ion cyclotron resonance mass spectrometry (LC-FTICR) is initially demonstrated. 28186137 11 14 gly glycoproteins 1513:1525 arg1 glycoproteins glycoproteins Fterm glycoproteins Taken together, this study demonstrates that GlcNAc6ST-1 modulates PNS myelination and myelinated axonal survival through the GlcNAc-6-O-sulfation of N-glycans on glycoproteins. 28186137 11 57 gly GlcNAc-6-O-sulfation 1476:1495 arg1 glycoproteins glycoproteins GlcNAc-6-O-sulfation Fterm glycoproteins Taken together, this study demonstrates that GlcNAc6ST-1 modulates PNS myelination and myelinated axonal survival through the GlcNAc-6-O-sulfation of N-glycans on glycoproteins. 11263562 1 16 gly glycopeptide 153:164 arg2 Selective glycopeptide mapping Selective glycopeptide mapping glycopeptide Selective glycopeptide mapping of recombinant human erythropoietin (rhEPO) used as a model glycoprotein was successfully carried out by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) using a Vydac C18 column eluted in acetonitrile-1 mM ammonium acetate, pH 6.8. 11263562 1 20 gly glycoprotein 234:245 arg1 a model glycoprotein a model glycoprotein Fterm glycoprotein Selective glycopeptide mapping of recombinant human erythropoietin (rhEPO) used as a model glycoprotein was successfully carried out by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) using a Vydac C18 column eluted in acetonitrile-1 mM ammonium acetate, pH 6.8. 21053369 0 79 gly glycosylation 66:78 arg2 glycosylation sites glycosylation sites sites Glycosylation analysis of interleukin-23 receptor: elucidation of glycosylation sites and characterization of attached glycan structures. 2041080 8 58 part_of HA1 1676:1678 arg1 the carboxy terminus HA1 the carboxy terminus Cterm Site HA1 terminus Factors important for cleavability are the number of basic residues at the cleavage site, the oligosaccharide at asparagine 22, and the length of the carboxy terminus of HA1. 26231935 8 45 part_of AChE 1346:1349 arg1 AChE sequence AChE AChE sequence PUBTATOR Site AChE 43 sequence Although the three glycosylation sites within AChE sequence have different extent in affecting the enzymatic activity, their glycan compositions are very similar. 15448154 2 81 gly N-glycosylation 355:369 arg2 An N-glycosylation site An N-glycosylation site site An N-glycosylation site was introduced into the I-like/hybrid domain interface to act as a wedge and to stabilize the open conformation of this interface and hence the open conformation of the alpha(4) beta(7) headpiece. 8496594 0 64 part_of protein 85:91 arg1 a C-type lectin domain protein a C-type lectin domain Fterm Site protein domain Expression cloning of the early activation antigen CD69, a type II integral membrane protein with a C-type lectin domain. 2456913 10 74 gly glycosylation 1384:1396 arg2 the individual glycosylation sites TSH sites OGER TSH sites The present study demonstrates that the early processing of oligosaccharides differs at the individual glycosylation sites of TSH and free alpha-subunits, perhaps because of local conformational differences. 2456913 10 74 gly glycosylation 1384:1396 arg2 the individual glycosylation sites alpha-subunits sites Fterm alpha-subunits sites The present study demonstrates that the early processing of oligosaccharides differs at the individual glycosylation sites of TSH and free alpha-subunits, perhaps because of local conformational differences. 30850477 5 92 gly N-glycosylation 553:567 arg2 N-glycosylation sites N-glycosylation sites sites The aim of the current study is to establish patterns of N-glycosylation sites in Ab V regions of naive and memory B cell subsets. 22582156 3 55 part_of GPIHBP1 599:605 arg1 Comparative GPIHBP1 amino acid sequences Comparative GPIHBP1 Comparative GPIHBP1 amino acid sequences PUBTATOR Site Comparative GPIHBP1 338328 sequences Comparative GPIHBP1 amino acid sequences and structures and GPIHBP1 gene locations were examined using data from several mammalian genome projects. 22582156 3 104 part_of Comparative 587:597 arg1 Comparative GPIHBP1 amino acid sequences Comparative GPIHBP1 Comparative GPIHBP1 amino acid sequences PUBTATOR Site Comparative GPIHBP1 338328 sequences Comparative GPIHBP1 amino acid sequences and structures and GPIHBP1 gene locations were examined using data from several mammalian genome projects. 23661698 5 50 gly deglycosylated 651:664 arg1 deglycosylated ephrin-A1 deglycosylated ephrin-A1 PUBTATOR ephrin-A1 1942 We found that deglycosylated ephrin-A1 does not efficiently induce EphA2 receptor internalization and degradation, and does not activate the downstream signaling pathways involved in cell migration and proliferation. 19277548 2 36 gly glycopeptides 474:486 arg2 the glycopeptides the glycopeptides glycopeptides Several methods have been reported for this purpose in the past, commonly divided into a three-step approach (1) affinity purification of glycoproteins/-peptides, (2) processing/trimming of the glycopeptides and (3) elucidation of the glycan attachment site by mass spectrometry. 32321762 4 97 gly PrPC isolated 744:756 arg1 GPI-glycan structures PrPC GPI-glycan structures PUBTATOR PrPC 5621 Here, we report GPI-glycan structures of human PrPC isolated from human brain and from brains of a knock-in mouse model in which the mouse prion protein (Prnp) gene was replaced with the human PRNP gene. 14692455 9 23 gly fucosylated 1577:1587 arg1 fucosylated proteins fucosylated proteins Fterm proteins When this method was applied to a study of lymphosarcoma in canines, it was found that during chemotherapy, a series of fucosylated proteins in the blood of patients decreased in concentration more than 2-fold. 30594968 2 29 gly glycosylation 474:486 arg2 the glycosylation sites the glycosylation sites sites Based on the variations in the glycosylation sites at these amino acids, H9N2 avian influenza viruses could be divided into three categories. 25544388 8 72 gly N-glycosylation 1301:1315 arg2 the new N-glycosylation site the new N-glycosylation site site These modeling procedures indicated that the addition of the new N-glycosylation site in the loop regions had lower constraining effects on the tertiary structure of the protein. 18829751 8 76 part_of variant 1374:1380 arg1 variant sequences variant variant sequences Fterm Site variant sequences Furthermore, there was strong selective pressure for the emergence of variant sequences in this region during the course of infection. 10211957 5 53 gly glycosylation 755:767 arg2 the unused glycosylation site the unused glycosylation site site In this work, the unused glycosylation site on the E1 glycoprotein was identified and the influence of N-linked glycosylation on the formation of the HCV glycoprotein complex was studied by expressing a panel of E1 glycosylation mutants in HepG2 cells. 10211957 5 65 gly glycoprotein 784:795 arg1 the E1 glycoprotein the E1 glycoprotein Fterm glycoprotein In this work, the unused glycosylation site on the E1 glycoprotein was identified and the influence of N-linked glycosylation on the formation of the HCV glycoprotein complex was studied by expressing a panel of E1 glycosylation mutants in HepG2 cells. 10211957 5 101 gly glycoprotein 884:895 arg1 the HCV glycoprotein complex the HCV glycoprotein complex Fterm glycoprotein In this work, the unused glycosylation site on the E1 glycoprotein was identified and the influence of N-linked glycosylation on the formation of the HCV glycoprotein complex was studied by expressing a panel of E1 glycosylation mutants in HepG2 cells. 26458842 3 35 gly N-glycosylation 471:485 arg2 40 ancestral N-glycosylation sites 40 ancestral N-glycosylation sites sites In the present study, a mouse glycoproteome dataset and mammalian proteome data were assessed to identify 40 ancestral N-glycosylation sites in 37 proteins that disappeared during human evolution since the last common ancestor of the Euarchonta (primates and treeshrews). 2503511 5 43 gly rt-PA 1121:1125 arg1 the total carbohydrate content rt-PA the total carbohydrate content Cterm rt-PA P00750 High mannose oligosaccharides were found to account for 38% of the total carbohydrate content of rt-PA and consisted of Man5GlcNAc2, Man6GlcNAc2, and Man7GlcNAc2 in the ratio 1.8:1.7:1. 21053369 7 94 gly glycopeptides 1208:1220 arg2 target glycopeptides target glycopeptides glycopeptides The attached glycan structures were elucidated by collision-induced dissociation (CID) fragmentation of target glycopeptides in combination with accurate mass measurement. 18524885 4 53 gly glycosylation 819:831 arg2 an asparagine-linked glycosylation site an asparagine-linked glycosylation site site In the present study, we show that the addition of an asparagine-linked glycosylation site to the N terminus of the human trace amine associated receptor 1 (TAAR1) is sufficient to enable its plasma membrane expression, and thus its pharmacological characterization with a novel cAMP EPAC (exchange protein directly activated by cAMP) protein based bioluminescence resonance energy transfer (BRET) biosensor. 14699159 5 58 part_of p90ATF6 1119:1125 arg1 the carboxyl terminus p90ATF6 the carboxyl terminus Cterm Site p90ATF6 22926 terminus By mutating a single amino acid within the N-linked glycosylation site closest to the carboxyl terminus of p90ATF6, we recreated ATF6(f). 31501225 6 26 part_of IgA2 991:994 arg1 the glycopeptides IgA2 the glycopeptides OGER Site IgA2 P01877 glycopeptides TPLTAN 205ITK (H5N5S1F1) and (H5N4S2F1) corresponding to the glycopeptides of IgA2 were significantly elevated in serum from patients with HBV infection and even higher in HBV-related LC patients, as compared with healthy donor. 10215412 6 52 part_of hLHR 452:455 arg1 the hLHR extracellular domain hLHR the hLHR extracellular domain PUBTATOR Site hLHR 3973 domain This Leu-Gln dipeptide insertion in the first Leucine repeat of the hLHR extracellular domain did not affect the ligand binding affinity of the receptor. 27058983 2 39 gly highlight 382:390 arg1 N-glycosylation site N-glycosylation site site In this review, we highlight the key structural features responsible for anion binding and translocation and have integrated the following topological markers within the Band 3 structure: blood group antigens, N-glycosylation site, protease cleavage sites, inhibitor and chemical labeling sites, and the results of scanning cysteine and N-glycosylation mutagenesis. 27058983 2 39 gly highlight 382:390 arg1 scanning cysteine and N-glycosylation mutagenesis scanning cysteine and N-glycosylation mutagenesis cysteine In this review, we highlight the key structural features responsible for anion binding and translocation and have integrated the following topological markers within the Band 3 structure: blood group antigens, N-glycosylation site, protease cleavage sites, inhibitor and chemical labeling sites, and the results of scanning cysteine and N-glycosylation mutagenesis. 27058983 2 56 gly N-glycosylation 573:587 arg2 N-glycosylation site N-glycosylation site site In this review, we highlight the key structural features responsible for anion binding and translocation and have integrated the following topological markers within the Band 3 structure: blood group antigens, N-glycosylation site, protease cleavage sites, inhibitor and chemical labeling sites, and the results of scanning cysteine and N-glycosylation mutagenesis. 27058983 2 56 gly N-glycosylation 573:587 arg1 scanning cysteine and N-glycosylation mutagenesis cysteine cysteine In this review, we highlight the key structural features responsible for anion binding and translocation and have integrated the following topological markers within the Band 3 structure: blood group antigens, N-glycosylation site, protease cleavage sites, inhibitor and chemical labeling sites, and the results of scanning cysteine and N-glycosylation mutagenesis. 9295302 8 74 gly modified 1378:1385 arg3 Asn1006 AND N-linked oligosaccharides Asn1006 N-linked oligosaccharides Asn1006 Subsequent site-directed mutagenesis studies established that Asn19 and Asn23 in the NH2-terminal MSD and Asn1006 in the COOH-terminal MSD are the only sites in MRP that are modified with N-linked oligosaccharides. 9295302 8 74 gly modified 1378:1385 arg3 the only sites AND N-linked oligosaccharides the only sites N-linked oligosaccharides sites Subsequent site-directed mutagenesis studies established that Asn19 and Asn23 in the NH2-terminal MSD and Asn1006 in the COOH-terminal MSD are the only sites in MRP that are modified with N-linked oligosaccharides. 9295302 8 74 gly modified 1378:1385 arg3 Asn23 AND N-linked oligosaccharides Asn19 and Asn23 N-linked oligosaccharides Asn19 and Asn23 Subsequent site-directed mutagenesis studies established that Asn19 and Asn23 in the NH2-terminal MSD and Asn1006 in the COOH-terminal MSD are the only sites in MRP that are modified with N-linked oligosaccharides. 31266872 4 30 part_of epitope 900:906 arg1 HIV-1 Env HIV-1 Env epitope Cterm HIV-1 Env Amino acid substitutions in the V2 loop of SIVmac239 corresponding to the epitope for PGT145 in HIV-1 Env modulate sensitivity to this antibody. 27356208 2 42 gly N-glycosylation 311:325 arg2 a new N-glycosylation site a new N-glycosylation site site Introduction of a new N-glycosylation site into a protein backbone leads to its hyper-glycosylation, and may improve the protein properties such as solubility, folding, stability, and secretion. 24468271 5 3 gly glycosylation 790:802 arg2 Asn105 Asn105 Asn105 Our results demonstrate that the glycosylation only occurs at position Asn38, but not Asn105. 24468271 5 3 gly glycosylation 790:802 arg2 position Asn38 position Asn38 position Asn38 Our results demonstrate that the glycosylation only occurs at position Asn38, but not Asn105. 24884609 9 6 gly contained 1294:1302 arg1 Site N274 AND high-mannose N-linked glycans ITIH4 N274 high-mannose N-linked glycans PUBTATOR SpecificSite ITIH4 3700 N274 Site N274 contained high-mannose N-linked glycans in both serum and recombinant ITIH4. 19176349 3 57 gly glycosylated 451:462 arg1 a 35-kDa protein a 35-kDa protein Fterm protein In vitro translated GLUT8 migrates as a 35-kDa protein that is glycosylated in the presence of microsomal membranes. 27356208 5 75 gly N-glycosylation 883:897 arg2 new N-glycosylation sites new N-glycosylation sites sites In this work, a computational approach was conducted to select suitable location(s) for introducing new N-glycosylation sites into the human coagulation factor IX (hFIX). 8379944 8 20 gly position 1172:1179 arg1 carbohydrate position 20, 84 carbohydrate position 20, 84 Loss of carbohydrate at position 20, 84 or 272 resulted in a decrease in the specific activity of the mutant enzymes by 18%, 82%, and 62% respectively. 23221548 2 32 gly glycosylation 577:589 arg2 a novel glycosylation site a novel glycosylation site site Transfection of 20 such mutants in a human hepatoma cell line identified many with severe impairment in virion secretion, which can be rescued to various extents by coexpression of wild-type envelope proteins or introduction of a novel glycosylation site. 15869468 9 63 gly aglycosylated 1333:1345 arg1 the aglycosylated receptor the aglycosylated receptor Fterm receptor This behaviour differed from that observed for the aglycosylated receptor, which accumulated in the endoplasmic reticulum. 29273683 5 79 gly N-glycosylation 502:516 arg2 conserved N-glycosylation sites conserved N-glycosylation sites sites We now show that mutations of conserved N-glycosylation sites at N238 in human CBG and N230 in rat CBG disrupt steroid binding. 2574658 5 16 gly cysteine-rich 681:693 arg1 seven epidermal growth factor-like cysteine-rich repeats cysteine seven epidermal growth factor-like cysteine-rich repeats cysteine The deduced amino acid sequence contains seven epidermal growth factor-like cysteine-rich repeats, one possible tyrosine O-sulfation site, and a possible N-glycosylation site. 2574658 5 68 gly N-glycosylation 759:773 arg2 a possible N-glycosylation site a possible N-glycosylation site site The deduced amino acid sequence contains seven epidermal growth factor-like cysteine-rich repeats, one possible tyrosine O-sulfation site, and a possible N-glycosylation site. 2574658 5 86 gly contains 637:644 arg1 The deduced amino acid sequence AND seven epidermal growth factor-like cysteine-rich repeats The deduced amino acid sequence The deduced amino acid sequence seven epidermal growth factor-like cysteine-rich repeats sequence The deduced amino acid sequence contains seven epidermal growth factor-like cysteine-rich repeats, one possible tyrosine O-sulfation site, and a possible N-glycosylation site. 9194614 1 73 gly glycoproteins 193:205 arg1 glycoproteins glycoproteins Fterm glycoproteins More than 95% of grass pollen allergic patients possess IgE antibodies against grass group I, a heterogeneous group of glycoproteins found in all temperate grasses. 27938679 2 49 part_of contains 330:337 arg1 The amino-terminal region AND conformational epitopes F, G and H The amino-terminal region conformational epitopes F, G and H epitopes The amino-terminal region of SU contains conformational epitopes F, G and H, which require a glycosylated SU to be recognized by monoclonal antibodies (MAbs) and antibodies from BLV-infected cattle. 30594968 0 23 part_of hemagglutinin 65:77 arg1 potential glycosylation sites hemagglutinin potential glycosylation sites Fterm Site hemagglutinin sites Impact of the variations in potential glycosylation sites of the hemagglutinin of H9N2 influenza virus. 30594968 0 25 part_of Impact 0:5 arg1 potential glycosylation sites Impact potential glycosylation sites OGER Site Impact Q9P2X3 sites Impact of the variations in potential glycosylation sites of the hemagglutinin of H9N2 influenza virus. 30594968 0 76 part_of sites 52:56 arg1 Impact Impact sites OGER Site Impact Q9P2X3 sites Impact of the variations in potential glycosylation sites of the hemagglutinin of H9N2 influenza virus. 3828456 1 63 part_of has 264:266 arg1 The proline-rich glycoprotein AND a common heptapeptide sequence The proline-rich glycoprotein a common heptapeptide sequence Fterm Site glycoprotein sequence The proline-rich glycoprotein from human parotid saliva has a common heptapeptide sequence around four of six N-glycosylation sites (Maeda, N., H. S. Kim, E. A. Azen, and O. J. Smithies, 1985, J. Biol. 9658108 7 22 part_of huhavcr-1 1198:1206 arg1 the cytoplasmic domain huhavcr-1 the cytoplasmic domain Cterm Site huhavcr-1 domain In addition, 12 C-terminal amino acids in the cytoplasmic domain of huhavcr-1 were deleted. 23527139 9 14 gly glycosylation 1315:1327 arg2 the glycosylation site ASN 67 and other conserved residues the glycosylation site ASN 67 and other conserved residues site ASN 67 Based on these interactions it was found that antibody successfully blocks the glycosylation site ASN 67 and other conserved residues present at DC-SIGN-Den-E complex interface. 23527139 9 74 gly site 1329:1332 arg1 ASN 67 ASN 67 site ASN 67 Based on these interactions it was found that antibody successfully blocks the glycosylation site ASN 67 and other conserved residues present at DC-SIGN-Den-E complex interface. 15582650 5 15 gly glycosylation 905:917 arg2 three glycosylation motifs three glycosylation motifs motifs A unique mutant designated 3G with mutations in three glycosylation motifs within the V3/C3 domains surrounding the CD4 binding site showed higher levels of binding to most broadly neutralizing Mabs (b12 and 2F5) in both insect and mammalian expression systems. 8798678 3 72 gly glycosylation 484:496 arg2 a new glycosylation site a new glycosylation site site This mutant has a deletion of the codon for Lys-251, which is located in the connecting strand between helix F and strand 3A, overlying beta sheet A. Deletion of this Lys modifies the amino acid sequence at this position from Asn-Lys-Ile-Ser to Asn-Ile-Ser and creates a new glycosylation site. 23562646 3 119 part_of contains 491:498 arg1 The hPIV-3 HN protein AND four potential sites The hPIV-3 HN protein four potential sites Fterm Site protein sites The hPIV-3 HN protein contains four potential sites (N308, N351, N485 and N523) for N-linked glycosylation. 23562646 3 119 part_of contains 491:498 arg1 The hPIV-3 HN protein AND N485 protein N308, N351, N485 and N523 Fterm SpecificSite protein N308, N351, N485 and N523 The hPIV-3 HN protein contains four potential sites (N308, N351, N485 and N523) for N-linked glycosylation. 23562646 3 119 part_of contains 491:498 arg1 The hPIV-3 HN protein AND N523 protein N308, N351, N485 and N523 Fterm SpecificSite protein N308, N351, N485 and N523 The hPIV-3 HN protein contains four potential sites (N308, N351, N485 and N523) for N-linked glycosylation. 23562646 3 119 part_of contains 491:498 arg1 The hPIV-3 HN protein AND N523 protein N308, N351, N485 and N523 Fterm SpecificSite protein N308, N351, N485 and N523 The hPIV-3 HN protein contains four potential sites (N308, N351, N485 and N523) for N-linked glycosylation. 21345964 2 31 gly glycoproteins 297:309 arg1 gE gE Cterm gE The two VZV glycoproteins gE and gI form a heterodimer that mediates efficient cell-to-cell spread. 21345964 2 31 gly glycoproteins 297:309 arg1 The two VZV glycoproteins The two VZV glycoproteins Fterm glycoproteins The two VZV glycoproteins gE and gI form a heterodimer that mediates efficient cell-to-cell spread. 22750213 4 4 part_of containing 695:704 arg1 PRiMA AND two putative N-linked glycosylation sites PRiMA two putative N-linked glycosylation sites PUBTATOR Site PRiMA 170952 sites PRiMA is a glycoprotein containing two putative N-linked glycosylation sites. 22750213 4 4 part_of containing 695:704 arg1 a glycoprotein AND two putative N-linked glycosylation sites a glycoprotein two putative N-linked glycosylation sites Fterm Site glycoprotein sites PRiMA is a glycoprotein containing two putative N-linked glycosylation sites. 8301235 3 15 gly glycosylation 522:534 arg2 four putative N-linked glycosylation sites four putative N-linked glycosylation sites sites Human HL is a glycoprotein and its predicted amino acid sequence contains four putative N-linked glycosylation sites at Asn residues 20, 56, 340, and 375. 8301235 3 77 gly glycoprotein 439:450 arg1 Human HL Human HL PUBTATOR Human HL 3280 Human HL is a glycoprotein and its predicted amino acid sequence contains four putative N-linked glycosylation sites at Asn residues 20, 56, 340, and 375. 8301235 3 77 gly glycoprotein 439:450 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Human HL is a glycoprotein and its predicted amino acid sequence contains four putative N-linked glycosylation sites at Asn residues 20, 56, 340, and 375. 8987398 4 28 gly glycoproteins 787:799 arg1 MHC class I glycoproteins MHC class I glycoproteins Fterm glycoproteins However, recognition of MHC class I molecules by antibodies and T cells is indifferent to the carbohydrate, although lines of circumstantial evidence implicate lectins and carbohydrates in the recognition of MHC class I glycoproteins by natural killer cells. 2318516 12 78 gly glycoprotein 2169:2180 arg1 the class I glycoprotein the class I glycoprotein Fterm glycoprotein These data demonstrate that the HLA/H-2 transport dichotomy in T2 is a function of the origin of the alpha 1 and/or alpha 2 domains of the class I glycoprotein, and is not a reflection of glycosylation differences between the human and mouse molecules. 10191360 0 93 gly glycosylation 31:43 arg1 voltage-gated K+ channels voltage-gated K+ channels Fterm channels Differential asparagine-linked glycosylation of voltage-gated K+ channels in mammalian brain and in transfected cells. 10970800 7 28 gly non-glycosylated 873:888 arg1 the non-glycosylated receptor the non-glycosylated receptor Fterm receptor Their joint elimination resulted in the synthesis of a receptor protein with full binding competence, biological activity and no reduction of affinity; however, the half-life of the non-glycosylated receptor was slightly reduced. 2350186 2 85 gly has 382:384 arg1 Normal murine IgM AND five N-linked oligosaccharides Normal murine IgM five N-linked oligosaccharides OGER IgM P01872 Normal murine IgM has five N-linked oligosaccharides in the constant region of each heavy or mu-chain. 20209506 0 25 part_of I 83:83 arg1 sialylated and fucosylated glycopeptides beta2-glycoprotein I sialylated and fucosylated glycopeptides PUBTATOR Site beta2-glycoprotein I 350 glycopeptides Characterization of sialylated and fucosylated glycopeptides of beta2-glycoprotein I by a combination of HILIC LC and MALDI MS/MS. 16331329 5 84 part_of protein 731:737 arg1 the deduced protein sequence protein the deduced protein sequence Fterm Site protein sequence Alignment analysis revealed that the deduced protein sequence shares 86%, 91% and 93% homology with that of its human, mouse and rat counterparts, respectively. 10459158 5 7 part_of HA1 548:550 arg1 HA1 domain HA1 HA1 domain OGER Site HA1 domain Sequence analysis of the hemagglutinin (HA) gene, HA1 domain, indicated that there were remarkable amino acid changes in the strain B/Taiwan/3143/97 compared to B/Victoria/2/87, B/Yamagata/16/88, and B/Taiwan/7/88. 10459158 5 40 part_of hemagglutinin 523:535 arg1 HA1 domain hemagglutinin HA1 domain Fterm Site hemagglutinin domain Sequence analysis of the hemagglutinin (HA) gene, HA1 domain, indicated that there were remarkable amino acid changes in the strain B/Taiwan/3143/97 compared to B/Victoria/2/87, B/Yamagata/16/88, and B/Taiwan/7/88. 21215105 8 13 part_of protein 1491:1497 arg1 303 protein 303 Fterm Site protein position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated. 21215105 8 13 part_of protein 1491:1497 arg1 site 40 protein site 40 Fterm Site protein site Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated. 21215105 8 66 part_of protein 1616:1622 arg1 303 protein 303 Fterm Site protein position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated. 21215105 8 66 part_of protein 1616:1622 arg1 site 40 protein site 40 Fterm Site protein site Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated. 29966421 1 15 gly glycoproteins 226:238 arg1 the most abundant glycoproteins the most abundant glycoproteins Fterm glycoproteins Fetuin, also known as alpha-2-Heremans Schmid glycoprotein (AHSG), belongs to some of the most abundant glycoproteins secreted into the bloodstream. 29966421 1 55 gly glycoprotein 168:179 arg1 alpha-2-Heremans Schmid glycoprotein alpha-2-Heremans Schmid glycoprotein PUBTATOR alpha-2-Heremans Schmid glycoprotein 197 Fetuin, also known as alpha-2-Heremans Schmid glycoprotein (AHSG), belongs to some of the most abundant glycoproteins secreted into the bloodstream. 29966421 1 55 gly glycoprotein 168:179 arg1 AHSG AHSG PUBTATOR AHSG 197 Fetuin, also known as alpha-2-Heremans Schmid glycoprotein (AHSG), belongs to some of the most abundant glycoproteins secreted into the bloodstream. 22691915 7 24 gly N-glycosylation 783:797 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site This marker is a highly sensitive indicator of N-glycosylation site occupancy. 20348522 4 3 gly glycosylated 620:631 arg1 The glycosylated variants The glycosylated variants Fterm variants The glycosylated variants were more virulent and had higher viremic levels than the non-glycosylated variants. 20348522 4 68 gly non-glycosylated 700:715 arg1 the non-glycosylated variants the non-glycosylated variants Fterm variants The glycosylated variants were more virulent and had higher viremic levels than the non-glycosylated variants. 8554050 6 24 part_of site 1040:1043 arg1 the Con1 protein protein site Fterm Site protein site A PRB2L CON1 allele contains a single nt missense change [TCT(Ser)-->CCT (Pro)] that abolishes the potential N-linked glycosylation site (NKS-->NKP) in the Con1 protein, and this explains the Con- type. 30898876 4 64 gly glycoproteins 1065:1077 arg1 the glycoproteins the glycoproteins Fterm glycoproteins Using isotope-coded glycosylation site-specific tagging (IGOT)-LC/MS analysis of Lec8 Chinese hamster cells lacking galactosylation and of cells transfected with the B3GALNT2 gene, we identified the glycoproteins that carry B3GALNT2-generated type-I LDN in their N-glycans. 30898876 4 35 gly carry 1084:1088 arg1 the glycoproteins AND B3GALNT2-generated type-I LDN the glycoproteins B3GALNT2-generated type-I LDN Fterm glycoproteins Using isotope-coded glycosylation site-specific tagging (IGOT)-LC/MS analysis of Lec8 Chinese hamster cells lacking galactosylation and of cells transfected with the B3GALNT2 gene, we identified the glycoproteins that carry B3GALNT2-generated type-I LDN in their N-glycans. 6195967 10 37 part_of fragment 1419:1426 arg1 Gc2 Gc2 fragment PUBTATOR Site Gc2 83733 fragment No detectable galactosamine could be found in the homologous cyanogen bromide fragment in Gc2. 26784534 5 57 gly occupied 671:678 arg2 all 10 predicted O-glycosylation sites all 10 predicted O-glycosylation sites sites RESULTS: We found that all 10 predicted O-glycosylation sites in VWF are occupied. 26784534 5 89 gly O-glycosylation 638:652 arg2 all 10 predicted O-glycosylation sites all 10 predicted O-glycosylation sites sites RESULTS: We found that all 10 predicted O-glycosylation sites in VWF are occupied. 10419520 7 61 part_of S2P 1074:1076 arg1 S2P face the cytosol S2P S2P face the cytosol PUBTATOR Site S2P 51360 face Both the NH(2) and COOH termini of S2P face the cytosol. 1282935 1 2 gly glycoprotein 173:184 arg1 the most abundant glycoprotein the most abundant glycoprotein Fterm glycoprotein The neural adhesion molecule P0, the most abundant glycoprotein in peripheral myelin of mammals, is a member of the immunoglobulin superfamily and expresses the L2/HNK-1 and L3 oligosaccharides at a single N-glycosylation site. 1282935 1 15 gly N-glycosylation 328:342 arg2 a single N-glycosylation site a single N-glycosylation site site The neural adhesion molecule P0, the most abundant glycoprotein in peripheral myelin of mammals, is a member of the immunoglobulin superfamily and expresses the L2/HNK-1 and L3 oligosaccharides at a single N-glycosylation site. 1282935 1 32 gly site 344:347 arg1 the L2/HNK-1 and L3 oligosaccharides site the L2/HNK-1 and L3 oligosaccharides site The neural adhesion molecule P0, the most abundant glycoprotein in peripheral myelin of mammals, is a member of the immunoglobulin superfamily and expresses the L2/HNK-1 and L3 oligosaccharides at a single N-glycosylation site. 9780042 1 6 part_of protein 246:252 arg1 envelope (E) protein regions protein envelope (E) protein regions Fterm Site protein regions Several neuroinvasive and non-neuroinvasive West Nile (WN) viruses were characterized by nucleotide sequencing of their envelope (E) protein regions. 8643111 7 8 gly found 1433:1437 arg2 mLL2 AND the VK-appended oligosaccharides mLL2 the VK-appended oligosaccharides PUBTATOR mLL2 Q9UMN6 The humanized LL2 (hLL2), lacking light chain variable region glycosylation, exhibited immunoreactivities that were comparable to that of chimeric LL2 (cLL2), which was shown previously to have antigen-binding properties similar to its murine counterpart, suggesting that the VK-appended oligosaccharides found in mLL2 are not necessary for antigen binding. 21647803 7 3 gly peptide 1032:1038 arg1 glycan and peptide isomers glycan and peptide isomers Integrated LC/MS/MS not only confirmed glycopeptide composition but also differentiated glycan and peptide isomers and yielded structural information on both the glycan and peptide moieties. 21647803 7 66 gly glycopeptide 972:983 arg2 glycopeptide composition glycopeptide composition glycopeptide Integrated LC/MS/MS not only confirmed glycopeptide composition but also differentiated glycan and peptide isomers and yielded structural information on both the glycan and peptide moieties. 21647803 7 80 gly peptide 1106:1112 arg1 both the glycan and peptide moieties both the glycan and peptide moieties Integrated LC/MS/MS not only confirmed glycopeptide composition but also differentiated glycan and peptide isomers and yielded structural information on both the glycan and peptide moieties. 15811651 3 35 gly glycosylation 454:466 arg1 the TBE virus prM and E proteins the TBE virus prM and E proteins Fterm proteins To reveal the function of glycosylation of the TBE virus prM and E proteins in the secretion of VLPs, we expressed glycosylation-mutated prM and E proteins and compared the secretion levels and biological properties of the VLPs. 1988041 1 35 part_of lipase 126:131 arg1 some functional sites bile salt activated lipase some functional sites PUBTATOR Site bile salt activated lipase P19835 sites The structure and some functional sites of human milk bile salt activated lipase (BAL) were studied by cDNA cloning and chemical analysis of the enzyme. 8624782 6 60 part_of LDL-PLA2 672:679 arg1 Extensive peptide sequence LDL-PLA2 Extensive peptide sequence PUBTATOR Site LDL-PLA2 7941 sequence Extensive peptide sequence from LDL-PLA2 facilitated identification of an expressed sequence tag partial cDNA. 8355714 6 46 gly glycosylation 976:988 arg2 the Asn-linked glycosylation site the Asn-linked glycosylation site site Removing or relocating the Asn-linked glycosylation site further impaired its release, and exchanging the signal peptide or carboxy terminus had little effect. 26085161 6 36 gly glycosylation 1045:1057 arg2 N230 N230 N230 Using reverse genetics of an infectious molecular provirus, we identified a N-linked envelope glycosylation site (N230) that limits viral replication and pathogenicity. 26085161 6 36 gly glycosylation 1045:1057 arg2 a N-linked envelope glycosylation site a N-linked envelope glycosylation site site Using reverse genetics of an infectious molecular provirus, we identified a N-linked envelope glycosylation site (N230) that limits viral replication and pathogenicity. 32125861 4 64 part_of glycoproteins 919:931 arg1 1700 glycopeptides glycoproteins 1700 glycopeptides Fterm Site glycoproteins glycopeptides We were able to map around 1700 glycopeptides from 110 glycoproteins covering 191 glycosites, of which 43 sites have not been previously reported with experimental evidence. 10682309 11 76 gly deglycosylated 1766:1779 arg1 the wild-type SAP-B the wild-type SAP-B OGER SAP O60880 SAP-B in the patient's cells was found to be slightly less stable than the protein in normal cells and corresponded in size to the deglycosylated form of the wild-type SAP-B. 20923142 1 4 gly glycoproteins 346:358 arg1 glycoproteins glycoproteins Fterm glycoproteins The accuracy in quantitative analysis of N-linked glycopeptides and glycosylation site mapping in cancer is critical to the fundamental question of whether the aberration is due to changes in the total concentration of glycoproteins or variations in the type of glycosylation of proteins. 20923142 1 49 gly glycosylation 389:401 arg1 proteins proteins Fterm proteins The accuracy in quantitative analysis of N-linked glycopeptides and glycosylation site mapping in cancer is critical to the fundamental question of whether the aberration is due to changes in the total concentration of glycoproteins or variations in the type of glycosylation of proteins. 20923142 1 52 gly glycopeptides 177:189 arg2 N-linked glycopeptides N-linked glycopeptides glycopeptides The accuracy in quantitative analysis of N-linked glycopeptides and glycosylation site mapping in cancer is critical to the fundamental question of whether the aberration is due to changes in the total concentration of glycoproteins or variations in the type of glycosylation of proteins. 20923142 1 57 gly glycosylation 195:207 arg2 glycosylation site glycosylation site site The accuracy in quantitative analysis of N-linked glycopeptides and glycosylation site mapping in cancer is critical to the fundamental question of whether the aberration is due to changes in the total concentration of glycoproteins or variations in the type of glycosylation of proteins. 7937884 8 45 part_of protein 968:974 arg1 The deduced protein sequence protein The deduced protein sequence Fterm Site protein sequence The deduced protein sequence is composed predominantly of hydrophobic amino acids; hydropathy analysis predicts three transmembrane domains connected by two hydrophilic loops. 19277548 6 11 part_of proteins 1083:1090 arg1 N-glycosylation sites proteins N-glycosylation sites Fterm Site proteins sites In the described protocol, the elucidation of N-glycosylation sites of human platelet proteins is demonstrated as an example. 10712595 8 41 gly glycosylation 1464:1476 arg2 a glycosylation site a glycosylation site site Thus a rapidly reacting pool of antithrombin may have evolved in two different ways: absence of a glycosylation site in lower vertebrates vs. incomplete glycosylation of a part of the circulating antithrombin in higher vertebrates. 32258897 9 7 gly di-sialylated 1402:1414 arg1 a di-sialylated, core-fucosylated bi-antennary structure a di-sialylated, core-fucosylated bi-antennary structure The major N-glycan, accounting for ∼42% of total N-glycans, had a di-sialylated, core-fucosylated bi-antennary structure. 17724331 8 56 part_of receptor 1692:1699 arg1 an extracellular region receptor an extracellular region Fterm Site receptor region Taken together, we demonstrate higher surface expression of sEPO-R, attributed at least in part to increased ER exit, mediated by an extracellular region of this receptor. 2317204 3 58 part_of link-protein 426:437 arg1 degraded link-protein fragments protein degraded link-protein fragments Fterm Site protein fragments It released products with size similar to that of single chondroitin sulphate chains, and a series of degraded link-protein fragments in the digestion mixtures. 23296536 2 0 gly glycosylation 397:409 arg2 glycosylation sites glycosylation sites sites However, from even before the term "glycome informatics" emerged, several groups have developed methods and tools on the analysis of glycosylation sites. 8626811 6 53 part_of has 1026:1028 arg1 the mature protein AND a single N-glycosylation site the mature protein a single N-glycosylation site Fterm Site protein site The gene encodes a polypeptide of 416 amino acids (Mr 45,947) with a leader peptide of 35 residues; the mature protein has a single N-glycosylation site. 11093789 1 26 gly glycosylation 234:246 arg2 potential glycosylation sites potential glycosylation sites sites Many gastrointestinal G protein-coupled receptors are glycosylated; however, which potential glycosylation sites are actually glycosylated and their role in receptor transduction or receptor modulation (internalization, down-regulation, desensitization) is largely unknown. 11093789 1 59 gly glycosylated 195:206 arg1 Many gastrointestinal G protein-coupled receptors Many gastrointestinal G protein-coupled receptors Fterm receptors Many gastrointestinal G protein-coupled receptors are glycosylated; however, which potential glycosylation sites are actually glycosylated and their role in receptor transduction or receptor modulation (internalization, down-regulation, desensitization) is largely unknown. 11093789 1 36 gly glycosylated 267:278 arg1 Many gastrointestinal G protein-coupled receptors receptors sites Fterm receptors sites Many gastrointestinal G protein-coupled receptors are glycosylated; however, which potential glycosylation sites are actually glycosylated and their role in receptor transduction or receptor modulation (internalization, down-regulation, desensitization) is largely unknown. 30355697 11 79 gly glycosites 1530:1539 arg2 glycosites glycosites their occupying glycan glycosites Mapping of glycosites with their occupying glycan to functional regions, including antigenic sites, lectin interaction regions, and fusion domains, was performed and has implications for immune processing, immune responses, and antigenic shielding. 11533192 6 37 part_of NA 939:940 arg1 a glycosylation site NA a glycosylation site Cterm Site NA 4758 site Furthermore, another mutant WSN virus, possessing an NA with a glycosylation site at position 130 (146 in N2 numbering), leading to the loss of neurovirulence, failed to grow in cell culture in the presence of plasminogen. 26957414 6 31 gly glycosylation 789:801 arg2 glycosylation sites glycosylation sites sites In ISF method, the identification of glycosylation sites depended on the detection of Y1 ion (ion of peptide backbone with an N-acetylglucosamine attached). 10024532 2 73 gly N-glycosylation 275:289 arg2 the conserved N-glycosylation site the conserved N-glycosylation site site In addition to the conserved N-glycosylation site at Asn-297, an N-glycosylation consensus sequence (Asn-Asn-Ser) is located at position 75 in the variable region of its heavy chain. 10024532 2 73 gly N-glycosylation 275:289 arg2 Asn-297 Asn-297 Asn-297 In addition to the conserved N-glycosylation site at Asn-297, an N-glycosylation consensus sequence (Asn-Asn-Ser) is located at position 75 in the variable region of its heavy chain. 12515161 0 16 part_of NS3 35:37 arg1 NS3 region NS3 NS3 region PUBTATOR Site NS3 3845 region [Cloning and sequencing of cDNA in NS3 region of Chinese hepatitis G virus isolated from Henan Province]. 7998391 6 6 gly glycosylation 967:979 arg2 glycosylation site glycosylation site site Consequently, adaptation to mice required at least one mutation in HA resulting in the loss of glycosylation site. 20153530 6 7 gly N-glycosylation 915:929 arg2 A new N-glycosylation site A new N-glycosylation site site A new N-glycosylation site (P26N) was also introduced close to the N-terminus of C9 to test whether this region was involved in C9 polymerization, which is thought to be required for cytolytic activity of C9. 17055129 8 4 gly N-glycosylation 1210:1224 arg2 the N-glycosylation site N576ST the N-glycosylation site N576ST site These results indicate that engineering of the N-glycosylation site N576ST of HCV E2 protein enhances specific cellular immune responses, providing insights into the development of E2-based DNA vaccines with enhanced immunogenicity. 20188224 12 21 part_of granulin 1759:1766 arg1 granulin domains granulin granulin domains PUBTATOR Site granulin 2896 domains Two of the observed glycosylation sites occur within granulin domains, which may have important implications for understanding the structural basis of PGRN action. 27038031 3 32 gly glycosylation 435:447 arg2 60 glycosylation sites 60 glycosylation sites sites IgM can exist as a pentamer with a connecting singly N-glycosylated J-chain (with a total of 51 glycosylation sites) or as a hexamer (60 glycosylation sites). 27038031 3 88 gly glycosylation 394:406 arg2 51 glycosylation sites 51 glycosylation sites sites IgM can exist as a pentamer with a connecting singly N-glycosylated J-chain (with a total of 51 glycosylation sites) or as a hexamer (60 glycosylation sites). 16622833 5 66 gly acids 733:737 arg1 glycosylation site N107 glycosylation site N107 glycosylation site N107 SpecificSite site N107 The variability of the number of antennae and hence sialic acids on glycosylation site N107, which even contained minute amounts of tetraantennary structures, emerged as a major cause for the IEF pattern of A1PI. 16622833 5 74 gly antennae 707:714 arg1 glycosylation site N107 glycosylation site N107 glycosylation site N107 SpecificSite site N107 The variability of the number of antennae and hence sialic acids on glycosylation site N107, which even contained minute amounts of tetraantennary structures, emerged as a major cause for the IEF pattern of A1PI. 16622833 5 29 gly glycosylation 742:754 arg2 glycosylation site N107 site N107 site N107 The variability of the number of antennae and hence sialic acids on glycosylation site N107, which even contained minute amounts of tetraantennary structures, emerged as a major cause for the IEF pattern of A1PI. 1448922 0 68 gly Asn-glycosylated 41:56 arg1 The E3-11.6K protein protein Fterm protein The E3-11.6K protein of adenovirus is an Asn-glycosylated integral membrane protein that localizes to the nuclear membrane. 29274340 2 60 gly glycosylation 453:465 arg1 rhGAA rhGAA glycosylation OGER rhGAA Q6P7A9 Mannose-6-phosphate (M6P) glycosylation on rhGAA is a key factor influencing lysosomal enzyme targeting and the efficacy of enzyme replacement therapy (ERT); however, its complex structure and relatively small quantity still remain to be characterized. 23029648 3 22 gly N-glycosylation 360:374 arg2 large-scale N-glycosylation site annotation large-scale N-glycosylation site annotation site However, a common workflow has emerged over the last decade for large-scale N-glycosylation site annotation by application of proteomic methodology. 9249051 3 59 gly presence 543:550 arg2 position 133 AND an O-linked carbohydrate chain position 133 an O-linked carbohydrate chain position 133 The presence of an O-linked carbohydrate chain at position 133 greatly improves the physical stability of the protein. 27574189 7 91 gly attached 828:835 arg2 Asn614 AND A high mannose-containing glycan Asn614 A high mannose-containing glycan Asn614 A high mannose-containing glycan was attached to Asn614 in the spacer domain. 27574189 7 91 gly attached 828:835 arg2 A high mannose-containing glycan AND the spacer domain the spacer domain A high mannose-containing glycan domain A high mannose-containing glycan was attached to Asn614 in the spacer domain. 17158203 0 66 gly leucine-rich 68:79 arg1 leucine-rich repeat leucine leucine-rich repeat leucine The low-density lipoprotein class A module of the relaxin receptor (leucine-rich repeat containing G-protein coupled receptor 7): its role in signaling and trafficking to the cell membrane. 19248770 4 1 gly N-glycosylation 655:669 arg2 the N-glycosylation site the N-glycosylation site site Introduction of the signal sequence from mIL-31 to human p53 protein failed to secrete the products, but further addition of the N-glycosylation site resulted in constitutive secretion of biologically active p53 protein into the medium in the N-glycosylated form. 26296369 5 67 gly CD69 1094:1097 arg1 the N-glycan composition CD69 the N-glycan composition PUBTATOR CD69 969 In agreement, the glycomics analysis determines the glycosylation site and the N-glycan composition of CD69, and terminal removal of sialic acid from that N-linked glycans reverses the generation of forkhead box P3-positive Treg cells (23.21%; P < 0.05). 26296369 5 84 gly glycosylation 1043:1055 arg1 CD69 CD69 site PUBTATOR CD69 969 site In agreement, the glycomics analysis determines the glycosylation site and the N-glycan composition of CD69, and terminal removal of sialic acid from that N-linked glycans reverses the generation of forkhead box P3-positive Treg cells (23.21%; P < 0.05). 12064867 6 14 part_of CD4-binding 948:958 arg1 the CD4-binding site CD4 the CD4-binding site PUBTATOR Site CD4 920 site These results demonstrated that both the CD4-binding site and the epitopes recognised by antibodies from HIV-infected individuals have N-glycans in the close vicinity. 22750213 6 56 gly glycosylation 877:889 arg1 mouse PRiMA mouse PRiMA PUBTATOR PRiMA 170952 Abolishing glycosylation on mouse PRiMA appeared not to affect its assembly with AChE(T), the enzymatic properties of AChE, and the membrane trafficking of PRiMA-linked AChE tetramers. 9557657 8 80 gly N-glycosylation 1715:1729 arg2 the N-glycosylation motif the N-glycosylation motif motif To test this hypothesis, havcr-1 mutants lacking the N-glycosylation motif at the first site (mut1), second site (mut2), and both (mut3) sites were constructed and transfected into dog cells. 12110528 9 35 gly proteins 1559:1566 arg1 enhanced O-GlcNAcylation proteins enhanced O-GlcNAcylation Fterm proteins In conclusion, chronically increased glucose flux, which raises UDP-GlcNAc in muscle, results in enhanced O-GlcNAcylation of membrane proteins in vivo. 8379944 12 36 part_of sites 1795:1799 arg1 LCAT LCAT sites PUBTATOR Site LCAT 3931 sites The results demonstrate that all four potential N-glycosylation sites in LCAT are used and the presence of carbohydrate at each site has diverse effects on the enzyme activity. 11263562 2 14 part_of peptides 567:574 arg1 endoproteinase Glu-C peptides endoproteinase Glu-C Glu rhEPO expressed in a Chinese hamster ovary clone was exhaustively digested into four glycopeptides and nine peptides with endoproteinase Glu-C. 21774247 10 72 gly glycosylation 1474:1486 arg2 glycosylation site glycosylation site site The results showed that the HA and NA genes of the epidemic strains were highly homologous, some mutations in the HA and NA proteins were found, the antigenic site and glycosylation site of some strains were changed during the epidemic process. 8496594 11 22 part_of proteins 1546:1553 arg1 a C-type lectin domain proteins a C-type lectin domain Fterm Site proteins domain Homology searches revealed sequence similarity with members of a supergene family of type II integral membrane proteins with a C-type lectin domain, indicating that CD69 is involved in signal transduction. 11439087 8 49 part_of sBST-1 1133:1138 arg1 N1-N4 sBST-1 N1-N4 Cterm SiteSequence sBST-1 683 N1-N4 Site-directed mutagenesis was performed to generate sBST-1 mutants (N1-N4), each preserving a single N-glycosylation site. 25673720 13 83 gly glycosylation 2026:2038 arg1 C C Cterm C Q9NP58 PrP(C) undergoes posttranslational glycosylation, and the addition of these glycans may play a role in disease transmission. 25673720 13 83 gly glycosylation 2026:2038 arg1 PrP PrP PUBTATOR PrP 19122 PrP(C) undergoes posttranslational glycosylation, and the addition of these glycans may play a role in disease transmission. 21661761 6 28 gly glycosylation 1079:1091 arg2 multiple sites multiple sites sites The method is applied to glycoproteins with contrasting glycans and multiple sites of glycosylation and identifies multiple glycan compositions at each individual glycosylation site. 21661761 6 37 gly glycosylation 1156:1168 arg2 each individual glycosylation site each individual glycosylation site site The method is applied to glycoproteins with contrasting glycans and multiple sites of glycosylation and identifies multiple glycan compositions at each individual glycosylation site. 21661761 6 43 gly glycoproteins 1018:1030 arg1 contrasting glycans glycoproteins contrasting glycans Fterm glycoproteins The method is applied to glycoproteins with contrasting glycans and multiple sites of glycosylation and identifies multiple glycan compositions at each individual glycosylation site. 25945896 3 12 gly glycopeptides 642:654 arg2 the glycopeptides the glycopeptides glycopeptides However, assigning these spectra, leading to identification of the glycopeptides, is challenging. 23958596 6 18 gly linked 959:964 arg1 the core protein AND different N-glycans the core protein different N-glycans Fterm protein N-glycosidase F digestion revealed that multiple forms of LPLA2 found in individual transfectants are due to different N-glycans linked to the core protein. 8644914 7 113 gly found 1452:1456 arg1 Asn296 AND Carbohydrate Asn296 Carbohydrate Asn296 Oxidation of a specific methionine residue to the sulfoxide was demonstrated by sequencing the N-terminally blocked peptide by tandem MS. Carbohydrate was found exclusively at Asn296 of the heavy chain. 16823988 6 90 gly glycoproteins 901:913 arg1 Extracted glycoproteins Extracted glycoproteins Fterm glycoproteins Extracted glycoproteins are fractionated using NPS-RP-HPLC followed by SDS-PAGE. 21264968 5 4 gly Thr3 1870:1873 arg1 four α-GalNAc residues residues at Thr2, Thr3, Thr7, and Thr8 four α-GalNAc residues residues at Thr2, Thr3, Thr7, and Thr8 On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8. 21264968 5 9 gly Thr2 1864:1867 arg1 four α-GalNAc residues residues at Thr2, Thr3, Thr7, and Thr8 four α-GalNAc residues residues at Thr2, Thr3, Thr7, and Thr8 On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8. 21264968 5 18 gly Thr7 1876:1879 arg1 four α-GalNAc residues residues at Thr2, Thr3, Thr7, and Thr8 four α-GalNAc residues residues at Thr2, Thr3, Thr7, and Thr8 On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8. 21264968 5 31 gly Thr8 1886:1889 arg1 four α-GalNAc residues residues at Thr2, Thr3, Thr7, and Thr8 four α-GalNAc residues residues at Thr2, Thr3, Thr7, and Thr8 On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8. 21264968 5 64 gly O-glycosylation 1724:1738 arg2 consecutive Thr residues consecutive Thr residues Thr residues On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8. 21264968 5 64 gly O-glycosylation 1724:1738 arg1 naked MUC5AC peptide naked MUC5AC peptide peptide On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8. 21264968 5 95 gly MUC5AC 1826:1831 arg1 four α-GalNAc residues MUC5AC four α-GalNAc residues PUBTATOR MUC5AC 4586 On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8. 8302297 3 29 gly glycosylated 328:339 arg1 The glycosylated variant The glycosylated variant Fterm variant The glycosylated variant has been identified as a concanavalin A-binding glycoprotein. 8302297 3 29 gly glycosylated 328:339 arg1 a concanavalin A-binding glycoprotein a concanavalin A-binding glycoprotein Fterm glycoprotein The glycosylated variant has been identified as a concanavalin A-binding glycoprotein. 8302297 3 70 gly glycoprotein 397:408 arg1 a concanavalin A-binding glycoprotein a concanavalin A-binding glycoprotein Fterm glycoprotein The glycosylated variant has been identified as a concanavalin A-binding glycoprotein. 8302297 3 70 gly glycoprotein 397:408 arg1 The glycosylated variant The glycosylated variant Fterm variant The glycosylated variant has been identified as a concanavalin A-binding glycoprotein. 9259114 7 6 gly glycosylation 682:694 arg2 Asn41 Asn41 Asn41 All cysteine residues, putative N-linked glycosylation site (Asn41), and putative phosphorylation site (Ser166) were conserved. 9259114 7 6 gly glycosylation 682:694 arg2 putative N-linked glycosylation site putative N-linked glycosylation site site All cysteine residues, putative N-linked glycosylation site (Asn41), and putative phosphorylation site (Ser166) were conserved. 2246248 8 5 part_of contains 888:895 arg1 Human CMP AND two homologous domains Human CMP two homologous domains PUBTATOR Site Human CMP P21941 domains Human CMP is 79% identical to chicken CMP and contains two homologous domains separated by an epidermal growth factor-like domain. 9266687 5 16 gly glycosylation 813:825 arg2 a glycosylation site a glycosylation site site The fourth, albumin Besana Brianza, has the same Asp494-->Asn mutation that introduces a glycosylation site which has been previously reported in a variant from New Zealand, albumin Casebrook. 31296534 0 15 gly N-glycosylation 79:93 arg2 STT3A- and STT3B-dependent N-glycosylation sites STT3A- and STT3B-dependent N-glycosylation sites sites Quantitative glycoproteomics reveals new classes of STT3A- and STT3B-dependent N-glycosylation sites. 18381078 1 33 part_of glycoprotein 175:186 arg1 four potential N-glycosylation sites glycoprotein four potential N-glycosylation sites Fterm Site glycoprotein sites A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 18381078 1 33 part_of glycoprotein 175:186 arg1 N439 glycoprotein N267, N278, N439 and N551 Fterm SpecificSite glycoprotein N267, N278, N439 and N551 A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 18381078 1 33 part_of glycoprotein 175:186 arg1 N278 glycoprotein N267, N278, N439 and N551 Fterm SpecificSite glycoprotein N267, N278, N439 and N551 A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 18381078 1 33 part_of glycoprotein 175:186 arg1 N278 glycoprotein N267, N278, N439 and N551 Fterm SpecificSite glycoprotein N267, N278, N439 and N551 A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 22009746 5 23 part_of nAChR 975:979 arg1 a pentameric humanoid nAChR extracellular domain nAChR a pentameric humanoid nAChR extracellular domain PUBTATOR Site nAChR 1137 domain We also present a pentameric humanoid nAChR extracellular domain with the structural determination of the α7 nAChR glycosylation site. 22009746 5 51 part_of α7 1043:1044 arg1 the α7 nAChR glycosylation site α7 nAChR the α7 nAChR glycosylation site PUBTATOR Site α7 nAChR 1137 site We also present a pentameric humanoid nAChR extracellular domain with the structural determination of the α7 nAChR glycosylation site. 22009746 5 55 part_of nAChR 1046:1050 arg1 the α7 nAChR glycosylation site α7 nAChR the α7 nAChR glycosylation site PUBTATOR Site α7 nAChR 1137 site We also present a pentameric humanoid nAChR extracellular domain with the structural determination of the α7 nAChR glycosylation site. 9600940 1 67 gly Ser- 195:198 arg1 Ser- (O-) linked oligosaccharides Ser Ser- (O-) linked oligosaccharides Ser To initiate fertilization, mouse sperm bind to Ser- (O-) linked oligosaccharides located at the sperm combining site of zona pellucida glycoprotein mZP3. 9600940 1 74 gly glycoprotein 283:294 arg1 zona pellucida glycoprotein mZP3 zona pellucida glycoprotein mZP3 Fterm glycoprotein To initiate fertilization, mouse sperm bind to Ser- (O-) linked oligosaccharides located at the sperm combining site of zona pellucida glycoprotein mZP3. 2457333 1 43 part_of fetuin 286:291 arg1 the three N-linked glycosylation sites fetuin the three N-linked glycosylation sites Fterm Site fetuin sites Plasma desorption mass spectrometry (PD-MS) was used to assess the molecular weight heterogeneity of glycopeptides (6-12 amino acids) from each of the three N-linked glycosylation sites of bovine fetuin (R.G. Spiro (1962) J. Biol. 15264219 2 12 gly glycoprotein 415:426 arg1 five glycoprotein subunits five glycoprotein subunits Fterm glycoprotein The 5-HT3(A)R, as with other LGICs, is a pentameric ion channel comprising five glycoprotein subunits. 24884609 3 41 gly glycosylation 443:455 arg1 recombinant and serum-derived ITIH4 recombinant and serum-derived ITIH4 PUBTATOR ITIH4 3700 In this study, we aimed to characterize glycosylation of recombinant and serum-derived ITIH4 using analytical mass spectrometry. 11864713 5 21 gly glycosylated 1113:1124 arg2 Asn243 Asn243 Asn243 Furthermore, the procoagulant protease-inhibitory and anticoagulant activities of N230S/N319Q (glycosylated on Asn243 only) compared favorably with those of N230S, and both of the mutants possessed highest activities in the purified mutants. 11686319 3 8 gly glycosylation 443:455 arg2 a new glycosylation site a new glycosylation site site The mutation results in a substitution of 82 Ser by Asn, creating a new glycosylation site. 10211957 1 19 gly glycoproteins 237:249 arg1 E1 E1 Cterm E1 The hepatitis C virus (HCV) genome encodes two membrane-associated envelope glycoproteins (E1 and E2), which are released from the viral polyprotein precursor by host signal peptidase cleavages. 10211957 1 19 gly glycoproteins 237:249 arg1 two membrane-associated envelope glycoproteins two membrane-associated envelope glycoproteins Fterm glycoproteins The hepatitis C virus (HCV) genome encodes two membrane-associated envelope glycoproteins (E1 and E2), which are released from the viral polyprotein precursor by host signal peptidase cleavages. 27314333 6 43 part_of N137 1080:1083 arg1 Rspo1 Rspo1 N137 PUBTATOR SpecificSite Rspo1 284654 N137 Introduction of the N-glycosylation site to Rspo2 mutant at the position homologous to N137 in Rspo1 restored full glycosylation and rescued the accumulation defect of nonglycosylated Rspo2 mutant in media. 21902591 9 64 part_of gp120 1628:1632 arg1 hypervariable regions gp120 hypervariable regions PUBTATOR Site gp120 3700 regions These data suggest that cryptic repeats of RNY may play a role in the genesis of multiple base insertions and deletions in hypervariable regions of gp120. 8034709 9 39 part_of protein 1163:1169 arg1 the same NH2-terminal amino acid sequence protein the same NH2-terminal amino acid sequence Fterm Site protein sequence Tryptic digestion removed this propeptide and yielded a proteolytically active protein with the same NH2-terminal amino acid sequence as native SCCE. 16512686 2 19 gly glycopeptides 593:605 arg2 glycopeptides glycopeptides glycopeptides Glycosylation sites on glycopeptides produced by trypsinization of complex glycoprotein mixtures, however, are particularly difficult to identify both because a repertoire of glycans may be expressed at a particular glycosylation site, and because glycopeptides are usually present in relatively low abundance (2% to 5%) in peptide mixtures compared to nonglycosylated peptides. 16512686 2 31 gly glycoprotein 420:431 arg1 complex glycoprotein mixtures complex glycoprotein mixtures Fterm glycoprotein Glycosylation sites on glycopeptides produced by trypsinization of complex glycoprotein mixtures, however, are particularly difficult to identify both because a repertoire of glycans may be expressed at a particular glycosylation site, and because glycopeptides are usually present in relatively low abundance (2% to 5%) in peptide mixtures compared to nonglycosylated peptides. 16512686 2 45 gly glycopeptides 368:380 arg2 glycopeptides glycopeptides glycopeptides Glycosylation sites on glycopeptides produced by trypsinization of complex glycoprotein mixtures, however, are particularly difficult to identify both because a repertoire of glycans may be expressed at a particular glycosylation site, and because glycopeptides are usually present in relatively low abundance (2% to 5%) in peptide mixtures compared to nonglycosylated peptides. 16512686 2 84 gly glycosylation 561:573 arg2 a particular glycosylation site a particular glycosylation site site Glycosylation sites on glycopeptides produced by trypsinization of complex glycoprotein mixtures, however, are particularly difficult to identify both because a repertoire of glycans may be expressed at a particular glycosylation site, and because glycopeptides are usually present in relatively low abundance (2% to 5%) in peptide mixtures compared to nonglycosylated peptides. 16512686 2 102 gly nonglycosylated 698:712 arg1 nonglycosylated peptides nonglycosylated peptides peptides Glycosylation sites on glycopeptides produced by trypsinization of complex glycoprotein mixtures, however, are particularly difficult to identify both because a repertoire of glycans may be expressed at a particular glycosylation site, and because glycopeptides are usually present in relatively low abundance (2% to 5%) in peptide mixtures compared to nonglycosylated peptides. 19527756 8 7 gly glycoprotein 1554:1565 arg1 glycoprotein profiling glycoprotein profiling Fterm glycoprotein Our data discloses for the first time the novel use of Agilent Bioanalyzer to detect glycoforms of proteins in crude and purified preparations and such a tool could be easily applied for glycoprotein profiling of monoclonal antibodies and other fusion proteins expressed in mammalian cells. 19527756 8 112 gly glycoforms 1452:1461 arg1 proteins proteins Fterm proteins Our data discloses for the first time the novel use of Agilent Bioanalyzer to detect glycoforms of proteins in crude and purified preparations and such a tool could be easily applied for glycoprotein profiling of monoclonal antibodies and other fusion proteins expressed in mammalian cells. 11386425 2 32 part_of strain 383:388 arg1 the coding region strain the coding region Fterm Site strain region The sequence analysis indicated several unique amino acid changes throughout the coding region of Mochizuki strain, mostly in envelope (E) protein. 26231935 1 22 part_of possessing 151:160 arg1 Acetylcholinesterase AND three conserved N-linked glycosylation sites Acetylcholinesterase three conserved N-linked glycosylation sites PUBTATOR Site Acetylcholinesterase 43 sites Acetylcholinesterase (AChE; EC 3.1.1.7) is a glycoprotein possessing three conserved N-linked glycosylation sites in mammalian species, locating at 296, 381, and 495 residues of the human sequence. 26231935 1 22 part_of possessing 151:160 arg1 a glycoprotein AND three conserved N-linked glycosylation sites a glycoprotein three conserved N-linked glycosylation sites Fterm Site glycoprotein sites Acetylcholinesterase (AChE; EC 3.1.1.7) is a glycoprotein possessing three conserved N-linked glycosylation sites in mammalian species, locating at 296, 381, and 495 residues of the human sequence. 17011210 8 34 gly N-glycosylation 1511:1525 arg2 all N-glycosylation sites all N-glycosylation sites sites In contrast, the C-terminal tagged genes and all N-glycosylation sites deleted gene failed to direct the secretion of functional hFasLECD. 16335806 4 44 part_of PRL 687:689 arg1 four domains PRL four domains PUBTATOR Site PRL 100481524 domains Six cysteine residues and 29 conserved residues distributed in four domains (PD1, PD2, PD3, and PD4) of PRL were observed. 25220145 11 2 gly CF-glycosylation 1863:1878 arg1 AFP-L3 AFP-L3 OGER AFP Q12899 For example, the CF-glycosylation of an α-fetoprotein isoform (AFP-L3) was approved as a biomarker of hepatocellular carcinoma (HCC). 25220145 11 2 gly CF-glycosylation 1863:1878 arg1 an α-fetoprotein isoform an α-fetoprotein isoform Fterm isoform For example, the CF-glycosylation of an α-fetoprotein isoform (AFP-L3) was approved as a biomarker of hepatocellular carcinoma (HCC). 16227249 2 110 gly glycosylation 263:275 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site While the prM protein of all WNV strains contains a single N-linked glycosylation site, not all strains contain an N-linked site in the E protein. 21672516 3 15 gly N-glycosylation 518:532 arg2 a signal peptide a signal peptide peptide The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site. 21672516 3 15 gly N-glycosylation 518:532 arg2 one putative N-glycosylation site one putative N-glycosylation site site The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site. 21672516 3 16 gly leucine-rich 467:478 arg1 LRR leucine LRR leucine The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site. 21672516 3 16 gly leucine-rich 467:478 arg1 21 leucine-rich repeat leucine 21 leucine-rich repeat leucine The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site. 21672516 3 36 gly has 399:401 arg1 The Podnl protein AND 21 leucine-rich repeat (LRR) motifs The Podnl protein a signal peptide 21 leucine-rich repeat (LRR) motifs Fterm Site protein peptide The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site. 19822741 0 10 gly Glycans 0:6 arg1 influenza hemagglutinin hemagglutinin Glycans Fterm hemagglutinin Glycans on influenza hemagglutinin affect receptor binding and immune response. 17660510 5 32 gly glycosylation 905:917 arg2 148 glycosylation sites 148 glycosylation sites sites Initial aqueous two-phase partitioning for membrane enrichment and single step strong cation exchange-based purification of glycopeptides resulted in identification of 148 glycosylation sites on 79 different protein species. 17660510 5 37 gly glycopeptides 857:869 arg2 glycopeptides glycopeptides glycopeptides Initial aqueous two-phase partitioning for membrane enrichment and single step strong cation exchange-based purification of glycopeptides resulted in identification of 148 glycosylation sites on 79 different protein species. 31826991 11 151 gly presence 1481:1488 arg1 the head region AND high-mannose glycan the head region high-mannose glycan region Since SP-D affinity for influenza HA depends on the presence of high-mannose glycan on the head region, our data demonstrate that SP-D may not protect against virus containing these HA subtypes. 31173582 8 40 gly glycosylation 1051:1063 arg2 A key glycosylation site A key glycosylation site site A key glycosylation site, α1(I) Lys-87, was underglycosylated while other sites were mostly overglycosylated in KO. 31173582 8 40 gly glycosylation 1051:1063 arg2 α1(I) Lys-87 α1(I) Lys-87 Lys-87 A key glycosylation site, α1(I) Lys-87, was underglycosylated while other sites were mostly overglycosylated in KO. 31173582 8 60 gly underglycosylated 1089:1105 arg1 A key glycosylation site A key glycosylation site site A key glycosylation site, α1(I) Lys-87, was underglycosylated while other sites were mostly overglycosylated in KO. 31173582 8 60 gly underglycosylated 1089:1105 arg1 α1(I) Lys-87 α1(I) Lys-87 Lys-87 A key glycosylation site, α1(I) Lys-87, was underglycosylated while other sites were mostly overglycosylated in KO. 31173582 8 67 gly overglycosylated 1137:1152 arg2 other sites sites sites A key glycosylation site, α1(I) Lys-87, was underglycosylated while other sites were mostly overglycosylated in KO. 26784534 5 39 part_of sites 654:658 arg1 VWF VWF sites PUBTATOR Site VWF 7450 sites RESULTS: We found that all 10 predicted O-glycosylation sites in VWF are occupied. 6604728 0 30 gly sites 70:74 arg1 Stable oligosaccharide microheterogeneity sites Stable oligosaccharide microheterogeneity sites Stable oligosaccharide microheterogeneity at individual glycosylation sites of a murine major histocompatibility antigen derived from a B-cell lymphoma. 6604728 0 43 gly glycosylation 56:68 arg2 individual glycosylation sites individual glycosylation sites sites Stable oligosaccharide microheterogeneity at individual glycosylation sites of a murine major histocompatibility antigen derived from a B-cell lymphoma. 19763269 10 60 gly sequence 1946:1953 arg1 potential glycan shifts sequence potential glycan shifts sequence Together the findings argue that a single mutational pathway is not sufficient to confer escape in early subtype C HIV-1 infection, and support a model in which multiple strategies, including potential glycan shifts, direct alteration of an epitope sequence, and cooperative Env domain conformational masking, are used to evade neutralization. 29891966 6 43 gly N-glycosylation 720:734 arg2 a highly conserved N-glycosylation site a highly conserved N-glycosylation site site In particular, we identified a highly conserved N-glycosylation site in the Ea-domain, which regulated intracellular proIGF-1Ea level preventing its proteasome-mediated degradation. 12527193 8 61 part_of have 1162:1165 arg1 Mouse and human CRB3 AND identical intracellular domains CRB3 domains PUBTATOR Site CRB3 92359 domains Mouse and human CRB3 have identical intracellular domains but divergent extracellular domains except for a conserved N-glycosylation site. 23001782 4 5 part_of sites 684:688 arg1 intact hSHBG hSHBG sites PUBTATOR Site hSHBG 6462 sites MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG. 23001782 4 91 part_of hSHBG 832:836 arg1 glycosylation sites hSHBG glycosylation sites PUBTATOR Site hSHBG 6462 sites MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG. 16118277 7 38 part_of HA 1198:1199 arg1 specific HA residues HA specific HA residues Cterm Site HA residues This observation indicates that specific HA residues, such as N223, increase the sensitivity of the HI assay by altering receptor specificity and/or antibody-antigen binding. 16118277 7 38 part_of HA 1198:1199 arg1 N223 HA N223 Cterm SpecificSite HA N223 This observation indicates that specific HA residues, such as N223, increase the sensitivity of the HI assay by altering receptor specificity and/or antibody-antigen binding. 21303814 2 54 part_of glycoproteins 501:513 arg1 the luminal extreme C-terminal residues glycoproteins the luminal extreme C-terminal residues Fterm Site glycoproteins residues Here, we describe the efficient utilization of an N-glycosylation site engineered within the luminal extreme C-terminal residues of distinct integral membrane glycoproteins, a native ER resident protein and an engineered secreted protein. 29867209 7 25 gly O-glycosylation 1049:1063 arg2 an engineered O-glycosylation site an engineered O-glycosylation site site Therefore we present an alternative method for the synthesis of active glycosylated EPO with an engineered O-glycosylation site by combining eukaryotic cell-free protein synthesis and site-directed incorporation of non-canonical amino acids with subsequent chemoselective modifications. 29867209 7 40 gly glycosylated 1013:1024 arg1 active glycosylated EPO active glycosylated EPO PUBTATOR EPO 2056 Therefore we present an alternative method for the synthesis of active glycosylated EPO with an engineered O-glycosylation site by combining eukaryotic cell-free protein synthesis and site-directed incorporation of non-canonical amino acids with subsequent chemoselective modifications. 22997027 5 4 gly glycopeptides 959:971 arg2 glycopeptides glycopeptides glycopeptides This is due to low proportions of glycopeptides in comparison to peptides obtained after glycoprotein digestion, the suppression of the glycopeptide MS signals in the presence of peptides, and the high heterogeneity of glycopeptides. 22997027 5 31 gly glycopeptides 774:786 arg2 glycopeptides glycopeptides glycopeptides This is due to low proportions of glycopeptides in comparison to peptides obtained after glycoprotein digestion, the suppression of the glycopeptide MS signals in the presence of peptides, and the high heterogeneity of glycopeptides. 22997027 5 40 gly glycoprotein 829:840 arg1 glycoprotein digestion glycoprotein digestion Fterm glycoprotein This is due to low proportions of glycopeptides in comparison to peptides obtained after glycoprotein digestion, the suppression of the glycopeptide MS signals in the presence of peptides, and the high heterogeneity of glycopeptides. 22997027 5 63 gly glycopeptide 876:887 arg2 glycopeptide glycopeptide glycopeptide This is due to low proportions of glycopeptides in comparison to peptides obtained after glycoprotein digestion, the suppression of the glycopeptide MS signals in the presence of peptides, and the high heterogeneity of glycopeptides. 22997027 5 69 gly heterogeneity 942:954 arg1 glycopeptides glycopeptides glycopeptides This is due to low proportions of glycopeptides in comparison to peptides obtained after glycoprotein digestion, the suppression of the glycopeptide MS signals in the presence of peptides, and the high heterogeneity of glycopeptides. 32109505 6 11 gly glycosylation 765:777 arg1 TRPM8 TRPM8 PUBTATOR TRPM8 79054 The glycosylation state of TRPM8 in cells untreated and treated with a deglycosylating agent was addressed with Terahertz (THz) spectroscopy. 21637915 5 19 part_of emp 618:620 arg1 Only the second peptide emp#2 Only the second peptide PUBTATOR Site emp#2 2013 peptide Only the second peptide (emp#2), which contains a putative N-glycosylation site sequence, inhibited emmprin-stimulated production of MMP-2 in co-cultures of fibroblasts and several different human tumor cells types, including carcinoma, sarcoma, melanoma, leukemia and glioma cells. 21637915 5 60 part_of contains 632:639 arg1 emp#2 AND a putative N-glycosylation site sequence emp#2 site sequence PUBTATOR Site emp#2 2013 site sequence Only the second peptide (emp#2), which contains a putative N-glycosylation site sequence, inhibited emmprin-stimulated production of MMP-2 in co-cultures of fibroblasts and several different human tumor cells types, including carcinoma, sarcoma, melanoma, leukemia and glioma cells. 23562646 13 60 gly N-glycosylation 2239:2253 arg1 hPIV-3 HN hPIV-3 HN Cterm hPIV-3 HN Taken together, these results indicated that N-glycosylation of hPIV-3 HN is critical to its receptor recognition activity, cleavage of the F protein, and fusion promotion activity, but had no influence on its interaction with the homologous F protein and NA activity. 20235580 5 78 gly glycoproteins 1176:1188 arg1 identified glycoproteins identified glycoproteins Fterm glycoproteins Depleting the plasma of 14 high abundance proteins improved detection sensitivity by approximately 1 order of magnitude compared to nondepleted plasma and resulted in an increase of 24% in the number of identified glycoproteins. 3882692 1 33 part_of lymphotoxin 116:126 arg1 The amino acid sequence lymphotoxin The amino acid sequence Fterm Site lymphotoxin sequence The amino acid sequence of human lymphotoxin derived from a 1788 lymphoblastoid cell line was determined. 17011210 6 7 gly N-glycosylation 1220:1234 arg2 either single or double N-glycosylation sites either single or double N-glycosylation sites sites The secretion of functional hFasLECD was retained after the N-terminal tagging and the deletion of either single or double N-glycosylation sites. 17011210 6 78 gly sites 1236:1240 arg1 the N-terminal tagging sites the N-terminal tagging sites The secretion of functional hFasLECD was retained after the N-terminal tagging and the deletion of either single or double N-glycosylation sites. 16372382 7 45 gly glycopeptides 1370:1382 arg2 the glycopeptides the glycopeptides glycopeptides The mixture of peptides and glycopeptides was subjected to RP-HPLC and the structures of the glycopeptides were determined by MALDI in conjunction with on-target exoglycosidase digestions. 16372382 7 119 gly glycopeptides 1305:1317 arg2 glycopeptides glycopeptides glycopeptides The mixture of peptides and glycopeptides was subjected to RP-HPLC and the structures of the glycopeptides were determined by MALDI in conjunction with on-target exoglycosidase digestions. 2318516 3 111 gly glycoproteins 645:657 arg1 the endogenous HLA-B5 glycoproteins the endogenous HLA-B5 glycoproteins Fterm glycoproteins We have previously shown that the products of human class I genes introduced into T2 by transfection behave like the endogenous HLA-B5 glycoproteins, while the products of mouse class I alleles similarly introduced are transported normally to the cell surface. 20209506 6 62 gly glycoprotein 1470:1481 arg1 complex glycoprotein samples complex glycoprotein samples Fterm glycoprotein Further exploration of the complementary nature of RP and HILIC stationary phases for glycopeptide isolation prior to MS analysis may eventually enable systematic analysis of complex glycoprotein samples in functional proteomic research and advance our understanding of the biological role of protein glycosylation. 20209506 6 88 gly glycopeptide 1373:1384 arg2 glycopeptide isolation glycopeptide isolation glycopeptide Further exploration of the complementary nature of RP and HILIC stationary phases for glycopeptide isolation prior to MS analysis may eventually enable systematic analysis of complex glycoprotein samples in functional proteomic research and advance our understanding of the biological role of protein glycosylation. 15135404 8 63 gly N-glycosylation 1070:1084 arg2 one N-glycosylation site one N-glycosylation site site, position Each monomer had one N-glycosylation site, positioned at the same site as for h-SAP. 8783018 0 48 gly glycosylated 39:50 arg1 glycosylated interferon-gamma variants glycosylated interferon-gamma variants PUBTATOR interferon-gamma variants 3458 Mass spectrometric characterization of glycosylated interferon-gamma variants separated by gel electrophoresis. 12911333 4 50 gly N-glycosylation 579:593 arg2 their N-glycosylation sites their N-glycosylation sites sites Kv1 channel S1-S2 linkers vary in length but their N-glycosylation sites are at similar relative positions from the S1 or S2 membrane domains. 24501222 6 2 part_of HRG 1004:1006 arg1 the N2 domain HRG the N2 domain PUBTATOR Site HRG P04196 domain Here, we present a 1.93 Å resolution crystal structure of the N2 domain of serum-purified rabbit HRG. 10992007 6 49 gly glycosylation 1167:1179 arg2 many glycosylation sites many glycosylation sites sites The next series of the mutants was therefore constructed to identify at least how many glycosylation sites are necessary. 9203958 7 65 part_of IgA 945:947 arg1 the deduced amino acid sequence IgA the deduced amino acid sequence OGER Site IgA P11912 sequence Comparison of the deduced amino acid sequence of bovine IgA with sequences available for other species indicated that the highest homology was with that of swine, another artiodactyl. 8509412 0 81 gly glycosylation 99:111 arg2 an asparagine-linked glycosylation site an asparagine-linked glycosylation site site A region of the C-terminal portion of the human transferrin receptor contains an asparagine-linked glycosylation site critical for receptor structure and function. 30011186 6 75 gly glycoproteins 1037:1049 arg1 many glycoproteins many glycoproteins Fterm glycoproteins Although the emergence of MS-based proteomics has provided a great opportunity to analyze glycoproteins globally, the low abundance of many glycoproteins and the heterogeneity of glycans dramatically increase the technical difficulties. 30011186 6 94 gly glycoproteins 987:999 arg1 glycoproteins glycoproteins Fterm glycoproteins Although the emergence of MS-based proteomics has provided a great opportunity to analyze glycoproteins globally, the low abundance of many glycoproteins and the heterogeneity of glycans dramatically increase the technical difficulties. 30011186 6 169 gly heterogeneity 1059:1071 arg1 many glycoproteins glycoproteins glycans Fterm glycoproteins Although the emergence of MS-based proteomics has provided a great opportunity to analyze glycoproteins globally, the low abundance of many glycoproteins and the heterogeneity of glycans dramatically increase the technical difficulties. 12626422 1 9 gly glycosylation 284:296 arg1 glycoproteins glycoproteins Fterm glycoproteins Conditions under which the glycosylation capacity of cells is limited provide an opportunity for studying the efficiency of site-specific glycosylation and the role of glycosylation in the maturation of glycoproteins. 12626422 1 68 gly glycoproteins 319:331 arg1 glycoproteins glycoproteins Fterm glycoproteins Conditions under which the glycosylation capacity of cells is limited provide an opportunity for studying the efficiency of site-specific glycosylation and the role of glycosylation in the maturation of glycoproteins. 26018173 2 112 gly epitopes 459:466 arg1 the glycans epitopes the glycans epitopes Extensive Env glycosylation provides HIV-1 with protection from the immune system, yet the glycans are also essential components of binding epitopes for numerous broadly neutralizing antibodies. 31184281 12 81 gly glycosylation 2013:2025 arg2 one less glycosylation site one less glycosylation site site The mouse TSHR A-subunit differs from the human TSHR A-subunit in terms of its amino acid sequence and has one less glycosylation site than the human TSHR A-subunit. 2143269 0 3 part_of Fc 66:67 arg1 the Fc fragment structure of the Fc the Fc fragment Cterm Site structure of the Fc fragment Proton nuclear magnetic resonance studies of the structure of the Fc fragment of human immunoglobulin G1: comparisons of native and recombinant proteins. 2143269 0 14 part_of G1 102:103 arg1 the Fc fragment immunoglobulin G1 the Fc fragment Cterm Site immunoglobulin G1 fragment Proton nuclear magnetic resonance studies of the structure of the Fc fragment of human immunoglobulin G1: comparisons of native and recombinant proteins. 7980452 6 46 gly N-glycosylation 1061:1075 arg2 the N-glycosylation site mutants the N-glycosylation site mutants site The Wt and the N-glycosylation site mutants were all secreted as dimers. 18930737 11 24 part_of PIP 1489:1491 arg1 alpha1-alpha2 domains PIP alpha1-alpha2 domains PUBTATOR Site PIP 5304 domains On the perpendicular interface involving alpha1-alpha2 domains of ZAG and a loop of PIP, another salt bridge is formed. 18930737 11 76 part_of ZAG 1471:1473 arg1 alpha1-alpha2 domains ZAG alpha1-alpha2 domains PUBTATOR Site ZAG 563 domains On the perpendicular interface involving alpha1-alpha2 domains of ZAG and a loop of PIP, another salt bridge is formed. 30094950 5 10 gly observed 847:854 arg2 four proteins AND changed expression levels four proteins changed expression levels Fterm proteins Their findings indicate glycopeptides with changed expression levels and the presence of altered glycan forms observed in four proteins derived from OSCC patients' sera. 30094950 5 39 gly forms 841:845 arg1 the presence proteins the presence Fterm proteins Their findings indicate glycopeptides with changed expression levels and the presence of altered glycan forms observed in four proteins derived from OSCC patients' sera. 30094950 5 39 gly forms 841:845 arg1 changed expression levels proteins changed expression levels Fterm proteins Their findings indicate glycopeptides with changed expression levels and the presence of altered glycan forms observed in four proteins derived from OSCC patients' sera. 30094950 5 71 gly glycopeptides 761:773 arg2 glycopeptides glycopeptides the presence glycopeptides Their findings indicate glycopeptides with changed expression levels and the presence of altered glycan forms observed in four proteins derived from OSCC patients' sera. 30094950 5 71 gly glycopeptides 761:773 arg2 glycopeptides glycopeptides changed expression levels glycopeptides Their findings indicate glycopeptides with changed expression levels and the presence of altered glycan forms observed in four proteins derived from OSCC patients' sera. 20589319 7 15 part_of gamma-chain 1729:1739 arg1 the fibrinogen gamma-chain C-terminal tail fibrinogen gamma-chain the fibrinogen gamma-chain C-terminal tail OGER Site fibrinogen gamma-chain P02679 tail Finally, the results of this study and our previous reports demonstrate that the fibrinogen gamma-chain C-terminal tail (388-411) is not necessary for protein assembly or secretion, but the aberrant amino acid sequence observed in the M-VII variant (especially 391-398) disturbs these functions. 20589319 7 46 part_of observed 1856:1863 arg2 the M-VII variant AND the aberrant amino acid sequence the M-VII variant the aberrant amino acid sequence Fterm Site variant sequence Finally, the results of this study and our previous reports demonstrate that the fibrinogen gamma-chain C-terminal tail (388-411) is not necessary for protein assembly or secretion, but the aberrant amino acid sequence observed in the M-VII variant (especially 391-398) disturbs these functions. 20589319 7 63 part_of fibrinogen 1718:1727 arg1 the fibrinogen gamma-chain C-terminal tail fibrinogen gamma-chain the fibrinogen gamma-chain C-terminal tail OGER Site fibrinogen gamma-chain P02679 tail Finally, the results of this study and our previous reports demonstrate that the fibrinogen gamma-chain C-terminal tail (388-411) is not necessary for protein assembly or secretion, but the aberrant amino acid sequence observed in the M-VII variant (especially 391-398) disturbs these functions. 26070719 5 28 gly glycoprotein 924:935 arg1 glycoprotein glycoprotein Fterm glycoprotein In this review, we discuss recent advances in glycoprotein and glycopeptide analysis, with topics covering sample preparation, analytical separation, MS and tandem MS techniques, as well as data interpretation and automation. 26070719 5 34 gly glycopeptide 941:952 arg2 glycopeptide analysis glycopeptide analysis glycopeptide In this review, we discuss recent advances in glycoprotein and glycopeptide analysis, with topics covering sample preparation, analytical separation, MS and tandem MS techniques, as well as data interpretation and automation. 20378933 9 20 gly N58 1411:1413 arg1 desialylation N58 desialylation N58 Furthermore, increased IgA binding was also observed on desialylated FcalphaR after neuraminidase treatment and desialylation of N58 contributed most to the increased IgA binding. 20378933 9 69 gly desialylation 1394:1406 arg1 N58 IgA N58 OGER IgA P11912 N58 Furthermore, increased IgA binding was also observed on desialylated FcalphaR after neuraminidase treatment and desialylation of N58 contributed most to the increased IgA binding. 25945896 8 96 gly glycosite 1415:1423 arg2 each glycosite each glycosite glycosite The glycan occupying each glycosite was determined by matching the mass difference between the precursor ion of intact glycopeptide and the glycosite-containing peptide to a glycan database. 25945896 8 120 gly glycopeptide 1508:1519 arg2 intact glycopeptide intact glycopeptide glycopeptide The glycan occupying each glycosite was determined by matching the mass difference between the precursor ion of intact glycopeptide and the glycosite-containing peptide to a glycan database. 8355714 8 51 gly glycosylation 1334:1346 arg2 glycosylation site glycosylation site site The data suggest that a structural feature of FGF3 involving the amino-terminal region and glycosylation site has a significant bearing on its passage through the Golgi complex and may regulate the secretion of the ligand. 16567801 2 82 gly glycosylation 767:779 arg2 the glycosylation site occupancy the glycosylation site occupancy site Using a sensitive approach that combines in-gel glycosidase and protease digestions, permethylation of released glycans, and mass spectrometry, we have elucidated for the first time the native glycoform structures of the mouse UPIa receptor and those of its non-binding homolog, UPIb, and have determined the glycosylation site occupancy. 26641950 11 18 gly glycoprotein 1744:1755 arg1 intact glycoprotein species intact glycoprotein species Fterm glycoprotein We demonstrate that high resolution CZE separation of intact glycoprotein species coupled to MS has significant potential for the in-depth characterization and quantitative analysis of biopharmaceutical proteoforms. 8442916 5 40 part_of PCR 709:711 arg1 PCR fragments PCR PCR fragments Cterm Site PCR fragments PCR fragments were cloned and sequenced and a phylogenetic tree constructed. 12610728 2 13 part_of mRNA 378:381 arg1 the 5'-untranslated region cathepsin B mRNA the 5'-untranslated region PUBTATOR Site cathepsin B mRNA 1508 region To investigate the roles of the alternatively spliced exons 2 and 3 in the 5'-untranslated region of cathepsin B mRNA we produced constructs of cathepsin B fused to green fluorescent protein. 11251288 0 56 gly glycosylation 19:31 arg1 recombinant proteins recombinant proteins Fterm proteins Selective in vitro glycosylation of recombinant proteins: semi-synthesis of novel homogeneous glycoforms of human erythropoietin. 11251288 0 108 gly glycoforms 94:103 arg1 human erythropoietin human erythropoietin PUBTATOR erythropoietin 2056 Selective in vitro glycosylation of recombinant proteins: semi-synthesis of novel homogeneous glycoforms of human erythropoietin. 24164424 10 80 gly glycosylation 1573:1585 arg2 the glycosylation site the glycosylation site site Relocating the glycosylation site in CNGA1 to the position found in CNGA3 recapitulated CNGA3-like protection from MMP-dependent processing. 1331508 7 52 gly N-glycosylation 1021:1035 arg2 N-glycosylation sites N-glycosylation sites sites In addition, a human PVR mutant without N-glycosylation sites in domain 1 also promoted viral infection. 25113421 3 47 gly glycoproteins 444:456 arg1 glycoproteins glycoproteins Fterm glycoproteins To reveal the biological functions of protein-linked glycans involved in numerous biological processes, the high-throughput identification of both glycoproteins and the attached glycan structures becomes fundamentally important. 11686319 0 61 gly glycosylation 26:38 arg2 an additional glycosylation site an additional glycosylation site site Creation of an additional glycosylation site as a mechanism for type I antithrombin deficiency. 21733886 0 9 gly Determinants 0:11 arg1 the envelope protein protein Determinants Fterm protein Determinants of attenuation in the envelope protein of the flavivirus Alfuy. 6300470 4 57 gly glycoproteins 511:523 arg1 The glycoproteins The glycoproteins Fterm glycoproteins The glycoproteins of the two viruses could be distinguished immunologically, by peptide mapping, and by size in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 12490395 5 85 gly glycosylation 933:945 arg2 a conserved N-linked glycosylation site a conserved N-linked glycosylation site site xcCAT1 cDNA encodes a protein with a single amino acid change that destroys a conserved N-linked glycosylation site proximal to the Env-binding motif. 10764840 6 19 part_of Epo-RPMI 979:986 arg1 the amino acid sequence Epo the amino acid sequence PUBTATOR Site Epo 2056 sequence As expected, the amino acid sequence of the Epo-RPMI conformed to that of uHuEpo. 26336134 2 12 gly glycoprotein 304:315 arg1 HRG HRG PUBTATOR HRG 3273 Significantly downregulated histidine-rich glycoprotein (HRG) during the dynamic stages (WB, WB7, and WB11) of neoplastic transformation of WB F344 hepatic oval-like cells was screened out by iTRAQ labeling followed by 2DLC-ESI-MS/MS analysis. 8107215 8 19 gly glycosylation 1192:1204 arg2 the Asn-67 glycosylation site the Asn-67 glycosylation site site Inactivation of the Asn-67 glycosylation site also reduced cell surface transport of mutant protein but had little effect on its ability to cause cell fusion. 1377692 4 98 part_of contains 464:471 arg1 The deduced amino acid sequence AND only one potential N-glycosylation site The deduced amino acid sequence only one potential N-glycosylation site site The deduced amino acid sequence contains only one potential N-glycosylation site located in the propeptide. 11390601 1 41 part_of sites 360:364 arg1 its gp120 subunit gp120 subunit sites PUBTATOR Site gp120 subunit 155971 sites The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is extensively glycosylated, containing approximately 23 asparagine (N)-linked glycosylation sites on its gp120 subunit. 32197300 6 2 gly glycoproteins 982:994 arg1 viral Env glycoproteins viral Env glycoproteins PUBTATOR Env glycoproteins 155971 Third, the N126K mutation did not interfere with the expression and processing of viral Env glycoproteins, but it disrupted the Asn126-based glycosylation site in gp41. 32197300 6 62 gly glycosylation 1031:1043 arg2 the Asn126-based glycosylation site the Asn126-based glycosylation site site Third, the N126K mutation did not interfere with the expression and processing of viral Env glycoproteins, but it disrupted the Asn126-based glycosylation site in gp41. 30578591 5 43 gly glycoproteins 906:918 arg1 functional glycoproteins functional glycoproteins Fterm glycoproteins The NA expressed in human cells has more complex glycans than that of insect cells, suggesting the importance of selecting an appropriate expression system for the production of functional glycoproteins. 8706738 17 1 gly N-deglycosylated 2013:2028 arg1 N-deglycosylated rGal-T N-deglycosylated rGal-T These data indicate that N-deglycosylated rGal-T was correctly folded, homogeneous and thus suitable for crystallization experiments. 23316195 7 28 part_of contains 1017:1024 arg1 The human PTX3 protein AND a single N-glycosylation site The human PTX3 protein a single N-glycosylation site OGER Site PTX3 protein P26022 site The human PTX3 protein contains a single N-glycosylation site that is fully occupied by complex type oligosaccharides, mainly fucosylated and sialylated biantennary glycans. 12765790 3 33 gly HNK-glycopeptides 664:680 arg2 HNK-glycopeptides HNK-glycopeptides PSA-glycopeptides, HNK-glycopeptides For characterization of N-glycan structures and attachment sites, PSA-NCAM was digested with trypsin, and the generated glycopeptides were fractionated by serial immunoaffinity chromatography using immobilized monoclonal antibodies specific for PSA or the HNK1 epitope, i.e., HSO(3)-3GlcA(beta 1-3)Gal(beta 1-4)GlcNAc(beta 1-, yielding PSA-glycopeptides, HNK-glycopeptides and non-PSA/HNK1-(glyco) peptides. 12765790 3 39 gly PSA-glycopeptides 645:661 arg2 PSA-glycopeptides PSA-glycopeptides PSA-glycopeptides, HNK-glycopeptides For characterization of N-glycan structures and attachment sites, PSA-NCAM was digested with trypsin, and the generated glycopeptides were fractionated by serial immunoaffinity chromatography using immobilized monoclonal antibodies specific for PSA or the HNK1 epitope, i.e., HSO(3)-3GlcA(beta 1-3)Gal(beta 1-4)GlcNAc(beta 1-, yielding PSA-glycopeptides, HNK-glycopeptides and non-PSA/HNK1-(glyco) peptides. 12765790 3 82 gly glycopeptides 429:441 arg2 the generated glycopeptides the generated glycopeptides glycopeptides For characterization of N-glycan structures and attachment sites, PSA-NCAM was digested with trypsin, and the generated glycopeptides were fractionated by serial immunoaffinity chromatography using immobilized monoclonal antibodies specific for PSA or the HNK1 epitope, i.e., HSO(3)-3GlcA(beta 1-3)Gal(beta 1-4)GlcNAc(beta 1-, yielding PSA-glycopeptides, HNK-glycopeptides and non-PSA/HNK1-(glyco) peptides. 16873272 0 15 gly glycoprotein 55:66 arg1 prototype foamy virus envelope glycoprotein prototype foamy virus envelope glycoprotein Fterm glycoprotein Characterization of the prototype foamy virus envelope glycoprotein receptor-binding domain. 25614584 0 25 part_of sites 48:52 arg1 the fusion protein protein sites Fterm Site protein sites Identification of conformational neutralization sites on the fusion protein of mumps virus. 12356334 5 10 gly glycosylation 780:792 arg1 the SP-B variant SP-B variant site, Asn129-Gln-Thr131 PUBTATOR SP-B variant 6439 site, Asn129-Gln-Thr131 The Thr131-->Ile substitution can eliminate a potential N-linked glycosylation site, Asn129-Gln-Thr131, which is present in the SP-B variant of the C allele (ACT/Thr) but not in that of the T allele (ATT/Ile). 12356334 5 10 gly glycosylation 780:792 arg2 a potential N-linked glycosylation site site, Asn129-Gln-Thr131 site, Asn129-Gln-Thr131 The Thr131-->Ile substitution can eliminate a potential N-linked glycosylation site, Asn129-Gln-Thr131, which is present in the SP-B variant of the C allele (ACT/Thr) but not in that of the T allele (ATT/Ile). 12356334 5 10 gly glycosylation 780:792 arg2 a potential N-linked glycosylation site SP-B variant site, Asn129-Gln-Thr131 PUBTATOR SP-B variant 6439 site, Asn129-Gln-Thr131 The Thr131-->Ile substitution can eliminate a potential N-linked glycosylation site, Asn129-Gln-Thr131, which is present in the SP-B variant of the C allele (ACT/Thr) but not in that of the T allele (ATT/Ile). 20844046 2 31 gly glycosylation 641:653 arg2 glycosylation site occupancy glycosylation site occupancy site Molecular strain typing of human prion diseases has focused extensively on differences in the fragment size and glycosylation site occupancy of the protease-resistant prion protein (PrP(res)) in conjunction with the presence of mutations and polymorphisms in the prion protein gene (PRNP). 20844046 2 21 gly occupancy 660:668 arg1 the protease-resistant prion protein protein site Fterm protein site Molecular strain typing of human prion diseases has focused extensively on differences in the fragment size and glycosylation site occupancy of the protease-resistant prion protein (PrP(res)) in conjunction with the presence of mutations and polymorphisms in the prion protein gene (PRNP). 29992770 3 77 gly N-glycopeptides 395:409 arg2 specific N-glycopeptides specific N-glycopeptides N-glycopeptides The authors aimed to use mass-spectrometry (MS) technology to find specific N-glycopeptides potentially serving as serum biomarkers for preclinical OSCC screening. 3121328 3 18 gly glycopeptides 540:552 arg2 Three glycopeptides Three glycopeptides glycopeptides Three glycopeptides were isolated and characterized by 1H-NMR, sugar determination, methylation analysis and amino acid determination. 2500441 5 54 gly glycosylation 835:847 arg2 No other glycosylation sites No other glycosylation sites sites No other glycosylation sites were found. 12372996 10 3 gly glycosylated 1249:1260 arg1 the glycosylated isoenzymes the glycosylated isoenzymes Fterm isoenzymes IgE antibodies in latex-positive sera chiefly recognized the glycosylated isoenzymes. 26598643 3 79 gly glycoproteins 445:457 arg1 many human blood plasma glycoproteins many human blood plasma glycoproteins Fterm glycoproteins In consequence, despite their clinical and biopharmaceutical importance, many human blood plasma glycoproteins have not been characterized comprehensively with respect to their O-glycosylation. 11485624 2 94 part_of gp120 467:471 arg1 other gp120 domains gp120 other gp120 domains PUBTATOR Site gp120 3700 domains Here, we determined whether N-linked glycans of other gp120 domains were also involved in protection of V3 neutralization epitopes. 19358553 4 30 gly sialoglycopeptides 1028:1045 arg1 fetuin fetuin sialoglycopeptides Fterm fetuin sialoglycopeptides Similarly, precise quantitation was observed for various forms of N-glycans (free, permethylated, and fluorescence-labeled) using MS. In addition, three different sialoglycopeptides from fetuin were site-specifically profiled, and good correlation between peak intensities and relative abundances was found with only a minor loss of sialic acids (r = 0.9664, n = 5). 9639536 8 76 gly glycopeptides 1430:1442 arg2 the five N-linked glycopeptides the five N-linked glycopeptides glycopeptides The analysis of OMD gave a pattern showing signal for the sialyl Lewis(x) antigen coeluting with each of the five N-linked glycopeptides. 25227423 6 22 gly N-glycosylation 1107:1121 arg2 an N-glycosylation site an N-glycosylation site site Fifteen of these residues occur within 10 Å of an N-glycosylation site. 21727639 5 14 part_of proteins 971:978 arg1 the N-glycosylation sites proteins the N-glycosylation sites Fterm Site proteins sites Changes were observed in the N-glycosylation sites of both surface proteins, along with the appearance of a new glycosylation site in the neuraminidase sequence isolated in 2007. 29109276 2 41 gly glycosylation 354:366 arg2 a new predicted glycosylation site a new predicted glycosylation site site During the 2014-2015 influenza season, clade 3C.2a H3N2 viruses possessing a new predicted glycosylation site in antigenic site B of HA emerged, and these viruses remain prevalent today. 1512415 4 40 part_of TSH-beta 627:634 arg1 the TSH-beta subunit glycosylation recognition sequence TSH-beta subunit sequence, Asn-Thr-Thr PUBTATOR Site TSH-beta subunit 7252 sequence, Asn-Thr-Thr Mutating the TSH-beta subunit glycosylation recognition sequence, Asn-Thr-Thr (codons 23-25), to either Gln-Thr-Thr or Asn-Thr-Tyr abolished subunit glycosylation, as demonstrated by the inability to incorporate 3H-carbohydrates. 1512415 4 81 part_of subunit 636:642 arg1 the TSH-beta subunit glycosylation recognition sequence TSH-beta subunit sequence, Asn-Thr-Thr PUBTATOR Site TSH-beta subunit 7252 sequence, Asn-Thr-Thr Mutating the TSH-beta subunit glycosylation recognition sequence, Asn-Thr-Thr (codons 23-25), to either Gln-Thr-Thr or Asn-Thr-Tyr abolished subunit glycosylation, as demonstrated by the inability to incorporate 3H-carbohydrates. 27567024 4 16 part_of site 465:468 arg1 EC-SOD EC-SOD site PUBTATOR Site EC-SOD 6649 site In this study, we found that the glycosylation site on EC-SOD is well conserved and that a glycosylation-deficient EC-SOD mutant retains its enzymatic activity, but is not secreted. 9114055 3 28 part_of has 531:533 arg1 The translated protein AND a potential N-linked glycosylation site The translated protein a potential N-linked glycosylation site Fterm Site protein site The translated protein has a calculated molecular mass of 18.2 kDa and a potential N-linked glycosylation site at amino acids 158-160, besides at least two O-linked glycosylation sites. 10713140 0 56 gly N-glycosylation 22:36 arg2 critical N-glycosylation sites critical N-glycosylation sites sites Mutations at critical N-glycosylation sites reduce tyrosinase activity by altering folding and quality control. 8176214 10 9 part_of IL-6R 1189:1193 arg1 the proteolytic cleavage site IL-6R the proteolytic cleavage site PUBTATOR Site IL-6R 3570 site It turned out that a potential N-glycosylation site close to the proteolytic cleavage site of the IL-6R is used. 19806925 8 19 part_of domain 1104:1109 arg1 the N-terminal region domain the N-terminal region region FcIRL contained a predicted N-terminal acetylation site (M1-K5) and a NADPH-binding motif (G10-G-T-G13-Y-I-G16) in the N-terminal region, a conserved NmrA (nitrogen metabolite repression regulator) domain (V6-N244), multi-phosphorylation sites and one conserved N-glycosylation site (N214). 19806925 8 72 part_of motif 990:994 arg1 the N-terminal region motif the N-terminal region region FcIRL contained a predicted N-terminal acetylation site (M1-K5) and a NADPH-binding motif (G10-G-T-G13-Y-I-G16) in the N-terminal region, a conserved NmrA (nitrogen metabolite repression regulator) domain (V6-N244), multi-phosphorylation sites and one conserved N-glycosylation site (N214). 28620050 6 21 gly glycosylation 1202:1214 arg2 an additional fully occupied N-linked glycosylation site an additional fully occupied N-linked glycosylation site site We also found that introduction of an additional fully occupied N-linked glycosylation site at the N terminus at position 1 (equivalent to Asp-221 in the Fc of IgG1) dramatically enhances overall sialic acid content of the Fc multimers. 28620050 6 21 gly glycosylation 1202:1214 arg2 the N terminus the N terminus terminus We also found that introduction of an additional fully occupied N-linked glycosylation site at the N terminus at position 1 (equivalent to Asp-221 in the Fc of IgG1) dramatically enhances overall sialic acid content of the Fc multimers. 8286855 1 61 part_of contains 184:191 arg1 The human red blood cell sialoglycoprotein AND a 'mucin-like' extensively O-glycosylated extracellular domain The human red blood cell sialoglycoprotein a 'mucin-like' extensively O-glycosylated extracellular domain Fterm Site sialoglycoprotein domain The human red blood cell sialoglycoprotein, glycophorin A (GpA), contains a 'mucin-like' extensively O-glycosylated extracellular domain which carries the MN blood group antigens. 8286855 1 61 part_of contains 184:191 arg1 glycophorin A AND a 'mucin-like' extensively O-glycosylated extracellular domain glycophorin A a 'mucin-like' extensively O-glycosylated extracellular domain PUBTATOR Site glycophorin A 2993 domain The human red blood cell sialoglycoprotein, glycophorin A (GpA), contains a 'mucin-like' extensively O-glycosylated extracellular domain which carries the MN blood group antigens. 12235182 1 3 gly glycosylation 155:167 arg1 apolipoprotein B apolipoprotein B PUBTATOR apolipoprotein B 54225 We determined the role of N-linked glycosylation of apolipoprotein B (apoB) in the assembly and secretion of lipoproteins using transfected rat hepatoma McA-RH7777 cells expressing human apoB-17, apoB-37, and apoB-50, three apoB variants with different ability to recruit neutral lipids. 12235182 1 3 gly glycosylation 155:167 arg1 apoB apoB PUBTATOR apoB 54225 We determined the role of N-linked glycosylation of apolipoprotein B (apoB) in the assembly and secretion of lipoproteins using transfected rat hepatoma McA-RH7777 cells expressing human apoB-17, apoB-37, and apoB-50, three apoB variants with different ability to recruit neutral lipids. 12235182 1 3 gly glycosylation 155:167 arg1 lipoproteins lipoproteins Fterm lipoproteins We determined the role of N-linked glycosylation of apolipoprotein B (apoB) in the assembly and secretion of lipoproteins using transfected rat hepatoma McA-RH7777 cells expressing human apoB-17, apoB-37, and apoB-50, three apoB variants with different ability to recruit neutral lipids. 22239659 7 0 gly glycopeptide 1591:1602 arg2 high-throughput semiautomated glycopeptide identification high-throughput semiautomated glycopeptide identification glycopeptide The optimized workflow, coupled with GlycoPeptideSearch, is expected to make high-throughput semiautomated glycopeptide identification feasible for a wide range of users. 22200957 5 7 part_of sites 992:996 arg1 the protein protein sites Fterm Site protein sites Bioinformatics analysis predicted several phosphorylation and myristoylation sites and a N-glycosylation site and a species-specific linear B epitope in the protein. 22200957 5 24 part_of site 1020:1023 arg1 the protein protein site Fterm Site protein site Bioinformatics analysis predicted several phosphorylation and myristoylation sites and a N-glycosylation site and a species-specific linear B epitope in the protein. 22200957 5 64 part_of epitope 1057:1063 arg1 the protein protein epitope Fterm Site protein epitope Bioinformatics analysis predicted several phosphorylation and myristoylation sites and a N-glycosylation site and a species-specific linear B epitope in the protein. 19065542 7 17 gly glycopeptide 1105:1116 arg2 the entire glycopeptide the entire glycopeptide glycopeptide When data acquired from both fragmentation techniques are combined, it is possible to characterize comprehensively the entire glycopeptide. 17640971 0 79 gly glycoforms 43:52 arg1 CD52 CD52 PUBTATOR CD52 1043 The sperm agglutination antigen-1 (SAGA-1) glycoforms of CD52 are O-glycosylated. 8980650 7 36 gly glycosylation 1318:1330 arg1 mitogenically active protein mitogenically active protein Fterm protein Our results suggest that N-linked glycosylation of the B-chain is not important for formation of mitogenically active protein, but that it plays a role in early intracellular sorting and proteolytic processing events. 8980650 7 36 gly glycosylation 1318:1330 arg1 the B-chain the B-chain Fterm B-chain Our results suggest that N-linked glycosylation of the B-chain is not important for formation of mitogenically active protein, but that it plays a role in early intracellular sorting and proteolytic processing events. 17134389 9 45 part_of contains 1617:1624 arg1 PIPP AND an N-glycosylation site PIPP an N-glycosylation site PUBTATOR Site PIPP 27124 site Furthermore, fusion of KDEL to the diabody derivative of PIPP, which contains an N-glycosylation site within the heavy chain variable domain, also resulted in a molecule lacking complex glycans. 12064867 1 1 gly glycoprotein 181:192 arg1 HIV-1 envelope glycoprotein gp120 HIV-1 envelope glycoprotein gp120 Fterm glycoprotein Several functions have been assigned to the extensive glycosylation of HIV-1 envelope glycoprotein gp120, especially immune escape mechanisms, but the intramolecular interactions between gp120 and its carbohydrate complement are not well understood. 12064867 1 43 gly glycosylation 149:161 arg1 HIV-1 envelope glycoprotein gp120 HIV-1 envelope glycoprotein gp120 PUBTATOR gp120 155971 Several functions have been assigned to the extensive glycosylation of HIV-1 envelope glycoprotein gp120, especially immune escape mechanisms, but the intramolecular interactions between gp120 and its carbohydrate complement are not well understood. 22180207 3 43 gly O-glycopeptides 573:587 arg2 mucin-like O-glycopeptides mucin-like O-glycopeptides O-glycopeptides The present work investigated β-elimination of mucin-like O-glycopeptides with a mild alkylamine base and concomitant Michael-type addition using 2-mercaptoethanol as nucleophile applied to synthetic GalNAcylated O-glycopeptides as well as exoglycosidase-treated endogenous peptides isolated from human blood plasma. 22180207 3 44 gly O-glycopeptides 728:742 arg2 synthetic GalNAcylated O-glycopeptides synthetic GalNAcylated O-glycopeptides O-glycopeptides The present work investigated β-elimination of mucin-like O-glycopeptides with a mild alkylamine base and concomitant Michael-type addition using 2-mercaptoethanol as nucleophile applied to synthetic GalNAcylated O-glycopeptides as well as exoglycosidase-treated endogenous peptides isolated from human blood plasma. 29632412 3 19 gly GlcNAc 962:967 arg1 murine IgGs IgG GlcNAc Cterm IgG By analyzing the IgG glycome composition of 95 CC strains, we made several important observations: (i) glycome variation between mouse strains was higher than between individual humans, despite all mice having the same environmental influences; (ii) five genetic loci were found to be associated with murine IgG glycosylation; (iii) variants outside traditional glycosylation site motifs affected glycome variation; (iv) bisecting N-acetylglucosamine (GlcNAc) was produced by several strains although most previous studies have reported the absence of glycans containing the bisecting GlcNAc on murine IgGs; and (v) common laboratory mouse strains are not optimal animal models for studying effects of glycosylation on IgG function. 29632412 3 35 gly glycosylation 1079:1091 arg1 IgG function IgG function Cterm IgG By analyzing the IgG glycome composition of 95 CC strains, we made several important observations: (i) glycome variation between mouse strains was higher than between individual humans, despite all mice having the same environmental influences; (ii) five genetic loci were found to be associated with murine IgG glycosylation; (iii) variants outside traditional glycosylation site motifs affected glycome variation; (iv) bisecting N-acetylglucosamine (GlcNAc) was produced by several strains although most previous studies have reported the absence of glycans containing the bisecting GlcNAc on murine IgGs; and (v) common laboratory mouse strains are not optimal animal models for studying effects of glycosylation on IgG function. 29632412 3 24 gly glycosylation 739:751 arg2 traditional glycosylation site motifs site motifs site motifs By analyzing the IgG glycome composition of 95 CC strains, we made several important observations: (i) glycome variation between mouse strains was higher than between individual humans, despite all mice having the same environmental influences; (ii) five genetic loci were found to be associated with murine IgG glycosylation; (iii) variants outside traditional glycosylation site motifs affected glycome variation; (iv) bisecting N-acetylglucosamine (GlcNAc) was produced by several strains although most previous studies have reported the absence of glycans containing the bisecting GlcNAc on murine IgGs; and (v) common laboratory mouse strains are not optimal animal models for studying effects of glycosylation on IgG function. 8636138 5 20 gly O-glycosylation 966:980 arg2 the O-glycosylation site the O-glycosylation site site Using mutational analysis we find that the glycosylation apparatus of COS7 cells can accommodate a broad range of changes in the flanking sequence without compromising glycosylation, but that the distribution of charged amino acids flanking the O-glycosylation site can have a profound influence on glycosylation with position -1 relative to the glycosylation site being particularly sensitive. 8636138 5 79 gly glycosylation 1067:1079 arg2 the glycosylation site the glycosylation site site Using mutational analysis we find that the glycosylation apparatus of COS7 cells can accommodate a broad range of changes in the flanking sequence without compromising glycosylation, but that the distribution of charged amino acids flanking the O-glycosylation site can have a profound influence on glycosylation with position -1 relative to the glycosylation site being particularly sensitive. 24338886 6 12 gly glycosylation 1324:1336 arg2 the orthogonal O-linked glycosylation site the orthogonal O-linked glycosylation site site In summary, the mass spectrometric analyses revealed that rhEPO derived from glycoengineered Pichia has a highly uniform bi-antennary N-linked glycan composition and preserves the orthogonal O-linked glycosylation site present on endogenous human EPO and CHO-derived rhEPO. 24338886 6 90 gly has 1224:1226 arg1 rhEPO AND a highly uniform bi-antennary N-linked glycan composition rhEPO a highly uniform bi-antennary N-linked glycan composition OGER rhEPO P29676 In summary, the mass spectrometric analyses revealed that rhEPO derived from glycoengineered Pichia has a highly uniform bi-antennary N-linked glycan composition and preserves the orthogonal O-linked glycosylation site present on endogenous human EPO and CHO-derived rhEPO. 2826671 2 8 part_of HindIII 252:258 arg1 a 1.8 kb HindIII fragment HindIII a 1.8 kb HindIII fragment Cterm Site HindIII fragment The gene was located on a 1.8 kb HindIII fragment and a 5.1 kb EcoRI fragment. 2826671 2 92 part_of EcoRI 282:286 arg1 a 5.1 kb EcoRI fragment EcoRI a 5.1 kb EcoRI fragment Cterm Site EcoRI fragment The gene was located on a 1.8 kb HindIII fragment and a 5.1 kb EcoRI fragment. 11231274 0 14 gly oligosaccharides 45:60 arg1 siglec-7 siglec-7 oligosaccharides OGER siglec-7 Q9Y286 A comparative study of the asparagine-linked oligosaccharides on siglec-5, siglec-7 and siglec-8, expressed in a CHO cell line, and their contribution to ligand recognition. 11231274 0 14 gly oligosaccharides 45:60 arg1 siglec-5 siglec-5 oligosaccharides OGER siglec-5 O15389 A comparative study of the asparagine-linked oligosaccharides on siglec-5, siglec-7 and siglec-8, expressed in a CHO cell line, and their contribution to ligand recognition. 11231274 0 14 gly oligosaccharides 45:60 arg1 siglec-8 siglec-8 oligosaccharides OGER siglec-8 Q9NYZ4 A comparative study of the asparagine-linked oligosaccharides on siglec-5, siglec-7 and siglec-8, expressed in a CHO cell line, and their contribution to ligand recognition. 11231274 0 40 gly asparagine-linked 27:43 arg1 the asparagine-linked oligosaccharides asparagine the asparagine-linked oligosaccharides asparagine A comparative study of the asparagine-linked oligosaccharides on siglec-5, siglec-7 and siglec-8, expressed in a CHO cell line, and their contribution to ligand recognition. 27927205 3 22 part_of Fc 512:513 arg1 IgG1 Fc fragments IgG1 Fc IgG1 Fc fragments OGER Site IgG1 Fc P01857 fragments Three different forms of IgG1 Fc fragments, including the wild type, aglycosylated homodimer and aglycosylated single chain, were each fused with IFN-α and designated as IFN-α/Fc-WT, IFN-α/Fc-MD, and IFN-α/Fc-SC, respectively. 11015576 1 1 gly glycoprotein 151:162 arg1 Fibroblast growth factor receptor 3 Fibroblast growth factor receptor 3 PUBTATOR Fibroblast growth factor receptor 3 2261 Fibroblast growth factor receptor 3 (FGFR3) is a glycoprotein that belongs to the family of tyrosine kinase receptors. 11015576 1 1 gly glycoprotein 151:162 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Fibroblast growth factor receptor 3 (FGFR3) is a glycoprotein that belongs to the family of tyrosine kinase receptors. 2787353 6 60 gly glycopeptide 1180:1191 arg2 the high mannose glycopeptide Man5GlcNAc2Asn the high mannose glycopeptide Man5GlcNAc2Asn glycopeptide The potential physiologic relevance of the carbohydrate binding activity is further elucidated by studies which show that 1) binding of soluble rIL-2 to immobilized uromodulin is enhanced at a pH of 4 to5 in the presence of divalent cations, and 2) neither uromodulin nor the high mannose glycopeptide Man5GlcNAc2Asn blocks the binding of rIL-2 to the IL-2R. 17960575 6 39 gly O-glycopeptide 836:849 arg2 an O-glycopeptide an O-glycopeptide O-glycopeptide Moreover, an O-glycopeptide carrying Gal-GalNAc at T(280) could be unambiguously identified. 17960575 6 61 gly carrying 851:858 arg1 an O-glycopeptide AND Gal-GalNAc an O-glycopeptide Gal-GalNAc O-glycopeptide Moreover, an O-glycopeptide carrying Gal-GalNAc at T(280) could be unambiguously identified. 10383441 7 47 gly residues 1358:1365 arg1 lysosomal enzymes enzymes residues Fterm enzymes Tyr54 and Ser190 are widely separated from each other and from Asn106 on the surface of DNase I, indicating that residues present over a broad area influence the interaction with UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase, which is responsible for the formation of mannose 6-phosphate residues on lysosomal enzymes. 8889821 6 72 gly glycosylation 1032:1044 arg2 N-linked glycosylation site N-linked glycosylation site site Sequencing revealed several putative sites phosphorylated by different types of protein kinases, but no signal sequence, transmembrane domain, N-linked glycosylation site or DNA-binding motif. 8357534 2 22 gly occupied 323:330 arg1 two N-glycosylation sites two N-glycosylation sites sites Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64). 8357534 2 45 gly N-glycosylation 301:315 arg2 two N-glycosylation sites two N-glycosylation sites sites Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64). 8357534 2 22 gly occupied 323:330 arg1 Asn-144 Asn-45 and Asn-144 Asn-45 and Asn-144 Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64). 8357534 2 45 gly N-glycosylation 301:315 arg2 Asn-45 Asn-45 and Asn-144 Asn-45 and Asn-144 Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64). 27966990 7 21 gly glycopeptides 1116:1128 arg2 glycopeptides glycopeptides glycopeptides MS/MS analyses of glycopeptides and deamidated, deglycosylated (PNGase F-treated) peptides from ectopically expressed VEGFR-2 in porcine aortic endothelial (PAE) cells identified N-glycans at the majority of the 17 potential N-glycosylation sites on VEGFR-2 in a site-specific manner. 27966990 7 38 gly N-glycosylation 1323:1337 arg2 the 17 potential N-glycosylation sites the 17 potential N-glycosylation sites sites MS/MS analyses of glycopeptides and deamidated, deglycosylated (PNGase F-treated) peptides from ectopically expressed VEGFR-2 in porcine aortic endothelial (PAE) cells identified N-glycans at the majority of the 17 potential N-glycosylation sites on VEGFR-2 in a site-specific manner. 27966990 7 25 gly deglycosylated 1146:1159 arg1 deamidated, deglycosylated (PNGase F-treated) peptides PNGase peptides PUBTATOR PNGase 59007 peptides MS/MS analyses of glycopeptides and deamidated, deglycosylated (PNGase F-treated) peptides from ectopically expressed VEGFR-2 in porcine aortic endothelial (PAE) cells identified N-glycans at the majority of the 17 potential N-glycosylation sites on VEGFR-2 in a site-specific manner. 25628020 3 27 part_of sites 556:560 arg1 91 proteins proteins sites Fterm Site proteins sites RESULTS: We analyzed the human glycoproteome data set (2,534 N-glycosylation sites in 1,027 proteins) and identified 112 novel N-glycosylation sites in 91 proteins that arose in the human lineage since the last common ancestor of Euarchonta (primates and treeshrews). 25628020 3 30 part_of sites 490:494 arg1 1,027 proteins proteins sites Fterm Site proteins sites RESULTS: We analyzed the human glycoproteome data set (2,534 N-glycosylation sites in 1,027 proteins) and identified 112 novel N-glycosylation sites in 91 proteins that arose in the human lineage since the last common ancestor of Euarchonta (primates and treeshrews). 28336547 3 78 gly N-glycosylation 491:505 arg2 the individual N-glycosylation site N50 site N50 site N50 Mutagenesis-induced disruption of the individual N-glycosylation site N50, which is highly conserved among mammals, was detected to significantly enhance the PEPT1-mediated inward transport of peptides. 16512686 4 22 gly glycopeptides 1191:1203 arg2 N-linked glycopeptides N-linked glycopeptides glycopeptides Because the N-linked glycans expressed on tryptic glycopeptides contribute substantially to their mass, we demonstrate that size exclusion chromatography (SEC) provided a significant enrichment of N-linked glycopeptides relative to nonglycosylated peptides. 16512686 4 100 gly nonglycosylated 1217:1231 arg1 nonglycosylated peptides nonglycosylated peptides peptides Because the N-linked glycans expressed on tryptic glycopeptides contribute substantially to their mass, we demonstrate that size exclusion chromatography (SEC) provided a significant enrichment of N-linked glycopeptides relative to nonglycosylated peptides. 16512686 4 103 gly glycopeptides 1035:1047 arg2 tryptic glycopeptides tryptic glycopeptides glycopeptides Because the N-linked glycans expressed on tryptic glycopeptides contribute substantially to their mass, we demonstrate that size exclusion chromatography (SEC) provided a significant enrichment of N-linked glycopeptides relative to nonglycosylated peptides. 9472610 7 43 gly glycosylation 1201:1213 arg2 an N-linked glycosylation site an N-linked glycosylation site site Comparison of the HIV-1 subpopulations in faeces and serum of these 7 persons, using resampling techniques, revealed a significant difference between faecal and serum subpopulations at an N-linked glycosylation site, C-terminal of the V3 loop (amino acids 331-333). 26683050 1 51 gly attached 191:198 arg1 a conserved N-glycosylation site AND glycans a conserved N-glycosylation site glycans site BACKGROUND: Immunoglobulin G (IgG) effector functions are regulated by the composition of glycans attached to a conserved N-glycosylation site in the Fc part. 26683050 1 90 gly N-glycosylation 215:229 arg2 a conserved N-glycosylation site a conserved N-glycosylation site site BACKGROUND: Immunoglobulin G (IgG) effector functions are regulated by the composition of glycans attached to a conserved N-glycosylation site in the Fc part. 8631761 7 34 gly fucosylated 1291:1301 arg1 the identically fucosylated and structurally related tissue plasminogen activator the identically fucosylated and structurally related tissue plasminogen activator OGER tissue plasminogen activator P00750 On the basis of these results, DSPAalpha1 is a suitable model for studying the influence of O-fucosylation on clearance rates, particularly in comparative studies with the identically fucosylated and structurally related tissue plasminogen activator. 17715132 6 17 gly glycosylation 788:800 arg1 Pannexin1 Pannexin1 PUBTATOR Pannexin1 24145 The glycosylation of Pannexin1 at its extracellular surface makes it unlikely that two oligomers could dock to form an intercellular channel. 17215147 4 4 gly glycosylation 422:434 arg2 A second conserved TRP channel glycosylation site A second conserved TRP channel glycosylation site site A second conserved TRP channel glycosylation site is found immediately adjacent to the channel pore-forming loop; both TRPV1 and TRPV4--and perhaps other TRPV family members--are influenced by glycosylation at this site. 10397812 2 67 gly N-glycosylation 265:279 arg1 recombinant human IFN-gamma recombinant human IFN-gamma PUBTATOR IFN-gamma 3458 Detailed analysis of the N-glycosylation of recombinant human IFN-gamma by matrix-assisted laser-desorption mass spectrometry showed that the protein secreted by Chinese hamster ovary and baculovirus-infected insect Sf9 cells was associated with complex sialylated or truncated tri-mannosyl core glycans, respectively. 10397812 2 117 gly sialylated 494:503 arg1 complex sialylated or truncated tri-mannosyl core glycans complex sialylated or truncated tri-mannosyl core glycans Detailed analysis of the N-glycosylation of recombinant human IFN-gamma by matrix-assisted laser-desorption mass spectrometry showed that the protein secreted by Chinese hamster ovary and baculovirus-infected insect Sf9 cells was associated with complex sialylated or truncated tri-mannosyl core glycans, respectively. 8189524 12 59 gly glycoprotein 1823:1834 arg1 the eighth PrV glycoprotein the eighth PrV glycoprotein Fterm glycoprotein In summary, we identified and characterized a novel structural PrV glycoprotein, gL, which represents the eighth PrV glycoprotein described. 8189524 12 76 gly glycoprotein 1773:1784 arg1 a novel structural PrV glycoprotein a novel structural PrV glycoprotein Fterm glycoprotein In summary, we identified and characterized a novel structural PrV glycoprotein, gL, which represents the eighth PrV glycoprotein described. 10712595 9 2 gly have 1629:1632 arg1 Salmon antithrombin AND three complex oligosaccharide side chains Salmon antithrombin three complex oligosaccharide side chains PUBTATOR antithrombin 462 Salmon antithrombin appears to have three complex oligosaccharide side chains containing sialic acid terminally linked alpha(2-3) to galactose, while trace amounts of Galbeta(1-4)GlcNAc suggest microheterogeneity due to partial loss of sialic acid. 14711516 3 43 gly glycosylation 672:684 arg2 the sites the sites sites The novel isoform of Thy-1 differs from the previously reported chicken isoform by eight amino acid residues, but these changes do not alter the secondary structure content, the disulfide bond pattern, or the sites of glycosylation. 15215246 3 56 gly N-glycosylation 556:570 arg2 a single N-glycosylation site a single N-glycosylation site site This protein has a molecular mass of about 30 kDa because of the presence of a single N-glycosylation site, which is reduced to 26 kDa after N-glycosidase treatment. 26161579 8 2 gly N-glycosylation 1259:1273 arg2 scale N-glycosylation sites scale N-glycosylation sites sites Compared to deglycosylation with endoglycosidase, this strategy is more convenient and efficient for large scale N-glycosylation sites identification and provides an important alternative approach for the study of N-glycoprotein function. 26161579 8 52 gly N-glycoprotein 1360:1373 arg1 N-glycoprotein function N-glycoprotein function Fterm N-glycoprotein Compared to deglycosylation with endoglycosidase, this strategy is more convenient and efficient for large scale N-glycosylation sites identification and provides an important alternative approach for the study of N-glycoprotein function. 25422509 1 14 gly glycosylation 167:179 arg2 five glycosylation sites five glycosylation sites sites Human serum IgM Abs are composed of heavily glycosylated polymers with five glycosylation sites on the μ (heavy) chain and one glycosylation site on the J chain. 25422509 1 26 gly glycosylation 218:230 arg2 one glycosylation site one glycosylation site site Human serum IgM Abs are composed of heavily glycosylated polymers with five glycosylation sites on the μ (heavy) chain and one glycosylation site on the J chain. 7527739 9 69 part_of protein 1734:1740 arg1 the two major linear antigenic regions protein the two major linear antigenic regions Fterm Site protein regions In a material of 114 confirmed anti-HCV positive sera, derived from patients during the acute or the chronic phase of HCV infection, the prevalence of antibodies to the two major linear antigenic regions of the e2 protein was found to be 55% among HCV RNA-positive sera, and 53% among HCV RNA-negative sera. 8347587 14 49 gly glycosylation 1716:1728 arg1 specific sites insulin receptor sites PUBTATOR insulin receptor P01308 sites Therefore, N-linked glycosylation of the insulin receptor at specific sites has multiple distinctive roles. 8347587 14 49 gly glycosylation 1716:1728 arg2 specific sites insulin receptor sites PUBTATOR insulin receptor P01308 sites Therefore, N-linked glycosylation of the insulin receptor at specific sites has multiple distinctive roles. 8347587 14 49 gly glycosylation 1716:1728 arg2 specific sites sites sites Therefore, N-linked glycosylation of the insulin receptor at specific sites has multiple distinctive roles. 22823882 8 21 gly glycoproteins 1257:1269 arg1 2556 glycoproteins 2556 glycoproteins Fterm glycoproteins In total, 5060 peptides derived from 2556 glycoproteins were identified. 27140194 4 11 gly glycopeptides 706:718 arg2 intact glycopeptides intact glycopeptides glycopeptides Recently, significant improvements have been made in the characterization of intact glycopeptides, ranging from enrichment and separation, mass spectroscopy (MS) detection, to bioinformatics analysis. 8107215 2 97 gly glycosylation 373:385 arg2 three potential N-linked glycosylation sites three potential N-linked glycosylation sites sites There are three potential N-linked glycosylation sites located on the F2 subunit polypeptide of MV F, at asparagine residues 29, 61, and 67. 9757569 2 26 gly glycosylated 391:402 arg1 S14N angiotensinogen S14N angiotensinogen Asn14 PUBTATOR S14N angiotensinogen P01019 Asn14 The molecular weight was about 3,000 larger than that of wild-type ovine angiotensinogen, indicating that S14N angiotensinogen was glycosylated at Asn14. 27743357 0 29 part_of IgG 28:30 arg1 IgG Fc Glycopeptides IgG IgG Fc Glycopeptides Cterm Site IgG Glycopeptides High-Throughput Analysis of IgG Fc Glycopeptides by LC-MS. 11428934 8 58 gly glycosylation 1224:1236 arg2 the Asn-Xaa-Thr glycosylation sites the Asn-Xaa-Thr glycosylation sites sites The presence in 1 of a low populated Asx-turn conformation characteristic of the Asn-Xaa-Thr glycosylation sites was the only conformational difference between peptides 1 and 2. 21698149 7 44 part_of env 1235:1237 arg1 the env V1-C4 env the env V1-C4 PUBTATOR SiteSequence env 155971 V1-C4 Signature amino acids within the constant domains of the env V1-C4 were identified for heterosexually transmitted HIV-1B from Trinidad relative to HIV-1B globally. 2307850 3 76 gly glycosylation 466:478 arg2 one glycosylation site one glycosylation site site The open reading frame translates into a protein of 248 amino acids that has one glycosylation site. 31611356 2 61 gly glycosylation 332:344 arg2 N295 N295 N295 A key factor for Grft potency is glycosylation at N295 of gp120, which is directly adjacent to N332, a target glycan for an entire class of broadly neutralizing antibodies (bNAbs). 9393962 4 25 gly glycosylation 419:431 arg2 residues 471-473 residues 471-473 residues 471-473 A region of the CH3 domain that is unique to IgG3 antibodies is the presence of an extra glycosylation site at residues 471-473. 9393962 4 25 gly glycosylation 419:431 arg2 an extra glycosylation site an extra glycosylation site site A region of the CH3 domain that is unique to IgG3 antibodies is the presence of an extra glycosylation site at residues 471-473. 9832151 5 47 gly glycosylation 767:779 arg2 each glycosylation site each glycosylation site site Mutation of each glycosylation site caused a minor and additive decrease in activity, up to the triple mutant, which retained at least 50% of the wild-type activity. 15650433 3 4 gly motifs 888:893 arg1 two late (L) domain motifs two late (L) domain motifs motifs Analysis of this sequence reveals that SIVcpzGAB2 is a member of the SIVcpzPtt group of viruses, but that it differs from other SIVcpzPtt strains by exhibiting a highly divergent Env V3 loop with an unusual crown (NLSPGTT) containing a canonical N-linked glycosylation site, an unpaired cysteine residue in Env V4, and two late (L) domain motifs (PTAP and YPSL) in Gag p6. 15650433 3 66 gly glycosylation 804:816 arg2 a canonical N-linked glycosylation site a canonical N-linked glycosylation site site Analysis of this sequence reveals that SIVcpzGAB2 is a member of the SIVcpzPtt group of viruses, but that it differs from other SIVcpzPtt strains by exhibiting a highly divergent Env V3 loop with an unusual crown (NLSPGTT) containing a canonical N-linked glycosylation site, an unpaired cysteine residue in Env V4, and two late (L) domain motifs (PTAP and YPSL) in Gag p6. 18712764 2 15 gly glycosylation 693:705 arg2 glycosylation site underoccupancy glycosylation site underoccupancy site The procedure was found feasible for the investigation of protein macroheterogeneity due to glycosylation site underoccupancy then ensuing the characterization of patients with CDG group I (N-glycan assembly disorders). 30659065 10 66 part_of containing 1731:1740 arg1 an unmodified peptide AND a proline residue an unmodified peptide a proline residue proline residue at position 93 In digests of the sera from a subset of donors, we detected an unmodified peptide containing a proline residue at position 93; this substitution would strongly disfavor N-glycosylation at N92. 11984879 5 54 gly N-glycosylation 752:766 arg2 an N-glycosylation site an N-glycosylation site site In this study, chick DAN was cloned and sequenced, revealing a conserved cystine knot region as well as an N-glycosylation site. 8286855 9 66 part_of GpA 1315:1317 arg1 the extracellular domain GpA the extracellular domain PUBTATOR Site GpA 2993 domain These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA. 16107205 3 21 gly glycosylation 708:720 arg1 Asn-243 Asn-243 Asn-243 Human DNase X, ectopically expressed in HeLa S3 cells, is located in the ER (endoplasmic reticulum) and is modified by an N-linked glycosylation at Asn-243. 2303254 1 102 part_of IX 314:315 arg1 the catalytic domain factor IX the catalytic domain PUBTATOR Site factor IX P00740 domain By means of RNA amplification with transcript sequencing (RAWTS) under low stringency conditions, sequence was obtained directly without cloning for the activation peptide and the catalytic domain of factor IX from six species--sheep, pig, rabbit, guinea pig, rat, and mouse. 2303254 1 102 part_of IX 314:315 arg1 the activation peptide factor IX the activation peptide PUBTATOR Site factor IX P00740 peptide By means of RNA amplification with transcript sequencing (RAWTS) under low stringency conditions, sequence was obtained directly without cloning for the activation peptide and the catalytic domain of factor IX from six species--sheep, pig, rabbit, guinea pig, rat, and mouse. 21752569 6 48 gly deglycoproteins 951:965 arg1 deglycoproteins deglycoproteins Fterm deglycoproteins These results matched those from deglycoproteins. 23339644 9 90 gly glycosylation 1933:1945 arg2 glycosylation site occupancy glycosylation site occupancy site Overall, glycosylation site occupancy of the CHO and 293T cell-derived 1086.C gp120 showed a high degree of similarity except for one site at N88 in the C1 region. 23339644 9 96 gly occupancy 1952:1960 arg2 glycosylation site occupancy gp120 site PUBTATOR gp120 3700 site Overall, glycosylation site occupancy of the CHO and 293T cell-derived 1086.C gp120 showed a high degree of similarity except for one site at N88 in the C1 region. 12177162 5 22 gly N-glycosylation 812:826 arg2 an N-glycosylation site an N-glycosylation site site Functionally significant conserved domains include an N-terminal hydrophobic domain, a glycosaminoglycan attachment site, an N-glycosylation site, and an ExxxLL internalization motif C-terminal to the putative internal transmembrane domain. 16261636 0 54 gly glycoprotein 50:61 arg1 human alpha-1-acid glycoprotein human alpha-1-acid glycoprotein Fterm glycoprotein Glycosylation site analysis of human alpha-1-acid glycoprotein (AGP) by capillary liquid chromatography-electrospray mass spectrometry. 10218949 5 10 gly glycosylation 904:916 arg2 mutated glycosylation sites mutated glycosylation sites sites However, an increasing number of mutated glycosylation sites was associated with decreasing cell surface receptor expression, which was minimal for the unglycosylated N4K/N176Q/N188Q receptor. 10218949 5 81 gly unglycosylated 1015:1028 arg1 the unglycosylated N4K/N176Q/N188Q receptor the unglycosylated N4K/N176Q/N188Q receptor Fterm receptor However, an increasing number of mutated glycosylation sites was associated with decreasing cell surface receptor expression, which was minimal for the unglycosylated N4K/N176Q/N188Q receptor. 2987810 7 10 gly glycosylation 694:706 arg2 a putative glycosylation site a putative glycosylation site site The deduced amino acid sequences show that four of the five genes contain a putative glycosylation site. 26956484 2 1 gly N-glycosylated 275:288 arg1 N-glycosylated subunits N-glycosylated subunits Fterm subunits Orai channels, which mediate store-operated Ca(2+) entry (SOCE), are composed of N-glycosylated subunits. 11822873 5 51 gly O-glycosylation 1119:1133 arg2 the first putative O-glycosylation site the first putative O-glycosylation site site Furthermore, moving the first putative O-glycosylation site (T216) two amino acids away from the membrane resulted in a loss of apical polarity of P75(NTR), suggesting that an important clue for apical sorting resides in this part of the stalk. 28327546 7 51 gly glycosylation 806:818 arg1 N582 N582 N582 Selected mutations also lead to partial glycosylation of N582, suggesting that rapid folding of local conformation prevents glycosylation of this site in wild-type FVIII. 28327546 7 60 gly glycosylation 890:902 arg1 wild-type FVIII FVIII site PUBTATOR FVIII 2157 site Selected mutations also lead to partial glycosylation of N582, suggesting that rapid folding of local conformation prevents glycosylation of this site in wild-type FVIII. 2318516 10 61 gly glycosylation 1806:1818 arg2 position 176 position 176 position 176 Two mutant B7 genes encoding either an extra glycosylation site at position 176 or no glycosylation sites were transfected into T2. 2318516 10 61 gly glycosylation 1806:1818 arg2 an extra glycosylation site an extra glycosylation site site Two mutant B7 genes encoding either an extra glycosylation site at position 176 or no glycosylation sites were transfected into T2. 2318516 10 121 gly glycosylation 1847:1859 arg2 no glycosylation sites no glycosylation sites sites Two mutant B7 genes encoding either an extra glycosylation site at position 176 or no glycosylation sites were transfected into T2. 2318516 10 121 gly glycosylation 1847:1859 arg2 position 176 position 176 position 176 Two mutant B7 genes encoding either an extra glycosylation site at position 176 or no glycosylation sites were transfected into T2. 23048041 6 21 gly N-glycosylation 1074:1088 arg2 an N-glycosylation site an N-glycosylation site site Using endo-β-N-acetylglucosaminidase H and peptide:N-glycosidase F sensitivity assays on CDKAL1 constructs carrying an N-glycosylation site within the luminal domain, we further established that CDKAL1 is an endoplasmic reticulum-resident protein. 10413093 0 35 gly variant 146:152 arg1 The N-linked glycan variant The N-linked glycan Fterm variant The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant. 10413093 0 37 gly region 30:35 arg1 The N-linked glycan region The N-linked glycan region The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant. 25629924 6 63 gly heterogeneity 1007:1019 arg1 each composition each composition position Site-specific heterogeneity and relative quantitation of each composition and the extent of occupation at each site were determined using nonspecific proteases. 11281648 1 53 gly glycoprotein 121:132 arg1 The glycoprotein calsequestrin The glycoprotein calsequestrin Fterm glycoprotein The glycoprotein calsequestrin (CS) is segregated to the junctional sarcoplasmic reticulum (jSR) and is responsible for intraluminal Ca(2+) binding. 8941718 0 31 gly N-glycosylation 73:87 arg2 a new N-glycosylation site a new N-glycosylation site site L273S missense substitution in human lysosomal acid lipase creates a new N-glycosylation site. 9140729 9 68 gly N-glycosylation 1458:1472 arg2 A N-glycosylation site A N-glycosylation site site A N-glycosylation site was introduced on the two heavy chains, by changing Ser to Asn at position 30. 2477364 7 57 gly glycosylation 1195:1207 arg2 only one glycosylation site only one glycosylation site site First, site-directed mutagenesis was used to alter the two N-linked oligosaccharide attachment sites, thus allowing the expression of alpha subunits containing only one glycosylation site. 12021274 6 20 gly glycosylation 865:877 arg2 Asn glycosylation site Asn glycosylation site site ICPP shares 52% sequence identity with human VEGF but lacks the heparin binding domain and Asn glycosylation site. 27743362 2 80 gly glycoproteins 375:387 arg1 glycoproteins glycoproteins Fterm glycoproteins Thus, the use of orthogonal approaches for comprehensive characterization of glycoproteins is a key requirement. 7475306 4 12 gly glycosylation 743:755 arg2 a glycosylation site a glycosylation site site Residues 230-257 is predicted to encode two beta-turn/loop regions at 240-244 (LYGPN), 248-257 (VPSSSSTPL) and a glycosylation site at N-244 (NVS). 7475306 4 12 gly glycosylation 743:755 arg2 N-244 N-244 N-244 Residues 230-257 is predicted to encode two beta-turn/loop regions at 240-244 (LYGPN), 248-257 (VPSSSSTPL) and a glycosylation site at N-244 (NVS). 19167329 5 4 part_of protein 866:872 arg1 the N-terminal signal sequence protein the N-terminal signal sequence Fterm Site protein sequence The STT3B isoform is required for efficient cotranslational glycosylation of an acceptor site adjacent to the N-terminal signal sequence of a secreted protein. 31516400 1 30 gly glycoprotein 147:158 arg1 N-linked glycoprotein N-linked glycoprotein Fterm glycoprotein Background: N-linked glycoprotein is a highly interesting class of proteins for clinical and biological research. 31516400 1 30 gly glycoprotein 147:158 arg1 Background Background Cterm Background: N-linked Background: N-linked glycoprotein is a highly interesting class of proteins for clinical and biological research. 18282281 0 42 part_of mucin-type 14:23 arg1 mucin-type O-glycosylation sites mucin mucin-type O-glycosylation sites PUBTATOR Site mucin 100508689 sites Prediction of mucin-type O-glycosylation sites in mammalian proteins using the composition of k-spaced amino acid pairs. 1990068 3 31 part_of has 559:561 arg1 Each subunit AND one potential N-linked glycosylation site Each subunit one potential N-linked glycosylation site Fterm Site subunit site Each subunit has one potential N-linked glycosylation site. 11310976 1 6 gly glycoproteins 458:470 arg1 glycoproteins glycoproteins Fterm glycoproteins Glycophorins A from erythrocyte membranes of two patients with congenital dyserythropoietic anemia type I and type II (CDA type I and II) were analyzed for carbohydrate molar composition employing a modification of the recently published method that allowed simultaneous determination of carbohydrates and protein in electrophoretic bands of glycoproteins separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Zdebska & Kościelak, 1999, Anal Biochem., 275, 171-179). 22189107 8 14 gly glycosylation 1435:1447 arg2 an extra N-linked glycosylation site an extra N-linked glycosylation site site In addition, the circulating Belgian G3 RVA strains were found to possibly possess an extra N-linked glycosylation site compared to the G3 RVA vaccine strain of RotaTeq. 11604992 2 32 gly glycosylation 229:241 arg2 an N-linked glycosylation site an N-linked glycosylation site site WNT14B encoded 357-amino acid WNT family protein with the signal peptide and an N-linked glycosylation site. 7573038 9 48 gly glycosylation 1468:1480 arg2 a potential glycosylation site a potential glycosylation site site They also suggested that a potential glycosylation site created by the mutation is utilized in approximately 50% of the enzyme expressed. 7573038 9 69 gly utilized 1514:1521 arg2 a potential glycosylation site a potential glycosylation site site They also suggested that a potential glycosylation site created by the mutation is utilized in approximately 50% of the enzyme expressed. 26956484 8 68 gly Orai1 1205:1209 arg1 the N-glycan Orai1 the N-glycan PUBTATOR Orai1 84876 In human mast cells, inhibition of sialyl sulfation altered the N-glycan of Orai1 (and other proteins) and increased SOCE. 15890930 3 38 gly glycosylation 872:884 arg2 an N-linked glycosylation site an N-linked glycosylation site site This epitope was introduced into two primary Envs, derived from a neutralization-sensitive (SF162) and a neutralization-resistant (JR-FL) isolate, by substitution of two residues and, for SF162, addition of an N-linked glycosylation site. 21338062 9 26 gly glycopeptides 2109:2121 arg2 low abundant glycopeptides low abundant glycopeptides glycopeptides At this sample consumption level, the high sensitivity of the PLOT LC-LTQ-CID/ETD-MS system allowed glycopeptide identification and structure determination, along with relative quantitation of glycans presented on the same peptide backbone, even for low abundant glycopeptides at the ∼100 amol level. 21338062 9 47 gly glycopeptide 1946:1957 arg2 glycopeptide identification glycopeptide identification glycopeptide At this sample consumption level, the high sensitivity of the PLOT LC-LTQ-CID/ETD-MS system allowed glycopeptide identification and structure determination, along with relative quantitation of glycans presented on the same peptide backbone, even for low abundant glycopeptides at the ∼100 amol level. 2538306 1 71 gly glycoprotein 394:405 arg1 the glycoprotein hormone alpha-subunit the glycoprotein hormone alpha-subunit Fterm glycoprotein Biosynthetic experiments were carried out in cultures of human malignant trophoblast cells (the JAR cell line) and in explants of normal first trimester human placental tissue to test the hypothesis that the O-glycosylation of the glycoprotein hormone alpha-subunit at Thr-39 regulates the assembly of the CG alpha beta dimer. 2538306 1 97 gly O-glycosylation 371:385 arg1 Thr-39 Thr-39 Thr-39 Biosynthetic experiments were carried out in cultures of human malignant trophoblast cells (the JAR cell line) and in explants of normal first trimester human placental tissue to test the hypothesis that the O-glycosylation of the glycoprotein hormone alpha-subunit at Thr-39 regulates the assembly of the CG alpha beta dimer. 2538306 1 97 gly O-glycosylation 371:385 arg1 the glycoprotein hormone alpha-subunit alpha-subunit Thr-39 Fterm alpha-subunit Thr-39 Biosynthetic experiments were carried out in cultures of human malignant trophoblast cells (the JAR cell line) and in explants of normal first trimester human placental tissue to test the hypothesis that the O-glycosylation of the glycoprotein hormone alpha-subunit at Thr-39 regulates the assembly of the CG alpha beta dimer. 2538306 1 97 gly O-glycosylation 371:385 arg1 the glycoprotein hormone alpha-subunit alpha-subunit Thr-39 Fterm alpha-subunit Thr-39 Biosynthetic experiments were carried out in cultures of human malignant trophoblast cells (the JAR cell line) and in explants of normal first trimester human placental tissue to test the hypothesis that the O-glycosylation of the glycoprotein hormone alpha-subunit at Thr-39 regulates the assembly of the CG alpha beta dimer. 16372382 12 1 gly Asn-beta23 1996:2005 arg1 the carbohydrate moieties Asn the carbohydrate moieties Asn Profiling of the carbohydrate moieties of Asn-beta23 indicates a large heterogeneity. 18638581 6 7 gly glycopeptides 1263:1275 arg2 tryptic glycopeptides tryptic glycopeptides glycopeptides The combination of lectin affinity enrichment of glycoproteins and subsequent HILIC enrichment of tryptic glycopeptides identified 81 N-glycosylation sites in 44 proteins. 18638581 6 19 gly glycoproteins 1206:1218 arg1 glycoproteins glycoproteins Fterm glycoproteins The combination of lectin affinity enrichment of glycoproteins and subsequent HILIC enrichment of tryptic glycopeptides identified 81 N-glycosylation sites in 44 proteins. 18638581 6 67 gly N-glycosylation 1291:1305 arg2 81 N-glycosylation sites 81 N-glycosylation sites sites The combination of lectin affinity enrichment of glycoproteins and subsequent HILIC enrichment of tryptic glycopeptides identified 81 N-glycosylation sites in 44 proteins. 20622017 10 69 gly glycosylation 1305:1317 arg2 Two glycosylation sites Two glycosylation sites sites Two glycosylation sites on renal GGT were modified exclusively by neutral glycans. 20622017 10 92 gly modified 1343:1350 arg1 Two glycosylation sites AND neutral glycans Two glycosylation sites neutral glycans sites Two glycosylation sites on renal GGT were modified exclusively by neutral glycans. 9126611 11 101 gly containing 2127:2136 arg1 the wild-type enzyme AND an additional high mannose oligosaccharide the wild-type enzyme an additional high mannose oligosaccharide Fterm enzyme The difference between the highest mass peaks of the two envelopes, of approximately 1500 Da, is consistent with the wild-type enzyme containing an additional high mannose oligosaccharide. 1492495 6 15 gly glycosylation 1026:1038 arg2 a cryptic glycosylation site a cryptic glycosylation site site However, due to a cryptic glycosylation site within CAT, glycosylated protein was secreted, which reduced enzymatic activity. 1492495 6 24 gly glycosylated 1057:1068 arg1 glycosylated protein glycosylated protein Fterm protein However, due to a cryptic glycosylation site within CAT, glycosylated protein was secreted, which reduced enzymatic activity. 10397812 0 55 gly glycosylation 33:45 arg1 recombinant IFN-gamma recombinant IFN-gamma PUBTATOR IFN-gamma 3458 Constraints on the transport and glycosylation of recombinant IFN-gamma in Chinese hamster ovary and insect cells. 12940452 3 18 gly N-glycosylation 493:507 arg2 a novel N-glycosylation site a novel N-glycosylation site site To obtain more information on the relationship between the structure and function of the alpha-subunit, we introduced a novel N-glycosylation site in the N-terminal region by mutating Asp3 and Gln5 into Asn and Thr, respectively. 22582156 6 75 gly N-glycosylation 983:997 arg2 The human N-glycosylation site The human N-glycosylation site site The human N-glycosylation site was predominantly conserved among other mammalian GPIHBP1 proteins except cow, dog and pig. 11680875 5 49 gly glycosylation 972:984 arg2 one N-linked glycosylation site one N-linked glycosylation site site CD59, for example, has over 100 different sugars at one N-linked glycosylation site. 8870657 9 11 gly glycosylation 1115:1127 arg1 natural hLF hLF Asn624 PUBTATOR hLF 3131 Asn624 29% and 40% of Asn479 and Asn138/479 mutant molecules respectively, which indicates that glycosylation at Asn624 in natural hLF might be limited by glycosylation at Asn479. 8870657 9 11 gly glycosylation 1115:1127 arg2 Asn624 Asn624 Asn624 29% and 40% of Asn479 and Asn138/479 mutant molecules respectively, which indicates that glycosylation at Asn624 in natural hLF might be limited by glycosylation at Asn479. 8870657 9 11 gly glycosylation 1115:1127 arg2 Asn624 hLF Asn624 PUBTATOR hLF 3131 Asn624 29% and 40% of Asn479 and Asn138/479 mutant molecules respectively, which indicates that glycosylation at Asn624 in natural hLF might be limited by glycosylation at Asn479. 8870657 9 29 gly glycosylation 1174:1186 arg2 Asn479 Asn479 Asn479 29% and 40% of Asn479 and Asn138/479 mutant molecules respectively, which indicates that glycosylation at Asn624 in natural hLF might be limited by glycosylation at Asn479. 17158203 1 17 gly leucine-rich 272:283 arg1 the leucine-rich repeat leucine the leucine-rich repeat leucine The relaxin receptor (LGR7, relaxin family peptide receptor 1) is a member of the leucine-rich repeat containing G protein-coupled receptors subgroup C. 21940909 0 92 part_of glycoproteins 128:140 arg1 nonglycosylated tryptic peptides glycoproteins nonglycosylated tryptic peptides Fterm Site glycoproteins peptides Targeted mass spectrometric approach for biomarker discovery and validation with nonglycosylated tryptic peptides from N-linked glycoproteins in human plasma. 12110528 1 57 gly glycosylation 119:131 arg1 Ser/Thr Ser/Thr Ser/Thr O-linked glycosylation on Ser/Thr with single N-acetylglucosamine (O-GlcNAcylation) is a reversible modification of many cytosolic/nuclear proteins, regulated in part by UDP-GlcNAc levels. 27489265 11 94 gly glycoprotein 1802:1813 arg1 The HIV-1 Env glycoprotein The HIV-1 Env glycoprotein PUBTATOR Env glycoprotein 155971 The HIV-1 Env glycoprotein presents a dense patchwork of host cell-derived N-linked glycans. 8411360 7 61 gly glycosylation 1514:1526 arg2 the two conserved glycosylation sites the two conserved glycosylation sites sites First, the single substitution of Ile for Thr-155 which ablated one of the two conserved glycosylation sites in parental E yielded a virus that was almost as neurovirulent as the mouse-adapted mutant. 23234360 4 34 gly attached 968:975 arg2 one to four Ser/Thr residues AND predominantly core-1-like HexHexNAc-O- structure one to four Ser/Thr residues predominantly core-1-like HexHexNAc-O- structure residues We used electron-capture and -transfer dissociation (ECD/ETD) to pinpoint the glycosylation site(s) of the glycopeptides, identified as predominantly core-1-like HexHexNAc-O- structure attached to one to four Ser/Thr residues. 23234360 4 39 gly glycosylation 861:873 arg2 the glycosylation site the glycosylation site site We used electron-capture and -transfer dissociation (ECD/ETD) to pinpoint the glycosylation site(s) of the glycopeptides, identified as predominantly core-1-like HexHexNAc-O- structure attached to one to four Ser/Thr residues. 23234360 4 56 gly glycopeptides 890:902 arg2 the glycopeptides the glycopeptides glycopeptides We used electron-capture and -transfer dissociation (ECD/ETD) to pinpoint the glycosylation site(s) of the glycopeptides, identified as predominantly core-1-like HexHexNAc-O- structure attached to one to four Ser/Thr residues. 23234360 4 39 gly glycosylation 861:873 arg2 the glycopeptides glycopeptides glycopeptides We used electron-capture and -transfer dissociation (ECD/ETD) to pinpoint the glycosylation site(s) of the glycopeptides, identified as predominantly core-1-like HexHexNAc-O- structure attached to one to four Ser/Thr residues. 8189524 9 20 gly glycosylation 1347:1359 arg2 a consensus N-linked glycosylation site a consensus N-linked glycosylation site site Since the PrV UL1 sequence did not reveal the presence of a consensus N-linked glycosylation site, concanavalin A affinity chromatography and enzymatic deglycosylation of virion glycoproteins were used to ascertain that the PrV UL1 product is O glycosylated. 8189524 9 37 gly glycoproteins 1446:1458 arg1 virion glycoproteins virion glycoproteins Fterm glycoproteins Since the PrV UL1 sequence did not reveal the presence of a consensus N-linked glycosylation site, concanavalin A affinity chromatography and enzymatic deglycosylation of virion glycoproteins were used to ascertain that the PrV UL1 product is O glycosylated. 8189524 9 79 gly deglycosylation 1420:1434 arg1 virion glycoproteins virion glycoproteins Fterm glycoproteins Since the PrV UL1 sequence did not reveal the presence of a consensus N-linked glycosylation site, concanavalin A affinity chromatography and enzymatic deglycosylation of virion glycoproteins were used to ascertain that the PrV UL1 product is O glycosylated. 7727375 6 36 gly O-glycosylation 999:1013 arg2 the O-glycosylation site the O-glycosylation site site We have also found that glycosylation is less efficient when rEPO is improperly folded and that prolines at -1 and +1 relative to the O-glycosylation site enhance glycosylation. 28931684 9 77 gly glycosylation 1630:1642 arg1 the E protein the E protein Our findings provide the first evidence that N-linked glycosylation of the E protein is an important determinant of ZIKV virulence and neuroinvasion.IMPORTANCE Recent emergence of Zika virus (ZIKV) in the Americas has caused major worldwide public health concern. 7530394 1 74 gly glycosylation 274:286 arg2 a potential glycosylation site a potential glycosylation site site Previous studies have found Kunjin (KUN) virus isolates from within Australia to be genetically homogenous and that the envelope protein of the type strain (MRM61C) was unglycosylated and lacked a potential glycosylation site. 1535241 6 62 part_of peptidase 1262:1270 arg1 a probable signal peptidase cleavage site peptidase a probable signal peptidase cleavage site Fterm Site peptidase site Changes in potential proteolytic processing sites (two basic dipeptides and a probable signal peptidase cleavage site) did not adversely impair biological activity or protein processing and uncovered a second site for cleavage by signal peptidase. 12954207 6 57 part_of receptor-binding 1158:1173 arg1 the receptor-binding regions receptor the receptor-binding regions Fterm Site receptor regions In this study, guided by the X-ray crystal structure of gp120, we deleted four N-linked glycosylation sites that flank the receptor-binding regions. 31325506 1 60 gly heavily-glycosylated 150:169 arg1 a heavily-glycosylated macromolecular (approximately 4 MDa) protein a heavily-glycosylated macromolecular (approximately 4 MDa) protein Fterm protein Bovine submaxillary mucin (BSM) is a heavily-glycosylated macromolecular (approximately 4 MDa) protein and is used in various biomaterial applications in light of its high viscosity and biocompatibility, in addition to use as a biochemical substrate or inhibitor as a result of its abundant O-glycans. 31325506 1 60 gly heavily-glycosylated 150:169 arg1 Bovine submaxillary mucin Bovine submaxillary mucin PUBTATOR mucin 281333 Bovine submaxillary mucin (BSM) is a heavily-glycosylated macromolecular (approximately 4 MDa) protein and is used in various biomaterial applications in light of its high viscosity and biocompatibility, in addition to use as a biochemical substrate or inhibitor as a result of its abundant O-glycans. 1427854 4 25 gly glycosylation 535:547 arg2 a glycosylation site a glycosylation site site A deletion of an asparagine in CGM9 results in loss of a glycosylation site, which is conserved throughout the CEA gene family. 21264968 7 89 gly glycosylation 2369:2381 arg2 the consecutive Thr residues MUC5AC Thr residues PUBTATOR MUC5AC 4586 Thr residues Such conformational impact on the underlying peptides was proved to be remarkable in the glycosylation at the consecutive Thr residues of MUC5AC. 21264968 7 89 gly glycosylation 2369:2381 arg1 the consecutive Thr residues MUC5AC Thr residues PUBTATOR MUC5AC 4586 Thr residues Such conformational impact on the underlying peptides was proved to be remarkable in the glycosylation at the consecutive Thr residues of MUC5AC. 21264968 7 89 gly glycosylation 2369:2381 arg1 the consecutive Thr residues Thr residues Thr residues Such conformational impact on the underlying peptides was proved to be remarkable in the glycosylation at the consecutive Thr residues of MUC5AC. 22613618 2 63 gly glycosylated 223:234 arg1 a heavily glycosylated membrane protein a heavily glycosylated membrane protein Fterm protein Kv1.3 is a heavily glycosylated membrane protein. 27938679 0 50 gly N-glycosylation 7:21 arg2 Single N-glycosylation site Single N-glycosylation site site Single N-glycosylation site of bovine leukemia virus SU is involved in conformation and viral escape. 21727639 3 49 part_of proteins 559:566 arg1 an in silico sequence proteins an in silico sequence Fterm Site proteins sequence METHODOLOGY: This study involved an in silico sequence, phylogenetic and antigenic analyses of hemagglutinin and neuraminidase proteins of avian influenza A (H9N2) strains that circulated in Pakistan's poultry flocks from 1999 to 2008 and determined variations among these sequences at different levels. 9311570 6 10 gly glycosylation 1027:1039 arg2 a new potential glycosylation site a new potential glycosylation site site A potential antigenic determinant changed from Ala to Thr at position 453 and there was a new potential glycosylation site present at position 88 for SwQc91 strain whereas it was absent at position 50 when compared with SwQc81 strain. 10080942 1 52 gly sites 221:225 arg1 three potential N-glycosylation sites three potential N-glycosylation sites sites Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 15 gly N-glycosylation 205:219 arg1 human deoxyribonuclease II deoxyribonuclease N86, N212, and N266 Fterm deoxyribonuclease N86, N212, and N266 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 15 gly N-glycosylation 205:219 arg2 N86 N86, N212, and N266 N86, N212, and N266 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 15 gly N-glycosylation 205:219 arg2 N212 N86, N212, and N266 N86, N212, and N266 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 15 gly N-glycosylation 205:219 arg1 human deoxyribonuclease II deoxyribonuclease sites Fterm deoxyribonuclease sites Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 15 gly N-glycosylation 205:219 arg2 N86 deoxyribonuclease N86, N212, and N266 Fterm deoxyribonuclease N86, N212, and N266 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 15 gly N-glycosylation 205:219 arg2 N212 deoxyribonuclease N86, N212, and N266 Fterm deoxyribonuclease N86, N212, and N266 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 15 gly N-glycosylation 205:219 arg2 N212 N86, N212, and N266 N86, N212, and N266 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 52 gly sites 221:225 arg1 N266 N86, N212, and N266 N86, N212, and N266 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 52 gly sites 221:225 arg1 N86 N86, N212, and N266 N86, N212, and N266 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 52 gly sites 221:225 arg1 N86 N86, N212, and N266 N86, N212, and N266 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 9832151 0 76 gly Glycosylation 0:12 arg1 a vesicular monoamine transporter a vesicular monoamine transporter OGER monoamine transporter Q01827 Glycosylation of a vesicular monoamine transporter: a mutation in a conserved proline residue affects the activity, glycosylation, and localization of the transporter. 29226084 6 0 gly N-glycosylation 1199:1213 arg1 GPR61 GPR61 OGER GPR61 Q9BZJ8 These results demonstrate that GPR61 is subject to N-glycosylation but suggest this is not a prerequisite for cell surface expression, although N-glycosylation of other proteins may be important for cell membrane expression of GPR61. 29226084 6 0 gly N-glycosylation 1199:1213 arg1 other proteins other proteins Fterm proteins These results demonstrate that GPR61 is subject to N-glycosylation but suggest this is not a prerequisite for cell surface expression, although N-glycosylation of other proteins may be important for cell membrane expression of GPR61. 27177499 16 31 gly glycoprotein 2238:2249 arg1 the major pregnancy glycoprotein hormone the major pregnancy glycoprotein hormone Fterm glycoprotein In conclusion, hCG is the major pregnancy glycoprotein hormone, whose maternal concentration and glycan structure change all along pregnancy. 2143269 2 28 part_of Fc 289:290 arg1 A recombinant human Fc fragment Fc A recombinant human Fc fragment Cterm Site Fc fragment A recombinant human Fc fragment was expressed by an E. coli system [Kitai K., Kudo T., Nakamura S., Masegi T., Ichikawa Y. and Horikoshi K. (1988) Appl. 8019599 4 1 gly glycosylated 560:571 arg1 both glycosylated and unglycosylated b3 both glycosylated and unglycosylated b3 Cterm b3 443978 Similar amounts of cleavage were observed with both glycosylated and unglycosylated b3. 8019599 4 3 gly unglycosylated 577:590 arg1 both glycosylated and unglycosylated b3 both glycosylated and unglycosylated b3 Cterm b3 443978 Similar amounts of cleavage were observed with both glycosylated and unglycosylated b3. 8189524 0 103 gly glycoprotein 58:69 arg1 a novel structural glycoprotein a novel structural glycoprotein Fterm glycoprotein Identification and characterization of a novel structural glycoprotein in pseudorabies virus, gL. 21970473 3 63 gly microheterogeneity 503:520 arg1 glycan modifications glycan modifications The study of protein glycosylation has been hindered by the technical challenges caused by the microheterogeneity of glycan modifications. 9524075 11 66 gly non-glycosylated 1245:1260 arg1 non-glycosylated procathepsin S non-glycosylated procathepsin S Cterm non-glycosylated procathepsin S 1520 Subcellular fractionation showed non-glycosylated procathepsin S in the membrane fraction. 9729121 4 35 part_of 111573-Da 893:901 arg1 a 111573-Da polypeptide 111573-Da a 111573-Da polypeptide Cterm Site 111573-Da polypeptide From a B. mori midgut cDNA library, we cloned the 110-kDa APN cDNA that possessed a 2958-bp open reading frame encoding a 111573-Da polypeptide of 986 residues. 3311885 3 1 gly N-glycosylation 721:735 arg2 at least one N-glycosylation site at least one N-glycosylation site site Despite the fact that both lymphokines contain at least one N-glycosylation site and have identical N-terminal residues (Ala-Pro-Thr), recombinant (R) GM-CSF was found to be heterogeneously glycosylated by yeast while RBoIL-2 was secreted without glycosylation. 3311885 3 40 gly glycosylated 851:862 arg1 recombinant (R) GM-CSF recombinant (R) GM-CSF OGER CSF Despite the fact that both lymphokines contain at least one N-glycosylation site and have identical N-terminal residues (Ala-Pro-Thr), recombinant (R) GM-CSF was found to be heterogeneously glycosylated by yeast while RBoIL-2 was secreted without glycosylation. 30158294 6 11 part_of site 877:880 arg1 SERINC5 SERINC5 site PUBTATOR SpecificSite SERINC5 256987 site, N294 Sequence alignment of SERINC family proteins led us to identify a conserved N-glycosylation site, N294, in SERINC5. 23001782 3 36 gly glycosylation 495:507 arg1 serum-derived hSHBG serum-derived hSHBG PUBTATOR hSHBG 6462 Here, we perform a detailed site-specific characterization of the N- and O-linked glycosylation of serum-derived hSHBG. 22209231 2 29 gly glycans 420:426 arg1 gp120 gp120 glycans PUBTATOR gp120 155971 The lectins griffithsin (GRFT), cyanovirin-N (CV-N) and scytovirin (SVN) inhibit HIV-1 infection by binding to mannose-rich glycans on gp120. 12765790 3 3 part_of non-PSA/HNK1- 686:698 arg1 non-PSA/HNK1-(glyco) peptides PSA non-PSA/HNK1-(glyco) peptides OGER Site PSA Q9Y617 peptides For characterization of N-glycan structures and attachment sites, PSA-NCAM was digested with trypsin, and the generated glycopeptides were fractionated by serial immunoaffinity chromatography using immobilized monoclonal antibodies specific for PSA or the HNK1 epitope, i.e., HSO(3)-3GlcA(beta 1-3)Gal(beta 1-4)GlcNAc(beta 1-, yielding PSA-glycopeptides, HNK-glycopeptides and non-PSA/HNK1-(glyco) peptides. 26278021 0 74 gly glycoprotein 37:48 arg1 N-glycosylation-mutated HCV envelope glycoprotein N-glycosylation-mutated HCV envelope glycoprotein Fterm glycoprotein N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses. 10905635 2 59 gly N-glycosylation 300:314 arg2 the only potential N-glycosylation site beta1,3galactosyltransferase site OGER beta1,3galactosyltransferase Q9NS00 site Here we examined the occupancy and relevance for the activity and intracellular trafficking of the only potential N-glycosylation site of the mouse beta1,3galactosyltransferase (Gal-T2 or GA1/GM1/GD1b synthase) in Gal-T2 cDNA transfected CHO-K1 cells. 20391591 1 87 gly glycoproteins 119:131 arg1 glycoproteins glycoproteins Fterm glycoproteins Assigning glycosylation sites of glycoproteins and their microheterogeneity is still a very challenging analytical task despite the rapid advancements in mass spectrometry. 20391591 1 28 gly glycosylation 96:108 arg2 Assigning glycosylation sites glycoproteins sites Fterm glycoproteins sites Assigning glycosylation sites of glycoproteins and their microheterogeneity is still a very challenging analytical task despite the rapid advancements in mass spectrometry. 12626422 5 22 gly underglycosylated 947:963 arg1 alpha1-antitrypsin alpha1-antitrypsin PUBTATOR alpha1-antitrypsin 5265 The state of glycosylation of the three asparagine residues was analyzed in all the underglycosylated forms of alpha1-antitrypsin by peptide mass fingerprinting using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. 12626422 5 59 gly glycosylation 876:888 arg1 the three asparagine residues the three asparagine residues asparagine residues The state of glycosylation of the three asparagine residues was analyzed in all the underglycosylated forms of alpha1-antitrypsin by peptide mass fingerprinting using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. 27506355 11 30 gly glycoprotein 1481:1492 arg1 glycoprotein datasets glycoprotein datasets Fterm glycoprotein We validated our method using a standard glycoprotein, human transferrin, and evaluated its potential to be used in site-specific glycosylation profiling of glycoprotein datasets from LC-MS/MS. 27506355 11 60 gly glycoprotein 1365:1376 arg1 a standard glycoprotein a standard glycoprotein Fterm glycoprotein We validated our method using a standard glycoprotein, human transferrin, and evaluated its potential to be used in site-specific glycosylation profiling of glycoprotein datasets from LC-MS/MS. 27506355 11 60 gly glycoprotein 1365:1376 arg1 human transferrin human transferrin PUBTATOR transferrin 7018 We validated our method using a standard glycoprotein, human transferrin, and evaluated its potential to be used in site-specific glycosylation profiling of glycoprotein datasets from LC-MS/MS. 21704619 2 4 gly protein 332:338 arg1 the N-glycan content protein the N-glycan content Fterm protein Here we report the design of a novel peptide tag with an unnatural N-glycosylation site, which may increase the N-glycan content of generally any protein. 21704619 2 8 gly N-glycosylation 253:267 arg2 an unnatural N-glycosylation site an unnatural N-glycosylation site site Here we report the design of a novel peptide tag with an unnatural N-glycosylation site, which may increase the N-glycan content of generally any protein. 21704619 2 20 gly peptide 223:229 arg1 a novel peptide tag a novel peptide tag Here we report the design of a novel peptide tag with an unnatural N-glycosylation site, which may increase the N-glycan content of generally any protein. 14669059 3 33 gly glycoproteins 480:492 arg1 glycoproteins glycoproteins Fterm glycoproteins Within the endoplasmic reticulum, CRT serves as a calcium modulator and a lectin-like chaperone for glycoproteins, especially class I major histocompatibility receptors. 15968392 9 48 gly glycosylation 1436:1448 arg2 the N-linked glycosylation site the N-linked glycosylation site site Surprisingly, substitution of Asn473 by Ala (which removes the N-linked glycosylation site) had no effect on the levels of FXI:Ag secreted. 8870657 4 68 part_of sequons 582:588 arg1 glutamine sequons glutamine glutamine The mutations involved replacement of asparagine residues with glutamine at one or more sequons for N-glycosylation (Asn138, Asn479 and Asn624). 22823882 6 11 gly glycosylation 993:1005 arg2 their glycosylation sites their glycosylation sites sites Therefore, we analyzed a series of glycoproteomes in several mouse tissues to identify glycosylated proteins and their glycosylation sites. 22823882 6 14 gly glycosylated 961:972 arg1 glycosylated proteins glycosylated proteins Fterm proteins Therefore, we analyzed a series of glycoproteomes in several mouse tissues to identify glycosylated proteins and their glycosylation sites. 23684631 5 36 gly glycosylation 1061:1073 arg2 a potential extra N-linked glycosylation site a potential extra N-linked glycosylation site site The Tunisian G3 RVA strains were found to possess a potential extra N-linked glycosylation site. 20335223 0 81 part_of factor 41:46 arg1 the von Willebrand factor (VWF) propeptide von Willebrand factor the von Willebrand factor (VWF) propeptide PUBTATOR Site von Willebrand factor 7450 propeptide The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF. 24018687 3 54 gly N-glycosylation 742:756 arg2 a conserved N-glycosylation site a conserved N-glycosylation site site Site-directed mutational analysis of the consensus N-glycosylation sites of the DDRs revealed that mutations of asparagine 213 of DDR2 and asparagine 211 of DDR1, a conserved N-glycosylation site among vertebrate DDRs, inhibited the generation of the high-molecular-mass isoform. 24018687 3 57 gly N-glycosylation 618:632 arg2 the consensus N-glycosylation sites the consensus N-glycosylation sites sites Site-directed mutational analysis of the consensus N-glycosylation sites of the DDRs revealed that mutations of asparagine 213 of DDR2 and asparagine 211 of DDR1, a conserved N-glycosylation site among vertebrate DDRs, inhibited the generation of the high-molecular-mass isoform. 27095603 0 50 gly glycoforms 33:42 arg1 transferrin glycoforms transferrin glycoforms PUBTATOR transferrin 7018 Mass spectrometry of transferrin glycoforms to detect congenital disorders of glycosylation: Site-specific profiles and pitfalls. 18703501 7 25 part_of contains 1209:1216 arg1 CA IX AND Asn(309) CA IX Asn(309) PUBTATOR SpecificSite CA IX 768 Asn(309) Mass spectrometry experiments showed that CA IX contains an intramolecular disulfide bridge (Cys(119)-Cys(299)) and a unique N-linked glycosylation site (Asn(309)) that bears high mannose-type glycan structures. 18703501 7 25 part_of contains 1209:1216 arg1 CA IX AND a unique N-linked glycosylation site CA IX a unique N-linked glycosylation site PUBTATOR Site CA IX 768 site Mass spectrometry experiments showed that CA IX contains an intramolecular disulfide bridge (Cys(119)-Cys(299)) and a unique N-linked glycosylation site (Asn(309)) that bears high mannose-type glycan structures. 9677334 12 5 part_of TPO 1654:1656 arg1 position 110 TPO position 110 PUBTATOR Site TPO 7066 position 110 We also demonstrate that the O-glycosylation site located at position 110 of TPO is not necessary for the bioactivity of the cytokine. 15351488 6 35 gly glycosylation 986:998 arg2 one site one site site Our data demonstrate that N-linked glycosylation occurs at three sites in Gn (N142, N357 and N409), and at one site in Gc (N937). 15351488 6 35 gly glycosylation 986:998 arg2 three sites three sites sites Our data demonstrate that N-linked glycosylation occurs at three sites in Gn (N142, N357 and N409), and at one site in Gc (N937). 15351488 6 62 gly Gn 1025:1026 arg1 N357 N142, N357 and N409 N142, N357 and N409 Our data demonstrate that N-linked glycosylation occurs at three sites in Gn (N142, N357 and N409), and at one site in Gc (N937). 29980609 5 14 gly glycoproteins 951:963 arg1 AICL glycoproteins AICL glycoproteins PUBTATOR AICL glycoproteins 9976 Cys87 residing within the C-type lectin-like domain not only ensures stable homodimerization of AICL glycoproteins by disulfide bonding, but Cys87 is also required for efficient cell surface expression of AICL homodimers and essential for AICL-NKp80 interaction. 6406481 8 49 gly glycosylation 777:789 arg2 A single glycosylation site A single glycosylation site site A single glycosylation site is located at residue 70 of the cathepsin D light chain. 6406481 8 49 gly glycosylation 777:789 arg2 residue 70 residue 70 residue 70 A single glycosylation site is located at residue 70 of the cathepsin D light chain. 15474009 0 6 part_of transferrin 62:72 arg1 the Asn-Xaa-Cys motif transferrin the Asn-Xaa-Cys motif PUBTATOR AminoAcid transferrin 7018 Cys motif N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin. 16335806 2 51 gly N-glycosylation 393:407 arg2 one potential N-glycosylation site one potential N-glycosylation site site The results revealed that panda PRL cDNA encodes a precursor protein of 229 amino acids including a putative signal peptide of 30 amino acids and a mature protein of 199 residues with one potential N-glycosylation site. 25879854 8 5 gly glycosylation 846:858 arg2 one N-linked glycosylation site one N-linked glycosylation site site In catfishes, there are 13 cysteine residues and one N-linked glycosylation site. 26869352 5 21 gly glycosylation 1138:1150 arg2 all glycosylation sites all glycosylation sites sites In all cancer samples, monofucosylated N-glycans were significantly increased at all glycosylation sites. 26869352 5 65 gly monofucosylated 1076:1090 arg1 monofucosylated N-glycans monofucosylated N-glycans In all cancer samples, monofucosylated N-glycans were significantly increased at all glycosylation sites. 7688323 0 37 gly O-glycosylation 19:33 arg2 an O-glycosylation site an O-glycosylation site site Localization of an O-glycosylation site in the alpha-subunit of the human platelet integrin GPIIb/IIIa involved in Baka (HPA-3a) alloantigen expression. 26022737 8 62 part_of possessing 1032:1041 arg1 the amino acid sequence AND N102 glycosylation site the amino acid sequence N102 glycosylation site site We successfully applied tandem MS to verify the amino acid sequence possessing N102 glycosylation site and associated glycoforms of PSA samples acquired from different suppliers. 19088065 12 35 gly sialylation 1587:1597 arg1 KLK6 KLK6 Cterm KLK6 Therefore, the extensive and almost exclusive sialylation of KLK6 from ovarian cancer cells could lead to the development of an improved biomarker for the early diagnosis of ovarian carcinoma. 19088065 12 85 gly KLK6 1602:1605 arg1 the extensive and almost exclusive sialylation KLK6 the extensive and almost exclusive sialylation Cterm KLK6 Therefore, the extensive and almost exclusive sialylation of KLK6 from ovarian cancer cells could lead to the development of an improved biomarker for the early diagnosis of ovarian carcinoma. 1421757 3 4 gly O-glycosylation 426:440 arg2 the site the site site Amino acid sequence analysis reveals that the site of O-glycosylation is Thr-104. 1421757 3 4 gly O-glycosylation 426:440 arg2 Thr-104 Thr-104 Thr-104 Amino acid sequence analysis reveals that the site of O-glycosylation is Thr-104. 9694881 1 41 gly glycoprotein 125:136 arg1 Human angiotensinogen Human angiotensinogen PUBTATOR Human angiotensinogen 183 Human angiotensinogen, the specific substrate of renin, is a heterogeneous glycoprotein constitutively secreted by the liver. 9694881 1 41 gly glycoprotein 125:136 arg1 a heterogeneous glycoprotein a heterogeneous glycoprotein Fterm glycoprotein Human angiotensinogen, the specific substrate of renin, is a heterogeneous glycoprotein constitutively secreted by the liver. 8157687 1 88 part_of glycoprotein 657:668 arg1 various physiologically derived fragments glycoprotein various physiologically derived fragments Fterm Site glycoprotein fragments In the present study, the interactions of conglutinin and mannan-binding protein were evaluated with the complement glycoprotein C3, including various physiologically derived fragments of this glycoprotein, and neoglycolipids prepared from oligosaccharides released from C3 and its isolated alpha and beta chains. 9343410 7 58 gly domain 1315:1320 arg1 a signal a signal We propose the hypothesis that the removal of O-GlcNAc from an interaction domain can be a signal for protein association. 9343410 7 58 gly domain 1315:1320 arg1 the removal the removal We propose the hypothesis that the removal of O-GlcNAc from an interaction domain can be a signal for protein association. 22171062 5 91 gly glycoproteins 942:954 arg1 recombinant soluble G (sG) glycoproteins glycoproteins glycan composition Fterm glycoproteins We examined the site occupancy and glycan composition of recombinant soluble G (sG) glycoproteins expressed in two different mammalian cell systems, transient human embryonic kidney 293 (HEK293) cells and vaccinia virus (VV)-HeLa cells, using a suite of biochemical and biophysical tools: electrophoresis, lectin binding and tandem mass spectrometry. 22171062 5 86 gly occupancy 879:887 arg1 recombinant soluble G (sG) glycoproteins glycoproteins site Fterm glycoproteins site We examined the site occupancy and glycan composition of recombinant soluble G (sG) glycoproteins expressed in two different mammalian cell systems, transient human embryonic kidney 293 (HEK293) cells and vaccinia virus (VV)-HeLa cells, using a suite of biochemical and biophysical tools: electrophoresis, lectin binding and tandem mass spectrometry. 31944613 3 30 gly glycosylation 450:462 arg2 158 or 169 glycosylation site 158 or 169 glycosylation site site Our previous study shows that deletion of 158 or 169 glycosylation site on the HA head of the H5 subtype AIV strain rS-144-/158+/169+ increases the viral virulence in mammals; however, the mechanism remains unknown. 26070719 4 38 gly glycopeptides 805:817 arg2 glycopeptides glycopeptides glycopeptides Viewing the urgent need to address these challenges, emerging methods and techniques are being developed with the goal of analyzing glycopeptides in a sensitive, comprehensive, and high-throughput manner. 9520292 7 4 part_of terminus 1236:1243 arg1 two peptides terminus two peptides peptides This protocol identified four epitopes: two peptides within the propeptide, a third at the carboxy terminus and the fourth at the glycosylation site of the mature enzyme. 9520292 7 43 part_of enzyme 1300:1305 arg1 the glycosylation site enzyme the glycosylation site Fterm Site enzyme site This protocol identified four epitopes: two peptides within the propeptide, a third at the carboxy terminus and the fourth at the glycosylation site of the mature enzyme. 23613470 9 62 part_of Wnt11 1421:1425 arg1 the Asn40 glycosylation site Wnt11 the Asn40 glycosylation site PUBTATOR Site Wnt11 7481 site By the fusion of the Asn40 glycosylation site of Wnt11, Wnt3a was secreted apically. 1703533 5 47 gly N-glycosylation 987:1001 arg2 any potential N-glycosylation sites any potential N-glycosylation sites sites The first 30 amino acid residues of Art v II did not contain any potential N-glycosylation sites. 12765790 7 7 gly fucosylated 1326:1336 arg1 mainly fucosylated, partially sulfated diantennary, triantennary or tetraantennary glycans mainly fucosylated, partially sulfated diantennary, triantennary or tetraantennary glycans Carbohydrate chains bearing PSA or the HNK1 epitope comprised mainly fucosylated, partially sulfated diantennary, triantennary or tetraantennary glycans without bisecting GlcNAc or fucosylated diantennary and triantennary species carrying, in part, bisecting GlcNAc residues, respectively. 10889209 5 53 part_of GIRK1 729:733 arg1 GIRK1 membrane-spanning domain 1 GIRK1 GIRK1 membrane-spanning domain 1 PUBTATOR Site GIRK1 3760 domain GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site. 10889209 5 67 part_of GIRK4 846:850 arg1 GIRK4 membrane-spanning domain 1 GIRK4 GIRK4 membrane-spanning domain 1 PUBTATOR Site GIRK4 3762 domain GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site. 8380463 7 82 gly residue 905:911 arg1 glycans residue 41 glycans residue 41 Absence of glycans at residue 41 (gN1) showed no significant effect on the conformation of the protein or induction of a serum neutralizing antibody response. 24632142 0 12 gly glycoprotein 63:74 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Reexamination of aspartoacylase: is this human enzyme really a glycoprotein? 22180207 4 3 gly O-glycosylated 854:867 arg1 O-glycosylated sites O-glycosylated sites sites This strategy permits O-glycosylated sites to be unambiguously localized, even in multiple-glycosylated peptides. 22180207 4 28 gly multiple-glycosylated 914:934 arg1 multiple-glycosylated peptides multiple-glycosylated peptides peptides This strategy permits O-glycosylated sites to be unambiguously localized, even in multiple-glycosylated peptides. 24899172 12 26 gly nonglycosylated 2239:2253 arg1 nonglycosylated and glycosylated N146 nonglycosylated and glycosylated N146 N146 Our data suggest that the coexistence of nonglycosylated and glycosylated N146 at the surface of HBV reflects the dual function of this determinant in infectivity and immune escape. 24899172 12 102 gly glycosylated 2259:2270 arg1 nonglycosylated and glycosylated N146 nonglycosylated and glycosylated N146 N146 Our data suggest that the coexistence of nonglycosylated and glycosylated N146 at the surface of HBV reflects the dual function of this determinant in infectivity and immune escape. 25451932 8 52 part_of protease 1061:1068 arg1 the protease domain protease the protease domain Fterm Site protease domain Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation. 3192519 0 45 gly glycosylation 19:31 arg1 human ApoCIII ApoCIII site PUBTATOR ApoCIII 345 site Mutagenesis of the glycosylation site of human ApoCIII. 19692476 6 25 part_of CD4 1216:1218 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 920 site The adaptive amino acid changes had no impact on CCR5 antagonist resistance but made virus more sensitive to neutralization by antibodies to the CD4 binding site, modestly enhanced affinity for CD4, and made TA1 more responsive to CD4 binding. 15956584 0 29 gly glycoproteins 72:84 arg1 hepatitis C virus envelope glycoproteins hepatitis C virus envelope glycoproteins Fterm glycoproteins Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. 29944110 8 38 gly glycosylation 1135:1147 arg2 an additional potential glycosylation site an additional potential glycosylation site site We found that clade 3C.2a viruses, possessing an additional potential glycosylation site at HA1 position N158, were poorly recognized by some of the mAbs, but other residues, notably at position 159, also affected antibody binding. 7998391 9 5 gly glycosylation 1384:1396 arg2 glycosylation site glycosylation site site These properties may be also associated with the loss of glycosylation site in the receptor-binding region of hemagglutinin molecule. 29562594 3 41 part_of containing 625:634 arg1 CMG2-Fc AND one N-glycosylation site CMG2-Fc one N-glycosylation site PUBTATOR Site 2 (CMG2 118429 site Fc-fused capillary morphogenesis protein 2 (CMG2-Fc) containing one N-glycosylation site on the Fc domain, produced in Nicotiana benthamiana whole plants, served as a model protein. 29562594 3 41 part_of containing 625:634 arg1 a model protein AND one N-glycosylation site a model protein one N-glycosylation site Fterm Site protein site Fc-fused capillary morphogenesis protein 2 (CMG2-Fc) containing one N-glycosylation site on the Fc domain, produced in Nicotiana benthamiana whole plants, served as a model protein. 29562594 3 41 part_of containing 625:634 arg1 Fc-fused capillary morphogenesis protein 2 AND one N-glycosylation site Fc-fused capillary morphogenesis protein 2 one N-glycosylation site Fterm Site protein 2 site Fc-fused capillary morphogenesis protein 2 (CMG2-Fc) containing one N-glycosylation site on the Fc domain, produced in Nicotiana benthamiana whole plants, served as a model protein. 10889209 4 55 gly glycosylated 655:666 arg2 Asn Asn(119) Asn(119) Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132). 10889209 4 55 gly glycosylated 655:666 arg1 GIRK1 GIRK1 Asn(119) PUBTATOR GIRK1 3760 Asn(119) Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132). 10889209 4 55 gly glycosylated 655:666 arg1 GIRK1 GIRK1 Asn(119) PUBTATOR GIRK1 3760 Asn(119) Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132). 10889209 4 68 gly glycosylated 703:714 arg2 Asn Asn(132) Asn(132) Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132). 10889209 4 68 gly glycosylated 703:714 arg1 GIRK4 GIRK4 Asn(132) PUBTATOR GIRK4 3762 Asn(132) Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132). 10889209 4 68 gly glycosylated 703:714 arg1 GIRK4 GIRK4 Asn(132) PUBTATOR GIRK4 3762 Asn(132) Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132). 10080942 5 33 gly attachment 885:894 arg1 N266 AND a carbohydrate moiety N86 and N266 a carbohydrate moiety N86 and N266 Therefore, a simultaneous attachment of a carbohydrate moiety to N86 and N266, cleavage of the propeptide from the single DNase II precursor, and the inherent signal peptide might be required for subcellular sorting and proteolytic maturation of the enzyme. 22257732 5 7 part_of contained 1157:1165 arg1 the extracellular domain AND one O-glycosylation site the extracellular domain one O-glycosylation site site The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 7 part_of contained 1157:1165 arg1 the extracellular domain AND three N-glycosylation sites the extracellular domain three N-glycosylation sites sites The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 7 part_of contained 1157:1165 arg1 the extracellular domain AND N-62 N-12, N-62, and N-111 N-12, N-62, and N-111 The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 7 part_of contained 1157:1165 arg1 the extracellular domain AND N-111 N-12, N-62, and N-111 N-12, N-62, and N-111 The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 7 part_of contained 1157:1165 arg1 the extracellular domain AND N-111 N-12, N-62, and N-111 N-12, N-62, and N-111 The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 8740419 3 43 gly occupied 659:666 arg2 its single N-glycosylation site its single N-glycosylation site site The NGFRe portion was disulphide-bonded and its single N-glycosylation site was occupied. 8740419 3 58 gly N-glycosylation 634:648 arg2 its single N-glycosylation site its single N-glycosylation site site The NGFRe portion was disulphide-bonded and its single N-glycosylation site was occupied. 19808681 2 37 gly glycosylation 323:335 arg2 the most N-linked glycosylation sites sites sites Kv12.2 features the longest S5-P loop among all known mammalian Kv channels with the most N-linked glycosylation sites (three sites). 10419520 9 39 gly glycosylated 1223:1234 arg1 the long hydrophilic sequences the long hydrophilic sequences sequences All three of the long hydrophilic sequences of S2P can be glycosylated, indicating that they all project into the lumen. 8643111 5 31 gly glycosylation 892:904 arg2 The light chain glycosylation site The light chain glycosylation site site The light chain glycosylation site, however, was not included. 32211339 3 4 gly N-glycosylation 477:491 arg2 the GP N-glycosylation sites the GP N-glycosylation sites sites We aimed to characterize (i) the GP N-glycosylation sites contributing to the shielding, and (ii) the effect of mutating these sites on immune subversion by the EBOV-GP. 17015441 1 47 gly glycosylation 118:130 arg1 mouse TRPM8 mouse TRPM8 PUBTATOR TRPM8 Q7Z2W7 We have investigated the glycosylation, disulfide bonding, and subunit structure of mouse TRPM8. 17606981 0 47 gly glycosylation 59:71 arg1 CD45 CD45 PUBTATOR CD45 5788 T-cell activation results in microheterogeneous changes in glycosylation of CD45. 20795641 6 42 part_of terminus 1153:1160 arg1 N-linked glycopeptides terminus N-linked glycopeptides glycopeptides Three (18)O atoms ((18)O(3)) are incorporated into N-linked glycopeptides for samples treated in (18)O-water, two at the carboxyl terminus by trypsin during hydrazide coupling and the third at the N-glycosylation site through PNGaseF-mediated deglycosylation. 24725402 7 7 gly glycosylation 754:766 arg2 a glycosylation site a glycosylation site site The loss of a glycosylation site in HA enhanced overall binding to receptors. 26156869 7 71 gly Fc-glycosylation 1644:1659 arg2 the Fc-glycosylation site the Fc-glycosylation site site We conclude that EndoS and EndoS2 hydrolyze different glycoforms from the Fc-glycosylation site on therapeutic mAbs and that this can be used for rapid quantification of high mannose content. 30578591 4 2 gly glycosylated 640:651 arg1 four potential N-linked glycosylation sites four potential N-linked glycosylation sites sites The data indicate that three of four potential N-linked glycosylation sites are glycosylated, including one partial glycosylation site from both cell lines. 30578591 4 19 gly glycosylation 616:628 arg2 four potential N-linked glycosylation sites four potential N-linked glycosylation sites sites The data indicate that three of four potential N-linked glycosylation sites are glycosylated, including one partial glycosylation site from both cell lines. 30578591 4 50 gly glycosylation 676:688 arg2 one partial glycosylation site one partial glycosylation site site The data indicate that three of four potential N-linked glycosylation sites are glycosylated, including one partial glycosylation site from both cell lines. 3980466 1 20 gly asparagine-linked 152:168 arg1 asparagine-linked oligosaccharides asparagine asparagine-linked oligosaccharides asparagine Reproducible site-specific patterns of sialylation and branching in asparagine-linked oligosaccharides. 9658108 6 70 gly region 1072:1077 arg1 hexameric repeats region hexameric repeats region However, the number of hexameric repeats of the mucin-like region was reduced from 27 in havcr-1 to 13 in huhavcr-1. 9050863 7 20 gly glycosylation 1057:1069 arg2 the glycosylation sequon the glycosylation sequon sequon Site-directed mutagenesis provides evidence that virion secretion requires the glycosylation sequon in the pre-S2 domain of M. 7559653 7 36 gly non-glycosylated 1634:1649 arg1 the non-glycosylated PAF receptor the non-glycosylated PAF receptor PUBTATOR PAF receptor 9768 The binding affinity for PAF is not significantly effected by the presence or location of the carbohydrate, and variations in cell surface expression have little influence on signal transduction, as the non-glycosylated PAF receptor is equally effective for activation of phospholipase C as the native molecule. 22538665 5 29 gly proteins 1359:1366 arg1 humanized glycans proteins humanized glycans Fterm proteins Furthermore, by comparative analysis of byproduct formation and the glycosylation site occupancy, we propose that the Hpoch1Δ strain would be more suitable than the Hpoch1ΔHpalg3Δ strain as a host for the production of recombinant proteins with humanized glycans. 22538665 5 62 gly glycosylation 1196:1208 arg2 the glycosylation site occupancy the glycosylation site occupancy site Furthermore, by comparative analysis of byproduct formation and the glycosylation site occupancy, we propose that the Hpoch1Δ strain would be more suitable than the Hpoch1ΔHpalg3Δ strain as a host for the production of recombinant proteins with humanized glycans. 30158294 11 88 gly non-glycosylated 1726:1741 arg1 non-glycosylated SERINC5 non-glycosylated SERINC5 PUBTATOR SERINC5 256987 We conclude that although not required for restrictive-activity or Nef-sensitivity, N-linked glycosylation is important for maintaining the steady-state expression of SERINC5 and that non-glycosylated SERINC5 is likely subjected to a quality-control mechanism that induces its proteasomal degradation.IMPORTANCE SERINC5 is a member of a family of multi-pass transmembrane proteins that inhibit the infectivity of retroviruses including HIV-1. 12488050 9 71 part_of DRM 1596:1598 arg1 a raft-like DRM domain DRM a raft-like DRM domain OGER Site DRM O60565 domain These results suggest that in non-polarized mammalian cells, GLUT1 can be organized into a raft-like DRM domain but GLUT3 may distribute to fluid membrane domains. 10992007 0 40 part_of sites 22:26 arg1 the human thyrotropin receptor thyrotropin receptor sites PUBTATOR Site thyrotropin receptor 7253 sites Identification of the sites of asparagine-linked glycosylation on the human thyrotropin receptor and studies on their role in receptor function and expression. 1918071 6 85 part_of containing 1268:1277 arg1 peptides AND N-glycosylation sites peptides N-glycosylation sites sites Thus, binding is not restricted to peptides containing N-glycosylation sites. 28493121 8 15 gly glycosylation 1189:1201 arg1 glycan heterogeneity site glycan heterogeneity site Finally, this review also covers other strategies such as the glycosylation site insertion and manipulation of glycan heterogeneity to produce desired glycoforms for diverse biotechnology applications. 15804357 9 19 part_of regions 1063:1069 arg1 phosphorylation sites regions phosphorylation sites sites It possesses five putative transmembrane (TM) regions with a cleavage site, a N-glycosylation site, and a number of phosphorylation sites. 15804357 9 19 part_of regions 1063:1069 arg1 a cleavage site site site It possesses five putative transmembrane (TM) regions with a cleavage site, a N-glycosylation site, and a number of phosphorylation sites. 23069765 2 1 gly N-glycosylation 323:337 arg2 Asn68 Asn68 Asn68 Its polypeptide monomer contains one canonical N-glycosylation site at Asn68, and human recombinant IL-17A was partly N-glycosylated when expressed in human kidney (HEK293) cells as a fusion protein with a melittin signal sequence and an N-terminal hexahistidine tag. 23069765 2 1 gly N-glycosylation 323:337 arg2 one canonical N-glycosylation site one canonical N-glycosylation site site Its polypeptide monomer contains one canonical N-glycosylation site at Asn68, and human recombinant IL-17A was partly N-glycosylated when expressed in human kidney (HEK293) cells as a fusion protein with a melittin signal sequence and an N-terminal hexahistidine tag. 23069765 2 34 gly N-glycosylated 394:407 arg1 human recombinant IL-17A human recombinant IL-17A PUBTATOR IL-17A 3605 Its polypeptide monomer contains one canonical N-glycosylation site at Asn68, and human recombinant IL-17A was partly N-glycosylated when expressed in human kidney (HEK293) cells as a fusion protein with a melittin signal sequence and an N-terminal hexahistidine tag. 15890930 0 0 part_of epitope 10:16 arg1 gp120 gp120 epitope PUBTATOR Site gp120 155971 epitope The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. 15890930 0 0 part_of epitope 10:16 arg1 the V2 domain epitope the V2 domain domain The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. 15890930 0 78 part_of gp120 38:42 arg1 the V2 domain gp120 the V2 domain PUBTATOR Site gp120 155971 domain The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. 30659065 11 16 part_of IgM 1842:1844 arg1 N272 IgM sites N46, N209, and N272 OGER SpecificSite IgM P01871 sites N46, N209, and N272 IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms. 30659065 11 16 part_of IgM 1842:1844 arg1 N46 IgM sites N46, N209, and N272 OGER SpecificSite IgM P01871 sites N46, N209, and N272 IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms. 30659065 11 16 part_of IgM 1842:1844 arg1 IgM sites IgM sites N46, N209, and N272 OGER SpecificSite IgM P01871 sites N46, N209, and N272 IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms. 30659065 11 16 part_of IgM 1842:1844 arg1 N46 IgM sites N46, N209, and N272 OGER SpecificSite IgM P01871 sites N46, N209, and N272 IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms. 30659065 11 16 part_of IgM 1842:1844 arg1 IgM sites IgM sites N46, N209, and N272 OGER SpecificSite IgM P01871 sites N46, N209, and N272 IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms. 30659065 11 16 part_of IgM 1842:1844 arg1 IgM sites IgM sites N46, N209, and N272 OGER SpecificSite IgM P01871 sites N46, N209, and N272 IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms. 16755913 7 24 gly N-glycosylation 1248:1262 arg2 N-glycosylation modification sites N-glycosylation modification sites sites The mutant of wild type human PRNP gene at N-glycosylation modification sites and six modified mutants with mono- or non-N-glycosylation had been obtained successfully in the study. 23001782 9 81 gly heterogeneity 1608:1620 arg1 the isoforms the isoforms Fterm isoforms Electrophoretic analysis of intact hSHBG revealed size and charge heterogeneity of the isoforms circulating in blood serum. 11595658 1 42 part_of contains 154:161 arg1 The corticotropin-releasing factor (CRF) receptor type 1 AND five potential N-glycosylation sites The corticotropin-releasing factor (CRF) receptor type 1 five potential N-glycosylation sites PUBTATOR Site corticotropin-releasing factor (CRF) receptor type 1 1394 sites The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 CRFR1 AND five potential N-glycosylation sites CRFR1 five potential N-glycosylation sites PUBTATOR Site CRFR1 1394 sites The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 The corticotropin-releasing factor (CRF) receptor type 1 AND N98 corticotropin-releasing factor (CRF) receptor type 1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite corticotropin-releasing factor (CRF) receptor type 1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 The corticotropin-releasing factor (CRF) receptor type 1 AND N90 corticotropin-releasing factor (CRF) receptor type 1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite corticotropin-releasing factor (CRF) receptor type 1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 The corticotropin-releasing factor (CRF) receptor type 1 AND N45 corticotropin-releasing factor (CRF) receptor type 1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite corticotropin-releasing factor (CRF) receptor type 1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 The corticotropin-releasing factor (CRF) receptor type 1 AND N78 corticotropin-releasing factor (CRF) receptor type 1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite corticotropin-releasing factor (CRF) receptor type 1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 The corticotropin-releasing factor (CRF) receptor type 1 AND N90 corticotropin-releasing factor (CRF) receptor type 1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite corticotropin-releasing factor (CRF) receptor type 1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 The corticotropin-releasing factor (CRF) receptor type 1 AND N45 corticotropin-releasing factor (CRF) receptor type 1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite corticotropin-releasing factor (CRF) receptor type 1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 The corticotropin-releasing factor (CRF) receptor type 1 AND N78 corticotropin-releasing factor (CRF) receptor type 1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite corticotropin-releasing factor (CRF) receptor type 1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 The corticotropin-releasing factor (CRF) receptor type 1 AND N45 corticotropin-releasing factor (CRF) receptor type 1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite corticotropin-releasing factor (CRF) receptor type 1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 The corticotropin-releasing factor (CRF) receptor type 1 AND N78 corticotropin-releasing factor (CRF) receptor type 1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite corticotropin-releasing factor (CRF) receptor type 1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 The corticotropin-releasing factor (CRF) receptor type 1 AND N78 corticotropin-releasing factor (CRF) receptor type 1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite corticotropin-releasing factor (CRF) receptor type 1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 CRFR1 AND N98 CRFR1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite CRFR1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 CRFR1 AND N90 CRFR1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite CRFR1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 CRFR1 AND N45 CRFR1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite CRFR1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 CRFR1 AND N78 CRFR1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite CRFR1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 CRFR1 AND N90 CRFR1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite CRFR1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 CRFR1 AND N45 CRFR1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite CRFR1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 CRFR1 AND N78 CRFR1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite CRFR1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 CRFR1 AND N45 CRFR1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite CRFR1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 CRFR1 AND N78 CRFR1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite CRFR1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 11595658 1 42 part_of contains 154:161 arg1 CRFR1 AND N78 CRFR1 N38, N45, N78, N90, and N98 PUBTATOR SpecificSite CRFR1 1394 N38, N45, N78, N90, and N98 The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. 8099782 1 63 gly glycoproteins 276:288 arg1 four small glycoproteins four small glycoproteins Fterm glycoproteins Saposin B is one of four small glycoproteins (saposins) derived from prosaposin. 30904681 2 5 gly Glycosylation 295:307 arg1 B2GP1 B2GP1 PUBTATOR B2GP1 350 Glycosylation of B2GP1 can impact auto antibody recognition leading to the development of antiphospholipid syndrome (APS), which can result in miscarriages or thrombosis. 20498311 6 69 gly N-glycosylation 1122:1136 arg2 several concomitant N-glycosylation site deletions several concomitant N-glycosylation site deletions site In contrast to 2G12, AH has a high genetic barrier, since several concomitant N-glycosylation site deletions in gp120 are required to afford significant phenotypic drug resistance. 31065929 0 38 gly Glycosylation 0:12 arg1 dentin matrix protein 1 dentin matrix protein 1 PUBTATOR dentin matrix protein 1 13406 Glycosylation of dentin matrix protein 1 is critical for fracture healing via promoting chondrogenesis. 16873272 5 105 part_of SU 906:907 arg1 the SU domain SU the SU domain Cterm Site SU domain N- and C-terminal deletion analysis of the SU domain revealed a minimal continuous RBD spanning amino acids (aa) 225 to 555; however, internal deletions covering the region from aa 397 to 483, but not aa 262 to 300 or aa 342 to 396, were tolerated without significant influence on host cell binding. 30708139 2 17 gly hyper-glycosylated 390:407 arg1 hyper-glycosylated protein hyper-glycosylated protein Fterm protein One aspect of glycoengineering is to introduce new N-glycosylation site (Asn-X-Thr/Ser, where X ≠ Pro) into desirable positions in the peptide backbone, resulting in the generation of hyper-glycosylated protein. 30708139 2 38 gly N-glycosylation 257:271 arg2 new N-glycosylation site new N-glycosylation site site One aspect of glycoengineering is to introduce new N-glycosylation site (Asn-X-Thr/Ser, where X ≠ Pro) into desirable positions in the peptide backbone, resulting in the generation of hyper-glycosylated protein. 30708139 2 46 gly site 273:276 arg1 Asn-X-Thr/Ser Asn-X-Thr/Ser Asn One aspect of glycoengineering is to introduce new N-glycosylation site (Asn-X-Thr/Ser, where X ≠ Pro) into desirable positions in the peptide backbone, resulting in the generation of hyper-glycosylated protein. 12527303 4 62 gly glycosylation 562:574 arg1 IgG-Fc IgG-Fc Cterm IgG It is established that glycosylation of IgG-Fc is essential for recognition and activation of these ligands. 23763973 11 25 part_of has 1064:1066 arg1 CL2 AND a predicted N-linked glycosylation site CL2 a predicted N-linked glycosylation site OGER Site CL2 Q8N568 site CL2 has a predicted N-linked glycosylation site confirmed by using mass spectrometry. 9393962 7 36 gly glycosylated 811:822 arg1 the glycosylated residues the glycosylated residues residues These findings provided evidence that a direct interaction exists between the glycosylated residues and other residues within the constant and/or variable domains. 9027352 12 117 gly glycoprotein 1155:1166 arg1 the glycoprotein hormone beta-subunits the glycoprotein hormone beta-subunits Fterm glycoprotein The substituted Gln residue is conserved in each of the glycoprotein hormone beta-subunits. 15616123 6 50 gly glycopeptide 994:1005 arg2 glycopeptide glycopeptide glycopeptide The peptide moiety of glycopeptide was determined by the presence of the b- and y-series ions derived from its amino acid sequence in the product ion spectrum, and the oligosaccharide moiety was deduced from the calculated molecular mass of the oligosaccharide. 10837482 7 73 gly glycosylation 1537:1549 arg1 oligosaccharide site oligosaccharide site These results indicate that there is no one specific glycosylation site or type of oligosaccharide (high mannose- or complex-type) that determines apical sorting, but that core N-linked carbohydrates are required for optimal enzymatic activity and for secretion of meprin alpha. 1590788 3 8 gly glycosylation 463:475 arg2 a potential glycosylation site a potential glycosylation site site Mouse saposin also has four functional domains, which are structurally similar to each other, and each domain has cysteines, prolines, and a potential glycosylation site at an almost identical position. 19800422 2 65 gly N-glycosylation 409:423 arg2 the N-glycosylation site the N-glycosylation site site It has been found that the activation of matriptase zymogen occurs via a mechanism requiring its own activity and that the N-glycosylation site is critical for the activation. 17640971 1 6 gly glycosylation 178:190 arg2 the single potential glycosylation site the single potential glycosylation site site CD52 is composed of a 12 amino acid peptide with N-linked glycans bound to the single potential glycosylation site at position 3, and a glycosylphosphatidylinositol-anchor attached at the C-terminus. 17640971 1 6 gly glycosylation 178:190 arg2 position 3 position 3 position 3, CD52 is composed of a 12 amino acid peptide with N-linked glycans bound to the single potential glycosylation site at position 3, and a glycosylphosphatidylinositol-anchor attached at the C-terminus. 17640971 1 20 gly peptide 118:124 arg1 N-linked glycans peptide N-linked glycans peptide CD52 is composed of a 12 amino acid peptide with N-linked glycans bound to the single potential glycosylation site at position 3, and a glycosylphosphatidylinositol-anchor attached at the C-terminus. 9201996 2 8 gly transfer 356:363 arg1 these peptides these peptides these peptides Site peptides To determine the shortest motif sequence required for high level mucin-type O-glycosylation, we prepared more than 100 synthetic peptides and assayed in vitro O-GalNAc transfer to serine or threonine in these peptides using a bovine colostrum UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyl transferase (O-GalNAcT). 9201996 2 29 gly N-acetylgalactosaminyl 469:490 arg1 O-GalNAcT N-acetylgalactosaminyl O-GalNAcT Cterm N-acetylgalactosaminyl To determine the shortest motif sequence required for high level mucin-type O-glycosylation, we prepared more than 100 synthetic peptides and assayed in vitro O-GalNAc transfer to serine or threonine in these peptides using a bovine colostrum UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyl transferase (O-GalNAcT). 17671839 0 25 gly glycoprotein 69:80 arg1 GP5 glycoprotein N-linked glycans GP5 glycoprotein N-linked glycans Influence of porcine reproductive and respiratory syndrome virus GP5 glycoprotein N-linked glycans on immune responses in mice. 21526855 3 8 gly glycoproteins 636:648 arg1 intact glycoproteins intact glycoproteins Fterm glycoproteins The top-down sequencing on the protein level by MALDI-MS is based on the in-source decay (ISD) of intact glycoproteins induced by hydrogen radical transfer from the matrix. 15859596 1 78 gly glycoproteins 178:190 arg1 human serum glycoproteins human serum glycoproteins Fterm glycoproteins This paper reports studies comparing the relative degree of sialylation among human serum glycoproteins carrying complex biantennary N-linked, hybrid, and high-mannose oligosaccharides. 15859596 1 41 gly carrying 192:199 arg1 human serum glycoproteins AND complex biantennary N-linked, hybrid, and high-mannose oligosaccharides glycoproteins complex biantennary N-linked, hybrid, and high-mannose oligosaccharides Fterm glycoproteins This paper reports studies comparing the relative degree of sialylation among human serum glycoproteins carrying complex biantennary N-linked, hybrid, and high-mannose oligosaccharides. 8542022 10 0 gly N-glycosylation 1150:1164 arg2 an N-glycosylation site an N-glycosylation site site This mutation disrupts an N-glycosylation site. 11948877 6 27 gly glycoproteins 2043:2055 arg1 recombinant and native glycoproteins recombinant and native glycoproteins Fterm glycoproteins The potential of this biotinylated UDP-Gal as a novel donor substrate for human galactosyltransferases lies in the targeting of distinct acceptor structures, for example, under-galactosylated glycoconjugates, which are related to diseases, or in the quality control of glycosylation of recombinant and native glycoproteins. 11948877 6 50 gly glycosylation 2003:2015 arg1 recombinant and native glycoproteins recombinant and native glycoproteins Fterm glycoproteins The potential of this biotinylated UDP-Gal as a novel donor substrate for human galactosyltransferases lies in the targeting of distinct acceptor structures, for example, under-galactosylated glycoconjugates, which are related to diseases, or in the quality control of glycosylation of recombinant and native glycoproteins. 21940909 8 134 gly nonglycosylated 1876:1890 arg1 nonglycosylated tryptic peptide nonglycosylated tryptic peptide peptide The area under the receiver operating characteristic curve generated through analyses of nonglycosylated tryptic peptide from vitronectin precursor protein was 0.978, the highest observed in a group of patients with hepatocellular carcinoma. 19527756 7 11 gly Thr 1237:1239 arg1 Leu(133) Leu(133) Leu(133) Mutagenesis of the O-glycosylation site of rhGCSF (Thr(133) to Leu(133)) showed a single peak on bioanalyzer, which overlapped with the peak obtained for a non-glycosylated rhGCSF. 19527756 7 49 gly rhGCSF 1229:1234 arg1 Thr(133) Thr(133) Thr(133) Mutagenesis of the O-glycosylation site of rhGCSF (Thr(133) to Leu(133)) showed a single peak on bioanalyzer, which overlapped with the peak obtained for a non-glycosylated rhGCSF. 19527756 7 76 gly non-glycosylated 1342:1357 arg1 a non-glycosylated rhGCSF a non-glycosylated rhGCSF OGER rhGCSF P09919 Mutagenesis of the O-glycosylation site of rhGCSF (Thr(133) to Leu(133)) showed a single peak on bioanalyzer, which overlapped with the peak obtained for a non-glycosylated rhGCSF. 19527756 7 38 gly O-glycosylation 1205:1219 arg1 rhGCSF rhGCSF site OGER rhGCSF P09919 site Mutagenesis of the O-glycosylation site of rhGCSF (Thr(133) to Leu(133)) showed a single peak on bioanalyzer, which overlapped with the peak obtained for a non-glycosylated rhGCSF. 2771955 8 3 part_of LRG 1468:1470 arg1 a leucine-rich glycoprotein (LRG) sequence LRG a leucine-rich glycoprotein (LRG) sequence PUBTATOR Site LRG 116844 sequence GPIX contains a leucine-rich glycoprotein (LRG) sequence of 24 amino acids similar to conserved LRG sequences in GPIb and other proteins from humans, Drosophila, and yeast. 2771955 8 4 part_of LRG 1521:1523 arg1 conserved LRG sequences LRG conserved LRG sequences PUBTATOR Site LRG 116844 sequences GPIX contains a leucine-rich glycoprotein (LRG) sequence of 24 amino acids similar to conserved LRG sequences in GPIb and other proteins from humans, Drosophila, and yeast. 2771955 8 106 part_of contains 1430:1437 arg1 GPIX AND a leucine-rich glycoprotein (LRG) sequence GPIX a leucine-rich glycoprotein (LRG) sequence PUBTATOR Site GPIX 2815 sequence GPIX contains a leucine-rich glycoprotein (LRG) sequence of 24 amino acids similar to conserved LRG sequences in GPIb and other proteins from humans, Drosophila, and yeast. 15557236 2 58 gly glycosylated 370:381 arg1 these strain variants these strain variants Fterm variants The E protein was glycosylated in only two of these strain variants. 15557236 2 58 gly glycosylated 370:381 arg1 The E protein The E protein Fterm protein The E protein was glycosylated in only two of these strain variants. 8798755 2 34 part_of contains 561:568 arg1 The 376-amino acid intracellular region AND a single catalytic domain The 376-amino acid intracellular region a single catalytic domain domain The 376-amino acid intracellular region contains a single catalytic domain. 7688818 1 69 gly glycoproteins 127:139 arg1 Sindbis virus glycoproteins Sindbis virus glycoproteins Fterm glycoproteins Sindbis virus glycoproteins E1 and E2 undergo a conformational alteration during early virus-cell interaction at the cell surface (D. Flynn, W. J. Meyer, J. M. MacKenzie, Jr., and R. E. Johnston, J. Virol. 7688818 1 69 gly glycoproteins 127:139 arg1 E2 E2 Cterm E2 Sindbis virus glycoproteins E1 and E2 undergo a conformational alteration during early virus-cell interaction at the cell surface (D. Flynn, W. J. Meyer, J. M. MacKenzie, Jr., and R. E. Johnston, J. Virol. 7688818 1 69 gly glycoproteins 127:139 arg1 E1 E1 Cterm E1 Sindbis virus glycoproteins E1 and E2 undergo a conformational alteration during early virus-cell interaction at the cell surface (D. Flynn, W. J. Meyer, J. M. MacKenzie, Jr., and R. E. Johnston, J. Virol. 21940909 3 16 gly units 741:745 arg1 N-linked glycoproteins glycoproteins units Fterm glycoproteins The current study exploited the steric hindrance of glycan units in N-linked glycoproteins, which significantly affects the efficiency of proteolytic digestion if an enzymatically active amino acid is adjacent to the N-linked glycosylation site. 21940909 3 50 gly glycoproteins 759:771 arg1 N-linked glycoproteins N-linked glycoproteins Fterm glycoproteins The current study exploited the steric hindrance of glycan units in N-linked glycoproteins, which significantly affects the efficiency of proteolytic digestion if an enzymatically active amino acid is adjacent to the N-linked glycosylation site. 21940909 3 108 gly glycosylation 908:920 arg2 the N-linked glycosylation site the N-linked glycosylation site site The current study exploited the steric hindrance of glycan units in N-linked glycoproteins, which significantly affects the efficiency of proteolytic digestion if an enzymatically active amino acid is adjacent to the N-linked glycosylation site. 25300029 0 16 gly structures 50:59 arg1 α3 integrin integrin structures Fterm integrin Identification of novel glycans with disialylated structures in α3 integrin from mouse kidney cells with the phenotype of polycystic kidney disease. 25300029 0 61 gly disialylated 37:48 arg1 disialylated structures disialylated structures Identification of novel glycans with disialylated structures in α3 integrin from mouse kidney cells with the phenotype of polycystic kidney disease. 32321762 7 32 gly acid 1511:1514 arg1 PrPC's GPI side-chain side-chain acid Fterm side-chain Using a sialic acid linkage-specific alkylamidation (SALSA) method to discriminate α2,3-linkage from α2,6-linkage, we found that N-acetylneuraminic acid in PrPC's GPI side-chain is linked to galactose through an α2,3-linkage. 7522502 8 14 part_of ATP- 1340:1343 arg1 partial ATP- and GTP-binding sites ATP partial ATP- and GTP-binding sites OGER Site ATP sites A primary sequence analysis showed that each of these polypeptides contains an N-glycosylation site, phosphorylation sites for Ca2+/calmodulin-dependent protein kinase, protein kinase C and casein kinase II, and partial ATP- and GTP-binding sites. 7849028 6 60 gly p62 758:760 arg1 O-linked GlcNAc glycosylation p62 O-linked GlcNAc glycosylation PUBTATOR p62 117268 Localization of the sites of O-linked GlcNAc glycosylation of rat p62 was performed by a combination of deletion analysis of in vitro translation products and by immunoprecipitation of [14C]GlcNAc-labeled proteolytic fragments. 7849028 6 30 gly glycosylation 737:749 arg2 the sites p62 sites PUBTATOR p62 117268 sites Localization of the sites of O-linked GlcNAc glycosylation of rat p62 was performed by a combination of deletion analysis of in vitro translation products and by immunoprecipitation of [14C]GlcNAc-labeled proteolytic fragments. 11344537 1 6 gly present 204:210 arg1 several proteins AND O-Fucosylation several proteins O-Fucosylation Fterm proteins O-Fucosylation is an unusual posttranslational modification present in several proteins that play important roles in physiological processes such as coagulation, cell signaling and metastasis. 17707131 8 40 part_of acyltransferase 1593:1607 arg1 the acyltransferase motifs acyltransferase the acyltransferase motifs Fterm Site acyltransferase motifs Modifications of the sidechain structures of His104, Asp109, Phe146, Arg149, Glu178, Gly179, Thr180, Arg181 and Ile208 all affected AGPAT1 activity, indicating that the acyltransferase motifs indeed are important for AGPAT catalysis. 8286855 5 48 gly O-glycosylation 812:826 arg2 potential O-glycosylation sites potential O-glycosylation sites sites We propose that the glycosyltransferases present in erythrocytes recognize specific flanking sequences around potential O-glycosylation sites. 18815274 7 36 part_of SV2A 930:933 arg1 the fourth luminal domain SV2A the fourth luminal domain PUBTATOR Site SV2A 64051 domain Furthermore, we found disruption of a N-glycosylation site (N573Q) within the fourth luminal domain of SV2A rendered the mutant unable to mediate the entry of BoNT/E and also reduced the entry of BoNT/A. 16512686 0 3 gly glycopeptides 103:115 arg2 tryptic glycopeptides tryptic glycopeptides glycopeptides Tools for glycoproteomic analysis: size exclusion chromatography facilitates identification of tryptic glycopeptides with N-linked glycosylation sites. 16512686 0 44 gly glycosylation 131:143 arg2 N-linked glycosylation sites N-linked glycosylation sites sites Tools for glycoproteomic analysis: size exclusion chromatography facilitates identification of tryptic glycopeptides with N-linked glycosylation sites. 24798328 10 27 gly glycosylation 1596:1608 arg1 three of four linker regions three of four linker regions regions This was supported by expression of LDLR in HEK293 cells, where knock-out of the GalNAc-T11 isoform resulted in the loss of glycosylation of three of four linker regions. 25389233 14 92 part_of IgG-CH2 2488:2494 arg1 the IgG-CH2 domain IgG the IgG-CH2 domain Cterm Site IgG domain Two putative mechanisms may contribute to the increased exposure of these glycans: (1) the canonical N-glycosylation site of the IgG-CH2 domain; (2) an IgG binding non-IgG molecule, like complement or C-reactive protein. 8286061 12 128 gly glycosylation 2060:2072 arg2 the glycosylation site the glycosylation site site These flexible regions of the V3 loop lead to conformational flexure of the entire V3 loop without altering the local structures of the glycosylation site or the GPG-crest. 1492495 8 49 gly glycosylation 1195:1207 arg2 the glycosylation site the glycosylation site site Removal of the glycosylation site by site-directed mutagenesis abolished glycosylation with no effect on secretion, although CAT activity was again reduced, possibly due to an effect on the active site. 1457969 1 52 part_of thyrotrophin 192:203 arg1 the three glycosylation sites thyrotrophin the three glycosylation sites Fterm Site thyrotrophin sites The asparagine-linked carbohydrate structures at each of the three glycosylation sites of human thyrotrophin were investigated by 400 MHz 1H-NMR spectroscopy. 22997027 7 46 gly glycopeptide 1268:1279 arg2 glycopeptide enrichment/separation glycopeptide enrichment/separation glycopeptide This review summarizes the different methodologies that can be employed for glycopeptide enrichment/separation from complex samples including methods based on lectin affinity enrichment, covalent interactions, or chromatographic separations and solid-phase extraction. 8797097 1 1 gly glycosylation 158:170 arg2 a glycosylation site a glycosylation site site Inhibin-A is a glycoprotein composed of an alpha subunit containing a glycosylation site and a beta A subunit, whereas activin-A is a homodimer of two inhibin beta A subunits. 8797097 1 17 gly glycoprotein 103:114 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Inhibin-A is a glycoprotein composed of an alpha subunit containing a glycosylation site and a beta A subunit, whereas activin-A is a homodimer of two inhibin beta A subunits. 8286855 2 2 gly Ser 496:498 arg1 residues residues Ser and Thr residues We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site. 8286855 2 29 gly O-glycosylated 481:494 arg1 O-glycosylated Ser O-glycosylated Ser Ser and Thr residues We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site. 8286855 2 68 gly N-glycosylation 540:554 arg2 the single N-glycosylation site the single N-glycosylation site site We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site. 8286855 2 38 gly O-glycosylation 328:342 arg1 the extracellular domain GpA domain PUBTATOR GpA 2993 domain We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site. 8286855 2 38 gly O-glycosylation 328:342 arg2 the single N-glycosylation site GpA site PUBTATOR GpA 2993 site We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site. 8286855 2 38 gly O-glycosylation 328:342 arg2 the sites GpA sites PUBTATOR GpA 2993 sites We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site. 18844296 1 39 gly glycoproteins 212:224 arg1 the N-linked sugar moiety glycoproteins the N-linked sugar moiety Fterm glycoproteins Human genetic diseases that affect N-glycosylation result from the defective synthesis of the N-linked sugar moiety (glycan) of glycoproteins. 18844296 1 39 gly glycoproteins 212:224 arg1 glycan glycoproteins glycan Fterm glycoproteins Human genetic diseases that affect N-glycosylation result from the defective synthesis of the N-linked sugar moiety (glycan) of glycoproteins. 12438611 8 64 part_of sites 1436:1440 arg1 gp120 gp120 sites OGER Site gp120 Q14624 sites We showed that 2G12 and DC-SIGN bound to nonoverlapping sites in gp120 because (i) 2G12 did not block soluble gp120 or virion binding to DC-SIGN, (ii) 2G12 bound to gp120-Fc that was prebound to cell surface DC-SIGN, and (iii) gp120-Fc mutants that lack glycosylation sites involved in 2G12's epitope were also fully capable of binding DC-SIGN. 2886334 4 37 gly glycoforms 806:815 arg1 same polypeptide same polypeptide polypeptide We suggest, therefore, that by controlling N-glycosylation a tissue creates an unique set of glycoforms (same polypeptide but with oligosaccharides that differ either in sequence or disposition). 2886334 4 61 gly polypeptide 823:833 arg1 oligosaccharides polypeptide oligosaccharides polypeptide We suggest, therefore, that by controlling N-glycosylation a tissue creates an unique set of glycoforms (same polypeptide but with oligosaccharides that differ either in sequence or disposition). 19610667 1 11 gly glycosylation 87:99 arg1 gp120/gp41 gp120/gp41 PUBTATOR gp120 155971 The extensive glycosylation of HIV-1 envelope proteins (Envs), gp120/gp41, is known to play an important role in evasion of host immune response by masking key neutralization epitopes and presenting the Env glycosylation as "self" to the host immune system. 19610667 1 11 gly glycosylation 87:99 arg1 HIV-1 envelope proteins HIV-1 envelope proteins Fterm proteins The extensive glycosylation of HIV-1 envelope proteins (Envs), gp120/gp41, is known to play an important role in evasion of host immune response by masking key neutralization epitopes and presenting the Env glycosylation as "self" to the host immune system. 1869556 4 70 gly N-glycosylated 753:766 arg1 N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1 beta protein N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1 beta protein Fterm protein Upon expression in Saccharomyces cerevisiae, approximately equimolar amounts of N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1 beta protein were secreted. 1869556 4 80 gly unglycosylated 781:794 arg1 N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1 beta protein N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1 beta protein Fterm protein Upon expression in Saccharomyces cerevisiae, approximately equimolar amounts of N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1 beta protein were secreted. 6604728 4 22 gly site 791:794 arg1 the oligosaccharides site the oligosaccharides site After removal from the peptide backbone by the almond emulsin peptide: N-glycosidase, the oligosaccharides from each isolated site were analyzed by gel filtration, ion exchange chromatography, concanavalin A affinity chromatography, and glycosidase treatment to assess the contribution of sialic acid and branching patterns of the oligosaccharide backbones to the overall microheterogeneity. 22823882 0 26 gly glycoprotein 93:104 arg1 a glycoprotein database a glycoprotein database Fterm glycoprotein Large-scale identification of N-glycosylated proteins of mouse tissues and construction of a glycoprotein database, GlycoProtDB. 22823882 0 54 gly N-glycosylated 30:43 arg1 N-glycosylated proteins N-glycosylated proteins Fterm proteins Large-scale identification of N-glycosylated proteins of mouse tissues and construction of a glycoprotein database, GlycoProtDB. 2503511 2 46 gly Asn-linked 379:388 arg1 the Asn-linked oligosaccharides Asn the Asn-linked oligosaccharides Asn In this study, the structures of the Asn-linked oligosaccharides of Chinese hamster ovary-expressed rt-PA have been elucidated. 2503511 2 56 gly rt-PA 442:446 arg1 the Asn-linked oligosaccharides rt-PA the Asn-linked oligosaccharides Cterm rt-PA P00750 In this study, the structures of the Asn-linked oligosaccharides of Chinese hamster ovary-expressed rt-PA have been elucidated. 10211957 3 30 gly glycoproteins 482:494 arg1 E1 E1 Cterm E1 HCV glycoproteins, E1 and E2, are heavily modified by N-linked glycosylation. 10211957 3 30 gly glycoproteins 482:494 arg1 HCV glycoproteins HCV glycoproteins Fterm glycoproteins HCV glycoproteins, E1 and E2, are heavily modified by N-linked glycosylation. 20520733 5 29 part_of have 862:865 arg1 both proteins AND six-transmembrane-domains both proteins six-transmembrane-domains Fterm Site proteins six-transmembrane-domains These methods indicate that both proteins have six-transmembrane-domains with both N- and C-termini localized to the cytosol. 2303059 1 43 part_of glycoproteins 256:268 arg1 the conserved glycosylation site glycoproteins the conserved glycosylation site Fterm Site glycoproteins site The complete primary structures of the Asn-linked oligosaccharides from the conserved glycosylation site of the type-I variant surface glycoproteins of Trypanosoma brucei MITat 1.4 and MITat 1.6 were determined using a combination of exoglycosidase digestions, permethylation analysis, acetolysis and 1H NMR. 7831962 4 39 gly glycosylation 778:790 arg2 one glycosylation site one glycosylation site site Nucleotide sequence analysis of the HA gene of these two variants demonstrated differences at several amino acid positions in the HA1 subunit including one glycosylation site. 8837707 4 19 gly N-glycosylation 651:665 arg2 the N-glycosylation site variant the N-glycosylation site variant site Previously, the polyadenylation signal site variant was observed only in the presence of the N-glycosylation site variant, although the latter has been reported to occur in the absence of the polyadenylation signal site variant. 22921534 2 24 gly glycosylation 329:341 arg2 the glycosylation site the glycosylation site site To investigate the role(s) of CM2 glycosylation in the virus replication, we generated rN11A, a recombinant influenza C virus lacking the glycosylation site. 3849428 7 8 gly glycosylation 1031:1043 arg2 Asn154 Asn154 Asn154 During biosynthesis, HA-T antigen is co-translationally translocated across the membrane of the ER, the signal peptide is cleaved and a mannose-rich oligosaccharide is attached to the polypeptide (T antigen contains one potential N-linked glycosylation site at Asn154). 3849428 7 8 gly glycosylation 1031:1043 arg2 one potential N-linked glycosylation site one potential N-linked glycosylation site site During biosynthesis, HA-T antigen is co-translationally translocated across the membrane of the ER, the signal peptide is cleaved and a mannose-rich oligosaccharide is attached to the polypeptide (T antigen contains one potential N-linked glycosylation site at Asn154). 3849428 7 34 gly attached 960:967 arg1 the polypeptide AND a mannose-rich oligosaccharide the polypeptide a mannose-rich oligosaccharide polypeptide During biosynthesis, HA-T antigen is co-translationally translocated across the membrane of the ER, the signal peptide is cleaved and a mannose-rich oligosaccharide is attached to the polypeptide (T antigen contains one potential N-linked glycosylation site at Asn154). 20335223 5 55 gly N-glycosylation 908:922 arg2 an additional N-glycosylation site an additional N-glycosylation site site We identified an N528S homozygous mutation in the VWF propeptide D2 domain, predicting the introduction of an additional N-glycosylation site at amino acid 526 in close vicinity to a "CGLC" disulphide isomerase consensus sequence. 8837707 6 5 gly N-glycosylation 935:949 arg2 the N-glycosylation site variant the N-glycosylation site variant site While the N-glycosylation site variant had a high frequency in the Bantu-speaking people from Southern Africa (0.44), the San of Southern Africa (0.22), African Americans (0.37), and Cheyenne Indians (0.375), the polyadenylation signal site variant was absent in these groups. 17924005 6 52 part_of CK-2 1088:1091 arg1 a CK-2 phosphorylation site CK-2 a CK-2 phosphorylation site OGER Site CK-2 site The potential protein domain analysis of Env sequences showed the loss of a CK-2 phosphorylation site caused by D197N mutation in one epitope, and a N-glycosylation site caused by S246Y and V247I mutations in another epitope. 17924005 6 64 part_of Env 1053:1055 arg1 Env sequences Env Env sequences PUBTATOR Site Env 30816 sequences The potential protein domain analysis of Env sequences showed the loss of a CK-2 phosphorylation site caused by D197N mutation in one epitope, and a N-glycosylation site caused by S246Y and V247I mutations in another epitope. 19167329 0 44 gly N-glycosylation 38:52 arg1 polypeptides polypeptides polypeptides Cotranslational and posttranslational N-glycosylation of polypeptides by distinct mammalian OST isoforms. 29992770 7 51 part_of N-glycosylation 1046:1060 arg1 19 unique N-glycosylation sites glycoproteins 19 unique N-glycosylation sites Fterm Site glycoproteins sites Thirty-eight tryptic N-glycopeptides are identified, having 19 unique N-glycosylation sites representing 14 glycoproteins. 29992770 7 65 part_of unique 1039:1044 arg1 19 unique N-glycosylation sites 14 19 unique N-glycosylation sites Cterm Site 14 sites Thirty-eight tryptic N-glycopeptides are identified, having 19 unique N-glycosylation sites representing 14 glycoproteins. 26161579 7 30 gly N-glycosylation 1074:1088 arg2 257 N-glycosylation sites 257 N-glycosylation sites sites Using this method, we identified a total of 257 N-glycosylation sites and 144 N-glycoproteins from healthy human serum. 26161579 7 43 gly N-glycoproteins 1104:1118 arg1 144 N-glycoproteins 144 N-glycoproteins Fterm N-glycoproteins Using this method, we identified a total of 257 N-glycosylation sites and 144 N-glycoproteins from healthy human serum. 15924140 2 10 gly N-glycosylation 412:426 arg2 a new N-glycosylation site a new N-glycosylation site site We identified three children with mendelian susceptibility to mycobacterial disease who were homozygous with respect to a missense mutation in IFNGR2 creating a new N-glycosylation site in the IFNgammaR2 chain. 9792708 5 76 gly O-glycosylation 723:737 arg2 a functional O-glycosylation site a functional O-glycosylation site site Downstream amino acids are required to introduce a functional O-glycosylation site into a foreign protein. 29463651 6 77 gly N-glycosylation 1335:1349 arg1 flavivirus E protein flavivirus E protein Fterm protein Here, by mutagenesis, we found a major role of the N-glycosylation of flavivirus E protein in its transmission circle, facilitating its survival against the vector immune system during invasion of the mosquito midgut while blood feeding on the host. 9155874 3 26 gly glycosylation 734:746 arg2 a second potential glycosylation site a second potential glycosylation site site Further adaptation of Phil82/BS by sequential lung passage in mice yielded a strain of greater virulence, Phil82/BS/ML 10, in which a change at residue 246 of HA resulted in loss of a second potential glycosylation site. 10905635 2 53 part_of beta1,3galactosyltransferase 334:361 arg1 the only potential N-glycosylation site beta1,3galactosyltransferase the only potential N-glycosylation site OGER Site beta1,3galactosyltransferase Q9NS00 site Here we examined the occupancy and relevance for the activity and intracellular trafficking of the only potential N-glycosylation site of the mouse beta1,3galactosyltransferase (Gal-T2 or GA1/GM1/GD1b synthase) in Gal-T2 cDNA transfected CHO-K1 cells. 11371512 3 26 gly glycosylation 458:470 arg2 one glycosylation site one glycosylation site site Six cysteines and one glycosylation site are strictly conserved in all four saposins. 8437218 4 48 gly glycosylation 1154:1166 arg1 SFFVAP-L env SFFVAP-L env PUBTATOR SFFVAP-L env 30816 Mutants carrying Asn-->Asp mutations at each of the two consensus signals for N-linked glycosylation in the N-terminal domain of SFFVAP-L env (gs1 and gs2), the gs1-2- double mutant, and the gs0 quadruple mutant (mutated at all four signals utilized for N-linked glycosylation in SFFVAP-L env) were made. 26656560 9 25 gly N-glycosylation 1163:1177 arg2 one N-glycosylation site TF site Cterm TF 7018 site p.N432S is a novel mutation that abolishes one N-glycosylation site of TF, while p.P589S is the polymorphism that defines the C2 isoform of TF. 23250752 9 14 gly nonglycosylated 1635:1649 arg1 nonglycosylated K(2P)3.1 channels nonglycosylated K(2P)3.1 channels Fterm channels Because nonglycosylated channels appear to pass through the secretory pathway in a manner comparable with glycosylated channels, the evidence presented here suggests that the decreased number of nonglycosylated K(2P)3.1 channels on the cell surface may be due to their decreased stability. 23250752 9 45 gly nonglycosylated 1448:1462 arg1 nonglycosylated channels nonglycosylated channels Fterm channels Because nonglycosylated channels appear to pass through the secretory pathway in a manner comparable with glycosylated channels, the evidence presented here suggests that the decreased number of nonglycosylated K(2P)3.1 channels on the cell surface may be due to their decreased stability. 23250752 9 51 gly glycosylated 1546:1557 arg1 glycosylated channels glycosylated channels Fterm channels Because nonglycosylated channels appear to pass through the secretory pathway in a manner comparable with glycosylated channels, the evidence presented here suggests that the decreased number of nonglycosylated K(2P)3.1 channels on the cell surface may be due to their decreased stability. 8212855 1 76 gly glycoprotein 252:263 arg1 the glycoprotein 60 (gp60) gene the glycoprotein 60 (gp60) gene Fterm glycoprotein The nucleotide sequence of an infectious laryngotracheitis virus (ILTV) gene which maps immediately upstream from the glycoprotein 60 (gp60) gene was determined. 12706077 4 11 gly glycosylation 903:915 arg1 the influenza virus HA1 domain the influenza virus HA1 domain domain We conclude that the glycosylation pattern of the influenza virus HA1 domain has little impact on the murine antibody response raised to a DNA vaccine encoding the H5 HA, thereby minimizing the concern that the pattern of glycosylation sites encoded by the vaccine match those of closely related H5 viruses. 12706077 4 12 gly glycosylation 1104:1116 arg2 glycosylation sites glycosylation sites sites We conclude that the glycosylation pattern of the influenza virus HA1 domain has little impact on the murine antibody response raised to a DNA vaccine encoding the H5 HA, thereby minimizing the concern that the pattern of glycosylation sites encoded by the vaccine match those of closely related H5 viruses. 10889259 0 41 part_of N-acetyl 40:47 arg1 plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences N-acetyl glucosaminyltransferase I plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences PUBTATOR Site N-acetyl glucosaminyltransferase I 829981 sequences Isolation and characterization of plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences. 10889259 0 51 part_of I 73:73 arg1 plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences N-acetyl glucosaminyltransferase I plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences PUBTATOR Site N-acetyl glucosaminyltransferase I 829981 sequences Isolation and characterization of plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences. 10889259 0 56 part_of glucosaminyltransferase 49:71 arg1 plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences N-acetyl glucosaminyltransferase I plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences PUBTATOR Site N-acetyl glucosaminyltransferase I 829981 sequences Isolation and characterization of plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences. 10889259 0 69 part_of GntI 76:79 arg1 plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences GntI plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences PUBTATOR Site GntI 829981 sequences Isolation and characterization of plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences. 19947664 1 77 gly glycoprotein 245:256 arg1 a well-characterized glycoprotein a well-characterized glycoprotein Fterm glycoprotein Recombinant tissue plasminogen activator (rt-PA) is a well-characterized glycoprotein with a great deal of published information on its structure, post-translational modifications, and O- and N-glycosylation. 19947664 1 77 gly glycoprotein 245:256 arg1 Recombinant tissue plasminogen activator Recombinant tissue plasminogen activator OGER Recombinant tissue plasminogen activator P00750 Recombinant tissue plasminogen activator (rt-PA) is a well-characterized glycoprotein with a great deal of published information on its structure, post-translational modifications, and O- and N-glycosylation. 15308721 4 11 gly occupied 706:713 arg1 the first Asn glycosylation site the first Asn glycosylation site site We demonstrate that these antibodies discriminate the PrP monoglycosylated species, since two of them recognize molecules that have the first Asn glycosylation site occupied (mono1) while the other two recognize molecules glycosylated at the second site (mono2). 15308721 4 47 gly glycosylation 687:699 arg2 the first Asn glycosylation site the first Asn glycosylation site site We demonstrate that these antibodies discriminate the PrP monoglycosylated species, since two of them recognize molecules that have the first Asn glycosylation site occupied (mono1) while the other two recognize molecules glycosylated at the second site (mono2). 15308721 4 62 gly glycosylated 763:774 arg2 the second site the second site site We demonstrate that these antibodies discriminate the PrP monoglycosylated species, since two of them recognize molecules that have the first Asn glycosylation site occupied (mono1) while the other two recognize molecules glycosylated at the second site (mono2). 24884609 5 12 part_of ITIH4 745:749 arg1 ITIH4 tryptic/GluC glycopeptides ITIH4 ITIH4 tryptic/GluC glycopeptides PUBTATOR Site ITIH4 3700 glycopeptides First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 22 part_of tryptic/GluC 751:762 arg1 ITIH4 tryptic/GluC glycopeptides GluC ITIH4 tryptic/GluC glycopeptides PUBTATOR Site GluC 57733 glycopeptides First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 68 part_of ITIH4 665:669 arg1 the four ITIH4 N-X-S/T sequons ITIH4 N81, N207, N517, and N577 PUBTATOR SpecificSite ITIH4 3700 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 68 part_of ITIH4 665:669 arg1 N517 ITIH4 N81, N207, N517, and N577 PUBTATOR SpecificSite ITIH4 3700 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 68 part_of ITIH4 665:669 arg1 N577 ITIH4 N81, N207, N517, and N577 PUBTATOR SpecificSite ITIH4 3700 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 68 part_of ITIH4 665:669 arg1 N207 ITIH4 N81, N207, N517, and N577 PUBTATOR SpecificSite ITIH4 3700 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 68 part_of ITIH4 665:669 arg1 N517 ITIH4 N81, N207, N517, and N577 PUBTATOR SpecificSite ITIH4 3700 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 68 part_of ITIH4 665:669 arg1 N577 ITIH4 N81, N207, N517, and N577 PUBTATOR SpecificSite ITIH4 3700 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 68 part_of ITIH4 665:669 arg1 N207 ITIH4 N81, N207, N517, and N577 PUBTATOR SpecificSite ITIH4 3700 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 68 part_of ITIH4 665:669 arg1 N577 ITIH4 N81, N207, N517, and N577 PUBTATOR SpecificSite ITIH4 3700 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 68 part_of ITIH4 665:669 arg1 N207 ITIH4 N81, N207, N517, and N577 PUBTATOR SpecificSite ITIH4 3700 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 24884609 5 68 part_of ITIH4 665:669 arg1 N207 ITIH4 N81, N207, N517, and N577 PUBTATOR SpecificSite ITIH4 3700 N81, N207, N517, and N577 First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water. 10474032 10 17 gly N-glycosylation 1137:1151 arg2 position 4-6 position 4-6 position 4 The predicted amino acid sequence has one potential N-glycosylation site at position 4-6 and a cytosolic fatty acid-binding protein signature at position 5-22. 10474032 10 17 gly N-glycosylation 1137:1151 arg2 one potential N-glycosylation site one potential N-glycosylation site site The predicted amino acid sequence has one potential N-glycosylation site at position 4-6 and a cytosolic fatty acid-binding protein signature at position 5-22. 7505572 5 14 gly glycosylation 716:728 arg2 one N-linked glycosylation site one N-linked glycosylation site site Analysis of the predicted amino acid sequence indicated a hydrophobic protein with 4-6 membrane-spanning domains, with one N-linked glycosylation site, two conserved NPA boxes common to MIP26 family proteins, and conserved residue C189 common to water channels. 2503511 0 66 gly activator 52:60 arg1 Carbohydrate structures tissue plasminogen activator Carbohydrate structures PUBTATOR tissue plasminogen activator P00750 Carbohydrate structures of human tissue plasminogen activator expressed in Chinese hamster ovary cells. 25389233 14 64 gly N-glycosylation 2460:2474 arg2 the canonical N-glycosylation site the canonical N-glycosylation site site Two putative mechanisms may contribute to the increased exposure of these glycans: (1) the canonical N-glycosylation site of the IgG-CH2 domain; (2) an IgG binding non-IgG molecule, like complement or C-reactive protein. 25389233 14 150 gly exposure 2415:2422 arg1 the IgG-CH2 domain the IgG-CH2 domain domain Two putative mechanisms may contribute to the increased exposure of these glycans: (1) the canonical N-glycosylation site of the IgG-CH2 domain; (2) an IgG binding non-IgG molecule, like complement or C-reactive protein. 25389233 14 150 gly exposure 2415:2422 arg1 the canonical N-glycosylation site the canonical N-glycosylation site site Two putative mechanisms may contribute to the increased exposure of these glycans: (1) the canonical N-glycosylation site of the IgG-CH2 domain; (2) an IgG binding non-IgG molecule, like complement or C-reactive protein. 25389233 14 64 gly N-glycosylation 2460:2474 arg2 the IgG-CH2 domain domain domain Two putative mechanisms may contribute to the increased exposure of these glycans: (1) the canonical N-glycosylation site of the IgG-CH2 domain; (2) an IgG binding non-IgG molecule, like complement or C-reactive protein. 12080076 3 1 gly glycosylation 577:589 arg2 a single potential N-linked glycosylation site a single potential N-linked glycosylation site site The cDNA predicts an open reading frame encoding a type II membrane protein of 341 amino acids with a 12-amino acid cytoplasmic domain and a 311-amino acid luminal domain containing a single potential N-linked glycosylation site. 10103002 5 82 part_of gp42 767:770 arg1 The deduced amino acid sequence gp42 The deduced amino acid sequence Cterm Site gp42 sequence The deduced amino acid sequence of gp42 showed significant similarity to egg-envelope glycoproteins of the ZPC family of several other vertebrate species, including human ZP3, mouse ZP3, Xenopus laevis gp43 and medaka (Oryzias latipes) ZI3 (LS-F), which play important roles for sperm-egg interaction. 23326351 6 0 gly glycosylation 1055:1067 arg2 a glycosylation site a glycosylation site site All sera showed enhanced neutralizing activity toward an Env variant that lacked a glycosylation site in V4. 7689829 8 11 gly N-glycosylation 1069:1083 arg2 a single N-glycosylation site a single N-glycosylation site site There is a single N-glycosylation site in the mouse GM2 activator protein sequence (Asn151-Phe-Thr) which differs in its location from the single site reported in the human GM2 activator protein sequence (Asn63-Val-Thr). 7689829 8 22 gly site 1085:1088 arg1 the mouse GM2 activator protein sequence site the mouse GM2 activator protein sequence site There is a single N-glycosylation site in the mouse GM2 activator protein sequence (Asn151-Phe-Thr) which differs in its location from the single site reported in the human GM2 activator protein sequence (Asn63-Val-Thr). 8234161 8 0 gly glycosylation 941:953 arg2 the glycosylation site the glycosylation site site In addition, N-acetylglucosamine glycopeptides were significantly stabilized, even when the glycosylation site was several amino acids from the predominant site(s) of cleavage. 12928435 7 36 gly glycosylated 1093:1104 arg1 native as well as recombinant HCN channels native as well as recombinant HCN channels Fterm channels Using N-glycosidase F we show that native as well as recombinant HCN channels are glycosylated resulting in a 10-20-kDa shift in the molecular weight. 28822114 0 49 gly Glycosylation 0:12 arg1 dentin matrix protein 1 dentin matrix protein 1 PUBTATOR dentin matrix protein 1 13406 Glycosylation of dentin matrix protein 1 is a novel key element for astrocyte maturation and BBB integrity. 26018173 5 136 gly glycopeptide 1057:1068 arg2 glycopeptide analysis glycopeptide analysis glycopeptide Additionally, because we characterized the glycosylation with a high-fidelity profiling method, glycopeptide analysis, an unprecedented level of molecular detail regarding membrane Env glycosylation and its heterogeneity is presented. 8638940 0 76 gly Glycosylation 0:12 arg1 lysosomal glycosylasparaginase lysosomal glycosylasparaginase OGER glycosylasparaginase P20933 Glycosylation and phosphorylation of lysosomal glycosylasparaginase. 28770921 7 84 part_of HsPLG 1208:1212 arg1 the K5 domain HsPLG the K5 domain Cterm Site HsPLG P00747 domain Our docking results performed with multiple MD snapshots of the closed GiENO conformation showed that Lys266 preferentially binds to the K5 domain of HsPLG. 22407978 0 15 gly aglycosylated 61:73 arg1 aglycosylated immunoglobulin G1 aglycosylated immunoglobulin G1 Cterm immunoglobulin G1 Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1. 26784534 6 12 gly structures 708:717 arg1 all glycosylation sites all glycosylation sites all glycosylation sites Site sites The majority of the glycan structures on all glycosylation sites is represented by disialyl core 1 O-glycan. 26784534 6 45 gly glycosylation 726:738 arg2 all glycosylation sites all glycosylation sites sites The majority of the glycan structures on all glycosylation sites is represented by disialyl core 1 O-glycan. 15863355 1 32 gly glycoprotein 144:155 arg1 alpha(1)-Acid glycoprotein alpha(1)-Acid glycoprotein Fterm glycoprotein BACKGROUND: alpha(1)-Acid glycoprotein (AGP), an acute phase reactant, is extensively glycosylated at five Asn-linked glycosylation sites. 15863355 1 103 gly glycosylation 236:248 arg2 five Asn-linked glycosylation sites five Asn-linked glycosylation sites sites BACKGROUND: alpha(1)-Acid glycoprotein (AGP), an acute phase reactant, is extensively glycosylated at five Asn-linked glycosylation sites. 15863355 1 97 gly glycosylated 204:215 arg1 alpha(1)-Acid glycoprotein glycoprotein sites Fterm glycoprotein sites BACKGROUND: alpha(1)-Acid glycoprotein (AGP), an acute phase reactant, is extensively glycosylated at five Asn-linked glycosylation sites. 2787353 7 37 gly rIL-2 1288:1292 arg1 the carbohydrate-binding site rIL-2 the carbohydrate-binding site PUBTATOR rIL-2 116562 Thus the carbohydrate-binding site of rIL-2 is distinct from the cell surface receptor-binding site, and might function preferentially in acidic microenvironments. 2787353 7 51 gly site 1345:1348 arg1 the carbohydrate-binding site site the carbohydrate-binding site site Thus the carbohydrate-binding site of rIL-2 is distinct from the cell surface receptor-binding site, and might function preferentially in acidic microenvironments. 21569239 2 3 part_of F-spondin 339:347 arg1 FS domain F-spondin domain PUBTATOR Site F-spondin 10418 domain The reelin_N domain and the F-spondin domain (FS domain) comprise a proteolytic fragment that interacts with the cell membrane and guides the projection of commissural axons to floor plate. 23891555 8 10 gly O-glycosylation 1198:1212 arg2 up to six O-glycosylation sites up to six O-glycosylation sites sites This allowed assigning up to six O-glycosylation sites and demonstration, for the first time, of the distribution of isomeric O-glycoforms having the same molecular mass, but a different glycosylation pattern. 3334850 0 52 part_of cDNA 65:68 arg1 nucleotide sequence growth hormone cDNA nucleotide sequence OGER Site growth hormone cDNA P01241 sequence Molecular cloning and nucleotide sequence of tuna growth hormone cDNA. 22001408 3 36 gly glycosylation 489:501 arg2 glycosylation site analyses glycosylation site analyses site Primary structure analysis, antigenic and glycosylation site analyses revealed that this protein has evolved from 1918 pandemic. 18672252 3 58 gly glycosylation 820:832 arg2 a vicinal glycosylation site a vicinal glycosylation site site This propensity to adapt to human receptors is primarily dependent on arginine at position 193 within the receptor-binding site, as well as loss of a vicinal glycosylation site. 8797097 9 16 part_of subunit 1844:1850 arg1 region responsible for follistatin binding within the activin beta A subunit is spanned by amino acids 87-105, and (3) the mode of binding of inhibin-A to follistatin is quite different from that of activin-A to follistatin subunit region responsible for follistatin binding within the activin beta A subunit is spanned by amino acids 87-105, and (3) the mode of binding of inhibin-A to follistatin is quite different from that of activin-A to follistatin Fterm Site subunit region The present data suggest that (1) amino acids 87-105 of the inhibin/activin beta A subunit are located on the molecular surface, although this region of inhibin-A is concealed by the carbohydrate chain of the alpha subunit, (2) the region responsible for follistatin binding within the activin beta A subunit is spanned by amino acids 87-105, and (3) the mode of binding of inhibin-A to follistatin is quite different from that of activin-A to follistatin, and the former may be influenced by glycosylation. 7717992 4 25 gly N-glycosylation 667:681 arg2 one N-glycosylation site one N-glycosylation site site This includes a 19-amino acid signal sequence and the mature protein containing 676 amino acids and one N-glycosylation site in the C-terminal domain at residue 490. 12097564 10 45 part_of receptor 1806:1813 arg1 the receptor binding site receptor the receptor binding site Fterm Site receptor site The apparent interference of the monoclonal with the EnvA-Tva complex formation suggests that the epitope seen by mc8C5 overlaps with the receptor binding site. 8132647 0 37 gly glycoprotein 28:39 arg1 a newly characterized glycoprotein a newly characterized glycoprotein Fterm glycoprotein GP-3, a newly characterized glycoprotein on the inner surface of the zymogen granule membrane, undergoes regulated secretion. 8132647 0 37 gly glycoprotein 28:39 arg1 GP-3 GP-3 OGER GP-3, a P05106 GP-3, a newly characterized glycoprotein on the inner surface of the zymogen granule membrane, undergoes regulated secretion. 1566570 0 73 part_of protein 26:32 arg1 envelope protein sequence protein envelope protein sequence Fterm Site protein sequence Heterogeneity in envelope protein sequence and N-linked glycosylation among yellow fever virus vaccine strains. 3485444 3 5 gly glycoprotein 448:459 arg1 the end radiolabeled glycoprotein the end radiolabeled glycoprotein Fterm glycoprotein Peptides resulting from partial proteolysis of the end radiolabeled glycoprotein were separated by lectin-Sepharose chromatography and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography. 9729121 5 29 part_of APN 1074:1076 arg1 the N-terminal sequence APN the N-terminal sequence PUBTATOR Site APN P15144 sequence The sequence of the eicosa-peptide Asp42Thr61 deduced from the cDNA was completely matched with the N-terminal sequence of the mature 110-kDa APN. 9729121 5 88 part_of Asp42Thr61 967:976 arg1 The sequence Asp42Thr61 The sequence Cterm Site Asp42Thr61 sequence The sequence of the eicosa-peptide Asp42Thr61 deduced from the cDNA was completely matched with the N-terminal sequence of the mature 110-kDa APN. 15557236 1 24 gly glycosylation 281:293 arg2 the N-linked glycosylation site the N-linked glycosylation site site Two New York (NY) strains of the West Nile (WN) virus were plaque-purified and four variants that had different amino acid sequences at the N-linked glycosylation site in the envelope (E) protein sequence were isolated. 7755594 10 51 gly glycosylation 1557:1569 arg1 rIFN-gamma rIFN-gamma PUBTATOR rIFN-gamma 25712 Whether the differential glycosylation of n- and recombinant IFN-gamma (rIFN-gamma) is reflected in their biological activities in tissues or their clinical applicability is not known. 7755594 10 51 gly glycosylation 1557:1569 arg1 recombinant IFN-gamma recombinant IFN-gamma PUBTATOR IFN-gamma 3458 Whether the differential glycosylation of n- and recombinant IFN-gamma (rIFN-gamma) is reflected in their biological activities in tissues or their clinical applicability is not known. 10318794 4 12 part_of G6PT 649:652 arg1 A region G6PT A region PUBTATOR Site G6PT 2538 region A region of G6PT corresponding to amino acid residues 50-71, which constitute a transmembrane segment in the twelve-domain model, are situated in a 51-residue luminal loop in the ten-domain model. 10419520 13 74 part_of S2P 1706:1708 arg1 the active site S2P the active site PUBTATOR Site S2P 51360 site The hydrophobicity of these sequences suggests that the active site of S2P is located within the membrane in an ideal position to cleave its target, a Leu-Cys bond in the first transmembrane helix of SREBPs. 9804815 0 81 gly O-glycosylation 155:169 arg1 the MUC1 tandem repeat the MUC1 tandem repeat Cloning of a human UDP-N-acetyl-alpha-D-Galactosamine:polypeptide N-acetylgalactosaminyltransferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat. 20923142 2 19 gly glycopeptides 552:564 arg2 sialylated glycopeptides sialylated glycopeptides glycopeptides Toward this goal, we developed a lectin-directed tandem labeling (LTL) quantitative proteomics strategy in which we enriched sialylated glycopeptides by SNA, labeled them at the N-terminus by acetic anhydride ((1)H(6)/(2)D(6)) reagents, enzymatically deglycosylated the differentially labeled peptides in the presence of heavy water (H(2)(18)O), and performed LC/MS/MS analysis to identify glycopeptides. 20923142 2 25 gly H 629:629 arg1 (2)D(6) (2)D(6) D(6) Toward this goal, we developed a lectin-directed tandem labeling (LTL) quantitative proteomics strategy in which we enriched sialylated glycopeptides by SNA, labeled them at the N-terminus by acetic anhydride ((1)H(6)/(2)D(6)) reagents, enzymatically deglycosylated the differentially labeled peptides in the presence of heavy water (H(2)(18)O), and performed LC/MS/MS analysis to identify glycopeptides. 20923142 2 68 gly anhydride 615:623 arg1 (1)H(6) (1)H(6) H(6) Toward this goal, we developed a lectin-directed tandem labeling (LTL) quantitative proteomics strategy in which we enriched sialylated glycopeptides by SNA, labeled them at the N-terminus by acetic anhydride ((1)H(6)/(2)D(6)) reagents, enzymatically deglycosylated the differentially labeled peptides in the presence of heavy water (H(2)(18)O), and performed LC/MS/MS analysis to identify glycopeptides. 20923142 2 72 gly glycopeptides 806:818 arg2 glycopeptides glycopeptides glycopeptides Toward this goal, we developed a lectin-directed tandem labeling (LTL) quantitative proteomics strategy in which we enriched sialylated glycopeptides by SNA, labeled them at the N-terminus by acetic anhydride ((1)H(6)/(2)D(6)) reagents, enzymatically deglycosylated the differentially labeled peptides in the presence of heavy water (H(2)(18)O), and performed LC/MS/MS analysis to identify glycopeptides. 20923142 2 74 gly sialylated 541:550 arg1 sialylated glycopeptides sialylated glycopeptides glycopeptides Toward this goal, we developed a lectin-directed tandem labeling (LTL) quantitative proteomics strategy in which we enriched sialylated glycopeptides by SNA, labeled them at the N-terminus by acetic anhydride ((1)H(6)/(2)D(6)) reagents, enzymatically deglycosylated the differentially labeled peptides in the presence of heavy water (H(2)(18)O), and performed LC/MS/MS analysis to identify glycopeptides. 22122935 1 27 gly glycoforms 271:280 arg1 rhEPO rhEPO OGER rhEPO P29676 Capillary electrophoresis electrospray-mass spectrometry was used to detect and characterize the great variety of O- and N-glycopeptide glycoforms of recombinant human erythropoietin (rhEPO) using an orthogonal accelerating time-of-flight mass spectrometer to obtain their exact molecular masses (CE-TOF-MS). 22122935 1 27 gly glycoforms 271:280 arg1 recombinant human erythropoietin recombinant human erythropoietin PUBTATOR erythropoietin 2056 Capillary electrophoresis electrospray-mass spectrometry was used to detect and characterize the great variety of O- and N-glycopeptide glycoforms of recombinant human erythropoietin (rhEPO) using an orthogonal accelerating time-of-flight mass spectrometer to obtain their exact molecular masses (CE-TOF-MS). 22122935 1 31 gly N-glycopeptide 256:269 arg2 N-glycopeptide N-glycopeptide N-glycopeptide Capillary electrophoresis electrospray-mass spectrometry was used to detect and characterize the great variety of O- and N-glycopeptide glycoforms of recombinant human erythropoietin (rhEPO) using an orthogonal accelerating time-of-flight mass spectrometer to obtain their exact molecular masses (CE-TOF-MS). 12928435 9 53 gly N-glycosylation 1315:1329 arg2 the putative N-glycosylation site the putative N-glycosylation site site Similarly, a mutant HCN2 channel in which the putative N-glycosylation site in the loop between S5 and the pore helix was replaced by glutamine (HCN2N380Q) was not inserted into the plasma membrane and did not yield detectable whole-cell currents. 28900186 0 22 gly N-glycosylated 124:137 arg1 N-glycosylated asparagine N-glycosylated asparagine asparagine Improvement of the glycoproteomic toolbox with the discovery of a unique C-terminal cleavage specificity of flavastacin for N-glycosylated asparagine. 9774483 12 31 gly polysialylated 2109:2122 arg1 polysialylated NCAM polysialylated NCAM PUBTATOR NCAM 4684 The results also suggest that PST and STX form polysialylated NCAM in a synergistic manner. 31102353 5 46 gly glycosylation 763:775 arg2 The glycosylation site N934 site N934 site N934 The glycosylation site N934 was located outside the pore region and its side chain directed to the extracellular water environment. 19193194 3 8 part_of domains 662:668 arg1 a serine protease domain domains a serine protease domain domain The deduced protein, BbPlgl, consisted of 430 amino acids, which is structurally characterized by the presence of an N-terminal signal peptide of 16 amino acids, 2 kringle domains with a Lys-binding site structure, a serine protease domain with the putative tPA (tissue plasminogen activator)-cleavage site (between Arg297 and Val298), the catalytic triad His237-Asp288-Ser379 expected for protease function, and a potential N-linked glycosylation site, all characteristic of Plgs. 19193194 3 36 part_of protease 714:721 arg1 a serine protease domain protease a serine protease domain Fterm Site protease domain The deduced protein, BbPlgl, consisted of 430 amino acids, which is structurally characterized by the presence of an N-terminal signal peptide of 16 amino acids, 2 kringle domains with a Lys-binding site structure, a serine protease domain with the putative tPA (tissue plasminogen activator)-cleavage site (between Arg297 and Val298), the catalytic triad His237-Asp288-Ser379 expected for protease function, and a potential N-linked glycosylation site, all characteristic of Plgs. 19193194 3 76 part_of tPA 748:750 arg1 the putative tPA (tissue plasminogen activator)-cleavage site tPA the putative tPA (tissue plasminogen activator)-cleavage site OGER Site tPA P00750 site The deduced protein, BbPlgl, consisted of 430 amino acids, which is structurally characterized by the presence of an N-terminal signal peptide of 16 amino acids, 2 kringle domains with a Lys-binding site structure, a serine protease domain with the putative tPA (tissue plasminogen activator)-cleavage site (between Arg297 and Val298), the catalytic triad His237-Asp288-Ser379 expected for protease function, and a potential N-linked glycosylation site, all characteristic of Plgs. 19193194 3 38 part_of domain 723:728 arg1 the putative tPA (tissue plasminogen activator)-cleavage site site site The deduced protein, BbPlgl, consisted of 430 amino acids, which is structurally characterized by the presence of an N-terminal signal peptide of 16 amino acids, 2 kringle domains with a Lys-binding site structure, a serine protease domain with the putative tPA (tissue plasminogen activator)-cleavage site (between Arg297 and Val298), the catalytic triad His237-Asp288-Ser379 expected for protease function, and a potential N-linked glycosylation site, all characteristic of Plgs. 24018687 0 56 gly N-glycosylation 30:44 arg2 a conserved N-glycosylation site a conserved N-glycosylation site site Low stability and a conserved N-glycosylation site are associated with regulation of the discoidin domain receptor family by glucose via post-translational N-glycosylation. 23909558 2 50 gly O-glycosylation 231:245 arg2 the O-glycosylation site the O-glycosylation site site Different from N-linked glycans, the O-glycosylation site is not within a known consensus sequence. 17986444 9 28 gly site 1519:1522 arg1 the polysialylation pattern site the polysialylation pattern site These variations were most pronounced at N-glycosylation site 5, whereas the polysialylation pattern at N-glycosylation site 6 did not differ between NCAM from wild-type and ST8SiaII- or ST8SiaIV-deficient mice. 17986444 9 29 gly N-glycosylation 1440:1454 arg2 N-glycosylation site 5 N-glycosylation site 5 site These variations were most pronounced at N-glycosylation site 5, whereas the polysialylation pattern at N-glycosylation site 6 did not differ between NCAM from wild-type and ST8SiaII- or ST8SiaIV-deficient mice. 17986444 9 35 gly polysialylation 1476:1490 arg2 N-glycosylation site 6 N-glycosylation site 6 site These variations were most pronounced at N-glycosylation site 5, whereas the polysialylation pattern at N-glycosylation site 6 did not differ between NCAM from wild-type and ST8SiaII- or ST8SiaIV-deficient mice. 17986444 9 86 gly N-glycosylation 1503:1517 arg2 N-glycosylation site 6 N-glycosylation site 6 site These variations were most pronounced at N-glycosylation site 5, whereas the polysialylation pattern at N-glycosylation site 6 did not differ between NCAM from wild-type and ST8SiaII- or ST8SiaIV-deficient mice. 2886334 7 22 gly glycosylation 1454:1466 arg2 other sites sites sites Analysis of oligosaccharide structures at the 'passenger' sites (23 and 98) suggests that either Thy-1 L+ and Thy-1 L- molecules are made in different cell-types or that the biosynthesis of oligosaccharides at one site is influenced by the glycosylation at other sites. 10406958 11 47 gly glycosylation 1896:1908 arg2 the glycosylation site the glycosylation site site Deglycosylation had no effect on the interaction of saposin D with phospholipid membranes, indicating that the glycosylation site is not related to the lipid-binding site. 8749713 6 9 gly N-glycosylation 724:738 arg2 A single potential N-glycosylation site A single potential N-glycosylation site site A single potential N-glycosylation site is present. 8663003 6 3 gly N-glycosylation 902:916 arg2 Asn37 Asn37 Asn37 These flank the single N-glycosylation site (Asn37), with the cleavage site toward the C-terminal side of this residue being between residues 39 and 40. 8663003 6 3 gly N-glycosylation 902:916 arg2 the single N-glycosylation site the single N-glycosylation site site These flank the single N-glycosylation site (Asn37), with the cleavage site toward the C-terminal side of this residue being between residues 39 and 40. 28501204 6 4 gly glycoproteins 1079:1091 arg1 target glycoproteins target glycoproteins Fterm glycoproteins This review summarizes the labeling and label-free quantitative MS approaches for quantifying N-glycosylation site occupancy, including its quantification for target glycoproteins in recent years. 28501204 6 16 gly N-glycosylation 1007:1021 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site This review summarizes the labeling and label-free quantitative MS approaches for quantifying N-glycosylation site occupancy, including its quantification for target glycoproteins in recent years. 8870657 5 48 gly glycosylation 751:763 arg2 two sites hLF sites PUBTATOR hLF 3131 sites Comparative SDS/PAGE analyses of rhLF, mutated rhLF and human-milk-derived (natural) hLF led us to propose that glycosylation of hLF occurs at two sites (at Asn138 and Asn479) in approx. 11019861 6 60 part_of domain 1091:1096 arg1 the amino acid positions domain the amino acid positions positions These features include loss of conserved residues or the gain of particular residues through mutation at sites involving a repertoire of approximately 20% of the amino acid positions in the light chain variable domain (V(L)). 30659065 11 97 gly sites 1914:1918 arg1 sites N279 and N439 sites N279 and N439 sites N279 and N439 IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms. 30659065 11 97 gly sites 1914:1918 arg1 N439 sites N279 and N439 sites N279 and N439 IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms. 30659065 11 97 gly sites 1914:1918 arg1 N439 sites N279 and N439 sites N279 and N439 IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms. 22180206 7 39 gly sialylated 1325:1334 arg1 Highly sialylated O-glycopeptides Highly sialylated O-glycopeptides O-glycopeptides Highly sialylated O-glycopeptides showed less efficient peptide fragmentation, but some sequence and glycosylation site information was still obtained. 22180206 7 93 gly glycosylation 1419:1431 arg2 some sequence and glycosylation site information some sequence and glycosylation site information site Highly sialylated O-glycopeptides showed less efficient peptide fragmentation, but some sequence and glycosylation site information was still obtained. 22180206 7 98 gly O-glycopeptides 1336:1350 arg2 Highly sialylated O-glycopeptides Highly sialylated O-glycopeptides O-glycopeptides Highly sialylated O-glycopeptides showed less efficient peptide fragmentation, but some sequence and glycosylation site information was still obtained. 28501204 4 20 gly N-glycosylation 650:664 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site Quantification of N-glycosylation site occupancy would uncover the critical role of macroheterogeneity in a variety of biological properties. 18077336 7 2 gly glycosylated 984:995 arg1 A mutant MRAP A mutant MRAP PUBTATOR MRAP Q8TCY5 A mutant MRAP with potential glycosylation sites on both sides of the membrane was singly but not doubly glycosylated, suggesting that MRAP is not monotopic. 18077336 7 82 gly glycosylation 908:920 arg2 potential glycosylation sites potential glycosylation sites sites A mutant MRAP with potential glycosylation sites on both sides of the membrane was singly but not doubly glycosylated, suggesting that MRAP is not monotopic. 2503511 9 36 gly Asn-linked 1712:1721 arg1 the Asn-linked N-acetylglucosamine residue Asn the Asn-linked N-acetylglucosamine residue Asn Most (greater than 90%) of the N-acetyllactosamine-type structures contained fucose alpha (1----6) linked to the Asn-linked N-acetylglucosamine residue. 2350186 3 72 gly has 481:483 arg1 Each mu-chain AND a single high mannose-type oligosaccharide Each mu-chain a single high mannose-type oligosaccharide Fterm mu-chain Each mu-chain has four complex-type oligosaccharides as well as a single high mannose-type oligosaccharide near the carboxyl terminus of the molecule. 2350186 3 72 gly has 481:483 arg1 Each mu-chain AND four complex-type oligosaccharides Each mu-chain four complex-type oligosaccharides Fterm mu-chain Each mu-chain has four complex-type oligosaccharides as well as a single high mannose-type oligosaccharide near the carboxyl terminus of the molecule. 9210490 2 22 gly N-glycosylation 352:366 arg2 eight potential N-glycosylation sites eight potential N-glycosylation sites sites The primary structure of rat wild-type DPPIV contains eight potential N-glycosylation sites. 28060516 2 20 gly glycoform 559:567 arg1 predominantly the canonical Man5GlcNAc2 glycoform predominantly the canonical Man5GlcNAc2 glycoform The proteins were expressed in (i) HEK293T cells to produce complex glycoforms, (ii) HEK293T cells treated with Vibrio cholera neuraminidase to provide asialo-complex glycoforms, (iii) HEK293S GnTI(-) cells with predominantly the canonical Man5GlcNAc2 glycoform, and (iv) Drosophila S2 insect cells producing primarily paucimannose glycoforms. 28060516 2 68 gly glycoforms 474:483 arg1 asialo-complex glycoforms asialo-complex glycoforms The proteins were expressed in (i) HEK293T cells to produce complex glycoforms, (ii) HEK293T cells treated with Vibrio cholera neuraminidase to provide asialo-complex glycoforms, (iii) HEK293S GnTI(-) cells with predominantly the canonical Man5GlcNAc2 glycoform, and (iv) Drosophila S2 insect cells producing primarily paucimannose glycoforms. 10878356 2 25 gly glycosylation 392:404 arg2 V alpha residue 82 V alpha residue 82 residue 82 In the current study a possible role for this region in T cell activation has been investigated by inserting a potential glycosylation site at V alpha residue 82. 10878356 2 25 gly glycosylation 392:404 arg2 a potential glycosylation site a potential glycosylation site site In the current study a possible role for this region in T cell activation has been investigated by inserting a potential glycosylation site at V alpha residue 82. 8185569 1 4 gly glycosylation 159:171 arg2 a possible asparagine-linked glycosylation site a possible asparagine-linked glycosylation site site Residue 113 of the thyrotropin receptor (TSHR) is a possible asparagine-linked glycosylation site in the human TSHR, but not in rat or dog TSHR. 27506355 8 40 gly glycopeptides 922:934 arg2 intact glycopeptides intact glycopeptides glycopeptides Specifically, this tool enables the determination of the glycan structure directly from low-energy collision-induced dissociation (CID) spectra of intact glycopeptides. 17095532 3 28 gly glycoproteins 424:436 arg1 glycoproteins glycoproteins Fterm glycoproteins Sera from many of the patients examined recognize a range of glycoproteins and neoglycoconjugates containing beta1,2-xylose and core alpha1,3-fucose on their N-glycans. 17095532 3 10 gly containing 461:470 arg1 glycoproteins AND beta1,2-xylose glycoproteins beta1,2-xylose Fterm glycoproteins Sera from many of the patients examined recognize a range of glycoproteins and neoglycoconjugates containing beta1,2-xylose and core alpha1,3-fucose on their N-glycans. 17095532 3 10 gly containing 461:470 arg1 glycoproteins AND core alpha1,3-fucose glycoproteins core alpha1,3-fucose Fterm glycoproteins Sera from many of the patients examined recognize a range of glycoproteins and neoglycoconjugates containing beta1,2-xylose and core alpha1,3-fucose on their N-glycans. 27573070 2 49 gly glycopeptides 488:500 arg2 glycopeptides glycopeptides glycopeptides The identification and characterization of glycoprotein and glycosylation sites by mass spectrometry (MS) remain challenging tasks, and great efforts have been devoted to the development of proteome informatics tools that facilitate the MS analysis of glycans and glycopeptides. 27573070 2 61 gly glycosylation 284:296 arg2 glycosylation sites glycosylation sites sites The identification and characterization of glycoprotein and glycosylation sites by mass spectrometry (MS) remain challenging tasks, and great efforts have been devoted to the development of proteome informatics tools that facilitate the MS analysis of glycans and glycopeptides. 27573070 2 65 gly glycoprotein 267:278 arg1 glycoprotein glycoprotein Fterm glycoprotein The identification and characterization of glycoprotein and glycosylation sites by mass spectrometry (MS) remain challenging tasks, and great efforts have been devoted to the development of proteome informatics tools that facilitate the MS analysis of glycans and glycopeptides. 8207403 0 48 part_of protein 81:87 arg1 a single N-linked glycosylation site protein a single N-linked glycosylation site Fterm Site protein site Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gp160 preventing env-mediated fusion. 9348299 5 56 gly N-glycosylation 856:870 arg2 one N-glycosylation site one N-glycosylation site site The extracellular Thr49 to Ile substitution abrogates one N-glycosylation site in the naturally occurring BALB/c IL-4R as well as in the experimentally point mutated C57BL/6-T49I sIL-4R, and both molecules display a nearly threefold reduction in IL-4-neutralizing activity compared to the C57BL/6 sIL-4R. 11251288 8 124 gly glycosylation 1599:1611 arg1 the mutant proteins the mutant proteins Fterm proteins Chemical glycosylation with glycosyl-beta-N-iodoacetamides could be monitored by electrospray MS. Both in the wild-type and in the mutant proteins, the potential side reaction of the other four cysteine residues (all involved in disulfide bonds) were not observed. 26231935 3 48 part_of AChE 598:601 arg1 wild-type human AChE(T) sequence AChE wild-type human AChE(T) sequence PUBTATOR Site AChE 43 sequence In order to determine the role of three N-glycosylation sites in AChE activity and glycan composition, the site-directed mutagenesis of N-glycosylation sites in wild-type human AChE(T) sequence was employed to generate the single-site mutants (i.e., AChE(T) (N296Q), AChET (N381Q), and AChE(T) (N495Q)) and all site mutant (i.e., AChE(T) (3N→3Q)). 26231935 3 70 part_of T 603:603 arg1 wild-type human AChE(T) sequence T wild-type human AChE(T) sequence Cterm Site T 43 sequence In order to determine the role of three N-glycosylation sites in AChE activity and glycan composition, the site-directed mutagenesis of N-glycosylation sites in wild-type human AChE(T) sequence was employed to generate the single-site mutants (i.e., AChE(T) (N296Q), AChET (N381Q), and AChE(T) (N495Q)) and all site mutant (i.e., AChE(T) (3N→3Q)). 7635146 11 70 part_of I 2079:2079 arg1 an approximately 4-kDa polypeptide glucosidase I an approximately 4-kDa polypeptide PUBTATOR Site glucosidase I 7841 polypeptide The hydrophobicity profile as well as the removal by trypsin of an approximately 4-kDa polypeptide from the membrane-associated glucosidase I in intact microsomal structures, supports the view that the enzyme is a type-II transmembrane glycoprotein, which contains a short cytosolic tail of approximately 37 amino acids, followed by a single transmembrane domain and a large C-terminal catalytic domain located on the luminal side of the endoplasmic reticulum membrane. 7635146 11 65 part_of contains 2195:2202 arg1 a type-II transmembrane glycoprotein AND a short cytosolic tail a type-II transmembrane glycoprotein a short cytosolic tail Fterm Site glycoprotein tail The hydrophobicity profile as well as the removal by trypsin of an approximately 4-kDa polypeptide from the membrane-associated glucosidase I in intact microsomal structures, supports the view that the enzyme is a type-II transmembrane glycoprotein, which contains a short cytosolic tail of approximately 37 amino acids, followed by a single transmembrane domain and a large C-terminal catalytic domain located on the luminal side of the endoplasmic reticulum membrane. 7635146 11 65 part_of contains 2195:2202 arg1 the enzyme AND a short cytosolic tail the enzyme a short cytosolic tail Fterm Site enzyme tail The hydrophobicity profile as well as the removal by trypsin of an approximately 4-kDa polypeptide from the membrane-associated glucosidase I in intact microsomal structures, supports the view that the enzyme is a type-II transmembrane glycoprotein, which contains a short cytosolic tail of approximately 37 amino acids, followed by a single transmembrane domain and a large C-terminal catalytic domain located on the luminal side of the endoplasmic reticulum membrane. 15113889 1 33 gly glycoprotein 209:220 arg1 the vesicular stomatitis virus (VSV) glycoprotein glycoprotein (G OGER glycoprotein (G P07996 We developed a rational approach to identify a site in the vesicular stomatitis virus (VSV) glycoprotein (G) that is exposed on the protein surface and tolerant of foreign epitope insertion. 25690651 3 53 part_of has 431:433 arg1 human GPR109A AND an N-glycosylation site human GPR109A an N-glycosylation site PUBTATOR Site GPR109A 338442 site We found that human GPR109A (hGPR109A) has an N-glycosylation site at Asn(17) in the N-terminal atypical motif, Asn(17)-Cys(18)-Cys(19). 25690651 3 53 part_of has 431:433 arg1 hGPR109A AND an N-glycosylation site hGPR109A an N-glycosylation site PUBTATOR Site hGPR109A 338442 site We found that human GPR109A (hGPR109A) has an N-glycosylation site at Asn(17) in the N-terminal atypical motif, Asn(17)-Cys(18)-Cys(19). 9287313 6 34 part_of CD69 1620:1623 arg1 the CD69 extracellular domain CD69 the CD69 extracellular domain PUBTATOR Site CD69 969 domain The results in this study provide a molecular basis for human CD69 heterogeneity and show that multiple dimeric forms of human CD69 result from the variable addition of N-glycans to atypical and typical glycosylation motifs within the CD69 extracellular domain. 10989127 9 77 gly N-glycosylation 1274:1288 arg2 site 1 site site A potential N-glycosylation site (site 1) with similar tripeptide patterns was observed at the same position in human plasma (HYAL1), human lysosomes (HYAL2) and in two newly reported hyaluronidases (HYAL4 and HYALP1). 8325864 2 59 gly occupancy 241:249 arg2 site occupancy site occupancy site The five potential N-glycosylation sites (sequons) of human acid beta-glucosidase were individually mutated to determine site occupancy and the effect of site occupancy on selected catalytic and stability properties of this enzyme. 8325864 2 31 gly N-glycosylation 134:148 arg1 human acid beta-glucosidase acid beta-glucosidase OGER acid beta-glucosidase P04062 The five potential N-glycosylation sites (sequons) of human acid beta-glucosidase were individually mutated to determine site occupancy and the effect of site occupancy on selected catalytic and stability properties of this enzyme. 8325864 2 31 gly N-glycosylation 134:148 arg2 The five potential N-glycosylation sites sites sites The five potential N-glycosylation sites (sequons) of human acid beta-glucosidase were individually mutated to determine site occupancy and the effect of site occupancy on selected catalytic and stability properties of this enzyme. 8325864 2 31 gly N-glycosylation 134:148 arg2 The five potential N-glycosylation sites acid beta-glucosidase sites OGER acid beta-glucosidase P04062 sites The five potential N-glycosylation sites (sequons) of human acid beta-glucosidase were individually mutated to determine site occupancy and the effect of site occupancy on selected catalytic and stability properties of this enzyme. 25504159 2 13 gly glycosylation 362:374 arg2 position 158 position 158 position 158 The N-linked glycosylation site at position 158 of highly pathogenic H5N1 virus was previously shown to affect viral receptor-binding preference. 25504159 2 13 gly glycosylation 362:374 arg2 The N-linked glycosylation site The N-linked glycosylation site site The N-linked glycosylation site at position 158 of highly pathogenic H5N1 virus was previously shown to affect viral receptor-binding preference. 22688517 4 16 gly N-glycosylation 549:563 arg2 N-glycosylation sites N-glycosylation sites sites The present study was aimed at elucidating the N-glycosylation of recombinant human LOX-1 with regard to N-glycan profile and N-glycosylation sites. 22688517 4 43 gly N-glycosylation 470:484 arg1 recombinant human LOX-1 recombinant human LOX-1 PUBTATOR LOX-1 4973 The present study was aimed at elucidating the N-glycosylation of recombinant human LOX-1 with regard to N-glycan profile and N-glycosylation sites. 14736728 3 39 gly glycosylation 582:594 arg1 the CLN2 protein the CLN2 protein PUBTATOR CLN2 protein 1200 We introduced the p.Asn286Ser mutation into the wild-type CLN2 cDNA and performed transient expression analysis to determine the effect on the catalytic activity, intracellular targeting, and glycosylation of the CLN2 protein. 8349598 11 44 gly glycoproteins 2219:2231 arg1 glycoproteins glycoproteins Fterm glycoproteins The Trf-specific GalNAc-transferase may account for the presence of beta 1,4-linked GalNAc on glycoproteins which do not contain the PXR/K motif. 8349598 11 68 gly presence 2181:2188 arg2 glycoproteins AND beta 1,4-linked GalNAc glycoproteins beta 1,4-linked GalNAc Fterm glycoproteins The Trf-specific GalNAc-transferase may account for the presence of beta 1,4-linked GalNAc on glycoproteins which do not contain the PXR/K motif. 3455414 5 82 part_of v-ros 766:770 arg1 the v-ros sequence ros the v-ros sequence OGER Site ros Q63132 sequence These results strongly suggest that proto-oncogene c-ros encodes for a receptor of cell growth or differentiation factor(s) and that the v-ros sequence is a truncated form of this receptor molecule. 15616124 11 65 gly glycoproteins 1782:1794 arg1 glycoproteins glycoproteins Fterm glycoproteins Thus, the present study demonstrates that posttranslational N-glycosylation can be a part of the normal processing of glycoproteins. 7543206 0 22 gly glycosylation 84:96 arg2 glycosylation site mutants glycosylation site mutants site Secretion of recombinant human IgE-Fc by mammalian cells and biological activity of glycosylation site mutants. 10970800 10 73 gly glycosylation 1381:1393 arg1 the EP3beta receptor the EP3beta receptor PUBTATOR EP3beta receptor 64184 Therefore, glycosylation of the EP3beta receptor seems not to be necessary for correct folding of the receptor protein but for the efficient transport of the receptor protein to the plasma membrane. 18282281 4 105 gly O-glycosylation 621:635 arg2 mucin-type O-glycosylation serine/threonine (S/T) sites mucin-type O-glycosylation serine/threonine (S/T) sites sites RESULTS: A new protein bioinformatics tool, CKSAAP_OGlySite, was developed to predict mucin-type O-glycosylation serine/threonine (S/T) sites in mammalian proteins. 7513281 7 26 gly N-glycosylation 1080:1094 arg2 a potential N-glycosylation site a potential N-glycosylation site site These clones code for a polymorphic protein of 145 residues with a derived molecular mass of about 16,400Da, which contains a potential N-glycosylation site. 21604132 4 0 gly sialylated 693:702 arg1 N-linked sialylated glycoproteins N-linked sialylated glycoproteins Fterm glycoproteins In this context, the aim of this chapter is to describe a methodology to identify the glycosylation site of N-linked sialylated glycoproteins. 21604132 4 2 gly glycoproteins 704:716 arg1 N-linked sialylated glycoproteins N-linked sialylated glycoproteins Fterm glycoproteins In this context, the aim of this chapter is to describe a methodology to identify the glycosylation site of N-linked sialylated glycoproteins. 21604132 4 14 gly glycosylation 662:674 arg2 the glycosylation site glycoproteins site Fterm glycoproteins site In this context, the aim of this chapter is to describe a methodology to identify the glycosylation site of N-linked sialylated glycoproteins. 21535396 5 84 part_of sites 608:612 arg1 TF TF sites Cterm Site TF 2152 sites Site-specific mutagenesis of one or more potential N-linked glycosylation sites in TF was used to generate TF mutants lacking glycans. 23908491 6 6 part_of glycoprotein 792:803 arg1 selected HCV glycoprotein sequences glycoprotein selected HCV glycoprotein sequences Fterm Site glycoprotein sequences The entry functions and the sensitivity to antibody neutralization of selected HCV glycoprotein sequences were tested in the HCV pseudotyped particles (HCVpp) system. 24501222 1 58 gly glycoprotein 173:184 arg1 a plasma protein a plasma protein Fterm protein Histidine-rich glycoprotein (HRG) is a plasma protein consisting of 6 distinct functional domains and is an important regulator of key cardiovascular processes, including angiogenesis and coagulation. 24501222 1 58 gly glycoprotein 173:184 arg1 HRG HRG PUBTATOR HRG P04196 Histidine-rich glycoprotein (HRG) is a plasma protein consisting of 6 distinct functional domains and is an important regulator of key cardiovascular processes, including angiogenesis and coagulation. 3778488 4 0 part_of present 656:662 arg2 aFGF AND A potential glycosylation site Asn114-Gly115-Ser116 aFGF A potential glycosylation site Asn114-Gly115-Ser116 PUBTATOR Site aFGF 2246 site A potential glycosylation site Asn114-Gly115-Ser116 is present in aFGF but the mitogen does not bind to lectins suggesting that it may not be glycosylated. 3778488 4 34 part_of aFGF 667:670 arg1 A potential glycosylation site Asn114-Gly115-Ser116 aFGF A potential glycosylation site Asn114-Gly115-Ser116 PUBTATOR Site aFGF 2246 site A potential glycosylation site Asn114-Gly115-Ser116 is present in aFGF but the mitogen does not bind to lectins suggesting that it may not be glycosylated. 18815311 4 30 gly glycoprotein 788:799 arg1 the envelope glycoprotein the envelope glycoprotein Fterm glycoprotein Comparison with its ephrin-B2-bound form reveals that conformational changes within the envelope glycoprotein are required to achieve viral attachment. 8832092 2 13 gly glycoprotein 320:331 arg1 glycoprotein glucosyltransferase glycoprotein glucosyltransferase The method is based on the fact that incubation of rat liver UDP-Glc:glycoprotein glucosyltransferase, glucose-labelled UDP-Glc and a denatured high mannose-type glycoprotein target leads to the glucosylation of the oligosaccharide. 8832092 2 22 gly glycoprotein 413:424 arg1 a denatured high mannose-type glycoprotein target a denatured high mannose-type glycoprotein target Fterm glycoprotein The method is based on the fact that incubation of rat liver UDP-Glc:glycoprotein glucosyltransferase, glucose-labelled UDP-Glc and a denatured high mannose-type glycoprotein target leads to the glucosylation of the oligosaccharide. 12080076 3 0 part_of containing 538:547 arg1 a 12-amino acid cytoplasmic domain AND a single potential N-linked glycosylation site a 12-amino acid cytoplasmic domain a single potential N-linked glycosylation site site The cDNA predicts an open reading frame encoding a type II membrane protein of 341 amino acids with a 12-amino acid cytoplasmic domain and a 311-amino acid luminal domain containing a single potential N-linked glycosylation site. 12080076 3 9 part_of protein 435:441 arg1 a 311-amino acid luminal domain protein domain Fterm Site protein domain The cDNA predicts an open reading frame encoding a type II membrane protein of 341 amino acids with a 12-amino acid cytoplasmic domain and a 311-amino acid luminal domain containing a single potential N-linked glycosylation site. 8349699 9 70 gly Glycosylation 1267:1279 arg1 PGH synthase-2 PGH synthase-2 PUBTATOR PGH synthase-2 19225 Glycosylation of PGH synthase-2 is necessary for expression of enzyme activity, but glycosylation of PGH synthase-2 at Asn580 per se does not affect activity. 8349699 9 31 gly glycosylation 1351:1363 arg1 Asn580 Asn580 Asn580 Glycosylation of PGH synthase-2 is necessary for expression of enzyme activity, but glycosylation of PGH synthase-2 at Asn580 per se does not affect activity. 8349699 9 31 gly glycosylation 1351:1363 arg1 PGH synthase-2 PGH synthase-2 Asn580 PUBTATOR PGH synthase-2 19225 Asn580 Glycosylation of PGH synthase-2 is necessary for expression of enzyme activity, but glycosylation of PGH synthase-2 at Asn580 per se does not affect activity. 8349699 9 31 gly glycosylation 1351:1363 arg1 PGH synthase-2 PGH synthase-2 Asn580 PUBTATOR PGH synthase-2 19225 Asn580 Glycosylation of PGH synthase-2 is necessary for expression of enzyme activity, but glycosylation of PGH synthase-2 at Asn580 per se does not affect activity. 1390770 8 15 gly O-glycosylation 987:1001 arg2 Ser126 Ser126 Ser126 All the mutations at Ser126, the O-glycosylation site, were secreted normally. 1390770 8 15 gly O-glycosylation 987:1001 arg2 the O-glycosylation site the O-glycosylation site site All the mutations at Ser126, the O-glycosylation site, were secreted normally. 18320936 2 56 gly oligosaccharides 340:355 arg1 the viral haemagglutinin 1 (HA1) subunit subunit oligosaccharides Fterm subunit CVN neutralizes virus infectivity by binding to specific high-mannose oligosaccharides on the viral haemagglutinin 1 (HA1) subunit. 20209506 0 54 gly sialylated 20:29 arg1 sialylated and fucosylated glycopeptides sialylated and fucosylated glycopeptides glycopeptides Characterization of sialylated and fucosylated glycopeptides of beta2-glycoprotein I by a combination of HILIC LC and MALDI MS/MS. 20209506 0 100 gly beta2-glycoprotein 64:81 arg1 beta2-glycoprotein I beta2-glycoprotein I PUBTATOR beta2-glycoprotein I 350 Characterization of sialylated and fucosylated glycopeptides of beta2-glycoprotein I by a combination of HILIC LC and MALDI MS/MS. 20209506 0 101 gly fucosylated 35:45 arg1 sialylated and fucosylated glycopeptides sialylated and fucosylated glycopeptides glycopeptides Characterization of sialylated and fucosylated glycopeptides of beta2-glycoprotein I by a combination of HILIC LC and MALDI MS/MS. 20209506 0 48 gly glycopeptides 47:59 arg1 beta2-glycoprotein I beta2-glycoprotein I glycopeptides PUBTATOR beta2-glycoprotein I 350 glycopeptides Characterization of sialylated and fucosylated glycopeptides of beta2-glycoprotein I by a combination of HILIC LC and MALDI MS/MS. 10024532 1 16 gly IgG 179:181 arg1 The variable-domain-attached oligosaccharide side chains IgG The variable-domain-attached oligosaccharide side chains Cterm IgG The variable-domain-attached oligosaccharide side chains of a human IgG produced by a human-human-mouse heterohybridoma were analysed. 12237433 1 78 part_of haemagglutinin 210:223 arg1 the antigenic sites haemagglutinin the antigenic sites Fterm Site haemagglutinin sites To elucidate the structure of the antigenic sites of avian H5 influenza virus haemagglutinin (HA) we analysed escape mutants of a mouse-adapted variant of the H5N2 strain A/Mallard/Pennsylvania/10218/84. 9916943 4 7 part_of CD44 812:815 arg1 CD44 exon-specific epitopes CD44 CD44 exon-specific epitopes PUBTATOR Site CD44 960 epitopes In the present work we demonstrate that the immunoreactivity of some mAbs directed to CD44 exon-specific epitopes can be impaired by the structural variability of the molecule. 8193553 9 48 gly glycoprotein 1587:1598 arg1 the transfected glycoprotein the transfected glycoprotein Fterm glycoprotein This indicates that the level of expression of the transfected glycoprotein did not affect its O-glycan composition. 11251288 4 3 gly glycoproteins 700:712 arg1 novel glycoproteins novel glycoproteins Fterm glycoproteins The synthesis of novel glycoproteins through the selective reaction of glycosyl iodoacetamides with the thiol groups of cysteine residues, placed by site-directed mutagenesis at desired glycosylation sites has been developed. 11251288 4 45 gly glycosylation 863:875 arg2 desired glycosylation sites desired glycosylation sites sites The synthesis of novel glycoproteins through the selective reaction of glycosyl iodoacetamides with the thiol groups of cysteine residues, placed by site-directed mutagenesis at desired glycosylation sites has been developed. 17229854 8 20 gly glycosylation 1406:1418 arg2 a potential glycosylation site a potential glycosylation site site The 2005 G4P[8] strain compared to a G4P[8] strain from 2002 had a substitution of an asparagine residue for threonine (Asn-->Thr) at position 96 within antigenic region A, thus eliminating a potential glycosylation site. 25456591 10 89 gly O-glycosylation 1678:1692 arg1 the same site site site Moreover, the phosphorylation and O-glycosylation on the same site such as T159 of Factor IX and T170 of kappa-casein were able to be unambiguously differentiated. 12954207 1 48 gly glycoprotein 184:195 arg1 gp120 gp120 PUBTATOR gp120 155971 The human immunodeficiency virus (HIV-1) exterior envelope glycoprotein, gp120, mediates receptor binding and is the major target for neutralizing antibodies. 12954207 1 48 gly glycoprotein 184:195 arg1 The human immunodeficiency virus (HIV-1) exterior envelope glycoprotein The human immunodeficiency virus (HIV-1) exterior envelope glycoprotein PUBTATOR envelope glycoprotein 155971 The human immunodeficiency virus (HIV-1) exterior envelope glycoprotein, gp120, mediates receptor binding and is the major target for neutralizing antibodies. 14711516 1 24 gly glycosylation 234:246 arg2 individual glycosylation sites individual glycosylation sites sites Structural studies of asparagine-linked glycoproteins are complicated by the oligosaccharide heterogeneity inherent to individual glycosylation sites. 14711516 1 54 gly glycoproteins 144:156 arg1 asparagine-linked glycoproteins asparagine-linked glycoproteins Fterm glycoproteins Structural studies of asparagine-linked glycoproteins are complicated by the oligosaccharide heterogeneity inherent to individual glycosylation sites. 9249051 0 23 gly glycosylated 54:65 arg1 glycosylated recombinant human granulocyte-colony-stimulating factor glycosylated recombinant human granulocyte-colony-stimulating factor PUBTATOR granulocyte-colony-stimulating factor 1440 NMR investigations of the role of the sugar moiety in glycosylated recombinant human granulocyte-colony-stimulating factor. 10099468 3 77 gly sites 819:823 arg1 one Asn site one Asn site Asn site Rapid analysis of IFN-gamma by micellar electrokinetic capillary chromatography resolved the three glycosylation site occupancy variants of recombinant IFN-gamma (two Asn sites occupied, one Asn site occupied and nonglycosylated) in under 10 min per sample; the relative proportions of these variants remained constant during culture. 10099468 3 99 gly glycosylation 747:759 arg2 the three glycosylation site occupancy variants the three glycosylation site occupancy variants site Rapid analysis of IFN-gamma by micellar electrokinetic capillary chromatography resolved the three glycosylation site occupancy variants of recombinant IFN-gamma (two Asn sites occupied, one Asn site occupied and nonglycosylated) in under 10 min per sample; the relative proportions of these variants remained constant during culture. 10099468 3 100 gly nonglycosylated 861:875 arg1 one Asn site one Asn site Asn site Rapid analysis of IFN-gamma by micellar electrokinetic capillary chromatography resolved the three glycosylation site occupancy variants of recombinant IFN-gamma (two Asn sites occupied, one Asn site occupied and nonglycosylated) in under 10 min per sample; the relative proportions of these variants remained constant during culture. 10099468 3 103 gly IFN-gamma 800:808 arg1 two Asn sites two Asn sites Asn sites Rapid analysis of IFN-gamma by micellar electrokinetic capillary chromatography resolved the three glycosylation site occupancy variants of recombinant IFN-gamma (two Asn sites occupied, one Asn site occupied and nonglycosylated) in under 10 min per sample; the relative proportions of these variants remained constant during culture. 1380164 1 50 part_of subunit 209:215 arg1 a short peptide subunit a short peptide OGER Site subunit P02708 peptide The ligand binding site of the nicotinic acetylcholine receptor (AcChoR) is within a short peptide from the alpha subunit that includes the tandem cysteine residues at positions 192 and 193. 1380164 1 77 part_of receptor 150:157 arg1 The ligand binding site acetylcholine receptor The ligand binding site OGER Site acetylcholine receptor site The ligand binding site of the nicotinic acetylcholine receptor (AcChoR) is within a short peptide from the alpha subunit that includes the tandem cysteine residues at positions 192 and 193. 24174280 5 20 gly glycosylation 1090:1102 arg2 a potential glycosylation site a potential glycosylation site site Point mutations in several positions in the gene encoding the H3 of Tunisian strains were shown to ablate a glycan attachment site and also loss of a potential glycosylation site. 12954207 6 81 gly glycosylation 1123:1135 arg2 four N-linked glycosylation sites four N-linked glycosylation sites sites In this study, guided by the X-ray crystal structure of gp120, we deleted four N-linked glycosylation sites that flank the receptor-binding regions. 17899080 0 14 gly glycosylation 64:76 arg2 the N terminus the N terminus terminus Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. 17899080 0 14 gly glycosylation 64:76 arg2 a glycosylation site a glycosylation site site Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. 10103002 6 4 gly carbohydrate 1135:1146 arg1 gp42 gp42 Cterm gp42 A single N-glycosylation site present in chicken gp42 is conserved among all five of these proteins: carbohydrate analysis of gp42 revealed the presence of a complex type glycan chain at this site. 10103002 6 18 gly presence 1178:1185 arg2 this site AND a complex type glycan chain this site a complex type glycan chain site A single N-glycosylation site present in chicken gp42 is conserved among all five of these proteins: carbohydrate analysis of gp42 revealed the presence of a complex type glycan chain at this site. 10103002 6 66 gly N-glycosylation 1043:1057 arg2 A single N-glycosylation site A single N-glycosylation site site A single N-glycosylation site present in chicken gp42 is conserved among all five of these proteins: carbohydrate analysis of gp42 revealed the presence of a complex type glycan chain at this site. 32109505 4 62 gly N-glycosylation 463:477 arg1 TRPM8 channel TRPM8 channel PUBTATOR TRPM8 channel 79054 This work focuses on the N-glycosylation of TRPM8 channel that was previously studied by our group in relation to proliferation and migration of tumoral cells. 26256267 11 76 gly glycosylation 1783:1795 arg2 specific glycosylation sites specific glycosylation sites sites To determine the glycosylation heterogeneity at specific glycosylation sites, we further identified and quantified 1145 N-linked glycopeptides with attached glycans in the same iTRAQ-labeled samples. 26256267 11 99 gly glycosylation 1823:1835 arg2 specific glycosylation sites specific glycosylation sites sites To determine the glycosylation heterogeneity at specific glycosylation sites, we further identified and quantified 1145 N-linked glycopeptides with attached glycans in the same iTRAQ-labeled samples. 26256267 11 109 gly glycopeptides 1895:1907 arg2 1145 N-linked glycopeptides glycopeptides attached glycans glycopeptides To determine the glycosylation heterogeneity at specific glycosylation sites, we further identified and quantified 1145 N-linked glycopeptides with attached glycans in the same iTRAQ-labeled samples. 27743362 8 60 part_of Y-ion 1359:1363 arg1 B- and Y-ion fragments Y-ion B- and Y-ion fragments Cterm Site Y-ion fragments Stepping-energy CID results in B- and Y-ion fragments originating from the glycan moiety as well as b- and y-ions derived from the peptide part. 1725860 4 57 part_of possess 831:837 arg1 human IGFBP-4 AND two extra cysteines human IGFBP-4 two extra cysteines PUBTATOR AminoAcid IGFBP-4 3487 cysteines Both rat and human IGFBP-4 possess two extra cysteines at the mid-region of the molecule. 11897784 4 28 part_of IRE1alpha 853:861 arg1 the soluble luminal domain IRE1alpha the soluble luminal domain PUBTATOR Site IRE1alpha 2081 domain To provide an experimental system amenable to detailed biochemical and structural analysis to elucidate the mechanism of ER-transmembrane signaling mechanism mediated by the NLD, we overexpressed the soluble luminal domain of human IRE1alpha in COS-1 cells by transient DNA transfection. 25170432 8 31 gly N-glycosylation 769:783 arg1 the purified recombinant proteins the purified recombinant proteins Fterm proteins The N-glycosylation patterns of the purified recombinant proteins were characterised using nano-LC/MS/MS. 7904239 6 11 gly glycosylated 1127:1138 arg1 the glycosylated propeptide-CAT the glycosylated propeptide-CAT propeptide-CAT Surprisingly, the glycosylated propeptide-CAT and signal without CAT were degraded intracellularly with half-lives of 30 min and 90 min, respectively. 16212939 2 73 gly N-glycosylation 323:337 arg1 target proteins proteins peptide Fterm proteins peptide We investigated the effect of N-glycosylation of the secretion enhancer peptide on the secretion of target proteins. 9616152 9 13 gly glycosylation 1330:1342 arg2 the Asn 155 glycosylation site the Asn 155 glycosylation site site We postulate that the increase in affinity for heparin found with rhAT resulted from the presence of oligomannose-type structures on the Asn 155 glycosylation site and differences in sialylation. 9616152 9 16 gly site 1344:1347 arg1 sialylation site sialylation site We postulate that the increase in affinity for heparin found with rhAT resulted from the presence of oligomannose-type structures on the Asn 155 glycosylation site and differences in sialylation. 9616152 9 17 gly presence 1274:1281 arg1 the Asn 155 glycosylation site AND oligomannose-type structures the Asn 155 glycosylation site oligomannose-type structures site We postulate that the increase in affinity for heparin found with rhAT resulted from the presence of oligomannose-type structures on the Asn 155 glycosylation site and differences in sialylation. 25945896 12 36 gly glycosites 2216:2225 arg2 specific glycosites specific glycosites glycosites Additionally, spectral library matching gives the user the possibility of identifying novel or modified glycans on specific glycosites that might be missing from the predetermined glycan databases. 31445105 6 44 gly glycosylation 955:967 arg2 a new glycosylation site a new glycosylation site site The IAVs presented the substitution S162 N, which introduces a new glycosylation site in the hemagglutinin. 19371135 9 8 gly glycosylation 1100:1112 arg2 one glycosylation site one glycosylation site site All cysteine residues responsible for disulfide bonds and one glycosylation site have identical positions in the primary structures. 21264968 6 5 gly Thr1 2169:2172 arg1 a single α-GalNAc residue residue at Thr1, Thr6 a single α-GalNAc residue residue at Thr1, Thr6 The solution structures determined by NMR spectroscopic studies elicited that the preferential introduction of α-GalNAc at Thr10 of MUC4 stabilizes specifically a β-like extended backbone structure at this area, whereas other synthetic models with a single α-GalNAc residue at Thr1, Thr6, or Thr15 did not exhibit any converged three-dimensional structure at the proximal peptide moiety. 21264968 6 59 gly Thr15 2184:2188 arg1 a single α-GalNAc residue Thr15 a single α-GalNAc residue Thr15 The solution structures determined by NMR spectroscopic studies elicited that the preferential introduction of α-GalNAc at Thr10 of MUC4 stabilizes specifically a β-like extended backbone structure at this area, whereas other synthetic models with a single α-GalNAc residue at Thr1, Thr6, or Thr15 did not exhibit any converged three-dimensional structure at the proximal peptide moiety. 21264968 6 91 gly Thr6 2175:2178 arg1 a single α-GalNAc residue residue at Thr1, Thr6 a single α-GalNAc residue residue at Thr1, Thr6 The solution structures determined by NMR spectroscopic studies elicited that the preferential introduction of α-GalNAc at Thr10 of MUC4 stabilizes specifically a β-like extended backbone structure at this area, whereas other synthetic models with a single α-GalNAc residue at Thr1, Thr6, or Thr15 did not exhibit any converged three-dimensional structure at the proximal peptide moiety. 12356334 8 75 part_of contain 1473:1479 arg1 both SP-B variants AND another N-linked glycosylation site SP-B variants site, Asn311-Ser-Ser313 PUBTATOR Site SP-B variants 6439 site, Asn311-Ser-Ser313 In addition, we also confirmed that both SP-B variants contain another N-linked glycosylation site, Asn311-Ser-Ser313. 8388021 7 65 gly glycosylation 1113:1125 arg2 a potential glycosylation site a potential glycosylation site site A change from the amino acid aspartate to asparagine at amino acid position 308, which represented a potential glycosylation site, was the most effective substitution in reducing mouse neurovirulence. 12364335 8 60 gly Asp 1267:1269 arg1 the alpha repeat Asp(444) the alpha repeat Asp(444) Site-directed mutagenesis of the lectin domain selectively reduced the former activity and identified Asp(444) in the alpha repeat as the most important site for GalNAc recognition. 16981714 2 10 part_of PTX3 300:303 arg1 The PTX3 C-terminal domain PTX3 The PTX3 C-terminal domain PUBTATOR Site PTX3 5806 domain The PTX3 C-terminal domain is required for C1q recognition and complement activation and contains a single N-glycosylation site on Asn 220. 16981714 2 15 part_of contains 385:392 arg1 The PTX3 C-terminal domain AND a single N-glycosylation site The PTX3 C-terminal domain a single N-glycosylation site site The PTX3 C-terminal domain is required for C1q recognition and complement activation and contains a single N-glycosylation site on Asn 220. 18524814 2 83 gly glycosylation 768:780 arg2 the glycosylation site the glycosylation site site To investigate the role of this site in JEV replication and pathogenesis, we manipulated the RNA genome by using infectious JEV cDNA to generate three prM mutants (N15A, T17A, and N15A/T17A) with alanine substituting for N(15) and/or T(17) and one mutant with silent point mutations introduced into the nucleotide sequences corresponding to all three residues in the glycosylation site. 28970103 10 74 gly glycosylation 1970:1982 arg2 one glycosylation site one glycosylation site site However, site-specific O-glycosylation analysis is challenging because of the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of O-glycosylation. 1492495 2 3 part_of 35K 417:419 arg1 a signal peptide 35K a signal peptide Cterm Site 35K peptide Previous studies identified a cleavable, hydrophobic region of 17 amino acids in the 35K protein which could potentially function as a signal peptide to target the protein to the secretory pathway. 14715137 6 46 part_of synaptotagmin 1009:1021 arg1 the intravesicular N-glycosylation site synaptotagmin 1 the intravesicular N-glycosylation site PUBTATOR Site synaptotagmin 1 6857 site Our data suggest that the intravesicular N-glycosylation site of synaptotagmin 1 collaborates with its cytoplasmic C(2) domains in directing synaptotagmin 1 to synaptic vesicles via a novel N-glycosylation-dependent mechanism. 8157687 5 59 gly glycoproteins 1463:1475 arg1 C3-derived glycoproteins C3-derived glycoproteins Fterm glycoproteins Third, although conglutinin shows a more restricted binding relative to mannan-binding protein toward the oligosaccharides free of protein, it has a broader binding pattern toward the oligosaccharides as presented on C3-derived glycoproteins. 22365690 0 18 gly glycoprotein 43:54 arg1 target glycoprotein analysis target glycoprotein analysis Fterm glycoprotein iTRAQ plus 18O: a new technique for target glycoprotein analysis. 8107215 2 50 part_of subunit 411:417 arg1 the F2 subunit polypeptide subunit the F2 subunit polypeptide Fterm Site subunit polypeptide There are three potential N-linked glycosylation sites located on the F2 subunit polypeptide of MV F, at asparagine residues 29, 61, and 67. 8107215 2 101 part_of F2 408:409 arg1 the F2 subunit polypeptide F2 the F2 subunit polypeptide Cterm Site F2 polypeptide There are three potential N-linked glycosylation sites located on the F2 subunit polypeptide of MV F, at asparagine residues 29, 61, and 67. 8364023 1 25 gly site 154:157 arg1 Asn-X-Ser/Thr Asn-X-Ser/Thr Asn There are four potential N-glycosylation site (Asn-X-Ser/Thr) in human lecithin:cholesterol acyltransferase (LCAT, residues 20, 84, 272, and 384). 8364023 1 31 gly N-glycosylation 138:152 arg2 four potential N-glycosylation site four potential N-glycosylation site site There are four potential N-glycosylation site (Asn-X-Ser/Thr) in human lecithin:cholesterol acyltransferase (LCAT, residues 20, 84, 272, and 384). 8364023 1 57 gly acyltransferase 205:219 arg1 residues 20, 84, 272, and 384 residues 20, 84, 272, and 384 residues 20, 84, 272, and 384 There are four potential N-glycosylation site (Asn-X-Ser/Thr) in human lecithin:cholesterol acyltransferase (LCAT, residues 20, 84, 272, and 384). 21704619 4 2 gly N-glycosylation 503:517 arg2 the attached unnatural N-glycosylation site the attached unnatural N-glycosylation site site Hereby we could prove that the attached unnatural N-glycosylation site is decorated with complex-type N-glycans and that the spacer as well as the C-terminal "tail" sequence are critical for the usage of the novel N-glycosylation site. 21704619 4 23 gly N-glycosylation 667:681 arg2 the novel N-glycosylation site the novel N-glycosylation site site Hereby we could prove that the attached unnatural N-glycosylation site is decorated with complex-type N-glycans and that the spacer as well as the C-terminal "tail" sequence are critical for the usage of the novel N-glycosylation site. 10682309 8 59 gly glycosylation 1335:1347 arg1 SAP-B SAP site OGER SAP O60880 site A 643A > C transversion results in the exchange of asparagine 215 to histidine and eliminates the single glycosylation site of SAP-B. 21647803 8 18 part_of site 1262:1265 arg1 bovine ribonuclease B bovine ribonuclease B site Cterm Site bovine ribonuclease B site Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 28 part_of sites 1508:1512 arg1 bovine κ-casein κ-casein sites Fterm Site κ-casein sites Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 15342690 1 60 part_of has 164:166 arg1 EL AND five potential N-linked glycosylation sites EL five potential N-linked glycosylation sites PUBTATOR Site EL 9388 sites Human endothelial lipase (EL), a member of the triglyceride lipase gene family, has five potential N-linked glycosylation sites, two of which are conserved in both lipoprotein lipase and hepatic lipase. 15342690 1 60 part_of has 164:166 arg1 Human endothelial lipase AND five potential N-linked glycosylation sites Human endothelial lipase five potential N-linked glycosylation sites PUBTATOR Site Human endothelial lipase 9388 sites Human endothelial lipase (EL), a member of the triglyceride lipase gene family, has five potential N-linked glycosylation sites, two of which are conserved in both lipoprotein lipase and hepatic lipase. 8384766 5 18 gly glycosylation 1038:1050 arg2 position position position When compared with other tick-borne flaviviruses, Vs virus had 12 unique amino acid substitutions including an additional potential glycosylation site at position (315-317). 8384766 5 18 gly glycosylation 1038:1050 arg2 an additional potential glycosylation site an additional potential glycosylation site site When compared with other tick-borne flaviviruses, Vs virus had 12 unique amino acid substitutions including an additional potential glycosylation site at position (315-317). 6300470 8 54 gly glycoproteins 1024:1036 arg1 the glycoproteins the glycoproteins Fterm glycoproteins The data show that the glycoproteins are encoded by related yet distinct genes. 7524670 2 44 gly beta-subunit 408:419 arg1 the N-linked oligosaccharides beta-subunit the N-linked oligosaccharides Fterm beta-subunit To elucidate the molecular difference between these gonadotropins, the structure of the N-linked oligosaccharides of each beta-subunit was determined. 29069609 9 34 gly glycoforms 1490:1499 arg1 IgG1 glycopeptides IgG1 glycopeptides glycopeptides 21 glycoforms of IgG1 glycopeptides were identified including two truncated structures that are rarely reported. 29069609 9 92 gly glycopeptides 1509:1521 arg2 IgG1 glycopeptides IgG1 glycopeptides glycopeptides 21 glycoforms of IgG1 glycopeptides were identified including two truncated structures that are rarely reported. 9989600 6 19 gly N-glycosylation 747:761 arg2 The potential N-glycosylation site The potential N-glycosylation site site The potential N-glycosylation site was deduced from automatic Edman degradation and amino acid analysis, and glycan heterogeneity was evidenced by ESMS. 17986444 3 66 part_of NCAM 516:519 arg1 the two NCAM N-glycosylation sites NCAM the two NCAM N-glycosylation sites PUBTATOR Site NCAM 17967 sites Previous in vitro studies defined differences between the two enzymes in their usage of the two NCAM N-glycosylation sites affected and suggested a synergistic effect. 26729457 10 26 gly glycopeptide 1813:1824 arg2 The Q-TOF based glycopeptide analysis platform The Q-TOF based glycopeptide analysis platform glycopeptide The Q-TOF based glycopeptide analysis platform presented here opens the way to a range of different applications in glycoproteomics research as well as biopharmaceutical development and quality control. 29752426 10 90 gly hyperglycosylated 1530:1546 arg1 This hyperglycosylated variant This hyperglycosylated variant Fterm variant This hyperglycosylated variant showed a 10-fold improved exposure and decreased clearance in mice compared with an IgG1 Fc fusion protein containing the native FS sequence. 20209506 5 87 part_of beta2-GPI 1276:1284 arg1 three N-glycosylation sites GPI three N-glycosylation sites PUBTATOR Site GPI 350 sites A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI. 20209506 5 87 part_of beta2-GPI 1276:1284 arg1 Asn-174 GPI Asn-143, Asn-174 and Asn-234 PUBTATOR SpecificSite GPI 350 Asn-143, Asn-174 and Asn-234 A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI. 20209506 5 87 part_of beta2-GPI 1276:1284 arg1 Asn-143 GPI Asn-143, Asn-174 and Asn-234 PUBTATOR SpecificSite GPI 350 Asn-143, Asn-174 and Asn-234 A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI. 20209506 5 87 part_of beta2-GPI 1276:1284 arg1 Asn-143 GPI Asn-143, Asn-174 and Asn-234 PUBTATOR SpecificSite GPI 350 Asn-143, Asn-174 and Asn-234 A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI. 12626422 8 39 gly glycosylation 1483:1495 arg2 glycosylation sites glycosylation sites sites It is concluded that the nonoccupancy of glycosylation sites is not random under conditions of decreased glycosylation capacity and that the efficiency of glycosylation site occupancy depends on structural features at each site. 12626422 8 62 gly glycosylation 1597:1609 arg2 glycosylation site occupancy glycosylation site occupancy site It is concluded that the nonoccupancy of glycosylation sites is not random under conditions of decreased glycosylation capacity and that the efficiency of glycosylation site occupancy depends on structural features at each site. 18385254 7 71 gly glycosylation 980:992 arg2 residue N386 residue N386 residue N386 However, a potential glycosylation site at residue N386 completely modulated b12 resistance but required the presence of an arginine at residue 373. 18385254 7 71 gly glycosylation 980:992 arg2 a potential glycosylation site a potential glycosylation site site However, a potential glycosylation site at residue N386 completely modulated b12 resistance but required the presence of an arginine at residue 373. 10413465 0 12 part_of E 126:126 arg1 carboxy-terminal domains apolipoprotein E carboxy-terminal domains PUBTATOR Site apolipoprotein E 348 domains Contribution of cysteine 158, the glycosylation site threonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide beta (1-40). 10584881 4 34 gly AFP 816:818 arg1 the glycan structures AFP the glycan structures PUBTATOR AFP 174 We report here the application of fluorescence labelling, sequential exoglycosidase digestion, high-performance liquid chromatography and matrix-assisted laser desorption ionization in time-of-flight mass spectrometry, to determine the glycan structures of purified serum AFP from patients with HCC and NSGCT. 15718224 6 33 gly glycosylation 1205:1217 arg2 The affected glycosylation sites The affected glycosylation sites sites The affected glycosylation sites were predominantly clustered in regions of gp120 that are not involved in the direct interaction with either CD4, CCR5, CXCR4, or gp41. 8884270 5 44 gly N-glycosylation 871:885 arg2 this novel N-glycosylation site this novel N-glycosylation site site Metabolic labeling of the patient fibroblast culture and in vitro expression of the mutagenized cDNA construct suggest that this novel N-glycosylation site is actually utilized. 8884270 5 53 gly utilized 904:911 arg2 this novel N-glycosylation site this novel N-glycosylation site site Metabolic labeling of the patient fibroblast culture and in vitro expression of the mutagenized cDNA construct suggest that this novel N-glycosylation site is actually utilized. 26254591 3 15 part_of TNF 535:537 arg1 the lectin-like domain TNF the lectin-like domain PUBTATOR Site TNF 7124 domain Solnatide (named TIP-peptide, AP301), a 17 residue peptide mimicking the lectin-like domain of TNF has been shown to activate ENaC in several experimental animal models of acute lung injury and is being evaluated as a potential therapy for pulmonary oedema. 8407981 1 64 part_of P-450 111:115 arg1 N terminus cytochrome P-450 N terminus PUBTATOR Site cytochrome P-450 4051 terminus Evidence for localization of N terminus of microsomal cytochrome P-450 in the lumen. 22823882 7 16 gly glycopeptide 1082:1093 arg2 glycopeptide glycopeptide glycopeptide Comprehensive analysis was performed by lectin- or HILIC-capture of glycopeptide subsets followed by enzymatic deglycosylation in stable isotope-labeled water (H₂¹⁸O, IGOT) and finally LC-MS analyses. 6604728 3 16 gly glycosylation 552:564 arg2 Each glycosylation site Each glycosylation site site Each glycosylation site was then isolated by reverse phase high performance liquid chromatography using a C18 column. 30359034 8 56 gly glycopeptides 968:980 arg2 intact glycopeptides intact glycopeptides glycopeptides Next, the progress of analytical methods for intact glycopeptides is outlined. 19830736 5 25 gly glycosylation 656:668 arg2 The IL-24 glycosylation site mutant The IL-24 glycosylation site mutant site The IL-24 glycosylation site mutant, in contrast, showed a decreased protective effect. 29273683 8 20 gly glycosylation 1115:1127 arg2 only one glycosylation site only one glycosylation site site When expressed in N-acetylglucosaminyltransferase-I-deficient Lec1 cells, human and rat CBGs, and a human CBG mutant with only one glycosylation site at N238, have higher (2-4 fold) steroid-binding affinities than when produced by sialylation-deficient Lec2 cells or glycosylation-competent CHO-S cells. 29333671 2 57 gly glycopeptides 464:476 arg2 glycopeptides glycopeptides glycopeptides In this study, a customized dextran-bonded silica-based stationary phase was introduced for selective enrichment of glycopeptides and glycans from complex biological samples. 22997027 4 25 gly glycoprotein 610:621 arg1 glycoprotein identification glycoprotein identification Fterm glycoprotein Although recent advances in LC-MS analysis have made possible glycoprotein glycosylation site identification, characterization of glycoprotein glycan structures, as well as glycoprotein identification and quantification, protein glycosylation analysis in complex samples still remains a difficult task. 22997027 4 43 gly glycoprotein 499:510 arg1 possible glycoprotein glycosylation site possible glycoprotein glycosylation site Fterm glycoprotein Although recent advances in LC-MS analysis have made possible glycoprotein glycosylation site identification, characterization of glycoprotein glycan structures, as well as glycoprotein identification and quantification, protein glycosylation analysis in complex samples still remains a difficult task. 22997027 4 48 gly glycosylation 512:524 arg2 possible glycoprotein glycosylation site possible glycoprotein glycosylation site site Although recent advances in LC-MS analysis have made possible glycoprotein glycosylation site identification, characterization of glycoprotein glycan structures, as well as glycoprotein identification and quantification, protein glycosylation analysis in complex samples still remains a difficult task. 22997027 4 75 gly glycoprotein 567:578 arg1 glycoprotein glycan structures glycoprotein glycan structures Although recent advances in LC-MS analysis have made possible glycoprotein glycosylation site identification, characterization of glycoprotein glycan structures, as well as glycoprotein identification and quantification, protein glycosylation analysis in complex samples still remains a difficult task. 6300470 6 14 part_of gp71 883:886 arg1 Amino-terminal sequences gp71 Amino-terminal sequences Cterm Site gp71 sequences Amino-terminal sequences of gp69 and gp71 were determined. 6300470 6 50 part_of gp69 874:877 arg1 Amino-terminal sequences gp69 Amino-terminal sequences Cterm Site gp69 sequences Amino-terminal sequences of gp69 and gp71 were determined. 20795641 0 47 gly glycoproteins 36:48 arg1 N-linked glycoproteins N-linked glycoproteins Fterm glycoproteins An approach to quantifying N-linked glycoproteins by enzyme-catalyzed 18O3-labeling of solid-phase enriched glycopeptides. 20795641 0 81 gly glycopeptides 108:120 arg2 solid-phase enriched glycopeptides solid-phase enriched glycopeptides glycopeptides An approach to quantifying N-linked glycoproteins by enzyme-catalyzed 18O3-labeling of solid-phase enriched glycopeptides. 2780569 11 42 gly N-glycosylation 1970:1984 arg2 a putative N-glycosylation site a putative N-glycosylation site site In addition, Asn-189 is a putative N-glycosylation site, present only in the snake. 2780569 11 42 gly N-glycosylation 1970:1984 arg2 Asn-189 Asn-189 Asn-189 In addition, Asn-189 is a putative N-glycosylation site, present only in the snake. 9114055 3 34 gly glycosylation 673:685 arg2 at least two O-linked glycosylation sites at least two O-linked glycosylation sites sites The translated protein has a calculated molecular mass of 18.2 kDa and a potential N-linked glycosylation site at amino acids 158-160, besides at least two O-linked glycosylation sites. 9114055 3 53 gly glycosylation 600:612 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site The translated protein has a calculated molecular mass of 18.2 kDa and a potential N-linked glycosylation site at amino acids 158-160, besides at least two O-linked glycosylation sites. 1703533 1 14 gly glycoprotein 114:125 arg1 The glycoprotein allergen Art v II The glycoprotein allergen Art v II Fterm glycoprotein The glycoprotein allergen Art v II, from the pollen of mugwort (Artemisia vulgaris L.) was treated with peptide:N-glycosidase F (PNGase F) to release asparagine-linked oligosaccharides. 1703533 1 74 gly asparagine-linked 260:276 arg1 asparagine-linked oligosaccharides asparagine asparagine-linked oligosaccharides asparagine The glycoprotein allergen Art v II, from the pollen of mugwort (Artemisia vulgaris L.) was treated with peptide:N-glycosidase F (PNGase F) to release asparagine-linked oligosaccharides. 7750470 4 103 gly N-glycosylation 928:942 arg2 a single potential N-glycosylation site a single potential N-glycosylation site site The composite cDNA possessed an open reading frame of 1633 bases with a single potential N-glycosylation site. 23530120 2 13 part_of site 360:363 arg1 Env Env site PUBTATOR Site Env 100616444 site Neutralizing antibodies against the evolutionarily conserved CD4-binding site (CD4-BS) on the HIV envelope glycoprotein (Env) are capable of inhibiting infection of diverse HIV strains, and have been isolated from HIV-infected individuals. 23530120 2 13 part_of site 360:363 arg1 the HIV envelope glycoprotein V envelope glycoprotein site PUBTATOR Site V envelope glycoprotein 100616444 site Neutralizing antibodies against the evolutionarily conserved CD4-binding site (CD4-BS) on the HIV envelope glycoprotein (Env) are capable of inhibiting infection of diverse HIV strains, and have been isolated from HIV-infected individuals. 23530120 2 58 part_of CD4-binding 348:358 arg1 the evolutionarily conserved CD4-binding site CD4 the evolutionarily conserved CD4-binding site PUBTATOR Site CD4 920 site Neutralizing antibodies against the evolutionarily conserved CD4-binding site (CD4-BS) on the HIV envelope glycoprotein (Env) are capable of inhibiting infection of diverse HIV strains, and have been isolated from HIV-infected individuals. 11864713 2 27 gly Asn-linked 441:450 arg1 each Asn-linked glycan Asn each Asn-linked glycan Asn To examine the importance of each Asn-linked glycan in the activity of PCI, we compared wtPCI with the mutants of N-glycosylation site(s) in terms of the procoagulant protease-inhibitory and anticoagulant activities. 11864713 2 46 gly N-glycosylation 521:535 arg2 N-glycosylation site(s) N-glycosylation site(s) site To examine the importance of each Asn-linked glycan in the activity of PCI, we compared wtPCI with the mutants of N-glycosylation site(s) in terms of the procoagulant protease-inhibitory and anticoagulant activities. 25759508 8 19 gly N-glycosylation 1214:1228 arg1 the Fc CH2 domain the Fc CH2 domain domain For IgG3 samples from six donors we found similar O-glycan structures and site occupancies, whereas for the same samples the conserved N-glycosylation of the Fc CH2 domain showed considerable interindividual variation. 23002422 1 42 gly motifs 296:301 arg1 certain proteins proteins motifs Fterm proteins Model organisms containing deletion or mutation in a glycosyltransferase-gene exhibit various physiological abnormalities, suggesting that specific glycan motifs on certain proteins play important roles in vivo. 23991039 0 26 part_of gp120 44:48 arg1 the CD4 binding site gp120 the CD4 binding site PUBTATOR Site gp120 155971 site A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. 23991039 0 78 part_of CD4 24:26 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 920 site A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. 27574189 9 27 gly attached 987:994 arg2 one to Thr AND Five O-linked glycans one to Thr Five O-linked glycans Thr Five O-linked glycans were attached to a Ser and one to Thr. 27574189 9 27 gly attached 987:994 arg1 a Ser AND Five O-linked glycans a Ser Five O-linked glycans Ser Five O-linked glycans were attached to a Ser and one to Thr. 3517854 7 44 gly glycosylation 761:773 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site Bovine IL-2 is unique among IL-2 homologs in that it has a single N-linked glycosylation site. 26729457 8 2 gly O-glycopeptides 1476:1490 arg2 O-glycopeptides O-glycopeptides O-glycopeptides These optimized fragmentation parameters also enabled software-assisted glycopeptide assignment of both N- and O-glycopeptides including information about the most abundant glycan compositions, peptide sequence and putative structures. 26729457 8 101 gly glycopeptide 1437:1448 arg2 software-assisted glycopeptide assignment software-assisted glycopeptide assignment glycopeptide These optimized fragmentation parameters also enabled software-assisted glycopeptide assignment of both N- and O-glycopeptides including information about the most abundant glycan compositions, peptide sequence and putative structures. 18562306 4 74 gly glycosylation 962:974 arg2 glycosylation site selection glycosylation site selection site We demonstrate that the lectin domain of hT2 directs glycosylation site selection for glycopeptide substrates. 18562306 4 93 gly glycopeptide 995:1006 arg2 glycopeptide substrates glycopeptide substrates glycopeptide We demonstrate that the lectin domain of hT2 directs glycosylation site selection for glycopeptide substrates. 25521995 1 13 gly glycoprotein 169:180 arg1 glycoprotein quantitation glycoprotein quantitation Fterm glycoprotein PNGase F-catalyzed glycosylation site (18)O-labeling is a widely used method for glycoprotein quantitation owing to its efficiency and simplicity. 25521995 1 24 gly glycosylation 107:119 arg2 PNGase F-catalyzed glycosylation site PNGase F-catalyzed glycosylation site site PNGase F-catalyzed glycosylation site (18)O-labeling is a widely used method for glycoprotein quantitation owing to its efficiency and simplicity. 9030779 8 61 gly glycosylation 1352:1364 arg2 the second and third glycosylation sites the second and third glycosylation sites sites Our results also provide evidence that the site of early proteolytic cleavage of newly synthesized ASM must be located between the second and third glycosylation sites. 22015141 1 20 gly glycosylation 204:216 arg2 a putative N-linked glycosylation site a putative N-linked glycosylation site site The immunogenicity of a putative N-linked glycosylation site located at amino acids 143-145 (N143YS) of the porcine circovirus 2 (PCV2) Cap protein was investigated. 1331508 0 66 part_of has 68:70 arg1 the African green monkey poliovirus receptor AND no putative N-glycosylation site the African green monkey poliovirus receptor no putative N-glycosylation site OGER Site poliovirus receptor P15151 site A second gene for the African green monkey poliovirus receptor that has no putative N-glycosylation site in the functional N-terminal immunoglobulin-like domain. 11263562 5 27 gly observed 1130:1137 arg1 Ser126 AND two different O-linked oligosaccharides Ser126 two different O-linked oligosaccharides Ser126 Twenty, 16 and 22 different N-linked oligosaccharides were determined at Asn24, 38, and 83, respectively, and two different O-linked oligosaccharides were observed at Ser126. 9343410 4 13 part_of Sp1 696:698 arg1 the model Sp1 peptide Sp1 the model Sp1 peptide OGER Site Sp1 Q8N907 peptide When the model Sp1 peptide was overexpressed in primate cells, this 97-amino-acid domain of Sp1 was found to contain a dominant O-GlcNAc residue at high stoichiometry, which allowed the mapping and mutagenesis of this glycosylation site. 9343410 4 52 part_of Sp1 773:775 arg1 this 97-amino-acid domain Sp1 this 97-amino-acid domain OGER Site Sp1 Q8N907 domain When the model Sp1 peptide was overexpressed in primate cells, this 97-amino-acid domain of Sp1 was found to contain a dominant O-GlcNAc residue at high stoichiometry, which allowed the mapping and mutagenesis of this glycosylation site. 16862459 1 18 gly N-glycosylation 169:183 arg2 six potential N-glycosylation sites six potential N-glycosylation sites sites Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser). 16862459 1 18 gly N-glycosylation 169:183 arg2 Asn-X-Ser Asn-X-Ser Asn-X-Ser Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser). 1446688 0 9 gly N-glycosylation 61:75 arg1 human interleukin-6 human interleukin-6 PUBTATOR interleukin-6 3569 Improvement in the heterogeneous N-termini and the defective N-glycosylation of human interleukin-6 by genetic engineering. 18203712 7 61 gly N-glycosylation 957:971 arg1 Asn-594 Asn-594 Asn-594 We provide evidence from site-directed mutagenesis that a 27-amino acid instability motif (27-IM) regulates posttranslational N-glycosylation of Asn-594. 10024532 4 57 part_of Fab 542:544 arg1 the Fab fragment Fab the Fab fragment PUBTATOR Site Fab 2187 fragment The oligosaccharides of the Fab fragment were released by digestion with various endo- and exoglycosidases and analysed by anion-exchange chromatography and fluorophore-assisted carbohydrate electrophoresis. 9398598 0 57 part_of CD4 59:61 arg1 a murine CD4 fragment CD4 a murine CD4 fragment PUBTATOR Site CD4 12504 fragment Expression, purification, and characterization of a murine CD4 fragment containing the first two N-terminal domains. 30392906 6 33 gly glycosylation 705:717 arg2 a unique glycosylation site a unique glycosylation site site Unexpectedly, we found Asn50 is a unique glycosylation site and the glycosylation mediates its interaction with ConA. 30392906 6 33 gly glycosylation 705:717 arg2 Asn50 Asn50 Asn50 Unexpectedly, we found Asn50 is a unique glycosylation site and the glycosylation mediates its interaction with ConA. 6935656 8 79 gly glycosylation 1687:1699 arg2 an extra glycosylation site an extra glycosylation site site Recent nucleotide sequence analyses of selected RNase T1 oligonucleotides from the genomes of viruses that differ in GIX phenotype have similarly suggested that there may be a correlation between the GIX- phenotype and an extra glycosylation site [Donis-Keller, H., Rommelaere, J., Ellis, R. W. & Hopkins, N. (1980) Proc. 15247302 3 26 gly glycosylated 413:424 arg1 this residue this residue residue To determine whether this residue is glycosylated and to ascertain function, all possible single/multiple Asn --> Gln mutations were made in the human beta(2) AR at positions 6, 15, and 187 and were expressed in Chinese hamster fibroblast cells. 20621099 4 30 gly glycosylated 713:724 arg1 the originally glycosylated site the originally glycosylated site site We found that a major part of this mutant is sulfated at Tyr296, which adjacently precedes the originally glycosylated site. 16195790 6 53 part_of site 973:976 arg1 HA1 HA1 site OGER Site HA1 site Group II viruses, which predominated in Finland during the 2003-2004 season, were characterized by loss of the glycosylation site at position 126 in HA1. 25451932 8 69 gly N-glycosylation 978:992 arg1 corin cell surface targeting corin domain PUBTATOR corin 10699 domain Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation. 25451932 8 69 gly N-glycosylation 978:992 arg1 the scavenger receptor domain domain domain Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation. 25451932 8 69 gly N-glycosylation 978:992 arg1 corin cell surface targeting corin Asn-1022 PUBTATOR corin 10699 Asn-1022 Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation. 25451932 8 69 gly N-glycosylation 978:992 arg2 Asn-1022 Asn-1022 Asn-1022 Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation. 25451932 8 69 gly N-glycosylation 978:992 arg2 Asn-697 corin Asn-697 PUBTATOR corin 10699 Asn-697 Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation. 25451932 8 69 gly N-glycosylation 978:992 arg1 the scavenger receptor domain corin domain PUBTATOR corin 10699 domain Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation. 25451932 8 69 gly N-glycosylation 978:992 arg2 Asn-1022 corin Asn-1022 PUBTATOR corin 10699 Asn-1022 Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation. 25451932 8 69 gly N-glycosylation 978:992 arg1 Asn-697 corin Asn-697 PUBTATOR corin 10699 Asn-697 Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation. 25451932 8 69 gly N-glycosylation 978:992 arg1 Asn-697 Asn-697 Asn-697 Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation. 8189524 2 0 gly glycoproteins 309:321 arg1 glycoproteins glycoproteins Fterm glycoproteins In the alphaherpesvirus pseudorabies virus (PrV), seven glycoproteins that all constitute homologs of glycoproteins found in herpes simplex virus type 1 (HSV-1) have been characterized, including a homolog of HSV-1 glycoprotein H (gH). 8189524 2 1 gly glycoprotein 422:433 arg1 HSV-1 glycoprotein H HSV-1 glycoprotein H Cterm HSV-1 glycoprotein H (gH In the alphaherpesvirus pseudorabies virus (PrV), seven glycoproteins that all constitute homologs of glycoproteins found in herpes simplex virus type 1 (HSV-1) have been characterized, including a homolog of HSV-1 glycoprotein H (gH). 8189524 2 5 gly glycoproteins 263:275 arg1 seven glycoproteins seven glycoproteins Fterm glycoproteins In the alphaherpesvirus pseudorabies virus (PrV), seven glycoproteins that all constitute homologs of glycoproteins found in herpes simplex virus type 1 (HSV-1) have been characterized, including a homolog of HSV-1 glycoprotein H (gH). 7741215 5 7 gly glycosylation 905:917 arg2 All glycosylation sites All glycosylation sites sites All glycosylation sites exhibited some level of O-acetylation of Neu5Ac residues. 31266872 5 84 gly glycosylation 1018:1030 arg2 a conserved N-linked glycosylation site a conserved N-linked glycosylation site site Whereas a substitution in a conserved N-linked glycosylation site (N171Q) eliminates sensitivity to ADCC, a lysine-to-serine substitution in this region (K180S) increases ADCC and renders the virus susceptible to neutralization. 22688517 2 57 gly N-glycosylation 216:230 arg1 LOX-1 LOX-1 PUBTATOR LOX-1 4973 The N-glycosylation of LOX-1 has been shown to affect its biological functions in vivo and modulate the pathogenesis of atherosclerosis. 12235182 4 26 gly glycosylation 964:976 arg2 all five N-linked glycosylation sites all five N-linked glycosylation sites sites When all five N-linked glycosylation sites were mutated within apoB-37, the secretion efficiency and association with lipoproteins were decreased by >50% as compared with wild-type apoB-37. 27301377 7 74 gly glycosylated 1849:1860 arg1 the identical glycosylated 17.5 kDa pull-down protein the identical glycosylated 17.5 kDa pull-down protein Fterm protein Western blot analysis using anti-DEspR mAbs targeting distinct DEspR epitopes detect the identical glycosylated 17.5 kDa pull-down protein. 17996106 3 82 gly glycosylation 413:425 arg2 glycosylation sites glycosylation sites sites Experimental identification of glycosylation sites is expensive and laborious. 18369607 6 50 part_of CDR 1168:1170 arg1 the CDR 2 region CDR 2 the CDR 2 region PUBTATOR Site CDR 2 1039 region Surprisingly, pronounced sequence microheterogeneities were determined for the CDR 2 region of the light chain, indicating that changes at the protein level derived from somatic hypermutation of the Ig V(L) genes in mature B-cells might contribute to unexpected structural diversity. 26485397 3 25 part_of furin 434:438 arg1 a putative furin protease cleavage site furin a putative furin protease cleavage site OGER Site furin P09958 site Sequence analysis showed that the open reading frame (ORF) of cAPRIL contains a putative furin protease cleavage site (R-R-K-R), a conserved putative N-glycosylation site (Asn(124)), and two conservative cysteine residues (Cys(196) and Cys(211)). 26582203 3 1 gly carries 525:531 arg1 Asn-95 AND a core glycan Asn-95 a core glycan Asn-95 Mass spectrometry revealed that Asn-95 carries a core glycan, consisting of two GlcNAc and three hexoses. 32168410 8 97 gly deglycosylated 971:984 arg1 deglycosylated and native FXIII-B deglycosylated and native FXIII-B PUBTATOR FXIII-B 2165 The clearance of deglycosylated and native FXIII-B from plasma was compared in FXIII-B knock out mice. 7532677 8 111 part_of Bw4 1536:1538 arg1 the Bw4 epitope Bw4 the Bw4 epitope PUBTATOR Site Bw4 474272 epitope Sequences outside of the Bw4 region must also affect recognition by NKB1+ NK cells, because lysis of transfectants expressing HLA-A*2403 or A*2501, which possess the Bw4 epitope but are in other ways substantially different from HLA-B molecules, was not increased by addition of the anti-NKB1 antibody. 7532677 8 124 part_of Bw4 1395:1397 arg1 the Bw4 region Bw4 the Bw4 region PUBTATOR Site Bw4 474272 region Sequences outside of the Bw4 region must also affect recognition by NKB1+ NK cells, because lysis of transfectants expressing HLA-A*2403 or A*2501, which possess the Bw4 epitope but are in other ways substantially different from HLA-B molecules, was not increased by addition of the anti-NKB1 antibody. 16200726 7 22 part_of CETP 1349:1352 arg1 CETP amino acid sequence CETP CETP amino acid sequence PUBTATOR Site CETP P11597 sequence The regions concerning the CETP function of binding and transferring neutral lipids in tree shrew CETP amino acid sequence are highly conservative. 8543009 7 8 part_of has 608:610 arg1 ClC-6 AND a highly conserved glycosylation site ClC-6 a highly conserved glycosylation site PUBTATOR Site ClC-6 1185 site ClC-6 has a highly conserved glycosylation site between transmembrane domains D8 and D9, while ClC-7 is the only known eukaryotic ClC protein which lacks this site. 18533687 3 2 part_of contains 406:413 arg1 RXFP1 AND six putative Asn-linked glycosylation sites RXFP1 six putative Asn-linked glycosylation sites PUBTATOR Site RXFP1 59350 sites RXFP1 contains six putative Asn-linked glycosylation sites in the ectodomain at positions Asn-14, Asn-105, Asn-242, Asn-250, Asn-303, and Asn-346, which are highly conserved across species. 23952973 6 57 gly glycosylation 941:953 arg2 a potential glycosylation site a potential glycosylation site site Site 193 was found to be a potential glycosylation site and located in receptor-binding domain. 26439794 3 2 gly glycopeptide 417:428 arg2 a glycopeptide enrichment method a glycopeptide enrichment method glycopeptide Previously, we developed a glycopeptide enrichment method by acetone precipitation, and it was successfully applied to human serum glycoproteomics. 1376147 3 8 part_of chymase 389:395 arg1 The deduced amino acid sequence chymase 1 The deduced amino acid sequence OGER Site chymase 1 P21844 sequence The deduced amino acid sequence of mouse chymase 1 consists of a 226 amino acid catalytic portion and a 21 amino acid preprosequence. 1869556 8 56 gly deglycosylation 1232:1246 arg1 the 22-kDa protein the 22-kDa protein Fterm protein The 17-kDa protein, which was found to lack core sugars, does not result from deglycosylation of the 22-kDa protein in vivo and does not result from saturation of the glycosylation enzymatic machinery through overexpression. 14692455 7 80 gly deglycosylated 1116:1129 arg1 deglycosylated peptides deglycosylated peptides peptides After deglycosylated peptides were transferred to a reversed phase chromatography (RPC) column and fractionated by gradient elution with increasing amounts of acetonitrile. 12765790 9 25 gly GlcNAc 1772:1777 arg1 residues residues residues Non-PSA/HNK1-glycans exhibited a heterogeneous pattern of partially truncated, mostly diantennary structures with one to three fucose residues, bisecting GlcNAc and/or sulfate residues. 25227423 5 46 gly N-glycosylation 955:969 arg2 N-glycosylation sites N-glycosylation sites sites We identify, from an analysis of over 6000 influenza A H3N2 sequences, a set of residues adjacent to N-glycosylation sites that are highly likely to be involved in antigenic escape from host antibodies. 23909558 6 46 gly O-glycopeptides 799:813 arg2 O-glycopeptides O-glycopeptides O-glycopeptides To address the urgent need, we studied the fragmentation of O-glycopeptides in ETD and found useful rules that facilitate their identification. 25629924 7 54 gly O-glycopeptide 1290:1303 arg2 a theoretical O-glycopeptide library a theoretical O-glycopeptide library O-glycopeptide Additionally, 54 O-linked glycan compositions located at the IgA1 hinge region (HR) were identified by comparison against a theoretical O-glycopeptide library. 6148073 7 12 gly glycosylated 1328:1339 arg1 the other two sites the other two sites sites Amino acid analysis of the glycopeptides showed that the predominant oligosaccharide at glycosylation-site Asn-23 was of 'high-mannose' type, whereas the other two sites (Asn-75 and Asn-99) were glycosylated with 'complex-type' chains. 6148073 7 26 gly glycopeptides 1160:1172 arg2 the glycopeptides the glycopeptides glycopeptides Amino acid analysis of the glycopeptides showed that the predominant oligosaccharide at glycosylation-site Asn-23 was of 'high-mannose' type, whereas the other two sites (Asn-75 and Asn-99) were glycosylated with 'complex-type' chains. 6148073 7 58 gly Asn-23 1240:1245 arg1 the predominant oligosaccharide Asn-23 the predominant oligosaccharide Asn-23 Amino acid analysis of the glycopeptides showed that the predominant oligosaccharide at glycosylation-site Asn-23 was of 'high-mannose' type, whereas the other two sites (Asn-75 and Asn-99) were glycosylated with 'complex-type' chains. 6148073 7 62 gly sites 1297:1301 arg1 the other two sites the other two sites sites Amino acid analysis of the glycopeptides showed that the predominant oligosaccharide at glycosylation-site Asn-23 was of 'high-mannose' type, whereas the other two sites (Asn-75 and Asn-99) were glycosylated with 'complex-type' chains. 6148073 7 12 gly glycosylated 1328:1339 arg1 Asn-99 Asn-75 and Asn-99 Asn-75 and Asn-99 Amino acid analysis of the glycopeptides showed that the predominant oligosaccharide at glycosylation-site Asn-23 was of 'high-mannose' type, whereas the other two sites (Asn-75 and Asn-99) were glycosylated with 'complex-type' chains. 6148073 7 62 gly sites 1297:1301 arg1 Asn-99 Asn-75 and Asn-99 Asn-75 and Asn-99 Amino acid analysis of the glycopeptides showed that the predominant oligosaccharide at glycosylation-site Asn-23 was of 'high-mannose' type, whereas the other two sites (Asn-75 and Asn-99) were glycosylated with 'complex-type' chains. 17636988 10 63 gly O-glycosylated 1650:1663 arg1 Several O-glycosylated peptides Several O-glycosylated peptides peptides Several O-glycosylated peptides were also identified with a single N-acetylhexosamine attached, arguably due to partial deglycosylation of O-glycan structures by the exoglycosidases used together with Endo D/H. 17636988 10 65 gly deglycosylation 1762:1776 arg1 O-glycan structures O-glycan structures Several O-glycosylated peptides were also identified with a single N-acetylhexosamine attached, arguably due to partial deglycosylation of O-glycan structures by the exoglycosidases used together with Endo D/H. 1457204 2 61 part_of CD4 174:176 arg1 The overall amino-acid sequence CD4 The overall amino-acid sequence PUBTATOR Site CD4 920 sequence The overall amino-acid sequence of cat CD4 is similar to that from the primate and rodent CD4 molecules, with a 58% identity between the cat and human sequences. 8193553 10 88 gly glycosylation 1666:1678 arg2 the N-linked glycosylation site the N-linked glycosylation site site Deletion of the N-linked glycosylation site at Asn26, by introducing the Mi.I mutation (Thr28-->Met) by site-directed mutagenesis, did not markedly affect the O-glycan composition of the resulting recombinant glycoprotein expressed in wild type CHO cells. 8193553 10 88 gly glycosylation 1666:1678 arg2 Asn26 Asn26 Asn26 Deletion of the N-linked glycosylation site at Asn26, by introducing the Mi.I mutation (Thr28-->Met) by site-directed mutagenesis, did not markedly affect the O-glycan composition of the resulting recombinant glycoprotein expressed in wild type CHO cells. 8193553 10 20 gly glycoprotein 1850:1861 arg1 the O-glycan composition glycoprotein the O-glycan composition Fterm glycoprotein Deletion of the N-linked glycosylation site at Asn26, by introducing the Mi.I mutation (Thr28-->Met) by site-directed mutagenesis, did not markedly affect the O-glycan composition of the resulting recombinant glycoprotein expressed in wild type CHO cells. 11063734 9 4 part_of SP-B 1311:1314 arg1 the SP-B genotype Thr/Thr SP-B the SP-B genotype Thr/Thr PUBTATOR Site SP-B 6439 Thr/Thr Among the infants born before 32 weeks of gestation and having the SP-B genotype Thr/Thr, the SP-A1 allele 6A(2) was over-represented in RDS group compared with controls (P = 0.001, OR = 4.7, CI 1.8-12.2). 16823988 12 5 gly proteins 1608:1615 arg1 the glycan structures proteins the glycan structures Fterm proteins In addition, the glycan structures of the altered proteins are assigned using MALDI-QIT-MS. 20589574 8 68 part_of site 1385:1388 arg1 EIF1 EIF1 site PUBTATOR Site EIF1 P41567 site In addition, there is a protein kinase C phosphorylation site in EIF1 of the giant panda. 20589574 8 90 part_of C 1367:1367 arg1 a protein kinase C phosphorylation site protein kinase C a protein kinase C phosphorylation site Cterm Site protein kinase C site In addition, there is a protein kinase C phosphorylation site in EIF1 of the giant panda. 10471642 4 38 part_of transferrin 871:881 arg1 the N-432 N-glycosylation site transferrin the N-432 N-glycosylation site PUBTATOR Site transferrin 7018 site A specific antibody directed against the amino acid sequence surrounding the N-432 N-glycosylation site of transferrin was prepared (SZ-350 antibody). 9254646 2 25 gly glycosylation 575:587 arg2 an N-linked glycosylation site an N-linked glycosylation site site Introducing an N-linked glycosylation site into the determinant selectively reduced presentation of SNP. 3980466 5 72 gly glycosylation 945:957 arg2 each glycosylation site each glycosylation site site The data indicate: 1) a unique distribution of oligosaccharide structures is present at each glycosylation site; 2) each site-specific oligosaccharide pattern is highly reproducible, independent of the number of in vivo tumor passages. 8307000 8 46 part_of GS-tPA 1623:1628 arg1 Asn117 tPA Asn117 OGER AminoAcid tPA P00750 Asn117 In contrast, Asn117 of GS-tPA carried only small amounts (about 25%) of high-mannose and hybrid-type species and predominantly complex-type sugar chains (about 75%) which were partially incomplete and mostly devoid of fucose. 16368742 1 7 gly glycosylation 158:170 arg2 a consensus N-linked glycosylation motif a consensus N-linked glycosylation motif motif We identified a consensus N-linked glycosylation motif within the pore-forming loop between the fifth and sixth transmembrane segments of the osmoresponsive transient receptor potential (TRP) channel TRPV4. 25673720 0 44 gly glycosylation 4:16 arg1 PrPC PrPC PUBTATOR PrPC 19122 The glycosylation status of PrPC is a key factor in determining transmissible spongiform encephalopathy transmission between species. 16331960 5 45 part_of transferrin 1044:1054 arg1 the C-lobe transferrin the C-lobe PUBTATOR Site transferrin 7018 C-lobe The observed peptide fragmentation profile showed that the C-lobe of recombinant full-length nonglycosylated transferrin (rhTf-NG) appeared to be preferentially cleaved, while cleavage of the N-lobe was restricted to the N-terminal and link sequence regions. 19947664 5 10 gly glycoforms 912:921 arg1 rt-PA rt-PA Cterm rt-PA P00750 In this work, we applied LC-MS with state-of-the-art instrumentation to the characterization of glycoforms of rt-PA. 9348299 5 70 part_of site 872:875 arg1 the experimentally point mutated C57BL/6-T49I sIL-4R sIL site OGER Site sIL Q60988 site The extracellular Thr49 to Ile substitution abrogates one N-glycosylation site in the naturally occurring BALB/c IL-4R as well as in the experimentally point mutated C57BL/6-T49I sIL-4R, and both molecules display a nearly threefold reduction in IL-4-neutralizing activity compared to the C57BL/6 sIL-4R. 9348299 5 70 part_of site 872:875 arg1 the naturally occurring BALB/c IL-4R BALB/c IL-4R site PUBTATOR Site BALB/c IL-4R 16190 site The extracellular Thr49 to Ile substitution abrogates one N-glycosylation site in the naturally occurring BALB/c IL-4R as well as in the experimentally point mutated C57BL/6-T49I sIL-4R, and both molecules display a nearly threefold reduction in IL-4-neutralizing activity compared to the C57BL/6 sIL-4R. 22733248 1 5 gly glycoprotein 86:97 arg1 A glycoprotein A glycoprotein Fterm glycoprotein A glycoprotein exists as a heterogeneous mixture of forms due to differential glycosylation, each of which may confer different functionality and/or serve as a biochemical marker for disease. 11278567 6 49 gly glycosylation 954:966 arg2 this V3 N-linked glycosylation site this V3 N-linked glycosylation site site The loss of this V3 N-linked glycosylation site was also linked with the broadening of the coreceptor repertoire to incorporate CCR3. 31611356 1 45 gly sites 277:281 arg1 HIV-1 gp120 HIV-1 gp120 sites PUBTATOR HIV-1 gp120 155971 Griffithsin (Grft) is an antiviral lectin that has been shown to potently inhibit HIV-1 by binding high-mannose N-linked glycosylation sites on HIV-1 gp120. 26701645 4 71 part_of tyrosinase 629:638 arg1 all seven sites tyrosinase all seven sites PUBTATOR Site tyrosinase 7299 sites By LC-MS/MS analysis of human tyrosinase expressed in a melanoma cell, we show that all seven sites of tyrosinase are at least partially N-glycosylated. 12356334 7 84 gly glycosylated 1309:1320 arg1 the C allele variant variant site Fterm variant site Using both the stably transfected cell lines and fetal lung explants, we observed that the C allele variant is indeed glycosylated at the Asn129-Gln-Thr131 site, whereas the T allele variant, which served as a control, is not. 12867358 0 50 gly N-glycosylation 19:33 arg2 the N-glycosylation site hNaSi-1 site PUBTATOR hNaSi-1 6561 site Mutagenesis of the N-glycosylation site of hNaSi-1 reduces transport activity. 30011186 8 40 gly glycoprotein 1557:1568 arg1 surface glycoprotein dynamics surface glycoprotein dynamics Fterm glycoprotein In our lab, we developed effective MS-based chemical and enzymatic methods to (1) globally analyze glycoproteins in complex biological samples, (2) target glycoproteins specifically on the surface of human cells, (3) systematically quantify glycoprotein and surface glycoprotein dynamics (the abundance changes of glycoproteins as a function of time), and (4) selectively characterize glycoproteins with a particular and important glycan. 30011186 8 89 gly glycoproteins 1446:1458 arg1 (2) target glycoproteins (2) target glycoproteins Fterm glycoproteins In our lab, we developed effective MS-based chemical and enzymatic methods to (1) globally analyze glycoproteins in complex biological samples, (2) target glycoproteins specifically on the surface of human cells, (3) systematically quantify glycoprotein and surface glycoprotein dynamics (the abundance changes of glycoproteins as a function of time), and (4) selectively characterize glycoproteins with a particular and important glycan. 30011186 8 122 gly glycoprotein 1532:1543 arg1 glycoprotein glycoprotein Fterm glycoprotein In our lab, we developed effective MS-based chemical and enzymatic methods to (1) globally analyze glycoproteins in complex biological samples, (2) target glycoproteins specifically on the surface of human cells, (3) systematically quantify glycoprotein and surface glycoprotein dynamics (the abundance changes of glycoproteins as a function of time), and (4) selectively characterize glycoproteins with a particular and important glycan. 30011186 8 129 gly glycoproteins 1390:1402 arg1 glycoproteins glycoproteins Fterm glycoproteins In our lab, we developed effective MS-based chemical and enzymatic methods to (1) globally analyze glycoproteins in complex biological samples, (2) target glycoproteins specifically on the surface of human cells, (3) systematically quantify glycoprotein and surface glycoprotein dynamics (the abundance changes of glycoproteins as a function of time), and (4) selectively characterize glycoproteins with a particular and important glycan. 30011186 8 149 gly glycoproteins 1605:1617 arg1 glycoproteins glycoproteins Fterm glycoproteins In our lab, we developed effective MS-based chemical and enzymatic methods to (1) globally analyze glycoproteins in complex biological samples, (2) target glycoproteins specifically on the surface of human cells, (3) systematically quantify glycoprotein and surface glycoprotein dynamics (the abundance changes of glycoproteins as a function of time), and (4) selectively characterize glycoproteins with a particular and important glycan. 30011186 8 158 gly glycoproteins 1676:1688 arg1 a particular and important glycan glycoproteins a particular and important glycan Fterm glycoproteins In our lab, we developed effective MS-based chemical and enzymatic methods to (1) globally analyze glycoproteins in complex biological samples, (2) target glycoproteins specifically on the surface of human cells, (3) systematically quantify glycoprotein and surface glycoprotein dynamics (the abundance changes of glycoproteins as a function of time), and (4) selectively characterize glycoproteins with a particular and important glycan. 23339644 5 24 gly glycopeptide 1157:1168 arg2 glycopeptide identification glycopeptide identification glycopeptide The inclusion of ETD facilitated the analysis by providing additional validation for glycopeptide identification and expanding the identified glycopeptides to include coverage of O-linked glycosylation. 23339644 5 100 gly glycopeptides 1214:1226 arg2 the identified glycopeptides the identified glycopeptides glycopeptides The inclusion of ETD facilitated the analysis by providing additional validation for glycopeptide identification and expanding the identified glycopeptides to include coverage of O-linked glycosylation. 8288048 0 66 gly glycosylation 40:52 arg1 the insulin receptor alpha-subunit subunit sites OGER subunit 3643 sites Mutational analysis of the NH2-terminal glycosylation sites of the insulin receptor alpha-subunit. 6510420 1 10 part_of lactotransferrin 164:179 arg1 703 amino acid residues lactotransferrin 703 amino acid residues PUBTATOR Site lactotransferrin 4057 residues The complete amino acid sequence (703 amino acid residues) of human lactotransferrin has been determined. 6510420 1 10 part_of lactotransferrin 164:179 arg1 The complete amino acid sequence lactotransferrin The complete amino acid sequence PUBTATOR Site lactotransferrin 4057 sequence The complete amino acid sequence (703 amino acid residues) of human lactotransferrin has been determined. 15968392 1 12 part_of FXI 332:334 arg1 the serine protease domain FXI the serine protease domain PUBTATOR Site FXI 2160 domain PCR-SSCP and DNA sequence analysis of a factor XI (FXI) deficient patient (FXI:C 39 U/dL; FXI:Ag 27 U/dL) identified a C to T transition in exon 12 of the FXI gene (F11 c.1521C>T) that predicts the substitution of Thr475 by Ile (FXI T475I) within the serine protease domain of FXI. 15968392 1 67 part_of FXI 284:286 arg1 Ile FXI Ile PUBTATOR AminoAcid FXI 2160 Ile PCR-SSCP and DNA sequence analysis of a factor XI (FXI) deficient patient (FXI:C 39 U/dL; FXI:Ag 27 U/dL) identified a C to T transition in exon 12 of the FXI gene (F11 c.1521C>T) that predicts the substitution of Thr475 by Ile (FXI T475I) within the serine protease domain of FXI. 19008394 6 63 gly deglycosylated 1224:1237 arg1 the epitope protein epitope Fterm protein epitope Failure of most WNV- and MVEV-positive horse sera to recognize the epitope as a deglycosylated fusion protein confirmed that the N-linked glycan was important for antibody recognition of the peptide. 12438611 8 13 gly glycosylation 1634:1646 arg2 glycosylation sites glycosylation sites sites We showed that 2G12 and DC-SIGN bound to nonoverlapping sites in gp120 because (i) 2G12 did not block soluble gp120 or virion binding to DC-SIGN, (ii) 2G12 bound to gp120-Fc that was prebound to cell surface DC-SIGN, and (iii) gp120-Fc mutants that lack glycosylation sites involved in 2G12's epitope were also fully capable of binding DC-SIGN. 29479800 0 20 gly glycoproteins 99:111 arg1 recombinant glycoproteins recombinant glycoproteins Fterm glycoproteins An oligosaccharyltransferase from Leishmania major increases the N-glycan occupancy on recombinant glycoproteins produced in Nicotiana benthamiana. 29479800 0 45 gly occupancy 74:82 arg1 recombinant glycoproteins glycoproteins occupancy Fterm glycoproteins An oligosaccharyltransferase from Leishmania major increases the N-glycan occupancy on recombinant glycoproteins produced in Nicotiana benthamiana. 17010165 6 52 gly glycosylation 1462:1474 arg2 an additional N-linked glycosylation site an additional N-linked glycosylation site site Viruses with higher V3 charges are more readily transferred to CD4(+) lymphocytes when the V1V2 region is longer and contains an additional N-linked glycosylation site, whereas transfer of viruses with lower V3 charges is greater when the V1V2 region is shorter. 23776650 7 42 gly present 936:942 arg1 purified DCIR AND the glycans purified DCIR the glycans PUBTATOR DCIR 50856 Removing or truncating the glycans present on purified DCIR increased the affinity for DCIR-binding glycans. 9352200 10 19 gly glycoproteins 1612:1624 arg1 glycoproteins glycoproteins Fterm glycoproteins The consensus sequence was used to make structure-fertilization function predictions for this phylogenetically conserved family of glycoproteins. 9352200 10 74 gly used 1508:1511 arg2 The consensus sequence The consensus sequence sequence The consensus sequence was used to make structure-fertilization function predictions for this phylogenetically conserved family of glycoproteins. 19131501 3 74 part_of Stc2 450:453 arg1 the opossum Stc2 cDNA sequence Stc2 the opossum Stc2 cDNA sequence PUBTATOR Site Stc2 8614 sequence In this study, we identified the opossum Stc2 cDNA sequence. 31244828 4 12 gly N-glycosylation 734:748 arg2 one known N-glycosylation site one known N-glycosylation site site MOG has one known N-glycosylation site at N31 located in the BC loop linking two beta-sheets. 31244828 4 12 gly N-glycosylation 734:748 arg2 N31 N31 N31 MOG has one known N-glycosylation site at N31 located in the BC loop linking two beta-sheets. 19241033 1 68 gly N-glycosylated 98:111 arg1 N-glycosylated peptides N-glycosylated peptides peptides General mass spectrometry-based strategies for analysis of N-glycosylated peptides are described. 7727375 6 8 part_of -1 973:974 arg1 prolines at -1 prolines OGER AminoAcid at -1 O00400 prolines We have also found that glycosylation is less efficient when rEPO is improperly folded and that prolines at -1 and +1 relative to the O-glycosylation site enhance glycosylation. 8706658 5 106 part_of synthase 1031:1038 arg1 The deduced 150-amino-acid sequence leukotriene C4 synthase The deduced 150-amino-acid sequence PUBTATOR Site leukotriene C4 synthase 17001 sequence The deduced 150-amino-acid sequence of mouse leukotriene C4 synthase (differs from the human enzyme by only 18 amino acids, of which 9 reside at the C terminus. 29966421 7 44 gly N-glycosylation 1376:1390 arg2 two N-glycosylation sites two N-glycosylation sites sites Although two N-glycosylation sites, one O-glycosylation site, and a phosphorylation site are conserved from bovine to human, the stoichiometry of the modifications and the specific glycoforms they harbor are quite distinct. 29966421 7 51 gly O-glycosylation 1403:1417 arg2 one O-glycosylation site one O-glycosylation site site Although two N-glycosylation sites, one O-glycosylation site, and a phosphorylation site are conserved from bovine to human, the stoichiometry of the modifications and the specific glycoforms they harbor are quite distinct. 3192519 9 17 gly glycosylation 1391:1403 arg1 apoCIII apoCIII PUBTATOR apoCIII 345 These findings suggest that the intracellular glycosylation of apoCIII is not required for its intracellular transport and secretion. 10374967 2 14 gly glycoprotein 397:408 arg1 HHV-6 glycoprotein gH HHV-6 glycoprotein gH Fterm glycoprotein Anti-fusion monoclonal antibodies (MAbs) specific for HHV-6 glycoprotein gH inhibit infection and prevent cellular spread by syncytia formation. 1421757 1 40 part_of containing 134:143 arg1 a glycoprotein AND three N-linked and one O-linked glycosylation sites a glycoprotein three N-linked and one O-linked glycosylation sites Fterm Site glycoprotein sites The human transferrin receptor is a glycoprotein containing three N-linked and one O-linked glycosylation sites. 1421757 1 40 part_of containing 134:143 arg1 The human transferrin receptor AND three N-linked and one O-linked glycosylation sites The human transferrin receptor three N-linked and one O-linked glycosylation sites PUBTATOR Site transferrin receptor 7018 sites The human transferrin receptor is a glycoprotein containing three N-linked and one O-linked glycosylation sites. 17406563 3 16 gly N-glycosylation 904:918 arg2 the N-glycosylation site the N-glycosylation site site The steps of this approach are: (1) lectin column-mediated affinity capture of glycopeptides generated by protease digestion of protein mixtures; (2) purification of the enriched glycopeptides by hydrophilic interaction chromatography (HIC); (3) peptide-N-glycanase-mediated incorporation of a stable isotope tag, 18O18O, specifically at the N-glycosylation site; and (4) identification of 18O-tagged peptides by liquid chromatography-coupled mass spectrometry (LC/MS)-based proteomics technology. 17406563 3 29 gly glycopeptides 741:753 arg2 the enriched glycopeptides the enriched glycopeptides glycopeptides The steps of this approach are: (1) lectin column-mediated affinity capture of glycopeptides generated by protease digestion of protein mixtures; (2) purification of the enriched glycopeptides by hydrophilic interaction chromatography (HIC); (3) peptide-N-glycanase-mediated incorporation of a stable isotope tag, 18O18O, specifically at the N-glycosylation site; and (4) identification of 18O-tagged peptides by liquid chromatography-coupled mass spectrometry (LC/MS)-based proteomics technology. 17406563 3 48 gly glycopeptides 641:653 arg2 glycopeptides glycopeptides glycopeptides The steps of this approach are: (1) lectin column-mediated affinity capture of glycopeptides generated by protease digestion of protein mixtures; (2) purification of the enriched glycopeptides by hydrophilic interaction chromatography (HIC); (3) peptide-N-glycanase-mediated incorporation of a stable isotope tag, 18O18O, specifically at the N-glycosylation site; and (4) identification of 18O-tagged peptides by liquid chromatography-coupled mass spectrometry (LC/MS)-based proteomics technology. 9029108 5 31 part_of mu 648:649 arg1 the C mu 4 domain mu 4 the C mu 4 domain OGER Site mu 4 Q9JKC7 domain Three altered forms of mouse IgM were analyzed: IgM lacking the C mu 1 domain, IgM in which the C mu 2 and C mu 3 domains were replaced by the hinge region and the C gamma 2 domain of IgG2b, and IgM, in which the C mu 4 domain was replaced by C gamma 3. 9029108 5 40 part_of IgM 628:630 arg1 the C gamma 2 domain IgM domain OGER Site IgM P01872 domain Three altered forms of mouse IgM were analyzed: IgM lacking the C mu 1 domain, IgM in which the C mu 2 and C mu 3 domains were replaced by the hinge region and the C gamma 2 domain of IgG2b, and IgM, in which the C mu 4 domain was replaced by C gamma 3. 9029108 5 49 part_of IgG2b 617:621 arg1 the C gamma 2 domain IgG2b domain PUBTATOR Site IgG2b 16016 domain Three altered forms of mouse IgM were analyzed: IgM lacking the C mu 1 domain, IgM in which the C mu 2 and C mu 3 domains were replaced by the hinge region and the C gamma 2 domain of IgG2b, and IgM, in which the C mu 4 domain was replaced by C gamma 3. 9191841 10 86 gly Asn 1789:1791 arg1 The oligosaccharide Asn 153 The oligosaccharide Asn 153 The oligosaccharide at Asn 153 also appears to be involved in flavivirus fusion. 9820842 2 5 gly glycoprotein 399:410 arg1 a glycoprotein a glycoprotein Fterm glycoprotein However, the US5 gene product has not been identified and the identity of gJ as a glycoprotein has not been confirmed. 19748988 2 30 part_of receptor 309:316 arg1 the receptor ligand interaction site receptor the receptor ligand interaction site Fterm Site receptor site In this study, we have characterized the receptor ligand interaction site by consecutive truncations of the Fcv IgY domains and mutational analyses of selected residues. 26018173 13 81 gly glycoproteins 2416:2428 arg1 the HIV-1 membrane envelope glycoproteins the HIV-1 membrane envelope glycoproteins Fterm glycoproteins We found that the HIV-1 membrane envelope glycoproteins have a unique pattern of carbohydrates, with many high-mannose glycans and also, in some places, complex glycans. 9223509 11 82 gly glycosylation 1694:1706 arg2 the SCR2 glycosylation site the SCR2 glycosylation site site Mutations which mimicked the change found in baboon CD46 or another which deleted the SCR2 glycosylation site reduced binding substantially. 27743362 1 4 gly glycosylation 194:206 arg2 only one glycosylation site only one glycosylation site site The vast heterogeneity of protein glycosylation, even of a single glycoprotein with only one glycosylation site, can give rise to a set of macromolecules with different physicochemical properties. 27743362 1 20 gly glycoprotein 167:178 arg1 a single glycoprotein a single glycoprotein Fterm glycoprotein The vast heterogeneity of protein glycosylation, even of a single glycoprotein with only one glycosylation site, can give rise to a set of macromolecules with different physicochemical properties. 27743362 1 70 gly heterogeneity 110:122 arg1 a single glycoprotein a single glycoprotein Fterm glycoprotein The vast heterogeneity of protein glycosylation, even of a single glycoprotein with only one glycosylation site, can give rise to a set of macromolecules with different physicochemical properties. 23184955 0 39 gly glycosylation 121:133 arg2 the glycosylation site the glycosylation site site A single N-acetylgalactosamine residue at threonine 106 modifies the dynamics and structure of interferon α2a around the glycosylation site. 15253437 4 2 gly glycosylation 987:999 arg2 the glycosylation site the glycosylation site site The removal of the major part of the glycan simplifies the MS/MS fragment ion spectra of glycopeptides, while the remaining GlcNAc residue enables unambiguous assignment of the glycosylation site together with the amino acid sequence. 15253437 4 29 gly glycopeptides 899:911 arg2 glycopeptides glycopeptides glycopeptides The removal of the major part of the glycan simplifies the MS/MS fragment ion spectra of glycopeptides, while the remaining GlcNAc residue enables unambiguous assignment of the glycosylation site together with the amino acid sequence. 8892291 3 26 gly used 438:441 arg2 cDNA insert sequences cDNA insert sequences sequences cDNA insert sequences from positive plaques were determined and used to isolate additional clones encoding p23 coding sequences. 12940452 2 69 part_of has 317:319 arg1 The alpha-subunit AND two N-glycosylation sites The alpha-subunit two N-glycosylation sites Fterm Site alpha-subunit sites The alpha-subunit has two N-glycosylation sites at Asn52 and Asn78. 22872643 1 88 part_of Notch 292:296 arg1 the extracellular domain Notch the extracellular domain PUBTATOR Site Notch 18128 domain O-Glucosylation of epidermal growth factor-like (EGF) repeats in the extracellular domain of Notch is essential for Notch function. 10828967 6 50 gly glycosylation 954:966 arg2 all four glycosylation sites all four glycosylation sites sites In contrast, the nonglycosylated receptor, in which all four glycosylation sites were mutated, is deficient in these functions. 10828967 6 56 gly nonglycosylated 910:924 arg1 the nonglycosylated receptor the nonglycosylated receptor Fterm receptor In contrast, the nonglycosylated receptor, in which all four glycosylation sites were mutated, is deficient in these functions. 25628020 7 40 gly N-glycosylation 1282:1296 arg2 the novel N-glycosylation sites the novel N-glycosylation sites sites CONCLUSIONS: We propose that the novel N-glycosylation sites described in this study may be useful candidates for functional analyses to identify innovative genetic modifications for beneficial phenotypes acquired in the human lineage. 11072064 4 105 gly contains 557:564 arg1 The predicted protein AND a 124 aa carbohydrate-recognition domain The predicted protein a 46 aa stalk region a 124 aa carbohydrate-recognition domain Fterm Site protein region The predicted protein from this sequence contains a 48 aa cytoplasmic domain, a 20 aa transmembrane domain (TM), a 46 aa stalk region and a 124 aa carbohydrate-recognition domain (CRD). 1331083 4 18 part_of phosphotransferase 1034:1051 arg1 the phosphotransferase recognition domain phosphotransferase the phosphotransferase recognition domain Fterm Site phosphotransferase domain However, oligosaccharides located closer to the essential components of the phosphotransferase recognition domain (lysine 203 and amino acids 265-292) were phosphorylated better than oligosaccharides located further away. 18381078 1 3 gly N-glycosylation 208:222 arg2 four potential N-glycosylation sites four potential N-glycosylation sites sites A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 18381078 1 8 gly glycoprotein 175:186 arg1 a type I transmembrane glycoprotein a type I transmembrane glycoprotein Fterm glycoprotein A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 18381078 1 25 gly sites 224:228 arg1 four potential N-glycosylation sites four potential N-glycosylation sites sites A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 18381078 1 3 gly N-glycosylation 208:222 arg2 N278 N267, N278, N439 and N551 N267, N278, N439 and N551 A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 18381078 1 3 gly N-glycosylation 208:222 arg2 N551 N267, N278, N439 and N551 N267, N278, N439 and N551 A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 18381078 1 3 gly N-glycosylation 208:222 arg2 N551 N267, N278, N439 and N551 N267, N278, N439 and N551 A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 18381078 1 8 gly glycoprotein 175:186 arg1 A disintegrin A disintegrin and metalloprotease 10 PUBTATOR A disintegrin and metalloprotease 10 102 A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 18381078 1 25 gly sites 224:228 arg1 N439 N267, N278, N439 and N551 N267, N278, N439 and N551 A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 18381078 1 25 gly sites 224:228 arg1 N278 N267, N278, N439 and N551 N267, N278, N439 and N551 A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 18381078 1 25 gly sites 224:228 arg1 N278 N267, N278, N439 and N551 N267, N278, N439 and N551 A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins. 27343203 0 22 part_of CD23 39:42 arg1 the CD23 stalk region CD23 the CD23 stalk region PUBTATOR Site CD23 2208 region Critical and direct involvement of the CD23 stalk region in IgE binding. 1725860 3 75 part_of contain 556:562 arg1 all rat and human IGFBPs AND 18 homologous cysteines all rat and human IGFBPs 18 homologous cysteines PUBTATOR AminoAcid IGFBPs 3484 cysteines Except for IGFBP-6, all rat and human IGFBPs contain 18 homologous cysteines; twelve are located at the N-terminal and span approximately one-third of the total amino acid sequence, while the remaining six are distributed at the C-terminal and span the last one-third of the protein sequence. 30944176 11 21 gly glycosylated 1930:1941 arg1 a viral envelope protein a viral envelope protein Fterm protein All isolates from recent outbreaks encode a viral envelope protein that is glycosylated, whereas many historical ZIKV strains lack this glycosylation. 7765932 0 11 gly glycosylation 50:62 arg2 the glycosylation site occupancy the glycosylation site occupancy site The effect of protein synthesis inhibitors on the glycosylation site occupancy of recombinant human prolactin. 7765932 0 16 gly occupancy 69:77 arg2 the glycosylation site occupancy prolactin site PUBTATOR prolactin 5617 site The effect of protein synthesis inhibitors on the glycosylation site occupancy of recombinant human prolactin. 25213400 4 81 part_of has 377:379 arg1 the glycoprotein OMgp AND 11 glycosylation sites the glycoprotein OMgp 11 glycosylation sites PUBTATOR Site OMgp 4974 sites The MAG has 10 glycosylation sites; the glycoprotein OMgp has 11 glycosylation sites. 12766998 3 24 gly glycosylation 687:699 arg2 one fewer glycosylation site one fewer glycosylation site site The principal differences predicted between E2 of HCV3a-Gla and the corresponding H77c genotype 1a protein were that the former contained six more amino acids (361 vs. 355), but it had one fewer glycosylation site. 31533374 2 0 part_of protein 573:579 arg1 dengue virus (DENV) envelope protein glycosylation site protein dengue virus (DENV) envelope protein glycosylation site Fterm Site protein site The virtual approach was based on generating different docking cycles of tetra, penta, hexa, and heptapeptide libraries by maximizing the discrimination between the amino acid motif in the ZIKV and dengue virus (DENV) envelope protein glycosylation site. 16037490 5 7 gly glycopeptide 1263:1274 arg2 the glycopeptide the glycopeptide glycopeptide In addition, a new O-glycosylation site was identified at Thr279 in the connecting segment between the fibrin- and heparin-binding domain and the collagen-binding domain, and the glycopeptide was reactive to a peanut agglutinin lectin. 16037490 5 79 gly O-glycosylation 1103:1117 arg2 a new O-glycosylation site a new O-glycosylation site site In addition, a new O-glycosylation site was identified at Thr279 in the connecting segment between the fibrin- and heparin-binding domain and the collagen-binding domain, and the glycopeptide was reactive to a peanut agglutinin lectin. 20848033 3 23 gly glycoforms 407:416 arg1 distinct CD52 glycoforms distinct CD52 glycoforms PUBTATOR CD52 1043 To facilitate functional and immunological studies of distinct CD52 glycoforms, we report in this paper the first chemoenzymatic synthesis of homogeneous CD52 glycoforms carrying both N- and O-glycans. 20848033 3 45 gly glycoforms 498:507 arg1 homogeneous CD52 glycoforms homogeneous CD52 glycoforms PUBTATOR CD52 1043 To facilitate functional and immunological studies of distinct CD52 glycoforms, we report in this paper the first chemoenzymatic synthesis of homogeneous CD52 glycoforms carrying both N- and O-glycans. 26106863 11 64 gly glycosylation 1639:1651 arg2 a glycosylation site modification a glycosylation site modification site The viral GP is characterized by a glycosylation site modification and mutations in the mucin-like domain that could modify the outer shape of the virion. 26957414 0 117 gly glycopeptides 50:62 arg2 in-source fragmented glycopeptides in-source fragmented glycopeptides glycopeptides Parallel data acquisition of in-source fragmented glycopeptides to sequence the glycosylation sites of proteins. 26957414 0 97 gly glycosylation 80:92 arg2 the glycosylation sites proteins sites Fterm proteins sites Parallel data acquisition of in-source fragmented glycopeptides to sequence the glycosylation sites of proteins. 2082620 1 38 gly glycoprotein 263:274 arg1 its exterior envelope glycoprotein gp120 its exterior envelope glycoprotein gp120 Fterm glycoprotein Infection by the human immunodeficiency virus type 1 (HIV-1) is initiated through interaction of its exterior envelope glycoprotein gp120 with the CD4 receptor on target cells. 15582650 3 40 gly glycosylation 481:493 arg2 glycosylation site mutations glycosylation site mutations site In this study, we have investigated the effects of modifications of the HIV Env protein by glycosylation site mutations, deletions of variable loops, or combinations of both types of mutations on their protein functions and reactivities with neutralizing antibodies. 17606981 10 10 gly glycans 1711:1717 arg1 specific glycoproteins glycoproteins glycans Fterm glycoproteins Thus, changes in glycan structure during T-cell activation are microheterogeneous and unique to individual glycans on specific glycoproteins, implying that these glycans have precise functions in T-cell biology. 17606981 10 50 gly glycoproteins 1731:1743 arg1 specific glycoproteins specific glycoproteins Fterm glycoproteins Thus, changes in glycan structure during T-cell activation are microheterogeneous and unique to individual glycans on specific glycoproteins, implying that these glycans have precise functions in T-cell biology. 23588719 9 29 gly glycosylation 1408:1420 arg2 Two additional N-linked glycosylation sites Two additional N-linked glycosylation sites sites Two additional N-linked glycosylation sites in the NA stalk region (residues 42 and 44) were found in 12 (9.5%) NA sequences. 20188224 4 71 gly glycopeptides 578:590 arg2 glycopeptides glycopeptides glycopeptides A method tailored to enable detailed analysis of the PGRN oligosaccharides and glycopeptides has been developed. 16834341 3 30 part_of hormone 435:441 arg1 the negatively charged glycopeptides follicle stimulating hormone the negatively charged glycopeptides Cterm Site follicle stimulating hormone glycopeptides In the present study the negatively charged glycopeptides of equine and human pituitary follicle stimulating hormone (eFSH and hFSH) have been characterized in a glycosylation site-specific manner using FT-ICR-MS and Edman sequencing. 31004621 6 1 gly N-glycosylation 1092:1106 arg2 single N-glycosylation sites single N-glycosylation sites sites Mutant viruses with single N-glycosylation sites removed could be recovered, while this was not possible with the mutant with all N-glycosylation sites removed. 31004621 6 47 gly N-glycosylation 1195:1209 arg2 all N-glycosylation sites all N-glycosylation sites sites Mutant viruses with single N-glycosylation sites removed could be recovered, while this was not possible with the mutant with all N-glycosylation sites removed. 1989393 3 10 gly glycosylation 429:441 arg2 a single glycosylation site a single glycosylation site site Loss of a single glycosylation site at amino acid 400, however, was sufficient to cause a reduction of at least 50-fold in the efficiency of receptor binding. 2844797 9 75 part_of contains 1976:1983 arg1 a 50-amino acid sequence AND a potential transmembrane domain a 50-amino acid sequence a potential transmembrane domain domain Whereas the muscle isoform consists of 997 amino acids and terminates with the sequence Ala-Ile-Leu-Glu, the second isoform is 1043 amino acids in length due to the replacement of these last 4 amino acids with a 50-amino acid sequence that contains a potential transmembrane domain followed by a consensus sequence for an N-linked glycosylation site. 23533650 4 81 gly glycosylation 787:799 arg2 the four gp41 glycosylation sites the four gp41 glycosylation sites sites One Env, CM243(N610Q), was selected on the basis of studies of the effects of single and multiple mutations of the four gp41 glycosylation sites. 28935113 4 33 gly site 539:542 arg1 Glycan structure site Glycan structure site Glycan structure at each glycosylation site is not genetically encoded, and yeast and mammalian cells produce a heterogeneous mixture of glycoforms at each site on the protein. 28935113 4 66 gly glycosylation 525:537 arg2 each glycosylation site each glycosylation site site Glycan structure at each glycosylation site is not genetically encoded, and yeast and mammalian cells produce a heterogeneous mixture of glycoforms at each site on the protein. 24475074 8 59 part_of PTMs 1651:1654 arg1 Lys PTMs Lys OGER AminoAcid PTMs P20962 Lys Given the topology of the genetic code, mutation of (A) is more often nonsynonomous, and Lys, another target of many PTMs, is also encoded by two (A)-rich codons. 19961828 9 29 gly N-glycosylation 1519:1533 arg2 the N-glycosylation site the N-glycosylation site site Conversely, K(v)1.4 gating was unaffected by changes in channel sialylation or following mutagenesis to remove the N-glycosylation site. 16415006 5 30 gly glycosylation 708:720 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site The presence of a single N-linked glycosylation site on either the prM or E glycoprotein of WNV was sufficient to allow DC-SIGNR-mediated infection, demonstrating that uncleaved prM protein present on a flavivirus virion can influence viral tropism under certain circumstances. 16415006 5 56 gly glycoprotein 750:761 arg1 either the prM or E glycoprotein either the prM or E glycoprotein Fterm glycoprotein The presence of a single N-linked glycosylation site on either the prM or E glycoprotein of WNV was sufficient to allow DC-SIGNR-mediated infection, demonstrating that uncleaved prM protein present on a flavivirus virion can influence viral tropism under certain circumstances. 10992007 3 26 gly glycosylation 499:511 arg2 the first and third glycosylation sites the first and third glycosylation sites sites Because our previous mutagenesis study by Asn to Gln substitutions suggested the critical role of the first and third glycosylation sites (amino acids 77 and 113) for expression of the functional TSHR, we first constructed TSHR mutants having these two glycosylation sites to elucidate whether these two sites are sufficient for TSHR function and expression; this mutant however proved to be nonfunctional. 10992007 3 98 gly glycosylation 634:646 arg2 these two glycosylation sites these two glycosylation sites sites Because our previous mutagenesis study by Asn to Gln substitutions suggested the critical role of the first and third glycosylation sites (amino acids 77 and 113) for expression of the functional TSHR, we first constructed TSHR mutants having these two glycosylation sites to elucidate whether these two sites are sufficient for TSHR function and expression; this mutant however proved to be nonfunctional. 26278021 2 2 gly glycoprotein 326:337 arg1 The heavily glycosylated viral envelope glycoprotein The heavily glycosylated viral envelope glycoprotein Fterm glycoprotein The heavily glycosylated viral envelope glycoprotein E1E2 complex is a candidate vaccine antigen. 26278021 2 66 gly glycosylated 298:309 arg1 The heavily glycosylated viral envelope glycoprotein The heavily glycosylated viral envelope glycoprotein Fterm glycoprotein The heavily glycosylated viral envelope glycoprotein E1E2 complex is a candidate vaccine antigen. 8126562 9 66 gly glycosylation 1474:1486 arg2 N207 N207 N207 Mutation of the extracellular glycosylation site (N207) yielded two proteins at steady state, a 55 kDa core peptide and a 57 kDa species. 8126562 9 66 gly glycosylation 1474:1486 arg2 the extracellular glycosylation site the extracellular glycosylation site site Mutation of the extracellular glycosylation site (N207) yielded two proteins at steady state, a 55 kDa core peptide and a 57 kDa species. 9574531 1 6 gly glycosylation 219:231 arg2 Asn94 Asn94 Asn94 The HLA-DR hemizygous B lymphoblastoid cell line, 10.24.6, has a DRA mutation (Pro96-->Ser) that creates a novel glycosylation site at Asn94. 9574531 1 6 gly glycosylation 219:231 arg2 a novel glycosylation site a novel glycosylation site site The HLA-DR hemizygous B lymphoblastoid cell line, 10.24.6, has a DRA mutation (Pro96-->Ser) that creates a novel glycosylation site at Asn94. 16489763 3 4 gly N-glycosylation 522:536 arg2 N-glycosylation site N-glycosylation site site This was by means of detailed molecular analysis of the cell surface forms of N-glycosylation site mutant and wild-type receptors that were treated with glycosidases, neuraminidase, and/or the reducing agent dithiothreitol or not treated before Western blotting. 30683699 3 36 gly glycosylation 696:708 arg2 the unique N-linked glycosylation site the unique N-linked glycosylation site site The efficacy of sialylated Fc has generated an incentive to modify the unique N-linked glycosylation site at Asn297, either through chemical and enzymatic methods or by mutagenesis of the Fc, that disrupts the protein-Asn297 carbohydrate interface. 30683699 3 36 gly glycosylation 696:708 arg2 Asn297 Asn297 Asn297 The efficacy of sialylated Fc has generated an incentive to modify the unique N-linked glycosylation site at Asn297, either through chemical and enzymatic methods or by mutagenesis of the Fc, that disrupts the protein-Asn297 carbohydrate interface. 30683699 3 67 gly protein-Asn297 819:832 arg1 the protein-Asn297 carbohydrate interface Asn297 the protein-Asn297 carbohydrate interface Asn297 The efficacy of sialylated Fc has generated an incentive to modify the unique N-linked glycosylation site at Asn297, either through chemical and enzymatic methods or by mutagenesis of the Fc, that disrupts the protein-Asn297 carbohydrate interface. 20848033 4 1 gly O-glycosylation 682:696 arg2 O-glycosylation sites O-glycosylation sites sites The synthetic strategy consists of two key steps: monosaccharide primers GlcNAc and GalNAc were first installed at the pre-determined N- and O-glycosylation sites by a facile solid-phase peptide synthesis, and then the N- and O-glycans were extended by respective enzymatic glycosylations. 25324212 5 3 part_of MUC1 775:778 arg1 non-glycosylated MUC1 peptides MUC1 non-glycosylated MUC1 peptides PUBTATOR Site MUC1 4582 peptides Moreover, control experiments with non-glycosylated MUC1 peptides unequivocally showed that the sugar residue is essential for MGL binding, as is Ca(2+) . 32252658 8 67 gly glycosylation 1114:1126 arg2 a new N-linked glycosylation site a new N-linked glycosylation site site In mutated SERPINC1 protein a new N-linked glycosylation site is formed, however, it is unclear if the glycosylation at 219-221 site is possible. 32252658 8 85 gly glycosylation 1174:1186 arg1 the glycosylation at 219-221 site site site In mutated SERPINC1 protein a new N-linked glycosylation site is formed, however, it is unclear if the glycosylation at 219-221 site is possible. 30158294 0 50 gly N-glycosylated 3:16 arg1 SERINC5 N-Glycosylated Form of SERINC5 PUBTATOR N-Glycosylated Form of SERINC5 256987 An N-glycosylated form of SERINC5 is specifically incorporated into HIV-1 virions. 17684490 3 30 part_of containing 361:370 arg1 a novel splice variant AND a predicted type I PDZ-binding peptide variant of the NRG4 peptide PUBTATOR Site variant of the NRG4 Q8WWG1 peptide We describe here a novel splice variant of the NRG4 gene, NRG4A2, which encodes a C-terminal region containing a predicted type I PDZ-binding peptide. 28186137 4 38 gly glycoproteins 370:382 arg1 Many glycoproteins Many glycoproteins Fterm glycoproteins Many glycoproteins have been identified in myelin, and a lack of one myelin glycoprotein results in abnormal myelin structures in many cases. 28186137 4 55 gly glycoprotein 441:452 arg1 one myelin glycoprotein one myelin glycoprotein Fterm glycoprotein Many glycoproteins have been identified in myelin, and a lack of one myelin glycoprotein results in abnormal myelin structures in many cases. 25567004 6 21 gly glycosylation 1542:1554 arg2 its single potential glycosylation site its single potential glycosylation site site In summary, we conclude that a non-glycosylated secreted BHc isoform can be prepared in yeast by deleting the pro-peptide of the α-factor signal and mutating its single potential glycosylation site. 25567004 6 48 gly non-glycosylated 1394:1409 arg1 a non-glycosylated secreted BHc isoform a non-glycosylated secreted BHc isoform PUBTATOR BHc isoform 192285 In summary, we conclude that a non-glycosylated secreted BHc isoform can be prepared in yeast by deleting the pro-peptide of the α-factor signal and mutating its single potential glycosylation site. 25501675 8 104 gly glycopeptides 1377:1389 arg2 over 90 glycopeptides over 90 glycopeptides glycopeptides From the trypsin-digested mixture of these two products, over 90 glycopeptides were identified by accurate mass matching. 32280962 3 50 gly PSG1 528:531 arg1 the glycan composition PSG1 the glycan composition PUBTATOR PSG1 5669 We carried out glycomic and glycoproteomic studies to characterize the glycan composition of PSG1 purified from serum of pregnant women and identified the presence of complex N-glycans containing poly LacNAc epitopes with α2,3 sialyation at four sites. 2040275 7 35 gly glycosylation 1179:1191 arg2 the glycosylation site the glycosylation site site However, the presence of oligosaccharide causes a decrease in the conformational mobility of the backbone and sidechains of the peptide in the region of the glycosylation site. 23991039 6 37 gly glycosylation 942:954 arg2 Putative N-linked glycosylation site Putative N-linked glycosylation site site Putative N-linked glycosylation site (PNGS) mutations, notably at position 197, allowed 1F7 to neutralize JR-CSF potently without improving binding to the cognate, monomeric gp120. 29596458 9 96 gly N-glycopeptides 1207:1221 arg2 Three hundred and sixty eight potential N-glycopeptides Three hundred and sixty eight potential N-glycopeptides N-glycopeptides Three hundred and sixty eight potential N-glycopeptides were quantified by mass spectrometry and 149 were further selected for identification. 17899080 4 18 gly glycosylation 686:698 arg2 three N-linked glycosylation consensus sites three N-linked glycosylation consensus sites sites To improve FVIII secretion, a 14-amino-acid-long polypeptide with (G3) or without (G0; control) three N-linked glycosylation consensus sites was inserted upstream of the NH(2) terminus of a B-domain deleted FVIII protein. 30904681 0 47 gly sites 80:84 arg1 N-glycans sites N-glycans sites Simultaneous characterization of SNPs and N-glycans from multiple glycosylation sites of intact β-2-glycoprotein-1 (B2GP1) by ESI-qTOF-MS. 30904681 0 11 gly glycosylation 66:78 arg2 multiple glycosylation sites B2GP1 sites PUBTATOR B2GP1 350 sites Simultaneous characterization of SNPs and N-glycans from multiple glycosylation sites of intact β-2-glycoprotein-1 (B2GP1) by ESI-qTOF-MS. 30904681 0 11 gly glycosylation 66:78 arg2 multiple glycosylation sites -2-glycoprotein-1 sites PUBTATOR -2-glycoprotein-1 350 sites Simultaneous characterization of SNPs and N-glycans from multiple glycosylation sites of intact β-2-glycoprotein-1 (B2GP1) by ESI-qTOF-MS. 11390601 2 103 gly glycosylation 412:424 arg2 specific glycosylation sites specific glycosylation sites sites In this study, specific glycosylation sites on gp120 of a dualtropic primary HIV-1 isolate, DH12, were eliminated by site-directed mutagenesis and the properties of the resulting mutant envelopes were evaluated using a recombinant vaccinia virus-based cell-to-cell fusion assay alone or in the context of viral infections. 2041080 8 29 gly asparagine 1619:1628 arg1 the oligosaccharide asparagine 22 the oligosaccharide asparagine 22 Factors important for cleavability are the number of basic residues at the cleavage site, the oligosaccharide at asparagine 22, and the length of the carboxy terminus of HA1. 2041080 8 32 gly site 1590:1593 arg1 the oligosaccharide site the oligosaccharide site Factors important for cleavability are the number of basic residues at the cleavage site, the oligosaccharide at asparagine 22, and the length of the carboxy terminus of HA1. 2041080 8 38 gly oligosaccharide 1600:1614 arg1 the cleavage site the cleavage site the cleavage site Site site Factors important for cleavability are the number of basic residues at the cleavage site, the oligosaccharide at asparagine 22, and the length of the carboxy terminus of HA1. 2041080 8 39 gly terminus 1664:1671 arg1 the oligosaccharide terminus the oligosaccharide terminus Factors important for cleavability are the number of basic residues at the cleavage site, the oligosaccharide at asparagine 22, and the length of the carboxy terminus of HA1. 2041080 8 73 gly residues 1565:1572 arg1 the oligosaccharide residues at the oligosaccharide residues at Factors important for cleavability are the number of basic residues at the cleavage site, the oligosaccharide at asparagine 22, and the length of the carboxy terminus of HA1. 16343462 0 15 gly sites 64:68 arg1 the same and different carbohydrate structures sites the same and different carbohydrate structures sites Chemo-enzymatic synthesis of eel calcitonin glycosylated at two sites with the same and different carbohydrate structures. 16343462 0 57 gly glycosylated 44:55 arg2 two sites two sites sites Chemo-enzymatic synthesis of eel calcitonin glycosylated at two sites with the same and different carbohydrate structures. 6838832 1 24 part_of sequences 124:132 arg1 the region sequences the region region The amino acid sequences of the two major carbohydrate variants in the region of Asn288 have been determined. 6838832 1 54 part_of region 180:185 arg1 The amino acid sequences region The amino acid sequences sequences The amino acid sequences of the two major carbohydrate variants in the region of Asn288 have been determined. 2745457 5 73 gly glycosylation 998:1010 arg2 a glycosylation site a glycosylation site site Amino acid analyses and sequencing through 49 Edman cycles revealed that the protein preparation is composed of the intact and desoctapeptide (des-(1-8] polypeptide chains and suggested a glycosylation site at Asn-45. 9989600 5 53 gly N-glycosylated 654:667 arg2 a single site a single site site It consists of 66 amino acid residues and is heterogeneously N-glycosylated at a single site, on asparagine 9, of the Asn-Gly-Thr sequence. 9989600 5 53 gly N-glycosylated 654:667 arg2 the Asn-Gly-Thr sequence the Asn-Gly-Thr sequence sequence It consists of 66 amino acid residues and is heterogeneously N-glycosylated at a single site, on asparagine 9, of the Asn-Gly-Thr sequence. 22421407 9 6 gly groups 1579:1584 arg1 the same glycosylation site the same glycosylation site the same glycosylation site Site site The value of Rb(1) is higher than that of Rb(2) or Rb(3), indicating that ginsenosides with hexose and hydroxyl groups (Rb(1)) could present better pharmacokinetic behaviors than those with pentose groups in the same glycosylation site by oral administration. 22421407 9 42 gly glycosylation 1598:1610 arg2 the same glycosylation site the same glycosylation site site The value of Rb(1) is higher than that of Rb(2) or Rb(3), indicating that ginsenosides with hexose and hydroxyl groups (Rb(1)) could present better pharmacokinetic behaviors than those with pentose groups in the same glycosylation site by oral administration. 26869352 3 80 gly fucosylated 524:534 arg1 fucosylated haptoglobin fucosylated haptoglobin PUBTATOR haptoglobin 3240 However, an increase in fucosylated haptoglobin has been reported in various types of cancer. 26858738 0 88 gly IgA1 51:54 arg1 O-Glycans IgA1 O-Glycans PUBTATOR IgA1 P01876 Transient Glyco-Engineering to Produce Recombinant IgA1 with Defined N- and O-Glycans in Plants. 26858738 0 88 gly IgA1 51:54 arg1 N- IgA1 N- PUBTATOR IgA1 P01876 Transient Glyco-Engineering to Produce Recombinant IgA1 with Defined N- and O-Glycans in Plants. 31516400 2 26 gly glycoproteins 285:297 arg1 N-linked glycoproteins N-linked glycoproteins Fterm glycoproteins The large-scale characterization of N-linked glycoproteins accomplished by mass spectrometry-based glycoproteomics has provided valuable insights into the interdependence of glycoprotein structure and protein function. 31516400 2 44 gly glycoprotein 414:425 arg1 glycoprotein structure glycoprotein structure Fterm glycoprotein The large-scale characterization of N-linked glycoproteins accomplished by mass spectrometry-based glycoproteomics has provided valuable insights into the interdependence of glycoprotein structure and protein function. 12911333 7 42 part_of position 1251:1258 arg1 the endoplasmic reticulum glycotransferase glycotransferase position Fterm Site glycotransferase position These findings suggested that the middle section of the S1-S2 linker was accessible to the endoplasmic reticulum glycotransferase at every position and was in the extracellular aqueous phase, and presumably in a flexible conformation. 17606981 8 78 gly sialylated 1291:1300 arg1 the sialylated O-glycan epitope the sialylated O-glycan epitope We define the sialylated O-glycan epitope recognized by CZ-1, and find that, paradoxically, CZ-1 and PNA binding are simultaneously increased on activated CD4(+) T cells, demonstrating site-specific changes in CD45 sialylation. 23530821 1 16 gly N-glycosylation 302:316 arg2 single potential N-glycosylation site single potential N-glycosylation site site Premembrane (prM) and envelope (E) proteins, the major structural proteins of Japanese encephalitis virus (JEV) each contain single potential N-glycosylation site. 21106559 6 12 gly derived 1349:1355 arg1 acutobin AND the hybrid- and complex-type N-glycans acutobin the hybrid- and complex-type N-glycans Fterm acutobin In contrast, each antennae of the hybrid- and complex-type N-glycans derived from acutobin was found to be rather homogeneously disialylated. 21106559 6 26 gly disialylated 1408:1419 arg1 each antennae each antennae In contrast, each antennae of the hybrid- and complex-type N-glycans derived from acutobin was found to be rather homogeneously disialylated. 6433976 7 45 gly found 1467:1471 arg2 two other positions AND Carbohydrate two other positions Carbohydrate positions Carbohydrate was also found at two other positions in the protein, corresponding to Asn-117 and Asn-448. 31429052 7 8 gly conjugation/glycosylation 1635:1659 arg2 drug conjugation/glycosylation site assessment drug conjugation/glycosylation site assessment site In addition, our results highlight the complementarity of ETD and UVPD for both primary sequence validation and drug conjugation/glycosylation site assessment. 16883437 7 43 gly glycoproteins 1094:1106 arg1 glycoproteins glycoproteins Fterm glycoproteins To predict the epitopes of glycoproteins, 21 different scales were used. 28935113 8 37 gly glycopeptide 1311:1322 arg2 glycopeptide mRNA display libraries glycopeptide mRNA display libraries glycopeptide Here, we provide an updated and optimized protocol for this method, which is designed to create glycopeptide mRNA display libraries containing ~1013 sequences and select them for target binding. 19297464 1 35 part_of has 162:164 arg1 Each Sindbis virus (SINV) surface glycoprotein AND two sites Each Sindbis virus (SINV) surface glycoprotein two sites Fterm Site glycoprotein sites Each Sindbis virus (SINV) surface glycoprotein has two sites for N-linked glycosylation (E1 positions 139 and 245 [E1-139 and E1-245] and E2 positions 196 and 318 [E2-196 and E2-318]). 20800224 8 32 gly sialylated 1089:1098 arg1 the more abundant N-glycans the more abundant N-glycans Forty-three N-glycans were detected in sample F and the more abundant N-glycans were sialylated. 9677334 11 9 gly Arg10 1485:1489 arg1 specific determinants Arg10 and Arg17 residues specific determinants Arg10 and Arg17 residues Moreover we found that the Arg10 and Arg17 residues of TPO seem to be specific determinants for TPO/c-Mpl recognition. 9677334 11 66 gly Arg17 1495:1499 arg1 specific determinants Arg10 and Arg17 residues specific determinants Arg10 and Arg17 residues Moreover we found that the Arg10 and Arg17 residues of TPO seem to be specific determinants for TPO/c-Mpl recognition. 9677334 11 70 gly TPO 1513:1515 arg1 specific determinants TPO specific determinants PUBTATOR TPO 7066 Moreover we found that the Arg10 and Arg17 residues of TPO seem to be specific determinants for TPO/c-Mpl recognition. 9820847 2 30 gly glycoprotein 432:443 arg1 VP7 VP7 Cterm VP7 The nucleotide sequence of the human (ID 45/2) rotavirus genome segment 8/9, which encodes the serotype-specific glycoprotein (VP7) has been determined. 9820847 2 30 gly glycoprotein 432:443 arg1 the serotype-specific glycoprotein the serotype-specific glycoprotein Fterm glycoprotein The nucleotide sequence of the human (ID 45/2) rotavirus genome segment 8/9, which encodes the serotype-specific glycoprotein (VP7) has been determined. 9295302 5 24 part_of sequons 799:805 arg1 this protein protein sequons Fterm protein To aid in determining the topology most likely to be correct, we have identified which of the 14 N-glycosylation sequons in this protein are utilized. 30135544 2 26 gly glycosylation 241:253 arg1 prion protein prion protein PUBTATOR prion protein 5621 The effects of glycosylation on prion protein (PrP) structure and function have not been thoroughly elucidated to date. 30135544 2 26 gly glycosylation 241:253 arg1 PrP PrP PUBTATOR PrP 5621 The effects of glycosylation on prion protein (PrP) structure and function have not been thoroughly elucidated to date. 2780569 2 36 part_of subunit 427:433 arg1 positions 192 and 193 subunit positions 192 and 193 Fterm SpecificSite subunit cysteine residues at positions 192 and 193 Numerous studies indicate that the ligand-binding site of the AcChoR includes cysteine residues at positions 192 and 193 of the alpha subunit. 22180206 6 23 gly peptide 1300:1306 arg1 the attached glycan mass and peptide identity the attached glycan mass and peptide identity Thus, the glycosylation sites were unambiguously determined, while simultaneously obtaining information about the attached glycan mass and peptide identity. 22180206 6 91 gly glycosylation 1171:1183 arg2 the glycosylation sites the glycosylation sites sites Thus, the glycosylation sites were unambiguously determined, while simultaneously obtaining information about the attached glycan mass and peptide identity. 8624782 10 31 gly glycosylation 1174:1186 arg2 the glycosylation site the glycosylation site site The protein is extensively glycosylated, and the glycosylation site has been identified. 8624782 10 52 gly glycosylated 1152:1163 arg1 The protein The protein Fterm protein The protein is extensively glycosylated, and the glycosylation site has been identified. 9203958 9 9 part_of position 1282:1289 arg1 rabbit IgA3 IgA3 position Cterm Site IgA3 position 282 Bovine IgA shares with rabbit IgA3 and IgA4, an additional N-linked glycosylation site at position 282. 21752569 1 50 gly glycoprotein 328:339 arg1 a model glycoprotein a model glycoprotein Fterm glycoprotein Human IgA1 was used as a model glycoprotein to demonstrate this technique. 21752569 1 50 gly glycoprotein 328:339 arg1 Human IgA1 Human IgA1 PUBTATOR Human IgA1 P01876 Human IgA1 was used as a model glycoprotein to demonstrate this technique. 23668542 9 30 part_of neoglycoprotein 1290:1304 arg1 an additional N-glycosylation site A1AT neoglycoprotein an additional N-glycosylation site PUBTATOR Site A1AT neoglycoprotein 5265 site The A1AT neoglycoprotein with an additional N-glycosylation site at position N123 exhibited a 62% increase in serum half-life. 7711058 0 63 part_of dehydrogenase 72:84 arg1 putative glycosylation sites dehydrogenase putative glycosylation sites Fterm Site dehydrogenase sites Mutations in putative glycosylation sites of rat 11 beta-hydroxysteroid dehydrogenase affect enzymatic activity. 11680875 6 66 gly glycoproteins 1117:1129 arg1 glycoproteins glycoproteins Fterm glycoproteins Applications of recently developed technology suggest that it is now becoming realistic to extend the proteomics analysis of glycoproteins to include details of glycosylation. 21303814 4 47 gly proteins 928:935 arg1 the natural N-glycans proteins the natural N-glycans Fterm proteins Pulse-chase assays revealed that the natural N-glycans of the proteins studied were attached co-translationally, whereas C-terminal N-glycosylation occurred post-translocationally within a time frame of hours in Xenopus laevis oocytes and minutes in human embryonic kidney 293 (HEK293) cells. 12087059 5 0 gly nonglycosylated 1012:1026 arg1 nonglycosylated Edg-1 nonglycosylated Edg-1 PUBTATOR Edg-1 1901 Although there was no difference in ligand binding ability and ligand-induced MAP kinase activation in the wild-type and mutant receptors, nonglycosylated Edg-1 was much less responsive for ligand-induced internalization. 18642129 12 71 gly modified 1741:1748 arg1 position Ser(60) and Ser(52) AND Glc position Ser(60) and Ser(52) Glc position Ser(60) and Ser(52) Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively. 18642129 12 71 gly modified 1741:1748 arg1 position Ser(60) and Ser(52) AND oligosaccharide structures position Ser(60) and Ser(52) oligosaccharide structures position Ser(60) and Ser(52) Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively. 18642129 12 71 gly modified 1741:1748 arg3 position Ser(60) and Ser(52) AND fucose position Ser(60) and Ser(52) fucose position Ser(60) and Ser(52) Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively. 18642129 12 83 gly O-glycosylated 1665:1678 arg1 FVII FVII OGER FVII P08709 Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively. 18642129 12 83 gly O-glycosylated 1665:1678 arg1 the light chain the light chain OGER chain P08709 Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively. 18642129 12 1 gly position 1702:1709 arg1 Ser(60) position Ser(60) and Ser(52) position Ser(60) and Ser(52) Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively. 15890930 2 5 part_of epitope 520:526 arg1 BaL gp120s BaL gp120s epitope OGER Site BaL gp120s Q8IXQ6 epitope The most potent of these is C108g, directed against a type-specific epitope in HXB2 and BaL gp120s, which is glycan dependent and, in contrast to previous reports, dependent on intact disulfide bonds. 8652881 11 18 gly glycosylation 2072:2084 arg2 its single potential glycosylation site its single potential glycosylation site site By contrast, the similarity between the experimental and theoretical masses of the A2 domain indicated that its single potential glycosylation site has not been utilized. 8652881 11 41 gly utilized 2104:2111 arg2 its single potential glycosylation site its single potential glycosylation site site By contrast, the similarity between the experimental and theoretical masses of the A2 domain indicated that its single potential glycosylation site has not been utilized. 3980466 13 38 gly glycoproteins 2358:2370 arg1 structurally related glycoproteins structurally related glycoproteins Fterm glycoproteins These data suggest that subtle changes in peptide structure are reflected in the extent of sialylation and branching of oligosaccharides found at corresponding glycosylation sites of structurally related glycoproteins. 3980466 13 50 gly sialylation 2245:2255 arg1 oligosaccharides oligosaccharides These data suggest that subtle changes in peptide structure are reflected in the extent of sialylation and branching of oligosaccharides found at corresponding glycosylation sites of structurally related glycoproteins. 3980466 13 74 gly found 2291:2295 arg2 corresponding glycosylation sites AND oligosaccharides glycoproteins sites oligosaccharides Fterm glycoproteins sites These data suggest that subtle changes in peptide structure are reflected in the extent of sialylation and branching of oligosaccharides found at corresponding glycosylation sites of structurally related glycoproteins. 3980466 13 87 gly glycosylation 2314:2326 arg2 corresponding glycosylation sites glycoproteins sites Fterm glycoproteins sites These data suggest that subtle changes in peptide structure are reflected in the extent of sialylation and branching of oligosaccharides found at corresponding glycosylation sites of structurally related glycoproteins. 1697592 11 87 part_of protein 1838:1844 arg1 The COOH-terminal sequence protein The COOH-terminal sequence Fterm Site protein sequence The COOH-terminal sequence of the protein, Arg-Asp-Glu-Leu (RDEL), is similar to but different from that proposed to be an endoplasmic reticulum retention signal; Lys-Asp-Glu-Leu (KDEL) (Munro, S., and Pelham, H.R.B. (1987) Cell 48, 899-907). 25324212 4 6 gly glycosylation 656:668 arg2 the glycosylation site the glycosylation site site Only the amino acids close to the glycosylation site in the peptides are involved in lectin contact. 19396578 4 22 gly glycosylation 575:587 arg2 a potential glycosylation site a potential glycosylation site site One substitution caused the loss of a potential glycosylation site, and two substitutions, located at the cleavage site and adjacent to the receptor-binding pocket, respectively, had been reported previously in canine H3 HAs. 3980466 6 32 part_of contain 1145:1151 arg1 H-2Kk AND two and three sites H-2Kk two and three sites PUBTATOR Site H-2Kk 14972 sites The heavy chain of the class I antigens, H-2Kk and H-2Dk contain two and three sites, respectively, in which biantennary structures predominate. 20235580 0 60 gly glycopeptide 26:37 arg2 glycopeptide capture glycopeptide capture glycopeptide Optimizing performance of glycopeptide capture for plasma proteomics. 20470225 0 6 gly glycosylation 62:74 arg2 glycosylation site substitutions glycosylation site substitutions site Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions. 16274239 1 57 part_of receptor 186:193 arg1 579 epidermal growth factor receptor N(579) PUBTATOR SpecificSite epidermal growth factor receptor 13649 N(579) We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR). 23530120 2 21 gly glycoprotein 394:405 arg1 Env Env PUBTATOR Env 100616444 Neutralizing antibodies against the evolutionarily conserved CD4-binding site (CD4-BS) on the HIV envelope glycoprotein (Env) are capable of inhibiting infection of diverse HIV strains, and have been isolated from HIV-infected individuals. 23530120 2 21 gly glycoprotein 394:405 arg1 the HIV envelope glycoprotein the HIV envelope glycoprotein PUBTATOR V envelope glycoprotein 100616444 Neutralizing antibodies against the evolutionarily conserved CD4-binding site (CD4-BS) on the HIV envelope glycoprotein (Env) are capable of inhibiting infection of diverse HIV strains, and have been isolated from HIV-infected individuals. 8638940 2 41 gly glycoprotein 314:325 arg1 glycoprotein degradation glycoprotein degradation Fterm glycoprotein Deficiency of the enzyme results in aspartylglycosaminuria (AGU), the most common disorder of glycoprotein degradation. 28970103 12 112 gly O-glycosylated 2303:2316 arg1 O-glycosylated peptides O-glycosylated peptides peptides This study took advantage of the inherent properties of the new fragmentation method called EThcD, which provides more complete fragmentation information about O-glycosylated peptides and a more confident site localization of O-glycans than collision-induced dissociation (HCD). 23632316 0 23 gly glycoproteins 83:95 arg1 recombinant glycoproteins recombinant glycoproteins Fterm glycoproteins Mass spectrometry investigation of glycosylation on the NXS/T sites in recombinant glycoproteins. 11087995 7 9 gly glycosylation 1219:1231 arg2 the two glycosylation sites the two glycosylation sites sites Truncation of the amino-terminal region by 32 amino acid residues including the two glycosylation sites caused similar but much stronger effects. 10191360 1 80 gly Glycosylation 119:131 arg1 ion channel proteins ion channel proteins Fterm proteins Glycosylation of ion channel proteins dramatically impacts channel function. 16883437 11 3 gly glycoproteins 1762:1774 arg1 HTLV-1 glycoproteins HTLV-1 glycoproteins Fterm glycoproteins Antigenic sites represent potential candidates for use in a peptide vaccine against HTLV-1 glycoproteins and since most of the properties of a particular protein depend on its structural properties, this type of study can help in better understanding of HTLV-1 isolates present in Iran. 2347365 8 12 part_of leukosialin 996:1006 arg1 The sequence leukosialin The sequence PUBTATOR Site leukosialin P16150 sequence The sequence of mouse leukosialin suggested an extracellular segment with a high content of O-linked carbohydrate, as is the case in the rat and human. 27480168 0 51 gly glycosylation 9:21 arg1 equilibrative nucleoside transporter 1 equilibrative nucleoside transporter 1 N48 PUBTATOR equilibrative nucleoside transporter 1 2030 N48 N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function. 27480168 0 51 gly glycosylation 9:21 arg1 ENT1 ENT1 N48 PUBTATOR ENT1 2030 N48 N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function. 26231935 7 10 gly N-glycosylation 1277:1291 arg2 different N-glycosylation sites different N-glycosylation sites sites The binding affinity with lectins showed no significant difference between various N-glycosylation mutants, which suggested that similar glycan composition should be resulted from different N-glycosylation sites. 23192877 4 63 gly glycoproteins 844:856 arg1 glycoproteins glycoproteins Fterm glycoproteins NiV entry requires both the fusion (F) and attachment (G) glycoproteins. 8841141 3 80 part_of NPR-A 437:441 arg1 A chymotryptic fragment NPR-A A chymotryptic fragment PUBTATOR Site NPR-A 24603 fragment A chymotryptic fragment of the affinity labeled NPR-A was isolated by chromatography and electrophoresis. 10648510 2 84 gly N-glycosylation 363:377 arg2 a single N-glycosylation site a single N-glycosylation site site The ability of RNase B, a model glycoprotein with a single N-glycosylation site occupied by a family of high-mannose-type glycans (Man(5)- to Man(9)-GlcNAc(2)), to support growth of E. faecalis was investigated. 10648510 2 92 gly glycoprotein 336:347 arg1 a model glycoprotein a model glycoprotein Fterm glycoprotein The ability of RNase B, a model glycoprotein with a single N-glycosylation site occupied by a family of high-mannose-type glycans (Man(5)- to Man(9)-GlcNAc(2)), to support growth of E. faecalis was investigated. 10648510 2 92 gly glycoprotein 336:347 arg1 RNase B RNase B OGER RNase B P07998 The ability of RNase B, a model glycoprotein with a single N-glycosylation site occupied by a family of high-mannose-type glycans (Man(5)- to Man(9)-GlcNAc(2)), to support growth of E. faecalis was investigated. 9063619 2 9 gly glycosylation 410:422 arg2 each glycosylation site each glycosylation site site Although the same glycosylation machinery is available to all proteins that enter the secretory pathway in a given cell, most glycoproteins emerge with characteristic glycosylation patterns and heterogeneous populations of glycans at each glycosylation site. 9063619 2 52 gly glycosylation 338:350 arg1 glycans glycans Although the same glycosylation machinery is available to all proteins that enter the secretory pathway in a given cell, most glycoproteins emerge with characteristic glycosylation patterns and heterogeneous populations of glycans at each glycosylation site. 9063619 2 68 gly glycoproteins 297:309 arg1 most glycoproteins most glycoproteins Fterm glycoproteins Although the same glycosylation machinery is available to all proteins that enter the secretory pathway in a given cell, most glycoproteins emerge with characteristic glycosylation patterns and heterogeneous populations of glycans at each glycosylation site. 8435067 3 50 gly glycosylation 485:497 arg2 seven potential glycosylation sites seven potential glycosylation sites sites The primary structure of lysosomal alpha-glucosidase, as deduced from the cDNA sequence, indicates that there are seven potential glycosylation sites. 8985413 3 77 gly glycosylation 573:585 arg2 a conserved glycosylation site a conserved glycosylation site site However, deletion of amino acids 186 to 188, encoding a conserved glycosylation site, resulted in a nonviable virus, suggesting a minimal length requirement of 40 amino acids for a functional V2 loop. 6433976 8 4 gly glycosylation 1578:1590 arg2 a fourth potential glycosylation site site, Asn-218 site, Asn-218 However, a fourth potential glycosylation site, Asn-218, is apparently not utilized for carbohydrate attachment. 6433976 8 53 gly utilized 1625:1632 arg2 a fourth potential glycosylation site site, Asn-218 site, Asn-218 However, a fourth potential glycosylation site, Asn-218, is apparently not utilized for carbohydrate attachment. 17715132 0 15 part_of contain 19:25 arg1 Pannexin1 channels AND a glycosylation site Pannexin1 channels a glycosylation site PUBTATOR Site Pannexin1 channels 24145 site Pannexin1 channels contain a glycosylation site that targets the hexamer to the plasma membrane. 17899080 4 27 part_of 14-amino-acid-long 605:622 arg1 a 14-amino-acid-long polypeptide 14-amino-acid-long a 14-amino-acid-long polypeptide Cterm Site 14-amino-acid-long polypeptide To improve FVIII secretion, a 14-amino-acid-long polypeptide with (G3) or without (G0; control) three N-linked glycosylation consensus sites was inserted upstream of the NH(2) terminus of a B-domain deleted FVIII protein. 17899080 4 32 part_of protein 788:794 arg1 the NH(2) terminus FVIII protein the NH(2) terminus PUBTATOR Site FVIII protein 2157 terminus To improve FVIII secretion, a 14-amino-acid-long polypeptide with (G3) or without (G0; control) three N-linked glycosylation consensus sites was inserted upstream of the NH(2) terminus of a B-domain deleted FVIII protein. 31572358 8 90 part_of BCR 1427:1429 arg1 full-length BCR sequences BCR full-length BCR sequences OGER Site BCR P11274 sequences These sites, obtained from full-length BCR sequences of ACPA-expressing B cells from 12 ACPA-positive RA patients, were here analyzed in detail. 16372382 4 52 gly sialylated 877:886 arg1 NeuAcalpha2-3Galbeta1-4GlcNAc NeuAcalpha2-3Galbeta1-4GlcNAc The major non-reducing epitope in the complex-type glycans is: NeuAcalpha2-3Galbeta1-4GlcNAc (sialylated LacNAc). 16372382 4 98 gly epitope 806:812 arg1 the complex-type glycans epitope the complex-type glycans epitope The major non-reducing epitope in the complex-type glycans is: NeuAcalpha2-3Galbeta1-4GlcNAc (sialylated LacNAc). 16335952 2 77 gly glycoprotein 569:580 arg1 glycoprotein capture glycoprotein capture Fterm glycoprotein Here, we describe an approach for broad analysis of human plasma N-glycoproteins using a combination of immunoaffinity subtraction and glycoprotein capture to reduce both the protein concentration range and the overall sample complexity. 16335952 2 87 gly N-glycoproteins 499:513 arg1 human plasma N-glycoproteins human plasma N-glycoproteins Fterm N-glycoproteins Here, we describe an approach for broad analysis of human plasma N-glycoproteins using a combination of immunoaffinity subtraction and glycoprotein capture to reduce both the protein concentration range and the overall sample complexity. 8798624 3 25 part_of ICAM-3 858:863 arg1 domain 1 ICAM-3 domain 1 PUBTATOR Site ICAM-3 3385 domain Epitope mapping and functional studies performed with 17 anti-ICAM-3 monoclonal antibodies demonstrated that only some monoclonal antibodies, with epitopes wholly within domain 1 of ICAM-3, were able to block binding of ICAM-3 bearing cells to purified LFA-1, in agreement with the data obtained from the domain deletion mutants and CD21 chimeras. 25327667 8 36 gly glycopeptides 1043:1055 arg2 Three sulfated/phosphorylated glycopeptides Three sulfated/phosphorylated glycopeptides glycopeptides Three sulfated/phosphorylated glycopeptides were detected, the identification of which was supported by tandem MS data. 22187327 4 13 gly glycosylation 683:695 arg2 the most N-terminal glycosylation site the most N-terminal glycosylation site site Only the N54Q mutant, which is the mutant for the most N-terminal glycosylation site, failed to induce filopodia-like protrusions in N2a cells. 23263199 7 17 gly N-glycosylation 1196:1210 arg2 the individual N-glycosylation sites the individual N-glycosylation sites sites The variants showed lower activity than the wt FucT, whereas the individual N-glycosylation sites had different effects on the enzyme activity and kinetic parameters. 10677208 0 63 part_of LTBP-1 114:119 arg1 the third eight-cysteine domain LTBP-1 the third eight-cysteine domain OGER AminoAcid LTBP-1 Q14766 cysteine domain Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells. 25452312 14 79 gly N-glycopeptides 1611:1625 arg2 these N-glycopeptides these N-glycopeptides N-glycopeptides The peptide sequences of these N-glycopeptides were identified unambiguously and their glycan composition (for 125 N-glycopeptides) and structures (for 87 N-glycopeptides) were proposed. 25452312 14 81 gly N-glycopeptides 1695:1709 arg2 125 N-glycopeptides 125 N-glycopeptides N-glycopeptides The peptide sequences of these N-glycopeptides were identified unambiguously and their glycan composition (for 125 N-glycopeptides) and structures (for 87 N-glycopeptides) were proposed. 25452312 14 91 gly N-glycopeptides 1735:1749 arg2 87 N-glycopeptides 87 N-glycopeptides N-glycopeptides The peptide sequences of these N-glycopeptides were identified unambiguously and their glycan composition (for 125 N-glycopeptides) and structures (for 87 N-glycopeptides) were proposed. 28694069 2 91 gly aglycosylated 396:408 arg1 aglycosylated human IgG1 Fc variants aglycosylated human IgG1 Fc variants Fterm variants Previously, we demonstrated that aglycosylated human IgG1 Fc variants can engage the human FcγRII class of the low-affinity hFcγRs, demonstrating that N-linked glycosylation of the Fc is not a strict requirement for hFcγR engagement. 9352200 1 71 gly glycoproteins 93:105 arg1 The glycoproteins The glycoproteins Fterm glycoproteins The glycoproteins of the Xenopus laevis egg envelope function in fertilization and development. 21846136 0 90 gly glycosylation 51:63 arg2 N-linked glycosylation site N-linked glycosylation site site Integrated sample pretreatment system for N-linked glycosylation site profiling with combination of hydrophilic interaction chromatography and PNGase F immobilized enzymatic reactor via a strong cation exchange precolumn. 10419520 10 53 part_of S2P 1308:1310 arg1 The HEIGH sequence S2P The HEIGH sequence PUBTATOR Site S2P 51360 sequence The HEIGH sequence of S2P, which contains two potential zinc-coordinating residues, is contained within a long hydrophobic segment. 10419520 10 27 part_of contains 1319:1326 arg1 The HEIGH sequence AND two potential zinc-coordinating residues The HEIGH sequence two potential zinc-coordinating residues residues The HEIGH sequence of S2P, which contains two potential zinc-coordinating residues, is contained within a long hydrophobic segment. 1388166 2 32 gly sequence 381:388 arg1 the sequence SO4-4GalNAc beta 1 the sequence SO4-4GalNAc beta 1 We have determined that greater than 70% of the oligosaccharides on recombinant TFPI expressed in 293 cells terminate with the sequence SO4-4GalNAc beta 1, 4GlcNAc beta 1, 2Man alpha. 1388166 2 32 gly sequence 381:388 arg1 4GlcNAc beta 1 4GlcNAc beta 1 We have determined that greater than 70% of the oligosaccharides on recombinant TFPI expressed in 293 cells terminate with the sequence SO4-4GalNAc beta 1, 4GlcNAc beta 1, 2Man alpha. 1388166 2 48 gly TFPI 334:337 arg1 the oligosaccharides TFPI the oligosaccharides PUBTATOR TFPI 7035 We have determined that greater than 70% of the oligosaccharides on recombinant TFPI expressed in 293 cells terminate with the sequence SO4-4GalNAc beta 1, 4GlcNAc beta 1, 2Man alpha. 1388166 2 75 gly oligosaccharides 302:317 arg1 recombinant TFPI TFPI oligosaccharides PUBTATOR TFPI 7035 We have determined that greater than 70% of the oligosaccharides on recombinant TFPI expressed in 293 cells terminate with the sequence SO4-4GalNAc beta 1, 4GlcNAc beta 1, 2Man alpha. 22256424 6 47 gly polypeptide 1105:1115 arg1 an endo H-resistant oligosaccharide polypeptide an endo H-resistant oligosaccharide polypeptide By contrast, the polypeptide with an endo H-resistant oligosaccharide was the predominant form of FLAG-tagged AE1. 8603082 0 59 gly glycosylation 148:160 arg1 MCT1 function MCT1 function PUBTATOR MCT1 P53985 Cloning and sequencing of the monocarboxylate transporter from mouse Ehrlich Lettré tumour cell confirms its identity as MCT1 and demonstrates that glycosylation is not required for MCT1 function. 8349598 5 78 part_of PXR/K 1282:1286 arg1 the PXR/K motif PXR the PXR/K motif PUBTATOR Site PXR 8856 motif We have examined a number of tissues and cultured cell lines for the transfer of sulfate to the trisaccharide acceptor GGnM and transfer of GalNAc to oligosaccharide acceptors on protein which do, human chorionic gonadotropin (hCG), and do not, transferrin (Trf), contain the PXR/K motif. 8638940 3 42 part_of single-chain 495:506 arg1 the initial single-chain 49-kDa polypeptide chain the initial single-chain 49-kDa polypeptide OGER Site chain P20933 polypeptide Mature enzyme is formed by two proteolytic cleavage steps subsequent to removal of its signal peptide: (1) an activation cleavage in the ER of the initial single-chain 49-kDa polypeptide into a 27-kDa alpha- and 19-kDa beta-subunit; (2) a cleavage in lysosomes which removes 10 amino acids from the C-terminus of the alpha-subunit without affecting enzyme activity. 9194614 10 84 gly glycoprotein 1599:1610 arg1 a heterogeneous glycoprotein fraction a heterogeneous glycoprotein fraction Fterm glycoprotein While the E. coli products were free from post-translational modifications, rPhl p 1 from Pichia is a heterogeneous glycoprotein fraction with a carbohydrate content of about 15%. 2320574 0 37 gly glycosylation 72:84 arg2 a glycosylation site defect a glycosylation site defect site Characterization of a mutation in a family with saposin B deficiency: a glycosylation site defect. 22674977 7 7 gly glycosylation 1293:1305 arg2 the additional glycosylation sequon the additional glycosylation sequon sequon The results suggest that the additional glycosylation sequon increases binding affinity to avian-type α2-3-linked sialosides rather than switching to a human-like receptor specificity and highlight the mechanistic diversity of these pathogens, which calls attention to the need for further studies to fully understand the unique properties of these viruses. 2411731 3 6 part_of alpha 665:669 arg1 the alpha 2(V) COOH-terminal propeptide structure of the alpha 2(V) COOH-terminal the alpha 2(V) COOH-terminal propeptide PUBTATOR Site structure of the alpha 2(V) COOH-terminal 1290 propeptide Here we report the complete primary structure of the alpha 2(V) COOH-terminal propeptide. 2411731 3 63 part_of COOH-terminal 676:688 arg1 the alpha 2(V) COOH-terminal propeptide structure of the alpha 2(V) COOH-terminal the alpha 2(V) COOH-terminal propeptide PUBTATOR Site structure of the alpha 2(V) COOH-terminal 1290 propeptide Here we report the complete primary structure of the alpha 2(V) COOH-terminal propeptide. 2411731 3 64 part_of V 673:673 arg1 the alpha 2(V) COOH-terminal propeptide structure of the alpha 2(V) COOH-terminal the alpha 2(V) COOH-terminal propeptide PUBTATOR Site structure of the alpha 2(V) COOH-terminal 1290 propeptide Here we report the complete primary structure of the alpha 2(V) COOH-terminal propeptide. 21674342 2 78 gly nonglycosylated 349:363 arg1 the full-length nonglycosylated peptide the full-length nonglycosylated peptide peptide In this method, the full-length nonglycosylated peptide is first synthesized on a solid-phase support using standard Fmoc chemistry. 16504352 4 75 gly each 698:701 arg1 Gly4 Gly4 Gly4 Four plasmid DNAs were constructed, each encoding 1-4 N-glycosylation-site deletions: Gly4, Gly2/4, Gly1/2/4 and Gly1/2/3/4. 12847483 13 43 gly N-glycosylation 1981:1995 arg2 a single N-glycosylation site a single N-glycosylation site site The calculated molecular weight of the mature protein is 50 kd, and the amino acid sequence contains a single N-glycosylation site. 27339457 1 64 gly glycoprotein 160:171 arg1 Fibulin-4 Fibulin-4 PUBTATOR Fibulin-4 30008 Fibulin-4 is a 60kDa calcium binding glycoprotein that has an important role in development and integrity of extracellular matrices. 27339457 1 64 gly glycoprotein 160:171 arg1 a 60kDa calcium binding glycoprotein a 60kDa calcium binding glycoprotein Fterm glycoprotein Fibulin-4 is a 60kDa calcium binding glycoprotein that has an important role in development and integrity of extracellular matrices. 17634239 3 17 part_of position 529:536 arg1 most subtype C gp120s gp120s position Cterm Site gp120s 155971 position 295 This has been attributed to the absence of a glycosylation site at position 295 in most subtype C gp120s, which instead is typically occupied by a Val residue. 11263562 4 19 gly glycopeptide 856:867 arg2 each glycopeptide each glycopeptide glycopeptide Furthermore, many glycoforms included in each glycopeptide were found to be separated by differences in the numbers of sialic acid and N-acetyllactosaminyl repeats. 31063103 8 26 gly glycosylation 1181:1193 arg2 The predicted N-linked glycosylation site The predicted N-linked glycosylation site site The predicted N-linked glycosylation site between amino acids 6 and 8 in the V3 region was conserved in CCR5 viruses, but not in CXCR4 viruses. 9705240 0 43 gly glycosylation 23:35 arg2 a putative glycosylation site biotinidase site PUBTATOR biotinidase 686 site Mutation in a putative glycosylation site (N489T) of biotinidase in the only known Japanese child with biotinidase deficiency. 32258897 0 48 gly Heterogeneity 14:26 arg1 rhIFN-β rhIFN-β Cterm rhIFN-β 3456 Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β). 32258897 0 48 gly Heterogeneity 14:26 arg1 Hyperglycosylated Recombinant Human Interferon-β Hyperglycosylated Recombinant Human Interferon-β PUBTATOR Human Interferon-β 3456 Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β). 32258897 0 57 gly Hyperglycosylated 31:47 arg1 rhIFN-β rhIFN-β Cterm rhIFN-β 3456 Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β). 32258897 0 57 gly Hyperglycosylated 31:47 arg1 Hyperglycosylated Recombinant Human Interferon-β Hyperglycosylated Recombinant Human Interferon-β PUBTATOR Human Interferon-β 3456 Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β). 18076768 0 32 part_of Asn 0:2 arg1 gp120 gp120 Asn PUBTATOR SpecificSite gp120 155971 Asn 362 Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. 19371135 10 47 gly glycosylation 1197:1209 arg2 four possible glycosylation sites four possible glycosylation sites sites Altogether, four possible glycosylation sites were identified. 20800224 2 3 gly glycans 306:312 arg1 NGAL NGAL glycans PUBTATOR NGAL 3934 There is little information available about complex glycans on NGAL. 10103002 9 1 gly glycoprotein 1787:1798 arg1 the glycoprotein the glycoprotein Fterm glycoprotein Furthermore, a metabolically radio-labeled gp42 was immunopreciptated from both cell lysate and culture supernatant of the granulosa cells with specific anti-gp42 antibody, suggesting granulosa cell-specific synthesis and secretion of the glycoprotein. 10913840 0 36 gly N-glycosylation 0:14 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site N-glycosylation site occupancy of rat alpha-1,3-fucosyltransferase IV and the effect of glycosylation on enzymatic activity. 10913840 0 45 gly occupancy 21:29 arg2 N-glycosylation site occupancy fucosyltransferase IV site OGER fucosyltransferase IV Q62994 site N-glycosylation site occupancy of rat alpha-1,3-fucosyltransferase IV and the effect of glycosylation on enzymatic activity. 9343410 3 2 part_of Sp1 485:487 arg1 the previously characterized glutamine-rich transactivation domain Sp1 the previously characterized glutamine-rich transactivation domain OGER Site Sp1 Q8N907 domain In this paper we describe the use of the previously characterized glutamine-rich transactivation domain of Sp1 (B-c) as a model to investigate the role of O-GlcNAc in Sp1's transcriptionally relevant protein-to-protein interactions with the TATA-binding-protein-associated factor (TAF110) and holo-Sp1. 7685965 4 63 part_of containing 834:843 arg1 a peptide AND Asp63 a peptide Asp63 Asp63 A synthetic peptide encompassing the two determinants and extended to include residue Asn63 stimulated levels of proliferation of the clones similar to those obtained with a peptide containing Asp63. 9741100 10 35 gly glycosylation 1404:1416 arg2 Ser222 Ser222 Ser222 The glycosylation site was identified by peptide mapping and amino acid sequence analysis as Ser222. 9741100 10 35 gly glycosylation 1404:1416 arg2 The glycosylation site The glycosylation site site The glycosylation site was identified by peptide mapping and amino acid sequence analysis as Ser222. 20084883 4 31 gly glycosylation 1076:1088 arg2 the 3 glycosylation site the 3 glycosylation site site RESULTS: Among 9 representative strains circulated in China in 2006, the homology of nucleotide acid and amino acid were 98.5%-99.8% and 99%-100% respectively, and they were 95.4%-96.2% and 96.7%-97.2% respectively compared with Chinese Vaccine strains, the homology of nucleotide acid and amino acid were 97.9%-99.7% and 98.1%-100% respectively compared with strains of 1999-2003, In F gene, the 3 glycosylation site (aa32, aa64 and aa70), aa112 and aa195, which played the important role to viral fusion, that have no changes. 26729457 4 7 gly disialylated 657:668 arg1 synthetic disialylated, biantennary N-glycopeptides synthetic disialylated, biantennary N-glycopeptides N-glycopeptides Here, we used a small set of synthetic disialylated, biantennary N-glycopeptides to systematically tune Q-TOF instrument parameters towards optimal energy stepping collision induced dissociation (CID) of glycopeptides. 26729457 4 49 gly glycopeptides 822:834 arg2 glycopeptides glycopeptides glycopeptides Here, we used a small set of synthetic disialylated, biantennary N-glycopeptides to systematically tune Q-TOF instrument parameters towards optimal energy stepping collision induced dissociation (CID) of glycopeptides. 26729457 4 50 gly N-glycopeptides 683:697 arg2 synthetic disialylated, biantennary N-glycopeptides synthetic disialylated, biantennary N-glycopeptides N-glycopeptides Here, we used a small set of synthetic disialylated, biantennary N-glycopeptides to systematically tune Q-TOF instrument parameters towards optimal energy stepping collision induced dissociation (CID) of glycopeptides. 20498311 5 29 gly N-glycosylation 951:965 arg2 N-glycosylation site deletions N-glycosylation site deletions site Prolonged exposure of HIV-1-infected CEM T-cell cultures with escalating AH concentrations selects for mutant virus strains containing N-glycosylation site deletions (predominantly affecting high-mannose-type glycans) in gp120. 22209231 5 3 gly glycosylation 733:745 arg2 the 234 glycosylation site the 234 glycosylation site site The introduction of the 234 glycosylation site abolished HIV-1 sensitivity to lectin inhibition of binding to DC-SIGN and virus transfer to susceptible cells. 9820620 7 34 gly N-glycosylation 1356:1370 arg1 hGH-V hGH-V site PUBTATOR hGH-V 2689 site hGH-Vdelta4 has lost the N-glycosylation site at Asn 140 of hGH-V, but acquires a novel site at position 148 as well as a cystein-rich domain in the 65 carboxyl-terminal amino acids, potentially involved in multiple disulfide-bridge formation. 9820620 7 34 gly N-glycosylation 1356:1370 arg2 Asn 140 hGH-V Asn 140 PUBTATOR hGH-V 2689 Asn 140 hGH-Vdelta4 has lost the N-glycosylation site at Asn 140 of hGH-V, but acquires a novel site at position 148 as well as a cystein-rich domain in the 65 carboxyl-terminal amino acids, potentially involved in multiple disulfide-bridge formation. 9169007 9 47 part_of site 1655:1658 arg1 the X-ray structure X-ray structure of antithrombin site PUBTATOR Site X-ray structure of antithrombin 462 site The extent of heparin-affinity enhancement was correlated with the distance of the mutated glycosylation site to the putative heparin-binding site in the X-ray structure of antithrombin. 9169007 9 75 part_of heparin-binding 1639:1653 arg1 the putative heparin-binding site heparin the putative heparin-binding site Fterm Site heparin site The extent of heparin-affinity enhancement was correlated with the distance of the mutated glycosylation site to the putative heparin-binding site in the X-ray structure of antithrombin. 9126611 5 123 gly N-glycosylation 952:966 arg2 this site site site Results of the expression of WT and N580Q hCox-2 in a Drosophila S2 cell system were also consistent with the N-glycosylation at this site, but low levels of activity were obtained. 19065542 3 9 gly glycoproteins 502:514 arg1 Model glycoproteins Model glycoproteins Fterm glycoproteins Model glycoproteins, including ribonuclease B, fetuin, horseradish peroxidase, and haptoglobin, were used here. 19065542 3 9 gly glycoproteins 502:514 arg1 fetuin fetuin Fterm fetuin Model glycoproteins, including ribonuclease B, fetuin, horseradish peroxidase, and haptoglobin, were used here. 19065542 3 9 gly glycoproteins 502:514 arg1 horseradish peroxidase horseradish peroxidase Fterm peroxidase Model glycoproteins, including ribonuclease B, fetuin, horseradish peroxidase, and haptoglobin, were used here. 19065542 3 9 gly glycoproteins 502:514 arg1 ribonuclease B ribonuclease B Cterm ribonuclease B Model glycoproteins, including ribonuclease B, fetuin, horseradish peroxidase, and haptoglobin, were used here. 19065542 3 9 gly glycoproteins 502:514 arg1 haptoglobin haptoglobin OGER haptoglobin P00738 Model glycoproteins, including ribonuclease B, fetuin, horseradish peroxidase, and haptoglobin, were used here. 17660510 4 6 gly N-glycosylation 663:677 arg2 target N-glycosylation sites target N-glycosylation sites sites Here we present a novel strategy to target N-glycosylation sites with application to platelet membrane proteins. 8740419 4 16 part_of glycoprotein 767:778 arg1 fragment glycoprotein fragment Fterm Site glycoprotein fragment The hsp150 delta-carrier is an N-terminal signal peptide-containing fragment of a yeast secretory glycoprotein. 12638188 0 9 gly glycoprotein 56:67 arg1 glycoprotein products glycoprotein products Fterm glycoprotein [Study on evaluating methods for the quality control of glycoprotein products. 14669059 6 19 gly N-glycosylation 1148:1162 arg2 a potential N-glycosylation site a potential N-glycosylation site site Like its mammalian counterparts, this cDNA contains conserved cysteine residues believed to form a disulphide bond, a proline-rich region which includes a potential N-glycosylation site, and a highly acidic C-terminal domain terminating with the endoplasmic reticulum retrieval sequence, KDEL. 7875221 2 55 part_of factor 496:501 arg1 the C3 convertase and factor I cleavage sites factor I the C3 convertase and factor I cleavage sites Cterm Site factor I sites We now present (a) 95% of the cDNA sequence encoding C3 from a Xenopus laevis/Xenopus gilli (Xenopus LG) hybrid (b) an analysis of the C3 convertase and factor I cleavage sites in Xenopus C3, and (c) evidence for an alternative form of C3. 7875221 2 108 part_of sites 514:518 arg1 Xenopus C3 C3 sites Cterm Site C3 sites We now present (a) 95% of the cDNA sequence encoding C3 from a Xenopus laevis/Xenopus gilli (Xenopus LG) hybrid (b) an analysis of the C3 convertase and factor I cleavage sites in Xenopus C3, and (c) evidence for an alternative form of C3. 27480293 3 26 gly N-glycosylation 513:527 arg2 mapping N-glycosylation sites mapping N-glycosylation sites sites Five enrichment methods, including IP-ZIC-HILIC, hydrazide chemistry, lectin affinity, ZIC-HILIC-FA, and TiO2 affinity were evaluated and compared in the study of mapping N-glycosylation sites in mouse brain. 15626342 2 63 part_of contain 299:305 arg1 The M protein AND a single N-glycosylation site The M protein a single N-glycosylation site PUBTATOR Site M protein 9172 site The M protein is predicted to contain a triple-spanning transmembrane (TM) region, a single N-glycosylation site near its N-terminus that is in the exterior of the virion, and a long C-terminal region in the interior. 15626342 2 63 part_of contain 299:305 arg1 The M protein AND a long C-terminal region M protein region PUBTATOR Site M protein 9172 region The M protein is predicted to contain a triple-spanning transmembrane (TM) region, a single N-glycosylation site near its N-terminus that is in the exterior of the virion, and a long C-terminal region in the interior. 19800422 1 51 gly glycosylation 220:232 arg1 Asn772 Asn772 Asn772 Matriptase is a type II transmembrane serine protease containing one potential site for asparagine-linked glycosylation (N-glycosylation) on the catalytic domain (Asn772). 19800422 1 51 gly glycosylation 220:232 arg1 the catalytic domain domain domain Matriptase is a type II transmembrane serine protease containing one potential site for asparagine-linked glycosylation (N-glycosylation) on the catalytic domain (Asn772). 14760718 0 10 gly N-glycosylated 14:27 arg1 N-glycosylated proteins N-glycosylated proteins Fterm proteins Screening for N-glycosylated proteins by liquid chromatography mass spectrometry. 32273875 2 42 gly carbohydrates 251:263 arg1 factor VIII factor VIII carbohydrates PUBTATOR factor VIII 14069 Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes. 32273875 2 46 gly N239 268:271 arg1 Oligomannose carbohydrates N239 Oligomannose carbohydrates N239 Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes. 32273875 2 51 gly N2118 280:284 arg1 Oligomannose carbohydrates N2118 Oligomannose carbohydrates N2118 Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes. 14699159 9 69 gly glycosylation 1805:1817 arg1 p90ATF6 p90ATF6 Cterm p90ATF6 22926 Because accumulation of underglycosylated proteins in the ER is a potent inducer for the UPR, these studies uncover a novel mechanism whereby the glycosylation status of p90ATF6 can serve as a sensor for ER homeostasis, resulting in ATF6 activation to trigger the UPR. 14699159 9 80 gly underglycosylated 1683:1699 arg1 underglycosylated proteins underglycosylated proteins Fterm proteins Because accumulation of underglycosylated proteins in the ER is a potent inducer for the UPR, these studies uncover a novel mechanism whereby the glycosylation status of p90ATF6 can serve as a sensor for ER homeostasis, resulting in ATF6 activation to trigger the UPR. 15809769 7 74 gly glycosylation 785:797 arg2 one Asn-linked glycosylation site one Asn-linked glycosylation site site Rat Wnt9a protein (365 aa) with N-terminal signal peptide, 24 Cys residues and one Asn-linked glycosylation site showed 100%, 98.1% and 82.5% total amino-acid identity with mouse Wnt9a, human WNT9A and chicken wnt9a, respectively. 23714211 3 122 part_of has 569:571 arg1 Intercellular adhesion molecule-2 AND six N-linked glycosylation sites Intercellular adhesion molecule-2 six N-linked glycosylation sites PUBTATOR Site Intercellular adhesion molecule-2 3384 sites Intercellular adhesion molecule-2 (ICAM-2), a member of the immunoglobulin superfamily of CAMs, has six N-linked glycosylation sites at amino acids (asparagines) 47, 82, 105, 153, 178 and 187. 23714211 3 122 part_of has 569:571 arg1 ICAM-2 AND six N-linked glycosylation sites ICAM-2 six N-linked glycosylation sites PUBTATOR Site ICAM-2 3384 sites Intercellular adhesion molecule-2 (ICAM-2), a member of the immunoglobulin superfamily of CAMs, has six N-linked glycosylation sites at amino acids (asparagines) 47, 82, 105, 153, 178 and 187. 22872643 8 23 gly factor 1231:1236 arg1 EGF repeats factor 9 EGF repeats Fterm factor 9 A panel of EGF repeats from human coagulation factor 9 (FA9), mouse Notch1, and Notch2 were bacterially expressed and purified by reverse phase HPLC for use in in vitro enzyme assays. 22872643 8 30 gly Notch2 1265:1270 arg1 EGF repeats Notch2 EGF repeats PUBTATOR Notch2 18129 A panel of EGF repeats from human coagulation factor 9 (FA9), mouse Notch1, and Notch2 were bacterially expressed and purified by reverse phase HPLC for use in in vitro enzyme assays. 22872643 8 74 gly Notch1 1253:1258 arg1 EGF repeats Notch1 EGF repeats PUBTATOR Notch1 18128 A panel of EGF repeats from human coagulation factor 9 (FA9), mouse Notch1, and Notch2 were bacterially expressed and purified by reverse phase HPLC for use in in vitro enzyme assays. 7613162 0 42 gly glycosylation 8:20 arg2 glycosylation sites glycosylation sites sites Role of glycosylation sites in the IgE Fc molecule. 10318794 7 22 gly glycoprotein 1216:1227 arg1 wild-type G6PT wild-type G6PT PUBTATOR G6PT 2538 Whereas wild-type G6PT is not a glycoprotein, both T53N and S55N mutants are glycosylated, strongly supporting the ten-helical model for G6PT. 10318794 7 22 gly glycoprotein 1216:1227 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Whereas wild-type G6PT is not a glycoprotein, both T53N and S55N mutants are glycosylated, strongly supporting the ten-helical model for G6PT. 25628020 3 15 gly N-glycosylation 540:554 arg2 112 novel N-glycosylation sites 112 novel N-glycosylation sites sites RESULTS: We analyzed the human glycoproteome data set (2,534 N-glycosylation sites in 1,027 proteins) and identified 112 novel N-glycosylation sites in 91 proteins that arose in the human lineage since the last common ancestor of Euarchonta (primates and treeshrews). 25628020 3 26 gly N-glycosylation 474:488 arg2 2,534 N-glycosylation sites 2,534 N-glycosylation sites sites RESULTS: We analyzed the human glycoproteome data set (2,534 N-glycosylation sites in 1,027 proteins) and identified 112 novel N-glycosylation sites in 91 proteins that arose in the human lineage since the last common ancestor of Euarchonta (primates and treeshrews). 25628020 3 56 gly set 463:465 arg1 2,534 N-glycosylation sites 2,534 N-glycosylation sites sites RESULTS: We analyzed the human glycoproteome data set (2,534 N-glycosylation sites in 1,027 proteins) and identified 112 novel N-glycosylation sites in 91 proteins that arose in the human lineage since the last common ancestor of Euarchonta (primates and treeshrews). 22688517 6 24 gly glycosylation 1145:1157 arg1 recombinant human LOX-1 LOX-1 site PUBTATOR LOX-1 4973 site With this approach, one potential glycosylation site of recombinant human LOX-1 on Asn(139) is readily identified and found to carry heterogeneous complex type N-glycans. 22688517 6 30 gly carry 1238:1242 arg1 recombinant human LOX-1 AND heterogeneous complex type N-glycans LOX-1 site heterogeneous complex type N-glycans PUBTATOR LOX-1 4973 site With this approach, one potential glycosylation site of recombinant human LOX-1 on Asn(139) is readily identified and found to carry heterogeneous complex type N-glycans. 26869352 4 69 gly has 980:982 arg1 Asn184 Asn184 Asn184, Asn207, Asn211, Asn241 To ascertain if characteristic fucosylation is observed in each cancer type, we undertook site-specific analyses of N-glycans on haptoglobin in the sera of patients with five types of operable gastroenterological cancer (esophageal, gastric, colon, gallbladder, pancreatic), a non-gastroenterological cancer (prostate cancer) and normal controls using ODS column LC-ESI MS. Haptoglobin has four potential glycosylation sites (Asn184, Asn207, Asn211, Asn241). 26869352 4 91 gly glycosylation 999:1011 arg2 four potential glycosylation sites four potential glycosylation sites sites To ascertain if characteristic fucosylation is observed in each cancer type, we undertook site-specific analyses of N-glycans on haptoglobin in the sera of patients with five types of operable gastroenterological cancer (esophageal, gastric, colon, gallbladder, pancreatic), a non-gastroenterological cancer (prostate cancer) and normal controls using ODS column LC-ESI MS. Haptoglobin has four potential glycosylation sites (Asn184, Asn207, Asn211, Asn241). 26869352 4 59 gly Asn184 1020:1025 arg1 Asn211 Asn184, Asn207, Asn211, Asn241 Asn184, Asn207, Asn211, Asn241 To ascertain if characteristic fucosylation is observed in each cancer type, we undertook site-specific analyses of N-glycans on haptoglobin in the sera of patients with five types of operable gastroenterological cancer (esophageal, gastric, colon, gallbladder, pancreatic), a non-gastroenterological cancer (prostate cancer) and normal controls using ODS column LC-ESI MS. Haptoglobin has four potential glycosylation sites (Asn184, Asn207, Asn211, Asn241). 10191272 6 74 gly N-glycosylation 1580:1594 arg1 the AT1 receptor expression the AT1 receptor expression Cterm AT1 These results demonstrate that N-glycosylation is required for the AT1 receptor expression. 10191272 6 74 gly N-glycosylation 1580:1594 arg1 the AT1 receptor expression the AT1 receptor expression Fterm receptor These results demonstrate that N-glycosylation is required for the AT1 receptor expression. 26773038 9 11 part_of VWF 1338:1340 arg1 the VWF A2 domain VWF the VWF A2 domain PUBTATOR Site VWF 7450 domain Glycan stabilization of the VWF A2 domain acts together with the Ca(2+)binding site and vicinal cysteine disulfide bond to control unfolding and ADAMTS13 proteolysis. 26773038 9 58 part_of Ca 1375:1376 arg1 the Ca(2+)binding site Ca(2 the Ca(2+)binding site OGER Site Ca(2 P00918 site Glycan stabilization of the VWF A2 domain acts together with the Ca(2+)binding site and vicinal cysteine disulfide bond to control unfolding and ADAMTS13 proteolysis. 2721453 4 101 part_of alpha 656:660 arg1 two glycosylation sites TSH alpha two glycosylation sites PUBTATOR Site TSH alpha 12640 sites Six species were obtained from TSH alpha (with two glycosylation sites), including neutral oligosaccharides as well as those with one or two negative charges. 1445329 4 9 gly N-glycosylation 551:565 arg2 One N-glycosylation site One N-glycosylation site site One N-glycosylation site exists in sEPO-R but the glycosylation did not affect the binding affinity to EPO. 20348522 6 15 gly non-glycosylated 907:922 arg1 non-glycosylated variants non-glycosylated variants Fterm variants Glycosylated variants showed more heat-stable propagation than non-glycosylated variants in mammalian (BHK) and avian (QT6) cells but not in mosquito (C6/36) cells. 1733280 3 36 part_of contained 511:519 arg1 The 410 base 3' untranslated region AND a novel sequence The 410 base 3' untranslated region a novel sequence sequence The 410 base 3' untranslated region contained a novel sequence consisting of a (CCA)21 repeat. 11961269 3 54 gly position 837:844 arg1 an oligosaccharide position 160, 187 an oligosaccharide position 160, 187 Here, to examine whether the H2 HA has the potential to gain two new oligosaccharides on its tip, 31 double escape mutants were isolated by using a single escape mutant with an oligosaccharide at position 160, 187 or 131 as a parental virus and a mAb to an antigenic site different from that to which the mAb used for selection of the parental virus was directed as a selecting antibody, but there were no mutants with two new oligosaccharides. 10940860 3 23 gly occupancy 472:480 arg2 the site occupancy t-PA site OGER t-PA P00750 site In this report, the site occupancy of t-PA is shown to increase gradually over the course of batch and fed-batch CHO cultures. 2477364 12 84 gly sites 1782:1786 arg1 the oligosaccharides sites the oligosaccharides sites Both sites are processed independently because no significant differences were observed between the oligosaccharides at the same sites in wild-type and mutant monomeric alpha subunits. 10536368 8 17 part_of tPA 1384:1386 arg1 N-terminal sequences tPA N-terminal sequences OGER Site tPA P00750 sequences This study demonstrates that N-terminal sequences of tPA are unexpectedly efficient in facilitating transport from the ER to the GA and suggests that these sequences contain a previously unrecognized structural element that promotes intracellular transport. 26853155 6 5 gly glycosylated 1368:1379 arg1 N332 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N146 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N133 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N146 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N332 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N146 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N133 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N146 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N332 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N146 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N133 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N146 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N332 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N133 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N146 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N332 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N133 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N146 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N332 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N146 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N332 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N146 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N332 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N332 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N241 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N332 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N332 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N177 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg2 N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 26853155 6 5 gly glycosylated 1368:1379 arg1 N312 N133, N146, N177, N220, N241, N247, N312, N332 and N443 N133, N146, N177, N220, N241, N247, N312, N332 and N443 We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells. 21528535 8 5 part_of HA1 1212:1214 arg1 HA1 domain HA1 HA1 domain OGER Site HA1 domain HA1 domain of H3N2 influenza strains in 2009 has lost a glycosylation site at amino acid position 144 while the glycosylation sites of HA1 domain of H3N2 influenza stains isolated in 2008 remained. 21528535 8 22 part_of HA1 1347:1349 arg1 HA1 domain HA1 HA1 domain OGER Site HA1 domain HA1 domain of H3N2 influenza strains in 2009 has lost a glycosylation site at amino acid position 144 while the glycosylation sites of HA1 domain of H3N2 influenza stains isolated in 2008 remained. 21824222 11 76 part_of P2-0 1488:1491 arg1 the complementary determining region P2-0 the complementary determining region PUBTATOR Site P2-0 13184 region Subsequently, we cloned the complementary determining region of P2-0 and produced the murine/human chimeric P2-0 antibody. 17045261 3 26 gly protein 588:594 arg1 a glycan structure predictive protein a glycan structure predictive Fterm protein In all cells examined, CSQ was a highly phosphorylated protein with a glycan structure predictive of ER-retained proteins: Man9,8GlcNAc2 lacking terminal GlcNAc. 17045261 3 62 gly proteins 646:653 arg1 a glycan structure predictive proteins a glycan structure predictive Fterm proteins In all cells examined, CSQ was a highly phosphorylated protein with a glycan structure predictive of ER-retained proteins: Man9,8GlcNAc2 lacking terminal GlcNAc. 2350186 7 67 gly glycosylation 1406:1418 arg2 the glycosylation sites the glycosylation sites sites In contrast, a deletion of the C-terminal peptide region of the heavy chain of IgM synthesized by a second variant cell line resulted in intracellular processing to more highly branched oligosaccharide structures at several of the glycosylation sites not involved in the deletion. 18308854 5 13 gly glycosylation 930:942 arg2 glycosylation sites glycosylation sites sites To map glycosylation sites, the asparagines at the each of the four N-linked glycosylation consensus sites were mutagenized to glutamines. 18308854 5 39 gly glycosylation 1000:1012 arg2 the four N-linked glycosylation consensus sites the four N-linked glycosylation consensus sites sites To map glycosylation sites, the asparagines at the each of the four N-linked glycosylation consensus sites were mutagenized to glutamines. 18416605 5 15 part_of PrP 1169:1171 arg1 the glycosylation sites PrP the glycosylation sites OGER Site PrP Q9NP58 sites We have further dissected the requirement of each glycosylation site and have shown that different TSE strains have dramatically different requirements for each of the glycosylation sites of host PrP, and moreover, we have shown that the host PrP has a major role in determining the glycosylation state of de novo generated PrP(Sc). 19921957 1 9 gly N-glycosylation 156:170 arg2 the N-glycosylation site occupancy the N-glycosylation site occupancy site A new strategy using tandem (18)O stable isotope labeling (TOSIL) to quantify the N-glycosylation site occupancy is reported. 28661444 11 16 gly glycosylated 1871:1882 arg1 additional lysines additional lysines lysines Furthermore, additional lysines included in different epitopes (Lys103, -123 and -282) are also glycosylated. 9337875 2 62 gly N-glycosylation 311:325 arg2 each N-glycosylation site each N-glycosylation site site The aim of this work was to evaluate the functional importance of each N-glycosylation site, and of the cysteine-84 residue. 15863355 0 107 gly Glycosylation 0:12 arg1 site-specific glycans site-specific glycans Glycosylation of site-specific glycans of alpha1-acid glycoprotein and alterations in acute and chronic inflammation. 15863355 0 113 gly glycoprotein 54:65 arg1 alpha1-acid glycoprotein glycoprotein site-specific glycans Fterm glycoprotein Glycosylation of site-specific glycans of alpha1-acid glycoprotein and alterations in acute and chronic inflammation. 26278021 4 5 gly glycoproteins 659:671 arg1 five CpG-coupled E1E2 N-glycosylation mutated glycoproteins five CpG-coupled E1E2 N-glycosylation mutated glycoproteins Fterm glycoproteins METHODS: Here, the immunogenicities of wild type (WT) E1E2, five N-glycosylation site mutated E1E2 glycoproteins, and five CpG-coupled E1E2 N-glycosylation mutated glycoproteins were analyzed in BALB/c mice by DNA vaccination using in vivo electroporation. 26278021 4 81 gly N-glycosylation 560:574 arg2 five N-glycosylation site mutated E1E2 glycoproteins five N-glycosylation site mutated E1E2 glycoproteins site METHODS: Here, the immunogenicities of wild type (WT) E1E2, five N-glycosylation site mutated E1E2 glycoproteins, and five CpG-coupled E1E2 N-glycosylation mutated glycoproteins were analyzed in BALB/c mice by DNA vaccination using in vivo electroporation. 26278021 4 101 gly glycoproteins 594:606 arg1 five N-glycosylation site mutated E1E2 glycoproteins five N-glycosylation site mutated E1E2 glycoproteins Fterm glycoproteins METHODS: Here, the immunogenicities of wild type (WT) E1E2, five N-glycosylation site mutated E1E2 glycoproteins, and five CpG-coupled E1E2 N-glycosylation mutated glycoproteins were analyzed in BALB/c mice by DNA vaccination using in vivo electroporation. 23422691 6 53 part_of MFα1 861:864 arg1 the MFα1 prepro signal sequence MFα1 the MFα1 prepro signal sequence PUBTATOR Site MFα1 855914 sequence Interestingly, non-glycosylated VEGF165 was secreted when guided by the MFα1 prepro signal sequence, albeit to a lesser degree, compared to glycosylated VEGF165. 20622017 10 84 part_of sites 1319:1323 arg1 renal GGT GGT sites OGER Site GGT sites Two glycosylation sites on renal GGT were modified exclusively by neutral glycans. 11248207 4 41 gly epitope 482:488 arg1 The Flag epitope tag The Flag epitope tag The Flag epitope tag (DYKDDDDK) was fused to the amino terminus of NaDC-1 (Flag-NaDC-1), and a monoclonal antibody against the Flag epitope was used to determine the location of the N-terminus. 22355413 4 18 gly glycosite 701:709 arg2 glycosite migration glycosite migration glycosite In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA. 22355413 4 33 gly glycosylation 830:842 arg2 antigenic sites sites sites In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA. 22355413 4 33 gly glycosylation 830:842 arg1 NA proteins NA proteins sites Cterm NA proteins 4758 sites In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA. 22355413 4 33 gly glycosylation 830:842 arg1 NA NA sites Cterm NA 4758 sites In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA. 22355413 4 33 gly glycosylation 830:842 arg1 NA proteins NA proteins sites Cterm NA proteins 4758 sites In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA. 22355413 4 33 gly glycosylation 830:842 arg1 NA NA sites Cterm NA 4758 sites In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA. 26620227 3 50 gly glycosylation 455:467 arg2 this glycosylation site this glycosylation site site The SNP causes an altered N-linked glycosylation modification at Asn129 of proSP-B, e.g. the C allele with this glycosylation site but not in the T allele. 15287381 0 53 gly glycosylation 111:123 arg2 the V3 glycosylation site the V3 glycosylation site site Demonstration of neutralizing mucosal IgA response to intranasal HIV-1 env DNA vaccines with or without the V3 glycosylation site. 8509412 0 47 part_of contains 69:76 arg1 A region AND an asparagine-linked glycosylation site A region an asparagine-linked glycosylation site site A region of the C-terminal portion of the human transferrin receptor contains an asparagine-linked glycosylation site critical for receptor structure and function. 9140729 4 0 gly deglycosylated 654:667 arg1 the mouse SK2 Fab and its deglycosylated fragments the mouse SK2 Fab and its deglycosylated fragments fragments A biosensor study showed that the mouse SK2 Fab and its deglycosylated fragments had almost equal Kd (Kon/Koff), 26.8 nM (1.05 x 10(6)/2.81 x 10(-2)) and 24.7 nM (1.28 x 10(6)/3.15 x 10(-2)), respectively. 1856695 6 78 part_of proteins 1082:1089 arg1 The amino acid sequences proteins The amino acid sequences Fterm Site proteins sequences The amino acid sequences of both the N and M proteins were more than 99% similar to those published for BCV. 10383441 1 17 part_of protein 407:413 arg1 positions 27 and 74 protein positions 27 and 74 Fterm Site protein positions 27 and 74 We have reported that bovine DNase I, a secretory glycoprotein, acquires mannose 6-phosphate residues on 12.6% of its Asn-linked oligosaccharides when expressed in COS-1 cells and that the extent of phosphorylation increases to 79.2% when lysines are placed at positions 27 and 74 of the mature protein (Nishikawa, A., Gregory, W. , Frenz, J., Cacia, J., and Kornfeld, S. (1997) J. Biol. 26858738 3 65 part_of sites 589:593 arg1 immunoglobulin A immunoglobulin A sites PUBTATOR Site immunoglobulin A 973 sites Compared to immunoglobulin G (IgG), less effort has been undertaken to express immunoglobulin A (IgA), which is the most prevalent antibody class at mucosal sites and a promising candidate for novel recombinant biopharmaceuticals with enhanced anti-tumor activity. 26947874 2 34 part_of antitrypsin 337:347 arg1 the unstructured region alpha-1 antitrypsin region PUBTATOR Site alpha-1 antitrypsin 5265 region However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown. 8663003 5 55 gly glycoprotein 799:810 arg1 The Rh glycoprotein The Rh glycoprotein Fterm glycoprotein The Rh glycoprotein has two bromelain cleavage sites within the first external domain. 27506355 7 0 gly glycopeptide 726:737 arg2 intact glycopeptide analysis intact glycopeptide analysis glycopeptide Chem.2010, 82, 10194-10202) for intact glycopeptide analysis has been developed. 30853725 1 0 gly glycosylation 302:314 arg2 the native glycosylation site the native glycosylation site site The β-subunit of human thyroid stimulating hormone (hTSH) has been synthesized as a single glycoform bearing a chitobiose disaccharide at the native glycosylation site. 30853725 1 2 gly site 316:319 arg1 a chitobiose disaccharide site a chitobiose disaccharide site The β-subunit of human thyroid stimulating hormone (hTSH) has been synthesized as a single glycoform bearing a chitobiose disaccharide at the native glycosylation site. 23925152 1 18 gly glycoprotein 158:169 arg1 HIV-1 envelope glycoprotein gp120 HIV-1 envelope glycoprotein gp120 PUBTATOR envelope glycoprotein gp120 155971 The third variable region (V3) of HIV-1 envelope glycoprotein gp120 plays a key role in determination of viral coreceptor usage (tropism). 23891555 19 17 gly O-glycosylation 2921:2935 arg2 up to six O-glycosylation sites up to six O-glycosylation sites sites The acquired MS/MS allowed assigning up to six O-glycosylation sites and identification of isomeric O-glycoforms. 32168410 3 21 gly linked 375:380 arg2 FXIII-B AND the glycan structures FXIII-B the glycan structures PUBTATOR FXIII-B 2165 OBJECTIVE: To reveal the glycan structures linked to FXIII-B, to design a method for deglycosylating the native protein, to find out if deglycosylation influences the dimeric structure of FXIII-B and its clearance from the circulation. 16037490 6 25 gly O-glycosylation 1356:1370 arg2 another mucin-type O-glycosylation site another mucin-type O-glycosylation site site Considering that another mucin-type O-glycosylation site lies within a different connecting segment, the O-glycosylation of FN was suggested to play a significant role in segregating the neighboring domains and thus maintaining the topology of FN and the domain functions. 8663003 2 29 gly glycoprotein 415:426 arg1 Rh glycoprotein Rh glycoprotein Fterm glycoprotein Previously unrecognized exofacial protease sites have been identified on Rh CcEe, D proteins, and Rh glycoprotein. 22122935 5 70 gly glycopeptide 954:965 arg2 this glycopeptide this glycopeptide glycopeptide Twelve sialoforms corresponding to 5 different glycoforms were detected in N(83), and for the first time, a sulfated sialoform of this glycopeptide was also detected. 8631761 2 16 part_of factor 395:400 arg1 the epidermal growth factor domain factor the epidermal growth factor domain Fterm Site factor domain An unusual type of posttranslational modification, in which L-fucose is O-glycosidically linked to threonine 61 in the epidermal growth factor domain was found for natural DSPAalpha1 and its recombinant form isolated from Chinese hamster ovary cells. 2780569 7 39 part_of subunit 1094:1100 arg1 The domain subunit The domain Fterm Site subunit domain The domain of the alpha subunit from Natrix and cobra AcChoR (amino acid residues 119-222), which contains the four extracellular cysteines (128, 142, 192, and 193), was amplified by reverse transcription of mRNA and the polymerase chain reaction and then sequenced. 2780569 7 43 part_of domain 1074:1079 arg1 amino acid residues 119-222 domain amino acid residues 119-222 residues 119-222 The domain of the alpha subunit from Natrix and cobra AcChoR (amino acid residues 119-222), which contains the four extracellular cysteines (128, 142, 192, and 193), was amplified by reverse transcription of mRNA and the polymerase chain reaction and then sequenced. 2780569 7 25 part_of contains 1168:1175 arg1 The domain AND the four extracellular cysteines subunit cysteines (128, 142, 192, and 193) Fterm SpecificSite subunit cysteines (128, 142, 192, and 193) The domain of the alpha subunit from Natrix and cobra AcChoR (amino acid residues 119-222), which contains the four extracellular cysteines (128, 142, 192, and 193), was amplified by reverse transcription of mRNA and the polymerase chain reaction and then sequenced. 23720719 1 27 part_of V3 508:509 arg1 the V3 region V3 the V3 region Cterm Site V3 region Neutralization-resistant simian-human immunodeficiency virus AD8 (SHIVAD8) variants that emerged in an infected macaque elite neutralizer targeting the human immunodeficiency virus type 1 (HIV-1) gp120 N332 glycan acquired substitutions of critical amino acids in the V3 region rather than losing the N332 glycosylation site. 31637569 4 17 gly N-glycopeptides 998:1012 arg2 sialylated, triply charged N-glycopeptides sialylated, triply charged N-glycopeptides N-glycopeptides Generally, high charge/low m/z precursors (>3+) and glycopeptides carrying neutral, smaller N-glycans gave better product ion spectra, while hardly any product ions were detectable for sialylated, triply charged N-glycopeptides. 31637569 4 23 gly glycopeptides 838:850 arg2 glycopeptides glycopeptides glycopeptides Generally, high charge/low m/z precursors (>3+) and glycopeptides carrying neutral, smaller N-glycans gave better product ion spectra, while hardly any product ions were detectable for sialylated, triply charged N-glycopeptides. 31637569 4 57 gly sialylated 971:980 arg1 sialylated, triply charged N-glycopeptides sialylated, triply charged N-glycopeptides N-glycopeptides Generally, high charge/low m/z precursors (>3+) and glycopeptides carrying neutral, smaller N-glycans gave better product ion spectra, while hardly any product ions were detectable for sialylated, triply charged N-glycopeptides. 31637569 4 20 gly carrying 852:859 arg1 glycopeptides AND neutral, smaller N-glycans glycopeptides neutral, smaller N-glycans glycopeptides Generally, high charge/low m/z precursors (>3+) and glycopeptides carrying neutral, smaller N-glycans gave better product ion spectra, while hardly any product ions were detectable for sialylated, triply charged N-glycopeptides. 14691230 10 54 gly glycosylated 1515:1526 arg1 the highly glycosylated beta-propeller domain DPPIV domain PUBTATOR DPPIV 1803 domain ADA binds to the highly glycosylated beta-propeller domain of DPPIV, but the impact of glycosylation on binding had not previously been determined. 17095532 6 82 part_of protein 1126:1132 arg1 the single N-glycosylation site protein the single N-glycosylation site Fterm Site protein site Indeed, we achieved complete sequence coverage of the mature protein compared with the translation of an expressed sequence tag cDNA clone and demonstrated that the single N-glycosylation site of this protein carries oligosaccharides with xylose and fucose residues. 11428934 3 8 gly glycosylation 494:506 arg1 a MOG peptide epitope a MOG peptide epitope epitope It has been recently described that glycosylation of a MOG peptide epitope improved the detection of specific autoantibodies in sera of MS patients. 21980282 8 35 gly glycosylation 1340:1352 arg2 an N-linked glycosylation site an N-linked glycosylation site site The second was the loss of an N-linked glycosylation site at positions 413-415; the presence of this site has been recently found to be associated with escape from potent and broad neutralizing antibodies, consistent with enabling a common pathway for immune escape during chronic infection. 21980282 8 55 gly positions 1362:1370 arg1 413-415 413-415 positions 413 The second was the loss of an N-linked glycosylation site at positions 413-415; the presence of this site has been recently found to be associated with escape from potent and broad neutralizing antibodies, consistent with enabling a common pathway for immune escape during chronic infection. 11386425 3 8 part_of protein 477:483 arg1 Ile-69 protein Ile-69 Fterm SpecificSite protein Ile-69 A unique amino acid, Ile-69 for Mochizuki strain at E protein resulted in the loss of an Asn-67-linked glycosylation site. 8799206 7 1 gly glycosylation 1156:1168 arg2 a glycosylation site a glycosylation site site Finally, the increased virulence of the HA gene occurs by at least three different mechanisms: loss of a glycosylation site, a change at the cleavage site, and a substitution which may increase the pH of fusion. 9884403 3 13 gly glycosylation 719:731 arg2 the glycosylation sites the glycosylation sites sites The carbohydrate microheterogeneity on three of the glycosylation sites was studied in more detail by high-pH anion-exchange chromatographic profiling and 500 MHz1H-NMR spectroscopy. 9884403 3 20 gly microheterogeneity 684:701 arg1 the glycosylation sites the glycosylation sites the glycosylation sites Site sites The carbohydrate microheterogeneity on three of the glycosylation sites was studied in more detail by high-pH anion-exchange chromatographic profiling and 500 MHz1H-NMR spectroscopy. 22279061 2 56 gly glycosylation 456:468 arg2 three potential glycosylation sites sites, Asn(289), Asn(382) and Asn(393) sites, Asn(289), Asn(382) and Asn(393) We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated. 22279061 2 56 gly glycosylation 456:468 arg2 Asn(382) sites, Asn(289), Asn(382) and Asn(393) sites, Asn(289), Asn(382) and Asn(393) We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated. 22279061 2 56 gly glycosylation 456:468 arg2 Asn(393) sites, Asn(289), Asn(382) and Asn(393) sites, Asn(289), Asn(382) and Asn(393) We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated. 22279061 2 56 gly glycosylation 456:468 arg2 Asn(382) sites, Asn(289), Asn(382) and Asn(393) sites, Asn(289), Asn(382) and Asn(393) We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated. 22279061 2 56 gly glycosylation 456:468 arg2 Asn(393) sites, Asn(289), Asn(382) and Asn(393) sites, Asn(289), Asn(382) and Asn(393) We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated. 22279061 2 56 gly glycosylation 456:468 arg2 Asn(393) sites, Asn(289), Asn(382) and Asn(393) sites, Asn(289), Asn(382) and Asn(393) We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated. 22279061 2 72 gly glycosylated 525:536 arg1 Asn(393) sites, Asn(289), Asn(382) and Asn(393) sites, Asn(289), Asn(382) and Asn(393) We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated. 22279061 2 72 gly glycosylated 525:536 arg1 Asn(382) sites, Asn(289), Asn(382) and Asn(393) sites, Asn(289), Asn(382) and Asn(393) We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated. 22279061 2 72 gly glycosylated 525:536 arg1 Asn sites, Asn(289), Asn(382) and Asn(393) sites, Asn(289), Asn(382) and Asn(393) We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated. 22279061 2 72 gly glycosylated 525:536 arg1 Asn(382) sites, Asn(289), Asn(382) and Asn(393) sites, Asn(289), Asn(382) and Asn(393) We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated. 22279061 2 72 gly glycosylated 525:536 arg1 Asn sites, Asn(289), Asn(382) and Asn(393) sites, Asn(289), Asn(382) and Asn(393) We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated. 22279061 2 72 gly glycosylated 525:536 arg1 Asn sites, Asn(289), Asn(382) and Asn(393) sites, Asn(289), Asn(382) and Asn(393) We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated. 14658030 0 62 part_of NCAM 84:87 arg1 N-glycosylation sites NCAM N-glycosylation sites PUBTATOR Site NCAM 17967 sites Identification of N-glycosylation sites of the murine neural cell adhesion molecule NCAM by MALDI-TOF and MALDI-FTICR mass spectrometry. 26180195 3 31 gly N-glycosylation 458:472 arg2 a conserved N-glycosylation site a conserved N-glycosylation site site The missense mutation CLRN1(N48K), which affects a conserved N-glycosylation site in hCLRN1, is a common causative USH3 mutation among Ashkenazi Jews. 10839980 2 22 part_of protein 385:391 arg1 the 49th (site IV) and 68th (site II) amino acid residues protein the 49th (site IV) and 68th (site II) amino acid residues Fterm Site protein residues We reported previously that a combination of glycosylation sites at the 49th (site IV) and 68th (site II) amino acid residues of the protein particularly stimulates the synthesis of N-acetyl-lactosamine repeats [Melcher, Grosch, Grosse and Hasilik (1998) Glycoconjugate J. 15, 987-993]. 25113421 2 49 gly glycosylated 283:294 arg1 more than 50% eukaryotic proteins more than 50% eukaryotic proteins Fterm proteins It is believed that more than 50% eukaryotic proteins are glycosylated. 27007620 9 37 gly glycoproteins 1945:1957 arg1 glycoproteins glycoproteins Fterm glycoproteins Each will be discussed with particular emphasis on how protein-specific and site-specific approaches can contribute to improved discrimination between glycoproteomes and glycoproteins associated with healthy and unhealthy states. 28251889 3 2 gly glycosylation 539:551 arg2 a potential glycosylation site a potential glycosylation site site Most variants fell into a novel subclade (proposed as 3C.2a2); they possessed four unique amino acid substitutions in the HA protein and loss of a potential glycosylation site. 31336133 0 51 gly hyper-N-glycosylated 98:117 arg1 a hyper-N-glycosylated variant a hyper-N-glycosylated variant Fterm variant Effect of ANITVNITV peptide fusion on the bioactivity and pharmacokinetics of human IFN-α2b and a hyper-N-glycosylated variant. 11705953 3 58 part_of have 666:669 arg1 glycoproteins AND cleavable signal peptides glycoproteins cleavable signal peptides Fterm Site glycoproteins peptides The enzymes differ in only 10 amino acids, and both are glycoproteins that have cleavable signal peptides and unusual N-terminal extensions. 17259069 5 35 part_of protein 785:791 arg1 Ser106 protein Ser106 Fterm AminoAcid protein Ser106 Point mutations created in a glycosylation site (Asn51), a protein kinase C phosphorylation site (Ser106), and the enzymatic active site (Cys65) all inhibited L-PGDS-induced apoptosis as determined by both terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) and caspase3 activity. 17259069 5 35 part_of protein 785:791 arg1 a protein kinase C phosphorylation site protein a protein kinase C phosphorylation site Fterm Site protein site Point mutations created in a glycosylation site (Asn51), a protein kinase C phosphorylation site (Ser106), and the enzymatic active site (Cys65) all inhibited L-PGDS-induced apoptosis as determined by both terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) and caspase3 activity. 9139737 3 17 gly epitope 785:791 arg1 a triple epitope tag a triple epitope tag This site was identified through use of a vector encoding an SREBP-2/Ras fusion protein with a triple epitope tag that allowed immunoprecipitation of the cleaved COOH-terminal fragment. 9139737 3 25 gly protein 763:769 arg1 a triple epitope tag protein a triple epitope tag Fterm protein This site was identified through use of a vector encoding an SREBP-2/Ras fusion protein with a triple epitope tag that allowed immunoprecipitation of the cleaved COOH-terminal fragment. 8029814 8 17 part_of S 1166:1166 arg1 The amino acid sequence mouse protein S The amino acid sequence Cterm Site mouse protein S sequence The amino acid sequence of mouse protein S is about 80% identical to that of other species. 10989127 7 71 gly desialylated 918:929 arg1 desialylated hyaluronidase desialylated hyaluronidase Fterm hyaluronidase The native serum and placental hyaluronidases remained fully active after thermal inactivation but desialylated hyaluronidase was inactivated slowly in serum, and quickly in placenta suggesting a higher overall glycosylation of the plasma enzyme. 10989127 7 98 gly glycosylation 1030:1042 arg1 the plasma enzyme the plasma enzyme Fterm enzyme The native serum and placental hyaluronidases remained fully active after thermal inactivation but desialylated hyaluronidase was inactivated slowly in serum, and quickly in placenta suggesting a higher overall glycosylation of the plasma enzyme. 8411368 3 68 gly glycosylation 598:610 arg2 Asn-130 site Asn-130 site Asn-130 To investigate the role of this carbohydrate in viral pathogenicity, we used reverse genetics methods to generate a Glyc+ mutant virus, in which the glycosylation site Asn-130 was introduced into the WSN virus NA. 16862459 1 93 part_of contains 146:153 arg1 PLTP AND six potential N-glycosylation sites PLTP six potential N-glycosylation sites PUBTATOR Site PLTP 5360 sites Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser). 16862459 1 93 part_of contains 146:153 arg1 PLTP AND Asn-X-Ser PLTP Asn-X-Ser PUBTATOR Site PLTP 5360 Asn-X-Ser Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser). 16862459 1 93 part_of contains 146:153 arg1 Human plasma phospholipid transfer protein AND six potential N-glycosylation sites Human plasma phospholipid transfer protein six potential N-glycosylation sites PUBTATOR Site phospholipid transfer protein 5360 sites Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser). 16862459 1 93 part_of contains 146:153 arg1 Human plasma phospholipid transfer protein AND Asn-X-Ser Human plasma phospholipid transfer protein Asn-X-Ser PUBTATOR Site phospholipid transfer protein 5360 Asn-X-Ser Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser). 21569239 0 76 gly glycosylated 35:46 arg1 the Ca²+-binding, glycosylated F-spondin domain F-spondin domain PUBTATOR F-spondin 10418 domain The structure of the Ca²+-binding, glycosylated F-spondin domain of F-spondin - A C2-domain variant in an extracellular matrix protein. 18533687 3 105 gly glycosylation 439:451 arg2 positions Asn-14, Asn-105, Asn-242, Asn-250, Asn-303, and Asn-346 positions Asn-14, Asn-105, Asn-242, Asn-250, Asn-303, and Asn-346 positions Asn-14, Asn-105, Asn-242, Asn-250, Asn-303, and Asn-346 RXFP1 contains six putative Asn-linked glycosylation sites in the ectodomain at positions Asn-14, Asn-105, Asn-242, Asn-250, Asn-303, and Asn-346, which are highly conserved across species. 18533687 3 105 gly glycosylation 439:451 arg2 six putative Asn-linked glycosylation sites six putative Asn-linked glycosylation sites sites RXFP1 contains six putative Asn-linked glycosylation sites in the ectodomain at positions Asn-14, Asn-105, Asn-242, Asn-250, Asn-303, and Asn-346, which are highly conserved across species. 8543009 7 1 gly glycosylation 631:643 arg2 a highly conserved glycosylation site a highly conserved glycosylation site site ClC-6 has a highly conserved glycosylation site between transmembrane domains D8 and D9, while ClC-7 is the only known eukaryotic ClC protein which lacks this site. 8543009 7 32 gly domains 672:678 arg1 transmembrane domains D8 and D9 transmembrane domains D8 and D9 domains ClC-6 has a highly conserved glycosylation site between transmembrane domains D8 and D9, while ClC-7 is the only known eukaryotic ClC protein which lacks this site. 8960909 6 1 gly glycosylated 960:971 arg1 the glycosylated epitope the glycosylated epitope epitope We show here that that the glycosylated epitope is capable of loading onto newly synthesized HLA-A2 molecules in the ER of two melanoma cell lines. 16096263 1 25 gly glycoprotein 208:219 arg1 an integral membrane glycoprotein an integral membrane glycoprotein Fterm glycoprotein Anion exchanger 1 (AE1, or Band 3) is an integral membrane glycoprotein found in erythrocytes, responsible for the electroneutral exchange of chloride and bicarbonate ions across the plasma membrane. 16096263 1 25 gly glycoprotein 208:219 arg1 Anion exchanger 1 Anion exchanger 1 PUBTATOR Anion exchanger 1 (AE1, or Band 3 6521 Anion exchanger 1 (AE1, or Band 3) is an integral membrane glycoprotein found in erythrocytes, responsible for the electroneutral exchange of chloride and bicarbonate ions across the plasma membrane. 11226831 9 25 part_of sites 852:856 arg1 mER-alpha mER sites PUBTATOR Site mER 13982 sites Analyses of glycopeptides identified two additional sites of modification on mER-alpha, at Ser(10) and Thr(50) near the N-terminus. 31944613 9 78 gly de-glycosylation 1740:1755 arg2 HA head 158 or 169 site de-glycosylation AIV HA head 158 or 169 site de-glycosylation AIV site In vivo analysis of Kira6 intervention further confirmed that ER stress played a key role in higher virulence for HA head 158 or 169 site de-glycosylation AIV. 11550262 4 60 gly N-glycosylation 592:606 arg2 a potential N-glycosylation site a potential N-glycosylation site site The computer generated translated protein has a calculated molecular mass of 17.4 kDa and contains a potential N-glycosylation site at amino acids 122-124. 20032207 2 19 part_of HIV-1 468:472 arg1 the V2 region HIV-1 the V2 region Cterm Site HIV-1 region In this study, we induced insertion of a PNGS into the V2 region of HIV-1(BaL) with the KD-247 anti-V3 neutralizing monoclonal antibody. 12513911 3 32 gly glycosylation 522:534 arg2 a single potential N-linked glycosylation site a single potential N-linked glycosylation site site It contained a 507-bp open reading frame (ORF) predicted to encode a protein of 169 amino acids (aa) with a molecular mass of 18.9 kDa, a 27-residue NH(2)-terminal signal peptide, a single potential N-linked glycosylation site, and 6 cysteine residues conserved with mammalian IL-17. 12513911 3 32 gly glycosylation 522:534 arg2 a 27-residue NH(2)-terminal signal peptide a 27-residue NH(2)-terminal signal peptide peptide It contained a 507-bp open reading frame (ORF) predicted to encode a protein of 169 amino acids (aa) with a molecular mass of 18.9 kDa, a 27-residue NH(2)-terminal signal peptide, a single potential N-linked glycosylation site, and 6 cysteine residues conserved with mammalian IL-17. 10942407 2 67 part_of Jk 652:653 arg1 the Jk polypeptide Jk the Jk polypeptide Cterm Site Jk polypeptide The remaining 15 Jk(null) donors from Finland were homozygous for a new T871C transition resulting in a S291P amino acid substitution at a consensus N-glycosylation site of the Jk polypeptide. 8379944 0 75 gly glycosylation 55:67 arg1 enzyme function enzyme function Fterm enzyme Lecithin:cholesterol acyltransferase: role of N-linked glycosylation in enzyme function. 16331329 6 65 gly N-glycosylation 1227:1241 arg2 a single potential N-glycosylation site a single potential N-glycosylation site site The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart. 16331329 6 65 gly N-glycosylation 1227:1241 arg2 a novel cysteine-rich domain a novel cysteine-rich domain domain The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart. 29273683 7 31 gly glycosylated 723:734 arg1 human CBG human CBG PUBTATOR CBG 866 Deglycosylation of fully glycosylated human CBG or human CBG with only one N-glycan at N238 with Endo H-reduced steroid-binding affinity, while PNGase F-mediated deglycosylation does not, indicating that steroid binding is preserved by deamidation of N238 when its N-glycan is removed. 29273683 7 54 gly N238 785:788 arg1 only one N-glycan N238 only one N-glycan N238 Deglycosylation of fully glycosylated human CBG or human CBG with only one N-glycan at N238 with Endo H-reduced steroid-binding affinity, while PNGase F-mediated deglycosylation does not, indicating that steroid binding is preserved by deamidation of N238 when its N-glycan is removed. 29273683 7 51 gly Deglycosylation 698:712 arg1 human CBG CBG PUBTATOR CBG 866 Deglycosylation of fully glycosylated human CBG or human CBG with only one N-glycan at N238 with Endo H-reduced steroid-binding affinity, while PNGase F-mediated deglycosylation does not, indicating that steroid binding is preserved by deamidation of N238 when its N-glycan is removed. 23533650 12 70 gly glycosylation 1765:1777 arg2 the glycosylation site the glycosylation site site The results indicate that elimination of the glycosylation site near the gp41 loop results in enhanced immunogenicity, but that immunization of monkeys with these three distinct Envs was not more immunogenic than with one. 27679458 8 15 gly N-glycosylation 1166:1180 arg2 large-scale N-glycosylation site identification large-scale N-glycosylation site identification site This study provides an alternative approach for N-glycopeptide enrichment and the method employed is effective for large-scale N-glycosylation site identification. 27679458 8 42 gly N-glycopeptide 1087:1100 arg2 N-glycopeptide N-glycopeptide N-glycopeptide This study provides an alternative approach for N-glycopeptide enrichment and the method employed is effective for large-scale N-glycosylation site identification. 8601595 7 72 part_of motifs 1524:1529 arg1 the membrane proximal domain motifs the membrane proximal domain domain We also demonstrate that mutation of serine residues which constitute the four Ser-Gly motifs in the membrane proximal domain, and provide potential sites for glycosaminoglycan side chain attachment, impairs hyaluronate binding. 8407981 3 30 gly glycosylation 303:315 arg1 arom P-450(arom) PUBTATOR P-450(arom) 55010 The core glycosylation of P-450(arom) was examined with two heterologous expression systems, cultured insect cells and in vitro translation system. 21569239 7 80 gly glycosylation 1083:1095 arg2 a highly conserved N-linked glycosylation site a highly conserved N-linked glycosylation site site The unique feature of F-spondin FS domain is the presence of three disulfide bonds associated with the N- and C-termini of the domain and a highly conserved N-linked glycosylation site. 2721453 8 11 gly sialylated 1406:1415 arg1 Oligosaccharides Oligosaccharides Oligosaccharides from free alpha-subunit were more sialylated than those from TSH alpha, and the net negative charge was intermediate between those of TSH alpha and TSH beta. 2721453 8 67 gly alpha-subunit 1382:1394 arg1 Oligosaccharides alpha-subunit Oligosaccharides Fterm alpha-subunit Oligosaccharides from free alpha-subunit were more sialylated than those from TSH alpha, and the net negative charge was intermediate between those of TSH alpha and TSH beta. 20807536 7 2 part_of has 953:955 arg1 Ovalbumin AND a single N-glycosylation site Ovalbumin a single N-glycosylation site Fterm Site Ovalbumin site Ovalbumin has a single N-glycosylation site (Asn(292)) and is modified with oligomannose and hybrid-type oligosaccharides. 10858228 9 17 gly glycoproteins 1688:1700 arg1 these glycoproteins these glycoproteins Fterm glycoproteins The surface localization of gp40 and gp15 and their involvement in the host-parasite interaction suggest that either or both of these glycoproteins may serve as effective targets for specific preventive or therapeutic measures for cryptosporidiosis. 32273875 5 88 gly glycosylation 1014:1026 arg2 the N-linked glycosylation site the N-linked glycosylation site site Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells. 30359034 3 49 gly glycoprotein 369:380 arg1 glycoprotein functions glycoprotein functions Fterm glycoprotein However, a major limitation of glycomics is the lack of insight into glycoprotein functions. 3498943 7 49 gly glycosylation 1269:1281 arg2 asparagine-13 asparagine-13 asparagine-13 A single N-linked glycosylation site was found at asparagine-13. 3498943 7 49 gly glycosylation 1269:1281 arg2 A single N-linked glycosylation site A single N-linked glycosylation site site A single N-linked glycosylation site was found at asparagine-13. 23908491 11 32 gly glycosylation 1380:1392 arg2 a new glycosylation site a new glycosylation site site CONCLUSIONS: We identified a new glycosylation site within the HVR495 region of HCV subtype 3a that has a protective effect against antibody neutralization. 20302875 5 94 gly N-glycosylation 745:759 arg2 an additional N-glycosylation site an additional N-glycosylation site site The mutation created an additional N-glycosylation site resulting in a higher molecular weight form of the recombinant protein on immunoblots. 16212939 1 67 part_of hIL-1beta-derived 136:152 arg1 hIL-1beta-derived polypeptide hIL-1beta hIL-1beta-derived polypeptide PUBTATOR Site hIL-1beta 3553 polypeptide hIL-1beta-derived polypeptide, when fused to the N-terminal end of target proteins, exerts a potent secretion enhancer function in Saccharomyces cerevisiae. 17134389 9 86 gly N-glycosylation 1629:1643 arg2 an N-glycosylation site an N-glycosylation site site Furthermore, fusion of KDEL to the diabody derivative of PIPP, which contains an N-glycosylation site within the heavy chain variable domain, also resulted in a molecule lacking complex glycans. 7475306 0 27 gly peptide 24:30 arg1 Glycosylation-dependent peptide antigenic determinants Glycosylation-dependent peptide antigenic determinants Glycosylation-dependent peptide antigenic determinants of env gp46 HTLV-1. 7475306 0 44 gly env 58:60 arg1 Glycosylation-dependent peptide antigenic determinants env gp46 Glycosylation-dependent peptide antigenic determinants PUBTATOR env gp46 1491939 Glycosylation-dependent peptide antigenic determinants of env gp46 HTLV-1. 14760718 9 16 part_of sites 1307:1311 arg1 77 proteins proteins sites Fterm Site proteins sites Using two different lectins, concanavalin A and wheat germ agglutinin, this procedure was applied to human serum and a total of 86 N-glycosylation sites in 77 proteins were identified. 29426894 0 43 gly N-glycosylation 14:28 arg1 soluble Fcγ receptor IIIb soluble Fcγ receptor IIIb PUBTATOR Fcγ receptor IIIb 2215 Site-specific N-glycosylation analysis of soluble Fcγ receptor IIIb in human serum. 1990068 0 43 part_of glycoprotein 42:53 arg1 Deduced amino acid sequence glycoprotein Deduced amino acid sequence Fterm Site glycoprotein sequence Deduced amino acid sequence of the fusion glycoprotein of turkey rhinotracheitis virus has greater identity with that of human respiratory syncytial virus, a pneumovirus, than that of paramyxoviruses and morbilliviruses. 9694881 3 0 gly sites 307:311 arg1 Asn-X-Ser/Thr Asn-X-Ser/Thr Asn It contains four putative asparagine-linked glycosylation sites (Asn-X-Ser/Thr). 9694881 3 11 gly glycosylation 293:305 arg2 four putative asparagine-linked glycosylation sites four putative asparagine-linked glycosylation sites sites It contains four putative asparagine-linked glycosylation sites (Asn-X-Ser/Thr). 3594570 4 63 gly glycosylation 715:727 arg2 an extra glycosylation site an extra glycosylation site site We identified five distinct beta subunit phenotypes in LAD patients: undetectable beta subunit mRNA and protein precursor; low levels of beta subunit mRNA and precursor; an aberrantly large beta subunit precursor, probably due to an extra glycosylation site; an aberrantly small precursor; and a grossly normal precursor. 12766998 1 11 gly glycoproteins 139:151 arg1 the envelope E1 and E2 glycoproteins the envelope E1 and E2 glycoproteins Fterm glycoproteins Sequence variation in the envelope E1 and E2 glycoproteins of hepatitis C virus (HCV) could account for differences in disease pathogenesis in patients infected with different genotypes. 10362834 2 79 gly glycoprotein 522:533 arg1 the glycoprotein patterns the glycoprotein patterns Fterm glycoprotein In contrast to the samples from brain, which showed similar staining patterns in the two different age groups, the glycoprotein patterns of spinal cords showed marked differences by the age of donors. 31393126 10 67 gly glycoproteins 1565:1577 arg1 these glycoproteins these glycoproteins Fterm glycoproteins The diversity of N-glycans attached to each single glycosylation site of these glycoproteins confirmed that MRJP1 and MRJP2 heterogeneity was mostly associated with their glycoform populations. 31393126 10 19 gly attached 1513:1520 arg2 these glycoproteins AND N-glycans glycoproteins site N-glycans Fterm glycoproteins site The diversity of N-glycans attached to each single glycosylation site of these glycoproteins confirmed that MRJP1 and MRJP2 heterogeneity was mostly associated with their glycoform populations. 31393126 10 73 gly glycosylation 1537:1549 arg2 each single glycosylation site glycoproteins site Fterm glycoproteins site The diversity of N-glycans attached to each single glycosylation site of these glycoproteins confirmed that MRJP1 and MRJP2 heterogeneity was mostly associated with their glycoform populations. 9620884 7 11 gly glycosylation 1260:1272 arg2 site 3 site site Thus glycosylation at site 3 was crucial to the formation of soluble, active enzyme, as well as transport to the lysosome. 20963501 11 7 part_of Izumo1 1749:1754 arg1 Izumo1 cDNA sequences Izumo1 Izumo1 cDNA sequences PUBTATOR Site Izumo1 Q8IYV9 sequences Izumo1 cDNA sequences of goat, sheep, and cow were found to be largely homologous, and the molecular phylogenetic analysis is consistent with their morphological taxonomy. 1660522 6 68 gly glycosylation 1353:1365 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site The results indicate that preferential binding of EBV to human CR2 is not due to unique amino acids that are capable of binding the virus, but reflects a distinct receptor conformation that can be achieved in murine CR2 with single amino acid substitutions in two discontinuous regions of the primary structure: replacement of proline at position 15 with the corresponding serine from human CR2, and elimination of a potential N-linked glycosylation site between SCR-1 and SCR-2. 24632142 5 32 gly glycosylated 913:924 arg1 recombinantly-expressed human aspartoacylase recombinantly-expressed human aspartoacylase OGER aspartoacylase P45381 A more extensive study specifically designed to resolve this discrepancy has now shown that recombinantly-expressed human aspartoacylase is not glycosylated, but is still fully functional and stable even when produced from a bacterial expression system. 21752569 5 25 gly deglycopeptides 780:794 arg2 deglycopeptides deglycopeptides glycopeptides and deglycopeptides The glycopeptides and deglycopeptides were identified by UPLC-ESI TOF MS. Two N-glycan and four O-glycan sites were identified and confirmed at peptide levels. 21752569 5 47 gly glycopeptides 762:774 arg2 The glycopeptides The glycopeptides glycopeptides and deglycopeptides The glycopeptides and deglycopeptides were identified by UPLC-ESI TOF MS. Two N-glycan and four O-glycan sites were identified and confirmed at peptide levels. 16834341 7 6 gly Asn52 955:959 arg1 all complex type Asn52 all complex type Asn52 Also, glycoforms at Asn52 of hFSH are all complex type, whereas in eFSH, both complex and hybrid structures exist at this site. 16834341 7 11 gly glycoforms 941:950 arg2 Asn52 Asn52 Asn52 Also, glycoforms at Asn52 of hFSH are all complex type, whereas in eFSH, both complex and hybrid structures exist at this site. 23530821 0 42 gly N-glycosylation 0:14 arg1 the premembrane protein protein Fterm protein N-glycosylation of the premembrane protein of Japanese encephalitis virus is critical for folding of the envelope protein and assembly of virus-like particles. 22762186 5 26 part_of receptor 1518:1525 arg1 human Fas receptor extracellular domain Fas receptor human Fas receptor extracellular domain OGER Site Fas receptor P25445 domain On the other hand, the exploitation of insect cell systems is generally useful for the preparation of functional extracellular domains of death receptors containing many disulfide bridges in the absence of extended secondary structure, and a Bombyx mori larvae secretion system presented a superior productivity for human Fas receptor extracellular domain. 22762186 5 36 part_of receptors 1336:1344 arg1 functional extracellular domains receptors functional extracellular domains Fterm Site receptors domains On the other hand, the exploitation of insect cell systems is generally useful for the preparation of functional extracellular domains of death receptors containing many disulfide bridges in the absence of extended secondary structure, and a Bombyx mori larvae secretion system presented a superior productivity for human Fas receptor extracellular domain. 1446688 8 20 gly N-glycosylated 1039:1052 arg1 Asn46 Asn46 Asn46 Asn46, being exchanged for Gln by site-directed mutagenesis, was confirmed to be partially N-glycosylated. 17623277 8 18 gly N-glycosylation 867:881 arg2 Asn285 -Glu-Thr Asn285 -Glu-Thr -Glu-Thr A single N-glycosylation site (Asn285 -Glu-Thr) was identified in DCE and was proven to be fully glycosylated. 17623277 8 18 gly N-glycosylation 867:881 arg2 A single N-glycosylation site A single N-glycosylation site site A single N-glycosylation site (Asn285 -Glu-Thr) was identified in DCE and was proven to be fully glycosylated. 17623277 8 21 gly glycosylated 955:966 arg1 A single N-glycosylation site A single N-glycosylation site site A single N-glycosylation site (Asn285 -Glu-Thr) was identified in DCE and was proven to be fully glycosylated. 17623277 8 21 gly glycosylated 955:966 arg1 Asn285 -Glu-Thr Asn285 -Glu-Thr -Glu-Thr A single N-glycosylation site (Asn285 -Glu-Thr) was identified in DCE and was proven to be fully glycosylated. 23530821 2 22 gly N-glycosylation 351:365 arg1 these proteins these proteins Fterm proteins In this study, the role of N-glycosylation of these proteins on their folding and activity were investigated. 17850901 7 35 part_of fibronectin 812:822 arg1 two fibronectin type III domains fibronectin two fibronectin type III domains OGER Site fibronectin P02751 domains The predicted protein has a molecular weight of 25.1 kDa, one putative N-glycosylation site, two fibronectin type III domains, and one C terminal transmembrane domain. 17850901 7 59 part_of has 737:739 arg1 The predicted protein AND one putative N-glycosylation site The predicted protein one putative N-glycosylation site Fterm Site protein site The predicted protein has a molecular weight of 25.1 kDa, one putative N-glycosylation site, two fibronectin type III domains, and one C terminal transmembrane domain. 17850901 7 59 part_of has 737:739 arg1 The predicted protein AND one C terminal transmembrane domain The predicted protein one C terminal transmembrane domain Fterm Site protein domain The predicted protein has a molecular weight of 25.1 kDa, one putative N-glycosylation site, two fibronectin type III domains, and one C terminal transmembrane domain. 17850901 7 59 part_of has 737:739 arg1 The predicted protein AND two fibronectin type III domains The predicted protein two fibronectin type III domains Fterm Site protein domains The predicted protein has a molecular weight of 25.1 kDa, one putative N-glycosylation site, two fibronectin type III domains, and one C terminal transmembrane domain. 8497072 4 14 gly glycosylation 901:913 arg2 a potential asparagine-linked glycosylation site a potential asparagine-linked glycosylation site site The substitution of a glutamine for an asparagine residue (Q-267) at a potential asparagine-linked glycosylation site in C2, which severely impairs virus infectivity, reduces intracellular processing of gp160 into gp120, the association of gp120 with virions, and the ability of gp120 to bind to the HIV-1 cell surface receptor protein, CD4. 17091191 3 30 gly N-glycosylation 919:933 arg2 one N-glycosylation site one N-glycosylation site site Translation of the mRNA transcript revealed an open reading frame (ORF) of 86 amino acid residues encoding a nuclear location signal peptide, two overlapping casein kinase II phosphorylation sites and one N-glycosylation site with theoretical molecular weight of 9.3 kDa. 17091191 3 30 gly N-glycosylation 919:933 arg2 a nuclear location signal peptide a nuclear location signal peptide peptide Translation of the mRNA transcript revealed an open reading frame (ORF) of 86 amino acid residues encoding a nuclear location signal peptide, two overlapping casein kinase II phosphorylation sites and one N-glycosylation site with theoretical molecular weight of 9.3 kDa. 26956484 1 25 gly N-glycosylation 79:93 arg1 protein function protein function Fterm protein N-glycosylation of cell surface proteins affects protein function, stability, and interaction with other proteins. 26956484 1 25 gly N-glycosylation 79:93 arg1 cell surface proteins cell surface proteins Fterm proteins N-glycosylation of cell surface proteins affects protein function, stability, and interaction with other proteins. 32211339 4 14 part_of domain 672:677 arg1 three and six N-glycosylation sites domain three and six N-glycosylation sites sites The two highly glycosylated domains of GP are the mucin-like domain (MLD) and the glycan cap domain (GCD) with three and six N-glycosylation sites, respectively. 32211339 4 29 part_of domain 704:709 arg1 three and six N-glycosylation sites domain three and six N-glycosylation sites sites The two highly glycosylated domains of GP are the mucin-like domain (MLD) and the glycan cap domain (GCD) with three and six N-glycosylation sites, respectively. 17963278 8 65 gly alpha-2-glycoprotein 1336:1355 arg1 leucine-rich alpha-2-glycoprotein leucine-rich alpha-2-glycoprotein Fterm alpha-2-glycoprotein We identified several cancer-selective proteins that have been previously characterized as potential indicators of lung cancer in serum or plasma, including haptoglobin (HP), inter-alpha-trypsin inhibitor heavy chain 4 (ITI-H4), complement C3 precursor, and leucine-rich alpha-2-glycoprotein. 22688517 6 59 part_of LOX-1 1185:1189 arg1 one potential glycosylation site LOX-1 one potential glycosylation site PUBTATOR Site LOX-1 4973 site With this approach, one potential glycosylation site of recombinant human LOX-1 on Asn(139) is readily identified and found to carry heterogeneous complex type N-glycans. 15628971 2 47 gly glycoprotein 335:346 arg1 purified C4ST-1 purified C4ST-1 PUBTATOR C4ST-1 314694 We showed previously that purified C4ST-1 from the culture medium of rat chondrosarcoma cells was a glycoprotein containing approx. 15628971 2 47 gly glycoprotein 335:346 arg1 a glycoprotein a glycoprotein Fterm glycoprotein We showed previously that purified C4ST-1 from the culture medium of rat chondrosarcoma cells was a glycoprotein containing approx. 20507882 1 33 gly glycosylation 137:149 arg1 the extracellular protein alpha-dystroglycan the extracellular protein alpha-dystroglycan The glycosylation of the extracellular protein alpha-dystroglycan is important for its ligand-binding activity, and altered or blocked glycosylation is associated with several forms of congenital muscular dystrophies. 27095603 4 5 gly glycopeptides 684:696 arg2 glycopeptides glycopeptides glycopeptides On the other hand, MS of glycopeptides enables site-specific determination of glycoforms, and the affinity-based enrichment of glycopeptides from a complex mixture of proteolytic peptides facilitates efficient analysis. 27095603 4 22 gly glycopeptides 582:594 arg2 glycopeptides glycopeptides glycopeptides On the other hand, MS of glycopeptides enables site-specific determination of glycoforms, and the affinity-based enrichment of glycopeptides from a complex mixture of proteolytic peptides facilitates efficient analysis. 21215105 9 105 gly glycosylated 1773:1784 arg1 site 40 protein position 80, 106, 241, 248, 351, 369 and 386, site Fterm protein position 80, 106, 241, 248, 351, 369 and 386, site In NA protein, seven amino acids were changed, including position 80, 106, 241, 248, 351, 369 and 386, site 40 of NA protein were glycosylated. 7513281 4 55 gly glycosylated 424:435 arg1 a glycosylated polypeptide a glycosylated polypeptide polypeptide This protein consists of a glycosylated polypeptide of 20 kDa, which has an amino acid composition, spectroscopic properties, and an N-terminal sequence similar to the major allergen from olive pollen, Ole e I. 22246941 2 12 part_of furin 375:379 arg1 two cysteine residues furin two cysteine residues OGER AminoAcid furin P09958 cysteine residues Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)). 22246941 2 12 part_of furin 375:379 arg1 a furin protease cleavage site furin a furin protease cleavage site OGER Site furin P09958 site Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)). 22246941 2 3 part_of contains 317:324 arg1 Hedgehog APRIL AND two cysteine residues Hedgehog APRIL two cysteine residues PUBTATOR AminoAcid Hedgehog APRIL O75888 cysteine residues Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)). 22246941 2 3 part_of contains 317:324 arg1 Hedgehog APRIL AND a conserved putative N-glycosylation site Hedgehog APRIL site PUBTATOR Site Hedgehog APRIL O75888 site Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)). 22246941 2 3 part_of contains 317:324 arg1 Hedgehog APRIL AND Cys(211) Hedgehog APRIL Cys(196) and Cys(211) PUBTATOR SpecificSite Hedgehog APRIL O75888 Cys(196) and Cys(211) Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)). 22180206 2 103 part_of mucin-type 472:481 arg1 densely glycosylated mucin-type O-linked glycopeptides mucin densely glycosylated mucin-type O-linked glycopeptides PUBTATOR Site mucin 100508689 glycopeptides Here, we report the use of electron transfer dissociation (ETD) for the site-specific characterisation of densely glycosylated mucin-type O-linked glycopeptides using ESI-IT-MS/MS. 9574531 1 15 part_of DRA 171:173 arg1 Pro96-->Ser DRA Pro96-->Ser PUBTATOR AminoAcid DRA 1811 Pro96 The HLA-DR hemizygous B lymphoblastoid cell line, 10.24.6, has a DRA mutation (Pro96-->Ser) that creates a novel glycosylation site at Asn94. 24799124 4 24 gly core-fucosylated 821:836 arg1 four core-fucosylated sites sites sites This procedure simplified the structures for further analysis by mass spectrometry, where four core-fucosylated sites (sites 138, 358, 397, and 762) were detected in ceruloplasmin. 18593861 9 71 gly N-glycosylation 1852:1866 arg2 an N-glycosylation site an N-glycosylation site site We also report the full-length sequence of crucian carp NR1 mRNA and a novel NR1 splice cassette introducing an N-glycosylation site into the extracellular S1S2 domain. 17823199 2 54 part_of sites 384:388 arg1 glycoproteins glycoproteins sites Fterm Site glycoproteins sites In CDG type-I, deficiency of lipid-linked oligosaccharide assembly leads to the underoccupancy of N-glycosylation sites on glycoproteins. 12706347 5 64 gly N-glycosylation 925:939 arg2 this highly conserved N-glycosylation site this highly conserved N-glycosylation site site Using site-directed mutagenesis, mutants were constructed to eliminate this highly conserved N-glycosylation site in NTPDase3. 18340083 9 23 gly N-glycosylation 1212:1226 arg2 the N-glycosylation site the N-glycosylation site site Eliminating the N-glycosylation site in a truncated soluble version of GPIHBP1 causes a modest reduction in the secretion of the protein. 25629924 5 27 gly glycosites 768:777 arg2 Multiple glycosites Multiple glycosites glycosites Multiple glycosites were identified with nearly 30 glycan compositions located at seven sites on the secretory component, six compositions at a single site on the J chain, and 16 compositions at five sites on the IgA heavy (H) chain. 25629924 5 37 gly site 910:913 arg1 nearly 30 glycan compositions site nearly 30 glycan compositions site Multiple glycosites were identified with nearly 30 glycan compositions located at seven sites on the secretory component, six compositions at a single site on the J chain, and 16 compositions at five sites on the IgA heavy (H) chain. 6148073 5 80 gly glycopeptides 770:782 arg2 the glycopeptides the glycopeptides glycopeptides On the basis of these experiments and on the behaviour of the glycopeptides on the lectin columns, the following structures of the oligosaccharide chains were proposed: I, triantennary 'complex-type' with terminal fucose; IIA, biantennary 'complex-type' without fucose; IIB, biantennary 'complex-type' with fucose; III, a mixture of 'high-mannose' chains containing either five or six mannose residues (approx. 12034885 3 7 part_of contains 489:496 arg1 The vCD30 protein AND a 21-residue signal peptide The vCD30 protein a 21-residue signal peptide PUBTATOR Site vCD30 protein 1485890 peptide The vCD30 protein contains 110 aa, including a 21-residue signal peptide, a potential O-linked glycosylation site, and a 58-aa sequence sharing 51-59% identity with highly conserved extracellular segments of both mouse and human CD30. 12034885 3 7 part_of contains 489:496 arg1 The vCD30 protein AND a 58-aa sequence The vCD30 protein a 58-aa sequence PUBTATOR Site vCD30 protein 1485890 sequence The vCD30 protein contains 110 aa, including a 21-residue signal peptide, a potential O-linked glycosylation site, and a 58-aa sequence sharing 51-59% identity with highly conserved extracellular segments of both mouse and human CD30. 12034885 3 7 part_of contains 489:496 arg1 The vCD30 protein AND a potential O-linked glycosylation site The vCD30 protein a potential O-linked glycosylation site PUBTATOR Site vCD30 protein 1485890 site The vCD30 protein contains 110 aa, including a 21-residue signal peptide, a potential O-linked glycosylation site, and a 58-aa sequence sharing 51-59% identity with highly conserved extracellular segments of both mouse and human CD30. 17144668 8 9 gly glycosylation 1286:1298 arg2 the functional glycosylation sites the functional glycosylation sites sites Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. 17144668 8 27 gly used 1437:1440 arg2 the small FLEEL pentapeptide the small FLEEL pentapeptide pentapeptide Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. 17144668 8 49 gly glycosylation 1483:1495 arg1 carboxylase carboxylase Fterm carboxylase Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. 21431619 5 75 part_of transferrin 916:926 arg1 tryptic peptides transferrin tryptic peptides PUBTATOR Site transferrin 7018 peptides In two patients with abnormal serum transferrin IEF profiles, neuraminidase digestion and subsequent IEF showed profiles suggestive of the diagnosis of CDG type I. Mass spectrometry of tryptic peptides of immunopurified transferrin, however, revealed a novel mutation at the N-glycan attachment site. 20621099 1 0 gly glycosylation 186:198 arg2 a specific glycosylation site a specific glycosylation site site Mutagenesis directed to a specific glycosylation site has been widely used to examine biological roles of individual glycans. 2143269 1 33 part_of Fc 175:176 arg1 the Fc fragment structure of the Fc the Fc fragment Cterm Site structure of the Fc fragment The structure of the Fc fragment of human IgG1 immunoglobulin is compared for the native and recombinant proteins. 2143269 1 59 part_of immunoglobulin 201:214 arg1 the Fc fragment IgG1 immunoglobulin the Fc fragment OGER Site IgG1 immunoglobulin P01857 fragment The structure of the Fc fragment of human IgG1 immunoglobulin is compared for the native and recombinant proteins. 2295597 6 73 gly glycosylation 1126:1138 arg2 a glycosylation site a glycosylation site site Two bovine peptide sequences contained glycosylation sites and gave positive tests for carbohydrate residues, and two others contained the consensus sequence for a glycosylation site but were negative in the carbohydrate test. 2295597 6 84 gly glycosylation 1001:1013 arg2 glycosylation sites glycosylation sites sites Two bovine peptide sequences contained glycosylation sites and gave positive tests for carbohydrate residues, and two others contained the consensus sequence for a glycosylation site but were negative in the carbohydrate test. 9774483 8 19 gly N-glycosylation 1652:1666 arg2 the fifth N-glycosylation site the fifth N-glycosylation site site STX slightly prefer the sixth N-glycosylation site over the fifth N-glycosylation site. 9774483 8 60 gly N-glycosylation 1616:1630 arg2 the sixth N-glycosylation site the sixth N-glycosylation site site STX slightly prefer the sixth N-glycosylation site over the fifth N-glycosylation site. 21280237 2 62 part_of glycoproteins 613:625 arg1 potential glycosylation sites glycoproteins potential glycosylation sites Fterm Site glycoproteins sites Mounting evidence shows that alterations in glycosylation patterns influence the pathogenesis and progression of AD, but the vast number of glycan motifs and potential glycosylation sites of glycoproteins has made the field of glycobiology difficult. 8638940 8 12 part_of beta-subunit 1475:1486 arg1 the beta-subunit site subunit the beta-subunit site OGER Site subunit P20933 site Deletion of the beta-subunit oligosaccharide oat N308 by an aspartic acid substitution resulted in very little protein or enzyme activity in the transfected cells, reemphasizing that glycosylation of the beta-subunit site is important for efficient folding and/or targeting. 8910207 9 4 gly glycosylation 902:914 arg2 a potential glycosylation site a potential glycosylation site site Introduction of a potential glycosylation site in alpha D200N cannot account for the effect on channel gating because eliminating the consensus for glycosylation with the mutation alpha D200N + T202V fails to restore efficient gating. 22171062 8 9 gly glycosylation 1669:1681 arg2 O-linked glycosylation sites O-linked glycosylation sites sites We also report, for the first time, the existence of O-linked glycosylation sites in both proteins. 12504572 4 23 gly glycosylation 877:889 arg2 a V3 glycosylation site a V3 glycosylation site site Furthermore, we found a strong correlation between the loss of a V3 glycosylation site and the divergent strains. 14749323 5 1 gly glycosylation 734:746 arg2 putative glycosylation sites putative glycosylation sites sites In the present study, we investigated the effect of disrupting putative glycosylation sites in mOAT1 as well as its human counterpart, hOAT1, by mutating asparagine to glutamine and assessing mutant transporters in HeLa cells. 15555933 1 15 gly glycoprotein 165:176 arg1 a 68 kDa glycoprotein a 68 kDa glycoprotein Fterm glycoprotein Alpha-Fetoprotein (AFP) is a 68 kDa glycoprotein expressed at high levels by the fetal liver and yolk with transcription repressed to very low levels after birth. 15555933 1 15 gly glycoprotein 165:176 arg1 Alpha-Fetoprotein Alpha-Fetoprotein PUBTATOR Alpha-Fetoprotein 174 Alpha-Fetoprotein (AFP) is a 68 kDa glycoprotein expressed at high levels by the fetal liver and yolk with transcription repressed to very low levels after birth. 10744692 1 68 gly glycosylation 318:330 arg2 the glycosylation site the glycosylation site site TNK-tissue plasminogen activator (TNK-t-PA), a bioengineered variant of tissue-type plasminogen activator (t-PA), has a longer half-life than t-PA because the glycosylation site at amino acid 117 (N117Q, abbreviated N) has been shifted to amino acid 103 (T103N, abbreviated T) and is resistant to inactivation by plasminogen activator inhibitor 1 because of a tetra-alanine substitution in the protease domain (K296A/H297A/R298A/R299A, abbreviated K). 19527756 0 53 gly O-glycosylated 32:45 arg1 O-glycosylated recombinant human granulocyte colony stimulating factor O-glycosylated recombinant human granulocyte colony stimulating factor PUBTATOR granulocyte colony stimulating factor 1440 Over expression and analysis of O-glycosylated recombinant human granulocyte colony stimulating factor in Pichia pastoris using Agilent 2100 Bioanalyzer. 10839980 5 1 gly site 827:830 arg1 a third antenna site a third antenna site As a corollary of the glycosylation at site II, the synthesis of a third antenna at site IV is increased. 10839980 5 46 gly glycosylation 765:777 arg2 the glycosylation at site II site site As a corollary of the glycosylation at site II, the synthesis of a third antenna at site IV is increased. 26869352 4 105 part_of has 980:982 arg1 Haptoglobin AND four potential glycosylation sites Haptoglobin four potential glycosylation sites PUBTATOR Site Haptoglobin 3240 sites To ascertain if characteristic fucosylation is observed in each cancer type, we undertook site-specific analyses of N-glycans on haptoglobin in the sera of patients with five types of operable gastroenterological cancer (esophageal, gastric, colon, gallbladder, pancreatic), a non-gastroenterological cancer (prostate cancer) and normal controls using ODS column LC-ESI MS. Haptoglobin has four potential glycosylation sites (Asn184, Asn207, Asn211, Asn241). 29268168 5 10 gly N162-glycan 777:787 arg1 mFcγRIV FcγRIV N162-glycan PUBTATOR FcγRIV 246256 The N162-glycan in mFcγRIV was also responsible for enhancing the binding to mouse IgG with reduced fucose similar to hFcγRIIIa. 8878691 0 0 part_of protein 107:113 arg1 important functional domains protein important functional domains Fterm Site protein domains Coupled site-directed mutagenesis/transgenesis identifies important functional domains of the mouse agouti protein. 31572358 13 120 part_of ACPA-IgG 2329:2336 arg1 ACPA-IgG variable domains ACPA ACPA-IgG variable domains PUBTATOR Site ACPA 5657 domains Based on these data, and taking into account recent insights into the dynamics of the ACPA-response during disease development, we here discuss the hypothesis that N-glycosylation sites in ACPA-IgG variable domains could lead to alternative, possibly antibody affinity-independent selection forces. 8939156 10 74 gly glycosylation 1201:1213 arg2 No potential N-linked glycosylation site No potential N-linked glycosylation site site No potential N-linked glycosylation site was found. 8185569 0 39 gly glycosylation 23:35 arg1 the thyrotropin receptor the thyrotropin receptor PUBTATOR thyrotropin receptor 7253 Possible difference in glycosylation of the thyrotropin receptor among species. 19748988 3 33 part_of domains 510:516 arg1 the Fcv IgY domains domains the Fcv IgY domains domains Using several fusion proteins that linked the human Cgamma2 and Cgamma3 domains with the Fcv IgY domains, a binding assay revealed that both the Fcv3 and Fcv4 domains were essential for the IgY CHIR-AB1 interaction. 8354274 0 22 part_of deiminase 81:89 arg1 cDNA nucleotide sequence deiminase cDNA nucleotide sequence Fterm Site deiminase sequence cDNA nucleotide sequence and primary structure of mouse uterine peptidylarginine deiminase. 23640819 2 28 gly glycoproteins 371:383 arg1 particular glycoproteins particular glycoproteins Fterm glycoproteins The diagnostic potential of them was simply based on the cancer-specific alterations of glycan structures on particular glycoproteins in serum/plasma. 28409466 2 11 gly glycosylation 243:255 arg2 a glycosylation site a glycosylation site site Proteins containing a glycosylation site are quickly glycosylated by oligosaccharyltransferases once the glycosylation site is exposed to the ER lumen. 28409466 2 29 gly glycosylation 326:338 arg2 the glycosylation site the glycosylation site site Proteins containing a glycosylation site are quickly glycosylated by oligosaccharyltransferases once the glycosylation site is exposed to the ER lumen. 7904239 5 2 gly glycosylation 1074:1086 arg2 the single cryptic N-linked glycosylation site the single cryptic N-linked glycosylation site site Both molecules were translocated into the endoplasmic reticulum (ER) efficiently and core-glycosylated on the single cryptic N-linked glycosylation site present in CAT. 7904239 5 44 gly core-glycosylated 1025:1041 arg2 the single cryptic N-linked glycosylation site site site Both molecules were translocated into the endoplasmic reticulum (ER) efficiently and core-glycosylated on the single cryptic N-linked glycosylation site present in CAT. 8543840 6 29 part_of contains 732:739 arg1 this epitope AND an N-linked glycosylation signal sequence this epitope an N-linked glycosylation signal sequence sequence Although this epitope contains an N-linked glycosylation signal sequence, CTL specific for this epitope recognize a nonameric peptide that has not been previously modified by attachment of oligosaccharide. 8706738 11 16 gly U.N-deglycosylated 1416:1433 arg1 60 U.N-deglycosylated rGal-T 60 U.N-deglycosylated rGal-T The soluble mutated enzyme (N-deglycosylated rGal-T) was expressed in S. cerevisiae and its production scaled up to 60 U.N-deglycosylated rGal-T was purified to electrophoretic homogeneity. 8706738 11 13 gly N-deglycosylated 1325:1340 arg1 N-deglycosylated rGal-T enzyme N-deglycosylated rGal-T Fterm enzyme The soluble mutated enzyme (N-deglycosylated rGal-T) was expressed in S. cerevisiae and its production scaled up to 60 U.N-deglycosylated rGal-T was purified to electrophoretic homogeneity. 9971791 5 12 gly glycosylation 1005:1017 arg2 a glycosylation site a glycosylation site site This immunity was induced against both the homologous A/HK/156/97 (H5N1) virus, which has no glycosylation site at residue 154, and chicken isolate A/Ck/HK/258/97 (H5N1), which does have a glycosylation site at residue 154. 9971791 5 14 gly glycosylation 909:921 arg2 no glycosylation site no glycosylation site site This immunity was induced against both the homologous A/HK/156/97 (H5N1) virus, which has no glycosylation site at residue 154, and chicken isolate A/Ck/HK/258/97 (H5N1), which does have a glycosylation site at residue 154. 8019599 8 52 gly glycosylation 1127:1139 arg1 functional b3 functional b3 Cterm b3 443978 We suggest that glycosylation is not essential for the expression of functional b3 in oocytes, but may play a role in enabling the protein to acquire its correct folding with the highest anion transport activity. 23250914 1 76 part_of site 111:114 arg1 Berardinelli-Seip lipodystrophy (BSCL)-associated gene BSCL2/seipin seipin site PUBTATOR Site seipin Q96G97 site Mutations affecting the N-glycosylation site in Berardinelli-Seip lipodystrophy (BSCL)-associated gene BSCL2/seipin lead to a dominantly inherited spastic paraplegia termed seipinopathy. 9442070 5 37 gly sialylated 848:857 arg1 the N-glycans the N-glycans Over 90% of the N-glycans in IgA1 were sialylated, in contrast to IgG, where < 10% contain sialic acid. 9442070 5 66 gly N-glycans 825:833 arg1 IgA1 IgA1 N-glycans OGER IgA1 P01876 Over 90% of the N-glycans in IgA1 were sialylated, in contrast to IgG, where < 10% contain sialic acid. 9442070 5 77 gly IgA1 838:841 arg1 the N-glycans IgA1 the N-glycans OGER IgA1 P01876 Over 90% of the N-glycans in IgA1 were sialylated, in contrast to IgG, where < 10% contain sialic acid. 28900186 7 37 gly glycosylated 1451:1462 arg1 complex-type glycosylated human lactotransferrin and bovine serum albumin peptides complex-type glycosylated human lactotransferrin and bovine serum albumin peptides peptides and N-glycopeptides We demonstrate this newly discovered specificity of flavastacin by in-depth LC-MS(/MS) analysis of complex-type glycosylated human lactotransferrin and bovine serum albumin peptides and N-glycopeptides that were generated by trypsin and flavastacin digestion. 28900186 7 68 gly N-glycopeptides 1525:1539 arg2 N-glycopeptides N-glycopeptides peptides and N-glycopeptides We demonstrate this newly discovered specificity of flavastacin by in-depth LC-MS(/MS) analysis of complex-type glycosylated human lactotransferrin and bovine serum albumin peptides and N-glycopeptides that were generated by trypsin and flavastacin digestion. 20621099 0 31 gly glycosylated 132:143 arg1 the originally glycosylated site the originally glycosylated site site Mutational deglycosylation of the Fc portion of immunoglobulin G causes O-sulfation of tyrosine adjacently preceding the originally glycosylated site. 17623277 14 9 gly glycopeptide 1730:1741 arg2 the glycopeptide CID fragmentation pattern the glycopeptide CID fragmentation pattern glycopeptide Results of this study provide an interesting example in terms of potential complexity of the glycopeptide CID fragmentation pattern. 3219367 0 25 gly glycopeptides 77:89 arg2 glycopeptides glycopeptides glycopeptides Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. 3219367 0 35 gly glycosylation 14:26 arg1 human recombinant erythropoietin human recombinant erythropoietin PUBTATOR erythropoietin 2056 Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. 3219367 0 82 gly glycosylation 111:123 arg2 each glycosylation site each glycosylation site site Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. 9620884 4 1 gly glycosylation 714:726 arg2 glycosylation site 1 or 2 glycosylation site 1 or 2 site When expressed in COS-1 cells, glycoforms with glycosylation site 1 or 2 obliterated had more than 70% of wild-type activity, and both glycoforms were secreted. 29755357 8 17 gly N-glycosylation 1473:1487 arg1 LCN2 LCN2 PUBTATOR LCN2 3934 In sum, our data indicate that the N-glycosylation of LCN2 is not required for proper secretion and exosome cargo recruitment in different cell types, but might be relevant to increase overall solubility. 28257906 3 18 gly N-glycosylation 712:726 arg2 N-glycosylation sites N-glycosylation sites sites Several domain regions and key residues were conserved including signal peptides, active site residues, metal (Ca2+) and substrate binding sequences, transmembranes and N-glycosylation sites. 9020858 9 38 gly deglycosylation 1314:1328 arg1 glycosyl-phosphatidylinositol(GPI)-free APs APs OGER APs O14492 With regard to the oligomeric state of alkaline phosphatase (AP) isoforms, the dimer/tetramer equilibrium is dependent on the deglycosylation of glycosyl-phosphatidylinositol(GPI)-free APs, but not GPI-linked APs. 8496193 7 14 gly Nonglycosylated 1037:1051 arg1 Nonglycosylated protein Nonglycosylated protein Fterm protein Nonglycosylated protein was stable, both as unprocessed proenzyme and after processing at pH 4, and it was predominantly secreted instead of being delivered to lysosomes. 21172408 8 69 gly Asn11 944:948 arg1 Carbohydrate fractional abundance Asn11 Carbohydrate fractional abundance Asn11 Carbohydrate fractional abundance at Asn11 revealed that glycosylation in the natural placental TF is much more prevalent (~76%) than in the recombinant protein (~20%). 21172408 8 81 gly glycosylation 964:976 arg1 the natural placental TF the natural placental TF Cterm TF 2152 Carbohydrate fractional abundance at Asn11 revealed that glycosylation in the natural placental TF is much more prevalent (~76%) than in the recombinant protein (~20%). 11786923 5 10 part_of protein 803:809 arg1 an N-linked glycosylation site protein an N-linked glycosylation site Fterm Site protein site Mouse Wnt14b was found to encode a 359-amino-acid WNT family protein with the N-terminal signal peptide, an N-linked glycosylation site, and 24 conserved cysteine residues. 11786923 5 10 part_of protein 803:809 arg1 the N-terminal signal peptide protein the N-terminal signal peptide Fterm Site protein peptide Mouse Wnt14b was found to encode a 359-amino-acid WNT family protein with the N-terminal signal peptide, an N-linked glycosylation site, and 24 conserved cysteine residues. 11786923 5 10 part_of protein 803:809 arg1 24 conserved cysteine residues protein 24 conserved cysteine residues Fterm AminoAcid protein cysteine residues Mouse Wnt14b was found to encode a 359-amino-acid WNT family protein with the N-terminal signal peptide, an N-linked glycosylation site, and 24 conserved cysteine residues. 17947537 2 6 gly glycosylation 576:588 arg2 these positions these positions positions We have demonstrated that rodent neurovirulence is modulated by two mutations at amino acid positions 195 and 200 in the H protein, one of these positions (200) being a potential glycosylation site. 17947537 2 6 gly glycosylation 576:588 arg2 a potential glycosylation site a potential glycosylation site site We have demonstrated that rodent neurovirulence is modulated by two mutations at amino acid positions 195 and 200 in the H protein, one of these positions (200) being a potential glycosylation site. 9070436 5 56 gly N-glycosylation 941:955 arg2 the N-glycosylation site the N-glycosylation site site Residues close to the N-glycosylation site, and the first N-acetylglucosamine of the high mannose glycan are as rigid as the protein core. 16227249 2 104 part_of site 319:322 arg1 the E protein protein site Fterm Site protein site While the prM protein of all WNV strains contains a single N-linked glycosylation site, not all strains contain an N-linked site in the E protein. 16227249 2 97 part_of contains 236:243 arg1 the prM protein AND a single N-linked glycosylation site the prM protein a single N-linked glycosylation site Fterm Site protein site While the prM protein of all WNV strains contains a single N-linked glycosylation site, not all strains contain an N-linked site in the E protein. 7968693 6 37 gly glycosylation 1089:1101 arg2 The glycosylation site The glycosylation site site The glycosylation site in preM and hydrophobic regions at the carboxyl termini of M and E were well conserved. 7968693 6 37 gly glycosylation 1089:1101 arg2 the carboxyl termini the carboxyl termini termini The glycosylation site in preM and hydrophobic regions at the carboxyl termini of M and E were well conserved. 24612669 8 123 gly N-glycosylation 1896:1910 arg2 N-glycosylation site N-glycosylation site site All purified tag-free and chemically modified hFasLECDs showed an evident receptor binding activity in co-immunoprecipitation experiments mediated by wild-type and N-glycosylation site deficient mutant human Fas receptor extracellular domain derivatives. 25485983 0 10 part_of antithrombin 84:95 arg1 N135 antithrombin N135 PUBTATOR SpecificSite antithrombin 462 N135 Increased N-glycosylation efficiency by generation of an aromatic sequon on N135 of antithrombin. 25485983 0 57 part_of sequon 66:71 arg1 N135 sequon N135 N135 Increased N-glycosylation efficiency by generation of an aromatic sequon on N135 of antithrombin. 21647803 4 92 gly glycosite 493:501 arg2 comprehensive glycosite profiling comprehensive glycosite profiling glycosite Here, we developed a novel method of comprehensive glycosite profiling using nanoflow liquid chromatography/mass spectrometry (nano-LC/MS) that shows glycan isomer-specific differentiation on specific sites. 2590174 2 94 part_of protein 302:308 arg1 the yeast prepro alpha-mating factor sequence protein the yeast prepro alpha-mating factor sequence Fterm Site protein sequence A synthetic gene coding for human interleukin 4 (IL-4) was cloned and expressed in Saccharomyces cerevisiae (baker's yeast) as a C-terminal fusion protein with the yeast prepro alpha-mating factor sequence, resulting in secretion of mature IL-4 into the culture medium (0.6-0.8 micrograms/ml). 25690651 0 71 part_of motif 29:33 arg1 human GPR109A GPR109A motif PUBTATOR Site GPR109A 338442 motif, Asn-Cys-Cys The atypical N-glycosylation motif, Asn-Cys-Cys, in human GPR109A is required for normal cell surface expression and intracellular signaling. 18790849 7 57 part_of KCNQ1 1069:1073 arg1 the turret domain KCNQ1 the turret domain PUBTATOR Site KCNQ1 3784 domain A chimera consisting of KCNQ3 with the turret domain (TD) of KCNQ1 increased current density by about threefold. 18790849 7 127 part_of KCNQ3 1032:1036 arg1 the turret domain KCNQ3 the turret domain PUBTATOR Site KCNQ3 3786 domain A chimera consisting of KCNQ3 with the turret domain (TD) of KCNQ1 increased current density by about threefold. 15718224 5 44 gly glycosylation 1172:1184 arg2 a deleted glycosylation site a deleted glycosylation site site In one of the strains, a novel glycosylation site was created near a deleted glycosylation site. 15718224 5 91 gly glycosylation 1126:1138 arg2 a novel glycosylation site a novel glycosylation site site In one of the strains, a novel glycosylation site was created near a deleted glycosylation site. 26514585 4 18 gly glycosylation 835:847 arg2 a glycosylation site a glycosylation site site With the purpose of stabilizing bevacizumab with respect to aggregation, 2 strategies were undertaken: single point mutations of aggregation-prone residues and engineering a glycosylation site near aggregation-prone residues to mask these residues with a carbohydrate moiety. 18815274 7 7 gly N-glycosylation 865:879 arg2 a N-glycosylation site a N-glycosylation site site Furthermore, we found disruption of a N-glycosylation site (N573Q) within the fourth luminal domain of SV2A rendered the mutant unable to mediate the entry of BoNT/E and also reduced the entry of BoNT/A. 28970103 4 29 gly O-glycopeptide 757:770 arg2 O-glycopeptide O-glycopeptide O-glycopeptide Here, we developed a systematic strategy that combined multiple enzyme digestion, multidimensional separation for sample preparation and high-resolution tandem MS with Byonic software for intact O-glycopeptide characterization. 8877373 2 31 gly glycosylation 367:379 arg2 one glycosylation site one glycosylation site site The enzyme is composed of two non-identical alpha/beta subunits joined by strong non-covalent forces and has one glycosylation site located in the alpha subunit. 24104458 7 63 gly glycosylated 774:785 arg1 the N-domain glycosylated residues the N-domain glycosylated residues residues Removal of the N-domain glycosylated residues reduces B9 recognition, CD8α binding affinity, and activation of LcK. 8347587 7 20 gly contained 838:846 arg1 The proreceptor AND four less oligosaccharide chains The proreceptor four less oligosaccharide chains Fterm proreceptor The proreceptor was slightly smaller on SDS-PAGE gels than the wild-type proreceptor and contained four less oligosaccharide chains by tryptic peptide mapping. 27957769 2 84 gly glycopeptide 305:316 arg2 tumor-associated glycopeptide structures tumor-associated glycopeptide structures glycopeptide Many successful methodologies for reliably increasing the antigenicity toward tumor-associated glycopeptide structures have been reported. 12064867 8 17 gly site 1328:1331 arg1 the glycan site the glycan site Finally, we determined the structural class of the glycan of one V1 glycosylation site of prototype HIV-1 LAI gp120, which remained unsolved from previous studies, and found that it belonged to the complex type of glycans. 12064867 8 33 gly glycosylation 1314:1326 arg2 one V1 glycosylation site gp120 site PUBTATOR gp120 155971 site Finally, we determined the structural class of the glycan of one V1 glycosylation site of prototype HIV-1 LAI gp120, which remained unsolved from previous studies, and found that it belonged to the complex type of glycans. 21188626 6 7 gly N-glycosylation 954:968 arg2 an N-glycosylation site an N-glycosylation site site The sequence analysis showed two amino acid deletions and loss of an N-glycosylation site in transmissible gastroenteritis virus S protein after passages in piglets. 9581553 7 89 gly N-glycosylation 1064:1078 arg2 the N-glycosylation sites the N-glycosylation sites sites When all of the N-glycosylation sites were abolished, 2% and 8% of FR-alpha and FR-beta respectively were expressed on the cell surface compared with the corresponding wild-type proteins; the residual FR polypeptides in the cell lysates were unable to bind [3H]folic acid. 9690810 8 19 gly glycosylation 891:903 arg2 Asn44 Asn44 Asn44 All cysteine residues in extracytoplasmic domain and putative N-linked glycosylation site (Asn44) were conserved. 9690810 8 19 gly glycosylation 891:903 arg2 putative N-linked glycosylation site putative N-linked glycosylation site site All cysteine residues in extracytoplasmic domain and putative N-linked glycosylation site (Asn44) were conserved. 2603816 1 25 part_of kallikrein 124:133 arg1 The complete amino acid sequence kallikrein The complete amino acid sequence PUBTATOR Site kallikrein 9622 sequence The complete amino acid sequence of human urinary kallikrein has been determined. 9820842 0 28 gly glycoprotein 72:83 arg1 a glycoprotein a glycoprotein Fterm glycoprotein The US5 open reading frame of herpes simplex virus type 1 does encode a glycoprotein (gJ). 29966421 5 19 gly glycopeptide 938:949 arg2 glycopeptide glycopeptide glycopeptide Combining data from high-resolution native mass spectrometry and glycopeptide centric LC-MS analysis, we qualitatively and quantitatively gather information on fetuin protein maturation, N-glycosylation, O-glycosylation, and phosphorylation. 28303575 10 7 gly n-glycosylation 1220:1234 arg1 Dectin-1 Dectin-1 PUBTATOR Dectin-1 64581 We show here that n-glycosylation of Dectin-1 is crucial for its cell surface expression and consequently signal transduction. 8076650 6 61 gly glycosylated 1157:1168 arg1 fuctinin fuctinin Fterm fuctinin In spite of the presence of an N-glycosylation site, fuctinin is not glycosylated. 8076650 6 68 gly N-glycosylation 1119:1133 arg2 an N-glycosylation site an N-glycosylation site site In spite of the presence of an N-glycosylation site, fuctinin is not glycosylated. 25451932 9 7 part_of protease 1214:1221 arg1 the protease domain protease the protease domain Fterm Site protease domain We also found that the location of the N-glycosylation site in the protease domain was not critical. 26022737 2 45 part_of possessing 220:229 arg1 a glycoprotein AND a single glycosylation site a glycoprotein a single glycosylation site Fterm Site glycoprotein site It is a glycoprotein possessing a single glycosylation site at N69. 7685965 8 51 gly glycoprotein 1335:1346 arg1 a glycoprotein antigen a glycoprotein antigen Fterm glycoprotein These results illustrate that even when attached to residues outside a determinant, the carbohydrate of a glycoprotein antigen can influence T-cell recognition. 18085777 2 4 gly N-glycosylation 385:399 arg2 one N-glycosylation site one N-glycosylation site site We have examined the synthesis of a single glycoform of monocyte chemotactic protein-3 (MCP-3), a CC-chemokine that consists of 76 amino acids and one N-glycosylation site. 18085777 2 13 gly glycoform 277:285 arg1 monocyte chemotactic protein-3 monocyte chemotactic protein-3 PUBTATOR monocyte chemotactic protein-3 6354 We have examined the synthesis of a single glycoform of monocyte chemotactic protein-3 (MCP-3), a CC-chemokine that consists of 76 amino acids and one N-glycosylation site. 18085777 2 13 gly glycoform 277:285 arg1 MCP-3 MCP-3 PUBTATOR MCP-3 6354 We have examined the synthesis of a single glycoform of monocyte chemotactic protein-3 (MCP-3), a CC-chemokine that consists of 76 amino acids and one N-glycosylation site. 8294492 1 57 part_of variants 150:157 arg1 distinct carboxyl regions variants distinct carboxyl regions Fterm Site variants regions Differential expression of mRNA transcripts that predict three protein variants with distinct carboxyl regions. 31336133 3 4 gly N-glycosylation 558:572 arg2 2 potential N-glycosylation sites 2 potential N-glycosylation sites sites The ANITVNITV peptide described by Perlmann and coworkers presents 9 amino acids and 2 potential N-glycosylation sites. 28860626 6 12 part_of proteins 1461:1468 arg1 the specific glycosylation sites proteins the specific glycosylation sites Fterm Site proteins sites Interestingly, sulfation, fucosylation and bisecting N-acetylglucosamine of N-glycans were also reliably identified at the specific glycosylation sites of the two influenza proteins that may serve a crucial role in regulating the protein structure and increasing the protein abundance of the influenza virus reassortants. 7613477 2 20 gly glycopeptides 688:700 arg2 glycopeptides glycopeptides glycopeptides A recently described mass spectrometric technique involving monitoring of carbohydrate-specific fragment ions during HPLC/ESIMS was employed to locate eight different groups of glycopeptides in a digest of a human LCAT protein preparation. 7613477 2 26 gly fragment 607:614 arg1 carbohydrate-specific fragment ions carbohydrate-specific fragment ions A recently described mass spectrometric technique involving monitoring of carbohydrate-specific fragment ions during HPLC/ESIMS was employed to locate eight different groups of glycopeptides in a digest of a human LCAT protein preparation. 26333807 7 39 part_of Tf 983:984 arg1 a Tf glycosylations site Tf a Tf glycosylations site PUBTATOR Site Tf 7018 site Sanger sequencing revealed the Tf mutation c.1889 A>C, deleting a Tf glycosylations site and thereby causing elevated disialo-Tf levels. 20881037 0 39 gly glycosylation 136:148 arg2 a novel glycosylation site a novel glycosylation site site Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. 1468573 1 7 gly urokinase 220:228 arg1 enzymically released N-linked carbohydrate chains urokinase enzymically released N-linked carbohydrate chains Fterm urokinase Structural analysis of enzymically released N-linked carbohydrate chains of human urokinase (urinary-type plasminogen activator) by 1H NMR spectroscopy and FAB-MS demonstrated that the N-linked oligosaccharides on the only N-glycosylation site contain diantennary structures with the novel GalNAc beta (1-4) [Fuc alpha (1-3)]GlcNAc beta (1-2) element in the upper or the lower branch. 1468573 1 14 gly oligosaccharides 332:347 arg1 the only N-glycosylation site the only N-glycosylation site the only N-glycosylation site Site site Structural analysis of enzymically released N-linked carbohydrate chains of human urokinase (urinary-type plasminogen activator) by 1H NMR spectroscopy and FAB-MS demonstrated that the N-linked oligosaccharides on the only N-glycosylation site contain diantennary structures with the novel GalNAc beta (1-4) [Fuc alpha (1-3)]GlcNAc beta (1-2) element in the upper or the lower branch. 1468573 1 35 gly N-glycosylation 361:375 arg2 the only N-glycosylation site the only N-glycosylation site site Structural analysis of enzymically released N-linked carbohydrate chains of human urokinase (urinary-type plasminogen activator) by 1H NMR spectroscopy and FAB-MS demonstrated that the N-linked oligosaccharides on the only N-glycosylation site contain diantennary structures with the novel GalNAc beta (1-4) [Fuc alpha (1-3)]GlcNAc beta (1-2) element in the upper or the lower branch. 11471056 4 63 part_of has 684:686 arg1 canine chromosome region CFA10q26 AND a syntenic human chromosome region canine chromosome region CFA10q26 a syntenic human chromosome region region The CT locus in Bedlington terriers has been mapped to canine chromosome region CFA10q26, which has a syntenic human chromosome region, HAS2p13-21. 28661444 2 15 gly glycosylation 586:598 arg1 two recombinant MTB proteins two recombinant MTB proteins Cterm MTB In this work, we investigated the effect of the chemical glycosylation on two recombinant MTB proteins produced in E. coli with an additional seven-amino acid tag (recombinant Ag85B and TB10.4). 19874459 4 51 gly O-glycosylation 591:605 arg2 10 predicted O-glycosylation sites 10 predicted O-glycosylation sites sites Despite the presence of 10 predicted O-glycosylation sites, the O-glycome remains poorly characterized, impairing the complete elucidation of its influence on VWF functions. 9600940 8 62 gly glycosylation 1099:1111 arg2 Asn-330 Asn-330 Asn-330 Mutation of Asn-330, a potential N-linked glycosylation site, also had no effect on sperm receptor activity. 9600940 8 62 gly glycosylation 1099:1111 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Mutation of Asn-330, a potential N-linked glycosylation site, also had no effect on sperm receptor activity. 26066578 3 3 gly glycosylated 328:339 arg1 glycosylated peptides glycosylated peptides peptides However, current glycoproteomic methods focus on the identification and quantification of glycosylated peptides and glycosylation sites but not glycosylation occupancy or glycoform stoichiometry. 26066578 3 33 gly glycosylation 354:366 arg2 glycosylation sites glycosylation sites sites However, current glycoproteomic methods focus on the identification and quantification of glycosylated peptides and glycosylation sites but not glycosylation occupancy or glycoform stoichiometry. 32280962 1 35 gly glycoprotein 140:151 arg1 Pregnancy-specific beta 1 glycoprotein Pregnancy-specific beta 1 glycoprotein PUBTATOR Pregnancy-specific beta 1 glycoprotein 653492 Pregnancy-specific beta 1 glycoprotein (PSG1) is secreted from trophoblast cells of the human placenta in increasing concentrations as pregnancy progresses, becoming one of the most abundant proteins in maternal serum in the third trimester. 32280962 1 35 gly glycoprotein 140:151 arg1 PSG1 PSG1 PUBTATOR PSG1 5669 Pregnancy-specific beta 1 glycoprotein (PSG1) is secreted from trophoblast cells of the human placenta in increasing concentrations as pregnancy progresses, becoming one of the most abundant proteins in maternal serum in the third trimester. 11458001 2 58 gly glycosylation 613:625 arg2 the Asn148 glycosylation site the Asn148 glycosylation site site In addition, a mutant lacking the Asn148 glycosylation site was included in the study. 28708860 7 46 part_of Epitopes 1137:1144 arg1 HA1 HA1 Epitopes PUBTATOR HA1 23526 As great diversities occurred in 1990s, involving Epitope A, B and D mutations, the charged amino acids in Epitopes A, B, C and D in HA1 mutated at a high frequency in global circulating strains last decade. 2456913 7 23 gly glycosylation 1026:1038 arg2 each glycosylation site each glycosylation site site Man9GlcNac2 and Man8GlcNac2 units predominated at each time point and at each specific glycosylation site, but the processing of high Man oligosaccharides differed at each glycosylation site. 2456913 7 57 gly glycosylation 941:953 arg2 each specific glycosylation site each specific glycosylation site site Man9GlcNac2 and Man8GlcNac2 units predominated at each time point and at each specific glycosylation site, but the processing of high Man oligosaccharides differed at each glycosylation site. 16360109 7 21 gly glycans 1612:1618 arg1 the Fc region the Fc region the Fc region Site region Different glycans in the Fc region showed the same clearance rate as demonstrated previously. 19418565 1 50 gly glycoprotein 411:422 arg1 glycoprotein 2-GP2 glycoprotein 2-GP2 Fterm glycoprotein The effect of different cell culture conditions on N-glycosylation site-occupancy has been elucidated for two different recombinant glycoproteins expressed in Chinese hamster ovary (CHO) cells, recombinant human tissue plasminogen activator (t-PA) and a recombinant enzyme (glycoprotein 2-GP2). 19418565 1 74 gly glycoproteins 269:281 arg1 two different recombinant glycoproteins two different recombinant glycoproteins Fterm glycoproteins The effect of different cell culture conditions on N-glycosylation site-occupancy has been elucidated for two different recombinant glycoproteins expressed in Chinese hamster ovary (CHO) cells, recombinant human tissue plasminogen activator (t-PA) and a recombinant enzyme (glycoprotein 2-GP2). 18652900 8 37 gly glycosylation 1221:1233 arg2 a glycosylation site a glycosylation site site Asn225 was identified as a glycosylation site. 18652900 8 37 gly glycosylation 1221:1233 arg2 Asn225 Asn225 Asn225 Asn225 was identified as a glycosylation site. 22997027 4 27 part_of glycoprotein 499:510 arg1 possible glycoprotein glycosylation site glycoprotein possible glycoprotein glycosylation site Fterm Site glycoprotein site Although recent advances in LC-MS analysis have made possible glycoprotein glycosylation site identification, characterization of glycoprotein glycan structures, as well as glycoprotein identification and quantification, protein glycosylation analysis in complex samples still remains a difficult task. 17459925 0 78 gly glycosylation 50:62 arg2 asparagine-67 asparagine-67 asparagine-67 Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. 28694069 4 6 gly aglycosylated 833:845 arg1 the aglycosylated IgG variants the aglycosylated IgG variants Fterm variants We also assess the biophysical properties and serum half-life of the aglycosylated IgG variants to measure stability. 23683998 9 108 gly glycosylation 1545:1557 arg2 N-link glycosylation site site site Additionally, we identified numerous mutations with amino acid substitutions in the hemagglutinin: M226I, I239S located at N-link glycosylation site and 2H, 45N, 53K 120D, 133A and 14N mutations at antigenic site, which can affect receptor specificity as well as viral pathogenicity. 17877633 2 35 gly glycosylation 481:493 arg2 a potential extracellular glycosylation site a potential extracellular glycosylation site site This polymorphism codes for an asparagine to aspartic acid substitution at amino acid 40 in the amino-terminus, thereby removing a potential extracellular glycosylation site. 7688818 5 94 part_of exposition 800:809 arg1 the E1 and E2 glycoproteins glycoproteins exposition Fterm Site glycoproteins position Heating Sindbis virions at 51 degrees C for a short time induced a similar, although not identical, exposition of transitional epitopes on the E1 and E2 glycoproteins (W. J. Meyer, S. Gidwitz, V. K. Ayers, R. J. Schoepp, and R. E. Johnston, J. Virol. 9169007 7 85 gly glycoform 1192:1200 arg1 the low heparin affinity glycoform the low heparin affinity glycoform Fterm heparin These results demonstrate that heterogeneous glycosylation of Asn 155 of recombinant antithrombin is responsible for generating the low heparin affinity glycoform. 9169007 7 88 gly glycosylation 1084:1096 arg1 Asn 155 Asn 155 Asn 155 These results demonstrate that heterogeneous glycosylation of Asn 155 of recombinant antithrombin is responsible for generating the low heparin affinity glycoform. 10749666 7 28 gly SERP-1 1590:1595 arg1 viral sialylation SERP-1 viral sialylation PUBTATOR SERP-1 27230 Rather, the role of viral sialylation of SERP-1 likely relates to masking antigenicity or targeting SERP-1 to specific sites of action in vivo. 10749666 7 80 gly sialylation 1575:1585 arg1 SERP-1 SERP-1 PUBTATOR SERP-1 27230 Rather, the role of viral sialylation of SERP-1 likely relates to masking antigenicity or targeting SERP-1 to specific sites of action in vivo. 11259791 7 63 part_of AChE 1091:1094 arg1 the epitopes AChE the epitopes PUBTATOR Site AChE 43 epitopes The results indicate that the epitopes of human brain AChE and Torpedo AChEs have been highly conserved during evolution. 9241750 1 57 gly abolish 292:298 arg1 Ser460-->Gly Ser460-->Gly Gly To study the role of glycosylation at these sites, PCR mutagenesis was used to abolish the consensus sequence of each N-linked glycosylation site (Asn458-->Gln, Ser460-->Gly; Asn468-->Gln, Thr470-->Gly; Asn489-->Gln, Thr491-->Gly) in full-length HPS cDNA. 9241750 1 66 gly glycosylation 340:352 arg2 each N-linked glycosylation site each N-linked glycosylation site site To study the role of glycosylation at these sites, PCR mutagenesis was used to abolish the consensus sequence of each N-linked glycosylation site (Asn458-->Gln, Ser460-->Gly; Asn468-->Gln, Thr470-->Gly; Asn489-->Gln, Thr491-->Gly) in full-length HPS cDNA. 9241750 1 49 gly Ser460-->Gly 374:385 arg1 Thr491-->Gly Gly Gly To study the role of glycosylation at these sites, PCR mutagenesis was used to abolish the consensus sequence of each N-linked glycosylation site (Asn458-->Gln, Ser460-->Gly; Asn468-->Gln, Thr470-->Gly; Asn489-->Gln, Thr491-->Gly) in full-length HPS cDNA. 1639824 3 26 gly glycosylation 429:441 arg2 the glycosylation site the glycosylation site site We have expressed and purified a mutant form of rat procathepsin B whose active-site cysteine residue has been changed to a serine, and which also lacks the glycosylation site in the mature region of the protein. 17144668 10 72 gly glycosylation 1736:1748 arg1 protein folding protein folding Fterm protein Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability. 17144668 10 72 gly glycosylation 1736:1748 arg1 carboxylase enzymatic activity carboxylase enzymatic activity Fterm carboxylase Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability. 26957414 2 72 gly glycoproteins 270:282 arg1 aberrant glycoproteins aberrant glycoproteins Fterm glycoproteins In recent years, the correlation between aberrant glycoproteins and many diseases has been reported. 25281832 11 76 gly glycosylation 1522:1534 arg2 one glycosylation site one glycosylation site site All strains maintained their glycosylation sites except H1a that lost one glycosylation site. 25281832 11 81 gly glycosylation 1477:1489 arg2 their glycosylation sites their glycosylation sites sites All strains maintained their glycosylation sites except H1a that lost one glycosylation site. 16735497 10 17 gly glycosylation 1378:1390 arg2 its new glycosylation site its new glycosylation site site On the other hand, neither disruption of its new glycosylation site nor termination of TBG-CDNI at the normal length repaired its secretion defect. 1446688 6 40 part_of protein 879:885 arg1 the succeeding sequences protein the succeeding sequences Fterm Site protein sequences It is suggested that the heterogeneity of the N-terminus is caused not only by the signal sequence, but also by the succeeding sequences of the mature protein. 17599380 5 75 part_of CD4 1015:1017 arg1 the CD4 binding site CD4 the CD4 binding site OGER Site CD4 P01730 site A D386N mutation in the UK1br Env, which restores the N-linked glycan site, reduced neutralization sensitivity to the IgG1b12 (b12) monoclonal antibody, which recognizes a conserved neutralization epitope that overlaps the CD4 binding site. 2910856 3 24 part_of lectin 503:508 arg1 the 3'-untranslated region lectin the 3'-untranslated region Fterm Site lectin region The HL-60 cDNA clones that were isolated were used to design a synthetic primer representing the 3'-untranslated region of the HL-60 lectin. 26598643 14 93 gly disialylated 2049:2060 arg1 core-1 mucin-type O-glycans core-1 mucin-type O-glycans The identified O-glycan compositions most probably correspond to mono- and disialylated core-1 mucin-type O-glycans (T-antigen). 19116267 10 80 gly glycoprotein 1592:1603 arg1 VN1203 HA glycoprotein VN1203 HA glycoprotein Fterm glycoprotein These results show that VN1203 HA glycoprotein confers pathogenicity by facilitating systemic spread in mice; they also suggest that a minor change in receptor binding domain may modulate the virulence of H5N1 viruses. 15931076 3 9 gly glycosylation 723:735 arg1 the rTRPV1 receptor channel the rTRPV1 receptor channel Fterm channel Further, such a manipulation modified the sensitivity to the TRPV1 receptor-antagonist capsazepine and altered the dependence of the capsaicin effect on extracellular pH. Hence, glycosylation may affect the basic functional characteristics of the rTRPV1 receptor channel in accordance with the knowledge that N-glycosylation may regulate ligand binding or gating properties of ionotropic neurotransmitter receptors. 26256267 12 77 gly glycosylation 2100:2112 arg2 the examined glycosylation sites the examined glycosylation sites sites These intact glycopeptides contained 67 glycan compositions and showed increased fucosylation in PC3 cells in several of the examined glycosylation sites. 26256267 12 115 gly glycopeptides 1979:1991 arg2 These intact glycopeptides These intact glycopeptides glycopeptides These intact glycopeptides contained 67 glycan compositions and showed increased fucosylation in PC3 cells in several of the examined glycosylation sites. 26256267 12 104 gly contained 1993:2001 arg1 These intact glycopeptides AND 67 glycan compositions These intact glycopeptides 67 glycan compositions glycopeptides These intact glycopeptides contained 67 glycan compositions and showed increased fucosylation in PC3 cells in several of the examined glycosylation sites. 9581553 7 19 part_of FR 1249:1250 arg1 the residual FR polypeptides FR the residual FR polypeptides Cterm Site FR polypeptides When all of the N-glycosylation sites were abolished, 2% and 8% of FR-alpha and FR-beta respectively were expressed on the cell surface compared with the corresponding wild-type proteins; the residual FR polypeptides in the cell lysates were unable to bind [3H]folic acid. 22689482 1 72 gly glycoforms 243:252 arg1 a basic proline-rich protein a basic proline-rich protein Fterm protein This study describes the characterization of the glycan moieties and the peptide backbone of six glycoforms of IB-8a CON1(+), a basic proline-rich protein present in human saliva. 3219367 5 73 part_of erythropoietin 667:680 arg1 each glycosylation site erythropoietin each glycosylation site PUBTATOR Site erythropoietin 2056 site In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin. 23921623 0 31 gly position 80:87 arg1 an additional N-glycan position 247 an additional N-glycan position 247 Characterization of street rabies virus variants with an additional N-glycan at position 247 in the glycoprotein. 23921623 0 32 gly glycoprotein 100:111 arg1 the glycoprotein the glycoprotein Fterm glycoprotein Characterization of street rabies virus variants with an additional N-glycan at position 247 in the glycoprotein. 23921623 0 41 gly N-glycan 68:75 arg1 the glycoprotein glycoprotein N-glycan Fterm glycoprotein Characterization of street rabies virus variants with an additional N-glycan at position 247 in the glycoprotein. 23921623 0 68 gly variants 40:47 arg1 an additional N-glycan variants an additional N-glycan Fterm variants Characterization of street rabies virus variants with an additional N-glycan at position 247 in the glycoprotein. 8369176 0 0 gly glycosylation 94:106 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site V3 loops of HIV-1 specimens from pregnant women in Malawi uniformly lack a potential N-linked glycosylation site. 24174280 2 16 gly glycosylation 457:469 arg2 N-linked glycosylation sites N-linked glycosylation sites sites In the current study, we have characterized the dynamic amino acid changes at N-linked glycosylation sites of full length sequences of HA genes of 5 A/H3N2 Tunisian strains isolates from mild, severe, and fatal cases. 24174280 2 16 gly glycosylation 457:469 arg1 full length sequences sequences sequences In the current study, we have characterized the dynamic amino acid changes at N-linked glycosylation sites of full length sequences of HA genes of 5 A/H3N2 Tunisian strains isolates from mild, severe, and fatal cases. 15039521 2 35 part_of preS2 270:274 arg1 the preS2 domain preS2 the preS2 domain Cterm Site preS2 domain M-sAg contains the preS2 domain in addition to the S region. 15039521 2 40 part_of contains 257:264 arg1 M-sAg AND the preS2 domain M-sAg the preS2 domain OGER Site sAg Q9UBF6 domain M-sAg contains the preS2 domain in addition to the S region. 8912525 8 10 part_of ATP 1020:1022 arg1 one ATP binding site ATP one ATP binding site OGER Site ATP site This is in contrast to MRP (190 kDa, 172 kDa deglycosylated) and most other higher eukaryote ABC proteins, which consist of two similar halves, each having one ATP binding site. 20881037 3 11 part_of proteins 537:544 arg1 the S domain proteins the S domain Fterm Site proteins domain Here we used transcomplementation assay to confirm that the I110M, G119E, and R169P mutations in the S domain of viral envelope proteins impair virion secretion and that an M133T mutation rescues virion secretion of the I110M and G119E mutants. 24533768 4 54 gly glycans 569:575 arg1 Asn-297 Asn-297 Asn-297 SpecificSite Asn-297 The native glycans on Asn-297 of antibodies were enzymatically remodeled in vitro using galactosyl and sialyltransferases to introduce terminal sialic acids. 12773316 9 26 part_of sites 1425:1429 arg1 the beta-subunit beta-subunit sites Fterm Site beta-subunit sites Therefore, six of the seven glycosylation sites in the beta-subunit are essential for the plasma membrane delivery of the beta-subunit of the gastric H,K-ATPase, whereas the second glycosylation site (Asn103), which is not conserved among the beta-subunits from different species, is not critical for plasma delivery of the protein. 28747502 9 14 part_of has 1528:1530 arg1 mDPP4 AND a nonconserved glycosylation site mDPP4 a nonconserved glycosylation site PUBTATOR Site Specifically, mDPP4 13482 site Specifically, mDPP4 has a nonconserved glycosylation site that acts as a barrier to MERS-CoV infection. 2457333 10 31 gly glycopeptides 1512:1524 arg2 the Asn-Cys glycopeptides the Asn-Cys glycopeptides glycopeptides The presence of biantennary oligosaccharides at the Asn-Asp sites could be substantiated using 1H NMR but were not detected in the Asn-Cys glycopeptides. 2457333 10 52 gly presence 1377:1384 arg1 the Asn-Asp sites AND biantennary oligosaccharides the Asn-Asp sites biantennary oligosaccharides sites The presence of biantennary oligosaccharides at the Asn-Asp sites could be substantiated using 1H NMR but were not detected in the Asn-Cys glycopeptides. 17623277 7 29 gly glycopeptides 843:855 arg2 trypsin-digested DCE glycopeptides trypsin-digested DCE glycopeptides glycopeptides Glycosylation site and oligosaccharide structures were elucidated from MS and MS/MS spectra of trypsin-digested DCE glycopeptides. 26059044 8 5 gly N-glycosylation 1162:1176 arg2 this position position position The combination of site-directed mutagenesis of Asn54 and in vivo deglycosylation with PNGase F also revealed that N-glycosylation at this position is not required for proper protein folding. 26059044 8 5 gly N-glycosylation 1162:1176 arg1 proper protein folding protein position Fterm protein position The combination of site-directed mutagenesis of Asn54 and in vivo deglycosylation with PNGase F also revealed that N-glycosylation at this position is not required for proper protein folding. 26059044 8 5 gly N-glycosylation 1162:1176 arg1 proper protein folding protein position Fterm protein position The combination of site-directed mutagenesis of Asn54 and in vivo deglycosylation with PNGase F also revealed that N-glycosylation at this position is not required for proper protein folding. 9295302 5 26 gly N-glycosylation 783:797 arg2 the 14 N-glycosylation sequons the 14 N-glycosylation sequons To aid in determining the topology most likely to be correct, we have identified which of the 14 N-glycosylation sequons in this protein are utilized. 29966421 3 28 gly glycoprotein 484:495 arg1 Bovine fetuin Bovine fetuin PUBTATOR Bovine fetuin 397585 Bovine fetuin, which harbors 3 N-glycosylation sites and a suggested half dozen O-glycosylation sites, has been used often as a model glycoprotein to test novel analytical workflows in glycoproteomics. 29966421 3 28 gly glycoprotein 484:495 arg1 a model glycoprotein a model glycoprotein Fterm glycoprotein Bovine fetuin, which harbors 3 N-glycosylation sites and a suggested half dozen O-glycosylation sites, has been used often as a model glycoprotein to test novel analytical workflows in glycoproteomics. 29966421 3 39 gly N-glycosylation 381:395 arg2 3 N-glycosylation sites 3 N-glycosylation sites sites Bovine fetuin, which harbors 3 N-glycosylation sites and a suggested half dozen O-glycosylation sites, has been used often as a model glycoprotein to test novel analytical workflows in glycoproteomics. 29966421 3 83 gly O-glycosylation 430:444 arg2 a suggested half dozen O-glycosylation sites a suggested half dozen O-glycosylation sites sites Bovine fetuin, which harbors 3 N-glycosylation sites and a suggested half dozen O-glycosylation sites, has been used often as a model glycoprotein to test novel analytical workflows in glycoproteomics. 26957414 8 37 gly glycoproteins 1086:1098 arg1 glycoproteins glycoproteins Fterm glycoproteins A 45 V ISF voltage was found to be the most efficient voltage for the analysis of glycoproteins. 28322444 2 3 gly N-glycosylation 284:298 arg2 specific asparagine residues asparagine residues asparagine residues In the present study, we demonstrate the impact of N-glycosylation at specific asparagine residues on the trafficking of the Kv3.1b protein. 1535241 7 34 gly glycosylation 1555:1567 arg2 one glycosylation site mutant one glycosylation site mutant site Replacement of each of the four asparagine-linked glycosylation sites did not affect transforming activity at normal temperatures, but one glycosylation site mutant was found to be temperature-sensitive for transformation. 1535241 7 85 gly glycosylation 1466:1478 arg2 the four asparagine-linked glycosylation sites the four asparagine-linked glycosylation sites sites Replacement of each of the four asparagine-linked glycosylation sites did not affect transforming activity at normal temperatures, but one glycosylation site mutant was found to be temperature-sensitive for transformation. 1660522 2 44 gly contain 352:358 arg1 proteins AND short consensus repeats proteins short consensus repeats Fterm proteins One determinant of this narrow tropism is human CR2, the only viral receptor within the superfamily of proteins that contain short consensus repeats (SCRs). 11864713 1 44 gly N-glycosylation 95:109 arg2 The N-glycosylation site mutants The N-glycosylation site mutants site The N-glycosylation site mutants of human protein C inhibitor (PCI; N230S, N243Q, N319Q, N230S/N243Q, and N230S/N319Q) were prepared by amino acid replacement of the asparagine residue with a serine or glutamine residue using site-directed mutagenesis and expressed in the baculovirus/insect cell expression system. 12883358 8 29 gly O-glycosylation 1392:1406 arg1 four serine-glycine motifs four serine-glycine motifs motifs In fact, spontaneous CD44s shedding was dependent on the presence of partial or complete O-glycosylation of four serine-glycine motifs localized in the membrane-proximal CD44 ectodomain. 1970443 8 15 gly glycoproteins 1414:1426 arg1 Hantaan G1 and G2 envelope glycoproteins Hantaan G1 and G2 envelope glycoproteins Fterm glycoproteins Amino acid sequences predicted from the SR-11 M segment ORF were 75% homologous with those encoding Hantaan G1 and G2 envelope glycoproteins. 17095532 6 1 gly xylose 1164:1169 arg1 residues residues residues Indeed, we achieved complete sequence coverage of the mature protein compared with the translation of an expressed sequence tag cDNA clone and demonstrated that the single N-glycosylation site of this protein carries oligosaccharides with xylose and fucose residues. 17095532 6 20 gly sequence 1040:1047 arg1 an expressed sequence tag an expressed sequence tag Indeed, we achieved complete sequence coverage of the mature protein compared with the translation of an expressed sequence tag cDNA clone and demonstrated that the single N-glycosylation site of this protein carries oligosaccharides with xylose and fucose residues. 17095532 6 46 gly N-glycosylation 1097:1111 arg1 this protein protein site Fterm protein site Indeed, we achieved complete sequence coverage of the mature protein compared with the translation of an expressed sequence tag cDNA clone and demonstrated that the single N-glycosylation site of this protein carries oligosaccharides with xylose and fucose residues. 17095532 6 27 gly carries 1134:1140 arg1 this protein AND oligosaccharides protein site oligosaccharides Fterm protein site Indeed, we achieved complete sequence coverage of the mature protein compared with the translation of an expressed sequence tag cDNA clone and demonstrated that the single N-glycosylation site of this protein carries oligosaccharides with xylose and fucose residues. 21661761 6 43 part_of glycoproteins 1018:1030 arg1 multiple sites glycoproteins multiple sites Fterm Site glycoproteins sites The method is applied to glycoproteins with contrasting glycans and multiple sites of glycosylation and identifies multiple glycan compositions at each individual glycosylation site. 8798755 1 29 part_of RGDS 457:460 arg1 a possible adhesive recognition sequence RGDS a possible adhesive recognition sequence PUBTATOR Site RGDS 5900 sequence Cloning of the cDNA encoding a novel human protein- tyrosine phosphatase (PTP) called islet cell antigen-related PTP (IAR) predicts a receptor-like molecule with an extracellular domain of 614 amino acids containing a hydrophobic signal peptide, one potential N-glycosylation site, and an RGDS peptide which is a possible adhesive recognition sequence. 8798755 1 29 part_of RGDS 457:460 arg1 an RGDS peptide RGDS an RGDS peptide PUBTATOR Site RGDS 5900 peptide Cloning of the cDNA encoding a novel human protein- tyrosine phosphatase (PTP) called islet cell antigen-related PTP (IAR) predicts a receptor-like molecule with an extracellular domain of 614 amino acids containing a hydrophobic signal peptide, one potential N-glycosylation site, and an RGDS peptide which is a possible adhesive recognition sequence. 21899340 4 11 gly core-fucosylated 939:954 arg1 4 core-fucosylated glycans 4 core-fucosylated glycans In the analysis of complex serum samples, 32 N-linked glycans could be profiled, and 5 (4 core-fucosylated glycans) of them were distinguished from liver cancer and healthy samples. 15308721 0 43 gly protein 36:42 arg1 Glycan-controlled epitopes protein Glycan-controlled epitopes Fterm protein Glycan-controlled epitopes of prion protein include a major determinant of susceptibility to sheep scrapie. 19919546 5 4 gly glycoproteins 1171:1183 arg1 many glycoproteins many glycoproteins Fterm glycoproteins Using this strategy, we have identified many glycoproteins containing glycan structures that are altered in cancer cells. 19919546 5 3 gly containing 1185:1194 arg1 many glycoproteins AND glycan structures many glycoproteins glycan structures Fterm glycoproteins Using this strategy, we have identified many glycoproteins containing glycan structures that are altered in cancer cells. 28501204 3 11 gly glycoprotein 509:520 arg1 glycoprotein glycoprotein N-Glycan macroheterogeneity Fterm glycoprotein N-Glycan macroheterogeneity is a physiological property of glycoprotein and the technical obstacles have restricted research into the regulation and functions of this heterogeneity. 10764840 0 49 gly N-glycosylation 8:22 arg1 a recombinant human erythropoietin a recombinant human erythropoietin PUBTATOR erythropoietin 2056 Unusual N-glycosylation of a recombinant human erythropoietin expressed in a human lymphoblastoid cell line does not alter its biological properties. 2110456 5 8 gly occupancy 765:773 arg2 at least one glycosylation site at least one glycosylation site site These studies demonstrate that occupancy of at least one glycosylation site is required for the formation and maintenance of acid beta-glucosidase in an active conformation. 2110456 5 44 gly glycosylation 791:803 arg2 at least one glycosylation site at least one glycosylation site site These studies demonstrate that occupancy of at least one glycosylation site is required for the formation and maintenance of acid beta-glucosidase in an active conformation. 28900186 5 53 gly N-glycosylated 1095:1108 arg1 N-glycosylated asparagine residues N-glycosylated asparagine residues asparagine residues However, for the first time, we show a unique cleavage specificity of flavastacin towards the C-terminus of N-glycosylated asparagine residues. 1988041 13 5 part_of serine-194 1954:1963 arg1 human milk BAL BAL serine-194 PUBTATOR SpecificSite BAL P19835 serine-194 These chemical studies established that the active site of human milk BAL is located at serine-194, the N-glycosylation site is present at asparagine-187, the O-glycosylation region is in the 16 repeating units near the C-terminus, and the heparin binding domain is in the N-terminal region. 1988041 13 104 part_of BAL 1936:1938 arg1 the active site BAL the active site PUBTATOR Site BAL P19835 site These chemical studies established that the active site of human milk BAL is located at serine-194, the N-glycosylation site is present at asparagine-187, the O-glycosylation region is in the 16 repeating units near the C-terminus, and the heparin binding domain is in the N-terminal region. 15616124 3 2 gly N-glycosylation 424:438 arg2 two N-glycosylation sites two N-glycosylation sites sites Human FVII has two N-glycosylation sites (N145 and N322). 15616124 3 43 gly sites 440:444 arg1 two N-glycosylation sites two N-glycosylation sites sites Human FVII has two N-glycosylation sites (N145 and N322). 15616124 3 2 gly N-glycosylation 424:438 arg2 N145 N145 and N322 N145 and N322 Human FVII has two N-glycosylation sites (N145 and N322). 15616124 3 43 gly sites 440:444 arg1 N322 N145 and N322 N145 and N322 Human FVII has two N-glycosylation sites (N145 and N322). 25451932 2 40 gly N-glycosylation 255:269 arg2 19 predicted N-glycosylation sites 19 predicted N-glycosylation sites sites Human corin has 19 predicted N-glycosylation sites in its extracellular domains. 22613618 9 80 gly containing 1376:1385 arg1 membrane proteins AND complex type N-glycans membrane proteins complex type N-glycans Fterm proteins The GlcNAc effect appears to apply mainly to membrane proteins containing complex type N-glycans. 27259237 10 44 part_of sites 1474:1478 arg1 brain proteins proteins sites Fterm Site proteins sites These data confirm that N-glycosylation is important in both physiological and pathological processes in the brain, and provide useful details about numerous N-glycosylation sites in brain proteins. 2780569 6 46 part_of subunit 1061:1067 arg1 the first two cysteines subunit the first two cysteines Fterm AminoAcid subunit cysteines A genomic clone was isolated and was found to contain sequences homologous to the exon including the first two cysteines (Cys-128 and -142) of AcChoR alpha subunit. 24325898 1 14 gly N-glycosylation 129:143 arg2 the conserved N-glycosylation site the conserved N-glycosylation site site Fine structural details of glycans attached to the conserved N-glycosylation site significantly not only affect function of individual immunoglobulin G (IgG) molecules but also mediate inflammation at the systemic level. 24325898 1 49 gly attached 103:110 arg1 the conserved N-glycosylation site AND glycans the conserved N-glycosylation site glycans site Fine structural details of glycans attached to the conserved N-glycosylation site significantly not only affect function of individual immunoglobulin G (IgG) molecules but also mediate inflammation at the systemic level. 21264968 4 72 part_of MUC4 1474:1477 arg1 naked MUC4 peptide MUC4 naked MUC4 peptide PUBTATOR Site MUC4 4585 peptide In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 127 part_of containing 1629:1638 arg1 densely glycosylated MUC4 AND Thr6 MUC4 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 PUBTATOR AminoAcid MUC4 4585 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 127 part_of containing 1629:1638 arg1 densely glycosylated MUC4 AND Ser2 MUC4 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 PUBTATOR AminoAcid MUC4 4585 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 127 part_of containing 1629:1638 arg1 densely glycosylated MUC4 AND Thr10 MUC4 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 PUBTATOR AminoAcid MUC4 4585 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 127 part_of containing 1629:1638 arg1 densely glycosylated MUC4 AND Thr15 MUC4 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 PUBTATOR AminoAcid MUC4 4585 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 127 part_of containing 1629:1638 arg1 densely glycosylated MUC4 AND Ser2 MUC4 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 PUBTATOR AminoAcid MUC4 4585 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 127 part_of containing 1629:1638 arg1 densely glycosylated MUC4 AND Thr10 MUC4 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 PUBTATOR AminoAcid MUC4 4585 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 127 part_of containing 1629:1638 arg1 densely glycosylated MUC4 AND Thr15 MUC4 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 PUBTATOR AminoAcid MUC4 4585 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 127 part_of containing 1629:1638 arg1 densely glycosylated MUC4 AND Thr10 MUC4 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 PUBTATOR AminoAcid MUC4 4585 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 127 part_of containing 1629:1638 arg1 densely glycosylated MUC4 AND Thr15 MUC4 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 PUBTATOR AminoAcid MUC4 4585 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 127 part_of containing 1629:1638 arg1 densely glycosylated MUC4 AND Thr15 MUC4 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 PUBTATOR AminoAcid MUC4 4585 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 9581553 6 1 part_of sites 995:999 arg1 FR-beta FR-beta sites PUBTATOR Site FR-beta 2350 sites Treatment with N-glycanase and analysis by Western blotting of the wild-type and mutant proteins revealed that all of the candidate sites in both FR-alpha and FR-beta are glycosylated. 9581553 6 1 part_of sites 995:999 arg1 FR-alpha FR-alpha sites PUBTATOR Site FR-alpha 79874 sites Treatment with N-glycanase and analysis by Western blotting of the wild-type and mutant proteins revealed that all of the candidate sites in both FR-alpha and FR-beta are glycosylated. 21526855 5 32 part_of MUC1 1001:1004 arg1 synthetic O-glycopeptides MUC1 synthetic O-glycopeptides PUBTATOR Site MUC1 281333 O-glycopeptides The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein. 10861210 5 51 gly N-glycosylation 756:770 arg2 the N-glycosylation site the N-glycosylation site site Moving the N-glycosylation site to the preceding extracellular loop in an AE1 glycosylation mutant (N555) resulted in processing of the oligosaccharide and production of a complex form of AE1. 11231274 2 60 gly glycoprotein 446:457 arg1 myelin-associated glycoprotein myelin-associated glycoprotein PUBTATOR myelin-associated glycoprotein P20916 In addition to the previously characterized siglecs, sialoadhesin, CD22, CD33 and myelin-associated glycoprotein, several new ones, siglec-5, siglec-7 and siglec-8, have recently been cloned. 7841203 3 26 gly glycosylation 497:509 arg2 a potential glycosylation site a potential glycosylation site site The porcine VEGF is shorter by one amino acid as compared to human VEGF, but a potential glycosylation site is present at Asn-74. 7841203 3 26 gly glycosylation 497:509 arg1 Asn-74 Asn-74 Asn-74 The porcine VEGF is shorter by one amino acid as compared to human VEGF, but a potential glycosylation site is present at Asn-74. 8189524 1 7 gly glycoproteins 119:131 arg1 Herpesvirus envelope glycoproteins Herpesvirus envelope glycoproteins Fterm glycoproteins Herpesvirus envelope glycoproteins play important roles in the interaction between virions and target cells. 12970363 7 86 gly monoglycosylated 1252:1267 arg1 the monoglycosylated TRPC3 channel the monoglycosylated TRPC3 channel PUBTATOR TRPC3 channel 7222 Immunoblotting analysis of HEK 293 cell lysates expressing TRPC6 wild type and mutants favors a model of TRPC6 that is dually glycosylated within the first (e1) and second extracellular loop (e2) as opposed to the monoglycosylated TRPC3 channel (Vannier, B., Zhu, X., Brown, D., and Birnbaumer, L. (1998) J. Biol. 23714211 10 39 gly glycosylation 1639:1651 arg1 ICAM-2 ICAM-2 PUBTATOR ICAM-2 3384 METHODS: Because it is well documented that glycosylation facilitates essential steps in tumor progression and metastasis, we investigated whether the glycosylation status of ICAM-2 affected the phenotype of NB cells. 19297464 6 69 gly glycosylation 1004:1016 arg2 either E1 glycosylation site either E1 glycosylation site site Elimination of either E1 glycosylation site had no effect on heparin binding but resulted in an approximately 10-fold decrease in virus yield from BHK cells compared to the TE12 amount. 17916798 4 36 gly glycopeptides 718:730 arg2 glycopeptides glycopeptides glycopeptides selective capturing of glycopeptides and -proteins was attained by means of magnetic particles specifically functionalized with lectins or boronic acids that bind to various structural motifs. 2574462 4 18 gly N-glycosylation 625:639 arg2 a utilized N-glycosylation site a utilized N-glycosylation site site One changes Arg-350 to serine, which leads to the loss of a utilized N-glycosylation site. 26013384 8 12 gly O-glycosylated 997:1010 arg1 fully O-glycosylated rHu-EPO fully O-glycosylated rHu-EPO PUBTATOR EPO 2056 It is concluded that the variant peak is non-O-glycosylated rHu-EPO and the main peak is fully O-glycosylated rHu-EPO at Ser126. 26013384 8 43 gly non-O-glycosylated 943:960 arg1 non-O-glycosylated rHu-EPO non-O-glycosylated rHu-EPO PUBTATOR EPO 2056 It is concluded that the variant peak is non-O-glycosylated rHu-EPO and the main peak is fully O-glycosylated rHu-EPO at Ser126. 8985413 1 39 gly glycosylation 332:344 arg2 potential glycosylation sites potential glycosylation sites sites Sequential mutations were introduced into the V2 region of human immunodeficiency virus (HIV) type 1 HXB2, affecting the length, charge, and number of potential glycosylation sites. 15811651 8 37 gly glycosylation 1300:1312 arg2 position 154 position 154 position 154 These data suggest that the glycan associated with the N-linked glycosylation site at position 154 in protein E plays an important role in VLP secretion. 15811651 8 37 gly glycosylation 1300:1312 arg2 the N-linked glycosylation site the N-linked glycosylation site site These data suggest that the glycan associated with the N-linked glycosylation site at position 154 in protein E plays an important role in VLP secretion. 27567024 2 29 gly glycosylated 308:319 arg1 asparagine 89 asparagine 89 asparagine 89 It is the only SOD isozyme that is secreted and glycosylated (at asparagine 89). 17707131 9 19 part_of AGPAT1 1740:1745 arg1 the catalytic domain AGPAT1 the catalytic domain PUBTATOR Site AGPAT1 10554 domain In addition, we examined substrate accessibility to the catalytic domain of human AGPAT1 using a competition assay. 9705240 0 4 part_of biotinidase 53:63 arg1 a putative glycosylation site biotinidase a putative glycosylation site PUBTATOR Site biotinidase 686 site Mutation in a putative glycosylation site (N489T) of biotinidase in the only known Japanese child with biotinidase deficiency. 25113421 0 32 gly glycopeptides 76:88 arg2 N-linked glycopeptides N-linked glycopeptides glycopeptides GlycoMaster DB: software to assist the automated identification of N-linked glycopeptides by tandem mass spectrometry. 11312284 5 53 part_of subunits 866:873 arg1 the first ACh binding site subunits the first ACh binding site Fterm Site subunits site Without previous reduction, 20% of the alpha subunits could be alkylated by bromoacetylcholine bromide as the first ACh binding site formed, which further indicated that the disulfide bond between cysteines 192 and 193 does not form until the first ACh binding site appears soon after Bgt binding site formation. 3896487 1 33 part_of glycoprotein 230:241 arg1 individual N-glycosylation sites glycoprotein individual N-glycosylation sites Fterm Site glycoprotein sites Glycopeptides containing individual N-glycosylation sites of the glycoprotein from Friend murine leukemia virus were isolated by digestion of the viral glycoprotein with protease of S. aureus (V8) or with trypsin followed by fractionation of the resulting (glyco)peptides by gel filtration and reversed-phase, high-performance liquid chromatography at pH 6. 20923142 6 58 gly glycoproteins 1449:1461 arg1 the glycoproteins the glycoproteins Fterm glycoproteins Further quantitation of nonglycosylated peptides revealed that sialylation is increased in most of the glycoproteins, whereas the protein concentrations remain unchanged. 20923142 6 71 gly nonglycosylated 1370:1384 arg1 nonglycosylated peptides nonglycosylated peptides peptides Further quantitation of nonglycosylated peptides revealed that sialylation is increased in most of the glycoproteins, whereas the protein concentrations remain unchanged. 20923142 6 73 gly sialylation 1409:1419 arg1 the glycoproteins the glycoproteins Fterm glycoproteins Further quantitation of nonglycosylated peptides revealed that sialylation is increased in most of the glycoproteins, whereas the protein concentrations remain unchanged. 1906892 4 41 part_of DNA 529:531 arg1 the generated DNA fragments DNA the generated DNA fragments Cterm Site DNA fragments Genomic DNA from a Japanese male exhibiting TBG-CD was subjected to polymerase chain reaction, and the generated DNA fragments were sequenced. 18815311 3 37 gly glycoprotein 647:658 arg1 NiV glycoprotein NiV glycoprotein Fterm glycoprotein Here we present the structural analysis of the protein and carbohydrate components of the unbound viral attachment glycoprotein of NiV glycoprotein (NiV-G) at a 2.2-A resolution. 18815311 3 87 gly glycoprotein 627:638 arg1 the unbound viral attachment glycoprotein glycoprotein the protein and carbohydrate components Fterm glycoprotein Here we present the structural analysis of the protein and carbohydrate components of the unbound viral attachment glycoprotein of NiV glycoprotein (NiV-G) at a 2.2-A resolution. 8543840 3 78 part_of proteins 310:317 arg1 The extracellular domains env proteins The extracellular domains PUBTATOR Site env proteins 100616444 domains The extracellular domains of env proteins are not present in the cytosol, the site where the class I Ag processing pathway begins. 2538306 3 8 gly Thr-39 811:816 arg1 an O-linked carbohydrate chain Thr-39 an O-linked carbohydrate chain Thr-39 We have previously detected an O-linked carbohydrate chain at Thr-39 in preparations of secreted free alpha-subunit, but not dimer CG alpha from JAR culture medium. 31924694 9 75 gly N-glycosylation 1857:1871 arg1 proteins proteins Fterm proteins Both lectin blotting experiments as well as transcript expression analyses with complete insects and insect tissues confirmed the observed differences in N-glycosylation of proteins between sexes. 28931684 13 90 gly glycan 2477:2482 arg1 the E protein protein glycan Fterm protein To elucidate the functional significance of glycosylation in ZIKV pathogenicity, recombinant ZIKVs from infectious clones with or without the glycan on the E protein were generated. 8941718 7 76 gly deglycosylation 1238:1252 arg1 normal LAL normal LAL PUBTATOR LAL 3988 Furthermore, deglycosylation of normal LAL reduced the acid hydrolase activity towards both tri-oleyl glycerol and cholesteryl oleate by 50%, strongly suggesting that N-linked carbohydrate residues are important for optimal catalytic activity. 12147690 2 15 part_of CK2-sensitive 400:412 arg1 CK2-sensitive sites CK2 CK2-sensitive sites OGER Site CK2 sites During transit through the secretory pathway, it undergoes an as yet uncharacterized glycosylation and acquires phosphate on CK2-sensitive sites. 16343462 1 7 gly glycosylation 205:217 arg2 more than one glycosylation site more than one glycosylation site site Naturally occurring glycopeptides and glycoproteins usually contain more than one glycosylation site, and the structure of the carbohydrate attached is often different from site to site. 16343462 1 40 gly glycopeptides 143:155 arg2 Naturally occurring glycopeptides Naturally occurring glycopeptides glycopeptides Naturally occurring glycopeptides and glycoproteins usually contain more than one glycosylation site, and the structure of the carbohydrate attached is often different from site to site. 16343462 1 47 gly glycoproteins 161:173 arg1 glycoproteins glycoproteins Fterm glycoproteins Naturally occurring glycopeptides and glycoproteins usually contain more than one glycosylation site, and the structure of the carbohydrate attached is often different from site to site. 23562646 12 23 gly N-glycosylation 2122:2136 arg2 single or multiple N-glycosylation site mutations single or multiple N-glycosylation site mutations site Finally, we demonstrated that single or multiple N-glycosylation site mutations inhibited fusion at the earliest stages. 12097564 12 33 part_of receptor-binding 2118:2133 arg1 the receptor-binding site receptor the receptor-binding site Fterm Site receptor site Thus, anti-ASLV-SU-A mc8C5-4 proves to be a unique new immunoreagent that targets the receptor-binding site on a prototypical retroviral envelope. 29285644 9 40 gly glycopeptides 1505:1517 arg2 Three glycopeptides Three glycopeptides glycopeptides Three glycopeptides exhibited exceptionally high control-to-cancer fold changes along with receiver operating characteristic curve areas of 1.0, indicating perfect discrimination between the two groups. 28931684 4 42 part_of protein 916:922 arg1 this sequence motif protein this sequence motif Fterm Site protein motif In the present study, we interrogated the role of this sequence motif and glycosylation of the E protein in pathogenicity of ZIKV. 7510285 7 57 gly glycosylation 1003:1015 arg2 one possible N-linked glycosylation site one possible N-linked glycosylation site site Each of these hydrophobic domains is separated by a hydrophilic domain, the longest of which contains one possible N-linked glycosylation site and is located between the third and fourth hydrophobic domains. 12662294 9 57 gly N-glycosylation 1107:1121 arg2 the N-glycosylation site site, position 32 site, position 32 Monosaccharide compositional analysis of the threonine-containing peptide revealed an oligosaccharide in the N-glycosylation site, position 32-34. 30708139 3 69 gly glycosylation 557:569 arg2 new N-linked glycosylation sites new N-linked glycosylation sites sites In this study, human luteinizing hormone (LH) was considered for identification of the suitable positions for the addition of new N-linked glycosylation sites. 2747653 4 54 part_of albumin 847:853 arg1 the leader peptide albumin the leader peptide PUBTATOR Site albumin 24186 peptide The derived amino acid sequence yields a 24-amino acid hydrophobic leader sequence (terminating in Lys-Arg) that shares significant homology with the leader peptide of rat albumin. 11292534 6 71 gly N-glycosylation 1017:1031 arg2 a potential N-glycosylation site a potential N-glycosylation site site The hexapeptide motif (MYPPPY), five cysteine residues, a potential N-glycosylation site and a cytoplasmic phosphatidylinositol 3-kinase binding site in canine CD28 molecule are completely conserved in canine CTLA-4. 7841203 0 2 part_of factor 78:83 arg1 Nucleotide sequence vascular endothelial growth factor Nucleotide sequence PUBTATOR Site vascular endothelial growth factor 7422 sequence Nucleotide sequence and expression of the porcine vascular endothelial growth factor. 17001080 11 31 gly glycosylation 1599:1611 arg2 the N-linked glycosylation sites the N-linked glycosylation sites sites The location of the N-linked glycosylation sites on a virion determines the types of glycans incorporated, thus controlling viral tropism for CD209-expressing cells. 24884609 4 34 gly glycopeptide 575:586 arg2 glycopeptide analyses glycopeptide analyses glycopeptide Recombinant ITIH4 was analyzed to optimize glycopeptide analyses, followed by serum-derived ITIH4. 18295294 4 8 part_of nsp4 554:557 arg1 nsp4 glycosylation site N176 nsp4 nsp4 glycosylation site N176 PUBTATOR SpecificSite nsp4 400668 site N176 We used reverse genetics to generate infectious clone viruses (icv) with an alanine substitution at nsp4 glycosylation site N176 or N237, or an asparagine to threonine substitution (nsp4-N258T), which is proposed to confer a temperature sensitive phenotype. 18295294 4 18 part_of site 573:576 arg1 nsp4-N258T nsp4 site PUBTATOR SpecificSite nsp4 400668 site N176 We used reverse genetics to generate infectious clone viruses (icv) with an alanine substitution at nsp4 glycosylation site N176 or N237, or an asparagine to threonine substitution (nsp4-N258T), which is proposed to confer a temperature sensitive phenotype. 18295294 4 50 part_of N237 586:589 arg1 nsp4-N258T nsp4 N237 PUBTATOR SpecificSite nsp4 400668 N237 We used reverse genetics to generate infectious clone viruses (icv) with an alanine substitution at nsp4 glycosylation site N176 or N237, or an asparagine to threonine substitution (nsp4-N258T), which is proposed to confer a temperature sensitive phenotype. 15628971 5 16 part_of C4ST-1 827:832 arg1 the C-terminal region C4ST-1 the C-terminal region PUBTATOR Site C4ST-1 314694 region We found that (i) treatment of recombinant C4ST-1 with peptide N-glycosidase F caused a marked decrease in activity, (ii) production of the active form of C4ST-1 by COS-7 cells transfected with cDNA of C4ST-1 was inhibited by tunicamycin, (iii) deletion of the N-glycosylation site located at the C-terminal region of C4ST-1 abolished activity, (iv) attachment of a single N-glycan at the C-terminal region supported production of the active form of C4ST-1, but the resulting recombinant enzyme was much more unstable at 37 degrees C than the control recombinant protein, and (v) truncation of C-terminal region up to the N-glycosylation site at the C-terminal region resulted in total loss of activity. 15628971 5 18 part_of region 1170:1175 arg1 the N-glycosylation site region the N-glycosylation site site We found that (i) treatment of recombinant C4ST-1 with peptide N-glycosidase F caused a marked decrease in activity, (ii) production of the active form of C4ST-1 by COS-7 cells transfected with cDNA of C4ST-1 was inhibited by tunicamycin, (iii) deletion of the N-glycosylation site located at the C-terminal region of C4ST-1 abolished activity, (iv) attachment of a single N-glycan at the C-terminal region supported production of the active form of C4ST-1, but the resulting recombinant enzyme was much more unstable at 37 degrees C than the control recombinant protein, and (v) truncation of C-terminal region up to the N-glycosylation site at the C-terminal region resulted in total loss of activity. 18642129 0 75 gly VII 93:95 arg1 O-glycans coagulation factor VII O-glycans OGER coagulation factor VII P08709 Mass spectrometric characterization of N- and O-glycans of plasma-derived coagulation factor VII. 18642129 0 75 gly VII 93:95 arg1 N- coagulation factor VII N- OGER coagulation factor VII P08709 Mass spectrometric characterization of N- and O-glycans of plasma-derived coagulation factor VII. 24280012 7 58 part_of IL-17A 804:809 arg1 human IL-17A sequences IL-17A human IL-17A sequences PUBTATOR Site IL-17A 3605 sequences The amino acid sequence showed 95.9%, 84.6%, 45.0% and 38.4% similarity with the corresponding duck, chicken, rat, and human IL-17A sequences, respectively. 18952059 2 4 part_of domain 183:188 arg1 a conserved glycosylation site domain a conserved glycosylation site site It contains one immunoglobulin-like domain with a conserved glycosylation site within. 26773038 6 9 gly site 971:974 arg1 GlcNAc site GlcNAc site The essential component of the glycan structure is the first sugar residue (GlcNAc) at the N1574 attachment site. 26773038 6 9 gly site 971:974 arg1 the first sugar residue site the first sugar residue site The essential component of the glycan structure is the first sugar residue (GlcNAc) at the N1574 attachment site. 8749323 9 5 part_of TM 1315:1316 arg1 the D3 domain TM the D3 domain PUBTATOR Site TM 7056 domain This finding suggested that the D3 domain of TM plays an important role in stabilizing TM in vivo. 8157687 0 28 gly glycoprotein 163:174 arg1 complement glycoprotein C3 complement glycoprotein C3 Fterm glycoprotein Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type. 8157687 0 35 gly glycoproteins 112:124 arg1 glycoproteins glycoproteins Fterm glycoproteins Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type. 8157687 0 70 gly glycoprotein 399:410 arg1 the complement glycoprotein iC3b the complement glycoprotein iC3b Fterm glycoprotein Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type. 8157687 0 90 gly contains 424:431 arg1 the complement glycoprotein iC3b AND oligosaccharides the complement glycoprotein iC3b oligosaccharides Cterm iC3b Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type. 8157687 0 63 gly have 262:265 arg1 mannan-binding protein AND similar carbohydrate binding specificities mannan-binding protein similar carbohydrate binding specificities OGER mannan-binding protein P11226 Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type. 8157687 0 63 gly have 262:265 arg1 serum proteins AND similar carbohydrate binding specificities serum proteins similar carbohydrate binding specificities Fterm proteins Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type. 8019599 6 62 gly unglycosylated 789:802 arg1 either glycosylated or unglycosylated b3 either glycosylated or unglycosylated b3 Cterm b3 443978 The co-expression of GPA with either glycosylated or unglycosylated b3 increased the stilbene disulphonate-sensitive chloride transport into oocytes at low cRNA concentrations. 8019599 6 64 gly glycosylated 773:784 arg1 either glycosylated or unglycosylated b3 either glycosylated or unglycosylated b3 Cterm b3 443978 The co-expression of GPA with either glycosylated or unglycosylated b3 increased the stilbene disulphonate-sensitive chloride transport into oocytes at low cRNA concentrations. 8325864 1 53 gly occupancy 50:58 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. 24246999 2 27 part_of subunits 349:356 arg1 the extracellular domains subunits the extracellular domains Fterm Site subunits domains We created mutants of the extracellular domains (ECDs) of the human α1, β1, δ and ε AChR subunits, whereby their Cys-loop was exchanged for that of the acetylcholine binding protein. 11961269 0 18 part_of haemagglutinin 96:109 arg1 the globular head haemagglutinin the globular head Fterm Site haemagglutinin head Effect of addition of new oligosaccharide chains to the globular head of influenza A/H2N2 virus haemagglutinin on the intracellular transport and biological activities of the molecule. 23178744 3 21 gly N-glycosylation 622:636 arg2 an N-glycosylation site an N-glycosylation site site Recently we have developed monoclonal antibodies which recognise only the intact exposed elastase loop, including an N-glycosylation site, which, in concert with another monoclonal antibody to CBG, offered the potential for the determination of intact and total CBG which may both be present in circulation. 16415006 6 43 gly glycoproteins 1043:1055 arg1 the WNV envelope glycoproteins the WNV envelope glycoproteins Fterm glycoproteins Preferential utilization of DC-SIGNR was a specific property conferred by the WNV envelope glycoproteins. 27234584 7 3 gly B/MMP-9 1265:1271 arg1 N- MMP-9 N- OGER MMP-9 P14780 Validated glycobiological data on N- and O-linked oligosaccharides of gelatinase B/MMP-9 and on O-linked structures of membrane-type 1 MMP/MMP-14 indicate that in-depth research of other MMPs may yield important insights, e.g. about subcellular localizations and functions within macromolecular complexes. 27234584 7 56 gly MMP/MMP-14 1319:1328 arg1 O-linked structures MMP-14 O-linked structures OGER MMP-14 P50281 Validated glycobiological data on N- and O-linked oligosaccharides of gelatinase B/MMP-9 and on O-linked structures of membrane-type 1 MMP/MMP-14 indicate that in-depth research of other MMPs may yield important insights, e.g. about subcellular localizations and functions within macromolecular complexes. 8542022 3 4 gly glycoprotein 357:368 arg1 membrane glycoprotein membrane glycoprotein Fterm glycoprotein Molecular cloning established that Kell antigens are carried on a 93kDa, type II, membrane glycoprotein. 16300986 4 31 gly glycosylation 520:532 arg2 a potential glycosylation site a potential glycosylation site site In the present study, viruses were found to lose a potential glycosylation site near the receptor-binding pocket of hemagglutinin (HA), at the same time as they acquired the high-growth property. 26085161 10 14 gly glycosylation 1580:1592 arg2 all glycosylation sites all glycosylation sites sites Consistently, mutation of all glycosylation sites of a BLV provirus destroys infectivity in vivo. 18579437 10 16 gly glycosylation 1227:1239 arg2 A potential new glycosylation site A potential new glycosylation site site A potential new glycosylation site in HN, in addition to minor changes observed in the predicted structure for the variant strains could explain their antigenic variation. 30213862 0 43 gly CD16a 0:4 arg1 oligomannose-type N-glycans CD16a oligomannose-type N-glycans PUBTATOR CD16a 2214 CD16a with oligomannose-type N-glycans is the only "low affinity" Fc γ receptor that binds the IgG crystallizable fragment with high affinity in vitro. 19748988 8 77 gly glycosylation 1424:1436 arg2 the glycosylation site the glycosylation site site The importance of N-linked carbohydrates was demonstrated by the failure of the CHIR-AB1 interaction after mutation of the glycosylation site. 9342662 7 64 gly sialylated 1427:1436 arg1 sialylated forms sialylated forms CE conditions were optimized to allow the MS identification of sialylated forms. 10497235 9 50 gly glycosylation 1196:1208 arg1 triadin 1 triadin site OGER triadin Q13061 site The glycosylation site of triadin 1 was localized to asparagine residue 75, and its bitopic arrangement in the membrane was confirmed. 3455414 2 4 part_of kinase 276:281 arg1 the kinase domain kinase the kinase domain Fterm Site kinase domain v-ros sequence of UR2 avian sarcoma virus carries a hydrophobic short stretch upstream of the kinase domain, suggesting that its proto-oncogene encodes for a receptor molecule. 3455414 2 85 part_of v-ros 182:186 arg1 v-ros sequence ros v-ros sequence OGER Site ros Q63132 sequence v-ros sequence of UR2 avian sarcoma virus carries a hydrophobic short stretch upstream of the kinase domain, suggesting that its proto-oncogene encodes for a receptor molecule. 31501225 3 66 gly glycoproteins 426:438 arg1 serum glycoproteins serum glycoproteins Fterm glycoproteins Here, unbiased quantification of N-glycopeptides of a cluster of serum glycoproteins with 40-55 kDa molecular weight (40-kDa band) was investigated in hepatitis B virus (HBV)-related liver diseases. 31501225 3 73 gly N-glycopeptides 388:402 arg2 N-glycopeptides N-glycopeptides N-glycopeptides Here, unbiased quantification of N-glycopeptides of a cluster of serum glycoproteins with 40-55 kDa molecular weight (40-kDa band) was investigated in hepatitis B virus (HBV)-related liver diseases. 9401066 0 75 gly glycosylated 56:67 arg1 a new glycosylated fibrinogen variant a new glycosylated fibrinogen variant PUBTATOR fibrinogen variant 2244 Fibrinogen Kaiserslautern (gamma 380 Lys to Asn): a new glycosylated fibrinogen variant with delayed polymerization. 2328698 3 36 gly nonglycosylated 421:435 arg1 a nonsecreted nonglycosylated rPLP-B protein a nonsecreted nonglycosylated rPLP-B protein PUBTATOR rPLP-B protein 24657 The mol wt of a nonsecreted nonglycosylated rPLP-B protein would be 27,145 based on the mRNA sequence. 11683378 13 81 gly glycosylation 2111:2123 arg2 the first Thr the first Thr Thr Verification of the DC-PCR product by sequencing reveals that the T560 and B10.A IgA (Ig2b allotype) hinge is different from the BALB/c IgA (Ig2a allotype) hinge: it has two extra Cys and has eliminated the first Thr, a potential glycosylation site in BALB/c IgA. 11683378 13 81 gly glycosylation 2111:2123 arg2 a potential glycosylation site a potential glycosylation site site Verification of the DC-PCR product by sequencing reveals that the T560 and B10.A IgA (Ig2b allotype) hinge is different from the BALB/c IgA (Ig2a allotype) hinge: it has two extra Cys and has eliminated the first Thr, a potential glycosylation site in BALB/c IgA. 15863355 2 40 gly Asn-linked 372:381 arg1 N-glycans Asn N-glycans Asn In a number of pathophysiological states, including inflammation, rheumatoid arthritis, and cancer, alterations of Asn-linked glycans (N-glycans) have been reported. 15863355 2 40 gly Asn-linked 372:381 arg1 Asn-linked glycans Asn Asn-linked glycans Asn In a number of pathophysiological states, including inflammation, rheumatoid arthritis, and cancer, alterations of Asn-linked glycans (N-glycans) have been reported. 1899031 2 35 part_of site 885:888 arg1 HPg HPg site Cterm Site HPg 5340 site Employing high-performance anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the protein by glycopeptidase F, compared with elution positions of standard oligosaccharides, coupled with monosaccharide compositional determinations and analyses of sequential exoglycosidase digestions and specific lectin binding, we find that considerable microheterogeneity in oligosaccharide structure exists at this sole potential N-linked glycosylation site on HPg. 27127844 4 2 part_of has 440:442 arg1 The subunit AND conserved, predicted N-glycosylation sites The subunit conserved, predicted N-glycosylation sites Fterm Site subunit sites The subunit has conserved, predicted N-glycosylation sites, and the a3 isoform has been directly shown to be N-glycosylated. 18369607 7 25 gly site 1452:1455 arg1 core-fucosylated, biantennary, complex-type structures site, Asn-292 core-fucosylated, biantennary, complex-type structures site, Asn-292 Furthermore, the major glycoforms at the conserved heavy chain N-glycosylation site, Asn-292, were determined to be core-fucosylated, biantennary, complex-type structures containing zero to two galactose residues. 18369607 7 90 gly core-fucosylated 1489:1504 arg1 core-fucosylated, biantennary, complex-type structures core-fucosylated, biantennary, complex-type structures Furthermore, the major glycoforms at the conserved heavy chain N-glycosylation site, Asn-292, were determined to be core-fucosylated, biantennary, complex-type structures containing zero to two galactose residues. 18369607 7 14 gly glycoforms 1396:1405 arg2 the conserved heavy chain N-glycosylation site site, Asn-292 site, Asn-292 Furthermore, the major glycoforms at the conserved heavy chain N-glycosylation site, Asn-292, were determined to be core-fucosylated, biantennary, complex-type structures containing zero to two galactose residues. 18369607 7 99 gly N-glycosylation 1436:1450 arg2 the conserved heavy chain N-glycosylation site site, Asn-292 site, Asn-292 Furthermore, the major glycoforms at the conserved heavy chain N-glycosylation site, Asn-292, were determined to be core-fucosylated, biantennary, complex-type structures containing zero to two galactose residues. 27480293 1 19 gly N-Glycosylation 108:122 arg1 proteins proteins Fterm proteins N-Glycosylation of proteins plays a critical role in many biological pathways. 9259114 5 22 part_of beta 535:538 arg1 the genomic sequence GPIb beta the genomic sequence PUBTATOR Site GPIb beta 14724 sequence To obtain further information of GPIb beta, we have determined the genomic sequence of mouse GPIb beta (1466 bp). 32109505 0 81 gly N-glycosylation 0:14 arg1 TRPM8 protein TRPM8 protein PUBTATOR TRPM8 protein 79054 N-glycosylation state of TRPM8 protein revealed by terahertz spectroscopy and molecular modelling. 17899080 0 37 part_of protein 108:114 arg1 the N terminus protein the N terminus Fterm Site protein terminus Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. 17899080 0 45 part_of terminus 92:99 arg1 a glycosylation site terminus a glycosylation site site Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. 18464039 6 7 part_of DGAT1 717:721 arg1 the derived DGAT1 protein sequences DGAT1 the derived DGAT1 protein sequences PUBTATOR Site DGAT1 O75907 sequences Phylogenetic tree constructed from the derived DGAT1 protein sequences of 15 different species illustrated a unique branches for mammals, fly, nematode and plants. 16938437 4 24 gly glycosylation 782:794 arg2 these glycosylation sites these glycosylation sites sites The importance of these glycosylation sites is not fully understood. 17916798 9 62 gly glycosylation 1900:1912 arg2 predicted glycosylation sites predicted glycosylation sites sites By means of fast and simple glycospecific capturing applied in conjunction with extensive LC-MALDI-MS/MS analysis and novel data analysis tools, a high number of low-abundant proteins were identified, comprising known or predicted glycosylation sites. 23319596 9 8 part_of hLOX 1454:1457 arg1 The catalytic domain hLOX The catalytic domain PUBTATOR Site hLOX 4015 domain The catalytic domain of hLOX was not secreted from S2 cells using the same expression system. 19822741 7 16 gly glycosylation 1216:1228 arg2 each glycosylation site each glycosylation site site Antibodies raised against HA protein bearing only a single N-linked GlcNAc at each glycosylation site showed better binding affinity and neutralization activity against influenza subtypes than the fully glycosylated HAs elicited. 8626443 3 39 gly unglycosylated 510:523 arg1 unglycosylated ACET unglycosylated ACET Cterm ACET Similarly, unglycosylated ACET synthesized in HeLa cells, by using a cDNA in which all five potential N-glycosylation sites had been mutated, was inactive and rapidly degraded. 8626443 3 43 gly N-glycosylation 601:615 arg2 all five potential N-glycosylation sites all five potential N-glycosylation sites sites Similarly, unglycosylated ACET synthesized in HeLa cells, by using a cDNA in which all five potential N-glycosylation sites had been mutated, was inactive and rapidly degraded. 15113920 9 81 gly glycoprotein 1470:1481 arg1 HTNV glycoprotein folding HTNV glycoprotein folding Fterm glycoprotein The endoplasmic reticulum chaperones calnexin and calreticulin were found to be involved in HTNV glycoprotein folding. 7532209 8 80 gly N-glycosylation 1727:1741 arg1 GluR alpha 2 subunit protein GluR alpha 2 subunit protein Fterm protein Possible roles of N-glycosylation of GluR alpha 2 subunit protein are discussed. 27095603 5 9 gly glycopeptides 783:795 arg2 glycopeptides glycopeptides glycopeptides MS of glycopeptides reveals the presence of immature glycoforms even in healthy individuals, indicating that the diagnosis of CDG based on molecular phenotypes requires quantitative evaluation. 1697592 2 126 part_of protein 447:453 arg1 the NH2-terminal amino acid sequence protein the NH2-terminal amino acid sequence Fterm Site protein sequence The cDNA encoded a protein of 509 amino acids, and a comparison of the deduced amino acid sequence with the NH2-terminal amino acid sequence of the purified protein indicates that an 18-residue NH2-terminal signal sequence was removed during synthesis. 16720579 0 73 gly oligosaccharides 9:24 arg1 chondroitin 6-sulfotransferase-1 chondroitin 6-sulfotransferase oligosaccharides OGER chondroitin 6-sulfotransferase Q7LGC8 N-linked oligosaccharides on chondroitin 6-sulfotransferase-1 are required for production of the active enzyme, Golgi localization, and sulfotransferase activity toward keratan sulfate. 30042931 2 35 gly glycosylation 440:452 arg2 two glycosylation sites two glycosylation sites sites JEV E protein has one N-linked glycosylation site at N154 (G2 site), but the related dengue virus E protein has two glycosylation sites at N67 (G1 site) and N153 (G2 site). 30042931 2 85 gly glycosylation 355:367 arg2 one N-linked glycosylation site one N-linked glycosylation site site JEV E protein has one N-linked glycosylation site at N154 (G2 site), but the related dengue virus E protein has two glycosylation sites at N67 (G1 site) and N153 (G2 site). 1385399 3 67 gly attached 476:483 arg2 Asn65 AND the N-linked glycans Asn65 the N-linked glycans Asn65 We have defined an important role for the N-linked glycans attached to Asn65 of this domain in mediating CD2-CD58 interactions and also characterize its N-glycotype structure. 30944176 4 33 gly glycosylation 567:579 arg2 this glycosylation site this glycosylation site site All contemporary ZIKV isolates encode an N-linked glycosylation site in the envelope (E) protein (N154), but this glycosylation site is absent in many historical ZIKV isolates. 30944176 4 63 gly glycosylation 503:515 arg2 an N-linked glycosylation site an N-linked glycosylation site site All contemporary ZIKV isolates encode an N-linked glycosylation site in the envelope (E) protein (N154), but this glycosylation site is absent in many historical ZIKV isolates. 15590981 7 22 gly N-glycosylation 1178:1192 arg2 one unique seventh N-glycosylation site one unique seventh N-glycosylation site site The mature eLH/CG-R displayed 88.2-92.8% overall sequence homology with the other mammalian LH/CG-Rs and contained one unique seventh N-glycosylation site in its extracellular domain. 23891555 16 99 gly O-glycopeptides 2292:2306 arg2 O-glycopeptides O-glycopeptides O-glycopeptides O-glycopeptides were separated from the digest on capillary columns using a microgradient chromatographic device (replacing commonly used liquid chromatographs) and subjected to MALDI-TOF/TOF mass spectrometry (MS) and tandem mass spectrometry (MS/MS) involving post-source decay fragmentation. 7841203 2 16 part_of VEGF 326:329 arg1 164 (VEGF164), and 120 (VEGF120) residues VEGF 164 (VEGF164), and 120 (VEGF120) residues PUBTATOR Site VEGF 7422 residues Deduced amino acid sequence of the clone pPVE-18 and pPVE-5 predicted 164 (VEGF164), and 120 (VEGF120) residues of VEGF, respectively, with a putative N-terminal signal sequence of 26 amino acids. 7628611 0 35 part_of protein 32:38 arg1 a functional glycosylation site protein a functional glycosylation site Fterm Site protein site Asn-265 of frog kainate binding protein is a functional glycosylation site: implications for the transmembrane topology of glutamate receptors. 7628611 0 35 part_of protein 32:38 arg1 Asn-265 protein Asn-265 Fterm SpecificSite protein Asn-265 Asn-265 of frog kainate binding protein is a functional glycosylation site: implications for the transmembrane topology of glutamate receptors. 11251288 1 79 gly glycoprotein 152:163 arg1 A natural glycoprotein A natural glycoprotein Fterm glycoprotein BACKGROUND: A natural glycoprotein usually exists as a spectrum of glycosylated forms, where each protein molecule may be associated with an array of oligosaccharide structures. 31498587 3 24 part_of MUC1 434:437 arg1 MUC1 glycopeptides SAPDT*RPAP (T* is the glycosylation site) MUC1 MUC1 glycopeptides SAPDT*RPAP (T* is the glycosylation site) PUBTATOR Site MUC1 17829 glycopeptides In order to target these antigens as potential anticancer vaccines, MUC1 glycopeptides SAPDT*RPAP (T* is the glycosylation site) bearing the Tf and the STn antigen, respectively, have been synthesized. 21439032 2 11 gly glycoproteins 262:274 arg1 The two membrane glycoproteins The two membrane glycoproteins Fterm glycoproteins The two membrane glycoproteins of JEV, prM and E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively. 21439032 2 47 gly glycosylation 329:341 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site The two membrane glycoproteins of JEV, prM and E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively. 21439032 2 67 gly positions 352:360 arg1 positions N15 and N154 positions N15 and N154 positions N15 and N154 The two membrane glycoproteins of JEV, prM and E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively. 21439032 2 67 gly positions 352:360 arg1 N154 positions N15 and N154 positions N15 and N154 The two membrane glycoproteins of JEV, prM and E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively. 21439032 2 67 gly positions 352:360 arg1 N154 positions N15 and N154 positions N15 and N154 The two membrane glycoproteins of JEV, prM and E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively. 19961828 2 26 gly sialylated 264:273 arg1 sialylated N-glycans sialylated N-glycans Here, we show that sialylated N-glycans uniquely impact gating of a mammalian Shaker family K(v) channel isoform, K(v)1.5, but have no effect on gating of a second Shaker isoform, K(v)1.4. 26400346 4 25 part_of 270-amino-acid 631:644 arg1 a 270-amino-acid polypeptide 270-amino-acid a 270-amino-acid polypeptide Cterm Site 270-amino-acid polypeptide The cloned FGF5 cDNA was 813 base pairs (KM596772), including an open reading frame encoding a 270-amino-acid polypeptide. 8073042 2 48 gly glycosylation 375:387 arg2 the N-linked glycosylation site the N-linked glycosylation site site We have also expressed a mutant form of kringle IV type 2 in which the N-linked glycosylation site has been removed by replacement of an asparagine residue with an alanine. 16823988 3 2 gly sialylated 567:576 arg1 sialylated glycoproteins sialylated glycoproteins Fterm glycoproteins In this work, we use three different lectins (Wheat Germ Agglutinin, (WGA) Elderberry lectin,(SNA), Maackia amurensis lectin, (MAL)) to extract sialylated glycoproteins from normal and cancer serum. 16823988 3 48 gly glycoproteins 578:590 arg1 sialylated glycoproteins sialylated glycoproteins Fterm glycoproteins In this work, we use three different lectins (Wheat Germ Agglutinin, (WGA) Elderberry lectin,(SNA), Maackia amurensis lectin, (MAL)) to extract sialylated glycoproteins from normal and cancer serum. 16689758 1 34 gly N-glycosylation 119:133 arg2 the variable region the variable region region BACKGROUND: N-glycosylation occurs in the variable region of about 10% of antibodies but the role of carbohydrate at this location is still poorly understood. 1414488 5 26 part_of region 893:898 arg1 the C terminus region the C terminus terminus The N-terminal amino acid region of pBk2.1 (the first 82 amino acids) and 42 amino acids at the C terminus had the highest level of homology with the osteopontins at 86%. 1414488 5 67 part_of terminus 965:972 arg1 The N-terminal amino acid region terminus The N-terminal amino acid region region The N-terminal amino acid region of pBk2.1 (the first 82 amino acids) and 42 amino acids at the C terminus had the highest level of homology with the osteopontins at 86%. 30359034 5 51 gly glycoproteins 594:606 arg1 intact glycoproteins intact glycoproteins Fterm glycoproteins Glycoproteomics technologies aimed at obtaining a comprehensive understanding of intact glycoproteins, i.e., the kind of glycan structures that are attached to particular amino acids and proteins, have been developed. 30359034 5 67 gly attached 654:661 arg1 proteins AND glycan structures proteins glycan structures Fterm proteins Glycoproteomics technologies aimed at obtaining a comprehensive understanding of intact glycoproteins, i.e., the kind of glycan structures that are attached to particular amino acids and proteins, have been developed. 7755594 7 16 gly Unglycosylated 1073:1086 arg1 Unglycosylated recombinant IFN-gamma proteins Unglycosylated recombinant IFN-gamma proteins PUBTATOR IFN-gamma proteins 25712 Unglycosylated recombinant IFN-gamma proteins (from Escherichia coli and baculovirus) and N25Q IFN-gamma were sensitive to crude granulocyte protease, purified elastase, cathepsin G and plasmin degradation. 12527193 8 52 gly N-glycosylation 1258:1272 arg2 a conserved N-glycosylation site a conserved N-glycosylation site site Mouse and human CRB3 have identical intracellular domains but divergent extracellular domains except for a conserved N-glycosylation site. 12696120 0 27 part_of Hemagglutinin-neuraminidase 0:26 arg1 Hemagglutinin-neuraminidase sequence Hemagglutinin-neuraminidase Hemagglutinin-neuraminidase sequence PUBTATOR Site Hemagglutinin-neuraminidase 1489765 sequence Hemagglutinin-neuraminidase sequence and phylogenetic analyses of mumps virus isolates from a vaccinated population in Singapore. 12223479 7 83 gly deglycosylation 1018:1032 arg1 the N-linked glycosylation residues the N-linked glycosylation residues residues in Enzymatic deglycosylation or mutation of the N-linked glycosylation residues in beta4 converts it to a single lower molecular weight band, even in the presence of the hSlo alpha subunit, suggesting that the beta4 subunit can be present as an immature, core glycosylated form and a mature, highly glycosylated form. 12223479 7 88 gly residues 1076:1083 arg1 beta4 beta4 residues PUBTATOR beta4 10717 Enzymatic deglycosylation or mutation of the N-linked glycosylation residues in beta4 converts it to a single lower molecular weight band, even in the presence of the hSlo alpha subunit, suggesting that the beta4 subunit can be present as an immature, core glycosylated form and a mature, highly glycosylated form. 28947017 9 42 part_of AAT 1170:1172 arg1 position 83 AAT position 83 PUBTATOR Site AAT P01009 position 83 This mutation abolishes the N-glycosylation site in position 83 of the mature AAT. 17134389 3 27 gly glycoproteins 555:567 arg1 repeatedly administered glycoproteins repeatedly administered glycoproteins Fterm glycoproteins For treatments requiring large quantities of repeatedly administered glycoproteins, the immunological properties of these non-mammalian glycans are a concern. 29190644 1 0 gly glycoprotein 185:196 arg1 Human butyrylcholinesterase Human butyrylcholinesterase PUBTATOR Human butyrylcholinesterase 590 Human butyrylcholinesterase (BChE) is a glycoprotein capable of bioscavenging toxic compounds such as organophosphorus (OP) nerve agents. 29190644 1 0 gly glycoprotein 185:196 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Human butyrylcholinesterase (BChE) is a glycoprotein capable of bioscavenging toxic compounds such as organophosphorus (OP) nerve agents. 2110456 2 20 part_of has 200:202 arg1 This lysosomal enzyme AND five putative N-glycosylation sites This lysosomal enzyme five putative N-glycosylation sites Fterm Site enzyme sites This lysosomal enzyme has five putative N-glycosylation sites, four of which are occupied. 2825202 4 59 part_of SAP-1 803:807 arg1 the predicted carboxyl terminus SAP-1 the predicted carboxyl terminus PUBTATOR Site SAP-1 5660 terminus The open reading frame encodes 19 amino acids, which are colinear with the amino-terminal sequence of mature SAP-1, and extends far beyond the predicted carboxyl terminus of mature SAP-1, indicating extensive carboxyl-terminal processing. 2825202 4 111 part_of SAP-1 731:735 arg1 the amino-terminal sequence SAP-1 the amino-terminal sequence PUBTATOR Site SAP-1 5660 sequence The open reading frame encodes 19 amino acids, which are colinear with the amino-terminal sequence of mature SAP-1, and extends far beyond the predicted carboxyl terminus of mature SAP-1, indicating extensive carboxyl-terminal processing. 26018173 6 73 gly glycosylation 1201:1213 arg2 Each glycosylation site Each glycosylation site site Each glycosylation site was characterized individually, with about 500 glycoforms characterized per Env protein. 23069765 0 41 gly N-glycosylation 56:70 arg1 human recombinant interleukin-17A human recombinant interleukin-17A PUBTATOR interleukin-17A 3605 Unexpected mucin-type O-glycosylation and host-specific N-glycosylation of human recombinant interleukin-17A expressed in a human kidney cell line. 23069765 0 87 gly O-glycosylation 22:36 arg1 human recombinant interleukin-17A human recombinant interleukin-17A PUBTATOR interleukin-17A 3605 Unexpected mucin-type O-glycosylation and host-specific N-glycosylation of human recombinant interleukin-17A expressed in a human kidney cell line. 31611356 6 56 part_of CD4 1181:1183 arg1 the CD4 binding site CD4 the CD4 binding site OGER Site CD4 P01730 site Grft's ability to alter the structure of gp120, exposing the CD4 binding site, correlated with the presence of glycosylation at N295 only in clade B strains, not clade C strains. 2502393 6 4 gly glycosylation 1542:1554 arg2 a glycosylation site a glycosylation site site To monitor the transport steps from the endoplasmic reticulum to the Golgi compartment an RNA encoding a glycosylation site within the S-mutant precursor sequence was constructed. 26773038 5 44 part_of VWF 848:850 arg1 the VWF A2 domain VWF the VWF A2 domain PUBTATOR Site VWF 7450 domain We show by differential scanning fluorimetry that the N-linked glycans thermodynamically stabilize the VWF A2 domain. 12147690 5 69 gly glycoprotein 907:918 arg1 an endoplasmic reticulum-localized glycoprotein an endoplasmic reticulum-localized glycoprotein Fterm glycoprotein Mass spectra showed that calsequestrin glycan structure in nonmuscle cells was that expected for an endoplasmic reticulum-localized glycoprotein and showed that each glycoform existed as four mass peaks representing molecules that also had 0-3 phosphorylation sites occupied. 26947874 6 59 gly N-glycosylation 1178:1192 arg1 the flexible N-terminal region region region The results indicate that an additional N-glycosylation in the flexible N-terminal region increases the circulatory half-life of rA1AT without altering its protease inhibitory activity. 1331083 5 27 gly sites 1245:1249 arg1 oligosaccharides sites oligosaccharides sites Similar results were obtained for oligosaccharides at homologous sites on a pepsinogen/cathepsin D chimera containing only lysine 203 and residues 265-319 of cathepsin D, although the absolute levels of phosphorylation were lower. 1331083 5 54 gly residues 1318:1325 arg1 oligosaccharides lysine 203 and residues 265-319 oligosaccharides lysine 203 and residues 265-319 Similar results were obtained for oligosaccharides at homologous sites on a pepsinogen/cathepsin D chimera containing only lysine 203 and residues 265-319 of cathepsin D, although the absolute levels of phosphorylation were lower. 31498587 10 48 gly glycopeptide 1451:1462 arg2 Qβ-MUC1 glycopeptide conjugates Qβ-MUC1 glycopeptide conjugates glycopeptide As such, Qβ-MUC1 glycopeptide conjugates have great potential as anticancer vaccines. 15264219 5 42 gly glycosylation 956:968 arg2 each N-linked glycosylation site each N-linked glycosylation site site We show that the murine 5-HT3(A)R is glycosylated and that each N-linked glycosylation site plays a role in receptor regulation. 23714211 9 93 gly glycosylation 1409:1421 arg1 ICAM-2 ICAM-2 PUBTATOR ICAM-2 3384 The goal of the study presented here was to determine if the glycosylation status of ICAM-2 influenced its function in neuroblastoma cells. 11326277 10 7 gly interfere 1444:1452 arg1 an extra amino-terminal glycosylation site an extra amino-terminal glycosylation site site According to models of its structure, T1r3 from non-tasters is predicted to have an extra amino-terminal glycosylation site that, if used, would interfere with dimerization. 11326277 10 56 gly glycosylation 1404:1416 arg2 an extra amino-terminal glycosylation site an extra amino-terminal glycosylation site site According to models of its structure, T1r3 from non-tasters is predicted to have an extra amino-terminal glycosylation site that, if used, would interfere with dimerization. 3829888 2 5 part_of 114-amino-acid 262:275 arg1 a 114-amino-acid polypeptide 114-amino-acid a 114-amino-acid polypeptide Cterm Site 114-amino-acid polypeptide It is a 114-amino-acid polypeptide which differs from its seminal plasma derivative mainly by the presence of a 20-residue amino-terminal extension, a putative signal sequence, carrying a possible N-glycosylation site. 3829888 2 4 part_of carrying 431:438 arg1 a putative signal sequence AND a possible N-glycosylation site a putative signal sequence a possible N-glycosylation site site It is a 114-amino-acid polypeptide which differs from its seminal plasma derivative mainly by the presence of a 20-residue amino-terminal extension, a putative signal sequence, carrying a possible N-glycosylation site. 19767389 5 80 gly glycosylation 916:928 arg2 the second glycosylation site the second glycosylation site site Subsequent tryptic and chymotryptic peptide map data indicated that the second glycosylation site was associated with the amino acid sequence TVSWN(162)SGAL in the C(H)1 domain of the antibody. 19763269 9 37 part_of Env 1651:1653 arg1 the Env domains Env the Env domains PUBTATOR Site Env 155971 domains Spatial representation of the sequence changes in gp120 suggested that selective pressure acted upon the same regions of Env in these two subjects, even though the Env domains that drove escape were different. 19763269 9 77 part_of Env 1608:1610 arg1 the same regions Env the same regions PUBTATOR Site Env 100616444 regions Spatial representation of the sequence changes in gp120 suggested that selective pressure acted upon the same regions of Env in these two subjects, even though the Env domains that drove escape were different. 2965389 4 34 part_of Fc 915:916 arg1 The human Fc gamma R leader sequence Fc The human Fc gamma R leader sequence Cterm Site Fc sequence The human Fc gamma R leader sequence was shown to be similar to the mouse alpha Fc gamma R leader sequence, but the transmembrane region was most similar to the mouse beta 1 Fc gamma R. 18404400 3 26 part_of lysine 418:423 arg1 NTPDase3 NTPDase3 lysine PUBTATOR SpecificSite NTPDase3 956 lysine 79 The residue corresponding to lysine 79 in NTPDase3 is conserved in all known cell surface membrane NTPDases (NTPDase1, 2, 3, and 8), but not in the soluble, monomeric NTPDases (NTPDase5 and 6), or in the intracellular, two transmembrane NTPDases (NTPDase4 and 7). 31429052 6 38 gly drug/glycosylation 1478:1495 arg2 confident drug/glycosylation site identification confident drug/glycosylation site identification site UVPD used as a standalone technique for ADC subunit analysis afforded, within the same liquid chromatography-MS/MS run, enhanced performance in terms of primary sequence coverage compared to HCD- or ETD-based MD approaches, and generated substantially more MS/MS fragments containing either drug conjugation or glycosylation site information, leading to confident drug/glycosylation site identification. 31429052 6 83 gly glycosylation 1425:1437 arg2 glycosylation site information glycosylation site information site UVPD used as a standalone technique for ADC subunit analysis afforded, within the same liquid chromatography-MS/MS run, enhanced performance in terms of primary sequence coverage compared to HCD- or ETD-based MD approaches, and generated substantially more MS/MS fragments containing either drug conjugation or glycosylation site information, leading to confident drug/glycosylation site identification. 8286753 2 28 part_of TfR 374:376 arg1 the transmembrane domain TfR the transmembrane domain PUBTATOR Site TfR 7037 domain The function of the single O-linked oligosaccharide near the transmembrane domain of the TfR at amino acid Thr 104 is unknown. 8286753 2 69 part_of Thr 392:394 arg1 the TfR TfR Thr PUBTATOR SpecificSite TfR 7037 Thr 104 The function of the single O-linked oligosaccharide near the transmembrane domain of the TfR at amino acid Thr 104 is unknown. 2477364 7 73 part_of containing 1175:1184 arg1 alpha subunits AND only one glycosylation site alpha subunits only one glycosylation site Fterm Site subunits site First, site-directed mutagenesis was used to alter the two N-linked oligosaccharide attachment sites, thus allowing the expression of alpha subunits containing only one glycosylation site. 27480293 7 10 gly N-glycoproteins 1125:1139 arg1 the 57 novel transmembrane N-glycoproteins the 57 novel transmembrane N-glycoproteins Fterm N-glycoproteins N-glycosylation site information was used to confirm or correct the transmembrane topology of the 57 novel transmembrane N-glycoproteins. 27480293 7 58 gly N-glycosylation 1004:1018 arg2 N-glycosylation site information N-glycosylation site information site N-glycosylation site information was used to confirm or correct the transmembrane topology of the 57 novel transmembrane N-glycoproteins. 15113920 5 7 gly glycosylated 995:1006 arg1 the fifth site the fifth site site We determined that four sites (N134, -235, -347, and -399) on Gn and the only site (N928) on Gc in their ectodomains are utilized, whereas the fifth site on Gn (N609), which faces the cytoplasm, is not glycosylated. 15113920 5 64 gly utilized 914:921 arg2 four sites four sites sites We determined that four sites (N134, -235, -347, and -399) on Gn and the only site (N928) on Gc in their ectodomains are utilized, whereas the fifth site on Gn (N609), which faces the cytoplasm, is not glycosylated. 15113920 5 64 gly utilized 914:921 arg2 the only site the only site site We determined that four sites (N134, -235, -347, and -399) on Gn and the only site (N928) on Gc in their ectodomains are utilized, whereas the fifth site on Gn (N609), which faces the cytoplasm, is not glycosylated. 15113920 5 64 gly utilized 914:921 arg2 N928 N928 N928 We determined that four sites (N134, -235, -347, and -399) on Gn and the only site (N928) on Gc in their ectodomains are utilized, whereas the fifth site on Gn (N609), which faces the cytoplasm, is not glycosylated. 16816852 5 58 gly glycosylation 801:813 arg2 one more glycosylation site one more glycosylation site site The HA1 sequence data showed that the virus had amino acid mutation, and there was one more glycosylation site at 196th site. 9557657 6 32 gly N-glycosylated 1412:1425 arg1 havcr-1 havcr-1 PUBTATOR havcr-1 26762 Treatment of AGMK and cr5 cell extracts with peptide-N-glycosidase F resulted in the collapse of the havcr-1-specific bands into a single band of 56 kDa, which indicated that different N-glycosylated forms of havcr-1 were expressed in these cells. 26013384 8 53 part_of Ser126 1023:1028 arg1 fully O-glycosylated rHu-EPO EPO Ser126 PUBTATOR AminoAcid EPO 2056 Ser126 It is concluded that the variant peak is non-O-glycosylated rHu-EPO and the main peak is fully O-glycosylated rHu-EPO at Ser126. 7559653 6 43 part_of terminus 1216:1223 arg1 a functional glycosylation site terminus a functional glycosylation site site A mutant receptor encoding a functional glycosylation site at the NH2 terminus is better expressed at the cell surface compared with the non-glycosylated form, indicating that trafficking to the cell surface is facilitated by glycosylation, but its location is relatively unimportant. 15478466 0 27 gly glycosylated 29:40 arg1 a glycosylated AL-chain a glycosylated AL-chain Fterm AL-chain The amino acid sequence of a glycosylated AL-chain from a patient with primary amyloidosis. 27377235 7 102 gly contain 1266:1272 arg1 Kv1.2 channels AND complex N-linked glycans Kv1.2 channels complex N-linked glycans Fterm channels Kv1.2 channels can contain complex N-linked glycans, which facilitate cell surface expression of the channels. 7813575 3 49 part_of activator 691:699 arg1 the serine protease domains tissue-type plasminogen activator the serine protease domains PUBTATOR Site tissue-type plasminogen activator 25692 domains SUN9216, a modified tissue-type plasminogen activator, is a new thrombolytic agent which consists of the fibrin kringle 1 domain of plasminogen and the two kringles, the serine protease domains of the native tissue-type plasminogen activator. 7813575 3 61 part_of plasminogen 591:601 arg1 the fibrin kringle 1 domain plasminogen the fibrin kringle 1 domain OGER Site plasminogen P00747 domain SUN9216, a modified tissue-type plasminogen activator, is a new thrombolytic agent which consists of the fibrin kringle 1 domain of plasminogen and the two kringles, the serine protease domains of the native tissue-type plasminogen activator. 7813575 3 61 part_of plasminogen 591:601 arg1 the serine protease domains plasminogen the serine protease domains OGER Site plasminogen P00747 domains SUN9216, a modified tissue-type plasminogen activator, is a new thrombolytic agent which consists of the fibrin kringle 1 domain of plasminogen and the two kringles, the serine protease domains of the native tissue-type plasminogen activator. 7813575 3 85 part_of protease 636:643 arg1 the serine protease domains protease the serine protease domains Fterm Site protease domains SUN9216, a modified tissue-type plasminogen activator, is a new thrombolytic agent which consists of the fibrin kringle 1 domain of plasminogen and the two kringles, the serine protease domains of the native tissue-type plasminogen activator. 15557236 0 32 gly protein 15:21 arg1 a molecular determinant protein a molecular determinant Fterm protein Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. 23533650 3 67 gly glycoproteins 569:581 arg1 multiple HIV-1 envelope glycoproteins multiple HIV-1 envelope glycoproteins Fterm glycoproteins In the present study we tested the hypothesis that immunization with multiple HIV-1 envelope glycoproteins (Envs) would result in a more potent and cross-reactive neutralizing response. 7530394 7 78 gly glycosylation 1316:1328 arg2 the potential glycosylation site N-Y-S the potential glycosylation site N-Y-S site Nucleotide sequence of the 5' third of the E gene of selected KUN isolates revealed that a single base change in PNGase F sensitive strains changed the tripeptide N-Y-F (amino acids 154-156 of the published sequence) to the potential glycosylation site N-Y-S. 29115822 6 58 gly glycosylated 1006:1017 arg1 The resultant glycosylated Cy5/biotin-modified peptides The resultant glycosylated Cy5/biotin-modified peptides peptides The resultant glycosylated Cy5/biotin-modified peptides may assemble on the surface of the streptavidin-coated QD to obtain a QD-peptide-Cy5 nanostructure in which the fluorescence resonance energy transfer (FRET) from the QD to Cy5 can occur, leading to the emission of Cy5 which can be quantified by single-molecule detection. 20884611 7 54 gly N-glycosylation 1050:1064 arg2 N-glycosylation sites N-glycosylation sites sites The extended integrins were created by introducing N-glycosylation sites in amino acid residues located close to the α-genu, where the integrin legs fold backward. 30594968 1 7 part_of hemagglutinin 169:181 arg1 hemagglutinin (HA) sequences hemagglutinin hemagglutinin (HA) sequences Fterm Site hemagglutinin sequences Variations in the potential glycosylation sites were observed in hemagglutinin (HA) sequences of H9N2 avian influenza virus isolated in China, deposited in the Influenza Virus Resource of NCBI before 2017, which showed a deleted glycosylation site at amino acid residue 218, and an introduced glycosylation site at amino acid residue 313. 8323283 6 13 part_of containing 1094:1103 arg1 a short peptide AND a potential glycosylation site a short peptide a potential glycosylation site site Furthermore, if a short peptide containing a potential glycosylation site was fused to the N-terminus of the mutant protein, the new hybrid protein was glycosylated in COS1 cells and the carbohydrate moiety remained sensitive to cleavage by endoglycosidase H. 1402395 6 37 gly glycoprotein 740:751 arg1 a 70 kDa glycoprotein a 70 kDa glycoprotein Fterm glycoprotein Prosaposin is a 70 kDa glycoprotein containing four domains, one for each saposin, placed in tandem. 1402395 6 37 gly glycoprotein 740:751 arg1 Prosaposin Prosaposin PUBTATOR Prosaposin 5660 Prosaposin is a 70 kDa glycoprotein containing four domains, one for each saposin, placed in tandem. 15694591 3 59 gly N-glycosylation 385:399 arg2 one N-glycosylation site one N-glycosylation site site AvChit1 possesses the chitinase family 18 active site signature and one N-glycosylation site. 12069081 0 4 part_of factor 77:82 arg1 Nucleotide sequence vascular endothelial growth factor Nucleotide sequence PUBTATOR Site vascular endothelial growth factor 7422 sequence Nucleotide sequence and expression of the feline vascular endothelial growth factor. 8496594 10 37 part_of protein 1272:1278 arg1 a transmembrane domain protein a transmembrane domain Fterm Site protein domain Proteinase K degradation of the N-terminal part after in vitro protein synthesis supports the view of CD69 being a type II integral membrane protein with the N-terminal 40 amino acids in the cytoplasm, a transmembrane domain of 21 amino acids, and C-terminal 138 amino acids as the extracellular domain. 10536368 3 67 gly glycosylation 475:487 arg2 N-linked glycosylation sites N-linked glycosylation sites sites Site-directed mutagenesis was used to delete N-linked glycosylation sites from a chimeric protein, TNFR-IgG1. 15616124 3 7 part_of has 416:418 arg1 Human FVII AND two N-glycosylation sites Human FVII two N-glycosylation sites Cterm Site Human FVII 2155 sites Human FVII has two N-glycosylation sites (N145 and N322). 15616124 3 7 part_of has 416:418 arg1 Human FVII AND N145 Human FVII N145 and N322 Cterm SpecificSite Human FVII 2155 N145 and N322 Human FVII has two N-glycosylation sites (N145 and N322). 24369354 5 50 gly glycosylation 879:891 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Consistent with our previous observation, the resistant phenotype was associated with a single asparagine residue at position 460 (N460), a potential N-linked glycosylation site in the V5 region. 24369354 5 50 gly glycosylation 879:891 arg2 position 460 position 460 asparagine residue at position 460 Consistent with our previous observation, the resistant phenotype was associated with a single asparagine residue at position 460 (N460), a potential N-linked glycosylation site in the V5 region. 10913840 3 60 gly occupancy 555:563 arg2 site occupancy site occupancy site The two potential N-glycosylation sites of rFuc-TIV were mutated to determine site occupancy and the effect of site occupancy on enzyme activity and targeting of this enzyme. 10913840 3 26 gly N-glycosylation 490:504 arg2 The two potential N-glycosylation sites rFuc-TIV sites PUBTATOR rFuc-TIV 60670 sites The two potential N-glycosylation sites of rFuc-TIV were mutated to determine site occupancy and the effect of site occupancy on enzyme activity and targeting of this enzyme. 10524207 5 8 gly glycosylation 711:723 arg2 the N-linked glycosylation site the N-linked glycosylation site site While the short mature peptides are not apparently homologous, the N-linked glycosylation site is retained in both. 17986444 0 31 gly molecule 79:86 arg1 the polysialylation neural cell adhesion molecule the polysialylation PUBTATOR neural cell adhesion molecule 17967 Enzyme-dependent variations in the polysialylation of the neural cell adhesion molecule (NCAM) in vivo. 17986444 0 72 gly polysialylation 35:49 arg1 the neural cell adhesion molecule the neural cell adhesion molecule PUBTATOR neural cell adhesion molecule 17967 Enzyme-dependent variations in the polysialylation of the neural cell adhesion molecule (NCAM) in vivo. 17986444 0 72 gly polysialylation 35:49 arg1 NCAM NCAM PUBTATOR NCAM 17967 Enzyme-dependent variations in the polysialylation of the neural cell adhesion molecule (NCAM) in vivo. 22719948 0 1 part_of sites 18:22 arg1 H5N1 influenza virus hemagglutinin hemagglutinin sites Fterm Site hemagglutinin sites Two glycosylation sites in H5N1 influenza virus hemagglutinin that affect binding preference by computer-based analysis. 12364335 1 67 gly serine 223:228 arg1 residues residues serine and threonine residues Mucin type O-glycosylation begins with the transfer of GalNAc to serine and threonine residues on proteins by a family of UDP-GalNAc:polypeptide N-acetylgalactosaminlytransferases. 23527023 5 91 gly monoglycosylated 1263:1278 arg1 monoglycosylated (mono181) PrP monoglycosylated (mono181) PrP PUBTATOR PrP Q9NP58 In contrast to fCJD(T183A), both VPSPr and fCJD(V180I) exhibit glycosylation at residue 181 on di- and monoglycosylated (mono181) PrP prior to PK-treatment. 23527023 5 73 gly glycosylation 1223:1235 arg1 residue 181 residue 181 residue 181 In contrast to fCJD(T183A), both VPSPr and fCJD(V180I) exhibit glycosylation at residue 181 on di- and monoglycosylated (mono181) PrP prior to PK-treatment. 23527023 5 73 gly glycosylation 1223:1235 arg1 monoglycosylated (mono181) PrP PrP residue 181 PUBTATOR PrP Q9NP58 residue 181 In contrast to fCJD(T183A), both VPSPr and fCJD(V180I) exhibit glycosylation at residue 181 on di- and monoglycosylated (mono181) PrP prior to PK-treatment. 23527023 5 73 gly glycosylation 1223:1235 arg1 monoglycosylated (mono181) PrP PrP residue 181 PUBTATOR PrP Q9NP58 residue 181 In contrast to fCJD(T183A), both VPSPr and fCJD(V180I) exhibit glycosylation at residue 181 on di- and monoglycosylated (mono181) PrP prior to PK-treatment. 16331329 8 54 part_of pigs 1504:1507 arg1 the sequences pigs the sequences OGER Site pigs Q96S52 sequences In addition, four base mutations were detected by comparing the sequences of Large White pigs with those of Chinese Meishan pigs. 15532026 8 91 gly glycosylated 1442:1453 arg1 a 97 kDa glycosylated dimer a 97 kDa glycosylated dimer Fterm dimer Western blot analysis of extracts from control fibroblasts detect a 97 kDa glycosylated dimer whereas ML III cells contain a GNPTAG dimer of reduced molecular mass. 10588947 6 47 gly residues 1089:1096 arg1 2752 2752 Asn residues 2752 Similar peptide mapping of endogenous apoB-100 expressed in HepG2 cells was performed to monitor glycosylation at Asn residues 2752 (apoB-61), 2955 (apoB-65), and 3074 (apoB-68). 10588947 6 57 gly glycosylation 1068:1080 arg2 Asn residues 2752 (apoB-61), 2955 (apoB-65), and 3074 (apoB-68) Asn residues 2752 Asn residues 2752 Similar peptide mapping of endogenous apoB-100 expressed in HepG2 cells was performed to monitor glycosylation at Asn residues 2752 (apoB-61), 2955 (apoB-65), and 3074 (apoB-68). 8644914 9 127 gly glycopeptide 1713:1724 arg2 the isolated, tryptic glycopeptide the isolated, tryptic glycopeptide glycopeptide The qualitative distribution of glycoforms at this site was determined by MS of the isolated, tryptic glycopeptide and compared with results obtained by high-performance anion exchange chromatography and high-resolution gel permeation chromatography of oligosaccharides released by hydrazinolysis. 23581850 7 38 gly glycosylation 962:974 arg2 an OI-specific glycosylation site an OI-specific glycosylation site site Significant increases of GGHL were observed at respective glycosylation sites of type I collagen in OI, whereas an OI-specific glycosylation site was not found. 23581850 7 61 gly glycosylation 893:905 arg2 respective glycosylation sites respective glycosylation sites sites Significant increases of GGHL were observed at respective glycosylation sites of type I collagen in OI, whereas an OI-specific glycosylation site was not found. 32211339 4 8 gly N-glycosylation 736:750 arg2 three and six N-glycosylation sites three and six N-glycosylation sites sites The two highly glycosylated domains of GP are the mucin-like domain (MLD) and the glycan cap domain (GCD) with three and six N-glycosylation sites, respectively. 32211339 4 69 gly glycosylated 626:637 arg1 the mucin-like domain the mucin-like domain domain The two highly glycosylated domains of GP are the mucin-like domain (MLD) and the glycan cap domain (GCD) with three and six N-glycosylation sites, respectively. 32211339 4 69 gly glycosylated 626:637 arg1 The two highly glycosylated domains The two highly glycosylated domains domains The two highly glycosylated domains of GP are the mucin-like domain (MLD) and the glycan cap domain (GCD) with three and six N-glycosylation sites, respectively. 16360109 1 17 gly N-glycosylation 111:125 arg2 Variable (Fv) domain N-glycosylation sites Variable (Fv) domain N-glycosylation sites sites Variable (Fv) domain N-glycosylation sites are found in approximately 20% of human immunoglobulin Gs (IgGs) in addition to the conserved N-glycosylation sites in the C(H)2 domains. 16360109 1 115 gly N-glycosylation 227:241 arg2 the conserved N-glycosylation sites the conserved N-glycosylation sites sites Variable (Fv) domain N-glycosylation sites are found in approximately 20% of human immunoglobulin Gs (IgGs) in addition to the conserved N-glycosylation sites in the C(H)2 domains. 28956769 10 36 gly glycosylation 1849:1861 arg2 the glycosylation site N69/S71 the glycosylation site N69/S71 site We found that the glycosylation site N69/S71 of gL is involved in restricting epithelial cell fusion activity, strongly correlating with syncytium size. 27573070 4 32 gly N-glycopeptide 950:963 arg2 N-glycopeptide backbones N-glycopeptide backbones N-glycopeptide These merged spectra expedite the identification of both glycans and N-glycopeptide backbones in tandem MS data using the glycan database and a proteomic search tool (e.g., Mascot). 11746818 6 4 gly N-glycosylation 1253:1267 arg2 an N-glycosylation site an N-glycosylation site site Multiple peptide alignment showed several sequence motifs corresponding to putative catalytic domains that are conserved throughout all members of the beta 3-galactosyltransferase family, namely, a type II transmembrane domain, a conserved DxD motif, an N-glycosylation site, and five conserved cysteins. 7966620 6 51 gly glycosylation 788:800 arg2 the novel glycosylation site the novel glycosylation site site syn31 gK was analyzed by in vitro translation and found to utilize the novel glycosylation site. 23005037 4 1 gly non-glycosylated 678:693 arg1 non-glycosylated prokaryotic CD147 non-glycosylated prokaryotic CD147 PUBTATOR CD147 682 Moreover, native glycosylated CD147 existed exclusively as oligomers in solution and directly stimulated MMP production more efficiently than non-glycosylated prokaryotic CD147. 23005037 4 62 gly glycosylated 553:564 arg1 native glycosylated CD147 native glycosylated CD147 PUBTATOR CD147 682 Moreover, native glycosylated CD147 existed exclusively as oligomers in solution and directly stimulated MMP production more efficiently than non-glycosylated prokaryotic CD147. 18279659 3 52 gly has 416:418 arg1 ABCB6 AND a primary determinant ABCB6 a primary determinant PUBTATOR ABCB6 10058 We show here that ABCB6 has an N-terminal hydrophobic region of 220 residues that functions as a primary determinant of co-translational targeting to the endoplasmic reticulum (ER), but it does not have any known features of a mitochondrial targeting sequence. 1990068 2 2 part_of containing 453:462 arg1 the F2 and F1 subunits AND 102 (including the F2-F1 connecting peptide RRRR) and 436 residues the F2 and F1 subunits 102 (including the F2-F1 connecting peptide RRRR) and 436 residues Fterm Site subunits residues The protein consists of 538 amino acids, the F2 and F1 subunits containing 102 (including the F2-F1 connecting peptide RRRR) and 436 residues, respectively. 4038307 0 9 gly gamma-seminoprotein 80:98 arg1 the N-glycosidic carbohydrate units gamma-seminoprotein the N-glycosidic carbohydrate units PUBTATOR gamma-seminoprotein 354 Occurrence of the Y determinant on the N-glycosidic carbohydrate units of human gamma-seminoprotein. 30135544 5 34 gly glycosylation 715:727 arg2 the glycosylation site the glycosylation site site In contrast, PrP F198S, a pathological mutant with an altered residue within the glycosylation site, and an unglycosylated PrP mutant, N181D/N197D, primarily exist in the cytoplasm. 22123080 5 22 gly glycosylation 821:833 arg2 a putative glycosylation site a putative glycosylation site site The results reveal three N-glycosylation sites, and further demonstrate a putative glycosylation site at Asn(157) for the first time. 22123080 5 57 gly N-glycosylation 763:777 arg2 three N-glycosylation sites three N-glycosylation sites sites The results reveal three N-glycosylation sites, and further demonstrate a putative glycosylation site at Asn(157) for the first time. 22123080 5 22 gly glycosylation 821:833 arg2 Asn Asn(157) Asn(157) The results reveal three N-glycosylation sites, and further demonstrate a putative glycosylation site at Asn(157) for the first time. 19921957 4 19 gly N-glycosylated 858:871 arg1 N-glycosylated and its parent protein-levels N-glycosylated and its parent protein-levels Fterm protein-levels The relative quantities of N-glycosylated and its parent protein-levels were obtained simultaneous by measuring the intensity ratios of (18)O/(16)O for glycosylated (6 Da) and for nonglycosylated (4 Da) peptides, respectively. 19921957 4 55 gly nonglycosylated 1011:1025 arg1 nonglycosylated (4 Da) peptides nonglycosylated (4 Da) peptides peptides The relative quantities of N-glycosylated and its parent protein-levels were obtained simultaneous by measuring the intensity ratios of (18)O/(16)O for glycosylated (6 Da) and for nonglycosylated (4 Da) peptides, respectively. 9884403 2 24 gly glycosylation 594:606 arg2 the potential glycosylation site the potential glycosylation site site Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 24 gly glycosylation 594:606 arg2 Asn14 Asn14 Asn14 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 80 gly N-glycosylation 456:470 arg2 the eight potential N-glycosylation sites the eight potential N-glycosylation sites sites Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 82 gly used 661:664 arg2 the potential glycosylation site the potential glycosylation site site Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 82 gly used 661:664 arg2 Asn14 Asn14 Asn14 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn56 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn208 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn372 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn52 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn251 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn208 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn372 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn52 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn251 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn372 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn52 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn251 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn52 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn251 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn52 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn251 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 9884403 2 73 gly glycosylated 562:573 arg1 Asn251 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489 Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used. 12072497 8 43 gly N-glycosylation 1524:1538 arg2 an additional potential N-glycosylation site an additional potential N-glycosylation site site Sequence analysis of the V1/V2 and V3 regions of the viral envelope protein gp120 revealed that the more efficient CXCR4 usage of the later isolate might be caused by an additional potential N-glycosylation site in the V1/V2 loop. 20795641 10 87 gly glycoproteins 1788:1800 arg1 130 unique glycoproteins 130 unique glycoproteins Fterm glycoproteins Using this approach, we were able to identify and quantitate 224 N-glycopeptides representing 130 unique glycoproteins from 20 μL of the undepleted mouse serum samples. 20795641 10 91 gly N-glycopeptides 1748:1762 arg2 224 N-glycopeptides 224 N-glycopeptides N-glycopeptides Using this approach, we were able to identify and quantitate 224 N-glycopeptides representing 130 unique glycoproteins from 20 μL of the undepleted mouse serum samples. 20209506 1 51 gly glycoprotein 175:186 arg1 glycoprotein glycoprotein Fterm glycoprotein Characterization of low microgram levels of glycoprotein remains a challenge due to extensive heterogeneity of the conjugated N-glycans at each individual glycosylation site. 20209506 1 68 gly glycosylation 286:298 arg2 each individual glycosylation site each individual glycosylation site site Characterization of low microgram levels of glycoprotein remains a challenge due to extensive heterogeneity of the conjugated N-glycans at each individual glycosylation site. 20209506 1 80 gly heterogeneity 225:237 arg1 the conjugated N-glycans the conjugated N-glycans Characterization of low microgram levels of glycoprotein remains a challenge due to extensive heterogeneity of the conjugated N-glycans at each individual glycosylation site. 10713140 2 46 part_of tyrosinase 249:258 arg1 a single N-glycosylation sequon tyrosinase a single N-glycosylation sequon PUBTATOR Site tyrosinase 7299 sequon Mutations at a single N-glycosylation sequon of tyrosinase have been reported to be responsible for oculocutaneous albinism type IA in humans, characterized by inactive tyrosinase and the total absence of pigmentation. 11146224 4 52 part_of MRP7 596:599 arg1 The MRP7 cDNA sequence MRP7 The MRP7 cDNA sequence PUBTATOR Site MRP7 89845 sequence The MRP7 cDNA sequence encodes a 1492 amino acid ABC transporter whose structural architecture resembles that of MRP1, MRP2, MRP3, and MRP6, in that its transmembrane helices are arranged in three membrane spanning domains. 18340083 5 15 gly released 619:626 arg1 mouse GPIHBP1 AND The N-linked glycan mouse GPIHBP1 The N-linked glycan PUBTATOR GPIHBP1 68453 The N-linked glycan could be released from mouse GPIHBP1 with N-glycosidase F, endoglycosidase H, or endoglycosidase F1. 8349699 8 88 gly N-glycosylated 1120:1133 arg1 This site site site This site is N-glycosylated in about 50% of PGH synthase-2 molecules, resulting in two peptide bands on SDS-polyacrylamide gel electrophoresis (72 and 74 kDa). 31888963 9 84 gly contain 1324:1330 arg1 N74 AND highly processed complex-type N-glycans CD16a N38 and N74 highly processed complex-type N-glycans PUBTATOR CD16a 2214 N38 and N74 N38 and N74 of CD16a both contain highly processed complex-type N-glycans with N-acetyllactosamine repeats and complex-type biantennary N-glycans dominate at N169. 31888963 9 84 gly contain 1324:1330 arg1 N38 AND highly processed complex-type N-glycans CD16a N38 and N74 highly processed complex-type N-glycans PUBTATOR CD16a 2214 N38 and N74 N38 and N74 of CD16a both contain highly processed complex-type N-glycans with N-acetyllactosamine repeats and complex-type biantennary N-glycans dominate at N169. 31888963 9 84 gly contain 1324:1330 arg1 N38 AND highly processed complex-type N-glycans CD16a N38 and N74 highly processed complex-type N-glycans PUBTATOR CD16a 2214 N38 and N74 N38 and N74 of CD16a both contain highly processed complex-type N-glycans with N-acetyllactosamine repeats and complex-type biantennary N-glycans dominate at N169. 1899031 0 20 part_of plasminogen 74:84 arg1 asparagine-289 plasminogen asparagine-289 PUBTATOR SpecificSite plasminogen 5340 asparagine-289 Oligosaccharide structures present on asparagine-289 of recombinant human plasminogen expressed in a Chinese hamster ovary cell line. 28617578 3 31 gly N-glycosylation 401:415 arg1 two specific asparagine sites two specific asparagine sites asparagine sites We establish that MUC16 oncogenic effects are mediated through MGAT5-dependent N-glycosylation of two specific asparagine sites within its 58 amino acid ectodomain. 32125861 4 14 gly glycoproteins 919:931 arg1 110 glycoproteins 110 glycoproteins Fterm glycoproteins We were able to map around 1700 glycopeptides from 110 glycoproteins covering 191 glycosites, of which 43 sites have not been previously reported with experimental evidence. 32125861 4 41 gly glycosites 946:955 arg2 191 glycosites 191 glycosites glycosites We were able to map around 1700 glycopeptides from 110 glycoproteins covering 191 glycosites, of which 43 sites have not been previously reported with experimental evidence. 32125861 4 37 gly glycopeptides 896:908 arg2 1700 glycopeptides glycoproteins glycopeptides Fterm glycoproteins glycopeptides We were able to map around 1700 glycopeptides from 110 glycoproteins covering 191 glycosites, of which 43 sites have not been previously reported with experimental evidence. 31577193 7 8 gly non-glycosylation 947:963 arg2 253 non-glycosylation sites 253 non-glycosylation sites sites The method was trained using a dataset of 600 N-glycosylation sites and 600 non-glycosylation sites and tested on the dataset containing 295 Nglycosylation sites and 253 non-glycosylation sites. 31577193 7 24 gly N-glycosylation 823:837 arg2 600 N-glycosylation sites 600 N-glycosylation sites sites The method was trained using a dataset of 600 N-glycosylation sites and 600 non-glycosylation sites and tested on the dataset containing 295 Nglycosylation sites and 253 non-glycosylation sites. 31577193 7 48 gly non-glycosylation 853:869 arg2 600 non-glycosylation sites 600 non-glycosylation sites sites The method was trained using a dataset of 600 N-glycosylation sites and 600 non-glycosylation sites and tested on the dataset containing 295 Nglycosylation sites and 253 non-glycosylation sites. 31577193 7 69 gly Nglycosylation 918:931 arg2 295 Nglycosylation sites 295 Nglycosylation sites sites The method was trained using a dataset of 600 N-glycosylation sites and 600 non-glycosylation sites and tested on the dataset containing 295 Nglycosylation sites and 253 non-glycosylation sites. 18562306 4 65 part_of hT2 950:952 arg1 the lectin domain hT2 the lectin domain PUBTATOR Site hT2 292 domain We demonstrate that the lectin domain of hT2 directs glycosylation site selection for glycopeptide substrates. 1937055 4 41 gly glycosylation 656:668 arg2 an Asn-linked glycosylation site an Asn-linked glycosylation site site Even in the absence of an Asn-linked glycosylation site, secretion of hEGF using the synthetic prepro-leader was as efficient as that directed by the alpha-factor leader. 30605224 7 30 gly glycoprotein 1056:1067 arg1 glycoprotein dynamics glycoprotein dynamics Fterm glycoprotein Reversible protein glycosylation is dynamic, and systematic study of glycoprotein dynamics helps us gain insight into glycoprotein functions. 30605224 7 32 gly glycoprotein 1105:1116 arg1 glycoprotein functions glycoprotein functions Fterm glycoprotein Reversible protein glycosylation is dynamic, and systematic study of glycoprotein dynamics helps us gain insight into glycoprotein functions. 23692404 3 19 part_of FIX 812:814 arg1 spatially distinct regions FIX spatially distinct regions OGER Site FIX P16294 regions METHODS: Two hundred fifty-one variants, each containing one additional N-linked glycosylation site, were screened in vitro, and the PK profiles of selected variants mapping to spatially distinct regions of FIX were evaluated in mice. 23692404 3 10 part_of containing 651:660 arg1 Two hundred fifty-one variants AND one additional N-linked glycosylation site Two hundred fifty-one variants one additional N-linked glycosylation site Fterm Site variants site METHODS: Two hundred fifty-one variants, each containing one additional N-linked glycosylation site, were screened in vitro, and the PK profiles of selected variants mapping to spatially distinct regions of FIX were evaluated in mice. 1457969 7 34 gly glycosylation 1298:1310 arg2 glycosylation site glycosylation site site The relative amounts of the two major complete diantennary oligosaccharides and their core fucosylation differed according to glycosylation site; the sulphated/sialylated diantennary oligosaccharide was most abundant at the two sites on the alpha-subunit, whereas the disulphated, core-fucosylated oligosaccharide was more plentiful on the beta-subunit. 1457969 7 81 gly sulphated/sialylated 1322:1341 arg1 the sulphated/sialylated diantennary oligosaccharide the sulphated/sialylated diantennary oligosaccharide The relative amounts of the two major complete diantennary oligosaccharides and their core fucosylation differed according to glycosylation site; the sulphated/sialylated diantennary oligosaccharide was most abundant at the two sites on the alpha-subunit, whereas the disulphated, core-fucosylated oligosaccharide was more plentiful on the beta-subunit. 1840589 9 39 gly N-glycosylation 1033:1047 arg2 one N-glycosylation site one N-glycosylation site site CD9 antigen appears to be a 227-amino acid molecule with four hydrophobic domains and one N-glycosylation site. 18404209 6 26 gly glycosylation 1093:1105 arg2 a glycosylation site a glycosylation site site The triple N158S/Q226L/N248D HA mutation (which eliminates a glycosylation site at position 158) caused a switch from avian to human receptor specificity. 24475074 2 19 gly glycoproteins 216:228 arg1 glycoproteins glycoproteins Fterm glycoproteins In animals, glycoproteins transit through the Golgi where the N-glycans are trimmed and rebuilt with sequences that bind lectins, an innovation that greatly increases structural diversity and redundancy of glycoprotein-lectin interaction at the cell surface. 2503511 13 28 gly glycosylation 2177:2189 arg2 each glycosylation site each glycosylation site site The oligosaccharides released from each glycosylation site were analyzed by high pH anion exchange chromatography. 2503511 13 75 gly released 2158:2165 arg1 each glycosylation site AND The oligosaccharides each glycosylation site The oligosaccharides site The oligosaccharides released from each glycosylation site were analyzed by high pH anion exchange chromatography. 8382971 3 61 gly diglycosylated 592:605 arg1 diglycosylated tPA-6-variant diglycosylated tPA-6-variant OGER tPA P00750 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 95 gly glycosylation 643:655 arg1 Asn-448 Asn-448 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg1 Asn-184 tPA Asn-184 OGER tPA P00750 Asn-184 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg1 Asn-448 tPA Asn-448 OGER tPA P00750 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg1 Asn-448 tPA Asn-448 OGER tPA P00750 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg2 Asn-184 tPA Asn-184 OGER tPA P00750 Asn-184 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg2 Asn-448 tPA Asn-448 OGER tPA P00750 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg2 Asn-448 tPA Asn-448 OGER tPA P00750 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg1 the monoglycosylated tPA-6-primary tPA OGER tPA P00750 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg2 Asn-184 Asn-184 Asn-184 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg1 the monoglycosylated tPA-6-primary tPA Asn-184 OGER tPA P00750 Asn-184 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg1 Asn-448 Asn-448 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg2 Asn-448 Asn-448 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg2 Asn-448 Asn-448 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg1 the monoglycosylated tPA-6-primary tPA Asn-448 OGER tPA P00750 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg2 Asn-448 Asn-448 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg2 Asn-448 Asn-448 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg1 the monoglycosylated tPA-6-primary tPA Asn-448 OGER tPA P00750 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg1 the monoglycosylated tPA-6-primary tPA Asn-184 OGER tPA P00750 Asn-184 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg2 Asn-448 Asn-448 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg1 the monoglycosylated tPA-6-primary tPA Asn-448 OGER tPA P00750 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 16 gly glycosylation 533:545 arg1 the monoglycosylated tPA-6-primary tPA Asn-448 OGER tPA P00750 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 8382971 3 34 gly monoglycosylated 470:485 arg1 the monoglycosylated tPA-6-primary tPA OGER tPA P00750 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 24280012 11 42 part_of GoIL-17A 1195:1202 arg1 The GoIL-17A gene sequence GoIL-17A The GoIL-17A gene sequence Cterm Site GoIL-17A 3605 sequence The GoIL-17A gene sequence and the biologically active recombinant protein may be useful for understanding the role of IL-17A in immune regulation. 23776650 6 13 part_of has 758:760 arg1 DCIR AND an N-glycosylation site DCIR an N-glycosylation site PUBTATOR Site Since DCIR 50856 site Since DCIR has an N-glycosylation site inside its carbohydrate recognition domain (CRD), we investigated the effect of this glycan in ligand recognition. 29909010 8 2 gly glycosylation 1322:1334 arg1 the H-chain constant region the H-chain constant region region These results demonstrated that glycosylation at position 178 of the H-chain constant region of adalimumab Fab can prevent protein aggregation, and therefore serve as a potentially effective platform for drug development. 29909010 8 2 gly glycosylation 1322:1334 arg2 position 178 position 178 position 178 These results demonstrated that glycosylation at position 178 of the H-chain constant region of adalimumab Fab can prevent protein aggregation, and therefore serve as a potentially effective platform for drug development. 31065929 8 36 gly glycosylation 960:972 arg2 a glycosylation site mutant DMP1 mouse a glycosylation site mutant DMP1 mouse site To further detect the potential role of DMP1-PG in fracture repair, we established a mouse fracture model by using a glycosylation site mutant DMP1 mouse (S89G-DMP1 mouse). 15869468 1 8 gly N-glycosylated 193:206 arg1 G-protein-coupled receptors G-protein-coupled receptors Fterm receptors GPCRs (G-protein-coupled receptors) are preferentially N-glycosylated on ECL2 (extracellular loop 2). 21569239 7 19 part_of F-spondin 939:947 arg1 F-spondin FS domain F-spondin F-spondin FS domain PUBTATOR Site F-spondin 10418 domain The unique feature of F-spondin FS domain is the presence of three disulfide bonds associated with the N- and C-termini of the domain and a highly conserved N-linked glycosylation site. 15063126 5 14 gly glycoproteins 907:919 arg1 3.2N envelope glycoproteins 3.2N envelope glycoproteins Fterm glycoproteins By contrast, viruses with SHIV-HXBc2P 3.2 and SHIV-HXBc2P 3.2N envelope glycoproteins were neutralized equivalently by 2G12 and 2F5 antibodies, which are rarely elicited in HIV-1-infected humans. 31852790 0 100 gly Glycans 9:15 arg1 Hemagglutinin Hemagglutinin Glycans Fterm Hemagglutinin N-Linked Glycans and K147 Residue on Hemagglutinin Synergize To Elicit Broadly Reactive H1N1 Influenza Virus Antibodies. 31671706 5 1 gly glycosylation 1013:1025 arg2 each glycosylation site each glycosylation site site Finally, it was clearly confirmed that N-linked glycans for each glycosylation site showed significantly different patterns in microheterogeneity, which may indicate certain functions for each glycosylation site in the protein. 31671706 5 25 gly glycosylation 1141:1153 arg2 each glycosylation site each glycosylation site site Finally, it was clearly confirmed that N-linked glycans for each glycosylation site showed significantly different patterns in microheterogeneity, which may indicate certain functions for each glycosylation site in the protein. 24899172 5 13 part_of positions 956:964 arg1 the AGL AGL positions OGER Site AGL P35573 positions Several positions in the AGL could substitute for position 146 as the glycosylation acceptor site. 12706816 4 16 gly native 685:690 arg1 site-mutated site-mutated site-mutated To distinguish among a number of hypothetical models for the membrane topology of CLN3 we used in vitro translation of native, Flag epitope-labeled and glycosylation site-mutated CLN3 protein in the presence or absence of canine pancreatic microsomes. 22248643 6 8 gly N-glycosylation 1041:1055 arg2 an additional N-glycosylation site an additional N-glycosylation site site Street viruses usually possess one or two N-glycosylation sites on the G protein, 1088 has two, while an additional N-glycosylation site is observed in laboratory-adapted strains. 22248643 6 88 gly N-glycosylation 967:981 arg2 one or two N-glycosylation sites one or two N-glycosylation sites sites Street viruses usually possess one or two N-glycosylation sites on the G protein, 1088 has two, while an additional N-glycosylation site is observed in laboratory-adapted strains. 19763269 4 42 gly glycoprotein 755:766 arg1 envelope (Env) glycoprotein envelope (Env) glycoprotein Fterm glycoprotein 155971 To provide a detailed portrayal of the escape pathways, Nab resistant variants identified at multiple time points were used to create a series of envelope (Env) glycoprotein chimeras and mutants within the background of a corresponding newly transmitted Env. 22009746 5 33 gly glycosylation 1052:1064 arg2 the α7 nAChR glycosylation site the α7 nAChR glycosylation site site We also present a pentameric humanoid nAChR extracellular domain with the structural determination of the α7 nAChR glycosylation site. 23909558 4 2 gly glycopeptides 460:472 arg2 these glycopeptides these glycopeptides glycopeptides Electron transfer dissociation (ETD) is the method of choice in analyzing these glycopeptides since the glycan side chain remains intact in ETD, and the glycosylation site can be localized on the basis of the c and z fragment ions. 23909558 4 20 gly glycosylation 533:545 arg2 the glycosylation site the glycosylation site site Electron transfer dissociation (ETD) is the method of choice in analyzing these glycopeptides since the glycan side chain remains intact in ETD, and the glycosylation site can be localized on the basis of the c and z fragment ions. 25628020 2 0 gly N-glycosylation 296:310 arg2 a novel N-glycosylation site a novel N-glycosylation site site The acquisition of a novel N-glycosylation site may have significant effect on protein structure and function, and therefore, on the phenotype. 25690651 2 70 gly N-glycosylation 309:323 arg2 the N-glycosylation motif the N-glycosylation motif motif Asn Thus, many GPCRs possess the N-glycosylation motif Asn-X-Ser/Thr at their N-termini and/or extracellular loops. 2328698 9 23 part_of rPLP-B 1219:1224 arg1 the rPLP-B mRNA sequence rPLP-B the rPLP-B mRNA sequence PUBTATOR Site rPLP-B 24657 sequence These data are consistent with the presence of one potential N-glycosylation site derived from the rPLP-B mRNA sequence. 10099468 6 18 gly tetrasialylated 1515:1529 arg1 tri- and tetrasialylated N-glycans tri- and tetrasialylated N-glycans This was confirmed by cation-exchange HPLC analysis of released, fluorophore-labeled N-glycans, which showed an increase in the proportion of tri- and tetrasialylated N-glycans associated with IFN-gamma during culture, with a concomitant decrease in the proportion of monosialylated and neutral N-glycans. 10099468 6 48 gly monosialylated 1632:1645 arg1 monosialylated and neutral N-glycans monosialylated and neutral N-glycans This was confirmed by cation-exchange HPLC analysis of released, fluorophore-labeled N-glycans, which showed an increase in the proportion of tri- and tetrasialylated N-glycans associated with IFN-gamma during culture, with a concomitant decrease in the proportion of monosialylated and neutral N-glycans. 3219367 7 37 gly glycopeptides 992:1004 arg2 glycopeptides glycopeptides glycopeptides Fast atom bombardment mass spectrometry of the isolated glycopeptides combined with Edman degradation allowed us to elucidate the composition of glycopeptides and the amino acid attachment site. 3219367 7 44 gly glycopeptides 903:915 arg2 the isolated glycopeptides the isolated glycopeptides glycopeptides Fast atom bombardment mass spectrometry of the isolated glycopeptides combined with Edman degradation allowed us to elucidate the composition of glycopeptides and the amino acid attachment site. 21528263 6 20 gly P-glycoprotein 1076:1089 arg1 the P-glycoprotein the P-glycoprotein PUBTATOR P-glycoprotein 5243 An A to G nucleotide substitution giving rise to an amino acid substitution (Asn-->Asp) in codon 21 at the first potential N-glycosylation site of the P-glycoprotein was seen in primary tumors from four patients and in an axillar lymph node metastases from one of these patients. 21528263 6 13 gly N-glycosylation 1048:1062 arg1 the P-glycoprotein P-glycoprotein site PUBTATOR P-glycoprotein 5243 site An A to G nucleotide substitution giving rise to an amino acid substitution (Asn-->Asp) in codon 21 at the first potential N-glycosylation site of the P-glycoprotein was seen in primary tumors from four patients and in an axillar lymph node metastases from one of these patients. 11697887 9 19 part_of CTGF 1242:1245 arg1 this region CTGF this region PUBTATOR Site CTGF 1490 region Although within this region of human CTGF is a N-glycosylation site, tunicamycin, which blocks N-linked glycosylation, has no significant effect on CTGF secretion. 28336547 8 104 gly glycosylation 1567:1579 arg1 PEPT1 PEPT1 PUBTATOR PEPT1 56643 In addition, our experiments provide strong evidence that glycosylation of PEPT1 confers resistance against proteolytic cleavage by proteinase K, whereas a remarkable intrinsic stability against trypsin, even in the absence of N-linked glycans, was detected.NEW & NOTEWORTHY This study highlights the role of N50-linked glycans in modulating the bidirectional transport activity of the murine peptide transporter PEPT1. 9459000 6 35 part_of residue 890:896 arg1 the PI Zbristol protein protein residue Fterm SpecificSite protein residue 83 This disrupts the N-glycosylation site starting at Asn 83 preventing glycosylation at residue 83 in the PI Zbristol protein and explains the protein isoelectric focusing and SDS gel electrophoresis results. 9820847 5 11 gly glycosylation 1104:1116 arg2 the potential glycosylation site the potential glycosylation site site On the basis of other rotaviral characteristics, such as the conserved cysteine and proline residues together with the potential glycosylation site, it is proposed that this local strain (ID 45/2) might represent a new subtype related to serotype G1. 26853155 10 66 part_of syncytin-2 1926:1935 arg1 residues 133, 312, 332 and 443 syncytin-2 residues 133, 312, 332 and 443 PUBTATOR SpecificSite syncytin-2 P60508 residues 133, 312, 332 and 443 Taken together, our results suggest that N-glycans at residues 133, 312, 332 and 443 of syncytin-2 are required for optimal fusion induction, and that SNPs C46R, N118S, T367M, R417H, V483I and T522M can alter the fusogenic function of syncytin-2. 17010165 6 8 part_of contains 1430:1437 arg1 the V1V2 region AND an additional N-linked glycosylation site the V1V2 region an additional N-linked glycosylation site site Viruses with higher V3 charges are more readily transferred to CD4(+) lymphocytes when the V1V2 region is longer and contains an additional N-linked glycosylation site, whereas transfer of viruses with lower V3 charges is greater when the V1V2 region is shorter. 15924140 5 7 gly bore 900:903 arg1 Six mutant proteins AND new N-linked carbohydrate moieties Six mutant proteins new N-linked carbohydrate moieties Fterm proteins Six mutant proteins bore new N-linked carbohydrate moieties. 1388166 8 31 part_of contains 1484:1491 arg1 TFPI AND the sequence Pro-Phe-Lys, 9 residues TFPI the sequence Pro-Phe-Lys, 9 residues PUBTATOR Site TFPI 7035 residues TFPI contains the sequence Pro-Phe-Lys, 9 residues N-terminal to the glycosylation site at position 228; this tripeptide may act as the recognition sequence for the GalNAc-transferase. 17091191 3 10 part_of kinase 879:884 arg1 two overlapping casein kinase II phosphorylation sites casein kinase II two overlapping casein kinase II phosphorylation sites OGER Site casein kinase II sites Translation of the mRNA transcript revealed an open reading frame (ORF) of 86 amino acid residues encoding a nuclear location signal peptide, two overlapping casein kinase II phosphorylation sites and one N-glycosylation site with theoretical molecular weight of 9.3 kDa. 17091191 3 10 part_of kinase 879:884 arg1 a nuclear location signal peptide casein kinase II a nuclear location signal peptide OGER Site casein kinase II peptide Translation of the mRNA transcript revealed an open reading frame (ORF) of 86 amino acid residues encoding a nuclear location signal peptide, two overlapping casein kinase II phosphorylation sites and one N-glycosylation site with theoretical molecular weight of 9.3 kDa. 15247302 13 41 part_of AR 1920:1921 arg1 a previously unrecognized beta(2)AR regulatory motif beta(2)AR a previously unrecognized beta(2)AR regulatory motif PUBTATOR Site beta(2)AR 154 motif These data thus reveal a previously unrecognized beta(2)AR regulatory motif that appeared late in primate evolution and serves to direct internalized receptors to lysosomal degradation during long term agonist exposure. 15247302 13 46 part_of beta 1913:1916 arg1 a previously unrecognized beta(2)AR regulatory motif beta(2)AR a previously unrecognized beta(2)AR regulatory motif PUBTATOR Site beta(2)AR 154 motif These data thus reveal a previously unrecognized beta(2)AR regulatory motif that appeared late in primate evolution and serves to direct internalized receptors to lysosomal degradation during long term agonist exposure. 7753050 3 44 part_of CD9 418:420 arg1 The amino acid sequence CD9 The amino acid sequence PUBTATOR Site CD9 928 sequence The amino acid sequence of feline CD9 displays 95.1, 93.8 and 90.7% homology to human, murine and bovine CD9, respectively. 27743362 5 11 gly glycopeptides 692:704 arg2 These glycopeptides These glycopeptides glycopeptides These glycopeptides are then separated and detected using an integrated C18-porous graphitized carbon-liquid chromatography (PGC-LC) setup online coupled to a high-resolution electrospray ionization (ESI)-quadrupole time-of-flight (QTOF)-mass spectrometer operated in a combined higher- and lower-energy CID (stepping-energy CID) mode. 32211339 1 74 gly glycoprotein 122:133 arg1 The Ebola Virus (EBOV) glycoprotein The Ebola Virus (EBOV) glycoprotein Fterm glycoprotein The Ebola Virus (EBOV) glycoprotein (GP) sterically shields cell-membrane ligands to immune receptors such as human leukocyte antigen class-1 (HLA-I) and MHC class I polypeptide-related sequence A (MICA), thus mediating immunity evasion. 7711052 5 28 part_of Asn-288 1009:1015 arg1 plasminogen plasminogen Asn-288 OGER SpecificSite plasminogen P00747 Asn-288 The N-linked sugar on plasminogen (at Asn-288) within kringle 3 reduces the rate of the beta- to alpha-conformational change, modulates the transport of plasminogen into the extravascular compartment, decreases plasminogen binding to U937 cells and downregulates the activation of plasminogen by both urokinase and tissue plasminogen activator. 31501225 4 56 gly N-glycopeptide 565:578 arg2 N-glycopeptide N-glycopeptide N-glycopeptide We used an N-glycopeptide method based on 18O/16O C-terminal labeling to obtain 82 comparisons of serum from patients with HBV-related hepatocellular carcinoma (HCC) and liver cirrhosis (LC). 8212855 10 58 gly glycosylated 1637:1648 arg1 p32 p32 PUBTATOR p32 3622 Moreover tunicamycin treatment of cells infected with the virus indicated that p32 was glycosylated. 7522502 4 16 part_of receptor-binding 672:687 arg1 glucocorticoid receptor-binding sites glucocorticoid receptor glucocorticoid receptor-binding sites OGER Site glucocorticoid receptor P04150 sites It contains sequences similar to T-antigen, MyoD/E2A, and glucocorticoid receptor-binding sites. 7522502 4 18 part_of glucocorticoid 657:670 arg1 glucocorticoid receptor-binding sites glucocorticoid receptor glucocorticoid receptor-binding sites OGER Site glucocorticoid receptor P04150 sites It contains sequences similar to T-antigen, MyoD/E2A, and glucocorticoid receptor-binding sites. 8379944 3 51 part_of protein 477:483 arg1 the LCAT protein sequence LCAT protein the LCAT protein sequence PUBTATOR Site LCAT protein 3931 sequence 25% of the total LCAT mass, and four potential N-linked glycosylation sites have been predicted at residues 20, 84, 272 and 384 of the LCAT protein sequence. 8379944 3 94 part_of LCAT 472:475 arg1 the LCAT protein sequence LCAT protein the LCAT protein sequence PUBTATOR Site LCAT protein 3931 sequence 25% of the total LCAT mass, and four potential N-linked glycosylation sites have been predicted at residues 20, 84, 272 and 384 of the LCAT protein sequence. 1459141 5 59 gly glycosylation 979:991 arg2 asparagine-linked (N-linked) glycosylation site asparagine-linked (N-linked) glycosylation site site Additional mutations (Gly48-->Ser or Met29-->Thr) were created to make asparagine-linked (N-linked) glycosylation site in the [Ala128]lysozyme, and the resultant double mutants, [Ser48, Ala128]lysozyme and [Thr29, Ala128]lysozyme, were analyzed with respect to their intracellular degradation. 1697592 9 50 part_of protein 1591:1597 arg1 The COOH-terminal amino acid sequence protein The COOH-terminal amino acid sequence Fterm Site protein sequence The COOH-terminal amino acid sequence of the protein is highly enriched in acidic residues with 17 of the last 29 amino acids being negatively charged. 9352200 5 32 gly glycoproteins 593:605 arg1 glycoproteins glycoproteins Fterm glycoproteins The cDNA encoded a 454 amino acid protein homologous to the ZPC family of glycoproteins previously shown to be present in mammalian and fish egg envelopes. 7904345 1 45 gly glycosylation 50:62 arg1 soluble recombinant variants soluble recombinant variants Fterm variants The site-specific glycosylation of soluble recombinant variants of human and rat CD4 (sCD4) expressed in Chinese hamster ovary (CHO) cells has been characterized. 24073194 7 108 part_of protein 1148:1154 arg1 The predicted amino acid sequences H protein The predicted amino acid sequences OGER Site H protein Q13203 sequences The predicted amino acid sequences of the H protein were relatively conserved at most of the functionally significant amino acid positions. 30850477 1 30 gly glycans 137:143 arg1 their V regions their V regions their V regions Site regions Abs can acquire N-linked glycans in their V regions during Ag-specific B cell responses. 23075397 5 69 part_of greglin 905:911 arg1 the region greglin the region Fterm Site greglin region The crystal structure of the region of greglin comprising residues 21-78 in complex with subtilisin was determined at 1.75 Å resolution. 16274239 0 63 part_of receptor 78:85 arg1 Asn-579 epidermal growth factor receptor Asn-579 PUBTATOR SpecificSite epidermal growth factor receptor 13649 Asn-579 Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor. 21672516 0 47 gly leucine-rich 36:47 arg1 a novel small leucine-rich repeat matrix protein leucine a novel small leucine-rich repeat matrix protein leucine Podocan-like protein: a novel small leucine-rich repeat matrix protein in bone. 2110456 3 12 gly unglycosylated 273:286 arg1 The unglycosylated human protein The unglycosylated human protein Fterm protein The unglycosylated human protein was stable when expressed in bacteria or in Spodoptera frugiperda cells in the presence of tunicamycin but lacked catalytic activity. 19919546 4 5 gly glycoproteins 835:847 arg1 secreted glycoproteins secreted glycoproteins Here, we describe our strategy to approach the detection of these low-level glycoproteins: (a) a quantitative real-time PCR array for glycogenes to predict the glycan structures of secreted glycoproteins; (b) analysis by lectin microarray to select lectins that distinguish cancer-related glycan structures on secreted glycoproteins; and (c) an isotope-coded glycosylation site-specific tagging high-throughput method to identify carrier proteins with the specific lectin epitope. 19919546 4 8 gly glycoproteins 964:976 arg1 secreted glycoproteins secreted glycoproteins Here, we describe our strategy to approach the detection of these low-level glycoproteins: (a) a quantitative real-time PCR array for glycogenes to predict the glycan structures of secreted glycoproteins; (b) analysis by lectin microarray to select lectins that distinguish cancer-related glycan structures on secreted glycoproteins; and (c) an isotope-coded glycosylation site-specific tagging high-throughput method to identify carrier proteins with the specific lectin epitope. 19919546 4 20 gly glycoproteins 721:733 arg1 these low-level glycoproteins these low-level glycoproteins Here, we describe our strategy to approach the detection of these low-level glycoproteins: (a) a quantitative real-time PCR array for glycogenes to predict the glycan structures of secreted glycoproteins; (b) analysis by lectin microarray to select lectins that distinguish cancer-related glycan structures on secreted glycoproteins; and (c) an isotope-coded glycosylation site-specific tagging high-throughput method to identify carrier proteins with the specific lectin epitope. 21515415 4 19 gly utilized 664:671 arg2 all six sites all six sites sites The apparent size of each of the six PLTP mutants was slightly less than that of wild type by Western blot, indicating that all six sites are glycosylated or utilized. 21515415 4 69 gly glycosylated 648:659 arg1 all six sites all six sites sites The apparent size of each of the six PLTP mutants was slightly less than that of wild type by Western blot, indicating that all six sites are glycosylated or utilized. 1331083 1 74 gly Asn-linked 147:156 arg1 Asn-linked oligosaccharides Asn Asn-linked oligosaccharides Asn We have examined the phosphorylation of Asn-linked oligosaccharides introduced at seven novel sites on human cathepsin D to determine whether the location of an oligosaccharide on a lysosomal enzyme affects its ability to serve as a substrate for UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (phosphotransferase), the enzyme that catalyzes the initial step in the biosynthesis of mannose 6-phosphate residues. 26776361 3 9 gly full-glycosylated 810:826 arg1 full-glycosylated EPO full-glycosylated EPO PUBTATOR EPO 2056 PEGylation with two short 750 or 2000 Da PEG units at positions 24, 38, or 83 significantly decreased unspecific aggregation and proteolytic degradation while biological activity in vitro was preserved or even increased in comparison to full-glycosylated EPO. 16622833 2 52 gly N-glycosylation 245:259 arg2 The three N-glycosylation sites A1PI sites PUBTATOR A1PI 5265 sites The three N-glycosylation sites of A1PI contain diantennary N-glycans but also triantennary and even traces of tetraantennary structures leading to the typical IEF pattern observed for A1PI. 16622833 2 16 gly contain 275:281 arg1 The three N-glycosylation sites AND diantennary N-glycans but also triantennary and even traces A1PI sites diantennary N-glycans but also triantennary and even traces PUBTATOR A1PI 5265 sites The three N-glycosylation sites of A1PI contain diantennary N-glycans but also triantennary and even traces of tetraantennary structures leading to the typical IEF pattern observed for A1PI. 32110292 7 35 gly N-glycosylation 1393:1407 arg1 IgG IgG Cterm IgG Combined with high-energy collisional dissociation for the fragmentation of glycans, fine mapping of the N-glycosylation profile of IgG is achieved. 8760363 1 32 part_of cDNA 155:158 arg1 A 450 bp cDNA fragment cDNA A 450 bp cDNA fragment Cterm Site cDNA fragment A 450 bp cDNA fragment similar to that encoding bovine fibromodulin was isolated using a screening procedure to isolate genes differentially expressed between the pre- and post-growth phases of fibril growth in the developing chicken embryo metatarsal tendon. 2500441 2 27 gly glycosylated 442:453 arg1 a glycosylated variant a glycosylated variant Fterm variant Purified human IGF-I from yeast culture media was found to contain, in addition to the native form, also a glycosylated variant. 30841845 8 103 gly glycosylation 1383:1395 arg2 experimentally verified glycosylation sites experimentally verified glycosylation sites sites Moreover, supervised algorithms often fail to take advantage of large volumes of unlabelled data, which can aid in model learning in conjunction with positive samples (i.e. experimentally verified glycosylation sites). 31266872 1 49 gly glycoproteins 443:455 arg1 phylogenetically and antigenically distinct envelope glycoproteins phylogenetically and antigenically distinct envelope glycoproteins Fterm glycoproteins As a consequence of their independent evolutionary origins in apes and Old World monkeys, human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency viruses of the SIVsmm/mac lineage express phylogenetically and antigenically distinct envelope glycoproteins. 32168410 4 50 gly Asparagine-linked 577:593 arg1 Asparagine-linked carbohydrates Asparagine Asparagine-linked carbohydrates Asparagine METHODS: Asparagine-linked carbohydrates were released from human FXIIII-B by PNGase F digestion. 29463651 7 7 gly protein 1628:1634 arg1 N-glycan modification protein N-glycan modification Fterm protein In spite of the extensive studies of the involvement of N-glycan modification of flavivirus E protein in virus-host interactions, we discovered its critical role in virus-vector interaction and the evolution of flavivirus. 29463651 7 12 gly modification 1599:1610 arg3 flavivirus E protein AND N-glycan modification flavivirus E protein N-glycan modification Fterm protein In spite of the extensive studies of the involvement of N-glycan modification of flavivirus E protein in virus-host interactions, we discovered its critical role in virus-vector interaction and the evolution of flavivirus. 8188681 0 10 gly glycosylation 62:74 arg2 the glycosylation sites the glycosylation sites sites Site-directed mutagenesis defines the individual roles of the glycosylation sites on follicle-stimulating hormone. 20543007 6 74 part_of contains 965:972 arg1 H-CDR3 AND three residues CDR3 residues ((99) PUBTATOR SpecificSite CDR3 8163 residues ((99) Structural studies combined with mutagenesis data identified an aggregation 'hot spot' in heavy-chain CDR3 (H-CDR3) that contains three residues ((99)FHW(100a)). 21970473 8 29 part_of proteins 1547:1554 arg1 the CF peptides proteins the CF peptides Fterm Site proteins peptides To illustrate the feasibility of the quantification method, the CF peptides of target proteins in clinical serum were quantified and compared as a preliminary demonstration. 25759508 3 42 part_of IgG3 425:428 arg1 the IgG3 hinge region IgG3 the IgG3 hinge region PUBTATOR Site IgG3 P01860 region This study reports partial O-glycosylation of the IgG3 hinge region, observed with nanoLC-ESI-IT-MS(/MS) analysis after proteolytic digestion. 23891555 22 27 gly O-glycopeptide 3494:3507 arg2 O-glycopeptide isoforms O-glycopeptide isoforms O-glycopeptide As another new feature, we introduce a software solution for the interpretation of MS/MS data of O-glycopeptide isoforms, which provides the possibility of fast and easier data processing. 17670834 8 67 gly glycosylation 1412:1424 arg2 the recently acquired potential glycosylation sites the recently acquired potential glycosylation sites sites Deletion of either of the recently acquired potential glycosylation sites from HA led to increased NK lysis of cells infected with recombinant viruses carrying modified HA. 18723043 2 44 part_of protease 645:652 arg1 its amino acid sequence protease its amino acid sequence Fterm Site protease sequence KR-E-1 consisted of 235 amino acids and showed conservation of the catalytic amino acid residues (His(57), Asp(102), and Ser(195)) of the chymotrypsin family of serine protease in its amino acid sequence. 18930737 6 45 part_of PIP 831:833 arg1 The amino acid sequence PIP The amino acid sequence PUBTATOR Site PIP 5304 sequence The amino acid sequence of PIP contains one potential N-glycosylation site at Asn77, and the same is found glycosylated with four sugar residues. 18930737 6 66 part_of contains 835:842 arg1 The amino acid sequence AND one potential N-glycosylation site The amino acid sequence one potential N-glycosylation site site The amino acid sequence of PIP contains one potential N-glycosylation site at Asn77, and the same is found glycosylated with four sugar residues. 3123215 1 56 gly glycoprotein 115:126 arg1 Synaptophysin Synaptophysin PUBTATOR Synaptophysin 24804 Synaptophysin is a major glycoprotein of Mr approximately 38,000 (in deglycosylated form: Mr approximately 34,000) characteristic of a certain class of small (30-80 nm diameter) neurosecretory vesicles, including presynaptic vesicles, but also vesicles of various neuroendocrine cells of both neuronal and epithelial phenotype. 3123215 1 56 gly glycoprotein 115:126 arg1 a major glycoprotein a major glycoprotein Fterm glycoprotein Synaptophysin is a major glycoprotein of Mr approximately 38,000 (in deglycosylated form: Mr approximately 34,000) characteristic of a certain class of small (30-80 nm diameter) neurosecretory vesicles, including presynaptic vesicles, but also vesicles of various neuroendocrine cells of both neuronal and epithelial phenotype. 32258897 2 60 gly heterogeneity 335:347 arg1 carbohydrate moieties carbohydrate moieties Herein, we characterized N-glycosylation heterogeneity of R27T, which includes both N-glycan site occupancy heterogeneity (macro-heterogeneity) and complexity of carbohydrate moieties (micro-heterogeneity). 9792708 1 41 gly contains 144:151 arg1 The mouse hepatitis virus (MHV) membrane (M) protein AND only O-linked oligosaccharides The mouse hepatitis virus (MHV) membrane (M) protein only O-linked oligosaccharides OGER M) protein P54296 The mouse hepatitis virus (MHV) membrane (M) protein contains only O-linked oligosaccharides. 31393126 5 71 gly glycopeptides 779:791 arg2 tryptic glycopeptides tryptic glycopeptides glycopeptides Second, tryptic glycopeptides were enriched and separated by hydrophilic interaction liquid chromatography-ion trap-sequential mass spectrometry (HILIC-IT-MS). 25629924 3 89 gly glycosylation 408:420 arg1 sIgA sIgA Cterm IgA P11912 In this study, the site-specific glycosylation of sIgA isolated from human colostrum (n = 3) was analyzed using a combination of LC-MS and LC-MS/MS and in-house software (Glycopeptide Finder). 1697592 3 27 gly glycosylation 796:808 arg2 glycosylation site binding protein glycosylation site binding protein site The deduced amino acid sequence of the rabbit muscle clone suggested that this protein is related to human liver thyroid hormone binding protein, rat liver protein disulfide isomerase, human hepatoma beta-subunit of prolyl 4-hydroxylase and hen oviduct glycosylation site binding protein. 8982862 3 70 gly glycoprotein 654:665 arg1 glycoprotein glycoprotein Fterm glycoprotein In this study, the complete primary structure of porcine vitronectin was elucidated by cloned cDNA and glycoprotein analyses. 15247302 2 72 gly N-glycosylation 334:348 arg2 ECL2 residue 187 ECL2 residue 187 residue 187 However, the human beta(2)AR has a potential third N-glycosylation site at ECL2 residue 187. 15247302 2 72 gly N-glycosylation 334:348 arg2 a potential third N-glycosylation site a potential third N-glycosylation site site However, the human beta(2)AR has a potential third N-glycosylation site at ECL2 residue 187. 7505572 5 34 part_of protein 654:660 arg1 4-6 membrane-spanning domains protein 4-6 membrane-spanning domains Fterm Site protein domains Analysis of the predicted amino acid sequence indicated a hydrophobic protein with 4-6 membrane-spanning domains, with one N-linked glycosylation site, two conserved NPA boxes common to MIP26 family proteins, and conserved residue C189 common to water channels. 26022737 4 30 gly glycosylation 501:513 arg2 This extra glycosylation site PSA site PUBTATOR PSA P07288 site This extra glycosylation site of PSA is associated with a mutation in KLK3 genes. 29285644 5 9 gly glycopeptides 1041:1053 arg2 site-specific glycopeptides site-specific glycopeptides glycopeptides Serum haptoglobin enriched by immunoaffinity chromatography was subjected to multispecific proteolysis to generate site-specific glycopeptides and to investigate the macroheterogeneity and microheterogeneity. 9201996 5 45 part_of containing 1019:1028 arg1 peptides AND one to three proline residues peptides one to three proline residues proline residues To define the effect of proline residues around the glycosylation site, we analyzed a series of peptides containing one to three proline residues in a parent peptide AAATAAA. 7768336 1 12 part_of residues 155:162 arg1 the mouse gonadotropin-releasing hormone receptor gonadotropin-releasing hormone receptor residues PUBTATOR AminoAcid gonadotropin-releasing hormone receptor 14715 asparagine residues The asparagine residues of the three N-glycosylation consensus sequences in the mouse gonadotropin-releasing hormone receptor were mutated to determine which residues were glycosylated and the function of glycosylation. 7768336 1 47 part_of receptor 257:264 arg1 The asparagine residues gonadotropin-releasing hormone receptor The asparagine residues PUBTATOR AminoAcid gonadotropin-releasing hormone receptor 14715 asparagine residues The asparagine residues of the three N-glycosylation consensus sequences in the mouse gonadotropin-releasing hormone receptor were mutated to determine which residues were glycosylated and the function of glycosylation. 7768336 1 47 part_of receptor 257:264 arg1 the three N-glycosylation consensus sequences gonadotropin-releasing hormone receptor the three N-glycosylation consensus sequences PUBTATOR Site gonadotropin-releasing hormone receptor 14715 sequences The asparagine residues of the three N-glycosylation consensus sequences in the mouse gonadotropin-releasing hormone receptor were mutated to determine which residues were glycosylated and the function of glycosylation. 7768336 1 50 part_of sequences 203:211 arg1 the mouse gonadotropin-releasing hormone receptor gonadotropin-releasing hormone receptor sequences PUBTATOR Site gonadotropin-releasing hormone receptor 14715 sequences The asparagine residues of the three N-glycosylation consensus sequences in the mouse gonadotropin-releasing hormone receptor were mutated to determine which residues were glycosylated and the function of glycosylation. 8435067 6 32 gly alpha-glucosidase 862:878 arg1 the oligosaccharide side chains lysosomal alpha-glucosidase the oligosaccharide side chains PUBTATOR lysosomal alpha-glucosidase 2548 Evidence is presented that at least two of the oligosaccharide side chains of human lysosomal alpha-glucosidase are phosphorylated. 8099782 5 23 gly deglycosylated 863:876 arg1 deglycosylated saposin B deglycosylated saposin B Cterm deglycosylated saposin B Neither native saposin B nor deglycosylated saposin B were hydrolyzed by trypsin, endoproteinase Glu-C (V-8), chymotrypsin, or a mixture of acid proteases isolated from human testis. 21270153 7 40 part_of receptor 1402:1409 arg1 the specific glycosylation site PiT1 receptor the specific glycosylation site PUBTATOR Site PiT1 receptor 18736 site N-linked glycosylation of the receptors was not found to mediate resistance of receptor-expressing BHK cells to GALV or XMRV, as shown by tunicamycin treatment and mutation of the specific glycosylation site of the PiT1 receptor. 16567801 1 30 gly glycoprotein 193:204 arg1 a major glycoprotein a major glycoprotein Fterm glycoprotein Although it has been shown that mouse uroplakin (UP) Ia, a major glycoprotein of urothelial apical surface, can serve as the receptor for the FimH lectin adhesin of type 1-fimbriated Escherichia coli, the organism that causes a great majority of urinary tract infections, the glycan structure of this native receptor was unknown. 16567801 1 30 gly glycoprotein 193:204 arg1 mouse uroplakin (UP) Ia mouse uroplakin (UP) Ia PUBTATOR uroplakin (UP) Ia 109637 Although it has been shown that mouse uroplakin (UP) Ia, a major glycoprotein of urothelial apical surface, can serve as the receptor for the FimH lectin adhesin of type 1-fimbriated Escherichia coli, the organism that causes a great majority of urinary tract infections, the glycan structure of this native receptor was unknown. 16567801 1 45 gly receptor 436:443 arg1 the glycan structure receptor the glycan structure Fterm receptor Although it has been shown that mouse uroplakin (UP) Ia, a major glycoprotein of urothelial apical surface, can serve as the receptor for the FimH lectin adhesin of type 1-fimbriated Escherichia coli, the organism that causes a great majority of urinary tract infections, the glycan structure of this native receptor was unknown. 16432019 8 12 part_of site 1446:1449 arg1 the envelope protein protein site Fterm Site protein site Several nucleotide and amino acid deletions and/or substitutions with putative functional significance were identified in ALFV, including the abolition of a conserved glycosylation site in the envelope protein and the deletion of the terminal dinucleotide 5'-CU(OH)-3' found in all other members of the genus. 31958346 11 71 gly N401-glycosite 1764:1777 arg1 GluA1 GluA1 N401 PUBTATOR GluA1 2890 N401 Taken together, we propose that the N401-glycosite of GluA1 receives a unique control of modification, and we also propose a novel N-glycosylation occupancy regulatory mechanism by Bip that might be associated with α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors function in the brain. 12706347 9 4 gly glycosylation 1757:1769 arg1 this residue this residue residue Since this N-glycosylation site is invariant in cell membrane eNTPDases, it is postulated that glycosylation of this residue near ACR1 is crucial for full enzymatic activity of the cell membrane NTPDases. 12706347 9 48 gly N-glycosylation 1673:1687 arg2 this N-glycosylation site this N-glycosylation site site Since this N-glycosylation site is invariant in cell membrane eNTPDases, it is postulated that glycosylation of this residue near ACR1 is crucial for full enzymatic activity of the cell membrane NTPDases. 2189790 4 35 gly glycosylation 598:610 arg2 three N-linked glycosylation sites three N-linked glycosylation sites sites The extent of glycosylation was significantly reduced using the alpha-factor signal sequence, which itself contains three N-linked glycosylation sites known to be core glycosylated. 9287313 6 31 gly glycosylation 1588:1600 arg2 atypical and typical glycosylation motifs atypical and typical glycosylation motifs motifs The results in this study provide a molecular basis for human CD69 heterogeneity and show that multiple dimeric forms of human CD69 result from the variable addition of N-glycans to atypical and typical glycosylation motifs within the CD69 extracellular domain. 8354274 5 23 part_of enzyme 852:857 arg1 The N-terminal and C-terminal sequences enzyme The N-terminal and C-terminal sequences Fterm Site enzyme sequences The N-terminal and C-terminal sequences of the enzyme matched the sequences deduced from nucleotide analysis. 12235182 5 59 gly glycosylation 1182:1194 arg2 its N-linked glycosylation sites its N-linked glycosylation sites sites Similarly, mutant apoB-50 with all of its N-linked glycosylation sites mutagenized showed decreased secretion efficiency and decreased lipoprotein association in both d < 1.02 and d > 1.02 g/ml fractions. 20153530 1 1 gly oligosaccharides 170:185 arg1 native human C9 C9 oligosaccharides PUBTATOR C9 117512 The two N-linked oligosaccharides in native human C9 were deleted by site-specific mutagenesis. 8486693 6 64 part_of possesses 1248:1256 arg1 The GP-3 sequence AND the serine esterase consensus sequence G-X-S-X-G The GP-3 sequence the serine esterase consensus sequence G-X-S-X-G sequence The GP-3 sequence possesses the serine esterase consensus sequence G-X-S-X-G centered around Ser154 and the catalytic state triad Asp178-His265-Ser154 characteristic of pancreatic lipases. 27161092 6 26 gly O-glycosylation 987:1001 arg1 Muc5ac Muc5ac PUBTATOR Muc5ac P98088 Our results demonstrated that the FUT2 determines the O-glycosylation pattern of Muc5ac, with Fut2 knock-out leading to a marked decrease in α1,2-fucosylated structures and increased expression of the terminal type 1 glycan structure Lewis-a. 27161092 6 64 gly α1,2-fucosylated 1074:1089 arg1 α1,2-fucosylated structures α1,2-fucosylated structures Our results demonstrated that the FUT2 determines the O-glycosylation pattern of Muc5ac, with Fut2 knock-out leading to a marked decrease in α1,2-fucosylated structures and increased expression of the terminal type 1 glycan structure Lewis-a. 18824476 1 32 gly Glycosylation 124:136 arg1 proteins proteins Fterm proteins Glycosylation of proteins greatly affects their structure and function, but traditional genomics and transcriptomics are not able to precisely capture tissue- or species-specific glycosylation patterns. 2844797 1 94 part_of ATP-binding 287:297 arg1 the ATP-binding site ATP the ATP-binding site OGER Site ATP site Identification of cDNAs encoding Ca2+ and other cation-transporting ATPases using an oligonucleotide probe derived from the ATP-binding site. 10856884 11 105 part_of containing 1537:1546 arg1 a predicted 228 amino acid protein AND a 28 amino acid signal peptide a predicted 228 amino acid protein a 28 amino acid signal peptide Fterm Site protein peptide The rat PLP-K cDNA encodes for a predicted 228 amino acid protein containing a 31 amino acid signal peptide and one putative N-linked glycosylation site; the mouse PLP-M cDNA encodes for a predicted 228 amino acid protein containing a 28 amino acid signal peptide and one putative N-linked glycosylation site. 10856884 11 105 part_of containing 1537:1546 arg1 a predicted 228 amino acid protein AND one putative N-linked glycosylation site a predicted 228 amino acid protein one putative N-linked glycosylation site Fterm Site protein site The rat PLP-K cDNA encodes for a predicted 228 amino acid protein containing a 31 amino acid signal peptide and one putative N-linked glycosylation site; the mouse PLP-M cDNA encodes for a predicted 228 amino acid protein containing a 28 amino acid signal peptide and one putative N-linked glycosylation site. 10856884 11 29 part_of containing 1381:1390 arg1 a predicted 228 amino acid protein AND one putative N-linked glycosylation site a predicted 228 amino acid protein one putative N-linked glycosylation site Fterm Site protein site The rat PLP-K cDNA encodes for a predicted 228 amino acid protein containing a 31 amino acid signal peptide and one putative N-linked glycosylation site; the mouse PLP-M cDNA encodes for a predicted 228 amino acid protein containing a 28 amino acid signal peptide and one putative N-linked glycosylation site. 10856884 11 29 part_of containing 1381:1390 arg1 a predicted 228 amino acid protein AND a 31 amino acid signal peptide a predicted 228 amino acid protein a 31 amino acid signal peptide Fterm Site protein peptide The rat PLP-K cDNA encodes for a predicted 228 amino acid protein containing a 31 amino acid signal peptide and one putative N-linked glycosylation site; the mouse PLP-M cDNA encodes for a predicted 228 amino acid protein containing a 28 amino acid signal peptide and one putative N-linked glycosylation site. 10858228 3 70 gly glycoprotein 395:406 arg1 a mucin-like glycoprotein a mucin-like glycoprotein Fterm glycoprotein In this study we have shown that gp40, a mucin-like glycoprotein, is localized to the surface and apical region of invasive stages of the parasite and is shed from its surface. 10858228 3 70 gly glycoprotein 395:406 arg1 gp40 gp40 OGER gp40 P09564 In this study we have shown that gp40, a mucin-like glycoprotein, is localized to the surface and apical region of invasive stages of the parasite and is shed from its surface. 15147907 3 2 gly glycoprotein 510:521 arg1 a human serum glycoprotein a human serum glycoprotein Fterm glycoprotein This finding represents the first report of monoglucosylated glycans on a human serum glycoprotein from non-diseased individuals. 24899172 7 56 gly glycosylation 1223:1235 arg2 5 AGL glycosylation sites 5 AGL glycosylation sites sites Envelope proteins bearing 5 AGL glycosylation sites became hyperglycosylated, leading to an increased capacity for SVP secretion at the expense of HBV and HDV virion secretion. 1331508 6 33 gly N-glycosylation 928:942 arg2 a putative N-glycosylation site a putative N-glycosylation site site The NH2-terminal immunoglobulin-like domain, domain 1, of the second monkey PVR, which lacks a putative N-glycosylation site, mediated poliovirus infection. 28860626 1 38 part_of site 351:354 arg1 neuraminidase neuraminidase site Fterm Site neuraminidase site The outbreak of a pandemic influenza H1N1 in 2009 required the rapid generation of high-yielding vaccines against the A/California/7/2009 virus, which were achieved by either addition or deletion of a glycosylation site in the influenza proteins hemagglutinin and neuraminidase. 28860626 1 38 part_of site 351:354 arg1 the influenza proteins hemagglutinin hemagglutinin site Fterm Site hemagglutinin site The outbreak of a pandemic influenza H1N1 in 2009 required the rapid generation of high-yielding vaccines against the A/California/7/2009 virus, which were achieved by either addition or deletion of a glycosylation site in the influenza proteins hemagglutinin and neuraminidase. 24150277 13 22 gly glycosylation 1591:1603 arg2 the conserved CH2 glycosylation site the conserved CH2 glycosylation site site We successfully produced an antibody with an azido-sugar at the conserved CH2 glycosylation site. 24150277 13 41 gly site 1605:1608 arg1 an azido-sugar site an azido-sugar site We successfully produced an antibody with an azido-sugar at the conserved CH2 glycosylation site. 15750791 5 23 gly N-glycan 769:776 arg1 Edg-1/S1P1 Edg-1 N-glycan PUBTATOR Edg-1 1901 These studies revealed a possible regulatory role for the N-glycan on Edg-1/S1P1 in the dynamics of the receptor, such as its lateral and internal movements within the membrane, in ligand-stimulated mammalian cells. 29587225 5 24 gly glycosylation 749:761 arg2 the glycosylation sites the glycosylation sites sites The results revealed that desialylation enhances structural flexibility near the glycosylation sites, with greater effects observed around the O-glycosylation site relative to the N-glycosylation sites. 29587225 5 43 gly N-glycosylation 848:862 arg2 the N-glycosylation sites the N-glycosylation sites sites The results revealed that desialylation enhances structural flexibility near the glycosylation sites, with greater effects observed around the O-glycosylation site relative to the N-glycosylation sites. 29587225 5 47 gly O-glycosylation 811:825 arg2 the O-glycosylation site the O-glycosylation site site The results revealed that desialylation enhances structural flexibility near the glycosylation sites, with greater effects observed around the O-glycosylation site relative to the N-glycosylation sites. 16386114 0 28 part_of Full 0:3 arg1 Full sequence Full Full sequence OGER Site Full Q8N1N2 sequence Full sequence of HIV type 1 Korean subtype B in an AIDS case with atypical seroconversion: TAAAA at TATA box. 27038555 8 14 gly glycosylation 1219:1231 arg2 glycosylation sites glycosylation sites sites Inspecting these sequences revealed that frequent mutations occurred in neutralizing epitopes and glycosylation sites. 10191360 3 3 part_of have 388:391 arg1 Kv1.1 AND a single consensus glycosylation site Kv1.1 a single consensus glycosylation site PUBTATOR Site Kv1.1 3736 site We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains. 10191360 3 3 part_of have 388:391 arg1 Kv1.4 AND a single consensus glycosylation site Kv1.4 a single consensus glycosylation site PUBTATOR Site Kv1.4 3739 site We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains. 10191360 3 3 part_of have 388:391 arg1 Kv1.2 AND a single consensus glycosylation site Kv1.2 a single consensus glycosylation site PUBTATOR Site Kv1.2 3737 site We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains. 10207016 6 66 part_of protein 1316:1322 arg1 the pre-S2 domain M protein the pre-S2 domain OGER Site M protein P54296 domain In addition, the pre-S2 domain of M protein, but not that of L protein, was found to be partially O-glycosylated by a Gal(beta1-3)GalNAcalpha-, Neu5Ac(alpha2-3)Gal(beta1-3)GalNAcalpha-, or GalNAcalpha-residue. 10207016 6 96 part_of protein 1343:1349 arg1 the pre-S2 domain protein the pre-S2 domain Fterm Site protein domain In addition, the pre-S2 domain of M protein, but not that of L protein, was found to be partially O-glycosylated by a Gal(beta1-3)GalNAcalpha-, Neu5Ac(alpha2-3)Gal(beta1-3)GalNAcalpha-, or GalNAcalpha-residue. 22015153 7 19 part_of contained 964:972 arg1 Feline oviductin AND six O-linked glycosylation sites Feline oviductin six O-linked glycosylation sites OGER Site Feline oviductin Q12889 sites Feline oviductin contained one putative N-linked glycosylation site, six O-linked glycosylation sites, a potential heparin binding site, and two cholesterol recognition and/or interaction amino acid consensus (CRAC) domains. 22015153 7 19 part_of contained 964:972 arg1 Feline oviductin AND a potential heparin binding site Feline oviductin site OGER Site Feline oviductin Q12889 site Feline oviductin contained one putative N-linked glycosylation site, six O-linked glycosylation sites, a potential heparin binding site, and two cholesterol recognition and/or interaction amino acid consensus (CRAC) domains. 1402806 6 13 part_of protein 1007:1013 arg1 The amino acid sequence M protein The amino acid sequence OGER Site M protein P54296 sequence The amino acid sequence of the M protein of HCV-OC43 has 94% identity with that of the Mebus strain of BCV, and also contains six potential O-glycosylation sites in the exposed N-terminal domain. 1402806 6 93 part_of contains 1091:1098 arg1 the exposed N-terminal domain AND six potential O-glycosylation sites sites sites The amino acid sequence of the M protein of HCV-OC43 has 94% identity with that of the Mebus strain of BCV, and also contains six potential O-glycosylation sites in the exposed N-terminal domain. 1402806 6 93 part_of contains 1091:1098 arg1 the exposed N-terminal domain AND The amino acid sequence sequence sequence The amino acid sequence of the M protein of HCV-OC43 has 94% identity with that of the Mebus strain of BCV, and also contains six potential O-glycosylation sites in the exposed N-terminal domain. 30898876 6 53 gly glycoproteins 1400:1412 arg1 the identified glycoproteins the identified glycoproteins Fterm glycoproteins Our analysis also uncovered that most of the identified glycoproteins localize to intracellular organelles, particularly to the endoplasmic reticulum. 6980014 6 52 part_of contain 902:908 arg1 II AND fragments II and III each II fragments one carbohydrate chain Cterm Site II fragments On the other hand, fragments II and III each contain one carbohydrate chain exclusively by the biantennary type of complex N-glycoside. 31325506 7 32 part_of BSM 1539:1541 arg1 glycopeptides BSM glycopeptides Cterm Site BSM 281333 glycopeptides The N-glycosylation sites were identified from the analysis of glycopeptides from BSM. 24798328 5 58 gly O-glycosylation 702:716 arg2 O-glycosylation sites O-glycosylation sites sites Herein, we have systematically characterized O-glycosylation sites on recombinant LDLR shed from HEK293 SimpleCells and CHO wild-type cells. 29759137 2 30 gly glycosylation 199:211 arg1 IgG IgG Cterm IgG Changes in glycosylation of IgG occur in many autoimmune diseases but also in physiological conditions. 25452312 10 13 gly N-glycopeptides 1098:1112 arg2 These enriched N-glycopeptides These enriched N-glycopeptides N-glycopeptides These enriched N-glycopeptides were solved for their peptide sequence, glycan composition, structure, and glycosylation site using collision-induced dissociation MS/MS (CID-tandem MS) data interpreted by a publicly available software GlycopeptideId. 25452312 10 19 gly glycosylation 1189:1201 arg2 glycosylation site glycosylation site site These enriched N-glycopeptides were solved for their peptide sequence, glycan composition, structure, and glycosylation site using collision-induced dissociation MS/MS (CID-tandem MS) data interpreted by a publicly available software GlycopeptideId. 10731668 5 44 gly glycosylation 815:827 arg2 32 Asn(32 ) Asn(32 ) The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified. 10731668 5 44 gly glycosylation 815:827 arg1 Asn Asn(32 ) Asn(32 ) The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified. 10731668 5 44 gly glycosylation 815:827 arg2 Asn Asn(32 ) Asn(32 ) The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified. 10731668 5 44 gly glycosylation 815:827 arg1 CHO sEGFR CHO sEGFR Asn(32 ) PUBTATOR CHO sEGFR P00533 Asn(32 ) The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified. 10731668 5 44 gly glycosylation 815:827 arg1 Asn Asn(32 ) Asn(32 ) The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified. 10731668 5 44 gly glycosylation 815:827 arg2 Asn Asn(32 ) Asn(32 ) The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified. 10731668 5 44 gly glycosylation 815:827 arg1 CHO sEGFR CHO sEGFR Asn(32 ) PUBTATOR CHO sEGFR P00533 Asn(32 ) The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified. 10731668 5 44 gly glycosylation 815:827 arg2 Asn Asn(32 ) Asn(32 ) The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified. 10731668 5 44 gly glycosylation 815:827 arg1 CHO sEGFR CHO sEGFR Asn(32 ) PUBTATOR CHO sEGFR P00533 Asn(32 ) The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified. 10731668 5 44 gly glycosylation 815:827 arg1 CHO sEGFR CHO sEGFR Asn(32 ) PUBTATOR CHO sEGFR P00533 Asn(32 ) The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified. 23820512 7 14 gly N-glycosites 1077:1088 arg2 865 and 295 N-glycosites 865 and 295 N-glycosites N-glycosites Overall, a total of 865 and 295 N-glycosites were identified from three pairs of urine and plasma samples, respectively. 16873272 1 62 gly glycoprotein 114:125 arg1 Env Env Cterm Env P40189 The foamy virus (FV) glycoprotein precursor gp130(Env) undergoes a highly unusual biosynthesis, resulting in the generation of three particle-associated, mature subunits, leader peptide (LP), surface (SU), and transmembrane (TM). 16873272 1 62 gly glycoprotein 114:125 arg1 The foamy virus (FV) glycoprotein The foamy virus (FV) glycoprotein Fterm glycoprotein The foamy virus (FV) glycoprotein precursor gp130(Env) undergoes a highly unusual biosynthesis, resulting in the generation of three particle-associated, mature subunits, leader peptide (LP), surface (SU), and transmembrane (TM). 22365690 2 71 gly N-glycosylation 478:492 arg2 N-glycosylation sites N-glycosylation sites sites In this approach, all peptides of four biological samples are labeled with four iTRAQ reagents in parallel, followed by PNGase F catalyzed labeling of N-glycosylation sites with H(2)(16)O and H(2)(18)O. Two sample groups are labeled with H(2)(16)O and the other two are labeled with H(2)(18)O. 11955599 3 16 part_of receptors 372:380 arg1 the C-terminal domain receptors the C-terminal domain Fterm Site receptors domain Regions of the C-terminal domain of Fc receptors including the BC, C'E, FG loops, and the C' beta-strand interact with immunoglobulins. 19822741 8 1 gly glycans 1406:1412 arg1 viral surface glycoproteins glycoproteins glycans Fterm glycoproteins Thus, removal of structurally nonessential glycans on viral surface glycoproteins may be a very effective and general approach for vaccine design against influenza and other human viruses. 19822741 8 71 gly glycoproteins 1431:1443 arg1 viral surface glycoproteins viral surface glycoproteins Fterm glycoproteins Thus, removal of structurally nonessential glycans on viral surface glycoproteins may be a very effective and general approach for vaccine design against influenza and other human viruses. 2558633 1 20 gly glycoprotein 204:215 arg1 glycoprotein (i.e. VP7 or G) serotypes 3, 4, and 5 glycoprotein (i.e. VP7 or G) serotypes 3, 4, and 5 Fterm glycoprotein The genes coding for the rotavirus major neutralizing protein, VP7, from 5 Australian porcine rotaviruses representing glycoprotein (i.e. VP7 or G) serotypes 3, 4, and 5, were sequenced. 9142045 11 62 gly glycoproteins 2551:2563 arg1 the integrin glycoproteins the integrin glycoproteins Fterm glycoproteins The observed reversibility of the interactions between the integrin glycoproteins and uPAR or CD14 illustrates the fact that these associations can be highly dynamic and tied to cellular processes that include directed motility (Mo1-uPAR), adherence to substrates (Mo1-CD14), and energy metabolism (p150,95-uPAR). 19874459 9 83 gly present 1294:1300 arg1 VWF AND Eighteen O-glycan structures VWF Eighteen O-glycan structures PUBTATOR VWF 7450 Eighteen O-glycan structures including both core 1 and core 2 structures are now demonstrated to be present on VWF. 19874459 9 83 gly present 1294:1300 arg2 VWF AND core 2 VWF core 2 PUBTATOR VWF 7450 Eighteen O-glycan structures including both core 1 and core 2 structures are now demonstrated to be present on VWF. 19874459 9 83 gly present 1294:1300 arg2 VWF AND core 1 VWF core 1 PUBTATOR VWF 7450 Eighteen O-glycan structures including both core 1 and core 2 structures are now demonstrated to be present on VWF. 1990068 1 29 part_of glycoprotein 252:263 arg1 The sequence glycoprotein The sequence Fterm Site glycoprotein sequence The sequence of the fusion (F) glycoprotein of turkey rhinotracheitis virus (TRTV) has been deduced from cDNA clones derived from oligo(dT)-selected infected cell RNA. 9726253 8 50 gly glycosylation 1460:1472 arg2 200Asn-X-Thr202 200Asn-X-Thr202 Thr202 The R200N mutation in the gpP450c17 protein introduced a potential N-linked glycosylation site (200Asn-X-Thr202); however, substitution of the Thr202 residue by an asparagine (R200N/T202N), which abolishes the site, did not change the preference of the gpP450c17 mutant for pregnenolone. 9726253 8 50 gly glycosylation 1460:1472 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site The R200N mutation in the gpP450c17 protein introduced a potential N-linked glycosylation site (200Asn-X-Thr202); however, substitution of the Thr202 residue by an asparagine (R200N/T202N), which abolishes the site, did not change the preference of the gpP450c17 mutant for pregnenolone. 14757769 8 1 gly hyperglycosylated 1465:1481 arg2 sites sites sites However, it was noted that recombinant human erythropoietin analogs that were hyperglycosylated at sites that were normally buried had altered protein structures. 10497235 9 4 part_of triadin 1218:1224 arg1 The glycosylation site triadin The glycosylation site OGER Site triadin Q13061 site The glycosylation site of triadin 1 was localized to asparagine residue 75, and its bitopic arrangement in the membrane was confirmed. 4060580 6 44 gly position 1103:1110 arg1 an oligosaccharide structure position an oligosaccharide structure position Since the HA functions in adsorption of virus to cells, it is concluded that removal or modification of an oligosaccharide structure at this position is required for influenza B virus to attach to and infect the allantois cells of the egg and that this has important implications for the antigenic configuration of the molecule. 27881683 2 69 gly glycosylation 466:478 arg2 additional glycosylation sites additional glycosylation sites sites Increasing molecular stability, glycoengineering has been used to improve clinical efficacy for a number of therapeutics; however, often labor-intensive trail-and-error approaches are used to identify additional glycosylation sites. 1567356 3 74 gly glycosylation 430:442 arg2 each glycosylation site each glycosylation site site Standard h.p.l.c. profiles have been developed to analyse the percentage and distribution of the glycoforms present at each glycosylation site in OMD and its molecular variants. 7849028 7 6 gly glycosylation 1064:1076 arg2 one known glycosylation site one known glycosylation site site The amino terminus of rat p62 is poorly glycosylated with no O-linked GlcNAc sites between Lys22 and Lys97; the carboxyl terminus has one known glycosylation site at Ser471. 7849028 7 38 gly glycosylated 960:971 arg1 The amino terminus The amino terminus terminus The amino terminus of rat p62 is poorly glycosylated with no O-linked GlcNAc sites between Lys22 and Lys97; the carboxyl terminus has one known glycosylation site at Ser471. 15009203 4 47 gly glycoprotein 809:820 arg1 glycoprotein forms glycoprotein forms Fterm glycoprotein Both preparations exhibited size heterogeneity in SDS/PAGE with multiple bands containing glycoprotein forms with either two or one N-glycosylation sites occupied. 15009203 4 53 gly N-glycosylation 851:865 arg2 either two or one N-glycosylation sites either two or one N-glycosylation sites sites Both preparations exhibited size heterogeneity in SDS/PAGE with multiple bands containing glycoprotein forms with either two or one N-glycosylation sites occupied. 1468573 0 13 gly contains 16:23 arg1 Human urokinase AND GalNAc beta (1-4)[Fuc alpha (1-3)]GlcNAc beta (1-2) Human urokinase GalNAc beta (1-4)[Fuc alpha (1-3)]GlcNAc beta (1-2) Fterm urokinase Human urokinase contains GalNAc beta (1-4)[Fuc alpha (1-3)]GlcNAc beta (1-2) as a novel terminal element in N-linked carbohydrate chains. 31412214 7 21 gly glycosylation 1337:1349 arg1 non-GPI-anchored cytosolic CD59 non-GPI-anchored cytosolic CD59 PUBTATOR CD59 966 Our results suggest that CD59 is retrotranslocated from the endoplasmic reticulum to the cytosol, a process mediated by recognition of trimmed N-linked oligosaccharides, supported by the partial glycosylation of non-GPI-anchored cytosolic CD59 as well as the failure of N-linked glycosylation site mutant CD59 to reach the cytosol or rescue GSIS. 31412214 7 44 gly glycosylation 1421:1433 arg2 N-linked glycosylation site mutant CD59 N-linked glycosylation site mutant CD59 site Our results suggest that CD59 is retrotranslocated from the endoplasmic reticulum to the cytosol, a process mediated by recognition of trimmed N-linked oligosaccharides, supported by the partial glycosylation of non-GPI-anchored cytosolic CD59 as well as the failure of N-linked glycosylation site mutant CD59 to reach the cytosol or rescue GSIS. 21329800 3 23 gly glycosylation 350:362 arg2 glycosylation site occupancy glycosylation site occupancy site To better understand the impact of glycosylation in protein folding and maturation, parameters like glycosylation site occupancy and oligosaccharide structure must be measured quantitatively. 15199058 0 80 part_of E 50:50 arg1 Lys-352 immunoglobulin E Lys-352 PUBTATOR SpecificSite immunoglobulin E P01854 Lys-352 The importance of Lys-352 of human immunoglobulin E in FcepsilonRII/CD23 recognition. 6838832 1 2 gly variants 164:171 arg1 the region the region the region Site region The amino acid sequences of the two major carbohydrate variants in the region of Asn288 have been determined. 26968544 8 34 gly dystrophin-glycoprotein 1606:1628 arg1 overall dystrophin-glycoprotein complex function overall dystrophin-glycoprotein complex function OGER dystrophin P11532 Therefore, appropriate glycosylation of δ-sarcoglycan may also be necessary for proper δ-sarcoglycan function and overall dystrophin-glycoprotein complex function. 26968544 8 91 gly glycosylation 1507:1519 arg1 δ-sarcoglycan δ-sarcoglycan Therefore, appropriate glycosylation of δ-sarcoglycan may also be necessary for proper δ-sarcoglycan function and overall dystrophin-glycoprotein complex function. 20391591 8 83 gly glycosylation 1489:1501 arg2 associated glycosylation sites associated glycosylation sites sites The resulting MS(3) spectrum of the Y1 ion facilitates database searching and de novo sequencing thus prompting the subsequent identification of the peptide backbone and associated glycosylation sites. 7944407 5 54 gly glycosylation 1069:1081 arg2 the single glycosylation site the single glycosylation site site A mutant murine SPARC lacking the single glycosylation site was also expressed following substitution of Asn98 with Asp98 in the wild-type sequence. 17724331 7 57 gly N-glycosylation 1397:1411 arg2 the N-glycosylation site the N-glycosylation site site We found that an extracellular portion of sEPO-R, harboring the N-glycosylation site, conferred enhanced maturation and increased transport to the cell surface of the respective chimeric receptor. 9126611 8 66 gly hCox-2 1546:1551 arg1 N-linked oligosaccharide profiling hCox-2 N-linked oligosaccharide profiling PUBTATOR hCox-2 4513 N-linked oligosaccharide profiling of purified VV and BV WT and S582A mutant hCox-2 showed the presence of high mannose structures, (Man)n (GlcNAc)2, n = 9, 8, 7, 6. 28887103 9 66 gly glycosylation 1347:1359 arg2 the potential glycosylation site the potential glycosylation site site The neighbouring amino acids and local structural features around the potential glycosylation site also play a significant role in determining the extent of glycosylation. 27957769 5 122 gly glycopeptides 883:895 arg2 mucin 1 glycopeptides mucin 1 glycopeptides glycopeptides For assessment of the influence of the immune stimulant on antibody recognition, a comprehensive library of mucin 1 glycopeptides (>100 entries) is synthesized and employed in antibody microarray profiling; these range from small tumor-associated glycans (TN , STN , and T-antigen structures) to heavily extended O-glycan core structures (type-1 and type-2 elongated core 1-3 tri-, tetra-, and hexasaccharides) glycosylated in variable density at the five different sites of the MUC1 tandem repeat. 27957769 5 82 gly glycosylated 1178:1189 arg1 heavily extended O-glycan core structures sites heavily extended O-glycan core structures sites For assessment of the influence of the immune stimulant on antibody recognition, a comprehensive library of mucin 1 glycopeptides (>100 entries) is synthesized and employed in antibody microarray profiling; these range from small tumor-associated glycans (TN , STN , and T-antigen structures) to heavily extended O-glycan core structures (type-1 and type-2 elongated core 1-3 tri-, tetra-, and hexasaccharides) glycosylated in variable density at the five different sites of the MUC1 tandem repeat. 27957769 5 82 gly glycosylated 1178:1189 arg1 type-2 elongated core 1-3 tri- sites type-2 elongated core 1-3 tri- sites For assessment of the influence of the immune stimulant on antibody recognition, a comprehensive library of mucin 1 glycopeptides (>100 entries) is synthesized and employed in antibody microarray profiling; these range from small tumor-associated glycans (TN , STN , and T-antigen structures) to heavily extended O-glycan core structures (type-1 and type-2 elongated core 1-3 tri-, tetra-, and hexasaccharides) glycosylated in variable density at the five different sites of the MUC1 tandem repeat. 32211339 10 2 gly N-glycosylation 1571:1585 arg2 N-glycosylation sites N-glycosylation sites sites The co-localization of HLA-I and Ebola GP was unaffected by the disruption of steric shielding, as the removal of N-glycosylation sites on Ebola GP revealed similar FRET values with HLA-I. 1512415 1 16 gly glycoprotein 266:277 arg1 glycoprotein hormone subunits glycoprotein hormone subunits Fterm glycoprotein In recent studies, site-directed mutagenesis has been used to alter the tripeptide glycosylation recognition sequences of glycoprotein hormone subunits, thereby affecting their structure and function. 12388686 5 13 part_of DAF 1011:1013 arg1 the single N-linked glycosylation site DAF the single N-linked glycosylation site OGER Site DAF P08174 site Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface. 12388686 5 28 part_of protein 1042:1048 arg1 the single N-linked glycosylation site protein the single N-linked glycosylation site Fterm Site protein site Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface. 12388686 5 84 part_of DAF 1088:1090 arg1 the O-glycosylated domain DAF the O-glycosylated domain OGER Site DAF P08174 domain Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface. 18524814 1 28 gly glycosylation 284:296 arg2 a single potential N-linked glycosylation site a single potential N-linked glycosylation site site The prM protein of Japanese encephalitis virus (JEV) contains a single potential N-linked glycosylation site, N(15)-X(16)-T(17), which is highly conserved among JEV strains and closely related flaviviruses. 21431619 7 41 part_of asialotransferrin 1223:1239 arg1 the asialotransferrin position transferrin the asialotransferrin position PUBTATOR Site transferrin 7018 position, After neuraminidase digestion, a single band was found at the asialotransferrin position, indistinguishable from CDG type I patients. 26947874 0 5 part_of antitrypsin 81:91 arg1 the N-terminal region alpha-1 antitrypsin the N-terminal region PUBTATOR Site alpha-1 antitrypsin 5265 region Additional N-glycosylation in the N-terminal region of recombinant human alpha-1 antitrypsin enhances the circulatory half-life in Sprague-Dawley rats. 6175959 8 72 part_of alpha-chain 1038:1048 arg1 positions 345-610 alpha-chain positions 345-610 PUBTATOR Site alpha-chain 2217 positions 345 These results together indicate that fragment C3d occupies approximately positions 345-610 of the alpha-chain. 18952059 3 36 gly unglycosylated 302:315 arg1 unglycosylated IZUMO unglycosylated IZUMO PUBTATOR IZUMO 73456 In the present paper, we produced transgenic mouse lines expressing unglycosylated IZUMO (N204Q-IZUMO) in Izumo1 -/- background. 18952059 3 36 gly unglycosylated 302:315 arg1 N204Q-IZUMO N204Q-IZUMO PUBTATOR -IZUMO 73456 In the present paper, we produced transgenic mouse lines expressing unglycosylated IZUMO (N204Q-IZUMO) in Izumo1 -/- background. 12847483 13 113 part_of contains 1963:1970 arg1 the amino acid sequence AND a single N-glycosylation site the amino acid sequence a single N-glycosylation site site The calculated molecular weight of the mature protein is 50 kd, and the amino acid sequence contains a single N-glycosylation site. 10828967 5 38 gly glycosylation 826:838 arg2 at least one intact glycosylation site at least one intact glycosylation site site Receptors missing a single or multiple glycosylation consensus but with at least one intact glycosylation site expressed sufficiently and functioned normally. 10828967 5 45 gly Receptors 734:742 arg1 at least one intact glycosylation site at least one intact glycosylation site site Receptors missing a single or multiple glycosylation consensus but with at least one intact glycosylation site expressed sufficiently and functioned normally. 9820138 1 30 gly glycosylated 203:214 arg1 prM prM Cterm prM The three flavivirus glycoproteins prM, E and NS1 are formed by post-translational cleavage and are glycosylated by the addition of N-linked glycans. 9820138 1 30 gly glycosylated 203:214 arg1 NS1 NS1 PUBTATOR NS1 10625 The three flavivirus glycoproteins prM, E and NS1 are formed by post-translational cleavage and are glycosylated by the addition of N-linked glycans. 9820138 1 30 gly glycosylated 203:214 arg1 The three flavivirus glycoproteins prM, E and NS1 The three flavivirus glycoproteins prM, E and NS1 Fterm glycoproteins The three flavivirus glycoproteins prM, E and NS1 are formed by post-translational cleavage and are glycosylated by the addition of N-linked glycans. 9820138 1 34 gly glycoproteins 124:136 arg1 prM prM Cterm prM The three flavivirus glycoproteins prM, E and NS1 are formed by post-translational cleavage and are glycosylated by the addition of N-linked glycans. 9820138 1 34 gly glycoproteins 124:136 arg1 NS1 NS1 PUBTATOR NS1 10625 The three flavivirus glycoproteins prM, E and NS1 are formed by post-translational cleavage and are glycosylated by the addition of N-linked glycans. 9820138 1 34 gly glycoproteins 124:136 arg1 The three flavivirus glycoproteins prM, E and NS1 The three flavivirus glycoproteins prM, E and NS1 Fterm glycoproteins The three flavivirus glycoproteins prM, E and NS1 are formed by post-translational cleavage and are glycosylated by the addition of N-linked glycans. 8663003 8 30 part_of proteins 1280:1287 arg1 the C-terminal domain proteins the C-terminal domain Fterm Site proteins domain Immunoprecipitation experiments have revealed that anti-C, -c,E, -e, and -D immune complexes are reactive with antisera raised against the fourth predicted external loop of the Rh proteins and the C-terminal domain. 20591501 4 44 part_of furin 535:539 arg1 a putative furin protease cleavage site furin a putative furin protease cleavage site OGER Site furin P09958 site The deduced amino acid sequence contains a predicted transmembrane domain, a putative furin protease cleavage site, a potential N-glycosylation site and conserved cysteine residues similar to that identified in other mammalian BAFF. 20591501 4 55 part_of contains 481:488 arg1 The deduced amino acid sequence AND conserved cysteine residues The deduced amino acid sequence conserved cysteine residues cysteine residues The deduced amino acid sequence contains a predicted transmembrane domain, a putative furin protease cleavage site, a potential N-glycosylation site and conserved cysteine residues similar to that identified in other mammalian BAFF. 20591501 4 55 part_of contains 481:488 arg1 The deduced amino acid sequence AND a predicted transmembrane domain The deduced amino acid sequence a predicted transmembrane domain domain The deduced amino acid sequence contains a predicted transmembrane domain, a putative furin protease cleavage site, a potential N-glycosylation site and conserved cysteine residues similar to that identified in other mammalian BAFF. 20591501 4 55 part_of contains 481:488 arg1 The deduced amino acid sequence AND a putative furin protease cleavage site site site The deduced amino acid sequence contains a predicted transmembrane domain, a putative furin protease cleavage site, a potential N-glycosylation site and conserved cysteine residues similar to that identified in other mammalian BAFF. 2187475 11 1 gly glycosylation 1437:1449 arg2 additional glycosylation sites additional glycosylation sites sites This substitution reduced, but did not eliminate IGF-I glycosylation, suggesting additional glycosylation sites. 8626811 9 22 part_of gp43 1375:1378 arg1 Internal and COOH-terminal gene fragments gp43 Internal and COOH-terminal gene fragments Cterm Site gp43 fragments Internal and COOH-terminal gene fragments of the gp43 were expressed as recombinant fusion proteins, which reacted with antibodies elicited against the native antigen. 21604132 3 7 gly glycosylation 517:529 arg2 the glycosylation sites the glycosylation sites sites Methodological improvements in the sample preparation and analysis currently enable the detailed identification of the glycosylation sites and glycan structure characterization. 21604132 3 12 gly sites 531:535 arg1 glycan structure characterization sites glycan structure characterization sites Methodological improvements in the sample preparation and analysis currently enable the detailed identification of the glycosylation sites and glycan structure characterization. 8496594 8 27 gly N-glycosylation 925:939 arg2 one potential N-glycosylation site one potential N-glycosylation site site It has one potential N-glycosylation site at amino acid 166. 2737288 2 1 gly N-glycosylation 201:215 arg2 the potential N-glycosylation sites the potential N-glycosylation sites sites Two peptides, containing the potential N-glycosylation sites at Asn-86 and Asn-125, were isolated and analyzed by amino acid analysis, sequencing and carbohydrate component analysis. 24721674 11 25 part_of proteins 2162:2169 arg1 811 N-glycosylation sites proteins 811 N-glycosylation sites Fterm Site proteins sites Totally 811 N-glycosylation sites from 567 proteins were identified and 177 intact glycopeptides with both glycan composition and peptides sequence were characterized, which provided a solution for site-specific N-glycosylation characterization of membrane. 10102990 5 9 gly N-glycosylation 776:790 arg2 the single putative N-glycosylation site the single putative N-glycosylation site site The essential three amino acids in the active site triad, His, Asp, and Ser, and the single putative N-glycosylation site were conserved in human and mouse neuropsin. 21111695 3 23 gly glycosylation 724:736 arg2 a glycosylation site a glycosylation site site Results of western blot analysis showed that about 36 kDa make specific antibodies appeared specific antibodies in antiserum of immune mice, whereas the best immune effects became visible at the induction time of 48 h. Analyses of 2-dimensional electrophoresis identified the specific antigen was annexin A2, which was a glycosylated protein that contained a glycosylation site, closely related to oncogenesis, cancer development, invasion and metastasis. 21111695 3 42 gly glycosylated 686:697 arg1 annexin A2 annexin A2 PUBTATOR annexin A2 12306 Results of western blot analysis showed that about 36 kDa make specific antibodies appeared specific antibodies in antiserum of immune mice, whereas the best immune effects became visible at the induction time of 48 h. Analyses of 2-dimensional electrophoresis identified the specific antigen was annexin A2, which was a glycosylated protein that contained a glycosylation site, closely related to oncogenesis, cancer development, invasion and metastasis. 21111695 3 42 gly glycosylated 686:697 arg1 a glycosylated protein a glycosylated protein Fterm protein Results of western blot analysis showed that about 36 kDa make specific antibodies appeared specific antibodies in antiserum of immune mice, whereas the best immune effects became visible at the induction time of 48 h. Analyses of 2-dimensional electrophoresis identified the specific antigen was annexin A2, which was a glycosylated protein that contained a glycosylation site, closely related to oncogenesis, cancer development, invasion and metastasis. 8212855 5 73 gly glycosylation 789:801 arg2 one putative N-linked glycosylation site one putative N-linked glycosylation site site Within the conserved (N-terminus) region, one putative N-linked glycosylation site and four cysteine residues are aligned in these proteins. 10580643 6 82 gly glycosylated 1342:1353 arg1 the glycosylated asparagine the glycosylated asparagine asparagine residue Nuclear magnetic resonance spectroscopy and peptide sequencing identified the more hydrophobic deprotected peak as the target peptide, and the more hydrophilic deprotected peak as a peptide analog in which the aspartic acid-bond just preceding the glycosylated asparagine residue was isomerized resulting in the formation of a beta-peptide. 10536368 2 32 gly glycosylation 400:412 arg2 N-linked glycosylation sites N-linked glycosylation sites sites In the present study, we describe a method to rescue the intracellular transport and secretion of glycoproteins mutagenized to delete N-linked glycosylation sites. 10536368 2 45 gly glycoproteins 355:367 arg1 glycoproteins glycoproteins Fterm glycoproteins In the present study, we describe a method to rescue the intracellular transport and secretion of glycoproteins mutagenized to delete N-linked glycosylation sites. 16372382 9 12 gly contain 1743:1749 arg1 Asn-alpha78 AND bi- and triantennary complex-type glycans Asn-alpha78 bi- and triantennary complex-type glycans Asn Glycosylation sites Asn-alpha52 and Asn-alpha78 contain mainly bi- and triantennary complex-type glycans. 16372382 9 12 gly contain 1743:1749 arg1 Glycosylation sites Asn-alpha52 and Asn-alpha78 AND bi- and triantennary complex-type glycans sites Asn bi- and triantennary complex-type glycans sites Asn Glycosylation sites Asn-alpha52 and Asn-alpha78 contain mainly bi- and triantennary complex-type glycans. 9689128 4 14 gly N-glycosylation 825:839 arg2 a putative N-glycosylation site a putative N-glycosylation site site The most prevalent SNP is a nucleotide substitution at position 118 (A118G), predicting an amino acid change at a putative N-glycosylation site. 25389233 7 105 gly fucosylated 1186:1196 arg1 the fucosylated tri-mannose N-glycan core the fucosylated tri-mannose N-glycan core After specifically gathering IgG complexes from sera, biotinylated lectins Aleuria aurantia lectin and Lens culinaris agglutinin were employed to detect IgG-associated fucosyl residues and the fucosylated tri-mannose N-glycan core, respectively. 26896935 0 41 gly glycoprotein 6:17 arg1 The E glycoprotein The E glycoprotein Fterm glycoprotein The E glycoprotein plays an essential role in the high pathogenicity of European-Mediterranean IS98 strain of West Nile virus. 1935985 4 42 gly N-glycosylation 870:884 arg2 a major N-glycosylation site a major N-glycosylation site site In addition, a major N-glycosylation site has been identified by lectin affinity chromatography and amino acid sequencing at amino acid position 61, i.e., in the middle of the first extracellular domain. 17082223 2 16 gly glycosylation 458:470 arg2 putative glycosylation sites putative glycosylation sites sites Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 36 gly sites 472:476 arg1 putative glycosylation sites putative glycosylation sites sites Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 16 gly glycosylation 458:470 arg2 Asn(109) Asn(109), Asn(116), Asn(122), and Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 16 gly glycosylation 458:470 arg2 Asn(116) Asn(109), Asn(116), Asn(122), and Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 16 gly glycosylation 458:470 arg2 Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 16 gly glycosylation 458:470 arg2 Asn(116) Asn(109), Asn(116), Asn(122), and Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 16 gly glycosylation 458:470 arg2 Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 16 gly glycosylation 458:470 arg2 Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 36 gly sites 472:476 arg1 Asn(122) Asn(109), Asn(116), Asn(122), and Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 36 gly sites 472:476 arg1 Asn(116) Asn(109), Asn(116), Asn(122), and Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 36 gly sites 472:476 arg1 Asn(109) Asn(109), Asn(116), Asn(122), and Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 36 gly sites 472:476 arg1 Asn(116) Asn(109), Asn(116), Asn(122), and Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 36 gly sites 472:476 arg1 Asn(109) Asn(109), Asn(116), Asn(122), and Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 17082223 2 36 gly sites 472:476 arg1 Asn(109) Asn(109), Asn(116), Asn(122), and Asn(125) Asn(109), Asn(116), Asn(122), and Asn(125) Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q. 29268168 6 43 gly IgG 965:967 arg1 increased galactose IgG increased galactose Cterm IgG However, unlike hFcγRIIIa, mFcγRIV did not bind more avidly to IgG with increased galactose and reduced fucose. 29268168 6 43 gly IgG 965:967 arg1 reduced fucose IgG reduced fucose Cterm IgG However, unlike hFcγRIIIa, mFcγRIV did not bind more avidly to IgG with increased galactose and reduced fucose. 10536368 0 56 gly glycosylation 13:25 arg2 glycosylation site mutants glycosylation site mutants site Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activator. 15353267 11 98 part_of position 1423:1430 arg1 The TOP cDNA TOP cDNA position Cterm Site TOP cDNA position 507833 The TOP cDNA was found to be completely localized on the human chromosome 16 at the nt position 507833-506354, with the TOP ORF at the nt position 507770-506354. 23640819 3 12 gly glycoproteins 657:669 arg1 cancer-associated glycoproteins cancer-associated glycoproteins Fterm glycoproteins In spite of the facts that glycosylation disorders are feasible for cancer biomarkers and glycomic analysis technologies to explore them have been rapidly developed, it remains difficult to sensitively screen glycan structure changes on cancer-associated glycoproteins from clinical specimens. 26458842 6 57 gly N-glycosylation 1014:1028 arg2 the lost ancestrally conserved N-glycosylation sites the lost ancestrally conserved N-glycosylation sites sites Thus, the lost ancestrally conserved N-glycosylation sites identified in the present study may be useful targets for functional analyses to identify molecular changes linked with the evolution of human phenotypes. 18562306 6 64 gly glycopeptide 1418:1429 arg2 its apparent strict glycopeptide specificity its apparent strict glycopeptide specificity glycopeptide We find that glycosylation of peptide substrates by hT10 requires binding of existing GalNAcs on the substrate to either its catalytic or lectin domain, thereby resulting in its apparent strict glycopeptide specificity. 12526344 4 33 part_of position 644:651 arg1 the chicken strain strain position Fterm Site strain position Except one more glycosylation site located at 156 position in the chicken strain, there were 7 glycosylation sites at same positions in three virus HA protein molecules. 25324212 2 26 gly glycopeptides 425:437 arg2 synthetic Tn-bearing glycopeptides synthetic Tn-bearing glycopeptides glycopeptides NMR and modeling-based data on the molecular recognition features of synthetic Tn-bearing glycopeptides by MGL are presented. 26656560 0 27 gly N-glycosylation 55:69 arg2 one N-glycosylation site one N-glycosylation site site A novel mutation on the transferrin gene abolishes one N-glycosylation site and alters the pattern of transferrin isoforms, mimicking that observed after excessive alcohol consumption. 9507052 1 19 gly N-glycosylation 345:359 arg2 the N-glycosylation site the N-glycosylation site site A protein encoded by cDNAs from the human parasite Onchocerca volvulus and its homologs from Caenorhabditis elegans and Ancyclostoma caninum define a family of aspartic proteases that are most closely related to cathepsins D, but differ from them in lacking the N-glycosylation site known to be required for lysosomal targeting. 8379944 4 48 gly N-glycosylation 580:594 arg1 the enzyme the enzyme Fterm enzyme In the present study, we have examined which of these sites are utilized and how the N-glycosylation affects the secretion and function of the enzyme. 10419504 6 56 gly N-glycosylation 802:816 arg2 a single N-glycosylation site mutation a single N-glycosylation site mutation site Proteins with a single N-glycosylation site mutation localized to late endosome/lysosomal compartments, as did wild-type NPC1, and each corrected the cholesterol trafficking defect. 23050552 5 32 part_of fibrinogen 551:560 arg1 proteinase K-generated fibrinogen glycopeptides K-generated fibrinogen proteinase K-generated fibrinogen glycopeptides PUBTATOR Site K-generated fibrinogen 2244 glycopeptides Here, we make use of tryptic- and proteinase K-generated fibrinogen glycopeptides for the detailed analysis of the protein's O-glycosylation by combining information obtained from both one- and two-dimensional nanoLC-ESI-ion trap (IT)-MS approaches. 23050552 5 35 part_of K-generated 539:549 arg1 proteinase K-generated fibrinogen glycopeptides K-generated fibrinogen proteinase K-generated fibrinogen glycopeptides PUBTATOR Site K-generated fibrinogen 2244 glycopeptides Here, we make use of tryptic- and proteinase K-generated fibrinogen glycopeptides for the detailed analysis of the protein's O-glycosylation by combining information obtained from both one- and two-dimensional nanoLC-ESI-ion trap (IT)-MS approaches. 10995221 5 82 part_of contain 705:711 arg1 UGT2B20 AND three and four potential glycosylation sites UGT2B20 three and four potential glycosylation sites Cterm Site UGT2B20 sites Although UGT2B15 and UGT2B20 contain three and four potential glycosylation sites, respectively, site-directed mutagenesis revealed that both proteins are glycosylated at the same first site. 10995221 5 82 part_of contain 705:711 arg1 UGT2B15 AND three and four potential glycosylation sites UGT2B15 three and four potential glycosylation sites PUBTATOR Site UGT2B15 7366 sites Although UGT2B15 and UGT2B20 contain three and four potential glycosylation sites, respectively, site-directed mutagenesis revealed that both proteins are glycosylated at the same first site. 9070436 3 19 part_of CD2 657:659 arg1 the counterreceptor (CD58) binding site CD2 the counterreceptor (CD58) binding site PUBTATOR Site CD2 914 site Surprisingly, we found a large contiguous patch of residues in the counterreceptor (CD58) binding site of human CD2 exhibiting slow conformational exchange motions (ms-microsecond). 10764604 4 64 gly glycoprotein 796:807 arg1 pituitary glycoprotein hormone pituitary glycoprotein hormone Ion chromatography on a Dionex AS4A column in 1.8 mM Na(2)CO(3)/1.7 mM NaHCO(3); postcolumn, in-line anion micromembrane suppression; and conductivity detection can be used to quantify sulfate, a common component of pituitary glycoprotein hormone oligosaccharides. 20332087 4 38 gly presence 619:626 arg2 positions 323, 355, 391, 483, 729 AND five N-glycans positions 323, 355, 391, 483, 729 five N-glycans positions 323, 355, 391, 483, 729 Analyses showed the presence of five N-glycans at positions 323, 355, 391, 483, 729 in both proteins. 10861210 12 9 part_of site 1608:1611 arg1 human AE1 AE1 site PUBTATOR Site AE1 6521 site The results show that the oligosaccharide attached to the endogenous site in extracellular loop 4 in human AE1 is not processed in HEK-293 or COS-7 cells, while the oligosaccharide attached to the preceding loop is converted into the complex form. 20795641 11 31 gly glycoproteins 1906:1918 arg1 glycoproteins glycoproteins Fterm glycoproteins The strategy can be easily adapted to the analysis of glycoproteins in tissues, cell lines, and other sample origins. 8301235 10 62 gly glycosylation 1412:1424 arg2 Asn-43 Asn-43 Asn-43 The fact that the homologous N-linked glycosylation site (Asn-43) is required for both enzyme activity and secretion for human LPL (Semenkovich et al. 1990. 8301235 10 62 gly glycosylation 1412:1424 arg2 the homologous N-linked glycosylation site the homologous N-linked glycosylation site site The fact that the homologous N-linked glycosylation site (Asn-43) is required for both enzyme activity and secretion for human LPL (Semenkovich et al. 1990. 23028207 6 58 gly N-glycosylation 1023:1037 arg2 N-glycosylation site assignment N-glycosylation site assignment site This integrative approach was performed using only 10 μL of human serum for both N-glycosylation site assignment and site microheterogeneity determination. 26991339 1 9 gly glycoforms 162:171 arg1 the basic salivary proline-rich protein 3M the basic salivary proline-rich protein 3M Fterm protein In the present study, we show that the heterogeneous mixture of glycoforms of the basic salivary proline-rich protein 3M, encoded by PRB3-M locus, is a major component of the acidic soluble fraction of human whole saliva in the first years of life. 25614584 3 42 gly glycoproteins 555:567 arg1 the mumps virus surface glycoproteins the mumps virus surface glycoproteins Fterm glycoproteins In the work presented here we sought to identify new neutralization sites on the mumps virus surface glycoproteins. 9342662 5 22 gly linked 1014:1019 arg1 the unique N297-S-T glycosylation site AND different oligosaccharides the unique N297-S-T glycosylation site different oligosaccharides site The off-line CE-MS characterization revealed the presence of different oligosaccharides linked to the unique N297-S-T glycosylation site of the IgG heavy chain. 9342662 5 93 gly glycosylation 1044:1056 arg2 the unique N297-S-T glycosylation site the unique N297-S-T glycosylation site site The off-line CE-MS characterization revealed the presence of different oligosaccharides linked to the unique N297-S-T glycosylation site of the IgG heavy chain. 12697062 12 3 part_of MYOC 1647:1650 arg1 the rabbit MYOC cDNA sequence MYOC the rabbit MYOC cDNA sequence PUBTATOR Site MYOC 100008897 sequence Knowledge of the rabbit MYOC cDNA sequence will facilitate future studies in the rabbit animal model examining the role of myocilin in steroid-induced glaucoma and the gain-of-function hypothesis in open-angle glaucoma. 21248038 1 66 part_of gp120 355:359 arg1 three major potential N-linked glycosylation sites gp120 three major potential N-linked glycosylation sites PUBTATOR Site gp120 3700 sites The broadly neutralizing human monoclonal antibody 2G12 binds to a carbohydrate-dependent epitope involving three major potential N-linked glycosylation sites (PNGS) of gp120 (N295, N332, and N392). 23319596 10 28 part_of LOX 1630:1632 arg1 the LOX catalytic domain LOX the LOX catalytic domain PUBTATOR Site LOX 4015 domain These results suggest that the N-glycan at Asn-644 of hLOXL2 enhances the solubility and stability of the LOX catalytic domain. 7510240 3 74 part_of protein 583:589 arg1 the deduced 277-amino acid sequence protein sequence Fterm Site protein sequence The 1.4-kb nucleotide sequence and the deduced 277-amino acid sequence of the single transmembrane protein were 65% and 63% identical, in human and in rat, respectively. 2503511 11 119 gly Asn-184 1993:1999 arg1 carbohydrate Asn-184 carbohydrate Asn-184 rt-PA exists as two variants that differ by the presence (type I) or absence (type II) of carbohydrate at Asn-184. 19176349 2 0 gly N-glycosylation 366:380 arg2 the only N-glycosylation site the only N-glycosylation site site In contrast to the class I and class II transporters, hydrophobicity plots predict a short extracellular loop between transmembrane domain (TM)1 and TM2 and a long extracellular loop between TM9 and TM10 that contains the only N-glycosylation site. 24334224 2 54 gly glycosylation 489:501 arg1 rhG-CSF rhG-CSF OGER CSF Using liquid chromatography and tandem mass spectrometry techniques, we analyzed the O-linked glycosylation of recombinant human granulocyte colony-stimulating factor (rhG-CSF) derived from glycoengineered Pichia pastoris with regard to its nature, structure, occupancy, and location. 24334224 2 54 gly glycosylation 489:501 arg1 recombinant human granulocyte colony-stimulating factor recombinant human granulocyte colony-stimulating factor PUBTATOR granulocyte colony-stimulating factor 1440 Using liquid chromatography and tandem mass spectrometry techniques, we analyzed the O-linked glycosylation of recombinant human granulocyte colony-stimulating factor (rhG-CSF) derived from glycoengineered Pichia pastoris with regard to its nature, structure, occupancy, and location. 20470225 2 14 part_of MUC1 271:274 arg1 MUC1 peptides MUC1 MUC1 peptides PUBTATOR Site MUC1 4582 peptides As a step toward DNA vaccines, the goal of this work was to determine whether MUC1 peptides substituted with an asparagine at O-linked glycosylation sites, might expose MUC1 peptide backbone to serve as immunogens to generate cytotoxic T lymphocytes (CTL) from peripheral blood mononuclear cells of patients with ADCs. 26415233 4 35 gly N-glycosylation 929:943 arg2 N-glycosylation site omission N-glycosylation site omission site Spontaneous TrkAIII activation, facilitated by D4 IG-like domain and N-glycosylation site omission, increases spontaneous activation potential by altering intracellular trafficking, inhibiting cell surface expression and eliminating an important inhibitory domain. 2910856 4 17 gly used 650:653 arg2 restriction fragments restriction fragments fragments This primer was then used to synthesize a lambda GT10 human placenta cDNA library, and restriction fragments of the HL-60 cDNA clones were used to screen the library. 23296529 6 23 gly glycopeptides 1261:1273 arg2 glycopeptides glycopeptides glycopeptides In this chapter we present a straightforward HILIC SPE enrichment technique and then combine C18 RP and HILIC enrichment for analysis of glycopeptides. 12883358 8 33 part_of CD44 1473:1476 arg1 the membrane-proximal CD44 ectodomain CD44 the membrane-proximal CD44 ectodomain PUBTATOR Site CD44 960 ectodomain In fact, spontaneous CD44s shedding was dependent on the presence of partial or complete O-glycosylation of four serine-glycine motifs localized in the membrane-proximal CD44 ectodomain. 17158203 6 75 gly glycosylation 931:943 arg2 the putative N-linked glycosylation site the putative N-linked glycosylation site site The mutation of the putative N-linked glycosylation site (Asn(36)) decreased cAMP production and reduced cell surface expression to 37% of the wild-type LGR7. 17158203 6 75 gly glycosylation 931:943 arg2 Asn(36) Asn(36) Asn(36) The mutation of the putative N-linked glycosylation site (Asn(36)) decreased cAMP production and reduced cell surface expression to 37% of the wild-type LGR7. 10374967 9 44 gly glycoprotein 1449:1460 arg1 glycoprotein maturation glycoprotein maturation Fterm glycoprotein A model is discussed whereby gL binding gH at the N-terminal domain acts to draw together the C-terminal extracellular domain and this interaction affects a functional conformation during glycoprotein maturation. 10749666 4 8 gly glycosylation 699:711 arg1 172 SERP-1 Asn(172) PUBTATOR SERP-1 27230 Asn(172) In the present study, examination of SERP-1 glycosylation-site mutants showed that the N-linked glycosylation of Asn(172) was essential for SERP-1 secretion, whereas mutation of Asn(99) decreased secretion efficiency, indicating that N-linked glycosylation plays an essential role in the processing and trafficking of SERP-1. 10749666 4 8 gly glycosylation 699:711 arg1 Asn SERP-1 Asn(172) PUBTATOR SERP-1 27230 Asn(172) In the present study, examination of SERP-1 glycosylation-site mutants showed that the N-linked glycosylation of Asn(172) was essential for SERP-1 secretion, whereas mutation of Asn(99) decreased secretion efficiency, indicating that N-linked glycosylation plays an essential role in the processing and trafficking of SERP-1. 10749666 4 8 gly glycosylation 699:711 arg1 Asn Asn(172) Asn(172) In the present study, examination of SERP-1 glycosylation-site mutants showed that the N-linked glycosylation of Asn(172) was essential for SERP-1 secretion, whereas mutation of Asn(99) decreased secretion efficiency, indicating that N-linked glycosylation plays an essential role in the processing and trafficking of SERP-1. 22187327 0 28 gly Asn54-linked 0:11 arg1 Asn54-linked glycan Asn54 Asn54-linked glycan Asn54 Asn54-linked glycan is critical for functional folding of intercellular adhesion molecule-5. 19767389 4 37 gly glycosylation 789:801 arg2 the well documented canonical glycosylation site the well documented canonical glycosylation site site HPLC-MS results indicated that cation-exchange chromatography acidic variant populations were enriched in antibody with a second glycosylation site, in addition to the well documented canonical glycosylation site located in the C(H)2 domain. 19767389 4 113 gly glycosylation 724:736 arg2 a second glycosylation site a second glycosylation site site HPLC-MS results indicated that cation-exchange chromatography acidic variant populations were enriched in antibody with a second glycosylation site, in addition to the well documented canonical glycosylation site located in the C(H)2 domain. 8765170 4 52 gly glycosylation 846:858 arg2 an N-linked glycosylation site an N-linked glycosylation site site No scFv was detected in the cell supernatant although functional scFv, as assayed by ELISA, was detected in an NP-40 soluble fraction if an N-linked glycosylation site had been introduced into the antibody construct. 23874792 2 31 part_of CD4 356:358 arg1 the CD4 binding site (CD4bs) region CD4 the CD4 binding site (CD4bs) region PUBTATOR Site CD4 920 region A tier 2 neutralizing monoclonal antibody (mAb), HJ16 recognizes a new epitope in the CD4 binding site (CD4bs) region that only partially overlaps with the b12 epitope. 8212855 4 70 part_of protein 593:599 arg1 the NH2-terminal region p32 protein the NH2-terminal region PUBTATOR Site p32 protein 3622 region Amino acid residues in the NH2-terminal region of the p32 protein exhibit similarity to glycoprotein X (gX) of pseudorabies virus (PRV) and its homolog in equine herpesvirus type 1 (EHV-1). 7533854 0 37 part_of gp120 100:104 arg1 the V2 region 1 gp120 the V2 region PUBTATOR Site 1 gp120 3700 region Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. 2226797 2 3 gly glycopeptide 319:330 arg2 the tryptic glycopeptide the tryptic glycopeptide glycopeptide After isolation of the tryptic glycopeptide and liberation of the N-linked carbohydrates by polypeptide:N-glycosidase F, 6 major oligosaccharide fractions were separated by HPLC on NH2-bonded phase. 26869352 2 36 gly fucosylated 353:363 arg1 fucosylated N-glycans fucosylated N-glycans Previously, we reported that fucosylated N-glycans on haptoglobin in the sera of patients with pancreatic cancer were increased by lectin-ELISA and mass spectrometry analyses. 26869352 2 61 gly N-glycans 365:373 arg1 haptoglobin haptoglobin N-glycans PUBTATOR haptoglobin 3240 Previously, we reported that fucosylated N-glycans on haptoglobin in the sera of patients with pancreatic cancer were increased by lectin-ELISA and mass spectrometry analyses. 8288048 2 15 gly glycosylation 498:510 arg2 the first four sites the first four sites sites Previously (Collier E, Carpentier J-L, Beitz L, Caro LHP, Taylor SI, Gorden P: Biochemistry 32:7818-23, 1993), site directed mutagenesis of the asparagine in the first four sites of N-linked glycosylation to glutamine resulted in a receptor that was retained in the endoplasmic reticulum and not processed past the proreceptor form. 21846136 6 62 gly glycosylation 1507:1519 arg2 N-linked glycosylation site profiling N-linked glycosylation site profiling site All these results demonstrate that the integrated system is of great promise for N-linked glycosylation site profiling and could be further online coupled with nanoHPLC-ESI-MS/MS to achieve high-throughput glycoproteome analysis. 1535241 1 55 gly glycoprotein 225:236 arg1 The proto-oncogene Wnt-1 The proto-oncogene Wnt-1 PUBTATOR proto-oncogene Wnt-1 22408 The proto-oncogene Wnt-1 encodes a cysteine-rich, secretory glycoprotein implicated in virus-induced mouse mammary cancer and intercellular signaling during vertebrate neural development. 1535241 1 55 gly glycoprotein 225:236 arg1 a cysteine-rich, secretory glycoprotein a cysteine-rich, secretory glycoprotein Fterm glycoprotein The proto-oncogene Wnt-1 encodes a cysteine-rich, secretory glycoprotein implicated in virus-induced mouse mammary cancer and intercellular signaling during vertebrate neural development. 19269039 8 63 gly N-glycosylation 888:902 arg2 one N-glycosylation site one N-glycosylation site site Pig IL-27 p28 has one transmembrane region, one signal peptide, and one N-glycosylation site, two Protein kinase C phosphorylation sites, three Casein kinase II phosphorylation sites and one N-myristoylation site. 1331083 5 13 part_of D 1348:1348 arg1 homologous sites cathepsin D, homologous sites PUBTATOR Site cathepsin D, 1509 sites Similar results were obtained for oligosaccharides at homologous sites on a pepsinogen/cathepsin D chimera containing only lysine 203 and residues 265-319 of cathepsin D, although the absolute levels of phosphorylation were lower. 1331083 5 13 part_of D 1348:1348 arg1 residues 265-319 cathepsin D, residues 265-319 PUBTATOR SpecificSite cathepsin D, 1509 lysine 203 and residues 265-319 Similar results were obtained for oligosaccharides at homologous sites on a pepsinogen/cathepsin D chimera containing only lysine 203 and residues 265-319 of cathepsin D, although the absolute levels of phosphorylation were lower. 30295034 9 23 gly glycoproteins 1509:1521 arg1 desialylated glycoproteins desialylated glycoproteins Fterm glycoproteins AGP from human plasma samples of single individuals was analyzed as desialylated glycoproteins and showed variations in fucosylation and in the amount of antennary structures between individuals. 30295034 9 70 gly desialylated 1496:1507 arg1 desialylated glycoproteins desialylated glycoproteins Fterm glycoproteins AGP from human plasma samples of single individuals was analyzed as desialylated glycoproteins and showed variations in fucosylation and in the amount of antennary structures between individuals. 1371468 2 15 part_of MEL-14 539:544 arg1 Leu-8 gp90 MEL Leu-8 OGER SpecificSite gp90 MEL P14151 Leu-8 Here we tested the cross-reactivity of four anti-human peripheral lymph node homing receptor (LECAM-1) (also known as LAM-1, LEC-CAM-1, Leu-8, TQ-1, or human equivalent of gp90 MEL-14) antibodies on bovine lymphocytes. 10580643 7 53 gly glycopeptide 1636:1647 arg2 the other three glycopeptide variants the other three glycopeptide variants glycopeptide The anomalous chromatographic behavior of the acetylated beta-isomer could be explained on the basis of the generation of an extended hydrophobic surface which is not present in any of the other three glycopeptide variants. 15243097 0 3 gly glycosylation 44:56 arg2 a new glycosylation site a new glycosylation site site Influenza B virus victoria group with a new glycosylation site was epidemic in Japan in the 2002-2003 season. 10318794 2 13 part_of G6PT 502:505 arg1 G6PT face the cytoplasm G6PT G6PT face the cytoplasm PUBTATOR Site G6PT 2538 face Using amino- and carboxyl-terminal tagged G6PT, we demonstrate that proteolytic digestion of intact microsomes resulted in the cleavage of both tags, indicating that both termini of G6PT face the cytoplasm. 20507882 5 42 part_of Hex-O-Thr 899:907 arg1 Hex-O-Thr glycopeptides Hex Hex-O-Thr glycopeptides OGER AminoAcid Hex Thr glycopeptides The HexNAc-O-Ser/Thr, but not Hex-O-Thr glycopeptides, displayed heterogeneity regarding glycan core structures and level of glycosylation site occupancy. 9694881 8 6 gly deglycosylated 935:948 arg1 the deglycosylated protein the deglycosylated protein Fterm protein Pulse-chase experiments showed slight intracellular retention (15%) of the deglycosylated protein after 24 h. Interestingly, the N-4 mutant had a higher catalytic efficiency (kcat/Km = 5.0 versus 1.6 microM-1 . 19808681 9 22 gly glycosylated 1365:1376 arg1 the glycosylated site the glycosylated site site Although double mutants, retaining only one glycosylation site, are trafficked to the surface of CHO cells irrespective of the position of the glycosylated site, unglycosylated channels are not trafficked to the cell surface. 19808681 9 29 gly glycosylation 1266:1278 arg2 only one glycosylation site only one glycosylation site site Although double mutants, retaining only one glycosylation site, are trafficked to the surface of CHO cells irrespective of the position of the glycosylated site, unglycosylated channels are not trafficked to the cell surface. 19808681 9 66 gly unglycosylated 1384:1397 arg1 unglycosylated channels unglycosylated channels Fterm channels Although double mutants, retaining only one glycosylation site, are trafficked to the surface of CHO cells irrespective of the position of the glycosylated site, unglycosylated channels are not trafficked to the cell surface. 1457969 4 53 part_of hTSH 663:666 arg1 hTSH alpha glycopeptides hTSH hTSH alpha glycopeptides OGER Site hTSH glycopeptides The oligosaccharides were liberated from hTSH alpha glycopeptides and from intact hTSH beta by hydrazinolysis, and were fractionated as alditols by anion-exchange and ion-suppression amine-adsorption HPLC preparatory to structural analysis. 28835497 10 16 part_of K 2054:2054 arg1 the amino terminus HSV-1 glycoprotein K (gK the amino terminus Cterm Site HSV-1 glycoprotein K (gK terminus These results demonstrate a critical role for the N glycosylation sites and cysteines for the structure and function of the amino terminus of gK.IMPORTANCE We have previously identified important entry and neurotropic determinants in the amino terminus of HSV-1 glycoprotein K (gK). 31611356 4 59 gly N448 810:813 arg1 glycan absence N448 glycan absence N448 In addition to a significant loss of Grft activity by the removal of glycosylation at N295, glycan absence at N332 or N448 was found to have moderate effects on Grft potency. 31611356 4 72 gly N332 802:805 arg1 glycan absence N332 glycan absence N332 In addition to a significant loss of Grft activity by the removal of glycosylation at N295, glycan absence at N332 or N448 was found to have moderate effects on Grft potency. 20209506 3 4 gly N-glycosylation 683:697 arg2 multiple N-glycosylation sites multiple N-glycosylation sites sites The glycopeptide analysis workflow was applied to human beta2-glycoprotein I (beta2-GPI, apolipoprotein H), which contains multiple N-glycosylation sites. 20209506 3 21 gly beta2-glycoprotein 607:624 arg1 human beta2-glycoprotein I human beta2-glycoprotein I PUBTATOR beta2-glycoprotein I 350 The glycopeptide analysis workflow was applied to human beta2-glycoprotein I (beta2-GPI, apolipoprotein H), which contains multiple N-glycosylation sites. 20209506 3 81 gly glycopeptide 555:566 arg2 The glycopeptide analysis workflow The glycopeptide analysis workflow glycopeptide The glycopeptide analysis workflow was applied to human beta2-glycoprotein I (beta2-GPI, apolipoprotein H), which contains multiple N-glycosylation sites. 15754041 2 4 part_of WNT3A-WNT9A 281:291 arg1 paralogous regions WNT3A-WNT9A paralogous regions PUBTATOR Site WNT3A-WNT9A 89780 regions WNT3-WNT9B (WNT14B) locus (17q21.31) and WNT3A-WNT9A (WNT14) locus (1q42.13) are paralogous regions within the human genome. 15754041 2 11 part_of WNT14 294:298 arg1 paralogous regions WNT14 paralogous regions PUBTATOR Site WNT14 7483 regions WNT3-WNT9B (WNT14B) locus (17q21.31) and WNT3A-WNT9A (WNT14) locus (1q42.13) are paralogous regions within the human genome. 15754041 2 66 part_of WNT14B 252:257 arg1 paralogous regions WNT14B paralogous regions PUBTATOR Site WNT14B 7484 regions WNT3-WNT9B (WNT14B) locus (17q21.31) and WNT3A-WNT9A (WNT14) locus (1q42.13) are paralogous regions within the human genome. 15754041 2 69 part_of WNT3-WNT9B 240:249 arg1 paralogous regions WNT3 paralogous regions PUBTATOR Site WNT3 7473 regions WNT3-WNT9B (WNT14B) locus (17q21.31) and WNT3A-WNT9A (WNT14) locus (1q42.13) are paralogous regions within the human genome. 20391591 11 45 gly glycosylation 1918:1930 arg2 protein glycosylation sites protein glycosylation sites sites The high mass accuracy offered by the LTQ Orbitrap mass spectrometer is also an attractive feature that allows a confident assignment of protein glycosylation sites and the microheterogeneity of such sites. 20391591 11 104 gly microheterogeneity 1946:1963 arg1 such sites sites sites The high mass accuracy offered by the LTQ Orbitrap mass spectrometer is also an attractive feature that allows a confident assignment of protein glycosylation sites and the microheterogeneity of such sites. 14691230 9 40 gly glycosylation 1436:1448 arg2 the glycosylation site mutants the glycosylation site mutants site Size-exclusion chromatographic analysis showed that the glycosylation site mutants do not affect dimerization. 31004621 3 59 gly N-glycosylation 623:637 arg2 five N-glycosylation sites five N-glycosylation sites sites The RSV F sequence possesses five N-glycosylation sites located in the F2 subunit (N27 and N70), the p27 peptide (N116 and N126) and the F1 subunit (N500). 31004621 3 52 gly subunit 663:669 arg1 N27 N27 and N70 N27 and N70 The RSV F sequence possesses five N-glycosylation sites located in the F2 subunit (N27 and N70), the p27 peptide (N116 and N126) and the F1 subunit (N500). 31004621 3 102 gly peptide 694:700 arg1 N116 N116 and N126 N116 and N126 The RSV F sequence possesses five N-glycosylation sites located in the F2 subunit (N27 and N70), the p27 peptide (N116 and N126) and the F1 subunit (N500). 21645732 6 2 gly glycosites 1191:1200 arg2 11 glycosites 11 glycosites glycosites In addition, 11 glycosites were assigned with core-fucosylation by Endo H. 16873272 2 103 part_of Env 403:405 arg1 the extracellular domains FV Env the extracellular domains Cterm Site FV Env P40189 domains Little structural and functional information on the extracellular domains of FV Env is available. 20807536 7 34 gly modified 1005:1012 arg1 Ovalbumin AND hybrid-type oligosaccharides Ovalbumin hybrid-type oligosaccharides Fterm Ovalbumin Ovalbumin has a single N-glycosylation site (Asn(292)) and is modified with oligomannose and hybrid-type oligosaccharides. 20807536 7 42 gly N-glycosylation 966:980 arg2 a single N-glycosylation site a single N-glycosylation site site Ovalbumin has a single N-glycosylation site (Asn(292)) and is modified with oligomannose and hybrid-type oligosaccharides. 20807536 7 11 gly site 982:985 arg1 Asn Asn(292) Asn(292) Ovalbumin has a single N-glycosylation site (Asn(292)) and is modified with oligomannose and hybrid-type oligosaccharides. 11093789 9 32 gly glycosylation 1967:1979 arg2 separate and specific glycosylation sites separate and specific glycosylation sites sites These data show that separate and specific glycosylation sites are important for GRP-R trafficking to the cell surface, ligand binding, G protein coupling, chronic desensitization, and down-regulation. 1385399 7 4 gly N-glycosylation 1276:1290 arg1 human CD2 adhesion functions human CD2 adhesion functions PUBTATOR CD2 914 Thus, N-glycosylation is essential for human CD2 adhesion functions. 11054460 2 27 gly -glycosylation 700:713 arg2 a potential N:-glycosylation site a potential N:-glycosylation site site The first and second single-residue mutations were designed to introduce a potential N:-glycosylation site and to restrict backbone bond rotation, respectively, and therefore to decrease entropy during protein unfolding. 7510240 4 11 gly glycosylation 689:701 arg2 one N-linked glycosylation site one N-linked glycosylation site site Conservation included one N-linked glycosylation site and one protein kinase C phosphorylation site. 11955599 5 25 gly attached 593:600 arg1 the conserved glycosylation site AND Carbohydrates the conserved glycosylation site Carbohydrates site Carbohydrates attached to the conserved glycosylation site on Fc portion of an antibody are critical to the recognition of immunoglobulins by the low affinity Fcgamma receptor. 11955599 5 32 gly glycosylation 619:631 arg2 the conserved glycosylation site the conserved glycosylation site site Carbohydrates attached to the conserved glycosylation site on Fc portion of an antibody are critical to the recognition of immunoglobulins by the low affinity Fcgamma receptor. 28353332 7 47 gly glycosylation 1231:1243 arg2 that glycosylation site that glycosylation site site Since the MS2 transitions to be used for extracting DIA data is common to that glycosylation site and not dictated by a specific MS1 value, our workflow applies equally well to the identification of both targeted and unexpected glycoforms. 27574189 0 25 gly glycans 18:24 arg1 plasma-derived ADAMTS13 ADAMTS13 glycans PUBTATOR ADAMTS13 11093 Identification of glycans on plasma-derived ADAMTS13. 27381217 0 2 part_of site 80:83 arg1 hemagglutinin hemagglutinin site Fterm Site hemagglutinin site The S128N mutation combined with an additional potential N-linked glycosylation site at residue 133 in hemagglutinin affects the antigenicity of the human H7N9 virus. 8227277 4 73 part_of HA-1 832:835 arg1 The nucleotide sequences HA-1 The nucleotide sequences OGER Site HA-1 sequences The nucleotide sequences of the viral HA-1 from the nasopharynx of the infected volunteer were the same as that of the original infecting strain. 11251288 9 70 gly non-glycosylated 1948:1963 arg1 non-glycosylated protein non-glycosylated protein Fterm protein Yield of glycosylation was generally about 50% and purification of glycosylated protein from non-glycosylated protein was readily carried out using lectin affinity chromatography. 11251288 9 85 gly glycosylated 1922:1933 arg1 glycosylated protein glycosylated protein Fterm protein Yield of glycosylation was generally about 50% and purification of glycosylated protein from non-glycosylated protein was readily carried out using lectin affinity chromatography. 11072064 4 2 part_of sequence 548:555 arg1 The predicted protein protein sequence Fterm protein The predicted protein from this sequence contains a 48 aa cytoplasmic domain, a 20 aa transmembrane domain (TM), a 46 aa stalk region and a 124 aa carbohydrate-recognition domain (CRD). 11072064 4 105 part_of contains 557:564 arg1 The predicted protein AND a 46 aa stalk region The predicted protein a 46 aa stalk region Fterm Site protein region The predicted protein from this sequence contains a 48 aa cytoplasmic domain, a 20 aa transmembrane domain (TM), a 46 aa stalk region and a 124 aa carbohydrate-recognition domain (CRD). 11072064 4 105 part_of contains 557:564 arg1 The predicted protein AND a 20 aa transmembrane domain protein domain a 124 aa carbohydrate-recognition domain Fterm Site protein domain The predicted protein from this sequence contains a 48 aa cytoplasmic domain, a 20 aa transmembrane domain (TM), a 46 aa stalk region and a 124 aa carbohydrate-recognition domain (CRD). 8910207 2 110 part_of alpha-subunit 304:316 arg1 residue D200 alpha-subunit residue D200 Fterm Site alpha-subunit residue Single channel currents were recorded from HEK 293 cells expressing recombinant mouse adult (alpha 2 beta delta gamma) acetylcholine receptors (AChRs) containing a mutation at residue D200 of the alpha-subunit. 2457922 4 12 part_of BGP 803:805 arg1 The nucleotide sequence BGP I The nucleotide sequence PUBTATOR Site BGP I 634 sequence The nucleotide sequence of BGP I exhibited greater than 80% identity with CEA and nonspecific crossreacting antigen (NCA) in the leader peptide, N-terminal domain, and immunoglobulin-like domain. 22823882 9 40 gly glycoprotein 1310:1321 arg1 a glycoprotein database a glycoprotein database Fterm glycoprotein We then constructed a glycoprotein database, GlycoProtDB, using our experimental-based information to facilitate future studies in glycobiology. 22365192 10 25 part_of residue 1850:1856 arg1 the protein protein residue Fterm AminoAcid protein residue in This event results in the occurrence of an additional alanine (A) residue in the protein that disrupts a putative atypical N-glycosylation site (VNGC/VNAGC) described in human lactadherin. 9931494 8 26 gly N-glycosylation 1125:1139 arg2 a single, putative N-glycosylation site a single, putative N-glycosylation site site The translated protein contains a single, putative N-glycosylation site. 15754041 8 13 part_of MYB 1133:1135 arg1 MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites MYB MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites OGER Site MYB P10242 sites MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters. 15754041 8 20 part_of HNF4A 1167:1171 arg1 MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites HNF4A MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites PUBTATOR Site HNF4A 25735 sites MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters. 15754041 8 32 part_of NKX2-5 1205:1210 arg1 MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites NKX2-5 MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites PUBTATOR Site NKX2-5 114109 sites MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters. 15754041 8 61 part_of ELK1 1146:1149 arg1 MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites ELK1 MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites PUBTATOR Site ELK1 314436 sites MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters. 15754041 8 64 part_of POU2F1 1152:1157 arg1 MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites POU2F1 MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites PUBTATOR Site POU2F1 171068 sites MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters. 15754041 8 77 part_of COMP1 1182:1186 arg1 MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites COMP1, NFYA MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites PUBTATOR Site COMP1, NFYA 29508 sites MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters. 15754041 8 80 part_of NFYA 1189:1192 arg1 MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites COMP1, NFYA MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites PUBTATOR Site COMP1, NFYA 29508 sites MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters. 15859596 4 20 gly glycopeptides 732:744 arg2 glycopeptides glycopeptides glycopeptides A lectin column prepared from Sambucus nigra agglutinin (SNA) was used to select and compare the concentration of sialic acid containing glycopeptides. 18829751 1 13 part_of sites 238:242 arg1 the transmembrane protein gp41 gp41 sites Cterm Site gp41 sites Human immunodeficiency virus type 1 and simian immunodeficiency virus possess three closely spaced, highly conserved sites for N-linked carbohydrate attachment in the extracellular domain of the transmembrane protein gp41. 18829751 1 37 part_of gp41 338:341 arg1 the extracellular domain gp41 the extracellular domain Cterm Site gp41 domain Human immunodeficiency virus type 1 and simian immunodeficiency virus possess three closely spaced, highly conserved sites for N-linked carbohydrate attachment in the extracellular domain of the transmembrane protein gp41. 26683050 3 9 gly glycosylation 525:537 arg1 48 paired CSF and serum samples 48 paired CSF and serum samples OGER CSF METHODS: We applied mass spectrometry of tryptic Fc glycopeptides to analyze IgG Fc glycosylation (sialylation, galactosylation, fucosylation, and bisecting N-acetylglucosamine (GlcNAc)) in 48 paired CSF and serum samples from adult patients with MS or a first demyelinating event highly suggestive of MS (designated as MS cases), and from healthy volunteers and patients with other non-inflammatory diseases (control group). 26683050 3 75 gly glycopeptides 493:505 arg2 tryptic Fc glycopeptides tryptic Fc glycopeptides glycopeptides METHODS: We applied mass spectrometry of tryptic Fc glycopeptides to analyze IgG Fc glycosylation (sialylation, galactosylation, fucosylation, and bisecting N-acetylglucosamine (GlcNAc)) in 48 paired CSF and serum samples from adult patients with MS or a first demyelinating event highly suggestive of MS (designated as MS cases), and from healthy volunteers and patients with other non-inflammatory diseases (control group). 10419504 5 62 gly N-glycosylation 686:700 arg2 potential N-terminal N-glycosylation sites potential N-terminal N-glycosylation sites sites Mutation of all four asparagines in potential N-terminal N-glycosylation sites to glutamines resulted in a 20-kDa reduction of the expressed protein. 23632316 5 33 gly occupied 754:761 arg2 the glycosylation site the glycosylation site site We concluded that in control experiments, the glycosylation site was occupied as expected. 23632316 5 60 gly glycosylation 731:743 arg2 the glycosylation site the glycosylation site site We concluded that in control experiments, the glycosylation site was occupied as expected. 10764840 3 44 gly rHuEpo 542:547 arg1 the glycan chains rHuEpo the glycan chains Cterm rHuEpo 2056 The structure of the glycan chains of this rHuEpo slightly differ of those of the urinary human Epo (uHuEpo), considered as the natural Epo molecule. 14699159 5 28 gly glycosylation 1064:1076 arg2 the N-linked glycosylation site the N-linked glycosylation site site By mutating a single amino acid within the N-linked glycosylation site closest to the carboxyl terminus of p90ATF6, we recreated ATF6(f). 7475306 5 17 gly Asn244 892:897 arg1 GlcNAC Asn244 GlcNAC Asn244 We have successfully engineered and synthesized the 233-253 sequence of gp46 of HTLV-1 with and without GlcNAC at Asn244. 23265247 6 20 gly glycosylation 1017:1029 arg2 a new glycosylation site a new glycosylation site site Furthermore, residue Leu129 in site A of the HA protein was confirmed to be critical for maintenance of the reactivity with the DT antiserum, and Asn140, possessing a new glycosylation site, was confirmed to be critical for reducing reactivity with the Re-4 antiserum. 24048266 0 72 gly glycosylation 52:64 arg2 human GPCRs N-linked glycosylation sites human GPCRs N-linked glycosylation sites sites Using ensemble SVM to identify human GPCRs N-linked glycosylation sites based on the general form of Chou's PseAAC. 23909558 8 11 gly O-glycopeptide 1170:1183 arg2 The site-specific O-glycopeptide composition The site-specific O-glycopeptide composition O-glycopeptide The site-specific O-glycopeptide composition was correctly assigned in every case, proving the merits of our method in analyzing glycopeptide ETD data. 23909558 8 19 gly glycopeptide 1281:1292 arg2 glycopeptide ETD data glycopeptide ETD data glycopeptide The site-specific O-glycopeptide composition was correctly assigned in every case, proving the merits of our method in analyzing glycopeptide ETD data. 28822114 5 40 part_of DMP1 726:729 arg1 serine89 DMP1 serine89 PUBTATOR AminoAcid DMP1 13406 serine89 The only glycosylation site of DMP1 is serine89 (S89) in the N-terminal domain of the protein in mouse. 28822114 5 40 part_of DMP1 726:729 arg1 The only glycosylation site DMP1 The only glycosylation site PUBTATOR Site DMP1 13406 site The only glycosylation site of DMP1 is serine89 (S89) in the N-terminal domain of the protein in mouse. 28822114 5 57 part_of serine89 734:741 arg1 the protein protein serine89 Fterm AminoAcid protein serine89 The only glycosylation site of DMP1 is serine89 (S89) in the N-terminal domain of the protein in mouse. 28822114 5 62 part_of protein 781:787 arg1 the N-terminal domain protein the N-terminal domain Fterm Site protein domain The only glycosylation site of DMP1 is serine89 (S89) in the N-terminal domain of the protein in mouse. 9398598 1 54 gly glycoprotein 135:146 arg1 CD4 CD4 PUBTATOR CD4 12504 CD4 is a membrane glycoprotein on T lymphocytes that binds to the same peptide:major histocompatibility complex (MHC) class II molecules recognized by the antigen-specific T cell receptor (TcR). 9398598 1 54 gly glycoprotein 135:146 arg1 a membrane glycoprotein a membrane glycoprotein Fterm glycoprotein CD4 is a membrane glycoprotein on T lymphocytes that binds to the same peptide:major histocompatibility complex (MHC) class II molecules recognized by the antigen-specific T cell receptor (TcR). 27743362 4 5 gly glycoproteins 521:533 arg1 glycoproteins glycoproteins Fterm glycoproteins In a first step glycoproteins are treated with Pronase to generate glycopeptides containing small peptide sequences for enhanced glycosylation site assignment and characterization. 27743362 4 27 gly glycosylation 634:646 arg2 enhanced glycosylation site assignment enhanced glycosylation site assignment site In a first step glycoproteins are treated with Pronase to generate glycopeptides containing small peptide sequences for enhanced glycosylation site assignment and characterization. 27743362 4 68 gly glycopeptides 572:584 arg2 glycopeptides glycopeptides glycopeptides In a first step glycoproteins are treated with Pronase to generate glycopeptides containing small peptide sequences for enhanced glycosylation site assignment and characterization. 8027066 0 19 gly N-glycosylation 107:121 arg2 the four N-glycosylation sites the four N-glycosylation sites sites The functions of the human insulin receptor are affected in different ways by mutation of each of the four N-glycosylation sites in the beta subunit. 22078945 8 12 part_of contains 881:888 arg1 TTV ORF1 protein AND two non-regular secondary structure region protein region Fterm Site protein region CONCLUSIONS: TTV ORF1 protein may be a nuclear protein which contains two non-regular secondary structure region. 8347587 0 34 gly glycosylation 9:21 arg2 Specific glycosylation site mutations Specific glycosylation site mutations site Specific glycosylation site mutations of the insulin receptor alpha subunit impair intracellular transport. 22248643 0 54 gly glycoprotein 154:165 arg1 a viral glycoprotein a viral glycoprotein Fterm glycoprotein Serial passage of a street rabies virus in mouse neuroblastoma cells resulted in attenuation: potential role of the additional N-glycosylation of a viral glycoprotein in the reduced pathogenicity of street rabies virus. 22248643 0 69 gly N-glycosylation 127:141 arg1 a viral glycoprotein a viral glycoprotein Fterm glycoprotein Serial passage of a street rabies virus in mouse neuroblastoma cells resulted in attenuation: potential role of the additional N-glycosylation of a viral glycoprotein in the reduced pathogenicity of street rabies virus. 25636227 4 68 gly attached 691:698 arg2 the Ser or Thr residues AND an N-acetylgalacosamine (GalNAc) residue the Ser or Thr residues an N-acetylgalacosamine (GalNAc) residue Thr residues A mixture of exoglycosidases was used to partially remove O-glycan chains and leave an N-acetylgalacosamine (GalNAc) residue attached to the Ser or Thr residues. 1400492 7 62 gly glycosylation 726:738 arg2 A single glycosylation site A single glycosylation site site A single glycosylation site occurs in the mLAP sequence at a position corresponding to the first glycosylation site of cathepsins D. 1400492 7 85 gly glycosylation 814:826 arg2 the first glycosylation site cathepsins D site OGER cathepsins D P25774 site A single glycosylation site occurs in the mLAP sequence at a position corresponding to the first glycosylation site of cathepsins D. 15252014 8 36 gly glycosylation 1506:1518 arg2 an N-linked glycosylation site an N-linked glycosylation site site Using site-directed mutagenesis to insert an N-linked glycosylation site we show that a portion of this region is present in the lumen. 17459925 10 54 gly position 1344:1351 arg1 the carbohydrate position 67 the carbohydrate position 67 Finally, we found that viruses lacking the carbohydrate at position 67 showed reduced infection of immature dendritic cells, suggesting interaction between this glycan and the lectin DC-SIGN. 30061671 8 40 part_of N-glycosylation 976:990 arg1 a predicted N-glycosylation site N a predicted N-glycosylation site Cterm Site N 956592 site Candid#1 VHH-escape viruses had acquired a predicted N-glycosylation site in the surface glycoprotein GP1 that is present in highly pathogenic JUNV strains. 14747665 5 25 gly glycosylation 887:899 arg2 a N-linked glycosylation site a N-linked glycosylation site site This mutation disrupted a N-linked glycosylation site and generated a partially deglycosylated receptor. 14747665 5 55 gly deglycosylated 932:945 arg1 a partially deglycosylated receptor a partially deglycosylated receptor Fterm receptor This mutation disrupted a N-linked glycosylation site and generated a partially deglycosylated receptor. 11428934 9 10 gly Asn-linked 1445:1454 arg1 the Asn-linked sugar moiety Asn the Asn-linked sugar moiety Asn Thus, the specific antibody recognition of peptide 2 is most likely driven by direct interactions of the antibody binding site with the Asn-linked sugar moiety. 22171062 7 62 gly occupied 1487:1494 arg2 All seven consensus sequences All seven consensus sequences sequences All seven consensus sequences for N-linked glycosylation were definitively found to be occupied in the VV-derived protein, whereas only four sites were found and characterized in the HEK293-derived protein. 11876646 4 43 gly glycosylation 596:608 arg2 the glycosylation site the glycosylation site site Trypsin, papain, and proteinase K do not cleave band 3 at or near K743 in intact red cells, even under conditions that cause cleavage on the C-terminal side of the glycosylation site (N642) in extracellular loop 4. 11876646 4 43 gly glycosylation 596:608 arg2 N642 N642 N642 Trypsin, papain, and proteinase K do not cleave band 3 at or near K743 in intact red cells, even under conditions that cause cleavage on the C-terminal side of the glycosylation site (N642) in extracellular loop 4. 1567356 11 28 gly glycosylation 1641:1653 arg2 the individual glycosylation sites OMD sites OGER OMD Q99983 sites The results indicate that the 'site-directed' model of processing offers the most consistent explanation for the structures seen at the individual glycosylation sites of OMD. 10103002 2 72 gly glycoprotein 208:219 arg1 A glycoprotein A glycoprotein Fterm glycoprotein A glycoprotein with molecular mass of 42 kDa was identified as the major component of the chicken egg-envelope, the filamentous, extracellular matrix known as the perivitelline layer. 9712881 2 46 part_of AE1 223:225 arg1 Glu681 AE1 Glu681 PUBTATOR AminoAcid AE1 6521 Glu681 Glu681 of human AE1 may form part of the anion translocation apparatus and the permeability barrier. 27033547 4 26 part_of site 561:564 arg1 the 180 envelope glycoproteins glycoproteins site Fterm Site glycoproteins site The structure of Zika virus is similar to other known flavivirus structures, except for the ~10 amino acids that surround the Asn(154) glycosylation site in each of the 180 envelope glycoproteins that make up the icosahedral shell. 8411368 8 76 gly glycosylation 1266:1278 arg2 a glycosylation site a glycosylation site site These results suggest that the absence of a glycosylation site at position 130 of the NA plays a key role in the neurovirulence of WSN virus in mice. 8411368 8 76 gly glycosylation 1266:1278 arg2 position 130 position 130 position 130 These results suggest that the absence of a glycosylation site at position 130 of the NA plays a key role in the neurovirulence of WSN virus in mice. 27038031 4 10 part_of GluC 683:686 arg1 HILIC-enriched tryptic and GluC glycopeptides GluC HILIC-enriched tryptic and GluC glycopeptides OGER Site GluC P04062 glycopeptides In this study, the N-glycosylation of recombinant pentameric and hexameric IgM produced by the same human cell type and culture conditions was site-specifically profiled by RP-LC-CID/ETD-MS/MS using HILIC-enriched tryptic and GluC glycopeptides. 2538306 0 132 gly O-glycosylation 0:14 arg1 the alpha-subunit the alpha-subunit Fterm alpha-subunit O-glycosylation of the alpha-subunit does not limit the assembly of chorionic gonadotropin alpha beta dimer in human malignant and nonmalignant trophoblast cells. 20391591 2 11 gly glycopeptide 281:292 arg2 glycopeptide ions glycopeptide ions glycopeptide It is shown here that glycopeptide ions can be fragmented efficiently using the higher-energy C-trap dissociation (HCD) feature of a linear ion trap orbitrap hybrid mass spectrometer (LTQ Orbitrap). 7772241 3 73 part_of neurophysin 724:734 arg1 The central region neurophysin The central region Fterm Site neurophysin region The central region of the lamprey neurophysin was very similar to those of previously characterized gnathostome neurophysins. 7479385 0 27 gly antigen 63:69 arg1 carbohydrate structure prostate specific antigen carbohydrate structure PUBTATOR prostate specific antigen 354 Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. 15199058 2 32 part_of IgE 388:390 arg1 the Cepsilon3 domain IgE the Cepsilon3 domain PUBTATOR Site IgE P01854 domain We have previously identified the importance of amino acid residues in the A-B loop of the Cepsilon3 domain of human IgE and implicated a region close to the glycosylation site at asparagine 371 as contributing to IgE-CD23 interaction. 8076650 0 48 part_of fuctinin 48:55 arg1 partial amino acid sequence fuctinin partial amino acid sequence Fterm Site fuctinin sequence Purification and partial amino acid sequence of fuctinin, an endogenous inhibitor of fucosyltransferase activities. 8088785 6 10 part_of protein 1033:1039 arg1 a short intracytoplasmic domain protein a short intracytoplasmic domain Fterm Site protein domain The deduced amino acid sequence comprised a 51-kDa type I membrane protein with a single spanning region and a short intracytoplasmic domain. 8088785 6 10 part_of protein 1033:1039 arg1 a single spanning region protein a single spanning region Fterm Site protein region The deduced amino acid sequence comprised a 51-kDa type I membrane protein with a single spanning region and a short intracytoplasmic domain. 1989393 1 2 gly glycosylation 149:161 arg2 selected glycosylation sites selected glycosylation sites sites The role of selected glycosylation sites in the ability of the envelope glycoprotein of HIV-2 (gp 105) to bind to CD4 has been investigated. 1989393 1 6 gly glycoprotein 200:211 arg1 the envelope glycoprotein the envelope glycoprotein Fterm glycoprotein The role of selected glycosylation sites in the ability of the envelope glycoprotein of HIV-2 (gp 105) to bind to CD4 has been investigated. 26947874 3 54 part_of sites 604:608 arg1 human A1AT A1AT sites PUBTATOR Site A1AT 5265 sites In this study, we investigated the role of an additional N-glycosylation site (Q4N/D6T, Q9N, D12N/S14T, A70N, G148T, R178N, or V212N) to the three naturally occurring N-glycosylation sites in human A1AT. 10551780 6 14 gly glycosylation 1015:1027 arg2 an N-linked glycosylation site an N-linked glycosylation site site However, binding affinity was 20-fold reduced by introduction of an N-linked glycosylation site at the turn between strands 2B and 3B (Leu246Thr) without compromising the proper folding of this mutant as assessed by immunological methods. 22586465 8 19 gly N-glycosylation 1243:1257 arg2 modified N-glycosylation sequons modified N-glycosylation sequons We find that 1091 proteins have modified N-glycosylation sequons due to nsSNVs in the genome. 26485397 3 33 gly residues 558:565 arg1 two conservative cysteine residues two conservative cysteine residues cysteine residues Sequence analysis showed that the open reading frame (ORF) of cAPRIL contains a putative furin protease cleavage site (R-R-K-R), a conserved putative N-glycosylation site (Asn(124)), and two conservative cysteine residues (Cys(196) and Cys(211)). 26485397 3 45 gly N-glycosylation 495:509 arg2 Asn(124) Asn(124) Asn(124) Sequence analysis showed that the open reading frame (ORF) of cAPRIL contains a putative furin protease cleavage site (R-R-K-R), a conserved putative N-glycosylation site (Asn(124)), and two conservative cysteine residues (Cys(196) and Cys(211)). 26485397 3 45 gly N-glycosylation 495:509 arg2 a conserved putative N-glycosylation site a conserved putative N-glycosylation site site Sequence analysis showed that the open reading frame (ORF) of cAPRIL contains a putative furin protease cleavage site (R-R-K-R), a conserved putative N-glycosylation site (Asn(124)), and two conservative cysteine residues (Cys(196) and Cys(211)). 26485397 3 33 gly residues 558:565 arg1 Cys(196) Cys(196) and Cys(211) Cys(196) and Cys(211) Sequence analysis showed that the open reading frame (ORF) of cAPRIL contains a putative furin protease cleavage site (R-R-K-R), a conserved putative N-glycosylation site (Asn(124)), and two conservative cysteine residues (Cys(196) and Cys(211)). 7533854 3 133 part_of gp120 632:636 arg1 the isolated V1/V2 domain gp120 the isolated V1/V2 domain PUBTATOR Site gp120 3700 domain A fusion glycoprotein expression system that expressed the isolated V1/V2 domain of gp120 in native form was used to analyze the structural characteristics of these epitopes. 8236140 6 47 part_of t-PA 1028:1031 arg1 different domains t-PA different domains PUBTATOR Site t-PA 25692 domains These results show that it is possible to combine mutations in different domains of t-PA to construct a variant which is simultaneously slower clearing, less reactive towards plasminogen in the absence of a fibrin clot, and resistant to inactivation by PAI-1. 11281648 0 42 gly glycosylation 97:109 arg2 its glycosylation site its glycosylation site site Targeting of calsequestrin to the sarcoplasmic reticulum of skeletal muscle upon deletion of its glycosylation site. 12631291 6 72 gly glycopeptide 794:805 arg2 the pineapple stem bromelain glycopeptide MUXF glycopeptide Man alpha 1-6(Xyl beta 1-2)Man beta 1-4GlcNAc beta 1-4(Fuc alpha 1-3)GlcNAc glycopeptide IgE-binding to natural Lyc e 2 was completely inhibited by the pineapple stem bromelain glycopeptide MUXF (Man alpha 1-6(Xyl beta 1-2)Man beta 1-4GlcNAc beta 1-4(Fuc alpha 1-3)GlcNAc). 29755357 7 11 gly N-glycosylation 1343:1357 arg2 the N-glycosylation site the N-glycosylation site site Furthermore, a hydrophobic cluster analysis revealed that the N-glycosylation site is embedded in a highly hydrophobic evolutionarily conserved surrounding. 27038031 0 36 gly N-Glycosylation 14:28 arg1 Hexameric Human IgM Hexameric Human IgM OGER IgM P01871 Site-Specific N-Glycosylation of Recombinant Pentameric and Hexameric Human IgM. 23339644 7 129 gly sites 1471:1475 arg1 two sites two sites sites For N-linked glycosylation, two sites (N386 and N392) in the V4 region were populated with high mannose glycans in the CHO cell-derived 1086.C gp120, while these sites had a mixture of high mannose and processed glycans in the 293T cell-derived 1086.C gp120. 23339644 7 138 gly glycans 1543:1549 arg1 the CHO cell-derived 1086.C gp120 gp120 glycans PUBTATOR gp120 3700 For N-linked glycosylation, two sites (N386 and N392) in the V4 region were populated with high mannose glycans in the CHO cell-derived 1086.C gp120, while these sites had a mixture of high mannose and processed glycans in the 293T cell-derived 1086.C gp120. 23339644 7 154 gly glycans 1651:1657 arg1 the 293T cell-derived 1086.C gp120 gp120 glycans PUBTATOR gp120 3700 For N-linked glycosylation, two sites (N386 and N392) in the V4 region were populated with high mannose glycans in the CHO cell-derived 1086.C gp120, while these sites had a mixture of high mannose and processed glycans in the 293T cell-derived 1086.C gp120. 23339644 7 21 gly had 1607:1609 arg1 these sites AND processed glycans these sites processed glycans sites For N-linked glycosylation, two sites (N386 and N392) in the V4 region were populated with high mannose glycans in the CHO cell-derived 1086.C gp120, while these sites had a mixture of high mannose and processed glycans in the 293T cell-derived 1086.C gp120. 23339644 7 129 gly sites 1471:1475 arg1 N392 N386 and N392 N386 and N392 For N-linked glycosylation, two sites (N386 and N392) in the V4 region were populated with high mannose glycans in the CHO cell-derived 1086.C gp120, while these sites had a mixture of high mannose and processed glycans in the 293T cell-derived 1086.C gp120. 27048837 4 9 part_of site 615:618 arg1 this novel variant variant site Fterm Site variant site We report a novel variant of Apo E (c.382G>A) predicting 110Asp→Asn identified by genotyping, we were prompted to investigate this further as the amino acid substitution produced a prospective N-glycosylation site in this novel variant. 11093789 3 87 gly glycosylation 553:565 arg2 the four potential glycosylation sites the four potential glycosylation sites sites Each of the four potential glycosylation sites was mutated by converting the Asn (N) to Gln (Q). 9393962 8 32 part_of IgG3 997:1000 arg1 the IgG3 constant region IgG3 the IgG3 constant region PUBTATOR Site IgG3 P01860 region It was, therefore, important to determine whether the glycosylated residue in the CH3 domain of the IgG3 constant region is influential in self-association. 27038031 2 54 gly N-glycosylation 247:261 arg2 five potential N-glycosylation sites five potential N-glycosylation sites sites Polymeric IgM, the largest known antibody in humans, displays five potential N-glycosylation sites on each heavy chain monomer. 8354274 7 34 gly glycosylation 1180:1192 arg2 the potential Asn-linked glycosylation site the potential Asn-linked glycosylation site site The Arg 352 of the enzyme was converted to a citrulline residue and the potential Asn-linked glycosylation site (Asn542-Glu543-Ser544) had no carbohydrate moiety. 8354274 7 79 gly had 1222:1224 arg1 the potential Asn-linked glycosylation site AND no carbohydrate moiety the potential Asn-linked glycosylation site no carbohydrate moiety site The Arg 352 of the enzyme was converted to a citrulline residue and the potential Asn-linked glycosylation site (Asn542-Glu543-Ser544) had no carbohydrate moiety. 8180202 0 42 gly Glycosylation 0:12 arg1 human corticosteroid-binding globulin human corticosteroid-binding globulin PUBTATOR corticosteroid-binding globulin 866 Glycosylation of human corticosteroid-binding globulin. 15532026 7 28 gly glycosylation 1347:1359 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site By direct sequencing a novel homozygous mutation, c.347_349delACA (p.Asn116del), was identified affecting a potential N-linked glycosylation site. 11680875 4 17 gly have 805:808 arg1 one protein AND many different oligosaccharides one protein many different oligosaccharides Fterm protein Since one protein may have many different oligosaccharides attached to it (glycoforms) this is a major technical challenge. 20338479 3 13 gly sialylated 507:516 arg1 sialylated integrin beta1 sialylated integrin beta1 PUBTATOR integrin beta1 3688 METHODS AND MATERIALS: We performed Western blotting and lectin affinity assay to analyze the expression and level of sialylated integrin beta1. 28617578 6 34 part_of MUC16 739:743 arg1 synthetic MUC16 glycopeptides MUC16 synthetic MUC16 glycopeptides PUBTATOR Site MUC16 73732 glycopeptides Using synthetic MUC16 glycopeptides, we developed novel N-glycosylation site directed monoclonal antibodies that block Galectin-3-mediated MUC16 interactions with cell surface signaling molecules. 1725860 7 105 part_of possess 1214:1220 arg1 human IGFBP-3 AND multiple N-linked glycosylation sites human IGFBP-3 multiple N-linked glycosylation sites PUBTATOR Site IGFBP-3 3486 sites Both rat and human IGFBP-3 possess multiple N-linked glycosylation sites at the mid-region of the molecule, which accounts for their apparent molecular size being larger than the calculated molecular weight, based on the amino acid sequence. 15863355 4 78 gly glycopeptides 636:648 arg2 the liberated glycopeptides the liberated glycopeptides glycopeptides METHODS: AGP purified from sera was digested with Glu-C and the liberated glycopeptides were isolated by reverse phase HPLC. 20512925 0 5 gly N-glycans 13:21 arg1 RAGE RAGE N-glycans PUBTATOR RAGE 177 Carboxylated N-glycans on RAGE promote S100A12 binding and signaling. 17041228 4 1 gly glycosylation 496:508 arg2 a potential glycosylation site a potential glycosylation site site One, N356 in conserved region 3, is a potential glycosylation site and has not previously been associated with coreceptor use. 14760718 5 15 gly N-glycosylation 655:669 arg2 N-glycosylation sites N-glycosylation sites sites Here we demonstrate a procedure for mapping N-glycosylation sites in complex mixtures by reducing sample complexity and enriching glycoprotein content. 14760718 5 52 gly glycoprotein 741:752 arg1 glycoprotein content glycoprotein content Fterm glycoprotein Here we demonstrate a procedure for mapping N-glycosylation sites in complex mixtures by reducing sample complexity and enriching glycoprotein content. 26776361 0 45 gly glycosylation 143:155 arg2 naturally occurring glycosylation sites naturally occurring glycosylation sites sites Stabilization of bacterially expressed erythropoietin by single site-specific introduction of short branched PEG chains at naturally occurring glycosylation sites. 27038031 9 2 gly peptide 1624:1630 arg1 global glycan or deglycosylated peptide profiling global glycan or deglycosylated peptide profiling This study highlights the information obtained by characterization of the site-heterogeneity of a highly glycosylated protein of high molecular mass with quaternary structure, revealing differences that would not be seen by global glycan or deglycosylated peptide profiling. 27038031 9 22 gly site-heterogeneity 1442:1459 arg1 a highly glycosylated protein a highly glycosylated protein Fterm protein This study highlights the information obtained by characterization of the site-heterogeneity of a highly glycosylated protein of high molecular mass with quaternary structure, revealing differences that would not be seen by global glycan or deglycosylated peptide profiling. 27038031 9 26 gly glycosylated 1473:1484 arg1 a highly glycosylated protein a highly glycosylated protein Fterm protein This study highlights the information obtained by characterization of the site-heterogeneity of a highly glycosylated protein of high molecular mass with quaternary structure, revealing differences that would not be seen by global glycan or deglycosylated peptide profiling. 2189790 0 33 gly N-glycosylated 13:26 arg1 N-glycosylated human recombinant interleukin-1 alpha N-glycosylated human recombinant interleukin-1 alpha PUBTATOR interleukin-1 alpha 3552 Secretion of N-glycosylated human recombinant interleukin-1 alpha in Saccharomyces cerevisiae. 28630087 1 25 gly N-glycosylated 170:183 arg1 Human neutrophil elastase Human neutrophil elastase PUBTATOR Human neutrophil elastase 1991 Human neutrophil elastase (HNE) is an important N-glycosylated serine protease in the innate immune system, but the structure and immune-modulating functions of HNE N-glycosylation remain undescribed. 22180206 0 81 gly O-glycosylated 42:55 arg1 densely O-glycosylated mucin-type peptides densely O-glycosylated mucin-type peptides peptides Site-specific characterisation of densely O-glycosylated mucin-type peptides using electron transfer dissociation ESI-MS/MS. 16432019 8 40 gly glycosylation 1432:1444 arg2 a conserved glycosylation site a conserved glycosylation site site Several nucleotide and amino acid deletions and/or substitutions with putative functional significance were identified in ALFV, including the abolition of a conserved glycosylation site in the envelope protein and the deletion of the terminal dinucleotide 5'-CU(OH)-3' found in all other members of the genus. 3778488 0 36 part_of factor 54:59 arg1 Amino acid sequence acidic fibroblast growth factor Amino acid sequence PUBTATOR Site acidic fibroblast growth factor 2246 sequence Amino acid sequence of human acidic fibroblast growth factor. 20848033 0 67 gly glycopeptide 45:56 arg2 glycopeptide glycopeptide glycopeptide Expeditious chemoenzymatic synthesis of CD52 glycopeptide antigens. 9884403 0 15 gly glycoprotein 75:86 arg1 human Tamm-Horsfall glycoprotein human Tamm-Horsfall glycoprotein OGER Tamm-Horsfall glycoprotein P07911 Glycosylation sites and site-specific glycosylation in human Tamm-Horsfall glycoprotein. 9884403 0 67 gly glycosylation 38:50 arg1 human Tamm-Horsfall glycoprotein human Tamm-Horsfall glycoprotein OGER Tamm-Horsfall glycoprotein P07911 Glycosylation sites and site-specific glycosylation in human Tamm-Horsfall glycoprotein. 2603816 3 14 part_of kallikrein 366:375 arg1 N-terminal isoleucine kallikrein N-terminal isoleucine PUBTATOR AminoAcid kallikrein 9622 isoleucine In the case of prokallikrein, a propeptide which was consisted of seven amino acid residues was attached to N-terminal isoleucine of kallikrein. 25636227 9 80 gly glycopeptides 1371:1383 arg1 36 distinctive glycoproteins 36 distinctive glycoproteins Fterm glycoproteins Using only one drop of blood, a total of 49 O-GalNAc-linked glycopeptides from 36 distinctive glycoproteins in human plasma were identified unambiguously. 25636227 9 56 gly glycoproteins 1405:1417 arg1 49 O-GalNAc-linked glycopeptides glycoproteins 49 O-GalNAc-linked glycopeptides Fterm glycoproteins Using only one drop of blood, a total of 49 O-GalNAc-linked glycopeptides from 36 distinctive glycoproteins in human plasma were identified unambiguously. 9242452 8 114 gly glycopeptides 1390:1402 arg2 Some glycopeptides Some glycopeptides glycopeptides Some glycopeptides were not immunogenic, suggesting that there may be holes in the T-cell repertoire due to a lack of T-cell receptor regions accommodating certain glycan structures. 14566028 4 24 gly glycosylation 747:759 arg2 the glycosylation site the glycosylation site site To reveal brush-border GLUT2 fully, it is necessary to digest the sugar chain at the glycosylation site close to the antigenic site. 9758750 2 8 part_of Ig 468:469 arg1 N-terminus Ig-like domain Ig CRH N-terminus Ig-like domain OGER Site Ig CRH P06850 domain A truncated receptor molecule consisting of the cytokine receptor homology domain and N-terminus Ig-like domain (Ig CRH) behaves quite similarly. 9758750 2 60 part_of receptor 412:419 arg1 the cytokine receptor homology domain receptor the cytokine receptor homology domain Fterm Site receptor domain A truncated receptor molecule consisting of the cytokine receptor homology domain and N-terminus Ig-like domain (Ig CRH) behaves quite similarly. 19277548 6 30 gly N-glycosylation 1043:1057 arg1 human platelet proteins proteins sites Fterm proteins sites In the described protocol, the elucidation of N-glycosylation sites of human platelet proteins is demonstrated as an example. 18941134 3 44 gly fucosylated 997:1007 arg1 highly fucosylated N-glycans highly fucosylated N-glycans The predominance of Lewis X/Y along with Neu5Acalpha2-6 sialylation was found to be a salient feature of the ULF glycome, and several other protein carriers were additionally identified including the highly abundant lactotransferrin, which is N-glycosylated at two sites, both with a similar range of highly fucosylated N-glycans. 18941134 3 67 gly N-glycosylated 932:945 arg2 two sites lactotransferrin sites PUBTATOR lactotransferrin 17002 sites The predominance of Lewis X/Y along with Neu5Acalpha2-6 sialylation was found to be a salient feature of the ULF glycome, and several other protein carriers were additionally identified including the highly abundant lactotransferrin, which is N-glycosylated at two sites, both with a similar range of highly fucosylated N-glycans. 7561759 2 87 gly glycoprotein 376:387 arg1 the major envelope glycoprotein the major envelope glycoprotein Fterm glycoprotein The antibodies, 93B, 74D(B) and 38F, recognized the major envelope glycoprotein (GL) encoded by open reading frame (ORF) 5 in immunoblots and by immunoprecipitation. 26615566 8 14 part_of protein 1244:1250 arg1 position 27 protein position 27 Fterm Site protein position 27 It could be concluded that the substitution of Phe in the codon 101 position, which may increase the binding activity of IFNβ with its receptors and introduction of an additional N glycosylation site (Asn-X-Thr) in the position 27 of IFNβ protein may cause such an effect. 7642555 9 10 gly c-Myc 1120:1124 arg1 the major O-GlcNAc glycosylation site c-Myc the major O-GlcNAc glycosylation site PUBTATOR c-Myc 4609 These analyses show that threonine 58, an in vivo phosphorylation site in the transactivation domain, is the major O-GlcNAc glycosylation site of c-Myc. 7642555 9 63 gly glycosylation 1098:1110 arg2 threonine 58 c-Myc threonine 58 PUBTATOR c-Myc 4609 threonine 58 These analyses show that threonine 58, an in vivo phosphorylation site in the transactivation domain, is the major O-GlcNAc glycosylation site of c-Myc. 22123080 1 31 gly glycoprotein 108:119 arg1 The membrane glycoprotein CD82 The membrane glycoprotein CD82 Fterm glycoprotein The membrane glycoprotein CD82 (KAI1) has attracted increasing attention as a suppressor of cell migration, related tumor invasion, as well as metastasis. 22123080 1 31 gly glycoprotein 108:119 arg1 KAI1 KAI1 PUBTATOR KAI1 3732 The membrane glycoprotein CD82 (KAI1) has attracted increasing attention as a suppressor of cell migration, related tumor invasion, as well as metastasis. 9201996 5 72 gly glycosylation 966:978 arg2 the glycosylation site the glycosylation site site To define the effect of proline residues around the glycosylation site, we analyzed a series of peptides containing one to three proline residues in a parent peptide AAATAAA. 16253890 3 33 part_of gp120 568:572 arg1 previously hidden gp120 epitopes gp120 previously hidden gp120 epitopes PUBTATOR Site gp120 3700 epitopes There is evidence that mutant HIV strains containing glycosylation site deletions trigger the production of specific neutralising antibodies to previously hidden gp120 epitopes. 30307368 0 37 part_of MICA 65:68 arg1 MICA epitope MICA MICA epitope PUBTATOR Site MICA 100507436 epitope High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodies. 9203958 9 52 gly glycosylation 1260:1272 arg2 position 282 position 282 position 282 Bovine IgA shares with rabbit IgA3 and IgA4, an additional N-linked glycosylation site at position 282. 9203958 9 52 gly glycosylation 1260:1272 arg2 an additional N-linked glycosylation site an additional N-linked glycosylation site site Bovine IgA shares with rabbit IgA3 and IgA4, an additional N-linked glycosylation site at position 282. 11711599 3 14 part_of protein 540:546 arg1 the four N-linked glycosylation sites protein the four N-linked glycosylation sites Fterm Site protein sites Eight plasmids were engineered, encoding E1 protein mutants in which the four N-linked glycosylation sites of the protein were mutated separately or in combination. 15956584 4 3 part_of glycoprotein 610:621 arg1 the relative position glycoprotein the relative position Fterm Site glycoprotein position The mutants were named with an N followed by a number related to the relative position of the potential glycosylation site in each glycoprotein (E1N1 to E1N4 for E1 mutants and E2N1 to E2N11 for E2 mutants). 15956584 4 17 part_of site 597:600 arg1 each glycoprotein glycoprotein site Fterm Site glycoprotein site The mutants were named with an N followed by a number related to the relative position of the potential glycosylation site in each glycoprotein (E1N1 to E1N4 for E1 mutants and E2N1 to E2N11 for E2 mutants). 15956584 4 40 part_of position 557:564 arg1 each glycoprotein glycoprotein position Fterm Site glycoprotein position The mutants were named with an N followed by a number related to the relative position of the potential glycosylation site in each glycoprotein (E1N1 to E1N4 for E1 mutants and E2N1 to E2N11 for E2 mutants). 28270583 6 49 gly glycosylation 929:941 arg2 a glycosylation site a glycosylation site site These include three versions of MR766, the prototype 1947 strain (with and without a glycosylation site in the envelope protein), and H/PF/2013, a 2013 human isolate from French Polynesia representative of the virus introduced to Brazil. 11428934 2 2 gly glycosylation 413:425 arg2 a glycosylation site a glycosylation site site The native structure of MOG presents a glycosylation site at position 31 (Asn(31)). 11428934 2 2 gly glycosylation 413:425 arg2 Asn(31) Asn(31) Asn(31) The native structure of MOG presents a glycosylation site at position 31 (Asn(31)). 11428934 2 2 gly glycosylation 413:425 arg2 position 31 position 31 position 31 The native structure of MOG presents a glycosylation site at position 31 (Asn(31)). 1703533 0 95 gly glycoprotein 27:38 arg1 the glycoprotein allergen Art v II the glycoprotein allergen Art v II Fterm glycoprotein Structural analysis of the glycoprotein allergen Art v II from the pollen of mugwort (Artemisia vulgaris L.). 7798256 3 1 gly glycosylation 541:553 arg1 the cytosolic domain the cytosolic domain domain Insertion of truncated Band 3 molecules into microsomal membranes was assayed by glycosylation, resistance to alkaline extraction, and tryptic removal of the cytosolic domain. 12490395 5 73 part_of Env-binding 968:978 arg1 the Env-binding motif Env the Env-binding motif PUBTATOR Site Env 30816 motif xcCAT1 cDNA encodes a protein with a single amino acid change that destroys a conserved N-linked glycosylation site proximal to the Env-binding motif. 3148445 5 3 gly N-glycosylation 845:859 arg2 two putative N-glycosylation sites two putative N-glycosylation sites sites The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187. 3148445 5 66 gly glycosylation 926:938 arg2 Asn-187 Asn-187 Asn-187 The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187. 3148445 5 66 gly glycosylation 926:938 arg2 an additional glycosylation site an additional glycosylation site site The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187. 30158294 8 95 gly N-glycosylation 1108:1122 arg1 SERINC5 SERINC5 site PUBTATOR SERINC5 256987 site Our results demonstrate that N294 is the major site of N-glycosylation in SERINC5. 30158294 8 95 gly N-glycosylation 1108:1122 arg1 SERINC5 SERINC5 N294 PUBTATOR SERINC5 256987 N294 Our results demonstrate that N294 is the major site of N-glycosylation in SERINC5. 20053750 1 60 gly glycoprotein 170:181 arg1 The hemagglutinin-neuraminidase (HN) glycoprotein The hemagglutinin-neuraminidase (HN) glycoprotein Fterm glycoprotein The hemagglutinin-neuraminidase (HN) glycoprotein plays a critical role in parainfluenza virus replication. 1367433 3 48 gly glycoprotein 672:683 arg1 a fibrinolytic glycoprotein a fibrinolytic glycoprotein Fterm glycoprotein In order to gain insight into the processing mechanisms, we studied the glycan pattern of a panel of related molecules constructed by insertion, duplication or deletion of the domains encoded by the cDNA of a fibrinolytic glycoprotein, tissue-type plasminogen activator (t-PA). 1367433 3 48 gly glycoprotein 672:683 arg1 tissue-type plasminogen activator tissue-type plasminogen activator PUBTATOR tissue-type plasminogen activator 18791 In order to gain insight into the processing mechanisms, we studied the glycan pattern of a panel of related molecules constructed by insertion, duplication or deletion of the domains encoded by the cDNA of a fibrinolytic glycoprotein, tissue-type plasminogen activator (t-PA). 11738084 0 10 gly glycosylated 43:54 arg1 a glycosylated variant a glycosylated variant Fterm variant The glycan structure of albumin Redhill, a glycosylated variant of human serum albumin. 23090399 8 8 part_of sites 1226:1230 arg1 huPrP PrP sites OGER Site PrP sites However, both of the glycosylation sites on huPrP(c) are positioned away from the POM1 Fab binding epitope; thus, the binding mode observed in this crystal structure and the binding affinity measured for this antibody are most likely to be the same as those for the native prion protein in vivo. 23090399 8 18 part_of epitope 1290:1296 arg1 positioned epitope positioned position However, both of the glycosylation sites on huPrP(c) are positioned away from the POM1 Fab binding epitope; thus, the binding mode observed in this crystal structure and the binding affinity measured for this antibody are most likely to be the same as those for the native prion protein in vivo. 23090399 8 22 part_of Fab 1278:1280 arg1 the POM1 Fab binding epitope POM1 Fab the POM1 Fab binding epitope PUBTATOR Site POM1 Fab 2187 epitope However, both of the glycosylation sites on huPrP(c) are positioned away from the POM1 Fab binding epitope; thus, the binding mode observed in this crystal structure and the binding affinity measured for this antibody are most likely to be the same as those for the native prion protein in vivo. 23090399 8 28 part_of POM1 1273:1276 arg1 the POM1 Fab binding epitope POM1 Fab the POM1 Fab binding epitope PUBTATOR Site POM1 Fab 2187 epitope However, both of the glycosylation sites on huPrP(c) are positioned away from the POM1 Fab binding epitope; thus, the binding mode observed in this crystal structure and the binding affinity measured for this antibody are most likely to be the same as those for the native prion protein in vivo. 7922031 10 30 gly glycosylation 1541:1553 arg2 the presumed binding site site site A glycosylation site implicated in signal transduction but not in binding is also close to the presumed binding site suggesting a possible coupling between ligand binding and signaling. 19950248 5 45 gly N-glycosylation 659:673 arg2 the N-glycosylation site the N-glycosylation site site Non-synonymous mutations resulting in the loss of the N-glycosylation site at positions 197-199 of hemagglutinin have been positively selected to a far greater degree in egg-cultured strains than in other strains. 19950248 5 45 gly N-glycosylation 659:673 arg2 positions 197-199 positions 197-199 positions 197 Non-synonymous mutations resulting in the loss of the N-glycosylation site at positions 197-199 of hemagglutinin have been positively selected to a far greater degree in egg-cultured strains than in other strains. 15869468 3 34 gly sites 450:454 arg1 a vital determinant sites a vital determinant sites Here, we ask whether positioning of the N-glycosylation sites within the various ECLs of the receptor is a vital determinant in the functional expression of hAT(1) receptor at the cell surface. 15869468 3 52 gly N-glycosylation 434:448 arg2 the N-glycosylation sites the N-glycosylation sites sites Here, we ask whether positioning of the N-glycosylation sites within the various ECLs of the receptor is a vital determinant in the functional expression of hAT(1) receptor at the cell surface. 29944110 9 65 gly glycosylated 1440:1451 arg1 HA1 HA1 residue 158 PUBTATOR HA1 23526 residue 158 Through a mass spectrometric (MS) analysis of HA, the glycosylated sites of HA1 were established and we determined that residue 158 of HA1 was glycosylated and so modified a neutralization-sensitive epitope. 29944110 9 70 gly glycosylated 1351:1362 arg1 HA1 HA1 sites PUBTATOR HA1 23526 sites Through a mass spectrometric (MS) analysis of HA, the glycosylated sites of HA1 were established and we determined that residue 158 of HA1 was glycosylated and so modified a neutralization-sensitive epitope. 31577193 5 3 gly Nglycosylation 572:585 arg2 Nglycosylation sites Nglycosylation sites sites OBJECTIVE: In this article, our motivation is to develop a computational method to predict Nglycosylation sites in eukaryotic protein sequences. 7711058 5 14 gly glycosylation 811:823 arg2 each putative glycosylation site each putative glycosylation site site, asparagine At each putative glycosylation site, asparagine (N) was changed to glutamine (Q) or aspartic acid (D), and serine (S) changed to alanine (A). 16622833 4 58 part_of A1PI 623:626 arg1 The single cysteine residue A1PI The single cysteine residue PUBTATOR AminoAcid A1PI 5265 cysteine residue The single cysteine residue of A1PI formed a disulfide bridge with free cysteine. 30904681 8 30 gly glycosylation 1242:1254 arg2 an unreported partially occupied fifth glycosylation site an unreported partially occupied fifth glycosylation site site Two of our samples showed an unreported partially occupied fifth glycosylation site presumably arising from the presence of SNP variant S88N. 23341449 8 59 gly N-glycosylation 1418:1432 arg2 an "extra" N-glycosylation site an "extra" N-glycosylation site site In addition, inserting non-conserved OCAM sequences into NCAM Ig5, including an "extra" N-glycosylation site, decreases or completely blocks NCAM polysialylation. 29470411 9 17 gly Hypoglycosylation 1015:1031 arg1 both CaV2.1 subunits both CaV2.1 subunits PUBTATOR CaV2.1 subunits 773 Hypoglycosylation of both CaV2.1 subunits (α1A and α2α) induced gain-of-function effects on channel gating that mirrored those reported for pathogenic CACNA1A mutations linked to FHM and ataxia. 12706347 6 50 gly glycosylation 985:997 arg1 this position position position The results indicate that glycosylation at this position is essential for full enzymatic activity, with mutant ATPase activity decreased more than ADPase activity. 9578495 0 22 gly deglycosylated 10:23 arg1 Partially deglycosylated human choriogonadotropin Partially deglycosylated human choriogonadotropin OGER choriogonadotropin Partially deglycosylated human choriogonadotropin, stabilized by intersubunit disulfide bonds, shows full bioactivity. 23090399 7 29 gly glycosylation 1060:1072 arg2 a prion glycosylation site a prion glycosylation site site The prion epitopes recognized by ICSM18 Fab and VRQ14 Fab are adjacent to a prion glycosylation site, indicating possible steric hindrance and/or an altered binding mode to the glycosylated prion protein in vivo. 23090399 7 56 gly glycosylated 1155:1166 arg1 the glycosylated prion protein the glycosylated prion protein Fterm protein The prion epitopes recognized by ICSM18 Fab and VRQ14 Fab are adjacent to a prion glycosylation site, indicating possible steric hindrance and/or an altered binding mode to the glycosylated prion protein in vivo. 31034685 9 73 part_of β-casein 1364:1371 arg1 specific phosphorylation sites β-casein specific phosphorylation sites Fterm Site β-casein sites RESULTS: PGC/MS/MS enabled accurate quantitation of the stoichiometry of specific phosphorylation sites from β-casein by efficient separation of the phosphopeptide and its non-phosphorylated counterpart, which cannot be achieved by reversed-phase chromatography. 26846480 7 7 part_of Nucleotide 863:872 arg1 Nucleotide SLC11A1 sequences Nucleotide SLC11A1 Nucleotide SLC11A1 sequences PUBTATOR Site Nucleotide SLC11A1 6556 sequences Nucleotide SLC11A1 sequences were shown to be highly conserved in ten equid species, with more than 97 % sequence identity across the family. 26846480 7 11 part_of SLC11A1 874:880 arg1 Nucleotide SLC11A1 sequences Nucleotide SLC11A1 Nucleotide SLC11A1 sequences PUBTATOR Site Nucleotide SLC11A1 6556 sequences Nucleotide SLC11A1 sequences were shown to be highly conserved in ten equid species, with more than 97 % sequence identity across the family. 22365690 3 8 gly non-glycopeptides 749:765 arg2 non-glycopeptides non-glycopeptides glycopeptides and non-glycopeptides After the modification of MS precursor ion isolation window, tagged peptides are identified by LC-MS/MS, both glycopeptides and non-glycopeptides are quantified simultaneously using ProteinPilot™ Software. 22365690 3 22 gly glycopeptides 731:743 arg2 glycopeptides glycopeptides glycopeptides and non-glycopeptides After the modification of MS precursor ion isolation window, tagged peptides are identified by LC-MS/MS, both glycopeptides and non-glycopeptides are quantified simultaneously using ProteinPilot™ Software. 2168975 9 30 gly glycoprotein 1334:1345 arg1 The mutant glycoprotein The mutant glycoprotein Fterm glycoprotein The mutant glycoprotein also interferes strongly with rescue of virus by wild-type G protein. 27808502 4 23 gly oligomannosylated 985:1001 arg1 the oligomannosylated glycopeptides the oligomannosylated glycopeptides glycopeptides The glycan structure of intact glycopeptides can be identified from MS/MS spectra of their own and their peptide sequences were identified by the MS3 spectra of the oligomannosylated glycopeptides with the same Y1 ion. 27808502 4 27 gly glycopeptides 1003:1015 arg2 the oligomannosylated glycopeptides the oligomannosylated glycopeptides glycopeptides The glycan structure of intact glycopeptides can be identified from MS/MS spectra of their own and their peptide sequences were identified by the MS3 spectra of the oligomannosylated glycopeptides with the same Y1 ion. 27808502 4 69 gly glycopeptides 851:863 arg1 The glycan structure glycopeptides The glycan structure glycopeptides The glycan structure of intact glycopeptides can be identified from MS/MS spectra of their own and their peptide sequences were identified by the MS3 spectra of the oligomannosylated glycopeptides with the same Y1 ion. 29220102 9 54 gly N-glycosylation 1168:1182 arg2 a putative N-glycosylation site a putative N-glycosylation site site Using a combined transcriptomic and proteomic approach, the high molecular mass allergen in A. annua pollen was shown to be a 62-kDa putative galactose oxidase, with a putative N-glycosylation site. 28617578 1 55 gly glycoprotein 167:178 arg1 the ovarian cancer glycoprotein MUC16 the ovarian cancer glycoprotein MUC16 Fterm glycoprotein Expression of the retained C-terminal extracellular portion of the ovarian cancer glycoprotein MUC16 induces transformation and tumor growth. 25793890 6 7 gly glycosylation 1048:1060 arg2 N-linked glycosylation sites N-linked glycosylation sites sites All three mutations created N-linked glycosylation sites (two at N136 and one at N149) proximal to the hypervariable connecting peptide between the C-terminus of the A strand and the N-terminus of the B strand in the four-stranded V1/V2 domain β-sheet structure. 25793890 6 31 gly sites 1062:1066 arg1 N-linked glycosylation sites N-linked glycosylation sites sites All three mutations created N-linked glycosylation sites (two at N136 and one at N149) proximal to the hypervariable connecting peptide between the C-terminus of the A strand and the N-terminus of the B strand in the four-stranded V1/V2 domain β-sheet structure. 29020646 2 53 gly glycoprotein 333:344 arg1 the Envelope (Env) glycoprotein the Envelope (Env) glycoprotein Fterm glycoprotein To determine if genotypic and/or phenotypic differences in the Envelope (Env) glycoprotein can explain subtype related differences, we cloned 37 full length Envs from Subtype B and AE HIV infected individuals from Singapore. 9343410 0 40 part_of Sp1-derived 22:32 arg1 an Sp1-derived peptide Sp1 an Sp1-derived peptide OGER Site Sp1 Q8N907 peptide O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. 2318516 2 116 gly glycoproteins 408:420 arg1 HLA-B5 glycoproteins HLA-B5 glycoproteins Fterm glycoproteins T2, a somatic cell hybrid of human B- and T-lymphoblastoid cell lines (B-LCL and T-LCL, respectively), synthesized HLA-A2 and HLA-B5 glycoproteins, but expresses only low levels of A2 and undetectable levels of B5 at the cell surface. 9342662 6 25 gly glycopeptides 1153:1165 arg2 the glycopeptides the glycopeptides glycopeptides The differences between calculated and experimental masses of the glycopeptides suggested the presence of a fucosylated biantennary structure containing one or two galactose units as major oligosaccharide, together with similar species bearing a bisecting N-acetylglucosamine. 9342662 6 62 gly fucosylated 1195:1205 arg1 a fucosylated biantennary structure a fucosylated biantennary structure The differences between calculated and experimental masses of the glycopeptides suggested the presence of a fucosylated biantennary structure containing one or two galactose units as major oligosaccharide, together with similar species bearing a bisecting N-acetylglucosamine. 26634432 0 33 gly Glycosylation 0:12 arg1 Dentin Matrix Protein 1 Dentin Matrix Protein 1 PUBTATOR Dentin Matrix Protein 1 13406 Glycosylation of Dentin Matrix Protein 1 is critical for osteogenesis. 9520292 7 63 gly glycosylation 1267:1279 arg2 the glycosylation site enzyme site Fterm enzyme site This protocol identified four epitopes: two peptides within the propeptide, a third at the carboxy terminus and the fourth at the glycosylation site of the mature enzyme. 8163463 5 59 part_of receptors 896:904 arg1 the sequences receptors the sequences Fterm Site receptors sequences Examination of the sequences of AMPA and kainate receptors revealed that kainate receptors have several additional consensus sites for N-linked glycosylation; interestingly, one of these is located in the proposed major intracellular loop of the receptor subunits. 8163463 5 75 part_of have 938:941 arg1 kainate receptors AND several additional consensus sites kainate receptors several additional consensus sites Fterm Site receptors sites Examination of the sequences of AMPA and kainate receptors revealed that kainate receptors have several additional consensus sites for N-linked glycosylation; interestingly, one of these is located in the proposed major intracellular loop of the receptor subunits. 25499076 6 6 gly glycosylation 1131:1143 arg2 the glycosylation site occupancy the glycosylation site occupancy site To obtain recombinant G-hPRL, genetically modified Chinese hamster ovary cells (CHO), adapted to growth in suspension, were treated with cycloheximide, thus increasing the glycosylation site occupancy from 5.5% to 38.3%, thereby facilitating G-hPRL purification. 2318516 9 45 gly glycosylation 1740:1752 arg2 altered glycosylation sites altered glycosylation sites sites The effects of glycosylation on class I antigen transport were also studied using mutant class I constructs with altered glycosylation sites. 29115822 4 57 gly glycosylation 696:708 arg2 the glycosylation site the glycosylation site site We design a Cy5/biotin-modified peptide with a serine hydroxyl group for sensing OGT and a protease site adjacent to the glycosylation site for proteinase cleavage, with a universal nonradioactive UDP-GlcNAc as the sugar donor and a Cy5/biotin-modified peptide as the substrate. 22773269 7 7 gly sialoglycoproteins 1061:1078 arg1 322 sialoglycoproteins 322 sialoglycoproteins Fterm sialoglycoproteins As a result, 614 N-glycosylation sites were identified in 582 sialoglycopeptides within 322 sialoglycoproteins from rat liver using PIAT. 22773269 7 28 gly 614 N-glycosylation 982:1000 arg2 614 N-glycosylation sites 614 N-glycosylation sites sites As a result, 614 N-glycosylation sites were identified in 582 sialoglycopeptides within 322 sialoglycoproteins from rat liver using PIAT. 22773269 7 56 gly sialoglycopeptides 1031:1048 arg2 582 sialoglycopeptides 582 sialoglycopeptides sialoglycopeptides As a result, 614 N-glycosylation sites were identified in 582 sialoglycopeptides within 322 sialoglycoproteins from rat liver using PIAT. 15823038 4 20 gly glycosylation 773:785 arg2 its sole glycosylation site its sole glycosylation site site The effects of tunicamycin on LRP folding were not due to an inhibition of RAP glycosylation since a mutant RAP that harbors a mutation at its sole glycosylation site was still capable of promoting LRP folding. 8325990 5 57 gly glycans 1244:1250 arg1 Asn289 Asn289 Asn289 AminoAcid Asn289 The most dramatic differences were observed for HPgs with high mannose-type glycans on Asn289. 17082223 3 0 gly glycosylated 795:806 arg1 each site each site site Immunoblot and glycosidase cleavage analysis demonstrated that each site was glycosylated. 14985108 2 11 gly glycosylation 239:251 arg2 an N-linked glycosylation site an N-linked glycosylation site site Despite the finding that ONC contains an N-linked glycosylation site (-N69-V70-T71-), only the non-glycosylated form of the protein has been identified to date. 14985108 2 40 gly non-glycosylated 284:299 arg1 only the non-glycosylated form form of the protein Fterm form of the protein Despite the finding that ONC contains an N-linked glycosylation site (-N69-V70-T71-), only the non-glycosylated form of the protein has been identified to date. 8878691 1 11 part_of containing 298:307 arg1 a C-terminal tail AND 10 cysteine (Cys) residues a C-terminal tail 10 cysteine (Cys) residues residues The agouti locus encodes a novel paracrine signaling molecule containing a signal sequence, an N-linked glycosylation site, a central lysine-rich basic domain, and a C-terminal tail containing 10 cysteine (Cys) residues capable of forming five disulfide bonds. 29891966 9 14 gly N-glycosylation 1256:1270 arg2 N-glycosylation sites N-glycosylation sites sites The proIGF-1Eb and proIGF-1Ec were devoid of N-glycosylation sites, and hence their production was unaffected by N-glycosylation inhibitors. 11984879 6 12 part_of DAN 817:819 arg1 the 3' chick DAN coding sequence DAN the 3' chick DAN coding sequence PUBTATOR Site DAN 17965 sequence A riboprobe was designed from the 3' chick DAN coding sequence and used for analysis of DAN in the developing chick embryo by in situ hybridization. 23001782 8 66 gly occupied 1355:1362 arg2 The N-terminal Thr Thr(7) Thr(7) The N-terminal Thr(7) was fully occupied by the two O-linked glycans NeuAcα3Galβ3(NeuAcα6)GalNAc (where NeuAc is N-acetylneuraminic acid and GalNAc is N-acetylgalactosamine) and NeuAcα3Galβ3GalNAc in a 1:6 molar ratio. 18723043 1 30 part_of enzyme 168:173 arg1 The amino acid sequence enzyme The amino acid sequence Fterm Site enzyme sequence The amino acid sequence of a bradykinin-releasing enzyme, named KR-E-1, isolated from the venom of Agkistrodon caliginosus (Kankoku-mamushi) was determined by Edman sequencing of the peptides which was derived from digests with cyanogen bromide, hydroxylamine, achromobacter protease I, trypsin, V8 protease, arginine endopeptidase, and endoproteinase Asp-N. 17927214 2 17 part_of CI-MPR 529:534 arg1 one low-affinity site CI-MPR one low-affinity site PUBTATOR Site CI-MPR 3482 site Previous studies have mapped two high-affinity Man-6-P binding sites of the CI-MPR to domains 1-3 and 9 and one low-affinity site to domain 5 within its 15-domain extracytoplasmic region. 16200726 4 21 part_of fragment 766:773 arg1 the coding region fragment the coding region region Results The tree shrew CETP cDNA sequence covers 1636 bp, including a 178 bp fragment at the 3' of untranslated region and a 1458 bp fragment in the coding region, coding the complete sequence of mature tree shrew CETP except the initiator methionine. 16200726 4 54 part_of CETP 903:906 arg1 the complete sequence CETP the complete sequence PUBTATOR Site CETP P11597 sequence Results The tree shrew CETP cDNA sequence covers 1636 bp, including a 178 bp fragment at the 3' of untranslated region and a 1458 bp fragment in the coding region, coding the complete sequence of mature tree shrew CETP except the initiator methionine. 16200726 4 67 part_of CETP 712:715 arg1 The tree shrew CETP cDNA sequence CETP The tree shrew CETP cDNA sequence PUBTATOR Site CETP P11597 sequence Results The tree shrew CETP cDNA sequence covers 1636 bp, including a 178 bp fragment at the 3' of untranslated region and a 1458 bp fragment in the coding region, coding the complete sequence of mature tree shrew CETP except the initiator methionine. 16200726 4 86 part_of fragment 822:829 arg1 the coding region fragment the coding region region Results The tree shrew CETP cDNA sequence covers 1636 bp, including a 178 bp fragment at the 3' of untranslated region and a 1458 bp fragment in the coding region, coding the complete sequence of mature tree shrew CETP except the initiator methionine. 12892756 6 29 gly glycosylation 902:914 arg2 one potential N-linked glycosylation site one potential N-linked glycosylation site site Although the bullfrog CE was deduced to contain one potential N-linked glycosylation site, its position (Asn(139)-Leu(140)-Thr(141)) was different from that of mammalian CEs. 9689919 6 2 gly glycosylation 876:888 arg2 a consensus glycosylation site a consensus glycosylation site site It has an N-terminal signal peptide, a consensus glycosylation site and homology with serpins including the conserved residues required for maintaining the serpin tertiary structure. 9393962 9 54 gly glycosylation 1086:1098 arg2 the glycosylation site the glycosylation site site We have found that removing the glycosylation site by site-directed mutagenesis of an IgG3 RF significantly reduced the self-associating ability of this antibody. 1385399 0 44 gly N-glycosylation 0:14 arg1 human CD2 immunoadhesion functions human CD2 immunoadhesion functions PUBTATOR CD2 914 N-glycosylation is required for human CD2 immunoadhesion functions. 3980466 11 91 part_of sites 1978:1982 arg1 structurally related glycoproteins glycoproteins sites Fterm Site glycoproteins sites First, the overall distributions of oligosaccharides at corresponding sites on structurally related glycoproteins are similar. 1697854 6 12 part_of p 731:731 arg1 the complete amino acid sequence Lol p the complete amino acid sequence OGER Site Lol p Q08397 sequence Based on the complete amino acid sequence of Lol p I, overlapping peptides covering the entire molecule were synthesized. 18340083 3 34 part_of Ly-6 541:544 arg1 the Ly-6 domain Ly-6 the Ly-6 domain PUBTATOR Site Ly-6 17062 domain Here, we show that mouse GPIHBP1 is N-glycosylated at Asn-76 within the Ly-6 domain. 11428934 0 12 gly glycoprotein 71:82 arg1 human myelin oligodendrocyte glycoprotein human myelin oligodendrocyte glycoprotein PUBTATOR myelin oligodendrocyte glycoprotein 4340 Conformational analysis of a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope able to detect antibody response in multiple sclerosis. 11428934 0 65 gly glycosylated 29:40 arg1 a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope epitope Conformational analysis of a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope able to detect antibody response in multiple sclerosis. 9820138 0 26 gly glycoproteins 88:100 arg1 virus-encoded glycoproteins virus-encoded glycoproteins Fterm glycoproteins Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus-encoded glycoproteins. 10839980 3 54 gly attached 596:603 arg2 site IV AND the carbohydrate site IV the carbohydrate site In the present study we show that it is the carbohydrate attached to site IV that is selectively affected. 30392906 0 3 part_of protein 73:79 arg1 the extracellular domain Myelin protein zero-like protein 1 the extracellular domain PUBTATOR Site Myelin protein zero-like protein 1 9019 domain Structural and biochemical studies of the extracellular domain of Myelin protein zero-like protein 1. 26339047 3 40 gly positions 782:790 arg1 positions T116 and G130 positions T116 and G130 positions For the generation of hypoglycosylated VLPs, the wild-type (WT) HBsAgS N146 glycosylation site was converted to N146Q; for constructing hyperglycosylated VLPs, potential glycosylation sites were introduced in the HBsAgS external loop region at positions T116 and G130 in addition to the WT site. 26339047 3 92 gly glycosylation 614:626 arg2 the wild-type (WT) HBsAgS N146 glycosylation site the wild-type (WT) HBsAgS N146 glycosylation site site For the generation of hypoglycosylated VLPs, the wild-type (WT) HBsAgS N146 glycosylation site was converted to N146Q; for constructing hyperglycosylated VLPs, potential glycosylation sites were introduced in the HBsAgS external loop region at positions T116 and G130 in addition to the WT site. 26339047 3 92 gly glycosylation 614:626 arg2 N146 N146 N146 For the generation of hypoglycosylated VLPs, the wild-type (WT) HBsAgS N146 glycosylation site was converted to N146Q; for constructing hyperglycosylated VLPs, potential glycosylation sites were introduced in the HBsAgS external loop region at positions T116 and G130 in addition to the WT site. 26339047 3 147 gly glycosylation 708:720 arg2 potential glycosylation sites potential glycosylation sites sites For the generation of hypoglycosylated VLPs, the wild-type (WT) HBsAgS N146 glycosylation site was converted to N146Q; for constructing hyperglycosylated VLPs, potential glycosylation sites were introduced in the HBsAgS external loop region at positions T116 and G130 in addition to the WT site. 2180485 2 1 part_of APP 553:555 arg1 60, 72 or 88 amino-acid fragments APP 60, 72 or 88 amino-acid fragments OGER Site APP P05067 fragments APPI derivatives containing 60, 72 or 88 amino-acid fragments (APPI-60, APPI-72 and APPI-88, respectively) of the longest APP were produced in COS-1 cell culture medium, with the APPI cDNA ligated to the signal sequence of tissue plasminogen activator. 2180485 2 6 part_of activator 673:681 arg1 the signal sequence tissue plasminogen activator the signal sequence OGER Site tissue plasminogen activator P00750 sequence APPI derivatives containing 60, 72 or 88 amino-acid fragments (APPI-60, APPI-72 and APPI-88, respectively) of the longest APP were produced in COS-1 cell culture medium, with the APPI cDNA ligated to the signal sequence of tissue plasminogen activator. 8666916 4 7 gly glycosylation 772:784 arg2 the C alpha 2 N-linked glycosylation site the C alpha 2 N-linked glycosylation site site Indeed, since the C alpha 2 N-linked glycosylation site lies near the Fab-distal pole of C alpha 2, the inability of a mutant IgA1 lacking C alpha 2 N-glycosylation to bind its cognate receptor suggested that the monocyte Fc alpha receptor (mFcalphaR) recognizes IgA at a hinge-distal site encompassing the boundary between the C alpha 2 and C alpha 3 domains. 19167329 6 62 part_of site 985:988 arg1 an unfolded protein protein site Fterm Site protein site Unlike STT3A, STT3B efficiently mediates posttranslational glycosylation of a carboxyl-terminal glycosylation site in an unfolded protein. 12901863 5 8 part_of ABCC6 872:876 arg1 the extracellular N-terminal region ABCC6 the extracellular N-terminal region PUBTATOR Site ABCC6 368 region Our results indicate that Asn15, which is located in the extracellular N-terminal region of human ABCC6, is the only N-glycosylation site in this protein. 12901863 5 21 part_of site 907:910 arg1 this protein protein site Fterm Site protein site Our results indicate that Asn15, which is located in the extracellular N-terminal region of human ABCC6, is the only N-glycosylation site in this protein. 1383332 9 38 part_of DAF 1683:1685 arg1 the DAF functional domains DAF the DAF functional domains PUBTATOR Site DAF 1604 domains Surprisingly, deletion of the S/T region totally abrogated DAF function, but this could be restored by a fusion construct placing the four SCR domains of DAF onto the HLA-B44 molecule, implying that the O-glycosylated S/T region serves as an important but nonspecific spacer projecting the DAF functional domains above the plasma membrane. 1383332 9 54 part_of DAF 1547:1549 arg1 the four SCR domains DAF the four SCR domains PUBTATOR Site DAF 1604 domains Surprisingly, deletion of the S/T region totally abrogated DAF function, but this could be restored by a fusion construct placing the four SCR domains of DAF onto the HLA-B44 molecule, implying that the O-glycosylated S/T region serves as an important but nonspecific spacer projecting the DAF functional domains above the plasma membrane. 18077336 7 60 part_of MRAP 888:891 arg1 potential glycosylation sites MRAP potential glycosylation sites PUBTATOR Site MRAP Q8TCY5 sites A mutant MRAP with potential glycosylation sites on both sides of the membrane was singly but not doubly glycosylated, suggesting that MRAP is not monotopic. 1918071 6 64 gly N-glycosylation 1279:1293 arg2 N-glycosylation sites N-glycosylation sites sites Thus, binding is not restricted to peptides containing N-glycosylation sites. 11550262 1 75 part_of cDNA 211:214 arg1 a testis-specific cDNA fragment cDNA a testis-specific cDNA fragment Cterm Site cDNA fragment A differential display-polymerase chain reaction was employed to obtain a testis-specific cDNA fragment. 3525855 7 52 gly glycosylation 1054:1066 arg2 the N-linked glycosylation site the N-linked glycosylation site site Mutant gene products lacking both the basic dipeptide processing site and the N-linked glycosylation site were found to be biologically active, indicating the dispensability of those processing steps. 10828943 10 95 part_of SP-A 1678:1681 arg1 The glycosylation site SP-A The glycosylation site PUBTATOR Site SP-A 24773 site The glycosylation site of SP-A was located at the side of each subunit, suggesting that the covalently linked carbohydrate moiety probably occupies the spaces between the adjacent globular domains, a location that would not sterically interfere with ligand binding. 23921623 2 47 gly had 558:560 arg1 the G proteins AND an additional N-glycan the G proteins an additional N-glycan Fterm proteins In this study, we successfully cloned two street virus strain 1088 variants, N5B#15 and N5B#10-28, in which the G proteins had an additional N-glycan at position 247, and we examined whether these variants were characterized by cell culture adaptation and attenuation after intramuscular inoculation as fixed viruses. 1448922 5 21 gly glycosylation 945:957 arg2 residue 14 residue 14 residue 14 The 11.6K protein is predicted to have a single signal-anchor sequence at residues 41-62 and only one potential Asn-linked glycosylation site at residue 14; thus, 11.6K must be oriented in the membranes with its NH2-terminus in the lumen and its COOH-terminus in the cytoplasm. 1448922 5 21 gly glycosylation 945:957 arg2 only one potential Asn-linked glycosylation site only one potential Asn-linked glycosylation site site The 11.6K protein is predicted to have a single signal-anchor sequence at residues 41-62 and only one potential Asn-linked glycosylation site at residue 14; thus, 11.6K must be oriented in the membranes with its NH2-terminus in the lumen and its COOH-terminus in the cytoplasm. 6138751 4 21 gly glycosylation 501:513 arg2 a potential glycosylation site a potential glycosylation site site A comparison of nucleotide sequences of mouse and human cDNA clones reveals conservation of residues involved in catalytic mechanisms and a potential glycosylation site. 21661761 3 41 gly glycopeptides 538:550 arg2 glycopeptides glycopeptides glycopeptides Nanoflow liquid chromatography with tandem mass spectrometry provides both separation of glycopeptides and the ability to determine glycan composition and site-specific glycosylation. 21038860 5 2 gly glycosylation 900:912 arg2 a glycosylation site a glycosylation site site In contrast, disrupting the interface by introducing a glycosylation site into either subunit activated integrins for ligand binding through a global conformational change. 30718403 10 21 part_of CD4 1541:1543 arg1 the D1 domain CD4 the D1 domain OGER Site CD4 P01730 domain These results indicate that substitutions in the D1 domain of the chimpanzee CD4 can prevent SIV cell entry. 2411731 5 50 gly residues 1037:1044 arg1 the conserved N-asparaginyl-linked carbohydrate attachment site residues 171-173 the conserved N-asparaginyl-linked carbohydrate attachment site residues 171-173 Compared to the interstitial procollagens, however, more divergence has occurred in alpha 2(V) surrounding the conserved N-asparaginyl-linked carbohydrate attachment site at residues 171-173, and alpha 2(V) possesses an additional potential glycosylation site (Asn-Lys-Thr) located in a hypervariable region near the NH2 terminus. 2411731 5 83 gly glycosylation 1104:1116 arg2 Asn-Lys-Thr Asn-Lys-Thr Asn-Lys-Thr Compared to the interstitial procollagens, however, more divergence has occurred in alpha 2(V) surrounding the conserved N-asparaginyl-linked carbohydrate attachment site at residues 171-173, and alpha 2(V) possesses an additional potential glycosylation site (Asn-Lys-Thr) located in a hypervariable region near the NH2 terminus. 2411731 5 83 gly glycosylation 1104:1116 arg2 an additional potential glycosylation site an additional potential glycosylation site site Compared to the interstitial procollagens, however, more divergence has occurred in alpha 2(V) surrounding the conserved N-asparaginyl-linked carbohydrate attachment site at residues 171-173, and alpha 2(V) possesses an additional potential glycosylation site (Asn-Lys-Thr) located in a hypervariable region near the NH2 terminus. 30605224 10 17 gly glycoproteins 1424:1436 arg1 glycoproteins glycoproteins Fterm glycoproteins Because of the importance of glycoproteins in complex biological systems, the field of glycoproteomics will continue to grow in the next decade. 26458842 4 40 gly N-glycosylation 734:748 arg2 an ancestrally conserved N-glycosylation site an ancestrally conserved N-glycosylation site site The results showed that each of the human proteins, CELSR1, ST3GAL5 and VSIG10, lost an ancestrally conserved N-glycosylation site following human-chimpanzee divergence. 31244828 12 66 gly glycoforms 1843:1852 arg1 MOG MOG PUBTATOR MOG 4340 The most abundant glycoforms of MOG expressed in HEK cells are diantennary, contain a core fucose, an antennary fucose, and are decorated with α2,6 linked Neu5Ac, while details of the glycoforms of MOG in myelin remain to be identified. 31244828 12 75 gly glycoforms 1677:1686 arg1 MOG MOG PUBTATOR MOG 4340 The most abundant glycoforms of MOG expressed in HEK cells are diantennary, contain a core fucose, an antennary fucose, and are decorated with α2,6 linked Neu5Ac, while details of the glycoforms of MOG in myelin remain to be identified. 25945896 7 34 gly glycopeptide 1317:1328 arg2 each intact glycopeptide MS/MS spectrum each intact glycopeptide MS/MS spectrum glycopeptide These oxonium-ion-containing spectra were then compared with the spectral library generated from glycosite-containing peptides, resulting in assignment of each intact glycopeptide MS/MS spectrum to a specific glycosite-containing peptide. 8234161 2 48 gly glycosylation 88:100 arg1 peptide reactivity peptide reactivity peptide Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. 16331329 6 1 part_of LIM 976:978 arg1 two LIM domains LIM two LIM domains PUBTATOR Site LIM 414421 domains The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart. 16331329 6 1 part_of LIM 976:978 arg1 a novel cysteine-rich domain LIM a novel cysteine-rich domain PUBTATOR Site LIM 414421 domain The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart. 16331329 6 51 part_of domains 980:986 arg1 the C-terminal region domains the C-terminal region region The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart. 16331329 6 63 part_of protein 1029:1035 arg1 a novel cysteine-rich domain protein a novel cysteine-rich domain Fterm Site protein domain The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart. 16331329 6 63 part_of protein 1029:1035 arg1 nine potential protein kinase C phosphorylation sites protein nine potential protein kinase C phosphorylation sites Fterm Site protein sites The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart. 16331329 6 64 part_of domain 939:944 arg1 the N-terminal region domain the N-terminal region region The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart. 16331329 6 30 part_of contain 909:915 arg1 The LMCD1 protein AND two LIM domains The LMCD1 protein two LIM domains PUBTATOR Site LMCD1 protein 29995 domains The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart. 16331329 6 30 part_of contain 909:915 arg1 The LMCD1 protein AND a novel cysteine-rich domain The LMCD1 protein a novel cysteine-rich domain PUBTATOR Site LMCD1 protein 29995 domain The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart. 16331329 6 30 part_of contain 909:915 arg1 The LMCD1 protein AND a tyrosine kinase phosphorylation site LMCD1 protein site PUBTATOR Site LMCD1 protein 29995 site The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart. 16331329 6 30 part_of contain 909:915 arg1 The LMCD1 protein AND nine potential protein kinase C phosphorylation sites LMCD1 protein sites PUBTATOR Site LMCD1 protein 29995 sites The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart. 9925876 0 44 gly glycosylation 9:21 arg2 N-linked glycosylation sites N-linked glycosylation sites sites N-linked glycosylation sites determine HERG channel surface membrane expression. 8180202 6 4 gly glycosylation 1094:1106 arg2 an additional glycosylation site an additional glycosylation site site These data indicate that oligosaccharide processing is site-specific, and analyses of three other mutants, in which an additional glycosylation site was preserved, demonstrated that the processing of individual oligosaccharides occurs independently. 10196694 1 43 gly glycoproteins 268:280 arg1 Sphingolipid activator proteins Sphingolipid activator proteins Fterm proteins Sphingolipid activator proteins are small glycoproteins required for the degradation of sphingolipids by specific lysosomal hydrolases. 10196694 1 43 gly glycoproteins 268:280 arg1 small glycoproteins small glycoproteins Fterm glycoproteins Sphingolipid activator proteins are small glycoproteins required for the degradation of sphingolipids by specific lysosomal hydrolases. 7768336 3 25 gly glycosylated 588:599 arg1 the receptor receptor Asn102 Fterm receptor Asn102 This indicates that the receptor is glycosylated at Asn4 and Asn18 but not at Asn102. 7768336 3 25 gly glycosylated 588:599 arg2 Asn4 receptor Asn4 and Asn18 Fterm receptor Asn4 and Asn18 This indicates that the receptor is glycosylated at Asn4 and Asn18 but not at Asn102. 25452312 9 37 gly N-glycopeptides 1046:1060 arg2 the N-glycopeptides the N-glycopeptides N-glycopeptides Here, we have enriched and identified the N-glycopeptides from these vesicles. 11711599 4 62 gly glycosylation 651:663 arg1 the mutated proteins the mutated proteins Fterm proteins In vitro expression studies showed an influence of N-linked glycosylation on expression efficiency, instability, and/or secretion of the mutated proteins. 31186110 6 86 gly Heterogeneity 941:953 arg1 hypermannosylation hypermannosylation Heterogeneity of glycosylation and hypermannosylation in the wild-type strains of Pichia pastoris was circumvented by employing glycoengineered strain (SuperMan5) to produce glycosylated IFN α2b with human type N-glycans. 31034685 11 24 gly glycosylation 1880:1892 arg1 peptides peptides peptides CONCLUSIONS: PGC has demonstrated superior separation of peptides with phosphorylation and glycosylation and can be used as an alternative in the proteomic characterization of post-translational modifications (PTMs) by polar groups. 22287049 0 41 gly glycopeptide 6:17 arg2 Rapid glycopeptide enrichment Rapid glycopeptide enrichment glycopeptide Rapid glycopeptide enrichment and N-glycosylation site mapping strategies based on amine-functionalized magnetic nanoparticles. 22287049 0 98 gly N-glycosylation 34:48 arg2 N-glycosylation site N-glycosylation site site Rapid glycopeptide enrichment and N-glycosylation site mapping strategies based on amine-functionalized magnetic nanoparticles. 14711516 4 49 part_of Thy-1 796:800 arg1 each N-glycosylation site Thy-1 each N-glycosylation site PUBTATOR Site Thy-1 P04216 site The disulfide linkage pattern and glycoform distribution on each N-glycosylation site of recombinant chicken Thy-1 from both cell lines were determined by a combination of amino-terminal sequencing and mass spectrometry. 24798328 7 18 gly glycosites 1079:1088 arg2 The glycosites The glycosites glycosites The glycosites in linker regions of LDLR class A repeats are conserved in LDLR from man to Xenopus and found in other homologous receptors. 24798328 7 23 gly man 1159:1161 arg1 LDLR LDLR man PUBTATOR LDLR 3949 The glycosites in linker regions of LDLR class A repeats are conserved in LDLR from man to Xenopus and found in other homologous receptors. 26980729 5 19 gly glycosylation 913:925 arg2 the Asn-24 glycosylation site the Asn-24 glycosylation site site Tunicamycin inhibition of glycosylation in the endoplasmic reticulum or mutation of the Asn-24 glycosylation site decreased GC activity, but neither inhibition of glycosylation in the Golgi by N-acetylglucosaminyltransferase I gene inactivation nor PNGase F deglycosylation of fully processed GC-B reduced GC activity. 26980729 5 44 gly deglycosylation 1076:1090 arg1 fully processed GC-B fully processed GC-B PUBTATOR GC-B 4882 Tunicamycin inhibition of glycosylation in the endoplasmic reticulum or mutation of the Asn-24 glycosylation site decreased GC activity, but neither inhibition of glycosylation in the Golgi by N-acetylglucosaminyltransferase I gene inactivation nor PNGase F deglycosylation of fully processed GC-B reduced GC activity. 26991339 2 44 gly N- 746:747 arg1 sites sites sites Reversed-phase high-performance liquid chromatography with high-resolution electrospray ionization mass spectrometry analysis of the intact proteoforms before and after N-deglycosylation with Peptide-N-Glycosidase F and tandem mass spectrometry sequencing of peptides obtained after Endoproteinase GluC digestion allowed the structural characterization of the peptide backbone and identification of N- and O-glycosylation sites. 11337488 10 40 part_of terminus 1617:1624 arg1 a short hydrophilic, highly charged peptide terminus a short hydrophilic, highly charged peptide peptide 7) Glypiation was not affected by the presence of an N-glycosylation site at omega or in its vicinity or by the addition of a short hydrophilic, highly charged peptide (FLAG; DYKDDDDK) at the C terminus of the hydrophobic region. 8163832 12 11 gly glycosylation 1614:1626 arg2 a potential glycosylation site a potential glycosylation site site The loss of a potential glycosylation site at amino acid position 196-198 in the viral HA was associated with attenuation of virulence. 8163832 12 11 gly glycosylation 1614:1626 arg2 amino acid position 196-198 amino acid position 196-198 position 196 The loss of a potential glycosylation site at amino acid position 196-198 in the viral HA was associated with attenuation of virulence. 9758750 7 36 gly O-glycosylation 1279:1293 arg2 the single O-glycosylation site the single O-glycosylation site site Cells transfected with mutant receptor cDNA were cotransfected with a cDNA construct expressing G-CSF in which the single O-glycosylation site was eliminated by mutation. 16227249 9 72 gly glycosylated 1116:1127 arg1 prM prM Cterm prM RVPs or virions bearing combinations of glycosylated and nonglycosylated forms of prM and E could infect mammalian, avian, and mosquito cells (BHK-21, QT6, and C6/36, respectively). 16227249 9 75 gly nonglycosylated 1133:1147 arg1 prM prM Cterm prM RVPs or virions bearing combinations of glycosylated and nonglycosylated forms of prM and E could infect mammalian, avian, and mosquito cells (BHK-21, QT6, and C6/36, respectively). 12731887 0 35 gly glycosylation 2:14 arg2 A glycosylation site p67 site PUBTATOR p67 64370 site A glycosylation site, 60SGTS63, of p67 is required for its ability to regulate the phosphorylation and activity of eukaryotic initiation factor 2alpha. 1725860 5 65 part_of contain 929:935 arg1 human IGFBP-6 AND 14 and 16 cysteines human IGFBP-6 14 and 16 cysteines PUBTATOR AminoAcid IGFBP-6 3489 cysteines By contrast, rat and human IGFBP-6 contain only 14 and 16 cysteines, respectively. 15616123 4 53 gly glycopeptides 666:678 arg2 glycopeptides glycopeptides glycopeptides The complex mixture of peptides and glycopeptides was subjected to LC/ESI MS/MS, where product ion spectra of the molecular ions were acquired data-dependently. 23263199 9 2 gly N-glycosylation 1542:1556 arg2 two or more putative N-glycosylation sites two or more putative N-glycosylation sites sites The same could be observed for variants missing two or more putative N-glycosylation sites, which indicated the importance of N-glycosylation for enzyme stability and activity. 14692455 5 1 gly carrying 729:736 arg1 Glycopeptides AND an alpha-L-fucose residue Glycopeptides an alpha-L-fucose residue Glycopeptides Glycopeptides carrying an alpha-L-fucose residue were selected with Lotus tetragonolobus agglutinin (LTA) immobilized on a chromatography matrix. 24627221 5 24 gly N-glycosylation 955:969 arg2 an N-glycosylation site an N-glycosylation site site A systematic study demonstrated that the loss of secreted protein was due not to the loss of an N-glycosylation site, but rather an SNP-specific targeting by miR-671-3p and miR-657. 1546316 1 27 part_of type-1 134:139 arg1 Multiple human immunodeficiency virus type-1 sequences type-1 Multiple human immunodeficiency virus type-1 sequences Cterm Site type-1 sequences Multiple human immunodeficiency virus type-1 sequences from the V3 and V4-V5 regions of the envelope gene were analyzed from three mother-infant pairs. 1546316 1 36 part_of regions 173:179 arg1 Multiple human immunodeficiency virus type-1 sequences regions Multiple human immunodeficiency virus type-1 sequences sequences Multiple human immunodeficiency virus type-1 sequences from the V3 and V4-V5 regions of the envelope gene were analyzed from three mother-infant pairs. 26869352 0 81 gly fucosylated 38:48 arg1 fucosylated N-glycans fucosylated N-glycans Site-specific and linkage analyses of fucosylated N-glycans on haptoglobin in sera of patients with various types of cancer: possible implication for the differential diagnosis of cancer. 7755594 0 23 gly N-glycosylation 0:14 arg1 protease resistance protease resistance Fterm protease N-glycosylation of human interferon-gamma: glycans at Asn-25 are critical for protease resistance. 7755594 0 23 gly N-glycosylation 0:14 arg1 human interferon-gamma human interferon-gamma PUBTATOR interferon-gamma 3458 N-glycosylation of human interferon-gamma: glycans at Asn-25 are critical for protease resistance. 7755594 0 57 gly Asn-25 54:59 arg1 glycans Asn-25 glycans Asn-25 N-glycosylation of human interferon-gamma: glycans at Asn-25 are critical for protease resistance. 19706343 10 52 part_of beta2GPI 1725:1732 arg1 the positively charged Gly40-Arg43 motif beta2GPI the positively charged Gly40-Arg43 motif PUBTATOR Site beta2GPI 350 motif This alteration of the electrostatic properties of the glycan moiety may attenuate the intramolecular interactions with the positively charged Gly40-Arg43 motif of beta2GPI and, in turn, leads to conformational instability and exposure of the disease-related linear epitope Gly40-Arg43 to the circulating autoantibody. 21264968 0 114 part_of mucin 139:143 arg1 synthetic mucin peptides mucin synthetic mucin peptides PUBTATOR Site mucin 100508689 peptides An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides. 21264968 0 120 part_of mucin-type 50:59 arg1 mucin-type glycopeptides mucin mucin-type glycopeptides PUBTATOR Site mucin 100508689 glycopeptides An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides. 23530120 3 15 part_of epitopes 600:607 arg1 recombinant Env Env epitopes PUBTATOR Site Env 100616444 epitopes Despite the presence of anti-CD4-BS broadly neutralizing antibody (bnAb) epitopes on recombinant Env, Env immunization has so far failed to elicit such antibodies. 14658030 5 22 gly glycopeptides 1205:1217 arg2 glycopeptides glycopeptides peptides and glycopeptides Unmodified peptides and glycopeptides each carrying a single glycosylation site were generated from NCAM by AspN and trypsin treatment and submitted to reversed-phase HPLC with or without prior enzymatic release of N-glycans. 14658030 5 56 gly glycosylation 1242:1254 arg2 a single glycosylation site a single glycosylation site site Unmodified peptides and glycopeptides each carrying a single glycosylation site were generated from NCAM by AspN and trypsin treatment and submitted to reversed-phase HPLC with or without prior enzymatic release of N-glycans. 8294492 6 24 gly glycosylation 956:968 arg2 a new glycosylation site a new glycosylation site site In exon 2-V a frameshift resulted in a unique V carboxyl terminus of 53 novel peptides with a new glycosylation site. 30295034 2 9 gly glycoprotein 537:548 arg1 the intact glycoprotein the intact glycoprotein Fterm glycoprotein Here, we show that glycan composition over all five glycosylation sites can be determined quantitatively by ESI-qTOF-MS of the intact glycoprotein in negative ion mode. 30295034 2 94 gly glycosylation 455:467 arg2 all five glycosylation sites all five glycosylation sites sites Here, we show that glycan composition over all five glycosylation sites can be determined quantitatively by ESI-qTOF-MS of the intact glycoprotein in negative ion mode. 29069609 0 28 gly glycopeptide 83:94 arg2 glycopeptide analysis glycopeptide analysis glycopeptide Development of a data independent acquisition mass spectrometry workflow to enable glycopeptide analysis without predefined glycan compositional knowledge. 8985413 7 7 part_of CD4 1422:1424 arg1 CD4 binding site CD4 CD4 binding site PUBTATOR Site CD4 920 site regions In summary, these data demonstrate that differences in V2 length modulate immunoreactivity of the envelope glycoprotein and support an association between the V2 and CD4 binding site regions. 9884403 0 8 part_of sites 14:18 arg1 human Tamm-Horsfall glycoprotein Tamm-Horsfall glycoprotein sites OGER Site Tamm-Horsfall glycoprotein P07911 sites Glycosylation sites and site-specific glycosylation in human Tamm-Horsfall glycoprotein. 26683050 2 110 gly glycosylation 376:388 arg1 CSF CSF OGER CSF Intrathecal production of IgG, especially IgG1, is a hallmark of multiple sclerosis (MS), but nothing is known about IgG Fc glycosylation in MS and in cerebrospinal fluid (CSF) in general. 28935113 5 86 gly glycosylation 789:801 arg2 all glycosylation sites all glycosylation sites sites Although yeast, mammalian and Escherichia coli cells can be engineered to produce a homogenous glycoform at all glycosylation sites, there are just a few specific glycan structures that can readily be accessed in this manner. 2350186 2 39 part_of mu-chain 457:464 arg1 the constant region mu-chain the constant region Fterm Site mu-chain region Normal murine IgM has five N-linked oligosaccharides in the constant region of each heavy or mu-chain. 7741215 6 4 gly glycosylation 998:1010 arg2 asparagine-83 site asparagine-83 site asparagine-83 Interestingly, glycosylation site asparagine-83 exhibits mono-O-acetyl and di-O-acetyl Neu5Ac residues, while the other sites, asparagine-24, asparagine-38, and serine-126, exhibit mainly mono-O-acetyl Neu5Ac derivatization. 18282281 12 44 gly O-glycosylation 2182:2196 arg2 mucin-type O-glycosylation sites mucin-type O-glycosylation sites sites CONCLUSION: Because of CKSAAP encoding's ability of reflecting characteristics of the sequences surrounding mucin-type O-glycosylation sites, CKSAAP_ OGlySite has been proved more powerful than the conventional binary encoding based method. 16834341 4 5 gly glycosylation 619:631 arg2 each glycosylation site each glycosylation site site The characteristic pattern of glycan distribution at each glycosylation site has been deduced and compared between horse and human FSH preparations. 9126611 7 51 gly N-glycosylation 1174:1188 arg2 a double N-glycosylation site mutant a double N-glycosylation site mutant site Expression of a double N-glycosylation site mutant in Sf9 cells, N580Q/N592Q, resulted in a decrease in glycosylation but no clear decrease in heterogeneity, indicating that the high degree of N-glycosylation heterogeneity observed with the BV-Sf9 system is not due to partial glycosylation of both Asn580 and Asn592. 9126611 7 54 gly glycosylation 1428:1440 arg1 Asn580 Asn580 and Asn592 Asn580 and Asn592 Expression of a double N-glycosylation site mutant in Sf9 cells, N580Q/N592Q, resulted in a decrease in glycosylation but no clear decrease in heterogeneity, indicating that the high degree of N-glycosylation heterogeneity observed with the BV-Sf9 system is not due to partial glycosylation of both Asn580 and Asn592. 9442070 4 29 gly Thr236 778:783 arg1 O-glycan sites Thr225 and Thr236 O-glycan sites Thr225 and Thr236 Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied. 9442070 4 33 gly Thr225 767:772 arg1 O-glycan sites Thr225 and Thr236 O-glycan sites Thr225 and Thr236 Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied. 9442070 4 4 gly located 704:710 arg1 Ser232 AND O-glycans Thr228, Ser230, and Ser232 O-glycans Thr228, Ser230, and Ser232 Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied. 9442070 4 4 gly located 704:710 arg1 Thr228 AND O-glycans Thr228, Ser230, and Ser232 O-glycans Thr228, Ser230, and Ser232 Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied. 9442070 4 4 gly located 704:710 arg1 Thr228 AND O-glycans Thr228, Ser230, and Ser232 O-glycans Thr228, Ser230, and Ser232 Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied. 9442070 4 110 gly occupied 799:806 arg2 Thr236 Thr225 and Thr236 Thr225 and Thr236 Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied. 8429003 5 37 gly glycopeptides 958:970 arg2 glycopeptides glycopeptides sites and glycopeptides Comparison of mutant rat sCD4 molecules with single glycosylation sites and glycopeptides indicated that site-specific and independent processing occurred at each glycosylation site. 8429003 5 49 gly glycosylation 1045:1057 arg2 each glycosylation site each glycosylation site site Comparison of mutant rat sCD4 molecules with single glycosylation sites and glycopeptides indicated that site-specific and independent processing occurred at each glycosylation site. 8429003 5 79 gly glycosylation 934:946 arg2 single glycosylation sites single glycosylation sites sites and glycopeptides Comparison of mutant rat sCD4 molecules with single glycosylation sites and glycopeptides indicated that site-specific and independent processing occurred at each glycosylation site. 16040252 2 63 part_of PEDF 227:230 arg1 PEDF sequences PEDF PEDF sequences PUBTATOR Site PEDF 5176 sequences In this study, we have assembled PEDF sequences for 9 additional species by data base mining and performed cross-species alignment for 14 PEDF sequences to identify conserved structural domains. 16040252 2 65 part_of PEDF 332:335 arg1 14 PEDF sequences 14 PEDF 14 PEDF sequences PUBTATOR Site 14 PEDF 5176 sequences In this study, we have assembled PEDF sequences for 9 additional species by data base mining and performed cross-species alignment for 14 PEDF sequences to identify conserved structural domains. 8349699 10 17 part_of PGH 1590:1592 arg1 Arg277 PGH synthase-1 Arg277 PUBTATOR AminoAcid PGH synthase-1 19224 Arg277 Assuming that the N-glycosylation sites of PGH synthase-1 are on the luminal side of the endoplasmic reticulum (ER), and that the site of tryptic cleavage of ovine PGH synthase-1 (Arg277) is on the cytoplasmic side of the ER, we propose that both the NH2 and COOH termini of PGH synthase-1 are located in the lumen of the ER and that there are two transmembrane domains located between Asn144 and Arg277 and between Arg277 and Asn410, respectively. 8349699 10 37 part_of synthase-1 1473:1482 arg1 the N-glycosylation sites PGH synthase-1 the N-glycosylation sites PUBTATOR Site PGH synthase-1 19224 sites Assuming that the N-glycosylation sites of PGH synthase-1 are on the luminal side of the endoplasmic reticulum (ER), and that the site of tryptic cleavage of ovine PGH synthase-1 (Arg277) is on the cytoplasmic side of the ER, we propose that both the NH2 and COOH termini of PGH synthase-1 are located in the lumen of the ER and that there are two transmembrane domains located between Asn144 and Arg277 and between Arg277 and Asn410, respectively. 8349699 10 68 part_of synthase-1 1705:1714 arg1 COOH termini PGH synthase-1 COOH termini PUBTATOR Site PGH synthase-1 19224 termini Assuming that the N-glycosylation sites of PGH synthase-1 are on the luminal side of the endoplasmic reticulum (ER), and that the site of tryptic cleavage of ovine PGH synthase-1 (Arg277) is on the cytoplasmic side of the ER, we propose that both the NH2 and COOH termini of PGH synthase-1 are located in the lumen of the ER and that there are two transmembrane domains located between Asn144 and Arg277 and between Arg277 and Asn410, respectively. 11344537 3 4 gly glycopeptides 683:695 arg2 O-fucosylated glycopeptides O-fucosylated glycopeptides glycopeptides Here we report on a rapid and straightforward approach in the analysis of glycosylation status and determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight (nano-ESI Q-TOF) mass spectrometry. 11344537 3 9 gly glycosylation 646:658 arg2 glycosylation sites glycosylation sites sites Here we report on a rapid and straightforward approach in the analysis of glycosylation status and determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight (nano-ESI Q-TOF) mass spectrometry. 11344537 3 48 gly O-fucosylated 669:681 arg1 O-fucosylated glycopeptides O-fucosylated glycopeptides glycopeptides Here we report on a rapid and straightforward approach in the analysis of glycosylation status and determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight (nano-ESI Q-TOF) mass spectrometry. 11344537 3 56 gly glycosylation 604:616 arg1 glycosylation sites glycosylation sites sites Here we report on a rapid and straightforward approach in the analysis of glycosylation status and determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight (nano-ESI Q-TOF) mass spectrometry. 9295302 6 73 part_of MRP 1056:1058 arg1 specific regions MRP specific regions PUBTATOR Site MRP 4363 regions Limited proteolysis of MRP-enriched membranes and deglycosylation of intact MRP and its tryptic fragments with PNGase F was carried out followed by immunoblotting with antibodies known to react with specific regions of MRP. 11259791 0 45 part_of acetylcholinesterase 48:67 arg1 Synthetic antigenic decapeptides acetylcholinesterase Synthetic antigenic decapeptides PUBTATOR Site acetylcholinesterase 43 decapeptides Synthetic antigenic decapeptides of human brain acetylcholinesterase cross-immunoreact with peptide-specific antibodies against Torpediniformes narcine timlei acetylcholinesterase. 1390770 7 53 gly N-glycosylation 850:864 arg2 the N-glycosylation sites the N-glycosylation sites sites Removal of any of the N-glycosylation sites reduced the in vivo but not the in vitro biological activity of the EPO molecule. 25879854 9 21 gly glycosylation 903:915 arg2 a potential glycosylation site a potential glycosylation site site In an extreme situation, a potential glycosylation site is lacking in some fishes. 6304692 5 12 gly residues 870:877 arg1 69-71 69-71 residues 69-71 The deduced amino acid sequence reveals VP7 to be 326 amino acids in length with two NH2-terminal hydrophobic regions and a single glycosylation site at residues 69-71. 6304692 5 40 gly glycosylation 848:860 arg2 residues 69-71 residues 69-71 residues 69-71 The deduced amino acid sequence reveals VP7 to be 326 amino acids in length with two NH2-terminal hydrophobic regions and a single glycosylation site at residues 69-71. 6304692 5 40 gly glycosylation 848:860 arg2 a single glycosylation site a single glycosylation site site The deduced amino acid sequence reveals VP7 to be 326 amino acids in length with two NH2-terminal hydrophobic regions and a single glycosylation site at residues 69-71. 17144668 6 60 gly glycosylation 1013:1025 arg2 a glycosylation site a glycosylation site site In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. 17144668 6 60 gly glycosylation 1013:1025 arg2 N525 N525 N525 In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. 2328698 10 48 gly 1-glycoprotein 1386:1399 arg1 human pregnancy-specific beta 1-glycoprotein human pregnancy-specific beta 1-glycoprotein PUBTATOR pregnancy-specific beta 1-glycoprotein 653492 The rPLP-B antiserum showed no cross-reactivity with proteins identified using antisera against rPLP-A, rPL-II, or human pregnancy-specific beta 1-glycoprotein. 31572358 5 0 gly N-glycosylation 932:946 arg1 the B-cell receptor (BCR) variable domain the B-cell receptor (BCR) variable domain domain Given recent technological advances that have rendered autoreactive human B cells accessible for analysis, we here discuss the phenomenon of extensive N-glycosylation of the B-cell receptor (BCR) variable domain of a prototypic human autoreactive B-cell response and its potential role in the generation of autoimmunity. 27796794 7 41 gly glycosylation 1126:1138 arg2 the asparagine-394 site asparagine-394 site asparagine-394 site However, recent data demonstrate that glycosylation of IgE at the asparagine-394 site of Cε3 is necessary for IgE interaction with the high affinity IgE receptor but, surprisingly, glycosylation has no effect on IgE interaction with its low-affinity lectin receptor, CD23. 27796794 7 41 gly glycosylation 1126:1138 arg1 IgE IgE asparagine-394 site OGER IgE P01854 asparagine-394 site However, recent data demonstrate that glycosylation of IgE at the asparagine-394 site of Cε3 is necessary for IgE interaction with the high affinity IgE receptor but, surprisingly, glycosylation has no effect on IgE interaction with its low-affinity lectin receptor, CD23. 27796794 7 41 gly glycosylation 1126:1138 arg1 IgE IgE asparagine-394 site OGER IgE P01854 asparagine-394 site However, recent data demonstrate that glycosylation of IgE at the asparagine-394 site of Cε3 is necessary for IgE interaction with the high affinity IgE receptor but, surprisingly, glycosylation has no effect on IgE interaction with its low-affinity lectin receptor, CD23. 30683699 6 6 gly attached 1335:1342 arg1 the N-terminal Asn221 sequon AND complex sialylated glycans the N-terminal Asn221 sequon complex sialylated glycans Asn221 sequon The IgG1 Fc fragments containing complex sialylated glycans attached to the N-terminal Asn221 sequon bound influenza virus hemagglutinin and disrupted influenza A-mediated agglutination of human erythrocytes. 30683699 6 56 gly sialylated 1316:1325 arg1 complex sialylated glycans complex sialylated glycans The IgG1 Fc fragments containing complex sialylated glycans attached to the N-terminal Asn221 sequon bound influenza virus hemagglutinin and disrupted influenza A-mediated agglutination of human erythrocytes. 30683699 6 71 gly containing 1297:1306 arg1 The IgG1 Fc fragments AND complex sialylated glycans The IgG1 Fc fragments complex sialylated glycans fragments The IgG1 Fc fragments containing complex sialylated glycans attached to the N-terminal Asn221 sequon bound influenza virus hemagglutinin and disrupted influenza A-mediated agglutination of human erythrocytes. 18844296 3 51 gly N-glycosylation 570:584 arg2 N-glycosylation sites N-glycosylation sites sites This family of inherited metabolic disorders includes defects in the assembly of the oligosaccharide precursor that lead to an under-occupancy of N-glycosylation sites (CDG-I), and defects of glycan remodeling (CDG-II). 17823199 5 14 gly N-glycosylation 955:969 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site Using isotopically labeled standard peptides, we directly quantified the level of N-glycosylation site occupancy on selected serum proteins. 30659065 9 80 part_of variants 1579:1586 arg1 proline IgA2 variants proline OGER AminoAcid IgA2 variants P01877 proline IgA2 variants with the either serine (S93) or proline (P93) were detected. 30659065 9 80 part_of variants 1579:1586 arg1 serine IgA2 variants serine OGER AminoAcid IgA2 variants P01877 serine IgA2 variants with the either serine (S93) or proline (P93) were detected. 7510285 6 40 part_of contains 745:752 arg1 This protein AND four hydrophobic regions This protein four hydrophobic regions Fterm Site protein regions This protein contains short NH2- and COOH-terminal hydrophilic domains and four hydrophobic regions, each long enough to span the plasma membrane. 7510285 6 40 part_of contains 745:752 arg1 This protein AND COOH-terminal hydrophilic domains This protein COOH-terminal hydrophilic domains Fterm Site protein domains This protein contains short NH2- and COOH-terminal hydrophilic domains and four hydrophobic regions, each long enough to span the plasma membrane. 2457922 0 33 gly glycoprotein 82:93 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Molecular cloning of a cDNA coding biliary glycoprotein I: primary structure of a glycoprotein immunologically crossreactive with carcinoembryonic antigen. 2457922 0 72 gly glycoprotein 43:54 arg1 biliary glycoprotein I biliary glycoprotein I PUBTATOR biliary glycoprotein I: 634 Molecular cloning of a cDNA coding biliary glycoprotein I: primary structure of a glycoprotein immunologically crossreactive with carcinoembryonic antigen. 14692455 11 57 gly fucosylation 1812:1823 arg1 these proteins these proteins Fterm proteins The observed aberrant fucosylation of these proteins is consistent with the hypothesis that CD44 and E-selectin play a key role in metastasis and the spread of cancer cells to remote sites. 14692455 11 67 gly proteins 1834:1841 arg1 The observed aberrant fucosylation proteins The observed aberrant fucosylation Fterm proteins The observed aberrant fucosylation of these proteins is consistent with the hypothesis that CD44 and E-selectin play a key role in metastasis and the spread of cancer cells to remote sites. 14749323 6 4 part_of site 931:934 arg1 mOAT1 mOAT1 site PUBTATOR SpecificSite mOAT1 18399 site Asp-39 We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated. 14749323 6 94 part_of site 995:998 arg1 hOAT1 hOAT1 site PUBTATOR Site hOAT1 9356 site We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated. 9343410 0 37 gly glycosylation 2:14 arg1 an Sp1-derived peptide an Sp1-derived peptide peptide O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. 6980014 3 13 part_of CNBr 452:455 arg1 these CNBr fragments CNBr these CNBr fragments Cterm Site CNBr fragments Composition data revealed that each of these CNBr fragments contained one oligosaccharide chain. 22354962 8 32 gly glycosylation 1399:1411 arg2 the glycosylation site(s) the glycosylation site(s) site Interaction of HGF-β and MR was diminished by EGTA, and by an enzymatic digestion of HGF-β sugar chains, suggesting that MR may recognize the glycosylation site(s) of HGF-β in a Ca(2+)-dependent fashion. 10383441 6 7 gly glycosylation 1027:1039 arg2 the Asn106 glycosylation site the Asn106 glycosylation site site We show that Val23 inhibits phosphorylation at the Asn18 glycosylation site, whereas Tyr54, Lys124, and Ser190 enhance phosphorylation at the Asn106 glycosylation site. 10383441 6 37 gly glycosylation 935:947 arg2 the Asn18 glycosylation site the Asn18 glycosylation site site We show that Val23 inhibits phosphorylation at the Asn18 glycosylation site, whereas Tyr54, Lys124, and Ser190 enhance phosphorylation at the Asn106 glycosylation site. 26871442 3 43 gly N-glycosylation 511:525 arg2 N-glycosylation site deletions N-glycosylation site deletions site In the case of HIV, it has been shown that CBAs select for mutant viruses with N-glycosylation site deletions which are more sensitive to neutralizing antibodies. 17670834 7 28 gly glycosylation 1133:1145 arg2 the potential glycosylation site motif site motif site motif Deletion of the potential glycosylation site motif at 133 to 135 in HA1 from a recent isolate partially restored the agglutination phenotype to a recombinant virus, indicating that the HA-SA interaction is inhibited by the glycosylation modification. 27038555 12 69 gly glycosylation 1682:1694 arg2 the glycosylation sites the glycosylation sites sites CONCLUSION: We highlighted the interplay between mutations in the glycosylation sites and epitope during HA evolution. 21978153 7 63 gly glycosylation 1358:1370 arg2 antigenic and glycosylation sites antigenic and glycosylation sites sites Some strains of 2009 H1N1 acquired mutations at antigenic and glycosylation sites. 27216994 13 26 part_of sites 2260:2264 arg1 GluN2B GluN2B sites PUBTATOR Site GluN2B 2904 sites Furthermore, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans. 27216994 13 26 part_of sites 2260:2264 arg1 GluN1 GluN1 sites PUBTATOR Site GluN1 2902 sites Furthermore, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans. 9098904 2 13 part_of protease 356:363 arg1 the wild-type sequence protease the wild-type sequence Fterm Site protease sequence To facilitate structural studies of the protein, the wild-type sequence of the protease has been mutated so as to replace a potential N-glycosylation site. 11410585 0 73 gly glycoprotein 61:72 arg1 bovine peripheral myelin glycoprotein bovine peripheral myelin glycoprotein Fterm glycoprotein Epitope diversity of N-glycans from bovine peripheral myelin glycoprotein P0 revealed by mass spectrometry and nano probe magic angle spinning 1H NMR spectroscopy. 25501675 12 2 gly glycoproteins 1954:1966 arg1 glycoproteins glycoproteins Fterm glycoproteins The results demonstrate that this method could be utilized for biosimilarity determination and counterfeit identification of glycoproteins. 21569239 10 79 part_of F-spondin 1413:1421 arg1 the F-spondin FS domain F-spondin the F-spondin FS domain PUBTATOR Site F-spondin 10418 domain The homology of its core structure to a common Ca2+- and lipid-binding C2 domain suggests that the F-spondin FS domain may be responsible for part of the membrane targeting of F-spondin in its regulation of axon development. 15342690 9 26 gly utilized 1185:1192 arg2 the site the site site Mutation of Asn-449 resulted in no change in secretion, activity, or molecular mass, indicating that the site is not utilized. 7688956 3 21 part_of glycoprotein 474:485 arg1 a mature peptide glycoprotein a mature peptide Fterm Site glycoprotein peptide We find that the antigen is a very small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids. 8631363 9 10 part_of factor-alpha 1590:1601 arg1 Ser 4 tumor necrosis factor-alpha Ser 4 PUBTATOR SpecificSite tumor necrosis factor-alpha 7124 Ser 4 An amino acid sequence analysis of the glycosylated peptides was performed after Staphylococcus aureus V8 protease digestion of tumor necrosis factor-alpha had been completed, and it was proved that the 0-glycosylation site of tumor necrosis factor-alpha was Ser 4. 8631363 9 10 part_of factor-alpha 1590:1601 arg1 the 0-glycosylation site tumor necrosis factor-alpha the 0-glycosylation site PUBTATOR Site tumor necrosis factor-alpha 7124 site An amino acid sequence analysis of the glycosylated peptides was performed after Staphylococcus aureus V8 protease digestion of tumor necrosis factor-alpha had been completed, and it was proved that the 0-glycosylation site of tumor necrosis factor-alpha was Ser 4. 10348716 7 36 part_of contains 927:934 arg1 The enzyme AND a single asparagine-linked glycosylation site The enzyme a single asparagine-linked glycosylation site Fterm Site enzyme site The enzyme contains a single asparagine-linked glycosylation site, NFT, bearing neutral and amino sugars that account for 8.3% of the enzyme's total molecular weight of 29,027. 21526855 7 26 part_of sites 1438:1442 arg1 fetuin fetuin sites Fterm Site fetuin sites Novel O-glycosylation sites in the C-terminal domains of fetuin (T334) and κ-caseinoglycopeptide (S154 and T156) were assigned, the former representing a sequence conflict with the published T154. 21526855 7 63 part_of fetuin 1473:1478 arg1 κ-caseinoglycopeptide fetuin κ-caseinoglycopeptide Fterm Site fetuin κ-caseinoglycopeptide Novel O-glycosylation sites in the C-terminal domains of fetuin (T334) and κ-caseinoglycopeptide (S154 and T156) were assigned, the former representing a sequence conflict with the published T154. 21526855 7 63 part_of fetuin 1473:1478 arg1 the C-terminal domains fetuin the C-terminal domains Fterm Site fetuin domains Novel O-glycosylation sites in the C-terminal domains of fetuin (T334) and κ-caseinoglycopeptide (S154 and T156) were assigned, the former representing a sequence conflict with the published T154. 19297464 3 50 gly glycosylation 525:537 arg1 heparin binding heparin binding Fterm heparin In the current study, the effects of altered glycosylation on virion infectivity, growth in cells of vertebrates and invertebrates, heparin binding, virulence in mice, and replication in mosquitoes were assessed. 11711599 6 94 gly glycosylation 983:995 arg2 the fourth glycosylation site the fourth glycosylation site site Whereas some mutations had no or only minor effects on the antibody titers induced, mutation of the fourth glycosylation site (N4) significantly enhanced the anti-E1 humoral response in terms of both seroconversion rates and antibody titers. 14715137 2 6 part_of synaptotagmin 264:276 arg1 the N-terminal intraluminal sequence synaptotagmin 1 the N-terminal intraluminal sequence PUBTATOR Site synaptotagmin 1 6857 sequence We now show that the N-terminal intraluminal sequence of synaptotagmin 1, when transplanted onto synaptotagmin 7, redirects synaptotagmin 7 from the plasma membrane to secretory vesicles. 31826991 4 2 gly region 527:532 arg1 head region high-mannose glycosites head region high-mannose glycosites Since the presence of head region high-mannose glycosites dictates SP-D activity, the ability to predict these glycosite glycan subtypes may be of value. 31826991 4 78 gly head 522:525 arg1 head region high-mannose glycosites head region high-mannose glycosites Since the presence of head region high-mannose glycosites dictates SP-D activity, the ability to predict these glycosite glycan subtypes may be of value. 16899459 7 12 gly N-glycosylation 1436:1450 arg2 the N-glycosylation site the N-glycosylation site site The cell surface-associated molecules were N-glycosylated in a normal manner, in contrast to the molecules retained within the cells, indicating that N-glycosylation of the ectodomain is required for targeting of collagen XVII to the plasma membrane and that reduced accessibility of the N-glycosylation site negatively regulates this process. 16899459 7 39 gly N-glycosylation 1298:1312 arg1 the ectodomain the ectodomain ectodomain The cell surface-associated molecules were N-glycosylated in a normal manner, in contrast to the molecules retained within the cells, indicating that N-glycosylation of the ectodomain is required for targeting of collagen XVII to the plasma membrane and that reduced accessibility of the N-glycosylation site negatively regulates this process. 17996106 6 97 gly glycosylation 1045:1057 arg2 experimentally determined N-linked, O-linked, and C-linked glycosylation sites experimentally determined N-linked, O-linked, and C-linked glycosylation sites sites We compare the performance of Support Vector Machine classifiers and ensembles of Support Vector Machine classifiers trained on a dataset of experimentally determined N-linked, O-linked, and C-linked glycosylation sites extracted from O-GlycBase version 6.00, a database of 242 proteins from several different species. 23530821 8 58 gly N-glycosylation 1139:1153 arg1 the prM protein the prM protein Fterm protein These results suggest that the N-glycosylation of the prM protein is critical to the folding of the E protein, which makes it pivotal in the cytotoxicity of JEV particles and their production. 26439794 8 13 gly found 1249:1253 arg1 lysosome proteins AND high-mannose lysosome proteins high-mannose Fterm proteins Several unexpected N-glycans, such as fucosylated complex-type and fucosylated high-mannose and/or fucosylated pauci-mannose types were found in ER and lysosome proteins. 26439794 8 13 gly found 1249:1253 arg2 lysosome proteins AND fucosylated pauci-mannose types lysosome proteins fucosylated pauci-mannose types Fterm proteins Several unexpected N-glycans, such as fucosylated complex-type and fucosylated high-mannose and/or fucosylated pauci-mannose types were found in ER and lysosome proteins. 26439794 8 13 gly found 1249:1253 arg2 lysosome proteins AND complex-type lysosome proteins complex-type Fterm proteins Several unexpected N-glycans, such as fucosylated complex-type and fucosylated high-mannose and/or fucosylated pauci-mannose types were found in ER and lysosome proteins. 26439794 8 13 gly found 1249:1253 arg2 lysosome proteins AND Several unexpected N-glycans lysosome proteins Several unexpected N-glycans Fterm proteins Several unexpected N-glycans, such as fucosylated complex-type and fucosylated high-mannose and/or fucosylated pauci-mannose types were found in ER and lysosome proteins. 26439794 8 48 gly fucosylated 1212:1222 arg1 fucosylated pauci-mannose types fucosylated pauci-mannose types Several unexpected N-glycans, such as fucosylated complex-type and fucosylated high-mannose and/or fucosylated pauci-mannose types were found in ER and lysosome proteins. 26980729 6 12 gly glycosylation 1185:1197 arg1 ligand-binding domain ligand-binding domain domain We conclude that endoplasmic reticulum-mediated glycosylation is required for the formation of an active catalytic, but not ligand-binding domain, and that mutations that inhibit this process cause dwarfism. 2464879 7 1 gly glycoprotein 1212:1223 arg1 the HN glycoprotein the HN glycoprotein Fterm glycoprotein The apparent molecular mass of the HN glycoprotein of one mutant was increased from 72 to 75 kDa. 31113887 3 33 part_of CD4 375:377 arg1 sequence CD4 sequence PUBTATOR Site CD4 450124 sequence By surveying the sequence and function of CD4 in 50 chimpanzee individuals, we find that all chimpanzee CD4 alleles encode a fixed, chimpanzee-specific substitution (34T) that creates a glycosylation site on the virus binding surface of the CD4 receptor. 10474032 13 91 part_of protein 1593:1599 arg1 The amino acid sequence protein The amino acid sequence Fterm Site protein sequence The amino acid sequence of the 17-kD protein was partly determined and it also showed high sequence homology with Blo t 13 and FABPs. 20936810 13 65 part_of Pin 1548:1550 arg1 the Pin WW domain Pin the Pin WW domain PUBTATOR Site Pin 8655 domain Here, we test this hypothesis experimentally and computationally by incorporating an N-linked GlcNAc residue at various positions within the Pin WW domain, a small β-sheet-rich protein. 10640760 8 0 gly glycosylation 1094:1106 arg2 a potential glycosylation site a potential glycosylation site site The other two differences, a potential glycosylation site and an insertion of three amino acids, lie in the loop regions of the carbohydrate recognition domain, close to the carbohydrate binding region and thus may have functional implications. 10593916 3 3 gly glycoprotein 802:813 arg1 the mature viral glycoprotein the mature viral glycoprotein Fterm glycoprotein LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response. 10593916 3 77 gly glycosylation 723:735 arg2 a glycosylation motif -NXS- a glycosylation motif -NXS- motif LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response. 10593916 3 55 gly N-glycosylated 767:780 arg2 a glycosylation motif -NXS- glycoprotein motif Fterm glycoprotein motif LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response. 10593916 3 55 gly N-glycosylated 767:780 arg1 a glycosylation motif -NXS- glycoprotein motif Fterm glycoprotein motif LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response. 10593916 3 55 gly N-glycosylated 767:780 arg1 a glycosylation motif -NXS- motif motif LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response. 12970363 11 17 part_of site 1668:1671 arg1 TRPC3 TRPC3 site PUBTATOR Site TRPC3 7222 site Reciprocally, engineering of an additional second glycosylated site in TRPC3 to mimic the glycosylation status in TRPC6 markedly reduced TRPC3 basal activity. 10861210 1 29 gly N-glycosylated 367:380 arg1 other isoforms other isoforms Fterm isoforms The human erythrocyte anion exchanger (AE)1 (Band 3) contains a single complex N-linked oligosaccharide that is attached to Asn(642) in the fourth extracellular loop of this polytopic membrane protein, while other isoforms (AE2, AE3 and trout AE1) are N-glycosylated on the preceding extracellular loop. 10861210 1 29 gly N-glycosylated 367:380 arg1 AE2 AE2 PUBTATOR AE2 6522 The human erythrocyte anion exchanger (AE)1 (Band 3) contains a single complex N-linked oligosaccharide that is attached to Asn(642) in the fourth extracellular loop of this polytopic membrane protein, while other isoforms (AE2, AE3 and trout AE1) are N-glycosylated on the preceding extracellular loop. 10861210 1 29 gly N-glycosylated 367:380 arg1 AE3 AE3 PUBTATOR AE3 6508 The human erythrocyte anion exchanger (AE)1 (Band 3) contains a single complex N-linked oligosaccharide that is attached to Asn(642) in the fourth extracellular loop of this polytopic membrane protein, while other isoforms (AE2, AE3 and trout AE1) are N-glycosylated on the preceding extracellular loop. 10861210 1 71 gly attached 227:234 arg1 Asn(642) AND a single complex N-linked oligosaccharide Asn(642) a single complex N-linked oligosaccharide Asn(642) The human erythrocyte anion exchanger (AE)1 (Band 3) contains a single complex N-linked oligosaccharide that is attached to Asn(642) in the fourth extracellular loop of this polytopic membrane protein, while other isoforms (AE2, AE3 and trout AE1) are N-glycosylated on the preceding extracellular loop. 11337488 10 58 gly N-glycosylation 1476:1490 arg2 an N-glycosylation site an N-glycosylation site site 7) Glypiation was not affected by the presence of an N-glycosylation site at omega or in its vicinity or by the addition of a short hydrophilic, highly charged peptide (FLAG; DYKDDDDK) at the C terminus of the hydrophobic region. 16335806 3 8 part_of PRL 508:510 arg1 other known PRL sequences PRL other known PRL sequences PUBTATOR Site PRL 100481524 sequences Sequence comparison indicated that panda PRL shares a high degree of identity to other known PRL sequences ranging from 98% with mink PRL to about 50% with rodent PRL. 23562646 0 83 gly glycosylation 17:29 arg1 the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein Fterm protein Role of N-linked glycosylation of the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein. 8554050 6 6 gly glycosylation 1026:1038 arg2 the potential N-linked glycosylation site the potential N-linked glycosylation site site A PRB2L CON1 allele contains a single nt missense change [TCT(Ser)-->CCT (Pro)] that abolishes the potential N-linked glycosylation site (NKS-->NKP) in the Con1 protein, and this explains the Con- type. 18638581 7 16 part_of sites 1357:1361 arg1 38 proteins proteins sites Fterm Site proteins sites A total of 63 glycosylation sites in 38 proteins were identified by both methods, demonstrating distinct differences and complementarity. 17924005 8 46 part_of Env 1452:1454 arg1 this Env region Env this Env region PUBTATOR Site Env 30816 region These studies underscore the importance of this Env region for the virus fitness, for the host immune response and, therefore, for the development of vaccine candidates. 16227249 11 44 gly glycosylation 1456:1468 arg1 WNV prM and E proteins WNV prM and E proteins Fterm proteins Thus, glycosylation of WNV prM and E proteins can affect the efficiency of virus release and infection in a manner that is cell type and perhaps species dependent. 1989393 0 16 gly glycosylation 70:82 arg2 a single glycosylation site a single glycosylation site site Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2. 1989393 0 33 gly glycoprotein 105:116 arg1 the external glycoprotein the external glycoprotein Fterm glycoprotein Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2. 11226831 10 38 gly glycosylation 942:954 arg2 The major glycosylation sites The major glycosylation sites sites The major glycosylation sites are within or near PEST regions, suggesting that O-GlcNAc may regulate mER-alpha turnover. 8307000 11 74 gly glycosylation 2250:2262 arg2 a new glycosylation site a new glycosylation site site Our study clearly demonstrates that creation of a new glycosylation site at Asn58 influenced the oligosaccharide processing and, hence, the glycosylation pattern at Asn117, whereas introduction of a new site at Asn67 did not. 8307000 11 74 gly glycosylation 2250:2262 arg2 Asn58 Asn58 Asn58 Our study clearly demonstrates that creation of a new glycosylation site at Asn58 influenced the oligosaccharide processing and, hence, the glycosylation pattern at Asn117, whereas introduction of a new site at Asn67 did not. 8307000 11 90 gly Asn117 2361:2366 arg1 the oligosaccharide processing Asn117 the oligosaccharide processing Asn117 Our study clearly demonstrates that creation of a new glycosylation site at Asn58 influenced the oligosaccharide processing and, hence, the glycosylation pattern at Asn117, whereas introduction of a new site at Asn67 did not. 8307000 11 104 gly glycosylation 2336:2348 arg2 Asn117 Asn117 Asn117 Our study clearly demonstrates that creation of a new glycosylation site at Asn58 influenced the oligosaccharide processing and, hence, the glycosylation pattern at Asn117, whereas introduction of a new site at Asn67 did not. 21515415 7 68 gly glycosylation 1000:1012 arg2 the six glycosylation sites the six glycosylation sites sites Removal of N-glycosylation at any one of the six glycosylation sites resulted in a significant 35-78% decrease in PLTP activity, and a significant 29-80% decrease in PLTP specific activity compared to wild type. 27356208 1 54 gly attaches 145:152 arg2 the asparagine residue AND a glycan moiety the asparagine residue a glycan moiety asparagine residue N-glycosylation is a process during which a glycan moiety attaches to the asparagine residue in the N-glycosylation consensus sequence (Asn-Xxx-Ser/Thr), where Xxx can be any amino acid except proline. 12147690 8 60 gly contained 1340:1348 arg1 calsequestrin AND glycan calsequestrin glycan Fterm calsequestrin Significant amounts of calsequestrin contained glycan with only a single mannose residue, indicative of a novel post-endoplasmic reticulum mannosidase activity. 22072749 9 3 gly glycosylation 1836:1848 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Furthermore, a potential N-linked glycosylation site located close to the HIR and postulated to be outside the cell in the alternate model was not glycosylated. 22072749 9 12 gly glycosylated 1949:1960 arg1 a potential N-linked glycosylation site a potential N-linked glycosylation site site Furthermore, a potential N-linked glycosylation site located close to the HIR and postulated to be outside the cell in the alternate model was not glycosylated. 2118657 0 28 gly N-glycosylation 80:94 arg2 an N-glycosylation site an N-glycosylation site site Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site. 15183061 8 29 gly N-glycosylation 1232:1246 arg1 N11 N11 N11 These findings demonstrate that N-glycosylation at N11 inhibits the binding of CXCR4 to X4 and R5 HIV-1 gp120, and provide a better understanding of the structural elements of CXCR4 involved in HIV-1 Env-co-receptor interactions. 31514875 4 39 gly glycoprotein 764:775 arg1 a glycoprotein a glycoprotein Fterm glycoprotein The performance of the supports was evaluated with the digestion of human Chorionic Gonadotropin hormone (hCG), a glycoprotein characterized by four N- and four O-glycosylation sites, prior to the analysis of the digests by nanoliquid chromatography coupled to tandem mass spectrometry (nanoLC-MS/MS). 31514875 4 60 gly O-glycosylation 811:825 arg2 four N- and four O-glycosylation sites four N- and four O-glycosylation sites sites The performance of the supports was evaluated with the digestion of human Chorionic Gonadotropin hormone (hCG), a glycoprotein characterized by four N- and four O-glycosylation sites, prior to the analysis of the digests by nanoliquid chromatography coupled to tandem mass spectrometry (nanoLC-MS/MS). 27966990 8 48 gly N-glycosylation 1484:1498 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site The data presented here provide direct evidence for site-specific, heterogeneous N-glycosylation and N-glycosylation site occupancy on VEGFR-2. 20506028 7 35 gly glycosylation 1324:1336 arg1 domain 1 domain domain These results indicate that glycosylation in domain 1 is critical for the structural integrity for biological functions of ChM-I in vitro. 9291187 6 5 part_of enzyme 861:866 arg1 the only putative N-glycosylation site enzyme the only putative N-glycosylation site Fterm Site enzyme site Next, the only putative N-glycosylation site (Asn394-Leu395-Ser396) of the cloned human kidney enzyme was eliminated by site-directed mutagenesis. 12954207 10 38 gly glycosylation 1748:1760 arg2 all four glycosylation sites all four glycosylation sites sites Absence of all four glycosylation sites rendered a primary isolate sensitive to CD4i antibody-mediated neutralization. 18260827 3 18 part_of proteins 747:754 arg1 membrane-spanning domains proteins membrane-spanning domains Fterm Site proteins domains To gain greater insight into the arrangement of membrane-spanning domains and cellular processing of Tweety proteins, in the present study we have examined the sequence homology, hydrophobicity and N-glycan content of members of this family and performed N-glycosylation site-mutagenesis studies on TTYH2 and TTYH3. 31516400 0 21 gly glycoprotein 81:92 arg1 mass spectrometry-based human N-linked glycoprotein mass spectrometry-based human N-linked glycoprotein Fterm glycoprotein N-GlycositeAtlas: a database resource for mass spectrometry-based human N-linked glycoprotein and glycosylation site mapping. 31516400 0 28 gly glycosylation 98:110 arg2 glycosylation site mapping glycosylation site mapping site N-GlycositeAtlas: a database resource for mass spectrometry-based human N-linked glycoprotein and glycosylation site mapping. 14691230 5 43 part_of DPPIV 976:980 arg1 the extracellular domain DPPIV the extracellular domain PUBTATOR Site DPPIV 1803 domain Individual Asn-->Ala point mutants were introduced at the nine glycosylation sites in the extracellular domain of DPPIV (residues 39-766). 26598643 10 68 gly O-glycosylation 1632:1646 arg2 31 O-glycosylation sites 31 O-glycosylation sites sites Overall, 31 O-glycosylation sites and regions belonging to 22 proteins were identified, the majority being acute-phase proteins. 2113054 6 5 gly glycosylation 1171:1183 arg1 sCD4 sCD4 PUBTATOR sCD4 499358 The role of glycosylation in the expression of sCD4 was investigated by mutagenesis of the constructs to remove each of the two N-linked glycosylation sites in turn and both together. 2113054 6 39 gly glycosylation 1296:1308 arg2 the two N-linked glycosylation sites the two N-linked glycosylation sites sites The role of glycosylation in the expression of sCD4 was investigated by mutagenesis of the constructs to remove each of the two N-linked glycosylation sites in turn and both together. 9820620 7 0 part_of Asn 1380:1382 arg1 hGH-V hGH-V Asn PUBTATOR SpecificSite hGH-V 2689 Asn 140 hGH-Vdelta4 has lost the N-glycosylation site at Asn 140 of hGH-V, but acquires a novel site at position 148 as well as a cystein-rich domain in the 65 carboxyl-terminal amino acids, potentially involved in multiple disulfide-bridge formation. 9820620 7 87 part_of hGH-V 1391:1395 arg1 the N-glycosylation site hGH-V the N-glycosylation site PUBTATOR Site hGH-V 2689 site hGH-Vdelta4 has lost the N-glycosylation site at Asn 140 of hGH-V, but acquires a novel site at position 148 as well as a cystein-rich domain in the 65 carboxyl-terminal amino acids, potentially involved in multiple disulfide-bridge formation. 19700364 2 19 gly glycosylated 215:226 arg1 human proteins human proteins Fterm proteins At least 50% of human proteins are glycosylated with some estimates being as high as 70%. 10970800 3 78 gly N-glycosylation 348:362 arg2 potential N-glycosylation sites potential N-glycosylation sites sites All of them have potential N-glycosylation sites. 2246248 9 45 gly N-glycosylation 987:1001 arg2 One potential N-glycosylation site One potential N-glycosylation site site One potential N-glycosylation site is conserved between the two species. 9689919 0 43 part_of factor 70:75 arg1 Sequence pigment epithelium-derived factor Sequence OGER pigment epithelium-derived factor P36955 Sequence and expression analysis of bovine pigment epithelium-derived factor. 4038307 1 12 gly derived 152:158 arg2 gamma-seminoprotein AND the oligosaccharides gamma-seminoprotein the oligosaccharides PUBTATOR gamma-seminoprotein 354 500-MHz H-NMR spectroscopy of the oligosaccharides derived from gamma-seminoprotein, a human seminal plasma glycoprotein, revealed considerable microheterogeneity both with respect to the degree of branching and with regard to the peripheral sugars. 4038307 1 12 gly derived 152:158 arg1 a human seminal plasma glycoprotein AND the oligosaccharides a human seminal plasma glycoprotein the oligosaccharides Fterm glycoprotein 500-MHz H-NMR spectroscopy of the oligosaccharides derived from gamma-seminoprotein, a human seminal plasma glycoprotein, revealed considerable microheterogeneity both with respect to the degree of branching and with regard to the peripheral sugars. 4038307 1 14 gly glycoprotein 209:220 arg1 gamma-seminoprotein gamma-seminoprotein PUBTATOR gamma-seminoprotein 354 500-MHz H-NMR spectroscopy of the oligosaccharides derived from gamma-seminoprotein, a human seminal plasma glycoprotein, revealed considerable microheterogeneity both with respect to the degree of branching and with regard to the peripheral sugars. 4038307 1 14 gly glycoprotein 209:220 arg1 a human seminal plasma glycoprotein a human seminal plasma glycoprotein Fterm glycoprotein 500-MHz H-NMR spectroscopy of the oligosaccharides derived from gamma-seminoprotein, a human seminal plasma glycoprotein, revealed considerable microheterogeneity both with respect to the degree of branching and with regard to the peripheral sugars. 22773269 9 50 gly sialoglycopeptide 1381:1397 arg2 the sialoglycopeptide enrichment the sialoglycopeptide enrichment sialoglycopeptide So the new strategy introduced here exhibits high efficiency and universality in the sialoglycopeptide enrichment, and is a powerful tool for sialoglycoproteome exploration. 2082620 2 25 part_of CD4 497:499 arg1 the putative CD4 binding site CD4 the putative CD4 binding site PUBTATOR Site CD4 920 site To address the possible role of N-glycosylation of HIV-1 gp120 in binding CD4, we mutated different conserved N-glycosylation site Asn-residues in the vicinity of the putative CD4 binding site, as single mutations or in combinations. 19276077 10 33 gly N-glycosylation 1762:1776 arg1 the alpha5 subunit subunit site-4 OGER subunit 3678 site-4 These results, taken together, strongly suggest that N-glycosylation of site-4 on the alpha5 subunit is the most important site for its biological functions. 14760718 3 28 gly glycoproteins 461:473 arg1 glycoproteins glycoproteins Fterm glycoproteins The detailed characterization of glycoproteins in complex biological samples is extremely challenging. 14749323 7 48 gly deglycosylation 1232:1246 arg1 Asp-39 Asp-39 Asp-39 Disrupting Asp-39 resulted in a complete loss of transport activity in both mOAT1 and hOAT1 without affecting their cell surface expression, suggesting that the loss of function is not because of deglycosylation of Asp-39 per se but rather is likely because of the change of this important amino acid critically involved in the substrate binding. 28443077 4 59 gly glycosylated 975:986 arg1 the glycosylated HA trimers the glycosylated HA trimers Fterm trimers Comparison of the equilibrated structures of the glycosylated HA trimers with and without the 3C.2a-specific mutations reveals that the mutations could induce a drastic reduction in the apical space for the ligand binding via glycan-shield rearrangement. 26641950 3 39 gly glycosylation 711:723 arg1 recombinant human interferon-β1 interferon-β1 site PUBTATOR interferon-β1 3456 site Here, we report on capillary zone electrophoresis (CZE) coupled via a commercial CESI sheathless interface to an Orbitrap ELITE MS for the intact analysis of recombinant human interferon-β1 (Avonex, rhIFN-β1), a biopharmaceutical with complex glycosylation at a single N-linked site. 26641950 3 39 gly glycosylation 711:723 arg1 a single N-linked site site site Here, we report on capillary zone electrophoresis (CZE) coupled via a commercial CESI sheathless interface to an Orbitrap ELITE MS for the intact analysis of recombinant human interferon-β1 (Avonex, rhIFN-β1), a biopharmaceutical with complex glycosylation at a single N-linked site. 26641950 3 39 gly glycosylation 711:723 arg1 a single N-linked site interferon-β1 site PUBTATOR interferon-β1 3456 site Here, we report on capillary zone electrophoresis (CZE) coupled via a commercial CESI sheathless interface to an Orbitrap ELITE MS for the intact analysis of recombinant human interferon-β1 (Avonex, rhIFN-β1), a biopharmaceutical with complex glycosylation at a single N-linked site. 10713140 5 8 gly N-glycosylation 894:908 arg2 any two N-glycosylation sites any two N-glycosylation sites sites Analysis of the folding pathway and activity of 15 tyrosinase mutants lacking one or more of the occupied N-glycosylation sites shows that glycans at any two N-glycosylation sites are sufficient to interact with calnexin and give partial activity, but a specific pair of sites (Asn(86) and Asn(371)) is required for full activity. 10713140 5 13 gly sites 910:914 arg1 glycans sites glycans sites Analysis of the folding pathway and activity of 15 tyrosinase mutants lacking one or more of the occupied N-glycosylation sites shows that glycans at any two N-glycosylation sites are sufficient to interact with calnexin and give partial activity, but a specific pair of sites (Asn(86) and Asn(371)) is required for full activity. 10713140 5 51 gly N-glycosylation 842:856 arg2 the occupied N-glycosylation sites the occupied N-glycosylation sites sites Analysis of the folding pathway and activity of 15 tyrosinase mutants lacking one or more of the occupied N-glycosylation sites shows that glycans at any two N-glycosylation sites are sufficient to interact with calnexin and give partial activity, but a specific pair of sites (Asn(86) and Asn(371)) is required for full activity. 10713140 5 67 gly sites 1007:1011 arg1 sites sites sites Analysis of the folding pathway and activity of 15 tyrosinase mutants lacking one or more of the occupied N-glycosylation sites shows that glycans at any two N-glycosylation sites are sufficient to interact with calnexin and give partial activity, but a specific pair of sites (Asn(86) and Asn(371)) is required for full activity. 10713140 5 67 gly sites 1007:1011 arg1 Asn(86) Asn(86) and Asn(371) Asn(86) and Asn(371) Analysis of the folding pathway and activity of 15 tyrosinase mutants lacking one or more of the occupied N-glycosylation sites shows that glycans at any two N-glycosylation sites are sufficient to interact with calnexin and give partial activity, but a specific pair of sites (Asn(86) and Asn(371)) is required for full activity. 17976852 4 11 gly glycosylated 479:490 arg1 Some vIL-10 isoforms Some vIL-10 isoforms Fterm isoforms Some vIL-10 isoforms were post-translationally glycosylated, depending on the existence of a predicted N-linked glycosylation site. 17976852 4 38 gly glycosylation 544:556 arg2 a predicted N-linked glycosylation site a predicted N-linked glycosylation site site Some vIL-10 isoforms were post-translationally glycosylated, depending on the existence of a predicted N-linked glycosylation site. 9169007 5 76 gly glycosylation 621:633 arg2 the four Asn residue sites the four Asn residue sites Asn residue sites To determine the source of the glycosylation heterogeneity responsible for these different heparin-affinity forms, each of the four Asn residue sites of glycosylation, residues 96, 135, 155, and 192, was mutated to Gln to block glycosylation at these sites. 9169007 5 54 gly glycosylation 696:708 arg2 these sites sites sites To determine the source of the glycosylation heterogeneity responsible for these different heparin-affinity forms, each of the four Asn residue sites of glycosylation, residues 96, 135, 155, and 192, was mutated to Gln to block glycosylation at these sites. 25673720 8 39 part_of PrP 1242:1244 arg1 both or the first PrP(C) glycosylation site PrP both or the first PrP(C) glycosylation site PUBTATOR Site PrP 19122 site The absence of glycosylation at both or the first PrP(C) glycosylation site in the host results in almost complete resistance to disease. 1559965 2 33 part_of Protein 205:211 arg1 a highly unusual multifunctional polypeptide Protein disulfide isomerase a highly unusual multifunctional polypeptide PUBTATOR Site Protein disulfide isomerase 5034 polypeptide Protein disulfide isomerase (PDI, EC 5.3.4.1) is a highly unusual multifunctional polypeptide, being identical to the beta subunit of prolyl 4-hydroxylase, a cellular thyroid hormone binding protein and a component of the microsomal triglyceride transfer protein complex, and highly similar to a polypeptide acting in vitro as a glycosylation site binding protein. 1559965 2 60 part_of disulfide 213:221 arg1 a highly unusual multifunctional polypeptide Protein disulfide isomerase a highly unusual multifunctional polypeptide PUBTATOR Site Protein disulfide isomerase 5034 polypeptide Protein disulfide isomerase (PDI, EC 5.3.4.1) is a highly unusual multifunctional polypeptide, being identical to the beta subunit of prolyl 4-hydroxylase, a cellular thyroid hormone binding protein and a component of the microsomal triglyceride transfer protein complex, and highly similar to a polypeptide acting in vitro as a glycosylation site binding protein. 7635146 11 116 gly glycoprotein 2175:2186 arg1 a type-II transmembrane glycoprotein a type-II transmembrane glycoprotein Fterm glycoprotein The hydrophobicity profile as well as the removal by trypsin of an approximately 4-kDa polypeptide from the membrane-associated glucosidase I in intact microsomal structures, supports the view that the enzyme is a type-II transmembrane glycoprotein, which contains a short cytosolic tail of approximately 37 amino acids, followed by a single transmembrane domain and a large C-terminal catalytic domain located on the luminal side of the endoplasmic reticulum membrane. 7635146 11 116 gly glycoprotein 2175:2186 arg1 the enzyme the enzyme Fterm enzyme The hydrophobicity profile as well as the removal by trypsin of an approximately 4-kDa polypeptide from the membrane-associated glucosidase I in intact microsomal structures, supports the view that the enzyme is a type-II transmembrane glycoprotein, which contains a short cytosolic tail of approximately 37 amino acids, followed by a single transmembrane domain and a large C-terminal catalytic domain located on the luminal side of the endoplasmic reticulum membrane. 7685769 1 20 gly glycosylated 286:297 arg1 Recombinant human granulocyte colony stimulating factor Recombinant human granulocyte colony stimulating factor PUBTATOR granulocyte colony stimulating factor 1440 Recombinant human granulocyte colony stimulating factor (G-CSF) produced in Chinese hamster ovary cells is glycosylated. 7685769 1 20 gly glycosylated 286:297 arg1 G-CSF G-CSF PUBTATOR G-CSF 1440 Recombinant human granulocyte colony stimulating factor (G-CSF) produced in Chinese hamster ovary cells is glycosylated. 9600940 2 10 part_of mZP3 432:435 arg1 the mZP3 polypeptide mZP3 the mZP3 polypeptide PUBTATOR Site mZP3 22788 polypeptide Apparently, the oligosaccharides are present on one or more of five Ser residues clustered in the carboxyl-terminal region of the mZP3 polypeptide. 20348522 5 65 gly glycosylation 731:743 arg1 the variant the variant Fterm variant The glycosylation status of the variant did not affect viral multiplication and dissemination in mosquitoes in vivo. 2457333 11 24 gly glycopeptides 1593:1605 arg2 these glycopeptides these glycopeptides glycopeptides PD-MS was also implemented in the purification protocol for these glycopeptides and proved to be useful in assessing purity of chromatographic fractions which were mixtures of glycopeptides displaying both carbohydrate and peptide heterogeneity. 2457333 11 49 gly glycopeptides 1703:1715 arg2 glycopeptides glycopeptides glycopeptides PD-MS was also implemented in the purification protocol for these glycopeptides and proved to be useful in assessing purity of chromatographic fractions which were mixtures of glycopeptides displaying both carbohydrate and peptide heterogeneity. 11741940 4 2 part_of proteins 824:831 arg1 homologous domains proteins homologous domains Fterm Site proteins domains Numbering sFRP-1 cysteines sequentially from the N terminus, the five disulfide linkages in the Fz domain are 1-5, 2-4, 3-8, 6-10, and 7-9, consistent with the disulfide pattern determined for homologous domains of several other proteins. 11741940 4 112 part_of sFRP-1 605:610 arg1 sFRP-1 cysteines Numbering sFRP-1 sFRP-1 cysteines PUBTATOR AminoAcid Numbering sFRP-1 6422 cysteines Numbering sFRP-1 cysteines sequentially from the N terminus, the five disulfide linkages in the Fz domain are 1-5, 2-4, 3-8, 6-10, and 7-9, consistent with the disulfide pattern determined for homologous domains of several other proteins. 10099545 8 31 gly glycosylation 1483:1495 arg2 reduced glycosylation site occupancy reduced glycosylation site occupancy site Lower nucleoside triphosphate pools in turn led to lower nucleotide sugar pools and reduced glycosylation site occupancy. 31377676 4 39 gly N-glycosylation 784:798 arg2 one N-glycosylation site one N-glycosylation site site RhIL-17A and rhIL-17F shared 96.8% and 93.9% amino acid sequence identity with human IL-17A (huIL-17A) and IL-17F (huIL-17F) respectively and the sequences also shared one N-glycosylation site and six conserved cysteine residues with huIL-17A and huIL-17F. 2411731 7 48 part_of alpha 1356:1360 arg1 Both the alpha 2(I) and alpha 2(V) telopeptides alpha 2(V) Both the alpha 2(I) and alpha 2(V) telopeptides PUBTATOR Site alpha 2(V) 1290 telopeptides Both the alpha 2(I) and alpha 2(V) telopeptides are devoid of a lysine, which in alpha 1 chains forms an interchain cross-link with residue 87 of the collagenous region. 11292534 6 70 part_of 3-kinase 1077:1084 arg1 a cytoplasmic phosphatidylinositol 3-kinase binding site phosphatidylinositol 3-kinase a cytoplasmic phosphatidylinositol 3-kinase binding site OGER Site phosphatidylinositol 3-kinase site The hexapeptide motif (MYPPPY), five cysteine residues, a potential N-glycosylation site and a cytoplasmic phosphatidylinositol 3-kinase binding site in canine CD28 molecule are completely conserved in canine CTLA-4. 26029999 1 38 gly glycoprotein 122:133 arg1 The membrane glycoprotein CD133 The membrane glycoprotein CD133 Fterm glycoprotein The membrane glycoprotein CD133 is a popular marker for cancer stem cells and contributes to cancer initiation and invasion in a number of tumor types. 9223227 2 23 part_of IL-1ra 318:323 arg1 the whole coding sequence IL-1ra the whole coding sequence PUBTATOR Site IL-1ra 100034236 sequence cDNA clones encoding the whole coding sequence of equine IL-1ra were isolated from equine peripheral blood mononuclear cells (PBMC) that had been stimulated with lipopolysaccharide (LPS). 30659065 5 29 gly occupancy 1225:1233 arg2 site occupancy site occupancy site Here we employ a nLC-MS/MS method using stepped-energy higher energy collisional dissociation to characterize the N-glycan repertoire and site occupancy of circulating serum antibodies. 11069304 4 14 gly glycosylated 1031:1042 arg1 K(V,Ca) beta-subunits K(V,Ca) beta-subunits Fterm beta-subunits Furthermore, tunicamycin treatment did not prevent apical segregation of hSlo, indicating that endogenous glycosylated proteins (e.g., K(V,Ca) beta-subunits) were not required. 11069304 4 14 gly glycosylated 1031:1042 arg1 endogenous glycosylated proteins endogenous glycosylated proteins Fterm proteins Furthermore, tunicamycin treatment did not prevent apical segregation of hSlo, indicating that endogenous glycosylated proteins (e.g., K(V,Ca) beta-subunits) were not required. 29285644 0 64 gly glycopeptides 27:39 arg2 fingerprint glycopeptides fingerprint glycopeptides glycopeptides Designation of fingerprint glycopeptides for targeted glycoproteomic analysis of serum haptoglobin: insights into gastric cancer biomarker discovery. 20507882 2 27 gly glycopeptides 453:465 arg2 tryptic glycopeptides glycopeptides alpha-dystroglycan glycopeptides By immunoprecipitation and sialic acid capture-and-release enrichment strategies, we isolated tryptic glycopeptides of alpha-dystroglycan from human skeletal muscle. 28493121 1 11 gly glycoproteins 227:239 arg1 recombinant biotherapeutic proteins recombinant biotherapeutic proteins Fterm proteins Chinese hamster ovary (CHO) cells represent the predominant platform in biopharmaceutical industry for the production of recombinant biotherapeutic proteins, especially glycoproteins. 28493121 1 11 gly glycoproteins 227:239 arg1 glycoproteins glycoproteins Fterm glycoproteins Chinese hamster ovary (CHO) cells represent the predominant platform in biopharmaceutical industry for the production of recombinant biotherapeutic proteins, especially glycoproteins. 3065335 2 51 part_of kallikrein 462:471 arg1 the propeptide kallikrein the propeptide PUBTATOR Site kallikrein 9622 propeptide Prokallikrein was a single chain polypeptide which comprised 238 amino acid residues of kallikrein and 7 amino acid residues of the propeptide. 3065335 2 51 part_of kallikrein 462:471 arg1 7 amino acid residues kallikrein residues PUBTATOR Site kallikrein 9622 residues Prokallikrein was a single chain polypeptide which comprised 238 amino acid residues of kallikrein and 7 amino acid residues of the propeptide. 9261431 8 71 gly glycosylation 1832:1844 arg2 a glycosylation site a glycosylation site site The conservation of a glycosylation site homologous to gs4 across a broad range of retroviruses suggests that this sequence may play a similar role in many retroviral Envs. 10675514 6 51 part_of has 751:753 arg1 Dog AQP1 AND two NPA motifs Dog AQP1 two NPA motifs PUBTATOR Site Dog AQP1 403732 motifs Dog AQP1 has six predicted transmembrane domains, two NPA motifs, one mercury-sensitive site and four consensus phosphorylation sites, the same as the other species. 10675514 6 51 part_of has 751:753 arg1 Dog AQP1 AND six predicted transmembrane domains Dog AQP1 six predicted transmembrane domains PUBTATOR Site Dog AQP1 403732 domains Dog AQP1 has six predicted transmembrane domains, two NPA motifs, one mercury-sensitive site and four consensus phosphorylation sites, the same as the other species. 10675514 6 51 part_of has 751:753 arg1 Dog AQP1 AND four consensus phosphorylation sites Dog AQP1 four consensus phosphorylation sites PUBTATOR Site Dog AQP1 403732 sites Dog AQP1 has six predicted transmembrane domains, two NPA motifs, one mercury-sensitive site and four consensus phosphorylation sites, the same as the other species. 10675514 6 51 part_of has 751:753 arg1 Dog AQP1 AND one mercury-sensitive site Dog AQP1 one mercury-sensitive site PUBTATOR Site Dog AQP1 403732 site Dog AQP1 has six predicted transmembrane domains, two NPA motifs, one mercury-sensitive site and four consensus phosphorylation sites, the same as the other species. 1566570 5 81 gly glycosylation 805:817 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site A major difference of 17DD and 17D-213 as compared to 17D-204 and Asibi was the existence of a potential N-linked glycosylation site located at amino acid residues 153 and 151 of 17DD and 17D-213, respectively. 22256424 3 14 gly N-glycosylation 538:552 arg2 the N-glycosylation site the N-glycosylation site site Several mutants of murine AE1 tagged with an N-terminal enhanced green fluorescent protein (EGFP) and/or an extracellular FLAG epitope inserted adjacent to the N-glycosylation site were prepared, and their expression was analyzed in HEK293 or COS-1 cells by immunofluorescence microscopy, biotinylation, and deglycosylation. 18076768 2 105 gly glycoprotein 408:419 arg1 Env Env To better understand envelope glycoprotein (Env) determinants contributing to pathogenicity of R5 viruses, we characterized 37 full-length R5 Envs from cross-sectional and longitudinal R5 viruses isolated from blood of patients with asymptomatic infection or AIDS, referred to as pre-AIDS (PA) and AIDS (A) R5 Envs, respectively. 18076768 2 105 gly glycoprotein 408:419 arg1 envelope glycoprotein envelope glycoprotein To better understand envelope glycoprotein (Env) determinants contributing to pathogenicity of R5 viruses, we characterized 37 full-length R5 Envs from cross-sectional and longitudinal R5 viruses isolated from blood of patients with asymptomatic infection or AIDS, referred to as pre-AIDS (PA) and AIDS (A) R5 Envs, respectively. 12954207 8 85 gly glycosylation 1364:1376 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site Surprisingly, removal of a single N-linked glycosylation site at the base of the gp120 third variable region (V3 loop) increased the sensitivity of the primary viruses to neutralization by CD4BS antibodies. 10207016 0 34 gly protein 64:70 arg1 pre-S2 N- protein pre-S2 N- Fterm protein Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus. 10207016 0 34 gly protein 64:70 arg1 O-linked glycans protein O-linked glycans Fterm protein Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus. 21704619 5 7 gly proteins 763:770 arg1 extra N-glycan moieties proteins extra N-glycan moieties Fterm proteins This demonstrates that the novel GlycoTag is a convenient tool to provide proteins with extra N-glycan moieties by simply adding a peptide tag sequence as small as 22 amino acids. 21704619 5 16 gly peptide 820:826 arg1 a peptide tag sequence a peptide tag sequence This demonstrates that the novel GlycoTag is a convenient tool to provide proteins with extra N-glycan moieties by simply adding a peptide tag sequence as small as 22 amino acids. 2303059 2 50 gly glycoproteins 554:566 arg1 mammalian glycoproteins mammalian glycoproteins Fterm glycoproteins Both variants contained almost exclusively oligomannose-type oligosaccharides, identical in structure to those of mammalian glycoproteins. 2303059 2 44 gly contained 444:452 arg1 Both variants AND oligomannose-type oligosaccharides Both variants oligomannose-type oligosaccharides Fterm variants Both variants contained almost exclusively oligomannose-type oligosaccharides, identical in structure to those of mammalian glycoproteins. 1331508 0 62 gly N-glycosylation 84:98 arg2 no putative N-glycosylation site no putative N-glycosylation site site A second gene for the African green monkey poliovirus receptor that has no putative N-glycosylation site in the functional N-terminal immunoglobulin-like domain. 8734414 3 18 gly N-glycosylation 461:475 arg2 an N-glycosylation site an N-glycosylation site site Both contain an A-to-G transition corresponding to substitution of Asn350 by Ser, with the resulting loss of an N-glycosylation site. 21264968 7 105 part_of MUC5AC 2418:2423 arg1 the consecutive Thr residues MUC5AC the consecutive Thr residues PUBTATOR AminoAcid MUC5AC 4586 Thr residues Such conformational impact on the underlying peptides was proved to be remarkable in the glycosylation at the consecutive Thr residues of MUC5AC. 30853725 2 12 gly glycopeptide 488:499 arg2 glycopeptide glycopeptide glycopeptide fragment Key to the successful completion of this synthesis was the introduction of an arginine-tagged acetamidomethyl group, which served to greatly facilitate handling of a glycopeptide fragment with poor aqueous solubility. 27957769 10 5 part_of MUC1 2029:2032 arg1 MUC1 peptides MUC1 MUC1 peptides OGER Site MUC1 P15941 peptides It is observed that the induced antibodies recognize MUC1 peptides with very high glycosylation site specificity. 7505151 1 48 part_of immunoglobulin 189:202 arg1 a single immunoglobulin (Ig) domain immunoglobulin a single immunoglobulin (Ig) domain Fterm Site immunoglobulin domain P0, the major structural protein of peripheral myelin, is a homophilic adhesion molecule with a single immunoglobulin (Ig) domain, which contains a single N-linked glycosylation site and two cysteines. 7505151 1 17 part_of contains 223:230 arg1 a single immunoglobulin (Ig) domain AND a single N-linked glycosylation site a single immunoglobulin (Ig) domain a single N-linked glycosylation site site P0, the major structural protein of peripheral myelin, is a homophilic adhesion molecule with a single immunoglobulin (Ig) domain, which contains a single N-linked glycosylation site and two cysteines. 7505151 1 17 part_of contains 223:230 arg1 a single immunoglobulin (Ig) domain AND two cysteines a single immunoglobulin (Ig) domain two cysteines cysteines P0, the major structural protein of peripheral myelin, is a homophilic adhesion molecule with a single immunoglobulin (Ig) domain, which contains a single N-linked glycosylation site and two cysteines. 16227249 7 66 part_of site 883:886 arg1 a lineage II strain strain site Fterm Site strain site Addition of the E protein glycosylation site in a lineage II strain that lacked this site increased SVP production. 16227249 7 74 part_of protein 861:867 arg1 the E protein glycosylation site protein the E protein glycosylation site Fterm Site protein site Addition of the E protein glycosylation site in a lineage II strain that lacked this site increased SVP production. 7635146 4 19 part_of contains 750:757 arg1 The 92-kDa protein AND a single N-glycosylation site The 92-kDa protein a single N-glycosylation site Fterm Site protein site The 92-kDa protein contains a single N-glycosylation site of the Asn-Xaa-Thr/Ser type at Asn655, as well as a strongly hydrophobic sequence close to its N-terminus (amino acids 38-58) which, most likely, functions as a transmembrane anchor. 7635146 4 19 part_of contains 750:757 arg1 The 92-kDa protein AND a strongly hydrophobic sequence The 92-kDa protein a strongly hydrophobic sequence Fterm Site protein sequence The 92-kDa protein contains a single N-glycosylation site of the Asn-Xaa-Thr/Ser type at Asn655, as well as a strongly hydrophobic sequence close to its N-terminus (amino acids 38-58) which, most likely, functions as a transmembrane anchor. 9690810 6 21 part_of GPIX 720:723 arg1 a cDNA sequence GPIX a cDNA sequence PUBTATOR Site GPIX 54368 sequence To obtain further information of GPIX, we have determined a cDNA sequence of mouse GPIX (811 bp). 9442070 11 35 gly used 1868:1871 arg2 primary sequence primary sequence sequence The primary sequence and disulfide bond pattern of IgA1, together with the crystal structures of IgG1 Fc and mouse IgA Fab and the glycan sequencing data, were used to generate a molecular model of IgA1. 8088785 7 19 part_of protein 1192:1198 arg1 no cysteine residues protein no cysteine residues Fterm AminoAcid protein cysteine residues Sequence analysis showed that NAGR1 is a glycine-, tryptophan-, and methionine-rich protein with no cysteine residues or glycosylation site. 8088785 7 19 part_of protein 1192:1198 arg1 glycosylation site protein glycosylation site Fterm Site protein site Sequence analysis showed that NAGR1 is a glycine-, tryptophan-, and methionine-rich protein with no cysteine residues or glycosylation site. 29779877 6 1 gly a N-glycosylation 1126:1142 arg2 N-139 N-139 N-139 This silencing activity is independent of Eph receptors and involves a N-glycosylation site (N-139) in the extracellular domain of Ephrin-B1. 29779877 6 1 gly a N-glycosylation 1126:1142 arg2 a N-glycosylation site a N-glycosylation site site This silencing activity is independent of Eph receptors and involves a N-glycosylation site (N-139) in the extracellular domain of Ephrin-B1. 16343462 5 38 gly glycopeptides 823:835 arg2 three glycopeptides three glycopeptides glycopeptides Using this enzymatic transglycosylation reaction, three glycopeptides were produced, a calcitonin derivative with the same complex-type carbohydrate at two sites, and two calcitonin derivatives each with one complex-type carbohydrate and one GlcNAc. 21674342 7 73 part_of gp120 1350:1354 arg1 a fragment gp120 a fragment PUBTATOR Site gp120 155971 fragment This approach has been applied to the solid-phase synthesis of the N-linked high mannose glycosylated form of peptide T (ASTTTNYT), a fragment of the HIV-1 envelope glycoprotein gp120. 30307368 5 47 part_of GEM 1129:1131 arg1 GEM epitopes GEM GEM epitopes OGER Site GEM P55040 epitopes Furthermore, we show that potent inhibition of MICA shedding can be achieved by antibodies that bind GEM epitopes adjacent to previously reported cleavage sites, and that these anti-MICA/B antibodies can prevent tumor growth in vivo. 10099468 8 34 gly glycoprotein 2045:2056 arg1 glycoprotein variation glycoprotein variation Fterm glycoprotein This study demonstrates that different modes of capillary electrophoresis can be employed to rapidly and quantitatively monitor the main sources of glycoprotein variation, and that the culture system and operation may influence the glycosylation of a recombinant glycoprotein. 10099468 8 68 gly glycosylation 2129:2141 arg1 a recombinant glycoprotein a recombinant glycoprotein Fterm glycoprotein This study demonstrates that different modes of capillary electrophoresis can be employed to rapidly and quantitatively monitor the main sources of glycoprotein variation, and that the culture system and operation may influence the glycosylation of a recombinant glycoprotein. 10099468 8 113 gly glycoprotein 2160:2171 arg1 a recombinant glycoprotein a recombinant glycoprotein Fterm glycoprotein This study demonstrates that different modes of capillary electrophoresis can be employed to rapidly and quantitatively monitor the main sources of glycoprotein variation, and that the culture system and operation may influence the glycosylation of a recombinant glycoprotein. 22855498 0 96 gly glycoprotein 27:38 arg1 Hepatitis C virus envelope glycoprotein Hepatitis C virus envelope glycoprotein Fterm glycoprotein Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. 7535613 11 82 gly glycosylation 1610:1622 arg2 The PSA glycosylation site site, Asn 61 site, Asn 61 The PSA glycosylation site, Asn 61, is fully accessible to the solvent and is enclosed in a positive region of the isopotential map. 11038011 0 98 gly neurophysin/glycopeptide 36:59 arg2 neurophysin/glycopeptide neurophysin/glycopeptide neurophysin/glycopeptide Effects of various mutations in the neurophysin/glycopeptide portion of the vasopressin gene on vasopressin expression in vitro. 30274288 1 53 gly glycosylation 322:334 arg2 glycosylation site glycosylation site site Pharmacokinetic and metabolism studies of 12-riboside-pseudoginsengenin DQ (RPDQ), a novel ginsenoside with an anti-cancer effect, were carried out, aiming at discussing the characteristics of the ginsenoside with glycosylation site at C-12. 19808681 11 68 gly glycosylated 1552:1563 arg1 only glycosylated Kv12.2 channels only glycosylated Kv12.2 channels PUBTATOR Kv12.2 channels 23416 Our data suggest that only glycosylated Kv12.2 channels show proper voltage dependence and are utilized in vivo. 31014754 5 54 gly N-glycosylation 764:778 arg2 N-glycosylation site N-glycosylation site site Hp was purified using affinity column chromatography and, peptide sequence, N-glycosylation site, glycan composition and glycoforms were identified using mass spectrometry. 11786923 4 71 part_of Wnt14b 602:607 arg1 mouse Wnt14b gene fragments Wnt14b mouse Wnt14b gene fragments PUBTATOR Site Wnt14b 22412 fragments Here, we identified mouse Wnt14b gene fragments in mouse genome draft sequence AL596108.5 by using bioinformatics, and isolated mouse Wnt14b cDNAs by using cDNA-PCR. 23824793 8 10 part_of Env 1541:1543 arg1 both known CD4-inducible and other Env epitopes Env both known CD4-inducible and other Env epitopes PUBTATOR Site Env 100429036 epitopes Enhanced sensitivity of CD4-independent Envs from day 42 CD4(+) T cell-depleted RM was also seen with monoclonal antibodies that target both known CD4-inducible and other Env epitopes. 23824793 8 66 part_of CD4-inducible 1517:1529 arg1 both known CD4-inducible and other Env epitopes CD4 both known CD4-inducible and other Env epitopes PUBTATOR Site CD4 713807 epitopes Enhanced sensitivity of CD4-independent Envs from day 42 CD4(+) T cell-depleted RM was also seen with monoclonal antibodies that target both known CD4-inducible and other Env epitopes. 21439032 6 40 gly N-glycosylation 1071:1085 arg2 N154 site N154 site N154 We conclude that mutation of the putative N-glycosylation site N154 in the E protein of JEV significantly enhances the induced humoral immune response and suggest that this mutant should be further investigated as a potential DNA vaccine against JEV. 11458001 1 5 gly residues 537:544 arg1 26-227 26-227 residues 26-227 To further define the major HS-binding domain of the HSV-1 attachment protein, i.e. glycoprotein C (gC), virus mutants carrying alterations of either two neighbouring basic amino acid residues or a single hydrophobic amino acid residue within the N-terminal domain of the protein (residues 26-227) were constructed. 11458001 1 62 gly glycoprotein 340:351 arg1 glycoprotein C glycoprotein C Fterm glycoprotein C To further define the major HS-binding domain of the HSV-1 attachment protein, i.e. glycoprotein C (gC), virus mutants carrying alterations of either two neighbouring basic amino acid residues or a single hydrophobic amino acid residue within the N-terminal domain of the protein (residues 26-227) were constructed. 26482295 1 35 part_of residues 307:314 arg1 target proteins proteins residues Fterm AminoAcid proteins asparagine residues The central enzyme in the Campylobacter jejuni asparagine-linked glycosylation pathway is the oligosaccharyltransferase (OST), PglB, which transfers preassembled glycans to specific asparagine residues in target proteins. 10099302 1 30 gly glycoproteins 259:271 arg1 therapeutic glycoproteins therapeutic glycoproteins Fterm glycoproteins Because the presence of sialic acid can extend circulatory lifetime, a high degree of sialylation is often a desirable feature of therapeutic glycoproteins. 17947537 8 40 part_of protein 1494:1500 arg1 the stem 2 region protein the stem 2 region Fterm Site protein region Our findings indicate that a structural alteration in the stem 2 region of the H protein at position 195 or 200 interferes with infectivity of rodent neurons, and suggest that the interaction of the viral attachment protein with cellular receptors on neurons is affected. 8301235 7 47 gly glycosylation 1014:1026 arg1 residues 20, 340, and 375 residues 20, 340, and 375 residues 20, 340, and 375 Abolition of N-linked glycosylation of three (residues 20, 340, and 375) of the four sites did not affect enzyme secretion or activity. 8301235 7 47 gly glycosylation 1014:1026 arg1 the four sites the four sites sites Abolition of N-linked glycosylation of three (residues 20, 340, and 375) of the four sites did not affect enzyme secretion or activity. 9435448 0 55 gly globulin 34:41 arg1 an additional carbohydrate chain sex hormone-binding globulin an additional carbohydrate chain PUBTATOR sex hormone-binding globulin 100009224 Human variant sex hormone-binding globulin (SHBG) with an additional carbohydrate chain has a reduced clearance rate in rabbit. 12223479 4 34 gly glycosylation 681:693 arg1 the beta4 subunit the beta4 subunit PUBTATOR beta4 subunit 10717 We investigated here the N-linked glycosylation of the beta4 subunit and its effect on the modulation of the hSlo alpha subunit. 15113920 1 2 gly glycoproteins 173:185 arg1 The membrane glycoproteins Gn and Gc The membrane glycoproteins Gn and Gc Fterm glycoproteins The membrane glycoproteins Gn and Gc of Hantaan virus (HTNV) (family Bunyaviridae) are modified by N-linked glycosylation. 15113920 1 2 gly glycoproteins 173:185 arg1 Gn Gn Cterm Gn The membrane glycoproteins Gn and Gc of Hantaan virus (HTNV) (family Bunyaviridae) are modified by N-linked glycosylation. 7642555 2 4 gly modified 337:344 arg1 c-Myc AND O-linked N-acetylglucosamine c-Myc O-linked N-acetylglucosamine PUBTATOR c-Myc 4609 Previously, we demonstrated that c-Myc is modified by O-linked N-acetylglucosamine (O-GlcNAc) within or nearby the N-terminal transcriptional activation domain (Chou, T.-Y., Dang, C.V., and Hart, G.W. (1995) Proc. 7642555 2 4 gly modified 337:344 arg1 c-Myc AND O-GlcNAc c-Myc O-GlcNAc PUBTATOR c-Myc 4609 Previously, we demonstrated that c-Myc is modified by O-linked N-acetylglucosamine (O-GlcNAc) within or nearby the N-terminal transcriptional activation domain (Chou, T.-Y., Dang, C.V., and Hart, G.W. (1995) Proc. 21431619 9 56 part_of transferrin 1404:1414 arg1 transferrin peptides transferrin transferrin peptides PUBTATOR Site transferrin 7018 peptides These results show the use of mass spectrometry of transferrin peptides in the diagnostic track of CDG type I. 20589574 2 36 part_of EIF1 338:341 arg1 the genomic sequences EIF1 the genomic sequences PUBTATOR Site EIF1 P41567 sequences The cDNA and the genomic sequences of EIF1 were cloned successfully from the giant panda (Ailuropoda melanoleuca) and the black bear (Ursus thibetanus mupinensis) using reverse transcription polymerase chain reaction (RT-PCR) technology and touchdown-polymerase chain reaction, respectively. 23714211 2 9 gly glycosylated 256:267 arg1 glycosylated, membrane-bound proteins glycosylated, membrane-bound proteins Fterm proteins Each of the four families of CAMs is comprised of glycosylated, membrane-bound proteins that participate in multiple cellular processes including cell-cell communication, cell motility, inside-out and outside-in signaling, tumorigenesis, angiogenesis and metastasis. 9774483 0 41 gly polysialylation 29:43 arg1 the neural cell adhesion molecule the neural cell adhesion molecule PUBTATOR neural cell adhesion molecule 4684 Differential and cooperative polysialylation of the neural cell adhesion molecule by two polysialyltransferases, PST and STX. 9774483 0 67 gly molecule 73:80 arg1 Differential and cooperative polysialylation neural cell adhesion molecule Differential and cooperative polysialylation PUBTATOR neural cell adhesion molecule 4684 Differential and cooperative polysialylation of the neural cell adhesion molecule by two polysialyltransferases, PST and STX. 29353432 7 25 gly glycoproteins 1019:1031 arg1 various glycoproteins various glycoproteins Fterm glycoproteins Lectins and antibodies are being used for identification and detection of the carbohydrate moiety with low level of discrimination among various glycoproteins. 22078945 1 2 part_of protein 122:128 arg1 the sequence protein the sequence Fterm Site protein sequence OBJECTIVE: To analyze the sequence of ORF1 protein of Torque teno virus to prepare for the future hybrid experiments. 2825202 11 26 gly glycosylated 1745:1756 arg1 glycosylated pro-SAP-1 glycosylated pro-SAP-1 PUBTATOR AminoAcid SAP-1 22941 The molecular mass of glycosylated pro-SAP-1 is estimated at approximately 69 kDa, assuming glycosylation of all four sites. 2825202 11 92 gly glycosylation 1815:1827 arg1 all four sites all four sites sites The molecular mass of glycosylated pro-SAP-1 is estimated at approximately 69 kDa, assuming glycosylation of all four sites. 28661444 5 11 gly neo-glycoproteins 1096:1112 arg1 the different neo-glycoproteins the different neo-glycoproteins Fterm neo-glycoproteins The glycosylation sites and the ex vivo evaluation of the immunogenic activity of the different neo-glycoproteins were investigated. 28661444 5 83 gly glycosylation 1004:1016 arg2 The glycosylation sites The glycosylation sites sites The glycosylation sites and the ex vivo evaluation of the immunogenic activity of the different neo-glycoproteins were investigated. 15147907 0 4 gly glycans 17:23 arg1 the secreted human complement component C3 C3 glycans Cterm C3 Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure. 24899172 4 98 gly glycosylation 719:731 arg2 the N146 glycosylation site the N146 glycosylation site site We observed that the removal of the N146 glycosylation site by mutagenesis was permissive to envelope protein synthesis and stability and to secretion of subviral particles (SVPs) and hepatitis delta virus (HDV) virions, but it was detrimental to HBV virion production. 10527944 5 48 gly O-glycosylated 884:897 arg1 lysine residues lysine residues lysine residues Proline and lysine residues were partly hydroxylated and lysine residues were further O-glycosylated with the disaccharide galactose-glucose. 1719383 8 60 part_of present 1403:1409 arg2 all other five IGFBPs AND the 18 homologous cysteines all other five IGFBPs the 18 homologous cysteines PUBTATOR AminoAcid IGFBPs 25662 cysteines In addition, a distinctive feature of human and rat IGFBP-6 is that they lack, respectively, two and four of the 18 homologous cysteines that are present in all other five IGFBPs. 1719383 8 69 part_of IGFBPs 1429:1434 arg1 the 18 homologous cysteines IGFBPs the 18 homologous cysteines PUBTATOR AminoAcid IGFBPs 25662 cysteines In addition, a distinctive feature of human and rat IGFBP-6 is that they lack, respectively, two and four of the 18 homologous cysteines that are present in all other five IGFBPs. 24799124 4 60 part_of detected 880:887 arg1 ceruloplasmin AND sites 138, 358, 397, and 762 ceruloplasmin sites PUBTATOR Site ceruloplasmin 1356 sites This procedure simplified the structures for further analysis by mass spectrometry, where four core-fucosylated sites (sites 138, 358, 397, and 762) were detected in ceruloplasmin. 8411368 0 44 gly Glycosylation 0:12 arg1 neuraminidase neuraminidase Fterm neuraminidase Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus. 14692455 6 62 gly deglycosylate 987:999 arg1 the selected peptides the selected peptides peptides Because the oligosaccharides of glycoproteins are generally heterogeneous and often of unknown structure, it was necessary to deglycosylate the selected peptides with PNGase F before they could be compared to sequences in DNA and protein databases. 14692455 6 48 gly glycoproteins 893:905 arg1 the oligosaccharides glycoproteins the oligosaccharides Fterm glycoproteins Because the oligosaccharides of glycoproteins are generally heterogeneous and often of unknown structure, it was necessary to deglycosylate the selected peptides with PNGase F before they could be compared to sequences in DNA and protein databases. 28921966 2 51 gly glycoprotein 354:365 arg1 glycoprotein analysis glycoprotein analysis This method has the potential to simplify glycoprotein analysis by integrating glycan sequencing and glycopeptide analysis in a single experiment. 17670834 7 15 part_of motif 1152:1156 arg1 HA1 HA1 motif OGER Site HA1 site motif Deletion of the potential glycosylation site motif at 133 to 135 in HA1 from a recent isolate partially restored the agglutination phenotype to a recombinant virus, indicating that the HA-SA interaction is inhibited by the glycosylation modification. 7609736 7 50 gly heterogeneity 756:768 arg1 its fragments its fragments fragments A noteworthy heterogeneity of CBGA1 and its fragments in SDS-PAGE and IEF was detected. 8624782 6 35 gly sequence 724:731 arg1 an expressed sequence tag an expressed sequence tag Extensive peptide sequence from LDL-PLA2 facilitated identification of an expressed sequence tag partial cDNA. 9927579 6 6 gly glycosylation 1099:1111 arg2 a potential glycosylation site a potential glycosylation site site HA sequences from the human isolates and a recent chicken isolate represent a separate clade, within which there are two subgroups that are distinguishable antigenically and by the presence of a potential glycosylation site. 8862412 9 19 gly glycosylation 1386:1398 arg2 an additional glycosylation site an additional glycosylation site site Seven potential glycosylation sites identified in the NA of A/Hong Kong/8/68 virus were conserved by the majority of isolates, with more recently circulating viruses having an additional glycosylation site. 8862412 9 61 gly glycosylation 1215:1227 arg2 Seven potential glycosylation sites Seven potential glycosylation sites sites Seven potential glycosylation sites identified in the NA of A/Hong Kong/8/68 virus were conserved by the majority of isolates, with more recently circulating viruses having an additional glycosylation site. 26013384 6 28 gly O-glycopeptide 797:810 arg2 O-glycopeptide profiles O-glycopeptide profiles O-glycopeptide Peptide mapping analysis for each peak fraction using Asp-N and Glu-C shows differences in O-glycopeptide profiles at Ser126. 12940452 9 59 gly O-glycosylation 1522:1536 arg1 free alpha-subunit free alpha-subunit Fterm alpha-subunit Furthermore, amino acid sequences in the N-terminus are involved in the O-glycosylation in free alpha-subunit. 15911445 6 16 part_of HA1 852:854 arg1 The HA1 region HA1 The HA1 region OGER Site HA1 region The HA1 region was analyzed by RT-PCR and subsequently sequenced to compare the HA1 genetic evolution of influenza A H1N1 and A H1N2 subtypes. 9753616 4 11 part_of has 417:419 arg1 STC2 AND 302 amino acid residues STC2 302 amino acid residues PUBTATOR Site STC2 8614 residues STC2 has 302 amino acid residues with 34% identity with STC1 and eel STC. 1726785 7 73 gly has 1211:1213 arg1 This same region AND a determinant This same region a determinant region This same region has, in addition, a determinant that is not important for receptor activity, yet is reactive with Graves' IgG. 7613486 9 65 gly glycosylation 1660:1672 arg1 this region region region Only partial glycosylation in this region of the receptor is required for its targeting to the cell membrane since single and double glycosylation mutants were found processed to their alpha and beta subunits on the cell surface. 22119577 3 39 gly glycoprotein 575:586 arg1 the sea bass (Dicentrarchus labrax) glycoprotein TPN the sea bass (Dicentrarchus labrax) glycoprotein TPN Fterm glycoprotein In this work, the gene and cDNA of the sea bass (Dicentrarchus labrax) glycoprotein TPN have been isolated and characterized. 18930737 6 41 gly N-glycosylation 858:872 arg2 Asn77 Asn77 Asn77 The amino acid sequence of PIP contains one potential N-glycosylation site at Asn77, and the same is found glycosylated with four sugar residues. 18930737 6 41 gly N-glycosylation 858:872 arg2 one potential N-glycosylation site one potential N-glycosylation site site The amino acid sequence of PIP contains one potential N-glycosylation site at Asn77, and the same is found glycosylated with four sugar residues. 17724331 0 53 part_of receptor 46:53 arg1 An extracellular region erythropoietin receptor An extracellular region OGER Site erythropoietin receptor P19235 region An extracellular region of the erythropoietin receptor of the subterranean blind mole rat Spalax enhances receptor maturation. 26022737 3 29 gly glycoproteins 452:464 arg1 impure glycoproteins impure glycoproteins Fterm glycoproteins During our previous study of PSA N69 glycosylation, additional glycopeptides were observed in the PSA sample that were not previously reported and did not match glycopeptides of impure glycoproteins existing in the sample. 26022737 3 31 gly glycopeptides 330:342 arg2 additional glycopeptides additional glycopeptides glycopeptides During our previous study of PSA N69 glycosylation, additional glycopeptides were observed in the PSA sample that were not previously reported and did not match glycopeptides of impure glycoproteins existing in the sample. 26022737 3 87 gly glycopeptides 428:440 arg1 impure glycoproteins glycoproteins glycopeptides Fterm glycoproteins glycopeptides During our previous study of PSA N69 glycosylation, additional glycopeptides were observed in the PSA sample that were not previously reported and did not match glycopeptides of impure glycoproteins existing in the sample. 15718224 4 7 part_of sites 968:972 arg1 the viral envelope glycoprotein gp120 gp120 sites PUBTATOR Site gp120 3700 sites These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs. 15718224 4 41 part_of gp120 1009:1013 arg1 the N-glycosylation motifs gp120 the N-glycosylation motifs PUBTATOR Site gp120 3700 motifs These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs. 15718224 4 41 part_of gp120 1009:1013 arg1 the Asn or Thr/Ser sites gp120 the Asn or Thr/Ser sites PUBTATOR Site gp120 3700 sites These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs. 15718224 4 84 part_of sites 1058:1062 arg1 the viral envelope glycoprotein gp120 gp120 sites PUBTATOR Site gp120 3700 sites These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs. 22997027 6 62 gly glycoprotein 1136:1147 arg1 glycoprotein glycosylation analysis glycoprotein glycosylation analysis Fterm glycoprotein Thus, in the recent years, continuous efforts have been devoted to the development of glycopeptide enrichment and separation strategies to facilitate and improve glycoprotein glycosylation analysis in complex samples. 22997027 6 70 gly glycopeptide 1060:1071 arg2 glycopeptide enrichment glycopeptide enrichment glycopeptide Thus, in the recent years, continuous efforts have been devoted to the development of glycopeptide enrichment and separation strategies to facilitate and improve glycoprotein glycosylation analysis in complex samples. 27641734 10 86 gly N-glycosylation 1795:1809 arg1 CD97 EGF1-5 isoform CD97 EGF1-5 isoform PUBTATOR CD97 EGF1-5 isoform 976 N-glycosylation affected the auto-proteolysis of CD97 EGF1-5 isoform in a similar way as the other previously reported CD97 isoforms. 25242514 6 45 gly N-glycosylation 1063:1077 arg2 N-glycosylation sites N-glycosylation sites sites KEY FINDINGS: Mutations of the CRD completely impaired SP-A secretion, whereas mutations of N-glycosylation sites had little effect. 19131501 4 55 part_of STC2 482:485 arg1 The opossum STC2 amino acid sequence STC2 The opossum STC2 amino acid sequence PUBTATOR Site STC2 8614 sequence The opossum STC2 amino acid sequence had 78.8% homology with human STC2, and has a conserved putative N-linked glycosylation site. 19131501 4 56 part_of has 547:549 arg1 The opossum STC2 amino acid sequence AND a conserved putative N-linked glycosylation site The opossum STC2 amino acid sequence a conserved putative N-linked glycosylation site site The opossum STC2 amino acid sequence had 78.8% homology with human STC2, and has a conserved putative N-linked glycosylation site. 10913840 7 61 gly N-glycosylation 1093:1107 arg1 the enzyme the enzyme Fterm enzyme However, N-glycosylation does not appear to affect the major intracellular location of the enzyme, as immunocytochemistry reveals the same perinuclear pattern of staining for the unglycosylated mutants as is seen for the wild-type rFuc-TIV in transfected cells. 10094503 3 35 gly N-glycosylation 606:620 arg2 one N-glycosylation site one N-glycosylation site site This protein contains six potential Ca(2+)-binding domains, one N-glycosylation site, and a large amount of acidic amino acid residues. 10094503 3 35 gly N-glycosylation 606:620 arg2 acidic amino acid residues residues residues This protein contains six potential Ca(2+)-binding domains, one N-glycosylation site, and a large amount of acidic amino acid residues. 2732722 3 24 gly glycosylation 705:717 arg2 a glycosylation site a glycosylation site site Only one pair of viruses had amino acid differences between the egg- and MDCK cell-derived viral subpopulations and this change did not affect a glycosylation site. 26957414 9 115 part_of glycoproteins 1166:1178 arg1 the glycosylation sites glycoproteins the glycosylation sites Fterm Site glycoproteins sites ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin. 7755594 4 26 gly dimers 880:885 arg1 the glycan composition dimers the glycan composition Fterm dimers In baculovirus-produced wild-type (Wt) and N-linked glycosylation site-defective mutant (N25Q or N97Q, Asn-25 or Asn-97 substituted by Gln) IFN-gamma proteins, the extent of core glycosylation of monomers reflected the glycan composition of dimers. 7755594 4 52 gly N25Q 728:731 arg1 Asn-97 Asn-97 Asn-97 In baculovirus-produced wild-type (Wt) and N-linked glycosylation site-defective mutant (N25Q or N97Q, Asn-25 or Asn-97 substituted by Gln) IFN-gamma proteins, the extent of core glycosylation of monomers reflected the glycan composition of dimers. 7755594 4 52 gly N25Q 728:731 arg1 Asn-25 Asn-25 Asn-25 In baculovirus-produced wild-type (Wt) and N-linked glycosylation site-defective mutant (N25Q or N97Q, Asn-25 or Asn-97 substituted by Gln) IFN-gamma proteins, the extent of core glycosylation of monomers reflected the glycan composition of dimers. 10712595 6 53 gly glycosylated 1104:1115 arg2 Asn135 antithrombin Asn135 PUBTATOR antithrombin 462 Asn135 The high heparin binding affinity of the salmon inhibitor, Kd of 2.2 and 48 nM at I = 0.15 and 0.3, respectively, is very similar to that of the minor human isoform beta-antithrombin, which is not glycosylated at Asn135. 2844797 9 0 gly glycosylation 2067:2079 arg2 an N-linked glycosylation site an N-linked glycosylation site site Whereas the muscle isoform consists of 997 amino acids and terminates with the sequence Ala-Ile-Leu-Glu, the second isoform is 1043 amino acids in length due to the replacement of these last 4 amino acids with a 50-amino acid sequence that contains a potential transmembrane domain followed by a consensus sequence for an N-linked glycosylation site. 31202607 7 0 part_of N565 1484:1487 arg1 GluN3A GluN3A N565 PUBTATOR SpecificSite GluN3A 116443 N565 We also found that AAL has the most profound effect on GluN1/GluN3 receptors, and this effect is mediated partly by a single N-glycosylation site on the GluN3 subunit (specifically, N565 on GluN3A and N465 on GluN3B). 31202607 7 0 part_of N565 1484:1487 arg1 GluN3B GluN3B N565 PUBTATOR SpecificSite GluN3B 116444 N565 We also found that AAL has the most profound effect on GluN1/GluN3 receptors, and this effect is mediated partly by a single N-glycosylation site on the GluN3 subunit (specifically, N565 on GluN3A and N465 on GluN3B). 31202607 7 8 part_of site 1443:1446 arg1 the GluN3 subunit subunit site Fterm Site subunit site We also found that AAL has the most profound effect on GluN1/GluN3 receptors, and this effect is mediated partly by a single N-glycosylation site on the GluN3 subunit (specifically, N565 on GluN3A and N465 on GluN3B). 9008840 11 39 part_of Gp21 1966:1969 arg1 the Gp21 peptide fragment Gp21 the Gp21 peptide fragment Cterm Site Gp21 fragment The close similarity of the 1H and 13C chemical shift values for the Gp21 glycan with the respective values for the peptide-free diantennary oligosaccharide (Wieruszeski et al., Glycoconjugate J., 6 (1989) 183-194) indicates that the 1H and 13C chemical shifts of the diantennary oligosaccharide are not perturbed by the presence of the Gp21 peptide fragment. 8870657 2 5 part_of sequons 316:322 arg1 hLF hLF sequons PUBTATOR hLF 3131 Our objective was to determine to what extent each of the three sequons for N-linked glycosylation in hLF is actually used. 18707900 2 0 part_of site 461:464 arg1 the fragment crystallizable (Fc) subunit subunit site Fterm Site subunit site IgG1s contain a conserved N-glycosylation site in the fragment crystallizable (Fc) subunit. 18707900 2 45 part_of contain 425:431 arg1 IgG1s AND a conserved N-glycosylation site IgG1s a conserved N-glycosylation site Cterm Site IgG1s site IgG1s contain a conserved N-glycosylation site in the fragment crystallizable (Fc) subunit. 26256267 10 14 gly glycoproteins 1612:1624 arg1 21 differentially expressed glycoproteins 21 differentially expressed glycoproteins Fterm glycoproteins However, alterations in 21 differentially expressed glycoproteins showed no change at the protein abundance level, indicating that the glycosylation site occupancy was different between the two cell lines. 26256267 10 114 gly glycosylation 1695:1707 arg2 the glycosylation site occupancy the glycosylation site occupancy site However, alterations in 21 differentially expressed glycoproteins showed no change at the protein abundance level, indicating that the glycosylation site occupancy was different between the two cell lines. 4060580 5 12 gly glycosylation 808:820 arg2 A specific glycosylation site A specific glycosylation site site A specific glycosylation site at the distal tip of the HA of influenza B virus grown exclusively in mammalian cell culture is lost or altered during egg adaptation. 8783018 3 23 gly glycosylated 600:611 arg2 the two potential glycosylation sites the two potential glycosylation sites sites MALDI-MS of the intact IFN-gamma, electroeluted from the two bands, confirmed that these correspond to IFN-gamma molecules glycosylated at one or both of the two potential glycosylation sites, respectively. 8783018 3 27 gly glycosylation 649:661 arg2 the two potential glycosylation sites the two potential glycosylation sites sites MALDI-MS of the intact IFN-gamma, electroeluted from the two bands, confirmed that these correspond to IFN-gamma molecules glycosylated at one or both of the two potential glycosylation sites, respectively. 25435177 10 60 part_of contained 1568:1576 arg1 The HA protein AND a glycosylation site The HA protein a glycosylation site Fterm Site protein site The HA protein of most of the Singaporean specimens isolated post 2000 contained a glycosylation site at position 211, which was not dominant prior to 2000. 2209609 2 79 part_of has 339:341 arg1 The glycoprotein AND Asn271 glycoprotein sites, Asn271 and Asn300 Fterm AminoAcid glycoprotein sites, Asn271 and Asn300 The glycoprotein has two N-glycosylation sites, Asn271 and Asn300, at both of which evidence for the presence of complex type biantennary sialo-oligosaccharides has been obtained previously by mass spectrometric analyses [Carr, S.A., Hemling, M.E., Folena-Wasserman, G., Sweet, R.W., Anumula, K., Barr, J.R., Huddleston, M.J. & Taylor, P. (1989) J. Biol. 2209609 2 79 part_of has 339:341 arg1 The glycoprotein AND two N-glycosylation sites glycoprotein sites, Asn271 and Asn300 Fterm AminoAcid glycoprotein sites, Asn271 and Asn300 The glycoprotein has two N-glycosylation sites, Asn271 and Asn300, at both of which evidence for the presence of complex type biantennary sialo-oligosaccharides has been obtained previously by mass spectrometric analyses [Carr, S.A., Hemling, M.E., Folena-Wasserman, G., Sweet, R.W., Anumula, K., Barr, J.R., Huddleston, M.J. & Taylor, P. (1989) J. Biol. 2209609 2 79 part_of has 339:341 arg1 The glycoprotein AND two N-glycosylation sites glycoprotein sites, Asn271 and Asn300 Fterm AminoAcid glycoprotein sites, Asn271 and Asn300 The glycoprotein has two N-glycosylation sites, Asn271 and Asn300, at both of which evidence for the presence of complex type biantennary sialo-oligosaccharides has been obtained previously by mass spectrometric analyses [Carr, S.A., Hemling, M.E., Folena-Wasserman, G., Sweet, R.W., Anumula, K., Barr, J.R., Huddleston, M.J. & Taylor, P. (1989) J. Biol. 27574189 1 16 gly glycoprotein 173:184 arg1 the plasma glycoprotein ADAMTS13 the plasma glycoprotein ADAMTS13 Fterm glycoprotein Patients suffering from acquired thrombotic thrombocytopenic purpura develop autoantibodies directed toward the plasma glycoprotein ADAMTS13. 17671839 9 53 gly glycosylations 1398:1411 arg2 N30 residues N30 residues N30 It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies. 17671839 9 53 gly glycosylations 1398:1411 arg1 GP5 GP5 residues N30 PUBTATOR GP5 P40197 residues N30 It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies. 17671839 9 53 gly glycosylations 1398:1411 arg1 GP5 GP5 residues N30 PUBTATOR GP5 P40197 residues N30 It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies. 17671839 9 53 gly glycosylations 1398:1411 arg1 GP5 GP5 N44 and N51 PUBTATOR GP5 P40197 N44 and N51 It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies. 17671839 9 53 gly glycosylations 1398:1411 arg2 N51 N44 and N51 N44 and N51 It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies. 17671839 9 53 gly glycosylations 1398:1411 arg2 N51 GP5 N44 and N51 PUBTATOR GP5 P40197 N44 and N51 It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies. 17671839 9 84 gly residues 1423:1430 arg1 N51 N44 and N51 N44 and N51 It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies. 17671839 9 84 gly residues 1423:1430 arg1 N30 residues N30 residues N30 It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies. 16873272 3 3 part_of receptor-binding 480:495 arg1 the prototype FV (PFV) Env receptor-binding domain PFV) Env receptor the prototype FV (PFV) Env receptor-binding domain Cterm Site PFV) Env receptor P40189 domain In this study, we characterized the prototype FV (PFV) Env receptor-binding domain (RBD) by flow cytometric analysis of recombinant PFV Env immunoadhesin binding to target cells. 16873272 3 55 part_of PFV 471:473 arg1 the prototype FV (PFV) Env receptor-binding domain PFV) Env receptor the prototype FV (PFV) Env receptor-binding domain Cterm Site PFV) Env receptor P40189 domain In this study, we characterized the prototype FV (PFV) Env receptor-binding domain (RBD) by flow cytometric analysis of recombinant PFV Env immunoadhesin binding to target cells. 16873272 3 63 part_of Env 476:478 arg1 the prototype FV (PFV) Env receptor-binding domain PFV) Env receptor the prototype FV (PFV) Env receptor-binding domain Cterm Site PFV) Env receptor P40189 domain In this study, we characterized the prototype FV (PFV) Env receptor-binding domain (RBD) by flow cytometric analysis of recombinant PFV Env immunoadhesin binding to target cells. 11683378 13 11 part_of site 2125:2128 arg1 BALB/c IgA IgA site PUBTATOR Site IgA 12518 site Verification of the DC-PCR product by sequencing reveals that the T560 and B10.A IgA (Ig2b allotype) hinge is different from the BALB/c IgA (Ig2a allotype) hinge: it has two extra Cys and has eliminated the first Thr, a potential glycosylation site in BALB/c IgA. 15931076 1 15 gly N-glycosylation 339:353 arg2 the potential N-glycosylation site the potential N-glycosylation site site Whole-cell patch-clamp recordings were performed on HEK293 cells transiently transfected with the rat (r) wild-type transient receptor potential vanilloid 1 (TRPV1) (rTRPV1) receptor or with a mutant that lacks the potential N-glycosylation site at position N604 (rTRPV1-N604T). 27314333 6 14 gly N-glycosylation 1013:1027 arg2 the N-glycosylation site the N-glycosylation site site Introduction of the N-glycosylation site to Rspo2 mutant at the position homologous to N137 in Rspo1 restored full glycosylation and rescued the accumulation defect of nonglycosylated Rspo2 mutant in media. 27506355 2 17 gly glycopeptides 368:380 arg2 intact glycopeptides intact glycopeptides glycopeptides However, computational tools for analyzing MS/MS spectra of intact glycopeptides are still limited and not well-integrated into existing workflows. 21153276 2 35 gly glycosylation 336:348 arg2 an extra glycosylation site an extra glycosylation site site We therefore investigated the effects of adding an extra glycosylation site to the human gonadotropin-releasing hormone receptor, as a means for increasing its expression. 15264219 3 18 gly glycosylation 512:524 arg2 three putative N-linked glycosylation sites three putative N-linked glycosylation sites sites Although the N-terminal of the 5-HT3(A)R contains three putative N-linked glycosylation sites, the importance of each glycosylation site has not yet been established. 15264219 3 64 gly glycosylation 556:568 arg2 each glycosylation site each glycosylation site site Although the N-terminal of the 5-HT3(A)R contains three putative N-linked glycosylation sites, the importance of each glycosylation site has not yet been established. 25456591 8 85 gly glycosylation 1411:1423 arg2 26 glycosylation sites 26 glycosylation sites sites A total of 26 glycosylation sites each of which corresponds to 1-4 glycans were positively mapped and confirmed. 21727639 5 76 gly glycosylation 1016:1028 arg2 a new glycosylation site a new glycosylation site site Changes were observed in the N-glycosylation sites of both surface proteins, along with the appearance of a new glycosylation site in the neuraminidase sequence isolated in 2007. 21727639 5 16 gly N-glycosylation 933:947 arg2 the N-glycosylation sites proteins sites Fterm proteins sites Changes were observed in the N-glycosylation sites of both surface proteins, along with the appearance of a new glycosylation site in the neuraminidase sequence isolated in 2007. 15616124 10 37 gly N-glycosylation 1561:1575 arg1 a non-modified protein a non-modified protein Fterm protein This is the first documentation of posttranslational N-glycosylation of a non-modified protein in mammalian cells with an intact N-glycosylation machinery. 21661761 0 8 gly glycopeptides 17:29 arg2 glycopeptides glycopeptides glycopeptides Nano-LC-MS/MS of glycopeptides produced by nonspecific proteolysis enables rapid and extensive site-specific glycosylation determination. 9741100 8 53 gly heterogeneity 1156:1168 arg1 the pepsin cleavage site the pepsin cleavage site site By LC-MS peptide mapping these isoforms could be attributed to the heterogeneity of the pepsin cleavage site in the hinge region of the antibody. 15009203 14 33 gly N-glycosylation 2316:2330 arg2 a single N-glycosylation site a single N-glycosylation site site The major difference between both preparations was found in the MALDI spectra of the desialylated glycoproteins, revealing a higher proportion of forms with a single N-glycosylation site occupied in the preparation derived from suspension culture. 15009203 14 70 gly glycoproteins 2248:2260 arg1 the desialylated glycoproteins the desialylated glycoproteins Fterm glycoproteins The major difference between both preparations was found in the MALDI spectra of the desialylated glycoproteins, revealing a higher proportion of forms with a single N-glycosylation site occupied in the preparation derived from suspension culture. 15009203 14 144 gly desialylated 2235:2246 arg1 the desialylated glycoproteins the desialylated glycoproteins Fterm glycoproteins The major difference between both preparations was found in the MALDI spectra of the desialylated glycoproteins, revealing a higher proportion of forms with a single N-glycosylation site occupied in the preparation derived from suspension culture. 8626811 1 46 gly glycoprotein 130:141 arg1 The 43,000-Da glycoprotein The 43,000-Da glycoprotein Fterm glycoprotein The 43,000-Da glycoprotein (gp43) of Paracoccidioides brasiliensis is an immunodominant antigen for antibody-dependent and immune cellular responses in patients with paracoccidioidomycosis. 8626811 1 46 gly glycoprotein 130:141 arg1 gp43 gp43 Cterm gp43 The 43,000-Da glycoprotein (gp43) of Paracoccidioides brasiliensis is an immunodominant antigen for antibody-dependent and immune cellular responses in patients with paracoccidioidomycosis. 8702538 6 81 part_of CD22 1059:1062 arg1 the first immunoglobulin domain CD22 the first immunoglobulin domain PUBTATOR Site CD22 933 domain We show that mutation of a single potential N-linked glycosylation site in the first immunoglobulin domain of CD22 completely abrogates ligand recognition. 518919 0 0 gly site 82:85 arg1 the asialo-carbohydrate units site the asialo-carbohydrate units site The primary structure of the asialo-carbohydrate units of the first glycosylation site of human plasma alpha 1-acid glycoprotein. 518919 0 41 gly glycoprotein 116:127 arg1 human plasma alpha 1-acid glycoprotein human plasma alpha 1-acid glycoprotein Fterm glycoprotein The primary structure of the asialo-carbohydrate units of the first glycosylation site of human plasma alpha 1-acid glycoprotein. 518919 0 11 gly glycosylation 68:80 arg1 human plasma alpha 1-acid glycoprotein glycoprotein site Fterm glycoprotein site The primary structure of the asialo-carbohydrate units of the first glycosylation site of human plasma alpha 1-acid glycoprotein. 12626422 0 36 gly underglycosylation 4:21 arg1 plasma alpha 1-antitrypsin plasma alpha 1-antitrypsin PUBTATOR alpha 1-antitrypsin 5265 The underglycosylation of plasma alpha 1-antitrypsin in congenital disorders of glycosylation type I is not random. 9820842 4 55 part_of US5 628:630 arg1 synthetic US5 peptides US5 synthetic US5 peptides PUBTATOR Site US5 2703406 peptides Western blotting, using polyclonal antibody raised against synthetic US5 peptides, revealed two major baculovirus-US5-expressed protein bands with apparent molecular weights of 16-17 and 10 kD. 27506355 5 57 gly glycopeptide 610:621 arg2 the glycopeptide fragmentation prediction tool the glycopeptide fragmentation prediction tool glycopeptide Methods2008, 5, 873-875), and the glycopeptide fragmentation prediction tool, MassAnalyzer (Zhang et al. 7904345 4 39 gly structures 964:973 arg1 a protein protein structures Fterm protein These and other analyses of sCD2 expressed in CHO cells and Thy-1 purified from various tissues suggest that the diversity of oligosaccharide structures on a protein is regulated by the location of the glycosylation sites and the nature of the target protein, cell and tissue. 7904345 4 55 gly glycosylation 1024:1036 arg2 the glycosylation sites the glycosylation sites sites These and other analyses of sCD2 expressed in CHO cells and Thy-1 purified from various tissues suggest that the diversity of oligosaccharide structures on a protein is regulated by the location of the glycosylation sites and the nature of the target protein, cell and tissue. 26773038 1 3 part_of factor 136:141 arg1 the von Willebrand factor (VWF) A2 domain von Willebrand factor the von Willebrand factor (VWF) A2 domain PUBTATOR Site von Willebrand factor 7450 domain Shear forces in the blood trigger a conformational transition in the von Willebrand factor (VWF) A2 domain, from its native folded to an unfolded state, in which the cryptic scissile bond (Y1605-M1606) is exposed and can then be proteolysed by ADAMTS13. 9295302 9 87 gly N-Glycosylation 1419:1433 arg1 Asn23 Asn19 and Asn23 Asn19 and Asn23 N-Glycosylation of Asn19 and Asn23 provides the first direct experimental evidence that MRP has an extracytosolic NH2 terminus. 23894062 8 56 part_of SOST 1039:1042 arg1 a SOST peptide SOST a SOST peptide PUBTATOR Site SOST 50964 peptide We showed a SOST peptide (SOST-S146, with homology to a bacterial glycotransferase peptide) binds to a NOG peptide (NOG-N54), which contains a N-glycosylation site. 23894062 8 94 part_of NOG 1130:1132 arg1 NOG-N54 NOG NOG-N54 PUBTATOR SpecificSite NOG 9241 N54 We showed a SOST peptide (SOST-S146, with homology to a bacterial glycotransferase peptide) binds to a NOG peptide (NOG-N54), which contains a N-glycosylation site. 23894062 8 94 part_of NOG 1130:1132 arg1 a NOG peptide NOG a NOG peptide PUBTATOR Site NOG 9241 peptide We showed a SOST peptide (SOST-S146, with homology to a bacterial glycotransferase peptide) binds to a NOG peptide (NOG-N54), which contains a N-glycosylation site. 23894062 8 68 part_of contains 1159:1166 arg1 a NOG peptide AND a N-glycosylation site NOG site PUBTATOR Site NOG 9241 site We showed a SOST peptide (SOST-S146, with homology to a bacterial glycotransferase peptide) binds to a NOG peptide (NOG-N54), which contains a N-glycosylation site. 21569239 3 9 part_of found 518:522 arg2 amphiF-spondin AND The FS domain amphiF-spondin The FS domain Fterm Site amphiF-spondin 10418 domain The FS domain is found in F-spondins, mindins, M-spondin and amphiF-spondin. 21569239 3 9 part_of found 518:522 arg2 M-spondin AND The FS domain M-spondin The FS domain PUBTATOR Site M-spondin 10417 domain The FS domain is found in F-spondins, mindins, M-spondin and amphiF-spondin. 18416605 5 27 gly glycosylation 1023:1035 arg2 each glycosylation site each glycosylation site site We have further dissected the requirement of each glycosylation site and have shown that different TSE strains have dramatically different requirements for each of the glycosylation sites of host PrP, and moreover, we have shown that the host PrP has a major role in determining the glycosylation state of de novo generated PrP(Sc). 18416605 5 58 gly glycosylation 1256:1268 arg1 Sc Sc Cterm Sc Q9NP58 We have further dissected the requirement of each glycosylation site and have shown that different TSE strains have dramatically different requirements for each of the glycosylation sites of host PrP, and moreover, we have shown that the host PrP has a major role in determining the glycosylation state of de novo generated PrP(Sc). 18416605 5 58 gly glycosylation 1256:1268 arg1 de novo generated PrP de novo generated PrP OGER PrP Q9NP58 We have further dissected the requirement of each glycosylation site and have shown that different TSE strains have dramatically different requirements for each of the glycosylation sites of host PrP, and moreover, we have shown that the host PrP has a major role in determining the glycosylation state of de novo generated PrP(Sc). 18416605 5 46 gly glycosylation 1141:1153 arg2 the glycosylation sites PrP sites OGER PrP Q9NP58 sites We have further dissected the requirement of each glycosylation site and have shown that different TSE strains have dramatically different requirements for each of the glycosylation sites of host PrP, and moreover, we have shown that the host PrP has a major role in determining the glycosylation state of de novo generated PrP(Sc). 27612916 6 86 gly N-glycosylation 1037:1051 arg2 a putative N-glycosylation motif NX(S/T) a putative N-glycosylation motif NX(S/T) motif This amino acid change was predicted to create a putative N-glycosylation motif NX(S/T) subsequently validated upon endoglycosidase H treatment of microsomal fractions and inhibition of N-glycosylation of endogenously produced UGT2B7 with tunicamycin in human embryonic kidney (HEK293) cells. 27612916 6 111 gly N-glycosylation 1165:1179 arg1 endogenously produced UGT2B7 endogenously produced UGT2B7 PUBTATOR UGT2B7 7364 This amino acid change was predicted to create a putative N-glycosylation motif NX(S/T) subsequently validated upon endoglycosidase H treatment of microsomal fractions and inhibition of N-glycosylation of endogenously produced UGT2B7 with tunicamycin in human embryonic kidney (HEK293) cells. 29333671 4 1 gly glycoprotein 724:735 arg1 α1 -acid glycoprotein α1 -acid glycoprotein Fterm glycoprotein Additionally, the glycomic analysis of fetuin, α1 -acid glycoprotein, and human serum N-glycome also indicated the relatively higher sensitivity, selectivity, and glycoform coverage of dextran-bonded silica than that of Sepharose and porous graphitized carbon. 24627221 4 32 gly N-glycosylation 837:851 arg2 an N-glycosylation site an N-glycosylation site site This missense SNP results in the N38S amino acid change and a loss of an N-glycosylation site. 21978153 5 36 part_of had 951:953 arg1 the HA, neuraminidase (NA), and nucleoprotein (NP) proteins AND highly conserved CTL epitopes the HA, neuraminidase (NA), and nucleoprotein (NP) proteins highly conserved CTL epitopes Fterm Site proteins epitopes Compared to seasonal H1N1 vaccine strains from 1999 to 2010, the HA, neuraminidase (NA), and nucleoprotein (NP) proteins of the isolates had highly conserved CTL epitopes (60.5-65.8%, 69.6-82.6%, and 76.7%, respectively). 32280962 2 11 gly glycosylation 390:402 arg2 seven potential N-linked glycosylation sites seven potential N-linked glycosylation sites sites PSG1 has seven potential N-linked glycosylation sites across its four domains. 12069081 5 7 part_of fVEGF 638:642 arg1 predicted fVEGF polypeptide fVEGF predicted fVEGF polypeptide Cterm Site fVEGF 7422 polypeptide Though predicted fVEGF polypeptide was two amino acid residues shorter than human VEGF165, a potential glycosylation site and regions critical for receptor binding were conserved in all the species examined. 18085777 0 39 gly glycoprotein 24:35 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Chemical synthesis of a glycoprotein having an intact human complex-type sialyloligosaccharide under the Boc and Fmoc synthetic strategies. 11258925 2 19 gly glycoprotein 176:187 arg1 a glycoprotein a glycoprotein Fterm glycoprotein It is a glycoprotein located in the endoplasmic reticulum and in the nuclear envelope, and it has been found to have two isoforms termed COX-1 and COX-2. 1402806 9 8 gly N-glycosylation 1543:1557 arg1 the S and HE structural proteins the S and HE structural proteins Fterm proteins Thus, inhibition of the N-glycosylation of the S and HE structural proteins prevented their incorporation into progeny virions, an indication that they are dispensable for virion morphogenesis, unlike the M protein. 3455414 4 7 part_of carrying 551:558 arg1 an extracellular domain AND an N glycosylation site an extracellular domain an N glycosylation site site These c-ros DNAs contained a tyrosine kinase domain, transmembrane domain and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus. 3455414 4 81 part_of kinase 477:482 arg1 a tyrosine kinase domain kinase domain Fterm Site kinase domain These c-ros DNAs contained a tyrosine kinase domain, transmembrane domain and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus. 3455414 4 45 part_of contained 456:464 arg1 These c-ros DNAs AND an extracellular domain ros DNAs domain OGER Site ros DNAs Q63132 domain These c-ros DNAs contained a tyrosine kinase domain, transmembrane domain and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus. 3455414 4 45 part_of contained 456:464 arg1 These c-ros DNAs AND a tyrosine kinase domain ros DNAs domain OGER Site ros DNAs Q63132 domain These c-ros DNAs contained a tyrosine kinase domain, transmembrane domain and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus. 3455414 4 45 part_of contained 456:464 arg1 These c-ros DNAs AND a tyrosine kinase domain ros DNAs domain OGER Site ros DNAs Q63132 domain These c-ros DNAs contained a tyrosine kinase domain, transmembrane domain and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus. 11344537 0 40 gly glycosylation 24:36 arg2 glycosylation sites glycosylation sites sites Direct determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight mass spectrometry. 11344537 0 81 gly glycopeptides 61:73 arg2 O-fucosylated glycopeptides O-fucosylated glycopeptides glycopeptides Direct determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight mass spectrometry. 11344537 0 84 gly O-fucosylated 47:59 arg1 O-fucosylated glycopeptides O-fucosylated glycopeptides glycopeptides Direct determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight mass spectrometry. 8236140 1 41 part_of contains 162:169 arg1 a t-PA variant AND an additional glycosylation site a t-PA variant an additional glycosylation site PUBTATOR Site t-PA variant 25692 site Site directed mutagenesis was used to construct a t-PA variant that contains an additional glycosylation site in the first kringle domain (T103N) combined with a tetra-alanine substitution in the protease domain (KHRR 296-299 AAAA). 6300470 5 51 gly glycoprotein 789:800 arg1 the heterogeneous glycoprotein the heterogeneous glycoprotein Fterm glycoprotein The MCF virus produced gp69, and the ecotropic virus produced gp71, explaining the origin of the heterogeneous glycoprotein (gp69 and gp71) of Rauscher leukemia virus. 8706738 13 33 gly deglycosylated 1651:1664 arg1 the completely deglycosylated Gal-T the completely deglycosylated Gal-T The O-glycans could be removed by jack bean alpha-mannosidase treatment and the completely deglycosylated Gal-T appeared homogeneous by IEF. 28928219 3 43 gly glycosylation 703:715 arg2 that position position position Prolyl hydroxylation of Skp1 contributes to O2-dependent Dictyostelium development, but full glycosylation at that position is required for optimal O2 sensing. 29932112 6 25 gly N-glycosylation 862:876 arg2 the only N-glycosylation site Panx2 site PUBTATOR Panx2 56666 site Our results showed that N86 is the only N-glycosylation site of Panx2. 29932112 6 25 gly N-glycosylation 862:876 arg2 N86 Panx2 N86 PUBTATOR Panx2 56666 N86 Our results showed that N86 is the only N-glycosylation site of Panx2. 8772226 9 46 gly N-glycosylation 1417:1431 arg2 a N-glycosylation site a N-glycosylation site site The presence of Ser at position 186 introduces a consensus sequence for a N-glycosylation site (Asn-X-Ser/Thr). 8772226 9 53 gly site 1433:1436 arg1 Asn-X-Ser/Thr Asn-X-Ser/Thr Asn The presence of Ser at position 186 introduces a consensus sequence for a N-glycosylation site (Asn-X-Ser/Thr). 23919378 7 15 gly N-glycosylation 1325:1339 arg2 one possible N-glycosylation site one possible N-glycosylation site site Moreover, bioinformatics analyses showed approximately 8 putative phosphorylation sites and one possible N-glycosylation site, suggesting its regulation by post-translational modifications. 27007620 2 5 gly glycoproteins 207:219 arg1 glycoproteins appealing targets glycoproteins appealing targets Fterm glycoproteins This makes glycoproteins appealing targets as potential biomarkers and focal points of molecular studies on the development and progression of human ailment. 19116267 0 42 part_of receptor 46:53 arg1 H5N1 influenza virus hemagglutinin receptor binding domain receptor H5N1 influenza virus hemagglutinin receptor binding domain Fterm Site receptor domain Changes in H5N1 influenza virus hemagglutinin receptor binding domain affect systemic spread. 19116267 0 84 part_of hemagglutinin 32:44 arg1 H5N1 influenza virus hemagglutinin receptor binding domain hemagglutinin H5N1 influenza virus hemagglutinin receptor binding domain Fterm Site hemagglutinin domain Changes in H5N1 influenza virus hemagglutinin receptor binding domain affect systemic spread. 8829802 2 18 part_of transferrin 437:447 arg1 the entire coding region transferrin the entire coding region PUBTATOR Site transferrin 24825 region To compare the structure of rat transferrin to that of transferrins and lactoferrins in other species, we isolated a cDNA clone containing the entire coding region of transferrin from rat liver and determined its sequence. 2747653 2 41 part_of mRNAs 453:457 arg1 the cDNA sequence albumin mRNAs sequence PUBTATOR Site albumin mRNAs 24186 sequence The present study reports the cDNA sequence of both the 68K and 74K Xenopus albumin mRNAs, their derived amino acid sequence, and the regulation of albumin gene expression during embryogenesis. 30147434 7 77 gly glycoproteins 1277:1289 arg1 glycoproteins glycoproteins Fterm glycoproteins We comprehensively compared the performance of the two methods in the identification and quantification of glycoproteins in statin-treated liver cells. 14691230 2 58 part_of peptidases 494:503 arg1 a prerequisite peptidases a prerequisite OGER Site peptidases P28838 prerequisite It has been generally accepted that glycosylation of DPPIV and of other transmembrane dipeptidyl peptidases is a prerequisite for enzyme activity and correct protein folding. 14691230 2 65 part_of DPPIV 450:454 arg1 a prerequisite DPPIV a prerequisite PUBTATOR Site DPPIV 1803 prerequisite It has been generally accepted that glycosylation of DPPIV and of other transmembrane dipeptidyl peptidases is a prerequisite for enzyme activity and correct protein folding. 22257732 2 92 gly glycoprotein 479:490 arg1 a cell surface acidic glycoprotein molecule a cell surface acidic glycoprotein molecule Fterm glycoprotein The active component of SRBC, which is responsible for such effects, was found to be a cell surface acidic glycoprotein molecule, known as T11 target structure (T11TS). 27035572 4 5 part_of HA1 726:728 arg1 HA1 domain HA1 HA1 domain OGER Site HA1 domain Four non-synonymous substitutions, three localizing at antigenic sites T144A, A; R158G, B; L173S, D, and one H9Y in close proximity to a potential glycosylation site aa8 in HA1 domain along with the substitution T329N in NA are likely to influence the antigenicity/virulence of Mo/H3N2 viruses. 12954207 4 7 part_of CD4 717:719 arg1 CD4 binding site CD4 CD4 binding site PUBTATOR Site CD4 920 site These antibodies are known as CD4 binding site (CD4BS) and CD4-induced (CD4i) antibodies, respectively. 10585855 1 46 part_of Asn-642 287:293 arg1 a multispanning membrane protein protein Asn-642 Fterm SpecificSite protein Asn-642 The red-cell anion exchanger (band 3; AE1) is a multispanning membrane protein that traverses the bilayer up to 14 times and is N-glycosylated at Asn-642. 8797097 9 16 gly subunit 1844:1850 arg1 the carbohydrate chain subunit the carbohydrate chain Fterm subunit The present data suggest that (1) amino acids 87-105 of the inhibin/activin beta A subunit are located on the molecular surface, although this region of inhibin-A is concealed by the carbohydrate chain of the alpha subunit, (2) the region responsible for follistatin binding within the activin beta A subunit is spanned by amino acids 87-105, and (3) the mode of binding of inhibin-A to follistatin is quite different from that of activin-A to follistatin, and the former may be influenced by glycosylation. 30605224 8 34 gly glycoproteins 1218:1230 arg1 glycoproteins glycoproteins Fterm glycoproteins The last part of this review focuses on the applications of MS-based proteomics to study glycoproteins in different biological systems, including yeasts, plants, mice, human cells, and clinical samples. 19961828 3 43 gly N-glycosylation 470:484 arg2 one potential N-glycosylation site one potential N-glycosylation site site Each isoform contains one potential N-glycosylation site located along the S1-S2 linker; immunoblot analyses verified that K(v)1.4 and K(v)1.5 were N-glycosylated. 17055129 3 26 part_of E2 432:433 arg1 the epitopes aa481-500 and aa551-570 E2 the epitopes aa481-500 and aa551-570 Cterm Site E2 epitopes Previous studies showed that the epitopes aa481-500 and aa551-570 of E2 might be important for immunoreactivity and that the binding site of E2 for hCD81 is located at aa480-493 and aa544-551 within the E2 protein. 17055129 3 33 part_of located 520:526 arg2 the E2 protein AND the binding site the E2 protein the binding site Fterm Site protein site Previous studies showed that the epitopes aa481-500 and aa551-570 of E2 might be important for immunoreactivity and that the binding site of E2 for hCD81 is located at aa480-493 and aa544-551 within the E2 protein. 17055129 3 77 part_of E2 504:505 arg1 the binding site E2 the binding site Cterm Site E2 site Previous studies showed that the epitopes aa481-500 and aa551-570 of E2 might be important for immunoreactivity and that the binding site of E2 for hCD81 is located at aa480-493 and aa544-551 within the E2 protein. 25224661 6 41 gly N-glycosylation 1072:1086 arg2 a putative N-glycosylation site a putative N-glycosylation site site RESULTS: Genetic analysis of full length genome revealed two hypervariable regions (HVR) in E2 region - HVR496 and HVR576, with a variable 5-8 amino-acid insertion sequence and a putative N-glycosylation site. 8207403 5 83 gly glycosylation 963:975 arg2 the glycosylation site the glycosylation site site Removal of the glycosylation site at position 642 resulted in the synthesis of precursor gp160 that was neither cleaved, to give gp120 and gp41, nor transported to the plasma membrane of transfected cells. 29932112 1 1 gly glycoproteins 147:159 arg1 channel-forming glycoproteins channel-forming glycoproteins Fterm glycoproteins Pannexins (Panx1, 2, 3) are channel-forming glycoproteins expressed in mammalian tissues. 29932112 1 1 gly glycoproteins 147:159 arg1 Pannexins Pannexins PUBTATOR Pannexins (Panx1 24145 Pannexins (Panx1, 2, 3) are channel-forming glycoproteins expressed in mammalian tissues. 22292921 3 37 part_of DC-SIGN 516:522 arg1 domain/motif DC-SIGN domain/motif PUBTATOR Site DC-SIGN Q9NNX6 domain/motif To determine which domain/motif of DC-SIGN facilitates its presence in microdomains, we studied mutations at key locations including truncation of the cytoplasmic tail, and ectodomain mutations that resulted in the removal of the N-linked glycosylation site, the tandem repeats and the carbohydrate recognition domain (CRD), as well as modification of the calcium sites in the CRD required for carbohydrate binding. 21774247 8 38 part_of protein 1228:1234 arg1 one glycosylation site protein one glycosylation site Fterm Site protein site Furthermore, one glycosylation site of HA protein and NA protein were changed respectively. 21774247 8 81 part_of protein 1213:1219 arg1 one glycosylation site protein one glycosylation site Fterm Site protein site Furthermore, one glycosylation site of HA protein and NA protein were changed respectively. 15890930 4 71 part_of CD4-binding 1011:1021 arg1 CD4-binding domains CD4 CD4-binding domains PUBTATOR Site CD4 920 domains C108g effectively neutralized both variant Envs with considerably higher potency than standard MAbs against the V3 and CD4-binding domains and the broadly neutralizing MAbs 2G12 and 2F5. 17986444 3 24 gly N-glycosylation 521:535 arg2 the two NCAM N-glycosylation sites the two NCAM N-glycosylation sites sites Previous in vitro studies defined differences between the two enzymes in their usage of the two NCAM N-glycosylation sites affected and suggested a synergistic effect. 9235960 7 16 gly N-glycosylation 1343:1357 arg1 a fully folded exogenous protein a fully folded exogenous protein Fterm protein Our results document the existence of a continuous pathway from the plasma membrane to the endoplasmic reticulum via the Golgi apparatus and show that a fully folded exogenous protein arriving in the endoplasmic reticulum via this pathway can undergo N-glycosylation. 28835497 10 19 gly determinants 1997:2008 arg1 the amino terminus the amino terminus the amino terminus Site terminus These results demonstrate a critical role for the N glycosylation sites and cysteines for the structure and function of the amino terminus of gK.IMPORTANCE We have previously identified important entry and neurotropic determinants in the amino terminus of HSV-1 glycoprotein K (gK). 28835497 10 77 gly glycosylation 1831:1843 arg2 the N glycosylation sites the N glycosylation sites sites and cysteines These results demonstrate a critical role for the N glycosylation sites and cysteines for the structure and function of the amino terminus of gK.IMPORTANCE We have previously identified important entry and neurotropic determinants in the amino terminus of HSV-1 glycoprotein K (gK). 28835497 10 97 gly entry 1975:1979 arg1 the amino terminus the amino terminus the amino terminus Site terminus These results demonstrate a critical role for the N glycosylation sites and cysteines for the structure and function of the amino terminus of gK.IMPORTANCE We have previously identified important entry and neurotropic determinants in the amino terminus of HSV-1 glycoprotein K (gK). 28835497 10 115 gly glycoprotein 2041:2052 arg1 HSV-1 glycoprotein K HSV-1 glycoprotein K Cterm HSV-1 glycoprotein K (gK These results demonstrate a critical role for the N glycosylation sites and cysteines for the structure and function of the amino terminus of gK.IMPORTANCE We have previously identified important entry and neurotropic determinants in the amino terminus of HSV-1 glycoprotein K (gK). 23829323 3 4 gly N-glycopeptide 684:697 arg2 direct N-glycopeptide analysis direct N-glycopeptide analysis N-glycopeptide However, successful implementation of direct N-glycopeptide analysis by tandem mass spectrometry remains a challenge. 27127844 6 3 gly glycosylation 827:839 arg2 the putative glycosylation site the putative glycosylation site site We transfected HEK 293 cells, using the pCDNA3.1 expression-vector system, to express cDNA constructs of epitope-tagged human a4 subunit, with or without mutations to eliminate the putative glycosylation site. 23908491 10 56 gly glycosylation 1280:1292 arg2 this new HVR495 glycosylation site this new HVR495 glycosylation site site Importantly, HCVpp and HCVcc that contained this new HVR495 glycosylation site were less sensitive to antibody neutralization. 8960909 4 63 part_of possesses 785:793 arg1 One such antigenic epitope AND an N-linked glycosylation site One such antigenic epitope an N-linked glycosylation site site One such antigenic epitope, corresponding to amino acids 369-377 of the enzyme tyrosinase, possesses an N-linked glycosylation site. 12706347 4 51 gly glycosylation 670:682 arg2 these putative glycosylation sites these putative glycosylation sites sites, asparagine 81 Only one of these putative glycosylation sites, asparagine 81 in NTPDase3, which is located near apyrase conserved region 1 (ACR1), is invariant in all the cell surface membrane eNTPDases. 15582650 8 73 gly glycosylation 1633:1645 arg1 modified HIV Env proteins HIV Env proteins domains PUBTATOR HIV Env proteins 100616444 domains Our study suggests that modified HIV Env proteins with reduced glycosylation in domains surrounding the CD4 binding site or variable loop-deleted mutants expose important neutralizing epitopes at higher levels than wild type and may provide novel vaccine immunogens. 15582650 8 101 gly glycosylation 1633:1645 arg1 domains domains domains Our study suggests that modified HIV Env proteins with reduced glycosylation in domains surrounding the CD4 binding site or variable loop-deleted mutants expose important neutralizing epitopes at higher levels than wild type and may provide novel vaccine immunogens. 15582650 8 101 gly glycosylation 1633:1645 arg1 domains HIV Env proteins domains PUBTATOR HIV Env proteins 100616444 domains Our study suggests that modified HIV Env proteins with reduced glycosylation in domains surrounding the CD4 binding site or variable loop-deleted mutants expose important neutralizing epitopes at higher levels than wild type and may provide novel vaccine immunogens. 2808434 1 99 gly glycosylated 104:115 arg1 a glycosylated rat liver esterase a glycosylated rat liver esterase Fterm esterase Purification, characterization, and properties of a glycosylated rat liver esterase specific for 9-O-acetylated sialic acids. 10551860 4 6 part_of 74-122 619:624 arg1 ovine PGHS-1 PGHS-1 74-122 PUBTATOR SpecificSite PGHS-1 5742 residues 74-122 X-ray crystallographic studies have led to the hypothesis that PGHS-1 and -2 associate with only one face of the membrane bilayer through a novel, monotopic membrane binding domain (MBD) that is comprised of four short, consecutive, amphipathic alpha-helices (helices A-D) that include residues 74-122 in ovine PGHS-1 (oPGHS-1) and residues 59-108 in human PGHS-2 (hPGHS-2). 10551860 4 54 part_of residues 610:617 arg1 hPGHS-2 hPGHS-2 residues PUBTATOR SpecificSite hPGHS-2 5743 residues 74-122 X-ray crystallographic studies have led to the hypothesis that PGHS-1 and -2 associate with only one face of the membrane bilayer through a novel, monotopic membrane binding domain (MBD) that is comprised of four short, consecutive, amphipathic alpha-helices (helices A-D) that include residues 74-122 in ovine PGHS-1 (oPGHS-1) and residues 59-108 in human PGHS-2 (hPGHS-2). 10551860 4 54 part_of residues 610:617 arg1 human PGHS-2 PGHS-2 residues PUBTATOR SpecificSite PGHS-2 5743 residues 74-122 X-ray crystallographic studies have led to the hypothesis that PGHS-1 and -2 associate with only one face of the membrane bilayer through a novel, monotopic membrane binding domain (MBD) that is comprised of four short, consecutive, amphipathic alpha-helices (helices A-D) that include residues 74-122 in ovine PGHS-1 (oPGHS-1) and residues 59-108 in human PGHS-2 (hPGHS-2). 10551860 4 92 part_of residues 656:663 arg1 hPGHS-2 hPGHS-2 residues PUBTATOR SpecificSite hPGHS-2 5743 residues 59-108 X-ray crystallographic studies have led to the hypothesis that PGHS-1 and -2 associate with only one face of the membrane bilayer through a novel, monotopic membrane binding domain (MBD) that is comprised of four short, consecutive, amphipathic alpha-helices (helices A-D) that include residues 74-122 in ovine PGHS-1 (oPGHS-1) and residues 59-108 in human PGHS-2 (hPGHS-2). 10551860 4 92 part_of residues 656:663 arg1 human PGHS-2 PGHS-2 residues PUBTATOR SpecificSite PGHS-2 5743 residues 59-108 X-ray crystallographic studies have led to the hypothesis that PGHS-1 and -2 associate with only one face of the membrane bilayer through a novel, monotopic membrane binding domain (MBD) that is comprised of four short, consecutive, amphipathic alpha-helices (helices A-D) that include residues 74-122 in ovine PGHS-1 (oPGHS-1) and residues 59-108 in human PGHS-2 (hPGHS-2). 17715132 3 18 gly N-glycosylated 480:493 arg1 Pannexin1 Pannexin1 PUBTATOR Pannexin1 24145 We show here that Pannexin1 forms a hexameric channel and reaches the cell surface but, unlike connexins, is N-glycosylated. 7532209 2 76 part_of has 419:421 arg1 The receptor subunit protein AND five putative N-glycosylation sites The receptor subunit protein five putative N-glycosylation sites Fterm Site protein sites The receptor subunit protein has five putative N-glycosylation sites. 23289760 6 80 gly N-glycosylation 1233:1247 arg2 potential N-glycosylation site potential N-glycosylation site site The neutralization sensitivity of HIV-1 B' isolates was inversely correlated with the neutralizing activity of plasmas from HIV-1 B'-infected patients (Spearman's r = -0.657, P = 0.020), and with the number of potential N-glycosylation site (PNGS) in V1-V5 region (Spearman's r = -0.493, P = 0.034), but positively correlated with the viral load (Spearman's r = 0.629, P = 0.028). 7916636 4 39 part_of contain 471:477 arg1 urinary kallikrein AND a Lys-162 urinary kallikrein a Lys-162 PUBTATOR SpecificSite kallikrein 9622 Lys-162 The human kallikrein gene and urinary kallikrein both contain a Lys-162 instead of the reported Glu-162. 12372996 4 13 gly glycosylation 315:327 arg1 this Asn residue this Asn residue Asn residue Heterogeneous glycosylation of this Asn residue could be a source of the multiplicity of natural Hev b 2. 22279061 12 38 gly SREC-I 1794:1799 arg1 Asn(289)-, Asn(382)- and Asn(393)-linked N-glycans SREC-I Asn(289)-, Asn(382)- and Asn(393)-linked N-glycans OGER SREC-I Q14162 These data indicate that Asn(289)-, Asn(382)- and Asn(393)-linked N-glycans of SREC-I have distinct functions in regulating proteolytic resistance, ligand-binding affinity and subcellular localization, all of which might be involved in the development of atherogenesis. 10837482 6 57 gly glycosylation 1301:1313 arg2 all the potential glycosylation sites all the potential glycosylation sites sites When all the potential glycosylation sites on a truncated form of meprin alpha (alpha-(1-445)) were mutated, the protein was not secreted into the medium, but was retained within the cells even after 10 h. 22511783 7 46 part_of IFITM3 1161:1166 arg1 IFITM3 ubiquitination sites IFITM3 IFITM3 ubiquitination sites OGER Site IFITM3 Q01628 sites Our characterization of IFITM3 ubiquitination sites also challenges the dual-pass membrane topology predicted for this protein family. 25629924 8 40 part_of site 1487:1490 arg1 milk sIgA IgA site Cterm Site IgA P11912 site This represents the most comprehensive report to date detailing the complexity of glycan micro-heterogeneity with relative quantitation of glycoforms for each glycosylation site on milk sIgA. 24884609 6 1 gly N-glycoforms 998:1009 arg1 ITIH4 N-glycoforms ITIH4 N-glycoforms PUBTATOR ITIH4 3700 Next, we performed glycosidase-assisted LC-MS/MS analysis of ITIH4 trypsin-GluC glycopeptides enriched via hydrophilic interaction liquid chromatography to characterize ITIH4 N-glycoforms. 24884609 6 11 gly glycopeptides 903:915 arg2 ITIH4 trypsin-GluC glycopeptides ITIH4 trypsin-GluC glycopeptides glycopeptides Next, we performed glycosidase-assisted LC-MS/MS analysis of ITIH4 trypsin-GluC glycopeptides enriched via hydrophilic interaction liquid chromatography to characterize ITIH4 N-glycoforms. 32258897 7 33 gly arm 1183:1185 arg1 outer arm fucose outer arm fucose N-glycans consisted of a mixture of bi-, tri-, and tetra-antennary glycans, some with N-acetyllactosamine extensions, but neither outer arm fucose nor α-galactose was detected. 23714211 11 18 gly glycosylation 1839:1851 arg2 glycosylation sites glycosylation sites sites We used site-directed mutagenesis to express hypo- or non-glycosylated variants of ICAM-2, by substituting alanine for asparagine at glycosylation sites, and compared the impact of each variant on NB cell motility, anchorage-independent growth, interaction with intracellular proteins, effect on F-actin distribution and metastatic potential in vivo. 23714211 11 57 gly non-glycosylated 1760:1775 arg1 hypo- or non-glycosylated variants hypo- or non-glycosylated variants Fterm variants We used site-directed mutagenesis to express hypo- or non-glycosylated variants of ICAM-2, by substituting alanine for asparagine at glycosylation sites, and compared the impact of each variant on NB cell motility, anchorage-independent growth, interaction with intracellular proteins, effect on F-actin distribution and metastatic potential in vivo. 15811651 1 18 gly glycoproteins 174:186 arg1 two membrane glycoproteins two membrane glycoproteins Fterm glycoproteins The tick-borne encephalitis (TBE) virus has two membrane glycoproteins (prM and E), which each has one N-linked glycan. 16200726 8 108 part_of Asn342 1462:1467 arg1 tree shrew protein protein Asn342 Fterm AminoAcid protein Asn342 However, there is a deletion of N-linked glycosylation site at Asn342 in tree shrew protein that may increase the ability of removing peripheral cholesterol and cholesteryl ester. 9690810 9 5 part_of glycoprotein 970:981 arg1 a leucine-rich glycoprotein sequence glycoprotein a leucine-rich glycoprotein sequence Fterm Site glycoprotein sequence Mouse GPIX contained a leucine-rich glycoprotein sequence composed of 24 amino acids, as did human GPIX. 9690810 9 27 part_of contained 945:953 arg1 Mouse GPIX AND a leucine-rich glycoprotein sequence Mouse GPIX a leucine-rich glycoprotein sequence PUBTATOR Site Mouse GPIX 54368 sequence Mouse GPIX contained a leucine-rich glycoprotein sequence composed of 24 amino acids, as did human GPIX. 22292921 4 42 gly glycosylation 1026:1038 arg2 the N-linked glycosylation site the N-linked glycosylation site site Confocal imaging and fluorescence recovery after photobleaching measurements showed that the cytoplasmic domain and the N-linked glycosylation site do not affect the ability of DC-SIGN to form stable microdomains. 9254646 1 46 gly nucleoprotein 347:359 arg1 a H-2Kd-restricted determinant nucleoprotein a H-2Kd-restricted determinant Fterm nucleoprotein We found that the presentation of a H-2Kd-restricted determinant from influenza virus nucleoprotein (NP) to T cells is strictly dependent on expression of the transporter associated with antigen presentation (TAP), regardless of whether NP is expressed as a cytosolic or secreted NP (SNP). 9342662 2 83 gly glycopeptide 428:439 arg2 glycopeptide identification glycopeptide identification glycopeptide Capillary electrophoresis (CE) has been employed for peptide mapping of the IgG heavy chain and glycopeptide identification. 24931470 1 11 gly glycoprotein 71:82 arg1 Env Env PUBTATOR Env 100616444 The HIV envelope glycoprotein (Env) trimer undergoes receptor-induced conformational changes that drive fusion of the viral and cellular membranes. 24931470 1 11 gly glycoprotein 71:82 arg1 HIV envelope glycoprotein HIV envelope glycoprotein PUBTATOR HIV envelope glycoprotein 155971 The HIV envelope glycoprotein (Env) trimer undergoes receptor-induced conformational changes that drive fusion of the viral and cellular membranes. 19800422 1 46 part_of containing 168:177 arg1 a type II transmembrane serine protease AND one potential site a type II transmembrane serine protease one potential site Fterm Site protease site Matriptase is a type II transmembrane serine protease containing one potential site for asparagine-linked glycosylation (N-glycosylation) on the catalytic domain (Asn772). 19800422 1 46 part_of containing 168:177 arg1 Matriptase AND one potential site Matriptase one potential site PUBTATOR Site Matriptase Q9Y5Y6 site Matriptase is a type II transmembrane serine protease containing one potential site for asparagine-linked glycosylation (N-glycosylation) on the catalytic domain (Asn772). 31572358 12 82 gly N-glycosylation 2019:2033 arg2 N-glycosylation sites N-glycosylation sites sites Our analyses revealed an abundance of N-glycosylation sites in ACPA-IgG HC that frequently required multiple mutations and predominated in specific positions. 18076768 4 20 part_of gp120 1067:1071 arg1 the C3 region gp120 the C3 region PUBTATOR Site gp120 3700 region Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs. 18076768 4 52 part_of CD4-binding 1013:1023 arg1 CD4-binding site (CD4bs) residues CD4 CD4-binding site (CD4bs) residues PUBTATOR AminoAcid CD4 920 residues in Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs. 14985108 0 24 gly Glycosylation 0:12 arg1 onconase onconase Fterm onconase Glycosylation of onconase increases its conformational stability and toxicity for cancer cells. 23991039 5 14 part_of Env 919:921 arg1 at least the C2 region Env at least the C2 region PUBTATOR Site Env 100616444 region In binding experiments using monomeric gp120s of select resistant isolates and domain-swap chimeras between JR-FL and JR-CSF, recognition by 1F7 was limited by sequence polymorphisms involving at least the C2 region of Env. 8626443 1 1 gly unglycosylated 338:351 arg1 enzymatically active ACET proteins enzymatically active ACET proteins Fterm proteins For facilitating crystallization and structural studies of the testicular isozyme of angiotensin-converting enzyme (ACE,), we attempted the production of enzymatically active ACET proteins which are unglycosylated or underglycosylated. 23326351 7 2 part_of sites 1220:1224 arg1 Env Env sites PUBTATOR Site Env 100616444 sites The JR-CSF gp120 epitopes recognized by the sera are generally distinct from those of several well characterized mAbs (targeting conserved sites on Env) or other type-specific responses (targeting V1, V2, or V3 variable regions). 23326351 7 50 part_of JR-CSF 1085:1090 arg1 The JR-CSF gp120 epitopes CSF The JR-CSF gp120 epitopes OGER Site CSF epitopes The JR-CSF gp120 epitopes recognized by the sera are generally distinct from those of several well characterized mAbs (targeting conserved sites on Env) or other type-specific responses (targeting V1, V2, or V3 variable regions). 23326351 7 60 part_of gp120 1092:1096 arg1 The JR-CSF gp120 epitopes gp120 The JR-CSF gp120 epitopes PUBTATOR Site gp120 3700 epitopes The JR-CSF gp120 epitopes recognized by the sera are generally distinct from those of several well characterized mAbs (targeting conserved sites on Env) or other type-specific responses (targeting V1, V2, or V3 variable regions). 23527852 7 13 gly fucosylated 981:991 arg1 more complex glycan moieties more complex glycan moieties These were characterized by more complex glycan moieties that are fucosylated instead of sialylated. 10080942 1 29 part_of deoxyribonuclease 258:274 arg1 Q46-R47 deoxyribonuclease Q46-R47 Fterm SiteSequence deoxyribonuclease Q46-R47 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 29 part_of deoxyribonuclease 258:274 arg1 three potential N-glycosylation sites deoxyribonuclease three potential N-glycosylation sites Fterm Site deoxyribonuclease sites Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 29 part_of deoxyribonuclease 258:274 arg1 a proteolytic processing site deoxyribonuclease a proteolytic processing site Fterm Site deoxyribonuclease site Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 29 part_of deoxyribonuclease 258:274 arg1 N212 deoxyribonuclease N86, N212, and N266 Fterm SpecificSite deoxyribonuclease N86, N212, and N266 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 29 part_of deoxyribonuclease 258:274 arg1 N266 deoxyribonuclease N86, N212, and N266 Fterm SpecificSite deoxyribonuclease N86, N212, and N266 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 10080942 1 29 part_of deoxyribonuclease 258:274 arg1 N266 deoxyribonuclease N86, N212, and N266 Fterm SpecificSite deoxyribonuclease N86, N212, and N266 Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme. 2571506 5 21 part_of Asn 826:828 arg1 CDR CDR)2 Asn PUBTATOR SpecificSite CDR)2 1039 Asn 58 The VH441 gene segment and all seven mAb contain a potential glycosylation site at Asn 58 in complementarity-determining region (CDR)2. 27358012 10 42 gly N-glycosylation 1483:1497 arg2 one potential N-glycosylation site one potential N-glycosylation site site Phylogenetic analysis indicated that, compared with the prototype strain A2, all ON1 and most NA1 isolates had lost one potential N-glycosylation site at amino acid 251 and 249 due to T251K and N249Y substitution, respectively. 21196036 4 71 gly glycosylation 766:778 arg2 a signal sequence a signal sequence sequence The bioinformatics analysis of the sequences revealed the presence of a signal sequence of 21 amino acids, one potential N-linked glycosylation site at position 402, 21 potential O-linked glycosylation sites and 36 potential phosphorylation sites. 21196036 4 71 gly glycosylation 766:778 arg2 21 21 position 402, 21 The bioinformatics analysis of the sequences revealed the presence of a signal sequence of 21 amino acids, one potential N-linked glycosylation site at position 402, 21 potential O-linked glycosylation sites and 36 potential phosphorylation sites. 21196036 4 71 gly glycosylation 766:778 arg2 21 potential O-linked glycosylation sites 21 potential O-linked glycosylation sites sites The bioinformatics analysis of the sequences revealed the presence of a signal sequence of 21 amino acids, one potential N-linked glycosylation site at position 402, 21 potential O-linked glycosylation sites and 36 potential phosphorylation sites. 21196036 4 78 gly glycosylation 708:720 arg2 a signal sequence a signal sequence sequence The bioinformatics analysis of the sequences revealed the presence of a signal sequence of 21 amino acids, one potential N-linked glycosylation site at position 402, 21 potential O-linked glycosylation sites and 36 potential phosphorylation sites. 21196036 4 78 gly glycosylation 708:720 arg2 position 402 position 402 position 402, 21 The bioinformatics analysis of the sequences revealed the presence of a signal sequence of 21 amino acids, one potential N-linked glycosylation site at position 402, 21 potential O-linked glycosylation sites and 36 potential phosphorylation sites. 21196036 4 78 gly glycosylation 708:720 arg2 one potential N-linked glycosylation site one potential N-linked glycosylation site site The bioinformatics analysis of the sequences revealed the presence of a signal sequence of 21 amino acids, one potential N-linked glycosylation site at position 402, 21 potential O-linked glycosylation sites and 36 potential phosphorylation sites. 18330979 5 29 gly glycosylation 1222:1234 arg2 each glycosylation site each glycosylation site site We have used a glycopeptide-based mass mapping approach to identify and characterize Env's glycosylation patterns by elucidating which sites are utilized and what type of glycan motif is present at each glycosylation site. 18330979 5 87 gly utilized 1164:1171 arg2 sites sites sites We have used a glycopeptide-based mass mapping approach to identify and characterize Env's glycosylation patterns by elucidating which sites are utilized and what type of glycan motif is present at each glycosylation site. 31572358 10 115 part_of IgG 1730:1732 arg1 IgG sequences IgG IgG sequences Cterm Site IgG sequences IgG sequences of 12 healthy donors were used as control. 1601309 5 36 gly glycosylation 1082:1094 arg2 one possible Asn-linked glycosylation site one possible Asn-linked glycosylation site site The aa sequence contains one possible Asn-linked glycosylation site. 31296534 0 51 part_of STT3A- 52:57 arg1 STT3A- and STT3B-dependent N-glycosylation sites STT3A STT3A- and STT3B-dependent N-glycosylation sites PUBTATOR Site STT3A 3703 sites Quantitative glycoproteomics reveals new classes of STT3A- and STT3B-dependent N-glycosylation sites. 31296534 0 67 part_of STT3B-dependent 63:77 arg1 STT3A- and STT3B-dependent N-glycosylation sites STT3B STT3A- and STT3B-dependent N-glycosylation sites PUBTATOR Site STT3B 201595 sites Quantitative glycoproteomics reveals new classes of STT3A- and STT3B-dependent N-glycosylation sites. 3829888 2 21 gly N-glycosylation 451:465 arg2 a possible N-glycosylation site a possible N-glycosylation site site It is a 114-amino-acid polypeptide which differs from its seminal plasma derivative mainly by the presence of a 20-residue amino-terminal extension, a putative signal sequence, carrying a possible N-glycosylation site. 11343303 9 40 part_of A 1377:1377 arg1 the extracellular domain ectodysplasin A the extracellular domain PUBTATOR Site ectodysplasin A 1896 domain Localization of the mutations in the extracellular domain of ectodysplasin A suggested that the primary cause of EDA is a defect in communication between the cells responsible for the development of skin appendages. 29470411 10 52 part_of α1A 1250:1252 arg1 Unoccupied N-glycosylation site N283 1A Unoccupied N-glycosylation site N283 PUBTATOR SpecificSite 1A 773 site N283 Unoccupied N-glycosylation site N283 at α1A contributes to a gain-of-function by lessening CaV2.1 inactivation. 26701645 2 40 gly glycoproteins 244:256 arg1 glycoproteins glycoproteins Fterm glycoproteins However, since many antigens are glycoproteins, including tumor antigens or viruses envelope proteins, their glycosylation status could also affect their processing and presentation. 26582203 5 57 part_of protease 804:811 arg1 protease cleavage sites protease protease cleavage sites Fterm Site protease sites The specificity patterns obtained by the PICS (proteomic identification of protease cleavage sites) method are similar for both KLK2 variants, with a major preference for P1-Arg. 9230129 6 84 gly N-glycosylation 1439:1453 arg2 a single N-glycosylation site a single N-glycosylation site site This identified a 17- or 21-amino-acid signal sequence, with the mature enzyme containing 260 amino acids and a single N-glycosylation site at Asn-18. 30594968 0 84 gly glycosylation 38:50 arg1 the hemagglutinin hemagglutinin sites Fterm hemagglutinin sites Impact of the variations in potential glycosylation sites of the hemagglutinin of H9N2 influenza virus. 26514585 0 23 gly glycosylation 105:117 arg2 glycosylation motifs glycosylation motifs motifs Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab. 9442070 11 34 part_of IgA1 1759:1762 arg1 primary sequence IgA1 primary sequence OGER Site IgA1 P01876 sequence The primary sequence and disulfide bond pattern of IgA1, together with the crystal structures of IgG1 Fc and mouse IgA Fab and the glycan sequencing data, were used to generate a molecular model of IgA1. 11680875 7 11 gly protein 1221:1227 arg1 the N-glycans protein the N-glycans Fterm protein This is achieved by releasing the N-glycans from the protein in a gel by optimised peptide-N-glycosidase F digestion. 28414420 3 11 gly glycopeptides 510:522 arg2 homogeneous V3 glycopeptides homogeneous V3 glycopeptides glycopeptides We report here a systematic chemoenzymatic synthesis of homogeneous V3 glycopeptides derived from the HIV-1 JR-FL strain carrying defined N-glycans at N332, N301, and N295 sites. 28414420 3 42 gly carrying 560:567 arg1 the HIV-1 JR-FL strain AND defined N-glycans the HIV-1 JR-FL strain defined N-glycans Fterm strain We report here a systematic chemoenzymatic synthesis of homogeneous V3 glycopeptides derived from the HIV-1 JR-FL strain carrying defined N-glycans at N332, N301, and N295 sites. 6267033 4 5 gly O-glycosylation 465:479 arg2 Thr 45 Thr 45 Thr 45 It bears an O-glycosylation site at Thr 45 and an N-glycosidic linkage at Asn 65. 6267033 4 5 gly O-glycosylation 465:479 arg2 an O-glycosylation site an O-glycosylation site site It bears an O-glycosylation site at Thr 45 and an N-glycosidic linkage at Asn 65. 6267033 4 5 gly O-glycosylation 465:479 arg2 Asn 65 Asn 65 Asn 65 It bears an O-glycosylation site at Thr 45 and an N-glycosidic linkage at Asn 65. 20881037 6 2 part_of proteins 979:986 arg1 the S domain proteins the S domain Fterm Site proteins domain Although the S domain is present in all three envelope proteins, the I110M, G119E, and R169P mutations impair virion secretion through the small envelope protein. 20881037 6 81 part_of present 949:955 arg2 all three envelope proteins AND the S domain all three envelope proteins the S domain Fterm Site proteins domain Although the S domain is present in all three envelope proteins, the I110M, G119E, and R169P mutations impair virion secretion through the small envelope protein. 31685900 5 51 gly glycosites 692:701 arg2 N-linked glycosites N-linked glycosites glycosites In this paper, we present N-GlyDE, a two-stage prediction tool trained on rigorously-constructed non-redundant datasets to predict N-linked glycosites in the human proteome. 21674342 6 6 gly glycopeptide 1005:1016 arg2 glycopeptide purification glycopeptide purification glycopeptide This strategy provides an effective route for conducting glycosylation reactions on a solid-phase support, simplifies the process of glycopeptide purification relative to solution-phase glycopeptide synthesis strategies, and enables the recovery of potentially valuable, un-reacted oligosaccharides. 21674342 6 34 gly glycopeptide 1058:1069 arg2 solution-phase glycopeptide synthesis strategies solution-phase glycopeptide synthesis strategies glycopeptide This strategy provides an effective route for conducting glycosylation reactions on a solid-phase support, simplifies the process of glycopeptide purification relative to solution-phase glycopeptide synthesis strategies, and enables the recovery of potentially valuable, un-reacted oligosaccharides. 23690449 7 81 gly O-glycosylation 1097:1111 arg2 an O-glycosylation site an O-glycosylation site site A novel, rare missense VWF variant that predicts disruption of an O-glycosylation site (p.Ser1486Leu) and a rare variant encoding p.Arg2287Trp were each associated with 30 to 40 IU/dL lower VWF level (P < .001). 8395123 1 17 part_of E2/NS1 223:228 arg1 the E and E2/NS1 regions NS1 the E and E2/NS1 regions OGER Site NS1 Q9Y6Y0 regions The amino acid sequence for the envelope protein(s) predicted from the nucleotide sequence of the E and E2/NS1 regions of the hepatitis C virus (HCV) genome is enriched with an N-linked glycosylation site motif, Asn-X-Thr/Ser, suggesting oligosaccharide moieties are present on the virion surface. 31831916 3 19 part_of N-glycoproteins 543:557 arg1 the N-glycoproteins and glycosylation sites N-glycoproteins the N-glycoproteins and glycosylation sites Fterm Site N-glycoproteins sites In this paper, we reviewed the human glycoproteomic profiles that have been reported in more than 80 individual studies, and mainly focused on the N-glycoproteins and glycosylation sites identified through their deglycosylated forms of glycosite-containing peptides. 9804815 6 19 gly glycoprotein 1117:1128 arg1 P-selectin glycoprotein ligand-1 P-selectin glycoprotein ligand-1 PUBTATOR P-selectin glycoprotein ligand-1 6404 Furthermore, GalNAc-T4 showed the best kinetic properties with an O-glycosylation site in the P-selectin glycoprotein ligand-1 molecule. 9804815 6 89 gly O-glycosylation 1078:1092 arg2 an O-glycosylation site an O-glycosylation site site Furthermore, GalNAc-T4 showed the best kinetic properties with an O-glycosylation site in the P-selectin glycoprotein ligand-1 molecule. 16261636 3 11 gly glycopeptides 535:547 arg2 ca 80 different AGP-derived glycopeptides ca 80 different AGP-derived glycopeptides glycopeptides On the basis of mass matching and MS/MS experiments ca 80 different AGP-derived glycopeptides were identified. 17727280 5 31 gly glycopeptide 744:755 arg2 glycopeptide identifications glycopeptide identifications glycopeptide Our program doubled the number of glycopeptide identifications, and also found several possible errors in the hand annotation. 15113889 0 86 gly glycoprotein 103:114 arg1 the vesicular stomatitis virus glycoprotein the vesicular stomatitis virus glycoprotein Fterm glycoprotein Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein. 16200726 3 48 part_of CETP 531:534 arg1 The CETP amino acid sequence CETP The CETP amino acid sequence PUBTATOR Site CETP P11597 sequence The sequence of tree shrew CETP cDNA was obtained by using techniques of switching mechanism at 5' end of RNA transcript (SMART) and rapid amplification of cDNA end (RACE), The CETP amino acid sequence was deduced from this cDNA and its primary and secondary structures were predicted by using DNAMAN, a software of molecular biology. 12087059 0 43 gly Edg-1 46:50 arg1 N-glycans Edg-1 N-glycans PUBTATOR Edg-1 1901 N-glycans of sphingosine 1-phosphate receptor Edg-1 regulate ligand-induced receptor internalization. 23703864 6 10 gly glycosylation 889:901 arg2 a conserved glycosylation site a conserved glycosylation site site Two of the mutations substituted highly conserved arginines in the second YWTD domain and the third substituted a conserved glycosylation site. 12110528 4 55 gly N-glycosylation 581:595 arg2 the N-glycosylation site the N-glycosylation site site To assess whether GLUT4 is a substrate for O-GlcNAcylation, we translated GLUT4 mRNA (mutated at the N-glycosylation site) in rabbit reticulocyte lysates supplemented with [(35)S]methionine. 7814877 8 35 gly N-glycosylation 1038:1052 arg2 position 15-17 position 15-17 position 15 In addition to conserved C-terminal sequences and serine blocks for phosphorylation in all eukaryotic ribosomal P2 proteins, this protein also contains a potential N-glycosylation site at position 15-17. 7814877 8 35 gly N-glycosylation 1038:1052 arg2 a potential N-glycosylation site a potential N-glycosylation site site In addition to conserved C-terminal sequences and serine blocks for phosphorylation in all eukaryotic ribosomal P2 proteins, this protein also contains a potential N-glycosylation site at position 15-17. 8631761 2 14 gly linked 348:353 arg3 L-fucose AND the epidermal growth factor domain the epidermal growth factor domain L-fucose domain An unusual type of posttranslational modification, in which L-fucose is O-glycosidically linked to threonine 61 in the epidermal growth factor domain was found for natural DSPAalpha1 and its recombinant form isolated from Chinese hamster ovary cells. 8631761 2 14 gly linked 348:353 arg1 threonine 61 AND L-fucose threonine 61 L-fucose threonine 61 An unusual type of posttranslational modification, in which L-fucose is O-glycosidically linked to threonine 61 in the epidermal growth factor domain was found for natural DSPAalpha1 and its recombinant form isolated from Chinese hamster ovary cells. 9030779 6 8 gly N-glycosylation 801:815 arg2 the two C-terminal N-glycosylation sites the two C-terminal N-glycosylation sites sites However, removal of the two C-terminal N-glycosylation sites inhibits the formation of mature enzyme. 17960575 8 29 part_of TRFE 1180:1183 arg1 both N-glycosylation sites TRFE both N-glycosylation sites PUBTATOR Site TRFE 7018 sites Disialylated diantennary glycans were observed in glycopeptides of both N-glycosylation sites of TRFE. 16227292 9 63 gly glycans 1369:1375 arg1 one site one site one site Site site Three viable N glycosylation-site-deficient viruses, lacking glycans on one site or both sites on Gc, were created by reverse genetics. 16227292 9 63 gly glycans 1369:1375 arg1 both sites both sites both sites Site sites Three viable N glycosylation-site-deficient viruses, lacking glycans on one site or both sites on Gc, were created by reverse genetics. 17715132 0 42 gly glycosylation 29:41 arg2 a glycosylation site a glycosylation site site Pannexin1 channels contain a glycosylation site that targets the hexamer to the plasma membrane. 24721674 6 24 gly N-glycosylation 1347:1361 arg2 811 N-glycosylation sites 811 N-glycosylation sites sites 200μg total protein digest was processed using this approach, leading to the identification of 811 N-glycosylation sites from 567 proteins within two experimental replicates. 17900180 4 38 part_of precursors 1412:1421 arg1 the peptide backbone sequence precursors the peptide backbone sequence Fterm Site precursors sequence The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors. 17900180 4 45 part_of site 1291:1294 arg1 t-PA t-PA site PUBTATOR Site t-PA 5327 site The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors. 17900180 4 45 part_of site 1291:1294 arg1 EGFR EGFR site PUBTATOR Site EGFR 1956 site The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors. 17900180 4 125 part_of EGFR 1256:1259 arg1 N-linked glycosylation sites EGFR N-linked glycosylation sites PUBTATOR Site EGFR 1956 sites The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors. 17900180 4 125 part_of EGFR 1256:1259 arg1 an O-linked glycosylation site EGFR an O-linked glycosylation site PUBTATOR Site EGFR 1956 site The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors. 17900180 4 129 part_of sites 1247:1251 arg1 EGFR EGFR sites PUBTATOR Site EGFR 1956 sites The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors. 8347587 13 2 part_of sites 1583:1587 arg1 the beta subunit subunit sites OGER Site subunit 16337 sites This is in contrast to glycosylation at the four sites on the beta subunit which appear not to be important for processing but necessary for signal transduction. 30295034 4 11 gly glycosylation 763:775 arg2 all glycosylation sites all glycosylation sites sites The dominant glycan compositions contain tri- and tetraantennary structures on all glycosylation sites. 30295034 4 0 gly contain 713:719 arg1 all glycosylation sites AND The dominant glycan compositions all glycosylation sites The dominant glycan compositions sites The dominant glycan compositions contain tri- and tetraantennary structures on all glycosylation sites. 30295034 4 0 gly contain 713:719 arg1 all glycosylation sites AND tri- and tetraantennary structures all glycosylation sites tri- and tetraantennary structures sites The dominant glycan compositions contain tri- and tetraantennary structures on all glycosylation sites. 8093354 4 22 gly glycosylation 573:585 arg2 a potential glycosylation site a potential glycosylation site site The largest extracellular loop with a potential glycosylation site was identified between membrane segments 7 and 8. 8347587 3 91 part_of contains 316:323 arg1 The proreceptor AND 18 potential sites The proreceptor 18 potential sites Fterm Site proreceptor sites The proreceptor contains 18 potential sites for N-linked glycosylation: 14 on the alpha subunit and 4 on the beta subunit. 12526344 3 60 part_of HA1 514:516 arg1 HA1 and HA2 domain HA1 HA1 and HA2 domain OGER Site HA1 domain All the three viruses share multiple basic amino acids (R-E-R-R-R-K-K-R) at the cleavage site between HA1 and HA2 domain, that is associated with highly pathogenic H5 avian viruses. 12526344 3 67 part_of HA2 522:524 arg1 HA1 and HA2 domain HA2 HA1 and HA2 domain OGER Site HA2 domain All the three viruses share multiple basic amino acids (R-E-R-R-R-K-K-R) at the cleavage site between HA1 and HA2 domain, that is associated with highly pathogenic H5 avian viruses. 25872915 2 68 gly glycosylation 447:459 arg2 a glycosylation site a glycosylation site site Most therapeutic mAbs are of IgG class and contain a glycosylation site in the Fc region at amino acid position 297 and, in some cases, in the Fab region. 25567004 4 18 gly glycosylation 975:987 arg2 fortuitous N-linked glycosylation sites fortuitous N-linked glycosylation sites sites Unexpectedly, deglycosylated proBHc contained an unexpected pro-peptide of an α-factor signal and fortuitous N-linked glycosylation sites in the non-cleaved pro-peptide sequences, but not in the BHc sequences. 25567004 4 90 gly deglycosylated 871:884 arg1 deglycosylated proBHc deglycosylated proBHc PUBTATOR BHc 192285 Unexpectedly, deglycosylated proBHc contained an unexpected pro-peptide of an α-factor signal and fortuitous N-linked glycosylation sites in the non-cleaved pro-peptide sequences, but not in the BHc sequences. 17076254 3 22 gly glycosylation 541:553 arg2 position 65 position 65 position 65 and 8 The deduced amino acid sequence includes a conserved domain typical of GM2APs between residues 53 and 224, a single N-linked glycosylation site at position 65 and 8 conserved cysteines. 17076254 3 22 gly glycosylation 541:553 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site The deduced amino acid sequence includes a conserved domain typical of GM2APs between residues 53 and 224, a single N-linked glycosylation site at position 65 and 8 conserved cysteines. 21380457 2 16 gly haptoglobin 247:257 arg1 glycan changes haptoglobin glycan changes PUBTATOR haptoglobin 3240 Many studies have reported glycan changes of haptoglobin in diseases such as breast cancer and pancreatic cancer. 19692476 8 32 part_of N 1604:1604 arg1 the CCR5 N terminus CCR5 N the CCR5 N terminus PUBTATOR Site CCR5 N 1234 terminus In contrast, TA1 interacted with CCR5 less efficiently and was highly sensitive to antibodies that bind to the CCR5 N terminus and ECL2. 19692476 8 47 part_of CCR5 1599:1602 arg1 the CCR5 N terminus CCR5 N the CCR5 N terminus PUBTATOR Site CCR5 N 1234 terminus In contrast, TA1 interacted with CCR5 less efficiently and was highly sensitive to antibodies that bind to the CCR5 N terminus and ECL2. 17960575 0 31 gly glycopeptides 94:106 arg2 proteolytic glycopeptides proteolytic glycopeptides glycopeptides Structure elucidation of glycoproteins by direct nanoESI MS and MS/MS analysis of proteolytic glycopeptides. 17960575 0 59 gly glycoproteins 25:37 arg1 glycoproteins glycoproteins Fterm glycoproteins Structure elucidation of glycoproteins by direct nanoESI MS and MS/MS analysis of proteolytic glycopeptides. 1379039 0 36 part_of precursors 77:86 arg1 Complementary DNA sequence precursors Complementary DNA sequence Fterm Site precursors sequence Complementary DNA sequence of human amyloidogenic immunoglobulin light-chain precursors. 18385254 1 30 part_of epitope 218:224 arg1 gp120 gp120 epitope PUBTATOR Site gp120 155971 epitope The human monoclonal antibody b12 recognizes a conserved epitope on gp120 that overlaps the CD4 binding site. 18385254 1 36 part_of CD4 253:255 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 920 site The human monoclonal antibody b12 recognizes a conserved epitope on gp120 that overlaps the CD4 binding site. 2503511 6 81 gly rt-PA 1298:1302 arg1 the carbohydrate rt-PA the carbohydrate Cterm rt-PA P00750 Two hybrid oligosaccharides were identified and accounted for 3% of the carbohydrate of rt-PA. 10211957 7 51 gly glycosylation 1287:1299 arg2 the fifth glycosylation site the fifth glycosylation site site Expression of the mutated E1 proteins in HepG2 cells indicated that the fifth glycosylation site is not used for the addition of N-linked oligosaccharides and the Pro immediately following the sequon (Asn-Trp-Ser) precludes core glycosylation. 10211957 7 67 gly used 1313:1316 arg2 the fifth glycosylation site the fifth glycosylation site site Expression of the mutated E1 proteins in HepG2 cells indicated that the fifth glycosylation site is not used for the addition of N-linked oligosaccharides and the Pro immediately following the sequon (Asn-Trp-Ser) precludes core glycosylation. 32005658 5 71 gly sialylated 1154:1163 arg1 heavily sialylated CHO-sKlotho heavily sialylated CHO-sKlotho Cterm CHO-sKlotho Q9UEF7 Chinese hamster ovary (CHO)- and human embryonic kidney (HEK)-derived WT sKlotho proteins had varied activities in FGF23 co-receptor and β-glucuronidase assays in vitro and distinct properties in vivo Sialidase treatment of heavily sialylated CHO-sKlotho increased its co-receptor activity 3-fold, yet it remained less active than hyposialylated HEK-sKlotho. 32005658 5 89 gly hyposialylated 1253:1266 arg1 hyposialylated HEK-sKlotho hyposialylated HEK-sKlotho OGER HEK P29319 Chinese hamster ovary (CHO)- and human embryonic kidney (HEK)-derived WT sKlotho proteins had varied activities in FGF23 co-receptor and β-glucuronidase assays in vitro and distinct properties in vivo Sialidase treatment of heavily sialylated CHO-sKlotho increased its co-receptor activity 3-fold, yet it remained less active than hyposialylated HEK-sKlotho. 8960909 7 21 part_of tyrosinase 1160:1169 arg1 the tyrosinase epitope tyrosinase the tyrosinase epitope PUBTATOR Site tyrosinase 7299 epitope The results are discussed in respect to the processing and presentation of the tyrosinase epitope. 20348522 1 52 part_of site 213:216 arg1 the envelope (E) protein protein site Fterm Site protein site Many West Nile (WN) virus isolates associated with significant outbreaks possess a glycosylation site on the envelope (E) protein. 9287313 5 43 part_of CD69 1229:1232 arg1 the human CD69 extracellular domain CD69 the human CD69 extracellular domain PUBTATOR Site CD69 969 domain Importantly, these data demonstrate that contrary to current belief, not one but two sites for N-glycan addition exist within the human CD69 extracellular domain and identify the second, "cryptic" CD69 N-glycan attachment site as the atypical Cys-containing glycosylation motif, Asn-Ala-Cys. 10536368 7 57 gly glycosylated 1309:1320 arg1 the fully glycosylated protein the fully glycosylated protein Fterm protein Ligand binding studies suggested that the secreted glycosylation variants possessed binding characteristics similar to the fully glycosylated protein. 12731887 2 22 gly glycosylation 365:377 arg1 this region region region To investigate whether glycosylation at the serine/threonine clusters at this region is important in protein synthesis, we selected (27)TSST(30) and (60)SGTS(63) clusters for further analysis. 9574531 0 43 gly glycosylation 6:18 arg1 HLA-DRalpha HLA-DRalpha OGER HLA Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization. 16200726 8 70 gly glycosylation 1440:1452 arg2 Asn342 Asn342 Asn342 However, there is a deletion of N-linked glycosylation site at Asn342 in tree shrew protein that may increase the ability of removing peripheral cholesterol and cholesteryl ester. 16200726 8 70 gly glycosylation 1440:1452 arg2 N-linked glycosylation site N-linked glycosylation site site However, there is a deletion of N-linked glycosylation site at Asn342 in tree shrew protein that may increase the ability of removing peripheral cholesterol and cholesteryl ester. 26687240 6 41 gly detected 1035:1042 arg1 Asn99 AND non-fucosylated complex glycans Asn99 non-fucosylated complex glycans Asn99 No glycosylation was found at Asn264, whilst high mannose glycans were only detected at Asn275, tri-antennary glycans were exclusively observed at Asn99 and Asn252, and non-fucosylated complex glycans were detected at Asn99. 26687240 6 47 gly detected 905:912 arg2 Asn275 AND high mannose glycans Asn275 high mannose glycans Asn275 No glycosylation was found at Asn264, whilst high mannose glycans were only detected at Asn275, tri-antennary glycans were exclusively observed at Asn99 and Asn252, and non-fucosylated complex glycans were detected at Asn99. 26687240 6 51 gly non-fucosylated 998:1012 arg1 non-fucosylated complex glycans non-fucosylated complex glycans No glycosylation was found at Asn264, whilst high mannose glycans were only detected at Asn275, tri-antennary glycans were exclusively observed at Asn99 and Asn252, and non-fucosylated complex glycans were detected at Asn99. 26687240 6 5 gly observed 964:971 arg2 Asn99 AND tri-antennary glycans Asn99 and Asn252 tri-antennary glycans Asn99 and Asn252 No glycosylation was found at Asn264, whilst high mannose glycans were only detected at Asn275, tri-antennary glycans were exclusively observed at Asn99 and Asn252, and non-fucosylated complex glycans were detected at Asn99. 26687240 6 46 gly glycosylation 832:844 arg1 Asn264 Asn264 Asn264 No glycosylation was found at Asn264, whilst high mannose glycans were only detected at Asn275, tri-antennary glycans were exclusively observed at Asn99 and Asn252, and non-fucosylated complex glycans were detected at Asn99. 31244828 4 47 part_of has 720:722 arg1 MOG AND one known N-glycosylation site MOG one known N-glycosylation site PUBTATOR Site MOG 4340 site MOG has one known N-glycosylation site at N31 located in the BC loop linking two beta-sheets. 21569239 4 55 part_of F-spondin 629:637 arg1 human F-spondin FS domain F-spondin human F-spondin FS domain PUBTATOR Site F-spondin 10418 domain RESULTS: We present the crystal structure of human F-spondin FS domain at 1.95Å resolution. 30063822 6 36 gly used 1119:1122 arg2 sites sites sites The construct has also been labeled with 15N at amide nitrogens of lysine residues to provide a set of sites that are used to derive an effective location of the paramagnetic nitroxide moiety of the TEMPO group. 14985108 6 45 gly contains 696:703 arg1 gONC AND a high-mannose core structure gONC a high-mannose core structure Cterm gONC We found that gONC contains a high-mannose core structure. 26333807 3 36 part_of Tf 409:410 arg1 the second glycosylation site Tf the second glycosylation site PUBTATOR Site Tf 7018 site We present a Tf variant affecting the second glycosylation site of Tf and the complications it causes in diagnosing alcoholism. 9780042 2 1 gly utilized 392:399 arg2 an N-linked glycosylation site an N-linked glycosylation site site Prolonged passage in mosquito cells caused loss of neuroinvasiveness and acquisition of an N-linked glycosylation site, which is utilized. 9780042 2 31 gly glycosylation 363:375 arg2 an N-linked glycosylation site an N-linked glycosylation site site Prolonged passage in mosquito cells caused loss of neuroinvasiveness and acquisition of an N-linked glycosylation site, which is utilized. 17459925 1 50 gly glycosylation 163:175 arg2 two N-linked glycosylation sites two N-linked glycosylation sites sites Dengue virus envelope protein (E) contains two N-linked glycosylation sites, at Asn-67 and Asn-153. 19700364 4 22 gly glycosylation 550:562 arg2 the glycosylation site the glycosylation site site Recent advances have led to the development of new analytical methods that employ mass spectrometry extensively making it possible to obtain the glycosylation site and the site microheterogeneity. 2787353 5 52 gly domain 850:855 arg1 a 33-residue sequence a 33-residue sequence The conclusion that rIL-2 is a lectin is further supported by the observation that the sequence of IL-2 shares 27% homology with a 33-residue sequence of the carbohydrate-binding domain of human mannose-binding protein. 31637569 5 30 gly glycopeptide 1046:1057 arg2 correct glycopeptide identification correct glycopeptide identification glycopeptide These factors impacted correct glycopeptide identification by proteomics software tools such as SEQUEST or Amanda. 30359034 10 42 gly glycopeptides 1209:1221 arg2 intact glycopeptides intact glycopeptides glycopeptides In addition, a unique approach to identify intact glycopeptides using MS1-based accurate masses is introduced. 28747502 9 62 gly glycosylation 1547:1559 arg2 a nonconserved glycosylation site a nonconserved glycosylation site site Specifically, mDPP4 has a nonconserved glycosylation site that acts as a barrier to MERS-CoV infection. 25636227 5 10 gly O-glycosylated 732:745 arg1 The O-glycosylated peptides The O-glycosylated peptides peptides The O-glycosylated peptides could then be identified by using liquid chromatography-tandem mass spectrometry (LC-MS-MS) to detect the 203 Da mass increase. 8652881 10 46 gly presence 1797:1804 arg2 the A1 domain AND N-linked oligosaccharides the A1 domain N-linked oligosaccharides domain MALDI-MS analysis of activated factor VIII-delta II suggested the presence of N-linked oligosaccharides in the proteolyzed light chain (A3-C1-C2 of 77,750 Da) and in the A1 domain (46,400 Da) of the heavy chain. 21431619 0 58 gly glycosylation 29:41 arg2 the glycosylation site the glycosylation site site Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type I. Congenital disorders of glycosylation (CDG) form a group of metabolic disorders caused by deficient glycosylation of proteins and/or lipids. 21431619 0 85 gly glycosylation 218:230 arg1 proteins proteins Fterm proteins Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type I. Congenital disorders of glycosylation (CDG) form a group of metabolic disorders caused by deficient glycosylation of proteins and/or lipids. 23891555 11 21 gly O-glycosylation 1665:1679 arg1 the hinge region the hinge region region BIOLOGICAL SIGNIFICANCE: In this work, we studied the O-glycosylation in the hinge region of human immunoglobulin A1 (IgA1). 26514585 6 42 gly glycosylation 1090:1102 arg1 the Fab domain the Fab domain domain These single mutations and the new glycosylation pattern of the Fab domain do not modify binding to the target. 8419363 6 64 gly linked 1174:1179 arg2 Asn238 AND an oligosaccharide Asn238 an oligosaccharide Asn238 Our data indicate that an oligosaccharide linked to Asn238 is essential for steroid binding, and we suggest that an interaction between this sugar chain and the polypeptide may be essential for the creation of a high affinity steroid-binding site. 25389233 7 13 part_of IgG-associated 1146:1159 arg1 IgG-associated fucosyl residues IgG IgG-associated fucosyl residues Cterm Site IgG residues After specifically gathering IgG complexes from sera, biotinylated lectins Aleuria aurantia lectin and Lens culinaris agglutinin were employed to detect IgG-associated fucosyl residues and the fucosylated tri-mannose N-glycan core, respectively. 8029814 1 89 part_of S 127:127 arg1 The cDNA sequence mouse protein S The cDNA sequence Cterm Site mouse protein S sequence The cDNA sequence of mouse protein S was derived by conventional PCR amplification from liver mRNA, initially using primers derived from the human cDNA sequence, followed by direct DNA sequencing. 8652881 2 86 gly glycosylation 411:423 arg2 seven potential glycosylation sites seven potential glycosylation sites sites This 1436-residues-long protein has a molecular mass, calculated from its sequence, of 164,954 Da and exhibits seven potential glycosylation sites. 16942785 8 90 gly glycosylation 1072:1084 arg2 a glycosylation site a glycosylation site site Sequence analysis of the V3 region showed that CXCR4-using viruses were often associated with an increased positive amino acid charge, insertions and loss of a glycosylation site, similar to HIV-1 subtype B. 12706347 5 76 part_of site 941:944 arg1 NTPDase3 NTPDase3 site PUBTATOR Site NTPDase3 956 site Using site-directed mutagenesis, mutants were constructed to eliminate this highly conserved N-glycosylation site in NTPDase3. 9925876 10 5 gly sites 1331:1335 arg1 the two putative extracellular N-linked glycosylation sites the two putative extracellular N-linked glycosylation sites sites Mutations at each of the two putative extracellular N-linked glycosylation sites (N598Q and N629Q) led to a perinuclear subcellular localization of HERGGFP stably expressed in HEK 293 cells, with no surface membrane expression. 9925876 10 26 gly glycosylation 1317:1329 arg2 the two putative extracellular N-linked glycosylation sites the two putative extracellular N-linked glycosylation sites sites Mutations at each of the two putative extracellular N-linked glycosylation sites (N598Q and N629Q) led to a perinuclear subcellular localization of HERGGFP stably expressed in HEK 293 cells, with no surface membrane expression. 31471966 3 26 gly methionine 491:500 arg1 a novel methionine tag methionine a novel methionine tag methionine Here, we report a novel methionine tag for 35 S-labelling added to the C-terminus of its prepro-form, which has no methionine and cysteine residue other than the initiation methionine that enables analyses of the molecular mechanism of its dual localization without the effects of the reporter proteins. 11978064 2 0 gly glycosylation 264:276 arg2 one glycosylation site one glycosylation site site PGH differs from pituitary growth hormone by 13 amino acids and possesses one glycosylation site. 11754244 4 11 gly nonglycosylated 1065:1079 arg1 nonglycosylated residues nonglycosylated residues residues The highly predictable fragmentation pathways of these fixed-charge phosphonium derivatives enable straightforward recognition of glycosylation site(s) based on the mass increment of +44 Da for originally glycosylated threonine compared to the mass of fragments containing nonglycosylated residues. 11754244 4 24 gly glycosylation 922:934 arg2 glycosylation site(s) glycosylation site(s) site The highly predictable fragmentation pathways of these fixed-charge phosphonium derivatives enable straightforward recognition of glycosylation site(s) based on the mass increment of +44 Da for originally glycosylated threonine compared to the mass of fragments containing nonglycosylated residues. 11754244 4 25 gly glycosylated 997:1008 arg1 originally glycosylated threonine originally glycosylated threonine threonine The highly predictable fragmentation pathways of these fixed-charge phosphonium derivatives enable straightforward recognition of glycosylation site(s) based on the mass increment of +44 Da for originally glycosylated threonine compared to the mass of fragments containing nonglycosylated residues. 11278567 1 3 gly glycoprotein 227:238 arg1 gp120 gp120 PUBTATOR gp120 155971 The variable V1V2 and V3 regions of the human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein (gp120) can influence viral coreceptor usage. 11278567 1 3 gly glycoprotein 227:238 arg1 the human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein the human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein Fterm glycoprotein The variable V1V2 and V3 regions of the human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein (gp120) can influence viral coreceptor usage. 19808681 10 19 gly unglycosylated 1481:1494 arg1 unglycosylated channels unglycosylated channels Fterm channels Furthermore, we could not detect unglycosylated channels in the mouse brain. 26022737 7 40 gly glycosylation 932:944 arg2 PSA N102 glycosylation site PSA N102 glycosylation site site Here we report the first qualitative and quantitative glycoproteomic study of PSA N102 glycosylation site by LC-MS/MS. 20943491 7 45 part_of CDS 1028:1030 arg1 the CDS sequence CDS the CDS sequence OGER Site CDS O35052 sequence The alignment similarities of the CDS sequence of swine CuZnSOD with those of cattle, human, rat, and mouse were 87.74%, 87.66%, 83.44%, and 83.23%, and the similarities of amino acid sequence were 90.26%, 94.12%, 92.21%, and 91.50%, respectively. 14520005 0 4 gly N-glycosylation 152:166 arg2 the N-glycosylation site the N-glycosylation site site 350-kDa royal jelly glycoprotein (apisin), which stimulates proliferation of human monocytes, bears the beta1-3galactosylated N-glycan: analysis of the N-glycosylation site. 14520005 0 37 gly glycoprotein 20:31 arg1 apisin apisin Fterm apisin 350-kDa royal jelly glycoprotein (apisin), which stimulates proliferation of human monocytes, bears the beta1-3galactosylated N-glycan: analysis of the N-glycosylation site. 14520005 0 37 gly glycoprotein 20:31 arg1 350-kDa royal jelly glycoprotein 350-kDa royal jelly glycoprotein Fterm glycoprotein 350-kDa royal jelly glycoprotein (apisin), which stimulates proliferation of human monocytes, bears the beta1-3galactosylated N-glycan: analysis of the N-glycosylation site. 1456441 9 23 gly N-glycosylation 1336:1350 arg2 the two N-glycosylation sites h-STF sites Cterm h-STF 7018 sites Di- and triantennary oligosaccharides were found to occur on each of the two N-glycosylation sites of h-STF (Asn413 and Asn611) in the ratio of approximately 85:15. 1456441 9 71 gly h-STF 1361:1365 arg1 Asn611 Asn413 and Asn611 Asn413 and Asn611 Di- and triantennary oligosaccharides were found to occur on each of the two N-glycosylation sites of h-STF (Asn413 and Asn611) in the ratio of approximately 85:15. 2868718 6 8 part_of SAP-1 640:644 arg1 the amino terminus SAP-1 the amino terminus PUBTATOR Site SAP-1 5660 terminus Colinearity was established between 19 amino acids obtained by sequencing the amino terminus of pure SAP-1 and 57 bp from the 5' end of S-1.1. 2209609 9 66 gly glycosylation 1521:1533 arg2 each glycosylation site each glycosylation site site The spectrum of oligosaccharide structures released from each glycosylation site was assessed as being similar to that of total oligosaccharides on the basis of their chromatographic profiles on the lectin columns and on Bio-Gel P-4. 2209609 9 75 gly released 1502:1509 arg1 each glycosylation site AND oligosaccharide structures each glycosylation site oligosaccharide structures site The spectrum of oligosaccharide structures released from each glycosylation site was assessed as being similar to that of total oligosaccharides on the basis of their chromatographic profiles on the lectin columns and on Bio-Gel P-4. 32321762 6 62 part_of PrPC 1188:1191 arg1 Ser-231 PrPC Ser-231 PUBTATOR SpecificSite PrPC 5621 Ser-231 Gly-229 in human PrPC does not correspond to Ser-231, the previously reported ω site of Syrian hamster PrPC We found that approximately 41% and 28% of GPI anchors in human PrPCs from human and mouse knock-in brains, respectively, have N-acetylneuraminic acid in the side-chain. 32321762 6 62 part_of PrPC 1188:1191 arg1 the previously reported ω site PrPC the previously reported ω site PUBTATOR Site PrPC 5621 site Gly-229 in human PrPC does not correspond to Ser-231, the previously reported ω site of Syrian hamster PrPC We found that approximately 41% and 28% of GPI anchors in human PrPCs from human and mouse knock-in brains, respectively, have N-acetylneuraminic acid in the side-chain. 32321762 6 70 part_of Gly-229 1085:1091 arg1 human PrPC PrPC Gly-229 PUBTATOR SpecificSite PrPC 5621 Gly-229 Gly-229 in human PrPC does not correspond to Ser-231, the previously reported ω site of Syrian hamster PrPC We found that approximately 41% and 28% of GPI anchors in human PrPCs from human and mouse knock-in brains, respectively, have N-acetylneuraminic acid in the side-chain. 26957414 9 64 gly glycoproteins 1166:1178 arg1 α1-acid glycoprotein α1-acid glycoprotein Fterm glycoprotein ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin. 26957414 9 64 gly glycoproteins 1166:1178 arg1 porcine thyroglobulin porcine thyroglobulin OGER thyroglobulin P01266 ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin. 26957414 9 64 gly glycoproteins 1166:1178 arg1 three model glycoproteins three model glycoproteins Fterm glycoproteins ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin. 26957414 9 64 gly glycoproteins 1166:1178 arg1 fetuin fetuin Fterm fetuin ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin. 26957414 9 75 gly glycoprotein 1207:1218 arg1 α1-acid glycoprotein α1-acid glycoprotein Fterm glycoprotein ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin. 26957414 9 112 gly glycosylation 1131:1143 arg2 the glycosylation sites glycoprotein sites Fterm glycoprotein sites ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin. 26957414 9 112 gly glycosylation 1131:1143 arg2 the glycosylation sites glycoproteins sites Fterm glycoproteins sites ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin. 26957414 9 112 gly glycosylation 1131:1143 arg1 fetuin fetuin sites Fterm fetuin sites ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin. 26957414 9 112 gly glycosylation 1131:1143 arg1 porcine thyroglobulin thyroglobulin sites OGER thyroglobulin P01266 sites ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin. 25501675 10 32 gly glycosylation 1592:1604 arg2 a specific glycosylation site a specific glycosylation site site The relative amount of each glycoform at a specific glycosylation site was determined based on reporter signal intensities of the TMT labeling reagents. 12237688 4 9 gly glycosylation 589:601 arg2 glycosylation site 97 glycosylation site 97 site The results were coincident with our previous supposition that mutagenesis at glycosylation site 97 from Asn to Cys and PEGylation at 97 Cys have no effect on the activity of IFN-gamma, which were about 7x10(6) IU/mg. 1457204 3 10 part_of CD4 426:428 arg1 the second Ig-like domain CD4 the second Ig-like domain PUBTATOR Site CD4 920 domain Comparison to the crystal structure of human CD4 does, however, reveal unusual features in the second Ig-like domain, D2, of cat CD4. 21673010 0 103 gly domain 133:138 arg1 N-Glycan synthesis N-Glycan synthesis N-Glycan synthesis in the apical and basolateral secretory pathway of epithelial MDCK cells and the influence of a glycosaminoglycan domain. 21604132 4 17 part_of glycoproteins 704:716 arg1 the glycosylation site glycoproteins the glycosylation site Fterm Site glycoproteins site In this context, the aim of this chapter is to describe a methodology to identify the glycosylation site of N-linked sialylated glycoproteins. 1377692 4 72 gly N-glycosylation 492:506 arg2 only one potential N-glycosylation site only one potential N-glycosylation site site The deduced amino acid sequence contains only one potential N-glycosylation site located in the propeptide. 22171062 3 25 gly glycosylation 496:508 arg1 viral envelope proteins viral envelope proteins Fterm proteins N-linked glycosylation of viral envelope proteins are critical post-translation modifications that have been implicated in roles of structural integrity, virus replication and evasion of the host immune response. 9352200 0 26 gly glycoprotein 70:81 arg1 the Xenopus laevis egg envelope glycoprotein gp43 the Xenopus laevis egg envelope glycoprotein gp43 Fterm glycoprotein cDNA cloning and sequence analysis of the Xenopus laevis egg envelope glycoprotein gp43. 28694069 3 35 gly aglycosylated 639:651 arg1 aglycosylated IgG variants aglycosylated IgG variants Fterm variants In the present study, we demonstrate that aglycosylated IgG variants can be engineered to productively engage with FcγRIIIA, as well as the human Fc gamma RII subset. 1456441 0 84 gly N-glycosylation 0:14 arg2 N-glycosylation site mapping N-glycosylation site mapping site N-glycosylation site mapping of human serotransferrin by serial lectin affinity chromatography, fast atom bombardment-mass spectrometry, and 1H nuclear magnetic resonance spectroscopy. 27127844 2 58 part_of has 263:265 arg1 this membrane protein AND a1-a4 this membrane protein a1-a4 Fterm SiteSequence protein a1-a4 In mammalian species this membrane protein has four paralogous isoforms, a1-a4. 22203233 0 8 gly glycoproteins 67:79 arg1 fucosylated glycoproteins fucosylated glycoproteins Fterm glycoproteins A chemoenzymatic approach toward the identification of fucosylated glycoproteins and mapping of N-glycan sites. 22203233 0 50 gly fucosylated 55:65 arg1 fucosylated glycoproteins fucosylated glycoproteins Fterm glycoproteins A chemoenzymatic approach toward the identification of fucosylated glycoproteins and mapping of N-glycan sites. 10858228 0 71 gly glycoproteins 75:87 arg1 Cryptosporidium parvum glycoproteins Cryptosporidium parvum glycoproteins Fterm glycoproteins Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15. 10858228 0 71 gly glycoproteins 75:87 arg1 gp15 gp15 Cterm gp15 Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15. 10858228 0 71 gly glycoproteins 75:87 arg1 gp40 gp40 OGER gp40 P09564 Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15. 17623277 7 40 part_of DCE 839:841 arg1 trypsin-digested DCE glycopeptides DCE trypsin-digested DCE glycopeptides PUBTATOR Site DCE 1718 glycopeptides Glycosylation site and oligosaccharide structures were elucidated from MS and MS/MS spectra of trypsin-digested DCE glycopeptides. 17494553 11 39 gly M 1779:1779 arg1 host specificity site host specificity site site In addition, genetic analysis showed that most avian influenza virus (AIV) isolates from Thailand had no major genetic changes in each gene such as HA (HA cleavage site, receptor binding site, N-link glycosylation site), NA (NA stalk region, oseltamivir resistance marker), M (the amantadine resistance marker, host specificity site), NS (five amino acid deletion site), and PB2 (host specificity site). 17494553 11 60 gly HA 1653:1654 arg1 N-link glycosylation site N-link glycosylation site site In addition, genetic analysis showed that most avian influenza virus (AIV) isolates from Thailand had no major genetic changes in each gene such as HA (HA cleavage site, receptor binding site, N-link glycosylation site), NA (NA stalk region, oseltamivir resistance marker), M (the amantadine resistance marker, host specificity site), NS (five amino acid deletion site), and PB2 (host specificity site). 17494553 11 51 gly glycosylation 1705:1717 arg2 HA cleavage site site site In addition, genetic analysis showed that most avian influenza virus (AIV) isolates from Thailand had no major genetic changes in each gene such as HA (HA cleavage site, receptor binding site, N-link glycosylation site), NA (NA stalk region, oseltamivir resistance marker), M (the amantadine resistance marker, host specificity site), NS (five amino acid deletion site), and PB2 (host specificity site). 31330090 9 87 gly glycosylation 1364:1376 arg2 a glycosylation site a glycosylation site site To further validate this, we disrupted a glycosylation site identified in AAV2 capsid (AAV2-N253Q), which severely compromised its packaging efficiency (~ 100-fold vs. AAV2 wild-type vectors). 15514484 1 27 gly residue 308:314 arg1 an N-acetyl-D-glucosamine residue residue an N-acetyl-D-glucosamine residue residue Starting from N-glycosylated eel calcitonin derivatives that contain an N-acetyl-D-glucosamine residue specifically at the 3rd, 14th, 20th or 26th amino acid residue, corresponding glycopeptides with a complex-type oligosaccharide attached to the respective amino acid residue were synthesized by means of a transglycosylation reaction catalyzed by an endo-beta-N-acetylglucosaminidase from Mucor hiemalis . 15514484 1 57 gly attached 381:388 arg1 the respective amino acid residue AND a complex-type oligosaccharide the respective amino acid residue a complex-type oligosaccharide residue Starting from N-glycosylated eel calcitonin derivatives that contain an N-acetyl-D-glucosamine residue specifically at the 3rd, 14th, 20th or 26th amino acid residue, corresponding glycopeptides with a complex-type oligosaccharide attached to the respective amino acid residue were synthesized by means of a transglycosylation reaction catalyzed by an endo-beta-N-acetylglucosaminidase from Mucor hiemalis . 15514484 1 40 gly glycopeptides 331:343 arg2 corresponding glycopeptides glycopeptides a complex-type oligosaccharide glycopeptides Starting from N-glycosylated eel calcitonin derivatives that contain an N-acetyl-D-glucosamine residue specifically at the 3rd, 14th, 20th or 26th amino acid residue, corresponding glycopeptides with a complex-type oligosaccharide attached to the respective amino acid residue were synthesized by means of a transglycosylation reaction catalyzed by an endo-beta-N-acetylglucosaminidase from Mucor hiemalis . 28630087 6 39 gly glycosylation 1261:1273 arg2 low glycosylation site solvent accessibility low glycosylation site solvent accessibility site In contrast, the mostly unoccupied Asn88 carried nonfucosylated paucimannosidic N-glycans probably resulting from low glycosylation site solvent accessibility. 28630087 6 121 gly nonfucosylated 1192:1205 arg1 nonfucosylated paucimannosidic N-glycans nonfucosylated paucimannosidic N-glycans In contrast, the mostly unoccupied Asn88 carried nonfucosylated paucimannosidic N-glycans probably resulting from low glycosylation site solvent accessibility. 23714211 14 52 gly fully-glycosylated 2441:2458 arg1 fully-glycosylated ICAM-2 fully-glycosylated ICAM-2 PUBTATOR ICAM-2 3384 However, unlike fully-glycosylated ICAM-2, glycosylation site variants did not completely suppress disseminated tumor development. 23714211 14 126 gly glycosylation 2468:2480 arg2 glycosylation site variants glycosylation site variants site However, unlike fully-glycosylated ICAM-2, glycosylation site variants did not completely suppress disseminated tumor development. 16360109 4 15 gly core-fucosylated 806:821 arg1 core-fucosylated biantennary oligosaccharides core-fucosylated biantennary oligosaccharides Results showed that the major N-linked oligosaccharide structures in the Fv region have three characteristics (core-fucosylated biantennary oligosaccharides with one or two N-glycolylneuraminic acid [NeuGc] residues, zero or one alpha-linked Gal residue, and zero or one beta-linked GalNAc residue), whereas N-linked oligosaccharides in the Fc region contained typical Fc glycans (core-fucosylated, biantennary oligosaccharides with zero to two Gal residues). 16360109 4 29 gly oligosaccharides 1012:1027 arg1 the Fc region the Fc region the Fc region Site region Results showed that the major N-linked oligosaccharide structures in the Fv region have three characteristics (core-fucosylated biantennary oligosaccharides with one or two N-glycolylneuraminic acid [NeuGc] residues, zero or one alpha-linked Gal residue, and zero or one beta-linked GalNAc residue), whereas N-linked oligosaccharides in the Fc region contained typical Fc glycans (core-fucosylated, biantennary oligosaccharides with zero to two Gal residues). 16360109 4 101 gly structures 750:759 arg1 the Fv region the Fv region the Fv region Site region Results showed that the major N-linked oligosaccharide structures in the Fv region have three characteristics (core-fucosylated biantennary oligosaccharides with one or two N-glycolylneuraminic acid [NeuGc] residues, zero or one alpha-linked Gal residue, and zero or one beta-linked GalNAc residue), whereas N-linked oligosaccharides in the Fc region contained typical Fc glycans (core-fucosylated, biantennary oligosaccharides with zero to two Gal residues). 15859596 15 12 gly sialylated 2153:2162 arg2 that specific glycosylation site that specific glycosylation site site Peptides in which the relative abundance of isotopic isoforms was equal were considered to indicate that the protein parent was fully sialylated at that specific glycosylation site. 15859596 15 19 gly glycosylation 2181:2193 arg2 that specific glycosylation site that specific glycosylation site site Peptides in which the relative abundance of isotopic isoforms was equal were considered to indicate that the protein parent was fully sialylated at that specific glycosylation site. 2347365 6 65 part_of leukosialin-related 737:755 arg1 a leukosialin-related sequence leukosialin a leukosialin-related sequence PUBTATOR Site leukosialin P16150 sequence The other mouse gene was an intronless pseudogene for a leukosialin-related sequence. 10648510 3 87 gly glycoprotein 640:651 arg1 this glycoprotein this glycoprotein Fterm glycoprotein Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of RNase B demonstrated a reduction in the molecular mass of this glycoprotein during bacterial growth. 31852790 5 67 part_of regions 955:961 arg1 the COBRA HA proteins proteins regions Fterm Site proteins regions In order to better understand how these HA antigens elicit broadly reactive immune responses, epitopes in the Cb, Sa, or Sb antigenic sites of seasonal-like and pandemic-like wild-type or COBRA HA antigens were exchanged with homologous regions in the COBRA HA proteins to determine which regions and residues were responsible for the elicited antibody profile. 31852790 5 106 part_of epitopes 812:819 arg1 Sb antigenic sites epitopes Sb antigenic sites sites In order to better understand how these HA antigens elicit broadly reactive immune responses, epitopes in the Cb, Sa, or Sb antigenic sites of seasonal-like and pandemic-like wild-type or COBRA HA antigens were exchanged with homologous regions in the COBRA HA proteins to determine which regions and residues were responsible for the elicited antibody profile. 18330979 7 8 gly glycosylation 1561:1573 arg2 each glycosylation site each glycosylation site site Thus, these techniques can be used to (1) define glycosylation profiles of recombinant Env proteins and Env on mature virions, (2) define specific carbohydrate moieties at each glycosylation site, and (3) determine the role of certain carbohydrates in HIV-1 infectivity and in modulation of Env immunogenicity. 18330979 7 92 gly glycosylation 1433:1445 arg1 Env Env PUBTATOR Env 155971 Thus, these techniques can be used to (1) define glycosylation profiles of recombinant Env proteins and Env on mature virions, (2) define specific carbohydrate moieties at each glycosylation site, and (3) determine the role of certain carbohydrates in HIV-1 infectivity and in modulation of Env immunogenicity. 18330979 7 92 gly glycosylation 1433:1445 arg1 recombinant Env proteins recombinant Env proteins PUBTATOR Env proteins 155971 Thus, these techniques can be used to (1) define glycosylation profiles of recombinant Env proteins and Env on mature virions, (2) define specific carbohydrate moieties at each glycosylation site, and (3) determine the role of certain carbohydrates in HIV-1 infectivity and in modulation of Env immunogenicity. 25456591 9 44 gly glycosylation 1623:1635 arg2 the same glycosylation sites the same glycosylation sites sites The FDR decreased from 33% to 3.3% by ΔRt filtering and exclusion of repeated peptide tags that covered the same glycosylation sites. 23661698 7 17 part_of site 1007:1010 arg1 ephrin-A1 ephrin-A1 site PUBTATOR Site ephrin-A1 1942 site Mutations in the glycosylation site on ephrin-A1 result in protein aggregation and mislocalization. 18625743 5 57 gly N-glycosylation 724:738 arg2 no new N-glycosylation site no new N-glycosylation site site The misfolding mutation was not gain-of-glycosylation, as it created no new N-glycosylation site. 11822873 7 46 part_of P75 1521:1523 arg1 the stalk domain P75(NTR) the stalk domain PUBTATOR Site P75(NTR) 4923 domain These data indicate that the position of O-glycans in the proximal part of the stalk domain of P75(NTR) is crucial for apical sorting and may regulate association with apical rafts. 29980609 4 30 gly glycoproteins 755:767 arg1 molecular determinants AICL glycoproteins molecular determinants PUBTATOR AICL glycoproteins 9976 In this study, we characterize molecular determinants of AICL glycoproteins that cause intracellular retention, thereby controlling AICL surface expression. 6148073 2 53 gly glycopeptide 284:295 arg2 the glycopeptide fraction the glycopeptide fraction glycopeptide The glycoprotein was digested with Pronase, and the glycopeptide fraction was isolated by gel filtration and acetylated with [3H]acetic anhydride. 6148073 2 61 gly glycoprotein 236:247 arg1 The glycoprotein The glycoprotein Fterm glycoprotein The glycoprotein was digested with Pronase, and the glycopeptide fraction was isolated by gel filtration and acetylated with [3H]acetic anhydride. 9126611 3 31 part_of site 586:589 arg1 the wild-type (WT) enzyme enzyme site Fterm Site enzyme site Removal of the N-glycosylation consensus sequence at Asn580 (N580Q and S582A mutants) resulted in the expression of protein comprising a single glycoform, consistent with the partial N-glycosylation at this site in the wild-type (WT) enzyme. 23958596 1 63 part_of sites 222:226 arg1 hLPLA2 hLPLA2 sites PUBTATOR Site hLPLA2 23659 sites To understand the role of N-glycosylation of lysosomal phospholipase A2 (LPLA2), four potential N-glycosylation sites in human LPLA2 (hLPLA2) were individually modified replacing asparagine (Asn) with alanine by site-direct mutagenesis. 23958596 1 63 part_of sites 222:226 arg1 human LPLA2 LPLA2 sites PUBTATOR Site LPLA2 23659 sites To understand the role of N-glycosylation of lysosomal phospholipase A2 (LPLA2), four potential N-glycosylation sites in human LPLA2 (hLPLA2) were individually modified replacing asparagine (Asn) with alanine by site-direct mutagenesis. 31445105 6 33 part_of site 969:972 arg1 the hemagglutinin hemagglutinin site Fterm Site hemagglutinin site The IAVs presented the substitution S162 N, which introduces a new glycosylation site in the hemagglutinin. 1697592 4 83 part_of isomerase 956:964 arg1 the active sites protein disulfide isomerase the active sites OGER Site protein disulfide isomerase P07237 sites The protein contains two repeated sequences Trp-Cys-Gly-His-Cys-Lys proposed to be in the active sites of protein disulfide isomerase. 1697592 4 104 part_of contains 844:851 arg1 The protein AND two repeated sequences protein sequences Trp-Cys-Gly-His-Cys-Lys Fterm Site protein sequences Trp-Cys-Gly-His-Cys-Lys The protein contains two repeated sequences Trp-Cys-Gly-His-Cys-Lys proposed to be in the active sites of protein disulfide isomerase. 29755357 3 29 gly N-glycosylation 474:488 arg2 one N-glycosylation site one N-glycosylation site site Human LCN2 contains one N-glycosylation site conserved in other species. 25456591 0 48 gly O-glycosylation 26:40 arg2 protein O-glycosylation site protein O-glycosylation site site Identification of protein O-glycosylation site and corresponding glycans using liquid chromatography-tandem mass spectrometry via mapping accurate mass and retention time shift. 20963501 2 19 part_of Izumo1 242:247 arg1 4.6 kb Izumo1 genomic sequences Izumo1 4.6 kb Izumo1 genomic sequences PUBTATOR Site Izumo1 Q8IYV9 sequences Analysis of 4.6 kb Izumo1 genomic sequences in sheep and goat revealed a canonical open reading frame (ORF) of 963 bp spliced by eight exons. 15737642 0 58 gly N-glycosylation 15:29 arg2 N-glycosylation sites N-glycosylation sites sites The effects of N-glycosylation sites and the N-terminal region on the biological function of beta1,3-N-acetylglucosaminyltransferase 2 and its secretion. 20826563 3 3 gly N-glycosylation 294:308 arg2 a single potential N-glycosylation site a single potential N-glycosylation site site Human GH variants with a single potential N-glycosylation site (N-X-S/T) introduced by site-directed mutagenesis were expressed in HEK293 cells. 20663928 3 15 gly glycoprotein 719:730 arg1 a cell surface glycoprotein a cell surface glycoprotein Fterm glycoprotein To enhance its potency and targeted tumor therapy, we describe the generation of a novel IgG-based immunotoxin, designated 2L-Rap(Q)-hRS7, comprising Rap(Q), a mutant Rap with the putative N-glycosylation site removed, and hRS7, an internalizing, humanized antibody against Trop-2, a cell surface glycoprotein overexpressed in variety of epithelial cancers. 20663928 3 15 gly glycoprotein 719:730 arg1 Trop-2 Trop-2 PUBTATOR Trop-2 4070 To enhance its potency and targeted tumor therapy, we describe the generation of a novel IgG-based immunotoxin, designated 2L-Rap(Q)-hRS7, comprising Rap(Q), a mutant Rap with the putative N-glycosylation site removed, and hRS7, an internalizing, humanized antibody against Trop-2, a cell surface glycoprotein overexpressed in variety of epithelial cancers. 20663928 3 48 gly N-glycosylation 611:625 arg2 the putative N-glycosylation site the putative N-glycosylation site site To enhance its potency and targeted tumor therapy, we describe the generation of a novel IgG-based immunotoxin, designated 2L-Rap(Q)-hRS7, comprising Rap(Q), a mutant Rap with the putative N-glycosylation site removed, and hRS7, an internalizing, humanized antibody against Trop-2, a cell surface glycoprotein overexpressed in variety of epithelial cancers. 12176026 1 35 gly N-glycosylation 139:153 arg2 an N-glycosylation site an N-glycosylation site site Prosomatostatin, the precursor of the hormone somatostatin, harbors an N-glycosylation site in its prodomain that has never been shown to be modified by the N-oligosaccharyl transferase (OST) of the endoplasmic reticulum (ER). 10942407 7 27 part_of Jk 1530:1531 arg1 the Jk(S291P) mutant polypeptide Jk the Jk(S291P) mutant polypeptide Cterm Site Jk polypeptide Because the Jk(S291P) mutant polypeptide was not present in human red cells from Jk(null) individuals, expression data in the erythroid context clearly indicates that the S-->P mutation is the molecular basis of the Finnish Jk(null) phenotype. 29992770 9 31 part_of haptoglobin 1267:1277 arg1 N-glycopeptides haptoglobin N-glycopeptides Fterm Site haptoglobin 3240 N-glycopeptides N-glycopeptides of IgG1, IgG4, haptoglobin, and transferrin have statistically significant different abundances between cases and controls. 29992770 9 59 part_of transferrin 1284:1294 arg1 N-glycopeptides transferrin N-glycopeptides Fterm Site transferrin 7018 N-glycopeptides N-glycopeptides of IgG1, IgG4, haptoglobin, and transferrin have statistically significant different abundances between cases and controls. 20188224 9 36 gly attached 1330:1337 arg3 N-glycan AND particular sites particular sites N-glycan sites In addition, glycopeptides were produced using in-solution pronase digestion to identify species of N-glycan attached at particular sites. 20188224 9 53 gly glycopeptides 1234:1246 arg2 glycopeptides glycopeptides glycopeptides In addition, glycopeptides were produced using in-solution pronase digestion to identify species of N-glycan attached at particular sites. 15175256 5 12 gly occupied 797:804 arg2 These sites These sites sites These sites tend to be occupied by high-mannose glycans. 16489763 4 30 gly glycosylation 752:764 arg1 the receptor the receptor Fterm receptor We found that the receptor undergoes similar glycosylation processes and similar cell surface organization in CHO-K1 and HEK 293 cells, used for stable and transient receptor expression, respectively. 21264968 3 40 gly O-glycosylation 1193:1207 arg2 multiple and potential O-glycosylation sites multiple and potential O-glycosylation sites sites An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly). 21264968 3 104 gly sites 1209:1213 arg1 the tandem repeats sites the tandem repeats sites An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly). 21264968 3 84 gly glycoproteins 1252:1264 arg1 human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly) mucin glycoproteins Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly PUBTATOR mucin glycoproteins 100508689 Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly). 21264968 3 84 gly glycoproteins 1252:1264 arg1 MUC5AC MUC5AC Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly PUBTATOR MUC5AC 4586 Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly). 21264968 3 84 gly glycoproteins 1252:1264 arg1 MUC4 MUC4 Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly PUBTATOR MUC4 4585 Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly). 21264968 3 128 gly glycoproteins 1252:1264 arg1 the tandem repeats mucin glycoproteins Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly the tandem repeats PUBTATOR mucin glycoproteins 100508689 Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly). 21264968 3 84 gly glycoproteins 1252:1264 arg1 human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly) mucin glycoproteins Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp PUBTATOR mucin glycoproteins 100508689 Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly). 21264968 3 84 gly glycoproteins 1252:1264 arg1 MUC5AC MUC5AC Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp PUBTATOR MUC5AC 4586 Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly). 21264968 3 84 gly glycoproteins 1252:1264 arg1 MUC4 MUC4 Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp PUBTATOR MUC4 4585 Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly). 21264968 3 128 gly glycoproteins 1252:1264 arg1 the tandem repeats mucin glycoproteins Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp the tandem repeats PUBTATOR mucin glycoproteins 100508689 Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly). 21264968 3 128 gly glycoproteins 1252:1264 arg1 the tandem repeats mucin glycoproteins the tandem repeats PUBTATOR mucin glycoproteins 100508689 An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly). 30063822 3 12 gly glycoproteins 504:516 arg1 Recombinantly expressing glycoproteins Recombinantly expressing glycoproteins Fterm glycoproteins Recombinantly expressing glycoproteins in HEK293S (GnT1-) cells results in N-glycans with high-mannose structures that can be processed to leave a single GlcNAc residue. 31030759 5 37 gly N-glycosylation 533:547 arg2 a single N-glycosylation site a single N-glycosylation site site All MAbs typically have a single N-glycosylation site on each of the Fc region. 1899031 2 8 gly glycosylation 871:883 arg2 this sole potential N-linked glycosylation site this sole potential N-linked glycosylation site site Employing high-performance anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the protein by glycopeptidase F, compared with elution positions of standard oligosaccharides, coupled with monosaccharide compositional determinations and analyses of sequential exoglycosidase digestions and specific lectin binding, we find that considerable microheterogeneity in oligosaccharide structure exists at this sole potential N-linked glycosylation site on HPg. 10713140 2 62 gly N-glycosylation 223:237 arg2 a single N-glycosylation sequon a single N-glycosylation sequon sequon Mutations at a single N-glycosylation sequon of tyrosinase have been reported to be responsible for oculocutaneous albinism type IA in humans, characterized by inactive tyrosinase and the total absence of pigmentation. 2350186 6 33 gly glycopeptides 941:953 arg2 glycopeptides glycopeptides glycopeptides Evaluation of glycopeptides containing individual glycosylation sites by Concanavalin A-Sepharose indicated that this deletion had no significant effect on the processing of structures from high mannose-type to complex-type oligosaccharide chains. 2350186 6 60 gly glycosylation 977:989 arg2 individual glycosylation sites individual glycosylation sites sites Evaluation of glycopeptides containing individual glycosylation sites by Concanavalin A-Sepharose indicated that this deletion had no significant effect on the processing of structures from high mannose-type to complex-type oligosaccharide chains. 27023253 13 10 gly glycosylation 1997:2009 arg2 direct glycosylation site analysis direct glycosylation site analysis site This allowed for direct glycosylation site analysis, though the protocol can accommodate (18)O site labeling as well. 21970473 5 44 gly glycosites 835:844 arg2 glycosites glycosites glycosites Although mass spectrometric analysis can be performed easily in this way, an increase in false positives when assigning glycosites was inevitable. 32125861 6 11 gly glycoprotein 1170:1181 arg1 each glycoprotein each glycoprotein Fterm glycoprotein Although each glycoprotein, N-glycosylation site, and attached glycan revealed distinct dynamic changes, we did observe a few general trends. 32125861 6 58 gly N-glycosylation 1184:1198 arg2 N-glycosylation site N-glycosylation site site Although each glycoprotein, N-glycosylation site, and attached glycan revealed distinct dynamic changes, we did observe a few general trends. 28931684 7 0 gly glycosylation 1321:1333 arg2 N-linked glycosylation site N-linked glycosylation site site In contrast, recombinant viruses from which the VNDT motif is deleted or from which N-linked glycosylation site is mutated by single amino acid substitution, are highly attenuated and non-lethal. 16037490 8 61 gly glycopeptide 1824:1835 arg2 the enriched glycopeptide the enriched glycopeptide glycopeptide The results also demonstrated that the enriched glycopeptide provides resources for site-specific analysis of oligosaccharides in glycoproteomics. 7527739 3 80 part_of protein 464:470 arg1 the two major antigenic regions protein the two major antigenic regions Fterm Site protein regions The sequence of the two major antigenic regions of the e2 protein are partly well conserved within the described types of HCV. 11258925 0 38 gly glycosylation 24:36 arg2 the glycosylation sites the glycosylation sites sites Characterization of the glycosylation sites in cyclooxygenase-2 using mass spectrometry. 21264968 4 27 gly glycosylated 1611:1622 arg1 densely glycosylated MUC4 densely glycosylated MUC4 PUBTATOR MUC4 4585 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 44 gly Thr1 1665:1668 arg1 six α-GalNAc residues residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 six α-GalNAc residues residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 98 gly O-glycosylation 1413:1427 arg1 naked MUC4 peptide naked MUC4 peptide peptide In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 98 gly O-glycosylation 1413:1427 arg1 Thr10 Thr10 Thr10 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 21264968 4 127 gly containing 1629:1638 arg1 densely glycosylated MUC4 AND six α-GalNAc residues densely glycosylated MUC4 Thr15 six α-GalNAc residues PUBTATOR AminoAcid MUC4 4585 residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15 In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15. 7559469 8 40 gly glycosylation 1402:1414 arg2 only the position 99 glycosylation site (Asn99-X-Thr101) only the position 99 glycosylation site (Asn99-X-Thr101) site These data suggest that only the position 99 glycosylation site (Asn99-X-Thr101) in tHON is important in the reduction of binding of osteonectin to collagen V. Consistent with the binding data is the observation that both the N71Q and T73A mutant proteins migrate on SDS-polyacrylamide gel electrophoresis gels identically to wild-type tHON, suggesting that there is little or no N-glycosylation of residue 71 in wild-type osteonectin. 7559469 8 40 gly glycosylation 1402:1414 arg2 99 99 position 99 These data suggest that only the position 99 glycosylation site (Asn99-X-Thr101) in tHON is important in the reduction of binding of osteonectin to collagen V. Consistent with the binding data is the observation that both the N71Q and T73A mutant proteins migrate on SDS-polyacrylamide gel electrophoresis gels identically to wild-type tHON, suggesting that there is little or no N-glycosylation of residue 71 in wild-type osteonectin. 7559469 8 65 gly N-glycosylation 1737:1751 arg1 residue 71 residue 71 residue 71 These data suggest that only the position 99 glycosylation site (Asn99-X-Thr101) in tHON is important in the reduction of binding of osteonectin to collagen V. Consistent with the binding data is the observation that both the N71Q and T73A mutant proteins migrate on SDS-polyacrylamide gel electrophoresis gels identically to wild-type tHON, suggesting that there is little or no N-glycosylation of residue 71 in wild-type osteonectin. 31244828 1 64 gly glycoprotein 172:183 arg1 myelin oligodendrocytes glycoprotein myelin oligodendrocytes glycoprotein Fterm glycoprotein Autoantibodies to myelin oligodendrocytes glycoprotein (MOG) are found in a fraction of patients with inflammatory demyelination and are detected with MOG-transfected cells. 31244828 1 64 gly glycoprotein 172:183 arg1 MOG MOG PUBTATOR MOG 4340 Autoantibodies to myelin oligodendrocytes glycoprotein (MOG) are found in a fraction of patients with inflammatory demyelination and are detected with MOG-transfected cells. 9459000 6 34 gly glycosylation 873:885 arg1 residue 83 residue 83 residue 83 This disrupts the N-glycosylation site starting at Asn 83 preventing glycosylation at residue 83 in the PI Zbristol protein and explains the protein isoelectric focusing and SDS gel electrophoresis results. 9459000 6 62 gly N-glycosylation 822:836 arg2 the N-glycosylation site the N-glycosylation site site This disrupts the N-glycosylation site starting at Asn 83 preventing glycosylation at residue 83 in the PI Zbristol protein and explains the protein isoelectric focusing and SDS gel electrophoresis results. 10731668 4 35 gly glycosylation 671:683 arg2 this atypical glycosylation site this atypical glycosylation site site Deletion of this atypical glycosylation site by replacement of Asn(32 ) with lysine changed neither the expression nor function of the full length EGFR in CHO cells. 15009203 0 41 gly N- 0:1 arg1 granulocyte-macrophage colony-stimulating factor granulocyte-macrophage colony-stimulating factor N- PUBTATOR granulocyte-macrophage colony-stimulating factor 1437 N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line. 15009203 0 65 gly glycosylation 34:46 arg2 glycosylation site occupancy glycosylation site occupancy site N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line. 15009203 0 109 gly carbohydrates 16:28 arg1 granulocyte-macrophage colony-stimulating factor granulocyte-macrophage colony-stimulating factor carbohydrates PUBTATOR granulocyte-macrophage colony-stimulating factor 1437 N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line. 26339047 0 50 gly Asparagine-Linked 16:32 arg1 Asparagine-Linked Glycan Density Asparagine Asparagine-Linked Glycan Density Asparagine Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity. 12626422 3 51 gly asparagine-linked 588:604 arg1 asparagine-linked glycans asparagine asparagine-linked glycans asparagine CDG-I is characterized by underglycosylation of glycoproteins due to defects in the assembly or transfer of the common dolichol-pyrophosphate-linked oligosaccharide precursor of asparagine-linked glycans. 12626422 3 85 gly glycoproteins 458:470 arg1 glycoproteins glycoproteins Fterm glycoproteins CDG-I is characterized by underglycosylation of glycoproteins due to defects in the assembly or transfer of the common dolichol-pyrophosphate-linked oligosaccharide precursor of asparagine-linked glycans. 12626422 3 88 gly underglycosylation 436:453 arg1 glycoproteins glycoproteins Fterm glycoproteins CDG-I is characterized by underglycosylation of glycoproteins due to defects in the assembly or transfer of the common dolichol-pyrophosphate-linked oligosaccharide precursor of asparagine-linked glycans. 23925152 0 74 gly glycosylation 40:52 arg2 N-linked glycosylation site N-linked glycosylation site site Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism. 8435067 8 19 gly glycosylation 1016:1028 arg2 the second glycosylation site the second glycosylation site site However, removal of the second glycosylation site at Asn-233 interferes dramatically with the formation of mature enzyme. 10712595 0 8 gly has 20:22 arg1 Salmon antithrombin AND only three carbohydrate side chains Salmon antithrombin only three carbohydrate side chains PUBTATOR antithrombin 462 Salmon antithrombin has only three carbohydrate side chains, and shows functional similarities to human beta-antithrombin. 2202300 3 25 gly glycosylation 567:579 arg2 a glycosylation site peptide probe a glycosylation site peptide probe site To accomplish this the level of glycosylation site binding protein (GSBP) activity, measured by photolabeling with a glycosylation site peptide probe, was carried out in preparations of 3T3 cells and in E. coli transformed with human thyroid hormone binding protein cDNA. 2202300 3 41 gly glycosylation 482:494 arg2 glycosylation site binding protein (GSBP) activity glycosylation site binding protein (GSBP) activity site To accomplish this the level of glycosylation site binding protein (GSBP) activity, measured by photolabeling with a glycosylation site peptide probe, was carried out in preparations of 3T3 cells and in E. coli transformed with human thyroid hormone binding protein cDNA. 17994628 6 39 gly glycopeptides 974:986 arg2 obtained glycopeptides obtained glycopeptides glycopeptides Isolated IgGs were digested with trypsin, and obtained glycopeptides were analyzed by nano-LC-MS. 21653661 3 7 gly glycopeptide 653:664 arg2 glycopeptide concentrations glycopeptide concentrations glycopeptide The successful completion of glycosylation analysis is still a major analytical challenge due to the complexity of samples, wide dynamic range of glycopeptide concentrations, and glycosylation heterogeneity. 29232830 7 43 gly glycopeptide 945:956 arg2 glycopeptide profiles glycopeptide profiles glycopeptide Whilst glycopeptide profiles largely paralleled those of their parent proteins, there was evidence of altered N-glycosylation site occupancy or sialic acid content prior to diagnosis for some proteins, most notably of immunoglobulin gamma chains. 29232830 7 51 gly N-glycosylation 1048:1062 arg2 altered N-glycosylation site occupancy altered N-glycosylation site occupancy site Whilst glycopeptide profiles largely paralleled those of their parent proteins, there was evidence of altered N-glycosylation site occupancy or sialic acid content prior to diagnosis for some proteins, most notably of immunoglobulin gamma chains. 24307706 2 24 gly N-glycosylation 351:365 arg2 one potential N-glycosylation site one potential N-glycosylation site site Spaca7 transcripts are detected only in testis and predict a 158-residue mature polypeptide with one potential N-glycosylation site and no cysteines. 27377235 0 43 gly glycosylation 9:21 arg1 Kv1.2 voltage-gated potassium channel Kv1.2 voltage-gated potassium channel OGER voltage-gated potassium channel N-linked glycosylation of Kv1.2 voltage-gated potassium channel facilitates cell surface expression and enhances the stability of internalized channels. 9662708 6 34 gly glycosylation 928:940 arg2 one O-linked glycosylation site one O-linked glycosylation site site From the amino acid sequence, we predicted two potential N-linked and one O-linked glycosylation site. 24799124 0 43 gly ceruloplasmin 49:61 arg1 Mass-selected site-specific core-fucosylation ceruloplasmin Mass-selected site-specific core-fucosylation PUBTATOR ceruloplasmin 1356 Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. 24799124 0 50 gly core-fucosylation 28:44 arg1 ceruloplasmin ceruloplasmin PUBTATOR ceruloplasmin 1356 Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. 3087774 3 5 part_of beta-chain 361:370 arg1 Asn-268 beta-chain Asn-268 Fterm SpecificSite beta-chain Asn-268 Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment. 3087774 3 5 part_of beta-chain 361:370 arg1 the sites beta-chain the sites Fterm Site beta-chain sites Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment. 3087774 3 5 part_of beta-chain 361:370 arg1 Asn-63 beta-chain Asn-63 Fterm SpecificSite beta-chain Asn-63 Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment. 3087774 3 6 part_of alpha-chain 391:401 arg1 Asn-268 alpha-chain Asn-268 PUBTATOR SpecificSite alpha-chain 2217 Asn-268 Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment. 3087774 3 6 part_of alpha-chain 391:401 arg1 the sites alpha-chain the sites PUBTATOR Site alpha-chain 2217 sites Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment. 3087774 3 6 part_of alpha-chain 391:401 arg1 Asn-63 alpha-chain Asn-63 PUBTATOR SpecificSite alpha-chain 2217 Asn-63 Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment. 8407981 0 51 gly glycosylation 5:17 arg1 cytochrome P-450 cytochrome P-450(arom) PUBTATOR cytochrome P-450(arom) 55010 Core glycosylation of cytochrome P-450(arom). 29775240 2 30 part_of PNGase 487:492 arg1 PNGase F-resistant N-glycopeptides PNGase PNGase F-resistant N-glycopeptides OGER Site PNGase Q96IV0 N-glycopeptides We report the migration of SugarQb to the latest and free version of Proteome Discoverer 2.1, and apply it to the analysis of PNGase F-resistant N-glycopeptides from mouse embryonic stem cells. 9712881 0 70 part_of protein 55:61 arg1 Glu681 AE1 protein Glu681 PUBTATOR AminoAcid AE1 protein 6521 Glu681 Topology of the region surrounding Glu681 of human AE1 protein, the erythrocyte anion exchanger. 8783018 2 45 gly glycosylated 406:417 arg1 two glycosylated variants two glycosylated variants Fterm variants Sodium dodecyl sulfate-polyacrylamide get electrophoresis (SDS-PAGE) of natural, human interferon-gamma (IFN-gamma) showed two glycosylated variants with apparent molecular masses of 20 and 24 kDa. 6604728 6 14 gly glycoprotein 1567:1578 arg1 the fully processed glycoprotein the fully processed glycoprotein Fterm glycoprotein Our results conclusively demonstrate that the pattern of oligosaccharide microheterogeneity at the two glycosylation sites of the H-2Kk antigen derived from AKTB-1b cells is stable and that each site differs as to the specific array of oligosaccharide types found on the fully processed glycoprotein. 6604728 6 29 gly found 1538:1542 arg1 the fully processed glycoprotein AND oligosaccharide types the fully processed glycoprotein oligosaccharide types Fterm glycoprotein Our results conclusively demonstrate that the pattern of oligosaccharide microheterogeneity at the two glycosylation sites of the H-2Kk antigen derived from AKTB-1b cells is stable and that each site differs as to the specific array of oligosaccharide types found on the fully processed glycoprotein. 6604728 6 87 gly glycosylation 1383:1395 arg2 the two glycosylation sites the two glycosylation sites sites Our results conclusively demonstrate that the pattern of oligosaccharide microheterogeneity at the two glycosylation sites of the H-2Kk antigen derived from AKTB-1b cells is stable and that each site differs as to the specific array of oligosaccharide types found on the fully processed glycoprotein. 26029999 5 51 gly N-glycosylation 788:802 arg2 individual N-glycosylation sites individual N-glycosylation sites sites Loss of individual N-glycosylation sites had no effect on the level of expression or membrane localization of CD133. 26224460 7 20 part_of site 1270:1273 arg1 the HA protein protein site Fterm Site protein site Moreover, reverse genetic studies established that an E627K substitution in PB2 and the loss of the N-glycosylation site in the HA protein (aa166) are critical virulence markers in the mouse-adapted H9N2 virus. 19763269 8 89 gly glycosylation 1461:1473 arg2 a single potential N-linked glycosylation site a single potential N-linked glycosylation site site This V1V2-dependent escape pathway was retained over time, and its utility was reflected in the virus's ability to escape from two distinct monoclonal antibodies (Mabs) derived from this same patient via introduction of a single potential N-linked glycosylation site in V2. 16823988 0 76 gly glycoproteins 68:80 arg1 sialic acid glycoproteins sialic acid glycoproteins Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. 23184955 1 9 gly glycoprotein 251:262 arg1 the O-linked glycoprotein GalNAcα-[(13)C the O-linked glycoprotein GalNAcα-[(13)C Enzymatic addition of GalNAc to isotopically labeled IFNα2a produced in Escherichia coli yielded the O-linked glycoprotein GalNAcα-[(13)C,(15)N]IFNα2a. 12214108 3 9 part_of protein 414:420 arg1 residue 183 protein residue 183 Fterm SpecificSite protein residue 183 One pathogenic mutation, Thr to Ala at residue 183 of the human prion protein, blocks addition of the first glycan to the Asp residue 181. 23776238 4 55 gly N-glycosylation 729:743 arg1 BCMA BCMA PUBTATOR BCMA 608 We then investigated the effect of N-glycosylation on the function of BCMA and found that the dexamethasone-induced apoptosis in malignant plasma cells can be rescued by treatment with BCMA ligands, such as a proliferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF), whereas removal of terminal sialic acid on plasma cells further potentiated the ligand-mediated protection. 28770921 8 23 part_of HsPLG 1339:1343 arg1 the HsPLG K4 domain HsPLG the HsPLG K4 domain Cterm Site HsPLG P00747 domain On the other hand, open GiENO conformations from all-atom and coarse-grained simulations indicated a high preference of the HsPLG K4 domain for lysine residues 186 and 188. 27038031 5 68 gly N-glycosylation 733:747 arg2 all putative N-glycosylation sites all putative N-glycosylation sites sites The occupancy of all putative N-glycosylation sites on the pentameric and hexameric IgM were able to be determined. 27038031 5 72 gly occupancy 707:715 arg2 all putative N-glycosylation sites all putative N-glycosylation sites sites The occupancy of all putative N-glycosylation sites on the pentameric and hexameric IgM were able to be determined. 24872415 7 73 gly N-glycosylation 1089:1103 arg2 this N-glycosylation site this N-glycosylation site site The frequently expressed MICA allele 008, with an altered transmembrane and intracellular domain, was not affected by mutation of this N-glycosylation site. 3898078 2 16 part_of MuTNF 398:402 arg1 a mature MuTNF sequence MuTNF a mature MuTNF sequence Cterm Site MuTNF P06804 sequence The cDNA encodes a polypeptide consisting of a 79 amino acid pre sequence followed by a mature MuTNF sequence of 156 amino acids. 14691230 11 11 gly glycosylation 1665:1677 arg1 ADA binding ADA binding OGER ADA P00813 Our studies indicate that glycosylation of DPPIV is not required for ADA binding. 14691230 11 11 gly glycosylation 1665:1677 arg1 DPPIV DPPIV PUBTATOR DPPIV 1803 Our studies indicate that glycosylation of DPPIV is not required for ADA binding. 26911932 3 46 gly glycoforms 338:347 arg1 macroheterogeneous FSH glycoforms macroheterogeneous FSH glycoforms PUBTATOR FSH 14308 Recently, macroheterogeneous FSH glycoforms consisting of β-subunits that differ in N-glycan number were identified in pituitaries of several species and subsequently the recombinant human FSH glycoforms biochemically characterized. 26911932 3 114 gly glycoforms 498:507 arg1 recombinant human FSH recombinant human FSH PUBTATOR FSH 14308 Recently, macroheterogeneous FSH glycoforms consisting of β-subunits that differ in N-glycan number were identified in pituitaries of several species and subsequently the recombinant human FSH glycoforms biochemically characterized. 29253009 2 16 part_of MHC-I-restricted 478:493 arg1 several MHC-I-restricted epitopes MHC several MHC-I-restricted epitopes PUBTATOR Site MHC 3107 epitopes Lymphocytic choriomeningitis virus (LCMV) infection of H-2b mice generates CD8+ CTL responses directed towards several MHC-I-restricted epitopes including the peptides GP92 (CSANNSHHYI) and GP392 (WLVTNGSYL), both with a N-glycosylation site. 29253009 2 16 part_of MHC-I-restricted 478:493 arg1 the peptides GP92 (CSANNSHHYI) and GP392 (WLVTNGSYL) MHC the peptides GP92 (CSANNSHHYI) and GP392 (WLVTNGSYL) PUBTATOR Site MHC 3107 peptides Lymphocytic choriomeningitis virus (LCMV) infection of H-2b mice generates CD8+ CTL responses directed towards several MHC-I-restricted epitopes including the peptides GP92 (CSANNSHHYI) and GP392 (WLVTNGSYL), both with a N-glycosylation site. 6604728 1 15 gly glycosylation 325:337 arg2 the two major glycosylation sites the two major glycosylation sites sites The H-2Kk glycoprotein has been isolated by monoclonal antibody affinity chromatography, and an analysis of the asparagine-linked oligosaccharides present at the two major glycosylation sites has been performed. 6604728 1 42 gly present 300:306 arg1 the two major glycosylation sites AND the asparagine-linked oligosaccharides the two major glycosylation sites the asparagine-linked oligosaccharides sites The H-2Kk glycoprotein has been isolated by monoclonal antibody affinity chromatography, and an analysis of the asparagine-linked oligosaccharides present at the two major glycosylation sites has been performed. 6604728 1 47 gly asparagine-linked 265:281 arg1 the asparagine-linked oligosaccharides asparagine the asparagine-linked oligosaccharides asparagine The H-2Kk glycoprotein has been isolated by monoclonal antibody affinity chromatography, and an analysis of the asparagine-linked oligosaccharides present at the two major glycosylation sites has been performed. 6604728 1 61 gly glycoprotein 163:174 arg1 The H-2Kk glycoprotein The H-2Kk glycoprotein PUBTATOR H-2Kk glycoprotein 14972 The H-2Kk glycoprotein has been isolated by monoclonal antibody affinity chromatography, and an analysis of the asparagine-linked oligosaccharides present at the two major glycosylation sites has been performed. 26968544 9 89 gly dystrophin-glycoprotein 1750:1772 arg1 dystrophin-glycoprotein dystrophin-glycoprotein OGER dystrophin P11532 These studies demonstrate that DCM mutations in δ-sarcoglycan can exert a dominant negative effect on dystrophin-glycoprotein complex function leading to myocardial mechanical instability that may underlie the pathogenesis of δ-sarcoglycan-associated DCM. 6980014 5 46 gly contains 765:772 arg1 fragment I AND one carbohydrate chain fragment I one carbohydrate chain fragment From the results of these studies, we propose that fragment I contains one carbohydrate chain that can be of either the biantennary or triantennary type. 20386867 5 67 gly N-glycosylation 1000:1014 arg2 a known N-glycosylation site a known N-glycosylation site site The c.1564A>G mutation obliterated a known N-glycosylation site and its p.N522S mutant enzyme had ~10% of expressed wild-type activity. 12765790 1 22 gly Polysialylated 77:90 arg1 NCAM NCAM PUBTATOR NCAM 17967 Polysialylated neural cell adhesion molecule (NCAM) was immunoaffinity-purified from the brains of newborn calves. 10024532 2 59 part_of region 402:407 arg1 an N-glycosylation consensus sequence region an N-glycosylation consensus sequence sequence In addition to the conserved N-glycosylation site at Asn-297, an N-glycosylation consensus sequence (Asn-Asn-Ser) is located at position 75 in the variable region of its heavy chain. 7685965 6 61 gly glycosylation 1026:1038 arg2 the glycosylation site the glycosylation site site Partial enzymatic deglycosylation of isolated HA possessing the glycosylation site restored the ability of the T-cell clones to proliferate. 15804357 9 108 gly N-glycosylation 1095:1109 arg2 a N-glycosylation site a N-glycosylation site site It possesses five putative transmembrane (TM) regions with a cleavage site, a N-glycosylation site, and a number of phosphorylation sites. 15804357 9 108 gly N-glycosylation 1095:1109 arg2 phosphorylation sites sites sites It possesses five putative transmembrane (TM) regions with a cleavage site, a N-glycosylation site, and a number of phosphorylation sites. 28714086 7 4 part_of sites 1269:1273 arg1 each subunit subunit sites Fterm Site subunit sites ABSTRACT: Ionotropic glutamate receptors (iGluRs) are tetrameric proteins with between four and 12 consensus sites for N-glycosylation on each subunit, which potentially allows for a high degree of structural diversity conferred by this post-translational modification. 12731887 3 9 part_of residues 667:674 arg1 full-length p67 p67 residues PUBTATOR AminoAcid p67 64370 residues in By site-directed mutagenesis, (27)TSST(30) and (60)SGTS(63) clusters were substituted with (27)AAGA(30) and (60)AGAA(63) amino acid residues in full-length p67, and their EGFP fusions were constitutively expressed in rat tumor hepatoma cells (KRC-7). 17606981 1 4 gly glycoproteins 195:207 arg1 cell-surface glycoproteins cell-surface glycoproteins Fterm glycoproteins During T-cell development and activation, dramatic changes occur in glycan structures that decorate cell-surface glycoproteins. 2721453 9 109 gly glycosylation 1594:1606 arg2 the single glycosylation site the single glycosylation site site Although great microheterogeneity is present even at the single glycosylation site on the beta-subunit of secreted TSH, a pattern of sialylation and sulfation could be discerned. 11251288 6 64 part_of glycoprotein 1192:1203 arg1 three sites glycoprotein three sites Fterm Site glycoprotein sites Here, we have shown that the approach can be applied to the glycoprotein hormone erythropoietin, an important therapeutic glycoprotein with three sites of N-glycosylation that are essential for in vivo biological activity. 15448154 5 40 part_of domain 833:838 arg1 the hybrid domain domain the hybrid domain domain The interaction between metal binding sites in the I-like domain and the interface with the hybrid domain was examined in double mutants. 9142045 5 56 gly glycosylation 1211:1223 arg2 a glycosylation site a glycosylation site site We speculate that ATF (residues 6-135) binds to uPAR while the carboxyl terminal fragment (residues 136-411), which includes a glycosylation site at residue 144, binds to the lectinlike site of Mo1, thus fostering the linkage between the two receptors. 9142045 5 56 gly glycosylation 1211:1223 arg2 residue 144 residue 144 residue 144 We speculate that ATF (residues 6-135) binds to uPAR while the carboxyl terminal fragment (residues 136-411), which includes a glycosylation site at residue 144, binds to the lectinlike site of Mo1, thus fostering the linkage between the two receptors. 3023956 0 25 part_of v-ros 37:41 arg1 the v-ros sequence ros the v-ros sequence OGER Site ros Q63132 sequence Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule. 1566570 1 45 part_of protein 154:160 arg1 the deduced envelope (E) protein sequences protein the deduced envelope (E) protein sequences Fterm Site protein sequences We have compared the deduced envelope (E) protein sequences of two biologically well-characterized yellow fever (YF) virus vaccine strains. 21329800 2 18 gly glycoproteins 235:247 arg1 most glycoproteins most glycoproteins Fterm glycoproteins The addition of N- and O-glycans affects intracellular processes like the folding and trafficking of most glycoproteins. 20053750 4 31 gly residue 846:852 arg1 the N-linked glycan residue 523 the N-linked glycan residue 523 Sequence analysis and superposition of the NDV and hPIV-3 HN dimer structures revealed that, similar to what was seen in hPIV-1, the N-linked glycan at residue 523 on hPIV-3 HN may cover a second receptor-binding site. 20053750 4 34 gly glycan 836:841 arg1 hPIV-3 HN hPIV-3 HN glycan Cterm hPIV-3 HN 4758 Sequence analysis and superposition of the NDV and hPIV-3 HN dimer structures revealed that, similar to what was seen in hPIV-1, the N-linked glycan at residue 523 on hPIV-3 HN may cover a second receptor-binding site. 11238869 4 41 gly glycosylation 612:624 arg2 asparagine 197 asparagine 197 asparagine 197 Here we show that elimination of a single glycosylation site at asparagine 197 in the V1/V2 stem is sufficient for CD4-independent gp120 binding to CCR5 and for HIV-1 entry into CD4-negative cells expressing CCR5. 11238869 4 41 gly glycosylation 612:624 arg2 a single glycosylation site a single glycosylation site site Here we show that elimination of a single glycosylation site at asparagine 197 in the V1/V2 stem is sufficient for CD4-independent gp120 binding to CCR5 and for HIV-1 entry into CD4-negative cells expressing CCR5. 1402806 8 29 gly glycoprotein 1426:1437 arg1 the M glycoprotein the M glycoprotein Fterm glycoprotein Virions released from tunicamycin-treated cells contained the M glycoprotein but were devoid of both peplomer (S) and haemagglutinin-esterase (HE) proteins. 23874792 5 48 gly glycosylation 889:901 arg2 an N-linked glycosylation site an N-linked glycosylation site site This mutation removes an N-linked glycosylation site. 31611356 2 28 part_of N295 349:352 arg1 A key factor factor N295 Fterm SpecificSite factor N295 A key factor for Grft potency is glycosylation at N295 of gp120, which is directly adjacent to N332, a target glycan for an entire class of broadly neutralizing antibodies (bNAbs). 31611356 2 74 part_of gp120 357:361 arg1 N295 gp120 N295 PUBTATOR SpecificSite gp120 3700 N295 A key factor for Grft potency is glycosylation at N295 of gp120, which is directly adjacent to N332, a target glycan for an entire class of broadly neutralizing antibodies (bNAbs). 24884609 7 52 gly N-glycosylation 1156:1170 arg2 N-glycosylation sites N-glycosylation sites sites While microheterogeneity of N-glycoforms differed between ITIH4 protein expressed in HEK293 cells and protein isolated from serum, occupancy of N-glycosylation sites did not differ. 24884609 7 79 gly occupancy 1143:1151 arg2 N-glycosylation sites N-glycosylation sites sites While microheterogeneity of N-glycoforms differed between ITIH4 protein expressed in HEK293 cells and protein isolated from serum, occupancy of N-glycosylation sites did not differ. 23341449 2 75 gly polysialylation 274:288 arg1 NCAM N-glycans NCAM N-glycans The polysialylation of NCAM N-glycans decreases cell adhesion and alters signaling. 7540044 0 72 gly glycoprotein 178:189 arg1 the rabies virus glycoprotein the rabies virus glycoprotein Fterm glycoprotein Comparison of the effects of amino acid substitutions and beta-N- vs. alpha-O-glycosylation on the T-cell stimulatory activity and conformation of an epitope on the rabies virus glycoprotein. 9524075 3 61 gly glycosylation 396:408 arg2 the only glycosylation site the only glycosylation site site HEK 293-cells which do not express cathepsin S were transfected with cDNA of either wild type human procathepsin S or a mutant procathepsin S in which Asn of the only glycosylation site in the proregion was replaced by Gln. 15243097 3 18 gly glycosylation 400:412 arg2 an N-linked glycosylation site an N-linked glycosylation site site An amino acid substitution in the HA1 region caused them to acquire an N-linked glycosylation site. 7849028 7 76 part_of p62 946:948 arg1 The amino terminus p62 The amino terminus PUBTATOR Site p62 117268 terminus The amino terminus of rat p62 is poorly glycosylated with no O-linked GlcNAc sites between Lys22 and Lys97; the carboxyl terminus has one known glycosylation site at Ser471. 7849028 7 23 part_of has 1050:1052 arg1 the carboxyl terminus AND one known glycosylation site the carboxyl terminus one known glycosylation site site The amino terminus of rat p62 is poorly glycosylated with no O-linked GlcNAc sites between Lys22 and Lys97; the carboxyl terminus has one known glycosylation site at Ser471. 9459000 0 33 part_of 1-antitrypsin 12:24 arg1 Thr-Met 85 alpha 1-antitrypsin Thr-Met 85 PUBTATOR Site alpha 1-antitrypsin 5265 Thr-Met A new alpha 1-antitrypsin mutation, Thr-Met 85, (PI Zbristol) associated with novel electrophoretic properties. 9459000 0 38 part_of alpha 6:10 arg1 Thr-Met 85 alpha 1-antitrypsin Thr-Met 85 PUBTATOR Site alpha 1-antitrypsin 5265 Thr-Met A new alpha 1-antitrypsin mutation, Thr-Met 85, (PI Zbristol) associated with novel electrophoretic properties. 18085777 7 22 gly glycoprotein 963:974 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Using these strategies, we successfully synthesized a glycoprotein having an intact and homogeneous complex-type sialyloligosaccharide. 18085777 7 9 gly having 976:981 arg1 a glycoprotein AND an intact and homogeneous complex-type sialyloligosaccharide a glycoprotein an intact and homogeneous complex-type sialyloligosaccharide Fterm glycoprotein Using these strategies, we successfully synthesized a glycoprotein having an intact and homogeneous complex-type sialyloligosaccharide. 8771709 11 94 part_of MPR 1711:1713 arg1 the shortened prepeptide sequence MPR the shortened prepeptide sequence OGER Site MPR O00264 sequence N-terminal amino acid sequencing of the purified preparation showed that the shortened prepeptide sequence of MPR was correctly processed by the Pichia yeast. 25213400 8 32 gly glycosylated 741:752 arg1 glycosylated P0 protein glycosylated P0 protein Fterm protein The pI of glycosylated P0 protein varies from pH 9.32 to 9.46. 8286855 6 34 gly O-glycosylation 842:856 arg2 All 16 O-glycosylation sites All 16 O-glycosylation sites sites All 16 O-glycosylation sites are explained on the basis of four motifs. 28935113 6 89 gly glycopeptide 970:981 arg2 glycopeptide libraries glycopeptide libraries glycopeptide Recently, we reported a novel system for the directed evolution of glycopeptide libraries, which could in principle be decorated with any desired glycan. 12527193 9 62 gly glycosylation 1367:1379 arg2 the conserved N linked glycosylation site the conserved N linked glycosylation site site CRB3 is localized to the apical surface and tight junctions but the conserved N linked glycosylation site does not appear to be necessary for CRB3 apical targeting. 23891555 3 63 part_of Normal 421:426 arg1 Normal IgA1 hinge region Normal IgA1 Normal IgA1 hinge region OGER Site Normal IgA1 P01876 region Normal IgA1 hinge region carries 3 to 6 O-glycans consisting of N-acetylgalactosamine (GalNAc) and galactose (Gal); both sugars may be sialylated. 23891555 3 164 part_of IgA1 428:431 arg1 Normal IgA1 hinge region Normal IgA1 Normal IgA1 hinge region OGER Site Normal IgA1 P01876 region Normal IgA1 hinge region carries 3 to 6 O-glycans consisting of N-acetylgalactosamine (GalNAc) and galactose (Gal); both sugars may be sialylated. 21215105 8 10 gly glycosylated 1629:1640 arg1 HA protein protein Fterm protein Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated. 21215105 8 10 gly glycosylated 1629:1640 arg1 303 protein position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 Fterm protein position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated. 21215105 8 10 gly glycosylated 1629:1640 arg1 site 40 protein site Fterm protein site Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated. 21215105 8 10 gly glycosylated 1629:1640 arg1 303 protein position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 Fterm protein position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated. 21215105 8 10 gly glycosylated 1629:1640 arg1 site 40 protein site Fterm protein site Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated. 27356208 4 22 gly N-glycosylation 739:753 arg2 a new N-glycosylation site a new N-glycosylation site site In this regard, selection of a suitable location on the surface of a protein for introduction of a new N-glycosylation site is a main concern. 8185569 1 1 part_of site 173:176 arg1 the human TSHR TSHR site PUBTATOR Site TSHR 7253 site Residue 113 of the thyrotropin receptor (TSHR) is a possible asparagine-linked glycosylation site in the human TSHR, but not in rat or dog TSHR. 8185569 1 36 part_of receptor 111:118 arg1 a possible asparagine-linked glycosylation site thyrotropin receptor a possible asparagine-linked glycosylation site PUBTATOR Site thyrotropin receptor 7253 site Residue 113 of the thyrotropin receptor (TSHR) is a possible asparagine-linked glycosylation site in the human TSHR, but not in rat or dog TSHR. 16227292 9 15 part_of site 1384:1387 arg1 Gc Gc site Cterm Site Gc site Three viable N glycosylation-site-deficient viruses, lacking glycans on one site or both sites on Gc, were created by reverse genetics. 16227292 9 57 part_of sites 1397:1401 arg1 Gc Gc sites Cterm Site Gc sites Three viable N glycosylation-site-deficient viruses, lacking glycans on one site or both sites on Gc, were created by reverse genetics. 8429003 4 62 gly glycoprotein 827:838 arg1 a glycoprotein a glycoprotein Fterm glycoprotein This is the first report of the occurrence of alpha-galactose residues on a glycoprotein expressed in Chinese hamster ovary cells. 1791827 3 61 part_of contains 568:575 arg1 a sequence AND 7 glutamic acid a sequence 7 glutamic acid glutamic acid The deduced amino acid sequence reveals a sequence of 492 amino acids that contains a stretch of 7 glutamic acid from position 169 and one potential glycosylation site at position 274. 1791827 3 61 part_of contains 568:575 arg1 a sequence AND one potential glycosylation site a sequence one potential glycosylation site site The deduced amino acid sequence reveals a sequence of 492 amino acids that contains a stretch of 7 glutamic acid from position 169 and one potential glycosylation site at position 274. 8443586 0 6 gly glycosylation 31:43 arg2 a silent glycosylation site a silent glycosylation site site Pro to Gly (P219G) in a silent glycosylation site results in complete glycosylation in tissue plasminogen activator. 8443586 0 8 gly glycosylation 70:82 arg1 tissue plasminogen activator tissue plasminogen activator OGER tissue plasminogen activator P00750 Pro to Gly (P219G) in a silent glycosylation site results in complete glycosylation in tissue plasminogen activator. 12867358 3 22 part_of hNaSi-1 529:535 arg1 a 65-amino acid peptide hNaSi-1 a 65-amino acid peptide PUBTATOR Site hNaSi-1 6561 peptide Polyclonal antibodies against a glutathione S-transferase fusion protein containing a 65-amino acid peptide of hNaSi-1 (GST-Si65) were raised in rabbits, purified, and then used in Western blotting and immunofluorescence experiments. 12867358 3 9 part_of containing 491:500 arg1 a glutathione S-transferase fusion protein AND a 65-amino acid peptide a glutathione S-transferase fusion protein a 65-amino acid peptide Fterm Site protein peptide Polyclonal antibodies against a glutathione S-transferase fusion protein containing a 65-amino acid peptide of hNaSi-1 (GST-Si65) were raised in rabbits, purified, and then used in Western blotting and immunofluorescence experiments. 31958346 11 42 part_of GluA1 1782:1786 arg1 the N401-glycosite GluA1 the N401-glycosite PUBTATOR SpecificSite GluA1 2890 N401 Taken together, we propose that the N401-glycosite of GluA1 receives a unique control of modification, and we also propose a novel N-glycosylation occupancy regulatory mechanism by Bip that might be associated with α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors function in the brain. 25451932 7 50 gly N-glycosylation 881:895 arg2 Asn-231 Asn-231 Asn-231 Similarly, N-glycosylation at Asn-231 protected corin from autocleavage in the frizzled-1 domain. 23339644 11 63 gly glycopeptide 2182:2193 arg2 Site-specific glycopeptide analysis Site-specific glycopeptide analysis glycopeptide Site-specific glycopeptide analysis of transmitted/founder 1086.C gp120 expressed in CHO cells revealed the presence of phosphorylated glycans, while 293T cell-produced 1086.C gp120 glycans were not phosphorylated. 8379944 1 4 gly glycoprotein 195:206 arg1 Lecithin:cholesterol acyltransferase Lecithin:cholesterol acyltransferase PUBTATOR Lecithin:cholesterol acyltransferase 3931 Lecithin:cholesterol acyltransferase (LCAT; phosphatidylcholine-sterol acyltransferase, EC 2.3.1.43) is a glycoprotein which is responsible for the formation of cholesteryl ester in plasma. 8379944 1 4 gly glycoprotein 195:206 arg1 a glycoprotein a glycoprotein Fterm glycoprotein Lecithin:cholesterol acyltransferase (LCAT; phosphatidylcholine-sterol acyltransferase, EC 2.3.1.43) is a glycoprotein which is responsible for the formation of cholesteryl ester in plasma. 23830432 2 32 gly sialylated 614:623 arg1 sialylated glycopeptides sialylated glycopeptides glycopeptides Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 23830432 2 41 gly glycoproteins 562:574 arg1 sialylated glycoproteins sialylated glycoproteins Fterm glycoproteins Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 23830432 2 81 gly glycopeptides 625:637 arg2 sialylated glycopeptides sialylated glycopeptides glycopeptides Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 23830432 2 88 gly sialylated 551:560 arg1 sialylated glycoproteins sialylated glycoproteins Fterm glycoproteins Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 23830432 2 37 gly glycosylation 418:430 arg2 three potential N-linked glycosylation sites sites sites Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 23830432 2 56 gly glycosylation 331:343 arg2 three potential N-linked glycosylation sites sites sites Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 23830432 2 56 gly glycosylation 331:343 arg2 six potential phosphorylation sites sites sites Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 23830432 2 56 gly glycosylation 331:343 arg2 six potential phosphorylation sites sites sites Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 23830432 2 40 gly containing 351:360 arg1 three potential N-linked glycosylation sites AND complex-type glycan structures sites complex-type glycan structures sites Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 23830432 2 40 gly containing 351:360 arg1 six potential phosphorylation sites AND complex-type glycan structures sites complex-type glycan structures sites Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 23830432 2 40 gly containing 351:360 arg1 six potential phosphorylation sites AND complex-type glycan structures sites complex-type glycan structures sites Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide. 8514796 9 14 gly N-glycosylation 1259:1273 arg2 the N-glycosylation site the N-glycosylation site site The sizes of these fragments and their reactivities with carboxyl-terminal-specific antibodies indicate that the receptor is cleaved at two sites in the exoplasmic domain, 7 kDa apart, and carboxyl-terminal to the N-glycosylation site. 12954207 5 59 part_of receptor-binding 859:874 arg1 the receptor-binding regions receptor the receptor-binding regions Fterm Site receptor regions Inspection of the gp120 crystal structure reveals that although the receptor-binding regions lack glycosylation, sugar moieties lie proximal to both receptor-binding sites on gp120 and thus in proximity to both the CD4BS and the CD4i epitopes. 12954207 5 62 part_of receptor-binding 940:955 arg1 both receptor-binding sites receptor both receptor-binding sites Fterm Site receptor sites Inspection of the gp120 crystal structure reveals that although the receptor-binding regions lack glycosylation, sugar moieties lie proximal to both receptor-binding sites on gp120 and thus in proximity to both the CD4BS and the CD4i epitopes. 10103002 0 57 gly glycoprotein 9:20 arg1 A 42-kDa glycoprotein A 42-kDa glycoprotein Fterm glycoprotein A 42-kDa glycoprotein from chicken egg-envelope, an avian homolog of the ZPC family glycoproteins in mammalian Zona pellucida. 10103002 0 97 gly glycoproteins 84:96 arg1 the ZPC family glycoproteins the ZPC family glycoproteins Fterm glycoproteins A 42-kDa glycoprotein from chicken egg-envelope, an avian homolog of the ZPC family glycoproteins in mammalian Zona pellucida. 16845394 1 2 part_of lectin 168:173 arg1 epidermal growth factor (EGF)-like domains lectin epidermal growth factor (EGF)-like domains Fterm Site lectin domains Crystal structures of the lectin and epidermal growth factor (EGF)-like domains of P-selectin show 'bent' and 'extended' conformations. 16845394 1 45 part_of P-selectin 225:234 arg1 epidermal growth factor (EGF)-like domains P-selectin epidermal growth factor (EGF)-like domains PUBTATOR Site P-selectin 6403 domains Crystal structures of the lectin and epidermal growth factor (EGF)-like domains of P-selectin show 'bent' and 'extended' conformations. 1686881 6 18 part_of contains 681:688 arg1 The deduced amino acid sequence AND two putative protease cleavage sites The deduced amino acid sequence two putative protease cleavage sites sites The deduced amino acid sequence contains a potential glycosylation site and two putative protease cleavage sites. 1686881 6 18 part_of contains 681:688 arg1 The deduced amino acid sequence AND a potential glycosylation site The deduced amino acid sequence a potential glycosylation site site The deduced amino acid sequence contains a potential glycosylation site and two putative protease cleavage sites. 20067810 3 14 gly glycosylated 539:550 arg1 G-hPRL hPRL PUBTATOR hPRL 5617 Although the biological activity of glycosylated hPRL (G-hPRL) has been found to be approximately 4-fold lower than that of hPRL, its physiological function is not yet well defined. 9352200 2 79 gly glycoprotein 344:355 arg1 the envelope glycoprotein gp43 the envelope glycoprotein gp43 Fterm glycoprotein As the unfertilizable coelomic egg transits the pars recta region of the oviduct, it is converted to a fertilizable egg by limited proteolysis of the envelope glycoprotein gp43 to gp41. 21940909 6 109 gly glycoprotein 1520:1531 arg1 N-linked glycoprotein enrichment N-linked glycoprotein enrichment Fterm glycoprotein Second, nonglycosylated tryptic peptide biomarkers, which generally show much higher sensitivity in mass spectrometric analyses than their glycosylated counterparts, were quantified in human hepatocellular carcinoma plasma using a label-free method with no need for N-linked glycoprotein enrichment. 28928219 0 68 part_of subunit 95:101 arg1 the F-box-combining site Dictyostelium Skp1 subunit the F-box-combining site PUBTATOR Site Dictyostelium Skp1 subunit 6500 site O2 sensing-associated glycosylation exposes the F-box-combining site of the Dictyostelium Skp1 subunit in E3 ubiquitin ligases. 21153276 0 55 gly glycosylation 31:43 arg2 an additional glycosylation site an additional glycosylation site site Incorporation of an additional glycosylation site enhances expression of functional human gonadotropin-releasing hormone receptor. 26957414 13 100 gly glycopeptides 1644:1656 arg2 glycopeptides glycopeptides glycopeptides With ISF facilitating the peptide backbone sequencing of glycopeptides, identified peptide sequence coverage was increased. 30135544 3 53 gly glycosylation 400:412 arg1 human PrP human PrP PUBTATOR PrP 5621 In this study, we attempt to elucidate the effects of glycosylation on the aggregation and toxicity of human PrP. 31244828 10 42 part_of MOG 1468:1470 arg1 the extracellular domain MOG the extracellular domain PUBTATOR Site MOG 4340 domain The folding of the extracellular domain of MOG with the formation of beta-sheets did not depend on its glycosylation as seen by circular dichroism. 7559469 8 13 part_of residue 1756:1762 arg1 wild-type osteonectin osteonectin residue PUBTATOR SpecificSite osteonectin 282077 residue 71 These data suggest that only the position 99 glycosylation site (Asn99-X-Thr101) in tHON is important in the reduction of binding of osteonectin to collagen V. Consistent with the binding data is the observation that both the N71Q and T73A mutant proteins migrate on SDS-polyacrylamide gel electrophoresis gels identically to wild-type tHON, suggesting that there is little or no N-glycosylation of residue 71 in wild-type osteonectin. 7559469 8 23 part_of site 1416:1419 arg1 tHON tHON site Cterm Site tHON 282077 site These data suggest that only the position 99 glycosylation site (Asn99-X-Thr101) in tHON is important in the reduction of binding of osteonectin to collagen V. Consistent with the binding data is the observation that both the N71Q and T73A mutant proteins migrate on SDS-polyacrylamide gel electrophoresis gels identically to wild-type tHON, suggesting that there is little or no N-glycosylation of residue 71 in wild-type osteonectin. 31511323 11 14 gly glycosylation 1654:1666 arg1 NaV1.5 NaV1.5 PUBTATOR NaV1.5 Q8NEY1 In conclusion, our results indicate that N-linked glycosylation of β2 is required for surface localization of NaV1.5, a property that is often defective in inherited cardiac arrhythmias. 14595005 3 36 part_of gp120 784:788 arg1 the V2 region gp120 the V2 region OGER Site gp120 Q14624 region The envelope glycoproteins carried by plasma virus in CD4-depleted animals were found to contain specific alterations affecting the V2 region of gp120; similar V2 changes were observed during independent monkey infections. 22354569 6 21 gly glycoprotein 825:836 arg1 glycoprotein characterization glycoprotein characterization Fterm glycoprotein The current paper describes two commonly used analytical techniques for glycoprotein characterization. 8099782 7 93 gly deglycosylated 1138:1151 arg1 native and deglycosylated saposin B native and deglycosylated saposin B Cterm native and deglycosylated saposin B When native and deglycosylated saposin B were reduced under denaturing conditions and refolded under identical conditions examination of the refolded products indicated that each protein was refolded in a qualitatively different way. 26618514 6 18 gly non-sialylated 897:910 arg1 non-sialylated anti-SNEC IgG non-sialylated anti-SNEC IgG Cterm anti-SNEC Ig In functional ex-vivo phagocytosis studies, non-sialylated anti-SNEC IgG directed SNEC preferentially into PMN but did not change their cytokine secretion profiles. 1370483 3 50 gly Gly-X-Y 471:477 arg1 59 Gly-X-Y repeats Gly 59 Gly-X-Y repeats Gly The protein consists of three regions: an NH2-terminal segment of 25 amino acids, a collagen-like domain consisting of 59 Gly-X-Y repeats, and a COOH-terminal carbohydrate recognition domain of 153 amino acids. 16415006 5 50 part_of site 722:725 arg1 either the prM or E glycoprotein glycoprotein site Fterm Site glycoprotein site The presence of a single N-linked glycosylation site on either the prM or E glycoprotein of WNV was sufficient to allow DC-SIGNR-mediated infection, demonstrating that uncleaved prM protein present on a flavivirus virion can influence viral tropism under certain circumstances. 14692455 2 20 gly glycopeptides 201:213 arg2 select glycopeptides select glycopeptides glycopeptides The studies described here exploit this fact to select glycopeptides carrying disease-associated modifications in their oligosaccharides. 23751365 7 63 gly glycosites 1146:1155 arg2 five glycosites five glycosites glycosites In the evaluation of glycosylation heterogeneity coverage, five glycosites and eleven glycopeptides from horseradish peroxidase were identified after enrichment with XCharge SAX. 23751365 7 8 gly glycopeptides 1168:1180 arg2 eleven glycopeptides peroxidase glycopeptides Fterm peroxidase glycopeptides In the evaluation of glycosylation heterogeneity coverage, five glycosites and eleven glycopeptides from horseradish peroxidase were identified after enrichment with XCharge SAX. 9507052 2 18 gly N-glycosylation 451:465 arg2 a potential N-glycosylation site a potential N-glycosylation site site The nematode proteins have a potential N-glycosylation site at the same position as mammalian cathepsins E and in common with these have atypically long N-terminal extensions. 9507052 2 18 gly N-glycosylation 451:465 arg2 the same position the same position position The nematode proteins have a potential N-glycosylation site at the same position as mammalian cathepsins E and in common with these have atypically long N-terminal extensions. 2808434 10 14 gly glycosylated 851:862 arg1 the glycosylated enzyme the glycosylated enzyme Fterm enzyme By using the latter as a source, the two enzymes were separated, and the glycosylated enzyme was purified to apparent homogeneity by multiple steps, including ConA-Sepharose affinity chromatography and Procion Red-agarose chromatography (yield, 13%; fold purification, approximately 3000). 2788224 6 41 part_of protein 1121:1127 arg1 the protein compositions protein the protein compositions Fterm Site protein positions Processing of viral precursor proteins was unaffected by the absence of vpu, and no differences were detected in the protein compositions of wild-type and mutant virions. 3778488 1 28 part_of factor 135:140 arg1 The complete amino acid sequence acidic fibroblast growth factor The complete amino acid sequence PUBTATOR Site acidic fibroblast growth factor 2246 sequence The complete amino acid sequence of human brain acidic fibroblast growth factor (aFGF) has been established. 10588947 5 66 gly glycosylated 896:907 arg1 the sites the sites sites When the C-terminal reporter peptide was released by cyanogen bromide cleavage, all of the sites were glycosylated irrespective of cell type, labeling time, or assembly status. 9925876 13 23 gly glycosylation 1672:1684 arg1 HERG HERG PUBTATOR HERG 3757 Taken together, these results strongly suggest that N-linked glycosylation is required for surface membrane expression of HERG. 22689482 0 88 gly multifucosylated 53:68 arg1 multifucosylated N-glycoforms multifucosylated N-glycoforms HPLC-ESI-MS and MS/MS structural characterization of multifucosylated N-glycoforms of the basic proline-rich protein IB-8a CON1+ in human saliva. 14749323 4 67 gly glycosylation 629:641 arg1 mOAT1 function mOAT1 function PUBTATOR mOAT1 18399 274, 1519-1524) that tunicamycin, an inhibitor of asparagine-linked glycosylation, significantly inhibited organic anion transport in COS-7 cells expressing a mouse organic anion transporter (mOAT1), suggesting an important role of glycosylation in mOAT1 function. 10677208 6 44 gly modified 1157:1164 arg1 the peptide AND hybrid and complex sugars the peptide hybrid and complex sugars peptide In High-Five cells, the peptide was found to be modified with a wide variety of hybrid and complex sugars in addition to paucomanosidic oligosaccharides. 10727230 1 16 gly glycosylation 142:154 arg1 many proteins many proteins Fterm proteins Posttranslational glycosylation is critical for biological function of many proteins, but its structural characterization is complicated by natural heterogeneity, multiple glycosylation sites, and different forms. 10727230 1 26 gly glycosylation 296:308 arg2 multiple glycosylation sites multiple glycosylation sites sites Posttranslational glycosylation is critical for biological function of many proteins, but its structural characterization is complicated by natural heterogeneity, multiple glycosylation sites, and different forms. 32321762 5 51 part_of site 1046:1049 arg1 PrPC PrPC site PUBTATOR Site PrPC 5621 site Liquid chromatography-electrospray ionization MS (LC-ESI-MS) analysis of human PrPC from both biological sources indicated that Gly-229 is the ω site in PrPC to which GPI is attached. 21829533 4 89 gly glycosylation 938:950 arg2 glycosylation site numbers glycosylation site numbers site Two alternative modes of glycosylation site alteration were involved in the evolution of human influenza virus: One was an increase in glycosylation site numbers, which mainly occurred with high frequency in the early stages of evolution. 21829533 4 94 gly glycosylation 828:840 arg2 glycosylation site alteration glycosylation site alteration site Two alternative modes of glycosylation site alteration were involved in the evolution of human influenza virus: One was an increase in glycosylation site numbers, which mainly occurred with high frequency in the early stages of evolution. 31826991 1 94 part_of hemagglutinin 183:195 arg1 Seasonal influenza carrying key hemagglutinin (HA) head region glycosylation sites hemagglutinin Seasonal influenza carrying key hemagglutinin (HA) head region glycosylation sites Fterm Site hemagglutinin sites Seasonal influenza carrying key hemagglutinin (HA) head region glycosylation sites can be removed from the lung by pulmonary surfactant protein D (SP-D). 10471296 0 29 part_of V 85:85 arg1 the second C-type domain factor V the second C-type domain OGER Site factor V P12259 domain Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. 8442916 3 6 part_of env 471:473 arg1 the env region env the env region PUBTATOR Site env 100616444 region The molecular analysis of the env region encompassed all variable domains of the external glycoprotein, gp120. 8442916 3 58 part_of glycoprotein 531:542 arg1 all variable domains glycoprotein all variable domains Fterm Site glycoprotein domains The molecular analysis of the env region encompassed all variable domains of the external glycoprotein, gp120. 3087774 4 0 part_of alpha-chain 513:523 arg1 A third potential Asn-Xaa-Thr/Ser glycosylation site alpha-chain site, Asn-946 PUBTATOR SpecificSite alpha-chain 2217 site, Asn-946 A third potential Asn-Xaa-Thr/Ser glycosylation site, Asn-946 of the alpha-chain, is not modified. 7689340 3 28 gly N-glycosylation 308:322 arg2 One potential N-glycosylation site One potential N-glycosylation site site One potential N-glycosylation site was identified at Asn-78. 18700760 7 45 gly sialylated 1083:1092 arg1 sialylated biantennary structures sialylated biantennary structures The glycans from the two glycosylation sites were analyzed with mass spectrometry and found to contain sialylated biantennary structures. 18700760 7 55 gly glycosylation 1005:1017 arg2 the two glycosylation sites the two glycosylation sites sites The glycans from the two glycosylation sites were analyzed with mass spectrometry and found to contain sialylated biantennary structures. 18700760 7 72 gly sites 1019:1023 arg1 The glycans sites The glycans sites The glycans from the two glycosylation sites were analyzed with mass spectrometry and found to contain sialylated biantennary structures. 8837707 8 71 gly N-glycosylation 1410:1424 arg2 the N-glycosylation site variant the N-glycosylation site variant site Two Caucasian sibs were identified with the pseudodeficiency polyadenylation signal site variant in the absence of the N-glycosylation site variant, indicating that linkage disequilibrium between the two polymorphisms is not perfect. 22689482 7 38 gly glycosylation 1248:1260 arg2 the glycosylation site the glycosylation site site Nonglycosylated IB-8a CON1(+) and the variant IB-8a CON1(-), lacking of the glycosylation site, have been also detected in human saliva. 11686319 4 12 gly glycosylation 527:539 arg2 this consensus site this consensus site site Expression studies were then carried out, to confirm Asn-linked glycosylation occurred at this consensus site and that this resulted in the AT deficient phenotype. 10191272 1 2 gly N-glycosylation 155:169 arg1 the rat AT1a angiotensin II (AII) receptor the rat AT1a angiotensin II (AII) receptor Fterm receptor The purpose of this work was to investigate the role of N-glycosylation in the expression and pharmacological properties of the the rat AT1a angiotensin II (AII) receptor. 11258925 6 5 gly glycopeptides 1076:1088 arg2 potential glycopeptides potential glycopeptides glycopeptides The MALDI MS analysis of a tryptic digest of the protein showed a number of potential glycopeptides. 12867358 2 30 gly N-glycosylation 336:350 arg1 hNaSi-1 hNaSi-1 site PUBTATOR hNaSi-1 6561 site In this study, the location and functional role of the N-glycosylation site of hNaSi-1 were studied using antifusion protein antibodies. 3023956 1 22 part_of v-ros 188:192 arg1 the v-ros sequence ros the v-ros sequence OGER Site ros Q63132 sequence We isolated a human gene (designated c-ros-1) homologous to the v-ros sequence of UR2 sarcoma virus. 9230129 6 113 part_of containing 1399:1408 arg1 the mature enzyme AND a single N-glycosylation site the mature enzyme a single N-glycosylation site Fterm Site enzyme site This identified a 17- or 21-amino-acid signal sequence, with the mature enzyme containing 260 amino acids and a single N-glycosylation site at Asn-18. 3498943 9 67 gly region 1492:1497 arg1 A murine B1 repeat region A murine B1 repeat region A murine B1 repeat was located in the 3' untranslated region of Ly-3 cDNA clones. 3498943 9 86 gly located 1461:1467 arg1 the 3' untranslated region AND A murine B1 repeat the 3' untranslated region A murine B1 repeat region A murine B1 repeat was located in the 3' untranslated region of Ly-3 cDNA clones. 2168975 4 20 gly glycoprotein 675:686 arg1 this glycoprotein this glycoprotein Fterm glycoprotein We found that one mutant protein (QN-1) having an additional N-linked oligosaccharide at amino acid 117 in the extracellular domain was incorporated into VSV virions but that the virions containing this glycoprotein were not infectious. 2168975 4 50 gly having 512:517 arg1 QN-1 AND an additional N-linked oligosaccharide QN-1 an additional N-linked oligosaccharide OGER QN-1 Q5TB80 We found that one mutant protein (QN-1) having an additional N-linked oligosaccharide at amino acid 117 in the extracellular domain was incorporated into VSV virions but that the virions containing this glycoprotein were not infectious. 2168975 4 50 gly having 512:517 arg1 one mutant protein AND an additional N-linked oligosaccharide one mutant protein an additional N-linked oligosaccharide Fterm protein We found that one mutant protein (QN-1) having an additional N-linked oligosaccharide at amino acid 117 in the extracellular domain was incorporated into VSV virions but that the virions containing this glycoprotein were not infectious. 16227249 6 28 gly glycosylation 798:810 arg2 the glycosylation site the glycosylation site site Removing the prM glycosylation site in a lineage I or II strain decreased SVP release, as did removal of the glycosylation site in a lineage I E protein. 16227249 6 65 gly glycosylation 706:718 arg2 the prM glycosylation site the prM glycosylation site site Removing the prM glycosylation site in a lineage I or II strain decreased SVP release, as did removal of the glycosylation site in a lineage I E protein. 9774483 11 15 gly NCAM 1950:1953 arg1 polysialylation NCAM polysialylation PUBTATOR NCAM 4684 These results suggest that polysialylation of NCAM is influenced by the difference between PST and STX in their preference for N-glycosylation sites on NCAM. 9774483 11 45 gly polysialylation 1931:1945 arg1 NCAM NCAM PUBTATOR NCAM 4684 These results suggest that polysialylation of NCAM is influenced by the difference between PST and STX in their preference for N-glycosylation sites on NCAM. 9774483 11 76 gly N-glycosylation 2031:2045 arg2 N-glycosylation sites N-glycosylation sites sites These results suggest that polysialylation of NCAM is influenced by the difference between PST and STX in their preference for N-glycosylation sites on NCAM. 26773038 8 39 part_of VWF 1285:1287 arg1 the VWF A2 domain VWF the VWF A2 domain PUBTATOR Site VWF 7450 domain Substitution of the surface-exposed Y1544 to aspartic acid is able to stabilize the domain in the absence of glycosylation and protect against ADAMTS13 proteolysis in both the VWF A2 domain and FLVWF. 29274340 4 84 gly released 883:890 arg1 rhGAA AND The glycans rhGAA The glycans OGER rhGAA Q6P7A9 The glycans released from rhGAA were labeled with procainamide to improve mass ionization efficiency and the sensitivity of MS/MS. 9140729 12 3 part_of SK2 2020:2022 arg1 the SK2 VH region SK2 the SK2 VH region PUBTATOR Site SK2 56848 region In contrast, both versions of the heavy chains were comparable, in yielding good humanized SK2 antibodies, suggesting that the glycosylation of the SK2 VH region has no influence in recreating a functional antigen-binding site in this humanization. 31516400 7 50 part_of N-glycoproteins 1308:1322 arg1 more than 30,000 glycosite-containing peptides N-glycoproteins more than 30,000 glycosite-containing peptides Fterm Site N-glycoproteins peptides Results: The N-GlycositeAtlas database contains more than 30,000 glycosite-containing peptides (representing > 14,000 N-glycosylation sites) from more than 7200 N-glycoproteins from different biological sources including human-derived tissues, body fluids and cell lines from over 100 studies. 31516400 7 50 part_of N-glycoproteins 1308:1322 arg1 representing > 14,000 N-glycosylation sites N-glycoproteins representing > 14,000 N-glycosylation sites Fterm Site N-glycoproteins sites Results: The N-GlycositeAtlas database contains more than 30,000 glycosite-containing peptides (representing > 14,000 N-glycosylation sites) from more than 7200 N-glycoproteins from different biological sources including human-derived tissues, body fluids and cell lines from over 100 studies. 31516400 7 72 part_of contains 1186:1193 arg1 The N-GlycositeAtlas database AND more than 30,000 glycosite-containing peptides The N-GlycositeAtlas database more than 30,000 glycosite-containing peptides Fterm Site database peptides Results: The N-GlycositeAtlas database contains more than 30,000 glycosite-containing peptides (representing > 14,000 N-glycosylation sites) from more than 7200 N-glycoproteins from different biological sources including human-derived tissues, body fluids and cell lines from over 100 studies. 31516400 7 72 part_of contains 1186:1193 arg1 The N-GlycositeAtlas database AND representing > 14,000 N-glycosylation sites The N-GlycositeAtlas database representing > 14,000 N-glycosylation sites Fterm Site database sites Results: The N-GlycositeAtlas database contains more than 30,000 glycosite-containing peptides (representing > 14,000 N-glycosylation sites) from more than 7200 N-glycoproteins from different biological sources including human-derived tissues, body fluids and cell lines from over 100 studies. 17986444 10 32 gly N-glycosylation 1814:1828 arg2 N-glycosylation site 5 N-glycosylation site 5 site Thus, our fine structure analyses suggest a comparable quality of polysialylation by ST8SiaII and ST8SiaIV and a distinct synergistic action of the two enzymes in the synthesis of long polySia chains at N-glycosylation site 5 in vivo. 25242514 11 77 gly glycosylation 1731:1743 arg1 SP-A SP-A PUBTATOR SP-A Q8IWL1 SIGNIFICANCE: Our data provide evidence that the differential glycosylation of SP-A may play distinct roles in SP-A secretion, aggregation and degradation which may contribute to familial pulmonary fibrosis caused by SP-A2 mutations. 21904849 4 68 gly glycosylation 1212:1224 arg2 the glycosylation site protein site Fterm protein site On the basis of the molecular analysis, we also found that there was a deletion of the glycosylation site (NSS) in amino acid 156 of the hemagglutinin (HA) protein when compared with that of the other Clade 2.3.2 viruses isolated between 2007 and 2011. 21672516 3 36 part_of has 399:401 arg1 The Podnl protein AND a signal peptide The Podnl protein a signal peptide Fterm Site protein peptide The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site. 21672516 3 36 part_of has 399:401 arg1 The Podnl protein AND one putative N-glycosylation site The Podnl protein one putative N-glycosylation site 21 leucine-rich repeat (LRR) motifs Fterm Site protein site The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site. 32110292 3 91 part_of region 649:654 arg1 a highly similar amino acid sequence region a highly similar amino acid sequence sequence N-Glycosylation of IgG is crucial for its effector function and makes IgG highly heterogeneous both in structure and function, although all four subclasses of IgG contain only a single N-glycosylation site in the Fc region with a highly similar amino acid sequence. 25737293 6 67 gly deglycosylated 1083:1096 arg1 deglycosylated peptides deglycosylated peptides peptides Ratiometric analysis of deglycosylated peptides and the total intensities of all peptides from the corresponding proteins allowed relative quantification of site-specific glycosylation occupancy between yeast strains with various isoforms of oligosaccharyltransferase. 9557657 1 101 gly glycoprotein 243:254 arg1 a class I integral membrane glycoprotein a class I integral membrane glycoprotein Fterm glycoprotein The hepatitis A virus cellular receptor 1 (HAVcr-1) cDNA codes for a class I integral membrane glycoprotein, termed havcr-1, of unknown natural function which serves as an African green monkey kidney (AGMK) cell receptor for HAV. 21940909 0 57 gly glycoproteins 128:140 arg1 N-linked glycoproteins N-linked glycoproteins Fterm glycoproteins Targeted mass spectrometric approach for biomarker discovery and validation with nonglycosylated tryptic peptides from N-linked glycoproteins in human plasma. 21940909 0 116 gly nonglycosylated 81:95 arg1 nonglycosylated tryptic peptides nonglycosylated tryptic peptides peptides Targeted mass spectrometric approach for biomarker discovery and validation with nonglycosylated tryptic peptides from N-linked glycoproteins in human plasma. 8193553 8 75 gly glycoprotein 1510:1521 arg1 the recombinant glycoprotein the recombinant glycoprotein Fterm glycoprotein Recombinant glycophorin A had the same O-glycan composition, whether purified from clones expressing high or moderate levels of the recombinant glycoprotein. 8193553 8 29 gly had 1392:1394 arg1 Recombinant glycophorin A AND the same O-glycan composition Recombinant glycophorin A the same O-glycan composition PUBTATOR Recombinant glycophorin A 2993 Recombinant glycophorin A had the same O-glycan composition, whether purified from clones expressing high or moderate levels of the recombinant glycoprotein. 26946944 5 47 gly glycosylation 655:667 arg2 glycosylation site glycosylation site site The carbohydrate recognition domain (CRD), metal-binding site and glycosylation site were characterized, and the structural basis for mannose/glucose-binding was elucidated. 10215412 6 44 gly domain 471:476 arg1 the first Leucine repeat domain the first Leucine repeat domain This Leu-Gln dipeptide insertion in the first Leucine repeat of the hLHR extracellular domain did not affect the ligand binding affinity of the receptor. 10215412 6 50 gly Leucine 430:436 arg1 the first Leucine repeat Leucine the first Leucine repeat Leucine This Leu-Gln dipeptide insertion in the first Leucine repeat of the hLHR extracellular domain did not affect the ligand binding affinity of the receptor. 11588155 1 79 gly B100 279:282 arg1 The carbohydrate composition apolipoprotein (apo) B100 The carbohydrate composition PUBTATOR apolipoprotein (apo) B100 338 The carbohydrate composition of apolipoprotein (apo) B100, particularly its degree of sialylation, may contribute to the atherogenic properties of low-density lipoprotein (LDL). 2242757 5 28 gly glycosylation 707:719 arg2 a second glycosylation site a second glycosylation site site Increased exposure of galactose was also detected, indicating that a second glycosylation site must be present on these molecules. 14760718 9 64 gly N-glycosylation 1291:1305 arg2 86 N-glycosylation sites 86 N-glycosylation sites sites Using two different lectins, concanavalin A and wheat germ agglutinin, this procedure was applied to human serum and a total of 86 N-glycosylation sites in 77 proteins were identified. 8331735 6 20 gly glycosylation 1132:1144 arg2 the first DEN4 NS1 glycosylation site the first DEN4 NS1 glycosylation site site These mutations ablated (i) the TBEV pre-M cleavage site, (ii) the TBEV E glycosylation site, or (iii) the first DEN4 NS1 glycosylation site. 8331735 6 53 gly glycosylation 1084:1096 arg2 the TBEV E glycosylation site the TBEV E glycosylation site site These mutations ablated (i) the TBEV pre-M cleavage site, (ii) the TBEV E glycosylation site, or (iii) the first DEN4 NS1 glycosylation site. 23661698 4 48 gly deglycosylated 518:531 arg1 Ephrin-A1 Ephrin-A1 PUBTATOR Ephrin-A1 1942 Ephrin-A1 was enzymatically deglycosylated, and its activity was evaluated in several assays using glioblastoma (GBM) cells and recombinant EphA2. 31051246 0 51 gly glycosylation 26:38 arg1 vasoinhibin vasoinhibin Fterm vasoinhibin Sequence optimization and glycosylation of vasoinhibin: Pitfalls of recombinant production. 15039521 5 29 gly glycosylation 648:660 arg1 M-sAg M-sAg OGER sAg Q9UBF6 In in vitro translation assays, the mutation Thr to Asn at aa 5 significantly impaired glycosylation of M-sAg. 17890101 2 10 gly glycosylation 406:418 arg2 the Fc glycosylation site the Fc glycosylation site site Here, we performed pharmacokinetic studies in mice with two preparations of a monoclonal IgG1 antibody enriched for complex type or high mannose type oligosaccharides at the Fc glycosylation site. 17924005 2 5 part_of Env 520:522 arg1 the Env sequences Env the Env sequences PUBTATOR Site Env 30816 sequences In 12 previously described peptides of the Env sequences we found 12 epitopes, while in 4 peptides of the Pol sequences we found 4 epitopes. 17924005 2 32 part_of Pol 583:585 arg1 the Pol sequences Pol the Pol sequences OGER Site Pol sequences In 12 previously described peptides of the Env sequences we found 12 epitopes, while in 4 peptides of the Pol sequences we found 4 epitopes. 17196421 5 19 gly glycosylation 750:762 arg2 the E-153 potential glycosylation site the E-153 potential glycosylation site site By contrast, some substitutions--charge changes in NS1 and NS5, side-chain differences in NS1, loss of the E-153 potential glycosylation site, and 11 nucleotide insertions in the 3'UTR--that have been suggested to result in an increase or attenuation of dengue infection, appeared to be associated with the level of inhibition. 10419504 4 46 gly N-glycosylated 613:626 arg1 NPC1 NPC1 PUBTATOR NPC1 O15118 Tunicamycin treatment resulted in a 140-kDa protein, the deduced size of NPC1, suggesting that NPC1 is N-glycosylated. 16040252 7 67 part_of motif 1027:1031 arg1 PEDF PEDF motif PUBTATOR PEDF 5176 We identified a motif in PEDF that is homologous to the nuclear localization signals of other proteins. 12713166 4 3 gly glycosylation 1096:1108 arg2 seven potential glycosylation sites seven potential glycosylation sites sites All the 29 mainland China isolates and six Hong Kong SAR strains also had the following common characteristics: sharing the same sequence of proteolytic cleavage site with one additional basic amino acid, RSSR, with only two exceptions; having the same amino acid motif of the receptor-binding site, YWTNV/ALY; 23 of 28 isolates bearing seven potential glycosylation sites and the remaining five having six; and sharing characteristic deduced amino acid residues Asn-183 at the receptor-binding site and Ser-130 at the potential glycosylation site. 12713166 4 59 gly glycosylation 1272:1284 arg2 the potential glycosylation site the potential glycosylation site site All the 29 mainland China isolates and six Hong Kong SAR strains also had the following common characteristics: sharing the same sequence of proteolytic cleavage site with one additional basic amino acid, RSSR, with only two exceptions; having the same amino acid motif of the receptor-binding site, YWTNV/ALY; 23 of 28 isolates bearing seven potential glycosylation sites and the remaining five having six; and sharing characteristic deduced amino acid residues Asn-183 at the receptor-binding site and Ser-130 at the potential glycosylation site. 2721453 2 35 gly released 422:429 arg2 the apoprotein AND oligosaccharides the apoprotein oligosaccharides Fterm apoprotein By dual metabolic labeling with [35S]sulfate and [3H]mannose, we have characterized oligosaccharides from secreted TSH alpha, TSH beta, and free alpha-subunits released from the apoprotein by enzymatic deglycosylation. 2721453 2 88 gly alpha-subunits 407:420 arg1 oligosaccharides alpha-subunits oligosaccharides Fterm alpha-subunits By dual metabolic labeling with [35S]sulfate and [3H]mannose, we have characterized oligosaccharides from secreted TSH alpha, TSH beta, and free alpha-subunits released from the apoprotein by enzymatic deglycosylation. 2721453 2 107 gly alpha 381:385 arg1 oligosaccharides TSH alpha oligosaccharides PUBTATOR TSH alpha 12640 By dual metabolic labeling with [35S]sulfate and [3H]mannose, we have characterized oligosaccharides from secreted TSH alpha, TSH beta, and free alpha-subunits released from the apoprotein by enzymatic deglycosylation. 17015441 4 25 gly glycoproteins 625:637 arg1 glycoproteins glycoproteins Fterm glycoproteins Unmodified TRPM8 migrates with an apparent mass of 129 kDa and can be glycosylated in Chinese hamster ovary cells to give glycoproteins with apparent masses of 136 and 147 kDa. 17015441 4 29 gly glycosylated 573:584 arg1 Unmodified TRPM8 Unmodified TRPM8 PUBTATOR Unmodified TRPM8 Q7Z2W7 Unmodified TRPM8 migrates with an apparent mass of 129 kDa and can be glycosylated in Chinese hamster ovary cells to give glycoproteins with apparent masses of 136 and 147 kDa. 12638188 8 15 gly glycoproteins 1010:1022 arg1 therapeutic glycoproteins therapeutic glycoproteins Fterm glycoproteins Our method can thus be useful in comparability assessment of therapeutic glycoproteins. 12610728 8 65 part_of B 1396:1396 arg1 The C-terminal, six-amino acid-long propeptide cathepsin B The C-terminal, six-amino acid-long propeptide PUBTATOR Site cathepsin B 1508 propeptide The C-terminal, six-amino acid-long propeptide of cathepsin B did not exhibit a discernible role in protein trafficking. 23829323 7 41 gly glycopeptides 1398:1410 arg2 glycopeptides glycopeptides glycopeptides We use a human glycoprotein standard, haptoglobin, digested with trypsin and GluC, enriched for glycopeptides using HILIC chromatography, and analyzed by LC-MS/MS to demonstrate our algorithmic strategy and evaluate its performance. 23829323 7 49 gly glycoprotein 1317:1328 arg1 a human glycoprotein standard a human glycoprotein standard Fterm glycoprotein We use a human glycoprotein standard, haptoglobin, digested with trypsin and GluC, enriched for glycopeptides using HILIC chromatography, and analyzed by LC-MS/MS to demonstrate our algorithmic strategy and evaluate its performance. 23829323 7 49 gly glycoprotein 1317:1328 arg1 haptoglobin haptoglobin PUBTATOR haptoglobin 3240 We use a human glycoprotein standard, haptoglobin, digested with trypsin and GluC, enriched for glycopeptides using HILIC chromatography, and analyzed by LC-MS/MS to demonstrate our algorithmic strategy and evaluate its performance. 28630087 2 58 gly glycoprotein 371:382 arg1 LC-MS/MS-based glycan, glycopeptide and glycoprotein profiling LC-MS/MS-based glycan, glycopeptide and glycoprotein profiling Herein, LC-MS/MS-based glycan, glycopeptide and glycoprotein profiling were utilized to first determine the heterogeneous N-glycosylation of HNE purified from neutrophil lysates and then from isolated neutrophil granules of healthy individuals. 28630087 2 108 gly N-glycosylation 445:459 arg1 HNE HNE PUBTATOR HNE 1991 Herein, LC-MS/MS-based glycan, glycopeptide and glycoprotein profiling were utilized to first determine the heterogeneous N-glycosylation of HNE purified from neutrophil lysates and then from isolated neutrophil granules of healthy individuals. 23776650 3 64 part_of contains 508:515 arg1 the Dendritic Cell Immunoreceptor AND an intracellular immunoreceptor tyrosine-based inhibitory motif the Dendritic Cell Immunoreceptor an intracellular immunoreceptor tyrosine-based inhibitory motif OGER Site Dendritic Cell Immunoreceptor Q9UMR7 motif Little is known on the glycan specificity and ligands of the Dendritic Cell Immunoreceptor (DCIR), the only classical C-type lectin that contains an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM). 23776650 3 64 part_of contains 508:515 arg1 the only classical C-type lectin AND an intracellular immunoreceptor tyrosine-based inhibitory motif the only classical C-type lectin an intracellular immunoreceptor tyrosine-based inhibitory motif Fterm Site lectin motif Little is known on the glycan specificity and ligands of the Dendritic Cell Immunoreceptor (DCIR), the only classical C-type lectin that contains an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM). 14759610 5 18 gly N-glycosylation 795:809 arg1 mutant yeast protein disulfide isomerase protein disulfide isomerase site OGER protein disulfide isomerase P07237 site The scFv proteins recognized NCS/T and N-glycosylation site of mutant yeast protein disulfide isomerase when they were in their native but not denatured state. 3964822 3 20 gly domain 552:557 arg1 the carbohydrate moiety domain the carbohydrate moiety domain The highly conserved glycosylation site at amino acid position 86 was changed from asparagine to lysine to remove the carbohydrate moiety from the first external domain of the H-2 molecule, and the phenylalanine at position 116 was changed to tyrosine, replacing the Ld residue with the Kb type amino acid analogous to Kb mutants: bm5 and bm16 mutants derived from the Kb antigen have the Ld-type residue at this position. 3964822 3 69 gly glycosylation 411:423 arg2 The highly conserved glycosylation site The highly conserved glycosylation site site The highly conserved glycosylation site at amino acid position 86 was changed from asparagine to lysine to remove the carbohydrate moiety from the first external domain of the H-2 molecule, and the phenylalanine at position 116 was changed to tyrosine, replacing the Ld residue with the Kb type amino acid analogous to Kb mutants: bm5 and bm16 mutants derived from the Kb antigen have the Ld-type residue at this position. 3964822 3 69 gly glycosylation 411:423 arg2 amino acid position 86 amino acid position 86 position 86 The highly conserved glycosylation site at amino acid position 86 was changed from asparagine to lysine to remove the carbohydrate moiety from the first external domain of the H-2 molecule, and the phenylalanine at position 116 was changed to tyrosine, replacing the Ld residue with the Kb type amino acid analogous to Kb mutants: bm5 and bm16 mutants derived from the Kb antigen have the Ld-type residue at this position. 9848675 5 2 gly glycosylation 996:1008 arg2 glycosylation site occupancy glycosylation site occupancy site Glycosylation sites and carbohydrate branch patterns were easily determined, site specific microheterogeneity (either O-acetylation of N-acetylneuraminic acids or lactosamine extensions of the carbohydrate chain length) was assessed directly, glycosylation site occupancy was evaluated qualitatively, and nonglycopeptides were resolved and analyzed on-line with ease. 9848675 5 57 gly nonglycopeptides 1058:1073 arg2 nonglycopeptides nonglycopeptides nonglycopeptides Glycosylation sites and carbohydrate branch patterns were easily determined, site specific microheterogeneity (either O-acetylation of N-acetylneuraminic acids or lactosamine extensions of the carbohydrate chain length) was assessed directly, glycosylation site occupancy was evaluated qualitatively, and nonglycopeptides were resolved and analyzed on-line with ease. 18941134 3 119 part_of sites 954:958 arg1 the highly abundant lactotransferrin lactotransferrin sites PUBTATOR Site lactotransferrin 17002 sites The predominance of Lewis X/Y along with Neu5Acalpha2-6 sialylation was found to be a salient feature of the ULF glycome, and several other protein carriers were additionally identified including the highly abundant lactotransferrin, which is N-glycosylated at two sites, both with a similar range of highly fucosylated N-glycans. 7620335 7 47 gly glycosylation 1209:1221 arg2 both N-linked glycosylation sites both N-linked glycosylation sites sites Six neutral and twelve monosialyl oligosaccharides isolated from both N-linked glycosylation sites showed similar elution profiles composed of bi-, tri- and tetra-antennary complex type oligosaccharides. 7620335 7 80 gly isolated 1181:1188 arg1 both N-linked glycosylation sites AND Six neutral and twelve monosialyl oligosaccharides both N-linked glycosylation sites Six neutral and twelve monosialyl oligosaccharides sites Six neutral and twelve monosialyl oligosaccharides isolated from both N-linked glycosylation sites showed similar elution profiles composed of bi-, tri- and tetra-antennary complex type oligosaccharides. 25452312 4 11 gly glycopeptide 331:342 arg2 glycopeptide glycopeptide glycopeptide This makes the glycopeptide analysis of exosomes important. 9008840 0 100 gly glycopeptide 61:72 arg2 a 21-amino acid glycopeptide a 21-amino acid glycopeptide glycopeptide Complete 1H and 13C resonance assignments of a 21-amino acid glycopeptide prepared from human serum transferrin. 2320574 10 0 gly glycosylation 1980:1992 arg2 the glycosylation site the glycosylation site site One explanation for the deficiency of saposin B in this disease is that the mutation may increase the degradation of saposin B by exposing a potential proteolytic cleavage site (arginine) two amino acids to the amino-terminal side of the glycosylation site when the carbohydrate side chain is absent. 6175959 12 70 gly glycosylation 1445:1457 arg1 alpha(2)-macroglobulin alpha(2)-macroglobulin site PUBTATOR alpha(2)-macroglobulin 2 site 255, 8087-8091] shows a previously recognized identity of seven residues around the thiol ester site and a second region of identity around a known glycosylation site of alpha(2)-macroglobulin. 18340083 10 66 gly N-glycosylation 1365:1379 arg1 GPIHBP1 GPIHBP1 PUBTATOR GPIHBP1 68453 These studies demonstrate that N-glycosylation of GPIHBP1 is important for the trafficking of GPIHBP1 to the cell surface. 10940860 8 50 gly glycosylated 1442:1453 arg1 consistently glycosylated recombinant glycoproteins consistently glycosylated recombinant glycoproteins Fterm glycoproteins These results support a correlation between growth state and site occupancy, which fundamentally differs from site occupancy trends previously observed and illustrates the importance of the growth profile of CHO cultures in producing consistently glycosylated recombinant glycoproteins. 10940860 8 54 gly glycoproteins 1467:1479 arg1 consistently glycosylated recombinant glycoproteins consistently glycosylated recombinant glycoproteins Fterm glycoproteins These results support a correlation between growth state and site occupancy, which fundamentally differs from site occupancy trends previously observed and illustrates the importance of the growth profile of CHO cultures in producing consistently glycosylated recombinant glycoproteins. 10474032 10 16 part_of position 1161:1168 arg1 a cytosolic fatty acid-binding protein fatty acid-binding protein position OGER Site fatty acid-binding protein P00505 position 4 The predicted amino acid sequence has one potential N-glycosylation site at position 4-6 and a cytosolic fatty acid-binding protein signature at position 5-22. 10474032 10 2 part_of has 1119:1121 arg1 The predicted amino acid sequence AND one potential N-glycosylation site The predicted amino acid sequence one potential N-glycosylation site site The predicted amino acid sequence has one potential N-glycosylation site at position 4-6 and a cytosolic fatty acid-binding protein signature at position 5-22. 2328698 8 52 gly glycosylated 1106:1117 arg1 the proteins the proteins Fterm proteins De novo synthesized rPLP-B proteins were not secreted by the explant tissue in the presence of tunicamycin, suggesting that the proteins are glycosylated. 30147434 8 33 gly glycopeptides 1397:1409 arg2 glycopeptides glycopeptides glycopeptides Based on the current results, the BA method is more universal in enriching glycopeptides, while with the MC method, cell surface glycoproteins were highly enriched, and the quantification results appear to be more dynamic because only the newly-synthesized glycoproteins were analyzed. 30147434 8 69 gly glycoproteins 1579:1591 arg1 only the newly-synthesized glycoproteins only the newly-synthesized glycoproteins Fterm glycoproteins Based on the current results, the BA method is more universal in enriching glycopeptides, while with the MC method, cell surface glycoproteins were highly enriched, and the quantification results appear to be more dynamic because only the newly-synthesized glycoproteins were analyzed. 30147434 8 72 gly glycoproteins 1451:1463 arg1 cell surface glycoproteins cell surface glycoproteins Fterm glycoproteins Based on the current results, the BA method is more universal in enriching glycopeptides, while with the MC method, cell surface glycoproteins were highly enriched, and the quantification results appear to be more dynamic because only the newly-synthesized glycoproteins were analyzed. 14693913 0 56 gly glycosylation 36:48 arg1 recombinant human bile salt-stimulated lipase recombinant human bile salt-stimulated lipase OGER bile salt-stimulated lipase P19835 Characterization of N- and O-linked glycosylation of recombinant human bile salt-stimulated lipase secreted by Pichia pastoris. 26634432 4 14 gly glycosylation 462:474 arg2 the key glycosylation site the key glycosylation site site In vitro investigations showed that Ser(89) is the key glycosylation site in mouse DMP1. 26634432 4 14 gly glycosylation 462:474 arg2 Ser(89) Ser(89) Ser(89) In vitro investigations showed that Ser(89) is the key glycosylation site in mouse DMP1. 16862459 10 77 gly glycosylation 1361:1373 arg2 no single glycosylation site no single glycosylation site site These results suggest that secretion-competent PLTP requires glycosylation but that no single glycosylation site is required. 7530394 3 29 gly glycosylation 476:488 arg1 the E protein the E protein Fterm protein The glycosylation status of the E protein of each virus was also determined by N glycosidase F (PNGase F) digestion and limited sequence analysis. 22586465 3 14 gly attach 436:441 arg1 asparagines AND The N-linked glycans asparagines The N-linked glycans asparagines The N-linked glycans attach to asparagines in the sequence context Asn-X-Ser/Thr, where X is any amino acid except proline. 16622833 8 22 gly Fucosylation 1416:1427 arg1 diantennary structures diantennary structures Fucosylation of diantennary structures was marginal and of the core alpha1,6 type. 23002422 5 29 part_of lectin-captured 1038:1052 arg1 lectin-captured N-glycopeptides lectin lectin-captured N-glycopeptides PUBTATOR Site lectin 108489979 N-glycopeptides We identified a large number of candidates for the target proteins specific to β4GalT-I by comparative analysis of β4GalT-I-deleted and wild-type mice using the LC/MS-based technique with the isotope-coded glycosylation site-specific tagging (IGOT) of lectin-captured N-glycopeptides. 9352200 6 80 gly glycosylation 788:800 arg2 an N-linked glycosylation site an N-linked glycosylation site site Conserved ZPC domains and motifs present in the Xenopus sequence included a signal peptide sequence, an N-linked glycosylation site, and 12 aligned Cys residues. 28694069 5 70 gly Aglycosylated 882:894 arg1 N297D/S298A-IYG N297D/S298A-IYG PUBTATOR D/S298A- 6531 Aglycosylated constructs N297D/S298T (DTT)-K326I/A327Y/L328G (IYG) and N297D/S298A-IYG optimally drove tumor cell phagocytosis. 2168975 1 16 gly glycoprotein 212:223 arg1 a glycoprotein a glycoprotein Fterm glycoprotein We have recently described an assay in which a temperature-sensitive mutant of vesicular stomatitis virus (VSV; mutant tsO45), encoding a glycoprotein that is not transported to the cell surface, can be rescued by expression of wild-type VSV glycoproteins from cDNA (M. Whitt, L. Chong, and J. Rose, J. Virol. 2168975 1 36 gly glycoproteins 316:328 arg1 wild-type VSV glycoproteins wild-type VSV glycoproteins Fterm glycoproteins We have recently described an assay in which a temperature-sensitive mutant of vesicular stomatitis virus (VSV; mutant tsO45), encoding a glycoprotein that is not transported to the cell surface, can be rescued by expression of wild-type VSV glycoproteins from cDNA (M. Whitt, L. Chong, and J. Rose, J. Virol. 21280237 2 69 gly glycoproteins 613:625 arg1 glycoproteins glycoproteins glycan motifs Fterm glycoproteins Mounting evidence shows that alterations in glycosylation patterns influence the pathogenesis and progression of AD, but the vast number of glycan motifs and potential glycosylation sites of glycoproteins has made the field of glycobiology difficult. 21280237 2 73 gly glycosylation 590:602 arg2 potential glycosylation sites glycoproteins sites Fterm glycoproteins sites Mounting evidence shows that alterations in glycosylation patterns influence the pathogenesis and progression of AD, but the vast number of glycan motifs and potential glycosylation sites of glycoproteins has made the field of glycobiology difficult. 25213400 4 4 gly glycosylation 384:396 arg2 11 glycosylation sites 11 glycosylation sites sites The MAG has 10 glycosylation sites; the glycoprotein OMgp has 11 glycosylation sites. 25213400 4 19 gly glycoprotein 359:370 arg1 the glycoprotein OMgp the glycoprotein OMgp Fterm glycoprotein The MAG has 10 glycosylation sites; the glycoprotein OMgp has 11 glycosylation sites. 25213400 4 42 gly glycosylation 334:346 arg2 10 glycosylation sites 10 glycosylation sites sites The MAG has 10 glycosylation sites; the glycoprotein OMgp has 11 glycosylation sites. 16227292 1 55 gly glycoproteins 142:154 arg1 The membrane glycoproteins The membrane glycoproteins Fterm glycoproteins The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc. 16227292 1 55 gly glycoproteins 142:154 arg1 Gc Gc Cterm Gc The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc. 16227292 1 34 gly two 310:312 arg1 N624 N624 and N1169 N624 and N1169 The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc. 27007620 4 57 gly glycoforms 775:784 arg1 specific proteins specific proteins Fterm proteins While these approaches have demonstrated some diagnostic potential, they are inherently insensitive to the fine molecular detail which distinguishes unique and possibly disease relevant glycoforms of specific proteins. 19706343 4 3 gly Asn-143 684:690 arg1 the glycan Asn-143 the glycan Asn-143 We hypothesized that the structure or composition of the glycan at Asn-143 might be associated with the APS symptom by shielding or exposing the Gly40-Arg43 motif towards the anti-beta2GPI autoantibody. 22354569 3 32 gly glycoprotein 348:359 arg1 a glycoprotein a glycoprotein Fterm glycoprotein As a result, a glycoprotein consists of a number of glycoforms with different combinations of glycans, potentially resulting in different stability, toxicity, and activity. 8783018 6 61 gly glycosylated 1088:1099 arg1 A second glycosylated peptide A second glycosylated peptide peptide A second glycosylated peptide, due to a very heterogeneous glycan structure, could only be observed after separation of the peptides by high performance liquid chromatography (HPLC). 8382971 1 63 part_of has 146:148 arg1 ntPA AND a variable glycosylation site ntPA a variable glycosylation site Cterm Site ntPA P00750 site Native tissue plasminogen activator (ntPA) has a variable glycosylation site on its kringle-2 domain. 8382971 1 63 part_of has 146:148 arg1 Native tissue plasminogen activator AND a variable glycosylation site Native tissue plasminogen activator a variable glycosylation site PUBTATOR Site Native tissue plasminogen activator P00750 site Native tissue plasminogen activator (ntPA) has a variable glycosylation site on its kringle-2 domain. 3455414 4 9 gly glycosylation 565:577 arg2 an N glycosylation site an N glycosylation site site These c-ros DNAs contained a tyrosine kinase domain, transmembrane domain and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus. 9832151 10 70 gly glycosylation 1485:1497 arg2 glycosylation sites glycosylation sites sites It is remarkable that despite the presence of glycosylation sites, the mutant transporter was not glycosylated. 16689758 4 61 gly N-glycosylation 688:702 arg2 the N-glycosylation site the N-glycosylation site site A mutant antibody lacking the N-glycosylation site in the variable region of the heavy chain inhibited FVIII activity by up to 40%, while inhibition by the native antibody was 80%. 9599010 3 3 gly glycosylated 509:520 arg1 The mongoose glycosylated alpha-subunit The mongoose glycosylated alpha-subunit Fterm alpha-subunit The mongoose glycosylated alpha-subunit has a higher apparent molecular mass than that of the rat glycosylated alpha-subunit, probably resulting from the additional glycosylation at Asn-187 of the mongoose subunit. 9599010 3 46 gly glycosylated 594:605 arg1 the rat glycosylated alpha-subunit the rat glycosylated alpha-subunit Fterm alpha-subunit The mongoose glycosylated alpha-subunit has a higher apparent molecular mass than that of the rat glycosylated alpha-subunit, probably resulting from the additional glycosylation at Asn-187 of the mongoose subunit. 9599010 3 41 gly glycosylation 661:673 arg1 the additional glycosylation at Asn-187 Asn-187 Asn-187 The mongoose glycosylated alpha-subunit has a higher apparent molecular mass than that of the rat glycosylated alpha-subunit, probably resulting from the additional glycosylation at Asn-187 of the mongoose subunit. 20963501 8 32 gly glycosylation 1516:1528 arg2 the putative N-linked glycosylation site the putative N-linked glycosylation site site Alignment of Izumo1 protein sequences among 15 mammalian species displayed several highly conserved regions, including LDC and YRC motifs with cysteine residues for potential disulfide bridge formation, CPNKCG motif upstream of the Ig-like domain, GLTDYSFYRVW motif upstream of the putative N-linked glycosylation site, and a number of scattered cysteine residues. 7753050 5 58 gly glycosylation 909:921 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Feline CD9 is unique in that it lacks a potential N-linked glycosylation site in the first extracellular loop, a feature common to CD9 of other species. 28300864 9 110 gly N-glycosylation 1471:1485 arg2 a known N-glycosylation site a known N-glycosylation site site The rare variants in the HYAL2 gene-based association included a missense variant (N357S) at a known N-glycosylation site and a nonsense variant (Q406*) that removes a glycophosphatidylinositol (GPI) anchor from the resulting protein. 8196176 1 7 gly glycosylation 527:539 arg2 glycosylation site binding protein glycosylation site binding protein site The protein or cDNA sequencing revealed that the membrane-associated 3,5,3'-triiodo-thyronine binding protein (T3BP) acts as a multifunctional protein:protein disulfide isomerase (PDI) catalyzing isomerization of intra- and inter-molecular disulfide bridge in the proteins, beta-subunit of prolyl 4-hydroxylase catalyzing the formation of 4-hydroxyproline in collagen molecules, glycosylation site binding protein which is a component of oligosaccharyl transferase transferring oligosaccharide chains to the asparagine residues of Asn-X-Ser/Thr site in nascent polypeptide, and a component of triglyceride transfer protein complex involved in the transfer unit of triglyceride, cholesteryl ester and phosphatidylcholine between biomembranes. 8878691 5 18 gly glycosylation 1017:1029 arg2 the N-linked glycosylation site the N-linked glycosylation site site These studies demonstrate that the signal sequence, the N-linked glycosylation site, and the C-terminal Cys residues are important for full biological activity, while at least a portion of the lysine-rich basic domain is dispensable for normal function. 30605224 6 9 gly glycoprotein 964:975 arg1 glycoprotein dynamics glycoprotein dynamics Fterm glycoprotein We next discuss the systematic and quantitative analysis of glycoprotein dynamics. 9210490 1 13 gly N-glycosylated 234:247 arg1 Dipeptidyl peptidase IV Dipeptidyl peptidase IV PUBTATOR Dipeptidyl peptidase IV 25253 Dipeptidyl peptidase IV (DPPIV, CD26) is an N-glycosylated type II plasma membrane protein. 9210490 1 13 gly N-glycosylated 234:247 arg1 an N-glycosylated type II plasma membrane protein an N-glycosylated type II plasma membrane protein Fterm protein Dipeptidyl peptidase IV (DPPIV, CD26) is an N-glycosylated type II plasma membrane protein. 28501204 0 7 gly N-glycosylation 18:32 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site Quantification of N-glycosylation site occupancy status based on labeling/label-free strategies with LC-MS/MS. 2666404 8 40 gly N-glycosylation 1166:1180 arg2 its only N-glycosylation site its only N-glycosylation site site However, its only N-glycosylation site occurs in a charged, hydrophilic segment. 16372382 10 76 gly fucosylated 1843:1853 arg1 fucosylated N-glycans fucosylated N-glycans Only glycosylation site Asn-alpha52 bears fucosylated N-glycans. 16372382 10 8 gly bears 1837:1841 arg1 Only glycosylation site Asn-alpha52 AND fucosylated N-glycans Only glycosylation site Asn-alpha52 fucosylated N-glycans site Asn Only glycosylation site Asn-alpha52 bears fucosylated N-glycans. 16372382 10 80 gly glycosylation 1806:1818 arg2 Only glycosylation site Asn-alpha52 site Asn site Asn Only glycosylation site Asn-alpha52 bears fucosylated N-glycans. 18420026 7 26 gly glycosylation 1694:1706 arg2 the glycosylation site mutation the glycosylation site mutation site Cell aggregation assay further showed there was an increased adhesion activity after the glycosylation site mutation of NECL1 molecule. 28270583 6 87 part_of site 943:946 arg1 the envelope protein protein site Fterm Site protein site These include three versions of MR766, the prototype 1947 strain (with and without a glycosylation site in the envelope protein), and H/PF/2013, a 2013 human isolate from French Polynesia representative of the virus introduced to Brazil. 12911333 11 101 part_of have 2009:2012 arg1 other ion channels AND similarly positioned native N-glycosylation sites other ion channels similarly positioned native N-glycosylation sites Fterm Site channels sites Thus other ion channels or membrane proteins may also have a high glycosylation potential on a linker but yet have similarly positioned native N-glycosylation sites among isoforms. 17899080 1 40 gly glycoproteins 145:157 arg1 N-glycans glycoproteins N-glycans Fterm glycoproteins Recently, it was shown that glycoproteins with N-glycans close to the NH(2) terminus can directly enter the calnexin/calreticulin cycle and bypass BiP binding. 9030779 4 58 gly used 628:631 arg2 these sites these sites sites Evidence is presented that five of these sites are used. 6195967 6 32 part_of Gc1 924:926 arg1 the Gc1 sequence Gc1 the Gc1 sequence PUBTATOR Site Gc1 79751 sequence This study demonstrates a post-translational glycosylation difference occurring in a single area of the Gc1 sequence which accounts for the heterogeneity observed previously. 24338886 5 79 gly glycosylation 1057:1069 arg2 the O-linked glycosylation site the O-linked glycosylation site site A low level of O-linked mannosylation was detected on Pichia-produced rhEPO at position Ser126, which is also the O-linked glycosylation site for endogenous human EPO and CHO-derived rhEPO. 6148073 0 65 gly glycoprotein 74:85 arg1 the oligosaccharides Thy-1 glycoprotein the oligosaccharides OGER Thy-1 glycoprotein P01831 Partial characterization of the oligosaccharides of mouse thymocyte Thy-1 glycoprotein. 25629924 0 30 gly glycosylation 14:26 arg1 secretory immunoglobulin A secretory immunoglobulin A Cterm secretory immunoglobulin A Site-specific glycosylation of secretory immunoglobulin A from human colostrum. 28620050 2 34 part_of IgG1 420:423 arg1 The Fc region IgG1 The Fc region OGER Site IgG1 P01857 region The Fc region of human IgG1 (IgG1-Fc) can be engineered into multimeric structures (hexa-Fcs) that bind their cognate receptors with high avidity. 10424400 10 30 gly glycosylated 1782:1793 arg1 the additionally glycosylated SHBG the additionally glycosylated SHBG PUBTATOR SHBG 6462 This observation suggests the existence of a close link between the estrogen-dependence of breast cancer and the additionally glycosylated SHBG, further supporting a critical role of the protein in the neoplasm. 24174280 3 48 gly glycosylation 816:828 arg2 N-linked glycosylation sites N-linked glycosylation sites sites Compared to the reference strain, A/Perth/16/2009 substitutions in potential N-glycosylation sites were observed in 5 HA genes at five different positions (45, 124, 128, 144, and 145) generating the losses and gains of N-linked glycosylation sites. 24174280 3 56 gly N-glycosylation 665:679 arg2 potential N-glycosylation sites potential N-glycosylation sites sites Compared to the reference strain, A/Perth/16/2009 substitutions in potential N-glycosylation sites were observed in 5 HA genes at five different positions (45, 124, 128, 144, and 145) generating the losses and gains of N-linked glycosylation sites. 11222739 9 7 part_of hFSH 1478:1481 arg1 hFSH residues 62-73 hFSH hFSH residues 62-73 OGER SpecificSite hFSH residues 62-73 These differences include conformational changes and/or differential distributions of polar or charged residues in loops L3beta (hFSH residues 62-73), the cystine noose, or determinant loop (residues 87-94), and the carboxy-terminal loop (residues 94-104). 8832092 0 37 gly glycoprotein 19:30 arg1 glycoprotein glucosyltransferase glycoprotein glucosyltransferase The use of UDP-Glc:glycoprotein glucosyltransferase for radiolabeling protein-linked high mannose-type oligosaccharides. 2347365 9 34 gly glycosylation 1183:1195 arg2 one possible N-linked glycosylation site one possible N-linked glycosylation site site In addition the mouse molecule had one possible N-linked glycosylation site. 1972631 6 51 part_of sequences 585:593 arg1 this region sequences this region region Specific sequences in this region support the hypothesis that two mRNA species found for human LPL are generated by differential utilization of polyadenylation signals. 25113421 13 31 gly glycopeptide 1927:1938 arg2 the N-linked glycopeptide sequon the N-linked glycopeptide sequon glycopeptide sequon When only HCD spectra are available, GlycoMaster DB can still help to identify the glycans, and a list of possible peptide sequences are reported according to the accurate precursor mass and the N-linked glycopeptide sequon. 11146224 5 37 gly glycosylation 886:898 arg2 a conserved N-linked glycosylation site a conserved N-linked glycosylation site site However, in contrast to the latter transporters, a conserved N-linked glycosylation site is not found at the N-terminus of MRP7. 21672516 1 20 gly leucine-rich 151:162 arg1 small leucine-rich repeat proteoglycans leucine small leucine-rich repeat proteoglycans leucine Recently, significant attention has been drawn to the biology of small leucine-rich repeat proteoglycans (SLRPs) due to their multiple functionalities in various cell types and tissues. 6651835 1 27 part_of Fc 209:210 arg1 Fc fragments Fc Fc fragments Cterm Site Fc fragments The purified protein was used to prepare Fc fragments which were cleaved by cyanogen bromide. 8573180 7 33 gly glycosylation 1164:1176 arg1 GLUT4 GLUT4 PUBTATOR GLUT4 25139 Thus, in the physiologically relevant adipose cell, glycosylation of GLUT4 appears to play an important functional role. 28970103 15 111 part_of samples 2890:2896 arg1 intact O-glycopeptides IgAN intact O-glycopeptides PUBTATOR Site IgAN 60498 O-glycopeptides Furthermore, quantitative analysis of intact O-glycopeptides from the serum samples of IgA nephropathy (IgAN) patients and healthy donors was performed, and the results showed the potential of the strategy to discover O-glycosylation biomarkers. 25690651 7 35 gly N-glycosylated 1032:1045 arg1 hGPR109A/C19T hGPR109A Asn(17) PUBTATOR hGPR109A 338442 Asn(17) This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor. 25690651 7 35 gly N-glycosylated 1032:1045 arg2 Asn Asn(17) Asn(17) This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor. 25690651 7 35 gly N-glycosylated 1032:1045 arg1 hGPR109A/C19S hGPR109A Asn(17) PUBTATOR hGPR109A 338442 Asn(17) This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor. 25690651 7 35 gly N-glycosylated 1032:1045 arg2 Asn hGPR109A Asn(17) PUBTATOR hGPR109A 338442 Asn(17) This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor. 25690651 7 35 gly N-glycosylated 1032:1045 arg1 hGPR109A/C19S hGPR109A PUBTATOR hGPR109A 338442 This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor. 25690651 7 35 gly N-glycosylated 1032:1045 arg1 hGPR109A/C19S hGPR109A Asn(17) PUBTATOR hGPR109A 338442 Asn(17) This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor. 20881037 11 52 gly glycosylation 1811:1823 arg2 an extra glycosylation site an extra glycosylation site site Our findings demonstrate that N-linked glycosylation of HBV envelope proteins is critical for virion secretion and that the secretion defect caused by mutations in the S protein can be rescued by an extra glycosylation site. 20881037 11 84 gly glycosylation 1645:1657 arg1 HBV envelope proteins HBV envelope proteins Fterm proteins Our findings demonstrate that N-linked glycosylation of HBV envelope proteins is critical for virion secretion and that the secretion defect caused by mutations in the S protein can be rescued by an extra glycosylation site. 1459141 1 7 gly protein 153:159 arg1 no oligosaccharides protein no oligosaccharides Fterm protein Human lysozyme is a monomeric secretory protein composed of 130 amino acid residues, with four intramolecular disulfide bonds and no oligosaccharides. 7798256 2 70 gly N-glycosylation 427:441 arg2 Asn-642 Asn-642 Asn-642 Band 3 consists of a 43-kDa amino-terminal cytosolic domain and a carboxyl-terminal 52-kDa membrane domain containing up to 14 transmembrane segments with a single N-glycosylation site at Asn-642. 7798256 2 70 gly N-glycosylation 427:441 arg2 a single N-glycosylation site a single N-glycosylation site site Band 3 consists of a 43-kDa amino-terminal cytosolic domain and a carboxyl-terminal 52-kDa membrane domain containing up to 14 transmembrane segments with a single N-glycosylation site at Asn-642. 18340083 8 26 gly nonglycosylated 1126:1140 arg1 a nonglycosylated GPIHBP1 a nonglycosylated GPIHBP1 PUBTATOR GPIHBP1 68453 Consistent with this finding, cells expressing a nonglycosylated GPIHBP1 lack the ability to bind LPL or chylomicrons. 11864713 0 38 gly Asn-linked 13:22 arg1 each Asn-linked glycan Asn each Asn-linked glycan Asn Role of each Asn-linked glycan in the anticoagulant activity of human protein C inhibitor. 18815311 0 26 gly glycoprotein 70:81 arg1 Nipah virus attachment glycoprotein Nipah virus attachment glycoprotein Fterm glycoprotein Crystal structure and carbohydrate analysis of Nipah virus attachment glycoprotein: a template for antiviral and vaccine design. 18815311 0 36 gly carbohydrate 22:33 arg1 Nipah virus attachment glycoprotein Nipah virus attachment glycoprotein Fterm glycoprotein Crystal structure and carbohydrate analysis of Nipah virus attachment glycoprotein: a template for antiviral and vaccine design. 10992007 1 13 part_of receptor 211:218 arg1 The amino-terminal ectodomain thyrotropin receptor The amino-terminal ectodomain PUBTATOR Site thyrotropin receptor 7253 ectodomain The amino-terminal ectodomain of human thyrotropin receptor (TSHR) contains six potential N-linked glycosylation sites (N-Xaa-S/T). 10992007 1 68 part_of contains 227:234 arg1 human thyrotropin receptor AND six potential N-linked glycosylation sites human thyrotropin receptor six potential N-linked glycosylation sites PUBTATOR Site thyrotropin receptor 7253 sites The amino-terminal ectodomain of human thyrotropin receptor (TSHR) contains six potential N-linked glycosylation sites (N-Xaa-S/T). 22677411 13 88 gly glycoprotein 1819:1830 arg1 haptoglobin haptoglobin PUBTATOR haptoglobin 3240 Specific examples of site-specific glycosylation patterns of alpha-1-acid glycoprotein, haptoglobin and on a therapeutic monoclonal antibody, Infliximab are also discussed. 22677411 13 88 gly glycoprotein 1819:1830 arg1 alpha-1-acid glycoprotein alpha-1-acid glycoprotein Fterm glycoprotein Specific examples of site-specific glycosylation patterns of alpha-1-acid glycoprotein, haptoglobin and on a therapeutic monoclonal antibody, Infliximab are also discussed. 22677411 13 93 gly glycosylation 1780:1792 arg1 haptoglobin haptoglobin PUBTATOR haptoglobin 3240 Specific examples of site-specific glycosylation patterns of alpha-1-acid glycoprotein, haptoglobin and on a therapeutic monoclonal antibody, Infliximab are also discussed. 22677411 13 93 gly glycosylation 1780:1792 arg1 alpha-1-acid glycoprotein alpha-1-acid glycoprotein Fterm glycoprotein Specific examples of site-specific glycosylation patterns of alpha-1-acid glycoprotein, haptoglobin and on a therapeutic monoclonal antibody, Infliximab are also discussed. 18642129 5 69 part_of pd-FVII 749:755 arg1 N- and O-glycosylation sites FVII N- and O-glycosylation sites OGER Site FVII P08709 sites N- and O-glycosylation sites and site specific heterogeneity of pd-FVII were studied by various complementary qualitative and quantitative techniques. 12364335 10 27 gly glycosylation 1590:1602 arg1 polypeptides polypeptides polypeptides This suggests a cooperative involvement of each repeat unit in the glycosylation of polypeptides with multiple acceptor sites. 16372382 5 0 gly glycosylation 946:958 arg2 the three glycosylation sites the three glycosylation sites sites The carbohydrate microheterogeneity at the three glycosylation sites was studied using reversed-phase high-performance liquid chromatography (RP-HPLC), concanavalin A affinity chromatography and mass spectrometric techniques, including both matrix-assisted laser desorption/ionization (MALDI) and electrospray. 16372382 5 20 gly sites 960:964 arg1 The carbohydrate microheterogeneity sites The carbohydrate microheterogeneity sites The carbohydrate microheterogeneity at the three glycosylation sites was studied using reversed-phase high-performance liquid chromatography (RP-HPLC), concanavalin A affinity chromatography and mass spectrometric techniques, including both matrix-assisted laser desorption/ionization (MALDI) and electrospray. 25690651 0 48 gly N-glycosylation 13:27 arg2 The atypical N-glycosylation motif motif, Asn-Cys-Cys motif, Asn-Cys-Cys The atypical N-glycosylation motif, Asn-Cys-Cys, in human GPR109A is required for normal cell surface expression and intracellular signaling. 9757569 1 11 gly N-glycosylation 211:225 arg2 a N-glycosylation site a N-glycosylation site site A mutant angiotensinogen, S14N, in which Ser14 of ovine angiotensinogen was replaced by Asn to form a N-glycosylation site, was produced in CHO cells. 23632316 7 65 gly glycosylation 1082:1094 arg2 the original NST/S glycosylation site the original NST/S glycosylation site site We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated. 23632316 7 68 gly glycosylation 1022:1034 arg2 additional potential NXS/T glycosylation sites additional potential NXS/T glycosylation sites sites We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated. 23632316 7 10 gly glycosylated 1161:1172 arg1 the original NST/S glycosylation site site site We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated. 23632316 7 10 gly glycosylated 1161:1172 arg1 the IgG-Fc-ZP3E7 protein IgG-Fc-ZP3E7 protein site PUBTATOR IgG-Fc-ZP3E7 protein 7784 site We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated. 23632316 7 10 gly glycosylated 1161:1172 arg1 the IgG-Fc-ZP3E7 protein IgG-Fc-ZP3E7 protein site PUBTATOR IgG-Fc-ZP3E7 protein 7784 site We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated. 7688323 2 16 gly sialylated 380:389 arg1 sialylated oligosaccharide chain(s) sialylated oligosaccharide chain(s) Recent immunological studies indicate that sialylated oligosaccharide chain(s) are also implicated in expression of the Baka determinant. 8176214 2 19 part_of proteins 105:112 arg1 a single transmembrane domain proteins a single transmembrane domain Fterm Site proteins domain Like many proteins with a single transmembrane domain the IL-6R exists in a membrane-associated and soluble form. 2411731 2 27 part_of alpha 220:224 arg1 the human alpha 2(V) Gly-X-Y region alpha 2(V) the human alpha 2(V) Gly-X-Y region PUBTATOR Site alpha 2(V) 1290 region Analysis of amino acids 796-1020 in the human alpha 2(V) Gly-X-Y region showed strong conservation of charged positions with the interstitial collagens but also revealed substitutions unique to type V. To gain more information about this procollagen and primarily to resolve the ambiguous nature of the 3' noncollagenous propeptide, we sequenced several cDNA clones coding for amino acids adjacent to the carboxyl end of the alpha chain. 2411731 2 70 part_of V 228:228 arg1 the human alpha 2(V) Gly-X-Y region alpha 2(V) the human alpha 2(V) Gly-X-Y region PUBTATOR Site alpha 2(V) 1290 region Analysis of amino acids 796-1020 in the human alpha 2(V) Gly-X-Y region showed strong conservation of charged positions with the interstitial collagens but also revealed substitutions unique to type V. To gain more information about this procollagen and primarily to resolve the ambiguous nature of the 3' noncollagenous propeptide, we sequenced several cDNA clones coding for amino acids adjacent to the carboxyl end of the alpha chain. 8107215 1 79 gly glycosylation 162:174 arg1 the measles virus (MV) fusion (F) protein the measles virus (MV) fusion (F) protein Fterm protein The role of N-linked glycosylation in the biological activity of the measles virus (MV) fusion (F) protein was analyzed by expressing glycosylation mutants with recombinant vaccinia virus vectors. 15128311 6 24 part_of glycoprotein 658:669 arg1 The N-terminal sequence glycoprotein The N-terminal sequence Fterm Site glycoprotein sequence The N-terminal sequence of the glycoprotein was identical to that of cytotoxin 3 (CX3) from N. kaouthia, and CD spectra of the glycoprotein and CX3 were almost the same. 10940860 2 36 gly presence 329:336 arg1 this site AND an oligosaccharide this site an oligosaccharide site The presence of an oligosaccharide at this site has previously been shown to reduce specific activity and fibrin binding. 20391591 3 82 part_of glycoproteins 628:640 arg1 N-glycosylation sites glycoproteins N-glycosylation sites Fterm Site glycoproteins sites An attractive aspect of this dissociation option is the generation of distinct Y1 ions (peptide+GlcNAc), thus allowing unequivocal assignment of N-glycosylation sites of glycoproteins. 9241750 0 21 gly glycosylation 172:184 arg2 three potential N-linked glycosylation sites three potential N-linked glycosylation sites sites The effect of N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. Human protein S (HPS) has three potential N-linked glycosylation sites at Asn458, 468, 489. 9241750 0 119 gly glycosylation 23:35 arg1 HPS HPS OGER HPS Q08830 The effect of N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. Human protein S (HPS) has three potential N-linked glycosylation sites at Asn458, 468, 489. 9241750 0 119 gly glycosylation 23:35 arg1 human protein human protein Fterm protein S The effect of N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. Human protein S (HPS) has three potential N-linked glycosylation sites at Asn458, 468, 489. 9241750 0 119 gly glycosylation 23:35 arg1 thrombin cleavage thrombin cleavage PUBTATOR thrombin 2147 The effect of N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. Human protein S (HPS) has three potential N-linked glycosylation sites at Asn458, 468, 489. 27339457 9 0 gly O-glycosylation 1441:1455 arg2 an extra O-glycosylation site an extra O-glycosylation site site The A397T mutation introduced an extra O-glycosylation site and deleted binding to LTBP1s. 18203712 5 46 gly N-glycosylation 669:683 arg2 Asn-594 Asn-594 Asn-594 One pathway is initiated by post-translational N-glycosylation at Asn-594. 10889209 6 0 gly glycosylated 1021:1032 arg2 Asn Asn(132) Asn(132) This finding may partly account for the reason that GIRK4 is not glycosylated at Asn(132), either as a homomer or when coexpressed with GIRK1. 10889209 6 0 gly glycosylated 1021:1032 arg1 GIRK4 GIRK4 Asn(132) PUBTATOR GIRK4 3762 Asn(132) This finding may partly account for the reason that GIRK4 is not glycosylated at Asn(132), either as a homomer or when coexpressed with GIRK1. 10889209 6 0 gly glycosylated 1021:1032 arg1 GIRK4 GIRK4 Asn(132) PUBTATOR GIRK4 3762 Asn(132) This finding may partly account for the reason that GIRK4 is not glycosylated at Asn(132), either as a homomer or when coexpressed with GIRK1. 9925876 4 65 gly glycosylation 478:490 arg2 a consensus extracellular N-linked glycosylation site a consensus extracellular N-linked glycosylation site site While a recent report indicates that LQT in some patients is associated with a mutation of HERG at a consensus extracellular N-linked glycosylation site (N629), earlier studies failed to identify a role for N-linked glycosylation in the functional expression of voltage-gated K+ channels. 9925876 4 65 gly glycosylation 478:490 arg2 N629 N629 N629 While a recent report indicates that LQT in some patients is associated with a mutation of HERG at a consensus extracellular N-linked glycosylation site (N629), earlier studies failed to identify a role for N-linked glycosylation in the functional expression of voltage-gated K+ channels. 12466483 7 60 gly glycosylation 1338:1350 arg2 the two overlapping glycosylation sequons the two overlapping glycosylation sequons Thus it is reasonable to conclude that the two overlapping glycosylation sequons at positions 20-23 and 169-172 are conserved among all of the HAs of influenza A/H2N2 viruses because conservation of the amino acid sequence itself rather than that of N-glycosylation is essential for the formation of the proper conformation, intracellular transport and biological activities of the H2 subtype HA. 26022737 9 8 gly glycoform 1204:1212 arg2 N102 N102 N102 Among the three PSA samples, HexNAc2Hex5 was the predominant glycoform at N102, while HexNAc4Hex5Fuc1NeuAc1 or HexNAc4Hex5Fuc1NeuAc2 was the primary glycoforms at N69. 26022737 9 44 gly N102 1217:1220 arg1 HexNAc2Hex5 N102 HexNAc2Hex5 N102 Among the three PSA samples, HexNAc2Hex5 was the predominant glycoform at N102, while HexNAc4Hex5Fuc1NeuAc1 or HexNAc4Hex5Fuc1NeuAc2 was the primary glycoforms at N69. 26022737 9 70 gly glycoforms 1292:1301 arg2 N69 N69 N69 Among the three PSA samples, HexNAc2Hex5 was the predominant glycoform at N102, while HexNAc4Hex5Fuc1NeuAc1 or HexNAc4Hex5Fuc1NeuAc2 was the primary glycoforms at N69. 26022737 9 72 gly N69 1306:1308 arg1 HexNAc4Hex5Fuc1NeuAc1 N69 HexNAc4Hex5Fuc1NeuAc1 N69 Among the three PSA samples, HexNAc2Hex5 was the predominant glycoform at N102, while HexNAc4Hex5Fuc1NeuAc1 or HexNAc4Hex5Fuc1NeuAc2 was the primary glycoforms at N69. 26022737 9 72 gly N69 1306:1308 arg1 HexNAc4Hex5Fuc1NeuAc2 N69 HexNAc4Hex5Fuc1NeuAc2 N69 Among the three PSA samples, HexNAc2Hex5 was the predominant glycoform at N102, while HexNAc4Hex5Fuc1NeuAc1 or HexNAc4Hex5Fuc1NeuAc2 was the primary glycoforms at N69. 7980452 4 1 gly N-glycosylation 610:624 arg2 the N-glycosylation site the N-glycosylation site site Elimination of the N-glycosylation site at position Asn-97 (N97Q) resulted in secreted protein yields of 70-90% as compared with the Wt production, whereas only 10-25% (N25Q) and 1-10% (N25Q,N97Q) levels of protein production was observed when the first or both sites were mutated, respectively. 26042409 12 13 gly glycosylation 1694:1706 arg2 a predicted glycosylation site a predicted glycosylation site site N- and C-termini of OC-STAMP were intracellular, and a predicted glycosylation site was shown to be utilized and to lie on an extracellular loop. 17313760 1 65 gly glycoprotein 136:147 arg1 full length glycoprotein 120 gene variations full length glycoprotein 120 gene variations Fterm glycoprotein OBJECTIVE: To characterize full length glycoprotein 120 gene variations of 21 HIV-1 CRF01_AE isolated in Fujian, China, so as to help in the immunogenic research and vaccine design. 10731668 0 31 part_of receptor 132:139 arg1 the atypical Asn-X-Cys sequence epidermal growth factor receptor the atypical Asn-X-Cys sequence PUBTATOR Site epidermal growth factor receptor 1956 sequence Characterization of the N-oligosaccharides attached to the atypical Asn-X-Cys sequence of recombinant human epidermal growth factor receptor. 21153276 3 43 gly glycosylated 675:686 arg1 the new site site site Covalent labeling of the mutant receptor expressed in COS-1 cells with a gonadotropin-releasing hormone (GnRH) photoreactive analog demonstrated a shift in apparent molecular weight, indicating that the new site was in fact glycosylated. 21637915 3 43 part_of emmprin 439:445 arg1 The first Ig domain emmprin The first Ig domain PUBTATOR Site emmprin 682 domain The first Ig domain (ECI) of emmprin contains the biologically active site. 21637915 3 37 part_of contains 447:454 arg1 emmprin AND the biologically active site emmprin the biologically active site PUBTATOR Site emmprin 682 site The first Ig domain (ECI) of emmprin contains the biologically active site. 21637915 3 37 part_of contains 447:454 arg1 The first Ig domain AND the biologically active site ECI site OGER Site ECI Q9BS40 site The first Ig domain (ECI) of emmprin contains the biologically active site. 28585084 4 29 gly glycoproteins 986:998 arg1 glycoproteins glycoproteins Fterm glycoproteins Glycomics includes the comprehensive study of the structure and function of the glycans expressed in a given cell or organism along with identification of all the genes that encode glycoproteins and glycosyltransferases. 27679458 4 34 gly N-glycopeptide 581:594 arg2 N-glycopeptide enrichment N-glycopeptide enrichment N-glycopeptide In this research, we applied diethylaminoethanol (DEAE) Sepharose solid-phase extraction microcolumns for N-glycopeptide enrichment. 27038031 8 43 gly glycosylation 1119:1131 arg2 Asn563 Asn563 Asn563 Asn563, a high mannose-rich glycosylation site that locates in the center of the IgM polymer, was only approximately 60% occupied in both the pentameric and hexameric IgM forms, with a difference in relative abundance of the glycan structures between the pentamer and hexamer. 30594968 8 35 gly glycosylation 1237:1249 arg2 amino acid residue 218 amino acid residue 218 residue 218 The absence of the glycosylation site at amino acid residue 218 and the presence of the glycosylation site at amino acid residue 313 increased antibody binding and moderately prevented the virus from escaping neutralization with homologous antisera. 30594968 8 35 gly glycosylation 1237:1249 arg2 the glycosylation site the glycosylation site site The absence of the glycosylation site at amino acid residue 218 and the presence of the glycosylation site at amino acid residue 313 increased antibody binding and moderately prevented the virus from escaping neutralization with homologous antisera. 30594968 8 52 gly glycosylation 1306:1318 arg2 the glycosylation site the glycosylation site site The absence of the glycosylation site at amino acid residue 218 and the presence of the glycosylation site at amino acid residue 313 increased antibody binding and moderately prevented the virus from escaping neutralization with homologous antisera. 3200844 10 61 gly glycosylation 1407:1419 arg2 a presumptive glycosylation site a presumptive glycosylation site site Analysis of the residues making up a presumptive glycosylation site suggests that the sequence is unlike any known sites for enzymatic N- or O-linked glycosylation. 2110456 4 55 gly Deglycosylation 436:450 arg1 purified acid beta-glucosidase purified acid beta-glucosidase PUBTATOR acid beta-glucosidase 2629 Deglycosylation of purified acid beta-glucosidase from human placenta with N-Glycanase under native conditions resulted in the removal of an accessible oligosaccharide chain from a single site with no effect on activity, whereas complete deglycosylation resulted in proportionate loss of activity. 19921957 9 33 gly glycopeptides 1704:1716 arg2 56 glycopeptides 56 glycopeptides glycopeptides A total of 86 N-glycosylation sites were quantified and N-glycosylation levels of 56 glycopeptides showed significant changes. 19921957 9 76 gly N-glycosylation 1633:1647 arg2 86 N-glycosylation sites 86 N-glycosylation sites sites A total of 86 N-glycosylation sites were quantified and N-glycosylation levels of 56 glycopeptides showed significant changes. 7559469 4 37 gly site 902:905 arg1 the carbohydrate site the carbohydrate site These data suggest that glycosylation of osteonectin has a direct or regulatory effect on osteonectin binding to collagen V and that the increase in tHON binding upon removal of carbohydrate is the result of a loss of a down-regulation site or direct interference of the carbohydrate at the binding site. 7559469 4 61 gly glycosylation 627:639 arg1 osteonectin osteonectin PUBTATOR osteonectin 282077 These data suggest that glycosylation of osteonectin has a direct or regulatory effect on osteonectin binding to collagen V and that the increase in tHON binding upon removal of carbohydrate is the result of a loss of a down-regulation site or direct interference of the carbohydrate at the binding site. 21698149 8 95 gly glycosylation 1463:1475 arg2 one more glycosylation site one more glycosylation site site HIV-1B obtained from Trinidadian heterosexuals soon after seroconversion had significantly longer V2 loops with one more glycosylation site, shorter V3 loops and no significant difference in V1 or V4 when compared to HIV-1B obtained soon after seroconversion from infected individuals in the rest of the world. 8991508 0 70 gly N-glycosylation 62:76 arg2 repeated N-glycosylation sites repeated N-glycosylation sites sites Mouse submandibular gland salivary apomucin contains repeated N-glycosylation sites. 31888963 9 77 part_of CD16a 1313:1317 arg1 N38 CD16a N38 PUBTATOR SpecificSite CD16a 2214 N38 and N74 N38 and N74 of CD16a both contain highly processed complex-type N-glycans with N-acetyllactosamine repeats and complex-type biantennary N-glycans dominate at N169. 25242514 4 54 gly N-glycosylation 618:632 arg2 N-glycosylation site mutations N-glycosylation site mutations site MAIN METHODS: We generated rat SP-A constructs with two types of mutations that impair its glycosylation: N-glycosylation site mutations (N21T, N207S and N21T/N207S) and disease-associated CRD mutations (G231V, F198S). 1331083 3 6 gly glycosylation 797:809 arg2 each glycosylation site each glycosylation site site When the constructs were expressed in Xenopus oocytes, the oligosaccharides at each glycosylation site were phosphorylated at levels considerably above background (19-70% phosphorylation versus < 0.4% for the secretory protein glycopepsinogen). 1331083 3 10 gly site 811:814 arg1 the oligosaccharides site the oligosaccharides site When the constructs were expressed in Xenopus oocytes, the oligosaccharides at each glycosylation site were phosphorylated at levels considerably above background (19-70% phosphorylation versus < 0.4% for the secretory protein glycopepsinogen). 31461788 0 80 gly Glycosylation 0:12 arg1 DMP1 DMP1 PUBTATOR DMP1 13406 Glycosylation of DMP1 maintains cranial sutures in mice. 25737293 7 34 gly glycoproteins 1415:1427 arg1 human salivary glycoproteins human salivary glycoproteins Fterm glycoproteins This approach also allowed robust measurement of glycosylation sites in human salivary glycoproteins. 25737293 7 63 gly glycosylation 1377:1389 arg2 glycosylation sites glycosylation sites sites This approach also allowed robust measurement of glycosylation sites in human salivary glycoproteins. 7914890 2 5 gly N-glycosylation 297:311 arg2 Asn residues 158, 184, and 350 Asn residues 158, 184, and 350 Asn residues 158, 184, and 350 The results demonstrate that all three potential N-glycosylation sites at Asn residues 158, 184, and 350 are utilized in arylsufatase A and carry high mannose or hybride type oligosaccharides. 7914890 2 5 gly N-glycosylation 297:311 arg2 all three potential N-glycosylation sites all three potential N-glycosylation sites sites The results demonstrate that all three potential N-glycosylation sites at Asn residues 158, 184, and 350 are utilized in arylsufatase A and carry high mannose or hybride type oligosaccharides. 7914890 2 10 gly utilized 357:364 arg2 Asn residues 158, 184, and 350 Asn residues 158, 184, and 350 Asn residues 158, 184, and 350 The results demonstrate that all three potential N-glycosylation sites at Asn residues 158, 184, and 350 are utilized in arylsufatase A and carry high mannose or hybride type oligosaccharides. 7914890 2 10 gly utilized 357:364 arg2 all three potential N-glycosylation sites all three potential N-glycosylation sites sites The results demonstrate that all three potential N-glycosylation sites at Asn residues 158, 184, and 350 are utilized in arylsufatase A and carry high mannose or hybride type oligosaccharides. 7914890 2 41 gly carry 388:392 arg1 all three potential N-glycosylation sites AND high mannose or hybride type oligosaccharides sites high mannose or hybride type oligosaccharides sites The results demonstrate that all three potential N-glycosylation sites at Asn residues 158, 184, and 350 are utilized in arylsufatase A and carry high mannose or hybride type oligosaccharides. 10764840 8 2 gly motif 1285:1289 arg1 a second fucose residue motif a second fucose residue motif Thus, 80% of N-glycans possess a bisecting GlcNAc residue, 25% bear a second fucose residue which is present, in a large part, in a sialyl Le(x)motif, and 13% contain more than three LacNAc repeats (up to five per molecule). 10764840 8 18 gly present 1242:1248 arg2 a sialyl Le(x)motif AND a second fucose residue motif a second fucose residue motif Thus, 80% of N-glycans possess a bisecting GlcNAc residue, 25% bear a second fucose residue which is present, in a large part, in a sialyl Le(x)motif, and 13% contain more than three LacNAc repeats (up to five per molecule). 2590174 5 72 gly N-glycosylation 904:918 arg2 the C-terminal N-glycosylation site the C-terminal N-glycosylation site site Thermospray liquid chromatography-mass spectrometry showed the C-terminal N-glycosylation site to be largely unmodified, and also showed that the N-terminus of the purified recombinant IL-4 (rIL-4) was authentic. 19309691 11 18 gly N-glycosylation 1375:1389 arg2 a used N-glycosylation site a used N-glycosylation site site Expression analysis showed that mutant p.Leu358AlafsX4 CLN5 is truncated and lacks a used N-glycosylation site at Asn401. 24018687 5 1 gly N-glycosylation 1239:1253 arg2 a conserved N-glycosylation site a conserved N-glycosylation site site Due to low stability, the steady-state population of functional DDR proteins in the cell surface depends sensitively on its maturation process via post-translational N-glycosylation, which is controlled by the glucose supply and the presence of a conserved N-glycosylation site. 24018687 5 51 gly site 1255:1258 arg1 the glucose supply site the glucose supply site Due to low stability, the steady-state population of functional DDR proteins in the cell surface depends sensitively on its maturation process via post-translational N-glycosylation, which is controlled by the glucose supply and the presence of a conserved N-glycosylation site. 17823199 9 96 gly N-glycosylation 1588:1602 arg2 the first, third, and second N-glycosylation sites the first, third, and second N-glycosylation sites sites In transferrin, a preferred occupancy for the first N-glycosylation site was observed, and a decreasing preference for the first, third, and second N-glycosylation sites was observed in alpha(1)-antitrypsin. 17823199 9 115 gly N-glycosylation 1492:1506 arg2 the first N-glycosylation site the first N-glycosylation site site In transferrin, a preferred occupancy for the first N-glycosylation site was observed, and a decreasing preference for the first, third, and second N-glycosylation sites was observed in alpha(1)-antitrypsin. 19874459 10 78 gly tetra-sialylated 1362:1377 arg1 unusual tetra-sialylated core 1 O-glycans unusual tetra-sialylated core 1 O-glycans Amongst the newly determined structures are unusual tetra-sialylated core 1 O-glycans and ABH antigen-containing core 2 O-glycans. 1840295 9 43 gly tPA 1197:1199 arg1 sugars tPA sugars PUBTATOR tPA P00750 In the dMM-treated sample, type I tPA (with sugars at sites 117, 184 and 448) was found to have 2- to 3-fold increased catalytic activity and an affinity for lysine which was greater than that of type I from untreated preparations, but less than that of control type II tPA (containing sugar only at sites 117 and 448). 1840295 9 34 gly containing 1438:1447 arg1 control type II tPA AND sugar control type II tPA sugar PUBTATOR tPA P00750 In the dMM-treated sample, type I tPA (with sugars at sites 117, 184 and 448) was found to have 2- to 3-fold increased catalytic activity and an affinity for lysine which was greater than that of type I from untreated preparations, but less than that of control type II tPA (containing sugar only at sites 117 and 448). 22119577 4 28 gly N-glycosylation 821:835 arg2 three conserved mammalian tapasin motifs three conserved mammalian tapasin motifs motifs The coding sequence has a 1329 bp ORF encoding a 442-residue precursor protein with a predicted 24-amino acid leader peptide, generating a 418-amino acid mature form that retains a conserved N-glycosylation site, three conserved mammalian tapasin motifs, two Ig superfamily domains, a transmembrane domain and an ER-retention di-lysine motif at the C-terminus, suggestive of a function similar to mammalian tapasins. 22119577 4 28 gly N-glycosylation 821:835 arg2 two Ig superfamily domains two Ig superfamily domains domains The coding sequence has a 1329 bp ORF encoding a 442-residue precursor protein with a predicted 24-amino acid leader peptide, generating a 418-amino acid mature form that retains a conserved N-glycosylation site, three conserved mammalian tapasin motifs, two Ig superfamily domains, a transmembrane domain and an ER-retention di-lysine motif at the C-terminus, suggestive of a function similar to mammalian tapasins. 22119577 4 28 gly N-glycosylation 821:835 arg2 a conserved N-glycosylation site a conserved N-glycosylation site site The coding sequence has a 1329 bp ORF encoding a 442-residue precursor protein with a predicted 24-amino acid leader peptide, generating a 418-amino acid mature form that retains a conserved N-glycosylation site, three conserved mammalian tapasin motifs, two Ig superfamily domains, a transmembrane domain and an ER-retention di-lysine motif at the C-terminus, suggestive of a function similar to mammalian tapasins. 6195967 10 55 gly found 1378:1382 arg2 the homologous cyanogen bromide fragment AND No detectable galactosamine the homologous cyanogen bromide fragment No detectable galactosamine fragment No detectable galactosamine could be found in the homologous cyanogen bromide fragment in Gc2. 16845394 4 39 gly glycoprotein 734:745 arg1 its ligand P-selectin glycoprotein 1 its ligand P-selectin glycoprotein 1 PUBTATOR P-selectin glycoprotein 1 6404 This alteration increased the affinity of P-selectin for its ligand P-selectin glycoprotein 1 (PSGL-1) and thereby the strength of P-selectin-mediated rolling adhesion. 16845394 4 39 gly glycoprotein 734:745 arg1 PSGL-1 PSGL-1 PUBTATOR PSGL-1 6404 This alteration increased the affinity of P-selectin for its ligand P-selectin glycoprotein 1 (PSGL-1) and thereby the strength of P-selectin-mediated rolling adhesion. 26156869 7 15 part_of Fc-glycosylation 1644:1659 arg1 the Fc-glycosylation site Fc the Fc-glycosylation site Cterm Site Fc site We conclude that EndoS and EndoS2 hydrolyze different glycoforms from the Fc-glycosylation site on therapeutic mAbs and that this can be used for rapid quantification of high mannose content. 26156869 7 47 part_of site 1661:1664 arg1 therapeutic mAbs mAbs site PUBTATOR Site mAbs 72935 site We conclude that EndoS and EndoS2 hydrolyze different glycoforms from the Fc-glycosylation site on therapeutic mAbs and that this can be used for rapid quantification of high mannose content. 8554050 3 56 gly glycosylation 550:562 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site The Con1 glycoprotein is encoded in exon 3 of a PRB2 allele (PRB2L CON1+) with a potential N-linked glycosylation site. 8554050 3 86 gly glycoprotein 459:470 arg1 The Con1 glycoprotein The Con1 glycoprotein PUBTATOR Con1 glycoprotein P02812 The Con1 glycoprotein is encoded in exon 3 of a PRB2 allele (PRB2L CON1+) with a potential N-linked glycosylation site. 9287313 2 53 part_of contains 397:404 arg1 Human CD69 AND only a single consensus sequence Human CD69 only a single consensus sequence PUBTATOR Site CD69 969 sequence Human CD69 contains only a single consensus sequence for N-linked oligosaccharide addition within its extracellular domain (Asn-Val-Thr), yet exists as two distinct glycoforms that are assembled together into disulfide-linked homodimers and heterodimers. 11463517 6 16 gly glycosylation 1264:1276 arg2 a potential protein glycosylation site a potential protein glycosylation site site We report one subject with childhood absence epilepsy (CAE) that evolved to juvenile myoclonic epilepsy (JME) that has a unique de novo mutation that results in a non-conservative amino acid change at a potential protein glycosylation site. 1377692 9 35 part_of S 1270:1270 arg1 The deduced amino acid sequence cathepsin S The deduced amino acid sequence PUBTATOR Site cathepsin S 1520 sequence The deduced amino acid sequence of human cathepsin S exhibits a substantial degree of similarity with other human cysteine proteinases and papain indicating that they have a common ancestral gene and are members of a gene family. 28759313 0 76 gly Glycosylation 0:12 arg1 DMP1 DMP1 PUBTATOR DMP1 13406 Glycosylation of DMP1 Is Essential for Chondrogenesis of Condylar Cartilage. 11072064 5 23 part_of contains 719:726 arg1 The stalk region AND a leucine-zipper The stalk region a leucine-zipper leucine The stalk region contains a leucine-zipper, and an N-glycosylation site was also found in the CRD. 9020858 7 72 gly N-glycosylation 875:889 arg1 the placental or intestinal enzymes the placental or intestinal enzymes Fterm enzymes Interestingly, N-glycosylation is absolutely essential for TNAP activity, but not for that of the placental or intestinal enzymes. 17823199 10 77 gly glycoproteins 1726:1738 arg1 multiple glycoproteins multiple glycoproteins Fterm glycoproteins This multiple reaction monitoring LC-MS/MS method can be extended to multiple glycoproteins, thereby enabling a glycoproteomics survey of N-glycosylation site occupancies in biological samples. 17823199 10 92 gly N-glycosylation 1786:1800 arg2 N-glycosylation site occupancies N-glycosylation site occupancies site This multiple reaction monitoring LC-MS/MS method can be extended to multiple glycoproteins, thereby enabling a glycoproteomics survey of N-glycosylation site occupancies in biological samples. 14711516 6 6 part_of Thy-1 1015:1019 arg1 asparagine 60 Recombinant Thy-1 asparagine 60 PUBTATOR SpecificSite Recombinant Thy-1 P04216 asparagine 60 Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5). 10362588 4 20 gly glycoproteins 541:553 arg1 two cell surface-associated glycoproteins two cell surface-associated glycoproteins Fterm glycoproteins A primary translation product of 120 kDa was cleaved into two cell surface-associated glycoproteins of 86 and 34 kDa in transfected HEK-293 cells. 21784854 5 2 part_of contains 891:898 arg1 mouse but not rat IgA AND pathogen-binding site IgA site OGER Site IgA P11912 site Curiously, mouse but not rat IgA contains a putative N-linked glycosylation site in the center of this host receptor and pathogen-binding site. 16689758 8 22 part_of FVIII 1544:1548 arg1 the active site FVIII the active site PUBTATOR Site FVIII 14069 site CONCLUSIONS: Modification of glycosylation in the variable region of antibodies contributes to the diversity of FVIII type II inhibition possibly by steric hindrance of the active site of FVIII by glycans, and may provide a novel strategy to modulate the functional activity of therapeutic antibodies. 32054416 6 18 gly N-glycosylation 827:841 arg2 an N-glycosylation site an N-glycosylation site site In addition to the amino acid residues interacting with ligands CD80 and CD86, an N-glycosylation site on N110, conserved in CTLA-4 of human, monkey, and mouse, was identified as the specific epitope that might contribute to the cross-species binding and function of this antibody. 32054416 6 18 gly N-glycosylation 827:841 arg2 the specific epitope the specific epitope epitope In addition to the amino acid residues interacting with ligands CD80 and CD86, an N-glycosylation site on N110, conserved in CTLA-4 of human, monkey, and mouse, was identified as the specific epitope that might contribute to the cross-species binding and function of this antibody. 11428934 1 68 gly glycoprotein 179:190 arg1 MOG MOG PUBTATOR MOG 4340 Myelin oligodendrocyte glycoprotein (MOG), a minor myelin component, is an important central nervous system specific target autoantigen for primary demyelination in autoimmune diseases such as multiple sclerosis (MS). 11428934 1 68 gly glycoprotein 179:190 arg1 Myelin oligodendrocyte glycoprotein Myelin oligodendrocyte glycoprotein PUBTATOR Myelin oligodendrocyte glycoprotein 4340 Myelin oligodendrocyte glycoprotein (MOG), a minor myelin component, is an important central nervous system specific target autoantigen for primary demyelination in autoimmune diseases such as multiple sclerosis (MS). 18638581 5 0 gly glycopeptide 1132:1143 arg2 glycopeptide enrichment glycopeptide enrichment glycopeptide The methods were successfully applied to human serum samples and a total of 86 N-glycosylation sites in 45 proteins were identified using a mixture of three immobilized lectins for consecutive glycoprotein enrichment and glycopeptide enrichment. 18638581 5 5 gly N-glycosylation 990:1004 arg2 86 N-glycosylation sites 86 N-glycosylation sites sites The methods were successfully applied to human serum samples and a total of 86 N-glycosylation sites in 45 proteins were identified using a mixture of three immobilized lectins for consecutive glycoprotein enrichment and glycopeptide enrichment. 18638581 5 29 gly glycoprotein 1104:1115 arg1 consecutive glycoprotein enrichment consecutive glycoprotein enrichment Fterm glycoprotein The methods were successfully applied to human serum samples and a total of 86 N-glycosylation sites in 45 proteins were identified using a mixture of three immobilized lectins for consecutive glycoprotein enrichment and glycopeptide enrichment. 7688956 0 5 gly glycoprotein 76:87 arg1 a glycosylphosphatidylinositol-anchored glycoprotein a glycosylphosphatidylinositol-anchored glycoprotein Fterm glycoprotein Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. 7688956 0 5 gly glycoprotein 76:87 arg1 Structure Structure PUBTATOR structure of the CAMPATH-1 antigen 1043 Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. 21569239 9 26 part_of F-spondin 1224:1232 arg1 the F-spondin FS domain structure of the F-spondin the F-spondin FS domain PUBTATOR Site structure of the F-spondin 10418 domain CONCLUSION: The structure of the F-spondin FS domain completes the structural studies of the multiple-domain ECM molecule. 8626443 2 63 gly unglycosylated 462:475 arg1 an unglycosylated but inactive protein an unglycosylated but inactive protein Fterm protein Expression in Escherichia coli of the rabbit ACET cDNA resulted in the synthesis of an unglycosylated but inactive protein. 9291187 0 39 gly N-glycosylation 0:14 arg1 11beta-hydroxysteroid dehydrogenase type 2 11beta-hydroxysteroid dehydrogenase type 2 OGER 11beta-hydroxysteroid dehydrogenase type 2 P80365 N-glycosylation is not essential for enzyme activity of 11beta-hydroxysteroid dehydrogenase type 2. 9291187 0 39 gly N-glycosylation 0:14 arg1 enzyme activity enzyme activity Fterm enzyme N-glycosylation is not essential for enzyme activity of 11beta-hydroxysteroid dehydrogenase type 2. 26015261 8 16 gly glycosylation 1502:1514 arg1 afucosylated anti-CS1 mAb afucosylated anti-CS1 mAb OGER CS1 O94985 Our results indicate that Fc glycosylation is critical for in vivo efficacy and afucosylated anti-CS1 mAb expressed in glycoengineered Pichia pastoris shows a better in vivo efficacy in tumor regression when compared to fucosylated anti-CS1 mAb expressed in HEK293 cells. 26911932 2 135 gly Asn-linked 277:286 arg1 Asn-linked N-glycan chains Asn Asn-linked N-glycan chains Asn Both the common α- and hormone-specific β subunits contain Asn-linked N-glycan chains. 26911932 2 132 gly contain 269:275 arg1 Both the common α- and hormone-specific β subunits AND Asn-linked N-glycan chains Both the common α- and hormone-specific β subunits Asn-linked N-glycan chains Fterm subunits Both the common α- and hormone-specific β subunits contain Asn-linked N-glycan chains. 31113887 8 46 gly glycosylation 1299:1311 arg2 the glycosylation sites the glycosylation sites sites Full restoration of virus infection in cells bearing chimpanzee CD4 requires reversion of both threonines at sites 34 and 68, destroying both of the glycosylation sites, suggesting that the effects of the glycans are additive. 12021274 2 24 part_of protein 252:258 arg1 The partial sequence protein The partial sequence Fterm Site protein sequence The partial sequence of the increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom revealed a strong homology to vascular endothelial growth factor (VEGF)-A. 1856695 7 11 part_of proteins 1406:1413 arg1 the amino acid sequences proteins the amino acid sequences Fterm Site proteins sequences Extensive similarity was also observed between the amino acid sequences of the TCV N protein and those of murine hepatitis virus (MHV) (70%) and human respiratory coronavirus strain OC43 (HCV-OC43) (98%) and between the amino acid sequences of the predicted M proteins of TCV and MHV (86%). 1856695 7 43 part_of protein 1231:1237 arg1 the amino acid sequences protein the amino acid sequences Fterm Site protein sequences Extensive similarity was also observed between the amino acid sequences of the TCV N protein and those of murine hepatitis virus (MHV) (70%) and human respiratory coronavirus strain OC43 (HCV-OC43) (98%) and between the amino acid sequences of the predicted M proteins of TCV and MHV (86%). 10593916 0 61 gly glycosylation 135:147 arg2 a glycosylation motif a glycosylation motif motif Genetically encoded and post-translationally modified forms of a major histocompatibility complex class I-restricted antigen bearing a glycosylation motif are independently processed and co-presented to cytotoxic T lymphocytes. 8379944 7 33 gly glycosylation 1116:1128 arg2 the glycosylation site the glycosylation site site The specific activity of each mutant LCAT was significantly different from the wild-type; however, the magnitude and direction of the change depended on the glycosylation site mutagenized. 1651590 8 23 gly glycoprotein 1344:1355 arg1 the glycoprotein the glycoprotein Fterm glycoprotein The results indicate that enhanced cleavability of the glycoprotein, a feature often associated with multiple basic residues within the cleavage site of paramyxovirus F proteins and influenza virus hemagglutinins, can also be determined by a single basic amino acid following proline. 24104458 2 30 gly glycoprotein 256:267 arg1 An epithelial cell surface glycoprotein An epithelial cell surface glycoprotein Fterm glycoprotein An epithelial cell surface glycoprotein, gp180, recognized by monoclonal antibodies B9 and L12 was determined to be critical in this process. 27234584 6 78 gly attached 999:1006 arg1 specific protein domains AND O-linked oligosaccharides specific protein domains O-linked oligosaccharides domains Both N- and O-linked oligosaccharides, attached to specific protein domains, endow these domains with novel functions such as the binding to lectins, cell-surface receptors and tissue inhibitors of metalloproteases (TIMPs). 14749183 2 48 part_of residue 566:572 arg1 457 457; Arch residue OGER AminoAcid 457; Arch Q8IWT0 residue in By evaluation of chimeric hPIV3-Newcastle disease virus (NDV) HN proteins, we have previously shown that hPIV3-F-specificity is determined by a domain that extends from the middle of the membrane anchor to the 82nd residue in the ectodomain [Virology 209, (1995) 457; Arch. 20795641 6 5 gly N-glycosylation 1220:1234 arg2 the N-glycosylation site the N-glycosylation site site Three (18)O atoms ((18)O(3)) are incorporated into N-linked glycopeptides for samples treated in (18)O-water, two at the carboxyl terminus by trypsin during hydrazide coupling and the third at the N-glycosylation site through PNGaseF-mediated deglycosylation. 20795641 6 46 gly glycopeptides 1083:1095 arg2 N-linked glycopeptides N-linked glycopeptides glycopeptides Three (18)O atoms ((18)O(3)) are incorporated into N-linked glycopeptides for samples treated in (18)O-water, two at the carboxyl terminus by trypsin during hydrazide coupling and the third at the N-glycosylation site through PNGaseF-mediated deglycosylation. 17144668 5 44 gly glycosylated 880:891 arg1 these sites these sites sites Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. 17144668 5 62 gly glycosylation 713:725 arg2 these glycosylation sites these glycosylation sites sites Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. 1847449 6 76 gly glycosylation 1177:1189 arg2 the potential glycosylation site the potential glycosylation site site Deletion of the potential glycosylation site had no effect on the cleavability of these mutants; hence, the oligosaccharide side chain appears to have no role in human influenza virus HA cleavage. 7944407 1 4 gly glycoprotein 163:174 arg1 a secreted, Ca+2-binding glycoprotein a secreted, Ca+2-binding glycoprotein Fterm glycoprotein SPARC (secreted protein, acidic and rich in cysteine) is a secreted, Ca+2-binding glycoprotein that modulates interactions between cells and their immediate extracellular matrix. 7944407 1 4 gly glycoprotein 163:174 arg1 SPARC SPARC PUBTATOR SPARC 20692 SPARC (secreted protein, acidic and rich in cysteine) is a secreted, Ca+2-binding glycoprotein that modulates interactions between cells and their immediate extracellular matrix. 24780636 6 86 gly modified 1033:1040 arg1 Asn432 AND single GlcNAc Asn432 single GlcNAc Asn432 On the other hand, Tf-1 is site-specifically modified: Asn630 has biantennary agalacto-complex-type glycan with bisecting N-acetylglucosamine (GlcNAc) and core fucose while Asn432 is modified with complex/high mannose-type glycans and possibly single GlcNAc. 24780636 6 86 gly modified 1033:1040 arg1 Asn432 AND complex/high mannose-type glycans Asn432 complex/high mannose-type glycans Asn432 On the other hand, Tf-1 is site-specifically modified: Asn630 has biantennary agalacto-complex-type glycan with bisecting N-acetylglucosamine (GlcNAc) and core fucose while Asn432 is modified with complex/high mannose-type glycans and possibly single GlcNAc. 22719948 5 51 gly glycosylation 734:746 arg2 Two glycosylation sites Two glycosylation sites sites Two glycosylation sites, 158N and 169N, also participate in receptor recognition. 23829323 0 51 gly glycopeptide 80:91 arg2 glycopeptide CID tandem mass spectra glycopeptide CID tandem mass spectra glycopeptide Exploring site-specific N-glycosylation microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan database search. 23829323 0 63 gly microheterogeneity 40:57 arg1 haptoglobin haptoglobin PUBTATOR haptoglobin 3240 Exploring site-specific N-glycosylation microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan database search. 23829323 0 104 gly N-glycosylation 24:38 arg1 haptoglobin haptoglobin PUBTATOR haptoglobin 3240 Exploring site-specific N-glycosylation microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan database search. 22577028 2 48 gly glycoprotein 477:488 arg1 HA HA Cterm HA 23526 HA is a surface glycoprotein of the influenza virus that plays a key role in viral infectivity and pathogenesis. 22577028 2 48 gly glycoprotein 477:488 arg1 a surface glycoprotein a surface glycoprotein Fterm glycoprotein HA is a surface glycoprotein of the influenza virus that plays a key role in viral infectivity and pathogenesis. 10677208 5 10 gly fucosylated 975:985 arg1 the fucosylated paucomannosidic structure (GlcNAc)(2)(Mannose)(3)Fucose the fucosylated paucomannosidic structure (GlcNAc)(2)(Mannose)(3)Fucose Sf9 cells mainly processed the fucosylated paucomannosidic structure (GlcNAc)(2)(Mannose)(3)Fucose, although hybrid and complex N-glycosylations were also detected. 31516400 5 59 gly glycoproteins 971:983 arg1 glycoproteins glycoproteins Fterm glycoproteins A database resource termed N-GlycositeAtlas was created and further used for the distribution analyses of glycoproteins among different human cells, tissues and body fluids. 7747487 7 27 gly glycosylated 899:910 arg2 position 238 position 238 position 238 Variants selected from G3 parent viruses glycosylated at position 238 had a mutation at aa 96 in the A region, otherwise a C-region mutation at 211 was selected. 7613162 3 38 gly glycosylation 367:379 arg2 the glycosylation sites the glycosylation sites sites To determine the effect of the glycosylation sites on IgE Fc synthesis and on Fc epsilon RI alpha binding, site-directed mutagenesis was performed. 7829269 5 27 gly glycosylation 1174:1186 arg2 a corresponding glycosylation site a corresponding glycosylation site site The finding is interesting because it enables a wider choice of human framework sequences, which in most cases do not have a corresponding glycosylation site, for the humanization of the LL2 VK domain, as well as a greater latitude of host expression systems. 15616123 5 6 gly fragment 883:890 arg1 carbohydrate-specific fragment ions carbohydrate-specific fragment ions The glycopeptide ions were extracted and confirmed by the presence of carbohydrate-specific fragment ions, such as m/z 204 (HexNAc) and 366 (HexHexNAc), in the product ion spectra. 15616123 5 94 gly glycopeptide 795:806 arg2 glycopeptide glycopeptide glycopeptide The glycopeptide ions were extracted and confirmed by the presence of carbohydrate-specific fragment ions, such as m/z 204 (HexNAc) and 366 (HexHexNAc), in the product ion spectra. 20506028 1 48 gly glycoprotein 114:125 arg1 a 25-kDa glycoprotein a 25-kDa glycoprotein Fterm glycoprotein Chondromodulin-I (ChM-I) is a 25-kDa glycoprotein that specifically localizes in the extracellular matrix of cartilage and negatively regulates angiogenesis. 20506028 1 48 gly glycoprotein 114:125 arg1 Chondromodulin-I Chondromodulin-I PUBTATOR Chondromodulin-I 11061 Chondromodulin-I (ChM-I) is a 25-kDa glycoprotein that specifically localizes in the extracellular matrix of cartilage and negatively regulates angiogenesis. 14692455 0 34 gly glycoproteins 26:38 arg1 glycoproteins glycoproteins Fterm glycoproteins Comparative proteomics of glycoproteins based on lectin selection and isotope coding. 21970473 7 17 gly glycopeptides 1145:1157 arg2 partially deglycosylated glycopeptides partially deglycosylated glycopeptides glycopeptides In this research, fragmentations of partially deglycosylated glycopeptides were studied using a triple quadrupole mass spectrometer, and a quantification method that coupled our published identification strategy with multiple reaction monitoring-mass spectrometry (MRM-MS) analysis was developed to obtain site-specific quantification information of core fucosylated peptides. 21970473 7 24 gly fucosylated 1439:1449 arg1 core fucosylated peptides core fucosylated peptides peptides In this research, fragmentations of partially deglycosylated glycopeptides were studied using a triple quadrupole mass spectrometer, and a quantification method that coupled our published identification strategy with multiple reaction monitoring-mass spectrometry (MRM-MS) analysis was developed to obtain site-specific quantification information of core fucosylated peptides. 21970473 7 41 gly deglycosylated 1130:1143 arg1 partially deglycosylated glycopeptides partially deglycosylated glycopeptides glycopeptides In this research, fragmentations of partially deglycosylated glycopeptides were studied using a triple quadrupole mass spectrometer, and a quantification method that coupled our published identification strategy with multiple reaction monitoring-mass spectrometry (MRM-MS) analysis was developed to obtain site-specific quantification information of core fucosylated peptides. 10441114 0 47 part_of endostatin 41:50 arg1 circulating endostatin-related fragments endostatin circulating endostatin-related fragments PUBTATOR Site endostatin 80781 fragments Novel glycosylated forms of human plasma endostatin and circulating endostatin-related fragments of collagen XV. 10441114 0 74 part_of endostatin-related 68:85 arg1 circulating endostatin-related fragments endostatin circulating endostatin-related fragments PUBTATOR Site endostatin 80781 fragments Novel glycosylated forms of human plasma endostatin and circulating endostatin-related fragments of collagen XV. 10712595 3 110 part_of antithrombin 473:484 arg1 Asn135 antithrombin Asn135 PUBTATOR AminoAcid antithrombin 462 Asn135 Due to a single nucleotide replacement, Asn135 of the antithrombin in higher vertebrates is substituted by Asp in the salmon homolog. 16253890 2 38 gly glycoprotein 315:326 arg1 the HIV envelope glycoprotein gp120 the HIV envelope glycoprotein gp120 Fterm glycoprotein Furthermore, vaccine development faces huge problems, mainly because of the low antigenicity and immunogenicity of the HIV envelope glycoprotein gp120 and the efficient hiding of highly immunogenic epitopes by its glycans. 17927214 3 77 part_of CI-MPR 846:851 arg1 domains 1-3 and 9 CI-MPR domains 1-3 and 9 PUBTATOR Site CI-MPR 3482 domains A structure-based sequence alignment predicts that domain 5 contains the four conserved residues (Gln, Arg, Glu, Tyr) identified as essential for Man-6-P binding by the CD-MPR and domains 1-3 and 9 of the CI-MPR. 17927214 3 36 part_of contains 701:708 arg1 domain 5 AND the four conserved residues domain 5 the four conserved residues residues A structure-based sequence alignment predicts that domain 5 contains the four conserved residues (Gln, Arg, Glu, Tyr) identified as essential for Man-6-P binding by the CD-MPR and domains 1-3 and 9 of the CI-MPR. 15532026 0 42 gly glycosylation 146:158 arg2 a used glycosylation site a used glycosylation site site A novel mutation in UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) in two siblings with mucolipidosis type III alters a used glycosylation site. 27957769 5 111 part_of mucin 875:879 arg1 mucin 1 glycopeptides mucin 1 mucin 1 glycopeptides OGER Site mucin 1 P15941 glycopeptides For assessment of the influence of the immune stimulant on antibody recognition, a comprehensive library of mucin 1 glycopeptides (>100 entries) is synthesized and employed in antibody microarray profiling; these range from small tumor-associated glycans (TN , STN , and T-antigen structures) to heavily extended O-glycan core structures (type-1 and type-2 elongated core 1-3 tri-, tetra-, and hexasaccharides) glycosylated in variable density at the five different sites of the MUC1 tandem repeat. 17670834 1 56 gly acid 272:275 arg1 activating NK receptors receptors acid Fterm receptors Natural killer (NK) cell recognition of influenza virus-infected cells involves hemagglutinin (HA) binding to sialic acid (SA) on activating NK receptors. 22642577 0 26 part_of haemagglutinin 31:44 arg1 Asn91 haemagglutinin Asn91 Fterm AminoAcid haemagglutinin Asn91 Glycosylation at Asn91 of H1N1 haemagglutinin affects binding to glycan receptors. 21153780 7 65 part_of CK2 888:890 arg1 4 CK2 sites CK2 4 CK2 sites OGER Site CK2 sites According to this analysis 1 N-glycosylation site, 2 PKC sites, 4 CK2 sites and 3 disulfide sites were predicted. 16274239 10 38 gly N-glycosylation 1882:1896 arg2 a specific N-glycosylation site a specific N-glycosylation site site This is the first study of which we are aware to show that selective glycosylation of a specific N-glycosylation site can produce two functionally distinct receptors. 16274239 10 43 gly glycosylation 1854:1866 arg1 a specific N-glycosylation site a specific N-glycosylation site site This is the first study of which we are aware to show that selective glycosylation of a specific N-glycosylation site can produce two functionally distinct receptors. 12970363 6 1 part_of motifs 906:911 arg1 TRPC6 TRPC6 motifs PUBTATOR Site TRPC6 7225 motifs Two NX(S/T) motifs in TRPC6 were mutated (Asn to Gln) by in vitro mutagenesis to delete one or both extracellular N-linked glycosylation sites. 1370483 5 1 part_of contains 735:742 arg1 The collagenous domain AND one possible N-glycosylation site The collagenous domain one possible N-glycosylation site site The collagenous domain contains one possible N-glycosylation site. 30904461 5 57 gly glycosylation 877:889 arg2 a glycosylation site a glycosylation site site The most frequent ancestral mutations that occur on at least two occasions are I/L307M, G/A414S/T, I312T, I/L307S, P386S and S367N; the latter introducing a glycosylation site. 22187327 3 17 gly ICAM-5 519:524 arg1 the N-glycans ICAM-5 the N-glycans PUBTATOR ICAM-5 15898 Here, we produced fifteen ICAM-5 gene constructs, in which each potential N-glycosylation site was mutated, to elucidate the function of the N-glycans of ICAM-5, and observed the effects of transfection of them on a neuronal cell line, Neuro-2a (N2a). 22187327 3 58 gly N-glycosylation 439:453 arg2 each potential N-glycosylation site each potential N-glycosylation site site Here, we produced fifteen ICAM-5 gene constructs, in which each potential N-glycosylation site was mutated, to elucidate the function of the N-glycans of ICAM-5, and observed the effects of transfection of them on a neuronal cell line, Neuro-2a (N2a). 21439032 3 64 gly glycosylation 591:603 arg2 the putative N-linked glycosylation sites the putative N-linked glycosylation sites sites We constructed plasmids that contain the genes encoding wild-type prME (contain the signal of the prM, the prM, and the E coding regions) and three mutant prME proteins, in which the putative N-linked glycosylation sites are mutated individually or in combination, by site-directed mutagenesis. 10764604 0 43 gly glycoprotein 25:36 arg1 glycoprotein hormones glycoprotein hormones Fterm glycoprotein Carbohydrate analysis of glycoprotein hormones. 29932112 4 9 part_of Panx2 571:575 arg1 the predicted N-glycosylation site Panx2 the predicted N-glycosylation site PUBTATOR Site Panx2 56666 site Our objectives were to validate the predicted N-glycosylation site of Panx2 and to study the effects of Panx2 glycosylation on localization and its capacity to interact with Panx1. 11281648 8 43 gly N-glycosylation 961:975 arg2 the unique N-glycosylation site Asn316 site Asn316 site Asn316 To test this hypothesis, CS-HA1DeltaGly, a mutant in which the unique N-glycosylation site Asn316 was changed to Ile, was engineered by site-directed mutagenesis. 24838853 4 26 gly glycosylation 519:531 arg2 a potential glycosylation site a potential glycosylation site site The P315S mutation in seven strains added a potential glycosylation site in HA. 8286855 7 53 gly Thr-glycosylation 940:956 arg1 Xaa-Pro-Xaa-Xaa Xaa-Pro-Xaa-Xaa Pro Three motifs are associated with Thr-glycosylation: Xaa-Pro-Xaa-Xaa where at least one Xaa = Thr; Thr-Xaa-Xaa-Xaa where at least one Xaa = Thr; Xaa-Xaa-Thr-Xaa where at least one X = Arg or Lys. 8286855 7 53 gly Thr-glycosylation 940:956 arg1 Thr-Xaa-Xaa-Xaa Thr Thr Three motifs are associated with Thr-glycosylation: Xaa-Pro-Xaa-Xaa where at least one Xaa = Thr; Thr-Xaa-Xaa-Xaa where at least one Xaa = Thr; Xaa-Xaa-Thr-Xaa where at least one X = Arg or Lys. 8126562 11 49 gly glycosylation 1788:1800 arg1 subunit assembly subunit assembly Fterm subunit Together these results suggest (1) heteromeric assembly of Shaker-like channels is cotranslational, and (2) N207 glycosylation of Kv1.1 occurs but is not required for subunit assembly, transport, or function. 8126562 11 49 gly glycosylation 1788:1800 arg1 Kv1.1 Kv1.1 PUBTATOR Kv1.1 16485 Together these results suggest (1) heteromeric assembly of Shaker-like channels is cotranslational, and (2) N207 glycosylation of Kv1.1 occurs but is not required for subunit assembly, transport, or function. 15718224 0 26 part_of sites 34:38 arg1 HIV-1 gp120 HIV-1 gp120 sites PUBTATOR Site HIV-1 gp120 155971 sites Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis. 2457333 9 0 gly glycopeptides 1079:1091 arg2 glycopeptides glycopeptides glycopeptides Ion groups differing in mass by one N-acetyllactosamine unit were observed in glycopeptides from the Asn-Asp and Asn-Cys sites, localizing these previously observed biantennary oligosaccharide structures (R.R. Townsend, M.R. Hardy, T.C. Wong, and Y.C. Lee (1986) Biochemistry 25, 5716-5725; S. Takasaki and A. Kobata (1986) Biochemistry 25, 5709-5715) to these two sites. 2457333 9 0 gly glycopeptides 1079:1091 arg1 the Asn-Asp and Asn-Cys sites the Asn-Asp and Asn-Cys sites sites Ion groups differing in mass by one N-acetyllactosamine unit were observed in glycopeptides from the Asn-Asp and Asn-Cys sites, localizing these previously observed biantennary oligosaccharide structures (R.R. Townsend, M.R. Hardy, T.C. Wong, and Y.C. Lee (1986) Biochemistry 25, 5716-5725; S. Takasaki and A. Kobata (1986) Biochemistry 25, 5709-5715) to these two sites. 9249051 5 14 gly N-acetylgalactosamine-threonine 1238:1268 arg1 the N-acetylgalactosamine-threonine linkage threonine the N-acetylgalactosamine-threonine linkage threonine The present NMR study reports assignments of 1H and 13C resonances of the bound saccharidic chain NeuNAc(alpha2-3)Gal(beta1-3)[NeuNAc(alpha2-6)]GalNAc, where NeuNAc represents N-acetylneuraminic acid, and demonstrates the alpha-anomeric configuration of the N-acetylgalactosamine-threonine linkage. 17766267 10 27 gly glycosylation 1971:1983 arg1 human proteins human proteins Fterm proteins This constitutes the first report of the in vitro synthesis of the O-linked T-antigen glycan on a human protein by a bacterial glycosyltransferase and illustrates the potential of bacterial glycosyltransferases as tools for in vitro glycosylation of human proteins of therapeutic value. 17766267 10 83 gly glycan 1824:1829 arg1 a human protein protein glycan Fterm protein This constitutes the first report of the in vitro synthesis of the O-linked T-antigen glycan on a human protein by a bacterial glycosyltransferase and illustrates the potential of bacterial glycosyltransferases as tools for in vitro glycosylation of human proteins of therapeutic value. 8392347 4 29 part_of protein 787:793 arg1 The sequence protein The sequence Fterm Site protein sequence The sequence of the Clone 5-encoded protein was nearly identical to those previously reported for the rat and human beta 1 ARs. 29757379 0 58 gly glycosite 38:46 arg2 Quiescin sulfhydryl oxidase 1 (QSOX1) glycosite mutation Quiescin sulfhydryl oxidase 1 (QSOX1) glycosite mutation glycosite Quiescin sulfhydryl oxidase 1 (QSOX1) glycosite mutation perturbs secretion but not Golgi localization. 15094369 0 66 gly glycosylated 38:49 arg1 glycosylated Cu/Zn-superoxide dismutase glycosylated Cu/Zn-superoxide dismutase Fterm dismutase Structural and functional analysis of glycosylated Cu/Zn-superoxide dismutase from the fungal strain Humicola lutea 103. 8323283 6 16 gly glycosylated 1214:1225 arg1 the new hybrid protein the new hybrid protein Fterm protein Furthermore, if a short peptide containing a potential glycosylation site was fused to the N-terminus of the mutant protein, the new hybrid protein was glycosylated in COS1 cells and the carbohydrate moiety remained sensitive to cleavage by endoglycosidase H. 8323283 6 56 gly glycosylation 1117:1129 arg2 a potential glycosylation site a potential glycosylation site site Furthermore, if a short peptide containing a potential glycosylation site was fused to the N-terminus of the mutant protein, the new hybrid protein was glycosylated in COS1 cells and the carbohydrate moiety remained sensitive to cleavage by endoglycosidase H. 24554659 10 29 gly glycosylation 1693:1705 arg2 the N173 N-linked glycosylation site the N173 N-linked glycosylation site site These findings suggest that the loss of the N173 N-linked glycosylation site increases SIVmac239 replication in macrophages by enhancing CD4-independent cell-to-cell virus transmission through CCR5-mediated fusion. 28931684 3 8 part_of site 667:670 arg1 the envelope (E) protein protein site Fterm Site protein site One sequence motif, VNDT, containing an N-linked glycosylation site in the envelope (E) protein, is polymorphic, being absent in many of the African isolates while present in all isolates from the recent outbreaks. 28931684 3 130 part_of containing 630:639 arg1 One sequence motif AND an N-linked glycosylation site One sequence motif an N-linked glycosylation site site One sequence motif, VNDT, containing an N-linked glycosylation site in the envelope (E) protein, is polymorphic, being absent in many of the African isolates while present in all isolates from the recent outbreaks. 7688818 11 71 part_of E2 1940:1941 arg1 two major neutralization sites E2 two major neutralization sites Cterm Site E2 sites One of the transitional epitopes identified (E2 residues 200 to 202) lies in the E2 190-216 region, which harbors two major neutralization sites, E2a and E2b, and an N-linked glycosylation site at E2 196. 7688818 11 71 part_of E2 1940:1941 arg1 an N-linked glycosylation site E2 an N-linked glycosylation site Cterm Site E2 site One of the transitional epitopes identified (E2 residues 200 to 202) lies in the E2 190-216 region, which harbors two major neutralization sites, E2a and E2b, and an N-linked glycosylation site at E2 196. 7688818 11 82 part_of E2 1824:1825 arg1 the E2 190-216 region E2 the E2 190-216 region Cterm Site E2 region One of the transitional epitopes identified (E2 residues 200 to 202) lies in the E2 190-216 region, which harbors two major neutralization sites, E2a and E2b, and an N-linked glycosylation site at E2 196. 7688818 11 119 part_of E2 1788:1789 arg1 the transitional epitopes E2 the transitional epitopes Cterm Site E2 epitopes One of the transitional epitopes identified (E2 residues 200 to 202) lies in the E2 190-216 region, which harbors two major neutralization sites, E2a and E2b, and an N-linked glycosylation site at E2 196. 7688818 11 119 part_of E2 1788:1789 arg1 E2 residues 200 to 202 E2 E2 residues 200 to 202 Cterm SpecificSite E2 residues 200 One of the transitional epitopes identified (E2 residues 200 to 202) lies in the E2 190-216 region, which harbors two major neutralization sites, E2a and E2b, and an N-linked glycosylation site at E2 196. 9427707 0 73 part_of VIII 127:130 arg1 the A2-domain factor VIII the A2-domain PUBTATOR Site factor VIII 2157 A2-domain The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. 16077958 7 44 part_of proteins 820:827 arg1 two Cys-rich regions proteins two Cys-rich regions Fterm Site proteins regions Mammalian Dkk family members were secreted proteins with two Cys-rich regions, each containing ten conserved Cys residues. 16077958 7 51 part_of containing 861:870 arg1 two Cys-rich regions AND ten conserved Cys residues two Cys-rich regions ten conserved Cys residues Cys residues Mammalian Dkk family members were secreted proteins with two Cys-rich regions, each containing ten conserved Cys residues. 24884609 1 70 gly glycoprotein 167:178 arg1 Inter-alpha-trypsin inhibitor heavy chain H4 Inter-alpha-trypsin inhibitor heavy chain H4 PUBTATOR Inter-alpha-trypsin inhibitor heavy chain H4 3700 Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) is a 120 kDa acute-phase glycoprotein produced primarily in the liver, secreted into the blood, and identified in serum. 24884609 1 70 gly glycoprotein 167:178 arg1 a 120 kDa acute-phase glycoprotein a 120 kDa acute-phase glycoprotein Fterm glycoprotein Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) is a 120 kDa acute-phase glycoprotein produced primarily in the liver, secreted into the blood, and identified in serum. 22586465 7 76 gly N-glycosylation 1179:1193 arg2 the N-glycosylation motif the N-glycosylation motif motif In this study, we focus on a comprehensive analysis of non-synonymous single nucleotide variations (nsSNV) that lead to either loss or gain of the N-glycosylation motif. 26853155 10 7 gly residues 1892:1899 arg1 N-glycans residues 133, 312, 332 and 443 N-glycans residues 133, 312, 332 and 443 Taken together, our results suggest that N-glycans at residues 133, 312, 332 and 443 of syncytin-2 are required for optimal fusion induction, and that SNPs C46R, N118S, T367M, R417H, V483I and T522M can alter the fusogenic function of syncytin-2. 10620492 2 25 part_of LPP-1 357:361 arg1 three conserved domains LPP-1 three conserved domains PUBTATOR Site LPP-1 19012 domains Mutation of seven amino acids in three conserved domains of mouse LPP-1 abolished its activity. 11072064 12 47 part_of Tc1-like 1529:1536 arg1 A transposon Tc1-like fragment Tc1 A transposon Tc1-like fragment OGER Site Tc1 O60779 fragment A transposon Tc1-like fragment was found in intron III. 8542022 6 64 part_of contain 514:520 arg1 The promoter region AND TATA sequences The promoter region TATA sequences sequences The promoter region does not contain TATA sequences but has possible transcription binding sites for GATA-1 and Sp1. 8542022 6 67 part_of has 541:543 arg1 The promoter region AND possible transcription binding sites The promoter region possible transcription binding sites sites The promoter region does not contain TATA sequences but has possible transcription binding sites for GATA-1 and Sp1. 18636497 2 30 gly sialylation 410:420 arg1 human interferon-gamma human interferon-gamma PUBTATOR interferon-gamma 3458 This study reports site- and branch-specific differences in sialylation of human interferon-gamma (IFN-gamma) derived from Chinese hamster ovary (CHO) cell culture. 18636497 2 30 gly sialylation 410:420 arg1 IFN-gamma IFN-gamma PUBTATOR IFN-gamma 3458 This study reports site- and branch-specific differences in sialylation of human interferon-gamma (IFN-gamma) derived from Chinese hamster ovary (CHO) cell culture. 18636497 2 37 gly interferon-gamma 431:446 arg1 sialylation interferon-gamma sialylation PUBTATOR interferon-gamma 3458 This study reports site- and branch-specific differences in sialylation of human interferon-gamma (IFN-gamma) derived from Chinese hamster ovary (CHO) cell culture. 19747940 4 59 gly glycosylation 601:613 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site A CCG motif, a potential N-linked glycosylation site and 10 cysteine residues were well conserved. 28714086 1 96 gly contain 212:218 arg1 mature receptors AND high-mannose, hybrid and complex oligosaccharides mature receptors high-mannose, hybrid and complex oligosaccharides Fterm receptorsn KEY POINTS: Ionotropic glutamate receptor (iGluR) subunits are N-glycosylated at 4-12 sites, and Golgi processing produces mature receptors that contain high-mannose, hybrid and complex oligosaccharides. 28714086 1 67 gly N-glycosylated 130:143 arg1 Ionotropic glutamate receptor (iGluR) subunits subunits sites Fterm subunits sites KEY POINTS: Ionotropic glutamate receptor (iGluR) subunits are N-glycosylated at 4-12 sites, and Golgi processing produces mature receptors that contain high-mannose, hybrid and complex oligosaccharides. 8411360 8 17 gly glycosylation 1649:1661 arg2 an E glycosylation site an E glycosylation site site Thus, the loss of an E glycosylation site appears to play a role in DEN4 neurovirulence. 8912525 7 56 part_of ATP 805:807 arg1 one ATP binding site ATP one ATP binding site OGER Site ATP site ARA has one ATP binding site and associated transmembrane regions. 8912525 7 12 part_of has 797:799 arg1 ARA AND one ATP binding site ARA one ATP binding site PUBTATOR Site ARA 368 site ARA has one ATP binding site and associated transmembrane regions. 8912525 7 12 part_of has 797:799 arg1 ARA AND associated transmembrane regions ARA associated transmembrane regions PUBTATOR Site ARA 368 regions ARA has one ATP binding site and associated transmembrane regions. 8437218 3 96 gly glycosylation 851:863 arg2 glycosylation site mutants glycosylation site mutants site The dependence of these in vitro activities on env protein processing and their relationship to pathogenicity of SFFV were explored by using glycosylation site mutants of SFFV env. 18320936 7 60 part_of sites 1151:1155 arg1 HA1 HA1 sites OGER Site HA1 sites Propagating these viruses in cells treated with 1 mM deoxymannojirimycin (dMJ, mannosidase inhibitor) increased sensitivity to CVN, suggesting that glycans attached at other sites on HA1 that typically are not high-mannosidic became so due to dMJ treatment. 10995221 5 57 gly glycosylation 738:750 arg2 three and four potential glycosylation sites three and four potential glycosylation sites sites Although UGT2B15 and UGT2B20 contain three and four potential glycosylation sites, respectively, site-directed mutagenesis revealed that both proteins are glycosylated at the same first site. 10995221 5 83 gly glycosylated 831:842 arg1 both proteins proteins site Fterm proteins site Although UGT2B15 and UGT2B20 contain three and four potential glycosylation sites, respectively, site-directed mutagenesis revealed that both proteins are glycosylated at the same first site. 22573926 5 82 gly glycosylation 740:752 arg2 a conserved putative N-linked glycosylation site a conserved putative N-linked glycosylation site site The opossum stanniocalcin 1 amino acid sequence had 83% homology with human stanniocalcin 1, and has a conserved putative N-linked glycosylation site. 25651845 9 42 gly revealed 1241:1248 arg1 a consensus N-linked glycosylation site a consensus N-linked glycosylation site site Sequence analysis revealed Thr-315 is a consensus N-linked glycosylation site for Asn-313 and that its elimination significantly (∼four- to fivefold) improves the maximum velocity of PC activation by the thrombin-TM complex, explaining the basis for the proband's negative VTE pedigree. 25651845 9 43 gly glycosylation 1282:1294 arg2 Thr-315 Thr-315 Thr-315 Sequence analysis revealed Thr-315 is a consensus N-linked glycosylation site for Asn-313 and that its elimination significantly (∼four- to fivefold) improves the maximum velocity of PC activation by the thrombin-TM complex, explaining the basis for the proband's negative VTE pedigree. 25651845 9 43 gly glycosylation 1282:1294 arg2 a consensus N-linked glycosylation site a consensus N-linked glycosylation site site Sequence analysis revealed Thr-315 is a consensus N-linked glycosylation site for Asn-313 and that its elimination significantly (∼four- to fivefold) improves the maximum velocity of PC activation by the thrombin-TM complex, explaining the basis for the proband's negative VTE pedigree. 19088065 11 61 gly isoforms 1426:1433 arg1 glycans isoforms glycans Fterm isoforms The structure and composition of glycans of both KLK6 isoforms was elucidated by glycopeptide monitoring with electrospray ionization-Orbitrap tandem mass spectrometry. 19088065 11 77 gly glycopeptide 1453:1464 arg2 glycopeptide glycopeptide glycopeptide The structure and composition of glycans of both KLK6 isoforms was elucidated by glycopeptide monitoring with electrospray ionization-Orbitrap tandem mass spectrometry. 8841141 9 35 gly glycosylation 1542:1554 arg2 Asn180 site Asn180 site Asn180 This hydrophilic region is adjacent to the epitope Ile181-Phe188 and to the glycosylation site Asn180. 10712595 4 17 gly glycosylation 658:670 arg2 the potential glycosylation site the potential glycosylation site site Hence, in contrast to the vertebrate antithrombins known so far, salmon antithrombin lacks the potential glycosylation site located close to the heparin binding site. 2154881 0 46 part_of D 118:118 arg1 a neutralization site glycoprotein D a neutralization site PUBTATOR Site glycoprotein D 2532 site Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D. Herpes simplex virus glycoprotein D is a component of the virion envelope and appears to be involved in attachment, penetration, and cell fusion. 9008840 1 18 gly glycopeptide 129:140 arg2 A 21-amino acid glycopeptide A 21-amino acid glycopeptide glycopeptide A 21-amino acid glycopeptide (Gp21) was isolated and purified in multi-milligram yields from commercially available human serum transferrin (HSTF) by a combination of tryptic digestion, Con A affinity chromatography, and reverse phase HPLC. 15859596 7 68 gly glycoproteins 1093:1105 arg1 four or five glycoproteins four or five glycoproteins Fterm glycoproteins It was found that sialylation varied less than 2-fold in all but four or five glycoproteins. 12372996 3 19 gly is 235:236 arg1 Asn Asn Asn There is one potential N-glycosylation site in this molecule ((27)Asn). 12372996 3 56 gly N-glycosylation 252:266 arg2 one potential N-glycosylation site one potential N-glycosylation site site There is one potential N-glycosylation site in this molecule ((27)Asn). 31685900 6 3 gly non-glycoproteins 820:836 arg1 non-glycoproteins non-glycoproteins Fterm non-glycoproteins The first stage uses a protein similarity voting algorithm trained  on both glycoproteins and non-glycoproteins to predict a score for a protein to improve glycosite prediction. 31685900 6 14 gly glycoproteins 802:814 arg1 glycoproteins glycoproteins Fterm glycoproteins The first stage uses a protein similarity voting algorithm trained  on both glycoproteins and non-glycoproteins to predict a score for a protein to improve glycosite prediction. 31685900 6 29 gly glycosite 882:890 arg2 glycosite prediction glycosite prediction glycosite The first stage uses a protein similarity voting algorithm trained  on both glycoproteins and non-glycoproteins to predict a score for a protein to improve glycosite prediction. 23184955 6 23 gly O-glycoprotein 890:903 arg1 an O-glycoprotein an O-glycoprotein Fterm O-glycoprotein The methodology used here allowed the first such description of the structure and dynamics of an O-glycoprotein and opens the way to the study of this class of proteins. 3087774 4 28 gly glycosylation 478:490 arg2 Asn-946 site, Asn-946 site, Asn-946 A third potential Asn-Xaa-Thr/Ser glycosylation site, Asn-946 of the alpha-chain, is not modified. 25673720 6 48 gly glycosylation 938:950 arg1 C C Cterm C Q9NP58 Here, we show in vivo that glycosylation of the host PrP(C) has a significant impact on the transmission of TSE between different host species. 25673720 6 48 gly glycosylation 938:950 arg1 the host PrP the host PrP PUBTATOR PrP 19122 Here, we show in vivo that glycosylation of the host PrP(C) has a significant impact on the transmission of TSE between different host species. 16107205 2 62 part_of have 465:468 arg1 all the mammalian DNase X proteins AND an N-terminal signal peptide all the mammalian DNase X proteins an N-terminal signal peptide PUBTATOR Site DNase X proteins 1774 peptide A sequence comparison reveals some conserved characteristics: all the mammalian DNase X proteins have an N-terminal signal peptide, a potential N-linked glycosylation site and a C-terminal hydrophobic domain. 16107205 2 62 part_of have 465:468 arg1 all the mammalian DNase X proteins AND a C-terminal hydrophobic domain all the mammalian DNase X proteins a C-terminal hydrophobic domain PUBTATOR Site DNase X proteins 1774 domain A sequence comparison reveals some conserved characteristics: all the mammalian DNase X proteins have an N-terminal signal peptide, a potential N-linked glycosylation site and a C-terminal hydrophobic domain. 16107205 2 62 part_of have 465:468 arg1 all the mammalian DNase X proteins AND a potential N-linked glycosylation site all the mammalian DNase X proteins a potential N-linked glycosylation site PUBTATOR Site DNase X proteins 1774 site A sequence comparison reveals some conserved characteristics: all the mammalian DNase X proteins have an N-terminal signal peptide, a potential N-linked glycosylation site and a C-terminal hydrophobic domain. 31051246 2 27 part_of PRL 307:309 arg1 the first 159 residues PRL the first 159 residues PUBTATOR Site PRL 5617 residues Vasoinhibin isoforms range from the first 79 to the first 159 residues of PRL. 17521765 5 42 gly glycosylation 868:880 arg2 a glycosylation site a glycosylation site site The HA and NA genes had a synergistic effect on virulence and the absence of a glycosylation site at aa154 in the HA gene also increased virulence of virus. 12970363 11 35 gly glycosylated 1655:1666 arg1 an additional second glycosylated site an additional second glycosylated site site Reciprocally, engineering of an additional second glycosylated site in TRPC3 to mimic the glycosylation status in TRPC6 markedly reduced TRPC3 basal activity. 2154881 0 23 gly glycoprotein 68:79 arg1 HSV-1 glycoprotein D. Herpes simplex virus HSV-1 glycoprotein D. Herpes simplex virus PUBTATOR HSV-1 glycoprotein D 2532 Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D. Herpes simplex virus glycoprotein D is a component of the virion envelope and appears to be involved in attachment, penetration, and cell fusion. 2154881 0 48 gly glycoprotein 105:116 arg1 HSV-1 glycoprotein D. Herpes simplex virus glycoprotein D HSV-1 glycoprotein D. Herpes simplex virus glycoprotein D PUBTATOR glycoprotein D 2532 Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D. Herpes simplex virus glycoprotein D is a component of the virion envelope and appears to be involved in attachment, penetration, and cell fusion. 11697887 1 53 part_of Connective 95:104 arg1 a cysteine-rich heparin-binding polypeptide Connective tissue growth factor a cysteine-rich heparin-binding polypeptide PUBTATOR Site Connective tissue growth factor 1490 polypeptide Connective tissue growth factor (CTGF) is a cysteine-rich heparin-binding polypeptide that promotes proliferation, collagen synthesis, and chemotaxis in mesanchymal cells. 11697887 1 57 part_of tissue 106:111 arg1 a cysteine-rich heparin-binding polypeptide Connective tissue growth factor a cysteine-rich heparin-binding polypeptide PUBTATOR Site Connective tissue growth factor 1490 polypeptide Connective tissue growth factor (CTGF) is a cysteine-rich heparin-binding polypeptide that promotes proliferation, collagen synthesis, and chemotaxis in mesanchymal cells. 11697887 1 59 part_of growth 113:118 arg1 a cysteine-rich heparin-binding polypeptide Connective tissue growth factor a cysteine-rich heparin-binding polypeptide PUBTATOR Site Connective tissue growth factor 1490 polypeptide Connective tissue growth factor (CTGF) is a cysteine-rich heparin-binding polypeptide that promotes proliferation, collagen synthesis, and chemotaxis in mesanchymal cells. 10992007 0 97 gly glycosylation 49:61 arg2 the sites the sites sites Identification of the sites of asparagine-linked glycosylation on the human thyrotropin receptor and studies on their role in receptor function and expression. 32109505 2 73 part_of protein 312:318 arg1 its residues protein its residues Fterm Site protein residues TRPM8 is a large tetrameric protein with more than 70% of its residues located in the cytoplasm. 23588719 8 13 gly glycosylation 1319:1331 arg2 a N-linked glycosylation site a N-linked glycosylation site site Four out of 126 (3.2%) NA sequences from patients with severe infection lost a N-linked glycosylation site due to the change from N to K at residue 386. 9030779 7 9 gly glycosylation 875:887 arg2 glycosylation site five glycosylation site five site Absence of glycosylation site five resulted in rapid cleavage of the primary translation product to an enzymatically inactive protein which accumulated inside the endoplasmic reticulum/Golgi, whereas deletion of glycosylation site six led to the formation of an inactive ASM precursor, also retained inside the endoplasmic reticulum/Golgi. 9030779 7 33 gly glycosylation 1076:1088 arg2 glycosylation site six glycosylation site six site Absence of glycosylation site five resulted in rapid cleavage of the primary translation product to an enzymatically inactive protein which accumulated inside the endoplasmic reticulum/Golgi, whereas deletion of glycosylation site six led to the formation of an inactive ASM precursor, also retained inside the endoplasmic reticulum/Golgi. 10889209 3 5 part_of have 493:496 arg1 GIRK4 AND one extracellular consensus N-glycosylation site GIRK4 one extracellular consensus N-glycosylation site PUBTATOR Site GIRK4 3762 site Both GIRK1 and GIRK4 have one extracellular consensus N-glycosylation site. 10889209 3 5 part_of have 493:496 arg1 GIRK1 AND one extracellular consensus N-glycosylation site GIRK1 one extracellular consensus N-glycosylation site PUBTATOR Site Both GIRK1 3760 site Both GIRK1 and GIRK4 have one extracellular consensus N-glycosylation site. 10858228 6 69 gly O-glycosylation 1067:1081 arg2 the C terminus the C terminus terminus Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor. 10858228 6 69 gly O-glycosylation 1067:1081 arg2 multiple predicted O-glycosylation sites multiple predicted O-glycosylation sites sites Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor. 10858228 6 75 gly N-glycosylation 1109:1123 arg2 a single potential N-glycosylation site a single potential N-glycosylation site site Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor. 10858228 6 75 gly N-glycosylation 1109:1123 arg2 the C terminus the C terminus terminus Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor. 1281197 9 5 gly glycosylation 1394:1406 arg2 the putative glycosylation site the putative glycosylation site site One segment of 23 amino acids contained both a T cell and B cell epitope as well as the putative glycosylation site. 8985413 6 9 part_of CD4 1238:1240 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 920 site Soluble gp120 mutant glycoproteins showed increased affinities for soluble CD4 and monoclonal antibodies specific for a number of epitopes overlapping the CD4 binding site, confirming that length increases in V2 affect exposure of the CD4 binding site. 8985413 6 75 part_of CD4 1158:1160 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 920 site Soluble gp120 mutant glycoproteins showed increased affinities for soluble CD4 and monoclonal antibodies specific for a number of epitopes overlapping the CD4 binding site, confirming that length increases in V2 affect exposure of the CD4 binding site. 1918071 4 28 gly glycosylation 950:962 arg2 the glycosylation site sequence site sequence site sequence The results reveal that although N-glycosylation by oligosaccharyl transferase in the endoplasmic reticulum has an absolute requirement for an hydroxyamino acid in the third amino acid residue of the glycosylation site sequence, no such specificity is observed in the binding of such peptides to PDI. 16912309 11 30 gly N-glycosylation 1244:1258 arg2 An additional N-glycosylation site An additional N-glycosylation site site An additional N-glycosylation site was created by one of the mutations. 15859596 9 97 gly glycopeptides 1400:1412 arg1 complex biantennary N-linked, hybrid, and high-mannose glycans glycopeptides complex biantennary N-linked, hybrid, and high-mannose glycans glycopeptides Samples labeled with the light isoform of the coding agent were applied to a set of serial lectin columns consisting of a concanavalin A (Con A) column coupled to an SNA column for selecting sialic acid appended to glycopeptides with complex biantennary N-linked, hybrid, and high-mannose glycans. 15859596 9 108 gly glycopeptides 1400:1412 arg2 glycopeptides glycopeptides complex biantennary N-linked, hybrid, and high-mannose glycans glycopeptides Samples labeled with the light isoform of the coding agent were applied to a set of serial lectin columns consisting of a concanavalin A (Con A) column coupled to an SNA column for selecting sialic acid appended to glycopeptides with complex biantennary N-linked, hybrid, and high-mannose glycans. 15859596 9 108 gly glycopeptides 1400:1412 arg2 glycopeptides glycopeptides complex biantennary N-linked, hybrid, and high-mannose glycans glycopeptides Samples labeled with the light isoform of the coding agent were applied to a set of serial lectin columns consisting of a concanavalin A (Con A) column coupled to an SNA column for selecting sialic acid appended to glycopeptides with complex biantennary N-linked, hybrid, and high-mannose glycans. 9597548 4 1 gly sialylated 765:774 arg1 various sialylated complex-type oligosaccharides various sialylated complex-type oligosaccharides The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 18 gly 563 880:882 arg1 various sialylated complex-type oligosaccharides Asn 402 and 563 various sialylated complex-type oligosaccharides Asn 402 and 563 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 18 gly 563 880:882 arg1 high-mannose-type oligosaccharides Asn 402 and 563 high-mannose-type oligosaccharides Asn 402 and 563 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 23 gly Asn 809:811 arg1 various sialylated complex-type oligosaccharides Asn 332 and 395 various sialylated complex-type oligosaccharides Asn 332 and 395 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 23 gly Asn 809:811 arg1 high-mannose-type oligosaccharides Asn 332 and 395 high-mannose-type oligosaccharides Asn 332 and 395 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 31 gly Asn 868:870 arg1 various sialylated complex-type oligosaccharides Asn 402 and 563 various sialylated complex-type oligosaccharides Asn 402 and 563 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 31 gly Asn 868:870 arg1 high-mannose-type oligosaccharides Asn 402 and 563 high-mannose-type oligosaccharides Asn 402 and 563 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 41 gly Asn 748:750 arg1 various sialylated complex-type oligosaccharides Asn 171 various sialylated complex-type oligosaccharides Asn 171 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 41 gly Asn 748:750 arg1 high-mannose-type oligosaccharides Asn 171 high-mannose-type oligosaccharides Asn 171 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 66 gly 395 821:823 arg1 various sialylated complex-type oligosaccharides Asn 332 and 395 various sialylated complex-type oligosaccharides Asn 332 and 395 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 66 gly 395 821:823 arg1 high-mannose-type oligosaccharides Asn 332 and 395 high-mannose-type oligosaccharides Asn 332 and 395 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 18 gly 563 880:882 arg1 various complex- and hybrid-type oligosaccharide structures Asn 402 and 563 various complex- and hybrid-type oligosaccharide structures Asn 402 and 563 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 23 gly Asn 809:811 arg1 various complex- and hybrid-type oligosaccharide structures Asn 332 and 395 various complex- and hybrid-type oligosaccharide structures Asn 332 and 395 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 31 gly Asn 868:870 arg1 various complex- and hybrid-type oligosaccharide structures Asn 402 and 563 various complex- and hybrid-type oligosaccharide structures Asn 402 and 563 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 41 gly Asn 748:750 arg1 various complex- and hybrid-type oligosaccharide structures Asn 171 various complex- and hybrid-type oligosaccharide structures Asn 171 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 9597548 4 66 gly 395 821:823 arg1 various complex- and hybrid-type oligosaccharide structures Asn 332 and 395 various complex- and hybrid-type oligosaccharide structures Asn 332 and 395 The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563. 18282281 4 25 part_of sites 660:664 arg1 mammalian proteins proteins sites Fterm Site proteins sites RESULTS: A new protein bioinformatics tool, CKSAAP_OGlySite, was developed to predict mucin-type O-glycosylation serine/threonine (S/T) sites in mammalian proteins. 18282281 4 64 part_of mucin-type 610:619 arg1 mucin-type O-glycosylation serine/threonine (S/T) sites mucin mucin-type O-glycosylation serine/threonine (S/T) sites PUBTATOR Site mucin 100508689 sites RESULTS: A new protein bioinformatics tool, CKSAAP_OGlySite, was developed to predict mucin-type O-glycosylation serine/threonine (S/T) sites in mammalian proteins. 8163832 6 66 gly glycoprotein 811:822 arg1 the influenza B viral haemagglutinin (HA) glycoprotein the influenza B viral haemagglutinin (HA) glycoprotein Fterm glycoprotein Isolates were analysed by means of monoclonal antibodies (MAbs) raised against the influenza B viral haemagglutinin (HA) glycoprotein. 16981714 4 41 gly fucosylated 791:801 arg1 fucosylated and sialylated complex-type sugars fucosylated and sialylated complex-type sugars By specific endo and exoglycosidases digestion and direct mass spectrometric analysis, we found that both recombinant and naturally occurring PTX3 were N-linked to fucosylated and sialylated complex-type sugars. 16981714 4 59 gly sialylated 807:816 arg1 fucosylated and sialylated complex-type sugars fucosylated and sialylated complex-type sugars By specific endo and exoglycosidases digestion and direct mass spectrometric analysis, we found that both recombinant and naturally occurring PTX3 were N-linked to fucosylated and sialylated complex-type sugars. 9857985 2 51 gly glycoproteins 279:291 arg1 the spike (S) glycoproteins the spike (S) glycoproteins Fterm glycoproteins The nucleotide sequences of the genes encoding the hemagglutinin-esterase (HE) and the spike (S) glycoproteins from DVIM were determined and compared with those of other MHVs. 8393577 4 53 gly glycosylation 1060:1072 arg2 Asn-70 Asn-70 Asn-70 Mutagenesis studies have identified a phosphotransferase recognition region that is required for oligosaccharide phosphorylation but is 32 A distant from the N-domain glycosylation site at Asn-70. 8393577 4 53 gly glycosylation 1060:1072 arg2 the N-domain glycosylation site the N-domain glycosylation site site Mutagenesis studies have identified a phosphotransferase recognition region that is required for oligosaccharide phosphorylation but is 32 A distant from the N-domain glycosylation site at Asn-70. 23661698 7 29 gly glycosylation 993:1005 arg2 the glycosylation site the glycosylation site site Mutations in the glycosylation site on ephrin-A1 result in protein aggregation and mislocalization. 1380164 3 56 part_of receptor 644:651 arg1 the ligand binding site receptor the ligand binding site Fterm Site receptor site We have previously reported that the resistance of snake AcChoR to alpha-bungarotoxin (alpha-BTX) may be accounted for by several major substitutions in the ligand binding site of the receptor. 17313760 0 47 gly glycoprotein 38:49 arg1 the full-length glycoprotein 120 gene the full-length glycoprotein 120 gene Fterm glycoprotein [Sequence analysis of the full-length glycoprotein 120 gene of HIV-1 CRF01_AE in Fujian, China]. 19193194 6 63 part_of PAN 1441:1443 arg1 the PAN domain PAN the PAN domain OGER Site PAN domain These results demonstrate that BbPlgl is a novel member of the Plg family, with a domain structure of K-K-SP (kringle-kringle-serine protease) lacking the PAN domain, pushing the evolutionary origin of Plg to the protochordate. 19619305 3 3 part_of CD4 675:677 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 713807 site Here, we use a panel of primary HIV envelopes from brain and lymphoid tissues to examine the relationship between neutralization sensitivity to reagents targeting the CD4 binding site and virus entry into macrophages. 4038307 2 24 gly N-glycosylation 391:405 arg2 only one N-glycosylation site only one N-glycosylation site site Although the protein possesses only one N-glycosylation site, di-, tri- and tetra-antennary glycans in a ratio of 40:15:45 were found to be present. 2574658 5 86 part_of contains 637:644 arg1 The deduced amino acid sequence AND one possible tyrosine O-sulfation site site seven epidermal growth factor-like cysteine-rich repeats site The deduced amino acid sequence contains seven epidermal growth factor-like cysteine-rich repeats, one possible tyrosine O-sulfation site, and a possible N-glycosylation site. 8244420 5 43 part_of contains 544:551 arg1 The deduced amino acid sequence AND an asparagine-linked glycosylation site The deduced amino acid sequence an asparagine-linked glycosylation site site The deduced amino acid sequence of VL contains an asparagine-linked glycosylation site in framework 3 (N74 I75 S76). 19838169 4 1 gly glycosylation 604:616 arg2 36 N-linked and 44 O-linked glycosylation sites 36 N-linked and 44 O-linked glycosylation sites sites We identified 36 N-linked and 44 O-linked glycosylation sites on glycoproteins from human cerebrospinal fluid. 19838169 4 32 gly glycoproteins 627:639 arg1 glycoproteins glycoproteins Fterm glycoproteins We identified 36 N-linked and 44 O-linked glycosylation sites on glycoproteins from human cerebrospinal fluid. 9774483 10 72 gly acid 1868:1871 arg1 NCAM NCAM acid PUBTATOR NCAM 4684 Moreover, a mixture of PST and STX more efficiently synthesized polysialic acid on NCAM than PST or STX alone. 9774483 10 72 gly acid 1868:1871 arg1 STX STX acid PUBTATOR STX 8128 Moreover, a mixture of PST and STX more efficiently synthesized polysialic acid on NCAM than PST or STX alone. 11038011 3 82 gly neurophysin/glycopeptide 499:522 arg2 neurophysin/glycopeptide neurophysin/glycopeptide neurophysin/glycopeptide In the present study, we investigated the effects of various mutations within the neurophysin/glycopeptide portion of the vasopressin gene on vasopressin secretion in vitro, to clarify the role of each peptide in vasopressin biosynthesis. 27957769 11 8 part_of GSTA 2247:2250 arg1 the GSTA domain GSTA the GSTA domain OGER Site GSTA domain The nature of the antibody response is characteristically different for antibodies directed to glycosylation sites in either the immune-dominant PDTR or the GSTA domain. 12139935 1 78 gly glycosylated 152:163 arg1 a highly glycosylated phospholipid-binding plasma protein a highly glycosylated phospholipid-binding plasma protein Fterm protein beta(2)-Glycoprotein I (beta(2)GPI) is a highly glycosylated phospholipid-binding plasma protein comprised of four complement control protein (CCP) domains and a distinct fifth domain. 12139935 1 78 gly glycosylated 152:163 arg1 beta(2)-Glycoprotein I beta(2)-Glycoprotein I PUBTATOR beta(2)-Glycoprotein I 350 beta(2)-Glycoprotein I (beta(2)GPI) is a highly glycosylated phospholipid-binding plasma protein comprised of four complement control protein (CCP) domains and a distinct fifth domain. 2846584 14 12 gly glycosylation 2261:2273 arg2 the glycosylation site the glycosylation site site We conclude that two regions of VP7 mediate its retention in the ER, the first lies within the sequence 51-61 and the second within the sequence 62-111, which contains the glycosylation site for VP7. 20848033 1 38 gly glycopeptide 122:133 arg2 a glycosylphosphatidylinositol (GPI)-anchored glycopeptide antigen a glycosylphosphatidylinositol (GPI)-anchored glycopeptide antigen glycopeptide CD52 is a glycosylphosphatidylinositol (GPI)-anchored glycopeptide antigen found on sperm cells and human lymphocytes. 15865444 7 22 gly detected 1204:1211 arg2 the potential N-glycosylation site AND No glycan the potential N-glycosylation site No glycan site No glycan was detected at the potential N-glycosylation site. 15865444 7 68 gly N-glycosylation 1230:1244 arg2 the potential N-glycosylation site the potential N-glycosylation site site No glycan was detected at the potential N-glycosylation site. 31004621 3 20 part_of p27 690:692 arg1 the p27 peptide p27 the p27 peptide OGER Site p27 P40305 peptide The RSV F sequence possesses five N-glycosylation sites located in the F2 subunit (N27 and N70), the p27 peptide (N116 and N126) and the F1 subunit (N500). 31004621 3 53 part_of RSV 593:595 arg1 The RSV F sequence RSV F The RSV F sequence Cterm Site RSV F sequence The RSV F sequence possesses five N-glycosylation sites located in the F2 subunit (N27 and N70), the p27 peptide (N116 and N126) and the F1 subunit (N500). 31004621 3 100 part_of F1 726:727 arg1 N500 F1 N500 Cterm SpecificSite F1 N500 The RSV F sequence possesses five N-glycosylation sites located in the F2 subunit (N27 and N70), the p27 peptide (N116 and N126) and the F1 subunit (N500). 31004621 3 114 part_of F 597:597 arg1 The RSV F sequence RSV F The RSV F sequence Cterm Site RSV F sequence The RSV F sequence possesses five N-glycosylation sites located in the F2 subunit (N27 and N70), the p27 peptide (N116 and N126) and the F1 subunit (N500). 31004621 3 77 part_of possesses 608:616 arg1 The RSV F sequence AND five N-glycosylation sites The RSV F sequence five N-glycosylation sites sites The RSV F sequence possesses five N-glycosylation sites located in the F2 subunit (N27 and N70), the p27 peptide (N116 and N126) and the F1 subunit (N500). 8344280 11 16 gly N-glycosylation 1742:1756 arg2 its only N-glycosylation site its only N-glycosylation site site An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins. 8344280 11 59 gly fucosylated 1801:1811 arg1 truncated proximally fucosylated oligomannosidic glycans truncated proximally fucosylated oligomannosidic glycans An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins. 1602549 6 80 gly glycosylation 826:838 arg2 this glycosylation site this glycosylation site site For the H3-subtype virus A/Memphis/1/71 x A/Bel/42 (H3N1), sensitivity to beta inhibitors is determined by the oligosaccharide at residue 165 of the hemagglutinin, this glycosylation site being lost in a resistant mutant selected by growth in the presence of bovine serum. 20235580 2 21 gly containing 355:364 arg1 polypeptides AND a N-linked carbohydrate polypeptides a N-linked carbohydrate polypeptides In this work, a protocol based on capture of polypeptides containing a N-linked carbohydrate from human plasma using commercially available magnetic beads coupled with hydrazide chemistry was optimized and partially automated through the use of a KingFisher magnetic particle processor. 11222739 9 47 gly residues 1452:1459 arg1 determinant loop residues in determinant loop residues in These differences include conformational changes and/or differential distributions of polar or charged residues in loops L3beta (hFSH residues 62-73), the cystine noose, or determinant loop (residues 87-94), and the carboxy-terminal loop (residues 94-104). 12223479 9 58 gly Glycosylation 1480:1492 arg1 the beta4 subunit the beta4 subunit PUBTATOR beta4 subunit 10717 Glycosylation of the beta4 subunit is not required for its binding to the hSlo channel alpha subunit. 1725860 8 41 gly glycosylation 1588:1600 arg2 one N-linked glycosylation site one N-linked glycosylation site site One potential N-linked glycosylation site is located at the mid-region of rat and human IGFBP-4, whereas only human but not rat IGFBP-6 possesses one N-linked glycosylation site at the extreme C-terminal of the molecule. 1725860 8 60 gly glycosylation 1452:1464 arg2 One potential N-linked glycosylation site One potential N-linked glycosylation site site One potential N-linked glycosylation site is located at the mid-region of rat and human IGFBP-4, whereas only human but not rat IGFBP-6 possesses one N-linked glycosylation site at the extreme C-terminal of the molecule. 28630087 12 18 gly N-glycosylated 2047:2060 arg1 α1-antitrypsin α1-antitrypsin PUBTATOR 1-antitrypsin 5265 The heavily N-glycosylated HNE protease inhibitor, α1-antitrypsin, displayed concentration-dependent complex formation and preferred glycoform-glycoform interactions with HNE. 22762186 4 63 gly N-glycosylation 1141:1155 arg2 potential N-glycosylation site potential N-glycosylation site site In contrast to the efficient production of the functional extracellular domains of TRAIL, TNFα and LTα by intracellular expression systems using Escherichia coli or Pichia pastoris, that of Fas ligand requires the secretory expression systems using P. pastoris or Dictyostelium discoideum, and the productivity in P. pastoris was largely dependent on tag sequence, potential N-glycosylation site and expressed protein region. 17459925 2 64 gly glycosylation 211:223 arg2 position 153 position 153 position 153 The glycosylation site at position 153 is conserved in most flaviviruses, while the site at position 67 is thought to be unique for dengue viruses. 17459925 2 64 gly glycosylation 211:223 arg2 The glycosylation site The glycosylation site site The glycosylation site at position 153 is conserved in most flaviviruses, while the site at position 67 is thought to be unique for dengue viruses. 23090399 8 68 gly glycosylation 1212:1224 arg2 the glycosylation sites the glycosylation sites sites However, both of the glycosylation sites on huPrP(c) are positioned away from the POM1 Fab binding epitope; thus, the binding mode observed in this crystal structure and the binding affinity measured for this antibody are most likely to be the same as those for the native prion protein in vivo. 27177499 5 19 part_of contains 716:723 arg1 The α-subunit AND two N-glycosylation sites The α-subunit two N-glycosylation sites Fterm Site α-subunit sites The α-subunit is identical to the pituitary gonadotropin hormones (LH, FSH, TSH), contains two N-glycosylation sites, and is encoded by a single gene (CGA). 19706343 6 1 gly sialylation 1065:1075 arg1 Asn-143 Asn-143 Asn-143 SpecificSite Asn-143 It revealed significant differences in the extent of sialylation and branching of glycans at Asn-143. 19706343 6 7 gly branching 1081:1089 arg1 Asn-143 Asn-143 Asn-143 SpecificSite Asn-143 It revealed significant differences in the extent of sialylation and branching of glycans at Asn-143. 19706343 6 84 gly sialylation 1065:1075 arg1 glycans glycans It revealed significant differences in the extent of sialylation and branching of glycans at Asn-143. 19706343 6 106 gly Asn-143 1105:1111 arg1 sialylation Asn-143 sialylation Asn-143 It revealed significant differences in the extent of sialylation and branching of glycans at Asn-143. 19706343 6 106 gly Asn-143 1105:1111 arg1 glycans Asn-143 glycans Asn-143 It revealed significant differences in the extent of sialylation and branching of glycans at Asn-143. 19706343 6 106 gly Asn-143 1105:1111 arg1 branching Asn-143 branching Asn-143 It revealed significant differences in the extent of sialylation and branching of glycans at Asn-143. 7609736 6 19 part_of Fc 682:683 arg1 Fab and Fc fragments Fc Fab and Fc fragments Cterm Site Fc fragments Fab and Fc fragments of the purified mAb were prepared and analysed. 7609736 6 26 part_of Fab 674:676 arg1 Fab and Fc fragments Fab Fab and Fc fragments PUBTATOR Site Fab 2187 fragments Fab and Fc fragments of the purified mAb were prepared and analysed. 21345964 7 51 gly glycosylation 844:856 arg2 A glycosylation site site, N116 site, N116 A glycosylation site, N116, in this region did not affect virulence. 23830432 0 47 gly glycoprotein 28:39 arg1 intact glycoprotein intact glycoprotein Fterm glycoprotein Dephosphorylation of intact glycoprotein to greatly improve digestion efficiency coupled with matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometric analysis. 18636497 1 62 gly glycoproteins 211:223 arg1 glycoproteins glycoproteins Fterm glycoproteins Since sialic acid content is known to be a critical determinant of the biological properties of glycoproteins, it is essential to characterize and monitor sialylation patterns of recombinant glycoproteins intended for therapeutic use. 18636497 1 71 gly sialylation 270:280 arg1 recombinant glycoproteins recombinant glycoproteins Fterm glycoproteins Since sialic acid content is known to be a critical determinant of the biological properties of glycoproteins, it is essential to characterize and monitor sialylation patterns of recombinant glycoproteins intended for therapeutic use. 18636497 1 54 gly glycoproteins 306:318 arg1 recombinant glycoproteins glycoproteins sialylation patterns Fterm glycoproteins Since sialic acid content is known to be a critical determinant of the biological properties of glycoproteins, it is essential to characterize and monitor sialylation patterns of recombinant glycoproteins intended for therapeutic use. 2737288 0 5 part_of elastase 80:87 arg1 the glycosylation site pancreatic elastase 1 the glycosylation site PUBTATOR Site pancreatic elastase 1 1990 site Localization and characterization of the glycosylation site of human pancreatic elastase 1. 22238065 7 88 part_of Fab 1690:1692 arg1 Fab fragments Fab Fab fragments Cterm Site Fab fragments All H10 antibody glyco-forms revealed greater degradation compared to the original, resulting mostly in the formation of Fab fragments. 18638581 3 65 gly glycopeptides 658:670 arg2 glycopeptides glycopeptides glycopeptides Glycoprotein analysis by mass spectrometry of biological samples, such as blood serum, is hampered by sample complexity and the low concentration of the potentially informative glycopeptides and -proteins. 10648510 0 31 gly glycoprotein 124:135 arg1 a high-mannose-type glycoprotein a high-mannose-type glycoprotein Production of an endo-beta-N-acetylglucosaminidase activity mediates growth of Enterococcus faecalis on a high-mannose-type glycoprotein. 2451667 2 4 gly glycoprotein 424:435 arg1 the vesicular stomatitis virus glycoprotein the vesicular stomatitis virus glycoprotein Fterm glycoprotein DNA encoding the entire precursor of human chorionic gonadotropin (hCG, alpha subunit) was fused precisely to DNA encoding the transmembrane and cytoplasmic domains of the vesicular stomatitis virus glycoprotein. 10698685 6 12 gly glycosylated 846:857 arg1 Recombinant HFARP Recombinant HFARP PUBTATOR HFARP 51129 Recombinant HFARP expressed in COS-7 cells is secreted and glycosylated. 7532209 1 3 gly glycosylation 217:229 arg1 the alpha 2 subunit the alpha 2 subunit Fterm subunit The N-linked glycosylation of the alpha 2 subunit of the mouse alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)-selective glutamate receptor (GluR) channel was characterized. 11738084 2 53 gly Redhill 287:293 arg1 -1 Arg -1 Arg Arg We have determined the structure of the glycan bound to the double-mutant albumin Redhill (-1 Arg, 320 Ala-->Thr). 11738084 2 53 gly Redhill 287:293 arg1 320 Ala-->Thr 320 Ala-->Thr Ala We have determined the structure of the glycan bound to the double-mutant albumin Redhill (-1 Arg, 320 Ala-->Thr). 18404209 3 28 part_of site 616:619 arg1 the hemagglutinin (HA) glycoprotein glycoprotein site Fterm Site glycoprotein 4758 site We generated and tested 31 recombinants of A/Vietnam/1203/04 (H5N1) influenza virus carrying single, double, or triple mutations located within or near the receptor binding site in the hemagglutinin (HA) glycoprotein that alter H5 HA binding affinity or specificity. 32302771 7 56 part_of contains 1125:1132 arg1 The chst11 AND one N-glycosylation site The chst11 one N-glycosylation site PUBTATOR Site chst11 50515 site The chst11 contains a Sulfotransfer_2 domain, one N-glycosylation site and three O-glycosylation sites. 32302771 7 56 part_of contains 1125:1132 arg1 The chst11 AND three O-glycosylation sites The chst11 three O-glycosylation sites PUBTATOR Site chst11 50515 sites The chst11 contains a Sulfotransfer_2 domain, one N-glycosylation site and three O-glycosylation sites. 32302771 7 56 part_of contains 1125:1132 arg1 The chst11 AND a Sulfotransfer_2 domain The chst11 a Sulfotransfer_2 domain PUBTATOR Site chst11 50515 domain The chst11 contains a Sulfotransfer_2 domain, one N-glycosylation site and three O-glycosylation sites. 9712881 4 42 gly glycosylation 461:473 arg2 the glycosylation site the glycosylation site site Residues of the Ser643 (adjacent to the glycosylation site) to Ser690 region of cysteineless mutant (AE1C-) were replaced individually with cysteine. 21752569 0 4 gly glycosylation 185:197 arg1 glycoprotein glycoprotein Fterm glycoprotein Glycosylation characterization of Human IgA1 with differential deglycosylation by UPLC-ESI TOF MS. Differential deglycosylation was introduced as an effective technique to characterize glycosylation in glycoprotein containing both N-linked and O-linked glycans at both protein and peptide levels. 21752569 0 18 gly glycoprotein 202:213 arg1 glycoprotein glycoprotein Fterm glycoprotein Glycosylation characterization of Human IgA1 with differential deglycosylation by UPLC-ESI TOF MS. Differential deglycosylation was introduced as an effective technique to characterize glycosylation in glycoprotein containing both N-linked and O-linked glycans at both protein and peptide levels. 21752569 0 54 gly deglycosylation 63:77 arg1 Human IgA1 Human IgA1 PUBTATOR Human IgA1 P01876 Glycosylation characterization of Human IgA1 with differential deglycosylation by UPLC-ESI TOF MS. Differential deglycosylation was introduced as an effective technique to characterize glycosylation in glycoprotein containing both N-linked and O-linked glycans at both protein and peptide levels. 21752569 0 11 gly containing 215:224 arg1 glycoprotein AND both N-linked and O-linked glycans glycoprotein both N-linked and O-linked glycans Fterm glycoprotein Glycosylation characterization of Human IgA1 with differential deglycosylation by UPLC-ESI TOF MS. Differential deglycosylation was introduced as an effective technique to characterize glycosylation in glycoprotein containing both N-linked and O-linked glycans at both protein and peptide levels. 31855143 4 28 gly glycosylation 604:616 arg2 the glycosylation site the glycosylation site site Sequence alignments indicated conservation of the ephrin-B2 and ephrin-B3 receptor binding sites, the glycosylation site on the G attachment protein, as well as the editing site in phosphoprotein, suggesting production of nonstructural proteins V and W, known to counteract the host innate immunity. 8360166 6 6 part_of receptor 1539:1546 arg1 the extracellular and transmembrane domains epidermal growth factor receptor the extracellular and transmembrane domains OGER Site epidermal growth factor receptor P00533 domains In addition, alkaline phosphatase fused to the extracellular and transmembrane domains of epidermal growth factor receptor was transported to the plasma membrane in COS1 cells, which establishes that alkaline phosphatase as a cytoplasmic domain does not prevent transport from the ER. 2780569 0 11 part_of subunit 109:115 arg1 the four extracellular cysteines subunit the four extracellular cysteines Fterm AminoAcid subunit cysteines Snake acetylcholine receptor: cloning of the domain containing the four extracellular cysteines of the alpha subunit. 2780569 0 114 part_of containing 52:61 arg1 the domain AND the four extracellular cysteines the domain the four extracellular cysteines cysteines Snake acetylcholine receptor: cloning of the domain containing the four extracellular cysteines of the alpha subunit. 19800422 5 23 part_of matriptase 969:978 arg1 a recombinant catalytic domain matriptase a recombinant catalytic domain PUBTATOR Site matriptase Q9Y5Y6 domain This was evidenced by the observations that (i) a recombinant catalytic domain of matriptase with glutamine substitution at the site corresponding to matriptase Asn772 [N772Q-CD-Myc(His)(6)] was not detected in the medium conditioned by transfected cells but was on the cell surface and (ii) purified N772Q-CD-Myc(His)(6) exhibited markedly reduced activity toward a peptide substrate. 19800422 5 55 part_of matriptase 1037:1046 arg1 His matriptase His PUBTATOR AminoAcid matriptase Q9Y5Y6 His This was evidenced by the observations that (i) a recombinant catalytic domain of matriptase with glutamine substitution at the site corresponding to matriptase Asn772 [N772Q-CD-Myc(His)(6)] was not detected in the medium conditioned by transfected cells but was on the cell surface and (ii) purified N772Q-CD-Myc(His)(6) exhibited markedly reduced activity toward a peptide substrate. 19035324 4 7 gly N-glycosylation 601:615 arg1 HA2 HA2 position 11, 23, 87 and 276 sites OGER HA2 position 11, 23, 87 and 276 sites HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2. 19035324 4 7 gly N-glycosylation 601:615 arg1 HA1 HA1 position 11, 23, 87 and 276 sites OGER HA1 position 11, 23, 87 and 276 sites HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2. 19035324 4 7 gly N-glycosylation 601:615 arg1 HA2 HA2 site OGER HA2 site HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2. 19035324 4 7 gly N-glycosylation 601:615 arg1 HA1 HA1 site OGER HA1 site HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2. 18703501 8 44 gly glycosylation 1520:1532 arg2 Thr(78) Thr(78) Thr(78) Parallel experiments on a recombinant protein obtained by a mammalian cell expression system demonstrated the occurrence of an additional O-linked glycosylation site (Thr(78)) and characterized the nature of the oligosaccharide structures. 18703501 8 44 gly glycosylation 1520:1532 arg2 an additional O-linked glycosylation site an additional O-linked glycosylation site site Parallel experiments on a recombinant protein obtained by a mammalian cell expression system demonstrated the occurrence of an additional O-linked glycosylation site (Thr(78)) and characterized the nature of the oligosaccharide structures. 20512925 3 23 gly glycans 396:402 arg1 RAGE RAGE glycans PUBTATOR RAGE Q15109 We earlier showed that carboxylated glycans on the V-domain of RAGE promote the binding of HMGB1 and S100A8/A9. 20512925 3 23 gly glycans 396:402 arg1 the V-domain the V-domain the V-domain Site V-domain We earlier showed that carboxylated glycans on the V-domain of RAGE promote the binding of HMGB1 and S100A8/A9. 11485624 3 10 gly region 696:701 arg1 three N-linked glycans region three N-linked glycans region Two molecular clones of HIV-1, one lacking three N-linked glycans of the V1 region (HIV-1(3N/V1)) and another lacking three N-linked glycans of the C2 region (HIV-1(3N/C2)), were created and characterized. 11485624 3 95 gly region 621:626 arg1 three N-linked glycans region three N-linked glycans region Two molecular clones of HIV-1, one lacking three N-linked glycans of the V1 region (HIV-1(3N/V1)) and another lacking three N-linked glycans of the C2 region (HIV-1(3N/C2)), were created and characterized. 9472610 8 72 part_of contained 1324:1332 arg1 Sequences AND a glycosylation site Sequences a glycosylation site site Sequences from faecal subpopulations of all 7 persons contained a glycosylation site at amino acid position 331-333. 21431619 6 2 part_of disialotransferrin 1125:1142 arg1 disialotransferrin position transferrin disialotransferrin position PUBTATOR Site transferrin 7018 position In case 1, a peptide with mutation p.Asn630Thr in the 2nd glycosylation site was identified, resulting in an additional band at disialotransferrin position on IEF. 2477364 9 123 part_of subunit 1427:1433 arg1 each glycosylation site subunit each glycosylation site Fterm Site subunit site Concanavalin A (ConA) binding and sialic acid content indicated that the oligosaccharides at each glycosylation site of the uncombined alpha subunit are processed differently. 12527108 2 26 gly N-glycosylation 279:293 arg2 two potential N-glycosylation sites two potential N-glycosylation sites sites FT3 has two potential N-glycosylation sites at Asn(154) and Asn(185). 23751365 3 36 gly glycoproteins 453:465 arg1 glycoproteins glycoproteins Fterm glycoproteins For detailed elucidation of the biological functions of glycoproteins, selective enrichment of glycopeptides from non-glycosylated peptides is crucial. 23751365 3 64 gly non-glycosylated 511:526 arg1 non-glycosylated peptides non-glycosylated peptides peptides For detailed elucidation of the biological functions of glycoproteins, selective enrichment of glycopeptides from non-glycosylated peptides is crucial. 23751365 3 69 gly glycopeptides 492:504 arg2 glycopeptides glycopeptides glycopeptides For detailed elucidation of the biological functions of glycoproteins, selective enrichment of glycopeptides from non-glycosylated peptides is crucial. 15478466 1 8 gly glycosylated 173:184 arg1 An amyloid fibril protein An amyloid fibril protein Fterm protein An amyloid fibril protein (Owe) related to primary amyloidosis was found to be a glycosylated complete immunoglobulin light chain (AL). 8429003 0 39 gly glycosylation 14:26 arg1 recombinant rat and human soluble CD4 variants recombinant rat and human soluble CD4 variants PUBTATOR CD4 variants 920 Site-specific glycosylation of recombinant rat and human soluble CD4 variants expressed in Chinese hamster ovary cells. 20391591 3 65 gly glycoproteins 628:640 arg1 glycoproteins glycoproteins Fterm glycoproteins An attractive aspect of this dissociation option is the generation of distinct Y1 ions (peptide+GlcNAc), thus allowing unequivocal assignment of N-glycosylation sites of glycoproteins. 20391591 3 102 gly N-glycosylation 603:617 arg2 N-glycosylation sites glycoproteins sites Fterm glycoproteins sites An attractive aspect of this dissociation option is the generation of distinct Y1 ions (peptide+GlcNAc), thus allowing unequivocal assignment of N-glycosylation sites of glycoproteins. 7914890 5 12 gly N-glycosylation 714:728 arg2 only the second N-glycosylation site only the second N-glycosylation site site An earlier study had shown that a mutant arylsulfatase A containing only the second N-glycosylation site at Asn-184 folds correctly and is phosphorylated (Gieselmann, V., Schmidt, B., and von Figura, K. (1992) J. Biol. 21277709 2 19 gly N-glycosylation 341:355 arg2 a putative N-glycosylation site a putative N-glycosylation site site The 118A>G (rs1799971) polymorphism in exon 1 of the μ-opioid receptor gene (OPRM1) leads to an Asn40Asp amino acid change that affects a putative N-glycosylation site. 32273875 0 65 gly Removal 0:6 arg3 Mannose-Ending Glycan AND Asn2118 Asn2118 Mannose-Ending Glycan Asn2118 Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells. 11326277 10 22 part_of have 1375:1378 arg1 T1r3 AND an extra amino-terminal glycosylation site T1r3 an extra amino-terminal glycosylation site PUBTATOR Site T1r3 83771 site According to models of its structure, T1r3 from non-tasters is predicted to have an extra amino-terminal glycosylation site that, if used, would interfere with dimerization. 10211957 0 93 part_of E1 76:77 arg1 the glycosylation sites E1 the glycosylation sites Cterm Site E1 sites Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. 1856695 9 40 gly N-glycosylation 1558:1572 arg2 A potential N-glycosylation site A potential N-glycosylation site site A potential N-glycosylation site was found at the N terminus of the TCV M protein and is situated at the same location in BCV, MHV and transmissible gastroenteritis virus. 1856695 9 40 gly N-glycosylation 1558:1572 arg2 the N terminus the N terminus terminus A potential N-glycosylation site was found at the N terminus of the TCV M protein and is situated at the same location in BCV, MHV and transmissible gastroenteritis virus. 8706738 6 37 gly hyperglycosylation 843:860 arg1 the single N-glycosylation site the single N-glycosylation site site Analysis by SDS/PAGE revealed hyperglycosylation at the single N-glycosylation site, preventing recognition by antibodies. 8706738 6 55 gly N-glycosylation 876:890 arg2 the single N-glycosylation site the single N-glycosylation site site Analysis by SDS/PAGE revealed hyperglycosylation at the single N-glycosylation site, preventing recognition by antibodies. 18464039 8 40 part_of DGAT1 979:983 arg1 buffalo DGAT1 peptide sequence DGAT1 buffalo DGAT1 peptide sequence PUBTATOR Site DGAT1 O75907 sequence Four motifs were predicted in buffalo DGAT1 peptide sequence, one N-linked glycosylation site (246th position), two putative tyrosine phosphorylation site (316 and 261), one putative diacylglycerol binding site (382-392 amino acid position) and a conserved domain MBOAT (membrane bound acyl transferase from 150 to 474 amino acids) with a histidine as an active residue. 18464039 8 56 part_of sequence 993:1000 arg1 a histidine sequence a histidine histidine Four motifs were predicted in buffalo DGAT1 peptide sequence, one N-linked glycosylation site (246th position), two putative tyrosine phosphorylation site (316 and 261), one putative diacylglycerol binding site (382-392 amino acid position) and a conserved domain MBOAT (membrane bound acyl transferase from 150 to 474 amino acids) with a histidine as an active residue. 18652900 4 38 part_of protein 621:627 arg1 The complete mature protein sequence protein The complete mature protein sequence Fterm Site protein sequence The complete mature protein sequence was obtained from N-terminal protein sequencing and partial DNA sequencing, confirmed by high resolution crystal structure analysis. 2158103 3 67 part_of found 373:377 arg1 all biogenic amine receptors AND a highly conserved region all biogenic amine receptors a highly conserved region Fterm Site receptors region A rat kidney cDNA library was screened with an oligonucleotide complementary to a highly conserved region found in all biogenic amine receptors described to date. 31302509 7 0 gly glycosylation 990:1002 arg2 an N-linked glycosylation site an N-linked glycosylation site site While this substitution introduces an N-linked glycosylation site, XPR1 receptors are not glycosylated indicating that this replacement alters the virus-receptor interface independently of glycosylation. 31302509 7 25 gly glycosylated 1033:1044 arg1 XPR1 receptors XPR1 receptors PUBTATOR XPR1 receptors 9213 While this substitution introduces an N-linked glycosylation site, XPR1 receptors are not glycosylated indicating that this replacement alters the virus-receptor interface independently of glycosylation. 24104458 8 55 part_of CEACAM5 903:909 arg1 CEACAM5 glycosylation site CEACAM5 CEACAM5 glycosylation site PUBTATOR Site CEACAM5 1048 site Therefore, conformational changes in CEACAM5 glycosylation site are critical for its interaction with CD8α. 17899080 2 26 gly glycoproteins 318:330 arg1 factor VIII factor VIII PUBTATOR factor VIII 2157 This should allow efficient secretion of glycoproteins such as factor VIII (FVIII) whose secretion is negatively affected by BiP interaction. 17899080 2 26 gly glycoproteins 318:330 arg1 glycoproteins glycoproteins Fterm glycoproteins This should allow efficient secretion of glycoproteins such as factor VIII (FVIII) whose secretion is negatively affected by BiP interaction. 26041282 13 76 part_of protein 2492:2498 arg1 hypervariable region 1 protein hypervariable region 1 Fterm Site protein region Thanks to these mutants, we highlighted the importance of hypervariable region 1 (HVR1) of the E2 envelope protein for the association of particles with apolipoprotein E, which in turn might control the pH dependency of cell-free and cell-to-cell transmission. 8982862 1 36 gly glycoprotein 250:261 arg1 Vitronectin Vitronectin PUBTATOR Vitronectin 7448 Vitronectin is a multifunctional glycoprotein regulating the fibrinolysis, complement, and coagulation systems in plasma, besides exhibiting cell-spreading activity. 8982862 1 36 gly glycoprotein 250:261 arg1 a multifunctional glycoprotein a multifunctional glycoprotein Fterm glycoprotein Vitronectin is a multifunctional glycoprotein regulating the fibrinolysis, complement, and coagulation systems in plasma, besides exhibiting cell-spreading activity. 26853155 3 11 gly 10 N-glycosylation 589:606 arg2 10 N-glycosylation sites 10 N-glycosylation sites sites We constructed expression plasmids of wild-type and 21 single-amino-acid substitution mutants of syncytin-2, including 10 N-glycosylation sites individually silenced by mutagenizing N to Q, 1 naturally occurring single-nucleotide polymorphism (SNP) N118S that introduced an N-glycosylation site, and another 10 non-synonymous SNPs located within important functional domains. 26853155 3 74 gly N-glycosylation 744:758 arg2 an N-glycosylation site an N-glycosylation site site We constructed expression plasmids of wild-type and 21 single-amino-acid substitution mutants of syncytin-2, including 10 N-glycosylation sites individually silenced by mutagenizing N to Q, 1 naturally occurring single-nucleotide polymorphism (SNP) N118S that introduced an N-glycosylation site, and another 10 non-synonymous SNPs located within important functional domains. 15737642 5 4 gly glycosylation 1213:1225 arg1 Asn219 Asn219 Asn219 When Ser221 was replaced with Thr, fusion protein was expressed as a single band, indicating that the double band of the expressed fusion protein was due to the heterogeneity of the glycosylation at Asn219. 1719383 10 5 gly glycosylation 1630:1642 arg2 a single Asn-linked glycosylation site a single Asn-linked glycosylation site site Human IGFBP-6 possesses a single Asn-linked glycosylation site near the carboxyl-terminal, whereas no potential Asn-linked glycosylation sites are present in the rat sequence. 1719383 10 13 gly glycosylation 1709:1721 arg1 the rat sequence the rat sequence sequence Human IGFBP-6 possesses a single Asn-linked glycosylation site near the carboxyl-terminal, whereas no potential Asn-linked glycosylation sites are present in the rat sequence. 1719383 10 13 gly glycosylation 1709:1721 arg2 no potential Asn-linked glycosylation sites no potential Asn-linked glycosylation sites sites Human IGFBP-6 possesses a single Asn-linked glycosylation site near the carboxyl-terminal, whereas no potential Asn-linked glycosylation sites are present in the rat sequence. 23069765 1 53 gly glycosylated 222:233 arg1 a variably glycosylated disulfide-linked homodimer a variably glycosylated disulfide-linked homodimer Fterm homodimer The T helper cell-derived cytokine interleukin-17A (IL-17A) is a variably glycosylated disulfide-linked homodimer of 34-38 kDa. 23069765 1 53 gly glycosylated 222:233 arg1 The T helper cell-derived cytokine interleukin-17A The T helper cell-derived cytokine interleukin-17A PUBTATOR interleukin-17A 3605 The T helper cell-derived cytokine interleukin-17A (IL-17A) is a variably glycosylated disulfide-linked homodimer of 34-38 kDa. 31671706 4 43 gly glycosylation 761:773 arg2 The expected N-linked glycosylation sites The expected N-linked glycosylation sites sites The expected N-linked glycosylation sites were successfully identified and site-specific glycopeptide mapping was completed by Integrated GlycoProteome Analyzer (I-GPA) for the resulting raw tandem mass data. 31671706 4 61 gly glycopeptide 828:839 arg2 site-specific glycopeptide mapping site-specific glycopeptide mapping glycopeptide The expected N-linked glycosylation sites were successfully identified and site-specific glycopeptide mapping was completed by Integrated GlycoProteome Analyzer (I-GPA) for the resulting raw tandem mass data. 7849028 8 48 part_of sites 1128:1132 arg1 rat p62 p62 sites PUBTATOR Site p62 117268 sites The majority of the glycosylation sites in rat p62 are likely to occur on the six clustered Ser residues in the central Ser/Thr-rich region from Ser270 to Thr294. 19527756 9 18 gly glycoproteins 1756:1768 arg1 glycoproteins glycoproteins Fterm glycoproteins This is the first report of a simple, rapid, sensitive and a cost-efficient tool for detection of glycoproteins. 23581850 5 68 gly glycopeptide 649:660 arg2 the glycopeptide purification procedure the glycopeptide purification procedure glycopeptide Many GHL/GGHL sites were identified in normal and OI type I collagens by LC-MS analysis after the glycopeptide purification procedure. 17960575 5 2 part_of FETUA 681:685 arg1 all three N-glycosylation sites FETUA all three N-glycosylation sites PUBTATOR Site FETUA 197 sites Glycopeptides derived from all three N-glycosylation sites of FETUA were observed, and the corresponding CID spectra proved the respective glycans to be oligosaccharides of the triantennary complex type. 18638581 6 81 part_of sites 1307:1311 arg1 44 proteins proteins sites Fterm Site proteins sites The combination of lectin affinity enrichment of glycoproteins and subsequent HILIC enrichment of tryptic glycopeptides identified 81 N-glycosylation sites in 44 proteins. 10374967 0 10 gly glycoprotein 58:69 arg1 glycoprotein H glycoprotein H Cterm herpesvirus-6 glycoprotein H N- and C-terminal external domains of human herpesvirus-6 glycoprotein H affect a fusion-associated conformation mediated by glycoprotein L binding the N terminus. 10374967 0 45 gly glycoprotein 125:136 arg1 glycoprotein L glycoprotein L Cterm glycoprotein L N- and C-terminal external domains of human herpesvirus-6 glycoprotein H affect a fusion-associated conformation mediated by glycoprotein L binding the N terminus. 17460245 15 105 gly glycosylation 2202:2214 arg2 the glycosylation site the glycosylation site site The results suggest that elimination of the glycosylation site at N15 is associated with increased sensitivity to light-induced damage. 1703533 6 40 part_of CNBr 1074:1077 arg1 the CNBr fragments CNBr the CNBr fragments Cterm Site CNBr fragments One potential N-glycosylation site was identified in one of the CNBr fragments. 1388166 3 65 gly glycoproteins 569:581 arg1 glycoproteins glycoproteins Fterm glycoproteins Oligosaccharides terminating with this sequence have previously been described on lutropin, thyrotropin, and pro-opiomelanocortin: glycoproteins synthesized in the anterior pituitary. 17001080 5 64 gly glycosylation 930:942 arg2 glycosylation sites glycosylation sites sites We also introduced glycosylation sites at several novel positions. 6304692 0 52 gly glycoprotein 18:29 arg1 gene sequence glycoprotein sequence Fterm glycoprotein sequence Serotype-specific glycoprotein of simian 11 rotavirus: coding assignment and gene sequence. 16040252 3 13 part_of PEDF 541:544 arg1 four specific conserved PEDF peptides PEDF four specific conserved PEDF peptides PUBTATOR Site PEDF 5176 peptides We found evolutionary conservation of a leader sequence, a single C-terminal glycosylation site, collagen-binding residues, and four specific conserved PEDF peptides. 32280962 0 42 gly glycoprotein 46:57 arg1 pregnancy-specific glycoprotein 1 pregnancy-specific glycoprotein 1 Glycan characterization OGER pregnancy-specific glycoprotein 1 P11464 Glycan characterization of pregnancy-specific glycoprotein 1 and its identification as a novel Galectin-1 ligand. 23632316 6 3 gly glycosylation 860:872 arg2 three NXS/T glycosylation sites three NXS/T glycosylation sites sites However, in the IgG-Fc-ZP3E7 protein, we concluded that only one out of three NXS/T glycosylation sites is occupied by N-linked oligosaccharides. 9757569 0 23 gly glycosylation 11:23 arg1 the residue residue at position 14 residue at position 14 Effects of glycosylation of the residue at position 14 in ovine angiotensinogen on the human renin reaction. 9757569 0 23 gly glycosylation 11:23 arg1 the human renin reaction renin residue at position 14 PUBTATOR renin 5972 residue at position 14 Effects of glycosylation of the residue at position 14 in ovine angiotensinogen on the human renin reaction. 9757569 0 23 gly glycosylation 11:23 arg1 the human renin reaction renin residue at position 14 PUBTATOR renin 5972 residue at position 14 Effects of glycosylation of the residue at position 14 in ovine angiotensinogen on the human renin reaction. 22213703 0 42 gly glycosylation 30:42 arg2 the glycosylation site the glycosylation site site Analysis of glycoforms on the glycosylation site and the glycans in monoclonal antibody biopharmaceuticals. 1385399 4 10 gly deglycosylated 605:618 arg1 deglycosylated soluble recombinant CD2 deglycosylated soluble recombinant CD2 PUBTATOR CD2 914 Analysis of deglycosylated soluble recombinant CD2 as well as a mutant transmembrane CD2 molecule containing a single Asn65-Gln65 substitution demonstrates that neither deglycosylated CD2 nor the mutant CD2 transmembrane receptor binds CD58 or monoclonal antibodies directed at native CD2 adhesion domain epitopes. 1385399 4 13 gly deglycosylated 762:775 arg1 deglycosylated CD2 deglycosylated CD2 PUBTATOR CD2 914 Analysis of deglycosylated soluble recombinant CD2 as well as a mutant transmembrane CD2 molecule containing a single Asn65-Gln65 substitution demonstrates that neither deglycosylated CD2 nor the mutant CD2 transmembrane receptor binds CD58 or monoclonal antibodies directed at native CD2 adhesion domain epitopes. 9690810 0 49 gly glycoprotein 61:72 arg1 full-length mouse platelet glycoprotein IX full-length mouse platelet glycoprotein IX PUBTATOR platelet glycoprotein IX 54368 Characterization of cDNA encoding full-length mouse platelet glycoprotein IX. 9689128 2 5 part_of mu 289:290 arg1 the primary site mu opioid receptor the primary site OGER Site mu opioid receptor P35372 site The mu opioid receptor is the primary site of action for the most commonly used opioids, including morphine, heroin, fentanyl, and methadone. 9689128 2 55 part_of opioid 292:297 arg1 the primary site mu opioid receptor the primary site OGER Site mu opioid receptor P35372 site The mu opioid receptor is the primary site of action for the most commonly used opioids, including morphine, heroin, fentanyl, and methadone. 27377235 3 84 gly non-glycosylated 563:578 arg1 both wild-type and non-glycosylated mutant Kv1.2 channels both wild-type and non-glycosylated mutant Kv1.2 channels Fterm channels Although both wild-type and non-glycosylated mutant Kv1.2 channels that have reached the cell membrane are internalized at a comparable rate, mutant channels are degraded at a faster rate. 31826991 1 130 gly glycosylation 214:226 arg2 Seasonal influenza carrying key hemagglutinin (HA) head region glycosylation sites Seasonal influenza carrying key hemagglutinin (HA) head region glycosylation sites sites Seasonal influenza carrying key hemagglutinin (HA) head region glycosylation sites can be removed from the lung by pulmonary surfactant protein D (SP-D). 26029999 9 40 gly glycosylated 1396:1407 arg1 glycosylated CD133 glycosylated CD133 PUBTATOR CD133 8842 These data could potentially shed light on molecular regulation of CD133 by glycosylation and enhance our understanding of the utility of glycosylated CD133 as a target for cancer therapies. 27490136 4 27 part_of contains 860:867 arg1 The M protein AND an additional site The M protein an additional site OGER Site M protein P54296 site The M protein contains an additional site in its preS2 domain, which is always functional. 23714211 3 17 gly glycosylation 586:598 arg2 six N-linked glycosylation sites six N-linked glycosylation sites sites Intercellular adhesion molecule-2 (ICAM-2), a member of the immunoglobulin superfamily of CAMs, has six N-linked glycosylation sites at amino acids (asparagines) 47, 82, 105, 153, 178 and 187. 26911932 6 22 gly N-glycosylation 1148:1162 arg2 the human FSHβ(Asn7Δ 24Δ) double N-glycosylation site mutant subunit the human FSHβ(Asn7Δ 24Δ) double N-glycosylation site mutant subunit site We demonstrate that the human FSHβ(Asn7Δ 24Δ) double N-glycosylation site mutant subunit, unlike human FSHβ WT subunit, inefficiently combines with the mouse α-subunit in pituitaries of Fshb null mice. 16343462 4 42 gly contained 625:633 arg1 different sites AND two N-acetyl-D-glucosamine (GlcNAc) residues different sites two N-acetyl-D-glucosamine (GlcNAc) residues sites Complex-type oligosaccharides were introduced to the calcitonin derivatives that contained two N-acetyl-D-glucosamine (GlcNAc) residues at different sites by treatment with Mucor hiemalis endo-beta-N-acetylglucosaminidase. 9029108 8 65 gly glycosylation 930:942 arg2 the glycosylation site the glycosylation site site Also, we found that the glycosylation site at asparagine 563 of mu tp was important for J chain incorporation. 9029108 8 65 gly glycosylation 930:942 arg2 asparagine 563 asparagine 563 asparagine 563 Also, we found that the glycosylation site at asparagine 563 of mu tp was important for J chain incorporation. 1686881 6 1 gly glycosylation 702:714 arg2 a potential glycosylation site a potential glycosylation site site The deduced amino acid sequence contains a potential glycosylation site and two putative protease cleavage sites. 7768336 1 32 gly glycosylated 312:323 arg1 residues residues residues The asparagine residues of the three N-glycosylation consensus sequences in the mouse gonadotropin-releasing hormone receptor were mutated to determine which residues were glycosylated and the function of glycosylation. 8307000 12 24 part_of GS-tPA 2480:2485 arg1 Asn117 tPA Asn117 OGER AminoAcid tPA P00750 Asn117 The relative amounts of complex-type glycans at Asn117 of GS-tPA correlated with the degree of carbohydrate substitution of Asn58. 8382971 3 20 part_of Asn-448 550:556 arg1 diglycosylated tPA-6-variant tPA Asn-448 OGER SpecificSite tPA P00750 Asn-448 tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2. 28860626 3 52 part_of hemagglutinin 844:856 arg1 9 N-glycosylation sites hemagglutinin 9 N-glycosylation sites Fterm Site hemagglutinin sites Proteomic data analyses of the full-length protein sequences determined 9 N-glycosylation sites of hemagglutinin, and defined 6 N-glycosylation sites and the glycan structures of low abundance neuraminidase, which were occupied by high-mannose, hybrid and complex-type N-glycans. 28860626 3 60 part_of neuraminidase 938:950 arg1 6 N-glycosylation sites neuraminidase 6 N-glycosylation sites Fterm Site neuraminidase sites Proteomic data analyses of the full-length protein sequences determined 9 N-glycosylation sites of hemagglutinin, and defined 6 N-glycosylation sites and the glycan structures of low abundance neuraminidase, which were occupied by high-mannose, hybrid and complex-type N-glycans. 25504159 4 42 gly glycosylation 663:675 arg2 this glycosylation site this glycosylation site site Clade 1 viruses that caused outbreaks in Southeast Asia in 2004 contained this glycosylation site, while the site is absent in the more recent clade 2 viruses. 31034685 10 65 gly glycopeptides 1614:1626 arg2 isomeric glycopeptides isomeric glycopeptides glycopeptides PGC/MS/MS also enabled comprehensive characterization of protein sialoglycosylation as isomeric glycopeptides with different combinations of α2-3- and α2-6-linked sialic acids can be separated and the ratios of each combination were verified by exoglycosidase digestion. 10861210 12 23 gly attached 1581:1588 arg1 the endogenous site AND the oligosaccharide the endogenous site the oligosaccharide site The results show that the oligosaccharide attached to the endogenous site in extracellular loop 4 in human AE1 is not processed in HEK-293 or COS-7 cells, while the oligosaccharide attached to the preceding loop is converted into the complex form. 26993603 3 12 gly N-glycosylation 565:579 arg2 three GP73 N-glycosylation sites three GP73 N-glycosylation sites sites We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26993603 3 51 gly sites 581:585 arg1 three GP73 N-glycosylation sites three GP73 N-glycosylation sites sites We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26993603 3 12 gly N-glycosylation 565:579 arg2 Asn109 Asn109, Asn144 and Asn398 Asn109, Asn144 and Asn398 We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26993603 3 12 gly N-glycosylation 565:579 arg2 Asn398 Asn109, Asn144 and Asn398 Asn109, Asn144 and Asn398 We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26993603 3 12 gly N-glycosylation 565:579 arg2 Asn398 Asn109, Asn144 and Asn398 Asn109, Asn144 and Asn398 We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26993603 3 51 gly sites 581:585 arg1 Asn144 Asn109, Asn144 and Asn398 Asn109, Asn144 and Asn398 We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26993603 3 51 gly sites 581:585 arg1 Asn109 Asn109, Asn144 and Asn398 Asn109, Asn144 and Asn398 We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26993603 3 51 gly sites 581:585 arg1 Asn109 Asn109, Asn144 and Asn398 Asn109, Asn144 and Asn398 We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 12175779 6 56 gly glycosylation 796:808 arg2 The putative glycosylation site GLUT11 site PUBTATOR GLUT11 66035 site The putative glycosylation site of GLUT11 is present in loop 1. 10620492 0 26 part_of phosphatase-1 68:80 arg1 structurally important domains lipid phosphate phosphatase-1 structurally important domains PUBTATOR Site lipid phosphate phosphatase-1 19012 domains Identification of structurally important domains of lipid phosphate phosphatase-1: implications for its sites of action. 21661761 4 33 gly glycopeptides 793:805 arg2 glycopeptides glycopeptides glycopeptides However, because of the size of glycopeptides, they are not often amenable to tandem MS. In this work, proteins are digested with multiple proteases to produce glycopeptides that are of suitable size for tandem MS analysis. 21661761 4 47 gly glycopeptides 665:677 arg2 glycopeptides glycopeptides glycopeptides However, because of the size of glycopeptides, they are not often amenable to tandem MS. In this work, proteins are digested with multiple proteases to produce glycopeptides that are of suitable size for tandem MS analysis. 14691230 12 50 gly glycosylation 1806:1818 arg1 DPPIV DPPIV PUBTATOR DPPIV 1803 Taken together, these data indicate that in contrast to the generally accepted view, glycosylation of DPPIV is not a prerequisite for catalysis, dimerization, or ADA binding. 29909010 3 38 gly N-glycosylation 448:462 arg2 an N-glycosylation site an N-glycosylation site site To examine the effect of glycosylation on the properties of the Fab of a therapeutic antibody, an N-glycosylation site was introduced at position 178 of the H-chain constant region of adalimumab Fab through site-directed mutagenesis of L178 N (H:L178 N Fab), and then H:L178 N Fab was expressed in Pichia pastoris. 27177499 10 83 gly hyperglycosylated 1500:1516 arg1 hCG hCG OGER hCG The invasive extravillous trophoblast (iEVT) also secretes hCG, and in particular hyperglycosylated forms of hCG (hCG-H) also produced by choriocarcinoma cells. 26022737 7 17 part_of PSA 923:925 arg1 PSA N102 glycosylation site PSA PSA N102 glycosylation site PUBTATOR Site PSA P07288 site Here we report the first qualitative and quantitative glycoproteomic study of PSA N102 glycosylation site by LC-MS/MS. 23908491 9 50 gly glycosylation 1123:1135 arg2 glycosylation sites glycosylation sites sites Indeed, changes in glycosylation sites were observed with the appearance of a new glycosylation site within HVR495. 23908491 9 68 gly glycosylation 1186:1198 arg2 a new glycosylation site a new glycosylation site site Indeed, changes in glycosylation sites were observed with the appearance of a new glycosylation site within HVR495. 9409770 8 52 part_of have 1182:1185 arg1 rainbow trout cathepsin D AND only one putative N-glycosylation site rainbow trout cathepsin D only one putative N-glycosylation site PUBTATOR Site cathepsin D P07339 site Unlike cathepsin Ds in other species, however, rainbow trout cathepsin D appears to have only one putative N-glycosylation site, rather than two. 2110456 2 10 gly occupied 259:266 arg2 five putative N-glycosylation sites five putative N-glycosylation sites sites This lysosomal enzyme has five putative N-glycosylation sites, four of which are occupied. 2110456 2 39 gly N-glycosylation 218:232 arg2 five putative N-glycosylation sites five putative N-glycosylation sites sites This lysosomal enzyme has five putative N-glycosylation sites, four of which are occupied. 29109276 6 32 part_of possesses 1029:1037 arg1 the current circulating H3N2 viral strain AND the glycosylation site the current circulating H3N2 viral strain the glycosylation site Fterm Site strain site Importantly, antibodies elicited in ferrets infected with the current circulating H3N2 viral strain (that possesses the glycosylation site) and humans vaccinated with baculovirus-expressed H3 antigens (that possess the glycosylation site motif) were able to efficiently recognize a glycosylated clade 3C.2a H3N2 virus. 11485624 0 28 gly glycoprotein 103:114 arg1 glycoprotein 120 glycoprotein 120 Fterm glycoprotein Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region. 11485624 0 100 gly oligosaccharides 132:147 arg1 the V1 region the V1 region the V1 region Site region Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region. 1899031 1 2 gly linked 165:170 arg1 Asn289 AND The oligosaccharide structures Asn289 The oligosaccharide structures Asn289 The oligosaccharide structures linked to Asn289 of a recombinant (r) variant (R561S) human plasminogen (HPg) expressed in Chinese hamster ovary (CHO) cells, after transfection of these cells with a plasmid containing the cDNA coding for the variant HPg, have been determined. 8185569 5 23 gly glycosylation 808:820 arg1 the TSHR the TSHR PUBTATOR TSHR 7253 These results might suggest a real difference in glycosylation of the TSHR among species. 29759137 6 3 gly IgG4 596:599 arg1 sialylation IgG4 sialylation OGER IgG4 P01861 Galactosylation and sialylation of IgG4 also differed significantly. 29759137 6 10 gly sialylation 581:591 arg1 IgG4 IgG4 OGER IgG4 P01861 Galactosylation and sialylation of IgG4 also differed significantly. 8099782 8 52 gly glycosylation 1439:1451 arg2 its glycosylation site its glycosylation site site A human mutation in saposin B-deficient metachromatic leukodystrophy, in which its glycosylation site is eliminated, has been reported. 27884519 4 64 gly O-glycosylation 457:471 arg2 N- or O-glycosylation site N- or O-glycosylation site site Modified vectors were constructed by introducing N- or O-glycosylation site on the region of hIL-11 that does not belong to the core α-helical motif based on the predicted secondary structure. 15253437 1 5 gly glycoproteins 189:201 arg1 glycoproteins glycoproteins Fterm glycoproteins Characterization of glycoproteins using mass spectrometry ranges from determination of carbohydrate-protein linkages to the full characterization of all glycan structures attached to each glycosylation site. 15253437 1 17 gly attached 340:347 arg2 each glycosylation site AND all glycan structures each glycosylation site all glycan structures site Characterization of glycoproteins using mass spectrometry ranges from determination of carbohydrate-protein linkages to the full characterization of all glycan structures attached to each glycosylation site. 15253437 1 62 gly glycosylation 357:369 arg2 each glycosylation site each glycosylation site site Characterization of glycoproteins using mass spectrometry ranges from determination of carbohydrate-protein linkages to the full characterization of all glycan structures attached to each glycosylation site. 1367433 7 47 gly glycosylation 1340:1352 arg2 the glycosylation site the glycosylation site site The exception was a molecule that retains the original domain arrangement up to and through the glycosylation site at asn 117. 1367433 7 47 gly glycosylation 1340:1352 arg2 asn 117 asn 117 asn 117 The exception was a molecule that retains the original domain arrangement up to and through the glycosylation site at asn 117. 8892291 3 55 part_of p23 481:483 arg1 p23 coding sequences p23 p23 coding sequences PUBTATOR Site p23 56351 sequences cDNA insert sequences from positive plaques were determined and used to isolate additional clones encoding p23 coding sequences. 28336547 0 24 gly Glycans 0:6 arg1 the intestinal peptide transporter PEPT1 PEPT1 Glycans PUBTATOR PEPT1 56643 Glycans in the intestinal peptide transporter PEPT1 contribute to function and protect from proteolysis. 27641734 11 150 gly deglycosylated 1950:1963 arg1 WT and deglycosylated CD97ECD WT and deglycosylated CD97ECD PUBTATOR CD97 976 SAXS data for WT and deglycosylated CD97ECD revealed a spatula-like shape with GAIN and EGF domains constituting the body and handle, respectively. 18829751 9 48 gly glycosylation 1588:1600 arg2 the glycosylation site mutations the glycosylation site mutations site By analyzing the neutralization profiles of sequence variants, we were able to define three mutations (Q625R, K631N, and Q634H) in the region of the glycosylation site mutations that conferred resistance to neutralization by plasma from the monkeys infected with mutant virus. 30605224 9 58 gly glycopeptide 1339:1350 arg2 Intact glycopeptide analysis Intact glycopeptide analysis glycopeptide Intact glycopeptide analysis is also included in this section. 27490136 2 0 gly proteins 604:611 arg1 the N-linked glycans proteins the N-linked glycans Fterm proteins Owing to their α-1,2 mannosidase activity, the EDEM1-3 proteins are able to process the N-linked glycans of misfolded or incompletely folded proteins, providing the recognition signal for their subsequent degradation. 28947017 9 49 gly N-glycosylation 1120:1134 arg2 the N-glycosylation site the N-glycosylation site site This mutation abolishes the N-glycosylation site in position 83 of the mature AAT. 7620335 5 77 gly glycosylation 943:955 arg2 each glycosylation site each glycosylation site site Structures of oligosaccharides and their contents at each glycosylation site were determined by a two-dimensional sugar mapping method. 2841801 8 29 gly glycosylation 1088:1100 arg1 the F2 subunit subunit site Fterm subunit site Nucleotide sequence analyses revealed that ts-f1 and F1-R differed from the wild-type virus by mutations at the region of the cleavage site of F and at the glycosylation site of the F2 subunit. 2835268 3 9 gly glycosylation 486:498 arg2 one potential glycosylation site one potential glycosylation site site The sequence indicates the presence of one potential glycosylation site. 19065542 1 36 gly glycopeptide 170:181 arg2 a glycopeptide a glycopeptide glycopeptide Structural characterization of a glycopeptide is not easily attained through collision-induced dissociation (CID), due to the extensive fragmentation of glycan moieties and minimal fragmentation of peptide backbones. 9455905 2 28 part_of factor 562:567 arg1 a known glycosylation site von Willebrand factor a known glycosylation site PUBTATOR Site von Willebrand factor 7450 site Previously, we demonstrated that the in vivo O-glycosylation of a sequence derived from a known glycosylation site of human von Willebrand factor (PHMAQVTVGPGL) was markedly reduced when charged residues were substituted at position -1 and +3 relative to the single threonine. 8437218 4 87 part_of env 1029:1031 arg1 the N-terminal domain SFFVAP-L env the N-terminal domain PUBTATOR Site SFFVAP-L env 30816 domain Mutants carrying Asn-->Asp mutations at each of the two consensus signals for N-linked glycosylation in the N-terminal domain of SFFVAP-L env (gs1 and gs2), the gs1-2- double mutant, and the gs0 quadruple mutant (mutated at all four signals utilized for N-linked glycosylation in SFFVAP-L env) were made. 8107215 5 21 gly glycosylation 830:842 arg1 Asn-61 Asn-61 Asn-61 Cell surface expression of mutant proteins was reduced by 50% relative to the wild-type level when glycosylation at either Asn-29 or Asn-61 was abolished. 8107215 5 21 gly glycosylation 830:842 arg1 Asn-29 Asn-29 Asn-29 Cell surface expression of mutant proteins was reduced by 50% relative to the wild-type level when glycosylation at either Asn-29 or Asn-61 was abolished. 28166830 2 44 gly glycosylation 621:633 arg2 a glycosylation site a glycosylation site site The results show that the T160A substitution resulted in the loss of a glycosylation site at 158N and led not only to enhanced binding specificity for human-type receptors but also transmissibility among guinea pigs, which could be considered as an important molecular marker for assessing pandemic potential of H5 subtype avian influenza isolates. 20963501 8 25 part_of motifs 1347:1352 arg1 cysteine residues motifs cysteine residues cysteine residues Alignment of Izumo1 protein sequences among 15 mammalian species displayed several highly conserved regions, including LDC and YRC motifs with cysteine residues for potential disulfide bridge formation, CPNKCG motif upstream of the Ig-like domain, GLTDYSFYRVW motif upstream of the putative N-linked glycosylation site, and a number of scattered cysteine residues. 20963501 8 33 part_of Izumo1 1229:1234 arg1 Izumo1 protein sequences Izumo1 Izumo1 protein sequences PUBTATOR Site Izumo1 Q8IYV9 sequences Alignment of Izumo1 protein sequences among 15 mammalian species displayed several highly conserved regions, including LDC and YRC motifs with cysteine residues for potential disulfide bridge formation, CPNKCG motif upstream of the Ig-like domain, GLTDYSFYRVW motif upstream of the putative N-linked glycosylation site, and a number of scattered cysteine residues. 20963501 8 56 part_of LDC 1335:1337 arg1 LDC and YRC motifs LDC LDC and YRC motifs OGER Site LDC P51884 motifs Alignment of Izumo1 protein sequences among 15 mammalian species displayed several highly conserved regions, including LDC and YRC motifs with cysteine residues for potential disulfide bridge formation, CPNKCG motif upstream of the Ig-like domain, GLTDYSFYRVW motif upstream of the putative N-linked glycosylation site, and a number of scattered cysteine residues. 20963501 8 101 part_of motif 1476:1480 arg1 cysteine residues motif cysteine residues cysteine residues Alignment of Izumo1 protein sequences among 15 mammalian species displayed several highly conserved regions, including LDC and YRC motifs with cysteine residues for potential disulfide bridge formation, CPNKCG motif upstream of the Ig-like domain, GLTDYSFYRVW motif upstream of the putative N-linked glycosylation site, and a number of scattered cysteine residues. 20963501 8 110 part_of motif 1426:1430 arg1 cysteine residues motif cysteine residues cysteine residues Alignment of Izumo1 protein sequences among 15 mammalian species displayed several highly conserved regions, including LDC and YRC motifs with cysteine residues for potential disulfide bridge formation, CPNKCG motif upstream of the Ig-like domain, GLTDYSFYRVW motif upstream of the putative N-linked glycosylation site, and a number of scattered cysteine residues. 19919546 3 10 gly glycoproteins 579:591 arg1 the relevant glycoproteins the relevant glycoproteins Fterm glycoproteins However, as cancer tissue at the early stage probably constitutes less than 1% of the normal tissue in the relevant organ, only 1% of the relevant glycoproteins in the serum should have altered glycan structures. 19919546 3 24 gly have 613:616 arg1 the relevant glycoproteins AND altered glycan structures the relevant glycoproteins altered glycan structures Fterm glycoproteins However, as cancer tissue at the early stage probably constitutes less than 1% of the normal tissue in the relevant organ, only 1% of the relevant glycoproteins in the serum should have altered glycan structures. 1601309 5 45 part_of contains 1049:1056 arg1 The aa sequence AND one possible Asn-linked glycosylation site The aa sequence one possible Asn-linked glycosylation site site The aa sequence contains one possible Asn-linked glycosylation site. 22649382 6 45 gly N-glycosylation 959:973 arg2 three N-glycosylation sites three N-glycosylation sites sites TpoR mutants lacking three N-glycosylation sites were defective in maturation, but N-glycosylation on the single remaining site could be detected by sensitivity to PNGaseF. 22649382 6 34 gly N-glycosylation 1015:1029 arg1 the single remaining site site site TpoR mutants lacking three N-glycosylation sites were defective in maturation, but N-glycosylation on the single remaining site could be detected by sensitivity to PNGaseF. 32302771 7 27 gly O-glycosylation 1195:1209 arg2 a Sulfotransfer_2 domain a Sulfotransfer_2 domain domain The chst11 contains a Sulfotransfer_2 domain, one N-glycosylation site and three O-glycosylation sites. 32302771 7 27 gly O-glycosylation 1195:1209 arg2 three O-glycosylation sites three O-glycosylation sites sites The chst11 contains a Sulfotransfer_2 domain, one N-glycosylation site and three O-glycosylation sites. 32302771 7 51 gly N-glycosylation 1164:1178 arg2 one N-glycosylation site one N-glycosylation site site The chst11 contains a Sulfotransfer_2 domain, one N-glycosylation site and three O-glycosylation sites. 32302771 7 51 gly N-glycosylation 1164:1178 arg2 a Sulfotransfer_2 domain a Sulfotransfer_2 domain domain The chst11 contains a Sulfotransfer_2 domain, one N-glycosylation site and three O-glycosylation sites. 26022737 8 82 gly glycosylation 1048:1060 arg2 N102 glycosylation site N102 glycosylation site site We successfully applied tandem MS to verify the amino acid sequence possessing N102 glycosylation site and associated glycoforms of PSA samples acquired from different suppliers. 25636227 10 26 gly O-glycosylated 1572:1585 arg1 core 4 O-glycosylated proteins core 4 O-glycosylated proteins The approach described herein is simple, sensitive, and global for site analysis of core 1 through core 4 O-glycosylated proteins. 18956678 14 11 gly glycosylation 1909:1921 arg2 glycosylation site glycosylation site site Four amino acid substitution resulted in the deletion of glycosylation site. 8870657 0 80 gly sites 48:52 arg1 Asn138 sites Asn624 and Asn138 sites Asn624 and Asn138 Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants. 8870657 0 80 gly sites 48:52 arg1 Asn624 sites Asn624 and Asn138 sites Asn624 and Asn138 Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants. 8870657 0 80 gly sites 48:52 arg1 Asn624 sites Asn624 and Asn138 sites Asn624 and Asn138 Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants. 8870657 0 84 gly N-glycosylation 32:46 arg2 N-glycosylation sites Asn624 and Asn138 sites Asn624 and Asn138 sites Asn624 and Asn138 Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants. 8870657 0 84 gly N-glycosylation 32:46 arg2 Asn624 sites Asn624 and Asn138 sites Asn624 and Asn138 Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants. 8870657 0 84 gly N-glycosylation 32:46 arg2 Asn624 sites Asn624 and Asn138 sites Asn624 and Asn138 Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants. 20172850 10 6 part_of nephrin 1275:1281 arg1 a glycosylation site nephrin a glycosylation site PUBTATOR Site nephrin 4868 site In an additional patient with later manifestation, we discovered two further novel mutations, including the first one affecting a glycosylation site of nephrin. 29069609 8 23 gly N-glycosylation 1392:1406 arg2 59 N-glycosylation sites 59 N-glycosylation sites sites This workflow was demonstrated by detection of 59 N-glycosylation sites from 41 glycoproteins from a HILIC enriched human plasma tryptic digest. 29069609 8 27 gly glycoproteins 1422:1434 arg1 41 glycoproteins 41 glycoproteins Fterm glycoproteins This workflow was demonstrated by detection of 59 N-glycosylation sites from 41 glycoproteins from a HILIC enriched human plasma tryptic digest. 19706343 0 50 gly beta-2-glycoprotein 26:44 arg1 beta-2-glycoprotein I beta-2-glycoprotein I OGER beta-2-glycoprotein I P02749 Glycopeptide profiling of beta-2-glycoprotein I by mass spectrometry reveals attenuated sialylation in patients with antiphospholipid syndrome. 29932112 6 13 part_of Panx2 886:890 arg1 the only N-glycosylation site Panx2 the only N-glycosylation site PUBTATOR Site Panx2 56666 site Our results showed that N86 is the only N-glycosylation site of Panx2. 29932112 6 13 part_of Panx2 886:890 arg1 N86 Panx2 N86 PUBTATOR SpecificSite Panx2 56666 N86 Our results showed that N86 is the only N-glycosylation site of Panx2. 10073697 6 71 gly N-glycosylation 1279:1293 arg2 an additional N-glycosylation site an additional N-glycosylation site site Genetic comparison showed sequence differences in all three genome segments of the two DOB isolates, including an additional N-glycosylation site in the deduced sequence of the G2 protein from the Estonian virus. 30158294 5 61 gly modified 626:633 arg1 virion-associated SERINC5 AND N-linked, complex glycans virion-associated SERINC5 N-linked, complex glycans PUBTATOR SERINC5 256987 We used various glycosidases to establish that virion-associated SERINC5 is modified by N-linked, complex glycans, whereas the majority of SERINC5 in cells is of relatively low molecular weight and is modified by high-mannose glycans. 22573926 1 5 gly glycoprotein 176:187 arg1 two glycoprotein hormones two glycoprotein hormones Fterm glycoprotein Stanniocalcin 1 and stanniocalcin 2 are two glycoprotein hormones, which act as calcium phosphate-regulating factor on intestine and kidney. 1379039 4 71 gly N-glycosylation 854:868 arg2 a potential N-glycosylation site a potential N-glycosylation site site The unusual presence of Asn-70 determined a potential N-glycosylation site. 17727280 0 26 gly N-glycopeptide 10:23 arg2 Automated N-glycopeptide identification Automated N-glycopeptide identification N-glycopeptide Automated N-glycopeptide identification using a combination of single- and tandem-MS. 18642129 1 6 gly glycoprotein 141:152 arg1 Factor VII Factor VII OGER Factor VII P08709 Factor VII (FVII) is a vitamin K-dependent glycoprotein which, in its activated form (FVIIa), participates in the coagulation process by activating factor X and factor IX. 18642129 1 6 gly glycoprotein 141:152 arg1 a vitamin K-dependent glycoprotein a vitamin K-dependent glycoprotein Fterm glycoprotein Factor VII (FVII) is a vitamin K-dependent glycoprotein which, in its activated form (FVIIa), participates in the coagulation process by activating factor X and factor IX. 22577028 0 101 gly glycosylation 36:48 arg1 an influenza hemagglutinin an influenza hemagglutinin Fterm hemagglutinin Comparative characterization of the glycosylation profiles of an influenza hemagglutinin produced in plant and insect hosts. 25220145 5 7 part_of CF-glycoproteins 1106:1121 arg1 357 unique CF-glycosylation sites CF-glycoproteins 357 unique CF-glycosylation sites Fterm Site CF-glycoproteins sites To demonstrate the feasibility of LHNCE, the CF-glycopeptides of target proteins in clinical plasma samples were applied and compared as a preliminary demonstration and resulted in the assignment of 357 unique CF-glycosylation sites from 209 CF-glycoproteins. 25220145 5 53 part_of proteins 936:943 arg1 the CF-glycopeptides proteins the CF-glycopeptides Fterm Site proteins CF-glycopeptides To demonstrate the feasibility of LHNCE, the CF-glycopeptides of target proteins in clinical plasma samples were applied and compared as a preliminary demonstration and resulted in the assignment of 357 unique CF-glycosylation sites from 209 CF-glycoproteins. 8780172 5 66 gly nonglycosylated 809:823 arg1 nonglycosylated VEGF/VPF nonglycosylated VEGF/VPF PUBTATOR VEGF 281572 Specifically unaddressed to date is the concern that nonglycosylated VEGF/VPF may be less stable, and therefore characterized by a shorter half-life, reducing its utility for therapeutic angiogenesis. 31572358 10 42 gly used 1770:1773 arg2 IgG sequences IgG sequences sequences IgG sequences of 12 healthy donors were used as control. 1660522 6 52 part_of CR2 1308:1310 arg1 the corresponding serine CR2 the corresponding serine OGER AminoAcid CR2 P19070 serine The results indicate that preferential binding of EBV to human CR2 is not due to unique amino acids that are capable of binding the virus, but reflects a distinct receptor conformation that can be achieved in murine CR2 with single amino acid substitutions in two discontinuous regions of the primary structure: replacement of proline at position 15 with the corresponding serine from human CR2, and elimination of a potential N-linked glycosylation site between SCR-1 and SCR-2. 15931076 0 10 gly N-glycosylation 87:101 arg2 the N-glycosylation site N604 site N604 site N604 Characterization of rat transient receptor potential vanilloid 1 receptors lacking the N-glycosylation site N604. 15863355 10 45 gly glycosylation 1949:1961 arg2 each glycosylation site each glycosylation site site CONCLUSION: Little variation in the N-glycan composition of the glycosylation sites of AGP was observed among healthy individuals, while the sera of patients with acute inflammation demonstrated increased numbers of bi-antennary and alpha1,3-fucosylated N-glycan structures at each glycosylation site. 15863355 10 50 gly glycosylation 1731:1743 arg2 the glycosylation sites the glycosylation sites sites CONCLUSION: Little variation in the N-glycan composition of the glycosylation sites of AGP was observed among healthy individuals, while the sera of patients with acute inflammation demonstrated increased numbers of bi-antennary and alpha1,3-fucosylated N-glycan structures at each glycosylation site. 15863355 10 65 gly alpha1,3-fucosylated 1900:1919 arg1 bi-antennary and alpha1,3-fucosylated N-glycan structures bi-antennary and alpha1,3-fucosylated N-glycan structures CONCLUSION: Little variation in the N-glycan composition of the glycosylation sites of AGP was observed among healthy individuals, while the sera of patients with acute inflammation demonstrated increased numbers of bi-antennary and alpha1,3-fucosylated N-glycan structures at each glycosylation site. 15863355 10 68 gly sites 1745:1749 arg1 the N-glycan composition sites the N-glycan composition sites CONCLUSION: Little variation in the N-glycan composition of the glycosylation sites of AGP was observed among healthy individuals, while the sera of patients with acute inflammation demonstrated increased numbers of bi-antennary and alpha1,3-fucosylated N-glycan structures at each glycosylation site. 16873272 8 9 gly N-glycosylation 1729:1743 arg2 position 391 position 391 position 391 Taken together, these results suggest that a bipartite sequence motif spanning aa 225 to 396 and aa 484 to 555 is essential for formation of the PFV Env RBD, with N-glycosylation site at position 391 playing a crucial role for host cell binding. 16873272 8 9 gly N-glycosylation 1729:1743 arg2 N-glycosylation site N-glycosylation site site Taken together, these results suggest that a bipartite sequence motif spanning aa 225 to 396 and aa 484 to 555 is essential for formation of the PFV Env RBD, with N-glycosylation site at position 391 playing a crucial role for host cell binding. 1601309 4 30 gly unglycosylated 946:959 arg1 unglycosylated bIL4 unglycosylated bIL4 Cterm bIL4 280824 The bIL4 cDNA is 570 bp in length and contains an open reading frame of 405 nucleotides (nt), coding for a 15.1-kDa precursor of 135 amino acids (aa), which should be reduced to 12.6 kDa for unglycosylated bIL4 after cleavage of a putative hydrophobic leader sequence of 24 aa. 8771709 1 31 gly N-glycosylation 272:286 arg2 an N-glycosylation site an N-glycosylation site site Human single-chain urokinase-type plasminogen activator without an N-glycosylation site (scu-PA-Q302) was produced in the methylotrophic yeast, Pichia pastoris using the shortened prepeptide sequence of a fungal aspartic proteinase, Mucor pusillus rennin (MPR). 18076768 4 16 gly glycosylation 968:980 arg2 Asn 362 Asn 362 Asn 362 Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs. 18076768 4 16 gly glycosylation 968:980 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs. 9210490 3 12 gly N-glycosylation 402:416 arg1 DPPIV DPPIV PUBTATOR DPPIV 25253 To investigate the role of N-glycosylation in the function of DPPIV, three of its asparagine residues were separately converted to glutamine by site-directed mutagenesis. 1377975 2 6 gly N-glycosylation 577:591 arg2 the amino acid position 79 the amino acid position 79 position 79, The amino acid sequence, deduced from the nucleotide sequence by comparing it with the sequences of other mammalian IFNs, consists of 171 amino acids with 6 cysteins and an N-glycosylation site at the amino acid position 79, and has about 60% homology to human IFN alpha 1. 1377975 2 6 gly N-glycosylation 577:591 arg2 an N-glycosylation site an N-glycosylation site site The amino acid sequence, deduced from the nucleotide sequence by comparing it with the sequences of other mammalian IFNs, consists of 171 amino acids with 6 cysteins and an N-glycosylation site at the amino acid position 79, and has about 60% homology to human IFN alpha 1. 1421757 1 0 gly glycosylation 177:189 arg2 three N-linked and one O-linked glycosylation sites three N-linked and one O-linked glycosylation sites sites The human transferrin receptor is a glycoprotein containing three N-linked and one O-linked glycosylation sites. 1421757 1 30 gly glycoprotein 121:132 arg1 a glycoprotein a glycoprotein Fterm glycoprotein The human transferrin receptor is a glycoprotein containing three N-linked and one O-linked glycosylation sites. 1421757 1 30 gly glycoprotein 121:132 arg1 The human transferrin receptor The human transferrin receptor PUBTATOR transferrin receptor 7018 The human transferrin receptor is a glycoprotein containing three N-linked and one O-linked glycosylation sites. 7914890 1 56 gly glycosylation 58:70 arg1 the lysosomal enzyme arylsulfatase A the lysosomal enzyme arylsulfatase A PUBTATOR arylsulfatase A 410 The glycosylation and phosphorylation of the lysosomal enzyme arylsulfatase A was analyzed by a combination of metabolic labeling, tryptic fragmentation, mass spectrometry, and radiosequencing. 410438 5 3 gly glycosylation 952:964 arg2 CH2 domain CH2 domain domain Gel analysis of specifically immunoprecipitated nascent chains indicates that the carbohydrate moiety can be added to the nascent heavy chains very soon after the presumptive asparaginyl glycosylation site (CH2 domain) is synthesized on the ribosome. 410438 5 3 gly glycosylation 952:964 arg2 the presumptive asparaginyl glycosylation site the presumptive asparaginyl glycosylation site site Gel analysis of specifically immunoprecipitated nascent chains indicates that the carbohydrate moiety can be added to the nascent heavy chains very soon after the presumptive asparaginyl glycosylation site (CH2 domain) is synthesized on the ribosome. 15694591 4 16 part_of chitin 629:634 arg1 the serine/threonine and chitin binding domains chitin the serine/threonine and chitin binding domains Fterm Site chitin domains The deduced amino acid sequence of AvChit1 cDNA showed 43% identity to both Glossina morsitans morsitans chitinase and a human chitotriosidase, and 30-40% to some insect chitinases which lack both the serine/threonine and chitin binding domains. 8034709 11 76 gly unglycosylated 1365:1378 arg1 unglycosylated active SCCE unglycosylated active SCCE PUBTATOR SCCE 5650 The calculated molecular mass of unglycosylated active SCCE was 24.4 kDa. 12901863 6 18 gly glycosylation 1049:1061 arg1 the normal and pathological variants the normal and pathological variants Fterm variants The polarized mammalian expression system characterized here provides a useful tool for further examination of routing, glycosylation, and function of the normal and pathological variants of human ABCC6. 31498587 5 57 part_of MUC1-Tf 659:665 arg1 MUC1-Tf and -STn glycopeptides MUC1 MUC1-Tf and -STn glycopeptides PUBTATOR Site MUC1 4582 glycopeptides The conjugates of MUC1-Tf and -STn glycopeptides with Qβ were utilized to immunize immune-tolerant human MUC1 transgenic (MUC1.Tg) mice, which elicited superior levels of anti-MUC1 IgG antibodies with titers reaching over 2 million units. 31498587 5 59 part_of -STn 671:674 arg1 MUC1-Tf and -STn glycopeptides STn MUC1-Tf and -STn glycopeptides OGER Site STn P62631 glycopeptides The conjugates of MUC1-Tf and -STn glycopeptides with Qβ were utilized to immunize immune-tolerant human MUC1 transgenic (MUC1.Tg) mice, which elicited superior levels of anti-MUC1 IgG antibodies with titers reaching over 2 million units. 15750791 3 4 gly glycosylated 422:433 arg1 Edg-1/S1P1 Edg-1/S1P1 PUBTATOR S1P1 1901 Our recent novel studies established that Edg-1/S1P1 is glycosylated in its N-terminal extracellular portion and further identified the specific glycosylation site as asparagine 30. 15750791 3 18 gly glycosylation 511:523 arg2 the specific glycosylation site the specific glycosylation site site Our recent novel studies established that Edg-1/S1P1 is glycosylated in its N-terminal extracellular portion and further identified the specific glycosylation site as asparagine 30. 1414488 4 22 part_of had 644:646 arg1 osteopontin-k AND a potential glycosylation site osteopontin site PUBTATOR Site osteopontin 6696 site The peptide (osteopontin-k) had a potential glycosylation site (Asn-X-Ser/Thr), a GRGDS receptor binding region, a high level of asparagine residues, and a high abundance of acid amino acids characteristic of osteopontin-like cell adhesion molecules. 1414488 4 22 part_of had 644:646 arg1 osteopontin-k AND a GRGDS receptor binding region osteopontin region PUBTATOR Site osteopontin 6696 region The peptide (osteopontin-k) had a potential glycosylation site (Asn-X-Ser/Thr), a GRGDS receptor binding region, a high level of asparagine residues, and a high abundance of acid amino acids characteristic of osteopontin-like cell adhesion molecules. 1414488 4 22 part_of had 644:646 arg1 osteopontin-k AND asparagine residues osteopontin asparagine residues PUBTATOR AminoAcid osteopontin 6696 asparagine residues The peptide (osteopontin-k) had a potential glycosylation site (Asn-X-Ser/Thr), a GRGDS receptor binding region, a high level of asparagine residues, and a high abundance of acid amino acids characteristic of osteopontin-like cell adhesion molecules. 19800422 0 0 part_of matriptase 76:85 arg1 the catalytic domain matriptase the catalytic domain PUBTATOR Site matriptase Q9Y5Y6 domain The role of asparagine-linked glycosylation site on the catalytic domain of matriptase in its zymogen activation. 19800422 0 21 part_of site 44:47 arg1 matriptase matriptase site PUBTATOR Site matriptase Q9Y5Y6 site The role of asparagine-linked glycosylation site on the catalytic domain of matriptase in its zymogen activation. 24798328 4 48 gly O-glycosylation 474:488 arg2 O-glycosylation sites O-glycosylation sites sites Recently we identified O-glycosylation sites in the linker regions between the characteristic LDLR class A repeats in several LDLR-related receptors using the "SimpleCell" O-glycoproteome shotgun strategy. 24798328 4 93 gly repeats 558:564 arg1 several LDLR-related receptors receptors repeats Fterm receptors Recently we identified O-glycosylation sites in the linker regions between the characteristic LDLR class A repeats in several LDLR-related receptors using the "SimpleCell" O-glycoproteome shotgun strategy. 21704619 0 12 gly N-glycosylation 73:87 arg2 an unnatural N-glycosylation site an unnatural N-glycosylation site site Construction and analysis of a novel peptide tag containing an unnatural N-glycosylation site. 21704619 0 29 gly peptide 37:43 arg1 a novel peptide tag a novel peptide tag Construction and analysis of a novel peptide tag containing an unnatural N-glycosylation site. 24554659 2 25 gly glycoprotein 555:566 arg1 Env Env PUBTATOR Env 1490007 Here, we identify a highly conserved N-linked glycosylation site (N173 in SIV, corresponding to N160 in HIV) in the V2 region of the SIV envelope glycoprotein (Env) as a novel determinant of macrophage tropism and characterize mechanisms underlying this phenotype. 24554659 2 25 gly glycoprotein 555:566 arg1 the SIV envelope glycoprotein the SIV envelope glycoprotein PUBTATOR SIV envelope glycoprotein 1490007 Here, we identify a highly conserved N-linked glycosylation site (N173 in SIV, corresponding to N160 in HIV) in the V2 region of the SIV envelope glycoprotein (Env) as a novel determinant of macrophage tropism and characterize mechanisms underlying this phenotype. 24554659 2 116 gly site 469:472 arg1 N173 N173 N173 Here, we identify a highly conserved N-linked glycosylation site (N173 in SIV, corresponding to N160 in HIV) in the V2 region of the SIV envelope glycoprotein (Env) as a novel determinant of macrophage tropism and characterize mechanisms underlying this phenotype. 24554659 2 132 gly glycosylation 455:467 arg2 a highly conserved N-linked glycosylation site a highly conserved N-linked glycosylation site site Here, we identify a highly conserved N-linked glycosylation site (N173 in SIV, corresponding to N160 in HIV) in the V2 region of the SIV envelope glycoprotein (Env) as a novel determinant of macrophage tropism and characterize mechanisms underlying this phenotype. 2341397 1 21 gly glycosylated 241:252 arg1 a highly glycosylated membrane protein a highly glycosylated membrane protein Fterm protein Nonspecific cross-reacting antigen (NCA) is a highly glycosylated membrane protein which is immunologically and structurally related to carcinoembryonic antigen, an important tumor-associated antigen. 10989127 15 26 gly N-glycosylation 2155:2169 arg2 actual N-glycosylation sites actual N-glycosylation sites sites Such conserved sites strongly suggest that they may represent actual N-glycosylation sites. 26598643 6 36 gly O-glycopeptide 1110:1123 arg2 Enriched O-glycopeptide fractions Enriched O-glycopeptide fractions O-glycopeptide Enriched O-glycopeptide fractions were subjected to mass spectrometric analysis using reversed-phase liquid chromatography coupled online to an ion trap mass spectrometer operated in positive-ion mode. 27342663 5 14 gly glycosylation 1222:1234 arg2 the single, conserved N-linked glycosylation site the single, conserved N-linked glycosylation site site The large majority of the glycoforms present on the single, conserved N-linked glycosylation site of the heavy chain is elucidated, although some of the very low abundance glycoforms are not determined by this protocol. 7613486 4 40 gly glycosylation 823:835 arg2 these independent glycosylation sites these independent glycosylation sites sites In the present study, the contribution of these independent glycosylation sites to dimerization and insulin binding has been evaluated. 1401897 6 24 gly glycosylation 736:748 arg2 the N-linked glycosylation site the N-linked glycosylation site site Generation of an expressible cDNA for the mouse C5a receptor was accomplished using the polymerase chain reaction and a sense oligodeoxynucleotide primer which included an initiation codon just 5' to the sequence encoding the N-linked glycosylation site. 8627227 7 36 gly glycosylation 1195:1207 arg2 a new, utilized glycosylation site a new, utilized glycosylation site site The monotype G4b N-MAb 3A3 selected an antigenic variant with an amino acid mutation at position 96, whereas variants of the G4a-reactive N-MAb ST-3:1 showed a mutation at position 94, which produced a new, utilized glycosylation site. 7642555 0 52 gly glycosylated 9:20 arg2 threonine 58 c-Myc threonine 58 PUBTATOR c-Myc 4609 threonine 58 c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. 7642555 0 52 gly glycosylated 9:20 arg2 a known phosphorylation site c-Myc site PUBTATOR c-Myc 4609 site c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. 10828967 4 14 part_of sites 684:688 arg1 the PTH/PTHrP receptor PTHrP receptor sites PUBTATOR Site PTHrP receptor 24695 sites The results revealed that all four potential N-glycosylation sites in the PTH/PTHrP receptor are glycosylated. 2571506 10 33 gly Glycosylation 1494:1506 arg1 CDR2 CDR2 PUBTATOR CDR2 1039 Glycosylation of CDR2 might contribute to the unique properties of this VH domain. 30011186 4 16 gly glycoproteins 502:514 arg1 glycoproteins glycoproteins Fterm glycoproteins Therefore, glycoproteins can serve as effective biomarkers for disease detection and targets for drug and vaccine development. 28931684 3 19 gly glycosylation 653:665 arg2 an N-linked glycosylation site an N-linked glycosylation site site One sequence motif, VNDT, containing an N-linked glycosylation site in the envelope (E) protein, is polymorphic, being absent in many of the African isolates while present in all isolates from the recent outbreaks. 20348522 2 0 gly glycosylated 257:268 arg1 E-protein glycosylated variants E-protein glycosylated variants Fterm variants E-protein glycosylated variants of New York (NY) strains of WN virus are more neuroinvasive in mice than the non-glycosylated variants. 20348522 2 6 gly non-glycosylated 356:371 arg1 the non-glycosylated variants the non-glycosylated variants Fterm variants E-protein glycosylated variants of New York (NY) strains of WN virus are more neuroinvasive in mice than the non-glycosylated variants. 1725860 8 93 part_of possesses 1565:1573 arg1 rat IGFBP-6 AND one N-linked glycosylation site rat IGFBP-6 one N-linked glycosylation site PUBTATOR Site IGFBP-6 25641 site One potential N-linked glycosylation site is located at the mid-region of rat and human IGFBP-4, whereas only human but not rat IGFBP-6 possesses one N-linked glycosylation site at the extreme C-terminal of the molecule. 12773316 3 1 part_of beta-subunit 601:612 arg1 the seven beta-subunit glycosylation sites beta-subunit the seven beta-subunit glycosylation sites Fterm Site beta-subunit sites Then plasma membrane delivery of wild-type CFP-alpha, wild-type YFP-beta, and YFP-beta mutants lacking one or two of the seven beta-subunit glycosylation sites was determined using confocal microscopy and surface biotinylation. 9464523 5 26 part_of C5a 783:785 arg1 the murine, human and canine C5a receptor sequences C5a receptor the murine, human and canine C5a receptor sequences PUBTATOR Site C5a receptor 728 sequences The overall nucleotide acid sequence identity, compared to the murine, human and canine C5a receptor sequences, was 85.8, 70.5 and 68.9%, respectively. 9464523 5 79 part_of receptor 787:794 arg1 the murine, human and canine C5a receptor sequences C5a receptor the murine, human and canine C5a receptor sequences PUBTATOR Site C5a receptor 728 sequences The overall nucleotide acid sequence identity, compared to the murine, human and canine C5a receptor sequences, was 85.8, 70.5 and 68.9%, respectively. 20067810 0 73 gly glycosylated 60:71 arg1 G-hPRL G-hPRL PUBTATOR hPRL 5617 Synthesis, purification and characterization of recombinant glycosylated human prolactin (G-hPRL) secreted by cycloheximide-treated CHO cells. 20067810 0 73 gly glycosylated 60:71 arg1 recombinant glycosylated human prolactin recombinant glycosylated human prolactin PUBTATOR prolactin 5617 Synthesis, purification and characterization of recombinant glycosylated human prolactin (G-hPRL) secreted by cycloheximide-treated CHO cells. 6148073 10 75 gly heterogeneity 1626:1638 arg1 thymocyte Thy-1 glycoprotein thymocyte Thy-1 glycoprotein OGER Thy-1 glycoprotein P01831 The results presented explain the previously reported carbohydrate heterogeneity of thymocyte Thy-1 glycoprotein. 6148073 10 70 gly glycoprotein 1659:1670 arg1 thymocyte Thy-1 glycoprotein Thy-1 glycoprotein the previously reported carbohydrate heterogeneity OGER Thy-1 glycoprotein P01831 The results presented explain the previously reported carbohydrate heterogeneity of thymocyte Thy-1 glycoprotein. 31429052 8 14 gly conjugation/glycosylation 1766:1790 arg2 drug conjugation/glycosylation site assessment drug conjugation/glycosylation site assessment site Altogether, our results highlight the potential of UVPD for ADC MD MS analysis for drug conjugation/glycosylation site assessment, and indicate that MD MS strategies can improve structural characterization of empowered next-generation mAb-based formats, especially for PTMs and drug conjugation sites validation. 30147434 6 15 gly glycopeptides 803:815 arg2 glycopeptides glycopeptides glycopeptides Here, we compared two lectin-independent methods to enrich glycopeptides for the global analysis of protein N-glycosylation by MS. The first boronic acid-based enrichment (BA) method benefits from the universal and reversible interactions between boronic acid and sugars; the other method utilizes metabolic labeling and click chemistry (MC) to incorporate a chemical handle into glycoproteins for future affinity enrichment. 30147434 6 94 gly glycoproteins 1124:1136 arg1 glycoproteins glycoproteins Fterm glycoproteins Here, we compared two lectin-independent methods to enrich glycopeptides for the global analysis of protein N-glycosylation by MS. The first boronic acid-based enrichment (BA) method benefits from the universal and reversible interactions between boronic acid and sugars; the other method utilizes metabolic labeling and click chemistry (MC) to incorporate a chemical handle into glycoproteins for future affinity enrichment. 26156869 6 20 part_of Fc 1535:1536 arg1 the Fc fragments Fc the Fc fragments Cterm Site Fc fragments We utilized this difference in glycoform selectivity, in combination with the IdeS protease, and developed a LC separation method to quantify high mannose content in the Fc fragments of the selected mAbs. 26156869 6 76 part_of mAbs 1564:1567 arg1 the Fc fragments mAbs the Fc fragments PUBTATOR Site mAbs 72935 fragments We utilized this difference in glycoform selectivity, in combination with the IdeS protease, and developed a LC separation method to quantify high mannose content in the Fc fragments of the selected mAbs. 1512415 0 74 gly glycosylation 48:60 arg2 the human thyrotropin-beta subunit glycosylation site the human thyrotropin-beta subunit glycosylation site site Mutations of the human thyrotropin-beta subunit glycosylation site reduce thyrotropin synthesis independent of changes in glycosylation status. 26813162 4 67 part_of E1-141 691:696 arg1 the E1-141 glycosylation site E1 the E1-141 glycosylation site Cterm Site E1 site A viral mutant lacking the E1-141 glycosylation site was attenuated for virus-induced disease, with reduced myositis and higher levels of IFN-γ induction at peak disease contributing to improved viral clearance, suggesting that glycosylation of the E1 glycoprotein plays a major role in the pathogenesis of RRV. 15500847 0 30 part_of thrombin 25:32 arg1 Amino acid sequence thrombin Amino acid sequence PUBTATOR Site thrombin 280685 sequence Amino acid sequence of a thrombin like enzyme, elegaxobin II, from the venom of Trimeresurus elegans (Sakishima-Habu). 15968392 10 63 gly glycosylation 1663:1675 arg2 a glycosylation site a glycosylation site site In conclusion, although the FXI-T475I mutation destroys an N-linked glycosylation consensus sequence, the cause of failure to secrete FXI is not the loss of a glycosylation site but rather a direct effect of the substitution of this highly conserved residue. 12466483 3 54 gly glycosylated 611:622 arg1 their overlapping glycosylated sequons their overlapping glycosylated sequons Glycosylation-site HA mutants with mutation(s) in their overlapping glycosylated sequons, each of which had one or two oligosaccharide attachment sites removed, were constructed. 25135642 6 52 part_of ARSG 785:788 arg1 proteolytically processed ARSG fragments ARSG proteolytically processed ARSG fragments PUBTATOR Site ARSG Q96EG1 fragments In contrast, proteolytically processed ARSG fragments of 34-, 18-, and 10-kDa were found in lysosomal fractions and lost their membrane association. 20807536 0 54 gly present 89:95 arg2 ovalbumin AND carbohydrates ovalbumin carbohydrates Fterm ovalbumin Evidence for a novel Entamoeba histolytica lectin activity that recognises carbohydrates present on ovalbumin. 9337875 0 32 gly N-glycosylation 59:73 arg2 N-glycosylation sites N-glycosylation sites sites Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue. 26400346 7 11 gly N-glycosylation 1064:1078 arg2 1 N-glycosylation site 1 N-glycosylation site site There was 1 cAMP- and cGMP-dependent protein kinase phosphorylation site, 11 protein kinase C phosphorylation sites, 4 casein kinase II phosphorylation sites, 1 amidation site, 1 N-glycosylation site, and 1 tyrosine kinase phosphorylation site in FGF5. 23751365 4 71 gly glycopeptides 678:690 arg2 specifically enriching glycopeptides specifically enriching glycopeptides glycopeptides In the present study, a SAX material, XCharge SAX, was used in a column in the ERLIC mode with the aim of specifically enriching glycopeptides. 9139737 7 69 part_of receptor 1512:1519 arg1 the membrane-spanning region low density lipoprotein receptor the membrane-spanning region PUBTATOR Site low density lipoprotein receptor 3949 region Cleavage was not affected when the second transmembrane helix of SREBP-2 was replaced with the membrane-spanning region of the low density lipoprotein receptor, indicating that this sequence is not required for regulation. 20573835 0 32 gly glycoprotein 105:116 arg1 the severe acute respiratory syndrome coronavirus spike glycoprotein the severe acute respiratory syndrome coronavirus spike glycoprotein Fterm glycoprotein A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. 20573835 0 48 gly glycosylation 27:39 arg2 A single asparagine-linked glycosylation site glycoprotein site Fterm glycoprotein site A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. 31445105 9 40 gly glycosylation 1252:1264 arg2 The new glycosylation site The new glycosylation site site The new glycosylation site in HA (S162 N) is a major change that may affect the efficacy of the current vaccine. 10383441 4 35 part_of contains 571:578 arg1 murine DNase I AND Lys27 DNase I Lys27 and Lys74 PUBTATOR AminoAcid DNase I 13419 Lys27 and Lys74 We now demonstrate that murine DNase I, which contains Lys27 and Lys74, is phosphorylated only 20.9% when expressed in the same COS-1 cell system. 16823988 7 47 gly glycosylation 1087:1099 arg2 glycosylation site glycosylation site site Target glycoproteins are characterized further using mass spectrometry to elucidate the carbohydrate structure and glycosylation site. 16823988 7 63 gly glycoproteins 979:991 arg1 Target glycoproteins Target glycoproteins Fterm glycoproteins Target glycoproteins are characterized further using mass spectrometry to elucidate the carbohydrate structure and glycosylation site. 22119577 4 16 part_of tapasin 869:875 arg1 a conserved N-glycosylation site tapasin a conserved N-glycosylation site PUBTATOR Site tapasin 6892 site The coding sequence has a 1329 bp ORF encoding a 442-residue precursor protein with a predicted 24-amino acid leader peptide, generating a 418-amino acid mature form that retains a conserved N-glycosylation site, three conserved mammalian tapasin motifs, two Ig superfamily domains, a transmembrane domain and an ER-retention di-lysine motif at the C-terminus, suggestive of a function similar to mammalian tapasins. 22119577 4 16 part_of tapasin 869:875 arg1 three conserved mammalian tapasin motifs tapasin three conserved mammalian tapasin motifs PUBTATOR Site tapasin 6892 motifs The coding sequence has a 1329 bp ORF encoding a 442-residue precursor protein with a predicted 24-amino acid leader peptide, generating a 418-amino acid mature form that retains a conserved N-glycosylation site, three conserved mammalian tapasin motifs, two Ig superfamily domains, a transmembrane domain and an ER-retention di-lysine motif at the C-terminus, suggestive of a function similar to mammalian tapasins. 22119577 4 67 part_of protein 701:707 arg1 a predicted 24-amino acid leader peptide protein a predicted 24-amino acid leader peptide Fterm Site protein peptide The coding sequence has a 1329 bp ORF encoding a 442-residue precursor protein with a predicted 24-amino acid leader peptide, generating a 418-amino acid mature form that retains a conserved N-glycosylation site, three conserved mammalian tapasin motifs, two Ig superfamily domains, a transmembrane domain and an ER-retention di-lysine motif at the C-terminus, suggestive of a function similar to mammalian tapasins. 8212855 4 78 gly glycoprotein 623:634 arg1 glycoprotein X (gX) glycoprotein X (gX) Fterm glycoprotein X Amino acid residues in the NH2-terminal region of the p32 protein exhibit similarity to glycoprotein X (gX) of pseudorabies virus (PRV) and its homolog in equine herpesvirus type 1 (EHV-1). 27725718 8 9 gly glycosylation 1023:1035 arg2 In NAFLD haptoglobin and transferrin glycosylation sites In NAFLD haptoglobin and transferrin glycosylation sites sites In NAFLD haptoglobin and transferrin glycosylation sites were hyper-glycosylated, a property qualifying for its use as a potential biomarker. 27725718 8 24 gly hyper-glycosylated 1048:1065 arg1 In NAFLD haptoglobin and transferrin glycosylation sites haptoglobin sites PUBTATOR haptoglobin 3240 sites In NAFLD haptoglobin and transferrin glycosylation sites were hyper-glycosylated, a property qualifying for its use as a potential biomarker. 20622883 5 16 gly glycosylation 581:593 arg2 position 46 position 46 position 46 A conserved asparagine (N)-linked glycosylation site at position 46 (N46) in the first conserved domain of muHC was absolutely required for pre-BCR function, and swapping that domain with deltaHC resulted in a functional deltaHC-containing pre-BCR. 20622883 5 16 gly glycosylation 581:593 arg2 A conserved asparagine (N)-linked glycosylation site A conserved asparagine (N)-linked glycosylation site site A conserved asparagine (N)-linked glycosylation site at position 46 (N46) in the first conserved domain of muHC was absolutely required for pre-BCR function, and swapping that domain with deltaHC resulted in a functional deltaHC-containing pre-BCR. 20622883 5 16 gly glycosylation 581:593 arg2 N46 N46 N46 A conserved asparagine (N)-linked glycosylation site at position 46 (N46) in the first conserved domain of muHC was absolutely required for pre-BCR function, and swapping that domain with deltaHC resulted in a functional deltaHC-containing pre-BCR. 1421757 0 32 gly glycosylation 31:43 arg2 the O-linked glycosylation site transferrin receptor site PUBTATOR transferrin receptor 7037 site Identification of the O-linked glycosylation site of the human transferrin receptor. 22245433 0 17 gly Glycosylation 0:12 arg1 COX-2 COX-2 PUBTATOR COX-2 5743 Glycosylation of human cyclooxygenase-2 (COX-2) decreases the efficacy of certain COX-2 inhibitors. 22245433 0 17 gly Glycosylation 0:12 arg1 human cyclooxygenase-2 human cyclooxygenase-2 PUBTATOR cyclooxygenase-2 5743 Glycosylation of human cyclooxygenase-2 (COX-2) decreases the efficacy of certain COX-2 inhibitors. 23069765 8 7 gly O-glycosylate 1567:1579 arg1 a protein a protein Fterm protein Mammalian host cell lines for recombinant protein expression generally impose their characteristic patterns of N-glycosylation on the product, but this work exemplifies how a host may also unpredictably O-glycosylate a protein that is probably not normally O-glycosylated. 23069765 8 27 gly O-glycosylated 1621:1634 arg1 a protein a protein Fterm protein Mammalian host cell lines for recombinant protein expression generally impose their characteristic patterns of N-glycosylation on the product, but this work exemplifies how a host may also unpredictably O-glycosylate a protein that is probably not normally O-glycosylated. 23776650 8 3 part_of DCIR 1126:1129 arg1 the N-glycosylation site DCIR the N-glycosylation site PUBTATOR Site DCIR 50856 site Nevertheless, altering the glycosylation status of the DCIR expressing cell or mutating the N-glycosylation site of DCIR itself did not increase glycan binding. 12176026 4 41 gly glycosylated 649:660 arg1 the glycosylated hormone precursor the glycosylated hormone precursor Fterm precursor In addition, a significant proportion of the glycosylated hormone precursor remains in the cell. 3121328 4 62 gly glycopeptides 782:794 arg2 the glycopeptides the glycopeptides glycopeptides The exact attachment site for each of the three glycans could be deduced from the amino acid compositions of the glycopeptides. 23316195 0 23 gly glycosylation 42:54 arg1 PTX3 functions PTX3 functions PUBTATOR PTX3 5806 The "sweet" side of a long pentraxin: how glycosylation affects PTX3 functions in innate immunity and inflammation. 1331508 8 59 gly attached 1223:1230 arg1 this domain AND sugar moieties PVR domain sugar moieties PUBTATOR PVR 5817 domain These results suggest that domain 1 of the monkey receptor also harbors the binding site for poliovirus and that sugar moieties possibly attached to this domain of human PVR are dispensable for the virus-receptor interaction. 10226365 0 52 gly O-glycosylation 20:34 arg2 O-glycosylation sites O-glycosylation sites sites Characterization of O-glycosylation sites in MUC2 glycopeptides by nanoelectrospray QTOF mass spectrometry. 10226365 0 67 gly glycopeptides 50:62 arg2 glycopeptides glycopeptides glycopeptides Characterization of O-glycosylation sites in MUC2 glycopeptides by nanoelectrospray QTOF mass spectrometry. 1719383 10 95 part_of possesses 1600:1608 arg1 Human IGFBP-6 AND a single Asn-linked glycosylation site Human IGFBP-6 a single Asn-linked glycosylation site PUBTATOR Site Human IGFBP-6 P24592 site Human IGFBP-6 possesses a single Asn-linked glycosylation site near the carboxyl-terminal, whereas no potential Asn-linked glycosylation sites are present in the rat sequence. 12176026 3 4 gly deglycosylated 495:508 arg1 the glycosylated hormone precursor the glycosylated hormone precursor Fterm precursor Upon removal of the BFA the glycosylated hormone precursor is not deglycosylated, and is secreted after maturation of its oligosaccharide chain in the late secretory pathway. 12176026 3 21 gly glycosylated 457:468 arg1 the glycosylated hormone precursor the glycosylated hormone precursor Fterm precursor Upon removal of the BFA the glycosylated hormone precursor is not deglycosylated, and is secreted after maturation of its oligosaccharide chain in the late secretory pathway. 8702538 2 27 gly glycoproteins 418:430 arg1 selected cell surface glycoproteins selected cell surface glycoproteins Fterm glycoproteins Recent work has shown that CD22 specifically recognizes sialic acid linked alpha2,6 to terminal N-linked oligosaccharides on selected cell surface glycoproteins. 8702538 2 47 gly oligosaccharides 376:391 arg1 selected cell surface glycoproteins glycoproteins oligosaccharides Fterm glycoproteins Recent work has shown that CD22 specifically recognizes sialic acid linked alpha2,6 to terminal N-linked oligosaccharides on selected cell surface glycoproteins. 1856695 3 55 part_of protein 589:595 arg1 the N terminus M protein the N terminus OGER Site M protein P54296 terminus Furthermore, five TCV DNA fragments, obtained by PCR on RNA from clinical specimens and corresponding to either the N terminus of the M protein or the complete M protein were also cloned and sequenced. 25389233 6 119 gly glycosylation 901:913 arg1 complexed random IgG complexed random IgG Cterm IgG The levels and type of glycosylation of complexed random IgG was measured with lectin enzyme-immunosorbent assays. 31097672 9 56 gly glycosylation 1423:1435 arg1 fetuin fetuin Fterm fetuin Our data reveal a crucial effect of the gene polymorphism on the glycosylation pattern of fetuin. 2307850 3 43 part_of has 458:460 arg1 a protein AND one glycosylation site a protein one glycosylation site Fterm Site protein site The open reading frame translates into a protein of 248 amino acids that has one glycosylation site. 24931470 3 41 gly CD4-bound 468:476 arg1 their glycan composition CD4 their glycan composition PUBTATOR CD4 920 Here, we use hydrogen-deuterium exchange and oxidative labeling to gain a more precise understanding of the unliganded and CD4-bound forms of soluble Env trimers (SOSIP.664), including their glycan composition. 24931470 3 43 gly trimers 499:505 arg1 their glycan composition Env trimers their glycan composition PUBTATOR Env trimers 100616444 Here, we use hydrogen-deuterium exchange and oxidative labeling to gain a more precise understanding of the unliganded and CD4-bound forms of soluble Env trimers (SOSIP.664), including their glycan composition. 21153276 7 19 gly glycosylation 1205:1217 arg2 extra glycosylation site extra glycosylation site site The GnRH receptor (GnRHR) with extra glycosylation site conferred a markedly enhanced signaling response to agonist. 7533854 4 48 gly glycoprotein 889:900 arg1 a fusion glycoprotein a fusion glycoprotein Fterm glycoprotein A number of MAbs (C108G, G3-4, 684-238, SC258, 11/68b, 38/66a, 38/66c, 38/62c, and CRA3) that did not bind with high affinity to peptides immunoprecipitated a fusion glycoprotein expressing the V1/V2 domain of HXB2 gp120 in the absence of other human immunodeficiency virus sequences, establishing that their epitopes were fully specified within this region. 8543840 0 34 gly glycosylation 80:92 arg2 an N-linked glycosylation site an N-linked glycosylation site site Class I-restricted presentation of an HIV-1 gp41 epitope containing an N-linked glycosylation site. 18308854 3 4 gly glycosylation 556:568 arg2 oatp1a1's four potential N-linked glycosylation sites oatp1a1's four potential N-linked glycosylation sites sites Which of oatp1a1's four potential N-linked glycosylation sites are actually glycosylated and their influence on transport function have not been investigated in a mammalian system. 1402395 1 4 gly glycoproteins 115:127 arg1 small heat-stable glycoproteins small heat-stable glycoproteins Fterm glycoproteins Saposins A, B, C, and D are small heat-stable glycoproteins derived from a common precursor protein, prosaposin. 29604477 4 26 gly glycosylation 710:722 arg2 other novel N-linked glycosylation sites other novel N-linked glycosylation sites sites Here we demonstrate that other novel N-linked glycosylation sites could rescue virion secretion of the G145R and N146Q mutants to variable extents. 1594597 5 52 gly N-glycosylation 938:952 arg2 a potential new N-glycosylation site a potential new N-glycosylation site site In patient ARC-22, an isoleucine-to-threonine substitution at position 566 creates a potential new N-glycosylation site at asparagine-564 in the A2 domain of the factor VIII heavy chain. 1594597 5 52 gly N-glycosylation 938:952 arg2 asparagine-564 asparagine-564 asparagine-564 In patient ARC-22, an isoleucine-to-threonine substitution at position 566 creates a potential new N-glycosylation site at asparagine-564 in the A2 domain of the factor VIII heavy chain. 2737288 3 17 gly glycosylated 389:400 arg1 only Asn-86 only Asn-86 Asn-86 The results demonstrate that only Asn-86 is glycosylated. 9581553 2 4 part_of have 372:375 arg1 The human FR isoforms AND three and two candidate sites The human FR isoforms three and two candidate sites Fterm Site isoforms sites The human FR isoforms type alpha and type beta have three and two candidate sites for N-glycosylation respectively, only one of which is conserved. 26701645 3 55 gly glycosylated 456:467 arg1 tyrosinase tyrosinase PUBTATOR tyrosinase 7299 Here, we investigate the processing of tyrosinase, a multiple glycosylated tumor antigen overexpressed in human malignant melanoma. 20795641 4 29 gly glycoproteins 659:671 arg1 glycoproteins glycoproteins Fterm glycoproteins We describe an integrated strategy allowing for relative quantitation of glycoproteins in complex biological mixtures using this approach. 9442070 0 60 gly glycosylation 4:16 arg1 human serum IgA1 IgA1 regions OGER IgA1 P01876 regions The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions. 7532677 9 60 part_of Bw4/Bw6 1781:1787 arg1 the Bw4/Bw6 region Bw4 the Bw4/Bw6 region PUBTATOR Site Bw4 474272 region Asparagine 86, the single site of N-linked glycosylation on class I molecules, is in close proximity to the Bw4/Bw6 region. 2776749 6 13 part_of protein 972:978 arg1 the amino acid composition protein the amino acid composition Fterm Site protein position One fourth of the amino acid composition of this protein was Glx (14.6%) plus Asx (11.7%) and the pI of this protein was 4.5. 14660594 7 39 part_of domains 1338:1344 arg1 SCAP SCAP domains PUBTATOR Site SCAP 22937 domains The membranous nature of Insig-1 is consistent with its sterol-dependent binding to hydrophobic sterol-sensing domains in SCAP and HMG CoA reductase. 14660594 7 39 part_of domains 1338:1344 arg1 HMG CoA reductase HMG CoA reductase domains OGER Site HMG CoA reductase P04035 domains The membranous nature of Insig-1 is consistent with its sterol-dependent binding to hydrophobic sterol-sensing domains in SCAP and HMG CoA reductase. 25872915 2 17 part_of Fab 537:539 arg1 the Fab region Fab the Fab region PUBTATOR Site Fab 2187 region Most therapeutic mAbs are of IgG class and contain a glycosylation site in the Fc region at amino acid position 297 and, in some cases, in the Fab region. 25872915 2 88 part_of Fc 473:474 arg1 the Fc region Fc the Fc region Cterm Site Fc region Most therapeutic mAbs are of IgG class and contain a glycosylation site in the Fc region at amino acid position 297 and, in some cases, in the Fab region. 25872915 2 2 part_of contain 437:443 arg1 the Fc region AND a glycosylation site the Fc region a glycosylation site site Most therapeutic mAbs are of IgG class and contain a glycosylation site in the Fc region at amino acid position 297 and, in some cases, in the Fab region. 1733280 0 12 part_of mRNA 77:80 arg1 Sequence protein B mRNA Sequence OGER protein B mRNA Q8CG70 Sequence, ontogeny, and cellular localization of murine surfactant protein B mRNA. 21604132 2 6 gly proteins 312:319 arg1 the glycan structures proteins the glycan structures Fterm proteins In particular aberrant sialylation, at the terminal position of the glycan structures of cell surface proteins, occurs in numerous diseases such as cancer metastasis and viral infections. 21071054 4 9 part_of envelope 993:1000 arg1 isogenic envelope sequences envelope isogenic envelope sequences PUBTATOR Site envelope 100616444 sequences Our assumptions, based upon examination of patient viruses, were largely confirmed by characterizing the coreceptor utilization of five distinct panels of isogenic envelope sequences containing V3 amino acid substitutions introduced by site-directed mutagenesis. 10970800 11 45 gly glycosylation 1717:1729 arg2 the distal glycosylation site the distal glycosylation site site This contrasts with a previous finding which described a reduction of the affinity for PGE(2) of the EP3alpha receptor by elimination of the distal glycosylation site when the receptor protein was expressed in insect cells. 28365498 3 11 gly glycoproteins 308:320 arg1 glycoproteins glycoproteins Fterm glycoproteins Characterization of glycoproteins, including identification of glycan structure and components, their attachment sites and protein carriers, remains challenging. 20084966 2 16 gly glycosylated 751:762 arg1 glycosylated domains glycosylated domains domains METHODS: 5 representative strains of measles virus circulated in Jilin provine in 2001-2008 were chosen to conduct the RNA extraction and the Reverse Transcription-Polymerase Chain Reaction (RT-PCR) for amplifying H gene and to do sequence analysis of the PCR products, and then to compare with Chinese vaccine strain S191 and 23 kinds of genotypes of measles virus representative strains from genebank for analysis of phylogenetic, nucleotide and amino acid sequence identity and variation, glycosylated domains variation. 28921966 1 36 gly glycopeptides 252:264 arg2 glycopeptides glycopeptides glycopeptides To overcome the challenges in the analysis of protein glycosylation, we have developed a comprehensive and universal tool through permethylation of glycopeptides and their tandem mass spectrometric analysis. 9398598 5 38 part_of CD4 851:853 arg1 the purified CD4 fragment CD4 the purified CD4 fragment PUBTATOR Site CD4 12504 fragment N-Terminal amino acid sequencing of the purified CD4 fragment demonstrates that the leader signal sequence is properly cleaved off the expressed protein. 18638581 7 86 gly glycosylation 1343:1355 arg2 63 glycosylation sites 63 glycosylation sites sites A total of 63 glycosylation sites in 38 proteins were identified by both methods, demonstrating distinct differences and complementarity. 9648712 5 91 gly N-glycosylation 905:919 arg2 any potential N-glycosylation site any potential N-glycosylation site site Two clones, C6 and C17, were sequenced, and we found encoding proteins of 228 and 274 amino acids with no cysteine or any potential N-glycosylation site, with predicted masses of 25.8 and 31.14 kd, respectively. 1446688 3 1 part_of -1 414:415 arg1 Pro at -1 Pro OGER AminoAcid at -1 O00400 Pro To obtain homogeneous IL-6, Pro at -1 was exchanged for Ala by site-directed mutagenesis. 17623277 3 43 part_of Several 273:279 arg1 Several DCE sequences Several DCE Several DCE sequences PUBTATOR Site Several DCE 1718 sequences Several DCE sequences have been available, but enzyme structure and catalytic mechanism are unclear. 17623277 3 66 part_of DCE 281:283 arg1 Several DCE sequences Several DCE Several DCE sequences PUBTATOR Site Several DCE 1718 sequences Several DCE sequences have been available, but enzyme structure and catalytic mechanism are unclear. 10413093 6 23 gly glycosylation 982:994 arg2 the N306 glycosylation site the N306 glycosylation site site These results corroborate our original observation, confirming that the induced mutation in the N306 glycosylation site neither impairs nor improves the ability of mutant virus to replicate in permissive cells. 10992007 1 29 gly glycosylation 259:271 arg2 six potential N-linked glycosylation sites six potential N-linked glycosylation sites sites The amino-terminal ectodomain of human thyrotropin receptor (TSHR) contains six potential N-linked glycosylation sites (N-Xaa-S/T). 8288048 4 38 gly glycosylation 764:776 arg2 the first or second glycosylation site the first or second glycosylation site site Mutation in the first or second glycosylation site does not significantly impair processing of the receptor; the receptor is found on the cell surface and binds insulin normally. 22203233 3 55 gly fucosylated 464:474 arg1 fucosylated structures fucosylated structures In this study, we demonstrate an alternative way of labeling of fucosylated structures by metabolic engineering, using a chemoenzymatic approach. 22274805 0 39 part_of env 23:25 arg1 partial env gene sequences env partial env gene sequences PUBTATOR Site env 100616444 sequences Correlation of partial env gene sequences with disease progression parameters in HIV-positive pregnant women from India. 26029999 4 30 part_of CD133 724:728 arg1 all eight potential N-glycosylation sites CD133 all eight potential N-glycosylation sites PUBTATOR Site CD133 8842 sites Here we analyzed the exact site(s) of N-glycosylation in CD133 by mass spectrometry and found that all eight potential N-glycosylation sites of CD133 could be indeed occupied by N-glycans. 10103002 4 65 part_of gp42 620:623 arg1 435 amino acid residues gp42 435 amino acid residues Cterm Site gp42 residues The gp42 open reading frame encoded 435 amino acid residues, including a putative signal peptide of 20 amino acids. 10103002 4 65 part_of gp42 620:623 arg1 a putative signal peptide gp42 a putative signal peptide Cterm Site gp42 peptide The gp42 open reading frame encoded 435 amino acid residues, including a putative signal peptide of 20 amino acids. 19035324 5 30 gly N-glycosylation 745:759 arg2 highly conservative N-glycosylation site highly conservative N-glycosylation site site NA had highly conservative N-glycosylation site at position 58, 63, 68, 88, 146, and two more at position 44 and 235 sites, which might be one molecular characteristics of H1N1 subtype of SIV. 24475074 0 48 gly glycoprotein 60:71 arg1 glycoprotein evolution glycoprotein evolution Fterm glycoprotein Encoding asymmetry of the N-glycosylation motif facilitates glycoprotein evolution. 24475074 0 97 gly N-glycosylation 26:40 arg2 the N-glycosylation motif the N-glycosylation motif motif Encoding asymmetry of the N-glycosylation motif facilitates glycoprotein evolution. 25544388 3 5 gly N-glycosylation 607:621 arg2 new N-glycosylation sites new N-glycosylation sites sites In the current work, human interferon beta (huIFN-β) was used as a model to identify the potential positions for the addition of new N-glycosylation sites. 22577028 6 12 gly occupied 1252:1259 arg2 all glycosylation sites all glycosylation sites sites More than 95% site occupancy was observed for all glycosylation sites except N11, which was 60% occupied. 22577028 6 31 gly glycosylation 1206:1218 arg2 all glycosylation sites all glycosylation sites sites More than 95% site occupancy was observed for all glycosylation sites except N11, which was 60% occupied. 31958346 2 22 part_of possesses 532:540 arg1 α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate type glutamate receptor AND six potential N-glycosylation sites α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate type glutamate receptor six potential N-glycosylation sites Fterm Site receptor sites In this study, we performed a comprehensive N-glycosylation analysis of mouse GluA1, one of the major subunits of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate type glutamate receptor, which possesses six potential N-glycosylation sites in the N-terminal domain. 12438611 0 61 part_of cyanovirin 148:157 arg1 cyanovirin binding sites cyanovirin cyanovirin binding sites Fterm Site cyanovirin sites Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding. 8740419 4 5 gly glycoprotein 767:778 arg1 a yeast secretory glycoprotein a yeast secretory glycoprotein Fterm glycoprotein The hsp150 delta-carrier is an N-terminal signal peptide-containing fragment of a yeast secretory glycoprotein. 21153780 8 30 gly glycosylated 1046:1057 arg1 Casein kinase II Casein kinase II OGER Casein kinase II Our computational study predicted that B cell epitope 1 was Casein kinase II phosphorylated (site No. 31) and glycosylated (site No. 29). 21106559 4 23 gly glycosylation 846:858 arg2 glycosylation site glycosylation site site Full structural definition and glycosylation site mapping were completed through advanced mass spectrometry analyses at both the glycan and glycopeptide levels in conjunction with chemical and enzymatic cleavages. 10970800 0 83 gly N-glycosylation 15:29 arg1 the prostaglandin E2 receptor EP3beta the prostaglandin E2 receptor EP3beta PUBTATOR EP3beta 64184 Requirement of N-glycosylation of the prostaglandin E2 receptor EP3beta for correct sorting to the plasma membrane but not for correct folding. 10593916 2 33 gly glycoprotein 687:698 arg1 the lymphocytic choriomeningitis virus (LCMV) GP1 glycoprotein the lymphocytic choriomeningitis virus (LCMV) GP1 glycoprotein Fterm glycoprotein With the aim of exploring these processes, we have dissected the structural and functional properties of the MHC-restricted peptide GP92-101 (CSANNSHHYI) generated from the lymphocytic choriomeningitis virus (LCMV) GP1 glycoprotein. 2538306 9 19 gly O-Glycosylation 1841:1855 arg1 alpha-subunit alpha-subunit Fterm alpha-subunit 1) O-Glycosylation of alpha-subunit is a late event in the secretory pathway of trophoblasts compared to the rapid combination in the rough endoplasmic reticulum of hCG subunit precursors to form alpha beta dimer. 29162128 5 13 gly glycosylation 1024:1036 arg2 their glycosylation sites their glycosylation sites sites Interestingly, both rSY-Δ11 and rSY-Δ10/11 mutant viruses reverted their glycosylation sites at 11N after passage, indicating that 11N is a true and critical glycosylation site. 29162128 5 84 gly glycosylation 1109:1121 arg2 a true and critical glycosylation site a true and critical glycosylation site site Interestingly, both rSY-Δ11 and rSY-Δ10/11 mutant viruses reverted their glycosylation sites at 11N after passage, indicating that 11N is a true and critical glycosylation site. 15869468 4 26 gly N-glycosylation 599:613 arg2 Artificial N-glycosylation sequons Asn Asn Artificial N-glycosylation sequons (Asn-Xaa-Ser/Thr) were engineered into ECL1, ECL2 and ECL3. 9194614 6 27 gly site 924:927 arg1 two hydroxylated proline residues two hydroxylated proline residues proline residues The post-translational modifications (one N-glycosylation site, two hydroxylated proline residues and seven cysteine residues for potential disulfide formations), which contribute to IgE reactivity, were identical in all. 9194614 6 27 gly site 924:927 arg1 seven cysteine residues seven cysteine residues cysteine residues The post-translational modifications (one N-glycosylation site, two hydroxylated proline residues and seven cysteine residues for potential disulfide formations), which contribute to IgE reactivity, were identical in all. 9194614 6 31 gly N-glycosylation 908:922 arg2 one N-glycosylation site one N-glycosylation site site The post-translational modifications (one N-glycosylation site, two hydroxylated proline residues and seven cysteine residues for potential disulfide formations), which contribute to IgE reactivity, were identical in all. 9194614 6 79 gly modifications 889:901 arg1 one N-glycosylation site one N-glycosylation site site The post-translational modifications (one N-glycosylation site, two hydroxylated proline residues and seven cysteine residues for potential disulfide formations), which contribute to IgE reactivity, were identical in all. 26348848 3 101 gly N-glycosylated 530:543 arg1 other N-glycosylated Kv channels other N-glycosylated Kv channels Fterm channels To extrapolate this mechanism to other N-glycosylated Kv channels, we evaluated the impact of N-glycosylation occupancy of Kv3.1a and Kv1.1 channels. 25567004 5 37 gly non-glycosylated 1078:1093 arg1 mBHc mBHc PUBTATOR mBHc 192285 Notably, a non-glycosylated secreted homogeneous BHc isoform (mBHc), which we successfully prepared after deleting the pro-peptide and removing its single potential glycosylation site, was immunologically active and could confer effective protective immunity, similarly to non-glycosylated rBHc. 25567004 5 37 gly non-glycosylated 1078:1093 arg1 a non-glycosylated secreted homogeneous BHc isoform a non-glycosylated secreted homogeneous BHc isoform PUBTATOR BHc isoform 192285 Notably, a non-glycosylated secreted homogeneous BHc isoform (mBHc), which we successfully prepared after deleting the pro-peptide and removing its single potential glycosylation site, was immunologically active and could confer effective protective immunity, similarly to non-glycosylated rBHc. 25567004 5 40 gly non-glycosylated 1340:1355 arg1 non-glycosylated rBHc non-glycosylated rBHc PUBTATOR BHc 192285 Notably, a non-glycosylated secreted homogeneous BHc isoform (mBHc), which we successfully prepared after deleting the pro-peptide and removing its single potential glycosylation site, was immunologically active and could confer effective protective immunity, similarly to non-glycosylated rBHc. 25567004 5 60 gly glycosylation 1232:1244 arg2 its single potential glycosylation site its single potential glycosylation site site Notably, a non-glycosylated secreted homogeneous BHc isoform (mBHc), which we successfully prepared after deleting the pro-peptide and removing its single potential glycosylation site, was immunologically active and could confer effective protective immunity, similarly to non-glycosylated rBHc. 15823038 1 41 gly glycosylation 282:294 arg2 extensive glycosylation sites extensive glycosylation sites sites The low-density lipoprotein receptor-related protein (LRP) is a large receptor that contains extensive glycosylation sites and disulfide bonds. 20622883 6 52 gly N46-glycosylation 903:919 arg1 pre-BCR function pre-BCR function PUBTATOR BCR 613 When tested in the context of the BCR, muHC with a mutant N46 showed normal function, which indicated that N46-glycosylation is specifically required for pre-BCR function. 8780172 2 58 gly glycosylation 458:470 arg2 a putative N-linked glycosylation site a putative N-linked glycosylation site site Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a 45 kD heparin-binding, endothelial cell (EC) specific mitogen with a putative N-linked glycosylation site. 21752569 3 22 gly deglycoproteins 510:524 arg1 the resulting deglycoproteins the resulting deglycoproteins Fterm deglycoproteins After reduction by DTT, the resulting deglycoproteins were analyzed by UPLC-ESI TOF MS to estimate the numbers of N-glycan and O-glycan sites through differential masses. 26599345 0 35 gly glycoproteins 31:43 arg1 therapeutic glycoproteins therapeutic glycoproteins Fterm glycoproteins Glycan analysis of therapeutic glycoproteins. 27679458 0 10 gly glycopeptides 75:87 arg2 glycopeptides glycopeptides glycopeptides Diethylaminoethyl Sepharose (DEAE-Sepharose) microcolumn for enrichment of glycopeptides. 10471642 1 19 gly glycoprotein 380:391 arg1 carbohydrate-deficient glycoprotein syndrome type 1 carbohydrate-deficient glycoprotein syndrome type 1 This alteration could be similar to that present in patients with carbohydrate-deficient glycoprotein syndrome type 1 (CDG1). 30208353 7 23 gly O-glycosylation 1206:1220 arg1 ER-α ER-α domain PUBTATOR ER-α 2099 domain We confirmed GALNT6-dependent ER-α O-glycosylation and identified O-glycosylation of S573 in an F domain of ER-α by GALNT6 through LC-MS/MS analysis. 30208353 7 23 gly O-glycosylation 1206:1220 arg1 an F domain domain domain We confirmed GALNT6-dependent ER-α O-glycosylation and identified O-glycosylation of S573 in an F domain of ER-α by GALNT6 through LC-MS/MS analysis. 30208353 7 23 gly O-glycosylation 1206:1220 arg1 an F domain ER-α domain PUBTATOR ER-α 2099 domain We confirmed GALNT6-dependent ER-α O-glycosylation and identified O-glycosylation of S573 in an F domain of ER-α by GALNT6 through LC-MS/MS analysis. 27966990 5 0 gly occupancy 895:903 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides. 27966990 5 6 gly N-glycosylation 665:679 arg2 N-glycosylation sites N-glycosylation sites sites The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides. 27966990 5 9 gly N-glycosylation 874:888 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides. 27966990 5 68 gly heterogeneity 936:948 arg1 VEGFR-2 glycopeptides VEGFR-2 glycopeptides glycopeptides The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides. 27966990 5 79 gly N-glycosylated 786:799 arg1 formerly N-glycosylated sites formerly N-glycosylated sites sites The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides. 27966990 5 0 gly occupancy 895:903 arg2 VEGFR-2 glycopeptides glycopeptides glycopeptides The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides. 27966990 5 23 gly glycopeptides 961:973 arg1 the site-specific N-glycan heterogeneity glycopeptides the site-specific N-glycan heterogeneity glycopeptides The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides. 2187193 4 28 part_of tryptase 528:535 arg1 the three human tryptase catalytic domains tryptase the three human tryptase catalytic domains PUBTATOR Site tryptase 100049001 domains The differences among the three human tryptase catalytic domains include the loss of a consensus N-glycosylation site in one cDNA, which may explain some of the heterogeneity in size and susceptibility to deglycosylation seen in tryptase preparations. 27506355 1 19 gly glycopeptide 190:201 arg2 Intact glycopeptide MS analysis Intact glycopeptide MS analysis glycopeptide Intact glycopeptide MS analysis to reveal site-specific protein glycosylation is an important frontier of proteomics. 30904681 1 65 part_of protein 246:252 arg1 four or five N-glycosylation sites protein four or five N-glycosylation sites Fterm Site protein sites The highly glycosylated ß-2-glycoprotein-1 (B2GP1), also called apolipoprotein H, is a 50 kDa human plasma protein with four or five N-glycosylation sites. 17924005 5 84 part_of Env 901:903 arg1 the 12 Env epitopes 12 Env the 12 Env epitopes PUBTATOR Site 12 Env 30816 epitopes In 5 of the 12 Env epitopes the physico-chemical analysis demonstrated that the mutations magnified the antigenicity profile. 8289366 6 70 part_of cDNA 948:951 arg1 position 229 cDNA position 229 Cterm Site cDNA position 229 The glycosylation site at position 229 of the MDTF receptor cDNA was eliminated by substituting a threonine codon for the asparagine codon. 7537656 5 16 gly attached 757:764 arg2 asparagine 297 AND the sugar chain asparagine 297 the sugar chain asparagine 297 The glycosylated region was determined in the Fc portion from serine 239 to methionine 309 by a glycan detection method using mild periodate oxidation, which confirms that the sugar chain is attached to the conserved glycosylation site of asparagine 297. 7537656 5 16 gly attached 757:764 arg2 the conserved glycosylation site AND the sugar chain the conserved glycosylation site the sugar chain site The glycosylated region was determined in the Fc portion from serine 239 to methionine 309 by a glycan detection method using mild periodate oxidation, which confirms that the sugar chain is attached to the conserved glycosylation site of asparagine 297. 7537656 5 28 gly glycosylation 783:795 arg2 the conserved glycosylation site the conserved glycosylation site site The glycosylated region was determined in the Fc portion from serine 239 to methionine 309 by a glycan detection method using mild periodate oxidation, which confirms that the sugar chain is attached to the conserved glycosylation site of asparagine 297. 7537656 5 69 gly glycosylated 570:581 arg1 The glycosylated region The glycosylated region region The glycosylated region was determined in the Fc portion from serine 239 to methionine 309 by a glycan detection method using mild periodate oxidation, which confirms that the sugar chain is attached to the conserved glycosylation site of asparagine 297. 7537656 5 28 gly glycosylation 783:795 arg2 asparagine 297 asparagine 297 asparagine 297 The glycosylated region was determined in the Fc portion from serine 239 to methionine 309 by a glycan detection method using mild periodate oxidation, which confirms that the sugar chain is attached to the conserved glycosylation site of asparagine 297. 9365923 0 3 gly glycosylation 48:60 arg2 The unusual amino acid triplet Asn-Ile-Cys The unusual amino acid triplet Asn-Ile-Cys Asn-Ile-Cys The unusual amino acid triplet Asn-Ile-Cys is a glycosylation consensus site in human alpha-lactalbumin. 9365923 0 3 gly glycosylation 48:60 arg2 a glycosylation consensus site a glycosylation consensus site site The unusual amino acid triplet Asn-Ile-Cys is a glycosylation consensus site in human alpha-lactalbumin. 11822873 0 82 gly O-glycosylation 30:44 arg2 the membrane-proximal O-glycosylation site the membrane-proximal O-glycosylation site site Role of the membrane-proximal O-glycosylation site in sorting of the human receptor for neurotrophins to the apical membrane of MDCK cells. 20506028 3 29 gly nonglycosylated 476:490 arg1 NG-hChM-I NG-hChM-I PUBTATOR hChM-I 11061 We generated a nonglycosylated recombinant human ChM-I (NG-hChM-I) and compared its bioactivity with that of the glycosylated form of human ChM-I (G-hChM-I) expressed in Chinese hamster ovary cells in vitro. 20506028 3 29 gly nonglycosylated 476:490 arg1 a nonglycosylated recombinant human ChM-I a nonglycosylated recombinant human ChM-I PUBTATOR ChM-I 11061 We generated a nonglycosylated recombinant human ChM-I (NG-hChM-I) and compared its bioactivity with that of the glycosylated form of human ChM-I (G-hChM-I) expressed in Chinese hamster ovary cells in vitro. 20506028 3 44 gly glycosylated 574:585 arg1 G-hChM-I G-hChM-I PUBTATOR hChM-I 11061 We generated a nonglycosylated recombinant human ChM-I (NG-hChM-I) and compared its bioactivity with that of the glycosylated form of human ChM-I (G-hChM-I) expressed in Chinese hamster ovary cells in vitro. 20506028 3 44 gly glycosylated 574:585 arg1 human ChM-I human ChM-I PUBTATOR ChM-I 11061 We generated a nonglycosylated recombinant human ChM-I (NG-hChM-I) and compared its bioactivity with that of the glycosylated form of human ChM-I (G-hChM-I) expressed in Chinese hamster ovary cells in vitro. 27095603 2 29 gly di-sialylated 370:382 arg1 a di-sialylated biantennary oligosaccharide a di-sialylated biantennary oligosaccharide Transferrin is an 80 kDa glycoprotein and the glycoform at two N-glycosylation sites is comprised of a di-sialylated biantennary oligosaccharide as the major form and minor species with fucosylated or triantennary structures. 27095603 2 51 gly fucosylated 453:463 arg1 fucosylated or triantennary structures fucosylated or triantennary structures Transferrin is an 80 kDa glycoprotein and the glycoform at two N-glycosylation sites is comprised of a di-sialylated biantennary oligosaccharide as the major form and minor species with fucosylated or triantennary structures. 27095603 2 55 gly N-glycosylation 330:344 arg2 two N-glycosylation sites two N-glycosylation sites sites Transferrin is an 80 kDa glycoprotein and the glycoform at two N-glycosylation sites is comprised of a di-sialylated biantennary oligosaccharide as the major form and minor species with fucosylated or triantennary structures. 27095603 2 60 gly glycoform 313:321 arg2 two N-glycosylation sites two N-glycosylation sites sites Transferrin is an 80 kDa glycoprotein and the glycoform at two N-glycosylation sites is comprised of a di-sialylated biantennary oligosaccharide as the major form and minor species with fucosylated or triantennary structures. 27095603 2 67 gly glycoprotein 292:303 arg1 an 80 kDa glycoprotein an 80 kDa glycoprotein Fterm glycoprotein Transferrin is an 80 kDa glycoprotein and the glycoform at two N-glycosylation sites is comprised of a di-sialylated biantennary oligosaccharide as the major form and minor species with fucosylated or triantennary structures. 27095603 2 67 gly glycoprotein 292:303 arg1 Transferrin Transferrin PUBTATOR Transferrin 7018 Transferrin is an 80 kDa glycoprotein and the glycoform at two N-glycosylation sites is comprised of a di-sialylated biantennary oligosaccharide as the major form and minor species with fucosylated or triantennary structures. 8497072 0 65 gly glycoprotein 60:71 arg1 human immunodeficiency virus type 1 envelope glycoprotein human immunodeficiency virus type 1 envelope glycoprotein Fterm glycoprotein Association of human immunodeficiency virus type 1 envelope glycoprotein with particles depends on interactions between the third variable and conserved regions of gp120. 26029999 8 39 gly glycosylation 1237:1249 arg2 CD133 glycosylation sites CD133 glycosylation sites sites Our results identified the characteristics and function of CD133 glycosylation sites. 9201996 12 10 gly O-glycosylation 1730:1744 arg2 a mucin-type O-glycosylation motif a mucin-type O-glycosylation motif motif We propose a mucin-type O-glycosylation motif, XTPXP, which may be suitable as a signal for protein O-glycosylation. 7945294 3 48 part_of contains 364:371 arg1 a leading peptide AND a leading peptide a leading peptide a leading peptide peptide It encodes for a protein of 390 amino acid residues of 41,746 KDa and contains a leading peptide of 28 amino acids. 23808883 8 36 gly sialylated 1465:1474 arg1 antigen-specific galactosylated and sialylated IgGs antigen-specific galactosylated and sialylated IgGs Cterm IgGs Therefore, antigen-specific galactosylated and sialylated IgGs may be a promising therapeutic tool for re-establishing tolerance against defined (self-) antigens in autoimmune or allergic patients. 23925152 4 14 gly glycosylation 550:562 arg2 the N-linked glycosylation site the N-linked glycosylation site site The insertion of arginine at position 11 and the loss of the N-linked glycosylation site were indispensable for acquiring pure CXCR4-tropism, which were confirmed by cell-cell fusion assay and phenotype analysis of recombinant HIV-1 variants. 15809769 7 46 part_of protein 701:707 arg1 N-terminal signal peptide Rat Wnt9a protein N-terminal signal peptide PUBTATOR Site Rat Wnt9a protein 287357 peptide Rat Wnt9a protein (365 aa) with N-terminal signal peptide, 24 Cys residues and one Asn-linked glycosylation site showed 100%, 98.1% and 82.5% total amino-acid identity with mouse Wnt9a, human WNT9A and chicken wnt9a, respectively. 15809769 7 46 part_of protein 701:707 arg1 one Asn-linked glycosylation site Rat Wnt9a protein one Asn-linked glycosylation site PUBTATOR Site Rat Wnt9a protein 287357 site Rat Wnt9a protein (365 aa) with N-terminal signal peptide, 24 Cys residues and one Asn-linked glycosylation site showed 100%, 98.1% and 82.5% total amino-acid identity with mouse Wnt9a, human WNT9A and chicken wnt9a, respectively. 15809769 7 46 part_of protein 701:707 arg1 24 Cys residues Rat Wnt9a protein 24 Cys residues PUBTATOR AminoAcid Rat Wnt9a protein 287357 Cys residues Rat Wnt9a protein (365 aa) with N-terminal signal peptide, 24 Cys residues and one Asn-linked glycosylation site showed 100%, 98.1% and 82.5% total amino-acid identity with mouse Wnt9a, human WNT9A and chicken wnt9a, respectively. 3219367 6 14 gly glycopeptides 761:773 arg2 glycopeptides glycopeptides glycopeptides By high-performance liquid chromatography, we have succeeded in separation of glycopeptides containing different O-linked saccharides to the same peptide backbone. 3219367 6 33 gly containing 775:784 arg1 glycopeptides AND different O-linked saccharides glycopeptides different O-linked saccharides glycopeptides By high-performance liquid chromatography, we have succeeded in separation of glycopeptides containing different O-linked saccharides to the same peptide backbone. 20589319 5 14 gly glycosylation 1189:1201 arg2 the canonical glycosylation site the canonical glycosylation site site In vitro expression of transfectants containing gammaDelta7651A and gammaDelta7651A/399T (gammaDelta7651A with an amino acid substitution of 399Asn by Thr and a variant lacking the canonical glycosylation site) demonstrated a reduction in secretion to approximately 20% of the level seen in the transfectants carrying the normal gamma-chain. 22187327 1 5 gly glycoprotein 196:207 arg1 a dendritically polarized type I membrane glycoprotein a dendritically polarized type I membrane glycoprotein Fterm glycoprotein Intercellular adhesion molecule-5 (ICAM-5, telencephalin) is a dendritically polarized type I membrane glycoprotein, and promotes dendritic filopodia formation. 22187327 1 5 gly glycoprotein 196:207 arg1 Intercellular adhesion molecule-5 Intercellular adhesion molecule-5 PUBTATOR Intercellular adhesion molecule-5 15898 Intercellular adhesion molecule-5 (ICAM-5, telencephalin) is a dendritically polarized type I membrane glycoprotein, and promotes dendritic filopodia formation. 9882683 9 39 gly glycosylation 1267:1279 arg2 an altered Ser63 glycosylation site an altered Ser63 glycosylation site site In order to determine whether the same was true for GC, we engineered various pilin derivatives with an altered Ser63 glycosylation site. 16037490 3 34 gly sites 788:792 arg1 glycan heterogeneities sites glycan heterogeneities sites The method was then applied to the analysis of glycan heterogeneities at seven N-glycosylation sites in each of the plasma and cellular fibronectins (FNs). 16037490 3 62 gly N-glycosylation 772:786 arg2 seven N-glycosylation sites seven N-glycosylation sites sites The method was then applied to the analysis of glycan heterogeneities at seven N-glycosylation sites in each of the plasma and cellular fibronectins (FNs). 16755913 0 23 gly N-glycosylation 83:97 arg2 modified N-glycosylation sites modified N-glycosylation sites sites [Construction and expression of various human prion proteins mutants with modified N-glycosylation sites in mammalian cells]. 16274239 4 50 gly glycosylation 718:730 arg1 579 N(579) N(579) Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR). 16274239 4 50 gly glycosylation 718:730 arg2 N N(579) N(579) Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR). 16274239 4 50 gly glycosylation 718:730 arg1 N N(579) N(579) Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR). 16274239 4 50 gly glycosylation 718:730 arg2 N N(579) N(579) Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR). 16274239 4 50 gly glycosylation 718:730 arg1 N N(579) N(579) Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR). 16274239 4 50 gly glycosylation 718:730 arg1 N N(579) N(579) Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR). 10913840 5 25 gly sites 785:789 arg1 these sites these sites sites Lack of glycosylation at sites 117-119, 218-220, or both of these sites, decreased enzyme activity to approximately 64%, 5% or 1%, respectively, of that seen in the unmutated enzyme. 10913840 5 16 gly glycosylation 768:780 arg2 sites 117-119, 218-220, or both of these sites sites sites Lack of glycosylation at sites 117-119, 218-220, or both of these sites, decreased enzyme activity to approximately 64%, 5% or 1%, respectively, of that seen in the unmutated enzyme. 30898876 7 15 gly glycoproteins 1558:1570 arg1 extracellular glycoproteins extracellular glycoproteins Fterm glycoproteins Whereas B4GALNT3 and B4GALNT4 synthesized LDN on extracellular glycoproteins, B3GALNT2 primarily transferred LDN to intracellular glycoproteins, thereby clearly delineating proteins that carry type-I or type-II LDNs. 30898876 7 56 gly glycoproteins 1625:1637 arg1 intracellular glycoproteins intracellular glycoproteins Fterm glycoproteins Whereas B4GALNT3 and B4GALNT4 synthesized LDN on extracellular glycoproteins, B3GALNT2 primarily transferred LDN to intracellular glycoproteins, thereby clearly delineating proteins that carry type-I or type-II LDNs. 30898876 7 89 gly LDN 1537:1539 arg1 extracellular glycoproteins glycoproteins LDN Fterm glycoproteins Whereas B4GALNT3 and B4GALNT4 synthesized LDN on extracellular glycoproteins, B3GALNT2 primarily transferred LDN to intracellular glycoproteins, thereby clearly delineating proteins that carry type-I or type-II LDNs. 11087995 5 73 gly glycosylation 819:831 arg2 the N-linked glycosylation site the N-linked glycosylation site site Mutation of the N-linked glycosylation site, Asn18Thr, had only a small effect on binding properties and inhibition of adenylyl cyclase. 31393126 8 36 gly sites 1269:1273 arg1 Two N-glycosylation sites Two N-glycosylation sites sites Two N-glycosylation sites (N177 and N394), 3 sites (N145, N178, and N92), and 1 site of N183 were identified in MRJP1, MRJP2, and MRJP3, respectively. 31393126 8 36 gly sites 1269:1273 arg1 N183 N183 N183 Two N-glycosylation sites (N177 and N394), 3 sites (N145, N178, and N92), and 1 site of N183 were identified in MRJP1, MRJP2, and MRJP3, respectively. 31393126 8 46 gly sites 1294:1298 arg1 3 sites 3 sites sites Two N-glycosylation sites (N177 and N394), 3 sites (N145, N178, and N92), and 1 site of N183 were identified in MRJP1, MRJP2, and MRJP3, respectively. 31393126 8 46 gly sites 1294:1298 arg1 N183 N183 N183 Two N-glycosylation sites (N177 and N394), 3 sites (N145, N178, and N92), and 1 site of N183 were identified in MRJP1, MRJP2, and MRJP3, respectively. 31393126 8 61 gly N-glycosylation 1253:1267 arg2 Two N-glycosylation sites Two N-glycosylation sites sites Two N-glycosylation sites (N177 and N394), 3 sites (N145, N178, and N92), and 1 site of N183 were identified in MRJP1, MRJP2, and MRJP3, respectively. 31393126 8 36 gly sites 1269:1273 arg1 N177 N177 and N394 N177 and N394 Two N-glycosylation sites (N177 and N394), 3 sites (N145, N178, and N92), and 1 site of N183 were identified in MRJP1, MRJP2, and MRJP3, respectively. 31393126 8 46 gly sites 1294:1298 arg1 N92 N145, N178, and N92 N145, N178, and N92 Two N-glycosylation sites (N177 and N394), 3 sites (N145, N178, and N92), and 1 site of N183 were identified in MRJP1, MRJP2, and MRJP3, respectively. 31393126 8 46 gly sites 1294:1298 arg1 N145 N145, N178, and N92 N145, N178, and N92 Two N-glycosylation sites (N177 and N394), 3 sites (N145, N178, and N92), and 1 site of N183 were identified in MRJP1, MRJP2, and MRJP3, respectively. 31393126 8 46 gly sites 1294:1298 arg1 N145 N145, N178, and N92 N145, N178, and N92 Two N-glycosylation sites (N177 and N394), 3 sites (N145, N178, and N92), and 1 site of N183 were identified in MRJP1, MRJP2, and MRJP3, respectively. 31393126 8 61 gly N-glycosylation 1253:1267 arg2 N394 N177 and N394 N177 and N394 Two N-glycosylation sites (N177 and N394), 3 sites (N145, N178, and N92), and 1 site of N183 were identified in MRJP1, MRJP2, and MRJP3, respectively. 31393126 8 61 gly N-glycosylation 1253:1267 arg1 N183 N183 N183 Two N-glycosylation sites (N177 and N394), 3 sites (N145, N178, and N92), and 1 site of N183 were identified in MRJP1, MRJP2, and MRJP3, respectively. 8631363 8 73 gly 0-glycosylated 1262:1275 arg1 tumor necrosis factor-alpha tumor necrosis factor-alpha PUBTATOR tumor necrosis factor-alpha 7124 About 20% of tumor necrosis factor-alpha was found to be 0-glycosylated, based on the results of the sugar composition and structure analyses. 7727375 3 1 gly glycosylation 556:568 arg2 Ser126 Ser126 Ser126 Variants with Thr mutations at positions 123 and 125, but not elsewhere, contained additional carbohydrate, which suggests that several positions around the existing O-linked glycosylation site (Ser126), but not elsewhere, contain the necessary information for O-linked carbohydrate addition. 7727375 3 1 gly glycosylation 556:568 arg2 the existing O-linked glycosylation site the existing O-linked glycosylation site site Variants with Thr mutations at positions 123 and 125, but not elsewhere, contained additional carbohydrate, which suggests that several positions around the existing O-linked glycosylation site (Ser126), but not elsewhere, contain the necessary information for O-linked carbohydrate addition. 2302219 6 24 gly glycosylation 830:842 arg2 the only glycosylation site the only glycosylation site site This eliminated the only glycosylation site in mature SAP-1 and could explain the findings made at the protein level. 26029999 8 63 part_of CD133 1231:1235 arg1 CD133 glycosylation sites CD133 CD133 glycosylation sites PUBTATOR Site CD133 8842 sites Our results identified the characteristics and function of CD133 glycosylation sites. 15859596 11 48 gly deglycosylated 1769:1782 arg1 Glycopeptides Glycopeptides Glycopeptides Glycopeptides thus selected were mixed, deglycosylated by PNGase F, and fractionated by reversed-phase chromatography (RPC). 14747665 8 1 gly glycoform 1445:1453 arg1 complex glycoform complex glycoform FR containing the 67(S-->P) mutation with either a 144(E-->D) or 201(N-->D) change was not processed from the high-mannose to complex glycoform but was still transported to the cell surface and able to transport folates. 9442070 3 15 gly glycosylation 479:491 arg1 IgA1 IgA1 OGER IgA1 P01876 In this paper, we have analyzed the glycosylation of IgA1 and IgA1 Fab and Fc as well as three recombinant IgA1 molecules, including two N-glycosylation mutants. 1400492 4 28 part_of pro-enzyme 473:482 arg1 a 35-amino acid putative pro-enzyme domain enzyme a 35-amino acid putative pro-enzyme domain Fterm Site enzyme domain The deduced amino acid sequence contains a signal pre-propeptide sequence of 18 amino acids followed by 369 amino acids with a 35-amino acid putative pro-enzyme domain in the NH2-terminal. 1400492 4 69 part_of contains 355:362 arg1 The deduced amino acid sequence AND a signal pre-propeptide sequence The deduced amino acid sequence a signal pre-propeptide sequence sequence The deduced amino acid sequence contains a signal pre-propeptide sequence of 18 amino acids followed by 369 amino acids with a 35-amino acid putative pro-enzyme domain in the NH2-terminal. 23296533 4 8 gly glycosylation 1023:1035 arg2 their sites their sites sites Coupled with advanced mass spectrometry-based proteomics technology, this method facilitates the identification of hundreds to thousands of N-glycoproteins, coupled with their sites of glycosylation, from a complex biological mixture. 23296533 4 43 gly N-glycoproteins 978:992 arg1 N-glycoproteins N-glycoproteins Fterm N-glycoproteins Coupled with advanced mass spectrometry-based proteomics technology, this method facilitates the identification of hundreds to thousands of N-glycoproteins, coupled with their sites of glycosylation, from a complex biological mixture. 9241750 3 44 gly N-glycosylation 833:847 arg2 the three potential N-glycosylation sites the three potential N-glycosylation sites sites SDS-PAGE gels revealed that glycosylation mutants migrate identically and faster than the wild-type rHPS, showing that each of the three potential N-glycosylation sites contain a similar amount of carbohydrate. 9241750 3 68 gly contain 855:861 arg1 the three potential N-glycosylation sites AND carbohydrate the three potential N-glycosylation sites carbohydrate sites SDS-PAGE gels revealed that glycosylation mutants migrate identically and faster than the wild-type rHPS, showing that each of the three potential N-glycosylation sites contain a similar amount of carbohydrate. 1457969 0 25 part_of sites 67:71 arg1 human thyrotrophin thyrotrophin sites Fterm Site thyrotrophin sites The asparagine-linked oligosaccharides at individual glycosylation sites in human thyrotrophin. 26254591 7 64 part_of subunit 1412:1418 arg1 the carboxy terminal domain subunit the carboxy terminal domain Fterm Site subunit domain Additionally, we generated αL576X and αN232,293,312,397,511Q,L576X deletion mutants of ENaC-α, since we have previously demonstrated that the carboxy terminal domain of this subunit is also involved in its interaction with solnatide. 2341397 5 39 gly glycosylation 1105:1117 arg2 the 12 predicted asparagine-linked glycosylation sites the 12 predicted asparagine-linked glycosylation sites sites This approach showed that TEX and NCA were identical with respect to primary sequence and provided direct evidence that 11 of the 12 predicted asparagine-linked glycosylation sites were glycosylated in both TEX and NCA. 2341397 5 44 gly glycosylated 1130:1141 arg1 NCA NCA sites PUBTATOR NCA 1089 sites This approach showed that TEX and NCA were identical with respect to primary sequence and provided direct evidence that 11 of the 12 predicted asparagine-linked glycosylation sites were glycosylated in both TEX and NCA. 2341397 5 44 gly glycosylated 1130:1141 arg2 the 12 predicted asparagine-linked glycosylation sites sites sites This approach showed that TEX and NCA were identical with respect to primary sequence and provided direct evidence that 11 of the 12 predicted asparagine-linked glycosylation sites were glycosylated in both TEX and NCA. 2341397 5 44 gly glycosylated 1130:1141 arg2 the 12 predicted asparagine-linked glycosylation sites NCA sites PUBTATOR NCA 1089 sites This approach showed that TEX and NCA were identical with respect to primary sequence and provided direct evidence that 11 of the 12 predicted asparagine-linked glycosylation sites were glycosylated in both TEX and NCA. 7499346 0 43 gly glycosylation 37:49 arg2 functional glycosylation site functional glycosylation site site Human cathepsin G lacking functional glycosylation site is proteolytically processed and targeted for storage in granules after transfection to the rat basophilic/mast cell line RBL or the murine myeloid cell line 32D. 21232091 6 32 part_of V1V4 1577:1580 arg1 the V1V4 gp120 env region V1V4 gp120 env the V1V4 gp120 env region PUBTATOR Site V1V4 gp120 env 155971 region Ten molecular clones 5 years apart, spanning the V1V4 gp120 env region (1,100 bp), were obtained. 21232091 6 81 part_of env 1588:1590 arg1 the V1V4 gp120 env region V1V4 gp120 env the V1V4 gp120 env region PUBTATOR Site V1V4 gp120 env 155971 region Ten molecular clones 5 years apart, spanning the V1V4 gp120 env region (1,100 bp), were obtained. 21232091 6 91 part_of gp120 1582:1586 arg1 the V1V4 gp120 env region V1V4 gp120 env the V1V4 gp120 env region PUBTATOR Site V1V4 gp120 env 155971 region Ten molecular clones 5 years apart, spanning the V1V4 gp120 env region (1,100 bp), were obtained. 10905635 4 20 gly N-glycosylation 664:678 arg2 the N-glycosylation site the N-glycosylation site site Inhibition of N-glycosylation by Tunicamycin or by point mutation of the N-glycosylation site resulted in the synthesis of a polypeptide of 40 kDa which lacked enzyme activity and was concentrated in the endoplasmic reticulum (ER). 27808502 2 70 gly glycopeptides 384:396 arg2 glycopeptides glycopeptides glycopeptides This approach is based on our discovery that the fragmentation of glycopeptides is glycan-structure dependent and glycans with core mannose structures overwhelmingly lead to the generation of Y1 ions when subjected to MS/MS in mass spectrometry. 8132208 4 28 part_of p56lck 551:556 arg1 the tyrosine kinase p56lck binding site p56lck the tyrosine kinase p56lck binding site PUBTATOR Site p56lck 3932 site Cysteine residues as well as the tyrosine kinase p56lck binding site are well conserved. 32211339 6 91 part_of GCD 913:915 arg1 both the MLD and GCD domains GCD both the MLD and GCD domains OGER Site GCD Q92947 domains We showed that the glycosylation sites in both the MLD and GCD domains contribute to the steric shielding. 32211339 6 95 part_of MLD 905:907 arg1 both the MLD and GCD domains MLD both the MLD and GCD domains OGER Site MLD O15121 domains We showed that the glycosylation sites in both the MLD and GCD domains contribute to the steric shielding. 11754244 4 29 part_of containing 1054:1063 arg1 fragments AND nonglycosylated residues fragments nonglycosylated residues residues The highly predictable fragmentation pathways of these fixed-charge phosphonium derivatives enable straightforward recognition of glycosylation site(s) based on the mass increment of +44 Da for originally glycosylated threonine compared to the mass of fragments containing nonglycosylated residues. 24150926 10 13 gly positions 1452:1460 arg1 197-199 197-199 positions 197 Riyadh strains were also found to contain N-glycosylation site in HA gene of both B/Vic and B/Yam lineages at positions 197-199 (NET) and 196-198 (NNK/DNK), respectively. 24150926 10 54 gly N-glycosylation 1384:1398 arg2 N-glycosylation site N-glycosylation site site Riyadh strains were also found to contain N-glycosylation site in HA gene of both B/Vic and B/Yam lineages at positions 197-199 (NET) and 196-198 (NNK/DNK), respectively. 1348029 7 21 gly glycosylation 950:962 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site All of the VH4 genes have a potential N-linked glycosylation site at Asn 60, and some genes encode a second site at Asn 52. 23751365 8 3 gly glycopeptides 1298:1310 arg2 glycopeptides glycopeptides glycopeptides In detection sensitivity assessment, glycopeptides within four orders of magnitude were identified after enrichment with XCharge SAX. 11303872 2 1 gly glycoprotein 416:427 arg1 a mucin-type glycoprotein a mucin-type glycoprotein Fterm glycoprotein A single GalNAc residue was incorporated at each glycosylation site using standard Fmoc-chemistry to achieve the first total synthesis of a mucin-type glycoprotein. 11303872 2 27 gly glycosylation 314:326 arg2 each glycosylation site each glycosylation site site A single GalNAc residue was incorporated at each glycosylation site using standard Fmoc-chemistry to achieve the first total synthesis of a mucin-type glycoprotein. 16227249 0 39 gly glycosylation 9:21 arg1 west nile virus envelope proteins west nile virus envelope proteins Fterm proteins N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity. 18955570 5 35 part_of GM-CSF-Ralpha 978:990 arg1 the cytokine binding domain GM-CSF-Ralpha the cytokine binding domain PUBTATOR Site GM-CSF-Ralpha 1438 domain The other, a point mutation in the paternal X chromosome allele encoding a G174R substitution, altered an N-linked glycosylation site within the cytokine binding domain and glycosylation of GM-CSF-Ralpha, severely reducing GM-CSF binding, receptor signaling, and GM-CSF-dependent functions in primary myeloid cells. 19008394 5 8 gly glycosylated 1009:1020 arg2 position E154 position E154 position Additional sera collected from horses infected with Murray Valley encephalitis virus (MVEV), which is similarly glycosylated at position E154 and exhibits high sequence identity to WNV NY99 in this region, also recognized the recombinant peptide. 1706753 4 5 gly N-glycosylation 1430:1444 arg2 a N-glycosylation site a N-glycosylation site site In addition, novel laboratory mutants were obtained containing substitutions in the HA1 subunit that had not been reported previously for H3 subtype viruses, either natural variants or laboratory mutants, at residues: HA1 62 Ile----Arg; HA1 165 Asn----Ser (resulting in the loss of a N-glycosylation site); and HA1 273 Pro----Leu. 22365690 4 62 gly glycopeptides 952:964 arg2 glycopeptides glycopeptides glycopeptides With four samples to be maximally analyzed in parallel, this workflow supports accurate identification and quantification of glycopeptides in a site-specific fashion. 8380463 0 66 gly glycoprotein 106:117 arg1 bovine herpesvirus 1 glycoprotein gIV bovine herpesvirus 1 glycoprotein gIV Fterm glycoprotein Role of N-linked glycans in antigenicity, processing, and cell surface expression of bovine herpesvirus 1 glycoprotein gIV. 28920453 1 35 gly Glycosylation 139:151 arg1 rhEPOs rhEPOs Cterm rhEPOs AIM: Glycosylation of recombinant human erythropoietins (rhEPOs) is significantly associated with drug's quality and potency. 28920453 1 35 gly Glycosylation 139:151 arg1 recombinant human erythropoietins recombinant human erythropoietins Cterm erythropoietins AIM: Glycosylation of recombinant human erythropoietins (rhEPOs) is significantly associated with drug's quality and potency. 15670775 7 51 gly N-glycosylation 894:908 arg2 the only putative N-glycosylation site the only putative N-glycosylation site site Analyses of the only putative N-glycosylation site by in vitro mutagenesis excluded the possibility of the contribution of N-glycosylation to this increase in molecular weight. 20506028 2 53 part_of containing 308:317 arg1 an N-terminal hydrophilic domain AND an N-linked glycosylation site site site ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein. 20506028 2 53 part_of containing 308:317 arg1 two domains AND an N-linked glycosylation site site site ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein. 20506028 2 53 part_of containing 308:317 arg1 two domains AND an N-linked glycosylation site site site ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein. 1388166 0 23 gly oligosaccharides 22:37 arg1 tissue factor pathway inhibitor tissue factor pathway inhibitor oligosaccharides PUBTATOR tissue factor pathway inhibitor 7035 The asparagine-linked oligosaccharides on tissue factor pathway inhibitor terminate with SO4-4GalNAc beta 1, 4GlcNAc beta 1,2 Mana alpha. 1388166 0 79 gly asparagine-linked 4:20 arg1 The asparagine-linked oligosaccharides asparagine The asparagine-linked oligosaccharides asparagine The asparagine-linked oligosaccharides on tissue factor pathway inhibitor terminate with SO4-4GalNAc beta 1, 4GlcNAc beta 1,2 Mana alpha. 17956937 4 91 gly fucosylated 887:897 arg1 fucosylated biantennary oligosaccharides fucosylated biantennary oligosaccharides The profiles of the PSA N-glycans from the free and complexed molecules were quite similar to each other and consisted of fucosylated biantennary oligosaccharides as the major class. 24721674 7 13 gly N-glycosites 1470:1481 arg2 82 N-glycosites 82 N-glycosites N-glycosites Furthermore, 177 glycopeptides representing 82 N-glycosites with both glycan composition and peptide sequence were identified by high energy collision dissociation. 24721674 7 83 gly glycopeptides 1440:1452 arg2 177 glycopeptides 177 glycopeptides glycopeptides Furthermore, 177 glycopeptides representing 82 N-glycosites with both glycan composition and peptide sequence were identified by high energy collision dissociation. 14759610 1 45 gly N-glycosylation 143:157 arg2 the Asn-Xaa-Ser/Thr(NXS/T) N-glycosylation site the Asn-Xaa-Ser/Thr(NXS/T) N-glycosylation site site We aimed to identify antibodies that can recognize the Asn-Xaa-Ser/Thr(NXS/T) N-glycosylation site that guides oligosaccharyltransferase (OT) activity. 22171062 6 79 gly disialylated 1309:1320 arg1 predominantly mono- and disialylated complex-type N-glycans predominantly mono- and disialylated complex-type N-glycans The N-linked glycans of both VV and HEK293-derived sG glycoproteins carried predominantly mono- and disialylated complex-type N-glycans and a smaller population of high mannose-type glycans. 22171062 6 87 gly glycoproteins 1263:1275 arg1 The N-linked glycans glycoproteins The N-linked glycans Fterm glycoproteins The N-linked glycans of both VV and HEK293-derived sG glycoproteins carried predominantly mono- and disialylated complex-type N-glycans and a smaller population of high mannose-type glycans. 29909010 0 59 gly glycosylation 18:30 arg2 a glycosylation site a glycosylation site site Introduction of a glycosylation site in the constant region decreases the aggregation of adalimumab Fab. 18524814 0 54 gly glycosylation 18:30 arg2 A single N-linked glycosylation site A single N-linked glycosylation site site A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice. 20506028 5 72 gly N-glycosylation 1046:1060 arg2 an N-glycosylation site an N-glycosylation site site Although domain 1 is predicted to be hydrophilic per se on the basis of its amino acid sequence, NG-hChM-I remains insoluble in aqueous solution as much as ΔN-hChM-I that lacks the N-terminal 37 amino acids containing an N-glycosylation site. 17823199 6 35 part_of -antitrypsin 1131:1142 arg1 all N-glycosylation sites alpha(1)-antitrypsin all N-glycosylation sites PUBTATOR Site alpha(1)-antitrypsin 5265 sites In healthy control samples, we determined 98-100% occupancy for all N-glycosylation sites of transferrin and alpha(1)-antitrypsin. 17823199 6 45 part_of transferrin 1107:1117 arg1 all N-glycosylation sites transferrin all N-glycosylation sites PUBTATOR Site transferrin 7018 sites In healthy control samples, we determined 98-100% occupancy for all N-glycosylation sites of transferrin and alpha(1)-antitrypsin. 9070436 1 17 gly glycosylated 224:235 arg1 the glycosylated human CD2 adhesion domain the glycosylated human CD2 adhesion domain domain We have used 15N NMR relaxation experiments to probe, for the glycosylated human CD2 adhesion domain, the overall molecular motion, as well as very fast nanosecond-picosecond (ns-ps) and slow millisecond-microsecond (ms-microsecond) internal motions. 12626422 7 67 gly underglycosylated 1379:1395 arg1 alpha1-antitrypsin alpha1-antitrypsin PUBTATOR alpha1-antitrypsin 5265 This showed that the asparagine residues are preferentially glycosylated in the order 46>247>83 in the mature underglycosylated forms of alpha1-antitrypsin found in plasma. 12626422 7 77 gly glycosylated 1329:1340 arg1 the asparagine residues asparagine residues asparagine residues This showed that the asparagine residues are preferentially glycosylated in the order 46>247>83 in the mature underglycosylated forms of alpha1-antitrypsin found in plasma. 11728339 3 6 gly glycosylation 492:504 arg2 a novel glycosylation site a novel glycosylation site site NZM2410/NZW Cr2 exhibits a single nucleotide polymorphism that introduces a novel glycosylation site, resulting in higher molecular weight proteins. 11428934 0 79 part_of glycoprotein 71:82 arg1 a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope myelin oligodendrocyte glycoprotein a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope PUBTATOR Site myelin oligodendrocyte glycoprotein 4340 epitope Conformational analysis of a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope able to detect antibody response in multiple sclerosis. 24612669 6 126 gly residue 1398:1404 arg1 the N-terminal tag-sequence region cysteine residue the N-terminal tag-sequence region cysteine residue The system was further applied to the production of a mutant, which contains an additional reactive cysteine residue in the N-terminal tag-sequence region. 11439087 11 8 gly N-glycosylation 1428:1442 arg1 sBST-1 sBST-1 Cterm sBST-1 683 We conclude that N-glycosylation of sBST-1 facilitates the folding of the nascent polypeptide chain into a conformation that is conductive for intracellular transport and enzymic activity. 10989127 1 76 part_of hyaluronidase 112:124 arg1 conserved hyaluronidase potential N-glycosylation sites hyaluronidase conserved hyaluronidase potential N-glycosylation sites Fterm Site hyaluronidase sites Evidence for conserved hyaluronidase potential N-glycosylation sites in different mammalian species. 21647803 8 8 gly N-glycosylation 1393:1407 arg2 one N-glycosylation site one N-glycosylation site site Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 21 gly glycans 1476:1482 arg1 bovine lactoferrin lactoferrin glycans PUBTATOR lactoferrin 280846 Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 24 gly N-glycosylation 1246:1260 arg2 the single N-glycosylation site the single N-glycosylation site site Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 27 gly O-glycosylation 1492:1506 arg2 five O-glycosylation sites five O-glycosylation sites sites Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 46 gly N-glycosylation 1321:1335 arg2 five N-glycosylation sites five N-glycosylation sites sites Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 50 gly glycans 1378:1384 arg1 bovine lactoferrin lactoferrin glycans PUBTATOR lactoferrin 280846 Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 54 gly site 1409:1412 arg1 at least 13 distinct glycans site at least 13 distinct glycans site Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 54 gly site 1409:1412 arg1 59 distinct glycans site 59 distinct glycans site Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 54 gly site 1409:1412 arg1 20 distinct glycans site 20 distinct glycans site Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 54 gly site 1409:1412 arg1 13 distinct glycans site 13 distinct glycans site Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 87 gly glycans 1305:1311 arg1 bovine lactoferrin lactoferrin glycans PUBTATOR lactoferrin 280846 Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 88 gly glycans 1169:1175 arg1 bovine lactoferrin lactoferrin glycans PUBTATOR lactoferrin 280846 Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 93 gly sites 1337:1341 arg1 20 distinct glycans sites 20 distinct glycans sites Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 93 gly sites 1337:1341 arg1 59 distinct glycans sites 59 distinct glycans sites Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 93 gly sites 1337:1341 arg1 at least 13 distinct glycans sites at least 13 distinct glycans sites Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 21647803 8 93 gly sites 1337:1341 arg1 13 distinct glycans sites 13 distinct glycans sites Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein. 1703533 3 101 gly asparagine-linked 680:696 arg1 all the asparagine-linked oligosaccharides asparagine all the asparagine-linked oligosaccharides asparagine The high-mannose oligosaccharides Man5GlcNAc2, Man6GlcNAc2, Man7GlcNAc2, Man8GlcNAc2, and Man9GlcNAc2 were present in the ratios 2:49:19:24:6 and accounted for all the asparagine-linked oligosaccharides released from Art v II by PNGase F. 11680875 2 26 gly glycoprotein 427:438 arg1 a glycoprotein a glycoprotein Fterm glycoprotein To appreciate the structure of a glycoprotein fully, to understand the roles for the attached oligosaccharides and to monitor disease associated changes it is necessary to visualise the sugars as well as the protein. 9116048 5 39 gly C5a 805:807 arg1 a 6 histidine tag C5a a 6 histidine tag PUBTATOR C5a 362119 Recombinant rat C5a with a 6 histidine tag at the N-terminus was expressed in bacteria, purified and renatured. 9116048 5 46 gly histidine 818:826 arg1 a 6 histidine tag histidine a 6 histidine tag histidine Recombinant rat C5a with a 6 histidine tag at the N-terminus was expressed in bacteria, purified and renatured. 12388686 6 86 gly glycosylation 1477:1489 arg1 EV70 binding EV70 binding Cterm EV70 Treatment of cells with metabolic inhibitors of glycosylation excluded a role for the N-linked oligosaccharides of glycoproteins but suggested that O-linked glycosylation is important for EV70 binding. 12388686 6 55 gly glycoproteins 1435:1447 arg1 the N-linked oligosaccharides glycoproteins the N-linked oligosaccharides Fterm glycoproteins Treatment of cells with metabolic inhibitors of glycosylation excluded a role for the N-linked oligosaccharides of glycoproteins but suggested that O-linked glycosylation is important for EV70 binding. 19534833 2 43 gly glycoprotein 466:477 arg1 the surface glycoprotein S. Using biochemical and immunofluorescence analyses we found that M consists of a short glycosylated N-terminal ectodomain, three transmembrane segments and a long, immunogenic C-terminal endodomain the surface glycoprotein S. Using biochemical and immunofluorescence analyses we found that M consists of a short glycosylated N-terminal ectodomain, three transmembrane segments and a long, immunogenic C-terminal endodomain Fterm glycoprotein S The membrane topology of SARS-CoV M and the functional significance of its N-glycosylation are not completely understood as is its interaction with the surface glycoprotein S. Using biochemical and immunofluorescence analyses we found that M consists of a short glycosylated N-terminal ectodomain, three transmembrane segments and a long, immunogenic C-terminal endodomain. 19534833 2 68 gly glycosylated 568:579 arg1 a short glycosylated N-terminal ectodomain a short glycosylated N-terminal ectodomain ectodomain The membrane topology of SARS-CoV M and the functional significance of its N-glycosylation are not completely understood as is its interaction with the surface glycoprotein S. Using biochemical and immunofluorescence analyses we found that M consists of a short glycosylated N-terminal ectodomain, three transmembrane segments and a long, immunogenic C-terminal endodomain. 16567801 5 34 gly UPIb 1326:1329 arg1 most terminally exposed glycans UPIb most terminally exposed glycans PUBTATOR UPIb 22268 In contrast, our results indicate that most terminally exposed glycans of mouse UPIb are non-mannose residues, thus explaining the failure of FimH to bind to this UPIb. 16567801 5 34 gly UPIb 1326:1329 arg1 non-mannose residues UPIb non-mannose residues PUBTATOR UPIb 22268 In contrast, our results indicate that most terminally exposed glycans of mouse UPIb are non-mannose residues, thus explaining the failure of FimH to bind to this UPIb. 21637915 0 27 part_of emmprin 10:16 arg1 Synthetic emmprin peptides emmprin Synthetic emmprin peptides PUBTATOR Site emmprin 682 peptides Synthetic emmprin peptides inhibit tumor cell-fibroblast interaction-stimulated upregulation of MMP-2 and tumor cell invasion. 7533854 8 27 gly glycosylation 1966:1978 arg2 the highly conserved glycosylation site the highly conserved glycosylation site site Mutation of glycosylation site 160 destroyed the C108G epitope but increased the fraction of the molecules that presented the conformational epitopes, while mutation of the highly conserved glycosylation site at position 156 greatly diminished the expression of the conformational epitopes and increased expression of the C108G epitope. 7533854 8 131 gly glycosylation 1788:1800 arg2 glycosylation site 160 glycosylation site 160 site Mutation of glycosylation site 160 destroyed the C108G epitope but increased the fraction of the molecules that presented the conformational epitopes, while mutation of the highly conserved glycosylation site at position 156 greatly diminished the expression of the conformational epitopes and increased expression of the C108G epitope. 11333905 1 93 part_of site 453:456 arg1 the gp120 subunit gp120 subunit site PUBTATOR Site gp120 subunit 155971 site A CD4-independent version of the X4 human immunodeficiency virus type 1 (HIV-1) HXBc2 envelope (Env) protein, termed 8x, mediates infection of CD4-negative, CXCR4-positive cells, binds directly to CXCR4 in the absence of CD4 due to constitutive exposure of a conserved coreceptor binding site in the gp120 subunit, and is more sensitive to antibody-mediated neutralization. 11152692 4 19 gly leucine-rich 462:473 arg1 10 leucine-rich repeats leucine 10 leucine-rich repeats leucine It contains a putative propeptide, 4 amino-terminal cysteines, 10 leucine-rich repeats, and 2 C-terminal cysteines. 23668542 1 62 gly glycoproteins 157:169 arg1 glycoproteins glycoproteins Fterm glycoproteins Therapeutic efficacy of glycoproteins is affected by many factors, including molecular size and net charge; both are influenced by the presence and composition of glycan structures. 11944983 1 68 part_of Ca2+-binding 171:182 arg1 Ca2+-binding motifs Ca2 Ca2+-binding motifs OGER Site Ca2 P00920 motifs S100 proteins form a growing subfamily of proteins related by Ca2+-binding motifs to the Efhand Ca2+-binding protein superfamily. 9857985 0 56 gly glycoproteins 55:67 arg1 hemagglutinin-esterase and spike glycoproteins hemagglutinin-esterase and spike glycoproteins Fterm glycoproteins Primary structures of hemagglutinin-esterase and spike glycoproteins of murine coronavirus DVIM. 23265247 7 4 gly glycosylation 1210:1222 arg1 amino acid residues amino acid residues residues in These results imply that there is an antigenic drift within clade 7 viruses, and insertion and glycosylation of amino acid residues in site A of the HA protein may contribute to the antigenic variation. 11535135 7 23 gly glycosylation 1034:1046 arg2 a conserved potential glycosylation site a conserved potential glycosylation site site Several non-mammalian features are notable, and include a conserved potential glycosylation site in chicken and fish, and an insertion at the boundary of exons 20 and 21 in fish. 17097085 7 38 gly N-glycosylation 1062:1076 arg2 a N-glycosylation site a N-glycosylation site site Sequence analysis showed that CP12 has a N-terminal signal peptide, a transmembrane region, a N-glycosylation site, a casein kinase II phosphorylation site and two N-myristoylation sites. 17097085 7 38 gly N-glycosylation 1062:1076 arg2 a N-terminal signal peptide a N-terminal signal peptide peptide Sequence analysis showed that CP12 has a N-terminal signal peptide, a transmembrane region, a N-glycosylation site, a casein kinase II phosphorylation site and two N-myristoylation sites. 9030779 3 67 gly N-glycosylation 471:485 arg2 Each N-glycosylation site Each N-glycosylation site site Each N-glycosylation site was modified by site-directed mutagenesis and subsequently expressed in COS-1 cells. 12466483 4 1 gly used 877:880 arg2 Asn residues 169 and 170 Asn residues 20 and 21 and Asn residues 169 and 170 Asn residues 20 and 21 and Asn residues 169 and 170 Comparison of electrophoretic mobility between the wt and mutant HA proteins showed that both Asn residues 20 and 21 and Asn residues 169 and 170 could be used for glycosylation. 12466483 4 1 gly used 877:880 arg2 21 Asn residues 20 and 21 and Asn residues 169 and 170 Asn residues 20 and 21 and Asn residues 169 and 170 Comparison of electrophoretic mobility between the wt and mutant HA proteins showed that both Asn residues 20 and 21 and Asn residues 169 and 170 could be used for glycosylation. 12466483 4 1 gly used 877:880 arg2 21 Asn residues 20 and 21 and Asn residues 169 and 170 Asn residues 20 and 21 and Asn residues 169 and 170 Comparison of electrophoretic mobility between the wt and mutant HA proteins showed that both Asn residues 20 and 21 and Asn residues 169 and 170 could be used for glycosylation. 10940860 0 78 gly glycosylation 45:57 arg1 Asn-184 tissue-type plasminogen activator Asn-184 OGER tissue-type plasminogen activator P00750 Asn-184 Multiple cell culture factors can affect the glycosylation of Asn-184 in CHO-produced tissue-type plasminogen activator. 7980452 7 8 gly glycosylation 1229:1241 arg2 the intact glycosylation site the intact glycosylation site site The formation of biologically active dimers was more efficient for IFN-gamma polypeptides that had the intact glycosylation site at Asn-25 as compared with the other two mutant forms of IFN-gamma. 25479596 6 70 part_of protein 1245:1251 arg1 positions 102-103 and 351-352 protein positions 102-103 and 351-352 Fterm Site protein positions 102 Strains isolated in South America differ from vaccine in two predicted B-cell epitope regions present at positions 102-103 and 351-352 of the NA protein. 11038011 1 64 gly glycopeptide 273:284 arg2 three polypeptides three polypeptides polypeptides The vasopressin gene encodes three polypeptides besides the signal peptide: vasopressin, neurophysin II (neurophysin), and the carboxy-terminal glycopeptide (glycopeptide). 11038011 1 86 gly polypeptides 164:175 arg1 glycopeptide glycopeptide glycopeptide The vasopressin gene encodes three polypeptides besides the signal peptide: vasopressin, neurophysin II (neurophysin), and the carboxy-terminal glycopeptide (glycopeptide). 11038011 1 64 gly glycopeptide 273:284 arg2 glycopeptide glycopeptide glycopeptide The vasopressin gene encodes three polypeptides besides the signal peptide: vasopressin, neurophysin II (neurophysin), and the carboxy-terminal glycopeptide (glycopeptide). 11038011 1 68 gly glycopeptide 287:298 arg2 glycopeptide glycopeptide glycopeptide The vasopressin gene encodes three polypeptides besides the signal peptide: vasopressin, neurophysin II (neurophysin), and the carboxy-terminal glycopeptide (glycopeptide). 30541852 7 40 part_of receptor 1158:1165 arg1 the extracellular domains receptor the extracellular domains Fterm Site receptor domains The ecotropic tropism exhibited by this envelope is due to the presence or absence of an N-linked glycosylation site in the first extracellular loop as well as the specific amino acid sequence of the extracellular domains of the receptor. 22078945 9 38 part_of protein 1130:1136 arg1 the functional positions protein the functional positions Fterm Site protein positions 265aa to 486aa and 510aa to 679aa may be the two approciate fragments to construct the plasmids, which would be prepared for the future hybrid experiments to study the functional positions of the protein and the interactions between TTV and its hosts. 12364335 2 76 gly terminus 413:420 arg1 a lectin-like (QXW)(3) repeat sequence terminus a lectin-like (QXW)(3) repeat sequence terminus These enzymes all contain a lectin-like (QXW)(3) repeat sequence at the C terminus that consists of three tandem repeats (alpha, beta, and gamma). 12364335 2 0 gly contain 357:363 arg1 These enzymes AND a lectin-like (QXW)(3) repeat sequence These enzymes a lectin-like (QXW)(3) repeat sequence Fterm enzymes These enzymes all contain a lectin-like (QXW)(3) repeat sequence at the C terminus that consists of three tandem repeats (alpha, beta, and gamma). 12460944 0 74 gly O-glycosylation 0:14 arg1 EGF repeats EGF repeats O-glycosylation of EGF repeats: identification and initial characterization of a UDP-glucose: protein O-glucosyltransferase. 27127844 4 10 gly N-glycosylated 537:550 arg1 the a3 isoform the a3 isoform Fterm isoform The subunit has conserved, predicted N-glycosylation sites, and the a3 isoform has been directly shown to be N-glycosylated. 27127844 4 70 gly N-glycosylation 465:479 arg2 conserved, predicted N-glycosylation sites conserved, predicted N-glycosylation sites sites The subunit has conserved, predicted N-glycosylation sites, and the a3 isoform has been directly shown to be N-glycosylated. 10099545 3 50 gly glycosylation 494:506 arg2 glycosylation site occupancy glycosylation site occupancy site To investigate the relationship between metabolism and glycosylation site occupancy, we studied the glycosylation of recombinant human interferon-gamma (IFN-gamma) produced in continuous culture of Chinese hamster ovary cells. 10099545 3 97 gly glycosylation 539:551 arg1 IFN-gamma IFN-gamma PUBTATOR IFN-gamma 3458 To investigate the relationship between metabolism and glycosylation site occupancy, we studied the glycosylation of recombinant human interferon-gamma (IFN-gamma) produced in continuous culture of Chinese hamster ovary cells. 10099545 3 97 gly glycosylation 539:551 arg1 recombinant human interferon-gamma recombinant human interferon-gamma PUBTATOR interferon-gamma P01579 To investigate the relationship between metabolism and glycosylation site occupancy, we studied the glycosylation of recombinant human interferon-gamma (IFN-gamma) produced in continuous culture of Chinese hamster ovary cells. 6433976 3 23 part_of CNBr 526:529 arg1 All seven CNBr fragments CNBr All seven CNBr fragments Cterm Site CNBr fragments All seven CNBr fragments were purified and found to be compatible with the cDNA-derived amino acid sequence [Pennica, D., Holmes, W. E., Kohr, W. J., Harkins, R. N., Vehar, G. A., Ward, C. A., Bennett, W. F., Ylverton, E., Seeburg, P. H., Heynecker, H. L., Goeddel, D. V., & Collen, D. (1983) Nature (London) 301, 214-221]. 21232091 8 88 gly N-glycosylation 1801:1815 arg2 N-glycosylation site frequency N-glycosylation site frequency site Over 5 years, N-glycosylation site frequency significantly increased (p < 0.0001). 24497285 8 1 gly glycoproteins 1402:1414 arg1 glycoproteins glycoproteins Fterm glycoproteins Enrichment of glycoproteins rather than glycopeptides allowed detection of both deglycosylated and nonglycosylated versions of each peptide, and thereby robust measurement of site-specific occupancy at 21 asparagines. 24497285 8 67 gly glycopeptides 1428:1440 arg2 glycopeptides glycopeptides glycopeptides Enrichment of glycoproteins rather than glycopeptides allowed detection of both deglycosylated and nonglycosylated versions of each peptide, and thereby robust measurement of site-specific occupancy at 21 asparagines. 29755357 6 33 gly non-glycosylated 1066:1081 arg1 the non-glycosylated LCN2 variants the non-glycosylated LCN2 variants PUBTATOR LCN2 variants 3934 Moreover, both the glycosylated and the non-glycosylated LCN2 variants are equally targeted to exosomes, demonstrating that this post-translational modification is not necessary for proper trafficking of LCN2 into these membranous extracellular vesicles. 22855498 5 78 part_of E1E2 582:585 arg1 E1E2 glycoprotein gene sequences E1E2 E1E2 glycoprotein gene sequences Cterm Site E1E2 sequences E1E2 glycoprotein gene sequences in the donor inoculum and recipient mice were determined following single-genome amplification (SGA). 22855498 5 79 part_of glycoprotein 587:598 arg1 E1E2 glycoprotein gene sequences glycoprotein E1E2 glycoprotein gene sequences Fterm Site glycoprotein sequences E1E2 glycoprotein gene sequences in the donor inoculum and recipient mice were determined following single-genome amplification (SGA). 29607359 3 7 gly glycosylation 801:813 arg2 NSS160-162 glycosylation site NSS160-162 glycosylation site site Despite these findings, we found N161S substitution in all four H3N2 influenza stains resulting in the gain of NSS160-162 glycosylation site. 25636227 8 0 gly O-glycosylation 1247:1261 arg2 most previously known O-glycosylation sites most previously known O-glycosylation sites sites The workflow indicated superior sensitivity by not only covering most previously known O-glycosylation sites but also discovering several novel sites. 29992770 11 55 gly N-glycopeptides 1559:1573 arg2 These N-glycopeptides These N-glycopeptides N-glycopeptides These N-glycopeptides are the lead candidates for validation as future diagnostic modalities of OSCC as early as stage I. 10998266 2 73 gly released 535:542 arg1 recombinant human EPO AND N-linked oligosaccharides recombinant human EPO N-linked oligosaccharides PUBTATOR EPO 2056 N-linked oligosaccharides were released from recombinant human EPO expressed in Chinese hamster ovary cells enzymatically and reduced with NaBH(4). 27356208 6 49 gly N-glycosylation 1109:1123 arg2 new N-glycosylation site new N-glycosylation site site With this aim, the first 45 residues of mature hFIX were explored to find out suitable positions for introducing either Asn or Ser/Thr residues, to create new N-glycosylation site(s). 29226084 4 15 gly N-glycosylation 814:828 arg2 disrupted consensus N-glycosylation site disrupted consensus N-glycosylation site site The N-glycosylation inhibitor tunicamycin reduced the apparent molecular weight of immunoreactivity associated with myc-tagged GPR61 by 1-2 kDa, which was comparable to the evident molecular weight of the myc-tagged N12S GPR61 mutant with disrupted consensus N-glycosylation site. 2477364 13 109 part_of alpha 1929:1933 arg1 both glycosylation sites dimer alpha both glycosylation sites Fterm Site dimer alpha sites By contrast, the majority of the oligosaccharides at both glycosylation sites of the dimer alpha are bound to ConA. 12765790 5 21 gly glycosylation 940:952 arg2 glycosylation site 2 glycosylation site 2 site Non-PSA/HNK1-glycans were assigned to glycosylation site 2, whereas PSA-N-glycans of bovine NCAM had been already previously shown to be restricted to glycosylation sites 5 and 6 (Glycobiology 12 (2002) 47). 12765790 5 43 gly NCAM 994:997 arg1 PSA-N-glycans NCAM PSA-N-glycans PUBTATOR NCAM 17967 Non-PSA/HNK1-glycans were assigned to glycosylation site 2, whereas PSA-N-glycans of bovine NCAM had been already previously shown to be restricted to glycosylation sites 5 and 6 (Glycobiology 12 (2002) 47). 12765790 5 60 gly glycosylation 1053:1065 arg2 glycosylation sites 5 and 6 glycosylation sites 5 and 6 sites Non-PSA/HNK1-glycans were assigned to glycosylation site 2, whereas PSA-N-glycans of bovine NCAM had been already previously shown to be restricted to glycosylation sites 5 and 6 (Glycobiology 12 (2002) 47). 22573318 1 83 part_of hydroxylase 464:474 arg1 generated MC3T3-E1 (MC)-derived clones stably suppressing lysyl hydroxylase 3 (LH3) (short hairpin (Sh) clones) and demonstrated the LH3 function as glucosyltransferase in type I collagen (Sricholpech, M., Perdivara, I., Nagaoka, H., Yokoyama, M., Tomer, K. B., and Yamauchi, M. (2011) Lysyl hydroxylase 3 glucosylates galactosylhydroxylysine residues 2011) Lysyl hydroxylase 3 generated MC3T3-E1 (MC)-derived clones stably suppressing lysyl hydroxylase 3 (LH3) (short hairpin (Sh) clones) and demonstrated the LH3 function as glucosyltransferase in type I collagen (Sricholpech, M., Perdivara, I., Nagaoka, H., Yokoyama, M., Tomer, K. B., and Yamauchi, M. (2011) Lysyl hydroxylase 3 glucosylates galactosylhydroxylysine residues PUBTATOR AminoAcid 2011) Lysyl hydroxylase 3 8985 residues in Recently, by employing the short hairpin RNA technology, we have generated MC3T3-E1 (MC)-derived clones stably suppressing lysyl hydroxylase 3 (LH3) (short hairpin (Sh) clones) and demonstrated the LH3 function as glucosyltransferase in type I collagen (Sricholpech, M., Perdivara, I., Nagaoka, H., Yokoyama, M., Tomer, K. B., and Yamauchi, M. (2011) Lysyl hydroxylase 3 glucosylates galactosylhydroxylysine residues in type I collagen in osteoblast culture. 9242452 4 113 gly attached 941:948 arg1 this position AND glycans this position glycans position The side chain of the amino acid in position 72 points away from the MHC binding site when the Hb(67-76) peptide is bound to E(k), so the assumption was that this was also the case for glycans attached to this position. 19740991 8 100 gly glycosylation 941:953 arg2 a putative glycosylation site a putative glycosylation site site A 5-amino-acid insertion found only in genotype 3a and a putative glycosylation site is contained within HVR575. 9600940 6 66 gly glycoproteins 814:826 arg1 The glycoproteins The glycoproteins Fterm glycoproteins The glycoproteins were partially purified and assayed for their ability to inhibit binding of sperm to ovulated eggs in vitro. 2350186 5 24 gly glycosylation 907:919 arg2 the C-terminal glycosylation site the C-terminal glycosylation site site In fact, the presence of this deletion resulted in more complete glycosylation at the C-terminal glycosylation site. 2350186 5 6 gly glycosylation 875:887 arg1 the C-terminal glycosylation site site site In fact, the presence of this deletion resulted in more complete glycosylation at the C-terminal glycosylation site. 7875221 4 50 part_of C3 906:907 arg1 Xenopus C3 fragments C3 Xenopus C3 fragments Cterm Site C3 fragments The deduced amino acid sequence showed that the C3 convertase and factor I cleavage sites (Arg-Ser) are conserved in Xenopus C3 and protein sequencing of Xenopus C3 fragments fixed on zymosan during complement activation demonstrated that Xenopus C3 is indeed cleaved by C3 convertase and factor I at these sites. 7875221 4 64 part_of factor 810:815 arg1 the C3 convertase and factor I cleavage sites factor I the C3 convertase and factor I cleavage sites Cterm Site factor I sites The deduced amino acid sequence showed that the C3 convertase and factor I cleavage sites (Arg-Ser) are conserved in Xenopus C3 and protein sequencing of Xenopus C3 fragments fixed on zymosan during complement activation demonstrated that Xenopus C3 is indeed cleaved by C3 convertase and factor I at these sites. 7875221 4 99 part_of C3 792:793 arg1 Arg-Ser C3 Arg-Ser Cterm Site C3 Arg-Ser The deduced amino acid sequence showed that the C3 convertase and factor I cleavage sites (Arg-Ser) are conserved in Xenopus C3 and protein sequencing of Xenopus C3 fragments fixed on zymosan during complement activation demonstrated that Xenopus C3 is indeed cleaved by C3 convertase and factor I at these sites. 30063822 5 31 part_of carries 936:942 arg1 a protein AND a single N-glycosylation site a protein a single N-glycosylation site Fterm Site protein site To illustrate the procedure, we have made an application to a two-domain construct of Robo1, a protein that carries a single N-glycosylation site in its N-terminal domains. 30063822 5 31 part_of carries 936:942 arg1 Robo1 AND a single N-glycosylation site Robo1 a single N-glycosylation site PUBTATOR Site Robo1 Q9Y6N7 site To illustrate the procedure, we have made an application to a two-domain construct of Robo1, a protein that carries a single N-glycosylation site in its N-terminal domains. 15616123 10 75 gly occupied 1816:1823 arg2 the nearest N-glycosylation site the nearest N-glycosylation site site Asn3384, the nearest N-glycosylation site to the LDL-receptor binding site (amino acids 3359-3369), was occupied by a variety of oligosaccharides, including high-mannose, hybrid, and complex types. 15616123 10 75 gly occupied 1816:1823 arg2 Asn3384 Asn3384 Asn3384 Asn3384, the nearest N-glycosylation site to the LDL-receptor binding site (amino acids 3359-3369), was occupied by a variety of oligosaccharides, including high-mannose, hybrid, and complex types. 15616123 10 95 gly N-glycosylation 1733:1747 arg2 the nearest N-glycosylation site the nearest N-glycosylation site site Asn3384, the nearest N-glycosylation site to the LDL-receptor binding site (amino acids 3359-3369), was occupied by a variety of oligosaccharides, including high-mannose, hybrid, and complex types. 15616123 10 95 gly N-glycosylation 1733:1747 arg2 Asn3384 Asn3384 Asn3384 Asn3384, the nearest N-glycosylation site to the LDL-receptor binding site (amino acids 3359-3369), was occupied by a variety of oligosaccharides, including high-mannose, hybrid, and complex types. 23776650 6 46 gly N-glycosylation 765:779 arg2 an N-glycosylation site an N-glycosylation site site Since DCIR has an N-glycosylation site inside its carbohydrate recognition domain (CRD), we investigated the effect of this glycan in ligand recognition. 16542136 3 23 gly glycosylation 736:748 arg2 a single potential N-linked glycosylation site a single potential N-linked glycosylation site site The rapid amplification of cDNA ends (RACE) method was used to obtain a cDNA of bovine IL-17 (BoIL-17) containing a 462-bp open reading frame (ORF) encoding a protein of 153 amino acids (aa) with a molecular mass of 17.2 kDa, a 23-residue NH(2)-terminal signal peptide, a single potential N-linked glycosylation site, and 6 cysteine residues. 16542136 3 23 gly glycosylation 736:748 arg2 a 23-residue NH(2)-terminal signal peptide a 23-residue NH(2)-terminal signal peptide peptide The rapid amplification of cDNA ends (RACE) method was used to obtain a cDNA of bovine IL-17 (BoIL-17) containing a 462-bp open reading frame (ORF) encoding a protein of 153 amino acids (aa) with a molecular mass of 17.2 kDa, a 23-residue NH(2)-terminal signal peptide, a single potential N-linked glycosylation site, and 6 cysteine residues. 9169007 11 8 part_of heparin-binding 2142:2156 arg1 the putative heparin-binding site heparin the putative heparin-binding site Fterm Site heparin site These results indicate that all carbohydrate chains of recombinant antithrombin adversely affect heparin-binding affinity to an extent that correlates with their relative proximity to the putative heparin-binding site in antithrombin. 9169007 11 105 part_of site 2158:2161 arg1 antithrombin antithrombin site PUBTATOR Site antithrombin 462 site These results indicate that all carbohydrate chains of recombinant antithrombin adversely affect heparin-binding affinity to an extent that correlates with their relative proximity to the putative heparin-binding site in antithrombin. 30257863 5 54 gly glycosylation 777:789 arg1 Kir7.1 Kir7.1 PUBTATOR Kir7.1 3769 Using Western blotting analysis, we observed that multiple GPCRs tested caused a striking reduction in the complex glycosylation of Kir7.1. 26940363 10 84 gly glycoproteins 1974:1986 arg1 glycoproteins glycoproteins Fterm glycoproteins The integration of site-specific glycosylation data obtained from large-scale glycoproteomics and introduction of cell line studies will improve the analysis of glycoproteins and entire glycomes. 12097564 11 88 gly glycosylation 1927:1939 arg2 the downstream glycosylation site the downstream glycosylation site site This is supported by the observation that mutations of basic residues in hr2 or of the downstream glycosylation site, which both impair Tva-binding to EnvA, have similar effects on the binding of mc8C5. 20602265 2 86 gly glycoprotein 451:462 arg1 the surface glycoprotein hemagglutinin the surface glycoprotein hemagglutinin Fterm glycoprotein In order to uncover clues about the determinants for virulence and pathogenicity of the virus, we characterized the functional modules of the surface glycoprotein hemagglutinin (HA), the most important protein in molecular epidemiology and pathogenesis of influenza viruses. 18623533 2 63 part_of IFN-gamma 501:509 arg1 each glycosylation site IFN-gamma each glycosylation site PUBTATOR Site IFN-gamma 3458 site In addition to cell growth, metabolite, and productivity data, a detailed analysis of the carbohydrate structures attached to each glycosylation site of IFN-gamma was achieved using matrix-assisted laser desorption mass spectrometry (MALDI-MS) in combination with exoglycosidase array sequencing. 10441114 4 70 part_of collagen 666:673 arg1 noncollagenous domain 1 collagen XVIII noncollagenous domain 1 PUBTATOR Site collagen XVIII 80781 domain lacking the last and final three residues of the noncollagenous domain 1 (NC-1) of collagen XVIII, respectively. 30541852 7 66 gly glycosylation 1027:1039 arg2 an N-linked glycosylation site an N-linked glycosylation site site The ecotropic tropism exhibited by this envelope is due to the presence or absence of an N-linked glycosylation site in the first extracellular loop as well as the specific amino acid sequence of the extracellular domains of the receptor. 23341449 6 12 gly polysialylated 998:1011 arg1 the polysialylated N-glycans the polysialylated N-glycans Specifically, two basic OCAM Ig5 residues (Lys and Arg) found near asparagines equivalent to those carrying the polysialylated N-glycans in NCAM substantially decrease or eliminate polysialylation when used to replace the smaller and more neutral residues (Ser and Asn) in analogous positions in NCAM Ig5. 23341449 6 17 gly residues 1133:1140 arg1 the smaller and more neutral residues the smaller and more neutral residues residues Specifically, two basic OCAM Ig5 residues (Lys and Arg) found near asparagines equivalent to those carrying the polysialylated N-glycans in NCAM substantially decrease or eliminate polysialylation when used to replace the smaller and more neutral residues (Ser and Asn) in analogous positions in NCAM Ig5. 23341449 6 64 gly N-glycans 1013:1021 arg1 NCAM NCAM N-glycans PUBTATOR NCAM 4684 Specifically, two basic OCAM Ig5 residues (Lys and Arg) found near asparagines equivalent to those carrying the polysialylated N-glycans in NCAM substantially decrease or eliminate polysialylation when used to replace the smaller and more neutral residues (Ser and Asn) in analogous positions in NCAM Ig5. 23341449 6 17 gly residues 1133:1140 arg1 Ser Ser and Asn Ser and Asn Specifically, two basic OCAM Ig5 residues (Lys and Arg) found near asparagines equivalent to those carrying the polysialylated N-glycans in NCAM substantially decrease or eliminate polysialylation when used to replace the smaller and more neutral residues (Ser and Asn) in analogous positions in NCAM Ig5. 24501222 4 51 part_of HRG 654:656 arg1 an HRG fragment HRG an HRG fragment PUBTATOR Site HRG P04196 fragment It is thought that an HRG fragment containing the HRR, released via plasmin-mediated cleavage, acts as a negative regulator of angiogenesis in vivo. 26598643 4 23 gly O-glycosylation 579:593 arg1 human blood plasma glycoproteins human blood plasma glycoproteins Fterm glycoproteins Here, we report on the site-specific O-glycosylation analysis of human blood plasma glycoproteins. 26598643 4 31 gly glycoproteins 626:638 arg1 human blood plasma glycoproteins human blood plasma glycoproteins Fterm glycoproteins Here, we report on the site-specific O-glycosylation analysis of human blood plasma glycoproteins. 15009203 1 9 gly glycoproteins 225:237 arg1 several naturally occurring glycoproteins several naturally occurring glycoproteins Fterm glycoproteins GM-CSF is one of several naturally occurring glycoproteins that regulate leukocyte production, migration and function. 2952720 3 3 part_of domain 575:580 arg1 one N-glycosylation site domain one N-glycosylation site site The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain. 2952720 3 3 part_of domain 575:580 arg1 a centrally located glutamic acid residue domain a centrally located glutamic acid residue glutamic acid residue The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain. 2952720 3 7 part_of peptide 536:542 arg1 one N-glycosylation site peptide one N-glycosylation site site The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain. 2952720 3 7 part_of peptide 536:542 arg1 a centrally located glutamic acid residue peptide a centrally located glutamic acid residue glutamic acid residue The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain. 2952720 3 12 part_of domain 716:721 arg1 one N-glycosylation site domain one N-glycosylation site site The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain. 2952720 3 12 part_of domain 716:721 arg1 a centrally located glutamic acid residue domain a centrally located glutamic acid residue glutamic acid residue The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain. 2952720 3 97 part_of domain 627:632 arg1 one N-glycosylation site domain one N-glycosylation site site The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain. 2952720 3 97 part_of domain 627:632 arg1 a centrally located glutamic acid residue domain a centrally located glutamic acid residue glutamic acid residue The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain. 17823199 4 34 gly N-glycosylation 794:808 arg2 N-glycosylation site occupancy N-glycosylation site occupancy site To quantify the extent of underglycosylation in healthy control and in CDG samples, we developed a quantitative method of N-glycosylation site occupancy based on multiple reaction monitoring LC-MS/MS. 21647803 10 11 gly glycopeptides 1688:1700 arg2 non-specifically cleaved glycopeptides non-specifically cleaved glycopeptides glycopeptides The integration of nano-LC with MS and MS/MS of non-specifically cleaved glycopeptides allows quantitative, isomer-sensitive, and site-specific glycoprotein analysis. 21647803 10 20 gly glycoprotein 1759:1770 arg1 quantitative, isomer-sensitive, and site-specific glycoprotein analysis quantitative, isomer-sensitive, and site-specific glycoprotein analysis Fterm glycoprotein The integration of nano-LC with MS and MS/MS of non-specifically cleaved glycopeptides allows quantitative, isomer-sensitive, and site-specific glycoprotein analysis. 30295034 3 60 gly glycoprotein 636:647 arg1 the glycoprotein species the glycoprotein species Fterm glycoprotein We find numerous glycan species extending the mass range of the glycoprotein species from 35.0 to 38.5 kDa. 1456441 1 6 gly N-glycosylation 211:225 arg2 N-glycosylation site N-glycosylation site site This report describes the N-glycosylation site mapping of human serotransferrin (h-STF). 23319596 10 10 gly hLOXL2 1578:1583 arg1 the N-glycan at Asn-644 hLOXL2 the N-glycan at Asn-644 PUBTATOR hLOXL2 4017 These results suggest that the N-glycan at Asn-644 of hLOXL2 enhances the solubility and stability of the LOX catalytic domain. 22674977 4 78 part_of site 677:680 arg1 the NL219 hemagglutinin hemagglutinin site Fterm Site hemagglutinin site A mutation which introduces a potential glycosylation site at Asn123 in the NL219 hemagglutinin was postulated to contribute to the pathogenic properties of this virus. 11361003 11 20 gly TfR 2050:2052 arg1 the N-linked carbohydrates TfR the N-linked carbohydrates PUBTATOR TfR 7037 Since the receptor did not exhibit detectable changes in the CD spectrum of the deglycosylated receptor, it can be concluded that the N-linked carbohydrates of the mature, fully processed TfR are not essential for transferrin binding and conformational stability. 11361003 11 56 gly deglycosylated 1942:1955 arg1 the deglycosylated receptor the deglycosylated receptor Fterm receptor Since the receptor did not exhibit detectable changes in the CD spectrum of the deglycosylated receptor, it can be concluded that the N-linked carbohydrates of the mature, fully processed TfR are not essential for transferrin binding and conformational stability. 17496250 10 79 part_of found 1301:1305 arg2 IGFBP-2 AND An in vivo phosphorylation site IGFBP-2 An in vivo phosphorylation site PUBTATOR Site IGFBP-2 3485 site An in vivo phosphorylation site was also found in IGFBP-2 at an analogous position, Ser(106). 8301235 6 17 gly utilized 951:958 arg2 all four putative sites all four putative sites sites The relative sizes of these site-specific mutants indicate that all four putative sites are utilized for glycosylation in CHO cells. 26683050 10 111 gly GlcNAc 1538:1543 arg1 CSF CSF GlcNAc OGER CSF Third, hypothesis-free regression analysis revealed that alterations of afucosylation and bisecting GlcNAc in CSF from MS cases peaked 2-3 months after the last relapse. 26683050 10 45 gly afucosylation 1510:1522 arg1 CSF CSF afucosylation OGER CSF Third, hypothesis-free regression analysis revealed that alterations of afucosylation and bisecting GlcNAc in CSF from MS cases peaked 2-3 months after the last relapse. 10364275 4 65 part_of gp120 897:901 arg1 the V1, V2, and V3 regions gp120 the V1, V2, and V3 regions PUBTATOR Site gp120 3700 regions Of interest are changes that resulted in the removal, repositioning, and addition of potential glycosylation sites within the V1, V2, and V3 regions of envelope gp120. 26977294 8 48 gly fucosylated/afucosylated 1313:1336 arg1 the fucosylated/afucosylated Fc fragments the fucosylated/afucosylated Fc fragments fragments After few thousand steps of energy minimization on the resulting 3D mAb models, minimized final models were used to quantify interactions occurring between Fcγ RIIIA and the fucosylated/afucosylated Fc fragments. 2168975 0 10 gly glycoprotein 60:71 arg1 the vesicular stomatitis virus glycoprotein the vesicular stomatitis virus glycoprotein Fterm glycoprotein A fusion-defective mutant of the vesicular stomatitis virus glycoprotein. 11011146 4 25 gly N-glycosylation 614:628 arg2 an artificial N-glycosylation site an artificial N-glycosylation site site In this study, we showed that the synaptotagmin family is a type I membrane protein (N(lumen)/C(cytoplasm)) by introducing an artificial N-glycosylation site at the N-terminal domain, and systematically examined all the possible combinations of hetero-oligomerization among synaptotagmin family proteins (Syts I-XI). 12883358 9 21 gly O-deglycosylation 1559:1575 arg1 these serine residues these serine residues serine residues Mutation of these serine residues, as well as an extensive metabolic O-deglycosylation, strongly impaired spontaneous CD44 shedding. 12460944 3 32 part_of sites 454:458 arg1 these proteins proteins sites Fterm Site proteins sites Comparison of the glycosylation sites on these proteins revealed a putative consensus sequence for O-glucose modification: C(1)XSXPC(2), where C(1) and C(2) are the first and second conserved cysteines of the EGF repeat. 7780197 0 45 gly glycosylation 13:25 arg1 human transferrin receptor transferrin receptor site PUBTATOR transferrin receptor 7037 site The critical glycosylation site of human transferrin receptor contains a high-mannose oligosaccharide. 7780197 0 65 gly contains 62:69 arg1 human transferrin receptor AND a high-mannose oligosaccharide transferrin receptor site a high-mannose oligosaccharide PUBTATOR transferrin receptor 7037 site The critical glycosylation site of human transferrin receptor contains a high-mannose oligosaccharide. 16883437 9 34 gly glycosylation 1327:1339 arg2 One potential glycosylation site One potential glycosylation site site One potential glycosylation site, on all these studied envelope glycoproteins, was predicted. 16883437 9 50 gly glycoproteins 1377:1389 arg1 all these studied envelope glycoproteins all these studied envelope glycoproteins Fterm glycoproteins One potential glycosylation site, on all these studied envelope glycoproteins, was predicted. 9767600 2 24 gly glycosylation 410:422 arg2 no glycosylation site no glycosylation site site We could study the antigenic properties of an E-coli synthesized fusion protein prepared with the cloned gene since no glycosylation site was expected from the deduced amino acid sequence. 21270153 7 3 gly glycosylation 1191:1203 arg1 the receptors the receptors Fterm receptors N-linked glycosylation of the receptors was not found to mediate resistance of receptor-expressing BHK cells to GALV or XMRV, as shown by tunicamycin treatment and mutation of the specific glycosylation site of the PiT1 receptor. 21270153 7 60 gly glycosylation 1371:1383 arg1 the PiT1 receptor PiT1 receptor site PUBTATOR PiT1 receptor 18736 site N-linked glycosylation of the receptors was not found to mediate resistance of receptor-expressing BHK cells to GALV or XMRV, as shown by tunicamycin treatment and mutation of the specific glycosylation site of the PiT1 receptor. 8663003 7 16 gly deglycosylate 1065:1077 arg1 the Rh glycoprotein the Rh glycoprotein Fterm glycoprotein Bromelain treatment was found to deglycosylate the Rh glycoprotein. 8663003 7 83 gly glycoprotein 1086:1097 arg1 the Rh glycoprotein the Rh glycoprotein Fterm glycoprotein Bromelain treatment was found to deglycosylate the Rh glycoprotein. 26634432 6 35 gly glycosylation 638:650 arg2 the glycosylation site S site S(89) site S(89) In this study, a mutant DMP1 mouse model was developed in which the glycosylation site S(89) was substituted with G(89) (S89G-DMP1). 26634432 6 35 gly glycosylation 638:650 arg2 89 site S(89) site S(89) In this study, a mutant DMP1 mouse model was developed in which the glycosylation site S(89) was substituted with G(89) (S89G-DMP1). 26634432 6 35 gly glycosylation 638:650 arg2 89 site S(89) site S(89) In this study, a mutant DMP1 mouse model was developed in which the glycosylation site S(89) was substituted with G(89) (S89G-DMP1). 1726785 2 98 part_of receptor 509:516 arg1 the extracellular domain TSH receptor the extracellular domain PUBTATOR Site TSH receptor 7253 domain Deletion mutants of the extracellular domain of the rat TSH receptor as well as point mutations of potential N-linked glycosylation sites were created. 19534833 1 23 gly glycosylated 98:109 arg1 The glycosylated membrane protein The glycosylated membrane protein Fterm protein M The glycosylated membrane protein M of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) is the main structural component of the virion and mediates assembly and budding of viral particles. 1970443 13 152 gly glycosylation 2138:2150 arg2 One potential glycosylation site One potential glycosylation site site One potential glycosylation site was identified in the SR-11 G2 coding sequences and was conserved among Hantaan, SR-11 and Hällnäs viruses. 9254646 3 18 part_of TAP-transported 714:728 arg1 TAP-transported peptides TAP TAP-transported peptides OGER Site TAP O75369 peptides This indicates that glycosylation does not interfere with TAP-transported peptides, and therefore that cytosolic peptides derived from SNP must have been exposed to the glycosylation machinery of the endoplasmic reticulum (ER) before their existence in the cytosol. 15128311 11 9 gly glycoprotein 1411:1422 arg1 the glycoprotein the glycoprotein Fterm glycoprotein In vivo toxicity of the glycoprotein to the cricket Gryllus assimilis was twofold lower than that of CX3. 8380463 11 64 gly glycosylation 1577:1589 arg2 N-linked glycosylation sites N-linked glycosylation sites sites Our results demonstrate that absence of N-linked glycans at one (residue 102) or both (residues 41 and 102) utilized N-linked glycosylation sites alters the conformation but does not prevent processing and transport of gIV to the cell surface. 1426517 2 8 gly O-glycosylation 229:243 arg2 O-glycosylation site O-glycosylation site site The "code-sequence" of N-glycosylation site(s), the amino acids located around O-glycosylation site(s), the sequence motifs of several kinases, the sequence motifs of--sulfation, amidation, isoprenylation, myristoylation, palmitoylation and N-acetylation, Aspartic and Asparagine hydroxylation-site, gamma-carboxyglutamate domain, phosphopantetheine attachment site etc. are extensively listed, compared to those reported by "PROSITE" Computer Screen Center and discussed. 1426517 2 29 gly N-glycosylation 173:187 arg2 N-glycosylation site N-glycosylation site site The "code-sequence" of N-glycosylation site(s), the amino acids located around O-glycosylation site(s), the sequence motifs of several kinases, the sequence motifs of--sulfation, amidation, isoprenylation, myristoylation, palmitoylation and N-acetylation, Aspartic and Asparagine hydroxylation-site, gamma-carboxyglutamate domain, phosphopantetheine attachment site etc. are extensively listed, compared to those reported by "PROSITE" Computer Screen Center and discussed. 1426517 2 29 gly N-glycosylation 173:187 arg2 gamma-carboxyglutamate domain gamma-carboxyglutamate domain domain The "code-sequence" of N-glycosylation site(s), the amino acids located around O-glycosylation site(s), the sequence motifs of several kinases, the sequence motifs of--sulfation, amidation, isoprenylation, myristoylation, palmitoylation and N-acetylation, Aspartic and Asparagine hydroxylation-site, gamma-carboxyglutamate domain, phosphopantetheine attachment site etc. are extensively listed, compared to those reported by "PROSITE" Computer Screen Center and discussed. 1426517 2 8 gly O-glycosylation 229:243 arg2 the sequence motifs motifs motifs The "code-sequence" of N-glycosylation site(s), the amino acids located around O-glycosylation site(s), the sequence motifs of several kinases, the sequence motifs of--sulfation, amidation, isoprenylation, myristoylation, palmitoylation and N-acetylation, Aspartic and Asparagine hydroxylation-site, gamma-carboxyglutamate domain, phosphopantetheine attachment site etc. are extensively listed, compared to those reported by "PROSITE" Computer Screen Center and discussed. 1426517 2 33 gly acids 208:212 arg1 Asparagine hydroxylation-site Aspartic and Asparagine hydroxylation-site Aspartic and Asparagine hydroxylation-site The "code-sequence" of N-glycosylation site(s), the amino acids located around O-glycosylation site(s), the sequence motifs of several kinases, the sequence motifs of--sulfation, amidation, isoprenylation, myristoylation, palmitoylation and N-acetylation, Aspartic and Asparagine hydroxylation-site, gamma-carboxyglutamate domain, phosphopantetheine attachment site etc. are extensively listed, compared to those reported by "PROSITE" Computer Screen Center and discussed. 2788224 3 49 part_of contains 615:622 arg1 the protein AND a potential glycosylation site the protein a potential glycosylation site Fterm Site protein site In contrast, our results suggest that vpu is not glycosylated, even though the protein contains a potential glycosylation site. 8289366 8 23 gly position 1197:1204 arg1 a glycan moiety position 229, a glycan moiety position 229, Thus, our studies suggest that without a glycan moiety at position 229, the valine residue at 214 is no longer restrictive for Mo-MuLV infection. 9140729 6 100 gly region 1102:1107 arg1 the carbohydrates region the carbohydrates region These data indicate the carbohydrates of mouse SK2 VH region do not significantly influence antigen-binding activity. 26873173 0 39 gly N-glycosylation 12:26 arg1 human haptoglobin human haptoglobin PUBTATOR haptoglobin 3240 Insights on N-glycosylation of human haptoglobin and its association with cancers. 22577028 1 7 gly glycosylation 191:203 arg1 recombinant hemagglutinin (HA) proteins recombinant hemagglutinin (HA) proteins Fterm proteins The main objective of this study was to characterize the N-linked glycosylation profiles of recombinant hemagglutinin (HA) proteins expressed in either insect or plant hosts, and to develop a mass spectrometry based workflow that can be used in quality control to assess batch-to-batch reproducibility for recombinant HA glycosylation. 11333905 6 52 gly glycosylation 1460:1472 arg2 the glycosylation site the glycosylation site site However, loss of the glycosylation site alone was sufficient to render Env neutralization sensitive, providing additional evidence that carbohydrate structures shield important neutralization determinants. 20943674 11 27 gly N-glycosylation 1597:1611 arg1 rhLF rhLF OGER rhLF P02788 The different N-glycosylation profile of rhLF when compared with that of hLF is in consistent with the widely held view that glycosylation is species- and tissue/cell-specific. 28186137 5 24 gly glycoproteins 547:559 arg1 myelin glycoproteins myelin glycoproteins Fterm glycoproteins However, the roles of glycans on myelin glycoproteins remain poorly understood. 17095532 0 74 gly glycosylated 52:63 arg1 the glycosylated orange allergen Cit s 1 the glycosylated orange allergen Cit s 1 PUBTATOR Cit s 1 11113 Molecular and immunological characterization of the glycosylated orange allergen Cit s 1. 8325864 5 85 gly occupied 781:788 arg2 The sequon at Asn-462 The sequon at Asn-462 Asn-462 The sequon at Asn-462 was never occupied. 21940909 5 32 gly deglycosylated 1203:1216 arg1 deglycosylated alpha-1-acid glycoprotein deglycosylated alpha-1-acid glycoprotein Fterm glycoprotein The effect of glycan steric hindrance on tryptic digestion was first demonstrated using alpha-1-acid glycoprotein (AGP) as a model compound versus deglycosylated alpha-1-acid glycoprotein. 21940909 5 39 gly glycoprotein 1231:1242 arg1 deglycosylated alpha-1-acid glycoprotein deglycosylated alpha-1-acid glycoprotein Fterm glycoprotein The effect of glycan steric hindrance on tryptic digestion was first demonstrated using alpha-1-acid glycoprotein (AGP) as a model compound versus deglycosylated alpha-1-acid glycoprotein. 21940909 5 66 gly glycoprotein 1157:1168 arg1 alpha-1-acid glycoprotein alpha-1-acid glycoprotein Fterm glycoprotein The effect of glycan steric hindrance on tryptic digestion was first demonstrated using alpha-1-acid glycoprotein (AGP) as a model compound versus deglycosylated alpha-1-acid glycoprotein. 9311148 1 33 gly heterogeneity 146:158 arg1 human urinary erythropoietin human urinary erythropoietin PUBTATOR erythropoietin 2056 The site-specific glycan heterogeneity of human urinary erythropoietin was investigated by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). 9311148 1 63 gly erythropoietin 177:190 arg1 The site-specific glycan heterogeneity erythropoietin The site-specific glycan heterogeneity PUBTATOR erythropoietin 2056 The site-specific glycan heterogeneity of human urinary erythropoietin was investigated by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). 10207016 6 35 gly O-glycosylated 1378:1391 arg1 M protein M protein domain OGER M protein P54296 domain In addition, the pre-S2 domain of M protein, but not that of L protein, was found to be partially O-glycosylated by a Gal(beta1-3)GalNAcalpha-, Neu5Ac(alpha2-3)Gal(beta1-3)GalNAcalpha-, or GalNAcalpha-residue. 10207016 6 35 gly O-glycosylated 1378:1391 arg1 L protein protein domain Fterm protein domain In addition, the pre-S2 domain of M protein, but not that of L protein, was found to be partially O-glycosylated by a Gal(beta1-3)GalNAcalpha-, Neu5Ac(alpha2-3)Gal(beta1-3)GalNAcalpha-, or GalNAcalpha-residue. 22279061 0 37 gly SREC-I 13:18 arg1 N-glycans SREC-I N-glycans OGER SREC-I Q14162 N-glycans of SREC-I (scavenger receptor expressed by endothelial cells): essential role for ligand binding, trafficking and stability. 7753050 4 21 part_of position 725:732 arg1 human CD9 CD9 position PUBTATOR Site CD9 928 position Although feline CD9 appears most homologous to human CD9, it has two important features in common with bovine and murine CD9: the presence of a histidine residue at position 192 which is absent from the corresponding position (194) in human CD9; and the absence of two asparagine residues which are found at positions 51 and 52 of human CD9. 7753050 4 85 part_of CD9 845:847 arg1 positions 51 and 52 CD9 positions 51 and 52 PUBTATOR Site CD9 928 positions 51 and 52 Although feline CD9 appears most homologous to human CD9, it has two important features in common with bovine and murine CD9: the presence of a histidine residue at position 192 which is absent from the corresponding position (194) in human CD9; and the absence of two asparagine residues which are found at positions 51 and 52 of human CD9. 1370483 5 54 gly N-glycosylation 757:771 arg2 one possible N-glycosylation site one possible N-glycosylation site site The collagenous domain contains one possible N-glycosylation site. 12970363 6 50 gly glycosylation 1017:1029 arg2 both extracellular N-linked glycosylation sites both extracellular N-linked glycosylation sites sites Two NX(S/T) motifs in TRPC6 were mutated (Asn to Gln) by in vitro mutagenesis to delete one or both extracellular N-linked glycosylation sites. 20573835 0 7 part_of glycoprotein 105:116 arg1 A single asparagine-linked glycosylation site glycoprotein A single asparagine-linked glycosylation site Fterm Site glycoprotein site A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. 8797097 1 65 part_of containing 145:154 arg1 an alpha subunit AND a glycosylation site an alpha subunit a glycosylation site Fterm Site subunit site Inhibin-A is a glycoprotein composed of an alpha subunit containing a glycosylation site and a beta A subunit, whereas activin-A is a homodimer of two inhibin beta A subunits. 8144579 4 6 part_of PCR1 821:824 arg1 The amino acid sequences PCR1 The amino acid sequences PUBTATOR Site PCR1 17155 sequences The amino acid sequences of PCR1 and PCR2 were 88 and 65% identical with the corresponding sequence of the rabbit enzyme, respectively. 8144579 4 11 part_of PCR2 830:833 arg1 The amino acid sequences PCR2 The amino acid sequences PUBTATOR Site PCR2 17156 sequences The amino acid sequences of PCR1 and PCR2 were 88 and 65% identical with the corresponding sequence of the rabbit enzyme, respectively. 8144579 4 31 part_of enzyme 907:912 arg1 the corresponding sequence enzyme the corresponding sequence Fterm Site enzyme sequence The amino acid sequences of PCR1 and PCR2 were 88 and 65% identical with the corresponding sequence of the rabbit enzyme, respectively. 17011210 1 101 gly glycoprotein 252:263 arg1 Human Fas ligand Human Fas ligand PUBTATOR Human Fas ligand 356 Human Fas ligand is a medically important membrane glycoprotein that induces the apoptosis of harmful cells. 17011210 1 101 gly glycoprotein 252:263 arg1 a medically important membrane glycoprotein a medically important membrane glycoprotein Fterm glycoprotein Human Fas ligand is a medically important membrane glycoprotein that induces the apoptosis of harmful cells. 27038555 9 42 gly N-glycosylation 1276:1290 arg2 N-glycosylation sites N-glycosylation sites sites Amino acid positions 212 and 214 of N-glycosylation sites, which are known to be critical determinants of receptor-binding specificity, were found to be subject to positive selection. 10585855 5 29 gly N-glycosylation 770:784 arg1 Asn-642 Asn-642 Asn-642 Furthermore, N-glycosylation of Asn-642 might facilitate the membrane integration of span 7. 31637569 6 1 gly glycopeptide 1334:1345 arg2 software assisted glycopeptide data analyses software assisted glycopeptide data analyses glycopeptide A better understanding how glycopeptide physico-chemical properties influence fragmentation will help optimizing fragmentation conditions and generate better data, which will facilitate software assisted glycopeptide data analyses. 31637569 6 84 gly glycopeptide 1157:1168 arg2 glycopeptide physico-chemical properties glycopeptide physico-chemical properties glycopeptide A better understanding how glycopeptide physico-chemical properties influence fragmentation will help optimizing fragmentation conditions and generate better data, which will facilitate software assisted glycopeptide data analyses. 1331083 0 15 part_of sites 64:68 arg1 the lysosomal enzyme cathepsin D cathepsin D sites PUBTATOR Site cathepsin D 1509 sites Phosphorylation of Asn-linked oligosaccharides located at novel sites on the lysosomal enzyme cathepsin D. 28336547 2 46 gly residues 392:399 arg1 N50 N50 N50, N406, N439, N510, N515, and N532 We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532). 28336547 2 36 gly N50 402:404 arg1 N532 N50, N406, N439, N510, N515, and N532 N50, N406, N439, N510, N515, and N532 We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532). 28336547 2 36 gly N50 402:404 arg1 N510 N50, N406, N439, N510, N515, and N532 N50, N406, N439, N510, N515, and N532 We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532). 28336547 2 36 gly N50 402:404 arg1 N439 N50, N406, N439, N510, N515, and N532 N50, N406, N439, N510, N515, and N532 We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532). 28336547 2 36 gly N50 402:404 arg1 N510 N50, N406, N439, N510, N515, and N532 N50, N406, N439, N510, N515, and N532 We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532). 28336547 2 36 gly N50 402:404 arg1 N439 N50, N406, N439, N510, N515, and N532 N50, N406, N439, N510, N515, and N532 We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532). 28336547 2 36 gly N50 402:404 arg1 N439 N50, N406, N439, N510, N515, and N532 N50, N406, N439, N510, N515, and N532 We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532). 28336547 2 90 gly glycosylated 361:372 arg1 the proton-coupled oligopeptide transporter 1 proton-coupled oligopeptide transporter 1 asparagine residues PUBTATOR proton-coupled oligopeptide transporter 1 56643 asparagine residues We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532). 28336547 2 90 gly glycosylated 361:372 arg1 PEPT1 PEPT1 asparagine residues PUBTATOR PEPT1 56643 asparagine residues We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532). 26062906 7 3 part_of contains 1048:1055 arg1 three mutant MHBs proteins AND a N-linked glycosylation site three mutant MHBs proteins a N-linked glycosylation site Fterm Site proteins site In addition, each of three mutant MHBs proteins contains a N-linked glycosylation site (N-X-S/T), relocated to position 5 (MQWQNTTFHQ), 6 (MQWQSNTSHQ) or 7 (MQWQSTNFTQ) in pre-S2 domain. 20188224 3 80 part_of granulin 481:488 arg1 granulin domains granulin granulin domains PUBTATOR Site granulin 2896 domains PGRN is a glycoprotein, containing five N-glycosylation consensus sequons, three of which fall within granulin domains. 20188224 3 65 part_of containing 403:412 arg1 PGRN AND five N-glycosylation consensus sequons PGRN five N-glycosylation consensus sequons PUBTATOR PGRN 2896 PGRN is a glycoprotein, containing five N-glycosylation consensus sequons, three of which fall within granulin domains. 20188224 3 65 part_of containing 403:412 arg1 a glycoprotein AND five N-glycosylation consensus sequons a glycoprotein five N-glycosylation consensus sequons Fterm glycoprotein PGRN is a glycoprotein, containing five N-glycosylation consensus sequons, three of which fall within granulin domains. 29596458 13 42 gly N-glycopeptides 1801:1815 arg2 high-confidence N-glycopeptides high-confidence N-glycopeptides N-glycopeptides We propose high-confidence N-glycopeptides which have the power to separate the bloodstream infections from blood culture negative febrile patients and shed light on host response during bacteremia. 7609029 6 26 gly glycosylation 1017:1029 arg2 a potential N-linked glycosylation site a potential N-linked glycosylation site site All the SI viruses lost a potential N-linked glycosylation site in V3 which is highly conserved among previously described subtype E HIV-1 isolates from asymptomatic patients from Thailand. 28694069 1 12 gly glycosylation 247:259 arg2 asparagine 297 asparagine 297 asparagine 297 The binding of human IgG1 to human Fc gamma receptors (hFcγRs) is highly sensitive to the presence of a single N-linked glycosylation site at asparagine 297 of the Fc, with deglycosylation resulting in a complete loss of hFcγR binding. 28694069 1 12 gly glycosylation 247:259 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site The binding of human IgG1 to human Fc gamma receptors (hFcγRs) is highly sensitive to the presence of a single N-linked glycosylation site at asparagine 297 of the Fc, with deglycosylation resulting in a complete loss of hFcγR binding. 16372382 11 34 gly observed 1916:1923 arg2 both glycosylation sites AND Minor tetraantennary complex structures both glycosylation sites Minor tetraantennary complex structures sites Minor tetraantennary complex structures were also observed on both glycosylation sites. 16372382 11 38 gly glycosylation 1933:1945 arg2 both glycosylation sites both glycosylation sites sites Minor tetraantennary complex structures were also observed on both glycosylation sites. 7922031 8 21 gly glycoprotein 1289:1300 arg1 the glycoprotein hormone chains the glycoprotein hormone chains Fterm glycoprotein CONCLUSIONS: Structural and sequence comparisons indicate an evolutionary homology, albeit remote, between the glycoprotein hormone chains and other cystine-knot proteins, notably platelet-derived growth factor. 28970103 5 1 gly O-glycosylated 980:993 arg1 singly O-glycosylated peptides singly O-glycosylated peptides peptides We demonstrated that multiple enzyme digestion or multidimensional separation can make sample preparation more efficient and that EThcD is not only suitable for the identification of singly O-glycosylated peptides (50.3%) but also doubly (21.2%) and triply (28.5%) O-glycosylated peptides. 28970103 5 152 gly O-glycosylated 1055:1068 arg1 doubly (21.2%) and triply (28.5%) O-glycosylated peptides doubly (21.2%) and triply (28.5%) O-glycosylated peptides peptides We demonstrated that multiple enzyme digestion or multidimensional separation can make sample preparation more efficient and that EThcD is not only suitable for the identification of singly O-glycosylated peptides (50.3%) but also doubly (21.2%) and triply (28.5%) O-glycosylated peptides. 2666404 7 33 gly N-glycoprotein 1132:1145 arg1 an N-glycoprotein an N-glycoprotein Fterm N-glycoprotein There is indirect evidence that the transporter is an N-glycoprotein. 7533854 1 108 part_of gp120s 318:323 arg1 the V1/V2 domain LAI-related gp120s the V1/V2 domain Cterm Site LAI-related gp120s 3700 domain A number of monoclonal antibodies (MAbs) with various levels of neutralizing activity that recognize epitopes in the V1/V2 domain of LAI-related gp120s have been described. 7533854 1 69 part_of epitopes 274:281 arg1 LAI-related gp120s LAI-related gp120s domain Cterm LAI-related gp120s 3700 domain A number of monoclonal antibodies (MAbs) with various levels of neutralizing activity that recognize epitopes in the V1/V2 domain of LAI-related gp120s have been described. 8442916 9 2 part_of CD4-binding 1322:1332 arg1 the CD4-binding domain CD4 the CD4-binding domain OGER Site CD4 P01730 domain Interestingly, the viruses of this subtype are characterized by an additional potential N-glycosylation site C-terminal to the CD4-binding domain. 8144579 7 7 gly N-glycosylation 1415:1429 arg2 a single N-glycosylation site a single N-glycosylation site site It contains an open reading frame which encodes a type II membrane protein of 73 kDa with a cytoplasmic region of about 35 amino acids, a Ca2+ binding consensus sequence, and a single N-glycosylation site. 1697854 4 5 gly glycosylation 599:611 arg2 one possible asparagine-linked glycosylation site one possible asparagine-linked glycosylation site site Both clones contained one possible asparagine-linked glycosylation site. 22677411 7 31 gly glycopeptide 1010:1021 arg2 glycopeptide glycopeptide glycopeptide Identification of glycopeptide structures based on MS/MS analysis has a false positive rate of 1%. 11916258 6 71 gly glycosylation 752:764 arg2 a common glycosylation site a common glycosylation site site There is a common glycosylation site at the fourth asparagine residue of N-terminus. 11916258 6 71 gly glycosylation 752:764 arg2 the fourth asparagine residue the fourth asparagine residue asparagine residue There is a common glycosylation site at the fourth asparagine residue of N-terminus. 7504082 2 45 gly residue 456:462 arg1 the protein protein residue Fterm protein One antibody, 2C9, has equivalent affinity for both the 5.6S (amphiphilic) and 11S (hydrophilic) enzyme forms; the other, 4E7, recognizes only the amphiphilic form and has been shown previously to require an N-linked oligosaccharide residue on the protein. 21829533 7 64 gly glycosylation 1427:1439 arg2 glycosylation sites glycosylation sites sites Importantly, the significant role of positional alteration of glycosylation sites in the host adaptation of influenza virus was elucidated. 10480910 4 37 gly N-glycosylation 765:779 arg2 a single N-glycosylation site a single N-glycosylation site site Both receptor forms displayed numerous glycosylation states, reflecting differential usage of a single N-glycosylation site as well as extensive O-glycosylations. 1383332 6 80 gly glycosylation 918:930 arg2 The single N-linked glycosylation site The single N-linked glycosylation site site The single N-linked glycosylation site was confirmed at a location between SCR1 and SCR2, and the multiple O-linked oligosaccharides were localized to the S/T region. 11251288 3 67 gly glycosylated 654:665 arg1 homogeneously glycosylated proteins homogeneously glycosylated proteins Fterm proteins Hence, there is clearly a need for synthetic methods that give access to natural and unnatural homogeneously glycosylated proteins. 11069304 3 53 gly N-glycosylation 705:719 arg2 its only potential N-glycosylation site its only potential N-glycosylation site site Both the wild-type and a mutant hSlo protein lacking its only potential N-glycosylation site were efficiently transported to the cell surface and concentrated in the apical domain even when they were overexpressed to levels 200- to 300-fold higher than the density of intrinsic Slo channels. 21698149 5 56 part_of env 860:862 arg1 the env V1-C4 env the env V1-C4 PUBTATOR SiteSequence env 155971 V1-C4 METHODOLOGY/PRINCIPAL FINDINGS: Quasispecies sampling was performed on the env V1-C4 of HIV-1B strains soon after transmission to heterosexual Trinidadians in a cohort of seroconverters. 8702538 10 23 gly glycosylation 1644:1656 arg2 a single N-linked glycosylation site a single N-linked glycosylation site site These observations suggest that a single N-linked glycosylation site located at a similar position in the CD22 and CD33 glycoproteins is critical for regulating ligand recognition by both receptors. 8702538 10 29 gly glycoproteins 1714:1726 arg1 the CD22 and CD33 glycoproteins the CD22 and CD33 glycoproteins PUBTATOR CD33 glycoproteins 945 These observations suggest that a single N-linked glycosylation site located at a similar position in the CD22 and CD33 glycoproteins is critical for regulating ligand recognition by both receptors. 11471056 7 44 gly glycosylation 1130:1142 arg2 a glycosylation site a glycosylation site site Canine ATP6H shows a conserved potential metal binding site, CSVCC, and a glycosylation site, NET. 1334131 7 61 gly glycosylation 1076:1088 arg2 an additional glycosylation site an additional glycosylation site site Predicted amino acid sequences of the VP7 gene showed marked epitope variation from other porcine type G3 isolates with amino acid substitutions and an additional glycosylation site at residue 238. 1334131 7 61 gly glycosylation 1076:1088 arg2 residue 238 residue 238 residue 238 Predicted amino acid sequences of the VP7 gene showed marked epitope variation from other porcine type G3 isolates with amino acid substitutions and an additional glycosylation site at residue 238. 12706379 8 92 part_of receptors 1141:1149 arg1 The amino-acid sequences receptors The amino-acid sequences Fterm Site receptors sequences The amino-acid sequences of the 14 TSH receptors were similar. 25451932 6 59 gly N-glycosylation 790:804 arg1 Asn-80 Asn-80 Asn-80 By Western analysis of corin proteins in cell lysate and conditioned medium from transfected HEK293 cells and HL-1 cardiomyocytes, we found that N-glycosylation at Asn-80 inhibited corin shedding in the juxtamembrane domain. 23001782 7 33 gly N-glycoforms 1251:1262 arg1 Asn(351) N-glycoforms Asn(351) N-glycoforms Asn(351) N-Glycoforms of Asn(367) were slightly more branched and core fucosylated than Asn(351) N-glycoforms due probably to a more surface-exposed glycosylation site. 23001782 7 102 gly glycosylation 1303:1315 arg2 a more surface-exposed glycosylation site a more surface-exposed glycosylation site site N-Glycoforms of Asn(367) were slightly more branched and core fucosylated than Asn(351) N-glycoforms due probably to a more surface-exposed glycosylation site. 16331960 5 0 gly nonglycosylated 1028:1042 arg1 rhTf-NG rhTf-NG OGER rhTf P12346 The observed peptide fragmentation profile showed that the C-lobe of recombinant full-length nonglycosylated transferrin (rhTf-NG) appeared to be preferentially cleaved, while cleavage of the N-lobe was restricted to the N-terminal and link sequence regions. 16331960 5 0 gly nonglycosylated 1028:1042 arg1 recombinant full-length nonglycosylated transferrin recombinant full-length nonglycosylated transferrin PUBTATOR transferrin 7018 The observed peptide fragmentation profile showed that the C-lobe of recombinant full-length nonglycosylated transferrin (rhTf-NG) appeared to be preferentially cleaved, while cleavage of the N-lobe was restricted to the N-terminal and link sequence regions. 16331960 5 54 gly N-terminal 1156:1165 arg1 regions regions sequence regions The observed peptide fragmentation profile showed that the C-lobe of recombinant full-length nonglycosylated transferrin (rhTf-NG) appeared to be preferentially cleaved, while cleavage of the N-lobe was restricted to the N-terminal and link sequence regions. 16873272 7 1 gly N-glycosylation 1377:1391 arg2 various N-glycosylation site mutants various N-glycosylation site mutants site Interestingly, analysis of various N-glycosylation site mutants suggests an important role of carbohydrate chain attachment to N391, either for direct interaction with the receptor or for correct folding of the PFV Env RBD. 7615551 5 9 gly N-glycosylation 825:839 arg2 one consensus N-glycosylation site one consensus N-glycosylation site site KS43 and KS32 encoded proteins with multiple hydrophobic domains, one consensus N-glycosylation site, and predicted molecular masses of 65 and 58 kDa, respectively. 3476950 0 32 part_of extracellular 59:71 arg1 sequence extracellular superoxide dismutase sequence PUBTATOR Site extracellular superoxide dismutase 6649 sequence Isolation and sequence of complementary DNA encoding human extracellular superoxide dismutase. 3476950 0 70 part_of superoxide 73:82 arg1 sequence extracellular superoxide dismutase sequence PUBTATOR Site extracellular superoxide dismutase 6649 sequence Isolation and sequence of complementary DNA encoding human extracellular superoxide dismutase. 23541464 8 19 gly O-glycosylation 1014:1028 arg2 no O-glycosylation sites no O-glycosylation sites sites Analysis identified 1 potential N-glycosylation site, 3 potential disulfide bonds and no O-glycosylation sites. 23541464 8 53 gly N-glycosylation 957:971 arg2 1 potential N-glycosylation site 1 potential N-glycosylation site site Analysis identified 1 potential N-glycosylation site, 3 potential disulfide bonds and no O-glycosylation sites. 7487957 6 52 gly N-glycosylation 1281:1295 arg2 N-glycosylation sites N-glycosylation sites sites These results imply that though the number of N-glycosylation sites plays a role in the circulatory life-time of the enzyme, the number of N-glycan units in itself does not determine the rate of clearance. 8749323 0 9 part_of thrombomodulin 63:76 arg1 the D2 and D3 domains thrombomodulin the D2 and D3 domains PUBTATOR Site thrombomodulin 7056 domains The roles played by the D2 and D3 domains of recombinant human thrombomodulin in its function. 22180207 0 13 gly O-glycopeptides 110:124 arg2 mucin-like O-glycopeptides mucin-like O-glycopeptides O-glycopeptides Evaluation of non-reductive β-elimination/Michael addition for glycosylation site determination in mucin-like O-glycopeptides. 22180207 0 50 gly glycosylation 63:75 arg2 glycosylation site determination glycosylation site determination site Evaluation of non-reductive β-elimination/Michael addition for glycosylation site determination in mucin-like O-glycopeptides. 2721453 7 91 gly sialylated 1253:1262 arg1 oligosaccharides oligosaccharides These data demonstrate that oligosaccharides from secreted TSH beta were more sialylated and sulfated, consistent with a more complex branching pattern, than those from TSH alpha. 11399819 15 68 gly N-glycosylation 2287:2301 arg2 an FcgammaRIIIb N-glycosylation site an FcgammaRIIIb N-glycosylation site site CONCLUSIONS: NA2 expression is affected by polymorphisms in FcgammaRIIIB 227 and FcgammaRIIIB 277, both of which are involved in an FcgammaRIIIb N-glycosylation site. 27127844 13 26 part_of V-ATPase 1741:1748 arg1 the V-ATPase V1 domain ATPase the V-ATPase V1 domain OGER Site ATPase domain Co-immunoprecipitation studies suggested that a4N489D does not assemble with the V-ATPase V1 domain. 14691230 2 81 gly glycosylation 433:445 arg1 DPPIV DPPIV PUBTATOR DPPIV 1803 It has been generally accepted that glycosylation of DPPIV and of other transmembrane dipeptidyl peptidases is a prerequisite for enzyme activity and correct protein folding. 14691230 2 81 gly glycosylation 433:445 arg1 other transmembrane dipeptidyl peptidases other transmembrane dipeptidyl peptidases OGER peptidases P28838 It has been generally accepted that glycosylation of DPPIV and of other transmembrane dipeptidyl peptidases is a prerequisite for enzyme activity and correct protein folding. 22750213 3 41 gly glycosylation 492:504 arg1 T T Cterm T 11423 The glycosylation of AChE(T) is known to be required for its proper assembly and trafficking; however, the role of PRiMA glycosylation in the oligomer assembly has not been revealed. 22750213 3 41 gly glycosylation 492:504 arg1 AChE AChE PUBTATOR AChE 11423 The glycosylation of AChE(T) is known to be required for its proper assembly and trafficking; however, the role of PRiMA glycosylation in the oligomer assembly has not been revealed. 8740419 1 29 part_of receptor 204:211 arg1 the extracellular domain low-affinity nerve growth factor receptor the extracellular domain PUBTATOR Site low-affinity nerve growth factor receptor 24596 domain When the extracellular domain of rat low-affinity nerve growth factor receptor (NGFRe) was synthesized in Saccharomyces cerevisiae with the signal peptide of invertase, NGFRe was translocated to the endoplasmic reticulum (ER) and retained there. 11386850 6 41 part_of have 790:793 arg1 The predicted Slc19a2 protein AND 12 transmembrane domains The predicted Slc19a2 protein 12 transmembrane domains PUBTATOR Site Slc19a2 protein 10560 domains The predicted Slc19a2 protein, like SLC19A2, was predicted to have 12 transmembrane domains and shared a number of other conserved sequence motifs with the human orthologue, including one potential N-glycosylation site (N(63)) and several potential phosphorylation sites. 16372382 8 53 gly glycopeptide 1518:1529 arg2 the glycopeptide the glycopeptide glycopeptide After PNGase F digestion, the peptide moiety of the glycopeptide was determined by the presence of the b- and y-series ions derived from its amino acid sequence in the quadrupole time-of-flight tandem mass (QTOF-MS/MS) spectrum. 30708139 5 61 gly N-glycosylation 856:870 arg2 new N-glycosylation sites new N-glycosylation sites sites As the first step, we explored the amino acid sequence of LH to find out desirable positions for introducing Asn or/and Thr to create new N-glycosylation sites. 9694881 6 52 gly glycosylation 677:689 arg2 the Asn14 glycosylation site the Asn14 glycosylation site site The suppression of the Asn14 glycosylation site led to 5 times lower Km and a 10 times lower kcat. 15175256 0 46 gly glycosylation 37:49 arg2 N-linked glycosylation site variation N-linked glycosylation site variation site Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. 15175256 0 83 gly glycoproteins 91:103 arg1 highly variable viral glycoproteins highly variable viral glycoproteins Fterm glycoproteins Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. 9884403 5 76 gly glycosylation 1013:1025 arg2 Only glycosylation site Asn251 site Asn251 site Asn251 Only glycosylation site Asn251 bears oligomannose-type carbohydrate chains ranging from Man5GlcNAc2to Man8GlcNAc2, in addition to a small amount of complex-type structures. 10828967 1 31 part_of receptor 188:195 arg1 four potential sites receptor four potential sites Fterm Site receptor sites The receptor for parathyroid hormone (PTH) and PTH-related peptide (PTHrP) is a G-protein-coupled receptor with four potential sites for N-linked glycosylation. 9581553 1 77 gly glycosylation 197:209 arg1 FR FR Cterm FR In a previous study with inhibitors of N-glycosylation, it was proposed that core glycosylation of the folate receptor (FR) is required for the proper folding of the protein [Luhrs (1991) Blood 77, 1171-1180]. 9581553 1 77 gly glycosylation 197:209 arg1 folate receptor folate receptor Fterm receptor In a previous study with inhibitors of N-glycosylation, it was proposed that core glycosylation of the folate receptor (FR) is required for the proper folding of the protein [Luhrs (1991) Blood 77, 1171-1180]. 9852167 6 49 gly site 1054:1057 arg1 mutagenesis site mutagenesis site RESULTS: Elimination of glycosylation by mutagenesis of the N-linked glycosylation site did not impair the ability of the resulting cone opsin to absorb light at the appropriate wavelength nor to activate transducin. 9852167 6 67 gly glycosylation 1040:1052 arg2 the N-linked glycosylation site the N-linked glycosylation site site RESULTS: Elimination of glycosylation by mutagenesis of the N-linked glycosylation site did not impair the ability of the resulting cone opsin to absorb light at the appropriate wavelength nor to activate transducin. 21992186 6 67 gly glycosylation 1035:1047 arg2 additional glycosylation site additional glycosylation site site and Leu at position 234 Deduced amino acid sequences of the hemagglutinin (HA) gene showed the presence of additional glycosylation site and Leu at position 234 indicating to binding preference to α (2, 6) sialic acid receptors, indicating their potential to directly infect humans. 9393962 8 49 gly glycosylated 951:962 arg1 the glycosylated residue the glycosylated residue residue in It was, therefore, important to determine whether the glycosylated residue in the CH3 domain of the IgG3 constant region is influential in self-association. 10725548 2 13 gly O-glycosylation 259:273 arg2 The predicted O-glycosylation site The predicted O-glycosylation site site The predicted O-glycosylation site consisting of four amino acid residues of Ser-Ser-Thr-Thr is located immediately adjacent to the initiator Met and is well conserved among MHV strains investigated so far. 24838853 3 67 gly glycosylation 445:457 arg2 a potential glycosylation site a potential glycosylation site site A T300I mutation in three strains resulted in the loss of a potential glycosylation site. 21525271 3 27 gly N-glycosylation 589:603 arg2 a putative N-glycosylation site a putative N-glycosylation site site Expressing chimeric GluN2 subunits, we identified a putative N-glycosylation site present in GluN2B, but not in GluN2A, as necessary and sufficient to drive NMDARs into synapses in an activity-independent manner. 12372996 9 29 gly non-glycosylated 1153:1168 arg1 one non-glycosylated isoenzyme one non-glycosylated isoenzyme Fterm isoenzyme RESULTS: Basic beta-1,3-glucanase was subdivided into two glycosylated isoenzymes (GI and GII) and one non-glycosylated isoenzyme (GIII). 12372996 9 89 gly glycosylated 1108:1119 arg1 two glycosylated isoenzymes two glycosylated isoenzymes Fterm isoenzymes RESULTS: Basic beta-1,3-glucanase was subdivided into two glycosylated isoenzymes (GI and GII) and one non-glycosylated isoenzyme (GIII). 26059044 0 0 gly interleukin-22 82:95 arg1 the atypical N-glycan composition interleukin-22 the atypical N-glycan composition PUBTATOR interleukin-22 50616 The N-glycan on Asn54 affects the atypical N-glycan composition of plant-produced interleukin-22, but does not influence its activity. 26059044 0 4 gly N-glycan 4:11 arg1 Asn54 Asn54 Asn54 AminoAcid Asn54 The N-glycan on Asn54 affects the atypical N-glycan composition of plant-produced interleukin-22, but does not influence its activity. 20543007 8 57 part_of site 1204:1207 arg1 H-CDR2 CDR2 site PUBTATOR Site CDR2 1039 site On the basis of the spatial proximity and germline sequence, we reintroduced the consensus N-glycosylation site in H-CDR2 which was found in the original antibody, anticipating that the carbohydrate moiety would shield the aggregation 'hot spot' in H-CDR3 while not interfering with antigen binding. 8157687 6 68 gly glycoproteins 1639:1651 arg1 these glycoproteins these glycoproteins Fterm glycoproteins From these and additional observations with RNase B, which contains high mannose-type oligosaccharides at Asn-34, it is clear that the protein moieties of these glycoproteins markedly influence the presentation of the oligosaccharides such that biological specificity is mediated by the commonly occurring high mannose-type oligosaccharides in the context of specific carrier proteins. 8157687 6 92 gly contains 1537:1544 arg1 RNase B AND high mannose-type oligosaccharides RNase B Asn-34 high mannose-type oligosaccharides OGER RNase B P07998 Asn-34 From these and additional observations with RNase B, which contains high mannose-type oligosaccharides at Asn-34, it is clear that the protein moieties of these glycoproteins markedly influence the presentation of the oligosaccharides such that biological specificity is mediated by the commonly occurring high mannose-type oligosaccharides in the context of specific carrier proteins. 8985413 4 55 part_of epitopes 856:863 arg1 CD4 CD4 epitopes PUBTATOR CD4 920 However, all amino acid insertions affected the sensitivity of the variants to neutralization by soluble CD4 and monoclonal antibodies specific for epitopes in the V3 and CD4 binding site regions. 10713140 4 19 gly N-glycosylation 658:672 arg2 the six potential N-glycosylation sites the six potential N-glycosylation sites sites We have determined that four of the six potential N-glycosylation sites, including that associated with albinism, are occupied. 10713140 4 25 gly occupied 726:733 arg2 the six potential N-glycosylation sites the six potential N-glycosylation sites sites We have determined that four of the six potential N-glycosylation sites, including that associated with albinism, are occupied. 20573953 6 28 gly glycosylation 1243:1255 arg2 glycosylation site location glycosylation site location site We observed some flexibility in glycosylation site location for polysialylation and demonstrate that the lack of polysialylation of a glycan attached to Asn-423 may be in part related to a lack of terminal processing. 20573953 6 54 gly attached 1352:1359 arg1 Asn-423 AND a glycan Asn-423 a glycan Asn-423 We observed some flexibility in glycosylation site location for polysialylation and demonstrate that the lack of polysialylation of a glycan attached to Asn-423 may be in part related to a lack of terminal processing. 20573953 6 63 gly polysialylation 1324:1338 arg1 a glycan a glycan We observed some flexibility in glycosylation site location for polysialylation and demonstrate that the lack of polysialylation of a glycan attached to Asn-423 may be in part related to a lack of terminal processing. 8644914 11 100 gly fucosylated 2189:2199 arg1 core fucosylated carbohydrates core fucosylated carbohydrates The set of glycoforms consists predominantly of biantennary, core fucosylated carbohydrates lacking sialic acid. 18642129 8 43 gly found 1216:1220 arg1 Asn AND triantennary structures Asn(322) triantennary structures Asn(322) Nevertheless, lower amounts of triantennary structures were found on Asn(322) compared to Asn(145). 24780636 2 18 gly glycoforms 191:200 arg1 Transferrin glycoforms Transferrin glycoforms PUBTATOR Transferrin 7018 Transferrin glycoforms Tf-1 and Tf-2, previously identified in human cerebrospinal fluid, are defined as the lower and upper bands in gel electrophoresis, respectively. 21177759 5 74 part_of motifs 850:855 arg1 ALS ALS motifs OGER Site ALS P35858 motifs The D440N mutation was proposed to generate an N-glycosylation site additional to the seven existing motifs in ALS. 15605411 9 43 gly glycosylation 1428:1440 arg2 an additional glycosylation site an additional glycosylation site site Processing of the mutant proteins was unaltered except for c.473T>G which was differently glycosylated due to the exposition of an additional glycosylation site. 18416605 2 19 gly glycosylation 459:471 arg1 PrP PrP OGER PrP Q9NP58 To address the hypothesis that glycosylation of host PrP is a major factor influencing TSE infection, we have inoculated gene-targeted transgenic mice that have restricted N-linked glycosylation of PrP with three TSE strains. 18416605 2 32 gly glycosylation 309:321 arg1 host PrP host PrP OGER PrP Q9NP58 To address the hypothesis that glycosylation of host PrP is a major factor influencing TSE infection, we have inoculated gene-targeted transgenic mice that have restricted N-linked glycosylation of PrP with three TSE strains. 8543280 3 22 gly glycosylation 514:526 arg2 one potential N-linked glycosylation site one potential N-linked glycosylation site site The deduced human AEG-like molecule was made up of 230 amino acids, excluding a signal peptide, and contained one potential N-linked glycosylation site. 15478466 2 13 gly glycosylation 307:319 arg2 a glycosylation site a glycosylation site site The amino acid sequence revealed a protein composed of 214 residues and with a glycosylation site in position 20. 28835497 4 114 gly glycosylation 594:606 arg2 the two conserved N-linked glycosylation (N48 and N58) sites the two conserved N-linked glycosylation (N48 and N58) sites sites Here, we determined the role of the two conserved N-linked glycosylation (N48 and N58) sites of gK in virus-induced cell fusion and replication. 28835497 4 28 gly glycosylation 594:606 arg1 N48 N48 and N58 N48 and N58 Here, we determined the role of the two conserved N-linked glycosylation (N48 and N58) sites of gK in virus-induced cell fusion and replication. 7768952 8 3 part_of chain 1121:1125 arg1 The deduced amino acid sequence chain The deduced amino acid sequence OGER Site chain 5652 sequence The deduced amino acid sequence of the heavy chain has 34-42% identity to human acrosin, plasma kallikrein, and hepsin. 25910922 4 76 part_of hemagglutinin 699:711 arg1 the antigenic sites hemagglutinin the antigenic sites Fterm Site hemagglutinin sites In this study, we introduced mutations at the antigenic sites of the hemagglutinin (HA) to broaden reactivity of the Egyptian H5N1 virus. 10713140 3 63 gly N-glycosylation 448:462 arg2 each N-glycosylation site each N-glycosylation site site To probe the role that each N-glycosylation site plays in the synthesis of biologically active tyrosinase, we analyzed the calnexin mediated folding of tyrosinase N-glycosylation mutants. 26022737 3 93 part_of glycoproteins 452:464 arg1 glycopeptides glycoproteins glycopeptides Fterm Site glycoproteins glycopeptides During our previous study of PSA N69 glycosylation, additional glycopeptides were observed in the PSA sample that were not previously reported and did not match glycopeptides of impure glycoproteins existing in the sample. 8027066 6 30 part_of subunit 1345:1351 arg1 each N-linked glycosylation site IR beta subunit each N-linked glycosylation site Cterm Site IR beta subunit 3643 site These data provide evidence for (i) glycosylation of each N-linked glycosylation site of the IR beta subunit, (ii) absence of correlation between internalization and transmembrane signaling, and (iii) a major role for oligosaccharide side chain(s) located close to the cell membrane in IR activation and transmembrane signaling. 15869468 6 74 gly glycosylation 843:855 arg2 the ECL2 glycosylation site the ECL2 glycosylation site site Shifting the position of the ECL2 glycosylation site by two residues led to the synthesis of a misfolded receptor which, nevertheless, was trafficked to the cell surface. 8780172 4 81 gly glycosylation 640:652 arg1 VEGF/VPF VEGF asparagine site PUBTATOR VEGF 281572 asparagine site The extent to which glycosylation of the 75 asparagine site affects the angiogenic properties of VEGF/VPF has not been studied in vivo. 24872415 5 2 gly N-glycosylation 720:734 arg1 the NKG2D ligand MICA itself the NKG2D ligand MICA itself PUBTATOR MICA 100507436 Here we investigated whether direct N-glycosylation of the NKG2D ligand MICA itself is critical for cell surface expression and sought to identify the essential residues. 1651590 8 57 part_of proteins 1458:1465 arg1 the cleavage site proteins the cleavage site Fterm Site proteins site The results indicate that enhanced cleavability of the glycoprotein, a feature often associated with multiple basic residues within the cleavage site of paramyxovirus F proteins and influenza virus hemagglutinins, can also be determined by a single basic amino acid following proline. 15911445 7 86 part_of HA1 1076:1078 arg1 the HA1 region HA1 the HA1 region OGER Site HA1 region RESULTS: Our results showed that 28 amino acid substitutions have accumulated in the HA1 region since the circulation of A/New Caledonia/20/99-like viruses in France. 31501225 5 79 gly N-glycopeptide 813:826 arg2 N-glycopeptide N-glycopeptide N-glycopeptide Then, multiple reaction monitoring (MRM) was performed to quantify N-glycopeptide relative to the protein content, especially in the healthy donor-HBV-LC-HCC cascade. 9401066 6 92 gly glycosylation 964:976 arg2 a new Asn-Lys-Thr glycosylation site a new Asn-Lys-Thr glycosylation site site Amplification of this region by PCR and subsequent DNA sequencing demonstrated a single base substitution altering the normal 380 Lys (AAG) codon to Asn (AAT), producing a new Asn-Lys-Thr glycosylation site. 26598643 2 52 gly O-glycosylated 323:336 arg1 O-glycosylated proteins O-glycosylated proteins Fterm proteins The analysis, though, is quite challenging and time consuming, in particular for O-glycosylated proteins. 7914890 3 1 gly site 550:553 arg1 oligosaccharides site oligosaccharides site Phosphorylation of mannose residues is restricted to oligosaccharides at the first and third N-glycosylation site (Asn-158 and Asn-350). 7914890 3 51 gly N-glycosylation 534:548 arg2 the first and third N-glycosylation site the first and third N-glycosylation site site Phosphorylation of mannose residues is restricted to oligosaccharides at the first and third N-glycosylation site (Asn-158 and Asn-350). 7914890 3 46 gly site 550:553 arg1 Asn-158 Asn-158 and Asn-350 Asn-158 and Asn-350 Phosphorylation of mannose residues is restricted to oligosaccharides at the first and third N-glycosylation site (Asn-158 and Asn-350). 7475306 8 9 gly glycosylated 1294:1305 arg1 the peptide the peptide peptide Additionally, antibodies to the glycosylated form of the peptide recognized the HTLV-I envelope precursor in radioimmunoassay precipitation assay and react with HTLV-I whole virus preparations in ELISA. 8554050 2 68 part_of protein 263:269 arg1 determined protein sequences protein determined protein sequences Fterm Site protein sequences From determined protein sequences and DNA sequence analysis of variant alleles, we here report the coding and molecular basis for Con (concanavalin A-binding) and Po (parotid "o") protein polymorphisms. 17634239 5 52 gly glycosylation 787:799 arg2 the glycosylation site the glycosylation site site Introduction of the glycosylation site at position 295 into three subtype C molecular clones, Du151.2, COT9.6, and COT6.15, did increase 2G12 binding to all three mutagenized gp120s, but at various levels. 8301235 3 52 part_of contains 490:497 arg1 its predicted amino acid sequence AND its predicted amino acid sequence its predicted amino acid sequence its predicted amino acid sequence sequence Human HL is a glycoprotein and its predicted amino acid sequence contains four putative N-linked glycosylation sites at Asn residues 20, 56, 340, and 375. 8301235 3 52 part_of contains 490:497 arg1 its predicted amino acid sequence AND four putative N-linked glycosylation sites its predicted amino acid sequence four putative N-linked glycosylation sites sites Human HL is a glycoprotein and its predicted amino acid sequence contains four putative N-linked glycosylation sites at Asn residues 20, 56, 340, and 375. 10226365 3 72 gly sequence 785:792 arg1 the B-type carbohydrate sequence ions the B-type carbohydrate sequence ions Beside the B-type carbohydrate sequence ions of high abundance, it is possible to register diagnostic b- and y-type glycosylated peptide ions of lower abundance due to high dynamic range of the QTOF analyser. 15809770 7 22 gly glycosylation 786:798 arg2 Two Asn-linked glycosylation sites Two Asn-linked glycosylation sites sites Two Asn-linked glycosylation sites within the N-terminal extracellular region were conserved among vertebrate Fzd8 orhologs. 29069609 7 32 gly N-glycopeptides 1298:1312 arg2 N-glycopeptides N-glycopeptides N-glycopeptides This allowed development of a targeted DIA method to identify N-glycopeptides without pre-defined knowledge of the glycan composition, thus providing the potential to identify N-glycopeptides with unexpected structures. 29069609 7 77 gly N-glycopeptides 1184:1198 arg2 N-glycopeptides N-glycopeptides N-glycopeptides This allowed development of a targeted DIA method to identify N-glycopeptides without pre-defined knowledge of the glycan composition, thus providing the potential to identify N-glycopeptides with unexpected structures. 9169007 6 51 gly variants 782:789 arg1 Heparin-agarose chromatography antithrombin variants Heparin-agarose chromatography PUBTATOR antithrombin variants 462 Heparin-agarose chromatography of the four antithrombin variants revealed that Gln 96, Gln 135, and Gln 192 variants still displayed the two functional heparin-affinity forms previously observed with the wild-type inhibitor, whereas the Gln 155 variant showed only a single functional high heparin affinity form. 17634239 7 86 gly glycosylation 1173:1185 arg2 a glycosylation site a glycosylation site site Introduction of a glycosylation site at position 448 into mutant COT6-V295N, which occurs naturally in COT9, resulted in a virus that was partially sensitive to 2G12. 1651590 5 89 gly glycosylation 842:854 arg2 a glycosylation site a glycosylation site site On the other hand, phenotypes of F1-R that remained unchanged by the revertants were bipolar budding in polarized epithelial cells, enhanced electrophoretic migration of the matrix protein, and the lack of a glycosylation site in the F2 subunit of the F protein. 17960575 3 60 gly glycopeptides 278:290 arg2 the obtained glycopeptides the obtained glycopeptides glycopeptides 2005, 5, 1758-1763) and the obtained glycopeptides were analyzed, respectively, by nanoelectrospray ionization mass spectrometry and collision-induced dissociation (CID) during the ongoing digest. 22274805 8 2 gly N-glycosylation 1105:1119 arg2 N-glycosylation site N-glycosylation site site The deduced amino acid sequence of the V3 region was used to predict co-receptor, determine sequence variability and N-glycosylation site. 22274805 8 44 gly used 1041:1044 arg2 The deduced amino acid sequence The deduced amino acid sequence sequence The deduced amino acid sequence of the V3 region was used to predict co-receptor, determine sequence variability and N-glycosylation site. 12696120 5 43 gly glycosylation 1048:1060 arg2 residues 400-402 residues 400-402 residues 400-402 Compared with the vaccine strains, six of the eight isolates lacked the extracellular glycosylation site at residues 400-402. 12696120 5 43 gly glycosylation 1048:1060 arg2 the extracellular glycosylation site the extracellular glycosylation site site Compared with the vaccine strains, six of the eight isolates lacked the extracellular glycosylation site at residues 400-402. 17640971 8 63 gly O-glycopeptides 1464:1478 arg2 O-glycopeptides O-glycopeptides O-glycopeptides Analysis of O-glycopeptides by tandem mass spectrometry provided an additional level of support for the O-glycosylation of SAGA-1. 11931388 8 36 part_of containing 1395:1404 arg1 the C-terminal cytoplasmic tail AND a region the C-terminal cytoplasmic tail a region region Amino acid sequence comparison of the mouse NHE-1 (derived from the fully processed message) with that of other mammalian species demonstrated two exceptionally divergent regions; the C-terminal cytoplasmic tail (residues 750-790), containing a region of 6-8 contiguous acidic amino acids variably composed of aspartate and glutamate residues, and the N-terminal extracellular domain that includes an N-linked glycosylation site (residues 60-80). 23830432 3 20 gly glycopeptides 938:950 arg2 multisialylated glycopeptides multisialylated glycopeptides glycopeptides The former according to the process of alkaline phosphatase digestion followed by tryptic digestion and then proteinase K digestion could greatly improve the enzymatic efficiency on fetuin, and the latter could obviously enhance the enrichment efficiency for multisialylated glycopeptides using phosphoric acid solution as elution buffer. 23830432 3 71 gly multisialylated 922:936 arg1 multisialylated glycopeptides multisialylated glycopeptides glycopeptides The former according to the process of alkaline phosphatase digestion followed by tryptic digestion and then proteinase K digestion could greatly improve the enzymatic efficiency on fetuin, and the latter could obviously enhance the enrichment efficiency for multisialylated glycopeptides using phosphoric acid solution as elution buffer. 28928219 6 3 gly glycosylated 1244:1255 arg1 glycosylated Skp1 glycosylated Skp1 PUBTATOR Skp1 6500 Molecular dynamics trajectories of glycosylated Skp1 whose calculated monosaccharide relaxation kinetics and rotational correlation times agreed with the NMR data indicated that the glycan interacts with the loop connecting two α-helices of the F-box-combining site. 29463651 2 90 gly N-glycosylation 303:317 arg1 the E protein the E protein Fterm protein Here, we report that N-glycosylation of the E protein, which is conserved among most flaviviruses, is critical for the Zika virus (ZIKV) to invade the vector midgut by inhibiting the reactive oxygen species (ROS) pathway of the mosquito immune system. 7980452 1 84 part_of has 166:168 arg1 a secretory glycoprotein AND two potential N-linked glycosylation sites a secretory glycoprotein two potential N-linked glycosylation sites Fterm Site glycoprotein sites Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain. 7980452 1 84 part_of has 166:168 arg1 Human interferon-gamma AND two potential N-linked glycosylation sites Human interferon-gamma two potential N-linked glycosylation sites PUBTATOR Site Human interferon-gamma 3458 sites Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain. 15869468 8 9 gly N-glycosylation 1125:1139 arg2 N-glycosylation motifs N-glycosylation motifs motifs Introduction of N-glycosylation motifs into ECL3 yielded mutant receptors with normal affinity, but low levels of cell surface expression caused by proteasomal degradation. 23766031 1 67 part_of IgG 126:128 arg1 IgG Fc region IgG IgG Fc region Cterm Site IgG region The interactions of IgG Fc region with Fc receptors are optimized by the tailoring of a single-conserved N-linked glycosylation site at Asn-297. 7781780 0 29 gly erythropoietin 119:132 arg1 a mannose-6-phosphate containing oligomannosidic N-glycan erythropoietin a mannose-6-phosphate containing oligomannosidic N-glycan PUBTATOR erythropoietin 2056 Identification and structural characterization of a mannose-6-phosphate containing oligomannosidic N-glycan from human erythropoietin secreted by recombinant BHK-21 cells. 26018173 7 99 gly contain 1333:1339 arg1 the sites AND high-mannose glycans the sites high-mannose glycans sites While many of the sites contain exclusively high-mannose glycans, others retain complex glycans, resulting in a glycan profile that cannot currently be mimicked on soluble gp120 or gp140 preparations. 26035318 8 47 part_of database 1365:1372 arg1 sequences database sequences Fterm Site database sequences These findings were confirmed by analysing sequences from the Los Alamos database that were selected and grouped according to timing of transmission. 17724331 6 3 part_of sEPO-R 1150:1155 arg1 these domains EPO these domains PUBTATOR Site EPO P01588 domains To map these domains of the sEPO-R that augment receptor maturation, we generated EPO-R derivatives in which parts of the extracellular region of mEPO-R were replaced with the corresponding fragments of sEPO-R. 17724331 6 69 part_of sEPO-R 1325:1330 arg1 the corresponding fragments EPO the corresponding fragments PUBTATOR Site EPO P01588 fragments To map these domains of the sEPO-R that augment receptor maturation, we generated EPO-R derivatives in which parts of the extracellular region of mEPO-R were replaced with the corresponding fragments of sEPO-R. 17724331 6 71 part_of mEPO-R 1268:1273 arg1 the extracellular region mEPO-R the extracellular region Cterm Site mEPO-R P01588 region To map these domains of the sEPO-R that augment receptor maturation, we generated EPO-R derivatives in which parts of the extracellular region of mEPO-R were replaced with the corresponding fragments of sEPO-R. 22009746 2 43 part_of receptor 543:550 arg1 the extracellular domain receptor the extracellular domain Fterm Site receptor domain Acetylcholine-binding proteins have proven to be valuable surrogates with structural similarity and sequence identity to the extracellular domain of the nicotinic receptor, yet these soluble proteins have their unique features and do not serve as exact replicates of the nAChRs of interest. 8227277 2 47 gly glycosylation 419:431 arg2 a potential glycosylation site a potential glycosylation site site A proportion of such viruses which lose a potential glycosylation site near the receptor binding region of the HA at amino acid positions 196-198 appear to have reduced virulence. 8227277 2 60 gly positions 495:503 arg1 196-198 196-198 positions 196 A proportion of such viruses which lose a potential glycosylation site near the receptor binding region of the HA at amino acid positions 196-198 appear to have reduced virulence. 12235182 5 13 part_of apoB-50 1149:1155 arg1 its N-linked glycosylation sites apoB its N-linked glycosylation sites PUBTATOR Site apoB 338 sites Similarly, mutant apoB-50 with all of its N-linked glycosylation sites mutagenized showed decreased secretion efficiency and decreased lipoprotein association in both d < 1.02 and d > 1.02 g/ml fractions. 23192877 6 15 gly glycosylation 1170:1182 arg2 an N-linked glycosylation site an N-linked glycosylation site site To further enhance the infectivity of NiVpp, we engineered a hyperfusogenic NiV-F protein lacking an N-linked glycosylation site (T5FΔN3). 17707131 0 37 part_of acyltransferase 12:26 arg1 acyltransferase motifs acyltransferase acyltransferase motifs Fterm Site acyltransferase motifs Topology of acyltransferase motifs and substrate specificity and accessibility in 1-acyl-sn-glycero-3-phosphate acyltransferase 1. 26896935 5 18 gly glycoprotein 808:819 arg1 KJMP-502 E glycoprotein KJMP-502 E glycoprotein Fterm glycoprotein In vivo analyses in a mouse model of WNV pathogenesis shows that chimeric virus where KJMP-502 E glycoprotein was replaced by that of IS98 is neuropathogenic, demonstrating that this protein is a major virulence determinant. 27489265 14 134 part_of CD4 2292:2294 arg1 the CD4 binding site CD4 the CD4 binding site PUBTATOR Site CD4 920 site In this study, we examine the conserved, CD4 binding site-proximal N197 glycan and demonstrate that its removal both facilitates neutralizing antibody access to the CD4 binding site and modestly impacts the structural dynamics at the trimer crown without drastically altering global Env trimer stability. 8286061 1 100 gly glycoprotein 227:238 arg1 the envelope glycoprotein gp120 the envelope glycoprotein gp120 Fterm glycoprotein The principal neutralizing determinant (PND) of human immunodeficiency virus (HIV) is located inside the third variable loop (designated the V3 loop) of the envelope glycoprotein gp120. 8841141 4 82 part_of receptor 594:601 arg1 the receptor extracellular domain receptor the receptor extracellular domain Fterm Site receptor domain This fragment yielded a major microsequence corresponding to a region from Met173 to Phe188 of the receptor extracellular domain and containing one N-glycosylation site at Asn180. 15194804 5 33 gly glycosylation 1008:1020 arg2 the potential glycosylation site the potential glycosylation site site Similar to a mutant lacking all N-glycans, g4 deletion mutants in which the potential glycosylation site was destroyed by introducing a glycine residue were neither cleaved nor transported to the cell surface and consequently were not able to mediate cell-to-cell fusion. 1634772 5 65 gly glycosylation 622:634 arg2 An additional glycosylation site An additional glycosylation site site An additional glycosylation site, compared with those of human DRA, was found in the second external domain of the protein. 12941638 0 101 part_of phosphatase 48:58 arg1 Amino acid sequence phosphatase Amino acid sequence Fterm Site phosphatase sequence Amino acid sequence of the cold-active alkaline phosphatase from Atlantic cod (Gadus morhua). 9442070 8 51 gly N-glycosylation 1390:1404 arg1 processing at one Fc N-glycosylation site site site Further analysis of these data suggested that processing at one Fc N-glycosylation site affects the other. 15628971 4 86 gly attached 489:496 arg1 C4ST-1 AND the N-linked oligosaccharides C4ST-1 the N-linked oligosaccharides PUBTATOR C4ST-1 314694 In the present paper, we investigated the functional role of the N-linked oligosaccharides attached to C4ST-1. 31296534 4 52 part_of STT3A-dependent 610:624 arg1 STT3A-dependent acceptor sites STT3A STT3A-dependent acceptor sites PUBTATOR Site STT3A 3703 sites Analysis of site occupancy data disclosed several new classes of STT3A-dependent acceptor sites including those with suboptimal flanking sequences and sites located within cysteine-rich protein domains. 23263199 4 10 part_of containing 580:589 arg1 human fucosyltransferase IX AND the soluble extracellular catalytic domain human fucosyltransferase IX the soluble extracellular catalytic domain PUBTATOR Site fucosyltransferase IX 10690 domain We produced truncated variants of human fucosyltransferase IX containing the soluble extracellular catalytic domain. 8832092 4 26 gly N-glycosylation 775:789 arg2 the N-glycosylation site the N-glycosylation site site It was thus determined that the N-glycosylation site in Asn33 of cruzipain is occupied by high mannose-type oligosaccharides. 8832092 4 32 gly occupied 821:828 arg2 the N-glycosylation site the N-glycosylation site site It was thus determined that the N-glycosylation site in Asn33 of cruzipain is occupied by high mannose-type oligosaccharides. 24018687 3 39 part_of DDR1 724:727 arg1 asparagine 211 DDR1 asparagine 211 PUBTATOR SpecificSite DDR1 780 asparagine 211 Site-directed mutational analysis of the consensus N-glycosylation sites of the DDRs revealed that mutations of asparagine 213 of DDR2 and asparagine 211 of DDR1, a conserved N-glycosylation site among vertebrate DDRs, inhibited the generation of the high-molecular-mass isoform. 24018687 3 39 part_of DDR1 724:727 arg1 a conserved N-glycosylation site DDR1 a conserved N-glycosylation site PUBTATOR Site DDR1 780 site Site-directed mutational analysis of the consensus N-glycosylation sites of the DDRs revealed that mutations of asparagine 213 of DDR2 and asparagine 211 of DDR1, a conserved N-glycosylation site among vertebrate DDRs, inhibited the generation of the high-molecular-mass isoform. 24018687 3 53 part_of DDR2 697:700 arg1 asparagine 213 DDR2 asparagine 213 PUBTATOR SpecificSite DDR2 4921 asparagine 213 Site-directed mutational analysis of the consensus N-glycosylation sites of the DDRs revealed that mutations of asparagine 213 of DDR2 and asparagine 211 of DDR1, a conserved N-glycosylation site among vertebrate DDRs, inhibited the generation of the high-molecular-mass isoform. 20391591 0 55 gly glycosylation 23:35 arg2 protein glycosylation sites protein glycosylation sites sites Characterizing protein glycosylation sites through higher-energy C-trap dissociation. 24475074 7 29 gly N-glycosylation 1426:1440 arg2 N-glycosylation site number N-glycosylation site number site Furthermore, secretory proteins have evolved at rates proportional to N-glycosylation site number, indicating adaptive interactions between the N-glycans and underlying protein. 9201996 13 9 gly O-glycosylation 1918:1932 arg2 mucin-type O-glycosylation sites mucin-type O-glycosylation sites sites The features observed in this study also appear to be very useful for prediction of mucin-type O-glycosylation sites in glycoproteins. 9201996 13 54 gly glycoproteins 1943:1955 arg1 glycoproteins glycoproteins Fterm glycoproteins The features observed in this study also appear to be very useful for prediction of mucin-type O-glycosylation sites in glycoproteins. 28860626 1 49 gly glycosylation 337:349 arg2 a glycosylation site a glycosylation site site The outbreak of a pandemic influenza H1N1 in 2009 required the rapid generation of high-yielding vaccines against the A/California/7/2009 virus, which were achieved by either addition or deletion of a glycosylation site in the influenza proteins hemagglutinin and neuraminidase. 10191360 4 10 gly N-glycosylated 634:647 arg1 Kv2.1 Kv2.1 PUBTATOR Kv2.1 3745 Kv2.1, which has a consensus site in the second extracellular interhelical domain, is not N-glycosylated. 8379944 9 50 part_of position 1357:1364 arg1 the mutant protein protein position Fterm Site protein position 384 In contrast, the mutant protein without glycosylation at position 384 displayed a 2-fold increase in enzyme activity. 23069765 4 30 gly unglycosylated 818:831 arg1 unglycosylated and N-glycosylated polypeptides unglycosylated and N-glycosylated polypeptides polypeptides The mass spectrum of IL-17A monomer also included peaks shifted by +948 Da from the respective masses of unglycosylated and N-glycosylated polypeptides. 23069765 4 86 gly N-glycosylated 837:850 arg1 unglycosylated and N-glycosylated polypeptides unglycosylated and N-glycosylated polypeptides polypeptides The mass spectrum of IL-17A monomer also included peaks shifted by +948 Da from the respective masses of unglycosylated and N-glycosylated polypeptides. 19008394 1 45 part_of protein 194:200 arg1 domain I protein domain I Fterm Site protein domain Using a monoclonal antibody directed to domain I of the West Nile virus (WNV) envelope (E) protein, we identified a continuous (linear) epitope that was immunogenic during WNV infection of horses. 3485444 1 32 gly glycosylation 108:120 arg2 a single glycosylation site a single glycosylation site site The band 3 protein has a single glycosylation site on the carboxy-terminal 55 000-dalton tryptic fragment that defines a sequence of the polypeptide on the extracytoplasmic surface of the cell. 24520765 10 9 gly N-glycosylation 966:980 arg2 26 N-glycosylation sites 26 N-glycosylation sites sites There were 26 N-glycosylation sites in the strain MuVi/Shandong. 11333905 2 32 part_of CD4-induced 636:646 arg1 CD4-induced epitopes CD4 CD4-induced epitopes PUBTATOR Site CD4 920 epitopes To study the relationships between CD4 independence, neutralization sensitivity, and exposure of CD4-induced epitopes associated with the coreceptor binding site, we generated a large panel of Env mutants and chimeras between 8x and its CD4-dependent parent, HXBc2. 31356638 7 42 gly glycosylation 1247:1259 arg2 the N207 glycosylation site the N207 glycosylation site site Finally, we found that the N207 glycosylation site is highly conserved among flaviviruses and is also essential for West Nile and Zika virus NS1 to trigger endothelial hyperpermeability via clathrin-mediated endocytosis. 15009203 11 135 gly occupied 1893:1900 arg2 the Asn37 the Asn37 Asn37 Site specific glycosylation was analysed by electrospray ionization MS and it was found that in the mono glycosylated GM-CSF form more than 90% of the Asn37 were occupied by N-glycans. 31514875 5 16 gly glycopeptides 1145:1157 arg2 glycopeptides glycopeptides glycopeptides Firstly, the repeatability of the nanoLC-MS/MS was evaluated and a method to control the identification of the identified glycans was developed to validate them regarding the retention time of glycopeptides in reversed phase nanoLC separation. 18320936 4 78 part_of HA1 676:678 arg1 position 94a HA1 position 94a OGER Site HA1 position 94 The CVN-R virus possessed a single amino acid change at position 94a (Asn94aAsp) of HA1 that eliminated this glycosylation site. 11356836 3 25 gly glycosylation 543:555 arg2 an additional glycosylation site an additional glycosylation site site Saposin A contains an additional glycosylation site and a single tryptophan. 17916798 8 73 gly glycopeptides 1381:1393 arg2 glycopeptides glycopeptides glycopeptides Detection of glycopeptides was achieved by means of a software algorithm that allows extraction and characterization of potential glycopeptide candidates from large LC-MALDI-MS/MS data sets, based on N-glycopeptide-specific fragmentation patterns and characteristic fragment mass peaks, respectively. 17916798 8 97 gly glycopeptide 1498:1509 arg2 potential glycopeptide candidates potential glycopeptide candidates glycopeptide Detection of glycopeptides was achieved by means of a software algorithm that allows extraction and characterization of potential glycopeptide candidates from large LC-MALDI-MS/MS data sets, based on N-glycopeptide-specific fragmentation patterns and characteristic fragment mass peaks, respectively. 9223509 4 49 part_of CD46 596:599 arg1 the virus binding regions CD46 the virus binding regions PUBTATOR Site CD46 P15529 regions In this study, receptors on different types of monkey erythrocytes were employed as "natural mutant proteins" to further define the virus binding regions of CD46. 10085102 9 12 gly glycosylation 1180:1192 arg2 N-linked glycosylation site N-linked glycosylation site site The predicted amino acid sequence showed 78% identity to human tapasin with identical consensus sequences of signal peptide, N-linked glycosylation site, transmembrane domain and double lysine motif. 10678398 0 46 part_of IgG1 30:33 arg1 two allelic IgG1 C(H) coding regions IgG1 two allelic IgG1 C(H) coding regions OGER Site IgG1 P01857 regions Identification of two allelic IgG1 C(H) coding regions (Cgamma1) of cat. 8379944 3 71 gly glycosylation 393:405 arg2 four potential N-linked glycosylation sites four potential N-linked glycosylation sites sites 25% of the total LCAT mass, and four potential N-linked glycosylation sites have been predicted at residues 20, 84, 272 and 384 of the LCAT protein sequence. 12883358 7 50 gly O-glycosylation 1249:1263 arg1 CD44s CD44s PUBTATOR CD44s 960 Furthermore, we observed that changes in N- and O-glycosylation of CD44s could modulate its cleavage. 28620050 6 85 part_of terminus 1230:1237 arg1 an additional fully occupied N-linked glycosylation site terminus an additional fully occupied N-linked glycosylation site site We also found that introduction of an additional fully occupied N-linked glycosylation site at the N terminus at position 1 (equivalent to Asp-221 in the Fc of IgG1) dramatically enhances overall sialic acid content of the Fc multimers. 19767389 1 98 gly present 179:185 arg2 an asparagine residue AND N-linked oligosaccharide structures asparagine residue N-linked oligosaccharide structures asparagine residue We report that N-linked oligosaccharide structures can be present on an asparagine residue not adhering to the consensus site motif NX(S/T), where X is not proline, described in the literature. 29992770 10 23 gly N-glycopeptides 1458:1472 arg2 specific N-glycopeptides specific N-glycopeptides N-glycopeptides CONCLUSIONS AND CLINICAL RELEVANCE: The authors are the first to suggest specific N-glycopeptides to serve as potential serum biomarkers to detect preclinical OSCC in patients. 2451667 5 8 gly glycans 776:782 arg1 the anchored form form of hCG-alpha glycans PUBTATOR form of hCG-alpha 1113 The two asparagine-linked glycans on the anchored form of hCG-alpha were large and heterogeneous when compared to those on the secretory form. 2451667 5 27 gly asparagine-linked 758:774 arg1 The two asparagine-linked glycans asparagine The two asparagine-linked glycans asparagine The two asparagine-linked glycans on the anchored form of hCG-alpha were large and heterogeneous when compared to those on the secretory form. 22171062 0 108 gly glycoprotein 100:111 arg1 the attachment glycoprotein the attachment glycoprotein Fterm glycoprotein Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus. 11263562 6 29 gly glycosylation 1242:1254 arg2 each glycosylation site each glycosylation site site Our method is simple, rapid, and useful for determining the carbohydrate structures at each glycosylation site and for elucidating the site-specific carbohydrate heterogeneity. 11263562 6 58 gly site 1256:1259 arg1 the carbohydrate structures site the carbohydrate structures site Our method is simple, rapid, and useful for determining the carbohydrate structures at each glycosylation site and for elucidating the site-specific carbohydrate heterogeneity. 8543840 4 35 part_of proteins 440:447 arg1 the ecto-domains env proteins the ecto-domains PUBTATOR Site env proteins 100616444 ecto-domains Rather, the ecto-domains of env proteins are cotranslationally translocated into the endoplasmic reticulum during biosynthesis. 7533854 0 95 gly glycosylation 115:127 arg1 the V1/V2 domain the V1/V2 domain domain Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. 24334224 0 37 gly glycosylation 9:21 arg1 recombinant human granulocyte colony-stimulating factor recombinant human granulocyte colony-stimulating factor PUBTATOR granulocyte colony-stimulating factor 1440 O-linked glycosylation analysis of recombinant human granulocyte colony-stimulating factor produced in glycoengineered Pichia pastoris by liquid chromatography and mass spectrometry. 25220145 2 27 gly CF-glycoproteins 415:430 arg1 CF-glycoproteins CF-glycoproteins Fterm CF-glycoproteins Therefore, global profiling and quantitative characterization of CF-glycoproteins may reveal potent biomarkers for clinical applications. 24135643 8 12 gly glycosylation 968:980 arg2 a glycosylation site a glycosylation site site Moreover, we found a glycosylation site and several conserved motifs in FZDs, which may be related to Wnt interaction. 22257732 5 71 gly sites 1189:1193 arg1 three N-glycosylation sites three N-glycosylation sites sites The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 79 gly glycosylation 1092:1104 arg2 The in silico glycosylation site analysis The in silico glycosylation site analysis site The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 104 gly N-glycosylation 1173:1187 arg2 three N-glycosylation sites three N-glycosylation sites sites The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 110 gly O-glycosylation 1227:1241 arg2 one O-glycosylation site one O-glycosylation site site The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 71 gly sites 1189:1193 arg1 N-111 N-12, N-62, and N-111 N-12, N-62, and N-111 The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 71 gly sites 1189:1193 arg1 N-12 N-12, N-62, and N-111 N-12, N-62, and N-111 The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 71 gly sites 1189:1193 arg1 N-12 N-12, N-62, and N-111 N-12, N-62, and N-111 The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 104 gly N-glycosylation 1173:1187 arg2 N-12 N-12, N-62, and N-111 N-12, N-62, and N-111 The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 104 gly N-glycosylation 1173:1187 arg2 N-111 N-12, N-62, and N-111 N-12, N-62, and N-111 The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 22257732 5 104 gly N-glycosylation 1173:1187 arg2 N-111 N-12, N-62, and N-111 N-12, N-62, and N-111 The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107). 24196967 7 58 gly ROM1 1126:1129 arg1 glycan composition ROM1 glycan composition PUBTATOR ROM1 6094 Peripherin, but not ROM1, is glycosylated and we examined the glycosylation site and glycan composition of ROM1 by liquid chromatographic tandem mass spectrometry. 24196967 7 76 gly glycosylated 1048:1059 arg1 ROM1 ROM1 PUBTATOR ROM1 6094 Peripherin, but not ROM1, is glycosylated and we examined the glycosylation site and glycan composition of ROM1 by liquid chromatographic tandem mass spectrometry. 24196967 7 76 gly glycosylated 1048:1059 arg1 Peripherin Peripherin PUBTATOR Peripherin 5630 Peripherin, but not ROM1, is glycosylated and we examined the glycosylation site and glycan composition of ROM1 by liquid chromatographic tandem mass spectrometry. 24196967 7 57 gly glycosylation 1081:1093 arg1 ROM1 ROM1 site PUBTATOR ROM1 6094 site Peripherin, but not ROM1, is glycosylated and we examined the glycosylation site and glycan composition of ROM1 by liquid chromatographic tandem mass spectrometry. 20172850 10 70 gly glycosylation 1253:1265 arg1 nephrin nephrin site PUBTATOR nephrin 4868 site In an additional patient with later manifestation, we discovered two further novel mutations, including the first one affecting a glycosylation site of nephrin. 8626443 6 22 gly glycosylation 1172:1184 arg2 only the third glycosylation site only the third glycosylation site site In contrast, ACETg3, which had only the third glycosylation site available, was unglycosylated, enzymatically inactive and rapidly degraded. 29932112 10 20 gly un-glycosylated 1353:1367 arg1 Panx1 Panx1 PUBTATOR Panx1 and 2 24145 We found that the un-glycosylated forms of Panx1 and 2 can readily interact, regulating their localization and potentially their channel function in cells where they are co-expressed. 3932069 3 18 part_of PstI 545:548 arg1 the unique PstI site PstI the unique PstI site OGER Site PstI P00995 site TNF mRNA was enriched by gradient centrifugation and this size-fractionated mRNA was used for synthesis of cDNA and inserted into the unique PstI site of pAT153. 18703501 4 10 part_of IX 775:776 arg1 the small transmembrane and intracytoplasmic regions CA IX the small transmembrane and intracytoplasmic regions PUBTATOR Site CA IX 768 regions The produced proteins lacked the small transmembrane and intracytoplasmic regions of CA IX. 9599010 2 11 gly N-glycosylation 474:488 arg2 a consensus N-glycosylation site a consensus N-glycosylation site site Four of these six substitutions cluster in the ligand binding site, and one of them, Asn-187, forms a consensus N-glycosylation site. 7613477 5 51 part_of LCAT 1156:1159 arg1 All four potential N-linked glycosylation sites LCAT All four potential N-linked glycosylation sites PUBTATOR Site LCAT 3931 sites All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 51 part_of LCAT 1156:1159 arg1 Asn384 LCAT Asn20, Asn84, Asn272, and Asn384 PUBTATOR AminoAcid LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 51 part_of LCAT 1156:1159 arg1 Asn84 LCAT Asn20, Asn84, Asn272, and Asn384 PUBTATOR AminoAcid LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 7613477 5 51 part_of LCAT 1156:1159 arg1 Asn84 LCAT Asn20, Asn84, Asn272, and Asn384 PUBTATOR AminoAcid LCAT 3931 Asn20, Asn84, Asn272, and Asn384 All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures. 2350186 1 30 gly asparagine-linked 134:150 arg1 the asparagine-linked oligosaccharides asparagine the asparagine-linked oligosaccharides asparagine The glycosylation and processing of the asparagine-linked oligosaccharides at individual glycosylation sites on the mu-chain of murine immunoglobulin M were investigated using variant cell lines that synthesize and secrete IgM heavy chains with known peptide deletions. 2350186 1 56 gly glycosylation 183:195 arg2 individual glycosylation sites individual glycosylation sites sites The glycosylation and processing of the asparagine-linked oligosaccharides at individual glycosylation sites on the mu-chain of murine immunoglobulin M were investigated using variant cell lines that synthesize and secrete IgM heavy chains with known peptide deletions. 2350186 1 15 gly glycosylation 98:110 arg1 the asparagine-linked oligosaccharides sites the asparagine-linked oligosaccharides sites The glycosylation and processing of the asparagine-linked oligosaccharides at individual glycosylation sites on the mu-chain of murine immunoglobulin M were investigated using variant cell lines that synthesize and secrete IgM heavy chains with known peptide deletions. 2350186 1 15 gly glycosylation 98:110 arg2 individual glycosylation sites sites sites The glycosylation and processing of the asparagine-linked oligosaccharides at individual glycosylation sites on the mu-chain of murine immunoglobulin M were investigated using variant cell lines that synthesize and secrete IgM heavy chains with known peptide deletions. 2350186 1 15 gly glycosylation 98:110 arg2 individual glycosylation sites sites the asparagine-linked oligosaccharides sites The glycosylation and processing of the asparagine-linked oligosaccharides at individual glycosylation sites on the mu-chain of murine immunoglobulin M were investigated using variant cell lines that synthesize and secrete IgM heavy chains with known peptide deletions. 2780569 3 64 part_of subunit 554:560 arg1 residues 185-196 subunit residues 185-196 Fterm SpecificSite subunit residues 185-196 We have previously shown that a synthetic dodecapeptide corresponding to residues 185-196 of the Torpedo AcChoR alpha subunit contains the essential elements of the ligand-binding site. 9524075 8 68 gly non-glycosylated 870:885 arg1 non-glycosylated procathepsin S non-glycosylated procathepsin S Cterm non-glycosylated procathepsin S 1520 In vitro processing of glycosylated as well as of non-glycosylated procathepsin S gave fully active enzymes thus indicating that the oligosaccharide chain was not necessary for proper folding. 15557236 4 45 gly non-glycosylated 731:746 arg1 the non-glycosylated E protein the non-glycosylated E protein Fterm protein Mice infected with viruses that carried the glycosylated E protein developed lethal infection, whereas mice infected with viruses that carried the non-glycosylated E protein showed low mortality. 15557236 4 57 gly glycosylated 628:639 arg1 the glycosylated E protein the glycosylated E protein Fterm protein Mice infected with viruses that carried the glycosylated E protein developed lethal infection, whereas mice infected with viruses that carried the non-glycosylated E protein showed low mortality. 30850477 8 105 gly N-glycosylation 1129:1143 arg2 an N-glycosylation site an N-glycosylation site site No evidence was found for an overall selection bias against acquiring an N-glycosylation site, except for the CDR3 of the H chain. 1733280 2 30 gly glycosylation 455:467 arg2 a single asparagine linked glycosylation site a single asparagine linked glycosylation site site The nucleotide sequence of the composite SP-B cDNAs and cloned genomic SP-B DNA predicted a primary translation product of 377 amino acids (molecular mass = 41.7 kDa) that contained a single asparagine linked glycosylation site. 2787353 3 30 gly glycoprotein 450:461 arg1 a glycoprotein a glycoprotein Fterm glycoprotein rIL-2 also binds OVA, a glycoprotein which contains approximately 50% high mannose chains at a single glycosylation site, and to yeast mannan. 2787353 3 34 gly glycosylation 528:540 arg2 a single glycosylation site a single glycosylation site site rIL-2 also binds OVA, a glycoprotein which contains approximately 50% high mannose chains at a single glycosylation site, and to yeast mannan. 2787353 3 3 gly contains 469:476 arg1 a glycoprotein AND approximately 50% high mannose chains glycoprotein site approximately 50% high mannose chains Fterm glycoprotein site rIL-2 also binds OVA, a glycoprotein which contains approximately 50% high mannose chains at a single glycosylation site, and to yeast mannan. 8663003 0 45 part_of Rh 49:50 arg1 the human erythrocyte Rh polypeptides Rh the human erythrocyte Rh polypeptides Cterm Site Rh polypeptides Immunochemical analysis of the human erythrocyte Rh polypeptides. 15867500 1 8 gly attached 231:238 arg1 glycoprotein gp120 AND high mannose carbohydrate groups glycoprotein gp120 high mannose carbohydrate groups PUBTATOR gp120 3700 Many clade C isolates of HIV-1 do not react with monoclonal antibody (MAb) 2G12, a broad-ranging human neutralizing MAb that recognizes high mannose carbohydrate groups attached to glycoprotein gp120. 15867500 1 29 gly glycoprotein 243:254 arg1 glycoprotein gp120 glycoprotein gp120 Fterm glycoprotein Many clade C isolates of HIV-1 do not react with monoclonal antibody (MAb) 2G12, a broad-ranging human neutralizing MAb that recognizes high mannose carbohydrate groups attached to glycoprotein gp120. 11087686 7 69 gly glycosylation 1063:1075 arg2 a mutated consensus N-linked glycosylation site a mutated consensus N-linked glycosylation site site A version of the pro-enzyme with a mutated consensus N-linked glycosylation site was secreted from P. pastoris as a mature, unglycosylated, approximately 25-kDa protein. 2456913 0 27 gly glycosylation 75:87 arg1 free alpha-subunits alpha-subunits sites Fterm alpha-subunits sites Rates of processing of the high mannose oligosaccharide units at the three glycosylation sites of mouse thyrotropin and the two sites of free alpha-subunits. 2456913 0 27 gly glycosylation 75:87 arg1 mouse thyrotropin thyrotropin sites OGER thyrotropin sites Rates of processing of the high mannose oligosaccharide units at the three glycosylation sites of mouse thyrotropin and the two sites of free alpha-subunits. 10995221 10 13 part_of isoleucine 1453:1462 arg1 UGT2B20 UGT2B20 isoleucine Cterm AminoAcid UGT2B20 isoleucine Changing the isoleucine in UGT2B20 to an arginine stabilized enzyme activity, while the reciprocal mutation in UGT2B15 R96I produced a more labile enzyme. 6935656 4 81 gly contained 747:755 arg1 the GIX+ viral protein AND six oligosaccharide chains the GIX+ viral protein six oligosaccharide chains Fterm protein Analysis of the envelope protein precursors by polyacrylamide gel electrophoresis and endoglycosidase treatment indicated that the GIX+ viral protein contained six oligosaccharide chains, whereas the GIX- viral protein contained seven. 25636227 0 15 gly O-glycosylation 67:81 arg2 O-glycosylation sites O-glycosylation sites sites From individual proteins to proteomic samples: characterization of O-glycosylation sites in human chorionic gonadotropin and human-plasma proteins. 2477364 0 34 gly subunit 100:106 arg1 the N-linked oligosaccharides subunit the N-linked oligosaccharides Fterm subunit Site-specific processing of the N-linked oligosaccharides of the human chorionic gonadotropin alpha subunit.